PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Pandolfi, PP				Pandolfi, PP			In vivo analysis of the molecular genetics of acute promyelocytic leukemia	ONCOGENE			English	Article						APL; cancer; transgenic mice; KO mice; animal models; transcription factors	ACID RECEPTOR-ALPHA; PML-RAR-ALPHA; TRANSFORMED-CELL DIFFERENTIATION; ZINC FINGER GENE; RETINOIC ACID; TRANSGENIC MICE; HISTONE DEACETYLASE; DNA-BINDING; TRANSCRIPTIONAL REGULATION; T(15-17) TRANSLOCATION	Acute promyelocytic leukemia (APL) is a distinct and paradigmatic subtype of myeloid leukemia associated with reciprocal chromosomal translocations always involving the Retinoic Acid Receptor alpha (RAR alpha) gene on chromosome 17 and variable partner genes (X genes) on different chromosomes. As a consequence of these translocations X-RAR alpha and RAR alpha -X fusion genes are generated. RAR alpha fuses to the PML gene in the vast majority of APL cases, and in a few cases to the PLZF, NPM, NuMA and STAT5b genes respectively. In the last few years, the functions of these aberrant fusion proteins and of the normal gene products involved in these translocations have been extensively characterized in vivo in transgenic and KO animal models. Here we will review the important conclusions, the novel questions and paradoxes that stem from this analysis.	Cornell Univ, Program Mol Biol, Dept Pathol, Sloan Kettering Div,Grad Sch Med Sci, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center	Pandolfi, PP (corresponding author), Cornell Univ, Program Mol Biol, Dept Pathol, Sloan Kettering Div,Grad Sch Med Sci, 1275 York Ave, New York, NY 10021 USA.	p-pandolfi@ski.mskcc.org						ALCALAY M, 1992, P NATL ACAD SCI USA, V89, P4840, DOI 10.1073/pnas.89.11.4840; Arnould C, 1999, HUM MOL GENET, V8, P1741, DOI 10.1093/hmg/8.9.1741; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHANG KS, 1992, MOL CELL BIOL, V12, P800, DOI 10.1128/MCB.12.2.800; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Early E, 1996, P NATL ACAD SCI USA, V93, P7900, DOI 10.1073/pnas.93.15.7900; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grimwade D, 1997, BLOOD, V90, P4876; Grimwade D, 1996, BRIT J HAEMATOL, V94, P557; GRISOLANO JL, 1994, P NATL ACAD SCI USA, V91, P8989, DOI 10.1073/pnas.91.19.8989; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gudas Lorraine J., 1994, P443; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; He LZ, 2000, MOL CELL, V6, P1131, DOI 10.1016/S1097-2765(00)00111-8; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; He LZ, 1999, ONCOGENE, V18, P5278, DOI 10.1038/sj.onc.1203088; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kogan SC, 2000, BLOOD, V95, P1541, DOI 10.1182/blood.V95.5.1541.005k28_1541_1550; Kogan SC, 2001, J EXP MED, V193, P531, DOI 10.1084/jem.193.4.531; Koken MHM, 1999, ONCOGENE, V18, P1113, DOI 10.1038/sj.onc.1202414; LAFAGEPOCHITALOFF M, 1995, BLOOD, V85, P1169, DOI 10.1182/blood.V85.5.1169.1169; LAGASSE E, 1994, J EXP MED, V179, P1047, DOI 10.1084/jem.179.3.1047; Lallemand-Breitenbach V, 1999, J EXP MED, V189, P1043, DOI 10.1084/jem.189.7.1043; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Li YP, 1997, BLOOD, V90, P306; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; LIU QR, 1991, EUR J BIOCHEM, V200, P715, DOI 10.1111/j.1432-1033.1991.tb16236.x; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Pandolfi PP, 2001, ONCOGENE, V20, P3116, DOI 10.1038/sj.onc.1204299; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Pollock JL, 1999, P NATL ACAD SCI USA, V96, P15103, DOI 10.1073/pnas.96.26.15103; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; Rego EM, 2000, P NATL ACAD SCI USA, V97, P10173, DOI 10.1073/pnas.180290497; Rego EM, 2001, J EXP MED, V193, P521, DOI 10.1084/jem.193.4.521; Richon VM, 1996, P NATL ACAD SCI USA, V93, P5705, DOI 10.1073/pnas.93.12.5705; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; Ruthardt M, 1997, MOL CELL BIOL, V17, P4859, DOI 10.1128/MCB.17.8.4859; Salomoni P, 2000, NAT MED, V6, P742, DOI 10.1038/77459; Sitterlin D, 1997, ONCOGENE, V14, P1067, DOI 10.1038/sj.onc.1200916; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001; Zimonjic DB, 2000, P NATL ACAD SCI USA, V97, P13306, DOI 10.1073/pnas.97.24.13306; Zong S, 1999, ONCOGENE, V18, P7941, DOI 10.1038/sj.onc.1203367	58	44	50	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2001	20	40					5726	5735		10.1038/sj.onc.1204600	http://dx.doi.org/10.1038/sj.onc.1204600			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	470TP	11607822				2022-12-17	WOS:000170887500013
J	Ma, X; Yang, K; Lindblad, P; Egevad, L; Hemminki, K				Ma, X; Yang, K; Lindblad, P; Egevad, L; Hemminki, K			VHL gene alterations in renal cell carcinoma patients: novel hotspot or founder mutations and linkage disequilibrium	ONCOGENE			English	Article						VHL gene; mutation; renal cell carcinoma; linkage disequilibrium; SSCP	TUMOR-SUPPRESSOR GENE; HIPPEL-LINDAU-DISEASE; SOMATIC MUTATIONS; CANCER; COMPLEX; DNA; IDENTIFICATION; PROTEIN; LINES	Mutations in the von Hippel-Lindau (VHL) gene are frequently detected in human sporadic renal cell carcinoma (RCC). We analysed 102 Swedish RCCs for VHL mutations by PCR-SSCP and sequencing. In 47 patients (46.1%), 70 different mutations were found, and most of them represented novel variations of the VHL gene. Mutations in the VHL gene were found in 54% of clear cell renal cell carcinomas (CCRCC) and in 18% of chromophilic cancers but in no chromophobe cancers or oncocytomas (P = 0.016). Three novel hotspot or founder mutations were detected in our study: four CCRCCs carried a missense mutation (glutamic acid to lysine) at codon 160 which is critical in the stabilization of the H1 helix of the alpha domain and the alpha-beta domain interface in the VHL protein. Five CCRCCs and one chromophilic RCC harbored a 15-nucleotide in-frame deletion (codons 41 - 45) at a duplex tandem repeat sequence site. Moreover, this deletion was in linkage disequilibrium with a C --> T transition in the promoter region. The frequency of linkage was 17 times more common than chance. Five patients with this linked mutation resided in the same hospital district and at least three of them showed the two sequence variants in the tumor-adjacent tissue. In 5/ 6 patients the wild-type allele was lost in the tumor samples, suggesting a causal role for the mutations in RCC. These linked mutations might be novel polymorphisms maintained in a relative isolated population. Multiple mutations in VHL were found in 17 tumors out of 47 tumors with the VHL mutation. A higher multiple mutation detected rate (33%) was observed in grade 3 CCRCCs than those in grade 1 (22%) and grade 2 (9%) (P=0.04). This is evidence on the association between VHL mutation and extent of nuclear atypia.	Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden; Karolinska Inst, Dept Med Epidemiol, S-17177 Stockholm, Sweden; Sundsvall Hosp, Dept Urol, S-85186 Sundsvall, Sweden; Karolinska Hosp, Dept Pathol & Cytol, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Hemminki, K (corresponding author), Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden.	kari.hemminki@cnt.ki.se		Egevad, Lars/0000-0001-8531-222X				Beroud C, 1998, NUCLEIC ACIDS RES, V26, P256, DOI 10.1093/nar/26.1.256; Brauch H, 2000, CANCER RES, V60, P1942; Brauch H, 1999, JNCI-J NATL CANCER I, V91, P854, DOI 10.1093/jnci/91.10.854; Bruning T, 1997, ARCH TOXICOL, V71, P332, DOI 10.1007/s002040050394; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; DAY RS, 1987, J CELL SCI, P333; Denissenko MF, 1997, P NATL ACAD SCI USA, V94, P3893, DOI 10.1073/pnas.94.8.3893; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gorospe M, 1999, MOL CELL BIOL, V19, P1289; GREENBLATT MS, 1994, CANCER RES, V54, P4855; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MANDEL JS, 1995, INT J CANCER, V61, P601, DOI 10.1002/ijc.2910610503; MCCREDIE M, 1995, INT J CANCER, V60, P345, DOI 10.1002/ijc.2910600312; McLaughlin JK, 2000, SEMIN ONCOL, V27, P115; MCLAUGHLIN JK, 1995, INT J CANCER, V60, P194, DOI 10.1002/ijc.2910600211; Meyer AJ, 2000, INT J CANCER, V87, P650, DOI 10.1002/1097-0215(20000901)87:5<650::AID-IJC5>3.0.CO;2-3; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Prowse AH, 1997, AM J HUM GENET, V60, P765; Schoenfeld AR, 2000, ONCOGENE, V19, P5851, DOI 10.1038/sj.onc.1203985; Schoenfeld AR, 2000, P NATL ACAD SCI USA, V97, P8507, DOI 10.1073/pnas.97.15.8507; Schraml P, 1999, Verh Dtsch Ges Pathol, V83, P218; SEKIDO Y, 1994, ONCOGENE, V9, P1599; Shiao YH, 1998, JNCI-J NATL CANCER I, V90, P1720, DOI 10.1093/jnci/90.22.1720; Siemeister G, 1996, CANCER RES, V56, P2299; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; THOENES W, 1990, KLIN WOCHENSCHR, V68, P1102, DOI 10.1007/BF01798060; THOENES W, 1990, EUR UROL, V18, P6; Yang K, 1999, CANCER LETT, V141, P1, DOI 10.1016/S0304-3835(99)00031-2; Yoshida M, 2000, JPN J CANCER RES, V91, P204, DOI 10.1111/j.1349-7006.2000.tb00933.x; Zhuang ZP, 1996, MODERN PATHOL, V9, P838	32	44	47	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2001	20	38					5393	5400		10.1038/sj.onc.1204692	http://dx.doi.org/10.1038/sj.onc.1204692			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536052				2022-12-17	WOS:000170575500015
J	Silva, J; Dominguez, G; Silva, JM; Garcia, JM; Gallego, I; Corbacho, C; Provencio, M; Espana, P; Bonilla, F				Silva, J; Dominguez, G; Silva, JM; Garcia, JM; Gallego, I; Corbacho, C; Provencio, M; Espana, P; Bonilla, F			Analysis of genetic and epigenetic processes that influence p14ARF expression in breast cancer	ONCOGENE			English	Article						allelic losses; p14ARF; breast cancer; hypermethylation; overexpression; mutations	CELL LUNG-CANCER; TUMOR-SUPPRESSOR GENE; INK4A/ARF LOCUS; STABILIZES P53; CYCLE ARREST; P19(ARF); METHYLATION; P16(INK4A); INACTIVATION; MUTATIONS	The INK4a/ARF locus encodes two unrelated cell cycle-regulatory proteins that both function in tumor suppression, p16INK4a and p14ARF. In human tumors including breast cancer, alterations affecting selectively p14ARF have been poorly analysed. We have performed a comprehensive analysis of the inactivation mechanisms (mutation, homozygous and hemizygous deletion, and promoter hypermethylation) in a large series of 100 primary breast carcinomas. RT-PCR showed expression variable of the p14ARF transcript, with 17% demonstrating overexpression and 26% demonstrating decreased expression. No detectable alterations were observed in the majority of cases with overexpressed p14ARF mRNA, but 77% of tumors with decreased expression presented at least one of these genetic/ epigenetic alterations. Nevertheless, a statistically significant correlation was observed between decreased p14ARF expression and several poor prognostic parameters.	Clin Puerta Hierro, Dept Med Oncol, E-28035 Madrid, Spain; Clin Puerta Hierro, Dept Pathol, E-28035 Madrid, Spain; Hosp Santa Cristina, Dept Pathol, E-28009 Madrid, Spain	Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda; Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda	Bonilla, F (corresponding author), Clin Puerta Hierro, Dept Med Oncol, E-28035 Madrid, Spain.		Gallego, Ignacio/GZK-5910-2022; Provencio, Mariano/ABE-8586-2020	Provencio, Mariano/0000-0001-9053-9197; Provencio Pulla, Mariano/0000-0001-6315-7919				Brenner AJ, 1996, CLIN CANCER RES, V2, P1993; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; Esteller M, 2000, CANCER RES, V60, P129; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; Gazzeri S, 1998, CANCER RES, V58, P3926; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Herranz M, 1999, LEUKEMIA, V13, P808, DOI 10.1038/sj.leu.2401409; Iida S, 2000, INT J CANCER, V87, P654, DOI 10.1002/1097-0215(20000901)87:5<654::AID-IJC6>3.0.CO;2-P; Iwato M, 2000, CANCER RES, V60, P2113; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kumar R, 1998, GENE CHROMOSOME CANC, V23, P273, DOI 10.1002/(SICI)1098-2264(199811)23:3<273::AID-GCC11>3.0.CO;2-N; Liggett WH, 1998, J CLIN ONCOL, V16, P1197, DOI 10.1200/JCO.1998.16.3.1197; Markl IDC, 1998, CANCER RES, V58, P5348; OTO M, 1993, ANAL BIOCHEM, V213, P19, DOI 10.1006/abio.1993.1379; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Sanchez-Cespedes M, 1999, ONCOGENE, V18, P5843, DOI 10.1038/sj.onc.1203003; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; STONE S, 1995, CANCER RES, V55, P2988; Takemoto S, 2000, BLOOD, V95, P3939; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Vonlanthen S, 1998, ONCOGENE, V17, P2779, DOI 10.1038/sj.onc.1202501; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zheng SC, 2000, CARCINOGENESIS, V21, P2057, DOI 10.1093/carcin/21.11.2057; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	26	44	45	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2001	20	33					4586	4590		10.1038/sj.onc.1204617	http://dx.doi.org/10.1038/sj.onc.1204617			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494155				2022-12-17	WOS:000170074900017
J	Cabeza-Arvelaiz, Y; Sepulveda, JL; Lebovitz, RM; Thompson, TC; Chinault, AC				Cabeza-Arvelaiz, Y; Sepulveda, JL; Lebovitz, RM; Thompson, TC; Chinault, AC			Functional identification of LZTS1 as a candidate prostate tumor suppressor gene on human chromosome 8p22	ONCOGENE			English	Article						prostate cancer; tumor suppressor; human; chromosome 8p; FEZ1; LZTS1	YEAST ARTIFICIAL CHROMOSOME; MAMMALIAN-CELLS; HUMAN GENOME; COLORECTAL-CANCER; BAND 8P22; EXPRESSION; P53; PROMOTER; PROTEIN; REGION	Deletions in the 8p21-22 region of the human genome are among the most common genetic alterations in prostate carcinomas. Several studies in different tumor tissues, including prostate, indicate that there are probably multiple tumor suppressor genes (TSGs) present in this region. To identify candidate TSGs on 8p22 a YAC contig spanning this region was assembled and YAC clones retrofitted with a selectable marker (neo) were transferred into rat prostate AT6,2 cells, Two overlapping YAC clones showed greatly reduced colony-forming efficiency, indicating they may carry a TSG, Two BAC clones encompassing the overlapping region also appeared to exert suppressive effects on the growth of AT6,2 cells, Database searches for genes mapped to the critical region identified a gene known as FEZ1 (LZTS1) as a potential candidate suppressor gene. Subsequent experiments showed that over-expression of LZTS1 cDNA inhibited stable colony-forming efficiencies of AT6,2, HEK-293 and LNCaP cells. In contrast, LZTS1-transfected Rat-1 and RM1 cells were growth-stimulated. Database searches also identified additional isoforms of the LZTS1 mRNA, as well as LZTS1 protein domains reminiscent of those found in transcription factors. Together these data suggest that the LZTS1 gene is involved in the regulation of cell growth and its loss of function may contribute to the development of prostatic carcinomas, as well as other cancers.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Urol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Chinault, AC (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [P50CA058204] Funding Source: NIH RePORTER; NCI NIH HHS [P50-CA58204] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; Allan LA, 2000, MOL CELL BIOL, V20, P1291, DOI 10.1128/MCB.20.4.1291-1298.2000; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDERSON MJ, 1993, FASEB J, V7, P826, DOI 10.1096/fasebj.7.10.8344482; Baker A, 1997, NUCLEIC ACIDS RES, V25, P1950, DOI 10.1093/nar/25.10.1950; BALEY PA, 1995, J STEROID BIOCHEM, V52, P403, DOI 10.1016/0960-0760(95)00001-G; BELLANNECHANTELOT C, 1992, CELL, V70, P1059, DOI 10.1016/0092-8674(92)90254-A; Bhatia-Gaur R, 1999, GENE DEV, V13, P966, DOI 10.1101/gad.13.8.966; BOOKSTEIN R, 1994, GENOMICS, V24, P317, DOI 10.1006/geno.1994.1622; Bova GS, 1996, GENOMICS, V35, P46, DOI 10.1006/geno.1996.0321; BURGERS PMJ, 1987, ANAL BIOCHEM, V163, P391, DOI 10.1016/0003-2697(87)90240-5; CABEZAARVELAIZ Y, 1993, DNA CELL BIOL, V12, P881, DOI 10.1089/dna.1993.12.881; Ceballos E, 2000, ONCOGENE, V19, P2194, DOI 10.1038/sj.onc.1203541; CHINAULT AC, 1994, CURRENT PROTOCOLS HU, V1; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHUMAKOV IM, 1995, NATURE, V377, P175; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Farrington SM, 1996, ONCOGENE, V12, P1803; FOULKES NS, 1996, BIOCHIM BIOPHYS ACTA, V1288, P101; FUJIWARA Y, 1995, ONCOGENE, V10, P891; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HARRIS H, 1969, NATURE, V223, P363, DOI 10.1038/223363a0; Hutton FG, 2000, ONCOGENE, V19, P452, DOI 10.1038/sj.onc.1203316; ICHIKAWA T, 1994, CANCER RES, V54, P2299; Ishii H, 1999, P NATL ACAD SCI USA, V96, P3928, DOI 10.1073/pnas.96.7.3928; Johnson DG, 2000, MOL CARCINOGEN, V27, P151, DOI 10.1002/(SICI)1098-2744(200003)27:3<151::AID-MC1>3.0.CO;2-C; KAGAN J, 1995, ONCOGENE, V11, P2121; Kirschner LS, 1999, BIOTECHNIQUES, V27, P72; Koreth J, 1999, ONCOGENE, V18, P1157, DOI 10.1038/sj.onc.1202372; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MacGrogan D, 1996, GENOMICS, V35, P55, DOI 10.1006/geno.1996.0322; MARKIE D, 1993, SOMAT CELL MOLEC GEN, V19, P161, DOI 10.1007/BF01233531; Mitchell KO, 1999, CELL GROWTH DIFFER, V10, P223; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; Murakami Y, 1998, P NATL ACAD SCI USA, V95, P8153, DOI 10.1073/pnas.95.14.8153; Murakami YS, 1996, CANCER RES, V56, P2157; PACHNIS V, 1990, P NATL ACAD SCI USA, V87, P5109, DOI 10.1073/pnas.87.13.5109; Park BJ, 2000, CANCER RES, V60, P3031; PIRROTTA V, 1987, EMBO J, V6, P791, DOI 10.1002/j.1460-2075.1987.tb04821.x; Reddy DE, 2000, ONCOGENE, V19, P217, DOI 10.1038/sj.onc.1203264; TSAI SY, 1987, CELL, V50, P701, DOI 10.1016/0092-8674(87)90328-X; TUCK SP, 1989, ONCOGENE RES, V4, P81; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78	49	44	47	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2001	20	31					4169	4179		10.1038/sj.onc.1204539	http://dx.doi.org/10.1038/sj.onc.1204539			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464283				2022-12-17	WOS:000169857200007
J	Zhu, JH; Nozell, S; Wang, J; Jiang, JY; Zhou, WJ; Chen, XB				Zhu, JH; Nozell, S; Wang, J; Jiang, JY; Zhou, WJ; Chen, XB			p73 cooperates with DNA damage agents to induce apoptosis in MCF7 cells in a p53-dependent manner	ONCOGENE			English	Article						p53; p73; DNA damage; apoptosis	P53 GENE FAMILY; KINASE C-ABL; ANTICANCER AGENTS; CANCER-CELLS; MUTANT P53; IDENTIFICATION; CYTOTOXICITY; NEUROBLASTOMA; ACTIVATION; CISPLATIN	p73, a member of the p53 family, can induce apoptosis in cancer cells, Since p53-mediated apoptosis can be augmented by various cancer chemotherapeutic agents, it has been hypothesized that the status of the endogenous p53 gene in cancer cells is a key determinant in the outcome of cancer therapy. To determine whether p73 can sensitize cancer cells to apoptosis by DNA damage agents, several MCF7 adenocarcinoma cell lines that inducibly express p73 or p53 under a tetracycline-regulated promoter were generated. We found that at relevant physiological levels, p73, but not p53, is capable of sensitizing MCF? cells to apoptosis induced by chemotherapeutic agents. In addition, we found that p73 can cooperate with the DNA damaging agent camptothecin to activate the initiator caspase 2. Furthermore, me found that p73 can cooperate with DNA damaging agents or p53 to induce some p53 target genes and activate their promoters. In contrast, in MCF7E6 cells that ectopically express the human papillomavirus E6 oncogene and are functionally p53-null,, the ability of p73 to sensitize cells to apoptosis is abrogated. Taken together, these results suggest that a functional interaction between p53 and p73 in MCF7 cells leads to enhanced induction of apoptosis.	Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Chen, XB (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, CB-2803, Augusta, GA 30912 USA.				NATIONAL CANCER INSTITUTE [R01CA081237] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA81237] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 1999, NATURE, V399, P809; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chen XB, 1999, MOL MED TODAY, V5, P387, DOI 10.1016/S1357-4310(99)01545-2; CHEN XB, 1995, CANCER RES, V55, P4257; Chresta CM, 1996, CANCER RES, V56, P1834; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; FAN SJ, 1995, CANCER RES, V55, P1649; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Gallardo D, 1996, CANCER RES, V56, P4891; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gong JG, 1999, NATURE, V399, P806; Gupta M, 1997, CLIN CANCER RES, V3, P1653; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LAURENZI VD, 1999, CELL DEATH DIFFER, V6, P389; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Mukhopadhyay T, 1997, ONCOGENE, V14, P379, DOI 10.1038/sj.onc.1200835; MUNGER K, 1989, J VIROL, V63, P4417; Nagata S, 2000, EXP CELL RES, V256, P12, DOI 10.1006/excr.2000.4834; OConnor PM, 1997, CANCER RES, V57, P4285; Prives C, 1999, J PATHOL, V187, P112; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; Wang YC, 1998, ONCOGENE, V17, P1923, DOI 10.1038/sj.onc.1202113; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; Xiao HY, 1999, J CELL BIOCHEM, V73, P291, DOI 10.1002/(SICI)1097-4644(19990601)73:3<291::AID-JCB1>3.0.CO;2-5; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika AI, 1999, CANCER RES, V59, P3257; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030; Zhu JH, 2000, J BIOL CHEM, V275, P39927, DOI 10.1074/jbc.M005676200; Zhu JH, 1998, CANCER RES, V58, P5061	46	44	47	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 5	2001	20	30					4050	4057		10.1038/sj.onc.1204516	http://dx.doi.org/10.1038/sj.onc.1204516			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494133				2022-12-17	WOS:000169681500013
J	Varley, JM; Attwooll, C; White, G; McGown, G; Thorncroft, M; Kelsey, AM; Greaves, M; Boyle, J; Birch, JM				Varley, JM; Attwooll, C; White, G; McGown, G; Thorncroft, M; Kelsey, AM; Greaves, M; Boyle, J; Birch, JM			Characterization of germline TP53 splicing mutations and their genetic and functional analysis	ONCOGENE			English	Article						TP53; Li-Fraumeni; splicing	LI-FRAUMENI FAMILIES; P53 MUTATIONS; HUMAN TUMORS; CANCER; EXPRESSION; SEQUENCE; PATIENT	Germline TP53 splicing mutations have been described infrequently (>2%) in the literature, however in a series of 40 patients and families identified by our group in which there are germline TP53 mutations, seven affect splicing (18%), The low figure reported in the literature might reflect the method of mutation detection, which in many studies does not include all splice junctions, These data indicate that a significant proportion of TP53 germline mutations are currently unrecognized. We have carried out detailed studies of the effects of the different mutations on splicing, and see distinct variations in the effects of the same mutation in different patients, Furthermore we have identified the usage of a nonconsensus splice donor site in four families with an intron 4 splice donor mutation.	Paterson Inst Canc Res, CRC, Canc Genet Grp, Manchester M20 4BX, Lancs, England; Royal Manchester Childrens Hosp, Dept Histopathol, Manchester M27 1HA, Lancs, England; Royal Manchester Childrens Hosp, CRC, PFCRG, Manchester M27 1HA, Lancs, England	Paterson Institute for Cancer Research; Royal Manchester Children's Hospital; Royal Manchester Children's Hospital	Varley, JM (corresponding author), Paterson Inst Canc Res, CRC, Canc Genet Grp, Wilmslow Rd, Manchester M20 4BX, Lancs, England.							BARTEK J, 1991, ONCOGENE, V6, P1699; Beroud C, 1998, NUCLEIC ACIDS RES, V26, P200, DOI 10.1093/nar/26.1.200; Birch JM, 1998, ONCOGENE, V17, P1061, DOI 10.1038/sj.onc.1202033; BIRCH JM, 1994, BRIT J CANCER, V70, P1176, DOI 10.1038/bjc.1994.468; BIRCH JM, 1994, CANCER RES, V54, P1298; Boyle JM, 1999, BRIT J CANCER, V79, P1657, DOI 10.1038/sj.bjc.6690265; Boyle JM, 1998, BRIT J CANCER, V77, P2181, DOI 10.1038/bjc.1998.364; BRUGIERES L, 1993, CANCER RES, V53, P452; Casey G, 1996, ONCOGENE, V13, P1971; Chen SY, 2000, P NATL ACAD SCI USA, V97, P593, DOI 10.1073/pnas.97.2.593; FELIX CA, 1993, ONCOGENE, V8, P1203; FREBOURG T, 1995, AM J HUM GENET, V56, P608; Hernandez-Boussard T, 1999, HUM MUTAT, V14, P1; JOLLY KW, 1994, ONCOGENE, V9, P97; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; MIDGLEY CA, 1992, J CELL SCI, V101, P183; Mount SM, 2000, AM J HUM GENET, V67, P788, DOI 10.1086/303098; Sedlacek Z, 1998, NUCLEIC ACIDS RES, V26, P214, DOI 10.1093/nar/26.1.214; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Varley JM, 1998, BRIT J CANCER, V78, P1081, DOI 10.1038/bjc.1998.631; Varley JM, 1999, AM J HUM GENET, V65, P995, DOI 10.1086/302575; Varley JM, 1998, ONCOGENE, V16, P3291, DOI 10.1038/sj.onc.1201878; Varley JM, 1997, ONCOGENE, V14, P865, DOI 10.1038/sj.onc.1201041; Varley JM, 1997, CANCER RES, V57, P3245; VARLEY JM, 1995, J MED GENET, V32, P942, DOI 10.1136/jmg.32.12.942; Varley JM, 1996, ONCOGENE, V12, P2437; Varley JM, 1997, BRIT J CANCER, V76, P1, DOI 10.1038/bjc.1997.328; Varley JM, 1996, CANCER GENET CYTOGEN, V90, P14, DOI 10.1016/0165-4608(96)00059-3; Verselis SJ, 2000, ONCOGENE, V19, P4230, DOI 10.1038/sj.onc.1203758; WARNEFORD SG, 1992, CELL GROWTH DIFFER, V3, P839	31	44	46	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 10	2001	20	21					2647	2654		10.1038/sj.onc.1204369	http://dx.doi.org/10.1038/sj.onc.1204369			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VN	11420676				2022-12-17	WOS:000168652600005
J	Nishimoto, A; Miura, N; Horikawa, I; Kugoh, H; Murakami, Y; Hirohashi, S; Kawasaki, H; Gazdar, AF; Shay, JW; Barrett, JC; Oshimura, M				Nishimoto, A; Miura, N; Horikawa, I; Kugoh, H; Murakami, Y; Hirohashi, S; Kawasaki, H; Gazdar, AF; Shay, JW; Barrett, JC; Oshimura, M			Functional evidence for a telomerase repressor gene on human chromosome 10p15.1	ONCOGENE			English	Article						microcell-mediated chromosome transfer; telomerase; chromosome 10p; telomerase repressor gene; hTERT	HUMAN PROSTATE-CANCER; CATALYTIC SUBUNIT HTERT; TUMOR-SUPPRESSOR GENES; CELLULAR SENESCENCE; EFFICIENT MODIFICATION; INSITU HYBRIDIZATION; MAMMALIAN TELOMERASE; IMMORTAL CELLS; HUMAN GLIOMAS; ALLELIC LOSS	Based on the sites of frequent allelic loss in hepatocellular carcinoma, five normal human chromosomes (2, 4, 5, 10 and 16) were transferred individually into a telomerase-positive human hepatocellular carcinoma cell line, Li7HM, by microcell-mediated chromosome transfer (MMCT). Chromosome 10, but not the others, repressed telomerase activity immediately and stopped cell growth after 50 population doublings (PDs), Loss of the transferred 10p loci resulted in the emergence of revertant cells that continued to proliferate and expressed telomerase activity, suggesting the presence of a telomerase repressor gene on this chromosomal arm. Transfer of a series of defined fragments from chromosome 10p successfully narrowed down the responsible region: a 28.9-cM region on 10p15 (between WI-4752 and D10S249), but not a 26.2-cM region (between D10S1728 and D10S249), caused repression of telomerase activity and progressive telomere shortening. A strong correlation between the expression level of telomerase catalytic subunit gene (hTERT) and telomerase activity was observed. These findings suggest that a novel telomerase repressor gene which controls the expression of hTERT is located on the 2.7-cM region (between WI-4752 and D10S1728) on chromosome 10p15.1.	Tottori Univ, Fac Med, Sch Life Sci, Dept Mol & Cell Genet, Tottori 6838503, Japan; NCI, Lab Biosyst & Canc, Canc & Aging Sect, Bethesda, MD 20892 USA; Natl Canc Ctr, Res Inst, Tumor Suppress & Funct Genom Project, Chuo Ku, Tokyo 1040045, Japan; Natl Canc Ctr, Res Inst, Div Pathol, Chuo Ku, Tokyo 1040045, Japan; Tottori Univ, Dept Internal Med 2, Tottori 6838503, Japan; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA	Tottori University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Cancer Center - Japan; National Cancer Center - Japan; Tottori University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Oshimura, M (corresponding author), Tottori Univ, Fac Med, Sch Life Sci, Dept Mol & Cell Genet, Tottori 6838503, Japan.		Shay, Jerry W/F-7878-2011					CHERIF D, 1989, HUM GENET, V81, P358, DOI 10.1007/BF00283691; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Cuthbert AP, 1999, JNCI-J NATL CANCER I, V91, P37, DOI 10.1093/jnci/91.1.37; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; Dieken ES, 1996, NAT GENET, V12, P174, DOI 10.1038/ng0296-174; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; HIROHASHI S, 1979, CANCER RES, V39, P1819; Horikawa I, 1998, MOL CARCINOGEN, V22, P65, DOI 10.1002/(SICI)1098-2744(199806)22:2<65::AID-MC1>3.0.CO;2-J; Horikawa I, 1999, CANCER RES, V59, P826; Ichimura K, 1998, GENE CHROMOSOME CANC, V22, P9, DOI 10.1002/(SICI)1098-2264(199805)22:1<9::AID-GCC2>3.0.CO;2-1; Ittmann M, 1996, CANCER RES, V56, P2143; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kimmelman AC, 1996, GENOMICS, V34, P250, DOI 10.1006/geno.1996.0277; KOI M, 1989, JPN J CANCER RES, V80, P413, DOI 10.1111/j.1349-7006.1989.tb02329.x; Komiya A, 1996, GENE CHROMOSOME CANC, V17, P245; Kon H, 1998, ONCOGENE, V16, P257, DOI 10.1038/sj.onc.1201488; Kugoh H, 1999, DNA Res, V6, P165, DOI 10.1093/dnares/6.3.165; Kuroiwa Y, 1998, NUCLEIC ACIDS RES, V26, P3447, DOI 10.1093/nar/26.14.3447; LENGAUER C, 1992, GENOMICS, V13, P826, DOI 10.1016/0888-7543(92)90160-T; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Miura N, 1997, CANCER GENET CYTOGEN, V93, P56, DOI 10.1016/S0165-4608(96)00329-9; Murakami Y, 2000, J HUM GENET, V45, P370, DOI 10.1007/s100380070011; Murakami YS, 1996, CANCER RES, V56, P2157; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; OHMURA H, 1995, JPN J CANCER RES, V86, P899, DOI 10.1111/j.1349-7006.1995.tb02998.x; Osada T, 1996, HEPATOLOGY, V24, P1460, DOI 10.1002/hep.510240627; Oshimura M, 1997, EUR J CANCER, V33, P710, DOI 10.1016/S0959-8049(97)00090-7; Robertson GP, 1999, CANCER RES, V59, P3596; Steenbergen RDM, 1996, ONCOGENE, V13, P1249; TAHARA H, 1995, CANCER RES, V55, P2734; Takakura M, 1999, CANCER RES, V59, P551; Tanaka H, 1998, GENE CHROMOSOME CANC, V23, P123, DOI 10.1002/(SICI)1098-2264(199810)23:2<123::AID-GCC5>3.0.CO;2-4; Trybus TM, 1996, CANCER RES, V56, P2263; UEJIMA H, 1995, GENE CHROMOSOME CANC, V14, P120, DOI 10.1002/gcc.2870140206; Voesten AMJ, 1997, GENE CHROMOSOME CANC, V20, P167, DOI 10.1002/(SICI)1098-2264(199710)20:2<167::AID-GCC7>3.0.CO;2-1; Wright WE, 1996, EMBO J, V15, P1734, DOI 10.1002/j.1460-2075.1996.tb00519.x; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794	41	44	46	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 15	2001	20	7					828	835		10.1038/sj.onc.1204165	http://dx.doi.org/10.1038/sj.onc.1204165			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314017				2022-12-17	WOS:000166924400006
J	Stivala, LA; Riva, F; Cazzalini, O; Savio, M; Prosperi, E				Stivala, LA; Riva, F; Cazzalini, O; Savio, M; Prosperi, E			p21(waf1/cip1)-null human fibroblasts are deficient in nucleotide excision repair downstream the recruitment of PCNA to DNA repair sites	ONCOGENE			English	Article						p21(waf1/cip1); nucleotide excision repair; PCNA; p21-null fibroblasts	CELL NUCLEAR ANTIGEN; DEPENDENT KINASE INHIBITOR; TRANSCRIPTION-COUPLED REPAIR; AGENTS 1,3-BIS(2-CHLOROETHYL)-1-NITROSOUREA; ULTRAVIOLET-IRRADIATION; QUIESCENT FIBROBLASTS; GLIOBLASTOMA CELLS; COMPLEX-FORMATION; POLYMERASE-DELTA; BINDING DOMAINS	The cyclin-dependent kinase inhibitor p21(waf1/cip1) is known to impair DNA synthesis by binding to PCNA, the cofactor of DNA polymerases delta and epsilon. However, a positive role for p21 in nucleotide excision repair (NER) has been suggested. In this study, the sensitivity to DNA damage and DNA repair efficiency were investigated in p21-null human fibroblasts obtained by targeted homologous recombination. After UV-C irradiation, p21(sic) cells showed a threefold reduction in clonogenic survival and an increased susceptibility to apoptosis, as compared with parental p21(+/+) cells. Removal of cyclobutane pyrimidine dimers was significantly reduced in p21(-/-) cells both in the whole genome, and at the level of the rDNA gene cluster, as determined by immunoassay and Southern blot, respectively. After DNA damage, the recruitment of PCNA as detergent-insoluble form associated to DNA repair sites in p21(sic) fibroblasts, was comparable to that observed in parental p21(+/+) cells, However, PCNA remained associated with DNA for a longer period in p21(sic) than in p21(+/+) cells, These results suggest that in human cells, p21 is required for NER at a step located downstream the recruitment of PCNA to DNA repair sites.	CNR, Ctr Studio Istochim, I-27100 Pavia, Italy; Univ Pavia, Dipartimento Med Sperimentale, Sez Patol Gen, I-27100 Pavia, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Pavia	Prosperi, E (corresponding author), CNR, Ctr Studio Istochim, Piazza Botta 10, I-27100 Pavia, Italy.		Prosperi, Ennio/A-3439-2014	Prosperi, Ennio/0000-0001-5391-5157				ABOUSSEKHRA A, 1995, EXP CELL RES, V221, P326, DOI 10.1006/excr.1995.1382; Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; Bohr VA, 1988, DNA REPAIR LABORATOR, V3, P347; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; CHEN IT, 1995, ONCOGENE, V11, P1931; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; CHRISTIANS FC, 1993, BIOCHEMISTRY-US, V32, P10512, DOI 10.1021/bi00090a030; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Cooper MP, 1999, MOL BIOL CELL, V10, P2119, DOI 10.1091/mbc.10.7.2119; Cox LS, 1997, TRENDS CELL BIOL, V7, P493, DOI 10.1016/S0962-8924(97)01170-7; Fan SJ, 1997, ONCOGENE, V14, P2127, DOI 10.1038/sj.onc.1201052; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; Ford JM, 1998, CANCER RES, V58, P599; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Fotedar R, 1996, ONCOGENE, V12, P2155; Fritz LK, 1996, J BIOL CHEM, V271, P12972, DOI 10.1074/jbc.271.22.12972; GOUBIN F, 1995, ONCOGENE, V10, P2281; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; McDonald E, 1996, CANCER RES, V56, P2250; McKay BC, 1998, ONCOGENE, V17, P545, DOI 10.1038/sj.onc.1201963; MITCHELL DL, 1990, BIOESSAYS, V12, P74, DOI 10.1002/bies.950120205; MIURA M, 1992, J CELL PHYSIOL, V150, P370, DOI 10.1002/jcp.1041500221; Mossi R, 1998, J BIOL CHEM, V273, P14322, DOI 10.1074/jbc.273.23.14322; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, pU3559; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; Prabhu NS, 1996, CLIN CANCER RES, V2, P1221; Prosperi E, 1997, Prog Cell Cycle Res, V3, P193; PROSPERI E, 1993, EXP CELL RES, V205, P320, DOI 10.1006/excr.1993.1092; Ruan S, 1998, CANCER RES, V58, P1538; Ruan SB, 1999, CLIN CANCER RES, V5, P197; Savio M, 1996, ONCOGENE, V13, P1591; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; Shivji MKK, 1998, ONCOGENE, V17, P2827, DOI 10.1038/sj.onc.1202352; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Therrien JP, 1999, P NATL ACAD SCI USA, V96, P15038, DOI 10.1073/pnas.96.26.15038; TOSCHI L, 1988, J CELL BIOL, V107, P1623, DOI 10.1083/jcb.107.5.1623; Van Sloun PPH, 1999, NUCLEIC ACIDS RES, V27, P3276, DOI 10.1093/nar/27.16.3276; VINK AA, 1994, J PHOTOCH PHOTOBIO B, V24, P25, DOI 10.1016/1011-1344(94)07005-9; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; Wood RD, 1997, CARCINOGENESIS, V18, P605, DOI 10.1093/carcin/18.4.605; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; Zhu QZ, 2000, J BIOL CHEM, V275, P11492, DOI 10.1074/jbc.275.15.11492	58	44	44	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 1	2001	20	5					563	570		10.1038/sj.onc.1204132	http://dx.doi.org/10.1038/sj.onc.1204132			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	398KE	11313988				2022-12-17	WOS:000166755000003
J	Inga, A; Monti, P; Fronza, G; Darden, T; Resnick, MA				Inga, A; Monti, P; Fronza, G; Darden, T; Resnick, MA			p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay	ONCOGENE			English	Article						p53; yeast; enhanced transactivation; dominance	TUMOR-SUPPRESSOR P53; WILD-TYPE; DNA-BINDING; SEQUENCE-SPECIFICITY; GENE-EXPRESSION; TERMINAL DOMAIN; CORE DOMAIN; CELL-LINES; CANCER; MUTATIONS	Changes in promoter specificity and binding affinity that may be associated with p53 mutations or post-translational modifications are useful in understanding p53 structure/ function relationships and categorizing tumor mutations. We have exploited variable expression of human p53 in yeast to identify mutants with novel phenotypes that would correspond to altered promoter selectivity and affinity. The p53 cDNA regions coding for the DNA binding and tetramerization domains were subjected to random PCR mutagenesis and were cloned directly by recombination in yeast into a vector with a GAL1 promoter whose level of expression could be easily varied. p53 variants exhibiting higher than wild type levels of transactivation (supertrans) for the RGC responsive element were identified at low level of p53 protein expression. All the p53 mutants obtained with this screen were located in the DNA binding domain. Two out of 17 supertrans mutants have been found in tumors. Six mutations were in the L1 loop region between amino acids 115 and 124, The transactivation potential of a panel of supertrans p53 mutants on different promoters was evaluated using the p53 responsive elements, RGC, PIG3, p21 and bax. Although all mutants retained some activity with all promoters, we found different patterns of induction based on strength and promoter specificity. In particular none of the mutants was supertrans for the p21 responsive element, Interestingly, further analysis in yeast showed that the transactivation function could be retained even in the presence of dominant-negative p53 tumor mutations that could inhibit wild type p53, Five mutants were also characterized in human cells in terms of growth suppression and transactivation of various promoters. These novel supertrans p53 mutants may be useful in studies aimed at dissecting p53 downstream pathways, understanding specific interactions between p53 and the DNA, and could replace wild type p53 in cancer gene therapy protocols. The approach may also prove useful in identifying p53 tumor mutations.	Natl Inst Environm Hlth Sci, Mol Genet Lab, Res Triangle Pk, NC 27709 USA; NCI, IST, Mutagenesis Lab, I-16132 Genoa, Italy; NIEHS, Struct Biol Lab, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Resnick, MA (corresponding author), Natl Inst Environm Hlth Sci, Mol Genet Lab, Mail Drop D3-01,111 TW Alexander Dr,POB 12233, Res Triangle Pk, NC 27709 USA.		resnick, Michael/F-1668-2019; Inga, Alberto/AAC-3815-2022; Monti, Paola/Y-1118-2019; Fronza, Gilberto/AAG-8735-2019	resnick, Michael/0000-0002-8473-7506; Inga, Alberto/0000-0002-8767-1637; Monti, Paola/0000-0002-1978-4998; Fronza, Gilberto/0000-0003-3722-553X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES065079, ZIAES065079] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aurelio ON, 2000, MOL CELL BIOL, V20, P770, DOI 10.1128/MCB.20.3.770-778.2000; Brachmann RK, 1996, P NATL ACAD SCI USA, V93, P4091, DOI 10.1073/pnas.93.9.4091; Brachmann RK, 1998, EMBO J, V17, P1847, DOI 10.1093/emboj/17.7.1847; Bullock AN, 2000, ONCOGENE, V19, P1245, DOI 10.1038/sj.onc.1203434; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; Chappuis PO, 1999, INT J CANCER, V84, P587, DOI 10.1002/(SICI)1097-0215(19991222)84:6<587::AID-IJC8>3.0.CO;2-8; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Cortes U, 2000, MOL CARCINOGEN, V27, P57, DOI 10.1002/(SICI)1098-2744(200002)27:2<57::AID-MC1>3.3.CO;2-9; Di Como CJ, 1998, ONCOGENE, V16, P2527; FERRIN TE, 1988, J MOL GRAPHICS, V6, P2, DOI 10.1016/0263-7855(88)80053-5; Flaman JM, 1998, ONCOGENE, V16, P1369, DOI 10.1038/sj.onc.1201889; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; FREBOURG T, 1994, CANCER RES, V54, P878; FREEMAN J, 1994, EMBO J, V13, P5393, DOI 10.1002/j.1460-2075.1994.tb06874.x; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Gagnebin J, 1998, ONCOGENE, V16, P685, DOI 10.1038/sj.onc.1201568; Gallagher WM, 1999, ANN ONCOL, V10, P139, DOI 10.1023/A:1008368500557; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hernandez-Boussard T, 1999, HUM MUTAT, V14, P1; HUXLEY C, 1990, TRENDS GENET, V6, P236, DOI 10.1016/0168-9525(90)90190-H; Inga A, 1997, CARCINOGENESIS, V18, P2019, DOI 10.1093/carcin/18.10.2019; Inga A, 1997, ONCOGENE, V14, P1307, DOI 10.1038/sj.onc.1200952; ISHIOKA C, 1995, ONCOGENE, V10, P1485; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; LIN JY, 1995, ONCOGENE, V10, P2387; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; McLure KG, 1999, EMBO J, V18, P763, DOI 10.1093/emboj/18.3.763; Meek DW, 1998, INT J RADIAT BIOL, V74, P729, DOI 10.1080/095530098141005; Nikolova PV, 2000, EMBO J, V19, P370, DOI 10.1093/emboj/19.3.370; Nikolova PV, 1998, P NATL ACAD SCI USA, V95, P14675, DOI 10.1073/pnas.95.25.14675; Okaichi K, 1999, INT J RADIAT ONCOL, V45, P975, DOI 10.1016/S0360-3016(99)00285-0; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Pan Y, 2000, ONCOGENE, V19, P3095, DOI 10.1038/sj.onc.1203663; Prives C, 1999, J PATHOL, V187, P112; Reis AM, 2000, CANCER RES, V60, P1571; Robert V, 2000, CARCINOGENESIS, V21, P563, DOI 10.1093/carcin/21.4.563; Saller E, 1999, EMBO J, V18, P4424, DOI 10.1093/emboj/18.16.4424; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; Selivanova G, 1999, MOL CELL BIOL, V19, P3395; Shimada A, 1999, CANCER RES, V59, P2781; Smith PD, 1999, ONCOGENE, V18, P2451, DOI 10.1038/sj.onc.1202565; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Swisher SG, 1999, J NATL CANCER I, V91, P763, DOI 10.1093/jnci/91.9.763; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Thornborrow EC, 1999, J BIOL CHEM, V274, P33747, DOI 10.1074/jbc.274.47.33747; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Vinyals A, 1999, GENE THER, V6, P22, DOI 10.1038/sj.gt.3300786; Walker DR, 1999, ONCOGENE, V18, P211, DOI 10.1038/sj.onc.1202298	57	44	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2001	20	4					501	513		10.1038/sj.onc.1204116	http://dx.doi.org/10.1038/sj.onc.1204116			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395DB	11313981				2022-12-17	WOS:000166562500010
J	Tsuji, T; Usui, S; Aida, T; Tachikawa, T; Hu, GF; Sasaki, A; Matsumura, T; Todd, R; Wong, DTW				Tsuji, T; Usui, S; Aida, T; Tachikawa, T; Hu, GF; Sasaki, A; Matsumura, T; Todd, R; Wong, DTW			Induction of epithelial differentiation and DNA demethylation in hamster malignant oral keratinocyte by ornithine decarboxylase antizyme	ONCOGENE			English	Article						oral cancer; hamster; ornithine decarboxylase antizyme; differentiation; DNA demethylation	MOUSE-TISSUE INHIBITOR; POUCH CARCINOGENESIS MODEL; ALPHA-DIFLUOROMETHYLORNITHINE; METHYLTRANSFERASE ACTIVITY; POLYAMINE LEVELS; GENE-EXPRESSION; RETINOIC ACID; COLON-CANCER; ANTITUMOR-ACTIVITY; METHYLATION STATUS	The hamster ornithine decarboxylase antizyme (ODC-Az) cDNA was transfected into the hamster malignant oral keratinocyte cell line, HCPC-1, Ectopic expression of ODC-Az resulted in the reversion of malignant phenotypes and alteration of DNA methylation status of CCGG sites. The phenotypes examined include ODC enzymatic activity, doubling time, morphological change, anchorage dependent growth, tumorigenicity in nude mice, induction of epithelial differentiation marker protein (involucrin), and change of cell cycle position. Comparison of CCGG DNA methylation status of the ODC-Az and control vector transfectants revealed a significant increase in demethylation of 5-methyl cytosines (m(5)C) of CCGG sites in the ODC-Az transfectants. Ectopic expression of ODC-Az gene in hamster malignant oral keratinocytes led to reduce ODC activity and the subsequent demethylation of 5-methyl cytosines, presumably via the ODC/ polyamines/ decarboxylated S-adenosylmethionine (dc-AdoMet) pathways. Our data suggest that ODC-Az shared the same pathway of polyamines/ dc-AdoMet/DNA methyltransferase (DNA MTase), We propose that ODC-Az mediates a novel mechanism in tumor suppression by DNA demethylation and presumably re-activation of key cellular genes silenced by DNA hypermethylation during cancer development.	Showa Univ, Sch Dent, Dept Oral Pathol, Tokyo 1428555, Japan; Harvard Univ, Sch Med, Dept Radiol, Ctr Biochem & Biophys Sci & Med, Boston, MA 02115 USA; Okayama Univ, Sch Dent, Dept Oral & Maxillofacial Surg 2, Okayama 7008525, Japan; Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA	Showa University; Harvard University; Harvard Medical School; Okayama University; Harvard University; Massachusetts General Hospital	Wong, DTW (corresponding author), Harvard Univ, Sch Dent Med, Dept Oral Med & Diagnost Sci, Div Oral Pathol, Boston, MA 02115 USA.				NIDCR NIH HHS [DE-12529, DE-11983, DE-12467] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R03DE012529, P01DE012467, R29DE011983] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Aringer M, 1999, LIFE SCI, V64, P2173, DOI 10.1016/S0024-3205(98)00538-4; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; Bachman KE, 1999, CANCER RES, V59, P798; BAYLIN SB, 1991, CANCER CELL-MON REV, V3, P383; Baylin SB, 1998, ADV CANCER RES, V72, P141; Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; BESTOR TH, 1984, MOL CELL BIOL, V4, P1800, DOI 10.1128/MCB.4.9.1800; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Chao C, 1996, CANCER RES, V56, P4811; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; CLIFFORD A, 1995, CANCER RES, V55, P1680; Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5; Duranton B, 1998, EXP CELL RES, V243, P319, DOI 10.1006/excr.1998.4148; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; FEUERSTEIN BG, 1991, J CELL BIOCHEM, V46, P37, DOI 10.1002/jcb.240460107; Freshney RI, 1994, CULTURE ANIMAL CELLS; Frostesjo L, 1997, J BIOL CHEM, V272, P4359, DOI 10.1074/jbc.272.7.4359; GAINES DW, 1988, ANAL BIOCHEM, V174, P88, DOI 10.1016/0003-2697(88)90522-2; GIMENEZCONTI IB, 1993, J CELL BIOCHEM, P83; GIMENEZCONTI IB, 1992, ADV EXP MED BIOL, V320, P63; GOSULE LC, 1978, J MOL BIOL, V121, P311, DOI 10.1016/0022-2836(78)90366-2; Harper JW, 1997, CANCER SURV, V29, P91; HAWTREY AO, 1984, MED HYPOTHESES, V15, P125, DOI 10.1016/0306-9877(84)90117-8; Hayashi S, 1996, TRENDS BIOCHEM SCI, V21, P27, DOI 10.1016/0968-0004(96)80882-6; HAYASHI S, 1989, ORNITHINE DECARBOXYL, P47; Heby O, 1995, INT J DEV BIOL, V39, P737; Heby O, 1988, Adv Exp Med Biol, V250, P291; Henkel AW, 1999, CELL TISSUE RES, V296, P229, DOI 10.1007/s004410051284; HICKOK NJ, 1992, J INVEST DERMATOL, V98, P327, DOI 10.1111/1523-1747.ep12499799; Iismaa T P, 1999, Results Probl Cell Differ, V26, P257; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; Ito T, 1999, HISTOL HISTOPATHOL, V14, P895, DOI 10.14670/HH-14.895; Iwata S, 1999, ONCOGENE, V18, P165, DOI 10.1038/sj.onc.1202275; Janssen BLM, 1999, MELANOMA RES, V9, P213, DOI 10.1097/00008390-199906000-00002; Kim HT, 1997, BIOCHEM J, V324, P547, DOI 10.1042/bj3240547; Kim SY, 1997, CANCER RES, V57, P38; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI XQ, 1994, MOL CELL BIOL, V14, P87, DOI 10.1128/MCB.14.1.87; LINDEN M, 1985, J CELL PHYSIOL, V125, P273, DOI 10.1002/jcp.1041250215; LUNDELL L, 1986, SCAND J GASTROENTERO, V21, P829, DOI 10.3109/00365528609011126; MAKOS M, 1992, P NATL ACAD SCI USA, V89, P1929, DOI 10.1073/pnas.89.5.1929; MAO Y, 1993, BIOCHEM J, V295, P641, DOI 10.1042/bj2950641; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; McCarty MF, 1997, MED HYPOTHESES, V48, P297, DOI 10.1016/S0306-9877(97)90098-0; MEGOSH L, 1995, CANCER RES, V55, P4205; Mehlen P, 1997, J BIOL CHEM, V272, P31657, DOI 10.1074/jbc.272.50.31657; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Mitchell JLA, 1996, BIOCHEM J, V317, P811, DOI 10.1042/bj3170811; Monzon RI, 1996, CELL GROWTH DIFFER, V7, P1751; ODUKOYA O, 1983, JNCI-J NATL CANCER I, V71, P1252; PAWELCZYK T, 1993, BIOCHEM PHARMACOL, V45, P493, DOI 10.1016/0006-2952(93)90087-D; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1987, BIOCHEM J, V241, P305, DOI 10.1042/bj2410305; Pennie WD, 1999, CELL GROWTH DIFFER, V10, P279; RADFORD DM, 1990, CANCER RES, V50, P6146; RIDEOUT WM, 1994, MOL CELL BIOL, V14, P6143, DOI 10.1128/MCB.14.9.6143; Rofstad EK, 2000, INT J RADIAT BIOL, V76, P589, DOI 10.1080/095530000138259; ROMANO M, 1986, INT J BIOL MARKER, V2, P77; Salzberg A, 1996, GENETICS, V144, P183; SAPIENZA C, 1991, BIOCHIM BIOPHYS ACTA, V1072, P51, DOI 10.1016/0304-419X(91)90006-7; Sark MWJ, 1998, J BIOL CHEM, V273, P24683, DOI 10.1074/jbc.273.38.24683; SEILER N, 1985, J CHROMATOGR, V339, P45, DOI 10.1016/S0378-4347(00)84626-5; SHIN DM, 1990, CANCER RES, V50, P2505; SUN Y, 1995, J BIOL CHEM, V270, P19312, DOI 10.1074/jbc.270.33.19312; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P747; Takaoka AS, 1998, J BIOL CHEM, V273, P33848, DOI 10.1074/jbc.273.50.33848; TAKIGAWA M, 1983, CANCER RES, V43, P3732; TAMORI A, 1994, HEPATOLOGY, V20, P1179, DOI 10.1002/hep.1840200512; TOMAYKO MM, 1989, CANCER CHEMOTH PHARM, V24, P148, DOI 10.1007/BF00300234; Tsuji T, 1998, ONCOGENE, V16, P3379, DOI 10.1038/sj.onc.1201887; Tulchinsky EM, 1996, ONCOGENE, V12, P1737; VERES DA, 1989, J INVEST DERMATOL, V93, P687, DOI 10.1111/1523-1747.ep12319883; VERMA AK, 1980, CANCER RES, V40, P308; Waltz DA, 1997, J CLIN INVEST, V100, P58, DOI 10.1172/JCI119521; WEEKS CE, 1982, P NATL ACAD SCI-BIOL, V79, P6028, DOI 10.1073/pnas.79.19.6028; WETTERS TV, 1989, NUCLEIC ACIDS RES, V17, P9843, DOI 10.1093/nar/17.23.9843; WILLIAMS HK, 1995, J ORAL PATHOL MED, V24, P322, DOI 10.1111/j.1600-0714.1995.tb01193.x; YEBRA MJ, 1995, BIOCHEMISTRY-US, V34, P14752, DOI 10.1021/bi00045a016; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179	83	44	49	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					24	33		10.1038/sj.onc.1204051	http://dx.doi.org/10.1038/sj.onc.1204051			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244502				2022-12-17	WOS:000166361400004
J	Schmid, M; Sen, M; Rosenbach, MD; Carrera, CJ; Friedman, H; Carson, DA				Schmid, M; Sen, M; Rosenbach, MD; Carrera, CJ; Friedman, H; Carson, DA			A methylthioadenosine phosphorylase (MTAP) fusion transcript identifies a new gene on chromosome 9p21 that is frequently deleted in cancer	ONCOGENE			English	Article						glioma; lung cancer; MTAP; tumor suppressor gene	SQUAMOUS-CELL CARCINOMA; IN-SITU HYBRIDIZATION; TUMOR-SUPPRESSOR GENE; CUTANEOUS MALIGNANT-MELANOMA; HOMOZYGOUS DELETIONS; BLADDER-CANCER; LUNG-CANCER; CDKN2 GENE; SHORT ARM; P15 MTS2	Homozygous deletions of human chromosome 9p21 occur frequently in malignant cell lines, and are also common in primary gliomas, lung cancers, and leukemias. Moving from the centromere to the telomere, this complex region encodes the tumor suppressor genes p15(INK4B) (CDKN2B), p14(ARF), P16(INK4A) (CDKN2A), and the housekeeping gene methylthioadenosine phosphorylase (MTAP). However, not all chromosome 9p21 deletions in tumors include these tumor suppressor genes. Here we describe the partial sequence and the exact localization of a nerv gene on chromosome 9p21 centromeric of p15(INK4B) that formed an in frame fusion transcript with MTAP in a glioma xenograft, and that is homozygously deleted in various malignant cell lines, Northern blot revealed corresponding 1.5 kb transcript in non-deleted cell lines as well as in normal lymphocytes, Using a RNA master blot membrane including 50 different tissues, we could show that this new transcript is expressed in all tissues of the adult but not or only at very low levels in most of the fetal tissues tested. The expression pattern is similar to that of p16(INK4A). The localization as well as the deletion pattern makes this transcript a candidate for a new tumor suppressor gene.	Univ Calif San Diego, Sam & Rose Stein Inst Res Aging, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Duke Univ, Dept Pediat, Durham, NC 27710 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Duke University	Friedman, H (corresponding author), Univ Ulm, Room 4608,Robert Koch Str 8, D-89070 Ulm, Germany.				NCI NIH HHS [CA6976] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An HX, 1996, GENE CHROMOSOME CANC, V17, P14, DOI 10.1002/(SICI)1098-2264(199609)17:1<14::AID-GCC3>3.3.CO;2-Y; Balazs M, 1997, GENE CHROMOSOME CANC, V19, P84, DOI 10.1002/(SICI)1098-2264(199706)19:2<84::AID-GCC3>3.3.CO;2-U; Batova A, 1996, BLOOD, V88, P3083, DOI 10.1182/blood.V88.8.3083.bloodjournal8883083; Cayuela JM, 1997, BLOOD, V90, P3720, DOI 10.1182/blood.V90.9.3720; Chen ZH, 1997, MOL PHARMACOL, V52, P903, DOI 10.1124/mol.52.5.903; Dreyling MH, 1998, GENE CHROMOSOME CANC, V22, P72, DOI 10.1002/(SICI)1098-2264(199805)22:1<72::AID-GCC10>3.3.CO;2-G; Farrell WE, 1997, CANCER RES, V57, P2703; Flores JF, 1996, CANCER RES, V56, P5023; Gonzalez MV, 1997, J CLIN PATHOL, V50, P509, DOI 10.1136/jcp.50.6.509; HABUCHI T, 1995, ONCOGENE, V11, P1671; HATTA Y, 1995, BLOOD, V85, P2699, DOI 10.1182/blood.V85.10.2699.bloodjournal85102699; Hori Y, 1998, INT J CANCER, V75, P51, DOI 10.1002/(SICI)1097-0215(19980105)75:1<51::AID-IJC9>3.0.CO;2-0; KEEN AJ, 1994, ONCOGENE, V9, P2083; Kim SK, 1997, CANCER RES, V57, P400; KRATZKE RA, 1995, J NATL CANCER I, V87, P1870, DOI 10.1093/jnci/87.24.1870; LI YJ, 1995, ONCOGENE, V11, P597; Marshall B, 1997, CANCER GENET CYTOGEN, V96, P134, DOI 10.1016/S0165-4608(96)00300-7; Matsuura K, 1998, ANTICANCER RES, V18, P453; MOULTON T, 1995, AM J PATHOL, V146, P613; NISHIKAWA R, 1995, CANCER RES, V55, P1941; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Okami K, 1997, INT J CANCER, V74, P588, DOI 10.1002/(SICI)1097-0215(19971219)74:6<588::AID-IJC5>3.3.CO;2-4; OLOPADE OI, 1992, CANCER RES, V52, P2523; ORLOW I, 1995, J NATL CANCER I, V87, P1524, DOI 10.1093/jnci/87.20.1524; Perry A, 1997, J NEUROPATH EXP NEUR, V56, P999, DOI 10.1097/00005072-199709000-00005; PUIG S, 1995, AM J HUM GENET, V57, P395; Ruiz A, 1998, INT J CANCER, V76, P312, DOI 10.1002/(SICI)1097-0215(19980504)76:3<312::AID-IJC4>3.3.CO;2-B; Schmid M, 1998, ONCOGENE, V17, P2669, DOI 10.1038/sj.onc.1202205; Stadler WM, 1996, UROL RES, V24, P239, DOI 10.1007/BF00295899; Tran PT, 1997, GENE, V186, P263, DOI 10.1016/S0378-1119(96)00718-4; Waber P, 1997, ONCOGENE, V15, P1699, DOI 10.1038/sj.onc.1201336; Wiest JS, 1997, CANCER RES, V57, P1; Yamada Y, 1997, J CLIN ONCOL, V15, P1778, DOI 10.1200/JCO.1997.15.5.1778	33	44	47	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 23	2000	19	50					5747	5754		10.1038/sj.onc.1203942	http://dx.doi.org/10.1038/sj.onc.1203942			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126361				2022-12-17	WOS:000165477700006
J	Holtrich, U; Wolf, G; Yuan, JP; Bereiter-Hahn, J; Karn, T; Weiler, M; Kauselmann, G; Rehli, M; Andreesen, R; Kaufmann, M; Kuhl, D; Strebhardt, K				Holtrich, U; Wolf, G; Yuan, JP; Bereiter-Hahn, J; Karn, T; Weiler, M; Kauselmann, G; Rehli, M; Andreesen, R; Kaufmann, M; Kuhl, D; Strebhardt, K			Adhesion induced expression of the serine/threonine kinase Fnk in human macrophages	ONCOGENE			English	Article						polo-like kinase; adhesion; macrophages; serine/threonine kinase	POLO-LIKE KINASES; PROTEIN-KINASE; DROSOPHILA-POLO; SIGNAL-TRANSDUCTION; BINDING PROTEIN; GENE; IDENTIFICATION; CLONING; SPINDLE; CELLS	Members of the polo subfamily of protein kinases play crucial roles in cell proliferation. To study the function of this family in more detail,,ve isolated the cDNA of human Fnk (FGF-inducible kinase) which codes for a serine/threonine kinase of 646 aa, Despite the homology to the proliferation-associated polo-like kinase (Plk), tissue distribution of Fnk transcripts and expression kinetics differed clearly, In contrast to Pile no correlation between cell proliferation and Fnk gene expression was found. Instead high levels of Fnk mRNA were detectable in blood cells undergoing adhesion. The transition of monocytes from peripheral blood to matrix bound macrophages was accompanied by increasing levels of Fnk with time in culture. Neither treatment of monocytes with inducers of differentiation nor withdrawal of serum did influence Fnk mRNA levels significantly, suggesting that cell attachment triggers the onset of Fnk gene transcription, The idea that Fnk is part of the signalling network controlling cellular adhesion was supported by the analysis of the cytoplasmic distribution of the Fnk protein and the influence of its overexpression on the cellular architecture. Fnk as fusion protein with GFP localized at the cellular membrane in COS cells. Dysregulated Fnk gene expression disrupted the cellular f-actin network and induced a spherical morphology. Furthermore, Fnk binds to the Ca2+/integrin-binding protein Cib in two-hybrid-analyses and co-immunoprecipitation in assays. Moreover, both proteins were shown to co-localize in mammalian cells, The homology of Cib with calmodulin and with calcineurin B suggests that Cib might be a regulatory subunit of polo-like kinases.	Goethe Univ Frankfurt, Dept Obstet & Gynecol, D-60590 Frankfurt, Germany; Goethe Univ Frankfurt, Dept Biol, D-60439 Frankfurt, Germany; Univ Hamburg, Zentrum Mol Neurobiol, ZMNH, D-20246 Hamburg, Germany; Univ Regensburg, Dept Hematol & Oncol, D-93042 Regensburg, Germany	Goethe University Frankfurt; Goethe University Frankfurt; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Regensburg	Strebhardt, K (corresponding author), Goethe Univ Frankfurt, Dept Obstet & Gynecol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.		Rehli, Michael/E-9093-2011; Kuhl, Dietmar/A-4689-2009; Strebhardt, Klaus/E-8765-2011; Karn, Thomas/AAE-7723-2019; karn, t/C-7452-2013	Rehli, Michael/0000-0003-3992-932X; Kuhl, Dietmar/0000-0002-4772-6701; Karn, Thomas/0000-0002-3264-6573; karn, t/0000-0002-3264-6573; Strebhardt, Klaus/0000-0003-2173-9763				BEREITERHAHN J, 1990, J CELL SCI, V96, P171; BRIESEN HV, 1990, VIROLOGY, V178, P597; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Chase D, 1998, BIOCHEM J, V333, P655, DOI 10.1042/bj3330655; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLAY FJ, 1993, P NATL ACAD SCI USA, V90, P4882, DOI 10.1073/pnas.90.11.4882; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; Feng Y, 1999, BIOCHEM J, V339, P435, DOI 10.1042/0264-6021:3390435; FENTON B, 1993, NATURE, V363, P637, DOI 10.1038/363637a0; FODE C, 1994, P NATL ACAD SCI USA, V91, P6388, DOI 10.1073/pnas.91.14.6388; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; HAMANAKA R, 1994, CELL GROWTH DIFFER, V5, P249; HOLTRICH U, 1991, P NATL ACAD SCI USA, V88, P10411, DOI 10.1073/pnas.88.23.10411; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Karn T, 1997, ONCOL REP, V4, P505; Kauselmann G, 1999, EMBO J, V18, P5528, DOI 10.1093/emboj/18.20.5528; Keenan C, 1998, CELL SIGNAL, V10, P225, DOI 10.1016/S0898-6568(97)00121-6; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; LAKE RJ, 1993, MOL CELL BIOL, V13, P7793, DOI 10.1128/MCB.13.12.7793; Lane HA, 1997, TRENDS CELL BIOL, V7, P63, DOI 10.1016/S0962-8924(96)10051-9; LEE KS, 1995, MOL CELL BIOL, V15, P7143; LI B, 1996, J BIOL CHEM, V271, P19042; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; Naik UP, 1997, J BIOL CHEM, V272, P4651, DOI 10.1074/jbc.272.8.4651; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; SUNKEL CE, 1988, J CELL SCI, V89, P25; Tavares AAM, 1996, EMBO J, V15, P4873, DOI 10.1002/j.1460-2075.1996.tb00868.x; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; VUORI K, 1993, J BIOL CHEM, V268, P21459	38	44	49	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2000	19	42					4832	4839		10.1038/sj.onc.1203845	http://dx.doi.org/10.1038/sj.onc.1203845			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039900				2022-12-17	WOS:000089757800005
J	Sitterlin, D; Bergametti, F; Transy, C				Sitterlin, D; Bergametti, F; Transy, C			UVDDB p127-binding modulates activities and intracellular distribution of hepatitis B virus X protein	ONCOGENE			English	Article						hepatitis B virus; X protein; UV-damaged DNA-binding protein; transactivation; apoptosis; nuclear import	NF-KAPPA-B; CELLULAR DNA-REPAIR; HBX PROTEIN; NUCLEAR IMPORT; GENE PRODUCT; DAMAGED DNA; TRANSACTIVATION FUNCTION; TRANSCRIPTION MACHINERY; BINDING; ACTIVATION	Mammalian hepatitis B, viruses encode a unique regulatory protein termed X, which is essential for infection and likely plays a role in the carcinogenic process associated with hepadnaviral infection. Among the numerous properties ascribed to X protein, two have been widely documented: promiscuous transcriptional transactivation and proapoptosis. However, full understanding of the mechanisms underlying these activities requires the identification of the genuine X partners among the multiple X-binding: host proteins. Here we show that (i) mutations in X protein, which markedly alter affinity for the host protein UVDDBp127, inactivate both transactivation and proapoptosis; (ii) ectopic fusion of a functional UVDDB-binding domain to a deficient binding;X mutant restored its activity; (iii) in contrast to the loss-of-binding mutants, a mutant with a strong gain-of-binding exerted trans-dominant negative effects on wt X activity and localized in the nucleus and (iv) increase in intracellular UVDDB concentration enhanced both wt X-mediated transactivation and apoptosis, Taken together, our data provide strong evidence for a common upstream step in X mode of action, consisting of its productive interaction with UVDDB, via a structurally and functionally autonomous module. In addition, they underscore a nuclear location step of the viral protein that depends on its ability to bind UVDDB.	Inst Pasteur, Unite Recombinais & Express Genet, INSERM, U163, F-75724 Paris 15, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Transy, C (corresponding author), Inst Pasteur, Unite Recombinais & Express Genet, INSERM, U163, 28 Rue Dr Roux, F-75724 Paris 15, France.							BEASLEY RP, 1981, LANCET, V2, P1129; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; Benning H, 1995, Ger J Ophthalmol, V4, P11; Bergametti F, 1999, ONCOGENE, V18, P2860, DOI 10.1038/sj.onc.1202643; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; Chirillo P, 1996, J VIROL, V70, P641, DOI 10.1128/JVI.70.1.641-646.1996; COLGROVE R, 1989, J VIROL, V63, P4019, DOI 10.1128/JVI.63.9.4019-4026.1989; Dandri M, 1998, J VIROL, V72, P9359, DOI 10.1128/JVI.72.11.9359-9364.1998; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; GIRONES R, 1989, P NATL ACAD SCI USA, V86, P1846, DOI 10.1073/pnas.86.6.1846; Haviv I, 1996, EMBO J, V15, P3413, DOI 10.1002/j.1460-2075.1996.tb00707.x; Henkler F, 1998, J GEN VIROL, V79, P2737, DOI 10.1099/0022-1317-79-11-2737; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HWANG BJ, 1993, BIOCHEMISTRY-US, V32, P1657, DOI 10.1021/bi00057a033; Kane MA, 1998, VACCINE, V16, pS104, DOI 10.1016/S0264-410X(98)00308-9; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; Kumar V, 1996, P NATL ACAD SCI USA, V93, P5647, DOI 10.1073/pnas.93.11.5647; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Lee YH, 1998, J BIOL CHEM, V273, P25510, DOI 10.1074/jbc.273.39.25510; Lin Y, 1998, J BIOL CHEM, V273, P27097, DOI 10.1074/jbc.273.42.27097; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; RUNKEL L, 1993, VIROLOGY, V197, P529, DOI 10.1006/viro.1993.1626; SCHODEL F, 1989, ADV VIRAL ONCOL, V8, P73; Shiyanov P, 1999, MOL CELL BIOL, V19, P4935; Sitterlin D, 2000, ONCOGENE, V19, P4427, DOI 10.1038/sj.onc.1203770; Sitterlin D, 1997, J VIROL, V71, P6194, DOI 10.1128/JVI.71.8.6194-6199.1997; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Su Q, 1998, HEPATOLOGY, V27, P1109, DOI 10.1002/hep.510270428; TAKAO M, 1993, NUCLEIC ACIDS RES, V21, P4111, DOI 10.1093/nar/21.17.4111; TRANSY C, 1995, MOL BIOL REP, V21, P119, DOI 10.1007/BF00986502; Turpin P, 1999, J BIOL CHEM, V274, P6804, DOI 10.1074/jbc.274.10.6804; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; Weil R, 1999, MOL CELL BIOL, V19, P6345; Yen T. S. Benedict, 1996, Journal of Biomedical Science, V3, P20	41	44	45	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	2000	19	38					4417	4426		10.1038/sj.onc.1203771	http://dx.doi.org/10.1038/sj.onc.1203771			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980617				2022-12-17	WOS:000089271900012
J	Yanagisawa, K; Uchida, K; Nagatake, M; Masuda, A; Sugiyama, M; Saito, T; Yamaki, K; Takahashi, T; Osada, H				Yanagisawa, K; Uchida, K; Nagatake, M; Masuda, A; Sugiyama, M; Saito, T; Yamaki, K; Takahashi, T; Osada, H			Heterogeneities in the biological and biochemical functions of Smad2 and Smad4 mutants naturally occurring in human lung cancers	ONCOGENE			English	Article						Smad; transforming growth factor-beta; lung cancer; growth inhibition; oligomerization	TRANSFORMING-GROWTH-FACTOR; MAD-RELATED PROTEIN; BRONCHIAL EPITHELIAL-CELLS; TUMOR-SUPPRESSOR SMAD4; IN-VIVO ALTERATIONS; TGF-BETA; SIGNAL-TRANSDUCTION; DNA-BINDING; DPC4 GENE; RECEPTOR	Smad family members are essential intracellular signaling components of the transforming growth factor-beta (TGF-beta) superfamily involved in a range of biological activities. The loss of sensitivity to TGF-beta is frequent in human lung cancers and inactivation of Smad family members are thought to play important roles in disruption of TGF-beta signaling. In the study presented here, we characterized the biological and biochemical functions of six Smad2 and Smad4 mutants, which we previously identified in human lung cancers. All mutant Smad2 and Smad4 were in fact found to be defective in transmitting growth inhibitory signals originating from TGF-beta and incapable of activating Smad/hFAST-1-mediated transcription. Transcriptional activation of plasminogen activator inhibitor type 1 (PAI-1) was impaired in four of the six mutants due to the defects in homo- and/or hetero-oligomerization with wild-type Smads, In contrast, the remaining two Smad mutants showed a modest reduction in the PAI-1 transcriptional activation and apparently retained the ability to oligomerize with wild-type Smads, Significant loss of growth inhibition and Smad/hFAST-1-mediated transcriptional activation by all of the six mutants suggested that Smad mutants are indeed functionally impaired Smad mutations and may play a role in lung tumorigenesis, Moreover, the present findings suggest that in addition to the impairment in the homo- and/or hetero-oligomerization, there may be an alternative mechanism producing disruption of TGF-beta signaling, involving hFAST-1-or possibly other transcriptional cofactor(s)-mediated transcriptional activation.	Aichi Canc Ctr, Res Inst, Lab Ultrastruct Res, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr, Res Inst, Pathophysiol Unit, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Nagoya Univ, Sch Med, Dept Internal Med 2, Showa Ku, Nagoya, Aichi 4668550, Japan	Aichi Cancer Center; Aichi Cancer Center; Nagoya University	Takahashi, T (corresponding author), Aichi Canc Ctr, Res Inst, Lab Ultrastruct Res, Chikusa Ku, Nagoya, Aichi 4648681, Japan.		Yanagisawa, Kiyoshi/I-7263-2014; Osada, Hiroyuki/AAY-6254-2020; Takahashi, Takashi/I-7262-2014	Takahashi, Takashi/0000-0003-0615-7001				Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Derynck R, 1996, CELL, V87, P173, DOI 10.1016/S0092-8674(00)81335-5; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; KINGSLEY DM, 1994, TRENDS GENET, V10, P16, DOI 10.1016/0168-9525(94)90014-0; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lechleider RJ, 1996, J BIOL CHEM, V271, P17617, DOI 10.1074/jbc.271.30.17617; LEDAI J, 1998, CANCER RES, V58, P4592; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Masuda A, 1997, CANCER RES, V57, P4898; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nagatake M, 1996, CANCER RES, V56, P2718; REDDEL RR, 1988, CANCER RES, V48, P1904; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Riggins GJ, 1997, CANCER RES, V57, P2578; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; Schutte M, 1996, CANCER RES, V56, P2527; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Uchida K, 1996, CANCER RES, V56, P5583; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	35	44	47	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 4	2000	19	19					2305	2311		10.1038/sj.onc.1203591	http://dx.doi.org/10.1038/sj.onc.1203591			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZR	10822381				2022-12-17	WOS:000086974300005
J	Chang, J; Lee, C; Hahm, KB; Yi, Y; Choi, SG; Kim, SJ				Chang, J; Lee, C; Hahm, KB; Yi, Y; Choi, SG; Kim, SJ			Over-expression of ERT(ESX/ESE-1/ELF3), an ets-related transcription factor, induces endogenous TGF-beta type II receptor expression and restores the TGF-beta signaling pathway in Hs578t human breast cancer cells	ONCOGENE			English	Article						transcription factor; cancer; TGF-beta; tumorigenicity	GROWTH-FACTOR-BETA; MICROSATELLITE INSTABILITY; DOMAIN PROTEIN; GENE; FAMILY; INHIBITION; MEMBER; COLON; CDNA	The epithelium-specific transcription factor, ERT/ESX/ ESE-1/ELF3, binds to the TGF-beta RII promoter in a sequence specific manner and regulates its expression, In this study, we investigated whether ERT could regulate endogenous TGF-beta RII expression in Hs578t breast cancer cells. Analyses of the Hs578t parental cell line revealed ion RII mRNA expression and resistance to the growth inhibitory effects of TGF-beta. Infection of this cell Line with a retroviral construct expressing ERT induced higher levels of endogenous RII mRNA expression and protein expression relative to cells infected with chloramphenicol acetyltransferase (CATneo) as a control. Relative to control cells, the ERTneo-expressing Hs578t cells show approximately a 50% reduction in cell growth in the presence of exogenous TGF-beta 1, as well as a fourfold higher induction of activation in transient transfection assays using the 3TP-luciferase reporter construct. When transplanted into athymic mice, ERT-expressing Hs578t cells showed decreased and delayed tumorigenicity compared with control cells. This data strongly suggests that ERT plays an important role as a transcriptional activator of TGF-P RII expression, and that deregulated ERT expression may play a critical role in rendering Hs578t human breast cancer cells insensitive to TGF-beta's growth inhibitory effects.	NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kim, SJ (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA.							CAPOCASALE RJ, 1995, P NATL ACAD SCI USA, V92, P5501, DOI 10.1073/pnas.92.12.5501; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Chang J, 1997, CANCER RES, V57, P2856; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; KADIN ME, 1994, P NATL ACAD SCI USA, V91, P6002, DOI 10.1073/pnas.91.13.6002; Kim David H., 1996, Journal of Biomedical Science, V3, P143, DOI 10.1007/BF02253095; Kim IY, 1996, CANCER RES, V56, P44; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; MYEROFF LL, 1995, CANCER RES, V55, P5545; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; OHASHI T, 1992, P NATL ACAD SCI USA, V89, P11332, DOI 10.1073/pnas.89.23.11332; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	25	44	49	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					151	154		10.1038/sj.onc.1203252	http://dx.doi.org/10.1038/sj.onc.1203252			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644990				2022-12-17	WOS:000084844300017
J	Kiaris, H; Schally, AV; Sun, B; Armatis, P; Groot, K				Kiaris, H; Schally, AV; Sun, B; Armatis, P; Groot, K			Inhibition of growth of human malignant glioblastoma in nude mice by antagonists of bombesin/gastrin-releasing peptide	ONCOGENE			English	Article						brain tumors; cancer therapy; peptide analogs; oncogene stimulation; autocrine; paracrine	CELL LUNG-CANCER; SOMATOSTATIN ANALOG RC-160; BINDING AFFINITIES; MESSENGER-RNA; IN-VITRO; C-FOS; RC-3095; RECEPTORS; CARCINOMA; LINES	The effects of antagonists of bombesin/gastrin-releasing peptide (GRP) on the growth of human malignant glioblastoma cell line U-87MG xenografted into nude mice were evaluated. Nude mice bearing s.c. implanted U-87MG tumors were treated with bombesin/GRP antagonists RC-3095 and RC-3940-II. RC-3095 and RC-3940-II administered s.c. at a dose of 20 mu g/day for 4 weeks decreased the volume of U-87MG xenografts by 60 and 74%, respectively, compared with controls. RT-PCR analysis showed that U-87MG xenografts expressed mRNA for bombesin receptor subtype (BRS)-1 (GRP receptor) and BRS-2 (neuromedin-B receptor), but the mRNA for GRP ligand was not detected in U-87MG cells suggesting that GRP may stimulate the growth of U-87MG glioblastomas by a paracrine mechanism. The levels of mRNA for c-fos oncogene mere decreased by 30-40% in U-87MG tumors treated with RC-3095 or RC-3940-II. In U-373MG glioblastoma cells, which also express BRS-1, and U-87MG cells, cultured in vitro, GRP(14-27) induced the expression of c-fos mRNA, and some c-jun mRNA, in a time-dependent manner with the maximal effect occurring 2 h after the stimulation and a return to basal levels after 8 h. Antagonist RC-3940-II inhibited the stimulation of c-fos by GRP(14-27), Our results indicate that antagonists of bombesin/GRP inhibit the growth of U-87MG glioblastomas by a mechanism that may involve the downregulation of c-fos oncogene.	Vet Adm Med Ctr, Inst Endocrine Polypeptide & Canc, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Dept Med, Sect Expt Med, New Orleans, LA 70112 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Tulane University	Schally, AV (corresponding author), Vet Adm Med Ctr, Inst Endocrine Polypeptide & Canc, 1601 Perdido St, New Orleans, LA 70112 USA.			Schally, Andrew/0000-0003-1273-6747; Kiaris, Hippokratis/0000-0002-8999-8289				DRAOUI M, 1993, CELL GROWTH DIFFER, V4, P723; DRAOUI M, 1995, PEPTIDES, V16, P289, DOI 10.1016/0196-9781(94)00173-1; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; Halmos G, 1997, P NATL ACAD SCI USA, V94, P956, DOI 10.1073/pnas.94.3.956; HOCHBERG F, 1987, HARRISONS PRINCIPLES, P1968; Koppan M, 1998, CANCER, V83, P1335, DOI 10.1002/(SICI)1097-0142(19981001)83:7<1335::AID-CNCR10>3.0.CO;2-5; LIEBOW C, 1994, P NATL ACAD SCI USA, V91, P3804, DOI 10.1073/pnas.91.9.3804; MAHMOUD S, 1991, CANCER RES, V51, P1798; MOODY TW, 1979, BIOCHEM BIOPH RES CO, V90, P7, DOI 10.1016/0006-291X(79)91582-1; MOODY TW, 1987, BIOCHEM BIOPH RES CO, V147, P189, DOI 10.1016/S0006-291X(87)80105-5; MOODY TW, 1981, SCIENCE, V214, P1246, DOI 10.1126/science.6272398; MOODY TW, 1989, J MOL NEUROSCI, V1, P235; OLSON JJ, 1988, CANCER, V61, P952, DOI 10.1002/1097-0142(19880301)61:5<952::AID-CNCR2820610516>3.0.CO;2-R; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; PAOLETTI P, 1990, J NEUROSURG, V73, P736, DOI 10.3171/jns.1990.73.5.0736; PINSKI J, 1994, BRIT J CANCER, V70, P886, DOI 10.1038/bjc.1994.415; PINSKI J, 1994, INT J CANCER, V57, P574, DOI 10.1002/ijc.2910570422; PINSKI J, 1993, J CLIN ENDOCR METAB, V77, P1388, DOI 10.1210/jc.77.5.1388; PINSKI J, 1994, CANCER RES, V54, P5895; PINSKI J, 1994, CANCER RES, V54, P169; Poisson M, 1983, J Neurooncol, V1, P179, DOI 10.1007/BF00165601; QIN YF, 1994, J CANCER RES CLIN, V120, P519, DOI 10.1007/BF01221028; QIN YF, 1994, CANCER RES, V54, P1035; RADULOVIC S, 1991, INT J PEPT PROT RES, V38, P593; REILE H, 1995, INT J ONCOL, V7, P749; Schally A.V., 1997, CANCER MED-US, V4th, P1067; SCHOENBERG BS, 1983, ONCOLOGY NERVOUS SYS, P1; Sharif TR, 1997, MOL CELL ENDOCRINOL, V130, P119, DOI 10.1016/S0303-7207(97)00080-4; SIEGFRIED JM, 1994, J BIOL CHEM, V269, P8596; SPINDEL ER, 1993, RECENT PROG HORM RES, V48, P365; STALEY J, 1993, J MOL NEUROSCI, V4, P29, DOI 10.1007/BF02736688; SZEPESHAZI K, 1992, J NATL CANCER I, V84, P1915, DOI 10.1093/jnci/84.24.1915; SZEPESHAZI K, 1991, CANCER RES, V51, P5980; WANG QJ, 1996, INT J CANCER, V68, P1; YANO T, 1992, CANCER RES, V52, P4545	35	44	47	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7168	7173		10.1038/sj.onc.1203213	http://dx.doi.org/10.1038/sj.onc.1203213			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597318				2022-12-17	WOS:000083901900024
J	Xi, HK; Eason, DD; Ghosh, D; Dovhey, S; Wright, KL; Blanck, G				Xi, HK; Eason, DD; Ghosh, D; Dovhey, S; Wright, KL; Blanck, G			Co-occupancy of the interferon regulatory element of the class II transactivator (CIITA) Type IV promoter by interferon regulatory factors 1 and 2	ONCOGENE			English	Article						IRF-1; IRF-2; CIITA	RETINOBLASTOMA PROTEIN RESCUE; TRANSCRIPTION FACTOR IRF-2; CELL-ADHESION MOLECULE-1; IFN-GAMMA INDUCIBILITY; DNA-BINDING DOMAIN; GENE-TRANSCRIPTION; IN-VIVO; ACTIVATION DOMAIN; MESSENGER-RNA; FACTOR FAMILY	Class II transactivator (CIITA) activates the expression of major histocompatibility class II genes, which encode antigen-presenting molecules recognized by the T-cell receptor of CD4+ T cells. IFN-gamma induced CIITA transcription in many cell types is directed by the CIITA Type IV promoter. Here we report that the human CIITA Type IV promoter TRF-E binds IRF-1 and can be activated by exogenous expression of IRF-1. Surprisingly, the CIITA Type IV promoter IRF-E is also activated by IRF-2, another member of the IRF family that generally acts as a transcriptional repressor. In addition, we found that IRF-1 and IRF-2 synergistically activate the CIITA Type IV promoter. Electrophoretic mobility shift assays revealed that IRF-1 and IRF-2 can simultaneously occupy the IRF-E of the CIITA Type IV promoter, suggesting a novel mechanism for the role of these two proteins in promoter activation. Our results also indicate that IRF-1 and IRF-2 can cooperatively activate and co-occupy the IRF-E of the guanylate binding protein (GBP) promoter. Finally, CIITA induction by IFN-gamma does not occur in a pancreatic tumor cell line that expresses a mutated IRF-2, representing the first IRF-2 mutation identified in a human tumor cell line.	Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Med Microbiol & Immunol, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Program Immunol, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Blanck, G (corresponding author), Univ S Florida, Coll Med, Dept Biochem & Mol Biol, 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.		Blanck, George/A-5365-2012					Aragane Y, 1997, J IMMUNOL, V158, P5393; BENECH P, 1987, MOL CELL BIOL, V7, P4498, DOI 10.1128/MCB.7.12.4498; Birnbaum MJ, 1997, J CELL BIOCHEM, V66, P175, DOI 10.1002/(SICI)1097-4644(19970801)66:2<175::AID-JCB5>3.0.CO;2-N; BLANAR MA, 1989, EMBO J, V8, P1139, DOI 10.1002/j.1460-2075.1989.tb03484.x; BLANCK G, 1990, HUM IMMUNOL, V29, P150, DOI 10.1016/0198-8859(90)90078-4; BRIKEN V, 1995, MOL CELL BIOL, V15, P975; CHA Y, 1994, J BIOL CHEM, V269, P5279; CHANG CH, 1995, J EXP MED, V181, P765, DOI 10.1084/jem.181.2.765; CHANG CH, 1992, IMMUNOGENETICS, V35, P378; CHIN KC, 1994, IMMUNITY, V1, P687, DOI 10.1016/1074-7613(94)90039-6; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Escalante CR, 1998, NATURE, V391, P103, DOI 10.1038/34224; Faggioli L, 1997, EUR J IMMUNOL, V27, P3022, DOI 10.1002/eji.1830271140; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; GRANT CE, 1995, NUCLEIC ACIDS RES, V23, P2137, DOI 10.1093/nar/23.12.2137; HARADA H, 1994, ONCOGENE, V9, P3313; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; Hobart M, 1997, J IMMUNOL, V158, P4260; Jesse TL, 1998, J CELL BIOL, V140, P1265, DOI 10.1083/jcb.140.5.1265; KERN I, 1995, INT IMMUNOL, V7, P1295, DOI 10.1093/intimm/7.8.1295; KINGSTON RE, 1997, CURRENT PROTOCOLS MO; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; Kusumoto M, 1998, J STRUCT BIOL, V121, P363, DOI 10.1006/jsbi.1998.3970; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; LIWEBER M, 1994, J IMMUNOL, V153, P4122; Lu Y, 1997, IMMUNOL CELL BIOL, V75, P325, DOI 10.1038/icb.1997.50; Lu YM, 1996, J IMMUNOL, V156, P2495; Luo W, 1996, J BIOL CHEM, V271, P23445, DOI 10.1074/jbc.271.38.23445; MartinezSoria E, 1996, INT IMMUNOL, V8, P543, DOI 10.1093/intimm/8.4.543; Min W, 1996, J IMMUNOL, V156, P3174; Muhlethaler-Mottet A, 1998, IMMUNITY, V8, P157, DOI 10.1016/S1074-7613(00)80468-9; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; NELSON N, 1993, MOL CELL BIOL, V13, P588, DOI 10.1128/MCB.13.1.588; Nozawa H, 1998, INT J CANCER, V77, P522, DOI 10.1002/(SICI)1097-0215(19980812)77:4<522::AID-IJC8>3.0.CO;2-W; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; Piskurich JF, 1999, MOL CELL BIOL, V19, P431; Pongubala JMR, 1997, P NATL ACAD SCI USA, V94, P127, DOI 10.1073/pnas.94.1.127; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; REITH W, 1990, GENE DEV, V4, P1528, DOI 10.1101/gad.4.9.1528; Sambrook J., 1989, MOL CLONING, pA1; Schaefer BC, 1997, MOL CELL BIOL, V17, P873, DOI 10.1128/MCB.17.2.873; SIEGRIST CA, 1995, J EXP MED, V182, P1793, DOI 10.1084/jem.182.6.1793; Spink J, 1997, J BIOL CHEM, V272, P24417, DOI 10.1074/jbc.272.39.24417; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TANIGUCHI T, 1995, J CANCER RES CLIN, V121, P516, DOI 10.1007/BF01197763; Taniguchi T, 1997, BBA-REV CANCER, V1333, pM9, DOI 10.1016/S0304-419X(97)00014-0; Ting JPY, 1997, J IMMUNOL, V159, P5457; VAUGHAN PS, 1995, NATURE, V377, P362, DOI 10.1038/377362a0; Vaughan PS, 1998, J BIOL CHEM, V273, P194, DOI 10.1074/jbc.273.1.194; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; Wang IM, 1996, MOL CELL BIOL, V16, P6313; Westerheide SD, 1997, J IMMUNOL, V158, P4812; White LC, 1996, IMMUNITY, V5, P365, DOI 10.1016/S1074-7613(00)80262-9; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; WRIGHT KL, 1995, J EXP MED, V181, P1459, DOI 10.1084/jem.181.4.1459; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; Yamagata T, 1996, MOL CELL BIOL, V16, P1283; YAMAMOTO H, 1994, ONCOGENE, V9, P1423; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang LW, 1997, MOL CELL BIOL, V17, P5748, DOI 10.1128/MCB.17.10.5748	68	44	44	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	1999	18	43					5889	5903		10.1038/sj.onc.1202969	http://dx.doi.org/10.1038/sj.onc.1202969			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248JE	10557076				2022-12-17	WOS:000083270700006
J	Kazianis, S; Morizot, DC; Della Coletta, L; Johnston, DA; Woolcock, B; Vielkind, JR; Nairn, RS				Kazianis, S; Morizot, DC; Della Coletta, L; Johnston, DA; Woolcock, B; Vielkind, JR; Nairn, RS			Comparative structure and characterization of a CDKN2 gene in a Xiphophorus fish melanoma model	ONCOGENE			English	Article						X. helleri; X. maculatus; CDKN2X; tumor suppressor; Xmrk; oncogene	GROWTH-FACTOR RECEPTOR; POLYMERASE CHAIN-REACTION; TUMOR-SUPPRESSOR GENE; CELL-CYCLE ARREST; LINKAGE GROUP-V; MALIGNANT-MELANOMA; HUMAN CANCERS; P16 PROTEIN; MOLECULAR MECHANISMS; XMRK ONCOGENE	We have cloned, sequenced, and characterized the RNA expression properties of a fish CDKN2 gene from Xiphophorus us helleri and X. maculatus. This gene, termed CDKN2X, shows a high degree of amino acid sequence similarity to members of the mammalian CDKN2 gene family, which includes the tumor suppressor loci CDKN2A (P16) and CDKN2B (P15). Comparative sequence analysis suggests that fish CDKN2X is similarly related to all four mammalian gene family members, and may represent a descendant of an ancestral prototypic CDKN2 gene. CDKN2X was mapped to a region on autosomal Xiphophorus linkage group V (LG V) known to contain the DIFF gene that acts as a tumor suppressor of melanoma formation in X. helleri/X. maculatus backcross hybrids. Thus, CDKN2X may be a candidate for the tumor suppressor DIFF gene. Here we have sequenced CDKN2X in both Xiphophorus species and have characterized its expression in normal. and melanotic tissues within control and backcross hybrid fish. A simultaneous expressional analysis of the Xmrk-2 tyrosine kinase receptor gene, which is strongly implicated in melanomagenesis in this system, was also performed. RT-PCR analyses revealed that both genes were highly expressed in melanomas. For CDKN2X, this result contrasts numerous findings in human tumors including human melanoma in which either CDKN2A (P16) deactivation or LOH was observed.	Univ Texas, MD Anderson Canc Ctr, Div Sci Pk Res, Dept Carcinogenesis, Smithville, TX 78957 USA; British Columbia Canc Res Ctr, Vancouver, BC V5Z 1L3, Canada	University of Texas System; UTMD Anderson Cancer Center; British Columbia Cancer Agency	Kazianis, S (corresponding author), Univ Texas, MD Anderson Canc Ctr, Div Sci Pk Res, Dept Carcinogenesis, POB 389, Smithville, TX 78957 USA.				NCI NIH HHS [CA76693, CA55245, CA09480] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009480, R01CA055245, F32CA076693] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAM D, 1993, SCIENCE, V259, P816, DOI 10.1126/science.8430335; ADAM D, 1991, ONCOGENE, V6, P73; AHUJA MR, 1980, J HERED, V71, P403, DOI 10.1093/oxfordjournals.jhered.a109395; ANDERS F, 1967, EXPERIENTIA, V23, P1, DOI 10.1007/BF02142235; ANDERS F, 1991, PIGM CELL RES, V3, P7; Asamoto M, 1998, CANCER LETT, V127, P9, DOI 10.1016/S0304-3835(97)00447-3; Baudler M, 1997, J BIOL CHEM, V272, P131; BENTLEY NJ, 1994, MOL CELL BIOL, V14, P7996, DOI 10.1128/MCB.14.12.7996; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CHIN L, 1997, GENE DEV, P22822; CLARK E, 1950, SCIENCE, V112, P722, DOI 10.1126/science.112.2920.722; DAVIES RL, 1980, P NATL ACAD SCI-BIOL, V77, P4188, DOI 10.1073/pnas.77.7.4188; DAYHOFF MO, 1979, P NATL ACAD SCI USA, V76, P2170, DOI 10.1073/pnas.76.5.2170; DEWIT PEJ, 1992, J INVEST DERMATOL, V99, P168, DOI 10.1111/1523-1747.ep12616793; Dimitrijevic N, 1998, ONCOGENE, V16, P1681, DOI 10.1038/sj.onc.1201693; DON RH, 1991, NUCLEIC ACIDS RES, V19, P5081; Dracopoli NC, 1996, CANCER SURV, V26, P115; Emig R, 1998, BRIT J CANCER, V78, P1661, DOI 10.1038/bjc.1998.739; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GORDON KL, 1994, GENE DEV, V8, P2939; Gordon M., 1931, AM J CANCER, V15, P1495; Goudet J., 2001, CLADISTICS; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hara E, 1996, MOL CELL BIOL, V16, P859; Haussler G, 1928, KLIN WOCHENSCHR, V7, P1561; HERLYN M, 1990, CANCER METAST REV, V9, P101, DOI 10.1007/BF00046337; HERMAN JG, 1995, CANCER RES, V55, P4525; HERRERA RJ, 1979, BIOCHEM GENET, V17, P223, DOI 10.1007/BF00498963; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Huang TSW, 1996, ANTICANCER RES, V16, P3557; IWAMOTO T, 1991, EMBO J, V10, P3167, DOI 10.1002/j.1460-2075.1991.tb04878.x; IWAMOTO T, 1992, EXP CELL RES, V200, P410, DOI 10.1016/0014-4827(92)90189-F; JEN J, 1994, CANCER RES, V54, P6353; Jiang P, 1995, J MOL EVOL, V41, P795; Kalus W, 1997, FEBS LETT, V401, P127, DOI 10.1016/S0014-5793(96)01465-2; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kazianis S, 1998, GENE, V212, P31, DOI 10.1016/S0378-1119(98)00144-9; Kazianis S, 1998, GENE CHROMOSOME CANC, V22, P210, DOI 10.1002/(SICI)1098-2264(199807)22:3<210::AID-GCC6>3.3.CO;2-E; Kazianis S, 1996, GENOME RES, V6, P280, DOI 10.1101/gr.6.4.280; Kosswig C., 1927, Zeitschrift fuer Induktive Abstammungs und Vererbungslehre Berlin, V44, P253, DOI 10.1007/BF01740990; KRAEHN GM, 1995, CANCER-AM CANCER SOC, V75, P1228, DOI 10.1002/1097-0142(19950315)75:6<1228::AID-CNCR2820750604>3.0.CO;2-T; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; LINARDOPOULOS S, 1995, CANCER RES, V55, P5168; Luh FY, 1997, NATURE, V389, P999, DOI 10.1038/40202; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MADDISON WP, 1992, MACCLADE 3 01; Maelandsmo GM, 1996, BRIT J CANCER, V73, P909, DOI 10.1038/bjc.1996.181; MAO L, 1995, CANCER RES, V55, P2995; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; MORIZOT D, 1998, IN PRESS ILAR J; MORIZOT DC, 1991, GENETICS, V127, P399; MORIZOT DC, 1982, GENETICS, V102, P539; MORIZOT DC, 1983, J NATL CANCER I, V71, P809; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; Nairn RS, 1996, P NATL ACAD SCI USA, V93, P13042, DOI 10.1073/pnas.93.23.13042; Nairn RS, 1996, PHOTOCHEM PHOTOBIOL, V64, P440, DOI 10.1111/j.1751-1097.1996.tb03089.x; Nairn RS, 1996, CANCER GENET CYTOGEN, V88, P144, DOI 10.1016/0165-4608(95)00296-0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OCHMAN H, 1988, GENETICS, V120, P621; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; QUELLE DE, 1995, CELL, V83, P993; REAL FX, 1986, CANCER RES, V46, P4726; Robinson WA, 1996, MELANOMA RES, V6, P285, DOI 10.1097/00008390-199608000-00002; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sano T, 1998, AM J PATHOL, V153, P1741, DOI 10.1016/S0002-9440(10)65689-1; Sano T, 1998, PATHOL INT, V48, P580, DOI 10.1111/j.1440-1827.1998.tb03954.x; Schartl A, 1997, Recent Results Cancer Res, V143, P225; SCHARTL M, 1995, TRENDS GENET, V11, P185, DOI 10.1016/S0168-9525(00)89041-1; SCHARTL M, 1990, GENETICS, V126, P1083; SCHOLL A, 1973, Archiv fuer Genetik, V46, P121; Scholl A., 1973, P301; SCHWAB M, 1978, Z KREBSFORSCH KLIN O, V91, P301, DOI 10.1007/BF00312292; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SETLOW RB, 1989, P NATL ACAD SCI USA, V86, P8922, DOI 10.1073/pnas.86.22.8922; SETLOW RB, 1993, P NATL ACAD SCI USA, V90, P6666, DOI 10.1073/pnas.90.14.6666; SHAPIRO M, 1995, BIOTECHNIQUES, V18, P1064; Shigemasa K, 1997, J SOC GYNECOL INVEST, V4, P95, DOI 10.1016/S1071-5576(97)81110-0; SICILIANO MJ, 1976, PIGMENT CELL, V2, P47; STONE S, 1995, CANCER RES, V55, P2988; Swafford DS, 1997, MOL CELL BIOL, V17, P1366, DOI 10.1128/MCB.17.3.1366; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Venkataramani R, 1998, NAT STRUCT BIOL, V5, P74, DOI 10.1038/nsb0198-74; Vielkind J. R., 1989, Journal of Aquatic Animal Health, V1, P69, DOI 10.1577/1548-8667(1989)001&lt;0069:GOMIXF&gt;2.3.CO;2; VIELKIND JR, 1993, AM J PATHOL, V143, P656; Vielkind JR, 1997, J CUTAN PATHOL, V24, P620, DOI 10.1111/j.1600-0560.1997.tb01093.x; VIELKIND U, 1976, J EXP ZOOL, V196, P197, DOI 10.1002/jez.1401960207; Weis S, 1998, GENETICS, V149, P1909; Wellbrock C, 1998, INT J CANCER, V76, P437, DOI 10.1002/(SICI)1097-0215(19980504)76:3<437::AID-IJC24>3.0.CO;2-6; WITTBRODT J, 1989, NATURE, V341, P415, DOI 10.1038/341415a0; WOOLCOCK BW, 1994, CELL GROWTH DIFFER, V5, P575; ZECHEL C, 1988, ONCOGENE, V3, P605; ZECHEL C, 1992, INT J CANCER, V52, P66, DOI 10.1002/ijc.2910520114; Zechel C, 1989, Haematol Blood Transfus, V32, P366; ZECHEL C, 1992, TRENDS ICHTHYOLOGY, P93	97	44	44	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	1999	18	36					5088	5099		10.1038/sj.onc.1202884	http://dx.doi.org/10.1038/sj.onc.1202884			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	234RA	10490845				2022-12-17	WOS:000082497100008
J	Belletti, B; Ferraro, P; Arra, C; Baldassarre, G; Bruni, P; Staibano, S; De Rosa, G; Salvatore, G; Fusco, AE; Persico, MG; Viglietto, G				Belletti, B; Ferraro, P; Arra, C; Baldassarre, G; Bruni, P; Staibano, S; De Rosa, G; Salvatore, G; Fusco, AE; Persico, MG; Viglietto, G			Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene	ONCOGENE			English	Article						thyroid tumor; VEGF; angiogenesis; antisense	PERMEABILITY FACTOR; UP-REGULATION; ANGIOGENIC FACTORS; IN-VIVO; EXPRESSION; RECEPTORS; ANGIOPOIETIN-1; METASTASIS; INHIBITION; SEQUENCE	Vascular endothelial growth factor A (VEGF) is a potent mitogen for endothelial cells in vitro and promotes neo-angiogenesis in vivo, VEGF overexpression occurs in most human malignancies including thyroid carcinomas in which elevated VEGF expression is associated with a high tumorigenic potential. To investigate the role of VEGF in angiogenesis associated with development of thyroid carcinomas, we constitutively expressed VEGF(121) into a poorly tumorigenic cell line (NPA) expressing minimal levels of endogenous VEGF. Here we report that VEGF overexpressing NPA cells showed the same growth potential as untransfected NPA in vitro but formed well-vascularized tumors when injected subcutaneously into nude mice with markedly reduced latency compared to parental cells. A complementary approach was to suppress VEGF expression in a highly tumorigenic anaplastic cell line (ARO) by the transfection of an antisense construct. Antisense-transfected ARO cells expressed reduced constitutive levels of VEGF, shelved the same growth potential as untransfected ARO cells in vitro and formed small tumors characterized by minimal vascularization, extensive necrosis and longer latency compared to parental or vector-transfected ARO cells in vivo. Finally, we investigated the expression of both VEGF tyrosine kinase receptors (Flt-1 and Flk-1/KDR) in tumor specimens by RT-PCR, Expression of (Flt-1 and Flk-1/KDR) was low in tissue specimens derived from NPA tumors, but was found enhanced in NPA VEGF tumors; conversely, the expression of VEGF receptors was high in tissue specimens derived from ARO tumors but was decreased in tumors derived from VEGF depleted ARO cells. These results clearly demonstrate that VEGF indirectly promotes the growth of thyroid tumors by stimulating angiogenesis.	Fdn Pascale, Ist Nazl Tumori, I-80131 Naples, Italy; Univ Naples Federico II, Fac Med & Chirurg, Inst Pathol, I-80131 Naples, Italy; Univ Naples Federico II, Fac Med & Chirurg, Dipartimento & Oncol Sperimentale & Clin, I-80131 Naples, Italy; Univ Reggio Calabria, Fac Med & Chirurg, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy; CNR, Int Inst Genet & Biophys, I-80125 Naples, Italy	IRCCS Fondazione Pascale; University of Naples Federico II; University of Naples Federico II; Universita Mediterranea di Reggio Calabria; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)	Viglietto, G (corresponding author), Fdn Pascale, Ist Nazl Tumori, Via M Semmola, I-80131 Naples, Italy.		Belletti, Barbara/J-2028-2018; Viglietto, Giuseppe/AAC-2852-2019; Baldassarre, Gustavo/K-1350-2016	Belletti, Barbara/0000-0003-2249-0285; Viglietto, Giuseppe/0000-0003-2327-7515; Baldassarre, Gustavo/0000-0002-9750-8825; Arra, Claudio/0000-0003-3162-2091; Fusco, Alfredo/0000-0003-3332-5197; DE ROSA, Gaetano/0000-0002-3635-5853				BERKMAN RA, 1993, J CLIN INVEST, V91, P153, DOI 10.1172/JCI116165; BROWN LF, 1993, CANCER RES, V53, P4727; Claffey KP, 1996, CANCER RES, V56, P172; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DEVITA VT, 1997, CANC PRINCIPLES PRAC, P1349; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FINNERTY H, 1993, ONCOGENE, V8, P2293; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; HEDINGER C, 1988, HISTOLGYCAL TYPING T; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; OELRICHS RB, 1993, ONCOGENE, V8, P11; OLSON TA, 1994, CANCER RES, V54, P276; PANG XP, 1989, ENDOCRINOLOGY, V125, P1783, DOI 10.1210/endo-125-4-1783; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLATE KH, 1993, CANCER RES, V53, P5822; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Saleh M, 1996, CANCER RES, V56, P393; Sambrook J, 1989, MOL CLONING LAB MANU; SHIBUYA M, 1990, ONCOGENE, V5, P519; STAUFFER JK, 1990, J BIOL CHEM, V265, P11773; Stratmann A, 1998, AM J PATHOL, V153, P1459, DOI 10.1016/S0002-9440(10)65733-1; TISHER E, 1991, J BIOL CHEM, V266, P11974; VIGLIETTO G, 1995, ONCOGENE, V11, P1569; Viglietto G, 1997, ONCOGENE, V15, P2687, DOI 10.1038/sj.onc.1201456; WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857	32	44	52	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 26	1999	18	34					4860	4869		10.1038/sj.onc.1202869	http://dx.doi.org/10.1038/sj.onc.1202869			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229GH	10490819				2022-12-17	WOS:000082184800010
J	Lazarova, DL; Spengler, BA; Biedler, JL; Ross, RA				Lazarova, DL; Spengler, BA; Biedler, JL; Ross, RA			HuD, a neuronal-specific RNA-binding protein, is a putative regulator of N-myc pre-mRNA processing/stability in malignant human neuroblasts	ONCOGENE			English	Article						HuD; N-myc; human neuroblastoma; RNA-binding protein	3' UNTRANSLATED REGION; ENCEPHALOMYELITIS SENSORY NEURONOPATHY; FACTOR MESSENGER-RNAS; CELL-LINES; NUCLEOTIDE-SEQUENCE; GENE-EXPRESSION; BLASTOMA CELLS; SEX-LETHAL; IN-VITRO; RICH	N-myc gene copy numbers and transcription rates are similar in N (neuroblastic, tumorigenic) and S (nonneuronal, non-tumorigenic) neuroblastoma cells with chromosomally integrated amplified N-myc genes. However, er, N cells show significantly higher N-myc mRNA levels than S cells. Therefore, post-transcriptional control of N-myc gene expression must differ between these cell types, Since no differences in N-myc mRNA half-life were found between N and S cells from two cell lines, steady-state levels of N-myc pre-mRNA processing intermediates were analysed. Results suggest that the differences in N-myc expression arise primarily at the nuclear post-transcriptional level. The neuronal-specific RNA-binding Hu proteins are present in cytoplasmic acid nuclear fractions of N cells and one of them, HuD, binds specifically to both exonic and intronic N-myc RNA sequences. In sense and antisense HuD-transfected N cells, there are coordinate changes in HuD and N-myc expression le,els, Thus, we propose that HuD plays a role in the nuclear processing/stability of N-myc pre-mRNA in N-type neuroblastoma cells.	Fordham Univ, Dept Biol Sci, Bronx, NY 10458 USA	Fordham University	Ross, RA (corresponding author), Fordham Univ, Dept Biol Sci, 441 E Fordham Rd, Bronx, NY 10458 USA.							BABISS LE, 1990, MOL CELL BIOL, V10, P6700, DOI 10.1128/MCB.10.12.6700; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BERGER SL, 1994, NUCLEIC ACIDS RES, V22, P3218, DOI 10.1093/nar/22.15.3218; BIEDLER JL, 1978, CANCER RES, V38, P3751; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1981, CANCER RES, V41, P4678; Chagnovich D, 1996, J BIOL CHEM, V271, P33587, DOI 10.1074/jbc.271.52.33587; Chagnovich D, 1996, J BIOL CHEM, V271, P33580, DOI 10.1074/jbc.271.52.33580; CHEN QY, 1995, MOL CELL BIOL, V15, P2010; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CICCARONE V, 1989, CANCER RES, V49, P219; CRIST WM, 1991, NEW ENGL J MED, V324, P461, DOI 10.1056/NEJM199102143240706; DALMAU J, 1991, NEUROLOGY, V41, P1757, DOI 10.1212/WNL.41.11.1757; DALMAU J, 1992, AM J PATHOL, V141, P881; ERBA HP, 1986, NUCLEIC ACIDS RES, V14, P5275, DOI 10.1093/nar/14.13.5275; Favaloro J, 1980, Methods Enzymol, V65, P718; Gao FB, 1996, J CELL SCI, V109, P579; GAO FB, 1994, P NATL ACAD SCI USA, V91, P11207, DOI 10.1073/pnas.91.23.11207; GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557; Graveley BR, 1996, MOL CELL BIOL, V16, P4942; HIRVONEN H, 1989, J CELL BIOL, V108, P1093, DOI 10.1083/jcb.108.3.1093; HORMIGO A, 1994, J NEUROIMMUNOL, V55, P205, DOI 10.1016/0165-5728(94)90011-6; IKEGAKI N, 1986, P NATL ACAD SCI USA, V83, P5929, DOI 10.1073/pnas.83.16.5929; Jain RG, 1997, MOL CELL BIOL, V17, P954, DOI 10.1128/MCB.17.2.954; KING PH, 1994, J NEUROSCI, V14, P1943; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; Kostyk SK, 1996, NEUROREPORT, V7, P1549, DOI 10.1097/00001756-199607080-00003; Koushika SP, 1996, CURR BIOL, V6, P1634, DOI 10.1016/S0960-9822(02)70787-2; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; LIU J, 1995, NEUROLOGY, V45, P544, DOI 10.1212/WNL.45.3.544; Lou H, 1996, GENE DEV, V10, P208, DOI 10.1101/gad.10.2.208; MANLEY GT, 1995, ANN NEUROL, V38, P102, DOI 10.1002/ana.410380117; MARUSICH MF, 1992, DEV BIOL, V149, P295, DOI 10.1016/0012-1606(92)90285-O; MARUSICH MF, 1994, J NEUROBIOL, V25, P143, DOI 10.1002/neu.480250206; MCCULLOUGH AJ, 1993, MOL CELL BIOL, V13, P7689, DOI 10.1128/MCB.13.12.7689; MULLER WEG, 1992, J MOL BIOL, V226, P721, DOI 10.1016/0022-2836(92)90628-W; Okano HJ, 1997, J NEUROSCI, V17, P3024; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; RETTIG WJ, 1987, CANCER RES, V47, P1383; ROSS RA, 1995, CELL GROWTH DIFFER, V6, P449; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SAKAI K, 1994, BIOCHEM BIOPH RES CO, V199, P1200, DOI 10.1006/bbrc.1994.1358; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SEEGER RC, 1977, CANCER RES, V37, P1364; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; Sivak L. E., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P187; Spengler BA, 1997, ONCOL RES, V9, P467; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; Tora M, 1997, NEUROLOGY, V48, P735, DOI 10.1212/WNL.48.3.735; Wakamatsu Y, 1997, DEVELOPMENT, V124, P3449; Wang JW, 1997, J BIOL CHEM, V272, P22227, DOI 10.1074/jbc.272.35.22227	56	44	45	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 29	1999	18	17					2703	2710		10.1038/sj.onc.1202621	http://dx.doi.org/10.1038/sj.onc.1202621			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348344				2022-12-17	WOS:000080124900005
J	Liang, SH; Clarke, MF				Liang, SH; Clarke, MF			The nuclear import of p53 is determined by the presence of a basic domain and its relative position to the nuclear localization signal	ONCOGENE			English	Article						p53; nuclear localization; tumor suppressor gene 5	STRUCTURAL ASPECTS; GENE EVOLUTION; CELL-CYCLE; PROTEIN; ACCUMULATION; TRAFFICKING; RECEPTOR; SEQUENCE; LOCATION; MYC	It has been reported that Lysine-305 is needed for the nuclear import of the p53 protein (Liang et al., 1998). In the present study, further mutagenesis analyses were carried out between Lys-305 and the major nuclear localization signal (NLS I) of p53. It was found that a single mutation of Arg-306 resulted in the defect of p53 nuclear import. This effect is the same as that of Lys-305 mutation. Other mutations between Arg-306 and NLS I have no effect on the nuclear import of p53. However, deletions of more than two amino acids between this region abolished the transport of p53 into the nucleus. These results indicate that a basic domain other than the well defined NLS is required for the nuclear import of p53. A spacer between this basic domain and NLS I is necessary for the entrance of p53 into the cell nucleus.	Univ Michigan, Med Ctr, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Clarke, MF (corresponding author), Univ Michigan, Med Ctr, Dept Internal Med, 4310 CCGC,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.				NCI NIH HHS [CA67140] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067140, R55CA067140] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOSARI S, 1995, AM J PATHOL, V147, P790; Carey KL, 1996, J CELL BIOL, V133, P985, DOI 10.1083/jcb.133.5.985; DANG CV, 1989, J BIOL CHEM, V264, P18019; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; HOLSTEIN M, 1991, SCIENCE, V253, P49; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Koepp DM, 1996, CELL, V87, P1, DOI 10.1016/S0092-8674(00)81315-X; Liang SH, 1998, J BIOL CHEM, V273, P19817, DOI 10.1074/jbc.273.31.19817; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROBERTS BL, 1987, CELL, V50, P465, DOI 10.1016/0092-8674(87)90500-9; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; SOUSSI T, 1990, ONCOGENE, V5, P945; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X	21	44	46	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 25	1999	18	12					2163	2166		10.1038/sj.onc.1202350	http://dx.doi.org/10.1038/sj.onc.1202350			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX	10321742	Bronze			2022-12-17	WOS:000079346200015
J	Hummel, JL; Wells, RA; Dube, ID; Licht, JD; Kamel-Reid, S				Hummel, JL; Wells, RA; Dube, ID; Licht, JD; Kamel-Reid, S			Deregulation of NPM and PLZF in a variant t(5;17) case of acute promyelocytic leukemia	ONCOGENE			English	Article						APL; NPM-RAR alpha; PLZF; subcellular localization	ACID RECEPTOR-ALPHA; MITOTIC APPARATUS PROTEIN; POLYMERASE CHAIN-REACTION; NON-HODGKINS-LYMPHOMA; ZINC FINGER GENE; PML-RAR-ALPHA; RETINOIC ACID; DNA-BINDING; MOLECULAR CHARACTERIZATION; T(15-17) TRANSLOCATION	Greater than 95% of acute promyelocytic leukemia (APL) cases are associated with the expression of PML-RAR alpha. This chimeric protein has been strongly implicated in APL pathogenesis because of its interactions with growth suppressors (PML), retinoid signaling molecules (RXR alpha), and nuclear hormone transcriptional co-repressors (N-CoR and SMRT), A small number of variant APL translocations have also been shown to involve rearrangements that fuse RAR alpha to partner genes other than PML, namely PLZF, NPM, and NuMA. We describe the molecular characterization of a t(5;17)(q35;q21) variant translocation involving the NPM gene, identified in a pediatric case of APL, RT-PCR, cloning, and sequence studies identified NPM as the RAR alpha partner on chromosome 5, and both NPM-RAR alpha and RAR alpha-NPM fusion mRNAs were expressed in this patient. We further explored the effects of the NPM-RAR alpha chimeric protein on the subcellular localization of PML, RXR alpha, NPM, and PLZF using immunofluorescent confocal microscopy. While PML remained localized to its normal 10-20 nuclear bodies, NPM nucleolar localization was disrupted and PLZF expression was upregulated in a microspeckled pattern in patient leukemic bone marrow cells, We also observed nuclear co-localization of NPM, RXRa, and NPM-RAR alpha in these cells. Our data support the hypothesis that while deregulation of both the retinoid signaling pathway and RAR alpha partner proteins are molecular consequences of APL translocations, APL pathogenesis is not dependent on disruption of PML nuclear bodies.	Toronto Hosp, Princess Margaret Hosp, Ontario Canc Inst, Canc Cytogenet & Mol Oncol Program, Toronto, ON M5G 2M9, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A8, Canada; Sunnybrook Hlth Sci Ctr, Lab Med, Toronto, ON M4N 3M5, Canada; Harvard Univ, Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat, Boston, MA 02115 USA; CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Mol Biol, New York, NY 10029 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Kamel-Reid, S (corresponding author), Toronto Hosp, Princess Margaret Hosp, Ontario Canc Inst, Canc Cytogenet & Mol Oncol Program, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.		Licht, Jonathan/L-4239-2019; Licht, Jonathan/AAL-9184-2020	Licht, Jonathan/0000-0002-3942-1369; Kamel-Reid, Suzanne/0000-0002-4386-0292	NCI NIH HHS [R01 CA 59936] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059936] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; ALCALAY M, 1992, P NATL ACAD SCI USA, V89, P4840, DOI 10.1073/pnas.89.11.4840; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Borden KLB, 1997, FEBS LETT, V418, P30, DOI 10.1016/S0014-5793(97)01344-6; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BORROW J, 1992, BRIT J HAEMATOL, V82, P529, DOI 10.1111/j.1365-2141.1992.tb06463.x; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CASTAIGNE S, 1992, BLOOD, V79, P3110; CHAN PK, 1990, BIOCHEM J, V270, P549, DOI 10.1042/bj2700549; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; DANIEL MT, 1993, BLOOD, V82, P1858; DAVIDSON RL, 1976, SOMAT CELL GENET, V2, P271, DOI 10.1007/BF01538965; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GRIGNANI F, 1994, BLOOD, V83, P10; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grignani F, 1996, EMBO J, V15, P4949, DOI 10.1002/j.1460-2075.1996.tb00875.x; Grimwade D, 1997, BLOOD, V90, P4876; Grimwade D, 1996, BRIT J HAEMATOL, V94, P557; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; HERRERA JE, 1995, NUCLEIC ACIDS RES, V23, P3974, DOI 10.1093/nar/23.19.3974; Herrera JE, 1996, BIOCHEMISTRY-US, V35, P2668, DOI 10.1021/bi9523320; HILLSTEAD LF, 1957, ACTA MED SCAND, V69, P189; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; JANSEN JH, 1995, P NATL ACAD SCI USA, V92, P7401, DOI 10.1073/pnas.92.16.7401; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KANG YJ, 1974, J BIOL CHEM, V249, P5580; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Koken MHM, 1997, P NATL ACAD SCI USA, V94, P10255, DOI 10.1073/pnas.94.19.10255; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Li YP, 1996, EUR J BIOCHEM, V237, P153, DOI 10.1111/j.1432-1033.1996.0153n.x; Licht JD, 1996, ONCOGENE, V12, P323; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; LYDERSEN BK, 1980, CELL, V22, P489, DOI 10.1016/0092-8674(80)90359-1; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NORWOOD TH, 1976, SOMAT CELL GENET, V2, P263, DOI 10.1007/BF01538964; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Redner RL, 1997, LEUKEMIA, V11, P1014, DOI 10.1038/sj.leu.2400661; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; Sitterlin D, 1997, ONCOGENE, V14, P1067, DOI 10.1038/sj.onc.1200916; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPARKS CA, 1993, GENOMICS, V17, P222, DOI 10.1006/geno.1993.1307; WANG DR, 1994, J BIOL CHEM, V269, P30994; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wells RA, 1996, LEUKEMIA, V10, P735; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; YonedaKato N, 1996, ONCOGENE, V12, P265; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	66	44	46	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					633	641		10.1038/sj.onc.1202357	http://dx.doi.org/10.1038/sj.onc.1202357			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989813				2022-12-17	WOS:000078394400008
J	Donzelli, M; Bernardi, R; Negri, C; Prosperi, E; Padovan, L; Lavialle, C; Brison, O; Scovassi, AI				Donzelli, M; Bernardi, R; Negri, C; Prosperi, E; Padovan, L; Lavialle, C; Brison, O; Scovassi, AI			Apoptosis-prone phenotype of human colon carcinoma cells with a high level amplification of the c-myc gene	ONCOGENE			English	Article						apoptosis; human colon carcinoma cells; serum starvation; c-myc; amplification; PARP proteolysis	WILD-TYPE P53; RADIATION-INDUCED APOPTOSIS; TUMOR-SUPPRESSOR GENES; POLY(ADP-RIBOSE) POLYMERASE; MEDIATED APOPTOSIS; EPITHELIAL-CELLS; CYCLE ARREST; HELA-CELLS; IN-VIVO; DEATH	Although apoptosis can be induced by the enforced expression of exogenously introduced c-myc genes, it is not clear whether overexpression resulting from the amplification of the resident c-myc gene in tumor cells is sufficient to induce apoptosis, We have investigated the relationship between c-myc gene amplification and the propensity of tumor cells to undergo apoptosis, using the SW613-12A1 and SW613-B3 cell lines, which are representatives, respectively, of tumorigenic and nontumorigenic clones isolated from the SW613-S human colon carcinoma cell line. Tumorigenic clones are characterized by a high level of amplification and expression of the c-myc gene, whereas cells of nontumorigenic clones have a small number of copies and a lower level of expression of this gene. Analysis of c-myc mRNA level in cells cultured under low serum conditions indicated that the expression of the gene is tightly regulated by serum growth factors in non-tumorigenic B3 cells, whereas it is poorly regulated in tumorigenic 12A1 cells, the level of mRNAs remaining relatively high in serum-started 12A1 cells, Under these conditions, 12A1 cells showed clear evidence of apoptosis, whereas B3 cells were completely refractory to the induction of apoptosis, Moreover, the study of cell lines derived from nontumorigenic apoptosis-resistant clones following the introduction by transfection of exogenous c-myc gene copies showed that they have acquired an apapoptosis-prone phenotype. Altogether, our results strongly suggest that deregulated c-myc expression due to high-level amplification confers an apoptosis-prone phenotype to tumor cells. The possible consequences of these observations for cancer therapy are discussed.	CNR, Ist Genet Biochim & Evoluzionist, I-27100 Pavia, Italy; CNR, Ctr Studio Istochim, I-27100 Pavia, Italy; Univ Pavia, Dipartimento Genet, I-27100 Pavia, Italy; Inst Gustave Roussy, CNRS UMR 1599, Lab Genet Oncol, Villejuif, France	Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR); University of Pavia; UNICANCER; Gustave Roussy	Scovassi, AI (corresponding author), CNR, Ist Genet Biochim & Evoluzionist, Via Abbiategrasso 207, I-27100 Pavia, Italy.		bernardi, rosa/B-1650-2013; Scovassi, Anna Ivana/F-2458-2010; Donzelli, Maddalena/ABD-3774-2020; Prosperi, Ennio/A-3439-2014; Lavialle, Christian/O-2329-2019	bernardi, rosa/0000-0002-3607-6336; Scovassi, Anna Ivana/0000-0003-3484-9881; Prosperi, Ennio/0000-0001-5391-5157; DONZELLI, MADDALENA/0000-0002-4045-0802				Alarcon RM, 1996, CANCER RES, V56, P4315; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; ASKEW DS, 1991, ONCOGENE, V6, P1915; Augenlicht LH, 1997, CANCER RES, V57, P1769; BARBU V, 1989, NUCLEIC ACIDS RES, V17, P7115, DOI 10.1093/nar/17.17.7115; BISHOP JM, 1995, GENE DEV, V9, P1309, DOI 10.1101/gad.9.11.1309; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BRACEY TS, 1995, ONCOGENE, V10, P2391; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; DAUTRY F, 1988, J BIOL CHEM, V263, P17615; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; Dong JA, 1997, ONCOGENE, V15, P639, DOI 10.1038/sj.onc.1201237; El-Deiry Wafik S., 1997, Current Opinion in Oncology, V9, P79; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; ERISMAN MD, 1985, MOL CELL BIOL, V5, P1969, DOI 10.1128/MCB.5.8.1969; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; GALDEMARD C, 1995, ONCOGENE, V10, P2331; Guano F, 1994, Cell Death Differ, V1, P101; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; Hague A, 1997, BRIT J CANCER, V75, P960, DOI 10.1038/bjc.1997.167; Han JW, 1997, CANCER RES, V57, P176; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HAUPT Y, 1995, ONCOGENE, V10, P1563; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOFFMAN B, 1994, ONCOGENE, V9, P1807; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Kangas AL, 1998, ONCOGENE, V16, P387, DOI 10.1038/sj.onc.1201779; LAMARRE D, 1988, BIOCHIM BIOPHYS ACTA, V950, P147, DOI 10.1016/0167-4781(88)90007-3; LAMONERIE T, 1995, INT J CANCER, V61, P587, DOI 10.1002/ijc.2910610425; LAVIALLE C, 1988, ONCOGENE, V3, P335; LAVIALLE C, 1990, ONCOGENE, V5, P245; LAVIALLE C, 1989, ANTICANCER RES, V9, P1265; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARX J, 1993, SCIENCE, V259, P760, DOI 10.1126/science.8430327; MODJTAHEDI N, 1992, INT J CANCER, V52, P483, DOI 10.1002/ijc.2910520325; MODJTAHEDI N, 1985, CANCER RES, V45, P4372; Negri C, 1995, BIOCHIMIE, V77, P893, DOI 10.1016/0300-9084(95)90009-8; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PELLEGATA NS, 1994, CANCER RES, V54, P1556; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; RENAULT B, 1993, CANCER RES, V53, P2614; Rupnow BA, 1998, CELL DEATH DIFFER, V5, P141, DOI 10.1038/sj.cdd.4400328; Sakamuro D, 1995, ONCOGENE, V11, P2411; SHAH GM, 1995, ANAL BIOCHEM, V227, P1, DOI 10.1006/abio.1995.1245; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SPENCER CA, 1991, ADV CANCER RES, V56, P1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	62	44	45	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	1999	18	2					439	448		10.1038/sj.onc.1202309	http://dx.doi.org/10.1038/sj.onc.1202309			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927200				2022-12-17	WOS:000078166500016
J	Saito, T; Schlegel, R; Andresson, T; Yuge, L; Yamamoto, M; Yamasaki, H				Saito, T; Schlegel, R; Andresson, T; Yuge, L; Yamamoto, M; Yamasaki, H			Induction of cell transformation by mutated 16K vacuolar H+-ATPase (ductin) is accompanied by down-regulation of gap junctional intercellular communication and translocation of connexin 43 in NIH3T3 cells	ONCOGENE			English	Article						gap junction; connexins; 16 K protein; ductin; cell transformation	GROWTH-CONTROL; E5 ONCOPROTEIN; POTENTIAL ROLE; PROTON PUMP; HELA-CELLS; SRC GENE; PROTEIN; CHANNEL; COMPONENT; CARCINOGENESIS	The 16 K subunit of the vacuolar H+-ATPase (ductin) has been suggested to also play a role in gap junction channels. Since mutated 16 K subunits have transforming ability when transfected into NIH3T3 cells and since aberrant gap junctional intercellular communication (GJIC) is a hallmark of cancer cells, we hypothesized that mutated 16 K subunits might transform these cells via alteration of GJIC, When GJIC was measured by the dye-transfer assay, NIH3T3 cells transfected with the mutant 16 K protein genes (deletion of the fourth transmembrane domain or a point mutation at codon 143 from glutamic acid to arginine) showed significantly lower levels of GJIC than those transfected with the vector alone or with the wild-type 16 K subunit gene. GJIC levels of NIH3T3 cells transformed by v-ras and v-src were not significantly decreased, suggesting that low GJIC levels are not necessarily the result of cell transformation pel se. NIH3T3 cells express Cx 43 as a major connexin gene. Although cells transfected with mutated 16 K subunits showed a level of Cx 43 protein expression similar to non-transfectants, their Cx43 protein was localized aberrantly, i.e. intracytoplasmically, These results indicate that mutant 16 K subunits with transforming ability translocate Cx43 proteins, thus inhibiting GJIC of NIH3T3 cells.	Int Agcy Res Canc, Unit Multistage Carcinogenesis, F-69372 Lyon 08, France; Georgetown Univ, Sch Med, Dept Pathol, Washington, DC 20007 USA; Hiroshima Univ, Sch Med, Inst Hlth Sci, Minami Ku, Hiroshima 734, Japan; Hiroshima Univ, Sch Med, Dept Anat, Minami Ku, Hiroshima 734, Japan	World Health Organization; International Agency for Research on Cancer (IARC); Georgetown University; Hiroshima University; Hiroshima University	Yamasaki, H (corresponding author), Sapporo Med Univ, Sch Med, Dept Obstet & Gynaecol, Chuo Ku, S1,W16, Sapporo, Hokkaido 060, Japan.				NCI NIH HHS [R01/CA40534] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040534] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRESSON T, 1995, J BIOL CHEM, V270, P6830, DOI 10.1074/jbc.270.12.6830; AZARNIA R, 1984, J MEMBRANE BIOL, V82, P191, DOI 10.1007/BF01871629; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Beyer E C, 1993, Int Rev Cytol, V137C, P1; BIGNAMI M, 1988, MOL CARCINOGEN, V1, P67, DOI 10.1002/mc.2940010113; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; CHANG CC, 1985, P NATL ACAD SCI USA, V82, P5360, DOI 10.1073/pnas.82.16.5360; deFeijter AW, 1996, MOL CARCINOGEN, V16, P203, DOI 10.1002/(SICI)1098-2744(199608)16:4<203::AID-MC4>3.3.CO;2-F; DuflotDancer A, 1997, ONCOGENE, V15, P2151, DOI 10.1038/sj.onc.1201393; DUNLOP J, 1995, EMBO J, V14, P3609, DOI 10.1002/j.1460-2075.1995.tb00030.x; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; Faccini AM, 1996, J VIROL, V70, P9041, DOI 10.1128/JVI.70.12.9041-9045.1996; FINBOW ME, 1993, J CELL SCI, V106, P463; FINBOW ME, 1984, EMBO J, V3, P2271, DOI 10.1002/j.1460-2075.1984.tb02125.x; FINBOW ME, 1983, EMBO J, V2, P1479, DOI 10.1002/j.1460-2075.1983.tb01611.x; FINBOW ME, 1995, BIOESSAYS, V17, P247, DOI 10.1002/bies.950170311; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GLICKMAN J, 1983, J CELL BIOL, V97, P1303, DOI 10.1083/jcb.97.4.1303; GOLDSTEIN DJ, 1992, J VIROL, V66, P405, DOI 10.1128/JVI.66.1.405-413.1992; GOLDSTEIN DJ, 1992, EMBO J, V11, P4851, DOI 10.1002/j.1460-2075.1992.tb05591.x; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; HARIKUMAR P, 1983, J BIOL CHEM, V258, P403; JONGEN WMF, 1991, J CELL BIOL, V114, P545, DOI 10.1083/jcb.114.3.545; KAESTNER KH, 1988, J BIOL CHEM, V263, P1282; Krutovskikh V, 1997, HISTOL HISTOPATHOL, V12, P761; KRUTOVSKIKH V, 1994, INT J CANCER, V56, P87; KRUTOVSKIKH VA, 1995, LAB INVEST, V72, P571; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; KUMAR NM, 1995, J CELL SCI, V108, P3725; LEITCH B, 1990, EXP CELL RES, V190, P218, DOI 10.1016/0014-4827(90)90189-H; LOEWENSTEIN WR, 1979, BIOCHIM BIOPHYS ACTA, V560, P1, DOI 10.1016/0304-419X(79)90002-7; LOO LWM, 1995, J BIOL CHEM, V270, P12751, DOI 10.1074/jbc.270.21.12751; MARQUEZSTERLING N, 1991, EUR J CELL BIOL, V56, P19; MERCHENTHALER I, 1989, J HISTOCHEM CYTOCHEM, V37, P1563, DOI 10.1177/37.10.2674275; MESNIL M, 1995, CANCER RES, V55, P629; MESNIL M, 1994, CELL ADHES COMMUN, V2, P377, DOI 10.3109/15419069409004449; MORIYAMA Y, 1986, BIOCHIM BIOPHYS ACTA, V854, P102, DOI 10.1016/0005-2736(86)90069-6; NELSON N, 1992, J EXP BIOL, V172, P19; OELZE I, 1995, J VIROL, V69, P4489, DOI 10.1128/JVI.69.7.4489-4494.1995; Sakaguchi T, 1996, J CELL BIOL, V133, P733, DOI 10.1083/jcb.133.4.733; SCHMID S, 1989, J CELL BIOL, V108, P1291, DOI 10.1083/jcb.108.4.1291; SUN SZ, 1987, J BIOL CHEM, V262, P14790; TROSKO JE, 1983, J AM COLL TOXICOL, V2, P5, DOI 10.3109/10915818309140689; XU HX, 1994, J BIOL CHEM, V269, P22875; Yamasaki H, 1996, MUTAT RES-REV GENET, V365, P91, DOI 10.1016/S0165-1110(96)90014-7; YAMASAKI H, 1990, CARCINOGENESIS, V11, P1051, DOI 10.1093/carcin/11.7.1051; Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199; Yeager M, 1996, CURR OPIN STRUC BIOL, V6, P183, DOI 10.1016/S0959-440X(96)80073-X	49	44	47	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	1998	17	13					1673	1680		10.1038/sj.onc.1202092	http://dx.doi.org/10.1038/sj.onc.1202092			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796696				2022-12-17	WOS:000076200100005
J	Hallberg, B; Ashcroft, M; Loeb, DM; Kaplan, DR; Downward, J				Hallberg, B; Ashcroft, M; Loeb, DM; Kaplan, DR; Downward, J			Nerve growth factor induced stimulation of Ras requires Trk interaction with Shc but does not involve phosphoinositide 3-OH kinase	ONCOGENE			English	Article						Ras; Trk; NGF; phosphatidylinositol 3-kinase; apoptosis; PKB	PHEOCHROMOCYTOMA PC12 CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; NEURITE OUTGROWTH; TYROSINE KINASE; PROTEIN-KINASE; NEURONAL DIFFERENTIATION; ACTIVATION; RECEPTOR; NGF	The TrkA receptor protein tyrosine kinase is involved in signalling PC12 cell differentiation and cessation of cell division in response to nerve growth factor (NGF), To assess the importance of adaptor proteins and Pas in NGF control of phosphoinositide 3-OH kinase (PI 3-kinase), specific receptor mutations in Trk have been employed.. We show that phosphorylation of tyrosine 490, but not 785, of Trk is essential for activation of both Ras and PI 3-kinase in vivo, correlating with tyrosine phosphorylation of Shc and binding of Shc to the adaptor Grb2 and the Pas exchange factor Sos. A mutant receptor that lacks Y490 and Y785, but contains an introduced YxxM motif which binds the regulatory domain of PI 3-kinase, is unable to activate Pas despite causing increased PI 3-kinase activity. This indicates clearly that activation of PI 3-kinase by itself is not sufficient to cause activation of Pas, arguing against a model in which PI 3-kinase acts upstream of Pas, The Shc site of Trk is thus crucial for the activation of Pas and PI 3-kinase.	Imperial Canc Res Fund, London WC2A 3PX, England; Umea Univ, Dept Cell & Mol Biol, S-90187 Umea, Sweden; McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA	Cancer Research UK; Umea University; McGill University; Columbia University	Downward, J (corresponding author), Imperial Canc Res Fund, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Downward, Julian/A-3251-2012	Downward, Julian/0000-0002-2331-4729				ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; BASU T, 1994, ONCOGENE, V9, P3483; BAXTER RM, 1995, EUR J BIOCHEM, V234, P84, DOI 10.1111/j.1432-1033.1995.084_c.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CARTER AN, 1992, J BIOL CHEM, V267, P14563; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HARRISONFINDIK D, 1995, ONCOGENE, V10, P1385; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Jackson TR, 1996, J CELL SCI, V109, P289; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LOEB DM, 1994, J BIOL CHEM, V269, P8901; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; PENG X, 1995, NEURON, V15, P395, DOI 10.1016/0896-6273(95)90043-8; QIU MS, 1991, NEURON, V7, P937, DOI 10.1016/0896-6273(91)90339-2; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; SOZERI O, 1992, ONCOGENE, V7, P2259; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	41	44	44	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 13	1998	17	6					691	697		10.1038/sj.onc.1201980	http://dx.doi.org/10.1038/sj.onc.1201980			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715270				2022-12-17	WOS:000075337200003
J	Vallian, S; Gaken, JA; Gingold, EB; Kouzarides, T; Chang, KS; Farzaneh, F				Vallian, S; Gaken, JA; Gingold, EB; Kouzarides, T; Chang, KS; Farzaneh, F			Modulation of Fos-mediated AP-1 transcription by the promyelocytic leukemia protein	ONCOGENE			English	Article						AP-1; PML; Fos; APL; transcription	RETINOIC ACID RECEPTOR; PML-RAR-ALPHA; CBP-INDUCED STIMULATION; C-FOS; DNA-BINDING; IN-VITRO; ACTIVATION DOMAIN; NUCLEAR RECEPTORS; JUN; GENE	The growth and transformation suppressor function of promyelocytic leukemia (PML) protein are disrupted in acute promyelocytic leukemia (APL) as a result of its fusion to the RAR alpha gene by t(15;17) translocation. There is significant sequence homology between the dimerization domain of PML and the Fos family of proteins, which imply that PML may be involved in AP-1 activity. Here we show that PML can cooperate with Fos to stimulate its AP-1-mediated transcriptional activity. Cotransfection of PML with GAL4/Fos strongly induced Fos-mediated activation of GAL4-responsive reporters, indicating a functional interaction between Fos and PML in vivo. Deletion analysis of Fos and PML demonstrated that the intact C-terminal domain of Fos (containing the dimerization domain), and the RING-finger, B1 box and nuclear localization domains of PML are involved in the cooperative activity of Fos and PML. Immunoprecipitation and electrophoretic mobility shift assay showed that PML is associated with the AP-1 complex. PMLRAR alpha was also found to enhance the transcriptional activity of GAL4/Fos. The addition of retinoic acid abrogated the PMLRAR alpha, but not PML-induced stimulation of GAL4/Fos activity in a dose-dependent manner. This study demonstrated that PML is involved in the AP-1 complex and can modulate Fos-mediated transcriptional activity, which may contribute to its growth suppressor function.	Univ Texas, MD Anderson Cancer Ctr, Div Lab Med, Houston, TX 77030 USA; Univ London Kings Coll, Sch Med & Dent, Dept Mol Med, London SE5 9NU, England; Univ Cambridge, Wellcome CRC Inst, Cambridge CB2 1QR, England	University of Texas System; UTMD Anderson Cancer Center; University of London; King's College London; University of Cambridge	Chang, KS (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Div Lab Med, Houston, TX 77030 USA.		Farzaneh, Farzin/B-4902-2009; Vallian, Sadeq/AAA-7085-2020	Farzaneh, Farzin/0000-0002-9275-2415; Vallian, Sadeq/0000-0002-5151-5923; Kouzarides, Tony/0000-0002-8918-4162	NATIONAL CANCER INSTITUTE [R01CA055577] Funding Source: NIH RePORTER; NCI NIH HHS [CA55577] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Wellcome Trust(Wellcome TrustEuropean Commission)		Altabef M, 1996, EMBO J, V15, P2707, DOI 10.1002/j.1460-2075.1996.tb00631.x; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bannister AJ, 1995, ONCOGENE, V11, P2509; Boddy MN, 1996, ONCOGENE, V13, P971; Borden KLB, 1996, P NATL ACAD SCI USA, V93, P1601, DOI 10.1073/pnas.93.4.1601; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; BROWN HJ, 1995, EMBO J, V14, P124, DOI 10.1002/j.1460-2075.1995.tb06982.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; COUSENS DJ, 1989, EMBO J, V8, P2337, DOI 10.1002/j.1460-2075.1989.tb08361.x; CURRAN T, 1996, ONCOGENE, V9, P675; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Doucas V, 1996, BBA-REV CANCER, V1288, pM25, DOI 10.1016/S0304-419X(96)00028-5; DOUCAS V, 1993, P NATL ACAD SCI USA, V90, P9345, DOI 10.1073/pnas.90.20.9345; Doyle GAR, 1997, J BIOL CHEM, V272, P11840, DOI 10.1074/jbc.272.18.11840; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Early E, 1996, P NATL ACAD SCI USA, V93, P7900, DOI 10.1073/pnas.93.15.7900; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GUIOCHONMANTEL A, 1995, MOL ENDOCRINOL, V9, P1791, DOI 10.1210/me.9.12.1791; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; He DL, 1997, CANCER RES, V57, P1868; HIRAI SI, 1990, ONCOGENE, V5, P39; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KOLLA SS, 1993, J CELL PHYSIOL, V156, P63, DOI 10.1002/jcp.1041560110; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; MULLER R, 1985, NATURE, V314, P546, DOI 10.1038/314546a0; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; Sambrook J., 1989, MOL CLONING LAB MANU, P655; Stadler M, 1995, ONCOGENE, V11, P2565; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; TEURICH S, 1995, CHEM SENSES, V20, P251, DOI 10.1093/chemse/20.2.251; Vallian S, 1997, EXP CELL RES, V237, P371, DOI 10.1006/excr.1997.3801; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YANG-YEN H-F, 1990, New Biologist, V2, P351; Yoshida H, 1996, CANCER RES, V56, P2945	53	44	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 4	1998	16	22					2843	2853		10.1038/sj.onc.1201837	http://dx.doi.org/10.1038/sj.onc.1201837			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544	9671405				2022-12-17	WOS:000073988200003
J	Castillo, AI; Tolon, RM; Aranda, A				Castillo, AI; Tolon, RM; Aranda, A			Insulin-like growth factor-1 stimulates rat prolactin gene expression by a Ras, ETS and phosphatidylinositol 3-kinase dependent mechanism	ONCOGENE			English	Article						prolactin; IGF-1; pituitary cells; Ras; Pl-3 kinase	THYROTROPIN-RELEASING-HORMONE; TRANSCRIPTION FACTOR; PROTEIN-KINASE; SIGNALING PATHWAYS; THYROID-HORMONE; NEUROENDOCRINE CELLS; NEGATIVE REGULATION; RESPONSE ELEMENT; PHORBOL ESTER; PROMOTER	We have examined the influence of insulin-like growth factor I(IGF-1) on prolactin gene expression in rat pituitary GH4C1 cells. Incubation with IGF-1 increases prolactin mRNA levels and activates the prolactin promoter in transient transfection assays. A similar degree of activation is observed with constructs extending to -3000 and -176 base pairs of the prolactin 5' flanking region, indicating that the IGF-I response element is located in the proximal promoter sequences. A plasmid containing 101 base pairs shows a partial stimulation by IGF-1, and the response is lost in a deletion to -76 base pairs. The Ras oncoproteins have been implicated as a critical signaling component in mediating the effect of growth factor receptor tyrosine kinases. Expression of oncogenic Ras(Val12) mimics the effect of IGF-1 on the prolactin promoter, and a dominant negative Ras, Ras(Asn17), blocks IGF-1-mediated stimulation. Dominant negative mitogen-activated protein kinase (MAPK) also reduces the activation of the prolactin promoter by IGF-1. Ets transcription factors have been described to lie downstream of Ras and MAPK in the signaling pathway leading to prolactin gene activation. Mutation of two Ets binding sites in the promoter region between -101 and -76 abolishes the response to IGF-1. Furthermore, a dominant negative Ets vector strongly reduces the response of the prolactin promoter to IGF-1 and Ras. The endogenous concentration of Ets-related proteins is not limiting in GH4C1 cells for the IGF-1 effect. However, c-Ets-1 and GHF-1 act synergistically in HeLa cells with the IGF-1 receptor, reconstituting pituitary IGF-1 responsiveness. The response to IGF-1 in GH4C1 cells is still observed after transfection with Ras(Val12) suggesting that, although Ras is required, IGF-1 could stimulate other pathway/s in addition to Ras. Wortmanin, an inhibitor of phosphatidylinositol-3 kinase (Pl-3 kinase), also prevents the response of the prolactin promoter to IGF-1. These results show that both the Ras/MAPK/Ets pathway, as well as the activation of Pl-3 kinase are involved in the signaling mechanism leading to prolactin expression by IGF-1 in GH4C1 cells.	CSIC, Inst Invest Biomed, E-28029 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Aranda, A (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.		Tolón, Rosa/AAA-9401-2019; Tolón, Rosa M M/N-4364-2015; Aranda, Ana/ABG-8820-2020; Castillo, Ana/I-1269-2017	Tolón, Rosa M M/0000-0003-1087-4505; Aranda, Ana/0000-0002-8338-9589; Castillo, Ana/0000-0002-2873-1206; Rafael, Rosa M/0000-0002-4441-1691				BERWAER M, 1993, MOL CELL ENDOCRINOL, V92, P1, DOI 10.1016/0303-7207(93)90068-U; BODNER M, 1987, CELL, V50, P267, DOI 10.1016/0092-8674(87)90222-4; Bradford AP, 1996, J BIOL CHEM, V271, P24639, DOI 10.1074/jbc.271.40.24639; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CAMPER SA, 1985, J BIOL CHEM, V260, P2246; CASTILLO AI, 1997, IN PRESS ENDOCRINOLO; CONRAD KE, 1994, MOL CELL BIOL, V14, P1553, DOI 10.1128/MCB.14.3.1553; CONRAD KE, 1992, ONCOGENE, V7, P1279; DAY RN, 1989, MOL ENDOCRINOL, V3, P931, DOI 10.1210/mend-3-6-931; DAY RN, 1990, MOL ENDOCRINOL, V4, P1964, DOI 10.1210/mend-4-12-1964; ELSHOLTZ HP, 1986, SCIENCE, V234, P1552, DOI 10.1126/science.3491428; ELSHOLTZ HP, 1991, J BIOL CHEM, V266, P22919; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GarciaVillalba P, 1996, MOL CELL BIOL, V16, P318; GUBBINS EJ, 1980, J BIOL CHEM, V255, P8655; HOWARD PW, 1995, J BIOL CHEM, V270, P20930, DOI 10.1074/jbc.270.36.20930; IVERSON RA, 1990, MOL ENDOCRINOL, V4, P1564, DOI 10.1210/mend-4-10-1564; JACOB KK, 1995, J BIOL CHEM, V270, P27773, DOI 10.1074/jbc.270.46.27773; JACOB KK, 1994, J BIOL CHEM, V269, P25515; KATO H, 1993, J BIOL CHEM, V268, P2655; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KUSHNER PJ, 1994, MOL ENDOCRINOL, V8, P405, DOI 10.1210/me.8.4.405; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MAURER RA, 1981, NATURE, V294, P94, DOI 10.1038/294094a0; MELMED S, 1986, ENDOCRINOLOGY, V118, P1483, DOI 10.1210/endo-118-4-1483; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MONTE D, 1995, ONCOGENE, V11, P771; MURDOCH GH, 1985, J BIOL CHEM, V260, P1852; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; OBERWETTER JM, 1993, MOL ENDOCRINOL, V7, P915, DOI 10.1210/me.7.7.915; Ouyang LH, 1996, J BIOL CHEM, V271, P10425, DOI 10.1074/jbc.271.18.10425; PICKETT CA, 1994, P NATL ACAD SCI USA, V91, P8612, DOI 10.1073/pnas.91.18.8612; PICKETT CA, 1995, MOL CELL BIOL, V15, P677; PRAGER D, 1988, J BIOL CHEM, V263, P16589; ROSENFELD RG, 1985, ENDOCRINOLOGY, V117, P2008, DOI 10.1210/endo-117-5-2008; SANCHEZPACHECO A, 1995, MOL CELL BIOL, V15, P6322; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SEEBURG PH, 1977, NATURE, V270, P486, DOI 10.1038/270486a0; STANLEY F, 1988, J BIOL CHEM, V263, P13444; STANLEY F, 1989, MOL ENDOCRINOL, V3, P1627, DOI 10.1210/mend-3-10-1627; STANLEY FM, 1992, J BIOL CHEM, V267, P16719; SUPOWIT SC, 1984, P NATL ACAD SCI-BIOL, V81, P2975, DOI 10.1073/pnas.81.10.2975; THEILL LE, 1992, EMBO J, V11, P2261, DOI 10.1002/j.1460-2075.1992.tb05285.x; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WEBSTER J, 1994, MOL ENDOCRINOL, V8, P539, DOI 10.1210/me.8.5.539; YAMASHITA S, 1987, J CLIN INVEST, V79, P449, DOI 10.1172/JCI112832	49	44	44	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 16	1998	16	15					1981	1991		10.1038/sj.onc.1200204	http://dx.doi.org/10.1038/sj.onc.1200204			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZH166	9591782				2022-12-17	WOS:000073079400010
J	Duh, FM; Scherer, SW; Tsui, LC; Lerman, MI; Zbar, B; Schmidt, L				Duh, FM; Scherer, SW; Tsui, LC; Lerman, MI; Zbar, B; Schmidt, L			Gene structure of the human MET proto-oncogene	ONCOGENE			English	Article						MET proto-oncogene; HGF/SF receptor; renal carcinoma	RENAL-CELL CARCINOMA; TYROSINE KINASE; C-MET; GROWTH-FACTOR; HGF RECEPTOR; OVEREXPRESSION; SEQUENCE; MUTATION; LINE; KIT	By direct sequencing of cosmids using primers designed from the known cDNA sequence, we identified 19 exons in the human MET proto-oncogene, and sequenced the corresponding 5' and 3' exon-intron junctions. By homology search in the database of the Washington University Genome Sequence Center (GSC), we identified one additional exon. These 20 exons, together with a previously reported exon, bring the total exon number of MET to 21. Oligonucleotide primers were designed to amplify each exon and adjacent intronic sequences to permit examination of each exon for mutations. By restriction mapping, we assembled a 110 kb genomic contig that covered almost the entire MET protooncogene, This information is relevant for the screening of recently reported mutations of the MET gene which cause hereditary papillary renal carcinomas and for the search for additional mutations of the same gene which may play a role in the pathogenesis of common human carcinomas including carcinomas of the breast, ovary and pancreas.	NCI,INTRAMURAL RES SUPPORT PROGRAM,SAIC FREDERICK,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21702; NCI,IMMUNOBIOL LAB,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21702; HOSP SICK CHILDREN,DEPT GENET,TORONTO,ON M5G 1X8,CANADA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Tsui, Lap-chee/A-1081-2010; Scherer, Stephen W./B-3785-2013	Scherer, Stephen W./0000-0002-8326-1999				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDRE C, 1992, ONCOGENE, V7, P685; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIRENZO MF, 1992, ONCOGENE, V7, P2549; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; GAMBAROTTA G, 1994, J BIOL CHEM, V269, P12852; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; KWOK JBJ, 1993, ONCOGENE, V8, P2575; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PONZETTO C, 1991, ONCOGENE, V6, P553; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; ZBAR B, 1994, J UROLOGY, V151, P561, DOI 10.1016/S0022-5347(17)35015-2; ZBAR B, 1995, J UROLOGY, V153, P907, DOI 10.1016/S0022-5347(01)67601-8	17	44	45	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 25	1997	15	13					1583	1586		10.1038/sj.onc.1201338	http://dx.doi.org/10.1038/sj.onc.1201338			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XX369	9380410				2022-12-17	WOS:A1997XX36900009
J	Resnick, RJ; Taylor, SJ; Lin, Q; Shalloway, D				Resnick, RJ; Taylor, SJ; Lin, Q; Shalloway, D			Phosphorylation of the Src substrate Sam68 by Cdc2 during mitosis	ONCOGENE			English	Article						Sam68; mitosis; Cdc2; Src	RNA-BINDING PROTEIN; C-SRC; KINASE; CELLS; GENE; ASSOCIATION; P62; PP60(C-SRC); ACTIVATION; POLYMERASE	Sam68 (Src-associated in mitosis) is an SH3 (Srchomology 3), SH2 (Src-homology 2), and RNA binding protein which associates with and is tyrosine phosphorylated by mild-type and activated forms of c-Src in a mitosis-specific manner. We now show that Sam68 immunoprecipitated from either HeLa S3 or NIH3T3 cells is phosphorylated on threonine residues exclusively during mitosis as well as on serine residues during both interphase and mitosis. Recombinant Sam68, expressed as a glutathione S-transferase (GST) fusion protein, was phosphorylated on threonine and serine residues after incubation with mitotic lysates several-fold more extensively than after incubation with unsynchronized lysates. Cdc2 was identified as the kinase responsible for the mitotic threonine phosphorylation by (1) immunodepletion of the mitotic Sam68 kinase from cell lysates with anti-Cdc2 antibodies, (2) inhibition of Sam68 phosphorylation in vitro and in vivo by the cyclin-dependent kinase inhibitor olomoucine and (3) phosphorylation of Sam68 by purified Cdc2. These data demonstrate that Sam68 is a direct target of Cdc2 and may therefore mediate some of its biological effects during mitosis.	CORNELL UNIV, BIOCHEM MOL & CELL BIOL SECT, ITHACA, NY 14853 USA	Cornell University					NATIONAL CANCER INSTITUTE [R01CA032317] Funding Source: NIH RePORTER; NCI NIH HHS [CA 32317] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; DEBOULLE K, 1993, NAT GENET, V3, P31, DOI 10.1038/ng0193-31; Ebersole TA, 1996, NAT GENET, V12, P260, DOI 10.1038/ng0396-260; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GOTTESFELD JM, 1994, SCIENCE, V263, P81, DOI 10.1126/science.8272869; HEIDER H, 1994, EUR J BIOCHEM, V219, P513, DOI 10.1111/j.1432-1033.1994.tb19966.x; JONES AR, 1995, GENE DEV, V9, P1491, DOI 10.1101/gad.9.12.1491; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIRD AD, 1995, J BIOL CHEM, V270, P26742, DOI 10.1074/jbc.270.45.26742; LEE KS, 1995, MOL CELL BIOL, V15, P7143; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; MAHONE M, 1995, EMBO J, V14, P2043, DOI 10.1002/j.1460-2075.1995.tb07196.x; McBride AE, 1996, P NATL ACAD SCI USA, V93, P2296, DOI 10.1073/pnas.93.6.2296; MEIJER L, 1991, EUR J BIOCHEM, V196, P557, DOI 10.1111/j.1432-1033.1991.tb15850.x; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; OCONNELL MJ, 1994, EMBO J, V13, P4926, DOI 10.1002/j.1460-2075.1994.tb06820.x; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; PETER M, 1991, EMBO J, V10, P1535, DOI 10.1002/j.1460-2075.1991.tb07673.x; PINOLROMA S, 1993, MOL CELL BIOL, V13, P5762, DOI 10.1128/MCB.13.9.5762; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; SHENOY S, 1992, P NATL ACAD SCI USA, V89, P7237, DOI 10.1073/pnas.89.15.7237; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; STOVER DR, 1994, J BIOL CHEM, V269, P26885; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; WANG LL, 1995, J BIOL CHEM, V270, P2010, DOI 10.1074/jbc.270.5.2010; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; YAMAKITA Y, 1994, J CELL BIOL, V124, P129, DOI 10.1083/jcb.124.1.129; YAMASHIRO S, 1990, NATURE, V344, P675, DOI 10.1038/344675a0	41	44	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	1997	15	11					1247	1253		10.1038/sj.onc.1201289	http://dx.doi.org/10.1038/sj.onc.1201289			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315091				2022-12-17	WOS:A1997XV84500001
J	Maier, D; Comparone, D; Taylor, E; Zhang, ZW; Gratzl, O; Van Meir, EG; Scott, RJ; Merlo, A				Maier, D; Comparone, D; Taylor, E; Zhang, ZW; Gratzl, O; Van Meir, EG; Scott, RJ; Merlo, A			New deletion in low-grade oligodendroglioma at the glioblastoma suppressor locus on chromosome 10q25-26	ONCOGENE			English	Article						oligodendroglioma; glioblastoma suppressor gene; deletion mapping; chromosome 10q25-26	HUMAN-BRAIN-TUMORS; HUMAN GLIOMAS; GENE; HETEROZYGOSITY; RETINOBLASTOMA; MUTATIONS; ORIGIN	Loss of heterozygosity on chromosome 10 is considered to be associated with the progression of glioblastomas. Two closely related regions have recently been proposed to contain the glioblastoma suppressor locus on chromosome 10q25-26; a 1 cM region between the polymorphic (CA)(n)-repeat markers D10S587 and D10S216, and an area of 5 cM between the markers D10S221 and D10S209, To confirm and further delineate this region, we analyzed 51 glioblastomas and 11 intermediate and low-grade gliomas for loss of heterozygosity on chromosome 10, 47/62 mostly malignant gliomas displayed complete loss of chromosome 10 and nine tumors were unaltered, whereas four glioblastomas and two low-grade oligodendrogliomas had partial loss on distal 10q, With these six tumors, we constructed a deletion map with increased marker density at 10q25-26 which shows two centromeric breakpoints at the markers D10S587 and D10S216, thus only confirming the distal, but not the proximal candidate glioblastoma suppressor locus, Two out of four low-grade oligodendrogliomas displayed partial deletions on 10q25-26, This suggests that deletion on chromosome 10 is not merely a late event in the progression of glioblastomas, but could play a role earlier in the development of gliomas.	UNIV BASEL HOSP, DEPT RES, CH-4031 BASEL, SWITZERLAND; UNIV BASEL HOSP, DEPT NEUROSURG, CH-4031 BASEL, SWITZERLAND; CHU VAUDOIS, LAB TUMOR BIOL & GENET, DEPT NEUROSURG, UNIV HOSP, CH-1011 LAUSANNE, SWITZERLAND	University of Basel; University of Basel; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)			Scott, Rodney J/B-2827-2013	Scott, Rodney J/0000-0001-7724-3404; Van Meir, Erwin G./0000-0003-2444-7707				Albarosa R, 1996, AM J HUM GENET, V58, P1260; BIGNER SH, 1990, CANCER GENET CYTOGEN, V47, P141, DOI 10.1016/0165-4608(90)90024-5; CAVENEE WK, 1985, SCIENCE, V228, P501, DOI 10.1126/science.3983638; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FULTS D, 1993, GENE CHROMOSOME CANC, V7, P173, DOI 10.1002/gcc.2870070311; GYAPAY G, 1994, NAT GENET, V7, P294; JAMES CD, 1988, CANCER RES, V48, P5546; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KARLBOM AE, 1993, HUM GENET, V92, P169; Kleihues P, 1993, HISTOLOGICAL TYPING; Li LM, 1997, CELL, V88, P143, DOI 10.1016/S0092-8674(00)81866-8; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MERLO A, 1994, CANCER RES, V54, P640; Moschonas N. K., 1996, Cytogenetics and Cell Genetics, V72, P99, DOI 10.1159/000134172; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; RANSOM DT, 1992, GENE CHROMOSOME CANC, V5, P357, DOI 10.1002/gcc.2870050412; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; RASHEED BKA, 1995, ONCOGENE, V10, P2243; STECK PA, 1995, GENE CHROMOSOME CANC, V12, P255; VENTER DJ, 1991, BRIT J CANCER, V63, P753, DOI 10.1038/bjc.1991.168; WALKER MD, 1980, NEW ENGL J MED, V303, P1323, DOI 10.1056/NEJM198012043032303; WU JK, 1993, J NEURO-ONCOL, V15, P29, DOI 10.1007/BF01050260	23	44	47	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 21	1997	15	8					997	1000		10.1038/sj.onc.1201209	http://dx.doi.org/10.1038/sj.onc.1201209			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XR767	9285695				2022-12-17	WOS:A1997XR76700013
J	Edelson, MI; Scherer, SW; Tsui, LC; Welch, WR; Bell, DA; Berkowitz, RS; Mok, SC				Edelson, MI; Scherer, SW; Tsui, LC; Welch, WR; Bell, DA; Berkowitz, RS; Mok, SC			Identification of a 1300 kilobase deletion unit on chromosome 7q31.3 in invasive epithelial ovarian carcinomas	ONCOGENE			English	Article						ovary; cancer; borderline; LOH; chromosome 7	TUMOR-SUPPRESSOR GENE; FREQUENT LOSS; HUMAN BORDERLINE; SQUAMOUS-CELL; ALLELIC LOSS; CANCER; HETEROZYGOSITY; HUMAN-CHROMOSOME-7; MALIGNANCIES; ALLELOTYPE	We have used polymerase chain reaction (PCR) amplification of tandem repeats to study the pattern of allelic loss on chromosome 7q31 in invasive epithelial ovarian carcinomas and borderline ovarian tumors. Using 13 primer sets spanning loci from 7q31 to 7q32, 16 borderline and 54 invasive ovarian tumor tissue, together with their corresponding normal tissue, were analysed. Invasive epithelial ovarian tumors demonstrated loss of heterozygosity (LOH) at one or more loci on 7q in 32 of 54 cases (59%). The invasive epithelial ovarian tumors demonstrated the highest percentage of LOH at the loci D7S643 (20 of 40 informative cases, 50%) and GATA44F09 (18 of 42 informative cases, 43%). In contrary, only one borderline ovarian tumor showed LOH at one locus (GATA44F09, one of 14 informative cases, 7%). Our results display a sharp contrast in the pattern of LOH between invasive and borderline ovarian tumors suggesting that allelic loss at chromosome 7q31.3 may be involved in the development and progression of invasive epithelial ovarian tumors but not borderline ovarian tumors. Further analysis of the deletion map for the invasive epithelial ovarian tumors showed two regions Likely to harbor ovarian tumor suppressor genes including a novel 1300 kilobase common loss region flanked by GATA44F09 and D7S643.	BRIGHAM & WOMENS HOSP,LAB GYNECOL ONCOL,DIV GYNECOL ONCOL,DEPT OBSTET GYNECOL & REPROD BIOL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114; HOSP SICK CHILDREN,DEPT GENET,TORONTO,ON M5G 1X8,CANADA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Tsui, Lap-chee/A-1081-2010; Scherer, Stephen W./B-3785-2013	Scherer, Stephen W./0000-0002-8326-1999	NATIONAL CANCER INSTITUTE [R01CA063381, R01CA069291, R01CA069453] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA69291, R01CA69453, R01CA63381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAMSON GM, 1993, AM J HEMATOL, V42, P171, DOI 10.1002/ajh.2830420206; ATKIN NB, 1993, CANCER GENET CYTOGEN, V67, P123, DOI 10.1016/0165-4608(93)90164-H; Bryan EJ, 1996, CANCER RES, V56, P719; Cheng PC, 1996, J NATL CANCER I, V88, P510, DOI 10.1093/jnci/88.8.510; CLIBY W, 1993, CANCER RES, V53, P2393; Davis M, 1996, CANCER RES, V56, P741; DODSON MK, 1993, CANCER RES, V53, P4456; ECCLES DM, 1992, ONCOGENE, V7, P2069; ECCLES DM, 1992, DIS MARKERS, V10, P95; FOULKES WD, 1993, INT J CANCER, V54, P220, DOI 10.1002/ijc.2910540210; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; GALLION HH, 1990, GYNECOL ONCOL, V38, P473, DOI 10.1016/0090-8258(90)90094-2; GALLION HH, 1992, GYNECOL ONCOL, V47, P137, DOI 10.1016/0090-8258(92)90096-2; Kerr J, 1996, ONCOGENE, V13, P1815; KUNZ J, 1994, GENOMICS, V22, P439, DOI 10.1006/geno.1994.1407; LEE JH, 1990, CANCER RES, V50, P2724; Lin JC, 1996, ONCOGENE, V13, P2001; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; PIERETTI M, 1995, HUM PATHOL, V26, P393, DOI 10.1016/0046-8177(95)90139-6; RODABAUGH KJ, 1995, ONCOGENE, V11, P1249; RODABAUGH KJ, 1995, CANCER RES, V55, P2169; SATO T, 1991, CANCER RES, V51, P5118; SCHERER SW, 1992, MAMM GENOME, V3, P179, DOI 10.1007/BF00352464; TAKAHASHI S, 1995, CANCER RES, V55, P4114; TANAKA K, 1989, CANCER GENET CYTOGEN, V43, P1, DOI 10.1016/0165-4608(89)90122-2; Tangir J, 1996, ONCOGENE, V12, P735; WEITZEL JN, 1994, GYNECOL ONCOL, V55, P245, DOI 10.1006/gyno.1994.1285; WERTHEIM I, 1994, J NATL CANCER I, V86, P1549, DOI 10.1093/jnci/86.20.1549; YANGFENG TL, 1992, INT J CANCER, V52, P575, DOI 10.1002/ijc.2910520414; YANGFENG TL, 1993, INT J CANCER, V54, P546, DOI 10.1002/ijc.2910540405; ZENKLUSEN JC, 1994, ONCOGENE, V9, P2817; Zenklusen JC, 1996, MOL CARCINOGEN, V15, P167; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347	37	44	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 19	1997	14	24					2979	2984		10.1038/sj.onc.1201271	http://dx.doi.org/10.1038/sj.onc.1201271			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XF555	9205105				2022-12-17	WOS:A1997XF55500012
J	Weyman, CM; Ramocki, MB; Taparowsky, EJ; Wolfman, A				Weyman, CM; Ramocki, MB; Taparowsky, EJ; Wolfman, A			Distinct signaling pathways regulate transformation and inhibition of skeletal muscle differentiation by oncogenic Ras	ONCOGENE			English	Article						skeletal muscle; differentiation; oncogenic Ras; MAP kinase	FIBROBLAST GROWTH-FACTOR; NUCLEOTIDE DISSOCIATION STIMULATOR; PROTEIN-KINASE CASCADE; MYOGENIC DIFFERENTIATION; H-RAS; B-RAF; TERMINAL DIFFERENTIATION; MYOBLAST DIFFERENTIATION; FACTOR-BETA; CELL-CYCLE	Expression of oncogenic Ras in 23A2 skeletal myoblasts is sufficient to induce both a transformed phenotype and a differentiation-defective phenotype, but the signaling pathways activated by oncogenic Ras in these cells and their respective contribution to each phenotype have not been explored, In this study, we investigated MAP kinase activity in control 23A2 myoblasts and in 23A2 myoblasts rendered differentiation-defective by the stable expression of an oncogenic (G12V)Ha-ras gene (Ras9 cells), The MAP kinase immunoprecipitated from Ras9 cells was 30-40% more active than that from control 23A2 cells, To establish if this elevated MAP kinase activity is essential to the maintenance of the onccogenic Ras-induced phenotype, we utilized the selective MAP kinase kinase 1 (MEK1) inhibitor, PD 098059. PD 098059 decreased the MAP kinase activity in Ras9 cells to the level found in 23A2 cells. PD 098059 did not affect the ability of 23A2 myoblasts to differentiate, PD 098059 reverted the transformed morphology of Ras9 cells but did not restore the ability of these cells to express the muscle-specific myosin heavy chain gene or to form muscle fibers, Treatment with PD 098059 also did not affect the ability of oncogenic Ha-Ras to establish a non-myogenic phenotype in C3H10T1/2 cells co-expressing MyoD. These results demonstrate that the activation of MAP kinase is necessary for the transformed morphology of Ras9 cells but is not required by oncogenic Ras to establish or to maintain a differentiation-defective phenotype. While these data do not rule out the possibility that constitutive signaling by MEK1 or MAP kinase could inhibit myoblast differentiation, they clearly demonstrate that other pathways activated by oncogenic Ras are sufficient to inhibit differentiation.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Weyman, CM (corresponding author), CLEVELAND CLIN FDN,DEPT CELL BIOL,CLEVELAND,OH 44195, USA.				NCI NIH HHS [T32 CA09634] Funding Source: Medline; NIGMS NIH HHS [GM 49652] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009634] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049652, R55GM049652] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEMA S, 1994, SEMIN CANCER BIOL, V5, P147; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; BOKOCH GM, 1993, BIOCHEM J, V289, P17, DOI 10.1042/bj2890017; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DIBATTISTE D, 1993, ONCOGENE, V8, P637; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; FLORINI JR, 1986, J BIOL CHEM, V261, P6509; FOX PL, 1994, ONCOGENE, V9, P3519; GOSSETT LA, 1988, J CELL BIOL, V106, P2127, DOI 10.1083/jcb.106.6.2127; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KONG YF, 1995, MOL CELL BIOL, V15, P5205; KONIECZNY SF, 1989, ONCOGENE, V4, P473; KONIECZNY SF, 1984, CELL, V38, P791, DOI 10.1016/0092-8674(84)90274-5; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; LATHROP B, 1985, J CELL BIOL, V100, P1540, DOI 10.1083/jcb.100.5.1540; LATHROP B, 1985, J CELL BIOL, V101, P2194, DOI 10.1083/jcb.101.6.2194; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Ludolph DC, 1995, FASEB J, V9, P1595, DOI 10.1096/fasebj.9.15.8529839; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; MCCORMICK F, 1995, CURR OPIN GENET DEV, V5, P51, DOI 10.1016/S0959-437X(95)90053-5; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; OLSON EN, 1986, J CELL BIOL, V103, P1799, DOI 10.1083/jcb.103.5.1799; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PAYNE PA, 1987, P NATL ACAD SCI USA, V84, P8956, DOI 10.1073/pnas.84.24.8956; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUDNICKI MA, 1995, BIOESSAYS, V17, P203, DOI 10.1002/bies.950170306; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHNEIDER MD, 1988, MOL NEUROBIOL, V2, P1, DOI 10.1007/BF02935631; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; SPIZZ G, 1986, J BIOL CHEM, V261, P9483; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; VAIDYA TB, 1991, J CELL BIOL, V114, P809, DOI 10.1083/jcb.114.4.809; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3	54	44	46	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 13	1997	14	6					697	704		10.1038/sj.onc.1200874	http://dx.doi.org/10.1038/sj.onc.1200874			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WG430	9038377				2022-12-17	WOS:A1997WG43000008
J	Kerr, J; Leary, JA; Hurst, T; Shih, YC; Antalis, TM; Friedlander, M; Crawford, E; Khoo, SK; Ward, B; ChenevixTrench, G				Kerr, J; Leary, JA; Hurst, T; Shih, YC; Antalis, TM; Friedlander, M; Crawford, E; Khoo, SK; Ward, B; ChenevixTrench, G			Allelic loss on chromosome 7q in ovarian adenocarcinomas: Two critical regions and a rearrangement of the PLANH1 locus	ONCOGENE			English	Article						loss of heterozygosity; ovarian adenocarcinomas; tumour suppressor genes; PAI-1	TUMOR-SUPPRESSOR GENE; SQUAMOUS-CELL; FREQUENT LOSS; CARCINOMAS; HETEROZYGOSITY; CANCER; EXPRESSION; DELETION; 7Q31.1	The presence of a tumour suppressor gene on chromosome 7q is indicated by cytogenetic, loss of heterozygosity (LOH) and chromosome transfer studies, One candidate gene in this region is Plasminogen Activator Inhibitor-1 (PAI-1), The PAI-1 gene product is involved in proteolysis and may therefore influence tumour spread and invasion, We have analysed a series of 139 ovarian epithelial tumours at four loci in the region 7q21-q31 which includes the PAI-1 gene, The highest rates of loss were found in malignant tumours (FIGO stages I-IV) at markers D7S471 (38%, 20/52 informative cases) and D7S522 (34%, 15/44), No loss was seen in benign tumours and only one out of 27 (4%) informative LMP tumours demonstrated LOH, The smallest region of overlap (SRO) lies between D7S471 and PAI-1, We also identified a rearrangement in one tumour in the PAI-1 gene, suggesting that this may be the inactivated gene in this region, In addition LOH at the more distal marker, D7S522, which lies outside the SRO, shows significant association with stage (P=0.0343) and with LOH on chromosome 13 (P=0.0024), This is in contrast to all other markers examined, These data suggest the presence of two critical regions on 7q which may be important in subsets of epithelial ovarian tumours.	QUEENSLAND INST MED RES, QUEENSLAND CANC FUND RES UNIT, BRISBANE, QLD 4029, AUSTRALIA; UNIV SYDNEY, WESTMEAD HOSP, DEPT MED ONCOL, SYDNEY, NSW 2006, AUSTRALIA; UNIV SYDNEY, WESTMEAD HOSP, DEPT OBSTET & GYNAECOL, SYDNEY, NSW 2006, AUSTRALIA; UNIV QUEENSLAND, ROYAL BRISBANE HOSP, DEPT OBSTET & GYNAECOL, HERSTON, QLD 4029, AUSTRALIA; PRINCE WALES HOSP, DEPT MED ONCOL, SYDNEY, NSW 2031, AUSTRALIA	QIMR Berghofer Medical Research Institute; University of Sydney; University of Sydney; Royal Brisbane & Women's Hospital; University of Queensland			Chenevix-Trench, Georgia/AAV-2014-2020	Chenevix-Trench, Georgia/0000-0002-1878-2587				ATKIN NB, 1993, CANCER GENET CYTOGEN, V67, P123, DOI 10.1016/0165-4608(93)90164-H; CHENEVIXTRENCH G, 1992, ONCOGENE, V7, P1059; CHENEVIXTRENCH G, 1994, AM J HUM GENET, V55, P143; CHENEVIXTRENCH G, 1996, IN PRESS GENES CHROM; DAWSON S, 1991, ARTERIOSCLER THROMB, V11, P183, DOI 10.1161/01.ATV.11.1.183; ECCLES DM, 1992, ONCOGENE, V7, P2069; FOLLO M, 1989, GENE, V84, P447, DOI 10.1016/0378-1119(89)90519-2; GALLION HH, 1992, GYNECOL ONCOL, V47, P137, DOI 10.1016/0090-8258(92)90096-2; KERE J, 1989, BLOOD, V73, P230; KUPRYJANCZYK J, 1995, HUM PATHOL, V26, P387, DOI 10.1016/0046-8177(95)90138-8; LEARY JA, 1995, INT J CANCER, V64, P189, DOI 10.1002/ijc.2910640308; LEVI S, 1991, CANCER RES, V51, P3497; LOSKUTOFF DJ, 1987, BIOCHEMISTRY-US, V26, P3763, DOI 10.1021/bi00387a004; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; OSELLA P, 1992, CANCER GENET CYTOGEN, V59, P73, DOI 10.1016/0165-4608(92)90162-2; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; PEJOVIC T, 1992, GENE CHROMOSOME CANC, V4, P58, DOI 10.1002/gcc.2870040108; ROBERTS CG, 1990, CANCER GENET CYTOGEN, V48, P243, DOI 10.1016/0165-4608(90)90127-V; RODABAUGH KJ, 1995, CANCER RES, V55, P2169; SHELLING AN, 1995, BRIT J CANCER, V72, P521, DOI 10.1038/bjc.1995.367; ZENKLUSEN JC, 1994, ONCOGENE, V9, P2817; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347	25	44	47	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	1996	13	8					1815	1818						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895529				2022-12-17	WOS:A1996VM88700028
J	Cannell, EJ; Farrell, PJ; Sinclair, AJ				Cannell, EJ; Farrell, PJ; Sinclair, AJ			Epstein-Barr virus exploits the normal cell pathway to regulate Rb activity during the immortalisation of primary B-cells	ONCOGENE			English	Article						Epstein-Barr virus; phosphorylation; cell cycle; immortalisation; Retinoblastoma protein	DEPENDENT KINASE INHIBITOR; SUSCEPTIBILITY GENE-PRODUCT; D-CDK COMPLEXES; RETINOBLASTOMA PROTEIN; CYCLE CONTROL; SUPPRESSOR GENES; LYMPHOCYTES-B; EXPRESSION; LINES; P16(INK4)	Infection of human primary B-lymphocytes with Epstein-Barr virus (EBV) drives quiescent cells into continual proliferation and results in the outgrowth of immortal cell lines. This requires re-programming of the mechanisms that, in the absence of appropriate antigenic stimulation, normally prevent the proliferation of B-lymphocyes. Since the Retinoblastoma protein (pRb) and its relatives, p107 and p130, play critical roles in controlling the mammalian cell division cycle, we have investigated the expression and phosphorylation status of these proteins following EBV immortalisation of primary B-lymphocytes. In this report, me show that EBV drives the hyperphosphorylation of pRb. This is achieved by a strategy involving the altered expression of several components of the signal transduction pathway that normally regulates the phosphorylation status of pRb, including the up regulation of a number of cyclins and cyclin-dependent kinases and the down regulation of a subset of cyclin-dependent kinase inhibitors. The net result is the formation of active cyclin-dependent kinase complexes that are capable of phosphorylating and inactivating pRb. The results presented here identify the activation of a normal signal transduction pathway as an important component of the strategy used by EBV to drive cell proliferation.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,LUDWIG INST CANC RES,LONDON W2 1PG,ENGLAND	Imperial College London; Ludwig Institute for Cancer Research				Sinclair, Alison/0000-0001-8510-8691; Farrell, Paul/0000-0002-6754-9351				AAGAARD L, 1995, INT J CANCER, V61, P115, DOI 10.1002/ijc.2910610120; ALFIERI C, 1991, VIROLOGY, V181, P595, DOI 10.1016/0042-6822(91)90893-G; ALLDAY MJ, 1995, EMBO J, V14, P1382, DOI 10.1002/j.1460-2075.1995.tb07124.x; ARVANITAKIS L, 1995, J IMMUNOL, V155, P1047; BATES S, 1994, ONCOGENE, V9, P1633; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; DEBOER CJ, 1995, ONCOGENE, V10, P1833; FREDERSDORF S, 1996, IN PRESS AM J PATH; FUNDERUD S, 1990, EUR J IMMUNOL, V20, P201, DOI 10.1002/eji.1830200129; GRANA X, 1995, ONCOGENE, V11, P211; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALL M, 1995, ONCOGENE, V11, P1581; HALVEY O, 1995, SCIENCE, V267, P1018; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARA E, 1996, IN PRESS MOL CELL BI; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HOLLYOAKE M, 1995, CANCER RES, V55, P4784; JEN J, 1994, CANCER RES, V54, P6353; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KEIFF E, 1994, VIRUSES CANC, V51, P123; KEMPKES B, 1995, EMBO J, V14, P88, DOI 10.1002/j.1460-2075.1995.tb06978.x; KOUZARIDES T, 1995, SEMIN CANCER BIOL, V6, P91, DOI 10.1006/scbi.1995.0012; LALLE P, 1995, ONCOGENE, V10, P2447; LAMMIE GA, 1992, ONCOGENE, V7, P2381; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LI Y, 1994, CANCER RES, V54, P6078; Liebowitz David, 1993, P107; LUDLOW JW, 1989, CELL, V56, P67; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MARTIN JM, 1993, J VIROL, V67, P5269, DOI 10.1128/JVI.67.9.5269-5278.1993; MAYOL X, 1995, ONCOGENE, V11, P801; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OTTERSON GA, 1994, ONCOGENE, V9, P3375; PALMERO I, 1993, ONCOGENE, V8, P1049; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PENG M, 1992, ONCOGENE, V7, P1175; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; QUELLE DE, 1995, ONCOGENE, V11, P635; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P505; SINCLAIR AJ, 1994, EMBO J, V13, P3321, DOI 10.1002/j.1460-2075.1994.tb06634.x; SINCLAIR AJ, 1995, METH MOL G, V7, P89; SZEKELY L, 1995, ONCOGENE, V10, P1869; TAM SW, 1994, CANCER RES, V54, P5816; TOYOSHIMA H, 1994, CELL, V78, P64; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; VOUSDEN KH, 1995, SEMIN CANCER BIOL, V6, P109, DOI 10.1006/scbi.1995.0014; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WHYTE P, 1995, SEMIN CANCER BIOL, V6, P83, DOI 10.1006/scbi.1995.0011; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XU HJ, 1989, ONCOGENE, V4, P807; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	57	44	46	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1413	1421						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875979				2022-12-17	WOS:A1996VL38400006
J	Knippschild, U; Milne, D; Campbell, L; Meek, D				Knippschild, U; Milne, D; Campbell, L; Meek, D			p53 N-terminus-targeted protein kinase activity is stimulated in response to wild type p53 and DNA damage	ONCOGENE			English	Article						p53; DNA damage; protein kinase	TEMPERATURE-SENSITIVE MUTANT; GENE AMPLIFICATION; SARCOMA-CELLS; MOUSE P53; 3T3 CELLS; PHOSPHORYLATION; ANTIGEN; RADIATION; METH; UV	The p53 tumour suppressor protein plays a central role in the cellular defence against agents which cause genetic damage, The activity of p53 is regulated at different levels and is subject to multi-site phosphorylation by a variety of different protein kinases. In this paper me have characterised p53 N-terminus-targeted protein kinase (p53NK) activities, present in a range of cell lines, following fractionation of cellular lysates by ion exchange chromatography on HiTrap Q and Mono Q resins, Three peaks of p53NK activity were observed following fractionation of HeLa cell lysates; these activities were each able to catalyse phosphorylation of up to three residues (serines 4, 6 and 9 in murine p53) within the N-terminus of the p53 protein, Similarly, multiple p53NK activities were detected in the MethAp53(ts) cell line (which expresses the valine 135 temperature-sensitive p53 protein), Strikingly, when these cells were shifted from 38 degrees C (the non-permissive temperature) to 28 degrees C, at which the p53 adopts a mild type conformation, a fivefold stimulation of kinase activity was detected, Moreover, when the DNA damage-inducing drugs etoposide or camptothecin were added to the cells, a further stimulation of kinase activity was observed following growth at 28 degrees C, but not 38 degrees C, These data are consistent with a regulatory model in which p53 is sensitive to stress or DNA damage through phosphorylation at its N-terminus.	UNIV DUNDEE, NINEWELLS HOSP & MED SCH, BIOMED RES CTR, DUNDEE DD1 9SY, SCOTLAND	University of Dundee								BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DELEO AB, 1977, J EXP MED, V146, P720, DOI 10.1084/jem.146.3.720; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DHILLON N, 1994, EMBO J, V13, P2777, DOI 10.1002/j.1460-2075.1994.tb06571.x; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELIYAHU D, 1988, ONCOGENE, V3, P313; GANNON JV, 1991, NATURE, V349, P802; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1991, CANCER RES, V51, P6304; KNIPPSCHILD U, 1995, ONCOGENE, V11, P683; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MAYR GA, 1995, CANCER RES, V55, P2410; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1992, ONCOGENE, V7, P1361; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OTTO A, 1993, ONCOGENE, V8, P2591; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SOUSSI T, 1990, ONCOGENE, V5, P945; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	35	44	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	1996	13	7					1387	1393						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875976				2022-12-17	WOS:A1996VL38400003
J	Jongmans, W; Artuso, M; Vuillaume, M; Bresil, H; Jackson, SP; Hall, J				Jongmans, W; Artuso, M; Vuillaume, M; Bresil, H; Jackson, SP; Hall, J			The role of Ataxia telangiectasia and the DNA-dependent protein kinase in the p53-mediated cellular response to ionising radiation	ONCOGENE			English	Article						DNA-PK; ataxia-telangiectasia; DNA-repair; cell cycle; WAF1/CIP1 (p21); Ku	IONIZING-RADIATION; V(D)J RECOMBINATION; BINDING FUNCTION; TERMINAL DOMAIN; SINGLE STRANDS; P53 PROTEIN; GENE; PHOSPHORYLATION; CELLS; INDUCTION	The DNA-dependent protein kinase (DNA-PK), whose catalytic subunit shows structural similarities to the Ataxia telangiectasia (AT) gene product (ATM), has also been implicated in the p53-mediated signal transduction pathway that activates the cellular response to DNA damage produced by ionizing radiation, DNA-PK activity however was not found to be related to the transcriptional induction of WAF1/CIP1(21) in AT lymphoblastoid cell lines, following treatment with ionizing radiation, Normal protein and transcription levels of Ku70 and Ku80, as sell as DNA-PK activity, mere found-in sis different AT cell lines, 1-4 h following exposure to ionizing radiation, timepoints where reduced and delayed transcriptional induction of WAF1/CIP1 (p21) was observed, WAF1/CIP1 (p21) was found to be transcriptionally induced by p53 in normal cell lines over this same time period following exposure to ionizing radiation, These results suggest that despite the findings that in vitro DNA-PK may phosphorylate p53, in vivo it mould not appear to play a central role in the activation of p53 as a transcription factor nor can it substitute for the ATM gene product in the cellular response following exposure to ionizing radiation.	INT AGCY RES CANC,UNIT MECH CARCINOGENESIS,F-69372 LYON 08,FRANCE; UNIV CAMBRIDGE,WELLCOME CRC INST,CAMBRIDGE CB2 1QR,ENGLAND	World Health Organization; International Agency for Research on Cancer (IARC); University of Cambridge			Jackson, Stephen Philip/R-4548-2019; Dry, Kate/I-2328-2014; hall, janet/G-1372-2013	Jackson, Stephen Philip/0000-0001-9317-7937; hall, janet/0000-0002-4397-6295	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARTUSO M, 1995, ONCOGENE, V11, P1427; BALKALKIN G, 1994, P NATL ACAD SCI USA, V94, P413; BLUNT T, 1995, CELL, V80, P1; Bogue MA, 1996, GENE DEV, V10, P553, DOI 10.1101/gad.10.5.553; CAI QQ, 1994, CYTOGENET CELL GENET, V65, P221, DOI 10.1159/000133635; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Errami A, 1996, MOL CELL BIOL, V16, P1519; FISCELLA M, 1993, ONCOGENE, V8, P1519; FUCHS B, 1995, ONCOGENE, V10, P789; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1995, ONCOGENE, V11, P609; KHANNA KK, 1993, ONCOGENE, V8, P3307; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; SHILOH Y, 1995, EUR J HUM GENET, V3, P116; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8	29	44	44	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1133	1138						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808686				2022-12-17	WOS:A1996VJ20200003
J	Puthenveettil, JA; Frederickson, SM; Reznikoff, CA				Puthenveettil, JA; Frederickson, SM; Reznikoff, CA			Apoptosis in human papillomavirus16 E7-, but not E6-immortalized human uroepithelial cells	ONCOGENE			English	Article						HPV16 E7; apoptosis; p53; BAX; BCL-2; human uroepithelial cells	WILD-TYPE P53; TUMOR-SUPPRESSOR P53; P53-DEPENDENT APOPTOSIS; RETINOBLASTOMA PROTEIN; HUMAN FIBROBLASTS; CYCLE REGULATION; DNA-DAMAGE; BAX GENE; E6; BLADDER	We compared the ability of E6-, versus E7-, immortalized human uroepithelial cells (HUC) to undergo apoptosis in response to gamma (gamma) radiation. Two independent HPV16 E6-immortalized cell lines, alpha E6#1 and alpha E6#2, that showed low or undetectable p53 levels, failed to undergo apoptosis in response to 18 Gray (Gy) gamma radiation as determined by DNA fragmentation. In contrast, two independent HPV16 E7-immortalized cell lines, alpha E7#1 and alpha E7#2, both of which showed stabilized wildtype p53, underwent apoptosis in the same experiment. Interestingly, both alpha E7#1 and alpha E7#2 showed constitutively elevated BAX and lowered BCL-2 levels, compared to either alpha E6#1 or alpha E6#2. However, elevated BAX and reduced BCL-2 per se were insufficient to trigger apoptosis, as apoptosis occurred only after exposure to gamma radiation. These results support a model in which HPV16 E7-immortalized cells are primed to undergo apoptosis, given an appropriate trigger. This apoptotic response was not observed in alpha E6/E7#1 cells which, like alpha E6-HUCs, showed low p53 levels, nor in late passage alpha E7#1 with spontaneously mutated TP53. These results suggest that E7 immortalization primes HUC for apoptosis in response to gamma radiation, and that this enhanced apoptotic response is p53 dependent.	UNIV WISCONSIN, SCH MED, DEPT HUMAN ONCOL, MADISON, WI 53792 USA; UNIV WISCONSIN, SCH MED, CTR ENVIRONM TOXICOL, MADISON, WI 53792 USA; UNIV WISCONSIN, CTR COMPREHENS CANC, MADISON, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NCI NIH HHS [CA 67158-01, CA-29525-16] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067158, R01CA029525] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antinore MJ, 1996, EMBO J, V15, P1950, DOI 10.1002/j.1460-2075.1996.tb00546.x; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEMERS GW, 1994, VIROLOGY, V198, P169, DOI 10.1006/viro.1994.1019; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; FRITSCHE M, 1993, ONCOGENE, V8, P307; GORCZYCA W, 1993, CANCER RES, V53, P3186; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; KAUFMANN WK, 1993, FASEB J, V7, P1188, DOI 10.1096/fasebj.7.12.8375618; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LARUE H, 1995, CLIN CANCER RES, V1, P435; LEONARDO AD, 1994, GENE DEV, V8, P2540; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OLUMI AF, 1990, CANCER RES, V50, P7081; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; REZNIKOFF CA, 1987, J CELL PHYSIOL, V131, P285, DOI 10.1002/jcp.1041310302; REZNIKOFF CA, 1994, GENE DEV, V8, P2227, DOI 10.1101/gad.8.18.2227; REZNIKOFF CA, 1996, IN PRESS SEM ONC; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SMITH ML, 1995, ONCOGENE, V10, P1053; SPRUCK CH, 1994, CANCER RES, V54, P784; TEODORO JG, 1995, ONCOGENE, V11, P467; VOUSDEN K, 1993, FASEB J, V7, P872, DOI 10.1096/fasebj.7.10.8393818; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; Yin DX, 1996, P NATL ACAD SCI USA, V93, P3394, DOI 10.1073/pnas.93.8.3394; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZHAN QM, 1994, ONCOGENE, V9, P3743	50	44	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	1996	13	6					1123	1131						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808685				2022-12-17	WOS:A1996VJ20200002
J	Vater, CA; Bartle, LM; Dionne, CA; Littlewood, TD; Goldmacher, VS				Vater, CA; Bartle, LM; Dionne, CA; Littlewood, TD; Goldmacher, VS			Induction of apoptosis by tamoxifen-activation of a p53-estrogen receptor fusion protein expressed in E1A and T24 H-ras transformed p53(-/-) mouse embryo fibroblasts	ONCOGENE			English	Article						p53; apoptosis; tamoxifen	WILD-TYPE P53; P53-DEPENDENT GROWTH ARREST; TUMOR-SUPPRESSOR GENE; BREAST-CANCER CELLS; P53-DEFICIENT MICE; MUTANT P53; COLORECTAL-CARCINOMA; FUNCTION MUTATIONS; ESTROGEN-RECEPTOR; BINDING DOMAIN	A fusion gene consisting of wild-type p53 linked to a modified ligand binding domain of the murine estrogen receptor has been constructed and should be a useful tool for studying controlled activation of wild-type p53 function in a variety of experimental cell systems, The protein product of this gene, p53ER(TM), is expressed in cells constitutively but is not functional unless associated with tamoxifen or 4-hydroxytamoxifen, p53ER(TM) was introduced into p53-deficient mouse embryo fibroblasts (MEFs) expressing the EIA and T24 H-ras oncogenes, Activation of p53 in these transformed cells by the addition of tamoxifen or 4-hydroxytamoxifen resulted in apoptosis, In addition to engaging the apoptotic machinery, the tamoxifen-activated fusion protein exhibited other functions characteristic of wild-type p53, such as induction of WAF1 and MDM2 gene expression and activation of the p53-dependent spindle checkpoint in cells treated with nocodazole. Activation of p53ER(TM) expressed in p53-positive MEFs coexpressing E1A and ras had, at most, only a small cytotoxic effect, When three cell Lines of transformed p53(+/+) fibroblasts not expressing p53ER(TM) were tested for sensitivity to the DNA-damaging drug doxorubicin, the p53(+/+) clones displayed either comparable sensitivity, or at most an increase in drug sensitivity of less than fourfold, as compared to several p53(-/-) cell lines, Our data show that restoration of wild-type p53 activity is sufficient to trigger apoptosis in p53(-/-) MEFs transformed with EIA and T24 H-ras and suggest that rare propagable clones of p53-normal MEPs expressing the EIA and T24 H-ras oncogenes have suffered compensatory alterations that compromise the ability to undergo p53-dependent apoptosis.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Cancer Research UK	Vater, CA (corresponding author), APOPTOSIS TECHNOL INC,148 SIDNEY ST,CAMBRIDGE,MA 02139, USA.			Goldmakher, Viktor/0000-0001-6130-4436				ALDERSON LM, 1995, CANCER RES, V55, P999; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BOND JA, 1994, ONCOGENE, V9, P1885; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHILOSI M, 1994, BLOOD, V84, P4295, DOI 10.1182/blood.V84.12.4295.bloodjournal84124295; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CRIPPS KJ, 1994, ONCOGENE, V9, P2739; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DANIELIAN PS, 1993, MOL ENDOCRINOL, V7, P232, DOI 10.1210/me.7.2.232; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELROUBY S, 1993, BLOOD, V82, P3452; ESRIG D, 1994, NEW ENGL J MED, V331, P1259, DOI 10.1056/NEJM199411103311903; FURTH EE, 1981, ANAL BIOCHEM, V110, P1, DOI 10.1016/0003-2697(81)90103-2; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HARVEY M, 1993, ONCOGENE, V8, P2457; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; HSIAO M, 1994, AM J PATHOL, V145, P702; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDERS JE, 1994, ONCOGENE, V9, P2745; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OTTO A, 1993, ONCOGENE, V8, P2591; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; RENZING J, 1995, ONCOGENE, V10, P1865; ROEMER K, 1993, P NATL ACAD SCI USA, V90, P9252, DOI 10.1073/pnas.90.20.9252; RUNNEBAUM IB, 1994, ANTICANCER RES, V14, P1137; Sambrook J, 1989, MOL CLONING LAB MANU; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SRIVASTAVA S, 1993, CANCER RES, V53, P4452; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; THOMPSON TC, 1995, ONCOGENE, V10, P869; TSUKADA T, 1993, ONCOGENE, V8, P3313; VAN MEIR EG, 1995, P NATL ACAD SCI USA, V92, P1008, DOI 10.1073/pnas.92.4.1008; WANG YS, 1993, CELL GROWTH DIFFER, V4, P467; WATTEL E, 1994, BLOOD, V84, P3148, DOI 10.1182/blood.V84.9.3148.3148; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZIGLER A, 1994, NATURE, V372, P773	55	44	44	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					739	748						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761295				2022-12-17	WOS:A1996VD43300009
J	Gutmann, DH; Giordano, MJ; Mahadeo, DK; Lau, N; Silbergeld, D; Guha, A				Gutmann, DH; Giordano, MJ; Mahadeo, DK; Lau, N; Silbergeld, D; Guha, A			Increased neurofibromatosis 1 gene expression in astrocytic tumors: Positive regulation by p21-ras	ONCOGENE			English	Article						tumor suppressor gene; gliomas; p21-ras; neurofibromin; GAP	TYPE-1 GENE; CELL-LINES; NF1 GENE; PRODUCT; GROWTH; NEUROBLASTOMA; MUTATIONS; ONCOGENES; MELANOMA; NEURONS	The neurofibromatosis 1 (NF1) gene has been implicated in astrocyte growth regulation in several studies, To determine whether loss of NF1 expression is associated with progression towards malignancy in sporadic astrocytomas from individuals without NF1, twenty-eight fresh astrocytoma operative specimens (low and high grade tumors) and seven primary human astrocytoma cell lines were examined for NF1 mRNA and protein expression, In all astrocytomas examined, increased NF1 expression was observed in the tumors relative to normal resting astrocytes, This increased neurofibromin expression correlated with elevated levels of activated p21-ras measured in both the fresh tumor specimens and the primary cell lines, Furthermore, when levels of activated p21 ras were decreased in astrocytoma cells expressing the ras inhibitory Asn-17 dominant-negative mutant, levels of neurofibromin expression decreased, In addition, fibroblasts induced to express oncogenic activated p21-ras(val12) had increased expression of NF1. These results suggested that neurofibromin expression is increased in human astrocytic tumors as a result of positive feedback regulation by increased levels of activated p21-ras.	WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT NEUROSURG,ST LOUIS,MO 63110; MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO,ON M5G 1X5,CANADA; TORONTO HOSP,DIV NEUROSURG,TORONTO,ON M5T 2S8,CANADA	Washington University (WUSTL); Washington University (WUSTL); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Gutmann, DH (corresponding author), WASHINGTON UNIV,SCH MED,DEPT NEUROL,BOX 8111,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.			Gutmann, David/0000-0002-3127-5045	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001590, R29NS033494] Funding Source: NIH RePORTER; NINDS NIH HHS [NS33494-01, NS01590-04] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSEN LB, 1993, MOL CELL BIOL, V13, P487, DOI 10.1128/MCB.13.1.487; ANDERSEN LB, 1993, NAT GENET, V3, P118, DOI 10.1038/ng0293-118; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BOS JL, 1989, CANCER RES, V49, P4682; DASTON MM, 1992, NEURON, V8, P415, DOI 10.1016/0896-6273(92)90270-N; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; Duffner P K, 1988, Neurofibromatosis, V1, P201; GIORDANO MJ, 1996, J NEUROSCIENCE RS, V46, P246; GREGORY PE, 1993, SOMAT CELL MOLEC GEN, V13, P487; GUHA A, 1995, INT J CANCER, V60, P168, DOI 10.1002/ijc.2910600206; Guha A, 1996, ONCOGENE, V12, P507; GUTMANN DH, 1993, J NEUROSCI RES, V36, P216, DOI 10.1002/jnr.490360212; GUTMANN DH, 1991, P NATL ACAD SCI USA, V88, P9658, DOI 10.1073/pnas.88.21.9658; GUTMANN DH, 1995, CELL GROWTH DIFFER, V6, P315; GUTMANN DH, 1994, J NEUROSCI RES, V37, P398, DOI 10.1002/jnr.490370312; HEWETT SJ, 1993, NEUROSCI LETT, V164, P229, DOI 10.1016/0304-3940(93)90898-U; HEWETT SJ, 1995, NEUROREPORT, V6, P1565, DOI 10.1097/00001756-199507310-00025; JOHNSON MR, 1993, P NATL ACAD SCI USA, V90, P5539, DOI 10.1073/pnas.90.12.5539; KIM HA, 1995, ONCOGENE, V11, P325; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; NISTER M, 1991, J BIOL CHEM, V266, P16755; NORDLUND M, 1993, J NEUROSCI, V13, P1588; NORTON KK, 1996, IN PRESS NEUROREPORT; RICCARDI VM, 1991, NEW ENGL J MED, V324, P1283, DOI 10.1056/NEJM199105023241812; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; SCHEELE JS, 1995, P NATL ACAD SCI USA, V92, P1097, DOI 10.1073/pnas.92.4.1097; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; SHAMAH SM, 1993, MOL CELL BIOL, V13, P7203, DOI 10.1128/MCB.13.12.7203; THE I, 1993, NAT GENET, V3, P62, DOI 10.1038/ng0193-62; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741	30	44	44	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2121	2127						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668337				2022-12-17	WOS:A1996UP28300010
J	Larsen, CJ				Larsen, CJ			p16(INK4a): A gene with a dual capacity to encode unrelated proteins that inhibit cell cycle progression	ONCOGENE			English	Review						CDK inhibitors; cell cycle; oncogenesis; methylation; mRNA splicing					Larsen, CJ (corresponding author), INSERM U301,INST MOLEC GENET,27 RUE JULIETTE DODU,F-75010 PARIS,FRANCE.							BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; Cayuela JM, 1996, BLOOD, V87, P2180, DOI 10.1182/blood.V87.6.2180.bloodjournal8762180; COLEMAN A, 1994, CANCER RES, V54, P344; CORDONCARDO C, 1995, AM J PATHOL, V147, P545; DURO D, 1994, CR ACAD SCI III-VIE, V317, P913; DURO D, 1995, ONCOGENE, V11, P21; DURO D, 1996, IN PRESS CANC RES; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MAO L, 1995, CANCER RES, V55, P2995; MERLO A, 1995, NAT MED, V1, P692; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OGAWA S, 1994, BLOOD, V84, P2431, DOI 10.1182/blood.V84.8.2431.bloodjournal8482431; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OKUDA T, 1995, BLOOD, V85, P2321, DOI 10.1182/blood.V85.9.2321.bloodjournal8592321; OLOPADE OI, 1992, GENOMICS, V14, P437, DOI 10.1016/S0888-7543(05)80238-1; OTTERSON GA, 1995, ONCOGENE, V11, P1211; QUELLE DE, 1995, CELL, V83, P993; QUESNEL B, 1995, BLOOD, V85, P657, DOI 10.1182/blood.V85.3.657.bloodjournal853657; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; STONE S, 1995, CANCER RES, V55, P2988; STRANKS G, 1995, BLOOD, V85, P893, DOI 10.1182/blood.V85.4.893.bloodjournal854893; TAKEUCHI S, 1995, BLOOD, V86, P755, DOI 10.1182/blood.V86.2.755.bloodjournal862755	37	44	47	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2041	2044						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668328				2022-12-17	WOS:A1996UP28300001
J	Wu, SJ; Pena, A; Korcz, A; Soprano, DR; Soprano, KJ				Wu, SJ; Pena, A; Korcz, A; Soprano, DR; Soprano, KJ			Overexpression of Mxi1 inhibits the induction of the human ornithine decarboxylase gene by the Myc/Max protein complex	ONCOGENE			English	Article						Mxi1; ODC; c-myc/max; cell growth; cell cycle	C-MYC; MESSENGER-RNA; GROWTH ARREST; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; CELL-TRANSFORMATION; SENSITIVE METHOD; MAMMALIAN-CELLS; MOUSE KIDNEY; EXPRESSION	We have previously shown that the Myc/Max protein complex plays a role in the growth-associated expression of the human ornithine decarboxylase gene. Mxi1 and Mad, novel Max-associated proteins have been identified and shown to form heterodimers with Max which bind efficiently to the Myc/Max consensus recognition sequence, CACGTG, in vitro. However, formation of Max/Mxi1 or Max/Mad heterodimers results in a reduction in Myc/Max dependent transcriptional activation of reporter plasmid constructs containing the consensus element. In light of the evidence that ODC is transcriptionally regulated in vitro and in vivo by the Myc/Max protein complex and the potential role of Mxi1 and Mad as antagonists of Myc transactivation activity, we set out to determine if one of these Max associated proteins, Mxi1, could affect the regulation of ODC expression by Myc/Max and if this regulation was correlated to growth status, Our results show that overexpression of Mxi1 does in fact inhibit ODC gene expression in a dose-dependent manner both in vivo and in vitro. In addition, evidence is presented which shows that levels of Mxi1 are up-regulated during long term quiescence and down-regulated following growth stimulation by serum. These results suggest that alterations in the levels of Max-associated proteins such as Mxi1 can modulate critical levels of functional Myc/Max protein complexes. This can alter transcriptional transactivation of Myc-regulated targets and as a consequence affect levels of genes essential for initiation and/or maintenance of growth.	TEMPLE UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University				Korcz, Aleksandra/0000-0002-9501-3343	NCI NIH HHS [CA 56309, CA 64945] Funding Source: Medline; NIDDK NIH HHS [DK 49045] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064945, P01CA056309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049045] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAMSEN MS, 1990, MOL CELL BIOL, V10, P5525, DOI 10.1128/MCB.10.10.5525; ALBAROSA R, 1995, HUM GENET, V95, P709; AUGENLICHT LH, 1974, EXP CELL RES, V89, P255, DOI 10.1016/0014-4827(74)90789-7; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERGER FG, 1984, J BIOL CHEM, V259, P7941; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTER R, 1991, ONCOGENE, V6, P229; COSENZA SC, 1988, J BIOL CHEM, V263, P12751; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HOLTTA E, 1993, J CELL BIOL, V122, P903, DOI 10.1083/jcb.122.4.903; HOLTTA E, 1988, J BIOL CHEM, V263, P4500; KAHANA C, 1984, P NATL ACAD SCI-BIOL, V81, P3645, DOI 10.1073/pnas.81.12.3645; KATZ A, 1987, MOL CELL BIOL, V7, P2641, DOI 10.1128/MCB.7.7.2641; KONTULA KK, 1984, P NATL ACAD SCI-BIOL, V81, P731, DOI 10.1073/pnas.81.3.731; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LARSSON LG, 1994, ONCOGENE, V9, P1247; LORD KA, 1990, ONCOGENE, V5, P387; LU L, 1991, BIOCHEM J, V277, P671, DOI 10.1042/bj2770671; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MANZELLA JM, 1990, J BIOL CHEM, V265, P11817; MCCONLOGUE L, 1984, P NATL ACAD SCI-BIOL, V81, P540, DOI 10.1073/pnas.81.2.540; MOONSLEHNER K, 1991, MOL CELL BIOL, V11, P886; MOSHIER JA, 1993, CANCER RES, V53, P2618; OWEN TA, 1987, J BIOL CHEM, V262, P15111; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1988, CANCER RES, V48, P759; PENA A, 1995, J CELL PHYSIOL, V162, P234, DOI 10.1002/jcp.1041620209; PENA A, 1993, J BIOL CHEM, V268, P27277; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RAPPOLEE DA, 1989, J CELL BIOCHEM, V39, P1, DOI 10.1002/jcb.240390102; REDDY CD, 1992, ONCOGENE, V7, P2085; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SETH A, 1986, GENE, V42, P49, DOI 10.1016/0378-1119(86)90149-6; SISTONEN L, 1989, J CELL BIOL, V109, P1911, DOI 10.1083/jcb.109.5.1911; SISTONEN L, 1989, EMBO J, V8, P815, DOI 10.1002/j.1460-2075.1989.tb03442.x; SISTONEN L, 1987, EXP CELL RES, V168, P518, DOI 10.1016/0014-4827(87)90024-3; SOPRANO KJ, 1987, MOL CELL BIOCHEM, V75, P61, DOI 10.1007/BF00231609; SOPRANO KJ, 1994, J CELL BIOCHEM, V54, P405, DOI 10.1002/jcb.240540407; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; THOMAS P, 1980, P NATL ACAD SCI USA, V77, P54201; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WETTERS TV, 1989, MOL CELL BIOL, V9, P5484, DOI 10.1128/MCB.9.12.5484; WETTERS TV, 1989, NUCLEIC ACIDS RES, V17, P9843, DOI 10.1093/nar/17.23.9843; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	54	44	44	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					621	629						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637719				2022-12-17	WOS:A1996TV59700019
J	Fromm, L; Overbeek, PA				Fromm, L; Overbeek, PA			Regulation of cyclin and cyclin-dependent kinase gene expression during lens differentiation requires the retinoblastoma protein	ONCOGENE			English	Article						retinoblastoma; cell cycle; cyclins; cyclin-dependent kinases; lens; crystallins	CELL-CYCLE; PRODUCT; PHOSPHORYLATION; MOUSE; IDENTIFICATION; ACTIVATION	The retinoblastoma protein (pRb) functions as a negative regulator of the cell cycle and is essential to maintain certain cell types in a post-mitotic state during terminal differentiation. In the ocular lens, inactivation of this protein is sufficient to cause lens fiber cells, which are normally post-mitotic, to enter the cell cycle. The current studies address whether regulation of the cell cycle during lens fiber differentiation in normal lenses or in lenses in which pRB has been inactivated is accompanied by changes in expression of cyclin and cyclin-dependent kinase genes. In the normal lens, our experiments using in-situ hybridization reveal that the expression of cyclin A, cyclin B1, cdc2 and cdk2 is restricted to the proliferative epithelial cells, with no expression in the differentiating fiber cells. Cyclins D1 and D2 and cdk4 show a less restrictive pattern and are expressed in some of the post-mitotic cells. Lenses from RB-deficient embryos, in contrast, show inappropriate expression in the fiber cells of cyclins A, B1 and E, as well as cdc2 and cdk2. The lens fiber cells in these embryos express protein markers for differentiation, such as beta- and gamma-crystallins, even though the cells do not withdraw from the cell cycle. These results indicate that the regulated expression of multiple cell cycle regulatory genes during lens fiber cell differentiation requires the presence of pRb.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT OPHTHALMOL,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine				Overbeek, Paul/0000-0001-9784-2084				CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P263, DOI 10.1002/cne.901880205; CHAPMAN DL, 1992, MOL REPROD DEV, V33, P259, DOI 10.1002/mrd.1080330305; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DAMJANOV I, 1994, BIOCHEM BIOPH RES CO, V201, P994, DOI 10.1006/bbrc.1994.1800; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FROMM L, 1994, MOL CELL BIOL, V14, P6743, DOI 10.1128/MCB.14.10.6743; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HOLLINGSWORTH RE, 1993, CURR OPIN GENET DEV, V3, P55, DOI 10.1016/S0959-437X(05)80341-7; ISHII T, 1993, EXP CELL RES, V208, P407, DOI 10.1006/excr.1993.1262; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; KATO J, 1993, GENE DEV, V7, P331; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCAVOY JW, 1978, J EMBRYOL EXP MORPH, V44, P149; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; NEVINS JR, 1992, SCIENCE, V258, P424; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PIATIGORSKY J, 1981, DIFFERENTIATION, V19, P134, DOI 10.1111/j.1432-0436.1981.tb01141.x; ROBINSON ML, 1995, DEVELOPMENT, V121, P505; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SPITKOVSKY D, 1994, J VIROL, V68, P2206, DOI 10.1128/JVI.68.4.2206-2214.1994; SPURR NK, 1990, J DNA SEQUENCING MAP, V1, P49; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	40	44	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					69	75						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552401				2022-12-17	WOS:A1996TQ01400009
J	Ekstrand, BC; Mansfield, TA; Bigner, SH; Fearon, ER				Ekstrand, BC; Mansfield, TA; Bigner, SH; Fearon, ER			DCC expression is altered by multiple mechanisms in brain tumors	ONCOGENE			English	Article						DCC (deleted in colorectal cancer) gene; brain tumor; tumor suppressor genes; chromosome 18q; glioblastoma; cancer genetics	MALIGNANT HUMAN GLIOMAS; CHROMOSOMAL-ABNORMALITIES; HUMAN MEDULLOBLASTOMA; COLORECTAL CANCERS; SUPPRESSOR GENES; HETEROZYGOSITY; AMPLIFICATION; ASTROCYTOMA; XENOGRAFTS; RNA	The DCC (deleted in colorectal cancer) candidate tumor suppressor gene spans greater than 1350 kilobases at chromosome 18q21.1 and encodes a transmembrane protein of unknown function. Although DCC is expressed in a number of adult tissues, its expression is highest in the brain and we have, therefore, undertaken studies to determine if DCC inactivation might contribute to tumors arising there, Decreased or absent DCC protein expression was noted in more than 50% of the thirty brain tumors studied. Although specific mutations in the DCC gene were not identified, a variety of mechanisms appeared to contribute to the altered DCC expression, including allelic loss, aberrant splicing of transcripts and allele-specific loss of transcripts. In total, the data suggest that DCC inactivation may be important in brain tumor pathogenesis.	YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510; DUKE UNIV,SCH MED,DEPT PATHOL,DURHAM,NC 27706	Yale University; Yale University; Yale University; Duke University					NICHD NIH HHS [HD07149] Funding Source: Medline; NIGMS NIH HHS [GM07205] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIGNER SH, 1988, CANCER RES, V48, P405; BIGNER SH, 1989, CANCER GENET CYTOGEN, V40, P111, DOI 10.1016/0165-4608(89)90152-0; BIGNER SH, 1988, CANCER GENET CYTOGEN, V30, P91, DOI 10.1016/0165-4608(88)90096-9; BIGNER SH, 1990, CANCER RES, V50, P2347; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; CHO KR, 1995, CURR OPIN GENET DEV, V5, P72, DOI 10.1016/S0959-437X(95)90056-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLEAVER JE, 1994, CELL, V76, P1, DOI 10.1016/0092-8674(94)90165-1; COLLINS VP, 1993, FASEB J, V7, P926, DOI 10.1096/fasebj.7.10.8344489; FAULKNER KW, 1983, J PEDIATR-US, V103, P600, DOI 10.1016/S0022-3476(83)80598-8; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FUJIMOTO M, 1989, GENOMICS, V4, P210, DOI 10.1016/0888-7543(89)90302-9; FULTS D, 1990, CANCER RES, V50, P5784; GIANI C, 1994, CANCER RES, V54, P6338; HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HUMPHREY PA, 1988, CANCER RES, V48, P2231; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; ILINO H, 1994, CANCER, V73, P1324; ITOH F, 1993, INT J CANCER, V53, P260, DOI 10.1002/ijc.2910530215; JAMES CD, 1988, CANCER RES, V48, P5546; JEN J, 1994, CANCER RES, V54, P6353; JOSYLN G, 1991, CELL, V66, P601; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KARLBOM AE, 1993, HUM GENET, V92, P169; KLEIHUES P, 1991, HISTOLOGICAL TYPING; KLINGELHUTZ AJ, 1995, ONCOGENE, V10, P1581; KNUDSON AG, 1993, NAT GENET, V5, P103, DOI 10.1038/ng1093-103; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KORNBLITH PL, 1987, NEUROLOGIC ONCOLOGY, P35; KRAFT R, 1988, BIOTECHNIQUES, V6, P554; LANG FF, 1994, J NEUROSURG, V81, P427, DOI 10.3171/jns.1994.81.3.0427; LEON SP, 1994, NEUROSURGERY, V34, P708, DOI 10.1227/00006123-199404000-00021; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MIYAKE S, 1994, CANCER RES, V54, P3007; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; PIERCEALL WE, 1994, DEV BIOL, V166, P654, DOI 10.1006/dbio.1994.1345; PIERCEALL WE, 1994, J CELL BIOL, V124, P1017, DOI 10.1083/jcb.124.6.1017; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; RASHEED BKA, 1994, CANCER RES, V54, P1324; REALE MA, 1994, CANCER RES, V54, P4493; ROYDS JA, 1986, ACTA NEUROPATHOL, V70, P320, DOI 10.1007/BF00686091; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHECK AC, 1993, CANCER RES, V53, P5605; SCHERER JH, 1940, AM J CANCER, V40, P159; SCHMIDT EE, 1994, CANCER RES, V54, P6321; Schold S C Jr, 1983, J Neurooncol, V1, P5; SHATKIN AJ, 1969, FUNDAMENTAL TECHNIQU, P231; VIELMETTER J, 1994, J CELL BIOL, V127, P2009, DOI 10.1083/jcb.127.6.2009; WAINWRIGHT B, 1994, NAT GENET, V8, P3, DOI 10.1038/ng0994-3; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WIKSTRAND CJ, 1983, CANCER RES, V43, P3327	54	44	45	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2393	2402						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570191				2022-12-17	WOS:A1995TK70200024
J	BUCK, V; ALLEN, KE; SORENSEN, T; BYBEE, A; HIJMANS, EM; VOORHOEVE, PM; BERNARDS, R; LATHANGUE, NB				BUCK, V; ALLEN, KE; SORENSEN, T; BYBEE, A; HIJMANS, EM; VOORHOEVE, PM; BERNARDS, R; LATHANGUE, NB			MOLECULAR AND FUNCTIONAL-CHARACTERIZATION OF E2F-5, A NEW MEMBER OF THE E2F FAMILY	ONCOGENE			English	Article						E2F; DP; TRANSCRIPTION FACTOR; CELL CYCLE	RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; CYCLIN-A; BINDING PROTEIN; CLONING; COMPLEX; CDNA; P107; IDENTIFICATION; EXPRESSION	The transcription factor DRTF1/E2F is implicated in the control of cellular proliferation due to its interaction with key regulators of cell cycle progression, such as the retinoblastoma tumour suppressor gene product and related pocket proteins, cyclins and cyclin-dependent kinases. DRTF1/E2F DNA binding activity arises when a member of two distinct families of proteins, DP and E2F, interact as DP/E2F heterodimers. Here, we report the isolation and characterisation of a new member of the E2F family of proteins, called E2F-5. E2F-5 was isolated through a yeast two hybrid assay in which a 14.5 d.p.c. mouse embryo library was screened for molecules capable of binding to murine DP-1, but also interacts with all known members of the DP family of proteins. E2F-5 exists as a physiological heterodimer with DP-1 in the generic DRTF1/E2F DNA binding activity present in mammalian cell extracts, an interaction which results in co-operative DNA binding activity and transcriptional activation through the E2F site. A potent transcriptional activation domain, which functions in both yeast and mammalian cells and resides in the C-terminal region of E2F-5, is specifically inactivated upon pocket protein binding. Comparison of the sequence with other members of the family indicates that E2F-5 shows a greater level of similarity with E2F-4 than to E2F-1, -2 and -3. The structural and functional similarity of E2F-5 and E2F-4 defines a subfamily of E2F proteins.	NATL INST MED RES,MRC,EUKARYOT MOLEC GENET LAB,LONDON NW7 1AA,ENGLAND; NETHERLANDS CANC INST,DIV MOLEC CARCINOGENESIS,1066 CX AMSTERDAM,NETHERLANDS	MRC National Institute for Medical Research; Netherlands Cancer Institute				Allen, Liz/0000-0001-8579-7730				BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; GIRLING R, 1994, MOL BIOL CELL, V5, P1081, DOI 10.1091/mbc.5.10.1081; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HEIBERT SW, 1992, GENE DEV, V6, P177; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIJMANS EM, 1995, IN PRESS MOL CELL BI; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOOSS KU, 1994, EMBO J, V13, P1467, DOI 10.1002/j.1460-2075.1994.tb06401.x; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LATHANGUE NB, 1990, NUCLEIC ACIDS RES, V18, P2929, DOI 10.1093/nar/18.10.2929; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; NEVINS JR, 1992, SCIENCE, V258, P424; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; WEBSTER NJG, 1989, EMBO J, V8, P1441, DOI 10.1002/j.1460-2075.1989.tb03526.x; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x	36	44	47	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					31	38						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7542760				2022-12-17	WOS:A1995RJ29500005
J	SU, LC; MUKHERJEE, AB; MUKHERJEE, BB				SU, LC; MUKHERJEE, AB; MUKHERJEE, BB			EXPRESSION OF ANTISENSE OSTEOPONTIN RNA INHIBITS TUMOR PROMOTER-INDUCED NEOPLASTIC TRANSFORMATION OF MOUSE JB6 EPIDERMAL-CELLS	ONCOGENE			English	Article						OSTEOPONTIN; ANTISENSE OPN; TUMOR PROMOTION	RAT-KIDNEY CELLS; SECRETED PHOSPHOPROTEIN; BONE SIALOPROTEIN; MESSENGER-RNA; PHYSIOLOGICAL-PROPERTIES; NONPHOSPHORYLATED FORMS; BINDING-PROPERTIES; MAMMALIAN-CELLS; PROTEINS; TUMORIGENICITY	Elevated expression of osteopontin (OPN), a secreted adhesive phosphoglycoprotein, is frequently associated with many transformed cell lines of epithelial and stromal origin. Moreover, several clonal lines of preneoplastic JB6 cells derived from Balb/c mouse epidermal cultures (Colburn et al., 1978, 1979), upon treatment with 12-O-tetradecanoyl phorbol-13-acetate (TPA), become irreversibly oncogenic and concomitantly synthesize OPN at elevated levels (Smith and Denhardt, 1989). In the present study we sought to determine whether OPN expression facilitates transformation of such preneoplastic (initiated) cells. We transfected TPA-promotable JB6 c141.5a cells with an expression vector containing mouse OPN cDNA in antisense orientation under transcriptional control of dexamethasone-inducible MMTV-LTR promoter. Four stably transfected clones, which expressed drastically reduced levels of OPN in the presence of both dexamethasone and TPA, were characterized. We found that (a) more than 20 copies of OPN antisense cDNA were stably incorporated into the genome of cells from two of these clones that were examined by Southern blot analysis; (b) dexamethasone-induced expression of antisense OPN RNA prevented augmented OPN expression at both mRNA and protein levels following TPA treatment; and (c) cells from all four clones failed to form colonies in soft agar medium containing both dexamethasone and TPA. Taken together, these data demonstrate that inhibition of elevated OPN expression blocks TPA-induced anchorage-independent growth of JB6 c141.5a cells, suggesting the possibility that OPN overproduction is causally related to transformation of preneoplastic cells.	MCGILL UNIV,DEPT BIOL,MONTREAL,PQ H3A 1B1,CANADA; MCGILL UNIV,DEPT HUMAN GENET,MONTREAL,PQ H3A 1B1,CANADA; NICHHD,HUMAN GENET BRANCH,DEV GENET SECT,BETHESDA,MD 20892	McGill University; McGill University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								BEHREND EI, 1993, J BIOL CHEM, V268, P11172; BEHREND EI, 1994, CANCER RES, V54, P832; BENINATI S, 1994, J BIOCHEM-TOKYO, V115, P675, DOI 10.1093/oxfordjournals.jbchem.a124395; BUTLER WT, 1989, CONNECT TISSUE RES, V23, P123, DOI 10.3109/03008208909002412; CASTAGNOLA P, 1991, J BIOL CHEM, V266, P9944; CHACKALAPARAMPI.I, 1985, J VIROL, V53, P841; CHAMBERS AF, 1992, ANTICANCER RES, V12, P43; CHAMBERS AF, 1993, CANCER RES, V53, P701; CHEN Y, 1992, J BIOL CHEM, V267, P24871; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COLBURN NH, 1978, CANCER RES, V38, P624; COLBURN NH, 1979, NATURE, V282, P589; CRAIG AM, 1988, BIOCHEM BIOPH RES CO, V157, P166, DOI 10.1016/S0006-291X(88)80028-7; CRAIG AM, 1990, INT J CANCER, V46, P133, DOI 10.1002/ijc.2910460124; CRAIG AM, 1989, J BIOL CHEM, V264, P9682; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; GARDNER HAR, 1994, ONCOGENE, V9, P2321; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; NEMIR M, 1989, J BIOL CHEM, V264, P18202; NOMURA S, 1988, J CELL BIOL, V106, P441, DOI 10.1083/jcb.106.2.441; NOSE K, 1990, CELL GROWTH DIFFER, V1, P511; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; OLDBERG A, 1988, J BIOL CHEM, V263, P19433; PRINCE CW, 1991, BIOCHEM BIOPH RES CO, V177, P1205, DOI 10.1016/0006-291X(91)90669-X; REINHOLT FP, 1990, P NATL ACAD SCI USA, V77, P4473; ROSS FP, 1993, J BIOL CHEM, V268, P9901; SENGER DR, 1979, CELL, V16, P885, DOI 10.1016/0092-8674(79)90103-X; SENGER DR, 1983, NATURE, V302, P714, DOI 10.1038/302714a0; SENGER DR, 1980, NATURE, V286, P619, DOI 10.1038/286619a0; SENGER DR, 1989, BIOCHIM BIOPHYS ACTA, V996, P43, DOI 10.1016/0167-4838(89)90092-7; SENGER DR, 1988, CANCER RES, V48, P5770; SINGH K, 1990, J BIOL CHEM, V265, P18696; SINGH K, 1993, J BIOCHEM-TOKYO, V114, P702, DOI 10.1093/oxfordjournals.jbchem.a124240; SINGH K, 1992, J BIOL CHEM, V267, P23847; SMITH BM, 1986, CANCER RES, V46, P701; SMITH JH, 1987, J CELL BIOCHEM, V34, P13, DOI 10.1002/jcb.240340103; SMITH JH, 1989, J CELL PHYSIOL, V139, P189, DOI 10.1002/jcp.1041390126	39	44	44	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2163	2169						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784060				2022-12-17	WOS:A1995RB70300011
J	FERNANDEZ, A; FOSDICK, LJ; MARIN, MC; DIAZ, C; MCDONNELL, TJ; ANANTHASWAMY, HN; MCCONKEY, DJ				FERNANDEZ, A; FOSDICK, LJ; MARIN, MC; DIAZ, C; MCDONNELL, TJ; ANANTHASWAMY, HN; MCCONKEY, DJ			DIFFERENTIAL REGULATION OF ENDOGENOUS ENDONUCLEASE ACTIVATION IN ISOLATED MURINE FIBROBLAST NUCLEI BY RAS AND BCL-2	ONCOGENE			English	Note						APOPTOSIS; RAS; BCL-2; NUCLEI	TUMOR NECROSIS FACTOR; FACTOR-MEDIATED CYTOTOXICITY; DNA FRAGMENTATION; MEMBRANE PROTEIN; CELL LINES; APOPTOSIS; EXPRESSION; THYMOCYTES; DEATH	Transfection of a murine fibroblast cell line with an activated form of the Harvey ras oncogene conferred sensitivity to apoptosis induced by various agents. This intrinsic sensitivity to apoptosis correlated with the expression of endogenous endonuclease activity in isolated nuclei that was undetectable in the untransfected parental cell line. Subsequent transfection with the human bcl-2 oncogene prevented the morphological and biochemical features of apoptosis in whole cells, although it failed to confer complete protection against cell death. Furthermore, transfection of the bcl-2 oncogene also inhibited the enhanced endonuclease activity in isolated nuclei. Our results indicate that some of the effects of Ha-ras and bcl-2 and potentially other oncogenes, are exerted on the biochemical machinery of apoptosis at the level of the nucleus.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CELL BIOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT IMMUNOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC PATHOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center			Marin, Maria C/G-1040-2010; Marín Vieira, María del Carmen/B-8108-2015	Marin, Maria C/0000-0002-7149-287X; Marín Vieira, María del Carmen/0000-0002-7149-287X	NATIONAL CANCER INSTITUTE [R01CA046523, R01CA062597] Funding Source: NIH RePORTER; NCI NIH HHS [CA-09255-02, R01-CA-46523, R01-CA-62597] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARENDS MJ, 1993, BRIT J CANCER, V68, P1127, DOI 10.1038/bjc.1993.492; BAFFY G, 1993, J BIOL CHEM, V268, P6511; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; DEJONG D, 1994, CANCER RES, V54, P256; FERNANDEZ A, 1994, ONCOGENE, V9, P2009; FERNANDEZSARABI.MJ, 1993, NATURE, V366, P274; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HENNET T, 1993, CANCER RES, V53, P1456; HEWISH DR, 1973, BIOCHEM BIOPH RES CO, V52, P504, DOI 10.1016/0006-291X(73)90740-7; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; ITOH N, 1993, J IMMUNOL, V151, P621; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LASTER SM, 1988, J IMMUNOL, V141, P2629; MCCONKEY DJ, 1988, SCIENCE, V242, P256, DOI 10.1126/science.3262923; MCCONKEY DJ, 1989, J BIOL CHEM, V264, P13399; NICOTERA P, 1989, P NATL ACAD SCI USA, V86, P453, DOI 10.1073/pnas.86.2.453; SCHMID DS, 1986, P NATL ACAD SCI USA, V83, P1881, DOI 10.1073/pnas.83.6.1881; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TOMEI LD, 1993, P NATL ACAD SCI USA, V90, P853, DOI 10.1073/pnas.90.3.853; VANHAESEBROECK B, 1993, ONCOGENE, V8, P1075; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	25	44	44	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					769	774						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862455				2022-12-17	WOS:A1995QH61200018
J	MUCA, C; VALLAR, L				MUCA, C; VALLAR, L			EXPRESSION OF MUTATIONALLY ACTIVATED G-ALPHA(S) STIMULATES GROWTH AND DIFFERENTIATION OF THYROID FRTL5 CELLS	ONCOGENE			English	Article							ADENYLATE-CYCLASE ACTIVITY; HUMAN PITUITARY-TUMORS; G-PROTEIN; THYROTROPIN RECEPTOR; IODIDE EFFLUX; GSP ONCOGENE; TSH RECEPTOR; CAMP; INHIBITION; ALPHA	The alpha subunit of the GTP-binding protein G(s) mediates hormonal stimulation of adenylyl cyclase. Human pituitary and thyroid tumours harbour mutations of G alpha(s) that constitutively activate the protein by inhibiting its intrinsic GTPase activity. We have investigated the mitogenic action of mutationally activated alpha(s) in thyroid FRTL5 cells, a cell line dependent upon thyroid-stimulating hormone (TSH) for both growth and differentiation. Introduction of alpha(s) carrying the substitution of glutamine-227 with leucine (Q227L alpha(s)) by retroviral infection of FRTL5 cells resulted in the expected stimulation of membrane adenylyl cyclase activity and in increased intracellular accumulation of cAMP. Measurements of cytosolic Ca2+ levels did not detect any concomitant effect on the polyphosphoinositide-Ca2+ signalling pathway. Expression of Q227L alpha(s) conferred to FRTL5 cells the ability to synthesize DNA in the absence of TSH, as revealed by [H-3]thymidine incorporation experiments, and to proliferate independently of the mitogenic hormone, although with a rate of growth slower than that observed with TSH stimulation. The effect of Q227L alpha(s) on cell proliferation was associated with the constitutive activation of iodide the constitutive uptake. The results indicate that expression of mutationally activated G alpha(s) is sufficient to bypass the requirement for TSH and promotes autonomous growth and activation of thyroid-specific differentiated functions in FRTL5 cells.	UNIV MILAN,DIBIT,SCI INST SAN RAFFAELE,I-20132 MILAN,ITALY; UNIV MILAN,CNR,CTR CYTOPHARMACOL,DEPT PHARMACOL,I-20132 MILAN,ITALY	University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Consiglio Nazionale delle Ricerche (CNR); University of Milan								AKAMIZU T, 1990, P NATL ACAD SCI USA, V87, P5677, DOI 10.1073/pnas.87.15.5677; BENDER JL, 1983, J BIOL CHEM, V258, P2432; BONE EA, 1986, ENDOCRINOLOGY, V119, P2193, DOI 10.1210/endo-119-5-2193; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BURTON FH, 1991, NATURE, V350, P74, DOI 10.1038/350074a0; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; CLEMENTI E, 1990, ONCOGENE, V5, P1059; CONTI M, 1991, ENDOCR REV, V12, P218, DOI 10.1210/edrv-12-3-218; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CORDA D, 1985, J BIOL CHEM, V260, P9230; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; FAURE M, 1994, J BIOL CHEM, V269, P7851; FRODIN M, 1994, J BIOL CHEM, V269, P6207; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HEN R, 1989, P NATL ACAD SCI USA, V86, P4785, DOI 10.1073/pnas.86.12.4785; KOSUGI S, 1992, J BIOL CHEM, V267, P24153; LAMY F, 1993, J BIOL CHEM, V268, P8398; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MA YH, 1994, ENDOCRINOLOGY, V134, P42, DOI 10.1210/en.134.1.42; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MEINKOTH JL, 1992, J BIOL CHEM, V267, P13239; MISRAHI M, 1990, BIOCHEM BIOPH RES CO, V166, P394, DOI 10.1016/0006-291X(90)91958-U; OKAJIMA F, 1988, ENDOCRINOLOGY, V123, P1035, DOI 10.1210/endo-123-2-1035; OSULLIVAN C, 1991, MOL CARCINOGEN, V4, P345, DOI 10.1002/mc.2940040503; PARMENTIER M, 1989, SCIENCE, V246, P1620, DOI 10.1126/science.2556796; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; SPADA A, 1990, J CLIN ENDOCR METAB, V71, P1421, DOI 10.1210/jcem-71-6-1421; STERNWEIS PC, 1994, CURR OPIN CELL BIOL, V6, P198, DOI 10.1016/0955-0674(94)90136-8; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; SUAREZ HG, 1991, ONCOGENE, V6, P677; TRAMONTANO D, 1988, ENDOCRINOLOGY, V122, P127, DOI 10.1210/endo-122-1-127; VALENTE WA, 1983, ENDOCRINOLOGY, V112, P71, DOI 10.1210/endo-112-1-71; VALLAR L, 1987, NATURE, V330, P566, DOI 10.1038/330566a0; VALLAR L, 1990, J BIOL CHEM, V265, P10320; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1099, DOI 10.1210/endo-114-4-1099; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YATANI A, 1987, SCIENCE, V238, P1288, DOI 10.1126/science.2446390; YATANI A, 1988, J BIOL CHEM, V263, P9887; ZACHARY I, 1990, BIOCHEM BIOPH RES CO, V168, P1184, DOI 10.1016/0006-291X(90)91154-K	43	44	44	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3647	3653						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7526317				2022-12-17	WOS:A1994PT39200028
J	STEINMANN, KE; PEI, XF; STOPPLER, H; SCHLEGEL, R; SCHLEGEL, R				STEINMANN, KE; PEI, XF; STOPPLER, H; SCHLEGEL, R; SCHLEGEL, R			ELEVATED EXPRESSION AND ACTIVITY OF MITOTIC REGULATORY PROTEINS IN HUMAN PAPILLOMAVIRUS IMMORTALIZED KERATINOCYTES	ONCOGENE			English	Article							SV40 LARGE-T; CELL-CYCLE REGULATION; RETINOBLASTOMA GENE-PRODUCT; ADENOVIRUS E1A PROTEINS; OPEN READING FRAMES; FISSION YEAST; TYROSINE PHOSPHORYLATION; ALTERED DIFFERENTIATION; TRANSCRIPTION FACTOR; ACTIVATES P34CDC2	The E6 and E7 proteins of human papillomavirus (HPV) types 16 and 18 are expressed in cell lines derived from cervical cancers and can immortalize primary human keratinocytes. Since expression of E6/E7 has been shown to induce mitotic defects and karyotype instability in primary human cells, we investigated the effect of these viral oncoproteins on the expression and activity of mitotic regulatory proteins. Primary human keratinocytes immortalized by the entire genome or by only the E6/E7 genes of HPV types 16 and 18 displayed 5- to 20-fold increases in the abundance of p34(cdc2), cyclin B and cyclin A when compared with normal parental cells. Results obtained from normal and immortalized cells that were derived from identical single donors were similar to those from mixed donor cultures. Increased protein levels were achieved without corresponding increases in mRNA, indicating alterations in translational and/or post-translational control. The histone H1 kinase activities associated with these regulatory proteins were also elevated, but to a lesser extent than the protein levels. Because p34(cdc2), cyclin B and cyclin A regulate the entry into and exit from mitosis, increased expression and activity of these proteins could contribute to the mitotic defects and chromosomal aberrations associated with HPV-induced immortalization.	HARVARD UNIV, SCH PUBL HLTH, DEPT MOLEC & CELLULAR TOXICOL, BOSTON, MA 02115 USA; GEORGETOWN UNIV, SCH MED, DEPT PATHOL, WASHINGTON, DC 20007 USA	Harvard University; Harvard T.H. Chan School of Public Health; Georgetown University					NATIONAL CANCER INSTITUTE [R01CA053371, F32CA009235] Funding Source: NIH RePORTER; NCI NIH HHS [NCI 5RO1CA4979, NCI 1F32CA09235, NCI 1RO1CA53371] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BANKSSCHLEGEL SP, 1983, J CELL BIOL, V96, P330, DOI 10.1083/jcb.96.2.330; BARBOSA MS, 1989, ONCOGENE, V4, P1529; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BRECHOT C, 1993, CURR OPIN GENET DEV, V3, P11, DOI 10.1016/S0959-437X(05)80335-1; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; BUCHOU T, 1993, ONCOGENE, V8, P1765; CRUM CP, 1984, NEW ENGL J MED, V310, P880, DOI 10.1056/NEJM198404053101403; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DAVIS LG, 1986, BASIC METHODS MOL BI, P130; DRAETTA G, 1988, ONCOGENE, V2, P553; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HASHIDA T, 1991, J GEN VIROL, V72, P1569, DOI 10.1099/0022-1317-72-7-1569; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; KAUR P, 1989, J GEN VIROL, V70, P1261, DOI 10.1099/0022-1317-70-5-1261; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MARRACCINO RL, 1992, MOL BIOL CELL, V3, P389, DOI 10.1091/mbc.3.4.389; MCGOWAN CH, 1990, MOL CELL BIOL, V10, P3847, DOI 10.1128/MCB.10.7.3847; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MEIKRANTZ W, 1991, J CELL SCI, V98, P303; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MUNGER K, 1993, BIOCHIM BIOPHYS ACTA, V1155, P111, DOI 10.1016/0304-419X(93)90025-8; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; NAGATA A, 1991, NEW BIOL, V3, P959; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OSHIMA J, 1993, ONCOGENE, V8, P2987; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RAY FA, 1990, J CELL BIOCHEM, V42, P13, DOI 10.1002/jcb.240420103; RESNICKSILVERMAN L, 1991, J VIROL, V65, P2845, DOI 10.1128/JVI.65.6.2845-2852.1991; RICE RH, 1993, MOL BIOL CELL, V4, P185, DOI 10.1091/mbc.4.2.185; ROY LM, 1991, J CELL BIOL, V113, P507, DOI 10.1083/jcb.113.3.507; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; STEWART N, 1991, VIROLOGY, V180, P49, DOI 10.1016/0042-6822(91)90008-Y; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; TAM SW, 1992, CELL GROWTH DIFFER, V3, P811; TOMMASINO M, 1993, ONCOGENE, V8, P195; TSAI LH, 1993, ONCOGENE, V8, P1593; VILLA LL, 1991, VIROLOGY, V181, P374; VOUSDEN KH, 1989, ONCOGENE, V4, P153; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WELCH PJ, 1992, P NATL ACAD SCI USA, V89, P3093, DOI 10.1073/pnas.89.7.3093; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YUSPA SH, 1974, EXP CELL RES, V86, P95, DOI 10.1016/0014-4827(74)90653-3; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821; zur Hausen H, 1987, PAPILLOMAVIRUSES, P245	92	44	45	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1994	9	2					387	394						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290252				2022-12-17	WOS:A1994MW24800005
J	LAROSE, L; GISH, G; SHOELSON, S; PAWSON, T				LAROSE, L; GISH, G; SHOELSON, S; PAWSON, T			IDENTIFICATION OF RESIDUES IN THE BETA PLATELET-DERIVED GROWTH-FACTOR RECEPTOR THAT CONFER SPECIFICITY FOR BINDING TO PHOSPHOLIPASE C-GAMMA-1	ONCOGENE			English	Article							PDGF RECEPTOR; V-SRC; TYROSINE KINASES; CDNA CLONING; SH2 DOMAINS; PHOSPHOTYROSINE; PROTEINS; PHOSPHORYLATION; SITE; GAP	The SH2 domains of cytoplasmic signaling proteins bind to autophosphorylated growth factor receptors by direct recognition of specific phosphotyrosine-containing sites. To identify the phosphotyrosine involved in association of phospholipase C (PLC)-gamma1 with the beta platelet-derived growth factor receptor (PDGFR), and to investigate which contiguous residues confer specificity for PLC-gamma1, phosphotyrosine-containing glutathione S-transferase (GST) fusion proteins possessing different regions of the beta-PDGFR were incubated with lysates of Rat-2 cells that overexpress PLC-gamma1. The phosphorylated C-terminal tail of the PDGFR bound PLC-gamma1, but did not associate with phosphatidylinositol (PI) 3'-kinase or GTPase-activating protein (GAP). High-affinity binding of PLC-gamma1 was dependent on phosphorylation of Tyr-1021. Creation of a new phosphorylation site by replacing Asp-1018 with tyrosine did not restore binding of PLC-gamma1 in the absence of Tyr-1021, indicating that the location of the phosphorylated tyrosine is important for PLC-gamma1 binding. Substitution of the proline at the +3 position relative to Tyr-1021 with methionine (Y1021IIP-->Y1021IIM) in the phosphorylated PDGFR tail did not alter PLC-gamma1 association, but conferred binding activity towards PI 3'-kinase, indicating that this residue is critical in discriminating between PLC-gamma1 and PI 3'-kinase. Progressive conversion of the three residues C-terminal to Tyr-1021 to the consensus for PI 3'-kinase binding (YMDM) allowed PI 3'-kinase association, but did not block PLC-gamma1 binding, suggesting that additional residues other than the three residues immediately following the phosphotyrosine may contribute to the association of PLC-gamma1 with the PDGFR. These results indicate that phosphorylation at Tyr-1021 in the tail of the PDGFR creates a specific binding site for PLC-gamma1. Proline at the +3 position relative to Tyr-1021 is crucial in conferring specificity for binding to PLC-gamma1.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV MOLEC & DEV BIOL,600 UNIV AVE,TORONTO M5G 1X5,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5G 1X5,ON,CANADA; HARVARD UNIV,SCH MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,JOSLEN DIABET CTR,DIV RES,BOSTON,MA 02115	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital			Gish, Gerald D/C-7228-2017; Pawson, Tony J/E-4578-2013					ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; ECK M, 1993, IN PRESS CELL; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KAMPS MP, 1988, ONCOGENE, V2, P305; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1993, IN PRESS P NATL ACAD; KOCH CA, 1992, MOL CELL BIOL, V12, P1366, DOI 10.1128/MCB.12.3.1366; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; SONGYANG Z, 1993, CELL, V72, P1; SULTZMAN L, 1991, MOL CELL BIOL, V11, P2018, DOI 10.1128/MCB.11.4.2018; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0	32	44	44	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2493	2499						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	7689724				2022-12-17	WOS:A1993LT36800021
J	YAMASHITA, T; SEGAWA, K; FUJINAGA, Y; NISHIKAWA, T; FUJINAGA, K				YAMASHITA, T; SEGAWA, K; FUJINAGA, Y; NISHIKAWA, T; FUJINAGA, K			BIOLOGICAL AND BIOCHEMICAL-ACTIVITY OF E7 GENES OF THE CUTANEOUS HUMAN PAPILLOMAVIRUS TYPE-5 AND TYPE-8	ONCOGENE			English	Article							LARGE T-ANTIGEN; CARCINOMA CELL-LINES; EPIDERMODYSPLASIA VERRUCIFORMIS; ADENOVIRUS E1A; TRANSFORMING ACTIVITY; EPITHELIAL-CELLS; PROTEIN-BINDING; RAT-CELLS; DNA; TRANSCRIPTION	In contrast to the observed activity of the E7 genes of the genital high-risk human papillomavirus (HPV)16 and HPV18, E7s of the cutaneous high-risk HPV5 and HPV8 show no in vitro transforming activity in established rodent cells. We recently reported that the HPV8 E7 driven by the SV40 enhancer/promoter oncogenically transforms primary rat embryo fibroblast (REF) cells collaboratively with the EJras oncogene (Jpn. J. Cancer Res., 82, 1340-1343, 1991). To study the functional differences between cutaneous HPV5 and HPV8 E7s and genital HPV16 E7, we cloned each of the E7 open reading frames and tested their immortalizing and transforming activities, the binding ability of their products with retinoblastoma protein (RB) and their complementation activity of a RB-nonbinding adenovirus E1A mutant. In contrast to results with HPV16 E7, transfection of HPV5 and HPV8 E7s did not produce any G418-resistant colonies in primary baby rat kidney (BRK) cells. However, they induced morphological transformation of primary BRK cells as well as of primary REF cells when cotransfected with the EJras oncogene. The ras-cooperating activity of HPV8 E7 appears to be extremely low, since, unlike the case of HPV5 and HPV16 E7s, transformed BRK colonies induced by HPV8 E7 plus ras have had a very low survival rate. The in vitro RB binding experiment showed that HPV5 and 8 E7s are able to form complexes with RB protein with reduced affinities of about one fourth and one nineteenth that of HPV16 E7, respectively. Moreover, not only HPV16 E7 but also HPV5 and 8 E7s complemented a nontransforming adenovirus 5 E1A mutant (dl922/947) incapable of binding to RB in inducing E1A-specific transformed foci on primary BRK cells. Since both the activities, the ras-collaborative transformation and complementation of the inert EIA mutant by E7s, all correlate with in vitro RB binding affinity (HPV16 E7 > HPV5 E7 > HPV8 E7), it is likely that RB binding of HPV5 and HPV8 E7s is an integral part of the biological activities of these proteins.	KEIO UNIV,SCH MED,DEPT MICROBIOL,SHINJUKU KU,TOKYO 160,JAPAN	Keio University	FUJINAGA, K (corresponding author), SAPPORO MED UNIV,SCH MED,CANC RES INST,DEPT MOLEC BIOL,S 1,W 17,CHUO KU,SAPPORO 060,JAPAN.							BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; BANKS L, 1988, VIROLOGY, V165, P326, DOI 10.1016/0042-6822(88)90695-2; BANKS L, 1990, ONCOGENE, V5, P1383; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BEDELL MA, 1989, J VIROL, V63, P1247, DOI 10.1128/JVI.63.3.1247-1255.1989; BUNNEY MH, 1987, LANCET, V2, P151; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; DYSON N, 1989, CANCER CEL, V7, P235; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; FIRZLAFF J M, 1989, New Biologist, V1, P44; FUCHS PG, 1986, J VIROL, V58, P626, DOI 10.1128/JVI.58.2.626-634.1986; GAGE JR, 1990, J VIROL, V64, P723, DOI 10.1128/JVI.64.2.723-730.1990; GIORDANO A, 1991, ONCOGENE, V6, P481; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HOWLEYNELSON P, 1989, EMBO J, V8, P3905; IFTNER T, 1990, VIROLOGY, V179, P428, DOI 10.1016/0042-6822(90)90311-E; IFTNER T, 1988, J VIROL, V62, P3655, DOI 10.1128/JVI.62.10.3655-3661.1988; KANDA T, 1988, VIROLOGY, V165, P321, DOI 10.1016/0042-6822(88)90694-0; KIYONO T, 1992, VIROLOGY, V186, P628, DOI 10.1016/0042-6822(92)90029-O; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; NISHIKAWA T, 1991, JPN J CANCER RES, V82, P1340, DOI 10.1111/j.1349-7006.1991.tb01802.x; ORTH G, 1987, PAPOVAVIRIDAE PAPILL, P199; OSTROW RS, 1982, P NATL ACAD SCI-BIOL, V79, P1634, DOI 10.1073/pnas.79.5.1634; PFISTER H, 1981, INT J CANCER, V27, P645, DOI 10.1002/ijc.2910270511; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; QUINLAN MP, 1988, MOL CELL BIOL, V8, P3191, DOI 10.1128/MCB.8.8.3191; SAMBROOK J, 1989, MOL CLONING LAB MANU, P931; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SEGAWA K, 1987, MOL CELL BIOL, V7, P556, DOI 10.1128/MCB.7.1.556; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STOREY A, 1990, J GEN VIROL, V71, P165, DOI 10.1099/0022-1317-71-1-165; TRAUGH JA, 1974, J BIOL CHEM, V249, P1207; van der Eb A J, 1980, Methods Enzymol, V65, P826; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; Yatsudo M, 1988, VIROLOGY, V166, P594; ZACHOW KR, 1987, VIROLOGY, V158, P251, DOI 10.1016/0042-6822(87)90263-7	45	44	46	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2433	2441						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8395681				2022-12-17	WOS:A1993LT36800014
J	CLEMENTS, DA; WANG, JK; DIONNE, CA; GOLDFARB, M				CLEMENTS, DA; WANG, JK; DIONNE, CA; GOLDFARB, M			ACTIVATION OF FIBROBLAST GROWTH-FACTOR (FGF) RECEPTORS BY RECOMBINANT HUMAN FGF-5	ONCOGENE			English	Article							EXPRESSION; BINDING; CELLS; PURIFICATION; CLONING; GENE; MUTANT; FAMILY	We have purified biologically active recombinant human fibroblast growth factor 5 (FGF-5) from Escherichia coli. In the presence of heparin, recombinant FGF-5 is as active as native growth factor, demonstrating that glycosylation does not significantly potentiate FGF-5 activity. FGF-5 can bind and induce autophosphorylation of human FGF receptors (FGFR) 1 and 2. Competition binding studies show that the K(D) for FGF-5-FGFR-1 and FGF-5-FGFR-2 interactions are both between 0.5 and 1.5 x 10(-9) M.	COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,INTEGRATED PROGRAM CELLULAR MOLEC & BIOPHYS STUDIES,NEW YORK,NY 10032; RHONE POULENC RORER CENT RES,COLLEGEVILLE,PA 19426	Columbia University; Columbia University					NCI NIH HHS [CA48054] Funding Source: Medline; NIGMS NIH HHS [GM07367] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048054] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BATES B, 1991, MOL CELL BIOL, V11, P1840, DOI 10.1128/MCB.11.4.1840; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; HAUB O, 1991, DEVELOPMENT, V112, P397; HAUB O, 1990, P NATL ACAD SCI USA, V87, P8022, DOI 10.1073/pnas.87.20.8022; HEBERT JM, 1991, DEVELOPMENT, V112, P407; HUGHES RA, 1993, IN PRESS NEURON; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LIPTON SA, 1988, P NATL ACAD SCI USA, V85, P2388, DOI 10.1073/pnas.85.7.2388; LOBB RR, 1986, ANAL BIOCHEM, V154, P1, DOI 10.1016/0003-2697(86)90487-2; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; REPRESA J, 1991, NATURE, V353, P561, DOI 10.1038/353561a0; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VAINIKKA S, 1992, EMBO J, V11, P4273, DOI 10.1002/j.1460-2075.1992.tb05526.x; VALLES AM, 1990, P NATL ACAD SCI USA, V87, P1124, DOI 10.1073/pnas.87.3.1124; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHAN X, 1987, ONCOGENE, V1, P369; ZHAN X, 1986, MOL CELL BIOL, V6, P3541, DOI 10.1128/MCB.6.10.3541; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	35	44	50	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1311	1316						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8386828				2022-12-17	WOS:A1993KY32800024
J	MOSIALOS, G; GILMORE, TD				MOSIALOS, G; GILMORE, TD			V-REL AND C-REL ARE DIFFERENTIALLY AFFECTED BY MUTATIONS AT A CONSENSUS PROTEIN-KINASE RECOGNITION SEQUENCE	ONCOGENE			English	Article							NF-KAPPA-B; VIRUS STRAIN-T; RETICULOENDOTHELIOSIS VIRUS; ONCOGENE; TRANSCRIPTION; TRANSFORMATION; DORSAL; EXPRESSION; CLONING; SUBUNIT	The avian retroviral oncoprotein v-Rel and its cellular homolog c-Rel are members of a family of related site-specific DNA-binding proteins. Towards the carboxy-terminal end of the highly conserved Rel homology (RH) domain in the majority of Rel proteins, there is a consensus recognition sequence for protein kinase A (PK-A). We have investigated the importance of this sequence (Arg-Arg-Pro-Ser) for several functional properties of v-Rel and c-Rel. Disruption of the PK-A sequence by a two amino acid insertion between the arginine and the proline residues completely abolished the ability of v-Rel and c-Rel to bind a kappaB site in vitro. When the phosphorylatable serine in this sequence (Ser-275 in v-Rel, Ser-266 in c-Rel) was replaced by an alanine, DNA binding by v-Rel was not affected, whereas the ability of c-Rel to bind DNA was reduced approximately fourfold by this mutation. Similarlv, a serine to tryptophan change greatly reduced the DNA-binding ability of c-Rel, whereas v-Rel was not appreciably affected by this change. When this serine was replaced by an acidic amino acid, DNA binding by v-Rel was reduced approximately twofold and the DNA-binding activity of c-Rel was nearly abolished. Glutaraldehyde cross-linking experiments indicated that mutations at the PK-A recognition site that reduced DNA binding also negatively affected protein oligomerization, which is likely to be responsible for the reduced ability of mutant v-Rel and c-Rel proteins to bind DNA. Domain-swapping experiments showed that structural differences between v-Rel and c-Rel in the central region of the proteins are primarily responsible for the higher sensitivity of c-Rel to a serine to alanine mutation in the PK-A site. One difference between v-Rel and c-Rel, a glutamine to alanine change in v-Rel located three amino acids carboxy-terminal to the PK-A phosphorylatable serine (Ala-278 in v-Rel; Glu-269 in c-Rel), is mainly responsible for the lack of an effect on DNA binding by v-Rel when Ser-275 is replaced by alanine. That is, a v-Rel double mutant (v-275A/278E) showed reduced DNA-binding and transforming abilities as compared with v-Rel and v-275A. Similarly, the mutations in c-Rel that affected DNA binding showed a corresponding effect on the ability of c-Rel proteins to activate transcription in yeast from a reporter gene containing upstream Rel binding sites. In summary, our results indicate that the structure of the PK-A recognition sequence is important for dimerization by Rel proteins, and that there is a good correlation between transformation by v-Rel and its ability to bind to kappaB target sites in vitro. In addition, our results show that c-Rel is more sensitive to mutations in the consensus PK-A recognition sequence than v-Rel, which has acquired mutations that may allow v-Rel to bind kappaB sites in a deregulated fashion.	BOSTON UNIV, DEPT CHEM, 5 CUMMINGTON ST, BOSTON, MA 02215 USA; BOSTON UNIV, DEPT BIOL, BOSTON, MA 02215 USA	Boston University; Boston University					NATIONAL CANCER INSTITUTE [R29CA047763, R01CA047763] Funding Source: NIH RePORTER; NCI NIH HHS [CA47763] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BHAT GV, 1990, ONCOGENE, V5, P625; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BROWNELL E, 1989, ONCOGENE, V4, P935; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CAPOBIANCO AJ, 1991, ONCOGENE, V6, P2203; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90421-L; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GILMORE TD, 1992, CANCER SURV, V15, P69; GLASS DB, 1986, J BIOL CHEM, V261, P2987; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; ISODA K, 1992, GENE DEV, V6, P619, DOI 10.1101/gad.6.4.619; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KAMENS J, 1991, NEW BIOL, V3, P1005; KAO KR, 1991, P NATL ACAD SCI USA, V88, P2697, DOI 10.1073/pnas.88.7.2697; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; MCDONNELL PC, 1992, ONCOGENE, V7, P163; MORIN PJ, 1992, NUCLEIC ACIDS RES, V20, P2453, DOI 10.1093/nar/20.10.2453; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; Sambrook J., 1989, MOL CLONING LAB MANU; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SIMEK S, 1988, ONCOGENE RES, V2, P103; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; WATANABE S, 1983, MOL CELL BIOL, V3, P2241, DOI 10.1128/MCB.3.12.2241; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984	42	44	45	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1993	8	3					721	730						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437855				2022-12-17	WOS:A1993KN00800024
J	NEBREDA, AR; PORRAS, A; SANTOS, E				NEBREDA, AR; PORRAS, A; SANTOS, E			P21RAS-INDUCED MEIOTIC MATURATION OF XENOPUS OOCYTES IN THE ABSENCE OF PROTEIN-SYNTHESIS - MPF ACTIVATION IS PRECEDED BY ACTIVATION OF MAP AND S6 KINASES	ONCOGENE			English	Article							ONCOGENIC RAS PROTEIN; LAEVIS OOCYTES; M-PHASE; CELL-CYCLE; TYROSINE PHOSPHORYLATION; OKADAIC ACID; P21; P34CDC2; INVIVO; SUBSTRATE	Microinjection of transforming p21ras into Xenopus oocytes caused a time-dependent increase in the level of total cell protein phosphorylation that culminated with germinal vesicle breakdown (GVBD). The same pattern of phosphorylation was observed in oocytes matured by either progesterone or insulin. Treatment with cycloheximide (CHX) completely blocked both GVBD and the associated de novo phosphorylations induced by the hormones, but did not abolish p21ras-induced maturation nor the occurrence of associated maturation promoting factor (MPF)-dependent and -independent phosphorylations. Thus, induction of GVBD by p21ras in the absence of protein synthesis correlated with the activation of cytosolic MPF-associated kinase activity similar in specificity on exogenous (histone H1) and endogenous (47 kDa and a 42 kDa proteins) substrates to the MPF activity of hormonally-matured oocytes. The injection of p21ras in the presence of CHX caused also activation of other kinase(s) preceding MPF activation which were responsible for the phosphorylation of endogenous substrates including a 41 kDa protein and a 92 kDa protein kinase that comigrated, respectively, with bands recognized specifically by antibodies to MAP2 kinase and S6 kinase. The phosphorylation of those bands correlated also with the activation of cytosolic kinases acting specifically on myelin basic protein (MBP) and a S6-derived peptide as substrates. These results indicate that, in the absence of protein synthesis, p21ras is able to activate phosphorylation events leading to GVBD and suggest that this oncoprotein can participate in at least two separate pathways of MPF activation. We propose that the activation of MAP/MBP kinases and S6 kinases is an early effect of p21ras oncoproteins.	NCI,CELLULAR & MOLEC BIOL LAB,BG 37,RM 1D28,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Nebreda, Angel Rodriguez/R-9594-2019; Porras, Almudena/N-2121-2015	Porras, Almudena/0000-0002-6495-3308				ALLENDE CC, 1988, FEBS LETT, V234, P426, DOI 10.1016/0014-5793(88)80130-3; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; BELLE R, 1989, FEBS LETT, V255, P101, DOI 10.1016/0014-5793(89)81069-5; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CICIRELLI MF, 1988, J BIOL CHEM, V263, P2009; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DEHERREROS AG, 1991, J BIOL CHEM, V266, P6825; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; ERIKSON AK, 1990, J BIOL CHEM, V265, P19728; ERIKSON E, 1989, J BIOL CHEM, V264, P13711; FERRELL JE, 1990, MOL CELL BIOL, V10, P3020, DOI 10.1128/MCB.10.6.3020; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GORIS J, 1989, FEBS LETT, V245, P91, DOI 10.1016/0014-5793(89)80198-X; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; JANSSEN GMC, 1991, J BIOL CHEM, V266, P14885; KAMATA T, 1990, MOL CELL BIOL, V10, P880, DOI 10.1128/MCB.10.3.880; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; LACAL JC, 1984, P NATL ACAD SCI-BIOL, V81, P5305, DOI 10.1073/pnas.81.17.5305; LACAL JC, 1990, MOL CELL BIOL, V10, P333, DOI 10.1128/MCB.10.1.333; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; MALLER JL, 1985, DEV BIOL, V109, P150, DOI 10.1016/0012-1606(85)90355-0; MINSHULL J, 1991, J CELL BIOL, V114, P767, DOI 10.1083/jcb.114.4.767; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MULNERLORILLON O, 1989, FEBS LETT, V251, P219, DOI 10.1016/0014-5793(89)81458-9; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAN BT, 1990, MOL CELL BIOL, V10, P923, DOI 10.1128/MCB.10.3.923; PINES J, 1990, New Biologist, V2, P389; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; RIME H, 1990, CELL DIFFER DEV, V29, P47, DOI 10.1016/0922-3371(90)90023-P; SADLER SE, 1990, MOL CELL BIOL, V10, P1689, DOI 10.1128/MCB.10.4.1689; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SANTOS E, 1988, J BIOL CHEM, V263, P9853; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0	50	44	45	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					467	477						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8381222				2022-12-17	WOS:A1993KN00600026
J	GOKKEL, E; GROSSMAN, Z; RAMOT, B; YARDEN, Y; RECHAVI, G; GIVOLI, D				GOKKEL, E; GROSSMAN, Z; RAMOT, B; YARDEN, Y; RECHAVI, G; GIVOLI, D			STRUCTURAL ORGANIZATION OF THE MURINE C-KIT PROTOONCOGENE	ONCOGENE			English	Article								The murine Kit receptor gene on chromosome 5 has been found to be frequently involved in germline mutations and rearrangements, leading to a characteristic set of severe developmental defects, known as the W phenotype. Here we describe the structure of the murine c-kit gene, based on restriction analysis of genomic phage clones and sequence determination of exon-intron boundaries. The Kit-coding region is distributed over 21 exons, most of which have sizes that range between 100 and 200 base pairs. The 3' non-translated sequence and the 3' end of the coding region form a single large exon, which encompasses 2.3 kb and is flanked by polyadenylation signals. The entire region spans a genomic distance of at least 70 kb. Though the exonic demarcations of c-kit show remarkable similarity to those of the human c-fms gene (which encodes the highly related colony-stimulating factor 1 receptor), no correlation could be found between the sizes of introns that separate homologous exon pairs. The data suggest that evolutionary pressures were confined to the conservation of structures of coding exons, whereas flanking regions were subject to large changes, owing to insertions and deletions. Finally, the analysis of the Kit genomic structure reveals that the inherited mutations of the Kit gene that have been reported thus far occur at various dispersed positions within the gene. Hence, the entire gene appears to have as yet unknown features which cause it to be frequently subject to mutations in murine germline tissues.	CHAIM SHEBA MED CTR, INST HEMATOL, IL-52621 TEL HASHOMER, ISRAEL	Chaim Sheba Medical Center	GOKKEL, E (corresponding author), WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL.		YARDEN, YOSEF/K-1467-2012					BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BLAKE CCF, 1985, INT REV CYTOL, V93, P149, DOI 10.1016/S0074-7696(08)61374-1; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; CRAIK CS, 1982, NATURE, V299, P180, DOI 10.1038/299180a0; CRAIK CS, 1983, SCIENCE, V220, P1125, DOI 10.1126/science.6344214; DUBREUIL P, 1990, ANN NY ACAD SCI, V599, P58; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GIEBEL LB, 1991, P NATL ACAD SCI USA, V88, P8696, DOI 10.1073/pnas.88.19.8696; GILBERT W, 1985, SCIENCE, V228, P823, DOI 10.1126/science.4001923; HAMPE A, 1989, ONCOGENE RES, V4, P9; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAYASHI SI, 1991, NUCLEIC ACIDS RES, V19, P1267, DOI 10.1093/nar/19.6.1267; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; HUNKAPILLER T, 1989, ADV IMMUNOL, V44, P1; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KESHET E, 1991, EMBO J, V10, P2425, DOI 10.1002/j.1460-2075.1991.tb07782.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; MAJUMDER S, 1988, MOL CELL BIOL, V8, P4896, DOI 10.1128/MCB.8.11.4896; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; MATSUSHIME H, 1986, MOL CELL BIOL, V6, P3000, DOI 10.1128/MCB.6.8.3000; MAYER TC, 1968, DEV BIOL, V18, P62, DOI 10.1016/0012-1606(68)90023-7; McLachlan A.D., 1980, PROTEINS RELATED SUB, V28, P29; MIETTINEN HM, 1989, CELL, V58, P317, DOI 10.1016/0092-8674(89)90846-5; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; ORRURTREGER A, 1990, DEVELOPMENT, V109, P911; OWENS GC, 1987, P NATL ACAD SCI USA, V84, P294, DOI 10.1073/pnas.84.1.294; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.biochem.55.1.1119; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; ROBERTS WM, 1988, CELL, V55, P655, DOI 10.1016/0092-8674(88)90224-3; ROGERS J, 1985, NATURE, V315, P458, DOI 10.1038/315458a0; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SANTONI MJ, 1989, EMBO J, V8, P385, DOI 10.1002/j.1460-2075.1989.tb03389.x; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SMITH EA, 1991, P NATL ACAD SCI USA, V88, P4811, DOI 10.1073/pnas.88.11.4811; STENMAN G, 1989, GENE CHROMOSOME CANC, V1, P155, DOI 10.1002/gcc.2870010208; STEPHENSON DA, 1991, P NATL ACAD SCI USA, V88, P6, DOI 10.1073/pnas.88.1.6; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; TOBAL K, 1990, LEUKEMIA, V4, P486; VISVADER J, 1989, MOL CELL BIOL, V9, P1336, DOI 10.1128/MCB.9.3.1336; VU TH, 1989, MOL CELL BIOL, V9, P4563, DOI 10.1128/MCB.9.10.4563; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4	62	44	49	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1992	7	7					1423	1429						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1377813				2022-12-17	WOS:A1992HZ97100022
J	HAUPT, Y; HARRIS, AW; ADAMS, JM				HAUPT, Y; HARRIS, AW; ADAMS, JM			RETROVIRAL INFECTION ACCELERATES T-LYMPHOMAGENESIS IN E-MU-N-RAS TRANSGENIC MICE BY ACTIVATING C-MYC OR N-MYC	ONCOGENE			English	Article							MURINE LEUKEMIA-VIRUS; CELL LYMPHOMAS; PROVIRAL INSERTION; ONCOGENES; GENE; CARCINOGENESIS; INVOLVEMENT; INTEGRATION; MUTATIONS; FREQUENCY	Transgenic mice bearing a mutant, activated N-ras oncogene directed to express within hematopoietic cells by an immunoglobulin enhancer (E-mu) sporadically develop T-cell lymphomas and non-lymphoid tumors that may be of macrophage origin. To identify genes that can collaborate with N-ras in hematopoietic neoplasia, Moloney murine leukemia virus was used as an insertional mutagen. Infection of newborn E-mu-N-ras mice with the virus greatly accelerated tumorigenesis, and nearly all the tumors proved to be T-cell lymphomas. Their variable surface phenotype (CD4+ CD8-, CD4+ CD8+ and CD4-CD8-) suggested that cells at several stages of T-cell development were susceptible to tumorigenesis. Southern blot analysis revealed that 68% of the tumors bore a proviral insert 5' to the c-myc gene, while 13% had an insert within the 3' untranslated region of the N-myc gene. Insertion was associated with elevated expression of these genes. Hence, activation of a myc gene appears to be the dominant pathway to tumorigenesis by insertional mutagenesis in lymphoid cells expressing a mutant ras gene. However, since many of the tumors were not transplantable, even the partnership of myc and ras may not suffice for full lymphoid malignancy.			HAUPT, Y (corresponding author), ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, PARKVILLE, VIC 3050, AUSTRALIA.		Adams, Jerry M/E-1199-2013	Adams, Jerry/0000-0002-4360-8628	NCI NIH HHS [CA43540] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043540] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ADAMS JM, 1991, BIOCHIM BIOPHYS ACTA, V1072, P9, DOI 10.1016/0304-419X(91)90004-5; ALEXANDER WS, 1989, ONCOGENE, V4, P575; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BOS JL, 1989, CANCER RES, V49, P4682; BREUER M, 1989, NATURE, V340, P61, DOI 10.1038/340061a0; BREUER M, 1991, CANCER RES, V51, P958; BREUER ML, 1989, EMBO J, V8, P743, DOI 10.1002/j.1460-2075.1989.tb03434.x; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CLURMAN BE, 1989, MOL CELL BIOL, V9, P2657, DOI 10.1128/MCB.9.6.2657; COMPERE SJ, 1988, BIOCHIM BIOPHYS ACTA, V948, P129, DOI 10.1016/0304-419X(88)90008-X; CORCORAN LM, 1984, CELL, V37, P113, DOI 10.1016/0092-8674(84)90306-4; CORY S, 1988, ANNU REV IMMUNOL, V6, P25; CUYPERS HT, 1984, CELL, V37, P141; DAVIS BR, 1987, P NATL ACAD SCI USA, V84, P4875, DOI 10.1073/pnas.84.14.4875; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; DIAMOND LE, 1988, MOL CELL BIOL, V8, P2233, DOI 10.1128/MCB.8.5.2233; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HARRIS AW, 1988, CURR TOP MICROBIOL, V141, P82; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KLINKEN SP, 1988, CELL, V53, P857, DOI 10.1016/S0092-8674(88)90309-1; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LAZO PA, 1990, P NATL ACAD SCI USA, V87, P170, DOI 10.1073/pnas.87.1.170; PETERS G, 1990, CELL GROWTH DIFFER, V1, P503; REIK W, 1985, P NATL ACAD SCI USA, V82, P1141, DOI 10.1073/pnas.82.4.1141; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; SELTEN G, 1984, EMBO J, V3, P3215, DOI 10.1002/j.1460-2075.1984.tb02281.x; SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; TSICHLIS PN, 1989, P NATL ACAD SCI USA, V86, P5487, DOI 10.1073/pnas.86.14.5487; VANLOHUIZEN M, 1989, EMBO J, V8, P133, DOI 10.1002/j.1460-2075.1989.tb03357.x; VANLOHUIZEN M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P213, DOI 10.1016/0304-419X(90)90005-L; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; WEINBERG RA, 1989, CANCER RES, V49, P3713; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0	40	44	44	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1992	7	5					981	986						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1570158				2022-12-17	WOS:A1992HP64200018
J	WHITE, MRA; HUNG, MC				WHITE, MRA; HUNG, MC			CLONING AND CHARACTERIZATION OF THE MOUSE NEU PROMOTER	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; FACTOR RECEPTOR; TRANSCRIPTION FACTOR; PROTO-ONCOGENE; EGF RECEPTOR; EUKARYOTIC TRANSCRIPTION; MOLECULAR-CLONING; C-ERBB-2 ONCOGENE; MAMMALIAN-CELLS	We have isolated a genomic clone containing the mouse neu gene. The 5' end of the mouse neu gene was localized by Southern analysis, subcloned and characterized. DNA sequence analysis revealed that the promoter region is 67% G + C-rich and lacks a TATA box, although a CAAT box is present. By sequence comparison, we identified several consensus recognition sequences for general transcription factors such as Sp1, E4TF1, AP2, OTF-1 and GCF, as well as recognition sequences for RVF, E1A and GTG, which have recently been identified in the rat neu promoter. Functional promoter activity was demonstrated by the ability of the promoter to drive transcription of the bacterial chloramphenicol acetyltransferase gene. Using a series of 5'-end deletion mutants, we have identified multiple positive and negative cis-acting elements that regulate mouse neu gene transcription.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT TUMOR BIOL, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740				BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BERCHUCK A, 1990, CANCER RES, V50, P4087; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DEMILIA J, 1989, ONCOGENE, V4, P1233; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FERNANDEZPOL JA, 1989, J BIOL CHEM, V264, P4151; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; FUKUSHIGE S, 1986, MOL CELL BIOL, V6, P955, DOI 10.1128/MCB.6.3.955; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; HUDSON LG, 1990, J BIOL CHEM, V265, P4389; HUNG M, 1991, IN PRESS CANCER LETT; HUNG M-C, 1988, Cancer Bulletin (Houston), V40, P300; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; ISHII S, 1987, P NATL ACAD SCI USA, V84, P4374, DOI 10.1073/pnas.84.13.4374; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; Jones N, 1990, Semin Cancer Biol, V1, P5; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KOKAI Y, 1987, P NATL ACAD SCI USA, V84, P8498, DOI 10.1073/pnas.84.23.8498; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACGREGOR GR, 1987, SOMAT CELL MOLEC GEN, V13, P253, DOI 10.1007/BF01535207; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PARK JB, 1989, CANCER RES, V49, P6605; POLYANOVSKY OL, 1990, BIOESSAYS, V12, P205, DOI 10.1002/bies.950120503; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; SCHWAB M, 1990, GENE CHROMOSOME CANC, V1, P181, DOI 10.1002/gcc.2870010302; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; SUEN TC, 1991, MOL CELL BIOL, V11, P354, DOI 10.1128/MCB.11.1.354; TAL M, 1987, MOL CELL BIOL, V7, P2597, DOI 10.1128/MCB.7.7.2597; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; WATANABE H, 1988, MOL CELL BIOL, V8, P1290, DOI 10.1128/MCB.8.3.1290; WEINER DB, 1990, CANCER RES, V50, P421; WINGENDER E, 1988, NUCLEIC ACIDS RES, V16, P1879, DOI 10.1093/nar/16.5.1879; WINGENDER E, 1990, Critical Reviews in Eukaryotic Gene Expression, V1, P11; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YAN DH, 1991, ONCOGENE, V6, P343; YAN DH, 1991, MOL CELL BIOL, V11, P1875, DOI 10.1128/MCB.11.4.1875; YOKOTA J, 1988, ONCOGENE, V2, P283; YOSHIDA K, 1989, VIRCHOWS ARCH B, V57, P285, DOI 10.1007/BF02899093; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; ZHANG X, 1989, ONCOGENE, V4, P985	63	44	45	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1992	7	4					677	683						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1348855				2022-12-17	WOS:A1992HQ68200009
J	FUJII, M; TSUCHIYA, H; SEIKI, M				FUJII, M; TSUCHIYA, H; SEIKI, M			HTLV-1 TAX HAS DISTINCT BUT OVERLAPPING DOMAINS FOR TRANSCRIPTIONAL ACTIVATION AND FOR ENHANCER SPECIFICITY	ONCOGENE			English	Note							CELL LEUKEMIA-VIRUS; LONG TERMINAL REPEAT; LEUCINE ZIPPER STRUCTURE; C-FOS; TRANS-ACTIVATION; MAMMALIAN-CELLS; GENE-EXPRESSION; DNA-BINDING; PROTEIN; INTERLEUKIN-2	Tax1 of human T-cell leukemia virus type 1 (HTLV-1) activates viral transcription dependent upon three 21-bp enhancer elements in the long terminal repeat. Difficulties in detecting any association of Tax1 with the viral enhancer have hampered elucidation of the molecular mechanisms of Tax1-mediated transcriptional activation. By constructing a fusion protein with the heterologous DNA-binding domain of yeast GAL4, Tax1 was shown to be a potent transcriptional activator dependent on the presence of GAL4-binding sites. Deletions of the Tax1 portion of the fusion protein revealed that almost the entire region of Tax1 (amino acids 2-337) is required for activation, and the activity correlated well with that of the viral enhancer. The GAL/Tax1 mutant lacking 41 residues of the C-terminus of Tax1. GAL/Tax1(2-312). was inactive for the viral enhancer, but activity was recovered by adding the heterologous activation domain of herpes simplex virus VP16. These results indicate that Tax1 has two distinct but overlapping functional domains for transcriptional activation and for enhancer specificity. Thus, Tax1 is thought to be a transcription factor acting in the enhancer complex rather than as a catalytic or allosteric modifier of pre-existing cellular transcription factors.	KANAZAWA UNIV,SCH MED,DEPT INTERNAL MED 3,KANAZAWA,ISHIKAWA 920,JAPAN	Kanazawa University	FUJII, M (corresponding author), KANAZAWA UNIV,SCH MED,CANC RES INST,DEPT VIROL,13-1 TAKARA MACHI,KANAZAWA,ISHIKAWA 920,JAPAN.		Seiki, Motoharu/K-9443-2015					ALTMAN R, 1988, J VIROL, V62, P1339, DOI 10.1128/JVI.62.4.1339-1346.1988; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BEIMLING P, 1989, ONCOGENE, V4, P511; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; GIAM CZ, 1989, J BIOL CHEM, V264, P15236; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; JEANG KT, 1988, J VIROL, V62, P4499, DOI 10.1128/JVI.62.12.4499-4509.1988; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NYBORG JK, 1988, P NATL ACAD SCI USA, V85, P1457, DOI 10.1073/pnas.85.5.1457; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; SADOWSKI I, 1986, NATURE, V332, P853; SEIKI M, 1985, SCIENCE, V228, P1532, DOI 10.1126/science.2990031; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; TSUJIMOTO A, 1991, J VIROL, V65, P1420, DOI 10.1128/JVI.65.3.1420-1426.1991; WILLEMS L, 1991, ONCOGENE, V6, P159; WRIGHT JJ, 1990, SCIENCE, V248, P588, DOI 10.1126/science.2110381; WU JY, 1990, CELL, V63, P687, DOI 10.1016/0092-8674(90)90135-2; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x	37	44	44	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2349	2352						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766679				2022-12-17	WOS:A1991GX73500025
J	PEREGO, R; RON, D; KRUH, GD				PEREGO, R; RON, D; KRUH, GD			ARG ENCODES A WIDELY EXPRESSED 145 KDA PROTEIN TYROSINE KINASE	ONCOGENE			English	Note							CHRONIC MYELOGENOUS LEUKEMIA; C-ABL; PHILADELPHIA-CHROMOSOME; GENE-PRODUCT; ONCOGENE; PHOSPHORYLATION; TRANSDUCTION; ACTIVATION; CELLS; K562	Arg encodes a protein highly related to the c-abl gene product with regard to overall structural architecture as well as the amino acid sequences of their tyrosine kinase, and src-homologous 2 and 3 domains. The two genes form a distinct subfamily of non-receptor tyrosine kinases and share a common homolog in Drosophila. In this study we characterized the arg protein product by expression of its coding sequence in bacteria. The recombinant arg protein was detected in bacterial lysates by immunoblotting and exhibited a molecular mass of 145 kDa. Phosphoamino acid analysis of the arg gene product following an immune complex autokinase reaction revealed tyrosine phosphorylation and established that it possesses tyrosine kinase activity. High-titer antibody capable of detecting the cellular arg gene product was generated by expressing a carboxy-terminal segment of arg in bacteria and using the recombinant protein as an immunogen. The arg gene product was identified in cultured human cells as a 145 kDa protein that exhibited autokinase activity. Analysis of arg expression in murine tissues revealed that arg, like c-abl, is widely expressed, further extending the similarities between the two genes, and suggesting that arg probably functions in signaling pathways fundamental to many cell types.	NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892; UNIV MILAN,INST GEN PATHOL,I-20122 MILAN,ITALY; CNR,CTR RES CELL PATHOL,I-20133 MILAN,ITALY; TECHNION ISRAEL INST TECHNOL,FAC BIOL,IL-32000 HAIFA,ISRAEL	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Milan; Consiglio Nazionale delle Ricerche (CNR); Technion Israel Institute of Technology								BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; DAVIS RL, 1985, MOL CELL BIOL, V5, P204, DOI 10.1128/MCB.5.1.204; HARING HU, 1984, BIOCHEMISTRY-US, V23, P3298, DOI 10.1021/bi00309a028; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KLOETZER W, 1985, VIROLOGY, V140, P230, DOI 10.1016/0042-6822(85)90361-7; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KRUH GD, 1986, SCIENCE, V234, P1545, DOI 10.1126/science.3787260; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; OPPI C, 1987, P NATL ACAD SCI USA, V84, P8200, DOI 10.1073/pnas.84.23.8200; PAWSON T, 1988, ONCOGENE, V3, P491; PONTICELLI AS, 1982, CELL, V3, P953; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SANDBERG AA, 1986, CANCER GENET CYTOGEN, V21, P129, DOI 10.1016/0165-4608(86)90039-7; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VANETTEN ER, 1989, CELL, V4, P669; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WANG JYJ, 1982, J BIOL CHEM, V257, P13181; WANG JYJ, 1988, ONCOGENE RES, V3, P293; WITTE ON, 1979, NATURE, V281, P396, DOI 10.1038/281396a0	24	44	45	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1899	1902						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923513				2022-12-17	WOS:A1991GX11800025
J	HELIN, K; VELU, T; MARTIN, P; VASS, WC; ALLEVATO, G; LOWY, DR; BEGUINOT, L				HELIN, K; VELU, T; MARTIN, P; VASS, WC; ALLEVATO, G; LOWY, DR; BEGUINOT, L			THE BIOLOGICAL-ACTIVITY OF THE HUMAN EPIDERMAL GROWTH-FACTOR RECEPTOR IS POSITIVELY REGULATED BY ITS C-TERMINAL TYROSINES	ONCOGENE			English	Article							ALTERED AUTOPHOSPHORYLATION SITES; FACTOR EGF RECEPTOR; KINASE-ACTIVITY; SELF-PHOSPHORYLATION; PROTEIN-KINASE; GENE-PRODUCT; INTERNALIZATION; PP60C-SRC; MUTATION; BINDING	The epidermal growth factor receptor (EGF-R) C-terminus contains three conserved tyrosines (Y-1068, Y-1148, Y-1173) which are phosphorylated upon EGF activation. To clarify the functional role of these tyrosines, each has been mutated to phenylalanine and studied as single, double and triple mutants in the full length receptor. EGF-dependent transforming ability of the single point mutants is similar to that of the wild type, while that of double mutants is decreased and an even lower activity is present in the triple mutant. In each bioassay, including EGF-dependent focal transformation, growth in agar and growth in low serum, mutant receptors display a similar hierarchy of activity. The lower activity is intrinsic in the mutants since they are expressed at similar level as the wild type and bind EGF with similar affinity. Deletion mutants lacking the last 19 or 63 amino acids (Velu et al., 1989a) show a similar decline in biological activity when compared to the corresponding point mutants, although the reduction is more pronounced than with the point mutants. Deletion of the last 123 aa, which removes all three tyrosines (Dc123), results in a receptor that is almost inactive biologically. The EGF-R kinase activity is affected by tyrosine substitution since in vitro phosphorylation of exogenous substrates is reduced in the double and triple mutants. Autophosphorylation, in vivo and in vitro, is also reduced, but not totally abolished in the triple point mutant and Dc123 indicating the existence of other autophosphorylation sites. A new site of autophosphorylation is found in the Dc123 mutant. We conclude, therefore, that the tyrosines at the extreme C-terminus positively regulate the biological and transforming activity of the EGF-R, probably via autophosphorylation.	UNIV COPENHAGEN,INST MICROBIOL,OSTER FARIMAGSGADE 2A,DK-1353 COPENHAGEN,DENMARK; NIH,CELLULAR ONCOL LAB,BETHESDA,MD 20892	University of Copenhagen; National Institutes of Health (NIH) - USA	BEGUINOT, L (corresponding author), UNIV COPENHAGEN,INST MICROBIOL,OSTER FARIMAGSGADE 2A,DK-1353 COPENHAGEN,DENMARK.		Helin, Kristian/HDM-8306-2022; Helin, Kristian/K-2526-2019	Helin, Kristian/0000-0003-1975-6097; 				BEGUINOT L, 1984, P NATL ACAD SCI-BIOL, V81, P2384, DOI 10.1073/pnas.81.8.2384; BEGUINOT L, 1985, P NATL ACAD SCI USA, V82, P2774, DOI 10.1073/pnas.82.9.2774; BEGUINOT L, 1986, J BIOL CHEM, V261, P1801; BERTICS PJ, 1988, J BIOL CHEM, V263, P3610; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CLARK AJL, 1986, BIOCHIM BIOPHYS ACTA, V867, P244, DOI 10.1016/0167-4781(86)90040-0; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; DOWNWARD J, 1984, NATURE, V311, P283; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FELDMAN RA, 1986, MOL CELL BIOL, V6, P1065, DOI 10.1128/MCB.6.4.1065; GILMORE T, 1985, CELL, V40, P609, DOI 10.1016/0092-8674(85)90209-0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALEY JD, 1989, ONCOGENE, V4, P273; HELIN K, 1991, IN PRESS J BIOL CHEM, V266; HONEGGER A, 1988, EMBO J, V7, P3053, DOI 10.1002/j.1460-2075.1988.tb03170.x; HONEGGER A, 1988, EMBO J, V7, P3045, DOI 10.1002/j.1460-2075.1988.tb03169.x; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HSUAN JJ, 1980, BIOCHEM J, V77, P1311; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGNI M, 1991, IN PRESS BIOCH J; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGATTO O, 1990, New Biologist, V2, P187; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; VELU TJ, 1989, J CELL BIOCHEM, V39, P153, DOI 10.1002/jcb.240390207; VELU TJ, 1989, MOL CELL BIOL, V9, P1772, DOI 10.1128/MCB.9.4.1772; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; YACIUK P, 1988, ONCOGENE RES, V3, P207; YAMAMOTO T, 1983, CELL, V34, P225, DOI 10.1016/0092-8674(83)90153-8; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	42	44	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					825	832						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1646987				2022-12-17	WOS:A1991GT82500019
J	MATTEI, MG; SIMONCHAZOTTES, D; HIRAI, SI; RYSECK, RP; GALCHEVAGARGOVA, Z; GUENET, JL; MATTEI, JF; BRAVO, R; YANIV, M				MATTEI, MG; SIMONCHAZOTTES, D; HIRAI, SI; RYSECK, RP; GALCHEVAGARGOVA, Z; GUENET, JL; MATTEI, JF; BRAVO, R; YANIV, M			CHROMOSOMAL LOCALIZATION OF THE 3 MEMBERS OF THE JUN PROTO-ONCOGENE FAMILY IN MOUSE AND MAN	ONCOGENE			English	Note									INST PASTEUR,CNRS,URA 152,UNITE VIRUS ONCOGENES,F-75724 PARIS 15,FRANCE; HOP ENFANTS LA TIMONE,INSERM,U242,F-13385 MARSEILLE 4,FRANCE; INST PASTEUR,CNRS,URA 146,UNITE GENET MAMMIFERES,F-75724 PARIS 15,FRANCE; EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite; European Molecular Biology Laboratory (EMBL)								ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; EISTETTER HR, 1988, P NATL ACAD SCI USA, V85, P3489, DOI 10.1073/pnas.85.10.3489; GUENET JL, 1988, CURR TOP MICROBIOL, V137, P13; HALUSKA FG, 1988, P NATL ACAD SCI USA, V85, P2215, DOI 10.1073/pnas.85.7.2215; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HIRAI SI, 1989, IN PRESS NEW BIOL; LALLEY PA, 1987, CYTOGENET CELL GENET, V46, P367, DOI 10.1159/000132486; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LYON MF, 1988, MOUSE NEWS LETT, V81, P20; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; PIETTE J, 1987, EMBO J, V6, P1331, DOI 10.1002/j.1460-2075.1987.tb02372.x; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; ROBERT B, 1985, NATURE, V314, P181, DOI 10.1038/314181a0; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; TRENT J M, 1988, Cytogenetics and Cell Genetics, V49, P236, DOI 10.1159/000132669; VOGT PK, 1987, P NATL ACAD SCI USA, V84, P3316, DOI 10.1073/pnas.84.10.3316	27	44	45	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1990	5	1					151	156						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM620	2108401				2022-12-17	WOS:A1990CM62000021
J	MAVILIO, F; KREIDER, BL; VALTIERI, M; NASO, G; SHIRSAT, N; VENTURELLI, D; REDDY, EP; ROVERA, G				MAVILIO, F; KREIDER, BL; VALTIERI, M; NASO, G; SHIRSAT, N; VENTURELLI, D; REDDY, EP; ROVERA, G			ALTERATION OF GROWTH AND DIFFERENTIATION FACTORS RESPONSE BY KIRSTEN AND HARVEY SARCOMA-VIRUSES IN THE IL-3-DEPENDENT MURINE HEMATOPOIETIC-CELL LINE 32D-C13(G)	ONCOGENE			English	Article									WISTAR INST ANAT & BIOL,36TH ST SPRUCE,PHILADELPHIA,PA 19104	The Wistar Institute			Reddy, E. Premkumar/F-6233-2011; valtieri, mauro/H-1044-2016	valtieri, mauro/0000-0002-9139-6754; Mavilio, Fulvio/0000-0003-0459-4320	NATIONAL CANCER INSTITUTE [P01CA021124, T32CA009171, P30CA010815] Funding Source: NIH RePORTER; NCI NIH HHS [5T32 CA 09171-13, 5P30 CA10815-21, 2PO1 CA 21124-11] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINO AP, 1984, NATURE, V308, P69, DOI 10.1038/308069a0; ANDERSEN PR, 1981, CELL, V26, P129, DOI 10.1016/0092-8674(81)90041-6; BALMAIN A, 1985, BRIT J CANCER, V51, P1, DOI 10.1038/bjc.1985.1; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BLICK M, 1984, BLOOD, V64, P1234; BOS JL, 1987, BLOOD, V69, P1237; BOS JL, 1985, NATURE, V315, P726, DOI 10.1038/315726a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COHEN JB, 1988, NATURE, V334, P119, DOI 10.1038/334119a0; COLLINS SJ, 1987, BLOOD, V70, P1233; COOPER GM, 1983, BIOCHIM BIOPHYS ACTA, V738, P9; DAHR R, 1982, SCIENCE, V217, P934; DEVRIES MV, 1986, GENE, V50, P313; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; EVA A, 1983, P NATL ACAD SCI-BIOL, V80, P4926, DOI 10.1073/pnas.80.16.4926; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; FUJITA J, 1984, NATURE, V309, P464, DOI 10.1038/309464a0; FUSCO A, 1982, CANCER RES, V42, P618; GAMBKE C, 1985, P NATL ACAD SCI USA, V82, P879, DOI 10.1073/pnas.82.3.879; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HANKINS WD, 1981, CELL, V26, P91, DOI 10.1016/0092-8674(81)90036-2; HARTLEY JW, 1976, J VIROL, V19, P19, DOI 10.1128/JVI.19.1.19-25.1976; Hayhoe FGJ, 1988, HAEMATOLOGICAL CYTOC; JANSSEN JWG, 1987, ONCOGENE, V1, P175; JOHNSON KR, 1987, NUCLEIC ACIDS RES, V15, P2013, DOI 10.1093/nar/15.5.2013; KLUVER H, 1953, J NEUROPATH EXP NEUR, V12, P400; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; MAVILIO F, 1986, P NATL ACAD SCI USA, V83, P4934; MCCOY MS, 1983, NATURE, V302, P79, DOI 10.1038/302079a0; METCALF D, 1984, HEMOPOIETIC COLONIES; MURRAY MJ, 1983, CELL, V33, P749, DOI 10.1016/0092-8674(83)90017-X; NAKAGAWA T, 1987, P NATL ACAD SCI USA, V84, P5923, DOI 10.1073/pnas.84.16.5923; NEEDLEMAN SW, 1986, BLOOD, V67, P753; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; PIERCE JH, 1982, J EXP MED, V156, P873, DOI 10.1084/jem.156.3.873; PIERCE JH, 1985, MOL CELL BIOL, V5, P667, DOI 10.1128/MCB.5.4.667; PONTEN J, 1968, ACTA PATHOL MIC SC, V74, P465; PULCIANI S, 1982, NATURE, V300, P539, DOI 10.1038/300539a0; RASHEED S, 1976, J VIROL, V19, P13, DOI 10.1128/JVI.19.1.13-18.1976; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; REIN A, 1985, MOL CELL BIOL, V5, P2257, DOI 10.1128/MCB.5.9.2257; ROVERA G, 1987, ONCOGENE, V1, P29; SANTOLI D, 1983, J IMMUNOL, V131, P736; SANTOS E, 1984, SCIENCE, V223, P661, DOI 10.1126/science.6695174; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SOUYRI M, 1983, P NATL ACAD SCI-BIOL, V80, P6676, DOI 10.1073/pnas.80.21.6676; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TWEARDY DJ, 1987, ONCOGENE RES, V1, P209; VALTIERI M, 1987, J IMMUNOL, V138, P3829; WARNER NL, 1969, J NATL CANCER I, V43, P963; WATANABE T, 1985, BIOCHEM BIOPH RES CO, V126, P999, DOI 10.1016/0006-291X(85)90284-0; WEINBERG RA, 1982, ADV CANCER RES, V36, P149, DOI 10.1016/S0065-230X(08)60424-8; WEISSMAN B, 1985, MOL CELL BIOL, V5, P3386, DOI 10.1128/MCB.5.12.3386; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490; YAM LT, 1971, AM J CLIN PATHOL, V55, P283; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0; YUSPA SH, 1985, NATURE, V314, P459, DOI 10.1038/314459a0	65	44	44	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1989	4	3					301	308						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5676	2468124				2022-12-17	WOS:A1989U567600005
J	LI, WJ; DREAZEN, O; KLOETZER, W; GALE, RP; ARLINGHAUS, RB				LI, WJ; DREAZEN, O; KLOETZER, W; GALE, RP; ARLINGHAUS, RB			CHARACTERIZATION OF BCR GENE-PRODUCTS IN HEMATOPOIETIC-CELLS	ONCOGENE			English	Article									UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,CTR CANC,DEPT MOLEC PATHOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030; JOHNSON & JOHNSON BIOTECHNOL CTR,LA JOLLA,CA 92038; UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,DIV HEMATOL & ONCOL,LOS ANGELES,CA 90024	University of Texas System; UTMD Anderson Cancer Center; Johnson & Johnson; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NCI NIH HHS [CA16672, CA47372] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA047372] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLLINS S, 1987, MOL CELL BIOL, V7, P2870, DOI 10.1128/MCB.7.8.2870; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CROCE CM, 1987, P NATL ACAD SCI USA, V84, P7174, DOI 10.1073/pnas.84.20.7174; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; DREAZEN O, 1987, BRIT J HAEMATOL, V67, P319, DOI 10.1111/j.1365-2141.1987.tb02353.x; GALE RP, 1984, P NATL ACAD SCI-BIOL, V81, P5648, DOI 10.1073/pnas.81.18.5648; GIBSON W, 1974, VIROLOGY, V62, P319, DOI 10.1016/0042-6822(74)90395-X; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; HUNTER T, 1986, ENZYMES, V17, P191; KLOETZER W, 1985, VIROLOGY, V140, P230, DOI 10.1016/0042-6822(85)90361-7; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI WJ, 1988, ONCOGENE, V2, P559; LIFSHITZ B, 1987, ONCOGENE, V2, P112; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MAXWELL SA, 1987, CANCER RES, V47, P1731; NOWELL PC, 1960, JNCI-J NATL CANCER I, V25, P85; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; Smith Linda D., 1987, ADV LEUKEMIA LYMPHOM, P95; SMITH RG, 1981, J IMMUNOL, V126, P596; STAM K, 1987, MOL CELL BIOL, V7, P1955, DOI 10.1128/MCB.7.5.1955; WALKER LC, 1987, NATURE, V329, P851, DOI 10.1038/329851a0	35	44	44	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1989	4	2					127	138						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5675	2648252				2022-12-17	WOS:A1989U567500002
J	TROJANOWSKA, M; WU, L; LEROY, EC				TROJANOWSKA, M; WU, L; LEROY, EC			ELEVATED EXPRESSION OF C-MYC PROTO-ONCOGENE IN SCLERODERMA FIBROBLASTS	ONCOGENE			English	Article											TROJANOWSKA, M (corresponding author), MED UNIV S CAROLINA,DEPT MED,DIV RHEUMATOL & IMMUNOL,CSB912,171 ASHLEY AVE,CHARLESTON,SC 29425, USA.			Trojanowska, Maria/0000-0001-9550-7178				ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; COLE MD, 1987, CURRENT COMMUNICATIO, P192; DALLAFAVERA R, 1987, CURRENT COMMUNICATIO, P152; FALANGA V, 1988, MAY ARA SCI M HOUST; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; LEROY EC, 1981, COLLAGEN REL RES, V1, P301; LEROY EC, 1974, J CLIN INVEST, V54, P880, DOI 10.1172/JCI107827; LEROY EC, 1982, P NATL ACAD SCI-BIOL, V79, P1286, DOI 10.1073/pnas.79.4.1286; MANIATIS T, 1982, MOL CLONING LABORATO; MARCU KB, 1987, BIOESSAYS, V6, P28, DOI 10.1002/bies.950060108; PENN A, 1986, P NATL ACAD SCI USA, V83, P7951, DOI 10.1073/pnas.83.20.7951; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; ROSSI P, 1988, IN PRESS CELL; RUSSELL SB, 1988, P NATL ACAD SCI USA, V85, P587, DOI 10.1073/pnas.85.2.587; Smith E., UNPUB; SORRENTINO V, 1986, P NATL ACAD SCI USA, V83, P8167, DOI 10.1073/pnas.83.21.8167; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; STUDZINSKI GP, 1986, SCIENCE, V234, P467, DOI 10.1126/science.3532322; UITTO J, 1979, J CLIN INVEST, V64, P921, DOI 10.1172/JCI109558; WHITE BA, 1982, J BIOL CHEM, V257, P8569	23	44	44	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1988	3	4					477	481						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q7739	3078955				2022-12-17	WOS:A1988Q773900018
J	PAULES, RS; PROPST, F; DUNN, KJ; BLAIR, DG; KAUL, K; PALMER, AE; WOUDE, GFV				PAULES, RS; PROPST, F; DUNN, KJ; BLAIR, DG; KAUL, K; PALMER, AE; WOUDE, GFV			PRIMATE CIS-MOS PROTO-ONCOGENE STRUCTURE AND EXPRESSION - TRANSCRIPTION INITIATION BOTH UPSTREAM AND WITHIN THE GENE IN A TISSUE-SPECIFIC MANNER	ONCOGENE			English	Article									NCI,FREDERICK CANC RES FACIL,BIONET RES INC,BASIC RES PROGRAM,FREDERICK,MD 21701; NCI,FREDERICK CANC RES FACIL,MOLEC ONCOL LAB,FREDERICK,MD 21701; NCI,FREDERICK CANC RES FACIL,COMPARAT CARCINOGENESIS LAB,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Paules, Richard S/0000-0001-9106-7486				BACHVAROVA R, 1985, DEV BIOL, V108, P325, DOI 10.1016/0012-1606(85)90036-3; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BLAIR DG, 1980, P NATL ACAD SCI-BIOL, V77, P3504, DOI 10.1073/pnas.77.6.3504; BLAIR DG, 1986, CELL, V46, P785, DOI 10.1016/0092-8674(86)90354-5; BLAIR DG, 1982, SCIENCE, V218, P1122, DOI 10.1126/science.6293052; BLAIR DG, 1981, SCIENCE, V212, P941, DOI 10.1126/science.7233190; BLAIR DG, 1984, CANCER CELL, V2, P281; BOLD RJ, 1985, MOL CELL BIOL, V5, P3131, DOI 10.1128/MCB.5.11.3131; BOND JF, 1983, MOL CELL BIOL, V3, P1333, DOI 10.1128/MCB.3.8.1333; BOWER PA, 1987, BIOL REPROD, V37, P479, DOI 10.1095/biolreprod37.2.479; DANOS O, 1984, CANCER CELLS ONCOGEN, V2, P291; Favaloro J, 1980, Methods Enzymol, V65, P718; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; HANNINK M, 1985, P NATL ACAD SCI USA, V82, P7894, DOI 10.1073/pnas.82.23.7894; HEARD JM, 1987, MOL CELL BIOL, V7, P2425, DOI 10.1128/MCB.7.7.2425; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HUARTE J, 1987, GENE DEV, V1, P1201, DOI 10.1101/gad.1.10.1201; HUNTER T, 1986, ENZYMES, V17, P191; JOHANSEN H, 1984, P NATL ACAD SCI-BIOL, V81, P7698, DOI 10.1073/pnas.81.24.7698; JONES M, 1980, P NATL ACAD SCI-BIOL, V77, P2651, DOI 10.1073/pnas.77.5.2651; KESHET E, 1988, ONCOGENE, V2, P235; KLEENE KC, 1984, DEV BIOL, V105, P71, DOI 10.1016/0012-1606(84)90262-8; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P3873, DOI 10.1093/nar/12.9.3873; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAMB FI, 1985, EUR J BIOCHEM, V148, P265, DOI 10.1111/j.1432-1033.1985.tb08834.x; LAMBERT PF, 1987, CELL, V50, P69, DOI 10.1016/0092-8674(87)90663-5; LI WH, 1985, MOL BIOL EVOL, V2, P150; LIU CC, 1984, NATURE, V309, P82, DOI 10.1038/309082a0; MANIATIS T, 1982, MOL CLONING LABORATO; Maxam A M, 1980, Methods Enzymol, V65, P499; MCGEADY ML, 1986, DNA-J MOLEC CELL BIO, V5, P289, DOI 10.1089/dna.1986.5.289; MOLONEY JOHN B., 1966, NAT CANCER INST MONOGR, V22, P139; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; PROPST F, 1988, ONCOGENE, V2, P227; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT M, 1988, MOL CELL BIOL, V8, P923, DOI 10.1128/MCB.8.2.923; SETH A, 1985, J VIROL, V56, P144, DOI 10.1128/JVI.56.1.144-152.1985; SIBLEY CG, 1984, J MOL EVOL, V20, P2, DOI 10.1007/BF02101980; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; VANDERHOORN FA, 1982, EMBO J, V1, P1313, DOI 10.1002/j.1460-2075.1982.tb01316.x; VANDERHOORN FA, 1984, NUCLEIC ACIDS RES, V12, P2147, DOI 10.1093/nar/12.4.2147; VANDEWOUDE GF, 1979, P NATL ACAD SCI USA, V76, P4464; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WATERS SH, 1985, MOL CELL BIOL, V5, P1649, DOI 10.1128/MCB.5.7.1649; WATSON R, 1982, P NATL ACAD SCI-BIOL, V79, P4078, DOI 10.1073/pnas.79.13.4078; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726; WOOD TG, 1984, P NATL ACAD SCI-BIOL, V81, P7817, DOI 10.1073/pnas.81.24.7817; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	57	44	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1988	3	1					59	68						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	P0354					2022-12-17	WOS:A1988P035400009
J	Asare-Werehene, M; Nakka, K; Reunov, A; Chiu, CT; Lee, WT; Abedini, MR; Wang, PW; Shieh, DB; Dilworth, FJ; Carmona, E; Le, T; Mes-Masson, AM; Burger, D; Tsang, BK				Asare-Werehene, Meshach; Nakka, Kiran; Reunov, Arkadiy; Chiu, Chen-Tzu; Lee, Wei-Ting; Abedini, Mohammad R.; Wang, Pei-Wen; Shieh, Dar-Bin; Dilworth, F. Jeffrey; Carmona, Euridice; Le, Tien; Mes-Masson, Anne-Marie; Burger, Dylan; Tsang, Benjamin K.			The exosome-mediated autocrine and paracrine actions of plasma gelsolin in ovarian cancer chemoresistance	ONCOGENE			English	Article							PROTEIN-KINASE B; CISPLATIN RESISTANCE; AKT; ACTIVATION; CELLS; PROGRESSION; HYPOXIA; P53; EXPRESSION; APOPTOSIS	Ovarian cancer (OVCA) is the most lethal gynecological cancer, due predominantly to late presentation, high recurrence rate and common chemoresistance development. The expression of the actin-associated protein cytosolic gelsolin (GSN) regulates the gynecological cancer cell fate resulting in dysregulation in chemosensitivity. In this study, we report that elevated expression of plasma gelsolin (pGSN), a secreted isoform of GSN and expressed from the same GSN gene, correlates with poorer overall survival and relapse-free survival in patients with OVCA. In addition, it is highly expressed and secreted in chemoresistant OVCA cells than its chemosensitive counterparts. pGSN, secreted and transported via exosomes (Ex-pGSN), upregulates HIF1 alpha-mediated pGSN expression in chemoresistant OVCA cells in an autocrine manner as well as confers cisplatin resistance in otherwise chemosensitive OVCA cells. These findings support our hypothesis that exosomal pGSN promotes OVCA cell survival through both autocrine and paracrine mechanisms that transform chemosensitive cells to resistant counterparts. Specifically, pGSN transported via exosomes is a determinant of chemoresistance in OVCA.	[Asare-Werehene, Meshach; Le, Tien; Tsang, Benjamin K.] Univ Ottawa, Dept Obstet & Gynecol, Ottawa, ON, Canada; [Asare-Werehene, Meshach; Nakka, Kiran; Dilworth, F. Jeffrey; Le, Tien; Burger, Dylan; Tsang, Benjamin K.] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada; [Asare-Werehene, Meshach; Nakka, Kiran; Abedini, Mohammad R.; Dilworth, F. Jeffrey; Le, Tien; Burger, Dylan; Tsang, Benjamin K.] Ottawa Hosp Res Inst, Chron Dis Program, Ottawa, ON K1H 8L6, Canada; [Asare-Werehene, Meshach; Nakka, Kiran; Abedini, Mohammad R.; Dilworth, F. Jeffrey; Le, Tien; Burger, Dylan; Tsang, Benjamin K.] Ottawa Hosp Res Inst, Regenerat Med Program, Ottawa, ON K1H 8L6, Canada; [Nakka, Kiran; Dilworth, F. Jeffrey; Burger, Dylan; Tsang, Benjamin K.] Univ Ottawa, Dept Med, Ottawa, ON, Canada; [Reunov, Arkadiy] St Francis Xavier Univ, Dept Biol, 2320 Notre Dame Ave, Antigonish, NS B2G 2W5, Canada; [Chiu, Chen-Tzu; Lee, Wei-Ting; Wang, Pei-Wen; Shieh, Dar-Bin] Natl Cheng Kung Univ, Inst Basic Med Sci, Inst Oral Med, Natl Cheng Kung Univ Hosp, Tainan 704, Taiwan; [Chiu, Chen-Tzu; Lee, Wei-Ting; Wang, Pei-Wen; Shieh, Dar-Bin] Natl Cheng Kung Univ, Dept Stomatol, Natl Cheng Kung Univ Hosp, Tainan 704, Taiwan; [Abedini, Mohammad R.] Birjand Univ Med Sci, Cellular & Mol Med Res Ctr, Dept Pharmacol, Birjand 97178, Iran; [Shieh, Dar-Bin] Natl Cheng Kung Univ, Adv Optoelect Technol Ctr, Tainan 701, Taiwan; [Shieh, Dar-Bin] Natl Cheng Kung Univ, Ctr Micro Nano Sci & Technol, Tainan 701, Taiwan; [Carmona, Euridice; Mes-Masson, Anne-Marie] Ctr Rech CHUM, Montreal, PQ H2X 0A9, Canada; [Carmona, Euridice; Mes-Masson, Anne-Marie] Inst Canc Montreal, Montreal, PQ H2X 0A9, Canada; [Carmona, Euridice; Mes-Masson, Anne-Marie] Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada	University of Ottawa; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Saint Francis Xavier University - Canada; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University; Universite de Montreal; Universite de Montreal; Universite de Montreal	Tsang, BK (corresponding author), Univ Ottawa, Dept Obstet & Gynecol, Ottawa, ON, Canada.; Tsang, BK (corresponding author), Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada.; Tsang, BK (corresponding author), Ottawa Hosp Res Inst, Chron Dis Program, Ottawa, ON K1H 8L6, Canada.; Tsang, BK (corresponding author), Ottawa Hosp Res Inst, Regenerat Med Program, Ottawa, ON K1H 8L6, Canada.; Tsang, BK (corresponding author), Univ Ottawa, Dept Med, Ottawa, ON, Canada.	btsang@ohri.ca	Nakka, Kiran/CAJ-3374-2022; Burger, Dylan/ABD-2727-2020	Burger, Dylan/0000-0003-3951-2911; Dilworth, F. Jeffrey/0000-0002-6265-8102; Nakka, Kiran/0000-0002-8418-9343; Wang, Pei-Wen/0000-0002-1863-3661	Canadian Institutes of Health Research [MOP-15691]; Taiwan Ministry of Science and Technology [MOST 104-2314-B-006-063-MY3, 106-2627-M-006-001, 107-2321-B-006-019, 107-2314-B-006-029]; Center of Applied Nanomedicine, National Cheng Kung University; Dragon Gate Program [MOST 105-2911-I-006-529]; Taiwan Ministry of Education	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Taiwan Ministry of Science and Technology; Center of Applied Nanomedicine, National Cheng Kung University; Dragon Gate Program; Taiwan Ministry of Education(Ministry of Education, Taiwan)	This work was supported by the Canadian Institutes of Health Research (MOP-15691), the Dragon Gate Program (MOST 105-2911-I-006-529), and research grants (MOST 104-2314-B-006-063-MY3, 106-2627-M-006-001, 107-2321-B-006-019, and 107-2314-B-006-029) from the Taiwan Ministry of Science and Technology, the Center of Applied Nanomedicine, National Cheng Kung University, The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project, the Taiwan Ministry of Education.	Abedini MR, 2010, ONCOGENE, V29, P11, DOI 10.1038/onc.2009.300; Abedini MR, 2014, P NATL ACAD SCI USA, V111, P14442, DOI 10.1073/pnas.1401166111; Abedini MR, 2004, ONCOGENE, V23, P6997, DOI 10.1038/sj.onc.1207925; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Ali AY, 2012, ONCOGENE, V31, P2175, DOI 10.1038/onc.2011.399; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Armstrong DK, 2006, NEW ENGL J MED, V354, P34, DOI 10.1056/NEJMoa052985; Ata R, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010189; Bohgaki M, 2011, J CELL MOL MED, V15, P141, DOI 10.1111/j.1582-4934.2009.00940.x; Bruney L, 2016, ONCOTARGET, V7, P21968, DOI 10.18632/oncotarget.7880; Budnik V, 2016, NAT REV NEUROSCI, V17, P160, DOI 10.1038/nrn.2015.29; Burger D, 2015, AM J PATHOL, V185, P2309, DOI 10.1016/j.ajpath.2015.04.010; Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824; Chen CC, 2017, ONCOTARGET, V8, P77152, DOI 10.18632/oncotarget.20414; Chen WX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095240; Crow J, 2017, ONCOTARGET, V8, P11917, DOI 10.18632/oncotarget.14440; Dai CL, 2013, J BIOL CHEM, V288, P23875, DOI 10.1074/jbc.M112.445148; Daponte A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-335; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Dengler VL, 2014, CRIT REV BIOCHEM MOL, V49, P1, DOI 10.3109/10409238.2013.838205; Elattar A, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD007565, 10.1002/14651858.CD007565.pub2]; Faridi J, 2003, AM J PHYSIOL-ENDOC M, V285, pE964, DOI 10.1152/ajpendo.00239.2003; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Fraser M, 2003, CANCER RES, V63, P7081; Fu LJ, 2013, J OVARIAN RES, V6, DOI 10.1186/1757-2215-6-92; Gomez-Roman N, 2016, ONCOTARGET, V7, P22650, DOI 10.18632/oncotarget.7998; Greijer AE, 2005, J PATHOL, V206, P291, DOI 10.1002/path.1778; Gyorffy B, 2012, ENDOCR-RELAT CANCER, V19, P197, DOI 10.1530/ERC-11-0329; Krieg T, 2003, CARDIOVASC RES, V58, P196, DOI 10.1016/S0008-6363(02)00861-1; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; Lee PS, 2006, AM J RESP CRIT CARE, V173, P685, DOI 10.1164/ajrccm.173.6.685; Liu PD, 2014, NATURE, V508, P541, DOI 10.1038/nature13079; Lofberg M, 1998, J NEUROL SCI, V157, P187, DOI 10.1016/S0022-510X(98)00056-2; Meng XD, 2016, ONCOTARGET, V7, P16923, DOI 10.18632/oncotarget.7850; Nakka KK, 2015, P NATL ACAD SCI USA, V112, pE3374, DOI 10.1073/pnas.1418603112; Nitulescu GM, 2016, INT J ONCOL, V48, P869, DOI 10.3892/ijo.2015.3306; Pal SK, 2010, EXPERT OPIN INV DRUG, V19, P1355, DOI 10.1517/13543784.2010.520701; Pink RC, 2015, GYNECOL ONCOL, V137, P143, DOI 10.1016/j.ygyno.2014.12.042; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Reunov A, 2018, GENE, V658, P1, DOI 10.1016/j.gene.2018.03.012; Roma-Rodrigues C, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/179486; Safaei R, 2005, MOL CANCER THER, V4, P1595, DOI 10.1158/1535-7163.MCT-05-0102; SMITH DB, 1987, J LAB CLIN MED, V110, P189; Spinardi L., 2007, V45, P55; Stefanou DT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117654; Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179; Tsai MH, 2012, J MOL MED, V90, P187, DOI 10.1007/s00109-011-0817-4; Vinas JL, 2016, KIDNEY INT, V90, P1238, DOI 10.1016/j.kint.2016.07.015; Wang PW, 2014, INT J CANCER, V135, P2760, DOI 10.1002/ijc.28928; Wefers C, 2015, GYNECOL ONCOL, V137, P335, DOI 10.1016/j.ygyno.2015.02.019; Wei YF, 2014, BREAST CANCER RES TR, V147, P423, DOI 10.1007/s10549-014-3037-0; Yang XK, 2006, CANCER RES, V66, P3126, DOI 10.1158/0008-5472.CAN-05-0425; Yang ZY, 2015, SCI REP-UK, V5, DOI 10.1038/srep07758; Yeung CLA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11150; YIN HL, 1984, J BIOL CHEM, V259, P5271; Yin J, 2012, J CELL MOL MED, V16, P337, DOI 10.1111/j.1582-4934.2011.01316.x; Ying X, 2016, ONCOTARGET, V7, P43076, DOI 10.18632/oncotarget.9246; Yu TC, 2017, YONSEI MED J, V58, P489, DOI 10.3349/ymj.2017.58.3.489; Zeng B, 2018, ONCOTARGETS THER, V11, P1333, DOI 10.2147/OTT.S154215	59	43	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	7					1600	1616		10.1038/s41388-019-1087-9	http://dx.doi.org/10.1038/s41388-019-1087-9			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KL2WP	31700155	Green Published, hybrid			2022-12-17	WOS:000513289600015
J	Contreras-Zarate, MJ; Day, NL; Ormond, DR; Borges, VF; Tobet, S; Gril, B; Steeg, PS; Cittelly, DM				Contreras-Zarate, Maria J.; Day, Nicole L.; Ormond, D. Ryan; Borges, Virginia F.; Tobet, Stuart; Gril, Brunilde; Steeg, Patricia S.; Cittelly, Diana M.			Estradiol induces BDNF/TrkB signaling in triple-negative breast cancer to promote brain metastases	ONCOGENE			English	Article							ESTROGEN-RECEPTOR-ALPHA; NEUROTROPHIC FACTOR; TUMOR-GROWTH; ASTROCYTES; CELLS; BDNF; SURVIVAL; TRKB; MICROENVIRONMENT; IDENTIFICATION	Breast cancer brain metastases (BM) affect younger women disproportionally, including those lacking estrogen receptor (ER), progesterone receptor, and HER2 (known as triple-negative breast cancer; TNBC). Previous studies in preclinical models showed that pre-menopausal levels of estradiol (E2) promote TNBC-BM through incompletely understood mechanisms involving reactive astrocytes. Herein, a novel mechanism involving E2-dependent upregulation of brain-derived neurotrophic factor (BDNF) in astrocytes, and subsequent activation of tumor cell tropomyosin kinase receptor B (TrkB), is identified. E2 increased experimental BM of TNBC 4T1BR5 and E0771 cells by 21 and 3.6 fold, respectively, compared to E2-depleted mice. ER alpha(+) reactive astrocytes were found at early and late stages of BM, and E2 upregulated BDNF in ER+ reactive astrocytes in vitro and in vivo. TrkB was expressed in TNBC brain-trophic cell lines, BM-patient-derived xenografts, and breast cancer BM. Conditioned media from E2-treated astrocytes (CM-E2) activated TrkB and downstream AKT, ERK, and PLC-gamma signaling in TNBC cells, increasing their invasiveness and tumor-initiating capability in vitro. The promotion of BM by E2-activated astrocytes was found to be more complex, involving feedback loops and other receptor tyrosine kinases. In 4T1BR5 cells, there was a positive feedback loop whereby astrocytic BDNF induced cancer cell BDNF translation. Upregulation of cancer cell BDNF was required to promote full invasiveness of 4T1BR5 in response to CM-E2, and was observed in brain metastatic cells in E2-treated mice in vivo. Moreover, the non-competitive BDNF/TrkB inhibitor ANA-12 reduced E2-induced 4T1BR5 BM to levels similar to OVX mice. BDNF also activated EGFR in TrkB(+)EGFR(+) TNBC cells, suggesting that E2 action through astrocytes activates redundant pathways promoting BM. These findings have important therapeutic implications, as they provide a rationale to use E2-depletion therapies or TrkB inhibitors to prevent or delay development of BM in younger women.	[Contreras-Zarate, Maria J.; Day, Nicole L.; Cittelly, Diana M.] Univ Colorado Denver, Dept Pathol, Anschutz Med Campus, Aurora, CO 80045 USA; [Ormond, D. Ryan] Univ Colorado Denver, Dept Neurosurg, Anschutz Med Campus, Aurora, CO USA; [Borges, Virginia F.] Univ Colorado Denver, Div Med Oncol, Dept Med, Anschutz Med Campus, Aurora, CO USA; [Tobet, Stuart] Colorado State Univ, Dept Biomed Sci, Ft Collins, CO 80523 USA; [Gril, Brunilde; Steeg, Patricia S.] NCI, Womens Malignancies Branch, Bethesda, MD 20892 USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Colorado State University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Cittelly, DM (corresponding author), Univ Colorado Denver, Dept Pathol, Anschutz Med Campus, Aurora, CO 80045 USA.	Diana.Cittelly@ucdenver.edu	; Ormond, David Ryan/R-4847-2017	Cittelly, Diana/0000-0002-8392-0800; Day, Nicole/0000-0003-3490-4908; Ormond, David Ryan/0000-0001-7027-2915; CONTRERAS-ZARATE, MARIA J/0000-0002-0045-549X	ACS IRG [57-001-53, K22CA181250, R37 CA227984]; Drink for Pink and Cancer League of Colorado; Metavivor Research Foundation; NCI [P30CA046934]; CTSA [UL1TR001082]; NATIONAL CANCER INSTITUTE [ZIABC010538, R37CA227984, P30CA046934] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001082] Funding Source: NIH RePORTER	ACS IRG(American Cancer Society); Drink for Pink and Cancer League of Colorado; Metavivor Research Foundation; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); CTSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	This work was supported by ACS IRG #57-001-53, K22CA181250, R37 CA227984, Drink for Pink and Cancer League of Colorado, and the Metavivor Research Foundation (DMC). University of Colorado Cancer Center Shared Resources were supported by NCI P30CA046934 and CTSA UL1TR001082 Center grants.	Anders C, 2008, ONCOLOGY-NY, V22, P1233; Anders CK, 2008, J CLIN ONCOL, V26, P3324, DOI 10.1200/JCO.2007.14.2471; Anders CK, 2009, SEMIN ONCOL, V36, P237, DOI 10.1053/j.seminoncol.2009.03.001; Azcoitia I, 2011, NEUROSCIENCE, V191, P139, DOI 10.1016/j.neuroscience.2011.02.012; Azcoitia I, 2006, ANN NY ACAD SCI, V1007, P298; Azcoitia I, 2010, EUR J NEUROSCI, V32, P1995, DOI 10.1111/j.1460-9568.2010.07516.x; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; Biegon A, 2015, J NUCL MED, V56, P580, DOI 10.2967/jnumed.114.150383; Blurton-Jones M, 2001, J COMP NEUROL, V433, P115, DOI 10.1002/cne.1129; Boyle P, 2012, ANN ONCOL, V23, P7, DOI 10.1093/annonc/mds187; Chen Q, 2016, NATURE, V533, P493, DOI 10.1038/nature18268; Cheng PL, 2011, P NATL ACAD SCI USA, V108, P18430, DOI 10.1073/pnas.1115907108; Choy C, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0844-3; Contreras-Zarate MJ, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00252; Cunha C, 2010, FRONT MOL NEUROSCI, V3, DOI 10.3389/neuro.02.001.2010; de Vellis J, 2012, METHODS MOL BIOL, V814, P49, DOI 10.1007/978-1-61779-452-0_4; Dittrich F, 1999, P NATL ACAD SCI USA, V96, P8241, DOI 10.1073/pnas.96.14.8241; Dougherty KD, 2000, NEUROBIOL DIS, V7, P574, DOI 10.1006/nbdi.2000.0318; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Evans AJ, 2004, CLIN ONCOL-UK, V16, P345, DOI 10.1016/j.clon.2004.03.012; Ferreira TA, 2014, NAT METHODS, V11, P982, DOI 10.1038/nmeth.3125; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Fulmer CG, 2014, J NEUROSCI, V34, P8186, DOI 10.1523/JNEUROSCI.4267-13.2014; Gotz R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100944; Gravanis I, 2005, GLIA, V49, P177, DOI 10.1002/glia.20115; Hicks DG, 2006, AM J SURG PATHOL, V30, P1097; Howe EN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049987; Hung MH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089389; Iyer V, 2012, CANCER RES, V72, P2705, DOI 10.1158/0008-5472.CAN-11-3287; Ji YY, 2010, NAT NEUROSCI, V13, P302, DOI 10.1038/nn.2505; Kim MS, 2015, ONCOTARGET, V6, P40158, DOI 10.18632/oncotarget.5522; Kim SJ, 2011, NEOPLASIA, V13, P286, DOI 10.1593/neo.11112; Kodack DP, 2015, CANCER CELL, V27, P163, DOI 10.1016/j.ccell.2015.01.001; Kuo J, 2010, J NEUROSCI, V30, P12950, DOI 10.1523/JNEUROSCI.1158-10.2010; Lockman PR, 2010, CLIN CANCER RES, V16, P5664, DOI 10.1158/1078-0432.CCR-10-1564; Lorger M, 2010, AM J PATHOL, V176, P2958, DOI 10.2353/ajpath.2010.090838; Matsumoto T, 2008, NAT NEUROSCI, V11, P131, DOI 10.1038/nn2038; Mccarthy MM, 2008, PHYSIOL REV, V88, P91, DOI 10.1152/physrev.00010.2007; Micevych P, 2009, J NEUROENDOCRINOL, V21, P249, DOI 10.1111/j.1365-2826.2009.01833.x; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; Miyamoto N, 2015, J NEUROSCI, V35, P14002, DOI 10.1523/JNEUROSCI.1592-15.2015; Morris PG, 2012, BREAST J, V18, P345, DOI 10.1111/j.1524-4741.2012.01246.x; Murer MG, 2001, PROG NEUROBIOL, V63, P71, DOI 10.1016/S0301-0082(00)00014-9; Palmieri D, 2007, CANCER RES, V67, P4190, DOI 10.1158/0008-5472.CAN-06-3316; Pang PT, 2004, SCIENCE, V306, P487, DOI 10.1126/science.1100135; Pequeux C, 2012, CANCER RES, V72, P3010, DOI 10.1158/0008-5472.CAN-11-3768; Priego N, 2018, NAT MED, V24, P1024, DOI 10.1038/s41591-018-0044-4; Rose CR, 2003, NATURE, V426, P74, DOI 10.1038/nature01983; Sartori CR, 2011, NEUROSCIENCE, V180, P9, DOI 10.1016/j.neuroscience.2011.02.055; Sartorius CA, 2016, ONCOGENE, V35, P2881, DOI 10.1038/onc.2015.353; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Shao MM, 2011, MED MOL MORPHOL, V44, P15, DOI 10.1007/s00795-010-0495-2; Sinkevicius KW, 2014, P NATL ACAD SCI USA, V111, P10299, DOI 10.1073/pnas.1404399111; SOHRABJI F, 1995, P NATL ACAD SCI USA, V92, P11110, DOI 10.1073/pnas.92.24.11110; Spence RD, 2011, P NATL ACAD SCI USA, V108, P8867, DOI 10.1073/pnas.1103833108; Svoronos N, 2017, CANCER DISCOV, V7, P72, DOI 10.1158/2159-8290.CD-16-0502; Tham YL, 2006, CANCER, V107, P696, DOI 10.1002/cncr.22041; Tseng LM, 2013, NEOPLASMA, V60, P290, DOI 10.4149/neo_2013_038; Valiente M, 2014, CELL, V156, P1002, DOI 10.1016/j.cell.2014.01.040; Wang L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080933; Yin B, 2015, ONCOGENE, V34, P761, DOI 10.1038/onc.2014.8; Yoneda T, 2001, J BONE MINER RES, V16, P1486, DOI 10.1359/jbmr.2001.16.8.1486; Zagar TM, 2016, ONCOLOGY-NY, V30, P923; Zhang L, 2015, NATURE, V527, P100, DOI 10.1038/nature15376; Zhou L, 2010, ENDOCRINOLOGY, V151, P1153, DOI 10.1210/en.2009-0254	65	43	44	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2019	38	24					4685	4699		10.1038/s41388-019-0756-z	http://dx.doi.org/10.1038/s41388-019-0756-z			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IC7ND	30796353	hybrid, Green Published, Green Accepted			2022-12-17	WOS:000471160500003
J	Kato, M; Placencio-Hickok, VR; Madhav, A; Haldar, S; Tripathi, M; Billet, S; Mishra, R; Smith, B; Rohena-Rivera, K; Agarwal, P; Duong, F; Angara, B; Hickok, D; Liu, ZQ; Bhowmick, NA				Kato, Manabu; Placencio-Hickok, Veronica R.; Madhav, Anisha; Haldar, Subhash; Tripathi, Manisha; Billet, Sandrine; Mishra, Rajeev; Smith, Bethany; Rohena-Rivera, Krizia; Agarwal, Priyanka; Duong, Frank; Angara, Bryan; Hickok, David; Liu, Zhenqiu; Bhowmick, Neil A.			Heterogeneous cancer-associated fibroblast population potentiates neuroendocrine differentiation and castrate resistance in a CD105-dependent manner	ONCOGENE			English	Article							FRIZZLED-RELATED PROTEIN-1; PROSTATE-CANCER; TGF-BETA; TUMOR PROGRESSION; ENDOGLIN CD105; UP-REGULATION; CELL; INHIBITION; IDENTIFICATION; MORPHOGENESIS	Heterogeneous prostatic carcinoma-associated fibroblasts (CAF) contribute to tumor progression and resistance to androgen signaling deprivation therapy (ADT). CAF subjected to extended passaging, compared to low passage CAF, were found to lose tumor expansion potential and heterogeneity. Cell surface endoglin (CD105), known to be expressed on proliferative endothelia and mesenchymal stem cells, was diminished in high passage CAF. RNA-sequencing revealed SFRP1 to be distinctly expressed by tumor-inductive CAF, which was further demonstrated to occur in a CD105-dependent manner. Moreover, ADT resulted in further expansion of the CD105(+) fibroblastic population and downstream SFRP1 in 3-dimensional cultures and patient-derived xenograft tissues. In patients, CD105(+) fibroblasts were found to circumscribe epithelia with neuroendocrine differentiation. CAF-derived SFRP1, driven by CD105 signaling, was necessary and sufficient to induce prostate cancer neuroendocrine differentiation in a paracrine manner. A partially humanized CD105 neutralizing antibody, TRC105, inhibited fibroblastic SFRP1 expression and epithelial neuroendocrine differentiation. In a novel synthetic lethality paradigm, we found that simultaneously targeting the epithelia and its microenvironment with ADT and TRC105, respectively, reduced castrate-resistant tumor progression, in a model where either ADT or TRC105 alone had little effect.	[Kato, Manabu] Mie Univ Hosp, Nephrourol Surg & Androl, Tsu, Mie, Japan; [Placencio-Hickok, Veronica R.; Madhav, Anisha; Haldar, Subhash; Tripathi, Manisha; Billet, Sandrine; Mishra, Rajeev; Smith, Bethany; Rohena-Rivera, Krizia; Agarwal, Priyanka; Duong, Frank; Angara, Bryan; Hickok, David; Liu, Zhenqiu; Bhowmick, Neil A.] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA	Mie University; Cedars Sinai Medical Center	Bhowmick, NA (corresponding author), Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA.	bhowmickn@cshs.org	Mishra, Rajeev/AEX-2208-2022; Smith, Bethany/GYT-9168-2022; Bhowmick, Neil/AAA-7302-2019	Mishra, Rajeev/0000-0002-7411-4022; Bhowmick, Neil/0000-0001-8747-5989; Haldar, Subhash/0000-0002-1230-1770	National Cancer Institute [CA108646]; Veterans Affairs [BX001040]; NATIONAL CANCER INSTITUTE [R01CA108646, P01CA098912] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007770] Funding Source: NIH RePORTER; Veterans Affairs [I01BX001040] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veterans Affairs(US Department of Veterans Affairs); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Veterans Affairs(US Department of Veterans Affairs)	We thank Charles Theurer at Tracon Pharmaceuticals, Inc. for the TRC105 and M1043 neutralizing antibodies. The RNA-sequencing and histology slide scanning was performed at the Cedars-Sinai Genomics Core and Microscopy Core, respectively. This work was supported by grants from the National Cancer Institute (CA108646) and Veterans Affairs (BX001040) to NAB.	Aggarwal RR, 2017, ONCOLOGY-NY, V31, P467; Ayala G, 2003, CLIN CANCER RES, V9, P4792; Banerjee J, 2014, ONCOGENE, V33, P4924, DOI 10.1038/onc.2013.431; Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095; Beltran H, 2012, J CLIN ONCOL, V30, pE386, DOI 10.1200/JCO.2011.41.5166; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; Bhowmick NA, 2003, P NATL ACAD SCI USA, V100, P15548, DOI 10.1073/pnas.2536483100; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Bovolenta P, 2008, J CELL SCI, V121, P737, DOI 10.1242/jcs.026096; Brennen WN, 2013, ONCOTARGET, V4, P106, DOI 10.18632/oncotarget.805; Bussard KM, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0740-2; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Dayyani F, 2013, PROSTATE, V73, P979, DOI 10.1002/pros.22645; Melo FDE, 2013, EMBO REP, V14, P686, DOI 10.1038/embor.2013.92; DeGraff DJ, 2009, AM J TRANSL RES, V1, P115; Erho N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066855; Esteve P, 2011, DEVELOPMENT, V138, P4179, DOI 10.1242/dev.065839; Fonsatti E, 2003, ONCOGENE, V22, P6557, DOI 10.1038/sj.onc.1206813; Franco OE, 2011, CANCER RES, V71, P1272, DOI 10.1158/0008-5472.CAN-10-3142; Fuyuhiro Y, 2011, BRIT J CANCER, V105, P996, DOI 10.1038/bjc.2011.330; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Ghajar CM, 2013, NAT CELL BIOL, V15, P807, DOI 10.1038/ncb2767; GLEAVE M, 1991, CANCER RES, V51, P3753; Hayward SW, 2001, CANCER RES, V61, P8135; Igarashi Atsushi, 2016, Nihon Hinyokika Gakkai Zasshi, V107, P155, DOI 10.5980/jpnjurol.107.155; Joesting MS, 2008, DEV BIOL, V317, P161, DOI 10.1016/j.ydbio.2008.02.021; Joesting MS, 2005, CANCER RES, V65, P10423, DOI 10.1158/0008-5472.CAN-05-0824; Kanayama M, 2017, PROSTATE, V77, P1489, DOI 10.1002/pros.23425; Karzai FH, 2015, BJU INT, V116, P546, DOI 10.1111/bju.12986; Kawano Y, 2009, BRIT J CANCER, V100, P1165, DOI 10.1038/sj.bjc.6604976; Kiskowski MA, 2011, CANCER RES, V71, P3459, DOI 10.1158/0008-5472.CAN-10-2999; Laskaratos FM, 2017, CANCER-AM CANCER SOC, V123, P4770, DOI 10.1002/cncr.31079; Li X, 2008, ONCOGENE, V27, P7118, DOI 10.1038/onc.2008.293; Miyata Y, 2015, PROSTATE, V75, P84, DOI 10.1002/pros.22894; Mu P, 2017, SCIENCE, V355, P84, DOI 10.1126/science.aah4307; Nolan-Stevaux O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050920; Olumi AF, 1999, CANCER RES, V59, P5002; Placencio VR, 2008, CANCER RES, V68, P4709, DOI 10.1158/0008-5472.CAN-07-6289; Qi JF, 2013, CANCER CELL, V23, P332, DOI 10.1016/j.ccr.2013.02.016; Romero D, 2011, CANCER RES, V71, P3482, DOI 10.1158/0008-5472.CAN-10-2665; Siamakpour-Reihani S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020412; Stark HJ, 1999, J INVEST DERMATOL, V112, P681, DOI 10.1046/j.1523-1747.1999.00573.x; Sun F, 2016, CARCINOGENESIS, V37, P701, DOI 10.1093/carcin/bgw044; Sun Y, 2016, ONCOGENE, V35, P4321, DOI 10.1038/onc.2015.494; True LD, 2010, MODERN PATHOL, V23, P1346, DOI 10.1038/modpathol.2010.122; Wadosky KM, 2016, ONCOTARGET, V7, P64447, DOI 10.18632/oncotarget.10901; Zhao HJ, 2009, PROSTATE, V69, P991, DOI 10.1002/pros.20946; Zheng L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118276; Zhu YT, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv129; Zikusoka MN, 2005, CANCER-AM CANCER SOC, V104, P2292, DOI 10.1002/cncr.21451	50	43	44	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2019	38	5					716	730		10.1038/s41388-018-0461-3	http://dx.doi.org/10.1038/s41388-018-0461-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HJ6LI	30177832	Green Accepted, Green Submitted			2022-12-17	WOS:000457300300008
J	Kanda, M; Tanaka, H; Shimizu, D; Miwa, T; Umeda, S; Tanaka, C; Kobayashi, D; Hattori, N; Suenaga, M; Hayashi, M; Iwata, N; Yamada, S; Fujiwara, M; Kodera, Y				Kanda, Mitsuro; Tanaka, Haruyoshi; Shimizu, Dai; Miwa, Takashi; Umeda, Shinichi; Tanaka, Chie; Kobayashi, Daisuke; Hattori, Norifumi; Suenaga, Masaya; Hayashi, Masamichi; Iwata, Naoki; Yamada, Suguru; Fujiwara, Michitaka; Kodera, Yasuhiro			SYT7 acts as a driver of hepatic metastasis formation of gastric cancer cells	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; PERITONEAL METASTASIS; MALIGNANT PHENOTYPE; SYNAPTOTAGMIN 7; TRIAL; CHEMOTHERAPY; GUIDELINES; BIOMARKER; SENSOR; EMT	Liver metastasis remains a serious problem in the management of gastric cancer (GC). Our aims were to identify through transcriptome analysis a molecule that mediates hepatic metastasis in GC, and to evaluate its potential as a diagnostic marker and a therapeutic target. The effects of knocking out a relevant molecule using genome editing were evaluated in vitro experiments and in mouse xenograft models. Expression levels of candidate molecule in 300 pairs of gastric tissues were determined to assess whether differentially expressed genes predicted hepatic recurrence, metastasis, or both. Transcriptome data identified the overexpression of synaptotagmin VII (SYT7) in GC tissues with hepatic metastasis. Its expression in the GC cell lines was high, particularly in those that exhibited a differentiated phenotype, and positively correlated with the expression of SNAI1 and TGFB3, and inversely with RGS2. SYT7 knockout inhibited the proliferation of GC cells, indicated by increased apoptosis with activated caspase and loss of mitochondria membrane potential, G2/M cell-cycle arrest and attenuated cell migration, invasion, and adhesion. The tumorigenicity of SYT7-knockout cells was moderately reduced in a mouse model of subcutaneous metastasis in which the levels of BCL2 and HIF1A were decreased and was more strikingly attenuated in a model of hepatic metastasis. The SYT7 levels in the primary GC tissues were significantly associated with hepatic recurrence, metastasis, and adverse prognosis. SYT7 represents a tool for prediction and monitoring of hepatic metastasis from GC as well as being a promising therapeutic target.	[Kanda, Mitsuro; Tanaka, Haruyoshi; Shimizu, Dai; Miwa, Takashi; Umeda, Shinichi; Tanaka, Chie; Kobayashi, Daisuke; Hattori, Norifumi; Suenaga, Masaya; Hayashi, Masamichi; Iwata, Naoki; Yamada, Suguru; Fujiwara, Michitaka; Kodera, Yasuhiro] Nagoya Univ, Grad Sch Med, Dept Surg Gastroenterol Surg 2, Nagoya, Aichi, Japan	Nagoya University	Kanda, M (corresponding author), Nagoya Univ, Grad Sch Med, Dept Surg Gastroenterol Surg 2, Nagoya, Aichi, Japan.	m-kanda@med.nagoya-u.ac.jp	Kanda, Mitsuro/M-4891-2014; Fujiwara, Michitaka/AAV-9715-2021	Kanda, Mitsuro/0000-0001-5464-3819; Kodera, Yasuhiro/0000-0002-6173-7474	JSS Young Researcher Award 2014;  [16K19889]	JSS Young Researcher Award 2014; 	This work was supported by a Grant-in-Aid for Encouragement of Young Scientists (B, 16K19889, Japan) and JSS Young Researcher Award 2014.	Acikgoz E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141090; Bang YJ, 2010, LANCET, V376, P1302; Bang YJ, 2012, LANCET, V379, P315, DOI 10.1016/S0140-6736(11)61873-4; Chen XY, 2016, HUM GENOMICS, V10, DOI 10.1186/s40246-016-0070-6; Cheng CH, 2016, MOL MED REP, V13, P1495, DOI 10.3892/mmr.2015.4717; Chiang AC, 2008, NEW ENGL J MED, V359, P2814, DOI 10.1056/NEJMra0805239; Gao JF, 2014, CANCER CELL INT, V14, DOI 10.1186/s12935-014-0072-1; Goodman KA, 2015, J CLIN ONCOL, V33, P3082, DOI 10.1200/JCO.2014.59.1941; Gustavsson N, 2009, J PHYSIOL-LONDON, V587, P1169, DOI 10.1113/jphysiol.2008.168005; Jackman SL, 2016, NATURE, V529, P88, DOI 10.1038/nature16507; Kanda M, 2018, ANN SURG, V267, P495, DOI 10.1097/SLA.0000000000002096; Kanda M, 2016, INT J CANCER, V139, P2290, DOI 10.1002/ijc.30286; Kanda M, 2016, ANN SURG ONCOL, V23, P532, DOI 10.1245/s10434-016-5375-0; Kanda M, 2016, INT J ONCOL, V49, P1195, DOI 10.3892/ijo.2016.3584; Kanda M, 2016, ONCOTARGET, V7, P13667, DOI 10.18632/oncotarget.7269; Kanda M, 2016, INT J CANCER, V138, P721, DOI 10.1002/ijc.29803; Kanda M, 2015, EXPERT REV GASTROENT, V9, P1549, DOI 10.1586/17474124.2015.1094373; Kanda M, 2016, ANN SURG ONCOL, V23, P214, DOI 10.1245/s10434-015-4457-8; Kanda M, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0066-9; Kodera Y, 2014, GASTRIC CANCER, V17, P206, DOI 10.1007/s10120-013-0299-x; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Liu H, 2014, TRANSL NEURODEGENER, V3, DOI 10.1186/2047-9158-3-7; Liu XD, 2010, INT J MOL SCI, V11, P2267, DOI 10.3390/ijms11062267; McLean MIH, 2014, NAT REV GASTRO HEPAT, V11, P664, DOI 10.1038/nrgastro.2014.143; Miwa T, 2017, ANN SURG ONCOL, V24, P3771, DOI 10.1245/s10434-017-5882-7; Nie Hui, 2017, J Cell Signal, V2; Oki E, 2016, GASTRIC CANCER, V19, P968, DOI 10.1007/s10120-015-0530-z; Okines A, 2010, ANN ONCOL, V21, pv50, DOI 10.1093/annonc/mdq164; Poli G, 2013, ENDOCR-RELAT CANCER, V20, P537, DOI 10.1530/ERC-13-0150; Qi YM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132743; Razzak M, 2014, NAT REV CLIN ONCOL, V11, P689, DOI [10.1038/nrclinonc.2014.176, 10.1038/nrclinonc.2013.235, 10.1038/nrclinonc.2013.201]; Resende C, 2011, HELICOBACTER, V16, P38, DOI 10.1111/j.1523-5378.2011.00879.x; Samykutty A, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/287358; Sasako M, 2011, J CLIN ONCOL, V29, P4387, DOI 10.1200/JCO.2011.36.5908; Schrag D, 2014, J CLIN ONCOL, V32, P513, DOI 10.1200/JCO.2013.51.7904; Segovia M, 2010, P NATL ACAD SCI USA, V107, P19032, DOI 10.1073/pnas.1014070107; Shih AM, 2016, J CELL BIOCHEM, V117, P1446, DOI 10.1002/jcb.25436; Shimizu D, 2017, SCI REP-UK, V7, DOI 10.1038/srep42089; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Szasz AM, 2016, ONCOTARGET, V7, P49322, DOI 10.18632/oncotarget.10337; Van Cutsem E, 2016, LANCET, V388, P2654, DOI 10.1016/S0140-6736(16)30354-3; Wadhwa R, 2013, NAT REV CLIN ONCOL, V10, P643, DOI 10.1038/nrclinonc.2013.170; Wang YF, 2013, CURR CANCER DRUG TAR, V13, P963, DOI 10.2174/15680096113136660102; Weber JP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114033; Wolff DW, 2012, INT J CANCER, V130, P1521, DOI 10.1002/ijc.26138; Wu L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088913; Yang F, 2012, EMBO J, V31, P110, DOI 10.1038/emboj.2011.364	47	43	44	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2018	37	39					5355	5366		10.1038/s41388-018-0335-8	http://dx.doi.org/10.1038/s41388-018-0335-8			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV0NW	29858600				2022-12-17	WOS:000445759700008
J	Zhu, B; Tang, LM; Chen, SY; Yin, CQ; Peng, SG; Li, X; Liu, TZ; Liu, W; Han, CP; Stawski, L; Xu, ZX; Zhou, GB; Chen, X; Gao, XM; Goding, CR; Xu, N; Cui, RT; Cao, P				Zhu, Bo; Tang, Liming; Chen, Shuyang; Yin, Chengqian; Peng, Shiguang; Li, Xin; Liu, Tongzheng; Liu, Wei; Han, Changpeng; Stawski, Lukasz; Xu, Zhi-Xiang; Zhou, Guangbiao; Chen, Xiang; Gao, Xiumei; Goding, Colin R.; Xu, Nan; Cui, Rutao; Cao, Peng			Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy	ONCOGENE			English	Article							OXIDATIVE STRESS; MESSENGER-RNA; EXPRESSION; PTEN; STABILIZATION; PEMBROLIZUMAB; MODULATION; MECHANISMS; IPILIMUMAB; NIVOLUMAB	Programmed cell death ligand 1 (PD-L1) interacts with programmed cell death protein-1 (PD-1) as an immune checkpoint. Reactivating the immune response by inhibiting PD-L1 using therapeutic antibodies provides substantial clinical benefits in many, though not all, melanoma patients. However, transcriptional suppression of PD-L1 expression as an alternative therapeutic anti-melanoma strategy has not been exploited. Here we provide biochemical evidence demonstrating that ultraviolet radiation (UVR) induction of PD-L1 in skin is directly controlled by nuclear factor E2-related transcription factor 2 (NRF2). Depletion of NRF2 significantly induces tumor infiltration by both CD8(+) and CD4(+) T cells to suppress melanoma progression, and combining NRF2 inhibition with anti-PD-1 treatment enhanced its anti-tumor function. Our studies identify a critical and targetable PD-L1 upstream regulator and provide an alternative strategy to inhibit the PD-1/PD-L1 signaling in melanoma treatment.	[Zhu, Bo; Chen, Shuyang; Yin, Chengqian; Peng, Shiguang; Li, Xin; Liu, Tongzheng; Liu, Wei; Han, Changpeng; Cui, Rutao] Boston Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02118 USA; [Tang, Liming; Cao, Peng] Nanjing Univ Chinese Med, Affiliated Hosp Integrated Tradit Chinese & Weste, Nanjing 210028, Jiangsu, Peoples R China; [Tang, Liming] Nanjing Med Univ, Affiliated Changzhou Peoples Hosp 2, Changzhou, Jiangsu, Peoples R China; [Peng, Shiguang] Capital Med Univ, Beijing Chaoyang Hosp, Dept Dermatol, Beijing 100020, Peoples R China; [Liu, Wei; Gao, Xiumei] Tianjin Univ Tradit Chinese Med, Tianjin State Key Lab Modern Chinese Med, Tianjin 300193, Peoples R China; [Stawski, Lukasz] Boston Univ, Sch Med, Arthrit Ctr, Sect Rheumatol, Boston, MA 02118 USA; [Xu, Zhi-Xiang] Univ Alabama Birmingham, Sch Med, Dept Med, Div Hematol & Oncol, Birmingham, AL 35233 USA; [Zhou, Guangbiao] Chinese Acad Sci, Inst Zool, State Key Lab Membrane Biol, 1 Beichen West Rd, Beijing 100101, Peoples R China; [Chen, Xiang] Cent Suth Univ, Xiangya Hosp, Hunan Key Lab Skin Canc & Psoriasis, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China; [Chen, Xiang] Cent Suth Univ, Xiangya Hosp, Dept Dermatol, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China; [Goding, Colin R.] Univ Oxford, Ludwig Inst Canc Res, Oxford OX3 7DQ, England; [Xu, Nan] Tongji Univ, Shanghai East Hosp, Dermatol Dept, Shanghai 200120, Peoples R China; [Cao, Peng] Nanjing Med Univ, Collaborat Innovat Ctr Canc Med, Nanjing 211166, Jiangsu, Peoples R China	Boston University; Nanjing University of Chinese Medicine; Nanjing Medical University; Capital Medical University; Tianjin University of Traditional Chinese Medicine; Boston University; University of Alabama System; University of Alabama Birmingham; Chinese Academy of Sciences; Institute of Zoology, CAS; Central South University; Central South University; Ludwig Institute for Cancer Research; University of Oxford; Tongji University; Nanjing Medical University	Cui, RT (corresponding author), Boston Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02118 USA.; Cao, P (corresponding author), Nanjing Univ Chinese Med, Affiliated Hosp Integrated Tradit Chinese & Weste, Nanjing 210028, Jiangsu, Peoples R China.; Xu, N (corresponding author), Tongji Univ, Shanghai East Hosp, Dermatol Dept, Shanghai 200120, Peoples R China.; Cao, P (corresponding author), Nanjing Med Univ, Collaborat Innovat Ctr Canc Med, Nanjing 211166, Jiangsu, Peoples R China.	xnhrb@aliyun.com; rutaocui@bu.edu; pcao79@yahoo.com	Yin, Chengqian/AAK-2991-2020; Zhou, Guang-Biao/ABG-5795-2021; Zhou, Guangbiao/J-6575-2017; Liu, Wei/E-8826-2018	Zhou, Guangbiao/0000-0002-6327-2316; Yin, Chengqian/0000-0003-4247-6245; , Peng/0000-0002-2044-3074; Zhou, Guang-Biao/0000-0001-6778-7133; Li, Xin/0000-0003-2525-9679; Liu, Wei/0000-0003-1792-6048	National Institutes of Health [R01CA137098, R01CA193913, R01CA196896]; Melanoma Research Foundation Establish Investigator Award, Hong Kong; National Natural Science Foundation of China [81428025, 81630106, 31771619, 81673977]; Priority Academic Program Development of Jiangsu Higher Education Institutions (Integration of Chinese and Western Medicine) grant	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Melanoma Research Foundation Establish Investigator Award, Hong Kong; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development of Jiangsu Higher Education Institutions (Integration of Chinese and Western Medicine) grant	We thank Drs. Wenshu Wu and Rui He for carefully reading and suggestions. This work was supported by the National Institutes of Health (RC: R01CA137098, R01CA193913 and R01CA196896), Melanoma Research Foundation Establish Investigator Award (RC), Hong Kong, Macao Young Scientists of the National Natural Science Foundation of China (Grant No. 81428025 for RC) and National Natural Science Foundation of China (81630106), and the Priority Academic Program Development of Jiangsu Higher Education Institutions (Integration of Chinese and Western Medicine) grant (PC). National Natural Science Foundation of China (31771619) for HH. The National Natural Science Foundation of China (Grant No. 81673977 for 2016 for XM). RC is an American Cancer Society Research Scholar.	Beyer TA, 2007, CELL DEATH DIFFER, V14, P1250, DOI 10.1038/sj.cdd.4402133; Blattner C, 2000, MOL CELL BIOL, V20, P3616, DOI 10.1128/MCB.20.10.3616-3625.2000; Cao JX, 2013, MOL CELL, V51, P409, DOI 10.1016/j.molcel.2013.08.010; Chorley BN, 2012, NUCLEIC ACIDS RES, V40, P7416, DOI 10.1093/nar/gks409; Clydesdale GJ, 2001, IMMUNOL CELL BIOL, V79, P547, DOI 10.1046/j.1440-1711.2001.01047.x; Cortez MA, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv303; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Fourcade J, 2010, J EXP MED, V207, P2175, DOI 10.1084/jem.20100637; Garcia-Diaz A, 2017, CELL REP, V19, P1189, DOI 10.1016/j.celrep.2017.04.031; Gogas H, 2015, AM J THER, V22, P54, DOI 10.1097/MJT.0b013e31829e883d; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133; Hart PH, 2011, NAT REV IMMUNOL, V11, P584, DOI 10.1038/nri3045; Heckman CJ, 2013, JOVE-J VIS EXP, V75, P50175, DOI DOI 10.3791/5017523748556; Hintsala HR, 2016, ANTICANCER RES, V36, P1497; Hybertson BM, 2014, CLIN GENET, V86, P447, DOI 10.1111/cge.12474; Hybertson BM, 2011, MOL ASPECTS MED, V32, P234, DOI 10.1016/j.mam.2011.10.006; ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Kim JH, 2016, J ALLERGY CLIN IMMUN, V137, P1466, DOI 10.1016/j.jaci.2015.11.021; Kondo A, 2010, BLOOD, V116, P1124, DOI 10.1182/blood-2009-12-255125; Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Lastwika KJ, 2016, CANCER RES, V76, P227, DOI 10.1158/0008-5472.CAN-14-3362; Li J, 2004, PHYSIOL GENOMICS, V18, P261, DOI 10.1152/physiolgenomics.00209.2003; Menter A, 2010, J AM ACAD DERMATOL, V62, P114, DOI 10.1016/j.jaad.2009.08.026; Nguyen T, 2004, FREE RADICAL BIO MED, V37, P433, DOI 10.1016/j.freeradbiomed.2004.04.033; Nishimura H, 1996, INT IMMUNOL, V8, P773, DOI 10.1093/intimm/8.5.773; Noman MZ, 2014, J EXP MED, V211, P781, DOI 10.1084/jem.20131916; Ott PA, 2013, CLIN CANCER RES, V19, P5300, DOI 10.1158/1078-0432.CCR-13-0143; Parsa AT, 2007, NAT MED, V13, P84, DOI 10.1038/nm1517; Postow MA, 2015, J CLIN ONCOL, V33, P1974, DOI 10.1200/JCO.2014.59.4358; Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146; Ren DM, 2011, P NATL ACAD SCI USA, V108, P1433, DOI 10.1073/pnas.1014275108; Ribas A, 2016, JAMA-J AM MED ASSOC, V315, P1600, DOI 10.1001/jama.2016.4059; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Romero Diana, 2016, Nat Rev Clin Oncol, V13, P266, DOI 10.1038/nrclinonc.2016.52; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; Sato E, 2005, P NATL ACAD SCI USA, V102, P18538, DOI 10.1073/pnas.0509182102; Schadendorf D, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.3; Sidaway Peter, 2016, Nat Rev Clin Oncol, V13, P652, DOI [10.1038/nrclinonc.2016.158, 10.1038/nrclinonc.2016.156]; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tsao H, 2012, GENE DEV, V26, P1131, DOI 10.1101/gad.191999.112; Umansky V, 2014, J DTSCH DERMATOL GES, V12, P1021, DOI 10.1111/ddg.12411; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Westmark CJ, 2005, ONCOGENE, V24, P502, DOI 10.1038/sj.onc.1208224; Yoh K, 2001, KIDNEY INT, V60, P1343, DOI 10.1046/j.1523-1755.2001.00939.x; Zhu B, 2016, ONCOGENE, V35, P4212, DOI 10.1038/onc.2015.486	48	43	45	2	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 6	2018	37	36					4941	4954		10.1038/s41388-018-0314-0	http://dx.doi.org/10.1038/s41388-018-0314-0			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GS6QR	29786078	Green Submitted			2022-12-17	WOS:000443823600003
J	Li, ZH; Takenobu, H; Setyawati, AN; Akita, N; Haruta, M; Satoh, S; Shinno, Y; Chikaraishi, K; Mukae, K; Akter, J; Sugino, RP; Nakazawa, A; Nakagawara, A; Aburatani, H; Ohira, M; Kamijo, T				Li, Zhenghao; Takenobu, Hisanori; Setyawati, Amallia Nuggetsiana; Akita, Nobuhiro; Haruta, Masayuki; Satoh, Shunpei; Shinno, Yoshitaka; Chikaraishi, Koji; Mukae, Kyosuke; Akter, Jesmin; Sugino, Ryuichi P.; Nakazawa, Atsuko; Nakagawara, Akira; Aburatani, Hiroyuki; Ohira, Miki; Kamijo, Takehiko			EZH2 regulates neuroblastoma cell differentiation via NTRK1 promoter epigenetic modifications	ONCOGENE			English	Article							NERVE GROWTH-FACTOR; ISLAND METHYLATOR PHENOTYPE; HIGH-RISK NEUROBLASTOMA; PROGNOSTIC-SIGNIFICANCE; FAVORABLE PROGNOSIS; TRK PROTOONCOGENE; H3K27 METHYLATION; PROSTATE-CANCER; FACTOR RECEPTOR; TARGET GENE	The polycomb repressor complex 2 molecule EZH2 is now known to play a role in essential cellular processes, namely, cell fate decisions, cell cycle regulation, senescence, cell differentiation, and cancer development/progression. EZH2 inhibitors have recently been developed; however, their effectiveness and underlying molecular mechanisms in many malignancies have not yet been elucidated in detail. Although the functional role of EZH2 in tumorigenesis in neuroblastoma (NB) has been investigated, mutations of EZH2 have not been reported. A Kaplan-Meier analysis on the event free survival and overall survival of NB patients indicated that the high expression of EZH2 correlated with an unfavorable prognosis. In order to elucidate the functional roles of EZH2 in NB tumorigenesis and its aggressiveness, we knocked down EZH2 in NB cell lines using lentivirus systems. The knockdown of EZH2 significantly induced NB cell differentiation, e.g., neurite extension, and the neuronal differentiation markers, NF68 and GAP43. EZH2 inhibitors also induced NB cell differentiation. We performed a comprehensive transcriptome analysis using Human Gene Expression Microarrays and found that NTRK1 (TrkA) is one of the EZH2-related suppression targets. The depletion of NTRK1 canceled EZH2 knockdown-induced NB cell differentiation. Our integrative methylome, transcriptome, and chromatin immunoprecipitation assays using NB cell lines and clinical samples clarified that the NTRK1 P1 and P2 promoter regions were regulated differently by DNA methylation and EZH2-related histone modifications. The NTRK1 transcript variants 1/2, which were regulated by EZH2-related H3K27me3 modifications at the P1 promoter region, were strongly expressed in favorable, but not unfavorable NB. The depletion and inhibition of EZH2 successfully induced NTRK1 transcripts and functional proteins. Collectively, these results indicate that EZH2 plays important roles in preventing the differentiation of NB cells and also that EZH2-related NTRK1 transcriptional regulation may be the key pathway for NB cell differentiation.	[Li, Zhenghao; Takenobu, Hisanori; Haruta, Masayuki; Satoh, Shunpei; Shinno, Yoshitaka; Chikaraishi, Koji; Mukae, Kyosuke; Akter, Jesmin; Sugino, Ryuichi P.; Ohira, Miki; Kamijo, Takehiko] Saitama Canc Ctr, Res Inst Clin Oncol, Ina, Saitama, Japan; [Li, Zhenghao; Kamijo, Takehiko] Saitama Univ, Lab Tumor Mol Biol, Dept Grad Sch Sci & Engn, Saitama, Saitama, Japan; [Setyawati, Amallia Nuggetsiana; Akita, Nobuhiro] Chiba Canc Ctr, Res Inst, Chiba, Chiba, Japan; [Setyawati, Amallia Nuggetsiana] Diponegoro Univ, Dept Biochem, Fac Med, Kota Semarang, Jawa Tengah, Indonesia; [Akita, Nobuhiro] Nagoya Med Ctr, Dept Pediat, Nagoya, Aichi, Japan; [Chikaraishi, Koji] Chiba Univ, Grad Sch Med, Dept Pediat, Chiba, Japan; [Nakazawa, Atsuko] Saitama Childrens Med Ctr, Dept Clin Res, Saitama, Saitama, Japan; [Nakagawara, Akira] Saga Med Ctr KOSEIKAN, Life Sci Res Inst, Saga, Japan; [Aburatani, Hiroyuki] Univ Tokyo, Div Genome Sci, Res Ctr Adv Sci & Technol, Tokyo, Japan	Saitama University; Chiba Cancer Center; Diponegoro University; Nagoya Medical Center; Chiba University; Saitama Children's Medical Center; University of Tokyo	Kamijo, T (corresponding author), Saitama Canc Ctr, Res Inst Clin Oncol, Ina, Saitama, Japan.; Kamijo, T (corresponding author), Saitama Univ, Lab Tumor Mol Biol, Dept Grad Sch Sci & Engn, Saitama, Saitama, Japan.	tkamijo@cancer-c.pref.saitama.jp	Mukae, Kyosuke/K-5181-2019	Mukae, Kyosuke/0000-0001-6411-2990	Practical Research for Innovative Cancer Control [16ck0106011j0003, 17ck0106332h0001]; Tailor-made Medical Treatment Program from the Japan Agency for Medical Research and Development, AMED [15km0305013h0101]; JSPS KAKENHI [17K19623]; Grants-in-Aid for Scientific Research [16K10051, 17K10131] Funding Source: KAKEN	Practical Research for Innovative Cancer Control; Tailor-made Medical Treatment Program from the Japan Agency for Medical Research and Development, AMED(Japan Agency for Medical Research and Development (AMED)); JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Ms. K Sakurai and Ms. N Kawanabe for their technical assistance and Mr. Daniel Mrozek (Medical English Service, Kyoto) for his English editorial assistance. This work was supported in part by Practical Research for Innovative Cancer Control (No. 16ck0106011j0003; No. 17ck0106332h0001) and the Tailor-made Medical Treatment Program (No. 15km0305013h0101) from the Japan Agency for Medical Research and Development, AMED, and JSPS KAKENHI Grant-in-Aid for Challenging Exploratory Research (17K19623).	Abe M, 2005, CANCER RES, V65, P828; Abe M, 2007, CANCER LETT, V247, P253, DOI 10.1016/j.canlet.2006.05.001; Atsuta T, 2001, HYBRIDOMA, V20, P43, DOI 10.1089/027245701300060427; Bate-Eya LT, 2017, EUR J CANCER, V75, P63, DOI 10.1016/j.ejca.2016.12.019; Chang BB, 1998, J BIOL CHEM, V273, P39, DOI 10.1074/jbc.273.1.39; Chase A, 2011, CLIN CANCER RES, V17, P2613, DOI 10.1158/1078-0432.CCR-10-2156; Dardenne E, 2016, CANCER CELL, V30, P563, DOI 10.1016/j.ccell.2016.09.005; Frumm SM, 2013, CHEM BIOL, V20, P713, DOI 10.1016/j.chembiol.2013.03.020; Fujimura Y, 2006, DEVELOPMENT, V133, P2371, DOI 10.1242/dev.02405; Haruta M, 2014, CANCER LETT, V348, P167, DOI 10.1016/j.canlet.2014.03.022; He AB, 2012, GENE DEV, V26, P37, DOI 10.1101/gad.173930.111; Henrich KO, 2016, CANCER RES, V76, P5523, DOI 10.1158/0008-5472.CAN-15-2507; Huang R, 2011, FASEB J, V25, P4138, DOI 10.1096/fj.11-185033; Indo Y, 1997, JPN J HUM GENET, V42, P343, DOI 10.1007/BF02766957; Iraci N, 2011, CANCER RES, V71, P404, DOI 10.1158/0008-5472.CAN-10-2627; Kamijo T, 2012, INT J CLIN ONCOL, V17, P190, DOI 10.1007/s10147-012-0415-7; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; Kim E, 2013, CANCER CELL, V23, P839, DOI 10.1016/j.ccr.2013.04.008; Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036; Knutson SK, 2014, MOL CANCER THER, V13, P842, DOI 10.1158/1535-7163.MCT-13-0773; Knutson SK, 2012, NAT CHEM BIOL, V8, P890, DOI [10.1038/NCHEMBIO.1084, 10.1038/nchembio.1084]; KOGNER P, 1993, CANCER RES, V53, P2044; Kurata K, 2008, ONCOGENE, V27, P741, DOI 10.1038/sj.onc.1210672; Kutmon M, 2016, NUCLEIC ACIDS RES, V44, pD488, DOI 10.1093/nar/gkv1024; Lau DT, 2012, CLIN CANCER RES, V18, P5690, DOI 10.1158/1078-0432.CCR-12-0294; Lee ST, 2011, MOL CELL, V43, P798, DOI 10.1016/j.molcel.2011.08.011; Martinez-Garcia E, 2010, NAT GENET, V42, P100, DOI 10.1038/ng0210-100; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Niizuma H, 2006, ONCOGENE, V25, P5046, DOI 10.1038/sj.onc.1209515; Ochiai H, 2010, ONCOGENE, V29, P2681, DOI 10.1038/onc.2010.22; Ohira M, 2005, CANCER CELL, V7, P337, DOI 10.1016/j.ccr.2005.03.019; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Peifer M, 2015, NATURE, V526, P700, DOI 10.1038/nature14980; Pugh TJ, 2013, NAT GENET, V45, P279, DOI 10.1038/ng.2529; Satoh S, 2016, SCI REP-UK, V6, DOI 10.1038/srep32682; Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002; Scaruffi P, 1999, INT J ONCOL, V14, P935; Schramm A, 2015, NAT GENET, V47, P872, DOI 10.1038/ng.3349; Sugawara W, 2007, PEDIATR BLOOD CANCER, V49, P240, DOI 10.1002/pbc.21031; Tacconelli A, 2004, CANCER CELL, V6, P347, DOI 10.1016/j.ccr.2004.09.011; Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; de Souza DRV, 2011, PEDIATR BLOOD CANCER, V56, P749, DOI 10.1002/pbc.22823; Vermeulen J, 2009, LANCET ONCOL, V10, P663, DOI 10.1016/S1470-2045(09)70154-8; Wang CX, 2012, CANCER RES, V72, P315, DOI 10.1158/0008-5472.CAN-11-0961; Westermann F, 2002, CANCER LETT, V184, P127, DOI 10.1016/S0304-3835(02)00199-4; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604	49	43	44	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	20					2714	2727		10.1038/s41388-018-0133-3	http://dx.doi.org/10.1038/s41388-018-0133-3			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GG2TH	29507419	Green Published, hybrid			2022-12-17	WOS:000432545100008
J	Martinez-Ordonez, A; Seoane, S; Cabezas, P; Eiro, N; Sendon-Lago, J; Macia, M; Garcia-Caballero, T; Gonzalez, LO; Sanchez, L; Vizoso, F; Perez-Fernandez, R				Martinez-Ordonez, Anxo; Seoane, Samuel; Cabezas, Pablo; Eiro, Noemi; Sendon-Lago, Juan; Macia, Manuel; Garcia-Caballero, Tomas; Gonzalez, Luis O.; Sanchez, Laura; Vizoso, Francisco; Perez-Fernandez, Roman			Breast cancer metastasis to liver and lung is facilitated by Pit-1-CXCL12-CXCR4 axis	ONCOGENE			English	Article							CHEMOKINE RECEPTOR CXCR4; PREDICTS POOR-PROGNOSIS; TRANSCRIPTION FACTOR; TUMOR-GROWTH; CXCR4/CXCL12 AXIS; CELL-MIGRATION; EXPRESSION; PIT-1; CXCL12/CXCR4; MICROENVIRONMENT	Development of human tumors is driven by accumulation of alterations in tumor suppressor genes and oncogenes in cells. The POU1F1 transcription factor (also known Pit-1) is expressed in the mammary gland and its overexpression induces profound phenotypic changes in proteins involved in breast cancer progression. Patients with breast cancer and elevated expression of Pit-1 show a positive correlation with the occurrence of distant metastasis and poor overall survival. However, some mediators of Pit-1 actions are still unknown. Here, we show that CXCR4 chemokine receptor and its ligand CXCL12 play a critical role in the pro-tumoral process induced by Pit-1. We found that Pit-1 increases mRNA and protein in both CXCR4 and CXCL12. Knock-down of CXCR4 reduces tumor growth and spread of Pit-1 overexpressing cells in a zebrafish xenograft model. Furthermore, we described for the first time pro-angiogenic effects of Pit-1 through the CXCL12-CXCR4 axis, and that extravasation of Pit-1 overexpressing breast cancer cells is strongly reduced in CXCL12-deprived target tissues. Finally, in breast cancer patients, expression of Pit-1 in primary tumors was found to be positively correlated with CXCR4 and CXCL12, with specific metastasis in liver and lung, and with clinical outcome. Our results suggest that Pit-1-CXCL12-CXCR4 axis could be involved in chemotaxis guidance during the metastatic process, and may represent prognostic and/or therapeutic targets in breast tumors.	[Martinez-Ordonez, Anxo; Seoane, Samuel; Sendon-Lago, Juan; Perez-Fernandez, Roman] Univ Santiago de Compostela, Ctr Res Mol Med & Chron Dis CIMUS, Dept Physiol, Santiago De Compostela, Spain; [Cabezas, Pablo; Sanchez, Laura] Univ Santiago de Compostela, Dept Genet, Campus Lugo, Lugo, Spain; [Eiro, Noemi; Gonzalez, Luis O.; Vizoso, Francisco] Hosp Fdn Jove, Res Unit, Gijon, Spain; [Macia, Manuel] Univ Santiago de Compostela, Dept Obstet & Gynecol, Santiago De Compostela, Spain; [Garcia-Caballero, Tomas] Univ Santiago de Compostela, Dept Morphol Sci, Santiago De Compostela, Spain	Universidade de Santiago de Compostela; Universidade de Santiago de Compostela; Universidade de Santiago de Compostela; Universidade de Santiago de Compostela	Perez-Fernandez, R (corresponding author), Univ Santiago de Compostela, Ctr Res Mol Med & Chron Dis CIMUS, Dept Physiol, Santiago De Compostela, Spain.	roman.perez.fernandez@usc.es	Sánchez, Laura/L-2411-2014; Perez-Fernandez, Roman/L-6342-2014; Sainz, Pablo Cabezas/AAB-5798-2019; Gómez, ACUIGEN/ABD-5337-2020; Lago, Juan José Sendón/L-1227-2014; Eiro, Noemi/C-9510-2018; Seoane Ruzo, Samuel/H-6299-2015	Sánchez, Laura/0000-0001-7927-5303; Perez-Fernandez, Roman/0000-0002-5894-0615; Lago, Juan José Sendón/0000-0001-8360-0033; Eiro, Noemi/0000-0001-5840-4807; Cabezas Sainz, Pablo/0000-0002-7158-4459; Garcia-Caballero, Tomas/0000-0002-7938-1437; Seoane Ruzo, Samuel/0000-0002-9178-0887	Ministerio de Economia y Competividad (MINECO/FEDER) [SAF2015-69221-R]; Conselleria de Cultura, Educacion e Ordenacion Universitaria [GPC2014/001]; Ministerio de Educacion [FPU14/00548]; BioBank Complejo Hospitalario Universitario de Santiago (CHUS) [PT17/0015/0002]	Ministerio de Economia y Competividad (MINECO/FEDER); Conselleria de Cultura, Educacion e Ordenacion Universitaria; Ministerio de Educacion; BioBank Complejo Hospitalario Universitario de Santiago (CHUS)	This study was supported by Ministerio de Economia y Competividad (SAF2015-69221-R, MINECO/FEDER), and Conselleria de Cultura, Educacion e Ordenacion Universitaria (GPC2014/001) to RP-F, and Ministerio de Educacion, FPU14/00548 to AM-O. We want to particularly acknowledge the patients and the BioBank Complejo Hospitalario Universitario de Santiago (CHUS) (PT17/0015/0002), integrated in the Spanish National Biobanks Network for its collaboration, to P. Penas for providing biological samples, and to M. Fraile for help us with histological analyses.	Bachelder RE, 2002, CANCER RES, V62, P7203; Ben-Batalla I, 2010, J CLIN INVEST, V120, P4289, DOI 10.1172/JCI42015; Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood-2005-08-3182; Chen HW, 2013, CURR MOL MED, V13, P410; Deshane J, 2007, J EXP MED, V204, P605, DOI 10.1084/jem.20061609; DeVries ME, 2006, J IMMUNOL, V176, P401, DOI 10.4049/jimmunol.176.1.401; Doitsidou M, 2002, CELL, V111, P647, DOI 10.1016/S0092-8674(02)01135-2; Domanska UM, 2013, EUR J CANCER, V49, P219, DOI 10.1016/j.ejca.2012.05.005; Eiro N, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.992222; Gao ZC, 2016, MED SCI MONITOR, V22, P4121, DOI 10.12659/MSM.896107; Gil M, 2013, P NATL ACAD SCI USA, V110, pE1291, DOI 10.1073/pnas.1220580110; Gil-Puig C, 2005, EUR J ENDOCRINOL, V153, P335, DOI 10.1530/eje.1.01962; Gil-Puig C, 2002, J ENDOCRINOL, V173, P161, DOI 10.1677/joe.0.1730161; Guo F, 2016, ONCOGENE, V35, P816, DOI 10.1038/onc.2015.139; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hassan S, 2011, INT J CANCER, V129, P225, DOI 10.1002/ijc.25665; Huang EH, 2009, J SURG RES, V155, P231, DOI 10.1016/j.jss.2008.06.044; Kim J, 2006, ANN SURG, V244, P113, DOI 10.1097/01.sla.0000217690.65909.9c; Kryczek I, 2005, CANCER RES, V65, P465; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lazennec G, 2010, TRENDS MOL MED, V16, P133, DOI 10.1016/j.molmed.2010.01.003; LEFEVRE C, 1987, EMBO J, V6, P971, DOI 10.1002/j.1460-2075.1987.tb04847.x; Lefort S, 2017, ONCOGENE, V36, P1211, DOI 10.1038/onc.2016.284; Liang Z, 2007, BIOCHEM BIOPH RES CO, V359, P716, DOI 10.1016/j.bbrc.2007.05.182; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Nica G, 2004, MOL ENDOCRINOL, V18, P1196, DOI 10.1210/me.2003-0377; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Palevitch O, 2010, GEN COMP ENDOCR, V165, P262, DOI 10.1016/j.ygcen.2009.07.001; Peixoto P, 2008, NUCLEIC ACIDS RES, V36, P3341, DOI 10.1093/nar/gkn208; Salvucci O, 2002, BLOOD, V99, P2703, DOI 10.1182/blood.V99.8.2703; Scala S, 2015, CLIN CANCER RES, V21, P4278, DOI 10.1158/1078-0432.CCR-14-0914; Sendon-Lago J, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0505-8; Seoane S, 2006, MOL ENDOCRINOL, V20, P735, DOI 10.1210/me.2005-0253; Seoane S, 2015, ONCOTARGET, V6, P14456, DOI 10.18632/oncotarget.3894; Smith MCP, 2004, CANCER RES, V64, P8604, DOI 10.1158/0008-5472.CAN-04-1844; Tiveron MC, 2008, CURR OPIN NEUROBIOL, V18, P237, DOI 10.1016/j.conb.2008.06.004; Tulotta C, 2016, DIS MODEL MECH, V9, P141, DOI 10.1242/dmm.023275; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Xu C, 2015, DRUG DES DEV THER, V9, P4953, DOI 10.2147/DDDT.S84932; Zlotnik A, 2011, NAT REV IMMUNOL, V11, P597, DOI 10.1038/nri3049; Zudaire E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027385	43	43	45	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	11					1430	1444		10.1038/s41388-017-0036-8	http://dx.doi.org/10.1038/s41388-017-0036-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ3AZ	29321662				2022-12-17	WOS:000427459500003
J	Klymenko, Y; Kim, O; Loughran, E; Yang, J; Lombard, R; Alber, M; Stack, MS				Klymenko, Y.; Kim, O.; Loughran, E.; Yang, J.; Lombard, R.; Alber, M.; Stack, M. S.			Cadherin composition and multicellular aggregate invasion in organotypic models of epithelial ovarian cancer intraperitoneal metastasis	ONCOGENE			English	Article							COLLECTIVE CELL-MIGRATION; TYPE-1 MATRIX-METALLOPROTEINASE; N-CADHERIN; CARCINOMA-CELLS; EXTRACELLULAR-MATRIX; MONOCLONAL-ANTIBODY; SURFACE EPITHELIUM; MALIGNANT-MELANOMA; MESSENGER-RNA; TUMOR-GROWTH	During epithelial ovarian cancer (EOC) progression, intraperitoneally disseminating tumor cells and multicellular aggregates (MCAs) present in ascites fluid adhere to the peritoneum and induce retraction of the peritoneal mesothelial monolayer prior to invasion of the collagen-rich submesothelial matrix and proliferation into macro-metastases. Clinical studies have shown heterogeneity among EOC metastatic units with respect to cadherin expression profiles and invasive behavior; however, the impact of distinct cadherin profiles on peritoneal anchoring of metastatic lesions remains poorly understood. In the current study, we demonstrate that metastasis-associated behaviors of ovarian cancer cells and MCAs are influenced by cellular cadherin composition. Our results show that mesenchymal N-cadherin-expressing (Ncad+) cells and MCAs invade much more efficiently than E-cadherin-expressing (Ecad+) cells. Ncad+ MCAs exhibit rapid lateral dispersal prior to penetration of three-dimensional collagen matrices. When seeded as individual cells, lateral migration and cell-cell junction formation precede matrix invasion. Neutralizing the Ncad extracellular domain with the monoclonal antibody GC-4 suppresses lateral dispersal and cell penetration of collagen gels. In contrast, use of a broad-spectrum matrix metalloproteinase (MMP) inhibitor (GM6001) to block endogenous membrane type 1 matrix metalloproteinase (MT1-MMP) activity does not fully inhibit cell invasion. Using intact tissue explants, Ncad+ MCAs were also shown to efficiently rupture peritoneal mesothelial cells, exposing the submesothelial collagen matrix. Acquisition of Ncad by Ecad+ cells increased mesothelial clearance activity but was not sufficient to induce matrix invasion. Furthermore, co-culture of Ncad+ with Ecad+ cells did not promote a 'leader-follower' mode of collective cell invasion, demonstrating that matrix remodeling and creation of invasive micro-tracks are not sufficient for cell penetration of collagen matrices in the absence of Ncad. Collectively, our data emphasize the role of Ncad in intraperitoneal seeding of EOC and provide the rationale for future studies targeting Ncad in preclinical models of EOC metastasis.	[Klymenko, Y.] Univ Notre Dame, Dept Biol Sci, Notre Dame, IN USA; [Klymenko, Y.; Kim, O.; Loughran, E.; Yang, J.; Lombard, R.; Alber, M.; Stack, M. S.] Univ Notre Dame, Harper Canc Res Inst, South Bend, IN USA; [Kim, O.; Alber, M.] Univ Notre Dame, Dept Appl & Computat Math & Stat, 153 Hurley Hall, Notre Dame, IN 46556 USA; [Kim, O.; Alber, M.] Univ Calif Riverside, Dept Math, Riverside, CA USA; [Loughran, E.; Yang, J.; Stack, M. S.] Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN USA	University of Notre Dame; University of Notre Dame; University of Notre Dame; University of California System; University of California Riverside; University of Notre Dame	Alber, M (corresponding author), Univ Notre Dame, Dept Appl & Computat Math & Stat, 153 Hurley Hall, Notre Dame, IN 46556 USA.; Stack, MS (corresponding author), Univ Notre Dame, Dept Chem & Biochem, Harper Canc Res Inst, A200 Harper Hall,1234 Notre Dame Ave, South Bend, IN 46617 USA.	malber@nd.edu; sstack@nd.edu	Alber, Mark/AAR-1280-2020; Loughran, Elizabeth/D-6511-2015	/0000-0001-7324-8427; Loughran, Elizabeth/0000-0002-7940-3157	National Institutes of Health/National Cancer Institute [RO1CA109545, RO1CA086984]; Leo and Anne Albert Charitable Trust; Research Like a Champion grant; Walther Cancer Foundation Seeding Research in Cancer grant; NSF [DGE1313583]; University of Notre Dame Integrated Imaging Facility;  [U01-HL116330]; NATIONAL CANCER INSTITUTE [R01CA086984, R01CA109545] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL116330] Funding Source: NIH RePORTER	National Institutes of Health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Leo and Anne Albert Charitable Trust; Research Like a Champion grant; Walther Cancer Foundation Seeding Research in Cancer grant; NSF(National Science Foundation (NSF)); University of Notre Dame Integrated Imaging Facility; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported in part by Research Grants RO1CA109545 and RO1CA086984 (both to MSS) from the National Institutes of Health/National Cancer Institute, the Leo and Anne Albert Charitable Trust (to MSS); the Research Like a Champion grant (to YK and RL); the Walther Cancer Foundation Seeding Research in Cancer grant (to OK); NSF DGE1313583 (to EL); U01-HL116330 (to OK and MA) and University of Notre Dame Integrated Imaging Facility. We thank Dr Charles Tessier, Indiana University School of Medicine-South Bend for assistance with second-harmonic-generation imaging microscopy.	ACKERMAN AB, 1984, AM J DERMATOPATH, V6, P63; Afzal S, 1998, HUM PATHOL, V29, P155, DOI 10.1016/S0046-8177(98)90226-X; Ahmed N, 2007, J CELL PHYSIOL, V213, P581, DOI 10.1002/jcp.21240; Aragona M, 2013, CELL, V154, P1047, DOI 10.1016/j.cell.2013.07.042; Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; Augustine CK, 2008, CANCER RES, V68, P3777, DOI 10.1158/0008-5472.CAN-07-5949; Barbolina MV, 2007, J BIOL CHEM, V282, P4924, DOI 10.1074/jbc.M608428200; BELL CD, 1986, J SURG ONCOL, V31, P39, DOI 10.1002/jso.2930310109; Blaschuk OW, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0039; Blaschuk OW, 2009, EUR J PHARMACOL, V625, P195, DOI 10.1016/j.ejphar.2009.05.033; Bruney L, 2014, BIOL CHEM, V395, P1221, DOI 10.1515/hsz-2014-0155; Burleson KM, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-6; Burleson KM, 2004, GYNECOL ONCOL, V93, P170, DOI 10.1016/j.ygyno.2003.12.034; Carey SP, 2013, CLIN EXP METASTAS, V30, P615, DOI 10.1007/s10585-013-9565-x; Coffman LG, 2016, TRANSL RES, V175, P92, DOI 10.1016/j.trsl.2016.03.016; Cosgrove BD, 2016, NAT MATER, V15, P1297, DOI [10.1038/NMAT4725, 10.1038/nmat4725]; Davidowitz RA, 2012, JOVE-J VIS EXP, DOI 10.3791/3888; Davidowitz RA, 2014, J CLIN INVEST, V124, P2611, DOI 10.1172/JCI69815; Davidson B, 2002, MOL CELL ENDOCRINOL, V187, P39, DOI 10.1016/S0303-7207(01)00709-2; Davidson B, 2001, AM J CLIN PATHOL, V115, P517; DAY CL, 1981, ANN SURG, V194, P108, DOI 10.1097/00000658-198107000-00019; Desai RA, 2009, J CELL SCI, V122, P905, DOI 10.1242/jcs.028183; Devemy E, 2008, PEPTIDES, V29, P1853, DOI 10.1016/j.peptides.2008.06.025; Doherty P, 1996, MOL CELL NEUROSCI, V8, P99, DOI 10.1006/mcne.1996.0049; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Ellerbroek SM, 2001, J BIOL CHEM, V276, P24833, DOI 10.1074/jbc.M005631200; Fraley SI, 2015, SCI REP-UK, V5, DOI 10.1038/srep14580; Friedl P, 2004, CURR OPIN CELL BIOL, V16, P14, DOI 10.1016/j.ceb.2003.11.001; Friedl P, 2004, INT J DEV BIOL, V48, P441, DOI 10.1387/ijdb.041821pf; Friedl P, 2008, CANCER RES, V68, P7247, DOI 10.1158/0008-5472.CAN-08-0784; Friedl P, 2012, NAT CELL BIOL, V14, P777, DOI 10.1038/ncb2548; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; Friedl P, 2009, NAT REV MOL CELL BIO, V10, P445, DOI 10.1038/nrm2720; Gaggioli C, 2007, NAT CELL BIOL, V9, P1392, DOI 10.1038/ncb1658; Hazan RB, 1996, CELL ADHES COMMUN, V4, P399, DOI 10.3109/15419069709004457; Hegerfeldt Y, 2002, CANCER RES, V62, P2125; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Howlader N, 2011, SEER CANC STAT REV 1, P19; Hudson LG, 2008, CLIN EXP METASTAS, V25, P643, DOI 10.1007/s10585-008-9171-5; Ilina O, 2009, J CELL SCI, V122, P3203, DOI 10.1242/jcs.036525; Iwanicki MP, 2011, CANCER DISCOV, V1, P144, DOI 10.1158/2159-8274.CD-11-0010; King SM, 2011, ENDOCR-RELAT CANCER, V18, P627, DOI 10.1530/ERC-11-0107; Klymenko Y, 2017, NEOPLASIA, V19, P549, DOI 10.1016/j.neo.2017.04.002; Labernadie A, 2017, NAT CELL BIOL, V19, P224, DOI 10.1038/ncb3478; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Lautscham LA, 2015, BIOPHYS J, V109, P900, DOI 10.1016/j.bpj.2015.07.025; Lengyel E, 2014, ONCOGENE, V33, P3619, DOI 10.1038/onc.2013.321; Levanon K, 2008, J CLIN ONCOL, V26, P5284, DOI 10.1200/JCO.2008.18.1107; Liu YY, 2015, CANCER RES, V75, P5046, DOI 10.1158/0008-5472.CAN-15-0706; Marcus CS, 2014, J CANCER, V5, P25, DOI 10.7150/jca.7810; Mariotti A, 2007, EXPERT OPIN INV DRUG, V16, P451, DOI 10.1517/13543784.16.4.451; Mitra AK, 2015, GYNECOL ONCOL, V138, P372, DOI 10.1016/j.ygyno.2015.05.040; Moser TL, 1996, INT J CANCER, V67, P695, DOI 10.1002/(SICI)1097-0215(19960904)67:5<695::AID-IJC18>3.3.CO;2-2; Moss NM, 2009, CANCER RES, V69, P7121, DOI 10.1158/0008-5472.CAN-08-4151; NIEDBALA MJ, 1985, EXP CELL RES, V160, P499, DOI 10.1016/0014-4827(85)90197-1; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Page DL, 1987, DIAGNOSTIC HISTOPATH; Pasapera AM, 2015, CURR BIOL, V25, P175, DOI 10.1016/j.cub.2014.11.043; Poncelet C, 2010, FERTIL STERIL, V94, P2909, DOI 10.1016/j.fertnstert.2010.04.055; Pradeep S, 2014, CANCER CELL, V26, P77, DOI 10.1016/j.ccr.2014.05.002; Roussos ET, 2011, J CELL SCI, V124, P2120, DOI 10.1242/jcs.086231; Sadler NM, 2013, AM J BLOOD RES, V3, P271; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Shaw TJ, 2004, MOL THER, V10, P1032, DOI 10.1016/j.ymthe.2004.08.013; Shih WT, 2012, J CELL SCI, V125, P3661, DOI 10.1242/jcs.103861; Shintani Y, 2008, INT J CANCER, V122, P71, DOI 10.1002/ijc.23027; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Sodek KL, 2007, BRIT J CANCER, V97, P358, DOI 10.1038/sj.bjc.6603863; Stewart DJ, 2006, J CLIN ONCOL, V24, p124S; Takai N, 2005, CANCER-AM CANCER SOC, V104, P2701, DOI 10.1002/cncr.21533; Takeda H, 1999, NAT STRUCT BIOL, V6, P310, DOI 10.1038/7542; Tanaka H, 2010, NAT MED, V16, P1414, DOI 10.1038/nm.2236; Utton MA, 2001, J NEUROCHEM, V76, P1421, DOI 10.1046/j.1471-4159.2001.00140.x; Wolf K, 2007, NAT CELL BIOL, V9, P893, DOI 10.1038/ncb1616; Wolf K, 2006, BRIT J DERMATOL, V154, P11, DOI 10.1111/j.1365-2133.2006.07231.x	75	43	44	0	29	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2017	36	42					5840	5851		10.1038/onc.2017.171	http://dx.doi.org/10.1038/onc.2017.171			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK2DN	28628116	Green Accepted, Green Submitted			2022-12-17	WOS:000413292900006
J	Sechler, M; Parrish, JK; Birks, DK; Jedlicka, P				Sechler, M.; Parrish, J. K.; Birks, D. K.; Jedlicka, P.			The histone demethylase KDM3A, and its downstream target MCAM, promote Ewing Sarcoma cell migration and metastasis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR-GROWTH; TRANSCRIPTIONAL REPRESSION; CANCER METASTASIS; HUMAN-MELANOMA; IN-VITRO; EXPRESSION; CD146; GENE; CARCINOMA	Ewing Sarcoma is the second most common solid pediatric malignant neoplasm of bone and soft tissue. Driven by EWS/Ets, or rarely variant, oncogenic fusions, Ewing Sarcoma is a biologically and clinically aggressive disease with a high propensity for metastasis. However, the mechanisms underpinning Ewing Sarcoma metastasis are currently not well understood. In the present study, we identify and characterize a novel metastasis-promotional pathway in Ewing Sarcoma, involving the histone demethylase KDM3A, previously identified by our laboratory as a new cancer-promoting gene in this disease. Using global gene expression profiling, we show that KDM3A positively regulates genes and pathways implicated in cell migration and metastasis, and demonstrate, using functional assays, that KDM3A promotes migration in vitro and experimental, post-intravasation, metastasis in vivo. We further identify the melanoma cell adhesion molecule (MCAM) as a novel KDM3A target gene in Ewing Sarcoma, and an important effector of KDM3A pro-metastatic action. Specifically, we demonstrate that MCAM depletion, like KDM3A depletion, inhibits cell migration in vitro and experimental metastasis in vivo, and that MCAM partially rescues impaired migration due to KDM3A knock-down. Mechanistically, we show that KDM3A regulates MCAM expression both through a direct mechanism, involving modulation of H3K9 methylation at the MCAM promoter, and an indirect mechanism, via the Ets1 transcription factor. Finally, we identify an association between high MCAM levels in patient tumors and poor survival, in two different Ewing Sarcoma clinical cohorts. Taken together, our studies uncover a new metastasis-promoting pathway in Ewing Sarcoma, with therapeutically targetable components.	[Sechler, M.; Jedlicka, P.] Canc Biol Grad Training Program, Aurora, CO USA; [Sechler, M.; Parrish, J. K.; Birks, D. K.; Jedlicka, P.] Univ Colorado Denver, Anschutz Med Campus, Aurora, CO 80045 USA; [Parrish, J. K.; Jedlicka, P.] Univ Colorado Denver, Dept Pathol, Anschutz Med Campus,12800 E 19th Ave,MS 8104, Aurora, CO 80045 USA; [Birks, D. K.] Univ Colorado Denver, Dept Neurosurg, Anschutz Med Campus, Aurora, CO 80045 USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Jedlicka, P (corresponding author), Univ Colorado Denver, Dept Pathol, Anschutz Med Campus,12800 E 19th Ave,MS 8104, Aurora, CO 80045 USA.	paul.jedlicka@ucdenver.edu			Front Range Cancer Challenge; Children's Hospital Colorado Research Institute; University of Colorado School of Medicine Academic Enrichment Funds; Cancer League of Colorado;  [P30-CA046934];  [R01CA183874];  [F31-CA203053]; NATIONAL CANCER INSTITUTE [F31CA203053, P30CA046934, R01CA183874] Funding Source: NIH RePORTER	Front Range Cancer Challenge; Children's Hospital Colorado Research Institute; University of Colorado School of Medicine Academic Enrichment Funds; Cancer League of Colorado; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We wish to thank Elizabeth Wellberg for assistance with gene expression profiling studies; members of the Tobias Neff and Kathrin Bernt laboratories for assistance with ChIP studies; Elizabeth Lawlor at the University of Michigan for the TC32 cell line, and tumor expression profiling and patient outcome data; and Steve Lessnick at Nationwide Children's Hospital for retroviral packaging constructs. We further wish to thank the University of Colorado Cancer Center Flow Cytometry, Functional Genomics, Tissue Culture, DNA Sequencing and Small Animal Imaging Core Facilities, supported by P30-CA046934. Funding support for this work was provided by the Front Range Cancer Challenge, Children's Hospital Colorado Research Institute, University of Colorado School of Medicine Academic Enrichment Funds, and R01CA183874 (PJ); the Cancer League of Colorado (PJ and MS); and F31-CA203053 (MS).	Pavon MA, 2015, ONCOTARGET, V6, P29016, DOI 10.18632/oncotarget.5032; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bardin N, 2009, ARTERIOSCL THROM VAS, V29, P746, DOI 10.1161/ATVBAHA.108.183251; Bennani-Baiti IM, 2012, HUM PATHOL, V43, P1300, DOI 10.1016/j.humpath.2011.10.010; Burchill SA, 2003, J CLIN PATHOL, V56, P96, DOI 10.1136/jcp.56.2.96; Chaturvedi A, 2014, MOL BIOL CELL, V25, P2695, DOI 10.1091/mbc.E14-01-0007; Chaturvedi Aashi, 2012, Genes Cancer, V3, P102, DOI 10.1177/1947601912457024; Cho HS, 2012, INT J CANCER, V131, pE179, DOI 10.1002/ijc.26501; Choy E, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-813; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Dittmer J, 2015, SEMIN CANCER BIOL, V35, P20, DOI 10.1016/j.semcancer.2015.09.010; Dittmer Jurgen, 2003, Mol Cancer, V2, P29, DOI 10.1186/1476-4598-2-29; Douglas D, 2008, CANCER RES, V68, P6507, DOI 10.1158/0008-5472.CAN-07-6152; Du C, 2016, FEBS LETT, V590, P408, DOI 10.1002/1873-3468.12069; Esiashvili N, 2008, J PEDIAT HEMATOL ONC, V30, P425, DOI 10.1097/MPH.0b013e31816e22f3; Fadul John, 2015, Genes Cancer, V6, P129; Feinberg AP, 2016, NAT REV GENET, V17, P284, DOI 10.1038/nrg.2016.13; Gao Y, 2015, ONCOTARGET, V6, P7828, DOI 10.18632/oncotarget.3488; Gaspar N, 2015, J CLIN ONCOL, V33, P3036, DOI 10.1200/JCO.2014.59.5256; Grohar PJ, 2013, PHARMACOL THERAPEUT, V137, P216, DOI 10.1016/j.pharmthera.2012.10.004; Habel N, 2015, ONCOGENE, V34, P3207, DOI 10.1038/onc.2014.232; Hansen AG, 2014, CANCER RES, V74, P1404, DOI 10.1158/0008-5472.CAN-13-1296; Heidenreich B, 2014, CURR OPIN GENET DEV, V24, P30, DOI 10.1016/j.gde.2013.11.005; Herr MJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067766; Hospital SJCsR, DIS INF; Hou CH, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-236; Hou ZY, 2008, MOL CELL BIOL, V28, P3198, DOI 10.1128/MCB.01435-07; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Imbert AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043752; Jia L, 2016, ONCOGENE, V35, P2040, DOI 10.1038/onc.2015.263; Jouve N, 2015, INT J CANCER, V137, P50, DOI 10.1002/ijc.29370; Jouve N, 2013, J BIOL CHEM, V288, P2571, DOI 10.1074/jbc.M112.418848; Kitamura T, 2015, J EXP MED, V212, P1043, DOI 10.1084/jem.20141836; Lawlor ER, 2012, CLIN CANCER RES, V18, P2768, DOI 10.1158/1078-0432.CCR-11-1921; Li L, 2016, MOL MED REP, V14, P521, DOI 10.3892/mmr.2016.5273; Li XC, 2014, CANCER CELL, V25, P575, DOI 10.1016/j.ccr.2014.03.020; Liang XH, 2014, CANCER SCI, V105, P660, DOI 10.1111/cas.12404; Lim SY, 2016, ONCOTARGET, V7, P28697, DOI 10.18632/oncotarget.7376; Lin Y, 2007, ANTICANCER RES, V27, P4219; Liu XS, 2015, MOL CANCER RES, V13, P1206, DOI 10.1158/1541-7786.MCR-15-0169; Mahajan K, 2014, J BIOL CHEM, V289, P28179, DOI 10.1074/jbc.M114.584425; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; McFarlane S, 2015, ONCOTARGET, V6, P11465, DOI 10.18632/oncotarget.3410; McKinsey EL, 2011, ONCOGENE, V30, P4910, DOI 10.1038/onc.2011.197; Miller NLG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037830; Moreno-Bueno G, 2011, EMBO MOL MED, V3, P528, DOI 10.1002/emmm.201100156; Ohguchi H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10258; Orentas RJ, 2012, FRONT ONCOL, V2, DOI [10.3389/fonc.2012.00194, 10.3389/fonc.2012.00003]; Oskarsson T, 2011, NAT MED, V17, P867, DOI 10.1038/nm.2379; Owen LA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001965; Pa ML, 2016, J MOL HISTOL, V47, P103, DOI 10.1007/s10735-016-9653-8; Park JS, 2016, ONCOTARGET, V7, P42539, DOI 10.18632/oncotarget.9918; Paron I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021684; Parrish JK, 2015, ONCOGENE, V34, P257, DOI 10.1038/onc.2013.541; Patel M, 2012, GENOME RES, V22, P259, DOI 10.1101/gr.125666.111; Pedersen EA, 2016, CANCER RES, V76, P5040, DOI 10.1158/0008-5472.CAN-15-3422; Peng DH, 2016, ONCOGENE; Penna E, 2013, CANCER RES, V73, P4098, DOI 10.1158/0008-5472.CAN-12-3686; Ponomarev V, 2004, EUR J NUCL MED MOL I, V31, P740, DOI 10.1007/s00259-003-1441-5; Prieur A, 2004, MOL CELL BIOL, V24, P7275, DOI 10.1128/MCB.24.16.7275-7283.2004; Ramadoss S, 2017, ONCOGENE, V36, P47, DOI 10.1038/onc.2016.174; Ramadoss S., 2016, ONCOGENE; Rappa G, 2015, ONCOTARGET, V6, P7970, DOI 10.18632/oncotarget.3419; Richter GHS, 2009, P NATL ACAD SCI USA, V106, P5324, DOI 10.1073/pnas.0810759106; Riggi N, 2014, CANCER CELL, V26, P668, DOI 10.1016/j.ccell.2014.10.004; Rodriguez-Galindo C, 2008, ANN ONCOL, V19, P814, DOI 10.1093/annonc/mdm521; Sang Y, 2015, ONCOTARGET, V6, P29240, DOI 10.18632/oncotarget.5074; Sankar S, 2013, ONCOGENE, V32, P5089, DOI 10.1038/onc.2012.525; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Schiano C, 2012, MED ONCOL, V29, P2998, DOI 10.1007/s12032-012-0158-3; Shi WD, 2016, ONCOTARGET, V7, P73160, DOI 10.18632/oncotarget.12248; SHIH IM, 1994, CANCER RES, V54, P2514; Smith R, 2006, CANCER CELL, V9, P405, DOI 10.1016/j.ccr.2006.04.004; Sohni A, 2013, STEM CELLS INT, V2013, DOI 10.1155/2013/130763; Steingen C, 2008, J MOL CELL CARDIOL, V44, P1072, DOI 10.1016/j.yjmcc.2008.03.010; Svoboda LK, 2014, EPIGENETICS-US, V9, P1613, DOI 10.4161/15592294.2014.988048; Tee AE, 2014, ONCOTARGET, V5, P1793, DOI 10.18632/oncotarget.1785; Tsai HC, 2014, ONCOTARGET, V5, P3800, DOI 10.18632/oncotarget.1998; Volchenboum SL, 2015, J PATHOL CLIN RES, V1, P83, DOI 10.1002/cjp2.9; Wade MA, 2015, NUCLEIC ACIDS RES, V43, P196, DOI 10.1093/nar/gku1298; Wang ZQ, 2013, CANCER LETT, V330, P150, DOI 10.1016/j.canlet.2012.11.049; Wu GJ, 2008, MOL CANCER RES, V6, P1666, DOI 10.1158/1541-7786.MCR-07-2200; Wu ZJ, 2004, J AM STAT ASSOC, V99, P909, DOI 10.1198/016214504000000683; Xie SH, 1997, CANCER RES, V57, P2295; Yang HY, 2015, INT J CLIN EXP PATHO, V8, P11092; Yang J, 2016, ONCOTARGET, V7, P15632, DOI 10.18632/oncotarget.6695; Yu HG, 2011, CANCER RES, V71, P360, DOI 10.1158/0008-5472.CAN-10-2894; Yu XM, 2016, CLIN CANCER RES, V22, P3582, DOI 10.1158/1078-0432.CCR-15-1749; Zeng QQ, 2012, P NATL ACAD SCI USA, V109, P1127, DOI 10.1073/pnas.1111053108; Zhan M, 2016, TUMOR BIOL, V37, P11237, DOI 10.1007/s13277-016-4999-9; Zhang X, 2014, CLIN TRANSL ONCOL, V16, P178, DOI 10.1007/s12094-013-1057-6; Zheng LD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055719	92	43	44	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2017	36	29					4150	4160		10.1038/onc.2017.44	http://dx.doi.org/10.1038/onc.2017.44			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB0LE	28319067	Green Accepted			2022-12-17	WOS:000405835800006
J	Ros, S; Floter, J; Kaymak, I; Da Costa, C; Houddane, A; Dubuis, S; Griffiths, B; Mitter, R; Walz, S; Blake, S; Behrens, A; Brindle, KM; Zamboni, N; Rider, MH; Schulze, A				Ros, S.; Floeter, J.; Kaymak, I.; Da Costa, C.; Houddane, A.; Dubuis, S.; Griffiths, B.; Mitter, R.; Walz, S.; Blake, S.; Behrens, A.; Brindle, K. M.; Zamboni, N.; Rider, M. H.; Schulze, A.			6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 is essential for p53-null cancer cells	ONCOGENE			English	Article							REGULATES GLUCOSE-METABOLISM; WILD-TYPE P53; TRANSCRIPTIONAL REPRESSION; TUMOR; GLYCOLYSIS; EXPRESSION; BIOSYNTHESIS; ACTIVATION; SURVIVAL; HYPOXIA	The bifunctional enzyme 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase-4 (PFKFB4) controls metabolic flux through allosteric regulation of glycolysis. Here we show that p53 regulates the expression of PFKFB4 and that p53-deficient cancer cells are highly dependent on the function of this enzyme. We found that p53 downregulates PFKFB4 expression by binding to its promoter and mediating transcriptional repression via histone deacetylases. Depletion of PFKFB4 from p53-deficient cancer cells increased levels of the allosteric regulator fructose-2,6-bisphosphate, leading to increased glycolytic activity but decreased routing of metabolites through the oxidative arm of the pentose-phosphate pathway. PFKFB4 was also required to support the synthesis and regeneration of nicotinamide adenine dinucleotide phosphate (NADPH) in p53-deficient cancer cells. Moreover, depletion of PFKFB4-attenuated cellular biosynthetic activity and resulted in the accumulation of reactive oxygen species and cell death in the absence of p53. Finally, silencing of PFKFB4-induced apoptosis in p53-deficient cancer cells in vivo and interfered with tumour growth. These results demonstrate that PFKFB4 is essential to support anabolic metabolism in p53-deficient cancer cells and suggest that inhibition of PFKFB4 could be an effective strategy for cancer treatment.	[Ros, S.; Griffiths, B.; Schulze, A.] Canc Res UK London Res Inst, Gene Express Anal Lab, London, England; [Ros, S.; Brindle, K. M.] Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge, England; [Floeter, J.; Kaymak, I.; Schulze, A.] Theodor Boveri Inst, Bioctr, D-97074 Wurzburg, Germany; [Da Costa, C.; Blake, S.; Behrens, A.] Francis Crick Inst, Adult Stem Cell Lab, London, England; [Houddane, A.; Rider, M. H.] Catholic Univ Louvain, de Duve Inst, Prot Phosphorylat Unit, Brussels, Belgium; [Dubuis, S.; Zamboni, N.] ETH, Inst Mol Syst Biol, Zurich, Switzerland; [Mitter, R.] Francis Crick Inst, Bioinformat & Biostat, London, England; [Walz, S.] Comprehens Canc Ctr, Core Unit Bioinformat, Bioctr, Wurzburg, Germany; [Behrens, A.] Kings Coll London, Fac Life Sci & Med, Guys Campus, London, England	Cancer Research UK; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; University of Wurzburg; Francis Crick Institute; Universite Catholique Louvain; Swiss Federal Institutes of Technology Domain; ETH Zurich; Francis Crick Institute; University of Wurzburg; University of London; King's College London	Schulze, A (corresponding author), Theodor Boveri Inst, Bioctr, D-97074 Wurzburg, Germany.	almut.schulze@uni-wuerzburg.de	Ros, Susana/B-6350-2019; Zamboni, Nicola/K-3042-2012; Schulze, Almut/AAX-8257-2020	Zamboni, Nicola/0000-0003-1271-1021; Schulze, Almut/0000-0002-8199-6422; Behrens, Axel/0000-0002-1557-1143; Ros, Susana/0000-0002-5451-1880; Mitter, Richard/0000-0002-1279-3760; Da Costa, Clive/0000-0002-0435-6747	Cancer Research UK; German Cancer Aid [111917]; German Research Foundation [FOR 2314]; CRUK-EPSRC Imaging Centre in Cambridge and Manchester [16465]; The Francis Crick Institute [10002, 10039] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); German Cancer Aid(Deutsche Krebshilfe); German Research Foundation(German Research Foundation (DFG)); CRUK-EPSRC Imaging Centre in Cambridge and Manchester; The Francis Crick Institute	We thank C. Esnault (LRI) for advice on ChIP and H. Miess for help with Seahorse Analysis, C. Watkins and J. Bee (LRI, BRU) for help with animal experimentation, F. Lassailly, P. Johnson and T. Snoeks (In vivo imaging facility, LRI) for assistance with in vivo imaging and the LRI research services for technical support. We also thank C. Ade and Barbara Bauer (Theodor-Boveri-Institute, Wurzburg) for help with RNAseq analysis and histology, Beatrice Dankworth for help with cell line generation and W. Schmitz for insightful discussions. Cancer Research UK, the German Cancer Aid (grant 111917), the German Research Foundation (FOR 2314), and the CRUK-EPSRC Imaging Centre in Cambridge and Manchester (grant 16465) supported this work.	Bengoechea-Alonso MT, 2007, CURR OPIN CELL BIOL, V19, P215, DOI 10.1016/j.ceb.2007.02.004; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Buescher JM, 2010, ANAL CHEM, V82, P4403, DOI 10.1021/ac100101d; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CASCIARI JJ, 1992, J CELL PHYSIOL, V151, P386, DOI 10.1002/jcp.1041510220; Chesney J, 2014, ONCOTARGET, V5, P6670, DOI 10.18632/oncotarget.2213; Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Feng ZH, 2007, CANCER RES, V67, P3043, DOI 10.1158/0008-5472.CAN-06-4149; Freed-Pastor WA, 2012, CELL, V148, P244, DOI 10.1016/j.cell.2011.12.017; Goswami Chirayu Pankaj, 2013, J Clin Bioinforma, V3, P22, DOI 10.1186/2043-9113-3-22; Hitosugi T, 2012, CANCER CELL, V22, P585, DOI 10.1016/j.ccr.2012.09.020; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Huang DW, 2007, NUCLEIC ACIDS RES, V35, pW169, DOI 10.1093/nar/gkm415; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Ivshina AV, 2006, CANCER RES, V66, P10292, DOI 10.1158/0008-5472.CAN-05-4414; Jiang P, 2013, NATURE, V493, P689, DOI 10.1038/nature11776; Jiang P, 2011, NAT CELL BIOL, V13, P310, DOI 10.1038/ncb2172; Kawauchi K, 2008, NAT CELL BIOL, V10, P611, DOI 10.1038/ncb1724; Kim HR, 2013, BIOCHEM BIOPH RES CO, V437, P225, DOI 10.1016/j.bbrc.2013.06.043; Kruiswijk F, 2015, NAT REV MOL CELL BIO, V16, P393, DOI 10.1038/nrm4007; Laplante M, 2009, CURR BIOL, V19, pR1046, DOI 10.1016/j.cub.2009.09.058; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Lee ES, 2008, CLIN CANCER RES, V14, P7397, DOI 10.1158/1078-0432.CCR-07-4937; Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026; Lunt SY, 2011, ANNU REV CELL DEV BI, V27, P441, DOI 10.1146/annurev-cellbio-092910-154237; Maddocks ODK, 2013, NATURE, V493, P542, DOI 10.1038/nature11743; Maddocks ODK, 2011, J MOL MED, V89, P237, DOI 10.1007/s00109-011-0735-5; Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863; Mayers JR, 2015, TRENDS BIOCHEM SCI, V40, P130, DOI 10.1016/j.tibs.2015.01.004; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Okar DO, 2001, TRENDS BIOCHEM SCI, V26, P30, DOI 10.1016/S0968-0004(00)01699-6; Ralser M, 2007, J BIOL, V6, P10, DOI [10.1186/jbiol61, DOI 10.1186/jbiol61]; Rinn JL, 2011, TRENDS CELL BIOL, V21, P344, DOI 10.1016/j.tcb.2011.04.002; Ros S, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-8; Ros S, 2012, CANCER DISCOV, V2, P328, DOI 10.1158/2159-8290.CD-11-0234; Ruhl M, 2012, BIOTECHNOL BIOENG, V109, P763, DOI 10.1002/bit.24344; Schwartzenberg-Bar-Yoseph F, 2004, CANCER RES, V64, P2627, DOI 10.1158/0008-5472.CAN-03-0846; Strohecker AM, 2015, ONCOGENE, V34, P5662, DOI 10.1038/onc.2015.23; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Swinnen JV, 2000, ONCOGENE, V19, P5173, DOI 10.1038/sj.onc.1203889; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; Willis A, 2004, ONCOGENE, V23, P2330, DOI 10.1038/sj.onc.1207396; Yahagi N, 2003, J BIOL CHEM, V278, P25395, DOI 10.1074/jbc.M302364200; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871	45	43	43	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2017	36	23					3287	3299		10.1038/onc.2016.477	http://dx.doi.org/10.1038/onc.2016.477			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW9WJ	28092678	Green Submitted			2022-12-17	WOS:000402869800008
J	Brown, K; Yang, P; Salvador, D; Kulikauskas, R; Ruohola-Baker, H; Robitaille, AM; Chien, AJ; Moon, RT; Sherwood, V				Brown, K.; Yang, P.; Salvador, D.; Kulikauskas, R.; Ruohola-Baker, H.; Robitaille, A. M.; Chien, A. J.; Moon, R. T.; Sherwood, V.			WNT/beta-catenin signaling regulates mitochondrial activity to alter the oncogenic potential of melanoma in a PTEN-dependent manner	ONCOGENE			English	Article							BETA-CATENIN; BRAF MUTATIONS; CLINICOPATHOLOGICAL FEATURES; DISEASE PROGRESSION; SECRETED PROTEINS; EXPRESSION; CANCER; TUMORS; PARKIN; DEGRADATION	Aberrant regulation of WNT/beta-catenin signaling has a crucial role in the onset and progression of cancers, where the effects are not always predictable depending on tumor context. In melanoma, for example, models of the disease predict differing effects of the WNT/beta-catenin pathway on metastatic progression. Understanding the processes that underpin the highly context-dependent nature of WNT/beta-catenin signaling in tumors is essential to achieve maximal therapeutic benefit from WNT inhibitory compounds. In this study, we have found that expression of the tumor suppressor, phosphatase and tensin homolog deleted on chromosome 10 (PTEN), alters the invasive potential of melanoma cells in response to WNT/beta-catenin signaling, correlating with differing metabolic profiles. This alters the bioenergetic potential and mitochondrial activity of melanoma cells, triggered through regulation of prosurvival autophagy. Thus, WNT/beta-catenin signaling is a regulator of catabolic processes in cancer cells, which varies depending on the metabolic requirements of tumors.	[Brown, K.; Sherwood, V.] Univ East Anglia, Sch Pharm, Norwich Res Pk, Norwich, Norfolk, England; [Yang, P.; Kulikauskas, R.; Robitaille, A. M.; Chien, A. J.; Moon, R. T.] Inst Stem Cell & Regenerat Med, Howard Hughes Med Inst, Dept Pharmacol, Seattle, WA USA; [Salvador, D.; Sherwood, V.] Univ Dundee, Ninewells Hosp & Med Sch, Div Canc Res, Jacqui Wood Canc Ctr, Dundee DD1 9SY, Angus, Scotland; [Ruohola-Baker, H.] Univ Washington, Dept Biochem, Seattle, WA 98195 USA; [Chien, A. J.] Univ Washington, Div Dermatol, Seattle, WA 98195 USA; [Brown, K.] NCI, Thorac & GI Oncol Branch, NIH, Bethesda, MD 20892 USA	University of East Anglia; Howard Hughes Medical Institute; University of Dundee; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Sherwood, V (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Div Canc Res, Jacqui Wood Canc Ctr, Dundee DD1 9SY, Angus, Scotland.	v.sherwood@dundee.ac.uk		Robitaille, Aaron Mark/0000-0003-2774-2066	Royal Society, London; British Skin Foundation; CRUK program; Howard Hughes Medical Institute; University of Washington's Proteomics Resource [UWPR95794]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM097372] Funding Source: NIH RePORTER	Royal Society, London(Royal Society of London); British Skin Foundation; CRUK program; Howard Hughes Medical Institute(Howard Hughes Medical Institute); University of Washington's Proteomics Resource; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank members of the CRUK Skin Tumor Laboratory (CRUK-STL), University of Dundee, for useful discussions throughout this work and in particular Kenneth Fernandes for technical support. We also thank Brian Johnson (Histology and Imaging core, School of Medicine, University of Washington) for help with IHC. This work was supported by start-up funding awarded to VS and grants from the Royal Society, London, and the British Skin Foundation (also awarded to VS). VS is supported by a CRUK program grant awarded to the CRUK-STL, School of Medicine, University of Dundee. RTM is an investigator of the Howard Hughes Medical Institute, which partially funded this work. This work was supported in part by the University of Washington's Proteomics Resource (UWPR95794).	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200; Arozarena I, 2011, ONCOGENE, V30, P4531, DOI 10.1038/onc.2011.162; Barthel A, 1999, J BIOL CHEM, V274, P20281, DOI 10.1074/jbc.274.29.20281; Bastian BC, 2003, AM J PATHOL, V163, P1765, DOI 10.1016/S0002-9440(10)63536-5; Bjorkoy G, 2009, METHOD ENZYMOL, V452, P181, DOI 10.1016/S0076-6879(08)03612-4; Brand MD, 2011, BIOCHEM J, V435, P297, DOI 10.1042/BJ20110162; Brembeck FH, 2006, CURR OPIN GENET DEV, V16, P51, DOI 10.1016/j.gde.2005.12.007; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Chien AJ, 2009, J INVEST DERMATOL, V129, P1614, DOI 10.1038/jid.2008.445; Chien AJ, 2009, P NATL ACAD SCI USA, V106, P1193, DOI 10.1073/pnas.0811902106; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Conde-Perez A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9093; Cox J, 2014, MOL CELL PROTEOMICS, V13, P2513, DOI 10.1074/mcp.M113.031591; Damsky WE, 2011, CANCER CELL, V20, P741, DOI 10.1016/j.ccr.2011.10.030; Daniotti M, 2004, ONCOGENE, V23, P5968, DOI 10.1038/sj.onc.1207780; de Moura MB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040690; Degtyarev M, 2008, J CELL BIOL, V183, P101, DOI 10.1083/jcb.200801099; Delmas V, 2007, GENE DEV, V21, P2923, DOI 10.1101/gad.450107; Ding WX, 2010, J BIOL CHEM, V285, P27879, DOI 10.1074/jbc.M110.119537; Eichhoff OM, 2011, PIGM CELL MELANOMA R, V24, P631, DOI 10.1111/j.1755-148X.2011.00871.x; Ellison DW, 2005, J CLIN ONCOL, V23, P7951, DOI 10.1200/JCO.2005.01.5479; Errafiy R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083318; Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149; Fu L, 2011, GUT, V60, P1635, DOI 10.1136/gut.2011.241638; Gallagher SJ, 2013, ONCOGENE, V32, P2230, DOI 10.1038/onc.2012.229; Gamallo C, 1999, AM J PATHOL, V155, P527, DOI 10.1016/S0002-9440(10)65148-6; Garcia-Cao I, 2012, CELL, V149, P49, DOI 10.1016/j.cell.2012.02.030; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Godoy JA, 2014, J BIOL CHEM, V289, P36179, DOI 10.1074/jbc.M114.557009; Goel VK, 2006, J INVEST DERMATOL, V126, P154, DOI 10.1038/sj.jid.5700026; Greene AW, 2012, EMBO REP, V13, P378, DOI 10.1038/embor.2012.14; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Ho JH, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-76; Horvath LG, 2005, INT J CANCER, V113, P415, DOI 10.1002/ijc.20599; James RG, 2013, J BIOL CHEM, V288, P34658, DOI 10.1074/jbc.M113.500314; Jemal A, 2011, J AM ACAD DERMATOL, V65, pS17, DOI 10.1016/j.jaad.2011.04.032; Jenei V, 2009, P NATL ACAD SCI USA, V106, P19473, DOI 10.1073/pnas.0909409106; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Jin SM, 2010, J CELL BIOL, V191, P933, DOI 10.1083/jcb.201008084; Kageshita T, 2001, BRIT J DERMATOL, V145, P210, DOI 10.1046/j.1365-2133.2001.04336.x; Kaur A, 2016, NATURE, V532, P250, DOI 10.1038/nature17392; Kielhorn E, 2003, INT J CANCER, V103, P652, DOI 10.1002/ijc.10893; Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389; Kraya AA, 2015, AUTOPHAGY, V11, P60, DOI 10.4161/15548627.2014.984273; Kurayoshi M, 2006, CANCER RES, V66, P10439, DOI 10.1158/0008-5472.CAN-06-2359; Larue L, 2009, PATHOL BIOL, V57, P543, DOI 10.1016/j.patbio.2008.11.003; Lazarou M, 2012, DEV CELL, V22, P320, DOI 10.1016/j.devcel.2011.12.014; Liesa M, 2013, CELL METAB, V17, P491, DOI 10.1016/j.cmet.2013.03.002; Lin DC, 2015, CANCER RES, V75, P1815, DOI 10.1158/0008-5472.CAN-14-1433; Maelandsmo GM, 2003, CLIN CANCER RES, V9, P3383; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Matsuda N, 2010, J CELL BIOL, V189, P211, DOI 10.1083/jcb.200910140; Mikhail M, 2005, CLIN CANCER RES, V11, P5153, DOI 10.1158/1078-0432.CCR-05-0397; Miyamoto S, 2008, CELL DEATH DIFFER, V15, P521, DOI 10.1038/sj.cdd.4402285; Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028; Narendra D, 2008, J CELL BIOL, V183, P795, DOI 10.1083/jcb.200809125; Narendra DP, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000298; Niehrs C, 2012, EMBO J, V31, P2705, DOI 10.1038/emboj.2012.124; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Nogueira C, 2010, ONCOGENE, V29, P6222, DOI 10.1038/onc.2010.349; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Omholt K, 2003, CLIN CANCER RES, V9, P6483; Osborne JE, 2002, BRIT J DERMATOL, V146, P1104, DOI 10.1046/j.1365-2133.2002.47322.x; Pate KT, 2014, EMBO J, V33, P1454, DOI 10.15252/embj.201488598; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Petherick KJ, 2013, EMBO J, V32, P1903, DOI 10.1038/emboj.2013.123; Ploper D, 2015, P NATL ACAD SCI USA, V112, pE420, DOI 10.1073/pnas.1424576112; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Pukrop T, 2006, P NATL ACAD SCI USA, V103, P5454, DOI 10.1073/pnas.0509703103; Purdue MP, 2008, J INVEST DERMATOL, V128, P2905, DOI 10.1038/jid.2008.159; Qiang YW, 2005, BLOOD, V106, P1786, DOI 10.1182/blood-2005-01-0049; Rimm DL, 1999, AM J PATHOL, V154, P325, DOI 10.1016/S0002-9440(10)65278-9; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Serrat R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067773; Sherwood V, 2015, MOL CELL BIOL, V35, P2, DOI 10.1128/MCB.00992-14; Sherwood V, 2014, CARCINOGENESIS, V35, P784, DOI 10.1093/carcin/bgt390; Silva-Alvarez C, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00097; Sinnberg T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023429; Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404; Tanaka A, 2010, J CELL BIOL, V191, P1367, DOI 10.1083/jcb.201007013; Tsao H, 2004, J INVEST DERMATOL, V122, P337, DOI 10.1046/j.0022-202X.2004.22243.x; Tsao H, 2003, J AM ACAD DERMATOL, V49, P865, DOI 10.1016/S0190-9622(03)02473-3; Tsao HS, 1998, ONCOGENE, V16, P3397, DOI 10.1038/sj.onc.1201881; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Twig G, 2008, EMBO J, V27, P433, DOI 10.1038/sj.emboj.7601963; Twig G, 2011, ANTIOXID REDOX SIGN, V14, P1939, DOI 10.1089/ars.2010.3779; Ulivieri A, 2008, J PATHOL, V215, P87, DOI 10.1002/path.2331; van Amerongen R, 2009, DEVELOPMENT, V136, P3205, DOI 10.1242/dev.033910; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Veeman MT, 2003, CURR BIOL, V13, P680, DOI 10.1016/S0960-9822(03)00240-9; Vives-Bauza C, 2010, P NATL ACAD SCI USA, V107, P378, DOI 10.1073/pnas.0911187107; Whiteman DC, 2002, INT J CANCER, V99, P63, DOI 10.1002/ijc.10294; Wu H, 2003, ONCOGENE, V22, P3113, DOI 10.1038/sj.onc.1206451; Yoon JC, 2010, GENE DEV, V24, P1507, DOI 10.1101/gad.1924910; Yoshii SR, 2011, J BIOL CHEM, V286, P19630, DOI 10.1074/jbc.M110.209338; Zi XL, 2005, CANCER RES, V65, P9762, DOI 10.1158/0008-5472.CAN-05-0103	103	43	49	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2017	36	22					3119	3136		10.1038/onc.2016.450	http://dx.doi.org/10.1038/onc.2016.450			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW6KA	28092677	Green Accepted, Green Published, hybrid			2022-12-17	WOS:000402617900005
J	Jia, H; Song, L; Cong, Q; Wang, J; Xu, H; Chu, Y; Li, Q; Zhang, Y; Zou, X; Zhang, C; Chin, YE; Zhang, X; Li, Z; Zhu, K; Wang, B; Peng, H; Hou, Z				Jia, H.; Song, L.; Cong, Q.; Wang, J.; Xu, H.; Chu, Y.; Li, Q.; Zhang, Y.; Zou, X.; Zhang, C.; Chin, Y. E.; Zhang, X.; Li, Z.; Zhu, K.; Wang, B.; Peng, H.; Hou, Z.			The LIM protein AJUBA promotes colorectal cancer cell survival through suppression of JAK1/STAT1/IFIT2 network	ONCOGENE			English	Article							TRANSCRIPTIONAL REPRESSION; EXPRESSION; RECEPTOR; PATHWAY; FAMILY; GAMMA; SOCS; LOCALIZATION; MIGRATION; ACTIVATOR	The LIM protein AJUBA is a scaffold protein participating in the regulation of cell adhesion, mitosis, DNA damage, cell differentiation, proliferation, migration and gene transcription. However, its roles in tumorigenesis and progression are poorly defined. Here, we report that AJUBA is highly expressed in colorectal cancer (CRC) and promotes CRC cell growth in culture and in xenografted mice via an inhibition of apoptosis. AJUBA represses the expression of IFIT2 gene, an interferon-stimulated gene and a known apoptosis inducer and tumour suppressor to mediate its resistance to apoptosis. Mechanistic investigations reveal that AJUBA specifically binds the FERM domain of JAK1 to dissociate JAK1 from the IFN gamma recepter, resulting in an inhibition of STAT1 phosporylation and concomitantly its nuclear translocation. Clinically, the level of AJUBA in CRC specimens is negatively correlated with the levels of IFIT2 and pSTAT1. Collectively, these studies demonstrate that AJUBA can promote CRC growth via inhibiting apoptosis and serve as a target for the therapeutics and a marker for diagnosis of CRC.	[Jia, H.; Song, L.; Wang, J.; Xu, H.; Li, Q.; Zhang, Y.; Zou, X.; Peng, H.; Hou, Z.] Shanghai Jiao Tong Univ, Sch Med, Fac Basic Med, Hongqiao Inst Med,Shanghai Tongren Hosp, Shanghai, Peoples R China; [Jia, H.; Chu, Y.; Peng, H.; Hou, Z.] Shanghai Jiao Tong Univ, Sch Med, Shanghai Tongren Hosp, Digest Endoscopy Ctr, 1111 Xianxia Rd, Shanghai 200336, Peoples R China; [Jia, H.; Wang, J.; Xu, H.; Li, Q.; Zhang, Y.; Zou, X.; Hou, Z.] Shanghai Jiao Tong Univ, Sch Med, Dept Biochem & Mol Cellular Biol, Shanghai Key Lab Tumor Microenvironm & Inflammat, Shanghai, Peoples R China; [Song, L.; Wang, B.] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Dept Gen Surg, Shanghai 200011, Peoples R China; [Cong, Q.] Shanghai Jiao Tong Univ, Minist Educ, Key Lab Genet Dev & Neuropsychiat Disorders, Bio X Inst, Shanghai, Peoples R China; [Zhang, C.; Chin, Y. E.] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Shanghai, Peoples R China; [Zhang, X.; Li, Z.] Dalian Med Univ, Canc Ctr, Inst Canc Stem Cells, Dalian, Liaoning, Peoples R China; [Zhu, K.] Fudan Univ, Zhongshan Hosp, Liver Canc Inst, Shanghai, Peoples R China; [Hou, Z.] Shanghai Jiao Tong Univ, Sch Med, Key Lab Cell Differentiat & Apoptosis Chinese Min, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Dalian Medical University; Fudan University; Shanghai Jiao Tong University	Peng, H (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Tongren Hosp, Digest Endoscopy Ctr, 1111 Xianxia Rd, Shanghai 200336, Peoples R China.; Wang, B (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Dept Gen Surg, Shanghai 200011, Peoples R China.; Hou, Z (corresponding author), Shanghai Jiao Tong Univ, Dept Biochem & Mol Cell Biol, Sch Med, 280 South Chongqing Rd,Bldg 7,Room 110, Shanghai 200025, Peoples R China.	wangbin1766@163.com; haixiapeng@163.com; houzy@sjtu.edu.cn	Cong, Qian/AAZ-4404-2021	Cong, Qian/0000-0002-9493-5784; Jia, Hao/0000-0003-1856-6013	Ministry of Sciences & Technology of China [2013CB 910900]; National Science Foundation of China [81372309, 81402376, 31671415, 31601114, 81402177]; Shanghai Committee of Science and Technology [13JC1401302, 15410724200]; Shanghai Municipal Commission of Health and Family Planning [201440426]; Science and Technology Commission of Changning District of Shanghai [CNKW2014F01]; China Postdoctoral Science Foundation [2015M570369]	Ministry of Sciences & Technology of China; National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Committee of Science and Technology(Shanghai Science & Technology Committee); Shanghai Municipal Commission of Health and Family Planning; Science and Technology Commission of Changning District of Shanghai; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	We thank Dr Frank J Rauscher III for his critical reading and insightful suggestions, and Xinyu Hou for her technical support. This work was supported by the Ministry of Sciences & Technology of China (2013CB 910900); the National Science Foundation of China (grant Nos. 81372309, 81402376, 31671415, 31601114, 81402177); Shanghai Committee of Science and Technology (13JC1401302, 15410724200); Shanghai Municipal Commission of Health and Family Planning (No. 201440426); and Science and Technology Commission of Changning District of Shanghai No. CNKW2014F01); and the China Postdoctoral Science Foundation (No. 2015M570369).	Ayyanathan K, 2007, CANCER RES, V67, P9097, DOI 10.1158/0008-5472.CAN-07-2987; Baetz A, 2004, J BIOL CHEM, V279, P54708, DOI 10.1074/jbc.M410992200; Blouin CM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00267; BLUYSSEN HAR, 1994, GENOMICS, V24, P137, DOI 10.1006/geno.1994.1591; Burglin TR, 2016, CHROMOSOMA, V125, P497, DOI 10.1007/s00412-015-0543-8; Chen JZ, 2014, CANCER RES, V74, P4353, DOI 10.1158/0008-5472.CAN-14-0181; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Decker T, 1997, J INTERF CYTOK RES, V17, P121, DOI 10.1089/jir.1997.17.121; Du LY, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-51; Gongora C, 1999, B CANCER, V86, P911; Goyal RK, 1999, MOL CELL BIOL, V19, P4379; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Hou ZY, 2008, MOL CELL BIOL, V28, P3198, DOI 10.1128/MCB.01435-07; Jia H, 2015, ONCOGENE, V34, P3568, DOI 10.1038/onc.2014.287; Kotenko SV, 2000, ONCOGENE, V19, P2557, DOI 10.1038/sj.onc.1203524; Krebs DL, 2000, J CELL SCI, V113, P2813; Langer EM, 2008, DEV CELL, V14, P424, DOI 10.1016/j.devcel.2008.01.005; Li Q, 2016, CELL DEATH DIFFER, V23, P158, DOI 10.1038/cdd.2015.83; Mertens C, 2007, CELL, V131, DOI 10.1016/j.cell.2007.10.033; O'Connell D, 2015, AM J PHYSIOL-LUNG C, V309, pL348, DOI 10.1152/ajplung.00099.2015; Pratt SJ, 2005, J CELL BIOL, V168, P813, DOI 10.1083/jcb.200406083; Qin HW, 2012, P NATL ACAD SCI USA, V109, P5004, DOI 10.1073/pnas.1117218109; Quispel WT, 2014, J CLIN IMMUNOL, V34, P84, DOI 10.1007/s10875-013-9959-1; Reich Nancy C, 2013, JAKSTAT, V2, pe27080, DOI 10.4161/jkst.27080; Reich NC, 2013, J INTERF CYTOK RES, V33, P199, DOI 10.1089/jir.2012.0159; Schimizzi GV, 2015, CURR BIOL, V25, pR445, DOI 10.1016/j.cub.2015.02.034; Srichai MB, 2004, J BIOL CHEM, V279, P14398, DOI 10.1074/jbc.M314155200; Stark GR, 2012, IMMUNITY, V36, P503, DOI 10.1016/j.immuni.2012.03.013; Stawowczyk M, 2011, J BIOL CHEM, V286, P7257, DOI 10.1074/jbc.M110.207068; Sun GP, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004324; Tiwari M, 2015, APOPTOSIS, V20, P1019, DOI 10.1007/s10495-015-1136-y; Vlotides G, 2004, BIOCHEM BIOPH RES CO, V320, P1007, DOI 10.1016/j.bbrc.2004.06.051; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; Zhou X, 2013, INT J BIOL SCI, V9, P200, DOI 10.7150/ijbs.5613	34	43	44	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 11	2017	36	19					2655	2666		10.1038/onc.2016.418	http://dx.doi.org/10.1038/onc.2016.418			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EU6CF	27893714				2022-12-17	WOS:000401120900004
J	Cacace, A; Sboarina, M; Vazeille, T; Sonveaux, P				Cacace, A.; Sboarina, M.; Vazeille, T.; Sonveaux, P.			Glutamine activates STAT3 to control cancer cell proliferation independently of glutamine metabolism	ONCOGENE			English	Article							PENTOSE-PHOSPHATE PATHWAY; TUMOR-CELLS; SERINE PHOSPHORYLATION; SIGNALING PATHWAYS; TRANSPORTER MCT4; GROWTH; LACTATE; HYPOXIA; RESISTANCE; INHIBITION	Cancer cells can use a variety of metabolic substrates to fulfill the bioenergetic and biosynthetic needs of their oncogenic program. Besides bioenergetics, cancer cell metabolism also directly influences genetic, epigenetic and signaling events associated with tumor progression. Many cancer cells are addicted to glutamine, and this addiction is observed in oxidative as well as in glycolytic cells. Although both oxidative and bioreductive glutamine metabolism can contribute to cancer progression and glutamine can further serve to generate peptides (including glutathione) and proteins, we report that glutamine promotes the proliferation of cancer cells independently of its use as a metabolic fuel or as a precursor of glutathione. Extracellular glutamine activates transcription factor signal transducer and activator of transcription 3 (STAT3), which is necessary and sufficient to mediate the proliferative effects of glutamine on glycolytic and oxidative cancer cells. Glutamine also activates transcription factors hypoxia-inducible factor-1, mammalian target of rapamycin and c-Myc, but these factors do not mediate the effects of glutamine on cancer cell proliferation. Our findings shed a new light on the anticancer effects of L-asparaginase that possesses glutaminase activity and converts glutamine into glutamate extracellularly. Conversely, cancer resistance to treatments that block glutamine metabolism could arise from glutamine-independent STAT3 reactivation.	[Cacace, A.; Sboarina, M.; Vazeille, T.; Sonveaux, P.] Catholic Univ Louvain, IREC, Pole Pharmacol, Ave Emmanuel Mounier 52 Box B1-53-09, B-1200 Brussels, Belgium	Universite Catholique Louvain	Sonveaux, P (corresponding author), Catholic Univ Louvain, IREC, Pole Pharmacol, Ave Emmanuel Mounier 52 Box B1-53-09, B-1200 Brussels, Belgium.	pierre.sonveaux@uclouvain.be			Starting Grant from the European Research Council (ERC) [243188 TUMETABO]; Interuniversity Attraction Pole (IAP) from the Belgian Science Policy Office (Belspo), an Action de Recherche Concertee from the Communaute Francaise de Belgique [UP7-03, ARC 14/19-058]; Belgian Fonds National de la Recherche Scientifique (FRS-FNRS); Televie and the Belgian Fondation contre le Cancer [2012-186]	Starting Grant from the European Research Council (ERC); Interuniversity Attraction Pole (IAP) from the Belgian Science Policy Office (Belspo), an Action de Recherche Concertee from the Communaute Francaise de Belgique; Belgian Fonds National de la Recherche Scientifique (FRS-FNRS)(Fonds de la Recherche Scientifique - FNRS); Televie and the Belgian Fondation contre le Cancer	This work was supported by a Starting Grant from the European Research Council (ERC no. 243188 TUMETABO), Interuniversity Attraction Pole (IAP) grant #UP7-03 from the Belgian Science Policy Office (Belspo), an Action de Recherche Concertee from the Communaute Francaise de Belgique (ARC 14/19-058), the Belgian Fonds National de la Recherche Scientifique (FRS-FNRS), the Televie and the Belgian Fondation contre le Cancer (2012-186). PS is a FRS-FNRS Research Associate. AC is a Postdoctoral Fellow and MS a Research Fellow of the Televie. We thank Marylene Focant from Promega (Leiden, The Netherlands) for having provided glutamine/glutamate-Glo Assay kits.	Avramis VI, 2006, INT J NANOMED, V1, P241; Banda M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0081126; Bellance N, 2009, FRONT BIOSCI-LANDMRK, V14, P4015, DOI 10.2741/3509; BERGSTROM J, 1974, J APPL PHYSIOL, V36, P693, DOI 10.1152/jappl.1974.36.6.693; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chandra V, 2015, ARCH PHARM RES, V38, P321, DOI 10.1007/s12272-015-0561-3; Chresta CM, 2010, CANCER RES, V70, P288, DOI 10.1158/0008-5472.CAN-09-1751; Commisso C, 2013, NATURE, V497, P633, DOI 10.1038/nature12138; Corbet C, 2014, CANCER RES, V74, P5507, DOI 10.1158/0008-5472.CAN-14-0705; De Preter G, 2016, ONCOTARGET, V7, P2910, DOI 10.18632/oncotarget.6272; De Saedeleer CJ, 2014, ONCOGENE, V33, P4060, DOI 10.1038/onc.2013.454; De Saedeleer CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046571; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Dimmer KS, 2000, BIOCHEM J, V350, P219, DOI 10.1042/0264-6021:3500219; Gough DJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083395; Groner Bernd, 2012, JAKSTAT, V1, P211, DOI 10.4161/jkst.21469; Guillaumond F, 2013, P NATL ACAD SCI USA, V110, P3919, DOI 10.1073/pnas.1219555110; HAKIMI J, 1979, RES COMMUN CHEM PATH, V26, P581; Hassanein M, 2013, CLIN CANCER RES, V19, P560, DOI 10.1158/1078-0432.CCR-12-2334; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hensley CT, 2013, J CLIN INVEST, V123, P3678, DOI 10.1172/JCI69600; Hou PF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113865; Jewell JL, 2015, SCIENCE, V347, P194, DOI 10.1126/science.1259472; Jin LT, 2015, CANCER CELL, V27, P257, DOI 10.1016/j.ccell.2014.12.006; Kumarevel T, 2008, NUCLEIC ACIDS RES, V36, P4808, DOI 10.1093/nar/gkn456; Li F, 2013, J GENET GENOMICS, V40, P367, DOI 10.1016/j.jgg.2013.05.002; Lincet H, 2015, ONCOGENE, V34, P3751, DOI 10.1038/onc.2014.320; Mates JM, 2013, CURR MOL MED, V13, P514; Metallo CM, 2012, NATURE, V481, P380, DOI 10.1038/nature10602; METZEN E, 1995, RESP PHYSIOL, V100, P101, DOI 10.1016/0034-5687(94)00125-J; Munoz J, 2014, ONCOLOGIST, V19, P536, DOI 10.1634/theoncologist.2013-0407; Nicklin P, 2009, CELL, V136, P521, DOI 10.1016/j.cell.2008.11.044; Niu GL, 2008, MOL CANCER RES, V6, P1099, DOI 10.1158/1541-7786.MCR-07-2177; Parmentier JH, 2015, LEUKEMIA RES, V39, P757, DOI 10.1016/j.leukres.2015.04.008; Patra KC, 2014, TRENDS BIOCHEM SCI, V39, P347, DOI 10.1016/j.tibs.2014.06.005; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Pawlus MR, 2014, ONCOGENE, V33, P1670, DOI 10.1038/onc.2013.115; Payen VL, 2015, CANCER J, V21, P75, DOI 10.1097/PPO.0000000000000098; Poli V, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00121; Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350; Prickett TD, 2012, CLIN CANCER RES, V18, P4240, DOI 10.1158/1078-0432.CCR-11-1217; Ratnikov B, 2015, ONCOTARGET, V6, P7379, DOI 10.18632/oncotarget.3132; REITZER LJ, 1979, J BIOL CHEM, V254, P2669; Robinson MM, 2007, BIOCHEM J, V406, P407, DOI 10.1042/BJ20070039; Roland CL, 2014, CANCER RES, V74, P5301, DOI 10.1158/0008-5472.CAN-14-0319; Schust J, 2006, CHEM BIOL, V13, P1235, DOI 10.1016/j.chembiol.2006.09.018; Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009; Shanware NP, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5900; Siveen KS, 2014, BBA-REV CANCER, V1845, P136, DOI 10.1016/j.bbcan.2013.12.005; Sonveaux P, 2008, J CLIN INVEST, V118, P3930, DOI 10.1172/JCI36843; Tardito S, 2015, NAT CELL BIOL, V17, P1556, DOI 10.1038/ncb3272; Thorne JL, 2015, INT J CANCER, V137, P1519, DOI 10.1002/ijc.29012; Ullah MS, 2006, J BIOL CHEM, V281, P9030, DOI 10.1074/jbc.M511397200; Van Hee VF, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00228; Wise DR, 2010, TRENDS BIOCHEM SCI, V35, P427, DOI 10.1016/j.tibs.2010.05.003; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Xu Q, 2005, ONCOGENE, V24, P5552, DOI 10.1038/sj.onc.1208719; Yaguchi T, 2010, CELL PHYSIOL BIOCHEM, V26, P125, DOI 10.1159/000320518; Yang CD, 2009, CANCER RES, V69, P7986, DOI 10.1158/0008-5472.CAN-09-2266; Yang LF, 2014, MOL SYST BIOL, V10, DOI 10.1002/msb.20134892; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Zaganas IV, 2014, NEUROCHEM RES, V39, P471, DOI 10.1007/s11064-014-1251-0; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	64	43	44	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2017	36	15					2074	2084		10.1038/onc.2016.364	http://dx.doi.org/10.1038/onc.2016.364			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DK	27748760	Green Accepted			2022-12-17	WOS:000399782500004
J	Kang, J; Kim, W; Lee, S; Kwon, D; Chun, J; Son, B; Kim, E; Lee, JM; Youn, H; Youn, B				Kang, J.; Kim, W.; Lee, S.; Kwon, D.; Chun, J.; Son, B.; Kim, E.; Lee, J-M; Youn, H.; Youn, B.			TFAP2C promotes lung tumorigenesis and aggressiveness through miR-183-and miR-33a-mediated cell cycle regulation	ONCOGENE			English	Article							AP-2-GAMMA TRANSCRIPTION FACTOR; CANCER CELLS; BREAST-CANCER; TUMOR-SUPPRESSOR; GENE-EXPRESSION; AP-2 FAMILY; PROTEIN; RADIORESISTANCE; INHIBITION; GROWTH	Non-small cell lung cancer (NSCLC) remains one of the leading causes of death worldwide, and thus new molecular targets need to be identified to improve treatment efficacy. Although epidermal growth factor receptor (EGFR)/KRAS mutation-driven lung tumorigenesis is well understood, the mechanism of EGFR/KRAS-independent signal activation remains elusive. Enhanced TFAP2C (transcription factor activating enhancer-binding protein 2C) expression is associated with poor prognosis in some types of cancer patients, but little is known of its relation with the pathogenesis of lung cancer. In the present study, we found that TFAP2C overexpression was associated with cell cycle activation and NSCLC cell tumorigenesis. Interestingly, TFAP2C blocked AKAP12mediated cyclin D1 inhibition by inducing the overexpression of oncogenic microRNA (miRNA)-183 and simultaneously activated cyclin-dependent kinase 6-mediated cell cycle progression by downregulating tumor-suppressive miRNA-33a. In a mouse xenograft model, TFAP2C promoted lung tumorigenesis and disease aggressiveness via the miR-183 and miR-33a pathways. The study provides a mechanism of mitogenic and oncogenic signaling via two functionally opposed miRNAs and suggests that TFAP2Cinduced cell cycle hyperactivation contributes to lung tumorigenesis.	[Kang, J.; Lee, S.; Kwon, D.; Chun, J.; Son, B.; Kim, E.; Youn, B.] Pusan Natl Univ, Dept Integrated Biol Sci, Busan, South Korea; [Kim, W.; Youn, B.] Pusan Natl Univ, Dept Biol Sci, 303 Biol Bldg, Busan 46241, South Korea; [Kim, W.] Pusan Natl Univ, Integrat Grad Program, Ship & Offshore Plant Technol Ocean Energy Resour, Busan, South Korea; [Lee, J-M] Pusan Natl Univ, Dept Naval Architecture & Ocean Engn, Busan, South Korea; [Youn, H.] Sejong Univ, Dept Integrat Biosci & Biotechnol, 209 Neungdong ro, Seoul 05006, South Korea	Pusan National University; Pusan National University; Pusan National University; Pusan National University; Sejong University	Youn, B (corresponding author), Pusan Natl Univ, Dept Biol Sci, 303 Biol Bldg, Busan 46241, South Korea.; Youn, H (corresponding author), Sejong Univ, Dept Integrat Biosci & Biotechnol, 209 Neungdong ro, Seoul 05006, South Korea.	hsyoun@sejong.ac.kr; bhyoun72@pusan.ac.kr	Kim, EunGi/AAZ-6121-2021		National Research Foundation of Korea - Ministry of Science, ICT & Future Planning [2014R1A1A1A05002112, 2013M2A2A7042502]; Ministry of Education [2013R1A1A2059832, 2014R1A1A2004061]; Ministry of Science, ICT & Future Planning through GCRC-SOP [2011-0030013]	National Research Foundation of Korea - Ministry of Science, ICT & Future Planning; Ministry of Education; Ministry of Science, ICT & Future Planning through GCRC-SOP	This work was supported by the National Research Foundation of Korea funded by the Ministry of Science, ICT & Future Planning (2014R1A1A1A05002112 and 2013M2A2A7042502), the Ministry of Education (2013R1A1A2059832 to W Kim and 2014R1A1A2004061 to H Youn) and the Ministry of Science, ICT & Future Planning through GCRC-SOP (2011-0030013).	Akakura S, 2008, CANCER RES, V68, P5096, DOI 10.1158/0008-5472.CAN-07-5619; Aqeilan RI, 2004, CANCER RES, V64, P8256, DOI 10.1158/0008-5472.CAN-04-2055; Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Baines AT, 2011, FUTURE MED CHEM, V3, P1787, DOI [10.4155/FMC.11.121, 10.4155/fmc.11.121]; Bamforth SD, 2001, NAT GENET, V29, P469, DOI 10.1038/ng768; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Bogachek MV, 2014, CANCER CELL, V25, P748, DOI 10.1016/j.ccr.2014.04.008; Braganca J, 2002, J BIOL CHEM, V277, P8559, DOI 10.1074/jbc.M110850200; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Cho WCS, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-1; Cirera-Salinas D, 2012, CELL CYCLE, V11, P922, DOI 10.4161/cc.11.5.19421; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Cyr AR, 2015, ONCOGENE, V34, P436, DOI 10.1038/onc.2013.569; Eckert D, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-13-246; Ettinger DS, 2010, J NATL COMPR CANC NE, V8, P740, DOI 10.6004/jnccn.2010.0056; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Gee JMW, 2009, J PATHOL, V217, P32, DOI 10.1002/path.2430; Grossel MJ, 2006, CELL CYCLE, V5, P266, DOI 10.4161/cc.5.3.2385; Guin S, 2015, ACTA PHARMACOL SIN, V36, P291, DOI 10.1038/aps.2014.129; He AL, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-279; Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714; Hilger-Eversheim K, 2000, GENE, V260, P1, DOI 10.1016/S0378-1119(00)00454-6; Hou J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010312; Huang MH, 2013, MOL ONCOL, V7, P112, DOI 10.1016/j.molonc.2012.09.002; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Imielinski M, 2014, J CLIN INVEST, V124, P1582, DOI 10.1172/JCI72763; Janku F, 2010, NAT REV CLIN ONCOL, V7, P401, DOI 10.1038/nrclinonc.2010.64; Kim E, 2014, CANCER RES, V74, P5520, DOI 10.1158/0008-5472.CAN-14-0735; Kim W, 2015, EXP DERMATOL, V24, P611, DOI 10.1111/exd.12735; Kim W, 2011, RADIAT RES, V176, P539, DOI 10.1667/RR2609.1; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kwon T, 2016, ONCOTARGET, V7, P7193, DOI 10.18632/oncotarget.6887; Landis MW, 2006, CANCER CELL, V9, P13, DOI 10.1016/j.ccr.2005.12.019; Lazar V, 2013, BMC MED GENOMICS, V6, DOI 10.1186/1755-8794-6-53; Leung WKC, 2015, CANCER LETT, V362, P97, DOI 10.1016/j.canlet.2015.03.023; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lin H, 2013, EXP MOL PATHOL, V94, P73, DOI 10.1016/j.yexmp.2012.08.004; Liu H, 2007, EMBO REP, V8, P394, DOI 10.1038/sj.embor.7400909; Mansi L, 2011, B CANCER, V98, P1019, DOI 10.1684/bdc.2011.1380; Musgrove EA, 2011, NAT REV CANCER, V11, P558, DOI 10.1038/nrc3090; Odegaard E, 2006, GYNECOL ONCOL, V100, P462, DOI 10.1016/j.ygyno.2005.09.022; Okayama H, 2012, CANCER RES, V72, P100, DOI 10.1158/0008-5472.CAN-11-1403; Perkins SM, 2015, BREAST CANCER RES TR, V152, P519, DOI 10.1007/s10549-015-3492-2; Shai A, 2015, CANCER RES, V75, P3167, DOI 10.1158/0008-5472.CAN-14-3701; Su B, 2006, CANCER RES, V66, P5599, DOI 10.1158/0008-5472.CAN-05-4123; Su B, 2010, J BIOL CHEM, V285, P4578, DOI 10.1074/jbc.M109.073494; Williams CMJ, 2009, EMBO J, V28, P3591, DOI 10.1038/emboj.2009.290; Williamson JA, 1996, GENOMICS, V35, P262, DOI 10.1006/geno.1996.0351; Wong PP, 2012, MOL CELL BIOL, V32, P1633, DOI 10.1128/MCB.06373-11; Woodfield GW, 2010, GENE CHROMOSOME CANC, V49, P948, DOI 10.1002/gcc.20807; Yamagata N, 2003, CLIN CANCER RES, V9, P4695; Yang HJ, 2013, J BIOL CHEM, V288, P2965, DOI 10.1074/jbc.M112.385989; Yang HJ, 2011, BIOCHEM PHARMACOL, V82, P524, DOI 10.1016/j.bcp.2011.05.027; Yoon DK, 2007, CANCER LETT, V254, P111, DOI 10.1016/j.canlet.2007.02.017; Zhang LQ, 2015, TUMOR BIOL, V36, P8121, DOI 10.1007/s13277-015-3550-8; Zhou JD, 2015, CANCER BIOL THER, V16, P846, DOI 10.1080/15384047.2015.1030545	56	43	43	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	11					1585	1596		10.1038/onc.2016.328	http://dx.doi.org/10.1038/onc.2016.328			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP5ZR	27593936				2022-12-17	WOS:000397458100012
J	Harjes, U; Bridges, E; Gharpure, KM; Roxanis, I; Sheldon, H; Miranda, F; Mangala, LS; Pradeep, S; Lopez-Berestein, G; Ahmed, A; Fielding, B; Sood, AK; Harris, AL				Harjes, U.; Bridges, E.; Gharpure, K. M.; Roxanis, I.; Sheldon, H.; Miranda, F.; Mangala, L. S.; Pradeep, S.; Lopez-Berestein, G.; Ahmed, A.; Fielding, B.; Sood, A. K.; Harris, A. L.			Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4	ONCOGENE			English	Article							ACID-BINDING PROTEIN; OXYGEN SPECIES PRODUCTION; OVARIAN-CANCER; FATTY-ACIDS; CELLS; GROWTH; PHOSPHORYLATION; ANGIOGENESIS; METABOLISM; ACTIVATION	Fatty acid binding protein 4 (FABP4) is a fatty acid chaperone, which is induced during adipocyte differentiation. Previously we have shown that FABP4 in endothelial cells is induced by the NOTCH1 signalling pathway, the latter of which is involved in mechanisms of resistance to antiangiogenic tumour therapy. Here, we investigated the role of FABP4 in endothelial fatty acid metabolism and tumour angiogenesis. We analysed the effect of transient FABP4 knockdown in human umbilical vein endothelial cells on fatty acid metabolism, viability and angiogenesis. Through therapeutic delivery of siRNA targeting mouse FABP4, we investigated the effect of endothelial FABP4 knockdown on tumour growth and blood vessel formation. In vitro, siRNA-mediated FABP4 knockdown in endothelial cells led to a marked increase of endothelial fatty acid oxidation, an increase of reactive oxygen species and decreased angiogenesis. In vivo, we found that increased NOTCH1 signalling in tumour xenografts led to increased expression of endothelial FABP4 that decreased when NOTCH1 and VEGFA inhibitors were used in combination. Angiogenesis, growth and metastasis in ovarian tumour xenografts were markedly inhibited by therapeutic siRNA delivery targeting mouse endothelial FABP4. Therapeutic targeting of endothelial FABP4 by siRNA in vivo has antiangiogenic and antitumour effects with minimal toxicity and should be investigated further.	[Harjes, U.; Bridges, E.; Sheldon, H.; Harris, A. L.] Univ Oxford, Dept Oncol, WIMM, Hypoxia & Growth Factor Grp, Oxford OX1 2JD, England; [Gharpure, K. M.; Mangala, L. S.; Pradeep, S.; Sood, A. K.] Univ Texas Austin, Dept Gynecol Oncol, Austin, TX 78712 USA; [Roxanis, I.] Oxford Univ Hosp, Dept Cellular Pathol, Oxford, England; [Roxanis, I.] John Radcliffe Hosp, NIHR Biomed Res Ctr Oxford, Oxford, England; [Miranda, F.; Ahmed, A.] Univ Oxford, Nuffield Dept Obstet & Gynaecol, WIMM, Ovarian Canc Cell Lab, Oxford OX1 2JD, England; [Mangala, L. S.; Lopez-Berestein, G.; Sood, A. K.] Univ Texas Austin, MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNA, Dept Gynecol Oncol, Austin, TX 78712 USA; [Lopez-Berestein, G.; Sood, A. K.] Univ Texas Austin, Dept Canc Biol, Austin, TX 78712 USA; [Fielding, B.] Univ Surrey, Dept Nutr Sci, Guildford GU2 5XH, Surrey, England; [Harjes, U.] Univ Leuven, Dept Oncol, Lab Angiogenesis & Vasc Metab, B-3000 Leuven, Belgium; [Harjes, U.] VIB, Vesalius Res Ctr, Lab Angiogenesis & Vasc Metab, B-3000 Leuven, Belgium	University of Oxford; University of Texas System; University of Texas Austin; University of Oxford; University of Oxford; University of Texas System; University of Texas Austin; UTMD Anderson Cancer Center; University of Texas System; University of Texas Austin; University of Surrey; KU Leuven; Flanders Institute for Biotechnology (VIB)	Harris, AL (corresponding author), John Radcliffe Hosp, Weatherall Inst Mol Med, Osler Rd Headington, Oxford OX3 9DS, England.	aharris.lab@imm.ox.ac.uk	Sood, Anoop Kumar/A-7344-2013; Harris, Adrian L/ABA-3343-2020	Sood, Anoop Kumar/0000-0001-5702-4108; Harris, Adrian L/0000-0003-1376-8409; Gharpure, Kshipra/0000-0003-4954-5696; Sheldon, Helen/0000-0002-0945-5496; Harjes, Ulrike/0000-0003-0376-1262	Cancer Research UK; Breast Cancer Research Foundation; NIH [CA109298, P50 CA083639, P50 CA098258, UH2 TR000943]; RGK Foundation; Glider Foundation; Betty Anne Asche Murray Distinguished Professorship; Altman Goldstein Discovery Fellowship; Medical research Council; Ovarian Cancer Action; Oxford Biomedical Research Centre, the National Institute of Health Research; National Health Service Biomedical Research Centre; MRC [G0902418] Funding Source: UKRI; Cancer Research UK [16466, 11359, 18974] Funding Source: researchfish; Medical Research Council [G0300648, G0902418] Funding Source: researchfish; National Institute for Health Research [NF-SI-0611-10163] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [P50CA098258, P30CA016672, P50CA083639, R01CA109298] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UH2TR000943] Funding Source: NIH RePORTER	Cancer Research UK(Cancer Research UK); Breast Cancer Research Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); RGK Foundation; Glider Foundation; Betty Anne Asche Murray Distinguished Professorship; Altman Goldstein Discovery Fellowship; Medical research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Ovarian Cancer Action(Ovarian Cancer Action); Oxford Biomedical Research Centre, the National Institute of Health Research; National Health Service Biomedical Research Centre; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	Portions of this work were supported by Cancer Research UK, Breast Cancer Research Foundation and National Health Service Biomedical Research Centre, the NIH (CA109298, P50 CA083639, P50 CA098258, UH2 TR000943), the RGK Foundation, the Glider Foundation and the Betty Anne Asche Murray Distinguished Professorship. KMG is supported by Altman Goldstein Discovery Fellowship. AA and FM are funded by the Medical research Council, Ovarian Cancer Action and the Oxford Biomedical Research Centre, the National Institute of Health Research.	Bao Zhengzheng, 2013, Genes Cancer, V4, P297, DOI 10.1177/1947601913499155; Bensaad K, 2014, CELL REP, V9, P349, DOI 10.1016/j.celrep.2014.08.056; Brandes RP, 2014, FREE RADICAL BIO MED, V76, P208, DOI 10.1016/j.freeradbiomed.2014.07.046; Cataltepe O, 2012, NEUROPATH APPL NEURO, V38, P400, DOI 10.1111/j.1365-2990.2011.01237.x; Coe NR, 1999, J LIPID RES, V40, P967; Currie E, 2013, CELL METAB, V18, P153, DOI 10.1016/j.cmet.2013.05.017; Elmasri H, 2009, FASEB J, V23, P3865, DOI 10.1096/fj.09-134882; Garin-Shkolnik T, 2014, DIABETES, V63, P900, DOI 10.2337/db13-0436; Harjes U, 2016, CRIT REV ONCOL HEMAT, V97, P15, DOI 10.1016/j.critrevonc.2015.10.011; Harjes U, 2014, J BIOL CHEM, V289, P23168, DOI 10.1074/jbc.M114.576512; Herbert SP, 2011, NAT REV MOL CELL BIO, V12, P551, DOI 10.1038/nrm3176; Hu W, 2011, CANCER RES, V71, P6030, DOI 10.1158/0008-5472.CAN-10-2719; Huang J, 2016, MOL CANCER THER, V15, P1344, DOI 10.1158/1535-7163.MCT-15-0144; Huttemann M, 2008, J BIOENERG BIOMEMBR, V40, P445, DOI 10.1007/s10863-008-9169-3; Inoguchi T, 2000, DIABETES, V49, P1939, DOI 10.2337/diabetes.49.11.1939; Levi L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9794; Li JL, 2011, CANCER RES, V71, P6073, DOI 10.1158/0008-5472.CAN-11-1704; Lu CH, 2010, CANCER CELL, V18, P185, DOI 10.1016/j.ccr.2010.06.016; Lu CH, 2007, CANCER RES, V67, P1757, DOI 10.1158/0008-5472.CAN-06-3700; Mashek DG, 2006, CURR OPIN LIPIDOL, V17, P274, DOI 10.1097/01.mol.0000226119.20307.2b; Masiero M, 2013, CANCER CELL, V24, P229, DOI 10.1016/j.ccr.2013.06.004; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Olsauskas-Kuprys R, 2013, ONCOTARGETS THER, V6, P943, DOI 10.2147/OTT.S33766; Oza AM, 2015, LANCET ONCOL, V16, P928, DOI 10.1016/S1470-2045(15)00086-8; Pike LS, 2011, BBA-BIOENERGETICS, V1807, P726, DOI 10.1016/j.bbabio.2010.10.022; Rosca MG, 2012, DIABETES, V61, P2074, DOI 10.2337/db11-1437; Schoors S, 2015, NATURE, V520, P192, DOI 10.1038/nature14362; Schultheis B, 2014, J CLIN ONCOL, V32, P4141, DOI 10.1200/JCO.2013.55.0376; Smith AJ, 2007, J BIOL CHEM, V282, P32424, DOI 10.1074/jbc.M703730200; Smith NR, 2013, CLIN CANCER RES, V19, P6943, DOI 10.1158/1078-0432.CCR-13-1637; Wang HC, 2014, CLIN CHIM ACTA, V436, P243, DOI 10.1016/j.cca.2014.06.005; Wu JR, 2010, J BIOPHARM STAT, V20, P954, DOI 10.1080/10543401003618983	32	43	46	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	2017	36	7					912	921		10.1038/onc.2016.256	http://dx.doi.org/10.1038/onc.2016.256			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8JG	27568980	Green Submitted, Green Published, hybrid			2022-12-17	WOS:000394169100004
J	Yang, CF; Yang, GD; Huang, TJ; Li, R; Chu, QQ; Xu, L; Wang, MS; Cai, MD; Zhong, L; Wei, HJ; Huang, HB; Huang, JL; Qian, CN; Huang, BJ				Yang, C-F; Yang, G-D; Huang, T-J; Li, R.; Chu, Q-Q; Xu, L.; Wang, M-S; Cai, M-D; Zhong, L.; Wei, H-J; Huang, H-B; Huang, J-L; Qian, C-N; Huang, B-J			EB-virus latent membrane protein 1 potentiates the stemness of nasopharyngeal carcinoma via preferential activation of PI3K/AKT pathway by a positive feedback loop	ONCOGENE			English	Article							EPSTEIN-BARR-VIRUS; TUMOR-SUPPRESSOR GENE; NF-KAPPA-B; CANCER CELLS; MICRORNA-21; EXPRESSION; IDENTIFICATION; PTEN; MEMBRANE-PROTEIN-1; HEAD	Our previous study reported that Epstein-Barr virus(EBV)-encoded latent membrane protein 1 (LMP1) could induce development of CD44(+/High) stem-like cells in nasopharyngeal carcinoma (NPC). However, the molecular mechanisms that underlie modulation of cancer stem cells (CSCs) in NPC remain unclear. Here, we show that LMP1 induced CSC-like properties through promotion of the expression of epithelial-mesenchymal transition-like cellular markers and through alterations in differentiation markers. Furthermore, LMP1 activated and triggered phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) pathway, which subsequently stimulated expression of CSC markers, development of side population and tumor sphere formation. This suggests that PI3K/AKT pathway has an important role in the induction and maintenance of CSC properties in NPC. Similarly, PI3K/AKT pathway was also activated by phosphorylase in LMP1-induced CD44(+/High) cells. In addition, LMP1 greatly increased expression of miR-21 and downregulated expression of the miR-21 target, PTEN. Overexpression of miR-21 by transfection of miR-21 mimics into LMP1-transformed cells led to phosphorylase-mediated activation of the PI3K/AKT pathway and induction of CSCs. On the contrary, phosphorylation of the PI3K/AKT pathway and the expression of CSC were reversed by an miR-21 inhibitor. The specific inhibitor (Ly294002) of PI3K/AKT pathway significantly decreased expression of miR-21 and CSC markers and upregulated the expression of PTEN, which indicates that miR-21 and PTEN are the downstream effectors of PI3K/AKT and that expression of these two effectors are related to the development of NPC CSCs. Taken together, our novel findings indicate that LMP1, PI3K/AKT, miR-21 and PTEN constitute a positive feedback loop and have a key role in LMP1-induced CSCs in NPC.	[Yang, C-F; Xu, L.; Qian, C-N; Huang, B-J] Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, Dept Expt Res,State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China; [Yang, C-F; Wang, M-S; Cai, M-D; Zhong, L.; Wei, H-J] Gaozhou Peoples Hosp, Dept Canc Chemotherapy, Gaozhou, Peoples R China; [Yang, G-D] Sun Yat Sen Univ, BoJi Affiliated Hosp, Zengcheng Peoples Hosp, Dept Canc Chemotherapy, Zengcheng, Peoples R China; [Huang, T-J] Second Peoples Hosp Shenzhen, Dept Nucl Med, Shenzhen, Peoples R China; [Li, R.] Soothern Med Univ, Coll Clin Med 2, Guangzhou, Guangdong, Peoples R China; [Chu, Q-Q] Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou, Guangdong, Peoples R China; [Huang, H-B] Sun Yat Sen Univ, Ctr Canc, Dept Pharm, Guangzhou, Guangdong, Peoples R China; [Huang, J-L] St Barnabas Hosp, Dept Pathol, Livingston, NJ USA; [Qian, C-N] Sun Yat Sen Univ, Ctr Canc, Dept Nasopharyngeal Carcinoma, Guangzhou, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Second People's Hospital of Shenzhen; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Qian, CN; Huang, BJ (corresponding author), Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Dept Expt Res, 651 Dongfeng East Rd, Guangzhou 510060, Guangdong, Peoples R China.	qianchn@sysucc.org.cn; huangbj@sysucc.org.cn	Huang, Bi-Jun/GSD-2430-2022; Huang, Huang/AAN-5671-2020		National Natural Science Foundation of China [81572901, 31170151, 81272340, 30770108, 81030043]; Science and Technology Planning Project of Guangdong Province, China [2014B020212017, 2014A020209024, 2009A030331005]; Guangzhou Key Program of Science and Technology [2012Y2-00026]; Shenzhen Basic Research Program of Science and Technology RD [JC201105170709A, JCYJ20150330102720115]; Guangdong Natural Science Foundation [2014A030310029]; National High Technology Research and Development Program of China (863 Program) [2012AA02A501]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Planning Project of Guangdong Province, China; Guangzhou Key Program of Science and Technology; Shenzhen Basic Research Program of Science and Technology RD; Guangdong Natural Science Foundation(National Natural Science Foundation of Guangdong Province); National High Technology Research and Development Program of China (863 Program)(National High Technology Research and Development Program of China)	This work was supported by grants from the National Natural Science Foundation of China (grant no. 81572901, 31170151, 81272340, 30770108 and 81030043), the Science and Technology Planning Project of Guangdong Province, China (grant no. 2014B020212017, 2014A020209024 and 2009A030331005), the Guangzhou Key Program of Science and Technology (grant no. 2012Y2-00026), the Shenzhen Basic Research Program of Science and Technology R&D (grant no. JC201105170709A and JCYJ20150330102720115), the Guangdong Natural Science Foundation (grant no. 2014A030310029) and the National High Technology Research and Development Program of China (863 Program; No. 2012AA02A501).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Asuthkar S, 2012, ONCOTARGET, V3, P1439; Bao B, 2012, BBA-REV CANCER, V1826, P272, DOI 10.1016/j.bbcan.2012.04.008; Bao LL, 2013, CANCER LETT, V337, P226, DOI 10.1016/j.canlet.2013.05.007; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Castellino RC, 2007, NAT CLIN PRACT NEURO, V3, P682, DOI 10.1038/ncpneuro0661; Chen CC, 2010, CELL SIGNAL, V22, P1132, DOI 10.1016/j.cellsig.2010.03.008; Chen Jiezhong, 2012, World J Virol, V1, P154, DOI 10.5501/wjv.v1.i6.154; Chen YR, 2008, J VIROL, V82, P8124, DOI 10.1128/JVI.00430-08; Chew MMS, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-574; Chung WM, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt247; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Dawson CW, 2012, SEMIN CANCER BIOL, V22, P144, DOI 10.1016/j.semcancer.2012.01.004; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Dubrovska A, 2010, CLIN CANCER RES, V16, P5692, DOI 10.1158/1078-0432.CCR-10-1601; Dubrovska A, 2009, P NATL ACAD SCI USA, V106, P268, DOI 10.1073/pnas.0810956106; Frank NY, 2010, J CLIN INVEST, V120, P41, DOI 10.1172/JCI41004; Gong C, 2011, J BIOL CHEM, V286, P19127, DOI 10.1074/jbc.M110.216887; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Han M, 2012, CANCER SCI, V4, P1058; Hannigan A, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-184; Kondo S, 2011, J VIROL, V85, P11255, DOI 10.1128/JVI.00188-11; Kutz H, 2008, VIROLOGY, V371, P246, DOI 10.1016/j.virol.2007.09.044; Lambert SL, 2007, J IMMUNOL, V179, P8225, DOI 10.4049/jimmunol.179.12.8225; Lavorgna A, 2012, P NATL ACAD SCI USA, V109, P2188, DOI 10.1073/pnas.1121357109; Lee JW, 2009, CANCER LETT, V279, P193, DOI 10.1016/j.canlet.2009.01.037; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Ma S, 2008, ONCOGENE, V27, P1749, DOI 10.1038/sj.onc.1210811; Mainou BA, 2005, ONCOGENE, V24, P6917, DOI 10.1038/sj.onc.1208846; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; Patrawala L, 2006, ONCOGENE, V25, P1696, DOI 10.1038/sj.onc.1209327; Pedrero JMG, 2005, INT J CANCER, V114, P242, DOI 10.1002/ijc.20711; Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104; Prince MEP, 2008, J CLIN ONCOL, V26, P2871, DOI 10.1200/JCO.2007.15.1613; Qian CN, 2009, CANCER RES, V69, P8256, DOI 10.1158/0008-5472.CAN-09-1689; Sayed D, 2010, J BIOL CHEM, V285, P20281, DOI 10.1074/jbc.M110.109207; Selcuklu SD, 2009, BIOCHEM SOC T, V37, P918, DOI 10.1042/BST0370918; Singh SK, 2003, CANCER RES, V63, P5821; Takaishi S, 2009, STEM CELLS, V27, P1006, DOI 10.1002/stem.30; Tellez CS, 2011, CANCER RES, V71, P3087, DOI 10.1158/0008-5472.CAN-10-3035; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Yamamoto C, 2010, CANCER RES, V70, P8715, DOI 10.1158/0008-5472.CAN-10-0043; Yang CF, 2014, CANCER LETT, V344, P260, DOI 10.1016/j.canlet.2013.11.006; Yang GW, 2013, DISCRETE DYN NAT SOC, V2013, DOI 10.1155/2013/507828; Yang SM, 2013, TOXICOLOGY, V306, P162, DOI 10.1016/j.tox.2013.02.014; Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452; Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24; Zhu XS, 2013, CANCER IMMUNOL IMMUN, V62, P689, DOI 10.1007/s00262-012-1367-5	51	43	45	1	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2016	35	26					3419	3431		10.1038/onc.2015.402	http://dx.doi.org/10.1038/onc.2015.402			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DQ5UI	26568302				2022-12-17	WOS:000379270100007
J	Kurppa, KJ; Denessiouk, K; Johnson, MS; Elenius, K				Kurppa, K. J.; Denessiouk, K.; Johnson, M. S.; Elenius, K.			Activating ERBB4 mutations in non-small cell lung cancer	ONCOGENE			English	Article							KINASE DOMAIN; GROWTH; MECHANISM; CLEAVAGE; INHIBITION; RECEPTORS; SURVIVAL; ISOFORMS; LIGAND	Recent efforts to comprehensively characterize the mutational landscape of non-small cell lung cancer have identified frequent mutations in the receptor tyrosine kinase ERBB4. However, the significance of mutated ERBB4 in non-small cell lung cancer remains elusive. Here, we have functionally characterized nine ERBB4 mutations previously identified in lung adenocarcinoma. Four out of the nine mutations, Y285C, D595V, D931Y and K935I, were found to be activating, increasing both basal and ligand-induced ErbB4 phosphorylation. According to structural analysis, the four activating mutations were located at critical positions at the dimerization interfaces of the ErbB4 extracellular (Y285C and D595V) and kinase (D931Y and K935I) domains. Consistently, the mutations enhanced ErbB4 dimerization and increased the trans activation in ErbB4 homodimers and ErbB4-ErbB2 heterodimers. The expression of the activating ERBB4 mutants promoted survival of NIH 3T3 cells in the absence of serum. Interestingly, serum starvation of NIH 3T3 cells expressing the ERBB4 mutants only moderately increased the phosphorylation of canonical ErbB signaling pathway effectors Erk1/2 and Akt as compared with wild-type ERBB4. In contrast, the mutations clearly enhanced the proteolytic release of signaling-competent ErbB4 intracellular domain. These results suggest the presence of activating driver mutations of ERBB4 in non-small cell lung cancer.	[Kurppa, K. J.; Elenius, K.] Univ Turku, Dept Med Biochem & Genet, MediC Res Labs, FIN-20520 Turku, Finland; [Kurppa, K. J.] Turku Doctoral Programme Mol Med, Turku, Finland; [Denessiouk, K.; Johnson, M. S.] Abo Akad Univ, Fac Sci & Engn, Biochem, Struct Bioinformat Lab, Turku, Finland; [Elenius, K.] Turku Univ Hosp, Dept Oncol, FIN-20520 Turku, Finland	University of Turku; Abo Akademi University; University of Turku	Elenius, K (corresponding author), Univ Turku, Dept Med Biochem & Genet, Kiinamyllynkatu 10, FIN-20520 Turku, Finland.	klaus.elenius@utu.fi	Elenius, Klaus/AAI-7594-2021	Elenius, Klaus/0000-0001-5700-0827	Academy of Finland, Finnish Cancer Organizations; Sigrid Juselius Foundation; Turku University Central Hospital; Abo Akademi Center fo Excellence in Cell Stress and Aging; Joe, Pentti and Tor Borg memorial fund; Cancer Foundation Finland sr [130077, 160067] Funding Source: researchfish	Academy of Finland, Finnish Cancer Organizations(Academy of Finland); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Turku University Central Hospital; Abo Akademi Center fo Excellence in Cell Stress and Aging; Joe, Pentti and Tor Borg memorial fund; Cancer Foundation Finland sr	We thank Maria Tuominen, Minna Santanen and Mika Savisalo for excellent technical assistance. This work was financially supported by the Academy of Finland, Finnish Cancer Organizations, the Sigrid Juselius Foundation, the Turku University Central Hospital, the Abo Akademi Center fo Excellence in Cell Stress and Aging and the Joe, Pentti and Tor Borg memorial fund. The use of computational infrastructures of Biocenter Finland (bioinformatics) and CSC IT Center for Science is gratefully acknowledged.	Aertgeerts K, 2011, J BIOL CHEM, V286, P18756, DOI 10.1074/jbc.M110.206193; Alvarado D, 2010, CELL, V142, P568, DOI 10.1016/j.cell.2010.07.015; Bouyain S, 2005, P NATL ACAD SCI USA, V102, P15024, DOI 10.1073/pnas.0507591102; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Greulich H, 2012, P NATL ACAD SCI USA, V109, P14476, DOI 10.1073/pnas.1203201109; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hegde GV, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004438; Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Jaiswal BS, 2013, CANCER CELL, V23, P603, DOI 10.1016/j.ccr.2013.04.012; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Junttila TT, 2005, CANCER RES, V65, P1384, DOI 10.1158/0008-5472.CAN-04-3150; Junttila TT, 2003, CLIN CANCER RES, V9, P5346; Komuro A, 2003, J BIOL CHEM, V278, P33334, DOI 10.1074/jbc.M305597200; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Kurppa K, 2009, PIGM CELL MELANOMA R, V22, P708, DOI 10.1111/j.1755-148X.2009.00635.x; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Lehtonen JV, 2004, J COMPUT AID MOL DES, V18, P401, DOI 10.1007/s10822-004-3752-4; Liu P, 2012, P NATL ACAD SCI USA, V109, P10861, DOI 10.1073/pnas.1201114109; Maatta JA, 2006, MOL BIOL CELL, V17, P67, DOI 10.1091/mbc.E05-05-0402; Monsey J, 2010, J BIOL CHEM, V285, P7035, DOI 10.1074/jbc.M109.096032; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2010, NAT REV CANCER, V10, P760, DOI 10.1038/nrc2947; Prickett TD, 2009, NAT GENET, V41, P1127, DOI 10.1038/ng.438; Qiu C, 2008, STRUCTURE, V16, P460, DOI 10.1016/j.str.2007.12.016; Reck M, 2013, LANCET, V382, P709, DOI 10.1016/S0140-6736(13)61502-0; Red Brewer M, 2013, P NATL ACAD SCI USA, V110, pE3595, DOI 10.1073/pnas.1220050110; Sardi SP, 2006, CELL, V127, P185, DOI 10.1016/j.cell.2006.07.037; Settleman J, 2009, CANCER CELL, V16, P278, DOI 10.1016/j.ccr.2009.09.013; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Sundvall M, 2010, MOL BIOL CELL, V21, P4275, DOI 10.1091/mbc.E10-04-0332; Takahashi Y, 2013, AM J HUM GENET, V93, P900, DOI 10.1016/j.ajhg.2013.09.008; Toivanen PI, 2009, J BIOL CHEM, V284, P16037, DOI 10.1074/jbc.M109.001123; Tvorogov D, 2009, J BIOL CHEM, V284, P5582, DOI 10.1074/jbc.M805438200; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013	40	43	44	0	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2016	35	10					1283	1291		10.1038/onc.2015.185	http://dx.doi.org/10.1038/onc.2015.185			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG0NY	26050618				2022-12-17	WOS:000371763100008
J	Goka, ET; Lippman, ME				Goka, E. T.; Lippman, M. E.			Loss of the E3 ubiquitin ligase HACE1 results in enhanced Rac1 signaling contributing to breast cancer progression	ONCOGENE			English	Article							CARCINOMA IN-SITU; SMALL-MOLECULE INHIBITOR; FAMILY SMALL GTPASES; GROWTH-FACTOR-BETA; EPITHELIAL-CELLS; ACTIVE RAC1; OVEREXPRESSION; TUMOR; UBIQUITYLATION; METHYLATION	The transition from ductal carcinoma in situ (DCIS) to invasive breast cancer (IBC) is a crucial step in breast cancer progression. The specific alterations that govern this transition have not been elucidated. HER2/neu is frequently overexpressed in DCIS but is less common in IBC, thereby suggesting additional requirements for transformation. To identify genes capable of cooperating with HER2/neu to fully transform mammary epithelial cells, we used an insertional mutagenesis screen on cells isolated from wild-type neu expressing mice and identified the E3 ligase HACE1 as HER2 cooperative tumor suppressor gene. Loss of HACE1 expression is commonly seen in clinical breast cancer data sets. HACE1 downregulation in normal human mammary epithelial cells (HMECs) results in the accumulation of the activated GTP-bound Rac1 partially transforming these cells. Overexpression of HER2 activates Rac1, which further accumulates upon HACE1 loss resulting in Rac1 hyperactivation. Although the knockdown of HACE1 or overexpression of HER2 alone in HMECs is not sufficient for tumorigenesis, HER2 overexpression combined with HACE1 downregulation fully transforms HMECs resulting in robust tumor formation. The pharmaceutical interference of Rac function abrogates the effects of HACE1 loss both in vitro and in vivo, resulting in marked reduction in tumor burden. Our work supports a critical role for HACE1 in breast cancer progression and identifies patients that may benefit from Rac-targeted therapies.	[Goka, E. T.] Univ Miami, Miller Sch Med, Shelia & David Fuente Grad Program Canc Biol, Miami, FL 33101 USA; [Lippman, M. E.] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33101 USA	University of Miami; University of Miami	Lippman, ME (corresponding author), Univ Miami, Miller Sch Med, Dept Med, Biomedical Res Bldg,1501 NW 10th Ave,POB 016960, Miami, FL 33101 USA.	mlippman@med.miami.edu						Anglesio MS, 2004, HUM MOL GENET, V13, P2061, DOI 10.1093/hmg/ddh215; BARNES DM, 1992, EUR J CANCER, V28A, P644, DOI 10.1016/S0959-8049(05)80117-0; Baxter NN, 2004, JNCI-J NATL CANCER I, V96, P443, DOI 10.1093/jnci/djh069; Castillo-Lluva S, 2012, ONCOGENE; Drews-Elger K, 2014, BREAST CANCER RES TR, V144, P503, DOI 10.1007/s10549-014-2887-9; Ernster V L, 1997, J Natl Cancer Inst Monogr, P151; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Heasman SJ, 2008, NAT REV MOL CELL BIO, V9, P690, DOI 10.1038/nrm2476; Hernandez E, 2010, P R HEALTH SCI J, V29, P348; Hibi K, 2008, ANTICANCER RES, V28, P1581; Hyytinen ER, 2002, GENE CHROMOSOME CANC, V34, P306, DOI 10.1002/gcc.10065; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kawazu M, 2013, P NATL ACAD SCI USA, V110, P3029, DOI 10.1073/pnas.1216141110; Kim IY, 2009, CANCER LETT, V275, P227, DOI 10.1016/j.canlet.2008.10.013; Lachance V, 2014, J CELL SCI, V127, P111, DOI 10.1242/jcs.132944; Latta EK, 2002, MODERN PATHOL, V15, P1318, DOI 10.1097/01.MP.0000038462.62634.B1; Laurin M, 2013, P NATL ACAD SCI USA, V110, P7434, DOI 10.1073/pnas.1213050110; Lu T, 2009, P NATL ACAD SCI USA, V106, P16339, DOI 10.1073/pnas.0908560106; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; Marcotte R, 2008, J MAMMARY GLAND BIOL, V13, P323, DOI 10.1007/s10911-008-9087-3; Melino G, 2008, CELL DEATH DIFFER, V15, P1103, DOI 10.1038/cdd.2008.60; Nethe M, 2010, J CELL SCI, V123, P4011, DOI 10.1242/jcs.078360; Onesto C, 2008, METHOD ENZYMOL, V439, P111, DOI 10.1016/S0076-6879(07)00409-0; Porter D, 2003, MOL CANCER RES, V1, P362; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Sakata M, 2013, HEPATO-GASTROENTEROL, V60, P781, DOI 10.5754/hge10439; Sakata M, 2009, ANTICANCER RES, V29, P2231; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Shutes A, 2007, J BIOL CHEM, V282, P35666, DOI 10.1074/jbc.M703571200; Singh A, 2004, ONCOGENE, V23, P9369, DOI 10.1038/sj.onc.1208182; Sosa MS, 2010, MOL CELL, V40, P877, DOI 10.1016/j.molcel.2010.11.029; Tang DM, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1509; Tina E, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-350; Torrino S, 2011, DEV CELL, V21, P959, DOI 10.1016/j.devcel.2011.08.015; Ueda Y, 2004, J BIOL CHEM, V279, P24505, DOI 10.1074/jbc.M400081200; Visvikis O, 2010, BIOL CELL, V102, P377, DOI 10.1042/BC20090151; Wang SZE, 2006, CANCER RES, V66, P9591, DOI 10.1158/0008-5472.CAN-06-2071; Wertheimer E, 2012, CELL SIGNAL, V24, P353, DOI 10.1016/j.cellsig.2011.08.011; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Yang CF, 2006, MOL CELL BIOL, V26, P831, DOI 10.1128/MCB.26.3.831-842.2006; Zhang L, 2007, NAT MED, V13, P1060, DOI 10.1038/nm1621	41	43	44	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2015	34	42					5395	5405		10.1038/onc.2014.468	http://dx.doi.org/10.1038/onc.2014.468			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EI	25659579	hybrid, Green Published			2022-12-17	WOS:000363479200009
J	Kern, D; Regl, G; Hofbauer, SW; Altenhofer, P; Achatz, G; Dlugosz, A; Schnidar, H; Greil, R; Hartmann, TN; Aberger, F				Kern, D.; Regl, G.; Hofbauer, S. W.; Altenhofer, P.; Achatz, G.; Dlugosz, A.; Schnidar, H.; Greil, R.; Hartmann, T. N.; Aberger, F.			Hedgehog/GLI and PI3K signaling in the initiation and maintenance of chronic lymphocytic leukemia	ONCOGENE			English	Article							BASAL-CELL CARCINOMAS; PATHWAY INHIBITOR; GLI ACTIVATION; STEM-CELLS; BCR-ABL; CANCER; GROWTH; AKT; MECHANISMS; PROTEIN	The initiation and maintenance of a malignant phenotype requires complex and synergistic interactions of multiple oncogenic signals. The Hedgehog (HH)/GLI pathway has been implicated in a variety of cancer entities and targeted pathway inhibition is of therapeutic relevance. Signal cross-talk with other cancer pathways including PI3K/AKT modulates HH/GLI signal strength and its oncogenicity. In this study, we addressed the role of HH/GLI and its putative interaction with the PI3K/AKT cascade in the initiation and maintenance of chronic lymphocytic leukemia (CLL). Using transgenic mouse models, we show that B-cell-specific constitutive activation of HH/GLI signaling either at the level of the HH effector and drug target Smoothened or at the level of the GLI transcription factors does not suffice to initiate a CLL-like phenotype characterized by the accumulation of CD5(+) B cells in the lymphatic system and peripheral blood. Furthermore, Hh/Gli activation in Pten-deficient B cells with activated Pi3K/Akt signaling failed to enhance the expansion of leukemic CD5(+) B cells, suggesting that genetic or epigenetic alterations leading to aberrant HH/GLI signaling in B cells do not suffice to elicit a CLL-like phenotype in mice. By contrast, we identify a critical role of GLI and PI3K signaling for the survival of human primary CLL cells. We show that combined targeting of GLI and PI3K/AKT/mTOR signaling can have a synergistic therapeutic effect in cells from a subgroup of CLL patients, thereby providing a basis for the evaluation of future combination therapies targeting HH/GLI and PI3K signaling in this common hematopoietic malignancy.	[Kern, D.; Regl, G.; Achatz, G.; Schnidar, H.; Aberger, F.] Paris Lodron Univ Salzburg, Dept Mol Biol, Salzburg, Austria; [Hofbauer, S. W.; Altenhofer, P.; Greil, R.; Hartmann, T. N.] Paracelsus Med Univ, Ctr Oncol, Lab Immunol & Mol Canc Res, Med Dept Haematol Med Oncol Haemostaseol Infect D, Salzburg, Austria; [Hofbauer, S. W.; Altenhofer, P.; Greil, R.; Hartmann, T. N.] Salzburg Canc Res Inst, Salzburg, Austria; [Dlugosz, A.] Univ Michigan, Dermatol & Comprehens Canc Ctr, Ann Arbor, MI 48109 USA; [Schnidar, H.] APEIRON Biol AG, Vienna, Austria	Salzburg University; Paracelsus Private Medical University; University of Michigan System; University of Michigan	Aberger, F (corresponding author), Salzburg Univ, Dept Mol Biol, A-5020 Salzburg, Austria.	Fritz.Aberger@sbg.ac.at	Aberger, Fritz/B-6357-2012; Hartmann, Tanja Nicole/AAA-6735-2020; Hartmann, Tanja Nicole/C-9345-2017; Greil, Richard F/C-7673-2017; Hartmann, Tanja Nicole/C-9345-2017	Aberger, Fritz/0000-0003-2009-6305; Hartmann, Tanja Nicole/0000-0002-0377-7179; Hartmann, Tanja Nicole/0000-0002-0377-7179; Greil, Richard F/0000-0002-4462-3694; Hartmann, Tanja Nicole/0000-0002-2633-7301	Austrian Science Fund FWF [W1213, SFB-P021]; Austrian Genome Project GEN-AU; priority program Biosciences and Health of the Paris-Lodron University of Salzburg; SCRI-LIMCR GmbH; province of Salzburg; NATIONAL CANCER INSTITUTE [P30CA046592, R01CA087837] Funding Source: NIH RePORTER	Austrian Science Fund FWF(Austrian Science Fund (FWF)); Austrian Genome Project GEN-AU; priority program Biosciences and Health of the Paris-Lodron University of Salzburg; SCRI-LIMCR GmbH; province of Salzburg; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Professors Tak Mak and Josef Penninger for providing transgenic mouse strains, and Dr Sandrine Tonon and Professor Christoph Binder for help with B-cell analysis. Work of FA has been supported by the Austrian Science Fund FWF (project W1213), the Austrian Genome Project GEN-AU and the priority program Biosciences and Health of the Paris-Lodron University of Salzburg. Work of RG, TNH, SWH and PA was supported by the Austrian Science Fund FWF (SFB-P021 and W1213 to RG), the SCRI-LIMCR GmbH and the province of Salzburg. We dedicate this study to Gernot Achatz who tragically passed away during the course of this study.	Aberger F, 2014, SEMIN CELL DEV BIOL, V33, P93, DOI 10.1016/j.semcdb.2014.05.003; Aberger F, 2012, VITAM HORM, V88, P25, DOI 10.1016/B978-0-12-394622-5.00002-X; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Atwood SX, 2013, NATURE, V494, P484, DOI 10.1038/nature11889; Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; Beauchamp E, 2009, J BIOL CHEM, V284, P9074, DOI 10.1074/jbc.M806233200; Beauchamp EM, 2011, J CLIN INVEST, V121, P148, DOI 10.1172/JCI42874; Bichi R, 2002, P NATL ACAD SCI USA, V99, P6955, DOI 10.1073/pnas.102181599; Brennan D, 2012, VITAM HORM, V88, P55, DOI 10.1016/B978-0-12-394622-5.00003-1; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Brown JR, 2014, BLOOD, V123, P3390, DOI 10.1182/blood-2013-11-535047; Buonamici S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001599; Burger JA, 2009, BLOOD, V114, P3367, DOI 10.1182/blood-2009-06-225326; Corbit KC, 2005, NATURE, V437, P1018, DOI 10.1038/nature04117; Dao KHT, 2013, CLIN CANCER RES, V19, P1309, DOI 10.1158/1078-0432.CCR-12-3934; de Frias M, 2009, HAEMATOL-HEMATOL J, V94, P1698, DOI 10.3324/haematol.2008.004028; Decker S, 2012, BLOOD, V119, P997, DOI 10.1182/blood-2011-06-359075; Dennler S, 2007, CANCER RES, V67, P6981, DOI 10.1158/0008-5472.CAN-07-0491; Desch P, 2010, ONCOGENE, V29, P4885, DOI 10.1038/onc.2010.243; di Magliano MP, 2006, GENE DEV, V20, P3161, DOI 10.1101/gad.1470806; Dierks C, 2008, CANCER CELL, V14, P238, DOI 10.1016/j.ccr.2008.08.003; Dierks C, 2007, NAT MED, V13, P944, DOI 10.1038/nm1614; Eberl M, 2012, EMBO MOL MED, V4, P218, DOI 10.1002/emmm.201100201; Epstein EH, 2008, NAT REV CANCER, V8, P743, DOI 10.1038/nrc2503; Filbin MG, 2013, NAT MED, V19, P1518, DOI 10.1038/nm.3328; Finetti F, 2011, TRENDS IMMUNOL, V32, P139, DOI 10.1016/j.it.2011.02.001; Folkes AJ, 2008, J MED CHEM, V51, P5522, DOI 10.1021/jm800295d; Furman RR, 2014, NEW ENGL J MED, V370, P997, DOI 10.1056/NEJMoa1315226; Gold MR, 2003, TRENDS IMMUNOL, V24, P104, DOI 10.1016/S1471-4906(03)00022-X; Grachtchouk V, 2003, EMBO J, V22, P2741, DOI 10.1093/emboj/cdg271; Gulino A, 2007, PSYCHONEUROENDOCRINO, V32, pS52, DOI 10.1016/j.psyneuen.2007.03.017; Hegde GV, 2008, MOL CANCER RES, V6, P1928, DOI 10.1158/1541-7786.MCR-08-0142; Herman SEM, 2010, BLOOD, V116, P2078, DOI 10.1182/blood-2010-02-271171; Hooper JE, 2005, NAT REV MOL CELL BIO, V6, P306, DOI 10.1038/nrm1622; Huangfu D, 2005, P NATL ACAD SCI USA, V102, P11325, DOI 10.1073/pnas.0505328102; Hui CC, 2011, ANNU REV CELL DEV BI, V27, P513, DOI 10.1146/annurev-cellbio-092910-154048; Ingham PW, 2011, NAT REV GENET, V12, P393, DOI 10.1038/nrg2984; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jeong JH, 2004, GENE DEV, V18, P937, DOI 10.1101/gad.1190304; Ju BS, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-40; Kasper M, 2006, MOL CELL BIOL, V26, P6283, DOI 10.1128/MCB.02317-05; Kasper Maria, 2007, V397, P67; Katagiri S, 2013, CLIN CANCER RES, V19, P1422, DOI 10.1158/1078-0432.CCR-12-1777; Kim JE, 2009, MODERN PATHOL, V22, P1312, DOI 10.1038/modpathol.2009.98; Kim J, 2010, P NATL ACAD SCI USA, V107, P13432, DOI 10.1073/pnas.1006822107; Lauth M, 2007, ONCOGENE, V26, P5163, DOI 10.1038/sj.onc.1210321; Lauth M, 2007, P NATL ACAD SCI USA, V104, P8455, DOI 10.1073/pnas.0609699104; Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017; Mangelberger D, 2012, FRONT BIOSCI-LANDMRK, V17, P90, DOI 10.2741/3917; Mann KK, 2008, MOL CANCER THER, V7, P1680, DOI 10.1158/1535-7163.MCT-07-2164; Merchant A, 2010, BLOOD, V115, P2391, DOI 10.1182/blood-2009-09-241703; Merkel O, 2008, J MOL MED-JMM, V86, P541, DOI 10.1007/s00109-008-0314-6; Nolan-Stevaux O, 2009, GENE DEV, V23, P24, DOI 10.1101/gad.1753809; Peacock CD, 2007, P NATL ACAD SCI USA, V104, P4048, DOI 10.1073/pnas.0611682104; Pelczar P, 2013, GASTROENTEROLOGY, V144, P134, DOI 10.1053/j.gastro.2012.09.061; Pleyer L, 2009, NAT REV CLIN ONCOL, V6, P405, DOI 10.1038/nrclinonc.2009.72; Rickert RC, 1997, NUCLEIC ACIDS RES, V25, P1317, DOI 10.1093/nar/25.6.1317; Riobo NA, 2006, P NATL ACAD SCI USA, V103, P4505, DOI 10.1073/pnas.0504337103; Riobo NA, 2006, CANCER RES, V66, P839, DOI 10.1158/0008-5472.CAN-05-2539; Rohatgi R, 2007, NAT CELL BIOL, V9, P1005, DOI 10.1038/ncb435; Rohatgi R, 2007, SCIENCE, V317, P372, DOI 10.1126/science.1139740; Rudin CM, 2009, NEW ENGL J MED, V361, P1173, DOI 10.1056/NEJMoa0902903; Ruiz I, 2007, TRENDS CELL BIOL, V17, P438, DOI DOI 10.1016/J.TCB.2007.06.007; Scales SJ, 2009, TRENDS PHARMACOL SCI, V30, P303, DOI 10.1016/j.tips.2009.03.007; Schnidar H, 2009, CANCER RES, V69, P1284, DOI 10.1158/0008-5472.CAN-08-2331; Sekulic A, 2012, NEW ENGL J MED, V366, P2171, DOI 10.1056/NEJMoa1113713; Skvara H, 2011, J INVEST DERMATOL, V131, P1735, DOI 10.1038/jid.2011.48; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Stacchini A, 1999, LEUKEMIA RES, V23, P127, DOI 10.1016/S0145-2126(98)00154-4; Stecca B, 2007, P NATL ACAD SCI USA, V104, P5895, DOI 10.1073/pnas.0700776104; Stecca B, 2010, J MOL CELL BIOL, V2, P84, DOI 10.1093/jmcb/mjp052; Stevenson FK, 2011, BLOOD, V118, P4313, DOI 10.1182/blood-2011-06-338855; Suzuki A, 2003, J EXP MED, V197, P657, DOI 10.1084/jem.20021101; Suzuki A, 2001, IMMUNITY, V14, P523, DOI 10.1016/S1074-7613(01)00134-0; Tang JY, 2012, NEW ENGL J MED, V366, P2180, DOI 10.1056/NEJMoa1113538; Teglund S, 2010, BBA-REV CANCER, V1805, P181, DOI 10.1016/j.bbcan.2010.01.003; Tsimberidou AM, 2005, CANCER-AM CANCER SOC, V103, P216, DOI 10.1002/cncr.20773; Von Hoff DD, 2009, NEW ENGL J MED, V361, P1164, DOI 10.1056/NEJMoa0905360; Wang Y, 2012, CANCER CELL, V21, P374, DOI 10.1016/j.ccr.2011.12.028; Wu M, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-36; Xue P, 2011, BIOCHEM BIOPH RES CO, V407, P360, DOI 10.1016/j.bbrc.2011.03.024; Yauch RL, 2009, SCIENCE, V326, P572, DOI 10.1126/science.1179386; Zahreddine HA, 2014, NATURE, V511, P90, DOI 10.1038/nature13283; Zenz T, 2010, NAT REV CANCER, V10, P37, DOI 10.1038/nrc2764; Zhao C, 2009, NATURE, V458, P776, DOI 10.1038/nature07737	85	43	47	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2015	34	42					5341	5351		10.1038/onc.2014.450	http://dx.doi.org/10.1038/onc.2014.450			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EI	25639866	Green Accepted, hybrid, Green Published			2022-12-17	WOS:000363479200004
J	Wang, P; Chen, SH; Hung, WC; Paul, C; Zhu, F; Guan, PP; Huso, DL; Kontrogianni-Konstantopoulos, A; Konstantopoulos, K				Wang, P.; Chen, S-H; Hung, W-C; Paul, C.; Zhu, F.; Guan, P-P; Huso, D. L.; Kontrogianni-Konstantopoulos, A.; Konstantopoulos, K.			Fluid shear promotes chondrosarcoma cell invasion by activating matrix metalloproteinase 12 via IGF-2 and VEGF signaling pathways	ONCOGENE			English	Article							MACROPHAGE METALLOELASTASE MMP-12; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); INTERSTITIAL CONVECTION; ENDOTHELIAL-CELLS; LOCAL RECURRENCE; EXPRESSION; METASTASIS; CHONDROCYTES; STRESS; FLOW	Interstitial fluid flow in and around the tumor tissue is a physiologically relevant mechanical signal that regulates intracellular signaling pathways throughout the tumor. Yet, the effects of interstitial flow and associated fluid shear stress on the tumor cell function have been largely overlooked. Using in vitro bioengineering models in conjunction with molecular cell biology tools, we found that fluid shear (2 dyn/cm(2)) markedly upregulates matrix metalloproteinase 12 (MMP-12) expression and its activity in human chondrosarcoma cells. MMP-12 expression is induced in human chondrocytes during malignant transformation. However, the signaling pathway regulating MMP-12 expression and its potential role in human chondrosarcoma cell invasion and metastasis have yet to be delineated. We discovered that fluid shear stress induces the synthesis of insulin growth factor-2 (IGF-2) and vascular endothelial growth factor (VEGF) B and D, which in turn transactivate MMP-12 via PI3-K, p38 and JNK signaling pathways. IGF-2-, VEGF-B-or VEGF-D-stimulated chondrosarcoma cells display markedly higher migratory and invasive potentials in vitro, which are blocked by inhibiting MMP-12, PI3-K, p38 or JNK activity. Moreover, recombinant human MMP-12 or MMP-12 overexpression can potentiate chondrosarcoma cell invasion in vitro and the lung colonization in vivo. By reconstructing and delineating the signaling pathway regulating MMP-12 activation, potential therapeutic strategies that interfere with chondrosarcoma cell invasion may be identified.	[Wang, P.; Guan, P-P] Northeastern Univ, Coll Life & Hlth Sci, Shenyang 110819, Peoples R China; [Wang, P.; Chen, S-H; Hung, W-C; Paul, C.; Zhu, F.; Guan, P-P; Konstantopoulos, K.] Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA; [Chen, S-H; Konstantopoulos, K.] Johns Hopkins Univ, Johns Hopkins Phys Sci Oncol Ctr, Baltimore, MD 21218 USA; [Hung, W-C; Konstantopoulos, K.] Johns Hopkins Univ, Ctr Canc Nanotechonol Excellence, Baltimore, MD 21218 USA; [Paul, C.; Konstantopoulos, K.] Johns Hopkins Univ, Johns Hopkins Inst NanoBioTechnol, Baltimore, MD 21218 USA; [Huso, D. L.] Johns Hopkins Med Inst, Dept Mol & Comparat Pathobiol, Baltimore, MD 21205 USA; [Huso, D. L.] Johns Hopkins Med Inst, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA; [Kontrogianni-Konstantopoulos, A.] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; [Kontrogianni-Konstantopoulos, A.] Univ Maryland, Sch Med, Marlene & Stewart Greenebaum Natl Canc Inst Canc, Baltimore, MD 21201 USA; [Konstantopoulos, K.] Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21218 USA	Northeastern University - China; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University	Wang, P (corresponding author), Northeastern Univ, Coll Life & Hlth Sci, 3-11 Wenhua Rd, Shenyang 110819, Peoples R China.	wangpu@mail.neu.edu.cn; konstant@jhu.edu			NCI [R01 CA186286, U54 CA143868]; Kleberg Foundation; National Science Foundation [1159823]; Natural Science Foundation of China [31300777]; Fundamental Research Funds of China [N120520001, N120320001, N130120002]; Liaoning Provincial Talent Support Program [LJQ2013029]; NATIONAL CANCER INSTITUTE [P30CA006973, R01CA186286, U54CA143868] Funding Source: NIH RePORTER; Div Of Chem, Bioeng, Env, & Transp Sys [1159823] Funding Source: National Science Foundation	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Kleberg Foundation; National Science Foundation(National Science Foundation (NSF)); Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds of China; Liaoning Provincial Talent Support Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Div Of Chem, Bioeng, Env, & Transp Sys(National Science Foundation (NSF)NSF - Directorate for Engineering (ENG))	This work was supported in part or in whole by the NCI (R01 CA186286, U54 CA143868), the Kleberg Foundation, the National Science Foundation (1159823), the Natural Science Foundation of China (31300777), the Fundamental Research Funds of China (N120520001, N120320001 and N130120002) and the Liaoning Provincial Talent Support Program (LJQ2013029).	Abulencia JP, 2003, J BIOL CHEM, V278, P28388, DOI 10.1074/jbc.M301378200; Aigner T, 2002, CANCER, V94, P2273, DOI 10.1002/cncr.10461; Balzer EM, 2012, FASEB J, V26, P4045, DOI 10.1096/fj.12-211441; Berend KR, 1998, J BONE JOINT SURG AM, V80A, P11, DOI 10.2106/00004623-199801000-00004; Chang SF, 2008, P NATL ACAD SCI USA, V105, P3927, DOI 10.1073/pnas.0712353105; Chao W, 2008, CYTOKINE GROWTH F R, V19, P111, DOI 10.1016/j.cytogfr.2008.01.005; CHARY SR, 1989, P NATL ACAD SCI USA, V86, P5385, DOI 10.1073/pnas.86.14.5385; Chen SH, 2013, SCI REP-UK, V3, DOI 10.1038/srep01870; Cheng P, 2010, DIGEST DIS SCI, V55, P3138, DOI 10.1007/s10620-010-1127-3; Dafni H, 2002, CANCER RES, V62, P6731; Dallas MR, 2012, FASEB J, V26, P2648, DOI 10.1096/fj.12-203786; dela Paz NG, 2012, J CELL SCI, V125, P831, DOI 10.1242/jcs.084301; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; Fritton SP, 2009, ANNU REV FLUID MECH, V41, P347, DOI 10.1146/annurev.fluid.010908.165136; Gunningham SP, 2001, J PATHOL, V193, P325, DOI 10.1002/path.814; Hamamura K, 2008, CELL BIOL INT, V32, P1238, DOI 10.1016/j.cellbi.2008.07.007; Healy ZR, 2008, AM J PHYSIOL-CELL PH, V294, pC1146, DOI 10.1152/ajpcell.00542.2007; Healy ZR, 2005, P NATL ACAD SCI USA, V102, P14010, DOI 10.1073/pnas.0506620102; HILLSLEY MV, 1994, BIOTECHNOL BIOENG, V43, P573, DOI 10.1002/bit.260430706; Hofmann HS, 2005, CLIN CANCER RES, V11, P1086; Houghton AM, 2006, CANCER RES, V66, P6149, DOI 10.1158/0008-5472.CAN-04-0297; Hung WC, 2013, J CELL BIOL, V202, P807, DOI 10.1083/jcb.201302132; Jain RK, 2007, CANCER RES, V67, P2729, DOI 10.1158/0008-5472.CAN-06-4102; Jia HY, 2004, J BIOL CHEM, V279, P36148, DOI 10.1074/jbc.M401538200; Karnezis T, 2012, CANCER CELL, V21, P181, DOI 10.1016/j.ccr.2011.12.026; Kerkela E, 2001, BONE, V29, P487, DOI 10.1016/S8756-3282(01)00595-6; Milkiewicz M, 2001, MICROCIRCULATION, V8, P229, DOI 10.1038/sj.mn.7800074; Orr AW, 2005, J CELL BIOL, V169, P191, DOI 10.1083/jcb.200410073; Ottaviano L, 2010, GENE CHROMOSOME CANC, V49, P40, DOI 10.1002/gcc.20717; Qazi H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020348; Rago C, 2007, CANCER RES, V67, P9364, DOI 10.1158/0008-5472.CAN-07-0605; Rutkowski JM, 2007, TRENDS CELL BIOL, V17, P44, DOI 10.1016/j.tcb.2006.11.007; Salven P, 1998, AM J PATHOL, V153, P103, DOI 10.1016/S0002-9440(10)65550-2; Sarkar S, 2006, CANCER RES, V66, P11771, DOI 10.1158/0008-5472.CAN-05-0470; Soderstrom M, 2001, APMIS, V109, P305, DOI 10.1034/j.1600-0463.2001.d01-125.x; Stroka KM, 2014, CELL, V157, P611, DOI 10.1016/j.cell.2014.02.052; Tang CH, 2012, BIOMEDICINE-TAIWAN, V2, P92, DOI 10.1016/j.biomed.2012.01.001; Tong ZQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029211; Wang P, 2012, J BIOL CHEM, V287, P31877, DOI 10.1074/jbc.M112.362731; Yang W, 2001, CANCER, V91, P1277, DOI 10.1002/1097-0142(20010401)91:7<1277::AID-CNCR1129>3.0.CO;2-H; Yang XS, 2007, PATHOL RES PRACT, V203, P499, DOI 10.1016/j.prp.2007.03.008; Yilmaz A, 2003, BIOCHEM BIOPH RES CO, V306, P730, DOI 10.1016/S0006-291X(03)01064-7; Zhu F, 2010, CELL DEATH DIFFER, V17, P1325, DOI 10.1038/cdd.2010.13	44	43	45	4	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2015	34	35					4558	4569		10.1038/onc.2014.397	http://dx.doi.org/10.1038/onc.2014.397			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BS	25435370	Green Accepted			2022-12-17	WOS:000360189300002
J	Packham, S; Warsito, D; Lin, Y; Sadi, S; Karlsson, R; Sehat, B; Larsson, O				Packham, S.; Warsito, D.; Lin, Y.; Sadi, S.; Karlsson, R.; Sehat, B.; Larsson, O.			Nuclear translocation of IGF-1R via p150(Glued) and an importin-beta/RanBP2-dependent pathway in cancer cells	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; FACTOR-I RECEPTOR; IMPORTIN-BETA; DYNACTIN COMPLEX; EARLY ENDOSOME; TUMOR-CELLS; INSULIN; PROTEIN; TRANSPORT; SUMOYLATION	Mounting evidence has shown that the insulin-like growth factor-1 receptor (IGF-1R) has critical roles in cancer cell growth. This has prompted pharmacological companies to develop agents targeting the receptor. Surprisingly, clinical trials using specific IGF-1R antibodies have, however, revealed disappointing results. Further understanding of the role of IGF-1R in cancer cells is therefore necessary for development of efficient therapeutic strategies. Recently, we showed that IGF-1R is sumoylated and translocated into the cell nucleus where it activates gene transcription. Several other studies have confirmed our findings and it has been reported that nuclear IGF-1R (nIGF-1R) has prognostic and predictive impact in cancer. To increase the understanding of IGF-1R in cancer cells, we here present the first study that proposes a pathway by which IGF-1R translocates into the cell nucleus. We could demonstrate that IGF-1R first associates with the dynactin subunit p150(Glued), which transports the receptor to the nuclear pore complex, where it co-localizes with importin-beta followed by association with RanBP2. Sumoylation of IGF-1R seems to be required for interaction with RanBP2, which in turn may serve as the SUMO E3 ligase. In the context of sumoylation, we provided evidence that it may favor nIGF-1R accumulation by increasing the stability of the receptor. Taken together, topographic and functional interactions between dynactin, importin-beta and RanBP2 are involved in nuclear translocation of IGF-1R. Our results provide new understanding of IGF-1R in cancer, which in turn may contribute to development of new therapeutic strategies.	[Packham, S.; Warsito, D.; Lin, Y.; Sehat, B.; Larsson, O.] Karolinska Inst, Dept Pathol & Oncol, SE-17176 Stockholm, Sweden; [Sadi, S.; Karlsson, R.] Stockholm Univ, Dept Mol Biosci, Wenner Gren Inst, S-10691 Stockholm, Sweden	Karolinska Institutet; Stockholm University	Packham, S (corresponding author), Karolinska Inst, Dept Pathol & Oncol, CCK R8 04, SE-17176 Stockholm, Sweden.	Sylvia.packham@ki.se			Swedish Cancer Foundation; Swedish Research Council; Cancer Society in Stockholm; Swedish Children Cancer Society; Stockholm County Council; Karolinska Institutet	Swedish Cancer Foundation; Swedish Research Council(Swedish Research CouncilEuropean Commission); Cancer Society in Stockholm; Swedish Children Cancer Society(Swedish Cancer Society); Stockholm County Council(Stockholm County Council); Karolinska Institutet(Karolinska Institutet)	This work was supported by the Swedish Cancer Foundation, the Swedish Research Council, the Cancer Society in Stockholm, the Swedish Children Cancer Society, the Stockholm County Council and the Karolinska Institutet.	Aleksic T, 2010, CANCER RES, V70, P6412, DOI 10.1158/0008-5472.CAN-10-0052; Asmane I, 2012, EUR J CANCER, V48, P3027, DOI 10.1016/j.ejca.2012.05.009; BASERGA R, 1995, CANCER RES, V55, P249; Baserga R, 2013, J CELL PHYSIOL, V228, P675, DOI 10.1002/jcp.24217; Ben-Efraim I, 2001, J CELL BIOL, V152, P411, DOI 10.1083/jcb.152.2.411; Bodzin AS, 2012, J CELL PHYSIOL, V227, P2947, DOI 10.1002/jcp.23041; Deacon SW, 2003, J CELL BIOL, V160, P297, DOI 10.1083/jcb.200210066; Deng H, 2011, BIOCHEM BIOPH RES CO, V404, P667, DOI 10.1016/j.bbrc.2010.12.038; Dumas JJ, 2001, MOL CELL, V8, P947, DOI 10.1016/S1097-2765(01)00385-9; Flores-Rodriguez N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024479; Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; Giri DK, 2005, MOL CELL BIOL, V25, P11005, DOI 10.1128/MCB.25.24.11005-11018.2005; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; Hamada M, 2011, J CELL BIOL, V194, P597, DOI 10.1083/jcb.201102018; Hilgarth Roland S., 2005, V301, P329; Hutten S, 2008, MOL BIOL CELL, V19, P2300, DOI 10.1091/mbc.E07-12-1279; Ibarra C, 2013, CIRC RES, V112, P236, DOI 10.1161/CIRCRESAHA.112.273839; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Joseph J, 2004, CURR BIOL, V14, P611, DOI 10.1016/j.cub.2004.03.031; Kazgan N, 2010, MOL BIOL CELL, V21, P3433, DOI 10.1091/mbc.E10-04-0347; Klenk C, 2006, J BIOL CHEM, V281, P8357, DOI 10.1074/jbc.M513703200; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Lo HW, 2006, J CELL BIOCHEM, V98, P1570, DOI 10.1002/jcb.20876; Miyauchi Y, 2002, J BIOL CHEM, V277, P50131, DOI 10.1074/jbc.M208319200; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Ozaki Y, 2011, J BIOL CHEM, V286, P5589, DOI 10.1074/jbc.M110.167742; Palmeri D, 1999, MOL CELL BIOL, V19, P1218; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Pollak M, 2012, NAT REV CANCER, V12, P159, DOI 10.1038/nrc3215; Prisco M, 2002, J BIOL CHEM, V277, P32078, DOI 10.1074/jbc.M204658200; Quintyne NJ, 1999, J CELL BIOL, V147, P321, DOI 10.1083/jcb.147.2.321; Resnicoff M, 1996, J Exp Ther Oncol, V1, P385; Roscioli E, 2012, J CELL BIOL, V196, P435, DOI 10.1083/jcb.201109104; Sarfstein R, 2012, J BIOL CHEM, V287, P2766, DOI 10.1074/jbc.M111.281782; Schroer TA, 2004, ANNU REV CELL DEV BI, V20, P759, DOI 10.1146/annurev.cellbio.20.012103.094623; SCHROER TA, 1991, J CELL BIOL, V115, P1309, DOI 10.1083/jcb.115.5.1309; Sciacca L, 2002, ONCOGENE, V21, P8240, DOI 10.1038/sj.onc.1206058; Sehat B, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000628; Shrum CK, 2009, P NATL ACAD SCI USA, V106, P2647, DOI 10.1073/pnas.0806677106; SKOUFIAS DA, 1992, BIOCHEMISTRY-US, V31, P738, DOI 10.1021/bi00118a015; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; Strom AC, 2001, GENOME BIOL, V2; van Gaal JC, 2013, EUR J CANCER, V49, P3462, DOI 10.1016/j.ejca.2013.06.022; Warsito D, 2012, EMBO REP, V13, P244, DOI 10.1038/embor.2011.251; WATERMANSTORER CM, 1995, P NATL ACAD SCI USA, V92, P1634, DOI 10.1073/pnas.92.5.1634; Wu YC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042483; Yeh TY, 2012, MOL BIOL CELL, V23, P3827, DOI 10.1091/mbc.E12-07-0496; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472; Zhou Y, 2013, J OPTIMIZ THEORY APP, V156, P1, DOI 10.1007/s10957-013-0271-2	51	43	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 23	2015	34	17					2227	2238		10.1038/onc.2014.165	http://dx.doi.org/10.1038/onc.2014.165			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG7HG	24909165				2022-12-17	WOS:000353473000008
J	Ma, H; Zhou, H; Song, X; Shi, S; Zhang, J; Jia, L				Ma, H.; Zhou, H.; Song, X.; Shi, S.; Zhang, J.; Jia, L.			Modification of sialylation is associated with multidrug resistance in human acute myeloid leukemia	ONCOGENE			English	Article						sialylation; MDR; AML; PI3K/Akt signaling; P-gp; MRP1	BREAST-CANCER; SIALYLTRANSFERASE EXPRESSION; P-GLYCOPROTEIN; PATHWAY; CELLS; INHIBITION; ACTIVATION; PROLIFERATION; GLYCOSYLATION; GLYCANS	Aberrant cell surface sialylation patterns have been shown to correlate with tumor progression and metastasis. However, the role of sialylation regulation of cancer multidrug resistance (MDR) remains poorly understood. This study investigated sialylation in modification on MDR in acute myeloid leukemia (AML). Using mass spectrometry (MS) analysis, the composition profiling of sialylated N-glycans differed in three pairs of AML cell lines. Real-time PCR showed the differential expressional profiles of 20 sialyltransferase (ST) genes in the both AML cell lines and bone marrow mononuclear cells (BMMCs) of AML patients. The expression levels of ST3GAL5 and ST8SIA4 were detected, which were overexpressed in HL60 and HL60/adriamycin-resistant (ADR) cells. The altered levels of ST3GAL5 and ST8SIA4 were found in close association with the MDR phenotype changing of HL60 and HL60/ADR cells both in vitro and in vivo. Further data demonstrated that manipulation of these two genes' expression modulated the activity of phosphoinositide-3 kinase (PI3K)/Akt signaling pathway and its downstream target thus regulated the proportionally mutative expression of P-glycoprotein (P-gp) and MDR-related protein 1 (MRP1), both of which are known to be involved in MDR. Blocking the PI3K/Akt pathway by its specific inhibitor LY294002 or by Akt small interfering RNA resulted in the reduced chemosensitivity of HL60/ADR cells. Therefore, this study indicated that sialylation involved in the development of MDR of AML cells probably through ST3GAL5 or ST8SIA4 regulating the activity of PI3K/Akt signaling and the expression of P-gp and MRP1.	[Ma, H.; Shi, S.; Jia, L.] Dalian Med Univ, Coll Lab Med, Dept Med Basic Lab, Dalian 116044, Liaoning, Peoples R China; [Zhou, H.] Dalian Med Univ, Dept Microbiol, Dalian 116044, Liaoning, Peoples R China; [Song, X.] Univ Tromso, Fac Hlth Sci, Dept Med Biol, Tromso, Norway; [Zhang, J.] Dalian Med Univ, Inst Glycobiol, Dept Biochem, Dalian 116044, Liaoning, Peoples R China; [Zhang, J.] Dalian Univ Technol, Sch Life Sci & Med, Dept Biochem, Panjin, Peoples R China	Dalian Medical University; Dalian Medical University; UiT The Arctic University of Tromso; Dalian Medical University; Dalian University of Technology	Jia, L (corresponding author), Dalian Med Univ, Coll Lab Med, Dept Med Basic Lab, 9 Lvshunnan Rd Xiduan, Dalian 116044, Liaoning, Peoples R China.	jiali@dlmedu.edu.cn	li, jia/GVT-7587-2022; Jia, li/GPW-8015-2022		National Key Basic Research and Development Program (973 program) of China [2012CB822100]; National Natural Science Foundation of China [81271910]; Project for Liaoning BaiQianWan Talents Program [2012921014]	National Key Basic Research and Development Program (973 program) of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Project for Liaoning BaiQianWan Talents Program	This work was supported by grants from National Key Basic Research and Development Program (973 program) of China (no. 2012CB822100), from National Natural Science Foundation of China (81271910), and supported by Project for Liaoning BaiQianWan Talents Program (2012921014).	Abdul-Ghani R, 2006, ONCOGENE, V25, P1743, DOI 10.1038/sj.onc.1209201; Badura S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080070; Barancik M, 2006, EUR J PHARM SCI, V29, P426, DOI 10.1016/j.ejps.2006.08.006; Bellacosa A, 2005, ADV CANCER RES, V94, P29, DOI 10.1016/S0065-230X(05)94002-5; Billottet C, 2009, CANCER RES, V69, P1027, DOI 10.1158/0008-5472.CAN-08-2608; Deschler B, 2006, CANCER-AM CANCER SOC, V107, P2099, DOI 10.1002/cncr.22233; Dobbin ZC, 2013, INT J MOL SCI, V14, P8213, DOI 10.3390/ijms14048213; Domon B, 2006, SCIENCE, V312, P212, DOI 10.1126/science.1124619; Dwek RA, 1996, CHEM REV, V96, P683, DOI 10.1021/cr940283b; Garcia MG, 2009, LEUKEMIA RES, V33, P288, DOI 10.1016/j.leukres.2008.06.010; Harvey DJ, 2005, EXPERT REV PROTEOMIC, V2, P87, DOI 10.1586/14789450.2.1.87; Hebbar M, 2003, INT J BIOL MARKER, V18, P116, DOI 10.1177/172460080301800204; Ishihara T, 2011, J PROTEOMICS, V74, P2159, DOI 10.1016/j.jprot.2011.06.010; Kim YJ, 1996, BIOCHEM BIOPH RES CO, V228, P324, DOI 10.1006/bbrc.1996.1660; Kourti M, 2007, INT J HEMATOL, V86, P166, DOI 10.1532/IJH97.E0624; Martelli AM, 2006, LEUKEMIA, V20, P911, DOI 10.1038/sj.leu.2404245; Martersteck CM, 1996, GLYCOBIOLOGY, V6, P289, DOI 10.1093/glycob/6.3.289; Mirkin BL, 2002, CELL PROLIFERAT, V35, P105, DOI 10.1046/j.1365-2184.2002.00228.x; Miyagi T, 2003, GLYCOCONJUGATE J, V20, P189, DOI 10.1023/B:GLYC.0000024250.48506.bf; Mondal S, 2010, LEUKEMIA RES, V34, P463, DOI 10.1016/j.leukres.2009.07.042; Morishita N, 2012, PEDIATR BLOOD CANCER, V59, P83, DOI 10.1002/pbc.24034; Nakano M, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.009001; Nakayama J, 2006, METHOD ENZYMOL, V416, P120, DOI 10.1016/S0076-6879(06)16008-5; Neiiendam JL, 2004, J NEUROCHEM, V91, P920, DOI 10.1111/j.1471-4159.2004.02779.x; Parasrampuria Ridhi, 2011, Drug Metab Lett, V5, P64, DOI 10.2174/187231211794455244; Perez-Garay M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012524; Recchi MA, 1998, CANCER RES, V58, P4066; Russo RIC, 2008, INT J CANCER, V122, P1012, DOI 10.1002/ijc.23122; Schauer R, 2000, GLYCOCONJUGATE J, V17, P485, DOI 10.1023/A:1011062223612; Sewell R, 2006, J BIOL CHEM, V281, P3586, DOI 10.1074/jbc.M511826200; Su H., 2009, MOL CELL BIOCHEM, V331, P81, DOI DOI 10.1007/s11010-009-0147-9; Tang W, 2004, MOL BIOL CELL, V15, P4043, DOI 10.1091/mbc.E04-05-0402; Tazzari PL, 2007, LEUKEMIA, V21, P427, DOI 10.1038/sj.leu.2404523; Van Der Kolk DM, 2002, LEUKEMIA LYMPHOMA, V43, P685, DOI 10.1080/10428190290016773; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Varki NM, 2007, LAB INVEST, V87, P851, DOI 10.1038/labinvest.3700656; Wang XQ, 2003, J BIOL CHEM, V278, P48770, DOI 10.1074/jbc.M308818200; Yamada K, 2012, ANAL BIOCHEM, V421, P595, DOI 10.1016/j.ab.2011.12.017; Yu SC, 2011, MEDCHEMCOMM, V2, P524, DOI 10.1039/c1md00033k; Zhang ZH, 2012, INT J BIOCHEM CELL B, V44, P1244, DOI 10.1016/j.biocel.2012.04.026; Zhou H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.186; Zhu YT, 2001, BBA-MOL BASIS DIS, V1536, P148, DOI 10.1016/S0925-4439(01)00044-8	42	43	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2015	34	6					726	740		10.1038/onc.2014.7	http://dx.doi.org/10.1038/onc.2014.7			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DG	24531716	Green Submitted			2022-12-17	WOS:000348853800006
J	Petrova, E; Matevossian, A; Resh, MD				Petrova, E.; Matevossian, A.; Resh, M. D.			Hedgehog acyltransferase as a target in pancreatic ductal adenocarcinoma	ONCOGENE			English	Article						hedgehog; palmitoylation; pancreatic cancer	SONIC-HEDGEHOG; SIGNALING PATHWAY; CANCER; PALMITOYLATION; PROTEIN; CELLS; IDENTIFICATION; TUMORIGENESIS; REQUIREMENT; MECHANISMS	Sonic Hedgehog (Shh) is abnormally expressed in pancreatic cancer and is associated with disease onset and progression. Inhibition of Shh signaling is thus an attractive clinical target for therapeutic intervention. Most efforts to block Shh signaling have focused on inhibitors of Smoothened, which target the canonical Shh signaling pathway. These approaches have met with limited success, in part due to development of resistance-conferring mutations and contributions from non-canonical signaling pathways. Here, we show that Hedgehog acyltransferase (Hhat), the enzyme responsible for the attachment of palmitate onto Shh, is a novel target for inhibition of Shh signaling in pancreatic cancer cells. Depletion of Hhat with lentivirally delivered small hairpin RNA decreased both anchorage-dependent and independent proliferation of human pancreatic cancer cells. In vivo, Hhat knockdown led to reduction of tumor growth in a mouse xenograft model of pancreatic cancer. RU-SKI 43, a small molecule inhibitor of Hhat recently developed by our group, reduced pancreatic cancer cell proliferation and Gli-1 activation through Smoothened-independent non-canonical signaling. In addition, RU-SKI 43 treatment inhibited two key proliferative pathways regulated by Akt and mTOR. This work demonstrates that Hhat has a critical role in pancreatic cancer and that a small molecule inhibitor of Hhat can successfully block pancreatic cancer cell proliferation. It also highlights the importance of developing optimized Hhat inhibitors to be used as therapeutics in pancreatic cancer, as well as in other malignancies characterized by Shh overexpression.	[Petrova, E.; Matevossian, A.; Resh, M. D.] Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; [Petrova, E.] Cornell Univ, Weill Grad Sch Med Sci, Grad Program Pharmacol, New York, NY 10021 USA; [Matevossian, A.; Resh, M. D.] Gerstner Sloan Kettering Grad Sch Biomed Sci, New York, NY USA; [Resh, M. D.] Cornell Univ, Weill Grad Sch Med Sci, Grad Program Cell Biol, New York, NY 10021 USA; [Resh, M. D.] Cornell Univ, Weill Grad Sch Med Sci, Grad Program Biochem, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Cornell University	Resh, MD (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave,Box 143, New York, NY 10021 USA.	reshm@mskcc.org		Resh, Marilyn/0000-0001-6118-9466	NIH [GM57966, CA158474]; MSKCC Cycle for Survival; Geoffrey Beene Cancer Research Foundation; Commonwealth Foundation for Cancer Research; Experimental Therapeutics Center of Memorial Sloan-Kettering Cancer Center; NATIONAL CANCER INSTITUTE [R21CA186957, P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057966] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MSKCC Cycle for Survival; Geoffrey Beene Cancer Research Foundation; Commonwealth Foundation for Cancer Research; Experimental Therapeutics Center of Memorial Sloan-Kettering Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Raisa Louft-Nisenbaum for technical assistance, Dr Elisa de Stanchina for performing tumor xenograft studies, Dr Nian Wu for pharmacokinetic analyses, the MSKCC Genomics and Molecular Cytology Cores, and Jessica Rios-Esteves and Rayshonda Hardy for reading the manuscript. This work was supported by NIH grants GM57966 and CA158474, by MSKCC Cycle for Survival, by the Geoffrey Beene Cancer Research Foundation, by Mr William H Goodwin and Mrs Alice Goodwin and by the Commonwealth Foundation for Cancer Research and the Experimental Therapeutics Center of Memorial Sloan-Kettering Cancer Center.	Barakat MT, 2010, TRENDS MOL MED, V16, P337, DOI 10.1016/j.molmed.2010.05.003; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Buglino JA, 2008, J BIOL CHEM, V283, P22076, DOI 10.1074/jbc.M803901200; Buglino JA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011195; Chen MH, 2004, GENE DEV, V18, P641, DOI 10.1101/gad.1185804; Chinchilla P, 2010, CELL CYCLE, V9, P570, DOI 10.4161/cc.9.3.10591; Dawber RJ, 2005, BMC DEV BIOL, V5, DOI 10.1186/1471-213X-5-21; Hardy RY, 2012, J BIOL CHEM, V287, P42881, DOI 10.1074/jbc.M112.426833; Jiang J, 2008, DEV CELL, V15, P801, DOI 10.1016/j.devcel.2008.11.010; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Lum L, 2004, SCIENCE, V304, P1755, DOI 10.1126/science.1098020; Mann RK, 2004, ANNU REV BIOCHEM, V73, P891, DOI 10.1146/annurev.biochem.73.011303.073933; Metcalfe C, 2011, CANCER RES, V71, P5057, DOI 10.1158/0008-5472.CAN-11-0923; Miura GI, 2006, DEV CELL, V10, P167, DOI 10.1016/j.devcel.2005.11.017; Morton JP, 2007, P NATL ACAD SCI USA, V104, P5103, DOI 10.1073/pnas.0701158104; Nolan-Stevaux O, 2009, GENE DEV, V23, P24, DOI 10.1101/gad.1753809; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Pan SF, 2010, ACS MED CHEM LETT, V1, P130, DOI 10.1021/ml1000307; Petrova E, 2013, NAT CHEM BIOL, V9, P247, DOI [10.1038/NCHEMBIO.1184, 10.1038/nchembio.1184]; Peukert S, 2010, CHEMMEDCHEM, V5, P500, DOI 10.1002/cmdc.201000011; Rodriguez-Blanco J, 2013, ONCOGENE, V32, P2335, DOI 10.1038/onc.2012.243; Rubin LL, 2006, NAT REV DRUG DISCOV, V5, P1026, DOI 10.1038/nrd2086; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Skvara H, 2011, J INVEST DERMATOL, V131, P1735, DOI 10.1038/jid.2011.48; Testaz S, 2001, P NATL ACAD SCI USA, V98, P12521, DOI 10.1073/pnas.221108698; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Tian H, 2009, P NATL ACAD SCI USA, V106, P4254, DOI 10.1073/pnas.0813203106; Wu X, 2004, CHEM BIOL, V11, P1229, DOI 10.1016/j.chembiol.2004.06.010; Yauch RL, 2008, NATURE, V455, P406, DOI 10.1038/nature07275	29	43	47	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2015	34	2					263	268		10.1038/onc.2013.575	http://dx.doi.org/10.1038/onc.2013.575			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AY8FS	24469057	Green Accepted			2022-12-17	WOS:000347790500014
J	Chen, WT; Zhu, G; Pfaffenbach, K; Kanel, G; Stiles, B; Lee, AS				Chen, W-T; Zhu, G.; Pfaffenbach, K.; Kanel, G.; Stiles, B.; Lee, A. S.			GRP78 as a regulator of liver steatosis and cancer progression mediated by loss of the tumor suppressor PTEN	ONCOGENE			English	Article						liver cancer; PTEN; GRP78; genetic model; steatosis; signaling pathway	UNFOLDED PROTEIN RESPONSE; KNOCKOUT; RECEPTOR; STRESS; GROWTH; CELLS; HEPATOCYTES; HOMEOSTASIS; ACTIVATION; PATHWAYS	Glucose-regulated protein 78 (GRP78), a molecular chaperone widely elevated in human cancers, is critical for endoplasmic reticulum (ER) protein folding, stress signaling and PI3K/AKT activation. Genetic knockout models of GRP78 revealed that GRP78 maintains homeostasis of metabolic organs, including liver, pancreas and adipose tissues. Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) are the most common liver cancers. There is a lack of effective therapeutics for HCC and CC, highlighting the need to further understand liver tumorigenic mechanisms. PTEN (phosphatase and tenson homolog deleted on chromosome 10), a tumor suppressor that antagonizes the PI3K/AKT pathway, is inactivated in a wide range of tumors, including 40-50% of human liver cancers. To elucidate the role of GRP78 in liver cancer, we created a mouse model with biallelic liver-specific deletion of Pten and Grp78 mediated by Albumin-Cre-recombinase (cP(f/f)78(f/f)). Interestingly, in contrast to PTEN, deletion of GRP78 was progressive but incomplete. At 3 months, cP(f/f)78(f/f) livers showed hepatomegaly, activation of lipogenic genes, exacerbated steatosis and liver injury, implying that GRP78 protects the liver against PTEN-null-mediated pathogenesis. Furthermore, in response to liver injury, we observed increased proliferation and expansion of bile duct and liver progenitor cells in cP(f/f)78(f/f) livers. Strikingly, bile duct cells in cP(f/f)78(f/f) livers maintained wild-type (WT) GRP78 level, whereas adjacent areas showed GRP78 reduction. Analysis of signaling pathways revealed selective JNK activation, beta-catenin downregulation, along with PDGFR alpha upregulation, which was unique to cP(f/f)78(f/f) livers at 6 months. Development of both HCC and CC was accelerated and was evident in cP(f/f)78(f/f) livers at 8-9 months, coinciding with intense GRP78 expression in the cancer lesions, and GRP78 expression in adjacent normal areas reverted back to the WT level. In contrast, c78(f/f) livers showed no malignancy even at 14 months. These studies reveal that GRP78 is a novel regulator for PTEN-loss-mediated liver injury and cancer progression.	[Chen, W-T; Zhu, G.; Lee, A. S.] Univ So Calif, Keck Sch Med, USC Norris Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; [Pfaffenbach, K.] Eastern Oregon Univ, Dept Biol, La Grande, OR USA; [Kanel, G.] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90089 USA; [Stiles, B.] Univ So Calif, Sch Pharm, Dept Pharmacol & Pharmaceut Sci, Los Angeles, CA 90089 USA	University of Southern California; Eastern Oregon University; University of Southern California; University of Southern California	Lee, AS (corresponding author), Univ So Calif, Keck Sch Med, USC Norris Comprehens Canc Ctr, Dept Biochem & Mol Biol, 1441 Eastlake Ave,Room 5308, Los Angeles, CA 90089 USA.	amylee@ccnt.usc.edu	Zhu, Genyuan/R-8142-2016		NCI [P30 CA014089]; Tissue Imaging Core Facility of the USC Research Center for Liver Diseases [P30 DK048522]; National Institutes of Health [R01 CA027607, P01 AG034906]; NATIONAL CANCER INSTITUTE [R01CA154986, P30CA014089, R01CA027607] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK075928, P30DK048522, R01DK084241] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG034906] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Tissue Imaging Core Facility of the USC Research Center for Liver Diseases; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We like to thank Dr Louis Dubeau and members of the Lee laboratory for their helpful discussions and Dr Chengyu Liang for the gift of antibodies. We also like to thank the USC Norris Comprehensive Cancer Center Cell and Tissue Imaging and Translational Pathology Core Facilities supported by NCI grant P30 CA014089 for histology and the Tissue Imaging Core Facility of the USC Research Center for Liver Diseases (P30 DK048522) for microscopy. This work was supported in part by funding from the National Institutes of Health (R01 CA027607 and P01 AG034906) to ASL.	Behari J, 2010, AM J PATHOL, V176, P744, DOI 10.2353/ajpath.2010.090667; DESMET V, 1995, PATHOL RES PRACT, V191, P513, DOI 10.1016/S0344-0338(11)80870-8; Ding Wen-Xing, 2010, World J Biol Chem, V1, P3, DOI 10.4331/wjbc.v1.i1.3; Fu Y, 2008, P NATL ACAD SCI USA, V105, P19444, DOI 10.1073/pnas.0807691105; Galicia VA, 2010, GASTROENTEROLOGY, V139, P2170, DOI 10.1053/j.gastro.2010.09.002; Gonzalez-Gronow M, 2009, ANTIOXID REDOX SIGN, V11, P2299, DOI [10.1089/ars.2009.2568, 10.1089/ARS.2009.2568]; Heijmans J, 2013, CELL REP, V3, P1128, DOI 10.1016/j.celrep.2013.02.031; Hendershot LM, 2004, MT SINAI J MED, V71, P289; Hensel F, 2013, MELANOMA RES, V23, P264, DOI 10.1097/CMR.0b013e328362cbc8; Ji C, 2011, HEPATOLOGY, V54, P229, DOI 10.1002/hep.24368; Lee AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008-5472.CAN-07-0325; Lee AH, 2008, SCIENCE, V320, P1492, DOI 10.1126/science.1158042; Liu R, CLIN CANC RES; Luk JM, 2006, PROTEOMICS, V6, P1049, DOI 10.1002/pmic.200500306; Luo B, 2013, ONCOGENE, V32, P805, DOI 10.1038/onc.2012.130; Luo BQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020364; Luo SZ, 2006, MOL CELL BIOL, V26, P5688, DOI 10.1128/MCB.00779-06; Michalopoulos GK, 2005, HEPATOLOGY, V41, P535, DOI 10.1002/hep.20600; Nakagawa Hayato, 2012, Patholog Res Int, V2012, P172894, DOI 10.1155/2012/172894; Nejak-Bowen KN, 2011, SEMIN CANCER BIOL, V21, P44, DOI 10.1016/j.semcancer.2010.12.010; Ni M, 2007, FEBS LETT, V581, P3641, DOI 10.1016/j.febslet.2007.04.045; Ni M, 2011, BIOCHEM J, V434, P181, DOI 10.1042/BJ20101569; Ni M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006868; Nikolaou K, 2013, CLIN CANCER RES, V19, P2810, DOI 10.1158/1078-0432.CCR-12-1961; Pfaffenbach KT, 2011, CURR OPIN CELL BIOL, V23, P150, DOI 10.1016/j.ceb.2010.09.007; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Roskams T, 2006, ONCOGENE, V25, P3818, DOI 10.1038/sj.onc.1209558; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Stiles B, 2004, P NATL ACAD SCI USA, V101, P2082, DOI 10.1073/pnas.0308617100; Stock P, 2007, MOL CANCER THER, V6, P1932, DOI 10.1158/1535-7163.MCT-06-0720; Su RJ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-20; Tanaka M, 2011, J BIOCHEM, V149, P231, DOI 10.1093/jb/mvr001; Thompson MD, 2011, HEPATOLOGY, V54, P1333, DOI 10.1002/hep.24506; Wang CX, 2010, CELL RES, V20, P174, DOI 10.1038/cr.2010.4; Wang C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055981; Wang M, 2010, CELL DEATH DIFFER, V17, P488, DOI 10.1038/cdd.2009.144; Wey S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039047; Wey S, 2012, BLOOD, V119, P817, DOI 10.1182/blood-2011-06-357384; Whittaker S, 2010, ONCOGENE, V29, P4989, DOI 10.1038/onc.2010.236; Ye RS, 2010, AM J PATHOL, V177, P2827, DOI 10.2353/ajpath.2010.100368; Ye RS, 2010, DIABETES, V59, P6, DOI 10.2337/db09-0755; Zeng N, 2011, MOL CANCER RES, V9, P1708, DOI 10.1158/1541-7786.MCR-11-0299; Zhang XF, 2010, HEPATOLOGY, V52, P954, DOI 10.1002/hep.23747; Zhu GY, 2013, FASEB J, V27, P955, DOI 10.1096/fj.12-213330	45	43	49	2	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2014	33	42					4997	5005		10.1038/onc.2013.437	http://dx.doi.org/10.1038/onc.2013.437			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OB		Green Accepted			2022-12-17	WOS:000343768000004
J	Yu, H; Liu, T; Zhao, Z; Chen, Y; Zeng, J; Liu, S; Zhu, F				Yu, H.; Liu, T.; Zhao, Z.; Chen, Y.; Zeng, J.; Liu, S.; Zhu, F.			Mutations in 3 '-long terminal repeat of HERV-W family in chromosome 7 upregulate syncytin-1 expression in urothelial cell carcinoma of the bladder through interacting with c-Myb	ONCOGENE			English	Article						urothelial cell carcinoma of the bladder; syncytin-1; human endogenous retrovirus; long terminal repeat; c-Myb	MARROW-DERIVED CELLS; HUMAN BREAST-CANCER; MOLECULAR-DYNAMICS; ENDOGENOUS RETROVIRUSES; HUMAN TISSUES; IN-VITRO; PROTEIN; FUSION; GENE; TRANSFORMATION	Human endogenous retrovirus (HERV) accounts for similar to 8% of the human genome. Recent studies have reported that multiple HERV genes and long terminal repeats (LTRs) are involved in human tumorigenesis. Here we demonstrated that HERV-W env (syncytin-1) was overexpressed in 75.6% (62/82) of urothelial cell carcinoma (UCC) tissues of the bladder compared with only 6.1% (5/82) of matched tumor-adjacent tissues (P<0.001). Syncytin-1 overexpression increased proliferation and viability of immortalized human uroepithelial cells. Colony-formation experiments and in-vivo tumor xenografts suggested that syncytin-1 overexpression had oncogenic potential. Syncytin-1 3'-LTR mutations (142T>C and 277A>G) were present in 87.8% (72/82) of UCC tissues. Normal 3'-LTR was found in 12.2% (10/82) of UCC tissues compared with 95.1% (78/82) of matched tumor-adjacent tissues (P<0.001). Interestingly, 3'-LTR mutations were significantly associated with syncytin-1 overexpression. Luciferase assay and expression analysis revealed that 3'-LTR mutations, especially the 142T>C mutation, enhanced the syncytin-1 promoter activity and expression. In-silico analysis, electrophoretic mobility shift assays and chromatin immunoprecipitation assays demonstrated the binding of c-Myb to 3'-LTRs when the mutations occurred. This alternative interaction was found to be dependent on 142T>C mutation. C-Myb activated syncytin-1 promoter activity and expression by binding to mutant 3'-LTRs. Taken together, these data indicate that syncytin-1 overexpression may be an indicator of UCC risk. The 3'-LTR mutations may upregulate syncytin-1 expression, enabling it to participate in UCC tumorigenesis and development by interacting with c-Myb.	[Yu, H.; Chen, Y.; Zeng, J.; Zhu, F.] Wuhan Univ, Sch Med, Dept Med Microbiol, Wuhan 430071, Peoples R China; [Liu, T.; Liu, S.] Beijing Inst Basic Med Sci, State Key Lab Prote, Dept Neurobiol, Beijing, Peoples R China; [Zhao, Z.] Wuhan Univ, Zhongnan Hosp, Dept Urol, Wuhan, Peoples R China	Wuhan University; Academy of Military Medical Sciences - China; Wuhan University	Zhu, F (corresponding author), Wuhan Univ, Sch Med, Dept Med Microbiol, 185 Donghu Rd, Wuhan 430071, Peoples R China.	zhufan@hotmail.com	; Liu, Tao/C-7796-2011	Yu, Honglian/0000-0003-3915-056X; zhu, fan/0000-0001-7031-2956; Liu, Tao/0000-0003-1701-6618	National Natural Sciences Foundation of China [81271820, 30870789, 30300117]; Stanley Foundation from the Stanley Medical Research Institute (SMRI), USA [06R-1366]; Hubei Provincial Natural Science Foundation for Innovative Research Team [2012FFA043]; Wuhan University [274041]	National Natural Sciences Foundation of China(National Natural Science Foundation of China (NSFC)); Stanley Foundation from the Stanley Medical Research Institute (SMRI), USA; Hubei Provincial Natural Science Foundation for Innovative Research Team; Wuhan University	We thank Wei Jin (Fudan University, Shanghai, China) for providing the plasmid pCMV-c-Myb. We would like to thank Don Banting, Awadhesh Kumar Sah and Navin Shrestha for polishing our writing. This work was supported by grants from the National Natural Sciences Foundation of China (No. 81271820, No. 30870789 and No. 30300117), the Stanley Foundation from the Stanley Medical Research Institute (SMRI), USA (No. 06R-1366) for Dr F Zhu, Hubei Provincial Natural Science Foundation for Innovative Research Team (No. 2012FFA043) and the project of Innovative Research Team of Wuhan University (No. 274041).	Ahn K, 2009, MOL CELLS, V28, P99, DOI 10.1007/s10059-009-0107-y; Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Bjerregaard B, 2006, CELL MOL LIFE SCI, V63, P1906, DOI 10.1007/s00018-006-6201-9; Boese A, 2000, ONCOGENE, V19, P4328, DOI 10.1038/sj.onc.1203794; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CHRISTIAN BJ, 1987, CANCER RES, V47, P6066; Chung KY, 2005, J CLIN ONCOL, V23, P1803, DOI 10.1200/JCO.2005.08.037; Delidaki M, 2011, MOL CELL ENDOCRINOL, V332, P213, DOI 10.1016/j.mce.2010.10.013; Doern CD, 2008, MICROBIOL-SGM, V154, P1998, DOI 10.1099/mic.0.2007/013466-0; Eble JN, 2004, PATHOLOGY GENETICS T; Edge S. B., 2010, AJCC CANC STAGING MA, P291; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Feng WJN, 2007, INT J CANCER, V120, P81, DOI 10.1002/ijc.22256; Frendo JL, 2003, MOL CELL BIOL, V23, P3566, DOI 10.1128/MCB.23.10.3566-3574.2003; Gimenez J, 2010, NUCLEIC ACIDS RES, V38, P2229, DOI 10.1093/nar/gkp1214; Huang WJ, 2011, SCHIZOPHRENIA BULL, V37, P988, DOI 10.1093/schbul/sbp166; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Joshi R, 2007, CELL, V131, P530, DOI 10.1016/j.cell.2007.09.024; KERBEL RS, 1983, MOL CELL BIOL, V3, P523, DOI 10.1128/MCB.3.4.523; Knerr I, 2007, APOPTOSIS, V12, P37, DOI 10.1007/s10495-006-0329-9; Lamprecht B, 2010, NAT MED, V16, P571, DOI 10.1038/nm.2129; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Landry JR, 2002, GENOMICS, V80, P499, DOI 10.1006/geno.2002.6863; Liu F, 2006, ONCOGENE, V25, P795, DOI 10.1038/sj.onc.1209105; Lu X, 2011, ADV EXP MED BIOL, V714, P129, DOI 10.1007/978-94-007-0782-5_6; Lu X, 2009, CANCER RES, V69, P8536, DOI 10.1158/0008-5472.CAN-09-2159; LUTY BA, 1994, MOL SIMULAT, V14, P11, DOI 10.1080/08927029408022004; Mackerell AD, 2004, J COMPUT CHEM, V25, P1400, DOI 10.1002/jcc.20065; Mallet F, 2004, P NATL ACAD SCI USA, V101, P1731, DOI 10.1073/pnas.0305763101; Nellaker C, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-44; Okamoto M, 1996, CANCER RES, V56, P4649; Perron H, 2012, MULT SCLER J, V18, P1721, DOI 10.1177/1352458512441381; Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289; Prudhomme S, 2004, J VIROL, V78, P12157, DOI 10.1128/JVI.78.22.12157-12168.2004; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; Ramsay RG, 2008, NAT REV CANCER, V8, P523, DOI 10.1038/nrc2439; Rizvi AZ, 2006, P NATL ACAD SCI USA, V103, P6321, DOI 10.1073/pnas.0508593103; Romanish MT, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030010; ROSZELL JA, 1977, CANCER RES, V37, P239; Ruprecht K, 2008, CELL MOL LIFE SCI, V65, P3366, DOI 10.1007/s00018-008-8496-1; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schubert SW, 2008, NUCLEIC ACIDS RES, V36, P3834, DOI 10.1093/nar/gkn306; Sin HS, 2006, ARCH VIROL, V151, P1985, DOI 10.1007/s00705-006-0764-5; Stauffer Yves, 2004, Cancer Immun, V4, P2; Strick R, 2007, J MOL MED, V85, P23, DOI 10.1007/s00109-006-0104-y; Tahirov TH, 2002, CELL, V108, P57, DOI 10.1016/S0092-8674(01)00636-5; Wang-Johanning F, 2003, ONCOGENE, V22, P1528, DOI 10.1038/sj.onc.1206241; Wang-Johanning F, 2001, CLIN CANCER RES, V7, P1553; Wei W, 2006, CANCER LETT, V244, P119, DOI 10.1016/j.canlet.2005.12.008; Xiao X, 2010, CURR CANCER DRUG TAR, V10, P384, DOI 10.2174/156800910791208535; Yu CC, 2002, J BIOL CHEM, V277, P50062, DOI 10.1074/jbc.M209316200; Zhao Jing, 2011, Genes Cancer, V2, P914, DOI 10.1177/1947601911431841; Zhu F, 2005, BIOCHEMISTRY-MOSCOW+, V70, P920, DOI 10.1007/s10541-005-0203-3	53	43	44	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2014	33	30					3947	3958		10.1038/onc.2013.366	http://dx.doi.org/10.1038/onc.2013.366			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8NA	24013223				2022-12-17	WOS:000339394700007
J	Wang, C; Li, Y; Zhang, H; Liu, F; Cheng, Z; Wang, D; Wang, G; Xu, H; Zhao, Y; Cao, L; Li, F				Wang, C.; Li, Y.; Zhang, H.; Liu, F.; Cheng, Z.; Wang, D.; Wang, G.; Xu, H.; Zhao, Y.; Cao, L.; Li, F.			Oncogenic PAK4 regulates Smad2/3 axis involving gastric tumorigenesis	ONCOGENE			English	Article						PAK4; TGF-beta; Smad2; Smad3; gastric cancer	GROWTH-FACTOR-BETA; TGF-BETA; TRANSCRIPTIONAL REPRESSION; SIGNALING PATHWAY; DOWN-REGULATION; C-MYC; CANCER; CELLS; PHOSPHORYLATION; PROLIFERATION	The alteration of p21-activated kinase 4 (PAK4) and transforming growth factor-beta (TGF-beta) signaling effector Smad2/3 was detected in several types of tumors, which acts as oncogenic factor and tumor suppressor, but the relationship between these events has not been explored. Here, we demonstrate that PAK4 interacts with and modulates phosphorylation of Smad2/3 via both kinase-dependent and kinase-independent mechanisms, which attenuate Smad2/3 axis transactivation and TGF-beta-mediated growth inhibition in gastric cancer cells. First, PAK4 interaction with Smad2/3, which is independent of PAK4 kinase activity, blocks TGF-beta-induced phosphorylation of Smad2 Ser465/467 or Smad3 Ser4231425 and the consequent activation. In addition, PAK4 phosphorylates Smad2 on Ser465, leading to the degradation of Smad2 through ubiquitin-proteasome-dependent pathway under hepatocyte growth factor (HGF) stimulation. Interestingly, PAK4 expression correlates negatively with phospho-Ser465/467 Smad2 but positively with phospho-Ser465 Smad2 in gastric cancer tissues. Furthermore, the expressions of HGF, phospho-Ser474 PAK4 and phospho-Ser465 Smad2 are markedly increased in gastric cancer tissues, and the expression of Smad2 is decreased in gastric cancer tissues. Our results document an oncogenic role of PAK4 in repression of Smad2/3 transactivation that involved in tumorigenesis, and suggest PAK4 as a potential therapeutic target for gastric cancer.	[Wang, C.; Li, Y.; Zhang, H.; Cheng, Z.; Wang, D.; Wang, G.; Zhao, Y.; Cao, L.; Li, F.] China Med Univ, Minist Publ Hlth, Key Lab Cell Biol, Dept Cell Biol, Shenyang 110001, Peoples R China; [Wang, C.; Li, Y.; Zhang, H.; Cheng, Z.; Wang, D.; Wang, G.; Zhao, Y.; Cao, L.; Li, F.] China Med Univ, Minist Educ, Key Lab Med Cell Biol, Shenyang 110001, Peoples R China; [Liu, F.; Xu, H.] China Med Univ, Hosp 1, Dept Surg Oncol, Shenyang 110001, Peoples R China	China Medical University; China Medical University; China Medical University	Li, F (corresponding author), China Med Univ, Minist Publ Hlth, Key Lab Cell Biol, Dept Cell Biol, 92 Beier Rd, Shenyang 110001, Peoples R China.	fli@mail.cmu.edu.cn		Li, Feng/0000-0001-5868-7456; Wang, Guiling/0000-0001-7304-1610	National Natural Science Foundation of China [90813038, 31171360, 81001092, 31171259, 30900752]; Ministry of Education of China [20102104110016]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Education of China(Ministry of Education, China)	We thank Azeddine Atfi, Isabelle VAN SEUNINGEN, Koichi Shimada, Susumu Itoh, Bert Vogelstein and Carl-Henrik Heldin, Masa-Aki Ikeda and Cobb MH for providing the plasmids. This work was supported by grants from the National Natural Science Foundation of China (90813038, 31171360, 81001092, 31171259 and 30900752) and Doctoral fund of Ministry of Education of China (No. 20102104110016).	Achyut BR, 2011, GASTROENTEROLOGY, V141, P1167, DOI 10.1053/j.gastro.2011.07.048; Ahn HK, 2011, TRANSL ONCOL, V4, P345, DOI 10.1593/tlo.11145; Bauer J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039381; Baughn LB, 2009, J IMMUNOL, V182, P1810, DOI 10.4049/jimmunol.0713726; BERCHUCK A, 1989, CANCER RES, V49, P2091; Callow MG, 2002, J BIOL CHEM, V277, P550, DOI 10.1074/jbc.M105732200; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Dai CS, 2004, J AM SOC NEPHROL, V15, P1402, DOI 10.1097/01.ASN.0000130568.53923.FD; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Drabsch Y, 2012, CANCER METAST REV, V31, P553, DOI 10.1007/s10555-012-9375-7; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Eswaran J, 2009, CANCER METAST REV, V28, P209, DOI 10.1007/s10555-008-9181-4; Frederick JP, 2004, MOL CELL BIOL, V24, P2546, DOI 10.1128/MCB.24.6.2546-2559.2004; Gnesutta N, 2003, MOL CELL BIOL, V23, P7838, DOI 10.1128/MCB.23.21.7838-7848.2003; Gnesutta N, 2001, J BIOL CHEM, V276, P14414, DOI 10.1074/jbc.M011046200; Guo W, 2012, MOL BIOL REP, V39, P9453, DOI 10.1007/s11033-012-1810-x; Han SU, 2004, ONCOGENE, V23, P1333, DOI 10.1038/sj.onc.1207259; Herszenyi L, 2010, EUR REV MED PHARMACO, V14, P249; Ijichi H, 2001, BIOCHEM BIOPH RES CO, V289, P350, DOI 10.1006/bbrc.2001.5988; Itoh S, 2011, GROWTH FACTORS, V29, P163, DOI 10.3109/08977194.2011.614236; Jonckheere N, 2004, ONCOGENE, V23, P5729, DOI 10.1038/sj.onc.1207769; Kimmelman AC, 2008, P NATL ACAD SCI USA, V105, P19372, DOI 10.1073/pnas.0809966105; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892; Lee BH, 2007, J BIOL CHEM, V282, P17985, DOI 10.1074/jbc.M702664200; Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200; Li XD, 2010, EXPERT OPIN THER TAR, V14, P419, DOI 10.1517/14728221003642019; Li XD, 2010, INT J BIOCHEM CELL B, V42, P70, DOI 10.1016/j.biocel.2009.09.008; Li Y, 2012, BBA-MOL CELL RES, V1823, P465, DOI 10.1016/j.bbamcr.2011.11.013; Li Ze, 2008, Zhonghua Zhongliu Zazhi, V30, P30; Liu FN, 2009, INT J CANCER, V125, P2511, DOI 10.1002/ijc.24588; Liu T, 2010, BIOCHEM J, V430, P191, DOI 10.1042/BJ20100427; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Minden Audrey, 2012, Cell Logist, V2, P95; Mori S, 2004, ONCOGENE, V23, P7416, DOI 10.1038/sj.onc.1207981; Noda D, 2006, ONCOGENE, V25, P5591, DOI 10.1038/sj.onc.1209571; Orian A, 2001, Sci STKE, V2001, ppe1; Shimada K, 2008, BONE, V42, P886, DOI 10.1016/j.bone.2008.01.009; Shitara Y, 1999, JPN J CLIN ONCOL, V29, P3, DOI 10.1093/jjco/29.1.3; Shukla MN, 2009, AM J RESP CELL MOL, V40, P643, DOI 10.1165/rcmb.2008-0217OC; Siu MKY, 2010, P NATL ACAD SCI USA, V107, P18622, DOI 10.1073/pnas.0907481107; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Suganuma T, 2002, P NATL ACAD SCI USA, V99, P13073, DOI 10.1073/pnas.192586699; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; Wells CM, 2010, J CELL SCI, V123, P1663, DOI 10.1242/jcs.055707; Wells CM, 2002, J CELL SCI, V115, P3947, DOI 10.1242/jcs.00080; Wrighton KH, 2009, CELL RES, V19, P8, DOI 10.1038/cr.2008.327; Wu WKK, 2010, CANCER LETT, V295, P144, DOI 10.1016/j.canlet.2010.04.025; Wu YJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035684; Yan XH, 2012, J BIOL CHEM, V287, P13705, DOI 10.1074/jbc.M112.346221; Yang L, 2008, CANCER RES, V68, P9107, DOI 10.1158/0008-5472.CAN-08-2556; Zhang HJ, 2011, CARCINOGENESIS, V32, P765, DOI 10.1093/carcin/bgr033; Zhang J, 2012, CANCER LETT, V317, P24, DOI 10.1016/j.canlet.2011.11.007	56	43	44	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2014	33	26					3473	3484		10.1038/onc.2013.300	http://dx.doi.org/10.1038/onc.2013.300			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK9WM	23934187				2022-12-17	WOS:000338779300014
J	Ieguchi, K; Tomita, T; Omori, T; Komatsu, A; Deguchi, A; Masuda, J; Duffy, SL; Coulthard, MG; Boyd, A; Maru, Y				Ieguchi, K.; Tomita, T.; Omori, T.; Komatsu, A.; Deguchi, A.; Masuda, J.; Duffy, S. L.; Coulthard, M. G.; Boyd, A.; Maru, Y.			ADAM12-cleaved ephrin-A1 contributes to lung metastasis	ONCOGENE			English	Article						Eph; tyrosine kinase; cell adhesion; permeability	EPH RECEPTORS; TYROSINE KINASE; CELL-PROLIFERATION; TUMOR-CELLS; ADAM12; CANCER; EXPRESSION; LIGAND; MIGRATION; BINDING	Eph receptor tyrosine kinases and their ephrin ligands have been implicated in neuronal development and neovascularization. Overexpression of ephrin-A1 has been implicated in tumor progression and poor prognosis. However, the mechanisms are not clear. Here, we report a role of the Eph/ephrin system in a cell adhesion mechanism. Clustered erythropoietin-producing hepatocellular receptor A1 ( EphA1)/ephrin-A1 complexes on the plasma membrane did not undergo endocytosis, and the cell remained adherent to one another. The cell-cell contacts were maintained in an Eph tyrosine kinase activity-independent manner even in the absence of E-cadherin. EphA1 and ephrin-A1 co-localized in pulmonary endothelial cells, and regulated vascular permeability and metastasis in the lungs. We identified ADAM12 ( A disintegrin and metalloproteinase 12) as an EphA1-binding partner by yeast two-hybrid screening and found that ADAM12 enhanced ephrin-A1 cleavage in response to transforming growth factor-b1 in primary tumors. Released soluble ephrin-A1 in the serum deteriorated the EphA1/ephrin-A1-mediated cell adhesion in the lungs in an endocrine manner, causing lung hyperpermeability that facilitated tumor cell entry into the lungs. Depletion of soluble ephrin-A1 by its neutralizing antibody significantly inhibited lung metastasis.	[Ieguchi, K.; Tomita, T.; Omori, T.; Komatsu, A.; Deguchi, A.; Masuda, J.; Maru, Y.] Tokyo Womens Med Univ, Dept Pharmacol, Tokyo 1828666, Japan; [Duffy, S. L.] Inst Curie, CNRS, UMR 144, Lab Morphogenese & Signalisat Cellulaires, F-75231 Paris, France; [Coulthard, M. G.; Boyd, A.] Queensland Inst Med Res, Leukemia Fdn Res Lab, Brisbane, Qld 4006, Australia	Tokyo Women's Medical University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Universite Paris Cite	Maru, Y (corresponding author), Tokyo Womens Med Univ, Dept Pharmacol, 8-1 Kawadacho, Tokyo 1828666, Japan.	ymaru@research.twmu.ac.jp	Coulthard, Mark G/AAT-7735-2021; Coulthard, Mark Graeme/E-9444-2010	Coulthard, Mark G/0000-0001-7400-5582; Coulthard, Mark Graeme/0000-0001-7400-5582; Tomita, Takeshi/0000-0001-6815-2244	Ministry of Education, Culture, Sports, Science and Technology of Japan [21117008, 23590347, 25122716, 25870760]; Global COE program, Multidisciplinary Education and Research Center for Regenerative Medicine from Japan	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Global COE program, Multidisciplinary Education and Research Center for Regenerative Medicine from Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank Dr Yoichiro Iwakura at the University of Tokyo for providing EphA2-KO mice, Dr Ulla Wewer at the University of Copenhagen for providing human ADAM12 cDNA clones and Ms. Helen Jeays at the Queensland Institute of Medical Research for proofreading. This work was supported by grant-in-aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan, grant nos. 21117008 (to YM), 23590347 (to TT), 25122716 and 25870760 (to KI), and the Global COE program, Multidisciplinary Education and Research Center for Regenerative Medicine from Japan.	Aasheim HC, 2005, BLOOD, V105, P2869, DOI 10.1182/blood-2004-08-2981; Alford S, 2010, CANCER CELL INT, V10, DOI 10.1186/1475-2867-10-41; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Atfi A, 2007, J CELL BIOL, V178, P201, DOI 10.1083/jcb.200612046; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; Beauchamp A, 2012, MOL CELL BIOL, V32, P3253, DOI 10.1128/MCB.06791-11; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Brantley-Sieders DM, 2006, CANCER RES, V66, P10315, DOI 10.1158/0008-5472.CAN-06-1560; Brantley-Sieders DM, 2005, FASEB J, V19, P1884, DOI 10.1096/fj.05-4038fje; Brantley-Sieders DM, 2004, J CELL SCI, V117, P2037, DOI 10.1242/jcs.01061; Carpenter TC, 2012, AM J RESP CELL MOL, V46, P40, DOI 10.1165/rcmb.2011-0044OC; Davy A, 2000, EMBO J, V19, P5396, DOI 10.1093/emboj/19.20.5396; Davy A, 1999, GENE DEV, V13, P3125, DOI 10.1101/gad.13.23.3125; Dodelet VC, 2000, ONCOGENE, V19, P5614, DOI 10.1038/sj.onc.1203856; Duffy SL, 2008, GENESIS, V46, P553, DOI 10.1002/dvg.20434; Egea J, 2007, TRENDS CELL BIOL, V17, P230, DOI 10.1016/j.tcb.2007.03.004; Frohlich C, 2011, MOL CANCER RES, V9, P1449, DOI 10.1158/1541-7786.MCR-11-0100; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Gilpin BJ, 1998, J BIOL CHEM, V273, P157, DOI 10.1074/jbc.273.1.157; Hafner C, 2004, CLIN CHEM, V50, P490, DOI 10.1373/clinchem.2003.026849; Hattori M, 2000, SCIENCE, V289, P1360, DOI 10.1126/science.289.5483.1360; Hiratsuka S, 2008, NAT CELL BIOL, V10, P1349, DOI 10.1038/ncb1794; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Hiratsuka S, 2011, P NATL ACAD SCI USA, V108, P3725, DOI 10.1073/pnas.1100446108; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; Ieguchi K, 2007, J BIOL CHEM, V282, P23296, DOI 10.1074/jbc.M700950200; Ieguchi K, 2010, J BIOL CHEM, V285, P31388, DOI 10.1074/jbc.M110.113878; Janes PW, 2005, CELL, V123, P291, DOI 10.1016/j.cell.2005.08.014; Kodama T, 2004, AM J PATHOL, V165, P1743, DOI 10.1016/S0002-9440(10)63429-3; Larson J, 2008, AM J PHYSIOL-LUNG C, V295, pL431, DOI 10.1152/ajplung.90256.2008; Le Pabic H, 2003, HEPATOLOGY, V37, P1056, DOI 10.1053/jhep.2003.50205; Lu X, 2011, CANCER CELL, V20, P701, DOI 10.1016/j.ccr.2011.11.002; Masuda J, 2008, J BIOL CHEM, V283, P13148, DOI 10.1074/jbc.M702164200; Miao H, 2009, CANCER CELL, V16, P9, DOI 10.1016/j.ccr.2009.04.009; Mochizuki S, 2007, CANCER SCI, V98, P621, DOI 10.1111/j.1349-7006.2007.00434.x; Naruse-Nakajima C, 2001, MECH DEVELOP, V102, P95, DOI 10.1016/S0925-4773(01)00290-8; O'Leary DDM, 1999, CURR OPIN NEUROBIOL, V9, P65, DOI 10.1016/S0959-4388(99)80008-7; Okazaki T, 2009, AM J PATHOL, V174, P2388, DOI 10.2353/ajpath.2009.080949; Orsulic S, 2000, J CELL SCI, V113, P1793; Pasquale EB, 2010, NAT REV CANCER, V10, P165, DOI 10.1038/nrc2806; Roy R, 2004, J BIOL CHEM, V279, P51323, DOI 10.1074/jbc.M409565200; Shiomi T, 2003, CANCER METAST REV, V22, P145, DOI 10.1023/A:1023039230052; Sundberg C, 2004, J BIOL CHEM, V279, P51601, DOI 10.1074/jbc.M403753200; Tanaka M, 2005, J BIOL CHEM, V280, P42375, DOI 10.1074/jbc.M503786200; Vihanto MM, 2005, FASEB J, V19, P1689, DOI 10.1096/fj.04-3647fje; Wykosky J, 2008, ONCOGENE, V27, P7260, DOI 10.1038/onc.2008.328; Wykosky J, 2008, MOL CANCER RES, V6, P1795, DOI 10.1158/1541-7786.MCR-08-0244; Yamazaki T, 2009, J CELL SCI, V122, P243, DOI 10.1242/jcs.036467; Yoon S, 2012, ONCOGENE, V31, P3467, DOI 10.1038/onc.2011.517	50	43	44	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2014	33	17					2179	2190		10.1038/onc.2013.180	http://dx.doi.org/10.1038/onc.2013.180			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF8WJ	23686306				2022-12-17	WOS:000334996000004
J	Okochi-Takada, E; Hattori, N; Tsukamoto, T; Miyamoto, K; Ando, T; Ito, S; Yamamura, Y; Wakabayashi, M; Nobeyama, Y; Ushijima, T				Okochi-Takada, E.; Hattori, N.; Tsukamoto, T.; Miyamoto, K.; Ando, T.; Ito, S.; Yamamura, Y.; Wakabayashi, M.; Nobeyama, Y.; Ushijima, T.			ANGPTL4 is a secreted tumor suppressor that inhibits angiogenesis	ONCOGENE			English	Article						epigenetics; angiogenesis; tumor suppressor; gastric cancer; DNA methylation	ANGIOPOIETIN-LIKE 4; ISLAND METHYLATOR PHENOTYPE; VASCULAR-PERMEABILITY; EPIGENETIC FIELD; DNA METHYLATION; FREQUENT LOSS; PROTEINS; CANCER; 19P13.3; GENES	Tumor suppressors with extracellular function are likely to have advantages as targets for cancer therapy, but few are known. Here, we focused on angiopoietin-like 4 (ANGPTL4), which is a secreted glycoprotein involved in lipoprotein metabolism and angiogenesis, is methylation-silenced in human cancers, but has unclear roles in cancer development and progression. We found a deletion mutation in its coiled-coil domain at its N-terminal in human gastric cancers, in addition to hypermethylation of the ANGPTL4 promoter CpG islands. Forced expression of wild-type ANGPTL4, but not ANGPTL4 with the deletion, at physiological levels markedly suppressed in vivo tumorigenicity and tumor angiogenesis, indicating that the latter caused the former. Tumor-derived ANGPTL4 suppressed in vitro vascular tube formation and proliferation of human umbilical vascular endothelial cells, partly due to suppression of ERK signaling. These showed that ANGPTL4 is a genetically and epigenetically inactivated secreted tumor suppressor that inhibits tumor angiogenesis.	[Okochi-Takada, E.; Hattori, N.; Ando, T.; Wakabayashi, M.; Nobeyama, Y.; Ushijima, T.] Natl Canc Ctr, Div Epigen, Tokyo 1040045, Japan; [Tsukamoto, T.] Aichi Canc Ctr, Res Inst, Oncol Pathol Div, Nagoya, Aichi 464, Japan; [Miyamoto, K.] Natl Hosp Org, Kure Med Ctr, Div Mol Oncol, Kureshi, Japan; [Miyamoto, K.] Chugoku Canc Ctr, Kureshi, Japan; [Ando, T.] Toyama Univ, Dept Internal Med 3, Toyama 930, Japan; [Ito, S.; Yamamura, Y.] Aichi Canc Ctr, Cent Hosp, Dept Surg Gastroenterol, Nagoya, Aichi 464, Japan; [Nobeyama, Y.] Jikei Univ, Sch Med, Dept Dermatol, Tokyo, Japan	National Cancer Center - Japan; Aichi Cancer Center; University of Toyama; Aichi Cancer Center; Jikei University	Ushijima, T (corresponding author), Natl Canc Ctr, Div Epigen, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	tushijim@ncc.go.jp	Tsukamoto, Tetsuya/ABD-4397-2020; Ushijima, Toshikazu/AAP-5742-2021	Tsukamoto, Tetsuya/0000-0002-7502-8724; Ushijima, Toshikazu/0000-0003-3405-7817; Hattori, Naoko/0000-0002-0901-4869	Third-term Comprehensive Cancer Control Strategy from the Ministry of Health, Labour and Welfare, Japan; National Cancer Center Research and Development Fund; Research Resident Fellowships from the Foundation for Promotion of Cancer Research	Third-term Comprehensive Cancer Control Strategy from the Ministry of Health, Labour and Welfare, Japan; National Cancer Center Research and Development Fund(National Cancer Center - Japan); Research Resident Fellowships from the Foundation for Promotion of Cancer Research	We are grateful to Dr Masabumi Shibuya, Tokyo Medical and Dental University, for his expert advice. This study was supported by the Third-term Comprehensive Cancer Control Strategy from the Ministry of Health, Labour and Welfare, Japan and by National Cancer Center Research and Development Fund. YN is a recipient of a Research Resident Fellowships from the Foundation for Promotion of Cancer Research.	Ando T, 2009, INT J CANCER, V124, P2367, DOI 10.1002/ijc.24219; Asada K, 2013, ONCOGENE, V32, P2140, DOI 10.1038/onc.2012.228; Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; Chomel C, 2009, FASEB J, V23, P940, DOI 10.1096/fj.08-115170; Enomoto S, 2007, CANCER SCI, V98, P1853, DOI 10.1111/j.1349-7006.2007.00625.x; Galaup A, 2006, P NATL ACAD SCI USA, V103, P18721, DOI 10.1073/pnas.0609025103; Ge HF, 2004, J BIOL CHEM, V279, P2038, DOI 10.1074/jbc.M307583200; Hato T, 2008, TRENDS CARDIOVAS MED, V18, P6, DOI 10.1016/j.tcm.2007.10.003; Hattori N, 2011, CANCER SCI, V102, P1337, DOI 10.1111/j.1349-7006.2011.01955.x; Hermann LM, 2005, CLIN IMMUNOL, V115, P93, DOI 10.1016/j.clim.2004.12.002; Hoglund M, 1998, GENE CHROMOSOME CANC, V21, P8; Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507; Ito Y, 2003, CANCER RES, V63, P6651; Kaneda A, 2002, CANCER RES, V62, P6645; Kishore R, 2007, J MOL CELL CARDIOL, V42, P461, DOI 10.1016/j.yjmcc.2006.11.012; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Lane DP, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001222; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Li KQ, 2004, CHINESE MED J-PEKING, V117, P1364; Ma T, 2010, P NATL ACAD SCI USA, V107, P14363, DOI 10.1073/pnas.1001065107; Mei R, 2000, GENOME RES, V10, P1126, DOI 10.1101/gr.10.8.1126; Miida T, 2010, CURR OPIN LIPIDOL, V21, P70, DOI 10.1097/MOL.0b013e328333269e; Nakayama T, 2010, ONCOL REP, V24, P599, DOI 10.3892/or_00000897; Oike Y, 2005, TRENDS MOL MED, V11, P473, DOI 10.1016/j.molmed.2005.08.002; Ota N, 2006, ANTICANCER RES, V26, P3729; Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046; Shi Y, 2007, ACTA PHARMACOL SIN, V28, P1499, DOI 10.1111/j.1745-7254.2007.00692.x; Sobottka SB, 2000, J NEURO-ONCOL, V49, P187, DOI 10.1023/A:1006442024874; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Tanner JE, 2004, MOL CANCER RES, V2, P281; Trojan J, 2000, GUT, V47, P272, DOI 10.1136/gut.47.2.272; Ushijima T, 2007, J BIOCHEM MOL BIOL, V40, P142; Yang YH, 2008, ARTERIOSCL THROM VAS, V28, P835, DOI 10.1161/ATVBAHA.107.157776; Yin W, 2009, J BIOL CHEM, V284, P13213, DOI 10.1074/jbc.M900553200; Zhu HB, 2004, ONCOGENE, V23, P4984, DOI 10.1038/sj.onc.1207645; Zhu PC, 2011, CANCER CELL, V19, P401, DOI 10.1016/j.ccr.2011.01.018	36	43	44	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2014	33	17					2273	2278		10.1038/onc.2013.174	http://dx.doi.org/10.1038/onc.2013.174			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF8WJ	23686315				2022-12-17	WOS:000334996000013
J	Sheu, JJC; Lee, CC; Hua, CH; Li, CI; Lai, MT; Lee, SC; Cheng, J; Chen, CM; Chan, C; Chao, SCC; Chen, JY; Chang, JY; Lee, CH				Sheu, J. J-C; Lee, C-C; Hua, C-H; Li, C-I; Lai, M-T; Lee, S-C; Cheng, J.; Chen, C-M; Chan, C.; Chao, S. C-C; Chen, J-Y; Chang, J-Y; Lee, C-H			LRIG1 modulates aggressiveness of head and neck cancers by regulating EGFR-MAPK-SPHK1 signaling and extracellular matrix remodeling	ONCOGENE			English	Article						LRIG1; head and neck cancers; EGFR; MAPK; SPHK1; ECM remodeling	GROWTH-FACTOR RECEPTOR; SQUAMOUS-CELL CARCINOMA; NASOPHARYNGEAL CARCINOMA; NEGATIVE REGULATOR; BREAST-CANCER; SPHINGOSINE 1-PHOSPHATE; MESENCHYMAL TRANSITION; TUMOR PROGRESSION; GENE-EXPRESSION; ACTIVATION	EGFR overexpression and chromosome 3p deletion are two frequent events in head and neck cancers. We previously mapped the smallest region of recurrent copy-number loss at 3p12.2-p14.1. LRIG1, a negative regulator of EGFR, was found at 3p14, and its copy-number loss correlated with poor clinical outcome. Inducible expression of LRIG1 in head and neck cancer TW01 cells, a line with low LRIG1 levels, suppressed cell proliferation in vitro and tumor growth in vivo. Gene expression profiling, quantitative RT-PCR, chromatin immunoprecipitation, and western blot analysis demonstrated that LRIG1 modulated extracellular matrix (ECM) remodeling and EGFR-MAPK-SPHK1 transduction pathway by suppressing expression of EGFR ligands/activators, MMPs and SPHK1. In addition, LRIG1 induction triggered cell morphology changes and integrin inactivation, which coupled with reduced SNAI2 expression. By contrast, knockdown of endogenous LRIG1 in TW06 cells, a line with normal LRIG1 levels, significantly enhanced cell proliferation, migration and invasiveness. Such tumor-promoting effects could be abolished by specific MAPK or SPHK1 inhibitors. Our data suggest LRIG1 as a tumor suppressor for head and neck cancers; LRIG1 downregulation in cancer cells enhances EGFR-MAPK-SPHK1 signaling and ECM remodeling activity, leading to malignant phenotypes of head and neck cancers.	[Sheu, J. J-C; Cheng, J.; Chen, C-M; Chan, C.; Chao, S. C-C] China Med Univ Hosp, Ctr Human Genet, Taichung, Taiwan; [Sheu, J. J-C] China Med Univ, Sch Chinese Med, Taichung, Taiwan; [Sheu, J. J-C] Asia Univ, Dept Hlth & Nutr Biotechnol, Taichung, Taiwan; [Lee, C-C; Li, C-I; Chen, J-Y; Chang, J-Y; Lee, C-H] Natl Inst Canc Res, Natl Hlth Res Inst, Zhunan Town 35053, Taiwan; [Hua, C-H] China Med Univ Hosp, Dept Otolaryngol, Taichung, Taiwan; [Lai, M-T] Chung Shan Med Univ Hosp, Dept Pathol, Taichung, Taiwan; [Lai, M-T] Chung Shan Med Univ, Sch Med, Taichung, Taiwan; [Lee, S-C] Chung Shan Med Univ, Coll Med Sci & Technol, Taichung, Taiwan	China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; Asia University Taiwan; National Health Research Institutes - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; Chung Shan Medical University; Chung Shan Medical University Hospital; Chung Shan Medical University; Chung Shan Medical University	Lee, CH (corresponding author), Natl Inst Canc Res, Natl Hlth Res Inst, R2,R1211,Keyan Rd, Zhunan Town 35053, Taiwan.	jimsheu@mail.cmu.edu.tw; chlee124@nhri.org.tw	Chen, Jen-Yang/D-2085-2010; Lee, Chia-Huei/B-1063-2010; Chang, Jang-Yang/D-2099-2010	Lee, Shan-Chih/0000-0001-6583-1575; Cheng, Jack/0000-0002-9305-0781; Lee, Chia-Huei/0000-0002-8847-3288	National Science Council, Taiwan [NSC99-2320-B-400-009, NSC100-2325-B-400-014, NSC101-2320-B-039-006]; National Health Research Institutes, Taiwan [CA-101-PP-01]; China Medical University Hospital, Taiwan [DMR99-047]; Department of Health, Taiwan [DOH101-TD-C-111-004, DOH101-TD-C-111-005]	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); National Health Research Institutes, Taiwan(National Health Research Institutes - Taiwan); China Medical University Hospital, Taiwan; Department of Health, Taiwan	We thank Dr Mien-Chie Hung (MD Anderson Cancer Center, TX, USA) and Dr Yosef Yarden (Weizmann Institute, Israel) for their critical comments on this study, which was supported by grants from the National Science Council, Taiwan (NSC99-2320-B-400-009, NSC100-2325-B-400-014, NSC101-2320-B-039-006 and NSC101-2320-B-039-006), the National Health Research Institutes, Taiwan (CA-101-PP-01), China Medical University Hospital, Taiwan (DMR99-047), and the Department of Health, Taiwan (DOH101-TD-C-111-004 and DOH101-TD-C-111-005).	Abhold EL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032459; Burtness B, 2005, EXPERT OPIN BIOL TH, V5, P1085, DOI 10.1517/14712598.5.8.1085; Chang H, 2002, CELL COMMUN ADHES, V9, P239, DOI 10.1080/15419060216303; Chang SJ, 2007, J ENDOCRINOL, V193, P393, DOI 10.1677/JOE-06-0168; Chevronnay HPG, 2012, BBA-PROTEINS PROTEOM, V1824, P146, DOI 10.1016/j.bbapap.2011.09.003; Fang CY, 2009, INT J CANCER, V124, P2016, DOI 10.1002/ijc.24179; Goldoni S, 2007, ONCOGENE, V26, P368, DOI 10.1038/sj.onc.1209803; Gur G, 2004, EMBO J, V23, P3270, DOI 10.1038/sj.emboj.7600342; Hedman H, 2002, ACTA ONCOL, V41, P352, DOI 10.1080/028418602760169398; Hedman H, 2007, EUR J CANCER, V43, P676, DOI 10.1016/j.ejca.2006.10.021; Huang ZX, 2004, GENE CHROMOSOME CANC, V40, P307, DOI 10.1002/gcc.20036; Jensen KB, 2008, CANCER LETT, V272, P23, DOI 10.1016/j.canlet.2008.06.014; Jensen KB, 2009, CELL STEM CELL, V4, P427, DOI 10.1016/j.stem.2009.04.014; Jin YS, 2005, CANCER GENET CYTOGEN, V156, P1, DOI 10.1016/j.cancergencyto.2004.04.023; Koy S, 2008, HEAD NECK-J SCI SPEC, V30, P1105, DOI 10.1002/hed.20857; Krig SR, 2011, MOL CANCER RES, V9, P1406, DOI 10.1158/1541-7786.MCR-11-0227; Laederich MB, 2004, J BIOL CHEM, V279, P47050, DOI 10.1074/jbc.M409703200; Ledda F, 2008, J NEUROSCI, V28, P39, DOI 10.1523/JNEUROSCI.2196-07.2008; LIN CT, 1990, LAB INVEST, V62, P713; Lindstrom AK, 2008, INT J GYNECOL CANCER, V18, P312, DOI 10.1111/j.1525-1438.2007.01021.x; Ljuslinder I, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2248; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Ma BBT, 2003, HEAD NECK-J SCI SPEC, V25, P864, DOI 10.1002/hed.10307; Maseki S, 2012, BRIT J CANCER, V106, P1196, DOI 10.1038/bjc.2012.24; Milara J, 2012, THORAX, V67, P147, DOI 10.1136/thoraxjnl-2011-200026; Miller JK, 2008, CANCER RES, V68, P8286, DOI 10.1158/0008-5472.CAN-07-6316; Munger JS, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005017; Ordonez-Moran P, 2012, EMBO J, V31, P2064, DOI 10.1038/emboj.2012.73; Pai SI, 2009, ANNU REV PATHOL-MECH, V4, P49, DOI 10.1146/annurev.pathol.4.110807.092158; Pitson SM, 2003, EMBO J, V22, P5491, DOI 10.1093/emboj/cdg540; Powell AE, 2012, CELL, V149, P146, DOI 10.1016/j.cell.2012.02.042; Pyne NJ, 2012, BIOCHEM SOC T, V40, P94, DOI 10.1042/BST20110602; Pyne NJ, 2010, NAT REV CANCER, V10, P489, DOI 10.1038/nrc2875; Pyne S, 2011, CANCER RES, V71, P6576, DOI 10.1158/0008-5472.CAN-11-2364; Radisky ES, 2010, J MAMMARY GLAND BIOL, V15, P201, DOI 10.1007/s10911-010-9177-x; Ruan L, 2011, PROTEOME SCI, V9, DOI 10.1186/1477-5956-9-35; Shattuck DL, 2007, MOL CELL BIOL, V27, P1934, DOI 10.1128/MCB.00757-06; Sheu JJC, 2009, CANCER EPIDEM BIOMAR, V18, P2709, DOI 10.1158/1055-9965.EPI-09-0349; Sheu JJC, 2009, CANCER RES, V69, P2568, DOI 10.1158/0008-5472.CAN-08-3199; Shida D, 2004, FEBS LETT, V577, P333, DOI 10.1016/j.febslet.2004.10.024; Shida D, 2008, CURR DRUG TARGETS, V9, P662, DOI 10.2174/138945008785132402; Song WM, 2000, DEV BIOL, V227, P606, DOI 10.1006/dbio.2000.9919; Stutz MA, 2008, ONCOGENE, V27, P5741, DOI 10.1038/onc.2008.185; Thomasson M, 2003, BRIT J CANCER, V89, P1285, DOI 10.1038/sj.bjc.6601208; Watt FM, 2009, EMBO MOL MED, V1, P260, DOI 10.1002/emmm.200900033; Wong VWY, 2012, NAT CELL BIOL, V14, P401, DOI 10.1038/ncb2464; Ye F, 2009, J NEURO-ONCOL, V94, P183, DOI 10.1007/s11060-009-9836-1; Yi W, 2011, EXP CELL RES, V317, P504, DOI 10.1016/j.yexcr.2010.11.005	48	43	43	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2014	33	11					1375	1384		10.1038/onc.2013.98	http://dx.doi.org/10.1038/onc.2013.98			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD0SD	23624915				2022-12-17	WOS:000332943500005
J	Wen, W; Peng, C; Kim, MO; Jeong, CH; Zhu, F; Yao, K; Zykova, T; Ma, W; Carper, A; Langfald, A; Bode, AM; Dong, Z				Wen, W.; Peng, C.; Kim, M. O.; Jeong, C. Ho; Zhu, F.; Yao, K.; Zykova, T.; Ma, W.; Carper, A.; Langfald, A.; Bode, A. M.; Dong, Z.			Knockdown of RNF2 induces apoptosis by regulating MDM2 and p53 stability	ONCOGENE			English	Article						RNF2; PcG; p53; MDM2; ubiquitination	DEVELOPMENTAL REGULATORS; POLYCOMB COMPLEXES; CELL-PROLIFERATION; BREAST-CANCER; EZH2; ENHANCER; BMI-1; METHYLATION; PROTEINS; TARGET	RNF2, also known as Ring1B/Ring2, is a component of the polycomb repression complex 1. RNF2 is highly expressed in many tumors, suggesting that it might have an oncogenic function, but the mechanism is unknown. Here, we show that knockdown of RNF2 significantly inhibits both cell proliferation and colony formation in soft agar, and induces apoptosis in cancer cells. Knockdown of RNF2 in HCT116 p53(+/+) cells resulted in significantly more apoptosis than was observed in RNF2 knockdown HCT116 p53(-/-) cells, indicating that RNF2 knockdown-induced apoptosis is partially dependent on p53. Various p53-targeted genes were increased in RNF2 knockdown cells. Further studies revealed that in RNF2 knockdown cells, the p53 protein level was increased, the half-life of p53 was prolonged and p53 ubiquitination was decreased. In contrast, cells overexpressing RNF2 showed a decreased p53 protein level, a shorter p53 half-life and increased p53 ubiquitination. Importantly, we found that RNF2 directly binds with both p53 and MDM2 and promotes MDM2-mediated p53 ubiquitination. RNF2 overexpression could also increase the half-life of MDM2 and inhibit its ubiquitination. The regulation on p53 and MDM2 stability by RNF2 was also observed during the etoposide-induced DNA damage response. These results provide a possible mechanism explaining the oncogenic function of RNF2, and because RNF2 is important for cancer cell survival and proliferation, it might be an ideal target for cancer therapy or prevention.	[Wen, W.; Peng, C.; Kim, M. O.; Jeong, C. Ho; Zhu, F.; Yao, K.; Zykova, T.; Ma, W.; Carper, A.; Langfald, A.; Bode, A. M.; Dong, Z.] Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; [Wen, W.] Fourth Mil Med Univ, Dept Immunol, State Key Lab Canc Biol, Xian 710032, Peoples R China; [Kim, M. O.] Kyungpook Natl Univ, Ctr Lab Anim Resources, Taegu, South Korea	University of Minnesota System; Air Force Military Medical University; Kyungpook National University	Dong, Z (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	zgdong@hi.umn.edu	温, 家琦/GYV-3177-2022; ZHU, Feng/C-1303-2010	Zhu, Feng/0000-0003-1172-0102	Hormel Foundation; National Institutes of Health [CA077646, CA027502, CA111536, CA120388, R37CA081064, ES017548]; National Natural Sciences Foundation of China [81171924]; NATIONAL CANCER INSTITUTE [R01CA111536, P01CA027502, R01CA077646, R37CA081064, R01CA111356, R01CA120388] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES016548] Funding Source: NIH RePORTER	Hormel Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Sciences Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Dr Bert Vogelstein (Johns Hopkins Oncology Center) for the HCT116 p53<SUP>+/+</SUP>, HCT116 p53<SUP>-/-</SUP> cells, Dr Seongman Kang (Korea University, South Korea) for the pCDNA3-Xpress-RNF2 plasmid. We also thank Dr Yibin Deng at The Hormel Institute for very helpful discussion and advice. We thank Tonya M Poorman for help submitting our manuscript. This work was supported by The Hormel Foundation and National Institutes of Health Grants CA077646, CA027502, CA111536, CA120388, R37CA081064, ES017548 and the National Natural Sciences Foundation of China (No. 81171924).	Alajez NM, 2009, CELL DEATH DIFFER, V16, P1469, DOI 10.1038/cdd.2009.85; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Fischle W, 2003, GENE DEV, V17, P1870, DOI 10.1101/gad.1110503; Fujii S, 2008, J BIOL CHEM, V283, P17324, DOI 10.1074/jbc.M800224200; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Jagani Z, 2010, CANCER RES, V70, P5528, DOI 10.1158/0008-5472.CAN-09-4229; Kalushkova A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011483; Kirmizis A, 2004, GENE DEV, V18, P1592, DOI 10.1101/gad.1200204; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Lee SJ, 2001, FEBS LETT, V503, P61, DOI 10.1016/S0014-5793(01)02689-8; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Levine SS, 2004, TRENDS BIOCHEM SCI, V29, P478, DOI 10.1016/j.tibs.2004.07.007; Liu L, 2006, ONCOGENE, V25, P4370, DOI 10.1038/sj.onc.1209454; Lund AH, 2004, CURR OPIN CELL BIOL, V16, P239, DOI 10.1016/j.ceb.2004.03.010; Ougolkov AV, 2008, CLIN CANCER RES, V14, P6790, DOI 10.1158/1078-0432.CCR-08-1013; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Sanchez-Beato M, 2006, MODERN PATHOL, V19, P684, DOI 10.1038/modpathol.3800577; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Voncken JW, 2003, P NATL ACAD SCI USA, V100, P2468, DOI 10.1073/pnas.0434312100; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Yang XJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005011	29	43	47	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2014	33	4					421	428		10.1038/onc.2012.605	http://dx.doi.org/10.1038/onc.2012.605			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VX	23318437	Green Accepted			2022-12-17	WOS:000330214600003
J	Zhang, J; Bai, D; Ma, X; Guan, J; Zheng, X				Zhang, J.; Bai, D.; Ma, X.; Guan, J.; Zheng, X.			hCINAP is a novel regulator of ribosomal protein-HDM2-p53 pathway by controlling NEDDylation of ribosomal protein S14	ONCOGENE			English	Article						hCINAP; RPS14; NEDDylation; HDM2; p53	ADENYLATE KINASE; P53; HDM2; MDM2; IDENTIFICATION; DEGRADATION; ACTIVATION; FAP7	The tumor-suppressor p53 provides a critical brake on tumor development. HDM2 (human double-minute 2), a p53 E3 ubiquitin ligase, is the principal cellular antagonist of p53. Mounting evidence has suggested that ribosomal proteins (RPs) modulate HDM2-p53 as a novel pathway for regulating p53 signaling. However, the upstream regulators that mediate RP-HDM2-p53 circuits remain poorly understood. Here we identify human coilin-interacting nuclear ATPase protein (hCINAP) as an interacting partner of ribosomal protein S14 (RPS14). RPS14 stabilized and activated p53 by inhibiting HDM2-mediated p53 polyubiquitination and degradation. More importantly, RPS14 was specifically modified with NEDD8 and hCINAP inhibited RPS14 NEDDylation by recruiting NEDD8-specific protease 1. The decrease in RPS14 NEDDylation led to reduced stability and incorrect localization of RPS14, thereby attenuating the interaction between RPS14 and HDM2. Free HDM2 stimulated p53 polyubiquitination and degradation. In conclusion, we demonstrate that hCINAP acts as a novel regulator of RPS14-HDM2-p53 by regulating the interaction between RPS14 and HDM2 through the control of RPS14 NEDDylation. These findings suggest that hCINAP is an important regulator of RP-HDM2-p53 pathway and a potential anticancer drug target.	[Zhang, J.; Bai, D.; Guan, J.; Zheng, X.] State Key Lab Prot & Plant Gene Res, Beijing, Peoples R China; [Zhang, J.; Bai, D.; Ma, X.; Guan, J.; Zheng, X.] Peking Univ, Dept Biochem & Mol Biol, Sch Life Sci, Beijing 100871, Peoples R China	Peking University	Zheng, X (corresponding author), Peking Univ, Dept Biochem & Mol Biol, Sch Life Sci, Beijing 100871, Peoples R China.	xiaofengz@pku.edu.cn	关, 俊宏/AAG-1046-2021	关, 俊宏/0000-0003-4900-0610	National Science Foundation of China [31170709, 30930020]; National High Technology and Development Program of China (973 Program) [2010CB911804]; International Center for Genetic Engineering and Biotechnology [CRP/CHN09-01]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); National High Technology and Development Program of China (973 Program)(National Basic Research Program of ChinaNational High Technology Research and Development Program of China); International Center for Genetic Engineering and Biotechnology	We sincerely thank Dr Jian Wang from the State Key Laboratory of Proteomics, Beijing Proteome Research Center for providing plasmids for HDM2 and its truncation constructs. We thank Dr Jun Gu at Peking University for providing the HCT116 cells and reporter plasmids. This work was supported by Grants from the National Science Foundation of China (31170709, 30930020), the National High Technology and Development Program of China (973 Program, 2010CB911804) and the International Center for Genetic Engineering and Biotechnology (project no. CRP/CHN09-01). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Barlow JL, 2010, NAT MED, V16, P59, DOI 10.1038/nm.2063; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Chen D, 2007, ONCOGENE, V26, P5029, DOI 10.1038/sj.onc.1210327; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; de Marval PLM, 2011, ONCOTARGET, V2, P234; Deisenroth C, 2010, ONCOGENE, V29, P4253, DOI 10.1038/onc.2010.189; Deisenroth Chad, 2011, Genes Cancer, V2, P392, DOI 10.1177/1947601911409737; Dey A, 2010, SEMIN CANCER BIOL, V20, P3, DOI 10.1016/j.semcancer.2010.02.004; Dutt S, 2011, BLOOD, V117, P2567, DOI 10.1182/blood-2010-07-295238; Ebert BL, 2008, NATURE, V451, P335, DOI 10.1038/nature06494; Fumagalli S, 2012, GENE DEV, V26, P1028, DOI 10.1101/gad.189951.112; Granneman S, 2005, MOL CELL BIOL, V25, P10352, DOI 10.1128/MCB.25.23.10352-10364.2005; Ha BH, 2008, BMB REP, V41, P435, DOI 10.5483/BMBRep.2008.41.6.435; Juhnke H, 2000, MOL MICROBIOL, V35, P936, DOI 10.1046/j.1365-2958.2000.01768.x; Lane D, 2010, COLD SPRING HARB PER, V2; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Malekkou A, 2010, FEBS LETT, V584, P4559, DOI 10.1016/j.febslet.2010.10.044; Meng G, 2008, BIOCHEMISTRY-MOSCOW+, V73, P38, DOI 10.1134/S0006297908010057; Moll UM, 2003, MOL CANCER RES, V1, P1001; Narla A, 2010, BLOOD, V115, P3196, DOI 10.1182/blood-2009-10-178129; Pan WQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021625; Santama N, 2005, J BIOL CHEM, V280, P36429, DOI 10.1074/jbc.M501982200; Sasaki M, 2011, NAT MED, V17, P944, DOI 10.1038/nm.2392; Sundqvist A, 2009, EMBO REP, V10, P1132, DOI 10.1038/embor.2009.178; Takahashi T, 2010, J TOXICOL SCI, V35, P945, DOI 10.2131/jts.35.945; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Warner JR, 2009, MOL CELL, V34, P3, DOI 10.1016/j.molcel.2009.03.006; Xiong X, 2011, ONCOGENE, V30, P1798, DOI 10.1038/onc.2010.569; Xirodimas DP, 2008, EMBO REP, V9, P280, DOI 10.1038/embor.2008.10; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016; Yadavilli S, 2009, DNA REPAIR, V8, P1215, DOI 10.1016/j.dnarep.2009.07.003; Zhai RT, 2006, FEBS LETT, V580, P3811, DOI 10.1016/j.febslet.2006.05.074; Zhang JF, 2010, CELL MOL LIFE SCI, V67, P1907, DOI 10.1007/s00018-010-0301-2; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zhang Y, 2010, NUCLEIC ACIDS RES, V38, P6544, DOI 10.1093/nar/gkq536; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zhou X, 2012, ONCOGENE, V63, P1; Zhu Y, 2009, MOL CELL, V35, P316, DOI 10.1016/j.molcel.2009.07.014	39	43	45	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2014	33	2					246	254		10.1038/onc.2012.560	http://dx.doi.org/10.1038/onc.2012.560			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286BY	23246961				2022-12-17	WOS:000329440700012
J	Castoldi, R; Ecker, V; Wiehle, L; Majety, M; Busl-Schuller, R; Asmussen, M; Nopora, A; Jucknischke, U; Osl, F; Kobold, S; Scheuer, W; Venturi, M; Klein, C; Niederfellner, G; Sustmann, C				Castoldi, R.; Ecker, V.; Wiehle, L.; Majety, M.; Busl-Schuller, R.; Asmussen, M.; Nopora, A.; Jucknischke, U.; Osl, F.; Kobold, S.; Scheuer, W.; Venturi, M.; Klein, C.; Niederfellner, G.; Sustmann, C.			A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity	ONCOGENE			English	Article						EGFR; Met; HGF; EGF; bispecific antibody	GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITORS; HEPATOCYTE GROWTH; LUNG-CANCER; C-MET; GEFITINIB RESISTANCE; ACQUIRED-RESISTANCE; SIGNALING NETWORKS; CARCINOMA CELLS; TARGETING MET	Simultaneous targeting of epidermal growth factor receptor (EGFR) and Met in cancer therapy is under pre-clinical and clinical evaluation. Here, we report the finding that treatment with EGFR inhibitors of various tumor cells, when stimulated with hepatocyte growth factor (HGF) and EGF, results in transient upregulation of phosphorylated AKT. Furthermore, EGFR inhibition in this setting stimulates a pro-invasive phenotype as assessed in Matrigel-based assays. Simultaneous treatment with AKT and EGFR inhibitors abrogates this invasive growth, hence functionally linking signaling and phenotype. This observation implies that during treatment of tumors a balanced ratio of EGFR and Met inhibition is required. To address this, we designed a bispecific antibody targeting EGFR and Met, which has the advantage of a fixed 2:1 stoichiometry. This bispecific antibody inhibits proliferation in tumor cell cultures and co-cultures with fibroblasts in an additive manner compared with treatment with both single agents. In addition, cell migration assays reveal a higher potency of the bispecific antibody in comparison with the antibodies' combination at low doses. We demonstrate that the bispecific antibody inhibits invasive growth, which is specifically observed with cetuximab. Finally, the bispecific antibody potently inhibits tumor growth in a non-small cell lung cancer xenograft model bearing a strong autocrine HGF-loop. Together, our findings strongly support a combination treatment of EGFR and Met inhibitors and further evaluation of resistance mechanisms to EGFR inhibition in the context of active Met signaling.	[Castoldi, R.; Ecker, V.; Wiehle, L.; Majety, M.; Busl-Schuller, R.; Asmussen, M.; Nopora, A.; Jucknischke, U.; Osl, F.; Scheuer, W.; Venturi, M.; Niederfellner, G.; Sustmann, C.] Roche Diagnost GmbH, Pharma Res & Early Dev pRED, D-82377 Penzberg, Germany; [Kobold, S.] Univ Munich, Dept Internal Med 4, Div Clin Pharmacol, Munich, Germany; [Klein, C.] Glycart AG, pRED, Schlieren, Switzerland	Roche Holding; University of Munich	Sustmann, C (corresponding author), Roche Diagnost GmbH, Pharma Res & Early Dev pRED, Nonnenwald 2, D-82377 Penzberg, Germany.	claudio.sustmann@roche.com	Klein, Christian/G-1336-2010	Klein, Christian/0000-0001-7594-7280; Kobold, Sebastian/0000-0002-5612-4673; Wiehle, Laura/0000-0001-6081-3925	Bayerisches Immuntherapie-Netzwerk (BayImmuNet)	Bayerisches Immuntherapie-Netzwerk (BayImmuNet)	S.K. is supported by the Bayerisches Immuntherapie-Netzwerk (BayImmuNet).	Alexander S, 2012, TRENDS MOL MED, V18, P13, DOI 10.1016/j.molmed.2011.11.003; Amit I, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100195; Bachleitner-Hofmann T, 2008, MOL CANCER THER, V7, P3499, DOI 10.1158/1535-7163.MCT-08-0374; Bean J, 2007, P NATL ACAD SCI USA, V104, P20932, DOI 10.1073/pnas.0710370104; Bonine-Summers AR, 2007, CANCER BIOL THER, V6, P561, DOI 10.4161/cbt.6.4.3851; Brehmer D, 2005, CANCER RES, V65, P379; Chhatwani Laveena, 2009, Proc Am Thorac Soc, V6, P194, DOI 10.1513/pats.200807-068LC; Corso S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-121; Croasdale R, 2012, ARCH BIOCHEM BIOPHYS, V526, P206, DOI 10.1016/j.abb.2012.03.016; Dikmen E, 2006, EUR RESPIR J, V27, P73, DOI 10.1183/09031936.06.00148704; Dong JY, 2011, MABS-AUSTIN, V3, P273, DOI 10.4161/mabs.3.3.15188; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205; Guo A, 2008, P NATL ACAD SCI USA, V105, P692, DOI 10.1073/pnas.0707270105; Gusenbauer S, 2013, ONCOGENE, V32, P3846, DOI 10.1038/onc.2012.396; Hammond DE, 2010, J PROTEOME RES, V9, P2734, DOI 10.1021/pr100145w; Jo MJ, 2000, J BIOL CHEM, V275, P8806, DOI 10.1074/jbc.275.12.8806; Karamouzis MV, 2009, LANCET ONCOL, V10, P709, DOI 10.1016/S1470-2045(09)70137-8; Kawaguchi K, 2009, CARCINOGENESIS, V30, P1097, DOI 10.1093/carcin/bgp097; Liska D, 2011, CLIN CANCER RES, V17, P472, DOI 10.1158/1078-0432.CCR-10-0568; Lu D, 2005, J BIOL CHEM, V280, P19665, DOI 10.1074/jbc.M500815200; Lu D, 2004, J BIOL CHEM, V279, P2856, DOI 10.1074/jbc.M310132200; Maseki S, 2012, BRIT J CANCER, V106, P1196, DOI 10.1038/bjc.2012.24; Merchant AM, 1998, NAT BIOTECHNOL, V16, P677, DOI 10.1038/nbt0798-677; Metz S, 2011, P NATL ACAD SCI USA, V108, P8194, DOI 10.1073/pnas.1018565108; Naito Y, 2012, CELL CYCLE, V11, P604, DOI 10.4161/cc.11.3.19114; Nedergaard MK, 2012, BIODRUGS, V26, P83, DOI 10.2165/11599760-000000000-00000; Nguyen KSH, 2009, CLIN LUNG CANCER, V10, P281, DOI 10.3816/CLC.2009.n.039; Puri Neelu, 2008, J Carcinog, V7, P9; Reusch U, 2006, CLIN CANCER RES, V12, P183, DOI 10.1158/1078-0432.CCR-05-1855; Ridgway JBB, 1996, PROTEIN ENG, V9, P617, DOI 10.1093/protein/9.7.617; Serrels A, 2011, CELL ADHES MIGR, V5, P360, DOI 10.4161/cam.5.4.17290; Sugahara K, 1998, INTENS CARE MED, V24, P434, DOI 10.1007/s001340050592; Surati M, 2011, EXPERT OPIN BIOL TH, V11, P1655, DOI 10.1517/14712598.2011.626762; Takata M, 2012, CANCER BIOL THER, V13, P6; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012; Uchiyama A, 1999, BRIT J CANCER, V81, P721, DOI 10.1038/sj.bjc.6690754; Ungewickell EJ, 2007, CURR OPIN CELL BIOL, V19, P417, DOI 10.1016/j.ceb.2007.05.003; Wang SY, 2011, ANTI-CANCER AGENT ME, V11, P993, DOI 10.2174/187152011797927661; Xu H, 2011, CLIN CANCER RES, V17, P4425, DOI 10.1158/1078-0432.CCR-10-3339; Yamada T, 2012, J THORAC ONCOL, V7, P272, DOI 10.1097/JTO.0b013e3182398e69; Yang SY, 2011, FRONT BIOSCI-LANDMRK, V16, P531, DOI 10.2741/3703; Yano S, 2008, CANCER RES, V68, P9479, DOI 10.1158/0008-5472.CAN-08-1643; Yap TA, 2011, CURR DRUG TARGETS, V12, P2045; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang YW, 2010, CANCER RES, V70, P6880, DOI 10.1158/0008-5472.CAN-10-0898	47	43	53	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2013	32	50					5593	5601		10.1038/onc.2013.245	http://dx.doi.org/10.1038/onc.2013.245			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272LF	23812422	Green Published, hybrid			2022-12-17	WOS:000328461400004
J	Shabbeer, S; Omer, D; Berneman, D; Weitzman, O; Alpaugh, A; Pietraszkiewicz, A; Metsuyanim, S; Shainskaya, A; Papa, MZ; Yarden, RI				Shabbeer, S.; Omer, D.; Berneman, D.; Weitzman, O.; Alpaugh, A.; Pietraszkiewicz, A.; Metsuyanim, S.; Shainskaya, A.; Papa, M. Z.; Yarden, R. I.			BRCA1 targets G2/M cell cycle proteins for ubiquitination and proteasomal degradation	ONCOGENE			English	Article						BRCA1; cyclin B; Cdc25; ubiquitination; proteasome; G2/M cell cycle checkpoint	E3 LIGASE ACTIVITY; KEN-BOX; BINDING; PHOSPHORYLATION; CHECKPOINT; RING; COMPLEX; DOMAIN; CHK1; B1	The BRCA1 tumor suppressor protein heterodimerizes with its partner protein, BARD1, via the RING domain present in both proteins. The heterodimer contains an E3 ubiquitin ligase activity and participates in multiple cellular functions such as cell cycle control, DNA repair and regulation of gene transcription, collectively aimed at maintaining genomic stability and tumor suppression. Yet, the precise role of BRCA1 E3 ligase in these cellular functions is poorly understood. We present data showing that BRCA1 ubiquitinates G2/M cell cycle proteins, cyclin B and Cdc25C, leading to their accelerated degradation via a mechanism that is independent of APC/C. BRCA1-dependent degradation of cyclin B and Cdc25C is reversed by proteasome inhibitors and is enhanced following DNA damage, which may represent a possible mechanism to prevent cyclin B and Cdc25C accumulation, a requirement for mitotic entry. Our data provide mechanistic insight into how BRCA1 E3 ligase activity regulates the G2/M cell cycle checkpoint and, thus, contributes to maintenance of genomic stability.	[Shabbeer, S.; Alpaugh, A.; Pietraszkiewicz, A.; Yarden, R. I.] Georgetown Univ, Med Ctr, Dept Human Sci, SNHS, Washington, DC 20057 USA; [Shabbeer, S.; Yarden, R. I.] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA; [Omer, D.; Berneman, D.; Weitzman, O.; Metsuyanim, S.; Papa, M. Z.; Yarden, R. I.] Chaim Sheba Med Ctr, Dept Surg Oncol, Lab Genom Applicat, IL-52621 Tel Hashomer, Israel; [Shainskaya, A.] Weizmann Inst Sci, Laraine & Alan A Fischer Lab Biol Mass Spectromet, IL-76100 Rehovot, Israel	Georgetown University; Georgetown University; Chaim Sheba Medical Center; Weizmann Institute of Science	Yarden, RI (corresponding author), Georgetown Univ, Med Ctr, Dept Human Sci, SNHS, St Marys Hall Rm 260,3700 Reservoir Rd NW, Washington, DC 20057 USA.	riy2@georgetown.edu		Pietraszkiewicz, Alexandra/0000-0002-9982-6261	Israel Cancer Research Fund; Health Ministry; Israeli Cancer Association; Georgetown University, SNHS; NATIONAL CANCER INSTITUTE [P30CA051008] Funding Source: NIH RePORTER	Israel Cancer Research Fund; Health Ministry; Israeli Cancer Association; Georgetown University, SNHS; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs B Henderson, J Pines, R Agami, E Rosen and M Brandeis for providing plasmids and Dr L Brody for reagents. We thank the microscopy unit in Bar-Ilan University for assistance with immunofluorescence studies and Dr I Goldstein and the flow cytometry unit at the Sheba medical center for assistance with fluorescence-activated cell sorting analysis. We thank Allison Hall for technical assistance. We thank Drs Eliot Rosen, Claire Pollack, Michael Brandeis and Gad Lavie for stimulating discussions and critical reading of the manuscript. This study was supported by a Research Career Development Award from the Israel Cancer Research Fund (to RIY) and by the funding from the Health Ministry (to RIY and MZP), the Israeli Cancer Association (RIY) and funds from Georgetown University, SNHS to RIY.	Acquaviva C, 2006, J CELL SCI, V119, P2401, DOI 10.1242/jcs.02937; Aprelikova O, 2001, J BIOL CHEM, V276, P25647, DOI 10.1074/jbc.C100265200; Au WWY, 2005, J BIOL CHEM, V280, P6993, DOI 10.1074/jbc.M408879200; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; Brodie S G, 2001, Trends Genet, V17, pS18, DOI 10.1016/S0168-9525(01)02451-9; Calvo V, 2011, CANCER RES, V71, P3422, DOI 10.1158/0008-5472.CAN-10-3670; Chen F, 2002, P NATL ACAD SCI USA, V99, P1990, DOI 10.1073/pnas.032428899; Christensen DE, 2007, NAT STRUCT MOL BIOL, V14, P941, DOI 10.1038/nsmb1295; Eakin CM, 2007, P NATL ACAD SCI USA, V104, P5794, DOI 10.1073/pnas.0610887104; Hershko A, 1999, PHILOS T R SOC B, V354, P1571, DOI 10.1098/rstb.1999.0500; Homer HA, 2005, REPRODUCTION, V130, P829, DOI 10.1530/rep.1.00856; Horwitz AA, 2007, P NATL ACAD SCI USA, V104, P6614, DOI 10.1073/pnas.0610481104; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Kim H, 2007, NAT STRUCT MOL BIOL, V14, P710, DOI 10.1038/nsmb1277; Kirkpatrick DS, 2006, NAT CELL BIOL, V8, P700, DOI 10.1038/ncb1436; Lim KL, 2005, J NEUROSCI, V25, P2002, DOI 10.1523/JNEUROSCI.4474-04.2005; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Ma YX, 2010, MOL ENDOCRINOL, V24, P76, DOI 10.1210/me.2009-0218; Mallery DL, 2002, EMBO J, V21, P6755, DOI 10.1093/emboj/cdf691; Morris JR, 2009, NATURE, V462, P886, DOI 10.1038/nature08593; Ohta T, 2011, FEBS LETT, V585, P2836, DOI 10.1016/j.febslet.2011.05.005; Palacios J, 2005, BREAST CANCER RES TR, V90, P5, DOI 10.1007/s10549-004-1536-0; Pfleger CM, 2000, GENE DEV, V14, P655; Poole AJ, 2006, SCIENCE, V314, P1467, DOI 10.1126/science.1130471; Reid LJ, 2008, P NATL ACAD SCI USA, V105, P20876, DOI 10.1073/pnas.0811203106; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Sato K, 2004, J BIOL CHEM, V279, P30919, DOI 10.1074/jbc.C400169200; Sato K, 2012, CURR BIOL, V22, P1659, DOI 10.1016/j.cub.2012.07.034; Shakya R, 2011, SCIENCE, V334, P525, DOI 10.1126/science.1209909; Sobhian B, 2007, SCIENCE, V316, P1198, DOI 10.1126/science.1139516; Starita LM, 2004, MOL CELL BIOL, V24, P8457, DOI 10.1128/MCB.24.19.8457-8466.2004; Starita LM, 2005, J BIOL CHEM, V280, P24498, DOI 10.1074/jbc.M414020200; Stegmeier F, 2007, NATURE, V446, P876, DOI 10.1038/nature05694; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Wang B, 2007, SCIENCE, V316, P1194, DOI 10.1126/science.1139476; Wang RH, 2004, P NATL ACAD SCI USA, V101, P17108, DOI 10.1073/pnas.0407585101; Wu WW, 2008, CELL DIV, V3, DOI 10.1186/1747-1028-3-1; Wu WW, 2007, CANCER RES, V67, P951, DOI 10.1158/0008-5472.CAN-06-3187; Wu-Baer F, 2003, J BIOL CHEM, V278, P34743, DOI 10.1074/jbc.C300249200; Wu-Baer F, 2010, MOL CELL BIOL, V30, P2787, DOI 10.1128/MCB.01056-09; Xia Y, 2003, J BIOL CHEM, V278, P5255, DOI 10.1074/jbc.M204591200; Xu B, 2002, CANCER RES, V62, P4588; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Yan Y, 2005, ONCOGENE, V24, P3285, DOI 10.1038/sj.onc.1208492; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Yarden RI, 2006, MOL CANCER THER, V5, P1396, DOI 10.1158/1535-7163.MCT-05-0471; Yarden RI, 2012, INT J BIOCHEM CELL B, V44, P1761, DOI 10.1016/j.biocel.2012.06.026; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Yu XC, 2004, MOL CELL BIOL, V24, P9478, DOI 10.1128/MCB.24.21.9478-9486.2004; Yu XC, 2006, GENE DEV, V20, P1721, DOI 10.1101/gad.1431006; Zhu Q, 2011, NATURE, V477, P179, DOI 10.1038/nature10371	53	43	44	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2013	32	42					5005	5016		10.1038/onc.2012.522	http://dx.doi.org/10.1038/onc.2012.522			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238IB	23246971	Green Accepted			2022-12-17	WOS:000325937900002
J	Norris, AM; Gore, A; Balboni, A; Young, A; Longnecker, DS; Korc, M				Norris, A. M.; Gore, A.; Balboni, A.; Young, A.; Longnecker, D. S.; Korc, M.			AGR2 is a SMAD4-suppressible gene that modulates MUC1 levels and promotes the initiation and progression of pancreatic intraepithelial neoplasia	ONCOGENE			English	Article						TGF-beta; AGR2; pancreatic cancer; MUC1; SMAD4	GROWTH-FACTOR RECEPTOR; TGF-BETA; ANTERIOR GRADIENT-2; EXPRESSION PATTERNS; HUMAN HOMOLOG; TUMOR-GROWTH; CANCER; PROTEIN; ADENOCARCINOMA; ANTIGEN	The mechanisms controlling expression of the putative oncogene Anterior gradient 2 (AGR2) in pancreatic ductal adenocarcinoma (PDAC) are not well understood. We now show that AGR2 is a transforming growth factor-beta (TGF-beta)-responsive gene in human pancreatic cancer cells, whose downregulation is SMAD4 dependent. We also provide evidence supporting a role for AGR2 as an ER-chaperone for the cancer-associated mucin, MUC1. AGR2 is both sufficient and required for MUC1 expression in pancreatic cancer cells. Furthermore, AGR2 is coexpressed with MUC1 in mouse pancreatic intraepithelial neoplasia (mPanIN)-like lesions and in the cancer cells of four distinct genetically engineered mouse models of PDAC. We also show that Pdx1-Cre/LSL-Kras(G12D)/Smad4(lox/lox) mice heterozygous for Agr2 exhibit a delay in mPanIN initiation and progression to PDAC. It is proposed that loss of Smad4 may convert TGF-beta from a tumor suppressor to a tumor promoter by causing the upregulation of AGR2, which then leads to increased MUC1 expression, at which point both AGR2 and MUC1 facilitate mPanIN initiation and progression to PDAC.	[Norris, A. M.; Young, A.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Med, Hanover, NH 03756 USA; [Gore, A.; Korc, M.] Indiana Univ Sch Med, Melvin & Bren Simon Canc Ctr, Dept Med, Indianapolis, IN 46202 USA; [Gore, A.; Korc, M.] Indiana Univ Sch Med, Melvin & Bren Simon Canc Ctr, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; [Gore, A.; Korc, M.] Pancreat Canc Signature Ctr, Indianapolis, IN USA; [Balboni, A.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Pharmacol & Toxicol, Hanover, NH 03756 USA; [Longnecker, D. S.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Pathol, Hanover, NH 03756 USA	Dartmouth College; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Dartmouth College; Dartmouth College	Korc, M (corresponding author), Indiana Univ Sch Med, Dept Med, 980 West Walnut St, Indianapolis, IN 46202 USA.	mkorc@iupui.edu			US Public Health Service [CA-R37-075059]; National Cancer Institute; NRSA Molecular and Toxicology Program fellowship [5T32CA009658-18]; Program in Experimental and Molecular Medicine; NATIONAL CANCER INSTITUTE [R37CA075059, R01CA075059, T32CA009658] Funding Source: NIH RePORTER	US Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NRSA Molecular and Toxicology Program fellowship; Program in Experimental and Molecular Medicine; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Ted R Hupp (U of Edinburgh) for the AGR2-RFP and pcDNA-AGR2 plasmids; Dr Park (UCSF) for providing the Agr2<SUP>-/-</SUP> mice; Dr J Gore for helpful discussions; and Ms Catherine Chen for excellent laboratory work. This research was supported by the US Public Health Service Grant CA-R37-075059, awarded by the National Cancer Institute to MK. AMN was supported by the NRSA Molecular and Toxicology Program fellowship 5T32CA009658-18. AB was supported by the Program in Experimental and Molecular Medicine.	Ambolet-Camoit A, 2010, TOXICOL SCI, V115, P501, DOI 10.1093/toxsci/kfq082; AMERICAN CANCER SOCIETY, 2007, CANC FACTS FIG; Andrianifahanana M, 2001, CLIN CANCER RES, V7, P4033; Arnold NB, 2005, J BIOL CHEM, V280, P21858, DOI 10.1074/jbc.M500583200; Arnold NB, 2004, CANCER RES, V64, P3599, DOI 10.1158/0008-5472.CAN-03-2999; BALAGUE C, 1994, GASTROENTEROLOGY, V106, P1054, DOI 10.1016/0016-5085(94)90767-6; Baldwin RL, 1996, INT J CANCER, V67, P283, DOI 10.1002/(SICI)1097-0215(19960717)67:2<283::AID-IJC21>3.0.CO;2-B; Bardeesy N, 2006, P NATL ACAD SCI USA, V103, P5947, DOI 10.1073/pnas.0601273103; Bardeesy N, 2006, GENE DEV, V20, P3130, DOI 10.1101/gad.1478706; Besmer DM, 2011, CANCER RES, V71, P4432, DOI 10.1158/0008-5472.CAN-10-4439; Brychtova V, 2011, CANCER LETT, V304, P1, DOI 10.1016/j.canlet.2010.12.023; Carraway KL, 2002, PROG NUCLEIC ACID RE, V71, P149, DOI 10.1016/S0079-6603(02)71043-X; Carriere C, 2007, P NATL ACAD SCI USA, V104, P4437, DOI 10.1073/pnas.0701117104; Carriere C, 2011, GASTROENTEROLOGY, V141, P1091, DOI 10.1053/j.gastro.2011.05.041; Chang Ken Chien-Neng, 2007, V383, P31; Chen R, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-149; Choudhury A, 2000, J BIOCHEM-TOKYO, V128, P233, DOI 10.1093/oxfordjournals.jbchem.a022746; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dumartin L, 2011, CANCER RES, V71, P7091, DOI 10.1158/0008-5472.CAN-11-1367; FORSTNER G, 1995, ANNU REV PHYSIOL, V57, P585, DOI 10.1146/annurev.ph.57.030195.003101; FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U; Fritzsche FR, 2006, CLIN CANCER RES, V12, P1728, DOI 10.1158/1078-0432.CCR-05-2057; Gu GQ, 2002, DEVELOPMENT, V129, P2447; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 1996, CANCER RES, V56, P490; Hansel DE, 2003, ANNU REV GENOM HUM G, V4, P237, DOI 10.1146/annurev.genom.4.070802.110341; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Higa A, 2011, J BIOL CHEM, V286, P44855, DOI 10.1074/jbc.M111.275529; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hrstka R, 2010, ONCOGENE, V29, P4838, DOI 10.1038/onc.2010.228; Hruban RH, 2000, AM J PATHOL, V156, P1821, DOI 10.1016/S0002-9440(10)65054-7; Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9; Innes HE, 2006, BRIT J CANCER, V94, P1057, DOI 10.1038/sj.bjc.6603065; Jaffee EM, 2002, CANCER CELL, V2, P25, DOI 10.1016/S1535-6108(02)00093-4; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kleeff J, 1999, BIOCHEM BIOPH RES CO, V255, P268, DOI 10.1006/bbrc.1999.0171; Kristiansen G, 2005, J PATHOL, V205, P359, DOI 10.1002/path.1676; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Levi E, 2004, J CLIN PATHOL, V57, P456, DOI 10.1136/jcp.2003.013292; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Liu D, 2005, CANCER RES, V65, P3796, DOI 10.1158/0008-5472.CAN-04-3823; Lowe AW, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000323; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Moniaux N, 2004, BRIT J CANCER, V91, P1633, DOI 10.1038/sj.bjc.6602163; Nagata K, 2007, J HEPATO-BILIARY-PAN, V14, P243, DOI 10.1007/s00534-006-1169-2; Norris AM, 2009, PANCREATIC CANC; Park SW, 2009, P NATL ACAD SCI USA, V106, P6950, DOI 10.1073/pnas.0808722106; Persson S, 2005, MOL PHYLOGENET EVOL, V36, P734, DOI 10.1016/j.ympev.2005.04.002; Pohler E, 2004, MOL CELL PROTEOMICS, V3, P534, DOI 10.1074/mcp.M300089-MCP200; Ramachandran V, 2008, CANCER RES, V68, P7811, DOI 10.1158/0008-5472.CAN-08-1320; Riener MO, 2009, HISTOL HISTOPATHOL, V24, P1121, DOI 10.14670/HH-24.1121; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Roy LD, 2011, ONCOGENE, V30, P1449, DOI 10.1038/onc.2010.526; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; Sempere LF, 2011, CANCER BIOL THER, V12, P198, DOI 10.4161/cbt.12.3.15979; Sipos B, 2003, VIRCHOWS ARCH, V442, P444, DOI 10.1007/s00428-003-0784-4; Thompson DA, 1998, BIOCHEM BIOPH RES CO, V251, P111, DOI 10.1006/bbrc.1998.9440; van Heek T, 2002, AM J CLIN PATHOL, V117, P755; Wagner M, 1998, INT J CANCER, V78, P255, DOI 10.1002/(SICI)1097-0215(19981005)78:2<255::AID-IJC21>3.0.CO;2-8; Wang Z, 2008, CANCER RES, V68, P492, DOI 10.1158/0008-5472.CAN-07-2930; Wilentz R E, 1998, Surg Oncol Clin N Am, V7, P43; Wilentz RE, 2000, CANCER RES, V60, P2002; Wilson CL, 2006, ENDOCR-RELAT CANCER, V13, P617, DOI 10.1677/erc.1.01165; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang JS, 2005, GENE CHROMOSOME CANC, V43, P249, DOI 10.1002/gcc.20188; Zhang YX, 2010, CANCER RES, V70, P240, DOI 10.1158/0008-5472.CAN-09-2904; Zheng W, 2006, GENES IMMUN, V7, P11, DOI 10.1038/sj.gene.6364263	69	43	44	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2013	32	33					3867	3876		10.1038/onc.2012.394	http://dx.doi.org/10.1038/onc.2012.394			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202JH	22945649	Green Accepted			2022-12-17	WOS:000323210200009
J	Loffler, H; Fechter, A; Liu, FY; Poppelreuther, S; Kramer, A				Loeffler, H.; Fechter, A.; Liu, F. Y.; Poppelreuther, S.; Kraemer, A.			DNA damage-induced centrosome amplification occurs via excessive formation of centriolar satellites	ONCOGENE			English	Article						DNA damage; centrosome amplification; centriolar satellites; Chk1	CHROMOSOMAL INSTABILITY; GENOME MAINTENANCE; MAMMALIAN-CELLS; DUPLICATION; CHECKPOINT; INVOLVEMENT; INDUCTION; RADIATION; INTEGRITY; PATHWAY	Centrosome amplification is a frequent phenomenon in malignancies and may facilitate tumorigenesis by promoting chromosomal instability. On the other hand, a centrosome inactivation checkpoint comprising centrosome amplification leading to elimination of cells by mitotic catastrophe has been described in response to DNA damage by ionizing radiation or cytostatic drugs. So far, the exact nature of DNA damage-induced centrosome amplification, which might be overduplication or fragmentation of existing centrosomes, has been controversial. To solve this controversy, we have established a method to distinguish between these two possibilities using A549 cells expressing photoconvertible CETN2-Dendra2. In response to various DNA-damaging treatments, centrosome amplification but not fragmentation was observed. Moreover, centrosome amplification was preceded by excessive formation of centrin-containing centriolar satellites, which were identified as de novo-generated atypical centrin dots staining positive for centriolar satellite markers but negative or only weakly positive for other established centrosomal markers, and which could be verified as centriolar satellites using immunogold electron microscopy. In line with this notion, disruption of dynein-mediated recruitment of centrosomal proteins via centriolar satellites suppressed centrosome amplification after DNA damage, and excessive formation of centriolar satellites could be inhibited by interference with Chk1, a known mediator of centrosome amplification in response to DNA damage. In conclusion, we provide a model in which a Chk1-mediated DNA damage checkpoint induces excessive formation of centriolar satellites constituting assembly platforms for centrosomal proteins, which subsequently leads to centrosome amplification.	[Loeffler, H.; Fechter, A.; Liu, F. Y.; Kraemer, A.] German Canc Res Ctr, Clin Cooperat Unit Mol Hematol Oncol, D-69120 Heidelberg, Germany; [Loeffler, H.; Fechter, A.; Liu, F. Y.; Kraemer, A.] Heidelberg Univ, Dept Internal Med 5, Heidelberg, Germany; [Poppelreuther, S.] Carl Zeiss Applicat Ctr, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Carl Zeiss AG	Kramer, A (corresponding author), German Canc Res Ctr, Clin Cooperat Unit Mol Hematol Oncol, D-69120 Heidelberg, Germany.	a.kraemer@dkfz.de			Deutsche Krebshilfe [108560]	Deutsche Krebshilfe(Deutsche Krebshilfe)	We thank Birgit Hub and Sigrid Heil for excellent technical assistance, and Andrew M Fry, Andreas Merdes, Jeffrey L Salisbury and Richard B Vallee for important reagents. This work was supported by the Deutsche Krebshilfe (grant 108560).	Barenz F, 2011, EUR J CELL BIOL, V90, P983, DOI 10.1016/j.ejcb.2011.07.007; Bourke E, 2010, ONCOGENE, V29, P616, DOI 10.1038/onc.2009.340; Bourke E, 2007, EMBO REP, V8, P603, DOI 10.1038/sj.embor.7400962; Boutros R, 2007, CANCER RES, V67, P11557, DOI 10.1158/0008-5472.CAN-07-2415; Dammermann A, 2002, J CELL BIOL, V159, P255, DOI 10.1083/jcb.200204023; Doxsey S, 2005, TRENDS CELL BIOL, V15, P303, DOI 10.1016/j.tcb.2005.04.008; FETNER RH, 1965, EXP CELL RES, V37, P429, DOI 10.1016/0014-4827(65)90190-4; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Gurskaya NG, 2006, NAT BIOTECHNOL, V24, P461, DOI 10.1038/nbt1191; Habedanck R, 2005, NAT CELL BIOL, V7, P1140, DOI 10.1038/ncb1320; Heilig CE, 2010, J CELL MOL MED, V14, P895, DOI 10.1111/j.1582-4934.2009.00905.x; Hut HMJ, 2003, MOL BIOL CELL, V14, P1993, DOI 10.1091/mbc.E02-08-0510; KOBAYASHI T, 1978, BIOCHEM BIOPH RES CO, V81, P1313, DOI 10.1016/0006-291X(78)91279-2; Kodani A, 2010, MOL BIOL CELL, V21, P3376, DOI 10.1091/mbc.E10-05-0430; Kramer A, 2004, NAT CELL BIOL, V6, P884, DOI 10.1038/ncb1165; Kramer A, 2005, LEUKEMIA, V19, P1142, DOI 10.1038/sj.leu.2403780; Kramer A, 2004, CELL CYCLE, V3, P1390, DOI 10.4161/cc.3.11.1252; Kubo A, 2003, J CELL SCI, V116, P919, DOI 10.1242/jcs.00282; Kubo A, 1999, J CELL BIOL, V147, P969, DOI 10.1083/jcb.147.5.969; Leidel S, 2005, NAT CELL BIOL, V7, P115, DOI 10.1038/ncb1220; LEVIS AG, 1963, EXP CELL RES, V31, P448, DOI 10.1016/0014-4827(63)90026-0; Loffler H, 2007, CELL CYCLE, V6, P2541; Loffler H, 2006, EXP CELL RES, V312, P2633, DOI 10.1016/j.yexcr.2006.06.008; Loffler H, 2011, CANCER RES, V71, P2129, DOI 10.1158/0008-5472.CAN-10-2684; Lopes CAM, 2011, J CELL SCI, V124, P600, DOI 10.1242/jcs.077156; Nigg EA, 2009, CELL, V139, P663, DOI 10.1016/j.cell.2009.10.036; Prosser SL, 2009, MOL CELL BIOL, V29, P1760, DOI 10.1128/MCB.01124-08; Robinson HMR, 2007, CELL CYCLE, V6, P982, DOI 10.4161/cc.6.8.4111; SATO C, 1983, J CELL BIOL, V96, P776, DOI 10.1083/jcb.96.3.776; Sibon OCM, 2000, NAT CELL BIOL, V2, P90, DOI 10.1038/35000041; Stevens NR, 2010, DEV CELL, V19, P913, DOI 10.1016/j.devcel.2010.11.010; Takada S, 2003, CELL, V113, P87, DOI 10.1016/S0092-8674(03)00202-2; White RA, 2000, MICROSC RES TECHNIQ, V49, P451, DOI 10.1002/(SICI)1097-0029(20000601)49:5<451::AID-JEMT7>3.0.CO;2-9; Yih LH, 2006, CANCER RES, V66, P2098, DOI 10.1158/0008-5472.CAN-05-2308; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zyss D, 2009, TRENDS CELL BIOL, V19, P334, DOI 10.1016/j.tcb.2009.04.001	36	43	44	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 13	2013	32	24					2963	2972		10.1038/onc.2012.310	http://dx.doi.org/10.1038/onc.2012.310			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163WV	22824794				2022-12-17	WOS:000320369700006
J	Romeo, Y; Moreau, J; Zindy, PJ; Saba-El-Leil, M; Lavoie, G; Dandachi, F; Baptissart, M; Borden, KLB; Meloche, S; Roux, PP				Romeo, Y.; Moreau, J.; Zindy, P-J; Saba-El-Leil, M.; Lavoie, G.; Dandachi, F.; Baptissart, M.; Borden, K. L. B.; Meloche, S.; Roux, P. P.			RSK regulates activated BRAF signalling to mTORC1 and promotes melanoma growth	ONCOGENE			English	Article						Melanoma; BRAF; MAPK; RSK; mTOR	PROTEIN-KINASE PATHWAY; INITIATION-FACTOR 4E; TRANSLATION INITIATION; B-RAF; DEPENDENT TRANSLATION; MOLECULAR-MECHANISMS; TUBEROUS SCLEROSIS; CELL-PROLIFERATION; S6 KINASE; PHOSPHORYLATION	The Ras/mitogen-activated protein kinase (MAPK) signalling cascade regulates various biological functions, including cell growth, proliferation and survival. As such, this pathway is often deregulated in cancer, including melanomas, which frequently harbour activating mutations in the NRAS and BRAF oncogenes. Hyperactive MAPK signalling is known to promote protein synthesis, but the mechanisms by which this occurs remain poorly understood. Here, we show that expression of oncogenic forms of Ras and Raf promotes the constitutive activation of the mammalian target of rapamycin (mTOR). Using pharmacological inhibitors and RNA interference, we find that the MAPK-activated protein kinase RSK (p90 ribosomal S6 kinase) is partly required for these effects. Using melanoma cell lines carrying activating BRAF mutations, we show that ERK/RSK signalling regulates assembly of the translation initiation complex and polysome formation, as well as the translation of growth-related messenger RNAs containing a 50-terminal oligopyrimidine (TOP) motif. Accordingly, we find that RSK inhibition abrogates tumour growth in mice. Our findings indicate that RSK may be a valuable therapeutic target for the treatment of tumours characterized by deregulated MAPK signalling, such as melanoma.	[Romeo, Y.; Moreau, J.; Zindy, P-J; Saba-El-Leil, M.; Lavoie, G.; Dandachi, F.; Baptissart, M.; Borden, K. L. B.; Meloche, S.; Roux, P. P.] Univ Montreal, Inst Res Immunol & Canc, Montreal, PQ H3C 3J7, Canada; [Borden, K. L. B.; Roux, P. P.] Univ Montreal, Fac Med, Dept Pathol & Cell Biol, Montreal, PQ H3C 3J7, Canada; [Meloche, S.] Univ Montreal, Fac Med, Dept Pharmacol, Montreal, PQ H3C 3J7, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal	Roux, PP (corresponding author), Univ Montreal, IRIC Univ Montreal, POB 6128,Stn Ctr Ville, Montreal, PQ H3C 3J7, Canada.	philippe.roux@umontreal.ca	Romeo, Yves/AAC-1669-2021; Roux, Philippe P./J-3996-2012	Roux, Philippe P./0000-0002-5962-0250	Canadian Cancer Society Research Institute; Cancer Research Society; Natural Sciences and Engineering Research Council of Canada; Human Frontier Science Programme (HFSP); FRSQ; NATIONAL CANCER INSTITUTE [R01CA080728, R01CA098571] Funding Source: NIH RePORTER	Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); Cancer Research Society; Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Human Frontier Science Programme (HFSP)(Human Frontier Science Program); FRSQ(Fonds de la Recherche en Sante du Quebec); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the Canadian Cancer Society Research Institute (PPR), the Cancer Research Society (PPR and SM), and the Natural Sciences and Engineering Research Council of Canada (PPR). We thank Dr Nahum Sonenberg for the phospho-4E-BP1 antibody. PP Roux holds a Canada Research Chair in Signal Transduction and Proteomics and a Career Development Award from the Human Frontier Science Programme (HFSP). K Borden and S Meloche hold Canada Research Chairs in Molecular Biology of the Cell Nucleus, and in Cellular Signalling, respectively. IRIC core facilities are supported by the FRSQ.	Anjum R, 2008, NAT REV MOL CELL BIO, V9, P747, DOI 10.1038/nrm2509; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; Bilanges B, 2007, ONCOGENE, V26, P5973, DOI 10.1038/sj.onc.1210431; Bilanges B, 2007, MOL CELL BIOL, V27, P5746, DOI 10.1128/MCB.02136-06; Buxade M, 2008, FRONT BIOSCI-LANDMRK, V13, P5359, DOI 10.2741/3086; Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031-10; Caron E, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.68; Carriere A, 2008, CURR BIOL, V18, P1269, DOI 10.1016/j.cub.2008.07.078; Carriere A, 2008, FRONT BIOSCI-LANDMRK, V13, P4258, DOI 10.2741/3003; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dowling RJO, 2010, SCIENCE, V328, P1172, DOI 10.1126/science.1187532; Eisenmann KM, 2003, CANCER RES, V63, P8330; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Fecher LA, 2008, CURR OPIN ONCOL, V20, P183, DOI 10.1097/CCO.0b013e3282f5271c; Foster KG, 2010, J BIOL CHEM, V285, P14071, DOI 10.1074/jbc.R109.094003; Furic L, 2010, P NATL ACAD SCI USA, V107, P14134, DOI 10.1073/pnas.1005320107; Gaestel M, 2008, FRONT BIOSCI, V13, P6050, DOI 10.2741/3136; Gray-Schopfer VC, 2005, CANCER METAST REV, V24, P165, DOI 10.1007/s10555-005-5865-1; Guertin DA, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.267pe24; Jacinto E, 2008, IUBMB LIFE, V60, P483, DOI 10.1002/iub.56; Karbowniczek M, 2008, J INVEST DERMATOL, V128, P980, DOI 10.1038/sj.jid.5701074; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Mamane Y, 2006, ONCOGENE, V25, P6416, DOI 10.1038/sj.onc.1209888; Max X, 2008, CELL, V133, P303, DOI 10.1016/j.cell.2008.02.031; Meloche S, 2007, ONCOGENE, V26, P3227, DOI 10.1038/sj.onc.1210414; Menon S, 2008, Oncogene, V27 Suppl 2, pS43, DOI 10.1038/onc.2009.352; Meyuhas O, 2009, PROG MOL BIOL TRANSL, V90, P109, DOI 10.1016/S1877-1173(09)90003-5; Miller AJ, 2006, NEW ENGL J MED, V355, P51, DOI 10.1056/NEJMra052166; Murphy LO, 2006, TRENDS BIOCHEM SCI, V31, P268, DOI 10.1016/j.tibs.2006.03.009; O'Reilly KE, 2009, CLIN CANCER RES, V15, P2872, DOI 10.1158/1078-0432.CCR-08-2336; Old WM, 2009, MOL CELL, V34, P115, DOI 10.1016/j.molcel.2009.03.007; Rajalingam K, 2007, BBA-MOL CELL RES, V1773, P1177, DOI 10.1016/j.bbamcr.2007.01.012; Romeo Y, 2012, BIOCHEM J, V441, P553, DOI 10.1042/BJ20110289; Romeo Y, 2011, EXPERT OPIN THER TAR, V15, P5, DOI 10.1517/14728222.2010.531014; Roux PP, 2007, J BIOL CHEM, V282, P14056, DOI 10.1074/jbc.M700906200; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Scheier B, 2011, IMMUNOTHERAPY-UK, V3, P1461, DOI [10.2217/IMT.11.136, 10.2217/imt.11.136]; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; Sengupta S, 2010, MOL CELL, V40, P310, DOI 10.1016/j.molcel.2010.09.026; Servant MJ, 1996, J BIOL CHEM, V271, P16047, DOI 10.1074/jbc.271.27.16047; Shahbazian D, 2006, EMBO J, V25, P2781, DOI 10.1038/sj.emboj.7601166; She QB, 2010, CANCER CELL, V18, P39, DOI 10.1016/j.ccr.2010.05.023; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Ueda T, 2004, MOL CELL BIOL, V24, P6539, DOI 10.1128/MCB.24.15.6539-6549.2004; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yamashita R, 2008, NUCLEIC ACIDS RES, V36, P3707, DOI 10.1093/nar/gkn248; Zheng B, 2009, MOL CELL, V33, P237, DOI 10.1016/j.molcel.2008.12.026	50	43	43	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2013	32	24					2917	2926		10.1038/onc.2012.312	http://dx.doi.org/10.1038/onc.2012.312			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163WV	22797077	Green Accepted			2022-12-17	WOS:000320369700002
J	Braig, S; Bosserhoff, AK				Braig, S.; Bosserhoff, A-K			Death inducer-obliterator 1 (Didol) is a BMP target gene and promotes BMP-induced melanoma progression	ONCOGENE			English	Article						malignant melanoma; bone morphogenic protein; Dido1; integrin alpha V; migration; invasion	BONE MORPHOGENETIC PROTEINS; TRANSCRIPTION FACTOR; CELL INVASION; IN-VITRO; EXPRESSION; INTEGRINS; APOPTOSIS; ANGIOGENESIS; INVOLVEMENT; MECHANISMS	Bone morphogenetic proteins (BMPs) are known to play an important role in melanoma development and progression. However, the downstream targets of BMPs have not been investigated thus far. Therefore, we treated melanoma cell lines with the Smad-specific BMP inhibitor Dorsomorphin and performed a cDNA microarray. We identified death inducer-obliterator 1 (Dido1) as a BMP-specific Smad-regulated target gene, which was confirmed by qRT-PCR, immunofluorescence staining and electrophoretic mobility shift assay experiments. An analysis of Dido1 expression revealed an upregulation of Dido1 levels in melanoma cell lines and tissues compared with normal melanocytes. Colony-formation assays showed that siDido1-transfected cells formed significantly smaller colonies when grown in soft agar compared with control cells. In addition, fluorescence-activated cell sorting and western blot experiments revealed that transfection of melanoma cells with Dido1 small interfering RNAs led to an upregulation of apoptosis. Furthermore, cell migratory and invasive potentials were strongly reduced in siDido1-transfected cells compared with control cells. Finally, we demonstrated that Didol induces the expression of lntegrin alpha V, thereby promoting the attachment, migration, invasion and apoptosis resistance of melanoma cells. Oncogene (2013) 32, 837-848; doi:10.1038/onc.2012.115; published online 2 April 2012	[Braig, S.; Bosserhoff, A-K] Univ Regensburg, Sch Med, Inst Pathol, D-93053 Regensburg, Germany	University of Regensburg	Bosserhoff, AK (corresponding author), Univ Regensburg, Inst Pathol, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.	anja.bosserhoff@klinik.uni-regensburg.de	Bosserhoff, Anja/GNH-4801-2022	Bosserhoff, Anja/0000-0001-8147-394X				Anderson GJ, 2008, NAT CHEM BIOL, V4, P15, DOI 10.1038/nchembio0108-15; Arndt S, 2007, MOL CELL NEUROSCI, V34, P603, DOI 10.1016/j.mcn.2007.01.002; Boergermann JH, 2010, INT J BIOCHEM CELL B, V42, P1802, DOI 10.1016/j.biocel.2010.07.018; Braig S, 2010, CELL MOL LIFE SCI, V67, P3535, DOI 10.1007/s00018-010-0394-7; Busch C, 2008, INT J CANCER, V122, P526, DOI 10.1002/ijc.23139; Cavallaro U, 2000, J NEURO-ONCOL, V50, P63, DOI 10.1023/A:1006414621286; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Felding-Habermann B, 2002, CLIN EXP METASTAS, V19, P427, DOI 10.1023/A:1016377114119; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Garcia-Domingo D, 2003, MOL CELL BIOL, V23, P3216, DOI 10.1128/MCB.23.9.3216-3225.2003; Garcia-Domingo D, 1999, P NATL ACAD SCI USA, V96, P7992, DOI 10.1073/pnas.96.14.7992; Gazzerro E, 2006, REV ENDOCR METAB DIS, V7, P51, DOI 10.1007/s11154-006-9000-6; Hendrix MJC, 2003, NAT REV CANCER, V3, P411, DOI 10.1038/nrc1092; Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Houghton AN, 2002, CANCER CELL, V2, P275, DOI 10.1016/S1535-6108(02)00161-7; Hsu MY, 2005, CANCER METAST REV, V24, P251, DOI 10.1007/s10555-005-1575-y; Ivanov VN, 2003, ONCOGENE, V22, P3152, DOI 10.1038/sj.onc.1206456; Koistinen P, 2004, INT J CANCER, V112, P61, DOI 10.1002/ijc.20377; Kuphal S, 2005, CANCER METAST REV, V24, P195, DOI 10.1007/s10555-005-1572-1; Marshall JF, 1996, SEMIN CANCER BIOL, V7, P129, DOI 10.1006/scbi.1996.0018; Moschos Stergios J, 2007, Oncology (Williston Park), V21, P13; Na YR, 2009, CANCER SCI, V100, P2218, DOI 10.1111/j.1349-7006.2009.01301.x; Peters KG, 2004, RECENT PROG HORM RES, V59, P51, DOI 10.1210/rp.59.1.51; Rockmann H, 2003, ONKOLOGIE, V26, P581, DOI 10.1159/000074156; Rojas AM, 2005, FEBS J, V272, P3505, DOI 10.1111/j.1742-4658.2005.04759.x; Rothhammer T, 2007, ONCOGENE, V26, P4158, DOI 10.1038/sj.onc.1210182; Rothhammer T, 2005, CANCER RES, V65, P448; Rothhammer T, 2004, CELL MOL LIFE SCI, V61, P118, DOI 10.1007/s00018-003-3337-8; Rothhammer T, 2008, EUR J CANCER, V44, P2526, DOI 10.1016/j.ejca.2008.07.029; Thawani JP, 2010, NEUROSURGERY, V66, P233, DOI 10.1227/01.NEU.0000363722.42097.C2; Trachana V, 2007, P NATL ACAD SCI USA, V104, P2691, DOI 10.1073/pnas.0611132104; Vachon Pierre H, 2011, J Signal Transduct, V2011, P738137, DOI 10.1155/2011/738137; Voura EB, 2001, MOL BIOL CELL, V12, P2699, DOI 10.1091/mbc.12.9.2699; Wenke AK, 2007, CELL ONCOL, V29, P373; Wenke AK, 2009, FEBS J, V276, P2494, DOI 10.1111/j.1742-4658.2009.06973.x; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Zhang YC, 2011, INVEST NEW DRUG, V29, P666, DOI 10.1007/s10637-010-9616-y	38	43	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2013	32	7					837	848		10.1038/onc.2012.115	http://dx.doi.org/10.1038/onc.2012.115			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GQ	22469980				2022-12-17	WOS:000316581100004
J	Palorini, R; De Rasmo, D; Gaviraghi, M; Danna, LS; Signorile, A; Cirulli, C; Chiaradonna, F; Alberghina, L; Papa, S				Palorini, R.; De Rasmo, D.; Gaviraghi, M.; Danna, L. Sala; Signorile, A.; Cirulli, C.; Chiaradonna, F.; Alberghina, L.; Papa, S.			Oncogenic K-ras expression is associated with derangement of the cAMP/PKA pathway and forskolin-reversible alterations of mitochondrial dynamics and respiration	ONCOGENE			English	Article						cancer cell metabolism; oncogenic K-ras; PKA; mitochondrial morphology; mitochondrial activity; glucose deprivation	DEPENDENT PROTEIN-KINASE; ADENYLATE-CYCLASE ACTIVITY; CYCLIC-AMP; COMPLEX-I; REGULATORY SUBUNITS; GENE-EXPRESSION; THYROID-CELLS; HUMAN CANCER; METABOLISM; PHOSPHORYLATION	The Warburg effect in cancer cells has been proposed to involve several mechanisms, including adaptation to hypoxia, oncogenes activation or loss of oncosuppressors and impaired mitochondria! function. In previous papers, it has been shown that K-ras transformed mouse cells are much more sensitive as compared with normal cells to glucose withdrawal (undergoing apoptosis) and present a high glycolytic rate and a strong reduction of mitochondrial complex I. Recent observations suggest that transformed cells have a derangement in the cyclic adenosine nnonophosphate/cAMP-dependent protein kinase (cAMP/PKA) pathway, which is known to regulate several mitochondrial functions. Herein, the derangement of the cAMP/PKA pathway and its impact on transformation-linked changes of mitochondrial functions is investigated. Exogenous stimulation of PKA activity, achieved by forskolin treatment protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels. Several of these effects were almost completely prevented by inhibiting the PKA activity. Short-time treatment with compounds favoring mitochondrial fusion strongly decreased the cellular ROS levels especially in transformed cells. These findings support the notion that glucose shortage-induced apoptosis, specific of K-ras-transformed cells, is associated to a derangement of PKA signaling that leads to mitochondrial complex I decrease, reduction of ATP formation, prevalence of mitochondrial fission over fusion, and thereby opening new approaches for development of anticancer drugs. Oncogene (2013) 32, 352-362; doi:10.1038/onc.2012.50; published online 12 March 2012	[Palorini, R.; Gaviraghi, M.; Danna, L. Sala; Cirulli, C.; Chiaradonna, F.; Alberghina, L.] Univ Milano Bicocca, Dept Biosci & Biotechnol, I-20126 Milan, MI, Italy; [De Rasmo, D.; Signorile, A.; Papa, S.] Univ Bari, Dept Med Biochem Biol & Phys DIBIFIM, Bari, Italy; [De Rasmo, D.; Papa, S.] CNR, Inst Biomembranes & Bioenerget IBBE, I-70126 Bari, Italy	University of Milano-Bicocca; Universita degli Studi di Bari Aldo Moro; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biomembrane e Bioenergetica (IBBE-CNR)	Chiaradonna, F (corresponding author), Univ Milano Bicocca, Dept Biosci & Biotechnol, Piazza Sci 2, I-20126 Milan, MI, Italy.	ferdinando.chiaradonna@unimib.it	Gaviraghi, Marco/AAB-1582-2020; De Rasmo, Domenico/AAC-4672-2020; CHIARADONNA, Ferdinando/K-4959-2016	Gaviraghi, Marco/0000-0003-2791-3638; De Rasmo, Domenico/0000-0002-3917-2411; CHIARADONNA, Ferdinando/0000-0001-8529-2732; Papa, Sergio/0000-0002-4417-1763; Signorile, Anna/0000-0001-9045-891X; Alberghina, Lilia/0000-0003-1694-931X	MIUR (FIRB-ITALBIONET); Italian Government (FAR); MIUR (Progetto FIRB Rete Nazionale per lo Studio della Proteomica Umana-Italian Human ProteomeNet); Progetto Strategico [Ric.002]; Cip [PS 101]; FOR [2000/06]	MIUR (FIRB-ITALBIONET)(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); Italian Government (FAR); MIUR (Progetto FIRB Rete Nazionale per lo Studio della Proteomica Umana-Italian Human ProteomeNet)(Ministry of Education, Universities and Research (MIUR)); Progetto Strategico; Cip; FOR	This work has been supported by a grant to LA from MIUR (FIRB-ITALBIONET), grants to FC from the Italian Government (FAR) and MIUR (Prin 2008), grant to DDR and CC from MIUR (Progetto FIRB futuro in ricerca, 2008), grants to SP from MIUR (Progetto FIRB Rete Nazionale per lo Studio della Proteomica Umana-Italian Human ProteomeNet, 2009) and Progetto Strategico Ric.002, Cip PS 101, FOR 2000/06.	Acin-Perez R, 2009, CELL METAB, V9, P265, DOI 10.1016/j.cmet.2009.01.012; Alchanati I, 2006, ONCOGENE, V25, P7138, DOI 10.1038/sj.onc.1209708; Balestrieri C, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-S12-S1; Baracca A, 2010, BBA-BIOENERGETICS, V1797, P314, DOI 10.1016/j.bbabio.2009.11.006; Baratta MG, 2009, MOL ENDOCRINOL, V23, P838, DOI 10.1210/me.2008-0353; Bellis A, 2009, ARTERIOSCL THROM VAS, V29, P1207, DOI 10.1161/ATVBAHA.109.184135; Benard G, 2007, J CELL SCI, V120, P838, DOI 10.1242/jcs.03381; Borlikova G, 2009, MOL NEUROBIOL, V40, P73, DOI 10.1007/s12035-009-8072-1; BOS JL, 1989, CANCER RES, V49, P4682; Bossu P, 2000, ONCOGENE, V19, P2147, DOI 10.1038/sj.onc.1203539; Buchet K, 1998, J BIOL CHEM, V273, P22983, DOI 10.1074/jbc.273.36.22983; Capaldi RA, 2002, BBA-BIOENERGETICS, V1555, P192, DOI 10.1016/S0005-2728(02)00277-3; Chang CR, 2007, J BIOL CHEM, V282, P21583, DOI 10.1074/jbc.C700083200; Chen Q, 1997, J BIOL CHEM, V272, P15247, DOI 10.1074/jbc.272.24.15247; Chiaradonna F, 2006, ONCOGENE, V25, P5391, DOI 10.1038/sj.onc.1209528; Chiaradonna F, 2012, BIOTECHNOL ADV, V30, P30, DOI 10.1016/j.biotechadv.2011.07.006; Chiaradonna F, 2008, FRONT BIOSCI-LANDMRK, V13, P5257, DOI 10.2741/3079; Chiaradonna F, 2006, BBA-BIOENERGETICS, V1757, P1338, DOI 10.1016/j.bbabio.2006.08.001; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Cribbs JT, 2007, EMBO REP, V8, P939, DOI 10.1038/sj.embor.7401062; De Rasmo D, 2011, EUR J PHARMACOL, V652, P15, DOI 10.1016/j.ejphar.2010.11.016; De Rasmo D, 2009, FEBS J, V276, P4325, DOI 10.1111/j.1742-4658.2009.07133.x; Depre C, 1998, J CLIN INVEST, V101, P390, DOI 10.1172/JCI1168; Feliciello A, 1996, J BIOL CHEM, V271, P25350, DOI 10.1074/jbc.271.41.25350; FRANKS DJ, 1987, J CELL BIOCHEM, V33, P87, DOI 10.1002/jcb.240330203; Gaglio D, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.56; Gaglio D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004715; GALLO A, 1995, CELL GROWTH DIFFER, V6, P91; Gerits N, 2008, CELL SIGNAL, V20, P1592, DOI 10.1016/j.cellsig.2008.02.022; Gomes LC, 2011, NAT CELL BIOL, V13, P589, DOI 10.1038/ncb2220; Grandemange S, 2009, SEMIN CANCER BIOL, V19, P50, DOI 10.1016/j.semcancer.2008.12.001; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; HIRAKI Y, 1989, MOL ENDOCRINOL, V3, P1470, DOI 10.1210/mend-3-9-1470; HOSAKA Y, 1992, ENDOCRINOLOGY, V131, P159, DOI 10.1210/en.131.1.159; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; KONISHIIMAMURA L, 1988, BIOCHEM BIOPH RES CO, V153, P1214, DOI 10.1016/S0006-291X(88)81357-3; KONISHIIMAMURA L, 1987, BIOCHEM BIOPH RES CO, V146, P47, DOI 10.1016/0006-291X(87)90688-7; Koopman WJH, 2005, AM J PHYSIOL-CELL PH, V289, pC881, DOI 10.1152/ajpcell.00104.2005; Lee HC, 2009, INT J MOL SCI, V10, P674, DOI 10.3390/ijms10020674; Lenaz G, 2010, BBA-BIOENERGETICS, V1797, P633, DOI 10.1016/j.bbabio.2010.01.025; Lu JX, 2009, CELL RES, V19, P802, DOI 10.1038/cr.2009.69; Ma WZ, 2007, J BIOENERG BIOMEMBR, V39, P243, DOI 10.1007/s10863-007-9083-0; Mathupala SP, 1997, J BIOENERG BIOMEMBR, V29, P339, DOI 10.1023/A:1022494613613; Mazurek S, 2003, ANTICANCER RES, V23, P1149; McFate T, 2008, J BIOL CHEM, V283, P22700, DOI 10.1074/jbc.M801765200; Merrill RA, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1000612; Moreno-Sanchez R, 2007, FEBS J, V274, P1393, DOI 10.1111/j.1742-4658.2007.05686.x; OSAWA H, 1995, DIABETES, V44, P1426, DOI 10.2337/diabetes.44.12.1426; Palmer CS, 2011, CELL SIGNAL, V23, P1534, DOI 10.1016/j.cellsig.2011.05.021; Papa S, 1996, EUR J BIOCHEM, V240, P461, DOI 10.1111/j.1432-1033.1996.0461h.x; Papa S, 2008, BBA-BIOENERGETICS, V1777, P719, DOI 10.1016/j.bbabio.2008.04.005; Papa S, 2006, IUBMB LIFE, V58, P173, DOI 10.1080/15216540500494516; Piccoli C, 2006, FEBS LETT, V580, P4539, DOI 10.1016/j.febslet.2006.06.085; Plecita-Hlavata L, 2008, BBA-BIOENERGETICS, V1777, P834, DOI 10.1016/j.bbabio.2008.04.002; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; Rarnanathan A, 2005, P NATL ACAD SCI USA, V102, P5992, DOI 10.1073/pnas.0502267102; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Sardanelli AM, 2006, FEBS LETT, V580, P5690, DOI 10.1016/j.febslet.2006.09.020; SCHWOCH G, 1990, BIOCHEM J, V270, P181, DOI 10.1042/bj2700181; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Signorile A, 2002, FEBS LETT, V512, P91, DOI 10.1016/S0014-5793(02)02226-3; Simonnet H, 2003, CARCINOGENESIS, V24, P1461, DOI 10.1093/carcin/bgg109; Tortora G, 2002, ANN NY ACAD SCI, V968, P139, DOI 10.1111/j.1749-6632.2002.tb04332.x; Vizan P, 2005, CANCER RES, V65, P5512, DOI 10.1158/0008-5472.CAN-05-0074; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; YAMAMOTO F, 1984, NUCLEIC ACIDS RES, V12, P8873, DOI 10.1093/nar/12.23.8873; Yun JY, 2009, SCIENCE, V325, P1555, DOI 10.1126/science.1174229; Zippin JH, 2002, FASEB J, V16, P82, DOI 10.1096/fj.02-0598fje; Zu XL, 2004, BIOCHEM BIOPH RES CO, V313, P459, DOI 10.1016/j.bbrc.2003.11.136	72	43	44	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2013	32	3					352	362		10.1038/onc.2012.50	http://dx.doi.org/10.1038/onc.2012.50			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087BP	22410778				2022-12-17	WOS:000314736600009
J	Lemaitre, C; Fischer, B; Kalousi, A; Hoffbeck, AS; Guirouilh-Barbat, J; Shahar, OD; Genet, D; Goldberg, M; Bertrand, P; Lopez, B; Brino, L; Soutoglou, E				Lemaitre, C.; Fischer, B.; Kalousi, A.; Hoffbeck, A-S; Guirouilh-Barbat, J.; Shahar, O. D.; Genet, D.; Goldberg, M.; Bertrand, P.; Lopez, B.; Brino, L.; Soutoglou, E.			The nucleoporin 153, a novel factor in double-strand break repair and DNA damage response	ONCOGENE			English	Article						DNA repair; nuclear pore; 53BP1	MAMMALIAN-CELLS; 53BP1; ATM; REPLICATION; STABILITY; DISTINCT; PATHWAY; COMPLEX; MDC1	DNA repair is essential in maintaining genome integrity and defects in different steps of the process have been linked to cancer and aging. It is a long lasting question how DNA repair is spatially and temporarily organized in the highly compartmentalized nucleus and whether the diverse nuclear compartments regulate differently the efficiency of repair. Increasing evidence suggest the involvement of nuclear pore complexes in repair of double-strand breaks (DSBs) in yeast. Here, we show that the human nucleoporin 153 (NUP153) has a role in repair of DSBs and in the activation of DNA damage checkpoints. We explore the mechanism of action of NUP153 and we propose its potential as a novel therapeutic target in cancers.	[Soutoglou, E.] CU Strasbourg, INSERM U964, UMR CNRS 7104, IGBMC,UdS, F-67404 Illkirch Graffenstaden, France; [Fischer, B.; Brino, L.] CU Strasbourg, UMR CNRS 7104, IGBMC, High Throughput Screening Facil, F-67404 Illkirch Graffenstaden, France; [Guirouilh-Barbat, J.; Genet, D.; Bertrand, P.; Lopez, B.] CNRS, UMR217, Inst Cellular & Mol Radiobiol, Fontenay Aux Roses, France; [Shahar, O. D.; Goldberg, M.] Hebrew Univ Jerusalem, Inst Life Sci, Dept Genet, IL-91904 Jerusalem, Israel	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Hebrew University of Jerusalem	Soutoglou, E (corresponding author), CU Strasbourg, INSERM U964, UMR CNRS 7104, IGBMC,UdS, BP 10142, F-67404 Illkirch Graffenstaden, France.	evisou@igbmc.fr	Shahar, Or/ABG-9168-2020; Boumendil, Charlene/GPS-4811-2022; guirouilh-barbat, josée/AAX-7140-2020; Lopez, Bernard S/O-7308-2017; guirouilh-barbat, josee/O-7286-2017	Boumendil, Charlene/0000-0002-1953-3902; Lopez, Bernard S/0000-0001-5088-0155; BERTRAND, Pascale/0000-0002-9019-742X; Soutoglou, Evi/0000-0002-3724-5613; Brino, laurent/0000-0002-9036-1461; Shahar, Or/0000-0002-5039-8307; Goldberg, Michal/0000-0001-9397-2383; guirouilh-barbat, josee/0000-0002-8845-7333	Region Alsace; CNRS; ANR; INCA; HFSP	Region Alsace(Region Grand-Est); CNRS(Centre National de la Recherche Scientifique (CNRS)); ANR(French National Research Agency (ANR)); INCA(Institut National du Cancer (INCA) France); HFSP(Human Frontier Science Program)	We thank Amelie Weiss, Laure Froidevaux and Audrey Furst for excellent technical assistance. The GFP-NUP153 vector was provided by Ian Ellenberg (EMBL, Heidelberg). We are grateful to Zita Nagy and Tibor Pankotai for critical reading of the manuscript. C.L. is supported by the Region Alsace. The research in E.S. lab is funded by CNRS, ANR, INCA and HFSP. We thank the imaging center of IGBMC and particularly Marc Koch for the help with the multi photon laser experiments.	Bartek J, 2007, CURR OPIN CELL BIOL, V19, P238, DOI 10.1016/j.ceb.2007.02.009; Bermejo R, 2011, CELL, V146, P233, DOI 10.1016/j.cell.2011.06.033; Bouwman P, 2010, NAT STRUCT MOL BIOL, V17, P688, DOI 10.1038/nsmb.1831; Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012; Guirouilh-Barbat J, 2004, MOL CELL, V14, P611, DOI 10.1016/j.molcel.2004.05.008; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Lee JH, 2010, EMBO J, V29, P574, DOI 10.1038/emboj.2009.372; Lisby M, 2003, NAT CELL BIOL, V5, P572, DOI 10.1038/ncb997; Loeillet S, 2005, DNA REPAIR, V4, P459, DOI 10.1016/j.dnarep.2004.11.010; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Miller KM, 2010, NAT STRUCT MOL BIOL, V17, P1144, DOI 10.1038/nsmb.1899; Minter-Dykhouse K, 2008, J CELL BIOL, V181, P727, DOI 10.1083/jcb.200801083; Misteli T, 2009, NAT REV MOL CELL BIO, V10, P243, DOI 10.1038/nrm2651; Mochan TA, 2003, CANCER RES, V63, P8586; Moudry P, 2012, CELL DEATH DIFFER, V19, P798, DOI 10.1038/cdd.2011.150; Nagai S, 2008, SCIENCE, V322, P597, DOI 10.1126/science.1162790; Noon AT, 2010, NAT CELL BIOL, V12, P177, DOI 10.1038/ncb2017; Oza P, 2009, GENE DEV, V23, P912, DOI 10.1101/gad.1782209; Palancade B, 2007, MOL BIOL CELL, V18, P2912, DOI 10.1091/mbc.E07-02-0123; Rass E, 2009, NAT STRUCT MOL BIOL, V16, P819, DOI 10.1038/nsmb.1641; Reddy KL, 2008, METHODS, V45, P242, DOI 10.1016/j.ymeth.2008.06.013; Soutoglou E, 2008, SCIENCE, V320, P1507, DOI [10.1126/science.1159051, 10.1126/science.ll59051]; Soutoglou E, 2007, NAT CELL BIOL, V9, P675, DOI 10.1038/ncb1591; Walther TC, 2001, EMBO J, V20, P5703, DOI 10.1093/emboj/20.20.5703; Weinstock DM, 2006, METHOD ENZYMOL, V409, P524, DOI 10.1016/S0076-6879(05)09031-2; Xie AY, 2007, MOL CELL, V28, P1045, DOI 10.1016/j.molcel.2007.12.005; Yoshida M, 1999, ANN NY ACAD SCI, V886, P23, DOI 10.1111/j.1749-6632.1999.tb09397.x	27	43	43	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2012	31	45					4803	4809		10.1038/onc.2011.638	http://dx.doi.org/10.1038/onc.2011.638			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036NF	22249246				2022-12-17	WOS:000311033000009
J	Sadagopan, S; Veettil, MV; Chakraborty, S; Sharma-Walia, N; Paudel, N; Bottero, V; Chandran, B				Sadagopan, S.; Veettil, M. V.; Chakraborty, S.; Sharma-Walia, N.; Paudel, N.; Bottero, V.; Chandran, B.			Angiogenin functionally interacts with p53 and regulates p53-mediated apoptosis and cell survival	ONCOGENE			English	Article						angiogenin; p53; KSHV; cancer; anti-apoptosis; p53 ubiquitination	ENDOTHELIAL-CELLS; SERUM-LEVELS; EXPRESSION; PROTEIN; GROWTH; PHOSPHORYLATION; PROLIFERATION; REQUIREMENT; INDUCTION; PROMOTES	Angiogenin, a 14-kDa multifunctional pro-angiogenic growth factor, is upregulated in several types of cancers. Anti-angiogenin monoclonal antibodies used as antagonists inhibited the establishment, progression and metastasis of human cancer cells in athymic mice (Olson et al., 1994). Silencing angiogenin and inhibition of angiogenin's nuclear translocation blocked cell survival and induced cell death in B-lymphoma and endothelial cells latently infected with Kaposi sarcoma-associated herpesvirus (Sadagopan et al., 2009), suggesting that actively proliferating cancer cells could be inducing angiogenin for inhibiting apoptotic pathways. However, the mechanism of cell survival and apoptosis regulation by angiogenin and their functional significance in cancer is not known. We demonstrate that angiogenin interacts with p53 and colocalizes in the nucleus. Silencing endogenous angiogenin induced p53 promoter activation and p53 target gene (p53, p21 and Bax) expression, downregulated anti-apoptotic Bcl-2 gene expression and increased p53-mediated cell death. In contrast, angiogenin expression blocked pro-apoptotic Bax and p21 expression, induced Bcl-2 and blocked cell death. Angiogenin also co-immunoprecipitated with p53 regulator protein Mdm2. Angiogenin expression resulted in the inhibition of p53 phosphorylation, increased p53-Mdm2 interaction, and consequently increased ubiquitination of p53. Taken together, these studies demonstrate that angiogenin promotes the inhibition of p53 function to mediate anti-apoptosis and cell survival. Our results reveal for the first time a novel p53 interacting function of angiogenin in anti-apoptosis and survival of cancer cells and suggest that targeting angiogenin could be an effective therapy for several cancers. Oncogene (2012) 31, 4835-4847; doi:10.1038/onc.2011.648; published online 23 January 2012	[Sadagopan, S.; Veettil, M. V.; Chakraborty, S.; Sharma-Walia, N.; Paudel, N.; Bottero, V.; Chandran, B.] Rosalind Franklin Univ Med & Sci, Chicago Med Sch, Dept Microbiol & Immunol, HM Bligh Canc Res Labs, N Chicago, IL 60064 USA	Chicago Medical School; Rosalind Franklin University Medical & Science	Chandran, B (corresponding author), Rosalind Franklin Univ Med & Sci, Chicago Med Sch, Dept Microbiol & Immunol, HM Bligh Canc Res Labs, 3333 Green Bay Rd, N Chicago, IL 60064 USA.	bala.chandran@rosalindfranklin.edu	Chakraborty, Sayan/AAC-5622-2019	Chakraborty, Sayan/0000-0002-5591-8164	Public Health Service [AI 091767]; RFUMS-HM Bligh Cancer Research Fund; NATIONAL CANCER INSTITUTE [R01CA075911] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI091767] Funding Source: NIH RePORTER	Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); RFUMS-HM Bligh Cancer Research Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was supported in part by Public Health Service grants, AI 091767 and the RFUMS-HM Bligh Cancer Research Fund to BC. We thank Dr AP Rapoport (University of Maryland) for providing p53 constructs. We thank Dr B Vogelstein (Johns Hopkins University) for the p53<SUP>+/+</SUP> and p53 <SUP>/</SUP> HCT116 cell lines. We thank Keith Philibert for critically reading the manuscript and Bob Dickinson for FACS analysis at the RFUMS core facility.	Adams JM, 2007, CURR OPIN IMMUNOL, V19, P488, DOI 10.1016/j.coi.2007.05.004; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Barton DPJ, 1997, CLIN CANCER RES, V3, P1579; Chopra V, 1998, CANCER INVEST, V16, P152, DOI 10.3109/07357909809050029; Chopra V, 1997, J CANCER RES CLIN, V123, P167, DOI 10.1007/BF01214669; FETT JW, 1985, BIOCHEMISTRY-US, V24, P5480, DOI 10.1021/bi00341a030; Foulkes WD, 2007, NEW ENGL J MED, V357, P2539, DOI 10.1056/NEJMp0707422; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hemann MT, 2006, CELL DEATH DIFFER, V13, P1256, DOI 10.1038/sj.cdd.4401962; Hu F, 2010, ONCOGENE, V29, P5464, DOI 10.1038/onc.2010.275; Hu GF, 1998, P NATL ACAD SCI USA, V95, P9791, DOI 10.1073/pnas.95.17.9791; Kishimoto K, 2005, ONCOGENE, V24, P445, DOI 10.1038/sj.onc.1208223; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Li DWC, 2006, ONCOGENE, V25, P3006, DOI 10.1038/sj.onc.1209334; LI DC, 1994, J PATHOL, V172, P171, DOI 10.1002/path.1711720203; Liu SM, 2001, BIOCHEM BIOPH RES CO, V287, P305, DOI 10.1006/bbrc.2001.5568; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Marchenko ND, 2007, EMBO J, V26, P923, DOI 10.1038/sj.emboj.7601560; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; Milczarek GJ, 1996, LIFE SCI, V60, P1, DOI 10.1016/S0024-3205(96)00479-1; Montero S, 1998, CLIN CANCER RES, V4, P2161; MOROIANU J, 1994, P NATL ACAD SCI USA, V91, P1677, DOI 10.1073/pnas.91.5.1677; OLSON KA, 1994, CANCER RES, V54, P4576; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Perfettini JL, 2005, J EXP MED, V201, P279, DOI 10.1084/jem.20041502; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Sadagopan S, 2011, J VIROL, V85, P2666, DOI 10.1128/JVI.01532-10; Sadagopan S, 2009, J VIROL, V83, P3342, DOI 10.1128/JVI.02052-08; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 2000, GENE DEV, V14, P289; Shimoyama S, 1996, CANCER RES, V56, P2703; Tsuji T, 2005, CANCER RES, V65, P1352, DOI 10.1158/0008-5472.CAN-04-2058; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WALDMAN T, 1995, CANCER RES, V55, P5187; Xu ZP, 2003, BIOCHEMISTRY-US, V42, P121, DOI 10.1021/bi020465x; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221	40	43	47	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	46					4835	4847		10.1038/onc.2011.648	http://dx.doi.org/10.1038/onc.2011.648			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	038YT	22266868	Green Accepted			2022-12-17	WOS:000311210700004
J	Sangwan, M; McCurdy, SR; Livne-bar, I; Ahmad, M; Wrana, JL; Chen, D; Bremner, R				Sangwan, M.; McCurdy, S. R.; Livne-bar, I.; Ahmad, M.; Wrana, J. L.; Chen, D.; Bremner, R.			Established and new mouse models reveal E2f1 and Cdk2 dependency of retinoblastoma, and expose effective strategies to block tumor initiation	ONCOGENE			English	Article						chemoprevention; retinoblastoma; Cdk; E2f; p107	CELL-CYCLE INHIBITION; FUNCTIONALLY ANTAGONIZE; DNA-BINDING; RB; P107; PROLIFERATION; APOPTOSIS; CANCER; SUPPRESSOR; PRB	RB+/- individuals develop retinoblastoma and, subsequently, many other tumors. The Rb relatives p107 and p130 protect the tumor-resistant Rb-/- mouse retina. Determining the mechanism underlying this tumor suppressor function may expose novel strategies to block Rb pathway cancers. p107/p130 are best known as E2f inhibitors, but here we implicate E2f-independent Cdk2 inhibition as the critical p107 tumor suppressor function in vivo. Like p107 loss, deleting p27 or inactivating its Cdk inhibitor (CKI) function (p27(CK-)) cooperated with Rb loss to induce retinoblastoma. Genetically, p107 behaved like a CKI because inactivating Rb and one allele each of p27 and p107 was tumorigenic. Although Rb loss induced canonical E2f targets, unexpectedly p107 loss did not further induce these genes, but instead caused post-transcriptional Skp2 induction and Cdk2 activation. Strikingly, Cdk2 activity correlated with tumor penetrance across all the retinoblastoma models. Therefore, Rb restrains E2f, but p107 inhibits cross talk to Cdk. While removing either E2f2 or E2f3 genes had little effect, removing only one E2f1 allele blocked tumorigenesis. More importantly, exposing retinoblastoma-prone fetuses to small molecule inhibitors of E2f (HLM006474) or Cdk (R547) for merely 1 week dramatically inhibited subsequent tumorigenesis in adult mice. Protection was achieved without disrupting normal proliferation. Thus, exquisite sensitivity of the cell-of-origin to E2f and Cdk activity can be exploited to prevent Rb pathway-induced cancer in vivo without perturbing normal cell division. These data suggest that E2f inhibitors, never before tested in vivo, or CKIs, largely disappointing as therapeutics, may be effective preventive agents. Oncogene (2012) 31, 5019-5028; doi:10.1038/onc.2011.654; published online 30 January 2012	[Sangwan, M.; McCurdy, S. R.; Livne-bar, I.; Ahmad, M.; Chen, D.; Bremner, R.] Univ Toronto, Toronto Western Res Inst, Univ Hlth Network, Dept Ophthalmol & Visual Sci, Toronto, ON M5T 2S8, Canada; [Sangwan, M.; McCurdy, S. R.; Livne-bar, I.; Ahmad, M.; Chen, D.; Bremner, R.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5T 2S8, Canada; [Wrana, J. L.] Univ Toronto, Dept Mol Genet, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5T 2S8, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Bremner, R (corresponding author), Univ Toronto, Toronto Western Res Inst, Univ Hlth Network, Dept Ophthalmol & Visual Sci, Room Mc6-424,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	dchen@uhnres.utoronto.ca; rbremner@uhnres.utoronto.ca	Chen, Danian/GXV-7996-2022; Bremner, Rod/I-6490-2012; Wrana, Jeffrey/F-8857-2013	Bremner, Rod/0000-0001-9184-7212; Chen, Danian/0000-0002-6916-2978	Canadian Institutes for Health Research (CIHR); Foundation Fighting Blindness Canada; Ontario Institute for Cancer Research through Government of Ontario; Terry Fox Research Institute; CIHR	Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Foundation Fighting Blindness Canada; Ontario Institute for Cancer Research through Government of Ontario; Terry Fox Research Institute; CIHR(Canadian Institutes of Health Research (CIHR))	We thank Arnaud Besson and James Roberts for sharing p27<SUP>CK-/CK-</SUP> mice, and Fred Dick, Gustavo Leone and Philippe Monnier for comments. This project was funded by grants to RB from the Canadian Institutes for Health Research (CIHR), Foundation Fighting Blindness Canada, Ontario Institute for Cancer Research through funding provided by the Government of Ontario and the Terry Fox Research Institute. MS, MA and SRM were supported in part by fellowships from a CIHR training program.	Balmer A, 2006, ONCOGENE, V25, P5341, DOI 10.1038/sj.onc.1209622; Bandara LR, 1997, NAT BIOTECHNOL, V15, P896, DOI 10.1038/nbt0997-896; Besson A, 2007, GENE DEV, V21, P1731, DOI 10.1101/gad.1556607; Binne UK, 2007, NAT CELL BIOL, V9, P225, DOI 10.1038/ncb1532; Black EP, 2003, CANCER RES, V63, P3716; Boquoi A, 2009, CANCER PREV RES, V2, P800, DOI 10.1158/1940-6207.CAPR-09-0053; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; Buttitta LA, 2007, DEV CELL, V12, P631, DOI 10.1016/j.devcel.2007.02.020; Castano E, 1998, MOL CELL BIOL, V18, P5380, DOI 10.1128/MCB.18.9.5380; Chen D, 2004, CANCER CELL, V5, P539, DOI 10.1016/j.ccr.2004.05.025; Chen D, 2007, PLOS BIOL, V5, P1504, DOI 10.1371/journal.pbio.0050179; Chen DN, 2009, NATURE, V462, P925, DOI 10.1038/nature08544; Chibazakura T, 2004, P NATL ACAD SCI USA, V101, P4465, DOI 10.1073/pnas.0400655101; Chicas A, 2010, CANCER CELL, V17, P376, DOI 10.1016/j.ccr.2010.01.023; Chong JL, 2009, NATURE, V462, P930, DOI 10.1038/nature08677; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Classon M, 2000, P NATL ACAD SCI USA, V97, P10820, DOI 10.1073/pnas.190343497; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Conkrite K, 2011, GENE DEV, V25, P1734, DOI 10.1101/gad.17027411; Dannenberg JH, 2004, GENE DEV, V18, P2952, DOI 10.1101/gad.322004; DePinto W, 2006, MOL CANCER THER, V5, P2644, DOI 10.1158/1535-7163.MCT-06-0355; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; Fabbrizio E, 1999, ONCOGENE, V18, P4357, DOI 10.1038/sj.onc.1202825; Franklin DS, 1998, GENE DEV, V12, P2899, DOI 10.1101/gad.12.18.2899; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Ji P, 2004, MOL CELL, V16, P47, DOI 10.1016/j.molcel.2004.09.029; Kelloff GJ, 2006, CLIN CANCER RES, V12, P3661, DOI 10.1158/1078-0432.CCR-06-1104; Lara MF, 2008, MOL CARCINOGEN, V47, P209, DOI 10.1002/mc.20376; Lara MF, 2008, MOL CARCINOGEN, V47, P105, DOI 10.1002/mc.20367; Lee EY, 2002, CANCER CELL, V2, P463, DOI 10.1016/S1535-6108(02)00207-6; Lindor NM, 2008, J NATL CANC I MONOGR, V38, P1, DOI DOI 10.1093/JNCIMONOGRAPHS/LGN001; Ma YH, 2008, CANCER RES, V68, P6292, DOI 10.1158/0008-5472.CAN-08-0121; MacPherson D, 2004, GENE DEV, V18, P1681, DOI 10.1101/gad.1203304; Malumbres M, 2008, TRENDS PHARMACOL SCI, V29, P16, DOI 10.1016/j.tips.2007.10.012; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Martin A, 2005, CANCER CELL, V7, P591, DOI 10.1016/j.ccr.2005.05.006; McClellan KA, 2007, MOL CELL BIOL, V27, P4825, DOI 10.1128/MCB.02100-06; Montigiani S, 2003, ONCOGENE, V22, P4943, DOI 10.1038/sj.onc.1206495; Ng AK, 2010, SEMIN RADIAT ONCOL, V20, P67, DOI 10.1016/j.semradonc.2009.09.002; Padmakumar VC, 2009, MOL CELL BIOL, V29, P2582, DOI 10.1128/MCB.00952-08; Park MS, 1999, P NATL ACAD SCI USA, V96, P6382, DOI 10.1073/pnas.96.11.6382; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; Rodier G, 2005, J CELL BIOL, V168, P55, DOI 10.1083/jcb.200404146; Santamaria D, 2007, NATURE, V448, P811, DOI 10.1038/nature06046; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Wang HB, 2010, NAT GENET, V42, P83, DOI 10.1038/ng.498; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Yu CL, 2009, JNCI-J NATL CANCER I, V101, P581, DOI 10.1093/jnci/djp046; Zhang JK, 2004, CELL CYCLE, V3, P952; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801	51	43	45	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	48					5019	5028		10.1038/onc.2011.654	http://dx.doi.org/10.1038/onc.2011.654			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048CU	22286767	Green Accepted			2022-12-17	WOS:000311888600006
J	Santo, EE; Ebus, ME; Koster, J; Schulte, JH; Lakeman, A; van Sluis, P; Vermeulen, J; Gisselsson, D; Ora, I; Lindner, S; Buckley, PG; Stallings, RL; Vandesompele, J; Eggert, A; Caron, HN; Versteeg, R; Molenaar, JJ				Santo, E. E.; Ebus, M. E.; Koster, J.; Schulte, J. H.; Lakeman, A.; van Sluis, P.; Vermeulen, J.; Gisselsson, D.; Ora, I.; Lindner, S.; Buckley, P. G.; Stallings, R. L.; Vandesompele, J.; Eggert, A.; Caron, H. N.; Versteeg, R.; Molenaar, J. J.			Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma	ONCOGENE			English	Article						FOXR1; FOXO; forkhead-box; neuroblastoma; MLL; 11q23	FORKHEAD TRANSCRIPTION FACTOR; TUMOR-SUPPRESSOR GENE; ALVEOLAR RHABDOMYOSARCOMA; EXPRESSION PATTERNS; CELL-SURVIVAL; IN-SILICO; IDENTIFICATION; CANCER; COMMON; MLL	Neuroblastoma tumors frequently show loss of heterozygosity of chromosome 11q with a shortest region of overlap in the 11q23 region. These deletions are thought to cause inactivation of tumor suppressor genes leading to haploinsufficiency. Alternatively, micro-deletions could lead to gene fusion products that are tumor driving. To identify such events we analyzed a series of neuroblastomas by comparative genomic hybridization and single-nucleotide polymorphism arrays and integrated these data with Affymetrix mRNA profiling data with the bioinformatic tool R2 (http://r2.amc.nl). We identified three neuroblastoma samples with small interstitial deletions at 11q23, upstream of the forkhead-box R1 transcription factor (FOXR1). Genes at the proximal side of the deletion were fused to FOXR1, resulting in fusion transcripts of MLL-FOXR1 and PAFAH1B2-FOXR1. FOXR1 expression has only been detected in early embryogenesis. Affymetrix microarray analysis showed high FOXR1 mRNA expression exclusively in the neuroblastomas with micro-deletions and rare cases of other tumor types, including osteosarcoma cell line HOS. RNAi silencing of FOXR1 strongly inhibited proliferation of HOS cells and triggered apoptosis. Expression profiling of these cells and reporter assays suggested that FOXR1 is a negative regulator of fork-head box factor-mediated transcription. The neural crest stem cell line JoMa1 proliferates in culture conditional to activity of a MYC-ER transgene. Over-expression of the wild-type FOXR1 could functionally replace MYC and drive proliferation of JoMa1. We conclude that FOXR1 is recurrently activated in neuroblastoma by intrachromosomal deletion/fusion events, resulting in overexpression of fusion transcripts. Forkhead-box transcription factors have not been previously implicated in neuroblastoma pathogenesis. Furthermore, this is the first identification of intrachromosomal fusion genes in neuroblastoma. Oncogene (2012) 31, 1571-1581; doi:10.1038/onc.2011.344; published online 22 August 2011	[Santo, E. E.; Ebus, M. E.; Koster, J.; Lakeman, A.; van Sluis, P.; Versteeg, R.; Molenaar, J. J.] Univ Amsterdam, Acad Med Ctr, Dept Oncogenom, NL-1105 AZ Amsterdam, Netherlands; [Schulte, J. H.; Lindner, S.; Eggert, A.] Univ Childrens Hosp Essen, Dept Pediat Oncol, Essen, Germany; [Vermeulen, J.; Vandesompele, J.] Ghent Univ Hosp, Ctr Med Genet, Ghent, Belgium; [Gisselsson, D.; Ora, I.] Lund Univ, Dept Clin Genet, Lund, Sweden; [Buckley, P. G.; Stallings, R. L.] Royal Coll Surgeons Ireland, Natl Childrens Res Ctr, Dept Canc Genet, Dublin, Ireland; [Caron, H. N.] Univ Amsterdam, Acad Med Ctr, Dept Pediat Oncol, Emma Kinderziekenhuis, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Duisburg Essen; Ghent University; Ghent University Hospital; Lund University; National Children's Research Centre (NCRC); Royal College of Surgeons - Ireland; Trinity College Dublin; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam	Molenaar, JJ (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Oncogenom, M1-132,Meibergdreef 15, NL-1105 AZ Amsterdam, Netherlands.	j.j.molenaar@amc.uva.nl	Versteeg, Rogier/AAQ-1765-2020; Øra, Ingrid/J-2596-2013; Schulte, Johannes H/G-3981-2010; Eggert, Angelika/AAE-6907-2022; Vandesompele, Jo/W-3411-2018; Schulte, Johannes H./V-2474-2018; Koster, Jan/C-5934-2008; Stallings, Raymond/A-7213-2008	Øra, Ingrid/0000-0002-3931-4125; Eggert, Angelika/0000-0003-3476-8184; Vandesompele, Jo/0000-0001-6274-0184; Koster, Jan/0000-0002-0890-7585; Versteeg, Rogier/0000-0001-7172-0388; Schulte, Johannes Hubertus/0000-0003-0671-1201	Stichting Koningin Wilhelmina Fonds (KWF); Stichting Kindergeneeskundig Kankeronderzoek (SKK); Stichting Kinderen Kankervrij (KiKa)	Stichting Koningin Wilhelmina Fonds (KWF); Stichting Kindergeneeskundig Kankeronderzoek (SKK); Stichting Kinderen Kankervrij (KiKa)	This work was supported by the Stichting Koningin Wilhelmina Fonds (KWF), Stichting Kindergeneeskundig Kankeronderzoek (SKK) and the Stichting Kinderen Kankervrij (KiKa).	Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Buckley PG, 2010, CLIN CANCER RES, V16, P2971, DOI 10.1158/1078-0432.CCR-09-3215; Chen CC, 2010, DEV CELL, V18, P592, DOI 10.1016/j.devcel.2010.03.008; Cole KA, 2008, MOL CANCER RES, V6, P735, DOI 10.1158/1541-7786.MCR-07-2102; DAVIS RJ, 1994, CANCER RES, V54, P2869; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Gomez-Ferreria MA, 2003, J MOL BIOL, V329, P631, DOI 10.1016/S0022-2836(03)00524-2; Gomis RR, 2006, P NATL ACAD SCI USA, V103, P12747, DOI 10.1073/pnas.0605333103; Guo C, 1999, ONCOGENE, V18, P4948, DOI 10.1038/sj.onc.1202887; HAMPTON GM, 1994, CANCER RES, V54, P4586; Hellemans J, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-2-r19; Hoeller S, 2010, HISTOPATHOLOGY, V57, P73, DOI 10.1111/j.1365-2559.2010.03600.x; Katoh M, 2004, INT J MOL MED, V14, P463; Katoh M, 2004, INT J ONCOL, V25, P219; Katoh M, 2004, INT J ONCOL, V24, P1339; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Lee ASG, 2000, BRIT J CANCER, V83, P750, DOI 10.1054/bjoc.2000.1366; Lefever S, 2009, NUCLEIC ACIDS RES, V37, pD942, DOI 10.1093/nar/gkn777; Liu H, 2009, CANCER BIOL THER, V8, P1204, DOI 10.4161/cbt.8.13.8924; Mahony S, 2007, NUCLEIC ACIDS RES, V35, pW253, DOI 10.1093/nar/gkm272; Martinez MJ, 2007, BIOINFORMATICS, V23, P21, DOI 10.1093/bioinformatics/btl531; Matys V, 2006, NUCLEIC ACIDS RES, V34, pD108, DOI 10.1093/nar/gkj143; Maurer J, 2007, DIFFERENTIATION, V75, P580, DOI 10.1111/j.1432-0436.2007.00164.x; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Nowacki S, 2008, ONCOGENE, V27, P3329, DOI 10.1038/sj.onc.1210996; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Pulido HA, 2000, CANCER RES, V60, P6677; Schones DE, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-19; Schuller U, 2007, MOL CELL BIOL, V27, P8259, DOI 10.1128/MCB.00707-07; Schuff M, 2006, INT J DEV BIOL, V50, P429, DOI 10.1387/ijdb.052126ms; Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735; So CW, 2003, BLOOD, V101, P633, DOI 10.1182/blood-2002-06-1785; So CW, 2002, MOL CELL BIOL, V22, P6542, DOI 10.1128/MCB.22.18.6542-6552.2002; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; van Noesel MM, 2004, GENE, V325, P1, DOI 10.1016/j.gene.2003.09.042; Vermeulen J, 2009, LANCET ONCOL, V10, P663, DOI 10.1016/S1470-2045(09)70154-8; Wakaguri H, 2008, NUCLEIC ACIDS RES, V36, pD97, DOI 10.1093/nar/gkm901; Wierstra I, 2007, BIOL CHEM, V388, P1257, DOI 10.1515/BC.2007.159; Wlodarska I, 2005, LEUKEMIA, V19, P1299, DOI 10.1038/sj.leu.2403813; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245	41	43	44	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	12					1571	1581		10.1038/onc.2011.344	http://dx.doi.org/10.1038/onc.2011.344			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916VT	21860421				2022-12-17	WOS:000302132000009
J	Maquoi, E; Assent, D; Detilleux, J; Pequeux, C; Foidart, JM; Noel, A				Maquoi, E.; Assent, D.; Detilleux, J.; Pequeux, C.; Foidart, J-M; Noel, A.			MT1-MMP protects breast carcinoma cells against type I collagen-induced apoptosis	ONCOGENE			English	Article						breast cancer; MT1-MMP; apoptosis; type I collagen; BIK	MEMBRANE-TYPE-1 MATRIX-METALLOPROTEINASE; EXTRACELLULAR-MATRIX; GENE-EXPRESSION; GROWTH-FACTOR; CANCER-CELLS; MESENCHYMAL TRANSITION; BH3-ONLY PROTEIN; UP-REGULATION; TUMOR-GROWTH; ACTIVATION	As invading breast carcinoma cells breach their underlying basement membrane, they become confronted with a dense three-dimensional reactive stroma dominated by type I collagen. To develop metastatic capabilities, invading tumor cells must acquire the capacity to negotiate this novel microenvironment. Collagen influences the fate of epithelial cells by inducing apoptosis. However, the mechanisms used by invading tumor cells to evade collagen-induced apoptosis remain to be defined. We demonstrate that membrane type-1 matrix metalloproteinase (MT1-MMP/MMP-14) confers breast cancer cells with the ability to escape apoptosis when embedded in a collagen gel and after orthotopic implantation in vivo. In the absence of MMP-14-dependent proteolysis, type I collagen triggers apoptosis by inducing the expression of the pro-apoptotic Bcl-2-interacting killer in luminal-like breast cancer cells. These findings reveal a new mechanism whereby MMP-14 activity promotes tumor progression by circumventing apoptosis. Oncogene (2012) 31, 480-493; doi: 10.1038/onc.2011.249; published online 27 June 2011	[Maquoi, E.; Assent, D.; Detilleux, J.; Pequeux, C.; Foidart, J-M; Noel, A.] Univ Liege, Lab Tumor & Dev Biol, GIGA Canc, Inst Pathol, B-4000 Liege, Belgium	University of Liege	Maquoi, E (corresponding author), Univ Liege, Lab Tumor & Dev Biol, GIGA Canc, Inst Pathol, CHU B23, B-4000 Liege, Belgium.	erik.maquoi@ulg.ac.be		Pequeux, Christel/0000-0001-8275-1489; Noel, Agnes/0000-0002-7670-6179	MICROENVIMET [FP7-HEALTH-2007-A, 201279]; Fonds de la Recherche Scientifique Medicale; Fonds de la Recherche Scientifique - FNRS (FRS-FNRS, Belgium); Foundation against Cancer (foundation of public interest, Belgium); CGRI-FNRS-INSERM Cooperation; Fonds speciaux de la Recherche (University of Liege); Centre Anticancereux pres l'Universite de Liege; Fonds Leon Fredericq (University of Liege); Direction Generale Operationnelle de l'Economie; SPW (Region Wallonne, Belgium); Fonds Social Europeen (FSE, Belgium); Fonds d'Investissements de la Recherche Scientifique (FIRS, CHU Liege, Belgium); Belgian Science Policy (Brussels, Belgium)	MICROENVIMET; Fonds de la Recherche Scientifique Medicale(Fonds de la Recherche Scientifique - FNRS); Fonds de la Recherche Scientifique - FNRS (FRS-FNRS, Belgium)(Fonds de la Recherche Scientifique - FNRS); Foundation against Cancer (foundation of public interest, Belgium); CGRI-FNRS-INSERM Cooperation(Fonds de la Recherche Scientifique - FNRS); Fonds speciaux de la Recherche (University of Liege)(University of Liege); Centre Anticancereux pres l'Universite de Liege; Fonds Leon Fredericq (University of Liege)(University of Liege); Direction Generale Operationnelle de l'Economie; SPW (Region Wallonne, Belgium); Fonds Social Europeen (FSE, Belgium)(European Social Fund (ESF)); Fonds d'Investissements de la Recherche Scientifique (FIRS, CHU Liege, Belgium); Belgian Science Policy (Brussels, Belgium)(Belgian Federal Science Policy Office)	We thank M Fringuellini, P Gavitelli, E Konradovski and N Lefin for their excellent technical assistance. This work was supported by grants from the FP7-HEALTH-2007-A Proposal No 201279 'MICROENVIMET', the Fonds de la Recherche Scientifique Medicale, the Fonds de la Recherche Scientifique - FNRS (FRS-FNRS, Belgium), the Foundation against Cancer (foundation of public interest, Belgium), the CGRI-FNRS-INSERM Cooperation, the Fonds speciaux de la Recherche (University of Liege), the Centre Anticancereux pres l'Universite de Liege, the Fonds Leon Fredericq (University of Liege), the Direction Generale Operationnelle de l'Economie, de l'Emploi et de la Recherche from the SPW (Region Wallonne, Belgium), the Fonds Social Europeen (FSE, Belgium), the Fonds d'Investissements de la Recherche Scientifique (FIRS, CHU Liege, Belgium), the Interuniversity Attraction Poles Program - Belgian Science Policy (Brussels, Belgium). EM is a Research Associate from the F.R.S.-FNRS (Belgium).	Bao WJ, 2004, J CELL BIOL, V167, P745, DOI 10.1083/jcb.200404018; Barbolina MV, 2008, SEMIN CELL DEV BIOL, V19, P24, DOI 10.1016/j.semcdb.2007.06.008; Barkan D, 2010, CANCER RES, V70, P5706, DOI 10.1158/0008-5472.CAN-09-2356; Bindels S, 2006, ONCOGENE, V25, P4975, DOI 10.1038/sj.onc.1209511; BIRKEDALHANSEN H, 1987, METHOD ENZYMOL, V144, P140; Bissell MJ, 2003, CURR OPIN CELL BIOL, V15, P753, DOI 10.1016/j.ceb.2003.10.016; Blick T, 2010, J MAMMARY GLAND BIOL, V15, P235, DOI 10.1007/s10911-010-9175-z; Butler GS, 2008, MOL CELL BIOL, V28, P4896, DOI 10.1128/MCB.01775-07; Chinnadurai G, 2008, ONCOGENE, V27, pS20, DOI 10.1038/onc.2009.40; Eccles SA, 1996, CANCER RES, V56, P2815; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Figueira RCS, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-20; Fujisaki H, 2002, EXP CELL RES, V280, P255, DOI 10.1006/excr.2002.5639; Galluzzi L, 2009, CELL DEATH DIFFER, V16, P1093, DOI 10.1038/cdd.2009.44; Giam M, 2008, ONCOGENE, V27, pS128, DOI 10.1038/onc.2009.50; Gingras D, 2010, BBA-MOL CELL RES, V1803, P142, DOI 10.1016/j.bbamcr.2009.04.011; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Henriet P, 2000, P NATL ACAD SCI USA, V97, P10026, DOI 10.1073/pnas.170290997; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Hotary KB, 2002, J EXP MED, V195, P295, DOI 10.1084/jem.20010815; Hotary K, 2006, GENE DEV, V20, P2673, DOI 10.1101/gad.1451806; Hur JY, 2004, P NATL ACAD SCI USA, V101, P2351, DOI 10.1073/pnas.0307337101; Hynes RO, 2009, SCIENCE, V326, P1216, DOI 10.1126/science.1176009; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146; Kauppila S, 1998, J PATHOL, V186, P262, DOI 10.1002/(SICI)1096-9896(1998110)186:3<262::AID-PATH191>3.0.CO;2-3; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kim TY, 2006, CANCER RES, V66, P7490, DOI 10.1158/0008-5472.CAN-05-4552; Koshikawa N, 2011, CANCER SCI, V102, P111, DOI 10.1111/j.1349-7006.2010.01748.x; Lehti K, 2000, J BIOL CHEM, V275, P15006, DOI 10.1074/jbc.M910220199; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Lomonosova E, 2009, MOL CANCER RES, V7, P1268, DOI 10.1158/1541-7786.MCR-08-0183; Lopez-Otin C, 2010, NAT REV CANCER, V10, P278, DOI 10.1038/nrc2823; Mathai JP, 2005, J BIOL CHEM, V280, P23829, DOI 10.1074/jbc.M500800200; McGowan PM, 2008, ANN ONCOL, V19, P1566, DOI 10.1093/annonc/mdn180; Mizushima H, 2009, J CELL SCI, V122, P4277, DOI 10.1242/jcs.054551; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; Morrison CJ, 2006, J BIOL CHEM, V281, P26528, DOI 10.1074/jbc.M603331200; Nagase H, 2006, CARDIOVASC RES, V69, P562, DOI 10.1016/j.cardiores.2005.12.002; Naumann U, 2003, HUM GENE THER, V14, P1235, DOI 10.1089/104303403767740777; Noel A, 2008, SEMIN CELL DEV BIOL, V19, P52, DOI 10.1016/j.semcdb.2007.05.011; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; Ota I, 2009, P NATL ACAD SCI USA, V106, P20318, DOI 10.1073/pnas.0910962106; Perumal S, 2008, P NATL ACAD SCI USA, V105, P2824, DOI 10.1073/pnas.0710588105; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Rodriguez D, 2010, BBA-MOL CELL RES, V1803, P39, DOI 10.1016/j.bbamcr.2009.09.015; Rouzier R, 2005, CLIN CANCER RES, V11, P5678, DOI 10.1158/1078-0432.CCR-04-2421; Sabeh F, 2004, J CELL BIOL, V167, P769, DOI 10.1083/jcb.200408028; Sabeh F, 2009, J BIOL CHEM, V284, P23001, DOI 10.1074/jbc.M109.002808; Sabeh F, 2009, J CELL BIOL, V185, P11, DOI 10.1083/jcb.200807195; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Sato H, 2005, CANCER SCI, V96, P212, DOI 10.1111/j.1349-7006.2005.00039.x; Sodek KL, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-223; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sounni NE, 2004, J BIOL CHEM, V279, P13564, DOI 10.1074/jbc.M307688200; Sounni NE, 2002, FASEB J, V16, P555, DOI 10.1096/fj.01-0790com; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Sturm I, 2006, CELL DEATH DIFFER, V13, P619, DOI 10.1038/sj.cdd.4401782; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Yamada KM, 2007, CELL, V130, P601, DOI 10.1016/j.cell.2007.08.006; Zou YY, 2002, CANCER RES, V62, P8	65	43	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	4					480	493		10.1038/onc.2011.249	http://dx.doi.org/10.1038/onc.2011.249			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891LU	21706048				2022-12-17	WOS:000300219300007
J	Davies, AH; Barrett, I; Pambid, MR; Hu, K; Stratford, AL; Freeman, S; Berquin, IM; Pelech, S; Hieter, P; Maxwell, C; Dunn, SE				Davies, A. H.; Barrett, I.; Pambid, M. R.; Hu, K.; Stratford, A. L.; Freeman, S.; Berquin, I. M.; Pelech, S.; Hieter, P.; Maxwell, C.; Dunn, S. E.			YB-1 evokes susceptibility to cancer through cytokinesis failure, mitotic dysfunction and HER2 amplification	ONCOGENE			English	Article						YB-1; premalignancy; centrosome; cell cycle; HER2 amplification; breast cancer	MAMMARY EPITHELIAL-CELLS; BOX-BINDING-PROTEIN; GROWTH-FACTOR RECEPTOR; HUMAN-BREAST-CANCER; COLD SHOCK DOMAIN; CHROMOSOMAL INSTABILITY; CENTROSOME AMPLIFICATION; TUMOR-SUPPRESSOR; DRUG-RESISTANCE; LIM KINASES	Y-box binding protein-1 (YB-1) expression in the mammary gland promotes breast carcinoma that demonstrates a high degree of genomic instability. In the present study, we developed a model of pre-malignancy to characterize the role of this gene during breast cancer initiation and early progression. Antibody microarray technology was used to ascertain global changes in signal transduction following the conditional expression of YB-1 in human mammary epithelial cells (HMEC). Cell cycle-associated proteins were frequently altered with the most dramatic being LIM kinase 1/2 (LIMK1/2). Consequently, the misexpression of LIMK1/2 was associated with cytokinesis failure that acted as a precursor to centrosome amplification. Detailed investigation revealed that YB-1 localized to the centrosome in a phosphorylation-dependent manner, where it complexed with pericentrin and gamma-tubulin. This was found to be essential in maintaining the structural integrity and microtubule nucleation capacity of the organelle. Prolonged exposure to YB-1 led to rampant acceleration toward tumorigenesis, with the majority of cells acquiring numerical and structural chromosomal abnormalities. Slippage through the G(1)/S checkpoint due to overexpression of cyclin E promoted continued proliferation of these genomically compromised cells. As malignancy further progressed, we identified a subset of cells harboring HER2 amplification. Our results recognize YB-1 as a cancer susceptibility gene, with the capacity to prime cells for tumorigenesis. Oncogene (2011) 30, 3649-3660; doi:10.1038/onc.2011.82; published online 21 March 2011	[Davies, A. H.; Pambid, M. R.; Hu, K.; Stratford, A. L.; Dunn, S. E.] Univ British Columbia, Dept Pediat, Lab Oncogenom Res, Child & Family Res Inst, Vancouver, BC V5Z 4H4, Canada; [Davies, A. H.; Pambid, M. R.; Hu, K.; Stratford, A. L.; Dunn, S. E.] Univ British Columbia, Dept Expt Med, Lab Oncogenom Res, Child & Family Res Inst, Vancouver, BC V5Z 4H4, Canada; [Barrett, I.; Hieter, P.] Univ British Columbia, Michael Smith Labs, Vancouver, BC V5Z 4H4, Canada; [Freeman, S.] Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V5Z 4H4, Canada; [Berquin, I. M.] Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC USA; [Pelech, S.] Wake Forest Univ, Brain Res Ctr, Div Neurol, Winston Salem, NC USA; [Pelech, S.] Kinexus Bioinformat Corp, Vancouver, BC, Canada	Child & Family Research Institute; University of British Columbia; Child & Family Research Institute; University of British Columbia; University of British Columbia; University of British Columbia; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University	Dunn, SE (corresponding author), Univ British Columbia, Dept Pediat, Lab Oncogenom Res, Child & Family Res Inst, 950 W 28th Ave,Room 3083, Vancouver, BC V5Z 4H4, Canada.	sedunn@interchange.ubc.ca	Maxwell, Christopher A/B-3044-2011	Maxwell, Christopher A/0000-0002-0713-7136; Maxwell, Christopher/0000-0002-0860-4031	National Institutes of Health [RO1 CA114017]; Michael Smith Foundation for Health Research; Canadian Institutes of Health Research; Canadian Breast Cancer Foundation; NATIONAL CANCER INSTITUTE [R01CA114017] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Michael Smith Foundation for Health Research(Michael Smith Foundation for Health Research); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Ching-Shih Chen (The Ohio State University) for providing BI-D1870 and Michel Lebel (l'Universite Laval) for providing plasmid encoding GFP-tagged YB-1. This study was supported by the National Institutes of Health RO1 CA114017 (SED, IMB), the Michael Smith Foundation for Health Research (AHD), the Canadian Institutes of Health Research (AHD, SED) and the Canadian Breast Cancer Foundation (ALS).	Alliegro MC, 2006, P NATL ACAD SCI USA, V103, P9034, DOI 10.1073/pnas.0602859103; Amano T, 2002, J BIOL CHEM, V277, P22093, DOI 10.1074/jbc.M201444200; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; Barber TD, 2008, P NATL ACAD SCI USA, V105, P3443, DOI 10.1073/pnas.0712384105; Basaki Y, 2010, EUR J CANCER, V46, P954, DOI 10.1016/j.ejca.2009.12.024; Basto R, 2008, CELL, V133, P1032, DOI 10.1016/j.cell.2008.05.039; Bergmann S, 2005, CANCER RES, V65, P4078, DOI 10.1158/0008-5472.CAN-04-4056; Bernard O, 2007, INT J BIOCHEM CELL B, V39, P1071, DOI 10.1016/j.biocel.2006.11.011; Berquin IM, 2005, ONCOGENE, V24, P3177, DOI 10.1038/sj.onc.1208504; BOUVET P, 1995, J BIOL CHEM, V270, P28297; Chakrabarti R, 2007, CELL CYCLE, V6, P2944, DOI 10.4161/cc.6.23.4957; Davila M, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-40; Dhillon J, 2010, ONCOGENE, V29, P6294, DOI 10.1038/onc.2010.365; Dimri G, 2005, BREAST CANCER RES, V7, P171, DOI 10.1186/bcr1275; Dumont N, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2457; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Evdokimova V, 2009, CANCER CELL, V15, P402, DOI 10.1016/j.ccr.2009.03.017; Finkbeiner MR, 2009, ONCOGENE, V28, P1421, DOI 10.1038/onc.2008.485; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Fukasawa K, 2007, NAT REV CANCER, V7, P911, DOI 10.1038/nrc2249; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Gaudreault I, 2004, NUCLEIC ACIDS RES, V32, P316, DOI 10.1093/nar/gkh170; Guay D, 2006, INT J BIOCHEM CELL B, V38, P1300, DOI 10.1016/j.biocel.2006.01.008; Habibi G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2156; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Holland AJ, 2009, NAT REV MOL CELL BIO, V10, P478, DOI 10.1038/nrm2718; Ise T, 1999, CANCER RES, V59, P342; Janz M, 2002, INT J CANCER, V97, P278, DOI 10.1002/ijc.1610; Jurchott K, 2003, J BIOL CHEM, V278, P27988, DOI 10.1074/jbc.M212966200; Kohno K, 2003, BIOESSAYS, V25, P691, DOI 10.1002/bies.10300; Lee C, 2008, CANCER RES, V68, P8661, DOI 10.1158/0008-5472.CAN-08-1082; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Nigg EA, 2006, INT J CANCER, V119, P2717, DOI 10.1002/ijc.22245; Nigg EA, 2009, CELL, V139, P663, DOI 10.1016/j.cell.2009.10.036; Raouf A, 2005, JNCI-J NATL CANCER I, V97, P1302, DOI 10.1093/jnci/dji254; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Scully R, 2000, BREAST CANCER RES, V2, P324, DOI 10.1186/bcr76; Shi QH, 2005, NATURE, V437, P1038, DOI 10.1038/nature03958; Shibao K, 1999, INT J CANCER, V83, P732; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Stratford AL, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1767; Stratford AL, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2202; Sumi T, 2006, EXP CELL RES, V312, P1021, DOI 10.1016/j.yexcr.2005.12.030; Sutherland BW, 2005, ONCOGENE, V24, P4281, DOI 10.1038/sj.onc.1208590; Takai N, 2005, ONCOGENE, V24, P287, DOI 10.1038/sj.onc.1208272; Tlsty TD, 2004, J MAMMARY GLAND BIOL, V9, P263, DOI 10.1023/B:JOMG.0000048773.95897.5f; To K, 2010, CANCER RES, V70, P2840, DOI 10.1158/0008-5472.CAN-09-3155; Wang X, 2006, ONCOGENE, V25, P7148, DOI 10.1038/sj.onc.1209707; Wu J, 2006, CANCER RES, V66, P4872, DOI 10.1158/0008-5472.CAN-05-3561; Yang XL, 2004, NAT CELL BIOL, V6, P609, DOI 10.1038/ncb1140; Yoshioka K, 2003, P NATL ACAD SCI USA, V100, P7247, DOI 10.1073/pnas.1232344100; Yu YN, 2010, INT J ONCOL, V37, P483, DOI 10.3892/ijo_00000697	52	43	43	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2011	30	34					3649	3660		10.1038/onc.2011.82	http://dx.doi.org/10.1038/onc.2011.82			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	21423216	Green Accepted			2022-12-17	WOS:000294244500001
J	Garcia-Marcos, M; Ghosh, P; Farquhar, MG				Garcia-Marcos, M.; Ghosh, P.; Farquhar, M. G.			Molecular basis of a novel oncogenic mutation in GNAO1	ONCOGENE			English	Article						oncoprotein; somatic mutation; heterotrimeric G protein; GAIP/RGS19; neoplasia; STAT3	GUANINE-NUCLEOTIDE-BINDING; PROTEIN ALPHA-SUBUNITS; RECEPTOR-MEDIATED ACTIVATION; GTPASE ACTIVITY; CELL-MIGRATION; NIH-3T3 CELLS; MUTANT; TRANSFORMATION; TUMORS; DOMAIN	Heterotrimeric G proteins are molecular switches that control signal transduction, and their dysregulation can promote oncogenesis. Somatic mutations in GNAS, GNAI2 and GNAQ genes induce oncogenesis by rendering G alpha subunits constitutively activated. Recently the first somatic mutation, arginine(243)-> histidine (R243H) in the GNAO1 (G alpha o) gene was identified in breast carcinomas and shown to promote oncogenic transformation when introduced into cells. Here, we provide the molecular basis for the oncogenic properties of the G alpha o R243H mutant. Using limited proteolysis assays, nucleotide-binding assays, and single-turnover and steady-state GTPase assays, we demonstrate that the oncogenic R234H mutation renders G alpha o constitutively active by accelerating the rate of nucleotide exchange; however, this mutation does not affect G alpha o's ability to become deactivated by GTPase-activating proteins (GAPs) or by its intrinsic GTPase activity. This mechanism differs from that of previously reported oncogenic mutations that impair GTPase activity and GAP sensitivity without affecting nucleotide exchange. The constitutively active G alpha o R243H mutant also enhances Src-STAT3 signaling in NIH-3T3 cells, a pathway previously shown to be directly triggered by active G alpha o proteins to promote cellular transformation. Based on structural analyses, we propose that the enhanced rate of nucleotide exchange in G alpha o R243H results from loss of the highly conserved electrostatic interaction of R243 with E43, located in the in the P-loop that represents the binding site for the alpha- and beta-phosphates of the nucleotide. We conclude that the novel R234H mutation imparts oncogenic properties to G alpha o by accelerating nucleotide exchange and rendering it constitutively active, thereby enhancing signaling pathways, for example, src-STAT3, responsible for neoplastic transformation. Oncogene (2011) 30, 2691-2696; doi:10.1038/onc.2010.645; published online 14 February 2011	[Garcia-Marcos, M.] Univ Calif San Diego, Dept Cellular & Mol Med, San Diego Sch Med, George E Palade Labs Cellular & Mol Med, La Jolla, CA 92093 USA; [Ghosh, P.] Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Garcia-Marcos, M (corresponding author), Univ Calif San Diego, Dept Cellular & Mol Med, San Diego Sch Med, George E Palade Labs Cellular & Mol Med, 9500 Gilman Dr,Room 218, La Jolla, CA 92093 USA.	mgarciamarcos@ucsd.edu			NIH [CA100768, DKI7780]; Susan G Komen postdoctoral fellowship [KG080079]; American Gastroenterology Association FDN; NATIONAL CANCER INSTITUTE [R01CA100768] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007202] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Susan G Komen postdoctoral fellowship(Susan G. Komen Breast Cancer Foundation); American Gastroenterology Association FDN; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was funded by NIH grants CA100768 and DKI7780 (to MGF). MGM was supported by a Susan G Komen postdoctoral fellowship KG080079 and PG by Burroughs Wellcome Fund and Research Scholar Award (American Gastroenterology Association FDN).	Barren B, 2006, MOL VIS, V12, P492; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Bourne HR, 1997, NATURE, V389, P673, DOI 10.1038/39470; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; Doi M, 2002, NEURON, V33, P249, DOI 10.1016/S0896-6273(01)00587-6; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Farfel Z, 1999, NEW ENGL J MED, V340, P1012, DOI 10.1056/NEJM199904013401306; Forbes S A, 2008, Curr Protoc Hum Genet, VChapter 10, DOI 10.1002/0471142905.hg1011s57; Garcia-Marcos M, 2010, J BIOL CHEM, V285, P12765, DOI 10.1074/jbc.M109.045161; Garcia-Marcos M, 2009, P NATL ACAD SCI USA, V106, P3178, DOI 10.1073/pnas.0900294106; Ghosh P, 2008, J CELL BIOL, V182, P381, DOI 10.1083/jcb.200712066; Ghosh P, 2010, MOL BIOL CELL, V21, P2338, DOI 10.1091/mbc.E10-01-0028; Grishina G, 1998, J BIOL CHEM, V273, P15053, DOI 10.1074/jbc.273.24.15053; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; Iiri T, 1998, NATURE, V394, P35, DOI 10.1038/27831; Johnston CA, 2007, P NATL ACAD SCI USA, V104, P17317, DOI 10.1073/pnas.0704751104; Kan ZY, 2010, NATURE, V466, P869, DOI 10.1038/nature09208; KLEUSS C, 1994, P NATL ACAD SCI USA, V91, P9828, DOI 10.1073/pnas.91.21.9828; KROLL SD, 1992, J BIOL CHEM, V267, P23183; Lamba S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006833; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LINDER ME, 1990, J BIOL CHEM, V265, P8243; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; Makita N, 2007, P NATL ACAD SCI USA, V104, P17424, DOI 10.1073/pnas.0708561104; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Mukhopadhyay S, 2002, METHOD ENZYMOL, V344, P350; Pereira R, 2005, J BIOL CHEM, V280, P35696, DOI 10.1074/jbc.M504935200; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; Radhika V, 2001, ONCOGENE, V20, P1607, DOI 10.1038/sj.onc.1204274; Ram PT, 2000, SCIENCE, V287, P142, DOI 10.1126/science.287.5450.142; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; Warner DR, 1999, P NATL ACAD SCI USA, V96, P4268, DOI 10.1073/pnas.96.8.4268; WONG YH, 1995, ONCOGENE, V10, P1927; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; Zurita AR, 2008, P NATL ACAD SCI USA, V105, P2363, DOI 10.1073/pnas.0712261105	41	43	44	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	23					2691	2696		10.1038/onc.2010.645	http://dx.doi.org/10.1038/onc.2010.645			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778CV	21317923	Green Accepted			2022-12-17	WOS:000291677800009
J	Jung, J; Kim, HY; Kim, M; Sohn, K; Kim, M; Lee, K				Jung, J.; Kim, H. Y.; Kim, M.; Sohn, K.; Kim, M.; Lee, K.			Translationally controlled tumor protein induces human breast epithelial cell transformation through the activation of Src	ONCOGENE			English	Article						Na; K-ATPase; Src; TCTP; tumorigenesis	HISTAMINE-RELEASING FACTOR; NA,K-ATPASE ALPHA-SUBUNIT; GROWTH-FACTOR RECEPTOR; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; NA+/K+-ATPASE; PHOSPHATIDYLINOSITOL 3-KINASE; STIMULATES SYNTHESIS; SIGNAL-TRANSDUCTION; EGF RECEPTOR	Translationally controlled tumor protein (TCTP) is implicated in cell growth and malignant transformation. TCTP has been found to interact directly with the third cytoplasmic domain of the alpha subunit of Na, K-ATPase, but whether this interaction has a role in tumorigenesis is unclear. In this study, we examined TCTP-induced tumor progression signaling networks in human breast epithelial cells, using adenoviral infection. We found that TCTP (a) induces Src release from Na, K-ATPase alpha subunit and Src activation; (b) phosphorylates tyrosine residues 845, 992, 1086, 1148 and 1173 on anti-epidermal growth factor receptor (EGFR); (c) activates PI3K (phosphatidylinositol 3-kinase)-AKT, Ras-Raf-MEK-ERK1/2, Rac-PAK1/2, MKK3/6-p38 and phospholipase C (PLC)-gamma pathways; (d) enhances NADPH oxidase-dependent reactive oxygen species (ROS) generation; (e) stimulates cytoskeletal remodeling and cell motility and (f) upregulates matrix metalloproteinase (MMP) 3 and 13. These findings suggest that TCTP induces tumorigenesis through distinct multicellular signaling pathways involving Src-dependent EGFR transactivation, ROS generation and MMP expression. Oncogene (2011) 30, 2264-2274; doi:10.1038/onc.2010.604; published online 31 January 2011	[Jung, J.; Kim, H. Y.; Kim, M.; Sohn, K.; Kim, M.; Lee, K.] Ewha Womans Univ, Coll Pharm, Ctr Cell Signalling & Drug Discovery Res, Seoul 120750, South Korea	Ewha Womans University	Lee, K (corresponding author), Ewha Womans Univ, Coll Pharm, Ctr Cell Signalling & Drug Discovery Res, Daehyun Dong 11-1, Seoul 120750, South Korea.	klyoon@ewha.ac.kr			Ministry for Health, Welfare Family Affairs [A090030]; Korean Government [2009-0064401]; MEST [R01-2007-000-20263-0]; Seoul RBD Program [ST090801]; MOST/KOSEF [R15-2006-020]	Ministry for Health, Welfare Family Affairs; Korean Government(Korean Government); MEST(Ministry of Education, Science & Technology (MEST), Republic of Korea); Seoul RBD Program(Seoul RBD program); MOST/KOSEF(Korea Science and Engineering Foundation)	This study was supported by a grant of the Korea Healthcare Technology R&D Project, Ministry for Health, Welfare & Family Affairs (A090030), NRF of Korea Grant funded by the Korean Government (2009-0064401), Mid-career Research Program through NRF grant funded by the MEST (R01-2007-000-20263-0), Seoul R&BD Program (ST090801) and the NCRC program of MOST/KOSEF (R15-2006-020).	Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Barwe SP, 2005, MOL BIOL CELL, V16, P1082, DOI 10.1091/mbc.E04-05-0427; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen JQ, 2006, BREAST CANCER RES TR, V96, P1, DOI 10.1007/s10549-005-9053-3; Cheon MS, 2008, BIOMED CHROMATOGR, V22, P1091, DOI 10.1002/bmc.1029; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; Dolado I, 2007, CANCER CELL, V11, P191, DOI 10.1016/j.ccr.2006.12.013; Emlet DR, 1997, J BIOL CHEM, V272, P4079, DOI 10.1074/jbc.272.7.4079; Espineda C, 2003, CANCER-AM CANCER SOC, V97, P1859, DOI 10.1002/cncr.11267; Gnanasekar M, 2007, PARASITOL RES, V101, P1533, DOI 10.1007/s00436-007-0671-z; Haas A, 2002, J BIOL CHEM, V277, P18694, DOI 10.1074/jbc.M111357200; Haux J, 1999, MED HYPOTHESES, V53, P543, DOI 10.1054/mehy.1999.0985; Impola U, 2005, BRIT J DERMATOL, V152, P720, DOI 10.1111/j.1365-2133.2005.06447.x; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Jung J, 2004, J BIOL CHEM, V279, P49868, DOI 10.1074/jbc.M400895200; Jung J, 2006, CELL SIGNAL, V18, P2033, DOI 10.1016/j.cellsig.2006.03.014; Kim M, 2009, ARCH BIOCHEM BIOPHYS, V485, P82, DOI 10.1016/j.abb.2009.02.002; Kometiani P, 2005, MOL PHARMACOL, V67, P929, DOI 10.1124/mol.104.007302; Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892; Liu J, 2000, J BIOL CHEM, V275, P27838; Lo HW, 2006, BREAST CANCER RES TR, V95, P211, DOI 10.1007/s10549-005-9011-0; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Mori K, 2004, CANCER RES, V64, P7464, DOI 10.1158/0008-5472.CAN-04-1725; Nagano-Ito M, 2009, FEBS LETT, V583, P1363, DOI 10.1016/j.febslet.2009.03.045; Nielsen HV, 1998, ALLERGY, V53, P642, DOI 10.1111/j.1398-9995.1998.tb03950.x; Oikawa K, 2002, BIOCHEM BIOPH RES CO, V290, P984, DOI 10.1006/bbrc.2001.6302; Park HS, 2004, MOL CELL BIOL, V24, P4384, DOI 10.1128/MCB.24.10.4384-4394.2004; Rajasekaran SA, 2001, MOL BIOL CELL, V12, P279, DOI 10.1091/mbc.12.2.279; Rajasekaran SA, 2001, MOL BIOL CELL, V12, P3717, DOI 10.1091/mbc.12.12.3717; Rowe RG, 2008, TRENDS CELL BIOL, V18, P560, DOI 10.1016/j.tcb.2008.08.007; Shin I, 2005, J BIOL CHEM, V280, P14675, DOI 10.1074/jbc.M411625200; Song H, 2006, CANCER RES, V66, P10487, DOI 10.1158/0008-5472.CAN-06-1461; Sternlicht MD, 2000, ONCOGENE, V19, P1102, DOI 10.1038/sj.onc.1203347; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Teshima S, 1998, J IMMUNOL, V161, P6356; Tian J, 2006, MOL BIOL CELL, V17, P317, DOI 10.1091/mbc.E05-08-0735; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Tuynder M, 2004, P NATL ACAD SCI USA, V101, P15364, DOI 10.1073/pnas.0406776101; Tuynder M, 2002, P NATL ACAD SCI USA, V99, P14976, DOI 10.1073/pnas.222470799; Xie ZJ, 2003, ANN NY ACAD SCI, V986, P497, DOI 10.1111/j.1749-6632.2003.tb07234.x; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Yudowski GA, 2000, P NATL ACAD SCI USA, V97, P6556, DOI 10.1073/pnas.100128297; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5	45	43	45	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	19					2264	2274		10.1038/onc.2010.604	http://dx.doi.org/10.1038/onc.2010.604			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	762XD	21278788				2022-12-17	WOS:000290514600009
J	Boissinot, M; Cleyrat, C; Vilaine, M; Jacques, Y; Corre, I; Hermouet, S				Boissinot, M.; Cleyrat, C.; Vilaine, M.; Jacques, Y.; Corre, I.; Hermouet, S.			Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F	ONCOGENE			English	Article						Polycythemia vera; JAK2V617F; hepatocyte growth factor (HGF); interleukin 11 (IL-11); interleukin 6 (IL-6); inflammation	MARROW STROMAL CELLS; INDUCIBLE FACTOR-I; MYELOPROLIFERATIVE NEOPLASMS; MULTIPLE-MYELOMA; INTERFERON-ALPHA; COLONY FORMATION; TYROSINE KINASE; JAK2 HAPLOTYPE; MUTATION; MET	The V617F activating mutation of janus kinase 2 (JAK2), a kinase essential for cytokine signalling, characterizes Polycythemia vera (PV), one of the myeloproliferative neoplasms (MPN). However, not all MPNs carry mutations of JAK2, and in JAK2-mutated patients, expression of JAK2V617F does not always result in clone expansion. In the present study, we provide evidence that inflammation-linked cytokines are required for the growth of JAK2V617F-mutated erythroid progenitors. In a first series of experiments, we searched for cytokines over-expressed in PV using cytokine antibody (Ab) arrays, and enzyme-linked immunosorbent assays for analyses of serum and bone marrow (BM) plasma, and quantitative reverse transcription-PCRs for analyses of cells purified from PV patients and controls. We found that PV patients over-expressed anti-inflammatory hepatocyte growth factor (HGF) and interleukin-11 (IL-11), BM mesenchymal stromal cells (BMMSCs) and erythroblasts being the main producers. In a second series of experiments, autocrine/paracrine cytokine stimulation of erythroblasts was blocked using neutralizing Abs specific for IL-11 or c-MET, the HGF receptor. The growth of JAK2V617F-mutated HEL cells and PV erythroblasts was inhibited, indicating that JAK2-mutated cells depend on HGF and IL-11 for their growth. Additional experiments showed that transient expression of JAK2V617F in BaF-3/erythropoietin receptor cells, and invalidation of JAK2V617F in HEL cells using anti-JAK2 small interfering RNA, did not affect HGF and IL-11 expression. Thus, anti-inflammatory HGF and IL-11 are upregulated in PV and their overproduction is not a consequence of JAK2V617F. As both cytokines contribute to the proliferation of PV erythroblasts, blocking the c-MET/HGF/IL-11 pathways could be of interest as an additional therapeutic option in PV. Oncogene (2011) 30, 990-1001; doi:10.1038/onc.2010.479; published online 1 November 2010	[Boissinot, M.; Cleyrat, C.; Vilaine, M.; Jacques, Y.; Corre, I.; Hermouet, S.] CHU Nantes, Inst Biol, INSERM, UMR 892, F-44093 Nantes, France; [Hermouet, S.] CHU Nantes, Inst Biol, Hematol Lab, F-44093 Nantes, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes	Hermouet, S (corresponding author), CHU Nantes, Inst Biol, INSERM, UMR 892, F-44093 Nantes, France.	sylvie.hermouet@chu-nantes.fr	Cleyrat, Cedric/F-1824-2016; Vilaine, Mathias/L-3054-2015; Corre, Isabelle/L-2583-2015; Jacques, Yannick/K-9294-2015	Cleyrat, Cedric/0000-0002-1928-6497; CORRE, Isabelle/0000-0001-6444-1145; Boissinot, Marjorie/0000-0002-5241-2520	Ligue Nationale contre le Cancer (Comite de Loire-Atlantique); Association pour la Recherche contre le Cancer; French Ministry of Research [MB: 2004-2007, CC: 2007-2010, MV: 2009-2010]	Ligue Nationale contre le Cancer (Comite de Loire-Atlantique); Association pour la Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); French Ministry of Research(Ministry of Research, FranceEuropean Commission)	We are indebted to Mrs Danielle Pineau for excellent technical help and to colleagues of the Clinical Hematology Departments of the hospitals of Nantes, La Roche-sur-Yon and Lorient for providing patient samples. The study was supported by grants from the Ligue Nationale contre le Cancer (Comite de Loire-Atlantique) and the Association pour la Recherche contre le Cancer. MB, CC and MV have been recipients of scholarships from the French Ministry of Research (MB: 2004-2007; CC: 2007-2010; MV: 2009-2010) and from the Association pour la Recherche contre le Cancer (MB, 2008).	Aman MJ, 1996, EXP HEMATOL, V24, P863; Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Bernet Agnes, 2007, Bull Cancer, V94, pE12; Cleyrat C, 2010, LEUKEMIA, V24, P1069, DOI 10.1038/leu.2010.23; Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530; Coppo P, 2009, CELL SIGNAL, V21, P52, DOI 10.1016/j.cellsig.2008.09.006; Corre-Buscail I, 2005, EXP HEMATOL, V33, P1299, DOI 10.1016/j.exphem.2005.07.002; Derksen PWB, 2003, LEUKEMIA, V17, P764, DOI 10.1038/sj.leu.2402875; Dobo L, 2004, HEMATOL J, V5, P161, DOI 10.1038/sj.thj.6200344; Du WL, 2007, BLOOD, V109, P3042, DOI 10.1182/blood-2006-02-003103; Ferguson LR, 2010, MUTAT RES-FUND MOL M, V690, P108, DOI 10.1016/j.mrfmmm.2010.01.017; Geissler K, 1998, BLOOD, V92, P1967, DOI 10.1182/blood.V92.6.1967.418k27_1967_1972; Girodon F, 2008, HAEMATOL-HEMATOL J, V93, P1723, DOI 10.3324/haematol.13081; Giuliani N, 2004, HAEMATOLOGICA, V89, P1118; Hermouet S, 2002, CYTOKINE, V20, P178, DOI 10.1006/cyto.2002.1994; Hitoshi Y, 2010, INT J HEMATOL, V91, P189, DOI 10.1007/s12185-010-0531-y; Ho CL, 2007, LEUKEMIA RES, V31, P1389, DOI 10.1016/j.leukres.2006.12.024; Ishii T, 2007, LEUKEMIA, V21, P2433, DOI 10.1038/sj.leu.2404899; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Jenkins BJ, 2005, BLOOD, V105, P3512, DOI 10.1182/blood-2004-09-3751; Jenkins BJ, 2007, BLOOD, V109, P2380, DOI 10.1182/blood-2006-08-040352; Jones AV, 2009, NAT GENET, V41, P446, DOI 10.1038/ng.334; Kiladjian JJ, 2006, BLOOD, V108, P2037, DOI 10.1182/blood-2006-03-009860; Kilpivaara O, 2009, NAT GENET, V41, P455, DOI 10.1038/ng.342; Kitajima Y, 2008, CANCER SCI, V99, P1341, DOI 10.1111/j.1349-7006.2008.00828.x; Kopitz C, 2007, CANCER RES, V67, P8615, DOI 10.1158/0008-5472.CAN-07-0232; Kralovics R, 2008, LEUKEMIA, V22, P1841, DOI 10.1038/leu.2008.233; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Lacout C, 2006, BLOOD, V108, P1652, DOI 10.1182/blood-2006-02-002030; Lambert JR, 2009, BLOOD, V114, P3018, DOI 10.1182/blood-2009-03-209916; Le Bousse-Kerdiles MC, 1999, ANN HEMATOL, V78, P437, DOI 10.1007/s002770050595; Lippert E, 2006, BLOOD, V108, P1865, DOI 10.1182/blood-2006-01-013540; Lippert E, 2009, HAEMATOL-HEMATOL J, V94, P38, DOI 10.3324/haematol.13486; Matsuda-Hashii Y, 2004, EXP HEMATOL, V32, P955, DOI 10.1016/j.exphem.2004.06.012; Musolino C, 2002, AM J HEMATOL, V69, P159, DOI 10.1002/ajh.10020; Naifeld V, 2007, EXP HEMATOL, V35, P1668, DOI 10.1016/j.exphem.2007.08.025; Nussenzveig RH, 2007, EXP HEMATOL, V35, P32, DOI 10.1016/j.exphem.2006.11.012; Olcaydu D, 2009, NAT GENET, V41, P450, DOI 10.1038/ng.341; Panteli KE, 2005, BRIT J HAEMATOL, V130, P709, DOI 10.1111/j.1365-2141.2005.05674.x; QUESNIAUX VFJ, 1992, BLOOD, V80, P1218; Radaeva S, 2002, GASTROENTEROLOGY, V122, P1020, DOI 10.1053/gast.2002.32388; Sattler Martin, 2007, Curr Oncol Rep, V9, P102, DOI 10.1007/s11912-007-0005-4; Schaub FX, 2009, BLOOD, V113, P2022, DOI 10.1182/blood-2008-07-167056; Schwertschlag US, 1999, LEUKEMIA, V13, P1307, DOI 10.1038/sj.leu.2401514; Shinomiya N, 2004, CANCER RES, V64, P7962, DOI 10.1158/0008-5472.CAN-04-1043; Stellrecht CM, 2007, CANCER RES, V67, P9913, DOI 10.1158/0008-5472.CAN-07-0770; Tacchini L, 2001, CARCINOGENESIS, V22, P1363, DOI 10.1093/carcin/22.9.1363; TEFFERI A, 2010, HEMATOLOGIST, V7, P5; Tiedt R, 2008, BLOOD, V111, P3931, DOI 10.1182/blood-2007-08-107748; UCHIYAMA H, 1993, BLOOD, V82, P3712; Vardiman JW, 2002, BLOOD, V100, P2292, DOI 10.1182/blood-2002-04-1199; Verstovsek S, 2010, CLIN CANCER RES, V16, P1988, DOI 10.1158/1078-0432.CCR-09-2836; Wernig G, 2006, BLOOD, V107, P4274, DOI 10.1182/blood-2005-12-4824; Wickenhauser C, 1999, LEUKEMIA, V13, P327, DOI 10.1038/sj.leu.2401314; Zdzisinska B, 2008, ARCH IMMUNOL THER EX, V56, P207, DOI 10.1007/s00005-008-0022-5	55	43	46	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	8					990	1001		10.1038/onc.2010.479	http://dx.doi.org/10.1038/onc.2010.479			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	726CJ	21042281				2022-12-17	WOS:000287695900010
J	Ingemarsdotter, CK; Baird, SK; Connell, CM; Oberg, D; Hallden, G; McNeish, IA				Ingemarsdotter, C. K.; Baird, S. K.; Connell, C. M.; Oeberg, D.; Hallden, G.; McNeish, I. A.			Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer	ONCOGENE			English	Article						oncolytic adenovirus; paclitaxel; mitosis; apoptosis; microtubule	CELL-CYCLE PROGRESSION; E4ORF4 PROTEIN; GROWTH ARREST; MICROTUBULE; INFECTION; MITOSIS; DEATH; BIOLUMINESCENCE; INSTABILITY; CHECKPOINTS	The microtubule-stabilizing drug paclitaxel has activity in relapsed ovarian cancer. dl922-947, an oncolytic adenovirus with a 24-bp deletion in E1A CR2, replicates selectively within and lyses cells with a dysregulated Rb pathway and has efficacy in ovarian cancer. In the aggressive A2780CP xenograft, combination treatment with weekly dl922-947 and paclitaxel has significantly greater efficacy than either treatment alone and can produce complete tumor eradication in some animals. We investigated the mechanisms of paclitaxel's synergy with dl922-947 in ovarian cancer. The host-cell microtubule network is grossly rearranged and stabilized following adenovirus infection, but paclitaxel does not increase this significantly. Paclitaxel does not synergize by increasing infectivity, viral protein expression or virus release. However, destabilizing the microtubule network with nocodazole reduces viral exit, revealing a novel microtubule-dependent pathway for non-lytic adenoviral exit. dl922-947 can override multiple cell cycle checkpoints but induces cell death by a non-apoptotic mechanism. In combination, dl922-947 and low-dose paclitaxel induces aberrant, multipolar mitoses, mitotic slippage and multinucleation, triggering an apoptotic cell death. Oncogene (2010) 29, 6051-6063; doi:10.1038/onc.2010.335; published online 23 August 2010	[McNeish, I. A.] Queen Mary Univ London, Barts & London Sch Med, John Vane Sci Ctr, Ctr Mol Oncol & Imaging,Inst Canc, London EC1M 6BQ, England	University of London; Queen Mary University London	McNeish, IA (corresponding author), Queen Mary Univ London, Barts & London Sch Med, John Vane Sci Ctr, Ctr Mol Oncol & Imaging,Inst Canc, Charterhouse Sq, London EC1M 6BQ, England.	i.a.mcneish@qmul.ac.uk		McNeish, Iain/0000-0002-9387-7586	Medical Research Council [G0601891] Funding Source: Medline; MRC [G0601891] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Akhmanova A, 2001, CELL, V104, P923, DOI 10.1016/S0092-8674(01)00288-4; Baird SK, 2008, ONCOGENE, V27, P3081, DOI 10.1038/sj.onc.1210977; BELIN MT, 1987, J VIROL, V61, P2559, DOI 10.1128/JVI.61.8.2559-2566.1987; Chang YC, 2008, MOL BIOL CELL, V19, P2147, DOI 10.1091/mbc.E07-12-1269; Chen JG, 2002, CANCER RES, V62, P1935; Cheong SC, 2008, CANCER GENE THER, V15, P40, DOI 10.1038/sj.cgt.7701099; Cherubini G, 2006, CELL CYCLE, V5, P2244, DOI 10.4161/cc.5.19.3263; Connell CM, 2008, CANCER RES, V68, P7923, DOI 10.1158/0008-5472.CAN-08-0817; De Luca A, 2003, CANCER RES, V63, P1430; Decordier I, 2008, MUTAT RES-GEN TOX EN, V651, P30, DOI 10.1016/j.mrgentox.2007.10.016; Demidenko ZN, 2008, ONCOGENE, V27, P4402, DOI 10.1038/onc.2008.82; Felsani A, 2006, ONCOGENE, V25, P5277, DOI 10.1038/sj.onc.1209621; Flak MB, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-175; Gartner M, 2005, CHEMBIOCHEM, V6, P1173, DOI 10.1002/cbic.200500005; Giannakakou P, 1998, INT J CANCER, V75, P57, DOI 10.1002/(SICI)1097-0215(19980105)75:1<57::AID-IJC10>3.3.CO;2-V; Hassan MAIA, 2006, CANCER GENE THER, V13, P1105, DOI 10.1038/sj.cgt.7700984; Hecht JR, 2003, CLIN CANCER RES, V9, P555; Heise C, 2000, NAT MED, V6, P1134, DOI 10.1038/80474; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; Katsumata N, 2009, LANCET, V374, P1331, DOI 10.1016/S0140-6736(09)61157-0; Kornitzer D, 2001, J CELL BIOL, V154, P331, DOI 10.1083/jcb.200104104; Le LP, 2004, MOL IMAGING, V3, P105, DOI 10.1162/1535350041464874; Le T, 2006, GYNECOL ONCOL, V102, P49, DOI 10.1016/j.ygyno.2005.11.025; Leopold PL, 2007, ADV DRUG DELIVER REV, V59, P810, DOI 10.1016/j.addr.2007.06.007; Leyton J, 2006, CANCER RES, V66, P9178, DOI 10.1158/0008-5472.CAN-06-1539; Li S, 2009, ONCOGENE, V28, P390, DOI 10.1038/onc.2008.393; Lockley M, 2006, CANCER RES, V66, P989, DOI 10.1158/0008-5472.CAN-05-2691; Markman M, 2002, J CLIN ONCOL, V20, P2365, DOI 10.1200/JCO.2002.09.130; McGuire WP, 1996, NEW ENGL J MED, V334, P1, DOI 10.1056/NEJM199601043340101; Meulenbroek RA, 2004, MOL THER, V9, P617, DOI 10.1016/j.ymthe.2004.01.012; Mimori-Kiyosue Y, 2005, J CELL BIOL, V168, P141, DOI 10.1083/jcb.200405094; MURRAY JD, 1982, J CELL PHYSIOL, V111, P89, DOI 10.1002/jcp.1041110114; Paoletti A, 1997, J CELL SCI, V110, P2403; Pines J, 2006, TRENDS CELL BIOL, V16, P55, DOI 10.1016/j.tcb.2005.11.006; Reed JC, 2006, NAT CLIN PRACT ONCOL, V3, P388, DOI 10.1038/ncponc0538; Seidman MA, 2001, MOL THER, V4, P13, DOI 10.1006/mthe.2001.0414; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Shtrichman R, 1999, P NATL ACAD SCI USA, V96, P10080, DOI 10.1073/pnas.96.18.10080; STAUFENBIEL M, 1986, J VIROL, V60, P1186, DOI 10.1128/JVI.60.3.1186-1191.1986; Tollefson AE, 1996, J VIROL, V70, P2296, DOI 10.1128/JVI.70.4.2296-2306.1996; Warren JC, 2006, MOL BIOL CELL, V17, P3557, DOI 10.1091/mbc.E05-09-0850; Westermann S, 2003, NAT REV MOL CELL BIO, V4, P938, DOI 10.1038/nrm1260; WHITE E, 1989, P NATL ACAD SCI USA, V86, P9886, DOI 10.1073/pnas.86.24.9886; Ying BL, 2003, VIROLOGY, V313, P224, DOI 10.1016/S0042-6822(03)00287-3	45	43	46	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	45					6051	6063		10.1038/onc.2010.335	http://dx.doi.org/10.1038/onc.2010.335			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	678VA	20729921	Green Published, hybrid			2022-12-17	WOS:000284108700007
J	Okamoto, J; Hirata, T; Chen, Z; Zhou, HM; Mikami, I; Li, H; Beltran, A; Johansson, M; Coussens, LM; Clement, G; Shi, Y; Zhang, F; Koizumi, K; Shimizu, K; Jablons, D; He, B				Okamoto, J.; Hirata, T.; Chen, Z.; Zhou, H-M; Mikami, I.; Li, H.; Beltran, A.; Johansson, M.; Coussens, L. M.; Clement, G.; Shi, Y.; Zhang, F.; Koizumi, K.; Shimizu, K.; Jablons, D.; He, B.			EMX2 is epigenetically silenced and suppresses growth in human lung cancer	ONCOGENE			English	Article						EMX2; methylation; lung cancer; WNT signaling; tumor suppression	INHIBITORY FACTOR-I; PROMOTER HYPERMETHYLATION; S100 PROTEINS; EXPRESSION; METHYLATION; GENE; METASTASIS; PATHOLOGY; FAMILY; TARGET	Lung cancer is a common cancer and the leading cause of cancer-related death worldwide. Aberrant activation of WNT signaling is implicated in lung carcinogenesis. EMX2, a human homologue of the Drosophila empty spiracles gene is a homeodomain-containing transcription factor. The function of EMX2 has been linked to the WNT signaling pathway during embryonic patterning in mice. However, little is known about the role of EMX2 in human tumorigenesis. In this study, we found that EMX2 was dramatically downregulated in lung cancer tissue samples and this downregulation was associated with methylation of the EMX2 promoter. Restoration of EMX2 expression in lung cancer cells lacking endogenous EMX2 expression suppressed cell proliferation and invasive phenotypes, inhibited canonical WNT signaling, and sensitized lung cancer cells to the treatment of the chemo cytotoxic drug cisplatin. On the other hand, knockdown of EMX2 expression in lung cancer cells expressing endogenous EMX2 promoted cell proliferation, invasive phenotypes and canonical WNT signaling. Taken together, our study suggests that EMX2 may have important roles as a novel suppressor in human lung cancer. Oncogene (2010) 29, 5969-5975; doi:10.1038/onc.2010.330; published online 9 August 2010	[Okamoto, J.; Hirata, T.; Chen, Z.; Mikami, I.; Li, H.; Beltran, A.; Clement, G.; Shi, Y.; Zhang, F.; Jablons, D.; He, B.] Univ Calif San Francisco, Thorac Oncol Program, Dept Surg, San Francisco, CA 94115 USA; [Okamoto, J.; Hirata, T.; Mikami, I.; Koizumi, K.; Shimizu, K.] Nippon Med Sch, Div Thorac Surg, Dept Surg, Tokyo 113, Japan; [Chen, Z.; Zhou, H-M] Tsinghua Univ, Dept Biol Sci & Biotechnol, Beijing 100084, Peoples R China; [Johansson, M.; Coussens, L. M.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94115 USA; [Johansson, M.; Coussens, L. M.; Jablons, D.; He, B.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94115 USA; [Shi, Y.] SRI Int, Biosci Div, Menlo Pk, CA 94025 USA	University of California System; University of California San Francisco; Nippon Medical School; Tsinghua University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; SRI International	He, B (corresponding author), Univ Calif San Francisco, Thorac Oncol Program, Dept Surg, 2340 Sutter St,Room N222, San Francisco, CA 94115 USA.	biao.he@ucsfmedctr.org	Coussens, Lisa/ABH-9834-2020		Joan's Legacy: uniting against Lung Cancer Research Grant; NIH/NCI [R01CA125030, R01CA130980, R01CA13256]; Eileen D Ludwig endowed for Thoracic Oncology Research; Bonnie J Addario Lung Cancer Foundation; Kazan foundation; McClain foundation; Abrams foundation; Fernandez foundation; Lyons foundation; Greenwood foundation; Harley and Oberman Foundation; Barbara Isackson Lung Cancer Research Fund; Swedish Cancer Institute; DOD [W81XWH-06-1-0416]; NATIONAL CANCER INSTITUTE [R01CA125030, R01CA132566, R01CA130980] Funding Source: NIH RePORTER	Joan's Legacy: uniting against Lung Cancer Research Grant; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Eileen D Ludwig endowed for Thoracic Oncology Research; Bonnie J Addario Lung Cancer Foundation; Kazan foundation; McClain foundation; Abrams foundation; Fernandez foundation; Lyons foundation; Greenwood foundation; Harley and Oberman Foundation; Barbara Isackson Lung Cancer Research Fund; Swedish Cancer Institute; DOD(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by grant from Joan's Legacy: uniting against Lung Cancer Research Grant, NIH/NCI grant R01CA125030 and the Eileen D Ludwig endowed for Thoracic Oncology Research (to BH); the Bonnie J Addario Lung Cancer Foundation, the Kazan, McClain, Abrams, Fernandez, Lyons, Greenwood, Harley and Oberman Foundation and the Barbara Isackson Lung Cancer Research Fund (DJ); Swedish Cancer Institute (MJ); NIH/NCI grants R01CA130980, R01CA13256 and DOD BCRP Era of Hope Scholar Award (W81XWH-06-1-0416) (to LMC). Microarray profiling was done by the UCSF Shared Microarray Core Facilities. We thank M Roshni Ray for editing this paper.	Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Akiri G, 2009, ONCOGENE, V28, P2163, DOI 10.1038/onc.2009.82; American Cancer Society, 2008, CANC FACTS FIG; BOERSMA CJ, 1999, MOL CELL BIOL RES CO, V2, P117; Clement G, 2008, CANCER SCI, V99, P46, DOI 10.1111/j.1349-7006.2007.00663.x; DALTON D, 1989, GENE DEV, V3, P1940, DOI 10.1101/gad.3.12a.1940; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341; Fong KM, 2003, THORAX, V58, P892, DOI 10.1136/thorax.58.10.892; Fukui T, 2005, ONCOGENE, V24, P6323, DOI 10.1038/sj.onc.1208777; Galli R, 2002, DEVELOPMENT, V129, P1633; Ganesan K, 2008, CANCER RES, V68, P4277, DOI 10.1158/0008-5472.CAN-07-6517; Grote HJ, 2006, CANCER CYTOPATHOL, V108, P129, DOI 10.1002/cncr.21717; Grote HJ, 2005, INT J CANCER, V116, P720, DOI 10.1002/ijc.21090; He B, 2005, CANCER RES, V65, P743; Heizmann CW, 2002, FRONT BIOSCI-LANDMRK, V7, pD1356, DOI 10.2741/heizmann; Huang CL, 2008, EUR J CANCER, V44, P2680, DOI 10.1016/j.ejca.2008.08.004; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389; Ligon KL, 2003, DEVELOPMENT, V130, P2275, DOI 10.1242/dev.00421; Lind GE, 2006, J PATHOL, V210, P441, DOI 10.1002/path.2064; Marenholz I, 2004, BIOCHEM BIOPH RES CO, V322, P1111, DOI 10.1016/j.bbrc.2004.07.096; Mazieres J, 2004, CANCER RES, V64, P4717, DOI 10.1158/0008-5472.CAN-04-1389; Nguyen DX, 2009, CELL, V138, P51, DOI 10.1016/j.cell.2009.04.030; Noonan FC, 2003, GENOMICS, V81, P58, DOI 10.1016/S0888-7543(02)00023-X; Noonan FC, 2001, GENOMICS, V76, P37, DOI 10.1006/geno.2001.6590; Raman V, 2000, J BIOL CHEM, V275, P26551, DOI 10.1074/jbc.C000324200; Raz DJ, 2008, CLIN CANCER RES, V14, P5565, DOI 10.1158/1078-0432.CCR-08-0544; Samuel S, 2005, EUR J CANCER, V41, P2428, DOI 10.1016/j.ejca.2005.08.014; Stein U, 2006, GASTROENTEROLOGY, V131, P1486, DOI 10.1053/j.gastro.2006.08.041; Taylor HS, 2005, MOL ENDOCRINOL, V19, P2839, DOI 10.1210/me.2005-0130; Travis WD, 2002, CLIN CHEST MED, V23, P65, DOI 10.1016/S0272-5231(03)00061-3; Yoshida HY, 2006, CANCER RES, V66, P889, DOI 10.1158/0008-5472.CAN-05-2828; You L, 2004, ONCOGENE, V23, P6170, DOI 10.1038/sj.onc.1207844; Zimmer DB, 2003, MICROSC RES TECHNIQ, V60, P552, DOI 10.1002/jemt.10297; Zochbauer-Muller S, 2000, Clin Lung Cancer, V2, P141, DOI 10.3816/CLC.2000.n.027	36	43	45	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	44					5969	5975		10.1038/onc.2010.330	http://dx.doi.org/10.1038/onc.2010.330			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	675PS	20697358	Green Accepted			2022-12-17	WOS:000283843400010
J	Antico-Arciuch, VG; Dima, M; Liao, XH; Refetoff, S; Di Cristofano, A				Antico-Arciuch, V. G.; Dima, M.; Liao, X-H; Refetoff, S.; Di Cristofano, A.			Cross-talk between PI3K and estrogen in the mouse thyroid predisposes to the development of follicular carcinomas with a higher incidence in females	ONCOGENE			English	Article						thyroid cancer; Pten; estrogen	GENETIC ALTERATIONS; CANCER CELLS; MOLECULAR-MECHANISMS; TARGETED EXPRESSION; PAPILLARY; PATHWAY; MICE; GROWTH; TUMORS; PROLIFERATION	It is well known that thyroid disease is more frequent in women than in men; however, the molecular basis for this gender-based difference is still poorly understood. The activation of phosphoinositide 3-kinase (PI3K), through different mechanisms including loss of the PTEN tumor suppressor, is being increasingly recognized as a major player in the development of thyroid neoplastic lesions. Loss of Pten in the mouse thyroid results in a significant increase in the thyrocyte proliferative index, which is more prominent in the female mice. In this study, we show that 52% of the Pten(-/-) female mice, but only 12% of the males, develop follicular adenomas by 1 year of age. In addition, 50% of female mutants, but only 35% of males older than 1 year of age develop invasive, and often metastatic, follicular carcinomas. Mutant females have a significantly shorter overall survival compared with male mutants. Hormonal manipulation experiments established a direct role of estrogens in controlling the increased thyrocyte proliferation index in mutant females. Further-more, while genetic ablation of one Cdkn1b allele accelerated the development of neoplastic lesions, it also abolished the gender differences in survival and reduced the difference in neoplastic lesion development rate, underlining a key role of p27 in mediating estrogen action in the thyroid follicular cells. These data, based on a clinically relevant model of thyroid follicular carcinoma, provide, to the best of our knowledge, for the first time in vivo evidence that circulating estrogens are directly responsible for the increased female susceptibility to thyroid disease, at least on activation of the PI3K pathway, and provide new insights into the gender-based differences characterizing thyroid neoplastic disorders. Oncogene (2010) 29, 5678-5686; doi:10.1038/onc.2010.308; published online 2 August 2010	[Di Cristofano, A.] Albert Einstein Coll Med, Dept Dev & Mol Biol, Price Ctr Genet & Translat Med, Bronx, NY 10461 USA; [Liao, X-H; Refetoff, S.] Univ Chicago, Dept Med, Chicago, IL 60637 USA; [Refetoff, S.] Univ Chicago, Dept Pediat, Chicago, IL 60637 USA; [Refetoff, S.] Univ Chicago, Comm Genet, Chicago, IL 60637 USA	Yeshiva University; Albert Einstein College of Medicine; University of Chicago; University of Chicago; University of Chicago	Di Cristofano, A (corresponding author), Albert Einstein Coll Med, Dept Dev & Mol Biol, Price Ctr Genet & Translat Med, 1301 Morris Pk Ave,Room 302, Bronx, NY 10461 USA.	antonio.dicristofano@einstein.yu.edu	Di Cristofano, Antonio/B-4148-2016; Refetoff, Samuel/ABB-1263-2021; di cristofano, antonio/AAJ-3796-2020	Refetoff, Samuel/0000-0003-0164-8231; di cristofano, antonio/0000-0003-2537-3228	AECC; NIH [CA97097, CA128943, DK15070, DK20595]; NATIONAL CANCER INSTITUTE [R01CA128943, R01CA097097] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020595, R01DK015070, P60DK020595, R37DK015070] Funding Source: NIH RePORTER	AECC; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank the Animal Housing and the Histotechnology and Comparative Pathology Facilities of Albert Einstein College of Medicine. This study was supported by the AECC Core Grant, and by NIH grants to ADC (CA97097 and CA128943) and SR (DK15070 and DK20595).	Chen GG, 2008, CURR CANCER DRUG TAR, V8, P367, DOI 10.2174/156800908785133150; Foster JS, 2003, J BIOL CHEM, V278, P41355, DOI 10.1074/jbc.M302830200; Garcia-Rostan G, 2005, CANCER RES, V65, P10199, DOI 10.1158/0008-5472.CAN-04-4259; Hou P, 2008, CANCER, V113, P2440, DOI 10.1002/cncr.23869; Hou P, 2007, CLIN CANCER RES, V13, P1161, DOI 10.1158/1078-0432.CCR-06-1125; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Knauf JA, 2005, CANCER RES, V65, P4238, DOI 10.1158/0008-5472.CAN-05-0047; Kumar A, 2010, INT J ONCOL, V36, P1067, DOI 10.3892/ijo_00000588; Lacroix L, 2001, THYROID, V11, P1017, DOI 10.1089/105072501753271699; Libutti SK, 2005, CANCER J, V11, P104, DOI 10.1097/00130404-200503000-00003; Lu CX, 2010, ENDOCRINOLOGY, V151, P1929, DOI 10.1210/en.2009-1017; Manole D, 2001, J CLIN ENDOCR METAB, V86, P1072, DOI 10.1210/jc.86.3.1072; Miller KA, 2009, CANCER RES, V69, P3689, DOI 10.1158/0008-5472.CAN-09-0024; Pohlenz J, 1999, THYROID, V9, P1265, DOI 10.1089/thy.1999.9.1265; Rajoria S, 2010, THYROID, V20, P33, DOI 10.1089/thy.2009.0296; Sodre AKMB, 2008, J CLIN ENDOCR METAB, V93, P4141, DOI 10.1210/jc.2007-0353; Suzuki H, 2002, THYROID, V12, P963, DOI 10.1089/105072502320908295; Vasko VV, 2007, CURR OPIN ONCOL, V19, P11, DOI 10.1097/CCO.0b013e328011ab86; Vitagliano D, 2006, ONCOGENE, V25, P5467, DOI 10.1038/sj.onc.1209527; Vivacqua A, 2006, MOL PHARMACOL, V70, P1414, DOI 10.1124/mol.106.026344; Wang YG, 2007, J CLIN ENDOCR METAB, V92, P2387, DOI 10.1210/jc.2006-2019; Yeager N, 2008, CANCER RES, V68, P444, DOI 10.1158/0008-5472.CAN-07-3030; Yeager N, 2007, CANCER RES, V67, P959, DOI 10.1158/0008-5472.CAN-06-3524	24	43	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	42					5678	5686		10.1038/onc.2010.308	http://dx.doi.org/10.1038/onc.2010.308			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	668IT	20676139	Green Accepted			2022-12-17	WOS:000283262500004
J	Ma, Z; Liu, Z; Wu, RF; Terada, LS				Ma, Z.; Liu, Z.; Wu, R-F; Terada, L. S.			p66(Shc) restrains Ras hyperactivation and suppresses metastatic behavior	ONCOGENE			English	Article						anoikis; Shc; pRB; metastasis; small cell lung cancer	PAPILLOMAVIRUS TYPE-16 E7; CELL-CYCLE; RETINOBLASTOMA PROTEIN; TUMOR-SUPPRESSOR; K-RAS; ACTIVATION; ANOIKIS; KINASE; PATHWAY; DIFFERENTIATION	Normal tissue cells survive and proliferate only while anchored to solid substrate. Conversely, transformed cells both survive and proliferate following detachment, having lost attachment context through unclear mechanisms. p66(Shc) is a focal adhesion-associated protein that reports cell attachment through a RhoA-dependent mechanosensory test. We find that human small cell lung cancer (SCLC) cells and mouse Lewis lung carcinoma (LLC), which display aggressive metastatic behavior, lack both p66(Shc) and retinoblastoma (pRB) and bypass anoikis. Re-expression of p66(Shc) in these cells restores anoikis and provides striking protection from metastasis by LLC cells in vivo. Notably, knockdown of p66(Shc) in normal epithelial cells leads to unrestrained Ras activation, preventing anoikis through downstream suppression of RhoA but blocking proliferation in a pRB-dependent manner, thus mimicking oncogenic Ras. Conversely, LLC and SCLC cells display constitutive Ras activation necessary to bypass anoikis, which is reversed by re-expression of p66(Shc). p66(Shc) therefore coordinates Ras-dependent control of proliferation and anchorage sensation, which can be defeated in the evolution of highly metastatic tumors by combined loss of both p66(Shc) and pRB. Oncogene (2010) 29, 5559-5567; doi:10.1038/onc.2010.326; published online 2 August 2010	[Ma, Z.; Liu, Z.; Wu, R-F; Terada, L. S.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Div Pulm & Crit Care, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas	Terada, LS (corresponding author), Univ Texas SW, Dept Internal Med, 5323 Harry Hines Blvd,MC 8558, Dallas, TX 75390 USA.	Lance.Terada@utsouthwestern.edu		Terada, Lance/0000-0001-7441-9734	NHLBI [R01-HL067256, R01-HL061897]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061897, R01HL067256] Funding Source: NIH RePORTER	NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We are grateful to Dr John Shelton for assistance with histology and Drs Ralph P Mason and Li Liu for technical support with in vivo GFP imaging. This work was supported by grants to LST by the NHLBI (R01-HL067256 and R01-HL061897).	Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Giorgio M, 2005, CELL, V122, P221, DOI 10.1016/j.cell.2005.05.011; Gonzalez SL, 2001, J VIROL, V75, P7583, DOI 10.1128/JVI.75.16.7583-7591.2001; Grignani F, 1998, CANCER RES, V58, P14; Ho VM, 2009, ONCOGENE, V28, P1393, DOI 10.1038/onc.2008.491; Khanday FA, 2006, J CELL BIOL, V172, P817, DOI 10.1083/jcb.200506001; Lundberg AS, 2000, CURR OPIN CELL BIOL, V12, P705, DOI 10.1016/S0955-0674(00)00155-1; Ma Z, 2007, J CELL BIOL, V179, P23, DOI 10.1083/jcb.200706097; MABRY M, 1988, P NATL ACAD SCI USA, V85, P6523, DOI 10.1073/pnas.85.17.6523; McFall A, 2001, MOL CELL BIOL, V21, P5488, DOI 10.1128/MCB.21.16.5488-5499.2001; Mettouchi A, 2001, MOL CELL, V8, P115, DOI 10.1016/S1097-2765(01)00285-4; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Mittnacht S, 1997, CURR BIOL, V7, P219, DOI 10.1016/S0960-9822(97)70094-0; Okada S, 1997, J BIOL CHEM, V272, P28042, DOI 10.1074/jbc.272.44.28042; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Takahashi C, 2006, NAT GENET, V38, P118, DOI 10.1038/ng1703; Takahashi C, 2004, MOL CELL BIOL, V24, P10406, DOI 10.1128/MCB.24.23.10406-10415.2004; Wistuba II, 2001, SEMIN ONCOL, V28, P3, DOI 10.1053/sonc.2001.25738; Wu RF, 2007, J BIOL CHEM, V282, P37412, DOI 10.1074/jbc.M704481200	26	43	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2010	29	41					5559	5567		10.1038/onc.2010.326	http://dx.doi.org/10.1038/onc.2010.326			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FX	20676142	Green Accepted			2022-12-17	WOS:000282946900003
J	Basu, D; Nguyen, TTK; Montone, KT; Zhang, G; Wang, LP; Diehl, JA; Rustgi, AK; Lee, JT; Weinstein, GS; Herlyn, M				Basu, D.; Nguyen, T-T K.; Montone, K. T.; Zhang, G.; Wang, L-P; Diehl, J. A.; Rustgi, A. K.; Lee, J. T.; Weinstein, G. S.; Herlyn, M.			Evidence for mesenchymal-like sub-populations within squamous cell carcinomas possessing chemoresistance and phenotypic plasticity	ONCOGENE			English	Article						epithelial to mesenchymal transition; squamous cell carcinoma; head and neck; chemotherapy resistance; tumor heterogeneity	CANCER CELLS; TRANSITION PHENOTYPE; ACQUIRED-RESISTANCE; EGFR INHIBITORS; COPY NUMBER; HEAD; SENSITIVITY; SNAIL; LINES; EXPRESSION	Variable drug responses among malignant cells within individual tumors may represent a barrier to their eradication using chemotherapy. Carcinoma cells expressing mesenchymal markers resist conventional and epidermal growth factor receptor (EGFR)-targeted chemotherapy. In this study, we evaluated whether mesenchymal-like sub-populations within human squamous cell carcinomas (SCCs) with predominantly epithelial features contribute to overall therapy resistance. We identified a mesenchymal-like subset expressing low E-cadherin (Ecad-lo) and high vimentin within the upper aerodigestive tract SCCs. This subset was both isolated from the cell lines and was identified in xenografts and primary clinical specimens. The Ecad-lo subset contained more low-turnover cells, correlating with resistance to the conventional chemotherapeutic paclitaxel in vitro. Epidermal growth factor induced less stimulation of the mitogen-activated protein kinase and phosphatidylinositol-3-kinase pathways in Ecad-lo cells, which was likely due to lower EGFR expression in this subset and correlated with in vivo resistance to the EGFR-targeted antibody, cetuximab. The Ecad-lo and high E-cadherin subsets were dynamic in phenotype, showing the capacity to repopulate each other from single-cell clones. Taken together, these results provide evidence for a low-turnover, mesenchymal-like sub-population in SCCs with diminished EGFR pathway function and intrinsic resistance to conventional and EGFR-targeted chemotherapies. Oncogene ( 2010) 29, 4170-4182; doi: 10.1038/onc.2010.170; published online 24 May 2010	[Basu, D.; Nguyen, T-T K.; Zhang, G.; Lee, J. T.; Herlyn, M.] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; [Basu, D.; Weinstein, G. S.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA; [Basu, D.] Vet Adm Med Ctr, Philadelphia, PA 19104 USA; [Montone, K. T.; Wang, L-P] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Diehl, J. A.] Univ Penn, Dept Canc Biol, Philadelphia, PA 19104 USA; [Rustgi, A. K.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA	The Wistar Institute; University of Pennsylvania; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Basu, D (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	devraj.basu@uphs.upenn.edu; herlynm@wistar.org	Zhang, Gao/D-3471-2017		NIH [NCI P01 CA098101]; Wistar Cancer Center [P30 CA10815]; American Cancer Society [IRG-78-002-30]; Philadelphia VA Medical Center; NATIONAL CANCER INSTITUTE [P01CA098101, P30CA010815, P30CA016520] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Wistar Cancer Center; American Cancer Society(American Cancer Society); Philadelphia VA Medical Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge Fredrick Keeny in the Wistar Institute Microscopy Core for assistance with digital image processing and Ademi Santiago-Walker, PhD for critical review of the paper. This work is supported by grants from the NIH (NCI P01 CA098101 to M Herlyn, A Rustgi and D Basu), the Wistar Cancer Center Core Grant (P30 CA10815), and the American Cancer Society (IRG-78-002-30 to D Basu). This work is also supported in part with resources and use of facilities at the Philadelphia VA Medical Center.	Adam L, 2009, CLIN CANCER RES, V15, P5060, DOI 10.1158/1078-0432.CCR-08-2245; Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005; Bianco R, 2005, ENDOCR-RELAT CANCER, V12, pS159, DOI 10.1677/erc.1.00999; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Christiansen JJ, 2006, CANCER RES, V66, P8319, DOI 10.1158/0008-5472.CAN-06-0410; Chung CH, 2006, J CLIN ONCOL, V24, P4170, DOI 10.1200/JCO.2006.07.2587; Cooper JB, 2009, HEAD NECK-J SCI SPEC, V31, P1086, DOI 10.1002/hed.21109; Du P, 2008, BIOINFORMATICS, V24, P1547, DOI 10.1093/bioinformatics/btn224; Erjala K, 2006, CLIN CANCER RES, V12, P4103, DOI 10.1158/1078-0432.CCR-05-2404; Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343; Frederick BA, 2007, MOL CANCER THER, V6, P1683, DOI 10.1158/1535-7163.MCT-07-0138; Fuchs BC, 2008, CANCER RES, V68, P2391, DOI 10.1158/0008-5472.CAN-07-2460; Gazdar AF, 2009, ONCOGENE, V28, pS24, DOI 10.1038/onc.2009.198; Ghoul A, 2009, CANCER RES, V69, P4260, DOI 10.1158/0008-5472.CAN-08-2837; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Haddad Y, 2009, CLIN CANCER RES, V15, P532, DOI 10.1158/1078-0432.CCR-08-1733; Herbst RS, 2005, J CLIN ONCOL, V23, P5578, DOI 10.1200/JCO.2005.07.120; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Kalyankrishna S, 2006, J CLIN ONCOL, V24, P2666, DOI 10.1200/JCO.2005.04.8306; Kawaguchi Y, 2007, BRIT J CANCER, V97, P494, DOI 10.1038/sj.bjc.6603885; Kurrey NK, 2009, STEM CELLS, V27, P2059, DOI 10.1002/stem.154; Li C, 2009, ONCOGENE, V28, P3801, DOI 10.1038/onc.2009.234; Li QQ, 2009, CLIN CANCER RES, V15, P2657, DOI 10.1158/1078-0432.CCR-08-2372; Li YW, 2009, CANCER RES, V69, P6704, DOI 10.1158/0008-5472.CAN-09-1298; MANCANIELLO D, 2008, CURR PROTOC CYTOM, P168; Mandal M, 2008, CANCER-AM CANCER SOC, V112, P2088, DOI 10.1002/cncr.23410; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Okano J, 2000, J BIOL CHEM, V275, P30934, DOI 10.1074/jbc.M004112200; Opitz OG, 1998, J BIOL CHEM, V273, P23912, DOI 10.1074/jbc.273.37.23912; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Posner MR, 2007, NEW ENGL J MED, V357, P1705, DOI 10.1056/NEJMoa070956; RHEINWALD JG, 1981, CANCER RES, V41, P1657; Shackleton M, 2009, CELL, V138, P822, DOI 10.1016/j.cell.2009.08.017; Shrader M, 2007, MOL CANCER THER, V6, P277, DOI 10.1158/1535-7163.MCT-06-0513; Smalley KSM, 2006, MOL CANCER THER, V5, P1136, DOI 10.1158/1535-7163.MCT-06-0084; Smalley KSM, 2005, AM J PATHOL, V166, P1541, DOI 10.1016/S0002-9440(10)62370-X; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Strauss R, 2009, CANCER RES, V69, P5115, DOI 10.1158/0008-5472.CAN-09-0645; Tarin D, 2005, CANCER RES, V65, P5996, DOI 10.1158/0008-5472.CAN-05-0699; Temam S, 2007, J CLIN ONCOL, V25, P2164, DOI 10.1200/JCO.2006.06.6605; Thomson S, 2005, CANCER RES, V65, P9455, DOI 10.1158/0008-5472.CAN-05-1058; Vermorken JB, 2007, NEW ENGL J MED, V357, P1695, DOI 10.1056/NEJMoa071028; Wang ZW, 2009, CANCER RES, V69, P2400, DOI 10.1158/0008-5472.CAN-08-4312; Wu K, 2009, CRIT REV IMMUNOL, V29, P241, DOI 10.1615/CritRevImmunol.v29.i3.40; Yang AD, 2006, CLIN CANCER RES, V12, P4147, DOI 10.1158/1078-0432.CCR-06-0038; Yauch RL, 2005, CLIN CANCER RES, V11, P8686, DOI 10.1158/1078-0432.CCR-05-1492	47	43	45	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2010	29	29					4170	4182		10.1038/onc.2010.170	http://dx.doi.org/10.1038/onc.2010.170			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	628VL	20498638	Green Accepted			2022-12-17	WOS:000280151500005
J	Puhlmann, J; Puehler, F; Mumberg, D; Boukamp, P; Beier, R				Puhlmann, J.; Puehler, F.; Mumberg, D.; Boukamp, P.; Beier, R.			Rac1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus	ONCOGENE			English	Article						Newcastle disease virus; transformation; oncolytic; Rac1; Ras; interferon	NEWCASTLE-DISEASE-VIRUS; RAS SIGNALING PATHWAY; TUMOR PROGRESSION; INTERFERON RESPONSE; ACTIVATION; INFECTION; TRANSFORMATION; EXPRESSION; GTPASE; PERMISSIVENESS	Oncolytic Newcastle disease virus (NDV) replicates selectively in most human tumor cells but not in normal cells. The relationship between tumorigenesis and the selective susceptibility of most tumor cells to oncolytic NDV replication is poorly understood. A multistage skin carcinogenesis model derived from non-tumorigenic HaCaT cells was used to systematically investigate the molecular mechanisms involved in the oncolytic NDV-sensitivity associated with tumorigenic transformation. No significant differences in interferon signaling were observed between the virus-sensitive tumor cells and the virus-resistant non-tumorigenic parental cells. Oncogenic H-Ras, which had been used for tumorigenic transformation, was shown to be necessary for virus replication but was not sufficient to render cells susceptible to NDV replication. By using an siRNA screening approach to search for virus-sensitizing genes in the tumorigenic cells, we could identify the small GTPase Rac1 as an oncogenic protein that is essential for NDV replication and anchorage-independent growth in tumorigenic cells. Furthermore, Rac1 expression was sufficient to render non-tumorigenic cells susceptible to NDV replication and to oncolytic cytotoxicity. This study establishes Rac1 as a link between tumorigenesis and oncolytic virus sensitivity in the HaCaT multistage skin carcinogenesis model. Oncogene (2010) 29, 2205-2216; doi: 10.1038/onc.2009.507; published online 25 January 2010	[Beier, R.] Bayer Schering Pharma AG, TRG Oncol, Global Drug Discovery, D-13342 Berlin, Germany; [Puhlmann, J.] FU Berlin, Inst Biol, Berlin, Germany; [Boukamp, P.] Deutsch Krebsforschungszentrum, Div Genet Skin Carcinogenesis, D-6900 Heidelberg, Germany	Bayer AG; Bayer Healthcare Pharmaceuticals; Free University of Berlin; Helmholtz Association; German Cancer Research Center (DKFZ)	Beier, R (corresponding author), Bayer Schering Pharma AG, TRG Oncol, Global Drug Discovery, Mullerstr 178, D-13342 Berlin, Germany.	Rudolf.Beier@bayerhealthcare.com			Tumorzentrum Heidelberg-Mannheim	Tumorzentrum Heidelberg-Mannheim(European Commission)	The authors thank Katja Kockritz, Steve Baethge, Anica Hoegner and Andreas Jung for their excellent technical assistance and Sanna-Maria Kakonen and David Light for carefully reading this paper. This work was in part supported by a grant from the Tumorzentrum Heidelberg-Mannheim to Petra Boukamp.	Balachandran S, 2004, CANCER CELL, V5, P51, DOI 10.1016/S1535-6108(03)00330-1; Bergmann M, 2001, CANCER RES, V61, P8188; Bosco EE, 2009, CELL MOL LIFE SCI, V66, P370, DOI 10.1007/s00018-008-8552-x; BOUKAMP P, 1990, CANCER RES, V50, P2840; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CASSEL WA, 1965, CANCER, V18, P863, DOI 10.1002/1097-0142(196507)18:7<863::AID-CNCR2820180714>3.0.CO;2-V; Chan AY, 2005, ONCOGENE, V24, P7821, DOI 10.1038/sj.onc.1208909; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Espina C, 2008, AM J PATHOL, V172, P156, DOI 10.2353/ajpath.2008.070561; Farassati F, 2001, NAT CELL BIOL, V3, P745, DOI 10.1038/35087061; Fiola C, 2006, INT J CANCER, V119, P328, DOI 10.1002/ijc.21821; Fusenig NE, 1998, MOL CARCINOGEN, V23, P144, DOI 10.1002/(SICI)1098-2744(199811)23:3<144::AID-MC3>3.0.CO;2-U; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Gros A, 2008, CANCER RES, V68, P8928, DOI 10.1158/0008-5472.CAN-08-1145; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Hoppe S, 2006, J GEN VIROL, V87, P3483, DOI 10.1099/vir.0.82231-0; Hotte SJ, 2007, CLIN CANCER RES, V13, P977, DOI 10.1158/1078-0432.CCR-06-1817; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kissil JL, 2007, CANCER RES, V67, P8089, DOI 10.1158/0008-5472.CAN-07-2300; Krishnamurthy S, 2006, J VIROL, V80, P5145, DOI 10.1128/JVI.02618-05; Kwei KA, 2006, CANCER LETT, V231, P326, DOI 10.1016/j.canlet.2005.02.031; LORENCE RM, 1994, CANCER RES, V54, P6017; Lu XB, 1996, CURR BIOL, V6, P1677, DOI 10.1016/S0960-9822(02)70792-6; Mueller MM, 2001, AM J PATHOL, V159, P1567, DOI 10.1016/S0002-9440(10)62541-2; MUNDSCHAU LJ, 1992, J BIOL CHEM, V267, P23092; Norman KL, 2004, P NATL ACAD SCI USA, V101, P11099, DOI 10.1073/pnas.0404310101; Noser JA, 2007, MOL THER, V15, P1531, DOI 10.1038/sj.mt.6300193; Pecora AL, 2002, J CLIN ONCOL, V20, P2251, DOI 10.1200/JCO.2002.08.042; Puhler F, 2008, GENE THER, V15, P371, DOI 10.1038/sj.gt.3303095; REICHARD KW, 1992, J SURG RES, V52, P448, DOI 10.1016/0022-4804(92)90310-V; Saeed MF, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000141; Schirrmacher Volker, 2009, V542, P565, DOI 10.1007/978-1-59745-561-9_30; Schowalter RM, 2006, VIROLOGY, V350, P323, DOI 10.1016/j.virol.2006.01.033; Singh A, 2004, ONCOGENE, V23, P9369, DOI 10.1038/sj.onc.1208182; Sinkovics JG, 2000, J CLIN VIROL, V16, P1, DOI 10.1016/S1386-6532(99)00072-4; Smith KD, 2006, J VIROL, V80, P1110, DOI 10.1128/JVI.80.3.1110-1120.2006; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stojdl DF, 2000, NAT MED, V6, P821, DOI 10.1038/77558; Strong JE, 1998, EMBO J, V17, P3351, DOI 10.1093/emboj/17.12.3351; Tang Y, 1999, MOL CELL BIOL, V19, P1881; WHEELOCK EF, 1964, NEW ENGL J MED, V271, P645, DOI 10.1056/NEJM196409242711302; Wilden H, 2009, INT J ONCOL, V34, P971, DOI 10.3892/ijo_00000223	42	43	47	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	15					2205	2216		10.1038/onc.2009.507	http://dx.doi.org/10.1038/onc.2009.507			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583NT	20101224				2022-12-17	WOS:000276685200006
J	Cheung, M; Pei, J; Pei, Y; Jhanwar, SC; Pass, HI; Testa, JR				Cheung, M.; Pei, J.; Pei, Y.; Jhanwar, S. C.; Pass, H. I.; Testa, J. R.			The promyelocytic leukemia zinc-finger gene, PLZF, is frequently downregulated in malignant mesothelioma cells and contributes to cell survival	ONCOGENE			English	Article						mesothelioma; PLZF; genomic imbalances; tumor suppressors; transcription factor	METHYLTHIOADENOSINE PHOSPHORYLASE; GROWTH SUPPRESSION; TUMOR-SUPPRESSOR; PROTEIN PLZF; EXPRESSION; DELETION; TRANSLOCATION; REPRESSION; MECHANISM; APOPTOSIS	DNA copy number analysis was performed, using single-nucleotide polymorphism mapping arrays, to. ne map genomic imbalances in human malignant mesothelioma (MM) cell lines derived from primary tumors. Chromosomal losses accounted for the majority of genomic imbalances. All 22 cell lines examined showed homozygous deletions of 9p21.3, centering at the CDKN2A/ARF and CDKN2B loci. Other commonly underrepresented segments included 1p36, 1p22, 3p21-22, 4q13, 4q34, 11q23, 13q12-13, 14q32, 15q15, 18q12, and 22q12, each observed in 55-90% of cell lines. Focal deletions of 11q23 encompassed the transcriptional repressor gene promyelocytic leukemia zinc finger (PLZF), which was validated by analysis of genomic DNA using real-time polymerase chain reaction (PCR). Semi-quantitative RT PCR and immunoblot analysis revealed that PLZF is greatly downregulated in MM cell lines compared with non-malignant mesothelial cells. Ectopic expression of PLZF in PLZF-deficient MM cells resulted in decreased cell viability, reduced colony formation, as well as increased apoptosis, the latter based on results of various cell death assays and the observation of increased cleavage of caspase 3, PARP, and Mcl-1. These data indicate that deletions of PLZF are a common occurrence in MM and that downregulation of PLZF may contribute to MM pathogenesis by promoting cell survival. Oncogene (2010) 29, 1633-1640; doi:10.1038/onc.2009.455; published online 14 December 2009	[Cheung, M.; Pei, J.; Pei, Y.; Testa, J. R.] Fox Chase Canc Ctr, Canc Genet & Signaling Program, Philadelphia, PA 19111 USA; [Jhanwar, S. C.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; [Pass, H. I.] NYU, Sch Med, Dept Cardiothorac Surg, New York, NY USA	Fox Chase Cancer Center; Memorial Sloan Kettering Cancer Center; New York University	Testa, JR (corresponding author), Fox Chase Canc Ctr, Canc Genet & Signaling Program, 333 Cottman Ave,P3032, Philadelphia, PA 19111 USA.	Joseph.Testa@fccc.edu		Pass, Harvey/0000-0003-3222-3471	National Cancer Institute [CA-114047, CA-06927]; Commonwealth of Pennsylvania; International Association of Heat and Frost Insulators Allied Workers; NATIONAL CANCER INSTITUTE [P30CA006927, P01CA114047] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Commonwealth of Pennsylvania; International Association of Heat and Frost Insulators Allied Workers; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Craig Menges for helpful suggestions about some of the experiments and Jin Fang for technical assistance on some of the array hybridizations. This work was supported by National Cancer Institute Grants CA-114047 and CA-06927, by an appropriation from the Commonwealth of Pennsylvania, and by a gift from the Local #14 Mesothelioma Fund of the International Association of Heat and Frost Insulators & Allied Workers in memory of Hank Vaughan and Alice Haas. The following Fox Chase Cancer Center shared facilities were used in the course of this work: Cell Culture, Genomics, Flow Cytometry, and DNA Synthesis Facilities.	Altomare DA, 2005, CANCER RES, V65, P8090, DOI 10.1158/0008-5472.CAN-05-2312; Balsara BR, 1999, CANCER RES, V59, P450; Barna M, 2002, DEV CELL, V3, P499, DOI 10.1016/S1534-5807(02)00289-7; Bernardo MV, 2007, BIOCHEM BIOPH RES CO, V359, P317, DOI 10.1016/j.bbrc.2007.05.085; CHEN SJ, 1993, J CLIN INVEST, V91, P2260, DOI 10.1172/JCI116453; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; Cheng JQ, 1999, GENE CHROMOSOME CANC, V24, P238, DOI 10.1002/(SICI)1098-2264(199903)24:3<238::AID-GCC9>3.0.CO;2-M; CHENG JQ, 1994, CANCER RES, V54, P5547; Christopher SA, 2002, CANCER RES, V62, P6639; Costoya JA, 2004, NAT GENET, V36, P653, DOI 10.1038/ng1367; CRAIGHEAD JE, 1982, NEW ENGL J MED, V306, P1446, DOI 10.1056/NEJM198206173062403; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Felicetti F, 2004, ONCOGENE, V23, P4567, DOI 10.1038/sj.onc.1207597; Frizelle SP, 1998, ONCOGENE, V16, P3087, DOI 10.1038/sj.onc.1201870; Greshock J, 2007, CANCER RES, V67, P10173, DOI 10.1158/0008-5472.CAN-07-2102; Illei PB, 2003, CLIN CANCER RES, V9, P2108; McConnell MJ, 2007, CURR TOP MICROBIOL, V313, P31; McConnell MJ, 2003, MOL CELL BIOL, V23, P9375, DOI 10.1128/MCB.23.24.9375-9388.2003; Michels J, 2004, ONCOGENE, V23, P4818, DOI 10.1038/sj.onc.1207648; Murthy SS, 1999, J CELL PHYSIOL, V180, P150, DOI 10.1002/(SICI)1097-4652(199908)180:2<150::AID-JCP2>3.0.CO;2-H; Musti M, 2006, CANCER GENET CYTOGEN, V170, P9, DOI 10.1016/j.cancergencyto.2006.04.011; Pei JM, 2006, CANCER GENET CYTOGEN, V170, P65, DOI 10.1016/j.cancergencyto.2006.05.002; Rho SB, 2007, J CELL BIOCHEM, V101, P57, DOI 10.1002/jcb.21127; Shiraishi K, 2007, ONCOGENE, V26, P339, DOI 10.1038/sj.onc.1209800; Snowden RT, 2003, LEUKEMIA, V17, P1981, DOI 10.1038/sj.leu.2403088; TAGUCHI T, 1993, CANCER RES, V53, P4349; WAGNER J C, 1960, Br J Ind Med, V17, P260; Yang CT, 2000, J NATL CANCER I, V92, P636, DOI 10.1093/jnci/92.8.636; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375	29	43	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	2010	29	11					1633	1640		10.1038/onc.2009.455	http://dx.doi.org/10.1038/onc.2009.455			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	570RC	20010871	Green Accepted			2022-12-17	WOS:000275694700008
J	Liang, MC; Ma, J; Chen, L; Kozlowski, P; Qin, W; Li, D; Goto, J; Shimamura, T; Hayes, DN; Meyerson, M; Kwiatkowski, DJ; Wong, KK				Liang, M-C; Ma, J.; Chen, L.; Kozlowski, P.; Qin, W.; Li, D.; Goto, J.; Shimamura, T.; Hayes, D. N.; Meyerson, M.; Kwiatkowski, D. J.; Wong, K-K			TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity	ONCOGENE			English	Article						lung cancer; TSC1; KRAS; TSC2; mTOR	TUBEROUS SCLEROSIS COMPLEX; PEUTZ-JEGHERS-SYNDROME; ONCOGENIC K-RAS; TSC1-TSC2 COMPLEX; MAMMALIAN TARGET; MTOR INHIBITORS; BLADDER-CANCER; GENE TSC1; MODEL; LKB1	Germline TSC1 or TSC2 mutations cause tuberous sclerosis complex (TSC), a hamartoma syndrome with lung involvement. To explore the potential interaction between TSC1 and KRAS activation in lung cancer, mice in which Tsc1 loss and KrasG12D expression occur in a small fraction of lung epithelial cells were generated. Mice with a combined Tsc1-KrasG12D mutation had dramatically reduced tumor latency (median survival: 11.6-15.6 weeks) in comparison with KrasG12D alone mutant mice (median survival: 27.5 weeks). Tsc1-KrasG12D tumors showed consistent activation of mTOR (mammalian target of rapamycin) C1 and responded to treatment with rapamycin, leading to significantly improved survival, whereas rapamycin had minor effects on cancers in KrasG12D alone mice. Loss of heterozygosity for TSC1 or TSC2 was found in 22% of 86 human lung cancer specimens. However, none of the 80 lung cancer lines studied showed evidence of the lack of expression of either TSC1 or TSC2 or a signaling pattern corresponding to complete loss. These data indicate that Tsc1 loss synergizes with the Kras mutation to enhance lung tumorigenesis in the mouse, but that this is a rare event in human lung cancer. Rapamycin may have unique benefit for patients with lung cancer, for whom the TSC1/TSC2 function is limited. Oncogene (2010) 29, 1588-1597; doi:10.1038/onc.2009.452; published online 7 December 2009	[Ma, J.; Kozlowski, P.; Qin, W.; Goto, J.; Kwiatkowski, D. J.] Brigham & Womens Hosp, Dept Med, Div Translat Med, Boston, MA 02115 USA; [Liang, M-C; Chen, L.; Li, D.; Wong, K-K] Harvard Canc Ctr, Ludwig Ctr Dana Farber, Boston, MA USA; [Liang, M-C; Chen, L.; Li, D.; Shimamura, T.; Meyerson, M.; Wong, K-K] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Hayes, D. N.] Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Dept Med, Chapel Hill, NC USA; [Meyerson, M.] MIT, Cambridge, MA 02139 USA; [Meyerson, M.] Harvard Univ, Broad Inst, Cambridge, MA 02138 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard University; Dana-Farber Cancer Institute; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute	Kwiatkowski, DJ (corresponding author), Brigham & Womens Hosp, Dept Med, Div Translat Med, 1 Blackfan Circle,Room 6-216, Boston, MA 02115 USA.	dk@rics.bwh.harvard.edu	Meyerson, Matthew L/E-7123-2012; Kozlowski, Piotr/I-1860-2019	Kozlowski, Piotr/0000-0003-3770-7715; Liang, Mei-Chih/0000-0002-7389-2455; Goto, June/0000-0002-4000-9750; Chen, Liang/0000-0001-7300-6604; Hayes, D. Neil/0000-0001-6203-7771	NIH [R01 AG2400401, R01 CA122794, K08 AG024004, P01 CA120964]; Sidney Kimmel Foundation for Cancer Research; Joan Scarangello Foundation to Conquer Lung Cancer; Flight Attendant Medical Research Institute; NATIONAL CANCER INSTITUTE [P01CA120964, R01CA122794] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS024279] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K08AG024004] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Sidney Kimmel Foundation for Cancer Research; Joan Scarangello Foundation to Conquer Lung Cancer; Flight Attendant Medical Research Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Kate McNamara and Sara Zaghlul (Dana-Farber Cancer Institute, Boston), Christine Lam, Iza Malinowska-Kolodziej and Mei Zheng (Brigham and Women's Hospital, Boston) for their technical assistance and Roderick T. Bronson (Harvard Medical School, Boston) and Robert Padera and Lucian Chirieac (Brigham and Women's Hospital, Boston) for assistance with pathology review. This study was supported in part by the NIH Grant nos R01 AG2400401 (K-KW), R01 CA122794 (K-KW), K08 AG024004 (K-KW), P01 CA120964 (DJK), the Sidney Kimmel Foundation for Cancer Research (K-KW), the Joan Scarangello Foundation to Conquer Lung Cancer (K-KW and DJK) and the Flight Attendant Medical Research Institute (K-KW).	Adachi H, 2003, J UROLOGY, V170, P601, DOI 10.1097/01.ju.0000074621.74361.10; Alessi DR, 2006, ANNU REV BIOCHEM, V75, P137, DOI 10.1146/annurev.biochem.75.103004.142702; Bissler JJ, 2008, NEW ENGL J MED, V358, P140, DOI 10.1056/NEJMoa063564; Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704; Corradetti MN, 2004, GENE DEV, V18, P1533, DOI 10.1101/gad.1199104; Crino PB, 2006, NEW ENGL J MED, V355, P1345, DOI 10.1056/NEJMra055323; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Gridelli C, 2008, ONCOLOGIST, V13, P139, DOI 10.1634/theoncologist.2007-0171; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Hardie DG, 2006, PHYSIOLOGY, V21, P48, DOI 10.1152/physiol.00044.2005; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Henske EP, 1996, AM J HUM GENET, V59, P400; Hornigold N, 1999, ONCOGENE, V18, P2657, DOI 10.1038/sj.onc.1202854; Huang JX, 2008, MOL CELL BIOL, V28, P4104, DOI 10.1128/MCB.00289-08; Huang J, 2008, BIOCHEM J, V412, P179, DOI 10.1042/BJ20080281; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Kenerson H, 2005, PEDIATR RES, V57, P67, DOI 10.1203/01.PDR.0000147727.78571.07; Kozlowski P, 2007, HUM GENET, V121, P389, DOI 10.1007/s00439-006-0308-9; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Lee L, 2005, GENE CHROMOSOME CANC, V42, P213, DOI 10.1002/gcc.20118; Li DN, 2007, CANCER CELL, V12, P81, DOI 10.1016/j.ccr.2007.06.005; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; McCormack FX, 2008, CHEST, V133, P507, DOI 10.1378/chest.07-0898; Meikle L, 2008, J NEUROSCI, V28, P5422, DOI 10.1523/JNEUROSCI.0955-08.2008; Milton DT, 2007, CANCER-AM CANCER SOC, V110, P599, DOI 10.1002/cncr.22816; Molina JR, 2008, MAYO CLIN PROC, V83, P584, DOI 10.4065/83.5.584; Muir TE, 1998, AM J SURG PATHOL, V22, P465, DOI 10.1097/00000478-199804000-00012; Platt FM, 2009, CLIN CANCER RES, V15, P6008, DOI 10.1158/1078-0432.CCR-09-0898; Pollizzi K, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-38; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Sanchez-Cespedes M, 2007, ONCOGENE, V26, P7825, DOI 10.1038/sj.onc.1210594; Santarosa M, 2004, BBA-REV CANCER, V1654, P105, DOI 10.1016/j.bbcan.2004.01.001; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Smilenov LB, 2006, CANCER LETT, V240, P17, DOI 10.1016/j.canlet.2005.08.015; Takamochi K, 2001, AM J PATHOL, V159, P1941, DOI 10.1016/S0002-9440(10)63041-6; Thomas RK, 2007, NAT GENET, V39, P347, DOI 10.1038/ng1975; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Wislez M, 2005, CANCER RES, V65, P3226, DOI 10.1158/0008-5472.CAN-04-4420; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222	41	43	44	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	2010	29	11					1588	1597		10.1038/onc.2009.452	http://dx.doi.org/10.1038/onc.2009.452			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	570RC	19966866	Green Submitted, Green Accepted			2022-12-17	WOS:000275694700004
J	Koehl, GE; Spitzner, M; Ousingsawat, J; Schreiber, R; Geissler, EK; Kunzelmann, K				Koehl, G. E.; Spitzner, M.; Ousingsawat, J.; Schreiber, R.; Geissler, E. K.; Kunzelmann, K.			Rapamycin inhibits oncogenic intestinal ion channels and neoplasia in APC(Min/+) mice	ONCOGENE			English	Article						mTOR; familial adenomatous polyposis; ion channels; APCMin/ plus mice; rapamycin; Sirolimus	GATED POTASSIUM CHANNELS; K+ CHANNELS; ADENOMATOUS POLYPOSIS; COLORECTAL-CANCER; COLONIC-CARCINOMA; APC GENE; CELLS; PROLIFERATION; MTOR; COMBINATION	The adenomatous polyposis coli (APC) gene is mutated in familial adenomatous polyposis. Mice with a heterozygous APC(Min) mutation develop multiple intestinal neoplasia (Min) leading to premature death. Early in colorectal carcinogenesis, APC(Min/+) mice show enhanced Akt-mammalian target of rapamycin (mTOR) signaling, which is paralleled by upregulation of oncogenic K+ channels. In this study, we tested the effect of mTOR inhibition with rapamycin on tumor formation in APC(Min/+) mice and evaluated ion channel regulation. We found that continuous long-term rapamycin treatment of APC(Min/+) mice dramatically inhibits intestinal neoplasia. Moreover, although untreated APC(Min/+) mice lose weight, experience intestinal bleeding and succumb to multiple neoplasia by 22.3 +/- 1.4 weeks of age, mice treated with rapamycin maintain stable weight and survive long term (39.6 +/- 3.4 weeks), with more than 30% surviving > 1 year. Impressively, abnormalities in colonic electrolyte transport typical for APC(Min/+) mice are abolished, along with the suppression of epithelial Na+ channel (ENaC) and oncogenic K+ ion channels BK, Elk1 and Erg1, both functionally and at mRNA levels. These results show that continuous prophylaxis by rapamycin markedly inhibits the development of APC mutation-related polyposis, and suggest a novel contributing mechanism of action through the blockade of intestinal oncogenic ion channels. Oncogene (2010) 29, 1553-1560; doi:10.1038/onc.2009.435; published online 7 December 2009	[Koehl, G. E.; Geissler, E. K.] Univ Regensburg, Univ Hosp Regensburg, Dept Surg, Regensburg, Bavaria, Germany; [Spitzner, M.; Ousingsawat, J.; Schreiber, R.; Kunzelmann, K.] Univ Regensburg, Dept Physiol, Regensburg, Germany	University of Regensburg; University of Regensburg	Koehl, GE (corresponding author), Univ Regensburg, Univ Hosp Regensburg, Dept Surg, Franz Josef Str Allee 11,H4, Regensburg, Bavaria, Germany.	gudrun.koehl@klinik.uni-regensburg.de	Schreiber, Robert/Q-7550-2019; Geissler, Edward/R-4131-2016	Kunzelmann, Karl/0000-0002-4583-7037; Spitzner, Melanie/0000-0002-3673-0625	Deutsche Forschungsgemeinschaft [SCHR 752/2-2, SFB699, KU 756/8-2]; Wilhelm Sander-Stiftung [2005.063.1]; Roche Organ Transplant Research Foundation	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Wilhelm Sander-Stiftung; Roche Organ Transplant Research Foundation	We thank Anna Hoehn, Astrid Schwend and Ernestine Tartler for their excellent technical assistance. This study was supported by grants from the Deutsche Forschungsgemeinschaft to RS and KK (SCHR 752/2-2, SFB699, KU 756/8-2), the Wilhelm Sander-Stiftung (2005.063.1; to KK) and the Roche Organ Transplant Research Foundation (to EKG).	Aoki K, 2003, NAT GENET, V35, P323, DOI 10.1038/ng1265; Aoki K, 2007, J CELL SCI, V120, P3327, DOI 10.1242/jcs.03485; Dihlmann S, 2005, CARCINOGENESIS, V26, P1503, DOI 10.1093/carcin/bgi120; Dikovskaya D, 2007, J CELL BIOL, V176, P183, DOI 10.1083/jcb.200610099; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Fujishita T, 2008, P NATL ACAD SCI USA, V105, P13544, DOI 10.1073/pnas.0800041105; Gaber AO, 2008, TRANSPLANTATION, V86, P1187, DOI 10.1097/TP.0b013e318187bab0; Guba M, 2005, TRANSPL INT, V18, P89, DOI 10.1111/j.1432-2277.2004.00026.x; Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055; KOEHL GE, 2005, TRANSPLANT REV, V19, P20; Koehl GE, 2006, TRANSPLANTATION, V82, P741, DOI 10.1097/01.tp.0000233852.75162.74; Kunzelmann K, 2005, J MEMBRANE BIOL, V205, P159, DOI 10.1007/s00232-005-0781-4; Moran AE, 2004, J BIOL CHEM, V279, P43261, DOI 10.1074/jbc.M404276200; MOSER AR, 1995, EUR J CANCER, V31A, P1061, DOI 10.1016/0959-8049(95)00181-H; Otulakowski G, 2007, AM J RESP CELL MOL, V37, P457, DOI 10.1165/rcmb.2007-0055OC; Ousingsawat J, 2008, PFLUG ARCH EUR J PHY, V456, P847, DOI 10.1007/s00424-008-0451-3; Ousingsawat J, 2007, CLIN CANCER RES, V13, P824, DOI 10.1158/1078-0432.CCR-06-1940; Pardo LA, 1999, EMBO J, V18, P5540, DOI 10.1093/emboj/18.20.5540; Pardo LA, 2005, J MEMBRANE BIOL, V205, P115, DOI 10.1007/s00232-005-0776-1; Pillozzi S, 2007, BLOOD, V110, P1238, DOI 10.1182/blood-2006-02-003772; Puntheeranurak S, 2007, CELL PHYSIOL BIOCHEM, V19, P77, DOI 10.1159/000099194; Schreiber R, 2005, J MEMBRANE BIOL, V205, P129, DOI 10.1007/s00232-005-0778-z; Spitzner M, 2008, J BIOL CHEM, V283, P7421, DOI 10.1074/jbc.M703758200; Spitzner M, 2007, FASEB J, V21, P35, DOI 10.1096/fj.06-6200com; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Swamy MV, 2006, CANCER RES, V66, P7370, DOI 10.1158/0008-5472.CAN-05-4619; Valverde MA, 1999, SCIENCE, V285, P1929, DOI 10.1126/science.285.5435.1929; Wonderlin WF, 1996, J MEMBRANE BIOL, V154, P91, DOI 10.1007/s002329900135; Yao XQ, 1999, LIFE SCI, V65, P55, DOI 10.1016/S0024-3205(99)00218-0; Zhang YQ, 2003, FEBS LETT, V534, P125, DOI 10.1016/S0014-5793(02)03804-8	32	43	46	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2010	29	10					1553	1560		10.1038/onc.2009.435	http://dx.doi.org/10.1038/onc.2009.435			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	566SD	19966863				2022-12-17	WOS:000275392400013
J	Argast, GM; Croy, CH; Couts, KL; Zhang, Z; Litman, E; Chan, DC; Ahn, NG				Argast, G. M.; Croy, C. H.; Couts, K. L.; Zhang, Z.; Litman, E.; Chan, D. C.; Ahn, N. G.			Plexin B1 is repressed by oncogenic B-Raf signaling and functions as a tumor suppressor in melanoma cells	ONCOGENE			English	Article						plexin; semaphorin; B-Raf; melanoma; tumor suppressor	GTPASE-ACTIVATING PROTEIN; CONTROLS INVASIVE GROWTH; R-RAS; GENE-EXPRESSION; BRAF MUTATIONS; SEMAPHORIN RECEPTORS; EPITHELIAL-CELLS; AXON GUIDANCE; CANCER; RHO	Human melanomas show oncogenic B-Raf mutations, which activate the B-Raf/MKK/ERK cascade. We screened microarrays to identify cellular targets of this pathway, and found that genes upregulated by B-Raf/MKK/ERK showed highest association with cell-cycle regulators, whereas genes downregulated were most highly associated with axon guidance genes, including plexin-semaphorin family members. Plexin B1 was strongly inhibited by mitogen-activated protein kinase signaling in melanoma cells and melanocytes. In primary melanoma cells, plexin B1 blocked tumorigenesis as measured by growth of colonies in soft agar, spheroids in extracellular matrix and xenograft tumors. Tumor suppression depended on residues in the C-terminal domain of plexin B1, which mediate receptor GTPase activating protein activity, and also correlated with AKT inhibition. Interestingly, the inhibitory response to plexin B1 was reduced or absent in cells from a matched metastatic tumor, suggesting that changes occur in metastatic cells which bypass the tumor-suppressor mechanisms. Plexin B1 also inhibited cell migration, but this was seen in metastatic cells and not in matched primary cells. Thus, plexin B1 has tumor-suppressor function in early-stage cells, although suppressing migration in late-stage cells. Our findings suggest that B-Raf/MKK/ERK provides a permissive environment for melanoma genesis by modulating plexin B1. Oncogene (2009) 28, 2697-2709; doi:10.1038/onc.2009.133; published online 1 June 2009	[Litman, E.; Ahn, N. G.] Univ Colorado, Howard Hughes Med Inst, Dept Chem & Biochem, Boulder, CO 80309 USA; [Zhang, Z.; Chan, D. C.] Univ Colorado, Hlth Sci Ctr, Dept Med, Div Med Oncol, Aurora, CO USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Anschutz Medical Campus	Ahn, NG (corresponding author), Univ Colorado, Howard Hughes Med Inst, Dept Chem & Biochem, Campus Box 215,Room 76,Cristol Bldg, Boulder, CO 80309 USA.	natalie.ahn@colorado.edu			NIH [R01-CA118972, P50-CA058187, F32-CA105796, ACS-PF-04- 152, T32-GM008759]; NATIONAL CANCER INSTITUTE [R01CA118972, F32CA105796, P50CA058187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008759] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Meenhard Herlyn for providing melanoma cell lines used in this study, and Silvio Gutkind, Kun-liang Guan, Xuedong Liu and Andrey Sorokin for expression plasmids. We also thank Norma Aumen for tumor sectioning, Helen Marshall for microarray analysis and Micah Hamady and Rob Knight for providing access to GO-Getter. This work was supported by NIH awards R01-CA118972 (NGA) and P50-CA058187 ( DC), and fellowship awards F32-CA105796 (GMA), ACS-PF-04- 152 (CHC) and T32-GM008759 (KLC).	Aurandt J, 2002, P NATL ACAD SCI USA, V99, P12085, DOI 10.1073/pnas.142433199; Basile JR, 2007, J BIOL CHEM, V282, P34888, DOI 10.1074/jbc.M705467200; Basile JR, 2006, P NATL ACAD SCI USA, V103, P9017, DOI 10.1073/pnas.0508825103; Basile JR, 2004, CANCER RES, V64, P5212, DOI 10.1158/0008-5472.CAN-04-0126; Bielenberg DR, 2004, J CLIN INVEST, V114, P1260, DOI 10.1172/JCI200421378; Bloethner S, 2005, CARCINOGENESIS, V26, P1224, DOI 10.1093/carcin/bgi066; Bogenrieder T, 2002, CRIT REV ONCOL HEMAT, V44, P1, DOI 10.1016/S1040-8428(01)00196-2; Breitling R, 2004, FEBS LETT, V573, P83, DOI 10.1016/j.febslet.2004.07.055; Brose MS, 2002, CANCER RES, V62, P6997; Charest PG, 2007, BIOCHEM J, V401, P377, DOI 10.1042/BJ20061432; Conrotto P, 2005, BLOOD, V105, P4321, DOI 10.1182/blood-2004-07-2885; Conrotto P, 2004, ONCOGENE, V23, P5131, DOI 10.1038/sj.onc.1207650; COX AD, 1994, ONCOGENE, V9, P3281; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dhomen N, 2007, CURR OPIN GENET DEV, V17, P31, DOI 10.1016/j.gde.2006.12.005; Dickson BJ, 2001, CURR OPIN NEUROBIOL, V11, P103, DOI 10.1016/S0959-4388(00)00180-X; Driessens MHE, 2001, CURR BIOL, V11, P339, DOI 10.1016/S0960-9822(01)00092-6; Fujisawa H, 2004, J NEUROBIOL, V59, P24, DOI 10.1002/neu.10337; Fukata M, 2003, CURR OPIN CELL BIOL, V15, P590, DOI 10.1016/S0955-0674(03)00097-8; Giordano S, 2002, NAT CELL BIOL, V4, P720, DOI 10.1038/ncb843; Hingorani SR, 2003, CANCER RES, V63, P5198; Hoek KS, 2006, PIGM CELL RES, V19, P290, DOI 10.1111/j.1600-0749.2006.00322.x; Hsu MY, 1999, HUMAN CELL CULTURE, V1, P259; Ito Y, 2006, EMBO REP, V7, P704, DOI 10.1038/sj.embor.7400737; Johansson P, 2007, PIGM CELL RES, V20, P216, DOI 10.1111/j.1600-0749.2007.00375.x; Keely PJ, 1999, J CELL BIOL, V145, P1077, DOI 10.1083/jcb.145.5.1077; Kessler O, 2004, CANCER RES, V64, P1008, DOI 10.1158/0008-5472.CAN-03-3090; Koo HM, 2002, P NATL ACAD SCI USA, V99, P3052, DOI 10.1073/pnas.052707699; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Mora N, 2007, CANCER IMMUNOL IMMUN, V56, P535, DOI 10.1007/s00262-006-0205-z; Nakada M, 2005, AM J PATHOL, V167, P565, DOI 10.1016/S0002-9440(10)62998-7; Negishi M, 2005, CELL MOL LIFE SCI, V62, P1363, DOI 10.1007/s00018-005-5018-2; Nishigaki M, 2005, CANCER RES, V65, P2115, DOI 10.1158/0008-5472.CAN-04-3340; Oinuma I, 2004, J NEUROSCI, V24, P11473, DOI 10.1523/JNEUROSCI.3257-04.2004; Oinuma I, 2004, SCIENCE, V305, P862, DOI 10.1126/science.1097545; Omholt K, 2003, CLIN CANCER RES, V9, P6483; Osada M, 1999, MOL CELL BIOL, V19, P6333; Pavey S, 2004, ONCOGENE, V23, P4060, DOI 10.1038/sj.onc.1207563; Perrot V, 2002, J BIOL CHEM, V277, P43115, DOI 10.1074/jbc.M206005200; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Rincon-Arano H, 2003, CANCER, V97, P575, DOI 10.1002/cncr.11093; Rody A, 2007, CLIN CANCER RES, V13, P1115, DOI 10.1158/1078-0432.CCR-06-2433; Sharma A, 2005, CANCER RES, V65, P2412, DOI 10.1158/0008-5472.CAN-04-2423; Shields JM, 2007, CANCER RES, V67, P1502, DOI 10.1158/0008-5472.CAN-06-3311; Smalley KSM, 2006, MOL CANCER THER, V5, P1136, DOI 10.1158/1535-7163.MCT-06-0084; Swiercz JM, 2008, J BIOL CHEM, V283, P1893, DOI 10.1074/jbc.M706822200; Swiercz JM, 2002, NEURON, V35, P51, DOI 10.1016/S0896-6273(02)00750-X; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; Tian F, 2003, CANCER RES, V63, P8284; Vikis HG, 2002, GENE DEV, V16, P836, DOI 10.1101/gad.966402; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wong OGW, 2007, P NATL ACAD SCI USA, V104, P19040, DOI 10.1073/pnas.0702544104; Yu Y, 2002, ONCOGENE, V21, P7557, DOI 10.1038/sj.onc.1205961; Zhuang L, 2005, J CLIN PATHOL, V58, P1163, DOI 10.1136/jcp.2005.025957	54	43	44	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	30					2697	2709		10.1038/onc.2009.133	http://dx.doi.org/10.1038/onc.2009.133			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476OW	19483722	Green Accepted			2022-12-17	WOS:000268452900001
J	Chung, BM; Dimri, M; George, M; Reddi, AL; Chen, G; Band, V; Band, H				Chung, B. M.; Dimri, M.; George, M.; Reddi, A. L.; Chen, G.; Band, V.; Band, H.			The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancer-associated EGF receptor mutants	ONCOGENE			English	Article						mutant EGFR; Src; transformation	GROWTH-FACTOR-RECEPTOR; C-SRC; KINASE INHIBITOR; SIGNAL TRANSDUCERS; TYROSINE KINASES; DOWN-REGULATION; MUTATIONS; ACTIVATION; GEFITINIB; SURVIVAL	Non-small cell lung cancer (NSCLC)-associated epidermal growth factor receptor (EGFR) mutants are constitutively active and induce ligand-independent transformation in non-malignant cell lines. We investigated the possibility that the ability of mutant EGFRs to transform cells reflects a constitutive cooperativity with Src using a system in which the overexpression of mutant, but not wild-type, EGFR induced anchorage-independent cell growth. Src was constitutively activated and showed enhanced interaction with mutant EGFRs, suggesting that constitutive EGFR-Src cooperativity may contribute to mutant EGFR-mediated oncogenesis. Indeed, the mutant EGFR-mediated cell transformation was inhibited by Src- as well as EGFR-directed inhibitors. Importantly, a tyrosine to phenylalanine mutation of the major Src phosphorylation site on EGFR, Y845, reduced the constitutive phosphorylation of NSCLC-EGFR mutants, as well as that of STAT3, Akt, Erk and Src, and reduced the mutant EGFR-Src association as well as proliferation, migration and anchorage-independent growth. Reduced anchorage-independent growth and migration were also observed when dominant-negative-Src was expressed in mutant EGFR-expressing cells. Overall, our findings show that mutant EGFR-Src interaction and cooperativity play critical roles in constitutive engagement of the downstream signaling pathways that allow NSCLC-associated EGFR mutants to mediate oncogenesis, and support the rationale to target Src- dependent signaling pathways in mutant EGFR-mediated malignancies.	[Chung, B. M.; George, M.; Band, H.] Univ Nebraska Med Ctr, Eppley Inst Canc & Allied Dis, Nebraska Med Ctr, Omaha, NE 68198 USA; [Band, H.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Nebraska Med Ctr, Omaha, NE 68198 USA; [Band, V.; Band, H.] Univ Nebraska Med Ctr, Coll Med, Dept Genet Cell Biol & Anat, Nebraska Med Ctr, Omaha, NE 68198 USA; [Band, V.; Band, H.] Univ Nebraska Med Ctr, UNMC Eppley Canc Ctr, Nebraska Med Ctr, Omaha, NE 68198 USA; [Chung, B. M.; Dimri, M.; George, M.; Reddi, A. L.; Chen, G.; Band, V.; Band, H.] Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Feinberg Sch Med, Evanston NW Healthcare Res Inst,Dept Med, Evanston, IL USA; [Chung, B. M.; Dimri, M.; George, M.; Reddi, A. L.; Chen, G.; Band, V.; Band, H.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Band, H (corresponding author), Univ Nebraska Med Ctr, Eppley Inst Canc & Allied Dis, Nebraska Med Ctr, 986805 Nebraska Med Ctr, Omaha, NE 68198 USA.	hband@unmc.edu	Chung, Byung Min/H-6219-2019	Chung, Byung Min/0000-0003-1262-5107	NIH [CA87986, CA105489, CA99900, CA116552, CA99163, CA94143, CA96844, CA81076]; Department of Defense Breast Cancer Research [W81XVVH-08-1-0617, DAMD17-02-1-0508]; NCI Cancer Center of Nanotechnology Excellence [1U54 CA119341-01]; NCI Breast Cancer SPORE and AVON Breast Cancer Fund; H Foundation, Chicago, IL, USA; Jean Ruggles-Romoser Chair of Cancer Research; Duckworth Family Chair of Breast Cancer Research; Malkin Scholarship; NCI Cancer Center Core Grant; NATIONAL CANCER INSTITUTE [R01CA099900, R01CA076118, R01CA099163, R01CA081076, R01CA087986, R01CA094143, R01CA105489, R01CA096844, U54CA119341, R01CA116552] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense Breast Cancer Research(United States Department of Defense); NCI Cancer Center of Nanotechnology Excellence; NCI Breast Cancer SPORE and AVON Breast Cancer Fund; H Foundation, Chicago, IL, USA; Jean Ruggles-Romoser Chair of Cancer Research; Duckworth Family Chair of Breast Cancer Research; Malkin Scholarship; NCI Cancer Center Core Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank members of the Band laboratories for helpful suggestions and discussion. This work was supported by: the NIH grants CA87986, CA105489, CA99900, CA116552 and CA99163 to HB, and CA94143, CA96844 and CA81076 to VB; Department of Defense Breast Cancer Research Grants W81XVVH-08-1-0617 (HB) and DAMD17-02-1-0508 (VB); the NCI Cancer Center of Nanotechnology Excellence Grant NCI 1U54 CA119341-01 (HB and VB); the NCI Breast Cancer SPORE and AVON Breast Cancer Fund at Robert H Lurie Cancer Center, Northwestern University; the H Foundation, Chicago, IL, USA; the Jean Ruggles-Romoser Chair of Cancer Research (HB) and the Duckworth Family Chair of Breast Cancer Research (VB); and the Malkin Scholarship (BMC). UNMC-Eppley Cancer Center is supported by an NCI Cancer Center Core Grant.	Alvarez JV, 2006, CANCER RES, V66, P3162, DOI 10.1158/0008-5472.CAN-05-3757; ANN PAB, 2004, ONCOGENE, V23, P7957; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; Dimri M, 2007, CANCER RES, V67, P4164, DOI 10.1158/0008-5472.CAN-06-2580; Fu YN, 2008, ONCOGENE, V27, P957, DOI 10.1038/sj.onc.1210684; Golas JM, 2003, CANCER RES, V63, P375; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360; Haura EB, 2005, CLIN CANCER RES, V11, P8288, DOI 10.1158/1078-0432.CCR-05-0827; Herbst RS, 2004, INT J RADIAT ONCOL, V59, P21, DOI 10.1016/j.ijrobp.2003.11.041; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Kazansky AV, 2001, CELL GROWTH DIFFER, V12, P1; Kim H, 2005, ONCOGENE, V24, P7599, DOI 10.1038/sj.onc.1208898; Kloth MT, 2003, J BIOL CHEM, V278, P1671, DOI 10.1074/jbc.M207289200; Lombardo LJ, 2004, J MED CHEM, V47, P6658, DOI 10.1021/jm049486a; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Maeda M, 2006, J BIOL CHEM, V281, P59, DOI 10.1074/jbc.M503304200; Masaki T, 2003, EUR J CANCER, V39, P1447, DOI 10.1016/S0959-8049(03)00276-4; Mitsudomi T, 2005, J CLIN ONCOL, V23, P2513, DOI 10.1200/JCO.2005.00.992; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Politi K, 2006, GENE DEV, V20, P1496, DOI 10.1101/gad.1417406; Reddi AL, 2007, J BIOL CHEM, V282, P29336, DOI 10.1074/jbc.M701797200; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Shimamura T, 2005, CANCER RES, V65, P6401, DOI 10.1158/0008-5472.CAN-05-0933; Shtiegman K, 2007, ONCOGENE, V26, P6968, DOI 10.1038/sj.onc.1210503; Silva CM, 2004, ONCOGENE, V23, P8017, DOI 10.1038/sj.onc.1208159; Song LX, 2006, CANCER RES, V66, P5542, DOI 10.1158/0008-5472.CAN-05-4620; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Tatton L, 2003, J BIOL CHEM, V278, P4847, DOI 10.1074/jbc.M209321200; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Wiley HS, 2001, TRAFFIC, V2, P12, DOI 10.1034/j.1600-0854.2001.020103.x; Yang SC, 2006, CANCER RES, V66, P6990, DOI 10.1158/0008-5472.CAN-06-1042; Yanga S, 2008, EXP CELL RES, V314, P413, DOI 10.1016/j.yexcr.2007.09.002; Yun CH, 2007, CANCER CELL, V11, P217, DOI 10.1016/j.ccr.2006.12.017; Zhang J, 2007, AM J PATHOL, V170, P366, DOI 10.2353/ajpath.2007.060706; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013	40	43	46	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 23	2009	28	16					1821	1832		10.1038/onc.2009.31	http://dx.doi.org/10.1038/onc.2009.31			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	439PW	19305428	Green Accepted			2022-12-17	WOS:000265640500001
J	Jang, M; Park, BC; Kang, S; Chi, SW; Cho, S; Chung, SJ; Lee, SC; Bae, KH; Park, SG				Jang, M.; Park, B. C.; Kang, S.; Chi, S-W; Cho, S.; Chung, S. J.; Lee, S. C.; Bae, K-H; Park, S. G.			Far upstream element-binding protein-1, a novel caspase substrate, acts as a cross-talker between apoptosis and the c-myc oncogene	ONCOGENE			English	Article						apoptosis; caspase; c-Myc; FBP-1; FUSE	CELL-DEATH; IDENTIFICATION; EXPRESSION; MITOCHONDRIAL; CLEAVAGE; BAX	Far upstream element-binding protein-1 (FBP-1) binds to an upstream element of the c-myc promoter and regulates the c-myc mRNA level. Earlier, FBP-1 was identified as a candidate substrate of caspase-7. Here, we report that FBP-1 is cleaved by executor caspases, both in vitro and during apoptosis. Cleavage occurs at the caspase consensus site (DQPD74) located within the classical bipartite nuclear localization signal sequence. In cells subjected to apoptotic stimuli, the caspase-mediated cleavage of FBP-1 leads to its decreased presence in the nucleus, concomitant with the marked downregulation of c-Myc and its various target proteins. By contrast, cells transfected with a non-cleavable mutant of FBP-1 (D74A) maintain higher levels of c-Myc and are protected from apoptosis. On the basis of these results, we suggest that the oncogenic potential of c-Myc is 'switched off' after apoptosis induction as a consequence of the caspase-mediated cleavage of FBP-1.	[Jang, M.; Park, B. C.; Kang, S.; Chi, S-W; Lee, S. C.; Bae, K-H; Park, S. G.] Korea Res Inst Biosci & Biotechnol, Med Prote Res Ctr, Taejon 305806, South Korea; [Cho, S.] Chung Ang Univ, Coll Pharm, Seoul 156756, South Korea; [Chung, S. J.] Korea Res Inst Biosci & Biotechnol, BioNano Res Ctr, Taejon 305806, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Chung Ang University; Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Bae, KH (corresponding author), Korea Res Inst Biosci & Biotechnol, Med Prote Res Ctr, Taejon 305806, South Korea.	khbae@kribb.re.kr		Bae, Kwang-Hee/0000-0002-5868-2556; Kang, Sunghyun/0000-0003-1542-9750	KRIBB; Korea Science and Engineering Foundation [2008-01050]	KRIBB; Korea Science and Engineering Foundation(Korea Science and Engineering Foundation)	We thank Drs Young Il Yeom, Seung Jun Kim and Do Hee Lee for their helpful advices. This study was supported by a grant sponsored by KRIBB (to K-H Bae) and Korea Science and Engineering Foundation (Basic Research Program no. 2008-01050) (to SG Park).	BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Cao XF, 2008, J BIOL CHEM, V283, P14490, DOI 10.1074/jbc.M801107200; Chung HJ, 2005, MOL CELLS, V20, P157; Chung HJ, 2006, MOL CELL BIOL, V26, P6584, DOI 10.1128/MCB.00754-06; Denault JB, 2002, CHEM REV, V102, P4489, DOI 10.1021/cr010183n; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; He LS, 2000, NUCLEIC ACIDS RES, V28, P4558, DOI 10.1093/nar/28.22.4558; He LS, 2000, EMBO J, V19, P1034, DOI 10.1093/emboj/19.5.1034; Jang M, 2007, BIOCHEM BIOPH RES CO, V363, P388, DOI 10.1016/j.bbrc.2007.08.183; Krysko DV, 2006, CELL DEATH DIFFER, V13, P2011, DOI 10.1038/sj.cdd.4401900; Lalier L, 2007, APOPTOSIS, V12, P887, DOI 10.1007/s10495-007-0749-1; Lee AY, 2004, PROTEOMICS, V4, P3429, DOI 10.1002/pmic.200400979; Lee MW, 2003, ONCOGENE, V22, P6340, DOI 10.1038/sj.onc.1206729; Liu JB, 2007, CANCER CHEMOTH PHARM, V59, P217, DOI 10.1007/s00280-006-0260-3; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nieminen AI, 2007, CELL CYCLE, V6, P2464, DOI 10.4161/cc.6.20.4917; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Raff M, 1998, NATURE, V396, P119, DOI 10.1038/24055; Stennicke HR, 1999, METHODS, V17, P313, DOI 10.1006/meth.1999.0745; Thiede B, 2001, J BIOL CHEM, V276, P26044, DOI 10.1074/jbc.M101062200; Timmer JC, 2007, CELL DEATH DIFFER, V14, P66, DOI 10.1038/sj.cdd.4402059; Vindigni A, 2001, NUCLEIC ACIDS RES, V29, P1061, DOI 10.1093/nar/29.5.1061; Wierstra I, 2008, ADV CANCER RES, V99, P113, DOI 10.1016/S0065-230X(07)99004-1	23	43	47	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	12					1529	1536		10.1038/onc.2009.11	http://dx.doi.org/10.1038/onc.2009.11			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	424AH	19219071				2022-12-17	WOS:000264537400005
J	Danielian, PS; Friesenhahn, LB; Faust, AM; West, JC; Caron, AM; Bronson, RT; Lees, JA				Danielian, P. S.; Friesenhahn, L. B.; Faust, A. M.; West, J. C.; Caron, A. M.; Bronson, R. T.; Lees, J. A.			E2f3a and E2f3b make overlapping but different contributions to total E2f3 activity	ONCOGENE			English	Article						E2f3; Arf; cell cycle; E2f1	HUMAN BLADDER-CANCER; CELLULAR PROLIFERATION; TRANSCRIPTION FACTOR; OVEREXPRESSION; AMPLIFICATION; EXPRESSION; IDENTIFICATION; SPECIFICITY; REPRESSION; APOPTOSIS	The E2f transcription factors are key downstream targets of the retinoblastoma protein tumor suppressor that control cell proliferation. E2F3 has garnered particular attention because it is amplified in various human tumors. E2f3 mutant mice typically die around birth and E2f3-deficient cells have a proliferation defect that correlates with impaired E2f target gene activation and also induction of p19(Arf) and p53. The E2f3 locus encodes two isoforms, E2f3a and E2f3b, which differ in their N-termini. However, it is unclear how E2f3a versus E2f3b contributes to E2f3's requirement in either proliferation or development. To address this, we use E2f3a- and E2f3b-specific knockouts. We show that inactivation of E2f3a results in a low penetrance proliferation defect in vitro whereas loss of E2f3b has no effect. This proliferation defect appears insuficient to disrupt normal development as E2f3a and E2f3b mutant mice are both fully viable and have no detectable defects. However, when combined with E2f1 mutation, inactivation of E2f3a, but not E2f3b, causes significant proliferation defects in vitro, neonatal lethality and also a striking cartilage defect. Thus, we conclude that E2f3a and E2f3b have largely overlapping functions in vivo and that E2f3a can fully substitute for E2f1 and E2f3 in most murine tissues.	[Danielian, P. S.; Friesenhahn, L. B.; Faust, A. M.; West, J. C.; Caron, A. M.; Lees, J. A.] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA; [Bronson, R. T.] Tufts Cummings Sch Vet Med, North Grafton, MA USA	Massachusetts Institute of Technology (MIT)	Lees, JA (corresponding author), MIT, David H Koch Inst Integrat Canc Res, 77 Mass Ave,E17-517B, Cambridge, MA 02139 USA.	jalees@mit.edu		Danielian, Paul/0000-0003-2651-0386	NIH [CA118757]; NATIONAL CANCER INSTITUTE [R01CA118757] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Aurora Burds Connor and the MIT Fannie E Rippel transgenic facility; the KI Flow Cytometry facility for technical assistance; Donald Court, Neal Copeland, Nancy Jenkins and Lili Yamasaki for reagents and mouse strains and Keara Lane, Daniel Garcia, GuangJun Zhang and Lees laboratory members for helpful suggestions. This work was supported by an NIH grant to JAL (CA118757). JAL is a Ludwig Scholar.	Adams MR, 2000, MOL CELL BIOL, V20, P3633, DOI 10.1128/MCB.20.10.3633-3639.2000; Aslanian A, 2004, GENE DEV, V18, P1413, DOI 10.1101/gad.1196704; Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; Berthet C, 2007, ONCOGENE, V26, P4469, DOI 10.1038/sj.onc.1210243; Blais A, 2007, CURR OPIN CELL BIOL, V19, P658, DOI 10.1016/j.ceb.2007.10.003; Cloud JE, 2002, MOL CELL BIOL, V22, P2663, DOI 10.1128/MCB.22.8.2663-2672.2002; Cooper CS, 2006, LUNG CANCER, V54, P155, DOI 10.1016/j.lungcan.2006.07.005; Courel M, 2008, DEV DYNAM, V237, P1232, DOI 10.1002/dvdy.21516; Danielian PS, 2007, DEV BIOL, V305, P564, DOI 10.1016/j.ydbio.2007.02.037; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Feber A, 2004, ONCOGENE, V23, P1627, DOI 10.1038/sj.onc.1207274; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Foster CS, 2004, ONCOGENE, V23, P5871, DOI 10.1038/sj.onc.1207800; He YW, 2000, ONCOGENE, V19, P3422, DOI 10.1038/sj.onc.1203682; Humbert PO, 2000, GENE DEV, V14, P690; Hurst CD, 2008, ONCOGENE, V27, P2716, DOI 10.1038/sj.onc.1210934; Janumyan YM, 2003, EMBO J, V22, P5459, DOI 10.1093/emboj/cdg533; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Oeggerli M, 2006, ONCOGENE, V25, P6538, DOI 10.1038/sj.onc.1209946; Oeggerli M, 2004, ONCOGENE, V23, P5616, DOI 10.1038/sj.onc.1207749; Orlic M, 2006, GENE CHROMOSOME CANC, V45, P72, DOI 10.1002/gcc.20263; Parisi T, 2007, MOL CELL BIOL, V27, P2283, DOI 10.1128/MCB.01854-06; Sharma N, 2006, J BIOL CHEM, V281, P36124, DOI 10.1074/jbc.M604152200; Timmers C, 2007, MOL CELL BIOL, V27, P65, DOI 10.1128/MCB.02147-06; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Ziebold U, 2003, MOL CELL BIOL, V23, P6542, DOI 10.1128/MCB.23.18.6542-6552.2003	27	43	43	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2008	27	51					6561	6570		10.1038/onc.2008.253	http://dx.doi.org/10.1038/onc.2008.253			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	366RS	18663357	Green Submitted, Green Accepted			2022-12-17	WOS:000260501700003
J	De Luca, M; Brunetto, L; Asteriti, IA; Giubettini, M; Lavia, P; Guarguaglini, G				De Luca, M.; Brunetto, L.; Asteriti, I. A.; Giubettini, M.; Lavia, P.; Guarguaglini, G.			Aurora-A and ch-TOG act in a common pathway in control of spindle pole integrity	ONCOGENE			English	Article						Aurora-A; ch-TOG; MCAK; mitosis; spindle pole	D-TACC; CENTROSOME; KINASE; ORGANIZATION; ANEUPLOIDY; PROTEIN; CANCER; PHOSPHORYLATION; AMPLIFICATION; LOCALIZATION	Mitotic spindle assembly is a highly regulated process, crucial to ensure the correct segregation of duplicated chromosomes in daughter cells and to avoid aneuploidy, a common feature of tumors. Among the most important spindle regulators is Aurora-A, a mitotic centrosomal kinase frequently overexpressed in tumors. Here, we investigated the role of Aurora-A in spindle pole organization in human cells. We show that RNA interference-mediated Aurora-A inactivation causes pericentriolar material fragmentation in prometaphase, yielding the formation of spindles with supernumerary poles. This fragmentation does not necessarily involve centrioles and requires microtubules (MTs). Aurora-A-depleted prometaphases mislocalize the MT-stabilizing protein colonic hepatic tumor-overexpressed gene (ch-TOG), which abnormally accumulates at spindle poles, as well as the mitotic centromere-associated kinesin ( MCAK), the major functional antagonist of ch-TOG, which delocalizes from poles. ch-TOG is required for extrapole formation in prometaphases lacking Aurora-A, because co-depletion of Aurora-A and ch-TOG mitigates the fragmented pole phenotype. These results indicate a novel function of Aurora-A, the regulation of ch-TOG and MCAK localization, and highlight a common pathway involving the three factors in control of spindle pole integrity.	[De Luca, M.; Brunetto, L.; Asteriti, I. A.; Giubettini, M.; Lavia, P.; Guarguaglini, G.] Univ Roma La Sapienza, CNR, Inst Mol Biol & Pathol, Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome	Guarguaglini, G (corresponding author), Univ Roma La Sapienza, CNR, IBPM, Via Apuli 4, I-00185 Rome, Italy.	giulia.guarguaglini@uniroma1.it	Lavia, Patrizia/J-5793-2019; Lavia, Patrizia/AAL-3982-2021	Lavia, Patrizia/0000-0003-3310-6701; DE LUCA, Maria/0000-0003-2329-776X; Giubettini, Maria/0000-0001-5863-1911	AIRC (Italian Association for Cancer Research)	AIRC (Italian Association for Cancer Research)(Fondazione AIRC per la ricerca sul cancro)	We thank M Ciciarello and R Mangiacasale for helpful discussions and JL Salisbury and C Walczak for reagents. This work was supported by AIRC ( Italian Association for Cancer Research) grants ( to PL).	Agnese V, 2007, ANN ONCOL, V18, P47, DOI 10.1093/annonc/mdm224; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Andrews PD, 2005, ONCOGENE, V24, P5005, DOI 10.1038/sj.onc.1208752; Barr AR, 2007, J CELL SCI, V120, P2987, DOI 10.1242/jcs.013136; Barros TP, 2005, J CELL BIOL, V170, P1039, DOI 10.1083/jcb.200504097; Blagden SP, 2003, NAT CELL BIOL, V5, P505, DOI 10.1038/ncb0603-505; Cassimeris L, 2004, MOL BIOL CELL, V15, P1580, DOI 10.1091/mbc.E03-07-0544; Ciciarello M, 2007, CELL MOL LIFE SCI, V64, P1891, DOI 10.1007/s00018-007-6568-2; De Luca M, 2006, CELL CYCLE, V5, P296; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Fielding AB, 2008, J CELL BIOL, V180, P681, DOI 10.1083/jcb.200710074; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Gadde S, 2004, CURR BIOL, V14, pR797, DOI 10.1016/j.cub.2004.09.021; Gard DL, 2004, INT REV CYTOL, V239, P179, DOI 10.1016/S0074-7696(04)39004-2; Gergely F, 2003, GENE DEV, V17, P336, DOI 10.1101/gad.245603; Giet R, 2005, TRENDS CELL BIOL, V15, P241, DOI 10.1016/j.tcb.2005.03.004; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; Hoar K, 2007, MOL CELL BIOL, V27, P4513, DOI 10.1128/MCB.02364-06; Holmfeldt P, 2005, EMBO J, V24, P1256, DOI 10.1038/sj.emboj.7600601; Kinoshita K, 2005, J CELL BIOL, V170, P1047, DOI 10.1083/jcb.200503023; Koffa MD, 2006, CURR BIOL, V16, P743, DOI 10.1016/j.cub.2006.03.056; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; Lee MJ, 2001, NAT CELL BIOL, V3, P643, DOI 10.1038/35083033; LeRoy PJ, 2007, CANCER RES, V67, P5362, DOI 10.1158/0008-5472.CAN-07-0122; Luders J, 2007, NAT REV MOL CELL BIO, V8, P161, DOI 10.1038/nrm2100; Manning AL, 2007, CURR BIOL, V17, P260, DOI 10.1016/j.cub.2006.11.071; Marumoto T, 2005, NAT REV CANCER, V5, P42, DOI 10.1038/nrc1526; Marumoto T, 2003, J BIOL CHEM, V278, P51786, DOI 10.1074/jbc.M306275200; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Nigg EA, 2006, INT J CANCER, V119, P2717, DOI 10.1002/ijc.22245; Peset I, 2005, J CELL BIOL, V170, P1057, DOI 10.1083/jcb.200504037; Sharp DJ, 2000, NATURE, V407, P41, DOI 10.1038/35024000; Weaver BAA, 2005, CANCER CELL, V8, P7, DOI 10.1016/j.ccr.2005.06.011; Weaver BAA, 2006, CURR OPIN CELL BIOL, V18, P658, DOI 10.1016/j.ceb.2006.10.002; Zhang X, 2008, MOL BIOL CELL, V19, P2752, DOI 10.1091/mbc.E08-02-0198	36	43	43	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2008	27	51					6539	6549		10.1038/onc.2008.252	http://dx.doi.org/10.1038/onc.2008.252			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	366RS	18663358				2022-12-17	WOS:000260501700001
J	Muller, A; Duque, J; Shizuru, JA; Lubbert, M				Mueller, Ams; Duque, J.; Shizuru, J. A.; Luebbert, M.			Complementing mutations in core binding factor leukemias: from mouse models to clinical applications	ONCOGENE			English	Review						core binding factor leukemias; AML1-ETO; CBF beta-MYH11; receptor tyrosine kinase; c-KIT mutation	ACUTE MYELOID-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; ACUTE MYELOBLASTIC-LEUKEMIA; MYOSIN HEAVY-CHAIN; INTERNAL TANDEM DUPLICATION; RECEPTOR TYROSINE KINASE; C-KIT MUTATIONS; FUSION PROTEIN; TRANSCRIPTION FACTOR; FETAL LIVER	A great proportion of acute myeloid leukemias (AMLs) display cytogenetic abnormalities including chromosomal aberrations and/or submicroscopic mutations. These abnormalities significantly influence the prognosis of the disease. Hence, a thorough genetic work-up is an essential constituent of standard diagnostic procedures. Core binding factor (CBF) leukemias denote AMLs with chromosomal aberrations disrupting one of the CBF transcription factor genes; the most common examples are translocation t(8;21) and inversion inv(16), which result in the generation of the AML1-ETO and CBF beta-MYH11 fusion proteins, respectively. However, in murine models, these alterations alone do not suffice to generate full-blown leukemia, but rather, complementary events are required. In fact, a substantial proportion of primary CBF leukemias display additional activating mutations, mostly of the receptor tyrosine kinase (RTK) c-KIT. The awareness of the impact and prognostic relevance of these 'second hits' is increasing with a wider range of mutations tested in clinical trials. Furthermore, novel agents targeting RTKs are emanating rapidly and entering therapeutic regimens. Here, we present a concise review on complementing mutations in CBF leukemias including pathophysiology, mouse models, and clinical implications.	[Mueller, Ams; Duque, J.; Luebbert, M.] Univ Med Ctr Freiburg, Dept Hematol Oncol, D-79106 Freiburg, Germany; [Mueller, Ams; Shizuru, J. A.] Stanford Univ, Med Ctr, Dept Med, Div Blood & Marrow Transplantat, Stanford, CA 94305 USA	University of Freiburg; Stanford University	Lubbert, M (corresponding author), Univ Med Ctr Freiburg, Dept Hematol Oncol, Hugstetterstr 55, D-79106 Freiburg, Germany.	michael.luebbert@uniklinik-freiburg.de	Müller, Antonia/HCI-4374-2022	Muller, Antonia Maria Susanne/0000-0003-4420-9466	Deutsche Forschungsgemeinschaft (DFG), Germany; La Caixa Stiftung-Deutscher Akademischer Austauschdienst (DAAD), Germany; German Jose-Carreras Leukemia Foundation	Deutsche Forschungsgemeinschaft (DFG), Germany(German Research Foundation (DFG)); La Caixa Stiftung-Deutscher Akademischer Austauschdienst (DAAD), Germany(Deutscher Akademischer Austausch Dienst (DAAD)); German Jose-Carreras Leukemia Foundation	We are grateful for outstanding support by the comments and remarks of both reviewers of this paper. This study was supported by the Deutsche Forschungsgemeinschaft (DFG), Germany (AM), the La Caixa Stiftung-Deutscher Akademischer Austauschdienst (DAAD), Germany (JD), and the German Jose-Carreras Leukemia Foundation (ML), respectively.	Adya N, 1998, MOL CELL BIOL, V18, P7432, DOI 10.1128/MCB.18.12.7432; Alcalay M, 2001, ONCOGENE, V20, P5680, DOI 10.1038/sj.onc.1204642; Bacher U, 2006, BLOOD, V107, P3847, DOI 10.1182/blood-2005-08-3522; Baer MR, 1997, BLOOD, V90, P1643, DOI 10.1182/blood.V90.4.1643.1643_1643_1648; Beghini A, 2000, BLOOD, V95, P726, DOI 10.1182/blood.V95.2.726; Beghini A, 2004, HAEMATOLOGICA, V89, P920; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; Boissel N, 2006, LEUKEMIA, V20, P965, DOI 10.1038/sj.leu.2404188; Bowen DT, 2005, BLOOD, V106, P2113, DOI 10.1182/blood-2005-03-0867; Buchholz F, 2000, EMBO REP, V1, P133, DOI 10.1093/embo-reports/kvd027; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; Byrd JC, 2002, BLOOD, V100, P4325, DOI 10.1182/blood-2002-03-0772; Cairoli R, 2006, BLOOD, V107, P3463, DOI 10.1182/blood-2005-09-3640; Cairoli R, 2003, LEUKEMIA, V17, P471, DOI 10.1038/sj.leu.2402795; Calabi F, 2001, MOL CELL BIOL, V21, P5658, DOI 10.1128/MCB.21.16.5658-5666.2001; CAMERON S, 1994, BLOOD, V83, P2851, DOI 10.1182/blood.V83.10.2851.2851; Care RS, 2003, BRIT J HAEMATOL, V121, P775, DOI 10.1046/j.1365-2141.2003.04362.x; Castilla LH, 1999, NAT GENET, V23, P144, DOI 10.1038/13776; Castilla LH, 2004, P NATL ACAD SCI USA, V101, P4924, DOI 10.1073/pnas.0400930101; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Chan EM, 2005, BLOOD, V105, P4523, DOI 10.1182/blood-2004-07-2762; Chinen Y, 2008, ONCOGENE, V27, P2249, DOI 10.1038/sj.onc.1210857; Costello R, 1997, LEUKEMIA, V11, P644, DOI 10.1038/sj.leu.2400629; de Guzman CG, 2002, MOL CELL BIOL, V22, P5506, DOI 10.1128/MCB.22.15.5506-5517.2002; Dohner K, 2006, HAEMATOLOGICA, V91, P1569; Downing JR, 1999, BRIT J HAEMATOL, V106, P296, DOI 10.1046/j.1365-2141.1999.01377.x; Elsasser A, 2003, ONCOGENE, V22, P5646, DOI 10.1038/sj.onc.1206673; ERICKSON P, 1992, BLOOD, V80, P1825; Fenske TS, 2004, P NATL ACAD SCI USA, V101, P15184, DOI 10.1073/pnas.0400751101; Gamou T, 1998, BLOOD, V91, P4028, DOI 10.1182/blood.V91.11.4028.411a45_4028_4037; Gari M, 1999, BRIT J HAEMATOL, V105, P894, DOI 10.1046/j.1365-2141.1999.01449.x; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Goemans BF, 2005, LEUKEMIA, V19, P1536, DOI 10.1038/sj.leu.2403870; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Grisolano JL, 2003, P NATL ACAD SCI USA, V100, P9506, DOI 10.1073/pnas.1531730100; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; Hromas R, 2001, BLOOD, V97, P2168, DOI 10.1182/blood.V97.7.2168; Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723; Illmer T, 2007, HAEMATOL-HEMATOL J, V92, P137, DOI 10.3324/haematol.10489; Kanno Y, 1998, MOL CELL BIOL, V18, P4252, DOI 10.1128/MCB.18.7.4252; Kelly LM, 2002, ANNU REV GENOM HUM G, V3, P179, DOI 10.1146/annurev.genom.3.032802.115046; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; Kogan SC, 1998, P NATL ACAD SCI USA, V95, P11863, DOI 10.1073/pnas.95.20.11863; Kohl TM, 2005, BLOOD, V105, P3319, DOI 10.1182/blood-2004-06-2068; Kottaridis PD, 2001, BLOOD, V98, P1752, DOI 10.1182/blood.V98.6.1752; Kuchenbauer F, 2006, BRIT J HAEMATOL, V134, P616, DOI 10.1111/j.1365-2141.2006.06229.x; Kuchenbauer F, 2005, BRIT J HAEMATOL, V130, P196, DOI 10.1111/j.1365-2141.2005.05595.x; Kundu M, 2005, BLOOD, V106, P3621, DOI 10.1182/blood-2005-04-1447; Kuo YH, 2006, CANCER CELL, V9, P57, DOI 10.1016/j.ccr.2005.12.014; Landrette SF, 2005, BLOOD, V105, P2900, DOI 10.1182/blood-2004-09-3630; Lasa A, 2006, HAEMATOLOGICA, V91, P1283; Lee JW, 2006, ONCOGENE, V25, P1434, DOI 10.1038/sj.onc.1209163; Li X, 2006, J CELL PHYSIOL, V208, P594, DOI 10.1002/jcp.20695; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lu Y, 2006, LEUKEMIA, V20, P987, DOI 10.1038/sj.leu.2404218; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Marcucci G, 2005, J CLIN ONCOL, V23, P5705, DOI 10.1200/JCO.2005.15.610; MARLTON P, 1995, BLOOD, V85, P772, DOI 10.1182/blood.V85.3.772.bloodjournal853772; Merchant SH, 2004, J MOL DIAGN, V6, P271, DOI 10.1016/S1525-1578(10)60521-1; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Miyamoto T, 2000, P NATL ACAD SCI USA, V97, P7521, DOI 10.1073/pnas.97.13.7521; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Monma F, 2006, EUR J HAEMATOL, V76, P18, DOI 10.1111/j.1600-0609.2005.00543.x; Moreno-Miralles I, 2005, J BIOL CHEM, V280, P40097, DOI 10.1074/jbc.M506855200; Mrozek K, 2004, BLOOD REV, V18, P115, DOI 10.1016/S0268-960X(03)00040-7; Mrozek K, 2001, J CLIN ONCOL, V19, P2482, DOI 10.1200/JCO.2001.19.9.2482; Nanri T, 2005, LEUKEMIA, V19, P1673, DOI 10.1038/sj.leu.2403889; Nanri T, 2005, LEUKEMIA, V19, P1361, DOI 10.1038/sj.leu.2403803; Nguyen S, 2002, BLOOD, V99, P3517, DOI 10.1182/blood.V99.10.3517; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; Nishida S, 2006, BLOOD, V107, P3303, DOI 10.1182/blood-2005-04-1656; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; NUCIFORA G, 1993, BLOOD, V82, P712; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Paschka P, 2006, J CLIN ONCOL, V24, P3904, DOI 10.1200/JCO.2006.06.9500; Passegue E, 2003, P NATL ACAD SCI USA, V100, P11842, DOI 10.1073/pnas.2034201100; Paulsson K, 2006, LEUKEMIA, V20, P224, DOI 10.1038/sj.leu.2404076; Peterson LF, 2004, ONCOGENE, V23, P4255, DOI 10.1038/sj.onc.1207727; Peterson LF, 2007, BLOOD, V109, P4392, DOI 10.1182/blood-2006-03-012575; Ramsey H, 2003, LEUKEMIA, V17, P1665, DOI 10.1038/sj.leu.2403048; Rhoades KL, 2000, BLOOD, V96, P2108; Rochford JJ, 2004, MOL CELL BIOL, V24, P9863, DOI 10.1128/MCB.24.22.9863-9872.2004; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; Roskoski R, 2005, BIOCHEM BIOPH RES CO, V338, P1307, DOI 10.1016/j.bbrc.2005.09.150; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Schessl C, 2005, J CLIN INVEST, V115, P2159, DOI 10.1172/JCI24225; Schittenhelm MM, 2006, CANCER RES, V66, P473, DOI 10.1158/0008-5472.CAN-05-2050; Schlenk RF, 2004, J CLIN ONCOL, V22, P3741, DOI 10.1200/JCO.2004.03.012; Schnittger S, 2007, LEUKEMIA, V21, P1843, DOI 10.1038/sj.leu.2404707; Schnittger S, 2007, LEUKEMIA, V21, P183, DOI 10.1038/sj.leu.2404465; Schnittger S, 2006, BLOOD, V107, P1791, DOI 10.1182/blood-2005-04-1466; Schnittger S, 2002, BLOOD, V100, P59, DOI 10.1182/blood.V100.1.59; Schwieger M, 2002, J EXP MED, V196, P1227, DOI 10.1084/jem.20020824; Shimada A, 2006, BLOOD, V107, P1806, DOI 10.1182/blood-2005-08-3408; Shimada H, 2000, BLOOD, V96, P655; SHURTLEFF SA, 1995, BLOOD, V85, P3695, DOI 10.1182/blood.V85.12.3695.bloodjournal85123695; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; Slovak ML, 2000, BLOOD, V96, P4075, DOI 10.1182/blood.V96.13.4075; Stirewalt DL, 2001, BLOOD, V97, P3589, DOI 10.1182/blood.V97.11.3589; Sun W, 2004, BLOOD, V104, P3565, DOI 10.1182/blood-2003-12-4349; Tahirov TH, 2001, CELL, V104, P755, DOI 10.1016/S0092-8674(02)02053-6; Thiede C, 2002, BLOOD, V99, P4326, DOI 10.1182/blood.V99.12.4326; Valk PJM, 2004, HAEMATOLOGICA, V89, P106; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Wang YY, 2005, P NATL ACAD SCI USA, V102, P1104, DOI 10.1073/pnas.0408831102; Wiemels JL, 2002, BLOOD, V99, P3801, DOI 10.1182/blood.V99.10.3801; Yan M, 2004, P NATL ACAD SCI USA, V101, P17468, DOI 10.1073/pnas.0406142101; Yan M, 2006, NAT MED, V12, P945, DOI 10.1038/nm1443; Yang YD, 2002, CANCER RES, V62, P2232; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	119	43	47	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2008	27	44					5759	5773		10.1038/onc.2008.196	http://dx.doi.org/10.1038/onc.2008.196			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	355QC	18604246				2022-12-17	WOS:000259722400001
J	Yde, CW; Olsen, BB; Meek, D; Watanabe, N; Guerra, B				Yde, C. W.; Olsen, B. B.; Meek, D.; Watanabe, N.; Guerra, B.			The regulatory beta-subunit of protein kinase CK2 regulates cell-cycle progression at the onset of mitosis	ONCOGENE			English	Article						CK2 beta; Wee1; PLK1; CDC25A; cell cycle	NEGATIVE REGULATION; CDC25A PHOSPHATASE; SOMATIC WEE1; INDUCED S; PHOSPHORYLATION; CHECKPOINT; INACTIVATION; DEGRADATION; CHK1; LOCALIZATION	Cell-cycle transition from the G(2) phase into mitosis is regulated by the cyclin-dependent protein kinase 1 (CDK1) in complex with cyclin B. CDK1 activity is controlled by both inhibitory phosphorylation, catalysed by the Myt1 and Wee1 kinases, and activating dephosphorylation, mediated by the CDC25 dual-specificity phosphatase family members. In somatic cells, Wee1 is downregulated by phosphorylation and ubiquitin-mediated degradation to ensure rapid activation of CDK1 at the beginning of M phase. Here, we show that downregulation of the regulatory beta-subunit of protein kinase CK2 by RNA interference results in delayed cell-cycle progression at the onset of mitosis. Knockdown of CK2 beta causes stabilization of Wee1 and increased phosphorylation of CDK1 at the inhibitory Tyr15. PLK1-Wee1 association is an essential event in the degradation of Wee1 in unperturbed cell cycle. We have found that CK2 beta participates in PLK1-Wee1 complex formation whereas its cellular depletion leads to disruption of PLK1-Wee1 interaction and reduced Wee1 phosphorylation at Ser53 and 121. The data reported here reinforce the notion that CK2 beta has functions that are independent of its role as the CK2 regulatory subunit, identifying it as a new component of signaling pathways that regulate cell-cycle progression at the entry of mitosis.	[Yde, C. W.; Olsen, B. B.; Guerra, B.] Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense, Denmark; [Meek, D.] Univ Dundee, Biomed Res Ctr, Ninewells Hosp, Dundee, Scotland; [Meek, D.] Univ Dundee, Sch Med, Dundee, Scotland; [Watanabe, N.] RIKEN, Antibiot Lab, Discovery Res Inst, Wako, Saitama, Japan	University of Southern Denmark; University of Dundee; University of Dundee; RIKEN	Guerra, B (corresponding author), Univ So Denmark, Dept Biochem & Mol Biol, Campusvej 55, DK-5230 Odense, Denmark.	bag@bmb.sdu.dk	Olsen, Birgitte B/U-2382-2017; Watanabe, Nobumoto/N-6959-2015	Olsen, Birgitte B/0000-0002-6130-0387; Watanabe, Nobumoto/0000-0002-2130-1334; Guerra, Barbara/0000-0003-1136-2413	Novo Nordisk Foundation [5373]; Danish Medical Research Council [271-07-0464]	Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank T Holm for technical assistance. This study was supported by the Novo Nordisk Foundation, grant no. 5373 and the Danish Medical Research Council, grant no. 271-07-0464 to BG.	Bibby AC, 2005, INT J BIOL SCI, V1, P67; Boutros R, 2006, CURR OPIN CELL BIOL, V18, P185, DOI 10.1016/j.ceb.2006.02.003; Busino L, 2004, ONCOGENE, V23, P2050, DOI 10.1038/sj.onc.1207394; COLEMAN TR, 1993, CELL, V72, P919, DOI 10.1016/0092-8674(93)90580-J; Faust M, 2000, CELL TISSUE RES, V301, P329, DOI 10.1007/s004410000256; Glover CVC, 1998, PROG NUCLEIC ACID RE, V59, P95; Guerra B, 1999, FEBS LETT, V462, P353, DOI 10.1016/S0014-5793(99)01553-7; Guerra B, 2003, ONCOGENE, V22, P4933, DOI 10.1038/sj.onc.1206721; Karisson-Rosenthal C, 2006, TRENDS CELL BIOL, V16, P285, DOI 10.1016/j.tcb.2006.04.002; Katayama K, 2005, MOL CELL BIOL, V25, P5725, DOI 10.1128/MCB.25.13.5725-5737.2005; Kohn EA, 2003, CANCER RES, V63, P31; Kreutzer J, 2007, INT J ONCOL, V31, P1251; Kurki S, 2004, CANCER CELL, V5, P465, DOI 10.1016/S1535-6108(04)00110-2; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; LUSCHER B, 1994, EUR J BIOCHEM, V220, P521, DOI 10.1111/j.1432-1033.1994.tb18651.x; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Molinari M, 2000, EMBO REP, V1, P71, DOI 10.1093/embo-reports/kvd018; PARKER LL, 1993, NATURE, V363, P736, DOI 10.1038/363736a0; Perry JA, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-12; Pines J, 1999, NAT CELL BIOL, V1, pE73, DOI 10.1038/11041; Seeber S, 2005, APOPTOSIS, V10, P875, DOI 10.1007/s10495-005-0380-y; Sia RAL, 1998, EMBO J, V17, P6678, DOI 10.1093/emboj/17.22.6678; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; STALTER G, 1994, BIOCHEM BIOPH RES CO, V202, P141, DOI 10.1006/bbrc.1994.1904; TANG ZH, 1993, EMBO J, V12, P3427, DOI 10.1002/j.1460-2075.1993.tb06017.x; Timofeeva OA, 2006, ONCOGENE, V25, P7555, DOI 10.1038/sj.onc.1209742; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; van Vugt MATM, 2004, MOL CELL, V15, P799, DOI 10.1016/j.molcel.2004.07.015; Watanabe N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/pnas.0307700101; Watanabe N, 2005, P NATL ACAD SCI USA, V102, P11663, DOI 10.1073/pnas.0500410102; WU L, 1993, NATURE, V363, P738, DOI 10.1038/363738a0; Xiao Z, 2003, J BIOL CHEM, V278, P21767, DOI 10.1074/jbc.M300229200; Yamane K, 2005, CANCER RES, V65, P4362, DOI 10.1158/0008-5472.CAN-04-3941; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299	34	43	48	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2008	27	37					4986	4997		10.1038/onc.2008.146	http://dx.doi.org/10.1038/onc.2008.146			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GL	18469858				2022-12-17	WOS:000258914800002
J	Roue, G; Pichereau, V; Lincet, H; Colomer, D; Sola, B				Roue, G.; Pichereau, V.; Lincet, H.; Colomer, D.; Sola, B.			Cyclin D1 mediates resistance to apoptosis through upregulation of molecular chaperones and consequent redistribution of cell death regulators	ONCOGENE			English	Article						cyclin D1; heat shock protein; apoptotic factor; B-cell lymphoma; multiple myeloma	HEAT-SHOCK PROTEINS; BREAST-CANCER CELLS; NF-KAPPA-B; ECTOPIC EXPRESSION; D1 OVEREXPRESSION; MULTIPLE-MYELOMA; LINE; CARCINOMA; HSP70; P53	Cyclin D1 is a key regulator of cell proliferation. It also controls other aspects of the cell fate, such as cellular senescence, apoptosis and tumourigenesis. We used B-lymphoid cell lines producing cyclin D1 to investigate the role of this protein in B-cell lymphomas and leukaemias. Constitutive low levels of cyclin D1 had no effect per se on cell proliferation, but conferred resistance to various apoptotic stimuli in B cells. Activation of the proapoptotic protein, Bax, was reduced and mitochondrial permeabilization and phosphatidylserine exposure following cytokine withdrawal were delayed in cyclin D1-producing cells. Proteomic analysis showed that the presence of cyclin D1 led to intracellular accumulation of various molecular chaperones. The chaperone, heat shock protein ( Hsp) 70, bound to both Bax and the mitochondrial apoptosis inducing factor following cytokine withdrawal, and impeded inhibitors of kappa B (I kappa B)mediated inhibition of nuclear factor-kappa B anti-apoptotic signalling. Impairment of Hsp70 activity-using a pharmacological Hsp inhibitor or transfecting cells with an Hsp70-blocking antibody-restored the cellular response to mitochondrial apoptosis triggering. Thus, constitutive de-novo cyclin D1 production in B cells delays commitment to apoptosis by inducing Hsp70 chaperoning activity on pre- and post-mitochondrial pro-apoptotic factors.	[Roue, G.; Colomer, D.] Inst Invest Biomed August Pi & Sunyer, Hosp Clin, Unitat Hematopathol, Barcelona 08036, Spain; [Roue, G.; Sola, B.] Univ Caen, IFR 146, EA 3919, F-14032 Caen, France; [Pichereau, V.] Univ Caen, IFR 146, EA 956, USC INRA 2017,Lab Microbiol Environm, F-14032 Caen, France; [Lincet, H.] Ctr Lutte Canc Francois Baclesse, IFR 146, EA1773, GRECAN, Caen, France	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Universite de Caen Normandie; INRAE; Universite de Caen Normandie; UNICANCER; Centre Francois Baclesse	Roue, G (corresponding author), Inst Invest Biomed August Pi & Sunyer, Hosp Clin, Unitat Hematopathol, Villarroel 170, Barcelona 08036, Spain.	groue@clinic.ub.es	PICHEREAU, Vianney/Q-7236-2019; ROUÉ, GAËL/D-4759-2014; COLOMER, DOLORS/ABG-6894-2020; PICHEREAU, Vianney/B-2168-2008	PICHEREAU, Vianney/0000-0003-1078-9407; ROUÉ, GAËL/0000-0003-0245-2257; PICHEREAU, Vianney/0000-0003-1078-9407; Sola, Brigitte/0000-0001-7278-9651; COLOMER, DOLORS/0000-0001-7486-8484	Cancer-Comite du Calvados; Association pour la Recherche contre le Cancer [7791, 3426]; Spanish Ministry of Education and Science [SAF06/8850]; Ligue Nationale contre le Cancer-Comite du Calvados; C-RED programme	Cancer-Comite du Calvados; Association pour la Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); Spanish Ministry of Education and Science(Spanish Government); Ligue Nationale contre le Cancer-Comite du Calvados; C-RED programme	We thank A Barbaras and S Cabezas for expert technical assistance and JM Renoir (CNRS UMR 8612, Universite de Paris Sud, France) for the gift of anti-Hsp70/90 antibody. The work was financially supported by the Ligue contre le Cancer-Comite du Calvados, Cent pour sang la vie and the Association pour la Recherche contre le Cancer ( grant nos. 7791 and 3426) to BS, and by the Spanish Ministry of Education and Science (grant SAF06/8850) to DC. GR received a scholarship from the Ligue Nationale contre le Cancer-Comite du Calvados and has a postdoctoral position with the C-RED programme (Generalitat de Catalunya, Spain).	Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Alao JP, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-24; Andoh T, 2002, J BIOL CHEM, V277, P9655, DOI 10.1074/jbc.M110701200; Beere H M, 2001, Sci STKE, V2001, pre1, DOI 10.1126/stke.2001.93.re1; Bertoni F, 2004, CURR OPIN HEMATOL, V11, P411, DOI 10.1097/01.moh.0000138682.13354.da; Bible KC, 2000, CLIN CANCER RES, V6, P661; Burstein E, 2003, CURR OPIN CELL BIOL, V15, P732, DOI 10.1016/j.ceb.2003.10.005; Calderwood SK, 2006, TRENDS BIOCHEM SCI, V31, P164, DOI 10.1016/j.tibs.2006.01.006; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Casanovas O, 2000, J BIOL CHEM, V275, P35091, DOI 10.1074/jbc.M006324200; Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; Duquesne F, 2001, CELL DEATH DIFFER, V8, P51, DOI 10.1038/sj.cdd.4400768; Ewen ME, 2004, TRENDS MOL MED, V10, P158, DOI 10.1016/j.molmed.2004.02.005; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Garrido C, 2001, BIOCHEM BIOPH RES CO, V286, P433, DOI 10.1006/bbrc.2001.5427; Garrido C, 2006, CELL CYCLE, V5, P2592, DOI 10.4161/cc.5.22.3448; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gotoh T, 2004, CELL DEATH DIFFER, V11, P390, DOI 10.1038/sj.cdd.4401369; Han EKH, 1996, CELL GROWTH DIFFER, V7, P699; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hochhauser D, 1996, J NATL CANCER I, V88, P1269, DOI 10.1093/jnci/88.18.1269; Kamano H, 1997, ONCOGENE, V14, P1223, DOI 10.1038/sj.onc.1200945; Kehn K, 2007, ONCOGENE, V26, P5060, DOI 10.1038/sj.onc.1210319; Kornmann M, 1999, CANCER RES, V59, P3505; Krieger S, 2005, EXP HEMATOL, V33, P652, DOI 10.1016/j.exphem.2005.03.011; Kuhn DJ, 2003, J CELL BIOCHEM, V89, P824, DOI 10.1002/jcb.10557; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Lamb J, 2003, CELL CYCLE, V2, P525, DOI 10.4161/cc.2.6.584; Le Moguen K, 2006, PROTEOMICS, V6, P5183, DOI 10.1002/pmic.200500925; Lee KH, 2005, EXP CELL RES, V307, P276, DOI 10.1016/j.yexcr.2005.03.014; Liu M, 2006, J BIOL CHEM, V281, P18090, DOI 10.1074/jbc.M601324200; Macario AJL, 2007, FEBS LETT, V581, P3681, DOI 10.1016/j.febslet.2007.04.030; Martin JMC, 1999, CANCER RES, V59, P1134; Mesaeli N, 2004, MOL BIOL CELL, V15, P1862, DOI 10.1091/mbc.E03-04-0251; Niu MY, 2001, ONCOGENE, V20, P3506, DOI 10.1038/sj.onc.1204453; Orr MS, 1998, J BIOL CHEM, V273, P3803, DOI 10.1074/jbc.273.7.3803; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; Palacios C, 2000, ONCOGENE, V19, P3556, DOI 10.1038/sj.onc.1203683; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Perez-Galan P, 2006, BLOOD, V107, P257, DOI 10.1182/blood-2005-05-2091; Ruchalski K, 2006, J BIOL CHEM, V281, P7873, DOI 10.1074/jbc.M513728200; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Sauvageot N, 2002, EUR J BIOCHEM, V269, P5731, DOI 10.1046/j.1432-1033.2002.03288.x; Seidl S, 2003, LANCET ONCOL, V4, P557, DOI 10.1016/S1470-2045(03)01195-1; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Silva A, 1997, BLOOD, V89, P2717, DOI 10.1182/blood.V89.8.2717; Steel R, 2004, J BIOL CHEM, V279, P51490, DOI 10.1074/jbc.M401314200; Stuart JK, 1998, J BIOL CHEM, V273, P22506, DOI 10.1074/jbc.273.35.22506; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; Wang Chenguang, 2004, Cancer Treat Res, V119, P217; Yokota S, 2000, CANCER RES, V60, P2942; Zahnow CA, 2002, BREAST CANCER RES, V4, P109, DOI 10.1186/bcr428	55	43	45	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2008	27	36					4909	4920		10.1038/onc.2008.126	http://dx.doi.org/10.1038/onc.2008.126			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	339SF	18438428				2022-12-17	WOS:000258596900005
J	Llobet, D; Eritja, N; Encinas, M; Llecha, N; Yeramian, A; Pallares, J; Sorolla, A; Gonzalez-Tallada, FJ; Matias-Guiu, X; Dolcet, X				Llobet, D.; Eritja, N.; Encinas, M.; Llecha, N.; Yeramian, A.; Pallares, J.; Sorolla, A.; Gonzalez-Tallada, F. J.; Matias-Guiu, X.; Dolcet, X.			CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells	ONCOGENE			English	Article						endometrial carcinoma; apoptosis; death receptor; casein kinase 2; FLIP	PROTEIN-KINASE CK2; LIGAND-MEDIATED APOPTOSIS; C-FLIP; CANCER-CELLS; DEATH RECEPTORS; DOWN-REGULATION; TUMOR-CELLS; SIGNALING COMPLEX; MOLECULAR-CLONING; PROSTATE-CANCER	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has emerged as a promising antineoplastic agent because of its ability to selectively kill tumoral cells. However, some cancer cells are resistant to TRAIL-induced apoptosis. We have previously demonstrated that in endometrial carcinoma cells such resistance is caused by elevated FLICE-inhibitory protein (FLIP) levels. The present study focuses on the mechanisms by which FLIP could be modulated to sensitize endometrial carcinoma cells to TRAIL-induced apoptosis. We find that inhibition of casein kinase (CK2) sensitizes endometrial carcinoma cells to TRAIL-and Fas-induced apoptosis. CK2 inhibition correlates with a reduction of FLIP protein, suggesting that CK2 regulates resistance to TRAIL and Fas by controlling FLIP levels. FLIP downregulation correlates with a reduction of mRNA and is prevented by addition of the MG-132, suggesting that CK2 inhibition results in a proteasome-mediated degradation of FLIP. Consistently, forced expression of FLIP restores resistance to TRAIL and Fas. Moreover, knockdown of either FADD or caspase-8 abrogates apoptosis triggered by inhibition of CK2, indicating that CK2 sensitization requires formation of functional DISC. Finally, because of the possible role of both TRAIL and CK2 in cancer therapy, we demonstrate that CK2 inhibition sensitizes primary endometrial carcinoma explants to TRAIL apoptosis. In conclusion, we demonstrate that CK2 regulates endometrial carcinoma cell sensitivity to TRAIL and Fas by regulating FLIP levels.	[Llobet, D.; Eritja, N.; Llecha, N.; Yeramian, A.; Pallares, J.; Sorolla, A.; Matias-Guiu, X.; Dolcet, X.] IRBLleida, Inst Recerca Biomed Lleida, Oncol Pathol Grp, Hosp Univ Arnau de Vilanova,Lab Recerca Biomed, Lleida 25198, Spain; [Encinas, M.] IRBLleida, Inst Recerca Biomed Lleida, Cell Signaling & Apoptosis Grp, Lleida 25198, Spain; [Gonzalez-Tallada, F. J.] IRBLleida, Inst Recerca Biomed Lleida, Dept Gynecol, Lleida 25198, Spain	Institut de Recerca Biomedica - IRB Lleida; University Hospital Arnau de Vilanova; Institut de Recerca Biomedica - IRB Lleida; Institut de Recerca Biomedica - IRB Lleida	Dolcet, X (corresponding author), IRBLleida, Inst Recerca Biomed Lleida, Oncol Pathol Grp, Hosp Univ Arnau de Vilanova,Lab Recerca Biomed, Av Rovira Roure 80, Lleida 25198, Spain.	dolcet@cmb.udl.es	Yeramian, Andree/P-6724-2019; matias-guiu, xavier/C-3039-2009; Eritja, Núria/S-3700-2019; yeramian, andree/B-5936-2009; Sorolla, Anabel/E-2546-2012; Encinas, Mario/B-5600-2009; Llobet-Navas, David/AAT-4676-2021; Dolcet, Xavi/B-5665-2009; Eritja, Nuria/M-1347-2015; Eritja Sanchez, Nuria/C-4465-2011; Sorolla Bardaji, Anabel/C-6614-2011; Llobet-Navas, David/B-5660-2009; Pallares, Judit/A-6635-2010	matias-guiu, xavier/0000-0002-7201-6605; Eritja, Núria/0000-0003-2131-7915; yeramian, andree/0000-0002-9569-6316; Sorolla, Anabel/0000-0001-8238-8763; Encinas, Mario/0000-0003-3509-7431; Dolcet, Xavi/0000-0003-1921-0449; Eritja, Nuria/0000-0003-1018-6649; Llobet-Navas, David/0000-0003-1443-7003; 				Ahmad KA, 2005, ANTI-CANCER DRUG, V16, P1037, DOI 10.1097/00001813-200511000-00001; Ahmed K, 2002, TRENDS CELL BIOL, V12, P226, DOI 10.1016/S0962-8924(02)02279-1; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Dolcet X, 2005, LAB INVEST, V85, P885, DOI 10.1038/labinvest.3700286; Dolcet X, 2006, J BIOL CHEM, V281, P22118, DOI 10.1074/jbc.M601350200; Droin N, 2001, BLOOD, V97, P1835, DOI 10.1182/blood.V97.6.1835; Dutton A, 2004, P NATL ACAD SCI USA, V101, P6611, DOI 10.1073/pnas.0400765101; Galligan L, 2005, MOL CANCER THER, V4, P2026, DOI 10.1158/1535-7163.MCT-05-0262; Irmler M, 2000, FEBS LETT, V468, P129, DOI 10.1016/S0014-5793(00)01206-0; Izeradjene K, 2005, ONCOGENE, V24, P2050, DOI 10.1038/sj.onc.1208397; Izeradjene K, 2004, CLIN CANCER RES, V10, P6650, DOI 10.1158/1078-0432.CCR-04-0576; KIKKAWA U, 1992, MOL CELL BIOL, V12, P5711, DOI 10.1128/MCB.12.12.5711; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Korkolopoulou P, 2004, UROLOGY, V63, P1198, DOI 10.1016/j.urology.2004.01.007; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lavrik IN, 2006, BLOOD, V108, P559, DOI 10.1182/blood-2005-07-007096; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lee SH, 2003, APMIS, V111, P309, DOI 10.1034/j.1600-0463.2003.1110203.x; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Liu X, 2006, CANCER RES, V66, P11115, DOI 10.1158/0008-5472.CAN-06-2471; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; Palacios C, 2006, CANCER RES, V66, P8858, DOI 10.1158/0008-5472.CAN-06-0808; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1998, FEBS LETT, V424, P41, DOI 10.1016/S0014-5793(98)00135-5; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Poukkula M, 2005, J BIOL CHEM, V280, P27345, DOI 10.1074/jbc.M504019200; Ravi R, 2002, CANCER RES, V62, P4180; Rippo MR, 2004, ONCOGENE, V23, P7753, DOI 10.1038/sj.onc.1208051; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shin S, 2005, EMBO J, V24, P3532, DOI 10.1038/sj.emboj.7600827; Son YG, 2007, CANCER RES, V67, P8274, DOI 10.1158/0008-5472.CAN-07-0407; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Srivastava RK, 2001, NEOPLASIA, V3, P535, DOI 10.1038/sj.neo.7900203; Takeda K, 2007, ONCOGENE, V26, P3745, DOI 10.1038/sj.onc.1210374; Tawfic S, 2001, HISTOL HISTOPATHOL, V16, P573, DOI 10.14670/HH-16.573; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Wagner KW, 2004, J BIOL CHEM, V279, P35047, DOI 10.1074/jbc.M400708200; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang GX, 2006, CANCER RES, V66, P2242, DOI 10.1158/0008-5472.CAN-05-2772; Wang GX, 2005, MOL CELL BIOCHEM, V274, P77, DOI 10.1007/s11010-005-3077-1; Wang GX, 2005, MOL CELL BIOCHEM, V274, P201, DOI 10.1007/s11010-005-2952-0; Zhang XP, 2004, CANCER RES, V64, P7086, DOI 10.1158/0008-5472.CAN-04-1498	52	43	48	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2008	27	18					2513	2524		10.1038/sj.onc.1210924	http://dx.doi.org/10.1038/sj.onc.1210924			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	289LW	17982483				2022-12-17	WOS:000255057000001
J	Eckert, A; Bock, BC; Tagscherer, KE; Haas, TL; Grund, K; Sykora, J; Herold-Mende, C; Ehemann, V; Hollstein, M; Chneiweiss, H; Wiestler, OD; Walczak, H; Roth, W				Eckert, A.; Boeck, B. C.; Tagscherer, K. E.; Haas, T. L.; Grund, K.; Sykora, J.; Herold-Mende, C.; Ehemann, V.; Hollstein, M.; Chneiweiss, H.; Wiestler, O. D.; Walczak, H.; Roth, W.			The PEA-15/PED protein protects glioblastoma cells from glucose deprivation-induced apoptosis via the ERK/MAP kinase pathway	ONCOGENE			English	Article						apoptosis; brain tumors; PEA-15/PED; glucose; MAP kinases; ERK1/2	DEATH EFFECTOR DOMAIN; CANCER-CELLS; CYTOPLASMIC SEQUESTRATION; INTEGRIN ACTIVATION; GLIOMA-CELLS; IN-VITRO; PED/PEA-15; EXPRESSION; ASTROCYTES; PHOSPHOPROTEIN	PEA-15 ( phosphoprotein enriched in astrocytes 15 kDa) is a death effector domain-containing protein, which is involved in the regulation of apoptotic cell death. Since PEA-15 is highly expressed in cells of glia l origin, we studied the role of PEA-15 in human malignant brain tumors. Immunohistochemical analysis of PEA-15 expression shows strong immunoreactivity in astrocytomas and glioblastomas. Phosphorylation of PEA-15 at Ser(116) is found in vivo in perinecrotic areas in glioblastomas and in vitro after glucose deprivation of glioblastoma cells. Overexpression of PEA-15 induces a marked resistance against glucose deprivation-induced apoptosis, whereas small interfering RNA (siRNA)-mediated downregulation of endogenous PEA-15 results in the sensitization to glucose withdrawal-mediated cell death. This antiapoptotic activity of PEA-15 under low glucose conditions depends on its phosphorylation at Ser116. Moreover, siRNA-mediated knockdown of PEA-15 abolishes the tumorigenicity of U87MG glioblastoma cells in vivo. PEA-15 regulates the level of phosphorylated extracellular-regulated kinase ( ERK) 1/ 2 in glioblastoma cells and the PEA-15-dependent protection from glucose deprivation-induced cell death requires ERK1/2 signaling. PEA-15 transcriptionally upregulates the Glucose Transporter 3, which is abrogated by the inhibition of ERK1/2 phosphorylation. Taken together, our findings suggest that Ser(116)-phosphorylated PEA-15 renders glioma cells resistant to glucose deprivation-mediated cell death as encountered in poor microenvironments, for example in perinecrotic areas of glioblastomas.	[Eckert, A.; Boeck, B. C.; Tagscherer, K. E.; Haas, T. L.; Grund, K.; Sykora, J.; Wiestler, O. D.; Walczak, H.; Roth, W.] German Canc Res Ctr, Div Apoptosis Regulat, D-69120 Heidelberg, Germany; [Herold-Mende, C.] Univ Heidelberg, Dept Neurosurg, Div Neurosurg Res, Heidelberg, Germany; [Ehemann, V.; Roth, W.] Univ Heidelberg, Inst Pathol, D-6900 Heidelberg, Germany; [Hollstein, M.] German Canc Res Ctr, Dept Genet Alterat Carcinogenesis, D-69120 Heidelberg, Germany; [Chneiweiss, H.] INSERM, U752, Paris, France	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Institut National de la Sante et de la Recherche Medicale (Inserm)	Roth, W (corresponding author), German Canc Res Ctr, Div Apoptosis Regulat, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	W.Roth@dkfz.de	Walczak, Henning/AAV-2214-2020; Tagscherer, Katrin/AAS-3809-2021; herve, chneiweiss/Q-6818-2019	Walczak, Henning/0000-0002-6312-4591; Tagscherer, Katrin/0000-0002-0657-6399; herve, chneiweiss/0000-0001-7675-5061; Haas, Tobias/0000-0003-2336-0263				ARAUJO H, 1993, J BIOL CHEM, V268, P5911; Bartholomeusz C, 2006, ONCOGENE, V25, P79, DOI 10.1038/sj.onc.1209014; Boulos S, 2007, NEUROBIOL DIS, V25, P54, DOI 10.1016/j.nbd.2006.08.012; Chou FL, 2003, J BIOL CHEM, V278, P52587, DOI 10.1074/jbc.M309322200; Condorelli G, 1998, EMBO J, V17, P3858, DOI 10.1093/emboj/17.14.3858; Condorelli G, 1999, ONCOGENE, V18, P4409, DOI 10.1038/sj.onc.1202831; Condorelli G, 2002, J BIOL CHEM, V277, P11013, DOI 10.1074/jbc.M110934200; DANZIGER N, 1995, J NEUROCHEM, V64, P1016; Del Duca D, 2004, J NEURO-ONCOL, V67, P295, DOI 10.1023/B:NEON.0000024220.07063.70; Dong G, 2001, CANCER RES, V61, P4797; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Estelles A, 1999, DEV BIOL, V216, P16, DOI 10.1006/dbio.1999.9510; Formisano P, 2005, ONCOGENE, V24, P7012, DOI 10.1038/sj.onc.1208871; Formstecher E, 2001, DEV CELL, V1, P239, DOI 10.1016/S1534-5807(01)00035-1; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; Hao CH, 2001, CANCER RES, V61, P1162; Karcher S, 2006, INT J CANCER, V118, P2182, DOI 10.1002/ijc.21648; Kitsberg D, 1999, J NEUROSCI, V19, P8244; Krueger J, 2005, MOL BIOL CELL, V16, P3552, DOI 10.1091/mbc.E04-11-1007; Kubes M, 1998, J NEUROCHEM, V71, P1307; Nelson DA, 2004, GENE DEV, V18, P2095, DOI 10.1101/gad.1204904; NISHIOKA T, 1992, CANCER RES, V52, P3972; Ramos JW, 2000, MOL BIOL CELL, V11, P2863, DOI 10.1091/mbc.11.9.2863; Ramos JW, 1998, J BIOL CHEM, V273, P33897, DOI 10.1074/jbc.273.51.33897; Renault-Mihara F, 2006, MOL BIOL CELL, V17, P5141, DOI 10.1091/mbc.E05-11-1072; Renganathan H, 2005, BIOCHEM J, V390, P729, DOI 10.1042/BJ20050378; Ricci-Vitiani L, 2004, J EXP MED, V200, P1257, DOI 10.1084/jem.20040921; Rong Y, 2006, J NEUROPATH EXP NEUR, V65, P529, DOI 10.1097/00005072-200606000-00001; Sharif A, 2004, NEUROSCIENCE, V126, P263, DOI 10.1016/j.neuroscience.2004.02.039; Song JH, 2006, J NEUROSCI, V26, P3299, DOI 10.1523/JNEUROSCI.5572-05.2006; Stassi G, 2005, CANCER RES, V65, P6668, DOI 10.1158/0008-5472.CAN-04-4009; Todaro M, 2006, CANCER RES, V66, P1491, DOI 10.1158/0008-5472.CAN-05-2514; Trencia A, 2003, MOL CELL BIOL, V23, P4511, DOI 10.1128/MCB.23.13.4511-4521.2003; Vigliotta G, 2004, MOL CELL BIOL, V24, P5005, DOI 10.1128/MCB.24.11.5005-5015.2004; Whitehurst AW, 2004, J BIOL CHEM, V279, P12840, DOI 10.1074/jbc.M310031200; Xiao C, 2002, J BIOL CHEM, V277, P25020, DOI 10.1074/jbc.M202946200; Ziegler A, 2001, CANCER RES, V61, P5595	37	43	43	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2008	27	8					1155	1166		10.1038/sj.onc.1210732	http://dx.doi.org/10.1038/sj.onc.1210732			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17700518				2022-12-17	WOS:000253136700015
J	Gadir, N; Jackson, DN; Lee, E; Foster, DA				Gadir, N.; Jackson, D. N.; Lee, E.; Foster, D. A.			Defective TGF-beta signaling sensitizes human cancer cells to rapamycin	ONCOGENE			English	Article						rapamycin; mTOR; TGF-beta; PKC delta; cancer	GROWTH-FACTOR-BETA; KINASE-C-DELTA; MTOR; INHIBITION; SURVIVAL; RECEPTOR; ARREST; SMAD3; LINES; EXPRESSION	mTOR, the mammalian target of rapamycin, is a critical target of survival signals in many human cancers. In the absence of serum, rapamycin induces apoptosis in MDA-MB-231 human breast cancer cells. However, in the presence of serum, rapamycin induces G1 cell cycle arrest - indicating that a factor( s) in serum suppresses rapamycin-induced apoptosis. We report here that transforming growth factor-beta (TGF-beta) suppresses rapamycin-induced apoptosis in serum-deprived MDA-MB-231 cells in a protein kinase C delta (PKC delta)-dependent manner. Importantly, if TGF-beta signaling or PKCd was suppressed, rapamycin induced apoptosis rather than G1 arrest in the presence of serum. And, if cells were allowed to progress into S phase, rapamycin induced apoptosis in the presence of serum. BT-549 and MDA-MB-468 breast, and SW-480 colon cancer cells have defects in TGF-beta signaling and rapamycin induced apoptosis in these cells in the presence of either serum or TGF-beta. Thus, in the absence of TGF-beta signaling, rapamycin becomes cytotoxic rather than cytostatic. Importantly, this study provides evidence indicating that tumors with defective TGF-beta signaling - common in colon and pancreatic cancers - will be selectively sensitive to rapamycin or other strategies that target mTOR.	[Gadir, N.; Jackson, D. N.; Lee, E.; Foster, D. A.] CUNY Hunter Coll, Dept Biol Sci, New York, NY 10021 USA	City University of New York (CUNY) System; Hunter College (CUNY)	Foster, DA (corresponding author), CUNY Hunter Coll, Dept Biol Sci, 695 Pk Ave, New York, NY 10021 USA.	foster@genectr.hunter.cuny.edu			NATIONAL CANCER INSTITUTE [R29CA046677, R01CA046677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM060654] Funding Source: NIH RePORTER; NCI NIH HHS [CA46677] Funding Source: Medline; NCRR NIH HHS [RR-03037] Funding Source: Medline; NIGMS NIH HHS [GM60654] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487; Borel F, 2002, J CELL SCI, V115, P2829; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Chen YH, 2005, ONCOGENE, V24, P672, DOI 10.1038/sj.onc.1208099; Chen YH, 2003, ONCOGENE, V22, P3937, DOI 10.1038/sj.onc.1206565; Fink SP, 2001, CANCER RES, V61, P256; Fink SP, 2003, ONCOGENE, V22, P1317, DOI 10.1038/sj.onc.1206128; Foster DA, 2006, CURR SIGNAL TRANSD T, V1, P295, DOI 10.2174/157436206778226941; Foster DA, 2007, CANCER RES, V67, P1, DOI 10.1158/0008-5472.CAN-06-3016; Foster David A, 2004, Expert Rev Anticancer Ther, V4, P691, DOI 10.1586/14737140.4.4.691; Guertin DA, 2005, TRENDS MOL MED, V11, P353, DOI 10.1016/j.molmed.2005.06.007; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Ho A, 2002, CURR OPIN GENET DEV, V12, P47, DOI 10.1016/S0959-437X(01)00263-5; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Jackson D, 2005, ONCOGENE, V24, P3067, DOI 10.1038/sj.onc.1208465; Jackson DN, 2004, FASEB J, V18, P627, DOI 10.1096/fj.03-0979rev; Jaffee EM, 2002, CANCER CELL, V2, P25, DOI 10.1016/S1535-6108(02)00093-4; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; Law BK, 2002, MOL CELL BIOL, V22, P8184, DOI 10.1128/MCB.22.23.8184-8198.2002; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Miyaki M, 2003, BIOCHEM BIOPH RES CO, V306, P799, DOI 10.1016/S0006-291X(03)01066-0; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Perillan PR, 2002, J BIOL CHEM, V277, P1974, DOI 10.1074/jbc.M107984200; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Popat S, 2005, EUR J CANCER, V41, P2060, DOI 10.1016/j.ejca.2005.04.039; Runyan CE, 2003, AM J PHYSIOL-RENAL, V285, pF413, DOI 10.1152/ajprenal.00082.2003; Sawyers CL, 2003, CANCER CELL, V4, P343, DOI 10.1016/S1535-6108(03)00275-7; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Song KY, 2006, EMBO J, V25, P58, DOI 10.1038/sj.emboj.7600917; Van der Poel HG, 2004, J UROLOGY, V172, P1333, DOI 10.1097/01.ju.0000138829.97838.19; van der Poel HG, 2003, UROL RES, V30, P380, DOI 10.1007/s00240-002-0282-1; Zhong MG, 2003, BIOCHEM BIOPH RES CO, V302, P615, DOI 10.1016/S0006-291X(03)00229-8	34	43	44	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2008	27	8					1055	1062		10.1038/sj.onc.1210721	http://dx.doi.org/10.1038/sj.onc.1210721			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17700525				2022-12-17	WOS:000253136700004
J	Minella, AC; Grim, JE; Welcker, M; Clurman, BE				Minella, A. C.; Grim, J. E.; Welcker, M.; Clurman, B. E.			P53 and SCFFbw7 cooperatively restrain cyclin E-associated genome instability	ONCOGENE			English	Article						cyclin E; p53; p21; Fbw7; hCdc4; genome instability	UBIQUITIN LIGASE; DEPENDENT DEGRADATION; C-MYC; PHOSPHORYLATION; FBW7; CANCER; NOTCH; HCDC4; TUMORIGENESIS; DEREGULATION	Cancers often exhibit high levels of cyclin E expression, and aberrant cyclin E activity causes genomic instability and increased tumorigenesis. Two tumor suppressor pathways protect cells against cyclin E deregulation. The p53 pathway is induced by excess cychn E in primary cells and opposes cyclin E activity through induction of p21Cip1. In contrast, the Fbw7 pathway targets cyclin E for degradation, and Fbw7 mutations occur commonly in cancers. We investigated the cooperativity of these two pathways in countering cyclin E-induced genomic instability in primary human cells. We find that loss of p53 and Fbw7 synergistically unmasks cyclin E-induced instability. In normal cells, impaired cychn E degradation produces genome instability, but this is rapidly mitigated by induction of p53 and p21. In contrast, p53 loss allows the high level of cyclin E kinase activity that results from Fbw7 loss to persist and continuously drive genome instability. Moreover, p21 plays a critical role in suppressing cyclin E when Fbw7 is disabled, and in the absence of p21, sustained cyclin E activity induces rapid cell death via apoptosis. These data directly demonstrate the cooperative roles of these Fbw7 and p53 pathways in restraining cyclin E activity and its associated genome instability.	Fred Hutchinson Canc Res Ctr, Div Clin Res & Human Biol, Seattle, WA 98109 USA; Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Clurman, BE (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res & Human Biol, 1100 Fairview Ave N,D2-100, Seattle, WA 98109 USA.	bclurman@fhcrc.org	Clurman, Bruce/AAV-3854-2021	Welcker, Markus/0000-0001-6723-4790; Minella, Alex/0000-0001-6693-3362	NATIONAL CANCER INSTITUTE [R01CA102742, K08CA101800, R01CA084069] Funding Source: NIH RePORTER; NCI NIH HHS [K08CA101800, R01CA84069, R01CA102742] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Ekholm-Reed S, 2004, J CELL BIOL, V165, P789, DOI 10.1083/jcb.200404092; Geng Y, 2007, MOL CELL, V25, P127, DOI 10.1016/j.molcel.2006.11.029; Hwang HC, 2005, ONCOGENE, V24, P2776, DOI 10.1038/sj.onc.1208613; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Loeb KR, 2005, CANCER CELL, V8, P35, DOI 10.1016/j.ccr.2005.06.010; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; Minella AC, 2005, P NATL ACAD SCI USA, V102, P9649, DOI 10.1073/pnas.0503677102; Minella AC, 2002, CURR BIOL, V12, P1817, DOI 10.1016/S0960-9822(02)01225-3; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Nateri AS, 2004, SCIENCE, V303, P1374, DOI 10.1126/science.1092880; Noseda M, 2004, MOL CELL BIOL, V24, P8813, DOI 10.1128/MCB.24.20.8813-8822.2004; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Smith APL, 2006, ONCOGENE, V25, P7245, DOI 10.1038/sj.onc.1209713; Spruck CH, 2002, CANCER RES, V62, P4535; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Welcker M, 2003, MOL CELL, V12, P381, DOI 10.1016/S1097-2765(03)00287-9; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217	27	43	44	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2007	26	48					6948	6953		10.1038/sj.onc.1210518	http://dx.doi.org/10.1038/sj.onc.1210518			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220WQ	17486057				2022-12-17	WOS:000250188400010
J	Reef, S; Shifman, O; Oren, M; Kimchi, A				Reef, S.; Shifman, O.; Oren, M.; Kimchi, A.			The autophagic inducer smARF interacts with and is stabilized bythe mitochondrial p32 protein	ONCOGENE			English	Article							TYPE-1 TAT TRANSACTIVATOR; IN-VITRO INTERACTION; CELLULAR-PROTEIN; BINDING-PROTEIN; SPLICING FACTOR; MOLECULAR-CLONING; ACTIVATION DOMAIN; GLOBULAR HEADS; VIRUS; RECEPTOR	The alternative reading frame ( ARF) mRNA encodes two pro- death proteins, the nucleolar p19ARF and a shorter mitochondrial isoform, named smARF ( hsmARF in human). While p19ARF can inhibit cell growth by causing cell cycle arrest or type I apoptotic cell death, smARF is able to induce type II autophagic cell death. Inappropriate proliferative signals generated by proto-oncogenes, such as c-Myc and E2F1, can elevate both p19ARF and smARF proteins. Here, we reveal a novel means of regulation of smARF protein steady state levels through its interactions with the mitochondrial p32. The p32 protein physically interacts with both human and murine smARF, and colocalizes with these short isoforms to the mitochondria. Remarkably, knocking down p32 protein levels significantly reduced the steady state levels of smARF by increasing its turn over. As a consequence, the ability of ectopically expressed smARF to induce autophagy and to cause mitochondrial membrane dissipation was significantly reduced. In contrast, the protein levels of full- length p19ARF, which mainly resides in the nucleolus, were not influenced by p32 depletion, suggesting that p32 exclusively stabilizes the mitochondrial smARF protein. Thus the interaction with p32 provides a means of specifically regulating the expression of the recently identified autophagic inducer, smARF, and adds yet another layer of complexity to the multifaceted regulation of the ARF gene.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Mol & Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Kimchi, A (corresponding author), Weizmann Inst Sci, Dept Mol Genet, Belfer 209, IL-76100 Rehovot, Israel.	adi.kimchi@weizmann.ac.il		Oren, Moshe/0000-0003-4311-7172				Brokstad KA, 2001, BIOCHEM BIOPH RES CO, V281, P1161, DOI 10.1006/bbrc.2001.4473; Bruni R, 1996, P NATL ACAD SCI USA, V93, P10423, DOI 10.1073/pnas.93.19.10423; Deb TB, 1996, J BIOL CHEM, V271, P2206, DOI 10.1074/jbc.271.4.2206; Dedio J, 1998, J IMMUNOL, V160, P3534; DESAI K, 1991, P NATL ACAD SCI USA, V88, P8875, DOI 10.1073/pnas.88.20.8875; FRIDELL RA, 1995, VIROLOGY, V209, P347, DOI 10.1006/viro.1995.1266; GHEBREHIWET B, 1994, J EXP MED, V179, P1809, DOI 10.1084/jem.179.6.1809; Granot Z, 2003, MOL ENDOCRINOL, V17, P2461, DOI 10.1210/me.2003-0074; Herwald H, 1996, J BIOL CHEM, V271, P13040, DOI 10.1074/jbc.271.22.13040; Jiang JZ, 1999, P NATL ACAD SCI USA, V96, P3572, DOI 10.1073/pnas.96.7.3572; Kuo ML, 2004, GENE DEV, V18, P1862, DOI 10.1101/gad.1213904; Lim BL, 1996, J BIOL CHEM, V271, P26739, DOI 10.1074/jbc.271.43.26739; LUO Y, 1994, J VIROL, V68, P3850, DOI 10.1128/JVI.68.6.3850-3856.1994; Matthews DA, 1998, J GEN VIROL, V79, P1677, DOI 10.1099/0022-1317-79-7-1677; Muta T, 1997, J BIOL CHEM, V272, P24363, DOI 10.1074/jbc.272.39.24363; Reef S, 2006, MOL CELL, V22, P463, DOI 10.1016/j.molcel.2006.04.014; Seytter T, 1998, YEAST, V14, P303, DOI 10.1002/(SICI)1097-0061(19980315)14:4<303::AID-YEA217>3.0.CO;2-N; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; SIMOS G, 1994, FEBS LETT, V346, P225, DOI 10.1016/0014-5793(94)00479-X; Soltys BJ, 2000, HISTOCHEM CELL BIOL, V114, P245; Sunayama J, 2004, CELL DEATH DIFFER, V11, P771, DOI 10.1038/sj.cdd.4401418; Tange TO, 1996, J BIOL CHEM, V271, P10066, DOI 10.1074/jbc.271.17.10066; Wang YL, 1997, VIROLOGY, V236, P18, DOI 10.1006/viro.1997.8739; YU L, 1995, J VIROL, V69, P3007, DOI 10.1128/JVI.69.5.3007-3016.1995; YU L, 1995, J VIROL, V69, P3017, DOI 10.1128/JVI.69.5.3017-3023.1995	25	43	47	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 11	2007	26	46					6677	6683		10.1038/sj.onc.1210485	http://dx.doi.org/10.1038/sj.onc.1210485			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	219JT	17486078				2022-12-17	WOS:000250081500009
J	Lucas, PC; Kuffa, P; Gu, S; Kohrt, D; Kim, DSL; Siu, K; Jin, X; Swenson, J; McAllister-Lucas, LM				Lucas, P. C.; Kuffa, P.; Gu, S.; Kohrt, D.; Kim, D. S. L.; Siu, K.; Jin, X.; Swenson, J.; McAllister-Lucas, L. M.			A dual role for the API2 moiety in API2-MALT1-dependent NF-kappa B activation: heterotypic oligomerization and TRAF2 recruitment	ONCOGENE			English	Article						MALT lymphoma; cIAP2; MALT1; NF-kappa B	HELICOBACTER-PYLORI ERADICATION; LYMPHOID-TISSUE LYMPHOMA; RECEPTOR-ASSOCIATED FACTOR-2; GASTRIC MALT LYMPHOMAS; CELL LYMPHOMA; UBIQUITIN LIGASE; BIR DOMAINS; FUSION; APOPTOSIS; BCL10	Mucosa-associated lymphoid tissue ( MALT) lymphoma is the most common extranodal lymphoid neoplasm. Chromosomal translocation t(11; 18)(q21, q21) is found in 30% of gastric MALT lymphomas and is associated with a failure to respond to standard treatment and a tendency to disseminate. This translocation generates a chimeric protein composed of N-terminal sequences of Inhibitor of Apoptosis 2 (API2, also known as BIRC3 and cIAP2) fused to C-terminal sequences of MALT1. API2-MALT1 promotes cell survival and proliferation via activation of nuclear factor-kappa B(NF-kappa B). Here, we investigate the mechanism by which the API2 moiety contributes to NF-kappa B stimulation. We find that the API2 moiety mediates oligomerization of API2-MALT1 as well as interaction with tumor necrosis factor receptor-associated factor 2 (TRAF2). Surprisingly, oligomerization does not occur via homotypic interaction; rather, the API2 moiety of one monomer interacts with the MALT1 moiety of another monomer. Further, the specific region of the API2 moiety responsible for mediating oligomerization is distinct from that mediating TRAF2 binding. Although deletion or mutation of the TRAF2 binding site does not inhibit oligomerization, it does lead to dramatically decreased NF-kappa B activation. Deletion of both TRAF2 binding and oligomerization regions results in near-complete loss of NF-kappa B activation. Thus, API2 moiety-mediated heterotypic oligomerization and TRAF2 binding both contribute to maximal API2-MALT1-dependent NF-kappa B stimulation.	Univ Michigan, Sch Med, Dept Pediat & Communicable Dis, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	McAllister-Lucas, LM (corresponding author), Univ Michigan, Sch Med, Dept Pediat & Communicable Dis, 3520D MSRB 1,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	lindaluc@umich.edu		Lucas, Peter/0000-0003-4880-7172	NCI NIH HHS [5K08 CA097986, 5K08 CA094920] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA094920, K08CA097986] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akagi T, 1999, ONCOGENE, V18, P5785, DOI 10.1038/sj.onc.1203018; Baens M, 2006, CANCER RES, V66, P5270, DOI 10.1158/0008-5472.CAN-05-4590; Bishop GA, 2004, NAT REV IMMUNOL, V4, P775, DOI 10.1038/nri1462; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Dierlamm J, 1999, BLOOD, V93, P3601, DOI 10.1182/blood.V93.11.3601; Dong W, 2006, J BIOL CHEM, V281, P26029, DOI 10.1074/jbc.M513057200; Ho L, 2005, BLOOD, V105, P2891, DOI 10.1182/blood-2004-06-2297; Hosokawa Y, 2004, CANCER RES, V64, P3452, DOI 10.1158/0008-5472.CAN-03-3677; Hostager BS, 2003, J BIOL CHEM, V278, P45382, DOI 10.1074/jbc.M306708200; Hu SM, 2006, J CLIN INVEST, V116, P174, DOI 10.1172/JCI25641; Inagaki H, 2004, AM J SURG PATHOL, V28, P1560, DOI 10.1097/00000478-200412000-00003; Isaacson PG, 1999, SEMIN HEMATOL, V36, P139; Iwano M, 2004, J GASTROENTEROL, V39, P739, DOI 10.1007/s00535-004-1382-1; Levy M, 2005, J CLIN ONCOL, V23, P5061, DOI 10.1200/JCO.2005.05.660; Liu HX, 2001, BLOOD, V98, P1182, DOI 10.1182/blood.V98.4.1182; Liu HX, 2001, LANCET, V357, P39, DOI 10.1016/S0140-6736(00)03571-6; Liu HX, 2002, GASTROENTEROLOGY, V122, P1286, DOI 10.1053/gast.2002.33047; Lucas PC, 2001, J BIOL CHEM, V276, P19012, DOI 10.1074/jbc.M009984200; Lucas PC, 2004, J CELL SCI, V117, P31, DOI 10.1242/jcs.00904; Luque LE, 2002, BIOCHEMISTRY-US, V41, P13663, DOI 10.1021/bi0263964; McAllister-Lucas LM, 2001, J BIOL CHEM, V276, P30589, DOI 10.1074/jbc.M103824200; Morgan JA, 1999, CANCER RES, V59, P6205; Okabe M, 2003, AM J PATHOL, V162, P1113, DOI 10.1016/S0002-9440(10)63908-9; Penas EMM, 2003, LEUKEMIA, V17, P2225, DOI 10.1038/sj.leu.2403122; Remstein ED, 2000, AM J PATHOL, V156, P1183, DOI 10.1016/S0002-9440(10)64988-7; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Ruland J, 2003, IMMUNITY, V19, P749, DOI 10.1016/S1074-7613(03)00293-0; Sakugawa ST, 2003, MODERN PATHOL, V16, P1232, DOI 10.1097/01.MP.0000097283.47637.58; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Samuel T, 2006, J BIOL CHEM, V281, P1080, DOI 10.1074/jbc.M509381200; Senyuk V, 2005, CANCER RES, V65, P7603, DOI 10.1158/0008-5472.CAN-05-0412; So CW, 2004, BLOOD, V104, P919, DOI 10.1182/blood-2004-03-0992; Stoffel A, 2004, P NATL ACAD SCI USA, V101, P9079, DOI 10.1073/pnas.0402415101; Streubel B, 2003, BLOOD, V101, P2335, DOI 10.1182/blood-2002-09-2963; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Turner SD, 2006, LEUKEMIA, V20, P572, DOI 10.1038/sj.leu.2404125; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(00)00094-0; Varfolomeev E, 2006, J BIOL CHEM, V281, P29022, DOI 10.1074/jbc.M605116200; Wang DH, 2002, NAT IMMUNOL, V3, P830, DOI 10.1038/ni824; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Wright CW, 2005, J CLIN INVEST, V115, P2673, DOI 10.1172/JCI26251; Ye HT, 2003, BLOOD, V101, P2547, DOI 10.1182/blood-2002-10-3167; Zhang QG, 1999, NAT GENET, V22, P63, DOI 10.1038/8767; Zhou HL, 2005, CANCER CELL, V7, P425, DOI 10.1016/j.ccr.2005.04.012; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273; Zucca E, 2000, BLOOD, V96, P410	47	43	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	38					5643	5654		10.1038/sj.onc.1210342	http://dx.doi.org/10.1038/sj.onc.1210342			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17334391				2022-12-17	WOS:000248801900010
J	Hurley, PJ; Wilsker, D; Bunz, F				Hurley, P. J.; Wilsker, D.; Bunz, F.			Human cancer cells require ATR for cell cycle progression following exposure to ionizing radiation	ONCOGENE			English	Article						ATR; IR; cell cycle; S-phase stasis; Chk1; Seckel	DOUBLE-STRAND BREAKS; DNA-DAMAGE RESPONSE; S-PHASE; ATAXIA-TELANGIECTASIA; TUMOR-SUPPRESSOR; SECKEL-SYNDROME; CHECKPOINT PATHWAY; HUMAN CHK1; REPLICATION; DEFECTS	The vast majority of cancer cells have defective checkpoints that permit the cell cycle to progress in the presence of double-strand DNA breaks (DSBs) caused by ionizing radiation (IR) and radiomimetic drugs. ATR (ataxia telangiectasia-mutated and Rad3-related) has recently been shown to be activated by DSBs, although the consequences of this activity are largely unknown. In this report, we use advanced gene targeting methods to generate biallelic hypomorphic ATR mutations in human colorectal cancer cells and d demonstrate that progression of the cancer cell cycle after IR treatment requires ATR. Cells with mutant ATR accumulated a defined point at the beginning of the S phase after IR treatment and were unable to progress beyond that point, where as cells at later stages of the S phase during the time of irradiation progresseda and completed DNA replication. The prolonged arrest of ATR mutant cancer cells did not involve the ataxia telangiectasia mutated-dependent S-phase checkpoint, but rather closely resembled a previously characterized form of cell cycle arrest termed S-phase stasis. As ATR strongly contributed to clonogenic survival after IR treatment, these data suggest that blocking ATR activity might be a useful strategy for inducing S-phase stasis and promoting the radiosensitization of checkpoint deficient cancer cells.	Johns Hopkins Univ, Sch Med, Dept Radiat Oncol & Mol Radiat Sci, Baltimore, MD 21231 USA	Johns Hopkins University	Bunz, F (corresponding author), Johns Hopkins Univ, Sch Med, Dept Radiat Oncol & Mol Radiat Sci, 1550 Orleans St,Room 453, Baltimore, MD 21231 USA.	fbunz@jhmi.edu			NATIONAL CANCER INSTITUTE [R01CA104253] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA104253] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Adams KE, 2006, ONCOGENE, V25, P3894, DOI 10.1038/sj.onc.1209426; Alderton GK, 2004, HUM MOL GENET, V13, P3127, DOI 10.1093/hmg/ddh335; Bernardi R, 2000, ONCOGENE, V19, P2447, DOI 10.1038/sj.onc.1203564; Borel F, 2002, J CELL SCI, V115, P2829; Brown EJ, 2000, GENE DEV, V14, P397; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cha RS, 2002, SCIENCE, V297, P602, DOI 10.1126/science.1071398; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Cuadrado M, 2006, J EXP MED, V203, P297, DOI 10.1084/jem.20051923; Donzelli M, 2003, EMBO REP, V4, P671, DOI 10.1038/sj.embor.embor887; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Falck J, 2001, ONCOGENE, V20, P5503, DOI 10.1038/sj.onc.1204811; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Jirmanova L, 2005, CELL CYCLE, V4, P1428, DOI 10.4161/cc.4.10.2055; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kumar S, 2004, J BIOL CHEM, V279, P43574, DOI 10.1074/jbc.M407819200; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; McGowan CH, 2004, CURR OPIN CELL BIOL, V16, P629, DOI 10.1016/j.ceb.2004.09.005; Myers JS, 2006, J BIOL CHEM, V281, P9346, DOI 10.1074/jbc.M513265200; O'Driscoll M, 2003, NAT GENET, V33, P497, DOI 10.1038/ng1129; O'Driscoll M, 2004, DNA REPAIR, V3, P1227, DOI 10.1016/j.dnarep.2004.03.025; OConnor PM, 1997, CANCER RES, V57, P4285; Osborn AJ, 2002, TRENDS CELL BIOL, V12, P509, DOI 10.1016/S0962-8924(02)02380-2; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; Saleh-Gohari N, 2005, MOL CELL BIOL, V25, P7158, DOI 10.1128/MCB.25.16.7158-7169.2005; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Seckel H.P.G., 1960, BIRD HEADED DWARFS S; Shechter D, 2004, NAT CELL BIOL, V6, P648, DOI 10.1038/ncb1145; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Syljuasen RG, 2005, MOL CELL BIOL, V25, P3553, DOI 10.1128/MCB.25.9.3553-3562.2005; Topaloglu O, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni160; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	38	43	50	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2007	26	18					2535	2542		10.1038/sj.onc.1210049	http://dx.doi.org/10.1038/sj.onc.1210049			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YI	17043640				2022-12-17	WOS:000245831200001
J	Hasegawa, M; Kawase, K; Inohara, N; Imamura, R; Yeh, WC; Kinoshita, T; Suda, T				Hasegawa, M.; Kawase, K.; Inohara, N.; Imamura, R.; Yeh, W. -C; Kinoshita, T.; Suda, T.			Mechanism of ASC-mediated apoptosis: Bid-dependent apoptosis in type II cells	ONCOGENE			English	Article						apoptosis; ASC; CARD12; caspase; Bid; Bax	NF-KAPPA-B; RECEPTOR-INDUCED APOPTOSIS; INTERLEUKIN-8 PRODUCTION; CONTAINING PROTEIN; FAMILY MEMBER; C-FLIP; ACTIVATION; DEATH; CASPASE-1; PATHWAY	Apoptosis-associated speck-like protein containing a CARD (ASC) is an adaptor molecule that mediates apoptotic and inflammatory signals, and implicated in tumor suppression. However, the mechanism of ASC-mediated apoptosis has not been well elucidated. Here, we investigated the molecular mechanisms of ASC-mediated apoptosis in several cell lines using a caspase recruitment domain 12-Nod2 chimeric protein that transduces the signal from muramyl dipeptide into ASC-mediated apoptosis. Experiments using dominant-negative mutants, small-interfering RNAs and peptide inhibitors for caspases indicated that caspase-8 was generally required for ASC-mediated apoptosis, whereas a requirement for caspase-9 depended on the cell type. In addition, caspase-like apoptosis-regulatory protein (CLARP)/Fas-like inhibitor protein, a natural caspase-8 inhibitor, suppressed ASC-mediated apoptosis, and Clarp-/- mouse embryonic fibroblasts were highly sensitive to ASC-mediated apoptosis. Bax-deficient HCT116 cells were resistant to ASC-mediated apoptosis as reported previously, although we failed to observe colocalization of ASC and Bax in cells. Like Fas-ligand-induced apoptosis, the ASC- mediated apoptosis was inhibited by Bcl-2 and/orBcl-XL in type-II but not type-I cell lines. Bid was cleaved upon ASC activation, and suppression of endogenous Bid expression using small-interfering RNAs in type-II cells reduced the ASC- mediated apoptosis. These results indicate that ASC, like death receptors, mediates two types of apoptosis depending on the cell type, in a manner involving caspase-8.	Kanazawa Univ, Inst Canc Res, Ctr Dev Mol Target Drugs, Kanazawa, Ishikawa 9200934, Japan; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Toronto, Dept Med Biophys, Toronto, ON M4X 1K9, Canada	Kanazawa University; University of Michigan System; University of Michigan; University of Toronto	Suda, T (corresponding author), Kanazawa Univ, Inst Canc Res, Ctr Dev Mol Target Drugs, 13-1 Takaramachi, Kanazawa, Ishikawa 9200934, Japan.	sudat@kenroku.kanazawa-u.ac.jp	IMAMURA, Ryu/D-8433-2015					Bullani RR, 2001, J INVEST DERMATOL, V117, P360, DOI 10.1046/j.0022-202x.2001.01418.x; Damiano JS, 2004, J IMMUNOL, V173, P6338, DOI 10.4049/jimmunol.173.10.6338; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Elnemr A, 2001, INT J ONCOL, V18, P311; Geddes BJ, 2001, BIOCHEM BIOPH RES CO, V284, P77, DOI 10.1006/bbrc.2001.4928; Gumucio DL, 2002, CLIN EXP RHEUMATOL, V20, pS45; Hasegawa M, 2005, J BIOL CHEM, V280, P15122, DOI 10.1074/jbc.M412284200; Imamura R, 2004, J BIOL CHEM, V279, P46415, DOI 10.1074/jbc.M403226200; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Jesenberger V, 2000, J EXP MED, V192, P1035, DOI 10.1084/jem.192.7.1035; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664; Mariathasan S, 2005, J EXP MED, V202, P1043, DOI 10.1084/jem.20050977; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Masumoto J, 2003, BIOCHEM BIOPH RES CO, V303, P69, DOI 10.1016/S0006-291X(03)00309-7; Mathas S, 2004, J EXP MED, V199, P1041, DOI 10.1084/jem.20031080; McConnell BB, 2004, APOPTOSIS, V9, P5, DOI 10.1023/B:APPT.0000012117.32430.0c; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Ohtsuka T, 2004, NAT CELL BIOL, V6, P121, DOI 10.1038/ncb1087; Poyet JL, 2001, J BIOL CHEM, V276, P28309, DOI 10.1074/jbc.C100250200; Sadasivam S, 2005, ONCOGENE, V24, P627, DOI 10.1038/sj.onc.1208201; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Sun XM, 2002, J BIOL CHEM, V277, P11345, DOI 10.1074/jbc.M109893200; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Wang L, 2002, J BIOL CHEM, V277, P29874, DOI 10.1074/jbc.M203915200; Wang YT, 2004, INT IMMUNOL, V16, P777, DOI 10.1093/intimm/dxh081; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; Zender L, 2003, P NATL ACAD SCI USA, V100, P7797, DOI 10.1073/pnas.1330920100	31	43	45	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	12					1748	1756		10.1038/sj.onc.1209965	http://dx.doi.org/10.1038/sj.onc.1209965			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	16964285	Green Submitted			2022-12-17	WOS:000244955600009
J	Scharf, S; Zech, J; Bursen, A; Schraets, D; Oliver, PL; Kliem, S; Pfitzner, E; Gillert, E; Dingermann, T; Marschalek, R				Scharf, S.; Zech, J.; Bursen, A.; Schraets, D.; Oliver, P. L.; Kliem, S.; Pfitzner, E.; Gillert, E.; Dingermann, T.; Marschalek, R.			Transcription linked to recombination: a gene-internal promoter coincides with the recombination hot spot II of the human MLL gene	ONCOGENE			English	Article						MLL gene; acute leukaemia; transcription; gene-internal promoter	BREAKPOINT-CLUSTER REGION; ACUTE LYMPHOBLASTIC-LEUKEMIA; CHROMOSOMAL TRANSLOCATIONS; DNA CLEAVAGE; REARRANGEMENTS; EXPRESSION; INHIBITORS; ETOPOSIDE; APOPTOSIS; T(4/11)	The MLL gene is frequently involved in chromosomal translocations associated with high-risk acute leukaemia. Infant and therapy-related acute leukaemia patients display chromosomal breakpoints preferentially clustered in the telomeric portion of the MLL breakpoint cluster region (SCII). Here, we demonstrate that SCII colocalizes with a gene-internal promoter element in the mouse and human MLL gene, respectively. The mRNA generated encodes an N-terminally truncated version of MLL that still exhibits many functional regions, including the C-terminal SET-domain. Etoposide-induced DNA double-strand breaks colocalize with the binding site of RNA polymerase II and the transcription initiation region, but not with a nearby Topo II consensus sequence. Thus, the observed genomic instability of the human MLL gene is presumably linked to transcriptional processes. The consequences of this novel finding for the creation of chromosomal translocations, the biology of the MLL protein and for MLL-mediated acute leukaemia are discussed.	Univ Frankfurt, Inst Pharmaceut Biol, ZAFES, Bioctr, D-60439 Frankfurt, Germany; Univ Oxford, Res Council Funct Genet Unit, Dept Physiol Anat & Genet, Oxford, England; Procompliance Verlag GmbH, Erlangen, Germany	Goethe University Frankfurt; University of Oxford	Marschalek, R (corresponding author), Univ Frankfurt, Inst Pharmaceut Biol, ZAFES, Bioctr, Marie Curie Str 9, D-60439 Frankfurt, Germany.	rolf.marschalek@em.uni-frankfurt.de	Marschalek, Rolf/D-3404-2011; Pfitzner, Edith/AAU-7927-2021; Oliver, Peter/F-1453-2010; Dingermann, Theodor/M-6970-2014	Marschalek, Rolf/0000-0003-4870-3445; Pfitzner, Edith/0000-0002-3484-9649; Dingermann, Theodor/0000-0002-2788-1085; Oliver, Peter/0000-0003-3347-2461				Andersen MK, 2001, BRIT J HAEMATOL, V114, P539, DOI 10.1046/j.1365-2141.2001.03000.x; Aplan PD, 1996, BLOOD, V87, P2649, DOI 10.1182/blood.V87.7.2649.bloodjournal8772649; Betti CJ, 2005, LEUKEMIA, V19, P2289, DOI 10.1038/sj.leu.2403966; Betti CJ, 2001, CANCER RES, V61, P4550; BLACKWELL TK, 1986, NATURE, V324, P585, DOI 10.1038/324585a0; Broeker PLS, 1996, BLOOD, V87, P1912, DOI 10.1182/blood.V87.5.1912.bloodjournal8751912; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Felix CA, 1998, P NATL ACAD SCI USA, V95, P13176, DOI 10.1073/pnas.95.22.13176; Gillert E, 1999, ONCOGENE, V18, P4663, DOI 10.1038/sj.onc.1202842; GOTO H, 1994, INT J HEMATOL, V60, P145; Hsieh JJD, 2003, CELL, V115, P293, DOI 10.1016/S0092-8674(03)00816-X; Khobta A, 2004, CANCER RES, V64, P2656, DOI 10.1158/0008-5472.CAN-03-1126; Libura J, 2005, BLOOD, V105, P2124, DOI 10.1182/blood-2004-07-2683; Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005; Mitterbauer-Hohendanner G, 2004, EUR J CLIN INVEST, V34, P12, DOI 10.1111/j.0960-135X.2004.01366.x; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Nasr F, 1997, LEUKEMIA LYMPHOMA, V25, P399, DOI 10.3109/10428199709114180; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Reichel M, 1998, ONCOGENE, V17, P3035, DOI 10.1038/sj.onc.1202229; Reichel M, 2001, ONCOGENE, V20, P2900, DOI 10.1038/sj.onc.1204401; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; Sim SP, 2001, J BIOL CHEM, V276, P31590, DOI 10.1074/jbc.M103962200; Stanulla M, 1997, MOL CELL BIOL, V17, P4070, DOI 10.1128/MCB.17.7.4070; Strissel PL, 1998, BLOOD, V92, P3793, DOI 10.1182/blood.V92.10.3793.422a24_3793_3803; Uhl J, 2002, J BIOL CHEM, V277, P4374, DOI 10.1074/jbc.M107665200; Yokoyama A, 2002, BLOOD, V100, P3710, DOI 10.1182/blood-2002-04-1015; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	28	43	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 1	2007	26	10					1361	1371		10.1038/sj.onc.1209948	http://dx.doi.org/10.1038/sj.onc.1209948			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16983345				2022-12-17	WOS:000244558800001
J	Trivedi, AK; Bararia, D; Christopeit, M; PeerZada, AA; Singh, SM; Kieser, A; Hiddemann, W; Behre, HM; Behre, G				Trivedi, A. K.; Bararia, D.; Christopeit, M.; PeerZada, A. A.; Singh, S. M.; Kieser, A.; Hiddemann, W.; Behre, H. M.; Behre, G.			Proteomic identification of C/EBP-DBD multiprotein complex: JNK1 activates stem cell regulator C/EBP alpha by inhibiting its ubiquitination	ONCOGENE			English	Article						JNK1; C/EBP alpha; ubiquitination; AML and proteomics	BINDING-PROTEIN-ALPHA; ACUTE MYELOID-LEUKEMIA; C-JUN EXPRESSION; GRANULOCYTIC DIFFERENTIATION; DNA-BINDING; TRANSCRIPTION FACTORS; LINEAGE COMMITMENT; DOWN-REGULATION; PHOSPHORYLATION; KINASE	Functional inactivation of transcription factors in hematopoietic stem cell development is involved in the pathogenesis of acute myeloid leukemia (AML). Stem cell regulator C/enhancer binding protein (EBP)alpha is among such transcription factors known to be inactive in AML. This is either due to mutations or inhibition by protein-protein interactions. Here, we applied a mass spectrometry-based proteomic approach to systematically identify putative co-activator proteins interacting with the DNA-binding domain (DBD) of C/EBP transcription factors. In our proteomic screen, we identified c-Jun N-terminal kinase (JNK) 1 among others such as PAK6, MADP-1, calmodulin-like skin proteins and ZNF45 as proteins interacting with DBD of C/EBPs from nuclear extract of myelomonocytic U937 cells. We show that kinase JNK1 physically interacts with DBD of C/EBP alpha in vitro and in vivo. Furthermore, we show that active JNK1 inhibits ubiquitination of C/EBP alpha possibly by phosphorylating in its DBD. Consequently, JNK1 prolongs C/EBP alpha protein half-life leading to its enhanced transactivation and DNA-binding capacity. In certain AML patients, however, the JNK1 mRNA expression and its kinase activity is decreased which suggests a possible reason for C/EBP alpha inactivation in AML. Thus, we report the first proteomic screen of C/EBP-interacting proteins, which identifies JNK1 as positive regulator of C/EBP alpha.	Univ Halle Wittenberg, Bone Marrow Transplantat Sect, Dept Internal Med 4, State Ctr Cell & Gene Therapy, Halle, SA, Germany; GSF Natl Res Ctr Environm & Hlth, Dept Gene Vectors, Munich, Germany; Univ Munich, Dept Internal Med 3, D-80539 Munich, Germany; Univ Halle Wittenberg, Androl Sect, D-4010 Halle, Germany	Martin Luther University Halle Wittenberg; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; University of Munich; Martin Luther University Halle Wittenberg	Behre, G (corresponding author), Univ Halle Wittenberg, Bone Marrow Transplantat Sect, Dept Internal Med 4, State Ctr Cell & Gene Therapy, Halle, SA, Germany.	gerhard.behre@medizin.uni-halle.de	Kieser, Arnd/M-4616-2014; Trivedi, Arun Kumar/W-1883-2019	Kieser, Arnd/0000-0003-0783-1950; Trivedi, Arun Kumar/0000-0002-6316-0947; Christopeit, Maximilian/0000-0003-4627-0412				BALKHI MY, 2006, EPUB ONCOGENE, V29; Behre G, 2002, J BIOL CHEM, V277, P26293, DOI 10.1074/jbc.M202301200; Behre Gerhard, 2002, Expert Opin Ther Targets, V6, P491, DOI 10.1517/14728222.6.4.491; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P29710; Cleaves R, 2004, ONCOGENE, V23, P716, DOI 10.1038/sj.onc.1207172; Cristea IM, 2004, BLOOD, V103, P3624, DOI 10.1182/blood-2003-09-3295; D'Alo F, 2003, BLOOD, V102, P3163, DOI 10.1182/blood-2003-02-0479; Friedman AD, 1996, CANCER RES, V56, P3250; Frohling S, 2004, J CLIN ONCOL, V22, P624, DOI 10.1200/JCO.2004.06.060; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Fuchs SY, 1996, ONCOGENE, V13, P1531; Gombart AF, 2002, BLOOD, V99, P1332, DOI 10.1182/blood.V99.4.1332; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI200112466; Hattori T, 2003, ONCOGENE, V22, P1273, DOI 10.1038/sj.onc.1206204; Iakova P, 2003, CELL, V113, P495, DOI 10.1016/S0092-8674(03)00318-0; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; MAHONEY CW, 1992, J BIOL CHEM, V267, P19396; Mann M, 2001, ANNU REV BIOCHEM, V70, P437, DOI 10.1146/annurev.biochem.70.1.437; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Morton S, 2003, EMBO J, V22, P3876, DOI 10.1093/emboj/cdg388; Muller C, 2004, J BIOL CHEM, V279, P7353, DOI 10.1074/jbc.M312709200; Muller C, 1995, EMBO J, V14, P6127, DOI 10.1002/j.1460-2075.1995.tb00303.x; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Perrotti D, 2004, J CLIN ONCOL, V22, P582, DOI 10.1200/JCO.2004.12.965; Perrotti D, 2002, NAT GENET, V30, P48, DOI 10.1038/ng791; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Rangatia J, 2002, MOL CELL BIOL, V22, P8681, DOI 10.1128/MCB.22.24.8681-8694.2002; Reddy VA, 2002, BLOOD, V100, P483, DOI 10.1182/blood.V100.2.483; Ronai Z, 2004, MOL CELL, V15, P843, DOI 10.1016/j.molcel.2004.09.011; Ross SE, 2004, MOL CELL BIOL, V24, P675, DOI 10.1128/MCB.24.2.675-686.2004; Ross SE, 1999, MOL CELL BIOL, V19, P8433; Schoch C, 2002, P NATL ACAD SCI USA, V99, P10008, DOI 10.1073/pnas.142103599; SCOTT LM, 1992, BLOOD, V80, P1725; Shim M, 2003, J BIOL CHEM, V278, P19674, DOI 10.1074/jbc.M301356200; Sieweke MH, 1998, CURR OPIN GENET DEV, V8, P545, DOI 10.1016/S0959-437X(98)80009-9; Smith ML, 2004, NEW ENGL J MED, V351, P2403, DOI 10.1056/NEJMoa041331; Subramanian L, 2003, J BIOL CHEM, V278, P9134, DOI 10.1074/jbc.M210440200; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; TERRANCE A, 2002, LEUKEMIA RES, V26, P55; Vangala RK, 2003, BLOOD, V101, P270, DOI 10.1182/blood-2002-04-1288; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Xu SC, 1997, J BIOL CHEM, V272, P32056, DOI 10.1074/jbc.272.51.32056; Yoon K, 2004, MOL CELL BIOL, V24, P10650, DOI 10.1128/MCB.24.24.10650-10660.2004; Zada AAP, 2003, ONCOGENE, V22, P2296, DOI 10.1038/sj.onc.1206330; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zheng R, 2004, BLOOD, V103, P1883, DOI 10.1182/blood-2003-06-1978	53	43	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	12					1789	1801		10.1038/sj.onc.1209964	http://dx.doi.org/10.1038/sj.onc.1209964			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	16983342				2022-12-17	WOS:000244955600013
J	Amiri, KI; Ha, HC; Smulson, ME; Richmond, A				Amiri, K. I.; Ha, H. C.; Smulson, M. E.; Richmond, A.			Differential regulation of CXC ligand 1 transcription in melanoma cell lines by poly(ADP-ribose) polymerase-1	ONCOGENE			English	Article						PARP-1; CXCL1; NF-kappa B; transcription; melanoma	NF-KAPPA-B; DNA-BINDING; GENE-EXPRESSION; CHROMATIN-STRUCTURE; GRO-ALPHA; ACTIVATION; PARP-1; IL-8; INTERLEUKIN-8; INHIBITION	The continuous production of the CXC ligand 1 ( CXCL1) chemokine by melanoma cells is a major effector of tumor growth. We have previously shown that the constitutive expression of this chemokine is dependent upon transcription factors nuclear factor- kappa B ( NF- kappa B), stimulating protein-1 (SP1), high- mobility group-I/Y ( HMGI/Y), CAAT displacement protein ( CDP) and poly( ADPribose) polymerase- 1 ( PARP-1). In this study, we demonstrate for the first time the mechanism of transcriptional regulation of CXCL1 through PARP-1 in melanoma cells. In its inactive state, PARP- 1 binds to the CXCL1 promoter in a sequence-specific manner and prevents binding of NF- kappa B ( p65/ p50) to its element. However, activation of the PARP- 1 enzymatic activity enhances CXCL1 expression, owing to the loss of PARP1 binding to the CXCL1 promoter, accompanied by enhanced binding of p65 to the promoter. The delineation of the role of NF-kappa B- interacting factors in the putative CXCL1 enhanceosome will provide key information in developing strategies to block constitutive expression of this and other chemokines in cancer and to develop targeted therapy.	Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Vet Affairs, Nashville, TN 37232 USA; Meharry Med Coll, Dept Microbiol, Nashville, TN 37208 USA; Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, Washington, DC USA	Vanderbilt University; Vanderbilt University; Meharry Medical College; Georgetown University	Richmond, A (corresponding author), Vanderbilt Univ, Sch Med, Dept Canc Biol, 771 PRB,23rd Ave S Pierce, Nashville, TN 37232 USA.	ann.richmond@vanderbilt.edu	Richmond, Ann/A-3048-2014	RICHMOND, ANN/0000-0002-9580-900X	NCI NIH HHS [P01CA-74175, CA-56704, R01 CA116021, R01 CA116021-03, R01 CA116021-02] Funding Source: Medline; BLRD VA [IK6 BX005225] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA116021, R01CA056704, P01CA074175] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); BLRD VA; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alvarez-Gonzalez R, 1999, J BIOL CHEM, V274, P32122, DOI 10.1074/jbc.274.45.32122; BALENTIEN E, 1991, ONCOGENE, V6, P1115; Boulares AH, 2003, AM J RESP CELL MOL, V28, P322, DOI 10.1165/rcmb.2001-0015OC; Burkle A, 2001, BIOESSAYS, V23, P795, DOI 10.1002/bies.1115; Cayuela ML, 2001, BIOCHEM BIOPH RES CO, V285, P289, DOI 10.1006/bbrc.2001.5178; Chang WJ, 2001, J BIOL CHEM, V276, P47664, DOI 10.1074/jbc.M104666200; Dhawan P, 2002, J BIOL CHEM, V277, P7920, DOI 10.1074/jbc.M112210200; Ha HC, 2004, P NATL ACAD SCI USA, V101, P5087, DOI 10.1073/pnas.0306895101; Haghnegahdar H, 2000, J LEUKOCYTE BIOL, V67, P53, DOI 10.1002/jlb.67.1.53; Haqq C, 2005, P NATL ACAD SCI USA, V102, P6092, DOI 10.1073/pnas.0501564102; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; Huang K, 2004, BIOCHEMISTRY-US, V43, P217, DOI 10.1021/bi0301800; Kameoka M, 2000, BIOCHEM J, V346, P641, DOI 10.1042/0264-6021:3460641; Keane MP, 1997, J IMMUNOL, V159, P1437; Kim MY, 2004, CELL, V119, P803, DOI 10.1016/j.cell.2004.11.002; Li AH, 2001, CLIN CANCER RES, V7, P3298; Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261; Nirodi C, 2001, J BIOL CHEM, V276, P9366, DOI 10.1074/jbc.M009897200; Olbina G, 1996, ANTICANCER RES, V16, P3525; Owen JD, 1997, INT J CANCER, V73, P94, DOI 10.1002/(SICI)1097-0215(19970926)73:1<94::AID-IJC15>3.0.CO;2-5; Richards BL, 1997, AM J SURG, V174, P507; Schadendorf D, 1996, BRIT J CANCER, V74, P194, DOI 10.1038/bjc.1996.337; Schadendorf M, 1994, J IMMUNOL, V153, P3360; SHATTUCK RL, 1994, MOL CELL BIOL, V14, P791, DOI 10.1128/MCB.14.1.791; Simbulan-Rosenthal CM, 1999, P NATL ACAD SCI USA, V96, P13191, DOI 10.1073/pnas.96.23.13191; Simbulan-Rosenthal CM, 2003, ONCOGENE, V22, P8460, DOI 10.1038/sj.onc.1206897; Smulson ME, 2000, ADV ENZYME REGUL, V40, P183, DOI 10.1016/S0065-2571(99)00024-2; Soldatenkov VA, 2002, J BIOL CHEM, V277, P665, DOI 10.1074/jbc.M108551200; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; Szabo E, 2001, J INVEST DERMATOL, V117, P74, DOI 10.1046/j.0022-202x.2001.01388.x; Takamori H, 2000, PANCREAS, V21, P52, DOI 10.1097/00006676-200007000-00051; Tulin A, 2003, SCIENCE, V299, P560, DOI 10.1126/science.1078764; Tulin A, 2003, CURR TOP DEV BIOL, V56, P55, DOI 10.1016/S0070-2153(03)01007-X; WOOD LD, 1995, NUCLEIC ACIDS RES, V23, P4210, DOI 10.1093/nar/23.20.4210; Yang JM, 2001, CANCER RES, V61, P4901; Zhang Z, 2002, VIROLOGY, V296, P107, DOI 10.1006/viro.2002.1385	36	43	46	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2006	25	59					7714	7722		10.1038/sj.onc.1209751	http://dx.doi.org/10.1038/sj.onc.1209751			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116VE	16799643	Green Accepted			2022-12-17	WOS:000242830800006
J	Singh, SR; Zhen, W; Zheng, Z; Wang, H; Oh, SW; Liu, W; Zbar, B; Schmidt, LS; Hou, SX				Singh, S. R.; Zhen, W.; Zheng, Z.; Wang, H.; Oh, S-W; Liu, W.; Zbar, B.; Schmidt, L. S.; Hou, S. X.			The Drosophila homolog of the human tumor suppressor gene BHD interacts with the JAK-STAT and Dpp signaling pathways in regulating male germline stem cell maintenance	ONCOGENE			English	Article						tumor suppressor; Drosophila BHD homolog; male germline stem cell; stem cell maintenance; JAK/STAT signaling pathway; Dpp signaling pathway	SELF-RENEWAL; SPONTANEOUS PNEUMOTHORAX; DIFFERENTIATION; PROTEIN; MUTATIONS; FOLLICLE; ENCODES	Birt-Hogg-Dube syndrome (BHD) is a rare, inherited genodermatosis characterized by hair follicle hamartomas, kidney tumors and spontaneous pneumothorax. The BHD locus was mapped to chromosome 17p11.2 by linkage analysis, and germ line mutations in a novel gene ( BHD) were identified in a panel of BHD families. Using RNA interference to decrease expression of the Drosophila BHD homolog (DBHD), we have demonstrated that DBHD is required for male germline stem cell (GSC) maintenance in the fly testis. Reduction of DBHD gene activity suppresses the GSC overproliferation phenotype associated with overexpression of either unpaired (upd) or decapentaplegic (dpp). Further genetic interaction experiments suggest that DBHD regulates GSC maintenance downstream or in parallel of the JAK/STAT and Dpp signal-transduction pathways. These findings suggest that the BHD protein may regulate tumorigenesis through modulating stem cells in human.	NCI, Mouse Canc Genet Program, NIH, Frederick, MD 21702 USA; NCI, Immunobiol Lab, NIH, Frederick, MD 21702 USA; NCI, Basic Res Program, SAIC Frederick Inc, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Singh, SR (corresponding author), NCI, Mouse Canc Genet Program, NIH, Frederick, MD 21702 USA.	sshreeram@ncifcrf.gov; shou@mail.ncifcrf.gov	Singh/B-7614-2008	Singh/0000-0001-6545-583X	NATIONAL CANCER INSTITUTE [Z01SC006659, Z01BC010738] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 CA999999] Funding Source: Medline; NCI NIH HHS [N01-CO-12400] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baksa K, 2002, DEV BIOL, V243, P166, DOI 10.1006/dbio.2001.0539; BIRT AR, 1977, ARCH DERMATOL, V113, P1674, DOI 10.1001/archderm.113.12.1674; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brawley C, 2004, SCIENCE, V304, P1331, DOI 10.1126/science.1097676; Chen DH, 2005, CURR BIOL, V15, P179, DOI 10.1016/j.cub.2005.01.004; Chen DH, 2003, CURR BIOL, V13, P1786, DOI 10.1016/j.cub.2003.09.033; Chen HW, 2002, GENE DEV, V16, P388, DOI 10.1101/gad.955202; CHOMETTE G, 1985, TESTICULAR CANC, P35; Fabrizio JJ, 2003, DEV BIOL, V258, P117, DOI 10.1016/S0012-1606(03)00127-1; Fuller Margaret T., 1993, P71; Fuller MT, 1998, SEMIN CELL DEV BIOL, V9, P433, DOI 10.1006/scdb.1998.0227; Gilboa L, 2004, CURR BIOL, V14, P981, DOI 10.1016/j.cub.2004.05.049; Giordano E, 2002, GENETICS, V160, P637; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; Kawase E, 2004, DEVELOPMENT, V131, P1365, DOI 10.1242/dev.01025; Kiger AA, 2000, NATURE, V407, P750, DOI 10.1038/35037606; Kiger AA, 2001, SCIENCE, V294, P2542, DOI 10.1126/science.1066707; Lingaas F, 2003, HUM MOL GENET, V12, P3043, DOI 10.1093/hmg/ddg336; Nickerson ML, 2002, CANCER CELL, V2, P157, DOI 10.1016/S1535-6108(02)00104-6; Okimoto K, 2004, P NATL ACAD SCI USA, V101, P2023, DOI 10.1073/pnas.0308071100; Pavlovich CP, 2002, AM J SURG PATHOL, V26, P1542, DOI 10.1097/00000478-200212000-00002; Pignoni F, 1997, DEVELOPMENT, V124, P271; Schmidt LS, 2001, AM J HUM GENET, V69, P876, DOI 10.1086/323744; Szakmary A, 2005, CURR BIOL, V15, P171, DOI 10.1016/j.cub.2005.01.005; Tran J, 2000, NATURE, V407, P754, DOI 10.1038/35037613; Tulina N, 2001, SCIENCE, V294, P2546, DOI 10.1126/science.1066700; Vocke CD, 2005, J NATL CANCER I, V97, P931, DOI 10.1093/jnci/dji154; Youngren KK, 2005, NATURE, V435, P360, DOI 10.1038/nature03595; Zbar B, 2002, CANCER EPIDEM BIOMAR, V11, P393	29	43	45	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2006	25	44					5933	5941		10.1038/sj.onc.1209593	http://dx.doi.org/10.1038/sj.onc.1209593			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	088QN	16636660				2022-12-17	WOS:000240826300002
J	Dang, LH; Chen, F; Ying, C; Chun, S; Knock, SA; Appelman, HD; Dang, DT				Dang, LH; Chen, F; Ying, C; Chun, S; Knock, SA; Appelman, HD; Dang, DT			CDX2 has tumorigenic potential in the human colon cancer cell lines LOVO and SW48	ONCOGENE			English	Article						CDX2; colon cancer; tumorigenesis; LOVO; SW48	HOMEOBOX GENE CDX2; COLORECTAL-CANCER; DOWN-REGULATION; PROTEIN EXPRESSION; RNA EXPRESSION; PROLIFERATION; ADENOCARCINOMA; APOPTOSIS; TUMORS; BCL-2	CDX2 is a Drosophila caudal-related homeo box transcription factor that is important for the establishment and maintenance of intestinal epithelial cells. CDX2 is a marker of colon cancer, with strong staining in up to 90% of colonic adenocarcinomas. CDX2 heterozygous-null mice develop colonic neoplasms, which have suggested that CDX2 is a tumor suppressor. However, CDX2 has not been reported to affect xenograft growth. Furthermore, CDX2 is rarely mutated in colon cancer, which has led to suggestions that it may play only a minor role as a tumor suppressor in colon cancer. To understand the functional contributions of CDX2 to colon cancer, we disrupted CDX2 in LOVO and SW48 human colon cancer cell lines by targeted homologous recombination. Consistent with the literature, disruption of CDX2 enhanced anchorage-dependent cell proliferation. However, homozygous loss of CDX2 led to significant inhibition of anchorage-independent growth in LOVO cells, and cell lethality in SW48 cells. Further analyses revealed that disruption of CDX2 led to anchorage-independent G1 to S growth arrest and anoikis. In vivo xenograft studies confirmed that disruption of CDX2 inhibited LOVO tumor growth. These data demonstrate that CDX2 mediates anchorage-independent growth and survival. Thus, CDX2 has tumorigenic potential in the human colon cancer cell lines LOVO and SW48.	Univ Michigan, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Div Anat Pathol, Dept Pathol, Ann Arbor, MI USA; Univ Michigan, Dept Internal Med, Div Gastroenterol, Ann Arbor, MI USA; Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Dang, DT (corresponding author), Univ Michigan, Dept Internal Med, Div Hematol Oncol, 1150 W Med Ctr Dr,MSRB I,Room 6514, Ann Arbor, MI 48109 USA.	dangd@umich.edu						Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Aoki K, 2003, NAT GENET, V35, P323, DOI 10.1038/ng1265; Bai YQ, 2003, ONCOGENE, V22, P7942, DOI 10.1038/sj.onc.1206634; Beck F, 2002, GUT, V51, P450, DOI 10.1136/gut.51.3.450; Bonhomme C, 2003, GUT, V52, P1465, DOI 10.1136/gut.52.10.1465; Brabletz T, 2004, CANCER RES, V64, P6973, DOI 10.1158/0008-5472.CAN-04-1132; Chan TA, 2002, P NATL ACAD SCI USA, V99, P8265, DOI 10.1073/pnas.082240999; Chawengsaksophak K, 2004, P NATL ACAD SCI USA, V101, P7641, DOI 10.1073/pnas.0401654101; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; Cummins JM, 2004, CANCER RES, V64, P3006, DOI 10.1158/0008-5472.CAN-04-0046; CUMMINS JM, 2004, NATURE, V428, P486, DOI [DOI 10.1038/NATURE02501, 10.1038/nature02501]; da Costa LT, 1999, ONCOGENE, V18, P5010, DOI 10.1038/sj.onc.1202872; Dang DT, 2001, ONCOGENE, V20, P4884, DOI 10.1038/sj.onc.1204645; DANG DT, 2005, CANCER RES, V65, P1; Dang LH, 2001, P NATL ACAD SCI USA, V98, P15155, DOI 10.1073/pnas.251543698; Dang LH, 2004, CANCER BIOL THER, V3, P326, DOI 10.4161/cbt.3.3.704; DANG LH, 2006, IN PRESS ONCOGENE; DONG Z, 2002, SCI STKE, pPL7; DREWINKO B, 1976, CANCER RES, V36, P467; EE HC, 1995, AM J PATHOL, V147, P586; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Freund JN, 1998, BIOCHEM CELL BIOL, V76, P957, DOI 10.1139/bcb-76-6-957; Guo RJ, 2004, CANCER BIOL THER, V3, P593, DOI 10.4161/cbt.3.7.913; Guo RJ, 2004, J BIOL CHEM, V279, P36865, DOI 10.1074/jbc.M405213200; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Heckman CA, 2000, J BIOL CHEM, V275, P6499, DOI 10.1074/jbc.275.9.6499; Hinoi T, 2001, AM J PATHOL, V159, P2239, DOI 10.1016/S0002-9440(10)63074-X; Hinoi T, 2003, J BIOL CHEM, V278, P44608, DOI 10.1074/jbc.M307435200; Hinoi T, 2005, GASTROENTEROLOGY, V128, P946, DOI 10.1053/j.gastro.2005.01.003; Hinoi T, 2002, GASTROENTEROLOGY, V123, P1565, DOI 10.1053/gast.2002.36598; Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JAMES R, 1994, J BIOL CHEM, V269, P15229; KAIMAKTCHIEV V, 2004, MOD PATHOL; Keller MS, 2004, AM J PHYSIOL-GASTR L, V287, pG104, DOI 10.1152/ajpgi.00484.2003; Kohli M, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh009; Koo HM, 1996, CANCER RES, V56, P5211; LEIBOVITZ A, 1976, CANCER RES, V36, P4562; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; Lynch J, 2003, ONCOGENE, V22, P6395, DOI 10.1038/sj.onc.1206770; Lynch J, 2000, J BIOL CHEM, V275, P4499, DOI 10.1074/jbc.275.6.4499; Mallo GV, 1998, J BIOL CHEM, V273, P14030, DOI 10.1074/jbc.273.22.14030; Mallo GV, 1997, INT J CANCER, V74, P35, DOI 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1; McLean GW, 2004, GENE DEV, V18, P2998, DOI 10.1101/gad.316304; Moskaluk CA, 2003, MODERN PATHOL, V16, P913, DOI 10.1097/01.MP.0000086073.92773.55; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rawat VPS, 2004, P NATL ACAD SCI USA, V101, P817, DOI 10.1073/pnas.0305555101; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Rozek LS, 2005, CANCER RES, V65, P5488, DOI 10.1158/0008-5472.CAN-04-3645; Russo P, 2002, INT J CANCER, V100, P266, DOI 10.1002/ijc.10461; Sebolt-Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503; Sugao Y, 1997, HISTOPATHOLOGY, V31, P123, DOI 10.1046/j.1365-2559.1997.2320843.x; Suh E, 1996, MOL CELL BIOL, V16, P619; Tamai Y, 1999, CANCER RES, V59, P2965; Wicking C, 1998, ONCOGENE, V17, P657, DOI 10.1038/sj.onc.1201971; Woodford-Richens KL, 2001, BRIT J CANCER, V84, P1314, DOI 10.1054/bjoc.2001.1800; Yagi OK, 1999, BRIT J CANCER, V79, P440, DOI 10.1038/sj.bjc.6690068	58	43	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	15					2264	2272		10.1038/sj.onc.1209247	http://dx.doi.org/10.1038/sj.onc.1209247			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029RD	16314840				2022-12-17	WOS:000236581200013
J	Larsen, E; Reite, K; Nesse, G; Gran, C; Seeberg, E; Klungland, A				Larsen, E; Reite, K; Nesse, G; Gran, C; Seeberg, E; Klungland, A			Repair and mutagenesis at oxidized DNA lesions in the developing brain of wild-type and Ogg1(-/-) mice	ONCOGENE			English	Article						OGG1; DNA damage; mouse; brain; mutagenesis; DNA repair	BASE EXCISION-REPAIR; MUTATIONAL SPECTRUM; MMH/OGG1 GENE; DAMAGE; HOGG1; OGG1; 8-HYDROXYGUANINE; CANCER; ENZYME; POLYMORPHISM	OGG1 (8-oxoguanine DNA glycosylase-1) is one of the main DNA glycosylases present in mammalian cells. The enzyme removes 7,8-dihydro-8-oxoguanine (8-oxoG) lesions, believed to be the most important oxidized lesions due to their relatively high incidence and their miscoding properties. This study shows that in prenatal mice brains the repair capacity for 8-oxoG is 5-10-fold higher than in adult mice brains. Western blot analysis and repair activity in extracts from Ogg1(-/-) mice revealed that OGG1 was responsible for the efficient 8-oxoG removal from prenatal mice. To investigate how OGG1 protects against oxidative stress-induced mutagenesis, pregnant Big Blue/wild-type and Big Blue/Ogg1(-/-) mice were exposed to nontoxic doses of gamma radiation. A 2.5-fold increase in the mutation frequency in Ogg1(-/-) mouse brains was obtained by exposure to 3.5 Gy at day 19 postfertilization. This was largely due to GC to TA transversions, believed to originate from 8-oxoG mispairing with A during replication. Furthermore, rapid cell divisions seemed to be required for fixation of mutations, as a similar dose of radiation did not increase the mutation frequency, or the frequency of GC to TA transversion, in the adult brain.	Univ Oslo, Natl Hosp, Ctr Mol Biol & Neurosci, N-0027 Oslo, Norway; Univ Oslo, Natl Hosp, Inst Med Microbiol, Oslo, Norway; Univ Oslo, Inst Basic Med Sci, Dept Nutr, Oslo, Norway	University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway; University of Oslo	Larsen, E (corresponding author), Univ Oslo, Natl Hosp, Ctr Mol Biol & Neurosci, N-0027 Oslo, Norway.	elisabeth.larsen@medisin.uio.no	Klungland, Arne/X-1233-2019	Klungland, Arne/0000-0001-7274-3661				Aburatani H, 1997, CANCER RES, V57, P2151; Achanta G, 2004, CANCER RES, V64, P6233, DOI 10.1158/0008-5472.CAN-04-0494; AMES BN, 1989, MUTAT RES, V214, P41, DOI 10.1016/0027-5107(89)90196-6; Andrew SE, 1997, ONCOGENE, V15, P123, DOI 10.1038/sj.onc.1201180; Andrew SE, 1998, P NATL ACAD SCI USA, V95, P1126, DOI 10.1073/pnas.95.3.1126; Arai T, 2003, CANCER RES, V63, P4287; Audebert M, 2000, CANCER RES, V60, P4740; Bjelland S, 2003, MUTAT RES-FUND MOL M, V531, P37, DOI 10.1016/j.mrfmmm.2003.07.002; Bjoras M, 1997, EMBO J, V16, P6314, DOI 10.1093/emboj/16.20.6314; Bohr VA, 2002, FREE RADICAL BIO MED, V32, P804, DOI 10.1016/S0891-5849(02)00787-6; BREEN AP, 1995, FREE RADICAL BIO MED, V18, P1033, DOI 10.1016/0891-5849(94)00209-3; Dianov GL, 2001, PROG NUCLEIC ACID RE, V68, P285; Dou H, 2003, J BIOL CHEM, V278, P49679, DOI 10.1074/jbc.M308658200; Elahi A, 2002, CARCINOGENESIS, V23, P1229, DOI 10.1093/carcin/23.7.1229; FRANKS LM, 1974, GERONTOLOGY, V20, P21, DOI 10.1159/000211994; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hyun JW, 2000, ONCOGENE, V19, P4476, DOI 10.1038/sj.onc.1203787; Ishida T, 1999, INT J CANCER, V80, P18; Karahalil B, 2002, FASEB J, V16, P1895, DOI 10.1096/fj.02-0463com; Kasai H, 1997, MUTAT RES-REV MUTAT, V387, P147, DOI 10.1016/S1383-5742(97)00035-5; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; KOHLER SW, 1991, ENVIRON MOL MUTAGEN, V18, P316, DOI 10.1002/em.2850180421; Korr H, 1980, Adv Anat Embryol Cell Biol, V61, P1; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; Kucherlapati M, 2002, P NATL ACAD SCI USA, V99, P9924, DOI 10.1073/pnas.152321699; Larsen E, 2003, MOL CELL BIOL, V23, P5346, DOI 10.1128/MCB.23.15.5346-5353.2003; Le Marchand L, 2002, CANCER EPIDEM BIOMAR, V11, P409; Lin LH, 2000, J NEUROCHEM, V74, P1098; Lipton L, 2003, CANCER RES, V63, P7595; Lovell MA, 2000, BRAIN RES, V855, P116, DOI 10.1016/S0006-8993(99)02335-5; Lovell MA, 1999, J NEUROCHEM, V72, P771, DOI 10.1046/j.1471-4159.1999.0720771.x; Ludwig DL, 1998, MUTAT RES-DNA REPAIR, V409, P17, DOI 10.1016/S0921-8777(98)00039-1; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; MICHAELS ML, 1991, NUCLEIC ACIDS RES, V19, P3629, DOI 10.1093/nar/19.13.3629; Minowa O, 2000, P NATL ACAD SCI USA, V97, P4156, DOI 10.1073/pnas.050404497; Morland I, 2002, NUCLEIC ACIDS RES, V30, P4926, DOI 10.1093/nar/gkf618; Nishino H, 1996, MUTAT RES-FUND MOL M, V372, P97, DOI 10.1016/S0027-5107(96)00172-8; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Rosenquist TA, 2003, DNA REPAIR, V2, P581, DOI 10.1016/S1568-7864(03)00025-9; Sakumi K, 2003, CANCER RES, V63, P902; Shinmura K, 1998, JPN J CANCER RES, V89, P825, DOI 10.1111/j.1349-7006.1998.tb00635.x; Sieber OM, 2003, NEW ENGL J MED, V348, P791, DOI 10.1056/NEJMoa025283; Stuart GR, 2000, GENETICS, V154, P1291; Sugo N, 2000, EMBO J, V19, P1397, DOI 10.1093/emboj/19.6.1397; Tebbs RS, 1999, DEV BIOL, V208, P513, DOI 10.1006/dbio.1999.9232; VERJAT T, 2000, MUTAT RES, V25, P127; Wikman H, 2000, INT J CANCER, V88, P932, DOI 10.1002/1097-0215(20001215)88:6<932::AID-IJC15>3.0.CO;2-P; Xie YL, 2004, CANCER RES, V64, P3096, DOI 10.1158/0008-5472.CAN-03-3834	53	43	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	17					2425	2432		10.1038/sj.onc.1209284	http://dx.doi.org/10.1038/sj.onc.1209284			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	034RJ	16369492				2022-12-17	WOS:000236948000001
J	He, YY; Huang, JL; Chignell, CF				He, YY; Huang, JL; Chignell, CF			Cleavage of epidermal growth factor receptor by caspase during apoptosis is independent of its internalization	ONCOGENE			English	Article						EGFR; caspase; apoptosis; internalization	DOWN-REGULATION; HUMAN KERATINOCYTES; KINASE-ACTIVITY; CELL-DEATH; ACTIVATION; CANCER; UVA; CHOLESTEROL	Epidermal growth factor receptor ( EGFR) plays a critical role in cell proliferation, differentiation, and transformation. EGFR downregulation attenuates its signaling intensity and duration to maintain cellular homeostasis. Here, we report that during apoptosis EGFR is cleaved by activated caspase-3 or related proteases at its C-terminus domain. EGFR downregulation by activation of caspases is neither stimulus- nor cell type-specific. EGFR internalization during apoptosis required dynamin and cholesterol since dominant-negative dynamin (K44A) or cholesterol depletion by methyl-beta-cyclodextrin prevented EGFR internalization. However, EGFR downregulation did not require its internalization. The EGFR cleavage fragment was detected in the membrane blebs in addition to the cell pellets. Mutations at the consensus sequence (DXXD) at the C-terminus domain revealed that DVVD1012 and to a lesser extent DNPD1172 may be target sites for active recombinant caspase-3 in vitro and activated caspase-3 or related proteases in vivo. We have detected the N-terminus and C-terminus fragments in vitro and in vivo. A cleavage-deficient EGFR mutant delayed apoptosis process. We conclude that the evolutionarily conserved C-terminus domain of EGFR is the target of caspases and subjected to degradation during apoptosis to shut down its signaling.	NIEHS, Chem Pharmacol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	He, YY (corresponding author), NIEHS, Chem Pharmacol Lab, NIH, MD F0-06,111 Alexander Dr,PO 12233, Res Triangle Pk, NC 27709 USA.	he3@niehs.nih.gov			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES050046, Z01ES050046] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Akunda JK, 2004, FASEB J, V18, P185, DOI 10.1096/fj.02-1192fje; Bae SS, 2001, FEBS LETT, V491, P16, DOI 10.1016/S0014-5793(01)02167-6; Benoit V, 2004, CANCER RES, V64, P2684, DOI 10.1158/0008-5472.CAN-03-2914; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Di Fiore PP, 1999, CURR OPIN CELL BIOL, V11, P483, DOI 10.1016/S0955-0674(99)80069-6; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; He YY, 2004, J BIOL CHEM, V279, P53867, DOI 10.1074/jbc.M405781200; He YY, 2003, J BIOL CHEM, V278, P42457, DOI 10.1074/jbc.M303376200; He YY, 2003, J BIOL CHEM, V278, P8058, DOI 10.1074/jbc.M207781200; HELDIN CH, 1979, NATURE, V282, P419, DOI 10.1038/282419a0; Herbst RS, 2004, NAT REV CANCER, V4, P956, DOI 10.1038/nrc1506; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Nusbaum P, 2005, J BIOL CHEM, V280, P5843, DOI 10.1074/jbc.M413405200; Park IC, 2000, INT J ONCOL, V16, P1243; Ricci JE, 2004, CELL, V117, P773, DOI 10.1016/j.cell.2004.05.008; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; Rowinsky EK, 2004, ANNU REV MED, V55, P433, DOI 10.1146/annurev.med.55.091902.104433; Stennicke HR, 2000, BIOCHEM J, V350, P563, DOI 10.1042/0264-6021:3500563; Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tulasne D, 2004, MOL CELL BIOL, V24, P10328, DOI 10.1128/MCB.24.23.10328-10339.2004; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zhuang SG, 2003, ONCOGENE, V22, P4413, DOI 10.1038/sj.onc.1206604	29	43	44	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2006	25	10					1521	1531		10.1038/sj.onc.1209184	http://dx.doi.org/10.1038/sj.onc.1209184			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16247443				2022-12-17	WOS:000235890400009
J	Tang, S; Tao, M; McCoy, J; Zheng, ZM				Tang, S; Tao, M; McCoy, J; Zheng, ZM			Short-term induction and long-term suppression of HPV16 oncogene silencing by RNA interference in cervical cancer cells	ONCOGENE			English	Article						HPV16; E6; E7; oncogene; siRNA; cervical cancer	HUMAN-PAPILLOMAVIRUS TYPE-16; VIRAL SUPPRESSOR; MESSENGER-RNA; IN-VITRO; EXPRESSION; E6; GENE; E7; ONCOPROTEIN; NUCLEAR	RNA interference-mediated gene silencing has the potential to block gene expression. A synthetic double-stranded small interfering RNA (siRNA) based on a sequence motif of 21 nucleotides from human papillomavirus 16 (HPV16) E6E7 bicistronic RNA was found to be a potent siRNA that suppresses expression of both the E6 and E7 oncogenes in HPV16(+) CaSki and SiHa cells. When stably expressed as a short hairpin RNA in these cells, however, siRNA silencing of E6 and E7 expression was efficient only at early cell passages, but became inefficient with increased cell passages despite the continued expression of the siRNA at the same level. The loss of the siRNA function was duplicable in stable p53 siRNA cells, but not in stable lamin A/C siRNA cells, suggesting that it is gene selective. The cells resistant to siRNA function retained normal siRNA processing, duplex unwinding and degradation of the unwound sense strand and RNA-induced silencing complex formation, suggesting that loss of the siRNA function occurred at a later step. Surprisingly, the siRNA-resistant cells were found to express notably a cytoplasmic protein of similar to 50 kDa that specifically and characteristically interacted with the unwound, antisense strand E7 siRNA. Altogether, our data indicate that a potent siRNA targeting to an essential or regulatory gene might induce a cell to develop siRNA-suppressive function.	NCI, HIV & AIDS Malignancy Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; NHLBI, Flow Cytometry Core Facil, NIH, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Zheng, ZM (corresponding author), NCI, HIV & AIDS Malignancy Branch, Ctr Canc Res, NIH, Bldg 10,Room10S255,MSC 1868,10 Ctr Dr, Bethesda, MD 20892 USA.	zhengt@exchange.nih.gov	Tang, Shuang/F-9115-2014	Tang, Shuang/0000-0002-3084-0903; Zheng, Zhi-Ming/0000-0001-5547-7912	NATIONAL CANCER INSTITUTE [Z01SC010357] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [Z01 SC010357-06] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AEBI U, 1986, NATURE, V323, P560, DOI 10.1038/323560a0; Boyer SN, 1996, CANCER RES, V56, P4620; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Butz K, 2003, ONCOGENE, V22, P5938, DOI 10.1038/sj.onc.1206894; Doench JG, 2003, GENE DEV, V17, P438, DOI 10.1101/gad.1064703; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Gonzalez SL, 2001, J VIROL, V75, P7583, DOI 10.1128/JVI.75.16.7583-7591.2001; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P10978, DOI 10.1073/pnas.97.20.10978; Haley B, 2004, NAT STRUCT MOL BIOL, V11, P599, DOI 10.1038/nsmb780; Hall AHS, 2003, J VIROL, V77, P6066, DOI 10.1128/JVI.77.10.6066-6069.2003; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Howley P. M., 2001, FIELDS VIROLOGY, V2, P2197; Jiang M, 2002, ONCOGENE, V21, P6041, DOI 10.1038/sj.onc.1205878; Kasschau KD, 2003, DEV CELL, V4, P205, DOI 10.1016/S1534-5807(03)00025-X; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Knight SW, 2002, MOL CELL, V10, P809, DOI 10.1016/S1097-2765(02)00649-4; Lecellier CH, 2005, SCIENCE, V308, P557, DOI 10.1126/science.1108784; Li HW, 2002, SCIENCE, V296, P1319, DOI 10.1126/science.1070948; Li WX, 2004, P NATL ACAD SCI USA, V101, P1350, DOI 10.1073/pnas.0308308100; Lu SH, 2004, J VIROL, V78, P12868, DOI 10.1128/JVI.78.23.12868-12876.2004; Mallory AC, 2002, P NATL ACAD SCI USA, V99, P15228, DOI 10.1073/pnas.232434999; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; Mayeda A, 1999, METH MOL B, V118, P309; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; PFEFFER S, 2003, CURRETN PROTOCOLS MO; Pham JW, 2004, CELL, V117, P83, DOI 10.1016/S0092-8674(04)00258-2; Provost P, 2002, EMBO J, V21, P5864, DOI 10.1093/emboj/cdf578; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; Scadden ADJ, 2001, EMBO REP, V2, P1107, DOI 10.1093/embo-reports/kve244; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schulze A, 1998, J VIROL, V72, P2323, DOI 10.1128/JVI.72.3.2323-2334.1998; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; Soldan SS, 2005, J VIROL, V79, P234, DOI 10.1128/JVI.79.1.234-244.2005; Tang S, 2002, J BIOL CHEM, V277, P14547, DOI 10.1074/jbc.M111308200; Tao MF, 2003, J VIROL, V77, P13232, DOI 10.1128/JVI.77.24.13232-13247.2003; Tomari Y, 2004, CELL, V116, P831, DOI 10.1016/S0092-8674(04)00218-1; VINDELOV LL, 1977, VIRCHOWS ARCH B, V24, P227; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; YAGINUMA Y, 1991, CANCER RES, V51, P6506; Yang WD, 2005, J BIOL CHEM, V280, P3946, DOI 10.1074/jbc.M407876200; Yoshinouchi M, 2003, MOL THER, V8, P762, DOI 10.1016/j.ymthe.2003.08.004; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zeng Y, 2003, P NATL ACAD SCI USA, V100, P9779, DOI 10.1073/pnas.1630797100; Zhang HD, 2002, EMBO J, V21, P5875, DOI 10.1093/emboj/cdf582; Zheng ZM, 2004, J MOL BIOL, V337, P1091, DOI 10.1016/j.jmb.2004.02.023; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	51	43	48	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2094	2104		10.1038/sj.onc.1209244	http://dx.doi.org/10.1038/sj.onc.1209244			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16369495	Green Accepted			2022-12-17	WOS:000236359700012
J	Vahsen, N; Cande, C; Dupaigne, P; Giordanetto, F; Kroemer, RT; Herker, E; Scholz, S; Modjtahedi, N; Madeo, F; Le Cam, E; Kroemer, G				Vahsen, N; Cande, C; Dupaigne, P; Giordanetto, F; Kroemer, RT; Herker, E; Scholz, S; Modjtahedi, N; Madeo, F; Le Cam, E; Kroemer, G			Physical interaction of apoptosis-inducing factor with DNA and RNA	ONCOGENE			English	Article						apoptosis; chromatin condensation; mitochondria	CELL-DEATH; REGULATES APOPTOSIS; ELECTRON-MICROSCOPY; CRYSTAL-STRUCTURE; CANCER-CELLS; AIF; CASPASE; PROTEIN; DEGRADATION; PATHWAYS	Apoptosis-inducing factor (AIF) is a mitochondrial flavoprotein, which upon apoptosis induction translocates to the nucleus where it interacts with DNA by virtue of positive charges clustered on the AIF surface. Here we show that the AIF interactome, as determined by mass spectroscopy, contains a large panel of ribonucleoproteins, which apparently bind to AIF through the RNA moiety. However, AIF is devoid of any detectable RNAse activity both in vitro and in vivo. Recombinant AIF can directly bind to DNA as well as to RNA. This binding can be visualized by electron microscopy, revealing that AIF can condense DNA, showing a preferential binding to single-stranded over double-stranded DNA. AIF also binds and aggregates single-stranded and structured RNA in vitro. Single-stranded poly A, poly G and poly C, as well double-stranded A/T and G/C RNA competed with DNA for AIF binding with a similar efficiency, thus corroborating a computer-calculated molecular model in which the binding site within AIF is the same for distinct nucleic acid species, without a clear sequence specificity. Among the preferred electron donors and acceptors of AIF, nicotine adenine dinucleotide phosphate (NADP) was particularly efficient in enhancing the generation of higher-order AIF/DNA and AIF/RNA complexes. Altogether, these data support a model in which a direct interaction of AIF contributes to the compaction of nucleic acids within apoptotic cells.	Inst Gustave Roussy, Ctr Natl Rech Sci, UMR 8125, F-94805 Villejuif, France; Inst Gustave Roussy, CNRS, Lab Microscopie Mol & Cellulaire, UMR 8126,IGR,UPS, F-94805 Villejuif, France; AstraZeneca R&D, Molndal, Sweden; Sanofi Aventis, Ctr Rech VA, Vitry Sur Seine, France; Karl Franzens Univ Graz, IMB, A-8010 Graz, Austria	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; AstraZeneca; Sanofi-Aventis; Sanofi France; University of Graz	Kroemer, G (corresponding author), Inst Gustave Roussy, Ctr Natl Rech Sci, UMR 8125, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	MODJTAHEDI, Nazanine/D-4377-2017; KROEMER, Guido/B-4263-2013; Giordanetto, Fabrizio/E-2811-2012; Dupaigne, Pauline/C-6873-2019; Kroemer, Guido/AAY-9859-2020; Herker, Eva/AAQ-1944-2021; Herker, Eva/B-9699-2014	KROEMER, Guido/0000-0002-9334-4405; Herker, Eva/0000-0001-9644-2484; Le cam, Eric/0000-0002-6832-6117; Dupaigne, Pauline/0000-0001-7033-4055; Madeo, Frank/0000-0002-5070-1329; MODJTAHEDI, NAZANINE/0000-0002-1832-0710				Asselbergs FAM, 2003, ANAL BIOCHEM, V318, P221, DOI 10.1016/S0003-2697(03)00218-5; Beloin C, 2003, J BIOL CHEM, V278, P5333, DOI 10.1074/jbc.M207489200; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Cande C, 2004, J CELL SCI, V117, P4461, DOI 10.1242/jcs.01356; Cande C, 2004, ONCOGENE, V23, P1514, DOI 10.1038/sj.onc.1207279; Cande C, 2002, J CELL SCI, V115, P4727, DOI 10.1242/jcs.00210; Cheung ECC, 2005, J NEUROSCI, V25, P1324, DOI 10.1523/JNEUROSCI.4261-04.2005; Cregan SP, 2002, J CELL BIOL, V158, P507, DOI 10.1083/jcb.200202130; Cregan SP, 2004, ONCOGENE, V23, P2785, DOI 10.1038/sj.onc.1207517; CRISSMAN HA, 1985, SCIENCE, V228, P1321, DOI 10.1126/science.2408339; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Delain E, 1995, VISUALIZATION NUCL A, P35; DUBOCHET J, 1971, J ULTRA MOL STRUCT R, V35, P147, DOI 10.1016/S0022-5320(71)80148-X; Gallego MA, 2004, ONCOGENE, V23, P6282, DOI 10.1038/sj.onc.1207835; Garrido C, 2004, CURR OPIN CELL BIOL, V16, P639, DOI 10.1016/j.ceb.2004.09.008; Giordanetto F, 2004, J CHEM INF COMP SCI, V44, P882, DOI 10.1021/ci0499626; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Gurbuxani S, 2003, ONCOGENE, V22, P6669, DOI 10.1038/sj.onc.1206794; Halicka HD, 2000, EXP CELL RES, V260, P248, DOI 10.1006/excr.2000.5027; Hameau L, 2001, J VIROL, V75, P3301, DOI 10.1128/JVI.75.7.3301-3313.2001; Hassan M, 1996, MOL DIVERS, V2, P64, DOI 10.1007/BF01718702; Herker E, 2004, J CELL BIOL, V164, P501, DOI 10.1083/jcb.200310014; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kang YH, 2004, CANCER RES, V64, P8960, DOI 10.1158/0008-5472.CAN-04-1830; King KL, 2000, CELL DEATH DIFFER, V7, P994, DOI 10.1038/sj.cdd.4400731; Klein JA, 2002, NATURE, V419, P367, DOI 10.1038/nature01034; Kroemer G, 2005, NAT MED, V11, P725, DOI 10.1038/nm1263; Le Cam E, 1998, BIOPOLYMERS, V45, P217, DOI 10.1002/(SICI)1097-0282(199803)45:3&lt;217::AID-BIP4&gt;3.0.CO;2-U; Loeffler M, 2001, FASEB J, V15, P758, DOI 10.1096/fj.00-0388com; Mate MJ, 2002, NAT STRUCT BIOL, V9, P442, DOI 10.1038/nsb793; Matsumori Y, 2005, J CEREBR BLOOD F MET, V25, P899, DOI 10.1038/sj.jcbfm.9600080; McMartin C, 1997, J COMPUT AID MOL DES, V11, P333, DOI 10.1023/A:1007907728892; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; Otera H, 2005, EMBO J, V24, P1375, DOI 10.1038/sj.emboj.7600614; Park MT, 2005, BLOOD, V105, P1724, DOI 10.1182/blood-2004-07-2938; Parrish JZ, 2003, MOL CELL, V11, P987, DOI 10.1016/S1097-2765(03)00095-9; Polster BM, 2005, J BIOL CHEM, V280, P6447, DOI 10.1074/jbc.M413269200; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Rutjes SK, 1999, J BIOL CHEM, V274, P24799, DOI 10.1074/jbc.274.35.24799; Senda T, 2000, J MOL BIOL, V304, P397, DOI 10.1006/jmbi.2000.4200; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Treuner K, 1996, J MOL BIOL, V259, P104, DOI 10.1006/jmbi.1996.0305; Urbano A, 2005, EMBO J, V24, P2815, DOI 10.1038/sj.emboj.7600746; Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461; Wissing S, 2004, J CELL BIOL, V166, P969, DOI 10.1083/jcb.200404138; Ye H, 2002, NAT STRUCT BIOL, V9, P680, DOI 10.1038/nsb836; Yuste VJ, 2005, J BIOL CHEM, V280, P35670, DOI 10.1074/jbc.M504015200; Zhu CL, 2003, J NEUROCHEM, V86, P306, DOI 10.1046/j.1471-4159.2003.01832.x	49	43	45	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	12					1763	1774		10.1038/sj.onc.1209206	http://dx.doi.org/10.1038/sj.onc.1209206			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16278674				2022-12-17	WOS:000236013700008
J	Williams, YN; Masuda, M; Sakurai-Yageta, M; Maruyama, T; Shibuya, M; Murakami, Y				Williams, YN; Masuda, M; Sakurai-Yageta, M; Maruyama, T; Shibuya, M; Murakami, Y			Cell adhesion and prostate tumor-suppressor activity of TSLL2/IGSF4C, an immunoglobulin superfamily molecule homologous to TSLC1/IGSF4	ONCOGENE			English	Article						TSLL2/IGSF4C; cell adhesion; tumor-suppressor gene; prostate cancer; TSLC1/IGSF4	CANCER AGGRESSIVENESS; PROMOTER METHYLATION; TSLC1 GENE; TUMORIGENICITY; IDENTIFICATION; INVOLVEMENT; LINKAGE; CLONING; TSLL2; LINE	The TSLL2/ IGSF4C encodes an immunoglobulin (Ig) superfamily molecule showing significant homology with a lung tumor suppressor, TSLC1. The TSLL2 protein of 55 kDa is mainly expressed in the kidney, bladder, and prostate in addition to the brain. Here, we report the biological signifance of TSLL2 in the urinary tissues. An immunohistochemical study reveals that TSLL2 is expressed at the cell-cell attachment sites in the renal tubules, the transitional epithelia of the bladder, and the glandular epithelia of the prostate. Confocal microscopy analysis demonstrates that TSLL2 is localized in the lateral membranes in polarized Mardin-Darby canine kidney (MDCK) cells. TSLL2 forms homo-dimers and its overexpression induces aggregation of suspended MDCK cells in a Ca2+/Mg2+ -independent manner, suggesting that it is involved in cell adhesion through homophilic trans-interaction. The TSLL2 gene is mapped on the chromosomal region 19q13.2, whose loss of heterozygosity has been frequently reported in prostate cancer. TSLL2 protein is lost in nine of nine primary prostate cancers and in a prostate cancer cell, PPC-1. Introduction of TSLL2 into PPC-1 strongly suppresses subcutaneous tumor formation in nude mice. These results suggest that TSLL2 is a new member of the Ig superfamily cell adhesion molecules and is a tumor-suppressor candidate in prostate cancer.	Natl Canc Ctr, Res Inst, Tumor Suppress & Funct Genom Project, Chuo Ku, Tokyo 1040045, Japan; Natl Canc Ctr, Inst Med Sci, Dept Genet, Minato Ku, Tokyo 1040045, Japan	National Cancer Center - Japan; National Cancer Center - Japan	Murakami, Y (corresponding author), Natl Canc Ctr, Res Inst, Tumor Suppress & Funct Genom Project, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	ymurakam@gan2.ncc.go.jp	Sakurai-Yageta, Mika/U-1842-2019	Sakurai-Yageta, Mika/0000-0001-5606-3324				Astbury C, 2001, GENE CHROMOSOME CANC, V31, P143, DOI 10.1002/gcc.1128; Benson DL, 2000, TRENDS CELL BIOL, V10, P473, DOI 10.1016/S0962-8924(00)01838-9; Biederer T, 2002, SCIENCE, V297, P1525, DOI 10.1126/science.1072356; BROTHMAN AR, 1991, J UROLOGY, V145, P1088, DOI 10.1016/S0022-5347(17)38540-3; Fujita E, 2003, EXP CELL RES, V287, P57, DOI 10.1016/S0014-4827(03)00095-8; Fukami T, 2003, GENE, V323, P11, DOI 10.1016/j.gene.2003.09.018; Fukami T, 2003, INT J CANCER, V107, P53, DOI 10.1002/ijc.11348; Fukuhara H, 2002, JPN J CANCER RES, V93, P605, DOI 10.1111/j.1349-7006.2002.tb01297.x; Fukuhara H, 2001, ONCOGENE, V20, P5401, DOI 10.1038/sj.onc.1204696; Gao AC, 1999, PROSTATE, V38, P46, DOI 10.1002/(SICI)1097-0045(19990101)38:1<46::AID-PROS6>3.0.CO;2-9; Gomyo H, 1999, GENOMICS, V62, P139, DOI 10.1006/geno.1999.6001; Hynes RO, 1999, TRENDS CELL BIOL, V9, pM33, DOI 10.1016/S0962-8924(99)01667-0; Ito T, 2003, CANCER RES, V63, P6320; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; Masuda M, 2002, J BIOL CHEM, V277, P31014, DOI 10.1074/jbc.M203620200; Murakami Y, 2005, CANCER SCI, V96, P543, DOI 10.1111/j.1349-7006.2005.00089.x; Murakami Y, 2002, ONCOGENE, V21, P6936, DOI 10.1038/sj.onc.1205825; Neville PJ, 2003, GENE CHROMOSOME CANC, V36, P332, DOI 10.1002/gcc.10165; Ozen M, 2000, ANTICANCER RES, V20, P1905; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Satoh-Horikawa K, 2000, J BIOL CHEM, V275, P10291, DOI 10.1074/jbc.275.14.10291; Shingai T, 2003, J BIOL CHEM, V278, P35421, DOI 10.1074/jbc.M305387200; Slager SL, 2003, AM J HUM GENET, V72, P759, DOI 10.1086/368230; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Takai Y, 2003, CANCER SCI, V94, P655, DOI 10.1111/j.1349-7006.2003.tb01499.x; Wakayama T, 2001, MOL REPROD DEV, V60, P158, DOI 10.1002/mrd.1072; YOSHIDA C, 1982, CELL, V28, P217, DOI 10.1016/0092-8674(82)90339-7	27	43	49	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	10					1446	1453		10.1038/sj.onc.1209192	http://dx.doi.org/10.1038/sj.onc.1209192			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16261159				2022-12-17	WOS:000235890400002
J	Yan, SR; Joseph, RR; Rosen, K; Reginato, MJ; Jackson, A; Allaire, N; Brugge, JS; Jobin, C; Stadnyk, AW				Yan, SR; Joseph, RR; Rosen, K; Reginato, MJ; Jackson, A; Allaire, N; Brugge, JS; Jobin, C; Stadnyk, AW			Activation of NF-kappa B following detachment delays apoptosis in intestinal epithelial cells	ONCOGENE			English	Article						anoikis; intestinal epithelial cell; apoptosis; NF-kappa B; detachment	INDUCED NEUTROPHIL APOPTOSIS; ULCERATIVE-COLITIS; GENE-EXPRESSION; KINASE; ALPHA; RECEPTOR; ANOIKIS; PHOSPHORYLATION; INHIBITION; CANCER	We reported earlier that IL-1 beta, an NF-kappa B-regulated cytokine, was made by intestinal epithelial cells during detachment-induced apoptosis (anoikis) and that IL-1 was antiapoptotic for detached cells. Since surviving anoikis is a prerequisite for cancer progression and metastases, we are further exploring the link between anoikis and cytokines. Here we determined that multiple genes are expressed following detachment including a number of NF-kappa B- regulated products and therefore aimed to determine whether NF-kappa B signalling plays any role in regulating apoptosis. Using Western blotting, we detected that I kappa B alpha becomes phosphorylated immediately following detachment and that levels of phospho-I kappa B alpha peaked within 20 min. Phosphorylation of I kappa B alpha was followed by Rel A (p65) nuclear translocation. Increased NF-kappa B activity following detachment was confirmed using the detection of NF-kappa B-promoted luciferase gene expression delivered by adenovirus infection. Infection of cells with adenovirus expressing a super-repressor I kappa B alpha protein and pharmacological inhibitors of NF-kappa B resulted in the failure to phosphorylate I kappa B alpha, a more rapid activation of caspases and earlier apoptosis. We also detected that I kappa B kinase alpha (IKK alpha) and not IKK beta became phosphorylated following detachment. Since IKK alpha is activated by NF-kappa B-inducing kinase (NIK), we overexpressed native NIK using an adenovirus vector that resulted in enhanced phospho-I kappa B alpha and nuclear p65 in detached cells compared to control detached cells but did not result in a significantly greater number of cells surviving to 24 h. We conclude that detachment directly activates NF-kappa B, which, in addition to launching an inflammatory cytokine wave, contributes to a delay in apoptosis in intestinal epithelial cells.	Dalhousie Univ, Dept Pediat, Halifax, NS B3H 4R2, Canada; Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS B3H 4R2, Canada; Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS B3H 4R2, Canada; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Aventis Pharmaceut, Cambridge, MA USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA	Dalhousie University; Dalhousie University; Dalhousie University; Harvard University; Harvard Medical School; Sanofi-Aventis; University of North Carolina; University of North Carolina Chapel Hill	Stadnyk, AW (corresponding author), IWK Hlth Ctr, Mucosal Immunol Res, 5850 Univ Ave, Halifax, NS B3K 6R8, Canada.	astadnyk@dal.ca	Reginato, Mauricio/I-6155-2013	Reginato, Mauricio/0000-0002-7541-4094	NCI NIH HHS [R01 CA105134] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA105134] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Bader T, 1996, J IMMUNOL, V157, P3089; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Beinke S, 2004, BIOCHEM J, V382, P393, DOI 10.1042/BJ20040544; BETT AJ, 1994, P NATL ACAD SCI USA, V91, P8802, DOI 10.1073/pnas.91.19.8802; Biswas DK, 2003, CANCER RES, V63, P290; Bonner S, 2001, INFECT IMMUN, V69, P3143, DOI 10.1128/IAI.69.5.3143-3149.2001; Chen YH, 2000, BIOCHEM BIOPH RES CO, V274, P576, DOI 10.1006/bbrc.2000.3176; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Clevers H, 2004, CELL, V118, P671, DOI 10.1016/j.cell.2004.09.005; Colell A, 2002, FEBS LETT, V526, P15, DOI 10.1016/S0014-5793(02)03106-X; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Elewaut D, 1999, J IMMUNOL, V163, P1457; Evertsson S, 2002, INT J MOL MED, V10, P547; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Gill JS, 2000, NEUROBIOL DIS, V7, P448, DOI 10.1006/nbdi.2000.0312; GILLEN CD, 1994, GUT, V35, P1590, DOI 10.1136/gut.35.11.1590; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; Jijon H, 2004, CELL SIGNAL, V16, P1023, DOI 10.1016/j.cellsig.2004.02.005; Jobin C, 1997, J IMMUNOL, V158, P226; Jobin C, 1998, J IMMUNOL, V160, P410; Jobin C, 1998, GUT, V42, P779, DOI 10.1136/gut.42.6.779; Karlen P, 1999, AM J GASTROENTEROL, V94, P1047; Kuhnel F, 2000, J BIOL CHEM, V275, P6421, DOI 10.1074/jbc.275.9.6421; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; Ma A, 2001, MOL BIOL CELL, V12, P1; MAHER PA, 1993, P NATL ACAD SCI USA, V90, P11177, DOI 10.1073/pnas.90.23.11177; Miller TL, 2002, IMMUNOLOGY, V105, P101, DOI 10.1046/j.0019-2805.2001.01352.x; Niwa M, 1999, EUR J PHARMACOL, V371, P59, DOI 10.1016/S0014-2999(99)00145-4; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; Ramakrishnan P, 2004, IMMUNITY, V21, P477, DOI 10.1016/j.immuni.2004.08.009; Rosen K, 2002, J BIOL CHEM, V277, P46123, DOI 10.1074/jbc.M207883200; Russo MP, 2004, CELL SIGNAL, V16, P741, DOI 10.1016/j.cellsig.2003.11.007; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Savkovic SD, 1997, AM J PHYSIOL-CELL PH, V273, pC1160, DOI 10.1152/ajpcell.1997.273.4.C1160; Scaife CL, 2002, CANCER RES, V62, P6870; Shanmugathasan M, 2000, PATHOL INT, V50, P273, DOI 10.1046/j.1440-1827.2000.01047.x; Shibata Y, 1996, J IMMUNOL, V156, P772; STADNYK AW, 1995, EXP CELL RES, V220, P298, DOI 10.1006/excr.1995.1319; Strater J, 1996, GASTROENTEROLOGY, V110, P1776, DOI 10.1053/gast.1996.v110.pm8964403; Theilhaber J, 2001, J COMPUT BIOL, V8, P585, DOI 10.1089/106652701753307502; Vachon PH, 2002, GASTROENTEROLOGY, V123, P1980, DOI 10.1053/gast.2002.37072; van der Woude CJ, 2004, APOPTOSIS, V9, P123, DOI 10.1023/B:APPT.0000018794.26438.22; Ward C, 1999, J BIOL CHEM, V274, P4309, DOI 10.1074/jbc.274.7.4309; Waterhouse CCM, 1999, CELL IMMUNOL, V193, P1, DOI 10.1006/cimm.1999.1468; Waterhouse CCM, 2001, EXP CELL RES, V269, P109, DOI 10.1006/excr.2001.5303; Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3; Yamashita K, 1999, BLOOD, V93, P674, DOI 10.1182/blood.V93.2.674.402k26_674_685; Yang CL, 2001, J BIOL CHEM, V276, P47277, DOI 10.1074/jbc.M105396200; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533	50	43	45	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	43					6482	6491		10.1038/sj.onc.1208810	http://dx.doi.org/10.1038/sj.onc.1208810			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	968ZV	16007176	Green Accepted			2022-12-17	WOS:000232204100002
J	Grm, HS; Massimi, P; Gammoh, N; Banks, L				Grm, HS; Massimi, P; Gammoh, N; Banks, L			Crosstalk between the human papillomavirus E2 transcriptional activator and the E6 oncoprotein	ONCOGENE			English	Article						HPV E6; HPV E2; replication; transactivation	DNA-BINDING DOMAIN; UBIQUITIN-PROTEIN LIGASE; CERVICAL-CARCINOMA CELLS; DISCS LARGE PROTEIN; P53 IN-VITRO; HPV-18 E6; HIGH-RISK; MEDIATED DEGRADATION; HUMAN KERATINOCYTES; TYPE-16 DNA	Human papillomaviruses are the causative agents of cervical cancer. Previous studies have shown that loss of the viral E2 protein during malignant progression is an important feature of HPV-induced malignancy due to the resulting uncontrolled expression of the viral oncoproteins E6 and E7. We now show however that the viral E2 and E6 proteins are both capable of regulating each other's activity. When coexpressed, E2 and E6 induce marked changes in the pattern of each other's expression, with preferential accumulation in nuclear speckles. The two proteins interact directly, resulting in changes in the substrate specificities of E6 and the biochemical activities of E2. Thus, while E6 efficiently degrades its PDZ domain-containing substrates in the absence of E2, this activity is greatly diminished when E2 is present. Likewise, E2 alone drives both viral DNA replication and viral gene expression. However, in the presence of E6, viral DNA replication is inhibited while the transcriptional activity of E2 is elevated. These studies de. ne a far more complex pattern of interaction between E2 and E6 than was previously thought and redefines the possible consequences of loss of E2 with respect to uncontrolled E6 activity and consequent malignant progression.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB)	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.	banks@icgeb.org						ANDROPHY EJ, 1987, NATURE, V325, P70, DOI 10.1038/325070a0; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; Bechtold V, 2003, J VIROL, V77, P2021, DOI 10.1128/JVI.77.3.2021-2028.2003; BEDROSIAN CL, 1990, VIROLOGY, V174, P557, DOI 10.1016/0042-6822(90)90109-5; Borden KLB, 2002, MOL CELL BIOL, V22, P5259, DOI 10.1128/MCB.22.15.5259-5269.2002; BOUVARD V, 1994, EMBO J, V13, P5451, DOI 10.1002/j.1460-2075.1994.tb06880.x; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; CRUM CP, 1989, AM J PATHOL, V134, P1183; Day PM, 1998, J VIROL, V72, P142, DOI 10.1128/JVI.72.1.142-150.1998; DELMARPENA L, 2002, PERSPECTIVES MED VIR, V8, P31; Demeret C, 2003, ONCOGENE, V22, P168, DOI 10.1038/sj.onc.1206108; Desaintes C, 1999, ONCOGENE, V18, P4538, DOI 10.1038/sj.onc.1202818; Desaintes C, 1997, EMBO J, V16, P504, DOI 10.1093/emboj/16.3.504; DOWHANICK JJ, 1995, J VIROL, V69, P7791, DOI 10.1128/JVI.69.12.7791-7799.1995; Dundr M, 2001, BIOCHEM J, V356, P297, DOI 10.1042/0264-6021:3560297; DURST M, 1992, VIROLOGY, V189, P132, DOI 10.1016/0042-6822(92)90688-L; DURST M, 1985, J GEN VIROL, V66, P1515, DOI 10.1099/0022-1317-66-7-1515; Francis DA, 2000, J VIROL, V74, P2679, DOI 10.1128/JVI.74.6.2679-2686.2000; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Gardiol D, 1998, J GEN VIROL, V79, P1963, DOI 10.1099/0022-1317-79-8-1963; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513; Guccione E, 2004, INT J CANCER, V110, P928, DOI 10.1002/ijc.20184; Guccione E, 2002, VIROLOGY, V293, P20, DOI 10.1006/viro.2001.1290; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; Hegde RS, 1998, J MOL BIOL, V284, P1479, DOI 10.1006/jmbi.1998.2260; Heino P, 2000, VIROLOGY, V276, P304, DOI 10.1006/viro.2000.0342; HIGGINS GD, 1992, J GEN VIROL, V73, P2047, DOI 10.1099/0022-1317-73-8-2047; Howley PM, 2001, VIROLOGY, P2197; Huang S, 1996, J CELL BIOL, V133, P719, DOI 10.1083/jcb.133.4.719; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HWANG ES, 1993, J VIROL, V67, P3720, DOI 10.1128/JVI.67.7.3720-3729.1993; JIMENEZGARCIA LF, 1993, CELL, V73, P47, DOI 10.1016/0092-8674(93)90159-N; Kuhne C, 2000, ONCOGENE, V19, P5884, DOI 10.1038/sj.onc.1203988; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee D, 2000, J BIOL CHEM, V275, P7045, DOI 10.1074/jbc.275.10.7045; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; LIU JS, 2002, PERSP MED V, V8, P53; Liu Y, 1999, J VIROL, V73, P7297, DOI 10.1128/JVI.73.9.7297-7307.1999; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Massimi P, 1996, ONCOGENE, V12, P2325; Massimi P, 1999, ONCOGENE, V18, P7748, DOI 10.1038/sj.onc.1203208; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; Misteli T, 1997, NATURE, V387, P523, DOI 10.1038/387523a0; MOEN PT, 1995, HUM MOL GENET, V4, P1779, DOI 10.1093/hmg/4.suppl_1.1779; Muller A, 2002, J VIROL, V76, P11042, DOI 10.1128/JVI.76.21.11042-11053.2002; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; MUNGER K, 1989, J VIROL, V63, P4417; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; NAKAGAWA S, 1995, VIROLOGY, V212, P535, DOI 10.1006/viro.1995.1511; Nguyen ML, 2003, J VIROL, V77, P6957, DOI 10.1128/JVI.77.12.6957-6964.2003; Okoye A, 2005, VIRUS RES, V108, P1, DOI 10.1016/j.virusres.2004.07.004; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; PICCINI A, 1995, J GEN VIROL, V76, P2909, DOI 10.1099/0022-1317-76-11-2909; Piccini A, 1997, J GEN VIROL, V78, P1963, DOI 10.1099/0022-1317-78-8-1963; Pim D, 2000, ONCOGENE, V19, P719, DOI 10.1038/sj.onc.1203374; Pim D, 1999, ONCOGENE, V18, P7403, DOI 10.1038/sj.onc.1203134; Pim D, 2002, ONCOGENE, V21, P8140, DOI 10.1038/sj.onc.1206026; PIM D, 1994, ONCOGENE, V9, P1869; Pim D, 1997, ONCOGENE, V15, P257, DOI 10.1038/sj.onc.1201202; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Sedman J, 1995, EMBO J, V14, P6218, DOI 10.1002/j.1460-2075.1995.tb00312.x; Sherman L, 1996, J VIROL, V70, P3269, DOI 10.1128/JVI.70.5.3269-3279.1996; Stein GS, 2000, J CELL SCI, V113, P2527; STOLER MH, 1989, VIROLOGY, V172, P331, DOI 10.1016/0042-6822(89)90135-9; STOREY A, 1995, J GEN VIROL, V76, P819, DOI 10.1099/0022-1317-76-4-819; TAURINA M, 1993, ONCOGENE, V8, P3165; Thomas JT, 1999, P NATL ACAD SCI USA, V96, P8449, DOI 10.1073/pnas.96.15.8449; Thomas M, 2001, ONCOGENE, V20, P5431, DOI 10.1038/sj.onc.1204719; Thomas M, 2002, ONCOGENE, V21, P5088, DOI 10.1038/sj.onc.1205668; Thomas M, 1996, ONCOGENE, V13, P471; Webster K, 2000, J BIOL CHEM, V275, P87, DOI 10.1074/jbc.275.1.87; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	78	43	49	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2005	24	33					5149	5164		10.1038/sj.onc.1208701	http://dx.doi.org/10.1038/sj.onc.1208701			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	951XB	15856010				2022-12-17	WOS:000230964600002
J	Lee, YJ; Lee, DH; Cho, CK; Chung, HY; Bae, S; Jhon, GJ; Soh, JW; Jeoung, DI; Lee, SJ; Lee, YS				Lee, YJ; Lee, DH; Cho, CK; Chung, HY; Bae, S; Jhon, GJ; Soh, JW; Jeoung, DI; Lee, SJ; Lee, YS			HSP25 inhibits radiation-induced apoptosis through reduction of PKC delta-mediated ROS production	ONCOGENE			English	Article						HSP25; radiation-induced apoptosis; reactive oxygen species; PKC delta; p38 MAP kinase	PROTEIN-KINASE-C; HEAT-SHOCK-PROTEIN; MANGANESE SUPEROXIDE-DISMUTASE; STRESS-INDUCED APOPTOSIS; INDUCED CELL-DEATH; OXIDATIVE STRESS; CYTOCHROME-C; PROTEOLYTIC ACTIVATION; PROTECTIVE ACTIVITY; CANCER-CELLS	Since radiation-induced caspase-dependent apoptosis and ROS generation were partially prevented by HSP25 overexpression, similar to the treatment of control cells with antioxidant agents such as DPI and tiron, questions arise whether radiation-mediated ROS generation contributes to the apoptotic cell death, and also whether HSP25 overexpression can reduce ROS mediated apoptotic cell death. In the present study, radiation-induced cytochrome c release from mitochondria and activation of caspases accompanied by a decrease of mitochondrial membrane potential in Jurkat T cells were shown to be inhibited by mitochondrial complex I inhibitor rotenone, suggesting that mitochondrial ROS might be important in radiation-induced caspase-dependent apoptosis. When HSP25 was overexpressed, effects similar to the treatment of cells with the antioxidants were obtained, indicating that HSP25 suppressed radiation-induced mitochondrial alteration that resulted in apoptosis. Furthermore, activation of p38 MAP kinase by radiation was associated with radiation-induced cell death and ROS production and PKC delta was an upstream molecule for p38 MAP kinase activation, ROS generation and subsequent caspase-dependent apoptotic events. However, in the HSP25 overexpressed cells, the above-described effects were blocked. In fact, radiation-induced membrane translocation of PKC delta and tyrosine phosphorylation were inhibited by HSP25. Based on the above data, we suggest that HSP25 downregulates PKC delta, which is a key molecule for radiation-induced ROS generation and mitochondrial-mediated caspase-dependent apoptotic events.	Korea Inst Radiol & Med Sci, Div Radiat Biol, Lab Radiat Effect, Seoul 139706, South Korea; Hanyang Univ, Coll Med, Dept Microbiol, Seoul 133791, South Korea; Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea; Inha Univ, Dept Chem, Lab Signal Transduct, Inchon 402751, South Korea; Kangweon Natl Univ, Coll Nat Sci, Div Life Sci, Chunchon 200701, South Korea	Korea Institute of Radiological & Medical Sciences; Hanyang University; Ewha Womans University; Inha University; Kangwon National University	Lee, YS (corresponding author), Korea Inst Radiol & Med Sci, Div Radiat Biol, Lab Radiat Effect, 215-4 Gongneung Dong, Seoul 139706, South Korea.	yslee@kcch.re.kr	Lee, Yun-Sil/AAP-1378-2020	Lee, Yun-Sil/0000-0002-7538-8850; Chung, Hee Yong/0000-0001-7580-0537				Brown GE, 2003, MOL CELL, V11, P35, DOI 10.1016/S1097-2765(03)00005-4; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Charette SJ, 2000, ANN NY ACAD SCI, V926, P126; Cho HN, 2002, CELL DEATH DIFFER, V9, P448, DOI 10.1038/sj.cdd.4400979; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Endo K, 2000, J BIOL CHEM, V275, P18476, DOI 10.1074/jbc.M002266200; Garrido C, 1996, EUR J BIOCHEM, V237, P653, DOI 10.1111/j.1432-1033.1996.0653p.x; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Gubina E, 1998, BLOOD, V91, P823, DOI 10.1182/blood.V91.3.823.823_823_829; HUOT J, 1991, CANCER RES, V51, P5245; Kajimoto T, 2001, MOL CELL BIOL, V21, P1769, DOI 10.1128/MCB.21.5.1769-1783.2001; Kessel D, 1999, CELL DEATH DIFFER, V6, P28, DOI 10.1038/sj.cdd.4400446; Kessel D, 1998, J PHOTOCH PHOTOBIO B, V42, P89, DOI 10.1016/S1011-1344(97)00127-9; Kim YS, 2003, EUR J BIOCHEM, V270, P4089, DOI 10.1046/j.1432-1033.2003.03800.x; Konishi H, 2001, P NATL ACAD SCI USA, V98, P6587, DOI 10.1073/pnas.111158798; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; Koriyama H, 1999, CELL SIGNAL, V11, P831, DOI 10.1016/S0898-6568(99)00055-8; Kovtun Y, 2000, P NATL ACAD SCI USA, V97, P2940, DOI 10.1073/pnas.97.6.2940; Kurata S, 2000, J BIOL CHEM, V275, P23413, DOI 10.1074/jbc.C000308200; Lee YJ, 2004, FREE RADICAL BIO MED, V36, P429, DOI 10.1016/j.freeradbiomed.2003.11.009; Lee YJ, 2003, EXP CELL RES, V291, P251, DOI 10.1016/S0014-4827(03)00391-4; Lee YJ, 2002, CELL GROWTH DIFFER, V13, P237; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Martelli AM, 1999, J CELL BIOCHEM, V74, P499, DOI 10.1002/(SICI)1097-4644(19990915)74:4<499::AID-JCB1>3.0.CO;2-X; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; Musashi M, 2000, INT J HEMATOL, V72, P12; OESTERREICH S, 1993, CANCER RES, V53, P4443; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Parcellier A, 2003, MOL CELL BIOL, V23, P5790, DOI 10.1128/MCB.23.16.5790-5802.2003; Park MT, 2003, J BIOL CHEM, V278, P50624, DOI 10.1074/jbc.M309011200; Park SH, 2000, RADIAT RES, V154, P421, DOI 10.1667/0033-7587(2000)154[0421:HIRIAW]2.0.CO;2; Rane MJ, 2003, J BIOL CHEM, V278, P27828, DOI 10.1074/jbc.M303417200; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Yi MJ, 2002, RADIAT RES, V158, P641, DOI 10.1667/0033-7587(2002)158[0641:HSPHRM]2.0.CO;2; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	40	43	49	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3715	3725		10.1038/sj.onc.1208440	http://dx.doi.org/10.1038/sj.onc.1208440			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15806174				2022-12-17	WOS:000229346300003
J	Meani, N; Minardi, S; Licciulli, S; Gelmetti, V; Lo Coco, F; Nervi, C; Pelicci, PG; Muller, H; Alcalay, M				Meani, N; Minardi, S; Licciulli, S; Gelmetti, V; Lo Coco, F; Nervi, C; Pelicci, PG; Muller, H; Alcalay, M			Molecular signature of retinoic acid treatment in acute promyelocytic leukemia	ONCOGENE			English	Article						differentiation therapy; acute myeloid leukemia; transcriptional regulation; expression profiling; transcription factor binding sites	PML-RAR-ALPHA; GENE-EXPRESSION; INDUCED DIFFERENTIATION; TRANSLOCATION PRODUCTS; FUSION PROTEINS; CELLS; IDENTIFICATION; HEMATOPOIESIS; METHYLATION; COMMITMENT	Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia characterized by a block of differentiation at the promyelocytic stage. APL patients respond to pharmacological concentrations of all-trans retinoic acid ( RA) and disease remission correlates with terminal differentiation of leukemic blasts. The PML/RAR oncogenic transcription factor is responsible for both the pathogenesis of APL and for its sensitivity to RA. In order to identify physiological targets of RA therapy, we analysed gene expression profiles of RA-treated APL blasts and found 1056 common target genes. Comparing these results to those obtained in RA-treated U937 cell lines revealed that transcriptional response to RA is largely dependent on the expression of PML/RAR. Several genes involved in the control of differentiation and stem cell renewal are early targets of RA regulation, and may be important effectors of RA response. Modulation of chromatin modifying genes was also observed, suggesting that specific structural changes in local chromatin domains may be required to promote RA-mediated differentiation. Computational analysis of upstream genomic regions in RA target genes revealed nonrandom distribution of transcription factor binding sites, indicating that specific transcriptional regulatory complexes may be involved in determining RA response.	Italian Fdn Canc Res, IFOM, Inst Mol Oncol, I-20139 Milan, Italy; European Inst Oncol, I-20141 Milan, Italy; San Raffaele Biomed Sci Pk Rome, I-00128 Rome, Italy; Univ Roma Tor Vergata, Dept Biopathol, Rome, Italy	IFOM - FIRC Institute of Molecular Oncology; IRCCS European Institute of Oncology (IEO); University of Rome Tor Vergata	Alcalay, M (corresponding author), Italian Fdn Canc Res, IFOM, Inst Mol Oncol, Via Adamello 16, I-20139 Milan, Italy.	myriam.alcalay@ifom-ieo-campus.it	Pelicci, Pier Giuseppe/AAL-6572-2020; Alcalay, Myriam/B-3182-2016; Alcalay, Myriam/AAB-4300-2019	Alcalay, Myriam/0000-0002-5558-4272; Alcalay, Myriam/0000-0002-5558-4272; Muller, Heiko/0000-0001-9873-3146; NERVI, Clara/0000-0001-9341-0188; Minardi, Simone Paolo/0000-0001-7303-3821				Alberta JA, 2003, BLOOD, V101, P2570, DOI 10.1182/blood-2002-06-1656; Alcalay M, 2001, ONCOGENE, V20, P5680, DOI 10.1038/sj.onc.1204642; Alcalay M, 2003, J CLIN INVEST, V112, P1751, DOI 10.1172/JCI17595; Benedetti L, 1996, BLOOD, V87, P1939; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; FAZI F, 2005, IN PRESS ONCOGENE; Finocchiaro G, 2004, BIOINFORMATICS, V20, P3670, DOI 10.1093/bioinformatics/bth416; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Guo Y, 2003, BLOOD, V102, P2428, DOI 10.1182/blood-2003-02-0634; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hollander M., 1999, NONPARAMETRIC STAT M; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Kamashev D, 2004, J EXP MED, V199, P1163, DOI 10.1084/jem.20032226; Kel AE, 2001, J MOL BIOL, V309, P99, DOI 10.1006/jmbi.2001.4650; Lacaud G, 2002, BLOOD, V100, P458, DOI 10.1182/blood-2001-12-0321; Lee KH, 2002, BIOCHEM BIOPH RES CO, V296, P1125, DOI 10.1016/S0006-291X(02)02043-0; Leone G, 2003, CLIN IMMUNOL, V109, P89, DOI 10.1016/S1521-6616(03)00207-9; Lin RJ, 1999, TRENDS GENET, V15, P179, DOI 10.1016/S0168-9525(99)01710-2; Liu TX, 2000, BLOOD, V96, P1496, DOI 10.1182/blood.V96.4.1496.h8001496_1496_1504; LOCOCO F, 1992, LANCET, V340, P1437, DOI 10.1016/0140-6736(92)92625-P; Meng GY, 2000, GENE, V242, P59, DOI 10.1016/S0378-1119(99)00477-1; Minucci S, 1999, SEMIN CELL DEV BIOL, V10, P215, DOI 10.1006/scdb.1999.0303; Muller-Tidow C, 2004, MOL CELL BIOL, V24, P2890, DOI 10.1128/MCB.24.7.2890-2904.2004; Ohneda O, 2001, BLOOD, V98, P2134, DOI 10.1182/blood.V98.7.2134; Park DJ, 2003, BLOOD, V102, P3727, DOI 10.1182/blood-2003-02-0412; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Radtke F, 2002, IMMUNOL REV, V187, P65, DOI 10.1034/j.1600-065X.2002.18706.x; Segalla S, 2003, MOL CELL BIOL, V23, P8795, DOI 10.1128/MCB.23.23.8795-8808.2003; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Vernell R, 2003, J BIOL CHEM, V278, P46124, DOI 10.1074/jbc.M304930200; Wang JR, 2004, MOL CELL BIOL, V24, P2423, DOI 10.1128/MCB.24.6.2423-2443.2004; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; Witcher M, 2003, BLOOD, V102, P237, DOI 10.1182/blood-2002-09-2725; Zheng XM, 2004, BLOOD, V103, P3535, DOI 10.1182/blood-2003-09-3335	37	43	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3358	3368		10.1038/sj.onc.1208498	http://dx.doi.org/10.1038/sj.onc.1208498			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735696				2022-12-17	WOS:000228881800014
J	Liu, MT; Chang, YT; Chen, SC; Chuang, YC; Chen, YR; Lin, CS; Chen, JY				Liu, MT; Chang, YT; Chen, SC; Chuang, YC; Chen, YR; Lin, CS; Chen, JY			Epstein-Barr virus latent membrane protein 1 represses p53-mediated DNA repair and transcriptional activity	ONCOGENE			English	Article						p53; Epstein-Barr virus LMP1; DNA repair	NF-KAPPA-B; NUCLEOTIDE EXCISION-REPAIR; PROGRAMMED CELL-DEATH; TYPE-1 TAX PROTEIN; HTLV-I TAX; MEMBRANE PROTEIN-1; GENOMIC INTEGRITY; SIGNALING PATHWAY; DAMAGING AGENTS; P53 GENE	The latent membrane protein 1 (LMP1) of Epstein-Barr virus (EBV), a viral oncogene, is essential for transformation of resting B cells by the virus. We previously demonstrated that LMP1 could repress DNA repair in p53-wild-type and p53-deficient human epithelial cells. In this study, using a host cell reactivation (HCR) assay, we demonstrated that p53-enhanced DNA repair was repressed by LMP1 in p53-deficient cells. Moreover, we found that LMP1 was able to repress p53-dependent transcriptional activity. Regarding the mechanisms of p53 repression by LMP1, we found that LMP1 did not inhibit p53 function through direct interaction, by promoting protein degradation or reducing its DNA-binding ability. Using chimeric proteins in the reporter assay, we demonstrated that LMP1 inhibited p53 transactivation by influencing the N-terminal transactivation domain of p53. Subsequent experiments using various LMP1 deletion mutants indicated that a C-terminus-activating region of LMP1, CTAR1 or CTAR2, is responsible for the repression of p53-mediated DNA repair and p53-dependent transcription, which is correlated with the region responsible for NF-kappa B activation. Furthermore, blockage of NF-kappa B signalling by I kappa B-Delta N was shown to abolish the repression of p53 by LMP1, suggesting that LMP1 likely repressed p53 function through the NF-kappa B pathway. Based on these results, we propose that inhibition of p53-dependent transcriptional activity and DNA repair by LMP1 results in the loss of p53 activity for maintaining genomic stability, which may contribute to the oncogenesis of LMP1 in human epithelial cells.	Natl Hlth Res Inst, Taipei 114, Taiwan; Natl Taiwan Univ, Coll Med, Grad Inst Microbiol, Taipei 100, Taiwan	National Health Research Institutes - Taiwan; National Taiwan University	Chen, JY (corresponding author), Natl Hlth Res Inst, 3F 109,Sect 6,Min Chuan E Rd, Taipei 114, Taiwan.	cjy@nhri.org.tw	Lin, Chang-Shen/X-2189-2019; Chen, Jen-Yang/D-2085-2010; Lin, Chang-Shen/D-5140-2009	Lin, Chang-Shen/0000-0001-7415-2187; Chuang, Yu-Chia/0000-0002-5069-9468				AB RICKINSON, 2001, FIELDS VIROLOGY, P2575; Adimoolam S, 2003, DNA REPAIR, V2, P947, DOI 10.1016/S1568-7864(03)00087-9; Adimoolam S, 2002, P NATL ACAD SCI USA, V99, P12985, DOI 10.1073/pnas.202485699; Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Atkinson PGP, 2003, J BIOL CHEM, V278, P51134, DOI 10.1074/jbc.M304771200; Bertrand P, 2004, TRENDS GENET, V20, P235, DOI 10.1016/j.tig.2004.04.003; Bohuslav J, 2004, J BIOL CHEM, V279, P26115, DOI 10.1074/jbc.M313509200; Burt EC, 2000, BRIT J CANCER, V83, P467, DOI 10.1054/bjoc.2000.1292; Capovilla A, 1997, BIOCHEM BIOPH RES CO, V232, P255, DOI 10.1006/bbrc.1997.6269; Chang NS, 2002, J BIOL CHEM, V277, P10323, DOI 10.1074/jbc.M106607200; Chien YC, 2001, NEW ENGL J MED, V345, P1877, DOI 10.1056/NEJMoa011610; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; Eliopoulos AG, 2001, SEMIN CANCER BIOL, V11, P435, DOI 10.1006/scbi.2001.0410; Eliopoulos AG, 2003, ONCOGENE, V22, P7557, DOI 10.1038/sj.onc.1207120; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; Fujioka S, 2004, J BIOL CHEM, V279, P27549, DOI 10.1074/jbc.M313435200; Groisman IJ, 1999, CARCINOGENESIS, V20, P479, DOI 10.1093/carcin/20.3.479; HARVEY M, 1993, ONCOGENE, V8, P2457; He ZM, 2000, CANCER RES, V60, P1845; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Honma M, 2000, MOL CARCINOGEN, V28, P203, DOI 10.1002/1098-2744(200008)28:4<203::AID-MC3>3.0.CO;2-1; HUEN DS, 1995, ONCOGENE, V10, P549; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Ikeda A, 2000, BIOCHEM BIOPH RES CO, V272, P375, DOI 10.1006/bbrc.2000.2786; Janus F, 1999, CELL MOL LIFE SCI, V55, P12, DOI 10.1007/s000180050266; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jeong SJ, 2004, BLOOD, V104, P1490, DOI 10.1182/blood-2003-12-4174; Kao SY, 2000, ONCOGENE, V19, P2240, DOI 10.1038/sj.onc.1203559; Kao SY, 2000, J BIOL CHEM, V275, P35926, DOI 10.1074/jbc.M004397200; Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li HP, 2003, J BIOMED SCI, V10, P490, DOI 10.1159/000072376; Lin CS, 2000, J MOL BIOL, V303, P7, DOI 10.1006/jmbi.2000.4121; Liu MT, 2004, ONCOGENE, V23, P2531, DOI 10.1038/sj.onc.1207375; MAJONE F, 1993, VIROLOGY, V193, P456, DOI 10.1006/viro.1993.1145; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; McFarland EDC, 1999, ONCOGENE, V18, P6959, DOI 10.1038/sj.onc.1203217; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Nowak MA, 2002, P NATL ACAD SCI USA, V99, P16226, DOI 10.1073/pnas.202617399; OKAN I, 1995, ONCOGENE, V11, P1027; Overholtzer M, 2003, P NATL ACAD SCI USA, V100, P11547, DOI 10.1073/pnas.1934852100; Philpott SM, 1999, J NATL CANCER I, V91, P933, DOI 10.1093/jnci/91.11.933; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Prost S, 1998, J BIOL CHEM, V273, P33327, DOI 10.1074/jbc.273.50.33327; Ravi R, 1998, CANCER RES, V58, P4531; Rubbi CP, 2003, EMBO J, V22, P975, DOI 10.1093/emboj/cdg082; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Saito N, 2003, J BIOL CHEM, V278, P46565, DOI 10.1074/jbc.M302549200; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SMITH ML, 1995, ONCOGENE, V10, P1053; Smith ML, 2002, MUTAGENESIS, V17, P149, DOI 10.1093/mutage/17.2.149; Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Yang XH, 2000, ONCOGENE, V19, P2002, DOI 10.1038/sj.onc.1203515; Yoshizaki T, 1998, P NATL ACAD SCI USA, V95, P3621, DOI 10.1073/pnas.95.7.3621; Zhou MX, 2003, ONCOGENE, V22, P8137, DOI 10.1038/sj.onc.1206911; Zurer I, 2004, CARCINOGENESIS, V25, P11, DOI 10.1093/carcin/bgg186	66	43	45	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2635	2646		10.1038/sj.onc.1208319	http://dx.doi.org/10.1038/sj.onc.1208319			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15829976				2022-12-17	WOS:000228356700005
J	Mukherjee, T; Hombria, JCG; Zeidler, MP				Mukherjee, T; Hombria, JCG; Zeidler, MP			Opposing roles for Drosophila JAK/STAT signalling during cellular proliferation	ONCOGENE			English	Article						hopscotch; janus kinase; proliferation; STAT92E; unpaired	STAT PROTEINS; PATHWAY; GENE; RECEPTOR; KINASE; GROWTH; CELLS; NOTCH; IDENTIFICATION; ONCOGENESIS	The JAK/STAT signalling pathway mediates both anti-proliferative responses following interferon stimulation and cellular proliferation in response to cytokines such as interleukins and growth factors. Central to these responses are the seven vertebrate STAT molecules, misregulation of which is implicated in a variety of malignancies. We have investigated the proliferative role of the single Drosophila STAT92E, part of the evolutionarily conserved JAK/STAT cascade. During second instar larval wing disc development pathway activity is both necessary and sufficient to promote proliferation of this epithelial cell type. However by later stages, endogenous STAT92E is stimulated by a noncannonical mechanism to exert pronounced antiproliferative effects. Ectopic canonical activation is sufficient to further decrease proliferation and leads to the premature arrest of cells in the G2 phase of the cell cycle. The single STAT92E present in Drosophila therefore mediates both proproliferative functions analogous to vertebrate interleukin-stimulated STAT3 and antiproliferative functions analogous to interferon-stimulated STAT1. Pro- and antiproliferative roles therefore represent ancestral activities conserved through evolution and subsequently assigned to distinct molecules.	Max Planck Inst Biophys Chem, Dept Mol Dev Biol, D-37077 Gottingen, Germany; Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England; Univ Pablo Olavide, Ctr Andaluz Biol Desarrollo, Seville 41013, Spain	Max Planck Society; University of Cambridge; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Pablo de Olavide; CSIC - Andalusian Center for Developmental Biology (CABD)	Zeidler, MP (corresponding author), Max Planck Inst Biophys Chem, Dept Mol Dev Biol, Fassberg 11, D-37077 Gottingen, Germany.	mzeidle@gwdg.de	Hombría, James C-G/L-2036-2014; Zeidler, Martin/E-6209-2010	Hombría, James C-G/0000-0003-4183-5250; Zeidler, Martin/0000-0003-2942-1135				Bach EA, 2003, GENETICS, V165, P1149; Baonza A, 2000, P NATL ACAD SCI USA, V97, P2609, DOI 10.1073/pnas.040576497; BINARI R, 1994, GENE DEV, V8, P300, DOI 10.1101/gad.8.3.300; Bluyssen HAR, 1997, J BIOL CHEM, V272, P4600, DOI 10.1074/jbc.272.7.4600; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; BRAND AH, 1993, DEVELOPMENT, V118, P401; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Brown S, 2001, CURR BIOL, V11, P1700, DOI 10.1016/S0960-9822(01)00524-3; Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; Castles FG, 2002, J EUR SOC POLICY, V12, P75, DOI 10.1177/0952872002012001564; Chen HW, 2002, GENE DEV, V16, P388, DOI 10.1101/gad.955202; Coffer PJ, 2000, ONCOGENE, V19, P2511, DOI 10.1038/sj.onc.1203479; Cohen S. M., 1993, DEV DROSOPHILA MELAN, P747; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P569; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; GARCIABELLIDO A, 1971, DEV BIOL, V24, P61, DOI 10.1016/0012-1606(71)90047-9; Giraldez AJ, 2003, DEVELOPMENT, V130, P6533, DOI 10.1242/dev.00904; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; HANRATTY WP, 1993, MOL GEN GENET, V238, P33, DOI 10.1007/BF00279527; Harrison DA, 1998, GENE DEV, V12, P3252, DOI 10.1101/gad.12.20.3252; Henriksen MA, 2002, GENE DEV, V16, P2379, DOI 10.1101/gad.1020702; Hou SX, 2002, DEV CELL, V3, P765, DOI 10.1016/S1534-5807(02)00376-3; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; Ito K, 1997, DEVELOPMENT, V124, P761; Jacobs HW, 1998, GENE DEV, V12, P3741, DOI 10.1101/gad.12.23.3741; Jager H, 2001, GENE DEV, V15, P2572, DOI 10.1101/gad.207301; Johansen KA, 2003, DEVELOPMENT, V130, P135, DOI 10.1242/dev.00202; Kamakura S, 2004, NAT CELL BIOL, V6, P547, DOI 10.1038/ncb1138; LEHMANN R, 1994, PRACTICAL US CELL MO, V44, P576; Li JH, 2003, DEV CELL, V5, P787, DOI 10.1016/S1534-5807(03)00328-9; Martin-Castellanos C, 2002, DEVELOPMENT, V129, P1003; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; PERRIMON N, 1986, DEV BIOL, V118, P28, DOI 10.1016/0012-1606(86)90070-9; Platanias LC, 1999, EXP HEMATOL, V27, P1583, DOI 10.1016/S0301-472X(99)00109-5; Ramana CV, 2002, TRENDS IMMUNOL, V23, P96, DOI 10.1016/S1471-4906(01)02118-4; Read RD, 2004, MOL CELL BIOL, V24, P6676, DOI 10.1128/mcb.24.15.6676-6689.2004; RODRIGUEZFRADE JM, 2003, ACTIVATION BIOL, P191; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; SILVA CM, 2003, SIGNAL TRANSDUCERS A, P223; Silver DL, 2001, CELL, V107, P831, DOI 10.1016/S0092-8674(01)00607-9; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; White K, 2001, METHOD CELL BIOL, V66, P321; WHITFIELD WGF, 1990, EMBO J, V9, P2563, DOI 10.1002/j.1460-2075.1990.tb07437.x; XU T, 1993, DEVELOPMENT, V117, P1223; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8; Yang LH, 2003, DEV CELL, V4, P359, DOI 10.1016/S1534-5807(03)00059-5; Zeidler MP, 1999, GENE DEV, V13, P1342, DOI 10.1101/gad.13.10.1342	48	43	43	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2503	2511		10.1038/sj.onc.1208487	http://dx.doi.org/10.1038/sj.onc.1208487			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735706				2022-12-17	WOS:000228180600008
J	Raafat, A; Bargo, S; Anver, MR; Callahan, R				Raafat, A; Bargo, S; Anver, MR; Callahan, R			Mammary development and tumorigenesis in mice expressing a truncated human Notch4/Int3 intracellular domain (h-Int3sh)	ONCOGENE			English	Article						Notch4/Int3 signaling; mammary tumorigenesis; mammary gland development	NEOPLASTIC TRANSFORMATION; GLAND TUMORIGENESIS; EPITHELIAL-CELLS; FVB/N MICE; INT3 GENE; NOTCH; DIFFERENTIATION; HYPERPLASIA; INTEGRATION; MEMBER	Recently, we have identified a novel 1.8 kb human Notch4/Int3 RNA species (designated h-Int3sh). The h-Int3sh RNA encodes a protein that is missing the CBF1-binding region (RAM23) of the Notch 4/Int3 intracellular domain (ICD). Expression of h-Int3sh in the MCF10A 'normal' human mammary epithelial cell line has been previously shown to induce changes characteristic of oncogenic transformation, including anchorage-independent growth in soft agar. To study the consequences of h-Int3sh expression in vivo on mammary gland development and tumorigenesis, three transgenic mouse lines were established, in which the transgene is the Whey acidic protein (WAP) promoter linked to h-Int3sh. Expression of WAP-Int3sh was detectable in the mammary gland at day 15 of pregnancy in each transgenic line. Mammary gland development in all founder lines is normal and the females can lactate. WAP-h-Int3sh females from each of the founder lines develop mammary tumors, but with a long latency (average age of 18 months). Tumor development was associated with activation of Notch pathway, as evidenced by upregulation of Hes-1. The long latency of mammary tumors in WAP-h-Int3sh mice could be due in part to the subcellular localization of h-Int3sh. Immuno. fluorescence analysis of transfected COS-1 cells showed that h-Int3sh is localized in the cytoplasm and nucleus, while Int3-ICD is detected only in the nucleus. We speculate that the Notch4/Int3 ICD-induced block to mammary gland development and tumorigenesis are consequences of an increasing gradient of CBF1-dependent Notch4/Int3 signaling.	NCI, Mammary Biol & Tumorignesis Lab, NIH, Bethesda, MD 20892 USA; NCI, Pathol & Histotechnol Lab, Sci Applicat Int Corp, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC)	Callahan, R (corresponding author), NCI, Mammary Biol & Tumorignesis Lab, NIH, Bldg 10 Room 5B50, Bethesda, MD 20892 USA.	rc54d@nih.gov			PHS HHS [N01-C0-12400] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Allenspach EJ, 2002, CANCER BIOL THER, V1, P466, DOI 10.4161/cbt.1.5.159; Arias AM, 2002, CURR OPIN GENET DEV, V12, P524, DOI 10.1016/S0959-437X(02)00336-2; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Callahan R, 2001, J MAMMARY GLAND BIOL, V6, P23, DOI 10.1023/A:1009512414430; Dumont E, 2000, ONCOGENE, V19, P556, DOI 10.1038/sj.onc.1203352; Gallahan D, 1997, ONCOGENE, V14, P1883, DOI 10.1038/sj.onc.1201035; Gallahan D, 1996, CANCER RES, V56, P1775; GALLAHAN D, 1987, J VIROL, V61, P218, DOI 10.1128/JVI.61.1.218-220.1987; Imatani A, 2000, ONCOGENE, V19, P223, DOI 10.1038/sj.onc.1203295; Jeffries S, 2002, MOL CELL BIOL, V22, P3927, DOI 10.1128/MCB.22.11.3927-3941.2002; Jeffries S, 2000, MOL CELL BIOL, V20, P3928, DOI 10.1128/MCB.20.11.3928-3941.2000; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; Li LH, 1998, GENOMICS, V51, P45, DOI 10.1006/geno.1998.5330; Mahler JF, 1996, TOXICOL PATHOL, V24, P710, DOI 10.1177/019262339602400606; Nieto AI, 2003, COMPARATIVE MED, V53, P433; Pirkmaier A, 2003, ONCOGENE, V22, P4425, DOI 10.1038/sj.onc.1206488; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; SMITH GH, 1995, CELL GROWTH DIFFER, V6, P563; Uyttendaele H, 1998, DEV BIOL, V196, P204, DOI 10.1006/dbio.1998.8863; Wakefield LM, 2003, COMPARATIVE MED, V53, P424; White DE, 2001, ONCOGENE, V20, P7064, DOI 10.1038/sj.onc.1204910	22	43	44	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9401	9407		10.1038/sj.onc.1208187	http://dx.doi.org/10.1038/sj.onc.1208187			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15531924				2022-12-17	WOS:000225764100011
J	Li, JF; Wang, FL; Protopopov, A; Malyukova, A; Kashuba, V; Minna, JD; Lerman, MI; Klein, G; Zabarovsky, E				Li, JF; Wang, FL; Protopopov, A; Malyukova, A; Kashuba, V; Minna, JD; Lerman, MI; Klein, G; Zabarovsky, E			Inactivation of RASSF1C during in vivo tumor growth identifies it as a tumor suppressor gene	ONCOGENE			English	Article						tumor suppressor gene; human chromosome 3p; gene mutation; lung cancer; renal carcinoma; prostate cancer	HUMAN-CHROMOSOME 3P21.3; HOMOZYGOUS DELETION REGION; EPIGENETIC INACTIVATION; CELL-GROWTH; LUNG; CANCER; SEARCH; BREAST; CONSTRUCTION; INHIBITION	RASSF1A, a major member of the RASSF1 gene family, is silenced by promoter methylation at a high frequency in a large number of human solid tumors. Controlled expression of RASSF1A reverts the tumorigenic phenotype of several human cancer cell lines. Here we investigated another main isoform, RASSF1C, and compared it with RASSF1A in the gene inactivation test (GIT), based on a tetracycline regulation system. In the small-cell lung cancer (SCLC) line U2020, only RASSF1A has shown growth inhibitory activity in vitro, while in the prostate cell line LNCaP and renal cell carcinoma (RCC) line KRC/Y both RASSF1A and RASSF1C showed similar (approximately 90%) suppressing activity in vitro. Both RASSF1C and RASSF1A suppressed the tumorigenicity of the KRC/Y RCC cell line in SCID mice. Mutations, deletions and loss of expression of RASSF1A and RASSF1C transgenes were identified in all 15 grown SCID tumors. In contrast, the mutant RASSF1A containing Cys65Arg and Val211Ala had reduced growth suppression activity both in vitro and in vivo and did not show any further changes in four grown SCID tumors. In addition, RASSF1C was shown to induce cell cycle arrest in KRC/Y cells. These results strongly imply that like RASSF1A the RASSF1C gene could serve a tumor suppressor function.	Karolinska Inst, Microbiol & Tumorbiol Ctr, S-17177 Stockholm, Sweden; Natl Acad Sci Ukraine, Inst Mol Biol & Genet, UA-03143 Kiev, Ukraine; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol, Dallas, TX 75390 USA; Natl Canc Inst, Canc Causing Genes Sect, Immunobiol Lab, Ctr Canc Res, Frederick, MD 21702 USA; Russian Acad Sci, Engelhardt Inst Mol Biol, Moscow 119991, Russia; Karolinska Inst, Ctr Genom & Bioinformat, S-17177 Stockholm, Sweden	Karolinska Institutet; National Academy of Sciences Ukraine; Institute of Molecular Biology & Genetics of NASU; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Karolinska Institutet	Li, JF (corresponding author), Karolinska Inst, Microbiol & Tumorbiol Ctr, S-17177 Stockholm, Sweden.	jinli@ki.se; eugzab@ki.se	Zabarovsky, Eugene R/A-6645-2010; Kashuba, Vladimir I/N-3732-2017; Kashuba, Vladimir/AAO-7742-2020	Kashuba, Vladimir I/0000-0001-9416-8282; 	NATIONAL CANCER INSTITUTE [P50CA070907, R01CA071618] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; NCI NIH HHS [CA71618, P50 CA 70907, N01-CO-56000] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Alimov A, 2000, ONCOGENE, V19, P1392, DOI 10.1038/sj.onc.1203449; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Hingorani SR, 2003, CURR OPIN GENET DEV, V13, P6, DOI 10.1016/S0959-437X(02)00017-5; Imreh S, 2003, GENE CHROMOSOME CANC, V38, P307, DOI 10.1002/gcc.10271; Ji L, 2002, CANCER RES, V62, P2715; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Kuzmin I, 2002, CANCER RES, V62, P3498; Lee MG, 2001, CANCER RES, V61, P6688; Lerman MI, 2000, CANCER RES, V60, P6116; Li JF, 1999, FEBS LETT, V451, P289, DOI 10.1016/S0014-5793(99)00598-0; Lo KW, 2001, CANCER RES, V61, P3877; Maruyama R, 2001, CANCER RES, V61, P8659; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Protopopov A, 2003, CANCER RES, V63, P404; Protopopov AI, 2002, J GENE MED, V4, P397, DOI 10.1002/jgm.283; Rubins JB, 2001, J LAB CLIN MED, V138, P101, DOI 10.1067/mlc.2001.116591; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Senchenko V, 2003, ONCOGENE, V22, P2984, DOI 10.1038/sj.onc.1206429; SENCHENKO VN, 2004, IN PRESS ONCOGENE; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Tomizawa Y, 2001, P NATL ACAD SCI USA, V98, P13954, DOI 10.1073/pnas.231490898; Tse C, 2002, CANCER RES, V62, P542; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Wei MH, 1996, CANCER RES, V56, P1487; Xiang RH, 2002, CANCER RES, V62, P2637; ZABAROVSKY ER, 1990, NUCLEIC ACIDS RES, V18, P6319, DOI 10.1093/nar/18.21.6319; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835	31	43	50	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					5941	5949		10.1038/sj.onc.1207789	http://dx.doi.org/10.1038/sj.onc.1207789			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15208682				2022-12-17	WOS:000222941100008
J	Erez, A; Perelman, M; Hewitt, SM; Cojacaru, G; Goldberg, I; Shahar, I; Yaron, P; Muler, I; Campaner, S; Amariglio, N; Rechavi, G; Kirsch, IR; Krupsky, M; Kaminski, N; Izraeli, S				Erez, A; Perelman, M; Hewitt, SM; Cojacaru, G; Goldberg, I; Shahar, I; Yaron, P; Muler, I; Campaner, S; Amariglio, N; Rechavi, G; Kirsch, IR; Krupsky, M; Kaminski, N; Izraeli, S			Sil overexpression in lung cancer characterizes tumors with increased mitotic activity	ONCOGENE			English	Article						Sil; mitosis; lung cancer; carcinogenesis	CELL-CYCLE; GENE; CHECKPOINT; EXPRESSION; IDENTIFICATION	Sil (SCL interrupting locus) was cloned from the most common chromosomal rearrangement in T-cell acute lymphoblastic leukemia. It is an immediate early gene whose expression is associated with cell proliferation. Sil protein levels are tightly regulated during the cell cycle, reaching peak levels in mitosis and disappearing on transition to G1. A recent study found Sil to be one of 17 genes whose overexpression in primary adenocarcinomas predicts metastatic spread. We hypothesized that Sil might have a role in carcinogenesis. To address this question, we utilized several approaches. Using a multi-tumor tissue array, we found that Sil protein expression was increased mostly in lung cancer, but also at lower levels, in a subset of other tumors. Microarray gene expression analysis and immunohistochemistry of lung cancer samples verified these observations. Sil gene expression in lung cancer correlated with the expression of several kinetochore check-point genes and with the histopathologic mitotic index. The se observations suggest that overexpression of the Sil gene characterizes tumors with increased mitotic activity.	Chaim Sheba Med Ctr, Chaim Sheba Canc Res Ctr, Dept Pediat Hematooncol, IL-52621 Tel Hashomer, Israel; Chaim Sheba Med Ctr, Chaim Sheba Canc Res Ctr, Dept Pathol, IL-52621 Tel Hashomer, Israel; NIH, Ctr Adv Technol, Bethesda, MD 20892 USA; Chaim Sheba Med Ctr, Chaim Sheba Canc Res Ctr, Dept Funct Gen, IL-52621 Tel Hashomer, Israel; Compugen LTD, Tel Aviv, Israel; Chaim Sheba Med Ctr, Chaim Sheba Canc Res Ctr, Dept Pulm Med, IL-52621 Tel Hashomer, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; NCI, NIH, Bethesda, MD 20892 USA; Univ Pittsburgh, Med Ctr, Dorothy P & Richard P Simmons Ctr, Pittsburgh, PA 15261 USA	Chaim Sheba Medical Center; Chaim Sheba Medical Center; National Institutes of Health (NIH) - USA; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kaminski, N (corresponding author), Univ Pittsburgh, Med Ctr, Dorothy P & Richard P Simmons Ctr Interstitial Lu, NW 628 MUH,3459 5th Av, Pittsburgh, PA 15261 USA.	kaminskin@upmc.edu; sizraeli@post.tau.ac.il		Hewitt, Stephen/0000-0001-8283-1788; Kaminski, Naftali/0000-0001-5917-4601; CAMPANER, Stefano/0000-0003-4547-6849	DIVISION OF CLINICAL SCIENCES - NCI [Z01SC006579] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [Z01SC010364] Funding Source: NIH RePORTER	DIVISION OF CLINICAL SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; APLAN PD, 1991, MOL CELL BIOL, V11, P5462, DOI 10.1128/MCB.11.11.5462; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; CollazoGarcia N, 1995, GENOMICS, V30, P506, DOI 10.1006/geno.1995.1271; Golling G, 2002, NAT GENET, V31, P135, DOI 10.1038/ng896; Izraeli S, 2001, GENESIS, V31, P72, DOI 10.1002/gene.10004; Izraeli S, 1999, NATURE, V399, P691, DOI 10.1038/21429; Izraeli S, 1997, CELL GROWTH DIFFER, V8, P1171; Kaminski N, 2002, AM J RESP CELL MOL, V27, P125, DOI 10.1165/ajrcmb.27.2.f247; Liu ST, 2003, MOL BIOL CELL, V14, P1638, DOI 10.1091/mbc.02-05-0074; Lynch J, 2002, J PATHOL, V196, P275, DOI 10.1002/path.1045; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Ortiz LA, 2003, P NATL ACAD SCI USA, V100, P8407, DOI 10.1073/pnas.1432929100; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Rattner JB, 1996, J CELL BIOL, V134, P1097, DOI 10.1083/jcb.134.5.1097; Starr DA, 2000, J CELL SCI, V113, P1939; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; Travis WD, 1999, HISTOLOGICAL TYPING; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Zhou J, 2002, J CELL SCI, V115, P3547, DOI 10.1242/jcs.00029	22	43	47	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2004	23	31					5371	5377		10.1038/sj.onc.1207685	http://dx.doi.org/10.1038/sj.onc.1207685			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15107824				2022-12-17	WOS:000222491600012
J	Ohtsuka, T; Jensen, MR; Kim, HG; Kim, KT; Lee, SW				Ohtsuka, T; Jensen, MR; Kim, HG; Kim, KT; Lee, SW			The negative role of cyclin G in ATM-dependent p53 activation	ONCOGENE			English	Article						p53; cyclin G; ATM; cell cycle; DNA damage	DNA-DAMAGE; G2/M ARREST; PHOSPHORYLATION; GROWTH; CELLS; MODULATION; P53-MDM2; PROTEIN; TARGET; MDM2	Cyclin G is one of the earliest p53 target genes to be identified, but its function in the p53 pathway has been elusive. Although the precise mechanisms of cyclin G in this novel network have not been explored, recent studies have demonstrated that cyclin G is a key regulator of the p53-Mdm2 network. Here we present evidence that cyclin G-mediated p53 regulation is dependent upon the status of ataxia-telangiectasia mutated (ATM) protein, which activates p53 in response to DNA damage. Abrogation of cyclin G enhances p53 accumulation and phosphorylation of p53 at the Ser-15 residue, resulting in cell cycle arrest. Ectopically expressed cyclin G significantly reduces the steady-state levels of p53 as well as that of phosphorylated p53 at Ser-15 after DNA damage in normal human dermal fibroblasts containing normal ATM. However, cyclin G does not cause similar reductions in p53 levels in ATM-mutated cells. We also show that translocation of cyclin G to the nucleus requires functional ATM. Thus, our findings identify a new role of cyclin G in ATM-dependent p53 regulation and in cell cycle regulation during DNA damage.	Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Canc Biol Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; FIRC Inst Mol Oncol, Milan, Italy	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; IFOM - FIRC Institute of Molecular Oncology	Lee, SW (corresponding author), Harvard Inst Med, 4 Blackfan Circle,Room 921, Boston, MA 02115 USA.	slee2@caregroup.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA078356, R01CA085681] Funding Source: NIH RePORTER; NCI NIH HHS [CA78356, CA85681] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chen XB, 2002, DEV CELL, V2, P518, DOI 10.1016/S1534-5807(02)00182-X; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Jensen MR, 2003, HEPATOLOGY, V37, P862, DOI 10.1053/jhep.2003.50137; Kimura SH, 2001, ONCOGENE, V20, P3290, DOI 10.1038/sj.onc.1204270; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Ohtsuka T, 2003, ONCOGENE, V22, P1678, DOI 10.1038/sj.onc.1206306; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Okamoto K, 1999, ONCOGENE, V18, P4606, DOI 10.1038/sj.onc.1202821; Okamoto K, 1996, MOL CELL BIOL, V16, P6593; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; Reimers L, 1999, J BIOL CHEM, V274, P11022, DOI 10.1074/jbc.274.16.11022; Shimizu A, 1998, BIOCHEM BIOPH RES CO, V242, P529, DOI 10.1006/bbrc.1997.8004; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SKOTZKO M, 1995, CANCER RES, V55, P5493; Smith ML, 1997, EXP CELL RES, V230, P61, DOI 10.1006/excr.1996.3402; TAMURA K, 1993, ONCOGENE, V8, P2113; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; Zhao L, 2003, MOL CANCER RES, V1, P195	20	43	47	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2004	23	31					5405	5408		10.1038/sj.onc.1207693	http://dx.doi.org/10.1038/sj.onc.1207693			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15077171				2022-12-17	WOS:000222491600016
J	Rabenau, KE; O'Toole, JM; Bassi, R; Kotanides, H; Witte, L; Ludwig, DL; Pereira, DS				Rabenau, KE; O'Toole, JM; Bassi, R; Kotanides, H; Witte, L; Ludwig, DL; Pereira, DS			DEGA/AMIGO-2, a leucine-rich repeat family member, differentially expressed in human gastric adenocarcinoma: effects on ploidy, chromosomal stability, cell adhesion/migration and tumorigenicity	ONCOGENE			English	Article						tumorigenicity; ploidy; chromosomal instability; leucine-rich repeat; gastric adenocarcinoma; antisense	GENOMIC INSTABILITY; FREQUENT AMPLIFICATION; MOLECULAR-BIOLOGY; GENE; CANCER; CARCINOMA; HER-2/NEU; ONCOGENE; MUTATION; LAMININ	We have discovered DEGA, a novel cDNA differentially expressed in human gastric adenocarcinomas. The DEGA gene product contains a signal peptide,five leucine-rich repeat motifs and a single IgG, and transmembrane domain, suggesting its residence on the plasma membrane. Transfection of 293 cells with a DEGA-GFP fusion construct confirmed its cell surface localization. Although the cytosolic portion of the DEGA gene product does not contain known protein domains, approximately one-fifth of these residues are either a serine or a threonine, suggesting that DEGA may play a role in signal transduction. BLAST searches revealed DEGA to be an exact match to AMIGO-2, a recently identified, but functionally uncharacterized protein related to AMIGO, a leucine-rich repeat containing cell adhesion molecule implicated in axon tract development. In this report, we show that DEGA/AMIGO-2 mRNA is differentially expressed in similar to45% of tumor versus normal tissue from gastric adenocarcinoma patients. Stable expression of a DEGA/AMIGO-2 antisense construct in the gastric adenocarcinoma cell line, AGS, led to altered morphology, increased ploidy, chromosomal instability, decreased cell adhesion/migration, and a nearly complete abrogation of tumorigenicity in nude mice. These findings suggest a potential etiologic role for DEGA/AMIGO-2 in gastric adenocarcinoma.	ImClone Syst Inc, Dept Mol & Cellular Biol, New York, NY 10014 USA; ImClone Syst Inc, Dept Immunol, New York, NY 10014 USA	Eli Lilly; Eli Lilly	Pereira, DS (corresponding author), ImClone Syst Inc, Dept Mol & Cellular Biol, 180 Varick St, New York, NY 10014 USA.	Daniel.Pereira@imclone.com						AKAMA Y, 1995, JPN J CANCER RES, V86, P617, DOI 10.1111/j.1349-7006.1995.tb02442.x; Arber N, 1996, GASTROENTEROLOGY, V110, P669, DOI 10.1053/gast.1996.v110.pm8608874; Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; Chan AOO, 1999, J GASTROEN HEPATOL, V14, P1150, DOI 10.1046/j.1440-1746.1999.02000.x; Crookes PF, 2002, CLIN OBSTET GYNECOL, V45, P892, DOI 10.1097/00003081-200209000-00036; Danesh J, 1999, ALIMENT PHARM THERAP, V13, P851; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; Ebert MPA, 2000, EUR J GASTROEN HEPAT, V12, P795, DOI 10.1097/00042737-200012070-00013; El-Rifai W, 2002, SEMIN RADIAT ONCOL, V12, P128, DOI 10.1053/srao.2002.30815; Hocking AM, 1998, MATRIX BIOL, V17, P1; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; Kono K, 2000, TUMOR BIOL, V21, P139, DOI 10.1159/000030120; Konturek P C, 2001, Med Sci Monit, V7, P1092; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; Kuja-Panula J, 2003, J CELL BIOL, V160, P963, DOI 10.1083/jcb.200209074; KUNIYASU H, 1993, INT J CANCER, V55, P72, DOI 10.1002/ijc.2910550114; KUNIYASU H, 1992, BIOCHEM BIOPH RES CO, V189, P227, DOI 10.1016/0006-291X(92)91548-5; MAFUNE K, 1992, J SURG RES, V52, P340, DOI 10.1016/0022-4804(92)90113-E; MAYER B, 1993, LANCET, V342, P1019, DOI 10.1016/0140-6736(93)92879-X; Moayyedi P, 2002, BMJ-BRIT MED J, V325, P1399, DOI 10.1136/bmj.325.7377.1399; Musio A, 2003, CANCER RES, V63, P2855; Nowak MA, 2002, P NATL ACAD SCI USA, V99, P16226, DOI 10.1073/pnas.202617399; Phillips RL, 2000, SCIENCE, V288, P1635, DOI 10.1126/science.288.5471.1635; Ross JS, 2001, CANCER INVEST, V19, P554, DOI 10.1081/CNV-100103852; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; Shun CT, 2001, ONCOLOGY-BASEL, V60, P339, DOI 10.1159/000058530; Sieber OM, 2003, NAT REV CANCER, V3, P701, DOI 10.1038/nrc1170; TERRANOVA VP, 1986, P NATL ACAD SCI USA, V83, P465, DOI 10.1073/pnas.83.2.465; Tomlinson I, 1999, NAT MED, V5, P11, DOI 10.1038/4687; Woo DK, 2001, INT J CANCER, V95, P108, DOI 10.1002/1097-0215(20010320)95:2<108::AID-IJC1019>3.0.CO;2-#; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Yasui W, 2001, Gastric Cancer, V4, P113, DOI 10.1007/PL00011733; YOKOZAKI H, 1994, CANCER LETT, V83, P229, DOI 10.1016/0304-3835(94)90324-7	38	43	50	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					5056	5067		10.1038/sj.onc.1207681	http://dx.doi.org/10.1038/sj.onc.1207681			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15107827				2022-12-17	WOS:000222237300012
J	Pedraza, LG; Stewart, RA; Li, DM; Xu, T				Pedraza, LG; Stewart, RA; Li, DM; Xu, T			Drosophila Src-family kinases function with Csk to regulate cell proliferation and apoptosis	ONCOGENE			English	Article						Src; Csk; oncogene; proliferation; apoptosis	C-SRC; TYROSINE KINASES; TRANSGENIC MICE; DEATH; GENE; EYE; EXPRESSION; ACTIVATION; CANCER; MATTER	Elevated Src protein levels and activity are associated with the development and progression of a variety of cancers. The consequences of deregulated Src activity have been studied extensively in cell culture; however, the effects of this deregulation in vivo, as well as the mechanisms of Src-induced tumorigenesis, remain poorly understood. In this study, the effect of expressing wildtype and constitutively active Drosophila Src-family kinases (SFKs) in the developing eye was examined. Overexpression of either wild-type Drosophila SFK (Src64 and Src42) is sufficient to induce ectopic proliferation in G(1)/G(0)-arrested, uncommitted cells in eye imaginal discs. In addition, both kinases trigger apoptosis in vivo, in a dosage-dependent manner. Constitutively active mutants are hypermorphic as they trigger proliferation and death more potently than their wild-type counterparts. Moreover, SFK-induced proliferation and apoptosis are largely independent events, as blocking ectopic proliferation does not block cell death. Further, DCsk (the Drosophila homolog of the C-terminal Src kinase) phosphorylates and interacts genetically with the wild-type SFKs, but not with the constitutively active mutants in which a conserved C-terminal tyrosine was mutated to phenylalanine, providing the first in vivo evidence that Csk regulates SFKs during development through phosphorylation of their C-terminal tyrosine.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Howard Hughes Med Inst,Dept Genet, New Haven, CT 06536 USA	Howard Hughes Medical Institute; Yale University	Xu, T (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Howard Hughes Med Inst,Dept Genet, 295 Congress Ave,POB 9812, New Haven, CT 06536 USA.	tian.xu@yale.edu	Stewart, Rodney/ABA-6757-2020	Stewart, Rodney/0000-0003-1220-1830	NATIONAL CANCER INSTITUTE [R01CA069408] Funding Source: NIH RePORTER; NCI NIH HHS [CA69408] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aouacheria A, 2002, BIOCHEM PHARMACOL, V64, P1605, DOI 10.1016/S0006-2952(02)01385-0; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Boudny V, 2002, BRIT J CANCER, V86, P463, DOI 10.1038/sj.bjc.6600080; BOUGERET C, 1993, ONCOGENE, V8, P1241; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; DENOOIJ JC, 1995, SCIENCE, V270, P983, DOI 10.1126/science.270.5238.983; Dodson GS, 1998, DEVELOPMENT, V125, P2883; Du W, 1996, EMBO J, V15, P3684, DOI 10.1002/j.1460-2075.1996.tb00738.x; Duffy JB, 2002, GENESIS, V34, P1, DOI 10.1002/gene.10150; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Evan G, 1997, INT J CANCER, V71, P709, DOI 10.1002/(SICI)1097-0215(19970529)71:5<709::AID-IJC2>3.0.CO;2-V; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Guo M, 1999, CURR OPIN CELL BIOL, V11, P745, DOI 10.1016/S0955-0674(99)00046-0; Igaki T, 2002, EMBO J, V21, P3009, DOI 10.1093/emboj/cdf306; Igaki T, 2000, P NATL ACAD SCI USA, V97, P662, DOI 10.1073/pnas.97.2.662; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; Johnson D, 2000, CELL DEATH DIFFER, V7, P685, DOI 10.1038/sj.cdd.4400700; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KUSSICK SJ, 1993, ONCOGENE, V8, P2791; KUSSICK SJ, 1992, ONCOGENE, V7, P2461; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; Ollmann M, 2000, CELL, V101, P91, DOI 10.1016/S0092-8674(00)80626-1; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; Stewart RA, 2003, ONCOGENE, V22, P6436, DOI 10.1038/sj.onc.1206820; Takahashi F, 1996, GENE DEV, V10, P1645, DOI 10.1101/gad.10.13.1645; Tateno M, 2000, SCIENCE, V287, P324, DOI 10.1126/science.287.5451.324; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Webb BL, 2000, MOL CELL BIOL, V20, P9271, DOI 10.1128/MCB.20.24.9271-9280.2000; WEBSTER MA, 1995, P NATL ACAD SCI USA, V92, P7849, DOI 10.1073/pnas.92.17.7849; Weissenberger J, 1997, ONCOGENE, V14, P2005, DOI 10.1038/sj.onc.1201168; WOLFF T, 1991, DEVELOPMENT, V113, P841	36	43	44	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2004	23	27					4754	4762		10.1038/sj.onc.1207635	http://dx.doi.org/10.1038/sj.onc.1207635			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZX	15107833				2022-12-17	WOS:000221799200010
J	Dhar, A; Hu, J; Reeves, R; Resar, LMS; Colburn, NH				Dhar, A; Hu, J; Reeves, R; Resar, LMS; Colburn, NH			Dominant-negative c-Jun (TAM67) target genes: HMGA1 is required for tumor promoter-induced transformation	ONCOGENE			English	Article						TAM67 target; AP-1; HMGA1; tumor promoter; transformation; JB6	NF-KAPPA-B; INHIBITS AP-1 TRANSACTIVATION; ACTIVATED PROTEIN-KINASE; MAMMARY EPITHELIAL-CELLS; MOUSE EPIDERMAL-CELLS; JB6 CELLS; NEOPLASTIC TRANSFORMATION; TRANSCRIPTION FACTOR; INCREASED EXPRESSION; SKIN CARCINOGENESIS	Activation of the transcription factor AP-1 (activator protein-1) is required for tumor promotion and maintenance of malignant phenotype. A number of AP-1-regulated genes that play a role in tumor progression have been identified. However, AP-1-regulated genes driving tumor induction are yet to be defined. Previous studies have established that expression of a dominant-negative c-Jun (TAM67) inhibits phorbol 12-tetradecanoyl-13-acetate (TPA)-induced AP-1 transactivation as well as transformation in mouse epidermal JB6/P+ cells and tumor promotion in mouse skin carcinogenesis. In this study, we utilized the tumor promotion-sensitive JB6/P+ cells to identify AP-1-regulated TAM67 target genes and to establish causal significance in transformation for one target gene. A 2700 cDNA microarray was queried with RNA from TPA-treated P+ cells with or without TAM67 expression. Under conditions in which TAM expression inhibited TPA-induced transformation, microarray analysis identified a subset of six genes induced by TPA and suppressed by TAM67. One of the identified genes, the high-mobility group protein A1 (Hmga1) is induced by TPA in P+, but not in transformation-resistant P cells. We show that TPA induction of the architectural transcription factor HMGA1 is inhibited by TAM67, is extracellular-signal-regulated kinase (ERK)-activation dependent, and is mediated by AP-1. HMGA1 antisense construct transfected into P+ cells blocked HMGA1 protein expression and inhibited TPA-induced transformation indicating that HMGA1 is required for transformation. HMGA1 is not however sufficient as HMGA1a or HMGA1b overexpression did not confer transformation sensitivity on P- cells. Although HMGA1 expression is ERK dependent, it is not the only ERK-dependent event required for transformation because it does not suffice to rescue ERK-deficient P- cells. Our study shows (a) TAM 67 when it inhibits AP-1 and transformation, targets a relatively small number of genes; (b) HMGA1, a TAM67 target gene, is causally related to transformation and therefore a potentially important target for cancer prevention.	NCI, Gene Regulat Sect, Lab Canc Prevent, CCR, Ft Detrick, MD 21702 USA; Washington State Univ, Sch Mol Biosci, Dept Biochem, Pullman, WA 99164 USA; Johns Hopkins Univ, Sch Med, Div Pediat Hematol, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Washington State University; Johns Hopkins University	Dhar, A (corresponding author), NCI, Gene Regulat Sect, Lab Canc Prevent, CCR, Bldg 567,Rm 180,Chandler St, Ft Detrick, MD 21702 USA.	adhar@ncifcrf.gov	Hu, Jing/M-3130-2014					Abe N, 1999, CANCER RES, V59, P1169; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; Balmain A, 2001, NAT REV CANCER, V1, P77, DOI 10.1038/35094086; Berlingieri MT, 2002, ONCOGENE, V21, P2971, DOI 10.1038/sj.onc.1205368; BERNSTEIN LR, 1994, J BIOL CHEM, V269, P9401; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BERNSTEIN LR, 1992, MOL CARCINOGEN, V6, P221, DOI 10.1002/mc.2940060308; Bouallaga I, 2003, MOL CELL BIOL, V23, P2329, DOI 10.1128/MCB.23.7.2329-2340.2003; BROWN PH, 1993, ONCOGENE, V8, P877; Budunova IV, 1999, ONCOGENE, V18, P7423, DOI 10.1038/sj.onc.1203104; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Chang PL, 2003, CARCINOGENESIS, V24, P1749, DOI 10.1093/carcin/bgg138; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; Chin MT, 1998, J BIOL CHEM, V273, P9755, DOI 10.1074/jbc.273.16.9755; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Cmarik JL, 1998, ONCOGENE, V16, P3387, DOI 10.1038/sj.onc.1201888; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; COLBURN NH, 1981, P NATL ACAD SCI-BIOL, V78, P6912, DOI 10.1073/pnas.78.11.6912; COLBURN NH, 1982, CANCER RES, V42, P3093; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; Cooper SJ, 2003, MOL CANCER RES, V1, P848; CRAIG AM, 1989, J BIOL CHEM, V264, P9682; Dhar A, 2002, MOL CELL BIOCHEM, V234, P185, DOI 10.1023/A:1015948505117; DONG ZG, 1995, CARCINOGENESIS, V16, P749, DOI 10.1093/carcin/16.4.749; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; Eto I, 1998, CELL PROLIFERAT, V31, P71, DOI 10.1046/j.1365-2184.1998.00112.x; FRIEDMANN M, 1993, NUCLEIC ACIDS RES, V21, P4259, DOI 10.1093/nar/21.18.4259; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Himes SR, 1996, IMMUNITY, V5, P479, DOI 10.1016/S1074-7613(00)80503-8; Himes SR, 2000, J IMMUNOL, V164, P3157, DOI 10.4049/jimmunol.164.6.3157; Hsu TC, 2001, CANCER RES, V61, P4160; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; Huang CS, 1999, ONCOGENE, V18, P2828, DOI 10.1038/sj.onc.1202639; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Johnston IMP, 2000, ONCOGENE, V19, P5348, DOI 10.1038/sj.onc.1203927; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kovacic P, 2001, CURR MED CHEM, V8, P773, DOI 10.2174/0929867013373084; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; Li JJ, 1997, CANCER RES, V57, P3569; Li JJ, 2000, MOL CARCINOGEN, V29, P159, DOI 10.1002/1098-2744(200011)29:3<159::AID-MC5>3.0.CO;2-W; OGRAM SA, 1995, J BIOL CHEM, V270, P14235, DOI 10.1074/jbc.270.23.14235; Ozanne BW, 2000, EUR J CANCER, V36, P1640, DOI 10.1016/S0959-8049(00)00175-1; Pedulla ML, 2001, GENE, V271, P51, DOI 10.1016/S0378-1119(01)00500-5; RAM TG, 1993, CANCER RES, V53, P2655; Reeves R, 1999, METHOD ENZYMOL, V304, P155; Reeves R, 2001, MOL CELL BIOL, V21, P575, DOI 10.1128/MCB.21.2.575-594.2001; ROBELS AI, 1995, CARCINOGENESIS, V16, P781, DOI 10.1093/carcin/16.4.781; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Suzukawa K, 2002, ENVIRON HEALTH PERSP, V110, P865, DOI 10.1289/ehp.02110865; TAMIMI Y, 1993, CANCER RES, V53, P5512; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; WATTS RG, 1995, MOL CARCINOGEN, V13, P27, DOI 10.1002/mc.2940130106; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; Wood LJ, 2000, MOL CELL BIOL, V20, P5490, DOI 10.1128/MCB.20.15.5490-5502.2000; Wood LJ, 2000, CANCER RES, V60, P4256; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Yang TY, 2002, IEEE T ADV PACKAGING, V25, P54, DOI 10.1109/TADVP.2002.1017686; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Young MR, 2003, TRENDS MOL MED, V9, P36, DOI 10.1016/S1471-4914(02)00009-6; Young MR, 2002, MOL CARCINOGEN, V34, P72, DOI 10.1002/mc.10050; Young MR, 2002, MOL CELL BIOL, V22, P587, DOI 10.1128/MCB.22.2.587-598.2002	68	43	49	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2004	23	25					4466	4476		10.1038/sj.onc.1207581	http://dx.doi.org/10.1038/sj.onc.1207581			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	824CJ	15064752				2022-12-17	WOS:000221661300012
J	Cheng, NL; Janumyan, YM; Didion, L; Van Hofwegen, C; Yang, E; Knudson, CM				Cheng, NL; Janumyan, YM; Didion, L; Van Hofwegen, C; Yang, E; Knudson, CM			Bcl-2 inhibition of T-cell proliferation is related to prolonged T-cell survival	ONCOGENE			English	Article						apoptosis; Bax; proliferation; T cells; quiescent; p27; Bcl-2	CYCLE ENTRY; TRANSGENIC MICE; PARADOXICAL INHIBITION; REDUCES PROLIFERATION; IN-VIVO; C-MYC; EXPRESSION; DEATH; APOPTOSIS; BAX	Bcl-2 promotes oncogenesis by inhibiting cell death. Bcl-2 also inhibits proliferation and suppresses tumorigenesis in some settings. To clarify the role of the antiproliferative function of Bcl-2, mice expressing a mutant form of Bcl-2 reported to lack antiproliferative activity were generated (tyrosine 28 to alanine, Bcl-2-Y28A). As expected, both wild type (WT) and Bcl-2-Y28A inhibited apoptosis similarly. In contrast to previous results in cell lines, Bcl-2-Y28A inhibited T-cell proliferation identical to WT-Bcl-2. Significantly, both Bcl-2-Y28A and WT-Bcl-2 inhibited proliferation of T cells isolated from older animals, but not proliferation of T cells from immature mice. Instead, inhibition of cell activation correlated with T-cell size, p27 levels, and RNA content, all indicators of quiescent G0 arrest. Consistent with this model, Bcl-2 inhibition of T-cell proliferation was reversed by expression of Bax, again correlating cell proliferation with cell size. These experiments do not support genetically separate effects of Bcl-2 on apoptosis and proliferation. Instead, the data support a model in which Bcl-2 and Bax regulate T-cell proliferation by changes in T-cell size and by increasing the markers of quiescent G0 arrest. These changes likely result from prolonged T-cell survival.	Univ Iowa, Roy J & Lucille P Carver Coll Med, Dept Pathol, Iowa City, IA 52242 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Pediat, Nashville, TN 37232 USA	University of Iowa; Vanderbilt University; Vanderbilt University	Knudson, CM (corresponding author), Univ Iowa, Roy J & Lucille P Carver Coll Med, Dept Pathol, 3160 ML, Iowa City, IA 52242 USA.	c-knudson@uiowa.edu		Knudson, Charles Michael/0000-0003-3964-5466	NATIONAL CANCER INSTITUTE [R01CA088967, R01CA078443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008554] Funding Source: NIH RePORTER; NCI NIH HHS [1R01CA88967, 1R01CA78443] Funding Source: Medline; NIGMS NIH HHS [T32GM08554] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bairey O, 1999, CLIN CANCER RES, V5, P2860; Buglioni S, 1999, INT J CANCER, V84, P545, DOI 10.1002/(SICI)1097-0215(19991222)84:6<545::AID-IJC1>3.0.CO;2-2; Bureau F, 2002, BLOOD, V99, P3683, DOI 10.1182/blood.V99.10.3683; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; DARZYNKIEWICZ Z, 1980, P NATL ACAD SCI-BIOL, V77, P6696, DOI 10.1073/pnas.77.11.6696; de la Coste A, 1999, CANCER RES, V59, P5017; GARVIN AM, 1990, INT IMMUNOL, V2, P173, DOI 10.1093/intimm/2.2.173; Greider C, 2002, ONCOGENE, V21, P7765, DOI 10.1038/sj.onc.1205928; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Harris MH, 2000, CELL DEATH DIFFER, V7, P1182, DOI 10.1038/sj.cdd.4400781; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hogarth LA, 1999, BLOOD, V93, P2671, DOI 10.1182/blood.V93.8.2671.408k26_2671_2678; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Janumyan YM, 2003, EMBO J, V22, P5459, DOI 10.1093/emboj/cdg533; Kaklamanis L, 1998, BRIT J CANCER, V77, P1864, DOI 10.1038/bjc.1998.310; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Knudson CM, 2001, CANCER RES, V61, P659; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; LINETTE GP, 1995, BLOOD, V86, P1255, DOI 10.1182/blood.V86.4.1255.bloodjournal8641255; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Luke JJ, 2003, CELL DEATH DIFFER, V10, P740, DOI 10.1038/sj.cdd.4401233; MacCarthy-Morrogh L, 1999, BIOCHEM SOC T, V27, P785, DOI 10.1042/bst0270785; Manne U, 1997, INT J CANCER, V74, P346, DOI 10.1002/(SICI)1097-0215(19970620)74:3<346::AID-IJC19>3.0.CO;2-9; MARVEL J, 1994, ONCOGENE, V9, P1117; Meterissian SH, 2001, ANN SURG ONCOL, V8, P533, DOI 10.1245/aso.2001.8.6.533; Murphy KL, 1999, ONCOGENE, V18, P6597, DOI 10.1038/sj.onc.1203099; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; OFNER D, 1995, BRIT J CANCER, V72, P981, DOI 10.1038/bjc.1995.446; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OReilly LA, 1997, J IMMUNOL, V159, P2301; OReilly LA, 1997, INT IMMUNOL, V9, P1291, DOI 10.1093/intimm/9.9.1291; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; PIETENPOL JA, 1994, CANCER RES, V54, P3714; Rathmell JC, 2000, MOL CELL, V6, P683, DOI 10.1016/S1097-2765(00)00066-6; Rossiter H, 2001, CANCER RES, V61, P3619; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SILVESTRINI R, 1994, J NATL CANCER I, V86, P499, DOI 10.1093/jnci/86.7.499; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; Uhlmann EJ, 1996, CANCER RES, V56, P2506; Vairo G, 2000, MOL CELL BIOL, V20, P4745, DOI 10.1128/MCB.20.13.4745-4753.2000; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0	43	43	43	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2004	23	21					3770	3780		10.1038/sj.onc.1207478	http://dx.doi.org/10.1038/sj.onc.1207478			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	15034548				2022-12-17	WOS:000221242500004
J	Halawani, D; Mondeh, R; Stanton, LA; Beier, F				Halawani, D; Mondeh, R; Stanton, LA; Beier, F			p38 MAP kinase signaling is necessary for rat chondrosarcoma cell proliferation	ONCOGENE			English	Article						chondrosarcoma; p38 MAPK; cell cycle; cyclins; p21(waf1/cip1)	ACTIVATED PROTEIN-KINASE; CYCLIN-A PROMOTER; TRANSCRIPTION FACTOR-2; RETINOBLASTOMA PROTEIN; MELANOMA-CELLS; D1; DIFFERENTIATION; INDUCTION; EXPRESSION; CHONDROCYTES	Chondrosarcomas represent the second most frequent class of primary skeletal malignancies. This tumor type is highly resistant to radiation therapy and currently available chemotherapies, thereby limiting treatment choice to surgical resection. Identifying the mechanisms responsible for chondrosarcoma cell proliferation is therefore crucial for the development of new treatment strategies. Here, we demonstrate a significant reduction in rat chondrosarcoma cell proliferation following treatment with pharmacological inhibitors (SB202190 and PD169316) of p38 mitogen-activated protein (MAP) kinases. In an attempt to dissect possible mechanisms, we investigated the effect of p38 inhibition on promoter activity of cell-cycle genes. Surprisingly, p38 inhibition resulted in upregulation of the activities of all three D-type cyclin promoters. In addition, p38 inhibitors induced increased transcription of the cell-cycle inhibitor p21(waf1/cip1). As expected, promoter activity of the cyclin A gene, which lies downstream of D-type cyclins and p21 in cell-cycle progression, was strongly reduced by p38 inhibitors. These effects were independent of a cyclic AMP response element and conferred by the proximal 150 nucleotides of the cyclin A promoter. Decreased transcription was accompanied by greatly reduced cyclin A protein levels upon p38 inhibition. These observations indicate complex regulation of chondrosarcoma cell-cycle progression by p38 signaling, and suggest that components of p38 MAP kinase pathways may be effective targets in the treatment of these tumors.	Univ Western Ontario, Dept Physiol & Pharmacol, Canadian Inst Hlth Res Grp Skeletal Dev & Remodel, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Beier, F (corresponding author), Univ Western Ontario, Dept Physiol & Pharmacol, Canadian Inst Hlth Res Grp Skeletal Dev & Remodel, London, ON N6A 5C1, Canada.	fbeier@uwo.ca	Beier, Frank/T-4734-2019; Halawani, Dalia/AAN-3261-2021; Beier, Frank/G-4595-2013	Beier, Frank/0000-0002-8505-7537; Beier, Frank/0000-0002-8505-7537				Aigner T, 2002, VIRCHOWS ARCH, V441, P219, DOI 10.1007/s00428-002-0641-X; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Alderton F, 2001, MOL PHARMACOL, V59, P1119, DOI 10.1124/mol.59.5.1119; Ambrosino C, 2001, BIOL CELL, V93, P47, DOI 10.1016/S0248-4900(01)01124-8; Beier F, 1999, J BIOL CHEM, V274, P30273, DOI 10.1074/jbc.274.42.30273; Beier F, 2000, J BIOL CHEM, V275, P12948, DOI 10.1074/jbc.275.17.12948; Beier F, 1999, P NATL ACAD SCI USA, V96, P1433, DOI 10.1073/pnas.96.4.1433; Beier F, 2002, MOL ENDOCRINOL, V16, P2163, DOI 10.1210/me.2001-0103; Beier F, 2001, MOL BIOL CELL, V12, P3852, DOI 10.1091/mbc.12.12.3852; Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090; Carnero A, 2002, BRIT J CANCER, V87, P129, DOI 10.1038/sj.bjc.6600458; Casanovas O, 2000, J BIOL CHEM, V275, P35091, DOI 10.1074/jbc.M006324200; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; Diehl NL, 2000, J EXP MED, V191, P321, DOI 10.1084/jem.191.2.321; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; Greenberg AK, 2002, AM J RESP CELL MOL, V26, P558, DOI 10.1165/ajrcmb.26.5.4689; Juretic N, 2001, J CELL BIOCHEM, V83, P92, DOI 10.1002/jcb.1211; Kakonen SM, 2002, J BIOL CHEM, V277, P24571, DOI 10.1074/jbc.M202561200; KIESS M, 1995, ONCOGENE, V10, P159; Maher P, 1999, J BIOL CHEM, V274, P17491, DOI 10.1074/jbc.274.25.17491; Meyyappan M, 1998, MOL CELL BIOL, V18, P3163, DOI 10.1128/MCB.18.6.3163; Mollano Anthony V, 2002, Iowa Orthop J, V22, P1; MUKHOPADHYAY K, 1995, J BIOL CHEM, V270, P27711, DOI 10.1074/jbc.270.46.27711; NAKAMURA T, 1995, EXP CELL RES, V216, P422, DOI 10.1006/excr.1995.1053; Neve RM, 2002, ONCOGENE, V21, P4567, DOI 10.1038/sj.onc.1205555; PETERS G, 1994, J CELL SCI, P89; Pring ME, 2001, J BONE JOINT SURG AM, V83A, P1630, DOI 10.2106/00004623-200111000-00003; Puri PL, 2000, GENE DEV, V14, P574; Recio JA, 2002, ONCOGENE, V21, P1000, DOI 10.1038/sj.onc.1205150; Royuela M, 2002, HUM PATHOL, V33, P299, DOI 10.1053/hupa.2002.32227; Shemirani B, 2002, ORAL ONCOL, V38, P251, DOI 10.1016/S1368-8375(01)00052-5; Shimizu M, 1998, EXP CELL RES, V239, P93, DOI 10.1006/excr.1997.3884; Smalley KSM, 2002, MELANOMA RES, V12, P187, DOI 10.1097/00008390-200206000-00001; Sylvester AM, 1998, J CLIN INVEST, V101, P940, DOI 10.1172/JCI1630; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; YAN GZ, 1995, J NEUROSCI, V15, P6200; Yosimichi G, 2001, EUR J BIOCHEM, V268, P6058, DOI 10.1046/j.0014-2956.2001.02553.x; Zhao M, 2002, ARCH BIOCHEM BIOPHYS, V400, P199, DOI 10.1016/S0003-9861(02)00028-0; Zhu T, 2000, J BIOL CHEM, V275, P2103, DOI 10.1074/jbc.275.3.2103	40	43	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3726	3731		10.1038/sj.onc.1207422	http://dx.doi.org/10.1038/sj.onc.1207422			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116104				2022-12-17	WOS:000221101700026
J	Hsu, JH; Shi, YJ; Frost, P; Yan, HJ; Hoang, B; Sharma, S; Gera, J; Lichtenstein, A				Hsu, JH; Shi, YJ; Frost, P; Yan, HJ; Hoang, B; Sharma, S; Gera, J; Lichtenstein, A			Interleukin-6 activates phosphoinositol-30 kinase in multiple myeloma tumor cells by signaling through RAS-dependent and, separately, through p85-dependent pathways	ONCOGENE			English	Article						multiple myeloma; interleukin-6; AKT; phosphatidylinositol-3 '-kinase	PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; TYROSINE PHOSPHORYLATION; GROWTH-FACTORS; AKT KINASE; N-RAS; SURVIVAL; RECEPTOR; PROTOONCOGENE; APOPTOSIS; RESPONSES	The IL-6-induced activation of the phosphatidylinositol-3' kinase (PI3-K)/AKTcascade in multiple myeloma (MM) cells is critical for tumor cell proliferation and viability. Since the IL-6 receptor does not contain binding sites for the p85 regulatory portion of PI3-K, intermediate molecules must play a role. Coimmunoprecipitation studies in MM cell lines demonstrated the IL-6-induced formation of two independent PI3-K-containing complexes: one containing p21 RAS but not STAT-3 and a second containing STAT-3 but not RAS. Both complexes demonstrated IL-6-induced lipid kinase activity. IL-6 also generated kinase activity in a mutant p110 molecule that could not bind p85. Use of dominant-negative (DN) constructs confirmed the presence of two independent pathways of activation: a DN RAS prevented the IL-6-induced generation of lipid kinase activity in the mutant p110 molecule but had no effect on activity generated in the STAT-3-containing complex. In contrast, a DN p85 prevented the generation of kinase activity in the STAT-3-containing complex but had no effect on activity generated in the p110 molecule. Both DN constructs significantly prevented the IL-6-induced activation of AKT. MM cells expressing activating RAS mutations demonstrated enhanced IL-6-independent growth and constitutive PI3-K activity. These data indicate two potential independent pathways of PI3-K/AKT activation in MM cells: one mediated via signaling through RAS which is independent of p85 and a second mediated via p85 and due to a STAT-3-containing complex.	W LA VA UCLA Med Ctr, Dept Med, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90073 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Lichtenstein, A (corresponding author), VA W LA Hosp, W111H,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.	alan.lichtenstein@med.va.gov		Gera, Joseph/0000-0002-2908-6894; Frost, Patrick/0000-0003-3348-5983				ANDERSON KC, 1989, BLOOD, V73, P1915; BILLADEAU D, 1995, CANCER RES, V55, P3640; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Hakak Y, 2000, ONCOGENE, V19, P3164, DOI 10.1038/sj.onc.1203655; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Hsu JH, 2002, ONCOGENE, V21, P1391, DOI 10.1038/sj/onc/1205194; Hsu JH, 2001, BLOOD, V98, P2853, DOI 10.1182/blood.V98.9.2853; Hu LP, 2003, BLOOD, V101, P3126, DOI 10.1182/blood-2002-08-2640; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; Lee IS, 1997, FEBS LETT, V401, P133, DOI 10.1016/S0014-5793(96)01456-1; Liu PC, 1996, BLOOD, V88, P2699, DOI 10.1182/blood.V88.7.2699.bloodjournal8872699; Ogata A, 1997, J IMMUNOL, V159, P2212; Oh H, 1998, J BIOL CHEM, V273, P9703, DOI 10.1074/jbc.273.16.9703; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; Podar K, 2002, J BIOL CHEM, V277, P7875, DOI 10.1074/jbc.M109068200; PODAR K, 2003, HEMATOL J, V4, pS140; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Rowley M, 2000, BLOOD, V96, P3175, DOI 10.1182/blood.V96.9.3175.h8003175_3175_3180; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; Shigematsu H, 1997, J BIOL CHEM, V272, P14334, DOI 10.1074/jbc.272.22.14334; SJOLANDER A, 1991, P NATL ACAD SCI USA, V88, P7908, DOI 10.1073/pnas.88.18.7908; Tu YP, 2000, CANCER RES, V60, P6763; Ueno H, 1998, BLOOD, V91, P46, DOI 10.1182/blood.V91.1.46.46_46_53	30	43	43	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3368	3375		10.1038/sj.onc.1207459	http://dx.doi.org/10.1038/sj.onc.1207459			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15021914				2022-12-17	WOS:000220975000011
J	Van Gele, M; Boyle, GM; Cook, AL; Vandesompele, J; Boonefaes, T; Rottiers, P; Van Roy, N; De Paepe, A; Parsons, PG; Leonard, JH; Speleman, F				Van Gele, M; Boyle, GM; Cook, AL; Vandesompele, J; Boonefaes, T; Rottiers, P; Van Roy, N; De Paepe, A; Parsons, PG; Leonard, JH; Speleman, F			Gene-expression profiling reveals distinct expression patterns for classic versus variant Merkel cell phenotypes and new classifier genes to distinguish Merkel cell from small-cell lung carcinoma	ONCOGENE			English	Article						Merkel cell carcinoma; small-cell lung carcinoma; differential expression profiling; differential diagnosis; classic/variant	INTERMEDIATE-FILAMENT PROTEINS; SHORT ARM; KINASE-C; CANCER; LINES; IDENTIFICATION; DIFFERENTIATION; ADENOCARCINOMA; PROLIFERATION; ESTABLISHMENT	Merkel cell carcinoma (MCC) is a rare aggressive skin tumor which shares histopathological and genetic features with small-cell lung carcinoma (SCLC), both are of neuroendocrine origin. Comparable to SCLC, MCC cell lines are classified into two different biochemical subgroups designated as 'Classic' and 'Variant'. With the aim to identify typical gene-expression signatures associated with these phenotypically different MCC cell lines subgroups and to search for differentially expressed genes between MCC and SCLC, we used cDNA arrays to pro. le 10 MCC cell lines and four SCLC cell lines. Using significance analysis of microarrays, we defined a set of 76 differentially expressed genes that allowed unequivocal identification of Classic and Variant MCC subgroups. We assume that the differential expression levels of some of these genes reflect, analogous to SCLC, the different biological and clinical properties of Classic and Variant MCC phenotypes. Therefore, they may serve as useful prognostic markers and potential targets for the development of new therapeutic interventions specific for each subgroup. Moreover, our analysis identified 17 powerful classifier genes capable of discriminating MCC from SCLC. Real-time quantitative RT-PCR analysis of these genes on 26 additional MCC and SCLC samples confirmed their diagnostic classification potential, opening opportunities for new investigations into these aggressive cancers.	Ghent Univ Hosp, Ctr Med Genet, B-9000 Ghent, Belgium; Queensland Inst Med Res, Melanoma Genom Grp, Brisbane, Qld 4006, Australia; Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Flanders Interuniv Inst Biotechnol, Dept Mol Biomed Res, B-9000 Ghent, Belgium; Univ Ghent, B-9000 Ghent, Belgium; Queensland Inst Med Res, Queensland Radium Inst Res Unit, Brisbane, Qld 4006, Australia	Ghent University; Ghent University Hospital; QIMR Berghofer Medical Research Institute; University of Queensland; Ghent University; QIMR Berghofer Medical Research Institute	Speleman, F (corresponding author), Ghent Univ Hosp, Ctr Med Genet, B-9000 Ghent, Belgium.	franki.speleman@UGent.be	Leonard, Helen/F-2022-2013; Boyle, Glen/G-1347-2013; speleman, frank/AAR-5184-2020; Parsons, Peter G/H-8163-2015; Cook, Anthony/K-9489-2018; Vandesompele, Jo/W-3411-2018	Boyle, Glen/0000-0002-1385-529X; speleman, frank/0000-0002-6628-8559; Parsons, Peter G/0000-0002-0473-3346; Cook, Anthony/0000-0003-1770-7910; Vandesompele, Jo/0000-0001-6274-0184				Baumann KI, 2000, INT CONGR SER, V1187, P73; BENZIL DL, 1992, CANCER RES, V52, P2951; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Borges M, 1997, NATURE, V386, P852, DOI 10.1038/386852a0; Botchkarev VA, 1999, J INVEST DERMATOL, V113, P691; BROERS JLV, 1986, J CELL SCI, V83, P37; BROERS JLV, 1985, P NATL ACAD SCI USA, V82, P4409, DOI 10.1073/pnas.82.13.4409; Buchner K, 2000, J CANCER RES CLIN, V126, P1, DOI 10.1007/PL00008458; CARNEY DN, 1985, CANCER RES, V45, P2913; Carroll P, 1998, NAT NEUROSCI, V1, P42, DOI 10.1038/242; Cook AL, 2001, INT J CANCER, V93, P361; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fong KM, 1999, J THORAC CARDIOV SUR, V118, P1136, DOI 10.1016/S0022-5223(99)70121-2; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; GAZDAR AF, 1985, CANCER RES, V45, P2924; Goessling W, 2002, J CLIN ONCOL, V20, P588, DOI 10.1200/JCO.20.2.588; Halata Z, 2003, ANAT REC PART A, V271A, P225, DOI 10.1002/ar.a.10029; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Leonard JH, 1997, GENE CHROMOSOME CANC, V20, P93, DOI 10.1002/(SICI)1098-2264(199709)20:1<93::AID-GCC14>3.0.CO;2-G; Leonard JH, 2002, INT J CANCER, V101, P103, DOI 10.1002/ijc.10554; LEONARD JH, 1995, INT J RADIAT ONCOL, V32, P1401, DOI 10.1016/0360-3016(94)00610-W; LEONARD JH, 1995, INT J CANCER, V60, P100, DOI 10.1002/ijc.2910600115; LEONARD JH, 1993, INT J CANCER, V55, P803, DOI 10.1002/ijc.2910550519; Leonard JH, 2000, CANCER DETECT PREV, V24, P620; LEONARD JH, 1997, AUSTRALAS J DERMATOL, V38, P91; LEVIN NA, 1995, GENE CHROMOSOME CANC, V13, P175, DOI 10.1002/gcc.2870130307; Metz KA, 1998, GRAEF ARCH CLIN EXP, V236, P561, DOI 10.1007/s004170050121; Miller RW, 1999, CANCER EPIDEM BIOMAR, V8, P153; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; Moll I, 1996, J CUTAN PATHOL, V23, P109, DOI 10.1111/j.1600-0560.1996.tb01283.x; Pattyn F, 2003, NUCLEIC ACIDS RES, V31, P122, DOI 10.1093/nar/gkg011; Pedersen N, 2003, CANCER RES, V63, P1943; Petersen I, 1997, BRIT J CANCER, V75, P79, DOI 10.1038/bjc.1997.13; Popp S, 2002, INT J CANCER, V99, P352, DOI 10.1002/ijc.10321; RATNER D, 1993, J AM ACAD DERMATOL, V29, P143, DOI 10.1016/0190-9622(93)70159-Q; RIED T, 1994, CANCER RES, V54, P1801; RONAN SG, 1993, J AM ACAD DERMATOL, V29, P715, DOI 10.1016/0190-9622(93)70236-M; ROSEN ST, 1987, LAB INVEST, V56, P302; Scaglione-Sewell B, 1998, CANCER RES, V58, P1074; Schmidt U, 1998, AM J DERMATOPATH, V20, P346, DOI 10.1097/00000372-199808000-00004; Tazaki M, 2000, INT CONGR SER, V1187, P63; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Van Gele M, 1998, CANCER RES, V58, P1503; Van Gele M, 2002, INT J CANCER, V101, P137, DOI 10.1002/ijc.10591; Van Gele M, 2000, BRIT J CANCER, V82, P823; Vandesompele J, 2002, ANAL BIOCHEM, V303, P95, DOI 10.1006/abio.2001.5564; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Zajchowski DA, 2001, CANCER RES, V61, P5168; Zhang L, 2000, J SURG RES, V93, P108, DOI 10.1006/jsre.2000.5957	49	43	44	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2004	23	15					2732	2742		10.1038/sj.onc.1207421	http://dx.doi.org/10.1038/sj.onc.1207421			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	810OZ	14755241				2022-12-17	WOS:000220714900015
J	Peirce, SK; Chen, WY				Peirce, SK; Chen, WY			Human prolactin and its antagonist, hPRL-G129R, regulate bax and bcl-2 gene expression in human breast cancer cells and transgenic mice	ONCOGENE			English	Article						prolactin antagonist; bax; bcl-2; cytochrome c; breast cancer; apoptosis	MAMMARY-GLAND; APOPTOSIS; GROWTH; FAMILY; PROMOTER	To gain insight into the molecular mechanisms involved in human prolactin receptor antagonist (hPRL-G129R)induced apoptosis, we used real-time reverse transcription - polymerase chain reaction to measure bax and bcl-2 gene expression in 11 human breast cancer cell lines following treatment with hPRL and hPRL-G129R. We also measured bax and bcl-2 gene expression in the mammary glands of transgenic mice expressing hPRL or hPRL-G129R. A time-course study of hPRL and antagonist treatment in T-47D cells indicated changing bax/bcl-2 mRNA ratios beginning at 24 h. We found that bax/bcl-2 mRNA ratios were significantly elevated in seven of the 11 hPRL-G129R-treated cell lines, as well as in the hPRL-G129R transgenic mice. To confirm these results, Bax and Bcl-2 proteins were analysed by Western blot methods in mammary gland tissue homogenates of transgenic mice. Bax/Bcl-2 ratios were highest in the 6-month group of hPRL-G129R transgenics, and lowest in the 6-month group of hPRL transgenics. We expanded our findings by examining the release of a downstream Bax-induced protein, cytochrome c, a hallmark protein of apoptosis, in transgenic mice. Again, cytochrome c levels were highest in the 6-month hPRL-G129R transgenic group. Thus, hPRL-G129R-induced breast cancer cell and/or mammary gland apoptosis is mediated, at least in part, through the regulation of Bax and Bcl-2 gene expression.	Greenville Hosp Syst, Oncol Res Inst, Greenville, SC 29605 USA; Clemson Univ, Dept Biol Sci, Clemson, SC 29630 USA; Clemson Univ, Dept Biochem & Genet, Clemson, SC 29630 USA	Greenville Health System; Clemson University; Clemson University	Chen, WY (corresponding author), Greenville Hosp Syst, Oncol Res Inst, 900 W Faris Rd, Greenville, SC 29605 USA.	wchen@ghs.org			NCI NIH HHS [CA87093] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA087093] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Beck MT, 2002, ONCOGENE, V21, P5047, DOI 10.1038/sj.onc.1205637; Ben-Jonathan N, 2002, TRENDS ENDOCRIN MET, V13, P245, DOI 10.1016/S1043-2760(02)00603-3; Bhatavdekar JM, 2000, EUR J SURG ONCOL, V26, P540, DOI 10.1053/ejso.2000.0943; Binart N, 2000, ADV EXP MED BIOL, V480, P85; Binder C, 1996, ANN ONCOL, V7, P129; BLACKWELL RE, 1999, HORMONAL CONTROL NOR, P3; Brockman JL, 2002, MOL ENDOCRINOL, V16, P774, DOI 10.1210/me.16.4.774; Chen NY, 2002, INT J ONCOL, V20, P813; Chen WY, 1999, CLIN CANCER RES, V5, P3583; CLEVENGER CV, 1995, AM J PATHOL, V146, P695; Clevenger CV, 2003, ENDOCR REV, V24, P1, DOI 10.1210/er.2001-0036; Corbacho AM, 2002, J ENDOCRINOL, V173, P219, DOI 10.1677/joe.0.1730219; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; GINSBURG E, 1995, CANCER RES, V55, P2591; Green DR, 1999, CANC DRUG DISC DEV, V5, P157; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; Krajewski S, 1999, ENDOCR-RELAT CANCER, V6, P29, DOI 10.1677/erc.0.0060029; Krumenacker JS, 1998, ENDOCRINE, V9, P163, DOI 10.1385/ENDO:9:2:163; Kumar R, 2000, ENDOCR-RELAT CANCER, V7, P257, DOI 10.1677/erc.0.0070257; Kuo CB, 2002, CELL TISSUE RES, V309, P429, DOI 10.1007/s00441-002-0598-8; Marti A, 1997, EUR J CELL BIOL, V73, P158; NAGASAWA H, 1985, EXP CLIN ENDOCRINOL, V86, P357, DOI 10.1055/s-0029-1210509; Peirce SK, 2001, J ENDOCRINOL, V171, pR1, DOI 10.1677/joe.0.171R001; Schorr K, 1999, CANCER RES, V59, P2541; Vonderhaar BK, 1998, PHARMACOL THERAPEUT, V79, P169, DOI 10.1016/S0163-7258(98)00017-5; Vonderhaar BK, 1999, ENDOCR-RELAT CANCER, V6, P389, DOI 10.1677/erc.0.0060389; Wennbo H, 1997, ENDOCRINOLOGY, V138, P4410, DOI 10.1210/en.138.10.4410; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zhang H, 2000, P NATL ACAD SCI USA, V97, P2597, DOI 10.1073/pnas.97.6.2597	31	43	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1248	1255		10.1038/sj.onc.1207245	http://dx.doi.org/10.1038/sj.onc.1207245			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14647416				2022-12-17	WOS:000188892200009
J	Perani, M; Ingram, CJE; Cooper, CS; Garrett, MD; Goodwin, GH				Perani, M; Ingram, CJE; Cooper, CS; Garrett, MD; Goodwin, GH			Conserved SNH domain of the proto-oncoprotein SYT interacts with components of the human chromatin remodelling complexes, while the QPGY repeat domain forms homo-oligomers	ONCOGENE			English	Article						SYT; SYT-SSX; synovial sarcoma; BRM; BRG1; chromatin remodelling	HUMAN SYNOVIAL SARCOMA; MAMMALIAN SWI/SNF COMPLEXES; CHIMERIC PROTEIN; DNA-BINDING; TRANSCRIPTIONAL ACTIVATOR; CHROMOSOME-TRANSLOCATION; SH3 DOMAINS; CELL-CYCLE; SSX; FUSION	Many studies have now established that the SWI/SNF chromatin remodelling complexes are involved in activation and repression of a variety of genes. In mammalian cells, these complexes contain the BRM and BRG1 helicase-like proteins that are thought to be responsible for nucleosome remodelling. The proto-oncoprotein SYT, involved in the unique translocation t(X;18) found in synovial sarcoma, is known to interact with human BRM (hBRM), thus providing a link between chromatin remodelling factors and human cancer. In this work, we address how SYT interacts with hBRM and BRG1. We demonstrate that the conserved N-terminal SNH domain of SYT, which is also present in the oncoproteins SYT-SSX, binds to both hBRM and BRG1. We have also found that in vivo the C-terminus transactivation QPGY region of SYT can interact with itself. This results in an amplified interaction with hBRM and highlights a possible regulatory function of this domain in cells.	Inst Canc Res, BLB, Sect Mol Carcinogenesis, Sutton SM 5NG, Surrey, England; Inst Canc Res, Canc Res UK Ctr Canc Therapeut, Sutton, Surrey, England	University of London; Institute of Cancer Research - UK; Cancer Research UK; University of London; Institute of Cancer Research - UK	Perani, M (corresponding author), Inst Canc Res, BLB, Sect Mol Carcinogenesis, 15 Cotswold Rd, Sutton SM 5NG, Surrey, England.	michela.perani@icr.ac.uk		Ingram, Catherine/0000-0003-2863-8930	Worldwide Cancer Research [99-0108] Funding Source: Medline	Worldwide Cancer Research		Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; Brett D, 1997, HUM MOL GENET, V6, P1559, DOI 10.1093/hmg/6.9.1559; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; Dallas PB, 2000, MOL CELL BIOL, V20, P3137, DOI 10.1128/MCB.20.9.3137-3146.2000; Dallas PB, 1998, MOL CELL BIOL, V18, P3596, DOI 10.1128/MCB.18.6.3596; de Bruijn DRH, 2001, ONCOGENE, V20, P3281, DOI 10.1038/sj.onc.1204419; deBruijn DRH, 1996, ONCOGENE, V13, P643; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DELEEUW B, 1995, HUM MOL GENET, V4, P1097, DOI 10.1093/hmg/4.6.1097; dos Santos NR, 2000, EXP CELL RES, V256, P192, DOI 10.1006/excr.2000.4813; dos Santos NR, 2001, GENE CHROMOSOME CANC, V30, P1, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1056>3.0.CO;2-G; Eid JE, 2000, CELL, V102, P839, DOI 10.1016/S0092-8674(00)00072-6; Fisher C, 1998, Ann Diagn Pathol, V2, P401, DOI 10.1016/S1092-9134(98)80042-7; Gure AO, 1997, INT J CANCER, V72, P965, DOI 10.1002/(SICI)1097-0215(19970917)72:6<965::AID-IJC8>3.0.CO;2-N; Hurlstone AFL, 2002, BIOCHEM J, V364, P255, DOI 10.1042/bj3640255; Kato H, 2002, J BIOL CHEM, V277, P5498, DOI 10.1074/jbc.M108702200; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Lim FL, 1998, ONCOGENE, V17, P2013, DOI 10.1038/sj.onc.1202122; Martens JA, 2002, GENE DEV, V16, P2231, DOI 10.1101/gad.1009902; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Muchardt C, 2001, ONCOGENE, V20, P3067, DOI 10.1038/sj.onc.1204331; Nagai M, 2001, P NATL ACAD SCI USA, V98, P3843, DOI 10.1073/pnas.061036798; Nie ZQ, 2000, MOL CELL BIOL, V20, P8879, DOI 10.1128/MCB.20.23.8879-8888.2000; O'Neill D, 1999, P NATL ACAD SCI USA, V96, P349, DOI 10.1073/pnas.96.2.349; OHNO T, 1993, CANCER RES, V53, P5859; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Peterson CL, 1996, CURR OPIN GENET DEV, V6, P171, DOI 10.1016/S0959-437X(96)80047-5; Skytting B, 1999, J NATL CANCER I, V91, P974, DOI 10.1093/jnci/91.11.974; SMITH S, 1987, CANCER GENET CYTOGEN, V26, P179, DOI 10.1016/0165-4608(87)90147-6; Soulez M, 1999, ONCOGENE, V18, P2739, DOI 10.1038/sj.onc.1202613; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Thaete C, 1999, HUM MOL GENET, V8, P585, DOI 10.1093/hmg/8.4.585; TREICH I, 1995, MOL CELL BIOL, V15, P4240; Tureci O, 1996, CANCER RES, V56, P4766; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Xie YT, 2002, ONCOGENE, V21, P5791, DOI 10.1038/sj.onc.1205700; Xie YT, 2002, CANCER RES, V62, P3861	41	43	44	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	2003	22	50					8156	8167		10.1038/sj.onc.1207031	http://dx.doi.org/10.1038/sj.onc.1207031			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603256				2022-12-17	WOS:000186403400010
J	Mor, O; Nativ, O; Stein, A; Novak, L; Lehavi, D; Shiboleth, Y; Rozen, A; Berent, E; Brodsky, L; Feinstein, E; Rahav, A; Morag, K; Rothenstein, D; Persi, N; Mor, Y; Skaliter, R; Regev, A				Mor, O; Nativ, O; Stein, A; Novak, L; Lehavi, D; Shiboleth, Y; Rozen, A; Berent, E; Brodsky, L; Feinstein, E; Rahav, A; Morag, K; Rothenstein, D; Persi, N; Mor, Y; Skaliter, R; Regev, A			Molecular analysis of transitional cell carcinoma using cDNA microarray	ONCOGENE			English	Article						transitional cell carcinoma; cDNA microarray; molecular markers; expression profiling; tumor classification	BLADDER-CANCER; GENE-EXPRESSION; URINARY-BLADDER; CATHEPSIN-E; CLASSIFICATION; IDENTIFICATION; PATTERNS; MARKERS; TUMORS; GROWTH	The incidence of transitional cell carcinoma (TCC), the fourth most common neoplasm diagnosed in men, is rising. Despite the development of several noninvasive diagnostic tests, none have gained full recognition by the clinicians. Gene expression pro. ling of tumors can identify new molecular markers for early diagnosis and disease follow-up. It also allows the classification of tumors into subclasses assisting in disease diagnosis and prognosis, as well as in treatment selection. In this paper, we employed expression pro. ling for molecular analysis of TCC. A TCC-derived cDNA microarray was constructed and hybridized with 19 probes from normal urothelium and TCC tissues. Hierarchical clustering analysis identified all normal urothelium samples to be tightly clustered and separated from the TCC samples, with 29 of the genes significantly induced (t-test, P<10(-5)) in noninvasive TCC compared to normal urothelium. The identified genes are involved in epithelial cells' functions, tumorigenesis or apoptosis, and could become molecular tools for noninvasive TCC diagnosis. Principal components analysis of the noninvasive and invasive TCC expression profiles further revealed sets of genes that are specifically induced in different tumor subsets, thus providing molecular fingerprints that expand the information gained from classical staging and grading.	QBI Enterprises Ltd, IL-70400 Ness Ziona, Israel; Bnei Zion Med Ctr, Dept Urol, Haifa, Israel; Carmel Hosp, Dept Urol, Haifa, Israel; Chaim Sheba Med Ctr, Dept Urol, IL-52621 Ramat Gan, Israel	Bnai Zion Medical Center; Clalit Health Services; Carmel Medical Center; Chaim Sheba Medical Center	Mor, O (corresponding author), QBI Enterprises Ltd, POB 4071, IL-70400 Ness Ziona, Israel.			Stein, Avi/0000-0002-7886-2458; Shiboleth, Yoel/0000-0001-5941-4978				Bayer-Garner IB, 2000, AM J DERMATOPATH, V22, P119, DOI 10.1097/00000372-200004000-00005; Bieller A, 2001, DNA CELL BIOL, V20, P555, DOI 10.1089/104454901317094963; Brown FM, 2000, UROL CLIN N AM, V27, P25, DOI 10.1016/S0094-0143(05)70231-7; Burchardt M, 2000, CLIN CHEM, V46, P595; Choudry GA, 2001, BRIT J CANCER, V85, P1137, DOI 10.1054/bjoc.2001.2056; Dobra K, 2000, EXP CELL RES, V258, P12, DOI 10.1006/excr.2000.4915; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; Dyrskjot L, 2003, NAT GENET, V33, P90, DOI 10.1038/ng1061; Engel LS, 2002, AM J EPIDEMIOL, V156, P95, DOI 10.1093/aje/kwf018; Feroze-Merzoug F, 2002, BIOTECHNIQUES, V32, P776, DOI 10.2144/02324st03; Giordano TJ, 2003, AM J PATHOL, V162, P521, DOI 10.1016/S0002-9440(10)63846-1; Giroldi Laurence A., 2000, Morphologie, V84, P31; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Itoh H, 2000, AM J PHYSIOL-GASTR L, V278, pG635, DOI 10.1152/ajpgi.2000.278.4.G635; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Kataoka H, 2000, CANCER LETT, V148, P127, DOI 10.1016/S0304-3835(99)00322-5; Kausch I, 2002, EUR UROL, V41, P15, DOI 10.1016/S0302-2838(01)00007-0; Koenig F, 2000, CLIN CHIM ACTA, V297, P191, DOI 10.1016/S0009-8981(00)00246-1; KWAK MK, 2002, J BIOL CHEM, V27, P27; Levy A, 1999, GENE CHROMOSOME CANC, V24, P42, DOI 10.1002/(SICI)1098-2264(199901)24:1<42::AID-GCC6>3.0.CO;2-F; Liu ET, 2003, CURR OPIN GENET DEV, V13, P97, DOI 10.1016/S0959-437X(03)00008-X; Liu NF, 2001, CANCER RES, V61, P5207; Liu YX, 2001, CHINESE MED J-PEKING, V114, P35; Macgregor PF, 2002, CLIN CHEM, V48, P1170; Menard S, 1998, BREAST CANCER RES TR, V52, P137, DOI 10.1023/A:1006171403765; Mohr S, 2002, J CLIN ONCOL, V20, P3165, DOI 10.1200/JCO.2002.12.073; Mota F, 1997, AM J PATHOL, V150, P1223; Rotem D, 2000, EUR UROL, V37, P601, DOI 10.1159/000020199; Schamhart DHJ, 2000, EUR UROL, V37, P16, DOI 10.1159/000052388; Simon R, 2002, ONCOGENE, V21, P2476, DOI 10.1038/sj.onc.1205304; Southgate J, 1999, HISTOL HISTOPATHOL, V14, P657, DOI 10.14670/HH-14.657; Thykjaer T, 2001, CANCER RES, V61, P2492; Turner KJ, 2002, BRIT J CANCER, V86, P1276, DOI 10.1038/sj.bjc.6600215; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vila MR, 2000, CANCER, V89, P152; Weiner HL, 2000, NEUROSURGERY, V47, P1400, DOI 10.1097/00006123-200012000-00028; Yamamoto S, 1996, VIRCHOWS ARCH, V427, P589; Yue HB, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.8.e41	39	43	45	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 23	2003	22	48					7702	7710		10.1038/sj.onc.1207039	http://dx.doi.org/10.1038/sj.onc.1207039			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KQ	14576834				2022-12-17	WOS:000186113000019
J	Henriksen, J; Aagesen, TH; Maelandsmo, GM; Lothe, RA; Myklebost, O; Forus, A				Henriksen, J; Aagesen, TH; Maelandsmo, GM; Lothe, RA; Myklebost, O; Forus, A			Amplification and overexpression of COPS3 in osteosarcomas potentially target TP53 for proteasome-mediated degradation	ONCOGENE			English	Article						COP9 signalosome; chromosome 17; mdm2; sarcoma; CSN3; CGH	COMPARATIVE GENOMIC HYBRIDIZATION; MDM2 GENE AMPLIFICATION; SMITH-MAGENIS-SYNDROME; ADIPOSE-TISSUE TUMORS; HUMAN SARCOMAS; CYTOGENETIC FINDINGS; SIGNAL-TRANSDUCTION; DNA-SEQUENCES; REGION; IDENTIFICATION	In sarcomas, the TP53 tumour suppressor pathway may be altered either by TP53 mutations or by amplification of MDM2, encoding a protein that inhibits TP53 and targets it for 26S-proteasome degradation. However, in the majority of the analysed clinical samples, neither of these types of aberrations are found, suggesting that additional mechanisms are involved. The present study shows that COPS3, located in 17p11 and encoding a component of the proteasome pathway, is more frequently amplified in osteosarcomas (OS) than is MDM2. We present detailed analysis of TP53 mutations and MDM2 and COPS3 expression levels in a set of 23 OS. Our results show that none of the tumours with COPS3 amplification had MDM2 amplification nor TP53 mutations, consistent with the hypothesis that one of the three aberrations is sufficient. The results suggest that inactivation of otherwise intact TP53 by aberrations in the proteasome pathway may contribute to the characteristic aneuploidy observed in OS.	Norwegian Radium Hosp, Inst Canc Res, Dept Tumor Biol, N-0310 Oslo, Norway; Norwegian Radium Hosp, Inst Canc Res, Dept Genet, N-0310 Oslo, Norway	University of Oslo; University of Oslo	Myklebost, O (corresponding author), Norwegian Radium Hosp, Inst Canc Res, Dept Tumor Biol, N-0310 Oslo, Norway.	olam@radium.uio.no	Myklebost, Ola/E-9335-2010	Myklebost, Ola/0000-0002-2866-3223; Lothe, Ragnhild A./0000-0002-1693-1032				Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Bech-Otschir D, 2002, J CELL SCI, V115, P467; Berner JM, 1996, GENE CHROMOSOME CANC, V17, P254, DOI 10.1002/(SICI)1098-2264(199612)17:4<254::AID-GCC7>3.0.CO;2-2; Bridge JA, 1997, CANCER GENET CYTOGEN, V95, P74, DOI 10.1016/S0165-4608(96)00306-8; Bridge JA, 1994, CYTOGENETICS BONE SO; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; El-Rifai W, 1998, AM J PATHOL, V153, P985, DOI 10.1016/S0002-9440(10)65640-4; Elsea SH, 1999, AM J MED GENET, V87, P342, DOI 10.1002/(SICI)1096-8628(19991203)87:4<342::AID-AJMG12>3.3.CO;2-1; FLETCHER JA, 1994, CANCER GENET CYTOGEN, V77, P81, DOI 10.1016/0165-4608(94)90154-6; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; FORUS A, 1995, GENE CHROMOSOME CANC, V14, P15, DOI 10.1002/gcc.2870140104; FORUS A, 1993, CELL GROWTH DIFFER, V4, P1065; FORUS A, 1995, GENE CHROMOSOME CANC, V14, P8, DOI 10.1002/gcc.2870140103; Hansen DV, 2002, ONCOGENE, V21, P6209, DOI 10.1038/sj.onc.1205824; HUANG LS, 1985, P NATL ACAD SCI USA, V82, P6825, DOI 10.1073/pnas.82.20.6825; Hulsebos TJM, 1997, GENE CHROMOSOME CANC, V18, P279, DOI 10.1002/(SICI)1098-2264(199704)18:4<279::AID-GCC5>3.0.CO;2-Y; LADANYI M, 1993, CANCER RES, V53, P16; LINK MP, 1993, CANC PRINCIPLES PRAC, P1534; Lothe RA, 2001, GENE CHROMOSOME CANC, V30, P202, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1079>3.3.CO;2-X; MERTENS F, 1993, INT J CANCER, V55, P44, DOI 10.1002/ijc.2910550109; NAKAYAMA T, 1995, INT J CANCER, V64, P342, DOI 10.1002/ijc.2910640511; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Pedeutour F, 1999, GENE CHROMOSOME CANC, V24, P30, DOI 10.1002/(SICI)1098-2264(199901)24:1<30::AID-GCC5>3.0.CO;2-P; Potocki L, 1999, GENOMICS, V57, P180, DOI 10.1006/geno.1998.5748; Simons A, 2000, CANCER GENET CYTOGEN, V118, P89, DOI 10.1016/S0165-4608(99)00178-8; Stock C, 2000, GENE CHROMOSOME CANC, V28, P329, DOI 10.1002/1098-2264(200007)28:3<329::AID-GCC11>3.0.CO;2-F; Szymanska J, 1996, GENE CHROMOSOME CANC, V15, P89, DOI 10.1002/(SICI)1098-2264(199602)15:2<89::AID-GCC2>3.0.CO;2-#; TARKKANEN M, 1993, CANCER GENET CYTOGEN, V68, P1, DOI 10.1016/0165-4608(93)90068-W; TARKKANEN M, 1995, CANCER RES, V55, P1334; Weiss SW, 1994, WHO HISTOLOGICAL CLA, V2nd; Wolf M, 1999, INT J CANCER, V82, P329, DOI 10.1002/(SICI)1097-0215(19990730)82:3<329::AID-IJC4>3.0.CO;2-1	31	43	46	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2003	22	34					5358	5361		10.1038/sj.onc.1206671	http://dx.doi.org/10.1038/sj.onc.1206671			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917637				2022-12-17	WOS:000184734900015
J	Krona, C; Ejeskar, K; Abel, F; Kogner, P; Bjelke, J; Bjork, E; Sjoberg, RM; Martinsson, T				Krona, C; Ejeskar, K; Abel, F; Kogner, P; Bjelke, J; Bjork, E; Sjoberg, RM; Martinsson, T			Screening for gene mutations in a 500 kb neuroblastoma tumor suppressor candidate region in chromosome 1p; mutation and stage-specific expression in UBE4B/UFD2	ONCOGENE			English	Article						1p36.2-3; neuroblastoma; mutation analysis; embryonal tumors	CASPASE-ACTIVATED DNASE; ARM 17Q; INTERNATIONAL CRITERIA; SPLICE SITES; DELETION; PROTEIN; GAIN; LOCI; FRAGMENTATION; DIAGNOSIS	Deletion of a part of the short arm of chromosome 1 is one of the most common chromosomal rearrangements observed in neuroblastoma (NBL) tumors and it is associated with a poor prognosis. No NBL tumor suppressor gene has yet been identified in the region. Our shortest region of overlap of deletions, ranging from marker D1S80 to D1S244, was shown to partly overlap a 500 kb region that was homozygously deleted in a NBL cell line. We have screened seven genes known to reside in or very close to this overlap consensus region, UBE4B/UFD2, KIF1B, DFFA, PGD, CORT, PEX14, and ICAT, for coding mutations in NBL tumor DNA. A few deviations from the reference sequences were identified; most interestingly being a splice site mutation that was detected in UBE4B/UFD2 in a stage 3 NBL with a fatal outcome. This mutation was neither present in the patients constitutional DNA nor in any of 192 control chromosomes analysed. Also, the expression of UBE4B/UFD2 was markedly diminished in the high-stage/poor-outcome tumors as compared to the low-stage/favorable-outcome tumors. Overall, the number of amino-acid changes in the genes of the region was low, which shows that mutations in these genes are rare events in NBL development. Given the data presented here, UBE4B/UFD2 stands out as the strongest candidate NBL tumor suppressor gene in the region at this stage.	Univ Gothenburg, Sahlgrens Univ Hosp E, Inst Hlth Women & Children, Dept Clin Genet, SE-41685 Gothenburg, Sweden; Royal Childrens Hosp, Murdoch childrens Res Inst, Cell & Gene Therapy Grp, Parkville, Vic 3052, Australia; Karolinska Inst, Karolinska Hosp, Childhood Canc Res Unit, SE-17176 Stockholm, Sweden	Sahlgrenska University Hospital; University of Gothenburg; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Karolinska Institutet; Karolinska University Hospital	Martinsson, T (corresponding author), Univ Gothenburg, Sahlgrens Univ Hosp E, Inst Hlth Women & Children, Dept Clin Genet, SE-41685 Gothenburg, Sweden.		Martinsson, Tommy/J-4140-2013	Martinsson, Tommy/0000-0002-9403-3123; Kogner, Per/0000-0002-2202-9694; Ejeskar, Katarina/0000-0001-8962-0860				Abel F, 1999, BRIT J CANCER, V81, P1402, DOI 10.1038/sj.bjc.6692231; Abel F, 2002, BRIT J CANCER, V86, P596, DOI 10.1038/sj.bjc.6600111; Antonarakis SE, 1998, HUM MUTAT, V11, P1; Bauer A, 2001, GENE CHROMOSOME CANC, V31, P228, DOI 10.1002/gcc.1139; Bown N, 1999, NEW ENGL J MED, V340, P1954, DOI 10.1056/NEJM199906243402504; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; BRODEUR GM, 1990, CANCER SURV, V9, P673; BRODEUR GM, 1988, J CLIN ONCOL, V6, P1874, DOI 10.1200/JCO.1988.6.12.1874; Burset M, 2000, NUCLEIC ACIDS RES, V28, P4364, DOI 10.1093/nar/28.21.4364; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CARON H, 1995, HUM MOL GENET, V4, P535, DOI 10.1093/hmg/4.4.535; Caron H, 2001, GENE CHROMOSOME CANC, V30, P168, DOI 10.1002/1098-2264(200102)30:2<168::AID-GCC1072>3.0.CO;2-E; Clark F, 2002, HUM MOL GENET, V11, P451, DOI 10.1093/hmg/11.4.451; Ejeskar K, 2000, CYTOGENET CELL GENET, V89, P62, DOI 10.1159/000015566; Ejeskar K, 2001, MED PEDIATR ONCOL, V36, P61, DOI 10.1002/1096-911X(20010101)36:1<61::AID-MPO1016>3.0.CO;2-0; Guo C, 1999, ONCOGENE, V18, P4948, DOI 10.1038/sj.onc.1202887; Guo C, 2000, MED PEDIATR ONCOL, V35, P544, DOI 10.1002/1096-911X(20001201)35:6<544::AID-MPO10>3.0.CO;2-2; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Lal SL, 1999, PLANT PHYSIOL, V121, P411, DOI 10.1104/pp.121.2.411; Lastowska M, 1997, EUR J CANCER, V33, P1627, DOI 10.1016/S0959-8049(97)00282-7; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; MARIS JM, 1995, CANCER RES, V55, P4664; Maris JM, 2001, MED PEDIATR ONCOL, V36, P32, DOI 10.1002/1096-911X(20010101)36:1<32::AID-MPO1009>3.0.CO;2-0; Martinsson T, 1997, EUR J CANCER, V33, P1997, DOI 10.1016/S0959-8049(97)00278-5; MARTINSSON T, 1995, CANCER RES, V55, P5681; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Ohira M, 2000, ONCOGENE, V19, P4302, DOI 10.1038/sj.onc.1203786; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Sakahira H, 2000, J BIOL CHEM, V275, P8091, DOI 10.1074/jbc.275.11.8091; Sakahira H, 1999, J BIOL CHEM, V274, P15740, DOI 10.1074/jbc.274.22.15740; Spieker N, 2001, GENE CHROMOSOME CANC, V31, P172, DOI 10.1002/gcc.1130.abs; Tago K, 2000, GENE DEV, V14, P1741; Thanaraj TA, 2001, NUCLEIC ACIDS RES, V29, P2581, DOI 10.1093/nar/29.12.2581; White PS, 2001, MED PEDIATR ONCOL, V36, P37, DOI 10.1002/1096-911X(20010101)36:1<37::AID-MPO1010>3.0.CO;2-L; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520	39	43	45	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 17	2003	22	15					2343	2351		10.1038/sj.onc.1206324	http://dx.doi.org/10.1038/sj.onc.1206324			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	667KV	12700669				2022-12-17	WOS:000182231500012
J	Li, J; Zhang, ZQ; Dai, ZY; Plass, C; Morrison, C; Wang, Y; Wiest, JS; Anderson, MW; You, M				Li, J; Zhang, ZQ; Dai, ZY; Plass, C; Morrison, C; Wang, Y; Wiest, JS; Anderson, MW; You, M			LOH of chromosome 12p correlates with Kras2 mutation in non-small cell lung cancer	ONCOGENE			English	Article						wild-type Kras2; mutations; lung cancer; loss of heterozygosity; tumor suppressor	ACUTE LYMPHOBLASTIC-LEUKEMIA; RAS ONCOGENE ACTIVATION; SUSCEPTIBILITY LOCUS; CLINICAL-SIGNIFICANCE; FREQUENT DELETION; POINT MUTATION; SHORT ARM; GENE; ADENOCARCINOMA; CARCINOGENESIS	Previous observation has shown that the wild-type Kras2 allele is a suppressor of lung cancer in mice. Here we report that loss of heterozygosity (LOH) of chromosome 12p was detected in similar to50% of human lung adenocarcinomas and large cell carcinomas, and Kras2 mutations were detected at codon 12 in similar to40% of adenocarcinomas and large cell carcinomas. Interestingly, all of the lung adenocarcinomas and large cell carcinomas containing a Kras2 mutation exhibited allelic loss of the wild-type Kras2 allele when a correlation between LOH of the region on chromosome 12p and Kras2 mutation was made. These results from human lung cancer tissues provide a strong evidence in support of our previous observation in mouse models that the wild-type Kras2 is a tumor suppressor of lung cancer.	Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, Columbus, OH 43210 USA; OncoImmune LTD, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Dept Pathol, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Sch Publ Hlth, Columbus, OH 43210 USA; Univ Cincinnati, Dept Environm Hlth, Cincinnati, OH 45267 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; University of Cincinnati	You, M (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, 420 W 12th Ave, Columbus, OH 43210 USA.	you-l@medctr.osu.edu	Plass, Christoph/H-7192-2014		Intramural NIH HHS [ZIA BC010448-09] Funding Source: Medline; NCI NIH HHS [R01 CA 78797, P30 CA016058, R41 CA 093204, P30 CA 16058, R01 CA 58554, R01 CA058554] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078797, R41CA093204, P30CA016058, R01CA058554] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON MW, 1992, ENVIRON HEALTH PERSP, V98, P13, DOI 10.2307/3431243; Baccichet A, 1997, BRIT J HAEMATOL, V99, P107, DOI 10.1046/j.1365-2141.1997.3663180.x; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Beaupre DM, 1999, J CLIN ONCOL, V17, P1071, DOI 10.1200/JCO.1999.17.3.1071; Beaupre DM, 1999, CANCER RES, V59, P2971; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BOS JL, 1989, CANCER RES, V49, P4682; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; BUCHMANN A, 1991, CANCER RES, V51, P4097; BURMER GC, 1991, ENVIRON HEALTH PERSP, V93, P27, DOI 10.2307/3431164; De Gregorio L, 1998, INT J CANCER, V79, P269, DOI 10.1002/(SICI)1097-0215(19980619)79:3<269::AID-IJC10>3.3.CO;2-J; Dragani TA, 2000, CANCER RES, V60, P5017; GARIBOLDI M, 1993, NAT GENET, V3, P132, DOI 10.1038/ng0293-132; HEGI ME, 1994, CANCER RES, V54, P6257; KIARIS H, 1995, INT J ONCOL, V7, P413; Kibel AS, 1998, CANCER RES, V58, P5652; LI SR, 1994, LUNG CANCER-J IASLC, V11, P19, DOI 10.1016/0169-5002(94)90279-8; Manenti G, 1997, MAMM GENOME, V8, P801, DOI 10.1007/s003359900582; MARIYAMA M, 1989, JPN J CANCER RES, V80, P622, DOI 10.1111/j.1349-7006.1989.tb01687.x; MARSHALL CJ, 1991, TRENDS GENET, V7, P91, DOI 10.1016/0168-9525(91)90063-V; MILLS NE, 1995, CANCER RES, V55, P1444; PERUCHO M, 1981, CELL, V27, P467, DOI 10.1016/0092-8674(81)90388-3; Pinto MM, 1997, ACTA CYTOL, V41, P427, DOI 10.1159/000332535; REYNOLDS SH, 1991, P NATL ACAD SCI USA, V88, P1085, DOI 10.1073/pnas.88.4.1085; RODENHUIS S, 1992, CANCER RES, V52, pS2665; RODENHUIS S, 1988, CANCER RES, V48, P5738; SHIBATA D, 1990, CANCER RES, V50, P1279; SUZUKI Y, 1990, ONCOGENE, V5, P1037; Takeuchi S, 1996, CANCER RES, V56, P738; Takeuchi S, 1996, BLOOD, V87, P3368, DOI 10.1182/blood.V87.8.3368.bloodjournal8783368; Thompson TA, 2002, ONCOGENE, V21, P2797, DOI 10.1038/sj.onc.1205391; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WANG Y, 1993, CANCER RES, V53, P1620; Yanagitani N, 2002, CARCINOGENESIS, V23, P1177, DOI 10.1093/carcin/23.7.1177; YOU M, 1992, P NATL ACAD SCI USA, V89, P5804, DOI 10.1073/pnas.89.13.5804; Zhang ZQ, 2001, NAT GENET, V29, P25, DOI 10.1038/ng721	36	43	45	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2003	22	8					1243	1246		10.1038/sj.onc.1206192	http://dx.doi.org/10.1038/sj.onc.1206192			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606951	Green Accepted			2022-12-17	WOS:000181249700013
J	Yunta, M; Lazo, PA				Yunta, M; Lazo, PA			Apoptosis protection and survival signal by the CD53 tetraspanin antigen	ONCOGENE			English	Article						CD53; tetraspanin antigen; apoptosis; AKT	B-CELL LYMPHOMA; GENE-EXPRESSION; KAI1/CD82 EXPRESSION; HOMOTYPIC ADHESION; PROTEIN MRP-1/CD9; BREAST-CANCER; GROWTH-FACTOR; MOTILITY; METASTASIS; IDENTIFICATION	The CD53 antigen is a tetraspanin protein of the lymphoid-myeloid lineage, but its implication in biological effects is hardly known. Radioresistant tumor cells express very high levels of this antigen. We have studied the effect of CD53 antigen ligation on the survival response of tumor cells to serum deprivation, a well-known stimulator of cell death that may mimic the tumor environment; for this aim IR938F and Jurkat cells, a Band T-cell lymphoma, were used. Ligation of CD53 triggers a survival response and reduces the number of cells that enter apoptosis. In CD53- stimulated cells there is a significant reduction in caspase activation, measured by caspase processing of poly ADP-ribose polymerase, as well as a reduction in the fragmentation of DNA. CD53-stimulated cells also have an increase in the level of bcl-X-L and a reduction of bax protein, two components of the mitochondrial apoptotic pathway, changing their ratio by 24-fold in the direction of survival. This survival signal appears to be mediated by activation of the AKT, as detected by its phosphorylation in Ser473 upon CD53 ligation. The CD53 antigen interactions might contribute to cell survival in poorly vascularized regions of the tumor mass.	Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, Ctr Invest Canc, E-37007 Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Lazo, PA (corresponding author), Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, Ctr Invest Canc, Campus Miguel de Unamuno, E-37007 Salamanca, Spain.		Lazo, Pedro A./M-6435-2014	Lazo, Pedro A./0000-0001-8997-3025; Yunta, Monica/0000-0002-8060-9582				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; ANGELISOVA P, 1990, IMMUNOGENETICS, V32, P281, DOI 10.1007/BF00187099; Barcia R, 1996, CELL IMMUNOL, V169, P107, DOI 10.1006/cimm.1996.0097; Berditchevski F, 2001, J CELL SCI, V114, P4143; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOSCA L, 1994, J EXP MED, V179, P1119, DOI 10.1084/jem.179.4.1119; Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Ferrer M, 1998, CLIN EXP IMMUNOL, V113, P346; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Guo XZ, 1996, CANCER RES, V56, P4876; Hemler ME, 2001, J CELL BIOL, V155, P1103, DOI 10.1083/jcb.200108061; Henkel GW, 2002, INT IMMUNOL, V14, P723, DOI 10.1093/intimm/dxf040; Hernandez-Torres J, 2001, J BIOL CHEM, V276, P35405, DOI 10.1074/jbc.M104723200; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; HIGASHIYAMA M, 1995, CANCER RES, V55, P6040; Higashiyama M, 1997, INT J CANCER, V74, P205, DOI 10.1002/(SICI)1097-0215(19970422)74:2<205::AID-IJC12>3.0.CO;2-C; Huang CI, 1998, AM J PATHOL, V153, P973, DOI 10.1016/S0002-9440(10)65639-8; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Lagaudriere-Gesbert C, 1997, CELL IMMUNOL, V182, P105, DOI 10.1006/cimm.1997.1223; Lazo PA, 1997, CELL IMMUNOL, V178, P132, DOI 10.1006/cimm.1997.1139; Levy S, 1998, ANNU REV IMMUNOL, V16, P89, DOI 10.1146/annurev.immunol.16.1.89; Longhurst CM, 2002, J BIOL CHEM, V277, P32445, DOI 10.1074/jbc.M204420200; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; MASELLISSMITH A, 1990, J IMMUNOL, V144, P1607; MIYAKE M, 1995, CANCER RES, V55, P4127; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Mollinedo F, 1997, CLIN DIAGN LAB IMMUN, V4, P229, DOI 10.1128/CDLI.4.2.229-231.1997; Musashi M, 2000, INT J HEMATOL, V72, P12; Puls KL, 2002, INT IMMUNOL, V14, P249, DOI 10.1093/intimm/14.3.249; RADFORD KJ, 1995, INT J CANCER, V62, P631, DOI 10.1002/ijc.2910620523; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shibagaki N, 1999, EUR J IMMUNOL, V29, P4081, DOI 10.1002/(SICI)1521-4141(199912)29:12<4081::AID-IMMU4081>3.3.CO;2-9; Stipp CS, 2001, J BIOL CHEM, V276, P40545, DOI 10.1074/jbc.M107338200; Sugiura T, 1999, J CELL BIOL, V146, P1375, DOI 10.1083/jcb.146.6.1375; Testa JE, 1999, CANCER RES, V59, P3812; TRAVIS GH, 1991, NEURON, V6, P61, DOI 10.1016/0896-6273(91)90122-G; Uchida S, 1999, BRIT J CANCER, V79, P1168, DOI 10.1038/sj.bjc.6690186; Van Soest S, 1999, SURV OPHTHALMOL, V43, P321, DOI 10.1016/S0039-6257(98)00046-0; Voehringer DW, 2000, P NATL ACAD SCI USA, V97, P2680, DOI 10.1073/pnas.97.6.2680; Wang YD, 2002, ONCOGENE, V21, P2584, DOI 10.1038/sj.onc.1205355; Yanez-Mo M, 1998, J CELL BIOL, V141, P791, DOI 10.1083/jcb.141.3.791; Yunta M, 2002, EUR J BIOCHEM, V269, P1012, DOI 10.1046/j.0014-2956.2001.02741.x; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200	49	43	46	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 27	2003	22	8					1219	1224		10.1038/sj.onc.1206183	http://dx.doi.org/10.1038/sj.onc.1206183			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606948				2022-12-17	WOS:000181249700010
J	El-Naggar, AK; Kim, HW; Clayman, GL; Coombes, MM; Le, B; Lai, S; Zhan, F; Luna, MA; Hong, WK; Lee, JJ				El-Naggar, AK; Kim, HW; Clayman, GL; Coombes, MM; Le, B; Lai, S; Zhan, F; Luna, MA; Hong, WK; Lee, JJ			Differential expression profiling of head and neck squamous carcinoma: significance in their phenotypic and biological classification	ONCOGENE			English	Article						gene expression; microarray analysis; head and neck squamous carcinoma; biological classification; squamous carcinoma subtypes	LASER CAPTURE MICRODISSECTION; NUCLEAR RIBONUCLEOPROTEIN B1; CELL CARCINOMA; CDNA MICROARRAY; EPITHELIAL DIFFERENTIATION; AERODIGESTIVE TRACT; KERATIN GENES; CANCER; IDENTIFICATION; GENOME	The genetic events associated with the development and progression of head and neck squamous carcinoma (HNSC) are largely unknown. We analysed 12 matched pairs of histologically normal squamous mucosa and tumor specimens from six conventional and six phenotypic variants HNSC to define the differentially expressed genes in these tumors. Parallel expression analysis of 8055 unique genes was performed, and the level of the hybridization signal for each gene was measured after normalization. Hierarchical cluster analysis of the expressed genes showed distinct inter-and intra-tumoral patterns in and between conventional squamous carcinoma and squamous carcinoma variants. We also identified 26 (0.32%) differentially expressed genes that were consistently different between matched pairs of normal and tumor specimens; a selected set of the overexpressed genes was validated using real-time quantitative RT-PCR. The majority of the genes were associated with differentiation and proliferation. Our study defines a set of genes that could form the basis for the construction of limited HNSC targeted expression array band indepth studies and further highlights gene profile differences that may be useful in pathobiologic classification of HNSC.	Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	El-Naggar, AK (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Pathol, 1515 Holcombe Blvd,Box 85, Houston, TX 77030 USA.	anaggar@mdanderson.org	Center, Univ of Texas-M D Anderson Cancer/AAE-8182-2019; Lee, Jack/P-7331-2019	Center, Univ of Texas-M D Anderson Cancer/0000-0001-5469-9214; Lee, Jack/0000-0002-4584-929X	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE011906] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Abraham JM, 1996, CELL GROWTH DIFFER, V7, P855; Alevizos I, 2001, ONCOGENE, V20, P6196, DOI 10.1038/sj.onc.1204685; Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Anbazhagan R, 1999, CANCER RES, V59, P5119; Austin SJ, 1996, J BIOL CHEM, V271, P3737, DOI 10.1074/jbc.271.7.3737; Balm AJM, 1996, EUR ARCH OTO-RHINO-L, V253, P227, DOI 10.1007/BF00171132; BANKS ER, 1992, AM J SURG PATHOL, V16, P939, DOI 10.1097/00000478-199210000-00003; Bertucci F, 2000, HUM MOL GENET, V9, P2981, DOI 10.1093/hmg/9.20.2981; Bockmuhl U, 2000, AM J PATHOL, V157, P369, DOI 10.1016/S0002-9440(10)64549-X; Califano J, 1996, CANCER RES, V56, P2488; Chaib H, 2001, NEOPLASIA, V3, P43, DOI 10.1038/sj.neo.7900126; Chu PG, 2001, HISTOPATHOLOGY, V39, P9, DOI 10.1046/j.1365-2559.2001.01105.x; De Benedetti VMG, 2000, INT J BIOL MARKER, V15, P1; Diehn M, 2000, NAT GENET, V25, P58, DOI 10.1038/75603; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; ELLIS GL, 1987, AM J SURG PATHOL, V11, P335, DOI 10.1097/00000478-198705000-00001; ELNAGGAR AK, 1995, CANCER RES, V55, P2656; ElNaggar AK, 1997, AM J PATHOL, V151, P1767; Emmert-Buck MR, 2000, J MOL DIAGN, V2, P60, DOI 10.1016/S1525-1578(10)60617-4; Freedberg IM, 2001, J INVEST DERMATOL, V116, P633, DOI 10.1046/j.1523-1747.2001.01327.x; Fujimoto W, 1997, J INVEST DERMATOL, V108, P200, DOI 10.1111/1523-1747.ep12334240; Goto Y, 1999, JPN J CANCER RES, V90, P1358, DOI 10.1111/j.1349-7006.1999.tb00720.x; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; HARVAT BL, 1997, J DERMATOL, V24, P711; Helliwell TR, 2001, J PATHOL, V194, P289, DOI 10.1002/1096-9896(200107)194:3<289::AID-PATH912>3.0.CO;2-L; Hesse M, 2001, J CELL SCI, V114, P2569; HEYDEN A, 1992, J ORAL PATHOL MED, V21, P7, DOI 10.1111/j.1600-0714.1992.tb00960.x; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Huang HT, 2000, CANCER RES, V60, P6868; IVANYI D, 1990, CANCER RES, V50, P5143; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; KLIJANIENKO J, 1993, ANAL QUANT CYTOL, V15, P335; LAI SL, 1995, ONCOL REP, V2, P1115; Leethanakul C, 2000, ONCOGENE, V19, P3220, DOI 10.1038/sj.onc.1203703; MEDINA JE, 1984, ARCH OTOLARYNGOL, V110, P437; Mischke D, 1998, Subcell Biochem, V31, P71; OGDEN GR, 1993, J CLIN PATHOL, V46, P352, DOI 10.1136/jcp.46.4.352; Ono K, 2000, CANCER RES, V60, P5007; Petersen S, 2000, INT J CANCER, V86, P512, DOI 10.1002/(SICI)1097-0215(20000515)86:4<512::AID-IJC11>3.0.CO;2-6; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Sallinen SL, 2000, CANCER RES, V60, P6617; Sgroi DC, 1999, CANCER RES, V59, P5656; Shim C, 1998, CLIN CANCER RES, V4, P3045; Suarez PA, 2000, HEAD NECK-J SCI SPEC, V22, P360; Sueoka E, 1999, CANCER RES, V59, P1404; TANAKA M, 1995, CANCER LETT, V89, P195, DOI 10.1016/0304-3835(94)03687-E; Villaret DB, 2000, LARYNGOSCOPE, V110, P374, DOI 10.1097/00005537-200003000-00008; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; WAIN SL, 1986, HUM PATHOL, V17, P1158, DOI 10.1016/S0046-8177(86)80422-1; Wang T, 2000, ONCOGENE, V19, P1519, DOI 10.1038/sj.onc.1203457; Weinstein LB, 1999, CURR OPIN CELL BIOL, V11, P378, DOI 10.1016/S0955-0674(99)80053-2; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	53	43	44	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2002	21	53					8206	8219		10.1038/sj.onc.1206021	http://dx.doi.org/10.1038/sj.onc.1206021			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615DW	12444558				2022-12-17	WOS:000179231400016
J	Garner, AP; Weston, CR; Todd, DE; Balmanno, K; Cook, SJ				Garner, AP; Weston, CR; Todd, DE; Balmanno, K; Cook, SJ			Delta MEKK3 : ER* activation induces a p38 alpha/beta 2-dependent cell cycle arrest at the G(2) checkpoint	ONCOGENE			English	Article						MEKK3; p38; G(2); cyclin; CDK; p21(Cip1)	DEPENDENT KINASE INHIBITOR; B1 MESSENGER-RNA; PROTEIN-KINASE; XENOPUS-OOCYTE; DNA-DAMAGE; POSTTRANSCRIPTIONAL REGULATION; SIGNAL-TRANSDUCTION; POTENTIAL MEDIATOR; PHOSPHORYLATION; P38	Whilst many studies have examined the role of the MAP Kinases in regulating the G(1)-->S transition, much less is known about the function of these pathways in regulating other cell cycle transitions. Stimulation of the conditional mutant DeltaMEKK3:ER* in asynchronous hamster (CCl39) and rat (Rat-1) fibroblasts resulted in the strong activation of endogenous JNK and p38 but only a weak activation of ERK. Activation of DeltaMEKK3:ER* inhibited cell proliferation through a combination of an initial G(1) and G(2) cell cycle arrest, followed by a delayed onset of apoptosis. When cells were synchronized in S phase with aphidicolin and then released, activation of DeltaMEKK3:ER* resulted in the up-regulation of p21(CIP1) and a pronounced inhibition of cyclin A/CDK2 and cyclin B1/CDK1 kinase activity. Analysis of mitotic figures indicated that cells failed to enter mitosis, arresting late in G(2). DeltaMEKK3:ER*-mediated CDK inhibition and G(2) arrest did not absolutely require p21(CIP1), since both events were observed in Rat-1 cells in which p21(CIP1) is transcriptionally silenced due to promoter methylation. Rather, CDK inhibition was associated with a down-regulation of cyclin A and 131 expression. Finally, application of the p38 inhibitor SB203580 partially restored cyclin B associated kinase activity and allowed cells to proceed through mitosis into the next G(1) phase, suggesting that activation of the p38alpha/beta2 pathway can promote a G(2) cell cycle arrest.	Babraham Inst, Signalling Programme, Inositide Lab, Cambridge CB2 4AT, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Cook, SJ (corresponding author), Babraham Inst, Signalling Programme, Inositide Lab, Babraham Hall, Cambridge CB2 4AT, England.	simon.cook@bbsrc.ac.uk		Balmanno, Kathryn/0000-0002-6417-3889				Alexander MR, 2001, MOL BIOL CELL, V12, P53, DOI 10.1091/mbc.12.1.53; Allan LA, 2000, MOL CELL BIOL, V20, P1291, DOI 10.1128/MCB.20.4.1291-1298.2000; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Blasina A, 1997, MOL BIOL CELL, V8, P1013, DOI 10.1091/mbc.8.6.1013; Booher RN, 1997, J BIOL CHEM, V272, P22300, DOI 10.1074/jbc.272.35.22300; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Clarke DJ, 2000, BIOESSAYS, V22, P351, DOI 10.1002/(SICI)1521-1878(200004)22:4<351::AID-BIES5>3.0.CO;2-W; Cook SJ, 2000, BIOCHEM SOC T, V28, P233, DOI 10.1042/bst0280233; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DAWSON IA, 1995, J CELL BIOL, V129, P725, DOI 10.1083/jcb.129.3.725; Deacon K, 1999, J BIOL CHEM, V274, P16604, DOI 10.1074/jbc.274.23.16604; Deacon K, 1997, J BIOL CHEM, V272, P14489, DOI 10.1074/jbc.272.22.14489; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Ellinger-Ziegelbauer H, 1999, MOL CELL BIOL, V19, P3857; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUARDAGNO TM, 1996, CELL, V84, P73; Guo N, 2000, J BIOL CHEM, V275, P1715, DOI 10.1074/jbc.275.3.1715; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; Hagting A, 1999, CURR BIOL, V9, P680, DOI 10.1016/S0960-9822(99)80308-X; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; Kotani S, 1999, J CELL BIOL, V146, P791, DOI 10.1083/jcb.146.4.791; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; LI JK, 1995, MOL BIOL CELL, V6, P1111, DOI 10.1091/mbc.6.9.1111; LI Y, 1994, ONCOGENE, V9, P2261; Liu QH, 2000, GENE DEV, V14, P1448; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Lukas C, 1999, NATURE, V401, P815, DOI 10.1038/44611; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MAITY A, 1995, EMBO J, V14, P603, DOI 10.1002/j.1460-2075.1995.tb07036.x; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; MEIJER L, 1991, EMBO J, V10, P1545, DOI 10.1002/j.1460-2075.1991.tb07674.x; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PARKER LL, 1995, P NATL ACAD SCI USA, V92, P9638, DOI 10.1073/pnas.92.21.9638; Passalaris TM, 1999, MOL CELL BIOL, V19, P5872, DOI 10.1128/mcb.19.9.5872; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Petrocelli T, 2000, ONCOGENE, V19, P4480, DOI 10.1038/sj.onc.1203808; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; Piwnica-Worms H, 1999, NATURE, V401, P535, DOI 10.1038/44029; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; Smith JL, 2000, MOL CELL BIOL, V20, P8026, DOI 10.1128/MCB.20.21.8026-8034.2000; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; Spitkovsky D, 1997, CELL GROWTH DIFFER, V8, P699; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang S, 1999, EMBO J, V18, P1559, DOI 10.1093/emboj/18.6.1559; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174; Yang Z, 2001, IEEE T ADV PACKAGING, V24, P309, DOI 10.1109/6040.938298	91	43	47	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2002	21	53					8089	8104		10.1038/sj.onc.1206000	http://dx.doi.org/10.1038/sj.onc.1206000			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615DW	12444545				2022-12-17	WOS:000179231400003
J	Hirano, T; Shino, Y; Saito, T; Komoda, F; Okutomi, Y; Takeda, A; Ishihara, T; Yamaguchi, T; Saisho, H; Shirasawa, H				Hirano, T; Shino, Y; Saito, T; Komoda, F; Okutomi, Y; Takeda, A; Ishihara, T; Yamaguchi, T; Saisho, H; Shirasawa, H			Dominant negative MEKK1 inhibits survival of pancreatic cancer cells	ONCOGENE			English	Article						MEKK1; ERK; JNK; AP-1; CRE; pancreatic cancer	ACTIVATED PROTEIN-KINASES; LUNG-CARCINOMA CELLS; C-JUN; CONSTITUTIVE ACTIVATION; AP-1 FUNCTION; RAS; TRANSFORMATION; GROWTH; PROLIFERATION; PATHWAY	Human pancreatic cancers harbor mutations in the K-ras gene, and these mutations convert the gene oncogenic and constitutively active forms. However, in pancreatic cancer cells little is known about the activation of the downstream pathways of Ras, MEK - ERK and MEKK1 - JNK, and their roles in cell survival and proliferation. An analysis of nine pancreatic cancer tissues revealed JNK activation in all tumor samples and ERK activation in three tumor samples. Colony formation assays by transfection of dominant negative mutants of Ras, ERK or MEKK1 into pancreatic cancer cell lines (BxPC-3, PANC-1, MIAPa-Ca-2 and AsPC-1) and an amnion-derived cell line (FL) revealed that DN - MEKK strongly inhibits the survival of colonies in pancreatic cancer cells, but not in FL cells. In vitro kinase assays and luciferase assays using the Gal4c-Jun system revealed that in pancreatic cancer cells DN-MEKK fails to inhibit JNK activation. In PANC-1 cells, c-Jun was found to be a major component of protein component binding to AP-1 site and CRE, but not in FL cells. The inhibitory effect of DN-MEKK in PANC-1 cells was thought to be the result of the inhibition of c-Jun DNA-binding. The difference of suppression in pancreatic cancer cells and non-pancreatic cancer cells suggested that the MEKK1 pathway mainly contributes to cell survival in pancreatic cancer cells and may provide an advantage for the gene therapy of pancreatic cancers using DN - MEKK expression vectors.	Chiba Univ, Dept Mol Virol E2, Grad Sch Med, Chiba 2608670, Japan; Chiba Univ, Dept Med & Clin Oncol K1, Grad Sch Med, Chiba 2608670, Japan	Chiba University; Chiba University	Shirasawa, H (corresponding author), Chiba Univ, Dept Mol Virol E2, Grad Sch Med, Chiba 2608670, Japan.							Antonyak MA, 1998, J BIOL CHEM, V273, P2817, DOI 10.1074/jbc.273.5.2817; BENBROOK DM, 1990, ONCOGENE, V5, P295; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; BRUNET A, 1994, ONCOGENE, V9, P3379; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Ferrell JE, 1996, CURR TOP DEV BIOL, V33, P1, DOI 10.1016/S0070-2153(08)60336-1; Giehl K, 2000, ONCOGENE, V19, P2930, DOI 10.1038/sj.onc.1203612; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; LEMOINE NR, 1992, GASTROENTEROLOGY, V102, P230, DOI 10.1016/0016-5085(92)91805-E; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Minamino T, 1999, P NATL ACAD SCI USA, V96, P15127, DOI 10.1073/pnas.96.26.15127; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; POSTON GJ, 1991, GUT, V32, P800, DOI 10.1136/gut.32.7.800; SCHNEIDER MTY, 1999, INT J ONCOL, V15, P271; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; Tessari G, 1999, ANTICANCER RES, V19, P863; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; Xiao L, 2000, CANCER RES, V60, P400; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911; Zoumpourlis V, 2000, ONCOGENE, V19, P4011, DOI 10.1038/sj.onc.1203732	28	43	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5923	5928		10.1038/sj.onc.1205643	http://dx.doi.org/10.1038/sj.onc.1205643			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185592				2022-12-17	WOS:000177520900012
J	Fluge, O; Bruland, O; Akslen, LA; Varhaug, JE; Lillehaug, JR				Fluge, O; Bruland, O; Akslen, LA; Varhaug, JE; Lillehaug, JR			NATH, a novel gene overexpressed in papillary thyroid carcinomas	ONCOGENE			English	Article						thyroid carcinoma; overexpression; NATH	N-TERMINAL ACETYLTRANSFERASE; SACCHAROMYCES-CEREVISIAE; TETRATRICOPEPTIDE REPEAT; TPR DOMAIN; E-CADHERIN; IN-VIVO; C-MET; EXPRESSION; PROTEIN; IDENTIFICATION	In this study a replica cDNA screening (RCS) approach to identify genes differentially expressed in papillary thyroid carcinomas (PTC) was used, as compared to non-neoplastic thyroid tissues. RCS is based on hybridization of radioactively labeled cDNA probes made from the biopsies to replica membranes with 15000 clones from a PTC cDNA library. Among the genes overexpressed in PTC, and especially in clinically aggressive tumors with histologic evidence of poorly differentiated or undifferentiated areas, a novel gene named NATH was found. NATH has two mRNA species, 4.6 and 5.8 kb, both harboring the same open reading frame encoding a putative protein of 866 amino acids. The NATH protein is; homologous to yeast N-acetyltransferase (NAT)1 and to mouse NARG1 (mNAT1) and contains four tetratricopeptide repeat (TPR) domains, suggesting that NATH may be part of a multiprotein complex. Overlapping RT-PCR fragments from several PTC biopsies confirmed the NATH mRNA sequence. Northern blots, semiquantitative RT-PCR experiments, TaqMan real-time RT-PCR experiments, and in situ hybridization verified the overexpression of NATH mRNA localized to tumor cells in PTC biopsies. NATH was expressed at a low level in most human adult tissues, including the normal thyroid gland. Increased NATH expression was seen especially in a Burkitt lymphoma cell line and in adult human testis. Recombinant in vitro expression showed that NATH protein was located mainly in the cytoplasm, and was present as a single protein band of the expected 105 kDa molecular weight. Heterologous expression of NATH in the papillary carcinoma cell line (NPA) and 293 cells did not alter the cellular proliferation rate. The biological function of NATH remains to be elucidated, but the overexpression in classic PTC and especially in poorly differentiated or undifferentiated components may indicate a function in the progression of papillary thyroid carcinomas.	Univ Bergen, Dept Biol Mol, N-5020 Bergen, Norway; Univ Bergen, Haukeland Hosp, Dept Med Genet & Mol Med, N-5021 Bergen, Norway; Univ Bergen, Haukeland Hosp, Gade Inst, Dept Pathol, N-5021 Bergen, Norway; Univ Bergen, Haukeland Hosp, Dept Surg, N-5021 Bergen, Norway	University of Bergen; University of Bergen; Haukeland University Hospital; University of Bergen; Haukeland University Hospital; University of Bergen; Haukeland University Hospital	Fluge, O (corresponding author), Univ Bergen, Dept Biol Mol, Thormohlens Gt 55, N-5020 Bergen, Norway.		Akslen, Lars A./AAG-6097-2021; Akslen, Lars A/C-1202-2017	Akslen, Lars A./0000-0003-2710-9543; Akslen, Lars A/0000-0003-2710-9543				Bernard K, 1996, NUCLEIC ACIDS RES, V24, P1435, DOI 10.1093/nar/24.8.1435; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.3.CO;2-E; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Bunone G, 1999, AM J PATHOL, V155, P1967, DOI 10.1016/S0002-9440(10)65515-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; de Nigris F, 1998, CANCER RES, V58, P4745; DIRENZO MF, 1992, ONCOGENE, V7, P2549; DRIESSEN HPC, 1985, CRIT REV BIOCHEM MOL, V18, P281, DOI 10.3109/10409238509086784; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Fluge O, 2000, INT J CANCER, V87, P763, DOI 10.1002/1097-0215(20000915)87:6<763::AID-IJC1>3.0.CO;2-T; Gendron RL, 2000, DEV DYNAM, V218, P300, DOI 10.1002/(SICI)1097-0177(200006)218:2<300::AID-DVDY5>3.0.CO;2-K; Gounalaki N, 2000, FEBS LETT, V473, P37, DOI 10.1016/S0014-5793(00)01480-0; Haugen DRF, 1996, CANCER RES, V56, P1184; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Huang Y, 2001, P NATL ACAD SCI USA, V98, P15044, DOI 10.1073/pnas.251547398; Kurozumi K, 1998, WORLD J SURG, V22, P1237, DOI 10.1007/s002689900551; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; LEE FJS, 1990, J BIOL CHEM, V265, P11576; Liu L, 1999, MOL CELL BIOL, V19, P1202; Mahlknecht U, 2000, MOL MED, V6, P623, DOI 10.1007/BF03402044; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; Nakatsu Y, 2000, J BIOL CHEM, V275, P34931, DOI 10.1074/jbc.M004936200; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Nishida T, 2002, AM J SURG, V183, P80, DOI 10.1016/S0002-9610(01)00843-1; PARK EC, 1992, EMBO J, V11, P2087, DOI 10.1002/j.1460-2075.1992.tb05267.x; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; PILOTTI S, 1995, SEMIN DIAGN PATHOL, V12, P249; Polevoda B, 1999, EMBO J, V18, P6155, DOI 10.1093/emboj/18.21.6155; Powell DJ, 1998, CANCER RES, V58, P5523; Resnick MB, 1998, MODERN PATHOL, V11, P735; Ryu S, 1997, CANCER LETT, V121, P189, DOI 10.1016/S0304-3835(97)00353-4; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; Santoro M, 1996, ONCOGENE, V12, P1821; Santoro M, 1999, BIOCHIMIE, V81, P397, DOI 10.1016/S0300-9084(99)80087-X; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; SCHEUMMAN GFW, 1995, J CLIN ENDOCR METAB, V80, P2168, DOI 10.1210/jc.80.7.2168; Shuja S, 1999, THYROID, V9, P569, DOI 10.1089/thy.1999.9.569; Sugiura N, 2001, J BIOL CHEM, V276, P14257, DOI 10.1074/jbc.M100011200; Takano T, 1998, BRIT J CANCER, V78, P221, DOI 10.1038/bjc.1998.468; TRIBIOLI C, 1994, HUM MOL GENET, V3, P1061, DOI 10.1093/hmg/3.7.1061; Trovato M, 1998, THYROID, V8, P125, DOI 10.1089/thy.1998.8.125; vonWasielewski R, 1997, CANCER RES, V57, P2501	44	43	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 1	2002	21	33					5056	5068		10.1038/sj.onc.1205687	http://dx.doi.org/10.1038/sj.onc.1205687			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140756				2022-12-17	WOS:000176975900004
J	Dhillon, NK; Mudryj, M				Dhillon, NK; Mudryj, M			Ectopic expression of cyclin E in estrogen responsive cells abrogates antiestrogen mediated growth arrest	ONCOGENE			English	Article						cyclin E; MCF7; tamoxifen; breast cancer; cell cycle	BREAST-CANCER CELLS; LASER-SCANNING CYTOMETRY; DEPENDENT KINASE; RETINOBLASTOMA PROTEIN; FUNCTIONAL INACTIVATION; CDK INHIBITORS; P27(KIP1); E2F; PHOSPHORYLATION; PROGRESSION	Estrogens stimulate proliferation of estrogen receptor positive MCF7 breast cancer cells; while antiestrogens signal a G0/G1 growth arrest. In MCF7 cells, arrest is mediated through the CDK inhibitors p21 and p27 and through a decrease in cyclin E/CDK2 kinase activity. We found that in MCF7 cells, overexpression of cyclin E partially abrogates a tamoxifen mediated growth arrest. Overexpression of cyclin E is accompanied by a decrease in the levels of RB and CDK inhibitor p21 but an increase in CDK inhibitor p27. Cyclin E overexpression also alters the composition of E2F transcription factor complexes. The E2F4/p107/cyclin E/CDK2 complex, a minor component in proliferating control cells that is absent in growth-arrested cells, is more abundant in both proliferating and tamoxifen treated cyclin E overexpressing cells. Conversely, levels of the quiescence associated E2F/p130 complex is not detected in these cells. Expression from the E2F dependant promoter is elevated in proliferating and tamoxifen treated cyclin E overexpressing cells. This study suggests that a modest overexpression of cyclin E abrogates the tamoxifen mediated growth arrest through modification of the RB/E2F pathway. Moreover, these, results provide one explanation of why some cells that express the estrogen receptor may be unresponsive to antiestrogens.	Univ Calif Davis, Dept Med Microbiol & Immunol, Sch Med, Davis, CA 95616 USA; Martinez VA, Martinez, CA 94553 USA	University of California System; University of California Davis	Mudryj, M (corresponding author), Univ Calif Davis, Dept Microbiol & Immunol, 3149 Tupper Hall, Davis, CA 95616 USA.							Arata Y, 2000, J BIOL CHEM, V275, P6337, DOI 10.1074/jbc.275.9.6337; Beato M, 1996, STEROIDS, V61, P240, DOI 10.1016/0039-128X(96)00030-X; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Cariou S, 2000, P NATL ACAD SCI USA, V97, P9042, DOI 10.1073/pnas.160016897; Carroll JS, 2000, J BIOL CHEM, V275, P38221, DOI 10.1074/jbc.M004424200; Chiarle R, 2001, BREAST CANCER RES, V3, P91; Darzynkiewicz Z, 1999, EXP CELL RES, V249, P1, DOI 10.1006/excr.1999.4477; Duronio RJ, 1996, GENE DEV, V10, P2505, DOI 10.1101/gad.10.19.2505; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ENCARNACION CA, 1993, BREAST CANCER RES TR, V26, P237, DOI 10.1007/BF00665801; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Howell A, 1996, BRIT J CANCER, V74, P300, DOI 10.1038/bjc.1996.357; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Kamentsky LA, 2001, METHOD CELL BIOL, V63, P51; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; KEYOMARSI K, 1994, CANCER RES, V54, P380; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LOEKEN MR, 1989, J BIOL CHEM, V264, P6572; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; Mayol X, 1997, Prog Cell Cycle Res, V3, P157; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Perlmann T, 1997, CELL, V90, P391, DOI 10.1016/S0092-8674(00)80498-5; Porter DC, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.23.e101; Robertson JFR, 1996, BRIT J CANCER, V73, P5, DOI 10.1038/bjc.1996.2; Ruffner H, 1999, MOL CELL BIOL, V19, P4843; SAMBROOK J, 1989, MOL CLONING LAB MANU, P737; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Sgambato A, 1996, CANCER RES, V56, P1389; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Su TT, 1997, J CELL BIOL, V139, P13, DOI 10.1083/jcb.139.1.13; Swanson C, 2000, P NATL ACAD SCI USA, V97, P7796, DOI 10.1073/pnas.97.14.7796; TAYLOR IW, 1983, CANCER RES, V43, P4007; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; Zhao JY, 1998, GENE DEV, V12, P456, DOI 10.1101/gad.12.4.456	51	43	46	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 11	2002	21	30					4626	4634		10.1038/sj.onc.1205576	http://dx.doi.org/10.1038/sj.onc.1205576			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	569WH	12096339				2022-12-17	WOS:000176625100004
J	Finkelstein, LD; Ney, PA; Liu, QP; Paulson, RF; Correll, PH				Finkelstein, LD; Ney, PA; Liu, QP; Paulson, RF; Correll, PH			Sf-Stk kinase activity and the Grb2 binding site are required for Epo-independent growth of primary erythroblasts infected with Friend virus	ONCOGENE			English	Article						erythroleukemia; receptor; tyrosine kinase; Stk; Fv2; signal transduction	MULTIFUNCTIONAL DOCKING SITE; CONSTITUTIVE ACTIVATION; ERYTHROPOIETIN RECEPTOR; CELL-TRANSFORMATION; MET PROTOONCOGENE; POINT MUTATIONS; TRUNCATED FORM; TYROSINE; INDUCTION; GENE	During the initial stage of Friend virus-induced erythro-leukemia in mice, interaction of the viral protein gp55 with the erythropoietin receptor, and other host factors, drives the expansion of erythroid precursor cells. Recently, we demonstrated that the Friend virus susceptibility locus, Fv2, which is required for the expansion of infected cells, encodes a naturally occurring, N-terminally truncated form of the Stk receptor tyrosine kinase (Sf-Stk). Here we show that in vitro expression of Sf-Stk confers Friend virus sensitivity to erythroid progenitor cells from Fv2(rr) mice. Furthermore, our data reveal that Sf-Stk kinase activity and Y436, but not Y429, are required for Epo-independent colony formation following Friend virus infection. Introduction of a mutation that results in failure to bind Grb2 abrogates the ability of Sf-Stk to induce colonies in response to Friend virus, while the Grb2 binding site from EGFR restores this response. Consistent with the ability of Grb2 to recruit SOS and Gab1, the Ras/MAPK and PI3K pathways are activated by Sf-Stk, and both of these pathways are required for gp55-mediated erythroblast proliferation. These data clearly demonstrate a requirement for signaling through Sf-Stk in the Epo-independent expansion of Friend virus-infected cells, and suggest a pivotal role for Grb2 in this response.	Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; St Jude Children's Research Hospital	Correll, PH (corresponding author), Penn State Univ, Dept Vet Sci, 115 Henning Bldg, University Pk, PA 16802 USA.	phc7@psu.edu			NATIONAL CANCER INSTITUTE [R01CA084214] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066471] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA084214-05, R01 CA084214-04, R01 CA084214, R01 CA084214-01, R01 CA084214-02, R01 CA084214-03] Funding Source: Medline; NHLBI NIH HHS [R01 HL66471, R01 HL066471] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BONDURANT MC, 1985, J GEN VIROL, V66, P83, DOI 10.1099/0022-1317-66-1-83; CLARKE BJ, 1975, P NATL ACAD SCI USA, V72, P3556, DOI 10.1073/pnas.72.9.3556; Correll Pamela H., 1997, Genes and Function, V1, P69; DANDREA AD, 1992, CANCER SURV, V15, P19; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; Gong K, 2001, NAT IMMUNOL, V2, P29, DOI 10.1038/83134; Hoatlin Maureen E., 1995, Trends in Microbiology, V3, P51, DOI 10.1016/S0966-842X(00)88875-7; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; Iwama A, 1996, EMBO J, V15, P5866, DOI 10.1002/j.1460-2075.1996.tb00973.x; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Leonard EJ, 1997, CIBA F SYMP, V212, P183; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; Liu QP, 1999, J IMMUNOL, V163, P6606; LONGATI P, 1994, ONCOGENE, V9, P49; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; Moriyama Y, 1996, J BIOL CHEM, V271, P3347; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Nishigaki K, 2001, J VIROL, V75, P7893, DOI 10.1128/JVI.75.17.7893-7903.2001; Nishigaki K, 2000, J VIROL, V74, P3037, DOI 10.1128/JVI.74.7.3037-3045.2000; OHASHI T, 1995, BLOOD, V85, P1454, DOI 10.1182/blood.V85.6.1454.bloodjournal8561454; Park CY, 1999, J BIOL CHEM, V274, P7583, DOI 10.1074/jbc.274.11.7583; Peace BE, 2001, ONCOGENE, V20, P6142, DOI 10.1038/sj.onc.1204836; Persons DA, 1999, NAT GENET, V23, P159, DOI 10.1038/13787; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Stefan M, 2001, J BIOL CHEM, V276, P3017, DOI 10.1074/jbc.M009333200; Yamamura Y, 1998, MOL CELL BIOL, V18, P1172, DOI 10.1128/MCB.18.3.1172; ZHEN Z, 1994, ONCOGENE, V9, P1691	38	43	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3562	3570		10.1038/sj.onc.1205442	http://dx.doi.org/10.1038/sj.onc.1205442			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032858				2022-12-17	WOS:000175793700007
J	Meza-Zepeda, LA; Forus, A; Lygren, B; Dahlberg, AB; Godager, LH; South, AP; Marenholz, I; Lioumi, M; Florenes, VA; Maelandsmo, GM; Serra, M; Mischke, D; Nizetic, D; Ragoussis, J; Tarkkanen, M; Nesland, JM; Knuutila, S; Myklebost, O				Meza-Zepeda, LA; Forus, A; Lygren, B; Dahlberg, AB; Godager, LH; South, AP; Marenholz, I; Lioumi, M; Florenes, VA; Maelandsmo, GM; Serra, M; Mischke, D; Nizetic, D; Ragoussis, J; Tarkkanen, M; Nesland, JM; Knuutila, S; Myklebost, O			Positional cloning identifies a novel cyclophilin as a candidate amplified oncogene in 1q21	ONCOGENE			English	Article						peptidyl-prolyl isomerase; cyclophilin; breast cancer; sarcoma; amplification; chromosome1	IMMUNOSUPPRESSANT FK506; CYCLOSPORINE-A; HUMAN SARCOMAS; BREAST-CANCER; IMBALANCES; GAINS; DNA; AMPLIFICATION; SEQUENCES; COMPLEX	Gains of 1q21-q23 have been associated with metastasis and chemotherapy response, particularly in bladder cancer, hepatocellular carcinomas and sarcomas. By positional cloning of amplified genes by yeast artificial chromosome-mediated cDNA capture using magnetic beads, we have identified three candidate genes (COAS1, -2 and -3) in the amplified region in sarcomas. COAS1 and -2 showed higher amplification levels than COAS3. Most notably, amplification was very common in osteosarcomas, where in particular COAS2 was highly expressed. COAS1 has multiple repeats and shows no homology to previously described genes, whereas COAS2 is a novel member of the cyclosporin-binding peptidylprolyl isomerase family, very similar to cyclophilin A. COAS2 was overexpressed almost exclusively in aggressive metastatic or chemotherapy resistanti tumours. Although COAS2 was generally more amplified than COAS1, it was not expressed in well-differentiated liposarcomas, where amplification of this region is very common. All three genes were found to be amplified and over-expressed also in breast carcinomas. The complex nature of the 1q21-23 amplicons and close proximity of the genes make unequivocal determination of the gene responsible difficult. Quite likely, the different genes may give selective advantages to different subsets of tumours.	Norwegian Radium Hosp, Dept Tumor Biol, N-0310 Oslo, Norway; Klinikum Rudolf Virchow, Inst Expt Onkol Transplantat Med, Berlin, Germany; Univ London Sch Pharm, Ctr Appl Mol Biol, London, England; Guys Hosp, UMDS, Div Med Genet, Genom Lab, London, England; Inst Ortoped Rizzoli, Lab Ricerca Oncol, Bologna, Italy; Norwegian Radium Hosp, Dept Pathol, N-0310 Oslo, Norway; Univ Helsinki, Haartman Inst, Dept Med Genet, Helsinki, Finland; Univ Oslo, Inst Biochem, N-0316 Oslo, Norway	University of Oslo; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of London; University College London; University of London School of Pharmacy; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Oslo; University of Helsinki; University of Oslo	Myklebost, O (corresponding author), Norwegian Radium Hosp, Dept Tumor Biol, N-0310 Oslo, Norway.	ola.myklebost@biokjemi.uio.no	Ragoussis, Ioannis/AAD-9790-2022; Meza-Zepeda, Leonardo Andres/CAG-5229-2022; Nizetic, Dean/F-9509-2015; Myklebost, Ola/E-9335-2010; Serra, Massimo/J-4878-2016	Meza-Zepeda, Leonardo Andres/0000-0003-3056-212X; Myklebost, Ola/0000-0002-2866-3223; Serra, Massimo/0000-0003-0742-1177; Nizetic, Dean/0000-0001-5486-5761				Alers JC, 2000, LAB INVEST, V80, P931, DOI 10.1038/labinvest.3780096; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ambros PF, 2001, MED PEDIATR ONCOL, V36, P1; Arevalo-Rodriguez M, 2000, EMBO J, V19, P3739, DOI 10.1093/emboj/19.14.3739; Berner JM, 1996, GENE CHROMOSOME CANC, V17, P254, DOI 10.1002/(SICI)1098-2264(199612)17:4<254::AID-GCC7>3.0.CO;2-2; Collins C, 1998, P NATL ACAD SCI USA, V95, P8703, DOI 10.1073/pnas.95.15.8703; Corton JC, 1998, CANCER LETT, V134, P61, DOI 10.1016/S0304-3835(98)00241-9; FORUS A, 1995, GENE CHROMOSOME CANC, V14, P15, DOI 10.1002/gcc.2870140104; Forus A, 1998, BRIT J CANCER, V78, P495, DOI 10.1038/bjc.1998.521; FORUS A, 1993, CELL GROWTH DIFFER, V4, P1065; FORUS A, 1995, GENE CHROMOSOME CANC, V14, P8, DOI 10.1002/gcc.2870140103; Forus A, 2001, CANCER GENET CYTOGEN, V125, P100, DOI 10.1016/S0165-4608(00)00369-1; Fukuda K, 1998, DEVELOPMENT, V125, P3535; Groet J, 1998, GENOME RES, V8, P385, DOI 10.1101/gr.8.4.385; Gronwald J, 1997, CANCER RES, V57, P481; Guan XY, 2000, GENE CHROMOSOME CANC, V29, P110; HAENDLER B, 1987, EMBO J, V6, P947, DOI 10.1002/j.1460-2075.1987.tb04843.x; HARDAS BD, 1994, GENOMICS, V21, P359, DOI 10.1006/geno.1994.1277; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; Hemenway CS, 1996, J BIOL CHEM, V271, P18527, DOI 10.1074/jbc.271.31.18527; Jin ZG, 2000, CIRC RES, V87, P789, DOI 10.1161/01.RES.87.9.789; Kiechle M, 2000, AM J PATHOL, V156, P1827, DOI 10.1016/S0002-9440(10)65055-9; Kim JO, 1998, ONCOGENE, V17, P1019, DOI 10.1038/sj.onc.1202006; KOLETSKY AJ, 1986, J IMMUNOL, V137, P1054; Kudoh K, 1999, CLIN CANCER RES, V5, P2526; Larramendy ML, 2000, CANCER GENET CYTOGEN, V119, P132, DOI 10.1016/S0165-4608(99)00226-5; Lioumi M, 1998, GENOMICS, V49, P200, DOI 10.1006/geno.1998.5234; LIU J, 1991, BIOCHEMISTRY-US, V30, P2306, DOI 10.1021/bi00223a003; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; Lu K P, 2000, Prog Cell Cycle Res, V4, P83; Lu KP, 1996, NATURE, V380, P544; Mairal A, 2000, GENE CHROMOSOME CANC, V28, P370, DOI 10.1002/1098-2264(200008)28:4<370::AID-GCC2>3.0.CO;2-8; Malamou-Mitsi VD, 1999, J EXP CLIN CANC RES, V18, P357; Matthews CP, 2000, P SOC EXP BIOL MED, V223, P316, DOI 10.1046/j.1525-1373.2000.22345.x; Meza-Zepeda LA, 2001, GENE CHROMOSOME CANC, V31, P264, DOI 10.1002/gcc.1143; Mischke D, 1996, J INVEST DERMATOL, V106, P989, DOI 10.1111/1523-1747.ep12338501; NIZETIC D, 1994, MAMM GENOME, V5, P801, DOI 10.1007/BF00292017; Ozaki K, 1996, CYTOGENET CELL GENET, V72, P242, DOI 10.1159/000134199; Pedeutour F, 1999, GENE CHROMOSOME CANC, V24, P30, DOI 10.1002/(SICI)1098-2264(199901)24:1<30::AID-GCC5>3.0.CO;2-P; RAHFELD JU, 1994, FEBS LETT, V352, P180, DOI 10.1016/0014-5793(94)00932-5; Rey O, 1999, ONCOGENE, V18, P827, DOI 10.1038/sj.onc.1202328; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SPITZFADEN C, 1992, FEBS LETT, V300, P291, DOI 10.1016/0014-5793(92)80866-F; Szymanska J, 1997, CANCER GENET CYTOGEN, V99, P14, DOI 10.1016/S0165-4608(96)00436-0; Tarkkanen M, 1999, INT J CANCER, V84, P114, DOI 10.1002/(SICI)1097-0215(19990420)84:2<114::AID-IJC4>3.0.CO;2-Q; TARKKANEN M, 1995, CANCER RES, V55, P1334; Weber RG, 2000, AM J PATHOL, V157, P571, DOI 10.1016/S0002-9440(10)64567-1; Weber T, 2000, BRAIN PATHOL, V10, P73; YEH WC, 1995, P NATL ACAD SCI USA, V92, P11081, DOI 10.1073/pnas.92.24.11081	49	43	49	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2261	2269		10.1038/sj.onc.1205339	http://dx.doi.org/10.1038/sj.onc.1205339			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948409				2022-12-17	WOS:000174555300015
J	Wach, S; Schirmacher, P; Protschka, M; Blessing, M				Wach, S; Schirmacher, P; Protschka, M; Blessing, M			Overexpression of bone morphogenetic protein-6 (BMP-6) in murine epidermis suppresses skin tumor formation by induction of apoptosis and downregulation of fos/jun family members	ONCOGENE			English	Article						BMP-6; skin; carcinogenesis; apoptosis, AP-1	GROWTH-FACTOR-BETA; PROGRAMMED CELL-DEATH; TRANSGENIC MICE; C-FOS; MOUSE SKIN; KINASE-C; TRANSFORMING GROWTH-FACTOR-BETA-1; KERATINOCYTE DIFFERENTIATION; ORNITHINE DECARBOXYLASE; EMBRYONIC-DEVELOPMENT	Bone morphogenetic protein-6 (BMP-6) is a member of the transforming growth factor-beta superfamily. In murine skin, BMP-6 is highly expressed in postmitotic keratinocytes from day 15.5 p.c. till day 6 p.p. Expression in adult skin remains at very low levels, but pathological conditions such as wounding induce the expression of BMP-6. We demonstrate that tumor promotion by TPA (12-O-tetradecanoylphorbol-13-acetate) also induces expression of BMP-6 in suprabasal keratinocytes. This induction is due to post-transcriptional regulation since the level of BMP-6 mRNA remained unchanged. We performed two-stage skin carcinogenesis experiments with transgenic mice epidermally overexpressing BMP-6. These mice display augmented mitotic indices in normal and TPA-treated epidermis when compared to controls. Despite this hyperproliferation, BMP-6 transgenics showed a delayed development and strong suppression of benign and malignant skin tumor formation. In order to resolve this paradox we determined apoptotic frequencies as well as the expression of constituents of AP-1 (activator protein-1) which is essential for tumor promotion. A higher rate of apoptotic keratinocytes was detectable in transgenic mice versus controls and a downregulation of mRNA for jun/fos family members in transgenic skin after TPA-treatment. Thus expression of BMP-6 augments apoptosis and downregulates the transcription of AP-1 family members thereby establishing tumor resistance.	Johannes Gutenberg Univ Mainz, Dept Med 1, Sect Pathophysiol, D-55131 Mainz, Germany; Univ Cologne, Inst Pathol, D-50931 Cologne, Germany	Johannes Gutenberg University of Mainz; University of Cologne	Blessing, M (corresponding author), Johannes Gutenberg Univ Mainz, Dept Med 1, Sect Pathophysiol, Obere Zahlbacher Str 63, D-55131 Mainz, Germany.	blessing@mail.uni-mainz.de						Amendt C, 1998, ONCOGENE, V17, P25, DOI 10.1038/sj.onc.1202161; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Autzen P, 1998, BRIT J CANCER, V78, P1219, DOI 10.1038/bjc.1998.658; BAILLEUL B, 1990, CELL, V62, P697, DOI 10.1016/0092-8674(90)90115-U; BLESSING M, 1995, TERATOGEN CARCIN MUT, V15, P11, DOI 10.1002/tcm.1770150103; Blessing M, 1996, J CELL BIOL, V135, P227, DOI 10.1083/jcb.135.1.227; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; Choi SE, 1999, CELL SIGNAL, V11, P71, DOI 10.1016/S0898-6568(98)00033-3; Clement JH, 1999, INT J CANCER, V80, P250, DOI 10.1002/(SICI)1097-0215(19990118)80:2<250::AID-IJC14>3.0.CO;2-D; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Denning MF, 1998, EXP CELL RES, V239, P50, DOI 10.1006/excr.1997.3890; DIGIOVANNI J, 1991, PROG EXP TUMOR RES, V33, P192; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; DOTTO GP, 1986, EMBO J, V5, P2853, DOI 10.1002/j.1460-2075.1986.tb04579.x; DROZDOFF V, 1994, P NATL ACAD SCI USA, V91, P5528, DOI 10.1073/pnas.91.12.5528; GLICK AB, 1993, P NATL ACAD SCI USA, V90, P6076, DOI 10.1073/pnas.90.13.6076; GREENHALGH DA, 1995, CELL GROWTH DIFFER, V6, P579; GREENHALGH DA, 1993, ONCOGENE, V8, P2145; Guo YP, 1999, CANCER RES, V59, P1366; Hamdy FC, 1997, CANCER RES, V57, P4427; Heikinheimo AK, 1999, CANCER RES, V59, P5815; HENNINGS H, 1993, P SOC EXP BIOL MED, V202, P1; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kaiser S, 1998, J INVEST DERMATOL, V111, P1145, DOI 10.1046/j.1523-1747.1998.00407.x; KENNARD MD, 1995, MOL CARCINOGEN, V12, P14, DOI 10.1002/mc.2940120104; LYONS KM, 1989, GENE DEV, V3, P1657, DOI 10.1101/gad.3.11.1657; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MATRISIAN LM, 1994, ANN NY ACAD SCI, V732, P42, DOI 10.1111/j.1749-6632.1994.tb24723.x; MEGOSH L, 1995, CANCER RES, V55, P4205; Merino R, 1998, DEV BIOL, V200, P35, DOI 10.1006/dbio.1998.8946; Motyl T, 1998, EUR J CELL BIOL, V75, P367, DOI 10.1016/S0171-9335(98)80070-8; Munz B, 1999, EMBO J, V18, P5205, DOI 10.1093/emboj/18.19.5205; PELTON RW, 1991, J CELL BIOL, V115, P1091, DOI 10.1083/jcb.115.4.1091; POTTEN CS, 1975, BRIT J DERMATOL, V93, P649, DOI 10.1111/j.1365-2133.1975.tb05115.x; POTTEN CS, 1984, BRIT J DERMATOL, V111, P695, DOI 10.1111/j.1365-2133.1984.tb14153.x; Raida M, 1999, INT J CANCER, V83, P38, DOI 10.1002/(SICI)1097-0215(19990924)83:1<38::AID-IJC8>3.3.CO;2-2; Rodriguez-Villanueva J, 1998, ONCOGENE, V16, P853, DOI 10.1038/sj.onc.1201610; ROSS R, 1995, PCR METH APPL, V4, P371; Rutberg SE, 1997, ONCOGENE, V15, P1337, DOI 10.1038/sj.onc.1201293; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SELLHEYER K, 1993, P NATL ACAD SCI USA, V90, P5237, DOI 10.1073/pnas.90.11.5237; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Tang MK, 2000, DEV BIOL, V218, P89, DOI 10.1006/dbio.1999.9578; Teramoto T, 1998, BIOCHEM BIOPH RES CO, V251, P56, DOI 10.1006/bbrc.1998.9411; Ueyama T, 1998, J MOL CELL CARDIOL, V30, P551, DOI 10.1006/jmcc.1997.0619; WALL NA, 1993, J CELL BIOL, V120, P493, DOI 10.1083/jcb.120.2.493; Yokouchi Y, 1996, DEVELOPMENT, V122, P3725; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; YOUNUS J, 1992, J CELL PHYSIOL, V152, P232, DOI 10.1002/jcp.1041520203	52	43	46	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2001	20	53					7761	7769		10.1038/sj.onc.1204962	http://dx.doi.org/10.1038/sj.onc.1204962			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492HE	11753654				2022-12-17	WOS:000172161700007
J	de Almodovar, CR; Ruiz-Ruiz, C; Munoz-Pinedo, C; Robledo, GH; Lopez-Rivas, A				de Almodovar, CR; Ruiz-Ruiz, C; Munoz-Pinedo, C; Robledo, GH; Lopez-Rivas, A			The differential sensitivity of Bcl-2-overexpressing human breast tumor cells to TRAIL or doxorubicin-induced apoptosis is dependent on Bcl-2 protein levels	ONCOGENE			English	Article						apoptosis; TRAIL; chemotherapy; mitochondria; Bcl-2	NF-KAPPA-B; CYTOCHROME-C; RECEPTOR; DEATH; LIGAND; MITOCHONDRIA; FAMILY; MEMBER; FADD; BAX	Bc1-2 protein is a potent anti-apoptotic protein that inhibits a mitochondria-operated pathway of apoptosis in many cells. DNA damaging agents and death receptor ligands can activate this mitochondrial apoptotic mechanism. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been suggested to escape from the inhibitory action of Bc1-2 protein. We show that in human breast tumor MCF-7 cells, TRAIL induced a mitochondrial pathway of apoptosis that involved cytochrome c release from mitochondria and activation of caspase 9. The DNA damaging drug doxorubicin also activated this mitochondria-regulated mechanism of apoptosis, which was inhibited in Bc1-2-overexpressing cells. We also demonstrate that in MCF-7 cells Bc1-2 might confer resistance to TRAIL-induced apoptosis, depending on the expression levels of the anti-apoptotic protein. These results indicate that enhanced expression of Bc1-2 in tumor cells can render these cells less sensitive not only to chemotherapeutic drugs but also to TRAIL.	CSIC, Inst Parasitol & Biomed, Granada 18001, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN)	Lopez-Rivas, A (corresponding author), CSIC, Inst Parasitol & Biomed, Calle Ventanilla 11, Granada 18001, Spain.	alrivas@ipb.csic.es	Ruiz-Ruiz, Carmen/I-8792-2017; Munoz-Pinedo, Cristina/B-6118-2008; Lopez-Rivas, Abelardo/E-5115-2015	Ruiz-Ruiz, Carmen/0000-0002-6243-6227; Munoz-Pinedo, Cristina/0000-0002-9120-664X; Lopez-Rivas, Abelardo/0000-0002-9351-9690				Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Griffith TS, 1999, J EXP MED, V189, P1343, DOI 10.1084/jem.189.8.1343; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hinz S, 2000, ONCOGENE, V19, P5477, DOI 10.1038/sj.onc.1203936; Kayagaki N, 1999, J IMMUNOL, V162, P2639; Keogh SA, 2000, FEBS LETT, V471, P93, DOI 10.1016/S0014-5793(00)01375-2; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MacFarlane M, 2000, J CELL BIOL, V148, P1239, DOI 10.1083/jcb.148.6.1239; Mariani SM, 1997, J CELL BIOL, V137, P221, DOI 10.1083/jcb.137.1.221; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Martinez-Lorenzo MJ, 1998, EUR J IMMUNOL, V28, P2714, DOI 10.1002/(SICI)1521-4141(199809)28:09<2714::AID-IMMU2714>3.0.CO;2-9; Mongkolsapaya J, 1999, NAT STRUCT BIOL, V6, P1048; Murphy KM, 2000, CELL DEATH DIFFER, V7, P102, DOI 10.1038/sj.cdd.4400597; Murphy KM, 1999, ONCOGENE, V18, P5991, DOI 10.1038/sj.onc.1203001; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Phillips TA, 1999, J IMMUNOL, V162, P6053; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rochaix P, 1999, J PATHOL, V187, P410, DOI 10.1002/(SICI)1096-9896(199903)187:4<410::AID-PATH266>3.0.CO;2-F; Ruiz-Ruiz C, 2000, CANCER RES, V60, P5673; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider P, 1997, FEBS LETT, V416, P329, DOI 10.1016/S0014-5793(97)01231-3; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; SHIYONG S, 2001, BIOCHEM BIOPH RES CO, V20, P788; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Walczak H, 2000, CANCER RES, V60, P3051; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang QF, 2000, BREAST CANCER RES TR, V61, P211, DOI 10.1023/A:1006474307180; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	44	43	43	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 25	2001	20	48					7128	7133		10.1038/sj.onc.1204887	http://dx.doi.org/10.1038/sj.onc.1204887			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704839				2022-12-17	WOS:000171739300018
J	Zhuang, SG; Demirs, JT; Kochevar, IE				Zhuang, SG; Demirs, JT; Kochevar, IE			Protein kinase C inhibits singlet oxygen-induced apoptosis by decreasing caspase-8 activation	ONCOGENE			English	Article						protein kinase C; singlet oxygen; caspase-8; Fas; apoptosis; p38	RECEPTOR-INDUCED APOPTOSIS; PROGRAMMED CELL-DEATH; RADIATION-INDUCED APOPTOSIS; PEROXIDE-INDUCED APOPTOSIS; THERAPY-INDUCED APOPTOSIS; PHOTODYNAMIC THERAPY; CYTOCHROME-C; HL-60 CELLS; HYDROGEN-PEROXIDE; MEDIATED APOPTOSIS	Although activation of protein kinase C (PKC) inhibits apoptosis induced by a variety of stimuli including singlet oxygen, the step at which PKC activation interferes with apoptotic signaling is not well defined. We have shown previously that caspase-8 and p38 mediate singlet oxygen-induced apoptosis in HL-60 cells. In this study, we investigated the influence of PKC on regulation of the caspase-8 and p38 pathways initiated by singlet oxygen. Singlet oxygen induced Fas clustering and subsequent recruitment of FADD and caspase-8. Treatment of cells with the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA), a PKC activator, did not affect the binding of caspase-8 to the aggregated Fas. Surprisingly, under the same conditions PKC activation was still able to prevent singlet oxygen-induced activation of caspase-8 and block its downstream signaling events including cleavage of Bid and caspase-3, decrease in mitochondrial transmembrane potential and release of cytochrome c from mitochondria. Inhibition of PKC by GF109203 or H7 counteracted the TPA-mediated effects on the cleavage of caspases -3 and -8. However, neither activation nor inhibition of PKC affected p38 phosphorylation. These data indicate that PKC inhibits singlet oxygen-induced apoptosis by blocking activation of caspase-8.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Labs Photomed, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Kochevar, IE (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Labs Photomed, WEL-224,55 Fruit St, Boston, MA 02114 USA.	kochevar@helix.mgh.harvard.edu			NIGMS NIH HHS [GM 30755] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030755] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL ML, 1991, CANCER RES, V51, P5993; Agarwal R, 1996, PHOTOCHEM PHOTOBIOL, V63, P547, DOI 10.1111/j.1751-1097.1996.tb03082.x; Ahmad N, 2000, J INVEST DERMATOL, V115, P1041, DOI 10.1046/j.1523-1747.2000.00147.x; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; ARAUJO H, 1993, J BIOL CHEM, V268, P5911; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Assefa Z, 2000, J BIOL CHEM, V275, P21416, DOI 10.1074/jbc.M002634200; BAKER A, 1992, PHOTOCHEM PHOTOBIOL, V55, P523, DOI 10.1111/j.1751-1097.1992.tb04273.x; Behrens MM, 1999, NEUROSCIENCE, V94, P917, DOI 10.1016/S0306-4522(99)00212-2; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Condorelli G, 1999, ONCOGENE, V18, P4409, DOI 10.1038/sj.onc.1202831; Cook SA, 1999, CIRC RES, V85, P940; Dispersyn G, 1999, BBA-GEN SUBJECTS, V1428, P357, DOI 10.1016/S0304-4165(99)00073-2; Dong SM, 2000, CHEM RES TOXICOL, V13, P585, DOI 10.1021/tx990199x; Dumont A, 1999, ONCOGENE, V18, P747, DOI 10.1038/sj.onc.1202325; Faubion WA, 1999, J CLIN INVEST, V103, P137, DOI 10.1172/JCI4765; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Galan A, 2000, J BIOL CHEM, V275, P11418, DOI 10.1074/jbc.275.15.11418; Gomez-Angelats M, 2000, J BIOL CHEM, V275, P19609, DOI 10.1074/jbc.M909563199; Granville DJ, 1999, BRIT J CANCER, V79, P95, DOI 10.1038/sj.bjc.6690017; GretherBeck S, 1996, P NATL ACAD SCI USA, V93, P14586, DOI 10.1073/pnas.93.25.14586; HE XY, 1994, PHOTOCHEM PHOTOBIOL, V59, P468, DOI 10.1111/j.1751-1097.1994.tb05066.x; HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; JARVIS WD, 1994, J BIOL CHEM, V269, P31685; Jun CD, 1999, CELL IMMUNOL, V194, P36, DOI 10.1006/cimm.1999.1480; Kessel D, 2000, PHOTOCHEM PHOTOBIOL, V71, P196, DOI 10.1562/0031-8655(2000)071<0196:DOTART>2.0.CO;2; Kitada S, 1999, BRIT J HAEMATOL, V106, P995, DOI 10.1046/j.1365-2141.1999.01642.x; Kowaltowski A, 2000, CELL DEATH DIFFER, V7, P903, DOI 10.1038/sj.cdd.4400722; Krutmann J, 2000, J DERMATOL SCI, V23, pS22, DOI 10.1016/S0923-1811(99)00077-8; Kwon D, 2001, J NEUROIMMUNOL, V113, P1, DOI 10.1016/S0165-5728(00)00321-0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LOTEM J, 1991, BLOOD, V78, P953; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Luo Y, 1997, PHOTOCHEM PHOTOBIOL, V66, P479, DOI 10.1111/j.1751-1097.1997.tb03176.x; Matsura T, 1999, FREE RADICAL RES, V30, P73, DOI 10.1080/10715769900300081; MAY WS, 1994, J BIOL CHEM, V269, P26865; Meinhardt G, 2000, EUR J CELL BIOL, V79, P824, DOI 10.1078/0171-9335-00100; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Morita A, 1997, J EXP MED, V186, P1763, DOI 10.1084/jem.186.10.1763; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Ochsner M, 1997, J PHOTOCH PHOTOBIO B, V39, P1, DOI 10.1016/S1011-1344(96)07428-3; Pae HO, 2000, IMMUNOPHARM IMMUNOT, V22, P61, DOI 10.3109/08923970009016406; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; RODRIGUEZTARDUCHY G, 1989, BIOCHEM BIOPH RES CO, V164, P1069, DOI 10.1016/0006-291X(89)91778-6; RuizRuiz MD, 1997, EUR J IMMUNOL, V27, P1442, DOI 10.1002/eji.1830270622; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Ryter SW, 1998, FREE RADICAL BIO MED, V24, P1520, DOI 10.1016/S0891-5849(97)00461-9; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Shen HM, 2001, FREE RADICAL BIO MED, V30, P9, DOI 10.1016/S0891-5849(00)00421-4; SOLARY E, 1993, BLOOD, V81, P1359; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; STOKA V, 2000, J BIOL CHEM, V9, P9; Suhara T, 1998, J IMMUNOL, V160, P4042; TAKAHASHI H, 1995, J INVEST DERMATOL, V105, P810, DOI 10.1111/1523-1747.ep12326577; TAKANO Y, 1993, PATHOL RES PRACT, V189, P197, DOI 10.1016/S0344-0338(11)80092-0; Umansky V, 2000, INT J ONCOL, V16, P109; Ushmorov A, 1999, BLOOD, V93, P2342, DOI 10.1182/blood.V93.7.2342.407k09_2342_2352; Varnes ME, 1999, BIOCHEM BIOPH RES CO, V255, P673, DOI 10.1006/bbrc.1999.0261; Vogt M, 1998, FEBS LETT, V429, P67, DOI 10.1016/S0014-5793(98)00562-6; Webber J, 1996, J PHOTOCH PHOTOBIO B, V35, P209, DOI 10.1016/S1011-1344(96)07291-0; WEISHAUPT KR, 1976, CANCER RES, V36, P2326; Xue LY, 1999, CELL DEATH DIFFER, V6, P855, DOI 10.1038/sj.cdd.4400558; Yabuki M, 2000, FREE RADICAL RES, V32, P507, DOI 10.1080/10715760000300511; Yeh JH, 1998, J EXP MED, V188, P1795, DOI 10.1084/jem.188.10.1795; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; ZAIDI SIA, 1993, PHOTOCHEM PHOTOBIOL, V58, P771, DOI 10.1111/j.1751-1097.1993.tb04969.x; Zhuang SG, 2000, J BIOL CHEM, V275, P25939, DOI 10.1074/jbc.M001185200; Zhuang SG, 1998, FEBS LETT, V437, P158, DOI 10.1016/S0014-5793(98)01222-8; Zhuang SG, 1999, EXP CELL RES, V250, P203, DOI 10.1006/excr.1999.4501; Zhuang SG, 2000, AM J PHYSIOL-CELL PH, V279, pC341, DOI 10.1152/ajpcell.2000.279.2.C341; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	83	43	44	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2001	20	46					6764	6776		10.1038/sj.onc.1204867	http://dx.doi.org/10.1038/sj.onc.1204867			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709711				2022-12-17	WOS:000171551600013
J	Azios, NG; Romero, FJ; Denton, MC; Doherty, JK; Clinton, GM				Azios, NG; Romero, FJ; Denton, MC; Doherty, JK; Clinton, GM			Expression of herstatin, an autoinhibitor of HER-2/neu, inhibits transactivation of HER-3 by HER-2 and blocks EGF activation of the EGF receptor	ONCOGENE			English	Article						herstatin; heregulin; EGF; HER-1; HER-2; HER-3; HER-2/HER-3 heterodimers	EPIDERMAL GROWTH-FACTOR; NEU DIFFERENTIATION FACTOR; HER2/NEU-OVEREXPRESSING METASTATIC BREAST; TYROSINE KINASE-ACTIVITY; ERBB SIGNALING NETWORK; MONOCLONAL-ANTIBODY; EXTRACELLULAR DOMAIN; BINDING-SITE; CARCINOMA-CELLS; PHASE-II	The four members of the EGF receptor family are capable of homomeric as well as heteromeric interactions. HER-2/neu (erbB-2) dominates as the preferred coreceptor that amplifies mitogenic signaling. An alternative HER-2/neu product, herstatin, consists of a segment of the ectodomain of p185HER-2 and an intronencoded C-terminus. Recombinant herstatin was found to bind with nm affinity and inhibit p185HER-2. To further examine the impact on receptor activity, herstatin was expressed with various receptor tyrosine kinases. In CHO cells that overexpressed HER-2, herstatin caused a sevenfold inhibition of colony formation that corresponded to a reduction in the tyrosine phosphorylation of p185HER-2. Herstatin also prevented HER-2 mediated transactivation of the kinase impaired HER-3 as reflected in transphosphorylation of HER-3 and heteromers between HER-2 and HER-3. In EGF receptor-overexpressing cells, EGF induction of receptor dimerization and tyrosine phosphorylation were reduced more than 90%, and receptor down-regulation as well as colony formation were also suppressed by coexpression with herstatin. Inhibition was selective for the EGF receptor family since herstatin expression did not reduce tyrosine phosphorylation mediated by the FGF receptor-2 or by insulin-like growth factor -1. Herstatin bound to the EGF receptor as well as to p185HER-2 in pull-down assays suggesting that complex formation may be involved in receptor inhibition. Our findings indicate that herstatin has the capability to negatively regulate combinations of interactions between group I receptor tyrosine kinases that confer synergistic growth signals.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Univ So Calif, Dept Otolaryngol, Los Angeles, CA 90033 USA	Oregon Health & Science University; University of Southern California	Clinton, GM (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA.	clinton@ohsu.edu						AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ALI IU, 1988, SCIENCE, V240, P1795, DOI 10.1126/science.3289120; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Baselga J, 1997, J MAMMARY GLAND BIOL, V2, P165, DOI 10.1023/A:1026355831693; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; CARTER TH, 1994, CRIT REV ONCOGENESIS, V5, P389, DOI 10.1615/CritRevOncog.v5.i4.40; CHAZIN VR, 1992, ONCOGENE, V7, P1859; CHOU CK, 1987, J BIOL CHEM, V262, P1842; Christianson TA, 1998, CANCER RES, V58, P5123; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Doherty JK, 1999, P NATL ACAD SCI USA, V96, P10869, DOI 10.1073/pnas.96.19.10869; DOUGALL WC, 1994, ONCOGENE, V9, P2109; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FENDLY BM, 1990, CANCER RES, V50, P1550; Fitzpatrick VD, 1998, FEBS LETT, V431, P102, DOI 10.1016/S0014-5793(98)00737-6; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Heldin Carl-Henrik, 1996, Cytokine and Growth Factor Reviews, V7, P3, DOI 10.1016/1359-6101(96)00002-0; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUDZIAK RM, 1988, P NATL ACAD SCI USA, V85, P5102, DOI 10.1073/pnas.85.14.5102; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HURWITZ E, 1995, P NATL ACAD SCI USA, V92, P3353, DOI 10.1073/pnas.92.8.3353; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KATSUMATA M, 1995, NAT MED, V1, P644, DOI 10.1038/nm0795-644; Klapper LN, 2000, ADV CANCER RES, V77, P25; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LAX I, 1988, MOL CELL BIOL, V8, P1831, DOI 10.1128/MCB.8.4.1831; LAX I, 1991, CELL REGUL, V2, P337, DOI 10.1091/mbc.2.5.337; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; LIN YZJ, 1991, ONCOGENE, V6, P639; LONARDO F, 1990, New Biologist, V2, P992; Mendelsohn J, 1997, CLIN CANCER RES, V3, P2703; Moscatello DK, 1996, ONCOGENE, V13, P85; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; ORourke DM, 1997, P NATL ACAD SCI USA, V94, P3250, DOI 10.1073/pnas.94.7.3250; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; Pinkas-Kramarski R, 1998, MOL CELL BIOL, V18, P6090, DOI 10.1128/MCB.18.10.6090; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; Qian XL, 1999, J BIOL CHEM, V274, P574, DOI 10.1074/jbc.274.2.574; Qian XL, 1996, ONCOGENE, V13, P2149; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; Ram TG, 2000, CELL GROWTH DIFFER, V11, P173; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Sambrook J., 1989, MOL CLONING; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; Spencer KSR, 2000, J CELL BIOL, V148, P385, DOI 10.1083/jcb.148.2.385; Tanner KG, 1999, J BIOL CHEM, V274, P35985, DOI 10.1074/jbc.274.50.35985; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Tzahar E, 1997, EMBO J, V16, P4938, DOI 10.1093/emboj/16.16.4938; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WEINTRAUB H, 1986, CELL, V46, P115, DOI 10.1016/0092-8674(86)90865-2; WOLTJER RL, 1992, P NATL ACAD SCI USA, V89, P7801, DOI 10.1073/pnas.89.16.7801; Ye DW, 1999, ONCOGENE, V18, P731, DOI 10.1038/sj.onc.1202319	64	43	53	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2001	20	37					5199	5209		10.1038/sj.onc.1204555	http://dx.doi.org/10.1038/sj.onc.1204555			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526509				2022-12-17	WOS:000170464000014
J	Chang, FM; McCubrey, JA				Chang, FM; McCubrey, JA			P21(Cip1) induced by Raf is associated with increased Cdk4 activity in hematopoietic cells	ONCOGENE			English	Article						Raf; p21(Cip1); p27(Kip1); cyclins; Cdks; cytokine independence	DEPENDENT KINASE INHIBITOR; ABROGATE CYTOKINE DEPENDENCY; ACTIVATED PROTEIN-KINASE; B-RAF; MAP KINASE; C-MYC; A-RAF; DIFFERENTIAL ABILITIES; INDUCED PROLIFERATION; TARGETED DISRUPTION		E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC 27858 USA; E Carolina Univ, Brody Sch Med, Member Leo Jenkins Canc Ctr, Greenville, NC 27858 USA	University of North Carolina; East Carolina University; University of North Carolina; East Carolina University	McCubrey, JA (corresponding author), E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC 27858 USA.	mccubreyj@mail.ecu.edu		McCubrey, James/0000-0001-6027-3156	NATIONAL CANCER INSTITUTE [R01CA051025] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA51025] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandrov I, 1997, FEBS LETT, V414, P465, DOI 10.1016/S0014-5793(97)00992-7; Baldassarre G, 1999, ONCOGENE, V18, P6241, DOI 10.1038/sj.onc.1203031; Beier F, 1999, J BIOL CHEM, V274, P30273, DOI 10.1074/jbc.274.42.30273; Blagosklonny MV, 2000, LEUKEMIA, V14, P1502, DOI 10.1038/sj.leu.2401864; Blalock WL, 1999, LEUKEMIA, V13, P1109, DOI 10.1038/sj.leu.2401493; BOS JL, 1989, CANCER RES, V49, P4682; Bosch E, 1997, ONCOGENE, V15, P1021, DOI 10.1038/sj.onc.1201270; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; Cai K, 1998, P NATL ACAD SCI USA, V95, P12254, DOI 10.1073/pnas.95.21.12254; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; CHUANG CF, 1994, FEBS LETT, V346, P229, DOI 10.1016/0014-5793(94)00480-3; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; Dent P, 1998, LEUKEMIA, V12, P1843, DOI 10.1038/sj.leu.2401222; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Estanyol JM, 1999, J BIOL CHEM, V274, P33161, DOI 10.1074/jbc.274.46.33161; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Frank DA, 1999, MOL MED, V5, P432; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FUKUI M, 1987, MOL CELL BIOL, V7, P1776, DOI 10.1128/MCB.7.5.1776; GUPTA S, 1994, FEBS LETT, V353, P281, DOI 10.1016/0014-5793(94)01052-8; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Hibi M, 1998, Int Rev Immunol, V17, P75, DOI 10.3109/08830189809084488; Hoyle PE, 2000, LEUKEMIA, V14, P642, DOI 10.1038/sj.leu.2401720; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; Isaacs JS, 1997, CANCER RES, V57, P2986; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; JOHNSON DE, 1998, FRONT BIOSCI, V3, P313; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; Kim TK, 1997, BIOCHEM BIOPH RES CO, V234, P300, DOI 10.1006/bbrc.1997.6637; Kuroda S, 1996, J BIOL CHEM, V271, P14680, DOI 10.1074/jbc.271.25.14680; Kwon EM, 2000, BLOOD, V95, P2552, DOI 10.1182/blood.V95.8.2552.008k30_2552_2558; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lee AW, 1999, BLOOD, V93, P537, DOI 10.1182/blood.V93.2.537.402k30_537_553; LEE JE, 1994, GENOMICS, V20, P43, DOI 10.1006/geno.1994.1125; Lee SJ, 1998, J BIOL CHEM, V273, P10618, DOI 10.1074/jbc.273.17.10618; Lin JY, 1996, MOL CELL BIOL, V16, P1786; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mangi MH, 1999, CYTOKINES CELL MOL T, V5, P87; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL M, 1995, MOL REPROD DEV, V42, P493, DOI 10.1002/mrd.1080420418; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; May W S Jr, 1997, Adv Pharmacol, V41, P219; McCubrey JA, 1998, LEUKEMIA, V12, P1903, DOI 10.1038/sj.leu.2401215; McCubrey JA, 2000, LEUKEMIA, V14, P9, DOI 10.1038/sj.leu.2401657; Morisset J, 1999, AM J PHYSIOL-GASTR L, V277, pG953, DOI 10.1152/ajpgi.1999.277.5.G953; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Moye PW, 2000, LEUKEMIA, V14, P1060, DOI 10.1038/sj.leu.2401792; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; MUSZYNSKI KW, 1995, J EXP MED, V181, P2189, DOI 10.1084/jem.181.6.2189; Nakanishi M, 1999, BIOCHEM BIOPH RES CO, V263, P35, DOI 10.1006/bbrc.1999.1296; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; Ogawa M, 1999, ANN NY ACAD SCI, V872, P17, DOI 10.1111/j.1749-6632.1999.tb08449.x; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pajic A, 2000, INT J CANCER, V87, P787, DOI 10.1002/1097-0215(20000915)87:6<787::AID-IJC4>3.0.CO;2-6; Papin C, 1996, ONCOGENE, V12, P2213; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; Pritchard C, 1997, NAT GENET, V16, P214, DOI 10.1038/ng0797-214; Pritchard CA, 1996, CURR BIOL, V6, P614, DOI 10.1016/S0960-9822(02)00548-1; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; Rosario M, 1999, EMBO J, V18, P1270, DOI 10.1093/emboj/18.5.1270; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; Steelman LS, 1996, LEUKEMIA, V10, P528; STORM SM, 1990, ONCOGENE, V5, P345; Sutor SL, 1999, J BIOL CHEM, V274, P7002, DOI 10.1074/jbc.274.11.7002; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Voice JK, 1999, J BIOL CHEM, V274, P17164, DOI 10.1074/jbc.274.24.17164; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WADEWITZ AG, 1993, ONCOGENE, V8, P1055; Weber CK, 2000, ONCOGENE, V19, P169, DOI 10.1038/sj.onc.1203261; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; Wojnowski L, 1998, MECH DEVELOP, V76, P141, DOI 10.1016/S0925-4773(98)00111-7; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Xiao HY, 1997, BIOCHEM BIOPH RES CO, V237, P457, DOI 10.1006/bbrc.1997.7158; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yamamoto T, 1999, J BIOCHEM-TOKYO, V126, P799, DOI 10.1093/oxfordjournals.jbchem.a022519; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zou X, 1997, CURR TOP MICROBIOL, V224, P57	99	43	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2001	20	32					4354	4364		10.1038/sj.onc.1204564	http://dx.doi.org/10.1038/sj.onc.1204564			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466616				2022-12-17	WOS:000169912600009
J	Thompson, DA; Zacny, V; Belinsky, GS; Classon, M; Jones, DL; Schlegel, R; Munger, K				Thompson, DA; Zacny, V; Belinsky, GS; Classon, M; Jones, DL; Schlegel, R; Munger, K			The HPV E7 oncoprotein inhibits tumor necrosis factor alpha-mediated apoptosis in normal human fibroblasts	ONCOGENE			English	Article						apoptosis; tumor necrosis factor-alpha; caspase 8; human papillomavirus	HUMAN-PAPILLOMAVIRUS TYPE-16; SIGNALING COMPLEX DISC; TNF RECEPTOR; CELL-DEATH; GROWTH ARREST; KAPPA-B; KINASE RIP; PROTEIN; ACTIVATION; PATHWAY	Tumor necrosis factor-alpha (TNF) is a cytokine that induces programmed cell death, apoptosis, in a number of cell types and is employed by cytotoxic T cells to eliminate virus infected cells. Consequently, many viruses have acquired mechanisms to undermine these host cell defense mechanisms and cause resistance to TNF-mediated apoptosis, Here we show that normal human diploid fibroblasts that express the human papillomavirus type 16 E7 oncoprotein have a decreased propensity to undergo apoptosis in response to TNF treatment. The ability of E7 to undermine TNF-mediated apoptosis correlates with cellular transformation. While E7 does not generally subvert signaling by tumor necrosis factor receptor I, pro-caspase 8 activation is decreased in E7-expressing cells, E7 also provides some protection from apoptosis caused by stimulation of the TNF receptor 1-related cytokine receptor Fas, where induction of apoptosis occurs much slower in this cell type. Hence, E7-expressing normal human fibroblasts exhibit specific defect that obstructs cytokine-mediated activation of pro-caspase 8 and apoptosis.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Harvard Ctr Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Canc Cell BIol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts General Hospital	Munger, K (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.			Munger, Karl/0000-0003-3288-9935; Thompson, David/0000-0003-2372-7766	NATIONAL CANCER INSTITUTE [T32CA072320, R01CA081135] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA81135, T32 CA72320] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTWERP DJV, 1996, SCIENCE, V274, P787; Baeuerle PA, 1998, CELL, V95, P729, DOI 10.1016/S0092-8674(00)81694-3; Baker SJ, 1996, ONCOGENE, V12, P1; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Boyer SN, 1996, CANCER RES, V56, P4620; Bulfone-Paus S, 1999, FASEB J, V13, P1575, DOI 10.1096/fasebj.13.12.1575; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; DARCY A, 1993, J MOL BIOL, V229, P555, DOI 10.1006/jmbi.1993.1055; Demers GW, 1996, J VIROL, V70, P6862, DOI 10.1128/JVI.70.10.6862-6869.1996; ECK MJ, 1989, J BIOL CHEM, V264, P17595; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; Jones DL, 1997, VIROLOGY, V239, P97, DOI 10.1006/viro.1997.8851; Jones DL, 1999, VIROLOGY, V258, P406, DOI 10.1006/viro.1999.9733; KIRSTEIN M, 1986, J IMMUNOL, V137, P2277; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; Perez D, 1998, J CELL BIOL, V141, P1255, DOI 10.1083/jcb.141.5.1255; PFIZENMAIER K, 1987, BLUT, V55, P1, DOI 10.1007/BF00319635; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Ramshaw IA, 1997, IMMUNOL REV, V159, P119, DOI 10.1111/j.1600-065X.1997.tb01011.x; REID TR, 1989, J BIOL CHEM, V264, P4583; Roulston A, 1999, ANNU REV MICROBIOL, V53, P577, DOI 10.1146/annurev.micro.53.1.577; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SMOTKIN D, 1987, J VIROL, V61, P1686, DOI 10.1128/JVI.61.5.1686-1689.1987; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Stoppler H, 1998, ONCOGENE, V17, P1207, DOI 10.1038/sj.onc.1202053; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Thompson DA, 1997, ONCOGENE, V15, P3025, DOI 10.1038/sj.onc.1201495; Vandevoorde V, 1997, J CELL BIOL, V137, P1627, DOI 10.1083/jcb.137.7.1627; WAKABAYASHI T, 1990, J BIOL CHEM, V265, P7604; Wold WSM, 1999, CURR OPIN IMMUNOL, V11, P380, DOI 10.1016/S0952-7915(99)80064-8; Wong GHW, 1992, TUMOR NECROSIS FACTO, P371; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806	55	43	49	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2001	20	28					3629	3640		10.1038/sj.onc.1204483	http://dx.doi.org/10.1038/sj.onc.1204483			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439326				2022-12-17	WOS:000169400200004
J	Bu, W; Su, LK				Bu, W; Su, LK			Regulation of microtubule assembly by human EB1 family proteins	ONCOGENE			English	Article						EB1; EBF3; microtubule-associated protein; microtubule; microtubule bundle	TUMOR-SUPPRESSOR PROTEIN; BINDING PROTEIN; CYTOPLASMIC DYNEIN; ALPHA-TUBULIN; DISTAL ENDS; CELL-CYCLE; APC; DYNAMICS; CANCER; YEAST	The EB1 family proteins are highly conserved microtubule-associated proteins, The EB1 protein in yeast has been shown to play an important role in regulating microtubule dynamics and chromosome segregation. Human EB1 family proteins include EB1, RP1 and EBF3. Although EB1 and RP1 have been shown to associate with microtubules, the subcellular localization of endogenous EBF3 had not been characterized. The function of human EB1 family proteins was also not clear. We therefore investigated the cellular localization of EBF3 and the regulation of microtubule organization by EB1 family proteins. As do EB1 and RP1, EBF3 was found to colocalize with microtubules, preferentially at their plus ends, throughout the cell cycle. Moreover, there was a very strong EBF3 signal at the centrosome in interphase cells and at the spindle poles in mitotic cells. When EB1 family proteins were overexpressed, they associated with the entire microtubule cytoskeleton, In addition, EB1 and EBF3 induced microtubule bundling in some cells overexpressing these proteins. These microtubule bundles were more resistant to nocodazole and were more acetylated than regular microtubules. Our results demonstrate for the first time that human EB1 family proteins could regulate microtubule assembly and stability.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Su, LK (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R29CA070371, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA 70371, CA 16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adames NR, 2000, J CELL BIOL, V149, P863, DOI 10.1083/jcb.149.4.863; Askham JM, 2000, ONCOGENE, V19, P1950, DOI 10.1038/sj.onc.1203498; Beinhauer JD, 1997, J CELL BIOL, V139, P717, DOI 10.1083/jcb.139.3.717; Berrueta L, 1999, CURR BIOL, V9, P425, DOI 10.1016/S0960-9822(99)80190-0; Berrueta L, 1998, P NATL ACAD SCI USA, V95, P10596, DOI 10.1073/pnas.95.18.10596; Cassimeris L, 1999, CURR OPIN CELL BIOL, V11, P134, DOI 10.1016/S0955-0674(99)80017-9; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Doxsey S, 1998, NAT GENET, V20, P104, DOI 10.1038/2392; Dumontet C, 1999, J CLIN ONCOL, V17, P1061, DOI 10.1200/JCO.1999.17.3.1061; Jordan MA, 1998, CURR OPIN CELL BIOL, V10, P123, DOI 10.1016/S0955-0674(98)80095-1; Juwana JP, 1999, INT J CANCER, V81, P275, DOI 10.1002/(SICI)1097-0215(19990412)81:2<275::AID-IJC18>3.0.CO;2-Z; KANAI Y, 1989, J CELL BIOL, V109, P1173, DOI 10.1083/jcb.109.3.1173; Korinek WS, 2000, SCIENCE, V287, P2257, DOI 10.1126/science.287.5461.2257; Lee L, 2000, SCIENCE, V287, P2260, DOI 10.1126/science.287.5461.2260; LEWIS SA, 1989, NATURE, V342, P498, DOI 10.1038/342498a0; Miller RK, 2000, MOL BIOL CELL, V11, P2949, DOI 10.1091/mbc.11.9.2949; Mimori-Kiyosue Y, 2000, CURR BIOL, V10, P865, DOI 10.1016/S0960-9822(00)00600-X; Mimori-Kiyosue Y, 2000, J CELL BIOL, V148, P505, DOI 10.1083/jcb.148.3.505; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morrison EE, 1997, NEUROSCIENCE, V81, P553, DOI 10.1016/S0306-4522(97)00099-7; Morrison EE, 1998, ONCOGENE, V17, P3471, DOI 10.1038/sj.onc.1202247; Muhua L, 1998, NATURE, V393, P487, DOI 10.1038/31014; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Nakagawa H, 2000, ONCOGENE, V19, P210, DOI 10.1038/sj.onc.1203308; Pancer Z, 1996, CANCER LETT, V109, P155, DOI 10.1016/S0304-3835(96)04440-0; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; PIPERNO G, 1987, J CELL BIOL, V104, P289, DOI 10.1083/jcb.104.2.289; Salisbury JL, 1999, BIOL CELL, V91, P451, DOI 10.1016/S0248-4900(99)80086-0; SCHULZE E, 1987, J CELL BIOL, V105, P2167, DOI 10.1083/jcb.105.5.2167; Schwartz K, 1997, MOL BIOL CELL, V8, P2677, DOI 10.1091/mbc.8.12.2677; SMITH KJ, 1994, CANCER RES, V54, P3672; Su LK, 2001, GENOMICS, V71, P142, DOI 10.1006/geno.2000.6428; SU LK, 1995, CANCER RES, V55, P2972; TAKEMURA R, 1992, J CELL SCI, V103, P953; Tirnauer JS, 2000, J CELL BIOL, V149, P761, DOI 10.1083/jcb.149.4.761; Tirnauer JS, 1999, J CELL BIOL, V145, P993, DOI 10.1083/jcb.145.5.993; Vaughan KT, 1999, J CELL SCI, V112, P1437	39	43	44	1	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 31	2001	20	25					3185	3192		10.1038/sj.onc.1204429	http://dx.doi.org/10.1038/sj.onc.1204429			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423968				2022-12-17	WOS:000169163500002
J	Ma, WB; Xia, CZ; Ling, P; Qiu, MS; Luo, Y; Tan, TH; Liu, MY				Ma, WB; Xia, CZ; Ling, P; Qiu, MS; Luo, Y; Tan, TH; Liu, MY			Leukocyte-specific adaptor protein Grap2 interacts with hematopoietic progenitor kinase 1 (HPK1) to activate JNK signaling pathway in T lymphocytes	ONCOGENE			English	Article						adaptor protein Grap2; HPK1; JNK; T-cells	N-TERMINAL KINASE; CELL ANTIGEN RECEPTOR; GERMINAL CENTER KINASE; TYROSINE KINASES; PHOSPHOLIPASE C-GAMMA-1; MOLECULAR-CLONING; NUCLEAR FACTOR; TRANSCRIPTIONAL ACTIVITY; LINKER PROTEIN; RAS PATHWAY	Immune cell-specific adaptor proteins create various combinations of multiprotein complexes and integrate signals from cell surface receptors to the nucleus, modulating the specificity and selectivity of intracellular signal transduction, Grap2 is a newly identified adaptor protein specifically expressed in lymphoid tissues. This protein shares 40-50% sequence homology in the SH3 and the SH2 domain with Grb2 and Grap, However, the Grap2 protein has a unique 120-amino acid glutamine-and proline-rich domain between the SH2 and C-terminal SH3 domains, The expression of Grap2 is highly restricted to lymphoid organs and T lymphocytes. In order to understand the role of this specific adaptor protein in immune cell signaling and activation, we searched for the Grap2 interacting protein in T lymphocytes. We found that Grap2 interacted with the hematopoietic progenitor kinase 1 (HPK1) in vitro and in Jurkat T cells. The interaction was mediated by the carboxyl-terminal SH3 domain of Grap2 with the second proline-rich motif of HPK1, Coexpression of Grap2 with HPK1 not only increased the kinase activity of HPK1 in the cell, but also had an additive effect on HPK1 mediated JNK activation. Furthermore, over expression of Grap2 and HPK1 induced significant transcriptional activation of c-Jun in the JNK signaling pathway and IL-2 gene reporter activity in stimulated Jurkat T cells, Therefore, our data suggest that the hematopoietic specific proteins Grap2 and HPK1 form a signaling complex to mediate the c-Jun NH2-terminal kinase (JNK) signaling pathway in T cells.	Texas A&M Univ, Hlth Sci Ctr, Dept Med Biochem & Genet, Ctr Canc Biol & Nutr,Inst Biosci & Technol, Houston, TX 77030 USA; Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA; Univ Louisville, Dept Anat Sci & Neurobiol, Sch Med, Louisville, KY 40202 USA; Shanghai Genom Inc, Shanghai 201204, Peoples R China	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; Baylor College of Medicine; University of Louisville	Liu, MY (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Dept Med Biochem & Genet, Ctr Canc Biol & Nutr,Inst Biosci & Technol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.		Tan, Tse-Hua/E-3983-2010; Tan, Tse-Hua/ABD-7080-2021	Tan, Tse-Hua/0000-0003-4969-3170; Tan, Tse-Hua/0000-0003-4969-3170; Ma, Wenbin/0000-0001-8774-7593	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038649, R01AI042532] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI42532, R01-AI38649] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anafi M, 1997, J BIOL CHEM, V272, P27804, DOI 10.1074/jbc.272.44.27804; Asada H, 1999, J EXP MED, V189, P1383, DOI 10.1084/jem.189.9.1383; Bourette RP, 1998, EMBO J, V17, P7273, DOI 10.1093/emboj/17.24.7273; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Cantrell DA, 1996, CANCER SURV, V27, P165; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; Chen YR, 2000, INT J ONCOL, V16, P651; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; CHOI KY, 1994, CELL, V78, P499; Clements JL, 1998, J IMMUNOL, V161, P3880; Clements JL, 1999, ANNU REV IMMUNOL, V17, P89, DOI 10.1146/annurev.immunol.17.1.89; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; Deckert M, 1998, IMMUNITY, V9, P595, DOI 10.1016/S1074-7613(00)80657-3; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Ellis JH, 2000, J IMMUNOL, V164, P5805, DOI 10.4049/jimmunol.164.11.5805; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Hua SB, 1997, PLASMID, V38, P91, DOI 10.1006/plas.1997.1305; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Law CL, 1999, J EXP MED, V189, P1243, DOI 10.1084/jem.189.8.1243; Ling P, 1999, MOL CELL BIOL, V19, P1359; Liou J, 2000, IMMUNITY, V12, P399, DOI 10.1016/S1074-7613(00)80192-2; Liu SK, 2000, J IMMUNOL, V165, P1417, DOI 10.4049/jimmunol.165.3.1417; Liu SK, 1998, ONCOGENE, V17, P3073, DOI 10.1038/sj.onc.1202337; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; LOWE VPW, 1991, ENVIRON POLLUT, V70, P1, DOI 10.1016/0269-7491(91)90128-J; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; Nagata Y, 1999, BLOOD, V93, P3347, DOI 10.1182/blood.V93.10.3347.410k06_3347_3354; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; Oehrl W, 1998, ONCOGENE, V17, P1893, DOI 10.1038/sj.onc.1202108; Pappu R, 1999, SCIENCE, V286, P1949, DOI 10.1126/science.286.5446.1949; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pivniouk V, 1998, CELL, V94, P229, DOI 10.1016/S0092-8674(00)81422-1; Qiu MS, 1998, BIOCHEM BIOPH RES CO, V253, P443, DOI 10.1006/bbrc.1998.9795; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Rudd CE, 1999, CELL, V96, P5, DOI 10.1016/S0092-8674(00)80953-8; SCHNEIDER H, 1995, EUR J IMMUNOL, V25, P1044, DOI 10.1002/eji.1830250428; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Trub T, 1997, J BIOL CHEM, V272, P894, DOI 10.1074/jbc.272.2.894; ULLMAN KS, 1993, GENE DEV, V7, P188, DOI 10.1101/gad.7.2.188; VERWEIJ CL, 1990, J BIOL CHEM, V265, P15788; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; Weber JR, 1998, J EXP MED, V187, P1157, DOI 10.1084/jem.187.7.1157; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Xia CZ, 2000, J BIOL CHEM, V275, P20942, DOI 10.1074/jbc.M002598200; Zhang WG, 2000, J BIOL CHEM, V275, P23355, DOI 10.1074/jbc.M000404200; Zhang WG, 2000, SEMIN IMMUNOL, V12, P35, DOI 10.1006/smim.2000.0205; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zhou GS, 1999, J BIOL CHEM, V274, P13133, DOI 10.1074/jbc.274.19.13133	65	43	46	1	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 29	2001	20	14					1703	1714		10.1038/sj.onc.1204224	http://dx.doi.org/10.1038/sj.onc.1204224			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415YJ	11313918				2022-12-17	WOS:000167750900004
J	Monaco, C; Visconti, R; Barone, MV; Pierantoni, GM; Berlingieri, MT; De Lorenzo, C; Mineo, A; Vecchio, G; Fusco, A; Santoro, M				Monaco, C; Visconti, R; Barone, MV; Pierantoni, GM; Berlingieri, MT; De Lorenzo, C; Mineo, A; Vecchio, G; Fusco, A; Santoro, M			The RFG oligomerization domain mediates kinase activation and re-localization of the RET/PTC3 oncoprotein to the plasma membrane	ONCOGENE			English	Article						tyrosine kinase; transformation; thyroid; coiled coil; dimerization	THYROID PAPILLARY CARCINOMAS; A ANCHORING PROTEIN; TYROSINE KINASE; MOLECULAR CHARACTERIZATION; REARRANGED FORM; ONCOGENE; GENE; PROTOONCOGENE; RECEPTOR; COACTIVATOR	The RET/PTC3 oncogene arises from the fusion between the N-terminal encoding domain of the RFG gene and the tyrosine kinase encoding domain of RET receptor, RET/PTC3 is,very frequent in papillary thyroid carcinomas, especially in children exposed to the Chernobyl accident. We have studied the functional consequences of the RFG - RET fusion, Here we show, that the N-terminal coiled-coil domain of RGF mediates oligomerization and activation of the kinase and of the transforming capability of RET/PTC3, In addition, the RFG coiled-coil domain mediates a physical association between RET/PTC3 and RGF proteins, rendering RFG a bona fide substrate of RET/PTC3 kinase, Finally, we show that the coiled-coil domain of RGF is essential for the distribution of the RET/PTC3 protein at the membrane/particulate cell compartment level, where also most of the RFG protein is localized. We propose that fusion to the RFG coiled-coil domain provides RET kinase with a scaffold that mediates oligomerization and re-localization of the RET/PTC3 protein, a process that may be crucial for the signalling of this specific RET/PTC variant.	Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, CNR,Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Univ Naples Federico II, Dept Organ & Biol Chem, I-80134 Naples, Italy; Fdn Senatore Pascale, I-80131 Naples, Italy; Univ Catanzaro, Fac Med & Chirurg, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; University of Naples Federico II; IRCCS Fondazione Pascale; Magna Graecia University of Catanzaro	Santoro, M (corresponding author), Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, CNR,Ctr Endocrinol & Oncol Sperimentale, Via S Pansini 5, I-80131 Naples, Italy.		Pierantoni, Giovanna Maria/O-7527-2015; Visconti, Roberta/C-5299-2009	Pierantoni, Giovanna Maria/0000-0003-4078-8528; De Lorenzo, Claudia/0000-0002-6195-5631; BARONE, Maria Vittoria/0000-0001-6190-4917; Fusco, Alfredo/0000-0003-3332-5197; Visconti, Roberta/0000-0001-7613-3801				Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; BORRELLO MG, 1994, ONCOGENE, V9, P1661; Durick K, 1998, MOL CELL BIOL, V18, P2298, DOI 10.1128/MCB.18.4.2298; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; Heinlein CA, 1999, J BIOL CHEM, V274, P16147, DOI 10.1074/jbc.274.23.16147; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; Huang LJS, 1997, P NATL ACAD SCI USA, V94, P11184, DOI 10.1073/pnas.94.21.11184; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; Klugbauer S, 1999, ONCOGENE, V18, P4388, DOI 10.1038/sj.onc.1202824; Klugbauer S, 1998, ONCOGENE, V16, P671, DOI 10.1038/sj.onc.1201526; Klugbauer S, 1998, CANCER RES, V58, P198; Nakata T, 1999, GENE CHROMOSOME CANC, V25, P97, DOI 10.1002/(SICI)1098-2264(199906)25:2<97::AID-GCC4>3.0.CO;2-L; Nikiforov YE, 1997, CANCER RES, V57, P1690; Nikiforova MN, 2000, SCIENCE, V290, P138, DOI 10.1126/science.290.5489.138; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pierotti MA, 1998, RECENT RES CANCER, V154, P237; Powell DJ, 1998, CANCER RES, V58, P5523; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; Salassidis K, 2000, CANCER RES, V60, P2786; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SANTORO M, 1994, ONCOGENE, V9, P509; Santoro M, 1996, ONCOGENE, V12, P1821; Sugg SL, 1998, J CLIN ENDOCR METAB, V83, P4116, DOI 10.1210/jc.83.11.4116; Thomas GA, 1999, J CLIN ENDOCR METAB, V84, P4232, DOI 10.1210/jc.84.11.4232; Tong Q, 1997, J BIOL CHEM, V272, P9043; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517	33	43	45	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	2001	20	5					599	608		10.1038/sj.onc.1204127	http://dx.doi.org/10.1038/sj.onc.1204127			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	398KE	11313992				2022-12-17	WOS:000166755000007
J	Tsuiki, H; Nitta, M; Tada, M; Inagaki, M; Ushio, Y; Saya, H				Tsuiki, H; Nitta, M; Tada, M; Inagaki, M; Ushio, Y; Saya, H			Mechanism of hyperploid cell formation induced by microtubule inhibiting drug in glioma cell lines	ONCOGENE			English	Article						hyperploidy; spindle assembly checkpoint; glioma; microtubule inhibitor; staurosporine	PROTEIN-KINASE; SPINDLE DISRUPTION; CYCLE CHECKPOINT; MAMMALIAN-CELLS; MITOTIC EXIT; P53; STAUROSPORINE; MITOSIS; PROGRESSION; ARREST	Checkpoint mechanism plays a crucial role in ensuring genomic integrity during cell cycle. Loss of checkpoint function is known to induce genomic instability and to alter ploidy of dividing cells. In this study, we examined mechanisms of hyperploid formation in glioma cells by treatment with nocodazole, which activates spindle assembly checkpoint by inhibiting microtubule polymerization. By prolonged nocodazole treatment, U251MG human glioma cell, which has a p53 mutation, underwent transient arrest at mitosis, and subsequently exited from mitotic arrest (termed 'mitotic slippage') followed by DNA replication without cytokinesis, resulting in hyperploid formation. Additionally, the heterogeneity in the number of centrosomes per cell increased during the hyperploid formation, suggesting that these hyperploid cells have genomic instability. By employing LN382 glioma cell that has a temperature-sensitive p53 mutation, Ne found that the activation of p53 prevents hyperploid formation after the prolonged nocodazole treatment. Furthermore, staurosporine, an inhibitor for a broad range of serine/threonine kinases including cdc2, was found to enhance hyperploid formation in U251MG cells by accelerating the induction of mitotic slippage. Interestingly, inhibitors specific for cdc2 kinase prevented the G2 to M transition but did not accelerate mitotic slippage, suggesting that staurosporine-sensitive kinases other than cdc2 are required for maintenance of spindle assembly checkpoint. Moreover, the enhancement of hyperploid formation by staurosporine was also blocked by p53-dependent G1 checkpoint. These results suggest that abrogation of G1 checkpoint is a critical factor for formation of hyperploid cells after the mitotic slippage.	Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 8600811, Japan; Kumamoto Univ, Sch Med, Dept Neurosurg, Kumamoto 8600811, Japan; Hokkaido Univ, Sch Med, Inst Canc, Div Cell Biol, Sapporo, Hokkaido 0608638, Japan; Aichi Canc Ctr, Res Inst, Biochem Lab, Chikusa Ku, Nagoya, Aichi 4640021, Japan	Kumamoto University; Kumamoto University; Hokkaido University; Aichi Cancer Center	Saya, H (corresponding author), Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, 2-2-1 Hongo, Kumamoto 8600811, Japan.		Saya, Hideyuki/J-4325-2013; Inagaki, Masaki/B-9920-2016					ABE K, 1991, EXP CELL RES, V192, P122, DOI 10.1016/0014-4827(91)90166-R; ANDREASSEN PR, 1994, J CELL BIOL, V127, P789, DOI 10.1083/jcb.127.3.789; BRUNO S, 1992, CANCER RES, V52, P470; Chau ASS, 1999, J BIOL CHEM, V274, P32085, DOI 10.1074/jbc.274.45.32085; CRISSMAN HA, 1991, P NATL ACAD SCI USA, V88, P7580, DOI 10.1073/pnas.88.17.7580; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; Di Leonardo A, 1997, CANCER RES, V57, P1013; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; Goto H, 1999, J BIOL CHEM, V274, P25543, DOI 10.1074/jbc.274.36.25543; Hall LL, 1996, CANCER RES, V56, P3551; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V171, P189, DOI 10.1016/0006-291X(90)91375-3; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; Khan SH, 1998, CANCER RES, V58, P396; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Li CJ, 1999, P NATL ACAD SCI USA, V96, P13369, DOI 10.1073/pnas.96.23.13369; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; PU RT, 1995, EMBO J, V14, P995, DOI 10.1002/j.1460-2075.1995.tb07080.x; RIEDER CL, 1992, J CELL SCI, V102, P387; Sablina AA, 1999, CELL BIOL INT, V23, P323, DOI 10.1006/cbir.1999.0362; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Tsuiki H, 2000, J CELL BIOCHEM, V76, P254, DOI 10.1002/(SICI)1097-4644(20000201)76:2<254::AID-JCB9>3.0.CO;2-G; USUI T, 1991, J CELL BIOL, V115, P1275, DOI 10.1083/jcb.115.5.1275; Verdoodt B, 1999, MUTAGENESIS, V14, P513, DOI 10.1093/mutage/14.5.513; Zachariae W, 1999, CURR OPIN CELL BIOL, V11, P708, DOI 10.1016/S0955-0674(99)00041-1	31	43	45	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2001	20	4					420	429		10.1038/sj.onc.1204126	http://dx.doi.org/10.1038/sj.onc.1204126			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395DB	11313973				2022-12-17	WOS:000166562500002
J	Nishioka, M; Kohno, T; Takahashi, M; Niki, T; Yamada, T; Sone, S; Yokota, J				Nishioka, M; Kohno, T; Takahashi, M; Niki, T; Yamada, T; Sone, S; Yokota, J			Identification of a 428-kb homozygously deleted region disrupting the SEZ6L gene at 22q12.1 in a lung cancer cell line	ONCOGENE			English	Article						lung cancer; tumor suppressor gene; chromosomal deletion; chromosome 22q; SEZ6L	TUMOR-SUPPRESSOR GENE; NEUROFIBROMATOSIS TYPE-2; POLYPYRIMIDINE TRACT; CARCINOMA; DNA; SEQUENCE; FREQUENT; METHYLATION; PREDICTION; EXPRESSION	Frequent allelic losses on chromosome 22q in small cell lung carcinomas (SCLCs) and advanced non-small cell lung carcinomas indicate the presence of tumor suppressor gene(s) on this chromosome arm. We detected a homozygous deletion at 22q12.1 in a SCLC cell line, Lu24. Cloning of the breakpoints of the Lu24 deletion revealed that the deletion was interstitial and 428, 131 bp in size. The deleted region contained the SEZ6L (Seizure 6-like) gene, whose structure had been partially determined by the chromosome 22 sequencing project, We determined the full length cDNA sequence for the SEZ6L gene based on the genomic sequence for the SEZ6L locus using the GENSCAN program and the RT-PCR method. The deduced SEZ6L protein was a transmembrane protein of 1024 amino acids with multiple domains involved in protein-protein interaction and signal transduction, SEZ6L expression was detected in a variety of human tissues, including lung, while its expression was detected in 14 (30%) of 46 lung cancer cell lines examined, Missense mutations were detected in three (7%) of the 46 cell lines, and a 1 bp deletion in the polypyrimidine tract preceding exon 4 was detected in one (2%) of 46 primary lung cancers. Therefore, it is possible that genetic and/or epigenetic SEZ6L alterations are involved in the development and/or progression in a subset of lung cancer, although functional analysis of the SEZ6L gene as well as molecular analysis of other genes in the homozygously deleted region is necessary to understand the pathogenetic significance of 220 deletions in human lung carcinogenesis.	Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tokyo 1040045, Japan; Natl Canc Ctr, Res Inst, Div Pathol, Chuo Ku, Tokyo 1040045, Japan; Univ Tokushima, Sch Med, Dept Internal Med 3, Tokushima 7708503, Japan	National Cancer Center - Japan; National Cancer Center - Japan; Tokushima University	Yokota, J (corresponding author), Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, 1-1 Tsukiji 5 Chome, Tokyo 1040045, Japan.		niki, toshiro/K-8917-2012					Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Anami Y, 2000, INT J CANCER, V89, P19, DOI 10.1002/(SICI)1097-0215(20000120)89:1<19::AID-IJC4>3.0.CO;2-3; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; CANNING S, 1989, P NATL ACAD SCI USA, V86, P5044, DOI 10.1073/pnas.86.13.5044; Castells A, 2000, CANCER RES, V60, P2836; Chen C, 1998, MOL CELL, V2, P9, DOI 10.1016/S1097-2765(00)80109-4; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Hamada K, 1998, GENE CHROMOSOME CANC, V22, P232, DOI 10.1002/(SICI)1098-2264(199807)22:3<232::AID-GCC9>3.0.CO;2-X; Herbst R, 1997, MOL BRAIN RES, V44, P309, DOI 10.1016/S0169-328X(96)00274-4; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Inoue H, 1997, P NATL ACAD SCI USA, V94, P14584, DOI 10.1073/pnas.94.26.14584; Kawanishi M, 1997, CARCINOGENESIS, V18, P2057, DOI 10.1093/carcin/18.11.2057; Kohno T, 1999, CARCINOGENESIS, V20, P1403, DOI 10.1093/carcin/20.8.1403; Kohno T, 1996, DNA Res, V3, P421, DOI 10.1093/dnares/3.6.421; Kohno T, 1998, GENE CHROMOSOME CANC, V22, P152, DOI 10.1002/(SICI)1098-2264(199806)22:2<152::AID-GCC10>3.0.CO;2-S; Kohno T, 1999, CANCER RES, V59, P4170; Kukita Y, 1997, HUM MUTAT, V10, P400, DOI 10.1002/(SICI)1098-1004(1997)10:5<400::AID-HUMU11>3.3.CO;2-1; LEVIN NA, 1994, CANCER RES, V54, P5086; Magnusson KP, 2000, GENE, V246, P247, DOI 10.1016/S0378-1119(00)00068-8; Manda R, 2000, CANCER LETT, V153, P57, DOI 10.1016/S0304-3835(00)00342-6; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Mertens F, 1997, CANCER RES, V57, P2765; NORTON PA, 1994, NUCLEIC ACIDS RES, V22, P3854, DOI 10.1093/nar/22.19.3854; POMYKALA HM, 1994, MOL CELL BIOL, V14, P7604, DOI 10.1128/MCB.14.11.7604; ROSCIGNO RF, 1993, J BIOL CHEM, V268, P11222; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; SEKIDO Y, 1995, CANCER RES, V55, P1227; SHIMIZUNISHIKAWA K, 1995, MOL BRAIN RES, V28, P201, DOI 10.1016/0169-328X(94)00203-Q; SHISEKI M, 1994, CANCER RES, V54, P5643; Shiseki M, 1996, GENE CHROMOSOME CANC, V17, P71, DOI 10.1002/(SICI)1098-2264(199610)17:2<71::AID-GCC1>3.0.CO;2-Y; Stanton SE, 2000, GENE CHROMOSOME CANC, V27, P323, DOI 10.1002/(SICI)1098-2264(200003)27:3<323::AID-GCC14>3.0.CO;2-P; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; TESTA JR, 1994, GENE CHROMOSOME CANC, V11, P178, DOI 10.1002/gcc.2870110307; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Ueda T, 1999, CANCER RES, V59, P6080; Ueki K, 1999, CANCER RES, V59, P5995; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; Wilmotte R, 1999, BRIT J HAEMATOL, V104, P855, DOI 10.1046/j.1365-2141.1999.01271.x; Yamada T, 2000, CANCER GENET CYTOGEN, V120, P11, DOI 10.1016/S0165-4608(99)00240-X	43	43	46	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6251	6260		10.1038/sj.onc.1204031	http://dx.doi.org/10.1038/sj.onc.1204031			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175339				2022-12-17	WOS:000166210500008
J	Kikuchi, M; Miki, T; Kumagai, T; Fukuda, T; Kamiyama, R; Miyasaka, N; Hirosawa, S				Kikuchi, M; Miki, T; Kumagai, T; Fukuda, T; Kamiyama, R; Miyasaka, N; Hirosawa, S			Identification of negative regulatory regions within the first exon and intron of the BCL6 gene	ONCOGENE			English	Article						BCL6; B-cell lymphoma; silencer element	NON-HODGKINS-LYMPHOMA; FINGER ENCODING GENE; B-CELL LYMPHOMA; SOMATIC HYPERMUTATION; 5'-NONCODING REGION; TRANSCRIPTIONAL REPRESSION; 3Q27 TRANSLOCATION; MUTATIONS; SEQUENCE; DELETIONS	Chromosomal translocations involving BCL6 gene are frequent in human B-cell lymphomas, Chromosomal breaks preferentially occur within a 3-kb region containing the first exon and intron, Recent reports have revealed that internal deletions or point mutations also are common in this region, suggesting that structural alteration of this region may be a crucial event in the development of lymphomas, In this study, we identified two regions in the BCL6 gene that negatively regulate BCL6 expression, One region, ES, is located within the first exon between nucleotides +472 and +543, and a second region, IS, is located between +783 and +918 of the first intron, A consensus nucleotide sequence for the binding of the BCL6 protein itself was found within the ES region. An electrophoretic mobility shift assay and a co-transfection experiment using a BCL6 expression vector showed that transcription of the BCL6 gene was negatively regulated by the BCL6 gene product. The IS region which is included in the regions commonly deleted in B-cell lymphomas had a silencer activity. Structural alterations of these two regions may play roles in the deregulated expression of the BCL6 gene in B-cell lymphomas.	Tokyo Med & Dent Univ, Fac Med, Dept Internal Med 1, Bunkyo Ku, Tokyo 1138519, Japan; Tokyo Med & Dent Univ, Fac Med, Sch Allied Hlth Sci, Bunkyo Ku, Tokyo 1138519, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Hirosawa, S (corresponding author), Tokyo Med & Dent Univ, Fac Med, Dept Internal Med 1, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.							Albagli O, 1996, BIOCHEM BIOPH RES CO, V220, P911, DOI 10.1006/bbrc.1996.0505; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; Bernardin F, 1997, ONCOGENE, V14, P849, DOI 10.1038/sj.onc.1200903; Capello D, 1997, BRIT J HAEMATOL, V99, P168, DOI 10.1046/j.1365-2141.1997.3573171.x; Cattoretti G., 1997, Blood, V90, p175A; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; Chen WY, 1998, ONCOGENE, V17, P1717, DOI 10.1038/sj.onc.1202098; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; Gaidano G, 1997, BLOOD, V89, P3755; KAWAMATA N, 1994, BIOCHEM BIOPH RES CO, V204, P366, DOI 10.1006/bbrc.1994.2468; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Klaus G G, 1997, Int Rev Immunol, V15, P5, DOI 10.3109/08830189709068169; Liang R, 1998, CANCER GENET CYTOGEN, V102, P110, DOI 10.1016/S0165-4608(97)00353-1; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; MIKI T, 1994, BLOOD, V83, P26; Nakamura Y, 1999, BRIT J HAEMATOL, V105, P274; Nakamura Y, 1996, LEUKEMIA, V10, P658; OHASHI K, 1995, BIOCHEM BIOPH RES CO, V214, P461, DOI 10.1006/bbrc.1995.2309; Pasqualucci L, 1998, P NATL ACAD SCI USA, V95, P11816, DOI 10.1073/pnas.95.20.11816; Seyfert VL, 1996, ONCOGENE, V12, P2331; Shen HM, 1998, SCIENCE, V280, P1750, DOI 10.1126/science.280.5370.1750; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596	22	43	43	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2000	19	42					4941	4945		10.1038/sj.onc.1203864	http://dx.doi.org/10.1038/sj.onc.1203864			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039912				2022-12-17	WOS:000089757800017
J	Kubota, S; Kondo, S; Eguchi, T; Hattori, T; Nakanishi, T; Pomerantz, RJ; Takigawa, M				Kubota, S; Kondo, S; Eguchi, T; Hattori, T; Nakanishi, T; Pomerantz, RJ; Takigawa, M			Identification of an RNA element that confers post-transcriptional repression of connective tissue growth factor/hypertrophic chondrocyte specific 24 (ctgf/hcs24) gene: Similarities to retroviral RNA-protein interactions	ONCOGENE			English	Article						CTGF; angiogenesis; chondrocyte; HIV-1 Rev; 3 '-UTR	ANCHORAGE-INDEPENDENT GROWTH; VASCULAR ENDOTHELIAL-CELLS; ANGIOGENESIS IN-VIVO; CAP-BINDING-PROTEIN; MESSENGER-RNAS; FACTOR-BETA; NEGATIVE REGULATOR; NUCLEAR EXPORT; LINE HCS-2/8; REV PROTEIN	The repressive effect of the 3'-untranslated region (3'-UTR) in human connective tissue growth factor/hypertrophic chondrocyte specific 24 (ctgf/hcs24) mRNA on gene expression had been demonstrated in our previous study. Here, we identified a minimal RNA element in the 3'-UTR, which acts as a cis-acting element of structure-anchored repression (CAESAR). Deletion analyses of the 3'-UTR led us to minimize the element of 84 bases at the junction of the coding region and the 3'-UTR. The minimized RNA segment is predicted, and actually capable of forming a stable secondary structure in vitro. Mutational analyses disclosed a significant relationship between the predicted structure and repressive effect. The utility of CAESAR as a post-transcriptional regulatory element was represented by the fact that steady-state mRNA levels were not affected by CAESAR linked in cis, while protein levels from such a chimeric gene were markedly reduced. Of note, the CAESAR sequence exerted no effect, when it was placed upstream of the promoter. Finally, RNA gel electromobility-shift analyses demonstrated a nuclear factor that interacts with the folded CAESAR. Taken together, it was uncovered that CAESAR of ctgf is a novel post-transcriptional structured RNA regulatory element, probably acting through direct interactions with a nuclear factor as observed in retroviral RNA elements with certain proteins.	Okayama Univ, Sch Dent, Dept Biochem & Mol Dent, Okayama 7008525, Japan; Thomas Jefferson Univ, Jefferson Med Coll, Dept Med,Dorrance H Hamilton Labs, Ctr Human Virol,Div Infect Dis, Philadelphia, PA 19107 USA	Okayama University; Jefferson University	Takigawa, M (corresponding author), Okayama Univ, Sch Dent, Dept Biochem & Mol Dent, 2-5-1 Shikata Cho, Okayama 7008525, Japan.		Kondo, Seiji/I-4332-2017; Kondo, Seiji/ABD-3982-2020	Kondo, Seiji/0000-0001-9341-5069; Kondo, Seiji/0000-0001-9341-5069; Eguchi, Takanori/0000-0002-3297-6126	PHS HHS [A143876] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARRIGO SJ, 1991, GENE DEV, V5, P808, DOI 10.1101/gad.5.5.808; Babic AM, 1999, MOL CELL BIOL, V19, P2958; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; DAGOSTINO DM, 1992, MOL CELL BIOL, V12, P1375, DOI 10.1128/MCB.12.3.1375; ENOMOTO M, 1992, BIOL REGULATION CHON, P321; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; GILMAN M, 1987, CURRENT PROTOCOLS MO; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; Hashimoto Y, 1998, J EXP MED, V187, P289, DOI 10.1084/jem.187.3.289; Hattori T, 1998, BIOCHEM BIOPH RES CO, V245, P679, DOI 10.1006/bbrc.1998.8505; HEAPHY S, 1991, P NATL ACAD SCI USA, V88, P7366, DOI 10.1073/pnas.88.16.7366; Hishikawa K, 1999, J BIOL CHEM, V274, P37461, DOI 10.1074/jbc.274.52.37461; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; KATAOKA N, 1995, NUCLEIC ACIDS RES, V23, P3638, DOI 10.1093/nar/23.18.3638; KIKUCHI K, 1995, J INVEST DERMATOL, V105, P128, DOI 10.1111/1523-1747.ep12313452; Kothapalli D, 1998, FASEB J, V12, P1151, DOI 10.1096/fasebj.12.12.1151; Kothapalli D, 1997, CELL GROWTH DIFFER, V8, P61; Kubo M, 1998, BRIT J DERMATOL, V139, P192; KUBOTA S, 1995, FEBS LETT, V375, P31, DOI 10.1016/0014-5793(95)01166-C; Kubota S, 1996, VIROLOGY, V220, P502, DOI 10.1006/viro.1996.0339; Kubota S, 1999, ONCOGENE, V18, P1503, DOI 10.1038/sj.onc.1202429; Kubota S, 1999, FEBS LETT, V450, P84, DOI 10.1016/S0014-5793(99)00480-9; Kumar S, 1999, J BIOL CHEM, V274, P17123, DOI 10.1074/jbc.274.24.17123; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; Moallem E, 1998, J BIOL CHEM, V273, P5253, DOI 10.1074/jbc.273.9.5253; Mori T, 1999, J CELL PHYSIOL, V181, P153, DOI 10.1002/(SICI)1097-4652(199910)181:1<153::AID-JCP16>3.0.CO;2-K; Nakanishi T, 2000, ENDOCRINOLOGY, V141, P264, DOI 10.1210/en.141.1.264; Nakanishi T, 1997, BIOCHEM BIOPH RES CO, V234, P206, DOI 10.1006/bbrc.1997.6528; Naveh-Many T, 1999, J BONE MINER RES, V14, pS167; Nishida T, 1998, BIOCHEM BIOPH RES CO, V247, P905, DOI 10.1006/bbrc.1998.8895; Oemar BS, 1997, ARTERIOSCL THROM VAS, V17, P1483, DOI 10.1161/01.ATV.17.8.1483; Ogbourne S, 1998, BIOCHEM J, V331, P1; OHBA Y, 1995, BBA-GEN SUBJECTS, V1245, P1, DOI 10.1016/0304-4165(95)00065-J; OHNO M, 1990, NUCLEIC ACIDS RES, V18, P6989, DOI 10.1093/nar/18.23.6989; Osman F, 1999, GENE DEV, V13, P3280, DOI 10.1101/gad.13.24.3280; POMERANTZ RJ, 1992, J VIROL, V66, P1809, DOI 10.1128/JVI.66.3.1809-1813.1992; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; SEIKI M, 1988, P NATL ACAD SCI USA, V85, P7124, DOI 10.1073/pnas.85.19.7124; Shimo T, 1999, J BIOCHEM-TOKYO, V126, P137, DOI 10.1093/oxfordjournals.jbchem.a022414; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; Sterling K, 1996, MOL PHARMACOL, V49, P329; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; TAKIGAWA M, 1989, CANCER RES, V49, P3996; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0; Zhang R, 1998, MOL CELL BIOL, V18, P6131, DOI 10.1128/MCB.18.10.6131; ZHU J, 1994, JPN J CANCER RES, V85, P364, DOI 10.1111/j.1349-7006.1994.tb02368.x	51	43	45	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2000	19	41					4773	4786		10.1038/sj.onc.1203835	http://dx.doi.org/10.1038/sj.onc.1203835			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	357YB	11032028				2022-12-17	WOS:000089528800012
J	Gil-Henn, H; Volohonsky, G; Toledano-Katchalski, H; Gandre, S; Elson, A				Gil-Henn, H; Volohonsky, G; Toledano-Katchalski, H; Gandre, S; Elson, A			Generation of novel cytoplasmic forms of protein tyrosine phosphatase epsilon by proteolytic processing and translational control	ONCOGENE			English	Article						phosphatase; tyrosine; proteolysis; MG132; translational regulation; cleavage	V-HA-RAS; TRANSGENIC MICE; MAMMARY-TUMORS; PTP-SIGMA; PROTEASOME; STEP; INITIATION; ISOFORM; CALPAIN; AUG	Two protein forms of tyrosine phosphatase epsilon (PTP epsilon) are known - receptor-like (tm-PTP epsilon) and non receptor-like (cyt-PTP epsilon), with each form possessing unique tissue-specific expression patterns, subcellular localization, and physiological functions. We describe two additional forms of PTP epsilon: protein - p67 and p65, p67 is produced by initiation of translation at an internal initiation codon of PTP epsilon mRNA molecules, while p65 is produced by specific proteolytic cleavage of larger PTP epsilon proteins. Cleavage is inhibited by MG132, but is proteasome-independent. In contrast with full-length tm-PTP epsilon and cyt-PTP epsilon, p67 and p65 are exclusively cytoplasmic, are not phosphorylated by Neu, and do not associate with Grb2 in unstimulated cells. p67 and p65 are catalytically active and can reduce Src-mediated phosphorylation of the Kv2.1 voltage-gated potassium channel, albeit with reduced efficiency which most likely results from their cytoplasmic localization. We also show that full-length cyt-PTP epsilon protein can be found at the cell membrane and in the nucleus and that it is the first 27 residues of cyt-PTP epsilon which determine this localization. p67 and p65 provide mechanisms for removing PTP epsilon activity from the cell membrane, possibly serving to down-regulate PTP epsilon activity there. PTP epsilon emerges as a family of four related proteins whose expression, subcellular localization and most likely physiological roles are subject to complex regulation at the transcriptional, translational and post-translational levels.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Elson, A (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.		Toledano, Hila/AGY-6574-2022	Toledano, Hila/0000-0001-9409-7728; Elson, Ari/0000-0001-9808-9135				ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; Aicher B, 1997, J CELL BIOL, V138, P681, DOI 10.1083/jcb.138.3.681; Blanchetot C, 2000, J BIOL CHEM, V275, P12446, DOI 10.1074/jbc.275.17.12446; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; Elson A, 1996, GENOMICS, V31, P373, DOI 10.1006/geno.1996.0061; Elson A, 1999, ONCOGENE, V18, P7535, DOI 10.1038/sj.onc.1203098; ELSON A, 1995, J BIOL CHEM, V270, P26116, DOI 10.1074/jbc.270.44.26116; Elson A, 1995, P NATL ACAD SCI USA, V92, P12235, DOI 10.1073/pnas.92.26.12235; Fischer EH, 1999, ADV ENZYME REGUL, V39, P359, DOI 10.1016/S0065-2571(98)00014-4; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; Gu MX, 1996, J BIOL CHEM, V271, P27751, DOI 10.1074/jbc.271.44.27751; Gurd JW, 1999, J NEUROCHEM, V73, P1990; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; MOLLER NPH, 1995, J BIOL CHEM, V270, P23126, DOI 10.1074/jbc.270.39.23126; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Nakamura K, 1996, BIOCHEM BIOPH RES CO, V218, P726, DOI 10.1006/bbrc.1996.0129; Nguyen TH, 1999, J NEUROCHEM, V73, P1995; PERETZ A, IN PRESS EMBO J; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; Rock MT, 1997, J BIOL CHEM, V272, P33377, DOI 10.1074/jbc.272.52.33377; Stein-Gerlach M, 1998, INT J BIOCHEM CELL B, V30, P559, DOI 10.1016/S1357-2725(98)00002-8; Tanuma N, 1999, EUR J BIOCHEM, V259, P46, DOI 10.1046/j.1432-1327.1999.00004.x; Toledano-Katchalski H, 1999, ONCOGENE, V18, P5024, DOI 10.1038/sj.onc.1202883; Wallace MJ, 1998, MOL CELL BIOL, V18, P2608, DOI 10.1128/MCB.18.5.2608; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6	38	43	47	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 7	2000	19	38					4375	4384		10.1038/sj.onc.1203790	http://dx.doi.org/10.1038/sj.onc.1203790			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980613				2022-12-17	WOS:000089271900008
J	Liao, DJ; Natarajan, G; Deming, SL; Jamerson, MH; Johnson, M; Chepko, G; Dickson, RB				Liao, DJ; Natarajan, G; Deming, SL; Jamerson, MH; Johnson, M; Chepko, G; Dickson, RB			Cell cycle basis for the onset and progression of c-Myc-induced, TGF alpha-enhanced mouse mammary gland carcinogenesis	ONCOGENE			English	Article						c-Myc; TGF alpha; E2F; cyclins; pRB; cell cycle	GROWTH-FACTOR-ALPHA; BREAST-CANCER CELLS; TRANSGENIC MICE; S-PHASE; SIGNAL-TRANSDUCTION; DEPENDENT KINASES; REDUNDANT CYCLIN; MESSENGER-RNA; EXPRESSION; D1	Using single and double transgenic mouse models, we investigated how c-Myc modulates the mammary epithelial cell cycle to induce cancer and how TGF alpha enhanced the process. In c-myc transgenic mice, c-myc expression was high in the hyperplastic mammary epithelium and in the majority of tumor areas. However, the tumors displayed focal areas of low expression of c-myc but high rates of proliferation. In contrast to E2F1 and cyclin A2, which were induced and co-localized with c-myc expression, induction of cyclins D1 and E occurred only in these tumor foci. Overexpression of cyclin D1 also occurred in the hyperplastic epithelium of tgf alpha-single and tgf alpha/c-myc-double transgenic mice. In tgf alpha/c-myc tumors, cells positive for cyclins D1 and E were randomly spread, without showing a reciprocal relationship to c-myc expression. In contrast to c-myc tumors, most tgf alpha/c-myc tumors showed undetectable levels of retinoblastoma protein (pRB), and the loss of PRB occurred in some cases at the mRNA level. These results suggest that E2F1 and cyclin A2 may be induced by c-Myc to mediate the onset of mammary cancer, whereas overexpression of cyclins D1 and E may occur later to facilitate tumor progression. TGF alpha may play its synergistic role, at least in part, by inducing cyclin D1 and facilitating the loss of pRB.	Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Pathol, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Oncol, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Cell Biol, Washington, DC 20007 USA	Georgetown University; Georgetown University; Georgetown University; Georgetown University	Dickson, RB (corresponding author), Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, 3970 Reservoir Rd NW,Res Bldg,W417, Washington, DC 20007 USA.		Chepko, Gloria/B-2235-2010	Chepko, Gloria/0000-0002-4691-9894	NCI NIH HHS [R01 CA72460] Funding Source: Medline; NIA NIH HHS [AG1496] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072460] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandrow MG, 1998, J CELL BIOCHEM, V70, P528, DOI 10.1002/(SICI)1097-4644(19980915)70:4<528::AID-JCB9>3.3.CO;2-K; Amati Bruno, 1998, Frontiers in Bioscience, V3, pD250; AMUNDADOTTIR LT, 1995, CELL GROWTH DIFFER, V6, P737; Amundadottir LT, 1996, ONCOGENE, V13, P757; Amundadottir LT, 1996, BREAST CANCER RES TR, V39, P119, DOI 10.1007/BF01806083; Auvinen PK, 1996, ACTA ONCOL, V35, P995, DOI 10.3109/02841869609100717; Barnes DM, 1998, BREAST CANCER RES TR, V52, P1, DOI 10.1023/A:1006103831990; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; CARDIFF RD, 1995, CANCER LETT, V90, P13, DOI 10.1016/0304-3835(94)03672-6; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; DAKSIS JI, 1994, ONCOGENE, V9, P3635; Dang CV, 1999, MOL CELL BIOL, V19, P1; Desdouets C, 1995, Prog Cell Cycle Res, V1, P115; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; ELDRIDGE SR, 1993, ENVIRON HEALTH PERSP, V101, P211, DOI 10.2307/3431870; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; GrayBablin J, 1996, P NATL ACAD SCI USA, V93, P15215, DOI 10.1073/pnas.93.26.15215; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HAN EKH, 1995, ONCOGENE, V10, P953; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; Johnson BE, 1998, MATH MECH SOLIDS, V3, P447, DOI 10.1177/108128659800300405; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; KEYOMARSI K, 1994, CANCER RES, V54, P380; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KOTANI S, 1995, ONCOGENE, V10, P663; Kwon TK, 1998, EXP CELL RES, V238, P128, DOI 10.1006/excr.1997.3816; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lavia P, 1999, BIOESSAYS, V21, P221; LEE DC, 1995, PHARMACOL REV, V47, P51; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Li JJ, 1999, CANCER RES, V59, P2340; LI Y, 1994, MOL CELL BIOL, V14, P1861, DOI 10.1128/MCB.14.3.1861; Liao DZJ, 1998, CARCINOGENESIS, V19, P2173, DOI 10.1093/carcin/19.12.2173; Lukas J, 1996, MOL CELL BIOL, V16, P6917; Lykkesfeldt AE, 1996, ACTA ONCOL, V35, P9, DOI 10.3109/02841869609083961; Marhin WW, 1996, ONCOGENE, V12, P43; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nass SJ, 1997, BREAST CANCER RES TR, V44, P1, DOI 10.1023/A:1005858611585; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; NOGUCHI E, 1993, BIOCHEM BIOPH RES CO, V197, P1524, DOI 10.1006/bbrc.1993.2650; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; Panico L, 1996, INT J CANCER, V65, P51, DOI 10.1002/(SICI)1097-0215(19960103)65:1<51::AID-IJC9>3.3.CO;2-N; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; Pilichowska M, 1997, MODERN PATHOL, V10, P969; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Prall OWJ, 1998, MOL CELL BIOL, V18, P4499, DOI 10.1128/MCB.18.8.4499; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Roussel ME, 1998, ADV CANCER RES, V74, P1, DOI 10.1016/S0065-230X(08)60763-0; SABATH DE, 1990, GENE, V91, P185, DOI 10.1016/0378-1119(90)90087-8; SAID TK, 1995, CARCINOGENESIS, V16, P823, DOI 10.1093/carcin/16.4.823; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; Santoni-Rugiu E, 1998, CANCER RES, V58, P123; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Seshadri R, 1996, CLIN CANCER RES, V2, P1177; Sgambato A, 1996, CANCER RES, V56, P1389; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SOLOMON DLC, 1995, ONCOGENE, V11, P1893; Steeg PS, 1998, BREAST CANCER RES TR, V52, P17, DOI 10.1023/A:1006102916060; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; Sweeney C, 1996, DEVELOPMENT, V122, P53; VALVERIUS EM, 1990, J CELL PHYSIOL, V145, P207, DOI 10.1002/jcp.1041450204; Wilcken NRC, 1997, CLIN CANCER RES, V3, P849; Yang R, 1997, CANCER RES, V57, P913	70	43	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2000	19	10					1307	1317		10.1038/sj.onc.1203430	http://dx.doi.org/10.1038/sj.onc.1203430			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	291NW	10713672				2022-12-17	WOS:000085743800007
J	Morimoto, AM; Tomlinson, MG; Nakatani, K; Bolen, JB; Roth, RA; Herbst, R				Morimoto, AM; Tomlinson, MG; Nakatani, K; Bolen, JB; Roth, RA; Herbst, R			The MMAC1 tumor suppressor phosphatase inhibits phospholipase C and integrin-linked kinase-activity	ONCOGENE			English	Article						MMAC1; PTEN; TEP1; ILK; PLC	PROTEIN-KINASE; SIGNAL-TRANSDUCTION; GLIOBLASTOMA CELLS; GERMLINE MUTATIONS; PTEN; GENE; GROWTH; GAMMA; DOMAIN; ACTIVATION	Loss of the tumor suppressor MMAC1 has been shown to be involved in breast, prostate and brain cancer, Consistent with its identification as a tumor suppressor, expression of MMAC1 has been demonstrated to reduce cell proliferation, tumorigenicity, and motility as well as affect cell-cell and cell-matrix interactions of malignant human glioma cells. Subsequently, MMAC1 was shown to have lipid phosphatase activity towards PIP, and protein phosphatase activity against focal adhesion kinase (FAK), The lipid phosphatase activity of MMAC1 results in decreased activation of the PIP3- dependent, anti-apoptotic kinase, AKT. It is thought that this inhibition of AKT culminates with reduced glioma cell proliferation, In contrast, MMAC1's effects on cell motility, cell-cell and cell-matrix interactions are thought to be due to its protein phosphatase activity towards FAK, However, recent studies suggest that the lipid phosphatase activity of MMAC1 correlates with its ability to be a tumor suppressor. The high rate of mutation of MMAC1 in late stage metastatic tumors suggests that effects of MMAC1 on motility, cell-cell and cell-matrix interactions are due to its tumor suppressor activity, Therefore the Lipid phosplratase activity of MMAC1 may affect PIP, dependent signaling pathways and result in reduced motility and altered cell-cell and cell-matrix interactions. We demonstrate here that expression of MMAC1 in human glioma cells reduced intracellular levels of inositol trisphosphate and inhibited extracellular Ca2+ influx, suggesting that MMAC1 affects the phospholipase C signaling pathway, In addition, we show that MMAC1 expression inhibits integrin-linked kinase activity. Furthermore, we show that these effects require the catalytic activity of MMAC1. Our data thus provide a link of MMAC1 to PIP, dependent signaling pathways that regulate cell-matrix and cell-cell interactions as well as motility. Lastly, we demonstrate that AKT3, an isoform of AKT highly expressed in the brain, is also a target for MMAC1 repression. These data suggest an important role for AKT3 in glioblastoma multiforme, We therefore propose that repression of multiple PIP, dependent signaling pathways may be required for MMAC1 to act as a tumor suppressor.	DNAX Res Inst Mol & Cellular Biol Inc, Dept Cell Signalling, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA; Hoechst Marion Roussel, Dept Oncol, Bridgewater, NJ 08807 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Stanford University	Herbst, R (corresponding author), DNAX Res Inst Mol & Cellular Biol Inc, Dept Cell Signalling, 901 Calif Ave, Palo Alto, CA 94304 USA.			Tomlinson, Michael/0000-0002-1189-0091				Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Baltuch GH, 1996, BRAIN RES, V710, P143, DOI 10.1016/0006-8993(95)01395-4; Brodbeck D, 1999, J BIOL CHEM, V274, P9133, DOI 10.1074/jbc.274.14.9133; Cheney IW, 1998, CANCER RES, V58, P2331; Corvera S, 1998, TRENDS CELL BIOL, V8, P442, DOI 10.1016/S0962-8924(98)01366-X; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Guldberg P, 1997, CANCER RES, V57, P3660; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Khoshyomn S, 1999, NEUROSURGERY, V44, P568, DOI 10.1097/00006123-199903000-00073; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Li DM, 1997, CANCER RES, V57, P2124; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Morimoto AM, 1999, ONCOGENE, V18, P1261, DOI 10.1038/sj.onc.1202441; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Rameh LE, 1998, J BIOL CHEM, V273, P23750, DOI 10.1074/jbc.273.37.23750; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Ronnstrand L, 1999, J BIOL CHEM, V274, P22089, DOI 10.1074/jbc.274.31.22089; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki M, 1998, J VESTIBUL RES-EQUIL, V8, P169, DOI 10.1016/S0957-4271(97)00003-7; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Turner T, 1997, CLIN CANCER RES, V3, P2275; VASSBOTN FS, 1994, J CELL PHYSIOL, V158, P381, DOI 10.1002/jcp.1041580221; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147	38	43	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2000	19	2					200	209		10.1038/sj.onc.1203288	http://dx.doi.org/10.1038/sj.onc.1203288			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10644997				2022-12-17	WOS:000084844400004
J	Shi, YJ; Pin, OY; Sugrue, SP				Shi, YJ; Pin, OY; Sugrue, SP			Characterization of the gene encoding pinin/DRS/memA and evidence for its potential tumor suppressor function	ONCOGENE			English	Article						pinin; tumor suppressor; 14q13; desmosome; DNA methylation; TCC	E-CADHERIN; CELL-LINES; DNA METHYLATION; PROSTATE-CANCER; ADHESION SYSTEM; ALPHA-CATENIN; BREAST-CANCER; LUNG CANCERS; EXPRESSION; CARCINOMA	Several cell adhesion-related proteins have been shown to act as tumor-suppressors (TS) in the neoplastic progression of epithelial-derived tumors. Pinin/DRS/memA was first identified in our laboratory and it was shown to be a cell adhesion-related molecule. Our previous study demonstrated that restoration of pinin expression in transformed cells not only positively influenced cellular adhesive properties but also reversed the transformed phenotype to more epithelial-like. Here, we show by FISH analysis that the gene locus for pinin is within 14q13. The alignment of the pinin gene with STS markers localized the gene to the previously identified TS Locus D14S75-D14S288. Northern analyses revealed diminished pinin mRNA in renal cell carcinomas (RCC) and certain cancer cell lines. Immunohistochemical examination of tumor samples demonstrated absent or greatly reduced pinin in transitional cell carcinoma (TCC) and RCC tumors, TCC-derived J82 cells as well as EcR-293 cells transfected with full-length pinin cDNA demonstrated inhibition of anchorage-independent growth of cells in soft agar. Furthermore, methylation analyses revealed that aberrant methylation of pinin CpG islands was correlated with decreased/absent pinin expression in a subset of tumor tissues. These data lend significant support to the hypothesis that pinin/DRS/memA may act as a tumor suppressor in certain types of cancers.	Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; Chang Gung Univ, Coll Med, Tau Yuan, Taiwan	State University System of Florida; University of Florida; Chang Gung University	Sugrue, SP (corresponding author), Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA.				NEI NIH HHS [EY07883] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007883] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Bandera CA, 1997, CANCER RES, V57, P513; Baylin SB, 1998, ADV CANCER RES, V72, P141; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Benedict WF, 1999, ONCOGENE, V18, P1197, DOI 10.1038/sj.onc.1202452; BenZeev A, 1997, CURR OPIN CELL BIOL, V9, P99, DOI 10.1016/S0955-0674(97)80158-5; Beroud C, 1996, GENE CHROMOSOME CANC, V17, P215, DOI 10.1002/(SICI)1098-2264(199612)17:4<215::AID-GCC3>3.0.CO;2-6; Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D; Birchmeier W, 1996, CURR TOP MICROBIOL, V213, P117; BIRCHMEIER W, 1995, BIOESSAYS, V17, P97, DOI 10.1002/bies.950170203; Brandner JM, 1997, DIFFERENTIATION, V62, P119, DOI 10.1046/j.1432-0436.1997.6230119.x; Bullions LC, 1997, MOL CELL BIOL, V17, P4501, DOI 10.1128/MCB.17.8.4501; CAVENEE WK, 1993, J CLIN INVEST, V91, P3, DOI 10.1172/JCI116185; CHANG WYH, 1995, CANCER RES, V55, P3246; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Clurman B, 1997, NATURE, V389, P122, DOI 10.1038/38116; CONN IG, 1990, BRIT J UROL, V65, P176, DOI 10.1111/j.1464-410X.1990.tb14694.x; Davies G, 1998, ONCOL REP, V5, P1567; Degen WGJ, 1999, BBA-GENE STRUCT EXPR, V1444, P384, DOI 10.1016/S0167-4781(99)00012-3; Doki Y, 1997, CARCINOGENESIS, V18, P1139, DOI 10.1093/carcin/18.6.1139; Emig R, 1998, BRIT J CANCER, V78, P1661, DOI 10.1038/bjc.1998.739; EWING CM, 1995, CANCER RES, V55, P4813; Fearon ER, 1997, SCIENCE, V278, P1043, DOI 10.1126/science.278.5340.1043; Garrod D, 1996, CURR OPIN CELL BIOL, V8, P670, DOI 10.1016/S0955-0674(96)80108-6; GARROD DR, 1995, CANCER SURV, V24, P97; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Hoover KB, 1998, AM J PATHOL, V153, P1767, DOI 10.1016/S0002-9440(10)65691-X; HSIEH JT, 1995, CANCER RES, V55, P190; Kane MF, 1997, CANCER RES, V57, P808; Kashiwabara K, 1998, INT J CANCER, V79, P215, DOI 10.1002/(SICI)1097-0215(19980619)79:3<215::AID-IJC1>3.0.CO;2-S; Kaur J, 1998, INT J CANCER, V79, P370, DOI 10.1002/(SICI)1097-0215(19980821)79:4&lt;370::AID-IJC11&gt;3.0.CO;2-9; KIRKPATRICK C, 1995, CURR OPIN GENET DEV, V5, P56, DOI 10.1016/S0959-437X(95)90054-3; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LICHTER P, 1992, HUMAN CYTOGENETICS P; MARSHALL CJ, 1977, J NATL CANCER I, V58, P1743, DOI 10.1093/jnci/58.6.1743; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; Mutirangura A, 1998, INT J CANCER, V78, P153, DOI 10.1002/(SICI)1097-0215(19981005)78:2<153::AID-IJC5>3.0.CO;2-Y; OUYANG P, 1992, J CELL BIOL, V118, P1477, DOI 10.1083/jcb.118.6.1477; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Pin OY, 1999, BIOCHEM BIOPH RES CO, V263, P192, DOI 10.1006/bbrc.1999.1353; Pin OY, 1996, J CELL BIOL, V135, P1027, DOI 10.1083/jcb.135.4.1027; SHAPIRO GI, 1995, CANCER RES, V55, P505; Shiozaki H, 1996, CANCER, V77, P1605, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1605::AID-CNCR4>3.3.CO;2-R; Simcha I, 1996, J CELL BIOL, V133, P199, DOI 10.1083/jcb.133.1.199; Taverna D, 1998, CANCER RES, V58, P848; Tlsty TD, 1998, CURR OPIN CELL BIOL, V10, P647, DOI 10.1016/S0955-0674(98)80041-0; Tselepis C, 1998, P NATL ACAD SCI USA, V95, P8064, DOI 10.1073/pnas.95.14.8064; WARNEFORD S, 1991, CELL GROWTH DIFFER, V2, P439; Weaver DA, 1997, CARCINOGENESIS, V18, P1251, DOI 10.1093/carcin/18.6.1251; Wong MKK, 1997, MOL BIOL CELL, V8, P1441; Yokomizo A, 1999, ONCOGENE, V18, P1629, DOI 10.1038/sj.onc.1202474	54	43	48	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2000	19	2					289	297		10.1038/sj.onc.1203328	http://dx.doi.org/10.1038/sj.onc.1203328			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10645008				2022-12-17	WOS:000084844400015
J	Kim, E; Rohaly, G; Heinrichs, S; Gimnopoulos, D; Meissner, H; Deppert, W				Kim, E; Rohaly, G; Heinrichs, S; Gimnopoulos, D; Meissner, H; Deppert, W			Influence of promoter DNA topology on sequence-specific DNA binding and transactivation by tumor suppressor p53	ONCOGENE			English	Article						p53; mdm2; DNA conformation; non-B-DNA; sequence-specific DNA binding; transcriptional activation	MDM2 GENE; CELL-GROWTH; EXPRESSION; ACTIVATION; PROTEIN; P21; IDENTIFICATION; MODULATION; RADIATION; TERMINUS	Transcriptional activation by the tumor suppressor p53 is regulated at multiple levels, including posttranslational modifications of the p53 protein, interaction of p53 with various regulatory proteins, or at the level of sequence-specific DNA binding to the response elements in p53's target genes. We here propose as an additional regulatory mechanism that the DNA topology of p53-responsive promoters may determine the interaction of p53 with its target genes. We demonstrate that sequence-specific DNA binding (SSDB) and transcriptional activation by p53 of the mdm2 promoter is inhibited when this promoter is present in supercoiled DNA, where it forms a non-B-DNA structure which spans the p53-responsive elements. Relaxation of the supercoiled DNA in vitro resulted in conversion of the non-B-DNA to a B-DNA conformation within the mdm2 promoter, and correlated with an enhanced SSDB of p53 and an elevated expression of a reporter gene. In contrast, sequence specific UNA binding and transcriptional activation of the p21 promoter were not inhibited by DNA supercoiling, We propose that conformational alterations within p53-responsive sites, which either promote or prohibit sequence specific DNA binding of p53, are an important feature in orchestrating the activation of different p53 responsive promoters.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany; Univ Hamburg, Klinikum Eppendorf, Abt Neurochirurg, D-20251 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg; University of Hamburg	Deppert, W (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.							ANKER L, 1993, INT J CANCER, V55, P982, DOI 10.1002/ijc.2910550618; Arriola EL, 1999, ONCOGENE, V18, P1081, DOI 10.1038/sj.onc.1202391; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Chin PL, 1997, ONCOGENE, V15, P87, DOI 10.1038/sj.onc.1201161; Di Como CJ, 1998, ONCOGENE, V16, P2527; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Garcia JF, 1997, HISTOPATHOLOGY, V30, P120, DOI 10.1046/j.1365-2559.1997.d01-577.x; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; GELLERT M, 1983, P NATL ACAD SCI-BIOL, V80, P5545, DOI 10.1073/pnas.80.18.5545; Gobert C, 1996, BIOCHEMISTRY-US, V35, P5778, DOI 10.1021/bi952327w; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kim E, 1997, ONCOGENE, V15, P857, DOI 10.1038/sj.onc.1201412; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Luna RMD, 1997, NAT GENET, V16, P336; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Saucedo LJ, 1998, CELL GROWTH DIFFER, V9, P119; Shaw P, 1996, ONCOGENE, V12, P921; SINDEN RR, 1983, P NATL ACAD SCI-BIOL, V80, P1797, DOI 10.1073/pnas.80.7.1797; Wang XJ, 1997, J RADIAT RES, V38, P179, DOI 10.1269/jrr.38.179; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xiao G, 1998, ONCOGENE, V16, P1171, DOI 10.1038/sj.onc.1201631; YAGIL G, 1991, CRIT REV BIOCHEM MOL, V26, P475, DOI 10.3109/10409239109086791; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584	31	43	43	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7310	7318		10.1038/sj.onc.1203139	http://dx.doi.org/10.1038/sj.onc.1203139			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602486				2022-12-17	WOS:000084119400016
J	El-Naggar, AK; Lai, SL; Tucker, SA; Clayman, GL; Goepfert, H; Hong, WK; Huff, V				El-Naggar, AK; Lai, SL; Tucker, SA; Clayman, GL; Goepfert, H; Hong, WK; Huff, V			Frequent loss of imprinting at the IGF2 and H19 genes in head and neck squamous carcinoma	ONCOGENE			English	Article						imprinting; loss of imprinting; head and neck squamous carcinoma; epigenetic alterations; insulin growth factor-2 and H19 genes	GROWTH-FACTOR-II; BECKWITH-WIEDEMANN SYNDROME; WILMS-TUMOR; CELL-CARCINOMA; REDUCED EXPRESSION; INVASIVE HEAD; HUMAN TISSUES; CANCER; INACTIVATION; METHYLATION	Genomic imprinting is an inherited epigenetic phenomenon that results in parental-origin-specific gene expression in somatic cells. Relaxation or loss of this feature in certain genes has been demonstrated in several pediatric and adult neoplasms, suggesting an association with tumorigenesis. We analysed 64 primary untreated head and neck squamous carcinoma for the loss of imprinting in the IGF2 and H19 genes to determine the implications of this alteration in the development and progression of these tumors. Forty-nine (77%) of the 64 tumors were informative for imprinting analyses of these genes. IGF2 and H19 were imprinted in all normal squamous epithelium examined. Twelve (37.5%) of 32 tumors informative for H19 and 11 (40.7%) of 27 tumors informative for IGF2 manifested loss of imprinting. Ten tumors were informative for both genes, of which four maintained the constitutional imprinting and six showed loss of imprinting at either H19 or IGF2. These data suggest that loss of imprinting at the IGF2 and H19 loci play a role in the oncogenesis of head and neck carcinoma.	Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biomath, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Pediat, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	El-Naggar, AK (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Box 85,1515 Holcombe Blvd, Houston, TX 77030 USA.				NIDCR NIH HHS [1P50DE11906-01] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE011906] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AHSEE KW, 1994, CANCER RES, V54, P1617; *AM CANC SOC INC, 1997, CANC FACTS FIG; Barlow DP, 1997, EMBO J, V16, P6899, DOI 10.1093/emboj/16.23.6899; BARTOLOMEI MS, 1994, NAT GENET, V6, P220, DOI 10.1038/ng0394-220; Baylin SB, 1997, SCIENCE, V277, P1948, DOI 10.1126/science.277.5334.1948; CATTANACH BM, 1990, DEVELOPMENT, P63; CHAO LY, 1993, NAT GENET, V3, P127, DOI 10.1038/ng0293-127; CHRISTOFORI G, 1995, NAT GENET, V10, P196, DOI 10.1038/ng0695-196; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; Chung WY, 1996, HUM MOL GENET, V5, P1101, DOI 10.1093/hmg/5.8.1101; CROUSE H, 1996, GENETICS, V45, P1425; Cui HM, 1998, NAT MED, V4, P1276, DOI 10.1038/3260; Cui HM, 1997, CANCER RES, V57, P4469; Dao D, 1999, HUM MOL GENET, V8, P1337, DOI 10.1093/hmg/8.7.1337; DAO DD, 1987, AM J HUM GENET, V41, P202; DAVIES SM, 1993, CANCER RES, V53, P4781; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; ElNaggar AK, 1996, CLIN CANCER RES, V2, P903; ELNAGGAR AK, 1995, CANCER RES, V55, P2656; ELNAGGAR AK, 1995, INT J CANCER, V64, P196, DOI 10.1002/ijc.2910640309; ElNaggar AK, 1997, AM J PATHOL, V151, P1767; EZZELL C, 1994, J NIH RES, V6, P53; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; Fukuzawa R, 1999, INT J CANCER, V82, P490, DOI 10.1002/(SICI)1097-0215(19990812)82:4<490::AID-IJC4>3.0.CO;2-I; Greally JM, 1998, HUM MOL GENET, V7, P91, DOI 10.1093/hmg/7.1.91; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; HERMAN JG, 1995, CANCER RES, V55, P4525; Hibi K, 1996, CANCER RES, V56, P480; JINNO Y, 1994, NAT GENET, V6, P305, DOI 10.1038/ng0394-305; Kim HT, 1998, AM J MED GENET, V80, P391, DOI 10.1002/(SICI)1096-8628(19981204)80:4<391::AID-AJMG16>3.0.CO;2-H; KONDO M, 1995, ONCOGENE, V10, P1193; Lee MP, 1999, HUM MOL GENET, V8, P683, DOI 10.1093/hmg/8.4.683; Li XR, 1997, CANCER RES, V57, P2048; Mannens M., 1994, European Journal of Human Genetics, V2, P3; McCann AH, 1996, HUM MOL GENET, V5, P1123, DOI 10.1093/hmg/5.8.1123; Mitsuya K, 1997, HUM MOL GENET, V6, P2243, DOI 10.1093/hmg/6.13.2243; MONTAGNA M, 1994, J CANCER RES CLIN, V120, P732, DOI 10.1007/BF01194272; MORRISON IM, 1996, NAT MED, V2, P331; NEUMANN B, 1995, NAT GENET, V9, P12, DOI 10.1038/ng0195-12; Nonomura N, 1997, CANCER RES, V57, P2575; Oda H, 1998, INT J CANCER, V75, P343, DOI 10.1002/(SICI)1097-0215(19980130)75:3<343::AID-IJC3>3.0.CO;2-2; Ouyang H, 1997, CANCER RES, V57, P1851; Papadimitrakopoulou VA, 1998, CLIN CANCER RES, V4, P539; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; Pershouse MA, 1997, ONCOGENE, V14, P369, DOI 10.1038/sj.onc.1200836; PETERSON K, 1993, ANNU REV GENET, V27, P7, DOI 10.1146/annurev.ge.27.120193.000255; Rachmilewitz J, 1996, ONCOGENE, V13, P1687; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; Randhawa GS, 1998, BLOOD, V91, P3144, DOI 10.1182/blood.V91.9.3144.3144_3144_3147; Reed AL, 1996, CANCER RES, V56, P3630; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; REIK W, 1994, HUM MOL GENET, V3, P1297, DOI 10.1093/hmg/3.8.1297; REIK W, 1995, HUM MOL GENET, V4, P2379, DOI 10.1093/hmg/4.12.2379; Ross JA, 1999, CANCER, V85, P1389, DOI 10.1002/(SICI)1097-0142(19990315)85:6<1389::AID-CNCR24>3.3.CO;2-M; Sabbioni S, 1997, CANCER RES, V57, P4493; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; SWAIN JL, 1987, CELL, V50, P719, DOI 10.1016/0092-8674(87)90330-8; TEMPLE IK, 1995, NAT GENET, V9, P109; Thompson JS, 1996, CANCER RES, V56, P5723; Uyeno S, 1996, CANCER RES, V56, P5356; van Roozendaal CEP, 1998, FEBS LETT, V437, P107, DOI 10.1016/S0014-5793(98)01211-3; Verkerk AJMH, 1997, ONCOGENE, V14, P95, DOI 10.1038/sj.onc.1200802; Vrana PB, 1998, NAT GENET, V20, P362, DOI 10.1038/3833; WADA M, 1995, CANCER RES, V55, P3386; Wu MS, 1997, CANCER LETT, V120, P9, DOI 10.1016/S0304-3835(97)00279-6; Zhan SL, 1995, ONCOGENE, V11, P2503	67	43	43	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7063	7069		10.1038/sj.onc.1203192	http://dx.doi.org/10.1038/sj.onc.1203192			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597307				2022-12-17	WOS:000083901900013
J	Ma, L; Gauville, C; Berthois, Y; Millot, G; Johnson, GR; Calvo, F				Ma, L; Gauville, C; Berthois, Y; Millot, G; Johnson, GR; Calvo, F			Antisense expression for amphiregulin suppresses tumorigenicity of a transformed human breast epithelial cell line	ONCOGENE			English	Article						epidermal growth factor receptor; amphiregulin; antisense RNA expression constructs; transformed phenotype	EPIDERMAL-GROWTH-FACTOR; MOUSE MAMMARY-GLAND; FACTOR RECEPTOR; FACTOR-ALPHA; CANCER CELLS; HUMAN COLON; CARCINOMA; EGF; INDUCTION; SURFACE	The epidermal growth factor (EGF) family of receptors and their respective ligands play a major role in breast cancer progression and are the targets of new therapeutic approaches. Following immortalization with SV40 T antigen of normal human breast epithelial cells, a transformed variant cell line (NS2T2A1) was selected for its increased tumorigenicity in nude mice. This cell line was shown to have a higher expression of EGF receptors (EGFR) and amphiregulin (AR) when compared to their normal counterparts or less aggressive transformed cells. Dual staining of EGFR and AR was observed in 50-60% of NS2T2A1 cells, while 30-40% cells expressed AR only, To explore the potential tumorigenic role of AR, a 1.1 kb AR cDNA in an antisense orientation was transfected in NS2T2A1 cells. Three clones, selected by hygromycin B, expressed AR antisense RNA (AR AS1, AR AS2 and AR AS3 cell lines) in which AR protein expression was reduced (ranging from about 50 to <5%), The anchorage-independent growth of AR AS cell lines was reduced to levels ranging from 32.4-6.8% relative to the control cell line transfected with the vector alone. The clones expressing AR antisense RNA showed a reversion of the malignant phenotype when injected in nude mice, since a significant reduction of tumor intake was observed coincident with a significant tumor mass reduction (>96%), Moreover, intra-tumoral vascularization decreased significantly in tumors derived from AR AS cells (26.7, 70.7 and 50.4% of control). These in vitro and in vivo data reveal the oncogenic nature of AR in transformed breast epithelial cells and imply a role for AR in tumor angiogenesis.	Inst Genet Mol, Lab Pharmacol Expt & Clin, INSERM, EP 9932, F-75010 Paris, France; Fac Med Nord, F-13916 Marseille, France; US FDA, Ctr Biol Evaluat & Res, Div Cytokine Biol, Bethesda, MD 20892 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; US Food & Drug Administration (FDA)	Ma, L (corresponding author), Inst Genet Mol, Lab Pharmacol Expt & Clin, INSERM, EP 9932, 27 Rue Juliette Dodu, F-75010 Paris, France.		Berthois, Yolande/O-1168-2017	calvo, fabien/0000-0002-0298-7633; BERTHOIS, Yolande/0000-0001-9603-1626				BARNARD JA, 1994, J BIOL CHEM, V269, P22817; Bennett KL, 1992, GROWTH FACTORS, V7, DOI 10.3109/08977199209046925; BERTHON P, 1992, INT J CANCER, V52, P92, DOI 10.1002/ijc.2910520117; Brown CL, 1998, J BIOL CHEM, V273, P17258, DOI 10.1074/jbc.273.27.17258; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141; DVIS LG, 1986, BASIC METHODS MOL BI, P130; ETHIER SP, 1995, J NATL CANCER I, V87, P964, DOI 10.1093/jnci/87.13.964; Funatomi H, 1997, INT J CANCER, V72, P512, DOI 10.1002/(SICI)1097-0215(19970729)72:3<512::AID-IJC21>3.0.CO;2-C; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; Herrington EE, 1997, J CELL PHYSIOL, V170, P47; IGLESIAS M, 1995, AM J PATHOL, V146, P944; JOHNSON GR, 1992, J CELL BIOL, V118, P741, DOI 10.1083/jcb.118.3.741; JOHNSON GR, 1991, BIOCHEM BIOPH RES CO, V180, P481, DOI 10.1016/S0006-291X(05)81090-3; JOHNSON GR, 1993, J BIOL CHEM, V268, P18835; JOHNSON GR, 1994, J BIOL CHEM, V269, P27149; JOHNSON GR, 1993, J BIOL CHEM, V268, P2924; Kenney Nicholas, 1993, Molecular and Cellular Differentiation, V1, P163; Kenney NJ, 1996, MOL CARCINOGEN, V15, P44; KENNEY NJ, 1995, MOL REPROD DEV, V41, P277, DOI 10.1002/mrd.1080410302; Kenney NJ, 1996, CELL GROWTH DIFFER, V7, P1769; KLIJN JGM, 1992, ENDOCR REV, V13, P3, DOI 10.1210/er.13.1.3; Kondapaka SB, 1997, INT J CANCER, V70, P722, DOI 10.1002/(SICI)1097-0215(19970317)70:6<722::AID-IJC15>3.3.CO;2-5; LEBEAU J, 1995, INT J CANCER, V60, P244, DOI 10.1002/ijc.2910600219; LEJEUNE S, 1993, CANCER RES, V53, P3597; LI SW, 1992, J CELL PHYSIOL, V153, P103, DOI 10.1002/jcp.1041530114; Ma L, 1998, INT J CANCER, V78, P112, DOI 10.1002/(SICI)1097-0215(19980925)78:1<112::AID-IJC18>3.0.CO;2-D; Ma L, 1996, FUND CLIN PHARMACOL, V10, P97, DOI 10.1111/j.1472-8206.1996.tb00153.x; MARTINEZLACACI I, 1995, ENDOCRINOLOGY, V136, P3983, DOI 10.1210/en.136.9.3983; MartinezLacaci I, 1996, J CELL PHYSIOL, V169, P497, DOI 10.1002/(SICI)1097-4652(199612)169:3<497::AID-JCP10>3.0.CO;2-3; MODJTAHEDI H, 1994, INT J ONCOL, V4, P277; NORMANNO N, 1994, P NATL ACAD SCI USA, V91, P2790, DOI 10.1073/pnas.91.7.2790; NORMANNO N, 1995, INT J CANCER, V62, P762, DOI 10.1002/ijc.2910620619; Panico L, 1996, INT J CANCER, V65, P51, DOI 10.1002/(SICI)1097-0215(19960103)65:1<51::AID-IJC9>3.3.CO;2-N; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; QI CF, 1994, BRIT J CANCER, V69, P903, DOI 10.1038/bjc.1994.174; SCHREIBER AB, 1986, SCIENCE, V232, P1250, DOI 10.1126/science.2422759; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; Silvy M, 1998, ENDOCRINOLOGY, V139, P2382, DOI 10.1210/en.139.5.2382; Solic N, 1997, EXP CELL RES, V234, P465, DOI 10.1006/excr.1997.3635; Thompson SA, 1996, J BIOL CHEM, V271, P17927, DOI 10.1074/jbc.271.30.17927; VARDY DA, 1995, J CELL PHYSIOL, V163, P257, DOI 10.1002/jcp.1041630206; WOODWORTH CD, 1995, P NATL ACAD SCI USA, V92, P2840, DOI 10.1073/pnas.92.7.2840	45	43	48	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6513	6520		10.1038/sj.onc.1203042	http://dx.doi.org/10.1038/sj.onc.1203042			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597254				2022-12-17	WOS:000083709200014
J	Wouters, BG; Denko, NC; Giaccia, AJ; Brown, JM				Wouters, BG; Denko, NC; Giaccia, AJ; Brown, JM			A p53 and apoptotic independent role for p21(waf1) in tumour response to radiation therapy	ONCOGENE			English	Article						apoptosis; cancer-therapy; radiosensitivity; cyclin-dependent; kinase inhibitor; xenografts	CYCLIN-DEPENDENT KINASE; CLONOGENIC SURVIVAL; CANCER-THERAPY; CELL-DEATH; IONIZING-RADIATION; SOLID TUMORS; BCL-2; P21; DELAYS; RESISTANCE	Loss of p21 in human cancer cells results in checkpoint failure, induction of polyploidy and subsequent apoptosis following DNA damage. Tumours in immunodeficient mice derived from cells lacking p21 are also more sensitive to ionizing radiation than their wild-type counterparts. Abrogation of p53 in the p21(+/+) parental cells results in an in vitro phenotype that is indistinguishable from that of the p21 knockout cells. Thus, the in vitro phenotype resulting from loss of p21 is consistent with its well-established role in the p53/p21 damage response pathway. However, despite the similar in vitro phenotype, p21(+/+) cells with abrogated p53 show no evidence of the sensitivity observed in the p21(-/-) cells when grown as tumours in immunodeficient mice. The increased radio-sensitization stabilization of p21(-/-) tumours is also unrelated to the increase in apoptosis observed in these tumours following radiation treatment. Apoptosis in the p21(-/-) tumours was significantly reduced by expression of bcl-2 without any corresponding change in the overall response of the tumour. Similarly, abrogation of p53 in the p21(+/+) tumours substantially increased radiation-induced apoptosis within the tumours without increasing their radiation sensitivity. Dissociation of these in vivo and in vitro phenotypes indicates that p21 participates in a novel in vivo specific damage response pathway that is distinct from its role in the p53 pathway, and therefore that it may be an effective therapeutic target for cancer therapy.	Stanford Univ, Sch Med, Dept Radiat Oncol, Stanford, CA 94305 USA	Stanford University	Wouters, BG (corresponding author), Ottawa Reg Canc Ctr, Canc Res Grp, 3rd Floor,501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.		Wouters, Bradly/T-1525-2017; denko, nicholas/F-8444-2010	Wouters, Bradly/0000-0002-8187-592X; 	NATIONAL CANCER INSTITUTE [R01CA064489, R01CA015201] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA15201, CA 64489, CA 09302] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BHATIA K, 1995, CANCER RES, V55, P1431; BIGGS JR, 1995, J MOL MED-JMM, V73, P509; Brizel DM, 1996, CANCER RES, V56, P941; Brown JM, 1996, NAT MED, V2, P1055, DOI 10.1038/nm1096-1055b; Brown JM, 1998, CANCER RES, V58, P1408; Fan SJ, 1997, ONCOGENE, V14, P2127, DOI 10.1038/sj.onc.1201052; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; GJERSET RA, 1997, ENCY CANC, P1785; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; HALBERT CL, 1992, J VIROL, V66, P2125, DOI 10.1128/JVI.66.4.2125-2134.1992; Han JW, 1997, CANCER RES, V57, P176; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hockel M, 1996, CANCER RES, V56, P4509; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Huang H, 1996, INT J RADIAT BIOL, V70, P151, DOI 10.1080/095530096145148; Kyprianou N, 1997, INT J CANCER, V70, P341, DOI 10.1002/(SICI)1097-0215(19970127)70:3<341::AID-IJC16>3.0.CO;2-I; Lock RB, 1996, CANCER RES, V56, P4006; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; Wouters BG, 1997, CANCER RES, V57, P4703; YIN DX, 1995, CANCER RES, V55, P4922	26	43	45	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6540	6545		10.1038/sj.onc.1203053	http://dx.doi.org/10.1038/sj.onc.1203053			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597257				2022-12-17	WOS:000083709200017
J	Wang, XZ; Jolicoeur, EM; Conte, N; Chaffanet, M; Zhang, YH; Mozziconacci, MJ; Feiner, H; Birnbaum, D; Pebusque, MJ; Ron, D				Wang, XZ; Jolicoeur, EM; Conte, N; Chaffanet, M; Zhang, YH; Mozziconacci, MJ; Feiner, H; Birnbaum, D; Pebusque, MJ; Ron, D			gamma-heregulin is the product of a chromosomal translocation fusing the DOC4 and HGL/NRG1 genes in the MDA-MB-175 breast cancer cell line	ONCOGENE			English	Article						signal transduction; EGF receptor; tyrosine kinase; tenascin; CHOP	PAIR-RULE GENE; WERNER-SYNDROME; GROWTH-FACTOR; REGION	gamma-heregulin is a recently described novel isoform of the heregulin/neuregulin class of EGF-like ligands that bind to and activate receptors of the ErbB family, Deregulated signaling through the heregulin-ErbB pathway is thought to be implicated in the development of a subset of human breast cancers. gamma-heregulin has been found to be expressed in the culture supernatant of MDA-MB-175, a breast carcinoma cell line. gamma-heregulin is characterized by the presence of a large N-terminal peptide extension that is not found in other heregulin isoforms, Here we report that this unique N-terminal extension of gamma-heregulin is identical to the N-terminus of DOC4, a product of a recent ly identified CHOP-dependent stress-induced gene, Human DOC4 and the heregulin-encoding genes map to different chromosomes and the MDA-MB-175 cell line contains a chromosomal translocation that leads to the fusion of DOC4 and HGL, on chromosomes 11 and 8, respectively. Thus, gamma-heregulin is a product of a mutant fusion gene and not a bona fide normal isoform, We speculate that the mutation may be selected for by virtue of its ability to activate ErbB signaling through the production of an autocrine ligand.	NYU, Med Ctr, Kaplan Canc Ctr, Dept Med,Skirball Inst Biomol Med, New York, NY 10016 USA; NYU, Med Ctr, Skirball Inst Biomol Med, Dept Cell Biol,Kaplan Canc Ctr, New York, NY 10016 USA; NYU, Med Ctr, Kaplan Canc Ctr, Dept Pathol,Skirball Inst Biomol Med, New York, NY 10016 USA; Inst J Paoli I Calmettes, Lab Cylogenet, F-13009 Marseille, France; Inst Cancerol & Immunol Marseille, Marseille, France	New York University; New York University; New York University; UNICANCER; Institut Paoli-Calmette (IPC)	Ron, D (corresponding author), NYU, Med Ctr, Kaplan Canc Ctr, Dept Med,Skirball Inst Biomol Med, 550 1St Ave, New York, NY 10016 USA.		CHAFFANET, Max/AAU-5743-2020	CHAFFANET, Max/0000-0002-2344-1488; Ron, David/0000-0002-3014-5636; Conte, Nathalie/0000-0002-1010-3121	NATIONAL CANCER INSTITUTE [R01CA060945] Funding Source: NIH RePORTER; NCI NIH HHS [CA60945] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUMGARTNER S, 1994, EMBO J, V13, P3728, DOI 10.1002/j.1460-2075.1994.tb06682.x; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; Chaffanet M, 1996, CYTOGENET CELL GENET, V72, P63, DOI 10.1159/000134164; Imbert A, 1996, GENOMICS, V32, P29, DOI 10.1006/geno.1996.0073; LEE J, 1993, GENOMICS, V16, P790, DOI 10.1006/geno.1993.1272; LEVINE A, 1994, CELL, V77, P587, DOI 10.1016/0092-8674(94)90220-8; Lupu R, 1996, BREAST CANCER RES TR, V38, P57, DOI 10.1007/BF01803784; NORMANNO N, 1994, BREAST CANCER RES TR, V29, P11, DOI 10.1007/BF00666178; Schaefer G, 1997, ONCOGENE, V15, P1385, DOI 10.1038/sj.onc.1201317; Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619	11	43	44	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 7	1999	18	41					5718	5721		10.1038/sj.onc.1202950	http://dx.doi.org/10.1038/sj.onc.1202950			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	243UW	10523851				2022-12-17	WOS:000083016500013
J	Hu, MCT; Wang, YP; Qiu, WR; Mikhail, A; Meyer, CF; Tan, TH				Hu, MCT; Wang, YP; Qiu, WR; Mikhail, A; Meyer, CF; Tan, TH			Hematopoietic progenitor kinase-1 (HPK1) stress response signaling pathway activates I kappa B kinases (IKK-alpha/beta) and IKK-beta is a developmentally regulated protein kinase	ONCOGENE			English	Article						NF-kappa B; I kappa B; HPK1; MEKK1; protein kinase; signal transduction	INDUCED APOPTOSIS; INSITU HYBRIDIZATION; CELL-DEATH; COMPLEX; PHOSPHORYLATION; INHIBITION; CONTAINS; CASCADES; GENES; MEKK1	Nuclear factor kappa-B (NF-kappa B) is a pleiotropic transcription factor that plays a central role in the immune and inflammatory responses, and is also involved in controlling viral transcription and apoptosis, A critical control in the activation of NF-kappa B is the phosphorylation of its inhibitory factor I kappa Bs by I kappa B kinases (IKK-alpha and -beta). Here, we present experiments addressing the regulation and global expression of murine IKK-beta, and localize the IKK-beta gene to mouse chromosome 8A3-A4. IKK-beta was expressed primarily in the liver, kidney and spleen, and at lower levels in the other adult tissues. While IKK-beta was expressed ubiquitously throughout the mouse embryo at 9.5 days, its expression began to be localized to the brain, mural ganglia, neural tube, and liver in the 12.5-day's embryo, At 15.5 days, the expression of IKK-beta was further restricted to specific tissues of the embryo, suggesting that IKK-beta is a developmentally regulated protein kinase, Interestingly, IKK-beta phosphorylated I kappa B constitutively, whereas IKK-alpha was not active in the absence of cell stimulation, Moreover, both IKK-alpha and -beta were activated by hematopoietic progenitor kinase-1 (HPK1) and MAPK/ERK kinase kinase-1 (MEKK1) specifically, suggesting that I kappa B/NF-kappa B is regulated through the HPK1-MEKK1 stress response signaling pathway.	Amgen Inc, Dept Cell Biol, Thousand Oaks, CA 91320 USA; Phylogeny Inc, Columbus, OH 43212 USA; Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA	Amgen; Baylor College of Medicine	Hu, MCT (corresponding author), Amgen Inc, Dept Cell Biol, Thousand Oaks, CA 91320 USA.		Tan, Tse-Hua/ABD-7080-2021; Tan, Tse-Hua/E-3983-2010	Tan, Tse-Hua/0000-0003-4969-3170; Tan, Tse-Hua/0000-0003-4969-3170				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; Connelly MA, 1995, CELL MOL BIOL RES, V41, P537; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; Hu MCT, 1997, ONCOGENE, V15, P2277, DOI 10.1038/sj.onc.1201401; Hu MCT, 1998, GENE, V222, P31, DOI 10.1016/S0378-1119(98)00462-4; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Shao RP, 1997, J BIOL CHEM, V272, P32739, DOI 10.1074/jbc.272.52.32739; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; YAN MH, 1994, NATURE, V372, P798; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	39	43	49	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	1999	18	40					5514	5524		10.1038/sj.onc.1202740	http://dx.doi.org/10.1038/sj.onc.1202740			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	241QU	10523828				2022-12-17	WOS:000082894700004
J	Dorman, CM; Johnson, SE				Dorman, CM; Johnson, SE			Activated Raf inhibits avian myogenesis through a MAPK-dependent mechanism	ONCOGENE			English	Article						Raf; MAPK; myogenesis	PROTEIN-KINASE-C; MUSCLE DIFFERENTIATION; GROWTH-FACTORS; MAMMALIAN-CELL; EXPRESSION; PATHWAY; PHOSPHORYLATION; TRANSFORMATION; APOPTOSIS; ONCOGENE	Chronic overexpression of the oncogenic form of Ras is a potent inhibitor of skeletal myogenesis. However, the intracellular signaling pathways that mediate the repressive actions of Ras on myogenic differentiation have yet to be identified. We examined the role of Raf-mediated signaling as a modulator of avian myogenesis. Raf overexpression elicited pronounced effects on both myoblasts and mature myocytes. Most notably, the embryonic chick myoblasts overexpressing a constitutively active form of Raf (RCAS-Raf CAAX or RCAS-Raf BXB) fail to form the large multinucleated myofibers characteristic of myogenic cultures. While residual myofibers were apparent in the RCAS-Raf BXB and RCAS-Raf CAAX infected cultures, these fibers had an atrophic phenotype, The altered morphology is not a result of reinitiation of the myonuclei cell cycle nor is it due to apoptosis, Furthermore, the mononucleated myoblasts misexpressing Raf BXB are differentiation-defective due to overt MAPK activity. Supplementation of the culture media with the MAPK kinase (MEK) inhibitor, PD98059, caused a reversal of the phenotype and allowed the formation of multinucleated myofibers at levels comparable to controls. Our results indicate that the Raf/MEK/MAPK axis is intact in chick myoblasts and that persistent activation of this signaling cascade is inhibitory to myogenesis.	Penn State Univ, Dept Poultry Sci, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Johnson, SE (corresponding author), Penn State Univ, Dept Poultry Sci, University Pk, PA 16802 USA.							ALEMA S, 1994, SEMIN CANCER BIOL, V5, P147; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; De Angelis L, 1998, P NATL ACAD SCI USA, V95, P12358, DOI 10.1073/pnas.95.21.12358; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; FUKUDA M, 1995, ONCOGENE, V11, P239; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; HARDY S, 1993, MOL CELL BIOL, V13, P5943, DOI 10.1128/MCB.13.10.5943; Hermann M., 1994, NUCLEIC ACIDS RES, V22, P5506; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Kaliman P, 1998, MOL ENDOCRINOL, V12, P66, DOI 10.1210/mend.12.1.0047; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KONG Y, 1995, MOL CELL BIOL, V15, P5202; KONIECZNY SF, 1989, ONCOGENE, V4, P473; Lassar AB, 1996, CURR OPIN NEUROBIOL, V6, P57, DOI 10.1016/S0959-4388(96)80009-2; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; Ludolph DC, 1995, FASEB J, V9, P1595, DOI 10.1096/fasebj.9.15.8529839; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PETROPOULOS CJ, 1991, J VIROL, V65, P3728, DOI 10.1128/JVI.65.7.3728-3737.1991; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; Takano H, 1998, MOL CELL BIOL, V18, P1580, DOI 10.1128/MCB.18.3.1580; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; VAIDYA TB, 1991, J CELL BIOL, V114, P809, DOI 10.1083/jcb.114.4.809; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Xu RH, 1996, P NATL ACAD SCI USA, V93, P834, DOI 10.1073/pnas.93.2.834	35	43	43	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 16	1999	18	37					5167	5176		10.1038/sj.onc.1202907	http://dx.doi.org/10.1038/sj.onc.1202907			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235RE	10498866				2022-12-17	WOS:000082555700005
J	Cho, JY; Sagartz, JE; Capen, CC; Mazzaferri, EL; Jhiang, SM				Cho, JY; Sagartz, JE; Capen, CC; Mazzaferri, EL; Jhiang, SM			Early cellular abnormalities induced by RET/PTC1 oncogene in thyroid-targeted transgenic mice	ONCOGENE			English	Article						RET; transgenic; papillary thyroid carcinoma; mouse NIS; radioiodide uptake	RECEPTOR TYROSINE KINASE; SODIUM-IODIDE SYMPORTER; RET ONCOGENE; CARCINOMAS; EXPRESSION; PROTEIN; DIFFERENTIATION; ORGANIZATION; ACTIVATION; CLONING	The RET/PTC1 oncogene, a rearranged form of the RET proto-oncogene, has been reported to be associated with human papillary thyroid carcinomas. We have shown that targeted expression of RET/PTC1 in the thyroid gland leads to the development of thyroid carcinomas in transgenic mice with histologic and cytologic similarities to human papillary thyroid carcinoma. To further investigate how RET/PTC1 expression contributes to the pathogenesis of papillary thyroid tumor, the time of tumor onset and the early phenotypic consequences of RET/PTC1 expression in thyrocytes were determined. All high copy transgenic mice developed bilateral thyroid tumors as early as 4 days of age. At embryological days 16-18, increased proliferation rate, distorted thyroid follicle formation and reduced radioiodide concentrating activity were identified in transgenic embryos. The reduced radioiodide concentrating activity was attributed to decreased expression of the sodium-iodide symporter. Our study showed that RET/PTC1 not only increased proliferation of thyrocytes, it also altered morphogenesis and differentiation. These findings provide a model for the role of RET/PTC1 in the formation of abnormal follicles with reduced iodide uptake ability observed in human papillary thyroid carcinoma.	Ohio State Univ, Dept Physiol, Columbus, OH 43210 USA; Ohio State Univ, Dept Vet Biosci, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Jhiang, SM (corresponding author), Ohio State Univ, Dept Physiol, Columbus, OH 43210 USA.				NATIONAL CANCER INSTITUTE [R29CA060074, R01CA060074] Funding Source: NIH RePORTER; NCI NIH HHS [CA 60074] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACHRACH LK, 1985, ENDOCRINOLOGY, V116, P1603, DOI 10.1210/endo-116-4-1603; BOND JA, 1994, ONCOGENE, V9, P281; Bongarzone I, 1996, J CLIN ENDOCR METAB, V81, P2006, DOI 10.1210/jc.81.5.2006; BujBello A, 1997, NATURE, V387, P721, DOI 10.1038/42729; Dai G, 1996, NATURE, V379, P458, DOI 10.1038/379458a0; DIRENZO MF, 1992, ONCOGENE, V7, P2549; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; JHIANG SM, 1994, J LAB CLIN MED, V123, P331; JOKINEN MP, 1994, PATHOLOGY TUMOURS LA, V2, P565; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; Klugbauer S, 1995, ONCOGENE, V11, P2459; Lindsay RM, 1996, NEURON, V17, P571, DOI 10.1016/S0896-6273(00)80189-0; SANTORO M, 1995, EUR J ENDOCRINOL, V133, P513, DOI 10.1530/eje.0.1330513; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; Smanik PA, 1996, BIOCHEM BIOPH RES CO, V226, P339, DOI 10.1006/bbrc.1996.1358; Smanik PA, 1997, ENDOCRINOLOGY, V138, P3555, DOI 10.1210/en.138.8.3555; Tong Q, 1997, J BIOL CHEM, V272, P9043; Vega QC, 1996, P NATL ACAD SCI USA, V93, P10657, DOI 10.1073/pnas.93.20.10657; Yap AS, 1997, ENDOCRINOLOGY, V138, P2315, DOI 10.1210/en.138.6.2315; Zannini M, 1997, EMBO J, V16, P3185, DOI 10.1093/emboj/16.11.3185	21	43	44	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	1999	18	24					3659	3665		10.1038/sj.onc.1202709	http://dx.doi.org/10.1038/sj.onc.1202709			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	206QZ	10380889				2022-12-17	WOS:000080891700013
J	Agapova, LS; Ivanov, AV; Sablina, AA; Kopnin, PB; Sokova, OI; Chumakov, PM; Kopnin, BP				Agapova, LS; Ivanov, AV; Sablina, AA; Kopnin, PB; Sokova, OI; Chumakov, PM; Kopnin, BP			p53-dependent effects of RAS oncogene on chromosome stability and cell cycle checkpoints	ONCOGENE			English	Article						ras; p53; genome stability; chromosome breaks; polyploidy; endoreduplication	P-GLYCOPROTEIN FUNCTION; WILD-TYPE P53; GROWTH ARREST; GENE AMPLIFICATION; DEPENDENT KINASES; HUMAN FIBROBLASTS; DNA-REPLICATION; NORMAL P21N-RAS; TUMOR-ANTIGEN; ACTIVATED RAS	Mutations activating the function of ras proto-oncogenes are often observed in human tumors. Their oncogenic potential is mainly due to permanent stimulation of cellular proliferation and dramatic changes in morphogenic reactions of the cell. To learn more on the role of ras activation in cancerogenesis we studied its effects on chromosome stability and cell cycle checkpoints. Since the ability of ras oncogenes to cause cell transformation may be dependent on activity of the p53 tumor-suppressor the cells with different p53 state were analysed. Ectopic expression of N-ras(asp12) caused in p53-deficient MDAH041 cell line an augmentation in the number of chromosome breaks in mitogenic cells, significant increase in the frequency of metaphases showing chromosome endoreduplication and accumulation of polyploid cells. Similar effects were induced by different exogenous ras genes (N-ras(asp12), H-ras(leu12), N-ras proto-oncogene) in Rat1 and Rat2 cells which have a defect in p53-upstream pathways. In contrast, in REF52 and human LIM1215 cells showing ras-induced p53 upregulation, ras expression caused only slight increase in the number of chromosome breaks and did not enhance the frequency of endoreduplication and polyploidy. Inactivation in these cells of p53 function by transduction of dominant-negative C-terminal p53 fragment (genetic suppressor element #22, GSE22) or mutant p53s significantly increased the frequency of both spontaneous and uas-induced karyotypic changes. In concordance with these observations we have found that expression of uns oncogene caused in p53-defective cells further mitigation of ethyl-metansulphonate-induced G1 and G2 cell cycle arrest, but did not abrogate G1 and G2 cell cycle checkpoints in cells with normal p53 function. These data indicate that along with stimulation of cell proliferation and morphological transformation uas activation can contribute to cancerogenesis by increasing genetic instability.	Moscow Med Ctr, Engelhardt Inst Mol Biol, Moscow, Russia; Moscow Med Ctr, Inst Carcinogenesis, Canc Res Ctr, Moscow, Russia; Univ Oslo, Moscow Med Ctr, Moscow, Russia	Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	Chumakov, PM (corresponding author), Moscow Med Ctr, Engelhardt Inst Mol Biol, Moscow, Russia.		Kopnin, Pavel/R-8213-2019; Chumakov, Peter M/E-7731-2014; Sablina, Anna/P-2818-2019; Sokova, Olga/R-7544-2019; Sablina, Anna/B-2217-2017; Ivanov, Alexey/I-9445-2012; Kopnin, Boris/R-8240-2019; Ivanov, Andrey/M-7039-2013	Kopnin, Pavel/0000-0002-2078-4274; Sablina, Anna/0000-0001-9526-4014; Sokova, Olga/0000-0001-7159-5302; Sablina, Anna/0000-0001-9526-4014; Kopnin, Boris/0000-0003-3100-2212; Ivanov, Andrey/0000-0001-7245-1108; Ivanov, Alexey/0000-0002-8617-4604; Chumakov, Peter/0000-0002-8078-2908				Agapova LS, 1996, MUTAT RES-FUND MOL M, V354, P129, DOI 10.1016/0027-5107(96)00062-0; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ALEXANDROVA AY, 1993, CELL MOTIL CYTOSKEL, V25, P254, DOI 10.1002/cm.970250306; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARBACID M, 1990, EUR J CLIN INVEST, V20, P225, DOI 10.1111/j.1365-2362.1990.tb01848.x; CARDER P, 1993, ONCOGENE, V8, P1397; Chen J, 1996, ONCOGENE, V13, P1395; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; Fan JG, 1997, ONCOGENE, V14, P2595, DOI 10.1038/sj.onc.1201105; FILMUS J, 1994, ONCOGENE, V9, P3627; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARVEY M, 1993, ONCOGENE, V8, P2456; HICKS GG, 1991, MOL CELL BIOL, V11, P1344, DOI 10.1128/MCB.11.3.1344; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; JENKINS JR, 1984, NATURE, V312, P851; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; KONDRATOV RV, 1996, MOL BIOL, V30, P636; KOPNIN BP, 1995, ONCOL RES, V7, P299; Levine AJ, 1995, ANN NY ACAD SCI, V768, P111, DOI 10.1111/j.1749-6632.1995.tb12115.x; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MCKAY IA, 1986, EMBO J, V5, P2617, DOI 10.1002/j.1460-2075.1986.tb04542.x; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; Mumberg D, 1996, ONCOGENE, V13, P2493; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; PRASOLOV V S, 1988, Molekulyarnaya Biologiya (Moscow), V22, P1371; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SOUYRI M, 1987, VIROLOGY, V158, P69, DOI 10.1016/0042-6822(87)90239-X; STEWART N, 1995, ONCOGENE, V10, P109; STROMSKAYA TP, 1995, FEBS LETT, V368, P373, DOI 10.1016/0014-5793(95)00662-S; Thompson DA, 1997, ONCOGENE, V15, P3025, DOI 10.1038/sj.onc.1201495; TSUKADA T, 1993, ONCOGENE, V8, P3313; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; WHITEHEAD RH, 1985, JNCI-J NATL CANCER I, V74, P759; Winston JT, 1996, ONCOGENE, V12, P127; WYLLIE FS, 1995, ONCOGENE, V10, P49; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAICHUK TA, 1993, P RUSSIAN ACAD SCI, V330, P386	56	43	47	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3135	3142		10.1038/sj.onc.1202386	http://dx.doi.org/10.1038/sj.onc.1202386			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340385				2022-12-17	WOS:000080388000009
J	Zehbe, I; Ratsch, A; Alunni-Fabbroni, M; Burzlaff, A; Bakos, E; Durst, M; Wilander, E; Tommasino, M				Zehbe, I; Ratsch, A; Alunni-Fabbroni, M; Burzlaff, A; Bakos, E; Durst, M; Wilander, E; Tommasino, M			Overriding of cyclin-dependent kinase inhibitors by high and low risk human papillomavirus types: evidence for an in vivo role in cervical lesions	ONCOGENE			English	Article						cervical lesions; high and low risk HPV types; CDK inhibitors; cell cycle	CELL-CYCLE; E7 ONCOPROTEIN; GENE-EXPRESSION; DNA-REPLICATION; P21(WAF1/CIP1) EXPRESSION; POTENTIAL MEDIATOR; DIFFERENTIATION; P27(KIP1); P53; PROTEIN	High risk types of human papillomavirus (HPV) are agents in the aetiology of cervical carcinoma. The products of two early genes, E6 and E7, appear to be the principal transforming proteins. Studies of various monolayer cell culture systems have shown that the E7 oncoprotein of human papillomavirus type 16 is able to neutralize or bypass the inhibitory effect of the cell cycle-dependent kinase (CDK) inhibitors (CKIs) p21(WAF1/CIP1) and p27(KIP1). To understand whether the p21(WAF1/CIP1) Or p27(KIP1) neutralization also plays a role in vivo, we performed studies on clinical specimens. Forty-five cervical biopsies, including HPV-negative mucosa, HPV 16-positive preinvasive (low and high grade lesions) and invasive neoplasia as well as HPV 6-positive condyloma acuminatum were analysed by single and double immunohistology. We examined the positive cell cycle regulator cyclin A and the universal cell cycle marker Ki67 as well as the negative cell cycle regulators p21(WAF1/CIP1) and p(27KIP1). Here, we show that in a significant fraction of cells the G1 block can be overcome despite high levels of CKIs in HPV lesions. This phenomenon, which was more evident for p21(WAF/CIP1) than for p27(KIP1) was most marked in low grade lesions and in condylomata acuminata, in which a high viral productivity is expected. These results indicate that the overriding of CKI inactivation by viral oncoproteins appears to be a conserved property between low and high risk HPV types. We conclude that the CKI neutralization by HPVs is likely to be required for viral DNA replication rather than for malignant transformation of the host cell.	Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany; Klin Frauenheilkunde & Geburtshilfe, D-07740 Jena, Germany; Univ Uppsala, Dept Genet & Pathol, S-75185 Uppsala, Sweden	Helmholtz Association; German Cancer Research Center (DKFZ); Uppsala University	Tommasino, M (corresponding author), Deutsch Krebsforschungszentrum, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.							Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BLANTON RA, 1992, CELL GROWTH DIFFER, V3, P791; Byrne C, 1997, BIOESSAYS, V19, P691, DOI 10.1002/bies.950190809; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; DAVIES R, 1993, J VIROL, V67, P2525; Demers GW, 1996, J VIROL, V70, P6862, DOI 10.1128/JVI.70.10.6862-6869.1996; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DURST M, 1992, VIROLOGY, V189, P132, DOI 10.1016/0042-6822(92)90688-L; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Fredersdorf S, 1996, AM J PATHOL, V148, P825; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; GISSMANN L, 1982, INT J CANCER, V29, P143, DOI 10.1002/ijc.2910290205; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; HICKMAN ES, 1994, ONCOGENE, V9, P2177; Hiyama H, 1998, ONCOGENE, V16, P1513, DOI 10.1038/sj.onc.1201667; Howley Peter M., 1996, P947; HU TH, 1995, INT J ONCOL, V6, P167; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mandal M, 1998, ONCOGENE, V16, P217, DOI 10.1038/sj.onc.1201529; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PINES J, 1995, ADV CANCER RES, V66, P181, DOI 10.1016/S0065-230X(08)60254-7; PINES J, 1990, NATURE, V46, P60; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Ruesch MN, 1997, J VIROL, V71, P5570, DOI 10.1128/JVI.71.7.5570-5578.1997; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schmidt-Grimminger DC, 1998, AM J PATHOL, V152, P1015; Schulze A, 1998, J VIROL, V72, P2323, DOI 10.1128/JVI.72.3.2323-2334.1998; TOMMASINO M, 1993, ONCOGENE, V8, P195; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zehbe I, 1997, J PATHOL, V181, P270; Zehbe I, 1996, DIAGN MOL PATHOL, V5, P206, DOI 10.1097/00019606-199609000-00010; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; ZerfassThome K, 1996, ONCOGENE, V13, P2323; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427; ZURHAUSEN H, 1986, LANCET, V2, P498	43	43	45	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 1	1999	18	13					2201	2211		10.1038/sj.onc.1202549	http://dx.doi.org/10.1038/sj.onc.1202549			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	182YE	10327066	Bronze			2022-12-17	WOS:000079525100004
J	Ess, KC; Witte, DP; Bascomb, CP; Aronow, BJ				Ess, KC; Witte, DP; Bascomb, CP; Aronow, BJ			Diverse developing mouse lineages exhibit high-level c-Myb expression in immature cells and loss of expression upon differentiation	ONCOGENE			English	Article						in situ hybridization; transcription factor; repression; anti-differentiation; development; stem cell; embryogenesis	ADENOSINE-DEAMINASE GENE; LOCUS-CONTROL REGION; B-MYB; A-MYB; TRANSGENIC MICE; HAIR FOLLICLE; TERMINAL DIFFERENTIATION; TRANSCRIPTION FACTORS; LUNG MORPHOGENESIS; GUT EPITHELIUM	The c-myb gene encodes a sequence specific transactivator that is required for fetal hematopoiesis, but its potential role in other tissues is less clear because of the early fetal demise of mice with targeted deletions of the c-myb gene and incomplete of knowledge about c-myb's expression pattern. In the hematopoietic system, c-Myb protein acts on target genes whose expression is restricted to individual lineages, despite Myb's presence and role in multiple immature lineages. This suggests that c-Myb actions within different cell type-specific contexts are strongly affected by combinatorial interactions, To consider the possibility of similar c-Myb actions could extend into non-hematopoietic systems in other cell and tissue compartments, we characterized c-myb expression in developing and adult mice using in situ hybridization and correlated this with stage-specific differentiation and mitotic activity, Diverse tissues exhibited strong c-myb expression during development, notably tooth buds, the thyroid primordium, developing trachea and proximal branching airway epithelium, hair follicles, hematopoietic cells, and gastrointestinal crypt epithelial cells, The latter three of these all maintained high expression into adulthood, but with characteristic restriction to immature cell lineages prior to their terminal differentiation. In all sites, during fetal and adult stages, loss of c-Myb expression correlated strikingly with the initiation of terminal differentiation, but not the loss of mitotic activity. Based on these data, we hypothesize that c-Myb's function during cellular differentiation is both an activator of immature gene expression and a suppressor of terminal differentiation in diverse lineages.	Univ Cincinnati, Childrens Hosp Res Fdn, Div Med & Mol Genet, Cincinnati, OH 45229 USA; Univ Cincinnati, Childrens Hosp Res Fdn, Dept Pathol, Cincinnati, OH 45229 USA; Miami Valley Lab, Div Corp Res, Cincinnati, OH 45061 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati	Aronow, BJ (corresponding author), Univ Cincinnati, Childrens Hosp Res Fdn, Div Med & Mol Genet, Cincinnati, OH 45229 USA.		Aronow, Bruce J/F-8438-2012		NHLBI NIH HHS [HL07527] Funding Source: Medline; NIDDK NIH HHS [DK47022] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047022] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONOW B, 1989, GENE DEV, V3, P1384, DOI 10.1101/gad.3.9.1384; ARONOW BJ, 1995, MOL CELL BIOL, V15, P1123; ARONOW BJ, 1992, MOL CELL BIOL, V12, P4170, DOI 10.1128/MCB.12.9.4170; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; BARLETTA C, 1992, European Journal of Gynaecological Oncology, V13, P53; Bellon T, 1997, BLOOD, V90, P1828, DOI 10.1182/blood.V90.5.1828; Bellusci S, 1996, DEVELOPMENT, V122, P1693; Bellusci S, 1997, DEVELOPMENT, V124, P53; BEPLER G, 1989, ONCOGENE, V4, P45; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; BritosBray M, 1997, MOL CELL BIOL, V17, P5127, DOI 10.1128/MCB.17.9.5127; CHANDRASENA G, 1992, CELL MOL BIOL, V38, P243; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; CUDDIHY AE, 1993, MOL CELL BIOL, V13, P3505, DOI 10.1128/MCB.13.6.3505; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; DESBIENS X, 1991, DEVELOPMENT, V111, P699; ESS KC, 1995, MOL CELL BIOL, V15, P5707; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GOODLAD RA, 1992, VIRCHOWS ARCH B, V61, P415, DOI 10.1007/BF02890445; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; HIJIYA N, 1994, P NATL ACAD SCI USA, V91, P4499, DOI 10.1073/pnas.91.10.4499; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HSIANG YHH, 1995, J IMMUNOL, V154, P5195; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; KaneiIshii C, 1997, SCIENCE, V277, P246, DOI 10.1126/science.277.5323.246; KIEFER PE, 1987, CANCER RES, V47, P6236; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; Kollar EJ, 1983, EPITHELIAL MESENCHYM, P27; KowenzLeutz E, 1997, CELL, V91, P185, DOI 10.1016/S0092-8674(00)80401-8; LAM EWF, 1992, ONCOGENE, V7, P1885; Latham KE, 1996, ONCOGENE, V13, P1161; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; LYON J, 1994, CRIT REV ONCOGENESIS, V5, P373, DOI 10.1615/CritRevOncog.v5.i4.30; MACKENZIE A, 1992, DEVELOPMENT, V115, P403; MCCRACKEN S, 1994, ONCOGENE, V9, P3609; MCDERMOTT FT, 1976, VIRCHOWS ARCH B, V22, P353; MIZUGUCHI G, 1995, J BIOL CHEM, V270, P9384, DOI 10.1074/jbc.270.16.9384; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; MUKHOPADHYAYA R, 1992, J VIROL, V66, P6035, DOI 10.1128/JVI.66.10.6035-6044.1992; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NASONBURCHENAL K, 1993, P NATL ACAD SCI USA, V90, P1619, DOI 10.1073/pnas.90.4.1619; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; Oh IH, 1997, J BIOL CHEM, V272, P21432, DOI 10.1074/jbc.272.34.21432; Postigo AA, 1997, EMBO J, V16, P3924, DOI 10.1093/emboj/16.13.3924; QUEVA C, 1992, DEVELOPMENT, V114, P125; Rosenthal MA, 1996, CELL GROWTH DIFFER, V7, P961; ROTTMAN JN, 1993, J BIOL CHEM, V268, P11994; SEIBERG M, 1995, J INVEST DERMATOL, V104, P78, DOI 10.1111/1523-1747.ep12613555; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SHAPIRO LH, 1995, J BIOL CHEM, V270, P8763, DOI 10.1074/jbc.270.15.8763; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; Sitzmann J, 1996, ONCOGENE, V12, P1889; STENN KS, 1994, J INVEST DERMATOL, V103, P107, DOI 10.1111/1523-1747.ep12391844; TASHIRO S, 1995, ONCOGENE, V10, P1699; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; THOMPSON MA, 1995, BIOESSAYS, V17, P341, DOI 10.1002/bies.950170410; Thompson MA, 1997, ONCOGENE, V14, P1715, DOI 10.1038/sj.onc.1201007; TORELLI G, 1987, CANCER RES, V47, P5266; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; Tung J, 1997, AM J PHYSIOL-GASTR L, V273, pG83, DOI 10.1152/ajpgi.1997.273.1.G83; VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691; Wallrapp C, 1997, CANCER RES, V57, P3135; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; WILSON C, 1994, DIFFERENTIATION, V55, P127, DOI 10.1046/j.1432-0436.1994.5520127.x; WITTE DP, 1991, J CELL BIOL, V115, P179, DOI 10.1083/jcb.115.1.179; WOLFF L, 1991, J VIROL, V65, P3607, DOI 10.1128/JVI.65.7.3607-3616.1991; Zannini M, 1997, EMBO J, V16, P3185, DOI 10.1093/emboj/16.11.3185; ZHOU PB, 1995, GENE DEV, V9, P700, DOI 10.1101/gad.9.6.700	71	43	45	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					1103	1111		10.1038/sj.onc.1202387	http://dx.doi.org/10.1038/sj.onc.1202387			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023687				2022-12-17	WOS:000078510600028
J	Giamarchi, C; Solanas, M; Chailleux, C; Augereau, P; Vignon, F; Rochefort, H; Richard-Foy, H				Giamarchi, C; Solanas, M; Chailleux, C; Augereau, P; Vignon, F; Rochefort, H; Richard-Foy, H			Chromatin structure of the regulatory regions of pS2 and cathepsin D genes in hormone-dependent and -independent breast cancer cell lines	ONCOGENE			English	Article						breast cancer; chromatin; pS2; cathepsin D; estrogens; IGFI	ESTROGEN-RESPONSIVE ELEMENT; GROWTH-FACTORS; RECEPTOR; PROMOTER; BINDING; ANTIESTROGENS; EXPRESSION; PROTEIN; CBP; TRANSFECTION	We have compared the DNase I hypersensitivity of the regulatory region of two estrogen-regulated genes, pS2 and cathepsin D in hormone-dependent and -independent breast carcinoma cell lines. This strategy allowed the identification of two important control regions, one in pS2 and the other in cathepsin D genes, In the hormone-dependent MCF7 cell line within the pS2 gene 5'-flanking region, we detected two major DNase I hypersensitive sites, induced by estrogens and/or IGFI: pS2-HS1, located in the proximal promoter and pS2-HS4, located -10.5 Kb from the CAP site, within a region that has not been cloned. The presence of these two DNase I hypersensitive sites correlates with pS2 expression. Interestingly in MCF7 cells, estrogens and IGFI induced indistinguishable chromatin structural changes over the pS2 regulatory region, suggesting that the two transduction-pathways converge to a unique chromatin target, In two cell lines that do not express pS2, MDA MB 231, a hormone-independent cell line that lacks the estrogen receptor alpha, and HE5, a cell line derived from MDA MB 231 by transfection that expresses estrogen receptor alpha, there was only one hormone-independent DNase I hypersensitive site. This site, pS2-HS2, was located immediately upstream of pS2-HS1, In MCF7 cells, two major DNase I hypersensitive sites were present in the 5'-flanking sequences of the cathepsin D gene, which is regulated by estrogens in these cells. These sites, catD-HS2 and catD-HS3, located at positions -2.3 Kb and -3.45 Kb, respectively, were both hormone-independent. A much weaker site, catD-HS1, covered the proximal promoter. In MDA MB 231 cells, that express cathepsin D constitutively we detected an additional strong hormone-independent DNase I hypersensitive site, catD-HS4, located at position -4.3 Kb, This region might control the constitutive over-expression of cathepsin D in hormone-independent breast cancer cells, All together, these data demonstrate that a local reorganization of the chromatin structure over pS2 and cathepsin D promoters accompanies the establishment of the hormone-independent phenotype of the cells.	CNRS, Lab Biol Mol Eucaryote, F-31062 Toulouse, France; Univ Autonoma Barcelona, Fac Med, Dept Biol Cellular & Fisiol, E-08193 Barcelona, Spain; INSERM, U148, Unite Hormones & Canc, F-34090 Montpellier, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Autonomous University of Barcelona; University of Barcelona; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Richard-Foy, H (corresponding author), CNRS, Lab Biol Mol Eucaryote, 118 Route Narbonne, F-31062 Toulouse, France.		Solanas Garcia, Montserrat/O-4684-2016; Medale Giamarchi, Claire/M-3263-2014	Solanas Garcia, Montserrat/0000-0003-2949-1344; 				AUGEREAU P, 1994, MOL ENDOCRINOL, V8, P693, DOI 10.1210/me.8.6.693; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; CARR KD, 1990, P NATL ACAD SCI USA, V87, P9300, DOI 10.1073/pnas.87.23.9300; CAVAILLES V, 1989, MOL ENDOCRINOL, V3, P552, DOI 10.1210/mend-3-3-552; CAVAILLES V, 1993, P NATL ACAD SCI USA, V90, P203, DOI 10.1073/pnas.90.1.203; CHALBOS D, 1993, ENDOCRINOLOGY, V133, P571, DOI 10.1210/en.133.2.571; CHALBOS D, 1992, J STEROID BIOCHEM, V43, P223, DOI 10.1016/0960-0760(92)90211-Z; Dumont JA, 1996, CELL GROWTH DIFFER, V7, P351; FOEKENS JA, 1993, J CLIN ONCOL, V11, P899, DOI 10.1200/JCO.1993.11.5.899; GARCIA M, 1992, P NATL ACAD SCI USA, V89, P11538, DOI 10.1073/pnas.89.23.11538; Gillesby BE, 1997, BIOCHEMISTRY-US, V36, P6080, DOI 10.1021/bi962131b; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KRISHNAN V, 1994, J BIOL CHEM, V269, P15912; LEVENSON AS, 1994, J STEROID BIOCHEM, V51, P229, DOI 10.1016/0960-0760(94)90035-3; Martin V, 1997, J CELL BIOCHEM, V65, P95, DOI 10.1002/(SICI)1097-4644(199704)65:1<95::AID-JCB10>3.0.CO;2-G; Montminy M, 1997, NATURE, V387, P654, DOI 10.1038/42594; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; NUNEZ AM, 1989, EMBO J, V8, P823, DOI 10.1002/j.1460-2075.1989.tb03443.x; REESE JC, 1992, MOL CELL BIOL, V12, P4531, DOI 10.1128/MCB.12.10.4531; RICHARDFOY H, 1987, MOL ENDOCRINOL, V1, P659, DOI 10.1210/mend-1-9-659; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; ROCHEFORT H, 1990, BREAST CANCER RES TR, V16, P3, DOI 10.1007/BF01806570; Sewack GF, 1997, J BIOL CHEM, V272, P31118, DOI 10.1074/jbc.272.49.31118; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TOUITOU I, 1991, J STEROID BIOCHEM, V40, P231, DOI 10.1016/0960-0760(91)90187-A; VIGNON F, 1987, BIOCHEM BIOPH RES CO, V146, P1502, DOI 10.1016/0006-291X(87)90819-9; Vladusic EA, 1998, CANCER RES, V58, P210	32	43	44	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					533	541		10.1038/sj.onc.1202317	http://dx.doi.org/10.1038/sj.onc.1202317			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927210				2022-12-17	WOS:000078166500026
J	Malumbres, M; Perez de Castro, I; Santos, J; Piqueras, JF; Pellicer, A				Malumbres, M; Perez de Castro, I; Santos, J; Piqueras, JF; Pellicer, A			Hypermethylation of the cell cycle inhibitor p15(INK4b) 3 '-untranslated region interferes with its transcriptional regulation in primary lymphomas	ONCOGENE			English	Article						DNA methylation; p15(INK4b) CDK inhibitor; 3'-UTR; T-cell; lymphoma	DEPENDENT KINASE INHIBITOR; TUMOR-SUPPRESSOR; DNA METHYLATION; TGF-BETA; P16(INK4) GENE; HUMAN CANCERS; EXPRESSION; INACTIVATION; MOUSE; P15	The cyclin-dependent kinase inhibitor p15(INK4h) has been shown to he involved in human and rodent tumors and seems to act as a tumor suppressor gene in hematological malignancies, Alterations of this gene in tumors include mainly homozygous deletions and hypermethylation of the CpG island in the promoter region. In this work, we describe a new area sensitive to methylation in the 3' untranslated region (UTR) of the murine p15(INK4b) gene, This region shows different levels of methylation depending on the tissues, being relatively highly methylated in brain and gut, and weakly methylated in liver, spleen or thymus, DNA methylation and expression is similar in both maternal and paternal alleles indicating no imprinting effect. Although methylation of the p15(INK4h) 3'-UTR is low in normal thymus, increased levels (up to 100%) of specific methylation in this region are found in up to 30% of radiation- or carcinogen-induced thymic Lymphomas, correlating with decreased gene expression. Hypermethylation of the p15(INK4b) 3'-UTR frequently occurs in tumors with loss of heterozygosity (LOH) but without methylation of the promoter CpG island or intragenic mutations. Furthermore, in vitro CpG methylation of the 3'-UTR produces reduced levels of a luciferase reporter in cultured cells, Methylation of two CpG sites in a 120 bp region is sufficient to interfere with transcription of the reporter gene. These data suggest that although the levels of p15(INK4h) in normal tissues can be mainly determined by promoter regulatory elements, strong hypermethylation of the 3'-UTR can interfere with transcription, Thus, hypermethylation of the 3'-UTR may explain the lack of p15(INK4b) gene expression in a subset of tumors with no promoter methylation and could be a new alternative mechanism for tumor suppressor gene inactivation in tumorigenesis.	NYU, Med Ctr, Dept Pathol, New York, NY 10016 USA; NYU, Med Ctr, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA; Univ Autonoma Madrid, Dept Biol, Lab Genet Mol Humana, E-28049 Madrid, Spain	New York University; New York University; Autonomous University of Madrid	Pellicer, A (corresponding author), NYU, Med Ctr, Dept Pathol, 550 1St Ave, New York, NY 10016 USA.		Holt, Janet E/B-2415-2013; Malumbres, Marcos/E-8834-2011; de Castro, Ignacio Pérez/A-6260-2012; MARTINEZ, ANTONIO PELLICER/C-4832-2015; Santos, Javier/ABF-5755-2021	Malumbres, Marcos/0000-0002-0829-6315; de Castro, Ignacio Pérez/0000-0002-8822-8274; Santos, Javier/0000-0002-4168-6251; Pellicer, Angel/0000-0002-5062-0692	NATIONAL CANCER INSTITUTE [R01CA050434, R01CA036327, R37CA036327] Funding Source: NIH RePORTER; NCI NIH HHS [CA 50434, CA 36327] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altschmied J, 1997, BIOTECHNIQUES, V23, P436, DOI 10.2144/97233bm19; Batova A, 1997, CANCER RES, V57, P832; BATTISTUZZI G, 1985, P NATL ACAD SCI USA, V82, P1465, DOI 10.1073/pnas.82.5.1465; Baylin SB, 1998, ADV CANCER RES, V72, P141; BORRELLO MG, 1992, ONCOGENE, V7, P269; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Cost GJ, 1997, CANCER RES, V57, P926; GLENDENING JM, 1995, CANCER RES, V55, P5531; GRANA X, 1995, ONCOGENE, V11, P211; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HATADA I, 1995, NAT GENET, V11, P204, DOI 10.1038/ng1095-204; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Herman JG, 1996, CANCER RES, V56, P722; Herman JG, 1997, CANCER RES, V57, P837; HIRAMA T, 1995, BLOOD, V86, P841; Iavarone A, 1997, NATURE, V387, P417; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kay PH, 1997, GENE, V184, P45, DOI 10.1016/S0378-1119(96)00572-0; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Li XS, 1996, CANCER RES, V56, P5055; LOIS AF, 1995, CANCER RES, V55, P4010; Malumbres M, 1997, ONCOGENE, V14, P1361, DOI 10.1038/sj.onc.1200969; Malumbres M, 1998, MAMM GENOME, V9, P183, DOI 10.1007/s003359900722; Matsuoka S, 1996, P NATL ACAD SCI USA, V93, P3026, DOI 10.1073/pnas.93.7.3026; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MULLINS LJ, 1987, MOL CELL BIOL, V7, P3916, DOI 10.1128/MCB.7.11.3916; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PETERS G, 1994, NATURE, V371, P204, DOI 10.1038/371204a0; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; QUELLE DE, 1995, ONCOGENE, V11, P635; RASOOL O, 1995, BLOOD, V85, P3431, DOI 10.1182/blood.V85.12.3431.bloodjournal85123431; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; RIGGS AD, 1983, ADV CANCER RES, V40, P1, DOI 10.1016/S0065-230X(08)60678-8; RIGGS AD, 1975, CYTOGENET CELL GENET, V14, P9, DOI 10.1159/000130315; Rishi AK, 1997, CANCER RES, V57, P5129; Santos J, 1996, ONCOGENE, V12, P669; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SHANDU C, 1997, MOL CELL BIOL, V17, P2458; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Tsubari M, 1997, CANCER RES, V57, P2966; Umezawa A, 1997, MOL CELL BIOL, V17, P4885, DOI 10.1128/MCB.17.9.4885; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	52	43	45	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					385	396		10.1038/sj.onc.1202299	http://dx.doi.org/10.1038/sj.onc.1202299			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927195				2022-12-17	WOS:000078166500011
J	Giani, C; Casalini, P; Pupa, SM; De Vecchi, R; Ardini, E; Colnaghi, MI; Giordano, A; Menard, S				Giani, C; Casalini, P; Pupa, SM; De Vecchi, R; Ardini, E; Colnaghi, MI; Giordano, A; Menard, S			Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation	ONCOGENE			English	Article						c-erbB-2; oncogene; breast cancer; estrogens; proliferation; differentiation	RECEPTOR TYROSINE KINASES; NEU-ONCOGENE; RETINOBLASTOMA PROTEIN; OVARIAN-CANCER; PC12 CELLS; IN-VIVO; OVEREXPRESSION; HEREGULIN; ESTROGEN; ERBB-2	c-erbB-2, a member of the tyrosine kinase oncogene family, is overexpressed in about 30% of human breast tumors where it correlates with poor prognosis. In vitro studies have suggested that increased expression of the receptor plays an important role in malignant progression. To better understand the direct effects of p185(HER2) overexpression, a human c-erbB-2 expression vector was transfected into the hormone-dependent MCF-7 human breast carcinoma cell line and cell growth was analysed. Unexpectedly, colony formation assay revealed a reduction in the number and size of colonies as compared with mock-transfected cells. In hormone-deprived medium, c-erbB-2 transfected cells acquired growth capability, consistent with previous reports. By contrast, two c-erbB-2-transfected clones grown in complete medium showed a reduced proliferation rate despite the activation of a fully functional oncoprotein capable of autophosphorylation and induction of the MAPK pathway. The number of c-erbB-2-overexpressing cells in the S phase of the cell cycle was about one-half the number of control and mock-transfected cells. Also, overexpression of c-erbB-2 induced overexpression of p21(WAF1), pRB hypophosphorylation and a mature differentiated cell phenotype with production of lipid droplets. Functional inactivation of p185(HER2) by means of a specific single chain antibody indicated the c-erbB-2-dependence of the observed alterations. These data show that the exogenous overexpression of the c-erbB-2 gene in hormone-dependent breast cancer cells inhibits proliferation and induces differentiation.	Ist Nazl Tumori, Div Expt Oncol E, I-20133 Milan, Italy; Thomas Jefferson Univ, Jefferson Med Coll, S Barro Inst Canc Res & Mol Med, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Fondazione IRCCS Istituto Nazionale Tumori Milan; Jefferson University	Colnaghi, MI (corresponding author), Ist Nazl Tumori, Div Expt Oncol E, Via Venezian 1, I-20133 Milan, Italy.		Giordano, Antonio/F-1927-2010; Pupa, Serenella/K-6388-2016; menard, sylvie mm/C-7940-2011	Giordano, Antonio/0000-0002-5959-016X; Pupa, Serenella/0000-0002-4592-6830; 				BACUS SS, 1990, MOL CARCINOGEN, V3, P350, DOI 10.1002/mc.2940030607; Bacus SS, 1996, ONCOGENE, V12, P2535; BACUS SS, 1994, AM J CLIN PATHOL, V102, pS13; BALDI A, 1995, J CELL BIOCHEM, V59, P402, DOI 10.1002/jcb.240590311; BEERLI RR, 1994, J BIOL CHEM, V269, P23931; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; Carlomagno C, 1996, J CLIN ONCOL, V14, P2702, DOI 10.1200/JCO.1996.14.10.2702; CENTIS F, 1992, HYBRIDOMA, V11, P267, DOI 10.1089/hyb.1992.11.267; CHEN PL, 1995, CRIT REV EUKAR GENE, V5, P79; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOUGALL WC, 1994, ONCOGENE, V9, P2109; Endoh H, 1997, BIOCHEM BIOPH RES CO, V235, P99, DOI 10.1006/bbrc.1997.6746; FELIP E, 1995, CANCER, V75, P2147, DOI 10.1002/1097-0142(19950415)75:8<2147::AID-CNCR2820750818>3.0.CO;2-8; Gorospe M, 1996, CELL GROWTH DIFFER, V7, P1609; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; JANES PW, 1994, ONCOGENE, V9, P3601; KERN JA, 1994, J CLIN INVEST, V93, P516, DOI 10.1172/JCI117001; KOKAI Y, 1987, P NATL ACAD SCI USA, V84, P8498, DOI 10.1073/pnas.84.23.8498; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU YL, 1995, BREAST CANCER RES TR, V34, P97, DOI 10.1007/BF00665783; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; POLLER DN, 1992, BRIT J CANCER, V66, P583, DOI 10.1038/bjc.1992.318; RILKE F, 1991, INT J CANCER, V49, P44, DOI 10.1002/ijc.2910490109; Sambrook J., 1989, MOL CLONING LAB MANU; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; TODD DM, 1992, DIAGN ONCOL, V2, P313; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Wang J, 1996, CELL GROWTH DIFFER, V7, P1471; Watters JJ, 1997, ENDOCRINOLOGY, V138, P4030, DOI 10.1210/en.138.9.4030; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	43	43	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 30	1998	17	4					425	432		10.1038/sj.onc.1201954	http://dx.doi.org/10.1038/sj.onc.1201954			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696035				2022-12-17	WOS:000075043000004
J	Chakravarti, D; Mailander, P; Franzen, J; Higginbotham, S; Cavalieri, EL; Rogan, EG				Chakravarti, D; Mailander, P; Franzen, J; Higginbotham, S; Cavalieri, EL; Rogan, EG			Detection of dibenzo[a,l]pyrene-induced H-ras codon 61 mutant genes in preneoplastic SENCAR mouse skin using a new PCR-RFLP method	ONCOGENE			English	Article						dibenzo[a,l]pyrene; SENCAR mouse; quantitative PCR; gleaning efficiency; in vivo mutation; DNA repair	MUTAGENIC SPECIFICITY; ADDUCTS; IDENTIFICATION; BENZO<A>PYRENE; PAPILLOMAS; MUTATIONS; EPOXIDE; TUMORS; ARISE; SITES	One of the key events in tumor initiation in mouse skin is mutational activation of the H-ras gene. Papillomas induced by the most carcinogenic environmental polycyclic aromatic hydrocarbon (PAH), dibenzo[a,l]pyrene (DB[a,l]P), in SENCAR mouse skin contain a specific H-ras codon 61 (CAA-->CTA) mutation. We describe here detection of these mutations in preneoplastic skin by measuring the frequency of an induced XbaI RFLP, created by the mutation. Development of the PCR-XbaI RFLP method, sensitive enough to detect 1 codon 61 mutant allele among 10 000 wild-type genes, is described. The results indicate that codon 61 mutations are induced 1 day (0.1%) after DB[a,l]P treatment on mouse skin, reach a high value (5%) by day 3, rapidly decline between days 7-9 and increase again during the clonal expansion of pre-papillomas into tumors. The detection of codon 61 mutations 1 day after DB[a,l]P exposure suggests that mutations occurred by pre-replication misrepair.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	Rogan, EG (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc, 600 S 42Nd St, Omaha, NE 68198 USA.				NCI NIH HHS [F32 CA 68761, CA36727, P01 CA49210] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA068761, P01CA049210, P30CA036727] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDAZ CM, 1985, CANCER RES, V45, P2753; Casale GP, 1997, FUND APPL TOXICOL, V36, P71, DOI 10.1006/faat.1997.2291; CHA RS, 1994, P NATL ACAD SCI USA, V91, P3749, DOI 10.1073/pnas.91.9.3749; CHAKRAVARTI D, 1995, P NATL ACAD SCI USA, V92, P10422, DOI 10.1073/pnas.92.22.10422; Chakravarti D., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P135; CHARY P, 1995, NUCLEIC ACIDS RES, V23, P1398, DOI 10.1093/nar/23.8.1398; DEVANESAN PD, 1993, CHEM RES TOXICOL, V6, P364, DOI 10.1021/tx00033a018; DROUIN EE, 1993, BIOCHEMISTRY-US, V32, P6555, DOI 10.1021/bi00077a009; Finch JS, 1996, CARCINOGENESIS, V17, P2551, DOI 10.1093/carcin/17.12.2551; GILL RD, 1991, ENVIRON MOL MUTAGEN, V18, P200, DOI 10.1002/em.2850180307; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; KEMP CJ, 1994, COLD SPRING HARB SYM, V59, P427, DOI 10.1101/SQB.1994.059.01.048; KOPPSCHNEIDER A, 1992, CARCINOGENESIS, V13, P973, DOI 10.1093/carcin/13.6.973; Lehmann AR, 1996, MUTAT RES-DNA REPAIR, V364, P245, DOI 10.1016/S0921-8777(96)00037-7; Li K.-M., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P127; NAKAJIMA H, 1993, RES COMMUN CHEM PATH, V79, P3; NAKAZAWA H, 1992, ONCOGENE, V7, P2295; NELSON MA, 1993, P NATL ACAD SCI USA, V90, P781; NELSON MA, 1992, P NATL ACAD SCI USA, V89, P6398, DOI 10.1073/pnas.89.14.6398; RODRIGUEZ H, 1993, CARCINOGENESIS, V14, P373, DOI 10.1093/carcin/14.3.373; RUANO G, 1989, NUCLEIC ACIDS RES, V17, P5407, DOI 10.1093/nar/17.13.5407; RYCHLIK W, 1995, BIOTECHNIQUES, V18, P84; SARKAR G, 1990, NUCLEIC ACIDS RES, V18, P7465, DOI 10.1093/nar/18.24.7465; SAWYER TW, 1988, CARCINOGENESIS, V9, P1197, DOI 10.1093/carcin/9.7.1197; SCHAAPER RM, 1987, J MOL BIOL, V198, P187, DOI 10.1016/0022-2836(87)90305-6; SLAGA TJ, 1974, CANCER RES, V34, P771	26	43	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 18	1998	16	24					3203	3210		10.1038/sj.onc.1201853	http://dx.doi.org/10.1038/sj.onc.1201853			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671400				2022-12-17	WOS:000074261300014
J	Oldham, SM; Cox, AD; Reynolds, ER; Sizemore, NS; Coffey, RJ; Der, CJ				Oldham, SM; Cox, AD; Reynolds, ER; Sizemore, NS; Coffey, RJ; Der, CJ			Ras, but not Src, transformation of RIE-1 epithelial cells is dependent on activation of the mitogen-activated protein kinase cascade	ONCOGENE			English	Article						autocrine; epidermal growth factor receptor; Raf	NUCLEOTIDE DISSOCIATION STIMULATOR; RECEPTOR TYROSINE KINASE; ONCOGENIC RAS; PLASMA-MEMBRANE; GROWTH-FACTORS; REQUIREMENT; SUFFICIENT; EFFECTOR; PATHWAY; CAAX	Src transformation of NIH3T3 mouse fibroblasts has been shown to be dependent on Ras function. Since we recently showed that the signaling pathways that mediate Ras transformation of RIE-1 rat intestinal epithelial cells are distinct from those that cause Ras transformation of fibroblasts, we utilized three approaches to determine if Src transformation of RIE-1 cells is dependent on Ras, First, although both Ras and Src cause upregulation of an epidermal growth factor (EGF) receptor-dependent autocrine growth loop, only Ras transformation required this activity, Second, whereas both Src and Ras caused upregulation of the p42 and p44 mitogen-activated protein kinases (MAPKs), only Ras transformation was blocked by the inhibition of MAPK activation by treatment with the PD 98059 MEK inhibitor, Third, treatment with the farnesyltransferase inhibitor FTI-277 blocked Ras, but not Src, transformation. Taken together, these observations suggest that Src transformation of RIE-1 cells is not dependent on Ras, Finally, we determined that Ras activation of Raf-independent pathways alone is sufficient to cause growth transformation of RIE-1 cells. Thus, both Ras and Src cause transformation of RIE-1 cells via pathways distinct from those required to cause transformation of NIH3T3 cells.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Radiat Oncol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Vanderbilt Univ, Dept Med, Nashville, TN USA; Vanderbilt Univ, Dept Cell Biol, Nashville, TN USA; Dept Vet Affairs Med Ctr, Nashville, TN 37232 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Der, CJ (corresponding author), Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA.			Cox, Adrienne D./0000-0002-4901-2454; Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA069577, R01CA042978, R01CA063071] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42978, CA 63071, CA 69577] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aftab DT, 1997, P NATL ACAD SCI USA, V94, P3028, DOI 10.1073/pnas.94.7.3028; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; Clark G. J., 1993, GTPASES BIOL, DOI 10.1007/978-3-642-78267-1_18; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; COX AD, 1994, J BIOL CHEM, V269, P19203; Cox AD, 1997, BBA-REV CANCER, V1333, pF51, DOI 10.1016/S0304-419X(97)00011-5; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DER CJ, 1986, MOL CELL BIOL, V6, P3291, DOI 10.1128/MCB.6.9.3291; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Gangarosa LM, 1997, J BIOL CHEM, V272, P18926, DOI 10.1074/jbc.272.30.18926; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HAN LM, 1995, MOL CELL BIOL, V15, P1318; Han LM, 1997, P NATL ACAD SCI USA, V94, P4954, DOI 10.1073/pnas.94.10.4954; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; LIU XQ, 1993, ONCOGENE, V8, P1119; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; Peterson SN, 1996, J BIOL CHEM, V271, P29903, DOI 10.1074/jbc.271.47.29903; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STACEY DW, 1991, ONCOGENE, V6, P2297; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; VOGT A, 1995, J BIOL CHEM, V270, P660, DOI 10.1074/jbc.270.2.660; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wolthuis RMF, 1996, ONCOGENE, V13, P353; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	55	43	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 21	1998	16	20					2565	2573		10.1038/sj.onc.1201784	http://dx.doi.org/10.1038/sj.onc.1201784			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN934	9632133				2022-12-17	WOS:000073698200001
J	Qian, Y; Baisden, JM; Westin, EH; Guappone, AC; Koay, TC; Flynn, DC				Qian, Y; Baisden, JM; Westin, EH; Guappone, AC; Koay, TC; Flynn, DC			Src can regulate carboxy terminal interactions with AFAP-110, which influence self-association, cell localization and actin filament integrity	ONCOGENE			English	Article						Src; AFAP-110; cytoskeleton; membrane; multimer	PP60C-SRC PROTEIN-KINASE; HUMAN-COLON CARCINOMA; LEUCINE-ZIPPER; V-SRC; MUTATIONAL ANALYSIS; STABLE ASSOCIATION; TYROSINE KINASES; IDENTIFICATION; ACTIVATION; DOMAIN	The SH2 and SH3 binding partner AFAP-110 is a tyrosine phosphorylated substrate of Src, AFAP-110 has been hypothesized to link Src to actin filaments, which may contribute to the effects of Src upon actin filament integrity, However, it has been unclear what effect activated Src (Src(527F)) has upon AFAP-110 structure or function and whether AFAP-110 plays a role in actin filament integrity. We report here that the carboxy terminal 127 amino acids of AFAP-110 are comprised of an alpha-helical region that contains a leucine zipper motif, This indicated the potential of AFAP-110 to self-associate, Expression of the carboxy terminus as a fusion protein (GST-cterm) mill permit affinity absorption of cellular AFAP-110, The integrity of the alpha-helical leucine zipper motif in GST-cterm is required for affinity absorption, but binding is not due to a classical leucine zipper interaction. Co-expression of Src(527F), unlike cSrc, mill abrogate affinity absorption of AFAP-110 with GST-cterm, These data indicate that Src(527F) has affected a change in the carboxy terminal structure that renders AFAP-110 unavailable for affinity absorption. Superose chromatography demonstrate that AFAP-110 will fractionate as a monomer or multimer, indicating AFAP-110 can be detected in a self-associated form in cell lysates. Go-expression of Src(527F) resulted in AFAP-110 fractionating with a molecular weight that predicts only a multimeric population. Deletional mutagenesis also indicate a biological role for the carboxy terminus in cellular localization and actin filament integrity. Deletion of the entire carboxy terminal alpha-helix (84 amino acids) will not permit AFAP-110 to efficiently colocalize with actin filaments or the cell membrane. Deletion of only the leucine zipper region of the carboxy terminal alpha-helix (44 amino acids) from AFAP-110 (AFAPA(Delta zip)) demonstrate that both AFAP(Delta lzip) and actin filaments are repositioned into rosette-like structures, similar to the effects of Src(527F), while co-expression of AFAP-110 with cSrc will not affect actin filaments. These data indicate that AFAP-110 can play an important role in modulating actin filament integrity through carboxy terminal interactions that can be affected by Sr-527F.	W Virginia Univ, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA; W Virginia Univ, Dept Microbiol & Immunol, Morgantown, WV 26506 USA	West Virginia University; West Virginia University	Flynn, DC (corresponding author), W Virginia Univ, Mary Babb Randolph Canc Ctr, POB 9300, Morgantown, WV 26506 USA.		Baisden, Joseph/AAN-7747-2021	Baisden, Joseph/0000-0002-8986-407X	NCI NIH HHS [CA 60731] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060731, R29CA060731] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bikle DD, 1996, J BIOL CHEM, V271, P9075, DOI 10.1074/jbc.271.15.9075; BLENIS J, 1985, P NATL ACAD SCI USA, V82, P7621, DOI 10.1073/pnas.82.22.7621; BLENIS J, 1987, J BIOL CHEM, V262, P14373; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN SSL, 1993, J VIROL, V67, P3615, DOI 10.1128/JVI.67.6.3615-3619.1993; COOPER JA, 1996, BIOCH BIOPHYS ACTA G, V1287, P121; EARL PL, 1993, AIDS RES HUM RETROV, V9, P589, DOI 10.1089/aid.1993.9.589; FELICE GR, 1990, EUR J CELL BIOL, V52, P47; FLYNN DC, 1995, J BIOL CHEM, V270, P3894, DOI 10.1074/jbc.270.8.3894; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; GAMM DM, 1995, J BIOL CHEM, V270, P27380, DOI 10.1074/jbc.270.45.27380; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; Guappone AC, 1997, MOL CELL BIOCHEM, V175, P243, DOI 10.1023/A:1006840104666; GUAPPONE AC, UNPUB; GUAPPONE AC, 1996, METH CELL SCI, V18, P1; HODGES RS, 1992, CURR BIOL, V2, P22; HURST HC, 1994, PROTEIN PROFILE, V1, P123; JACKSON P, 1989, J VIROL, V63, P311, DOI 10.1128/JVI.63.1.311-318.1989; JACOBS C, 1983, CANCER RES, V43, P1696; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KITAGAWA M, 1995, BIOCHEM J, V310, P657, DOI 10.1042/bj3100657; KLEIN NJ, 1993, INT IMMUNOL, V5, P293, DOI 10.1093/intimm/5.3.293; MAEKAWA T, 1993, J CELL SCI, V105, P589; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; NORI M, 1990, MOL CELL BIOL, V10, P4155, DOI 10.1128/MCB.10.8.4155; PEARLMAN JA, 1994, FEBS LETT, V354, P183, DOI 10.1016/0014-5793(94)01119-2; QURESHI SA, 1991, ONCOGENE, V6, P995; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; ROSEN N, 1986, J BIOL CHEM, V261, P3754; Ruth P, 1997, J BIOL CHEM, V272, P10522; SARAS J, 1994, J BIOL CHEM, V269, P24082; SCHALLER MD, 1993, PROG NUCLEIC ACID RE, V44, P205, DOI 10.1016/S0079-6603(08)60221-4; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; SPANGLER R, 1989, P NATL ACAD SCI USA, V86, P7017, DOI 10.1073/pnas.86.18.7017; Staley CA, 1997, CELL GROWTH DIFFER, V8, P269; STERNBERG DW, 1993, EMBO J, V12, P323, DOI 10.1002/j.1460-2075.1993.tb05660.x; STURGILL TW, 1988, NATURE, V353, P174; Taylor SJ, 1996, BIOESSAYS, V18, P9, DOI 10.1002/bies.950180105; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U	45	43	44	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 30	1998	16	17					2185	2195		10.1038/sj.onc.1201753	http://dx.doi.org/10.1038/sj.onc.1201753			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZK226	9619827				2022-12-17	WOS:000073298000003
J	Lang, D; Miknyoczki, SJ; Huang, LY; Ruggeri, BA				Lang, D; Miknyoczki, SJ; Huang, LY; Ruggeri, BA			Stable reintroduction of wild-type p53 (MTmp53ts) causes the induction of apoptosis and neuroendocrine-like differentiation in human ductal pancreatic carcinoma cells	ONCOGENE			English	Article						p53; pancreatic cancer; neuroendocrine; differentiation; apoptosis; temperature-sensitive p53 mutant	TUMOR-SUPPRESSOR GENE; THYMOCYTE APOPTOSIS; GROWTH SUPPRESSION; INHIBITS GROWTH; CYCLE CONTROL; HL-60 CELLS; CANCER; EXPRESSION; PROTEIN; MUTANT	Pancreatic ductal adenocarcinoma is one of the major causes of cancer mortality in the industrialized world, having among the poorest prognosis of any malignancy, Mutations or alterations in the p53 tumor suppressor gene/protein are observed in 50-70% of these cancers, yet little information is available regarding the phenotypic effects of restoration of wild-type (wt) p53 function in pancreatic ductal carcinoma cells, The consequences of stable reintroduction of wt p53 on apoptosis and differentiation was examined in a poorly differentiated pancreatic carcinoma cell line (Panc-1), possessing only mutant (mt) p53 (codon 273 mutation), Cells were transfected with a temperature-sensitive mouse p53(val135) (tsp53) vector under additional control of a genetically-modified metallothionein promoter, This tsp53 has a 'mt' phenotype at 37.5 degrees C, and a 'wt' phenotype at 32.5 degrees C and the presence of 100 mu M ZnCl2. Stable expression of wt p53 caused upregulation of the p21/WAF1 gene, and G(1) growth arrest as shown by flow cytometry and BrdU labeling. Additionally, apoptosis was induced 8-12 postinduction in the majority of the cells (60-70%), as demonstrated by morphological changes, ill situ TdT labeling and internucleosomal laddering. However, a subpopulation (30%) of the transfectants survived this apoptotic fate, Unlike the epithelial parental Pane-1 cells, these cells exhibited the appearance of a neuroendocrine-like phenotype with extensive branch-like processes, and marked cytoplasmic and cytoskeletal immunostaining for tau-2, synaptophysin, and chromogranin A. These studies suggest that stable and regulated expression of wt p53 can have multiple phenotypic consequences (apoptosis and altered differentiation to a neuroendocrine-like phenotype) in poorly-differentiate pancreatic carcinoma cells.	Allegheny Univ Hlth Sci, Dept Pathol & Lab Med, Philadelphia, PA 19102 USA	Drexel University	Ruggeri, BA (corresponding author), Allegheny Univ Hlth Sci, Dept Pathol & Lab Med, Broad & Vine St, Philadelphia, PA 19102 USA.			Lang, Deborah/0000-0003-1057-0923	NATIONAL CANCER INSTITUTE [R29CA060735] Funding Source: NIH RePORTER; NCI NIH HHS [CA 60735-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; BARTON CM, 1995, BRIT J CANCER, V71, P429, DOI 10.1038/bjc.1995.88; BARTON CM, 1991, BRIT J CANCER, V64, P1076, DOI 10.1038/bjc.1991.467; BATRA SK, 1991, J CELL SCI, V100, P841; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Bold RJ, 1996, PANCREAS, V12, P189, DOI 10.1097/00006676-199603000-00014; BOND JA, 1995, CANCER RES, V55, P2404; BRENNER L, 1993, CELL GROWTH DIFFER, V4, P993; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CARSON DA, 1993, LANCET, V341, P1251, DOI 10.1016/0140-6736(93)91154-E; CIRIELLI C, 1995, INT J CANCER, V63, P673, DOI 10.1002/ijc.2910630512; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FUJIWARA T, 1993, CANCER RES, V53, P4129; GANNON JV, 1991, NATURE, V349, P802; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GULLO L, 1994, NEW ENGL J MED, V331, P81, DOI 10.1056/NEJM199407143310203; HAHN SA, 1995, SURG CLIN N AM, V75, P857, DOI 10.1016/S0039-6109(16)46732-0; HALEVY O, 1993, BIOCHEM BIOPH RES CO, V192, P714, DOI 10.1006/bbrc.1993.1473; HALL PA, 1993, CANCER SURV, V16, P135; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; HORII A, 1992, CANCER RES, V52, P6696; ISHIURA M, 1982, MOL CELL BIOL, V2, P607, DOI 10.1128/MCB.2.6.607; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KASTAN MB, 1991, CANCER RES, V51, P6304; Kimura M, 1997, ANTICANCER RES, V17, P879; KOSAKA M, 1992, ONCOGENE, V7, P2455; LIU TJ, 1994, CANCER RES, V54, P3662; LOGSDON CD, 1995, GASTROENTEROLOGY, V109, P1005, DOI 10.1016/0016-5085(95)90415-8; MAKINO T, 1990, LAB INVESTI, V62, P522; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MCNEALL J, 1989, GENE, V76, P81, DOI 10.1016/0378-1119(89)90010-3; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MULLINS TD, 1991, PANCREAS, V6, P578, DOI 10.1097/00006676-199109000-00012; MURR MM, 1994, CA-CANCER J CLIN, V44, P304, DOI 10.3322/canjclin.44.5.304; NGSEE JK, 1990, COLD SH Q B, V55, P111; PELLEGATA NS, 1994, CANCER RES, V54, P1556; RADINSKY R, 1994, ONCOGENE, V9, P1877; REDSTON MS, 1994, CANCER RES, V54, P3025; REZNEK RH, 1993, CLIN RADIOL, V47, P373, DOI 10.1016/S0009-9260(05)81056-6; Ronen D, 1996, CELL GROWTH DIFFER, V7, P21; Rosenberg L, 1996, PANCREAS, V13, P38, DOI 10.1097/00006676-199607000-00005; RUGGERI B, 1992, ONCOGENE, V7, P1503; Ruggeri BA, 1997, CANCER, V79, P700, DOI 10.1002/(SICI)1097-0142(19970215)79:4<700::AID-CNCR7>3.0.CO;2-H; RUGGERI BA, 1994, CARCINOGENESIS, V15, P1613, DOI 10.1093/carcin/15.8.1613; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAULSKY G, 1991, CANCER RES, V51, P5232; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SODDU S, 1994, BLOOD, V83, P2230, DOI 10.1182/blood.V83.8.2230.bloodjournal8382230; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; TAUPENOT L, 1995, REGUL PEPTIDES, V56, P71, DOI 10.1016/0167-0115(95)00008-Y; WANG RN, 1995, DIABETOLOGIA, V38, P1405, DOI 10.1007/BF00400600; WANG Y, 1993, J CELL BIOL, V121, P257, DOI 10.1083/jcb.121.2.257; Weyrer K, 1996, LAB INVEST, V74, P279; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	63	43	44	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 26	1998	16	12					1593	1602		10.1038/sj.onc.1201665	http://dx.doi.org/10.1038/sj.onc.1201665			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZD962	9569027				2022-12-17	WOS:000072743200010
J	Mancini, A; Niedenthal, R; Joos, H; Koch, A; Trouliaris, S; Niemann, H; Tamura, T				Mancini, A; Niedenthal, R; Joos, H; Koch, A; Trouliaris, S; Niemann, H; Tamura, T			Identification of a second Grb2 binding site in the v-Fms tyrosine kinase	ONCOGENE			English	Article						M-CSF receptor; v-Fms tyrosine kinase; Grb2; tyrosine phosphorylation; SH2 domain	FACTOR-I RECEPTOR; GREEN FLUORESCENT PROTEIN; FELINE SARCOMA-VIRUS; ONCOGENE PRODUCT; CSF-1 RECEPTOR; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; POINT MUTATION; GROWTH-FACTOR; SH2 DOMAINS	Tyrosine autophosphorylation of the v-Fms oncogene product results in the formation of high-affinity binding sites for cellular proteins containing Src homology 2 (SH2) domains. These proteins transduce various mitogenic and morphogenic signals. As reported previously, (YKNI)-K-696 in the kinase insert domain of v-Fms binds to the growth factor receptor bound protein 2 (Grb2), a stimulator of the Ras/Raf1 pathway. Here, we mapped (YTNL)-T-921 within the C-terminal domain of Fms as a novel autophosphorylation site. We demonstrate that this site constitutes a second Grb2 binding site: a recombinant fusion protein (residues 904-944) containing phosphorylated Y921 bound Grb2 from FDCP-1Mac11 cell extracts significantly more efficiently than a corresponding protein (residues 617-759) containing Y696. A yeast two-hybrid system which allowed the formation of a functional Fms tyrosine kinase was employed to quantify binding of Grb2. Fms-protein containing either one of the two phosphorylation sites bound Grb2 equally well, binding was increased for proteins carrying both sites. In contrast, the simultaneous substitution of Y696 and Y921 by phenylalanines abolished Grb2 binding. Mouse NIH3T3 cells expressing the Y921F mutant Fms-protein showed a substantially higher content of fibronectin network than wild-type transformed cells and had largely lost their serum independent growth phenotype.	HANNOVER MED SCH,INST PHYSIOL CHEM,OE 4310,D-30623 HANNOVER,GERMANY	Hannover Medical School								BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P15337; Cormack BP, 1997, MICROBIOL-UK, V143, P303, DOI 10.1099/00221287-143-2-303; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GLINIAK BC, 1990, CELL, V63, P1073, DOI 10.1016/0092-8674(90)90510-L; HAMPE A, 1984, P NATL ACAD SCI-BIOL, V81, P85, DOI 10.1073/pnas.81.1.85; Husson H, 1997, ONCOGENE, V14, P2331, DOI 10.1038/sj.onc.1201074; Joos H, 1996, J BIOL CHEM, V271, P24476, DOI 10.1074/jbc.271.40.24476; KHARBANDA S, 1995, P NATL ACAD SCI USA, V92, P6132, DOI 10.1073/pnas.92.13.6132; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.0.CO;2-L; Novak U, 1996, ONCOGENE, V13, P2607; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SMOLA U, 1991, J VIROL, V65, P6181, DOI 10.1128/JVI.65.11.6181-6187.1991; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TAMURA T, 1986, MOL CELL BIOL, V6, P4745, DOI 10.1128/MCB.6.12.4745; TAPLEY P, 1990, MOL CELL BIOL, V10, P2528, DOI 10.1128/MCB.10.6.2528; TAYOR GR, 1989, EMBO J, V8, P2029; TROULIARIS S, 1995, ARCH VIROL, V140, P179, DOI 10.1007/BF01309733; TROULIARIS S, 1995, J VIROL, V69, P6010, DOI 10.1128/JVI.69.10.6010-6020.1995; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1991, MOL CELL BIOL, V11, P4698, DOI 10.1128/MCB.11.9.4698; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; VANDERGEER P, 1990, MOL CELL BIOL, V10, P2991, DOI 10.1128/MCB.10.6.2991; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5	36	43	43	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 25	1997	15	13					1565	1572		10.1038/sj.onc.1201518	http://dx.doi.org/10.1038/sj.onc.1201518			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XX369	9380408				2022-12-17	WOS:A1997XX36900007
J	Liu, X; Han, S; Baluda, MA; Park, NH				Liu, X; Han, S; Baluda, MA; Park, NH			HPV-16 oncogenes E6 and E7 are mutagenic in normal human oral keratinocytes	ONCOGENE			English	Article						HPV; genomic integrity; p53; Rb; oral cancer	HUMAN PAPILLOMAVIRUS TYPE-16; CELL NUCLEAR ANTIGEN; DNA-DAMAGE; SHUTTLE VECTOR; UV-IRRADIATION; G(1) ARREST; P53 PROTEIN; GADD45; EXPRESSION; REPAIR	The mutation frequency of pS189 shuttle vector plasmids is higher in human oral keratinocytes (NHOK) immortalized with cloned human papillomavirus-16 (HPV-16) genome than in primary normal NHOK OVHOK), To determine whether oncoproteins E6 and E7 of HPV-16 are responsible for the higher mutation frequency of the plasmids, we measured the mutation frequency in NHOK and in NHOK expressing the HPV-16 oncogenes (E6, E7, or E6 plus E7). We also measured the mutation frequency in NHOK expressing the E6 or E7 proteins of the non-oncogenic HPV-6b, The mutation frequency, either background or N-methyl-M-nitro-N-nitrosoguanidine (MNNG)-induced, in NHOK expressing the HPV-16 oncoproteins (E6, E7, or E6 plus E7) was significantly higher than in NHOK, The HPV-16 oncogenes did not alter the nature of the MNNG-induced mutations (G:C-->A:T), but increased the frequency of deletions and insertions with or without MNNG, The background or MNNG-induced mutation frequency in NHOK expressing the HPV-6b E6 or E7 proteins was the same as in NHOK, NHOK and NHOK expressing HPV6b-E6 or E7 were able to arrest the cell cycle and enhance cellular p53, p21(WAF1/ClP1) and Gadd45 levels when exposed to MNNG, whereas NHOK expressing the HPV-16 E6 oncogene did not demonstrate, NHOK expressing HPV-16 E7 were able to enhance cellular p53, p21(WAF1/ClP1), and Gadd45 levels, but failed to arrest cell cycle progression when exposed to MNNG, These data indicate that HPV-16 E6 and E7 oncogenes are mutagenic in human oral keratinocytes and enhance the mutagenic effect of MNNG, However, the E6 and E7 proteins of the 'low risk' HPV-6b did not demonstrate such an ability.	UNIV CALIF LOS ANGELES,INST DENT RES,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH DENT,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NIDCR NIH HHS [DE11229, DE10049, DE00371] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [K15DE000371, R01DE011229, R01DE010049] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AYYAGARI R, 1995, MOL CELL BIOL, V15, P4420; BAEK JH, 1994, INT J ONCOL, V5, P1023; BREDBERG A, 1986, P NATL ACAD SCI USA, V83, P8273, DOI 10.1073/pnas.83.21.8273; BURNS PA, 1987, J MOL BIOL, V194, P385, DOI 10.1016/0022-2836(87)90668-1; Demers GW, 1996, J VIROL, V70, P6862, DOI 10.1128/JVI.70.10.6862-6869.1996; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HARPER JW, 1993, CELL, V75, P805; HAVRE PA, 1995, CANCER RES, V55, P4420; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; KASTAN MB, 1991, CANCER RES, V51, P6304; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MIN BM, 1994, ORAL ONCOL, V30B, P338, DOI 10.1016/0964-1955(94)90036-1; PARK NH, 1995, ONCOGENE, V10, P2145; PARK NH, 1991, CARCINOGENESIS, V12, P1627, DOI 10.1093/carcin/12.9.1627; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEIDMAN M, 1989, MUTAT RES, V220, P55, DOI 10.1016/0165-1110(89)90010-9; SEIDMAN MM, 1987, P NATL ACAD SCI USA, V84, P4944, DOI 10.1073/pnas.84.14.4944; SHILLITOE EJ, 1993, CANCER RES, V53, P2189; SHIN KH, 1994, MOL CARCINOGEN, V9, P76, DOI 10.1002/mc.2940090205; Shin KH, 1996, ONCOGENE, V12, P1089; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SMITH ML, 1995, ONCOGENE, V10, P1053; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STARY A, 1992, MUTAT RES, V272, P101, DOI 10.1016/0165-1161(92)90038-N; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHAN QM, 1994, CANCER RES, V54, P2755	34	43	45	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 15	1997	14	19					2347	2353		10.1038/sj.onc.1201078	http://dx.doi.org/10.1038/sj.onc.1201078			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WY883	9178911				2022-12-17	WOS:A1997WY88300012
J	Franks, RR; Rencic, A; Gordon, J; Zoltick, PW; Curtis, M; Knobler, RL; Khalili, K				Franks, RR; Rencic, A; Gordon, J; Zoltick, PW; Curtis, M; Knobler, RL; Khalili, K			Formation of undifferentiated mesenteric tumors in transgenic mice expressing human neurotropic polyomavirus early protein	ONCOGENE			English	Article						T-antigen; JCV; animal model for CNS tumors	PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; HUMAN PAPOVAVIRUS JC; DNA-BINDING PROTEIN; HUMAN-BRAIN; STIMULATES TRANSCRIPTION; EARLY REGION; VIRUS; PROMOTER; DYSMYELINATION; INDUCTION	The human polyomavirus, JCV, is the established etiologic agent of the human demyelinating disease, progressive multifocal leukoencephalopathy (PML) seen in immunosuppressed individuals. In PML patients, the viral early protein, which is produced exclusively in glial cells is responsible for initiation of the viral lytic cycle. The JCV early protein, T-antigen, has greater than 70% homology to the web characterized SV40 early protein which has established oncogenic properties. To investigate the role of JCV T-antigen in tumorigenesis, transgenic mice containing the viral early genome were produced. Of the four positive transgenic animals, one developed severe neurological abnormalities and succumbed to death at 3 weeks of age. Another animal died with no visible gross pathology and the cause of death was not determined. The remaining two founders developed massive, undifferentiated, solid mesenteric tumors with no obvious neurological symptoms. Results from histologic analysis demonstrated the presence of highly cellular, poorly differentiated neoplastic cells in the tumor tissue. Electron microscopic evaluation of the tumor revealed the presence of a small blue cell-like tumor of epithelial/neuroectodermal origin. Results from RNA analysis by non-quantitative and highly sensitive RT-PCR indicated the presence of the JCV early transcript in various tissues, including kidney, liver, spleen, heart, lung, and brain, as well as in the tumors. However, analysis of the viral early protein by Western blot and immunohistochemistry indicated high level production of JCV early protein in the tumor tissue, but not in any other tissues. These observations present the first evidence for the development of inheritable neuroectodermal tumors induced by the human polyomavirus, JCV, early protein in a whole animal system.	THOMAS JEFFERSON UNIV,DEPT BIOCHEM & MOLEC BIOL,JEFFERSON INST MOLEC MED,MOLEC NEUROVIROL SECT,PHILADELPHIA,PA 19107; UNIV ILLINOIS,COLL MED,DEPT GENET,CHICAGO,IL 60612; THOMAS JEFFERSON UNIV,DEPT PATHOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT NEUROL,PHILADELPHIA,PA 19107	Jefferson University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Jefferson University; Jefferson University								AHMED S, 1990, J BIOL CHEM, V265, P13899; AMEMIYA K, 1989, J BIOL CHEM, V264, P7025; Ausubel F.M., 1989, SHORT PROTOCOLS MOL; BERGER JR, 1995, J NEUROVIROL, V1, P5, DOI 10.3109/13550289509111006; CASTAIGNE P, 1974, REV NEUROL-FRANCE, V130, P379; CHEN NN, 1995, P NATL ACAD SCI USA, V92, P1087, DOI 10.1073/pnas.92.4.1087; FEIGENBAUM L, 1987, P NATL ACAD SCI USA, V84, P3695, DOI 10.1073/pnas.84.11.3695; FEIGENBAUM L, 1992, J VIROL, V66, P1176, DOI 10.1128/JVI.66.2.1176-1182.1992; Flint S. J, 1981, DNA TUMOR VIRUSES; Frisque RJ, 1992, MOL NEUROVIROLOGY PA, P25; GIARUSSO MH, 1978, J NEUROL SCI, V35, P391, DOI 10.1016/0022-510X(78)90019-9; GORDON JW, 1983, METHOD ENZYMOL, V101, P411; HAAS S, 1994, VIROLOGY, V202, P89, DOI 10.1006/viro.1994.1325; HOUFF SA, 1983, POLYOMAVIRUSES NEURO, P223; KENNEY S, 1984, SCIENCE, V226, P1337, DOI 10.1126/science.6095453; KERR D, 1991, J BIOL CHEM, V266, P15876; KHALILI K, 1988, EMBO J, V7, P1205, DOI 10.1002/j.1460-2075.1988.tb02932.x; LONDON WT, 1978, SCIENCE, V201, P1246, DOI 10.1126/science.211583; MAJOR EO, 1992, CLIN MICROBIOL REV, V5, P49, DOI 10.1128/CMR.5.1.49-73.1992; OHSUMI S, 1986, ACTA PATHOL JAPON, V36, P815; PADGETT BL, 1977, CANCER RES, V37, P718; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; RAJ GV, 1994, MOL CELL BIOL, V14, P7770, DOI 10.1128/MCB.14.12.7770; RAJ GV, 1995, VIROLOGY, V213, P283, DOI 10.1006/viro.1995.0001; SIMA AAF, 1983, ANN NEUROL, V14, P183, DOI 10.1002/ana.410140205; SMALL JA, 1986, CELL, V46, P13, DOI 10.1016/0092-8674(86)90855-X; SMALL JA, 1986, P NATL ACAD SCI USA, V83, P8288, DOI 10.1073/pnas.83.21.8288; SOBRINHOSIMOES M, 1990, ARCH PATHOL LAB MED, V114, P369; TADA H, 1989, J VIROL, V63, P463, DOI 10.1128/JVI.63.1.463-466.1989; TADA H, 1991, VIROLOGY, V180, P327, DOI 10.1016/0042-6822(91)90037-C; TADA H, 1992, J VIROL, V66, P6885, DOI 10.1128/JVI.66.12.6885-6892.1992; TRAPP BD, 1988, ANN NEUROL, V23, P38, DOI 10.1002/ana.410230108; VARAKIS J, 1978, CANCER RES, V38, P1718; WALKER DL, 1973, SCIENCE, V181, P674, DOI 10.1126/science.181.4100.674; ZURHEIN GM, 1983, POLYOMAVIRUSES HUMAN, P205	35	43	44	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2573	2578						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700516				2022-12-17	WOS:A1996UW48700011
J	Duprez, E; Lillehaug, JR; Gaub, MP; Lanotte, M				Duprez, E; Lillehaug, JR; Gaub, MP; Lanotte, M			Differential changes of retinoid-X-receptor (RXR alpha) and its RAR alpha and PML-RAR alpha partners induced by retinoic acid and cAMP distinguish maturation sensitive and resistant t(15;17) promyelocytic leukemia NB4 cells	ONCOGENE			English	Article						acute promyelocytic leukemia; retinoic acid; nuclear receptor superfamily; transcription factors; differentiation; NB4 cells	TRANSLOCATION; PROTEIN; EXPRESSION; GENE; LINE; RNA; BREAKPOINT; EXTRACTION; LOCUS	The expression of retinoid receptors (RXR alpha, RAR alpha and the chimeric form PML-RAR alpha) was analysed both at the mRNA and protein level in the maturation sensitive NB4 and resistant NB4-R1 cell lines of t(15;17) promyelocytic leukemia (APL), All-trans RA and cAMP which show synergistic activity in inducing maturation of NB4 cells and maturation triggering of the RA 'primed' NB4-R1 resistant cells, distinctly modulate RXR alpha, RAR alpha and PML-RAR alpha mRNA. In the NB4 and NB4-R1 cells, RXR alpha mRNA was downregulated by RA, but only in RA-primed NB4-R1 cells a release from RXR alpha mRNA downregulation was obtained by cAMP treatment, RXR alpha protein (53 kDa) was decreased to the western-blot detection limit (97.5%) by RA in NB4 cells, but in NB4-R1 cells although it was frankly decreased (85%), the signal for RXR alpha protein remained very significant, More importantly, while cAMP slightly upregulated RXR alpha protein in RA-treated NB4 cells, it caused an increase of RXR alpha protein in RA-treated NB4-R1 cells bringing RXR alpha to the initial control level, RXR alpha partners in heterodimers (PML-RAR alpha, RAR alpha) were also analysed, In contrast to RXR alpha, RAR alpha and PML-RAR alpha mRNA were not modulated by RA and/or cAMP, while significant changes were observed at the protein levels, A putatively phosphorylated form of RAR alpha (52 kDa) during maturation of NB4 cells, but was in resistant NB4-R1 cells, Conversely, while PML-RAR alpha remained stable during RA-induced NB4 maturation, RA treatment which failed to induce maturation of NB4-R1 cells significantly down-regulated the chimeric receptor (120 kDa), These likely results from translational and post-translational regulation, This work reveals complex pattern of subtle changes at the protein level distinguishing RA-sensitive and RA-resistant cells, Our data show that the RA-cAMP synergistic effect on NB4 cell maturation and cooperation in triggering maturation of RA-primed NB4-R1 cells operate changes in the RXR/ PML-RAR alpha ratio which are both favouring RXR alpha. In both cell lines, variations of PML-RAR alpha and RXR alpha may result in a decrease in the formation of the PML-RAR alpha/RXR alpha heterodimers which are supposed involved in the block of maturation, This may prove crucial to embark cells on maturation.	HOP ST LOUIS,CTR G HAYEM,INSERM U301,F-75010 PARIS,FRANCE; IGBMC,INSERM U184,F-67404 ILLKIRCH GRAFFENS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)			duprez, estelle a/R-2357-2016					ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; BAIN G, 1994, BIOCHEM BIOPH RES CO, V200, P1252, DOI 10.1006/bbrc.1994.1585; BORDEN K, 1985, EMBO J, V14, P1532; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BRUEL A, 1995, LEUKEMIA, V9, P1173; CHEN A, 1994, BLOOD, V84, P2122, DOI 10.1182/blood.V84.7.2122.bloodjournal8472122; CHEN Z, 1990, LEUKEMIA, V5, P288; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DERMIME S, 1993, BLOOD, V82, P1573; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DIGMAN JDL, 1983, NUCLEIC ACIDS RES, V11, P1495; Duprez E, 1996, ONCOGENE, V12, P2451; DUPREZ E, 1992, LEUKEMIA, V6, P1281; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; FAGIOLI M, 1992, ONCOGENE, V7, P1083; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; GIANNI M, 1995, BLOOD, V85, P3619, DOI 10.1182/blood.V85.12.3619.bloodjournal85123619; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GREEN S, 1993, NATURE, V361, P590, DOI 10.1038/361590a0; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Gudas Lorraine J., 1994, P443; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; HUGGENVIK JI, 1993, MOL ENDOCRINOL, V7, P543, DOI 10.1210/me.7.4.543; KAKIZUKA A, 1991, CELL, V66, P653; Kastner P., 1994, Vitamin A in health and disease., P189; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KIZAKI M, 1993, BLOOD, V82, P3592; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LANOTTE M, 1991, BLOOD, V77, P1080; LAVAU C, 1994, LEUKEMIA, V8, P1615; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; Mangelsdorf David J., 1994, P319; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; MUINDI J, 1992, BLOOD, V79, P299; OLSON IL, 1982, CANCER RES, V42, P3922; PEMRICK SM, 1994, LEUKEMIA, V8, P1797; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; ROWLEY JD, 1977, LANCET, V1, P549; RUCHAUD S, 1994, P NATL ACAD SCI USA, V91, P8428, DOI 10.1073/pnas.91.18.8428; WAN YJY, 1994, EXP CELL RES, V210, P56, DOI 10.1006/excr.1994.1009; WARRELL RP, 1993, BLOOD, V82, P1949, DOI 10.1182/blood.V82.7.1949.bloodjournal8271949; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0	53	43	43	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2443	2450						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649786				2022-12-17	WOS:A1996UQ22000023
J	Enders, GH; Koh, J; Missero, C; Rustgi, AK; Harlow, E				Enders, GH; Koh, J; Missero, C; Rustgi, AK; Harlow, E			p16 inhibition of transformed and primary squamous epithelial cells	ONCOGENE			English	Article						p16; esophageal squamous cell carcinoma; retinoblastoma protein; squamous epithelial	RETINOBLASTOMA PROTEIN; CYCLE CONTROL; PHOSPHORYLATION; DIFFERENTIATION; MOUSE; GENE	We and others have recently shown that p16 can potently and specifically inhibit progression through the G1 phase of the replicative cycle in cells that express the retinoblastoma protein (pRB). However, none of these studies examined cell types in which p16 has been firmly implicated in tumorigenesis. We predicted that such cells would show sensitivity to p16 inhibition, perhaps conferred by proteins in addition to or other than pRB. Intragenic, inactivating mutations of p16 have been found at significant frequency in primary tumors derived from squamous epithelial cells of the esophagus (ESCC). We therefore examined p16 function in ESCC lines and in primary squamous epithelial cells cultured from mouse skin. We find that seven of eight ESCC lines tested are inhibited by p16 and fail to express the protein endogenously. The lone p16-resistant line expresses endogenous p16 but lacks functional pRB. Primary squamous epithelial cells are also inhibited by p16. These data suggest that squamous epithelial cells are generally sensitive to inhibition by a regulatory pathway that involves p16 and pRB, and that, by the time of establishment in culture, there is nearly universal inactivation of this pathway in ESCCs.	MASSACHUSETTS GEN HOSP,GASTROINTESTINAL UNIT,BOSTON,MA 02129; MASSACHUSETTS GEN HOSP,CUTANEOUS BIOL RES CTR,BOSTON,MA 02129	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Enders, GH (corresponding author), MASSACHUSETTS GEN HOSP,CTR CANC,BOSTON,MA 02129, USA.			Missero, Caterina/0000-0003-0905-5123				ARAP W, 1995, CANCER RES, V55, P1351; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; FILVAROFF E, 1990, MOL CELL BIOL, V10, P1164, DOI 10.1128/MCB.10.3.1164; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HARLOW E, 1988, ANTIBODIES; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; IGAKI H, 1994, BIOCHEM BIOPH RES CO, V203, P1090, DOI 10.1006/bbrc.1994.2294; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LEES JA, 1992, EMBO J, V359, P288; LIU QY, 1995, ONCOGENE, V10, P619; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MORI T, 1994, CANCER RES, V54, P3396; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1995, CANCER RES, V55, P1448; OTTERSON GA, 1994, ONCOGENE, V9, P3375; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; REED JA, 1995, CANCER RES, V55, P2713; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHEW JY, 1989, ONCOGENE RES, V4, P205; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TSAI LH, 1993, ONCOGENE, V8, P1593; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; ZHOU XL, 1994, ONCOGENE, V9, P3737; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	36	43	43	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1239	1245						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649826				2022-12-17	WOS:A1996UC06700009
J	Rao, G; Alland, L; Guida, P; SchreiberAgus, N; Chen, K; Chin, L; Rochelle, JM; Seldin, MF; Skoultchi, AI; DePinho, RA				Rao, G; Alland, L; Guida, P; SchreiberAgus, N; Chen, K; Chin, L; Rochelle, JM; Seldin, MF; Skoultchi, AI; DePinho, RA			Mouse Sin3A interacts with and can functionally substitute for the aminoterminal repression domain of the Myc antagonist Mxi1	ONCOGENE			English	Article						mSin3A; Mxi1; Myc; repression; cotransformation; PAH domain	C-MYC; ERYTHROLEUKEMIA-CELLS; DNA-BINDING; TRANSCRIPTIONAL REPRESSION; SACCHAROMYCES-CEREVISIAE; LINKAGE MAP; EXPRESSION; PROTEIN; DIFFERENTIATION; ONCOGENE	Mxi1 is a basic region helix-loop-helix leucine zipper (bHLH/LZ) protein that, in association with Max, antagonizes Myc oncogenic activities. A possible mechanistic basis for Mxi1-mediated repression was provided by the recent demonstration that the repressive potential of Mxi1 correlates with its ability to physically associate with mSin3B, one of two mammalian homologues of the yeast transcriptional repressor SIN3. Here, we sought to characterize more fully the physical properties of the second homologue, mSin3A and to determine whether the recruitment of mSin3A by Mxi1 is indeed required for anti-Myc activity. Transient transfection of mammalian cells showed that the mSin3A protein can associate with the strong repressive isoform of Mxi1 (Mxi1-SR) and that, like other Myc superfamily members, both mSin3A and Mxi1-SR localize to the nucleus. From a developmental standpoint, a comparative analysis of Myc, Mxi1-SR and Sin3A expression during postnatal mouse development and in differentiating mouse erythroleukemia (MEL) cells revealed that dramatic and reciprocal changes in Myc and Mxi1-SR mRNA levels are accompanied by minimal stage-specific changes in mSin3A gene expression. This constant expression profile, coupled with the observation that over-expression of mSin3A does not augment the anti-Myc activity of Mxi1-SR in the rat embryo fibroblast (REF) transformation assay, suggests that mSin3A is not a limiting factor in the regulation of Myc superfamily function. Finally, a mSin3A-Mxi1 fusion protein, in which the amino terminal mSin3-interacting domain of Mxi1-SR was replaced with the full-length mSin3A, exhibited a level of repression activity equivalent to, or greater than, the level of repression obtained with Mxi1-SR. Taken together, these observations directly demonstrate that the amino-terminal repression domain of Mxi1-SR functions solely to recruit mSin3A and possibly other proteins like mSin3A and this association is necessary for the anti-Myc activity of Mxi1-SR.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MICROBIOL & IMMUNOL, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT CELL BIOL, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MED, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DIV PEDIAT HEMATOL ONCOL, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DIV DERMATOL, BRONX, NY 10461 USA; DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MICROBIOL, DURHAM, NC 27710 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Duke University; Duke University				DePinho, Ronald/0000-0002-5625-577X	NATIONAL CANCER INSTITUTE [R37CA016368, T32CA009173] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000194] Funding Source: NIH RePORTER; NCI NIH HHS [RT32CA-09173, 5R37CA16368] Funding Source: Medline; NIA NIH HHS [2T32AG00194] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BARBU V, 1989, NUCLEIC ACIDS RES, V17, P7115, DOI 10.1093/nar/17.17.7115; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BISHOP D T, 1985, Genetic Epidemiology, V2, P349, DOI 10.1002/gepi.1370020404; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOULIKAS T, 1994, J CELL BIOCHEM, V55, P32, DOI 10.1002/jcb.240550106; CHEN J, 1995, NAT MED, V1, P638, DOI 10.1038/nm0795-638; CHIN L, 1995, P NATL ACAD SCI USA, V92, P8488, DOI 10.1073/pnas.92.18.8488; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DELGADO MD, 1995, ONCOGENE, V10, P1659; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DUNN BK, 1994, CELL GROWTH DIFFER, V5, P847; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; EDELHOFF S, 1994, ONCOGENE, V9, P665; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; FASANO O, 1983, Journal of Molecular and Applied Genetics, V2, P173; Green EL, 1981, GENETICS PROBABILITY, P77; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HALLECK MS, 1995, GENOMICS, V26, P403, DOI 10.1016/0888-7543(95)80229-F; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; HOWARD TA, 1991, GENOMICS, V10, P207, DOI 10.1016/0888-7543(91)90502-6; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LACHMAN HM, 1986, P NATL ACAD SCI USA, V83, P6480, DOI 10.1073/pnas.83.17.6480; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LARSSON LG, 1994, ONCOGENE, V9, P1247; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORGENBESSER SD, 1994, SEMIN CANCER BIOL, V5, P21; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; NAWAZ Z, 1994, MOL GEN GENET, V245, P724, DOI 10.1007/BF00297279; NISHIZAWA M, 1994, MOL GEN GENET, V245, P301, DOI 10.1007/BF00290110; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; PULVERER BJ, 1994, ONCOGENE, V9, P59; ROY B, 1985, CELL BIO INT, V19, P307; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SAUER F, 1995, NATURE, V375, P162, DOI 10.1038/375162a0; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SELDIN MF, 1991, GENOMICS, V9, P678, DOI 10.1016/0888-7543(91)90361-H; SHIMIZU E, 1995, GENE, V152, P283, DOI 10.1016/0378-1119(94)00722-5; TZAMARIAS D, 1995, GENE DEV, V9, P821, DOI 10.1101/gad.9.7.821; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; VIDAL M, 1991, MOL CELL BIOL, V11, P6306, DOI 10.1128/MCB.11.12.6306; WANG HM, 1993, MOL CELL BIOL, V13, P1805, DOI 10.1128/MCB.13.3.1805; WANG HM, 1990, MOL CELL BIOL, V10, P5927, DOI 10.1128/MCB.10.11.5927; WATKINS S, 1995, CURRENT PROTOCOLS MO; WILLIAMS FE, 1991, MOL CELL BIOL, V11, P3307, DOI 10.1128/MCB.11.6.3307; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	63	43	44	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	1996	12	5					1165	1172						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649810				2022-12-17	WOS:A1996UA88400027
J	Cowell, JK; Bia, B; Akoulitchev, A				Cowell, JK; Bia, B; Akoulitchev, A			A novel mutation in the promotor region in a family with a mild form of retinoblastoma indicates the location of a new regulatory domain for the RB1 gene	ONCOGENE			English	Article						RB1 gene; promoter; mutation	ONCOGENIC POINT MUTATIONS; HEREDITARY RETINOBLASTOMA; PENETRANCE; IDENTIFICATION; TRANSCRIPTION; CHROMOSOME-13; GERMLINE; LINKAGE	We describe a family segregating the retinoblastoma phenotype where the affected individuals have only unifocal tumours and where linkage analysis has identified unaffected mutant gene carriers. DNA from members of this 'low penetrance' pedigree was subjected to an exon-by-exon SSCP analysis of the RB1 gene, No mutations were found in the 27 exons of the coding region but an SSCP band shift was seen for PCR products covering the RB1 promotor region. Sequencing identified a G-->C change within a GGGCGG motif which is the core of the recognition sequence of the SP1 transcription factor. Electromobility shift assays demonstrated that SP1 does not bind to oligomers from this region of the RB1 promotor but bandshifts were seen for an, as yet, unidentified protein(s) which was not seen using an oligomer containing the G-->C mutation. Thus, identification of a naturally occurring mutation in a family with only 'mild' phenotypes has identified another regulatory sequence in the RB1 promotor which binds an endogenous cellular protein(s). Identification of this protein should allow a better understanding of the control of expression of the RB1 gene.	INST CHILD HLTH,IMPERIAL CANC RES FUND,ONCOL GRP,LONDON WC1N 1EH,ENGLAND; ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,RES LABS,HOWARD HUGHES MED INST,PISCATAWAY,NJ 08854	Cancer Research UK; University of London; University College London; Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center	Cowell, JK (corresponding author), CLEVELAND CLIN FDN,RES INST,DEPT NEUROSCI,9500 EUCLID AVE,NC30,CLEVELAND,OH 44195, USA.			Cowell, John/0000-0002-2079-5950				BLANQUET V, 1993, HUM MOL GENET, V2, P975, DOI 10.1093/hmg/2.7.975; CAVANEE WK, 1983, NATURE, V305, P779; COMINGS DE, 1973, P NATL ACAD SCI USA, V70, P3324, DOI 10.1073/pnas.70.12.3324; CONNOLLY MJ, 1983, HUM GENET, V65, P122, DOI 10.1007/BF00286647; Cowell John K., 1994, European Journal of Human Genetics, V2, P281; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRAPER GJ, 1992, BRIT J CANCER, V66, P211, DOI 10.1038/bjc.1992.244; DRYJA TP, 1993, AM J HUM GENET, V52, P1122; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; HOGG A, 1992, ONCOGENE, V7, P1445; HOGG A, 1993, P NATL ACAD SCI USA, V90, P7351, DOI 10.1073/pnas.90.15.7351; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KRATZKE RA, 1994, ONCOGENE, V9, P1321; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; OHTANIFUJITA N, 1994, ONCOGENE, V9, P1703; ONADIM Z, 1992, P NATL ACAD SCI USA, V89, P6177, DOI 10.1073/pnas.89.13.6177; ONADIM Z, 1991, BRIT J OPHTHALMOL, V75, P147, DOI 10.1136/bjo.75.3.147; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SAVOYSKY E, 1994, ONCOGENE, V9, P1839; SHIMIZU T, 1994, AM J HUM GENET, V54, P793; SPARKES RS, 1983, SCIENCE, V219, P971, DOI 10.1126/science.6823558; VOGEL F, 1979, HUM GENET, V52, P1; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501; YUNIS JJ, 1978, AM J DIS CHILD, V132, P161, DOI 10.1001/archpedi.1978.02120270059012	27	43	43	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					431	436						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570221				2022-12-17	WOS:A1996TR53800023
J	FERRAO, P; MACMILLAN, EM; ASHMAN, LK; GONDA, TJ				FERRAO, P; MACMILLAN, EM; ASHMAN, LK; GONDA, TJ			ENFORCED EXPRESSION OF FULL-LENGTH C-MYB LEADS TO DENSITY-DEPENDENT TRANSFORMATION OF MURINE HEMATOPOIETIC-CELLS	ONCOGENE			English	Article						MYB; TRANSFORMATION; FULL-LENGTH; DENSITY-DEPENDENCE; RETROVIRUS	AVIAN-MYELOBLASTOSIS VIRUS; PLASMACYTOID LYMPHOSARCOMAS; ERYTHROLEUKEMIA-CELLS; HEMATOPOIETIC-CELLS; PROTEIN TRUNCATION; ONCOGENE PRODUCT; COLON-CARCINOMA; DNA-BINDING; ACTIVATION; DIFFERENTIATION	The oncogenic activation of c-myb has been associated with structural alterations to the Myb protein. Although such alterations can increase the ability of Myb to transform haemopoietic cells, it has been unresolved whether over-expression of wild type (WT) c-Myb can lead to transformation. We show here that infection with a retrovirus that expresses WT i.e. full length c-Myb leads to transformation of primary haemopoietic cells (as indicated by clonogenic assays). The transformed cells are similar to those obtained with carboxyl-truncated (CT) c-Myb in that they show phenotypic and morphological characteristics of early myeloid cells and remain dependent on exogenous growth factors. Cells expressing WTMyb form lower numbers of colonies on average and have a greater tendency to spontaneously differentiate than those expressing truncated c-Myb. Additionally, our results show that transformation by both forms of Myb is dependent on the density at which the infected cells are cultured, and that low levels of transformation can be increased by addition of conditioned medium from myb transformed cells grown at high density. This implies that transformation can be enhanced by the effects of an autocrine growth factor. Moreover, the production of, or sensitivity to, such a factor may be influenced by Myb itself, since CT Myb-infected cells cultured at low densities show higher levels of transformation than WT Myb-infected cells.	INST MED & VET SCI,DIV HUMAN IMMUNOL,ADELAIDE,SA 5000,AUSTRALIA; INST MED & VET SCI,HANSON CTR CANC RES,ADELAIDE,SA 5000,AUSTRALIA; INST MED & VET SCI,DIV HAEMATOL,LEUKAEMIA RES UNIT,ADELAIDE,SA 5000,AUSTRALIA	Institute Medical & Veterinary Science Australia; Institute Medical & Veterinary Science Australia; Institute Medical & Veterinary Science Australia			ASHMAN, LEONIE/G-7631-2013	ASHMAN, LEONIE/0000-0003-3559-3611				ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; BARTELLA C, 1987, SCIENCE, V235, P1064; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CUDDIHY AE, 1993, MOL CELL BIOL, V13, P3505, DOI 10.1128/MCB.13.6.3505; GARRIDO C, 1992, J VIROL, V66, P6773, DOI 10.1128/JVI.66.11.6773-6776.1992; GONDA TJ, 1987, J VIROL, V61, P2754, DOI 10.1128/JVI.61.9.2754-2763.1987; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GONDA TJ, 1993, BLOOD, V82, P2813; GONDA TJ, 1991, SEMINARS VIROLOGY, V2, P351; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HU YL, 1991, ONCOGENE, V6, P1549; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; LAVU S, 1986, NUCLEIC ACIDS RES, V14, P5309, DOI 10.1093/nar/14.13.5309; MACMILLAN EM, 1994, BLOOD, V83, P209; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; METCALF D, 1982, INT J CANCER, V30, P773, DOI 10.1002/ijc.2910300616; MUSHINSKI JF, 1983, SCIENCE, V220, P795, DOI 10.1126/science.6687762; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; PELICCI PG, 1984, SCIENCE, V224, P1117, DOI 10.1126/science.6585957; RAMSAY RG, 1989, ONCOGENE RES, V4, P259; RAYNER JR, 1994, MOL CELL BIOL, V14, P880, DOI 10.1128/MCB.14.2.880; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SHENONG GLC, 1984, SCIENCE, V226, P1077, DOI 10.1126/science.6093260; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SHENONG GLC, 1986, MOL CELL BIOL, V6, P380, DOI 10.1128/MCB.6.2.380; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; WEINSTEIN Y, 1987, J VIROL, V61, P2339, DOI 10.1128/JVI.61.7.2339-2343.1987; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; WINQVIST R, 1985, CANCER GENET CYTOGEN, V18, P251, DOI 10.1016/0165-4608(85)90090-1; YANAGISAWA H, 1991, BIOCHIM BIOPHYS ACTA, V1088, P3810	38	43	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1631	1638						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478588				2022-12-17	WOS:A1995TC53500022
J	HAWLEY, RG; FONG, AZC; NGAN, BY; HAWLEY, TS				HAWLEY, RG; FONG, AZC; NGAN, BY; HAWLEY, TS			HEMATOPOIETIC TRANSFORMING POTENTIAL OF ACTIVATED RAS IN CHIMERIC MICE	ONCOGENE			English	Article						RAS ONCOGENE; LEUKEMOGENESIS; MSCV RETROVIRAL VECTOR	ACUTE MYELOID-LEUKEMIA; MURINE SARCOMA-VIRUS; CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; CELL ANTIGEN RECEPTOR; MODIFIED BONE-MARROW; V-HA-RAS; NUCLEOTIDE-SEQUENCE; GENE-TRANSFER; MYELOPROLIFERATIVE DISEASE	Although activating mutations in ras genes are the most common genetic abnormality in human hematologic malignancies, the role of ras mutations as an initiating event in leukemogenesis remains unclear, To assess the consequences of ectopic expression of an activated ras gene in normal hematopoietic cells in vivo, lethally irradiated mice were reconstituted with bone marrow cells infected with a mutant ras-containing retrovirus [murine stem cell virus (MSCV)-v-H-ras] based on the MSCV retroviral vector which efficiently transduces functional genes into hematopoietic stem/progenitor cells, Despite a marked myeloid leukocytosis detectable in the peripheral blood within 4 weeks of engraftment, none of 22 primary or secondary transplant recipients studied for longer periods of time presented with myeloid neoplasms, Instead, 18 of the MSCV-v-H-ras mice developed pre-T-celI thymic lymphomas and/or pre-B-cell lymphoblastic leukemia/lymphomas between 7 and 12 weeks post-transplantation. The pre-B and pre-T lymphoid tumors that arose in one animal were shown to harbor a; common MSCV-v-H-ras provirus, indicating that the target cell for transformation was a bipotential lymphoid precursor. To more precisely examine the effects of activated ras expression on the behavior of hematopoietic progenitors, infected bone marrow cells were assayed in methylcellulose cultures under conditions favorable for growth of multilineage myeloid colonies or were passaged as bulk suspension cultures in the presence of various hematopoietic growth factors, including interleukin (IL)-3, IL-4, IL-6 and IL-7. MSCV-directed expression of v-H-ras selectively promoted the formation of large dense colonies comprised of monocyte-macrophages in methylcellulose cultures. When transferred to liquid cultures, the vast majority of the cells underwent terminal macrophage differentiation, By comparison, tumorigenic B-lymphoid and mixed lymphoid/myeloid cell lines were routinely established from the bulk suspension cultures, with cell lines of predominantly myeloid phenotype emerging only in IL-6-supplemented cultures/ These results, considered together with previous findings, suggest that activating ras mutations could be an initiating genetic alteration in human acute lymphoblastic leukemia but are more Likely to be a postinitiation change in human acute myeloid leukemia.	UNIV TORONTO, SUNNYBROOK HLTH SCI CTR, DEPT MED BIOPHYS, TORONTO, ON M4N 3M5, CANADA; UNIV TORONTO, SUNNYBROOK HLTH SCI CTR, DEPT PATHOL, TORONTO, ON M4N 3M5, CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	HAWLEY, RG (corresponding author), UNIV TORONTO, SUNNYBROOK HLTH SCI CTR, DIV CANC BIOL, 2075 BAYVIEW AVE, TORONTO, ON M4N 3M5, CANADA.			Hawley, Robert/0000-0003-3512-5818				ADAMS JM, 1991, BIOCHIM BIOPHYS ACTA, V1072, P9, DOI 10.1016/0304-419X(91)90004-5; AHUJA HG, 1990, BLOOD, V75, P1684; ALT FW, 1984, EMBO J, V3, P1209, DOI 10.1002/j.1460-2075.1984.tb01955.x; ALT FW, 1986, IMMUNOL REV, V89, P5, DOI 10.1111/j.1600-065X.1986.tb01470.x; ANTICA M, 1994, BLOOD, V84, P111; BASHEY A, 1992, BLOOD, V79, P981; BECK E, 1982, GENE, V19, P327, DOI 10.1016/0378-1119(82)90023-3; BERGER LC, 1994, BIOCHEM BIOPH RES CO, V202, P596, DOI 10.1006/bbrc.1994.1970; BOS JL, 1989, CANCER RES, V49, P4682; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CARDIFF RD, 1993, AM J PATHOL, V142, P1199; COGSWELL PC, 1989, BLOOD, V74, P2629; CUMANO A, 1992, EMBO J, V11, P593, DOI 10.1002/j.1460-2075.1992.tb05091.x; CUMANO A, 1992, NATURE, V356, P612, DOI 10.1038/356612a0; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; DHAR R, 1982, SCIENCE, V217, P934, DOI 10.1126/science.6287572; DIBIRDIK I, 1991, BLOOD, V78, P564, DOI 10.1182/blood.V78.3.564.bloodjournal783564; DUNBAR CE, 1991, ONCOGENE RES, V6, P39; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINNEY RE, 1993, SCIENCE, V260, P1524, DOI 10.1126/science.8502998; FRANZ T, 1985, NATURE, V315, P149, DOI 10.1038/315149a0; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GOODWIN RG, 1991, CYTOKINE HDB, P191; HAGAG N, 1990, ONCOGENE, V5, P1481; HALL A, 1994, SCIENCE, V264, P1413, DOI 10.1126/science.8197454; HARRIS JF, 1992, J IMMUNOL METHODS, V148, P199, DOI 10.1016/0022-1759(92)90173-Q; HAUPT Y, 1992, ONCOGENE, V7, P981; HAWLEY RG, 1994, ONCOGENE, V9, P1; HAWLEY RG, 1994, GENE THER, V1, P136; HAWLEY RG, 1994, STEM CELLS, V12, P155; HAWLEY RG, 1993, J EXP MED, V178, P1175, DOI 10.1084/jem.178.4.1175; HAWLEY RG, 1992, J EXP MED, V176, P1149, DOI 10.1084/jem.176.4.1149; Hawley RG, 1995, ANN NY ACAD SCI, V762, P294; HAWLEY TS, 1991, LEUKEMIA RES, V15, P659, DOI 10.1016/0145-2126(91)90068-5; HAWLEY TS, 1991, CYTOKINE, V3, P60, DOI 10.1016/1043-4666(91)90011-2; HIBI S, 1993, BLOOD, V81, P1841; HIRSCHGINSBERG C, 1990, BLOOD, V76, P1214; HOANG T, 1988, BLOOD, V72, P823; HOLMES KL, 1985, P NATL ACAD SCI USA, V82, P6687, DOI 10.1073/pnas.82.19.6687; HOLMES KL, 1986, J EXP MED, V164, P443, DOI 10.1084/jem.164.2.443; IWAMOTO A, 1987, J EXP MED, V165, P591, DOI 10.1084/jem.165.3.591; JACOBSON DR, 1994, ONCOGENE, V9, P553; KALEKO M, 1990, BLOOD, V75, P1733; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KAWAKAMI T, 1980, NUCLEIC ACIDS RES, V8, P3933, DOI 10.1093/nar/8.17.3933; KELLER G, 1989, GENE DEV, V3, P827, DOI 10.1101/gad.3.6.827; KISHNER MB, 1994, P NATL ACAD SCI USA, V76, P253; LEONARD EJ, 1990, BIOTECHNIQUES, V9, P684; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LUBBERT M, 1992, ONCOGENE, V7, P263; LUBBERT M, 1990, BLOOD, V75, P1163; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MATSUZAKI Y, 1993, J EXP MED, V178, P1283, DOI 10.1084/jem.178.4.1283; MAYER A, 1982, NATURE, V295, P253; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; NAKAHATA T, 1982, P NATL ACAD SCI-BIOL, V79, P3843, DOI 10.1073/pnas.79.12.3843; NAOE T, 1993, BLOOD, V82, P2260, DOI 10.1182/blood.V82.7.2260.bloodjournal8272260; NERI A, 1988, P NATL ACAD SCI USA, V85, P9268, DOI 10.1073/pnas.85.23.9268; NEUBAUER A, 1994, BLOOD, V83, P1603; OVERELL RW, 1989, ONCOGENE, V4, P1425; PAQUETTE RL, 1993, BLOOD, V82, P590, DOI 10.1182/blood.V82.2.590.bloodjournal822590; PATTENGALE PK, 1983, AM J PATHOL, V113, P235; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; PIERCE JH, 1982, J EXP MED, V156, P873, DOI 10.1084/jem.156.3.873; PIERCE JH, 1985, MOL CELL BIOL, V5, P667, DOI 10.1128/MCB.5.4.667; PRICE CM, 1994, BRIT J HAEMATOL, V88, P338, DOI 10.1111/j.1365-2141.1994.tb05028.x; RADICH JP, 1990, BLOOD, V76, P801; Sambrook J., 1989, MOL CLONING LAB MANU; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHWARTZ RC, 1986, MOL CELL BIOL, V6, P3221, DOI 10.1128/MCB.6.9.3221; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SIRINIAN MI, 1993, ONCOGENE, V8, P157; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; WILLIAMS DA, 1990, HUM GENE THER, V1, P229, DOI 10.1089/hum.1990.1.3-229; WU L, 1991, J EXP MED, V174, P1617, DOI 10.1084/jem.174.6.1617	78	43	44	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	1995	11	6					1113	1123						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566971				2022-12-17	WOS:A1995RX18000014
J	OBEYESEKERE, MN; HERBERT, JR; ZIMMERMAN, SO				OBEYESEKERE, MN; HERBERT, JR; ZIMMERMAN, SO			A MODEL OF THE G1 PHASE OF THE CELL-CYCLE INCORPORATING CYCLIN E/CDK2 COMPLEX AND RETINOBLASTOMA PROTEIN	ONCOGENE			English	Article						CYCLIN E; CDK2; RB; G1; CELL CYCLE; MATHEMATICAL MODELS	SUSCEPTIBILITY GENE-PRODUCT; MAMMALIAN FIBROBLASTS; DNA-REPLICATION; DEPHOSPHORYLATION; PHOSPHORYLATION; BINDING; GROWTH; IDENTIFICATION; PROGRESSION; EXPRESSION	A mathematical model of cyclin E, cdk2 and retinoblastoma protein control of the G1 phase of the human cell cycle is proposed. The model includes retinoblastoma (Rb) protein phosphorylation by a cyclin E/cdk2 complex and its subsequent dephosphorylation at the end of the cell cycle. The numerical solutions to this model demonstrates the cyclic behavior of the cyclin E/cdk2 complex, with and without Rb function, cell cycle. This model suggests an inhibition of cyclin E/cdk2 complex formation (or its activation) by hypophosphorylated retinoblastoma protein. The experimental results of cell cycle arrest upon injection of transforming growth factor-beta, alpha-interferon or D-erythro-sphingosine during G1 phase are reproduced. Cell cycle behavior predicted by this model for increasing the concentration of hypophosphorylated retinoblastoma protein during the G1 phase is discussed. Additional results are obtained by numerical simulation.	UNIV TEXAS,SCH MED,HOUSTON,TX	University of Texas System	OBEYESEKERE, MN (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOMATH,BOX 237,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.				NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA-16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; BYBEE A, 1993, CELL CYCLE 93 REGULA; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CHAO R, 1992, J BIOL CHEM, V267, P23459; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; KATO J, 1993, GENE DEV, V7, P331; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, CELL CYCLE 93 REGULA; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; NOREL R, 1991, SCIENCE, V251, P1076, DOI 10.1126/science.1825521; OBEYESEKERE MN, 1994, CELL PROLIFERAT, V27, P105, DOI 10.1111/j.1365-2184.1994.tb01409.x; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; REED SI, 1991, COLD SH Q B, V56, P61; REED SI, 1992, P AM ASSOC CANC RES, V33, pA574; Sherr Charles J., 1994, Trends in Cell Biology, V4, P15, DOI 10.1016/0962-8924(94)90033-7; SHERR CJ, 1993, CELL CYCLE 93 REGULA; TYSON JJ, 1991, P NATL ACAD SCI USA, V88, P7328, DOI 10.1073/pnas.88.16.7328; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	32	43	44	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1199	1205						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566981				2022-12-17	WOS:A1995RX18000024
J	HAAPAJARVI, T; KIVINEN, L; PITKANEN, K; LAIHO, M				HAAPAJARVI, T; KIVINEN, L; PITKANEN, K; LAIHO, M			CELL-CYCLE DEPENDENT EFFECTS OF UV-RADIATION ON P53 EXPRESSION AND RETINOBLASTOMA PROTEIN-PHOSPHORYLATION	ONCOGENE			English	Article						P53; PRB; GROWTH ARREST; CELL CYCLE; UV RADIATION	WILD-TYPE P53; SUSCEPTIBILITY GENE-PRODUCT; TUMOR-SUPPRESSOR PROTEIN; DNA-DAMAGING AGENTS; IONIZING-RADIATION; APOPTOSIS; INDUCTION; PROLIFERATION; CHECKPOINT; GROWTH	Control of fate of cells encountered with DNA damaging agents is pivotal for normal cellular homeostasis. DNA damage leads in many cases to growth arrest of the cells ensuring sufficient time for damage repair. Growth arrest can be mediated by p53 tumor suppressor protein and loss pf its function leads to inability of the cells to both growth arrest and undergo apoptosis. We show here that followed by genotoxic stress, the retinoblastoma gene product, pRB, is associated with growth arrest of cells in a p53 independent manner. In u.v.-treated human and mouse fibroblasts, pRB is rapidly dephosphorylated. pRB dephosphorylation occurs concomitant with growth arrest of cells including cells with p53 mutations (SW 480 colon carcinoma cells), cells expressing SV40 T antigen and rat-transformed cells (T-24 bladder carcinoma cells) unresponsive in regard to p53 stimulation. Furthermore, how cytometry analysis of u.v.-radiated synchronized G1 cells indicates that the cells transiently arrest in G1 for 10-12 h with pRB dominating in its underphosphorylated form, whereas p53 accumulation occurs only after the cells have entered into S-phase. In addition, u.v.-radiation of late S- and G2/M-phase cells leads to p53 accumulation and cell cycle arrest. The results indicate that p53 accumulation upon u.v.-radiation occurs during DNA replication and is thus not involved in G1 arrest. We suggest that the events that lead to pRB dephosphorylation upon u.v.-radiation provide the cell an efficient G1 arrest which occurs prior and independently of p53.	HELSINKI UNIV,DEPT VIROL,SF-00014 HELSINKI,FINLAND	University of Helsinki								BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BERGES RR, 1993, P NATL ACAD SCI USA, V90, P8910, DOI 10.1073/pnas.90.19.8910; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FRITSCHE M, 1993, ONCOGENE, V8, P307; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HALL PA, 1993, ONCOGENE, V8, P203; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KATO J, 1993, GENE DEV, V7, P331; KELLEY LL, 1994, MOL CELL BIOL, V14, P4183, DOI 10.1128/MCB.14.6.4183; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NEVINS JR, 1992, SCIENCE, V258, P424; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PITKANEN K, 1993, EXP CELL RES, V207, P99, DOI 10.1006/excr.1993.1167; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RON D, 1994, P NATL ACAD SCI USA, V91, P1985, DOI 10.1073/pnas.91.6.1985; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Sherr Charles J., 1994, Trends in Cell Biology, V4, P15, DOI 10.1016/0962-8924(94)90033-7; STEWART N, 1995, ONCOGENE, V10, P109; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	49	43	43	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					151	159						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624123				2022-12-17	WOS:A1995RJ29500018
J	XIE, YM; LI, KY; HUNG, MC				XIE, YM; LI, KY; HUNG, MC			TYROSINE PHOSPHORYLATION OF SHC PROTEINS AND FORMATION OF SHC/GRB2 COMPLEX CORRELATE TO THE TRANSFORMATION OF NIH3T3 CELLS MEDIATED BY THE POINT-MUTATION ACTIVATED NEU	ONCOGENE			English	Note						SHC; GRB2; P185(NEU); TYROSINE PHOSPHORYLATION; TRANSFORMATION	GROWTH-FACTOR RECEPTOR; ONCOGENIC ACTIVATION; SIGNAL TRANSDUCTION; 3T3 CELLS; GENE; KINASE; DOMAIN	PLC-gamma, ras-GAP and She have been proposed to be in vivo substrates for the nea-encoded p185(neu) receptor tyrosine kinases. We compared the tyrosine phosphorylation levels of PLC-gamma, ras-GAP and She in two NIH3T3 derived cell lines, transformed B104-1-1 and non-transformed DHFR/G8 cells in which point-mutation activated and normal rat nea genes were transfected and expressed, respectively. We found that tyrosine phosphorylation of She and formation of Shc/ Grb2 complex were more significant in B104-1-1 cells than in DHFR/G8 cells, while no obvious difference could be detected for the tyrosine phosphorylation levels of ras-GAP and PLC-gamma between these two cell lines. Furthermore, we observed that association with She was severely impaired by deletion of most of the major autophosphorylation sites of the point-mutated neu. The truncated nea product, however, fully retained its ability to transform NIH3T3 cells, induce She tyrosine phosphorylation and Shc/Grb2 complex formation. Our results suggest that tyrosine phosphorylation of She which allows formation of Shc/Grb2 complex may play an important role for cell transformation induced by the point mutation-activated neu, and that stable binding to mutant p185(neu) may not be necessary for She to mediate this signaling pathway.	UNIV TEXAS, MD ANDERSON CANCER CTR, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740				BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; JANES PW, 1994, ONCOGENE, V9, P3601; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; SEGATTO O, 1993, ONCOGENE, V8, P2105; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YAN DH, 1993, MOL CARCINOGEN, V7, P44, DOI 10.1002/mc.2940070108; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	24	43	45	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	1995	10	12					2409	2413						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784091				2022-12-17	WOS:A1995RE54300018
J	SEIMIYA, H; SAWABE, T; INAZAWA, J; TSURUO, T				SEIMIYA, H; SAWABE, T; INAZAWA, J; TSURUO, T			CLONING, EXPRESSION AND CHROMOSOMAL LOCALIZATION OF A NOVEL GENE FOR PROTEIN-TYROSINE-PHOSPHATASE (PTP-U2) INDUCED BY VARIOUS DIFFERENTIATION-INDUCING AGENTS	ONCOGENE			English	Article						PTPASE; LEUKEMIA; DIFFERENTIATION	POLYMERASE CHAIN-REACTION; LEUKOCYTE-COMMON ANTIGEN; HL-60 LEUKEMIA-CELLS; C-JUN EXPRESSION; IMMUNOGLOBULIN SUPERFAMILY; CYTOGENETIC ANALYSIS; OKADAIC ACID; SINGLE GENE; RECEPTOR; AMPLIFICATION	Previously, we cloned two gene fragments encoding novel protein tyrosine phosphatases, termed PTP-U1 and PTP-U2. Here, we report the full-length sequence, expression, and chromosomal localization of the PTP-U2 gene. The cDNA for PTP-U2, which was obtained from a human normal kidney library, predicts a protein of 1216 amino acids, -140 kDa, that contains a single transmembrane domain and a single intracellular catalytic domain. The extracellular domain of PTP-U2 contains 14 putative N-glycosylation sites and eight repeats of fibronectin type III-like motif, These data suggest that PTP-U2 is structurally similar to HPTP beta and DPTP10D, which have been reported previously. Northern blot analysis revealed that there were two different transcripts for PTP-U2. In kidney and brain, gene expression of PTP-U2 was detected as a 5.4 kb mRNA and in lung and placenta as 3.5 kb. The 3.5 kb transcript was also detected in human leukemia cell lines (eg., U937), Interestingly, its gene expression was enhanced by various differentiation-inducing agents, such as phorbol ester, dihydroxy vitamin D-3, retinoic acid, and dimethyl sulfoxide. The bacterially expressed PTP-U2 fusion protein exhibited intrinsic tyrosine phosphatase activity. The PTP-U2 gene was assigned to chromosome 12p13.2-p13.3.	UNIV TOKYO,INST MOLEC & CELLULAR BIOSCI,BUNKYO KU,TOKYO 113,JAPAN; KYOTO PREFECTURAL UNIV MED,DEPT HYG,KAMIKYO KU,KYOTO 602,JAPAN; JAPANESE FDN CANC RES,CTR CANC CHEMOTHERAPY,TOSHIMA KU,TOKYO 170,JAPAN	University of Tokyo; Kyoto Prefectural University of Medicine; Japanese Foundation for Cancer Research				Seimiya, Hiroyuki/0000-0003-3314-9736				ADUNYAH SE, 1992, J CELL PHYSIOL, V151, P415, DOI 10.1002/jcp.1041510223; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BRAUTIGAN DL, 1992, BIOCHIM BIOPHYS ACTA, V1114, P63, DOI 10.1016/0304-419X(92)90007-L; BUTLER TM, 1990, CANCER RES, V50, P6323; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COLLINS SJ, 1987, BLOOD, V70, P1233; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FRANK DA, 1988, CANCER RES, V48, P4299; FRANK DA, 1988, CANCER RES, V48, P52; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; INAZAWA J, 1993, GENOMICS, V17, P153, DOI 10.1006/geno.1993.1297; INAZAWA J, 1991, GENOMICS, V10, P1075, DOI 10.1016/0888-7543(91)90202-P; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; KEENE P, 1987, BRIT J HAEMATOL, V67, P25, DOI 10.1111/j.1365-2141.1987.tb02291.x; KELLY AP, 1991, NATURE, V353, P571, DOI 10.1038/353571a0; KHARBANDA S, 1992, CELL GROWTH DIFFER, V3, P391; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATOZAKI T, 1994, J BIOL CHEM, V269, P2075; NISHI M, 1990, FEBS LETT, V271, P178, DOI 10.1016/0014-5793(90)80400-D; NOONAN KE, 1990, P NATL ACAD SCI USA, V87, P7160, DOI 10.1073/pnas.87.18.7160; PALLEN CJ, 1991, P NATL ACAD SCI USA, V88, P6996, DOI 10.1073/pnas.88.16.6996; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; RALPH SJ, 1987, EMBO J, V6, P1251, DOI 10.1002/j.1460-2075.1987.tb02361.x; RODRIGUEZ E, 1993, GENE CHROMOSOME CANC, V8, P230, DOI 10.1002/gcc.2870080405; SAGA Y, 1987, P NATL ACAD SCI USA, V84, P5364, DOI 10.1073/pnas.84.15.5364; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAMANIEGO F, 1990, GENE CHROMOSOME CANC, V1, P289, DOI 10.1002/gcc.2870010406; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAP J, 1994, MOL CELL BIOL, V14, P1; SAYA H, 1993, FEBS LETT, V327, P224, DOI 10.1016/0014-5793(93)80174-S; SEIMIYA H, 1993, CELL GROWTH DIFFER, V4, P1033; SEIMIYA H, 1993, J BIOCHEM-TOKYO, V113, P687, DOI 10.1093/oxfordjournals.jbchem.a124104; STREULI M, 1987, J EXP MED, V166, P1548, DOI 10.1084/jem.166.5.1548; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; THOMAS ML, 1987, P NATL ACAD SCI USA, V84, P5360, DOI 10.1073/pnas.84.15.5360; THOMAS PE, 1994, J BIOL CHEM, V269, P19953; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TROWBRIDGE IS, 1991, BIOCHIM BIOPHYS ACTA, V1095, P46, DOI 10.1016/0167-4889(91)90043-W; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YI TL, 1991, BLOOD, V78, P2222	56	43	44	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 4	1995	10	9					1731	1738						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753550				2022-12-17	WOS:A1995QX46900006
J	EKSTRAND, AJ; LIU, L; HE, J; HAMID, ML; LONGO, N; COLLINS, VP; JAMES, CD				EKSTRAND, AJ; LIU, L; HE, J; HAMID, ML; LONGO, N; COLLINS, VP; JAMES, CD			ALTERED SUBCELLULAR LOCATION OF AN ACTIVATED AND TUMOR-ASSOCIATED EPIDERMAL GROWTH-FACTOR RECEPTOR	ONCOGENE			English	Note						GLIO BLASTOMA; TYROSINE KINASE; ONCOGENE; ENDOPLASMIC RETICULUM; EGF-BINDING; CONFOCAL MICROSCOPY	AVIAN ERYTHROBLASTOSIS VIRUS; HUMAN-BRAIN-TUMORS; PROTEIN KINASE-C; B GENE-PRODUCT; EGF RECEPTOR; SIGNAL TRANSDUCTION; HUMAN GLIOBLASTOMAS; PLASMA-MEMBRANE; HUMAN GLIOMAS; CELL-SURFACE	The epidermal growth factor (EGF) receptor is a membrane bound tyrosine kinase whose activity is initiated by ligand binding, The malignant brain tumour glioblastoma frequently shows amplification and rearrangements of the EGF receptor gene that are associated with the synthesis of a constitutively activated tyrosine kinase, lacking amino acids 6-273 near the protein's N-terminus, When expressed in Chinese hamster ovary (CHO) cells, this mutant receptor (p140(EGFR)) displays ligand-independent tyrosine kinase activity, stimulates DNA synthesis, and promotes cell proliferation, Here, we investigate the subcellular location of p140(EGFR) in CHO cell transfectants as web as in human glioblastoma tumours, p140(EGFR) had an intracellular location that contrasted sharply with the plasma membrane location of the wild-type EGF receptor, Endoglycosidase H sensitivity analysis and the pattern of p140(EGFR) immunoreactivity suggested that the aberrant tyrosine kinase resided primarily in the endoplasmic reticulum, The half-life of p140(EGFR) in, the endoplasmic reticulum was extended several-fold over that of the ligand-activated wild-type receptor, The altered subcellular location of p140(EGFR) in combination with its prolonged half-life suggest that this activated tyrosine kinase may escape the regulatory mechanisms utilized for the attenuation of wild-type receptor signaling, Therefore, the previously reported growth stimulatory property of the ligand-independent p140(EGFR) may be attributed to a sustained tyrosine kinase activity resulting from an altered subcellular location.	EMORY UNIV, SCH MED, DEPT NEUROSURG, MOLEC NEUROONCOL LAB, ATLANTA, GA 30322 USA; KAROLINSKA HOSP, LUDWIG INST CANC RES, S-17176 STOCKHOLM, SWEDEN; KAROLINSKA HOSP, DEPT PATHOL & ONCOL, S-17176 STOCKHOLM, SWEDEN; EMORY UNIV, SCH MED, DEPT PEDIAT, DIV MED GENET, ATLANTA, GA 30322 USA	Emory University; Karolinska Institutet; Karolinska University Hospital; Ludwig Institute for Cancer Research; Karolinska Institutet; Karolinska University Hospital; Emory University			James, Charles D/E-2721-2012	James, Charles D/0000-0002-1027-203X	NATIONAL CANCER INSTITUTE [R01CA055728] Funding Source: NIH RePORTER; NCI NIH HHS [CA-55728] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEGUINOT L, 1984, P NATL ACAD SCI-BIOL, V81, P2384, DOI 10.1073/pnas.81.8.2384; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BEUG H, 1984, CELL, V36, P963, DOI 10.1016/0092-8674(84)90046-1; BOHMER FD, 1993, FEBS LETT, V331, P276, DOI 10.1016/0014-5793(93)80352-U; BOWEN S, 1991, J BIOL CHEM, V266, P1162; COCHET C, 1984, J BIOL CHEM, V259, P2553; CUMMINGS RD, 1985, J BIOL CHEM, V260, P1944; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DUNPHY WG, 1983, J CELL BIOL, V97, P270, DOI 10.1083/jcb.97.1.270; EKSTRAND AJ, 1994, ONCOGENE, V9, P2313; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; FAURE R, 1992, J BIOL CHEM, V267, P11215; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FOOD MR, 1994, J BIOL CHEM, V269, P3034; GILMORE T, 1985, CELL, V40, P609, DOI 10.1016/0092-8674(85)90209-0; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; HAYMAN MJ, 1984, NATURE, V309, P460, DOI 10.1038/309460a0; HAYMAN MJ, 1983, CELL, V32, P579, DOI 10.1016/0092-8674(83)90477-4; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; KRIS RM, 1985, CELL, V40, P619, DOI 10.1016/0092-8674(85)90210-7; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; MAYES ELV, 1984, EMBO J, V3, P531, DOI 10.1002/j.1460-2075.1984.tb01842.x; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISTER M, 1988, CANCER RES, V48, P3910; PRIVALSKY ML, 1984, VIROLOGY, V135, P356, DOI 10.1016/0042-6822(84)90192-2; SCHATZMAN RC, 1986, MOL CELL BIOL, V6, P1329, DOI 10.1128/MCB.6.4.1329; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WHITELEY B, 1986, J CELL BIOL, V103, P1355, DOI 10.1083/jcb.103.4.1355; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; YAMAMOTO T, 1983, CELL, V35, P71, DOI 10.1016/0092-8674(83)90209-X; YAMAZAKI H, 1990, JPN J CANCER RES, V81, P773, DOI 10.1111/j.1349-7006.1990.tb02644.x	39	43	47	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1455	1460						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731699				2022-12-17	WOS:A1995QR65100026
J	DIB, A; ADELAIDE, J; CHAFFANET, M; IMBERT, A; LEPASLIER, D; JACQUEMIER, J; GAUDRAY, P; THEILLET, C; BIRNBAUM, D; PEBUSQUE, MJ				DIB, A; ADELAIDE, J; CHAFFANET, M; IMBERT, A; LEPASLIER, D; JACQUEMIER, J; GAUDRAY, P; THEILLET, C; BIRNBAUM, D; PEBUSQUE, MJ			CHARACTERIZATION OF THE REGION OF THE SHORT ARM OF CHROMOSOME-8 AMPLIFIED IN BREAST-CARCINOMA	ONCOGENE			English	Article						AMPLIFICATION; BREAST CANCER; CHROMOSOME 8; MAPPING; ONCOGENE; YEAST ARTIFICIAL CHROMOSOMES	POLYMERASE CHAIN-REACTION; HUMAN GENOME; LINKAGE MAP; DNA AMPLIFICATION; HUMAN-TUMORS; PLAT GENES; CANCER; RECEPTOR; LIBRARY; CLONING	Chromosomal region 8p11.2-p12 is consistently amplified in human breast cancer, We have constructed a 2.8 Mb YAC contig of this region, centered on the human Fibroblast Growth Factor Receptor 1 (FGRF1) locus and encompassing the Adrenergic beta 3 Receptor (ADRB3) focus. A smaller centromeric YAC contig spanning 1.4 Mb was also assembled, and included the Ankyrin 1 (ANK1) and Tissue-type Plasminogen Activator (FLAT) genes, Results from mapping of the contigs showed physical linkage of the ADRB3 and FGFR1 genes, which were colocalized within the same YAC clone and separated by about 900 kb, FGFR1 being in centromeric position, It also showed physical linkage of ANK1 and FLAT genes, which appear to be separated by a maximum of 700 kb. In parallel, several loci were mapped according to their amplification status in a large panel of breast tumor samples. The overall amplification pattern suggested a continuous amplicon with a core around FGFR1. Data from both the detailed physical map and the amplification status allowed to establish the following gene order, from telomere to centromere: ADRB3-D8S105-FGFR1-ANK1-PLAT-POLB. The precise localization and YAC cloning of the core of the amplicon will allow to isolate a putative oncogene involved in mammary carcinogenesis.	INSERM,U119,MOLEC ONCOL LAB,F-13009 MARSEILLE,FRANCE; INST J PAOLI I CALMETTES,BIOL TUMEURS LAB,F-13009 MARSEILLE,FRANCE; CTR ETUD POLYMORPHISME HUMAIN,F-75010 PARIS,FRANCE; INST J PAOLI I CALMETTES,DEPT ANATOMOPATHOL,F-13009 MARSEILLE,FRANCE; IGMM,CNRS,URA 9942,MONTPELLIER,FRANCE; LGMCH,CNRS,URA 1462,NICE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Paoli-Calmette (IPC); Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)			Theillet, Charles/O-7634-2018; CHAFFANET, Max/AAU-5743-2020; ADELAIDE, José JA/O-4390-2017	ADELAIDE, José JA/0000-0003-4364-9857; Birnbaum, Daniel/0000-0001-7920-9883; Theillet, Charles/0000-0001-5555-2759; CHAFFANET, Max/0000-0002-2344-1488; Le Paslier, Denis/0000-0003-4335-9956				ADELAIDE J, 1994, GENE CHROMOSOME CANC, V11, P66, DOI 10.1002/gcc.2870110111; ADNANE J, 1991, ONCOGENE, V6, P659; ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; ANAND R, 1990, NUCLEIC ACIDS RES, V18, P1951, DOI 10.1093/nar/18.8.1951; BELLANNECHANTEL.C, 1992, CELL, V70, P1059; BRADFORD CR, 1991, GENE CHROMOSOME CANC, V3, P272, DOI 10.1002/gcc.2870030406; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; BROWNSTEIN BH, 1989, SCIENCE, V244, P1348, DOI 10.1126/science.2544027; BUETOW KH, 1994, NAT GENET, V6, P391, DOI 10.1038/ng0494-391; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DUTRILLAUX B, 1990, CANCER GENET CYTOGEN, V49, P203, DOI 10.1016/0165-4608(90)90143-X; EMI M, 1993, GENOMICS, V15, P530, DOI 10.1006/geno.1993.1105; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; H/CEPH Collaborative Mapping Group, 1992, SCIENCE, V258, P67; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HYNES NE, 1993, SEMIN CANCER BIOL, V4, P19; IMBERT A, 1994, CYTOGENET CELL GENET, V67, P175, DOI 10.1159/000133817; JACQUEMIER J, 1994, INT J CANCER, V59, P373, DOI 10.1002/ijc.2910590314; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; KARLSEDER J, 1994, GENE CHROMOSOME CANC, V9, P42, DOI 10.1002/gcc.2870090108; KERANGUEVEN F, 1995, IN PRESS ONCOGENE; LAFAGE M, 1992, GENE CHROMOSOME CANC, V5, P40, DOI 10.1002/gcc.2870050107; LAMBERT S, 1990, P NATL ACAD SCI US, V87; LI X, 1994, GENOMICS, V19, P470, DOI 10.1006/geno.1994.1096; MARICS I, 1989, ONCOGENE, V4, P335; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; MUENKE M, 1994, NAT GENET, V8, P269, DOI 10.1038/ng1194-269; NY T, 1984, P NATL ACAD SCI-BIOL, V81, P5355, DOI 10.1073/pnas.81.17.5355; OCHMAN H, 1988, GENETICS, V120, P621; OSHIMA J, 1994, GENOMICS, V23, P100, DOI 10.1006/geno.1994.1464; PEBUSQUE MJ, 1993, GENE CHROMOSOME CANC, V8, P119, DOI 10.1002/gcc.2870080209; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; SAINTRUF C, 1991, CANCER GENET CYTOGEN, V52, P27, DOI 10.1016/0165-4608(91)90050-5; SENGUPTA DN, 1986, BIOCHEM BIOPH RES CO, V136, P341, DOI 10.1016/0006-291X(86)90916-2; SZEPETOWSKI P, 1993, GENOMICS, V16, P745, DOI 10.1006/geno.1993.1257; SZEPETOWSKI P, 1992, ONCOGENE, V7, P2513; THEILLET C, 1989, ONCOGENE, V4, P915; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; TOMFOHRDE J, 1992, GENOMICS, V14, P144, DOI 10.1016/S0888-7543(05)80297-6; TRIGLIA T, 1988, NUCLEIC ACIDS RES, V16, P8186, DOI 10.1093/nar/16.16.8186; TUTIC M, 1990, EUR J BIOCHEM, V188, P523, DOI 10.1111/j.1432-1033.1990.tb15431.x; WAGNER MJ, 1991, GENOMICS, V10, P114, DOI 10.1016/0888-7543(91)90491-V; WATSON R, 1982, P NATL ACAD SCI-BIOL, V79, P4078, DOI 10.1073/pnas.79.13.4078; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WIEGANT J, 1991, GENOMICS, V10, P345, DOI 10.1016/0888-7543(91)90318-9; Wood S, 1993, Cytogenet Cell Genet, V64, P134; 1991, CYTOGENET CELL GENET, V58, P1	53	43	45	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					995	1001						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898940				2022-12-17	WOS:A1995QL03800021
J	SCHUCHARDT, A; SRINIVAS, S; PACHNIS, V; COSTANTINI, F				SCHUCHARDT, A; SRINIVAS, S; PACHNIS, V; COSTANTINI, F			ISOLATION AND CHARACTERIZATION OF A CHICKEN HOMOLOG OF THE C-RET PROTOONCOGENE	ONCOGENE			English	Article						RECEPTOR TYROSINE KINASE; RET; EVOLUTION; PROTOONCOGENE; EMBRYOGENESIS; NERVOUS SYSTEM; HIRSCHSPRUNGS DISEASE	CELL-ADHESION MOLECULE; PROTEIN-TYROSINE KINASE; TRANSGENIC MICE; SEQUENCE SIMILARITY; TRANSFORMING GENE; MESSENGER-RNAS; CDNA CLONING; EGF RECEPTOR; EXPRESSION; CADHERIN	The c-ret proto-oncogene encodes a receptor tyrosine kinase that plays important roles in human disease and in normal mammalian development. Mutations in the human RET gene are associated with multiple endocrine neoplasia syndromes and Hirschsprung's disease in humans, while targeted mutagenesis of murine c-ret resulted in severe developmental abnormalities affecting the excretory and peripheral nervous systems. To examine the evolutionary conservation of the ret protein sequence and its developmental expression pattern, we isolated and sequenced cDNA clones of chicken c-ret and examined its expression in chick embryos and adult tissues. The cytoplasmic domains of chicken and human ret were relatively well conserved (91% similar), but the extracellular domains were more divergent (68% similar), although the conservation of cysteine residues in this region suggests a conserved secondary structure. As in mouse and human, chicken c-ret encodes two protein isoforms, The number and sizes of the transcripts were similar to those in human and mouse cells, and during chick embryogenesis, c-ret mRNA was observed in many of the same sites as in the mouse, including the Wolffian duct and ureteric bud, the enteric, dorsal root, sympathetic and facioacoustic ganglia, and the ventral spinal cord. Evolutionary differences in expression were observed in the trigeminal ganglion, the ventral roots of the spinal cord, the mesenchymal cells of the branchial arches and the adult testes. The results are discussed with regard to the role of the ret receptor in normal development and disease.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT GENET & DEV,NEW YORK,NY 10032; NATL INST MED RES,GENE STRUCT & EXPRESS LAB,LONDON NW7 1AA,ENGLAND	Columbia University; MRC National Institute for Medical Research				Srinivas, Shankar/0000-0001-5726-7791; Pachnis, Vassilis/0000-0001-9733-7686	NCI NIH HHS [CA23767] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA023767] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CHEN J, 1991, ONCOGENE, V6, P157; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HATTA K, 1988, J CELL BIOL, V106, P873, DOI 10.1083/jcb.106.3.873; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; INUZUKA H, 1991, NEURON, V7, P69, DOI 10.1016/0896-6273(91)90075-B; IWAMOTO T, 1990, ONCOGENE, V5, P535; IWAMOTO T, 1993, ONCOGENE, V8, P1087; IWAMOTO T, 1991, EUR J IMMUNOL, V21, P1809, DOI 10.1002/eji.1830210805; IWAMOTO T, 1991, EMBO J, V10, P3167, DOI 10.1002/j.1460-2075.1991.tb04878.x; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUMA K, 1993, MOL BIOL EVOL, V10, P539; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; LEE JJ, 1992, DEVELOPMENT, V115, P277; MATSUSHIME H, 1990, J VIROL, V64, P2117, DOI 10.1128/JVI.64.5.2117-2125.1990; MOLE SE, 1993, HUM MOL GENET, V2, P247, DOI 10.1093/hmg/2.3.247; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NILSEN TW, 1985, CELL, V41, P719, DOI 10.1016/S0092-8674(85)80052-0; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; RANSCHT B, 1991, NEURON, V7, P391, DOI 10.1016/0896-6273(91)90291-7; RINGWALD M, 1987, EMBO J, V6, P3647, DOI 10.1002/j.1460-2075.1987.tb02697.x; ROMEO G, 1994, NATURE, V367, P367; SAJJADI FG, 1991, NEW BIOL, V3, P769; SANTORO M, 1990, ONCOGENE, V5, P1595; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SASAKI E, 1993, GENE, V128, P257, DOI 10.1016/0378-1119(93)90571-J; Saxen L., 1987, ORGANOGENESIS KIDNEY; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHNEIDER R, 1992, TRENDS BIOCHEM SCI, V17, P468, DOI 10.1016/0968-0004(92)90490-Z; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1993, ONCOGENE, V8, P2925; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WHITE MF, 1991, J BIOENERG BIOMEMBR, V23, P63; WILKS AF, 1993, ADV CANCER RES, V60, P43; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; 1991, PROGRAM MANUAL GCG P	54	43	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					641	649						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862441				2022-12-17	WOS:A1995QH61200003
J	BRAMBILLA, R; DRAETTA, G				BRAMBILLA, R; DRAETTA, G			MOLECULAR-CLONING OF PISSLRE, A NOVEL PUTATIVE MEMBER OF THE CDK FAMILY OF PROTEIN SERINE/THREONINE KINASES	ONCOGENE			English	Note							CYCLIN-DEPENDENT KINASES; CELL-DIVISION; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; GENE CDC2; P34(CDC2); HOMOLOGY; PHOSPHORYLATION; EXPRESSION; SEQUENCE	Several members of the cdk family of protein kinases are involved in the regulation of the eukaryotic cell cycle. Using a PCR-based strategy we have screened different human tumor cell lines for cdk-related cDNAs. One clone isolated from the bladder carcinoma cell line RT112 encodes a novel protein kinase named PISSLRE, based on its predicted sequence at the conserved PSTAIRE motif. PISSLRE showed 50% amino acid identity with the previously isolated p58(KGTA). PISSLRE contained all the structural elements featured by cyclin dependent kinases, including a proline in the PSTAIRE motif, which might be important for cyclin binding. PISSLRE was found expressed as 2.0 kb messenger RNA in a variety of human cell lines. Its expression was not restricted to tumor cells as it was detectable also in normal fibroblasts. In adult tissues, PISSLRE mRNA showed the highest expression in lung, liver and kidney. The broad expression pattern in adult tissues might suggest that PISSLRE could be involved in processes distinct from cell proliferation.	EUROPEAN MOLEC BIOL LAB, D-69012 HEIDELBERG, GERMANY	European Molecular Biology Laboratory (EMBL)			Brambilla, Riccardo/A-6082-2010	Brambilla, Riccardo/0000-0003-3569-5706				BEN DY, 1991, EMBO J, V10, P317; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BUNNELL BA, 1990, P NATL ACAD SCI USA, V87, P7467, DOI 10.1073/pnas.87.19.7467; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; DE BH, 1993, NATURE, V363, P595; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; Draetta Giulio, 1993, Trends in Cell Biology, V3, P287, DOI 10.1016/0962-8924(93)90001-H; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; IRIE K, 1991, CELL, V65, P785, DOI 10.1016/0092-8674(91)90386-D; JOHNSON KW, 1991, J BIOL CHEM, V266, P3402; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KREK W, 1989, EMBO J, V8, P3071, DOI 10.1002/j.1460-2075.1989.tb08458.x; LAPIDOT LY, 1992, P NATL ACAD SCI USA, V89, P579; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEHNER CF, 1990, EMBO J, V9, P3573, DOI 10.1002/j.1460-2075.1990.tb07568.x; LEW J, 1992, J BIOL CHEM, V267, P25922; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; MARCOTE MJ, 1993, MOL CELL BIOL, V13, P5122, DOI 10.1128/MCB.13.8.5122; MATSUSHIME H, 1990, MOL CELL BIOL, V10, P2261, DOI 10.1128/MCB.10.5.2261; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Pines J, 1991, Trends Cell Biol, V1, P117, DOI 10.1016/0962-8924(91)90116-Q; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PINES J, 1993, CURR BIOL, V3, P544, DOI 10.1016/0960-9822(93)90053-Q; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHUTTLEWORTH J, 1990, EMBO J, V9, P3233, DOI 10.1002/j.1460-2075.1990.tb07522.x; SIMON M, 1986, EMBO J, V5, P2697, DOI 10.1002/j.1460-2075.1986.tb04553.x; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SPURR NK, 1990, DNA SEQUENCE, V1, P48; UESONO Y, 1987, NUCLEIC ACIDS RES, V15, P10299, DOI 10.1093/nar/15.24.10299	42	43	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1994	9	10					3037	3041						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084611				2022-12-17	WOS:A1994PG82200034
J	WALKER, GJ; PALMER, JM; WALTERS, MK; NANCARROW, DJ; PARSONS, PG; HAYWARD, NK				WALKER, GJ; PALMER, JM; WALTERS, MK; NANCARROW, DJ; PARSONS, PG; HAYWARD, NK			REFINED LOCALIZATION OF THE MELANOMA (MLM) GENE ON CHROMOSOME 9P BY ANALYSIS OF ALLELIC DELETIONS	ONCOGENE			English	Article							LINKAGE MAP; POLYMORPHISMS; DNA	Various lines of evidence including linkage analysis, frequent homozygous and heterozygous deletions in melanoma DNAs, and the finding of a patient with multiple primary melanomas who harbours a 5p/9p translocation involving loss of several 9p markers, have indicated that the 9p22-p13 region harbours a gene important for the development of melanoma (MLM). We have used eight short tandem repeat polymorphism (STRP) markers mapping to this region to look for allelic losses in DNA from melanoma biopsies and cell lines. Heterozygous losses were found in 8/14 (57%) fresh melanoma biopsy DNAs with the smallest region of overlap (SRO) being between IFNA and D9S169. In addition, when DNA from 30 melanoma cell lines was studied, four cell lines (13%) were found to be homozygously deleted for various 9p markers. Two of these cell lines define the borders of overlapping homozygous deletions within a 4cM region of 9p21 between IFNA and D9S171. Moreover, a further 14 melanoma cell lines were hemizygous for the IFNA/ D9S171/D9S126 region. These data support the hypothesis that the MLM gene acts as a tumour suppressor, and provide a refinement of its localization on 9P.	QUEENSLAND INST MED RES,QUEENSLAND CANC FUND RES UNIT,JOINT EXPTL ONCOL PROGRAM,HERSTON,QLD 4029,AUSTRALIA	QIMR Berghofer Medical Research Institute			hayward, nick/AAV-8802-2020; hayward, nicholas k/C-1367-2015; Parsons, Peter G/H-8163-2015	hayward, nicholas k/0000-0003-4760-1033; Parsons, Peter G/0000-0002-0473-3346				CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; COWAN JN, 1988, J NATL CANCER I, V80, P201; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; FOUNTAIN JW, 1993, HUM MOL GENET, V2, P823, DOI 10.1093/hmg/2.6.823-a; KWIATKOWSKI DJ, 1993, CYTOGENET CELL GENET, V64, P94; KWIATKOWSKI DJ, 1993, HUM MOL GENET, V8, P658; LIMON J, 1988, CANCER GENET CYTOGEN, V30, P201, DOI 10.1016/0165-4608(88)90186-0; MACLENNAN R, 1992, J NATL CANCER I, V84, P1427, DOI 10.1093/jnci/84.18.1427; MCDANIEL DO, 1993, BIOTECHNIQUES, V15, P140; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NANCARROW DJ, 1993, AM J HUM GENET, V53, P936; OLOPADE OI, 1992, GENOMICS, V14, P437, DOI 10.1016/S0888-7543(05)80238-1; OLOPADE OI, 1993, CANCER RES, V53, P2410; PEDERSEN MI, 1986, CANCER GENET CYTOGEN, V20, P11, DOI 10.1016/0165-4608(86)90103-2; PETTY EM, 1993, AM J HUM GENET, V53, P96; WEBER JL, 1991, GENOMICS, V11, P695, DOI 10.1016/0888-7543(91)90077-R; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WILKIE PJ, 1992, GENOMICS, V12, P607, DOI 10.1016/0888-7543(92)90456-3	19	43	52	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					819	824						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108124				2022-12-17	WOS:A1994MW55100017
J	WU, C; AKIYAMA, Y; IMAI, K; MIYAKE, S; NAGASAKI, H; OTO, M; OKABE, S; IWAMA, T; MITAMURA, K; MASUMITSU, H; NOMIZU, T; BABA, S; MARUYAMA, K; YUASA, Y				WU, C; AKIYAMA, Y; IMAI, K; MIYAKE, S; NAGASAKI, H; OTO, M; OKABE, S; IWAMA, T; MITAMURA, K; MASUMITSU, H; NOMIZU, T; BABA, S; MARUYAMA, K; YUASA, Y			DNA ALTERATIONS IN CELLS FROM HEREDITARY NONPOLYPOSIS COLORECTAL-CANCER PATIENTS	ONCOGENE			English	Note							GENE; IDENTIFICATION; MUTATIONS; CHROMOSOME-5Q21; LOCUS; SUSCEPTIBILITY; CARCINOMA; PRODUCTS; FAP	To determine if the MCC, DCC or p53 gene is associated with susceptibility to hereditary non-polyposis colorectal cancer (HNPCC), these genes in normal cells from 12 HNPCC patients were analysed by polymerase chain reaction-single strand conformation polymorphism analysis. No changes which may alter the amino acid sequences of these genes were detected, suggesting that these genes are not associated with the susceptibility to HNPCC. Only one of nine HNPCC cancers showed mutations in the MCC and p53 genes on the same analysis. Loss of heterozygosity in chromosomes 5q, 17p, 18q and 22 was detected in four of the nine cancers, all of them being positive as to metastasis to lymph nodes. Abnormalities of the (CA)n repeat were found in six cancers, including all four without metastasis. These data indicate that tumor suppressor genes in chromosomes 5q, 17p, 18q and 22 are associated with the late stage of colorectal tumorigenesis in HNPCC, whereas the (CA)n repeat abnormalities are an early event of tumorigenesis and more essential to HNPCC.	TOKYO MED & DENT UNIV, SCH MED, DEPT HYG & ONCOL, TOKYO, TOKYO 113, JAPAN; TOKYO MED & DENT UNIV, SCH MED, DEPT SURG, TOKYO, TOKYO 113, JAPAN; SHOWA UNIV, SCH MED, DEPT INTERNAL MED, TOKYO, TOKYO 142, JAPAN; TOKYO METROPOLITAN PUBL HLTH PROMOT FDN, TAMA CANC DETECT CTR, TOKYO, TOKYO 183, JAPAN; HOSHI GEN HOSP, DEPT SURG, FUKUSHIMA, FUKUSHIMA 963, JAPAN; HAMAMATSU UNIV SCH MED, DEPT SURG, HAMAMATSU, SHIZUOKA 43131, JAPAN	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Showa University; Hamamatsu University School of Medicine								AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JINNAI D, 1983, JPN J SURG, V13, P557; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LYNCH HT, 1985, CANCER, V56, P939, DOI 10.1002/1097-0142(19850815)56:4<939::AID-CNCR2820560440>3.0.CO;2-T; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P5705, DOI 10.1093/nar/16.12.5705; NIGRO JM, 1991, CELL, V64, P607, DOI 10.1016/0092-8674(91)90244-S; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OTO M, 1993, ANAL BIOCHEM, V213, P19, DOI 10.1006/abio.1993.1379; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PELTOMAKI P, 1991, CANCER RES, V51, P4135; PELTOMAKI P, 1992, CANCER RES, V52, P4530; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UTSUNOMIYA J, 1990, HEREDITARY COLORECTA, P3	22	43	44	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					991	994						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108146				2022-12-17	WOS:A1994MW55100040
J	BAZENET, CE; KAZLAUSKAS, A				BAZENET, CE; KAZLAUSKAS, A			THE PDGF RECEPTOR-ALPHA SUBUNIT ACTIVATES P21(RAS) AND TRIGGERS DNA-SYNTHESIS WITHOUT INTERACTING WITH RASGAP	ONCOGENE			English	Article							PHOSPHOLIPASE-C-GAMMA; GROWTH-FACTOR RECEPTORS; GAP-ASSOCIATED PROTEINS; FACTOR-I RECEPTOR; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; PHOSPHATIDYLINOSITOL KINASE; BINDING; CELLS; SRC	There are two closely related, but distinct platelet-derived growth factor receptor (PDGFR) subunits: alpha and beta. Recent studies have indicated that relay of a biological signal from the activated PDGFR P subunit is determined to a large degree by the intracellular signal transduction enzymes with which the beta subunit associates. Like the beta subunit, the PDGFR alpha subunit encodes a tyrosine kinase that is activated and tyrosine phosphorylated upon binding of PDGF. To investigate the mechanism by which the PDGFR alpha subunit mediates signal transduction, we examined the proteins that associate with the activated PDGFR alpha subunit. The human alpha subunit was expressed in PhB cells, fibroblasts derived from Ph/Ph mouse embryos, which express the beta subunit but do not express the PDGFR alpha subunit. In response to binding of PDGF, the alpha subunit stably associated with phospholipase C gamma 1 (PLC-gamma 1), phosphatidylinositol 3 kinase (PI3K), the phosphotyrosine phosphatase Syp, and a 120 kd protein. These same proteins were detected binding to the activated PDGFR beta subunit. Unlike the PDGFR beta subunit, the PDGF-activated alpha subunit did not stably associate with the GTPase activating protein of ras (rasGAP), nor did it mediate tyrosine phosphorylation of rasGAP. Despite its apparent inability to interact with rasGAP, the alpha subunit was fully able to trigger PDGF-dependent p21(ras) activation and DNA synthesis. We conclude that the PDGFR alpha subunit does not mediate tyrosine phosphorylation or associate with rasGAP, and that these events are not required for PDGF-AA-mediated activation of p21(ras) or DNA synthesis.	NATL JEWISH CTR IMMUNOL & RESP MED, DEPT PEDIAT, DIV BASIC SCI, DENVER, CO 80206 USA	National Jewish Health					NCI NIH HHS [CA55063] Funding Source: Medline; NIGMS NIH HHS [GM48339] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA055063] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048339] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BALK SD, 1971, P NATL ACAD SCI USA, V68, P271, DOI 10.1073/pnas.68.2.271; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CLARK GJ, 1993, P NATL ACAD SCI USA, V90, P4887, DOI 10.1073/pnas.90.11.4887; COOPER JA, 1993, MOL CELL BIOL, V13, P1737, DOI 10.1128/MCB.13.3.1737; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; FRETTO LJ, 1993, J BIOL CHEM, V268, P3625; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HEIDARAN MA, 1993, J BIOL CHEM, V268, P9287; HEIDARAN MA, 1992, ONCOGENE, V7, P147; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HUANG DCS, 1993, MOL CELL BIOL, V13, P2420, DOI 10.1128/MCB.13.4.2420; KANAKARAJ P, 1991, BIOCHEMISTRY-US, V30, P1761, DOI 10.1021/bi00221a005; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MORRISONGRAHAM K, 1992, DEVELOPMENT, V115, P133; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; PALMIERI SL, 1992, MECH DEVELOP, V39, P181, DOI 10.1016/0925-4773(92)90045-L; PORRAS A, 1992, J BIOL CHEM, V267, P21124; PRONK GJ, 1992, J BIOL CHEM, V267, P24058; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; RICHARDSON WD, 1988, CELL, V53, P309, DOI 10.1016/0092-8674(88)90392-3; ROSS R, 1974, P NATL ACAD SCI USA, V71, P1207, DOI 10.1073/pnas.71.4.1207; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SCATTERMAN GC, 1992, DEVELOPMENT, V115, P123; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; SEIFERT RA, 1993, J BIOL CHEM, V268, P4473; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SERTH J, 1992, BIOCHEMISTRY-US, V31, P6361, DOI 10.1021/bi00143a001; STEPHENSON DA, 1991, P NATL ACAD SCI USA, V88, P6, DOI 10.1073/pnas.88.1.6; STOCKSCHLAEDER MAR, 1991, HUM GENE THER, V2, P33, DOI 10.1089/hum.1991.2.1-33; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; YEH HJ, 1993, P NATL ACAD SCI USA, V90, P1952, DOI 10.1073/pnas.90.5.1952; YEH HJ, 1991, CELL, V64, P209, DOI 10.1016/0092-8674(91)90222-K; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780; ZHANG K, 1992, SCIENCE, V257, P671, DOI 10.1126/science.1496380; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	77	43	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1994	9	2					517	525						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290262				2022-12-17	WOS:A1994MW24800019
J	SIF, S; CAPOBIANCO, AJ; GILMORE, TD				SIF, S; CAPOBIANCO, AJ; GILMORE, TD			THE V-REL ONCOPROTEIN INCREASES EXPRESSION FROM SP1 SITE-CONTAINING PROMOTERS IN CHICKEN-EMBRYO FIBROBLASTS	ONCOGENE			English	Article							NF-KAPPA-B; HUMAN-IMMUNODEFICIENCY-VIRUS; GTPASE-ACTIVATING PROTEIN; TRANSCRIPTION FACTOR SP1; RETICULOENDOTHELIOSIS VIRUS; C-REL; SPLEEN-CELLS; ONCOGENIC TRANSFORMATION; SYNERGISTIC ACTIVATION; CELLULAR PROTEINS	The v-Rel oncoprotein of the avian Rev-T retrovirus is a member of a family of related transcription factors, which also includes the subunits of NF-kappaB and several other interacting cellular proteins. We show here that v-Rel specifically increased expression from a reporter plasmid containing multiple Spl binding sites approximately sixfold in chicken embryo fibroblasts (CEFs), even though v-Rel did not bind directly to these sites. v-Rel also increased expression from a reporter plasmid containing a human immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR) in which the kappaB binding sites were mutated but which still contained intact Sp1 binding sites. The increase in Sp1-site transactivation does not precisely correlate with transformation by v-Rel since one non-transforming v-Rel mutant still induced expression from the Sp1 site-containing promoter. v-Rel appears to increase expression from Sp1 site-containing promoters by affecting the transactivation domain of Sp1, since v-Rel increased the activity of a Gal4-Sp1 fusion protein, which contains the Spl transactivation domain but lacks the Sp1 DNA-binding domain. As compared with v-Rel, c-Rel induced only a slight increase in expression from the reporter plasmid containing Sp1 sites. However, v-Ras and v-Src (but not v-Myb) induced increases in transcription from the reporter plasmid containing Sp1 sites to the same extent as v-Rel, but through pathways that appear to be independent from v-Rel. These results suggest that certain oncoproteins might increase transcription from many genes that contain Sp1 binding sites, and that this might be important for certain aspects of transformation by these proteins.	BOSTON UNIV,DEPT BIOL,5 CUMMINGTON ST,BOSTON,MA 02215	Boston University			Sif, Said/AAE-5554-2019	Capobianco, Anthony/0000-0002-3706-6797; Sif, Said/0000-0001-6268-1145	NATIONAL CANCER INSTITUTE [R01CA047763, R29CA047763] Funding Source: NIH RePORTER; NCI NIH HHS [CA47763] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BORELLINI F, 1991, J BIOL CHEM, V266, P15850; BORELLINI F, 1990, MOL CELL BIOL, V10, P5541, DOI 10.1128/MCB.10.10.5541; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CAPOBIANCO AJ, 1991, ONCOGENE, V6, P2203; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; DAVIS JN, 1990, ONCOGENE, V5, P1109; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DOUGHERTY JP, 1986, MOL CELL BIOL, V6, P4387, DOI 10.1128/MCB.6.12.4387; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FRANKLIN RB, 1977, VIROLOGY, V83, P313, DOI 10.1016/0042-6822(77)90176-3; GELINAS C, 1988, ONCOGENE, V3, P349; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90421-L; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GILMORE TD, 1992, CANCER SURV, V15, P69; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KAMENS J, 1991, NEW BIOL, V3, P1005; KAMINE J, 1991, P NATL ACAD SCI USA, V88, P8510, DOI 10.1073/pnas.88.19.8510; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KOCHEL T, 1991, ONCOGENE, V6, P615; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; LI YC, 1991, MOL CELL BIOL, V11, P1883, DOI 10.1128/MCB.11.4.1883; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MCDONNELL PC, 1992, ONCOGENE, V7, P163; MOORE BE, 1988, VIROLOGY, V162, P377, DOI 10.1016/0042-6822(88)90478-3; MORIN PJ, 1992, NUCLEIC ACIDS RES, V20, P2453, DOI 10.1093/nar/20.10.2453; MORIN PJ, 1993, NUCLEIC ACIDS RES, V21, P2157, DOI 10.1093/nar/21.9.2157; MORRISON LE, 1991, ONCOGENE, V6, P1657; MORRISON LE, 1989, ONCOGENE, V4, P677; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; MOSIALOS G, 1993, ONCOGENE, V8, P721; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SAFFER JD, 1990, GENE DEV, V4, P659, DOI 10.1101/gad.4.4.659; SARKAR S, 1993, IN PRESS ONCOGENE; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STACEY DW, 1991, ONCOGENE, V6, P2297; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; WATANABE S, 1983, MOL CELL BIOL, V3, P2241, DOI 10.1128/MCB.3.12.2241; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984	60	43	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2501	2509						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361761				2022-12-17	WOS:A1993LT36800022
J	ALGATE, PA; MCCUBREY, JA				ALGATE, PA; MCCUBREY, JA			AUTOCRINE TRANSFORMATION OF HEMATOPOIETIC-CELLS RESULTING FROM CYTOKINE MESSAGE STABILIZATION AFTER INTRACISTERNAL-A PARTICLE TRANSPOSITION	ONCOGENE			English	Article							DEPENDENT HEMATOPOIETIC-CELLS; C-MOS ONCOGENE; MESSENGER-RNA; NUCLEOTIDE-SEQUENCE; INTERLEUKIN-3 GENE; MURINE INTERLEUKIN-3; GROWTH-FACTORS; HOMEOBOX GENE; MALIGNANT TRANSFORMATION; TYROSINE PHOSPHORYLATION	Cell lines that no longer require exogenous interleukin 3 (IL-3) for growth were isolated from an IL-3-dependent cell tine that possesses characteristics of early lymphoid cells. Unlike the parental cells (FL5.12), these autocrine transformed lines (FL-IL3-R) constitutively secreted IL-3, were rearranged at the IL-3 locus and formed tumors upon injection into syngeneic mice. The rearrangement and IL-3 expression resulted from the transposition of an intracisternal A particle (IAP) provirus into the 3' untranslated region of the IL-3 gene. This region contained ATTTA sequence motifs that have been associated with cytokine and oncogene mRNA instability. IL-3 transcripts from the autocrine transformed cell lines had a longer half-life than similar transcripts isolated from either phorbol ester-stimulated T cells or the WEHI-3B myelomonocytic cell line. IAP proviral transposition did not alter the transcription rate of the IL-3 gene in FL-IL3-R cells. Therefore, IAP proviral transposition can activate IL-3 gene expression by prolonging mRNA stability, and this mechanism can contribute to the autocrine transformation of the hemopoietic cells.	E CAROLINA UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,GREENVILLE,NC 27858	University of North Carolina; East Carolina University				McCubrey, James/0000-0001-6027-3156	NCI NIH HHS [R01 CA51025] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051025] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BARLOW DP, 1987, EMBO J, V6, P617, DOI 10.1002/j.1460-2075.1987.tb04799.x; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BLANKENSTEIN T, 1990, J EXP MED, V171, P965, DOI 10.1084/jem.171.3.965; BLATT C, 1988, EMBO J, V7, P4283, DOI 10.1002/j.1460-2075.1988.tb03326.x; BROWDER TM, 1989, MOL CELL BIOL, V9, P204, DOI 10.1128/MCB.9.1.204; BROWN MA, 1987, CELL, V50, P809, DOI 10.1016/0092-8674(87)90339-4; CAMPBELL HD, 1985, EUR J BIOCHEM, V150, P297, DOI 10.1111/j.1432-1033.1985.tb09020.x; CANAANI E, 1983, P NATL ACAD SCI-BIOL, V80, P7118, DOI 10.1073/pnas.80.23.7118; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTY RJ, 1985, NUCLEIC ACIDS RES, V13, P289, DOI 10.1093/nar/13.1.289; CHRISTY RJ, 1988, MOL CELL BIOL, V8, P1093, DOI 10.1128/MCB.8.3.1093; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; CORNELIUS P, 1990, J BIOL CHEM, V265, P20506; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DUHRSEN U, 1990, EMBO J, V9, P1087, DOI 10.1002/j.1460-2075.1990.tb08214.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERRIS DK, 1988, BIOCHEM BIOPH RES CO, V154, P991, DOI 10.1016/0006-291X(88)90237-9; FUNG MC, 1984, NATURE, V307, P233, DOI 10.1038/307233a0; GOUGH NM, 1985, EMBO J, V4, P645, DOI 10.1002/j.1460-2075.1985.tb03678.x; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HAPEL AJ, 1986, LYMPHOKINE RES, V5, P249; HAWLEY RG, 1984, MOL CELL BIOL, V4, P2565, DOI 10.1128/MCB.4.12.2565; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; HOROWITZ M, 1984, EMBO J, V3, P2937, DOI 10.1002/j.1460-2075.1984.tb02235.x; Ihle J N, 1989, Year Immunol, V5, P59; IHLE JN, 1987, J IMMUNOL, V138, P3051; ISFORT R, 1988, J BIOL CHEM, V263, P19203; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; KONGSUWAN K, 1989, NUCLEIC ACIDS RES, V17, P1881, DOI 10.1093/nar/17.5.1881; KONO T, 1990, P NATL ACAD SCI USA, V87, P1806, DOI 10.1073/pnas.87.5.1806; KUFF EL, 1988, ADV CANCER RES, V51, P183, DOI 10.1016/S0065-230X(08)60223-7; LESLIE KB, 1991, MOL CELL BIOL, V11, P5562, DOI 10.1128/MCB.11.11.5562; Maniatis T., 1982, MOL CLONING; MATHEYPREVOT B, 1990, P NATL ACAD SCI USA, V87, P5046, DOI 10.1073/pnas.87.13.5046; MCCUBREY J, 1989, ONCOGENE RES, V4, P97; MCCUBREY J, 1983, J VIROL, V45, P950, DOI 10.1128/JVI.45.3.950-955.1983; MCCUBREY JA, 1990, BLOOD, V76, P63; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; MIETZ JA, 1992, MOL CELL BIOL, V12, P220, DOI 10.1128/MCB.12.1.220; MIETZ JA, 1987, J VIROL, V61, P3020, DOI 10.1128/JVI.61.10.3020-3029.1987; MIYATAKE S, 1985, P NATL ACAD SCI USA, V82, P316, DOI 10.1073/pnas.82.2.316; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MURATANI K, 1991, P NATL ACAD SCI USA, V88, P11315, DOI 10.1073/pnas.88.24.11315; OVERELL RW, 1987, MOL CELL BIOL, V7, P3394, DOI 10.1128/MCB.7.10.3394; PALACIOS R, 1984, NATURE, V309, P126, DOI 10.1038/309126a0; PARNES JR, 1982, CELL, V29, P661, DOI 10.1016/0092-8674(82)90182-9; PAYNE GS, 1982, NATURE, V295, P209, DOI 10.1038/295209a0; PERKINS A, 1990, P NATL ACAD SCI USA, V87, P8398, DOI 10.1073/pnas.87.21.8398; PETERS G, 1990, CELL GROWTH DIFFER, V1, P503; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHRADER JW, 1986, ANNU REV IMMUNOL, V4, P205, DOI 10.1146/annurev.iy.04.040186.001225; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; STOCKING C, 1988, CELL, V53, P869, DOI 10.1016/S0092-8674(88)90329-7; SUGITA T, 1990, J EXP MED, V171, P2001, DOI 10.1084/jem.171.6.2001; TOHYAMA K, 1990, EMBO J, V9, P1823, DOI 10.1002/j.1460-2075.1990.tb08307.x; VANBEVEREN C, 1980, P NATL ACAD SCI-BIOL, V77, P3307; WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0; WHEELER EF, 1987, MOL CELL BIOL, V7, P1673, DOI 10.1128/MCB.7.5.1673; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0; YMER S, 1986, NUCLEIC ACIDS RES, V14, P5901, DOI 10.1093/nar/14.14.5901; 1991, PROMEGA PROTOCOLS AP, P90	73	43	43	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1221	1232						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479745				2022-12-17	WOS:A1993KY32800013
J	BOUGERET, C; ROTHHUT, B; JULLIEN, P; FISCHER, S; BENAROUS, R				BOUGERET, C; ROTHHUT, B; JULLIEN, P; FISCHER, S; BENAROUS, R			RECOMBINANT CSK EXPRESSED IN ESCHERICHIA-COLI IS AUTOPHOSPHORYLATED ON TYROSINE RESIDUE(S)	ONCOGENE			English	Article							PROTEIN-KINASES; GENE-PRODUCT; PP60C-SRC; PHOSPHORYLATION; SITES; ACTIVATION; PP60V-SRC; MUTATION; INVITRO	The C-terminal src kinase (Csk) is responsible for the phosphorylation of the carboxy-terminal tyrosine of several tyrosine kinases of the Src family. This phosphorylation site has a negative regulatory function. Csk is unique among the members of the protein tyrosine kinase family because it lacks the conserved tyrosine autophosphorylation site and has been thought to be devoid of autophosphorylation activity. Using the glutathione S-transferase (GST) bacterial expression system, we have produced large amounts of a chimeric rat Csk protein. We have determined that the GST-Csk fusion protein isolated from bacteria is autophosphorylated on tyrosine residue(s). GST-Csk and purified Csk are capable of undergoing autophosphorylation on tyrosine residue(s) in vitro. The GST-Csk fusion protein also phosphorylates exogenous substrates, including the heteropolymer poly-Glu/Tyr and enolase. This is the first indication that Csk is autophosphorylated on tyrosine residue(s) both in vivo in bacteria expressing Csk cDNA and in vitro. These findings suggest that the autophosphorylation of Csk might play a role in the regulation of its kinase activity as well as its binding to other cellular proteins.	UNIV PARIS 05,INSERM,U332,INST COCHIN GENET MOLEC,22 RUE MECHAIN,F-75014 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite				Rothhut, Bernard/0000-0001-6467-8134				BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHRISMAN TD, 1981, J BIOL CHEM, V256, P2981; COOPER JA, 1984, J BIOL CHEM, V259, P7835; COOPER JA, 1990, SRC FAMILY PROTEIN T, P85; COOPER JA, 1983, METHOD ENZYMOL, V99, P937; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MARIN O, 1991, J BIOL CHEM, V266, P17798; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; PATANEN J, 1991, ONCOGENE, V6, P2013; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RESH MD, 1990, ONCOGENE, V5, P1437; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SNYDER MA, 1984, VIROLOGY, V136, P375, DOI 10.1016/0042-6822(84)90174-0; STERN DF, 1991, MOL CELL BIOL, V11, P937; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508	27	43	44	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1241	1247						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	7683130				2022-12-17	WOS:A1993KY32800015
J	ZANDER, NF; COOL, DE; DILTZ, CD; ROHRSCHNEIDER, LR; KREBS, EG; FISCHER, EH				ZANDER, NF; COOL, DE; DILTZ, CD; ROHRSCHNEIDER, LR; KREBS, EG; FISCHER, EH			SUPPRESSION OF V-FMS-INDUCED TRANSFORMATION BY OVEREXPRESSION OF A TRUNCATED T-CELL PROTEIN TYROSINE PHOSPHATASE	ONCOGENE			English	Article							FELINE SARCOMA-VIRUS; MCDONOUGH STRAIN; GROWTH-FACTOR; EXPRESSION; RECEPTOR; ACTIVATION; BINDING; CLONING; ANTIGEN; KINASE	Rat 2 cells stably transformed by murine v-fms (pB5 cells) were infected with retroviruses containing a human cDNA encoding either a full-length human T-cell protein tyrosine phosphatase (TC.PTP) or a truncated form (DELTAC11.PTP) in which an 11-kDa carboxy-terminal extension had been removed. This segment is responsible for enzyme localization and regulation. Clonal cell lines were isolated following G418 selection and their transforming properties analysed; pB5 cells containing the vector alone or TC.PTP remained transformed. These cells grew readily in soft agar, formed tumors in nude mice and were morphologically indistinguishable from the parental pB5 cells. In contrast, cells expressing DELTAC11.PTP showed dramatic changes in cell morphology, loss of anchorage-independent growth in soft agar and reduced or lack of tumor formation in nude mice. Both increases and decreases in tyrosine phosphorylation of specific proteins in the cells overexpressing the truncated enzyme were detected. These results indicate that coexpression of the deregulated, soluble tyrosine phosphatase with a constitutively active, oncogenic receptor tyrosine kinase leads to the suppression of the transformed phenotype.	UNIV WASHINGTON,DEPT BIOCHEM,SJ 70,SEATTLE,WA 98195; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104; UNIV WASHINGTON,DEPT PHARMACOL,SL 15,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle								ALEXANDER D R, 1990, New Biologist, V2, P1049; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNSHIMER S, 1990, P NATL ACAD SCI USA, V87, P5148, DOI 10.1073/pnas.87.13.5148; BROWNSHIMER S, 1992, CANCER RES, V52, P1234; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; COOL DE, 1992, P NATL ACAD SCI USA, V89, P5422, DOI 10.1073/pnas.89.12.5422; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; LYMAN SD, 1987, MOL CELL BIOL, V7, P3287, DOI 10.1128/MCB.7.9.3287; MANGER R, 1984, CELL, V39, P327, DOI 10.1016/0092-8674(84)90011-4; MCDONOUGH SK, 1971, CANCER RES, V31, P953; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MOSINGER B, 1992, P NATL ACAD SCI USA, V89, P499, DOI 10.1073/pnas.89.2.499; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; SAITO H, 1991, CELL GROWTH DIFFER, V2, P59; SHERR CJ, 1991, SEMIN HEMATOL, V28, P143; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; TONKS NK, 1988, J BIOL CHEM, V263, P6722; TUSHINSKI RJ, 1985, J CELL PHYSIOL, V122, P221, DOI 10.1002/jcp.1041220210; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; WOOLFORDTHOMAS T, 1992, J CELL BIOL, V117, P401; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZANDER NF, 1991, BIOCHEMISTRY-US, V30, P6964, DOI 10.1021/bi00242a022	34	43	44	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1175	1182						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	7683129				2022-12-17	WOS:A1993KY32800008
J	BERLINGIERI, MT; SANTORO, M; BATTAGLIA, C; GRIECO, M; FUSCO, A				BERLINGIERI, MT; SANTORO, M; BATTAGLIA, C; GRIECO, M; FUSCO, A			THE ADENOVIRUS E1A GENE BLOCKS THE DIFFERENTIATION OF A THYROID EPITHELIAL-CELL LINE, HOWEVER THE NEOPLASTIC PHENOTYPE IS ACHIEVED ONLY AFTER COOPERATION WITH OTHER ONCOGENES	ONCOGENE			English	Article							MURINE SARCOMA-VIRUS; TRANSFORMATION; TRANSCRIPTION; RETROVIRUS; SEQUENCES; DNA; THYROGLOBULIN; INFECTIVITY; ACTIVATION; EXPRESSION	The PC Cl 3 cell line is a well characterized epithelial thyroid cell fine of Fischer rat origin. This cell line has the peculiarity of retaining in vitro the typical markers of thyroid differentiation (i.e. thyroglobulin synthesis and secretion, iodide uptake and dependence on TSH for growth). The PC Cl 3 cells have been transfected with the E1A gene of Adenovirus 5. The E1A transfected cells, PC E1A, partially lost the dependency on TSH for growth and completely lost the ability to trap iodide and synthesize thyroglobulin; however they did not acquire the typical markers of the neoplastic phenotype. A highly malignant phenotype was achieved after infection of the PC E1A cells with retroviruses carrying the v-raf, v-abl and polyoma virus middle T oncogenes. In contrast, the PC E1A cells transfected with the E1B gene of Adenovirus were not tumorigenic at all, and those infected with retroviruses carrying oncogenes of the ras family displayed a very weak tumorigenic phenotype.	UNIV NAPOLI,FAC MED & CHIRURG 2,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC,CNR,I-80131 NAPLES,ITALY; UNIV REGGIO CALABRIA,FAC MED & CHIRURG CATANZARO,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria				Grieco, Michele/0000-0002-4212-7814; Fusco, Alfredo/0000-0003-3332-5197				AVVEDIMENTO VE, 1991, GENE DEV, V5, P22, DOI 10.1101/gad.5.1.22; BELLETT AJD, 1989, J VIROL, V63, P303, DOI 10.1128/JVI.63.1.303-310.1989; BERLINGIERI MT, 1988, MOL CELL BIOL, V8, P226; BRAITHWAITE AW, 1981, NEW BIOL, V3, P18; COLLETTA G, 1983, MOL CELL BIOL, V3, P2099, DOI 10.1128/MCB.3.11.2099; CONE RD, 1988, MOL CELL BIOL, V8, P1036, DOI 10.1128/MCB.8.3.1036; DEGROOT R, 1991, MOL CELL BIOL, V11, P192, DOI 10.1128/MCB.11.1.192; DILAURO R, 1982, GENE, V19, P117, DOI 10.1016/0378-1119(82)90196-2; FUSCO A, 1985, J VIROL, V56, P284, DOI 10.1128/JVI.56.1.284-292.1985; FUSCO A, 1982, CANCER RES, V42, P618; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; IKEKUBO K, 1980, METABOLISM, V29, P673, DOI 10.1016/0026-0495(80)90113-4; ITO T, 1992, CANCER RES, V52, P1369; JACKSON P, 1985, J VIROL, V55, P644, DOI 10.1128/JVI.55.3.644-650.1985; KELAKAR A, 1986, MOL CELL BIOL, V6, P7; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LYNCH MJ, 1989, CANCER RES, V49, P5429; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; Maniatis T., 1982, MOL CLONING; MONTANO X, 1987, MOL CELL BIOL, V7, P1782, DOI 10.1128/MCB.7.5.1782; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; PARASKEVA C, 1980, INT J CANCER, V25, P631, DOI 10.1002/ijc.2910250513; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SRINIVASAN A, 1981, P NATL ACAD SCI-BIOL, V78, P2077, DOI 10.1073/pnas.78.4.2077; STOW ND, 1982, NUCLEIC ACIDS RES, V10, P5105, DOI 10.1093/nar/10.17.5105; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WHITE P, 1988, NATURE, V334, P124; YAN DH, 1991, ONCOGENE, V6, P343; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	34	43	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					249	255						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426735				2022-12-17	WOS:A1993KN00600003
J	LUDLOW, JW; HOWELL, RL; SMITH, HC				LUDLOW, JW; HOWELL, RL; SMITH, HC			HYPOXIC STRESS INDUCES REVERSIBLE HYPOPHOSPHORYLATION OF PRB AND REDUCTION IN CYCLIN A ABUNDANCE INDEPENDENT OF CELL-CYCLE PROGRESSION	ONCOGENE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; GLUCOSE-REGULATED PROTEINS; HAMSTER OVARY CELLS; SEA-URCHIN EGGS; SV40 LARGE-T; TRANSCRIPTION FACTOR; MESSENGER-RNA; CDC2 KINASE; PRODUCT; INDUCTION	The effect of hypoxic stress on the phosphorylation state of the product of retinoblastoma susceptibility gene (pRB) and cyclin A abundance was examined in CV-1P monkey kidney cells. Flow cytometric DNA histogram analysis and [H-3]-thymidine incorporation assays demonstrated that hypoxia inhibited cell cycle progression and cell division. Within 6-12 h of hypoxia, pRB became hypophosphorylated and cyclin A abundance fell below detection limits. Hypophosphorylation of pRB and loss of cyclin A detection occurred without progression of cells through S-phase. These effects were found to be reversible by reoxygenation of the hypoxic cultures. Cells were shown to resume DNA synthesis within 12 - 16 h of reoxygenation concomitant with pRB hyperphosphorylation and an increase in cyclin A detection. These data demonstrate that hypoxic stress blocks the progression of these cells through the phases of the cell cycle and suggests that the effect might arise from the down regulation of key cell cycle controlling elements. The data also raise the possibility that maintaining pRB in a hyperphosphorylated state may be crucial for S-phase progression as well as S-phase entry.	UNIV ROCHESTER, SCH MED & DENT, DEPT BIOCHEM, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT, DEPT PATHOL, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester	LUDLOW, JW (corresponding author), UNIV ROCHESTER, CTR CANC, DIV TUMOR BIOL, BOX 704, 601 ELMWOOD AVE, ROCHESTER, NY 14642 USA.			Smith, Harold/0000-0001-6257-6791	NCI NIH HHS [CA56940, CA11198] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA011198, R29CA056940] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BUTLER AJ, 1991, J BIOL CHEM, V266, P18250; CHANG SC, 1989, MOL CELL BIOL, V9, P2153, DOI 10.1128/MCB.9.5.2153; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; COLEMAN CN, 1988, J NATL CANCER I, V80, P310, DOI 10.1093/jnci/80.5.310; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEWEY WC, 1976, RADIAT RES, V65, P511, DOI 10.2307/3574383; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; GIORDANO A, 1991, ONCOGENE, V6, P481; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HEACOCK CS, 1990, BRIT J CANCER, V62, P217, DOI 10.1038/bjc.1990.264; HEACOCK CS, 1986, INT J RADIAT ONCOL, V12, P1287, DOI 10.1016/0360-3016(86)90155-0; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; KOCH CJ, 1971, RADIAT RES, V48, P74, DOI 10.2307/3573396; KOWK TT, 1989, RADIAT RES, V119, P261; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; KWOK TT, 1989, INT J RADIAT ONCOL, V16, P1301; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE AS, 1983, J BIOL CHEM, V258, P597; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LOCK RB, 1990, CANCER RES, V50, P3761; LUCA FC, 1989, J CELL BIOL, V109, P1895, DOI 10.1083/jcb.109.5.1895; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; PELMAN HRB, 1986, CELL, V46, P959; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; RICE GC, 1985, INT J RADIAT ONCOL, V11, P1817, DOI 10.1016/0360-3016(85)90038-0; ROLL DE, 1991, MOL CELL BIOCHEM, V103, P141; SCIANDRA JJ, 1984, P NATL ACAD SCI-BIOL, V81, P4843, DOI 10.1073/pnas.81.15.4843; SHEN JW, 1989, MOL CELL BIOL, V9, P3284, DOI 10.1128/MCB.9.8.3284; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; Shew J.-Y., 1989, ONCOGENE RES, V1, P205; SORGER PK, 1987, J MOL BIOL, V194, P341, DOI 10.1016/0022-2836(87)90380-9; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; SUTHERLAND RM, 1982, INT J RADIAT ONCOL, V8, P745, DOI 10.1016/0360-3016(82)90726-X; SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAUPEL P, 1987, RADIAT RES, V2, P707; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WEBSTER KA, 1988, CAN J ZOOL, V66, P1046, DOI 10.1139/z88-155; WILSON RE, 1989, J NATL CANCER I, V81, P1235, DOI 10.1093/jnci/81.16.1235; XU HJ, 1989, ONCOGENE, V4, P807; YOUNG SD, 1988, P NATL ACAD SCI USA, V85, P9533, DOI 10.1073/pnas.85.24.9533	57	43	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1993	8	2					331	339						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426741				2022-12-17	WOS:A1993KN00600012
J	REYNOLDS, PJ; HURLEY, TR; SEFTON, BM				REYNOLDS, PJ; HURLEY, TR; SEFTON, BM			FUNCTIONAL-ANALYSIS OF THE SH2 AND SH3 DOMAINS OF THE LCK TYROSINE PROTEIN-KINASE	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; PHOSPHORYLATED CELLULAR PROTEINS; AMINO-TERMINAL DOMAIN; PHOSPHOLIPASE-C; SRC GENE; TRANSFORMING ACTIVITY; DIRECTED MUTAGENESIS; COMPLEMENTARY-DNA; POINT MUTATIONS; V-SRC	p56lck is a lymphoid cell-specific member of the src family of cytoplasmic tyrosine kinases. In helper and cytotoxic T cells it is physically associated with the CD4 and CD8 surface antigens and appears to play a role in signal transduction during T-cell activation. p56lck contains both an SH3 and an SH2 Src homology domain. Such domains have been suggested to play a role in the regulation of the activity or function of both receptor and non-receptor tyrosine protein kinases. Deletion of either or both domains in p56lck was found here to activate the protein and to lead to increased phosphorylation of the autophosphorylation site, Tyr-394, in vivo. These findings are consistent with the hypothesis that these domains participate in repression of the kinase activity of p56lck. None of the deleted forms was capable of transformation of fibroblasts. Deletion of the SH3 domain of a constitutively activated form of p56lck, p56lckF505, did not diminish the transforming activity of this protein. This suggests that this domain is dispensable for the transformation of fibroblasts by p56lck. In contrast, deletion of the SH2 domain abolished the transforming potential of activated p56lckF505. However, interpretation of this effect is made somewhat difficult because the mutation also lowered the steady-state abundance of the protein.	SALK INST,MOLEC BIOL & VIROL LAB,POB 85800,SAN DIEGO,CA 92186; UNIV CALIF SAN DIEGO,DEPT CHEM,LA JOLLA,CA 92093	Salk Institute; University of California System; University of California San Diego					NCI NIH HHS [CA 14129, CA 42350] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042350] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BRYANT D, 1982, J VIROL, V44, P683, DOI 10.1128/JVI.44.2.683-691.1982; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HIRAI J, 1990, MOL CELL BIOL, V10, P1307; HURLEY TR, 1989, ONCOGENE, V4, P265; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KAMPS MP, 1988, ONCOGENE, V2, P305; KANNER SB, 1989, J IMMUNOL METHODS, V120, P115, DOI 10.1016/0022-1759(89)90296-2; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KITAMURA N, 1983, J VIROL, V46, P985, DOI 10.1128/JVI.46.3.985-992.1983; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOGA Y, 1988, CANCER RES, V48, P856; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LUO K, 1990, ONCOGENE, V5, P921; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; Potts W M, 1988, Oncogene Res, V3, P343; RAYMOND VW, 1987, VIROLOGY, V160, P400, DOI 10.1016/0042-6822(87)90011-0; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SHORE SK, 1990, P NATL ACAD SCI USA, V87, P6502, DOI 10.1073/pnas.87.17.6502; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1987, ONCOGENE RES, V1, P357; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; VORONOVA AF, 1985, MOL CELL BIOL, V4, P2705; WANG HCR, 1989, J VIROL, V63, P291, DOI 10.1128/JVI.63.1.291-302.1989; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79; WENDLER PA, 1989, ONCOGENE, V4, P231; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	54	43	47	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					1949	1955						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408136				2022-12-17	WOS:A1992JP42400007
J	KELLY, K; DAVIS, P; MITSUYA, H; IRVING, S; WRIGHT, J; GRASSMANN, R; FLECKENSTEIN, B; WANO, Y; GREENE, W; SIEBENLIST, U				KELLY, K; DAVIS, P; MITSUYA, H; IRVING, S; WRIGHT, J; GRASSMANN, R; FLECKENSTEIN, B; WANO, Y; GREENE, W; SIEBENLIST, U			A HIGH PROPORTION OF EARLY RESPONSE GENES ARE CONSTITUTIVELY ACTIVATED IN T-CELLS BY HTLV-I	ONCOGENE			English	Article							VIRUS TYPE-I; COLONY-STIMULATING FACTOR; LEUKEMIA-LYMPHOMA VIRUS; GROWTH-FACTORS ENCODES; DNA-BINDING PROTEINS; LONG TERMINAL REPEAT; ZINC FINGER PROTEIN; INTERLEUKIN-2 RECEPTOR; TRANS-ACTIVATION; TAX GENE	Immortalization of T cells by HTLV-I is mediated by the X region of the virus and probably involves transactivation of cellular genes. We show that T cells transformed by HTLV-I constitutively express a high proportion of early response genes that are normally transiently induced following antigenic or mitogenic activation of T cells. Thus, HTLV-I-infected T cells display an `early activation' phenotype that is distinct from the gene expression pattern of continuously dividing T cells. Ten early response genes representing a diverse array of functional categories were assayed. Four DNA-binding proteins/transcription factors including the p50 subunit of NF-kappa-B were evaluated. A protein(s) encoded by the X region of HTLV-I appeared to contribute to up-regulated expression of most, if not all, of the early response genes. For those genes that could be assayed, increased transcriptional rates, but not substantial changes in mRNA half-life, were demonstrated in the presence of pX-encoded proteins, suggesting that the transcriptional transactivator, Tax, affects the induction or maintenance of transcription for these mitogen-inducible genes. Therefore, Tax may mimic or interact with a component(s) of the signal transduction pathway activated by antigen or mitogen treatment. These data demonstrate that early response genes, some of which probably play roles in initiating or maintaining cellular proliferation, are frequent targets of HTLV-I activation.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; NCI,CLIN ONCOL PROGRAM,BETHESDA,MD 20892; NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892; UNIV ERLANGEN NURNBERG,INST KLIN & MOLEK VIROL,W-8520 ERLANGEN,GERMANY; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Erlangen Nuremberg; Duke University; Duke University	KELLY, K (corresponding author), NCI,PATHOL LAB,BETHESDA,MD 20892, USA.							BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BOHNLEIN E, 1989, J VIROL, V63, P1578; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHAN JY, 1986, P NATL ACAD SCI USA, V83, P8669, DOI 10.1073/pnas.83.22.8669; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; FUJISAWA J, 1989, J VIROL, V63, P3234, DOI 10.1128/JVI.63.8.3234-3239.1989; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GREEN JE, 1989, MOL CELL BIOL, V9, P4731, DOI 10.1128/MCB.9.11.4731; HATTORI T, 1981, BLOOD, V58, P645; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HIDAKA M, 1988, EMBO J, V7, P519, DOI 10.1002/j.1460-2075.1988.tb02840.x; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; INOUE J, 1987, P NATL ACAD SCI USA, V84, P3653, DOI 10.1073/pnas.84.11.3653; IRVING SG, 1989, MOL CELL BIOL, V9, P1034, DOI 10.1128/MCB.9.3.1034; JEANG KT, 1988, J VIROL, V62, P4499, DOI 10.1128/JVI.62.12.4499-4509.1988; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KELLY K, 1988, J BIOL CHEM, V263, P4828; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LILIENBAUM A, 1990, J VIROL, V64, P256, DOI 10.1128/JVI.64.1.256-263.1990; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MITSUYA H, 1984, SCIENCE, V225, P1484, DOI 10.1126/science.6206569; MIYATAKE S, 1988, MOL CELL BIOL, V8, P5581, DOI 10.1128/MCB.8.12.5581; MIYOSHI I, 1981, NATURE, V299, P640; MONTAGNE J, 1990, EMBO J, V9, P957, DOI 10.1002/j.1460-2075.1990.tb08194.x; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NYBORG JK, 1988, P NATL ACAD SCI USA, V85, P1457, DOI 10.1073/pnas.85.5.1457; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POPOVIC M, 1983, P NATL ACAD SCI-BIOL, V80, P5402, DOI 10.1073/pnas.80.17.5402; POTEAT HT, 1989, J VIROL, V63, P1604, DOI 10.1128/JVI.63.4.1604-1611.1989; RANGNEKAR VM, 1990, NUCLEIC ACIDS RES, V18, P2749, DOI 10.1093/nar/18.9.2749; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; RYSECK RP, 1989, EMBO J, V8, P3327, DOI 10.1002/j.1460-2075.1989.tb08494.x; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5489; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; SOOD AK, 1981, P NATL ACAD SCI-BIOL, V78, P616, DOI 10.1073/pnas.78.1.616; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TAN TH, 1989, J VIROL, V63, P3761, DOI 10.1128/JVI.63.9.3761-3768.1989; VARNUM BC, 1989, MOL CELL BIOL, V9, P3580, DOI 10.1128/MCB.9.8.3580; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; WRIGHT JJ, 1990, SCIENCE, V248, P588, DOI 10.1126/science.2110381; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; YOSHIDA M, 1987, ANNU REV IMMUNOL, V5, P541, DOI 10.1146/annurev.iy.05.040187.002545; ZANDOMENI R, 1982, P NATL ACAD SCI-BIOL, V79, P3167, DOI 10.1073/pnas.79.10.3167; ZIPFEL PF, 1989, J IMMUNOL, V142, P1582; ZIPFEL PF, 1989, MOL CELL BIOL, V9, P1034	61	43	43	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1463	1470						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630809				2022-12-17	WOS:A1992JE81300001
J	OTTILIE, S; RAULF, F; BARNEKOW, A; HANNIG, G; SCHARTL, M				OTTILIE, S; RAULF, F; BARNEKOW, A; HANNIG, G; SCHARTL, M			MULTIPLE SRC-RELATED KINASE GENES, SRK1-4, IN THE FRESH-WATER SPONGE SPONGILLA-LACUSTRIS	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; AMINO-ACID SEQUENCE; ONCOGENE C-SRC; NUCLEOTIDE-SEQUENCE; MESSENGER-RNA; EXPRESSION; PP60C-SRC; CELLS; PRODUCT; DNA	In one of the simplest metazoan organisms, the sponge Spongilla lacustris, at least four different src-related kinase genes (srk1-4) are expressed, all of which show a high degree of similarity to the c-src genes of vertebrates. Whereas srk2 and srk3 are clearly unrelated at the nucleic acid level, srk1 and srk4 share identical sequences in the 5' parts of their cDNAs. The cloning of several primer extension clones and genomic polymerase chain reaction experiments confirmed the hypothesis of an alternative splicing of tandemly arranged carboxy-terminal parts of srk1 and srk4. The genomic sequence encoding both proteins was found to be interrupted at the splice point by an intron which is located in the same position as one of the introns in the chicken src gene, which is the only gene conserved in invertebrates and vertebrates. All four srk genes are expressed in adult sponges as mRNA transcripts of about 2.2 kb. Tyrosine kinase activity of a src-related kinase could be detected in adult sponges but not in their resting form (gemmulae), and may reflect the activity of the srk protein products. Spongilla lacustris is the simplest organism from which a protein tyrosine kinase gene has been isolated. The presence of at least four such genes in the evolutionary ancient and primitive phylum Porifera suggests that tyrosine kinase genes arose concomitantly with or shortly after the appearance of multicellular organisms and that their activity may be involved in aggregation and cell-cell recognition.	MAX PLANCK INST BIOCHEM, GENECTR, KLOPFERSPITZ 18A, W-8033 MARTINSRIED, GERMANY; UNIV MUNSTER, DEPT EXPTL TUMORBIOL, W-4400 MUNSTER, GERMANY	Max Planck Society; University of Munster				Schartl, Manfred/0000-0001-9882-5948				ANDERSON SK, 1985, MOL CELL BIOL, V5, P1122, DOI 10.1128/MCB.5.5.1122; BARNEKOW A, 1984, MOL CELL BIOL, V4, P1179, DOI 10.1128/MCB.4.6.1179; BARNEKOW A, 1990, ONCOGENE, V5, P1019; BARNEKOW A, 1989, Critical Reviews in Oncogenesis, V1, P277; BOSCH TCG, 1989, MOL CELL BIOL, V9, P4141, DOI 10.1128/MCB.9.10.4141; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; DAVIS LG, 1986, BASIC METHODS MOL BI, P133; DELORBE WJ, 1980, J VIROL, V36, P50, DOI 10.1128/JVI.36.1.50-61.1980; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; GREGORY RJ, 1987, MOL CELL BIOL, V7, P2119, DOI 10.1128/MCB.7.6.2119; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANNIG G, 1991, ONCOGENE, V6, P361; HIRSCHBEHNAM A, 1988, COMP BIOCHEM PHYS B, V91, P125, DOI 10.1016/0305-0491(88)90123-X; HOFFMANN FM, 1983, CELL, V35, P393, DOI 10.1016/0092-8674(83)90172-1; KATAMINE S, 1988, MOL CELL BIOL, V8, P259, DOI 10.1128/MCB.8.1.259; KAWAKAMI T, 1986, MOL CELL BIOL, V6, P4195, DOI 10.1128/MCB.6.12.4195; KOCHER TD, 1989, P NATL ACAD SCI USA, V86, P6196, DOI 10.1073/pnas.86.16.6196; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; MANESS PF, 1986, J NEUROSCI RES, V16, P127, DOI 10.1002/jnr.490160113; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MULLER WEG, 1976, EXP CELL RES, V98, P31, DOI 10.1016/0014-4827(76)90459-6; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; PARKER RC, 1985, MOL CELL BIOL, V5, P831, DOI 10.1128/MCB.5.4.831; PYPER JM, 1989, J NEUROSCI RES, V24, P89, DOI 10.1002/jnr.490240113; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; Rasmont R., 1975, Transactions Congr int Un Game Biol, V10, P141; RAULF F, 1989, ONCOGENE RES, V5, P39; RAULF F, 1989, J NEUROSCI RES, V24, P81, DOI 10.1002/jnr.490240112; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHARTL M, 1982, DIFFERENTIATION, V23, P109, DOI 10.1111/j.1432-0436.1982.tb01273.x; SCHARTL M, 1989, ONCOGENE, V4, P1185; SCHARTL M, 1984, DEV BIOL, V105, P415, DOI 10.1016/0012-1606(84)90298-7; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; STEELE RE, 1989, J BIOL CHEM, V264, P10649; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; WANG LH, 1987, ONCOGENE RES, V1, P43; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	48	43	50	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1992	7	8					1625	1630						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1378585				2022-12-17	WOS:A1992JE81300019
J	BRENNER, B; WILDHARDT, G; SCHNEIDER, S; ROYERPOKORA, B				BRENNER, B; WILDHARDT, G; SCHNEIDER, S; ROYERPOKORA, B			RNA-POLYMERASE CHAIN-REACTION DETECTS DIFFERENT LEVELS OF 4 ALTERNATIVELY SPLICED WT1 TRANSCRIPTS IN WILMS-TUMORS	ONCOGENE			English	Note							ENZYMATIC AMPLIFICATION; HUMAN CHROMOSOME-11; PHYSICAL MAP; PROTEIN; LOCUS; GENE	A Wilms' tumor susceptibility gene (WT1) localized to 11p13 was recently isolated and shown to be altered in some sporadic Wilms' tumors. This gene encodes a DNA-binding protein with four zinc fingers (ZFs) in the carboxy-terminal region and a glutamine/proline (Gln/Pro)-rich domain near the 5' end. Two alternative splice sites were described, splice I in the Gln/Pro-rich domain (51 bp) and splice II between ZFs 3 and 4 (9 bp). Using RNA polymerase chain reaction (PCR) we show that Wilms' tumors contain all four possible transcripts, which are also identified in normal adult and embryonic kidney cells. The transcripts containing the 9-bp ZF insert were always predominant in tumors and normal cells. The presence of all four WT1 transcripts in tumors and expressing tissues suggests that each encoded protein isoform has an important role for the function of the WT1 gene.	UNIV HEIDELBERG,INST HUMAN GENET & ANTHROPOL,NEUENHEIMER FELD 328,W-6900 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg								BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COMPTON DA, 1988, CELL, V55, P827, DOI 10.1016/0092-8674(88)90138-9; GESSLER M, 1989, GENOMICS, V5, P43, DOI 10.1016/0888-7543(89)90084-0; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MATSUNAGA E, 1981, HUM GENET, V57, P231; NOONAN KE, 1988, NUCLEIC ACIDS RES, V16, P10366, DOI 10.1093/nar/16.21.10366; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980	14	43	47	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1431	1433						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1320246				2022-12-17	WOS:A1992HZ97100023
J	KOCHEL, T; MUSHINSKI, JF; RICE, NR				KOCHEL, T; MUSHINSKI, JF; RICE, NR			THE V-REL AND C-REL PROTEINS EXIST IN HIGH-MOLECULAR-WEIGHT COMPLEXES IN AVIAN AND MURINE CELLS	ONCOGENE			English	Article							NF-KAPPA-B; VIRUS-STRAIN-T; TRANSFORMED LYMPHOID-CELLS; DNA-BINDING SUBUNIT; BONE-MARROW CELLS; RETICULOENDOTHELIOSIS VIRUS; ONCOGENE PRODUCT; PROTOONCOGENE PRODUCT; TRANSCRIPTION FACTOR; HEMATOPOIETIC-CELLS	We reported previously that the v-rel protein (p59v-rel) exists in a high molecular weight complex with at least four other proteins in the cytoplasm of v-rel-transformed chicken pre-B lymphoid cells (Simek, S. & Rice, N.R., J. Virol., 62, 4730-4736, 1989). One of these proteins is the chicken c-rel protein, but the identities of the others (of about 36 kDa, 115kDa, and 124 kDa) are unknown. In this report we extend that observation to additional v-rel-transformed cell lines of both pre-B and B cell phenotypes. We also introduced and expressed v-rel in several other avian cell lines (a chicken T cell line, chick embryo fibroblasts, and quail fibroblasts) and found that in these cells p59v-rel was complexed with the same proteins as observed in the v-rel-transformed cells. Thus, the associated proteins are not limited to pre-B cells, but occur and complex with p59v-rel in B cells, T cells, and fibroblasts. We next examined five uninfected avian cells and tissues and found that, with only one exception, p75c-rel was complexed with p36, p115, and p124. Thus, in most cases complex formation is not limited to or dependent on the presence of the transforming v-rel protein, but also occurs with the normal c-rel protein. To determine whether a mammalian c-rel protein is similarly associated with other proteins, we screened murine cell lines for the presence of c-rel mRNA. In agreement with our earlier findings, we found the highest expression in mature B cells, although several pre-B and myeloid cell lines were also strongly positive. Using one of the B cell lines, we detected the murine c-rel protein. We found that, like its avian counterpart, it is a protein of about 75 kDa and is associated with proteins of 36 kDa and 115 kDa. Sephacryl S-400 chromatography revealed that both the avian and murine complexes are of high molecular weight, with an average size of about 400 kDa.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,POB B,FREDERICK,MD 21701; NCI,GENET LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, COLD SPRING HARB SYM, V53, P789, DOI 10.1101/SQB.1988.053.01.089; BARTH CF, 1988, J EXP MED, V167, P89, DOI 10.1084/jem.167.1.89; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BRAVO R, 1988, COLD SPRING HARB SYM, V53, P901, DOI 10.1101/SQB.1988.053.01.103; BROWNELL E, 1988, ONCOGENE, V3, P93; BROWNELL E, 1986, AM J HUM GENET, V39, P194; BROWNELL E, 1985, MOL CELL BIOL, V5, P2826, DOI 10.1128/MCB.5.10.2826; BROWNELL E, 1987, MOL CELL BIOL, V7, P1304, DOI 10.1128/MCB.7.3.1304; BROWNELL E, 1989, ONCOGENE, V4, P935; BULL P, 1989, MOL CELL BIOL, V9, P5239, DOI 10.1128/MCB.9.11.5239; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CHEN ISY, 1981, J VIROL, V40, P800, DOI 10.1128/JVI.40.3.800-811.1981; CHEN L, 1988, P NATL ACAD SCI USA, V85, P549, DOI 10.1073/pnas.85.2.549; DAVIS JN, 1990, ONCOGENE, V5, P1109; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; DORN PL, 1988, J VIROL, V62, P3522, DOI 10.1128/JVI.62.9.3522-3526.1988; FRANKLIN RB, 1974, INTERVIROLOGY, V3, P342, DOI 10.1159/000149771; GARSON K, 1986, BIOCHEM BIOPH RES CO, V134, P716, DOI 10.1016/S0006-291X(86)80479-X; GELINAS C, 1988, ONCOGENE, V3, P349; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GRUMONT RJ, 1989, ONCOGENE RES, V4, P1; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HERZOG NK, 1986, P NATL ACAD SCI USA, V83, P812, DOI 10.1073/pnas.83.3.812; HOELZER JD, 1980, VIROLOGY, V100, P462, DOI 10.1016/0042-6822(80)90536-X; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LEWIS RB, 1981, CELL, V25, P421, DOI 10.1016/0092-8674(81)90060-X; LIM MY, 1990, VIROLOGY, V175, P149, DOI 10.1016/0042-6822(90)90195-W; Maniatis T., 1982, MOL CLONING; MOORE BE, 1989, ONCOGENE, V4, P845; MORRISON LE, 1989, ONCOGENE, V4, P677; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MUSHINSKI JF, 1987, CANCER INVEST, V5, P345; RICE NR, 1982, J VIROL, V42, P237, DOI 10.1128/JVI.42.1.237-252.1982; RICE NR, 1986, VIROLOGY, V149, P217, DOI 10.1016/0042-6822(86)90123-6; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHIBUYA T, 1982, CANCER RES, V42, P2722; SIMEK S, 1988, ONCOGENE RES, V2, P103; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; SIMEK SL, 1986, J VIROL, V59, P120, DOI 10.1128/JVI.59.1.120-126.1986; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TUNG HYL, 1988, P NATL ACAD SCI USA, V85, P2479, DOI 10.1073/pnas.85.8.2479; WALRO DS, 1987, VIROLOGY, V160, P433, DOI 10.1016/0042-6822(87)90015-8; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; WONG TC, 1981, VIROLOGY, V111, P289, DOI 10.1016/0042-6822(81)90674-7; ZABELU, 1990, CELL, V61, P255	51	43	43	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					615	626						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1851550				2022-12-17	WOS:A1991FR93900017
J	WASYLYK, C; SCHNEIKERT, J; WASYLYK, B				WASYLYK, C; SCHNEIKERT, J; WASYLYK, B			ONCOGENE V-JUN MODULATES DNA-REPLICATION	ONCOGENE			English	Note											WASYLYK, C (corresponding author), FAC MED STRASBOURG,FAC CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,F-67085 STRASBOURG,FRANCE.		Wasylyk, Bohdan/ABG-6778-2020	Wasylyk, Bohdan/0000-0002-1718-1237				CAMPBELL BA, 1988, MOL CELL BIOL, V8, P1993, DOI 10.1128/MCB.8.5.1993; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HERRLICH P, 1989, TRENDS GENET, V5, P112, DOI 10.1016/0168-9525(89)90041-3; Imler J L, 1989, Prog Growth Factor Res, V1, P69, DOI 10.1016/0955-2235(89)90001-X; IMLER JL, 1988, NUCLEIC ACIDS RES, V16, P3005, DOI 10.1093/nar/16.7.3005; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; KELLY TJ, 1988, J BIOL CHEM, V263, P17889; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; OCONNOR DT, 1988, NUCLEIC ACIDS RES, V16, P11207, DOI 10.1093/nar/16.23.11207; ONEILL EA, 1988, SCIENCE, V241, P1210, DOI 10.1126/science.3413485; PRUIJN GJM, 1989, NUCLEIC ACIDS RES, V17, P1845, DOI 10.1093/nar/17.5.1845; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SHARMA A, 1989, P NATL ACAD SCI USA, V86, P491, DOI 10.1073/pnas.86.2.491; STRUHL K, 1988, NATURE, V332, P649, DOI 10.1038/332649a0; VOGT PK, 1989, IN PRESS; WASYLYK B, 1988, P NATL ACAD SCI USA, V85, P7952, DOI 10.1073/pnas.85.21.7952; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; YAMAGUCHI Y, 1989, J VIROL, V63, P1040, DOI 10.1128/JVI.63.3.1040-1048.1989	21	43	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1990	5	7					1055	1058						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP415	2165232				2022-12-17	WOS:A1990DP41500015
J	TSUCHIE, H; CHANG, CHW; YOSHIDA, M; VOGT, PK				TSUCHIE, H; CHANG, CHW; YOSHIDA, M; VOGT, PK			A NEWLY ISOLATED AVIAN-SARCOMA VIRUS, ASV-1, CARRIES THE CRK ONCOGENE	ONCOGENE			English	Article									UNIV SO CALIF,SCH MED,NORRIS CANC CTR,2011 ZONAL AVE,HMR 401,LOS ANGELES,CA 90033; NATL INST HLTH,AIDS RES CTR,DIV AIDS VIRUS,MUSASHI MURAYAMA,TOKYO 19012,JAPAN; UNIV SO CALIF,SCH MED,DEPT MICROBIOL,LOS ANGELES,CA 90033; JAPANESE FDN CANC RES,INST CANC,DEPT VIRAL ONCOL,TOKYO 170,JAPAN	University of Southern California; University of Southern California; Japanese Foundation for Cancer Research			Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500	NATIONAL CANCER INSTITUTE [R35CA042564] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42564] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISTER K, 1977, VIROLOGY, V82, P431, DOI 10.1016/0042-6822(77)90017-4; Burk D, 1941, J NATL CANCER I, V2, P201; CAVALIERI F, 1985, VIROLOGY, V143, P680, DOI 10.1016/0042-6822(85)90412-X; CLAUDE A, 1947, CANCER RES, V7, P421; DELORBE WJ, 1980, J VIROL, V36, P50, DOI 10.1128/JVI.36.1.50-61.1980; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; Maniatis T., 1982, MOL CLONING; MAYER BJ, 1988, COLD SPRING HARB SYM, V53, P907, DOI 10.1101/SQB.1988.053.01.104; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Murphy JB, 1931, SCIENCE, V74, P180, DOI 10.1126/science.74.1911.180; PALESE P, 1976, J VIROL, V17, P876, DOI 10.1128/JVI.17.3.876-884.1976; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHANK PR, 1978, J VIROL, V25, P104, DOI 10.1128/JVI.25.1.104-104.1978; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; VANBEVEREN C, 1985, RNA TUMOR VIRUSES; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198	19	43	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1989	4	11					1281	1284						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AX659	2554234				2022-12-17	WOS:A1989AX65900002
J	SITHANANDAM, G; DEAN, M; BRENNSCHEIDT, U; BECK, T; GAZDAR, A; MINNA, JD; BRAUCH, H; ZBAR, B; RAPP, UR				SITHANANDAM, G; DEAN, M; BRENNSCHEIDT, U; BECK, T; GAZDAR, A; MINNA, JD; BRAUCH, H; ZBAR, B; RAPP, UR			LOSS OF HETEROZYGOSITY AT THE C-RAF LOCUS IN SMALL CELL LUNG-CARCINOMA	ONCOGENE			English	Article									NCI, VIRAL CARCINOGENESIS LAB, FREDERICK, MD 21701 USA; NCI, PROGRAM RESOURCES INC, FREDERICK, MD 21701 USA; USN, NCI, BETHESDA, MD 20892 USA; NCI, IMMUNOL LAB, FREDERICK, MD 21701 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Navy; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Dean, Michael C/G-8172-2012; Dean, Michael/R-7501-2019	Dean, Michael C/0000-0003-2234-0631; Brauch, Hiltrud/0000-0001-7531-2736				ARIYOSHI Y, 1986, Proceedings American Society of Clinical Oncology Annual Meeting, V5, P23; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BERGER CL, 1981, J CLIN ENDOCR METAB, V53, P422, DOI 10.1210/jcem-53-2-422; BONNER T, 1984, SCIENCE, V223, P71, DOI 10.1126/science.6691137; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; CARNEY DN, 1988, SEMIN ONCOL, V15, P199; CARNEY DN, 1985, SEMIN ONCOL, V12, P289; CARRITT B, 1986, AM J HUM GENET, V38, P428; CHENEVIXTRENCH G, 1987, LEUKEMIA, V1, P82; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; DEAN M, 1987, J PEDIATR-US, V111, P490, DOI 10.1016/S0022-3476(87)80106-3; FUJIMOTO E, 1987, NUCLEIC ACIDS RES, V15, P10078, DOI 10.1093/nar/15.23.10078; GAREAU JLP, 1988, NUCLEIC ACIDS RES, V16, P1223, DOI 10.1093/nar/16.3.1223; GAZDAR AF, 1987, P AN M AM SOC CLIN, V6, P16; GRAZIANO SL, 1987, CANCER RES, V47, P2148; HEIDECKER G, 1988, GENES SIGNAL TRANSDU, P339; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; MARK J, 1982, HEREDITAS, V96, P141, DOI 10.1111/j.1601-5223.1982.tb00044.x; MARK J, 1980, CANCER GENET CYTOGEN, V2, P231, DOI 10.1016/0165-4608(80)90030-8; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; PATHAK S, 1982, SCIENCE, V217, P939, DOI 10.1126/science.7112106; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAPP UR, 1987, MODERN TRENDS HUMA 7, V31, P450; SEIZINGER BR, 1988, NATURE, V332, P268, DOI 10.1038/332268a0; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WASYLYK C, 1989, IN PRESS MOL CELL BI; WHANGPENG J, 1982, CANCER GENET CYTOGEN, V6, P119, DOI 10.1016/0165-4608(82)90077-2; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0; ZECH L, 1985, CANCER GENET CYTOGEN, V45, P6024	34	43	43	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1989	4	4					451	455						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5677	2566144				2022-12-17	WOS:A1989U567700009
J	LAVIALLE, C; MODJTAHEDI, N; CASSINGENA, R; BRISON, O				LAVIALLE, C; MODJTAHEDI, N; CASSINGENA, R; BRISON, O			HIGH C-MYC AMPLIFICATION LEVEL CONTRIBUTES TO THE TUMORIGENIC PHENOTYPE OF THE HUMAN-BREAST CARCINOMA CELL-LINE SW-613-S	ONCOGENE			English	Article									INST GUSTAVE ROUSSY,ONCOL MOLEC LAB,CNRS,UA 1158,F-94805 VILLEJUIF,FRANCE; INST RECH SCI CANC,CNRS,ER 278,F-94802 VILLEJUIF,FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS)			MODJTAHEDI, Nazanine/D-4377-2017; Lavialle, Christian/B-3775-2009; Lavialle, Christian/O-2329-2019					ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; ALITALO K, 1987, BIOCHIM BIOPHYS ACTA, V907, P1, DOI 10.1016/0304-419X(87)90016-3; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CARLONI G, 1988, FEBS LETT, V233, P268, DOI 10.1016/0014-5793(88)80440-X; CHANG EH, 1982, NATURE, V297, P479, DOI 10.1038/297479a0; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DRON D, 1986, MOL CELL BIOL, V6, P1374; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; JOHNSON BE, 1986, J CLIN INVEST, V78, P525, DOI 10.1172/JCI112604; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; LEVINSON AD, 1986, TRENDS GENET, V2, P81, DOI 10.1016/0168-9525(86)90184-8; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; MACIEIRACOELHO A, 1982, EXP CELL RES, V141, P325, DOI 10.1016/0014-4827(82)90220-8; MODJTAHEDI N, 1985, CANCER RES, V45, P4372; MODJTAHEDI N, 1988, EXP CELL RES, V174, P58, DOI 10.1016/0014-4827(88)90142-5; MURRAY MJ, 1983, CELL, V33, P749, DOI 10.1016/0092-8674(83)90017-X; NICOLAS JF, 1983, COLD SPRING HARBOR C, V10, P469; NISHIMURA S, 1987, BIOCHEM J, V243, P313, DOI 10.1042/bj2430313; SANTOS E, 1983, P NATL ACAD SCI-BIOL, V80, P4679, DOI 10.1073/pnas.80.15.4679; SCHWAB M, 1985, NATURE, V315, P345, DOI 10.1038/315345a0; SHIMKE RT, 1984, CELL, V37, P705; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; SUAREZ HG, 1987, ONCOGENE RES, V1, P201; SUBRAMANI S, 1981, MOL CELL BIOL, V1, P854, DOI 10.1128/MCB.1.9.854; VARMUS HE, 1984, ANNU REV GENET, V18, P553; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513	36	43	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1988	3	3					335	339						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q4367	3060796				2022-12-17	WOS:A1988Q436700013
J	YANEZ, L; GROFFEN, J; VALENZUELA, DM				YANEZ, L; GROFFEN, J; VALENZUELA, DM			C-K-RAS MUTATIONS IN HUMAN CARCINOMAS OCCUR PREFERENTIALLY IN CODON-12	ONCOGENE			English	Article									ONCOGENE SCI INC,350 COMMUNITY DR,MANHASSET,NY 11030				Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273				BANASZUK AM, 1983, ANAL BIOCHEM, V128, P281, DOI 10.1016/0003-2697(83)90376-7; BOS JL, 1985, NATURE, V315, P726, DOI 10.1038/315726a0; BOS JL, 1984, NUCLEIC ACIDS RES, V12, P9155, DOI 10.1093/nar/12.23.9155; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; FUJITA J, 1985, P NATL ACAD SCI USA, V82, P3849, DOI 10.1073/pnas.82.11.3849; HALL A, 1983, NATURE, V303, P396, DOI 10.1038/303396a0; IKUTA S, 1987, NUCLEIC ACIDS RES, V15, P797, DOI 10.1093/nar/15.2.797; KIDD VJ, 1983, NATURE, V304, P230, DOI 10.1038/304230a0; MCCOY MS, 1983, NATURE, V302, P79, DOI 10.1038/302079a0; MCCOY MS, 1984, MOL CELL BIOL, V4, P1577, DOI 10.1128/MCB.4.8.1577; MURRAY MJ, 1983, CELL, V33, P749, DOI 10.1016/0092-8674(83)90017-X; NAKANO H, 1984, P NATL ACAD SCI-BIOL, V81, P71, DOI 10.1073/pnas.81.1.71; NAKANO H, 1984, CANCER CELL, V2, P447; PADUA RA, 1985, MOL CELL BIOL, V5, P582, DOI 10.1128/MCB.5.3.582; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; SANTOS E, 1984, SCIENCE, V223, P661, DOI 10.1126/science.6695174; SHIMIZU K, 1983, NATURE, V304, P497, DOI 10.1038/304497a0; STUDENCKI AB, 1984, DNA-J MOLEC CELL BIO, V3, P7, DOI 10.1089/dna.1.1984.3.7; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; VALENZUELA DM, 1986, NUCLEIC ACIDS RES, V14, P843, DOI 10.1093/nar/14.2.843; WALTER M, 1986, SCIENCE, V233, P649, DOI 10.1126/science.3487832; YAMAMOTO F, 1984, NUCLEIC ACIDS RES, V12, P8873, DOI 10.1093/nar/12.23.8873; YUASA Y, 1983, NATURE, V303, P775, DOI 10.1038/303775a0	23	43	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene		1987	1	3					315	318						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	J9705	3330777				2022-12-17	WOS:A1987J970500013
J	Lei, G; Zhang, YL; Hong, T; Zhang, XD; Liu, XG; Mao, C; Yan, YL; Koppula, P; Cheng, WJ; Sood, AK; Liu, JS; Gan, BY				Lei, Guang; Zhang, Yilei; Hong, Ting; Zhang, Xudong; Liu, Xiaoguang; Mao, Chao; Yan, Yuelong; Koppula, Pranavi; Cheng, Weijie; Sood, Anil K.; Liu, Jinsong; Gan, Boyi			Ferroptosis as a mechanism to mediate p53 function in tumor radiosensitivity	ONCOGENE			English	Article								Ferroptosis, a form of regulated cell death triggered by lipid peroxidation, was recently identified as an important mechanism in radiotherapy (RT)-mediated tumor suppression and radioresistance, although the exact genetic contexts in which to target ferroptosis in RT remains to be defined. p53 is the most commonly mutated gene in human cancers and a major effector to RT. Here, we identify ferroptosis as a critical mechanism to mediate p53 function in tumor radiosensitivity. Mechanistically, RT-mediated p53 activation antagonizes RT-induced SLC7A11 expression and represses glutathione synthesis, thereby promoting RT-induced lipid peroxidation and ferroptosis. p53 deficiency promotes radioresistance in cancer cells or tumors at least partly through SLC7A11-mediated ferroptosis inhibition. Ferroptosis inducers (FINs) that inhibit SLC7A11 exert significant radiosensitizing effects in tumor organoids and patient-derived xenografts with p53 mutation or deficiency. Finally, we show that RT-induced ferroptosis correlates with p53 activation and better clinical outcomes to RT in cancer patients. Together, our study uncovers a previously unappreciated role of ferroptosis in p53-mediated radiosensitization and suggest using FINs in combination with RT to treat p53-mutant cancers.	[Lei, Guang; Zhang, Yilei; Liu, Xiaoguang; Mao, Chao; Yan, Yuelong; Koppula, Pranavi; Cheng, Weijie; Gan, Boyi] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; [Hong, Ting; Zhang, Xudong; Liu, Jinsong] Univ Texas MD Anderson Canc Ctr, Dept Anat Pathol, Houston, TX 77030 USA; [Koppula, Pranavi; Gan, Boyi] Univ Texas MD Anderson Canc Ctr, UTHlth Grad Sch Biomed Sci, Houston, TX 77030 USA; [Sood, Anil K.] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Gan, BY (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA.; Gan, BY (corresponding author), Univ Texas MD Anderson Canc Ctr, UTHlth Grad Sch Biomed Sci, Houston, TX 77030 USA.	bgan@mdanderson.org	Gan, Boyi/HDM-4206-2022; Koppula, Pranavi/P-7226-2019; Zhang, Yilei/I-8997-2014; Sood, Anoop Kumar/A-7344-2013	Koppula, Pranavi/0000-0002-7567-1891; Zhang, Yilei/0000-0003-1407-0301; Sood, Anoop Kumar/0000-0001-5702-4108; Sood, Anil/0000-0003-4242-1762; LIU, XIAOGUANG/0000-0001-6977-5128; ZHANG, XUDONG/0000-0003-1896-4898; , chao/0000-0002-8685-8539; Lei, Guang/0000-0002-3282-0666; Gan, Boyi/0000-0001-8884-6040; Yan, Yuelong/0000-0001-8495-6445	Institutional Research Fund from The University of Texas MD Anderson Cancer Center; RO Strategic Initiatives (ROSI) Boot Walk Seed Award from The University of Texas MD Anderson Cancer Center; Department of Defense Kidney Cancer Research Program [KC180131]; National Institutes of Health [R01CA181196, R01CA244144, R01CA247992]; American Cancer Society [P50 CA217685]; MD Anderson Moon Shot Program in Ovarian Cancer; CPRIT Research Training Grant [RP170067]; University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences; National Institutes of Health Cancer Center Support Grant [P30CA016672]	Institutional Research Fund from The University of Texas MD Anderson Cancer Center; RO Strategic Initiatives (ROSI) Boot Walk Seed Award from The University of Texas MD Anderson Cancer Center; Department of Defense Kidney Cancer Research Program; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); MD Anderson Moon Shot Program in Ovarian Cancer; CPRIT Research Training Grant; University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences; National Institutes of Health Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This research was supported by Institutional Research Fund and RO Strategic Initiatives (ROSI) Boot Walk Seed Award from The University of Texas MD Anderson Cancer Center, KC180131 from Department of Defense Kidney Cancer Research Program, and R01CA181196, R01CA244144, and R01CA247992 from the National Institutes of Health (to BG); P50 CA217685, American Cancer Society, and MD Anderson Moon Shot Program in Ovarian Cancer (to AKS). BG was an Andrew Sabin Family Fellow. PK is supported by CPRIT Research Training Grant (RP170067) and Dr. John J. Kopchick Research Award from The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences. This research has also been supported by the National Institutes of Health Cancer Center Support Grant P30CA016672 to The University of Texas MD Anderson Cancer Center.	Angeli JPF, 2014, NAT CELL BIOL, V16, P1180, DOI 10.1038/ncb3064; Azzam EI, 2012, CANCER LETT, V327, P48, DOI 10.1016/j.canlet.2011.12.012; Baidoo KE, 2013, CLIN CANCER RES, V19, P530, DOI 10.1158/1078-0432.CCR-12-0298; Bykov VJN, 2018, NAT REV CANCER, V18, P89, DOI 10.1038/nrc.2017.109; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Chu B, 2019, NAT CELL BIOL, V21, P579, DOI 10.1038/s41556-019-0305-6; Conrad M, 2012, AMINO ACIDS, V42, P231, DOI 10.1007/s00726-011-0867-5; Delaney G, 2005, CANCER-AM CANCER SOC, V104, P1129, DOI 10.1002/cncr.21324; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Drost J, 2018, NAT REV CANCER, V18, P407, DOI 10.1038/s41568-018-0007-6; Fei PW, 2003, ONCOGENE, V22, P5774, DOI 10.1038/sj.onc.1206677; Feng H, 2020, CELL REP, V30, P3411, DOI 10.1016/j.celrep.2020.02.049; Gan BY, 2019, CANCER RES, V79, P1749, DOI 10.1158/0008-5472.CAN-19-0487; Gao MH, 2019, MOL CELL, V73, P354, DOI 10.1016/j.molcel.2018.10.042; Gout PW, 2001, LEUKEMIA, V15, P1633, DOI 10.1038/sj.leu.2402238; Gudkov AV, 2003, NAT REV CANCER, V3, P117, DOI 10.1038/nrc992; Jaffray DA, 2012, NAT REV CLIN ONCOL, V9, P688, DOI 10.1038/nrclinonc.2012.194; Jennis M, 2016, GENE DEV, V30, P918, DOI 10.1101/gad.275891.115; Jiang L, 2015, NATURE, V520, P57, DOI 10.1038/nature14344; Kopper O, 2019, NAT MED, V25, P838, DOI 10.1038/s41591-019-0422-6; Koppula P, 2021, PROTEIN CELL, V12, P599, DOI 10.1007/s13238-020-00789-5; Koppula P, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880-018-0288-x; Lang XT, 2019, CANCER DISCOV, V9, P1673, DOI 10.1158/2159-8290.CD-19-0338; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; Lei G, 2020, CELL RES, V30, P146, DOI 10.1038/s41422-019-0263-3; Leu JIJ, 2019, P NATL ACAD SCI USA, V116, P8390, DOI 10.1073/pnas.1821277116; Li M, 2019, NEW ENGL J MED, V380, P569, DOI 10.1056/NEJMra1806175; Lin AF, 2014, CANCER RES, V74, P1682, DOI 10.1158/0008-5472.CAN-13-1729; Liu T, 2019, CANCER RES, V79, P1913, DOI 10.1158/0008-5472.CAN-18-3037; Liu XG, 2021, GENES DIS, V8, P731, DOI 10.1016/j.gendis.2020.11.010; Liu XG, 2020, NAT CELL BIOL, V22, DOI 10.1038/s41556-020-0496-x; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Ou Y, 2016, P NATL ACAD SCI USA, V113, pE6806, DOI 10.1073/pnas.1607152113; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; Seibt TM, 2019, FREE RADICAL BIO MED, V133, P144, DOI 10.1016/j.freeradbiomed.2018.09.014; Stockwell BR, 2017, CELL, V171, P273, DOI 10.1016/j.cell.2017.09.021; Tarangelo A, 2018, CELL REP, V22, P569, DOI 10.1016/j.celrep.2017.12.077; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wang LY, 2020, CELL DEATH DIFFER, V27, P662, DOI 10.1038/s41418-019-0380-z; Xiao ZD, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00902-z; Xie L, 2011, J CANCER RES CLIN, V137, P1739, DOI 10.1007/s00432-011-1050-9; Xie YC, 2017, CELL REP, V20, P1692, DOI 10.1016/j.celrep.2017.07.055; Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010; Ye LF, 2020, ACS CHEM BIOL, V15, P469, DOI 10.1021/acschembio.9b00939; Zhang Y, 2019, CELL CHEM BIOL, V26, P623, DOI 10.1016/j.chembiol.2019.01.008; Zhang YL, 2020, CANCER RES, V80, P2243, DOI 10.1158/0008-5472.CAN-19-3580; Zhang YL, 2019, MOL CELL ONCOL, V6, DOI 10.1080/23723556.2018.1536845; Zhang YL, 2018, NAT CELL BIOL, V20, P1181, DOI 10.1038/s41556-018-0178-0; Zheng H, 2014, ONCOGENE, V33, P734, DOI 10.1038/onc.2013.6	50	42	43	9	38	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2021	40	20					3533	3547		10.1038/s41388-021-01790-w	http://dx.doi.org/10.1038/s41388-021-01790-w		APR 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE7RS	33927351	Green Accepted			2022-12-17	WOS:000645517200003
J	von Felden, J; Craig, AJ; Garcia-Lezana, T; Labgaa, I; Haber, PK; D'Avola, D; Asgharpour, A; Dieterich, D; Bonaccorso, A; Torres-Martin, M; Sia, D; Sung, MW; Tabrizian, P; Schwartz, M; Llovet, JM; Villanueva, A				von Felden, Johann; Craig, Amanda J.; Garcia-Lezana, Teresa; Labgaa, Ismail; Haber, Philipp K.; D'Avola, Delia; Asgharpour, Amon; Dieterich, Douglas; Bonaccorso, Antoinette; Torres-Martin, Miguel; Sia, Daniela; Sung, Max W.; Tabrizian, Parissa; Schwartz, Myron; Llovet, Josep M.; Villanueva, Augusto			Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma	ONCOGENE			English	Article							LIQUID BIOPSY; DOUBLE-BLIND; SORAFENIB; IDENTIFICATION; TARGETS	Little is known about the mutational landscape of advanced hepatocellular carcinoma (HCC), and predictive biomarkers of response to systemic therapies are lacking. We aimed to describe the mutational landscape of advanced HCC and to identify predictors of primary resistance to systemic therapies using circulating tumor DNA (ctDNA). We prospectively enrolled 121 patients between October 2015 and January 2019. We performed targeted ultra-deep sequencing of 25 genes and Digital Droplet PCR of TERT promoter, including sequential samples throughout treatment. Primary endpoint was progression-free survival (PFS) stratified by mutation profiles in ctDNA. Secondary endpoints were overall survival and objective response rate. The most frequent mutations in ctDNA of advanced HCC were TERT promoter (51%), TP53 (32%), CTNNB1 (17%), PTEN (8%), AXIN1, ARID2, KMT2D, and TSC2 (each 6%). TP53 and CTNNB1 mutations were mutually exclusive. Patients with mutations in the PI3K/MTOR pathway had significantly shorter PFS than those without these mutations after tyrosine kinase inhibitors (2.1 vs 3.7 months, p < 0.001), but not after immune checkpoint inhibition (CPI). WNT pathway mutations were not associated with PFS, overall survival, or objective response after CPI. Serial profiling of ctDNA in a subset correlated with treatment response. Mutation profiling of ctDNA in advanced HCC shows similar mutation frequencies for known HCC drivers compared to early stages and identifies predictive biomarkers of response to systemic therapies.	[von Felden, Johann] Univ Med Ctr Hamburg Eppendorf, Dept Med 1, Hamburg, Germany; [von Felden, Johann; Craig, Amanda J.; Garcia-Lezana, Teresa; Labgaa, Ismail; Haber, Philipp K.; D'Avola, Delia; Asgharpour, Amon; Dieterich, Douglas; Torres-Martin, Miguel; Sia, Daniela; Llovet, Josep M.; Villanueva, Augusto] Icahn Sch Med Mt Sinai, Liver Canc Program, Div Liver Dis, Tisch Canc Inst,Dept Med, New York, NY 10029 USA; [Labgaa, Ismail] Lausanne Univ Hosp CHUV, Dept Visceral Surg, Lausanne, Switzerland; [D'Avola, Delia] Clin Univ Navarra, Liver Unit, Pamplona, Spain; [D'Avola, Delia] Clin Univ Navarra, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Pamplona, Spain; [Bonaccorso, Antoinette; Tabrizian, Parissa; Schwartz, Myron] Icahn Sch Med Mt Sinai, Dept Surg, New York, NY 10029 USA; [Sung, Max W.; Villanueva, Augusto] Icahn Sch Med Mt Sinai, Dept Med, Div Hematol & Med Oncol, New York, NY 10029 USA; [Llovet, Josep M.] Univ Barcelona, Liver Canc Translat Res Lab, Hosp Clin, IDIBAPS, Catalonia, Spain; [Llovet, Josep M.] Inst Catalana Recerca & Estudis Avancats, Barcelona, Catalonia, Spain	University of Hamburg; University Medical Center Hamburg-Eppendorf; Icahn School of Medicine at Mount Sinai; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Navarra; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; University of Navarra; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; ICREA	Villanueva, A (corresponding author), Icahn Sch Med Mt Sinai, Liver Canc Program, Div Liver Dis, Tisch Canc Inst,Dept Med, New York, NY 10029 USA.; Villanueva, A (corresponding author), Icahn Sch Med Mt Sinai, Dept Med, Div Hematol & Med Oncol, New York, NY 10029 USA.	augusto.villanueva@mssm.edu	Llovet, Josep M/D-4340-2014; Llovet, Josep M/ABB-6264-2021	Llovet, Josep M/0000-0003-0547-2667; Llovet, Josep M/0000-0003-0547-2667; Labgaa, Ismail/0000-0003-4286-2170; Craig, Amanda/0000-0001-8987-019X; Torres Martin, Miguel/0000-0003-1589-8936; von Felden, Johann/0000-0003-2839-5174; Sia, Daniela/0000-0002-9000-611X	German Research Foundation [HA8754/1-1, FE1746/1-1]; National Cancer Institute Ruth L. Kirschstein NRSA Institutional Research Training Grant [CA078207]; Swiss National Science Foundation; Foundation Roberto Gianna Gonella; Foundation SICPA; Spanish Association for the Study of the Liver (Asociacion Espanola para el Estudio del Higado, AEEH); Nuovo Soldati Foundation; European Commission (EC)/Horizon 2020 Program (HEPCAR) [667273-2]; U.S. Department of Defense [CA150272P3]; Accelerator Award (CRUCK, AECC, AIRC) [C9380/A26813]; National Cancer Institute, Tisch Cancer Institute [P30-CA196521]; Samuel Waxman Cancer Research Foundation; Spanish National Health Institute [SAF2016-76390]; Generalitat de Catalunya/AGAUR [SGR-1358]	German Research Foundation(German Research Foundation (DFG)); National Cancer Institute Ruth L. Kirschstein NRSA Institutional Research Training Grant; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Foundation Roberto Gianna Gonella; Foundation SICPA; Spanish Association for the Study of the Liver (Asociacion Espanola para el Estudio del Higado, AEEH); Nuovo Soldati Foundation; European Commission (EC)/Horizon 2020 Program (HEPCAR)(European Commission); U.S. Department of Defense(United States Department of Defense); Accelerator Award (CRUCK, AECC, AIRC)(Fondazione AIRC per la ricerca sul cancro); National Cancer Institute, Tisch Cancer Institute; Samuel Waxman Cancer Research Foundation; Spanish National Health Institute(Spanish Government); Generalitat de Catalunya/AGAUR(Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR)Generalitat de Catalunya)	JvF is supported by the German Research Foundation (FE1746/1-1). AJC is supported by the National Cancer Institute Ruth L. Kirschstein NRSA Institutional Research Training Grant (CA078207). IL is supported by a grant from the Swiss National Science Foundation, from Foundation Roberto & Gianna Gonella and Foundation SICPA. PKH is supported by the German Research Foundation (HA8754/1-1). DD is supported by the Grant for Studies Broadening from the Spanish Association for the Study of the Liver (Asociacion Espanola para el Estudio del Higado, AEEH) and the Cancer Research Grant from Nuovo Soldati Foundation. JML is supported by the European Commission (EC)/Horizon 2020 Program (HEPCAR, Ref. 667273-2), U.S. Department of Defense (CA150272P3), an Accelerator Award (CRUCK, AECC, AIRC) (HUNTER, Ref. C9380/A26813), National Cancer Institute, Tisch Cancer Institute (P30-CA196521), Samuel Waxman Cancer Research Foundation, Spanish National Health Institute (SAF2016-76390) and the Generalitat de Catalunya/AGAUR (SGR-1358). AV is supported by the U.S. Department of Defense (CA150272P3).	Abou-Alfa GK, 2018, NEW ENGL J MED, V379, P54, DOI 10.1056/NEJMoa1717002; Ally A, 2017, CELL, V169, P1327, DOI 10.1016/j.cell.2017.05.046; [Anonymous], 2018, IARC DATA; [Anonymous], 2018, CDC LIVER CANC REPOR; Bruix J, 2017, LANCET, V389, P56, DOI 10.1016/S0140-6736(16)32453-9; Brunner SF, 2019, NATURE, V574, P538, DOI 10.1038/s41586-019-1670-9; Craig AJ, 2020, NAT REV GASTRO HEPAT, V17, P139, DOI 10.1038/s41575-019-0229-4; de Galarreta MR, 2019, CANCER DISCOV, V9, P1124, DOI 10.1158/2159-8290.CD-19-0074; El-Khoueiry AB, 2017, LANCET, V389, P2492, DOI 10.1016/S0140-6736(17)31046-2; European Assoc Study Liver, 2018, J HEPATOL, V69, P182, DOI 10.1016/j.jhep.2018.03.019; Finn RS, 2020, NEW ENGL J MED, V382, P1894, DOI 10.1056/NEJMoa1915745; Finn RS, 2020, J CLIN ONCOL, V38, P193, DOI 10.1200/JCO.19.01307; Goodall J, 2017, CANCER DISCOV, V7, P1006, DOI 10.1158/2159-8290.CD-17-0261; Harding JJ, 2019, CLIN CANCER RES, V25, P2116, DOI 10.1158/1078-0432.CCR-18-2293; Howell J, 2019, EUR J CANCER, V116, P56, DOI 10.1016/j.ejca.2019.04.014; Huang A, 2017, J HEPATOL, V67, P293, DOI 10.1016/j.jhep.2017.03.005; Jiang PY, 2019, J HEPATOL, V71, P409, DOI 10.1016/j.jhep.2019.04.003; Kudo M, 2018, LANCET, V391, P1163, DOI 10.1016/S0140-6736(18)30207-1; Labgaa I, 2018, ONCOGENE, V37, P3740, DOI 10.1038/s41388-018-0206-3; Labgaa I, 2015, DISCOV MED, V19, P263; Lencioni R, 2010, SEMIN LIVER DIS, V30, P52, DOI 10.1055/s-0030-1247132; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Llovet JM, 2019, J HEPATOL, V70, P1262, DOI 10.1016/j.jhep.2019.01.028; Luke JJ, 2019, CLIN CANCER RES, V25, P3074, DOI 10.1158/1078-0432.CCR-18-1942; Mansukhani S, 2018, CLIN CHEM, V64, P1626, DOI 10.1373/clinchem.2018.289629; Marrero JA, 2018, HEPATOLOGY, V68, P723, DOI 10.1002/hep.29913; Nault JC, 2020, HEPATOLOGY, V71, P164, DOI 10.1002/hep.30811; Nault JC, 2019, NAT REV GASTRO HEPAT, V16, P544, DOI 10.1038/s41575-019-0165-3; Ng CKY, 2018, ANN ONCOL, V29, P1286, DOI 10.1093/annonc/mdy083; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Rothwell DG, 2019, NAT MED, V25, P738, DOI 10.1038/s41591-019-0380-z; Schulze K, 2015, NAT GENET, V47, P505, DOI 10.1038/ng.3252; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Sia D, 2017, GASTROENTEROLOGY, V153, P812, DOI 10.1053/j.gastro.2017.06.007; Totoki Y, 2014, NAT GENET, V46, P1267, DOI 10.1038/ng.3126; Villanueva A, 2019, NEW ENGL J MED, V380, P1450, DOI 10.1056/NEJMra1713263; von Felden J, 2020, GUT, V69, P2025, DOI 10.1136/gutjnl-2019-320282; von Felden J, 2020, CURR OPIN GASTROEN, V36, P177, DOI 10.1097/MOG.0000000000000626; Wan JCM, 2017, NAT REV CANCER, V17, P223, DOI 10.1038/nrc.2017.7; Xia HP, 2013, HEPATOLOGY, V58, P629, DOI 10.1002/hep.26369; YAU T, 2019, ANN ONCOL, V30, P29; Zhang H, 2018, ONCOL LETT, V15, P9377, DOI 10.3892/ol.2018.8536; Zhu AX, 2019, LANCET ONCOL, V20, P282, DOI 10.1016/S1470-2045(18)30937-9; Zhu AX, 2018, LANCET ONCOL, V19, P940, DOI 10.1016/S1470-2045(18)30351-6; Zhu M, 2019, CELL, V177, P608, DOI 10.1016/j.cell.2019.03.026	45	42	43	1	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2021	40	1					140	151		10.1038/s41388-020-01519-1	http://dx.doi.org/10.1038/s41388-020-01519-1		OCT 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PR5VS	33097857				2022-12-17	WOS:000582109700001
J	Chronopoulos, A; Kalluri, R				Chronopoulos, Antonios; Kalluri, Raghu			Emerging role of bacterial extracellular vesicles in cancer	ONCOGENE			English	Review							OUTER-MEMBRANE VESICLES; DENDRITIC CELLS; GUT MICROBIOME; HOST-CELLS; NOD1; IMMUNITY; MEDIATE; RELEASE; ANTIGEN; INNATE	Shedding of microbial extracellular vesicles constitutes a universal mechanism for inter-kingdom and intra-kingdom communication that is conserved among prokaryotic and eukaryotic microbes. In this review we delineate fundamental aspects of bacterial extracellular vesicles (BEVs) including their biogenesis, cargo composition, and interactions with host cells. We critically examine the evidence that BEVs from the host gut microbiome can enter the circulatory system to disseminate to distant organs and tissues. The potential involvement of BEVs in carcinogenesis is evaluated and future research ideas explored. We further discuss the potential of BEVs in microbiome-based liquid biopsies for cancer diagnostics and bioengineering strategies for cancer therapy.	[Chronopoulos, Antonios; Kalluri, Raghu] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Metastasis Res Ctr, Houston, TX 77030 USA; [Kalluri, Raghu] Rice Univ, Dept Bioengn, Houston, TX 77005 USA; [Kalluri, Raghu] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Rice University; Baylor College of Medicine	Kalluri, R (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Metastasis Res Ctr, Houston, TX 77030 USA.; Kalluri, R (corresponding author), Rice Univ, Dept Bioengn, Houston, TX 77005 USA.; Kalluri, R (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.	rkalluri@mdanderson.org	Kalluri, Raghu/E-2677-2015	Kalluri, Raghu/0000-0002-2190-547X				Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Arroyo V, 2016, SEMIN LIVER DIS, V36, P109, DOI 10.1055/s-0036-1583202; Athman JJ, 2015, J IMMUNOL, V195, P1044, DOI 10.4049/jimmunol.1402894; Aykut B, 2019, NATURE, V574, P264, DOI 10.1038/s41586-019-1608-2; Balachandran VP, 2017, NATURE, V551, P512, DOI 10.1038/nature24462; Bitto NJ, 2018, IMMUNOL CELL BIOL, V96, P1120, DOI 10.1111/imcb.12190; Bitto NJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07288-4; Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511; Brown L, 2015, NAT REV MICROBIOL, V13, P620, DOI 10.1038/nrmicro3480; Canas MA, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00498; Castillo DJ, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00148; Cecil JD, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01017; Cecil JD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151967; Chatterjee D, 2013, J BIOL CHEM, V288, P4299, DOI 10.1074/jbc.M112.408302; Chen CC, 2016, CELL MOL BIOENG, V9, P509, DOI 10.1007/s12195-016-0458-3; Chu HT, 2016, SCIENCE, V352, P1116, DOI 10.1126/science.aad9948; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; Deatherage BL, 2012, INFECT IMMUN, V80, P1948, DOI 10.1128/IAI.06014-11; Ellis TN, 2010, MICROBIOL MOL BIOL R, V74, P81, DOI 10.1128/MMBR.00031-09; Emery DC, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00195; Geller LT, 2017, SCIENCE, V357, P1156, DOI 10.1126/science.aah5043; Gilbert JA, 2018, NAT MED, V24, P392, DOI 10.1038/nm.4517; Giri PK, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002461; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Gopalakrishnan V, 2018, CANCER CELL, V33, P570, DOI 10.1016/j.ccell.2018.03.015; Gu L, 2019, SHOCK, V51, P256, DOI 10.1097/SHK.0000000000001129; Hughes DT, 2008, NAT REV MICROBIOL, V6, P111, DOI 10.1038/nrmicro1836; Human Microbiome Project Consortium, 2012, Nature, V486, P207, DOI 10.1038/nature11234; Jones EJ, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00057; Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977; Kang CS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076520; Kaparakis M, 2010, CELL MICROBIOL, V12, P372, DOI 10.1111/j.1462-5822.2009.01404.x; Kaparakis-Liaskos M, 2015, NAT REV IMMUNOL, V15, P375, DOI 10.1038/nri3837; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kim OY, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00729-8; Lauder AP, 2016, MICROBIOME, V4, DOI 10.1186/s40168-016-0172-3; Lee EY, 2007, PROTEOMICS, V7, P3821, DOI 10.1002/pmic.200790083; Lee HSW, 2007, INFECT IMMUN, V75, P4449, DOI 10.1128/IAI.00222-07; Lelouard H, 2012, GASTROENTEROLOGY, V142, P592, DOI 10.1053/j.gastro.2011.11.039; Macia L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010107; Matson V, 2018, SCIENCE, V359, P104, DOI 10.1126/science.aao3290; McDole JR, 2012, NATURE, V483, P345, DOI 10.1038/nature10863; McQuade JL, 2019, LANCET ONCOL, V20, pE77, DOI 10.1016/S1470-2045(18)30952-5; Mima K, 2016, GUT, V65, P1973, DOI 10.1136/gutjnl-2015-310101; Morad G, 2019, ACS NANO, V13, P13853, DOI 10.1021/acsnano.9b04397; Motwani M, 2019, NAT REV GENET, V20, P657, DOI 10.1038/s41576-019-0151-1; Niess JH, 2005, SCIENCE, V307, P254, DOI 10.1126/science.1102901; O'Neill HC, 2008, SCI SIGNAL, V1, DOI 10.1126/stke.16pe8; Orench-Rivera N, 2016, CELL MICROBIOL, V18, P1525, DOI 10.1111/cmi.12676; Park JY, 2017, EXP NEUROBIOL, V26, P369, DOI 10.5607/en.2017.26.6.369; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Peterson J, 2009, GENOME RES, V19, P2317, DOI 10.1101/gr.096651.109; Petousis-Harris H, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00683; Petousis-Harris H, 2017, LANCET, V390, P1603, DOI 10.1016/S0140-6736(17)31449-6; Pleguezuelos-Manzano C, 2020, NATURE, V580, P269, DOI 10.1038/s41586-020-2080-8; Poore GD, 2020, NATURE, V579, P567, DOI 10.1038/s41586-020-2095-1; Prados-Rosales R, 2011, J CLIN INVEST, V121, P1471, DOI 10.1172/JCI44261; Pushalkar S, 2018, CANCER DISCOV, V8, P403, DOI 10.1158/2159-8290.CD-17-1134; Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821; Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373; Riley DR, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003107; Riquelme E, 2019, CELL, V178, P795, DOI 10.1016/j.cell.2019.07.008; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Salter SJ, 2014, BMC BIOL, V12, DOI 10.1186/s12915-014-0087-z; Schwechheimer C, 2015, NAT REV MICROBIOL, V13, P605, DOI 10.1038/nrmicro3525; Sender R, 2016, CELL, V164, P337, DOI 10.1016/j.cell.2016.01.013; Shah B, 2012, SHOCK, V37, P621, DOI 10.1097/SHK.0b013e318250de5d; Shen Y, 2012, CELL HOST MICROBE, V12, P509, DOI 10.1016/j.chom.2012.08.004; Stentz R, 2018, BIOCHEM SOC T, V46, P1021, DOI 10.1042/BST20180114; Takiishi T, 2017, TISSUE BARRIERS, V5, DOI 10.1080/21688370.2017.1373208; Thay B, 2014, INFECT IMMUN, V82, P4034, DOI 10.1128/IAI.01980-14; Tierney BT, 2019, CELL HOST MICROBE, V26, P283, DOI 10.1016/j.chom.2019.07.008; Toyofuku M, 2019, NAT REV MICROBIOL, V17, P13, DOI 10.1038/s41579-018-0112-2; Tsatsaronis JA, 2018, TRENDS MICROBIOL, V26, P401, DOI 10.1016/j.tim.2018.02.009; Tulkens J, 2020, NAT PROTOC, V15, P40, DOI 10.1038/s41596-019-0236-5; Tulkens J, 2020, GUT, V69, P191, DOI 10.1136/gutjnl-2018-317726; Turnbaugh PJ, 2010, P NATL ACAD SCI USA, V107, P7503, DOI 10.1073/pnas.1002355107; Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540; Ursell LK, 2012, NUTR REV, V70, pS38, DOI 10.1111/j.1753-4887.2012.00493.x; Vesikari T, 2013, LANCET, V381, P825, DOI 10.1016/S0140-6736(12)61961-8; Vidakovics MLAP, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000724; Wilson MR, 2019, SCIENCE, V363, P709, DOI 10.1126/science.aar7785; Yang Jinho, 2018, Transl Clin Pharmacol, V26, P103, DOI 10.12793/tcp.2018.26.3.103; Young VB, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j831; Yu YJ, 2018, ACTA PHARMACOL SIN, V39, P514, DOI 10.1038/aps.2017.82; Zhao KL, 2013, INFECT IMMUN, V81, P4509, DOI 10.1128/IAI.01008-13; Zitvogel L, 2018, SCIENCE, V359, P1366, DOI 10.1126/science.aar6918	87	42	43	6	28	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	2020	39	46					6951	6960		10.1038/s41388-020-01509-3	http://dx.doi.org/10.1038/s41388-020-01509-3		OCT 2020	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OQ9FF	33060855	Bronze, Green Published			2022-12-17	WOS:000577946300002
J	Peng, H; Wang, YF; Luo, WB				Peng, Hui; Wang, Yingfei; Luo, Weibo			Multifaceted role of branched-chain amino acid metabolism in cancer	ONCOGENE			English	Review							PROMOTES CELL-PROLIFERATION; HEPATOCELLULAR-CARCINOMA; BCAT1 PROMOTES; RADIOFREQUENCY ABLATION; ONCOMETABOLITE 2-HYDROXYGLUTARATE; ORAL SUPPLEMENTATION; ALPHA-KETOGLUTARATE; CATABOLISM; SURVIVAL; LEUCINE	Metabolic reprogramming fulfils increased nutrient demands and regulates numerous oncogenic processes in tumors, leading to tumor malignancy. Branched-chain amino acids (BCAAs, i.e., valine, leucine, and isoleucine) function as nitrogen donors to generate macromolecules such as nucleotides and are indispensable for human cancer cell growth. The cell-autonomous and non-autonomous roles of altered BCAA metabolism have been implicated in cancer progression and the key proteins in the BCAA metabolic pathway serve as possible prognostic and diagnostic biomarkers in human cancers. Here we summarize how BCAA metabolic reprogramming is regulated in cancer cells and how it influences cancer progression.	[Peng, Hui; Wang, Yingfei; Luo, Weibo] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Wang, Yingfei] Univ Texas Southwestern Med Ctr Dallas, Dept Neurol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Luo, Weibo] Univ Texas Southwestern Med Ctr Dallas, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Wang, YF; Luo, WB (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.; Wang, YF (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Neurol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.; Luo, WB (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Yingfei.Wang@UTSouthwestern.edu; Weibo.Luo@UTSouthwestern.edu		wang, yingfei/0000-0002-8723-252X; Luo, Weibo/0000-0002-1992-0320	NIH [R01AG066166, R35GM124693, R01CA222393]; CPRIT [RP190358]; Mary Kay Foundation [08-19]; Welch Foundation [I-1903-20190330]; UTSW startup funds	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CPRIT; Mary Kay Foundation; Welch Foundation(The Welch Foundation); UTSW startup funds	Work in authors' laboratories was supported by grants from NIH (R01CA222393), CPRIT (RP190358), Mary Kay Foundation (08-19), and Welch Foundation (I-1903-20190330) to WL; and NIH (R01AG066166, R35GM124693) and UTSW startup funds to YW. WL is a CPRIT Scholar in Cancer Research.	Abla H, 2020, SEMIN CELL DEV BIOL, V98, P26, DOI 10.1016/j.semcdb.2019.05.031; Ananieva EA, 2018, CURR OPIN CLIN NUTR, V21, P64, DOI 10.1097/MCO.0000000000000430; Ananieva EA, 2014, J BIOL CHEM, V289, P18793, DOI 10.1074/jbc.M114.554113; Arakawa M, 2011, ENDOCR J, V58, P161, DOI 10.1507/endocrj.K10E-221; Baracos VE, 2006, J NUTR, V136, p237S, DOI 10.1093/jn/136.1.237S; Biswas D, 2019, FASEB J, V33, P8711, DOI 10.1096/fj.201802842RR; Cha JH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077899; Chowdhury R, 2011, EMBO REP, V12, P463, DOI 10.1038/embor.2011.43; Cluntun AA, 2017, TRENDS CANCER, V3, P169, DOI 10.1016/j.trecan.2017.01.005; DeBerardinis RJ, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600200; Dey P, 2017, NATURE, V542, P119, DOI 10.1038/nature21052; Elorza A, 2012, MOL CELL, V48, P681, DOI 10.1016/j.molcel.2012.09.017; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Ericksen RE, 2019, CELL METAB, V29, P1151, DOI 10.1016/j.cmet.2018.12.020; Faubert B, 2020, SCIENCE, V368, P152, DOI 10.1126/science.aaw5473; Gu ZM, 2019, CANCER DISCOV, V9, P1228, DOI 10.1158/2159-8290.CD-19-0152; HALL TR, 1993, J BIOL CHEM, V268, P3092; Hatazawa Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091006; Hattori A, 2017, NATURE, V545, P500, DOI 10.1038/nature22314; Hayaishi S, 2011, DIGEST DIS, V29, P326, DOI 10.1159/000327571; Holecek M, 2018, NUTR METAB, V15, DOI 10.1186/s12986-018-0271-1; Ikeda K, 2017, CELL REP, V21, P1824, DOI 10.1016/j.celrep.2017.10.082; Imanaka K, 2016, HEPATOL RES, V46, P1002, DOI 10.1111/hepr.12640; Ivan M, 2017, MOL CELL, V66, P772, DOI 10.1016/j.molcel.2017.06.002; Iwasa M, 2015, J NUTR SCI VITAMINOL, V61, P433, DOI 10.3177/jnsv.61.433; Iwasa M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070309; Kaelin WG, 2013, CELL, V153, P56, DOI 10.1016/j.cell.2013.03.004; Kawaguchi T, 2014, CLIN GASTROENTEROL H, V12, P1012, DOI 10.1016/j.cgh.2013.08.050; Kim DK, 2004, NEUROSCI RES, V50, P437, DOI 10.1016/j.neures.2004.08.003; Kuroda H, 2010, J GASTROEN HEPATOL, V25, P1550, DOI 10.1111/j.1440-1746.2010.06306.x; Lee IJ, 2011, CANCER RES TREAT, V43, P24, DOI 10.4143/crt.2011.43.1.24; Lee JH, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0350-z; Li JT, 2020, NAT CELL BIOL, V22, P167, DOI 10.1038/s41556-019-0455-6; Liu XY, 2018, CELL REP, V23, P1461, DOI 10.1016/j.celrep.2018.03.140; Loenarz C, 2008, NAT CHEM BIOL, V4, P152, DOI 10.1038/nchembio0308-152; Luo WB, 2019, ADV EXP MED BIOL, V1136, P1, DOI 10.1007/978-3-030-12734-3_1; Luo WB, 2018, CELL MOL LIFE SCI, V75, P1043, DOI 10.1007/s00018-017-2684-9; Martin SB, 2020, BIOCHEM J, V477, P1579, DOI 10.1042/BCJ20190754; Mayers JR, 2016, SCIENCE, V353, P1161, DOI 10.1126/science.aaf5171; Mayers JR, 2014, NAT MED, V20, P1193, DOI 10.1038/nm.3686; McBrayer SK, 2018, CELL, V175, P101, DOI 10.1016/j.cell.2018.08.038; Morihara D, 2012, HEPATOL RES, V42, P658, DOI 10.1111/j.1872-034X.2012.00969.x; Mossmann D, 2018, NAT REV CANCER, V18, P744, DOI 10.1038/s41568-018-0074-8; Nojiri S, 2017, NUTRITION, V33, P20, DOI 10.1016/j.nut.2016.07.013; Qu YY, 2020, CANCER RES, V80, P319, DOI 10.1158/0008-5472.CAN-19-1023; Raffel S, 2017, NATURE, V551, P384, DOI 10.1038/nature24294; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Shennan DB, 2004, BBA-BIOMEMBRANES, V1664, P206, DOI 10.1016/j.bbamem.2004.05.008; Shimizu N, 2011, CELL METAB, V13, P170, DOI 10.1016/j.cmet.2011.01.001; Shimomura Y, 2004, J NUTR, V134, p1583S, DOI 10.1093/jn/134.6.1583S; Silva LS, 2017, EMBO REP, V18, P2172, DOI 10.15252/embr.201744154; Sivanand S, 2020, CANCER CELL, V37, P147, DOI 10.1016/j.ccell.2019.12.011; Tada T, 2014, HEPATOL RES, V44, P288, DOI 10.1111/hepr.12120; Takami T, 2016, WORLD J GASTROENTERO, V22, P7252, DOI 10.3748/wjg.v22.i32.7252; Takegoshi K, 2017, ONCOTARGET, V8, P18191, DOI 10.18632/oncotarget.15304; Terakura D, 2012, CARCINOGENESIS, V33, P2499, DOI 10.1093/carcin/bgs303; Tian Q, 2020, ONCOGENE, V39, P3980, DOI 10.1038/s41388-020-1262-z; Tian T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030755; Tonjes M, 2013, NAT MED, V19, P901, DOI 10.1038/nm.3217; Wang P, 2018, INT J CLIN EXP PATHO, V11, P5536; Wang YT, 2019, CELL REP, V28, P512, DOI 10.1016/j.celrep.2019.06.026; Wang ZQ, 2015, ONCOTARGET, V6, P31522, DOI 10.18632/oncotarget.5159; Wolfson RL, 2016, SCIENCE, V351, P43, DOI 10.1126/science.aab2674; Xu M, 2016, ONCOL LETT, V12, P2648, DOI 10.3892/ol.2016.4969; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Xue PP, 2017, EBIOMEDICINE, V20, P50, DOI 10.1016/j.ebiom.2017.05.001; Yoneshiro T, 2019, NATURE, V572, P614, DOI 10.1038/s41586-019-1503-x; Zdzisinska B, 2017, ARCH IMMUNOL THER EX, V65, P21, DOI 10.1007/s00005-016-0406-x; Zhang B, 2021, CELL MOL LIFE SCI, V78, P195, DOI 10.1007/s00018-020-03483-1; Zhang L, 2017, BIOCHEM BIOPH RES CO, V486, P224, DOI 10.1016/j.bbrc.2017.02.101; Zheng YH, 2016, LIVER INT, V36, P1836, DOI 10.1111/liv.13178; Zhenyukh O, 2017, FREE RADICAL BIO MED, V104, P165, DOI 10.1016/j.freeradbiomed.2017.01.009; Zhou W, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-53; Zhu ZW, 2020, NAT METAB, V2, P775, DOI 10.1038/s42255-020-0226-5; Zou HF, 2019, ONCOL LETT, V18, P5879, DOI 10.3892/ol.2019.10932	75	42	42	6	28	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2020	39	44					6747	6756		10.1038/s41388-020-01480-z	http://dx.doi.org/10.1038/s41388-020-01480-z		SEP 2020	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OH9QS	32978521	Green Accepted			2022-12-17	WOS:000572714000007
J	Hutchinson, MKND; Mierzwa, M; D'Silva, NJ				Hutchinson, Marsha-Kay N. D.; Mierzwa, Michelle; D'Silva, Nisha J.			Radiation resistance in head and neck squamous cell carcinoma: dire need for an appropriate sensitizer	ONCOGENE			English	Review							GROWTH-FACTOR RECEPTOR; STRAND BREAK REPAIR; DEPENDENT PROTEIN-KINASE; DNA-DAMAGE-RESPONSE; IONIZING-RADIATION; LIGASE-IV; HUMAN-PAPILLOMAVIRUS; SALVAGE SURGERY; XRCC4 PROTEIN; P53	Radiation is a significant treatment for patients with head and neck cancer. Despite advances to improve treatment, many tumors acquire radiation resistance resulting in poor survival. Radiation kills cancer cells by inducing DNA double-strand breaks. Therefore, radiation resistance is enhanced by efficient repair of damaged DNA. Head and neck cancers overexpress EGFR and have a high frequency of p53 mutations, both of which enhance DNA repair. This review discusses the clinical criteria for radiation resistance in patients with head and neck cancer and summarizes how cancer cells evade radiation-mediated apoptosis by p53- and epidermal growth factor receptor (EGFR)-mediated DNA repair. In addition, we explore the role of cancer stem cells in promoting radiation resistance, and how the abscopal effect provides rationale for combination strategies with immunotherapy.	[Hutchinson, Marsha-Kay N. D.; D'Silva, Nisha J.] Univ Michigan, Sch Dent, Dept Periodont & Oral Med, 1011 North Univ Ave, Ann Arbor, MI 48109 USA; [Mierzwa, Michelle] Univ Michigan, Sch Med, Dept Radiat Oncol, Ann Arbor, MI USA; [D'Silva, Nisha J.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	D'Silva, NJ (corresponding author), Univ Michigan, Sch Dent, Dept Periodont & Oral Med, 1011 North Univ Ave, Ann Arbor, MI 48109 USA.	njdsilva@umich.edu		Hutchinson, Marsha-Kay/0000-0002-1461-5810; D'Silva, Nisha/0000-0001-7030-3187	NIH/NIDCR [DE027551, DE007057-43]	NIH/NIDCR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This work was supported by grants from NIH/NIDCR DE027551 and DE007057-43.	Ang KK, 2014, J CLIN ONCOL, V32, P2940, DOI 10.1200/JCO.2013.53.5633; Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Ang KK, 2002, CANCER RES, V62, P7350; [Anonymous], 2019, 1 IN HUM STUD SAF TO; Bandyopadhyay D, 1998, J BIOL CHEM, V273, P1568, DOI 10.1074/jbc.273.3.1568; Banerjee R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5527; Bensaad K, 2007, TRENDS CELL BIOL, V17, P286, DOI 10.1016/j.tcb.2007.04.004; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Cadet J, 2008, ACCOUNTS CHEM RES, V41, P1075, DOI 10.1021/ar700245e; Chan TA, 2000, GENE DEV, V14, P1584; Chang HW, 2006, ORAL ONCOL, V42, P979, DOI 10.1016/j.oraloncology.2005.12.016; Chen BPC, 2007, J BIOL CHEM, V282, P6582, DOI 10.1074/jbc.M611605200; Chen X, 2008, CANCER RES, V68, P3169, DOI 10.1158/0008-5472.CAN-07-6636; Chung CH, 2014, J CLIN ONCOL, V32, P3930, DOI 10.1200/JCO.2013.54.5228; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Collis SJ, 2005, ONCOGENE, V24, P949, DOI 10.1038/sj.onc.1208332; Das AK, 2007, CANCER RES, V67, P5267, DOI 10.1158/0008-5472.CAN-07-0242; Davidson D, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00005; Davis AJ, 2013, TRANSL CANCER RES, V2, P130, DOI 10.3978/j.issn.2218-676X.2013.04.02; De Crevoisier R, 2001, CANCER-AM CANCER SOC, V91, P2071, DOI 10.1002/1097-0142(20010601)91:11<2071::AID-CNCR1234>3.0.CO;2-Z; De Felice F, 2015, ORAL ONCOL, V51, P1051, DOI 10.1016/j.oraloncology.2015.08.004; Deckbar D, 2010, CANCER RES, V70, P4412, DOI 10.1158/0008-5472.CAN-09-3198; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dittmann K, 2005, J BIOL CHEM, V280, P31182, DOI 10.1074/jbc.M506591200; Downs JA, 2004, NAT REV MOL CELL BIO, V5, P367, DOI 10.1038/nrm1367; Dynan W, 2008, NANOMEDICINE-UK, V3, P93, DOI 10.2217/17435889.3.1.93; Emerson CH, 2016, BIOCHEM CELL BIOL, V94, P396, DOI 10.1139/bcb-2016-0001; Eriksson D, 2010, TUMOR BIOL, V31, P363, DOI 10.1007/s13277-010-0042-8; Fakhry C, 2019, CANCER-AM CANCER SOC, V125, P2027, DOI 10.1002/cncr.32025; Fei PW, 2003, ONCOGENE, V22, P5774, DOI 10.1038/sj.onc.1206677; Ferlay J, 2018, INT J CANCER, V144, P31937, DOI [10.1002/ijc.31937.ijc, DOI 10.1002/IJC.31937.IJC]; Freschauf GK, 2009, CANCER RES, V69, P7739, DOI 10.1158/0008-5472.CAN-09-1805; Fu KK PT, 2000, INT J RADIAT ONCOL, V48, P7, DOI DOI 10.1016/S0360-3016(00)00663-5; Furness S, 2011, COCHRANE DB SYST REV, V2011, P1; Gatz SA, 2006, CELL DEATH DIFFER, V13, P1003, DOI 10.1038/sj.cdd.4401903; Ghisolfi L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043628; Gillison ML, 2019, LANCET, V393, P40, DOI 10.1016/S0140-6736(18)32779-X; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Grundy GJ, 2013, EMBO J, V32, P112, DOI 10.1038/emboj.2012.304; Gu JF, 2007, EMBO J, V26, P1010, DOI 10.1038/sj.emboj.7601559; Gunn GB, 2016, INT J RADIAT ONCOL, V95, P360, DOI 10.1016/j.ijrobp.2016.02.021; Haimovitz-Friedman, 1996, Semin Radiat Oncol, V6, P273, DOI 10.1016/S1053-4296(96)80023-3; HALDAR S, 1994, CANCER RES, V54, P2095; Hammel M, 2010, J BIOL CHEM, V285, P1414, DOI 10.1074/jbc.M109.065615; Hanai R, 1998, INT J RADIAT BIOL, V73, P475, DOI 10.1080/095530098142013; Harari PM, 2009, SEMIN RADIAT ONCOL, V19, P63, DOI 10.1016/j.semradonc.2008.09.009; HARPER JW, 1993, CELL, V75, P805; Helton ES, 2007, J CELL BIOCHEM, V100, P883, DOI 10.1002/jcb.21091; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Huang SM, 2000, CLIN CANCER RES, V6, P2166; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Janot F, 2008, J CLIN ONCOL, V26, P5518, DOI 10.1200/JCO.2007.15.0102; Karimi-Busheri F, 2007, CANCER RES, V67, P6619, DOI 10.1158/0008-5472.CAN-07-0480; Khan Atif J, 2018, Oncotarget, V9, P25833, DOI 10.18632/oncotarget.25383; Korzeniewski N, 2011, CANCER LETT, V305, P113, DOI 10.1016/j.canlet.2010.10.013; Lafarga V, 2009, MOL CELL BIOL, V29, P4341, DOI 10.1128/MCB.00210-09; Lee N, 2020, STUDY PROTON VERSUS; Li YH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039588; Liccardi G, 2011, CANCER RES, V71, P1103, DOI 10.1158/0008-5472.CAN-10-2384; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Lobrich M, 2007, NAT REV CANCER, V7, P861, DOI 10.1038/nrc2248; Lomax ME, 2013, CLIN ONCOL-UK, V25, P578, DOI 10.1016/j.clon.2013.06.007; Lucero H, 2003, J BIOL CHEM, V278, P22136, DOI 10.1074/jbc.M301579200; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Mansour WY, 2013, RADIOTHER ONCOL, V106, P147, DOI 10.1016/j.radonc.2012.10.020; Mari PO, 2006, P NATL ACAD SCI USA, V103, P18597, DOI 10.1073/pnas.0609061103; McCulloch HD, 1908, BRIT MED J, V1908, P1146, DOI 10.1136/bmj.2.2494.1146; Mehanna H, 2019, LANCET, V393, P51, DOI 10.1016/S0140-6736(18)32752-1; Michalak EM, 2008, CELL DEATH DIFFER, V15, P1019, DOI 10.1038/cdd.2008.16; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; Modesti M, 1999, EMBO J, V18, P2008, DOI 10.1093/emboj/18.7.2008; Moeller BJ, 2011, CLIN CANCER RES, V17, P2035, DOI 10.1158/1078-0432.CCR-10-2641; Nagasawa H, 2010, MUTAT RES-GEN TOX EN, V701, P12, DOI 10.1016/j.mrgentox.2010.03.003; Ngwa W, 2018, NAT REV CANCER, V18, P313, DOI 10.1038/nrc.2018.6; Nutley BP, 2005, BRIT J CANCER, V93, P1011, DOI 10.1038/sj.bjc.6602823; Oksuz DC, 2011, RADIAT ONCOL, V6, DOI 10.1186/1748-717X-6-54; Patel SH, 2014, LANCET ONCOL, V15, P1027, DOI 10.1016/S1470-2045(14)70268-2; Postow L, 2008, J CELL BIOL, V182, P467, DOI 10.1083/jcb.200802146; RADFORD IR, 1994, INT J RADIAT BIOL, V65, P217, DOI 10.1080/09553009414550251; Reynolds P, 2012, NUCLEIC ACIDS RES, V40, P10821, DOI 10.1093/nar/gks879; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; SchmidtUllrich RK, 1997, ONCOGENE, V15, P1191, DOI 10.1038/sj.onc.1201275; Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI [10.3322/caac.21601, 10.3322/caac.21590]; Skinner HD, 2012, CLIN CANCER RES, V18, P290, DOI 10.1158/1078-0432.CCR-11-2260; Spence T, 2016, CANCERS, V8, DOI 10.3390/cancers8080075; Srivastava M, 2012, CELL, V151, P1474, DOI 10.1016/j.cell.2012.11.054; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Stucki M, 2006, DNA REPAIR, V5, P534, DOI 10.1016/j.dnarep.2006.01.012; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Timme CR, 2018, MOL CANCER THER, V17, P1207, DOI 10.1158/1535-7163.MCT-17-1267; Tsai CJ, 2007, P NATL ACAD SCI USA, V104, P7851, DOI 10.1073/pnas.0702620104; Valente LJ, 2013, CELL REP, V3, P1339, DOI 10.1016/j.celrep.2013.04.012; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Weinberg RL, 2005, J MOL BIOL, V348, P589, DOI 10.1016/j.jmb.2005.03.014; Weisz L, 2007, ONCOGENE, V26, P2202, DOI 10.1038/sj.onc.1210294; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Zhao X, 2017, ACTA BIOCH BIOPH SIN, V49, P655, DOI 10.1093/abbs/gmx055; Zhou G, 2016, J CELL BIOCHEM, V117, P2682, DOI 10.1002/jcb.25592; Zhou X, 2019, J MOL CELL BIOL, V11, P293, DOI 10.1093/jmcb/mjy072	100	42	43	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	18					3638	3649		10.1038/s41388-020-1250-3	http://dx.doi.org/10.1038/s41388-020-1250-3		MAR 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LI5XR	32157215	hybrid, Green Accepted, Green Published			2022-12-17	WOS:000518886000007
J	Lu, X; Liu, R; Wang, MN; Kumar, AK; Pan, FY; He, LF; Hu, ZG; Guo, ZG				Lu, Xiao; Liu, Rui; Wang, Meina; Kumar, Alagamuthu Karthick; Pan, Feiyan; He, Lingfeng; Hu, Zhigang; Guo, Zhigang			MicroRNA-140 impedes DNA repair by targeting FEN1 and enhances chemotherapeutic response in breast cancer	ONCOGENE			English	Article							BASE EXCISION-REPAIR; YIN YANG 1; DAMAGE RESPONSE; FACTOR YY1; RESISTANCE; INVASION; MIR-140; EXPRESSION; MECHANISM; NUCLEASE	An increased DNA repair capacity is associated with drug resistance and limits the efficacy of chemotherapy in breast cancers. Flap endonuclease 1 (FEN1) participates in various DNA repair pathways and contributes to cancer progression and drug resistance in chemotherapy. Inhibition of FEN1 serves as a potent strategy for cancer therapy. Here, we demonstrate that microRNA-140 (miR-140) inhibits FEN1 expression via directly binding to its 3 ' untranslated region, leading to impaired DNA repair and repressed breast cancer progression. Overexpression of miR-140 sensitizes breast cancer cells to chemotherapeutic agents and overcomes drug resistance in breast cancer. Notably, ectopic expression of FEN1 abates the effects of miR-140 on DNA damage and the chemotherapy response in breast cancer cells. Furthermore, the transcription factor/repressor Ying Yang 1 (YY1) directly binds to the miR-140 promoter and activates miR-140 expression, which is attenuated in doxorubicin resistance. Our results demonstrate that miR-140 acts as a tumor suppressor in breast cancer by inhibiting FEN1 to repress DNA damage repair and reveal miR-140 to be a new anti-tumorigenesis factor for adjunctive breast cancer therapy. This novel mechanism will enhance the treatment effect of chemotherapy in breast cancer.	[Lu, Xiao; Liu, Rui; Wang, Meina; Kumar, Alagamuthu Karthick; Pan, Feiyan; He, Lingfeng; Hu, Zhigang; Guo, Zhigang] Nanjing Normal Univ, Jiangsu Key Lab Mol & Med Biotechnol, Coll Life Sci, 1 WenYuan Rd, Nanjing 210023, Jiangsu, Peoples R China	Nanjing Normal University	Hu, ZG; Guo, ZG (corresponding author), Nanjing Normal Univ, Jiangsu Key Lab Mol & Med Biotechnol, Coll Life Sci, 1 WenYuan Rd, Nanjing 210023, Jiangsu, Peoples R China.	huzg_2000@126.com; guo@njnu.edu.cn	kumar, Alagamuthu Karthick/X-4468-2019		National Natural Science Foundation of China [81872284, 31400659, 31701179]; China Postdoctoral Science Foundation [2016M591877]; Priority Academic Program Development of Jiangsu Higher Education Institutions	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Priority Academic Program Development of Jiangsu Higher Education Institutions	This work was supported by the National Natural Science Foundation of China (81872284, 31400659, and 31701179), China Postdoctoral Science Foundation (2016M591877), and the Priority Academic Program Development of Jiangsu Higher Education Institutions.	Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005; Balakrishnan L, 2013, ANNU REV BIOCHEM, V82, P119, DOI 10.1146/annurev-biochem-072511-122603; Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Castellano G, 2009, CELL CYCLE, V8, P1367, DOI 10.4161/cc.8.9.8314; Deng Z, 2009, ONCOGENE, V28, P3746, DOI 10.1038/onc.2009.231; di Fagagna FD, 2014, TRENDS CELL BIOL, V24, P171, DOI 10.1016/j.tcb.2013.09.008; Farre D, 2003, NUCLEIC ACIDS RES, V31, P3651, DOI 10.1093/nar/gkg605; Frasor J, 2006, CANCER RES, V66, P7334, DOI 10.1158/0008-5472.CAN-05-4269; Gordon S, 2006, ONCOGENE, V25, P1125, DOI 10.1038/sj.onc.1209080; Guo ZG, 2012, MOL CELL, V47, P444, DOI 10.1016/j.molcel.2012.05.042; He LF, 2018, DNA REPAIR, V63, P1, DOI 10.1016/j.dnarep.2018.01.003; He LF, 2017, MOL ONCOL, V11, P640, DOI 10.1002/1878-0261.12058; He LF, 2016, EBIOMEDICINE, V14, P32, DOI 10.1016/j.ebiom.2016.11.012; Hu HL, 2011, J MOL CELL BIOL, V3, P151, DOI 10.1093/jmcb/mjq042; Hu ZG, 2017, J MOL ENDOCRINOL, V59, P269, DOI 10.1530/JME-17-0011; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Kai Y, 2014, BIOCHEM BIOPH RES CO, V448, P308, DOI 10.1016/j.bbrc.2014.02.032; Kato M, 2009, ONCOGENE, V28, P3008, DOI 10.1038/onc.2009.218; Krishnan K, 2013, RNA, V19, P230, DOI 10.1261/rna.034926.112; Lee JH, 2015, CANCER RES, V75, P1298, DOI 10.1158/0008-5472.CAN-14-2783; Li Q, 2014, ONCOGENE, V33, P2589, DOI 10.1038/onc.2013.226; Liu L, 2012, CARCINOGENESIS, V33, P119, DOI 10.1093/carcin/bgr250; Lu Y, 2017, CANCER GENE THER, V24, P386, DOI 10.1038/cgt.2017.30; O'Connor MJ, 2015, MOL CELL, V60, P547, DOI 10.1016/j.molcel.2015.10.040; Ramos P, 2015, ONCOGENE, V34, P3617, DOI 10.1038/onc.2014.314; Rebucci M, 2013, BIOCHEM PHARMACOL, V85, P1219, DOI 10.1016/j.bcp.2013.02.017; Senkevich TG, 2009, P NATL ACAD SCI USA, V106, P17921, DOI 10.1073/pnas.0909529106; Singh P, 2008, MOL CANCER RES, V6, P1710, DOI 10.1158/1541-7786.MCR-08-0269; Song B, 2009, ONCOGENE, V28, P4065, DOI 10.1038/onc.2009.274; Sun H, 2017, ONCOGENE, V36, P194, DOI 10.1038/onc.2016.188; Tubbs A, 2017, CELL, V168, DOI 10.1016/j.cell.2017.01.002; Valeri N, 2010, P NATL ACAD SCI USA, V107, P21098, DOI 10.1073/pnas.1015541107; Wang CC, 2005, ONCOGENE, V24, P4081, DOI 10.1038/sj.onc.1208573; Wang JW, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1043-1; Wang MN, 2018, GENE, V668, P196, DOI 10.1016/j.gene.2018.05.072; Wu XT, 1999, P NATL ACAD SCI USA, V96, P1303, DOI 10.1073/pnas.96.4.1303; Xie QH, 2011, BIOCHEM BIOPH RES CO, V410, P440, DOI 10.1016/j.bbrc.2011.05.153; Yang H, 2013, HEPATOLOGY, V58, P205, DOI 10.1002/hep.26315; Yang M, 2009, HUM MUTAT, V30, P1320, DOI 10.1002/humu.21060; Yoon JH, 1999, BIOCHEMISTRY-US, V38, P4809, DOI 10.1021/bi990105i; Yuan YF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073604; Zhang YS, 2012, J BIOL CHEM, V287, P41514, DOI 10.1074/jbc.M112.404871; Zheng L, 2011, NUCLEIC ACIDS RES, V39, P781, DOI 10.1093/nar/gkq884; Zhou T, 2016, ONCOTARGET, V7, P6902, DOI 10.18632/oncotarget.6849	45	42	42	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	1					234	247		10.1038/s41388-019-0986-0	http://dx.doi.org/10.1038/s41388-019-0986-0			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG3NM	31471584				2022-12-17	WOS:000509849200016
J	Rathore, M; Girard, C; Ohanna, M; Tichet, M; Ben Jouira, R; Garcia, E; Larbret, F; Gesson, M; Audebert, S; Lacour, JP; Montaudie, H; Prod'Homme, V; Tartare-Deckert, S; Deckert, M				Rathore, M.; Girard, C.; Ohanna, M.; Tichet, M.; Ben Jouira, R.; Garcia, E.; Larbret, F.; Gesson, M.; Audebert, S.; Lacour, J. -P.; Montaudie, H.; Prod'Homme, V.; Tartare-Deckert, S.; Deckert, M.			Cancer cell-derived long pentraxin 3 (PTX3) promotes melanoma migration through a toll-like receptor 4 (TLR4)/NF-kappa B signaling pathway	ONCOGENE			English	Article							NF-KAPPA-B; EPITHELIAL-MESENCHYMAL TRANSITION; UP-REGULATION; INFLAMMATION; EXPRESSION; RESISTANCE; GROWTH; INHIBITION; PHENOTYPE; INVASION	Cutaneous melanoma is one of the most aggressive cancers characterized by a high plasticity, a propensity for metastasis, and drug resistance. Melanomas are composed of phenotypically diverse subpopulations of tumor cells with heterogeneous molecular profiles that reflect intrinsic invasive abilities. In an attempt to identify novel factors of the melanoma invasive cell state, we previously investigated the nature of the invasive secretome by using a comparative proteomic approach. Here, we have extended this analysis to show that PTX3, an acute phase inflammatory glycoprotein, is one such factor secreted by invasive melanoma to promote tumor cell invasiveness. Elevated PTX3 production was observed in the population of MITFlow invasive cells but not in the population of MITFhigh differentiated melanoma cells. Consistently, MITF knockdown increased PTX3 expression in MITFhigh proliferative and poorly invasive cells. High levels of PTX3 were found in tissues and blood of metastatic melanoma patients, and in BRAF inhibitor-resistant melanoma cells displaying a mesenchymal invasive MITFlow phenotype. Genetic silencing of PTX3 in invasive melanoma cells dramatically impaired migration and invasion in vitro and in experimental lung extravasation assay in xenografted mice. In contrast, addition of melanoma-derived or recombinant PTX3, or expression of PTX3 enhanced motility of low migratory cells. Mechanistically, autocrine production of PTX3 by melanoma cells triggered an IKIC/NF kappa B signaling pathway that promotes migration, invasion, and expression of the EMT factor TWIST1. Finally, we found that TLR4 and MYD88 knockdown inhibited PTX3-induced melanoma cell migration, suggesting that PTX3 functions through a TLR4-dependent pathway. Our work reveals that tumor-derived PTX3 contributes to melanoma cell invasion via targetable inflammation-related pathways. In addition to providing new insights into the biology of melanoma invasive behavior, this study underscores the notion that secreted PTX3 represents a potential biomarker and therapeutic target in a subpopulation of MITFlow invasive and/or refractory melanoma.	[Rathore, M.; Girard, C.; Ohanna, M.; Tichet, M.; Ben Jouira, R.; Garcia, E.; Larbret, F.; Gesson, M.; Prod'Homme, V.; Tartare-Deckert, S.; Deckert, M.] Univ Cote Azur, INSERM, C3M, Nice, France; [Rathore, M.; Girard, C.; Ohanna, M.; Larbret, F.; Prod'Homme, V.; Tartare-Deckert, S.; Deckert, M.] Equipe Labellisee Ligue Canc 2016, Nice, France; [Rathore, M.] Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA; [Audebert, S.] Aix Marseille Univ, Inst Paoli Calmettes, INSERM, CNRS,CRCM, Marseille, France; [Lacour, J. -P.; Montaudie, H.] Univ Cote Azur, CHU Nice, Nice, France; [Tichet, M.] Ecole Polytech Fed Lausanne, Lab Translat Oncol, ISREC, Lausanne, Switzerland	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; University of Minnesota System; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); CHU Nice; UDICE-French Research Universities; Universite Cote d'Azur; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Institute Experimental Cancer Research	Tartare-Deckert, S; Deckert, M (corresponding author), Univ Cote Azur, INSERM, C3M, Nice, France.; Tartare-Deckert, S; Deckert, M (corresponding author), Equipe Labellisee Ligue Canc 2016, Nice, France.	tartare@unice.fr; deckert@unice.fr	Girard, Christophe/O-8455-2016; Deckert, Marcel/T-3566-2019; Prod'homme, Virginie/A-3948-2012; Ohanna, Mickael/O-5784-2016; TARTARE-DECKERT, Sophie/P-6057-2015	Girard, Christophe/0000-0002-4560-4479; Deckert, Marcel/0000-0003-2094-559X; Prod'homme, Virginie/0000-0002-9664-4710; Ohanna, Mickael/0000-0002-7751-9164; TARTARE-DECKERT, Sophie/0000-0001-8680-5720; Ben Jouira, Rania/0000-0001-6999-4566; Audebert, Stephane/0000-0002-9409-2588	Ligue Contre le Cancer; Fondation ARC; Fondation de France; French Government (National Research Agency); (ANR) through the "Investments for the Future" LABEX SIGNALIFE [ANR-11-LABX-0028-01]; Conseil General des Alpes-Maritimes; Canceropole PACA; Region PACA; IBiSA (Infrastructures Biologie Sante et Agronomie); Institut Paoli-Calmettes	Ligue Contre le Cancer(Ligue nationale contre le cancer); Fondation ARC; Fondation de France(Fondation de France); French Government (National Research Agency); (ANR) through the "Investments for the Future" LABEX SIGNALIFE(French National Research Agency (ANR)); Conseil General des Alpes-Maritimes(Region Provence-Alpes-Cote d'Azur); Canceropole PACA(Region Grand-Est); Region PACA(Region Provence-Alpes-Cote d'Azur); IBiSA (Infrastructures Biologie Sante et Agronomie); Institut Paoli-Calmettes	We thank RS Lo and R Ballotti for melanoma cells. We acknowledge the C3M animal and imaging (Microscopy and Imaging platform Cote d'Azur, MICA) facilities. This work was supported by Ligue Contre le Cancer, Fondation ARC, Fondation de France and the French Government (National Research Agency, ANR) through the "Investments for the Future" LABEX SIGNALIFE: program reference #ANR-11-LABX-0028-01. We also thank financial supports by Conseil General des Alpes-Maritimes, Canceropole PACA and Region PACA. MR was a recipient of a post-doctoral fellowship from Fondation ARC. The Marseille Proteomic facility (MaP; http://map.univmed.fr/) is supported by IBiSA (Infrastructures Biologie Sante et Agronomie), Canceropole PACA, Region PACA, and Institut Paoli-Calmettes.	Ahn JH, 2008, EXP DERMATOL, V17, P412, DOI 10.1111/j.1600-0625.2008.00701.x; Bailet O, 2009, CANCER RES, V69, P2748, DOI 10.1158/0008-5472.CAN-08-2690; Bonavita E, 2015, CELL, V160, P700, DOI 10.1016/j.cell.2015.01.004; Bottazzi B, 2016, J HEPATOL, V64, P1416, DOI 10.1016/j.jhep.2016.02.029; Bozza S, 2014, J IMMUNOL, V193, P2340, DOI 10.4049/jimmunol.1400814; Caramel J, 2013, CANCER CELL, V24, P466, DOI 10.1016/j.ccr.2013.08.018; Carmo RF, 2016, J VIRAL HEPATITIS, V23, P116, DOI 10.1111/jvh.12472; Chan SH, 2017, ONCOTARGET, V8, P41364, DOI 10.18632/oncotarget.17326; Chang WC, 2015, ONCOTARGET, V6, P7741, DOI 10.18632/oncotarget.3482; Cheli Y, 2012, ONCOGENE, V31, P2461, DOI 10.1038/onc.2011.425; Choi B, 2015, ANTICANCER RES, V35, P2663; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Diamandis EP, 2011, CLIN CANCER RES, V17, P2395, DOI 10.1158/1078-0432.CCR-10-3024; Didier R, 2018, MOL CANCER THER, V17, P1416, DOI 10.1158/1535-7163.MCT-17-0919; Eiro N, 2013, ARCH DERMATOL RES, V305, P59, DOI 10.1007/s00403-012-1300-y; Fenouille N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040378; Fenouille N, 2011, PIGM CELL MELANOMA R, V24, P219, DOI 10.1111/j.1755-148X.2010.00790.x; Flaherty KT, 2012, NAT REV CANCER, V12, P349, DOI 10.1038/nrc3218; Garlanda C, 2016, CURR OPIN IMMUNOL, V38, P39, DOI 10.1016/j.coi.2015.11.002; Giacomini A, 2018, BBA-REV CANCER, V1869, P53, DOI 10.1016/j.bbcan.2017.11.004; Holderfield M, 2014, NAT REV CANCER, V14, P455, DOI 10.1038/nrc3760; Hu FQ, 2014, J BIOL REG HOMEOS AG, V28, P649; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kemper K, 2014, CANCER RES, V74, P5937, DOI 10.1158/0008-5472.CAN-14-1174; Kondo S, 2013, BRIT J CANCER, V109, P739, DOI 10.1038/bjc.2013.348; Leali D, 2011, MOL CANCER THER, V10, P1600, DOI 10.1158/1535-7163.MCT-11-0286; Li CW, 2012, CANCER RES, V72, P1290, DOI 10.1158/0008-5472.CAN-11-3123; Locatelli M, 2013, J NEUROIMMUNOL, V260, P99, DOI 10.1016/j.jneuroim.2013.04.009; Magrini E, 2016, TRENDS MOL MED, V22, P497, DOI 10.1016/j.molmed.2016.04.007; Margheri F, 2009, NEOPLASIA, V11, P1106, DOI 10.1593/neo.09934; Muller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6712; Na YR, 2013, MELANOMA RES, V23, P434, DOI 10.1097/CMR.0000000000000021; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Obenauf AC, 2015, TRENDS CANCER, V1, P76, DOI 10.1016/j.trecan.2015.07.009; Ohanna M, 2018, GENE DEV, V32, P448, DOI 10.1101/gad.305854.117; Ravenna L, 2009, PROSTATE, V69, P1245, DOI 10.1002/pros.20966; Riesenberg S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9755; Robert G, 2006, CANCER RES, V66, P7516, DOI 10.1158/0008-5472.CAN-05-3189; Ronca R, 2015, CANCER CELL, V28, P225, DOI 10.1016/j.ccell.2015.07.002; Ronca R, 2013, MOL CANCER THER, V12, P2760, DOI 10.1158/1535-7163.MCT-13-0487; Ronca R, 2013, J PATHOL, V230, P228, DOI 10.1002/path.4181; Rubino M, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1333215; Shaffer SM, 2017, NATURE, V546, P431, DOI 10.1038/nature22794; Shao YP, 2015, J INVEST DERMATOL, V135, P1839, DOI 10.1038/jid.2015.91; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Takazawa Y, 2014, TOHOKU J EXP MED, V234, P57, DOI 10.1620/tjem.234.57; Thomas C, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aah4674; Tichet M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7993; Titz B, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.28; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Tung JN, 2016, J NEURO-ONCOL, V129, P201, DOI 10.1007/s11060-016-2168-z; Verfaillie A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7683; Weiss MB, 2012, CANCER RES, V72, P6382, DOI 10.1158/0008-5472.CAN-12-1033; Widmer DS, 2012, PIGM CELL MELANOMA R, V25, P343, DOI 10.1111/j.1755-148X.2012.00986.x; Ying TH, 2016, SCI REP-UK, V6, DOI 10.1038/srep29385	55	42	44	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 25	2019	38	30					5873	5889		10.1038/s41388-019-0848-9	http://dx.doi.org/10.1038/s41388-019-0848-9			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IT3FY	31253871	Green Published			2022-12-17	WOS:000482739300003
J	Woosley, AN; Dalton, AC; Hussey, GS; Howley, BV; Mohanty, BK; Grelet, S; Dincman, T; Bloos, S; Olsen, SK; Howe, PH				Woosley, Alec N.; Dalton, Annamarie C.; Hussey, George S.; Howley, Breege V.; Mohanty, Bidyut K.; Grelet, Simon; Dincman, Toros; Bloos, Sean; Olsen, Shaun K.; Howe, Philip H.			TGF beta promotes breast cancer stem cell self-renewal through an ILEI/LIFR signaling axis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; METASTASIS SUPPRESSOR; TUMOR CELLS; IN-VITRO; LIFR; EMT; CARCINOMA; EVOLUTION; ILEI; IDENTIFICATION	FAM3C/Interleukin-like EMT Inducer (ILEI) is an oncogenic member of the FAM3 cytokine family and serves essential roles in both epithelial-mesenchymal transition (EMT) and breast cancer metastasis. ILEI expression levels are regulated through a non-canonical TGF beta signaling pathway by 3'-UTR-mediated translational silencing at the mRNA level by hnRNP E1. TGF beta stimulation or silencing of hnRNP E1 increases ILEI translation and induces an EMT program that correlates with enhanced invasion and migration. Recently, EMT has been linked to the formation of breast cancer stem cells (BCSCs) that confer both tumor cell heterogeneity as well as chemoresistant properties. Herein, we demonstrate that hnRNP E1 knockdown significantly shifts normal mammary epithelial cells to mesenchymal BCSCs in vitro and in vivo. We further validate that modulating ILEI protein levels results in the abrogation of these phenotypes, promoting further investigation into the unknown mechanism of ILEI signaling that drives tumor progression. We identify LIFR as the receptor for ILEI, which mediates signaling through STAT3 to drive both EMT and BCSC formation. Reduction of either ILEI or LIFR protein levels results in reduced tumor growth, fewer tumor initiating cells and reduced metastasis within the hnRNP E1 knockdown cell populations in vivo. These results reveal a novel ligand-receptor complex that drives the formation of BCSCs and represents a unique target for the development of metastatic breast cancer therapies.	[Woosley, Alec N.; Dalton, Annamarie C.; Hussey, George S.; Howley, Breege V.; Mohanty, Bidyut K.; Grelet, Simon; Dincman, Toros; Bloos, Sean; Olsen, Shaun K.; Howe, Philip H.] Med Univ South Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave, Charleston, SC 29425 USA	Medical University of South Carolina	Howe, PH (corresponding author), Med Univ South Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave, Charleston, SC 29425 USA.	howep@musc.edu	Bloos, Sean/AAD-4630-2021	Olsen, Shaun/0000-0002-1265-7101; Dincman, Toros/0000-0002-4449-0510; Bloos, Sean/0000-0002-1044-4823; Howe, Philip/0000-0002-1358-1313	DOD BCRP [BC170301]; NIH NCI [RO1CA154663, T32 CA193201, F31 CA213627]; Office of the Assistant Secretary of Defense for Health Affairs through the Breast Cancer Research Program [W81XWH-18-1-0003]; U.S. Army Medical Research Acquisition Activity, Chandler Street, Fort Detrick MD; NATIONAL CANCER INSTITUTE [F31CA213627, R01CA154663, T32CA193201] Funding Source: NIH RePORTER	DOD BCRP(United States Department of Defense); NIH NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Office of the Assistant Secretary of Defense for Health Affairs through the Breast Cancer Research Program; U.S. Army Medical Research Acquisition Activity, Chandler Street, Fort Detrick MD; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Ken Noguchi and the Howe laboratory members for their helpful discussions and critical reading of the manuscript. The SUM cell lines and HMLE cell lines were a generous gift from Dr. Steven Ethier and Dr. Juan Massague, respectively. Funding for this project was provided by DOD BCRP BC170301 to ACD, NIH NCI T32 CA193201 to ACD, NIH NCI F31 CA213627 to ANW, and NIH NCI RO1CA154663 to PHH. Cores at MUSC used for this project include the shRNA Shared Technology Resource, Flow Cytometry and Cell Sorting Unit, Laboratory Core in the Center for Oral Health Research, Cell and Molecular Imaging Core and the Biorepository and Tissue Analysis Shared Resource. The U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick MD 21702-5014 is the awarding and administering acquisition office for ACD. This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Breast Cancer Research Program, under Award No. W81XWH-18-1-0003. Opinions, interpretations, conclusions, and recommendations are those of the author and are not necessarily endorsed by the Department of Defense. In conducting research using animals, the investigators adhere to the laws of the United States and regulations of the Department of Agriculture.	Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Asiedu MK, 2011, CANCER RES, V71, P4707, DOI 10.1158/0008-5472.CAN-10-4554; Brill B, 2008, LAB ANIM-UK, V42, P104, DOI 10.1258/la.2007.06003e; Chaudhury A, 2010, NAT CELL BIOL, V12, P286, DOI 10.1038/ncb2029; Chen DH, 2012, NAT MED, V18, P1511, DOI 10.1038/nm.2940; Chiou SH, 2008, CLIN CANCER RES, V14, P4085, DOI 10.1158/1078-0432.CCR-07-4404; Csiszar A, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0433-7; Forozan F, 1999, BRIT J CANCER, V81, P1328, DOI 10.1038/sj.bjc.6695007; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Ginestier C, 2010, J CLIN INVEST, V120, P485, DOI 10.1172/JCI39397; Grelet S, 2017, NAT CELL BIOL, V19, P1105, DOI 10.1038/ncb3595; Guo HW, 2015, ONCOTARGET, V6, P25484, DOI 10.18632/oncotarget.4688; Hasegawa H, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4917; Hirai H, 2011, BIOCHEM J, V438, P11, DOI 10.1042/BJ20102152; Howley BV, 2016, ONCOGENE, V35, P1725, DOI 10.1038/onc.2015.238; Howley BV, 2018, ONCOGENE, V37, P1308, DOI 10.1038/s41388-017-0023-0; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Hussey GS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052624; Hussey GS, 2011, MOL CELL, V41, P419, DOI 10.1016/j.molcel.2011.02.003; Ishihara K, 2002, BBA-MOL CELL RES, V1592, P281, DOI 10.1016/S0167-4889(02)00321-X; James P, 1996, GENETICS, V144, P1425; Johnson RW, 2016, NAT CELL BIOL, V18, P1078, DOI 10.1038/ncb3408; Junk DJ, 2017, ONCOGENE, V36, P4001, DOI 10.1038/onc.2017.33; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Katahira T, 2010, BIOCHEM BIOPH RES CO, V392, P301, DOI 10.1016/j.bbrc.2009.12.180; Kim SY, 2013, CELL SIGNAL, V25, P961, DOI 10.1016/j.cellsig.2013.01.007; Korkaya H, 2012, MOL CELL, V47, P570, DOI 10.1016/j.molcel.2012.06.014; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Lahsnig C, 2009, ONCOGENE, V28, P638, DOI 10.1038/onc.2008.418; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Lebrun Jean-Jacques, 2012, ISRN Mol Biol, V2012, P381428, DOI 10.5402/2012/381428; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Li XY, 2014, ONCOTARGET, V5, P788, DOI 10.18632/oncotarget.1772; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Liu F, 2016, ONCOL LETT, V12, P4869, DOI 10.3892/ol.2016.5369; Luo Q, 2015, CARCINOGENESIS, V36, P1201, DOI 10.1093/carcin/bgv108; Lv SD, 2018, ONCOGENE, V37, P1354, DOI 10.1038/s41388-017-0026-x; Ma D, 2016, ONCOL REP, V36, P827, DOI 10.3892/or.2016.4865; Maatta JA, 2016, BONEKEY REP, V5, DOI 10.1038/bonekey.2016.14; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; MATSUI WH, 2016, MEDICINE S1, V95, DOI DOI 10.1097/MD.0000000000004765; Nicola NA, 2015, CYTOKINE GROWTH F R, V26, P533, DOI 10.1016/j.cytogfr.2015.07.001; Port MD, 2007, J NEUROCHEM, V101, P782, DOI 10.1111/j.1471-4159.2007.04471.x; Richards EJ, 2015, J BIOL CHEM, V290, P6857, DOI 10.1074/jbc.M114.610915; Schust J, 2006, CHEM BIOL, V13, P1235, DOI 10.1016/j.chembiol.2006.09.018; Thomas SJ, 2015, BRIT J CANCER, V113, P365, DOI 10.1038/bjc.2015.233; Tomita H, 2016, ONCOTARGET, V7, P11018, DOI 10.18632/oncotarget.6920; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Underhill-Day N, 2006, CANCER RES, V66, P10891, DOI 10.1158/0008-5472.CAN-06-1766; Velasco-Velazquez MA, 2012, INT J BIOCHEM CELL B, V44, P573, DOI 10.1016/j.biocel.2011.12.020; Waerner T, 2006, CANCER CELL, V10, P227, DOI 10.1016/j.ccr.2006.07.020; Wahl GM, 2017, NPJ BREAST CANCER, V3, DOI 10.1038/s41523-017-0012-z; Wang TY, 2018, CELL METAB, V27, P136, DOI 10.1016/j.cmet.2017.11.001; Wang XY, 2012, J BIOMED RES, V26, P325, DOI 10.7555/JBR.26.20110050; Yates LR, 2017, CANCER CELL, V32, P169, DOI 10.1016/j.ccell.2017.07.005; Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522; Yue Xuetian, 2015, Cancer Cell Microenviron, V2; Zhu Y, 2002, GENOMICS, V80, P144, DOI 10.1006/geno.2002.6816	60	42	43	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2019	38	20					3794	3811		10.1038/s41388-019-0703-z	http://dx.doi.org/10.1038/s41388-019-0703-z			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HY3OI	30692635	Green Accepted			2022-12-17	WOS:000468035600003
J	Tripathi, V; Shin, JH; Stuelten, CH; Zhang, YE				Tripathi, Veenu; Shin, Jee-Hye; Stuelten, Christina H.; Zhang, Ying E.			TGF-beta-induced alternative splicing of TAK1 promotes EMT and drug resistance	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; TO-MESENCHYMAL TRANSITION; CANCER; MAPKKK; TRAF6; P38; PHOSPHORYLATION; METASTASIS; REGULATOR	Transforming growth factor-beta (TGF-beta) is major inducer of epithelial-to-mesenchymal transition (EMT), which associates with cancer cell metastasis and resistance to chemotherapy and targeted drugs, through both transcriptional and non-transcriptional mechanisms. We previously reported that, in cancer cells, heightened mitogenic signaling allows TGF-beta-activated Smad3 to interact with poly(RC) binding protein 1 (PCBP1) and together they regulate many alternative splicing events that favors expression of protein isoforms essential for EMT, cytoskeletal rearrangement, and adherens junction signaling. Here we show that the exclusion of TGF-beta-activated kinase 1 (TAK1) variable exon 12 requires another RNA-binding protein, Fox-1 homolog 2 (Rbfox2), which binds intronic sequences in front of exon 12 independently of the Smad3-PCBP1 complex. Functionally, exon 12-excluded TAK1 Delta E12 and full-length TAK1FL are distinct. The short isoform TAK1 Delta E12 is constitutively active and supports TGF-beta-induced EMT and nuclear factor kappa B (NF-kappa B) signaling, whereas the full-length isoform TAK1FL promotes TGF-beta-induced apoptosis. These observations offer a harmonious explanation for how a single TAK1 kinase can mediate the opposing responses of cell survival and apoptosis in response to TGF-beta. They also reveal a propensity of the alternatively spliced TAK1 isoform TAK1 Delta E12 to cause drug resistance due to its activity in supporting EMT and NF-kappa B survival signaling.	[Tripathi, Veenu; Shin, Jee-Hye; Stuelten, Christina H.; Zhang, Ying E.] NCI, Lab Cellular & Mol Biol, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Zhang, YE (corresponding author), NCI, Lab Cellular & Mol Biol, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.	zhangyin@mail.nih.gov	Zhang, Ying E/G-3657-2015	Zhang, Ying E/0000-0003-2753-7601	NIH, National Cancer Institute, Center for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC010419] Funding Source: NIH RePORTER	NIH, National Cancer Institute, Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr. K. Matsumoto for providing HATAK1 (Delta E12) plasmids; Dr. ZG Liu for NF kappa B-Luc reporter construct; Dr. K Hunter, Dr. L. Yang, and Dr. T. Misteli for Met-1, 4T1, and hMSC cells, respectively. This research was supported by the intramural research program of the NIH, National Cancer Institute, Center for Cancer Research.	Akhurst RJ, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022301; Alcorn JF, 2008, J CELL SCI, V121, P1036, DOI 10.1242/jcs.019455; Arsura M, 2003, ONCOGENE, V22, P412, DOI 10.1038/sj.onc.1206132; Bakin AV, 2002, J CELL SCI, V115, P3193; Bianchini G, 2016, NAT REV CLIN ONCOL, V13, P674, DOI 10.1038/nrclinonc.2016.66; Borowsky AD, 2005, CLIN EXP METASTAS, V22, P47, DOI 10.1007/s10585-005-2908-5; Brown K, 2005, J MOL BIOL, V354, P1013, DOI 10.1016/j.jmb.2005.09.098; Brown M, 2008, EXPERT OPIN THER TAR, V12, P1109, DOI 10.1517/14728222.12.9.1109 ; Dempsey CE, 2000, BBA-GENE STRUCT EXPR, V1517, P46, DOI 10.1016/S0167-4781(00)00258-X; Derynck R, 2014, CURR OPIN CELL BIOL, V31, P56, DOI 10.1016/j.ceb.2014.09.001; Disterer P, 2014, HUM GENE THER, V25, P587, DOI 10.1089/hum.2013.234; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Gingery A, 2008, EXP CELL RES, V314, P2725, DOI 10.1016/j.yexcr.2008.06.006; Hamidi A, 2012, J BIOL CHEM, V287, P123, DOI 10.1074/jbc.M111.285122; Hata A, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a022061; Hirata Y, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010205; Huang SD, 2012, CELL, V151, P937, DOI 10.1016/j.cell.2012.10.035; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Ishitani T, 2003, EMBO J, V22, P6277, DOI 10.1093/emboj/cdg605; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Ouyang C, 2014, J BIOL CHEM, V289, P24226, DOI 10.1074/jbc.M114.559963; Sakurai H, 2000, FEBS LETT, V474, P141, DOI 10.1016/S0014-5793(00)01588-X; Scholz R, 2010, J BIOL CHEM, V285, P25753, DOI 10.1074/jbc.M109.093468; Seoane J, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022277; Shapiro IM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002218; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Sorrentino A, 2008, NAT CELL BIOL, V10, P1199, DOI 10.1038/ncb1780; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Tang LY, 2017, J BIOL CHEM, V292, P4302, DOI 10.1074/jbc.M116.773085; Tripathi V, 2016, MOL CELL, V64, P549, DOI 10.1016/j.molcel.2016.09.013; Venables JP, 2013, MOL CELL BIOL, V33, P396, DOI 10.1128/MCB.01174-12; Venables JP, 2012, MOL BIOL EVOL, V29, P260, DOI 10.1093/molbev/msr193; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamashita M, 2008, MOL CELL, V31, P918, DOI 10.1016/j.molcel.2008.09.002; Yeo GW, 2009, NAT STRUCT MOL BIOL, V16, P130, DOI 10.1038/nsmb.1545; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zhang CL, 2008, GENE DEV, V22, P2550, DOI 10.1101/gad.1703108; Zhang YE, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022129; Zhou DH, 2018, BIOCHEM BIOPH RES CO, V497, P1018, DOI 10.1016/j.bbrc.2018.02.160	43	42	46	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2019	38	17					3185	3200		10.1038/s41388-018-0655-8	http://dx.doi.org/10.1038/s41388-018-0655-8			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU8RI	30626936	Green Accepted			2022-12-17	WOS:000465557200006
J	Probert, C; Dottorini, T; Speakman, A; Hunt, S; Nafee, T; Fazeli, A; Wood, S; Brown, JE; James, V				Probert, C.; Dottorini, T.; Speakman, A.; Hunt, S.; Nafee, T.; Fazeli, A.; Wood, S.; Brown, J. E.; James, V.			Communication of prostate cancer cells with bone cells via extracellular vesicle RNA; a potential mechanism of metastasis	ONCOGENE			English	Article							STIMULATE ANGIOGENESIS; MEMBRANE-VESICLES; NICHE FORMATION; STEM-CELLS; EXOSOMES; EXPRESSION; GROWTH; MICROVESICLES; MICRORNAS; PROTEINS	The role of extracellular vesicles (EVs) as vehicles for cell-to-cell communication between a tumour and its environment is a relatively new concept. The hypothesis that EVs may be critical in co-opting tissues by tumours to generate distant metastatic niches is particularly pertinent to prostate cancer (PCa), where metastatic-tropism to bone predominates over other tissue types. The potential role of EVs as a means of communication between PCa cells and cells of the bone stroma such as osteoblasts, is yet to be fully explored. In this study, we demonstrate that PCa cell EVs both enhance osteoblast viability and produce a significantly more supportive growth environment for PCa cells when grown in co-culture with EV-treated osteoblasts (p < 0.005). Characterisation of the RNA cargo of EVs produced by the bone-metastatic PCa cell line PC3, highlights the EV-RNA cargo is significantly enriched in genes relating to cell surface signalling, cell-cell interaction, and protein translation (p < 0.01). Using novel techniques to track RNA, we demonstrate the delivery of a set of PCa-RNAs to osteoblast via PCa-EVs and show the effect on osteoblast endogenous transcript abundance. Taken together, by using proof-of-concept studies we demonstrate for the first time the contribution of the RNA element of the PCa EV cargo, providing evidence to support PCa EV communication via RNA molecules as a potential novel route to mediate bone metastasis. We propose targeting PCa EVs could offer a potentially important preventative therapy for men at risk of metastatic PCa.	[Probert, C.; Dottorini, T.; Speakman, A.; James, V.] Univ Nottingham, Sch Vet Med & Sci, Nottingham LE12 5RD, England; [Dottorini, T.] Univ Nottingham, Adv Data Anal Ctr, Nottingham LE12 5RD, England; [Hunt, S.] Univ Sheffield, Sch Clin Dent, Sheffield S10 2TA, S Yorkshire, England; [Nafee, T.; Fazeli, A.] Univ Sheffield, Acad Unit Reprod & Dev Med, Jessop Wing, Jessop Wing, Sheffield S10 2SF, S Yorkshire, England; [Fazeli, A.] Univ Tartu, Inst Biomed & Translat Med, Dept Pathophysiol, Tartu, Estonia; [Wood, S.; Brown, J. E.] Univ Sheffield, Western Pk Hosp, Dept Oncol & Metab, Whitham Rd, Sheffield S10 2SJ, S Yorkshire, England	University of Nottingham; University of Nottingham; University of Sheffield; University of Sheffield; University of Tartu; University of Sheffield; Weston Park Hospital	James, V (corresponding author), Univ Nottingham, Sch Vet Med & Sci, Nottingham LE12 5RD, England.	victoria.james@nottingham.ac.uk	Fazeli, Alireza/G-3679-2010	Fazeli, Alireza/0000-0003-0870-9914; Dottorini, Tania/0000-0001-7733-906X; James, Victoria/0000-0002-9926-2953	Prostate Cancer Research UK [PA14-007]	Prostate Cancer Research UK	We thank Dr Nigel Mongan, Professor Susan Anderson (University of Nottingham) and Dr Penny Ottewell (University of Sheffield) for supplying reagents. C.P was supported by funding from Prostate Cancer Research UK (PA14-007) awarded to VJ and JEB.	Anderson SI, 1998, J MATER SCI-MATER M, V9, P731, DOI 10.1023/A:1008955002955; Bryant RJ, 2012, BRIT J CANCER, V106, P768, DOI 10.1038/bjc.2011.595; Center MM, 2012, EUR UROL, V61, P1079, DOI 10.1016/j.eururo.2012.02.054; Colombo M, 2014, ANNU REV CELL DEV BI, V30, P255, DOI 10.1146/annurev-cellbio-101512-122326; Costa-Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169; Crescitelli R, 2013, J EXTRACELL VESICLES, V2, DOI 10.3402/jev.v2i0.20677; Cunningham David, 2015, J Biol Methods, V2; Deckers MML, 2002, ENDOCRINOLOGY, V143, P1545, DOI 10.1210/en.143.4.1545; Di Silvo I., 1995, THESIS; Ekstrom K, 2012, J EXTRACELL VESICLES, V1, DOI 10.3402/jev.v1i0.18389; Foj L, 2017, PROSTATE, V77, P573, DOI 10.1002/pros.23295; Grange C, 2011, CANCER RES, V71, P5346, DOI 10.1158/0008-5472.CAN-11-0241; He M, 2015, CARCINOGENESIS, V36, P1008, DOI 10.1093/carcin/bgv081; Heijnen HFG, 1999, BLOOD, V94, P3791, DOI 10.1182/blood.V94.11.3791.423a22_3791_3799; Hessvik NP, 2012, BBA-GENE REGUL MECH, V1819, P1154, DOI 10.1016/j.bbagrm.2012.08.016; Hood JL, 2011, CANCER RES, V71, P3792, DOI 10.1158/0008-5472.CAN-10-4455; Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756; Huang W, 2015, GENET TEST MOL BIOMA, V19, P469, DOI 10.1089/gtmb.2015.0088; Huang XY, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-319; Jung T, 2009, NEOPLASIA, V11, P1093, DOI 10.1593/neo.09822; Kalra H, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001450; Kashyap V, 2013, MOL ONCOL, V7, P555, DOI 10.1016/j.molonc.2013.01.003; Lasser C, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-9; Li M, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0502; Li X, 2007, J BIOL CHEM, V282, P33098, DOI 10.1074/jbc.M611781200; Liu YF, 2016, CANCER CELL, V30, P243, DOI 10.1016/j.ccell.2016.06.021; Matsuo K, 2012, CELL ADHES MIGR, V6, P148, DOI 10.4161/cam.20888; Montero A, 2000, J CLIN INVEST, V105, P1085, DOI 10.1172/JCI8641; Morhayim Jess, 2016, Curr Mol Biol Rep, V2, P48; Nolte-'t Hoen ENM, 2012, NUCLEIC ACIDS RES, V40, P9272, DOI 10.1093/nar/gks658; Pathan M, 2017, J EXTRACELL VESICLES, V6, DOI 10.1080/20013078.2017.1321455; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Prince M, 2001, J CELL BIOCHEM, V80, P424, DOI 10.1002/1097-4644(20010301)80:3<424::AID-JCB160>3.0.CO;2-6; Rana S, 2013, NEOPLASIA, V15, P281, DOI 10.1593/neo.122010; Rodriguez M, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0726-4; Sanchez CA, 2016, ONCOTARGET, V7, P3993, DOI 10.18632/oncotarget.6540; Sharp TV, 2004, P NATL ACAD SCI USA, V101, P16531, DOI 10.1073/pnas.0407123101; Suetsugu A, 2013, ADV DRUG DELIVER REV, V65, P383, DOI 10.1016/j.addr.2012.08.007; Thery C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Van Deun J, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.24858; Wang X, 2015, ONCOL REP, V33, P2445, DOI 10.3892/or.2015.3843; Yao GQ, 2002, CALCIFIED TISSUE INT, V70, P339, DOI 10.1007/s00223-001-1079-x; Yeung CLA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11150; Zomer A, 2015, CELL, V161, P1046, DOI 10.1016/j.cell.2015.04.042	45	42	44	2	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2019	38	10					1751	1763		10.1038/s41388-018-0540-5	http://dx.doi.org/10.1038/s41388-018-0540-5			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN8DD	30353168	Green Published, hybrid, Green Accepted			2022-12-17	WOS:000460423800013
J	Wei, N; Li, J; Fang, C; Chang, J; Xirou, V; Syrigos, NK; Marks, BJ; Chu, E; Schmitz, JC				Wei, Ning; Li, Jun; Fang, Cheng; Chang, Jin; Xirou, Vasiliki; Syrigos, Nick K.; Marks, Benjamin J.; Chu, Edward; Schmitz, John C.			Targeting colon cancer with the novel STAT3 inhibitor bruceantinol	ONCOGENE			English	Article							PROTEIN-KINASE-D; COMBINATION; METASTASIS; EXPRESSION; BRUSATOL; TRIAL	STAT3, a transcriptional mediator of oncogenic signaling, is constitutively active in similar to 70% of human cancers. The development of STAT3 inhibitors remains an active area of research as no inhibitors have yet to be approved for the treatment of human cancer. Herein, we revealed that bruceantinol (BOL) is a novel STAT3 inhibitor demonstrating potent antitumor activity in in vitro and in vivo human colorectal cancer (CRC) models. BOL strongly inhibited STAT3 DNA-binding ability (IC50 = 2.4 pM), blocked the constitutive and IL-6-induced STAT3 activation in a dose- and time-dependent manner, and suppressed transcription of STAT3 target genes encoding anti-apoptosis factors (MCL-1, PTTG1, and survivin) and cell-cycle regulators (c-Myc). Structure-activity relationship studies demonstrated that the C15 side chain on BOL affected its ability to bind STAT3. Administration of 4 mg/kg BOL significantly inhibited CRC tumor xenografts [p < 0.001], but no effect was observed in a STAT3(-/-) tumor model. Additional studies showed that BOL effectively sensitized MEK inhibitors through repression of p-STAT3 and MCL-1 induction, known resistance mechanisms of MEK inhibition. Taken together, our findings suggest BOL is a novel therapeutic STAT3 inhibitor that can be used either alone or in combination with MEK inhibitors for the treatment of human CRC.	[Wei, Ning; Marks, Benjamin J.; Chu, Edward; Schmitz, John C.] Univ Pittsburgh, Sch Med, Dept Med, Div Hematol Oncol, Pittsburgh, PA 15213 USA; [Wei, Ning; Marks, Benjamin J.; Chu, Edward; Schmitz, John C.] Univ Pittsburgh, UPMC Hillman Canc Ctr, Canc Therapeut Program, Pittsburgh, PA 15260 USA; [Li, Jun] Liaoning Univ Tradit Chinese Med, Basic Med Sci Coll, Shenyang, Liaoning, Peoples R China; [Fang, Cheng] Univ Pittsburgh, Computat Modeling & Simulat Program, Pittsburgh, PA USA; [Chang, Jin] Taishan Med Univ, Dept Oncol, Tai An, Shandong, Peoples R China; [Xirou, Vasiliki; Syrigos, Nick K.] Univ Athens, Med Sch, Athens, Greece	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Liaoning University of Traditional Chinese Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Shandong First Medical University & Shandong Academy of Medical Sciences; National & Kapodistrian University of Athens	Wei, N; Schmitz, JC (corresponding author), Univ Pittsburgh, Sch Med, Dept Med, Div Hematol Oncol, Pittsburgh, PA 15213 USA.; Wei, N; Schmitz, JC (corresponding author), Univ Pittsburgh, UPMC Hillman Canc Ctr, Canc Therapeut Program, Pittsburgh, PA 15260 USA.	chinaweining@yahoo.com; schmitzjc@upmc.edu	SYRIGOS, NIKOLAOS/ABB-6880-2021; WEI, NING/AAF-8368-2020; Syrigos, Nick/ABC-6339-2021; FANG, CHENG/B-6718-2016; WEI, NING/P-8505-2019	WEI, NING/0000-0003-2723-4061; Syrigos, Nick/0000-0001-8082-594X; FANG, CHENG/0000-0002-9767-2043; WEI, NING/0000-0003-2723-4061	UPCI NCI Cancer Center Support Grant Developmental Funds [P30CA047904]; China National Natural Sciences Foundation [81202556]; Pennsylvania Department of Health	UPCI NCI Cancer Center Support Grant Developmental Funds; China National Natural Sciences Foundation(National Natural Science Foundation of China (NSFC)); Pennsylvania Department of Health	This project was supported, in part, by funds from the UPCI NCI Cancer Center Support Grant Developmental Funds (P30CA047904). This project used the UPCI Cytometry Facility and the UPCI Animal Facility, which are supported, in part, by P30CA047904. This project also was supported, in part, by Grants (No. 81202556) from the China National Natural Sciences Foundation. This project is funded, in part, under a grant with the Pennsylvania Department of Health.	Arseneau J C, 1983, Invest New Drugs, V1, P239; Bhattacharya S, 2005, BIOCHEM J, V392, P335, DOI 10.1042/BJ20050465; Bibbins-Domingo K, 2016, JAMA-J AM MED ASSOC, V315, P2564, DOI 10.1001/jama.2016.5989; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Castelletti D, 2010, MOL CANCER THER, V9, P3145, DOI 10.1158/1535-7163.MCT-10-0539; Cragg GM, 2013, BBA-GEN SUBJECTS, V1830, P3670, DOI 10.1016/j.bbagen.2013.02.008; Cuendet M, 2004, CLIN CANCER RES, V10, P1170, DOI 10.1158/1078-0432.CCR-0362-3; Demain AL, 2011, MICROB BIOTECHNOL, V4, P687, DOI 10.1111/j.1751-7915.2010.00221.x; Gurel G, 2009, J MOL BIOL, V389, P146, DOI 10.1016/j.jmb.2009.04.005; Huang W, 2016, ONCOGENE, V35, P783, DOI 10.1038/onc.2015.215; Jung KH, 2017, CLIN CANCER RES, V23, P5537, DOI 10.1158/1078-0432.CCR-16-2253; Kohne CH, 2009, ONCOLOGIST, V14, P478, DOI 10.1634/theoncologist.2008-0202; Lam W, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001270; Lee HJ, 2014, CANCER CELL, V26, P207, DOI 10.1016/j.ccr.2014.05.019; Li YZ, 2015, P NATL ACAD SCI USA, V112, P1839, DOI 10.1073/pnas.1424171112; LIAO LL, 1976, MOL PHARMACOL, V12, P167; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; Mata-Greenwood E, 2002, LEUKEMIA, V16, P2275, DOI 10.1038/sj.leu.2402696; Morikawa T, 2011, CLIN CANCER RES, V17, P1452, DOI 10.1158/1078-0432.CCR-10-2694; Oh SB, 2014, CANCER LETT, V353, P95, DOI 10.1016/j.canlet.2014.07.007; Sen M, 2012, CANCER DISCOV, V2, P694, DOI 10.1158/2159-8290.CD-12-0191; Vartanian S, 2016, MOL CELL PROTEOMICS, V15, P1220, DOI 10.1074/mcp.M115.055509; Vultur A, 2014, ONCOGENE, V33, P1850, DOI 10.1038/onc.2013.131; Wei N, 2015, ONCOTARGET, V6, P4745, DOI 10.18632/oncotarget.2938; Wei N, 2014, MOL CANCER THER, V13, P1130, DOI 10.1158/1535-7163.MCT-13-0880; WISEMAN CL, 1982, AM J CLIN ONCOL-CANC, V5, P389, DOI 10.1097/00000421-198208000-00007; Wu SY, 2015, ONCOTARGET, V6, P40866, DOI 10.18632/oncotarget.5885; Yan Z, 2017, CHIN J INTEGR MED, V23, P153, DOI 10.1007/s11655-016-2501-6; Yang JH, 2013, J ETHNOPHARMACOL, V147, P442, DOI 10.1016/j.jep.2013.03.034; Zhao CG, 2015, ONCOTARGET, V6, P14472, DOI 10.18632/oncotarget.3991; Zhao C, 2016, ONCOTARGET, V7, P12917, DOI 10.18632/oncotarget.7338; Zhao M, 2011, PHYTOTHER RES, V25, P1796, DOI 10.1002/ptr.3477; Zhou C, 2014, ONCOGENE, V33, P851, DOI 10.1038/onc.2013.16	33	42	42	1	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2019	38	10					1676	1687		10.1038/s41388-018-0547-y	http://dx.doi.org/10.1038/s41388-018-0547-y			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN8DD	30348989				2022-12-17	WOS:000460423800008
J	Yang, XS; Qu, SB; Wang, L; Zhang, HT; Yang, ZX; Wang, JL; Dai, B; Tao, KS; Shang, RZ; Liu, ZC; Li, X; Zhang, ZC; Xia, CC; Ma, B; Liu, W; Li, HM; Dou, KF				Yang, Xisheng; Qu, Shibin; Wang, Lin; Zhang, Hongtao; Yang, Zhaoxu; Wang, Jianlin; Dai, Bin; Tao, Kaishan; Shang, Runze; Liu, Zhengcai; Li, Xiao; Zhang, Zhuochao; Xia, Congcong; Ma, Ben; Liu, Wei; Li, Haimin; Dou, Kefeng			PTBP3 splicing factor promotes hepatocellular carcinoma by destroying the splicing balance of NEAT1 and pre-miR-612	ONCOGENE			English	Article							LONG NONCODING RNA; CELL-PROLIFERATION; BINDING PROTEINS; EXPRESSION; GROWTH; CANCER; ANGIOGENESIS; GENERATION; SFPQ; P53	Nuclear-enriched RNA-binding proteins (RBPs) are mainly involved in transcriptional regulation, which is a critical checkpoint to tune gene diversity and expression levels. We analyzed nuclear RBPs in human HCC tissues and matched normal control tissues. Based on the gene expression levels, PTBP3 was identified as top-ranked in the nuclei of HCC cells. HCC cell lines then were transfected with siRNAs or lentiviral vectors. PTBP3 promoted HCC cell proliferation and metastasis both in vitro and in vivo. RNA immunoprecipitation (RIP), fluorescence in situ hybridization (FISH) and qRT-PCR assays verified that PTBP3 protein recruited abundant lnc-NEAT1 splicing variants (NEAT1_1 and NEAT1_2) and pre-miR-612 (precursor of miR-612) in the nucleus. NEAT1_1, NEAT1_2 and miR-612 expression levels were determined by PTBP3. Correlational analyses revealed that PTBP3 was positively correlated with NEAT1, but it was inversely correlated with miR-612 in HCC. The P53/CCND1 and AKT2/EMT pathways were determined by NEAT1 and miR-612 respectively in HCC. The PTBP3(high) and NEAT1(high)/miR-612(low) patients had a shorter overall survival. Therefore, nuclear-enriched RBP, PTBP3, promotes HCC cell malignant growth and metastasis by regulating the balance of splicing variants (NEAT1_1, NEAT1_2 and miR-612) in HCC.	[Yang, Xisheng; Qu, Shibin; Wang, Lin; Zhang, Hongtao; Yang, Zhaoxu; Wang, Jianlin; Dai, Bin; Tao, Kaishan; Shang, Runze; Liu, Zhengcai; Li, Xiao; Zhang, Zhuochao; Xia, Congcong; Ma, Ben; Liu, Wei; Li, Haimin; Dou, Kefeng] Fourth Mil Med Univ, Xijing Hosp, Dept Hepatobiliary Surg, Xian, Shaanxi, Peoples R China; [Qu, Shibin] Univ Michigan, Dept Surg, Sect Gen Surg, Ann Arbor, MI 48109 USA	Air Force Military Medical University; University of Michigan System; University of Michigan	Li, HM; Dou, KF (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Hepatobiliary Surg, Xian, Shaanxi, Peoples R China.	lihaim@fmmu.edu.cn; doukef@fmmu.edu.cn	wang, jian/GVS-0711-2022	/0000-0002-6624-5532; Liu, Zhengcai/0000-0001-5046-440X; Li, Haimin/0000-0003-0276-615X	National Natural Science Foundation of China [81672339]; Project of Scientific Research of Shaanxi [2011KTCL03-15]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Project of Scientific Research of Shaanxi	XY, KD and HL designed the experiments and wrote the paper; SQ, LW, HZ and ZY performed bioinformatics and statistical analyses; JW, KT, ZL, ZZ and BD performed the histopathologic analyses; CX, BM, RS, XL and WL provided expression data and patient sample material. This research was supported by the National Natural Science Foundation of China (No. 81672339) and the Project of Scientific Research of Shaanxi (No. 2011KTCL03-15).	Adriaens C, 2016, NAT MED, V22, P861, DOI 10.1038/nm.4135; Arslan AD, 2013, J BIOMOL SCREEN, V18, P180, DOI 10.1177/1087057112459901; Bhartiya D, 2016, GENOMICS, V107, P59, DOI 10.1016/j.ygeno.2016.01.005; Calabretta S, 2016, ONCOGENE, V35, P2031, DOI 10.1038/onc.2015.270; Castello A, 2016, MOL CELL, V63, P696, DOI 10.1016/j.molcel.2016.06.029; Chakravarty D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6383; Chen M, 2010, CANCER RES, V70, P8977, DOI 10.1158/0008-5472.CAN-10-2513; Cheung HC, 2009, BRAIN, V132, P2277, DOI 10.1093/brain/awp153; Choudhry H, 2015, ONCOGENE, V34, P4482, DOI 10.1038/onc.2014.378; Clemson CM, 2009, MOL CELL, V33, P717, DOI 10.1016/j.molcel.2009.01.026; Clower CV, 2010, P NATL ACAD SCI USA, V107, P1894, DOI 10.1073/pnas.0914845107; Fang L, 2017, AM J PHYSIOL-GASTR L, V313, pG150, DOI 10.1152/ajpgi.00426.2016; He X, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2013.47; Idogawa M, 2017, INT J CANCER, V140, P2785, DOI 10.1002/ijc.30689; Imamura K, 2014, MOL CELL, V53, P393, DOI 10.1016/j.molcel.2014.01.009; Ji Q, 2014, BRIT J CANCER, V111, P736, DOI 10.1038/bjc.2014.383; Koster T, 2017, TRENDS PLANT SCI, V22, P512, DOI 10.1016/j.tplants.2017.03.009; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lee HC, 2017, NUCLEIC ACIDS RES, V45, P6894, DOI 10.1093/nar/gkx307; Li Q, 2014, ELIFE, V3, DOI 10.7554/eLife.01201; Licatalosi DD, 2012, GENE DEV, V26, P1626, DOI 10.1101/gad.191338.112; Liu XF, 2012, EMBO J, V31, P4415, DOI 10.1038/emboj.2012.292; Mang YY, 2017, ONCOTARGETS THER, V10, P1003, DOI 10.2147/OTT.S116319; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Naganuma T, 2013, RNA BIOL, V10, P456, DOI 10.4161/rna.23547; Pang R, 2006, CANCER LETT, V242, P151, DOI 10.1016/j.canlet.2006.01.008; Peal L, 2011, MOL CELLS, V31, P55, DOI 10.1007/s10059-011-0001-2; Shen W, 2014, NUCLEIC ACIDS RES, V42, P8648, DOI 10.1093/nar/gku579; Shim JS, 2010, JNCI-J NATL CANCER I, V102, P1855, DOI 10.1093/jnci/djq457; Spellman R, 2007, MOL CELL, V27, P420, DOI 10.1016/j.molcel.2007.06.016; Tan HY, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17081277; Tan LY, 2015, NUCLEIC ACIDS RES, V43, P5586, DOI 10.1093/nar/gkv429; Tao ZH, 2013, J EXP MED, V210, P789, DOI 10.1084/jem.20120153; Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002; Ye QH, 2016, CANCER CELL, V30, P444, DOI 10.1016/j.ccell.2016.07.017; Zagore LL, 2015, MOL CELL BIOL, V35, P4030, DOI 10.1128/MCB.00676-15; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183; Zerbe LK, 2004, MOL CARCINOGEN, V41, P187, DOI 10.1002/mc.20053; Zhang L, 2017, HEPATOLOGY, V65, P604, DOI 10.1002/hep.28882	39	42	45	4	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	2018	37	50					6399	6413		10.1038/s41388-018-0416-8	http://dx.doi.org/10.1038/s41388-018-0416-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HE0WA	30068940				2022-12-17	WOS:000452989100002
J	Lu, CH; Yeh, DW; Lai, CY; Liu, YL; Huang, LR; Lee, AYL; Jin, SLC; Chuang, TH				Lu, Chih-Hao; Yeh, Da-Wei; Lai, Chao-Yang; Liu, Yi-Ling; Huang, Li-Rung; Lee, Alan Yueh-Luen; Jin, S-L Catherine; Chuang, Tsung-Hsien			USP17 mediates macrophage-promoted inflammation and stemness in lung cancer cells by regulating TRAF2/TRAF3 complex formation	ONCOGENE			English	Article							NF-KAPPA-B; DEUBIQUITINATING ENZYME USP17; TUMOR-ASSOCIATED MACROPHAGES; ACTIVATION; TRAF2; METASTASIS; MECHANISMS; EXPRESSION; INHIBITORS	Macrophage accumulation and inflammation in the lung owing to stresses and diseases is a cause of lung cancer development. However, molecular mechanisms underlying the interaction between macrophages and cancer cells, which drive inflammation and stemness in cancers, are poorly understood. In this study, we investigated the expression of ubiquitin-specific peptidase 17 (USP17) in lung cancers, and role of elevated USP17 in the interaction between macrophages and lung cancer cells. USP17 expression in lung cancers was associated with poor prognosis, macrophage, and inflammatory marker expressions. Macrophages promoted USP17 expression in cancer cells. TNFR-associated factor (TRAF) 2-binding and TRAF3-binding motifs were identified in USP17, through which it interacted with and disrupted the TRAF2/TRAF3 complex. This stabilized its client proteins, enhanced inflammation and stemness in cancer cells, and promoted macrophage recruitment. In different animal studies, co-injection of macrophages with cancer cells promoted USP17 expression in tumors and tumor growth. Conversely, depletion of macrophages in host animals by clodronate liposomes reduced USP17 expression and tumor growth. In addition, overexpression of USP17 in cancer cells promoted tumor growth and inflammation-associated and stemness-associated gene expressions in tumors. These results suggested that USP17 drives a positive-feedback interaction between macrophages and cancer cells to enhance inflammation and stemness in cancer cells, and promotes lung cancer growth.	[Lu, Chih-Hao; Yeh, Da-Wei; Lai, Chao-Yang; Liu, Yi-Ling; Chuang, Tsung-Hsien] Natl Hlth Res Inst, Immunol Res Ctr, Miaoli, Taiwan; [Lu, Chih-Hao; Jin, S-L Catherine] Natl Cent Univ, Dept Life Sci, Taoyuan, Taiwan; [Huang, Li-Rung] Natl Hlth Res Inst, Inst Mol & Genom Med, Miaoli, Taiwan; [Lee, Alan Yueh-Luen] Natl Inst Canc Res, Natl Hlth Res Inst, Miaoli, Taiwan; [Chuang, Tsung-Hsien] Kaohsiung Med Univ, Program Environm & Occupat Med, Kaohsiung, Taiwan	National Health Research Institutes - Taiwan; National Central University; National Health Research Institutes - Taiwan; National Health Research Institutes - Taiwan; Kaohsiung Medical University	Chuang, TH (corresponding author), Natl Hlth Res Inst, Immunol Res Ctr, Miaoli, Taiwan.; Chuang, TH (corresponding author), Kaohsiung Med Univ, Program Environm & Occupat Med, Kaohsiung, Taiwan.	thchuang@nhri.org.tw	Chuang, Tsung-Hsien/F-9679-2010	Lee, Alan Yueh-Luen/0000-0003-0252-0571	National Health Research Institutes, Taiwan [IM-106-PP-02, NHRI-EX106-10630SI]; Ministry of Science and Technology of Taiwan [MOST 105-2314-B-400-006, MOST 105-2320-B-400-013-MY3]	National Health Research Institutes, Taiwan(National Health Research Institutes - Taiwan); Ministry of Science and Technology of Taiwan(Ministry of Science and Technology, Taiwan)	We thank the Laboratory Animal Center of the National Health Research Institutes, Taiwan, for assistance with animal work. This work was supported by grants from National Health Research Institutes, Taiwan (IM-106-PP-02, NHRI-EX106-10630SI) and Ministry of Science and Technology of Taiwan (MOST 105-2314-B-400-006, and MOST 105-2320-B-400-013-MY3).	Bolli E, 2017, CURR OPIN ONCOL, V29, P55, DOI 10.1097/CCO.0000000000000344; Borbely G, 2015, ONCOTARGET, V6, P33623, DOI 10.18632/oncotarget.5601; Burrows JF, 2009, J BIOL CHEM, V284, P9587, DOI 10.1074/jbc.M807216200; Chen JQ, 2013, CURR OPIN IMMUNOL, V25, P4, DOI 10.1016/j.coi.2012.12.005; Chen R, 2010, CELL RES, V20, P802, DOI 10.1038/cr.2010.41; Conway EM, 2016, AM J RESP CRIT CARE, V193, P116, DOI 10.1164/rccm.201508-1545CI; de la Vega M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1243; Doedens AL, 2010, CANCER RES, V70, P7465, DOI 10.1158/0008-5472.CAN-10-1439; Elinav E, 2013, NAT REV CANCER, V13, P759, DOI 10.1038/nrc3611; Farshi P, 2015, EXPERT OPIN THER PAT, V25, P1191, DOI 10.1517/13543776.2015.1056737; Goswami KK, 2017, CELL IMMUNOL, V316, P1, DOI 10.1016/j.cellimm.2017.04.005; Guasparri I, 2006, EMBO REP, V7, P114, DOI 10.1038/sj.embor.7400580; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714; Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-86; Houghton AM, 2013, NAT REV CANCER, V13, P233, DOI 10.1038/nrc3477; Jin J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6930; Korkaya H, 2011, CLIN CANCER RES, V17, P6125, DOI 10.1158/1078-0432.CCR-10-2743; Lanczky A, 2016, BREAST CANCER RES TR, V160, P439, DOI 10.1007/s10549-016-4013-7; Lim KH, 2013, CYTOKINE GROWTH F R, V24, P427, DOI 10.1016/j.cytogfr.2013.05.007; Liu TZ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13923; MacDonagh L, 2016, CANCER LETT, V372, P147, DOI [10.1016/j.canlet.2016,01.012, 10.1016/j.canlet.2016.01.012]; Magee JA, 2012, CANCER CELL, V21, P283, DOI 10.1016/j.ccr.2012.03.003; Martinez FO, 2006, J IMMUNOL, V177, P7303, DOI 10.4049/jimmunol.177.10.7303; McFarlane C, 2013, ONCOTARGET, V4, P1836, DOI 10.18632/oncotarget.1282; McFarlane C, 2010, CANCER RES, V70, P3329, DOI 10.1158/0008-5472.CAN-09-4152; Ni YM, 2015, INT J MOL SCI, V16, P27956, DOI 10.3390/ijms161126063; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Pal A, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0461-3; Pereg Y, 2010, NAT CELL BIOL, V12, P400, DOI 10.1038/ncb2041; Popovic D, 1998, CLIN EXP METASTAS, V16, P623, DOI 10.1023/A:1006508413070; Quatromoni JG, 2012, AM J TRANSL RES, V4, P376; Ramakrishna S, 2015, BBA-REV CANCER, V1855, P83, DOI 10.1016/j.bbcan.2014.11.006; Ramakrishna S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037772; Ramakrishna S, 2011, J BIOL CHEM, V286, P10505, DOI 10.1074/jbc.M110.162321; Sainz B, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/9012369; Shigdar S, 2014, CANCER LETT, V345, P271, DOI 10.1016/j.canlet.2013.07.031; Sica A, 2008, CANCER LETT, V267, P204, DOI 10.1016/j.canlet.2008.03.028; Sica A, 2017, CANCER IMMUNOL IMMUN, V66, P1025, DOI 10.1007/s00262-017-1997-8; Suarez-Carmona M, 2017, MOL ONCOL, V11, P805, DOI 10.1002/1878-0261.12095; Suresh R, 2016, ADV EXP MED BIOL, V890, P57, DOI 10.1007/978-3-319-24932-2_4; Todoric J, 2016, CANCER PREV RES, V9, P895, DOI 10.1158/1940-6207.CAPR-16-0209; Torre LA, 2016, ADV EXP MED BIOL, V893, P1, DOI 10.1007/978-3-319-24223-1_1; Valavanidis A, 2013, INT J ENV RES PUB HE, V10, P3886, DOI 10.3390/ijerph10093886; Vallabhapurapu S, 2008, NAT IMMUNOL, V9, P1364, DOI 10.1038/ni.1678; Verstrepen L, 2008, CELL MOL LIFE SCI, V65, P2964, DOI 10.1007/s00018-008-8064-8; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Won M, 2016, ARCH PHARM RES, V39, P1075, DOI 10.1007/s12272-016-0772-2; Wu YD, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14228; Xie Ping, 2013, J Mol Signal, V8, P7, DOI 10.1186/1750-2187-8-7; Yang XD, 2015, IMMUNOL REV, V266, P56, DOI 10.1111/imr.12311; Ye H, 1999, MOL CELL, V4, P321, DOI 10.1016/S1097-2765(00)80334-2; Yeh DW, 2016, CELL DEATH DIFFER, V23, P841, DOI 10.1038/cdd.2015.147; Yeh DW, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/4368101; Zarnegar BJ, 2008, NAT IMMUNOL, V9, P1371, DOI 10.1038/ni.1676; Zhang S, 2016, ONCOL RES, V24	57	42	42	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2018	37	49					6327	6340		10.1038/s41388-018-0411-0	http://dx.doi.org/10.1038/s41388-018-0411-0			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HD3AP	30038267	hybrid, Green Published			2022-12-17	WOS:000452384400004
J	Rossow, L; Veitl, S; Vorlova, S; Wax, JK; Kuhn, AE; Maltzahn, V; Upcin, B; Karl, F; Hoffmann, H; Gatzner, S; Kallius, M; Nandigama, R; Scheld, D; Irmak, S; Herterich, S; Zernecke, A; Ergun, S; Henke, E				Rossow, Leonie; Veitl, Simona; Vorlova, Sandra; Wax, Jacqueline K.; Kuhn, Anja E.; Maltzahn, Verena; Upcin, Berin; Karl, Franziska; Hoffmann, Helene; Gaetzner, Sabine; Kallius, Matthias; Nandigama, Rajender; Scheld, Daniela; Irmak, Ster; Herterich, Sabine; Zernecke, Alma; Ergun, Sueleyman; Henke, Erik			LOX-catalyzed collagen stabilization is a proximal cause for intrinsic resistance to chemotherapy	ONCOGENE			English	Article							LYSYL OXIDASE; TUMOR ANGIOGENESIS; DRUG-DELIVERY; DOUBLE-BLIND; PHASE-II; DOXORUBICIN; IMPROVES; COMBINATION; SIMTUZUMAB; INHIBITION	The potential of altering the tumor ECM to improve drug response remains fairly unexplored. To identify targets for modification of the ECM aiming to improve drug response and overcome resistance, we analyzed expression data sets from pre-treatment patient cohorts. Cross-evaluation identified a subset of chemoresistant tumors characterized by increased expression of collagens and collagen-stabilizing enzymes. We demonstrate that strong collagen expression and stabilization sets off a vicious circle of self-propagating hypoxia, malignant signaling, and aberrant angiogenesis that can be broken by an appropriate auxiliary intervention: Interfering with collagen stabilization by inhibition of lysyl oxidases significantly enhanced response to chemotherapy in various tumor models, even in metastatic disease. Inhibition of collagen stabilization by itself can reduce or enhance tumor growth depending on the tumor type. The mechanistical basis for this behavior is the dependence of the individual tumor on nutritional supply on one hand and on high tissue stiffness for FAK signaling on the other.	[Rossow, Leonie; Veitl, Simona; Wax, Jacqueline K.; Kuhn, Anja E.; Maltzahn, Verena; Upcin, Berin; Karl, Franziska; Hoffmann, Helene; Kallius, Matthias; Nandigama, Rajender; Ergun, Sueleyman; Henke, Erik] Univ Wurzburg, Inst Anat & Cell Biol 2, Koellikerstr 6, D-97070 Wurzburg, Germany; [Vorlova, Sandra; Karl, Franziska; Hoffmann, Helene; Zernecke, Alma] Univ Klinikum Wurzburg, Inst Expt Biomed, Josef Schneider Str 2, D-97082 Wurzburg, Germany; [Upcin, Berin; Irmak, Ster] Bilgi Univ, Sch Hlth Sci, TR-34440 Beyoglu Istanbul, Turkey; [Gaetzner, Sabine] Univ Wurzburg, Inst Tissue Engn, Roentgenring 11, D-97070 Wurzburg, Germany; [Kallius, Matthias; Henke, Erik] Grad Sch Life Sci, Josef Schneider Str 2, D-97082 Wurzburg, Germany; [Scheld, Daniela; Herterich, Sabine] Univ Klinikum Wurzburg, Zent Lab, Josef Schneider Str 2, D-97082 Wurzburg, Germany	University of Wurzburg; University of Wurzburg; Istanbul Bilgi University; University of Wurzburg; University of Wurzburg	Henke, E (corresponding author), Univ Wurzburg, Inst Anat & Cell Biol 2, Koellikerstr 6, D-97070 Wurzburg, Germany.; Henke, E (corresponding author), Grad Sch Life Sci, Josef Schneider Str 2, D-97082 Wurzburg, Germany.	erik.henke@uni-wuerzburg.de	Henke, Erik/AAG-7053-2020	Henke, Erik/0000-0003-2380-2682; Nandigama, Rajender/0000-0002-7344-4732	DFG [HE3565/2-1, HE3565/3-1]	DFG(German Research Foundation (DFG))	We thank Prof. Almut Schulze (Institute for Biochemistry and Molecular Biology, Universitat Wurzburg) and Afsar Barlas (MCCF, Memorial Sloan-Kettering Cancer Center) for helpful discussion. We especially want to acknowledge the tremendous help of Erna Kleinschroth (Institute for Anatomy and Cell Biology II) with histological procedures. Funding was provided by the DFG (Grant Nos. HE3565/2-1 and HE3565/3-1 to EH).	Bailey AJ, 1998, MECH AGEING DEV, V106, P1, DOI 10.1016/S0047-6374(98)00119-5; Baish JW, 1996, MICROVASC RES, V51, P327, DOI 10.1006/mvre.1996.0031; Baker AM, 2013, ONCOGENE, V32, P1863, DOI 10.1038/onc.2012.202; Baker AM, 2013, CANCER RES, V73, P583, DOI 10.1158/0008-5472.CAN-12-2447; Barry-Hamilton V, 2010, NAT MED, V16, P1009, DOI 10.1038/nm.2208; Benjamin LE, 1998, DEVELOPMENT, V125, P1591; Benson AB, 2017, ONCOLOGIST, V22, P241, DOI 10.1634/theoncologist.2017-0024; Bondareva A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005620; Caino MC, 2013, J CLIN INVEST, V123, P2907, DOI 10.1172/JCI67841; Curnis F, 2002, J CLIN INVEST, V110, P475, DOI 10.1172/JCI200215223; de Jonge HJM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000898; DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028; DiChiara AS, 2016, ACS CHEM BIOL, V11, P1408, DOI 10.1021/acschembio.5b01083; Eikenes L, 2004, CANCER RES, V64, P4768, DOI 10.1158/0008-5472.CAN-03-1472; Eisinger-Mathason TSK, 2013, CANCER DISCOV, V3, P1190, DOI 10.1158/2159-8290.CD-13-0118; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Escorcia FE, 2010, CANCER RES, V70, P9277, DOI 10.1158/0008-5472.CAN-10-2029; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Feres EJ, 1995, J BIOL CHEM, V270, P30797, DOI 10.1074/jbc.270.51.30797; Granot Z, 2011, CANCER CELL, V20, P300, DOI 10.1016/j.ccr.2011.08.012; Guo HF, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02859-z; HARRISON K, 1978, J NUCL MED, V19, P84; Hecht JR, 2017, ONCOLOGIST, V22, P243, DOI 10.1634/theoncologist.2016-0479; Jacobetz MA, 2013, GUT, V62, P112, DOI 10.1136/gutjnl-2012-302529; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; Laginha KM, 2005, CLIN CANCER RES, V11, P6944, DOI 10.1158/1078-0432.CCR-05-0343; Lankelma J, 1999, CLIN CANCER RES, V5, P1703; Le Calve B, 2016, ONCOTARGET, V7, P32100, DOI 10.18632/oncotarget.8527; LEE TC, 1994, CVGIP-GRAPH MODEL IM, V56, P462, DOI 10.1006/cgip.1994.1042; LOPEZDELEON A, 1985, J HISTOCHEM CYTOCHEM, V33, P737, DOI 10.1177/33.8.2410480; Mammoto T, 2013, AM J PATHOL, V183, P1293, DOI 10.1016/j.ajpath.2013.06.026; Mancuso MR, 2006, J CLIN INVEST, V116, P2610, DOI 10.1172/JCI24612; Marturano JE, 2013, P NATL ACAD SCI USA, V110, P6370, DOI 10.1073/pnas.1300135110; Mih JD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019929; Naba A, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.014647; Netti PA, 2000, CANCER RES, V60, P2497; Pepin KM, 2014, MAGN RESON MED, V71, P1834, DOI 10.1002/mrm.24825; Provenzano PP, 2012, CANCER CELL, V21, P418, DOI 10.1016/j.ccr.2012.01.007; Rohrig F, 2017, ONCOGENE, V36, P1, DOI 10.1038/onc.2016.182; Rolny C, 2011, CANCER CELL, V19, P31, DOI 10.1016/j.ccr.2010.11.009; Samani A, 2007, PHYS MED BIOL, V52, P1565, DOI 10.1088/0031-9155/52/6/002; Schutze F, 2015, SCI REP-UK, V5, DOI 10.1038/srep17576; Schug ZT, 2015, CANCER CELL, V27, P57, DOI 10.1016/j.ccell.2014.12.002; Shah NR, 2014, GYNECOL ONCOL, V134, P104, DOI 10.1016/j.ygyno.2014.04.044; Shapiro IM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008639; Simon R, 2007, CANCER INFORM, V3, P11; Slack-Davis JK, 2007, J BIOL CHEM, V282, P14845, DOI 10.1074/jbc.M606695200; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Walser R, 2013, EUR CELLS MATER, V26, P222, DOI 10.22203/eCM.v026a16; Wong CCL, 2011, P NATL ACAD SCI USA, V108, P16369, DOI 10.1073/pnas.1113483108; Xie J, 2012, INT ORTHOP, V36, P207, DOI 10.1007/s00264-011-1261-3; Xu XJ, 2008, BIOINFORMATICS, V24, P137, DOI 10.1093/bioinformatics/btm541; Zaffryar-Eilot S, 2013, CARCINOGENESIS, V34, P2370, DOI 10.1093/carcin/bgt241	54	42	43	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 6	2018	37	36					4921	4940		10.1038/s41388-018-0320-2	http://dx.doi.org/10.1038/s41388-018-0320-2			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GS6QR	29780168	Green Published, hybrid			2022-12-17	WOS:000443823600002
J	Zhang, ZY; Lin, GH; Yan, YJ; Li, X; Hu, YB; Wang, J; Yin, BJ; Wu, YQ; Li, ZY; Yang, XP				Zhang, Zunyue; Lin, Guohong; Yan, Yujing; Li, Xiang; Hu, Yibing; Wang, Jing; Yin, Bingjiao; Wu, Yaqun; Li, Zhuoya; Yang, Xiang-Ping			Transmembrane TNF-alpha promotes chemoresistance in breast cancer cells	ONCOGENE			English	Article							TUMOR-NECROSIS-FACTOR; GLUTATHIONE-S-TRANSFERASE; NF-KAPPA-B; DRUG-RESISTANCE; DOXORUBICIN; EXPRESSION; DEATH; CYCLOPHOSPHAMIDE; CHEMOTHERAPY; ACTIVATION	Chemoresistance remains a major obstacle to successful treatment of breast cancer. Although soluble tumor necrosis factor-alpha (sTNF-alpha) has been implicated in mediating drug-resistance in human cancers, whether transmembrane tumor necrosis factor-alpha (tmTNF-alpha) plays a role in chemoresistance remains unclear. Here we found that over 50% of studied patients expressed tmTNF-alpha at high levels in breast cancer tissues and tmTNF-alpha expression positively correlated with resistance to anthracycline chemotherapy. Alteration of tmTNF-alpha expression changed the sensitivity of primary human breast cancer cells and breast cancer cell lines to doxorubicin (DOX). Overexpression of N-terminal fragment (NTF) of tmTNF-alpha, a mutant form with intact intracellular domain of tmTNF-alpha to transmit reverse signals, induced DOX-resistance. Mechanistically, the tmTNF-alpha/NTF-ERK-GST-p axis and tmTNF-alpha/NTF-NF-kappa B-mediated anti-apoptotic functions were required for tmTNF-alpha-induced DOX-resistance. In a xenograft mouse model, the combination of tmTNF-alpha suppression with chemotherapy significantly enhanced the efficacy of DOX. Our data indicate that tmTNF-alpha mediates DOX-resistance through reverse signaling and targeting tmTNF-a may be beneficial for the treatment of DOX-resistant breast cancer.	[Zhang, Zunyue; Lin, Guohong; Wang, Jing; Yin, Bingjiao; Li, Zhuoya; Yang, Xiang-Ping] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Basic Med, Dept Immunol, Wuhan 430030, Hubei, Peoples R China; [Yan, Yujing; Li, Xiang; Hu, Yibing; Wu, Yaqun] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Thyroid & Breast Surg, Wuhan 430030, Hubei, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology	Li, ZY; Yang, XP (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Basic Med, Dept Immunol, Wuhan 430030, Hubei, Peoples R China.	zhuoyali@mails.tjmu.edu.cn; yangxp@hust.edu.cn			National Scientific Foundation of China [30872376, 31671470, 81471899]; Integrated Innovative Team for Major Human Diseases Program of Tongji Medical College, HUST	National Scientific Foundation of China(National Natural Science Foundation of China (NSFC)); Integrated Innovative Team for Major Human Diseases Program of Tongji Medical College, HUST	This work was supported by the National Scientific Foundation of China (30872376, 31671470, and 81471899), and Integrated Innovative Team for Major Human Diseases Program of Tongji Medical College, HUST. We thank Doctor Arian Laurence for corrections of our manuscript and constructive suggestions.	Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; Arcamone F, 2000, BIOTECHNOL BIOENG, V67, P704, DOI 10.1002/(SICI)1097-0290(20000320)67:6<704::AID-BIT8>3.0.CO;2-L; Baldwin AS, 2012, IMMUNOL REV, V246, P327, DOI 10.1111/j.1600-065X.2012.01095.x; Balkwill F, 2006, CANCER METAST REV, V25, P409, DOI 10.1007/s10555-006-9005-3; Balkwill F, 2009, NAT REV CANCER, V9, P361, DOI 10.1038/nrc2628; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Brantley-Finley C, 2003, BIOCHEM PHARMACOL, V66, P459, DOI 10.1016/S0006-2952(03)00255-7; Casares N, 2005, J EXP MED, V202, P1691, DOI 10.1084/jem.20050915; Chen Q, 2016, NATURE, V533, P493, DOI 10.1038/nature18268; Dalpiaz Orietta, 2003, Arch Esp Urol, V56, P197; Daniel D, 2008, CURR CANCER DRUG TAR, V8, P124, DOI 10.2174/156800908783769346; Filipits M, 2003, CLIN CANCER RES, V9, P820; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Gahl RF, 2014, J BIOL CHEM, V289, DOI 10.1074/jbc.M114.593897; Garner TP, 2016, MOL CELL, V64, P431, DOI 10.1016/j.molcel.2016.10.005; Gordon GJ, 2007, J PATHOL, V211, P439, DOI 10.1002/path.2120; Gray-Schopfer VC, 2007, CANCER RES, V67, P122, DOI 10.1158/0008-5472.CAN-06-1880; Higgins CF, 2007, NATURE, V446, P749, DOI 10.1038/nature05630; Huang GX, 2007, MOL CANCER THER, V6, P1610, DOI 10.1158/1535-7163.MCT-06-0580; Johnson NA, 2012, J CLIN ONCOL, V30, P3452, DOI 10.1200/JCO.2011.41.0985; Kalinina EV, 2007, B EXP BIOL MED+, V143, P328, DOI 10.1007/s10517-007-0102-2; Kirchner S, 2004, J LEUKOCYTE BIOL, V75, P324, DOI 10.1189/jlb.0703343; Kresse M, 2005, J IMMUNOL, V175, P4076, DOI 10.4049/jimmunol.175.6.4076; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; Li F, 2015, ARCH TOXICOL, V89, P711, DOI 10.1007/s00204-015-1470-4; Lin AH, 2012, J AGR FOOD CHEM, V60, P6537, DOI 10.1021/jf301567m; Louie SM, 2016, CELL CHEM BIOL, V23, P567, DOI 10.1016/j.chembiol.2016.03.017; Mackey JR, 2013, LANCET ONCOL, V14, P72, DOI 10.1016/S1470-2045(12)70525-9; Martin M, 2013, J CLIN ONCOL, V31, P2593, DOI 10.1200/JCO.2012.46.9841; Meng HA, 2010, ACS NANO, V4, P4539, DOI 10.1021/nn100690m; Montagut C, 2006, ENDOCR-RELAT CANCER, V13, P607, DOI 10.1677/erc.1.01171; MYERS CE, 1977, SCIENCE, V197, P165, DOI 10.1126/science.877547; Pang BX, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2921; Pendleton M, 2014, ANN NY ACAD SCI, V1310, P98, DOI 10.1111/nyas.12358; Sharifi S, 2015, ADV PHARM BULL, V5, P351, DOI 10.15171/apb.2015.049; Sharom FJ, 2008, PHARMACOGENOMICS, V9, P105, DOI 10.2217/14622416.9.1.105; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Surova O, 2013, ONCOGENE, V32, P3789, DOI 10.1038/onc.2012.556; Sweeney C, 2000, CANCER RES, V60, P5621; Tapia MA, 2007, CELL CYCLE, V6, P2284, DOI 10.4161/cc.6.18.4721; Townsend DM, 2003, ONCOGENE, V22, P7369, DOI 10.1038/sj.onc.1206940; Verma S, 2008, CANCER TREAT REV, V34, P339, DOI 10.1016/j.ctrv.2008.01.005; Wang LC, 2005, J BIOL CHEM, V280, P7634, DOI 10.1074/jbc.M413384200; Yan D, 2009, BREAST CANCER RES TR, V116, P91, DOI 10.1007/s10549-008-0111-5; Yu MX, 2013, CANCER RES, V73, P4061, DOI 10.1158/0008-5472.CAN-12-3946; Yu MX, 2009, EUR J CELL BIOL, V88, P181, DOI 10.1016/j.ejcb.2008.09.001; Zajchowski DA, 2012, MOL CANCER THER, V11, P492, DOI 10.1158/1535-7163.MCT-11-0746; Zhang H, 2008, J LEUKOCYTE BIOL, V84, P789, DOI 10.1189/jlb.0208078; Zhou XX, 2015, BLOOD, V126, P1433, DOI 10.1182/blood-2015-01-624833	49	42	43	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	25					3456	3470		10.1038/s41388-018-0221-4	http://dx.doi.org/10.1038/s41388-018-0221-4			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GK7TC	29559745	Green Published, hybrid			2022-12-17	WOS:000436411300010
J	Bolin, S; Borgenvik, A; Persson, CU; Sundstrom, A; Qi, J; Bradner, JE; Weiss, WA; Cho, YJ; Weishaupt, H; Swartling, FJ				Bolin, Sara; Borgenvik, Anna; Persson, Camilla U.; Sundstrom, Anders; Qi, Jun; Bradner, James E.; Weiss, William A.; Cho, Yoon-Jae; Weishaupt, Holger; Swartling, Fredrik J.			Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma	ONCOGENE			English	Article							SELECTIVE-INHIBITION; KINASE INHIBITOR; BRAIN-TUMORS; PHOSPHORYLATION; STABILIZATION; DISCOVERY; APOPTOSIS; SUBTYPES; POTENT	Medulloblastoma (MB) is the most common malignant brain tumor in children. MYC genes are frequently amplified and correlate with poor prognosis in MB. BET bromodomains recognize acetylated lysine residues and often promote and maintain MYC transcription. Certain cyclin-dependent kinases (CDKs) are further known to support MYC stabilization in tumor cells. In this report, MB cells were suppressed by combined targeting of MYC expression and MYC stabilization using BET bromodomain inhibition and CDK2 inhibition, respectively. Such combination treatment worked synergistically and caused cell cycle arrest as well as massive apoptosis. Immediate transcriptional changes from this combined MYC blockade were found using RNA-Seq profiling and showed remarkable similarities to changes in MYC target gene expression when MYCN was turned off with doxycycline in our MYCN-inducible animal model for Group 3 MB. In addition, the combination treatment significantly prolonged survival as compared to single-agent therapy in orthotopically transplanted human Group 3 MB with MYC amplifications. Our data suggest that dual inhibition of CDK2 and BET bromodomains can be a novel treatment approach for suppressing MYC-driven cancer.	[Bolin, Sara; Borgenvik, Anna; Persson, Camilla U.; Sundstrom, Anders; Weishaupt, Holger; Swartling, Fredrik J.] Uppsala Univ, Dept Immunol Genet & Pathol, Sci Life Lab, Rudbeck Lab, Uppsala, Sweden; [Qi, Jun; Bradner, James E.] Harvard Med Sch, Dept Med, Boston, MA USA; [Qi, Jun; Bradner, James E.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Weiss, William A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Weiss, William A.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA; [Weiss, William A.] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA USA; [Cho, Yoon-Jae] Oregon Hlth & Sci Univ, Dept Pediat, Pape Family Pediat Res Inst, Knight Canc Inst, 3181 Sw Sam Jackson Pk Rd, Portland, OR 97201 USA	Uppsala University; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Oregon Health & Science University	Swartling, FJ (corresponding author), Uppsala Univ, Dept Immunol Genet & Pathol, Sci Life Lab, Rudbeck Lab, Uppsala, Sweden.	fredrik.swartling@igp.uu.se	Swartling, Fredrik J/B-8170-2014	Swartling, Fredrik J/0000-0002-8460-4367; Persson, Camilla/0000-0002-1312-6177; Weiss, William/0000-0003-2230-9132; Borgenvik, Anna/0000-0003-4696-7703	Swedish Childhood Cancer Foundation; Swedish Cancer Society; Swedish Research Council; Ragnar Soderberg Foundation; Swedish Society of Medicine; Swedish Brain Fund; Ake Wiberg Foundation; Worldwide Cancer Research/Association for International Cancer Research; NATIONAL CANCER INSTITUTE [P01CA066996] Funding Source: NIH RePORTER	Swedish Childhood Cancer Foundation(European Commission); Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Ragnar Soderberg Foundation; Swedish Society of Medicine; Swedish Brain Fund; Ake Wiberg Foundation; Worldwide Cancer Research/Association for International Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Grant support from the Swedish Childhood Cancer Foundation, the Swedish Cancer Society, the Swedish Research Council, the Ragnar Soderberg Foundation, the Swedish Society of Medicine, the Swedish Brain Fund, the Ake Wiberg Foundation, and Worldwide Cancer Research/Association for International Cancer Research.	Albanese C, 2013, BRIT J PHARMACOL, V169, P156, DOI 10.1111/bph.12112; Albert TK, 2014, BRIT J PHARMACOL, V171, P55, DOI 10.1111/bph.12408; Baker EK, 2015, SCI REP-UK, V5, DOI 10.1038/srep10120; Bandopadhayay P, 2014, CLIN CANCER RES, V20, P912, DOI 10.1158/1078-0432.CCR-13-2281; Belkina AC, 2012, NAT REV CANCER, V12, P465, DOI 10.1038/nrc3256; Benassi B, 2012, CANCER DISCOV, V2, P236, DOI 10.1158/2159-8290.CD-11-0219; Brasca MG, 2009, J MED CHEM, V52, P5152, DOI 10.1021/jm9006559; Bretones G, 2015, BBA-GENE REGUL MECH, V1849, P506, DOI 10.1016/j.bbagrm.2014.03.013; Caporali S, 2010, PHARMACOL RES, V61, P437, DOI 10.1016/j.phrs.2009.12.009; Cavalli FMG, 2017, CANCER CELL, V31, P737, DOI 10.1016/j.ccell.2017.05.005; Cheng ZX, 2013, CLIN CANCER RES, V19, P1748, DOI 10.1158/1078-0432.CCR-12-3066; Fiaschetti G, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-39; Filippakopoulos P, 2012, FEBS LETT, V586, P2692, DOI 10.1016/j.febslet.2012.04.045; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Gibson P, 2010, NATURE, V468, P1095, DOI 10.1038/nature09587; Goga A, 2007, NAT MED, V13, P820, DOI 10.1038/nm1606; Hede SM, 2014, ONCOGENE, V33, P4709, DOI 10.1038/onc.2013.445; Henssen A, 2013, ONCOTARGET, V4, DOI 10.18632/oncotarget.1534; Hill RM, 2015, CANCER CELL, V27, P72, DOI 10.1016/j.ccell.2014.11.002; Hydbring P, 2010, P NATL ACAD SCI USA, V107, P58, DOI 10.1073/pnas.0900121106; Kool M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003088; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Li MH, 2012, CANCER GENET-NY, V205, P220, DOI 10.1016/j.cancergen.2012.03.002; Loven J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036; McKeown MR, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014266; Mendrzyk F, 2005, J CLIN ONCOL, V23, P8853, DOI 10.1200/JCO.2005.02.8589; Molenaar JJ, 2009, P NATL ACAD SCI USA, V106, P12968, DOI 10.1073/pnas.0901418106; Morrissy AS, 2016, NATURE, V529, P351, DOI 10.1038/nature16478; Mulhern RK, 2004, LANCET ONCOL, V5, P399, DOI 10.1016/S1470-2045(04)01507-4; Northcott PA, 2012, NATURE, V488, P49, DOI 10.1038/nature11327; Painter MW, 2011, J IMMUNOL, V186, P3047, DOI 10.4049/jimmunol.1002695; Pfister S, 2009, J CLIN ONCOL, V27, P1627, DOI 10.1200/JCO.2008.17.9432; Puissant A, 2013, CANCER DISCOV, V3, P308, DOI 10.1158/2159-8290.CD-12-0418; Rahmanto AS, 2016, EMBO J, V35, P2192, DOI 10.15252/embj.201693889; Roussel MF, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014308; Ryan SL, 2012, ACTA NEUROPATHOL, V123, P501, DOI 10.1007/s00401-011-0923-y; Schmidt AL, 2010, CNS NEUROL DISORD-DR, V9, P335, DOI 10.2174/187152710791292602; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sjostrom SK, 2005, DEV CELL, V9, P327, DOI 10.1016/j.devcel.2005.07.014; Swartling FJ, 2012, CANCER CELL, V21, P601, DOI 10.1016/j.ccr.2012.04.012; Swartling FJ, 2010, GENE DEV, V24, P1059, DOI 10.1101/gad.1907510; Tailor J, 2013, J NEUROSCI, V33, P12407, DOI 10.1523/JNEUROSCI.0130-13.2013; Taylor MD, 2012, ACTA NEUROPATHOL, V123, P465, DOI 10.1007/s00401-011-0922-z; Toogood PL, 2005, J MED CHEM, V48, P2388, DOI 10.1021/jm049354h; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Villerbu N, 2002, INT J CANCER, V97, P761, DOI 10.1002/ijc.10125; Weiss GJ, 2012, INVEST NEW DRUG, V30, P2334, DOI 10.1007/s10637-011-9774-6; Wood ER, 2004, BIOORG MED CHEM LETT, V14, P953, DOI 10.1016/j.bmcl.2003.12.002; Yao WL, 2015, ONCOTARGET, V6, P34669, DOI 10.18632/oncotarget.5785	49	42	45	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	21					2850	2862		10.1038/s41388-018-0135-1	http://dx.doi.org/10.1038/s41388-018-0135-1			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GG8EE	29511348	Green Published, hybrid			2022-12-17	WOS:000432929800007
J	Li, L; Liu, TZ; Li, YH; Wu, CM; Luo, KT; Yin, YJ; Chen, YP; Nowsheen, S; Wu, JH; Lou, ZK; Yuan, J				Li, Lei; Liu, Tongzheng; Li, Yunhui; Wu, Chenming; Luo, Kuntian; Yin, Yujiao; Chen, Yuping; Nowsheen, Somaira; Wu, Jinhuan; Lou, Zhenkun; Yuan, Jian			The deubiquitinase USP9X promotes tumor cell survival and confers chemoresistance through YAP1 stabilization	ONCOGENE			English	Article							HIPPO PATHWAY; GROWTH-CONTROL; CANCER-CELLS; DNA-DAMAGE; DIFFERENTIATION; INHIBITION; PHOSPHORYLATION; TUMORIGENESIS; INACTIVATION; APOPTOSIS	The Yes-associated protein 1 (YAP1), a major downstream effector of the Hippo pathway, functions as a transcriptional regulator and has an important role in cellular control of organ size and tumor growth. Elevated oncogenic activity of YAP1 has been clarified in different types of human cancers, which contributes to cancer cell survival and chemoresistance. However, the molecular mechanism of YAP1 overexpression in cancer is still not clear. Here we demonstrate that the deubiquitination enzyme USP9X deubiquitinates and stabilizes YAP1, thereby promoting cancer cell survival. Increased USP9X expression correlates with increased YAP1 protein in human breast cancer cell lines and patient samples. Moreover, depletion of USP9X increases YAP1 polyubiquitination, which in turn elevates YAP1 turnover and cell sensitivity to chemotherapy. Overall, our study establishes the USP9X-YAP1 axis as an important regulatory mechanism of breast cancer and provides a rationale for potential therapeutic interventions in the treatment of breast cancer.	[Li, Lei; Li, Yunhui; Wu, Chenming; Luo, Kuntian; Yin, Yujiao; Chen, Yuping; Yuan, Jian] Tongji Univ, East Hosp, Res Ctr Translat Med, Sch Med, Shanghai 200120, Peoples R China; [Li, Lei; Li, Yunhui; Wu, Chenming; Luo, Kuntian; Yin, Yujiao; Chen, Yuping; Yuan, Jian] Tongji Univ, East Hosp, Key Lab Arrhythmias, Minist Educ China,Sch Med, Shanghai 200120, Peoples R China; [Liu, Tongzheng] Jinan Univ, Inst Tumor Pharmacol, Guangzhou 510632, Guangdong, Peoples R China; [Luo, Kuntian; Lou, Zhenkun; Yuan, Jian] Mayo Clin, Dept Oncol, Rochester, MN 55905 USA; [Nowsheen, Somaira] Mayo Clin, Grad Sch Biomed Sci, Sch Med, Med Scientist Training Program, Rochester, MN 55905 USA; [Wu, Jinhuan] Tianjin Med Univ, Sch Biomed Engn & Technol, Tianjin, Peoples R China	Tongji University; Ministry of Education, China; Tongji University; Jinan University; Mayo Clinic; Mayo Clinic; Tianjin Medical University	Yuan, J (corresponding author), Tongji Univ, East Hosp, Res Ctr Translat Med, Sch Med, Shanghai 200120, Peoples R China.; Yuan, J (corresponding author), Tongji Univ, East Hosp, Key Lab Arrhythmias, Minist Educ China,Sch Med, Shanghai 200120, Peoples R China.; Liu, TZ (corresponding author), Jinan Univ, Inst Tumor Pharmacol, Guangzhou 510632, Guangdong, Peoples R China.; Lou, ZK; Yuan, J (corresponding author), Mayo Clin, Dept Oncol, Rochester, MN 55905 USA.	Liutongzheng@jnu.edu.cn; Lou.zhenkun@mayo.edu; yuanjian229@hotmail.com	Li, Li/AEM-3636-2022; LI, LI/GVS-5344-2022	Yuan, Jian/0000-0002-2801-8849; Lou, Zhenkun/0000-0003-1938-3091	NSFC [81773758, 81572770, 31371367]; National Institutes of Health [CA203971, CA203561, CA189666, CA130996]; Ovarian Cancer SPORE in Mayo Clinic [P50CA136393]; Pilot Project Award Program of Mayo Clinic Fraternal Order of Eagles Cancer Research Fund; NATIONAL CANCER INSTITUTE [P50CA136393, R01CA130996, R01CA189666, R01CA203971, R01CA148940, R01CA129344] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM065841] Funding Source: NIH RePORTER	NSFC(National Natural Science Foundation of China (NSFC)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ovarian Cancer SPORE in Mayo Clinic; Pilot Project Award Program of Mayo Clinic Fraternal Order of Eagles Cancer Research Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Drs William G. Kaelin, Qing Zhang, Kunliang Guan, and Junjie Chen for kindly providing constructs. This study was supported by NSFC (81773758, 81572770, and 31371367), National Institutes of Health grant (CA203971, CA203561, CA189666, and CA130996), Ovarian Cancer SPORE in Mayo Clinic (P50CA136393), and the Pilot Project Award Program of Mayo Clinic Fraternal Order of Eagles Cancer Research Fund.	Basu-Roy U, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7411; Bora-Singhal N, 2015, STEM CELLS, V33, P1705, DOI 10.1002/stem.1993; Cottini F, 2014, NAT MED, V20, P599, DOI 10.1038/nm.3562; Dupont S, 2009, CELL, V136, P123, DOI 10.1016/j.cell.2008.10.051; Hansen CG, 2015, TRENDS CELL BIOL, V25, P499, DOI 10.1016/j.tcb.2015.05.002; Nguyen HT, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.1; Nguyen HT, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169587; Jung KH, 2016, STEM CELLS, V34, P1284, DOI 10.1002/stem.2283; Kapuria V, 2010, CANCER RES, V70, P9265, DOI 10.1158/0008-5472.CAN-10-1530; Kim MJ, 2016, EMBO REP, V17, P64, DOI 10.15252/embr.201540809; Levy D, 2008, MOL CELL, V29, P350, DOI 10.1016/j.molcel.2007.12.022; Liu TZ, 2016, CANCER RES, V76, P572, DOI 10.1158/0008-5472.CAN-15-0671; Luo KT, 2017, EMBO J, V36, P1434, DOI 10.15252/embj.201695669; Mo JS, 2015, NAT CELL BIOL, V17, P500, DOI 10.1038/ncb3111; Mohseni M, 2014, NAT CELL BIOL, V16, P108, DOI 10.1038/ncb2884; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; Nagai H, 2009, MOL CELL, V36, P805, DOI 10.1016/j.molcel.2009.10.016; Nguyen LT, 2015, CANCER CELL, V27, P797, DOI 10.1016/j.ccell.2015.05.005; Pefani DE, 2016, MOL CELL, V63, P156, DOI 10.1016/j.molcel.2016.05.012; Perez-Mancera PA, 2012, NATURE, V486, P266, DOI 10.1038/nature11114; Peterson LF, 2015, BLOOD, V125, P3588, DOI 10.1182/blood-2014-10-605584; Piersma B, 2015, AM J PATHOL, V185, P3326, DOI 10.1016/j.ajpath.2015.08.011; Rosenbluh J, 2012, CELL, V151, P1457, DOI 10.1016/j.cell.2012.11.026; Savio MG, 2016, CURR BIOL, V26, P173, DOI 10.1016/j.cub.2015.11.050; Schwickart M, 2010, NATURE, V463, P103, DOI 10.1038/nature08646; Sorrentino G, 2014, NAT CELL BIOL, V16, P357, DOI 10.1038/ncb2936; Strano S, 2007, MOL CELL, V27, P863, DOI 10.1016/j.molcel.2007.09.004; Svalina MN, 2014, CANCER CELL, V26, P154, DOI 10.1016/j.ccr.2014.07.011; Tremblay AM, 2014, CANCER CELL, V26, P273, DOI 10.1016/j.ccr.2014.05.029; Tu KS, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-110; Vitolol MI, 2007, CANCER BIOL THER, V6, P856, DOI 10.4161/cbt.6.6.4241; von Eyss B, 2015, CANCER CELL, V28, P743, DOI 10.1016/j.ccell.2015.10.013; Wang WQ, 2015, NAT CELL BIOL, V17, P490, DOI 10.1038/ncb3113; Wang WQ, 2012, GENE DEV, V26, P1959, DOI 10.1101/gad.192955.112; Wolfsperger F, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.405; Yu FX, 2015, ANNU REV PHYSIOL, V77, P201, DOI 10.1146/annurev-physiol-021014-071733; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810; Zheng XN, 2014, GENE DEV, V28, P1429, DOI 10.1101/gad.242131.114; Zhi X, 2012, AM J PATHOL, V180, P2452, DOI 10.1016/j.ajpath.2012.02.025; Zhou DW, 2009, CANCER CELL, V16, P425, DOI 10.1016/j.ccr.2009.09.026	42	42	42	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	18					2422	2431		10.1038/s41388-018-0134-2	http://dx.doi.org/10.1038/s41388-018-0134-2			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GE7BW	29449692	Green Accepted			2022-12-17	WOS:000431386000006
J	Cheng, TY; Yang, YC; Wang, HP; Tien, YW; Shun, CT; Huang, HY; Hsiao, M; Hua, KT				Cheng, Tsu-Yao; Yang, Yi-Chieh; Wang, Hsiu-Po; Tien, Yu-Wen; Shun, Chia-Tung; Huang, Hsin-Yi; Hsiao, Michael; Hua, Kuo-Tai			Pyruvate kinase M2 promotes pancreatic ductal adenocarcinoma invasion and metastasis through phosphorylation and stabilization of PAK2 protein	ONCOGENE			English	Article							TUMOR-CELLS; CANCER-CELLS; GENE-TRANSCRIPTION; PKM2; TUMORIGENESIS; ISOFORM; PROGRESSION; EXPRESSION; PROGNOSIS; STRESS	Pyruvate kinase muscle isozymes (PKMs) have crucial roles in regulating metabolic changes during carcinogenesis. A switch from PKM1 to PKM2 isoform was thought to lead to aerobic glycolysis promoting carcinogenesis, and was considered as one of the cancer signatures. However, recent evidence has argued against the existence of PKM isoform switch and related metabolic effects during cancer progression. We compared the effects of PKM1 and PKM2 in cell invasiveness and metastasis of pancreatic ductal adenocarcinoma (PDAC). Both PKM1 and PKM2 expression affected cell migration and invasion abilities of PDAC cells, but only knockdown of PKM2 suppressed metastasis in a xenograft model. By comparing the established PKM2 mutants in the regulation of cell invasion, we found that PKM2 may control cell mobility through its protein kinase and phopho-peptide binding abilities. Further survey for PKM2-associated proteins identified PAK2 as a possible phosphorylation target in PDAC. In vitro binding and kinase assays revealed that PKM2 directly phosphorylated PAK2 at Ser20, Ser141, and Ser192/197. Knockdown of PKM2 decreased PAK2 protein half-life by increasing ubiquitin-dependent proteasomal degradation. Moreover, we identified PAK2 as an HSP90 client protein and the mutation at Ser192/197 of PAK2 reduced PAK2-HSP90 association. Knockdown of PAK2 diminished in vitro cell mobility and in vivo metastatic ability of PKM2 overexpressed PDAC cells. PKM2 and PAK2 protein expression also positively correlated with each other in PDAC tissues. Our findings indicate that PKM2-PAK2 regulation is critical for developing metastasis in PDAC, and suggest that targeting the PKM2/HSP90/PAK2 complex has a potential therapeutic value in this deadly disease.	[Cheng, Tsu-Yao] Natl Taiwan Univ Hosp, Dept Lab Med, Taipei, Taiwan; [Cheng, Tsu-Yao; Wang, Hsiu-Po] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan; [Yang, Yi-Chieh] Taipei Med Univ, Grad Inst Clin Med, Coll Med, Taipei, Taiwan; [Tien, Yu-Wen] Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan; [Shun, Chia-Tung; Huang, Hsin-Yi] Natl Taiwan Univ Hosp, Dept Pathol, Taipei, Taiwan; [Hsiao, Michael] Acad Sinica, Genom Res Ctr, Taipei, Taiwan; [Hsiao, Michael] Kaohsiung Med Univ, Dept Biochem, Coll Med, Kaohsiung, Taiwan; [Hua, Kuo-Tai] Natl Taiwan Univ, Grad Inst Toxicol, Coll Med, Taipei, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; Taipei Medical University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; Academia Sinica - Taiwan; Kaohsiung Medical University; National Taiwan University	Hua, KT (corresponding author), Natl Taiwan Univ, Grad Inst Toxicol, Coll Med, Taipei, Taiwan.	kthua@ntu.edu.tw	Shun, Chia-Tung/M-1400-2019; Cheng, TY/X-1695-2019; Hsiao, Michael/U-6238-2019; Yang, Yi-Chieh/D-6248-2019	Hsiao, Michael/0000-0001-8529-9213; CHENG, TSU-YAO/0000-0002-7370-5605; Hua, Kuo-Tai/0000-0002-8468-4977; TIEN, YU-WEN/0000-0002-9126-2705; Huang, Hsin-Yi/0000-0003-0062-3091; SHUN, CHIA-TUNG/0000-0002-0468-4468	Ministry of Science and Technology of Taiwan [104-0210-01-09-02, 105-0210-01-13-01, 106-0210-01-15-02, 105-2320-B-002-035-MY3, 104-2314-B-002-027]	Ministry of Science and Technology of Taiwan(Ministry of Science and Technology, Taiwan)	We thank Dr. Zhi-Min Lu for the Flag-tagged K367M, K433E, and wild-type PKM2; Dr. Zhi-Ren Liu for HA-tagged R399E and wild-type PKM2. This work was supported by grants from the Ministry of Science and Technology of Taiwan, 104-0210-01-09-02, 105-0210-01-13-01, and 106-0210-01-15-02 (to M. H.); 105-2320-B-002-035-MY3 (to K.-T.H.); and 104-2314-B-002-027 (to T.-Y.C.).	Anastasiou D, 2012, NAT CHEM BIOL, V8, P839, DOI 10.1038/NCHEMBIO.1060; Bluemlein K, 2011, ONCOTARGET, V2, P393; Calabretta S, 2016, ONCOGENE, V35, P2031, DOI 10.1038/onc.2015.270; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Coniglio SJ, 2008, MOL CELL BIOL, V28, P4162, DOI 10.1128/MCB.01532-07; Desai S, 2014, ONCOTARGET, V5, P8202, DOI 10.18632/oncotarget.1159; EHRENFRIED JA, 1995, SURG ONCOL, V4, P197, DOI 10.1016/S0960-7404(10)80036-2; Gao XL, 2012, MOL CELL, V45, P598, DOI 10.1016/j.molcel.2012.01.001; Goonetilleke KS, 2007, PANCREAS, V34, P318, DOI 10.1097/MPA.0b013e31802ee9c7; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hitosugi T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000431; Hosios AM, 2015, MOL CELL, V59, P850, DOI 10.1016/j.molcel.2015.07.013; IMAMURA K, 1972, J BIOCHEM-TOKYO, V71, P1043, DOI 10.1093/oxfordjournals.jbchem.a129852; Israelsen WJ, 2013, CELL, V155, P397, DOI 10.1016/j.cell.2013.09.025; Jakobi R, 2003, J BIOL CHEM, V278, P38675, DOI 10.1074/jbc.M306494200; Jiang K, 2016, ONCOTARGET, V7, P23530, DOI 10.18632/oncotarget.8120; Jiang YH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6566; Jiang YH, 2014, MOL CELL, V53, P75, DOI 10.1016/j.molcel.2013.11.001; Joergensen MT, 2010, PANCREAS, V39, P243, DOI 10.1097/MPA.0b013e3181bae8ab; Keller KE, 2014, MOL CELL, V53, P700, DOI 10.1016/j.molcel.2014.02.015; Kumar R, 2017, GENE, V605, P20, DOI 10.1016/j.gene.2016.12.014; Kumar Y, 2007, PANCREAS, V35, P114, DOI 10.1097/mpa.0b013e3180537237; Lang SA, 2007, MOL CANCER THER, V6, P1123, DOI 10.1158/1535-7163.MCT-06-0628; Li CG, 2016, DIGEST DIS SCI, V61, P767, DOI 10.1007/s10620-015-3931-2; Li ZW, 2014, BBA-REV CANCER, V1846, P285, DOI 10.1016/j.bbcan.2014.07.008; Liang J, 2017, CELL RES, V27, P329, DOI 10.1038/cr.2016.159; Lockney Natalie A, 2015, J Gastrointest Cancer, V46, P390, DOI 10.1007/s12029-015-9764-6; Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054; Mazurek S, 2011, INT J BIOCHEM CELL B, V43, P969, DOI 10.1016/j.biocel.2010.02.005; MELLATI AA, 1992, CANCER BIOCHEM BIOPH, V13, P33; Mohammad GH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151635; Nakatsu D, 2015, P NATL ACAD SCI USA, V112, pE1067, DOI 10.1073/pnas.1417197112; NOGUCHI T, 1986, J BIOL CHEM, V261, P3807; Ogawa H, 2015, MOL CLIN ONCOL, V3, P563, DOI 10.3892/mco.2015.490; Radu M, 2014, NAT REV CANCER, V14, P13, DOI 10.1038/nrc3645; Schopf FH, 2017, NAT REV MOL CELL BIO, V18, P345, DOI 10.1038/nrm.2017.20; Vargas DA, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1005007; Wei Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14041; Wu JY, 2016, ONCOTARGETS THER, V9, P4277, DOI 10.2147/OTT.S106508; Yang WW, 2012, CELL, V150, P685, DOI 10.1016/j.cell.2012.07.018; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598; Yang YC, 2016, ONCOGENE, V35, P3387, DOI 10.1038/onc.2015.397; Zhan C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118663; Zhu HY, 2017, ONCOTARGET, V8, P1628, DOI 10.18632/oncotarget.13703	44	42	45	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	13					1730	1742		10.1038/s41388-017-0086-y	http://dx.doi.org/10.1038/s41388-017-0086-y			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GA9AE	29335522				2022-12-17	WOS:000428632600004
J	Weisenberger, DJ; Liang, G; Lenz, HJ				Weisenberger, D. J.; Liang, G.; Lenz, H-J			DNA methylation aberrancies delineate clinically distinct subsets of colorectal cancer and provide novel targets for epigenetic therapies	ONCOGENE			English	Review							INDEPENDENT PROGNOSTIC-FACTOR; PLUS CETUXIMAB TREATMENT; GENE BODY METHYLATION; PROMOTER METHYLATION; FECAL DNA; CPG METHYLATION; DOWN-REGULATION; RAS MUTATIONS; VIRAL MIMICRY; HUMAN COLON	Colorectal cancer (CRC) is a worldwide health concern with respect to both incidence and mortality, and as a result, CRC tumorigenesis, progression and metastasis have been heavily studied, especially with respect to identifying genetic, epigenetic, transcriptomic and proteomic profiles of disease. DNA methylation alterations are hallmarks of CRC, and epigenetic driver genes have been identified that are thought to be involved in early stages of tumorigenesis. Moreover, distinct CRC patient subgroups are organized based on DNA methylation profiles. CRC tumors displaying CpG island methylator phenotypes (CIMPs), defined as DNA hypermethylation at specific CpG islands in subsets of tumors, show high concordance with specific genetic alterations, disease risk factors and patient outcome. This review details the DNA methylation alterations in CRC, the significance of CIMP status, the development of treatments based on specific molecular profiles and the application of epigenetic therapies for CRC patient treatment.	[Weisenberger, D. J.] Univ Southern Calif, Dept Biochem & Mol Med, USC Norris Comprehens Canc Ctr, 1450 Biggy St,NRT G511D, Los Angeles, CA 90033 USA; [Liang, G.] Univ Southern Calif, Dept Urol, USC Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA; [Lenz, H-J] Univ Southern Calif, Dept Med, USC Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California; University of Southern California	Weisenberger, DJ; Liang, G; Lenz, HJ (corresponding author), Univ Southern Calif, Dept Biochem & Mol Med, USC Norris Comprehens Canc Ctr, 1450 Biggy St,NRT G511D, Los Angeles, CA 90033 USA.	dan.weisenberger@med.usc.edu; gliang@usc.edu; lenz@med.usc.edu	Weisenberger, Daniel/AAA-8314-2020	Weisenberger, Daniel/0000-0001-8303-2603	Vicky Joseph Cancer Research Lab; NIH [5R21 CA201865]; NIH/NCI [P30 CA014089]; NATIONAL CANCER INSTITUTE [R21CA201865] Funding Source: NIH RePORTER	Vicky Joseph Cancer Research Lab; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the Vicky Joseph Cancer Research Lab (to GL), NIH 5R21 CA201865 (to GL and DJW) and NIH/NCI P30 CA014089 (to DJW).	Adams BD, 2014, CURR BIOL, V24, pR762, DOI 10.1016/j.cub.2014.06.043; Ahn JB, 2011, CANCER-AM CANCER SOC, V117, P1847, DOI 10.1002/cncr.25737; Altobelli E, 2016, J CANCER, V7, P1984, DOI 10.7150/jca.16244; Azad NS, 2017, ONCOTARGET, V8, P35326, DOI 10.18632/oncotarget.15108; Balaguer F, 2010, CANCER RES, V70, P6609, DOI 10.1158/0008-5472.CAN-10-0622; Bettington M, 2013, HISTOPATHOLOGY, V62, P367, DOI 10.1111/his.12055; Blaschke K, 2013, NATURE, V500, P222, DOI 10.1038/nature12362; Bokemeyer C, 2015, EUR J CANCER, V51, P1243, DOI 10.1016/j.ejca.2015.04.007; Booth MJ, 2012, SCIENCE, V336, P934, DOI 10.1126/science.1220671; Bosch LJW, 2011, CLIN COLORECTAL CANC, V10, P8, DOI 10.3816/CCC.2011.n.002; Carter SL, 2012, NAT BIOTECHNOL, V30, P413, DOI 10.1038/nbt.2203; Chen WD, 2005, JNCI-J NATL CANCER I, V97, P1124, DOI 10.1093/jnci/dji204; Chiappinelli KB, 2016, CELL, V164, P1073, DOI 10.1016/j.cell.2015.10.020; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; Chuang JC, 2010, MOL CANCER THER, V9, P1443, DOI 10.1158/1535-7163.MCT-09-1048; Cohen AL, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0345-4; Cohen SA, 2016, CLIN COLORECTAL CANC, V15, P164, DOI 10.1016/j.clcc.2015.10.005; Dang L, 2010, NATURE, V465, P966, DOI 10.1038/nature09132; De Carvalho DD, 2012, CANCER CELL, V21, P655, DOI 10.1016/j.ccr.2012.03.045; Demurtas L, 2017, BRIT J CANCER, V117, P315, DOI 10.1038/bjc.2017.178; deVos T, 2009, CLIN CHEM, V55, P1337, DOI 10.1373/clinchem.2008.115808; Donada M, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471-230X-13-36; Duymich CE, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11453; Egger G, 2006, P NATL ACAD SCI USA, V103, P14080, DOI 10.1073/pnas.0604602103; EHRLICH M, 1981, SCIENCE, V212, P1350, DOI 10.1126/science.6262918; Fang MG, 2014, MOL CELL, V55, P904, DOI 10.1016/j.molcel.2014.08.010; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Flis S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092305; Gallois C, 2016, CRIT REV ONCOL HEMAT, V99, P74, DOI 10.1016/j.critrevonc.2015.11.001; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883; Garrido-Laguna I, 2013, INVEST NEW DRUG, V31, P1257, DOI 10.1007/s10637-013-9947-6; Geissler AL, 2017, ONCOTARGET, V8, P17164, DOI 10.18632/oncotarget.15211; Giacinti C, 2006, ONCOGENE, V25, P5220, DOI 10.1038/sj.onc.1209615; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Heinemann V, 2014, LANCET ONCOL, V15, pE583, DOI 10.1016/S1470-2045(14)71036-8; Herbst A, 2009, EUR J GASTROEN HEPAT, V21, P565, DOI 10.1097/MEG.0b013e328318ecf2; Hinoue T, 2012, GENOME RES, V22, P271, DOI 10.1101/gr.117523.110; Iacopetta B, 2008, INT J CLIN ONCOL, V13, P498, DOI 10.1007/s10147-008-0854-3; Ikehata M, 2014, BIOL PHARM BULL, V37, P67, DOI 10.1248/bpb.b13-00574; Ito S, 2011, SCIENCE, V333, P1300, DOI 10.1126/science.1210597; Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230; Jones PA, 2009, NAT REV GENET, V10, P805, DOI 10.1038/nrg2651; Juo YY, 2014, ANN ONCOL, V25, P2314, DOI 10.1093/annonc/mdu149; Kaneko M, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2984-8; Kasinathan S, 2014, CANCER CELL, V26, P449, DOI 10.1016/j.ccell.2014.09.004; Kaur S, 2016, ADV EXP MED BIOL, V937, P109, DOI 10.1007/978-3-319-42059-2_6; Kim SE, 2015, GENES NUTR, V10, DOI [10.1007/s12263-014-0444-0, 10.1007/s12263-015-0475-1]; Kisiel JB, 2012, CANCER-AM CANCER SOC, V118, P2623, DOI 10.1002/cncr.26558; Kita Y, 2014, EXPERT REV MOL DIAGN, V14, P673, DOI 10.1586/14737159.2014.925399; Kou CH, 2016, ONCOL LETT, V12, P4838, DOI 10.3892/ol.2016.5265; Lange CPE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050266; Lecomte T, 2002, INT J CANCER, V100, P542, DOI 10.1002/ijc.10526; Lenhard K, 2005, CLIN GASTROENTEROL H, V3, P142, DOI 10.1016/S1542-3565(04)00624-X; Li HL, 2014, ONCOTARGET, V5, P587, DOI 10.18632/oncotarget.1782; Lievre A, 2008, J CLIN ONCOL, V26, P374, DOI 10.1200/JCO.2007.12.5906; Limsui D, 2010, JNCI-J NATL CANCER I, V102, P1012, DOI 10.1093/jnci/djq201; Liu MM, 2016, P NATL ACAD SCI USA, V113, P10238, DOI 10.1073/pnas.1612262113; Loupakis F, 2015, J NATL CANC I, V107; Loupakis F, 2014, NEW ENGL J MED, V371, P1609, DOI 10.1056/NEJMoa1403108; Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218; Lynch HT, 2015, NAT REV CANCER, V15, P181, DOI 10.1038/nrc3878; Mansour H, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00182; Mayland CR, 2005, PALLIATIVE MED, V19, P17, DOI 10.1191/0269216305pm970oa; Menigatti M, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.21; Min BH, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-344; Missiaglia E, 2014, ANN ONCOL, V25, P1995, DOI 10.1093/annonc/mdu275; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nakayama H, 2003, INT J CANCER, V105, P491, DOI 10.1002/ijc.11117; Nilsson TK, 2013, INT J ONCOL, V42, P127, DOI 10.3892/ijo.2012.1682; Oberwalder M, 2008, INT J COLORECTAL DIS, V23, P15, DOI 10.1007/s00384-007-0355-2; Ogino S, 2006, J MOL DIAGN, V8, P582, DOI 10.2353/jmoldx.2006.060082; Overman MJ, 2016, ONCOTARGET, V7, P67495, DOI 10.18632/oncotarget.11317; Payne SR, 2010, EPIGENOMICS-UK, V2, P575, DOI [10.2217/epi.10.35, 10.2217/EPI.10.35]; Petko Z, 2005, CLIN CANCER RES, V11, P1203; Pfutze K, 2015, GENOMICS, V106, P348, DOI 10.1016/j.ygeno.2015.10.002; Powell AE, 2014, AM J PHYSIOL-GASTR L, V307, pG16, DOI 10.1152/ajpgi.00358.2013; Ramsahoye BH, 2000, P NATL ACAD SCI USA, V97, P5237, DOI 10.1073/pnas.97.10.5237; Raynal N.J., 2016, DRUG DISCOV CANC EPI, P169; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; Roulois D, 2015, CELL, V162, P961, DOI 10.1016/j.cell.2015.07.056; Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020; Samowitz WS, 2006, J NATL CANCER I, V98, P1731, DOI 10.1093/jnci/djj468; SANTI DV, 1984, P NATL ACAD SCI-BIOL, V81, P6993, DOI 10.1073/pnas.81.22.6993; Scartozzi M, 2011, BRIT J CANCER, V104, P1786, DOI 10.1038/bjc.2011.161; Schuebel KE, 2007, PLOS GENET, V3, P1709, DOI 10.1371/journal.pgen.0030157; Serra RW, 2014, ELIFE, V3, DOI 10.7554/eLife.02313; Sharma SV, 2007, GENE DEV, V21, P3214, DOI 10.1101/gad.1609907; Shen LL, 2007, P NATL ACAD SCI USA, V104, P18654, DOI 10.1073/pnas.0704652104; Shiovitz S, 2014, GASTROENTEROLOGY, V147, P637, DOI 10.1053/j.gastro.2014.05.009; Sottoriva A, 2015, NAT GENET, V47, P209, DOI 10.1038/ng.3214; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Tejpar S, 2017, JAMA ONCOL, V3, P194, DOI 10.1001/jamaoncol.2016.3797; Tham C, 2014, CANCER-AM CANCER SOC, V120, P3131, DOI 10.1002/cncr.28802; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Toth K, 2016, EXPERT REV MOL DIAGN, V16, P239, DOI 10.1586/14737159.2016.1132164; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Toyota M, 2008, CANCER RES, V68, P4123, DOI 10.1158/0008-5472.CAN-08-0325; Van Cutsem E, 2015, J CLIN ONCOL, V33, P692, DOI 10.1200/JCO.2014.59.4812; van Rijnsoever M, 2003, CLIN CANCER RES, V9, P2898; Venook AP, 2014, J CLIN ONCOL S, V32, p5S, DOI DOI 10.1200/JCO.2014.32.18_SUPPL.LBA3; Venook AP, 2016, J CLIN ONCOL S, V34; Wang H, 2011, CARCINOGENESIS, V32, P1033, DOI 10.1093/carcin/bgr081; Wang Y, 2013, BRIT J CANCER, V108, P1765, DOI 10.1038/bjc.2013.138; Weinstein IB, 2000, CARCINOGENESIS, V21, P857, DOI 10.1093/carcin/21.5.857; Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834; Weisenberger DJ, 2015, CANCER EPIDEM BIOMAR, V24, P512, DOI 10.1158/1055-9965.EPI-14-1161; Wu X, 2017, NAT REV GENET; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yagi K, 2010, CLIN CANCER RES, V16, P21, DOI 10.1158/1078-0432.CCR-09-2006; Yan HL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020628; Yang XJ, 2014, CANCER CELL, V26, P577, DOI 10.1016/j.ccr.2014.07.028; Yoo CB, 2007, CANCER RES, V67, P6400, DOI 10.1158/0008-5472.CAN-07-0251; Zarate R, 2012, INT J MOL SCI, V13, P840, DOI 10.3390/ijms13010840	117	42	45	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	2018	37	5					566	577		10.1038/onc.2017.374	http://dx.doi.org/10.1038/onc.2017.374			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FU4GT	28991233	Green Accepted			2022-12-17	WOS:000423812200003
J	Liu, L; He, J; Wei, X; Wan, G; Lao, Y; Xu, W; Li, Z; Hu, H; Hu, Z; Luo, X; Wu, J; Xie, W; Zhang, Y; Xu, N				Liu, L.; He, J.; Wei, X.; Wan, G.; Lao, Y.; Xu, W.; Li, Z.; Hu, H.; Hu, Z.; Luo, X.; Wu, J.; Xie, W.; Zhang, Y.; Xu, N.			MicroRNA-20a-mediated loss of autophagy contributes to breast tumorigenesis by promoting genomic damage and instability	ONCOGENE			English	Article							SET ENRICHMENT ANALYSIS; EXPRESSION PROFILES; CELL-PROLIFERATION; TUMOR-SUPPRESSOR; CANCER; MICRORNAS; GENE; BECLIN-1; CLUSTER; DISEASE	Gene expression analysis of The Cancer Genome Atlas (TCGA) breast cancer data set show that miR-20a is upregulated in human breast cancer, especially in triple-negative subtype. Gene Set Enrichment Analysis suggests that miR-20a expression negatively correlates with the autophagy/ lysosome pathway. We report here that miR-20a inhibits the basal and nutrient starvation-induced autophagic flux and lysosomal proteolytic activity, increases intracellular reactive oxygen species levels and DNA damage response by targeting several key regulators of autophagy, including BECN1, ATG16L1 and SQSTM1. Re-introduction of exogenous BECN1, ATG16L1 or SQSTM1 reverses the inhibitory effect of miR-20a on autophagy and decreases DNA damage. A negative correlation between miR-20a and its target genes is observed in breast cancer tissues. Lower levels of BECN1, ATG16L1 and SQSTM1 are more common in triple-negative cancers than in other subtypes. High levels of miR-20a also associate with higher frequency of copynumber alterations and DNA mutations in breast cancer patients. Further studies in a xenograft mouse model show that miR-20a promotes tumor initiation and tumor growth. Collectively, these findings suggest that miR-20a-mediated autophagy defect might be a new mechanism underlying the oncogenic function of miRNA during breast tumorigenesis.	[Liu, L.; Wan, G.; Xu, W.; Wu, J.] Tsinghua Univ, Sch Life Sci, Beijing, Peoples R China; [Liu, L.; He, J.; Wei, X.; Wan, G.; Xu, W.; Luo, X.; Wu, J.; Xie, W.; Zhang, Y.; Xu, N.] Tsinghua Univ, Div Life Sci, Key Lab Hlth Sci & Technol, Grad Sch Shenzhen, Shenzhen, Peoples R China; [Lao, Y.] Shanghai Univ Tradit Chinese Med, Sch Pharm, Shanghai, Peoples R China; [Li, Z.] Peking Univ, Grad Sch Shenzhen, Sch Chem Biol & Biotechnol, Shenzhen, Peoples R China; [Hu, H.] Peking Univ, Dept Breast Surg, Shenzhen Hosp, Shenzhen, Peoples R China; [Hu, Z.] Wuhan 1 Hosp, Dept Clin Oncol, Wuhan, Hubei, Peoples R China; [Xie, W.; Zhang, Y.; Xu, N.] Tsinghua Univ, Open FIESTA Ctr, Shenzhen, Peoples R China	Tsinghua University; Tsinghua University; University Town of Shenzhen; Tsinghua Shenzhen International Graduate School; Shanghai University of Traditional Chinese Medicine; Peking University; Peking University; Tsinghua University	Zhang, Y; Xu, N (corresponding author), Tsinghua Univ, Grad Sch Shenzhen, Key Lab Hlth Sci & Technol, Bldg L,Tsinghua Campus, Shenzhen 518055, Peoples R China.	zhangyo@sz.tsinghua.edu.cn; xu.naihan@sz.tsinghua.edu.cn	Wu, Jiangbin/GWC-7165-2022; Xu, Naihan/C-2778-2018; , Yuanzhi/D-3936-2015	Wu, Jiangbin/0000-0003-3109-417X; Zhang, Yaou/0000-0002-2501-8093; He, Jie/0000-0002-5880-8112; , Yuanzhi/0000-0002-7803-4484	National Natural Science Foundation of China [31571418, 31371315]; Shenzhen Science and Technology Innovation Committee [JCYJ20160226185623304, JCYJ20140417115840281]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shenzhen Science and Technology Innovation Committee	We thank the National Natural Science Foundation of China (No. 31571418 and 31371315) and the Shenzhen Science and Technology Innovation Committee (JCYJ20160226185623304, JCYJ20140417115840281) for financial support.	Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Cai ZQ, 2015, J BIOL CHEM, V290, P19967, DOI 10.1074/jbc.M115.661504; Cianfanelli V, 2015, NAT CELL BIOL, V17, P20, DOI 10.1038/ncb3072; Conkrite K, 2011, GENE DEV, V25, P1734, DOI 10.1101/gad.17027411; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Farazi TA, 2011, CANCER RES, V71, P4443, DOI 10.1158/0008-5472.CAN-11-0608; Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71; Jin SK, 2007, AUTOPHAGY, V3, P28, DOI 10.4161/auto.3269; Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707; Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451; Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356; Ko A, 2014, CELL DEATH DIFFER, V21, P92, DOI 10.1038/cdd.2013.124; Kongara S, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00171; Krol J, 2010, NAT REV GENET, V11, P597, DOI 10.1038/nrg2843; Lao YZ, 2014, AUTOPHAGY, V10, P736, DOI 10.4161/auto.28034; Levy JMM, 2014, CANCER DISCOV, V4, P773, DOI 10.1158/2159-8290.CD-14-0049; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Liu EY, 2015, P NATL ACAD SCI USA, V112, P773, DOI 10.1073/pnas.1409563112; Liu EY, 2012, J CELL SCI, V125, P2349, DOI 10.1242/jcs.093708; Mah LY, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008821; Mendell JT, 2005, CELL CYCLE, V4, P1179, DOI 10.4161/cc.4.9.2032; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Mogilyansky E, 2013, CELL DEATH DIFFER, V20, P1603, DOI 10.1038/cdd.2013.125; Murakami Y, 2006, ONCOGENE, V25, P2537, DOI 10.1038/sj.onc.1209283; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Olive V, 2010, INT J BIOCHEM CELL B, V42, P1348, DOI 10.1016/j.biocel.2010.03.004; Pickering MT, 2009, ONCOGENE, V28, P140, DOI 10.1038/onc.2008.372; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497; Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009; Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802; Shaid S, 2013, CELL DEATH DIFFER, V20, P21, DOI 10.1038/cdd.2012.72; Shi J, 2007, CURR BIOINFORM, V2, P133, DOI 10.2174/157489307780618231; Singh R, 2013, CANCER BIOL THER, V14, P201, DOI 10.4161/cbt.23296; Sridhar S, 2012, J PATHOL, V226, P255, DOI 10.1002/path.3025; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211; Tang H, 2015, EBIOMEDICINE, V2, P255, DOI 10.1016/j.ebiom.2015.01.008; Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697; Vazquez CL, 2009, METHOD ENZYMOL, V452, P85, DOI 10.1016/S0076-6879(08)03606-9; Wei HJ, 2011, GENE DEV, V25, P1510, DOI 10.1101/gad.2051011; Woods K, 2007, J BIOL CHEM, V282, P2130, DOI 10.1074/jbc.C600252200; Wu WKK, 2012, ONCOGENE, V31, P939, DOI 10.1038/onc.2011.295; Xu W, 2015, BIOCHEM BIOPH RES CO, V457, P300, DOI 10.1016/j.bbrc.2014.12.104; Yan HJ, 2010, HUM GENE THER, V21, P1723, DOI 10.1089/hum.2010.061; Yan HL, 2009, EMBO J, V28, P2719, DOI 10.1038/emboj.2009.214; Yu ZR, 2008, J CELL BIOL, V182, P509, DOI 10.1083/jcb.200801079; Yu ZR, 2010, P NATL ACAD SCI USA, V107, P8231, DOI 10.1073/pnas.1002080107; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100	54	42	45	4	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2017	36	42					5874	5884		10.1038/onc.2017.193	http://dx.doi.org/10.1038/onc.2017.193			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK2DN	28628113	Green Published, hybrid			2022-12-17	WOS:000413292900009
J	Zhang, H; Ma, RR; Wang, XJ; Su, ZX; Chen, X; Shi, DB; Guo, XY; Liu, HT; Gao, P				Zhang, H.; Ma, R-R; Wang, X-J; Su, Z-X; Chen, X.; Shi, D-B; Guo, X-Y; Liu, H-T; Gao, P.			KIF26B, a novel oncogene, promotes proliferation and metastasis by activating the VEGF pathway in gastric cancer	ONCOGENE			English	Article							KINESIN; EXPRESSION; THERAPY; GENE; THERAPEUTICS; INHIBITION; PROTEINS; ADHESION; BIOLOGY; STAGE	Tumor metastasis is the main reason of cancer-related death for gastric cancer (GC) patients and gene expression microarray data indicate that kinesin family member 26B (KIF26B) is one of the most upregulated genes in metastatic GC samples. Specifically, KIF26B expression was upregulated in a stepwise manner from non-tumorous gastric mucosa, primary GC tissues without metastasis, via primary GC tissues with metastasis, to secondary lymph node metastatic (LNM) foci. Increased expression of KIF26B was correlated with tumor size, positive LNM or distant metastases and poor prognosis. KIF26B, negatively regulated by miR-372, promoted GC cell proliferation and metastasis in vitro and in vivo. Mechanistic investigations confirmed that the main target of KIF26B was the vascular endothelial growth factor (VEGF) signaling pathway, particularly by inhibition or overexpression of VEGFA, PXN, FAK, PIK3CA, BCL2 and CREB1. Thus, KIF26B, a novel oncogene regulated by miR-372, promotes proliferation and metastasis through the VEGF pathway in GC.	[Zhang, H.; Ma, R-R; Wang, X-J; Chen, X.; Shi, D-B; Guo, X-Y; Liu, H-T; Gao, P.] Shandong Univ, Sch Med, Dept Pathol, Jinan Wen Hua Xi Rd 44, Jinan 250012, Shandong, Peoples R China; [Zhang, H.] Shandong Univ, Qilu Hosp, Dept Pathol, Shandong, Peoples R China; [Su, Z-X] Shandong Prov Hosp, Dept Hepatobiliary Surg, Shandong, Peoples R China	Shandong University; Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences	Gao, P (corresponding author), Shandong Univ, Sch Med, Dept Pathol, Jinan Wen Hua Xi Rd 44, Jinan 250012, Shandong, Peoples R China.	gaopeng@sdu.edu.cn			National Natural Science Foundation of China [81372856, 81672842]; Taishan Scholars Program of Shandong Province [ts201511096]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Taishan Scholars Program of Shandong Province	We thank LetPub (www.letpub.com) for its linguistic assistance during the preparation of the manuscript. This study was supported by the National Natural Science Foundation of China (grant no. 81372856 and 81672842) and the Taishan Scholars Program of Shandong Province (grant no. ts201511096).	Adomas A, 2008, TREE PHYSIOL, V28, P885, DOI 10.1093/treephys/28.6.885; Brenner Hermann, 2009, V472, P467, DOI 10.1007/978-1-60327-492-0_23; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chen X, 2003, MOL BIOL CELL, V14, P3208, DOI 10.1091/mbc.E02-12-0833; Coghlin C, 2010, J PATHOL, V222, P1, DOI 10.1002/path.2727; Crociani O, 2014, CLIN CANCER RES, V20, P1502, DOI 10.1158/1078-0432.CCR-13-2633; Cross MJ, 2003, TRENDS BIOCHEM SCI, V28, P488, DOI 10.1016/S0968-0004(03)00193-2; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; FIDLER IJ, 1990, CANCER RES, V50, P6130; Gandhi NS, 2014, J CONTROL RELEASE, V194, P238, DOI 10.1016/j.jconrel.2014.09.001; Gao P, 2013, ONCOGENE, V32, P491, DOI 10.1038/onc.2012.61; Gao P, 2011, J HEPATOL, V54, P1177, DOI 10.1016/j.jhep.2010.09.023; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Grothey A, 2013, LANCET ONCOL, V14, P2, DOI 10.1016/S1470-2045(12)70516-8; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hata AN, 2015, CANCER DISCOV, V5, P475, DOI 10.1158/2159-8290.CD-15-0011; Hippo Y, 2002, CANCER RES, V62, P233; Hirokawa N, 2009, NAT REV MOL CELL BIO, V10, P682, DOI 10.1038/nrm2774; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Ji P, 2003, ONCOGENE, V22, P8031, DOI 10.1038/sj.onc.1206928; Kieran MW, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006593; Liu XR, 2013, CANCER SCI, V104, P651, DOI 10.1111/cas.12138; Paul-Samojedny M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768181; Petri A, 2009, CANCER RES, V69, P393, DOI 10.1158/0008-5472.CAN-08-2749; Sakamoto KM, 2009, CLIN CANCER RES, V15, P2583, DOI 10.1158/1078-0432.CCR-08-1137; Terabayashi T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039714; Uchiyama Y, 2010, P NATL ACAD SCI USA, V107, P9240, DOI 10.1073/pnas.0913748107; Van Cutsem E, 2015, GASTRIC CANCER, V18, P476, DOI 10.1007/s10120-014-0402-y; Waller T, 2015, BIODATA MIN, V8, DOI 10.1186/s13040-015-0052-6; Wang JT, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0129-6; Wang Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061640; Wang YW, 2015, ONCOTARGET, V6, P10646, DOI 10.18632/oncotarget.3392; Wu DW, 2016, ONCOGENE, V35, P621, DOI 10.1038/onc.2015.120; Wu G, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-107; Zhao YJ, 2015, ONCOLOGIST, V20, P660, DOI 10.1634/theoncologist.2014-0465; Zhou RY, 2009, CELL, V139, P802, DOI 10.1016/j.cell.2009.10.023	36	42	42	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2017	36	40					5609	5619		10.1038/onc.2017.163	http://dx.doi.org/10.1038/onc.2017.163			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FI8ZW	28581513				2022-12-17	WOS:000412293600005
J	Kim, KJ; Kwon, SH; Yun, JH; Jeong, HS; Kim, HR; Lee, E; Ye, SK; Cho, CH				Kim, K-J; Kwon, S-H; Yun, J-H; Jeong, H-S; Kim, H-R; Lee, Eh; Ye, S-K; Cho, C-H			STAT3 activation in endothelial cells is important for tumor metastasis via increased cell adhesion molecule expression	ONCOGENE			English	Article							NF-KAPPA-B; SIGNAL TRANSDUCER; CANCER; ANGIOGENESIS; GROWTH; RECRUITMENT; INHIBITION; MECHANISMS; MIGRATION; CYTOKINES	Metastasis is a life-threatening feature of cancer and is primarily responsible for cancer patient mortality. Cross talk between tumor cells and endothelium is important for tumor progression and metastasis. However, very little is known about the mechanisms by which endothelial cells (ECs) that are close to tumor cells, respond to the tumor cells during tumor progression and metastasis. In this study, we exploited the use of EC-specific signal transducer activator of transcription 3 (STAT3) knockout mice to investigate the role of STAT3 in ECs in tumor progression and metastasis. We found that the loss of STAT3 in ECs did not affect primary Lewis lung carcinoma (LLC) tumor growth, but it reduced in vivo LLC metastasis in experimental and spontaneous metastasis models. Mechanistically, STAT3 activation upregulated cell adhesion molecule expression, including E-selectin and P-selectin, in murine endothelial MS-1 cells treated with tumor cell-conditioned media in vitro and in pre-metastatic lungs of tumor-bearing mice in vivo. We also found that both E-selectin and P-selectin were, at least in part, responsible for STAT3-induced adhesion and invasion of LLC cells through an EC monolayer. However, tumor cell-conditioned media from B16F10 melanoma cells did not activate STAT3 in MS-1 cells. As a result, EC STAT3 knockout did not affect B16F10 melanoma cell metastasis. In addition, various human cancer cells activated STAT3 in human ECs (HUVECs), resulting in increased cell adhesion molecule expression. Collectively, our findings demonstrate that STAT3 activation in ECs promotes tumor metastasis through the induction of cell adhesion molecules, demonstrating a role for ECs in response to tumor cells during tumor metastasis.	[Kim, K-J; Kwon, S-H; Yun, J-H; Jeong, H-S; Ye, S-K; Cho, C-H] Seoul Natl Univ, Dept Pharmacol, Coll Med, 103 Daehakro Dong, Seoul 110799, South Korea; [Kim, H-R] Seoul Natl Univ, Dept Anat & Cell Biol, Coll Med, Seoul, South Korea; [Lee, Eh] Catholic Univ Korea, Dept Physiol, Coll Med, Seoul, South Korea; [Ye, S-K; Cho, C-H] Seoul Natl Univ, Ischem Hypox Dis Inst, Coll Med, Seoul, South Korea; [Cho, C-H] Seoul Natl Univ, Canc Res Inst, Coll Med, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Catholic University of Korea; Seoul National University (SNU); Seoul National University (SNU)	Ye, SK; Cho, CH (corresponding author), Seoul Natl Univ, Dept Pharmacol, Coll Med, 103 Daehakro Dong, Seoul 110799, South Korea.	sangkyu@snu.ac.kr; iamhyun@snu.ac.kr		Kwon, Sun-Ho/0000-0003-1592-0638; Kim, Hang-Rae/0000-0002-3983-6193; Lee, Eun Hui/0000-0003-4555-1730	National Research Foundation of Korea grant - Korea government [2014R1A2A1A11050981, 2012R1A5A2A44671346]	National Research Foundation of Korea grant - Korea government	We acknowledge Daeho So for technical support of EV isolation and depletion, and Dr Jong-Wan Park for helpful suggestions during the course of this work. This work is supported by the National Research Foundation of Korea grant funded by the Korea government (2014R1A2A1A11050981 and 2012R1A5A2A44671346 to CHC).	Al-Mehdi AB, 2000, NAT MED, V6, P100, DOI 10.1038/71429; Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; Deng JH, 2012, CANCER CELL, V21, P642, DOI 10.1016/j.ccr.2012.03.039; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Gout S, 2008, CLIN EXP METASTAS, V25, P335, DOI 10.1007/s10585-007-9096-4; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Hiratsuka S, 2008, NAT CELL BIOL, V10, P1349, DOI 10.1038/ncb1794; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Hiratsuka S, 2011, P NATL ACAD SCI USA, V108, P3725, DOI 10.1073/pnas.1100446108; Hwang JA, 2009, MOL CANCER RES, V7, P1920, DOI 10.1158/1541-7786.MCR-09-0041; JAHROUDI N, 1995, J NEURO-ONCOL, V23, P99, DOI 10.1007/BF01053415; Kano A, 2003, J EXP MED, V198, P1517, DOI 10.1084/jem.20030077; Kaplan RN, 2006, CANCER RES, V66, P11089, DOI 10.1158/0008-5472.CAN-06-2407; Kim HJ, 2013, BBA-MOL BASIS DIS, V1832, P183, DOI 10.1016/j.bbadis.2012.09.002; Klemke M, 2007, J CELL PHYSIOL, V212, P368, DOI 10.1002/jcp.21029; Kujawski M, 2008, J CLIN INVEST, V118, P3367, DOI 10.1172/JCI35213; Langley RR, 2007, ENDOCR REV, V28, P297, DOI 10.1210/er.2006-0027; Laubli H, 2010, CANCER MICROENVIRON, V3, P97, DOI 10.1007/s12307-010-0043-6; Lee H, 2009, CANCER CELL, V15, P283, DOI 10.1016/j.ccr.2009.02.015; Lee HT, 2015, ONCOTARGET, V6, P10016, DOI 10.18632/oncotarget.3540; Liu Y, 2016, CANCER CELL, V30, P668, DOI 10.1016/j.ccell.2016.09.011; Lu T, 2004, ONCOGENE, V23, P2138, DOI 10.1038/sj.onc.1207332; Lu T, 2004, CELL CYCLE, V3, P1114; MACKAY F, 1993, J EXP MED, V177, P1277, DOI 10.1084/jem.177.5.1277; Miller AM, 2010, ALCOHOL CLIN EXP RES, V34, P719, DOI 10.1111/j.1530-0277.2009.01141.x; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PARHAR RS, 1987, J EXP MED, V165, P14, DOI 10.1084/jem.165.1.14; Qian F, 2005, BIOCHEM BIOPH RES CO, V333, P1269, DOI 10.1016/j.bbrc.2005.06.039; Rao RM, 2007, CIRC RES, V101, P234, DOI 10.1161/CIRCRESAHA.107.151860b; Ray Subrata, 1999, Journal of Environmental Pathology Toxicology and Oncology, V18, P251; Reymond N, 2013, NAT REV CANCER, V13, P858, DOI 10.1038/nrc3628; Roland CL, 2007, SURGERY, V141, P705, DOI 10.1016/j.surg.2007.01.016; Sengupta TK, 1996, P NATL ACAD SCI USA, V93, P9499, DOI 10.1073/pnas.93.18.9499; Severgnini M, 2004, AM J PHYSIOL-LUNG C, V286, pL1282, DOI 10.1152/ajplung.00349.2003; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Teng CB, 2004, REPRODUCTION, V128, P197, DOI 10.1530/rep.1.00053; Wang L, 2009, J EXP MED, V206, P1457, DOI 10.1084/jem.20090207; Yang XP, 2005, ARTERIOSCL THROM VAS, V25, P1395, DOI 10.1161/01.ATV.0000168428.96177.24; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Yu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995; Yun JH, 2017, J CELL PHYSIOL, V232, P1123, DOI 10.1002/jcp.25575; Zhang J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014525; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zhuang GL, 2012, EMBO J, V31, P3513, DOI 10.1038/emboj.2012.183	51	42	43	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2017	36	39					5445	5459		10.1038/onc.2017.148	http://dx.doi.org/10.1038/onc.2017.148			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FI4RG	28534515				2022-12-17	WOS:000411960500002
J	Principe, DR; Diaz, AM; Torres, C; Mangan, RJ; DeCant, B; McKinney, R; Tsao, MS; Lowy, A; Munshi, HG; Jung, B; Grippo, PJ				Principe, D. R.; Diaz, A. M.; Torres, C.; Mangan, R. J.; DeCant, B.; McKinney, R.; Tsao, M-S; Lowy, A.; Munshi, H. G.; Jung, B.; Grippo, P. J.			TGF beta engages MEK/ERK to differentially regulate benign and malignant pancreas cell function	ONCOGENE			English	Article							ERK MAP KINASE; SIGNALING PATHWAYS; CANCER CELLS; RAS; INHIBITION; EXPRESSION; P21; PROMOTES; ARREST; TRANSCRIPTION	While TGF beta signals are anti-proliferative in benign and well-differentiated pancreatic cells, TGF beta appears to promote the progression of advanced cancers. To better understand dysregulation of the TGF beta pathway, we first generated mouse models of neoplastic disease with TGF beta receptor deficiencies. These models displayed reduced levels of pERK irrespective of KRAS mutation. Furthermore, exogenous TGF beta led to rapid and sustained TGFBR1-dependent ERK phosphorylation in benign pancreatic duct cells. Similar to results that our group has published in colon cancer cells, inhibition of ERK phosphorylation in duct cells mitigated TGF beta-induced upregulation of growth suppressive pSMAD2 and p21, prevented downregulation of the pro-growth signal CDK2 and ablated TGF beta-induced EMT. These observations suggest that ERK is a key factor in growth suppressive TGF beta signals, yet may also contribute to detrimental TGF beta signaling such as EMT. In neoplastic PanIN cells, pERK was not necessary for either TGF beta-induced pSMAD2 phosphorylation or CDK2 repression, but was required for upregulation of p21 and EMT indicating a partial divergence between TGF beta and MEK/ERK in early carcinogenesis. In cancer cells, pERK had no effect on TGF beta-induced upregulation of pSMAD2 and p21, suggesting the two pathways have completely diverged with respect to the cell cycle. Furthermore, inhibition of pERK both reduced levels of CDK2 and prevented EMT independent of exogenous TGF beta, consistent with most observations identifying pERK as a tumor promoter. Combined, these data suggest that during carcinogenesis pERK initially facilitates and later antagonizes TGF beta-mediated cell cycle arrest, yet remains critical for the pathological, EMT-inducing arm of TGF beta signaling.	[Principe, D. R.] Univ Illinois, Coll Med, Chicago, IL USA; [Diaz, A. M.; Torres, C.; Mangan, R. J.; DeCant, B.; McKinney, R.; Jung, B.; Grippo, P. J.] Univ Illinois, Dept Med, Chicago, IL USA; [Tsao, M-S] Univ Toronto, Univ Hlth Network, Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON, Canada; [Lowy, A.] Univ Calif San Diego, Dept Surg, San Diego, CA 92103 USA; [Munshi, H. G.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of California System; University of California San Diego; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center	Principe, DR (corresponding author), Univ Illinois, Coll Med, Dept Med, 840 South Wood St,738A CSB, Chicago, IL 60612 USA.; Grippo, PJ (corresponding author), Univ Illinois, Dept Med, Div Gastroenterol & Hepatol, 840 South Wood St,738A CSB, Chicago, IL 60612 USA.	principe@illinois.edu; pgrippo@uic.edu	Tsao, Ming-Sound/M-3503-2017; Tsao, Ming Sound/AFQ-7332-2022; Torres, Carolina/M-1169-2014	Tsao, Ming Sound/0000-0002-9160-5405; Torres, Carolina/0000-0002-7908-6884	Barnum Foundation at Northwestern University; University of Illinois College of Medicine Hazel I. Craig fellowship; Zell Family Foundation at Northwestern University	Barnum Foundation at Northwestern University; University of Illinois College of Medicine Hazel I. Craig fellowship; Zell Family Foundation at Northwestern University	This work is dedicated to the memory of our friend Daniel Wang, who recently lost his long and courageous fight with cancer. We appreciate the contributions of Dr Nancy Krett for her critical evaluation of our work. The authors would also like to thank undergraduate students Carol Cavarson, Saminder Singh, Jacob Hoekstra, Danielle Calloway and Matthew J. Michalik for their hard work, as well as Dr Steven Waters (University of Illinois at Chicago) for his assistance with genotyping. This work was supported by the Barnum and Zell Family Foundations at Northwestern University to PG and the University of Illinois College of Medicine Hazel I. Craig fellowship to DP.	Bachmann J, 2013, NUTR CANCER, V65, P827, DOI 10.1080/01635581.2013.804580; Bauer J, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0456-4; Bauer J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039381; Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; Buonato JM, 2014, CANCER RES, V74, P309, DOI 10.1158/0008-5472.CAN-12-4721; Cagnol S, 2010, FEBS J, V277, P2, DOI 10.1111/j.1742-4658.2009.07366.x; Chow JYC, 2007, CARCINOGENESIS, V28, P2321, DOI 10.1093/carcin/bgm159; Ciccarelli C, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-41; Coleman ML, 2003, EMBO J, V22, P2036, DOI 10.1093/emboj/cdg189; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Fensterer H, 2004, GENE CHROMOSOME CANC, V39, P224, DOI 10.1002/gcc.20000; Filmus Jorge, 1993, Current Opinion in Oncology, V5, P123; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Grabliauskaite K, 2015, J PATHOL, V235, P502, DOI 10.1002/path.4440; Hashimoto K, 2001, PANCREAS, V22, P341, DOI 10.1097/00006676-200105000-00002; Ijichi H, 2004, ONCOGENE, V23, P1043, DOI 10.1038/sj.onc.1207222; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Lee MK, 2007, EMBO J, V26, P3957, DOI 10.1038/sj.emboj.7601818; Lu X, 2004, NEOPLASIA, V6, P603, DOI 10.1593/neo.04241; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Neuzillet C, 2013, CANCER METAST REV, V32, P147, DOI 10.1007/s10555-012-9396-2; Nicolas FJ, 2003, ONCOGENE, V22, P3698, DOI 10.1038/sj.onc.1206420; Pouyssegur J, 2002, BIOCHEM PHARMACOL, V64, P755, DOI 10.1016/S0006-2952(02)01135-8; Principe D. R., 2016, ONCOTARGET; Principe DR, 2016, CANCER RES, V76, P2525, DOI 10.1158/0008-5472.CAN-15-1293; Principe DR, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt369; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; SCHWARZ LC, 1988, CANCER RES, V48, P6999; Shen RZ, 2013, CANCER LETT, V339, P135, DOI 10.1016/j.canlet.2013.07.010; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Torii S, 2006, CANCER SCI, V97, P697, DOI 10.1111/j.1349-7006.2006.00244.x; Trobridge P, 2009, GASTROENTEROLOGY, V136, P1680, DOI 10.1053/j.gastro.2009.01.066; Voss M, 1999, INT J ONCOL, V14, P93; Warmflash A, 2012, P NATL ACAD SCI USA, V109, pE1947, DOI 10.1073/pnas.1207607109; Wrighton KH, 2009, CELL RES, V19, P8, DOI 10.1038/cr.2008.327; Yasutome M, 2005, CLIN EXP METASTAS, V22, P461, DOI 10.1007/s10585-005-2891-x; Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328; Zhou QD, 2012, J MOL MED, V90, P563, DOI 10.1007/s00109-011-0833-4	39	42	42	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2017	36	30					4336	4348		10.1038/onc.2016.500	http://dx.doi.org/10.1038/onc.2016.500			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB8AH	28368414	Green Published, hybrid			2022-12-17	WOS:000406360600010
J	Dawar, S; Lim, Y; Puccini, J; White, M; Thomas, P; Bouchier-Hayes, L; Green, DR; Dorstyn, L; Kumar, S				Dawar, S.; Lim, Y.; Puccini, J.; White, M.; Thomas, P.; Bouchier-Hayes, L.; Green, D. R.; Dorstyn, L.; Kumar, S.			Caspase-2-mediated cell death is required for deleting aneuploid cells	ONCOGENE			English	Article							POLO-LIKE KINASE; SPINDLE ASSEMBLY CHECKPOINT; STRESS-INDUCED APOPTOSIS; DNA-DAMAGE RESPONSE; MITOTIC CATASTROPHE; CHROMOSOMAL INSTABILITY; TUMOR SUPPRESSION; MECHANISM; CANCER; ACTIVATION	Caspase-2, one of the most evolutionarily conserved of the caspase family, has been implicated in maintenance of chromosomal stability and tumour suppression. Caspase-2 deficient (Casp2(-/-)) mice develop normally but show premature ageing-related traits and when challenged by certain stressors, succumb to enhanced tumour development and aneuploidy. To test how caspase-2 protects against chromosomal instability, we utilized an ex vivo system for aneuploidy where primary splenocytes from Casp2(-/-)mice were exposed to anti-mitotic drugs and followed up by live cell imaging. Our data show that caspase-2 is required for deleting mitotically aberrant cells. Acute silencing of caspase-2 in cultured human cells recapitulated these results. We further generated Casp2(C320S) mutant mice to demonstrate that caspase-2 catalytic activity is essential for its function in limiting aneuploidy. Our results provide direct evidence that the apoptotic activity of caspase-2 is necessary for deleting cells with mitotic aberrations to limit aneuploidy.	[Dawar, S.; Lim, Y.; Puccini, J.; Dorstyn, L.; Kumar, S.] Univ South Australia, Ctr Canc Biol, Frome Rd, Adelaide, SA 5001, Australia; [Puccini, J.] NYU, Dept Biochem & Mol Pharmacol, New York, NY USA; [Puccini, J.] NYU, Dept Med, 550 1St Ave, New York, NY 10016 USA; [White, M.; Thomas, P.] Univ Adelaide, Sch Biol Sci, SA Genome Editing Facil, Adelaide, SA, Australia; [White, M.; Thomas, P.] Univ Adelaide, Robinson Res Inst, Adelaide, SA, Australia; [Bouchier-Hayes, L.] Baylor Coll Med, Dept Pediat Hematol, Houston, TX 77030 USA; [Green, D. R.] St Jude Childrens Res Hosp, Immunol Dept, 332 N Lauderdale St, Memphis, TN 38105 USA	Centre for Cancer Biology; University of South Australia; New York University; New York University; University of Adelaide; Robinson Research Institute; University of Adelaide; Baylor College of Medicine; St Jude Children's Research Hospital	Kumar, S (corresponding author), Univ South Australia, Ctr Canc Biol, Frome Rd, Adelaide, SA 5001, Australia.	sharad.kumar@unisa.edu.au	Kumar, Sharad/AAX-7787-2020; Bouchier-Hayes, Lisa/T-9491-2019; Dorstyn, Loretta/F-3673-2013; Green, Douglas R/N-8083-2018; Dawar, Swati/AAX-1062-2021	Kumar, Sharad/0000-0001-7126-9814; Bouchier-Hayes, Lisa/0000-0003-3886-5977; Dorstyn, Loretta/0000-0001-9886-0989; Green, Douglas R/0000-0002-7332-1417; Lim, Yoon/0000-0003-1110-1969	National Health and Medical Research Council [1043057]; UniSA Presidential Award;  [1103006]	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); UniSA Presidential Award; 	We thank staff at the SA Pathology animal resource facility for help in maintaining the mouse strains and members of our laboratory for discussions and useful comments. Funding for this work was provided by the National Health and Medical Research Council project grant (1043057) and a Senior Principal Research Fellowship (1103006) to Sharad Kumar. Loretta Dorstyn was a Cancer Council Research Fellow and Swati Dawar is supported by a UniSA Presidential Award.	Andersen JL, 2009, EMBO J, V28, P3216, DOI 10.1038/emboj.2009.253; Baliga BC, 2004, CELL DEATH DIFFER, V11, P1234, DOI 10.1038/sj.cdd.4401492; Belkhiri A, 2012, CLIN CANCER RES, V18, P3889, DOI 10.1158/1078-0432.CCR-11-3182; Bouchier-Hayes L, 2009, MOL CELL, V35, P830, DOI 10.1016/j.molcel.2009.07.023; Brito DA, 2006, CURR BIOL, V16, P1194, DOI 10.1016/j.cub.2006.04.043; Castedo M, 2004, ONCOGENE, V23, P4362, DOI 10.1038/sj.onc.1207572; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Choi M, 2015, CANCER LETT, V357, P591, DOI 10.1016/j.canlet.2014.12.023; Cimini D, 2001, J CELL BIOL, V153, P517, DOI 10.1083/jcb.153.3.517; Decordier I, 2002, MUTAGENESIS, V17, P337, DOI 10.1093/mutage/17.4.337; Decordier I, 2008, MUTAT RES-GEN TOX EN, V651, P30, DOI 10.1016/j.mrgentox.2007.10.016; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; Dorstyn L, 2012, CELL DEATH DIFFER, V19, P1288, DOI 10.1038/cdd.2012.36; Dorstyn L, 2014, METHODS MOL BIOL, V1133, P71, DOI 10.1007/978-1-4939-0357-3_4; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Geigl JB, 2008, TRENDS GENET, V24, P64, DOI 10.1016/j.tig.2007.11.006; Giam M, 2015, CELL DIV, V10, DOI 10.1186/s13008-015-0009-7; Gordon DJ, 2012, NAT REV GENET, V13, P189, DOI 10.1038/nrg3123; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Ho LH, 2008, ONCOGENE, V27, P3393, DOI 10.1038/sj.onc.1211005; Ho LH, 2009, P NATL ACAD SCI USA, V106, P5336, DOI 10.1073/pnas.0811928106; Holland AJ, 2009, NAT REV MOL CELL BIO, V10, P478, DOI 10.1038/nrm2718; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; Kaufmann T, 2007, CELL, V129, P423, DOI 10.1016/j.cell.2007.03.017; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; Kumar S, 2009, NAT REV CANCER, V9, P897, DOI 10.1038/nrc2745; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Li M, 2009, CELL CYCLE, V8, P3440, DOI 10.4161/cc.8.21.9688; Lu B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012963; Manzl C, 2012, CELL DEATH DIFFER, V19, P1722, DOI 10.1038/cdd.2012.54; Mendelsohn AR, 2002, P NATL ACAD SCI USA, V99, P6871, DOI 10.1073/pnas.072290599; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Miki H, 2005, TRENDS CELL BIOL, V15, P467, DOI 10.1016/j.tcb.2005.07.006; O'Reilly LA, 2002, CELL DEATH DIFFER, V9, P832, DOI 10.1038/sj.cdd.4401033; Palmisiano ND, 2015, AM J HEMATOL, V90, P1071, DOI 10.1002/ajh.24177; Parsons MJ, 2013, CELL DEATH DIFFER, V20, P1174, DOI 10.1038/cdd.2013.38; Parsons MJ., 2015, COLD SPRING HARB PRO, V2015; Peterson SE, 2012, J NEUROSCI, V32, P16213, DOI 10.1523/JNEUROSCI.3706-12.2012; Puccini J, 2013, CELL DEATH DIFFER, V20, P1133, DOI 10.1038/cdd.2013.87; Puccini J, 2013, P NATL ACAD SCI USA, V110, P19920, DOI 10.1073/pnas.1311947110; Ren KQ, 2012, J BIOL CHEM, V287, P14792, DOI 10.1074/jbc.M112.347625; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Shalini S, 2016, CELL DEATH DIFFER, V23, P1727, DOI 10.1038/cdd.2016.81; Shalini S, 2015, CELL DEATH DIFFER, V22, P526, DOI 10.1038/cdd.2014.216; Shalini S, 2012, CELL DEATH DIFFER, V19, P1370, DOI 10.1038/cdd.2012.13; Taghiyev Agshin F, 2011, Genes Cancer, V2, P745, DOI 10.1177/1947601911426007; Terry MR, 2015, CELL DEATH DIFFER, V22, P719, DOI 10.1038/cdd.2014.159; Vitale I, 2011, NAT REV MOL CELL BIO, V12, P384, DOI 10.1038/nrm3115; Wasch R, 2010, RECENT RESULTS CANC, V184, P215, DOI 10.1007/978-3-642-01222-8_15; Wang Q, 2002, MOL CELL BIOL, V22, P3450, DOI 10.1128/MCB.22.10.3450-3459.2002; Yoo BH, 2011, J BIOL CHEM, V286, P38894, DOI 10.1074/jbc.M111.290692; Zhang YP, 2007, MECH AGEING DEV, V128, P213, DOI 10.1016/j.mad.2006.11.030	54	42	42	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 11	2017	36	19					2704	2714		10.1038/onc.2016.423	http://dx.doi.org/10.1038/onc.2016.423			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EU6CF	27991927	Green Published, hybrid, Green Accepted			2022-12-17	WOS:000401120900008
J	Matsuura, K; Huang, NJ; Cocce, K; Zhang, L; Kornbluth, S				Matsuura, K.; Huang, N-J; Cocce, K.; Zhang, L.; Kornbluth, S.			Downregulation of the proapoptotic protein MOAP-1 by the UBR5 ubiquitin ligase and its role in ovarian cancer resistance to cisplatin	ONCOGENE			English	Article							DNA-DAMAGE RESPONSE; E3 LIGASE; SUBSTRATE RECOGNITION; KINASE DYRK2; BAX; EDD; DEGRADATION; APOPTOSIS; RECEPTOR; TRIM39	Evasion of apoptosis allows many cancers to resist chemotherapy. Apoptosis is mediated by the serial activation of caspase family proteins. These proteases are often activated upon the release of cytochrome c from the mitochondria, which is promoted by the proapoptotic Bcl-2 family protein, Bax. This function of Bax is enhanced by the MOAP-1 (modulator of apoptosis protein 1) protein in response to DNA damage. Previously, we reported that MOAP-1 is targeted for ubiquitylation and degradation by the APC/CCdh1 ubiquitin ligase. In this study, we identify the HECT (homologous to the E6-AP carboxyl terminus) family E3 ubiquitin ligase, UBR5, as a novel ubiquitin ligase for MOAP-1. We demonstrate that UBR5 interacts physically with MOAP-1, ubiquitylates MOAP-1 in vitro and inhibits MOAP-1 stability in cultured cells. In addition, we show that Dyrk2 kinase, a reported UBR5 interactor, cooperates with UBR5 in mediating MOAP-1 ubiquitylation. Importantly, we found that cisplatin-resistant ovarian cancer cell lines exhibit lower levels of MOAP-1 accumulation than their sensitive counterparts upon cisplatin treatment, consistent with the previously reported role of MOAP-1 in modulating cisplatin-induced apoptosis. Accordingly, UBR5 knockdown increased MOAP-1 expression, enhanced Bax activation and sensitized otherwise resistant cells to cisplatin-induced apoptosis. Furthermore, UBR5 expression was higher in ovarian cancers from cisplatin-resistant patients than from cisplatin-responsive patients. These results show that UBR5 downregulates proapoptotic MOAP-1 and suggest that UBR5 can confer cisplatin resistance in ovarian cancer. Thus UBR5 may be an attractive therapeutic target for ovarian cancer treatment.	[Matsuura, K.; Huang, N-J; Cocce, K.; Zhang, L.; Kornbluth, S.] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, 220 Allen Bldg,Box 90005, Durham, NC 27710 USA; [Huang, N-J] Nine Cambridge Ctr, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	Duke University; Massachusetts Institute of Technology (MIT); Whitehead Institute	Huang, NJ; Zhang, L; Kornbluth, S (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, 220 Allen Bldg,Box 90005, Durham, NC 27710 USA.	njhuang@wi.mit.edu; liguo.zhang@duke.edu; sally.kornbluth@duke.edu		Matsuura, Kenkyo/0000-0003-4612-6031	NIH [CA102707]; NRSA [5F30CA183395-03]; NATIONAL CANCER INSTITUTE [F30CA183395, R01CA102707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM080333, T32GM007171] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NRSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Ethan Whitaker, Regina Whitaker and Susan Murphy (Duke University) for ovarian cancer cell lines, human ovarian cancer patient samples and technical help with staining and imaging; Meredith Turner and Will Thompson (Proteomics and Metabolomics Core Facility at Duke University) for mass spectrometric analysis; Subbareddy Maddika (The Centre for DNA Fingerprinting and Diagnostics) for UBR5, VprBP, DDB1 and Dyrk2 constructs. We also thank Denise Ribar for excellent technical assistance. We also appreciate the members of the Kornbluth laboratory for valuable discussion. This work was supported by NIH CA102707 to SK and NRSA 5F30CA183395-03 to KC.	Baksh S, 2005, MOL CELL, V18, P637, DOI 10.1016/j.molcel.2005.05.010; Barnett JC, 2010, GYNECOL ONCOL, V116, P556, DOI 10.1016/j.ygyno.2009.11.020; Bradley A, 2014, CARCINOGENESIS, V35, P1100, DOI 10.1093/carcin/bgt489; Choo Yeun Su, 2009, J Vis Exp, DOI 10.3791/1293; Clancy JL, 2003, ONCOGENE, V22, P5070, DOI 10.1038/sj.onc.1206775; Cojocaru M, 2011, J BIOL CHEM, V286, P5012, DOI 10.1074/jbc.M110.176628; Fernald K, 2013, TRENDS CELL BIOL, V23, P620, DOI 10.1016/j.tcb.2013.07.006; Fu NY, 2007, P NATL ACAD SCI USA, V104, P10051, DOI 10.1073/pnas.0700007104; Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384; Garcia-Higuera I, 2008, NAT CELL BIOL, V10, P802, DOI 10.1038/ncb1742; Gudjonsson T, 2012, CELL, V150, P697, DOI 10.1016/j.cell.2012.06.039; Gwack Y, 2006, NATURE, V441, P646, DOI 10.1038/nature04631; Henderson MJ, 2002, J BIOL CHEM, V277, P26468, DOI 10.1074/jbc.M203527200; Honda Y, 2002, J BIOL CHEM, V277, P3599, DOI 10.1074/jbc.M104347200; Huang NJ, 2012, J CELL BIOL, V197, P361, DOI [10.1083/jcb.201111141, 10.1083/jcb.201108062]; Jiang WQ, 2011, MOL CELL, V43, P33, DOI 10.1016/j.molcel.2011.04.028; Jung HY, 2013, J BIOL CHEM, V288, P7252, DOI 10.1074/jbc.M112.416792; Law J, 2015, J BIOL CHEM, V290, P24100, DOI 10.1074/jbc.M115.648345; Law Jennifer, 2012, Mol Biol Int, V2012, P536802, DOI 10.1155/2012/536802; Lee JT, 2010, CELL DEATH DIFFER, V17, P86, DOI 10.1038/cdd.2009.77; Lee SS, 2009, EXP CELL RES, V315, P1313, DOI 10.1016/j.yexcr.2008.11.021; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Ling SY, 2011, J BIOL CHEM, V286, P14972, DOI 10.1074/jbc.M110.182527; Maddika S, 2009, NAT CELL BIOL, V11, P409, DOI 10.1038/ncb1848; Meissner B, 2013, BLOOD, V121, P3161, DOI 10.1182/blood-2013-01-478834; Munoz MA, 2007, CELL CYCLE, V6, P3070, DOI 10.4161/cc.6.24.5021; Nakagawa T, 2013, BMC MOL BIOL, V14, DOI 10.1186/1471-2199-14-22; O'Brien PM, 2008, BRIT J CANCER, V98, P1085, DOI 10.1038/sj.bjc.6604281; Ong SS, 2014, BIOCHEM J, V459, P193, DOI 10.1042/BJ20130558; Rutz S, 2015, NATURE, V518, P417, DOI 10.1038/nature13979; Sriram SM, 2011, NAT REV MOL CELL BIO, V12, P735, DOI 10.1038/nrm3217; Tan KO, 2005, P NATL ACAD SCI USA, V102, P14623, DOI 10.1073/pnas.0503524102; Tan KO, 2001, J BIOL CHEM, V276, P2802, DOI 10.1074/jbc.M008955200; Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312; Zhang LG, 2012, P NATL ACAD SCI USA, V109, P20931, DOI 10.1073/pnas.1212047110	35	42	44	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	12					1698	1706		10.1038/onc.2016.336	http://dx.doi.org/10.1038/onc.2016.336			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP6AP	27721409	Green Published, hybrid			2022-12-17	WOS:000397460600009
J	Elf, S; Lin, R; Xia, S; Pan, Y; Shan, C; Wu, S; Lonial, S; Gaddh, M; Arellano, ML; Khoury, HJ; Khuri, FR; Lee, BH; Boggon, TJ; Fan, J; Chen, J				Elf, S.; Lin, R.; Xia, S.; Pan, Y.; Shan, C.; Wu, S.; Lonial, S.; Gaddh, M.; Arellano, M. L.; Khoury, H. J.; Khuri, F. R.; Lee, B. H.; Boggon, T. J.; Fan, J.; Chen, J.			Targeting 6-phosphogluconate dehydrogenase in the oxidative PPP sensitizes leukemia cells to antimalarial agent dihydroartemisinin	ONCOGENE			English	Article							PROTEIN-KINASE; CANCER CELLS; DEFICIENCY; AMPK; ATTACHMENT; FAMILY	The oxidative pentose phosphate pathway (PPP) is crucial for cancer cell metabolism and tumor growth. We recently reported that targeting a key oxidative PPP enzyme, 6-phosphogluconate dehydrogenase (6PGD), using our novel small-molecule 6PGD inhibitors Physcion and its derivative 53, shows anticancer effects. Notably, humans with genetic deficiency of either 6PGD or another oxidative PPP enzyme, glucose-6-phosphate dehydrogenase, exhibit non-immune hemolytic anemia upon exposure to aspirin and various antimalarial drugs. Inspired by these clinical observations, we examined the anticancer potential of combined treatment with 6PGD inhibitors and antimalarial drugs. We found that stable knockdown of 6PGD sensitizes leukemia cells to antimalarial agent dihydroartemisinin (DHA). Combined treatment with DHA and Physcion activates AMP-activated protein kinase, leading to synergistic inhibition of human leukemia cell viability. Moreover, our combined therapy synergistically attenuates tumor growth in xenograft nude mice injected with human K562 leukemia cells and cell viability of primary leukemia cells from human patients, but shows minimal toxicity to normal hematopoietic cells in mice as well as red blood cells and mononucleocytes from healthy human donors. Our findings reveal the potential for combined therapy using optimized doses of Physcion and DHA as a novel antileukemia treatment without inducing hemolysis.	[Elf, S.; Lin, R.; Xia, S.; Pan, Y.; Shan, C.; Lonial, S.; Gaddh, M.; Arellano, M. L.; Khoury, H. J.; Khuri, F. R.; Fan, J.; Chen, J.] Emory Univ, Sch Med, Winship Canc Inst Emory, Dept Hematol & Med Oncol, 1365-C Clifton Rd NE C3002, Atlanta, GA 30322 USA; [Wu, S.] Emory Univ, Sch Med, Dept Chem, Atlanta, GA 30322 USA; [Lee, B. H.] Novartis Inst BioMed Res, Cambridge, MA USA; [Boggon, T. J.] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA	Emory University; Emory University; Novartis; Yale University	Chen, J (corresponding author), Emory Univ, Sch Med, Winship Canc Inst Emory, Dept Hematol & Med Oncol, 1365-C Clifton Rd NE C3002, Atlanta, GA 30322 USA.	jchen@emory.edu	Khuri, Fadlo R./AAU-4942-2020; Xia, Siyuan/AAM-9606-2020	Khuri, Fadlo R./0000-0002-8638-7618; Xia, Siyuan/0000-0001-6756-3519	NIH [CA140515, CA183594, CA174786]; Pharmacological Sciences Training Grant [T32 GM008602]; DoD [W81XWH-12-1-0217]; NATIONAL CANCER INSTITUTE [R01CA120272, R01CA140515, R01CA174786, R01CA183594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008602] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pharmacological Sciences Training Grant; DoD(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the Hematology Division Tissue Bank, Winship Cancer Institute of Emory for providing primary tissue samples from leukemia patients. This work was supported in part by NIH grants CA140515, CA183594, CA174786 (to JC), the Pharmacological Sciences Training Grant T32 GM008602 (to SE), DoD grant W81XWH-12-1-0217 (to JC). SE is an NIH pre-doctoral fellow and an ARCS Foundation Scholar. JC is WCI 5K Scholar, Georgia Cancer Coalition Distinguished Scholar, American Cancer Society Basic Research Scholar and Scholar of the Leukemia and Lymphoma Society.	BEUTLER E, 1994, BLOOD, V84, P3613, DOI 10.1182/blood.V84.11.3613.bloodjournal84113613; Caprari P, 2001, ANN HEMATOL, V80, P41, DOI 10.1007/s002770000233; Chakrabarti KR, 2015, ONCOTARGET, V6, P36292, DOI 10.18632/oncotarget.5345; Choudhury Yashmin, 2014, Oncoscience, V1, P446; Corrons JLV, 1996, AM J HEMATOL, V53, P221; Di JM, 2010, MOL BIOL REP, V37, P1849, DOI 10.1007/s11033-009-9620-5; Din FVN, 2012, GASTROENTEROLOGY, V142, P1504, DOI 10.1053/j.gastro.2012.02.050; Fogarty S, 2010, BBA-PROTEINS PROTEOM, V1804, P581, DOI 10.1016/j.bbapap.2009.09.012; HA J, 1994, J BIOL CHEM, V269, P22162; Hadad S, 2008, 2008 ASCO BREAST CAN; Hadad SM, 2014, CLIN TRANSL ONCOL, V16, P746, DOI 10.1007/s12094-013-1144-8; Lin RT, 2015, NAT CELL BIOL, V17, P1484, DOI 10.1038/ncb3255; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Spears LD, 2010, FASEB J S, V24, pIb674; Wang SJ, 2011, CANCER CHEMOTH PHARM, V68, P1421, DOI 10.1007/s00280-011-1643-7	15	42	43	3	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2017	36	2					254	262		10.1038/onc.2016.196	http://dx.doi.org/10.1038/onc.2016.196			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK5AA	27270429	Green Accepted			2022-12-17	WOS:000393938100010
J	Yuan, S; Yu, Z; Liu, Q; Zhang, M; Xiang, Y; Wu, N; Wu, L; Hu, Z; Xu, B; Cai, T; Ma, X; Zhang, Y; Liao, C; Wang, L; Yang, P; Bai, L; Li, Y				Yuan, S.; Yu, Z.; Liu, Q.; Zhang, M.; Xiang, Y.; Wu, N.; Wu, L.; Hu, Z.; Xu, B.; Cai, T.; Ma, X.; Zhang, Y.; Liao, C.; Wang, L.; Yang, P.; Bai, L.; Li, Y.			GPC5, a novel epigenetically silenced tumor suppressor, inhibits tumor growth by suppressing Wnt/beta-catenin signaling in lung adenocarcinoma	ONCOGENE			English	Article							HEPARAN-SULFATE; CANCER; WNT; GENE; GLYPICAN-5; PATHWAY; EPIDEMIOLOGY; ENDOCYTOSIS; EXPRESSION; TARGET	Glypican-5 (GPC5) is a member of the heparin sulfate proteoglycans. Previous studies of GPC5 in lung tumorigenesis showed conflicting results. In this study, we confirmed that GPC5 was downregulated in lung adenocarcinoma tissues compared with adjacent normal lung tissues. The low expression of GPC5 was significantly associated with poor outcome in lung adenocarcinoma. To understand the biological mechanism of the downregulation, we examined the promoter methylation status of GPC5 gene. We found that GPC5 was significantly hypermethylated in lung cancer tissues and lung cancer cell lines compared with normal lung tissues. The methylation level of GPC5 was negatively correlated with its transcriptional expression. De-methylation experiments further confirmed that the loss of GPC5 expression was regulated by its hypermethylation. Overexpression of GPC5 inhibited proliferation, migration and invasion of lung cancer cells in vitro, and repressed tumor growth in vivo, whereas knockdown of GPC5 was able to reverse the effect. Furthermore, we demonstrated that GPC5 could suppress the Wnt/beta-catenin signaling by binding to Wnt3a at the cell surface, which mediated its function as a tumor suppressor. Overall, these findings demonstrate that GPC5 is a novel epigenetically silenced tumor suppressor, which inhibits tumor growth by suppressing Wnt/beta-catenin signaling in lung adenocarcinoma. Our findings substantially expand our understanding about the role and the molecular mechanism of GPC5 in tumorigenesis of lung cancer.	[Yuan, S.; Liu, Q.; Zhang, M.; Xiang, Y.; Wu, N.; Wu, L.; Hu, Z.; Xu, B.; Cai, T.; Ma, X.; Zhang, Y.; Li, Y.] Third Mil Med Univ, Coll Prevent Med, Dept Epidemiol, 30 Gaotanyan St, Chongqing 400038, Peoples R China; [Yu, Z.] Third Mil Med Univ, Xinqiao Hosp, Dept Thorac Surg, Chongqing, Peoples R China; [Liao, C.; Bai, L.] Third Mil Med Univ, Xinqiao Hosp, Dept Resp Dis, Chongqing, Peoples R China; [Wang, L.] Med Coll Wisconsin, Dept Pathol, MCW Canc Ctr, Milwaukee, WI 53226 USA; [Yang, P.] Mayo Clin, Coll Med, Hlth Sci Res, Rochester, MN USA	Army Medical University; Army Medical University; Army Medical University; Medical College of Wisconsin; Mayo Clinic	Li, Y (corresponding author), Third Mil Med Univ, Coll Prevent Med, Dept Epidemiol, 30 Gaotanyan St, Chongqing 400038, Peoples R China.	liyafei2008@hotmail.com	翔宇, 马/ABH-3164-2021; Cai, Tong-Jian/AAX-6338-2021	翔宇, 马/0000-0001-7967-3950; Cai, Tong-Jian/0000-0003-3188-6265; Liu, Qingyun/0000-0002-6315-6796	National Natural Science Foundation of China [81171903, 81472190, 81370139]; Chongqing Natural Science Foundation of China [cstc2015jcyjBX0110]; Discipline Construction and Development Foundation from Xinqiao Hospital, Third Military Medical University; Foundation for Clinical Research from Xinqiao Hospital, Third Military Medical University [2014YLC13]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chongqing Natural Science Foundation of China; Discipline Construction and Development Foundation from Xinqiao Hospital, Third Military Medical University; Foundation for Clinical Research from Xinqiao Hospital, Third Military Medical University	This work was supported by the National Natural Science Foundation of China (no. 81171903 and no. 81472190 to Y Li; no. 81370139 to L Bai), the Chongqing Natural Science Foundation of China (no. cstc2015jcyjBX0110 to Y Li), the Discipline Construction and Development Foundation from Xinqiao Hospital, Third Military Medical University (to L Bai), and Foundation for Clinical Research from Xinqiao Hospital, Third Military Medical University (no. 2014YLC13 to L Bai).	Avanesov A, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002503; Blitzer JT, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-28; Bourhis E, 2010, J BIOL CHEM, V285, P9172, DOI 10.1074/jbc.M109.092130; Capurro M, 2014, J CELL SCI, V127, P1565, DOI 10.1242/jcs.140871; Capurro MI, 2008, DEV CELL, V14, P700, DOI 10.1016/j.devcel.2008.03.006; Capurro MI, 2005, CANCER RES, V65, P6245, DOI 10.1158/0008-5472.CAN-04-4244; Christianson HC, 2014, MATRIX BIOL, V35, P51, DOI 10.1016/j.matbio.2013.10.004; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Cline MS, 2013, SCI REP-UK, V3, DOI 10.1038/srep02652; De Cat B, 2001, SEMIN CELL DEV BIOL, V12, P117, DOI 10.1006/scdb.2000.0240; Dela Cruz CS, 2011, CLIN CHEST MED, V32, P605, DOI 10.1016/j.ccm.2011.09.001; Filmus J, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-5-224; Filmus J, 2014, MATRIX BIOL, V35, P248, DOI 10.1016/j.matbio.2013.12.007; Grumolato L, 2010, GENE DEV, V24, P2517, DOI 10.1101/gad.1957710; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Han F, 2015, ONCOGENE, V34, P4391, DOI 10.1038/onc.2014.370; Hong SW, 2014, NUCLEIC ACID THER, V24, P192, DOI 10.1089/nat.2013.0466; Hu XY, 2004, NUCLEIC ACIDS RES, V32, P4609, DOI 10.1093/nar/gkh790; Janda CY, 2012, SCIENCE, V337, P59, DOI 10.1126/science.1222879; Knelson EH, 2014, TRENDS BIOCHEM SCI, V39, P277, DOI 10.1016/j.tibs.2014.03.001; Kumar S, 2014, BMC BIOL, V12, DOI 10.1186/1741-7007-12-44; Labidi-Galy SI, 2015, ONCOGENE, V34, P299, DOI 10.1038/onc.2013.562; Li FC, 2011, J CELL BIOL, V192, P691, DOI 10.1083/jcb.201008087; Li YF, 2011, J THORAC ONCOL, V6, P2, DOI 10.1097/JTO.0b013e3181fd6b04; Li YF, 2010, LANCET ONCOL, V11, P321, DOI 10.1016/S1470-2045(10)70042-5; Li Y, 2013, ONCOL LETT, V6, P1565, DOI 10.3892/ol.2013.1622; Liu DF, 2002, P NATL ACAD SCI USA, V99, P568, DOI 10.1073/pnas.012578299; Liu WB, 2012, BIOCHEM BIOPH RES CO, V429, P180, DOI 10.1016/j.bbrc.2012.10.116; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu L, 2007, CANCER RES, V67, P10117, DOI 10.1158/0008-5472.CAN-07-2544; Lv J, 2015, J VIRAL HEPATITIS, V22, P201, DOI 10.1111/jvh.12265; Neri S, 2014, ANN SURG, V260, P383, DOI 10.1097/SLA.0000000000000617; Nishimura R, 2013, CANCER SCI, V104, P856, DOI 10.1111/cas.12173; Okolicsanyi RK, 2014, J CELL BIOCHEM, V115, P967, DOI 10.1002/jcb.24746; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Song HH, 2002, BBA-GEN SUBJECTS, V1573, P241, DOI 10.1016/S0304-4165(02)00390-2; Stewart DJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt356; Teo JL, 2010, ADV DRUG DELIVER REV, V62, P1149, DOI 10.1016/j.addr.2010.09.012; Veugelers M, 1997, GENOMICS, V40, P24, DOI 10.1006/geno.1996.4518; Wanders R, 2011, EUR J CANCER, V47, P2691, DOI 10.1016/j.ejca.2011.06.023; Wang HQ, 2012, BIOCHEM BIOPH RES CO, V417, P62, DOI 10.1016/j.bbrc.2011.11.055; Williamson D, 2007, CANCER RES, V67, P57, DOI 10.1158/0008-5472.CAN-06-1650; Xi YM, 2014, CANCER LETT, V353, P8, DOI 10.1016/j.canlet.2014.07.010; Yang X, 2013, CANCER LETT, V341, P265, DOI 10.1016/j.canlet.2013.08.020; Zhang CW, 2011, MOL GENET METAB, V103, P104, DOI 10.1016/j.ymgme.2011.02.005; Zhang JJ, 2015, J THORAC ONCOL, V10, P682, DOI 10.1097/JTO.0000000000000456	46	42	42	2	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2016	35	47					6120	6131		10.1038/onc.2016.149	http://dx.doi.org/10.1038/onc.2016.149			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CE	27157618				2022-12-17	WOS:000388509800008
J	Liu, PP; Liu, J; Jiang, WQ; Carew, JS; Ogasawara, MA; Pelicano, H; Croce, CM; Estrov, Z; Xu, RH; Keating, MJ; Huang, P				Liu, P-P; Liu, J.; Jiang, W-Q; Carew, J. S.; Ogasawara, M. A.; Pelicano, H.; Croce, C. M.; Estrov, Z.; Xu, R-H; Keating, M. J.; Huang, P.			Elimination of chronic lymphocytic leukemia cells in stromal microenvironment by targeting CPT with an antiangina drug perhexiline	ONCOGENE			English	Article							LIPOPROTEIN-LIPASE EXPRESSION; PROGNOSTIC-FACTOR; CLL CELLS; SURVIVAL; METABOLISM; ENERGY; APOPTOSIS; GENES; MITOCHONDRIA; CARDIOLIPIN	Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the western countries and is currently incurable due, in part, to difficulty in eliminating the leukemia cells protected by stromal microenvironment. Based on previous observations that CLL cells exhibit mitochondrial dysfunction and altered lipid metabolism and that carnitine palmitoyltransferases (CPT) have a major role in transporting fatty acid into mitochondria to support cancer cell metabolism, we tested several clinically relevant inhibitors of lipid metabolism for their ability to eliminate primary CLL cells. We discovered that perhexiline, an antiangina agent that inhibits CPT, was highly effective in killing CLL cells in stromal microenvironment at clinically achievable concentrations. These effective concentrations caused low toxicity to normal lymphocytes and normal stromal cells. Mechanistic study revealed that CLL cells expressed high levels of CPT1 and CPT2. Suppression of fatty acid transport into mitochondria by inhibiting CPT using perhexiline resulted in a depletion of cardiolipin, a key component of mitochondrial membranes, and compromised mitochondrial integrity, leading to rapid depolarization and massive CLL cell death. The therapeutic activity of perhexiline was further demonstrated in vivo using a CLL transgenic mouse model. Perhexiline significantly prolonged the overall animal survival by only four drug injections. Our study suggests that targeting CPT using an antiangina drug is able to effectively eliminate leukemia cells in vivo, and is a novel therapeutic strategy for potential clinical treatment of CLL.	[Liu, P-P; Jiang, W-Q; Xu, R-H; Huang, P.] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China; [Liu, P-P; Liu, J.; Ogasawara, M. A.; Pelicano, H.; Huang, P.] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, 2130 West Holcombe Blvd, Houston, TX 77030 USA; [Carew, J. S.] Cleveland Clin, Taussig Canc Inst, Dept Translat Hematol & Oncol Res, Cleveland, OH 44106 USA; [Croce, C. M.] Ohio State Univ, Med Ctr, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; [Estrov, Z.; Keating, M. J.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA	State Key Lab Oncology South China; Sun Yat Sen University; University of Texas System; UTMD Anderson Cancer Center; Cleveland Clinic Foundation; University System of Ohio; Ohio State University; University of Texas System; UTMD Anderson Cancer Center	Huang, P (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, 2130 West Holcombe Blvd, Houston, TX 77030 USA.	phuang@mdanderson.org	jiang, wen/GYI-9662-2022; Young, Richard A/F-6495-2012; Xu, Rui-Hua/AAW-4766-2021	Young, Richard A/0000-0001-8855-8647; Xu, Rui-Hua/0000-0001-9771-8534; Liu, Jinyun/0000-0002-4763-2684	Natural Science Foundation of China [81430060]; National Institutes of Health [CA085563, CA172724]; CLL Global Research Foundation; NATIONAL CANCER INSTITUTE [P01CA081534, R01CA085563, R35CA197706, R01CA172724] Funding Source: NIH RePORTER	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CLL Global Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank BA Hayes and R LaPushin for their assistance in handling CLL samples. This work was supported, in part, by a grant from Natural Science Foundation of China ( No. 81430060), Grants CA085563 and CA172724 from the National Institutes of Health, and a grant for the CLL Global Research Foundation.	Abreu C, 2013, LEUKEMIA LYMPHOMA, V54, P1844, DOI 10.3109/10428194.2013.796057; Bilban M, 2006, LEUKEMIA, V20, P1080, DOI 10.1038/sj.leu.2404220; Bui T, 2006, CANCER CELL, V9, P419, DOI 10.1016/j.ccr.2006.05.012; Byrd JC, 2013, NEW ENGL J MED, V369, P32, DOI 10.1056/NEJMoa1215637; Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101; Carew JS, 2004, LEUKEMIA, V18, P1934, DOI 10.1038/sj.leu.2403545; Carew JS, 2003, LEUKEMIA, V17, P1437, DOI 10.1038/sj.leu.2403043; Chiorazzi N, 2005, NEW ENGL J MED, V352, P804, DOI 10.1056/NEJMra041720; Currie E, 2013, CELL METAB, V18, P153, DOI 10.1016/j.cmet.2013.05.017; DeFilippis RA, 2012, CANCER DISCOV, V2, P826, DOI 10.1158/2159-8290.CD-12-0107; Garber K, 2006, SCIENCE, V312, P1158, DOI 10.1126/science.312.5777.1158; Garber K, 2004, J NATL CANCER I, V96, P1805, DOI 10.1093/jnci/96.24.1805; Grdisa M, 2003, LEUKEMIA RES, V27, P951, DOI 10.1016/S0145-2126(03)00028-6; Hallek M, 2008, BLOOD, V111, P5446, DOI 10.1182/blood-2007-06-093906; Hegde GV, 2008, MOL CANCER RES, V6, P1928, DOI 10.1158/1541-7786.MCR-08-0142; Heintel D, 2005, LEUKEMIA, V19, P1216, DOI 10.1038/sj.leu.2403748; Huang P, 2000, LEUKEMIA, V14, P1405, DOI 10.1038/sj.leu.2401845; Kaderi MA, 2011, HAEMATOL-HEMATOL J, V96, P1153, DOI 10.3324/haematol.2010.039396; Lagneaux L, 1998, BLOOD, V91, P2387, DOI 10.1182/blood.V91.7.2387.2387_2387_2396; Liu J, 2014, LEUKEMIA, V28, P118, DOI 10.1038/leu.2013.125; Lupu R, 2006, CURR PHARM BIOTECHNO, V7, P483, DOI 10.2174/138920106779116928; Moreno P, 2013, LEUKEMIA, V27, P721, DOI 10.1038/leu.2012.212; NAKAHARA I, 1992, J NEUROSURG, V76, P244, DOI 10.3171/jns.1992.76.2.0244; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Nikitin EA, 2007, LEUKEMIA LYMPHOMA, V48, P912, DOI 10.1080/10428190701245112; Nomura K, 2000, BIOCHEM J, V351, P183, DOI 10.1042/0264-6021:3510183; Nuckel H, 2006, LEUKEMIA LYMPHOMA, V47, P1053, DOI 10.1080/10428190500464161; OKAYASU T, 1985, ARCH BIOCHEM BIOPHYS, V236, P638, DOI 10.1016/0003-9861(85)90668-X; Olivecrona T, 1997, P NUTR SOC, V56, P723, DOI 10.1079/PNS19970072; Oltra AM, 2001, FREE RADICAL BIO MED, V30, P1286, DOI 10.1016/S0891-5849(01)00521-4; Oppezzo P, 2005, BLOOD, V106, P650, DOI 10.1182/blood-2004-08-3344; Pallasch CP, 2008, LEUKEMIA, V22, P585, DOI 10.1038/sj.leu.2405058; Pandey PR, 2012, RECENT PAT ANTI-CANC, V7, P185; Pedersen IM, 2004, LEUKEMIA LYMPHOMA, V45, P2365, DOI 10.1080/10428190412331272703; Ponader S, 2012, BLOOD, V119, P1182, DOI 10.1182/blood-2011-10-386417; Porpaczy E, 2013, LEUKEMIA RES, V37, P631, DOI 10.1016/j.leukres.2013.02.008; Preiss-Landl K, 2002, CURR OPIN LIPIDOL, V13, P471, DOI 10.1097/00041433-200210000-00002; Roberts AW, 2012, J CLIN ONCOL, V30, P488, DOI 10.1200/JCO.2011.34.7898; Ros S, 2012, CANCER DISCOV, V2, P328, DOI 10.1158/2159-8290.CD-11-0234; Shaw RJ, 2006, CURR OPIN CELL BIOL, V18, P598, DOI 10.1016/j.ceb.2006.10.005; SINGLAS E, 1978, EUR J CLIN PHARMACOL, V14, P195, DOI 10.1007/BF02089960; Stamatopoulos B, 2012, HAEMATOL-HEMATOL J, V97, P608, DOI 10.3324/haematol.2011.052779; Taylor WA, 2002, BMC BIOCHEM, V3, DOI 10.1186/1472-2091-3-9; Trachootham D, 2008, BLOOD, V112, P1912, DOI 10.1182/blood-2008-04-149815; Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009; van't Veer MB, 2006, HAEMATOLOGICA, V91, P56; Vasconcelos Y, 2005, LEUKEMIA, V19, P2002, DOI 10.1038/sj.leu.2403865; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Woyach JA, 2012, LEUKEMIA, V26, P1442, DOI 10.1038/leu.2011.375; Zhang W, 2012, NAT CELL BIOL, V14, P276, DOI 10.1038/ncb2432; Zhou Y, 2003, BLOOD, V101, P4098, DOI 10.1182/blood-2002-08-2512	51	42	44	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2016	35	43					5663	5673		10.1038/onc.2016.103	http://dx.doi.org/10.1038/onc.2016.103			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XP	27065330	Green Accepted			2022-12-17	WOS:000386998300009
J	Fabris, L; Berton, S; Citron, F; D'Andrea, S; Segatto, I; Nicoloso, MS; Massarut, S; Armenia, J; Zafarana, G; Rossi, S; Ivan, C; Perin, T; Vaidya, JS; Avanzo, M; Roncadin, M; Schiappacassi, M; Bristow, RG; Calin, G; Baldassarre, G; Belletti, B				Fabris, L.; Berton, S.; Citron, F.; D'Andrea, S.; Segatto, I.; Nicoloso, M. S.; Massarut, S.; Armenia, J.; Zafarana, G.; Rossi, S.; Ivan, C.; Perin, T.; Vaidya, J. S.; Avanzo, M.; Roncadin, M.; Schiappacassi, M.; Bristow, R. G.; Calin, G.; Baldassarre, G.; Belletti, B.			Radiotherapy-induced miR-223 prevents relapse of breast cancer by targeting the EGF pathway	ONCOGENE			English	Article							GROWTH-FACTOR LEVELS; INTRAOPERATIVE RADIOTHERAPY; CELL-PROLIFERATION; ERBB RECEPTORS; RADIATION; SURGERY; MORPHOGENESIS; INHIBITION; SURVIVAL; INVASION	In breast cancer (BC) patients, local recurrences often arise in proximity of the surgical scar, suggesting that response to surgery may have a causative role. Radiotherapy (RT) after lumpectomy significantly reduces the risk of recurrence. We investigated the direct effects of surgery and of RT delivered intraoperatively (IORT), by collecting irradiated and non-irradiated breast tissues from BC patients, after tumor removal. These breast tissue specimens have been profiled for their microRNA (miR) expression, in search of differentially expressed miR among patients treated or not with IORT. Our results demonstrate that IORT elicits effects that go beyond the direct killing of residual tumor cells. IORT altered the wound response, inducing the expression of miR-223 in the peritumoral breast tissue. miR-223 downregulated the local expression of epidermal growth factor (EGF), leading to decreased activation of EGF receptor (EGFR) on target cells and, eventually, dampening a positive EGF-EGFR autocrine/paracrine stimulation loop induced by the post-surgical wound-healing response. Accordingly, both RT-induced miR-223 and peri-operative inhibition of EGFR efficiently prevented BC cell growth and reduced recurrence formation in mouse models of BC. Our study uncovers unknown effects of RT delivered on a wounded tissue and prompts to the use of anti-EGFR treatments, in a peri-operative treatment schedule, aimed to timely treat BC patients and restrain recurrence formation.	[Fabris, L.; Berton, S.; Citron, F.; D'Andrea, S.; Segatto, I.; Nicoloso, M. S.; Armenia, J.; Schiappacassi, M.; Baldassarre, G.; Belletti, B.] Natl Canc Inst, CRO Aviano, Dept Translat Res, Div Expt Oncol 2, Via Gallini 2, I-33081 Aviano, Italy; [Berton, S.; Zafarana, G.; Bristow, R. G.] Univ Toronto, Dept Radiat Oncol, Princess Margaret Canc Ctr, Toronto, ON, Canada; [Berton, S.; Zafarana, G.; Bristow, R. G.] Univ Toronto, Dept Med Biophys, Princess Margaret Canc Ctr, Toronto, ON, Canada; [Nicoloso, M. S.; Rossi, S.; Ivan, C.; Calin, G.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Massarut, S.] Natl Canc Inst, CRO Aviano, Dept Oncol & Surg, Breast Surg Unit, Aviano, Italy; [Perin, T.] Natl Canc Inst, CRO Aviano, Dept Translat Res, Pathol Unit, Aviano, Italy; [Vaidya, J. S.] UCL, Div Surg & Intervent Sci, London, England; [Avanzo, M.] Natl Canc Inst, CRO Aviano, Dept Radiotherapy & Oncol, Med Phys Unit, Aviano, Italy; [Roncadin, M.] Natl Canc Inst, CRO Aviano, Dept Radiotherapy & Oncol, Radiotherapy Unit, Aviano, Italy; [Rossi, S.] Swiss Inst Bioinformat, Batiment Genopode, CH-1015 Lausanne, Switzerland	IRCCS Aviano (CRO); University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Texas System; UTMD Anderson Cancer Center; IRCCS Aviano (CRO); IRCCS Aviano (CRO); University of London; University College London; IRCCS Aviano (CRO); IRCCS Aviano (CRO); Swiss Institute of Bioinformatics	Baldassarre, G; Belletti, B (corresponding author), Natl Canc Inst, CRO Aviano, Dept Translat Res, Div Expt Oncol 2, Via Gallini 2, I-33081 Aviano, Italy.	gbaldassarre@cro.it; bbelletti@cro.it	Vaidya, Jayant S/A-7218-2008; Belletti, Barbara/J-2028-2018; Baldassarre, Gustavo/K-1350-2016; Segatto, Ilenia/AAX-5513-2020; Massarut, Samuele/J-2995-2018; D'Andrea, Sara/AAC-2148-2020; Citron, Francesca/AAC-2249-2020; Nicoloso, Milena S/K-6411-2012; Avanzo, Michele/C-8529-2009; Schiappacassi, Monica/AAX-5505-2020; Perin, Tiziana/AAC-2403-2020; Calin, George/E-9390-2011; Vaidya, Jayant S/F-7717-2010	Vaidya, Jayant S/0000-0003-1760-1278; Belletti, Barbara/0000-0003-2249-0285; Baldassarre, Gustavo/0000-0002-9750-8825; Segatto, Ilenia/0000-0001-5282-1028; Massarut, Samuele/0000-0003-4717-0544; D'Andrea, Sara/0000-0001-5736-6431; Citron, Francesca/0000-0002-5896-3008; Nicoloso, Milena S/0000-0003-4231-9303; Avanzo, Michele/0000-0003-1711-4242; Schiappacassi, Monica/0000-0003-4804-4291; Perin, Tiziana/0000-0002-9823-0167; Vaidya, Jayant S/0000-0003-1760-1278; Calin, George/0000-0002-7427-0578; Bristow, Robert/0000-0002-8553-9544; Ivan, Cristina/0000-0002-4848-0168; Calin, George/0000-0001-6704-5615	Associazione Italiana Ricerca sul Cancro (AIRC) [IG 15902, IG 12854]; CRO Intramural Research Grant; Friuli Exchange Program; AIRC-Marie Curie Outgoing International Fellowship; AIRC fellowship [16620]; NATIONAL CANCER INSTITUTE [R01CA182905] Funding Source: NIH RePORTER; National Institute for Health Research [07/60/49, 10/104/07] Funding Source: researchfish	Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); CRO Intramural Research Grant; Friuli Exchange Program; AIRC-Marie Curie Outgoing International Fellowship(Fondazione AIRC per la ricerca sul cancro); AIRC fellowship(Fondazione AIRC per la ricerca sul cancro); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute for Health Research(National Institute for Health Research (NIHR))	This work is dedicated to the memory of Dr Mauro Gaetano Trovo, who strongly supported this research. We are grateful to the patients who participated to this study. We thank Dr Debora Martinuzzo for her valuable contribution, Sara Benevol for expert technical assistance, Maria Giulia Baldassarre for her useful observations and all members of the SCICC lab for supportive scientific discussions. We thank Dr Qiao Li (University of Michigan Medical Center, USA) for providing EO771E2 cell line and Dr Roberta Maestro (CRO Aviano, Aviano, Italy) for providing HMEC hTERT cells. This work was supported by research funding from Associazione Italiana Ricerca sul Cancro (AIRC) to BB (IG 15902) and to GB (IG 12854); from CRO Intramural Research Grant to GB and SM; from Friuli Exchange Program to SB. SB was a recipient of AIRC-Marie Curie Outgoing International Fellowship. IS was a recipient of AIRC fellowship (ref. 16620).	Armenia J, 2014, ONCOTARGET, V5, P1185, DOI 10.18632/oncotarget.1803; Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025; Arwert EN, 2012, NAT REV CANCER, V12, P170, DOI 10.1038/nrc3217; Barcellos-Hoff MH, 2005, NAT REV CANCER, V5, P867, DOI 10.1038/nrc1735; Baum M, 2005, EUR J CANCER, V41, P508, DOI 10.1016/j.ejca.2004.09.031; Begg AC, 2011, NAT REV CANCER, V11, P239, DOI 10.1038/nrc3007; Belletti B, 2008, CLIN CANCER RES, V14, P1325, DOI 10.1158/1078-0432.CCR-07-4453; Christensen ME, 1996, ACTA OTO-LARYNGOL, V116, P137, DOI 10.3109/00016489609137727; de Gonzalez AB, 2013, INT J RADIAT ONCOL, V86, P224, DOI 10.1016/j.ijrobp.2012.09.001; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Demicheli R, 2008, ANN ONCOL, V19, P1821, DOI 10.1093/annonc/mdn386; Demicheli R, 2001, BRIT J CANCER, V85, P490, DOI 10.1054/bjoc.2001.1969; Demicheli R, 2007, NAT CLIN PRACT ONCOL, V4, P699, DOI 10.1038/ncponc0999; Doan PL, 2013, NAT MED, V19, P295, DOI 10.1038/nm.3070; Dumbrigue HB, 2000, ORAL SURG ORAL MED O, V89, P710, DOI 10.1067/moe.2000.106343; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Early Breast Canc Trialists Collab, 2011, LANCET, V378, P1707, DOI 10.1016/S0140-6736(11)61629-2; Epstein JB, 2000, CANCER-AM CANCER SOC, V89, P2258, DOI 10.1002/1097-0142(20001201)89:11<2258::AID-CNCR14>3.0.CO;2-Z; Halvorsen AR, 2014, INT J CANCER, V135, P2085, DOI 10.1002/ijc.28862; Haraguchi T, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp040; Helland A, 2006, RADIOTHER ONCOL, V80, P230, DOI 10.1016/j.radonc.2006.07.007; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Inui M, 2012, CURR OPIN CELL BIOL, V24, P194, DOI 10.1016/j.ceb.2011.11.013; Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209; Johnnidis JB, 2008, NATURE, V451, P1125, DOI 10.1038/nature06607; Kuonen F, 2012, CLIN CANCER RES, V18, P5196, DOI 10.1158/1078-0432.CCR-11-1758; Liu CG, 2004, P NATL ACAD SCI USA, V101, P9740, DOI 10.1073/pnas.0403293101; Metheetrairut C, 2013, CURR OPIN GENET DEV, V23, P12, DOI 10.1016/j.gde.2013.01.002; Pinatel EM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084859; Pulikkan JA, 2010, BLOOD, V115, P1768, DOI 10.1182/blood-2009-08-240101; Redis RS, 2012, PHARMACOL THERAPEUT, V136, P169, DOI 10.1016/j.pharmthera.2012.08.003; Schmitz KH, 2012, CANCER-AM CANCER SOC, V118, P2270, DOI 10.1002/cncr.27462; Segatto I, 2014, ONCOTARGET, V5, P6267, DOI 10.18632/oncotarget.2195; Segatto I, 2014, MOL ONCOL, V8, P766, DOI 10.1016/j.molonc.2014.02.006; Segatto I, 2013, J MOL CELL BIOL, V5, P428, DOI 10.1093/jmcb/mjt027; Shao H, 2003, CANCER RES, V63, P3923; Tagliabue E, 2003, LANCET, V362, P527, DOI 10.1016/S0140-6736(03)14112-8; Vaidya JS, 2014, LANCET, V383, P603, DOI 10.1016/S0140-6736(13)61950-9; Vaidya JS, 2010, LANCET, V376, P91, DOI 10.1016/S0140-6736(10)60837-9; Wang SH, 2014, INT J BIOL SCI, V10, P25, DOI 10.7150/ijbs.6309; Yamada KM, 2007, CELL, V130, P601, DOI 10.1016/j.cell.2007.08.006	41	42	43	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 15	2016	35	37					4914	4926		10.1038/onc.2016.23	http://dx.doi.org/10.1038/onc.2016.23			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0LA	26876200	Green Published, hybrid, Green Submitted			2022-12-17	WOS:000383330700009
J	Lopez-Bertoni, H; Lal, B; Michelson, N; Guerrero-Cazares, H; Quinones-Hinojosa, A; Li, Y; Laterra, J				Lopez-Bertoni, H.; Lal, B.; Michelson, N.; Guerrero-Cazares, H.; Quinones-Hinojosa, A.; Li, Y.; Laterra, J.			Epigenetic modulation of a miR-296-5p:HMGA1 axis regulates Sox2 expression and glioblastoma stem cells	ONCOGENE			English	Article							HMGA PROTEINS; CANCER; PROLIFERATION; MICRORNAS; MIR-296; TRANSCRIPTION; MOBILITY; RENEWAL; PATHWAY; TARGETS	Solid malignancies contain subsets of multipotent cells that grow as spheres and efficiently propagate tumors in xenograft models, reflecting a stem-like, self-renewing and tumor-propagating phenotype. These cancer 'stem cells (SCs)' have been shown to maintain tumor growth, contribute to resistance and drive tumor recurrence. Cancer cell stemness is dynamically influenced by epigenetic mechanisms and differentially regulated coding and noncoding RNAs. How these mechanisms specifically contribute to the generation and/or maintenance of cancer SCs remains unclear. This study identifies a novel epigenetically regulated circuit that integrates microRNA, chromatin remodeling and the reprogramming transcription factor Sox2 to regulate glioblastoma (GBM)-propagating SCs. We show that miR-296-5p expression is repressed in a DNA methylation-dependent manner under conditions that promote GBM cell stemness and that miR-296-5p inhibits GBM cell stemness and their capacity to self-renew as spheres and propagate glioma xenografts in vivo. We show that the chromatin remodeling protein HMGA1 functions as a downstream effector of these biological responses to miR-296-5p and regulates Sox2 expression, a master driver of cell stemness, by modifying chromatin architecture at the Sox2 promoter. These results show for the first time that miR-296-5p inhibits transcriptional mechanisms that support GBM SCs and identify a miR-296-5p: HMGA1: Sox2 axis as a novel regulator of GBM SCs and candidate pathway for targeting therapies directed at depleting tumors of their tumor-propagating stem cell subsets.	[Lopez-Bertoni, H.; Lal, B.; Michelson, N.; Li, Y.; Laterra, J.] Hugo W Moser Res Inst Kennedy Krieger, Baltimore, MD USA; [Lopez-Bertoni, H.; Lal, B.; Li, Y.; Laterra, J.] Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD USA; [Guerrero-Cazares, H.; Quinones-Hinojosa, A.] Johns Hopkins Sch Med, Dept Neurosurg, Baltimore, MD USA; [Quinones-Hinojosa, A.; Laterra, J.] Johns Hopkins Sch Med, Dept Neurosci, Baltimore, MD USA; [Quinones-Hinojosa, A.; Laterra, J.] Johns Hopkins Sch Med, Dept Oncol, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Laterra, J (corresponding author), Johns Hopkins Sch Med, Kennedy Krieger Inst, Dept Neurol, 707 North Broadway, Baltimore, MD 21205 USA.	Laterra@kennedykrieger.org	Lopez, Hernando/AAY-7655-2020	Lopez, Hernando/0000-0001-6618-1092; Guerrero-Cazares, Hugo/0000-0003-1307-719X	American Brain Tumor Association; United States NIH [R01NS073611, R01NS070024]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS073611, R01NS070024] Funding Source: NIH RePORTER	American Brain Tumor Association; United States NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by grants from the American Brain Tumor Association (to HL-B), and the United States NIH Grants R01NS073611 (to JL) and R01NS070024 (to AQ-H).	Anokye-Danso F, 2011, CELL STEM CELL, V8, P376, DOI 10.1016/j.stem.2011.03.001; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799; Belton A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030034; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Catez F, 2006, NAT STRUCT MOL BIOL, V13, P305, DOI 10.1038/nsmb1077; Choi Jae Duk, 2013, Genomics & Informatics, V11, P164, DOI 10.5808/GI.2013.11.4.164; Cleynen I, 2008, INT J ONCOL, V32, P289; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fanelli M, 2008, ONCOGENE, V27, P358, DOI 10.1038/sj.onc.1210642; Fusco A, 2007, NAT REV CANCER, V7, P899, DOI 10.1038/nrc2271; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Glas M, 2010, ANN NEUROL, V68, P264, DOI 10.1002/ana.22036; Godlewski J, 2008, CANCER RES, V68, P9125, DOI 10.1158/0008-5472.CAN-08-2629; Gohel PH, 2012, INT J PHARM RES ALLI, V1, P1; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hong L, 2010, ANN SURG, V251, P1056, DOI 10.1097/SLA.0b013e3181dd4ea9; Lee KH, 2014, BBA-MOL CELL RES, V1843, P2055, DOI 10.1016/j.bbamcr.2014.06.001; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li YQ, 2005, CANCER RES, V65, P9355, DOI 10.1158/0008-5472.CAN-05-1946; Li YQ, 2012, CANCER RES, V72, P576, DOI 10.1158/0008-5472.CAN-11-3070; Li YQ, 2009, CANCER RES, V69, P7569, DOI 10.1158/0008-5472.CAN-09-0529; Lin SL, 2011, NUCLEIC ACIDS RES, V39, P1054, DOI 10.1093/nar/gkq850; Lopez-Bertoni H, 2015, ONCOGENE, V34, P3994, DOI 10.1038/onc.2014.334; LUND T, 1983, FEBS LETT, V152, P163, DOI 10.1016/0014-5793(83)80370-6; Marson A, 2008, CELL, V134, P521, DOI 10.1016/j.cell.2008.07.020; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; Miyoshi N, 2011, CELL STEM CELL, V8, P633, DOI 10.1016/j.stem.2011.05.001; Nguyen LV, 2012, NAT REV CANCER, V12, P133, DOI 10.1038/nrc3184; Pandita A, 2004, GENE CHROMOSOME CANC, V39, P29, DOI 10.1002/gcc.10300; Pardal R, 2005, COLD SH Q B, V70, P177, DOI 10.1101/sqb.2005.70.057; Rajendran G, 2011, J NEURO-ONCOL, V104, P483, DOI 10.1007/s11060-010-0520-2; Reeves R, 2001, BBA-GENE STRUCT EXPR, V1519, P13, DOI 10.1016/S0167-4781(01)00215-9; Robson JE, 2012, RNA, V18, P135, DOI 10.1261/rna.029561.111; Sato F, 2011, FEBS J, V278, P1598, DOI 10.1111/j.1742-4658.2011.08089.x; Shivapurkar N, 2013, INT J COLORECTAL DIS, V28, P887, DOI 10.1007/s00384-012-1560-1; Silber J, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-14; Singh RP, 2009, CELL TRANSPLANT, V18, P1197, DOI 10.3727/096368909X12483162197204; Somervaille TCP, 2009, CELL STEM CELL, V4, P129, DOI 10.1016/j.stem.2008.11.015; Son MJ, 2009, CELL STEM CELL, V4, P440, DOI 10.1016/j.stem.2009.03.003; Suva ML, 2014, CELL, V157, P580, DOI 10.1016/j.cell.2014.02.030; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Wei JJ, 2011, CLIN CANCER RES, V17, P1297, DOI 10.1158/1078-0432.CCR-10-0993; Wolffe AP, 2001, ONCOGENE, V20, P2988, DOI 10.1038/sj.onc.1204322; Xia HP, 2012, J BIOL CHEM, V287, P9962, DOI 10.1074/jbc.M111.332627; Xu Y, 2004, CANCER RES, V64, P3371, DOI 10.1158/0008-5472.CAN-04-0044	46	42	45	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 15	2016	35	37					4903	4913		10.1038/onc.2016.22	http://dx.doi.org/10.1038/onc.2016.22			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0LA	26898758	Green Accepted			2022-12-17	WOS:000383330700008
J	Lei, Y; Kansy, BA; Li, J; Cong, L; Liu, Y; Trivedi, S; Wen, H; Ting, JPY; Ouyang, H; Ferris, RL				Lei, Y.; Kansy, B. A.; Li, J.; Cong, L.; Liu, Y.; Trivedi, S.; Wen, H.; Ting, J. P-Y; Ouyang, H.; Ferris, R. L.			EGFR-targeted mAb therapy modulates autophagy in head and neck squamous cell carcinoma through NLRX1-TUFM protein complex	ONCOGENE			English	Article							NF-KAPPA-B; CANCER-CELLS; TUMOR PROGRESSION; NATURAL-KILLER; I INTERFERON; CETUXIMAB; RECEPTOR; GROWTH; P62/SQSTM1; CARFILZOMIB	Epidermal growth factor receptor (EGFR)-targeted therapy in head and neck squamous cell carcinoma (HNSCC) patients frequently results in tumor resistance to treatment. Autophagy is an emerging underlying resistance mechanism, however, the molecular autophagy machinery in HNSCC cells and potential biomarkers of patient response to EGFR-targeted therapy remain insufficiently characterized. Here we show that the EGFR blocking with cetuximab leads to varied autophagic responses, which modulate cancer cell susceptibility to EGFR inhibition. Inhibition of autophagy sensitizes HNSCC cells to EGFR blockade. Importantly, we identify a novel signaling hub centering on the NLRX1 (nucleotide-binding, lots of leucine-rich repeats-containing protein member X1)-TUFM (Tu translation elongation factor mitochondrial) protein complex, promoting autophagic flux. Defects in the expression of either NLRX1 or TUFM result in compromised autophagy when treated with EGFR inhibitors. As a previously undefined autophagy-promoting mechanism, we found that TUFM serves as a novel anchorage site, recruiting Beclin-1 to mitochondria, promoting its polyubiquitination, and interfering with its interaction with Rubicon. This protein complex is also essential for endoplasmic reticulum stress signaling induction, possibly as an additional mechanism to promote autophagy. Utilizing tumor specimens from a novel neoadjuvant clinical trial, we show that increased expression of the autophagy adaptor protein, SQSTM1/p62, is associated with poor response to cetuximab therapy. These findings expand our understanding of the components involved in HNSCC autophagy machinery that responds to EGFR inhibitors, and suggest potential combinatorial approaches to enhance its therapeutic efficacy.	[Lei, Y.; Kansy, B. A.; Li, J.; Cong, L.; Liu, Y.; Trivedi, S.; Ferris, R. L.] Univ Pittsburgh, Dept Otolaryngol, Sch Med, Inst Canc, 5117 Ctr Ave,Suite 2-26, Pittsburgh, PA 15260 USA; [Wen, H.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Sch Med, Dept Surg, Chapel Hill, NC 27599 USA; [Ting, J. P-Y] Univ N Carolina, Lineberger Comprehens Canc Ctr, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; [Ouyang, H.] Univ Pittsburgh, Sch Dent Med, Dept Restorat Dent & Comprehens Care, Pittsburgh, PA USA; [Ferris, R. L.] Univ Pittsburgh, Dept Immunol, Sch Med, Pittsburgh, PA USA; [Lei, Y.] Univ Michigan, Sch Dent, Dept Periodont & Oral Med,UM Comprehens Canc Ctr, Translat Oncol Program & Distributed Hlth Technol, Ann Arbor, MI 48109 USA; [Lei, Y.] Univ Michigan, UM Comprehens Canc Ctr, Dept Otolaryngol Head & Neck Surg, Sch Med,Translat Oncol Program & Distributed Hlth, Ann Arbor, MI 48109 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Ferris, RL (corresponding author), Univ Pittsburgh, Dept Otolaryngol, Sch Med, Inst Canc, 5117 Ctr Ave,Suite 2-26, Pittsburgh, PA 15260 USA.	ferrisrl@upmc.edu	Wen, Haitao/AAJ-7621-2020	Li, Jing/0000-0002-9285-9423; Lei, Y Leo/0000-0002-9868-9824	NIH [K99 DE024173, T32 CA060397, R01 DE019727, P50 CA097190, R01 CA182418, R21 CA161150];  [P30 CA047904]; NATIONAL CANCER INSTITUTE [P30CA047904, P30CA016086, P50CA097190, R01CA182418, R21CA161150, T32CA060397] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE019727, K99DE024173, R00DE024173] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This work is supported by NIH grants K99 DE024173 (YL), T32 CA060397 (RLF), R01 DE019727 (RLF), P50 CA097190 (RLF), R01 CA182418 (HO) and R21 CA161150 (HO). The UPCI core facilities are supported in part by P30 CA047904. We thank Dr Barton Branstetter for the interpretation of the radiographic findings of the enrolled patients.	Allen IC, 2011, IMMUNITY, V34, P854, DOI 10.1016/j.immuni.2011.03.026; Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634; Argiris A, 2008, LANCET, V371, P1695, DOI 10.1016/S0140-6736(08)60728-X; Argiris A, 2011, CLIN CANCER RES, V17, P5755, DOI 10.1158/1078-0432.CCR-11-0861; Baginska J, 2013, P NATL ACAD SCI USA, V110, P17450, DOI 10.1073/pnas.1304790110; Colosetti P, 2009, AUTOPHAGY, V5, P1092, DOI 10.4161/auto.5.8.9889; Davis BK, 2011, ANN REV IMMUNOL; Edwards BK, 2014, CANCER-AM CANCER SOC, V120, P1290, DOI 10.1002/cncr.28509; Hailey DW, 2010, CELL, V141, P656, DOI 10.1016/j.cell.2010.04.009; Jemal A, 2004, CANCER-AM CANCER SOC, V101, P3, DOI 10.1002/cncr.20288; Jie HB, 2015, CANCER RES, V75, P2200, DOI 10.1158/0008-5472.CAN-14-2788; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; Lei Y, 2013, AUTOPHAGY, V9, P432, DOI 10.4161/auto.23026; Lei Y, 2012, IMMUNITY, V36, P933, DOI 10.1016/j.immuni.2012.03.025; Li XQ, 2010, CANCER RES, V70, P5942, DOI 10.1158/0008-5472.CAN-10-0157; Liang XH, 2001, CANCER RES, V61, P3443; Liu JL, 2014, BRIT J CANCER, V111, P944, DOI 10.1038/bjc.2014.355; Liu JL, 2011, CELL, V147, P223, DOI 10.1016/j.cell.2011.08.037; Lopez-Albaitero A, 2009, CANCER IMMUNOL IMMUN, V58, P1855, DOI 10.1007/s00262-009-0697-4; Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048; Milani M, 2009, CANCER RES, V69, P4415, DOI 10.1158/0008-5472.CAN-08-2839; Moore CB, 2008, NATURE, V451, P573, DOI 10.1038/nature06501; Moore CB, 2010, METHODS MOL BIOL, V629, P139, DOI 10.1007/978-1-60761-657-3_10; Reeves TD, 2011, OTOLARYNG HEAD NECK, V144, P676, DOI 10.1177/0194599811399559; Rouschop KMA, 2010, J CLIN INVEST, V120, P127, DOI 10.1172/JCI40027; Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802; Sharafinski ME, 2010, HEAD NECK-J SCI SPEC, V32, P1412, DOI 10.1002/hed.21365; Shi CS, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000751; Srivastava RM, 2013, CLIN CANCER RES, V19, P1858, DOI 10.1158/1078-0432.CCR-12-2426; Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299; Tan XJ, 2015, CELL, V160, P145, DOI 10.1016/j.cell.2014.12.006; Tattoli I, 2008, EMBO REP, V9, P293, DOI 10.1038/sj.embor.7401161; Ting JPY, 2008, NAT REV IMMUNOL, V8, P372, DOI 10.1038/nri2296; Ting JPY, 2010, SCIENCE, V327, P286, DOI 10.1126/science.1184004; Toepfer N, 2011, CANCER BIOL THER, V12, P691, DOI 10.4161/cbt.12.8.15978; Wei HJ, 2014, GENE DEV, V28, P1204, DOI 10.1101/gad.237354.113; Wei YJ, 2013, CELL, V154, P1269, DOI 10.1016/j.cell.2013.08.015; Wen HT, 2011, NAT IMMUNOL, V12, P408, DOI 10.1038/ni.2022; White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262; White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023; Xia MH, 2014, INT J ONCOL, V45, P2341, DOI 10.3892/ijo.2014.2669; Xia XJ, 2011, IMMUNITY, V34, P843, DOI 10.1016/j.immuni.2011.02.022; Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814; Zang Y, 2012, AUTOPHAGY, V8, P1873, DOI 10.4161/auto.22185; Zang Y, 2012, CLIN CANCER RES, V18, P5639, DOI 10.1158/1078-0432.CCR-12-1213	46	42	46	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2016	35	36					4698	4707		10.1038/onc.2016.11	http://dx.doi.org/10.1038/onc.2016.11			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0IS	26876213	Green Submitted, Green Accepted			2022-12-17	WOS:000383324700003
J	Park, CS; Kim, TK; Kim, HG; Kim, YJ; Jeoung, MH; Lee, WR; Go, NK; Heo, K; Lee, S				Park, C. S.; Kim, T-K; Kim, H. G.; Kim, Y-J; Jeoung, M. H.; Lee, W. R.; Go, N. K.; Heo, K.; Lee, S.			Therapeutic targeting of tetraspanin8 in epithelial ovarian cancer invasion and metastasis	ONCOGENE			English	Article							COLORECTAL-CANCER; BREAST-CANCER; TUMOR-GROWTH; CO-029; ANTIBODY; DOMAIN; BEVACIZUMAB; MECHANISMS; CD151; CELLS	Epithelial ovarian cancer (EOC) invasion and metastasis are complex phenomena that result from the coordinated action of many metastatic regulators and must be overcome to improve clinical outcomes for patients with these cancers. The identification of novel therapeutic targets is critical because of the limited success of current treatment regimens, particularly in advanced-stage ovarian cancers. In this study, we found that tetraspanin 8 (TSPAN8) is overexpressed in about 52% (14/27) of EOC tissues and correlates with poor survival. Using small interfering RNA-mediated TSPAN8 knockdown and a competition assay with purified TSPAN8 large extracellular loop (TSPAN8-LEL) protein, we identified TSPAN8-LEL as a key regulator of EOC cell invasion. Furthermore, monotherapy with TSPAN8-blocking antibody we developed shows that antibody-based modulation of TSPAN8-LEL can significantly reduce the incidence of EOC metastasis without severe toxicity in vivo. Finally, we demonstrated that the TSPAN8-blocking antibody promotes the internalization and concomitant downregulation of cell surface TSPAN8. Collectively, our data suggest TSPAN8 as a potential novel therapeutic target in EOCs and antibody targeting of TSPAN8 as an effective strategy for inhibiting invasion and metastasis of TSPAN8-expressing EOCs.	[Park, C. S.; Kim, T-K; Jeoung, M. H.; Lee, W. R.; Go, N. K.; Lee, S.] Scripps Korea Antibody Inst, Lab Mol Canc Therapeut, Hyoja 2 Dong, Chuncheon Si 200701, Gangwon Do, South Korea; [Kim, H. G.; Heo, K.] Natl Canc Ctr, Res Inst, New Expt Therapeut Branch, 323 Ilsan Ro, Goyang Si 410769, South Korea; [Kim, Y-J] Natl Canc Ctr, Res Inst, Specif Organs Canc Branch, Goyang Si, South Korea; [Park, C. S.] Korea Inst Ceram Engn & Technol, Eco & Bio Convergence Team, 101 Soho Ro, Jinju Si 661031, Gyeongsangnam D, South Korea	National Cancer Center - Korea (NCC); National Cancer Center - Korea (NCC); Korea Institute of Ceramic Engineering & Technology	Lee, S (corresponding author), Scripps Korea Antibody Inst, Lab Mol Canc Therapeut, Hyoja 2 Dong, Chuncheon Si 200701, Gangwon Do, South Korea.; Heo, K (corresponding author), Natl Canc Ctr, Res Inst, New Expt Therapeut Branch, 323 Ilsan Ro, Goyang Si 410769, South Korea.	hk@ncc.re.kr; lees@skai.or.kr			Scripps Korea Antibody Institute [10TS03]	Scripps Korea Antibody Institute	This work was supported by a research grant (10TS03) from the Scripps Korea Antibody Institute.	Ailane N, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00364; Albanell J, 1999, J MAMMARY GLAND BIOL, V4, P337, DOI 10.1023/A:1018762216147; [Anonymous], 2011, J Natl Cancer Inst, V103, P1287, DOI 10.1093/jnci/djr342; Bardelli A, 2010, J CLIN ONCOL, V28, P1254, DOI 10.1200/JCO.2009.24.6116; Gesierich S, 2005, CLIN CANCER RES, V11, P2840, DOI 10.1158/1078-0432.CCR-04-1935; Hemler ME, 2014, NAT REV CANCER, V14, P49, DOI 10.1038/nrc3640; Huynh H, 2007, MOL CANCER THER, V6, P2959, DOI 10.1158/1535-7163.MCT-07-0237; Kanetaka K, 2003, J GASTROEN HEPATOL, V18, P1309, DOI 10.1046/j.1440-1746.2003.03182.x; Kanetaka K, 2001, J HEPATOL, V35, P637, DOI 10.1016/S0168-8278(01)00183-0; Keating GM, 2014, DRUGS, V74, P1891, DOI 10.1007/s40265-014-0302-9; Ki MK, 2013, ONCOGENE, V32, P5449, DOI 10.1038/onc.2013.156; Kim A, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-14; Kudo-Saito C, 2014, CANCER RES, V74, P1361, DOI 10.1158/0008-5472.CAN-13-1349; Kuhn S, 2007, MOL CANCER RES, V5, P553, DOI 10.1158/1541-7786.MCR-06-0384; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Lee S, 2012, J IMMUNOL, V189, P4592, DOI 10.4049/jimmunol.1103803; Lennon S, 2009, J CLIN ONCOL, V27, P1685, DOI 10.1200/JCO.2008.16.8351; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Novoa-Vargas Arturo, 2014, Ginecol Obstet Mex, V82, P613; Okada Y, 2014, DIGESTION, V89, P18, DOI 10.1159/000356202; Payne SJL, 2008, HISTOPATHOLOGY, V52, P82, DOI 10.1111/j.1365-2559.2007.02897.x; SZALA S, 1990, P NATL ACAD SCI USA, V87, P6833, DOI 10.1073/pnas.87.17.6833; Teo MCC, 2014, CURR OPIN OBSTET GYN, V26, P3, DOI 10.1097/GCO.0000000000000034; Thibault B, 2014, CANCER METAST REV, V33, P17, DOI 10.1007/s10555-013-9456-2; Xu Y, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-16; Yue SJ, 2013, EUR J CANCER, V49, P2934, DOI 10.1016/j.ejca.2013.03.032; Zhou Z, 2008, CLIN EXP METASTAS, V25, P537, DOI 10.1007/s10585-008-9168-0; Zoller M, 2009, NAT REV CANCER, V9, P40, DOI 10.1038/nrc2543	28	42	42	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	34					4540	4548		10.1038/onc.2015.520	http://dx.doi.org/10.1038/onc.2015.520			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU4AC	26804173				2022-12-17	WOS:000382153100011
J	Das, S; Rachagani, S; Sheinin, Y; Smith, LM; Gurumurthy, CB; Roy, HK; Batra, SK				Das, S.; Rachagani, S.; Sheinin, Y.; Smith, L. M.; Gurumurthy, C. B.; Roy, H. K.; Batra, S. K.			Mice deficient in Muc4 are resistant to experimental colitis and colitis-associated colorectal cancer	ONCOGENE			English	Article							CELL-SURFACE MUCIN; GENE-EXPRESSION; PROGNOSTIC-FACTOR; INTESTINAL INFLAMMATION; BARRIER; CARCINOMA; DIAGNOSIS; PROTECTS; PATHWAY	MUC4, a large transmembrane mucin normally expressed in the small and large intestine, is differentially expressed during inflammatory and malignant conditions of the colon. However, the expression pattern and the role of MUC4 in colitis and colorectal cancer (CRC) are inconclusive. Therefore, the aim of this study was to understand the role of Muc4 during inflammatory and malignant conditions of the colon. Here, we generated Muc4(-/-) mice and addressed its role in colitis and colitis-associated CRC using dextran sodium sulfate (DSS) and azoxymethane (AOM)-DSS experimental models, respectively. Muc4(-/-) mice were viable, fertile with no apparent defects. Muc4(-/-) mice displayed increased resistance to DSS-induced colitis compared with wild-type (WT) littermates that was evaluated by survival rate, body weight loss, diarrhea and fecal blood score, and histological score. Reduced infiltration of inflammatory cells, that is, CD3(+) lymphocytes and F4/80(+) macrophages was observed in the inflamed mucosa along with reduction in the mRNA levels of inflammatory cytokines interleukin (IL)-1 beta and tumor necrosis factor (TNF)-alpha and anti-microbial genes Lysozyme M and SLPI in the colon of Muc4(-/-) mice compared with WT littermates. Compensatory upregulation of Muc2 and Muc3 mucins under basal and DSS treatment conditions partly explains the resistance observed in Muc4(-/-) mice. Accordingly, Muc4(-/-) mice exhibited significantly reduced tumor burden compared with WT mice assessed in a colitis-induced tumor model using AOM/DSS. An increased percentage of Ki67(+) nuclei was observed in the tumors from WT compared with Muc4(-/-) mice suggesting Muc4 to be critical in intestinal cell proliferation during tumorigenesis. Taken together, we conclusively demonstrate for the first time the role of Muc4 in driving intestinal inflammation and inflammation-associated tumorigenesis using a novel Muc4(-/-) mouse model.	[Das, S.; Rachagani, S.; Batra, S. K.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Sheinin, Y.] Univ Nebraska Med Ctr, Dept Pathol, Omaha, NE 68198 USA; [Smith, L. M.] Univ Nebraska Med Ctr, Dept Biostat, Omaha, NE 68198 USA; [Gurumurthy, C. B.] Univ Nebraska Med Ctr, Dept Genet Cell Biol & Anat, Mouse Genome Engn Core Facil, Omaha, NE 68198 USA; [Roy, H. K.] Boston Univ, Sch Med, Ctr Digest Disorders, Boston, MA 02118 USA; [Batra, S. K.] Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Buffett Canc Ctr, Omaha, NE 68198 USA; [Das, S.] Karolinska Univ Sjukhuset, Dept Med, S-17176 Stockholm, Sweden	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; Boston University; University of Nebraska System; University of Nebraska Medical Center	Batra, SK (corresponding author), Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Buffett Canc Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.	sbatra@unmc.edu	Roy, Hemant/AAC-9096-2020; Gurumurthy, Channabasavaiah B/E-7205-2011; Gurumurthy, Channabasavaiah B/H-8268-2016; Das, Srustidhar/GVU-1044-2022	Gurumurthy, Channabasavaiah B/0000-0002-8022-4033; 	National Institutes of Health [RO1 CA 78590, RO1 CA183459, UO1CA111294, SPORE P50CA127297, TMEN U54CA163120, R03 CA167342]; NATIONAL CANCER INSTITUTE [U54CA163120, R01CA183459, R03CA167342, R01CA078590, P50CA127297, U01CA111294] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM110768] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Don Harms and Rolen Quadros of the mouse genome-engineering core at the University of Nebraska Medical Center (UNMC) for the electroporation, microinjection and generation of chimera for Muc4 knockout mice. We thank UNMC tissue sciences facility for processing of tissues used in the study. We also thank Dr Imayavaramban Lakshmanan and Kavita Mallya for technical assistance. The work in the manuscript, in parts, was supported by the grants from the National Institutes of Health (RO1 CA 78590, RO1 CA183459, UO1CA111294, SPORE P50CA127297, TMEN U54CA163120 and R03 CA167342).	Araki A, 2005, J GASTROENTEROL, V40, P16, DOI 10.1007/s00535-004-1492-9; Biemer-Huttmann AE, 1999, J HISTOCHEM CYTOCHEM, V47, P1039, DOI 10.1177/002215549904700808; Biemer-Huttmann AE, 2000, CLIN CANCER RES, V6, P1909; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Boltin D, 2013, J CLIN GASTROENTEROL, V47, P106, DOI 10.1097/MCG.0b013e3182688e73; Bouma G, 2003, NAT REV IMMUNOL, V3, P521, DOI 10.1038/nri1132; Buisine MP, 1999, INFLAMM BOWEL DIS, V5, P24, DOI 10.1097/00054725-199902000-00004; Chaturvedi P, 2008, FASEB J, V22, P966, DOI 10.1096/fj.07-9673rev; Chauhan SC, 2006, MODERN PATHOL, V19, P1386, DOI 10.1038/modpathol.3800646; Dharmani P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025058; Enss ML, 2000, INFLAMM RES, V49, P162, DOI 10.1007/s000110050576; Feagins LA, 2009, NAT REV GASTRO HEPAT, V6, P297, DOI 10.1038/nrgastro.2009.44; Ho SB, 2010, BBA-GEN SUBJECTS, V1800, P629, DOI 10.1016/j.bbagen.2010.03.010; Hoebler C, 2006, DIGEST DIS SCI, V51, P381, DOI 10.1007/s10620-006-3142-y; Iwashita J, 2003, IMMUNOL CELL BIOL, V81, P275, DOI 10.1046/j.1440-1711.2003.t01-1-01163.x; Kim YD, 2002, J KOREAN MED SCI, V17, P765, DOI 10.3346/jkms.2002.17.6.765; Lobe CG, 1999, DEV BIOL, V208, P281, DOI 10.1006/dbio.1999.9209; Longman RJ, 2006, J HISTOCHEM CYTOCHEM, V54, P1335, DOI 10.1369/jhc.5A6904.2006; Luu Y, 2010, INT J BIOCHEM CELL B, V42, P996, DOI 10.1016/j.biocel.2010.03.001; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Majhi PD, 2013, J THORAC ONCOL, V8, P398, DOI 10.1097/JTO.0b013e3182829e06; McAuley JL, 2007, J CLIN INVEST, V117, P2313, DOI 10.1172/JCI26705; McGuckin MA, 2011, NAT REV MICROBIOL, V9, P265, DOI 10.1038/nrmicro2538; Miyahara N, 2008, EUR J CANCER, V44, P1048, DOI 10.1016/j.ejca.2008.03.007; Mukhopadhyay P, 2011, BBA-REV CANCER, V1815, P224, DOI 10.1016/j.bbcan.2011.01.001; Myerscough N, 1995, BIOCHEM SOC T, V23, pS536, DOI 10.1042/bst023536s; OGATA S, 1992, CANCER RES, V52, P5971; Perse M, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/718617; Petersson J, 2011, AM J PHYSIOL-GASTR L, V300, pG327, DOI 10.1152/ajpgi.00422.2010; Ponnusamy MP, 2010, ONCOGENE, V29, P5741, DOI 10.1038/onc.2010.309; Ponnusamy MP, 2011, J OVARIAN RES, V4, DOI 10.1186/1757-2215-4-7; Resta-Lenert S, 2011, AM J PHYSIOL-GASTR L, V300, pG1144, DOI 10.1152/ajpgi.00138.2010; Saitou M, 2005, J CLIN PATHOL, V58, P845, DOI 10.1136/jcp.2004.023572; Senapati S, 2008, BRIT J CANCER, V99, P949, DOI 10.1038/sj.bjc.6604632; Senapati S, 2010, TRENDS BIOCHEM SCI, V35, P236, DOI 10.1016/j.tibs.2009.10.003; Shanmugam C, 2010, CANCER-AM CANCER SOC, V116, P3577, DOI 10.1002/cncr.25095; Shekels LL, 2003, BBA-GENE STRUCT EXPR, V1627, P90, DOI 10.1016/S0167-4781(03)00081-2; Sheng YH, 2012, J GASTROEN HEPATOL, V27, P28, DOI 10.1111/j.1440-1746.2011.06909.x; Sheng YH, 2011, GUT, V60, P1661, DOI 10.1136/gut.2011.239194; Shibahara H, 2004, HEPATOLOGY, V39, P220, DOI 10.1002/hep.20031; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Singh AP, 2008, LANCET ONCOL, V9, P1076, DOI 10.1016/S1470-2045(08)70277-8; Singh AP, 2007, CANCER RES, V67, P433, DOI 10.1158/0008-5472.CAN-06-3114; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Singh PK, 2006, TRENDS CELL BIOL, V16, P467, DOI 10.1016/j.tcb.2006.07.006; SPICER AP, 1995, J BIOL CHEM, V270, P30093; Tamada S, 2006, CLIN CANCER RES, V12, P4257, DOI 10.1158/1078-0432.CCR-05-2814; Van der Sluis M, 2006, GASTROENTEROLOGY, V131, P117, DOI 10.1053/j.gastro.2006.04.020; VanKlinken BJW, 1995, BIOCHEM SOC T, V23, P814, DOI 10.1042/bst0230814; Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094; Zhang J, 2006, TISSUE CELL, V38, P271, DOI 10.1016/j.tice.2006.06.004	51	42	45	0	31	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2016	35	20					2645	2654		10.1038/onc.2015.327	http://dx.doi.org/10.1038/onc.2015.327			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GS	26364605	Green Accepted			2022-12-17	WOS:000376165700011
J	Emmrich, S; Engeland, F; El-Khatib, M; Henke, K; Obulkasim, A; Schoning, J; Katsman-Kuipers, JE; Zwaan, CM; Pich, A; Stary, J; Baruchel, A; de Haas, V; Reinhardt, D; Fornerod, M; van den Heuvel-Eibrink, MM; Klusmann, JH				Emmrich, S.; Engeland, F.; El-Khatib, M.; Henke, K.; Obulkasim, A.; Schoening, J.; Katsman-Kuipers, J. E.; Zwaan, C. Michel; Pich, A.; Stary, J.; Baruchel, A.; de Haas, V.; Reinhardt, D.; Fornerod, M.; van den Heuvel-Eibrink, M. M.; Klusmann, J. H.			miR-139-5p controls translation in myeloid leukemia through EIF4G2	ONCOGENE			English	Article							DOWN-REGULATION; MALIGNANT-TRANSFORMATION; PROTEIN-SYNTHESIS; POOR-PROGNOSIS; UP-REGULATION; EXPRESSION; BTG3; PHOSPHORYLATION; PROLIFERATION; METHYLATION	MicroRNAs (miRNAs) are crucial components of homeostatic and developmental gene regulation. In turn, dysregulation of miRNA expression is a common feature of different types of cancer, which can be harnessed therapeutically. Here we identify miR-139-5p suppression across several cytogenetically defined acute myeloid leukemia (AML) subgroups. The promoter of mir-139 was transcriptionally silenced and could be reactivated by histone deacetylase inhibitors in a dose-dependent manner. Restoration of mir-139 expression in cell lines representing the major AML subgroups (t[8;21], inv[16], mixed lineage leukemia-rearranged and complex karyotype AML) caused cell cycle arrest and apoptosis in vitro and in xenograft mouse models in vivo. During normal hematopoiesis, mir-139 is exclusively expressed in terminally differentiated neutrophils and macrophages. Ectopic expression of mir-139 repressed proliferation of normal CD34(+)-hematopoietic stem and progenitor cells and perturbed myelomonocytic in vitro differentiation. Mechanistically, mir-139 exerts its effects by repressing the translation initiation factor EIF4G2, thereby reducing overall protein synthesis while specifically inducing the translation of cell cycle inhibitor p27(Kip1). Knockdown of EIF4G2 recapitulated the effects of mir-139, whereas restoring EIF4G2 expression rescued the mir-139 phenotype. Moreover, elevated miR-139-5p expression is associated with a favorable outcome in a cohort of 165 pediatric patients with AML. Thus, mir-139 acts as a global tumor suppressor-miR in AML by controlling protein translation. As AML cells are dependent on high protein synthesis rates controlling the expression of mir-139 constitutes a novel path for the treatment of AML.	[Emmrich, S.; Engeland, F.; El-Khatib, M.; Henke, K.; Schoening, J.; Klusmann, J. H.] Hannover Med Sch, Dept Pediat Hematol & Oncol, Carl Neuberg St 1, D-30625 Hannover, Germany; [Obulkasim, A.; Katsman-Kuipers, J. E.; Zwaan, C. Michel; Fornerod, M.; van den Heuvel-Eibrink, M. M.] Erasmus MC Sophia Childrens Hosp, Dept Pediat Oncol Hematol, Rotterdam, Netherlands; [Pich, A.] Hannover Med Sch, Inst Toxicol, D-30625 Hannover, Germany; [Stary, J.] Charles Univ Prague, Dept Pediat Hematol Oncol, Prague, Czech Republic; [Stary, J.] Univ Hosp Motol, Prague, Czech Republic; [Baruchel, A.] Hop Univ St Louis, St Louis Hosp, Dept Hematol, Paris, France; [de Haas, V.] Stichting Kinderoncol Nederland SKION, Dutch Childhood Oncol Grp, The Hague, Netherlands; [Reinhardt, D.] Univ Hosp Essen, Clin Pediat 3, Essen, Germany; [Fornerod, M.] Erasmus MC Sophia Childrens Hosp, Dept Biochem, Rotterdam, Netherlands	Hannover Medical School; Erasmus University Rotterdam; Erasmus MC; Hannover Medical School; Charles University Prague; Motol University Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Dutch Childhood Oncology Group; University of Duisburg Essen; Erasmus University Rotterdam; Erasmus MC	Klusmann, JH (corresponding author), Hannover Med Sch, Dept Pediat Hematol & Oncol, Carl Neuberg St 1, D-30625 Hannover, Germany.	klusmann.jan-henning@mh-hannover.de	Klusmann, Jan-Henning/M-9655-2015; Reinhardt, Dirk/N-7003-2016; Stary, Jan/AAB-9635-2020	Klusmann, Jan-Henning/0000-0002-1070-0727; Reinhardt, Dirk/0000-0002-7027-4483; Fornerod, Maarten/0000-0002-6166-3030	Children Cancer Free Foundation (KIKA) [49, 109]; KIKA project [109]; DFG [KL-2374/2-1]	Children Cancer Free Foundation (KIKA); KIKA project; DFG(German Research Foundation (DFG))	The authors thank Drs K Weber, B Fehse and D Heckl for providing plasmids; Dr M Ballmaier for sorting. SE, FE and KH were supported by the Hannover Biomedical Research School. JEK-K was supported by the Children Cancer Free Foundation (KIKA, project 49). JHK is a fellow of the Emmy Noether-Programme from the German Research Foundation (DFG; KL-2374/2-1). A.O. was supported by KIKA project 109. This work was supported by grants to CMZ and MMvdH-E from the Children Cancer Free Foundation (KIKA, projects 49 and 109) and to JHK from the DFG (KL-2374/2-1).	Alemdehy MF, 2015, BLOOD; Avdulov S, 2004, CANCER CELL, V5, P553, DOI 10.1016/j.ccr.2004.05.024; Bao W, 2011, GASTROENTEROLOGY, V141, P2076, DOI 10.1053/j.gastro.2011.08.050; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Berindan-Neagoe I, 2014, CA-CANCER J CLIN, V64, P311, DOI 10.3322/caac.21244; Boussemart L, 2014, NATURE, V513, P105, DOI 10.1038/nature13572; Breinbauer R, 2003, CHEMBIOCHEM, V4, P1147, DOI 10.1002/cbic.200300705; Caron S, 2004, MOL CELL BIOL, V24, P4920, DOI 10.1128/MCB.24.11.4920-4928.2004; Chen P, 2013, P NATL ACAD SCI USA, V110, P11511, DOI 10.1073/pnas.1310144110; Cheng JJ, 2013, CELL REP, V5, P471, DOI 10.1016/j.celrep.2013.08.050; Cheng YC, 2013, P NATL ACAD SCI USA, V110, P5993, DOI 10.1073/pnas.1220635110; Clemens MJ, 2004, ONCOGENE, V23, P3180, DOI 10.1038/sj.onc.1207544; Creutzig U, 2012, BLOOD, V120, P3187, DOI 10.1182/blood-2012-03-362608; Deng BY, 2013, TUMOR BIOL, V34, P2617, DOI 10.1007/s13277-013-0811-2; Dou L, 2012, ONCOGENE, V31, P507, DOI 10.1038/onc.2011.248; Emmrich S, 2014, LEUKEMIA, V28, P1022, DOI 10.1038/leu.2013.357; Fan Q, 2013, CELL BIOCHEM FUNCT, V31, P319, DOI 10.1002/cbf.2902; FukuchiShimogori T, 1997, CANCER RES, V57, P5041; Gradi A, 1998, MOL CELL BIOL, V18, P334, DOI 10.1128/MCB.18.1.334; Gu W, 2014, ONCOL REP, V31, P397, DOI 10.3892/or.2013.2831; Hariri F, 2013, LEUKEMIA, V27, P2047, DOI 10.1038/leu.2013.73; Henis-Korenblit S, 2002, P NATL ACAD SCI USA, V99, P5400, DOI 10.1073/pnas.082102499; Hinnebusch AG, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011544; Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618; Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480; Jiang H, 2011, CELL, V144, P513, DOI 10.1016/j.cell.2011.01.020; Kar AN, 2013, J NEUROSCI, V33, P7165, DOI 10.1523/JNEUROSCI.2040-12.2013; Klein U, 2010, CANCER CELL, V17, P28, DOI 10.1016/j.ccr.2009.11.019; Krishnan K, 2013, RNA, V19, P1767, DOI 10.1261/rna.042143.113; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Lee DW, 2012, ONCOGENE, V31, P4085, DOI 10.1038/onc.2011.579; Lee SH, 2006, EMBO J, V25, P4008, DOI 10.1038/sj.emboj.7601268; Li RY, 2013, CNS NEUROSCI THER, V19, P477, DOI 10.1111/cns.12089; Li ZJ, 2012, BLOOD, V119, P2314, DOI 10.1182/blood-2011-10-386235; Lin TY, 2012, ONCOGENE, V31, P3287, DOI 10.1038/onc.2011.491; Luo HN, 2014, MED ONCOL, V31, DOI 10.1007/s12032-013-0789-z; Marash L, 2008, MOL CELL, V30, P447, DOI 10.1016/j.molcel.2008.03.018; Martelli AM, 2006, LEUKEMIA, V20, P911, DOI 10.1038/sj.leu.2404245; Masaki S, 2007, BIOCHEM BIOPH RES CO, V364, P509, DOI 10.1016/j.bbrc.2007.10.077; Mazan-Mamczarz K, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004105; Nousch M, 2007, RNA, V13, P374, DOI 10.1261/rna.372307; Placke T, 2014, BLOOD, V124, P13, DOI 10.1182/blood-2014-02-558114; Qin H, 2003, J BIOL CHEM, V278, P48570, DOI 10.1074/jbc.M308781200; Sanders MA, 2013, CURR OPIN HEMATOL, V20, P79, DOI 10.1097/MOH.0b013e32835d821c; Scheicher R, 2015, BLOOD, V125, P90, DOI 10.1182/blood-2014-06-584417; Shen K, 2014, FEBS J, V281, P3609, DOI 10.1111/febs.12880; Solh M, 2014, AM J HEMATOL, V89, P1121, DOI 10.1002/ajh.23821; Srivastava T, 2012, J NEUROSCI, V32, P5620, DOI 10.1523/JNEUROSCI.0030-12.2012; Stankov MV, 2014, LEUKEMIA, V28, P577, DOI 10.1038/leu.2013.264; Tamburini J, 2009, CELL CYCLE, V8, P3893, DOI 10.4161/cc.8.23.10091; Tu LX, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-78; Vardiman JW, 2009, BLOOD, V114, P937, DOI 10.1182/blood-2009-03-209262; Vinther J, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl590; Virgili G, 2013, STRUCTURE, V21, P517, DOI 10.1016/j.str.2013.01.015; Wang ZY, 2013, MOL CELL BIOCHEM, V383, P59, DOI 10.1007/s11010-013-1754-z; Weber K, 2008, MOL THER, V16, P698, DOI 10.1038/mt.2008.6; Wong CCL, 2011, GASTROENTEROLOGY, V140, P322, DOI 10.1053/j.gastro.2010.10.006; YANAGISAWA K, 1991, BLOOD, V78, P451; Yu JW, 2008, GENE EXPRESSION, V14, P173; Zhang LJ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-124	60	42	44	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2016	35	14					1822	1831		10.1038/onc.2015.247	http://dx.doi.org/10.1038/onc.2015.247			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DI6LM	26165837				2022-12-17	WOS:000373610400008
J	Samanta, S; Sun, H; Goel, HL; Pursell, B; Chang, C; Khan, A; Greiner, DL; Cao, S; Lim, E; Shultz, LD; Mercurio, AM				Samanta, S.; Sun, H.; Goel, H. L.; Pursell, B.; Chang, C.; Khan, A.; Greiner, D. L.; Cao, S.; Lim, E.; Shultz, L. D.; Mercurio, A. M.			IMP3 promotes stem-like properties in triple-negative breast cancer by regulating SLUG	ONCOGENE			English	Article							REPRESSES E-CADHERIN; SELF-RENEWAL; CARCINOMA PHENOTYPE; TGF-BETA; CELLS; SOX2; EXPRESSION; IDENTIFICATION; TRANSITIONS; RESISTANCE	IMP3 (insulin-like growth factor-2 mRNA binding protein 3) is an oncofetal protein whose expression is prognostic for poor outcome in several cancers. Although IMP3 is expressed preferentially in triple-negative breast cancer (TNBC), its function is poorly understood. We observed that IMP3 expression is significantly higher in tumor initiating than in non-tumor initiating breast cancer cells and we demonstrate that IMP3 contributes to self-renewal and tumor initiation, properties associated with cancer stem cells (CSCs). The mechanism by which IMP3 contributes to this phenotype involves its ability to induce the stem cell factor SOX2. IMP3 does not interact with SOX2 mRNA significantly or regulate SOX2 expression directly. We discovered that IMP3 binds avidly to SNAI2 (SLUG) mRNA and regulates its expression by binding to the 5' UTR. This finding is significant because SLUG has been implicated in breast CSCs and TNBC. Moreover, we show that SOX2 is a transcriptional target of SLUG. These data establish a novel mechanism of breast tumor initiation involving IMP3 and they provide a rationale for its association with aggressive disease and poor outcome.	[Samanta, S.; Sun, H.; Goel, H. L.; Pursell, B.; Chang, C.; Mercurio, A. M.] Univ Massachusetts, Sch Med, Dept Mol Cell & Canc Biol, Lazare Res Bldg,364 Plantat St, Worcester, MA 01605 USA; [Khan, A.] Univ Massachusetts, Sch Med, Dept Pathol, Lazare Res Bldg,364 Plantat St, Worcester, MA 01605 USA; [Greiner, D. L.] Univ Massachusetts, Sch Med, Program Mol Med, Lazare Res Bldg,364 Plantat St, Worcester, MA 01605 USA; [Cao, S.; Lim, E.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Shultz, L. D.] Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Dana-Farber Cancer Institute; Jackson Laboratory	Mercurio, AM (corresponding author), Univ Massachusetts, Sch Med, Dept Mol Cell & Canc Biol, Lazare Res Bldg,364 Plantat St, Worcester, MA 01605 USA.	arthur.mercurio@umassmed.edu	Lim, Elgene/AAS-7280-2020	Lim, Elgene/0000-0001-8065-8838; Cao, Shiliang/0000-0003-4908-0091; /0000-0003-1726-3037	Megan Lally Memorial Fund; NIH [CA168464, CA034196, AI46629]; National Breast Cancer Foundation [PRAC-14-002] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [R01CA168464, P30CA034196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI046629] Funding Source: NIH RePORTER	Megan Lally Memorial Fund; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Breast Cancer Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank Dr Chung-Cheng Hsieh (University of Massachusetts Medical School) for statistical analysis of our in vivo data. This work was supported by the Megan Lally Memorial Fund and NIH Grants CA168464, CA034196 and AI46629.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Basu-Roy U, 2012, ONCOGENE, V31, P2270, DOI 10.1038/onc.2011.405; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bhola NE, 2013, J CLIN INVEST, V123, P1348, DOI 10.1172/JCI65416; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Boumahdi S, 2014, NATURE, V511, P246, DOI 10.1038/nature13305; Calcagno AM, 2010, JNCI-J NATL CANCER I, V102, P1637, DOI 10.1093/jnci/djq361; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chaudhary J, 1999, MOL ENDOCRINOL, V13, P774, DOI 10.1210/me.13.5.774; Chen CL, 2013, J CLIN INVEST, V123, P2832, DOI 10.1172/JCI65859; Chen YP, 2008, J BIOL CHEM, V283, P17969, DOI 10.1074/jbc.M802917200; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Fillmore CM, 2010, P NATL ACAD SCI USA, V107, P21737, DOI 10.1073/pnas.1007863107; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Goel HL, 2014, CELL REP, V7, P747, DOI 10.1016/j.celrep.2014.03.059; Goel HL, 2013, EMBO MOL MED, V5, P488, DOI 10.1002/emmm.201202078; Grimshaw MJ, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2106; Hajra KM, 2002, CANCER RES, V62, P1613; Idowu MO, 2012, HUM PATHOL, V43, P364, DOI 10.1016/j.humpath.2011.05.005; Iliopoulos D, 2011, P NATL ACAD SCI USA, V108, P1397, DOI 10.1073/pnas.1018898108; Janiszewska M, 2012, GENE DEV, V26, P1926, DOI 10.1101/gad.188292.112; Jiang Z, 2006, LANCET ONCOL, V7, P556, DOI 10.1016/S1470-2045(06)70732-X; Jonson L, 2014, CELL REP, V7, P539, DOI 10.1016/j.celrep.2014.03.015; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kono K, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-141; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Liu R, 2007, NEW ENGL J MED, V356, P217, DOI 10.1056/NEJMoa063994; Loi S, 2007, J CLIN ONCOL, V25, P1239, DOI 10.1200/JCO.2006.07.1522; Mak P, 2006, NEOPLASIA, V8, P896, DOI 10.1593/neo.06538; Nielsen J, 1999, MOL CELL BIOL, V19, P1262; Oguro H, 2010, CELL STEM CELL, V6, P279, DOI 10.1016/j.stem.2010.01.005; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Phillips S, 2014, STEM CELL REP, V2, P633, DOI 10.1016/j.stemcr.2014.03.008; Proia TA, 2011, CELL STEM CELL, V8, P149, DOI 10.1016/j.stem.2010.12.007; Rodriguez-Pinilla SM, 2007, MODERN PATHOL, V20, P474, DOI 10.1038/modpathol.3800760; Rybak AP, 2013, CELL SIGNAL, V25, P2734, DOI 10.1016/j.cellsig.2013.08.041; Samanta S, 2012, ONCOGENE, V31, P4689, DOI 10.1038/onc.2011.620; Samanta S, 2013, J BIOL CHEM, V288, P12569, DOI 10.1074/jbc.C112.442319; Siegle JM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5511; Singh S, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-73; Storci G, 2008, J PATHOL, V214, P25, DOI 10.1002/path.2254; Su P, 2014, INT J CLIN EXP PATHO, V7, P3008; Tada Y, 2015, ONCOGENE, V34, P752, DOI 10.1038/onc.2013.599; Tam WL, 2013, CANCER CELL, V24, P347, DOI 10.1016/j.ccr.2013.08.005; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Walter O, 2009, HUM PATHOL, V40, P1528, DOI 10.1016/j.humpath.2009.05.005; Zhao D, 2015, ONCOGENE, V34, P3107, DOI 10.1038/onc.2014.257; Zhao XL, 2015, ONCOL REP, V33, P149, DOI 10.3892/or.2014.3562	50	42	42	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2016	35	9					1111	1121		10.1038/onc.2015.164	http://dx.doi.org/10.1038/onc.2015.164			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DF4WH	25982283	Green Accepted			2022-12-17	WOS:000371351700005
J	Giotopoulos, G; Chan, WI; Horton, SJ; Ruau, D; Gallipoli, P; Fowler, A; Crawley, C; Papaemmanuil, E; Campbell, PJ; Gottgens, B; Van Deursen, JM; Cole, PA; Huntly, BJP				Giotopoulos, G.; Chan, W-I; Horton, S. J.; Ruau, D.; Gallipoli, P.; Fowler, A.; Crawley, C.; Papaemmanuil, E.; Campbell, P. J.; Goettgens, B.; Van Deursen, J. M.; Cole, P. A.; Huntly, B. J. P.			The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia	ONCOGENE			English	Article							CREB-BINDING-PROTEIN; MUTATIONS; GENE; RECRUITMENT; MECHANISMS; INTERACTS; CHROMATIN; REQUIRES	Growing evidence links abnormal epigenetic control to the development of hematological malignancies. Accordingly, inhibition of epigenetic regulators is emerging as a promising therapeutic strategy. The acetylation status of lysine residues in histone tails is one of a number of epigenetic post-translational modifications that alter DNA-templated processes, such as transcription, to facilitate malignant transformation. Although histone deacetylases are already being clinically targeted, the role of histone lysine acetyltransferases (KAT) in malignancy is less well characterized. We chose to study this question in the context of acute myeloid leukemia (AML), where, using in vitro and in vivo genetic ablation and knockdown experiments in murine models, we demonstrate a role for the epigenetic regulators CBP and p300 in the induction and maintenance of AML. Furthermore, using selective small molecule inhibitors of their lysine acetyltransferase activity, we validate CBP/p300 as therapeutic targets in vitro across a wide range of human AML subtypes. We proceed to show that growth retardation occurs through the induction of transcriptional changes that induce apoptosis and cell-cycle arrest in leukemia cells and finally demonstrate the efficacy of the KAT inhibitors in decreasing clonogenic growth of primary AML patient samples. Taken together, these data suggest that CBP/p300 are promising therapeutic targets across multiple subtypes in AML.	[Giotopoulos, G.; Chan, W-I; Horton, S. J.; Ruau, D.; Gallipoli, P.; Fowler, A.; Crawley, C.; Campbell, P. J.; Goettgens, B.; Huntly, B. J. P.] Univ Cambridge, Dept Haematol, Cambridge Inst Med Res, Hills Rd, Cambridge CB2 2XY, England; [Giotopoulos, G.; Chan, W-I; Horton, S. J.; Ruau, D.; Gallipoli, P.; Fowler, A.; Crawley, C.; Campbell, P. J.; Goettgens, B.; Huntly, B. J. P.] Univ Cambridge, Addenbrookes Hosp, Cambridge CB2 2QQ, England; [Giotopoulos, G.; Chan, W-I; Horton, S. J.; Ruau, D.; Gallipoli, P.; Goettgens, B.; Huntly, B. J. P.] Wellcome Trust Res Labs, Med Res Council, Cambridge Stem Cell Inst, Cambridge, England; [Chan, W-I] Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Taipa, Macau, Peoples R China; [Papaemmanuil, E.; Campbell, P. J.] Wellcome Trust Sanger Inst, Hinxton, England; [Van Deursen, J. M.] Mayo Clin, Dept Pediat & Adolescent Med, Coll Med, Rochester, MN USA; [Cole, P. A.] Johns Hopkins Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD USA	University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of Cambridge; Wellcome Trust Sanger Institute; Macau University of Science & Technology; Wellcome Trust Sanger Institute; Mayo Clinic; Johns Hopkins University; Johns Hopkins Medicine	Huntly, BJP (corresponding author), Univ Cambridge, Dept Haematol, Cambridge Inst Med Res, Hills Rd, Cambridge CB2 2XY, England.	bjph2@cam.ac.uk	Gallipoli, Paolo/AAA-7094-2019; huntly, brian/E-6725-2014	Gallipoli, Paolo/0000-0001-7254-2253; Gottgens, Berthold/0000-0001-6302-5705; Giotopoulos, George/0000-0003-1390-6592; huntly, brian/0000-0003-0312-161X	Cancer Research UK; Leukemia Lymphoma Research; Kay Kendal Leukemia Fund; Leukemia lymphoma Society of America; Wellcome Trust; Medical Research Council; NIHR Cambridge Biomedical Research Centre grant; BBSRC [BB/I00050X/1] Funding Source: UKRI; MRC [MR/M010392/1] Funding Source: UKRI; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062437, R37GM062437] Funding Source: NIH RePORTER; Academy of Medical Sciences (AMS) [AMS-SGCL10-Gallipoli] Funding Source: researchfish; Biotechnology and Biological Sciences Research Council [BB/I00050X/1] Funding Source: researchfish; Cancer Research UK [12765] Funding Source: researchfish; Medical Research Council [MR/M010392/1, MC_PC_12009] Funding Source: researchfish; Worldwide Cancer Research [14-1069] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Leukemia Lymphoma Research; Kay Kendal Leukemia Fund; Leukemia lymphoma Society of America(Leukemia and Lymphoma Society); Wellcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIHR Cambridge Biomedical Research Centre grant; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Academy of Medical Sciences (AMS)(Academy of Medical Sciences (AMS)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Worldwide Cancer Research	Funding in the Huntly laboratory comes from Cancer Research UK, Leukemia Lymphoma Research, the Kay Kendal Leukemia Fund, the Leukemia lymphoma Society of America, the Wellcome Trust, The Medical Research Council and an NIHR Cambridge Biomedical Research Centre grant. Patient samples were processed in the Cambridge Blood and Stem Cell Biobank.	Allard S, 2004, BBA-GENE STRUCT EXPR, V1677, P158, DOI 10.1016/j.bbaexp.2003.10.016; Baljeyic M, 2011, HEMATOL ONCOL CLIN N, V25, P1215, DOI 10.1016/j.hoc.2011.10.002; Bayly R, 2004, J BIOL CHEM, V279, P55362, DOI 10.1074/jbc.M408654200; Bedford DC, 2010, EPIGENETICS-US, V5, P9, DOI 10.4161/epi.5.1.10449; Blobel GA, 2000, BLOOD, V95, P745, DOI 10.1182/blood.V95.3.745.003k05_745_755; Bowers EM, 2010, CHEM BIOL, V17, P471, DOI 10.1016/j.chembiol.2010.03.006; Cao G., 2014, EVID-BASED COMPL ALT, V2014, P1, DOI DOI 10.1109/WCSP.2013.6677085; Chan WI, 2011, MOL CELL BIOL, V31, P5046, DOI 10.1128/MCB.05830-11; Dawson MA, 2012, NEW ENGL J MED, V367, P647, DOI 10.1056/NEJMra1112635; Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509; Deguchi K, 2003, CANCER CELL, V3, P259, DOI 10.1016/S1535-6108(03)00051-5; Estey E, 2006, LANCET, V368, P1894, DOI 10.1016/S0140-6736(06)69780-8; Gang EJ, 2014, ONCOGENE, V33, P2169, DOI 10.1038/onc.2013.169; Grunwald MR, 2013, INT J HEMATOL, V97, P683, DOI 10.1007/s12185-013-1334-8; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Holmfeldt L, 2013, NAT GENET, V45, P242, DOI 10.1038/ng.2532; Huntly BJP, 2004, CANCER CELL, V6, P587, DOI 10.1016/j.ccr.2004.10.015; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Ihaka R., 1996, J COMPUT GRAPH STAT, V5, P299, DOI [10.2307/1390807, DOI 10.1080/10618600.1996.10474713]; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Kasper LH, 1999, MOL CELL BIOL, V19, P764; Kimbrel EA, 2009, BLOOD, V114, P4804, DOI 10.1182/blood-2009-04-217794; Kung AL, 2000, GENE DEV, V14, P272; Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689; Mullighan CG, 2011, NATURE, V471, P235, DOI 10.1038/nature09727; Myers RM, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001046; Oki Y, 2010, CANCER TREAT RES, V145, P19, DOI 10.1007/978-0-387-69259-3_2; Papaemmanuil E, 2013, BLOOD, V122, P3616, DOI 10.1182/blood-2013-08-518886; Pasqualucci L, 2011, NATURE, V471, P189, DOI 10.1038/nature09730; Payne SR, 2005, CARCINOGENESIS, V26, P2031, DOI 10.1093/carcin/bgi223; Rebel VI, 2002, P NATL ACAD SCI USA, V99, P14789, DOI 10.1073/pnas.232568499; Roelfsema Jeroen H., 2007, Expert Reviews in Molecular Medicine, V9, P1, DOI 10.1017/S1462399407000415; So CW, 2002, MOL CELL BIOL, V22, P6542, DOI 10.1128/MCB.22.18.6542-6552.2002; Taki T, 1997, BLOOD, V89, P3945, DOI 10.1182/blood.V89.11.3945; Walter RB, 2012, BLOOD, V119, P6198, DOI 10.1182/blood-2011-11-325050; Wang L, 2011, SCIENCE, V333, P765, DOI 10.1126/science.1201662	36	42	45	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2016	35	3					279	289		10.1038/onc.2015.92	http://dx.doi.org/10.1038/onc.2015.92			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OF	25893291	Green Accepted			2022-12-17	WOS:000369055300002
J	Gong, J; Weng, D; Eguchi, T; Murshid, A; Sherman, MY; Song, B; Calderwood, SK				Gong, J.; Weng, D.; Eguchi, T.; Murshid, A.; Sherman, M. Y.; Song, B.; Calderwood, S. K.			Targeting the hsp70 gene delays mammary tumor initiation and inhibits tumor cell metastasis	ONCOGENE			English	Article							HEAT-SHOCK-PROTEIN; BREAST-CANCER; C-MET; PROGNOSTIC-SIGNIFICANCE; TANESPIMYCIN 17-AAG; MOUSE MODEL; EXPRESSION; HEAT-SHOCK-PROTEIN-70; ACTIVATION; HSP90	Elevated levels of the inducible heat-shock protein 70 (Hsp72) have been implicated in mammary tumorigenesis in histological investigations of human breast cancer. We therefore examined the role of Hsp72 in mice, using animals in which the hsp70 gene was inactivated. We used a spontaneous tumor system with mice expressing the polyomavirus middle T (PyMT) oncogene under control of the mouse mammary tumor virus (MMTV) long-terminal repeat (MMT mice). These mice developed spontaneous, metastatic mammary cancer. We then showed Hsp72 to be upregulated in a fraction of mammary cancer initiating cells (CIC) within the MMT tumor cell population. These cells were characterized by elevated surface levels of stem cell markers CD44 and Sca1 and by rapid metastasis. Inactivation of the hsp70 gene delayed the initiation of mammary tumors. This delay in tumor initiation imposed by loss of hsp70 was correlated with a decreased pool of CIC. Interestingly, hsp70 knockout significantly reduced invasion and metastasis by mammary tumor cells and implicated its product Hsp72 in cell migration and formation of secondary neoplasms. Impaired tumorigenesis and metastasis in hsp70-knockout MMT mice was associated with downregulation of the met gene and reduced activition of the oncogenic c-Met protein. These experiments therefore showed Hsp72 to be involved in the growth and progression of mammary carcinoma and highlighted this protein as a potential target for anticancer drug development.	[Gong, J.; Weng, D.; Song, B.] Boston Univ, Dept Med, Med Ctr, Boston, MA 02118 USA; [Eguchi, T.; Murshid, A.; Calderwood, S. K.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Mol & Cellular Radiat Oncol, Boston, MA 02215 USA; [Sherman, M. Y.] Boston Univ, Med Ctr, Dept Biochem, Boston, MA 02118 USA	Boston University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Boston University	Gong, J (corresponding author), Boston Univ, Dept Med, Sch Med, 650 Albany St,Room 309, Boston, MA 02118 USA.	jgong@bu.edu; scalderw@bidmc.harvard.edu		Eguchi, Takanori/0000-0002-3297-6126	Department of Radiation Oncology, Beth Israel Deaconess Medical Center; NIH [R01CA119045, RO1CA47407, RO1CA176326]; Harvard JCRT Foundation; NATIONAL CANCER INSTITUTE [R01CA176326, R01CA047407, R01CA119045] Funding Source: NIH RePORTER	Department of Radiation Oncology, Beth Israel Deaconess Medical Center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Harvard JCRT Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge the support of the Department of Radiation Oncology, Beth Israel Deaconess Medical Center. This work was supported by NIH research grants R01CA119045, RO1CA47407 and RO1CA176326 as well as the Harvard JCRT Foundation. We are grateful to Buzz Hunt for the kind gift of the hsp70 knockout mice.	Barrott JJ, 2013, FEBS J, V280, P1381, DOI 10.1111/febs.12147; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Boccaccio C, 2006, NAT REV CANCER, V6, P637, DOI 10.1038/nrc1912; Boroughs LK, 2011, J BIOL CHEM, V286, P37094, DOI 10.1074/jbc.M111.242438; Calderwood SK, 2012, CURR MOL MED, V12, P1102, DOI 10.2174/156652412803306675; Calderwood SK, 2012, J CELL BIOCHEM, V113, P1096, DOI 10.1002/jcb.23461; CARDIFF RD, 1993, CANCER SURV, V16, P97; Chmielowiec J, 2007, J CELL BIOL, V177, P151, DOI 10.1083/jcb.200701086; Chou SD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039679; Colvin TA, 2014, CANCER RES, V74, P4731, DOI 10.1158/0008-5472.CAN-14-0747; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; Dang CV, 2012, GENE DEV, V26, P877, DOI 10.1101/gad.189365.112; Eguchi T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058796; Gallego MI, 2003, ONCOGENE, V22, P8498, DOI 10.1038/sj.onc.1207063; Galluzzi L, 2009, MOL CELL, V36, P176, DOI 10.1016/j.molcel.2009.10.003; Gao TY, 2002, J BIOL CHEM, V277, P31585, DOI 10.1074/jbc.M204335200; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; Ghoussoub RAD, 1998, CANCER, V82, P1513, DOI 10.1002/(SICI)1097-0142(19980415)82:8<1513::AID-CNCR13>3.0.CO;2-7; Goloudina AR, 2012, CANCER LETT, V325, P117, DOI 10.1016/j.canlet.2012.06.003; Gomez AV, 2008, MOL CELL, V31, P222, DOI 10.1016/j.molcel.2008.06.015; Grange C, 2008, NEOPLASIA, V10, P1433, DOI 10.1593/neo.08902; Gurtner GC, 2008, NATURE, V453, P314, DOI 10.1038/nature07039; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hunt CR, 2004, MOL CELL BIOL, V24, P899, DOI 10.1128/MCB.24.2.899-911.2004; Jiang YF, 2001, CANCER RES, V61, P2365; Kalogeraki A, 2007, J EXP CLIN CANC RES, V26, P367; Kang Y, 2013, KOREAN J PATHOL, V47, P219, DOI 10.4132/KoreanJPathol.2013.47.3.219; Khaleque M, 2008, ONCOGENE, V27, P1886, DOI 10.1038/sj.onc.1210834; Kishor A, 2013, MOL CELL BIOL, V33, P71, DOI 10.1128/MCB.01275-12; Kluger HM, 2005, CANCER RES, V65, P5578, DOI 10.1158/0008-5472.CAN-05-0108; Kouspou MM, 2011, METHODS MOL BIOL, V787, P303, DOI 10.1007/978-1-61779-295-3_23; Lee WY, 2005, CLIN CANCER RES, V11, P2222, DOI 10.1158/1078-0432.CCR-04-1761; Lengyel E, 2005, INT J CANCER, V113, P678, DOI 10.1002/ijc.20598; Li F, 2007, CELL RES, V17, P3, DOI 10.1038/sj.cr.7310118; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Liu FF, 1996, INT J HYPERTHER, V12, P197, DOI 10.3109/02656739609022508; Locatelli A, 2012, HORM CANCER-US, V3, P14, DOI 10.1007/s12672-011-0097-z; Meng L, 2011, ONCOGENE, V30, P2836, DOI 10.1038/onc.2011.5; Modi S, 2007, J CLIN ONCOL, V25, P5410, DOI 10.1200/JCO.2007.11.7960; Modi S, 2011, CLIN CANCER RES, V17, P5132, DOI 10.1158/1078-0432.CCR-11-0072; Mukherjee P, 2003, J IMMUNOTHER, V26, P47, DOI 10.1097/00002371-200301000-00006; Nakajima M, 2002, CANCER LETT, V178, P99, DOI 10.1016/S0304-3835(01)00825-4; Neckers L, 2012, CLIN CANCER RES, V18, P64, DOI 10.1158/1078-0432.CCR-11-1000; Otsuka T, 1998, CANCER RES, V58, P5157; Pocaly M, 2007, LEUKEMIA, V21, P93, DOI 10.1038/sj.leu.2404463; Powers MV, 2010, CELL CYCLE, V9, P1542, DOI 10.4161/cc.9.8.11204; Rerole AL, 2011, METHODS MOL BIOL, V787, P205, DOI 10.1007/978-1-61779-295-3_16; Rodriguez Luis G., 2004, V294, P23; Rohde M, 2005, GENE DEV, V19, P570, DOI 10.1101/gad.305405; Santagata S, 2011, P NATL ACAD SCI USA, V108, P18378, DOI 10.1073/pnas.1115031108; SCHLESINGER MJ, 1994, PEDIATR RES, V36, P1; Slattery ML, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063165; STEVENSON MA, 1990, MOL CELL BIOL, V10, P1234, DOI 10.1128/MCB.10.3.1234; Sun BC, 2008, CLIN CANCER RES, V14, P7050, DOI 10.1158/1078-0432.CCR-08-0520; Takeuchi H, 2003, CLIN CANCER RES, V9, P1480; Tang D, 2005, CELL STRESS CHAPERON, V10, P46, DOI 10.1379/CSC-44R.1; Teng Y, 2012, J BIOL CHEM, V287, P10051, DOI 10.1074/jbc.M111.335000; Thanner F, 2003, ANTICANCER RES, V23, P1057; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; Weng DS, 2013, J IMMUNOL, V191, P755, DOI 10.4049/jimmunol.1203286; Weng DS, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3102; Xia JC, 2003, J IMMUNOL, V170, P1980, DOI 10.4049/jimmunol.170.4.1980	67	42	44	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2015	34	43					5460	5471		10.1038/onc.2015.1	http://dx.doi.org/10.1038/onc.2015.1			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EM	25659585	Green Accepted			2022-12-17	WOS:000363479700006
J	Manning, CS; Hooper, S; Sahai, EA				Manning, C. S.; Hooper, S.; Sahai, E. A.			Intravital imaging of SRF and Notch signalling identifies a key role for EZH2 in invasive melanoma cells	ONCOGENE			English	Article							CENTROMERE-ASSOCIATED KINESIN; BREAST-CANCER CELLS; STEM-CELLS; PROTEIN EZH2; EXPRESSION; TRANSCRIPTION; METASTASIS; GENE; DIFFERENTIATION; MELANOCYTES	The acquisition of cell motility is an early step in melanoma metastasis. Here we use intravital imaging of signalling reporter cell-lines combined with genome-wide transcriptional analysis to define signalling pathways and genes associated with melanoma metastasis. Intravital imaging revealed heterogeneous cell behaviour in vivo: < 10% of cells were motile and both singly moving cells and streams of cells were observed. Motile melanoma cells had increased Notch- and SRF-dependent transcription. Subsequent genome-wide analysis identified an overlapping set of genes associated with high Notch and SRF activity. We identified EZH2, a histone methyltransferase in the Polycomb repressive complex 2, as a regulator of these genes. Heterogeneity of EZH2 levels is observed in melanoma models, and co-ordinated upregulation of genes positively regulated by EZH2 is associated with melanoma metastasis. EZH2 was also identified as regulating the amelanotic phenotype of motile cells in vivo by suppressing expression of the P-glycoprotein Oca2. Analysis of patient samples confirmed an inverse relationship between EZH2 levels and pigment. EZH2 targeting with siRNA and chemical inhibition reduced invasion in mouse and human melanoma cell lines. The EZH2-regulated genes KIF2C and KIF22 are required for melanoma cell invasion and important for lung colonization. We propose that heterogeneity in EZH2 levels leads to heterogeneous expression of a cohort of genes associated with motile behaviour including KIF2C and KIF22. EZH2-dependent increased expression of these genes promotes melanoma cell motility and early steps in metastasis.	[Manning, C. S.; Hooper, S.; Sahai, E. A.] Canc Res UK London Res Inst, Tumour Cell Biol Lab, London WC2A 3LY, England	Cancer Research UK	Sahai, EA (corresponding author), Canc Res UK London Res Inst, Tumour Cell Biol, 44 Lincolns Inn Fields, London WC2A 3LY, England.	erik.sahai@cancer.org.uk		Sahai, Erik/0000-0002-3932-5086; Manning, Cerys/0000-0001-8656-5878	McGrath Charitable Trust via Cancer Research UK; Cancer Research UK; Cancer Research UK [15154] Funding Source: researchfish	McGrath Charitable Trust via Cancer Research UK; Cancer Research UK(Cancer Research UK); Cancer Research UK(Cancer Research UK)	We thank members of the Tumour Cell Biology laboratory for their discussion and comments. We thank Richard Treisman's laboratory for reagents. We are indebted to the Experimental Histopathology laboratory, FACS laboratory and Biological Resources Unit at the London Research Institute and Rosamond Nuamah and Charles Mein at Barts and The London Genome Centre. We are extremely grateful for PhD sponsorship of CSM from The McGrath Charitable Trust via Cancer Research UK. This study was supported by Cancer Research UK.	Andersson ER, 2011, DEVELOPMENT, V138, P3593, DOI 10.1242/dev.063610; Asangani IA, 2012, ONCOTARGET, V3, P1011, DOI 10.18632/oncotarget.622; Bailey CM, 2012, PIGM CELL MELANOMA R, V25, P573, DOI 10.1111/j.1755-148X.2012.01025.x; Balint K, 2005, J CLIN INVEST, V115, P3166, DOI 10.1172/JCI25001; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Chen K, 2002, MOL BIOL CELL, V13, P1953, DOI 10.1091/mbc.02-02-0022; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Donnelly MP, 2012, HUM GENET, V131, P683, DOI 10.1007/s00439-011-1110-x; Ezhkova E, 2009, CELL, V136, P1122, DOI 10.1016/j.cell.2008.12.043; Friedl P, 2012, NAT CELL BIOL, V14, P777, DOI 10.1038/ncb2548; Gaggioli C, 2007, NAT CELL BIOL, V9, P1392, DOI 10.1038/ncb1658; Giampieri S, 2009, NAT CELL BIOL, V11, P1287, DOI 10.1038/ncb1973; Goodall J, 2008, CANCER RES, V68, P7788, DOI 10.1158/0008-5472.CAN-08-1053; Goswami S, 2004, CANCER RES, V64, P7664, DOI 10.1158/0008-5472.CAN-04-2027; Gupta PB, 2005, NAT GENET, V37, P1047, DOI 10.1038/ng1634; Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491; Hoek KS, 2010, PIGM CELL MELANOMA R, V23, P746, DOI 10.1111/j.1755-148X.2010.00757.x; Hou P, 2012, CELL CYCLE, V11, P286, DOI 10.4161/cc.11.2.18707; Ishikawa K, 2008, BRIT J CANCER, V98, P1824, DOI 10.1038/sj.bjc.6604379; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Kitzing TM, 2010, ONCOGENE, V29, P2441, DOI 10.1038/onc.2009.515; Liu ZJ, 2006, CANCER RES, V66, P4182, DOI 10.1158/0008-5472.CAN-05-3589; Manning CS, 2013, INTRAVITAL, V2, P33; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; McHugh JB, 2007, J CUTAN PATHOL, V34, P597, DOI 10.1111/j.1600-0560.2006.00678.x; Medjkane S, 2009, NAT CELL BIOL, V11, P257, DOI 10.1038/ncb1833; Morey L, 2010, TRENDS BIOCHEM SCI, V35, P323, DOI 10.1016/j.tibs.2010.02.009; Moriyama M, 2006, J CELL BIOL, V173, P333, DOI 10.1083/jcb.200509084; Nakamura Y, 2007, BRIT J CANCER, V97, P543, DOI 10.1038/sj.bjc.6603905; Nuytten M, 2008, ONCOGENE, V27, P1449, DOI 10.1038/sj.onc.1210774; Olson EN, 2010, NAT REV MOL CELL BIO, V11, P353, DOI 10.1038/nrm2890; Pinner S, 2009, CANCER RES, V69, P7969, DOI 10.1158/0008-5472.CAN-09-0781; Pinnix CC, 2009, CANCER RES, V69, P5312, DOI 10.1158/0008-5472.CAN-08-3767; Ren G, 2012, CANCER RES, V72, P3091, DOI 10.1158/0008-5472.CAN-11-3546; ROSEMBLAT S, 1994, P NATL ACAD SCI USA, V91, P12071, DOI 10.1073/pnas.91.25.12071; Sahai E, 2005, BMC BIOTECHNOL, V5, DOI 10.1186/1472-6750-5-14; Sahlgren C, 2008, P NATL ACAD SCI USA, V105, P6392, DOI 10.1073/pnas.0802047105; Sanz-Moreno V, 2008, CELL, V135, P510, DOI 10.1016/j.cell.2008.09.043; Sanz-Moreno V, 2011, CANCER CELL, V20, P229, DOI 10.1016/j.ccr.2011.06.018; Tiwari N, 2013, CANCER CELL, V23, P768, DOI 10.1016/j.ccr.2013.04.020; Zabierowski SE, 2011, STEM CELLS, V29, P1752, DOI 10.1002/stem.740; Zhao XH, 2007, J CELL SCI, V120, P1801, DOI 10.1242/jcs.001586	42	42	42	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2015	34	33					4320	4332		10.1038/onc.2014.362	http://dx.doi.org/10.1038/onc.2014.362			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO9KK	25381824	Green Accepted			2022-12-17	WOS:000359494400004
J	Mounir, Z; Lin, F; Lin, VG; Korn, JM; Yu, Y; Valdez, R; Aina, OH; Buchwalter, G; Jaffe, AB; Korpal, M; Zhu, P; Brown, M; Cardiff, RD; Rocnik, JL; Yang, Y; Pagliarini, R				Mounir, Z.; Lin, F.; Lin, V. G.; Korn, J. M.; Yu, Y.; Valdez, R.; Aina, O. H.; Buchwalter, G.; Jaffe, A. B.; Korpal, M.; Zhu, P.; Brown, M.; Cardiff, R. D.; Rocnik, J. L.; Yang, Y.; Pagliarini, R.			TMPRSS2: ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation	ONCOGENE			English	Article							ANDROGEN RECEPTOR; MOLECULAR CHARACTERIZATION; GENOME BROWSER; GENE FUSIONS; IN-VIVO; PROGRESSION; EXPRESSION; TRANSDIFFERENTIATION; ADENOCARCINOMA; HYBRIDIZATION	The biological outcome of TMPRSS2: ERG chromosomal translocations in prostate cancer (PC) remains poorly understood. To address this, we compared the transcriptional effects of TMPRSS2: ERG expression in a transgenic mouse model with those of ERG knockdown in a TMPRSS2: ERG-positive PC cell line. This reveals that ERG represses the expression of a previously unreported set of androgen receptor (AR)-independent neuronal genes that are indicative of neuroendocrine (NE) cell differentiation-in addition to previously reported AR-regulated luminal genes. Cell sorting and proliferation assays performed after sustained ERG knockdown indicate that ERG drives proliferation and blocks the differentiation of prostate cells to both NE and luminal cell types. Inhibition of ERG expression in TMPRSS2: ERG-positive PC cells through blockade of AR signaling is tracked with increased NE gene expression. We also provide evidence that these NE cells are resistant to pharmacological AR inhibition and can revert to the phenotype of parental cells upon restoration of AR/ERG signaling. Our findings highlight an ERG-regulated mechanism capable of repopulating the parent tumor through the transient generation of an anti-androgen therapy-resistant cell population, suggesting that ERG may have a direct role in preventing resistance to anti-androgen therapy.	[Mounir, Z.; Lin, F.; Lin, V. G.; Korn, J. M.; Yu, Y.; Valdez, R.; Jaffe, A. B.; Korpal, M.; Zhu, P.; Rocnik, J. L.; Yang, Y.; Pagliarini, R.] Novartis Inst BioMed Res, Cambridge, MA 02139 USA; [Aina, O. H.; Cardiff, R. D.] Univ Calif Davis, Ctr Comparat Med, Davis, CA 95616 USA; [Buchwalter, G.; Brown, M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Buchwalter, G.; Brown, M.] Harvard Univ, Sch Med, Boston, MA USA; [Buchwalter, G.; Brown, M.] Dana Farber Canc Inst, Ctr Funct Canc Epigenet, Boston, MA 02115 USA	Novartis; University of California System; University of California Davis; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Pagliarini, R (corresponding author), Novartis Inst BioMed Res, 250 Massachusetts Ave, Cambridge, MA 02139 USA.	raymond.pagliarini@novartis.com	Brown, Myles/AAX-5332-2021; Brown, Myles/B-6906-2008	Brown, Myles/0000-0002-8213-1658; Jaffe, Aron/0000-0002-6220-0476	Novartis Institutes for Biomedical Research; Novartis	Novartis Institutes for Biomedical Research; Novartis(Novartis)	ZM is the recipient of presidential postdoctoral fellowship from the Novartis Institutes for Biomedical Research. ZM, FL, VGL, JMK, YY, RV, ABJ, YY and RP are all employees of Novartis Institutes for Biomedical Research. MK and PZ are employees of H3 Biomedicine. MB is a consultant to Novartis and the recipient of sponsored research support from Novartis. JLR is an employee of Sanofi. The other authors declare no conflict of interest.	Arora VK, 2013, CELL, V155, P1309, DOI 10.1016/j.cell.2013.11.012; Aumuller G, 1999, UROLOGY, V53, P1041, DOI 10.1016/S0090-4295(98)00631-1; Baena E, 2013, GENE DEV, V27, P683, DOI 10.1101/gad.211011.112; Balbas MD, 2013, ELIFE, V2, DOI 10.7554/eLife.00499; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; BOSTWICK DG, 1994, AM J SURG PATHOL, V18, P1240, DOI 10.1097/00000478-199412000-00007; Burchardt T, 1999, J UROLOGY, V162, P1800, DOI 10.1016/S0022-5347(05)68241-9; Carmichael CL, 2012, P NATL ACAD SCI USA, V109, P15437, DOI 10.1073/pnas.1213454109; Carver BS, 2009, NAT GENET, V41, P619, DOI 10.1038/ng.370; Casey OM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041668; Chen Y, 2013, NAT MED, V19, P1023, DOI 10.1038/nm.3216; Cher ML, 1996, CANCER RES, V56, P3091; Chinnaiyan AM, 2008, NEOPLASIA, V10, P177, DOI 10.1593/neo.07822; Clark JP, 2009, NAT REV UROL, V6, P429, DOI 10.1038/nrurol.2009.127; Gupta S, 2010, CANCER RES, V70, P6735, DOI 10.1158/0008-5472.CAN-10-0244; Jin RJ, 2004, CANCER RES, V64, P5489, DOI 10.1158/0008-5472.CAN-03-3117; Jongsma J, 2000, PROSTATE, V42, P34, DOI 10.1002/(SICI)1097-0045(20000101)42:1<34::AID-PROS5>3.0.CO;2-2; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; King JC, 2009, NAT GENET, V41, P524, DOI 10.1038/ng.371; Klezovitch O, 2008, P NATL ACAD SCI USA, V105, P2105, DOI 10.1073/pnas.0711711105; Korpal M, 2013, CANCER DISCOV, V3, P1030, DOI 10.1158/2159-8290.CD-13-0142; Lee LF, 2001, MOL CELL BIOL, V21, P8385, DOI 10.1128/MCB.21.24.8385-8397.2001; Li Z, 2013, ASIAN J ANDROL, V15, P328, DOI 10.1038/aja.2013.7; Lotan TL, 2011, MODERN PATHOL, V24, P820, DOI 10.1038/modpathol.2011.7; Mani RS, 2011, CANCER RES, V71, P5387, DOI 10.1158/0008-5472.CAN-11-0876; Matei DV, 2012, CLIN GENITOURIN CANC, V10, P164, DOI 10.1016/j.clgc.2011.12.004; Mertz KD, 2007, NEOPLASIA, V9, P200, DOI 10.1593/neo.07103; Meyer LR, 2013, NUCLEIC ACIDS RES, V41, pD64, DOI 10.1093/nar/gks1048; Palapattu GS, 2009, PROSTATE, V69, P787, DOI 10.1002/pros.20928; Papandreou CN, 1998, NAT MED, V4, P50, DOI 10.1038/nm0198-050; Schelling LA, 2013, HUM PATHOL, V44, P2227, DOI 10.1016/j.humpath.2013.05.005; SEHGAL I, 1994, P NATL ACAD SCI USA, V91, P4673, DOI 10.1073/pnas.91.11.4673; Setlur SR, 2008, JNCI-J NATL CANCER I, V100, P815, DOI 10.1093/jnci/djn150; Signoretti S, 2005, P NATL ACAD SCI USA, V102, P11355, DOI 10.1073/pnas.0500165102; Simon RA, 2009, HUM PATHOL, V40, P252, DOI 10.1016/j.humpath.2008.07.014; Sun C, 2008, ONCOGENE, V27, P5348, DOI 10.1038/onc.2008.183; Sun HF, 2013, BIOINFORMATICS, V29, P1352, DOI 10.1093/bioinformatics/btt135; Svensson C, 2014, NUCLEIC ACIDS RES, V42, P999, DOI 10.1093/nar/gkt921; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Wang JH, 2008, CANCER RES, V68, P8516, DOI 10.1158/0008-5472.CAN-08-1147; Yang JC, 2009, CANCER RES, V69, P151, DOI 10.1158/0008-5472.CAN-08-0442; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018; Yuan TC, 2007, ENDOCR-RELAT CANCER, V14, P531, DOI 10.1677/ERC-07-0061; Yuan TC, 2006, ENDOCR-RELAT CANCER, V13, P151, DOI 10.1677/erc.1.01043	46	42	47	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	29					3815	3825		10.1038/onc.2014.308	http://dx.doi.org/10.1038/onc.2014.308			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM9BV	25263440				2022-12-17	WOS:000358001600007
J	Nitta, RT; Gholamin, S; Feroze, AH; Agarwal, M; Cheshier, SH; Mitra, SS; Li, G				Nitta, R. T.; Gholamin, S.; Feroze, A. H.; Agarwal, M.; Cheshier, S. H.; Mitra, S. S.; Li, G.			Casein kinase 2 alpha regulates glioblastoma brain tumor-initiating cell growth through the beta-catenin pathway	ONCOGENE			English	Article							CANCER STEM-CELL; PROTEIN-KINASE; SELF-RENEWAL; IN-VIVO; ALPHA-CATENIN; CK2; INHIBITION; EXPRESSION; NOTCH; TUMORIGENICITY	Glioblastoma (GBM) is the most common and fatal primary brain tumor in humans, and it is essential that new and better therapies are developed to treat this disease. Previous research suggests that casein kinase 2 (CK2) may be a promising therapeutic target for GBMs. CK2 has enhanced expression or activity in numerous cancers, including GBM, and it has been demonstrated that inhibitors of CK2 regressed tumor growth in GBM xenograft mouse models. Our studies demonstrate that the CK2 subunit, CK2 alpha, is overexpressed in and has an important role in regulating brain tumor-initiating cells (BTIC) in GBM. Initial studies showed that two GBM cell lines (U87-MG and U138) transduced with CK2 alpha had enhanced proliferation and anchorage-independent growth. Inhibition of CKa using siRNA or small-molecule inhibitors (TBBz, CX-4945) reduced cell growth, decreased tumor size, and increased survival rates in GBM xenograft mouse models. We also verified that inhibition of CK2 alpha decreased the activity of a well-known GBM-initiating cell regulator, beta-catenin. Loss of CK2 alpha decreased two beta-catenin-regulated genes that are involved in GBM-initiating cell growth, OCT4 and NANOG. To determine the importance of CK2 alpha in GBM stem cell maintenance, we reduced CK2 alpha activity in primary GBM samples and tumor spheres derived from GBM patients. We discovered that loss of CK2 alpha activity reduced the sphere-forming capacity of BTIC and decreased numerous GBM stem cell markers, including CD133, CD90, CD49f and A2B5. Our study suggests that CK2 alpha is involved in GBM tumorigenesis by maintaining BTIC through the regulation of beta-catenin.	[Nitta, R. T.; Gholamin, S.; Agarwal, M.; Cheshier, S. H.; Mitra, S. S.; Li, G.] Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA; [Gholamin, S.; Feroze, A. H.; Cheshier, S. H.; Mitra, S. S.] Stanford Univ, Sch Med, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA	Stanford University; Stanford University	Li, G (corresponding author), Stanford Univ, Sch Med, Dept Neurosurg, 1201 Welch Rd P309, Stanford, CA 94305 USA.	gordonli@stanford.edu		Gholamin, Sharareh/0000-0001-7425-6074; Li, Gordon/0000-0001-8372-0676	K08 Mentored Research Grant [NIH-KNS085333A]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS085333] Funding Source: NIH RePORTER	K08 Mentored Research Grant; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Albert Wong for the use of equipment and resources. We also thank Tim Bui for his useful discussions and Cheryl Christensen for her critical review of the paper. This work was supported by the K08 Mentored Research Grant (NIH-KNS085333A) as well as the generous donation from Mr Keith Tsu and Ms Carmelita Ko.	Abdouh M, 2009, J NEUROSCI, V29, P8884, DOI 10.1523/JNEUROSCI.0968-09.2009; Adesina AM, 2009, HUM PATHOL, V40, P843, DOI 10.1016/j.humpath.2008.10.022; Androutsellis-Theotokis A, 2006, NATURE, V442, P823, DOI 10.1038/nature04940; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Beier Christoph P, 2011, Front Biosci (Elite Ed), V3, P701, DOI 10.2741/e280; Cheong JW, 2010, ANTICANCER RES, V30, P4625; Clement V, 2007, CURR BIOL, V17, P165, DOI 10.1016/j.cub.2006.11.033; D'Amour KA, 2002, NAT MED, V8, P213, DOI 10.1038/nm0302-213; Dalerba P, 2007, CELL STEM CELL, V1, P241, DOI 10.1016/j.stem.2007.08.012; Del Vecchio CA, 2012, CANCER RES, V72, P2657, DOI 10.1158/0008-5472.CAN-11-2656; Dixit D, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.10; Fan X, 2006, CANCER RES, V66, P7445, DOI 10.1158/0008-5472.CAN-06-0858; Grigoryan T, 2008, GENE DEV, V22, P2308, DOI 10.1101/gad.1686208; He J, 2012, CURR MED CHEM, V19, P6050; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Huillard E, 2010, MOL CELL BIOL, V30, P2737, DOI 10.1128/MCB.01566-09; Ikushima H, 2011, J BIOL CHEM, V286, P41434, DOI 10.1074/jbc.M111.300863; Ji HT, 2009, MOL CELL, V36, P547, DOI 10.1016/j.molcel.2009.09.034; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Lee Y, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-52; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Louis D, 1997, WHO CLASSIFICATION T, P33; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Moucadel V, 2011, ONCOTARGET, V2, P997; Murat A, 2008, J CLIN ONCOL, V26, P3015, DOI 10.1200/JCO.2007.15.7164; Nager Mireia, 2012, Chemother Res Pract, V2012, P192362, DOI 10.1155/2012/192362; Nitta RT, 2011, ONCOGENE, V30, P234, DOI 10.1038/onc.2010.414; Nitta RT, 2010, METHOD ENZYMOL, V484, P531, DOI [10.1016/S0076-6879(10)84026-1, 10.1016/B978-0-12-381298-8.00026-5]; Olsen BB, 2010, ONCOGENE, V29, P6016, DOI 10.1038/onc.2010.337; Pagano MA, 2008, BIOCHEM J, V415, P353, DOI 10.1042/BJ20080309; Pierfelice TJ, 2008, COLD SH Q B, V73, P367, DOI 10.1101/sqb.2008.73.013; Ponce DP, 2011, MOL CELL BIOCHEM, V356, P127, DOI 10.1007/s11010-011-0965-4; Ponce DP, 2011, J CELL PHYSIOL, V226, P1953, DOI 10.1002/jcp.22527; Prudent R, 2010, CANCER RES, V70, P9865, DOI 10.1158/0008-5472.CAN-10-0917; Prudent R, 2010, METHOD ENZYMOL, V485, P597, DOI [10.1016/B978-0-12-381296-4.00031-2, 10.1016/S0076-6879(10)85031-1]; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Scharenberg CW, 2002, BLOOD, V99, P507, DOI 10.1182/blood.V99.2.507; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Son YH, 2013, ARCH PHARM RES, V36, P840, DOI 10.1007/s12272-013-0103-9; Song DH, 2003, J BIOL CHEM, V278, P24018, DOI 10.1074/jbc.M212260200; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Trembley JH, 2010, BIOFACTORS, V36, P187, DOI 10.1002/biof.96; Zbinden M, 2010, EMBO J, V29, P2659, DOI 10.1038/emboj.2010.137; Zhang SL, 2013, J CELL MOL MED, V17, P854, DOI 10.1111/jcmm.12068; Zhang SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038996; Zheng Y, 2013, CLIN CANCER RES, V19, P6484, DOI 10.1158/1078-0432.CCR-13-0265	47	42	44	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	28					3688	3699		10.1038/onc.2014.299	http://dx.doi.org/10.1038/onc.2014.299			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM4TZ	25241897	Green Accepted			2022-12-17	WOS:000357679100007
J	Zhao, T; Du, H; Ding, X; Walls, K; Yan, C				Zhao, T.; Du, H.; Ding, X.; Walls, K.; Yan, C.			Activation of mTOR pathway in myeloid-derived suppressor cells stimulates cancer cell proliferation and metastasis in lal(-/-) mice	ONCOGENE			English	Article							LYSOSOMAL ACID LIPASE; SYSTEMIC INFLAMMATION; EXPRESSION; DISEASE; GROWTH; LUNG; ANGIOGENESIS; CHEMOTHERAPY; CARCINOMA; CORRELATE	Inflammation critically contributes to cancer metastasis, in which myeloid-derived suppressor cells (MDSCs) are an important participant. Although MDSCs are known to suppress immune surveillance, their roles in directly stimulating cancer cell proliferation and metastasis currently remain unclear. Lysosomal acid lipase (LAL) deficiency causes systemic expansion and infiltration of MDSCs in multiple organs and subsequent inflammation. In the LAL-deficient (lal(-/-)) mouse model, melanoma metastasized massively in allogeneic lal(-/-) mice, which was suppressed in allogeneic lal(+/+) mice owing to immune rejection. Here we report for the first time that MDSCs from lal(-/-) mice directly stimulated B16 melanoma cell in vitro proliferation and in vivo growth and metastasis. Cytokines, that is, interleukin-1 beta and tumor necrosis factor-alpha from MDSCs are required for B16 melanoma cell proliferation in vitro. Myeloid-specific expression of human LAL (hLAL) in lal(-/-) mice rescues these malignant phenotypes in vitro and in vivo. The tumor-promoting function of lal(-/-) MDSCs is mediated, at least in part, through overactivation of the mammalian target of rapamycin (mTOR) pathway. Knockdown of mTOR, Raptor or Rictor in lal(-/-) MDSCs suppressed their stimulation on proliferation of cancer cells, including B16 melanoma, Lewis lung carcinoma and transgenic mouse prostate cancer-C2 cancer cells. Our results indicate that LAL has a critical role in regulating MDSCs' ability to directly stimulate cancer cell proliferation and overcome immune rejection of cancer metastasis in allogeneic mice through modulation of the mTOR pathway, which provides a mechanistic basis for targeting MDSCs to reduce the risk of cancer metastasis. Therefore MDSCs possess dual functions to facilitate cancer metastasis: suppress immune surveillance and stimulate cancer cell proliferation and growth.	[Zhao, T.; Du, H.; Ding, X.; Walls, K.; Yan, C.] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA; [Du, H.; Yan, C.] Indiana Univ Sch Med, IU Simon Canc Ctr, Indianapolis, IN 46202 USA; [Yan, C.] Indiana Univ Sch Med, Ctr Immunobiol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington	Du, H (corresponding author), Indiana Univ Sch Med, Dept Pathol & Lab Med, 975 W Walnut St,IB424G, Indianapolis, IN 46202 USA.	hongdu@iupui.edu; coyan@iupui.edu	ding, xinchun/P-5490-2017		National Institutes of Health [CA138759, CA152099, HL087001]; NATIONAL CANCER INSTITUTE [R01CA138759, R01CA152099] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL087001] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by the National Institutes of Health Grants CA138759, CA152099 (to CY) and HL087001 (to HD).	Bonauer A, 2009, SCIENCE, V324, P1710, DOI 10.1126/science.1174381; Bruchard M, 2013, NAT MED, V19, P57, DOI 10.1038/nm.2999; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Diaz-Montero CM, 2009, CANCER IMMUNOL IMMUN, V58, P49, DOI 10.1007/s00262-008-0523-4; Ding XC, 2014, AM J PATHOL, V184, P397, DOI 10.1016/j.ajpath.2013.10.015; Du H, 2001, J LIPID RES, V42, P489; Elleder M, 2000, J HEPATOL, V32, P528, DOI 10.1016/S0168-8278(00)80407-9; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Hoechst B, 2009, HEPATOLOGY, V50, P799, DOI 10.1002/hep.23054; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Ko JS, 2009, CLIN CANCER RES, V15, P2148, DOI 10.1158/1078-0432.CCR-08-1332; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Lian XM, 2005, AM J PATHOL, V167, P813, DOI 10.1016/S0002-9440(10)62053-6; Lian XM, 2004, AM J PHYSIOL-LUNG C, V286, pL801, DOI 10.1152/ajplung.00335.2003; Mandruzzato S, 2009, J IMMUNOL, V182, P6562, DOI 10.4049/jimmunol.0803831; Meyer C, 2011, P NATL ACAD SCI USA, V108, P17111, DOI 10.1073/pnas.1108121108; Ostrand-Rosenberg S, 2009, J IMMUNOL, V182, P4499, DOI 10.4049/jimmunol.0802740; Qu P, 2011, J IMMUNOL, V187, P3854, DOI 10.4049/jimmunol.1003358; Qu P, 2011, BLOOD, V117, P4476, DOI 10.1182/blood-2010-07-298380; Qu P, 2010, AM J PATHOL, V176, P2394, DOI 10.2353/ajpath.2010.091063; Qu P, 2009, LUNG CANCER, V63, P341, DOI 10.1016/j.lungcan.2008.05.025; Qu P, 2009, J IMMUNOL, V182, P1648, DOI 10.4049/jimmunol.182.3.1648; Rothe G, 1997, ATHEROSCLEROSIS, V130, P215, DOI 10.1016/S0021-9150(97)06065-6; Talmadge JE, 2013, NAT REV CANCER, V13, P739, DOI 10.1038/nrc3581; Wang L, 2013, J IMMUNOL, V190, P794, DOI 10.4049/jimmunol.1202088; Wu L, 2012, BLOOD, V119, P115, DOI 10.1182/blood-2011-06-363093; Yan C, 2006, AM J PATHOL, V169, P916, DOI 10.2353/ajpath.2006.051327; Yan C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030701; Zhao T, 2010, AM J PHYSIOL-ENDOC M, V299, pE110, DOI 10.1152/ajpendo.00192.2010	31	42	42	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	2015	34	15					1938	1948		10.1038/onc.2014.143	http://dx.doi.org/10.1038/onc.2014.143			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CF7GY	24882582	Green Accepted, Green Submitted, Bronze			2022-12-17	WOS:000352725600008
J	Kwon, SJ; Park, JH; Park, EJ; Lee, SA; Lee, HS; Kang, SW; Kwon, J				Kwon, S-J; Park, J-H; Park, E-J; Lee, S-A; Lee, H-S; Kang, S. W.; Kwon, J.			ATM-mediated phosphorylation of the chromatin remodeling enzyme BRG1 modulates DNA double-strand break repair	ONCOGENE			English	Article						BRG1 chromatin remodeling enzyme; DNA double-strand break repair; ATM phosphorylation; gamma-H2AX	DAMAGE RESPONSE; INO80 COMPLEX; SWI/SNF; REPLICATION; GAMMA-H2AX; RSC; CANCER; SITES; RECRUITMENT; TRANSCRIPTION	ATP-dependent chromatin remodeling complexes such as SWI/SNF (SWItch/Sucrose NonFermentable) have been implicated in DNA double-strand break (DSB) repair and damage responses. However, the regulatory mechanisms that control the function of chromatin remodelers in DNA damage response are largely unknown. Here, we show that ataxia telangiectasia mutated (ATM) mediates the phosphorylation of BRG1, the catalytic ATPase of the SWI/SNF complex that contributes to DSB repair by binding g-H2AX-containing nucleosomes via interaction with acetylated histone H3 and stimulating gamma-H2AX formation, at Ser-721 in response to DNA damage. ATM-mediated phosphorylation of BRG1 occurs rapidly and transiently after DNA damage. Phosphorylated BRG1 binds g-H2AX-containing nucleosomes to form the repair foci. The Ser-721 phosphorylation of BRG1 is critical for binding g-H2AX-containing nucleosomes and stimulating g-H2AX formation and DSB repair. BRG1 binds to acetylated H3 peptides much better after phosphorylation at Ser-721 by DNA damage. However, the phosphorylation of Ser-721 does not significantly affect the ATPase and transcriptional activities of BRG1. These results, establishing BRG1 as a novel and functional ATM substrate, suggest that the ATM-mediated phosphorylation of BRG1 facilitates DSB repair by stimulating the association of this remodeler with g-H2AX nucleosomes via enhancing the affinity to acetylated H3. Our work also suggests that the mechanism of BRG1 stimulation of DNA repair is independent of the remodeler's enzymatic or transcriptional activities.	[Kwon, S-J; Park, J-H; Park, E-J; Lee, S-A; Lee, H-S; Kang, S. W.; Kwon, J.] Ewha Womans Univ, Res Ctr Cellular Homeostasis, Coll Nat Sci, Dept Life Sci, Seoul 120750, South Korea	Ewha Womans University	Kwon, J (corresponding author), Ewha Womans Univ, Res Ctr Cellular Homeostasis, Coll Nat Sci, Dept Life Sci, Daehyun Dong 11-1,Sci Bld C 308, Seoul 120750, South Korea.	jongkwon@ewha.ac.kr			National Research Foundation (NRF) - Korea Ministry of Education and Science (MEST) [2012R1A2A2A01003744]; MEST [2012R1A5A1048236]; Ewha Global Top5 Grant; Ewha Womans University	National Research Foundation (NRF) - Korea Ministry of Education and Science (MEST)(National Research Foundation of Korea); MEST(Ministry of Education, Science & Technology (MEST), Republic of Korea); Ewha Global Top5 Grant; Ewha Womans University	We thank Rho H Seong (Seoul National University) for kindly providing the plasmids pREP4-p53RE-luc and flag-p53, and Seul-Ki Lee and Shin-Kyoung Hur for technical assistance. This work was supported by the National Research Foundation (NRF) grant funded by the Korea Ministry of Education and Science (MEST) (2012R1A2A2A01003744 to JK); the NRF grant funded by the MEST (2012R1A5A1048236); Ewha Global Top5 Grant 2013 and RP-Grant 2009 (to J-HP) funded by Ewha Womans University.	Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bao YH, 2007, CURR OPIN GENET DEV, V17, P126, DOI 10.1016/j.gde.2007.02.010; Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523; Bultman SJ, 2008, ONCOGENE, V27, P460, DOI 10.1038/sj.onc.1210664; Chai B, 2005, GENE DEV, V19, P1656, DOI 10.1101/gad.1273105; Chambers AL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032016; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Cohen SM, 2010, NUCLEIC ACIDS RES, V38, P6906, DOI 10.1093/nar/gkq559; Conaway RC, 2009, TRENDS BIOCHEM SCI, V34, P71, DOI 10.1016/j.tibs.2008.10.010; Downs JA, 2004, MOL CELL, V16, P979, DOI 10.1016/j.molcel.2004.12.003; Downs JA, 2007, NATURE, V447, P951, DOI 10.1038/nature05980; Dykhuizen EC, 2013, NATURE, V497, P624, DOI 10.1038/nature12146; Falbo KB, 2009, NAT STRUCT MOL BIOL, V16, P1167, DOI 10.1038/nsmb.1686; Gong F, 2008, CELL CYCLE, V7, P1067, DOI 10.4161/cc.7.8.5647; Gospodinov A, 2011, MOL CELL BIOL, V31, P4735, DOI 10.1128/MCB.06182-11; Hendricks KB, 2004, MOL CELL BIOL, V24, P362, DOI 10.1128/MCB.24.1.362-376.2004; Hur SK, 2010, CELL MOL LIFE SCI, V67, P2283, DOI 10.1007/s00018-010-0337-3; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Kashiwaba S, 2010, BIOCHEM BIOPH RES CO, V402, P619, DOI 10.1016/j.bbrc.2010.10.066; Kato D, 2012, BIOCHEM BIOPH RES CO, V417, P433, DOI 10.1016/j.bbrc.2011.11.134; Kent NA, 2007, J BIOL CHEM, V282, P27693, DOI 10.1074/jbc.M704707200; Kinner A, 2008, NUCLEIC ACIDS RES, V36, P5678, DOI 10.1093/nar/gkn550; Lavin MF, 2008, NAT REV MOL CELL BIO, V9, P759, DOI 10.1038/nrm2514; Lee HS, 2010, EMBO J, V29, P1434, DOI 10.1038/emboj.2010.27; Liang B, 2007, CURR BIOL, V17, P1432, DOI 10.1016/j.cub.2007.07.035; Lukas J, 2011, NAT CELL BIOL, V13, P1161, DOI 10.1038/ncb2344; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Morrison AJ, 2004, CELL, V119, P767, DOI 10.1016/j.cell.2004.11.037; Morrison AJ, 2007, CELL, V130, P499, DOI 10.1016/j.cell.2007.06.010; Morrison AJ, 2009, NAT REV MOL CELL BIO, V10, P373, DOI 10.1038/nrm2693; Ogiwara H, 2011, ONCOGENE, V30, P2135, DOI [10.1038/onc.2010.592, 10.1038/onc.2010.592;]; Oh J, 2008, J BIOL CHEM, V283, P11924, DOI 10.1074/jbc.M705401200; Pandita TK, 2009, NUCLEIC ACIDS RES, V37, P1363, DOI 10.1093/nar/gkn1071; Papamichos-Chronakis M, 2008, NAT STRUCT MOL BIOL, V15, P338, DOI 10.1038/nsmb.1413; Papamichos-Chronakis M, 2006, GENE DEV, V20, P2437, DOI 10.1101/gad.1440206; Park EJ, 2010, BIOCHEM J, V431, P179, DOI 10.1042/BJ20100988; Park JH, 2006, EMBO J, V25, P3986, DOI 10.1038/sj.emboj.7601291; Park JH, 2009, DNA REPAIR, V8, P29, DOI 10.1016/j.dnarep.2008.08.011; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Polo SE, 2011, GENE DEV, V25, P409, DOI 10.1101/gad.2021311; Saha A, 2006, NAT REV MOL CELL BIO, V7, P437, DOI 10.1038/nrm1945; Shim EY, 2007, MOL CELL BIOL, V27, P1602, DOI 10.1128/MCB.01956-06; Shim EY, 2005, MOL CELL BIOL, V25, P3934, DOI 10.1128/MCB.25.10.3934-3944.2005; Shimada K, 2008, CURR BIOL, V18, P566, DOI 10.1016/j.cub.2008.03.049; Sinha M, 2009, CELL, V138, P1109, DOI 10.1016/j.cell.2009.07.013; Sulli G, 2012, NAT REV CANCER, V12, DOI 10.1038/nrc3344; Tsukuda T, 2005, NATURE, V438, P379, DOI 10.1038/nature04148; van Attikum H, 2004, CELL, V119, P777, DOI 10.1016/j.cell.2004.11.033; van Attikum H, 2009, TRENDS CELL BIOL, V19, P207, DOI 10.1016/j.tcb.2009.03.001; Vincent JA, 2008, NAT STRUCT MOL BIOL, V15, P477, DOI 10.1038/nsmb.1419; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068; Wu S, 2007, NAT STRUCT MOL BIOL, V14, P1165, DOI 10.1038/nsmb1332; Zhang L, 2009, CELL CYCLE, V8, P3953, DOI 10.4161/cc.8.23.10115; Zhao Q, 2009, J BIOL CHEM, V284, P30424, DOI 10.1074/jbc.M109.044982	54	42	42	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2015	34	3					351	361		10.1038/onc.2013.556	http://dx.doi.org/10.1038/onc.2013.556			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ3RY	24413084				2022-12-17	WOS:000348145500009
J	Shen, RR; Zhou, AY; Kim, E; O'Connell, JT; Hagerstrand, D; Beroukhim, R; Hahn, WC				Shen, R. R.; Zhou, A. Y.; Kim, E.; O'Connell, J. T.; Hagerstrand, D.; Beroukhim, R.; Hahn, W. C.			TRAF2 is an NF-kappa B-activating oncogene in epithelial cancers	ONCOGENE			English	Article						TRAF2; NF-kappa B; cancer; 9q34 amplification	TUMOR-SUPPRESSOR CYLD; K63-LINKED POLYUBIQUITINATION; MULTIPLE-MYELOMA; CELL LYMPHOMA; MOUSE MODEL; IKK; PHOSPHORYLATION; TUMORIGENESIS; MUTATIONS; PATHWAY	Aberrant nuclear factor (NF)-kappa B activation is frequently observed in human cancers. Genome characterization efforts have identified genetic alterations in multiple components of the NF-kappa B pathway, some of which have been shown to be essential for cancer initiation and tumor maintenance. Here, using patient tumors and cancer cell lines, we identify the NF-kappa B regulator, TRAF2 (tumor necrosis factor (TNF) receptor-associated factor 2), as an oncogene that is recurrently amplified and rearranged in 15% of human epithelial cancers. Suppression of TRAF2 in cancer cells harboring TRAF2 copy number gain inhibits proliferation, NF-kappa B activation, anchorage-independent growth and tumorigenesis. Cancer cells that are dependent on TRAF2 also require NF-kappa B for survival. The phosphorylation of TRAF2 at serine 11 is essential for the survival of cancer cells harboring TRAF2 amplification. Together, these observations identify TRAF2 as a frequently amplified oncogene.	[Shen, R. R.; Zhou, A. Y.; Kim, E.; O'Connell, J. T.; Hagerstrand, D.; Beroukhim, R.; Hahn, W. C.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA; [Shen, R. R.; Zhou, A. Y.; Kim, E.; O'Connell, J. T.; Hagerstrand, D.; Beroukhim, R.; Hahn, W. C.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA; [Shen, R. R.; Zhou, A. Y.; Kim, E.; O'Connell, J. T.; Hagerstrand, D.; Beroukhim, R.; Hahn, W. C.] Broad Inst Harvard & MIT, Cambridge, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute	Hahn, WC (corresponding author), Dana Farber Canc Inst, 450 Brookline Ave,Dana 1538, Boston, MA 02215 USA.	William_Hahn@dfci.harvard.edu	Hägerstrand, Daniel/AAH-3009-2019; Hägerstrand, Daniel C/D-1584-2014	Hägerstrand, Daniel/0000-0001-7270-0776; Hägerstrand, Daniel C/0000-0001-7270-0776; Zhou, Alicia/0000-0003-0388-8909	Ruth L. Kirschstein National Research Service Award [F32 CA128265]; Aid for Cancer Research;  [R01 CA130988]; NATIONAL CANCER INSTITUTE [P30CA006516, F32CA128265, P01CA154303, R01CA130988] Funding Source: NIH RePORTER	Ruth L. Kirschstein National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Aid for Cancer Research; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank members of the Hahn lab and the Cichowski lab for thoughtful discussion, reagents and technical assistance. We also thank Hasem Habelhah for providing the pTRAF2 (Ser11) antibody. We further thank Shumei Wang, Anita Hawkins, Chengzeng Zhang and Cynthia Morton at the DFCI Cytogenetics Core for TRAF2 FISH analysis and discussion. This work was supported in part by R01 CA130988 (to WCH), a Ruth L. Kirschstein National Research Service Award F32 CA128265 (to RRS) and The Aid for Cancer Research (to RRS).	Aggarwal BB, 2011, CANCER DISCOV, V1, P469, DOI 10.1158/2159-8290.CD-11-0260; Annunziata CM, 2007, CANCER CELL, V12, P115, DOI 10.1016/j.ccr.2007.07.004; Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Basseres DS, 2010, CANCER RES, V70, P3537, DOI 10.1158/0008-5472.CAN-09-4290; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Baud V, 2009, NAT REV DRUG DISCOV, V8, P33, DOI 10.1038/nrd2781; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Billie Au PY, 2007, ADV EXP MED BIOL, V597, P32; Bivona TG, 2011, NATURE, V471, P523, DOI 10.1038/nature09870; Blackwell K, 2009, MOL CELL BIOL, V29, P303, DOI 10.1128/MCB.00699-08; Boehm JS, 2007, CELL, V129, P1065, DOI 10.1016/j.cell.2007.03.052; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Compagno M, 2009, NATURE, V459, P717, DOI 10.1038/nature07968; Fuerer C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009370; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Hutti JE, 2009, MOL CELL, V34, P461, DOI 10.1016/j.molcel.2009.04.031; Kan ZY, 2010, NATURE, V466, P869, DOI 10.1038/nature09208; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Karin M, 2009, IMMUNOL REV, V228, P225, DOI 10.1111/j.1600-065X.2008.00755.x; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Lenz G, 2008, SCIENCE, V319, P1676, DOI 10.1126/science.1153629; Li S, 2009, MOL CELL, V33, P30, DOI 10.1016/j.molcel.2008.11.023; Ling JH, 2012, CANCER CELL, V21, P105, DOI 10.1016/j.ccr.2011.12.006; Meylan E, 2009, NATURE, V462, P104, DOI 10.1038/nature08462; Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Novak U, 2009, BLOOD, V113, P4918, DOI 10.1182/blood-2008-08-174110; Pflueger D, 2011, GENOME RES, V21, P56, DOI 10.1101/gr.110684.110; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Starczynowski DT, 2011, J CLIN INVEST, V121, P4095, DOI 10.1172/JCI58818; Staudt LM, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000109; Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943; Thomas GS, 2009, CANCER RES, V69, P3665, DOI 10.1158/0008-5472.CAN-08-4867; Wood KC, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002612; Zhou AY, 2013, CELL REP, V3, P724, DOI 10.1016/j.celrep.2013.01.031	43	42	44	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2015	34	2					209	216		10.1038/onc.2013.543	http://dx.doi.org/10.1038/onc.2013.543			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AY8FS	24362534	Green Accepted, Green Submitted			2022-12-17	WOS:000347790500008
J	Tamura, M; Sasaki, Y; Koyama, R; Takeda, K; Idogawa, M; Tokino, T				Tamura, M.; Sasaki, Y.; Koyama, R.; Takeda, K.; Idogawa, M.; Tokino, T.			Forkhead transcription factor FOXF1 is a novel target gene of the p53 family and regulates cancer cell migration and invasiveness	ONCOGENE			English	Article						FOXF1; p53 family; cell invasion; cell migration; E-cadherin	E-CADHERIN EXPRESSION; MESENCHYMAL TRANSITION; CARCINOMA-CELLS; P63; SUPPRESSOR; METASTASIS; ADHESION; PROTEIN; P73; IDENTIFICATION	p53 is an established tumor suppressor that can activate the transcription of multiple target genes. Recent evidence suggests that p53 may contribute to the regulation of cell invasion and migration. In this study, we show that the forkhead box transcription factor FOXF1 is a novel target of the p53 family because FOXF1 is upregulated by p53, TAp73 and TAp63. We show that FOXF1 is induced upon DNA damage in a p53-dependent manner. Furthermore, we identified a response element located within the FOXF1 gene that is responsive to wild-type p53, TAp73 beta and TAp63 gamma. The ectopic expression of FOXF1 inhibited cancer cell invasion and migration, whereas the inactivation of FOXF1 stimulated cell invasion and migration. We also show that FOXF1 regulates the transcriptional activity of E-cadherin (CDH1) by acting on its FOXF1 consensus binding site located upstream of the E-cadherin gene. Collectively, our results show that FOXF1 is a p53 family target gene, and our data suggest that FOXF1 and p53 form a portion of a regulatory transcriptional network that appears to have an important role in cancer cell invasion and migration.	[Tamura, M.; Sasaki, Y.; Koyama, R.; Takeda, K.; Idogawa, M.; Tokino, T.] Sapporo Med Univ, Res Inst Frontier Med, Dept Med Genome Sci, Sapporo, Hokkaido 0608556, Japan	Sapporo Medical University	Tokino, T (corresponding author), Sapporo Med Univ, Res Inst Frontier Med, Dept Med Genome Sci, Chuo Ku, S-1,W-17, Sapporo, Hokkaido 0608556, Japan.	yasushi@sapmed.ac.jp; tokino@sapmed.ac.jp	Sasaki, Yasushi/AAA-3079-2019; Idogawa, Masashi/B-5208-2008; Tokino, Takashi/AAI-9887-2021	Sasaki, Yasushi/0000-0002-3500-8059; Idogawa, Masashi/0000-0002-8507-1726; 	Ministry of Education, Culture, Sports, Science and Technology of Japan; Grants-in-Aid for Scientific Research [221S0001] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This research was supported in part by Grants-in-Aid for Cancer Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Barbieri CE, 2006, CANCER RES, V66, P7589, DOI 10.1158/0008-5472.CAN-06-2020; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; BUSSEMAKERS MJG, 1994, BIOCHEM BIOPH RES CO, V203, P1291, DOI 10.1006/bbrc.1994.2322; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173; Chen F, 2010, BIOCHEM PHARMACOL, V80, P724, DOI 10.1016/j.bcp.2010.04.031; Cheng JC, 2011, ONCOGENE, V30, P3930, DOI 10.1038/onc.2011.117; Don ASA, 2006, EXP CELL RES, V312, P4181, DOI 10.0116/j.yexcr.2006.09.023; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fomenkov A, 2004, CELL CYCLE, V3, P1285, DOI 10.4161/cc.3.10.1155; Giroldi LA, 1997, BIOCHEM BIOPH RES CO, V241, P453, DOI 10.1006/bbrc.1997.7831; Graziano V, 2011, BBA-REV CANCER, V1816, P57, DOI 10.1016/j.bbcan.2011.04.002; Gumbiner BM, 2005, NAT REV MOL CELL BIO, V6, P622, DOI 10.1038/nrm1699; Harms KL, 2006, CELL DEATH DIFFER, V13, P890, DOI 10.1038/sj.cdd.4401904; Hsiao BY, 2011, J MOL MED, V89, P481, DOI 10.1007/s00109-010-0717-z; Hwang CI, 2011, CELL CYCLE, V10, P3834, DOI 10.4161/cc.10.22.18294; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Ishida S, 2000, JPN J CANCER RES, V91, P174, DOI 10.1111/j.1349-7006.2000.tb00929.x; Ji XD, 1997, CELL GROWTH DIFFER, V8, P773; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Liefer KM, 2000, CANCER RES, V60, P4016; Liu JJ, 2010, FEBS LETT, V584, P619, DOI 10.1016/j.febslet.2009.12.011; Lo PK, 2013, EXP MOL PATHOL, V94, P262, DOI 10.1016/j.yexmp.2012.10.014; Lo PK, 2012, CELL SIGNAL, V24, P316, DOI 10.1016/j.cellsig.2011.09.017; Lo PK, 2010, CANCER RES, V70, P6047, DOI 10.1158/0008-5472.CAN-10-1576; Lomenick JP, 2006, AM J PHYSIOL-ENDOC M, V291, pE947, DOI 10.1152/ajpendo.00128.2006; Lu C, 2008, CANCER BIOL THER, V7, P2039, DOI 10.4161/cbt.7.12.7461; Melino G, 2011, CELL DEATH DIFFER, V18, P1487, DOI 10.1038/cdd.2011.81; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Mizuno H, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-18; Nilsson J, 2010, CANCER RES, V70, P2020, DOI 10.1158/0008-5472.CAN-09-1677; Pecina-Slaus N, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-17; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Sasaki Y, 2005, ONCOGENE, V24, P5131, DOI 10.1038/sj.onc.1208695; Sasaki Y, 2003, CANCER RES, V63, P8145; Sasaki Y, 2008, MOL CANCER RES, V6, P395, DOI 10.1158/1541-7786.MCR-07-0108; Sasaki Y, 2011, CANCER RES, V71, P7038, DOI 10.1158/0008-5472.CAN-11-1053; Shaw-Smith C, 2010, EUR J MED GENET, V53, P6, DOI 10.1016/j.ejmg.2009.10.001; Shiota M, 2010, CLIN CANCER RES, V16, P5654, DOI 10.1158/1078-0432.CCR-10-0376; Stankiewicz P, 2009, AM J HUM GENET, V84, P780, DOI 10.1016/j.ajhg.2009.05.005; Stiewe T, 2007, NAT REV CANCER, V7, P165, DOI 10.1038/nrc2072; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Su XH, 2013, NAT REV CANCER, V13, P136, DOI 10.1038/nrc3446; Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459; Teh MT, 2002, CANCER RES, V62, P4773; Tokino T, 2000, CRIT REV ONCOL HEMAT, V33, P1, DOI 10.1016/S1040-8428(99)00051-7; Tucci P, 2012, P NATL ACAD SCI USA, V109, P15312, DOI 10.1073/pnas.1110977109; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Watson JEV, 2004, ONCOGENE, V23, P3487, DOI 10.1038/sj.onc.1207474; Wu N, 2012, J BIOL CHEM, V287, P5627, DOI 10.1074/jbc.M111.328120; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zhang YH, 2012, J BIOL CHEM, V287, P17746, DOI 10.1074/jbc.M112.358143; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051	62	42	44	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2014	33	40					4837	4846		10.1038/onc.2013.427	http://dx.doi.org/10.1038/onc.2013.427			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR0EH	24186199				2022-12-17	WOS:000343240100005
J	Wiseman, DH; Greystoke, BF; Somervaille, TCP				Wiseman, D. H.; Greystoke, B. F.; Somervaille, T. C. P.			The variety of leukemic stem cells in myeloid malignancy	ONCOGENE			English	Review						AML; LSC; myeloid; leukemia; stem cell	ACUTE MYELOGENOUS LEUKEMIA; HEMATOPOIETIC STEM; CLONOGENIC CELLS; INITIATING CELLS; PROGENITOR CELLS; IN-VITRO; XENOTRANSPLANTATION MODEL; CLONAL REMISSIONS; SELF-RENEWAL; BCR-ABL	Human acute myeloid leukemias (AMLs) are sustained by leukemic stem cells (LSCs) that generate through aberrant differentiation the blast cells that make up the bulk of the malignant clone. LSCs were first identified as rare cells with an immunophenotype shared with normal hematopoietic stem cells (HSCs). However, refinements of xenotransplantation assays, alternative methods of quantitation and syngeneic murine models have all led to an appreciation that LSCs display marked variability in frequency, immunophenotype and differentiation potential, both between and even within leukemias. Insights from next-generation sequencing efforts have dramatically extended understanding of the mutational landscape and clonal organization of AML and have added an additional layer of complexity to the biology of LSCs: a requirement to consider the effect of the various recurrently occurring genetic lesions in AML on the initiation and maintenance of leukemic subclones. Despite these advances, cure rates in AML remain substantially unchanged in recent years. A renewed focus on the biological properties of chemotherapy-resistant LSCs, a cellular entity of prime clinical importance, will be required to develop additional therapeutic strategies to enhance patient outcomes.	[Wiseman, D. H.; Greystoke, B. F.; Somervaille, T. C. P.] Univ Manchester, Paterson Inst Canc Res, Canc Res UK Leukaemia Biol Lab, Manchester, Lancs, England	Paterson Institute for Cancer Research; University of Manchester	Somervaille, TCP (corresponding author), Paterson Inst Canc Res, Canc Res UK Leukaemia Biol Lab, Wilmslow Rd, Manchester M20 4BX, Lancs, England.	tsomervaille@picr.man.ac.uk	Wiseman, Daniel/AAG-9914-2020	Wiseman, Daniel/0000-0003-0715-1402; Somervaille, Tim/0000-0002-9188-4379	Leukaemia and Lymphoma Research Clinical Training Fellowships; Cancer Research UK [C5759/A12328]; Cancer Research UK [19280] Funding Source: researchfish	Leukaemia and Lymphoma Research Clinical Training Fellowships; Cancer Research UK(Cancer Research UK); Cancer Research UK(Cancer Research UK)	We apologize to the many clinicians and scientists who have contributed to this field whose work we were unable to cite because of space constraints. DW and BG are recipients of Leukaemia and Lymphoma Research Clinical Training Fellowships. TS is supported by Cancer Research UK grant number C5759/A12328.	Ailles LE, 1999, BLOOD, V94, P1761, DOI 10.1182/blood.V94.5.1761.417k23_1761_1772; Anderson K, 2011, NATURE, V469, P356, DOI 10.1038/nature09650; Beekman R, 2012, BLOOD, V119, P5071, DOI 10.1182/blood-2012-01-406116; Bereshchenko O, 2009, CANCER CELL, V16, P390, DOI 10.1016/j.ccr.2009.09.036; BLACKSTOCK AM, 1974, LANCET, V2, P1178; Blair A, 1997, BLOOD, V89, P3104, DOI 10.1182/blood.V89.9.3104; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; BUICK RN, 1979, BLOOD, V54, P95; Burnett A, 2011, J CLIN ONCOL, V29, P487, DOI 10.1200/JCO.2010.30.1820; Burnett AK, 2011, J CLIN ONCOL, V29, P369, DOI 10.1200/JCO.2010.31.4310; Busque L, 2012, NAT GENET, V44, P1179, DOI 10.1038/ng.2413; Castaigne S, 2012, LANCET, V379, P1508, DOI 10.1016/S0140-6736(12)60485-1; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; CROWTHER D, 1970, BMJ-BRIT MED J, V4, P513, DOI 10.1136/bmj.4.5734.513; Delhommeau F, 2009, NEW ENGL J MED, V360, P2289, DOI 10.1056/NEJMoa0810069; DICKE KA, 1976, NATURE, V259, P129, DOI 10.1038/259129a0; Ding L, 2012, NATURE, V481, P506, DOI 10.1038/nature10738; Eppert K, 2011, NAT MED, V17, P1086, DOI 10.1038/nm.2415; FEARON ER, 1986, NEW ENGL J MED, V315, P15, DOI 10.1056/NEJM198607033150103; FIALKOW PJ, 1991, BLOOD, V77, P1415; FIALKOW PJ, 1977, AM J MED, V63, P125, DOI 10.1016/0002-9343(77)90124-3; GALE RE, 1993, LANCET, V341, P138, DOI 10.1016/0140-6736(93)90004-Z; Gibbs KD, 2012, CELL STEM CELL, V10, P210, DOI 10.1016/j.stem.2012.01.004; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Goardon N, 2011, CANCER CELL, V19, P138, DOI 10.1016/j.ccr.2010.12.012; GRIFFIN JD, 1986, BLOOD, V68, P1185; Guan YH, 2003, BLOOD, V101, P3142, DOI 10.1182/blood-2002-10-3062; Guzman ML, 2001, BLOOD, V98, P2301, DOI 10.1182/blood.V98.8.2301; Harris WJ, 2012, CANCER CELL, V21, P473, DOI 10.1016/j.ccr.2012.03.014; Hosen N, 2007, P NATL ACAD SCI USA, V104, P11008, DOI 10.1073/pnas.0704271104; Huntly BJP, 2004, CANCER CELL, V6, P587, DOI 10.1016/j.ccr.2004.10.015; Ishikawa F, 2007, NAT BIOTECHNOL, V25, P1315, DOI 10.1038/nbt1350; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; JAN M, 2012, SCI TRANSL MED, V4; JANSSEN JWG, 1989, BLOOD, V73, P248; JINNAI I, 1995, LEUKEMIA, V9, P1756; JONAS D, 1992, BLOOD, V79, P1017; JOWITT SN, 1993, BRIT J HAEMATOL, V85, P698, DOI 10.1111/j.1365-2141.1993.tb03211.x; KEINANEN M, 1988, NEW ENGL J MED, V318, P1153, DOI 10.1056/NEJM198805053181803; Kelly PN, 2007, SCIENCE, V317, P337, DOI 10.1126/science.1142596; Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026; Kikushige Y, 2010, CELL STEM CELL, V7, P708, DOI 10.1016/j.stem.2010.11.014; Kottaridis PD, 2002, BLOOD, V100, P2393, DOI 10.1182/blood-2002-02-0420; Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980; LANGE B, 1984, BLOOD, V64, P693; Ley TJ, 2008, NATURE, V456, P66, DOI 10.1038/nature07485; Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689; Ley TJ, 2010, NEW ENGL J MED, V363, P2424, DOI 10.1056/NEJMoa1005143; LOCOCO F, 1993, BLOOD, V82, P606; Lowenberg B, 1999, NEW ENGL J MED, V341, P1051, DOI 10.1056/NEJM199909303411407; Majeti R, 2009, CELL, V138, P286, DOI 10.1016/j.cell.2009.05.045; Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840; Martelli MP, 2010, BLOOD, V116, P3907, DOI 10.1182/blood-2009-08-238899; MARTIN PJ, 1980, NATURE, V287, P49, DOI 10.1038/287049a0; Meyer JA, 2013, NAT GENET, V45, P290, DOI 10.1038/ng.2558; MINDEN MD, 1978, BLOOD, V52, P592; Miyamoto T, 2000, P NATL ACAD SCI USA, V97, P7521, DOI 10.1073/pnas.97.13.7521; Mullighan CG, 2008, SCIENCE, V322, P1377, DOI 10.1126/science.1164266; Nakano Y, 1999, BRIT J HAEMATOL, V104, P659, DOI 10.1046/j.1365-2141.1999.01256.x; Notta F, 2011, SCIENCE, V333, P218, DOI 10.1126/science.1201219; Notta F, 2011, NATURE, V469, P362, DOI 10.1038/nature09733; ORLIC D, 1994, BLOOD, V84, P3991, DOI 10.1182/blood.V84.12.3991.bloodjournal84123991; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Passegue E, 2003, P NATL ACAD SCI USA, V100, P11842, DOI 10.1073/pnas.2034201100; Patel S, 2012, LEUKEMIA, V26, P2432, DOI 10.1038/leu.2012.154; Pearce DJ, 2006, BLOOD, V107, P1166, DOI 10.1182/blood-2005-06-2325; SABBATH KD, 1985, J CLIN INVEST, V75, P746, DOI 10.1172/JCI111756; Saito Y, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000349; Sanchez PV, 2009, LEUKEMIA, V23, P2109, DOI 10.1038/leu.2009.143; Sarry JE, 2011, J CLIN INVEST, V121, P384, DOI 10.1172/JCI41495; Shih AH, 2012, NAT REV CANCER, V12, P599, DOI 10.1038/nrc3343; Shultz LD, 2005, J IMMUNOL, V174, P6477, DOI 10.4049/jimmunol.174.10.6477; Somervaille TCP, 2006, CANCER CELL, V10, P257, DOI 10.1016/j.ccr.2006.08.020; Somervaille TCP, 2009, CELL STEM CELL, V4, P129, DOI 10.1016/j.stem.2008.11.015; SPANGRUDE GJ, 1991, BLOOD, V78, P1395; SPITZER G, 1976, BLOOD, V48, P795; SWART K, 1982, BLOOD, V59, P816; Taussig DC, 2008, BLOOD, V112, P568, DOI 10.1182/blood-2007-10-118331; Taussig DC, 2010, BLOOD, V115, P1976, DOI 10.1182/blood-2009-02-206565; Taussig DC, 2005, BLOOD, V106, P4086, DOI 10.1182/blood-2005-03-1072; Terpstra W, 1996, BLOOD, V88, P1944, DOI 10.1182/blood.V88.6.1944.bloodjournal8861944; Terpstra W, 1996, BLOOD, V87, P2187, DOI 10.1182/blood.V87.6.2187.bloodjournal8762187; Tzoneva G, 2013, NAT MED, V19, P368, DOI 10.1038/nm.3078; Vago L, 2009, NEW ENGL J MED, V361, P478, DOI 10.1056/NEJMoa0811036; van Rhenen A, 2007, BLOOD, V110, P2659, DOI 10.1182/blood-2007-03-083048; Vargaftig J, 2012, LEUKEMIA, V26, P858, DOI 10.1038/leu.2011.250; Walter MJ, 2012, NEW ENGL J MED, V366, P1090, DOI 10.1056/NEJMoa1106968; WEIDEN PL, 1981, NEW ENGL J MED, V304, P1529, DOI 10.1056/NEJM198106183042507; Welch JS, 2012, CELL, V150, P264, DOI 10.1016/j.cell.2012.06.023; Wilhelm BT, 2011, BLOOD, V117, pE27, DOI 10.1182/blood-2010-07-293332; World Health Organization, 2008, CLASS TUM HAEM LYMPH; Wunderlich M, 2010, LEUKEMIA, V24, P1785, DOI 10.1038/leu.2010.158; Yan XJ, 2011, NAT GENET, V43, P309, DOI 10.1038/ng.788; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; Zuber J, 2009, GENE DEV, V23, P877, DOI 10.1101/gad.1771409	95	42	45	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2014	33	24					3091	3098		10.1038/onc.2013.269	http://dx.doi.org/10.1038/onc.2013.269			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK4QU	23831573				2022-12-17	WOS:000338410000002
J	Lu, H; Hu, L; Yu, L; Wang, X; Urvalek, AM; Li, T; Shen, C; Mukherjee, D; Lahiri, SK; Wason, MS; Zhao, J				Lu, H.; Hu, L.; Yu, L.; Wang, X.; Urvalek, A. M.; Li, T.; Shen, C.; Mukherjee, D.; Lahiri, S. K.; Wason, M. S.; Zhao, J.			KLF8 and FAK cooperatively enrich the active MMP14 on the cell surface required for the metastatic progression of breast cancer	ONCOGENE			English	Article						KLF8; FAK; MMP14; beta-catenin/TCF1; metastasis; breast cancer	FOCAL ADHESION KINASE; KRUPPEL-LIKE FACTOR-8; E-CADHERIN; 1-MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE-1; BETA-CATENIN/TCF4 COMPLEX; MESENCHYMAL TRANSITION; TUMOR-CELLS; TRANSCRIPTION; MT1-MMP	Kruppel-like factor 8 (KLF8) regulates critical gene transcription associated with cancer. The underlying mechanisms, however, remain largely unidentified. We have recently demonstrated that KLF8 expression enhances the activity but not expression of matrix metalloproteinase-2 (MMP2), the target substrate of MMP14. Here, we report a novel KLF8 to MMP14 signaling that promotes human breast cancer invasion and metastasis. Using cell lines for inducible expression and knockdown of KLF8, we demonstrate that KLF8 promotes MMP14 expression at the transcriptional level. Knocking down KLF8 expression inhibited the breast cancer cell invasion both in vitro and in vivo as well as the lung metastasis in mice, which could be rescued by ectopic expression of MMP14. Promoter reporter assays and oligonucleotide and chromatin immunoprecipitations determined that KLF8 activates the human MMP14 gene promoter by both directly acting on the promoter and indirectly via promoting the nuclear translocation of beta-catenin, the expression of T-cell factor-1 (TCF1) and subsequent activation of the promoter by the beta-catenin/TCF1 complex. Inhibition of focal adhesion kinase (FAK) using pharmacological inhibitor, RNA interference or knockout showed that the cell surface presentation of active MMP14 downstream of KLF8 depends on FAK expression and activity. Taken together, this work identified novel signaling mechanisms by which KLF8 and FAK work together to promote the extracellular activity of MMP14 critical for breast cancer metastasis.	[Lu, H.; Hu, L.; Yu, L.; Wang, X.; Urvalek, A. M.; Li, T.; Shen, C.; Mukherjee, D.; Lahiri, S. K.; Wason, M. S.; Zhao, J.] Univ Cent Florida, Coll Med, Burnett Sch Biomed Sci, Orlando, FL 32827 USA	State University System of Florida; University of Central Florida	Zhao, J (corresponding author), Univ Cent Florida, Coll Med, Burnett Sch Biomed Sci, 6900 Lake Nona Blvd, Orlando, FL 32827 USA.	Jihe.Zhao@ucf.edu	Li, Tianshu/L-6426-2014; Lahiri, Satadru/J-3483-2019	Li, Tianshu/0000-0002-9972-4644; 	NCI [CA132977]; Susan G Komen for Cure breast cancer foundation [KG090444, KG080616]; NATIONAL CANCER INSTITUTE [R01CA132977] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Susan G Komen for Cure breast cancer foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We appreciate Dr Jouko Lohi of University of Helsinki for kindly providing the human MMP14 gene promoter reporter vectors. This work was supported by grants from NCI (CA132977) and Susan G Komen for Cure breast cancer foundation (KG090444 and KG080616) to JZ.	Afsar NA, 2012, EUR J CLIN PHARMACOL, V68, P389, DOI 10.1007/s00228-011-1134-0; Ara T, 2000, CANCER LETT, V157, P115, DOI 10.1016/S0304-3835(00)00494-8; Barbolina MV, 2008, SEMIN CELL DEV BIOL, V19, P24, DOI 10.1016/j.semcdb.2007.06.008; Covington MD, 2006, AM J PHYSIOL-RENAL, V290, pF43, DOI 10.1152/ajprenal.00179.2005; Cristofanilli M, 2006, SEMIN ONCOL, V33, pS9, DOI 10.1053/j.seminoncol.2006.03.016; Dwivedi DJ, 2006, AM J PATHOL, V168, P69, DOI 10.2353/ajpath.2006.041089; Lahiri SK, 2012, AM J TRANSL RES, V4, P357; Liu P, 2010, J CELL PHYSIOL, V225, P810, DOI 10.1002/jcp.22292; Lohi J, 2000, GENE, V242, P75, DOI 10.1016/S0378-1119(99)00549-1; Lu H, 2014, ONCOGENE, V33, P10, DOI 10.1038/onc.2012.545; Lu H, 2012, J BIOL CHEM, V287, P43720, DOI 10.1074/jbc.M112.418053; Lu H, 2011, J BIOL CHEM, V286, P20335, DOI 10.1074/jbc.M110.215632; Mehta TS, 2009, CELL RES, V19, P1098, DOI 10.1038/cr.2009.64; Nawrocki-Raby B, 2003, INT J CANCER, V105, P790, DOI 10.1002/ijc.11168; Sanchez-Tillo E, 2011, P NATL ACAD SCI USA, V108, P19204, DOI 10.1073/pnas.1108977108; Schnell O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030429; Symowicz J, 2007, CANCER RES, V67, P2030, DOI 10.1158/0008-5472.CAN-06-2808; Takahashi M, 2002, ONCOGENE, V21, P5861, DOI 10.1038/sj.onc.1205755; Urvalek AM, 2011, AM J TRANSL RES, V3, P121; Urvalek AM, 2010, CELL CYCLE, V9, P601, DOI 10.4161/cc.9.3.10606; van Vliet J, 2000, NUCLEIC ACIDS RES, V28, P1955; Veeman MT, 2003, CURR BIOL, V13, P680, DOI 10.1016/S0960-9822(03)00240-9; Wang X, 2007, ONCOGENE, V26, P456, DOI 10.1038/sj.onc.1209796; Wang X, 2011, ONCOGENE, V30, P1901, DOI 10.1038/onc.2010.563; Wang XH, 2008, J BIOL CHEM, V283, P13934, DOI 10.1074/jbc.M709300200; Wang XH, 2007, CANCER RES, V67, P7184, DOI 10.1158/0008-5472.CAN-06-4729; Wei HJ, 2006, J BIOL CHEM, V281, P16664, DOI 10.1074/jbc.M513135200; Wu XY, 2005, DEV CELL, V9, P185, DOI 10.1016/j.devcel.2005.06.006; Zhang XL, 2012, P NATL ACAD SCI USA, V109, P9623, DOI 10.1073/pnas.1121606109; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997; Zhao JH, 2003, MOL CELL, V11, P1503, DOI 10.1016/S1097-2765(03)00179-5; Zhao J, 2009, CANCER METAST REV, V28, P35, DOI 10.1007/s10555-008-9165-4	32	42	46	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2014	33	22					2909	2917		10.1038/onc.2013.247	http://dx.doi.org/10.1038/onc.2013.247			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EI	23812425	Green Accepted			2022-12-17	WOS:000337231800010
J	Romero, OA; Sanchez-Cespedes, M				Romero, O. A.; Sanchez-Cespedes, M.			The SWI/SNF genetic blockade: effects in cell differentiation, cancer and developmental diseases	ONCOGENE			English	Review						SWI/SNF; chromatin remodeling; BRG1; MYC; cancer; cell differentiation	CHROMATIN-REMODELING COMPLEX; IDENTIFIES FREQUENT MUTATION; TUMOR-SUPPRESSOR; ESTROGEN-RECEPTOR; CRITICAL REGULATOR; SOMATIC MUTATIONS; BAF COMPLEX; BRG1; LUNG; ARID1A	Our rapidly growing knowledge about cancer genetics attests to the widespread occurrence of alterations at genes encoding different components of the SWI/SNF complex. This reveals an important new feature that sustains cancer development: the blockade of chromatin remodeling. Here, we provide an overview of our current knowledge on the gene alterations of chromatin-remodeling factors, and how they relate to cancer and human developmental diseases. We also consider the functional repercussions, particularly how the inactivation of the SWI/SNF complex impairs the appropriate cell response to nuclear receptor signaling, which, in turn, prevents cell differentiation and sustains cell growth independently of the environment.	[Romero, O. A.; Sanchez-Cespedes, M.] Hosp Llobregat, IDIBELL, Bellvitge Biomed Res Inst, PEBC,Canc Epigenet & Biol Program,Genes & Canc Gr, Barcelona 08908, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona	Sanchez-Cespedes, M (corresponding author), Hosp Llobregat, IDIBELL, Bellvitge Biomed Res Inst, PEBC,Canc Epigenet & Biol Program,Genes & Canc Gr, Barcelona 08908, Spain.	mscespedes@idibell.cat	Sanchez-Cespedes, Montse/H-8485-2012; Romero, Octavio A./AAA-8078-2020	Sanchez-Cespedes, Montse/0000-0002-6045-5627; Romero, Octavio A./0000-0003-0229-6530				Albanese P, 2006, EUR J CANCER, V42, P2326, DOI 10.1016/j.ejca.2006.03.028; Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Biddie SC, 2012, RHEUMATOLOGY, V51, P403, DOI 10.1093/rheumatology/ker215; Biegel JA, 1999, CANCER RES, V59, P74; Blanco R, 2009, HUM MUTAT, V30, P1199, DOI 10.1002/humu.21028; Bultman SJ, 2008, ONCOGENE, V27, P460, DOI 10.1038/sj.onc.1210664; Bultman SJ, 2005, GENE DEV, V19, P2849, DOI 10.1101/gad.1364105; Caramel J, 2008, ONCOGENE, V27, P2035, DOI 10.1038/sj.onc.1210847; Chai B, 2005, GENE DEV, V19, P1656, DOI 10.1101/gad.1273105; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; Debril MB, 2004, J BIOL CHEM, V279, P16677, DOI 10.1074/jbc.M312288200; DelBove J, 2011, EPIGENETICS-US, V6, P1444, DOI 10.4161/epi.6.12.18492; Euskirchen GM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002008; Flajollet S, 2007, MOL CELL ENDOCRINOL, V270, P23, DOI 10.1016/j.mce.2007.02.004; Forcales SV, 2012, EMBO J, V31, P301, DOI 10.1038/emboj.2011.391; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Fujimoto A, 2012, NAT GENET, V44, P760, DOI 10.1038/ng.2291; Garcia-Pedrero JM, 2006, J BIOL CHEM, V281, P22656, DOI 10.1074/jbc.M602561200; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Gebuhr TC, 2003, J EXP MED, V198, P1937, DOI 10.1084/jem.20030714; GERADTS J, 1993, CELL GROWTH DIFFER, V4, P799; GIBBONS RJ, 1995, CELL, V80, P837, DOI 10.1016/0092-8674(95)90287-2; Giulino-Roth L, 2012, BLOOD, V120, P5181, DOI 10.1182/blood-2012-06-437624; Glaros S, 2008, CANCER RES, V68, P3689, DOI 10.1158/0008-5472.CAN-07-6652; Gresh L, 2005, EMBO J, V24, P3313, DOI 10.1038/sj.emboj.7600802; Griffin CT, 2008, DEVELOPMENT, V135, P493, DOI 10.1242/dev.010090; Guan B, 2011, CANCER RES, V71, P6718, DOI 10.1158/0008-5472.CAN-11-1562; Gui YT, 2011, NAT GENET, V43, P875, DOI 10.1038/ng.907; Guichard C, 2012, NAT GENET, V44, P694, DOI 10.1038/ng.2256; Halgren C, 2012, CLIN GENET, V82, P248, DOI 10.1111/j.1399-0004.2011.01755.x; Hargreaves DC, 2011, CELL RES, V21, P396, DOI 10.1038/cr.2011.32; Hasselblatt M, 2011, AM J SURG PATHOL, V35, P933, DOI 10.1097/PAS.0b013e3182196a39; Hendricks KB, 2004, MOL CELL BIOL, V24, P362, DOI 10.1128/MCB.24.1.362-376.2004; Hood RL, 2012, AM J HUM GENET, V90, P308, DOI 10.1016/j.ajhg.2011.12.001; Hoyer J, 2012, AM J HUM GENET, V90, P565, DOI 10.1016/j.ajhg.2012.02.007; Huang J, 2012, NAT GENET, V44, P1117, DOI 10.1038/ng.2391; Huang JM, 2007, GENE CHROMOSOME CANC, V46, P745, DOI 10.1002/gcc.20459; Hulsebos TJM, 2007, AM J HUM GENET, V80, P805, DOI 10.1086/513207; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Johnson TA, 2008, MOL BIOL CELL, V19, P3308, DOI 10.1091/mbc.E08-02-0123; Jones DTW, 2012, NATURE, V488, P100, DOI 10.1038/nature11284; Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333; Jung DJ, 2001, J BIOL CHEM, V276, P37280, DOI 10.1074/jbc.M106860200; Kim JK, 2001, MOL CELL BIOL, V21, P7787, DOI 10.1128/MCB.21.22.7787-7795.2001; Kiskinis E, 2006, BREAST CANCER RES TR, V98, P191, DOI 10.1007/s10549-005-9149-9; Ko M, 2008, MUTAT RES-FUND MOL M, V647, P59, DOI 10.1016/j.mrfmmm.2008.08.004; Kwon CS, 2007, TRENDS GENET, V23, P403, DOI 10.1016/j.tig.2007.05.010; Lai AY, 2011, NAT REV CANCER, V11, P588, DOI 10.1038/nrc3091; Lamba DA, 2008, DEV DYNAM, V237, P3016, DOI 10.1002/dvdy.21697; Le Gallo M, 2012, NAT GENET, V44, P1310, DOI 10.1038/ng.2455; Li S, 2008, CELL METAB, V8, P105, DOI 10.1016/j.cmet.2008.06.013; Lickert H, 2004, NATURE, V432, P107, DOI 10.1038/nature03071; Love C, 2012, NAT GENET, V44, P1321, DOI 10.1038/ng.2468; Mamo A, 2012, ONCOGENE, V31, P2090, DOI 10.1038/onc.2011.386; Manceau G, 2013, INT J CANCER, V132, P2217, DOI 10.1002/ijc.27900; Marshall TW, 2003, J BIOL CHEM, V278, P30605, DOI 10.1074/jbc.M304582200; Masetti R, 2012, ADV THER, V29, P747, DOI 10.1007/s12325-012-0047-3; Matsumoto S, 2006, DEV BIOL, V289, P372, DOI 10.1016/j.ydbio.2005.10.044; Medina PP, 2008, HUM MUTAT, V29, P617, DOI 10.1002/humu.20730; Medina PP, 2005, HUM MOL GENET, V14, P973, DOI 10.1093/hmg/ddi091; Medina PP, 2004, GENE CHROMOSOME CANC, V41, P170, DOI 10.1002/gcc.20068; Pal S, 2003, MOL CELL BIOL, V23, P7475, DOI 10.1128/MCB.23.21.7475-7487.2003; Parsons DW, 2011, SCIENCE, V331, P435, DOI 10.1126/science.1198056; Pedersen TA, 2001, GENE DEV, V15, P3208, DOI 10.1101/gad.209901; Pottier N, 2008, JNCI-J NATL CANCER I, V100, P1792, DOI 10.1093/jnci/djn416; Pugh TJ, 2012, NATURE, V488, P106, DOI 10.1038/nature11329; Ramirez-Carrozzi VR, 2009, CELL, V138, P114, DOI 10.1016/j.cell.2009.04.020; Reisman D, 2009, ONCOGENE, V28, P1653, DOI 10.1038/onc.2009.4; Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979; Rhinn M, 2012, DEVELOPMENT, V139, P843, DOI 10.1242/dev.065938; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Rodriguez-Nieto S, 2011, HUM MUTAT, V32, pE1999, DOI 10.1002/humu.21415; Romero OA, 2012, EMBO MOL MED, V4, P603, DOI 10.1002/emmm.201200236; SAFFIOTTI U, 1967, CANCER-AM CANCER SOC, V20, P857, DOI 10.1002/1097-0142(1967)20:5&lt;857::AID-CNCR2820200545&gt;3.0.CO;2-3; Salma N, 2004, MOL CELL BIOL, V24, P4651, DOI 10.1128/MCB.24.11.4651-4663.2004; Santen GWE, 2012, NAT GENET, V44, P379, DOI 10.1038/ng.2217; Sausen M, 2013, NAT GENET, V45, P12, DOI 10.1038/ng.2493; Schmitz U, 2001, BRIT J CANCER, V84, P199, DOI 10.1054/bjoc.2000.1583; Schneppenheim R, 2010, AM J HUM GENET, V86, P279, DOI 10.1016/j.ajhg.2010.01.013; Schwartzentruber J, 2012, NATURE, V482, P226, DOI [10.1038/nature10833, 10.1007/s13311-012-0137-6]; Sevenet N, 1999, AM J HUM GENET, V65, P1342, DOI 10.1086/302639; Shain AH, 2012, P NATL ACAD SCI USA, V109, pE252, DOI 10.1073/pnas.1114817109; Shi Wei, 2009, Proc Am Thorac Soc, V6, P558, DOI 10.1513/pats.200905-031RM; Siersbaek R, 2012, TRENDS ENDOCRIN MET, V23, P56, DOI 10.1016/j.tem.2011.10.001; Singhal N, 2010, CELL, V141, P943, DOI 10.1016/j.cell.2010.04.037; Smith CL, 2005, MOL CELL BIOL, V25, P5880, DOI 10.1128/MCB.25.14.5880-5892.2005; Smith MJ, 2013, NAT GENET, V45, P295, DOI 10.1038/ng.2552; Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017; Tsurusaki Y, 2012, NAT GENET, V44, P376, DOI 10.1038/ng.2219; Van Houdt JKJ, 2012, NAT GENET, V44, P445, DOI 10.1038/ng.1105; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Wang K, 2011, NAT GENET, V43, P1219, DOI 10.1038/ng.982; Wang Y, 2012, MOL CELL S, VS1097-2765; Wang Z, 2004, GENE DEV, V18, P3106, DOI 10.1101/gad.1238104; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433; Wilson BG, 2010, CANCER CELL, V18, P316, DOI 10.1016/j.ccr.2010.09.006; Wilson GB., 2011, NAT REV CANCER, V11, P281; Wolff D, 2011, MOL SYNDROMOL, V2, P237, DOI 10.1159/000337323; Wong AKC, 2000, CANCER RES, V60, P6171; Wu JI, 2007, NEURON, V56, P94, DOI 10.1016/j.neuron.2007.08.021; Xia W, 2008, CANCER RES, V68, P1667, DOI 10.1158/0008-5472.CAN-07-5276; Xu FH, 2012, J BIOL CHEM, V287, P5033, DOI 10.1074/jbc.M111.279968; Xu X, 2012, CELL, V148, P886, DOI 10.1016/j.cell.2012.02.025; Zhang YJ, 2007, J CELL BIOCHEM, V102, P1256, DOI 10.1002/jcb.21356	106	42	43	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2014	33	21					2681	2689		10.1038/onc.2013.227	http://dx.doi.org/10.1038/onc.2013.227			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EH	23752187				2022-12-17	WOS:000337231700001
J	Brown, L; Waseem, A; Cruz, IN; Szary, J; Gunic, E; Mannan, T; Unadkat, M; Yang, M; Valderrama, F; O'Toole, EA; Wan, H				Brown, L.; Waseem, A.; Cruz, I. N.; Szary, J.; Gunic, E.; Mannan, T.; Unadkat, M.; Yang, M.; Valderrama, F.; O'Toole, E. A.; Wan, H.			Desmoglein 3 promotes cancer cell migration and invasion by regulating activator protein 1 and protein kinase C-dependent-Ezrin activation	ONCOGENE			English	Article						desmoglein; ERM proteins; AP-1 transcription factor; cell migration and invasion; keratinocytes	PEMPHIGUS-VULGARIS-IGG; EZRIN/RADIXIN/MOESIN ERM PROTEINS; CARCINOMA-CELLS; RHO-KINASE; HEPATOCELLULAR-CARCINOMA; ACTIN REORGANIZATION; UPSTREAM REGULATOR; ENDOTHELIAL-CELLS; INHIBITS INVASION; EPIDERMAL-GROWTH	Desmoglein 3 (Dsg3), the pemphigus vulgaris antigen, has recently been shown to be upregulated in squamous cell carcinoma (SCC) and has been identified as a good tumor-specific marker for clinical staging of cervical sentinel lymph nodes in head and neck SCC. However, little is known about its biological function in cancer. The actin-binding protein Ezrin and the activator protein 1 (AP-1) transcription factor are implicated in cancer progression and metastasis. Here, we report that Dsg3 regulates the activity of c-Jun/AP-1 as well as protein kinase C (PKC)-mediated phosphorylation of Ezrin-Thr567, which contributes to the accelerated motility of cancer cells. Ectopic expression of Dsg3 in cancer cell lines caused enhanced phosphorylation at Ezrin-Thr567 with concomitant augmented membrane protrusions, cell spreading and invasive phenotype. We showed that Dsg3 formed a complex with Ezrin at the plasma membrane that was required for its proper function of interacting with F-actin and CD44 as Dsg3 knockdown impaired these associations. The increased Ezrin phosphorylation in Dsg3-overexpressing cells could be abrogated substantially by various pharmacological inhibitors for Ser/Thr kinases, including PKC and Rho kinase that are known to activate Ezrin. Furthermore, a marked increase in c-Jun S63 phosphorylation, among others, was found in Dsg3-overexpressing cells and the activation of c-Jun/AP-1 was further supported by a luciferase reporter assay. Taken together, our study identifies a novel Dsg3mediated c-Jun/AP-1 regulatory mechanism and PKC-dependent Ezrin phosphorylation that could be responsible for Dsg3-associated cancer metastasis.	[Brown, L.; Waseem, A.; Szary, J.; Gunic, E.; Mannan, T.; Unadkat, M.; Wan, H.] Queen Mary Univ London, Barts & London Sch Med & Dent, Ctr Clin & Diagnost Oral Sci, Inst Dent, London E1 2AT, England; [Cruz, I. N.; Yang, M.] UCL Sch Pharm, Dept Pharmaceut & Biol Chem, London, England; [Valderrama, F.] Univ London, Div Biomed Sci, London, England; [O'Toole, E. A.] Queen Mary Univ London, Barts & London Sch Med & Dent, Ctr Cutaneous Res, Blizard Inst, London E1 2AT, England	University of London; Queen Mary University London; University of London; University College London; University of London; University of London; Queen Mary University London	Wan, H (corresponding author), Queen Mary Univ London, Barts & London Sch Med & Dent, Ctr Clin & Diagnost Oral Sci, Inst Dent, Blizard Bldg, London E1 2AT, England.	h.wan@qmul.ac.uk		O'Toole, Edel/0000-0002-4084-4836	British Skin Foundation; Institute of Dentistry; Facial Surgery Research Foundation-Saving Faces; Engineering and Physical Sciences Research Council [EP/K023071/1] Funding Source: researchfish; EPSRC [EP/K023071/1] Funding Source: UKRI	British Skin Foundation; Institute of Dentistry; Facial Surgery Research Foundation-Saving Faces; Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))	We thank Dr MT Teh, Professor K Parkinson, Dr SM Tsang, Dr MS Ikram and members of CDOS for helpful discussion and technical assistance. This work was supported by a British Skin Foundation-funded studentship awarded to HW and in part by the Institute of Dentistry as well as The Facial Surgery Research Foundation-Saving Faces.	AMAGAI, 1994, J INVEST DERMATOL, V103, P608, DOI 10.1111/1523-1747.ep12397292; AMAGAI M, 1991, CELL, V67, P869, DOI 10.1016/0092-8674(91)90360-B; Aoyama Y, 1999, EUR J IMMUNOL, V29, P2233, DOI 10.1002/(SICI)1521-4141(199907)29:07<2233::AID-IMMU2233>3.0.CO;2-4; Belkina NV, 2009, P NATL ACAD SCI USA, V106, P4707, DOI 10.1073/pnas.0805963106; Berkowitz P, 2005, J BIOL CHEM, V280, P23778, DOI 10.1074/jbc.M501365200; Bogatcheva NV, 2011, AM J RESP CELL MOL, V45, P1185, DOI 10.1165/rcmb.2011-0092OC; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; Calkins CC, 2006, J BIOL CHEM, V281, P7623, DOI 10.1074/jbc.M512447200; Chen YJ, 2007, ONCOGENE, V26, P467, DOI 10.1038/sj.onc.1209802; Chen Y, 2011, CANCER RES, V71, P1721, DOI 10.1158/0008-5472.CAN-09-4683; Chidgey M, 2007, BRIT J CANCER, V96, P1783, DOI 10.1038/sj.bjc.6603808; Chuan YC, 2006, J BIOL CHEM, V281, P29938, DOI 10.1074/jbc.M602237200; Crepaldi T, 1997, J CELL BIOL, V138, P423, DOI 10.1083/jcb.138.2.423; Cui YZ, 2010, CANCER INVEST, V28, P242, DOI 10.3109/07357900903124498; Delva E, 2008, J BIOL CHEM, V283, P18303, DOI 10.1074/jbc.M710046200; Elliott BE, 2004, J CELL BIOCHEM, V92, P16, DOI 10.1002/jcb.20033; Elzagheid A, 2008, HUM PATHOL, V39, P1737, DOI 10.1016/j.humpath.2008.04.020; Fan LL, 2011, CANCER BIOL THER, V11, P746, DOI 10.4161/cbt.11.8.14691; Fehon RG, 2010, NAT REV MOL CELL BIO, V11, P276, DOI 10.1038/nrm2866; Ferris RL, 2005, CANCER RES, V65, P2147, DOI 10.1158/0008-5472.CAN-04-3717; Ferris RL, 2011, CLIN CANCER RES, V17, P1858, DOI 10.1158/1078-0432.CCR-10-3110; Fievet BT, 2004, J CELL BIOL, V164, P653, DOI 10.1083/jcb.200307032; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; GARY R, 1993, P NATL ACAD SCI USA, V90, P10846, DOI 10.1073/pnas.90.22.10846; Gliem M, 2010, AM J PHYSIOL-CELL PH, V299, pC606, DOI 10.1152/ajpcell.00075.2010; Goley ED, 2006, NAT REV MOL CELL BIO, V7, P713, DOI 10.1038/nrm2026; Hong SH, 2011, VET COMP ONCOL, V9, P207, DOI 10.1111/j.1476-5829.2010.00249.x; Huang CC, 2010, LARYNGOSCOPE, V120, P26, DOI 10.1002/lary.20151; Hunter KW, 2004, TRENDS MOL MED, V10, P201, DOI 10.1016/j.molmed.2004.03.001; Ivanov AI, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-36; Jensen PV, 2004, HISTOCHEM CELL BIOL, V121, P361, DOI 10.1007/s00418-004-0648-2; Jeong HJ, 2011, KOREAN J PHYSIOL PHA, V15, P245, DOI 10.4196/kjpp.2011.15.4.245; Johnston IMP, 2000, ONCOGENE, V19, P5348, DOI 10.1038/sj.onc.1203927; Kanno M, 2008, EXP CELL RES, V314, P1683, DOI 10.1016/j.yexcr.2008.01.031; KARPATI S, 1994, DERMATOLOGY, V189, P24, DOI 10.1159/000246923; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Kobel M, 2006, INT J GYNECOL PATHOL, V25, P121, DOI 10.1097/01.pgp.0000185410.39050.ac; Koivunen J, 2004, CANCER RES, V64, P5693, DOI 10.1158/0008-5472.CAN-03-3511; Koss M, 2006, J IMMUNOL, V176, P1218, DOI 10.4049/jimmunol.176.2.1218; Legg JW, 2002, NAT CELL BIOL, V4, P399, DOI 10.1038/ncb797; Legg JW, 1998, CURR BIOL, V8, P705, DOI 10.1016/S0960-9822(98)70277-5; Ling ZQ, 2010, CANCER SCI, V101, P624, DOI 10.1111/j.1349-7006.2009.01470.x; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Meng YX, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-61; Morgan MR, 2011, ONCOGENE, V30, P1422, DOI 10.1038/onc.2010.535; Muller EJ, 2008, J INVEST DERMATOL, V128, P501, DOI 10.1038/sj.jid.5701248; Ng T, 2001, EMBO J, V20, P2723, DOI 10.1093/emboj/20.11.2723; Nystrom ML, 2005, J PATHOL, V205, P468, DOI 10.1002/path.1716; Ozanne BW, 2007, ONCOGENE, V26, P1, DOI 10.1038/sj.onc.1209759; Patel V, 2013, ORAL ONCOL, V49, P93, DOI 10.1016/j.oraloncology.2012.08.001; Payne AS, 2004, CURR OPIN CELL BIOL, V16, P536, DOI 10.1016/j.ceb.2004.07.006; Pujuguet P, 2003, MOL BIOL CELL, V14, P2181, DOI 10.1091/mbc.E02-07-0410; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Ren L, 2009, ONCOGENE, V28, P792, DOI 10.1038/onc.2008.437; Sahai E, 2002, NAT CELL BIOL, V4, P408, DOI 10.1038/ncb796; Savci-Heijink CD, 2009, AM J PATHOL, V174, P1629, DOI 10.2353/ajpath.2009.080778; Shinohara M, 1998, J PATHOL, V184, P369, DOI 10.1002/(SICI)1096-9896(199804)184:4<369::AID-PATH1236>3.0.CO;2-L; Solassol J, 2010, BRIT J CANCER, V102, P181, DOI 10.1038/sj.bjc.6605470; Stapleton G, 2002, J CELL SCI, V115, P2713; Tamma G, 2007, AM J PHYSIOL-CELL PH, V292, pC1476, DOI 10.1152/ajpcell.00375.2006; Tang FQ, 2011, J BIOL CHEM, V286, P36956, DOI 10.1074/jbc.M111.259234; Teh MT, 2011, J ORAL PATHOL MED, V40, P67, DOI 10.1111/j.1600-0714.2010.00951.x; Tsang SM, 2012, EXP CELL RES, V318, P2269, DOI 10.1016/j.yexcr.2012.07.002; Tsang SM, 2012, J PATHOL, V227, P81, DOI 10.1002/path.3982; Tsang SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014211; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; van Baal J, 2005, J BIOL CHEM, V280, P9870, DOI 10.1074/jbc.M409301200; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Wald FA, 2008, J CELL SCI, V121, P644, DOI 10.1242/jcs.016246; Wang HJ, 2009, J DIGEST DIS, V10, P258, DOI 10.1111/j.1751-2980.2009.00394.x; Wang Longyun, 2010, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V35, P969, DOI 10.3969/j.issn.1672-7347.2010.09.012; Wang YY, 2011, ORAL SURG ORAL MED O, V112, P96, DOI 10.1016/j.tripleo.2011.02.018; Williamson L, 2006, EMBO J, V25, P3298, DOI 10.1038/sj.emboj.7601224; Xie JJ, 2009, INT J CANCER, V124, P2549, DOI 10.1002/ijc.24216; Yeh CN, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-233; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Yonemura S, 2002, J CELL SCI, V115, P2569; Zh LX, 2007, AM J PHYSIOL-CELL PH, V293, pC874, DOI 10.1152/ajpcell.00111.2007; Zhu LX, 2010, AM J PHYSIOL-CELL PH, V299, pC431, DOI 10.1152/ajpcell.00090.2010	80	42	44	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2014	33	18					2363	2374		10.1038/onc.2013.186	http://dx.doi.org/10.1038/onc.2013.186			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AG5ID	23752190				2022-12-17	WOS:000335451800009
J	Sunaga, N; Kaira, K; Imai, H; Shimizu, K; Nakano, T; Shames, DS; Girard, L; Soh, J; Sato, M; Iwasaki, Y; Ishizuka, T; Gazdar, AF; Minna, JD; Mori, M				Sunaga, N.; Kaira, K.; Imai, H.; Shimizu, K.; Nakano, T.; Shames, D. S.; Girard, L.; Soh, J.; Sato, M.; Iwasaki, Y.; Ishizuka, T.; Gazdar, A. F.; Minna, J. D.; Mori, M.			Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer	ONCOGENE			English	Article						NSCLC; KRAS; EREG; therapeutic target	EPIDERMAL-GROWTH-FACTOR; COPY NUMBER GAINS; SIGNALING PATHWAY; RAS ONCOGENE; EXPRESSION; MUTATIONS; EGFR; ACTIVATION; RESISTANCE; GEFITINIB	KRAS mutations are one of the most common driver mutations in non-small-cell lung cancer (NSCLC) and finding druggable target molecules to inhibit oncogenic KRAS signaling is a significant challenge in NSCLC therapy. We recently identified epiregulin (EREG) as one of several putative transcriptional targets of oncogenic KRAS signaling in both KRAS-mutant NSCLC cells and immortalized bronchial epithelial cells expressing ectopic mutant KRAS. In the current study, we found that EREG is overexpressed in NSCLCs harboring KRAS, BRAF or EGFR mutations compared with NSCLCs with wild-type KRAS/BRAF/EGFR. Small interfering RNAs (siRNAs) targeting mutant KRAS, but not an siRNA targeting wild-type KRAS, significantly reduced EREG expression in KRAS-mutant and EREG-overexpressing NSCLC cell lines. In these cell lines, EREG expression was downregulated by MEK and ERK inhibitors. Importantly, EREG expression significantly correlated with KRAS expression or KRAS copy number in KRAS-mutant NSCLC cell lines. Further expression analysis using 89 NSCLC specimens showed that EREG was predominantly expressed in NSCLCs with pleural involvement, lymphatic permeation or vascular invasion and in KRAS-mutant adenocarcinomas. In addition, multivariate analysis revealed that EREG expression is an independent prognostic marker and EREG overexpression in combination with KRAS mutations was associated with an unfavorable prognosis for lung adenocarcinoma patients. In KRAS-mutant and EREG overexpressing NSCLC cells, siRNA-mediated EREG silencing inhibited anchorage-dependent and -independent growth and induced apoptosis. Our findings suggest that oncogenic KRAS-induced EREG overexpression contributes to an aggressive phenotype and could be a promising therapeutic target in oncogenic KRAS-driven NSCLC.	[Sunaga, N.; Kaira, K.; Imai, H.; Iwasaki, Y.; Ishizuka, T.; Mori, M.] Gunma Univ, Sch Med, Dept Med & Mol Sci, Maebashi, Gunma 3718511, Japan; [Shimizu, K.; Nakano, T.] Gunma Univ, Sch Med, Maebashi, Gunma 3718511, Japan; [Shames, D. S.] Genentech Inc, Oncol Diagnost, San Francisco, CA 94080 USA; [Shames, D. S.; Girard, L.; Minna, J. D.] Univ Texas SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; [Girard, L.; Minna, J. D.] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA; [Soh, J.; Gazdar, A. F.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA; [Minna, J. D.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA; [Sato, M.] Nagoya Univ, Grad Sch Med, Dept Resp Med, Showa Ku, Nagoya, Aichi 4648601, Japan; [Soh, J.] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Canc & Thorac Surg, Kita Ku, Okayama, Japan	Gunma University; Gunma University; Roche Holding; Genentech; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; Nagoya University; Okayama University	Sunaga, N (corresponding author), Gunma Univ, Sch Med, Dept Canc & Thorac Med & Mol Sci, 3-39-15 Showa Machi, Maebashi, Gunma 3718511, Japan.	nsunaga@showa.gunma-u.ac.jp	Sato, MITSUO/I-7280-2014; Soh, Junichi/AAV-1053-2020; Imai, Hisao/AAB-7248-2021; Soh, Junichi/AAT-7095-2021	Sato, MITSUO/0000-0001-5458-9576; Soh, Junichi/0000-0001-8532-7915; Imai, Hisao/0000-0003-3097-4255; Soh, Junichi/0000-0001-8532-7915	Japan Society for the Promotion of Science [23591134]; SPORE [P50CA70907]; DOD PROSPECT, Texas Higher Education Coordinating Board Advanced Technology Program [01001901392003]; Gillson Longenbaugh Foundation; NASA Specialized Center of Research [NNJ05HD36G]; NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific Research [23591134] Funding Source: KAKEN	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); SPORE; DOD PROSPECT, Texas Higher Education Coordinating Board Advanced Technology Program; Gillson Longenbaugh Foundation; NASA Specialized Center of Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by Grants-in-Aid for Scientific Research (C) (grant #23591134) from the Japan Society for the Promotion of Science. Funding for this work also came from SPORE (P50CA70907); DOD PROSPECT, Texas Higher Education Coordinating Board Advanced Technology Program (grant #01001901392003); Gillson Longenbaugh Foundation; NASA Specialized Center of Research (grant #NNJ05HD36G). We thank Drs Yoshio Tomizawa, Noriko Yanagitani, Hironobu Iijima, Takeshi Hisada, Mitsuyoshi Utsugi of the Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Gunma, Japan for technical support and critical advices. We also thank Drs Kenneth Huffman and Victor Stastny of the Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center at Dallas for kind assistance.	Baba I, 2000, CANCER RES, V60, P6886; Cho MC, 2008, BIOCHEM BIOPH RES CO, V377, P832, DOI 10.1016/j.bbrc.2008.10.053; Chu EK, 2005, AM J RESP CELL MOL, V32, P373, DOI 10.1165/rcmb.2004-0266OC; Devesa SS, 2005, INT J CANCER, V117, P294, DOI 10.1002/ijc.21183; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Draper BK, 2003, J CELL BIOCHEM, V89, P1126, DOI 10.1002/jcb.10584; Fujimoto N, 2005, CANCER RES, V65, P11478, DOI 10.1158/0008-5472.CAN-05-1977; Gandhi J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004576; Gazdar AF, 2009, ONCOGENE, V28, pS24, DOI 10.1038/onc.2009.198; Gazdar AF, 2008, CANCER PREV RES, V1, P156, DOI 10.1158/1940-6207.CAPR-08-0080; Gupta GP, 2007, NATURE, V446, P765, DOI 10.1038/nature05760; Hu K, 2009, ORAL ONCOL, V45, P156, DOI 10.1016/j.oraloncology.2008.04.009; Imai H, 2010, INT J IMMUNOPATH PH, V23, P153, DOI 10.1177/039463201002300114; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Kaira K, 2010, J CLIN ONCOL, V28, P3746, DOI 10.1200/JCO.2009.27.4662; Kris MG, 2011, J CLIN ONCOL, V29; Larsen JE, 2011, CLIN CHEST MED, V32, P703, DOI 10.1016/j.ccm.2011.08.003; Lee S, 2009, INT J ONCOL, V34, P161, DOI 10.3892/ijo_00000138; Lindvall C, 2003, CANCER RES, V63, P1743; Marchetti A, 2011, J CLIN ONCOL, V29, P3574, DOI 10.1200/JCO.2011.35.9638; Mascaux C, 2005, BRIT J CANCER, V92, P131, DOI 10.1038/sj.bjc.6602258; Massarelli E, 2007, CLIN CANCER RES, V13, P2890, DOI 10.1158/1078-0432.CCR-06-3043; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Morita S, 2009, CLIN CANCER RES, V15, P4493, DOI 10.1158/1078-0432.CCR-09-0391; Nicholson BE, 2004, CANCER RES, V64, P7813, DOI 10.1158/0008-5472.CAN-04-0826; Pao W, 2005, PLOS MED, V2, P57, DOI 10.1371/journal.pmed.0020017; Phelps RM, 1996, J CELL BIOCHEM, P32; Pratilas CA, 2008, CANCER RES, V68, P9375, DOI 10.1158/0008-5472.CAN-08-2223; Regales L, 2009, J CLIN INVEST, V119, P3000, DOI 10.1172/JCI38746; Revillion F, 2008, ANN ONCOL, V19, P73, DOI 10.1093/annonc/mdm431; Riese DJ, 1998, J BIOL CHEM, V273, P11288, DOI 10.1074/jbc.273.18.11288; Shelly M, 1998, J BIOL CHEM, V273, P10496, DOI 10.1074/jbc.273.17.10496; Soh J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007464; Suda K, 2010, CANCER METAST REV, V29, P49, DOI 10.1007/s10555-010-9209-4; Sun MH, 2009, CLIN CANCER RES, V15, P4829, DOI 10.1158/1078-0432.CCR-08-2921; Sunaga N, 2004, CANCER RES, V64, P4277, DOI 10.1158/0008-5472.CAN-03-3941; Sunaga N, 2012, INT J CANCER, V130, P1733, DOI 10.1002/ijc.26164; Sunaga N, 2011, MOL CANCER THER, V10, P336, DOI 10.1158/1535-7163.MCT-10-0750; Takahashi M, 2003, CIRCULATION, V108, P2524, DOI 10.1161/01.CIR.0000096482.02567.8C; Thogersen VB, 2001, CANCER RES, V61, P6227; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; Toyoda H, 1997, BIOCHEM J, V326, P69, DOI 10.1042/bj3260069; Wang XY, 2009, MOL CARCINOGEN, V48, P1, DOI 10.1002/mc.20449; Yamamoto H, 2008, CANCER RES, V68, P6913, DOI 10.1158/0008-5472.CAN-07-5084; Zhang J, 2008, CANCER PREV RES, V1, P201, DOI 10.1158/1940-6207.CAPR-08-0014; Zhao M, 2009, BIOCHEM BIOPH RES CO, V387, P239, DOI 10.1016/j.bbrc.2009.06.128; Zhu ZW, 2000, BIOCHEM BIOPH RES CO, V273, P1019, DOI 10.1006/bbrc.2000.3033	47	42	44	2	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2013	32	34					4034	4042		10.1038/onc.2012.402	http://dx.doi.org/10.1038/onc.2012.402			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IC	22964644	Green Accepted			2022-12-17	WOS:000323748100012
J	Zhao, J; Ramos, R; Demma, M				Zhao, J.; Ramos, R.; Demma, M.			CDK8 regulates E2F1 transcriptional activity through S375 phosphorylation	ONCOGENE			English	Article						CDK8; E2F1; tumor suppressor; phosphorylation; transcriptional regulation	POSITIVE REGULATOR; COLORECTAL-CANCER; CELL-CYCLE; BETA; MEDIATOR; SUPPRESSES; PROTEIN; KINASE; WNT; PRB	Activation of the Wnt/beta-catenin pathway is a critical step in the development of colorectal cancers. A key mediator of this activation is the recently described oncogene CDK8, which is amplified in a large number of colorectal tumors. CDK8 affects beta-catenin activation by interaction of the CDK8 submodule of the mediator complex with beta-catenin/TCF transcriptional complex, and by CDK8 interacting with and phosphorylating E2F1, which acts as a repressor of beta-catenin/TCF transcriptional activity. The amino-acid residue in E2F1 that CDK8 phosphorylates and how this phosphorylation impacts E2F1 activity in general is not known. Here, we describe that CDK8 phosphorylates serine 375 in E2F1 both in vitro and in cells, and that phosphorylation of this residue is required for E2F1 interaction with CDK8, and that the phosphorylation is dependent on CDK8 kinase activity. The phosphorylation of S375 by CDK8 regulates E2F1 ability to repress transcription of beta-catenin/TCF-dependent genes, as well as activation of E2F1-dependent genes. This regulation is due to inactivation of E2F1 transcriptional activation, and not to the interference of E2F1's ability to bind to E2F1-binding sites in various promoters or to interact with DP1.	[Zhao, J.] Dept Late Stage Analyt, Union, NJ USA; [Ramos, R.] Merck Res Labs, Dept Vitro Cell Pharmacol, Rahway, NJ USA; [Demma, M.] Merck Res Labs, Dept Oncol, Boston, MA 02115 USA	Merck & Company; Merck & Company	Demma, M (corresponding author), Merck Res Labs, Dept Oncol, BMB 9-107,33 Ave Louis Pasteur, Boston, MA 02115 USA.	Mark.Demma@merck.com						Agarwal A, 2005, ONCOGENE, V24, P1021, DOI 10.1038/sj.onc.1208296; Alarcon C, 2009, CELL, V139, P757, DOI 10.1016/j.cell.2009.09.035; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; Bieda M, 2006, GENOME RES, V16, P595, DOI 10.1101/gr.4887606; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Dephoure N, 2008, P NATL ACAD SCI USA, V105, P10762, DOI 10.1073/pnas.0805139105; Donner AJ, 2010, NAT STRUCT MOL BIOL, V17, P194, DOI 10.1038/nsmb.1752; Donner AJ, 2007, MOL CELL, V27, P121, DOI 10.1016/j.molcel.2007.05.026; Firestein R, 2008, NATURE, V455, P547, DOI 10.1038/nature07179; Firestein R, 2010, INT J CANCER, V126, P2863, DOI 10.1002/ijc.24908; Firestein R, 2009, CANCER RES, V69, P7899, DOI 10.1158/0008-5472.CAN-09-1704; Fryer CJ, 2004, MOL CELL, V16, P509, DOI 10.1016/j.molcel.2004.10.014; Galbraith MD, 2010, TRANSCR-AUSTIN, V1, P4, DOI 10.4161/trns.1.1.12373; Gao S, 2009, MOL CELL, V36, P457, DOI 10.1016/j.molcel.2009.09.043; Gordon MD, 2006, J BIOL CHEM, V281, P22429, DOI 10.1074/jbc.R600015200; Graham TA, 2002, MOL CELL, V10, P563, DOI 10.1016/S1097-2765(02)00637-8; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Ji JY, 2010, CONTEMP CANCER RES, P23, DOI 10.1007/978-1-4419-1770-6_2; Kapoor A, 2010, NATURE, V468, P1105, DOI 10.1038/nature09590; Kim S, 2006, J BIOL CHEM, V281, P14066, DOI 10.1074/jbc.M602696200; Knuesel MT, 2009, GENE DEV, V23, P439, DOI 10.1101/gad.1767009; Knuesel MT, 2009, MOL CELL BIOL, V29, P650, DOI 10.1128/MCB.00993-08; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Meyer KD, 2008, EMBO J, V27, P1447, DOI 10.1038/emboj.2008.78; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Morris EJ, 2008, NATURE, V455, P552, DOI 10.1038/nature07310; Mundle SD, 2003, FASEB J, V17, P569, DOI 10.1096/fj.02-0431rev; Nair JS, 2009, MOL BIOL CELL, V20, P2218, DOI 10.1091/mbc.E08-08-0885; Ohantani K, 1994, MOL CELL BIOL, V14, P1603; PEEPER DS, 1995, ONCOGENE, V10, P39; Rickert P, 1999, ONCOGENE, V18, P1093, DOI 10.1038/sj.onc.1202399; Taatjes DJ, 2010, TRENDS BIOCHEM SCI, V35, P315, DOI 10.1016/j.tibs.2010.02.004; Tago K, 2000, GENE DEV, V14, P1741; Vandel L, 1999, EMBO J, V18, P4280, DOI 10.1093/emboj/18.15.4280; Verma UN, 2003, CLIN CANCER RES, V9, P1291; Walther A, 2009, NAT REV CANCER, V9, P489, DOI 10.1038/nrc2645; Woychik NA, 2002, CELL, V108, P453, DOI 10.1016/S0092-8674(02)00646-3; Wu Z, 2011, ONCOGENE, V30, P3979, DOI 10.1038/onc.2011.129; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Xu W, 2011, J GENET GENOMICS, V38, P439, DOI 10.1016/j.jgg.2011.09.002; Zhang J, 2010, J NEUROSCI, V30, P5219, DOI 10.1523/JNEUROSCI.5628-09.2010	42	42	45	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 25	2013	32	30					3520	3530		10.1038/onc.2012.364	http://dx.doi.org/10.1038/onc.2012.364			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	188UQ	22945643				2022-12-17	WOS:000322220800005
J	Radulescu, S; Ridgway, RA; Cordero, J; Athineos, D; Salgueiro, P; Poulsom, R; Neumann, J; Jung, A; Patel, S; Woodgett, J; Barker, N; Pritchard, DM; Oien, K; Sansom, OJ				Radulescu, S.; Ridgway, R. A.; Cordero, J.; Athineos, D.; Salgueiro, P.; Poulsom, R.; Neumann, J.; Jung, A.; Patel, S.; Woodgett, J.; Barker, N.; Pritchard, D. M.; Oien, K.; Sansom, O. J.			Acute WNT signalling activation perturbs differentiation within the adult stomach and rapidly leads to tumour formation	ONCOGENE			English	Article						beta-catenin; gastric cancer; APC; GSK3	FAMILIAL ADENOMATOUS POLYPOSIS; FUNDIC GLAND POLYPS; WNT/BETA-CATENIN PATHWAY; E-CADHERIN GENE; BETA-CATENIN; STEM-CELLS; SOMATIC MUTATIONS; GASTRIC-CARCINOMA; APC GENE; FLUORESCENT PROTEIN	A role for WNT signalling in gastric carcinogenesis has been suggested due to two major observations. First, patients with germline mutations in adenomatous polyposis coli (APC) are susceptible to stomach polyps and second, in gastric cancer, WNT activation confers a poor prognosis. However, the functional significance of deregulated WNT signalling in gastric homoeostasis and cancer is still unclear. In this study we have addressed this by investigating the immediate effects of WNT signalling activation within the stomach epithelium. We have specifically activated the WNT signalling pathway within the mouse adult gastric epithelium via deletion of either glycogen synthase kinase 3 (GSK3) or APC or via expression of a constitutively active beta-catenin protein. WNT pathway deregulation dramatically affects stomach homoeostasis at very short latencies. In the corpus, there is rapid loss of parietal cells with fundic gland polyp (FGP) formation and adenomatous change, which are similar to those observed in familial adenomatous polyposis. In the antrum, adenomas occur from 4 days post-WNT activation. Taken together, these data show a pivotal role for WNT signalling in gastric homoeostasis, FGP formation and adenomagenesis. Loss of the parietal cell population and corresponding FGP formation, an early event in gastric carcinogenesis, as well as antral adenoma formation are immediate effects of nuclear beta-catenin translocation and WNT target gene expression. Furthermore, our inducible murine model will permit a better understanding of the molecular changes required to drive tumourigenesis in the stomach. Oncogene (2013) 32, 2048-2057; doi:10.1038/onc.2012.224; published online 4 June 2012	[Radulescu, S.; Ridgway, R. A.; Cordero, J.; Athineos, D.; Salgueiro, P.; Sansom, O. J.] CR UK Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; [Salgueiro, P.; Barker, N.] ASTAR, Inst Med Biol, Singapore, Singapore; [Poulsom, R.] CR UK London Res Inst, Histopathol Lab, London, England; [Neumann, J.; Jung, A.] Univ Munich, Inst Pathol, D-80539 Munich, Germany; [Patel, S.; Woodgett, J.] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; [Pritchard, D. M.] Univ Liverpool, Inst Translat Med, Dept Gastroenterol, Liverpool L69 3BX, Merseyside, England; [Oien, K.] Univ Glasgow, Coll Med Vet & Life Sci, Inst Canc Sci, Glasgow, Lanark, Scotland	Beatson Institute; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB); University of Munich; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Liverpool; University of Glasgow	Sansom, OJ (corresponding author), CR UK Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	o.sansom@beatson.gla.ac.uk	Barker, Nick/AAS-2774-2020; Barker, Nick/A-5535-2011; Woodgett, Jim/F-1087-2010; Barker, Nick/AAE-9833-2021; Oien, Karin/AAH-3849-2019	Woodgett, Jim/0000-0003-3731-5797; Barker, Nick/0000-0003-3566-4475; Sansom, Owen J./0000-0001-9540-3010; Athineos, Dimitris/0000-0001-5298-7941; Pritchard, David Mark/0000-0001-7971-3561	CR-UK; AICR [06-0614]; CRUK; Cancer Research UK [12481] Funding Source: researchfish	CR-UK(Cancer Research UK); AICR; CRUK(Cancer Research UK); Cancer Research UK(Cancer Research UK)	This work was funded by the CR-UK project and programme grants and AICR grant 06-0614 to Owen Sansom. Help from Colin Nixon with histology and from Derek Miller and Tom Hamilton with transgenic work was much appreciated. This work was funded by AICR and CRUK grants.	Abraham SC, 2000, AM J PATHOL, V157, P747, DOI 10.1016/S0002-9440(10)64588-9; Abraham SC, 2001, AM J PATHOL, V158, P1005, DOI 10.1016/S0002-9440(10)64047-3; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2010, CELL STEM CELL, V6, P25, DOI 10.1016/j.stem.2009.11.013; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Barker Nick, 2008, V468, P5, DOI 10.1007/978-1-59745-249-6_1; BECKER KF, 1995, JNCI-J NATL CANCER I, V87, P1082, DOI 10.1093/jnci/87.14.1082; Bianchi LK, 2008, CLIN GASTROENTEROL H, V6, P180, DOI 10.1016/j.cgh.2007.11.018; Blache P, 2004, J CELL BIOL, V166, P37, DOI 10.1083/jcb.200311021; Cavard C, 2008, FUTURE ONCOL, V4, P647, DOI 10.2217/14796694.4.5.647; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Clements WM, 2002, CANCER RES, V62, P3503; CORREA P, 1994, CANCER RES, V54, pS1941; CORREA P, 1992, CANCER RES, V52, P6735; Crabtree M, 2003, ONCOGENE, V22, P4257, DOI 10.1038/sj.onc.1206471; de Vries AC, 2008, GASTROENTEROLOGY, V134, P945, DOI 10.1053/j.gastro.2008.01.071; Ebert MPA, 2002, CARCINOGENESIS, V23, P87, DOI 10.1093/carcin/23.1.87; FORTE JG, 1983, J CLIN GASTROENTEROL, V5, P17, DOI 10.1097/00004836-198312001-00003; Franco AT, 2005, P NATL ACAD SCI USA, V102, P10646, DOI 10.1073/pnas.0504927102; Freeman HJ, 2008, WORLD J GASTROENTERO, V14, P1318, DOI 10.3748/wjg.14.1318; Garrean S, 2008, AM SURGEON, V74, P79; Gatta G, 2006, LANCET ONCOL, V7, P132, DOI 10.1016/S1470-2045(05)70471-X; Gnad T, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-31; Gregorieff A, 2005, GASTROENTEROLOGY, V129, P626, DOI 10.1053/j.gastro.2005.06.007; Guilford PJ, 1999, HUM MUTAT, V14, P249, DOI 10.1002/(SICI)1098-1004(1999)14:3<249::AID-HUMU8>3.0.CO;2-9; Guillen-Ahlers H, 2008, CURR DRUG TARGETS, V9, P591, DOI 10.2174/138945008784911813; Half E, 2009, ORPHANET J RARE DIS, V4, DOI 10.1186/1750-1172-4-22; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He XC, 2007, NAT GENET, V39, P189, DOI 10.1038/ng1928; HORII A, 1992, CANCER RES, V52, P3231; IIDA M, 1985, GASTROENTEROLOGY, V89, P1021, DOI 10.1016/0016-5085(85)90203-3; Ireland H, 2004, GASTROENTEROLOGY, V126, P1236, DOI 10.1053/j.gastro.2004.03.020; Kemp R, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh090; Kim B, 2010, PATHOLOGY, V42, P58, DOI 10.3109/00313020903356392; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Luche H, 2007, EUR J IMMUNOL, V37, P43, DOI 10.1002/eji.200636745; Milne AN, 2009, HUM GENET, V126, P615, DOI 10.1007/s00439-009-0722-x; Miyazawa K, 2000, VIRCHOWS ARCH, V437, P508, DOI 10.1007/s004280000283; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Murata-Kamiya N, 2007, ONCOGENE, V26, P4617, DOI 10.1038/sj.onc.1210251; Nagase Hiroki, 1992, Human Mutation, V1, P467, DOI 10.1002/humu.1380010603; NAKATSURU S, 1993, HUM MOL GENET, V2, P1463, DOI 10.1093/hmg/2.9.1463; Nakayama M, 2009, J BIOL CHEM, V284, P1612, DOI 10.1074/jbc.M806981200; Ng SW, 2009, J BIOL CHEM, V284, P24767, DOI 10.1074/jbc.M109.011692; Novak A, 2000, GENESIS, V28, P147, DOI 10.1002/1526-968X(200011/12)28:3/4<147::AID-GENE90>3.0.CO;2-G; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; Oshima H, 2006, GASTROENTEROLOGY, V131, P1086, DOI 10.1053/j.gastro.2006.07.014; Park DY, 2008, ARCH PATHOL LAB MED, V132, P633, DOI 10.1043/1543-2165(2008)132[633:GPCAM]2.0.CO;2; Park WS, 1999, CANCER RES, V59, P4257; Parkin DM, 2005, CA CANC J CLIN, V55, P74; Parsonnet J, 1997, GUT, V40, P297, DOI 10.1136/gut.40.3.297; Patel S, 2008, MOL CELL BIOL, V28, P6314, DOI 10.1128/MCB.00763-08; Przemeck SMC, 2007, AM J PHYSIOL-GASTR L, V292, pG620, DOI 10.1152/ajpgi.00391.2006; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Segditsas S, 2006, ONCOGENE, V25, P7531, DOI 10.1038/sj.onc.1210059; Sekine S, 2002, VIRCHOWS ARCH, V440, P381, DOI 10.1007/s004280100527; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Shitashige M, 2008, CANCER SCI, V99, P631, DOI 10.1111/j.1349-7006.2007.00716.x; Smith MG, 2006, WORLD J GASTROENTERO, V12, P2979, DOI 10.3748/wjg.v12.i19.2979; Sokolova O, 2008, J BIOL CHEM, V283, P29367, DOI 10.1074/jbc.M801818200; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Spicer Z, 2000, J BIOL CHEM, V275, P21555, DOI 10.1074/jbc.M001558200; Suzuki M, 2005, J EXP MED, V202, P1235, DOI 10.1084/jem.20051027; Suzuki M, 2009, CELL HOST MICROBE, V5, P23, DOI 10.1016/j.chom.2008.11.010; TAHARA E, 1995, WORLD J SURG, V19, P484, DOI 10.1007/BF00294705; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Torbenson M, 2002, MODERN PATHOL, V15, P718, DOI 10.1097/01.MP.0000018976.15044.9B; Tycko B, 2007, CURR MOL MED, V7, P479; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; WATANABE H, 1978, HUM PATHOL, V9, P269, DOI 10.1016/S0046-8177(78)80085-9; Zhang HF, 2008, HEPATO-GASTROENTEROL, V55, P1126; Zhao ZM, 2010, J GENET GENOMICS, V37, P647, DOI 10.1016/S1673-8527(09)60083-7; Zheng HC, 2010, HUM PATHOL, V41, P1255, DOI 10.1016/j.humpath.2010.02.003	75	42	42	1	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2013	32	16					2048	2057		10.1038/onc.2012.224	http://dx.doi.org/10.1038/onc.2012.224			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130LY	22665058	hybrid, Green Published, Green Accepted			2022-12-17	WOS:000317919900006
J	Agarwal, N; Adhikari, AS; Iyer, SV; Hekmatdoost, K; Welch, DR; Iwakuma, T				Agarwal, N.; Adhikari, A. S.; Iyer, S. V.; Hekmatdoost, K.; Welch, D. R.; Iwakuma, T.			MTBP suppresses cell migration and filopodia formation by inhibiting ACTN4	ONCOGENE			English	Article						MDM2; MTBP; ACTN4; filopodia; metastasis	ALPHA-ACTININ; GENE AMPLIFICATION; CANCER INVASION; METASTASIS; CARCINOMA; MOTILITY; MDM2; NETWORK; GROWTH	Murine double minute (MDM2) binding protein (MTBP) has been implicated in cancer progression. Here, we demonstrate one mechanism by which MTBP inhibits cancer metastasis. Overexpression of MTBP in human osteosarcoma cell lines lacking wildtype p53 did not alter primary tumor growth in mice, but significantly inhibited metastases. MTBP downregulation increased the migratory potential of MDM2(-/-)p53(-/-) mouse embryonic fibroblasts, suggesting that MTBP inhibited cell migration independently of the Mdm2-p53 pathway. Co-immunoprecipitation and mass spectrometric analysis identified alpha-actinin-4 (ACTN4) as an MTBP-interacting protein. Endogenous MTBP interacted with and partially colocalized with ACTN4. MTBP overexpression inhibited cell migration and filopodia formation mediated by ACTN4. Increased cell migration by MTBP downregulation was inhibited by concomitant downregulation of ACTN4. MTBP also inhibited ACTN4-mediated F-actin bundling. We furthermore demonstrated that nuclear localization of MTBP was dispensable for inhibiting ACTN4-mediated cell migration and filopodia formation. Thus, MTBP suppresses cell migration, at least partially, by inhibiting ACTN4 function. Our study not only provides a mechanism of metastasis suppression by MTBP, but also suggests MTBP as a potential biomarker for cancer progression. Oncogene (2013) 32, 462-470; doi:10.1038/onc.2012.69; published online 27 February 2012	[Agarwal, N.; Adhikari, A. S.; Iyer, S. V.; Hekmatdoost, K.; Iwakuma, T.] Louisiana State Univ, Hlth Sci Ctr, Dept Genet, New Orleans, LA USA; [Agarwal, N.; Iyer, S. V.; Welch, D. R.; Iwakuma, T.] Univ Kansas, Med Ctr, Dept Canc Biol, Kansas City, KS 66160 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; University of Kansas; University of Kansas Medical Center	Iwakuma, T (corresponding author), Univ Kansas, Med Ctr, Dept Canc Biol, Kansas City, KS 66160 USA.	tiwakuma@kumc.edu	Agarwal, Neeraj/F-2834-2016; Welch, Danny R/B-7310-2009	Welch, Danny R/0000-0002-1951-4947; Agarwal, Neeraj/0000-0001-7163-1043	LCRC start-up; National Foundation for Cancer Research-Center for Metastasis Research;  [P20 RR020152-02];  [RSG-09-169-01-CSM]; NATIONAL CANCER INSTITUTE [R01CA134981] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR020152] Funding Source: NIH RePORTER	LCRC start-up; National Foundation for Cancer Research-Center for Metastasis Research; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank Drs Indu Kheterpal, Yuki Tochigi and Louis Marrero for their technical assistance. We also thank Ms Kristy-Le T Nguyen for her technical assistance and editing the manuscript. This work was supported by grants from P20 RR020152-02 (PLD), RSG-09-169-01-CSM (JI), LCRC start-up (TI) and National Foundation for Cancer Research-Center for Metastasis Research (DRW).	Adhikari AS, 2010, CANCER RES, V70, P4602, DOI 10.1158/0008-5472.CAN-09-3463; Agarwal N, 2011, CELL DEATH DIFFER, V18, P1208, DOI 10.1038/cdd.2010.189; Ammer AG, 2008, CELL MOTIL CYTOSKEL, V65, P687, DOI 10.1002/cm.20296; Barbolina MV, 2008, LAB INVEST, V88, P602, DOI 10.1038/labinvest.2008.25; Boyd MT, 2000, J BIOL CHEM, V275, P31883, DOI 10.1074/jbc.M004252200; Brady M, 2005, MOL CELL BIOL, V25, P545, DOI 10.1128/MCB.25.2.545-553.2005; Chen XP, 2011, INT J BIOL MARKER, V26, P1, DOI 10.5301/JBM.2011.6267; Choi HS, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-122; Hayashida Y, 2005, CANCER RES, V65, P8836, DOI 10.1158/0008-5472.CAN-05-0718; Hendrix MJC, 1996, CANCER METAST REV, V15, P507, DOI 10.1007/BF00054016; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Honda K, 2005, GASTROENTEROLOGY, V128, P51, DOI 10.1053/j.gastro.2004.10.004; Hurst DR, 2011, INT REV CEL MOL BIO, V286, P107, DOI 10.1016/B978-0-12-385859-7.00003-3; Iwakuma T, 2008, ONCOGENE, V27, P1813, DOI 10.1038/sj.onc.1210827; Iwakuma T, 2003, MOL CANCER RES, V1, P993; Jia SF, 2002, ANTI-CANCER DRUG, V13, P155, DOI 10.1097/00001813-200202000-00007; Kikuchi S, 2008, CLIN CANCER RES, V14, P5348, DOI 10.1158/1078-0432.CCR-08-0075; Kirfel G, 2004, EUR J CELL BIOL, V83, P717, DOI 10.1078/0171-9335-00421; Koizumi T, 2010, UROLOGY, V75, P357, DOI 10.1016/j.urology.2009.09.037; Lindberg U, 2008, SEMIN CANCER BIOL, V18, P2, DOI 10.1016/j.semcancer.2007.10.002; Mattila PK, 2008, NAT REV MOL CELL BIO, V9, P446, DOI 10.1038/nrm2406; Menez J, 2004, ONCOGENE, V23, P2630, DOI 10.1038/sj.onc.1207347; Mierke CT, 2009, CELL BIOCHEM BIOPHYS, V53, P115, DOI 10.1007/s12013-009-9047-6; Mina LA, 2011, NAT REV CLIN ONCOL, V8, P325, DOI 10.1038/nrclinonc.2011.59; Mukhina S, 2007, DEV CELL, V13, P554, DOI 10.1016/j.devcel.2007.08.003; Odvody J, 2010, ONCOGENE, V29, P3287, DOI 10.1038/onc.2010.82; Quick Q, 2010, EXP CELL RES, V316, P1137, DOI 10.1016/j.yexcr.2010.02.011; Sen S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008427; Shao HS, 2010, J BIOL CHEM, V285, P2591, DOI 10.1074/jbc.M109.035790; Steeg Patricia S, 2003, Clin Breast Cancer, V4, P51, DOI 10.3816/CBC.2003.n.012; Vignjevic D, 2008, SEMIN CANCER BIOL, V18, P12, DOI 10.1016/j.semcancer.2007.08.001; Vlatkovic N, 2011, CANCER-AM CANCER SOC, V117, P2939, DOI 10.1002/cncr.25864; Weins A, 2007, P NATL ACAD SCI USA, V104, P16080, DOI 10.1073/pnas.0702451104; Yamaguchi H, 2005, CURR OPIN CELL BIOL, V17, P559, DOI 10.1016/j.ceb.2005.08.002; Yamamoto S, 2009, MODERN PATHOL, V22, P499, DOI 10.1038/modpathol.2008.234	35	42	43	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2013	32	4					462	470		10.1038/onc.2012.69	http://dx.doi.org/10.1038/onc.2012.69			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	098LR	22370640	Green Accepted			2022-12-17	WOS:000315551300007
J	Astanehe, A; Finkbeiner, MR; Krzywinski, M; Fotovati, A; Dhillon, J; Berquin, IM; Mills, GB; Marra, MA; Dunn, SE				Astanehe, A.; Finkbeiner, M. R.; Krzywinski, M.; Fotovati, A.; Dhillon, J.; Berquin, I. M.; Mills, G. B.; Marra, M. A.; Dunn, S. E.			MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition	ONCOGENE			English	Article						trastuzumab resistance; breast cancer; MNK; RSK; YB-1	GROWTH-FACTOR RECEPTOR; BREAST-CANCER CELLS; PROTEIN-1 SERINE 102; INTERACTING KINASE 1; RIBOSOMAL S6 KINASE; BINDING; MNK1; EXPRESSION; PHOSPHORYLATION; CONTRIBUTES	Trastuzumab (Herceptin) resistance is a major obstacle in the treatment of patients with HER2-positive breast cancers. We recently reported that the transcription factor Y-box binding protein-1 (YB-1) leads to acquisition of resistance to trastuzumab in a phosphorylation-dependent manner that relies on p90 ribosomal S6 kinase (RSK). To explore how this may occur we compared YB-1 target genes between trastuzumab-sensitive cells (BT474) and those with acquired resistance (HR5 and HR6) using genome-wide chromatin immunoprecipitation sequencing (ChIP-sequencing), which identified 1391 genes uniquely bound by YB-1 in the resistant cell lines. We then examined differences in protein expression and phosphorylation between these cell lines using the Kinexus Kinex antibody microarrays. Cross-referencing these two data sets identified the mitogen-activated protein kinase-interacting kinase (MNK) family as potentially being involved in acquired resistance downstream from YB-1. MNK1 and MNK2 were subsequently shown to be overexpressed in the resistant cell lines; however, only the former was a YB-1 target based on ChIP-PCR and small interfering RNA (siRNA) studies. Importantly, loss of MNK1 expression using siRNA enhanced sensitivity to trastuzumab. Further, MNK1 overexpression was sufficient to confer resistance to trastuzumab in cells that were previously sensitive. We then developed a de novo model of acquired resistance by exposing BT474 cells to trastuzumab for 60 days (BT474LT). Similar to the HR5/HR6 cells, the BT474LT cells had elevated MNK1 levels and were dependent on it for survival. In addition, we demonstrated that RSK phosphorylated MNK1, and that this phosphorylation was required for ability of MNK1 to mediate resistance to trastuzumab. Furthermore, inhibition of RSK with the small molecule BI-D1870 repressed the MNK1-mediated trastuzumab resistance. In conclusion, this unbiased integrated approach identified MNK1 as a player in mediating trastuzumab resistance as a consequence of YB-1 activation, and demonstrated RSK inhibition as a means to overcome recalcitrance to trastuzumab. Oncogene (2012) 31, 4434-4446; doi: 10.1038/onc.2011.617; published online 16 January 2012	[Astanehe, A.; Finkbeiner, M. R.; Fotovati, A.; Dhillon, J.; Dunn, S. E.] Univ British Columbia, Dept Paediat, Child & Family Res Inst, Vancouver, BC V5Z 4H4, Canada; [Krzywinski, M.; Marra, M. A.] Univ British Columbia, BC Canc Agcy, Genome Sci Ctr, Vancouver, BC V5Z 4H4, Canada; [Berquin, I. M.] Wake Forest Univ, Dept Canc Biol, Winston Salem, NC 27109 USA; [Mills, G. B.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Mills, G. B.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA	Child & Family Research Institute; University of British Columbia; British Columbia Cancer Agency; University of British Columbia; Wake Forest University; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center	Dunn, SE (corresponding author), Univ British Columbia, Dept Paediat, Child & Family Res Inst, 950 W 28th Ave, Vancouver, BC V5Z 4H4, Canada.	sedunn@mail.ubc.ca	Marra, Marco A/B-5987-2008	Marra, Marco A/0000-0001-7146-7175	Canadian Institute of Health Research; Canadian Cancer Research Institute; Canadian Institute of Health Research MD/PhD; Michael Smith Foundation for Health Research (MSFHR) Studentships;  [RO1 CA114017]; NATIONAL CANCER INSTITUTE [R01CA114017] Funding Source: NIH RePORTER	Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Cancer Research Institute; Canadian Institute of Health Research MD/PhD(Canadian Institutes of Health Research (CIHR)); Michael Smith Foundation for Health Research (MSFHR) Studentships; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the Canadian Institute of Health Research (SED), the Canadian Cancer Research Institute (formerly National Cancer Institute of Canada (SED)) and RO1 CA114017 (IMB and SED). AA was a recipient of the Canadian Institute of Health Research MD/PhD and the Michael Smith Foundation for Health Research (MSFHR) Studentships. MAM is a scholar of MSFHR.	Astanehe A, 2009, ONCOGENE, V28, P2406, DOI 10.1038/onc.2009.81; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Bianchini A, 2008, CARCINOGENESIS, V29, P2279, DOI 10.1093/carcin/bgn221; Buxade M, 2005, IMMUNITY, V23, P177, DOI 10.1016/j.immuni.2005.06.009; Buxade M, 2008, J BIOL CHEM, V283, P57, DOI 10.1074/jbc.M705286200; Camirand Anne, 2002, Med Sci Monit, V8, pBR521; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Chrestensen CA, 2007, J BIOL CHEM, V282, P4243, DOI 10.1074/jbc.M607368200; DaSilva J, 2006, MOL CELL BIOL, V26, P1898, DOI 10.1128/MCB.26.5.1898-1907.2006; Davies AH, 2011, ONCOGENE, V30, P3649, DOI 10.1038/onc.2011.82; Dhillon J, 2010, ONCOGENE, V29, P6294, DOI 10.1038/onc.2010.365; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; Diermeier S, 2005, EXP CELL RES, V304, P604, DOI 10.1016/j.yexcr.2004.12.008; Finkbeiner MR, 2009, ONCOGENE, V28, P1421, DOI 10.1038/onc.2008.485; Foster FM, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2328; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Grzmil M, 2011, CANCER RES, V71, P2392, DOI 10.1158/0008-5472.CAN-10-3112; Guil S, 2006, MOL CELL BIOL, V26, P5744, DOI 10.1128/MCB.00224-06; Habibi G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2156; Halatsch ME, 2009, J NEUROSURG, V111, P211, DOI 10.3171/2008.9.JNS08551; Hefner Y, 2000, J BIOL CHEM, V275, P37542, DOI 10.1074/jbc.M003395200; Henson ES, 2006, CLIN CANCER RES, V12, P845, DOI 10.1158/1078-0432.CCR-05-0754; Imamura T, 2001, J BIOL CHEM, V276, P43663, DOI 10.1074/jbc.M105364200; Judge AD, 2009, J CLIN INVEST, V119, P661, DOI 10.1172/JCI37515; Junttila TT, 2009, CANCER CELL, V15, P429, DOI 10.1016/j.ccr.2009.03.020; Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852; Mahalingam M, 2001, PROG MOLEC, V27, P131; Martin AP, 2008, MOL PHARMACOL, V74, P807, DOI 10.1124/mol.108.047365; Motoyama AB, 2002, CANCER RES, V62, P3151; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nahta R, 2005, CANCER RES, V65, P11118, DOI 10.1158/0008-5472.CAN-04-3841; Nahta R, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1612; Nguyen TL, 2008, ANTI-CANCER AGENT ME, V8, P710, DOI 10.2174/187152008785914770; Ritter CA, 2007, CLIN CANCER RES, V13, P4909, DOI 10.1158/1078-0432.CCR-07-0701; SESHADRI R, 1993, J CLIN ONCOL, V11, P1936, DOI 10.1200/JCO.1993.11.10.1936; Shattuck DL, 2008, CANCER RES, V68, P1471, DOI 10.1158/0008-5472.CAN-07-5962; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Smith JA, 2005, CANCER RES, V65, P1027; Stratford AL, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2202; Sutherland BW, 2005, ONCOGENE, V24, P4281, DOI 10.1038/sj.onc.1208590; To K, 2010, CANCER RES, V70, P2840, DOI 10.1158/0008-5472.CAN-09-3155; Treeck O, 2004, ANTI-CANCER DRUG, V15, P787, DOI 10.1097/00001813-200409000-00008; Ueda T, 2004, MOL CELL BIOL, V24, P6539, DOI 10.1128/MCB.24.15.6539-6549.2004; Ueda T, 2010, P NATL ACAD SCI USA, V107, P13984, DOI 10.1073/pnas.1008136107; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Wendel HG, 2007, GENE DEV, V21, P3232, DOI 10.1101/gad.1604407; Wu J, 2006, CANCER RES, V66, P4872, DOI 10.1158/0008-5472.CAN-05-3561; Zhang SY, 2011, NAT MED, V17, P461, DOI 10.1038/nm.2309; Zhuang GL, 2010, CANCER RES, V70, P299, DOI 10.1158/0008-5472.CAN-09-1845	52	42	42	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	41					4434	4446		10.1038/onc.2011.617	http://dx.doi.org/10.1038/onc.2011.617			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	018YR	22249268				2022-12-17	WOS:000309704500002
J	Kosa, P; Szabo, R; Molinolo, AA; Bugge, TH				Kosa, P.; Szabo, R.; Molinolo, A. A.; Bugge, T. H.			Suppression of Tumorigenicity-14, encoding matriptase, is a critical suppressor of colitis and colitis-associated colon carcinogenesis	ONCOGENE			English	Article						inflammatory bowel disease; intestinal barrier; colon carcinogenesis	INFLAMMATORY-BOWEL-DISEASE; SERINE-PROTEASE MATRIPTASE; HEPATOCYTE GROWTH-FACTOR; COLORECTAL-CANCER; ULCERATIVE-COLITIS; MOUSE MODEL; MATRIX METALLOPROTEINASES; PLASMINOGEN ACTIVATION; INTESTINAL HOMEOSTASIS; BARRIER FUNCTION	Colitis-associated colorectal cancers are an etiologically distinct subgroup of colon cancers that occur in individuals suffering from inflammatory bowel disease and arise as a consequence of persistent exposure of hyperproliferative epithelial stem cells to an inflammatory microenvironment. An intrinsic defect in the intestinal epithelial barrier has been proposed to be one of several factors that contribute to the inappropriate immune response to the commensal microbiota that underlies inflammatory bowel disease. Matriptase is a membrane-anchored serine protease encoded by Suppression of Tumorigenicity-14 (ST14) that strengthens the intestinal epithelial barrier by promoting tight junction formation. Here, we show that intestinal epithelial-specific ablation of St14 in mice causes formation of colon adenocarcinoma with very early onset and high penetrance. Neoplastic progression is preceded by a chronic inflammation of the colon that resembles human inflammatory bowel disease and is promoted by the commensal microbiota. This study demonstrates that inflammation-associated colon carcinogenesis can be initiated and promoted solely by an intrinsic intestinal permeability barrier perturbation, establishes St14 as a critical tumor-suppressor gene in the mouse gastrointestinal tract and adds matriptase to the expanding list of pericellular proteases with tumor-suppressive functions. Oncogene (2012) 31, 3679-3695; doi:10.1038/onc.2011.545; published online 5 December 2011	[Bugge, T. H.] Natl Inst Dent & Craniofacial Res, Proteases & Tissue Remodeling Sect, Oral & Pharyngeal Canc Branch, Natl Inst Hlth, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Bugge, TH (corresponding author), Natl Inst Dent & Craniofacial Res, Proteases & Tissue Remodeling Sect, Oral & Pharyngeal Canc Branch, Natl Inst Hlth, 30 Convent Dr,Room 211, Bethesda, MD 20892 USA.	thomas.bugge@nih.gov			NIDCR Intramural Research Program; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000699] Funding Source: NIH RePORTER	NIDCR Intramural Research Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank Drs Jerrold M Ward, Robert D Cardiff and Stephen M Hewitt for pathology advice, Drs Vyomesh Patel and Kantima Leelahavanichkul for help with the array analysis, Dr Myrna Mandel for helicobacter testing, as well as Drs Silvio Gutkind and Mary Jo Danton for critically reviewing this manuscript. Histology was performed by Histoserv Inc. (Germantown, MD, USA). This study was supported by the NIDCR Intramural Research Program (THB).	Acuff HB, 2006, CANCER RES, V66, P7968, DOI 10.1158/0008-5472.CAN-05-4279; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Balbin M, 2003, NAT GENET, V35, P252, DOI 10.1038/ng1249; Berg DJ, 1996, J CLIN INVEST, V98, P1010, DOI 10.1172/JCI118861; Bhatt AS, 2007, P NATL ACAD SCI USA, V104, P5771, DOI 10.1073/pnas.0606514104; Borgono CA, 2004, NAT REV CANCER, V4, P876, DOI 10.1038/nrc1474; Bugge TH, 2009, J BIOL CHEM, V284, P23177, DOI 10.1074/jbc.R109.021006; Buzza MS, 2010, P NATL ACAD SCI USA, V107, P4200, DOI 10.1073/pnas.0903923107; Cheng HX, 2009, CANCER RES, V69, P1828, DOI 10.1158/0008-5472.CAN-08-3728; Danese S, 2010, ONCOGENE, V29, P3313, DOI 10.1038/onc.2010.109; de Lau W, 2007, FRONT BIOSCI-LANDMRK, V12, P471, DOI 10.2741/2076; Deng L, 2010, AM J PATHOL, V176, P952, DOI 10.2353/ajpath.2010.090622; Engle SJ, 2002, CANCER RES, V62, P6362; Erdman SE, 2003, AM J PATHOL, V162, P691, DOI 10.1016/S0002-9440(10)63863-1; Feng SL, 2005, CLIN DIAGN LAB IMMUN, V12, P531, DOI 10.1128/CDLI.12.4.531-536.2005; Forbs D, 2005, INT J ONCOL, V27, P1061; Garrett WS, 2009, CANCER CELL, V16, P208, DOI 10.1016/j.ccr.2009.07.015; Gaspar C, 2008, AM J PATHOL, V172, P1363, DOI 10.2353/ajpath.2008.070851; Hale LP, 2007, HELICOBACTER, V12, P598, DOI 10.1111/j.1523-5378.2007.00552.x; Hardwick JC, 2008, NAT REV CANCER, V8, P806, DOI 10.1038/nrc2467; Ihara S, 2002, J BIOL CHEM, V277, P16960, DOI 10.1074/jbc.M200673200; Jin XL, 2006, CANCER SCI, V97, P1327, DOI 10.1111/j.1349-7006.2006.00328.x; Kaiser S, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-7-r131; Kaser A, 2010, ANNU REV IMMUNOL, V28, P573, DOI 10.1146/annurev-immunol-030409-101225; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kilpatrick LM, 2006, BLOOD, V108, P2616, DOI 10.1182/blood-2006-02-001073; Kim MG, 1999, IMMUNOGENETICS, V49, P420, DOI 10.1007/s002510050515; Lacy-Hulbert A, 2007, P NATL ACAD SCI USA, V104, P15823, DOI 10.1073/pnas.0707421104; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; Lin CY, 1999, J BIOL CHEM, V274, P18231, DOI 10.1074/jbc.274.26.18231; List K, 2002, ONCOGENE, V21, P3765, DOI 10.1038/sj.onc.1205502; List K, 2005, GENE DEV, V19, P1934, DOI 10.1101/gad.1300705; List K, 2009, AM J PATHOL, V175, P1453, DOI 10.2353/ajpath.2009.090240; Lopez-Otin C, 2007, NAT REV CANCER, V7, P800, DOI 10.1038/nrc2228; Lopez-Otin C, 2009, CELL CYCLE, V8, P3657, DOI 10.4161/cc.8.22.9956; Madison BB, 2002, J BIOL CHEM, V277, P33275, DOI 10.1074/jbc.M204935200; Maggio-Price L, 2006, CANCER RES, V66, P828, DOI 10.1158/0008-5472.CAN-05-2448; McCawley LJ, 2008, AM J PATHOL, V173, P1528, DOI 10.2353/ajpath.2008.080132; McCawley LJ, 2004, CANCER RES, V64, P6965, DOI 10.1158/0008-5472.CAN-04-0910; Medema JP, 2011, NATURE, V474, P318, DOI 10.1038/nature10212; Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949; Netzel-Arnett S, 2003, CANCER METAST REV, V22, P237, DOI 10.1023/A:1023003616848; Netzel-Arnett S, 2006, J BIOL CHEM, V281, P32941, DOI 10.1074/jbc.C600208200; Newman JV, 2001, J INFECT DIS, V184, P227, DOI 10.1086/321998; Oberst MD, 2003, J BIOL CHEM, V278, P26773, DOI 10.1074/jbc.M304282200; Okayasu I, 2002, J GASTROEN HEPATOL, V17, P1078, DOI 10.1046/j.1440-1746.2002.02853.x; Okayasu I, 1996, GUT, V39, P87, DOI 10.1136/gut.39.1.87; Owen KA, 2010, BIOCHEM J, V426, P219, DOI 10.1042/BJ20091448; Palavalli LH, 2009, NAT GENET, V41, P518, DOI 10.1038/ng.340; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Reinheckel T, 2005, J CELL SCI, V118, P3387, DOI 10.1242/jcs.02469; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Riley LK, 1996, J CLIN MICROBIOL, V34, P942, DOI 10.1128/JCM.34.4.942-946.1996; RUDOLPH U, 1995, NAT GENET, V10, P143, DOI 10.1038/ng0695-143; Saleh M, 2011, NAT REV IMMUNOL, V11, P9, DOI 10.1038/nri2891; Sales KU, 2010, NAT GENET, V42, P676, DOI 10.1038/ng.629; Sandilands A, 2009, J CELL SCI, V122, P1285, DOI 10.1242/jcs.033969; Schreiber S, 2005, NAT REV GENET, V6, P376, DOI 10.1038/nrg1607; Shah SA, 1998, INFLAMM BOWEL DIS, V4, P196, DOI 10.1097/00054725-199808000-00004; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Sternlicht MD, 2000, ONCOGENE, V19, P1102, DOI 10.1038/sj.onc.1203347; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Su LP, 2009, GASTROENTEROLOGY, V136, P551, DOI 10.1053/j.gastro.2008.10.081; Suzuki M, 2004, J BIOL CHEM, V279, P14899, DOI 10.1074/jbc.M313130200; Szabo R, 2011, ONCOGENE, V30, P2003, DOI 10.1038/onc.2010.586; Szabo R, 2011, ANNU REV CELL DEV BI, V27, P213, DOI 10.1146/annurev-cellbio-092910-154247; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Takeuchi T, 1999, P NATL ACAD SCI USA, V96, P11054, DOI 10.1073/pnas.96.20.11054; Tanimoto H, 2001, TUMOR BIOL, V22, P104, DOI 10.1159/000050604; Ustach CV, 2010, CANCER RES, V70, P9631, DOI 10.1158/0008-5472.CAN-10-0511; Van Limbergen J, 2009, ANNU REV GENOM HUM G, V10, P89, DOI 10.1146/annurev-genom-082908-150013; Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094; Xavier RJ, 2007, NATURE, V448, P427, DOI 10.1038/nature06005; Zeki SS, 2011, NAT REV GASTRO HEPAT, V8, P90, DOI 10.1038/nrgastro.2010.211; Zhang Y, 1998, CYTOGENET CELL GENET, V83, P56, DOI 10.1159/000015125	75	42	44	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2012	31	32					3679	3695		10.1038/onc.2011.545	http://dx.doi.org/10.1038/onc.2011.545			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	990TF	22139080	Green Accepted			2022-12-17	WOS:000307653800003
J	Jeanblanc, M; Ragu, S; Gey, C; Contrepois, K; Courbeyrette, R; Thuret, JY; Mann, C				Jeanblanc, M.; Ragu, S.; Gey, C.; Contrepois, K.; Courbeyrette, R.; Thuret, J-Y; Mann, C.			Parallel pathways in RAF-induced senescence and conditions for its reversion	ONCOGENE			English	Article						senescence; DNA damage; oxidative stress; RAF kinase; CKI	ONCOGENE-INDUCED SENESCENCE; NORMAL HUMAN FIBROBLASTS; CELL-CYCLE ARREST; PREMATURE SENESCENCE; HETEROCHROMATIN FORMATION; SIGNALING PATHWAY; IN-VITRO; S-PHASE; KINASE; P53	We developed a clonal WI-38hTERT/GFP-RAF1-ER immortal cell line to study RAF-induced senescence of human fibroblasts. Activation of the GFP-RAF1-ER kinase by addition of 4-hydroxy-tamoxifen led to a robust induction of senescence within one population doubling, accompanied by the assembly of heterochromatic foci. At least two pathways contribute in parallel to this senescence leading to the accumulation of p15, p16, p21 and p27 inhibitors of cyclin-dependent kinases (CKIs). Cells that traversed S phase after RAF1 kinase activation experienced a replicative stress manifested by phosphorylation of H2AX and Chk2 and synthesis of p21. However, about half the cells in the population were blocked without passing through S phase and did not show activation of DNA-damage checkpoints. When the cells were cultivated in 5% oxygen, RAF1 activation generated minimal reactive oxygen species, but RAF-induced senescence occurred efficiently in these conditions even in the presence of anti-oxidants or inhibitors of DNA checkpoint pathways. Despite the presence of heterochromatic foci, simultaneous knockdown of p16 and p21 with inactivation of the GFP-RAF1-ER kinase led to rapid reversion of the senescent state with the majority of cells becoming competent for long-term proliferation. These results demonstrate that replicative and oxidative stresses are not required for RAF-induced senescence, and this senescence is readily reversed upon loss of CKIs. Oncogene (2012) 31, 3072-3085; doi: 10.1038/onc.2011.481; published online 24 October 2011	[Jeanblanc, M.; Ragu, S.; Gey, C.; Contrepois, K.; Courbeyrette, R.; Thuret, J-Y; Mann, C.] CEA Saclay, CEA, Serv Biol Integrat & Genet Mol, iBiTec S, F-91191 Gif Sur Yvette, France	CEA; UDICE-French Research Universities; Universite Paris Saclay	Mann, C (corresponding author), CEA Saclay, CEA, Serv Biol Integrat & Genet Mol, iBiTec S, Bat 142, F-91191 Gif Sur Yvette, France.	carl.mann@cea.fr		Mann, Carl/0000-0001-7212-1512; Thuret, Jean-Yves/0000-0001-5385-7620	French National Research Agency [ANR-07-BLAN-0098-CSD8]; French Association for Cancer Research [ARC 4917]; French Association for Cancer Research; CEA Irtelis doctoral fellowship through the CEA Plasticity and Instability of the Genome Intramural Program	French National Research Agency(French National Research Agency (ANR)); French Association for Cancer Research; French Association for Cancer Research; CEA Irtelis doctoral fellowship through the CEA Plasticity and Instability of the Genome Intramural Program	We thank Chiara Castelli (Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy) for pLXSN-hTERT, Marco Crescenzi (Istituto Superiore di Sanita, Rome, Italy) for GST-CKI plasmids, and Martin McMahon (University of California San Francisco, USA) for the RAF1-ER plasmids, the IMR90/GFP-RAF1-ER cells and for invaluable advice. JYT thanks Masashi Narita for fruitful discussions and we also thank Michel Toledano for comments on the manuscript. This work was supported by grants from the French National Research Agency (ANR-07-BLAN-0098-CSD8) and the French Association for Cancer Research (ARC 4917), and benefited from discussions within the CEA/Curie network on Replication, Chromosomal Instability, and Cancer. SR is the recipient of a postdoctoral fellowship from the French Association for Cancer Research, and KC received a CEA Irtelis doctoral fellowship through the CEA Plasticity and Instability of the Genome Intramural Program.	[Anonymous], 2010, R LANG ENV STAT COMP; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Brahimi-Horn MC, 2007, FEBS LETT, V581, P3582, DOI 10.1016/j.febslet.2007.06.018; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Chicas A, 2010, CANCER CELL, V17, P376, DOI 10.1016/j.ccr.2010.01.023; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; Contrepois K, 2010, J PROTEOME RES, V9, P5501, DOI 10.1021/pr100497a; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Courtois-Cox S, 2006, CANCER CELL, V10, P459, DOI 10.1016/j.ccr.2006.10.003; Dalerba P, 2005, CANCER RES, V65, P2321, DOI 10.1158/0008-5472.CAN-04-3678; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Dolado I, 2007, CANCER CELL, V11, P191, DOI 10.1016/j.ccr.2006.12.013; Du W, 2006, ONCOGENE, V25, P5190, DOI 10.1038/sj.onc.1209651; Forsyth NR, 2003, AGING CELL, V2, P235, DOI 10.1046/j.1474-9728.2003.00057.x; Funayama R, 2006, J CELL BIOL, V175, P869, DOI 10.1083/jcb.200604005; Galvani A, 2008, MOL CELL BIOL, V28, P3672, DOI 10.1128/MCB.00510-07; Hahne F, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-106; Han JH, 2007, TRENDS BIOCHEM SCI, V32, P364, DOI 10.1016/j.tibs.2007.06.007; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Herbig U, 2004, MOL CELL, V14, P501, DOI 10.1016/S1097-2765(04)00256-4; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Iwasa H, 2003, GENES CELLS, V8, P131, DOI 10.1046/j.1365-2443.2003.00620.x; Jun JI, 2010, NAT CELL BIOL, V12, P676, DOI 10.1038/ncb2070; Kennedy AL, 2011, MOL CELL, V42, P36, DOI 10.1016/j.molcel.2011.02.020; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Meloche S, 2007, ONCOGENE, V26, P3227, DOI 10.1038/sj.onc.1210414; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Moiseeva O, 2009, MOL CELL BIOL, V29, P4495, DOI 10.1128/MCB.01868-08; NAKANISHI M, 1995, P NATL ACAD SCI USA, V92, P4352, DOI 10.1073/pnas.92.10.4352; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Narita M, 2006, CELL, V126, P503, DOI 10.1016/j.cell.2006.05.052; Niault TS, 2010, CARCINOGENESIS, V31, P1165, DOI 10.1093/carcin/bgp337; Pajalunga D, 2007, J CELL BIOL, V176, P807, DOI 10.1083/jcb.200608109; Popov N, 2010, EPIGENETICS-US, V5, P685, DOI 10.4161/epi.5.8.12996; Rai P, 2011, ONCOGENE, V30, P1489, DOI 10.1038/onc.2010.520; Rajalingam K, 2007, BBA-MOL CELL RES, V1773, P1177, DOI 10.1016/j.bbamcr.2007.01.012; Robles SJ, 1999, BIOCHEM PHARMACOL, V58, P675, DOI 10.1016/S0006-2952(99)00127-6; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Satyanarayana A, 2004, MOL CELL BIOL, V24, P5459, DOI 10.1128/MCB.24.12.5459-5474.2004; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Takahashi A, 2006, NAT CELL BIOL, V8, P1291, DOI 10.1038/ncb1491; Terry NHA, 2006, NAT PROTOC, V1, P859, DOI 10.1038/nprot.2006.113; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; Wei S, 1999, CANCER RES, V59, P1539; Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709; Yu Q, 2002, CANCER RES, V62, P5743; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	52	42	42	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2012	31	25					3072	3085		10.1038/onc.2011.481	http://dx.doi.org/10.1038/onc.2011.481			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964OP	22020327				2022-12-17	WOS:000305705900006
J	Sun, Z; Cao, X; Jiang, MM; Qiu, Y; Zhou, H; Chen, L; Qin, B; Wu, H; Jiang, F; Chen, J; Liu, J; Dai, Y; Chen, HF; Hu, QY; Wu, Z; Zeng, JZ; Yao, XS; Zhang, XK				Sun, Z.; Cao, X.; Jiang, M-M; Qiu, Y.; Zhou, H.; Chen, L.; Qin, B.; Wu, H.; Jiang, F.; Chen, J.; Liu, J.; Dai, Y.; Chen, H-F; Hu, Q-Y; Wu, Z.; Zeng, J-Z; Yao, X-S; Zhang, X-K			Inhibition of beta-catenin signaling by nongenomic action of orphan nuclear receptor Nur77	ONCOGENE			English	Article						Nur77; beta-catenin; nongenomic; cardenolide; cancer	COLON-CANCER CELLS; GENE-EXPRESSION; BREAST-CANCER; RXR-ALPHA; NGFI-B; APOPTOSIS; WNT; DEGRADATION; PATHWAY; PROTEIN	Dysregulation of beta-catenin turnover due to mutations of its regulatory proteins including adenomatous polyposis coli (APC) and p53 is implicated in the pathogenesis of cancer. Thus, intensive effort is being made to search for alternative approaches to reduce abnormally activated beta-catenin in cancer cells. Nur77, an orphan member of the nuclear receptor superfamily, has a role in the growth and apoptosis of cancer cells. Here, we reported that Nur77 could inhibit transcriptional activity of beta-catenin by inducing beta-catenin degradation via proteasomal degradation pathway that is glycogen synthase kinase 3 beta and Siah-1 independent. Nur77 induction of beta-catenin degradation required both the N-terminal region of Nur77, which was involved in Nur77 ubiquitination, and the C-terminal region, which was responsible for beta-catenin binding. Nur77/DDBD, a Nur77 mutant lacking its DNA-binding domain, resided in the cytoplasm, interacted with beta-catenin, and induced beta-catenin degradation, demonstrating that Nur77-mediated beta-catenin degradation was independent of its DNA binding and transactivation, and might occur in the cytoplasm. In addition, we reported our identification of two digitalis-like compounds (DLCs), H-9 and ATE-i2-b4, which potently induced Nur77 expression and beta-catenin degradation in SW620 colon cancer cells expressing mutant APC protein in vitro and in animals. DLC-induced Nur77 protein was mainly found in the cytoplasm, and inhibition of Nur77 nuclear export by the CRM1-dependent nuclear export inhibitor leptomycin B or Jun N-terminal kinase inhibitor prevented the effect of DLC on inducing beta-catenin degradation. Together, our results demonstrate that beta-catenin can be degraded by cytoplasmic Nur77 through their interaction and identify H-9 and ATE-i2-b4 as potent activators of the Nur77-mediated pathway for beta-catenin degradation. Oncogene (2012) 31, 2653-2667; doi:10.1038/onc.2011.448; published online 10 October 2011	[Dai, Y.; Yao, X-S] Jinan Univ, Inst Tradit Chinese Med, Guangzhou 510632, Guangdong, Peoples R China; [Dai, Y.; Yao, X-S] Jinan Univ, Inst Nat Prod, Guangzhou 510632, Guangdong, Peoples R China; [Sun, Z.; Qiu, Y.; Zhou, H.; Chen, L.; Qin, B.; Wu, H.; Jiang, F.; Liu, J.; Chen, H-F; Wu, Z.; Zeng, J-Z] Xiamen Univ, Sch Pharmaceut Sci, Xiamen, Peoples R China; [Cao, X.; Zhou, H.; Chen, J.; Liu, J.; Hu, Q-Y; Zhang, X-K] Sanford Burnham Med Res Inst, La Jolla, CA 92037 USA; [Jiang, M-M] Guangdong Pharmaceut Univ, Guangzhou, Guangdong, Peoples R China	Jinan University; Jinan University; Xiamen University; Sanford Burnham Prebys Medical Discovery Institute; Guangdong Pharmaceutical University	Yao, XS (corresponding author), Jinan Univ, Inst Tradit Chinese Med, Guangzhou 510632, Guangdong, Peoples R China.	yaoxinsheng@vip.tom.com; xzhang@sanfordburnham.org	Wu, Z/G-3993-2010; Chen, HF/G-3376-2010; Zeng, JZ/G-3377-2010; Wu, Hua/W-4204-2019		National Institutes of Health [CA140980, GM089927]; US Army Medical Research and Material Command; Xiamen University; National Natural Science Foundation of China (NSFC) [30971445, NSCF-81001373]; NSFC/Hong Kong Research Grants Council (RGC) [30931160431]; Natural Science Foundation of Fujian Province [2009J01198]; NATIONAL CANCER INSTITUTE [R01CA140980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM089927] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Army Medical Research and Material Command(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); Xiamen University(Xiamen University); National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); NSFC/Hong Kong Research Grants Council (RGC)(Hong Kong Research Grants CouncilNational Natural Science Foundation of China (NSFC)); Natural Science Foundation of Fujian Province(Natural Science Foundation of Fujian Province); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Zhuohua Zhang for providing beta-catenin expression vectors and TOPFLASH reporter plasmid. This work is in part supported by grants from the National Institutes of Health (CA140980, GM089927), the US Army Medical Research and Material Command, the 985 Project from Xiamen University, the National Natural Science Foundation of China (NSFC; 30971445 and NSCF-81001373) and NSFC/Hong Kong Research Grants Council (RGC; 30931160431) and the Natural Science Foundation of Fujian Province (2009J01198).	Camacho CP, 2009, CLIN ENDOCRINOL, V70, P475, DOI 10.1111/j.1365-2265.2008.03349.x; Cao XH, 2004, MOL CELL BIOL, V24, P9705, DOI 10.1128/MCB.24.22.9705-9725.2004; Chao LC, 2008, MOL ENDOCRINOL, V22, P2596, DOI 10.1210/me.2008-0161; Cho SD, 2007, CANCER RES, V67, P674, DOI 10.1158/0008-5472.CAN-06-2907; Chtarbova S, 2002, BIOCHEM J, V367, P723, DOI 10.1042/BJ20020699; Dawson MI, 2001, CANCER RES, V61, P4723; Dillard AC, 2008, NUTR CANCER, V60, P97, DOI 10.1080/01635580701586754; Dillard AC, 2007, MOL CARCINOGEN, V46, P315, DOI 10.1002/mc.20280; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Han YH, 2006, ONCOGENE, V25, P2974, DOI 10.1038/sj.onc.1209358; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hutchinson DA, 2007, P NATL ACAD SCI USA, V104, P2265, DOI 10.1073/pnas.0610785104; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Jiang MM, 2008, CHEM PHARM BULL, V56, P1005, DOI 10.1248/cpb.56.1005; Katagiri Y, 2000, NAT CELL BIOL, V2, P435, DOI 10.1038/35017072; Ke N, 2004, CANCER RES, V64, P8208, DOI 10.1158/0008-5472.CAN-04-2134; Kitagawa H, 2007, MOL CELL BIOL, V27, P7486, DOI 10.1128/MCB.00409-07; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kolluri SK, 2008, CANCER CELL, V14, P285, DOI 10.1016/j.ccr.2008.09.002; Kolluri SK, 2003, MOL CELL BIOL, V23, P8651, DOI 10.1128/MCB.23.23.8651-8667.2003; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Lee SO, 2010, CANCER RES, V70, P6824, DOI 10.1158/0008-5472.CAN-10-1992; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Liang B, 2007, EXP CELL RES, V313, P2833, DOI 10.1016/j.yexcr.2007.04.032; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Lopez-Lazaro M, 2007, EXPERT OPIN THER TAR, V11, P1043, DOI 10.1517/14728222.11.8.1043; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Maxwell Megan A, 2006, Nucl Recept Signal, V4, pe002; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Mullican SE, 2007, NAT MED, V13, P730, DOI 10.1038/nm1579; Nesher M, 2007, LIFE SCI, V80, P2093, DOI 10.1016/j.lfs.2007.03.013; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Phillips A, 1997, MOL CELL BIOL, V17, P5946, DOI 10.1128/MCB.17.10.5946; Polakis P, 2000, GENE DEV, V14, P1837; Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Safe S, 2008, CANCER LETT, V269, P326, DOI 10.1016/j.canlet.2008.04.021; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Steyn PS, 1998, NAT PROD REP, V15, P397; Uemura H, 1998, ENDOCRINOLOGY, V139, P2329, DOI 10.1210/en.139.5.2329; Ward RD, 2009, BIOFACTORS, V35, P528, DOI 10.1002/biof.66; Wilson AJ, 2003, CANCER RES, V63, P5401; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Wu FT, 2007, FRONT BIOSCI-LANDMRK, V12, P700, DOI 10.2741/2094; Wu H, 2011, FASEB J, V25, P192, DOI 10.1096/fj.10-166462; Wu Q, 1997, EMBO J, V16, P1656, DOI 10.1093/emboj/16.7.1656; Wu Q, 1997, MOL CELL BIOL, V17, P6598, DOI 10.1128/MCB.17.11.6598; Xiao JH, 2003, J BIOL CHEM, V278, P29954, DOI 10.1074/jbc.M304761200; Yochum GS, 2007, J BIOL CHEM, V282, P871, DOI 10.1074/jbc.M609391200; Zhan YP, 2008, NAT CHEM BIOL, V4, P548, DOI 10.1038/nchembio.106; Zhang XK, 2007, EXPERT OPIN THER TAR, V11, P69, DOI 10.1517/14728222.11.1.69; Zhao HY, 2010, J ASIAN NAT PROD RES, V12, P793, DOI 10.1080/10286020.2010.505187; Zhao Y, 2010, ARTERIOSCL THROM VAS, V30, P1535, DOI 10.1161/ATVBAHA.109.191163; Zhou H, 2010, CANCER CELL, V17, P560, DOI 10.1016/j.ccr.2010.04.023	61	42	45	3	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2012	31	21					2653	2667		10.1038/onc.2011.448	http://dx.doi.org/10.1038/onc.2011.448			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	948SS	21986938	Green Accepted			2022-12-17	WOS:000304523500005
J	Bakthavatchalu, V; Dey, S; Xu, Y; Noel, T; Jungsuwadee, P; Holley, AK; Dhar, SK; Batinic-Haberle, I; St Clair, DK				Bakthavatchalu, V.; Dey, S.; Xu, Y.; Noel, T.; Jungsuwadee, P.; Holley, A. K.; Dhar, S. K.; Batinic-Haberle, I.; St Clair, D. K.			Manganese superoxide dismutase is a mitochondrial fidelity protein that protects Pol gamma against UV-induced inactivation	ONCOGENE			English	Article						fidelity gene; polymerase gamma; p53; MnSOD; oxidative/nitrative stresses; (MnTE)-T-III-2-PyP5+	DNA-POLYMERASE GAMMA; BASE EXCISION-REPAIR; PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; OXIDATIVE STRESS; HUMAN SKIN; P53 PROTEIN; MOUSE KERATINOCYTES; SUNLIGHT EXPOSURE; ACCESSORY SUBUNIT; B IRRADIATION	Manganese superoxide dismutase is a nuclear encoded primary antioxidant enzyme localized exclusively in the mitochondrial matrix. Genotoxic agents, such as ultraviolet (UV) radiation, generates oxidative stress and cause mitochondrial DNA (mtDNA) damage. The mtDNA polymerase (Pol gamma), a major constituent of nucleoids, is responsible for the replication and repair of the mitochondrial genome. Recent studies suggest that the mitochondria contain fidelity proteins and MnSOD constitutes an integral part of the nucleoid complex. However, it is not known whether or how MnSOD participates in the mitochondrial repair processes. Using skin tissue from C57BL/6 mice exposed to UVB radiation, we demonstrate that MnSOD has a critical role in preventing mtDNA damage by protecting the function of Pol gamma. Quantitative-PCR analysis shows an increase in mtDNA damage after UVB exposure. Immunofluorescence and immunoblotting studies demonstrate p53 translocation to the mitochondria and interaction with Pol gamma after UVB exposure. The mtDNA immunoprecipitation assay with Pol gamma and p53 antibodies in p53(+/+) and p53(-/-) mice demonstrates an interaction between MnSOD, p53 and Pol gamma. The results suggest that these proteins form a complex for the repair of UVB-associated mtDNA damage. The data also demonstrate that UVB exposure injures the mtDNA D-loop in a p53-dependent manner. Using MnSOD-deficient mice we demonstrate that UVB-induced mtDNA damage is MnSOD dependent. Exposure to UVB results in nitration and inactivation of Pol gamma, which is prevented by addition of the MnSOD mimetic (MnTE)-T-III-2-PyP5+. These results demonstrate for the first time that MnSOD is a fidelity protein that maintains the activity of Pol gamma by preventing UVB-induced nitration and inactivation of Pol gamma. The data also demonstrate that MnSOD has a role along with p53 to prevent mtDNA damage. Oncogene (2012) 31, 2129-2139; doi:10.1038/onc.2011.407; published online 12 September 2011	[Bakthavatchalu, V.; Xu, Y.; Noel, T.; Jungsuwadee, P.; Holley, A. K.; Dhar, S. K.; St Clair, D. K.] Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA; [Dey, S.] Proctor & Gamble, Cincinnati, OH USA; [Jungsuwadee, P.] Husson Univ, Dept Pharmacol & Toxicol, Bangor, ME USA; [Batinic-Haberle, I.] Duke Univ, Med Ctr, Durham, NC USA	University of Kentucky; Procter & Gamble; Duke University	St Clair, DK (corresponding author), Univ Kentucky, Grad Ctr Toxicol, 1095 VA Dr,HSRB 454, Lexington, KY 40536 USA.	dstcl00@uky.edu	Jungsuwadee, Paiboon/AAE-4038-2020	Jungsuwadee, Paiboon/0000-0002-5430-6887	National Institutes of Health [RO1CA073599-11]; NATIONAL CANCER INSTITUTE [R01CA073599, R01CA049797] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007266] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by the National Institutes of Health (RO1CA073599-11). The National Cancer Institute CA 073599.	Achanta G, 2005, EMBO J, V24, P3482, DOI 10.1038/sj.emboj.7600819; Aitken GR, 2007, CLIN EXP DERMATOL, V32, P722, DOI 10.1111/j.1365-2230.2007.02474.x; Alvarez B, 2003, AMINO ACIDS, V25, P295, DOI 10.1007/s00726-003-0018-8; Bakhanashvili M, 2008, CELL DEATH DIFFER, V15, P1865, DOI 10.1038/cdd.2008.122; Batinic-Haberle I, 1999, INORG CHEM, V38, P4011, DOI 10.1021/ic990118k; Batinic-Haberle I, 2010, ANTIOXID REDOX SIGN, V13, P877, DOI 10.1089/ars.2009.2876; Batinic-Haberle IR, 2010, HDB PORPHYRIN SCI 2, P291; Berg RJW, 1996, P NATL ACAD SCI USA, V93, P274, DOI 10.1073/pnas.93.1.274; Bickers DR, 2006, J INVEST DERMATOL, V126, P2565, DOI 10.1038/sj.jid.5700340; Birch-Machin MA, 1998, J INVEST DERMATOL, V110, P149, DOI 10.1046/j.1523-1747.1998.00099.x; Bogenhagen DF, 2001, PROG NUCLEIC ACID RE, V68, P257; BOLDEN A, 1977, J BIOL CHEM, V252, P3351; Bonifacino J.S., 2001, CURR PROTOC MOL BIOL, V10; Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BROWN WM, 1979, P NATL ACAD SCI USA, V76, P1967, DOI 10.1073/pnas.76.4.1967; Cabiscol E, 2000, J BIOL CHEM, V275, P27393; Carrodeguas JA, 1999, MOL CELL BIOL, V19, P4039; Chen XJ, 2005, NAT REV GENET, V6, P815, DOI 10.1038/nrg1708; Decraene D, 2004, J INVEST DERMATOL, V122, P484, DOI 10.1046/j.0022-202X.2004.22215.x; Esworthy RS, 1997, ARCH BIOCHEM BIOPHYS, V340, P59, DOI 10.1006/abbi.1997.9901; Ferrer-Sueta G, 1999, CHEM RES TOXICOL, V12, P442, DOI 10.1021/tx980245d; Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399; GRAY H, 1992, J BIOL CHEM, V267, P5835; Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805; Graziewicz MA, 2002, NUCLEIC ACIDS RES, V30, P2817, DOI 10.1093/nar/gkf392; HALL PA, 1993, ONCOGENE, V8, P203; Harbottle A, 2006, BRIT J CANCER, V94, P1887, DOI 10.1038/sj.bjc.6603178; Heyne K, 2004, FEBS LETT, V578, P198, DOI 10.1016/j.febslet.2004.10.099; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.biochem.54.1.237; HUBSCHER U, 1979, P NATL ACAD SCI USA, V76, P2316, DOI 10.1073/pnas.76.5.2316; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Johnson AA, 2000, BIOCHEMISTRY-US, V39, P1702, DOI 10.1021/bi992104w; Kienhofer J, 2009, FASEB J, V23, P2034, DOI 10.1096/fj.08-113571; Kovalenko O.A., 2009, CURR PROTOC HUM GENE, V62; Krishnan KJ, 2004, J INVEST DERMATOL, V123, P1020, DOI 10.1111/j.0022-202X.2004.23457.x; Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125; Kulawiec Mariola, 2009, J Carcinog, V8, P8, DOI 10.4103/1477-3163.50893; Lebedeva MA, 2009, BBA-BIOENERGETICS, V1787, P328, DOI 10.1016/j.bbabio.2009.01.004; Legros F, 2004, J CELL SCI, V117, P2653, DOI 10.1242/jcs.01134; Lewis W, 2007, LAB INVEST, V87, P326, DOI 10.1038/labinvest.3700523; LI G, 1995, CANCER RES, V55, P2070; Li G, 1997, AM J PATHOL, V150, P1457; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Lim SE, 2003, J MOL BIOL, V329, P45, DOI 10.1016/S0022-2836(03)00405-4; LIU M, 1994, CARCINOGENESIS, V15, P1089, DOI 10.1093/carcin/15.6.1089; Longley Matthew J, 2002, Methods Mol Biol, V197, P245, DOI 10.1385/1-59259-284-8:245; Longley MJ, 1998, P NATL ACAD SCI USA, V95, P12244, DOI 10.1073/pnas.95.21.12244; Maglio DHG, 2005, PHOTODERMATOL PHOTO, V21, P311, DOI 10.1111/j.1600-0781.2005.00185.x; Melov S, 1999, P NATL ACAD SCI USA, V96, P846, DOI 10.1073/pnas.96.3.846; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Mihara Motohiro, 2003, Methods Mol Biol, V234, P203; O'Brien KM, 2004, J BIOL CHEM, V279, P51817, DOI 10.1074/jbc.M405958200; Ouhtit A, 2000, AM J PATHOL, V156, P201, DOI 10.1016/S0002-9440(10)64720-7; Ozden O, 2011, AGING-US, V3, P102, DOI 10.18632/aging.100291; Ray AJ, 2000, J INVEST DERMATOL, V115, P674, DOI 10.1046/j.1523-1747.2000.00092.x; Renzing J, 1996, J CELL SCI, V109, P1105; Shokolenko I, 2009, NUCLEIC ACIDS RES, V37, P2539, DOI 10.1093/nar/gkp100; Stuart JA, 2004, FASEB J, V18, P595, DOI 10.1096/fj.03-0890fje; Taanman JW, 2010, METHODS, V51, P374, DOI 10.1016/j.ymeth.2010.03.002; Tao RD, 2010, MOL CELL, V40, P893, DOI 10.1016/j.molcel.2010.12.013; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; Tron VA, 1998, AM J PATHOL, V153, P579, DOI 10.1016/S0002-9440(10)65600-3; Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034; Van Remmen H, 1999, ARCH BIOCHEM BIOPHYS, V363, P91, DOI 10.1006/abbi.1998.1060; Vaseva AV, 2009, BBA-BIOENERGETICS, V1787, P414, DOI 10.1016/j.bbabio.2008.10.005; Vermulst M, 2008, NAT GENET, V40, P392, DOI 10.1038/ng.95; Waster PK, 2009, J INVEST DERMATOL, V129, P1769, DOI 10.1038/jid.2008.421; WEISIGER RA, 1973, J BIOL CHEM, V248, P3582; Wu SY, 2010, PHOTOCHEM PHOTOBIOL, V86, P389, DOI 10.1111/j.1751-1097.2009.00682.x; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; Yakubovskaya E, 2006, J BIOL CHEM, V281, P374, DOI 10.1074/jbc.M509730200; Zhao YF, 2001, CANCER RES, V61, P6082; Zhao YF, 2005, CANCER RES, V65, P3745, DOI 10.1158/0008-5472.CAN-04-3835; Zhao YF, 2002, ONCOGENE, V21, P3836, DOI 10.1038/sj.onc.1205477	75	42	43	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2012	31	17					2129	2139		10.1038/onc.2011.407	http://dx.doi.org/10.1038/onc.2011.407			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BS	21909133	Green Accepted			2022-12-17	WOS:000303415900002
J	Chou, CH; Teng, CM; Tzen, KY; Chang, YC; Chen, JH; Cheng, JCH				Chou, C. H.; Teng, C-M; Tzen, K-Y; Chang, Y-C; Chen, J-H; Cheng, J. C-H			MMP-9 from sublethally irradiated tumor promotes Lewis lung carcinoma cell invasiveness and pulmonary metastasis	ONCOGENE			English	Article						MMP-9; radiation; Lewis lung carcinoma; invasiveness; metastasis	ENDOTHELIAL GROWTH-FACTOR; MARROW-DERIVED CELLS; MATRIX METALLOPROTEINASES; ANGIOGENESIS; MATRIX-METALLOPROTEINASE-9; CANCER; MICE; ANGIOSTATIN; EXPRESSION; CARCINOGENESIS	Matrix metalloproteinases (MMPs) associate with tumor progression and metastasis. We sought to investigate the role of MMP-9 from sublethally irradiated tumor in accelerated pulmonary metastasis of Lewis lung carcinoma (LLC-LM) and the corresponding anti-metastasis strategies in C57BL/6 mice. We used Matrigel-coated Boyden chamber assays and chicken chorioallantoic membrane assays to evaluate the invasion capability of irradiated LLC-LM cells (7.5 Gy), reverse transcription-polymerase chain reaction and the western blot assay to investigate the expression of MMPs by irradiated cells, and small interfering RNA duplexes to inhibit MMP-9 expression. LLC-LM cells differing in MMP-2 or -9 expression were subcutaneously injected into right thighs and the resulting tumors were irradiated (10 Gy x 5) to induce pulmonary metastasis. Radiation significantly enhanced MMP-9 at both the transcriptional and translational levels. MMP-9 siRNA significantly inhibited in vitro radiation-enhanced invasiveness. The number of radiation-accelerated pulmonary metastases was significantly reduced by MMP-9 knockdown and MMP-2/9 knockdown. Reverse transcription-polymerase chain reaction of LLC-LM cells in the blood and lung tissue revealed MMP-9 involvement in radiation-enhanced intravasation. Either higher-dose irradiation (30 Gy x 2) or pretreatment with prototypical MMP-9 inhibitor, zoledronic acid, significantly reduced the number of pulmonary metastases. The viability of irradiated tumor was seen on both positron emission tomography and magnetic resonance imaging, and tumor/serum MMP-9 levels suggested the association of local control of primary tumor and inhibition of time-dependent MMP-9 activities. Our results demonstrate that MMP-9 is crucially involved in radiation-enhanced LLC-LM cell invasiveness in vitro and in pulmonary metastasis from inadequately irradiated primary tumor in vivo. Oncogene (2012) 31, 458-468; doi: 10.1038/onc.2011.240; published online 27 June 2011	[Chou, C. H.; Cheng, J. C-H] Natl Taiwan Univ Hosp, Dept Oncol, Div Radiat Oncol, Taipei 100, Taiwan; [Chou, C. H.; Cheng, J. C-H] Natl Taiwan Univ, Grad Inst Oncol, Coll Med, Taipei 10764, Taiwan; [Teng, C-M] Natl Taiwan Univ, Coll Med, Inst Pharmacol, Taipei, Taiwan; [Tzen, K-Y] Natl Taiwan Univ Hosp, Dept Nucl Med, Taipei 100, Taiwan; [Tzen, K-Y] Natl Taiwan Univ, Mol Imaging Ctr, Taipei 10764, Taiwan; [Chang, Y-C] Natl Taiwan Univ Hosp, Dept Med Imaging, Taipei 100, Taiwan; [Chen, J-H; Cheng, J. C-H] Natl Taiwan Univ, Grad Inst Biomed Elect & Bioinformat, Coll Elect Engn & Comp Sci, Taipei 10764, Taiwan; [Cheng, J. C-H] Natl Taiwan Univ, Grad Inst Clin Med, Coll Med, Taipei 10764, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University	Cheng, JCH (corresponding author), Natl Taiwan Univ Hosp, Dept Oncol, Div Radiat Oncol, 7 Chung Shan S Rd, Taipei 100, Taiwan.	jasoncheng@ntu.edu.tw		CHANG, YEUN-CHUNG/0000-0001-9984-5713; TZEN, KAI-YUAN/0000-0002-5657-8579; TENG, CHE-MING/0000-0002-9719-7334; CHENG, JASON CHIA-HSIEN/0000-0002-2007-0220	National Science Council, Execute Yuan, Taiwan, ROC [NSC97-2314-B-002-113-MY3, NSC98-2627-B-002-017, NSC99-2627-B-002-008]; National Taiwan University Hospital [NTUH 98S1128]	National Science Council, Execute Yuan, Taiwan, ROC(Ministry of Science and Technology, Taiwan); National Taiwan University Hospital(National Taiwan University)	This work was supported by the National Science Council, Execute Yuan, Taiwan, ROC (Grant numbers NSC97-2314-B-002-113-MY3, NSC98-2627-B-002-017 and NSC99-2627-B-002-008), and the National Taiwan University Hospital (Grant number NTUH 98S1128). We appreciate the contribution of the Molecular Imaging Center, National Taiwan University, in providing the technical support of the dedicated small animal PET/CT scanner for imaging. We also thank Mr Samuel C Leu for his help with the PET/CT scans and image analysis.	Ahn GO, 2008, CANCER CELL, V13, P193, DOI 10.1016/j.ccr.2007.11.032; Ahn GO, 2009, CELL CYCLE, V8, P970, DOI 10.4161/cc.8.7.8075; Basile DP, 2004, AM J PHYSIOL-RENAL, V286, pF893, DOI 10.1152/ajprenal.00328.2003; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; Bode W, 2003, BIOL CHEM, V384, P863, DOI 10.1515/BC.2003.097; Camphausen K, 2001, CANCER RES, V61, P2207; Chakraborti S, 2003, MOL CELL BIOCHEM, V253, P269, DOI 10.1023/A:1026028303196; Chen XW, 2005, INT J CANCER, V116, P52, DOI 10.1002/ijc.20997; Cheng JCH, 2006, ONCOGENE, V25, P7009, DOI 10.1038/sj.onc.1209706; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Dong ZY, 1997, CELL, V88, P801, DOI 10.1016/S0092-8674(00)81926-1; Giraudo E, 2004, J CLIN INVEST, V114, P623, DOI 10.1172/JCI200422087; Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285; Hartford AC, 2000, CANCER RES, V60, P2128; Hiratsuka S, 2002, CANCER CELL, V2, P289, DOI 10.1016/S1535-6108(02)00153-8; Huang SY, 2002, J NATL CANCER I, V94, P1134; Jodele S, 2005, CANCER RES, V65, P3200, DOI 10.1158/0008-5472.CAN-04-3770; Leeman MF, 2003, J PATHOL, V201, P528, DOI 10.1002/path.1466; Martin FM, 1999, BIOORG MED CHEM LETT, V9, P2887, DOI 10.1016/S0960-894X(99)00494-1; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Osinsky SP, 2005, EXP ONCOL, V27, P202; Owen JL, 2003, J IMMUNOL, V171, P4340, DOI 10.4049/jimmunol.171.8.4340; Pozzi A, 2002, ONCOGENE, V21, P272, DOI 10.1038/sj.onc.1205045; Rundhaug JE, 2005, J CELL MOL MED, V9, P267, DOI 10.1111/j.1582-4934.2005.tb00355.x; Thwin MM, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2810; Tofts PS, 1999, J MAGN RESON IMAGING, V10, P223, DOI 10.1002/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S; TOFTS PS, 1991, MAGNET RESON MED, V17, P357, DOI 10.1002/mrm.1910170208; Vihinen P, 2005, CURR CANCER DRUG TAR, V5, P203, DOI 10.2174/1568009053765799; Zhang Q, 2006, J BIOL CHEM, V281, P18145, DOI 10.1074/jbc.M512566200	29	42	45	3	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2012	31	4					458	468		10.1038/onc.2011.240	http://dx.doi.org/10.1038/onc.2011.240			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891LU	21706046				2022-12-17	WOS:000300219300005
J	Kim, J; Roh, M; Doubinskaia, I; Algarroba, GN; Eltoum, IEA; Abdulkadir, SA				Kim, J.; Roh, M.; Doubinskaia, I.; Algarroba, G. N.; Eltoum, I-E A.; Abdulkadir, S. A.			A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53	ONCOGENE			English	Article						c-MYC; Pten; p53; prostate cancer; rate of mutations	TUMOR-SUPPRESSOR GENE; GENOMIC DELETION; TRANSGENIC MICE; ADVANCED-STAGE; IN-VIVO; MUTATIONS; EXPRESSION; CARCINOMA; PROGRESSION; TUMORIGENESIS	Human tumors are heterogeneous and evolve through a dynamic process of genetic mutation and selection. During this process, the effects of a specific mutation on the incipient cancer cell may dictate the nature of subsequent mutations that can be tolerated or selected for, affecting the rate at which subsequent mutations occur. Here we have used a new mouse model of prostate cancer that recapitulates several salient features of the human disease to examine the relative rates in which the remaining wildtype alleles of Pten and p53 tumor suppressor genes are lost. In this model, focal overexpression of c-MYC in a few prostate luminal epithelial cells provokes a mild proliferative response. In the context of compound Pten/p53 heterozygosity, c-MYC-initiated cells progress to prostatic intraepithelial neoplasia (mPIN) and adenocarcinoma lesions with marked heterogeneity within the same prostate glands. Using laser capture microdissection and gene copy number analyses, we found that the frequency of Pten loss was significantly higher than that of p53 loss in mPIN but not invasive carcinoma lesions. c-MYC overexpression, unlike Pten loss, did not activate the p53 pathway in transgenic mouse prostate cells, explaining the lack of selective pressure to lose p53 in the c-MYC-overexpressing cells. This model of heterogeneous prostate cancer based on alterations in genes relevant to the human disease may be useful for understanding pathogenesis of the disease and testing new therapeutic agents. Oncogene (2012) 31, 322-332; doi:10.1038/onc.2011.236; published online 20 June 2011	[Kim, J.; Roh, M.; Doubinskaia, I.; Algarroba, G. N.; Abdulkadir, S. A.] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; [Algarroba, G. N.] Univ Florida, Coll Agr & Life Sci, Gainesville, FL USA; [Eltoum, I-E A.] Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA	Vanderbilt University; State University System of Florida; University of Florida; University of Alabama System; University of Alabama Birmingham	Abdulkadir, SA (corresponding author), Vanderbilt Univ, Sch Med, Med Ctr N, Dept Pathol, Rm B3321, Nashville, TN 37232 USA.	sarki.abdulkadir@vanderbilt.edu		Kim, Jongchan/0000-0002-9733-9881; Algarroba, Gabriela/0000-0001-9401-5905	National Cancer Institute of the National Institutes of Health [CA094858, CA123484]; NATIONAL CANCER INSTITUTE [R01CA123484, R01CA094858] Funding Source: NIH RePORTER	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank the members of the Abdulkadir Lab for helpful discussions. This work was supported by Grants CA094858 and CA123484 (SAA) from the National Cancer Institute of the National Institutes of Health.	Abdulkadir SA, 2001, HUM PATHOL, V32, P935, DOI 10.1053/hupa.2001.27102; Abdulkadir SA, 2001, NAT MED, V7, P101, DOI 10.1038/83231; Andreoiu M, 2010, HUM PATHOL, V41, P781, DOI 10.1016/j.humpath.2010.02.011; BOOKSTEIN R, 1993, CANCER RES, V53, P3369; Brooks JD, 1996, CANCER RES, V56, P3814; Carver BS, 2009, NAT GENET, V41, P619, DOI 10.1038/ng.370; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Cheng L, 1998, J NATL CANCER I, V90, P233, DOI 10.1093/jnci/90.3.233; Cheung TH, 2004, GYNECOL ONCOL, V93, P621, DOI 10.1016/j.ygyno.2004.03.013; CHI SG, 1994, J NATL CANCER I, V86, P926, DOI 10.1093/jnci/86.12.926; DINJENS WNM, 1994, INT J CANCER, V56, P630, DOI 10.1002/ijc.2910560504; Dong JT, 2001, CLIN CANCER RES, V7, P304; EFFERT PJ, 1993, J UROLOGY, V150, P257, DOI 10.1016/S0022-5347(17)35458-7; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Feilotter HE, 1998, ONCOGENE, V16, P1743, DOI 10.1038/sj.onc.1200205; Fenic I, 2004, J PATHOL, V203, P559, DOI 10.1002/path.1545; Fernandez-Marcos PJ, 2009, P NATL ACAD SCI USA, V106, P12962, DOI 10.1073/pnas.0813055106; GREENE DR, 1991, BRIT J UROL, V68, P499, DOI 10.1111/j.1464-410X.1991.tb15394.x; GRIZZLE WE, 1994, J CELL BIOCHEM, P259; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Gurel B, 2008, MODERN PATHOL, V21, P1156, DOI 10.1038/modpathol.2008.111; Han B, 2009, MODERN PATHOL, V22, P1083, DOI 10.1038/modpathol.2009.69; Iwata T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009427; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kim J, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000542; KONISHI N, 1995, JPN J CANCER RES, V86, P57, DOI 10.1111/j.1349-7006.1995.tb02988.x; McCall P, 2008, BRIT J CANCER, V99, P1296, DOI 10.1038/sj.bjc.6604680; McMenamin ME, 1999, CANCER RES, V59, P4291; MELLON K, 1992, J UROLOGY, V147, P496, DOI 10.1016/S0022-5347(17)37287-7; Mentor-Marcel R, 2001, CANCER RES, V61, P6777; MIRCHANDANI D, 1995, AM J PATHOL, V147, P92; NAVONE NM, 1993, J NATL CANCER I, V85, P1657, DOI 10.1093/jnci/85.20.1657; Nesslinger NJ, 2003, CANCER RES, V63, P2228; Preacher KJ, 2001, CALCULATION CHI SQUA; Qian JQ, 2002, MODERN PATHOL, V15, P35, DOI 10.1038/modpathol.3880487; Roh M, 2006, GENESIS, V44, P447, DOI 10.1002/dvg.20235; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Schmitz M, 2007, INT J CANCER, V120, P1284, DOI 10.1002/ijc.22359; Sircar K, 2009, J PATHOL, V218, P505, DOI 10.1002/path.2559; SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q; Suzuki H, 1998, CANCER RES, V58, P204; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; VILLERS A, 1992, CANCER, V70, P2313, DOI 10.1002/1097-0142(19921101)70:9<2313::AID-CNCR2820700917>3.0.CO;2-T; VOELLER HJ, 1994, J UROLOGY, V151, P492; Wang L, 2007, HEPATOL RES, V37, P389, DOI 10.1111/j.1872-034X.2007.00042.x; Wang SI, 1998, CLIN CANCER RES, V4, P811; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wu XT, 2001, MECH DEVELOP, V101, P61, DOI 10.1016/S0925-4773(00)00551-7; Yeang CH, 2008, FASEB J, V22, P2605, DOI 10.1096/fj.08-108985; Yoshimoto M, 2007, BRIT J CANCER, V97, P678, DOI 10.1038/sj.bjc.6603924	51	42	43	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2012	31	3					322	332		10.1038/onc.2011.236	http://dx.doi.org/10.1038/onc.2011.236			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	882DQ	21685943	Green Accepted			2022-12-17	WOS:000299542100005
J	Dentelli, P; Rosso, A; Olgasi, C; Camussi, G; Brizzi, MF				Dentelli, P.; Rosso, A.; Olgasi, C.; Camussi, G.; Brizzi, M. F.			IL-3 is a novel target to interfere with tumor vasculature	ONCOGENE			English	Article						IL-3; tumor angiogenesis; Akt; inflammatory cells; mbKitL	ENDOTHELIAL PROGENITOR CELLS; POTENTIAL ROLE; C-KIT; ANGIOGENESIS; EXPRESSION; BETA-1-INTEGRIN; PROLIFERATION; RECRUITMENT; MACROPHAGES; ACTIVATION	Angiogenesis inhibiting agents are currently integral component of anticancer therapy. However, tumors, initially responsive to anti-angiogenic drugs or vascular targeting agents, can acquire resistance. The limited clinical efficacy might result from the heterogeneous nature of tumors or alternatively from the unique phenotype of tumor vascular cells, widely diverse from so-called 'normal' endothelium. Hence, defining the molecular mechanisms driving this diversity might provide a rational basis to design combinatory therapies that should be more effective in avoiding resistance. Herein, we demonstrated that tumor-derived endothelial cells (TECs) isolated from breast and kidney carcinomas retained an endothelial phenotype, but outspread independently of growth factors. Applying small interfering RNA approach, we demonstrated that interleukin (IL)-3, but not vascular endothelial growth factor, released by TECs, supports their autocrine growth and promotes in vivo vessel formation and tumor angiogenesis. Meanwhile, we found that the expression of the membrane-bound kit ligand (mbKitL) depends on IL-3, and it is crucial for adhesion of endothelial progenitor cells (EPCs) and inflammatory cells to TECs. These events required Akt activation. Finally, the finding that depletion of the mbKitL prevented EPC and inflammatory cell trafficking into vascular microenvironment, indicates that, as in bone marrow, the mbKitL can act as a membrane/adhesion molecule for c-Kit-expressing cells. These data provide evidences that an IL-3 autocrine loop can drive a tumor endothelial switch and that targeting IL-3 might confer a significant therapeutic advantage to hamper tumor angiogenesis. Oncogene (2011) 30, 4930-4940; doi:10.1038/onc.2011.204; published online 6 June 2011	[Dentelli, P.; Rosso, A.; Olgasi, C.; Camussi, G.; Brizzi, M. F.] Univ Turin, Dept Internal Med, I-10126 Turin, Italy	University of Turin	Brizzi, MF (corresponding author), Univ Turin, Dept Internal Med, Corso Dogliotti 14, I-10126 Turin, Italy.	mariafelice.brizzi@unito.it	Brizzi, Maria Felice/J-7882-2016; Camussi, Giovanni/J-7624-2016; olgasi, cristina/J-2934-2018	Camussi, Giovanni/0000-0003-2795-232X; olgasi, cristina/0000-0002-5738-213X	Italian Association for Cancer Research (AIRC); MIUR (Ministero dell'Universita e Ricerca Scientifica)	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); MIUR (Ministero dell'Universita e Ricerca Scientifica)(Ministry of Education, Universities and Research (MIUR))	This work was supported by grants of the Italian Association for Cancer Research (AIRC) to MFB and GC and by MIUR (Ministero dell'Universita e Ricerca Scientifica) to MFB and GC.	AVANZI GC, 1990, J CELL PHYSIOL, V145, P458, DOI 10.1002/jcp.1041450310; Baluk P, 2003, AM J PATHOL, V163, P1801, DOI 10.1016/S0002-9440(10)63540-7; Biancone L, 2004, J IMMUNOL, V173, P5268, DOI 10.4049/jimmunol.173.8.5268; BRIZZI MF, 1993, J CLIN INVEST, V91, P2887, DOI 10.1172/JCI116534; Brizzi MF, 2001, CIRCULATION, V103, P549, DOI 10.1161/01.CIR.103.4.549; Bussolati B, 2003, FASEB J, V17, P1159, DOI 10.1096/fj.02-0557fje; Bussolati B, 2006, J MOL MED-JMM, V84, P852, DOI 10.1007/s00109-006-0075-z; Bussolati B, 2010, CURR VASC PHARMACOL, V8, P220, DOI 10.2174/157016110790887036; Butler JM, 2010, NAT REV CANCER, V10, P138, DOI 10.1038/nrc2791; De Palma M, 2006, BBA-REV CANCER, V1766, P159, DOI 10.1016/j.bbcan.2006.06.003; Defilippi P, 2005, J CELL BIOL, V168, P1099, DOI 10.1083/jcb.200405116; Dentelli P, 2004, ONCOGENE, V23, P1681, DOI 10.1038/sj.onc.1207290; Dentelli P, 1999, J IMMUNOL, V163, P2151; Dentelli P, 2007, BLOOD, V109, P4264, DOI 10.1182/blood-2006-06-029603; Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115; Gao DC, 2009, BBA-REV CANCER, V1796, P33, DOI 10.1016/j.bbcan.2009.05.001; Grange C, 2006, ONCOL REP, V15, P381; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596; Leek RD, 2002, J MAMMARY GLAND BIOL, V7, P177, DOI 10.1023/A:1020304003704; Lin EY, 2006, CANCER RES, V66, P11238, DOI 10.1158/0008-5472.CAN-06-1278; Luster AD, 2005, NAT IMMUNOL, V6, P1182, DOI 10.1038/ni1275; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; MATSUDA R, 1993, AM J PATHOL, V142, P339; Nishie A, 1999, CLIN CANCER RES, V5, P1107; Nolan DJ, 2007, GENE DEV, V21, P1546, DOI 10.1101/gad.436307; Ribatti D, 2007, CANCER LETT, V248, P18, DOI 10.1016/j.canlet.2006.06.007; Shchors K, 2007, CANCER RES, V67, P7059, DOI 10.1158/0008-5472.CAN-07-2053; Sica A, 2007, EXPERT OPIN THER TAR, V11, P1219, DOI 10.1517/14728222.11.9.1219; St Croix B, 2000, SCIENCE, V289, P1197; Takakura N, 2006, CANCER SCI, V97, P568, DOI 10.1111/j.1349-7006.2006.00223.x; Togel F, 2005, AM J PHYSIOL-RENAL, V289, pF31, DOI 10.1152/ajprenal.00007.2005; Togliatto G, 2010, DIABETES, V59, P1016, DOI 10.2337/db09-0858; Tonini T, 2003, ONCOGENE, V22, P6549, DOI 10.1038/sj.onc.1206816; Uberti B, 2010, ONCOGENE, V29, P6581, DOI 10.1038/onc.2010.384; Vajkoczy P, 2003, J EXP MED, V197, P1755, DOI 10.1084/jem.20021659; van Beijnum Judy R, 2009, Front Biosci (Schol Ed), V1, P216; Verfaillie CM, 2008, CANCER CELL, V14, P193, DOI 10.1016/j.ccr.2008.08.005; Weber C, 2006, TRENDS IMMUNOL, V27, P268, DOI 10.1016/j.it.2006.04.002; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Yoder MC, 2007, BLOOD, V109, P1801, DOI 10.1182/blood-2006-08-043471; Yoder MC, 2009, BBA-REV CANCER, V1796, P50, DOI 10.1016/j.bbcan.2009.04.002; Zeoli A, 2008, BLOOD, V112, P350, DOI 10.1182/blood-2007-12-128215	45	42	44	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2011	30	50					4930	4940		10.1038/onc.2011.204	http://dx.doi.org/10.1038/onc.2011.204			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865YJ	21643009				2022-12-17	WOS:000298346500002
J	Li, CG; Nyman, JE; Braithwaite, AW; Eccles, MR				Li, C. G.; Nyman, J. E.; Braithwaite, A. W.; Eccles, M. R.			PAX8 promotes tumor cell growth by transcriptionally regulating E2F1 and stabilizing RB protein	ONCOGENE			English	Article						cell cycle; E2F1; PAX8; RB; senescence	UBIQUITIN-INDEPENDENT DEGRADATION; RETINOBLASTOMA PROTEIN; SUPPRESSOR PROTEIN; PROTEASOME PATHWAY; GENE-EXPRESSION; BINDING-SITES; THYROID-GLAND; WILMS-TUMORS; CYCLE; PRB	The retinoblastoma protein (RB)-E2F1 pathway has a central role in regulating the cell cycle. Several PAX proteins (tissue-specific developmental regulators), including PAX8, interact with the RB protein, and thus regulate the cell cycle directly or indirectly. Here, we report that PAX8 expression is frequent in renal cell carcinoma, bladder, ovarian and thyroid cancer cell lines, and that silencing of PAX8 in cancer cell lines leads to a striking reduction in the expression of E2F1 and its target genes, as well as a proteasome-dependent destabilization of RB protein, with the RB1 mRNA level remaining unaffected. Cancer cells expressing PAX8 undergo a G(1)/S arrest and eventually senesce following PAX8 silencing. We demonstrate that PAX8 transcriptionally regulates the E2F1 promoter directly, and E2F1 transcription is enhanced after RB depletion. RB is recruited to the PAX8-binding site, and is involved in PAX8-mediated E2F1 transcription in cancer cells. Therefore, our results suggest that, in cancer, frequent and persistent expression of PAX8 is required for cell growth control through transcriptional activation of E2F1 expression and upregulation of the RB-E2F1 pathway. Oncogene (2011) 30, 4824-4834; doi: 10.1038/onc.2011.190; published online 23 May 2011	[Li, C. G.; Nyman, J. E.; Braithwaite, A. W.; Eccles, M. R.] Univ Otago, Dept Pathol, Dunedin Sch Med, Dunedin 9054, Otago, New Zealand; [Braithwaite, A. W.] Univ Sydney, Childrens Med Res Inst, Cell Transformat Unit, Sydney, NSW 2006, Australia	University of Otago; Children's Medical Research Institute - Australia; University of Sydney	Eccles, MR (corresponding author), Univ Otago, Dept Pathol, Dunedin Sch Med, POB 913,Great King St, Dunedin 9054, Otago, New Zealand.	michael.eccles@otago.ac.nz			New Zealand Institute for Cancer Research Trust (Otago); CMRI (Sydney); Health Research Council; University of Otago; Dunedin School of Medicine; Health Research Council of New Zealand; University of Otago Faculty of Medicine Trust	New Zealand Institute for Cancer Research Trust (Otago); CMRI (Sydney); Health Research Council; University of Otago; Dunedin School of Medicine; Health Research Council of New Zealand(Health Research Council of New Zealand); University of Otago Faculty of Medicine Trust	MRE and AWB are supported by funds from the New Zealand Institute for Cancer Research Trust (Otago) and the CMRI (Sydney), respectively. CGL was supported by the Health Research Council, the University of Otago International Fees Scholarship and Postgraduate Publishing Bursary and the Dunedin School of Medicine Finishing Your PhD Scholarship. This work was supported by grants from the Health Research Council of New Zealand and the University of Otago Faculty of Medicine Trust Fund.	Berezutskaya E, 1997, J BIOL CHEM, V272, P30135, DOI 10.1074/jbc.272.48.30135; Bouchard M, 2002, GENE DEV, V16, P2958, DOI 10.1101/gad.240102; Bowen NJ, 2007, GYNECOL ONCOL, V104, P331, DOI 10.1016/j.ygyno.2006.08.052; Boyer SN, 1996, CANCER RES, V56, P4620; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Buttitta LA, 2007, CURR OPIN CELL BIOL, V19, P697, DOI 10.1016/j.ceb.2007.10.004; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chen YJ, 2008, CANCER RES, V68, P5724, DOI 10.1158/0008-5472.CAN-08-0058; Dahl E, 1997, BIOESSAYS, V19, P755, DOI 10.1002/bies.950190905; Dahl JA, 2008, NAT PROTOC, V3, P1032, DOI 10.1038/nprot.2008.68; Daniel L, 2001, HUM PATHOL, V32, P282, DOI 10.1053/hupa.2001.22753; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ECCLES MR, 1995, AM J PATHOL, V146, P40; Esposito C, 1998, BIOCHEM J, V331, P37, DOI 10.1042/bj3310037; Fabbro D, 1998, J MOL ENDOCRINOL, V21, P347, DOI 10.1677/jme.0.0210347; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; He SJ, 2010, J INVEST DERMATOL, V130, P1465, DOI 10.1038/jid.2009.434; Hibbs K, 2004, AM J PATHOL, V165, P397, DOI 10.1016/S0002-9440(10)63306-8; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Hooghe B, 2008, NUCLEIC ACIDS RES, V36, pW128, DOI 10.1093/nar/gkn195; Hsu SIH, 2001, EMBO J, V20, P2273, DOI 10.1093/emboj/20.9.2273; Hueber PA, 2006, KIDNEY INT, V69, P1139, DOI 10.1038/sj.ki.5000136; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Kalejta RF, 2003, P NATL ACAD SCI USA, V100, P3263, DOI 10.1073/pnas.0538058100; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; Knight JS, 2005, P NATL ACAD SCI USA, V102, P18562, DOI 10.1073/pnas.0503886102; Leung JY, 2008, ONCOGENE, V27, P4172, DOI 10.1038/onc.2008.55; Little MH, 2009, J AM SOC NEPHROL, V20, P2112, DOI 10.1681/ASN.2009010066; Long KB, 2010, AM J SURG PATHOL, V34, P723, DOI 10.1097/PAS.0b013e3181da0a20; Macchia PE, 1998, NAT GENET, V19, P83, DOI 10.1038/ng0598-83; Manning AL, 2010, GENE DEV, V24, P1364, DOI 10.1101/gad.1917310; Mansouri A, 1998, NAT GENET, V19, P87, DOI 10.1038/ng0598-87; Miccadei S, 2005, ONCOGENE, V24, P6993, DOI 10.1038/sj.onc.1208861; Munro S, 2010, ONCOGENE, V29, P2357, DOI 10.1038/onc.2009.511; Narlis M, 2007, J AM SOC NEPHROL, V18, P1121, DOI 10.1681/ASN.2006070739; Nitta RT, 2006, MOL CELL BIOL, V26, P5360, DOI 10.1128/MCB.02464-05; Ohno M, 1999, MOL CELL BIOL, V19, P2051; Peeper DS, 2001, NAT CELL BIOL, V3, P198, DOI 10.1038/35055110; Pfeffer PL, 1998, DEVELOPMENT, V125, P3063; PLACHOV D, 1990, DEVELOPMENT, V110, P643; POLEEV A, 1995, EUR J BIOCHEM, V228, P899, DOI 10.1111/j.1432-1033.1995.tb20338.x; ROSSI DL, 1995, J BIOL CHEM, V270, P23139, DOI 10.1074/jbc.270.39.23139; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Skapek SX, 2006, ONCOGENE, V25, P5268, DOI 10.1038/sj.onc.1209710; STOYKOVA A, 1994, J NEUROSCI, V14, P1395, DOI 10.1523/JNEUROSCI.14-03-01395.1994; Tong GX, 2009, MODERN PATHOL, V22, P1218, DOI 10.1038/modpathol.2009.88; Tong GX, 2006, MODERN PATHOL, V19, P356, DOI 10.1038/modpathol.3800535; Vilain C, 2001, J CLIN ENDOCR METAB, V86, P234, DOI 10.1210/jc.86.1.234; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wells J, 2003, ONCOGENE, V22, P1445, DOI 10.1038/sj.onc.1206264; Wyllie FS, 1999, BRIT J CANCER, V79, P1111, DOI 10.1038/sj.bjc.6690177; Yen A, 1997, EUR J CELL BIOL, V72, P159; Zalmas LP, 2008, EMBO REP, V9, P252, DOI 10.1038/sj.embor.7401158; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230; Zhang L, 2007, BIOCHEM BIOPH RES CO, V361, P611, DOI 10.1016/j.bbrc.2007.07.089; Zhang P, 2006, PATHOL INT, V56, P240, DOI 10.1111/j.1440-1827.2006.01959.x	62	42	43	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2011	30	48					4824	4834		10.1038/onc.2011.190	http://dx.doi.org/10.1038/onc.2011.190			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	863AH	21602887	hybrid, Green Published			2022-12-17	WOS:000298134700006
J	Gerstel, D; Wegwitz, F; Jannasch, K; Ludewig, P; Scheike, K; Alves, F; Beauchemin, N; Deppert, W; Wagener, C; Horst, AK				Gerstel, D.; Wegwitz, F.; Jannasch, K.; Ludewig, P.; Scheike, K.; Alves, F.; Beauchemin, N.; Deppert, W.; Wagener, C.; Horst, A. K.			CEACAM1 creates a pro-angiogenic tumor microenvironment that supports tumor vessel maturation	ONCOGENE			English	Article						CEACAM1; angiogenesis; tumor microenvironments; vessel maturation; MMP9-expressing leukocytes	CELL-ADHESION MOLECULE-1; VOLUME COMPUTED-TOMOGRAPHY; VASCULAR MORPHOGENESIS; BLOOD-VESSELS; MOUSE MODEL; IN-VIVO; CANCER; EXPRESSION; GROWTH; CARCINOGENESIS	We have studied the effects of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) on tumor angiogenesis in murine ductal mammary adenocarcinomas. We crossed transgenic mice with whey acidic protein promoter-driven large T-antigen expression (WAP-T mice) with oncogene-induced mammary carcinogenesis with CEA-CAM1null mice, and with Tie2-Ceacam1 transgenics, in which the Tie2 promoter drives endothelial overexpression of CEACAM1 (WAP-T x CEACAM1(endo+) mice), and analyzed tumor vascularization, angiogenesis and vessel maturation in these mice. Using flat-panel volume computed tomography (fpVCT) and histology, we found that WAP-T x CEACAM1(endo+) mice exhibited enhanced tumoral vascularization owing to CEACAM1(+) vessels in the tumor periphery, and increased intratumoral angiogenesis compared with controls. In contrast, vascularization of CEACAM1null/WAP-T-derived tumors was poor, and tumor vessels were dilated, leaky and showed poor pericyte coverage. Consequently, the tumoral vasculature could not be visualized in CEACAM1null/WAP-T mice by fpVCT, and we observed poor organization of the perivascular extracellular matrix (ECM), accompanied by the accumulation of collagen IV-degrading matrix metalloproteinase 9(+) (MMP9(+)) leukocytes and stromal cells. Vascular instability and alterations in ECM structure were accompanied by a significant increase in pulmonary metastases in CEACAM1null/WAP-T mice, whereas only occasional metastases were observed in CEACAM1(+) hosts. In CEACAM1(+) hosts, intratumoral vessels did not express CEACAM1, but they were intact, extensively covered with pericytes and framed by a well-organized perivascular ECM. MMP9(+) accessory cells were largely absent. Orthotopic transplantation of primary WAP-T- and CEACAM1null/WAP-T tumors into all three mouse lines confirmed that a CEACAM1(+) host environment is a prerequisite for productive angiogenic remodeling of the tumor microenvironment. Hence, CEACAM1 expression in the tumor periphery determines the vascular phenotype in a tumor, whereas systemic absence of CEACAM1 interferes with the formation of an organized tumor matrix and intratumoral vessel maturation. Oncogene (2011) 30, 4275-4288; doi: 10.1038/onc.2011.146; published online 2 May 2011	[Gerstel, D.; Ludewig, P.; Scheike, K.; Wagener, C.; Horst, A. K.] Univ Med Ctr Hamburg Eppendorf, Ctr Diagnost, Inst Clin Chem, D-20246 Hamburg, Germany; [Wegwitz, F.; Deppert, W.] Heinrich Pette Inst, Dept Tumor Virol, Hamburg, Germany; [Jannasch, K.; Alves, F.] Univ Gottingen, Dept Hematol & Oncol, Univ Med Ctr Gottingen, Gottingen, Germany; [Beauchemin, N.] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ, Canada	University of Hamburg; University Medical Center Hamburg-Eppendorf; Heinrich Pette Institute; University of Gottingen; McGill University	Horst, AK (corresponding author), Univ Med Ctr Hamburg Eppendorf, Ctr Diagnost, Inst Clin Chem, CAMPUS Res Bldg N27,02-089,52 Martinistr, D-20246 Hamburg, Germany.	ahorst@uke.de			German Research Foundation [SPP1190]	German Research Foundation(German Research Foundation (DFG))	This work was supported by the German Research Foundation, Priority Program SPP1190: the tumor vessel interface to WD, CW, AKH and FA.	Ahn GO, 2008, CANCER CELL, V13, P193, DOI 10.1016/j.ccr.2007.11.032; Ahn GO, 2009, ANGIOGENESIS, V12, P159, DOI 10.1007/s10456-009-9135-7; Baluk P, 2003, AM J PATHOL, V163, P1801, DOI 10.1016/S0002-9440(10)63540-7; Baluk P, 2005, CURR OPIN GENET DEV, V15, P102, DOI 10.1016/j.gde.2004.12.005; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Bergers G, 2005, NEURO-ONCOLOGY, V7, P452, DOI 10.1215/S1152851705000232; Betsholtz C, 2005, EXP SUPPL, V94, P115; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Connor KM, 2009, NAT PROTOC, V4, P1565, DOI 10.1038/nprot.2009.187; Dango S, 2008, LUNG CANCER, V60, P426, DOI 10.1016/j.lungcan.2007.11.015; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Ergun S, 2000, MOL CELL, V5, P311, DOI 10.1016/S1097-2765(00)80426-8; Fathers KE, 2005, AM J PATHOL, V167, P1753, DOI 10.1016/S0002-9440(10)61256-4; Francis SH, 2010, PHARMACOL REV, V62, P525, DOI 10.1124/pr.110.002907; Gocheva V, 2010, GENE DEV, V24, P241, DOI 10.1101/gad.1874010; Heinlein C, 2008, INT J CANCER, V122, P1701, DOI 10.1002/ijc.23317; Hellstrom M, 2001, J CELL BIOL, V153, P543, DOI 10.1083/jcb.153.3.543; Horst AK, 2004, HANDB EXP PHARM, V165, P283, DOI 10.1007/978-3-540-68170-0_10; Horst AK, 2009, BLOOD, V113, P6726, DOI 10.1182/blood-2008-10-184556; Horst AK, 2006, J CLIN INVEST, V116, P1596, DOI 10.1172/JCI24340; Huang FJ, 2010, DEV BIOL, V344, P1035, DOI 10.1016/j.ydbio.2010.06.023; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; Jannasch K, 2009, INT J CANCER, V125, P62, DOI 10.1002/ijc.24332; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kilic N, 2007, BLOOD, V110, P4223, DOI 10.1182/blood-2007-06-097592; Kirshner J, 2004, J MOL HISTOL, V35, P287, DOI 10.1023/B:HIJO.0000032360.01976.81; Kirshner J, 2003, P NATL ACAD SCI USA, V100, P521, DOI 10.1073/pnas.232711199; Kohler S, 2010, BRIT J CANCER, V102, P602, DOI 10.1038/sj.bjc.6605492; Leung N, 2006, ONCOGENE, V25, P5527, DOI 10.1038/sj.onc.1209541; Li CX, 2009, EXP CELL RES, V315, P1225, DOI 10.1016/j.yexcr.2008.12.015; Missbach-Guentner J, 2007, NEOPLASIA, V9, P755, DOI 10.1593/neo.07466; Nouvion AL, 2010, J CELL SCI, V123, P4221, DOI 10.1242/jcs.073635; Oliveira-Ferrer L, 2004, CANCER RES, V64, P8932, DOI 10.1158/0008-5472.CAN-04-0505; Ozerdem U, 2001, DEV DYNAM, V222, P218, DOI 10.1002/dvdy.1200; Pietras K, 2010, EXP CELL RES, V316, P1324, DOI 10.1016/j.yexcr.2010.02.045; SAWA H, 1994, DEV BRAIN RES, V78, P35, DOI 10.1016/0165-3806(94)90006-X; Sawamiphak S, 2010, NATURE, V465, P487, DOI 10.1038/nature08995; Schulze-Garg C, 2000, ONCOGENE, V19, P1028, DOI 10.1038/sj.onc.1203281; Seandel M, 2008, CANCER CELL, V13, P181, DOI 10.1016/j.ccr.2008.02.016; Tilki D, 2006, ONCOGENE, V25, P4965, DOI 10.1038/sj.onc.1209514; Wang YD, 2010, NATURE, V465, P483, DOI 10.1038/nature09002; Wegwitz F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012103	42	42	43	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2011	30	41					4275	4288		10.1038/onc.2011.146	http://dx.doi.org/10.1038/onc.2011.146			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HO	21532628				2022-12-17	WOS:000296356300005
J	Jakel, H; Weinl, C; Hengst, L				Jaekel, H.; Weinl, C.; Hengst, L.			Phosphorylation of p27Kip1 by JAK2 directly links cytokine receptor signaling to cell cycle control	ONCOGENE			English	Article						cell cycle control; CDK inhibitors; p27(Kip1); tyrosine kinases; JAK2; JAK2V617F	POLYCYTHEMIA-VERA; TYROSINE KINASE; DEPENDENT KINASES; MYELOPROLIFERATIVE DISEASE; SUBCELLULAR-LOCALIZATION; INHIBITORY-ACTIVITY; PROTEIN-KINASE; P27(KIP1); MUTATION; EXPRESSION	Janus kinase 2 (JAK2) couples ligand activation of cell surface cytokine receptors to the regulation of cellular functions including cell cycle progression, differentiation and apoptosis. It thereby coordinates biological programs such as development and hematopoiesis. Unscheduled activation of JAK2 by point mutations or chromosomal translocations can induce hyperproliferation and hematological malignancies. Typical signal transduction by the JAK2 tyrosine kinase comprises phosphorylation of STAT transcription factors. In this study, we describe the identification of the cyclin-dependent kinase (CDK) inhibitor p27(Kip1) as a novel JAK2 substrate. JAK2 can directly bind and phosphorylate p27(Kip1). Both, the JAK2 FERM domain and its kinase domain bind to p27(Kip1). JAK2 phosphorylates tyrosine residue 88 (Y88) of p27(Kip1). We previously reported that Y88 phosphorylation of p27(Kip1) by oncogenic tyrosine kinases impairs p27(Kip1)-mediated CDK inhibition, and initiates its ubiquitindependent proteasomal degradation. Consistently, we now find that active oncogenic JAK2V617F reduces p27(Kip1) stability and protein levels in patient-derived cell lines harboring the mutant JAK2V617F allele. Moreover, tyrosine phosphorylation of p27(Kip1) is impaired and p27(Kip1) expression is restored upon JAK2V617F inactivation by small hairpin RNA-mediated knockdown or by the pyridone-containing tetracycle JAK inhibitor-I, indicating that direct phosphorylation of p27(Kip1) can contribute to hyperproliferation of JAK2V617F-transformed cells. Activation of endogenous JAK2 by interleukin-3 (IL-3) induces Y88 phosphorylation of p27(Kip1), thus unveiling a novel link between cytokine signaling and cell cycle control in non-transformed cells. Oncogenic tyrosine kinases could use this novel pathway to promote hyperproliferation in tumor cells. Oncogene (2011) 30, 3502-3512; doi:10.1038/onc.2011.68; published online 21 March 2011	[Jaekel, H.; Weinl, C.; Hengst, L.] Innsbruck Med Univ, Bioctr, Div Med Biochem, A-6020 Innsbruck, Tyrolia, Austria	Medical University of Innsbruck	Hengst, L (corresponding author), Innsbruck Med Univ, Bioctr, Div Med Biochem, Fritz Pregl Str 3,6, A-6020 Innsbruck, Tyrolia, Austria.	ludger.hengst@i-med.ac.at		Hengst, Ludger/0000-0002-0605-0223	FWF [SFB F21-B12, P18873-B1]	FWF(Austrian Science Fund (FWF))	We thank Jakob Troppmair and Justus Duyster for providing cell lines, Wolfgang Doppler for providing plasmids and antibodies and Stephan Geley for providing plasmids. We thank Wolfgang Doppler, Michael Kullmann, Jonathan Vosper and all members of the Hengst lab for support, stimulating discussions and critical reading of the manuscript. The work was funded by the FWF Grants SFB F21-B12 and P18873-B1.	Agarwal A, 2008, BLOOD, V112, P1960, DOI 10.1182/blood-2007-09-113860; Baker SJ, 2007, ONCOGENE, V26, P6724, DOI 10.1038/sj.onc.1210757; Behrmann I, 2004, J BIOL CHEM, V279, P35486, DOI 10.1074/jbc.M404202200; Bruchova H, 2009, BLOOD CELL MOL DIS, V43, P81, DOI 10.1016/j.bcmd.2009.02.001; Chu I, 2007, CELL, V128, P281, DOI 10.1016/j.cell.2006.11.049; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Connor MK, 2003, MOL BIOL CELL, V14, P201, DOI 10.1091/mbc.E02-06-0319; Dawson MA, 2009, NATURE, V461, P819, DOI 10.1038/nature08448; Desrivieres S, 2006, J MAMMARY GLAND BIOL, V11, P75, DOI 10.1007/s10911-006-9014-4; Feng J, 1997, MOL CELL BIOL, V17, P2497, DOI 10.1128/MCB.17.5.2497; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Furuhata A, 2009, BIOCHEM BIOPH RES CO, V383, P411, DOI 10.1016/j.bbrc.2009.04.015; Grimmler M, 2007, CELL, V128, P269, DOI 10.1016/j.cell.2006.11.047; Halfter H, 2006, CANCER RES, V66, P6530, DOI 10.1158/0008-5472.CAN-04-3734; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Ihle JN, 2007, CURR OPIN GENET DEV, V17, P8, DOI 10.1016/j.gde.2006.12.009; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; James MK, 2008, MOL CELL BIOL, V28, P498, DOI 10.1128/MCB.02171-06; Kardinal C, 2006, BLOOD, V107, P1133, DOI 10.1182/blood-2005-05-1771; KELVIN DJ, 1986, J CELL PHYSIOL, V127, P403, DOI 10.1002/jcp.1041270308; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Larrea MD, 2008, MOL CELL BIOL, V28, P6462, DOI 10.1128/MCB.02300-07; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Levine RL, 2007, CURR OPIN HEMATOL, V14, P43, DOI 10.1097/00062752-200701000-00009; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Neilson LM, 2007, MOL ENDOCRINOL, V21, P2218, DOI 10.1210/me.2007-0173; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Ray A, 2009, MOL CELL BIOL, V29, P986, DOI 10.1128/MCB.00898-08; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Thompson JE, 2002, BIOORG MED CHEM LETT, V12, P1219, DOI 10.1016/S0960-894X(02)00106-3; Tossidou I, 2008, CELL CYCLE, V7, P3858, DOI 10.4161/cc.7.24.7260; Verstovsek Srdan, 2009, Hematology Am Soc Hematol Educ Program, P636, DOI 10.1182/asheducation-2009.1.636; Wallace TA, 2006, CELL BIOCHEM BIOPHYS, V44, P213, DOI 10.1385/CBB:44:2:213; Walz C, 2006, J BIOL CHEM, V281, P18177, DOI 10.1074/jbc.M600064200; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Wernig G, 2008, BLOOD, V111, P3751, DOI 10.1182/blood-2007-07-102186; Zhao RX, 2005, J BIOL CHEM, V280, P22788, DOI 10.1074/jbc.C500138200; ZHAO YM, 1995, J BIOL CHEM, V270, P13814, DOI 10.1074/jbc.270.23.13814	41	42	48	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2011	30	32					3502	3512		10.1038/onc.2011.68	http://dx.doi.org/10.1038/onc.2011.68			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806CR	21423214	Green Accepted			2022-12-17	WOS:000293782300003
J	Wagh, PK; Gray, JK; Zinser, GM; Vasiliauskas, J; James, L; Monga, SP; Waltz, SE				Wagh, P. K.; Gray, J. K.; Zinser, G. M.; Vasiliauskas, J.; James, L.; Monga, S. P.; Waltz, S. E.			beta-Catenin is required for Ron receptor-induced mammary tumorigenesis	ONCOGENE			English	Article						beta-catenin; hepatocyte growth factor-like protein; Ron receptor; breast cancer; receptor tyrosine kinase	BREAST-CANCER; TUMOR-FORMATION; OVEREXPRESSION; ACTIVATION; PATHWAY; CARCINOMAS; EXPRESSION; GENE; MICE; DIFFERENTIATION	Our previous studies demonstrated that selective overexpression of the Ron receptor tyrosine kinase in the murine mammary epithelium leads to mammary tumor formation. Biochemical analysis of mammary tumor lysates showed that Ron overexpression was associated with increases in beta-catenin expression and tyrosine phosphorylation. beta-Catenin has also been shown to be regulated through tyrosine phosphorylation by the receptor tyrosine kinases Met, Fer and Fyn. However, the molecular and physiological roles of beta-catenin and beta-catenin tyrosine phosphorylation downstream of Ron are not known. To investigate this association, we show that Ron and beta-catenin are coordinately elevated in human breast cancers. Our data also demonstrate that activation of Ron, through ligand binding by hepatocyte growth factor-like protein (HGFL), induces the tyrosine phosphorylation of beta-catenin, primarily on tyrosine residues Tyr 654 and Tyr 670. In addition, HGFL-mediated Ron activation induces both beta-catenin nuclear localization and transcriptional activity, with Tyr 654 and Tyr 670 residues of beta-catenin being critical for these processes. We also demonstrate that a knockdown of Ron in breast cancer cell lines leads to a loss of HGFL-induced beta-catenin-dependent transcriptional activation and cell growth, which can be rescued by activation of canonical Wnt/beta-catenin signaling. Moreover, we show that HGFL-dependent Ron activation mediates upregulation of the beta-catenin target genes cyclin D1 and c-myc, and that expression of these target genes in breast cancer cells is decreased following inhibition of Ron and/or beta-catenin. Finally, we show that genetic ablation of beta-catenin in Ron-expressing breast cancer cells decreases cellular proliferation in vitro, as well as mammary tumor growth and metastasis, following orthotopic transplantation into the mammary fat pad. Together, our data suggest that beta-catenin is a crucial downstream regulator of Ron receptor activation and is an important mediator of mammary tumorigenesis. Oncogene (2011) 30, 3694-3704; doi:10.1038/onc.2011.86; published online 21 March 2011	[Wagh, P. K.; Gray, J. K.; Vasiliauskas, J.; Waltz, S. E.] Univ Cincinnati, Coll Med, Dept Canc & Cell Biol, Cincinnati, OH 45267 USA; [Zinser, G. M.] Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA; [James, L.] Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH 45267 USA; [Monga, S. P.] Univ Pittsburgh, Div Expt Pathol, Pittsburgh, PA USA; [Waltz, S. E.] Cincinnati Vet Affairs Med Ctr, Cincinnati, OH USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center	Waltz, SE (corresponding author), Univ Cincinnati, Coll Med, Dept Canc & Cell Biol, Vontz Bldg Mol Studies,3125 Eden Ave, Cincinnati, OH 45267 USA.	susan.waltz@uc.edu		Waltz, Susan/0000-0003-3572-4642; Monga, Satdarshan/0000-0002-8437-3378	National Institutes of Health [CA100002]; Cincinnati Veteran's Administration Medical Center [1I01BX000803]; University of Cincinnati Cancer Center; University of Cincinnati Research Council; NATIONAL CANCER INSTITUTE [R01CA100002, T32CA117846, T32CA059268] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000803] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cincinnati Veteran's Administration Medical Center; University of Cincinnati Cancer Center; University of Cincinnati Research Council; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veterans Affairs(US Department of Veterans Affairs)	We would like to acknowledge Dr Susanne I Wells for providing adenoviral reagents and Allie K Varner for her technical support. This work was supported by Public Health Service Grant CA100002 (SEW) from the National Institutes of Health, by grant 1I01BX000803 (SEW) from the Cincinnati Veteran's Administration Medical Center, by a University of Cincinnati Cancer Center Grant (SEW) and University of Cincinnati Research Council Grant (PKW).	Apte U, 2006, HEPATOLOGY, V44, P992, DOI 10.1002/hep.21317; Brembeck FH, 2006, CURR OPIN GENET DEV, V16, P51, DOI 10.1016/j.gde.2005.12.007; Castellone MD, 2009, CANCER RES, V69, P1867, DOI 10.1158/0008-5472.CAN-08-1982; COOMBES RC, 1990, J STEROID BIOCHEM, V37, P833, DOI 10.1016/0960-0760(90)90428-N; Danilkovitch-Miagkova A, 2001, MOL CELL BIOL, V21, P5857, DOI 10.1128/MCB.21.17.5857-5868.2001; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Gavert N, 2007, J CELL BIOCHEM, V102, P820, DOI 10.1002/jcb.21505; Graveel CR, 2009, P NATL ACAD SCI USA, V106, P12909, DOI 10.1073/pnas.0810403106; Gujral TS, 2008, CANCER RES, V68, P1338, DOI 10.1158/0008-5472.CAN-07-6052; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Hynes NE, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2406; Kizildag S, 2008, J BUON, V13, P533; Lee CH, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-64; Lee WY, 2005, CLIN CANCER RES, V11, P2222, DOI 10.1158/1078-0432.CCR-04-1761; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; McClaine RJ, 2010, NEOPLASIA, V12, P650, DOI 10.1593/neo.10476; Meyer SE, 2009, DEV BIOL, V333, P173, DOI 10.1016/j.ydbio.2009.06.028; Micalizzi DS, 2010, J MAMMARY GLAND BIOL, V15, P117, DOI 10.1007/s10911-010-9178-9; Miller KD, 2006, CLIN CANCER RES, V12, P281, DOI 10.1158/1078-0432.CCR-05-0219; Nakopoulou L, 2006, MODERN PATHOL, V19, P556, DOI 10.1038/modpathol.3800562; O'Toole JM, 2006, CANCER RES, V66, P9162, DOI 10.1158/0008-5472.CAN-06-0283; Peace BE, 2005, CANCER RES, V65, P1285, DOI 10.1158/0008-5472.CAN-03-3580; Peace BE, 2001, ONCOGENE, V20, P6142, DOI 10.1038/sj.onc.1204836; Ranganathan S, 2005, PEDIATR DEVEL PATHOL, V8, P435, DOI 10.1007/s10024-005-0028-5; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Shien T, 2005, J CLIN PATHOL, V58, P1299, DOI 10.1136/jcp.2005.026096; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Takahashi-Yanaga F, 2010, CLIN CANCER RES, V16, P3153, DOI 10.1158/1078-0432.CCR-09-2943; Taneja P, 2010, CLIN MED INSIGHTS-ON, V4, P15; Thobe MN, 2010, ONCOGENE, V29, P214, DOI 10.1038/onc.2009.331; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Welm AL, 2007, P NATL ACAD SCI USA, V104, P7570, DOI 10.1073/pnas.0702095104; Zeng G, 2006, EXP CELL RES, V312, P3620, DOI 10.1016/j.yexcr.2006.08.003; Zinser GM, 2006, CANCER RES, V66, P11967, DOI 10.1158/0008-5472.CAN-06-2473	35	42	44	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2011	30	34					3694	3704		10.1038/onc.2011.86	http://dx.doi.org/10.1038/onc.2011.86			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	21423209	Green Accepted			2022-12-17	WOS:000294244500005
J	Tang, D; Lotze, MT; Kang, R; Zeh, HJ				Tang, D.; Lotze, M. T.; Kang, R.; Zeh, H. J.			Apoptosis promotes early tumorigenesis	ONCOGENE			English	Review						tumorigenesis; CD95; PUMA; apoptosis; autophagy; DAMP	CELL-DEATH; REGULATES AUTOPHAGY; CANCER-CELLS; TUMOR-GROWTH; PUMA; HMGB1; LYMPHOMAGENESIS; INFLAMMATION; MODULATION; CROSSTALK	One hallmark of cancer is intrinsic or acquired resistance to apoptosis. Surprisingly, recent studies demonstrate that CD95/Fas/Apo1 and p53 upregulated mediator of apoptosis/PUMA (potent inducers of the death receptor and the mitochondrial apoptotic pathways, respectively) promote tumorigenesis. These findings provide important insights into the multifaceted roles of apoptosis in tumorigenesis. Oncogene (2011) 30, 1851-1854; doi: 10.1038/onc.2010.573; published online 13 December 2010	[Tang, D.; Lotze, M. T.; Kang, R.; Zeh, H. J.] Univ Pittsburgh, Dept Surg, Hillman Canc Ctr, Inst Canc, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lotze, MT (corresponding author), Univ Pittsburgh, Dept Surg, Hillman Canc Ctr, Inst Canc, G-27A Hillman Canc Ctr,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	tangd2@upmc.edu; lotzemt@upmc.edu	Kang, Rui/ABD-5291-2021; Tang, Daolin/B-2905-2010; Tang, Daolin/ABD-5062-2021	Kang, Rui/0000-0003-2725-1574; Tang, Daolin/0000-0002-1903-6180				Chen L, 2010, NATURE, V465, P492, DOI 10.1038/nature09075; Gebhardt C, 2008, J EXP MED, V205, P275, DOI 10.1084/jem.20070679; Hemann MT, 2004, P NATL ACAD SCI USA, V101, P9333, DOI 10.1073/pnas.0403286101; Hou W, 2010, AUTOPHAGY, V6, P891, DOI 10.4161/auto.6.7.13038; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Kang R, 2010, CELL DEATH DIFFER, V17, P666, DOI 10.1038/cdd.2009.149; Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692; Labi V, 2010, GENE DEV, V24, P1602, DOI 10.1101/gad.1940210; Lee JS, 2009, NAT CELL BIOL, V11, P1355, DOI 10.1038/ncb1980; Lindsten T, 2006, CELL DEATH DIFFER, V13, P1272, DOI 10.1038/sj.cdd.4401953; Liu L, 2011, LEUKEMIA, V25, P23, DOI 10.1038/leu.2010.225; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254; Michalak EM, 2009, CELL DEATH DIFFER, V16, P684, DOI 10.1038/cdd.2008.195; Michalak EM, 2010, GENE DEV, V24, P1608, DOI 10.1101/gad.1940110; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Peter ME, 2007, CELL, V129, P447, DOI 10.1016/j.cell.2007.04.031; Qiu W, 2009, CANCER RES, V69, P4999, DOI 10.1158/0008-5472.CAN-09-0262; Ramenghi U, 2000, BLOOD, V95, P3176; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; Tang D, 2010, ONCOGENE, V29, P5299, DOI 10.1038/onc.2010.261; TANG D, 2010, ANTIOXID REDOX SIGNA; Tang DL, 2010, J CELL BIOL, V190, P881, DOI 10.1083/jcb.200911078; Tang DL, 2010, BBA-GENE REGUL MECH, V1799, P131, DOI 10.1016/j.bbagrm.2009.11.014; Tesniere A, 2008, CURR OPIN IMMUNOL, V20, P504, DOI 10.1016/j.coi.2008.05.007; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Villunger A, 2000, J IMMUNOL, V165, P1337, DOI 10.4049/jimmunol.165.3.1337; White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023; Wilson A, 2004, GENE DEV, V18, P2747, DOI 10.1101/gad.313104; Yee KS, 2009, CELL DEATH DIFFER, V16, P1135, DOI 10.1038/cdd.2009.28; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1	34	42	48	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2011	30	16					1851	1854		10.1038/onc.2010.573	http://dx.doi.org/10.1038/onc.2010.573			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	753MA	21151175				2022-12-17	WOS:000289777700001
J	Hill, VK; Underhill-Day, N; Krex, D; Robel, K; Sangan, CB; Summersgill, HR; Morris, M; Gentle, D; Chalmers, AD; Maher, ER; Latif, F				Hill, V. K.; Underhill-Day, N.; Krex, D.; Robel, K.; Sangan, C. B.; Summersgill, H. R.; Morris, M.; Gentle, D.; Chalmers, A. D.; Maher, E. R.; Latif, F.			Epigenetic inactivation of the RASSF10 candidate tumor suppressor gene is a frequent and an early event in gliomagenesis	ONCOGENE			English	Article						gliomas; RASSF10; epigenetics	GLIOBLASTOMA-MULTIFORME; IDH2 MUTATIONS; METHYLATION; GLIOMAS; DIFFERENTIATION; PROTEINS; FAMILY; CANCER; DOMAIN; MGMT	We have recently described the N-terminal RAS association domain family of genes, RASSF7-10. Previously, we cloned the N-terminal RASSF10 gene and demonstrated frequent methylation of the associated 50-CpG island in acute lymphoblastic leukemia. To characterize RASSF10 gene expression, we demonstrate that in developing Xenopus embryos, RASSF10 shows a very striking pattern in the rhombencephalon (hind brain). It is also expressed in other parts of the brain and other organs. Due to the well-defined expression pattern in the brain of Xenopus embryos, we analyzed the methylation status of the RASSF10-associated 5'-CpG island in astrocytic gliomas. RASSF10 was frequently methylated in WHO grade II-III astrocytomas and WHO grade IV primary glioblastomas (67.5%), but was unmethylated in grade I astrocytomas and in DNA from age matched control brain samples. RASSF10 gene expression both at the mRNA and protein levels could be switched back on in methylated glioma cell lines after treatment with 5-aza-2'-deoxycytidine. In secondary glioblastomas (sGBM), RASSF10 methylation was an independent prognostic factor associated with worst progression-free survival and overall survival and occurred at an early stage in their development. In cell culture experiments, overexpression of RASSF10 mediated a reduction in the colony forming ability of two RASSF10-methylated glioma cell lines. Conversely, RNAi-mediated knockdown of RASSF10-stimulated anchorage-independent growth of U87 glioma cells, increased their viability and caused an increase in the cells' proliferative ability. We generated and characterized a RASSF10-specific antibody and demonstrated for the first time that RASSF10 subcellular localization is cell-cycle dependent with RASSF10 colocalizing to centrosomes and associated microtubules during mitosis. This is the first report demonstrating that RASSF10 can act as a tumor suppressor gene and is frequently methylated in gliomas and can potentially be developed into a prognostic marker for sGBM. Oncogene (2011) 30, 978-989; doi:10.1038/onc.2010.471; published online 18 October 2010 Keywords: gliomas; RASSF10; epigenetics	[Latif, F.] Univ Birmingham, Inst Biomed Res, Coll Med & Dent Sci, Sch Clin & Expt Med, Birmingham B15 2TT, W Midlands, England; [Krex, D.; Robel, K.] Tech Univ Dresden, Univ Klinikum Carl Gustav Carus, Klin & Poliklin Neurochirurg, Dresden, Germany; [Sangan, C. B.; Summersgill, H. R.; Chalmers, A. D.] Univ Bath, Ctr Regenerat Med, Dept Biol & Biochem, Bath BA2 7AY, Avon, England	University of Birmingham; Technische Universitat Dresden; Carl Gustav Carus University Hospital; University of Bath	Latif, F (corresponding author), Univ Birmingham, Inst Biomed Res, Coll Med & Dent Sci, Sch Clin & Expt Med, Birmingham B15 2TT, W Midlands, England.	f.latif@bham.ac.uk	Chalmers, Andrew/D-4103-2009; Morris, Mark/C-6413-2008; MAHER, EAMONN R/A-9507-2008; Krex, Dietmar/E-6833-2014	Chalmers, Andrew/0000-0003-4182-6717; MAHER, EAMONN R/0000-0002-6226-6918; Morris, Mark/0000-0002-0700-355X	Breast Cancer Campaign; CRUK; Sport Aiding Medical Research for Kids (SPARKS)	Breast Cancer Campaign; CRUK(Cancer Research UK); Sport Aiding Medical Research for Kids (SPARKS)	We thank Dr Reinhard Dammann for providing the RASSF10 construct. F Latif laboratory funded in part by Breast Cancer Campaign, CRUK and Sport Aiding Medical Research for Kids (SPARKS).	Chalmers AD, 2002, DEV CELL, V2, P171, DOI 10.1016/S1534-5807(02)00113-2; Chen LH, 1998, J BIOL CHEM, V273, P33524, DOI 10.1074/jbc.273.50.33524; Dallol A, 2009, CURR BIOL, V19, P1227, DOI 10.1016/j.cub.2009.05.064; Donninger H, 2007, J CELL SCI, V120, P3163, DOI 10.1242/jcs.010389; Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901; Hartmann C, 2009, ACTA NEUROPATHOL, V118, P469, DOI 10.1007/s00401-009-0561-9; Hesson LB, 2007, ONCOGENE, V26, P7283, DOI 10.1038/sj.onc.1210547; Hesson LB, 2007, DIS MARKERS, V23, P73, DOI 10.1155/2007/291538; Hesson Luke B, 2008, Expert Rev Neurother, V8, P1475, DOI 10.1586/14737175.8.10.1475; Hesson LB, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-42; Honorio S, 2003, ONCOGENE, V22, P461, DOI 10.1038/sj.onc.1206119; Langton PF, 2009, CURR BIOL, V19, P1969, DOI 10.1016/j.cub.2009.10.027; Lock FE, 2010, ONCOGENE, V29, P4307, DOI 10.1038/onc.2010.192; Martinez R, 2009, EPIGENETICS-US, V4, P255, DOI 10.4161/epi.9130; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Reeves N, 2005, DEV CELL, V8, P413, DOI 10.1016/j.devcel.2005.01.020; Richter AM, 2009, BBA-REV CANCER, V1796, P114, DOI 10.1016/j.bbcan.2009.03.004; Rodriguez-Viciana P, 2004, MOL CELL BIOL, V24, P4943, DOI 10.1128/MCB.24.11.4943-4954.2004; Schagdarsurengin U, 2009, EPIGENETICS-US, V4, P571, DOI 10.4161/epi.4.8.10056; Sherwood V, 2008, MOL BIOL CELL, V19, P1772, DOI 10.1091/mbc.E07-07-0652; Sherwood V, 2010, BIOCHEM J, V425, P303, DOI 10.1042/BJ20091318; Tommasi S, 2005, CANCER RES, V65, P92; van der Weyden L, 2005, MOL CELL BIOL, V25, P8356, DOI 10.1128/MCB.25.18.8356-8367.2005; Weller M, 2010, NAT REV NEUROL, V6, P39, DOI 10.1038/nrneurol.2009.197; Wu XW, 2010, CANCER RES, V70, P2718, DOI 10.1158/0008-5472.CAN-09-3631; Yan H, 2009, CANCER RES, V69, P9157, DOI 10.1158/0008-5472.CAN-09-2650; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710	28	42	48	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	8					978	989		10.1038/onc.2010.471	http://dx.doi.org/10.1038/onc.2010.471			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	726CJ	20956940				2022-12-17	WOS:000287695900009
J	De Carvalho, DD; Binato, R; Pereira, WO; Leroy, JMG; Colassanti, MD; Proto-Siqueira, R; Bueno-Da-Silva, AEB; Zago, MA; Zanichelli, MA; Abdelhay, E; Castro, FA; Jacysyn, JF; Amarante-Mendes, GP				De Carvalho, D. D.; Binato, R.; Pereira, W. O.; Leroy, J. M. G.; Colassanti, M. D.; Proto-Siqueira, R.; Bueno-Da-Silva, A. E. B.; Zago, M. A.; Zanichelli, M. A.; Abdelhay, E.; Castro, F. A.; Jacysyn, J. F.; Amarante-Mendes, G. P.			BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients	ONCOGENE			English	Article						PRAME; TRAIL; TNFSF10; EZH2; CML; BCR-ABL	APOPTOSIS-INDUCING LIGAND; GENE-EXPRESSION PROFILES; CHRONIC MYELOID-LEUKEMIA; DOWN-REGULATION; ANTIGEN PRAME; TNF-FAMILY; TUMOR; MELANOMA; CELLS; ACTIVATION	Tumor necrosis factor-related apoptosis-inducing ligand-TNFSF10 (TRAIL), a member of the TNF-alpha family and a death receptor ligand, was shown to selectively kill tumor cells. Not surprisingly, TRAIL is downregulated in a variety of tumor cells, including BCR-ABL-positive leukemia. Although we know much about the molecular basis of TRAIL-mediated cell killing, the mechanism responsible for TRAIL inhibition in tumors remains elusive because (a) TRAIL can be regulated by retinoic acid (RA); (b) the tumor antigen preferentially expressed antigen of melanoma (PRAME) was shown to inhibit transcription of RA receptor target genes through the polycomb protein, enhancer of zeste homolog 2 (EZH2); and (c) we have found that TRAIL is inversely correlated with BCR-ABL in chronic myeloid leukemia (CML) patients. Thus, we decided to investigate the association of PRAME, EZH2 and TRAIL in BCR-ABL-positive leukemia. Here, we demonstrate that PRAME, but not EZH2, is upregulated in BCR-ABL cells and is associated with the progression of disease in CML patients. There is a positive correlation between PRAME and BCR-ABL and an inverse correlation between PRAME and TRAIL in these patients. Importantly, knocking down PRAME or EZH2 by RNA interference in a BCR-ABL-positive cell line restores TRAIL expression. Moreover, there is an enrichment of EZH2 binding on the promoter region of TRAIL in a CML cell line. This binding is lost after PRAME knockdown. Finally, knocking down PRAME or EZH2, and consequently induction of TRAIL expression, enhances Imatinib sensibility. Taken together, our data reveal a novel regulatory mechanism responsible for lowering TRAIL expression and provide the basis of alternative targets for combined therapeutic strategies for CML. Oncogene (2011) 30, 223-233; doi:10.1038/onc.2010.409; published online 13 September 2010	[De Carvalho, D. D.; Pereira, W. O.; Leroy, J. M. G.; Bueno-Da-Silva, A. E. B.; Amarante-Mendes, G. P.] Univ Sao Paulo, Dept Immunol, Inst Ciencias Biomed, BR-05508900 Sao Paulo, Brazil; [De Carvalho, D. D.; Pereira, W. O.; Leroy, J. M. G.; Bueno-Da-Silva, A. E. B.; Castro, F. A.; Amarante-Mendes, G. P.] Inst Nacl Ciencia & Tecnol, Inst Invest Imunol, Sao Paulo, Brazil; [Binato, R.; Abdelhay, E.] Inst Nacl Canc, Div Labs CEMO, Rio De Janeiro, Brazil; [Colassanti, M. D.; Zanichelli, M. A.] Hosp Brigadeiro, Sao Paulo, Brazil; [Proto-Siqueira, R.] Fleury Med & Hlth, Sao Paulo, Brazil; [Zago, M. A.] Univ Sao Paulo, Fac Med Ribeirao Preto, BR-05508900 Sao Paulo, Brazil; [Castro, F. A.] Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, BR-05508900 Sao Paulo, Brazil; [Jacysyn, J. F.] Univ Sao Paulo, Fac Med LIM62, BR-05508900 Sao Paulo, Brazil	Universidade de Sao Paulo; National Cancer Institute (Inca); Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo	Amarante-Mendes, GP (corresponding author), Univ Sao Paulo, Dept Immunol, Inst Ciencias Biomed, Av Prof Lineu Prestes,1730 Cidade Univ, BR-05508900 Sao Paulo, Brazil.	gpam@usp.br	ZAGO, MARCO A/E-9442-2017; De Carvalho, Daniel/F-4794-2011; de Castro, Fabiola Attie/D-4693-2012; Mendes, Gustavo P Amarante/C-8187-2012; Jacysyn, Jacqueline/C-9960-2012; De Carvalho, Daniel D/J-5503-2014	De Carvalho, Daniel/0000-0003-0771-2265; de Castro, Fabiola Attie/0000-0003-3347-5873; Mendes, Gustavo P Amarante/0000-0002-7851-6205; De Carvalho, Daniel D/0000-0002-8572-5259; Oliveira Pereira, Welbert/0000-0001-9546-1317	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP-Brazil); FAPESP; Brazilian Research Council (CNPq-Brazil)	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP-Brazil)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Brazilian Research Council (CNPq-Brazil)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	DDC, JMGL, WOP and AEBBS were recipients of fellowships from the Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP-Brazil). This work was supported by grants from FAPESP and from the Brazilian Research Council (CNPq-Brazil). We thank Drs Phillippa Taberlay, Jueng Soo You and Theresa Kelly for their critical review of the paper.	Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; AmaranteMendes GP, 1997, CELL DEATH DIFFER, V4, P548, DOI 10.1038/sj.cdd.4400276; BEDI A, 1994, BLOOD, V83, P2038; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Brumatti G, 2003, FEBS LETT, V541, P57, DOI 10.1016/S0014-5793(03)00299-0; Bueno-da-Silva AEB, 2003, CELL DEATH DIFFER, V10, P592, DOI 10.1038/sj.cdd.4401210; Clarke N, 2004, EMBO J, V23, P3051, DOI 10.1038/sj.emboj.7600302; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; Daniels RA, 2005, CELL RES, V15, P430, DOI 10.1038/sj.cr.7290311; Epping MT, 2007, P NATL ACAD SCI USA, V104, P17777, DOI 10.1073/pnas.0702518104; Epping MT, 2006, CANCER RES, V66, P10639, DOI 10.1158/0008-5472.CAN-06-2522; Epping MT, 2005, CELL, V122, P835, DOI 10.1016/j.cell.2005.07.003; Haqq C, 2005, P NATL ACAD SCI USA, V102, P6092, DOI 10.1073/pnas.0501564102; Hoek KS, 2006, PIGM CELL RES, V19, P290, DOI 10.1111/j.1600-0749.2006.00322.x; Ikeda H, 1997, IMMUNITY, V6, P199, DOI 10.1016/S1074-7613(00)80426-4; Insinga A, 2005, NAT MED, V11, P71, DOI 10.1038/nm1160; Kikuchi S, 2007, CANCER SCI, V98, P1949, DOI 10.1111/j.1349-7006.2007.00623.x; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; McGahon AJ, 1997, CELL DEATH DIFFER, V4, P95, DOI 10.1038/sj.cdd.4400213; Melo JV, 2007, NAT REV CANCER, V7, P441, DOI 10.1038/nrc2147; Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161; Nimmanapalli R, 2001, CLIN CANCER RES, V7, P350; Oberthuer A, 2004, CLIN CANCER RES, V10, P4307, DOI 10.1158/1078-0432.CCR-03-0813; Popnikolov NK, 2006, APPL IMMUNOHISTO M M, V14, P161, DOI 10.1097/01.pai.0000157905.30872.9f; Proto-Siqueira R, 2006, LEUKEMIA RES, V30, P1333, DOI 10.1016/j.leukres.2006.02.031; Radich JP, 2006, P NATL ACAD SCI USA, V103, P2794, DOI 10.1073/pnas.0510423103; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Sawyers CL, 1997, BAILLIERE CLIN HAEM, V10, P223, DOI 10.1016/S0950-3536(97)80004-2; Schmaltz C, 2002, NAT MED, V8, P1433, DOI 10.1038/nm797; Sedger LM, 2002, EUR J IMMUNOL, V32, P2246, DOI 10.1002/1521-4141(200208)32:8<2246::AID-IMMU2246>3.0.CO;2-6; Souza-Fagundes EM, 2003, EXP CELL RES, V290, P420, DOI 10.1016/S0014-4827(03)00350-1; Stearman RS, 2005, AM J PATHOL, V167, P1763, DOI 10.1016/S0002-9440(10)61257-6; Steinbach D, 2007, CANCER GENET CYTOGEN, V177, P51, DOI 10.1016/j.cancergencyto.2007.05.011; Tajeddine N, 2008, LEUKEMIA LYMPHOMA, V49, P1123, DOI 10.1080/10428190802035933; Takeda K, 2004, J EXP MED, V199, P437, DOI 10.1084/jem.20031457; Takeda K, 2001, CELL IMMUNOL, V214, P194, DOI 10.1006/cimm.2001.1896; Takeda K, 2002, J EXP MED, V195, P161, DOI 10.1084/jem.20011171; Umlauf David, 2004, Methods Mol Biol, V287, P99; Uno K, 2003, BLOOD, V101, P3658, DOI 10.1182/blood-2002-06-1770; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vigneswaran N, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-108; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Watari K, 2000, FEBS LETT, V466, P367, DOI 10.1016/S0014-5793(00)01112-1; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yong ASM, 2008, LEUKEMIA, V22, P1721, DOI 10.1038/leu.2008.161	49	42	42	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	2					223	233		10.1038/onc.2010.409	http://dx.doi.org/10.1038/onc.2010.409			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709LG	20838376				2022-12-17	WOS:000286438900010
J	Kalra, J; Sutherland, BW; Stratford, AL; Dragowska, W; Gelmon, KA; Dedhar, S; Dunn, SE; Bally, MB				Kalra, J.; Sutherland, B. W.; Stratford, A. L.; Dragowska, W.; Gelmon, K. A.; Dedhar, S.; Dunn, S. E.; Bally, M. B.			Suppression of Her2/neu expression through ILK inhibition is regulated by a pathway involving TWIST and YB-1	ONCOGENE			English	Article						integrin-linked kinase; QLT0267; Her2/neu; YB-1; TWIST; STAT-3	INTEGRIN-LINKED KINASE; BOX-BINDING PROTEIN-1; GROWTH-FACTOR RECEPTOR; EPITHELIAL-MESENCHYMAL TRANSITION; HUMAN BREAST-CANCER; ANCHORAGE-INDEPENDENT GROWTH; GLYCOGEN-SYNTHASE KINASE; SQUAMOUS-CELL CARCINOMA; POOR PATIENT SURVIVAL; HUMAN COLON-CANCER	In a previous study it was found that the therapeutic effects of QLT0267, a small molecule inhibitor of integrin-linked kinase (ILK), were influenced by Her2/neu expression. To understand how inhibition or silencing of ILK influences Her2/neu expression, Her2/neu signaling was evaluated in six Her2/neu-positive breast cancer cell lines (LCC6(Her2), MCF7(Her2), SKBR3, BT474, JIMT-1 and KPL-4). Treatment with QLT0267 engendered suppression (32-87%) of total Her2/neu protein in these cells. Suppression of Her2/neu was also observed following small interfering RNA-mediated silencing of ILK expression. Time course studies suggest that ILK inhibition or silencing caused transient decreases in P-AKT(ser473), which were not temporally related to Her2/neu down-regulation. Attenuation of ILK activity or expression was, however, associated with decreases in YB-1 (Y-box binding protein-1) protein and transcript levels. YB-1 is a known transcriptional regulator of Her2/neu expression, and in this study it is demonstrated that inhibition of ILK activity using QLT0267 decreased YB-1 promoter activity by 50.6%. ILK inhibition was associated with changes in YB-1 localization, as reflected by localization of cytoplasmic YB-1 into stress granules. ILK inhibition also suppressed TWIST (a regulator of YB-1 expression) protein expression. To confirm the role of ILK on YB-1 and TWIST, cells were engineered to overexpress ILK. This was associated with a fourfold increase in the level of YB-1 in the nucleus, and a 2- and 1.5-fold increase in TWIST and Her2/neu protein levels, respectively. Taken together, these data indicate that ILK regulates the expression of Her2/neu through TWIST and YB-1, lending support to the use of ILK inhibitors in the treatment of aggressive Her2/neu-positive tumors. Oncogene (2010) 29, 6343-6356; doi:10.1038/onc.2010.366; published online 13 September 2010	[Kalra, J.] Univ British Columbia, British Columbia Canc Agcy, Dept Expt Therapeut, Vancouver, BC V5Z 1L3, Canada; [Kalra, J.; Bally, M. B.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1L3, Canada; [Stratford, A. L.; Dunn, S. E.] Women & Childrens Hosp, Child & Family Res Inst, Vancouver, BC, Canada; [Dedhar, S.] Univ British Columbia, BC Canc Agcy, Dept Integrat Biol, Vancouver, BC V5Z 1L3, Canada; [Dedhar, S.] Univ British Columbia, Dept Biochem, Vancouver, BC V5Z 1L3, Canada; [Dunn, S. E.] Univ British Columbia, Dept Pediat, Vancouver, BC V5Z 1L3, Canada; [Bally, M. B.] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC V5Z 1L3, Canada; [Bally, M. B.] Ctr Drug Res & Dev, Vancouver, BC, Canada	British Columbia Cancer Agency; University of British Columbia; University of British Columbia; Child & Family Research Institute; British Columbia Cancer Agency; University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia	Kalra, J (corresponding author), Univ British Columbia, British Columbia Canc Agcy, Dept Expt Therapeut, 675 W 10th Ave,5th Floor, Vancouver, BC V5Z 1L3, Canada.	jkalra@bccrc.ca		Dedhar, Shoukat/0000-0003-4355-1657; Bally, Marcel/0000-0002-1994-4787	Canadian Breast Cancer Research Alliance (CBCRA); Canadian Breast Cancer Foundation; Pacific Century Graduate Scholarship; University of British Columbia University	Canadian Breast Cancer Research Alliance (CBCRA); Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS)); Pacific Century Graduate Scholarship; University of British Columbia University	Funding for this research was from the Canadian Breast Cancer Research Alliance (CBCRA) and the Canadian Breast Cancer Foundation (BC/Yukon Chapter). JK is the recipient of the Pacific Century Graduate Scholarship and the University of British Columbia University Graduate Fellowship. We acknowledge BC Cancer Agency's Cancer Integrative Oncology Department (Mykola Maydan, Paul MacDonald and Iveta Dobreva) as well as Hong Yan for excellent management of the departmental tissue culture facilities.	Ahmed N, 2003, J PATHOL, V201, P229, DOI 10.1002/path.1441; Anderson P, 2009, CURR BIOL, V19, pR397, DOI 10.1016/j.cub.2009.03.013; Anderson P, 2009, NAT REV MOL CELL BIO, V10, P430, DOI 10.1038/nrm2694; Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005; Bader AG, 2008, ONCOGENE, V27, P1179, DOI 10.1038/sj.onc.1210719; Balagopal V, 2009, CURR OPIN CELL BIOL, V21, P403, DOI 10.1016/j.ceb.2009.03.005; Basaki Y, 2007, ONCOGENE, V26, P2736, DOI 10.1038/sj.onc.1210084; Bergmann S, 2005, CANCER RES, V65, P4078, DOI 10.1158/0008-5472.CAN-04-4056; Berquin IM, 2005, ONCOGENE, V24, P3177, DOI 10.1038/sj.onc.1208504; Bravou V, 2006, J PATHOL, V208, P91, DOI 10.1002/path.1860; Bravou V, 2003, BRIT J CANCER, V89, P2340, DOI 10.1038/sj.bjc.6601482; Cates JMM, 2009, PANCREAS, V38, pE1, DOI 10.1097/MPA.0b013e3181878b7f; Chambers AF, 2009, CANCER RES, V69, P5292, DOI 10.1158/0008-5472.CAN-09-1528; Cheng GZ, 2008, J BIOL CHEM, V283, P14665, DOI 10.1074/jbc.M707429200; Cheng GZ, 2008, CANCER RES, V68, P957, DOI 10.1158/0008-5472.CAN-07-5067; Chernov KG, 2008, FEBS LETT, V582, P2875, DOI 10.1016/j.febslet.2008.07.019; Chernov KG, 2009, J BIOL CHEM, V284, P36569, DOI 10.1074/jbc.M109.042879; Chernov Konstantin G., 2008, BMC Biochemistry, V9, P23, DOI 10.1186/1471-2091-9-23; Coles LS, 2005, FEBS LETT, V579, P5372, DOI 10.1016/j.febslet.2005.08.075; Dai DL, 2003, CLIN CANCER RES, V9, P4409; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Dragowska WH, 2004, MOL CANCER RES, V2, P606; Dupont J, 2001, J BIOL CHEM, V276, P26699, DOI 10.1074/jbc.M102664200; Duxbury MS, 2005, CLIN CANCER RES, V11, P3433, DOI 10.1158/1078-0432.CCR-04-1510; Edwards LA, 2008, MOL CANCER THER, V7, P59, DOI 10.1158/1535-7163.MCT-07-0329; Elias MC, 2005, NEOPLASIA, V7, P824, DOI 10.1593/neo.04352; Evdokimova V, 2006, MOL CELL BIOL, V26, P277, DOI 10.1128/MCB.26.1.277-292.2006; Evdokimova V, 2006, CELL CYCLE, V5, P1143, DOI 10.4161/cc.5.11.2784; Flugel D, 2007, MOL CELL BIOL, V27, P3253, DOI 10.1128/MCB.00015-07; Fuchs BC, 2008, CANCER RES, V68, P2391, DOI 10.1158/0008-5472.CAN-07-2460; Fujii T, 2008, CANCER RES, V68, P1504, DOI 10.1158/0008-5472.CAN-07-2362; Gort EH, 2008, ONCOGENE, V27, P1501, DOI 10.1038/sj.onc.1210795; Graff JR, 2001, CLIN CANCER RES, V7, P1987; Hannigan GE, 1997, GENOMICS, V42, P177, DOI 10.1006/geno.1997.4719; Hasselblatt M, 2009, CANCER RES, V69, P2219, DOI 10.1158/0008-5472.CAN-08-3176; Hu L, 2008, CANCER RES, V68, P4296, DOI 10.1158/0008-5472.CAN-08-0067; Ito R, 2003, VIRCHOWS ARCH, V442, P118, DOI 10.1007/s00428-002-0718-6; Kajiyama H, 2007, INT J ONCOL, V31, P277; Kalra J, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2252; Karreth F, 2004, CANCER BIOL THER, V3, P1058, DOI 10.4161/cbt.3.11.1302; Kashihara M, 2009, J THORAC ONCOL, V4, P1066, DOI 10.1097/JTO.0b013e3181ae2828; Kedersha N, 2007, METHOD ENZYMOL, V431, P61, DOI 10.1016/S0076-6879(07)31005-7; Kohno K, 2003, BIOESSAYS, V25, P691, DOI 10.1002/bies.10300; Kumar AS, 2004, ONCOGENE, V23, P3454, DOI 10.1038/sj.onc.1207473; Kwok WK, 2005, CANCER RES, V65, P5153, DOI 10.1158/0008-5472.CAN-04-3785; Leonessa F, 1996, BRIT J CANCER, V73, P154, DOI 10.1038/bjc.1996.29; Li YJ, 2007, J AM SOC NEPHROL, V18, P2534, DOI 10.1681/ASN.2007030315; Li YJ, 2003, J CLIN INVEST, V112, P503, DOI 10.1172/JCI200317913; Ling XY, 2005, CANCER RES, V65, P2532, DOI 10.1158/0008-5472.CAN-04-2425; Lo HW, 2007, CANCER RES, V67, P9066, DOI 10.1158/0008-5472.CAN-07-0575; Luo GQ, 2008, WORLD J GASTROENTERO, V14, P2487, DOI 10.3748/wjg.14.2487; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Martin TA, 2005, ANN SURG ONCOL, V12, P488, DOI 10.1245/ASO.2005.04.010; Matsuo N, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-240; McDonald PC, 2008, J CELL SCI, V121, P3121, DOI 10.1242/jcs.017996; McDonald PC, 2008, CANCER RES, V68, P1618, DOI 10.1158/0008-5472.CAN-07-5869; Mironchik Y, 2005, CANCER RES, V65, P10801, DOI 10.1158/0008-5472.CAN-05-0712; Mottet D, 2003, J BIOL CHEM, V278, P31277, DOI 10.1074/jbc.M300763200; Niu RF, 2007, J EXP CLIN CANC RES, V26, P385; Obara S, 2004, CANCER LETT, V208, P115, DOI 10.1016/j.canlet.2003.11.020; Oda Y, 2007, CANCER SCI, V98, P1020, DOI 10.1111/j.1349-7006.2007.00492.x; Oloumi A, 2006, ONCOGENE, V25, P7747, DOI 10.1038/sj.onc.1209752; Oloumi A, 2004, BBA-MOL CELL RES, V1691, P1, DOI 10.1016/j.bbamcr.2003.12.002; OZER J, 1990, J BIOL CHEM, V265, P22143; Peinado H, 2008, NAT CELL BIOL, V10, P253, DOI 10.1038/ncb0308-253; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2003, CANCER METAST REV, V22, P375, DOI 10.1023/A:1023777013659; Pham CG, 2007, MOL CELL BIOL, V27, P3920, DOI 10.1128/MCB.01219-06; Pontier SM, 2010, ONCOGENE, V29, P3374, DOI 10.1038/onc.2010.86; Pore N, 2006, MOL CANCER RES, V4, P471, DOI 10.1158/1541-7786.MCR-05-0234; Puisieux A, 2006, BRIT J CANCER, V94, P13, DOI 10.1038/sj.bjc.6602876; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Sawai H, 2006, ONCOGENE, V25, P3237, DOI 10.1038/sj.onc.1209356; Shiota M, 2008, ONCOGENE, V27, P5543, DOI 10.1038/onc.2008.176; Shiota M, 2008, CANCER RES, V68, P98, DOI 10.1158/0008-5472.CAN-07-2981; Shiota M, 2009, CANCER RES, V69, P3148, DOI 10.1158/0008-5472.CAN-08-2334; Skabkina O V, 2004, Dokl Biochem Biophys, V395, P93, DOI 10.1023/B:DOBI.0000025554.28703.bf; Skabkina OV, 2005, MOL CELL BIOL, V25, P3317, DOI 10.1128/MCB.25.8.3317-3323.2005; Skabkina OV, 2003, J BIOL CHEM, V278, P18191, DOI 10.1074/jbc.M209073200; Stratford AL, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1767; Stratford AL, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2202; Sutherland BW, 2005, ONCOGENE, V24, P4281, DOI 10.1038/sj.onc.1208590; Takanami I, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-1; Takemoto S, 2009, BRIT J CANCER, V101, P967, DOI 10.1038/sj.bjc.6605212; To K, 2007, MOL PHARMACOL, V72, P641, DOI 10.1124/mol.107.036111; Troussard AA, 2006, CANCER RES, V66, P393, DOI 10.1158/0008-5472.CAN-05-2304; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; Valdes-Mora F, 2009, ANN SURG ONCOL, V16, P78, DOI 10.1245/s10434-008-0166-x; Verreault M, 2009, OLIGONUCLEOTIDES, V19, P129, DOI 10.1089/oli.2008.0157; Warburton C, 2004, CLIN CANCER RES, V10, P2512, DOI 10.1158/1078-0432.CCR-03-0244; Watanabe O, 2004, ANTICANCER RES, V24, P3851; White DE, 2001, ONCOGENE, V20, P7064, DOI 10.1038/sj.onc.1204910; Wu J, 2006, CANCER RES, V66, P4872, DOI 10.1158/0008-5472.CAN-05-3561; Yamasaki S, 2008, CURR OPIN CELL BIOL, V20, P222, DOI 10.1016/j.ceb.2008.01.013; Yang MH, 2008, CELL CYCLE, V7, P2090, DOI 10.4161/cc.7.14.6324; Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691; Yau CYF, 2005, CANCER RES, V65, P1497, DOI 10.1158/0008-5472.CAN-04-2940; Younes MN, 2007, ARCH OTOLARYNGOL, V133, P15, DOI 10.1001/archotol.133.1.15; Zhang XM, 2007, INT J CANCER, V120, P1891, DOI 10.1002/ijc.22489; Zhuo WL, 2008, BIOCHEM BIOPH RES CO, V369, P1098, DOI 10.1016/j.bbrc.2008.02.143	100	42	45	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	48					6343	6356		10.1038/onc.2010.366	http://dx.doi.org/10.1038/onc.2010.366			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	688SW	20838384	Green Published, hybrid			2022-12-17	WOS:000284874700005
J	Lu, C; Everhart, L; Tilan, J; Kuo, L; Sun, CCJ; Munivenkatappa, RB; Jonsson-Rylander, AC; Sun, J; Kuan-Celarier, A; Li, L; Abe, K; Zukowska, Z; Toretsky, JA; Kitlinska, J				Lu, C.; Everhart, L.; Tilan, J.; Kuo, L.; Sun, C-C J.; Munivenkatappa, R. B.; Jonsson-Rylander, A.-C.; Sun, J.; Kuan-Celarier, A.; Li, L.; Abe, K.; Zukowska, Z.; Toretsky, J. A.; Kitlinska, J.			Neuropeptide Y and its Y2 receptor: potential targets in neuroblastoma therapy	ONCOGENE			English	Article						neuropeptide Y; neuroblastoma; angiogenesis	BAX-DEPENDENT APOPTOSIS; SMOOTH-MUSCLE-CELLS; INDUCED ANGIOGENESIS; NEURO-BLASTOMA; ADRENAL-GLAND; YY2 RECEPTOR; EXPRESSION; BIM; TUMORS; PHOSPHORYLATION	Neuroblastomas are pediatric tumors that develop from sympathetic precursors and express neuronal proteins, such as neuropeptide Y (NPY). NPY is a sympathetic neurotransmitter acting via multiple receptors (Y1-Y5R). Both NPY and Y2Rs are commonly expressed in neuroblastoma cell lines and tissues. The peptide secreted from neuroblastomas stimulates tumor cell proliferation and angiogenesis. As both processes are Y2R-mediated, the aim of this study was to assess Y2R as a potential therapeutic target for neuroblastoma. In vitro, Y2R antagonist (BIIE0246) prevented activation of p44/42 mitogen-activated protein kinase (MAPK) induced by endogenous NPY, which resulted in decreased proliferation and induction of Bim-mediated apoptosis. Similar growth-inhibitory effects were achieved with NPY small interfering RNA (siRNA) and Y2R siRNA. In vivo, Y2R antagonist significantly inhibited growth of SK-N-BE(2) and SK-N-AS xenografts, which was associated with decreased activation of p44/42 MAPK, as well as reduced proliferation (Ki67) and increased apoptosis (TdT-mediated dUTP nick end labeling; TUNEL). The Y2R antagonist also exerted an antiangiogenic effect. In vitro, it reduced the proliferation of endothelial cells induced by neuroblastoma-conditioned media. Consequently, the Y2R antagonist-treated xenografts had decreased vascularization and a high degree of focal fibrosis. In human neuroblastoma tissues, the expression of Y2R was observed in both tumor and endothelial cells, while NPY was predominantly expressed in neuroblastoma cells. In summary, Y2R is a promising new target for neuroblastoma therapy affecting both cancer cells and tumor vasculature. Oncogene (2010) 29, 5630-5642; doi:10.1038/onc.2010.301; published online 2 August 2010	[Lu, C.; Everhart, L.; Tilan, J.; Kuo, L.; Kuan-Celarier, A.; Li, L.; Zukowska, Z.; Kitlinska, J.] Georgetown Univ, Dept Physiol & Biophys, Washington, DC 20057 USA; [Sun, C-C J.] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; [Munivenkatappa, R. B.] Univ Maryland, Sch Med, Dept Surg, Div Transplantat, Baltimore, MD 21201 USA; [Jonsson-Rylander, A.-C.] AstraZeneca, Dept Biosci, Molndal, Sweden; [Sun, J.] NIH, Dept Crit Care Med, Bethesda, MD 20892 USA; [Abe, K.] NHLBI, NIH, Bethesda, MD 20892 USA; [Toretsky, J. A.] Georgetown Univ, Dept Oncol, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA	Georgetown University; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; AstraZeneca; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Georgetown University	Kitlinska, J (corresponding author), Georgetown Univ, Dept Physiol & Biophys, BSB 231A,3900 Reservoir Rd NW, Washington, DC 20057 USA.	jbk4@georgetown.edu	Lu, Congyi/G-3984-2013		NIH [1R01CA123211-01]; Children's Cancer Foundation (Baltimore, MD, USA); NATIONAL CANCER INSTITUTE [R01CA123211] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Children's Cancer Foundation (Baltimore, MD, USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH Grant 1R01CA123211-01 and funding from Children's Cancer Foundation (Baltimore, MD, USA) to Joanna Kitlinska. The authors would like to thank John Styliaris and David Hur for help in performing experiments. We also thank the Flow Cytometry/Cell Sorting Shared Resources of Lombardi Comprehensive Cancer Center for technical assistance and Children's Oncology Group for providing human samples.	BIEDLER JL, 1978, CANCER RES, V38, P3751; Chen YY, 2008, NATURE, V455, P971, DOI 10.1038/nature07399; COHEN PS, 1990, CANCER RES, V50, P6055; Dotsch J, 1998, REGUL PEPTIDES, V75-6, P185, DOI 10.1016/S0167-0115(98)00067-6; Ekstrand AJ, 2003, P NATL ACAD SCI USA, V100, P6033, DOI 10.1073/pnas.1135965100; George RE, 2008, NATURE, V455, P975, DOI 10.1038/nature07397; Hansel DE, 2001, NATURE, V410, P940, DOI 10.1038/35073601; Jonsson-Rylander AC, 2003, PEPTIDES, V24, P255, DOI 10.1016/S0196-9781(03)00041-X; Kitlinska J, 2005, CANCER RES, V65, P1719, DOI 10.1158/0008-5472.CAN-04-2192; Kitlinska J, 2002, PEPTIDES, V23, P71, DOI 10.1016/S0196-9781(01)00581-2; KOGNER P, 1994, ACTA PAEDIATR, V83, P423, DOI 10.1111/j.1651-2227.1994.tb18134.x; Korner M, 2004, CLIN CANCER RES, V10, P8426, DOI 10.1158/1078-0432.CCR-04-0821; Koulu M, 2004, ANN MED, V36, P232, DOI 10.1080/07853890410031236; Lee EW, 2003, J CLIN INVEST, V111, P1853, DOI 10.1172/JCI200316929; Lee EW, 2003, PEPTIDES, V24, P99, DOI 10.1016/S0196-9781(02)00281-4; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Li Z, 2007, CELL DEATH DIFFER, V14, P318, DOI 10.1038/sj.cdd.4401983; Magni P, 2000, NEUROPHARMACOLOGY, V39, P1628, DOI 10.1016/S0028-3908(99)00231-2; Malmstrom RE, 2001, BRIT J PHARMACOL, V133, P1073, DOI 10.1038/sj.bjp.0704171; Maris JM, 2005, CURR OPIN PEDIATR, V17, P7, DOI 10.1097/01.mop.0000150631.60571.89; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Meitar D, 1996, J CLIN ONCOL, V14, P405, DOI 10.1200/JCO.1996.14.2.405; Mosse YP, 2008, NATURE, V455, P930, DOI 10.1038/nature07261; Movafagh S, 2006, FASEB J, V20, P1924, DOI 10.1096/fj.05-4770fje; Naveilhan P, 1999, NAT MED, V5, P1188, DOI 10.1038/13514; OHARE MMT, 1989, CANCER RES, V49, P7015; OHARE MMT, 1989, CANCER RES, V49, P7010; Park JR, 2008, PEDIATR CLIN N AM, V55, P97, DOI 10.1016/j.pcl.2007.10.014; Pons J, 2003, CAN J PHYSIOL PHARM, V81, P177, DOI 10.1139/Y02-166; Pons J, 2008, CAN J PHYSIOL PHARM, V86, P438, DOI [10.1139/Y08-054, 10.1139/y08-054]; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Ribattia Domenico, 2005, Cancer Treatment Reviews, V31, P27, DOI 10.1016/j.ctrv.2004.09.006; Rossler J, 2008, EUR J CANCER, V44, P1645, DOI 10.1016/j.ejca.2008.05.015; Sheriff' S, 1998, REGUL PEPTIDES, V75-6, P309, DOI 10.1016/S0167-0115(98)00083-4; Shusterman S, 2005, CANCER LETT, V228, P171, DOI 10.1016/j.canlet.2005.01.049; Uddman R, 2002, PEPTIDES, V23, P927, DOI 10.1016/S0196-9781(02)00003-7; Wassberg E, 1999, UPSALA J MED SCI, V104, P1; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Yoon HZ, 2002, CLIN EXP OPHTHALMOL, V30, P424, DOI 10.1046/j.1442-9071.2002.00573.x; Zukowska-Grojec Z, 1998, CIRC RES, V83, P187, DOI 10.1161/01.RES.83.2.187; ZUKOWSKAGROJEC Z, 1993, PEPTIDES, V14, P263, DOI 10.1016/0196-9781(93)90040-N	42	42	44	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2010	29	41					5630	5642		10.1038/onc.2010.301	http://dx.doi.org/10.1038/onc.2010.301			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FX	20676138	Green Accepted			2022-12-17	WOS:000282946900009
J	Improgo, MRD; Scofield, MD; Tapper, AR; Gardner, PD				Improgo, M. R. D.; Scofield, M. D.; Tapper, A. R.; Gardner, P. D.			From smoking to lung cancer: the CHRNA5/A3/B4 connection	ONCOGENE			English	Review						nicotine addiction; lung cancer; nicotinic acetylcholine receptors; CHRNA5/A3/B4 gene cluster	NICOTINIC ACETYLCHOLINE-RECEPTOR; ALPHA-3 GENE PROMOTER; SUBUNIT GENE; MICE LACKING; TRANSCRIPTIONAL REGULATION; SUSCEPTIBILITY LOCUS; BETA-4 SUBUNIT; GROWTH-FACTOR; TUMOR-GROWTH; PHYSIOLOGICAL DIVERSITY	Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels that modulate key physiological processes ranging from neurotransmission to cancer signaling. These receptors are activated by the neurotransmitter, acetylcholine, and the tobacco alkaloid, nicotine. Recently, the gene cluster encoding the alpha 3, alpha 5 and beta 4 nAChR subunits received heightened interest after a succession of linkage analyses and association studies identified multiple single-nucleotide polymorphisms in these genes that are associated with an increased risk for nicotine dependence and lung cancer. It is not clear whether the risk for lung cancer is direct or an effect of nicotine dependence, as evidence for both scenarios exist. In this study, we summarize the body of work implicating nAChRs in the pathogenesis of lung cancer, with special focus on the clustered nAChR subunits and their emerging role in this disease state. Oncogene (2010) 29, 4874-4884; doi: 10.1038/onc.2010.256; published online 28 June 2010	[Improgo, M. R. D.; Scofield, M. D.; Tapper, A. R.; Gardner, P. D.] Univ Massachusetts, Sch Med, Dept Psychiat, Brudnick Neuropsychiat Res Inst, Worcester, MA 01604 USA	University of Massachusetts System; University of Massachusetts Worcester	Gardner, PD (corresponding author), Univ Massachusetts, Sch Med, Dept Psychiat, Brudnick Neuropsychiat Res Inst, 303 Belmont St, Worcester, MA 01604 USA.	paul.gardner@umassmed.edu		Scofield, Michael/0000-0002-2330-6999	National Institutes of Health [NS030243, AA017656]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030243] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA017656] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	Work in the authors' laboratories is supported in part by grants NS030243 (PDG) and AA017656 (ART) from the National Institutes of Health.	Albuquerque EX, 2009, PHYSIOL REV, V89, P73, DOI 10.1152/physrev.00015.2008; American Cancer Society, 2009, CANC FACTS FIG 2009; Amos CI, 2008, NAT GENET, V40, P616, DOI 10.1038/ng.109; Arneric SP, 2007, BIOCHEM PHARMACOL, V74, P1092, DOI 10.1016/j.bcp.2007.06.033; Arredondo J, 2001, LAB INVEST, V81, P1653, DOI 10.1038/labinvest.3780379; Arredondo J, 2006, FASEB J, V20, P2093, DOI 10.1096/fj.06-6191com; Arredondo J, 2006, J CANCER RES CLIN, V132, P653, DOI 10.1007/s00432-006-0113-9; BALL DW, 1993, P NATL ACAD SCI USA, V90, P5648, DOI 10.1073/pnas.90.12.5648; Battaglioli E, 1998, J NEUROCHEM, V71, P1261; Benfante R, 2007, J BIOL CHEM, V282, P13290, DOI 10.1074/jbc.M608616200; Berrettine W, 2008, MOL PSYCHIATR, V13, P368, DOI 10.1038/sj.mp.4002154; Bierut LJ, 2008, AM J PSYCHIAT, V165, P1163, DOI 10.1176/appi.ajp.2008.07111711; Bigger CB, 1997, J BIOL CHEM, V272, P25976, DOI 10.1074/jbc.272.41.25976; Blanchet MR, 2004, AM J RESP CRIT CARE, V169, P903, DOI 10.1164/rccm.200210-1154OC; BOULTER J, 1990, J BIOL CHEM, V265, P4472; Boyd RT, 1997, CRIT REV TOXICOL, V27, P299, DOI 10.3109/10408449709089897; Bruschweiler-Li L, 2010, NEUROSCIENCE, V166, P864, DOI 10.1016/j.neuroscience.2010.01.026; CALABRESI P, 1989, BRIT J PHARMACOL, V98, P135, DOI 10.1111/j.1476-5381.1989.tb16873.x; Campos-Caro A, 1999, J BIOL CHEM, V274, P4693, DOI 10.1074/jbc.274.8.4693; Campos-Caro A, 2001, DNA CELL BIOL, V20, P657, DOI 10.1089/104454901753340640; Caporaso N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004653; Conklin BS, 2002, AM J PATHOL, V160, P413, DOI 10.1016/S0002-9440(10)64859-6; Conti-Fine BM, 2000, EUR J PHARMACOL, V393, P279, DOI 10.1016/S0014-2999(00)00036-4; Cooke JP, 2008, TRENDS CARDIOVAS MED, V18, P247, DOI 10.1016/j.tcm.2008.11.007; CORRIGALL WA, 1989, PHARMACOL BIOCHEM BE, V33, P559, DOI 10.1016/0091-3057(89)90387-0; CORRIGALL WA, 1991, PSYCHOPHARMACOLOGY, V104, P171, DOI 10.1007/BF02244174; CORRIGALL WA, 1992, PSYCHOPHARMACOLOGY, V107, P285, DOI 10.1007/BF02245149; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; CORRIVEAU RA, 1993, J NEUROSCI, V13, P2662, DOI 10.1523/JNEUROSCI.13-06-02662.1993; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; Dani JA, 2001, PHARMACOL BIOCHEM BE, V70, P439, DOI 10.1016/S0091-3057(01)00652-9; Dani JA, 2007, ANNU REV PHARMACOL, V47, P699, DOI 10.1146/annurev.pharmtox.47.120505.105214; Dasgupta P, 2006, CELL CYCLE, V5, P2324, DOI 10.4161/cc.5.20.3366; Davis R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007524; De Biasi M, 2008, EXP BIOL MED, V233, P917, DOI 10.3181/0712-MR-355; Di Chiara G, 2000, EUR J PHARMACOL, V393, P295, DOI 10.1016/S0014-2999(00)00122-9; DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274; Du Q, 1998, J BIOL CHEM, V273, P19877, DOI 10.1074/jbc.273.31.19877; Du Q, 1997, J BIOL CHEM, V272, P14990, DOI 10.1074/jbc.272.23.14990; Egleton RD, 2008, TRENDS PHARMACOL SCI, V29, P151, DOI 10.1016/j.tips.2007.12.006; ELGOYHEN AB, 1994, CELL, V79, P705, DOI 10.1016/0092-8674(94)90555-X; Elgoyhen AB, 2001, P NATL ACAD SCI USA, V98, P3501, DOI 10.1073/pnas.051622798; Falvella FS, 2009, CLIN CANCER RES, V15, P1837, DOI 10.1158/1078-0432.CCR-08-2107; Flora A, 2000, J NEUROCHEM, V75, P18, DOI 10.1046/j.1471-4159.2000.0750018.x; Flora A, 2000, EUR J PHARMACOL, V393, P85, DOI 10.1016/S0014-2999(00)00040-6; Freathy RM, 2009, HUM MOL GENET, V18, P2922, DOI 10.1093/hmg/ddp216; Fucile S, 2004, CELL CALCIUM, V35, P1, DOI 10.1016/j.ceca.2003.08.006; Gahring LC, 2005, AAPS J, V7, pE885, DOI 10.1208/aapsj070486; Gahring LC, 2004, J COMP NEUROL, V468, P334, DOI 10.1002/cne.10943; Gerzanich V, 1998, J PHARMACOL EXP THER, V286, P311; Gerzanich V, 1997, MOL PHARMACOL, V51, P320, DOI 10.1124/mol.51.2.320; Gotti C, 2006, TRENDS PHARMACOL SCI, V27, P482, DOI 10.1016/j.tips.2006.07.004; Grando SA, 2008, J PHARMACOL SCI, V106, P174, DOI 10.1254/jphs.FM0070087; Greenbaum L, 2009, MOL PSYCHIATR, V14, P912, DOI 10.1038/mp.2009.59; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; HECHT SS, 1988, CARCINOGENESIS, V9, P875, DOI 10.1093/carcin/9.6.875; Heeschen C, 2001, NAT MED, V7, P833, DOI 10.1038/89961; Hung RJ, 2008, NATURE, V452, P633, DOI 10.1038/nature06885; Improgo MRD, 2010, MOL CANCER RES, V8, P194, DOI 10.1158/1541-7786.MCR-09-0185; Jackman DM, 2005, LANCET, V366, P1385, DOI 10.1016/S0140-6736(05)67569-1; Jackson KJ, 2008, J PHARMACOL EXP THER, V325, P302, DOI 10.1124/jpet.107.132977; Jin ZH, 2004, J BIOL CHEM, V279, P23837, DOI 10.1074/jbc.M402566200; Jull BA, 2001, J CANCER RES CLIN, V127, P707; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; Kawashima K, 2003, LIFE SCI, V74, P675, DOI 10.1016/j.lfs.2003.09.037; Kenny PJ, 2001, PHARMACOL BIOCHEM BE, V70, P531, DOI 10.1016/S0091-3057(01)00651-7; Klink R, 2001, J NEUROSCI, V21, P1452, DOI 10.1523/JNEUROSCI.21-05-01452.2001; Lam DCL, 2007, CANCER RES, V67, P4638, DOI 10.1158/0008-5472.CAN-06-4628; LENOVERE N, 1995, J MOL EVOL, V40, P155, DOI 10.1007/BF00167110; Leonard S, 2001, Nicotine Tob Res, V3, P203; Levey MS, 1996, J NEUROSCI, V16, P6878; LEVEY MS, 1995, NEURON, V14, P153, DOI 10.1016/0896-6273(95)90249-X; Linnoila RI, 2000, CANCER RES, V60, P4005; Liu PY, 2008, JNCI-J NATL CANCER I, V100, P1326, DOI 10.1093/jnci/djn268; Liu Q, 1999, J NEUROSCI, V19, P9747; Liu Q, 2009, J NEUROSCI, V29, P918, DOI 10.1523/JNEUROSCI.3952-08.2009; LLOYD GK, 2000, WILLIAMS M EXP THER, V292, P461; Lustig LR, 2001, GENOMICS, V73, P272, DOI 10.1006/geno.2000.6503; Macklin KD, 1998, J PHARMACOL EXP THER, V287, P435; Mai HQ, 2003, J BIOL CHEM, V278, P1886, DOI 10.1074/jbc.M209044200; MANECKJEE R, 1990, P NATL ACAD SCI USA, V87, P3294, DOI 10.1073/pnas.87.9.3294; MANECKJEE R, 1994, CELL GROWTH DIFFER, V5, P1033; Marubio LM, 2003, EUR J NEUROSCI, V17, P1329, DOI 10.1046/j.1460-9568.2003.02564.x; Maskos U, 2005, NATURE, V436, P103, DOI 10.1038/nature03694; Maus ADJ, 1998, MOL PHARMACOL, V54, P779, DOI 10.1124/mol.54.5.779; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; McKeon A, 2009, ARCH NEUROL-CHICAGO, V66, P735, DOI 10.1001/archneurol.2009.78; Melnikova IN, 2000, NEUROPHARMACOLOGY, V39, P2615, DOI 10.1016/S0028-3908(00)00125-8; Melnikova IN, 2001, J BIOL CHEM, V276, P19040, DOI 10.1074/jbc.M010735200; Milton NGN, 1996, BIOCHEM J, V317, P419, DOI 10.1042/bj3170419; Nguyen VT, 2000, J DENT RES, V79, P939; NISELL M, 1994, SYNAPSE, V16, P36, DOI 10.1002/syn.890160105; Orr-Urtreger A, 2005, NEUROREPORT, V16, P1123, DOI 10.1097/00001756-200507130-00018; Paliwal A, 2010, CANCER RES, V70, P2779, DOI 10.1158/0008-5472.CAN-09-4550; PATRICK J, 1993, PROG BRAIN RES, V98, P113; Perry DC, 2002, J NEUROCHEM, V82, P468, DOI 10.1046/j.1471-4159.2002.00951.x; Picciotto MR, 1998, NATURE, V391, P173, DOI 10.1038/34413; Pidoplichko VI, 1997, NATURE, V390, P401, DOI 10.1038/37120; Pillai SG, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000421; Pons S, 2008, J NEUROSCI, V28, P12318, DOI 10.1523/JNEUROSCI.3918-08.2008; Pontieri FE, 1996, NATURE, V382, P255, DOI 10.1038/382255a0; Portugal GS, 2008, BEHAV BRAIN RES, V193, P1, DOI 10.1016/j.bbr.2008.05.006; Portugal GS, 2008, NEUROBIOL LEARN MEM, V89, P106, DOI 10.1016/j.nlm.2007.05.002; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUNTURIERI A, 2009, SHAPIRO DUBINETT SM, V101, P554; Quick MW, 1999, NEUROPHARMACOLOGY, V38, P769, DOI 10.1016/S0028-3908(99)00024-6; Richardson CE, 2001, GASTROENTEROLOGY, V121, P350, DOI 10.1053/gast.2001.26320; Role LW, 1996, NEURON, V16, P1077, DOI 10.1016/S0896-6273(00)80134-8; Romanelli MN, 2007, CHEMMEDCHEM, V2, P746, DOI 10.1002/cmdc.200600207; Rubin DT, 2000, EUR J GASTROEN HEPAT, V12, P855, DOI 10.1097/00042737-200012080-00004; Saccone NL, 2009, CANCER RES, V69, P6848, DOI 10.1158/0008-5472.CAN-09-0786; Saccone NL, 2009, AM J MED GENET B, V150B, P453, DOI 10.1002/ajmg.b.30828; Saccone SF, 2007, HUM MOL GENET, V16, P36, DOI 10.1093/hmg/ddl438; Salas R, 2004, J NEUROSCI, V24, P10035, DOI 10.1523/JNEUROSCI.1939-04.2004; Salas R, 2004, NEUROPHARMACOLOGY, V47, P401, DOI 10.1016/j.neuropharm.2004.05.002; Salas R, 2003, J NEUROSCI, V23, P6255; Salas R, 2007, NEUROPHARMACOLOGY, V53, P863, DOI 10.1016/j.neuropharm.2007.08.017; Salminen O, 2004, MOL PHARMACOL, V65, P1526, DOI 10.1124/mol.65.6.1526; Sartelet H, 2008, PATHOL RES PRACT, V204, P891, DOI 10.1016/j.prp.2008.05.006; Sasaki H, 2010, J SURG RES, V162, P75, DOI 10.1016/j.jss.2009.01.008; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Schlaelpfer IR, 2008, BIOL PSYCHIAT, V63, P1039, DOI 10.1016/j.biopsych.2007.10.024; SCHOEPFER R, 1990, NEURON, V5, P35, DOI 10.1016/0896-6273(90)90031-A; Schuller HM, 2009, NAT REV CANCER, V9, P195, DOI 10.1038/nrc2590; SCHULLER HM, 1992, CANCER RES, V52, pS2723; SCHULLER HM, 1989, BIOCHEM PHARMACOL, V38, P3439, DOI 10.1016/0006-2952(89)90112-3; Schuller HM, 1998, BIOCHEM PHARMACOL, V55, P1377, DOI 10.1016/S0006-2952(97)00651-5; Scofield MD, 2008, NEUROREPORT, V19, P687, DOI 10.1097/WNR.0b013e3282fbcef7; Sher E, 1998, ANN NY ACAD SCI, V841, P606, DOI 10.1111/j.1749-6632.1998.tb10993.x; Sherva R, 2008, ADDICTION, V103, P1544, DOI 10.1111/j.1360-0443.2008.02279.x; Shields PG, 2002, ONCOGENE, V21, P6870, DOI 10.1038/sj.onc.1205832; Shin VY, 2004, CARCINOGENESIS, V25, P2487, DOI 10.1093/carcin/bgh266; Shivji M, 2005, J BIOL CHEM, V280, P15219, DOI 10.1074/jbc.M413946200; Song PF, 2003, CANCER RES, V63, P214; Spindel ER, 2003, AM J PHYSIOL-LUNG C, V285, pL1201, DOI 10.1152/ajplung.00251.2003; Spitz Margaret R, 2008, J Natl Cancer Inst, V100, P1552, DOI 10.1093/jnci/djn363; Stevens VL, 2008, CANCER EPIDEM BIOMAR, V17, P3517, DOI 10.1158/1055-9965.EPI-08-0585; STOLERMAN IP, 1995, PSYCHOPHARMACOLOGY, V117, P2, DOI 10.1007/BF02245088; Sun XJ, 2009, CANCER RES, V69, P6445, DOI 10.1158/0008-5472.CAN-09-1001; Takahashi H, 2010, CANCER CELL, V17, P89, DOI 10.1016/j.ccr.2009.12.008; Taly A, 2009, NAT REV DRUG DISCOV, V8, P733, DOI 10.1038/nrd2927; Tapper AR, 2007, PHYSIOL GENOMICS, V31, P422, DOI 10.1152/physiolgenomics.00063.2007; Tapper AR, 2004, SCIENCE, V306, P1029, DOI 10.1126/science.1099420; Terzano S, 2000, J BIOL CHEM, V275, P41495, DOI 10.1074/jbc.M006197200; Thorgeirsson TE, 2008, NATURE, V452, P638, DOI 10.1038/nature06846; Turner JR, 2005, J NEUROSCI, V25, P9258, DOI 10.1523/JNEUROSCI.2112-05.2005; Unwin N, 2005, J MOL BIOL, V346, P967, DOI 10.1016/j.jmb.2004.12.031; Valor LM, 2002, J BIOL CHEM, V277, P8866, DOI 10.1074/jbc.M110454200; Vernino S, 1998, NEUROLOGY, V50, P1806, DOI 10.1212/WNL.50.6.1806; Vernino S, 2000, NEW ENGL J MED, V343, P847, DOI 10.1056/NEJM200009213431204; WACHOLDER S, 2008, CAPORASO N, V100, P1488; Wang N, 2002, J PHYSIOL-LONDON, V542, P347, DOI 10.1113/jphysiol.2001.013456; Wang NS, 2003, MOL PHARMACOL, V63, P574, DOI 10.1124/mol.63.3.574; Wang Y, 2001, MOL PHARMACOL, V60, P1201, DOI 10.1124/mol.60.6.1201; Weiss RB, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000125; Wessler I, 2008, BRIT J PHARMACOL, V154, P1558, DOI 10.1038/bjp.2008.185; West KA, 2003, J CLIN INVEST, V111, P81, DOI 10.1172/JCI200316147; Xin MG, 2005, J BIOL CHEM, V280, P10781, DOI 10.1074/jbc.M500084200; Xu W, 1999, P NATL ACAD SCI USA, V96, P5746, DOI 10.1073/pnas.96.10.5746; Xu W, 1999, J NEUROSCI, V19, P9298; Xu XH, 2006, MOL CELL BIOL, V26, P5636, DOI 10.1128/MCB.00456-06; YANG XD, 1994, J BIOL CHEM, V269, P10252; YANG XD, 1995, J BIOL CHEM, V270, P8514, DOI 10.1074/jbc.270.15.8514; Ye YN, 2004, J PHARMACOL EXP THER, V308, P66, DOI 10.1124/jpet.103.058321; Zeidler R, 2007, APOPTOSIS, V12, P1927, DOI 10.1007/s10495-007-0102-8; Zhang QZ, 2007, CLIN CANCER RES, V13, P4686, DOI 10.1158/1078-0432.CCR-06-2898; Zheng Y, 2007, AM J RESP CELL MOL, V37, P681, DOI 10.1165/rcmb.2007-0051OC; Zhou YF, 1998, J NEUROBIOL, V34, P164, DOI 10.1002/(SICI)1097-4695(19980205)34:2<164::AID-NEU6>3.0.CO;2-0; Zhu BQ, 2003, CANCER CELL, V4, P191, DOI 10.1016/S1535-6108(03)00219-8; Zoli M, 2002, J NEUROSCI, V22, P8785	170	42	45	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	35					4874	4884		10.1038/onc.2010.256	http://dx.doi.org/10.1038/onc.2010.256			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	646XP	20581870	Green Accepted, Green Published			2022-12-17	WOS:000281578700002
J	Li, H; Wang, W; Liu, X; Paulson, KE; Yee, AS; Zhang, X				Li, H.; Wang, W.; Liu, X.; Paulson, K. E.; Yee, A. S.; Zhang, X.			Transcriptional factor HBP1 targets P16(INK4A), upregulating its expression and consequently is involved in Ras-induced premature senescence	ONCOGENE			English	Article						Ras; HBP1; p16(INK4A); senescence; transformation	BREAST-CANCER CELLS; HUMAN MELANOCYTE; REPRESSOR HBP1; CYCLE ARREST; LIFE-SPAN; PROTEIN; KINASE; GENE; PATHWAY; TRANSFORMATION	Oncogene-mediated premature senescence has emerged as a potential tumor-suppressive mechanism in early cancer transitions. Many studies showed that Ras and p38 mitogen-activated protein kinase (MAPK) participate in premature senescence. Our previous work indicated that the HMG box-containing protein 1 (HBP1) transcription factor is involved in Ras- and p38 MAPK-induced premature senescence, but the mechanism of which has not yet been identified. Here, we showed that the p16(INK4A) cyclin-dependent kinase inhibitor is a novel target of HBP1 participating in Ras-induced premature senescence. The promoter of the p16(INK4A) gene contains an HBP1-binding site at position -426 to -433 bp from the transcriptional start site. HBP1 regulates the expression of the endogenous p16(INK4A) gene through direct sequence-specific binding. With HBP1 expression and the subsequent increase of p16(INK4A) gene expression, Ras induces premature senescence in primary cells. The data suggest a model in which Ras and p38 MAPK signaling engage HBP1 and p16(INK4A) to trigger premature senescence. In addition, we report that HBP1 knockdown is also required for Ras-induced transformation. All the data indicate that the mechanism of HBP1-mediated transcriptional regulation is important for not only premature senescence but also tumorigenesis. Oncogene (2010) 29, 5083-5094; doi:10.1038/onc.2010.252; published online 28 June 2010	[Li, H.; Wang, W.; Liu, X.; Zhang, X.] Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Beijing 100191, Peoples R China; [Paulson, K. E.] Tufts Univ New England Med Ctr, Dept Radiat Oncol, Boston, MA USA; [Yee, A. S.] Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA	Peking University; Tufts Medical Center; Tufts University	Zhang, X (corresponding author), Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Xueyuan Rd 38, Beijing 100191, Peoples R China.	xiaoweizhang@bjmu.edu.cn			National Natural Science Foundation of China [30770442]; National Basic Research Programs of China [2007CB507400]; NIH/NCI [CA94187, CA104236]; Susan B Komen Foundation for the Cure [BCTR0504367]; NATIONAL CANCER INSTITUTE [R01CA104236, R01CA094187] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Programs of China(National Basic Research Program of China); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Susan B Komen Foundation for the Cure(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the National Natural Science Foundation of China (no. 30770442) to Xiaowei Zhang, and from the National Basic Research Programs of China (no. 2007CB507400) to Tanjun Tong; from the NIH/NCI (CA94187 and CA104236) to Amy S Yee and the Susan B Komen Foundation for the Cure (BCTR0504367) to K Eric Paulson. We thank Dr Wengong Wang for helpful discussion on the paper.	Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005; Bandyopadhyay D, 2001, EXP GERONTOL, V36, P1265, DOI 10.1016/S0531-5565(01)00098-5; Bennett DC, 2003, ONCOGENE, V22, P3063, DOI 10.1038/sj.onc.1206446; Berasi SP, 2004, MOL CELL BIOL, V24, P3011, DOI 10.1128/MCB.24.7.3011-3024.2004; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bond JA, 1999, MOL CELL BIOL, V19, P3103; Bulavin DV, 2004, ADV CANCER RES, V92, P95, DOI 10.1016/S0065-230X(04)92005-2; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Deng QD, 2004, J BIOL CHEM, V279, P1050, DOI 10.1074/jbc.M308644200; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Haferkamp S, 2008, AGING CELL, V7, P733, DOI 10.1111/j.1474-9726.2008.00422.x; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Haq R, 2002, CANCER RES, V62, P5076; Hornsby PJ, 2007, J CLIN ONCOL, V25, P1852, DOI 10.1200/JCO.2006.10.3101; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; Iwasa H, 2003, GENES CELLS, V8, P131, DOI 10.1046/j.1365-2443.2003.00620.x; Kim GY, 2002, J BIOL CHEM, V277, P29792, DOI 10.1074/jbc.M201299200; Kim JE, 2008, INT J MOL MED, V22, P651, DOI 10.3892/ijmm_00000068; Kim JY, 2006, J BIOL CHEM, V281, P10865, DOI 10.1074/jbc.M513378200; Lavender P, 1997, ONCOGENE, V14, P2721, DOI 10.1038/sj.onc.1201243; Lemercier C, 2000, MOL CELL BIOL, V20, P6627, DOI 10.1128/MCB.20.18.6627-6637.2000; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229; Muscarella P, 2008, GENE EXPRESSION, V14, P207, DOI 10.3727/105221608786883825; Nelyudova A, 2007, CELL CYCLE, V6, P2171, DOI 10.4161/cc.6.17.4610; Ohtani Naoko, 2004, J Med Invest, V51, P146, DOI 10.2152/jmi.51.146; Paulson KE, 2007, CANCER RES, V67, P6136, DOI 10.1158/0008-5472.CAN-07-0567; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Sampson EM, 2001, EMBO J, V20, P4500, DOI 10.1093/emboj/20.16.4500; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shih HH, 1998, MOL CELL BIOL, V18, P4732, DOI 10.1128/MCB.18.8.4732; Shih HH, 2001, MOL CELL BIOL, V21, P5723, DOI 10.1128/MCB.21.17.5723-5732.2001; Signer RAJ, 2008, GENE DEV, V22, P3115, DOI 10.1101/gad.1715808; Smith JM, 2004, DEV DYNAM, V230, P366, DOI 10.1002/dvdy.20053; Sokol JP, 2005, BREAST CANCER RES, V7, pR844, DOI 10.1186/bcr1312; Swanson KA, 2004, NAT STRUCT MOL BIOL, V11, P738, DOI 10.1038/nsmb798; Takahashi A, 2006, NAT CELL BIOL, V8, P1291, DOI 10.1038/ncb1491; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; Xiu M, 2003, MOL CELL BIOL, V23, P8890, DOI 10.1128/MCB.23.23.8890-8901.2003; Yao CJ, 2005, LEUKEMIA, V19, P1958, DOI 10.1038/sj.leu.2403918; Yee AS, 2004, GENE, V336, P1, DOI 10.1016/j.gene.2004.04.004; Yee AS, 1999, PEDIATR PATHOL MOL M, V18, P275; Zhang XW, 2006, MOL CELL BIOL, V26, P8252, DOI 10.1128/MCB.00604-06; Zhao JJ, 2003, CANCER CELL, V3, P483, DOI 10.1016/S1535-6108(03)00088-6; Zhuma T, 1999, EMBO J, V18, P6396, DOI 10.1093/emboj/18.22.6396	48	42	48	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	36					5083	5094		10.1038/onc.2010.252	http://dx.doi.org/10.1038/onc.2010.252			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	647LN	20581871				2022-12-17	WOS:000281620100008
J	Kim, EH; Park, AK; Dong, SM; Ahn, JH; Park, WY				Kim, E-H; Park, A-K; Dong, S. M.; Ahn, J-H; Park, W-Y			Global analysis of CpG methylation reveals epigenetic control of the radiosensitivity in lung cancer cell lines	ONCOGENE			English	Article						CpG methylation; ionizing radiation; microarray; radiosensitivity	DNA METHYLATION; PROSTATE-CANCER; ATM PROMOTER; EXPRESSION; RADIORESISTANCE; CARCINOMA; MASPIN; BASONUCLIN; DISCOVERY; BREAST	Epigenetic regulation by CpG methylation has an important role in tumorigenesis as well as in the response to cancer therapy. To analyze the mechanism of epigenetic control of radiosensitivity, the CpG methylation profiles of radiosensitive H460 and radioresistant H1299 human non-small cell lung cancer (NSCLC) cell lines were analyzed using microarray profiling. These analyses revealed 1091 differentially methylated genes (DMG) (absolute difference of mean beta-values, |Delta(beta) over bar > 0.5), including genes involved in cell adhesion, cell communication, signal transduction and transcriptional regulation. Among the 747 genes hypermethylated in radioresistant H1299 cells, CpG methylation of SERPINB5 and S100A6 in radioresistant H1299 cells was confirmed by methylation-specific PCR. Reverse transcriptase-PCR showed higher expression of these two genes in radiosensitive H460 cells compared with radioresistant H1299 cells. Downregulation of SERPINB5 or S100A6 by small interfering RNA in H460 cells increased the resistance of these cells to ionizing radiation. In contrast, promoter CpG sites of 344 genes, including CAT and BNC1, were hypomethylated in radioresistant H1299 cells. Suppression of CAT or BNC1 mRNA expression in H1299 cells also reduced the resistance of these cells to ionizing radiation. Thus, we identified DMGs by genome-wide CpG methylation profiling in two NSCLC cell lines with different responses to ionizing radiation, and our data indicated that these differences may be critical for epigenetic regulation of radiosensitivity in lung cancer cells. Oncogene (2010) 29, 4725-4731; doi:10.1038/onc.2010.223; published online 7 June 2010	[Kim, E-H; Park, A-K; Park, W-Y] Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul 110799, South Korea; [Kim, E-H; Park, A-K; Park, W-Y] Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, Seoul 110799, South Korea; [Park, A-K; Park, W-Y] Seoul Natl Univ, Coll Med, Genom Core Lab, Seoul 110799, South Korea; [Dong, S. M.] Natl Canc Ctr, Div Translat & Clin Res 1, Res Inst, Seoul, South Korea; [Ahn, J-H] Ewha Womans Univ, Dept Biochem, Sch Med, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); National Cancer Center - Korea (NCC); Ewha Womans University	Park, WY (corresponding author), Seoul Natl Univ, Coll Med, Dept Biomed Sci, 103 Daehakro, Seoul 110799, South Korea.	wypark@snu.ac.kr	park, woongyang/D-5727-2012; Kim, Eunhye/ABG-2184-2021	Kim, Eunhye/0000-0002-9225-5865	Korea Science and Engineering Foundation (KOSEF); Ministry of Education, Science and Technology, Korea [M20706000020- 07M0600-02010]; Brain Korea21 (BK21) Program	Korea Science and Engineering Foundation (KOSEF)(Korea Science and Engineering Foundation); Ministry of Education, Science and Technology, Korea(Ministry of Education, Science & Technology (MEST), Republic of Korea); Brain Korea21 (BK21) Program(Ministry of Education & Human Resources Development (MOEHRD), Republic of Korea)	This research was supported by a grant from the Korea Science and Engineering Foundation (KOSEF), the Ministry of Education, Science and Technology, Korea (M20706000020- 07M0600-02010 to WYP), and the Brain Korea21 (BK21) Program (WYP).	Amundson SA, 2005, ONCOGENE, V24, P4572, DOI 10.1038/sj.onc.1208653; An JH, 2006, J RADIAT RES, V47, P147, DOI 10.1269/jrr.47.147; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Ding S, 2004, WORLD J GASTROENTERO, V10, P3433; Dunwell TL, 2009, EPIGENETICS-US, V4, P185, DOI 10.4161/epi.4.3.8752; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Epperly MW, 2009, RADIAT RES, V171, P588, DOI 10.1667/RR1424.1; Esteller M, 2002, SCIENCE, V297, P1807; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang KH, 2009, CLIN CANCER RES, V15, P4174, DOI 10.1158/1078-0432.CCR-08-2929; Jeong SH, 2009, EXP MOL MED, V41, P912, DOI 10.3858/emm.2009.41.12.097; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; Kim WJ, 2002, ONCOGENE, V21, P3864, DOI 10.1038/sj.onc.1205485; Koga Y, 2009, GENOME RES, V19, P1462, DOI 10.1101/gr.091447.109; Kron K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004830; Maass N, 2000, ACTA ONCOL, V39, P931; McCabe MT, 2009, CLIN CANCER RES, V15, P3927, DOI 10.1158/1078-0432.CCR-08-2784; Nagtegaal ID, 2005, VIRCHOWS ARCH, V446, P127, DOI 10.1007/s00428-004-1160-8; Orre LM, 2007, MOL CELL PROTEOMICS, V6, P2122, DOI 10.1074/mcp.M700202-MCP200; Park WY, 2002, ONCOGENE, V21, P8521, DOI 10.1038/sj.onc.1205977; Rehman I, 2004, BRIT J CANCER, V91, P739, DOI 10.1038/sj.bjc.6602034; RIBIERAS S, 1994, J CELL BIOCHEM, V56, P86, DOI 10.1002/jcb.240560113; Roy K, 2006, BIOCHEM BIOPH RES CO, V344, P821, DOI 10.1016/j.bbrc.2006.03.222; Sakakura C, 2007, ONCOGENE, V26, P5927, DOI 10.1038/sj.onc.1210403; Shames DS, 2006, PLOS MED, V3, P2244, DOI 10.1371/journal.pmed.0030486; Skvortsova I, 2008, PROTEOMICS, V8, P4521, DOI 10.1002/pmic.200800113; TSENG H, 1994, J CELL BIOL, V126, P495, DOI 10.1083/jcb.126.2.495; Wang L, 2008, MOL PHARMACOL, V73, P119, DOI 10.1124/mol.107.040873; Zhang XH, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001087; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051	32	42	48	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2010	29	33					4725	4731		10.1038/onc.2010.223	http://dx.doi.org/10.1038/onc.2010.223			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	641LK	20531302				2022-12-17	WOS:000281127400011
J	Su, L; Cheng, H; Sampaio, AV; Nielsen, TO; Underhill, TM				Su, L.; Cheng, H.; Sampaio, A. V.; Nielsen, T. O.; Underhill, T. M.			EGR1 reactivation by histone deacetylase inhibitors promotes synovial sarcoma cell death through the PTEN tumor suppressor	ONCOGENE			English	Article						HDAC inhibitors; synovial sarcoma; EGR1; PTEN; apoptosis	TRANSCRIPTION FACTOR; CANCER CELLS; INDUCED APOPTOSIS; IN-VITRO; GROWTH; EXPRESSION; PROTEIN; P53; TRANSFORMATION; TRICHOSTATIN	Synovial sarcoma is a high-grade soft tissue malignancy, for which current cytotoxic chemotherapies provide limited benefit. Although histone deacetylase (HDAC) inhibitors are known to suppress synovial sarcoma in vitro and in vivo, the exact mechanism is not clear. In this study, we report a central role of the transcription factor, early growth response-1 (EGR1), in the regulation of HDAC inhibitor-induced apoptotic cell death in synovial sarcoma. The SS18-SSX oncoprotein, characteristic of synovial sarcoma, maintains EGR1 expression at low levels, whereas it is significantly increased after HDAC inhibitor treatment. On the contrary, EGR1 knockdown leads to a decrease in HDAC inhibitor-induced apoptosis. Moreover, we find that under these conditions phosphatase and tensin homolog deleted in chromosome 10 (PTEN) is upregulated and this occurs through direct binding of EGR1 to an element upstream of the PTEN promoter. Using a combination of gain-and loss-of-function approaches, we show that EGR1 modulation of PTEN contributes to HDAC inhibitor-induced apoptosis in synovial sarcoma. Finally, restoration of EGR1 or PTEN expression is sufficient to induce synovial sarcoma cell death. Taken together, our findings indicate that SS18-SSX-mediated attenuation of an EGR1-PTEN network regulates synovial sarcoma cell survival, and that HDAC inhibitor-mediated apoptosis operates at least in part through reactivation of this pathway. Oncogene (2010) 29, 4352-4361; doi: 10.1038/onc.2010.204; published online 31 May 2010	[Underhill, T. M.] Univ British Columbia, Biomed Res Ctr, Dept Cellular & Physiol Sci, Vancouver, BC V6T 1Z3, Canada; [Cheng, H.; Nielsen, T. O.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia	Nielsen, TO (corresponding author), Vancouver Coastal Hlth Res Inst, Room JP1502,855 W 12th Ave, Vancouver, BC V5Z 1M9, Canada.	torsten@interchange.ubc.ca; tunderhi@brc.ubc.ca			Canadian Cancer Society Research Institute [018355]	Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS))	We thank Dr Diederik RH de Bruijn (Radbound University Nijmegen Medical Centre, Nijmegen, the Netherlands) for the gift of rabbit polyclonal antibody against SS18-SSX. This work was supported by a grant from the Canadian Cancer Society Research Institute (Grant #018355). Dr TO Nielsen is a scholar of the Michael Smith Foundation for Health Research, and Dr TM Underhill is an Arthritis Society Investigator.	Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Bozzi F, 2008, TRANSL ONCOL, V1, P95, DOI 10.1593/tlo.08121; Brett D, 1997, HUM MOL GENET, V6, P1559, DOI 10.1093/hmg/6.9.1559; Calogero A, 1996, ONCOGENE, V13, P2105; Calogero A, 2004, CANCER CELL INT, V4, DOI 10.1186/1475-2867-4-1; Condorelli F, 2008, BRIT J PHARMACOL, V153, P657, DOI 10.1038/sj.bjp.0707608; de Bruijn DRH, 2006, CANCER RES, V66, P9474, DOI 10.1158/0008-5472.CAN-05-3726; Downes CP, 2001, BIOCHEM SOC T, V29, P846, DOI 10.1042/BST0290846; Gan YH, 2009, ORAL ONCOL, V45, pE150, DOI 10.1016/j.oraloncology.2009.05.563; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; Habold C, 2008, J CELL MOL MED, V12, P607, DOI 10.1111/j.1582-4934.2007.00136.x; HUANG RP, 1994, ONCOGENE, V9, P1367; Huang RP, 1997, INT J CANCER, V72, P102, DOI 10.1002/(SICI)1097-0215(19970703)72:1<102::AID-IJC15>3.0.CO;2-L; HUANG RP, 1995, CANCER RES, V55, P5054; Italiano A, 2009, ANN ONCOL, V20, P425, DOI 10.1093/annonc/mdn678; Ito T, 2005, CANCER LETT, V224, P311, DOI 10.1016/j.canlet.2004.10.030; Khan O, 2008, NAT CLIN PRACT ONCOL, V5, P714, DOI 10.1038/ncponc1238; Kim J, 2006, CANCER RES, V66, P784, DOI 10.1158/0008-5472.CAN-05-1316; Krones-Herzig A, 2005, CANCER RES, V65, P5133, DOI 10.1158/0008-5472.CAN-04-3742; LEBEAU MM, 1993, P NATL ACAD SCI USA, V90, P5484, DOI 10.1073/pnas.90.12.5484; LEVIN WJ, 1995, ONCOGENE, V11, P1261; Lim FL, 1998, ONCOGENE, V17, P2013, DOI 10.1038/sj.onc.1202122; Liu CT, 1996, P NATL ACAD SCI USA, V93, P11831, DOI 10.1073/pnas.93.21.11831; Liu CT, 1999, J BIOL CHEM, V274, P4400, DOI 10.1074/jbc.274.7.4400; Liu J, 2001, INT J ONCOL, V18, P863; Lubieniecka JM, 2008, CANCER RES, V68, P4303, DOI 10.1158/0008-5472.CAN-08-0092; Ma DZ, 2005, WORLD J GASTROENTERO, V11, P4472, DOI 10.3748/wjg.v11.i29.4472; Medina V, 1997, CANCER RES, V57, P3697; Moradei O, 2008, CURR TOP MED CHEM, V8, P841, DOI 10.2174/156802608784911581; Nagai M, 2001, P NATL ACAD SCI USA, V98, P3843, DOI 10.1073/pnas.061036798; Nair P, 1997, J BIOL CHEM, V272, P20131, DOI 10.1074/jbc.272.32.20131; Okcu MF, 2003, J CLIN ONCOL, V21, P1602, DOI 10.1200/JCO.2003.07.008; Pan LN, 2007, CANCER, V109, P1676, DOI 10.1002/cncr.22585; Roeb W, 2008, CELL CYCLE, V7, P837, DOI 10.4161/cc.7.7.5652; Roeb W, 2007, P NATL ACAD SCI USA, V104, P18085, DOI 10.1073/pnas.0708910104; Roy S, 2007, J BIOL CHEM, V282, P4765, DOI 10.1074/jbc.M609588200; Soulez M, 1999, ONCOGENE, V18, P2739, DOI 10.1038/sj.onc.1202613; Stimson L, 2009, ANN ONCOL, V20, P1293, DOI 10.1093/annonc/mdn792; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; Thaete C, 1999, HUM MOL GENET, V8, P585, DOI 10.1093/hmg/8.4.585; Virolle T, 2003, J BIOL CHEM, V278, P11802, DOI 10.1074/jbc.M210279200; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Yu J, 2007, CELL DEATH DIFFER, V14, P436, DOI 10.1038/sj.cdd.4402029; Yu JX, 2009, EMBO J, V28, P21, DOI 10.1038/emboj.2008.238; Yu JX, 2004, MOL CELL, V15, P83, DOI 10.1016/j.molcel.2004.06.030; Zhao Y, 2006, MOL CELL BIOL, V26, P2782, DOI 10.1128/MCB.26.7.2782-2790.2006	48	42	44	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2010	29	30					4352	4361		10.1038/onc.2010.204	http://dx.doi.org/10.1038/onc.2010.204			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	633ZV	20514024				2022-12-17	WOS:000280547900011
J	Damiano, L; Di Stefano, P; Leal, MPC; Barba, M; Mainiero, F; Cabodi, S; Tordella, L; Sapino, A; Castellano, I; Canel, M; Frame, M; Turco, E; Defilippi, P				Damiano, L.; Di Stefano, P.; Leal, M. P. Camacho; Barba, M.; Mainiero, F.; Cabodi, S.; Tordella, L.; Sapino, A.; Castellano, I.; Canel, M.; Frame, M.; Turco, E.; Defilippi, P.			p140Cap dual regulation of E-cadherin/EGFR cross-talk and Ras signalling in tumour cell scatter and proliferation	ONCOGENE			English	Article						cell motility; p140Cap; Ras; Src; tumour growth	BREAST-CANCER; EGF RECEPTOR; GROWTH; TUMORIGENESIS; PROGRESSION; ACTIVATION	The adaptor protein p140Cap/SNIP is a novel Src-binding protein that regulates Src activation through C-terminal Src kinase (Csk). Here, by gain and loss of function approaches in breast and colon cancer cells, we report that p140Cap immobilizes E-cadherin at the cell membrane and inhibits EGFR and Erk1/2 signalling, blocking scatter and proliferation of cancer cells. p140Cap-dependent regulation of E-cadherin/EGFR cross-talk and cell motility is due to the inhibition of Src kinase. However, rescue of Src activity is not sufficient to restore Erk1/2 phosphorylation and proliferation. Indeed, p140Cap also impairs Erk1/2 phosphorylation by affecting Ras activity, downstream to the EGFR. In conclusion, p140Cap stabilizes adherens junctions and inhibits EGFR and Ras signalling through the dual control of both Src and Ras activities, thus affecting crucial cancer properties such as invasion and growth. Interestingly, p140Cap expression is lost in more aggressive human breast cancers, showing an inverse correlation with EGFR expression. Therefore, p140Cap mechanistically behaves as a tumour suppressor that inhibits signalling pathways leading to aggressive phenotypes. Oncogene (2010) 29, 3677-3690; doi: 10.1038/onc.2010.128; published online 10 May 2010	[Damiano, L.; Di Stefano, P.; Leal, M. P. Camacho; Cabodi, S.; Tordella, L.; Turco, E.; Defilippi, P.] Univ Turin, Dept Genet Biol & Biochem, I-10125 Turin, TO, Italy; [Damiano, L.; Di Stefano, P.; Leal, M. P. Camacho; Cabodi, S.; Tordella, L.; Turco, E.; Defilippi, P.] Univ Turin, Ctr Mol Biotechnol, I-10125 Turin, TO, Italy; [Barba, M.; Mainiero, F.] Univ Roma La Sapienza, Dept Expt Med & Pathol, Rome, Italy; [Sapino, A.; Castellano, I.] Univ Turin, Dept Biomed Sci & Human Oncol, I-10125 Turin, TO, Italy; [Frame, M.] Western Gen Hosp, Edinburgh Canc Res Ctr, Edinburgh EH4 2XU, Midlothian, Scotland	University of Turin; University of Turin; Sapienza University Rome; University of Turin; University of Edinburgh	Defilippi, P (corresponding author), Univ Turin, Dept Genet Biol & Biochem, Via Nizza 52, I-10125 Turin, TO, Italy.	paola.defilippi@unito.it	Sapino, Anna/J-4113-2018; Sapino, Anna/AGY-9901-2022; DEFILIPPI, Paola/L-2232-2014; Castellano, Isabella/K-1888-2018	Sapino, Anna/0000-0003-3542-9571; Sapino, Anna/0000-0003-3542-9571; Cabodi, Sara/0000-0003-1248-6549; Frame, Margaret/0000-0001-5882-1942; Tordella, Luca/0000-0002-0542-7834; Castellano, isabella/0000-0002-9072-1615; Mainiero, Fabrizio/0000-0002-7136-9839; Defilippi, Paola/0000-0001-6427-4906	AIRC; AICR; EU; MUR; Progetto Alfieri; Regione Piemonte (Oncoprot, Druidi, PiStem and BioTher); Regione Piemonte Sanita	AIRC(Fondazione AIRC per la ricerca sul cancro); AICR; EU(European Commission); MUR(Ministry of Education, Universities and Research (MIUR)); Progetto Alfieri; Regione Piemonte (Oncoprot, Druidi, PiStem and BioTher)(Regione Piemonte); Regione Piemonte Sanita	We thank PP Pandolfi (Boston, MA), A Sorkin (Denver, Co), J Stow (Brisbane, Australia), C Sasaki (Baltimore, Maryland) and K Nishida (Osaka, Japan) for reagent gifts. This work was supported by grants from the AIRC, AICR, EU FP7 Metafight program, MUR, Progetto Alfieri, Regione Piemonte (Oncoprot, Druidi, PiStem and BioTher), Regione Piemonte Sanita. MP Camacho Leal is supported by the AICR.	Alema S, 2007, BBA-MOL CELL RES, V1773, P47, DOI 10.1016/j.bbamcr.2006.06.001; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Arteaga CL, 2002, ONCOLOGIST, V7, P31; Berx G, 2001, BREAST CANCER RES, V3, P289, DOI 10.1186/bcr309; Berx G, 2007, CLIN EXP METASTAS, V24, P587, DOI 10.1007/s10585-007-9114-6; Cavallaro U, 2004, ANN NY ACAD SCI, V1014, P58, DOI 10.1196/annals.1294.006; Chin LS, 2000, J BIOL CHEM, V275, P1191, DOI 10.1074/jbc.275.2.1191; Coleman ML, 2004, NAT REV MOL CELL BIO, V5, P355, DOI 10.1038/nrm1365; Di Stefano P, 2004, MOL BIOL CELL, V15, P787, DOI 10.1091/mbc.E03-09-0689; Di Stefano P, 2007, EMBO J, V26, P2843, DOI 10.1038/sj.emboj.7601724; Giancotti FG, 2003, ANNU REV CELL DEV BI, V19, P173, DOI 10.1146/annurev.cellbio.19.031103.133334; Glynn RW, 2010, CANCER TREAT REV, V36, P224, DOI 10.1016/j.ctrv.2009.12.007; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Gutkind J. S., 2000, SCI STKE, pre1, DOI DOI 10.1126/STKE.2000.40.RE1; Kennedy S, 2008, BRIT J CANCER, V98, P1641, DOI 10.1038/sj.bjc.6604365; Kim H, 1999, EXP CELL RES, V253, P78, DOI 10.1006/excr.1999.4706; Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc; Miranda KC, 2001, J BIOL CHEM, V276, P22565, DOI 10.1074/jbc.M101907200; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; Normanno N, 2006, GENE, V366, P2, DOI 10.1016/j.gene.2005.10.018; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Perrais M, 2007, MOL BIOL CELL, V18, P2013, DOI 10.1091/mbc.E06-04-0348; Qian XL, 2004, EMBO J, V23, P1739, DOI 10.1038/sj.emboj.7600136; Reynolds AB, 2004, SEMIN CELL DEV BIOL, V15, P657, DOI 10.1016/j.semcdb.2004.09.003; Reynolds AB, 2007, BBA-MOL CELL RES, V1773, P2, DOI 10.1016/j.bbamcr.2006.09.019; Sasaki CY, 2000, CANCER RES, V60, P7057; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; Sorkin A, 2000, CURR BIOL, V10, P1395, DOI 10.1016/S0960-9822(00)00785-5; Takahashi K, 1996, EXP CELL RES, V226, P214, DOI 10.1006/excr.1996.0221; VESTWEBER D, 1985, EMBO J, V4, P3393, DOI 10.1002/j.1460-2075.1985.tb04095.x; Yamasaki S, 2003, ONCOGENE, V22, P1546, DOI 10.1038/sj.onc.1206284	32	42	42	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2010	29	25					3677	3690		10.1038/onc.2010.128	http://dx.doi.org/10.1038/onc.2010.128			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615CG	20453886				2022-12-17	WOS:000279108600008
J	Honaker, Y; Piwnica-Worms, H				Honaker, Y.; Piwnica-Worms, H.			Casein kinase 1 functions as both penultimate and ultimate kinase in regulating Cdc25A destruction	ONCOGENE			English	Article						cell cycle; Chk1; beta-TrCP; ubiquitin	BETA-TRCP; S-PHASE; DNA-DAMAGE; MEDIATED DEGRADATION; PHOSPHATASE; PHOSPHORYLATION; CHECKPOINT; INHIBITOR; TRANSITION; PATHWAY	The Cdc25A protein phosphatase drives cell-cycle transitions by activating cyclin-dependent protein kinases. Failure to regulate Cdc25A leads to deregulated cell-cycle progression, bypass of cell-cycle checkpoints and genome instability. Ubiquitin-mediated proteolysis has an important role in balancing Cdc25A levels. Cdc25A contains a DS(82)G motif whose phosphorylation is targeted by beta-TrCP E3 ligase during interphase. Targeting beta-TrCP to Cdc25A requires phosphorylation of serines 79 (S79) and 82 (S82). Here, we report that casein kinase 1 alpha (CK1 alpha) phosphorylates Cdc25A on both S79 and S82 in a hierarchical manner requiring prior phosphorylation of S76 by Chk1 or GSK-3 beta. This facilitates beta-TrCP binding and ubiquitin-mediated proteolysis of Cdc25A throughout interphase and after exposure to genotoxic stress. The priming of Cdc25A by at least three kinases (Chk1, GSK-3 beta, CK1 alpha), some of which also require priming, ensures diverse extra- and intracellular signals interface with Cdc25A to precisely control cell division. Oncogene (2010) 29, 3324-3334; doi:10.1038/onc.2010.96; published online 29 March 2010	[Honaker, Y.; Piwnica-Worms, H.] Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; [Piwnica-Worms, H.] Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA; [Piwnica-Worms, H.] Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)	Piwnica-Worms, H (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave,Campus Box 8228, St Louis, MO 63110 USA.	hpiwnica@cellbiology.wustl.edu	Piwnica-Worms, Helen/C-5214-2012		National Institutes of Health [GM047017, P50 CA94056]; NCI Cancer Center [P30 CA91842]; Howard Hughes Medical Institute; NATIONAL CANCER INSTITUTE [P50CA094056, P30CA091842] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047017] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Van Leung-Pineda and Dr Tiebang Kang for helpful suggestions. We also thank Chris Ryan for editorial assistance. We thank Chris Ryan, Yonghao Hou, Mei-Shya Chen, Dr Jiandong Chen and Dr Binhua P Zhou for providing expression plasmids. This work was supported by grants from the National Institutes of Health (GM047017 and P50 CA94056). We acknowledge the p50 Molecular Imaging Center and the Alvin J. Siteman Cancer Center at Washington University School of Medicine for the use of the High Throughput Core. The Siteman Cancer Center was supported in part by an NCI Cancer Center Support Grant No. P30 CA91842. H.P.-W. is an Investigator of the Howard Hughes Medical Institute.	Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Behrend L, 2000, ONCOGENE, V19, P5303, DOI 10.1038/sj.onc.1203939; Bernardi R, 2000, ONCOGENE, V19, P2447, DOI 10.1038/sj.onc.1203564; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Boutros R, 2006, CURR OPIN CELL BIOL, V18, P185, DOI 10.1016/j.ceb.2006.02.003; Busino L, 2004, ONCOGENE, V23, P2050, DOI 10.1038/sj.onc.1207394; Busino L, 2003, NATURE, V426, P87, DOI 10.1038/nature02082; Chen LH, 2005, MOL CELL BIOL, V25, P6509, DOI 10.1128/MCB.25.15.6509-6520.2005; Chen MS, 2003, MOL CELL BIOL, V23, P7488, DOI 10.1128/MCB.23.21.7488-7497.2003; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Donzelli M, 2002, EMBO J, V21, P4875, DOI 10.1093/emboj/cdf491; Donzelli M, 2004, CELL CYCLE, V3, P469; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Goloudina A, 2003, CELL CYCLE, V2, P473, DOI 10.4161/cc.2.5.482; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; Hassepass I, 2003, J BIOL CHEM, V278, P29824, DOI 10.1074/jbc.M302704200; Jin JP, 2003, GENE DEV, V17, P3062, DOI 10.1101/gad.1157503; Kanemori Y, 2005, P NATL ACAD SCI USA, V102, P6279, DOI 10.1073/pnas.0501873102; Kang T, 2008, CANCER CELL, V13, P36, DOI 10.1016/j.ccr.2007.12.002; Knippschild U, 2005, CELL SIGNAL, V17, P675, DOI 10.1016/j.cellsig.2004.12.011; Kristjansdottir K, 2004, CHEM BIOL, V11, P1043, DOI 10.1016/j.chembiol.2004.07.007; Loffler H, 2003, ONCOGENE, V22, P8063, DOI 10.1038/sj.onc.1206976; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Melixetian M, 2009, NAT CELL BIOL, V11, P1247, DOI 10.1038/ncb1969; Molinari M, 2000, EMBO REP, V1, P71, DOI 10.1093/embo-reports/kvd018; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; Ray D, 2005, MOL CELL BIOL, V25, P3338, DOI 10.1128/MCB.25.8.3338-3347.2005; Ray D, 2008, CANCER RES, V68, P1251, DOI 10.1158/0008-5472.CAN-07-5983; Rena G, 2004, EMBO REP, V5, P60, DOI 10.1038/sj.embor.7400048; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Zabludoff SD, 2008, MOL CANCER THER, V7, P2955, DOI 10.1158/1535-7163.MCT-08-0492; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	38	42	45	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2010	29	23					3324	3334		10.1038/onc.2010.96	http://dx.doi.org/10.1038/onc.2010.96			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	608YU	20348946	Green Accepted			2022-12-17	WOS:000278622700002
J	He, X; Zheng, Z; Song, T; Wei, C; Ma, H; Ma, Q; Zhang, Y; Xu, Y; Shi, W; Ye, Q; Zhong, H				He, X.; Zheng, Z.; Song, T.; Wei, C.; Ma, H.; Ma, Q.; Zhang, Y.; Xu, Y.; Shi, W.; Ye, Q.; Zhong, H.			c-Abl regulates estrogen receptor alpha transcription activity through its stabilization by phosphorylation	ONCOGENE			English	Article						c-Abl nonreceptor tyrosine kinases; estrogen receptor alpha; transcriptional activity	BREAST-CANCER CELLS; ESTRADIOL-INDUCED PHOSPHORYLATION; LIGAND-INDEPENDENT ACTIVATION; TYROSINE KINASE; DNA-DAMAGE; APOPTOTIC RESPONSE; PROTEIN-KINASE; IN-VIVO; HORMONE RECEPTORS; FAMILY KINASES	Estrogen receptors are members of the steroid hormone superfamily of nuclear receptors that act as ligand-activated transcription factors. Similar to other steroid hormone receptors, estrogen receptor alpha (ER alpha) is a substrate for protein kinases, and phosphorylation has profound effects on the function of this receptor. In this study, we show that ER alpha associates with c-Abl nonreceptor tyrosine kinase. The direct interaction is mediated by two PXXP motifs of ER alpha and the c-Abl SH3 domain. Mutational analysis and in vitro kinase assays show that ER alpha can be phosphorylated on two sites, tyrosine 52 (Y-52) and tyrosine 219 (Y-219). ER alpha phosphorylation by c-Abl stabilizes ER alpha, resulting in enhanced ER alpha transcriptional activity and increased expression of endogenous ER alpha target genes. Furthermore, ER alpha phosphorylation at the Y-219 site affects DNA binding and dimerization by ER alpha. Both the c-Abl inhibitor and the c-Abl kinase dead mutation abolish the c-Abl-induced accumulation of ER alpha and enhancement of ER alpha transcriptional activity, indicating that c-Abl kinase activity is required for regulation of the ER alpha function. Moreover, the ER alpha (Y52,219F) mutant shows reduced breast cancer cell growth and invasion. Taken together, these results show that c-Abl is a novel kinase that upregulates ER alpha expression and promotes breast cancer cell proliferation, suggesting a great potential for this kinase to function as a therapeutic target for breast cancer. Oncogene (2010) 29, 2238-2251; doi: 10.1038/onc.2009.513; published online 25 January 2010	[He, X.; Zheng, Z.; Song, T.; Wei, C.; Ma, H.; Ma, Q.; Ye, Q.; Zhong, H.] Beijing Inst Biotechnol, State Key Lab Pathogen & Biosecur, Beijing 100850, Peoples R China; [Xu, Y.; Shi, W.] Jilin Univ, Key Lab Mol Enzymol, Changchun 130023, Peoples R China; [He, X.] Inst Dis Control & Prevent, Beijing, Peoples R China	Jilin University	Zhong, H (corresponding author), Beijing Inst Biotechnol, State Key Lab Pathogen & Biosecur, 841 E Dist Bldg,27 Taipinglu, Beijing 100850, Peoples R China.	yeqn66@yahoo.com; towall@yahoo.com			National Natural Science Foundation [30772605, 30700413, 30870500, 30871276, 30530320]; Beijing Natural Science Foundation [7092081]	National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Beijing Natural Science Foundation(Beijing Natural Science Foundation)	This work was supported in part by the National Natural Science Foundation (30772605, 30700413, 30870500, 30871276 and 30530320) and by the Beijing Natural Science Foundation (7092081).	Acconcia F, 2006, CANCER RES, V66, P11030, DOI 10.1158/0008-5472.CAN-06-2676; Agami R, 1999, NATURE, V399, P809; Alen P, 1999, MOL ENDOCRINOL, V13, P117, DOI 10.1210/me.13.1.117; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Arnold SF, 1997, MOL ENDOCRINOL, V11, P48, DOI 10.1210/me.11.1.48; ARNOLD SF, 1994, MOL ENDOCRINOL, V8, P1208, DOI 10.1210/me.8.9.1208; ARNOLD SF, 1995, MOL ENDOCRINOL, V9, P24, DOI 10.1210/me.9.1.24; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Brasher BB, 2000, J BIOL CHEM, V275, P35631, DOI 10.1074/jbc.M005401200; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Castano E, 1997, BIOCHEM J, V326, P149, DOI 10.1042/bj3260149; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen DS, 1999, MOL CELL BIOL, V19, P1002; Clarkl DE, 2001, EMBO J, V20, P3484, DOI 10.1093/emboj/20.13.3484; DEBORAH AL, 2003, STEROIDS, V68, P1; Ding LH, 2003, NUCLEIC ACIDS RES, V31, P5266, DOI 10.1093/nar/gkg731; DRUKER BJ, 2001, NEW ENGL J MED, V344, P1037; Endoh H, 1999, MOL CELL BIOL, V19, P5363; Frech MS, 2005, CANCER RES, V65, P681; Han JQ, 2006, NUCLEIC ACIDS RES, V34, P3095, DOI 10.1093/nar/gkl389; He X, 2009, APOPTOSIS, V14, P268, DOI 10.1007/s10495-009-0313-2; HIROKO Y, 2005, BREAST CANCER RES, V7, P753; Jallal H, 2007, CANCER RES, V67, P1580, DOI 10.1158/0008-5472.CAN-06-2027; Joel PB, 1998, J BIOL CHEM, V273, P13317, DOI 10.1074/jbc.273.21.13317; JOEL PB, 1995, MOL ENDOCRINOL, V9, P1041, DOI 10.1210/me.9.8.1041; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Katzenellenbogen BS, 1997, BREAST CANCER RES TR, V44, P23, DOI 10.1023/A:1005835428423; Katzenellenbogen BS, 2000, BREAST CANCER RES, V2, P335, DOI 10.1186/bcr78; Katzenellenbogen BS, 1996, BIOL REPROD, V54, P287, DOI 10.1095/biolreprod54.2.287; Kim HJ, 2004, AM J HEMATOL, V76, P360, DOI 10.1002/ajh.20117; Klinge CM, 2000, STEROIDS, V65, P227, DOI 10.1016/S0039-128X(99)00107-5; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; Liu X, 2006, MOL CELL, V22, P317, DOI 10.1016/j.molcel.2006.04.007; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; Nagano K, 2006, ONCOGENE, V25, P493, DOI 10.1038/sj.onc.1208996; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; Nahta R, 2005, CANCER RES, V65, P11118, DOI 10.1158/0008-5472.CAN-04-3841; Noren NK, 2006, NAT CELL BIOL, V8, P815, DOI 10.1038/ncb1438; Pace P, 1997, J BIOL CHEM, V272, P25832, DOI 10.1074/jbc.272.41.25832; Pendergast AM, 2002, ADV CANCER RES, V85, P51, DOI 10.1016/S0065-230X(02)85003-5; PENDERGAST AM, 2001, CHRONIC MYELOID LEUK, P19; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Raina D, 2006, EMBO J, V25, P3774, DOI 10.1038/sj.emboj.7601263; Rayala SK, 2006, CANCER RES, V66, P1694, DOI 10.1158/0008-5472.CAN-05-2922; SENAD M, 2005, J BIOL CHEM, V280, P33006; Singer CF, 2004, ENDOCR-RELAT CANCER, V11, P861, DOI 10.1677/erc.1.00801; Skorski T, 1998, BLOOD, V91, P406, DOI 10.1182/blood.V91.2.406.406_406_418; Srinivasan D, 2008, ONCOGENE, V27, P1095, DOI 10.1038/sj.onc.1210714; Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008-5472.CAN-06-0734; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; Tsai KKC, 2003, CANCER RES, V63, P3418; van Diest PJ, 2004, J CLIN PATHOL, V57, P675, DOI 10.1136/jcp.2003.010777; Vantaggiato Chiara, 2006, J Biol, V5, P14, DOI 10.1186/jbiol38; Weigel NL, 1998, J MOL MED, V76, P469, DOI 10.1007/s001090050241; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Yoshida K, 2005, NAT CELL BIOL, V7, P278, DOI 10.1038/ncb1228; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704	61	42	43	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	15					2238	2251		10.1038/onc.2009.513	http://dx.doi.org/10.1038/onc.2009.513			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583NT	20101225				2022-12-17	WOS:000276685200009
J	Lam, S; Lodder, K; Teunisse, AFAS; Rabelink, MJWE; Schutte, M; Jochemsen, AG				Lam, S.; Lodder, K.; Teunisse, A. F. A. S.; Rabelink, M. J. W. E.; Schutte, M.; Jochemsen, A. G.			Role of Mdm4 in drug sensitivity of breast cancer cells	ONCOGENE			English	Article						Mdm4; p53; cancer; Nutlin; doxorubicin	P53 ACTIVATION; TUMOR-CELLS; POLY(ADP-RIBOSE) POLYMERASE; P53-BINDING PROTEIN; MALIGNANT GLIOMAS; DNA-DAMAGE; HDMX; AMPLIFICATION; INHIBITION; EXPRESSION	The p53 tumor suppressor protein is frequently mutated in human tumors. It is thought that the p53 pathway is indirectly impaired in the remaining tumors, for example by overexpression of its important regulators Mdm2 and Mdm4, making them attractive targets for the development of anti-cancer agents. Recent studies have suggested that Mdm4 levels determine the sensitivity of tumor cells for anti-cancer therapy. To investigate this possibility, we studied the drug sensitivity of several breast cancer cell lines containing wild-type p53, but expressing different Mdm4 levels. We show that endogenous Mdm4 levels can affect the sensitivity of breast cancer cells to anti-cancer agents, but in a cell line-dependent manner and depending on an intact apoptotic response. Furthermore, treatment with the non-genotoxic agent Nutlin-3 sensitizes cells for doxorubicin, showing that activation of p53 by targeting its regulators is an efficient strategy to decrease cell viability of breast cancer cells. These results confirm a function of Mdm4 in determining the efficacy of chemotherapeutic agents to induce apoptosis of cancer cells in a p53-dependent manner, although additional undetermined factors also influence the drug response. Targeting Mdm4 to sensitize tumor cells for chemotherapeutic drugs might be a strategy to effectively treat tumors harboring wild-type p53. Oncogene (2010) 29, 2415-2426; doi:10.1038/onc.2009.522; published online 8 February 2010	[Lam, S.; Lodder, K.; Teunisse, A. F. A. S.; Rabelink, M. J. W. E.; Jochemsen, A. G.] Leiden Univ, Dept Mol Cell Biol, Med Ctr, NL-2300 RC Leiden, Netherlands; [Schutte, M.] Erasmus Univ, Dept Med Oncol, Josephine Nefkens Inst, Med Ctr, Rotterdam, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Erasmus University Rotterdam; Erasmus MC	Jochemsen, AG (corresponding author), Leiden Univ, Dept Mol Cell Biol, Med Ctr, POB 9600,Postal Zone S1-P, NL-2300 RC Leiden, Netherlands.	A.G.Jochemsen@lumc.nl		Rabelink, Martijn/0000-0002-3274-7825	Association for International Cancer [05-273]; EC [503576]	Association for International Cancer; EC(European CommissionEuropean Commission Joint Research Centre)	We thank Dr G Selivanova for providing RITA, Dr A Levine and Dr G Peters for providing anti-Mdm2 and anti-p16 antibodies, respectively. This study was supported by grants from the Association for International Cancer Research (grant 05-273) and by EC FP6 funding (contract 503576) to AG Jochemsen. This publication reflects the authors' views and not necessarily those of the European Community. The EC is not liable for any use that may be made of the information contained.	Barbieri E, 2006, MOL CANCER THER, V5, P2358, DOI 10.1158/1535-7163.MCT-06-0305; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cao C, 2006, MOL CANCER THER, V5, P411, DOI 10.1158/1535-7163.MCT-05-0356; Carlotti F, 2004, MOL THER, V9, P209, DOI 10.1016/j.ymthe.2003.11.021; Coll-Mulet L, 2006, BLOOD, V107, P4109, DOI 10.1182/blood-2005-08-3273; Danovi D, 2004, MOL CELL BIOL, V24, P5835, DOI 10.1128/MCB.24.13.5835-5843.2004; de Graaf P, 2003, J BIOL CHEM, V278, P38315, DOI 10.1074/jbc.M213034200; Fuster JJ, 2007, TRENDS MOL MED, V13, P192, DOI 10.1016/j.molmed.2007.03.002; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLESTELLE A, 2009, BREAST CANC IN PRESS; Hu BL, 2006, J BIOL CHEM, V281, P33030, DOI 10.1074/jbc.C600147200; Issaeva N, 2004, NAT MED, V10, P1321, DOI 10.1038/nm1146; Kitagawa M, 2008, ONCOGENE, V27, P5303, DOI 10.1038/onc.2008.164; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194; Meulmeester E, 2005, CELL CYCLE, V4, P1166, DOI 10.4161/cc.4.9.1981; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533; Oruetxebarria I, 2004, J BIOL CHEM, V279, P3807, DOI 10.1074/jbc.M309333200; Patton JT, 2006, CANCER RES, V66, P3169, DOI 10.1158/0008-5472.CAN-05-3832; Pereg Y, 2005, P NATL ACAD SCI USA, V102, P5056, DOI 10.1073/pnas.0408595102; Pereg Y, 2006, MOL CELL BIOL, V26, P6819, DOI 10.1128/MCB.00562-06; Ramos YFM, 2001, CANCER RES, V61, P1839; Riemenschneider MJ, 2003, INT J CANCER, V104, P752, DOI 10.1002/ijc.11023; Riemenschneider MJ, 1999, CANCER RES, V59, P6091; Shangary S, 2008, P NATL ACAD SCI USA, V105, P3933, DOI 10.1073/pnas.0708917105; Shapiro CL, 2001, NEW ENGL J MED, V344, P1997, DOI 10.1056/NEJM200106283442607; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Shvarts A, 1997, GENOMICS, V43, P34, DOI 10.1006/geno.1997.4775; Stad R, 2000, J BIOL CHEM, V275, P28039; Stad R, 2001, EMBO REP, V2, P1029, DOI 10.1093/embo-reports/kve227; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Tovar C, 2006, P NATL ACAD SCI USA, V103, P1888, DOI 10.1073/pnas.0507493103; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Wade M, 2008, CELL CYCLE, V7, P1973, DOI 10.4161/cc.7.13.6072; Wade M, 2006, J BIOL CHEM, V281, P33036, DOI 10.1074/jbc.M605405200; Wasielewski M, 2006, BREAST CANCER RES TR, V99, P97, DOI 10.1007/s10549-006-9186-z	42	42	42	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	16					2415	2426		10.1038/onc.2009.522	http://dx.doi.org/10.1038/onc.2009.522			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	586YK	20140020				2022-12-17	WOS:000276951500010
J	Heinrich, C; Keller, C; Boulay, A; Vecchi, M; Bianchi, M; Sack, R; Lienhard, S; Duss, S; Hofsteenge, J; Hynes, NE				Heinrich, C.; Keller, C.; Boulay, A.; Vecchi, M.; Bianchi, M.; Sack, R.; Lienhard, S.; Duss, S.; Hofsteenge, J.; Hynes, N. E.			Copine-III interacts with ErbB2 and promotes tumor cell migration	ONCOGENE			English	Article						quantitative mass spectrometry; ErbB2; HRG; Copine-III; FRET acceptor photobleaching; cell migration	BREAST-CANCER; C2 DOMAIN; AUTOPHOSPHORYLATION SITES; PROTEIN; RECEPTOR; IDENTIFICATION; KINASE; RACK1; ADHESION; FAMILY	ErbB2 amplification and overexpression in breast cancer correlates with aggressive disease and poor prognosis. To find novel ErbB2-interacting proteins, we used stable isotope labeling of amino acids in cell culture followed by peptide affinity pull-downs and identified specific binders using relative quanti. cation by mass spectrometry. Copine-III, a member of a Ca2+-dependent phospholipid-binding protein family, was identified as binding to phosphorylated Tyr1248 of ErbB2. In breast cancer cells, Copine-III requires Ca2+ for binding to the plasma membrane, where it interacts with ErbB2 upon receptor stimulation, an interaction that is dependent on receptor activity. Copine-III also binds receptor of activated C kinase 1 and colocalizes with phosphorylated focal adhesion kinase at the leading edge of migrating cells. Importantly, knockdown of Copine-III in T47D breast cancer cells causes a decrease in Src kinase activation and ErbB2-dependent wound healing. Our data suggest that Copine-III is a novel player in the regulation of ErbB2-dependent cancer cell motility. In primary breast tumors, high CPNE3 RNA levels significantly correlate with ERBB2 amplification. Moreover, in an in situ tissue microarray analysis, we detected differential protein expression of Copine-III in normal versus breast, prostate and ovarian tumors, suggesting a more general role for Copine-III in carcinogenesis. Oncogene (2010) 29, 1598-1610; doi:10.1038/onc.2009.456; published online 14 December 2009	[Heinrich, C.; Keller, C.; Boulay, A.; Sack, R.; Lienhard, S.; Duss, S.; Hofsteenge, J.; Hynes, N. E.] Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland; [Vecchi, M.; Bianchi, M.] IFOM, FIRC Inst Mol Oncol Fdn, Milan, Italy	Friedrich Miescher Institute for Biomedical Research; IFOM - FIRC Institute of Molecular Oncology	Hynes, NE (corresponding author), Friedrich Miescher Inst Biomed Res, Maulbeerstr 66,WRO 1066-206, CH-4058 Basel, Switzerland.	nancy.hynes@fmi.ch	Vecchi, Manuela/L-3502-2017	Vecchi, Manuela/0000-0002-2750-9160; Duss, Stephan/0000-0002-0521-162X; Sack, Ragna/0000-0003-0963-8089; Keller Valsecchi, Claudia Isabelle/0000-0003-4135-5927	TRANSFOG FP6 IP [LSHC-CT-2004-503438]; Novartis Research Foundation	TRANSFOG FP6 IP; Novartis Research Foundation	We thank Elizabeth A Grimm for the polyclonal Copine-III antibody, Martin Spiess for the transferrin receptor antibody, Susanne Schenk for help in generating the Copine-III monoclonal antibody, Laurent Gelman for help with FRET, Michael Rebhan for some bioinformatic analyses and Gwen MacDonald and Julien Dey for helpful discussions. We also thank Daniel Hess and Florence Dalvai for help with establishing the 'MRM buddy'. The work of CH, MV and MB was partially supported by TRANSFOG FP6 IP funding (LSHC-CT-2004-503438). The laboratories of NEH and JH are supported by the Novartis Research Foundation.	AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; Benes CH, 2005, CELL, V121, P271, DOI 10.1016/j.cell.2005.02.019; Blagoev B, 2003, NAT BIOTECHNOL, V21, P315, DOI 10.1038/nbt790; Brunton VG, 2005, CANCER RES, V65, P1335, DOI 10.1158/0008-5472.CAN-04-1949; Church DL, 2003, GENETICS, V165, P563; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Cox EA, 2003, MOL BIOL CELL, V14, P658, DOI 10.1091/mbc.E02-03-0142; Creutz CE, 1998, J BIOL CHEM, V273, P1393, DOI 10.1074/jbc.273.3.1393; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; Farmer P, 2005, ONCOGENE, V24, P4660, DOI 10.1038/sj.onc.1208561; Gharbi S, 2002, MOL CELL PROTEOMICS, V1, P91, DOI 10.1074/mcp.T100007-MCP200; Gottschalk A, 2005, EMBO J, V24, P2566, DOI 10.1038/sj.emboj.7600741; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Guerrero-Valero M, 2007, J MOL BIOL, V371, P608, DOI 10.1016/j.jmb.2007.05.086; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; Hendrix ND, 2006, CANCER RES, V66, P1354, DOI 10.1158/0008-5472.CAN-05-3694; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440; Hua J, 2001, GENE DEV, V15, P2263, DOI 10.1101/gad.918101; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kenworthy AK, 2001, METHODS, V24, P289, DOI 10.1006/meth.2001.1189; Kheifets V, 2007, PHARMACOL RES, V55, P467, DOI 10.1016/j.phrs.2007.04.014; Kiely PA, 2009, J BIOL CHEM, V284, P20263, DOI 10.1074/jbc.M109.017640; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; Marone R, 2004, NAT CELL BIOL, V6, P515, DOI 10.1038/ncb1134; McCahill A, 2002, MOL PHARMACOL, V62, P1261, DOI 10.1124/mol.62.6.1261; Meira M, 2009, J CELL SCI, V122, P787, DOI 10.1242/jcs.032094; Miller LD, 2004, ONCOGENE, V23, P5682, DOI 10.1038/sj.onc.1207735; Nagy P, 1998, CYTOMETRY, V32, P120, DOI 10.1002/(SICI)1097-0320(19980601)32:2<120::AID-CYTO7>3.0.CO;2-P; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Patterson RL, 2005, TRENDS BIOCHEM SCI, V30, P688, DOI 10.1016/j.tibs.2005.10.005; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Ross JS, 1998, STEM CELLS, V16, P413, DOI 10.1002/stem.160413; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schulze WX, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100012; Schulze WX, 2004, J BIOL CHEM, V279, P10756, DOI 10.1074/jbc.M309909200; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Tomsig JL, 2004, BIOCHEM J, V378, P1089, DOI 10.1042/BJ20031654; Tomsig JL, 2003, J BIOL CHEM, V278, P10048, DOI 10.1074/jbc.M212632200; Tomsig JL, 2002, CELL MOL LIFE SCI, V59, P1467, DOI 10.1007/s00018-002-8522-7; Traxler P, 2004, CANCER RES, V64, P4931, DOI 10.1158/0008-5472.CAN-03-3681; White SL, 2004, BRIT J CANCER, V90, P173, DOI 10.1038/sj.bjc.6601458; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158	49	42	50	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2010	29	11					1598	1610		10.1038/onc.2009.456	http://dx.doi.org/10.1038/onc.2009.456			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	570RC	20010870	Green Submitted			2022-12-17	WOS:000275694700005
J	Powers, GL; Ellison-Zelski, SJ; Casa, AJ; Lee, AV; Alarid, ET				Powers, G. L.; Ellison-Zelski, S. J.; Casa, A. J.; Lee, A. V.; Alarid, E. T.			Proteasome inhibition represses ER alpha gene expression in ER plus cells: a new link between proteasome activity and estrogen signaling in breast cancer	ONCOGENE			English	Article						nuclear receptor; proteolysis; hormone-dependent cancer; bortezomib; transcription	RECEPTOR-ALPHA; ANTIESTROGEN ICI-182780; BORTEZOMIB PS-341; PURE ANTIESTROGEN; OVARIAN-CANCER; PHASE-II; PROTEIN; DEGRADATION; THERAPY; GROWTH	Estrogen receptor-alpha (ER alpha) is a major therapeutic target of hormonal therapies in breast cancer, and its expression in tumors is predictive of clinical response. Protein levels of ER alpha are tightly controlled by the 26S proteasome; yet, how the clinical proteasome inhibitor, bortezomib, affects ER alpha regulation has not been studied. Bortezomib selectively inhibits the chymotrypsin-like activity of the proteasome. Unlike other laboratory proteasome inhibitors, bortezomib failed to stabilize ER alpha protein at a dose exceeding 90% inhibition of the chymotrypsin-like activity. Unexpectedly, however, chronic bortezomib exposure caused a reduction of ER alpha levels in multiple ER+ breast cancer cell lines. This response can be explained by the fact that bortezomib induced a dramatic decrease in ER alpha mRNA because of direct transcriptional inhibition and loss of RNA polymerase II recruitment on the ER alpha gene promoter. Bortezomib treatment resulted in promoter-specific changes in estrogen-induced gene transcription that related with occupancy of ER alpha and RNA polymerase II (PolII) on endogenous promoters. In addition, bortezomib inhibited estrogen-dependent growth in soft agar. These results reveal a novel link between proteasome activity and expression of ER alpha in breast cancer and uncover distinct roles of the chymotrypsin-like activity of the proteasome in the regulation of the ER alpha pathway. Oncogene (2010) 29, 1509-1518; doi:10.1038/onc.2009.434; published online 30 November 2009	[Alarid, E. T.] Univ Wisconsin, Dept Oncol, Wisconsin Inst Med Res 6151, Madison, WI 53705 USA; [Casa, A. J.; Lee, A. V.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA; [Casa, A. J.; Lee, A. V.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	University of Wisconsin System; University of Wisconsin Madison; Baylor College of Medicine; Baylor College of Medicine	Alarid, ET (corresponding author), Univ Wisconsin, Dept Oncol, Wisconsin Inst Med Res 6151, 1111 Highland Ave, Madison, WI 53705 USA.	alarid@oncology.wisc.edu		Lee, Adrian/0000-0001-9917-514X	NIH [DK64034, DAMD-17-02-1-0286, T32CA009135, T32GM08688, W81XWH-06-1-0714]; NATIONAL CANCER INSTITUTE [T32CA009135, R01CA104708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064034] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008688] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by Grants NIH DK64034 (ETA), DAMD-17-02-1-0286 (AVL), T32CA009135 (GLP), T32GM08688 (GLP) and W81XWH-06-1-0714 (AJC). We thank Drs Shigeki Miyamoto and Michael Fritsch for reagents.	Adams BD, 2007, MOL ENDOCRINOL, V21, P1132, DOI 10.1210/me.2007-0022; Alarid ET, 2006, MOL ENDOCRINOL, V20, P1972, DOI 10.1210/me.2005-0481; Alarid ET, 1999, MOL ENDOCRINOL, V13, P1522, DOI 10.1210/me.13.9.1522; Bazzaro M, 2006, CANCER RES, V66, P3754, DOI 10.1158/0008-5472.CAN-05-2321; Bossola M, 2003, ANN SURG, V237, P384, DOI 10.1097/00000658-200303000-00013; Cardoso F, 2006, MOL CANCER THER, V5, P3042, DOI 10.1158/1535-7163.MCT-06-0104; Chen L, 2005, CANCER RES, V65, P5599, DOI 10.1158/0008-5472.CAN-05-0201; Chia S, 2008, J CLIN ONCOL, V26, P1664, DOI 10.1200/JCO.2007.13.5822; Clarke RB, 1997, CANCER RES, V57, P4987; Coates AS, 2007, J CLIN ONCOL, V25, P486, DOI 10.1200/JCO.2006.08.8617; Codony-Servat J, 2006, MOL CANCER THER, V5, P665, DOI 10.1158/1535-7163.MCT-05-0147; DAUVOIS S, 1993, J CELL SCI, V106, P1377; DEFRIEND DJ, 1994, BRIT J CANCER, V70, P204, DOI 10.1038/bjc.1994.281; DeNardo DG, 2007, MOL CELL ENDOCRINOL, V277, P13, DOI 10.1016/j.mce.2007.07.006; Denger S, 2001, MOL ENDOCRINOL, V15, P2064, DOI 10.1210/me.15.12.2064; Dhasarathy A, 2007, MOL ENDOCRINOL, V21, P2907, DOI 10.1210/me.2007-0293; DOWSETT M, 1985, BRIT J CANCER, V52, P31, DOI 10.1038/bjc.1985.144; El Khissiin A, 1999, FEBS LETT, V448, P160, DOI 10.1016/S0014-5793(99)00343-9; Ellison-Zelski SJ, 2009, MOL CELL BIOL, V29, P4949, DOI 10.1128/MCB.00383-09; Engel RH, 2007, CANCER INVEST, V25, P733, DOI 10.1080/07357900701506573; FABRIS G, 1987, J STEROID BIOCHEM, V27, P171, DOI 10.1016/0022-4731(87)90307-4; Fan MY, 2004, MOL ENDOCRINOL, V18, P2603, DOI 10.1210/me.2004-0164; Feng Y, 2007, P NATL ACAD SCI USA, V104, P14718, DOI 10.1073/pnas.0706933104; Fowler AM, 2006, MOL ENDOCRINOL, V20, P291, DOI 10.1210/me.2005-0288; Han YQ, 2008, MOL CANCER RES, V6, P1347, DOI 10.1158/1541-7786.MCR-07-2179; Harrell JC, 2007, CANCER RES, V67, P10582, DOI 10.1158/0008-5472.CAN-07-1655; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; Hui R, 2002, CANCER RES, V62, P6916; JORDAN VC, 1976, CANCER TREAT REP, V60, P1409; Khan SA, 1999, CANCER EPIDEM BIOMAR, V8, P867; Kisselev AF, 2006, J BIOL CHEM, V281, P8582, DOI 10.1074/jbc.M509043200; Kondo N, 2008, CANCER RES, V68, P5004, DOI 10.1158/0008-5472.CAN-08-0180; Kos M, 2001, MOL ENDOCRINOL, V15, P2057, DOI 10.1210/me.15.12.2057; KUMATORI A, 1990, P NATL ACAD SCI USA, V87, P7071, DOI 10.1073/pnas.87.18.7071; Lee S, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1367; Lee S, 2007, AM J PATHOL, V171, P252, DOI 10.2353/ajpath.2007.061010; Liedtke C, 2009, ANN ONCOL; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Maki CG, 1996, CANCER RES, V56, P2649; Marx C, 2007, MOL PHARMACOL, V71, P1525, DOI 10.1124/mol.107.034090; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; NOMURA Y, 1985, CANCER, V55, P546, DOI 10.1002/1097-0142(19850201)55:3<546::AID-CNCR2820550313>3.0.CO;2-V; O'Donnell AJM, 2005, ENDOCR-RELAT CANCER, V12, P851, DOI 10.1677/erc.1.01039; Oesterreich S, 2001, CANCER RES, V61, P5771; ORLOWSKI M, 1981, BIOCHEM BIOPH RES CO, V101, P814; Pandey DP, 2009, MOL CELL BIOL, V29, P3783, DOI 10.1128/MCB.01875-08; PARKER MG, 1993, BREAST CANCER RES TR, V26, P131, DOI 10.1007/BF00689686; Qin CH, 2002, MOL ENDOCRINOL, V16, P1793, DOI 10.1210/me.2002-0006; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Richardson PG, 2006, ANNU REV MED, V57, P33, DOI 10.1146/annurev.med.57.042905.122625; Robertson JFR, 2009, J CLIN ONCOL, V27, P4530, DOI 10.1200/JCO.2008.21.1136; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Shaaban AM, 2002, AM J PATHOL, V160, P597, DOI 10.1016/S0002-9440(10)64879-1; Shah MH, 2004, CLIN CANCER RES, V10, P6111, DOI 10.1158/1078-0432.CCR-04-0422; Shoker BS, 1999, AM J PATHOL, V155, P1811, DOI 10.1016/S0002-9440(10)65498-3; Taggart CC, 2002, J BIOL CHEM, V277, P33648, DOI 10.1074/jbc.M203710200; Teicher BA, 1999, CLIN CANCER RES, V5, P2638; Valley CC, 2005, MOL CELL BIOL, V25, P5417, DOI 10.1128/MCB.25.13.5417-5428.2005; Valley CC, 2008, J MOL ENDOCRINOL, V40, P23, DOI 10.1677/JME-07-0067; Viale G, 2007, J CLIN ONCOL, V25, P3846, DOI 10.1200/JCO.2007.11.9453; WAKELING AE, 1991, CANCER RES, V51, P3867; Wang XB, 2009, MOL CELL BIOL, V29, P3832, DOI 10.1128/MCB.00032-09; Wijayaratne AL, 2001, J BIOL CHEM, V276, P35684, DOI 10.1074/jbc.M101097200; Wong DJ, 2008, CANCER RES, V68, P369, DOI 10.1158/0008-5472.CAN-07-0382; Xu HM, 2008, BREAST CANCER RES TR, V107, P267, DOI 10.1007/s10549-007-9553-4; Yang CH, 2006, ANN ONCOL, V17, P813, DOI 10.1093/annonc/mdj131; Yuan JS, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-85	69	42	47	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	10					1509	1518		10.1038/onc.2009.434	http://dx.doi.org/10.1038/onc.2009.434			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	566SD	19946334	Green Accepted			2022-12-17	WOS:000275392400009
J	Wolf, I; Laitman, Y; Rubinek, T; Abramovitz, L; Novikov, I; Beeri, R; Kuro-O, M; Koeffler, HP; Catane, R; Freedman, LS; Levy-Lahad, E; Karlan, BY; Friedman, E; Kaufman, B				Wolf, I.; Laitman, Y.; Rubinek, T.; Abramovitz, L.; Novikov, I.; Beeri, R.; Kuro-O, M.; Koeffler, H. P.; Catane, R.; Freedman, L. S.; Levy-Lahad, E.; Karlan, B. Y.; Friedman, E.; Kaufman, B.			Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin	ONCOGENE			English	Article						breast cancer; klotho; BRCA; ovarian cancer; insulin growth factor-1; tumor suppressor	TRANSCRIPTS ENCODING MEMBRANE; MOLECULAR-CLONING; HORMONE KLOTHO; PROTEIN; GENE; SUSCEPTIBILITY; EXPRESSION; ASSOCIATION; PATHWAYS; CLEAVAGE	Klotho is a transmembrane protein that can be shed and act as a circulating hormone and is a putative tumor suppressor in breast cancer. A functional variant of KLOTHO (KL-VS) contains two amino acid substitutions F352V and C370S and shows reduced activity. Germ-line mutations in BRCA1 and BRCA2 substantially increase lifetime risk of breast and ovarian cancers. Yet, penetrance of deleterious BRCA1 and BRCA2 mutations is incomplete even among carriers of identical mutations. We examined the association between KL-VS and cancer risk among 1115 Ashkenazi Jewish women: 236 non-carriers, 631 BRCA1 (185delAG, 5382insC) carriers and 248 BRCA2 (6174delT) carriers. Among BRCA1 carriers, heterozygosity for the KL-VS allele was associated with increased breast and ovarian cancer risk (hazard ratio 1.40, 95% confidence intervals 1.08-1.83, P=0.01) and younger age at breast cancer diagnosis (median age 48 vs 43 P=0.04). KLOTHO and BRCA2 are located on 13q12, and we identified linkage disequilibrium between KL-VS and BRCA2 6174delT mutation. Studies in breast cancer cells showed reduced growth inhibitory activity and reduced secretion of klotho F352V compared with wildtype klotho. These data suggest KL-VS as a breast and ovarian cancer risk modifier among BRCA1 mutation carriers. If validated in additional cohorts, the presence of KL-VS may serve as a predictor of cancer risk among BRCA1 mutation carriers.	[Wolf, I.; Rubinek, T.; Abramovitz, L.; Catane, R.; Kaufman, B.] Chaim Sheba Med Ctr, Inst Oncol, IL-52621 Tel Hashomer, Ramat Gan, Israel; [Wolf, I.; Catane, R.; Friedman, E.] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; [Laitman, Y.; Friedman, E.] Chaim Sheba Med Ctr, Susanne Levy Gertner Oncogenet Unit, Inst Human Genet, IL-52621 Tel Hashomer, Ramat Gan, Israel; [Novikov, I.; Freedman, L. S.] Chaim Sheba Med Ctr, Gertner Inst Epidemiol & Hlth Policy Res, IL-52621 Tel Hashomer, Ramat Gan, Israel; [Beeri, R.; Levy-Lahad, E.] Shaare Zedek Med Ctr, Med Genet Unit, Jerusalem, Israel; [Kuro-O, M.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA; [Koeffler, H. P.] Cedars Sinai Med Ctr, Div Hematol Oncol, Los Angeles, CA 90048 USA; [Karlan, B. Y.] Cedars Sinai Med Ctr, Womens Canc Res Inst, Los Angeles, CA 90048 USA	Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Hebrew University of Jerusalem; Shaare Zedek Medical Center; University of Texas System; University of Texas Southwestern Medical Center Dallas; Cedars Sinai Medical Center; Cedars Sinai Medical Center	Wolf, I (corresponding author), Chaim Sheba Med Ctr, Inst Oncol, IL-52621 Tel Hashomer, Ramat Gan, Israel.	wolf-i@inter.net.il	Levy-Lahad, Ephrat/F-2186-2018	Levy-Lahad, Ephrat/0000-0002-2637-1921; Abramovitz, Lilach/0000-0001-9961-9986	United States-Israel Binational Science Foundation (BSF) [2005150]; Chief Scientist Office of the Ministry of Health, Israel [4055_3]; Koschitzky Family Foundation for Breast Cancer Research; Israel Cancer Association Research Grant; 'Talpiut' Sheba Career Development Award; Sackler Faculty of Medicine; Tel Aviv University; Tel Aviv, Israel; Breast Cancer Research Foundation	United States-Israel Binational Science Foundation (BSF)(US-Israel Binational Science Foundation); Chief Scientist Office of the Ministry of Health, Israel; Koschitzky Family Foundation for Breast Cancer Research; Israel Cancer Association Research Grant; 'Talpiut' Sheba Career Development Award; Sackler Faculty of Medicine; Tel Aviv University; Tel Aviv, Israel; Breast Cancer Research Foundation	This research was supported by the United States-Israel Binational Science Foundation (BSF) (grant no. 2005150 to IW and HPK); the Chief Scientist Office of the Ministry of Health, Israel (grant no. 4055_3 to IW); the Koschitzky Family Foundation for Breast Cancer Research; the Israel Cancer Association Research Grant; the 'Talpiut' Sheba Career Development Award; the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; and the Breast Cancer Research Foundation (to ELL). HPK is a member of the Molecular Biology Institute and Jonsson Comprehensive Cancer Center at UCLA, and holds the endowed Mark Goodson Chair of Oncology Research at Cedars-Sinai Medical Center/UCLA School of Medicine.	Antoniou AC, 2006, ONCOGENE, V25, P5898, DOI 10.1038/sj.onc.1209879; Antoniou AC, 2005, GENET EPIDEMIOL, V29, P1, DOI 10.1002/gepi.20074; Antoniou AC, 2008, AM J HUM GENET, V82, P937, DOI 10.1016/j.ajhg.2008.02.008; Antoniou AC, 2007, AM J HUM GENET, V81, P1186, DOI 10.1086/522611; Arking DE, 2005, CIRC RES, V96, P412, DOI 10.1161/01.RES.0000157171.04054.30; Arking DE, 2003, AM J HUM GENET, V72, P1154, DOI 10.1086/375035; Arking DE, 2002, P NATL ACAD SCI USA, V99, P856, DOI 10.1073/pnas.022484299; Begg CB, 2008, JAMA-J AM MED ASSOC, V299, P194, DOI 10.1001/jama.2007.55-a; Cha SK, 2008, P NATL ACAD SCI USA, V105, P9805, DOI 10.1073/pnas.0803223105; Chen CD, 2007, P NATL ACAD SCI USA, V104, P19796, DOI 10.1073/pnas.0709805104; Hudelist G, 2007, ENDOCR-RELAT CANCER, V14, P1053, DOI 10.1677/ERC-06-0075; Imura A, 2004, FEBS LETT, V565, P143, DOI 10.1016/j.febslet.2004.03.090; Ito S, 2000, MECH DEVELOP, V98, P115, DOI 10.1016/S0925-4773(00)00439-1; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; Kurosu H, 2006, J BIOL CHEM, V281, P6120, DOI 10.1074/jbc.C500457200; Kurosu H, 2005, SCIENCE, V309, P1829, DOI 10.1126/science.1112766; Levy-Lahad E, 2007, BRIT J CANCER, V96, P11, DOI 10.1038/sj.bjc.6603535; Maor S, 2007, CANCER LETT, V257, P236, DOI 10.1016/j.canlet.2007.07.019; Matsumura Y, 1998, BIOCHEM BIOPH RES CO, V242, P626, DOI 10.1006/bbrc.1997.8019; Ohyama Y, 1998, BIOCHEM BIOPH RES CO, V251, P920, DOI 10.1006/bbrc.1998.9576; Rohlfs EM, 1997, CLIN CHEM, V43, P24; Shiraki-Iida T, 1998, FEBS LETT, V424, P6, DOI 10.1016/S0014-5793(98)00127-6; Tomlinson GE, 1998, CANCER RES, V58, P3237; Urakawa I, 2006, NATURE, V444, P770, DOI 10.1038/nature05315; Wolf I, 2005, LANCET ONCOL, V6, P103, DOI 10.1016/S1470-2045(05)01736-5; Wolf I, 2008, ONCOGENE, V27, P7094, DOI 10.1038/onc.2008.292; Yamamoto M, 2005, J BIOL CHEM, V280, P38029, DOI 10.1074/jbc.M509039200; Yee D, 2006, BRIT J CANCER, V94, P465, DOI 10.1038/sj.bjc.6602963	28	42	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	2010	29	1					26	33		10.1038/onc.2009.301	http://dx.doi.org/10.1038/onc.2009.301			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540XE	19802015				2022-12-17	WOS:000273373500003
J	Po'uha, ST; Shum, MSY; Goebel, A; Bernard, O; Kavallaris, M				Po'uha, S. T.; Shum, M. S. Y.; Goebel, A.; Bernard, O.; Kavallaris, M.			LIM-kinase 2, a regulator of actin dynamics, is involved in mitotic spindle integrity and sensitivity to microtubule-destabilizing drugs	ONCOGENE			English	Article						LIM-kinase 2; neuroblastoma; microtubule-destabilizing drugs; mitosis; drug sensitivity	PROTEIN-KINASE; COFILIN PHOSPHORYLATION; CYTOSKELETAL DYNAMICS; CHILDHOOD LEUKEMIA; CELL-MIGRATION; CANCER-CELLS; ACTIVATION; RESISTANCE; SLINGSHOT; TUBULIN	LIM-kinase 2 (LIMK2) belongs to the LIMK family of proteins, which comprises LIMK1 and LIMK2. Both proteins regulate actin polymerization through phosphorylation and inactivation of the actin depolymerizing factor cofilin. In this study, we show that the level of LIMK2 protein is increased in neuroblastoma, BE(2)-C cells, selected for resistance to microtubule-destabilizing agents, vincristine and colchicine. However, the level of phosphorylated LIMK1 and LIMK2 was similar in the resistant and parental BE(2)-C cells. In contrast, the level of phospho-cofilin was greatly increased in the drug-resistant cells. Downregulation of LIMK2 expression increases sensitivity of neuroblastoma SH-EP cells to vincristine and vinblastine but not to microtubule-stabilizing agents, while it's overexpression increased its resistance to vincristine. Its vincristine-induced mitotic arrest was moderately inhibited in the LIMK2 knockdown cells, suggesting that the increased drug sensitivity is through an alternative mechanism other then mitotic arrest and apoptosis. Moreover, downregulation of LIMK2 expression induces formation of abnormal mitotic spindles, an effect enhanced in the presence of microtubule-destabilizing agents. LIMK2 is important for normal mitotic spindle formation and altered LIMK2 expression mediates sensitivity to microtubule destabilizing agents. These findings suggest that inhibition of LIMK2 activity may be used for the treatment of tumors resistant to microtubule-destabilizing drugs. Oncogene (2010) 29, 597-607; doi: 10.1038/onc.2009.367; published online 2 November 2009	[Kavallaris, M.] Childrens Canc Inst Australia Med Res, Pharmacoprote Program, Randwick, NSW 2031, Australia; [Po'uha, S. T.; Shum, M. S. Y.] Univ New S Wales, Sydney, NSW, Australia; [Bernard, O.] St Vincents Inst Med Res, Melbourne, Vic, Australia; [Bernard, O.] St Vincents Hosp, Dept Med, Melbourne, Vic, Australia	Children's Cancer Institute; University of New South Wales Sydney; St. Vincent's Institute of Medical Research; St Vincent's Hospital Melbourne	Kavallaris, M (corresponding author), Childrens Canc Inst Australia Med Res, Pharmacoprote Program, POB 81, Randwick, NSW 2031, Australia.	m.kavallaris@ccia.unsw.edu.au	Kavallaris, Maria/J-5240-2014		Children's Cancer Institute Australia for Medical Research; New South Wales Cancer Council; NHMRC; Endeavour International; Australian Postgraduate Award	Children's Cancer Institute Australia for Medical Research; New South Wales Cancer Council(Cancer Council New South Wales); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Endeavour International; Australian Postgraduate Award(Australian Government)	We thank Professor Kensaku Mizuno, Tohoku University, Japan, for providing the LIMK2 plasmid and Professor Peter Gunning, University of New South Wales, Sydney, Australia, for gamma-actin Ab. This work was supported by the Children's Cancer Institute Australia for Medical Research, which is affiliated with the University of New South Wales and Sydney Children's Hospital, and by grants from the New South Wales Cancer Council (MK). MK is supported by a NHMRC Senior Research Fellowship, STP was supported by an Endeavour International Postgraduate Research Scholarship and MSYS is supported by an Australian Postgraduate Award. OB is a NHMRC Principal Research Fellow.	Acevedo K, 2006, J HISTOCHEM CYTOCHEM, V54, P487, DOI 10.1369/jhc.5C6813.2006; Acevedo K, 2007, EXP CELL RES, V313, P4091, DOI 10.1016/j.yexcr.2007.08.012; Amano T, 2001, BIOCHEM J, V354, P149, DOI 10.1042/0264-6021:3540149; Ambach A, 2000, EUR J IMMUNOL, V30, P3422, DOI 10.1002/1521-4141(2000012)30:12<3422::AID-IMMU3422>3.0.CO;2-J; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Bhalla KN, 2003, ONCOGENE, V22, P9075, DOI 10.1038/sj.onc.1207233; Chakrabarti R, 2007, CELL CYCLE, V6, P2944, DOI 10.4161/cc.6.23.4957; Croft DR, 2006, MOL CELL BIOL, V26, P4612, DOI 10.1128/MCB.02061-05; Dan C, 2001, J BIOL CHEM, V276, P32115, DOI 10.1074/jbc.M100871200; Dan S, 2002, CANCER RES, V62, P1139; Davila M, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-40; Deschesnes RG, 2007, J PHARMACOL EXP THER, V320, P853, DOI 10.1124/jpet.106.110957; Don S, 2004, MOL CANCER THER, V3, P1137; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Eiseler T, 2009, NAT CELL BIOL, V11, P545, DOI 10.1038/ncb1861; Gohla A, 2005, NAT CELL BIOL, V7, P21, DOI 10.1038/ncb1201; Gorovoy M, 2005, J BIOL CHEM, V280, P26533, DOI 10.1074/jbc.M502921200; Groth-Pedersen L, 2007, CANCER RES, V67, P2217, DOI 10.1158/0008-5472.CAN-06-3520; JORDAN MA, 1991, CANCER RES, V51, P2212; Kaji N, 2008, J BIOL CHEM, V283, P4983, DOI 10.1074/jbc.M708644200; Kobayashi M, 2006, EMBO J, V25, P713, DOI 10.1038/sj.emboj.7600973; LAQUAGLIA MP, 1991, J PEDIATR SURG, V26, P1107, DOI 10.1016/0022-3468(91)90684-L; MIZUNO K, 1994, ONCOGENE, V9, P1605; Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092-8674(01)00638-9; NUNOUE K, 1995, ONCOGENE, V11, P701; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; Peterburs P, 2009, CANCER RES, V69, P5634, DOI 10.1158/0008-5472.CAN-09-0718; Sarmiere PD, 2004, J NEUROBIOL, V58, P103, DOI 10.1002/neu.10267; Soosairajah J, 2005, EMBO J, V24, P473, DOI 10.1038/sj.emboj.7600543; Sumi T, 2006, EXP CELL RES, V312, P1021, DOI 10.1016/j.yexcr.2005.12.030; Sumi T, 1999, J CELL BIOL, V147, P1519, DOI 10.1083/jcb.147.7.1519; Sumi T, 2001, J BIOL CHEM, V276, P670, DOI 10.1074/jbc.M007074200; Verrills NM, 2006, J NATL CANCER I, V98, P1363, DOI 10.1093/jnci/djj372; Verrills NM, 2006, PROTEOMICS, V6, P1681, DOI 10.1002/pmic.200500417; Verrills NM, 2005, CURR PHARM DESIGN, V11, P1719, DOI 10.2174/1381612053764706; Verrills NM, 2003, CHEM BIOL, V10, P597, DOI 10.1016/S1074-5521(03)00141-8; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735	37	42	44	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2010	29	4					597	607		10.1038/onc.2009.367	http://dx.doi.org/10.1038/onc.2009.367			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	549WH	19881550				2022-12-17	WOS:000274084600012
J	Ashley, N; Poulton, J				Ashley, N.; Poulton, J.			Anticancer DNA intercalators cause p53-dependent mitochondrial DNA nucleoid re-modelling	ONCOGENE			English	Article						anthracyclines; mtDNA; mitochondria; nucleoids; doxorubicin; mitofusin	HUMAN-CELLS; DOXORUBICIN; P53; ADRIAMYCIN; MUTATIONS; DEPLETION; FUSION; DRUGS; OPA1; CARDIOMYOPATHY	Many anticancer drugs, such as doxorubicin (DXR), intercalate into nuclear DNA of cancer cells, thereby inhibiting their growth. However, it is not well understood how such drugs interact with mitochondrial DNA (mtDNA). Using cell and molecular studies of cultured cells, we show that DXR and other DNA intercalators, such as ethidium bromide, can rapidly intercalate into mtDNA within living cells, causing aggregation of mtDNA nucleoids and altering the distribution of nucleoid proteins. Remodelled nucleoids excluded DXR and maintained mtDNA synthesis, whereas non-remodelled nucleoids became heavily intercalated with DXR, which inhibited their replication, thus leading to mtDNA depletion. Remodelling was accompanied by extensive mitochondrial elongation or interconnection, and was suppressed in cells lacking mitofusin 1 and optic atrophy 1 (OPA1), the key proteins for mitochondrial fusion. In contrast, remodelling was significantly increased by p53 or ataxia telangiectasia mutated inhibition (ATM), indicating a link between nucleoid dynamics and the genomic DNA damage response. Collectively, our results show that DNA intercalators can trigger a common mitochondrial response, which likely contributes to the marked clinical toxicity associated with these drugs. Oncogene (2009) 28, 3880-3891; doi:10.1038/onc.2009.242; published online 17 August 2009	[Ashley, N.; Poulton, J.] Univ Oxford, Nuffield Dept Obstet & Gynaecol, Womens Ctr, John Radcliffe Hosp, Oxford OX3 9DU, England	University of Oxford	Ashley, N (corresponding author), Univ Oxford, Nuffield Dept Obstet & Gynaecol, Womens Ctr, John Radcliffe Hosp, Level 3, Oxford OX3 9DU, England.	Neil.Ashley@clin-pharm.ox.ac.uk; Joanna.Poulton@obs-gyn.ox.ac.uk	Poulton, Joanna/AAB-4828-2021	Ashley, Neil/0000-0002-1655-5137; Poulton, Joanna/0000-0002-2460-5587	MRC/Wellcome Trust; MRC [G0500695] Funding Source: UKRI; Medical Research Council [G0500695] Funding Source: researchfish	MRC/Wellcome Trust(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank I Sargent for providing the equipment; E Brampton, M Zeviani, I Holt, B Roques, A Trifunovic, P Cook and D Chan for materials; and K Morten and F Brook for technical support. This work was funded by the MRC/Wellcome Trust.	Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Achanta G, 2005, EMBO J, V24, P3482, DOI 10.1038/sj.emboj.7600819; Ashley N, 2005, EXP CELL RES, V303, P432, DOI 10.1016/j.yexcr.2004.10.013; Ashley N, 2008, HUM MOL GENET, V17, P2496, DOI 10.1093/hmg/ddn150; Ashley N, 2007, HUM MOL GENET, V16, P1400, DOI 10.1093/hmg/ddm090; Ashley N, 2009, BIOCHEM BIOPH RES CO, V378, P450, DOI 10.1016/j.bbrc.2008.11.059; Bakhanashvili M, 2008, CELL DEATH DIFFER, V15, P1865, DOI 10.1038/cdd.2008.122; Bakhanashvili M, 2009, AIDS, V23, P779, DOI 10.1097/QAD.0b013e328329c74e; Bogenhagen DF, 2008, J BIOL CHEM, V283, P3665, DOI 10.1074/jbc.M708444200; Chen HC, 2005, J BIOL CHEM, V280, P26185, DOI 10.1074/jbc.M503062200; Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046; Chen XJ, 2005, SCIENCE, V307, P714, DOI 10.1126/science.1106391; Cipolat S, 2004, P NATL ACAD SCI USA, V101, P15927, DOI 10.1073/pnas.0407043101; Conklin Kenneth A, 2005, Integr Cancer Ther, V4, P110, DOI 10.1177/1534735405276191; Cullinane C, 2000, NUCLEIC ACIDS RES, V28, P1019, DOI 10.1093/nar/28.4.1019; ELLIS CN, 1987, BIOCHEM J, V245, P309, DOI 10.1042/bj2450309; Emmerson CF, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.2.e1; FELIX CA, 1992, CANCER RES, V52, P2243; Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399; Griparic L, 2007, J CELL BIOL, V178, P757, DOI 10.1083/jcb.200704112; Hande KR, 1998, BBA-GENE STRUCT EXPR, V1400, P173, DOI 10.1016/S0167-4781(98)00134-1; He JY, 2007, J CELL BIOL, V176, P141, DOI 10.1083/jcb.200609158; HIXON SC, 1981, J MOL CELL CARDIOL, V13, P855, DOI 10.1016/0022-2828(81)90242-X; Iborra FJ, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-9; Jung K, 2001, ADV DRUG DELIVER REV, V49, P87, DOI 10.1016/S0169-409X(01)00128-4; Kucej M, 2008, J CELL SCI, V121, P1861, DOI 10.1242/jcs.028605; Kurz EU, 2004, J BIOL CHEM, V279, P53272, DOI 10.1074/jbc.M406879200; Lebrecht D, 2005, J PATHOL, V207, P436, DOI 10.1002/path.1863; Lebrecht D, 2004, NEPHROL DIAL TRANSPL, V19, P329, DOI 10.1093/ndt/gfg564; Legros F, 2004, J CELL SCI, V117, P2653, DOI 10.1242/jcs.01134; Magnusson J, 2003, EXP CELL RES, V289, P133, DOI 10.1016/S0014-4827(03)00249-0; Martinez LA, 2002, P NATL ACAD SCI USA, V99, P14849, DOI 10.1073/pnas.222406899; McKenzie PP, 2002, MOL CANCER THER, V1, P1097; Nithipongvanitch R, 2007, J HISTOCHEM CYTOCHEM, V55, P629, DOI 10.1369/jhc.6A7146.2007; Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200; POULTON J, 1994, HUM MOL GENET, V3, P1763, DOI 10.1093/hmg/3.10.1763; Singal PK, 1998, NEW ENGL J MED, V339, P900, DOI 10.1056/NEJM199809243391307; STEINHERZ L, 1991, Pediatrician, V18, P49; Suliman HB, 2007, J CLIN INVEST, V117, P3730, DOI 10.1172/JCI32967; Tokarska-Schlattner M, 2006, CR BIOL, V329, P657, DOI 10.1016/j.crvi.2005.08.007; Tondera D, 2009, EMBO J, V28, P1589, DOI 10.1038/emboj.2009.89; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; von Wurmb-Schwark N, 2006, MUTAT RES-FUND MOL M, V596, P57, DOI 10.1016/j.mrfmmm.2005.12.003; Wallace KB, 2003, PHARMACOL TOXICOL, V93, P105, DOI 10.1034/j.1600-0773.2003.930301.x; Zhou SY, 2001, TOXICOL LETT, V121, P151, DOI 10.1016/S0378-4274(01)00329-0	45	42	42	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2009	28	44					3880	3891		10.1038/onc.2009.242	http://dx.doi.org/10.1038/onc.2009.242			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	515LJ	19684617	Green Accepted			2022-12-17	WOS:000271471900003
J	Mielgo, A; Torres, VA; Clair, K; Barbero, S; Stupack, DG				Mielgo, A.; Torres, V. A.; Clair, K.; Barbero, S.; Stupack, D. G.			Paclitaxel promotes a caspase 8-mediated apoptosis through death effector domain association with microtubules	ONCOGENE			English	Article						caspase; microtubule-organizing center; centrosome; cell survival; death effector domain	INDUCED CELL-DEATH; CANCER-CELLS; PROTEASOME INHIBITOR; IN-VIVO; PROTEIN FAMILY; LEUKEMIA-CELLS; LYMPHOID-CELLS; LUNG-CANCER; ACTIVATION; RECEPTOR	Microtubule-perturbing drugs have become front-line chemotherapeutics, inducing cell-cycle crisis as a major mechanism of action. However, these agents show pleiotropic effects on cells and can induce apoptosis through other means. Paclitaxel, a microtubule-stabilizing agent, induces a caspase-dependent apoptosis, although the precise mechanism(s) remain unclear. Here, we used genetic approaches to evaluate the role of caspase 8 in paclitaxel-mediated apoptosis. We observed that caspase 8-expressing cells are more sensitive to paclitaxel than caspase 8-deficient cells. Mechanistically, caspase 8 was found associated with microtubules, and this interaction increased after paclitaxel treatment. The prodomains death effector domains (DEDs) of caspase 8 were sufficient for interaction with microtubules, but the caspase 8 holoprotein was required for apoptosis. DED-only forms of caspase 8 were found in both primary and tumor cell lines, associating with perinuclear microtubules and the centrosome. Microtubule association, and paclitaxel sensitivity, depends on a critical lysine (K156) within a microtubule-binding motif (KLD) in DED-b of caspase 8. The results show an unexpected pathway of apoptosis mediated by caspase 8. Oncogene (2009) 28, 3551-3562; doi: 10.1038/onc.2009.210; published online 10 August 2009	[Stupack, D. G.] Univ Calif San Diego, Dept Pathol, Moores Canc Ctr, Sch Med, La Jolla, CA 92093 USA; [Mielgo, A.; Torres, V. A.; Clair, K.; Barbero, S.; Stupack, D. G.] Univ Calif San Diego, Sch Med, Moores Comprehens Canc Ctr, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Stupack, DG (corresponding author), Univ Calif San Diego, Dept Pathol, Moores Canc Ctr, Sch Med, 3855 Hlth Sci Dr, La Jolla, CA 92093 USA.	dstupack@ucsd.edu	Torres, Vicente/I-2437-2013	Torres, Vicente A/0000-0002-5973-7248	NIH/NCI [CA107263]; Swiss National Foundation; Novartis Foundation; Caja Madrid Foundation; NATIONAL CANCER INSTITUTE [R01CA107263] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Swiss National Foundation(Swiss National Science Foundation (SNSF)); Novartis Foundation(Novartis); Caja Madrid Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the NIH/NCI Grant CA107263 to DGS and by grants from the Swiss National Foundation, the Novartis Foundation and the Caja Madrid Foundation to AM. The authors thank Drs S Zeitlin and M Hogan for helpful comments and Drs Marcus Peter (Ben May Institute), Jill Lahti (St Jude Children's Research Hospital), Mark Ginsberg (UCSD) and Guy Salvesen (The Burnham Institute) for the kind gift of reagents.	Al-Bassam J, 2002, J CELL BIOL, V157, P1187, DOI 10.1083/jcb.200201048; Al-Bassam J, 2003, J CELL BIOL, V163, P743, DOI 10.1083/jcb.200308020; Barbero S, 2008, J BIOL CHEM, V283, P13031, DOI 10.1074/jbc.M800549200; Barnhart BC, 2003, ONCOGENE, V22, P8634, DOI 10.1038/sj.onc.1207103; Bayless KJ, 2004, J BIOL CHEM, V279, P11686, DOI 10.1074/jbc.M308373200; Beisner DR, 2003, J IMMUNOL, V171, P247, DOI 10.4049/jimmunol.171.1.247; Blaineau C, 2007, CURR BIOL, V17, P778, DOI 10.1016/j.cub.2007.03.048; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; BORNENS M, 1987, CELL MOTIL CYTOSKEL, V8, P238, DOI 10.1002/cm.970080305; Calvaruso G, 2006, MOL CELL BIOCHEM, V287, P13, DOI 10.1007/s11010-005-9016-3; Carrington PE, 2006, MOL CELL, V22, P599, DOI 10.1016/j.molcel.2006.04.018; Chauhan D, 2008, BLOOD, V111, P1654, DOI 10.1182/blood-2006-10-050476; Feng GP, 2000, J CLIN INVEST, V105, P329, DOI 10.1172/JCI7398; Garvey TL, 2002, VIROLOGY, V300, P217, DOI 10.1006/viro.2002.1518; Garvey TL, 2002, J VIROL, V76, P697, DOI 10.1128/JVI.76.2.697-706.2002; Gascoigne KE, 2008, CANCER CELL, V14, P111, DOI 10.1016/j.ccr.2008.07.002; Gdynia G, 2007, MOL CANCER RES, V5, P1232, DOI 10.1158/1541-7786.MCR-07-0343; GOODE BL, 1994, J CELL BIOL, V124, P769, DOI 10.1083/jcb.124.5.769; Hetz CA, 2002, J CELL SCI, V115, P4671, DOI 10.1242/jcs.00153; Kabore AF, 2006, APOPTOSIS, V11, P1175, DOI 10.1007/s10495-006-8048-9; Kasibhatla S, 2007, CANCER RES, V67, P5865, DOI 10.1158/0008-5472.CAN-07-0127; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Kim M, 2008, CANCER RES, V68, P3440, DOI 10.1158/0008-5472.CAN-08-0014; Kretschmar CS, 2004, J CLIN ONCOL, V22, P4119, DOI 10.1200/JCO.2004.08.174; McDonald ER, 2004, P NATL ACAD SCI USA, V101, P6170, DOI 10.1073/pnas.0307459101; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Miller CP, 2007, BLOOD, V110, P267, DOI 10.1182/blood-2006-03-013128; Mitsui C, 2001, J NEUROSCI RES, V66, P601, DOI 10.1002/jnr.10008; Nimmanapalli R, 2001, CANCER RES, V61, P759; Odoux C, 2002, INT J CANCER, V97, P458, DOI 10.1002/ijc.1640; Odoux C, 2004, VITAM HORM, V67, P385; Ogawa T, 2004, CELL, V116, P591, DOI 10.1016/S0092-8674(04)00129-1; Park SJ, 2004, J BIOL CHEM, V279, P51057, DOI 10.1074/jbc.M406543200; Pellegrini M, 2005, BLOOD, V106, P1581, DOI 10.1182/blood-2005-01-0284; Petit I, 2008, BLOOD, V111, P1951, DOI 10.1182/blood-2007-05-089219; Rozman-Pungercar J, 2003, CELL DEATH DIFFER, V10, P881, DOI 10.1038/sj.cdd.4401247; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Schneider-Brachert W, 2004, IMMUNITY, V21, P415, DOI 10.1016/j.immuni.2004.08.017; Shikama Y, 2002, BIOCHEM BIOPH RES CO, V291, P484, DOI 10.1006/bbrc.2002.6482; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; Singh TR, 2003, CANCER RES, V63, P5390; Stupack DG, 2006, NATURE, V439, P95, DOI 10.1038/nature04323; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Su H, 2005, SCIENCE, V307, P1465, DOI 10.1126/science.1104765; Tang MJ, 2007, J BIOL CHEM, V282, P34457, DOI 10.1074/jbc.M704459200; Teitz T, 2002, ONCOGENE, V21, P1848, DOI 10.1038/sj.onc.1205180; Teitz T, 2001, J MOL MED, V79, P428, DOI 10.1007/s001090100233; Tibbetts MD, 2003, NAT IMMUNOL, V4, P404, DOI 10.1038/ni0503-404; Torres VA, 2008, J BIOL CHEM, V283, P36280, DOI 10.1074/jbc.M805878200; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; Voortman J, 2007, MOL CANCER THER, V6, P2103, DOI 10.1158/1535-7163.MCT-07-0167; Weber CH, 2001, TRENDS BIOCHEM SCI, V26, P475, DOI 10.1016/S0968-0004(01)01905-3; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Yao Z, 2007, EMBO J, V26, P1068, DOI 10.1038/sj.emboj.7601571; Zhu HB, 2004, MOL THER, V9, P666, DOI 10.1016/j.ymthe.2004.02.007	55	42	45	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2009	28	40					3551	3562		10.1038/onc.2009.210	http://dx.doi.org/10.1038/onc.2009.210			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KI	19668227	Green Accepted			2022-12-17	WOS:000270851700004
J	De Martino, I; Visone, R; Fedele, M; Petrocca, F; Palmieri, D; Hoyos, JM; Forzati, F; Croce, CM; Fusco, A				De Martino, I.; Visone, R.; Fedele, M.; Petrocca, F.; Palmieri, D.; Hoyos, J. M.; Forzati, F.; Croce, C. M.; Fusco, A.			Regulation of microRNA expression by HMGA1 proteins	ONCOGENE			English	Article						HMGA1; microRNA; MEF; ATXN1; STC1; HMGA2	GROUP-A PROTEINS; GENE-EXPRESSION; STANNIOCALCIN-1 EXPRESSION; NEOPLASTIC TRANSFORMATION; MESSENGER-RNA; HUMAN CANCER; CELL LINES; C GENES; HMGI(Y); ATAXIN-1	The High Mobility Group proteins HMGA1 are nuclear architectural factors that play a critical role in a wide range of biological processes. Since recent studies have identified the microRNAs (miRNAs) as important regulators of gene expression, modulating critical cellular functions such as proliferation, apoptosis and differentiation, the aim of our work was to identify the miRNAs that are physiologically regulated by HMGA1 proteins. To this purpose, we have analysed the miRNA expression profile of mouse embryonic fibroblasts (MEFs) carrying two, one or no Hmga1 functional alleles using a microarray (miRNA microarray). By this approach, we found a miRNA expression profile that differentiates Hmga1-null MEFs from the wild-type ones. In particular, a significant decrease in miR-196a-2, miR-101b, miR-331 and miR-29a was detected in homozygous Hmga1-knockout MEFs in comparison with wild-type cells. Consistently, these miRNAs are downregulated in most of the analysed tissues of Hmga1-null mice in comparison with the wild-type mice. ChIP assay shows that HMGA1 is able to bind regions upstream of these miRNAs. Moreover, we identified the HMGA2 gene product as a putative target of miR-196a-2, suggesting that HMGA1 proteins are able to downregulate the expression of the other member of the HMGA family through the regulation of the miR-196a-2 expression. Finally, ATXN1 and STC1 gene products have been identified as targets of miR-101b. Therefore, it is reasonable to hypothesize that HMGA1 proteins are involved in several functions by regulating miRNA expression.	[De Martino, I.; Visone, R.; Fedele, M.; Palmieri, D.; Hoyos, J. M.; Forzati, F.; Fusco, A.] Univ Naples Federico II, Ist Endocrinol & Oncol Sperimentale, CNR, Dipartimento Biol Patol Cellulare Mol,Fac Med & C, I-80131 Naples, Italy; [De Martino, I.; Fedele, M.; Fusco, A.] European Sch Mol Med Naples Site, Naples, Italy; [De Martino, I.; Fedele, M.; Fusco, A.] CEINGE, NOGEC, Naples, Italy; [De Martino, I.; Visone, R.; Petrocca, F.; Croce, C. M.] Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; CEINGE Biotecnologie Avanzate; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	De Martino, I (corresponding author), Univ Naples Federico II, Ist Endocrinol & Oncol Sperimentale, CNR Gaetano Salvatore, Via Pansini 5, I-80131 Naples, Italy.	afusco@napoli.com	Fedele, Monica/C-1417-2015; Young, Richard A/F-6495-2012; visone, rosa/K-7910-2016	Fedele, Monica/0000-0002-9171-1312; Young, Richard A/0000-0001-8855-8647; VISONE, Rosa/0000-0002-4993-0220; Palmieri, Dario/0000-0002-0797-4268; Fusco, Alfredo/0000-0003-3332-5197; Martinez Hoyos, Josefina/0000-0002-6909-8259	Associazione Italiana Ricerca sul Cancro (AIRC); Ministero dell'Universita e della Ricerca Scientifica e Tecnologica (MIUR); NOGEC-Naples Oncogenomic Center; Associazione Partenopea per le Ricerche Oncologiche (APRO)	Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Ministero dell'Universita e della Ricerca Scientifica e Tecnologica (MIUR)(Ministry of Education, Universities and Research (MIUR)); NOGEC-Naples Oncogenomic Center; Associazione Partenopea per le Ricerche Oncologiche (APRO)	We thank Professor Stefano Volinia for miRNA microarray data analysis. This work was supported by grants from the Associazione Italiana Ricerca sul Cancro (AIRC), and the Ministero dell'Universita e della Ricerca Scientifica e Tecnologica (MIUR). This work was supported from NOGEC-Naples Oncogenomic Center. We thank the Associazione Partenopea per le Ricerche Oncologiche (APRO) for its support.	ASHAR HR, 1995, CELL, V82, P57; Baldassarre G, 2001, P NATL ACAD SCI USA, V98, P7970, DOI 10.1073/pnas.141224998; Battista S, 1999, CANCER RES, V59, P4793; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; Chang ACM, 2003, ENDOCR-RELAT CANCER, V10, P359, DOI 10.1677/erc.0.0100359; CHANG ACM, 1995, MOL CELL ENDOCRINOL, V112, P241, DOI 10.1016/0303-7207(95)03601-3; Chiappetta G, 1996, ONCOGENE, V13, P2439; De Martino I, 2007, ENDOCR-RELAT CANCER, V14, P875, DOI 10.1677/ERC-07-0036; Eisenhofer G, 2004, ENDOCR-RELAT CANCER, V11, P897, DOI 10.1677/erc.1.00838; Fedele M, 2006, CANCER RES, V66, P2536, DOI 10.1158/0008-5472.CAN-05-1889; Fedele M, 2005, ONCOGENE, V24, P3427, DOI 10.1038/sj.onc.1208501; Fedele M, 1998, ONCOGENE, V17, P413, DOI 10.1038/sj.onc.1201952; Fedele M, 2002, ONCOGENE, V21, P3190, DOI 10.1038/sj.onc.1205428; Fedele M, 2001, CARCINOGENESIS, V22, P1583, DOI 10.1093/carcin/22.10.1583; Foti D, 2005, NAT MED, V11, P765, DOI 10.1038/nm1254; Fujiwara Y, 2000, INT J ONCOL, V16, P799; Fusco A, 2007, NAT REV CANCER, V7, P899, DOI 10.1038/nrc2271; Galardi S, 2007, J BIOL CHEM, V282, P23716, DOI 10.1074/jbc.M701805200; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Gerritsen ME, 2002, PHYSIOL GENOMICS, V10, P13, DOI 10.1152/physiolgenomics.00035.2002; Giannini G, 1999, CANCER RES, V59, P2484; Giannini G, 2000, BRIT J CANCER, V83, P1503, DOI 10.1054/bjoc.2000.1494; Hebert C, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-5; Holmes DIR, 2008, CELL SIGNAL, V20, P569, DOI 10.1016/j.cellsig.2007.11.009; Hoyos JM, 2004, CANCER RES, V64, P5728, DOI 10.1158/0008-5472.CAN-04-1410; Irwin S, 2005, J CELL SCI, V118, P233, DOI 10.1242/jcs.01611; Ishibashi K, 2002, AM J PHYSIOL-RENAL, V282, pF367, DOI 10.1152/ajprenal.00364.2000; Ismail RS, 2000, CANCER RES, V60, P6744; Jellinek DA, 2000, BIOCHEM J, V350, P453, DOI 10.1042/0264-6021:3500453; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; Kent OA, 2006, ONCOGENE, V25, P6188, DOI 10.1038/sj.onc.1209913; Lai KP, 2007, BIOCHEM BIOPH RES CO, V356, P968, DOI 10.1016/j.bbrc.2007.03.074; Lee YS, 2007, GENE DEV, V21, P1025, DOI 10.1101/gad.1540407; Lee Y, 2008, NAT NEUROSCI, V11, P1137, DOI 10.1038/nn.2183; Liu CG, 2004, P NATL ACAD SCI USA, V101, P9740, DOI 10.1073/pnas.0403293101; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; McCudden CR, 2004, MOL CELL ENDOCRINOL, V213, P167, DOI 10.1016/j.mce.2003.10.042; Meister G, 2004, RNA, V10, P544, DOI 10.1261/rna.5235104; Melillo RM, 2001, MOL CELL BIOL, V21, P2485, DOI 10.1128/MCB.21.7.2485-2495.2001; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; Miska EA, 2005, CURR OPIN GENET DEV, V15, P563, DOI 10.1016/j.gde.2005.08.005; Negrini M, 2007, J CELL SCI, V120, P1833, DOI 10.1242/jcs.03450; Nishino J, 2008, CELL, V135, P227, DOI 10.1016/j.cell.2008.09.017; Okabe H, 2001, CANCER RES, V61, P2129; Olsen HS, 1996, P NATL ACAD SCI USA, V93, P1792, DOI 10.1073/pnas.93.5.1792; REEVES R, 1990, J BIOL CHEM, V265, P8573; Scala S, 2000, P NATL ACAD SCI USA, V97, P4256, DOI 10.1073/pnas.070029997; Schmittgen TD, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh040; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; SERVADIO A, 1995, NAT GENET, V10, P94, DOI 10.1038/ng0595-94; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; Tallini G, 1999, ADV ANAT PATHOL, V6, P237, DOI 10.1097/00125480-199909000-00001; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Tsai CC, 2004, P NATL ACAD SCI USA, V101, P4047, DOI 10.1073/pnas.0400615101; Varghese R, 1998, ENDOCRINOLOGY, V139, P4714, DOI 10.1210/en.139.11.4714; Visone R, 2007, ENDOCR-RELAT CANCER, V14, P791, DOI 10.1677/ERC-07-0129; WAGNER GF, 1986, GEN COMP ENDOCR, V63, P481, DOI 10.1016/0016-6480(86)90149-8; Wascher RA, 2003, CLIN CANCER RES, V9, P1427; Watanabe T, 2002, AM J PATHOL, V161, P249, DOI 10.1016/S0002-9440(10)64176-4; Wong CKC, 2002, J ENDOCRINOL, V173, P199, DOI 10.1677/joe.0.1730199; Yeung HY, 2005, ENDOCRINOLOGY, V146, P4951, DOI 10.1210/en.2005-0365; Yue S, 2001, HUM MOL GENET, V10, P25, DOI 10.1093/hmg/10.1.25; Zamore PD, 2005, SCIENCE, V309, P1519, DOI 10.1126/science.1111444; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	64	42	42	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	11					1432	1442		10.1038/onc.2008.495	http://dx.doi.org/10.1038/onc.2008.495			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421JE	19169275				2022-12-17	WOS:000264354400004
J	Hollmen, M; Maatta, JA; Bald, L; Sliwkowski, MX; Elenius, K				Hollmen, M.; Maatta, J. A.; Bald, L.; Sliwkowski, M. X.; Elenius, K.			Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms	ONCOGENE			English	Article						ectodomain shedding; EGFR; HER4; neuregulins; therapeutic antibodies	RECEPTOR TYROSINE KINASES; NUCLEAR-LOCALIZATION; ECTODOMAIN CLEAVAGE; EXPRESSION; HER2; PHOSPHORYLATION; DEGRADATION; ACTIVATION; SURVIVAL; PROTEIN	ErbB4 isoforms mediate different cellular activities depending on their susceptibility to proteolytic cleavage. The biological significance of ErbB4 cleavage in tumorigenesis, however, remains poorly understood. Here, we describe characterization of a monoclonal antibody (mAb 1479) that selectively recognizes the ectodomain of cleavable ErbB4 JM-a isoforms both in vitro and in vivo. mAb 1479 was used to analyse ErbB4 JM-a expression and ectodomain shedding in a series of 17 matched breast cancer/histologically normal peripheral breast tissue pairs. ErbB4 ectodomain was observed in 75% of tumors expressing ErbB4 but only in 18% of normal breast tissue samples expressing ErbB4. Difference in the relative quantity of ErbB4 ectodomain between normal and tumor tissue pairs was statistically significant (P=0.015). Treatment with mAb 1479 suppressed ErbB4 function by inhibiting ErbB4 tyrosine phosphorylation and ectodomain shedding, and by stimulating ErbB4 downregulation and ubiquitination. mAb 1479 suppressed both anchorage-dependent and -independent growth of human breast cancer cell lines that naturally express cleavable ErbB4 JM-a. These findings indicate that ErbB4 ectodomain shedding is enhanced in breast cancer tissue in vivo, and that mAb 1479 represents a potential drug candidate that suppresses breast cancer cell growth by selectively binding cleavable ErbB4 isoforms.	[Hollmen, M.; Maatta, J. A.; Elenius, K.] Univ Turku, Dept Med Biochem & Genet, Med Res Labs, FIN-20520 Turku, Finland; [Hollmen, M.] Turku Grad Sch Biomed Sci, Turku, Finland; [Bald, L.; Sliwkowski, M. X.] Genentech Inc, San Francisco, CA 94080 USA; [Elenius, K.] Turku Univ Hosp, Dept Oncol, FIN-20520 Turku, Finland	University of Turku; University of Turku; Roche Holding; Genentech; University of Turku	Elenius, K (corresponding author), Univ Turku, Dept Med Biochem & Genet, Med Res Labs, Kiinamyllynkatu 10, FIN-20520 Turku, Finland.	klaus.elenius@utu.fi	Hollmén, Maija/B-5831-2017; Elenius, Klaus/AAI-7594-2021	Hollmén, Maija/0000-0002-3250-7653; Elenius, Klaus/0000-0001-5700-0827; Maatta, Jorma/0000-0001-8752-6862	Academy of Finland; Finnish Cancer Organizations; Finnish Cultural Foundation; Foundation for the Finnish Cancer Institute; Jenny and Antti Wihuri Foundation; Sigrid Juselius Foundation; Turku University Central Hospital; Research and Science Foundation of Farmos	Academy of Finland(Academy of Finland); Finnish Cancer Organizations; Finnish Cultural Foundation(Finnish Cultural FoundationFinnish IT center for science); Foundation for the Finnish Cancer Institute; Jenny and Antti Wihuri Foundation; Sigrid Juselius Foundation(Sigrid Juselius Foundation); Turku University Central Hospital; Research and Science Foundation of Farmos	We thank Tero Vahlberg and Tuire Palokangas for statistical analyses, and Maria Tuominen, Minna Santanen and Mika Savisalo for excellent technical assistance. This work has been supported by Academy of Finland, Finnish Cancer Organizations, Finnish Cultural Foundation, Foundation for the Finnish Cancer Institute, Jenny and Antti Wihuri Foundation, Sigrid Juselius Foundation, Turku University Central Hospital and Research and Science Foundation of Farmos.	Agus DB, 2002, CANCER CELL, V2, P127, DOI 10.1016/S1535-6108(02)00097-1; Bao JX, 2003, J CELL BIOL, V161, P1133, DOI 10.1083/jcb.200212085; Borrell-Pages M, 2003, EMBO J, V22, P1114, DOI 10.1093/emboj/cdg111; Carter P, 2001, NAT REV CANCER, V1, P118, DOI 10.1038/35101072; Cheng QC, 2003, J BIOL CHEM, V278, P38421, DOI 10.1074/jbc.M302111200; Cho HS, 2003, NATURE, V421, P756, DOI 10.1038/nature01392; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Elenius K, 1997, J BIOL CHEM, V272, P26761, DOI 10.1074/jbc.272.42.26761; Franklin MC, 2004, CANCER CELL, V5, P317, DOI 10.1016/S1535-6108(04)00083-2; Furger C, 1998, CANCER RES, V58, P1773; Gilbertson RJ, 1997, CANCER RES, V57, P3272; Gilbertson RJ, 2002, CLIN CANCER RES, V8, P3054; Gilmore JL, 2004, ONCOL RES, V14, P589, DOI 10.3727/0965040042707907; Gomes AQ, 2003, MOL BIOL CELL, V14, P1882, DOI 10.1091/mbc.E02-10-0639; Haugen DRF, 1996, CANCER RES, V56, P1184; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Iivanainen E, 2007, EXP CELL RES, V313, P2896, DOI 10.1016/j.yexcr.2007.03.042; Junttila TT, 2005, CANCER RES, V65, P1384, DOI 10.1158/0008-5472.CAN-04-3150; Junttila TT, 2000, TRENDS CARDIOVAS MED, V10, P304, DOI 10.1016/S1050-1738(01)00065-2; Junttila TT, 2003, CLIN CANCER RES, V9, P5346; Kainulainen V, 2000, J BIOL CHEM, V275, P8641, DOI 10.1074/jbc.275.12.8641; Katz M, 2002, TRAFFIC, V3, P740, DOI 10.1034/j.1600-0854.2002.31006.x; Klapper LN, 2000, CANCER RES, V60, P3384; Komuro A, 2003, J BIOL CHEM, V278, P33334, DOI 10.1074/jbc.M305597200; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Maatta JA, 2006, MOL BIOL CELL, V17, P67, DOI 10.1091/mbc.E05-05-0402; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Molina MA, 2001, CANCER RES, V61, P4744; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Omerovic J, 2007, FASEB J, V21, P2849, DOI 10.1096/fj.06-7925com; Paatero Ilkka, 2008, Recent Pat DNA Gene Seq, V2, P27; PABORSKY LR, 1990, PROTEIN ENG, V3, P547, DOI 10.1093/protein/3.6.547; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; Prewett M, 1998, CLIN CANCER RES, V4, P2957; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; Schlessinger J, 2006, CELL, V127, P45, DOI 10.1016/j.cell.2006.09.013; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Srinivasan R, 1999, CLIN CANCER RES, V5, P2877; Srinivasan R, 1998, J PATHOL, V185, P236, DOI 10.1002/(SICI)1096-9896(199807)185:3<236::AID-PATH118>3.0.CO;2-7; SUNADA H, 1986, P NATL ACAD SCI USA, V83, P3825, DOI 10.1073/pnas.83.11.3825; Sundvall M, 2007, ONCOGENE, V26, P6905, DOI 10.1038/sj.onc.1210501; Sundvall M, 2008, J MAMMARY GLAND BIOL, V13, P259, DOI 10.1007/s10911-008-9079-3; Sundvall M, 2008, P NATL ACAD SCI USA, V105, P4162, DOI 10.1073/pnas.0708333105; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; Witton CJ, 2003, J PATHOL, V200, P290, DOI 10.1002/path.1370; Zhang K, 1996, J BIOL CHEM, V271, P3884	46	42	48	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	10					1309	1319		10.1038/onc.2008.481	http://dx.doi.org/10.1038/onc.2008.481			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	417ZC	19151766				2022-12-17	WOS:000264116000003
J	Zhou, Q; Geahlen, RL				Zhou, Q.; Geahlen, R. L.			The protein-tyrosine kinase Syk interacts with TRAF-interacting protein TRIP in breast epithelial cells	ONCOGENE			English	Article						Syk; tyrosine kinase; breast cancer; tumor necrosis factor; TRIP; NF-kappa B	KAPPA-B ACTIVATION; TUMOR-NECROSIS-FACTOR; ANTIGEN RECEPTOR; CANCER CELLS; LOCALIZES; LYN	The nonreceptor, protein-tyrosine kinase Syk is a suppressor of breast cancer progression whose expression is inversely correlated with the invasive behavior of cancer cells. In contrast, Syk has a positive function in murine mammary tumor virus-mediated tumorigenesis. A yeast two-hybrid screen using a library from human mammary gland identified tumor necrosis factor (TNF) receptor-associated factor-interacting protein (TRIP) as an Syk-binding partner. This interaction is mediated by the C-terminal region of TRIP and is enhanced by the treatment of cells with TNF and the tyrosine phosphorylation of Syk. Syk and TRIP have opposing functions in TNF-signaling pathways. Syk enhances the activation of nuclear factor-kappa B by TNF and this is antagonized by TRIP. The overexpression of TRIP sensitizes cells to TNF-induced apoptosis, an effect that can be reversed by the coexpression of Syk.	[Zhou, Q.; Geahlen, R. L.] Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA; [Zhou, Q.; Geahlen, R. L.] Purdue Univ, Purdue Canc Ctr, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Geahlen, RL (corresponding author), Purdue Univ, Dept Med Chem & Mol Pharmacol, Hansen Life Sci Res Bldg,201 S Univ St, W Lafayette, IN 47907 USA.	geahlen@purdue.edu		Geahlen, Robert/0000-0001-8400-2924	NATIONAL CANCER INSTITUTE [R01CA115465] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA115465, R01 CA115465-03, CA115465] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Besse A, 2007, BIOCHEM BIOPH RES CO, V359, P660, DOI 10.1016/j.bbrc.2007.05.149; Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086; Eliopoulos AG, 2006, J BIOL CHEM, V281, P1371, DOI 10.1074/jbc.M506790200; Katz E, 2005, J EXP MED, V201, P431, DOI 10.1084/jem.20041471; Keshvara LM, 1998, J IMMUNOL, V161, P5276; Kurosaki T, 2000, CURR OPIN IMMUNOL, V12, P276, DOI 10.1016/S0952-7915(00)00087-X; Latour S, 2001, CURR OPIN IMMUNOL, V13, P299, DOI 10.1016/S0952-7915(00)00219-3; Lee SY, 1997, J EXP MED, V185, P1275, DOI 10.1084/jem.185.7.1275; Lu J, 2006, J BIOL CHEM, V281, P8806, DOI 10.1074/jbc.M507305200; Ma H, 2001, J IMMUNOL, V166, P1507, DOI 10.4049/jimmunol.166.3.1507; Moon KD, 2005, J BIOL CHEM, V280, P1543, DOI 10.1074/jbc.M407805200; Moroni M, 2004, CANCER RES, V64, P7346, DOI 10.1158/0008-5472.CAN-03-3520; Peters JD, 1996, J BIOL CHEM, V271, P4755; Regamey A, 2003, J EXP MED, V198, P1959, DOI 10.1084/jem.20031187; Salomoni P, 2006, TRENDS CELL BIOL, V16, P97, DOI 10.1016/j.tcb.2005.12.002; Takada Y, 2004, J IMMUNOL, V173, P1066, DOI 10.4049/jimmunol.173.2.1066; Toyama T, 2003, CANCER LETT, V189, P97, DOI 10.1016/S0304-3835(02)00463-9; Ulanova M, 2005, AM J PHYSIOL-LUNG C, V288, pL497, DOI 10.1152/ajplung.00246.2004; Wang L, 2005, CANCER RES, V65, P10289, DOI 10.1158/0008-5472.CAN-05-2231; Wilson J, 2002, SEMIN CANCER BIOL, V12, P113, DOI 10.1006/scbi.2001.0419; Zhou F, 2006, MOL CELL BIOL, V26, P3478, DOI 10.1128/MCB.26.9.3478-3491.2006; Zyss D, 2005, CANCER RES, V65, P10872, DOI 10.1158/0008-5472.CAN-05-1270	22	42	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	10					1348	1356		10.1038/onc.2008.493	http://dx.doi.org/10.1038/onc.2008.493			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	417ZC	19151749	Green Accepted			2022-12-17	WOS:000264116000007
J	Bertoli, C; Copetti, T; Lam, EWF; Demarchi, F; Schneider, C				Bertoli, C.; Copetti, T.; Lam, E. W-F; Demarchi, F.; Schneider, C.			Calpain small-1 modulates Akt/FoxO3A signaling and apoptosis through PP2A	ONCOGENE			English	Article						CAPNS-1; FoxO3A; apoptosis; PP2A; B56; Akt	PROTEIN PHOSPHATASE 2A; FORKHEAD TRANSCRIPTION FACTORS; CELL-CYCLE ARREST; TUMOR-SUPPRESSOR; KINASE-B; MAMMALIAN-CELLS; AKT; DEATH; CANCER; SURVIVAL	Here, we show that FoxO3A transcription factor is upregulated upon calpain small-1 (CAPNS1) depletion both in mouse embryonic. broblasts (MEFs) and in the human mammary carcinoma cell line MCF-7. On starvation, CAPNS1 depletion is associated with a higher rate of FoxO3A dephosphorylation and translocation to the nucleus and to a sharper increase in the levels of p27Kip1 and Bim, the products of two FoxO target genes. Notably, FoxO3A depletion in CAPNS1(-/-) MEFs reduces both the induction of Bim and apoptosis. Both okadaic acid treatment and silencing of the protein phosphatase 2A (PP2A) catalytic subunit can partially reduce starvation-induced FoxO3A activation and apoptosis in CAPNS1(-/-). broblasts. PP2A associates more tightly with Akt in CAPNS1 knockout cells, indicating that PP2A is involved in calpain-mediated FoxO regulation. Finally, we show that PP2A regulatory subunits B56 alpha and gamma are in vitro substrates of calpain, and calpain regulates B56 alpha stability in vivo, suggesting a direct role of calpain in the regulation of PP2A function. In conclusion, for the fist time we report that CAPNS1 interferes with PP2A-Akt interaction consequently affecting FoxO3A-dependent cell death. Calpain inhibition might therefore be exploited as a tool to induce apoptosis in tumors sensitive to FoxO activation.	[Bertoli, C.; Copetti, T.; Demarchi, F.; Schneider, C.] LNCIB, I-34012 Trieste, Italy; [Lam, E. W-F] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Oncol, Canc Res United Kingdom Labs, London, England; [Schneider, C.] Univ Udine, Dipartimento Sci & Tecnol Biomed, I-33100 Udine, Italy	Cancer Research UK; Imperial College London; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine	Demarchi, F (corresponding author), LNCIB, AREA Sci Pk,Padriciano 99, I-34012 Trieste, Italy.	francesca.demarchi@lncib.it; schneide@lncib.it	Lam, Eric W-F/AAW-8566-2020	Lam, Eric W-F/0000-0003-1274-3576; Demarchi, Francesca/0000-0003-1565-3162	FIRC (Fondazione italiana per la ricerca sul cancro); PRIN (Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale) [2006-prot. 2006053543_003]; TRANSFOG (Translational and Functinal Onco-Genomics) EU [503438]; AIRC (Associazione italiana per la ricerca sul cancro) Grant proposal 2007 [Cod. 4752]; Progetto FAR CT cod. MIUR prog [10036]	FIRC (Fondazione italiana per la ricerca sul cancro)(Fondazione AIRC per la ricerca sul cancro); PRIN (Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale)(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); TRANSFOG (Translational and Functinal Onco-Genomics) EU(European Commission); AIRC (Associazione italiana per la ricerca sul cancro) Grant proposal 2007(Fondazione AIRC per la ricerca sul cancro); Progetto FAR CT cod. MIUR prog(Ministry of Education, Universities and Research (MIUR))	We acknowledge Silvano Piazza for help in statistics. CB was a recipient of an FIRC (Fondazione italiana per la ricerca sul cancro) fellowship. This study was supported by PRIN (Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale) 2006-prot. 2006053543_003, and TRANSFOG (Translational and Functinal Onco-Genomics) EU Contract 503438, AIRC (Associazione italiana per la ricerca sul cancro) Grant proposal 2007 Cod. 4752, and Progetto FAR CT cod. MIUR prog. 10036.	Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Andrabi S, 2007, P NATL ACAD SCI USA, V104, P19011, DOI 10.1073/pnas.0706696104; Arthur JSC, 2000, MOL CELL BIOL, V20, P4474, DOI 10.1128/MCB.20.12.4474-4481.2000; Barreyro FJ, 2007, J BIOL CHEM, V282, P27141, DOI 10.1074/jbc.M704391200; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Carragher NO, 2004, NEOPLASIA, V6, P53, DOI 10.1016/S1476-5586(04)80053-8; Darnell GA, 2007, J BIOL CHEM, V282, P37492, DOI 10.1074/jbc.M706860200; Demarchi F, 2005, CELL DEATH DIFFER, V12, P512, DOI 10.1038/sj.cdd.4401592; Demarchi F, 2007, AUTOPHAGY, V3, P235, DOI 10.4161/auto.3661; Demarchi F, 2006, J CELL BIOL, V175, P595, DOI 10.1083/jcb.200601024; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Dourdin N, 2001, J BIOL CHEM, V276, P48382, DOI 10.1074/jbc.M108893200; Essafi A, 2005, ONCOGENE, V24, P2317, DOI 10.1038/sj.onc.1208421; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Guan N, 2006, INT J ONCOL, V29, P655; Harriman JF, 2002, CELL DEATH DIFFER, V9, P734, DOI 10.1038/sj.cdd.4401029; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Libertini SJ, 2005, CANCER RES, V65, P10700, DOI 10.1158/0008-5472.CAN-05-1666; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Mumby M, 2007, CELL, V130, P21, DOI 10.1016/j.cell.2007.06.034; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Reagan-Shaw S, 2006, CANCER RES, V66, P1062, DOI 10.1158/0008-5472.CAN-05-1018; Resjo S, 2002, CELL SIGNAL, V14, P231, DOI 10.1016/S0898-6568(01)00238-8; Rocher G, 2007, J BIOL CHEM, V282, P5468, DOI 10.1074/jbc.M609712200; Sablina AA, 2007, CELL, V129, P969, DOI 10.1016/j.cell.2007.03.047; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Tan Y, 2006, J BIOL CHEM, V281, P17689, DOI 10.1074/jbc.M601978200; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; van der Horst A, 2007, NAT REV MOL CELL BIO, V8, P440, DOI 10.1038/nrm2190; Van Kanegan MJ, 2005, J BIOL CHEM, V280, P36029, DOI 10.1074/jbc.M506986200; Xu LJ, 2006, J BIOL CHEM, V281, P35567, DOI 10.1074/jbc.M607702200; Yan L, 2008, J BIOL CHEM, V283, P7411, DOI 10.1074/jbc.M708083200; Yin KJ, 2006, J NEUROSCI, V26, P2290, DOI 10.1523/JNEUROSCI.5103-05.2006; You H, 2006, J EXP MED, V203, P1657, DOI 10.1084/jem.20060353; Zatz M, 2005, NEW ENGL J MED, V352, P2413, DOI 10.1056/NEJMra043361; Zhang XH, 2002, J BIOL CHEM, V277, P45276, DOI 10.1074/jbc.M208063200	49	42	43	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2009	28	5					721	733		10.1038/onc.2008.425	http://dx.doi.org/10.1038/onc.2008.425			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	403IN	19029949				2022-12-17	WOS:000263076400009
J	Li, Y; Lau, YFC				Li, Y.; Lau, Y-F Chris			TSPY and its X-encoded homologue interact with cyclin B but exert contrasting functions on cyclin-dependent kinase 1 activities	ONCOGENE			English	Article						TSPY; TSPX; sex chromosomes; cyclin B-CDK1; kinase activities; protein-protein interaction	TGF-BETA-1 TARGET DENTT; TESTIS-SPECIFIC PROTEIN; GERM-CELL TUMORS; HUMAN Y-CHROMOSOME; CARCINOMA IN-SITU; GONADOBLASTOMA LOCUS; CANDIDATE GENE; EXPRESSION; SET; IDENTIFICATION	Testis-specific protein Y-encoded ( TSPY) is the putative gene for the gonadoblastoma locus on the Y chromosome (GBY). TSPY and an X-homologue, TSPX, harbor a conserved domain, designated as SET/NAP domain, but differ at their C termini. Ectopic expression of TSPY accelerates cell proliferation by abbreviating the G(2)/M stage, whereas overexpression of TSPX retards cells at the same stage of the cell cycle. Previous studies demonstrated that the SET oncoprotein is capable of binding to cyclin B. Using various protein interaction techniques, we demonstrated that TSPY and TSPX indeed bind competitively to cyclin B at their SET/NAP domains in vitro and in vivo. TSPY colocalizes with cyclin B1 during the cell cycle, particularly on the mitotic spindles at metaphase. TSPY enhances while TSPX represses the cyclin B1-CDK1 phosphorylation activity. The inhibitory effect of TSPX on the cyclin B1-CDK1 complex has been mapped to its carboxyl acidic domain that is absent in TSPY, suggesting that TSPX could serve a normal function in modulating cell-cycle progression at the G(2)/M stage, whereas TSPY has acquired a specialized function in germ cell renewal and differentiation. Epigenetic dysregulation of TSPY in incompatible germ or somatic cells could promote cell proliferation and predispose susceptible cells to tumorigenesis.	[Li, Y.; Lau, Y-F Chris] Univ Calif San Francisco, Dept Med, VA Med Ctr, San Francisco, CA 94121 USA	University of California System; University of California San Francisco	Lau, YFC (corresponding author), Univ Calif San Francisco, Dept Med, VA Med Ctr, 111C5,4150 Clement St, San Francisco, CA 94121 USA.	chris.lau@ucsf.edu	Lau, Yun-Fai C/E-4465-2014	Lau, Yun-Fai C/0000-0002-9119-7050	Merit Review; Prostate Cancer REAP from the Department of Veterans Affairs; Department of Defense to Y-FCL	Merit Review(US Department of Veterans Affairs); Prostate Cancer REAP from the Department of Veterans Affairs(US Department of Veterans Affairs); Department of Defense to Y-FCL(United States Department of Defense)	We thank Dr Tatsuo Kido for assistance in immuno fluorescence of transfected cells presented in Figures 4f-h. This work was partially supported by a Merit Review grant and a Prostate Cancer REAP from the Department of Veterans Affairs and an Idea Grant from the Department of Defense to Y-FCL. Y-FC Lau is a research career scientist of the Department of Veterans Affairs.	ADACHI Y, 1994, J BIOL CHEM, V269, P2258; Bowles J, 2007, DEVELOPMENT, V134, P3401, DOI 10.1242/dev.001107; Canela N, 2003, J BIOL CHEM, V278, P1158, DOI 10.1074/jbc.M207497200; Chai ZL, 2001, J BIOL CHEM, V276, P33665, DOI 10.1074/jbc.M007681200; Compagnone NA, 2000, MOL ENDOCRINOL, V14, P875, DOI 10.1210/me.14.6.875; Decordier I, 2008, MUTAT RES-GEN TOX EN, V651, P3, DOI 10.1016/j.mrgentox.2007.10.020; Delbridge ML, 2004, CHROMOSOME RES, V12, P345, DOI 10.1023/B:CHRO.0000034134.91243.1c; Estanyol JM, 1999, J BIOL CHEM, V274, P33161, DOI 10.1074/jbc.274.46.33161; Fukasawa K, 2007, NAT REV CANCER, V7, P911, DOI 10.1038/nrc2249; Gallagher WM, 2005, CARCINOGENESIS, V26, P1856, DOI 10.1093/carcin/bgi152; Gamble MJ, 2005, MOL CELL BIOL, V25, P797, DOI 10.1128/MCB.25.2.797-807.2005; Graves JAM, 1995, PHILOS T R SOC B, V350, P305, DOI 10.1098/rstb.1995.0166; Hoei-Hansen CE, 2006, J PATHOL, V209, P25, DOI 10.1002/path.1948; Honecker F, 2004, J PATHOL, V203, P849, DOI 10.1002/path.1587; Kandilci A, 2005, LEUKEMIA, V19, P1439, DOI 10.1038/sj.leu.2403826; KELLOGG DR, 1995, J CELL BIOL, V130, P661, DOI 10.1083/jcb.130.3.661; Kersemaekers AMF, 2005, HUM PATHOL, V36, P512, DOI 10.1016/j.humpath.2005.02.016; Kido T, 2005, GENESIS, V42, P263, DOI 10.1002/gene.20147; Kido T, 2006, BIOCHEM BIOPH RES CO, V350, P56, DOI 10.1016/j.bbrc.2006.08.191; Krick R, 2003, GENE, V302, P11, DOI 10.1016/S0378-1119(02)01104-6; Lau YFC, 2003, CYTOGENET GENOME RES, V101, P250, DOI 10.1159/000074345; Lau YFC, 2000, CYTOGENET CELL GENET, V91, P160, DOI 10.1159/000056838; Lau YFC, 2000, MOL CARCINOGEN, V27, P308, DOI 10.1002/(SICI)1098-2744(200004)27:4<308::AID-MC9>3.0.CO;2-R; Lau YFC, 1999, AM J HUM GENET, V64, P921, DOI 10.1086/302353; LAU YFC, 2007, CHROM MAL GERM CELL, P73; LI Y, 2006, MOL CELL ENDOCRINOL, V256, P69; Li YM, 2007, HUM PATHOL, V38, P1470, DOI 10.1016/j.humpath.2007.03.011; Li YM, 2007, UROL ONCOL-SEMIN ORI, V25, P141, DOI 10.1016/j.urolonc.2006.08.002; Lobrich M, 2007, NAT REV CANCER, V7, P861, DOI 10.1038/nrc2248; Looijenga LHJ, 2002, ANAL QUANT CYTOL, V24, P263; Masai H, 2000, J BIOL CHEM, V275, P29042, DOI 10.1074/jbc.M002713200; Oh H, 2005, BIOL REPROD, V72, P407, DOI 10.1095/biolreprod.104.034447; Oosterhuis JW, 2005, NAT REV CANCER, V5, P210, DOI 10.1038/nrc1568; Oram SW, 2006, BMC CANCER, V6, P1, DOI 10.1186/1471-2407-6-154; Ozbun LL, 2005, BBA-GENE STRUCT EXPR, V1728, P163, DOI 10.1016/j.bbaexp.2005.02.010; Ozbun LL, 2003, DEV DYNAM, V226, P491, DOI 10.1002/dvdy.10257; Ozbun LL, 2001, GENOMICS, V73, P179, DOI 10.1006/geno.2001.6505; PAGE DC, 1987, DEVELOPMENT, V101, P151; PINES J, 1992, CIBA F SYMP, V170, P187; PINES J, 1992, CIBA F SYMP, V170, P196; Porter Lisa A, 2003, Prog Cell Cycle Res, V5, P335; Puffenberger EG, 2004, P NATL ACAD SCI USA, V101, P11689, DOI 10.1073/pnas.0401194101; Rajesh Changanarnkandath, 2006, V42, P343, DOI 10.1007/003; Rajpert-De Meyts E, 2006, HUM REPROD UPDATE, V12, P303, DOI 10.1093/humupd/dmk006; Repping S, 2006, NAT GENET, V38, P463, DOI 10.1038/ng1754; Richter JD, 2001, P NATL ACAD SCI USA, V98, P7069, DOI 10.1073/pnas.111146498; SALO P, 1995, GENE CHROMOSOME CANC, V14, P210, DOI 10.1002/gcc.2870140309; Schmit TL, 2007, MOL CANCER THER, V6, P1920, DOI 10.1158/1535-7163.MCT-06-0781; Schnieders F, 1996, HUM MOL GENET, V5, P1801, DOI 10.1093/hmg/5.11.1801; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Skaletsky H, 2003, NATURE, V423, P825, DOI 10.1038/nature01722; Smits VAJ, 2001, BBA-GENE STRUCT EXPR, V1519, P1, DOI 10.1016/S0167-4781(01)00204-4; Tschop K, 2006, FEBS J, V273, P1681, DOI 10.1111/j.1742-4658.2006.05184.x; TSUCHIYA K, 1995, AM J HUM GENET, V57, P1400; Vera J, 2006, ONCOGENE, V25, P260, DOI 10.1038/sj.onc.1209050; Vijayakumar S, 2006, CANCER RES, V66, P4055, DOI 10.1158/0008-5472.CAN-05-3822; Vogel T, 1998, CYTOGENET CELL GENET, V81, P265, DOI 10.1159/000015042; Wang GS, 2004, NEURON, V42, P113, DOI 10.1016/S0896-6273(04)00139-4; Wang Q, 2004, DNA CELL BIOL, V23, P475, DOI 10.1089/1044549041562276; Whittaker SR, 2007, CELL CYCLE, V6, P3114, DOI 10.4161/cc.6.24.5142; Yin YH, 2005, BRIT J CANCER, V93, P458, DOI 10.1038/sj.bjc.6602716; Zhang Julie S., 1992, Human Molecular Genetics, V1, P717, DOI 10.1093/hmg/1.9.717	62	42	43	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2008	27	47					6141	6150		10.1038/onc.2008.206	http://dx.doi.org/10.1038/onc.2008.206			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	360UJ	18591933				2022-12-17	WOS:000260083100007
J	Suh, HC; Leeanansaksiri, W; Ji, M; Klarmann, KD; Renn, K; Gooya, J; Smith, D; McNiece, I; Lugthart, S; Valk, PJM; Delwel, R; Keller, JR				Suh, H. C.; Leeanansaksiri, W.; Ji, M.; Klarmann, K. D.; Renn, K.; Gooya, J.; Smith, D.; McNiece, I.; Lugthart, S.; Valk, P. J. M.; Delwel, R.; Keller, J. R.			Id1 immortalizes hematopoietic progenitors in vitro and promotes a myeloproliferative disease in vivo	ONCOGENE			English	Article						Id1; myeloproliferative disease; leukemia; therapeutic target; prevention	ACUTE MYELOID-LEUKEMIA; LOOP-HELIX PROTEINS; CELL-DEVELOPMENT; TRANSGENIC MICE; STEM-CELLS; TRANSCRIPTION FACTORS; BONE-MARROW; C/EBP-ALPHA; EXPRESSION; DIFFERENTIATION	Id1 is frequently overexpressed in many cancer cells, but the functional significance of these findings is not known. To determine if Id1 could contribute to the development of hematopoietic malignancy, we reconstituted mice with hematopoietic cells overexpressing Id1. We showed for the first time that deregulated expression of Id1 leads to a myeloproliferative disease in mice, and immortalizes myeloid progenitors in vitro. In human cells, we demonstrate that Id genes are expressed in human acute myelogenous leukemia cells, and that knock down of Id1 expression inhibits leukemic cell line growth, suggesting that Id1 is required for leukemic cell proliferation. These findings established a causal relationship between Id1 overexpression and hematologic malignancy. Thus, deregulated expression of Id1 may contribute to the initiation of myeloid malignancy, and Id1 may represent a potential therapeutic target for early stage intervention in the treatment of hematopoietic malignancy.	[Suh, H. C.; Leeanansaksiri, W.; Ji, M.; Klarmann, K. D.; Renn, K.; Gooya, J.; Keller, J. R.] NCI, Basic Res Program, SAIC Frederick Inc, Frederick, MD 21702 USA; [Suh, H. C.; Leeanansaksiri, W.; Ji, M.; Klarmann, K. D.; Renn, K.; Gooya, J.; Keller, J. R.] NCI, Canc Res Ctr, Frederick, MD 21702 USA; [Smith, D.; McNiece, I.] Sidney Kimmel Comprehens Canc Ctr, Div Hematol Malignancies, Baltimore, MD USA; [Lugthart, S.; Valk, P. J. M.; Delwel, R.] Erasmus Univ, Med Ctr, Dept Hematol, Rotterdam, Netherlands	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University; Johns Hopkins Medicine; Erasmus University Rotterdam; Erasmus MC	Keller, JR (corresponding author), NCI, Basic Res Program, SAIC Frederick Inc, Bldg 560,Room 12-03, Frederick, MD 21702 USA.	kellerj@ncifcrf.gov	Valk, Peter/AAX-2823-2020; Suh, Hyung/L-5912-2019; Ji, Ming/C-2795-2011; Keller, Jonathan R./O-6677-2018	Suh, Hyung/0000-0001-6912-4157; Lugthart, Sanne/0000-0003-3007-8303	National Cancer Institute; National Institutes of Health [NO1-CO-12400]; Intramural Research Program of NIH; Center for Cancer Research; Regional Oncology Research Center [5 P30 CA06973]; NATIONAL CANCER INSTITUTE [P30CA006973, ZIABC010001] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Intramural Research Program of NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Regional Oncology Research Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We gratefully acknowledge the technical support of Steve Stull, Kathleen Noer, Roberta Matthai and Samantha Bauchiero. We also thank Dr Nancy Colburn, Dr Sandra Ruscetti and Dr Kristbjorn Gudmundsson for their critical review of this article. This project has been funded, in part, with Federal funds from the National Cancer Institute, National Institutes of Health, under contract number NO1-CO-12400. This research was supported, in part, by the Intramural Research Program of NIH, National Cancer Institute, Center for Cancer Research. Clinical specimens were provided by the Sidney Kimmel Cancer Center at Johns Hopkins Tumor and Cell Procurement Bank, supported by the Regional Oncology Research Center Grant no. 5 P30 CA06973.	Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Akashi K, 2000, CURR OPIN IMMUNOL, V12, P144, DOI 10.1016/S0952-7915(99)00064-3; Akashi K, 2003, BLOOD, V101, P383, DOI 10.1182/blood-2002-06-1780; Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; Belletti B, 2002, EXP CELL RES, V277, P107, DOI 10.1006/excr.2002.5542; Buitenhuis M, 2005, BLOOD, V105, P4272, DOI 10.1182/blood-2004-12-4883; Bullinger L, 2005, J CLIN ONCOL, V23, P6296, DOI 10.1200/JCO.2005.05.020; Castilla LH, 1999, NAT GENET, V23, P144, DOI 10.1038/13776; Cooper CL, 1997, BLOOD, V89, P3155, DOI 10.1182/blood.V89.9.3155; Fong S, 2004, TRENDS MOL MED, V10, P387, DOI 10.1016/j.molmed.2004.06.008; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; Hu M, 1997, GENE DEV, V11, P774, DOI 10.1101/gad.11.6.774; Ishiguro A, 1995, LEUKEMIA RES, V19, P989, DOI 10.1016/0145-2126(95)00084-4; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Kim D, 1999, MOL CELL BIOL, V19, P8240; Kogan SC, 2002, BLOOD, V100, P238, DOI 10.1182/blood.V100.1.238; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; Koschmieder S, 2005, INT J HEMATOL, V81, P368, DOI 10.1532/IJH97.05051; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; Kunisato A, 2004, BLOOD, V103, P3336, DOI 10.1182/blood-2003-06-1935; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 2001, ONCOGENE, V20, P8326, DOI 10.1038/sj.onc.1205093; Leeanansaksiri W, 2005, J IMMUNOL, V174, P7014, DOI 10.4049/jimmunol.174.11.7014; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Nilsson L, 2007, BLOOD, V110, P3005, DOI 10.1182/blood-2007-03-079368; Norton JD, 2000, J CELL SCI, V113, P3897; O'Neil J, 2004, CANCER CELL, V5, P587, DOI 10.1016/j.ccr.2004.05.023; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Pagliuca A, 2000, CANCER RES, V60, P1376; Perk J, 2005, NAT REV CANCER, V5, P603, DOI 10.1038/nrc1673; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Quesenberry PJ, 1996, J CELL BIOCHEM, V61, P478; Rosenbauer F, 2005, BLOOD, V106, P1519, DOI 10.1182/blood-2005-02-0717; Rosmarin AG, 2005, EXP HEMATOL, V33, P131, DOI 10.1016/j.exphem.2004.08.015; Ruzinova MB, 2003, TRENDS CELL BIOL, V13, P410, DOI 10.1016/S0962-8924(03)00147-8; Sikder HA, 2003, CANCER CELL, V3, P525, DOI 10.1016/S1535-6108(03)00141-7; Suh HC, 2006, BLOOD, V107, P4308, DOI 10.1182/blood-2005-06-2216; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185; Wong YC, 2004, APOPTOSIS, V9, P279, DOI 10.1023/B:APPT.0000025804.25396.79; Yokota Y, 2002, J CELL PHYSIOL, V190, P21, DOI 10.1002/jcp.10042; Zhang JS, 2004, SCIENCE, V305, P1286, DOI 10.1126/science.1097937	49	42	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2008	27	42					5612	5623		10.1038/onc.2008.175	http://dx.doi.org/10.1038/onc.2008.175			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KX	18542061	Green Accepted			2022-12-17	WOS:000259280800007
J	Xu, Y				Xu, Y.			Induction of genetic instability by gain-of-function p53 cancer mutants	ONCOGENE			English	Review						p53 cancer mutants; gain-of-function; genetic stability; chromosomal translocation; ATM	P53-INDEPENDENT APOPTOTIC PATHWAYS; EMBRYONIC STEM-CELLS; LI-FRAUMENI-SYNDROME; DNA-DAMAGE; TUMOR SUPPRESSION; ATM ACTIVATION; P53-DEPENDENT APOPTOSIS; TRANSCRIPTION-FACTOR; WILD-TYPE; REPLICATIVE SENESCENCE	p53 plays critical roles in tumor suppression and the loss of its function is required for cancer progression. In this context, the p53 gene is the most commonly mutated tumor suppressor gene in human cancers. The majority of the p53 gene mutations in human cancers are missense mutations, leading to the expression of the full-length mutant p53 protein in cancer cells. In addition to the loss of tumor suppression activity, p53 cancer mutants gain new oncogenic activities to promote tumorigenesis and drug resistance. Recent studies have identified a novel gain-of-function of p53 cancer mutants in inducing genetic instability by inactivating critical tumor suppressors such as ATM. Genetic instability is a common mechanism by which cancer cells efficiently accumulate genetic mutations to promote their growth, survival and metastatic potential. Therefore, this gain-of-function of p53 cancer mutants could play important roles in tumorigenesis and drug resistance of various types of human cancers. In addition, because many cancer therapies such as radiation therapy suppress or kill cancer cells by activating ATM-dependent responses to DNA double-stranded break damage, elucidation of this gain-of-function of p53 cancer mutants will have important implications on cancer therapy.	Univ Calif San Diego, Div Biol Sci, Mol Biol Sect, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Xu, Y (corresponding author), Univ Calif San Diego, Div Biol Sci, Mol Biol Sect, 9500 Gilman Dr, La Jolla, CA 92093 USA.	yangxu@ucsd.edu		Xu, Yang/0000-0001-5574-921X	NCI NIH HHS [CA94254] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094254] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albor A, 1998, CANCER RES, V58, P2091; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Ben-Porath I, 2005, INT J BIOCHEM CELL B, V37, P961, DOI 10.1016/j.biocel.2004.10.013; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Chao C, 2003, J BIOL CHEM, V278, P41028, DOI 10.1074/jbc.M306938200; Chao C, 2006, EMBO J, V25, P2615, DOI 10.1038/sj.emboj.7601167; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Difilippantonio S, 2005, NAT CELL BIOL, V7, P675, DOI 10.1038/ncb1270; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; Feng LJ, 2006, CELL CYCLE, V5, P2812, DOI 10.4161/cc.5.23.3526; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Franco S, 2006, DNA REPAIR, V5, P1030, DOI 10.1016/j.dnarep.2006.05.024; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Goldie JH, 2001, CANCER METAST REV, V20, P63, DOI 10.1023/A:1013164609041; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Gudkov AV, 2003, CANCER BIOL THER, V2, P444, DOI 10.4161/cbt.2.4.480; Hainaut P, 2000, ADV CANCER RES, V77, P81; Hergenhahn M, 2004, CELL CYCLE, V3, P738; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Hopfner KP, 2002, NATURE, V418, P562, DOI 10.1038/nature00922; Hopfner KP, 2001, CELL, V105, P473, DOI 10.1016/S0092-8674(01)00335-X; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Joerger AC, 2007, ONCOGENE, V26, P2226, DOI 10.1038/sj.onc.1210291; Johnson TM, 2005, NAT GENET, V37, P145, DOI 10.1038/ng1498; Kang J, 2005, MOL CELL BIOL, V25, P661, DOI 10.1128/MCB.25.2.661-670.2005; Kang J, 2002, EMBO J, V21, P1447, DOI 10.1093/emboj/21.6.1447; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kitagawa R, 2004, GENE DEV, V18, P1423, DOI 10.1101/gad.1200304; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Kortlever RM, 2006, NAT CELL BIOL, V8, P877, DOI 10.1038/ncb1448; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; Li Y, 2007, ONCOGENE, V26, P2220, DOI 10.1038/sj.onc.1210311; Lin TX, 2005, NAT CELL BIOL, V7, P165, DOI 10.1038/ncb1211; Luo JL, 2001, ONCOGENE, V20, P320, DOI 10.1038/sj.onc.1204080; Meletis K, 2006, DEVELOPMENT, V133, P363, DOI 10.1242/dev.02208; Mitelman F, 2007, NAT REV CANCER, V7, P233, DOI 10.1038/nrc2091; Murphy ME, 2003, CANCER BIOL THER, V2, P381, DOI 10.4161/cbt.2.4.439; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Preuss U, 2000, INT J CANCER, V88, P162, DOI 10.1002/1097-0215(20001015)88:2<162::AID-IJC3>3.0.CO;2-M; Riballo E, 2004, MOL CELL, V16, P715, DOI 10.1016/j.molcel.2004.10.029; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; Song H, 2007, NAT CELL BIOL, V9, P573, DOI 10.1038/ncb1571; Stiewe T, 2007, NAT REV CANCER, V7, P165, DOI 10.1038/nrc2072; Strano S, 2007, ONCOGENE, V26, P2212, DOI 10.1038/sj.onc.1210296; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Taubert H, 1996, CANCER RES, V56, P4134; Theunissen JWF, 2003, MOL CELL, V12, P1511, DOI 10.1016/S1097-2765(03)00455-6; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Vega FJ, 1997, BRIT J CANCER, V76, P44, DOI 10.1038/bjc.1997.334; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Weisz L, 2007, ONCOGENE, V26, P2202, DOI 10.1038/sj.onc.1210294; Woerner Stefan M., 2006, Cancer Biomarkers, V2, P69; Xu Y, 2006, NAT REV IMMUNOL, V6, P261, DOI 10.1038/nri1804; Xu Y, 2005, CELL CYCLE, V4, P363, DOI 10.4161/cc.4.3.1529; Xu Y, 1998, MOL CELL BIOL, V18, P4385, DOI 10.1128/MCB.18.7.4385; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Yee KS, 2005, CARCINOGENESIS, V26, P1317, DOI 10.1093/carcin/bgi122; You ZS, 2005, MOL CELL BIOL, V25, P5363, DOI 10.1128/MCB.25.13.5363-5379.2005; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zalcenstein A, 2006, ONCOGENE, V25, P359, DOI 10.1038/sj.onc.1209061; Zalcenstein A, 2003, ONCOGENE, V22, P5667, DOI 10.1038/sj.onc.1206724; Zhang YM, 2006, DNA REPAIR, V5, P1282, DOI 10.1016/j.dnarep.2006.05.020	87	42	45	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2008	27	25					3501	3507		10.1038/sj.onc.1211023	http://dx.doi.org/10.1038/sj.onc.1211023			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18223686				2022-12-17	WOS:000256468500001
J	Taubert, H; Wurl, P; Greither, T; Kappler, M; Bache, M; Bartel, F; Kehlen, A; Lautenschlager, C; Harris, LC; Kaushal, D; Fussel, S; Meye, A; Bohnke, A; Schmidt, H				Taubert, H.; Wuerl, P.; Greither, T.; Kappler, M.; Bache, M.; Bartel, F.; Kehlen, A.; Lautenschlaeger, C.; Harris, L. C.; Kaushal, D.; Fuessel, S.; Meye, A.; Boehnke, A.; Schmidt, H.			Stem cell-associated genes are extremely poor prognostic factors for soft-tissue sarcoma patients	ONCOGENE			English	Article						stem cell-associated genes; soft-tissue sarcoma; prognosis; Hiwi; hTERT; survivin	TUMOR-RELATED DEATH; TELOMERASE ACTIVITY; CANCER; PROTEIN; EXPRESSION; SURVIVIN; HIWI; PROLIFERATION; PATHWAY; HTERT	Cancer stem cells can play an important role in tumorigenesis and tumor progression. However, it is still difficult to detect and isolate cancer stem cells. An alternative approach is to analyse stem cell-associated gene expression. We investigated the coexpression of three stem cell-associated genes, Hiwi, hTERT and survivin, by quantitative real-time-PCR in 104 primary soft-tissue sarcomas (STS). Multivariate Cox's proportional hazards regression analyses allowed correlating gene expression with overall survival for STS patients. Coexpression of all three stem cell-associated genes resulted in a significantly increased risk of tumor-related death. Importantly, tumors of patients with the poorest prognosis were of all four tumor stages, suggesting that their risk is based upon coexpression of stem cell-associated genes rather than on tumor stage.	Univ Halle Wittenberg, Fac Med, Inst Pathol, D-06097 Halle, Germany; Univ Ulm, Clin Gen & Transplantat Surg, Ulm, Germany; Univ Halle Wittenberg, Dept Radiotherapy, D-06097 Halle, Germany; Univ Halle Wittenberg, Inst Pathol, Junior Res Grp, D-06097 Halle, Germany; Probiodrug AG, Halle, Germany; Univ Halle Wittenberg, Inst Med Biometry & Informat, D-06097 Halle, Germany; St Jude Childrens Hosp, Hartwell Ctr Bioinformat & Biotechnol, Memphis, TN 38105 USA; Tech Univ Dresden, Dept Urol, D-8027 Dresden, Germany	Martin Luther University Halle Wittenberg; Ulm University; Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg; Vivoryon Therapeutics; Martin Luther University Halle Wittenberg; St Jude Children's Research Hospital; Technische Universitat Dresden	Taubert, H (corresponding author), Univ Halle Wittenberg, Fac Med, Inst Pathol, Magdeburger Str 14, D-06097 Halle, Germany.	helge.taubert@medizin.uni-halle.de	Greither, Thomas/M-5334-2019; Kappler, Matthias/ABG-9644-2020	Kappler, Matthias/0000-0003-2002-0271				Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Aravin A, 2006, NATURE, V442, P203, DOI 10.1038/nature04916; Endoh T, 2005, EXP CELL RES, V305, P300, DOI 10.1016/j.yexcr.2004.12.014; Girard A, 2006, NATURE, V442, P199, DOI 10.1038/nature04917; Hill RP, 2006, CANCER RES, V66, P1891, DOI 10.1158/0008-5472.CAN-05-3450; Ju ZY, 2006, EUR J CANCER, V42, P1197, DOI 10.1016/j.ejca.2006.01.040; Kirkpatrick KL, 2001, EUR J SURG ONCOL, V27, P754, DOI 10.1053/ejso.2001.1151; Lee JH, 2006, HUM MOL GENET, V15, P201, DOI 10.1093/hmg/ddi430; Lingel A, 2005, CURR OPIN STRUC BIOL, V15, P107, DOI 10.1016/j.sbi.2005.01.010; Liu XY, 2006, INT J CANCER, V118, P1922, DOI 10.1002/ijc.21575; Morrison SJ, 1996, IMMUNITY, V5, P207, DOI 10.1016/S1074-7613(00)80316-7; Nguyen HG, 2006, J CELL PHYSIOL, V208, P12, DOI 10.1002/jcp.20565; Pendino F, 2006, CURR CANCER DRUG TAR, V6, P147, DOI 10.2174/156800906776056482; Polyak K, 2006, NAT MED, V12, P296, DOI 10.1038/nm1379; Qiao D, 2002, ONCOGENE, V21, P3988, DOI 10.1038/sj.onc.1205505; Smith LL, 2003, NAT CELL BIOL, V5, P474, DOI 10.1038/ncb985; Soltysova A, 2005, NEOPLASMA, V52, P435; Taubert H, 2007, ONCOGENE, V26, P1098, DOI 10.1038/sj.onc.1209880; Wurl P, 2002, LANCET, V359, P943, DOI 10.1016/S0140-6736(02)07990-4; Zhu CQ, 2006, BRIT J CANCER, V94, P1452, DOI 10.1038/sj.bjc.6603110	20	42	45	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2007	26	50					7170	7174		10.1038/sj.onc.1210530	http://dx.doi.org/10.1038/sj.onc.1210530			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228GF	17525744				2022-12-17	WOS:000250715000012
J	Kida, A; Kakihana, K; Kotani, S; Kurosu, T; Miura, O				Kida, A.; Kakihana, K.; Kotani, S.; Kurosu, T.; Miura, O.			Glycogen synthase kinase-3 beta and p38 phosphorylate cyclin D2 on Thr280 to trigger its ubiquitin/proteasome-dependent degradation in hematopoietic cells	ONCOGENE			English	Article						cyclin D2; PI3K; GSK3 beta; p38; proteasomal degradation	ERYTHROPOIETIN RECEPTOR; CYCLE PROGRESSION; D2 EXPRESSION; BCR-ABL; D1; PROTEIN; DYSREGULATION; INHIBITION; PROLIFERATION; ACTIVATION	Cyclin D2 plays an important role in regulation of hematopoietic cell proliferation by cytokines and is implicated in oncogenesis of various hematopoietic malignancies. However, mechanisms regulating cyclin D2 stability and its expression level have remained to be known. Here, we demonstrate that interleukin- 3 signaling stabilizes cyclin D2 by inhibition of glycogen synthase kinase-3 beta ( GSK3 beta) through Janus kinase2-dependent activation of phosphatidylinositol 3'-kinase ( PI3K)/Akt signaling pathway in hematopoietic 32Dcl3 cells. On the other hand, osmotic stress was shown to induce a rapid proteasomal degradation of cyclin D2, which was mediated by activation of p38. GSK3 beta and p38 was demonstrated to phosphorylate cyclin D2 on Thr280 in vitro, while a cyclin D2 mutant with this residue substituted with Ala was found to be resistant to ubiquitination and proteasome- dependent degradation in 32Dcl3 cells. Inhibition of the PI3K pathway or induction of osmotic stress also caused a rapid proteasomal degradation of cyclin D2 in primary leukemic or myeloma cells. These results indicate that cyclin D2 expression in normal and malignant hematopoietic cells is regulated by ubiquitin/ proteasome- dependent degradation that is triggered by Thr280 phosphorylation by GSK3 beta or p38, which is induced by inhibition of the PI3K pathway or by osmotic stress, respectively.	Tokyo Med & Dent Univ, Grad Sch Med, Dept Hematol, Tokyo 1138519, Japan	Tokyo Medical & Dental University (TMDU)	Miura, O (corresponding author), Tokyo Med & Dent Univ, Grad Sch Med, Dept Hematol, 1-5-45 Yushima, Tokyo 1138519, Japan.	miura.hema@tmd.ac.jp		Miura, Osamu/0000-0002-0981-3054				Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; Benzeno S, 2006, ONCOGENE, V25, P6291, DOI 10.1038/sj.onc.1209644; Bergsagel PL, 2005, BLOOD, V106, P296, DOI 10.1182/blood-2005-01-0034; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Carthon BC, 2005, MOL CELL BIOL, V25, P1081, DOI 10.1128/MCB.25.3.1081-1088.2005; Casanovas O, 2000, J BIOL CHEM, V275, P35091, DOI 10.1074/jbc.M006324200; Casanovas O, 2004, ONCOGENE, V23, P7537, DOI 10.1038/sj.onc.1208040; Chiles TC, 2004, J IMMUNOL, V173, P2901, DOI 10.4049/jimmunol.173.5.2901; Chin H, 1998, BLOOD, V91, P3734; Clappier E, 2006, LEUKEMIA, V20, P82, DOI 10.1038/sj.leu.2404008; Deininger MWN, 2001, CANCER RES, V61, P8005; DELMER A, 1995, BLOOD, V85, P2870, DOI 10.1182/blood.V85.10.2870.bloodjournal85102870; Deshpande A, 2005, ONCOGENE, V24, P2909, DOI 10.1038/sj.onc.1208618; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Ely S, 2005, CANCER RES, V65, P11345, DOI 10.1158/0008-5472.CAN-05-2159; Fox BC, 2005, CELL SIGNAL, V17, P473, DOI 10.1016/j.cellsig.2004.09.004; Hu XT, 2002, J BIOL CHEM, V277, P16528, DOI 10.1074/jbc.M109929200; Huang W, 2007, ONCOGENE, V26, P2471, DOI 10.1038/sj.onc.1210033; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Jena N, 2002, CANCER RES, V62, P535; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Karrman K, 2006, EUR J HAEMATOL, V77, P27, DOI 10.1111/j.0902-4441.2006.t01-1-EJH2553.x; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; Kozar K, 2005, CELL CYCLE, V4, P388, DOI 10.4161/cc.4.3.1551; Kurosu T, 2005, APOPTOSIS, V10, P1111, DOI 10.1007/s10495-005-3372-z; Kwak YT, 2005, J BIOL CHEM, V280, P33945, DOI 10.1074/jbc.M506206200; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lin DI, 2006, MOL CELL, V24, P355, DOI 10.1016/j.molcel.2006.09.007; Lucet IS, 2006, BLOOD, V107, P176, DOI 10.1182/blood-2005-06-2413; Ma Y, 2005, CANCER RES, V65, P6476, DOI 10.1158/0008-5472.CAN-05-0370; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Naderi S, 2004, J CELL SCI, V117, P3769, DOI 10.1242/jcs.01210; Okabe H, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000128; Parada Y, 2001, J BIOL CHEM, V276, P23572, DOI 10.1074/jbc.M101885200; Radosevic N, 2001, LEUKEMIA, V15, P559, DOI 10.1038/sj.leu.2402092; Shao JY, 2000, J BIOL CHEM, V275, P22916, DOI 10.1074/jbc.M002235200; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Yang GX, 2003, RRD PL CE P, V1, P7	42	42	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2007	26	46					6630	6640		10.1038/sj.onc.1210490	http://dx.doi.org/10.1038/sj.onc.1210490			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	219JT	17486076				2022-12-17	WOS:000250081500005
J	Liu, X; Hu, Y; Hao, C; Rempel, SA; Ye, K				Liu, X.; Hu, Y.; Hao, C.; Rempel, S. A.; Ye, K.			PIKE-A is a proto-oncogene promoting cell growth, transformation and invasion	ONCOGENE			English	Article						PIKE-A; Akt; proto-oncogene; transformation; cell invasion	HUMAN-MALIGNANT GLIOMAS; PROTEIN-KINASE B/AKT; NUCLEAR GTPASE; AKT; AMPLIFICATION; PHOSPHORYLATION; ONCOGENE; CANCER; HETEROZYGOSITY; IDENTIFICATION	PIKE-A (phosphoinositide 3-kinases (PI 3)-kinase enhancer) is a ubiquitously expressed GTPase, which binds to and enhances protein kinase B (Akt) kinase activity in a guanine nucleotide-dependent manner. PIKE-A is one of the components of the CDK4 amplicon that is ampli. ed in numerous human cancers. However, whether PIKE-A itself can mediate cell transformation, proliferation and migration remains unknown. Here, we show that PIKE-A is overexpressed in various human cancer samples, escalates U87MG glioblastoma invasion and provokes NIH3T3 cell transformation. Overexpression of wild-type (WT) PIKE-A enhances NIH3T3 and U87MG cell growth, which is further increased by cancer cell-derived PIKE-A active mutants. In contrast, both the dominant-negative mutant and the phosphoinositide lipids interaction-defective mutant antagonize cell proliferation. Moreover, PIKE-A and its active and inactive mutants similarly enhance or antagonize U87MG cell survival and invasion, and their ability to do so is coupled with the catalytic effect they have on Akt activation. Furthermore, PIKE-A WT and its active mutants signifi. cantly elicit NIH3T3 cell transformation. Thus, our. ndings support the concept that PIKE-A acts as a proto-oncogene, promoting cell transformation through Akt activation.	Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; Henry Ford Hosp, Hermelin Brain Tumor Ctr, Dept Neurosurg, Barbara Jane Levy Lab Mol Neurooncol, Detroit, MI 48202 USA	Emory University; Henry Ford Health System; Henry Ford Hospital	Ye, K (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, Room 145,Whitehead Bldg,615 Michael St, Atlanta, GA 30322 USA.	kye@emory.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045627] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS045627] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahn JY, 2004, EMBO J, V23, P3995, DOI 10.1038/sj.emboj.7600392; Ahn JY, 2004, P NATL ACAD SCI USA, V101, P6993, DOI 10.1073/pnas.0400921101; Ahn JY, 2004, J BIOL CHEM, V279, P16441, DOI 10.1074/jbc.M312175200; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Coffer PJ, 1998, BIOCHEM J, V335, P1; COLLINS VP, 1995, GLIA, V15, P289, DOI 10.1002/glia.440150309; COX AD, 1994, METHOD ENZYMOL, V238, P277; Gallis B, 1999, J BIOL CHEM, V274, P30101, DOI 10.1074/jbc.274.42.30101; Hill MM, 2002, PHARMACOL THERAPEUT, V93, P243, DOI 10.1016/S0163-7258(02)00193-6; Hu YX, 2005, P NATL ACAD SCI USA, V102, P16853, DOI 10.1073/pnas.0507365102; Huang ZY, 2002, ONCOGENE, V21, P1325, DOI 10.1038/sj.onc.1205206; Lee MJ, 2001, MOL CELL, V8, P693, DOI 10.1016/S1097-2765(01)00324-0; Nakatani K, 1999, BIOCHEM BIOPH RES CO, V257, P906, DOI 10.1006/bbrc.1999.0559; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; Park BK, 2001, CANCER RES, V61, P7647; REIFENBERGER G, 1995, CANCER RES, V55, P731; REIFENBERGER G, 1994, CANCER RES, V54, P4299; Rempel SA, 2001, J NEURO-ONCOL, V53, P149, DOI 10.1023/A:1012201300188; Rong R, 2003, NAT NEUROSCI, V6, P1153, DOI 10.1038/nn1134; SMITH SH, 1992, CANCER RES, V52, P3746; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Ye KQ, 2000, CELL, V103, P919, DOI 10.1016/S0092-8674(00)00195-1; Ye KQ, 2005, J CELL BIOCHEM, V96, P463, DOI 10.1002/jcb.20549; Ye KQ, 2002, NATURE, V415, P541, DOI 10.1038/415541a	28	42	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	34					4918	4927		10.1038/sj.onc.1210290	http://dx.doi.org/10.1038/sj.onc.1210290			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17297440				2022-12-17	WOS:000248322500004
J	Narisawa-Saito, M; Handa, K; Yugawa, T; Ohno, S; Fujita, M; Kiyono, T				Narisawa-Saito, M.; Handa, K.; Yugawa, T.; Ohno, S.; Fujita, M.; Kiyono, T.			HPV16 E6-mediated stabilization of ErbB2 in neoplastic transformation of human cervical keratinocytes	ONCOGENE			English	Article						HPV16 E6; ErbB2; primary human cervical keratinocytes; cervical cancer	HUMAN-PAPILLOMAVIRUS TYPE-16; GROWTH-FACTOR RECEPTOR; PROGNOSTIC-SIGNIFICANCE; HER-2/NEU ONCOGENE; E6 ONCOPROTEIN; CARCINOMA; PROTEIN; CELLS; EXPRESSION; CANCER	Whether ErbB2 receptor tyrosine kinase contributes to cervical cancer is controversial. We have examined the effects of E6 and E7 genes of human papillomaviruses type 16 ( HPV-16) on ErbB2 expression in primary human cervical keratinocytes ( HCK) immortalized with hTERT ( HCK1T). In E6-positive cells ( HCK1T-E6 and HCK1T-E6E7), ErbB2 expression levels increased with the cell density. HCK1T-E6E7 showed impaired contact inhibition and anchorage-independent growth in soft agar which were abrogated with introduction of ErbB2-specific short hairpin RNA ( shRNA) or an ErbB2 specific inhibitor AG825. Furthermore, increased ErbB2 expression was also observed in HPV16 positive cervical cancer cell lines and this was diminished by introduction of HPV16E6- or E6AP-shRNA. At post-confluence cell densities, ErbB2 protein was stabilized in the presence of E6 whereas increased ErbB2 expression was not obvious with E6 mutants incapable of degrading p53. Furthermore, introduction of p53-shRNA to HCK1T resulted in increased ErbB2 protein stability, indicating possible ErbB2 regulation through p53. Finally, we showed that tumor formation of ErbB2-shRNA introduced SiHa cells were almost abolished. Taken together, these data indicate an important role of ErbB2 regulation by HPV16 E6 in oncogenic transformation of human cervical keratinocytes.	Natl Canc Ctr, Res Inst, Virol Div, Chuo Ku, Tokyo 1040045, Japan	National Cancer Center - Japan	Kiyono, T (corresponding author), Natl Canc Ctr, Res Inst, Virol Div, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	tkiyono@gan2.res.ncc.go.jp	Kiyono, Tohru/H-5834-2011	Fujita, Masatoshi/0000-0001-6617-2452				Al Moustafa AE, 2004, ONCOGENE, V23, P350, DOI 10.1038/sj.onc.1207148; Beger M, 2001, J MOL MED, V79, P314, DOI 10.1007/s001090100211; Bellone S, 2003, GYNECOL ONCOL, V91, P231, DOI 10.1016/S0090-8258(03)00460-8; Gewin L, 2004, GENE DEV, V18, P2269, DOI 10.1101/gad.1214704; Hudelist G, 2005, CANCER GENET CYTOGEN, V158, P35, DOI 10.1016/j.cancergencyto.2004.08.007; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Ignatoski KMW, 2005, NEOPLASIA, V7, P788, DOI 10.1593/neo.05106; Kansra S, 2004, MOL BIOL CELL, V15, P4299, DOI 10.1091/mbc.E04-03-0233; Kelley ML, 2005, J VIROL, V79, P3737, DOI 10.1128/JVI.79.6.3737-3747.2005; Kersemaekers AMF, 1999, CLIN CANCER RES, V5, P577; KIHANA T, 1994, CANCER, V73, P148, DOI 10.1002/1097-0142(19940101)73:1<148::AID-CNCR2820730125>3.0.CO;2-C; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; KIYONO T, 1994, J VIROL, V68, P4656, DOI 10.1128/JVI.68.7.4656-4661.1994; Kyo S, 2003, AM J PATHOL, V163, P2259, DOI 10.1016/S0002-9440(10)63583-3; Ma YY, 2000, ONCOGENE, V19, P2739, DOI 10.1038/sj.onc.1203597; Nakano T, 1997, CANCER, V79, P513, DOI 10.1002/(SICI)1097-0142(19970201)79:3<513::AID-CNCR13>3.0.CO;2-6; Ndubisi B, 1997, ANN CLIN LAB SCI, V27, P396; Ngan HYS, 2001, TUMOR BIOL, V22, P176, DOI 10.1159/000050613; Niibe Y, 2003, INT J GYNECOL CANCER, V13, P849, DOI 10.1111/j.1525-1438.2003.13397.x; PINION SB, 1991, LANCET, V337, P819, DOI 10.1016/0140-6736(91)92518-7; Roskoski R, 2004, BIOCHEM BIOPH RES CO, V319, P1, DOI 10.1016/j.bbrc.2004.04.150; Rosty C, 2004, INT J GYNECOL PATHOL, V23, P13, DOI 10.1097/01.pgp.0000092137.88121.8d; Sawada M, 2004, CELL DEATH DIFFER, V11, P997, DOI 10.1038/sj.cdd.4401438; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Sharma A, 1999, ONCOLOGY-BASEL, V56, P83, DOI 10.1159/000011934; Takeda Y, 2004, J GENE MED, V6, P833, DOI 10.1002/jgm.583; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; Yang G, 2004, J BIOL CHEM, V279, P4339, DOI 10.1074/jbc.M311153200; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	32	42	43	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 10	2007	26	21					2988	2996		10.1038/sj.onc.1210118	http://dx.doi.org/10.1038/sj.onc.1210118			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	166QX	17146442				2022-12-17	WOS:000246395400004
J	Graessmann, M; Berg, B; Fuchs, B; Klein, A; Graessmann, A				Graessmann, M.; Berg, B.; Fuchs, B.; Klein, A.; Graessmann, A.			Chemotherapy resistance of mouse WAP-SVT/t breast cancer cells is mediated by osteopontin, inhibiting apoptosis downstream of caspase-3	ONCOGENE			English	Article						breast cancer cells; therapy resistance; osteopontin; inhibition of apoptosis; caspase-3; microarray	MITOCHONDRIA; ACTIVATION; PROTEINS; STRESS; DEATH; RECEPTOR; PHOSPHORYLATION; IDENTIFICATION; CLUSTERS; BINDING	Impairment of the complex regulatory network of cell death and survival is frequently the reason for therapy resistance of breast cancer cells and a major cause of tumor progression. We established two independent cell lines from a fast growing mouse breast tumor (WAP-SVT/t transgenic animal). Cells from one line (ME-A cells) are sensitive to apoptotic stimuli such as growth factor depletion or treatment with antitumor agents (e.g. doxorubicin). Cells from the second line (ME-C cells), which carry a missense mutation at the p53 codon 242, are very insensitive to apoptotic stimuli. Co-cultivation experiments revealed that the ME-C cells mediate cell death resistance to the ME-A cells. Microarray and Western blot analysis showed that osteopontin (OPN) is selectively overexpressed by the ME-C cells. This glycoprotein is the most abundant protein secreted by the ME-C cells and we obtained strong indications that OPN is the main antiapoptotic factor. However, the OPN containing ME-C cell medium does not alter the expression level of pro- or antiapoptotic genes or known inhibitors of apoptosis (IAPs). Its signaling involves mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase (MEK)1/2 as the kinase inhibitor PD98059 restores apoptosis but not the Akt inhibitor. In the ME-A cells, mitochondrial cytochrome c release occurs with and without external apoptotic stimuli. OPN containing ME-C cell medium does not prevent the mitochondrial cytochrome c release and caspase-9 processing. In serum starved ME-A cells, the OPN containing ME-C cell medium prevents caspase-3 activation. However, in doxorubicin-treated cells, although apoptosis is blocked, it does not inhibit caspase-3. This indicates that the ME-A cells distinguish between the initial apoptotic stimuli and that the cells possess a further uncharacterized control element acting downstream from caspase-3.	Charite Univ Med Berlin, Inst Mol Biol & Bioinformat, D-14195 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Graessmann, M (corresponding author), Charite Univ Med Berlin, Inst Mol Biol & Bioinformat, Arnimallee 22,Farbeckstr,30, D-14195 Berlin, Germany.	adolf.graessmann@charite.de	Klein, Andreas/AAG-4506-2021	Klein, Andreas/0000-0002-3496-7215				Allan LA, 2003, NAT CELL BIOL, V5, P647, DOI 10.1038/ncb1005; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Beere HM, 2004, J CELL SCI, V117, P2641, DOI 10.1242/jcs.01284; Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560; Caudevilla C, 2001, FEBS LETT, V507, P269, DOI 10.1016/S0014-5793(01)02957-X; Christensen B, 2005, BIOCHEM J, V390, P285, DOI 10.1042/BJ20050341; Costantini P, 2002, CELL DEATH DIFFER, V9, P82, DOI 10.1038/sj.cdd.4400932; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; FUJII S, 1999, J CHINESE I ENV ENG, V9, P9; Furger Kara A., 2001, Current Molecular Medicine (Hilversum), V1, P621, DOI 10.2174/1566524013363339; Gardai SJ, 2004, J BIOL CHEM, V279, P44695, DOI 10.1074/jbc.M405313200; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HU DD, 1995, J BIOL CHEM, V270, P26232, DOI 10.1074/jbc.270.44.26232; Hu P, 2004, J BIOL CHEM, V279, P49420, DOI 10.1074/jbc.M407700200; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Johnson CR, 2004, APOPTOSIS, V9, P423, DOI 10.1023/B:APPT.0000031457.90890.13; Kanda H, 2004, J BIOCHEM, V136, P1, DOI 10.1093/jb/mvh098; Khan SA, 2002, J CELL BIOCHEM, V85, P728, DOI 10.1002/jcb.10170; Klein A, 2005, J MOL MED, V83, P362, DOI 10.1007/s00109-004-0625-1; Kohlhoff S, 2000, FREE RADICAL BIO MED, V29, P497, DOI 10.1016/S0891-5849(00)00340-3; Krause D, 2001, J BIOL CHEM, V276, P19244, DOI 10.1074/jbc.M008186200; Kreuz S, 2004, J CELL BIOL, V166, P369, DOI 10.1083/jcb.200401036; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Lin YH, 2001, J BIOL CHEM, V276, P46024, DOI 10.1074/jbc.M105132200; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Morimoto I, 2002, GENE CHROMOSOME CANC, V33, P270, DOI 10.1002/gcc.10020; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; Nomura M, 2003, J BIOL CHEM, V278, P2058, DOI 10.1074/jbc.M207880200; Osaki M, 2004, APOPTOSIS, V9, P667, DOI 10.1023/B:APPT.0000045801.15585.dd; Pommier Y, 2004, ONCOGENE, V23, P2934, DOI 10.1038/sj.onc.1207515; Reed JC, 2001, TRENDS MOL MED, V7, P314, DOI 10.1016/S1471-4914(01)02026-3; Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496; Schimmer AD, 2004, CANCER RES, V64, P7183, DOI 10.1158/0008-5472.CAN-04-1918; Shanmugam V, 1997, BIOCHEMISTRY-US, V36, P5729, DOI 10.1021/bi961687w; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tuck AB, 2001, J MAMMARY GLAND BIOL, V6, P419, DOI 10.1023/A:1014734930781; Tzeng YJ, 1998, ONCOGENE, V16, P2103, DOI 10.1038/sj.onc.1201733; TZENG YJ, 1993, ONCOGENE, V8, P1965; Wai PY, 2004, J SURG RES, V121, P228, DOI 10.1016/j.jss.2004.03.028; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; Wessel Ralf, 2006, In Silico Biology, V6, P61	46	42	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 3	2007	26	20					2840	2850		10.1038/sj.onc.1210096	http://dx.doi.org/10.1038/sj.onc.1210096			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CR	17160024				2022-12-17	WOS:000246210800004
J	Carvalho, G; Fabre, C; Braun, T; Grosjean, J; Ades, L; Agou, F; Tasdemir, E; Boehrer, S; Israel, A; Veron, M; Fenaux, P; Kroemer, G				Carvalho, G.; Fabre, C.; Braun, T.; Grosjean, J.; Ades, L.; Agou, F.; Tasdemir, E.; Boehrer, S.; Israel, A.; Veron, M.; Fenaux, P.; Kroemer, G.			Inhibition of NEMO, the regulatory subunit of the IKK complex, induces apoptosis in high-risk myelodysplastic syndrome and acute myeloid leukemia	ONCOGENE			English	Article						apoptosis; NF-kappa B; mitochondria	NF-KAPPA-B; MITOCHONDRIAL ALTERATIONS; PROTEIN INTERACTIONS; CELL-LINE; ACTIVATION; SYSTEM	In high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), blasts constitutively activate the antiapoptotic transcription factor nuclear factor-kappa B (NF-kappa B). Here, we show that this NF-kappa B activation relies on the constitutive activation of the I kappa B kinase (IKK) complex, which is formed by the IKK alpha, IKK beta and IKK gamma/NF-kappa B essential modulator (NEMO) subunits. A cell-permeable peptide that mimics the leucine zipper subdomain of IKK gamma, thus preventing its oligomerization, inhibited the constitutive NF-kappa B activation and induced apoptotic cell death in a panel of human MDS and AML cell lines (P39, MOLM13, THP1 and MV4-11). Small interfering RNA-mediated knockdown of the p65 NF-kappa B subunit or the three IKK subunits including IKK gamma/NEMO also induced apoptotic cell death in P39 cells. Cell death induced by the IKK gamma/NEMO-antagonistic peptide involved the caspase-independent loss of the mitochondrial transmembrane potential as well as signs of outer mitochondrial membrane permeabilization with the consequent release of cytochrome c, apoptosis-inducing factor and endonuclease G. Primary bone marrow CD34(+) cells from high-risk MDS and AML patients also succumbed to the IKK gamma/NEMO-antagonistic peptide, but not to a mutated control peptide. Altogether, these data indicate that malignant cells in high-risk MDS and AML cells critically depend on IKK gamma/NEMO to survive. Moreover, our data delineate a novel procedure for their therapeutic removal, through inhibition of IKK gamma/NEMO oligomerization.	Inst Gustave Roussy, CNRS, FRE 2939, F-94805 Villejuif, France; INSERM, Unit Apoptosis Canc & Immun, Villejuif, France; Univ Paris 11, Fac Med Paris Sud, Villejuif, France; Univ Paris 13, AP HP, Hop Avicenne, Hematol Unit, Bobigny, France; Inst Pasteur, CNRS, URA 2185, Unite Regulat Enzymat Activities Cellulaires, Paris, France; Inst Pasteur, CNRS, URA 2582, SMAC, Paris, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, FRE 2939, Rue Camille Desmoulins,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Ades, lionel/T-6882-2019; Kroemer, Guido/AAY-9859-2020; KROEMER, Guido/B-4263-2013; , AGOU/GXA-2760-2022	KROEMER, Guido/0000-0002-9334-4405; 				Agou F, 2004, J BIOL CHEM, V279, P54248, DOI 10.1074/jbc.M406423200; Agou F, 2004, J BIOL CHEM, V279, P27861, DOI 10.1074/jbc.M314278200; Arkin MR, 2004, NAT REV DRUG DISCOV, V3, P301, DOI 10.1038/nrd1343; Baumgartner B, 2002, LEUKEMIA, V16, P2062, DOI 10.1038/sj.leu.2402641; Braun T, 2006, CELL DEATH DIFFER, V13, P748, DOI 10.1038/sj.cdd.4401874; Braun T, 2006, BLOOD, V107, P1156; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Castedo M, 1996, J IMMUNOL, V157, P512; Dev KK, 2004, NAT REV DRUG DISCOV, V3, P1047, DOI 10.1038/nrd1578; Dombret H, 2002, SEMIN HEMATOL, V39, P8, DOI 10.1053/shem.2002.33608; Estrov Z, 2003, BLOOD, V102, P987, DOI 10.1182/blood-2002-11-3550; Fenaux P, 2005, SEMIN ONCOL, V32, pS11, DOI 10.1053/j.seminoncol.2005.06.016; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GLOIRE G, 2006, BIOCH PHARM; Greenberg P, 1997, BLOOD, V89, P2079, DOI 10.1182/blood.V89.6.2079; Guzman ML, 2001, BLOOD, V98, P2301, DOI 10.1182/blood.V98.8.2301; Guzman ML, 2002, P NATL ACAD SCI USA, V99, P16220, DOI 10.1073/pnas.252462599; Hassan Z, 1999, EXP HEMATOL, V27, P1322, DOI 10.1016/S0301-472X(99)00066-1; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Lindberg EH, 2005, CURR DRUG TARGETS, V6, P713, DOI 10.2174/1389450054863707; Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI26322; Matsuo Y, 1997, LEUKEMIA, V11, P1469, DOI 10.1038/sj.leu.2400768; Metivier D, 1998, IMMUNOL LETT, V61, P157, DOI 10.1016/S0165-2478(98)00013-3; NAGAI M, 1984, GANN, V75, P1100; Nakamori Y, 2006, J CELL BIOL, V173, P665, DOI 10.1083/jcb.200601065; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Smahi A, 2002, HUM MOL GENET, V11, P2371, DOI 10.1093/hmg/11.20.2371; Steensma DP, 2006, MAYO CLIN PROC, V81, P104, DOI 10.4065/81.1.104; Vardiman JW, 2002, BLOOD, V100, P2292, DOI 10.1182/blood-2002-04-1199; ZAMZAMI N, 2003, METH MOL B, V282, P103	30	42	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2007	26	16					2299	2307		10.1038/sj.onc.1210043	http://dx.doi.org/10.1038/sj.onc.1210043			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17043643				2022-12-17	WOS:000245466000006
J	Oyama, K; Okawa, T; Nakagawa, H; Takaoka, M; Andl, CD; Kim, SH; Klein-Szanto, A; Diehl, JA; Herlyn, M; El-Deiry, W; Rustgi, AK				Oyama, K.; Okawa, T.; Nakagawa, H.; Takaoka, M.; Andl, C. D.; Kim, S-H; Klein-Szanto, A.; Diehl, J. A.; Herlyn, M.; El-Deiry, W.; Rustgi, A. K.			AKT induces senescence in primary esophageal epithelial cells but is permissive for differentiation as revealed in organotypic culture	ONCOGENE			English	Article						AKT; EGFR; proliferation; differentiation; organotypic culture	SIGNALING PATHWAY; IN-VITRO; KINASE-B; GROWTH; KERATINOCYTES; ACTIVATION; ARCHITECTURE; CARCINOMA; CANCER; PROLIFERATION	Epidermal growth factor receptor (EGFR) overexpression and activation is critical in the initiation and progression of cancers, especially those of epithelial origin. EGFR activation is associated with the induction of divergent signal transduction pathways and a gamut of cellular processes; however, the cell-type and tissue-type specificity conferred by certain pathways remains to be elucidated. In the context of the esophageal epithelium, a prototype stratified squamous epithelium, EGFR overexpression is relevant in the earliest events of carcinogenesis as modeled in a three-dimensional organotypic culture system. We demonstrate that the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway, and not the MEK/MAPK (mitogen-activated protein kinase) pathway, is preferentially activated in EGFR-mediated esophageal epithelial hyperplasia, a premalignant lesion. The hyperplasia was abolished with direct inhibition of PI3K and of AKT but not with inhibition of the MAPK pathway. With the introduction of an inducible AKT vector in both primary and immortalized esophageal epithelial cells, we find that AKT overexpression and activation is permissive for complete epithelial formation in organotypic culture, but imposes a growth constraint in cells grown in monolayer. In organotypic culture, AKT mediates changes related to cell shape and size with an expansion of the differentiated compartment.	Univ Penn, Abramson Canc Ctr, Div Gastroenterol, Dept Med, Villanova, PA 19085 USA; Univ Penn, Abramson Canc Ctr, Div Gastroenterol, Dept Genet, Villanova, PA 19085 USA; Univ Penn, Div Hematol Oncol, Villanova, PA 19085 USA; Fox Chase Canc Ctr, Dept Pathol, Philadelphia, PA 19111 USA; Univ Penn, Wistar Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Fox Chase Cancer Center; The Wistar Institute; University of Pennsylvania	Rustgi, AK (corresponding author), Univ Penn, Abramson Canc Ctr, Div Gastroenterol, Dept Med, 600 CRB,415 Curie Blvd, Villanova, PA 19085 USA.	anil2@mail.med.upenn.edu	El-Deiry, Wafik/AAJ-6080-2020; Klein-Szanto, A./E-6218-2010	El-Deiry, Wafik/0000-0002-9577-8266; 	NCI NIH HHS [F32 CA108657, P01 CA025874, CA 80999, CA 25874, F32-CA108657, R01 CA080999] Funding Source: Medline; NIDCR NIH HHS [P01 DE12467, P01 DE012467] Funding Source: Medline; NIDDK NIH HHS [P30 DK050306, P30 DK50306, K01 DK066205, K01 DK075379, K01-DK0662059, K01 DK075379-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080999, P01CA025874, F32CA108657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012467] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK066205, P30DK050306, K01DK075379] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andl CD, 2003, J BIOL CHEM, V278, P1824, DOI 10.1074/jbc.M209148200; Asano T, 2004, ONCOGENE, V23, P8571, DOI 10.1038/sj.onc.1207902; Chan KS, 2004, CANCER RES, V64, P2382, DOI 10.1158/0008-5472.CAN-03-3197; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695; Debnath J, 2003, J CELL BIOL, V163, P315, DOI 10.1083/jcb.200304159; Harada H, 2003, MOL CANCER RES, V1, P729; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; ITOIZ ME, 1985, AM J PATHOL, V119, P456; Janda E, 2002, ONCOGENE, V21, P5148, DOI 10.1038/sj.onc.1205661; Janes SM, 2004, J CELL SCI, V117, P4157, DOI 10.1242/jcs.01302; Kamei T, 2002, MOL ENDOCRINOL, V16, P1469, DOI 10.1210/me.16.7.1469; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kim YT, 2002, GYNECOL ONCOL, V87, P84, DOI 10.1006/gyno.2002.6803; Kirkegaard T, 2005, J PATHOL, V207, P139, DOI 10.1002/path.1829; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Li WJ, 2005, J BIOL CHEM, V280, P6036, DOI 10.1074/jbc.M406546200; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lo HW, 2006, BREAST CANCER RES TR, V95, P211, DOI 10.1007/s10549-005-9011-0; Mandard AM, 2000, MUTAT RES-REV MUTAT, V462, P335, DOI 10.1016/S1383-5742(00)00019-3; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Miyauchi H, 2004, EMBO J, V23, P212, DOI 10.1038/sj.emboj.7600045; MURPHY GF, 2005, LEVERS HISTOPATHOLOG, P13; Nelson CM, 2005, SEMIN CANCER BIOL, V15, P342, DOI 10.1016/j.semcancer.2005.05.001; Okano J, 2000, J BIOL CHEM, V275, P30934, DOI 10.1074/jbc.M004112200; Okano Jun-ichi, 2003, Methods Mol Biol, V222, P131; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Scholle F, 2000, J VIROL, V74, P10681, DOI 10.1128/JVI.74.22.10681-10689.2000; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sugatani T, 2005, J BIOL CHEM, V280, P3583, DOI 10.1074/jbc.M410480200; Xing DY, 2005, P NATL ACAD SCI USA, V102, P6936, DOI 10.1073/pnas.0502256102; Zahir N, 2004, CURR OPIN GENET DEV, V14, P71, DOI 10.1016/j.gde.2003.12.005	33	42	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2007	26	16					2353	2364		10.1038/sj.onc.1210025	http://dx.doi.org/10.1038/sj.onc.1210025			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17043653	Green Accepted			2022-12-17	WOS:000245466000011
J	De Gregorio, G; Coppa, A; Cosentino, C; Ucci, S; Messina, S; Nicolussi, A; D'Inzeo, S; Di Pardo, A; Avvedimento, EV; Porcellini, A				De Gregorio, G.; Coppa, A.; Cosentino, C.; Ucci, S.; Messina, S.; Nicolussi, A.; D'Inzeo, S.; Di Pardo, A.; Avvedimento, E. V.; Porcellini, A.			The p85 regulatory subunit of PI3K mediates TSH-cAMP-PKA growth and survival signals	ONCOGENE			English	Article						phosphoinositide-3-kinase; signal trasduction; thyropropin receptor; protein kinase A; cAMP	DEPENDENT PROTEIN-KINASE; STIMULATING HORMONE TSH; DNA-SYNTHESIS; RAS; ACTIVATION; PATHWAYS; FIBROBLASTS; RECEPTOR; 3-KINASE; CELLS	Phosphatidylinositol 3-kinase (PI3K) is necessary for thyroid stimulating hormone (TSH)-induced cell cycle progression. To determine the molecular mechanism linking PI3K to TSH, we have identified a serine residue in p85 alpha(PI3K) phosphorylated by protein kinase A (PKA) in vitro and in vivo. Expression of an alanine mutant (p85A) abolished cyclic AMP/TSH- induced cell cycle progression and was lethal in thyroid cells (FRTL-5). The aspartic version of the p85 alpha(PI3K) (p85D) inhibited apoptosis following TSH withdrawal. The p85a PI3K wild type not the p85A bound PKA regulatory subunit RII beta in cells stimulated with cAMP or TSH. The binding of the aspartic version of p85a PI3K to RIIb was independent of cAMP or TSH stimulation. Similarly, binding of PI3K to p21Ras and activation of AKT, a downstream PI3K target, were severely impaired in cells expressing the p85A mutant. Finally, we found that the catalytic activity of PI3K was stimulated by TSH in cells expressing the wildtype p85a PI3K but not in cells expressing p85A. This latter mutant did not affect the epidermal growth factor-stimulated PI3K activity. We suggest that (1) TSH cAMP-induced PKA phosphorylates p85 alpha(PI3K) at serine 83, (2) phosphorylated p85 alpha(PI3K) binds RII beta-PKA and targets PKAII to the membrane, and (3) PI3K activity and p21Ras binding to PI3K increase and activate PI3K downstream targets. This pathway is essential for the transmission of TSH - cAMP growth signals.	Univ Roma La Sapienza, Dipartimento Med Sperimentale, I-00161 Rome, Italy; IRCCs Neuromed, Dipartimento Patol Mol, Pozzilli, Italy; Univ Naples Federico II, CNR, Ist Edocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Mol, Naples, Italy; Univ Naples Federico II, CNR, Ist Edocrinol & Oncol Sperimentale, Dipartimento Cellulaire, Naples, Italy	Sapienza University Rome; IRCCS Neuromed; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II	Porcellini, A (corresponding author), Univ Roma La Sapienza, Dipartimento Med Sperimentale, Viale Regina Elena, I-00161 Rome, Italy.	avvedim@unina.it; antonio.porcellini@uniroma1.it	Porcellini, Antonio/E-1900-2011; Cosentino, Claudia/AAF-1100-2019; coppa, anna/N-3274-2016; Porcellini, Antonio/AAC-6097-2019; Di Pardo, Alba/AAC-9393-2020	Porcellini, Antonio/0000-0001-6882-9518; Di Pardo, Alba/0000-0002-9514-0086; coppa, anna/0000-0001-9758-5444				Affaitati A, 2003, J BIOL CHEM, V278, P4286, DOI 10.1074/jbc.M209941200; ALALAWI N, 1995, MOL CELL BIOL, V15, P1162; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; Ciullo I, 2001, ONCOGENE, V20, P1186, DOI 10.1038/sj.onc.1204219; COSENTINO C, 2006, IN PRESS ONCOGENE; Filippa N, 1999, MOL CELL BIOL, V19, P4989; Grieco D, 1996, SCIENCE, V271, P1718, DOI 10.1126/science.271.5256.1718; KUPPERMAN E, 1993, MOL CELL BIOL, V13, P4477, DOI 10.1128/MCB.13.8.4477; MAGNALDO I, 1989, FEBS LETT, V245, P65, DOI 10.1016/0014-5793(89)80193-0; Maier U, 1999, J BIOL CHEM, V274, P29311, DOI 10.1074/jbc.274.41.29311; Miller MJ, 1998, MOL CELL BIOL, V18, P3718, DOI 10.1128/MCB.18.7.3718; Porcellini A, 2003, J BIOL CHEM, V278, P40621, DOI 10.1074/jbc.M307501200; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; Suh JM, 2003, J BIOL CHEM, V278, P21960, DOI 10.1074/jbc.M300805200; Wang XM, 2005, J BIOL CHEM, V280, P16705, DOI 10.1074/jbc.M501819200	16	42	42	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	14					2039	2047		10.1038/sj.onc.1210011	http://dx.doi.org/10.1038/sj.onc.1210011			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17043656				2022-12-17	WOS:000245313400006
J	Streicher, KL; Yang, ZQ; Draghici, S; Ethier, SP				Streicher, K. L.; Yang, Z. Q.; Draghici, S.; Ethier, S. P.			Transforming function of the LSM1 oncogene in human breast cancers with the 8p11-12 amplicon	ONCOGENE			English	Article						LSM1; breast cancer; chromosome 8p11-12	MESSENGER-RNA DEGRADATION; ANTISENSE GENE-THERAPY; SM-LIKE PROTEIN; ONTO-TOOLS; CELL-LINES; PANCREATIC-CANCER; EPITHELIAL-CELLS; EXPRESSION; CASM; CONTRIBUTES	Amplification of the 8p11 - 12 region occurs in 15 - 20% of breast cancers, but the driving oncogene at this locus has yet to be definitively identified. We mapped the 8p11 - 12 amplicon in breast cancer cell lines and primary human breast cancers and identified the candidate oncogene human Sm-like protein (hLsm1, LSM1) based on increases in copy number and expression level relative to human mammary epithelial cells. To examine the oncogenic role of LSM1, we overexpressed this gene in MCF10A mammary epithelial cells and inhibited its production in the SUM44 breast cancer cell line, which has a natural amplification and overexpression of LSM1. Our data confirmed that LSM1 is an oncogene from the 8p11 - 12 amplicon by showing that hLsm1 overexpression induced growth factor-independent proliferation and soft agar colony formation in MCF10A cells, and hLsm1 inhibition in SUM44 cells dramatically reduced soft agar growth. Little is known about hLsm1 function other than its involvement in mRNA degradation; therefore, we used expression microarray analysis to investigate how hLsm1 affects cell transformation in MCF10A and SUM44 cells. We identified numerous genes altered following hLsm1 overexpression common to SUM44 breast cancer cells that play important roles in cell cycle regulation, cell proliferation and other cancer-promoting processes. Future work will continue to characterize these important changes to achieve a more complete understanding of the mechanism of hLsm1's effect on cancer progression.	Karmanos Canc Inst, Breast Canc Program, Detroit, MI 48201 USA; Wayne State Univ, Dept Comp Sci, Detroit, MI 48202 USA; Karmanos Canc Inst, Detroit, MI USA; Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48202 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University	Streicher, KL (corresponding author), Karmanos Canc Inst, Breast Canc Program, 4100 John R St,815 HWCRC, Detroit, MI 48201 USA.	streiche@karmanos.org	Draghici, Sorin/B-3074-2013	Draghici, Sorin/0000-0002-0786-8377	NATIONAL CANCER INSTITUTE [P30CA022453, R21CA100740, R01CA100724] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR017857] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG003491] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R21EB000990] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045207] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA100724-01, R01 CA100724, P30 CA022453, P30 CA022453-25, R21 CA100740, R21 CA10074001, R21 CA100740-01] Funding Source: Medline; NCRR NIH HHS [1S10 RR01785701, S10 RR017857-01, S10 RR017857] Funding Source: Medline; NHGRI NIH HHS [R01 HG003491-01A1, R01 HG003491] Funding Source: Medline; NIBIB NIH HHS [R21 EB000990-01, R21 EB000990, 1R21 EB0099001] Funding Source: Medline; NINDS NIH HHS [R01 NS045207-01, 1R01NS04520701, R01 NS045207] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bouveret E, 2000, EMBO J, V19, P1661, DOI 10.1093/emboj/19.7.1661; Draghici S, 2003, GENOMICS, V81, P98, DOI 10.1016/S0888-7543(02)00021-6; Draghici S, 2003, NUCLEIC ACIDS RES, V31, P3775, DOI 10.1093/nar/gkg624; Draghici S., 2003, DATA ANAL TOOLS DNA; ETHIER SP, 1991, BREAST CANCER RES TR, V18, P73, DOI 10.1007/BF01980969; ETHIER SP, 1991, BREAST CANCER RES TR, V17, P221, DOI 10.1007/BF01806371; Ethier SP, 1996, J MAMMARY GLAND BIOL, V1, P111, DOI 10.1007/BF02096306; Forozan F, 1999, BRIT J CANCER, V81, P1328, DOI 10.1038/sj.bjc.6695007; Fraser MM, 2005, CANCER RES, V65, P6228, DOI 10.1158/0008-5472.CAN-05-0650; Garcia MJ, 2005, ONCOGENE, V24, P5235, DOI 10.1038/sj.onc.1208741; Gelsi-Boyer W, 2005, MOL CANCER RES, V3, P655, DOI 10.1158/1541-7786.MCR-05-0128; He WH, 2000, CURR OPIN CELL BIOL, V12, P346, DOI 10.1016/S0955-0674(00)00098-3; Ignatoski KMW, 2005, NEOPLASIA, V7, P788, DOI 10.1593/neo.05106; Ingelfinger D, 2002, RNA, V8, P1489, DOI 10.1017/S1355838202021726; Kelley JR, 2003, ANTICANCER RES, V23, P2007; Khatri P, 2002, GENOMICS, V79, P266, DOI 10.1006/geno.2002.6698; Khatri P, 2005, NUCLEIC ACIDS RES, V33, pW762, DOI 10.1093/nar/gki472; Khatri P, 2004, NUCLEIC ACIDS RES, V32, pW449, DOI 10.1093/nar/gkh409; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Paddison PJ, 2003, CURR OPIN MOL THER, V5, P217; Paddison PJ, 2002, P NATL ACAD SCI USA, V99, P1443, DOI 10.1073/pnas.032652399; Prentice LM, 2005, ONCOGENE, V24, P7281, DOI 10.1038/sj.onc.1208892; Ray ME, 2004, CANCER RES, V64, P40, DOI 10.1158/0008-5472.CAN-03-1022; Schweinfest CW, 1997, CANCER RES, V57, P2961; Sheth U, 2003, SCIENCE, V300, P805, DOI 10.1126/science.1082320; Surmacz E, 2000, J MAMMARY GLAND BIOL, V5, P95, DOI 10.1023/A:1009523501499; Yan Y, 2006, MOL THER, V13, P357, DOI 10.1016/j.ymthe.2005.06.485; Yang ZQ, 2004, CANCER GENET CYTOGEN, V155, P57, DOI 10.1016/j.cancergencyto.2004.03.013; Zaric B, 2005, J BIOL CHEM, V280, P16066, DOI 10.1074/jbc.M414481200	30	42	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	14					2104	2114		10.1038/sj.onc.1210002	http://dx.doi.org/10.1038/sj.onc.1210002			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17001308	Green Accepted			2022-12-17	WOS:000245313400012
J	Prabhu, S; Saadat, D; Zhang, M; Halbur, L; Fruehauf, JP; Ong, ST				Prabhu, S.; Saadat, D.; Zhang, M.; Halbur, L.; Fruehauf, J. P.; Ong, S. T.			A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation	ONCOGENE			English	Article						CML; eIF4F; mTOR; cap-dependent translation	CHRONIC MYELOGENOUS LEUKEMIA; CAP-DEPENDENT TRANSLATION; IMATINIB MESYLATE STI571; P70 S6 KINASE; MAMMALIAN TARGET; CYTOGENETIC RESPONSES; CYCLIN D2; RAPAMYCIN; BCR/ABL; INHIBITOR	The oncogenic kinase Bcr-Abl is thought to cause chronic myelogenous leukemia (CML) by altering the transcription of specific genes with growth- and survival-promoting functions. Recently, Bcr-Abl has also been shown to activate an important regulator of protein synthesis, the mammalian target of rapamycin ( mTOR), which suggests that dysregulated translation may also contribute to CML pathogenesis. In this study, we found that both Bcr-Abl and the rapamycin-sensitive mTORC1 complex contribute to the phosphorylation ( inactivation) of 4E-BP1, an inhibitor of the eIF4E translation initiation factor. Experiments with rapamycin and the Bcr-Abl inhibitor, imatinib mesylate, in Bcr-Abl-expressing cell lines and primary CML cells indicated that Bcr-Abl and mTORC1 induced formation of the translation initiation complex, eIF4F. This was characterized by reduced 4E-BP1 binding and increased eIF4G binding to eIF4E, two events that lead to the assembly of eIF4F. One target transcript is cyclin D3, which is regulated in Bcr-Abl-expressing cells by both Bcr-Abl and mTORC1 in a translational manner. In addition, the combination of imatinib and rapamycin was found to act synergistically against committed CML progenitors from chronic and blast phase patients. These experiments establish a novel mechanism of action for Bcr-Abl, and they provide insights into the modes of action of imatinib mesylate and rapamycin in treatment of CML. They also suggest that aberrant cap-dependent mRNA translation may be a therapeutic target in BcrAbl-driven malignancies.	Univ Calif Irvine, Dept Med, Div Hematol Oncol, Irvine, CA 92697 USA; Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Irvine, CA 92697 USA; Univ Calif Irvine, Canc Res Inst, Irvine, CA 92697 USA; Univ Calif Irvine, Ctr Immunol, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Ong, ST (corresponding author), Univ Calif Irvine, Dept Med, Div Hematol Oncol, 839 Med Sci Court,116 Sprague Hall, Irvine, CA 92697 USA.	ongt@uci.edu		Ong, S. Tiong/0000-0001-9460-3483	NCI NIH HHS [1R21 CA105514, R21 CA112936-01A1, R21 CA112936, R01 CA107041-02, R01 CA107041-01A1, 1R21 CA112936, R21 CA105514, R01 CA107041, 1R01 CA107041] Funding Source: Medline; NIBIB NIH HHS [R01 EB004436] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA107041, R21CA112936, R21CA105514] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB004436] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Altmann M, 1997, EMBO J, V16, P1114, DOI 10.1093/emboj/16.5.1114; Avdulov S, 2004, CANCER CELL, V5, P553, DOI 10.1016/j.ccr.2004.05.024; Bordeleau ME, 2005, P NATL ACAD SCI USA, V102, P10460, DOI 10.1073/pnas.0504249102; Bushell M, 2000, CELL DEATH DIFFER, V7, P628, DOI 10.1038/sj.cdd.4400699; Choi KM, 2003, J BIOL CHEM, V278, P19667, DOI 10.1074/jbc.M301142200; Chou T C, 1994, Contrib Gynecol Obstet, V19, P91; Chu S, 2004, BLOOD, V103, P3167, DOI 10.1182/blood-2003-04-1271; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Dancey JE, 2002, HEMATOL ONCOL CLIN N, V16, P1101, DOI 10.1016/S0889-8588(02)00051-5; Decker T, 2003, BLOOD, V101, P278, DOI 10.1182/blood-2002-01-0189; Deininger MWN, 2003, PHARMACOL REV, V55, P401, DOI 10.1124/pr.55.3.4; Deininger MWN, 1997, BLOOD, V90, P3691, DOI 10.1182/blood.V90.9.3691; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Donato NJ, 2003, BLOOD, V101, P690, DOI 10.1182/blood.V101.2.690; Edinger AL, 2003, CANCER RES, V63, P8451; Fruman DA, 2002, P NATL ACAD SCI USA, V99, P359, DOI 10.1073/pnas.012605099; Ghaffari S, 1999, LEUKEMIA, V13, P1200, DOI 10.1038/sj.leu.2401467; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 2001, GENE DEV, V15, P2852; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Hentze MW, 1997, SCIENCE, V275, P500, DOI 10.1126/science.275.5299.500; Hleb M, 2004, J BIOL CHEM, V279, P31948, DOI 10.1074/jbc.M400638200; Holtz MS, 2002, BLOOD, V99, P3792, DOI 10.1182/blood.V99.10.3792; Huang S, 2003, CURR OPIN PHARMACOL, V3, P371, DOI 10.1016/S1471-4892(03)00071-7; Iervolino A, 2002, MOL CELL BIOL, V22, P2255, DOI 10.1128/MCB.22.7.2255-2266.2002; Jacinto E, 2003, NAT REV MOL CELL BIO, V4, P117, DOI 10.1038/nrm1018; Jena N, 2002, CANCER RES, V62, P535; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; Kentsis A, 2004, P NATL ACAD SCI USA, V101, P18105, DOI 10.1073/pnas.0406927102; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; La Rosee P, 2002, CANCER RES, V62, P7149; Low WK, 2005, MOL CELL, V20, P709, DOI 10.1016/j.molcel.2005.10.008; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Ly C, 2003, CANCER RES, V63, P5716; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Meier-Kriesche HU, 2000, CLIN THER, V22, pB93, DOI 10.1016/S0149-2918(00)89026-8; Mohi MG, 2004, P NATL ACAD SCI USA, V101, P3130, DOI 10.1073/pnas.0400063101; Morley SJ, 1997, RNA, V3, P1085; Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200; Notari M, 2006, BLOOD, V107, P2507, DOI 10.1182/blood-2005-09-3732; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; Ottmann OG, 2002, BLOOD, V100, P1965, DOI 10.1182/blood-2001-12-0181; Parada Y, 2001, J BIOL CHEM, V276, P23572, DOI 10.1074/jbc.M101885200; Parmar S, 2005, BLOOD, V106, P2436, DOI 10.1182/blood-2004-10-4003; Perrotti D, 2005, CELL DEATH DIFFER, V12, P534, DOI 10.1038/sj.cdd.4401606; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0; Sawyers CL, 2002, BLOOD, V99, P3530, DOI 10.1182/blood.V99.10.3530; Sawyers CL, 2003, CANCER CELL, V4, P343, DOI 10.1016/S1535-6108(03)00275-7; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Sicinska E, 2003, CANCER CELL, V4, P451, DOI 10.1016/S1535-6108(03)00301-5; Trotta R, 2003, CANCER CELL, V3, P145, DOI 10.1016/S1535-6108(03)00020-5; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016	61	42	46	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2007	26	8					1188	1200		10.1038/sj.onc.1209901	http://dx.doi.org/10.1038/sj.onc.1209901			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	16936779	Green Accepted			2022-12-17	WOS:000244406400009
J	Kuo, AH; Stoica, GE; Riegel, AT; Wellstein, A				Kuo, A. H.; Stoica, G. E.; Riegel, A. T.; Wellstein, A.			Recruitment of insulin receptor substrate-1 and activation of NF-kappa B essential for midkine growth signaling through anaplastic lymphoma kinase	ONCOGENE			English	Article						ALK; MK; IRS-1; NF-kappa B; autocrine	IGF-I RECEPTOR; LEUKOCYTE TYROSINE KINASE; FUNCTIONAL-ANALYSIS; ALK KINASE; ATIC-ALK; GENE; PLEIOTROPHIN; EXPRESSION; TRANSFORMATION; TRANSCRIPTION	Anaplastic lymphoma kinase (ALK) is a transmembrane receptor tyrosine kinase in the insulin receptor superfamily. We recently demonstrated that the growth factors pleiotrophin (PTN) and midkine (MK) are ligands for ALK and that upon ALK activation, insulin receptor substrate-1 (IRS-1) and other substrates are phosphorylated. Here, the role of IRS-1 in ligand-mediated ALK signaling is investigated in interleukin-3 (IL-3)-dependent 32D murine myeloid cells. These cells do not express ALK and IRS family members, and do not respond to exogenously added PTN or MK. We show that expression of ALK plus IRS-1 renders these cells independent of IL-3 owing to the activation of ALK by endogenous MK. Mutational analysis reveals that this transformed phenotype of 32D cells requires kinase-active ALK as well as the interaction of ALK with IRS-1. Furthermore, 32D/IRS-1/ALK cells display an enhanced activation of mitogen-activated protein kinase and PI3-kinase pathways, and a selective transcriptional activation of nuclear factor (NF)-kappa B. Small interfering RNA-mediated knockdown of the endogenous MK or p65/NF-kappa B revealed that both these are rate limiting for the transformed phenotype induced by ALK plus IRS-1. We conclude that the recruitment of IRS-1 to activated ALK and the activation of NF-kappa B are essential for the autocrine growth and survival signaling of MK.	Georgetown Univ, Lombardi Canc Ctr, Dept Oncol, Washington, DC 20007 USA	Georgetown University	Wellstein, A (corresponding author), Georgetown Univ, Lombardi Canc Ctr, Dept Oncol, Res Bldg E311,3970 Reservoir Rd, Washington, DC 20007 USA.	wellstea@georgetown.edu			NATIONAL CANCER INSTITUTE [R01CA101811] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR014567] Funding Source: NIH RePORTER; NCI NIH HHS [CA101811] Funding Source: Medline; NCRR NIH HHS [C06 RR14567] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Ballinger MD, 1999, NAT BIOTECHNOL, V17, P1199, DOI 10.1038/70746; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Baserga R, 2000, GROWTH HORM IGF RES, V10, pS43, DOI 10.1016/S1096-6374(00)90021-2; Baserga R, 2000, ONCOGENE, V19, P5574, DOI 10.1038/sj.onc.1203854; Bowden ET, 2002, J BIOL CHEM, V277, P35862, DOI 10.1074/jbc.M203963200; Burks DJ, 2001, DIABETES, V50, pS140, DOI 10.2337/diabetes.50.2007.S140; Chang Q, 2002, CANCER RES, V62, P6035; Colleoni GWB, 2000, AM J PATHOL, V156, P781, DOI 10.1016/S0002-9440(10)64945-0; Cristofanelli B, 2000, ONCOGENE, V19, P3245, DOI 10.1038/sj.onc.1203664; Czubayko F, 1996, P NATL ACAD SCI USA, V93, P14753, DOI 10.1073/pnas.93.25.14753; Delsol G, 1997, BLOOD, V89, P1483, DOI 10.1182/blood.V89.5.1483.1483_1483_1490; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; Dirks WG, 2002, INT J CANCER, V100, P49, DOI 10.1002/ijc.10435; Englund C, 2003, NATURE, V425, P512, DOI 10.1038/nature01950; FANG WJ, 1992, J BIOL CHEM, V267, P25889; Feng SH, 1999, MOL CELL BIOL, V19, P7995; Freeman M, 2003, NATURE, V425, P468, DOI 10.1038/425468a; HEIDARAN MA, 1993, J BIOL CHEM, V268, P9287; Hernandez L, 1999, BLOOD, V94, P3265; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; Lamant L, 2000, AM J PATHOL, V156, P1711, DOI 10.1016/S0002-9440(10)65042-0; Lawrence B, 2000, AM J PATHOL, V157, P377, DOI 10.1016/S0002-9440(10)64550-6; Lee HH, 2003, NATURE, V425, P507, DOI 10.1038/nature01916; Li XQ, 2004, HUM PATHOL, V35, P711, DOI 10.1016/j.humpath.2003.12.004; Lu KV, 2005, J BIOL CHEM, V280, P26953, DOI 10.1074/jbc.M502614200; Ma ZG, 2000, BLOOD, V95, P2144, DOI 10.1182/blood.V95.6.2144; Maheshwari G, 2001, J CELL BIOL, V155, P1123, DOI 10.1083/jcb.200109060; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Mirkin BL, 2005, ONCOGENE, V24, P4965, DOI 10.1038/sj.onc.1208671; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Muramatsu T, 2002, J BIOCHEM, V132, P359, DOI 10.1093/oxfordjournals.jbchem.a003231; Osajima-Hakomori Y, 2005, AM J PATHOL, V167, P213, DOI 10.1016/S0002-9440(10)62966-5; Ozes ON, 1999, NATURE, V401, P82; Powers C, 2002, J BIOL CHEM, V277, P14153, DOI 10.1074/jbc.M112354200; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Pulford K, 2004, J CELL PHYSIOL, V199, P330, DOI 10.1002/jcp.10472; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Richmond A, 2002, NAT REV IMMUNOL, V2, P664, DOI 10.1038/nri887; Romano MF, 1999, BLOOD, V94, P4060, DOI 10.1182/blood.V94.12.4060.424k23_4060_4066; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Sachdev D, 2001, ENDOCR-RELAT CANCER, V8, P197, DOI 10.1677/erc.0.0080197; Scharf JG, 2003, HORM METAB RES, V35, P685; Schulte AM, 1997, TUMOUR ANGIOGENESIS, P273; Schulte AM, 1996, P NATL ACAD SCI USA, V93, P14759, DOI 10.1073/pnas.93.25.14759; Singh AB, 2005, CELL SIGNAL, V17, P1183, DOI 10.1016/j.cellsig.2005.03.026; Stoica GE, 2002, J BIOL CHEM, V277, P35990, DOI 10.1074/jbc.M205749200; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; Surmacz E, 2004, J EXP CLIN CANC RES, V23, P385; Surmacz E, 2000, J MAMMARY GLAND BIOL, V5, P95, DOI 10.1023/A:1009523501499; Touriol C, 2000, BLOOD, V95, P3204, DOI 10.1182/blood.V95.10.3204.010k04_3204_3207; Trinei M, 2000, CANCER RES, V60, P793; Ueno H, 1996, J BIOL CHEM, V271, P27707, DOI 10.1074/jbc.271.44.27707; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; Valentinis B, 2001, J CLIN PATHOL-MOL PA, V54, P133, DOI 10.1136/mp.54.3.133; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; White MF, 1998, RECENT PROG HORM RES, V53, P119; Zamorano J, 2001, INT IMMUNOL, V13, P1479, DOI 10.1093/intimm/13.12.1479; Zhang N, 1999, Curr Opin Hematol, V6, P44, DOI 10.1097/00062752-199901000-00008; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	69	42	46	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2007	26	6					859	869		10.1038/sj.onc.1209840	http://dx.doi.org/10.1038/sj.onc.1209840			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134DT	16878150				2022-12-17	WOS:000244063800007
J	Paltoglou, S; Roberts, BJ				Paltoglou, S.; Roberts, B. J.			HIF-1 alpha and EPAS ubiquitination mediated by the VHL tumour suppressor involves flexibility in the ubiquitination mechanism, similar to other RING E3 ligases	ONCOGENE			English	Article						HIF-1 alpha; HIF-2 alpha; VHL; EPAS; ubiquitin; SCF	HIPPEL-LINDAU PROTEIN; INDUCIBLE FACTOR-I; PROLYL HYDROXYLATION/; HIF-ALPHA; DEGRADATION; DOMAINS; DESTRUCTION; COMPLEX; FAMILY; SIC1	Hypoxia-inducible factor 1 alpha (HIF-1 alpha) degradation under normoxia is critical to modulating vascular growth. This degradation is mediated during normoxia by the von Hippel-Lindau tumour suppressor protein (VHL)-E3 ubiquitin ligase in partnership with the E2 enzyme UbcH5. In current models of the functionally similar Skp1, cullin, F-box (SCF)-E3 ligase, the E3 binds the target protein and the E2 catalyses ubiquitin transfer to lysines in an appropriately positioned domain. In the present study, we report that for efficient ubiquitination of HIF-1 alpha to occur, three conserved lysines are required in both the HIF-1 alpha and endothelial Per-ARNT-Sim domain protein (EPAS) sequences. The site of ubiquitin attachment via UbcH5 was mapped, and is shown to involve three HIF-1 alpha lysines, K532, K538 and K547, and the same aligned lysines in EPAS. Only one of these lysines need to be intact for full ubiquitination to occur, analogous to the mechanism of Sic1 ubiquitination by the SCF/Cdc34 complex and further strengthening the functional link between the VHL and SCF-E3 ubiquitin ligases. We also report that lysines can be moved around the HIF-1 alpha sequence with only minor losses in ubiquitination efficiency, thus suggesting HIF-1 alpha and EPAS regulation by hypoxia depends primarily on an interaction with VHL per se, rather than the highly specific positioning of flanking lysine acceptors.	Univ S Australia, Sch Pharmaceut Mol & Biomed Sci, Adelaide, SA 5000, Australia	University of South Australia	Roberts, BJ (corresponding author), Univ S Australia, Sch Pharmaceut Mol & Biomed Sci, 4 Froome Rd, Adelaide, SA 5000, Australia.	Ben.Roberts@unisa.edu.au						Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Chan DA, 2005, MOL CELL BIOL, V25, P6415, DOI 10.1128/MCB.25.15.6415-6426.2005; Deffenbaugh AE, 2003, CELL, V114, P611, DOI 10.1016/S0092-8674(03)00641-X; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; HATFIELD PM, 1990, J BIOL CHEM, V265, P15813; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jackson PK, 2002, MOL CELL, V9, P923, DOI 10.1016/S1097-2765(02)00538-5; Jensen JP, 1995, J BIOL CHEM, V270, P30408, DOI 10.1074/jbc.270.51.30408; Kondo K, 2001, EXP CELL RES, V264, P117, DOI 10.1006/excr.2000.5139; Lewis MD, 2004, ONCOGENE, V23, P2315, DOI 10.1038/sj.onc.1207384; Lewis MD, 2003, ONCOGENE, V22, P3992, DOI 10.1038/sj.onc.1206683; Lonser RR, 2003, LANCET, V361, P2059, DOI 10.1016/S0140-6736(03)13643-4; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maynard MA, 2003, J BIOL CHEM, V278, P11032, DOI 10.1074/jbc.M208681200; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Petroski MD, 2003, MOL CELL, V11, P1435, DOI 10.1016/S1097-2765(03)00221-1; Pugh CW, 2003, SEMIN CANCER BIOL, V13, P83, DOI 10.1016/S1044-579X(02)00103-7; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Yu F, 2001, CANCER RES, V61, P4136; Zhou MI, 2002, J BIOL CHEM, V277, P39887, DOI 10.1074/jbc.M205040200	23	42	43	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 25	2007	26	4					604	609		10.1038/sj.onc.1209818	http://dx.doi.org/10.1038/sj.onc.1209818			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	129LS	16862177				2022-12-17	WOS:000243731600012
J	Cowell, LN; D Graham, J; Bouton, AH; Clarke, CL; O'Neill, GM				Cowell, L. N.; D Graham, J.; Bouton, A. H.; Clarke, C. L.; O'Neill, G. M.			Tamoxifen treatment promotes phosphorylation of the adhesion molecules, p130Cas/BCAR1, FAK and Src, via an adhesion-dependent pathway	ONCOGENE			English	Article						p130Cas/BCAR1; Src kinase; estrogen receptor; adhesion; tamoxifen; FAK	BREAST-CANCER CELLS; CRK-ASSOCIATED SUBSTRATE; DOMAIN TYROSINE PHOSPHORYLATION; HUMAN ESTROGEN-RECEPTOR; DOCKING PROTEIN HEF1; C-SRC; ANTIESTROGEN RESISTANCE; TRANSFORMED-CELLS; FAMILY KINASES; IN-VIVO	Reports that the adhesion-associated molecule p130Cas/BCAR1 promotes resistance to tamoxifen suggested that adhesion-mediated signalling may be altered by tamoxifen treatment. We find that p130Cas/BCAR1 phosphorylation is enhanced in tamoxifen-treated estrogen receptor (ER)positive MCF-7 breast cancer cells. The effects of estrogen and tamoxifen were assessed independently and in combination, and the results demonstrate that tamoxifen antagonizes estrogen regulation of p130Cas/BCAR1 phosphorylation. Phosphorylation correlates with tamoxifen ER antagonist effects, as phosphorylation effects are replicated by the pure antiestrogen ICI 182, 780. Correspondingly, phosphorylation is not changed in ER-negative cells exposed to tamoxifen. We show that deletion of the p130Cas/BCAR1 substrate domain substantially reduces tamoxifen-induced phosphorylation of p130Cas/BCAR1 and confers enhanced sensitivity to tamoxifen. P130Cas/BCAR1 forms a phosphorylation-dependent signalling complex with focal adhesion kinase (FAK) and Src kinase that promotes adhesion-mediated cell survival. Therefore, we examined the kinetics of p130Cas/BCAR1, Src and FAK phosphorylation over a 14-day time course and find sustained phosphorylation of these molecules after 7 days exposure to tamoxifen. Inhibition of Src kinase is shown to reduce tamoxifen-promoted p130Cas/BCAR1 phosphorylation and reduce cell viability. Stimulation of the Src/FAK/p130Cas/BCAR1 adhesion signalling pathway in tamoxifen-treated MCF-7 cells does not cause increased migration; however, there is Src-dependent phosphorylation of the cell survival molecule Akt. Correspondingly, Akt inhibition reduces cell viability in cells treated with tamoxifen. We propose that prolonged activation of adhesion-dependent signalling may confer a survival advantage in response to additional cellular insults or alternatively, may poise cells to develop a migratory phenotype in response to additional cellular cues.	Univ Sydney, Focal Adhes Biol Grp, Oncol Res Unit, Childrens Hosp, Westmead, NSW 2145, Australia; Univ Sydney, Discipline Paediat & Child Hlth, Westmead, NSW 2145, Australia; Univ Sydney, Westmead Millennium Inst, Westmead Hosp, Westmead, NSW 2145, Australia; Univ Virginia Hlth Syst, Dept Microbiol, Charlottesville, VA USA; Univ Virginia Hlth Syst, Ctr Canc, Charlottesville, VA USA	University of Sydney; University of Sydney; University of Sydney; Westmead Institute for Medical Research; University of Virginia; University of Virginia	O'Neill, GM (corresponding author), Univ Sydney, Focal Adhes Biol Grp, Oncol Res Unit, Childrens Hosp, Westmead, NSW 2145, Australia.	geraldio@chw.edu.au	O'Neill, Geraldine/F-3112-2014	O'Neill, Geraldine/0000-0001-9997-8794; Clarke, Christine/0000-0001-7568-111X	NCI NIH HHS [CA096846] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096846] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Arnold SF, 1997, MOL ENDOCRINOL, V11, P48, DOI 10.1210/me.11.1.48; ARNOLD SF, 1995, MOL ENDOCRINOL, V9, P24, DOI 10.1210/me.9.1.24; AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; Bartholomew PJ, 1998, J STEROID BIOCHEM, V67, P241, DOI 10.1016/S0960-0760(98)00098-3; Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; Boulares AH, 1999, J BIOL CHEM, V274, P22932, DOI 10.1074/jbc.274.33.22932; Brabek J, 2005, MOL CANCER RES, V3, P307, DOI 10.1158/1541-7786.MCR-05-0015; Brabek J, 2004, ONCOGENE, V23, P7406, DOI 10.1038/sj.onc.1207965; Brinkman A, 2000, JNCI-J NATL CANCER I, V92, P112, DOI 10.1093/jnci/92.2.112; Cabodi S, 2004, J CELL SCI, V117, P1603, DOI 10.1242/jcs.01025; Cai DP, 1999, J IMMUNOL, V163, P2104; Cai DP, 2003, CANCER RES, V63, P6802; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Chodniewicz D, 2004, BBA-MOL CELL RES, V1692, P63, DOI 10.1016/j.bbamcr.2004.03.006; Clemons M, 2002, CANCER TREAT REV, V28, P165, DOI 10.1016/S0305-7372(02)00036-1; DORSSERS LCJ, 1993, MOL ENDOCRINOL, V7, P870, DOI 10.1210/me.7.7.870; Dorssers LCJ, 2001, DRUGS, V61, P1721, DOI 10.2165/00003495-200161120-00004; Fonseca PM, 2004, CELL SIGNAL, V16, P621, DOI 10.1016/j.cellsig.2003.10.004; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; GIERTHY JF, 1991, J CELL BIOCHEM, V45, P177, DOI 10.1002/jcb.240450209; Goldberg GS, 2003, J BIOL CHEM, V278, P46533, DOI 10.1074/jbc.M307526200; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Hiscox S, 2004, CLIN EXP METASTAS, V21, P201, DOI 10.1023/B:CLIN.0000037697.76011.1d; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Howell A, 2000, CANCER-AM CANCER SOC, V89, P817, DOI 10.1002/1097-0142(20000815)89:4<817::AID-CNCR14>3.0.CO;2-6; Huang JH, 2002, J BIOL CHEM, V277, P27265, DOI 10.1074/jbc.M203063200; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kim H, 2005, ONCOGENE, V24, P5629, DOI 10.1038/sj.onc.1208718; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Knowlden JM, 2003, ENDOCRINOLOGY, V144, P1032, DOI 10.1210/en.2002-220620; Korb T, 2004, EXP CELL RES, V299, P236, DOI 10.1016/j.yexcr.2004.06.001; Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc; Law SF, 1996, MOL CELL BIOL, V16, P3327; Law SF, 2000, MOL CELL BIOL, V20, P5184, DOI 10.1128/MCB.20.14.5184-5195.2000; Migliaccio A, 2002, ANN NY ACAD SCI, V963, P185; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; O'Neill GM, 2001, MOL CELL BIOL, V21, P5094, DOI 10.1128/MCB.21.15.5094-5108.2001; Osborne CK, 2005, J CLIN ONCOL, V23, P1616, DOI 10.1200/JCO.2005.10.036; Planas-Silva MD, 2006, BIOCHEM BIOPH RES CO, V341, P73, DOI 10.1016/j.bbrc.2005.12.164; Pratt SJ, 2005, J CELL BIOL, V168, P813, DOI 10.1083/jcb.200406083; Riggins RB, 2003, J BIOL CHEM, V278, P28264, DOI 10.1074/jbc.M303535200; Ring A, 2004, ENDOCR-RELAT CANCER, V11, P643, DOI 10.1677/erc.1.00776; Ruest PJ, 2001, MOL CELL BIOL, V21, P7641, DOI 10.1128/MCB.21.22.7641-7652.2001; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Shin NY, 2004, J BIOL CHEM, V279, P38331, DOI 10.1074/jbc.M404675200; Sisci D, 2004, ONCOGENE, V23, P8920, DOI 10.1038/sj.onc.1208098; Sweeney KJ, 1998, ONCOGENE, V16, P2865, DOI 10.1038/sj.onc.1201814; van Agthoven T, 1998, EMBO J, V17, P2799, DOI 10.1093/emboj/17.10.2799; van der Flier S, 2000, JNCI-J NATL CANCER I, V92, P120, DOI 10.1093/jnci/92.2.120; Vuori K, 1996, MOL CELL BIOL, V16, P2606	56	42	45	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2006	25	58					7597	7607		10.1038/sj.onc.1209747	http://dx.doi.org/10.1038/sj.onc.1209747			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114GU	16799644				2022-12-17	WOS:000242655500005
J	Zheng, R; Iwase, A; Shen, R; Goodman, OB; Sugimoto, N; Takuwa, Y; Lerner, DJ; Nanus, DM				Zheng, R.; Iwase, A.; Shen, R.; Goodman, O. B., Jr.; Sugimoto, N.; Takuwa, Y.; Lerner, D. J.; Nanus, D. M.			Neuropeptide-stimulated cell migration in prostate cancer cells is mediated by RhoA kinase signaling and inhibited by neutral endopeptidase	ONCOGENE			English	Article						neutral endopeptidase; neuropetide; Rho kinase; RhoGEF; G-protein	NUCLEOTIDE EXCHANGE FACTORS; GTP-BINDING PROTEIN; FOCAL ADHESION KINASE; HETEROTRIMERIC G-PROTEINS; LEUKEMIA-ASSOCIATED RHO; G-BETA-GAMMA; CARCINOMA-CELLS; TYROSINE PHOSPHORYLATION; GROWTH-FACTORS; ALPHA-SUBUNIT	The neuropeptides bombesin and endothelin-1 stimulate prostate cancer (PC) cell migration and invasion (J Clin Invest, 2000; 106: 1399-1407). The intracellular signaling pathways that direct this cell movement are not well delineated. The monomeric GTPase RhoA is required for migration in several cell types including neutrophils, monocytes and. broblasts. We demonstrate that bombesin-stimulated PC cell migration occurs via the heterotrimeric G-protein-coupled receptors (G-protein) G alpha 13 subunit leading to activation of RhoA, and Rho-associated coiled-coil forming protein kinase (ROCK). Using siRNA to suppress expression of the three known G-protein asubunitassociated RhoA guanine nucleotide exchange factors (GEFs), we also show that two of these RhoA GEFs, PDZ-RhoGEF and leukemia-associated RhoGEF (LARG), link bombesin receptors to RhoA in a non-redundant manner in PC cells. We next show that focal adhesion kinase, which activates PDZ-RhoGEF and LARG, is required for bombesin-stimulated RhoA activation. Neutral endopeptidase (NEP) is expressed on normal prostate epithelium whereas loss of NEP expression contributes to PC progression. We also demonstrate that NEP inhibits neuropeptide activation of RhoA. Together, these results establish a contiguous signaling pathway from the bombesin receptor to ROCK in PC cells, and they implicate NEP as a major regulator of neuropeptide-stimulated RhoA in these cells. This work also identifies members of this signaling pathway as potential targets for rational pharmacologic manipulation of neuropeptide-stimulated migration of PC cells.	Cornell Univ, Weill Med Coll, Div Hematol & Med Oncol, Dept Med,Gerintourinary Oncol Res Lab, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Urol, Urol Oncol Res Lab, New York, NY 10021 USA; New York Presbyterian Hosp, New York, NY USA; Kanazawa Univ, Sch Med, Dept Physiol, Kanazawa, Ishikawa 920, Japan; Cornell Univ, Weill Med Coll, Div Cardiol, Dept Med, New York, NY 10021 USA	Cornell University; Cornell University; NewYork-Presbyterian Hospital; Kanazawa University; Cornell University	Nanus, DM (corresponding author), Cornell Univ, Weill Med Coll, Div Hematol & Med Oncol, Dept Med,Gerintourinary Oncol Res Lab, 525 E 68th St,ST-359, New York, NY 10021 USA.	dnanus@med.cornell.edu	Sugimoto, Naotoshi/C-4739-2015	Sugimoto, Naotoshi/0000-0003-1995-5002; Goodman, Oscar/0000-0002-0882-3621	NATIONAL CANCER INSTITUTE [R01CA080240] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL004080] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060908] Funding Source: NIH RePORTER; NCI NIH HHS [CA80240] Funding Source: Medline; NHLBI NIH HHS [HL04080] Funding Source: Medline; NIDDK NIH HHS [DK60908] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aprikian AG, 1997, INT J CANCER, V72, P498, DOI 10.1002/(SICI)1097-0215(19970729)72:3<498::AID-IJC19>3.3.CO;2-P; Arai K, 2003, MOL PHARMACOL, V63, P478, DOI 10.1124/mol.63.3.478; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Braga V, 2000, NAT CELL BIOL, V2, pE182, DOI 10.1038/35036433; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; Dai J, 2001, CLIN CANCER RES, V7, P1370; DELOMBAERT S, 1994, J MED CHEM, V37, P498, DOI 10.1021/jm00030a009; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fukuhara S, 2001, ONCOGENE, V20, P1661, DOI 10.1038/sj.onc.1204182; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Grant K, 2003, BRIT J CANCER, V88, P163, DOI 10.1038/sj.bjc.6700750; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hersch E, 2004, AM J PHYSIOL-CELL PH, V287, pC1209, DOI 10.1152/ajpcell.00198.2004; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; Iwase A, 2004, J BIOL CHEM, V279, P11898, DOI 10.1074/jbc.M212737200; Jiang YD, 2003, MOL CANCER RES, V1, P453; Kajiyama H, 2005, CLIN CANCER RES, V11, P1798, DOI 10.1158/1078-0432.CCR-04-2395; Karnoub AE, 2004, BREAST CANCER RES TR, V84, P61, DOI 10.1023/B:BREA.0000018427.84929.5c; Kassis J, 2001, SEMIN CANCER BIOL, V11, P105, DOI 10.1006/scbi.2000.0362; Kitamura K, 1999, AM J PHYSIOL-CELL PH, V276, pC930, DOI 10.1152/ajpcell.1999.276.4.C930; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kurose H, 2003, LIFE SCI, V74, P155, DOI 10.1016/j.lfs.2003.09.003; Leung T, 1996, MOL CELL BIOL, V16, P5313; Li Z, 2003, CELL, V114, P215, DOI 10.1016/S0092-8674(03)00559-2; Liu B, 2003, J BIOL CHEM, V278, P2384, DOI 10.1074/jbc.M208683200; Lummen G, 1997, N-S ARCH PHARMACOL, V356, P769, DOI 10.1007/PL00005117; LYONS LS, 2005, MOL ENDOCRINOL  1229; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Nagakawa O, 2001, INT J UROL, V8, P65, DOI 10.1046/j.1442-2042.2001.00250.x; Nagakawa O, 1998, CANCER LETT, V133, P27, DOI 10.1016/S0304-3835(98)00186-4; Nakagawa T, 2005, BIOCHEM PHARMACOL, V69, P579, DOI 10.1016/j.bcp.2004.11.003; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Papandreou CN, 1998, NAT MED, V4, P50, DOI 10.1038/nm0198-050; Radhika V, 2004, J BIOL CHEM, V279, P49406, DOI 10.1074/jbc.M408836200; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; Reuther GW, 2001, J BIOL CHEM, V276, P27145, DOI 10.1074/jbc.M103565200; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rosano L, 2001, CANCER RES, V61, P8340; Rozengurt E, 2002, TRENDS ENDOCRIN MET, V13, P128, DOI 10.1016/S1043-2760(01)00544-6; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Saurin JC, 2002, CANCER RES, V62, P4829; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Shen RQ, 2000, ENDOCRINOLOGY, V141, P1699, DOI 10.1210/en.141.5.1699; SHIPP MA, 1993, BLOOD, V82, P1052, DOI 10.1182/blood.V82.4.1052.bloodjournal8241052; Somlyo AV, 2000, BIOCHEM BIOPH RES CO, V269, P652, DOI 10.1006/bbrc.2000.2343; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; Sugden PH, 2003, J MOL CELL CARDIOL, V35, P871, DOI 10.1016/S0022-2828(03)00153-6; Sugimoto N, 2003, MOL CELL BIOL, V23, P1534, DOI 10.1128/MCB.23.5.1534-1545.2003; Sumitomo M, 2000, J CLIN INVEST, V106, P1399, DOI 10.1172/JCI10536; Sumitomo M, 2005, BBA-PROTEINS PROTEOM, V1751, P52, DOI 10.1016/j.bbapap.2004.11.001; Sumitomo M, 2001, CANCER RES, V61, P3294; Suzuki N, 2003, P NATL ACAD SCI USA, V100, P733, DOI 10.1073/pnas.0234057100; Tangkijvanich P, 2001, HEPATOLOGY, V33, P74, DOI 10.1053/jhep.2001.20677; Turner M, 2002, NAT REV IMMUNOL, V2, P476, DOI 10.1038/nri840; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; VAN AL, 1997, GENE DEV, V11, P2295; Wang Q, 2004, METHOD ENZYMOL, V389, P244; Wang Q, 2004, J BIOL CHEM, V279, P28831, DOI 10.1074/jbc.C400105200; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; Worthylake RA, 2001, J CELL BIOL, V154, P147, DOI 10.1083/jcb.200103048; Xu JS, 2003, CELL, V114, P201, DOI 10.1016/S0092-8674(03)00555-5; Yuan JZ, 2001, J BIOL CHEM, V276, P38619, DOI 10.1074/jbc.M105530200; Zhao RB, 1997, J BIOL CHEM, V272, P21207, DOI 10.1074/jbc.272.34.21207; Zhou KM, 1998, J BIOL CHEM, V273, P16782, DOI 10.1074/jbc.273.27.16782	76	42	45	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 28	2006	25	44					5942	5952		10.1038/sj.onc.1209586	http://dx.doi.org/10.1038/sj.onc.1209586			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	088QN	16652149	Bronze			2022-12-17	WOS:000240826300003
J	Estecio, MRH; Youssef, EM; Rahal, P; Fukuyama, EE; Gois, JF; Maniglia, JV; Goloni-Bertollo, EM; Issa, JPJ; Tajara, EH				Estecio, M. R. H.; Youssef, E. M.; Rahal, P.; Fukuyama, E. E.; Gois-Filho, J. F.; Maniglia, J. V.; Goloni-Bertollo, E. M.; Issa, J-P J.; Tajara, E. H.			LHX6 is a sensitive methylation marker in head and neck carcinomas	ONCOGENE			English	Article						DNA methylation; head and neck cancer; solid tumors; early diagnosis; circulating DNA	DNA METHYLATION; PROMOTER HYPERMETHYLATION; CELL CARCINOMAS; CANCER PATIENTS; GENOMIC DNA; GENES; IDENTIFICATION; EXPRESSION; SEQUENCES; FREQUENT	Head and neck cancer remains a morbid and often fatal disease and at the present time few effective molecular markers have been identified. The purpose of the present work was to identify new molecular markers for head and neck squamous cell carcinoma (HNSCC). We applied methylation-sensitive arbitrarily primed PCR (MS/APPCR) to isolate sequences differentially methylated in HNSCC. The most frequently hypermethylated fragment we found maps close to a cytosine guanine dinucleotide (CpG) island on chromosome 9q33.2, and hypermethylation of this CpG island was associated with transcriptional silencing of an alternative transcript of the LHX6 gene. Using combined bisulfite restriction analysis (COBRA), hypermethylation of this fragment was detected in 13 of 14 (92.8%) HNSCC cell lines studied and 21 of 32 (65.6%) primary tumors, whereas little or no methylation was seen in 10 normal oral mucosa samples. We extended this investigation to other cancer cell lines and methylation was found in those derived from colon, breast, leukemia and lung, and methylation was also found in 12/14 primary colon tumors. These findings suggest that differentially methylated (DIME)-6 hypermethylation is a good cancer marker in HNSCC as well as in other kinds of neoplasias and confirm the importance of searching for markers of epigenetic dysregulation in cancer.	Sch Med, FAMERP, Dept Mol Biol, BR-15090000 Sao Jose Do Rio Preto, SP, Brazil; Sch Med, FAMERP, Dept Surg, BR-15090000 Sao Jose Do Rio Preto, SP, Brazil; Sch Med, FAMERP, Dept Mol Biol, BR-15090000 Sao Jose Do Rio Preto, SP, Brazil; UNESP, IBILCE, Dept Biol, BR-15090000 Sao Jose Do Rio Preto, SP, Brazil; Arnaldo Vieira Carvalho Hosp, Dept Head & Neck & Skull Base Surg, Sao Paulo, Brazil; Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA	Universidade de Sao Paulo; Faculdade de Medicina de Sao Jose do Rio Preto (FAMERP); Universidade de Sao Paulo; Faculdade de Medicina de Sao Jose do Rio Preto (FAMERP); Universidade de Sao Paulo; Faculdade de Medicina de Sao Jose do Rio Preto (FAMERP); Universidade Estadual Paulista; University of Texas System; UTMD Anderson Cancer Center	Tajara, EH (corresponding author), Sch Med, FAMERP, Dept Mol Biol, Av Brig Faria Lima 5416, BR-15090000 Sao Jose Do Rio Preto, SP, Brazil.	tajara@famerp.br	Goloni-Bertollo, Eny Maria/B-8405-2012; Maniglia, José V/K-3129-2016; Tajara, Eloiza H/G-7586-2012; Rahal, Paula/D-3871-2012	Goloni-Bertollo, Eny Maria/0000-0002-2622-4673; Maniglia, José V/0000-0002-9765-2659; Tajara, Eloiza H/0000-0002-2603-2057; Rahal, Paula/0000-0001-5693-6148; Estecio, Marcos/0000-0002-6874-7413; Issa, Jean-Pierre/0000-0003-2258-5030	NCI NIH HHS [R33CA89837] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R33CA089837] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alves G, 1996, GENE, V176, P39, DOI 10.1016/0378-1119(96)00205-3; Casiglia Jeffrey, 2001, General Dentistry, V49, P72; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Esteller M, 1999, CANCER RES, V59, P67; Florl AR, 1999, BRIT J CANCER, V80, P1312, DOI 10.1038/sj.bjc.6690524; Gonzalgo ML, 1997, CANCER RES, V57, P594; Grati FR, 2000, CANCER GENET CYTOGEN, V118, P57, DOI 10.1016/S0165-4608(99)00199-5; Grigoriou M, 1998, DEVELOPMENT, V125, P2063; International Union Against Cancer, 1992, UICC TNM ATL ILL GUI, V3rd, P50; Issa JP, 1999, CRIT REV ONCOL HEMAT, V32, P31, DOI 10.1016/S1040-8428(99)00019-0; Jones P A, 1990, Adv Cancer Res, V54, P1, DOI 10.1016/S0065-230X(08)60806-4; KAWAI J, 1993, NUCLEIC ACIDS RES, V21, P5604, DOI 10.1093/nar/21.24.5604; Li J, 2005, CANCER-AM CANCER SOC, V104, P771, DOI 10.1002/cncr.21215; Macluskey M, 2000, Dent Update, V27, P148; Reichart P A, 2001, Clin Oral Investig, V5, P207, DOI 10.1007/s00784-001-0132-5; Shintani S, 2001, ORAL ONCOL, V37, P498, DOI 10.1016/S1368-8375(00)00142-1; Toyota M, 1999, CANCER RES, V59, P2307; Viswanathan M, 2003, INT J CANCER, V105, P41, DOI 10.1002/ijc.11028; Wong DTW, 1996, CRIT REV ORAL BIOL M, V7, P319, DOI 10.1177/10454411960070040201; Wong IHN, 1999, CANCER RES, V59, P71; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Xu J, 1998, CANCER-AM CANCER SOC, V83, P204, DOI 10.1002/(SICI)1097-0142(19980715)83:2<204::AID-CNCR2>3.0.CO;2-Q; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	23	42	44	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2006	25	36					5018	5026		10.1038/sj.onc.1209509	http://dx.doi.org/10.1038/sj.onc.1209509			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	075XR	16732332				2022-12-17	WOS:000239921300007
J	Darby, S; Sahadevan, K; Khan, MM; Robson, CN; Leung, HY; Gnanapragasam, VJ				Darby, S.; Sahadevan, K.; Khan, M. M.; Robson, C. N.; Leung, H. Y.; Gnanapragasam, V. J.			Loss of Sef (similar expression to FGF) expression is associated with high grade and metastatic prostate cancer	ONCOGENE			English	Article						prostate cancer; similar expression to FGF; fibroblast growth factor; metastasis	ISOFORM-B; OVER-EXPRESSION; TUMOR-GROWTH; RECEPTOR; CELLS; FIBROBLAST-GROWTH-FACTOR-8; ACTIVATION; GENE; GBX2	Fibroblast growth factors (FGF), and in particular FGF8, have been strongly implicated in prostate carcinogenesis. This study investigated the expression of Sef, a key inhibitory regulator of FGF signalling, in prostate cancer. In a panel of cell lines, hSef was detected in both androgen-dependent and independent cells but was significantly reduced in highly metastatic derivative clones. hSef expression was not influenced by androgenic stimulation. Forced downregulation of hSef by siRNA increased FGF8b induced cell migration (P = 0.02) and invasion (P = 0.007). Reduced hSef levels also enhanced FGF8b stimulated expression of MMP9 (P = 0.005). mRNA in situ hybridization revealed hSef expression in 80% (8/10) of benign biopsies but in only 69% (23/33) of Gleason sum 4-7 and 35% (10/28) of Gleason sum 8-10 cancer biopsies (P = 0.004). Quantitative PCR of micro-dissected glands confirmed this trend (P = 0.001). hSef was expressed in 69% (27/39) of non-metastatic tumours but in only 18% (2/11) of metastatic tumours (P = 0.004, n = 50). hSef expression was next correlated with earlier data on FGF8b expression in a subgroup of cancers. In this cohort, 86% (19/22) of high-grade cancers expressed FGF8 but only 31% (7/22) expressed hSef. Positive FGF8 expression but a loss of hSef was observed in 88% (7/8) of metastatic tumours. In contrast, metastasis was evident in only 10% (1/10) of tumours, which co-expressed both FGF8 and hSef (P < 0.001). These results suggest evidence that hSef is downregulated in advanced prostate cancer and might facilitate an enhanced tumorigenic response to FGFs. Further research into the role of hSef in cancer cell signalling and the mechanism of its downregulation may contribute to more effective targeting of growth factors in prostate cancer.	Univ Newcastle Upon Tyne, Urol Res Grp, Canc Res UK, No Inst Canc Res,Sch Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Royal Victoria Infirm, Dept Pathol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	Cancer Research UK; Newcastle University - UK; Newcastle University - UK	Gnanapragasam, VJ (corresponding author), Univ Newcastle Upon Tyne, Urol Res Grp, Canc Res UK, No Inst Canc Res,Sch Med, Paul O'Gorman Bldg,Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	V.J.Gnanapragasam@ncl.ac.uk		Leung, Hing Y./0000-0002-3933-3975; darby, steven/0000-0002-7226-8634; Sahadevan, Kanagasabai/0000-0002-3141-3276	Medical Research Council [G0100100] Funding Source: Medline; MRC [G0100100] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Dorkin TJ, 1999, ONCOGENE, V18, P2755, DOI 10.1038/sj.onc.1202624; DORKIN TJ, 2000, BJU INT, V86, P392; Furthauer M, 2002, NAT CELL BIOL, V4, P170, DOI 10.1038/ncb750; Gao AC, 2000, CLIN CANCER RES, V6, P493; Giri D, 1999, CLIN CANCER RES, V5, P1063; Gnanapragasam V, 2003, BRIT J CANCER, V88, P1432, DOI 10.1038/sj.bjc.6600875; Gnanapragasam VJ, 2002, ONCOGENE, V21, P5069, DOI 10.1038/sj.onc.1205663; Gnanapragasam VJ, 2001, BRIT J CANCER, V85, P1928, DOI 10.1054/bjoc.2001.2179; Gowardhan B, 2005, BRIT J CANCER, V92, P320, DOI 10.1038/sj.bjc.6602274; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Johansson JE, 2004, JAMA-J AM MED ASSOC, V291, P2713, DOI 10.1001/jama.291.22.2713; KOSLOWSKI J, 1984, CANCER RES, V44, P3522; Kovalenko D, 2003, J BIOL CHEM, V278, P14087, DOI 10.1074/jbc.C200606200; Kwabi-Addo B, 2004, ENDOCR-RELAT CANCER, V11, P709, DOI 10.1677/erc.1.00535; Leung HY, 1996, ONCOGENE, V12, P1833; Lin W, 2005, GENESIS, V41, P110, DOI 10.1002/gene.20103; Lin W, 2002, MECH DEVELOP, V113, P163, DOI 10.1016/S0925-4773(02)00018-7; Mattila MMT, 2001, ONCOGENE, V20, P2791, DOI 10.1038/sj.onc.1204430; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Ozen M, 2001, J NATL CANCER I, V93, P1783, DOI 10.1093/jnci/93.23.1783; Pettaway CA, 1996, CLIN CANCER RES, V2, P1627; Rudra-Ganguly N, 1998, ONCOGENE, V16, P1487, DOI 10.1038/sj.onc.1201652; Ruohola JK, 2001, CANCER RES, V61, P4229; Song ZG, 2000, CANCER RES, V60, P6730; Song ZG, 2002, CANCER RES, V62, P5096; Torii S, 2004, DEV CELL, V7, P33, DOI 10.1016/j.devcel.2004.05.019; Tsang M, 2002, NAT CELL BIOL, V4, P165, DOI 10.1038/ncb749; Xiong SQ, 2003, J BIOL CHEM, V278, P50273, DOI 10.1074/jbc.M306936200; YAN G, 1992, MOL CELL BIOL, V13, P4513; Yang RB, 2003, J BIOL CHEM, V278, P33232, DOI 10.1074/jbc.M305022200; Yang XH, 2004, J BIOL CHEM, V279, P38099, DOI 10.1074/jbc.C400318200	31	42	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 6	2006	25	29					4122	4127		10.1038/sj.onc.1209428	http://dx.doi.org/10.1038/sj.onc.1209428			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	060KZ	16474841				2022-12-17	WOS:000238802400013
J	Egwuagu, CE; Li, W; Yu, CR; Lin, MCM; Chan, CC; Nakamura, T; Chepelinsky, AB				Egwuagu, CE; Li, W; Yu, CR; Lin, MCM; Chan, CC; Nakamura, T; Chepelinsky, AB			Interferon-gamma induces regression of epithelial cell carcinoma: critical roles of IRF-1 and ICSBP transcription factors	ONCOGENE			English	Article						IFN gamma; epithelial cell carcinoma; SV40 T-antigen; IRF-1; ICSBP; apoptosis	SEQUENCE-BINDING-PROTEIN; REGULATORY FACTOR-I; HUMAN-PAPILLOMAVIRUS INFECTION; FAS-MEDIATED APOPTOSIS; LARGE T-ANTIGEN; TRANSGENIC MICE; IFN-GAMMA; MAMMALIAN LENS; RISK FACTOR; EXPRESSION	We have developed an epithelial cell carcinoma model for studying efficacy of IFN gamma gene therapy and have identified components of IFN gamma-signaling pathway responsible for its direct anti-tumor actions. The tumor results from ectopic expression of SV40 Large T-Antigen ( SV40 T-Ag) oncogene in lens of transgenic mouse ( alpha T3) and complete regression of the tumor is induced by targeting expression of IFN gamma into malignant lens cells. In. ammatory cells are absent in lens of aT3 or DT ( co-expressing IFN gamma and SV40-T-Antigen) mice and the transformed lens cells are non-immunogenic, suggesting non- involvement of immunologic cells. We show that IFN gamma has direct growth-inhibitory effects on tumor cells, induces death of tumor cells by apoptosis and that these effects are mediated by two transcription factors, IRF-1 ( interferon-regulatory factor-1) and ICSBP ( interferon-consensus sequence-binding protein) induced by IFN gamma. Furthermore, stable transfection with ICSBP or IRF-1 construct inhibits lens carcinoma cell growth by upregulating Caspase-1, p21(WAF1) and p27 expression. In contrast, tumor progression in aT3 lens correlates with inhibition of IRF-1 and ICSBP expression. Our results suggest that IFN gamma gene therapy maybe effective in malignant diseases for which DNA tumor viruses are etiologic agents and that antitumor actions of IRF-1/ICSBP can be exploited therapeutically to circumvent adverse clinical effects associated with IFN therapy.	NEI, Lab Immunol Mol, Immunol Sect, NIH, Bethesda, MD 20892 USA; Mol & Dev Biol Natl Eye Inst, NIH, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Egwuagu, CE (corresponding author), NEI, Lab Immunol Mol, Immunol Sect, NIH, Bldg 10,Room 10N116,10 Ctr Dr, Bethesda, MD 20892 USA.	egwuaguc@nei.nih.gov		Yu, Cheng-Rong/0000-0001-7246-0362	NATIONAL EYE INSTITUTE [Z01EY000222, Z01EY000315, Z01EY000253, ZIAEY000315, ZIAEY000222] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Asamoto M, 2001, CANCER RES, V61, P4693; Awasthi N, 2004, INVEST OPHTH VIS SCI, V45, P222, DOI 10.1167/iovs.03-0571; Bjorge T, 2002, BRIT J CANCER, V87, P61, DOI 10.1038/sj.bjc.6600350; BOULTWOOD J, 1993, BLOOD, V82, P2611; Bowie ML, 2004, ONCOGENE, V23, P8743, DOI 10.1038/sj.onc.1208120; CHEPELINSKY AB, 1987, ENVIRON HEALTH PERSP, V75, P17, DOI 10.2307/3430571; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; De Vita VT, 2001, CANC PRINCIPLES PRAC; Detjen KM, 2001, GUT, V49, P251, DOI 10.1136/gut.49.2.251; Duan WM, 2005, ONCOGENE, V24, P1510, DOI 10.1038/sj.onc.1208229; Ebong S, 2004, MOL VIS, V10, P122; Ebong S, 2004, INVEST OPHTH VIS SCI, V45, P872, DOI 10.1167/iovs.03-0311; EGWUAGU CE, 1994, DEV BIOL, V166, P557, DOI 10.1006/dbio.1994.1337; Egwuagu CE, 1999, CLIN IMMUNOL, V91, P196, DOI 10.1006/clim.1999.4701; Egwuagu CE, 1999, J IMMUNOL, V162, P510; Gabril MY, 2005, MOL THER, V11, P348, DOI 10.1016/j.ymthe.2004.12.005; Garcia-Espana A, 2005, CANCER RES, V65, P1150, DOI 10.1158/0008-5472.CAN-04-2074; Garson K, 2003, J SOC GYNECOL INVEST, V10, P244, DOI 10.1016/S1071-5576(03)00073-X; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Horiuchi M, 1999, HYPERTENSION, V33, P162, DOI 10.1161/01.HYP.33.1.162; Hughes RS, 2005, AM J MED SCI, V329, P29; ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P258, DOI 10.1098/rspb.1957.0048; Janeway C.A., 1999, IMMUNOBIOLOGY IMMUNE; Jin M, 2004, J MED VIROL, V74, P668, DOI 10.1002/jmv.20219; JOLICOEUR C, 1994, P NATL ACAD SCI USA, V91, P6707, DOI 10.1073/pnas.91.14.6707; Jung YK, 1997, ONCOGENE, V14, P1207, DOI 10.1038/sj.onc.1200943; Kano A, 1999, BIOCHEM BIOPH RES CO, V257, P672, DOI 10.1006/bbrc.1999.0276; Lai JC, 1998, INVEST OPHTH VIS SCI, V39, P2049; LAKSO M, 1992, P NATL ACAD SCI USA, V89, P6232, DOI 10.1073/pnas.89.14.6232; Li WM, 1999, J BIOL CHEM, V274, P9686, DOI 10.1074/jbc.274.14.9686; Li WM, 1999, DEV BIOL, V210, P44, DOI 10.1006/dbio.1999.9267; Liu KB, 2003, J IMMUNOL, V170, P6329, DOI 10.4049/jimmunol.170.12.6329; MAHON KA, 1987, SCIENCE, V235, P1622, DOI 10.1126/science.3029873; MCAVOY JW, 1980, DIFFERENTIATION, V17, P137, DOI 10.1111/j.1432-0436.1980.tb01091.x; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; Mork J, 2001, NEW ENGL J MED, V344, P1125, DOI 10.1056/NEJM200104123441503; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Park JS, 2000, J BIOL CHEM, V275, P6764, DOI 10.1074/jbc.275.10.6764; Pfeffer LM, 1998, CANCER RES, V58, P2489; PIATIGORSKY J, 1981, DIFFERENTIATION, V19, P134, DOI 10.1111/j.1432-0436.1981.tb01141.x; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; Schaeffer AJ, 2004, CANCER RES, V64, P538, DOI 10.1158/0008-5472.CAN-03-0124; Schreiber K, 2004, ONCOGENE, V23, P3972, DOI 10.1038/sj.onc.1207507; Sharf R, 1997, J BIOL CHEM, V272, P9785; Tagliaferri P, 2005, CANCER IMMUNOL IMMUN, V54, P1, DOI 10.1007/s00262-004-0549-1; TANIGUCHI T, 1995, J CANCER RES CLIN, V121, P516, DOI 10.1007/BF01197763; Tomita Y, 2003, INT J CANCER, V104, P400, DOI 10.1002/ijc.10956; Vilchez RA, 2004, CLIN MICROBIOL REV, V17, P495, DOI [10.1128/CMR.17.3.495-508.2004, 10.1128/cmr.17.3.495-508.2004]; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; YAMADA T, 1990, CURR EYE RES, V9, P31, DOI 10.3109/02713689009000052; YE XH, 1994, P NATL ACAD SCI USA, V91, P3916, DOI 10.1073/pnas.91.9.3916; Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452; Yu CR, 2003, J BIOL CHEM, V278, P29752, DOI 10.1074/jbc.M300489200	54	42	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 22	2006	25	26					3670	3679		10.1038/sj.onc.1209402	http://dx.doi.org/10.1038/sj.onc.1209402			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KD	16462767				2022-12-17	WOS:000238448300006
J	Kommagani, R; Caserta, TM; Kadakia, MP				Kommagani, R.; Caserta, T. M.; Kadakia, M. P.			Identification of vitamin D receptor as a target of p63	ONCOGENE			English	Article						p63 gamma; VDR; p14(ARF); differentiation	FAMILY-MEMBER GENES; P53 HOMOLOG P63; TUMOR-SUPPRESSOR; EPIDERMAL DIFFERENTIATION; PROSTATE-CANCER; DEVELOPMENTAL SYNDROMES; EEC-SYNDROME; EXPRESSION; MUTATIONS; CELLS	p63, a p53 homolog has been shown to play a role in development and cancer. p63 is essential for both commitment of ectoderm to stratified epithelia and for the proliferative potential of epithelial stem cells. p63 knockout mice are born with severe development defects and lack organs of epithelial origin. In addition, p63 has also been shown to play a role in cancer development through the differential regulation of genes with tumor suppressor function and genes involved in metastasis. In order to understand the role of p63 in cancer and development, genes that are specifically regulated by p63 but not p53 were identified. In this study, we provide evidence that p63 gamma specifically upregulates vitamin D Receptor ( VDR). In contrast, p53 does not appear to be involved in upregulation of VDR expression. Additionally, we demonstrate that a naturally occurring p63 missense mutant, p63c ( R279H) and p14(ARF), both act in a dominant negative manner to inhibit p63 gamma-mediated upregulation of VDR. Furthermore, using chromatin immunoprecipitation assays, we demonstrated that p63 directly binds to the VDR promoter in vivo. Our findings clearly demonstrate that VDR is a direct target of p63 and suggests that p63 may play a role in cancer and differentiation through modulation of the VDR pathway.	Wright State Univ, Dept Biohchem & Mol Biol, Dayton, OH 45435 USA; Wright State Univ, Ctr Genom Res, Dayton, OH USA	University System of Ohio; Wright State University Dayton; University System of Ohio; Wright State University Dayton	Kadakia, MP (corresponding author), Wright State Univ, Dept Biohchem & Mol Biol, 3640 Col Glenn Highway,142 Biol Sci, Dayton, OH 45435 USA.	madhavi.kadakia@wright.edu		Kommagani, Ramakrishna/0000-0003-0403-0971				Banerjee P, 2003, MOL CELL BIOCHEM, V253, P247, DOI 10.1023/A:1026072118217; Barbieri CE, 2005, CANCER RES, V65, P2314, DOI 10.1158/0008-5472.CAN-04-3449; Barrow LL, 2002, J MED GENET, V39, P559, DOI 10.1136/jmg.39.8.559; Bikle DD, 2004, J NUTR, V134, p3472S, DOI 10.1093/jn/134.12.3472S; Bikle DD, 2004, J STEROID BIOCHEM, V89-90, P355, DOI 10.1016/j.jsbmb.2004.03.020; BIKLE DD, 1992, ENDOCR REV, V13, P765, DOI 10.1210/er.13.4.765; Bikle DD, 2003, J CELL BIOCHEM, V88, P290, DOI 10.1002/jcb.10339; Blutt SE, 1999, P SOC EXP BIOL MED, V221, P89, DOI 10.1046/j.1525-1373.1999.d01-60.x; Brunner HG, 2002, J MED GENET, V39, P377, DOI 10.1136/jmg.39.6.377; Brunner HG, 2002, AM J MED GENET, V112, P284, DOI 10.1002/ajmg.10778; Calabro V, 2004, MOL CELL BIOL, V24, P8529, DOI 10.1128/MCB.24.19.8529-8540.2004; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; Christakos S, 2003, J CELL BIOCHEM, V88, P238, DOI 10.1002/jcb.10349; Feldman D, 2000, ENDOCRINOLOGY, V141, P5, DOI 10.1210/en.141.1.5; Gressner O, 2005, EMBO J, V24, P2458, DOI 10.1038/sj.emboj.7600708; Guzey M, 2004, J CELL BIOCHEM, V93, P271, DOI 10.1002/jcb.20182; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hudson DL, 2004, PROSTATE CANCER P D, V7, P188, DOI 10.1038/sj.pcan.4500745; Kim S, 2004, CANCER RES, V64, P6900, DOI 10.1158/0008-5472.CAN-04-1657; Konety B R, 1999, Semin Urol Oncol, V17, P77; Koszewski NJ, 1996, J STEROID BIOCHEM, V59, P377, DOI 10.1016/S0960-0760(96)00127-6; Lian J. B., 2003, Current Pharmaceutical Design, V9, P2677, DOI 10.2174/1381612033453659; Lu JF, 2005, J INVEST DERMATOL, V124, P778, DOI 10.1111/j.0022-202X.2005.23641.x; Miller GJ, 1998, CANCER METAST REV, V17, P353, DOI 10.1023/A:1006102124548; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Miyamoto K, 1997, MOL ENDOCRINOL, V11, P1165, DOI 10.1210/me.11.8.1165; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; Osada M, 2005, MOL CELL BIOL, V25, P6077, DOI 10.1128/MCB.25.14.6077-6089.2005; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; Patturajan M, 2002, CANCER CELL, V1, P369, DOI 10.1016/S1535-6108(02)00057-0; Petitjean A, 2005, ONCOGENE, V24, P512, DOI 10.1038/sj.onc.1208215; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Sasaki Y, 2005, ONCOGENE, V24, P5131, DOI 10.1038/sj.onc.1208695; Sasaki Y, 2002, J BIOL CHEM, V277, P719, DOI 10.1074/jbc.M108080200; Senoo M, 2002, ONCOGENE, V21, P2455, DOI 10.1038/sj.onc.1205330; Shimada A, 1999, CANCER RES, V59, P2781; South AP, 2002, BRIT J DERMATOL, V146, P216, DOI 10.1046/j.1365-2133.2002.04638.x; Spiesbach K, 2005, INT J CANCER, V114, P555, DOI 10.1002/ijc.20766; van Bokhoven H, 2002, TRENDS MOL MED, V8, P133, DOI 10.1016/S1471-4914(01)02260-2; Wagner EF, 2001, CURR OPIN GENET DEV, V11, P527, DOI 10.1016/S0959-437X(00)00228-8; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Wu GJ, 2003, CANCER RES, V63, P2351; Xie ZJ, 2002, J INVEST DERMATOL, V118, P11, DOI 10.1046/j.1523-1747.2002.01644.x; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	47	42	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2006	25	26					3745	3751		10.1038/sj.onc.1209412	http://dx.doi.org/10.1038/sj.onc.1209412			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KD	16462763				2022-12-17	WOS:000238448300013
J	Horndasch, M; Lienkamp, S; Springer, E; Schmitt, A; Pavenstadt, H; Walz, G; Gloy, J				Horndasch, M.; Lienkamp, S.; Springer, E.; Schmitt, A.; Pavenstaedt, H.; Walz, G.; Gloy, J.			The C/EBP homologous protein CHOP (GADD153) is an inhibitor of Wnt/TCF signals	ONCOGENE			English	Article						C/EBP; CHOP; TCF; tumour cells; Wnt signalling	TRANSCRIPTION FACTORS C/EBP; BINDING-PROTEIN; BETA-CATENIN; UP-REGULATION; GROWTH ARREST; WNT; APOPTOSIS; PATHWAYS; EXPRESSION; KINASE	CHOP (GADD153) is a protein of the C/EBP family of transcriptional regulators, which dimerizes with other C/EBP members and changes their DNA-binding and transactivation properties. It induces growth arrest and apoptosis after endoplasmatic reticulum stress or DNA damage. CHOP is also expressed during early embryogenesis and upregulated in tumour tissues with defective Wnt signals. We report here that CHOP functions as a specific inhibitor of Wnt/T-cell factor (TCF) signalling. CHOP inhibits TCF-dependent transcription in human embryonic and colon cancer cell lines. Injection of CHOP mRNA into early Xenopus laevis embryos suppresses dorsal organizer formation and inhibits secondary axis formation and TCF-dependent transcription in response to Wnt-8, Dishevelled, beta-Catenin and TCF-VP16. In embryos and human cells, this inhibition depends on the N-terminal transactivation domain of CHOP, whereas the C-terminal dimerization domain is dispensable. CHOP binds to TCF factors, thereby preventing the binding of TCF to its DNA recognition site. Our findings demonstrate a novel function of CHOP as a Wnt repressor.	Univ Hosp Freiburg, Div Nephrol, Dept Med, Freiburg, Germany; UKM Munster, Div Nephrol & Hypertens, Dept Med, Munster, Germany	University of Freiburg; University of Munster	Gloy, J (corresponding author), Zentrum Klin Forsch, Breisacher Str 66, D-79106 Freiburg, Germany.	gloy@med1.ukl.uni-freiburg.de	Lienkamp, Soeren/AAH-6296-2020	Lienkamp, Soeren/0000-0003-2963-6865				BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; Clevers H, 2004, CANCER CELL, V5, P5, DOI 10.1016/S1535-6108(03)00339-8; Conn KJ, 2002, J NEUROSCI RES, V68, P755, DOI 10.1002/jnr.10252; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Fawcett TW, 1996, J BIOL CHEM, V271, P14285, DOI 10.1074/jbc.271.24.14285; Fleming JV, 1997, MOL REPROD DEV, V48, P310, DOI 10.1002/(SICI)1098-2795(199711)48:3&lt;310::AID-MRD2&gt;3.0.CO;2-U; Fontanier-Razzaq NC, 1999, MOL REPROD DEV, V54, P326, DOI 10.1002/(SICI)1098-2795(199912)54:4&lt;326::AID-MRD2&gt;3.0.CO;2-3; Friedman AD, 1996, CANCER RES, V56, P3250; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; Hecht A, 2000, EMBO REP, V1, P24, DOI 10.1093/embo-reports/kvd012; Houston DW, 2002, DEVELOPMENT, V129, P4015; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; Jaiswal AS, 2002, ONCOGENE, V21, P8414, DOI 10.1038/sj.onc.1205947; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; Kim CH, 2000, NATURE, V407, P913, DOI 10.1038/35038097; Kim DG, 2002, J BIOL CHEM, V277, P38930, DOI 10.1074/jbc.M205941200; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Maytin EV, 1998, J INVEST DERMATOL, V110, P238, DOI 10.1046/j.1523-1747.1998.00123.x; Maytin EV, 2001, EXP CELL RES, V267, P193, DOI 10.1006/excr.2001.5248; Meneghini MD, 1999, NATURE, V399, P793, DOI 10.1038/21666; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Oyadomari S, 2001, P NATL ACAD SCI USA, V98, P10845, DOI 10.1073/pnas.191207498; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Pereira RC, 2004, ENDOCRINOLOGY, V145, P1952, DOI 10.1210/en.2003-0868; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Rask K, 2000, INT J CANCER, V86, P337, DOI 10.1002/(SICI)1097-0215(20000501)86:3<337::AID-IJC6>3.3.CO;2-V; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Scott DW, 2004, CARCINOGENESIS, V25, P2155, DOI 10.1093/carcin/bgh239; Sokol SY, 1999, CURR OPIN GENET DEV, V9, P405, DOI 10.1016/S0959-437X(99)80061-6; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Talukder AH, 2002, ONCOGENE, V21, P4289, DOI 10.1038/sj.onc.1205529; Tang QQ, 2000, P NATL ACAD SCI USA, V97, P12446, DOI 10.1073/pnas.220425597; Ubeda M, 1999, MOL CELL BIOL, V19, P7589; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; Ubeda M, 2003, J BIOL CHEM, V278, P40514, DOI 10.1074/jbc.M306404200; Vonica A, 2000, DEV BIOL, V217, P230, DOI 10.1006/dbio.1999.9551; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	46	42	46	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2006	25	24					3397	3407		10.1038/sj.onc.1209380	http://dx.doi.org/10.1038/sj.onc.1209380			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KB	16434966				2022-12-17	WOS:000238448100005
J	Nguyen, QD; De Wever, O; Bruyneel, E; Hendrix, A; Xie, WZ; Lombet, A; Leibl, M; Mareel, M; Gieseler, F; Bracke, M; Gespach, C				Nguyen, QD; De Wever, O; Bruyneel, E; Hendrix, A; Xie, WZ; Lombet, A; Leibl, M; Mareel, M; Gieseler, F; Bracke, M; Gespach, C			Commutators of PAR-1 signaling in cancer cell invasion reveal an essential role of the Rho-Rho kinase axis and tumor microenvironment	ONCOGENE			English	Article						PKG; hypoxia; SPARC/BM-40; tenascin-C; peritoneal and pleural effusions; metastasis and thrombosis	PROTEASE-ACTIVATED RECEPTOR-1; VASCULAR SMOOTH-MUSCLE; GROWTH-FACTOR RECEPTOR; THROMBIN RECEPTOR; EPITHELIAL-CELLS; NEOPLASTIC PROGRESSION; TREFOIL PEPTIDES; FOCAL ADHESIONS; STRESS FIBERS; EXPRESSION	We recently reported that proteinase-activated receptors type I (PAR-1) are coupled to both negative and positive invasion pathways in colonic and kidney cancer cells cultured on collagen type I gels. Here, we found that treatments with the cell-permeant analog 8-Br-cGMP and the soluble guanylate cyclase activator BAY41-2272, and Rho kinase (ROK) inhibit ion by Y27632 or a dominant negative form of ROK lead to PAR-1-mediated invasion through differential Rac1 and Cdc42 signaling. Hypoxia or the counteradhesive matricellular protein SPARC/BM-40 ( SPARC: secreted protein acidic rich in cysteine) overexpressed during cancer progression also commutated PAR-1 to cellular invasion through the cGMP/protein kinase G (PKG) cascade, RhoA inactivation, and Rac1-dependent or -independent signaling. Cultured primary cancer cells isolated from peritoneal and pleural effusions from patients with colon cancer or other malignant tumors harbored PAR-1, as shown by RT-PCR and FACS analyses. These malignant effusions also contained high levels of activated thrombin and fibrin, and induced a proinvasive response in HCT8/S11 human colorectal cancer cells. Our data underline the essential role of the tumor microenvironment and of several commutators targeting cGMP/PKG signaling and the RhoA-ROK axis in the control of PAR-1 proinvasive activity and metastatic potential of cancer cells in distant organs and peritoneal or pleural cavities. We also add new insights into the mechanisms linking the coagulation mediators thrombin and PAR-1 in the context of blood coagulation disorders and venous thrombosis often observed in cancer patients, as described in 1865 by Armand Trousseau.	Hop St Antoine, INSERM, U673, F-75571 Paris, France; Ghent Univ Hosp, Expt Cancerol Lab, B-9000 Ghent, Belgium; Univ Kiel, Dept Internal Med, D-24105 Kiel, Germany; Zhejiang Univ, Affiliated Hosp 1, Coll Med, Zhejiang, Peoples R China; Hop Marie Lannelongue, CNRS, UMR8078, F-92350 Le Plessis Robinson, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Ghent University; Ghent University Hospital; University of Kiel; Zhejiang University; Centre National de la Recherche Scientifique (CNRS); Hopital Marie Lannelongue	Gespach, C (corresponding author), Hop St Antoine, INSERM, U673, 184 Rue Faubourg St Antoine, F-75571 Paris, France.	gespach@st-antoine.inserm.fr	de wever, olivier/J-3094-2013; Gieseler, Frank/E-8386-2012; Hendrix, An/L-5918-2019; Gieseler, Frank/L-4668-2013	de wever, olivier/0000-0002-5453-760X; Gieseler, Frank/0000-0001-6409-3822; 				Ahn B, 2001, CANCER RES, V61, P8357; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Andre T, 2000, INT J CANCER, V86, P174, DOI 10.1002/(SICI)1097-0215(20000415)86:2<174::AID-IJC5>3.3.CO;2-5; Begum N, 2002, J BIOL CHEM, V277, P6214, DOI 10.1074/jbc.M110508200; Bellanger JM, 2000, NAT CELL BIOL, V2, P888, DOI 10.1038/35046533; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Boccaccio C, 2005, NATURE, V434, P396, DOI 10.1038/nature03357; Boire A, 2005, CELL, V120, P303, DOI 10.1016/j.cell.2004.12.018; Booden MA, 2002, MOL CELL BIOL, V22, P4053, DOI 10.1128/MCB.22.12.4053-4061.2002; BRACKE ME, 2000, COLLAGEN INVASION AS, V58, P81; Bradshaw AD, 2001, J CLIN INVEST, V107, P1049, DOI 10.1172/JCI12939; Cerione RA, 2004, TRENDS CELL BIOL, V14, P127, DOI 10.1016/j.tcb.2004.01.008; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Darmoul D, 2004, MOL CANCER RES, V2, P514; Darmoul D, 2003, AM J PATHOL, V162, P1503, DOI 10.1016/S0002-9440(10)64283-6; De Wever O, 2004, FASEB J, V18, P1016, DOI 10.1096/fj.03-1110fje; EMAMI S, 1984, BIOCHIM BIOPHYS ACTA, V804, P77, DOI 10.1016/0167-4889(84)90101-0; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Even-Ram SC, 2001, J BIOL CHEM, V276, P10952, DOI 10.1074/jbc.M007027200; Faivre S, 2001, MOL PHARMACOL, V60, P363, DOI 10.1124/mol.60.2.363; Hansen SH, 2000, MOL CELL BIOL, V20, P9364, DOI 10.1128/MCB.20.24.9364-9375.2000; Hou YL, 2004, CELL SIGNAL, V16, P1061, DOI 10.1016/j.cellsig.2004.03.002; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kamath L, 2001, CANCER RES, V61, P5933; Kawasaki K, 2003, MOL CELL BIOL, V23, P5726, DOI 10.1128/MCB.23.16.5726-5737.2003; Kisley LR, 2002, CANCER RES, V62, P6850; Kotelevets L, 1998, J BIOL CHEM, V273, P14138, DOI 10.1074/jbc.273.23.14138; Kureishi Y, 1997, J BIOL CHEM, V272, P12257, DOI 10.1074/jbc.272.19.12257; Le Floch N, 2004, FASEB J, V18, P144, DOI 10.1096/fj.04-2373fje; Ledda MF, 1997, NAT MED, V3, P171, DOI 10.1038/nm0297-171; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Marinissen MJ, 2004, MOL CELL, V14, P29, DOI 10.1016/S1097-2765(04)00153-4; Maschler S, 2004, ONCOGENE, V23, P3622, DOI 10.1038/sj.onc.1207403; McHardy LM, 2004, CANCER RES, V64, P1468, DOI 10.1158/0008-5472.CAN-03-2733; MURPHYULLRICH JE, 1995, J CELL BIOCHEM, V57, P341, DOI 10.1002/jcb.240570218; Nguyen QD, 2002, FASEB J, V16, P565, DOI 10.1096/fj.01-0525com; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Poola I, 2005, NAT MED, V11, P481, DOI 10.1038/nm1243; PORTE H, 1995, INT J CANCER, V64, P70, DOI 10.1002/ijc.2910640114; Ricort JM, 2002, FEBS LETT, V527, P293, DOI 10.1016/S0014-5793(02)03250-7; Ridley AJ, 2001, J CELL SCI, V114, P2713; Rivat C, 2003, FASEB J, V17, P1721, DOI 10.1096/fj.03-0132fje; Rodrigues S, 2003, ONCOGENE, V22, P4488, DOI 10.1038/sj.onc.1206685; Rodrigues S, 2001, FASEB J, V15, P1517, DOI 10.1096/fj.00-0802com; Sandu OA, 2001, J APPL PHYSIOL, V91, P1475, DOI 10.1152/jappl.2001.91.3.1475; Sauzeau V, 2000, J BIOL CHEM, V275, P21722, DOI 10.1074/jbc.M000753200; Sawada N, 2001, BIOCHEM BIOPH RES CO, V280, P798, DOI 10.1006/bbrc.2000.4194; Schafer B, 2004, ONCOGENE, V23, P991, DOI 10.1038/sj.onc.1207278; Stasch JP, 2001, NATURE, V410, P212, DOI 10.1038/35065611; Thomas R, 2000, CLIN CANCER RES, V6, P1140; VanObberghenSchilling E, 1995, ANN NY ACAD SCI, V766, P431, DOI 10.1111/j.1749-6632.1995.tb26692.x; WOJTUKIEWICZ MZ, 1995, CANCER RES, V55, P698; Xie WZ, 2005, BIOMED PHARMACOTHER, V59, P70, DOI 10.1016/j.biopha.2005.01.001; Zhao DZ, 2004, J BIOL CHEM, V279, P43547, DOI 10.1074/jbc.M401453200	55	42	46	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2005	24	56					8240	8251		10.1038/sj.onc.1208990	http://dx.doi.org/10.1038/sj.onc.1208990			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	993LV	16091733				2022-12-17	WOS:000233956500003
J	Lingbeck, JM; Trausch-Azar, JS; Ciechanover, A; Schwartz, AL				Lingbeck, JM; Trausch-Azar, JS; Ciechanover, A; Schwartz, AL			E12 and E47 modulate cellular localization and proteasome-mediated degradation of MyoD and Id1	ONCOGENE			English	Article						E12; E47; Id1; MyoD; ubiquitin proteasome degradation	KAPPA-B-ALPHA; NUCLEAR-LOCALIZATION; DNA-BINDING; PROTEINS; PHOSPHORYLATION	Programs of tissue differentiation are likely controlled by factors regulating gene expression and protein degradation. In muscle, the degradation of the muscle transcription factor MyoD and its inhibitor Id1 occurs via the ubiquitin-proteasome system. E12 and E47, splice products of the E2A gene, interact with MyoD to activate transcription of the muscle program and are also degraded by the ubiquitin-proteasome system (t(1/2) = similar to 6 h). E12 and E47 each contain two regions of basic amino acids, which, when mutated, lead to cytoplasmic accumulation of the proteins. These NLS mutants ( E12(NLS), E47(NLS)) are degraded with a half-life similar to the wild-type proteins. In nonmuscle cells, cotransfection of either E12 or E47 with MyoD extended MyoD's half-life from similar to 1 to similar to 4h. In addition, cotransfection of either E12 or E47 with Id1 led to a marked reduction in Id1's degradation rate from t(1/2) of similar to 1 to similar to 8 h. Furthermore, the cotransfection of NLS deficient mutants of MyoD or Id1 with E12 or E47 resulted in altered intracellular localization of the proteins largely dependent upon the E12 or E47 moiety. Cotransfection of wild-type MyoD or Id1 with NLS deficient mutants of E12 or E47 also led to an altered intracellular localization of MyoD and Id1. These results demonstrate in vivo that E12 and E47 modulate both MyoD and Id1 degradation and may have implications for the physiological regulation of muscle development.	Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; St Louis Childrens Hosp, St Louis, MO 63110 USA; Technion Israel Inst Technol, Fac Med, Dept Biochem, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Fac Med, Rappaport Inst Res Med Sci, IL-31096 Haifa, Israel	Washington University (WUSTL); Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Schwartz, AL (corresponding author), Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, 660 S Euclid Ave,CB 8116, St Louis, MO 63110 USA.	schwartz@kids.wustl.edu	Ciechanover, Aaron J/C-9166-2017					BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; Collavoli A, 2003, J MOL CELL CARDIOL, V35, P1191, DOI 10.1016/S0022-2828(03)00231-1; Deed RW, 1996, J BIOL CHEM, V271, P23603, DOI 10.1074/jbc.271.39.23603; Floyd ZE, 2001, J BIOL CHEM, V276, P22468, DOI 10.1074/jbc.M009388200; Fukuchi M, 2001, MOL BIOL CELL, V12, P1431, DOI 10.1091/mbc.12.5.1431; Huggins GS, 1999, J BIOL CHEM, V274, P28690, DOI 10.1074/jbc.274.40.28690; Kho CJ, 1997, J BIOL CHEM, V272, P3845, DOI 10.1074/jbc.272.6.3845; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; Lingbeck JM, 2003, J BIOL CHEM, V278, P1817, DOI 10.1074/jbc.M208815200; NAGATA Y, 1995, BIOCHEM BIOPH RES CO, V207, P916, DOI 10.1006/bbrc.1995.1273; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; Sachdev S, 2000, MOL CELL BIOL, V20, P1571, DOI 10.1128/MCB.20.5.1571-1582.2000; Song A, 1998, MOL CELL BIOL, V18, P4994, DOI 10.1128/MCB.18.9.4994; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Tintignac LA, 2005, J BIOL CHEM, V280, P2847, DOI 10.1074/jbc.M411346200; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Trausch-Azar JS, 2004, J BIOL CHEM, V279, P32614, DOI 10.1074/jbc.M403794200; Yagita K, 2002, EMBO J, V21, P1301, DOI 10.1093/emboj/21.6.1301	19	42	47	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2005	24	42					6376	6384		10.1038/sj.onc.1208789	http://dx.doi.org/10.1038/sj.onc.1208789			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	966RI	16007194				2022-12-17	WOS:000232038200005
J	Al Masri, A; Gendler, SJ				Al Masri, A; Gendler, SJ			Muc1 affects c-Src signaling in PyV MT-induced mammary tumorigenesis	ONCOGENE			English	Article						mucin; oncogene; transgenic mice; breast cancer; mammary gland	CARCINOMA-ASSOCIATED ANTIGEN; INTERCELLULAR-ADHESION MOLECULE-1; MIDDLE T-ANTIGEN; BREAST-CANCER; BETA-CATENIN; TYROSINE KINASE; FOCAL ADHESIONS; CELL-ADHESION; STAT PROTEINS; V-SRC	MUC1 is an integral membrane mucin glycoprotein that is normally expressed on the apical surface of most simple, secretory epithelia and hematopoietic cells. Overexpression of aberrantly glycosylated MUC1 is a hallmark of many carcinomas including 90% of breast carcinomas. MUC1 has been shown to bind to c-Src tyrosine kinase in vitro, whereby c-Src phosphorylates the MUC1 cytoplasmic domain at a YEKV motif. c-Src is an extensively studied nonreceptor tyrosine kinase implicated in mammary tumorigenesis. Previously, mouse mammary tumor virus-driven polyoma middle T-antigen (MMTV-PyV MT) transgenic mice crossed onto a Muc1 null background exhibited a significant delay in tumor progression. c-Src has been shown to interact with PyV MT, and to play an integral and indispensable role in MMTV-PyV MT-induced mammary tumorigenesis. Here, we determine the effect of Muc1 expression on c-Src activation and signaling. Examination of MMTV-PyV MT glands on a wild-type or Muc1 null background demonstrates that Muc1 expression promotes c-Src signaling by influencing its association with known substrates such as the p85 subunit of phosphatidylinositol 3-kinase and beta-catenin. These findings may provide a mechanism for the delay in tumor progression that is observed in the absence of Muc1.	Mayo Clin, Coll Med, Dept Biochem & Mol Biol, Scottsdale, AZ 85259 USA; Mayo Clin, Coll Med, Tumor Biol Program, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix	Gendler, SJ (corresponding author), Mayo Clin, Coll Med, Dept Biochem & Mol Biol, 13400 E Shea Blvd,SC Johnson Med Res Bldg, Scottsdale, AZ 85259 USA.	gendler.sandra@mayo.edu			NCI NIH HHS [R01CA64389] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064389] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; Dilworth Stephen M., 1995, Trends in Microbiology, V3, P31, DOI 10.1016/S0966-842X(00)88866-6; Fincham VJ, 2000, MOL CELL BIOL, V20, P6518, DOI 10.1128/MCB.20.17.6518-6536.2000; Flury N, 1997, EUR J BIOCHEM, V249, P421, DOI 10.1111/j.1432-1033.1997.00421.x; FREUND R, 1992, AM J PATHOL, V141, P1409; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; Gendler SJ, 2001, J MAMMARY GLAND BIOL, V6, P339, DOI 10.1023/A:1011379725811; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; GENDLER SJ, 1987, P NATL ACAD SCI USA, V84, P6060, DOI 10.1073/pnas.84.17.6060; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hanks SK, 2003, FRONT BIOSCI-LANDMRK, V8, pD982, DOI 10.2741/1114; HILKENS J, 1995, CANCER LETT, V90, P27, DOI 10.1016/0304-3835(94)03674-8; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Jones RJ, 2000, EUR J CANCER, V36, P1595, DOI 10.1016/S0959-8049(00)00153-2; Kam JL, 1998, CANCER RES, V58, P5577; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; LAN MS, 1990, J BIOL CHEM, V265, P15294; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, BIOCHEM BIOPH RES CO, V281, P440, DOI 10.1006/bbrc.2001.4383; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; LIGTENBERG MJL, 1992, CANCER RES, V52, P2318; Meerzaman D, 2001, AM J PHYSIOL-LUNG C, V281, pL86, DOI 10.1152/ajplung.2001.281.1.L86; MOCKENSTURMGARD.M, 1998, P AM ASSOC CANC RES, V39, pA375; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PANDEY P, 1995, CANCER RES, V55, P4000; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; Regimbald LH, 1996, CANCER RES, V56, P4244; Ren J, 2002, J BIOL CHEM, V277, P17616, DOI 10.1074/jbc.M200436200; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Rowse GJ, 1998, CANCER RES, V58, P315; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schroeder JA, 2004, ONCOGENE, V23, P5739, DOI 10.1038/sj.onc.1207713; Schroeder JA, 2003, ONCOGENE, V22, P1324, DOI 10.1038/sj.onc.1206291; SCHROEDER JA, 2001, J BIOL CHEM, V22, P22; SPICER AP, 1995, J BIOL CHEM, V270, P30093; SPICER AP, 1995, MAMM GENOME, V6, P885, DOI 10.1007/BF00292441; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; WESSELING J, 1995, J CELL BIOL, V129, P255, DOI 10.1083/jcb.129.1.255; Wesseling J, 1996, MOL BIOL CELL, V7, P565, DOI 10.1091/mbc.7.4.565; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WRESCHNER DH, 1990, EUR J BIOCHEM, V189, P463, DOI 10.1111/j.1432-1033.1990.tb15511.x; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; ZOTTER S, 1988, Cancer Reviews, V11-12, P55; ZRIHANLICHT S, 1994, FEBS LETT, V356, P130, DOI 10.1016/0014-5793(94)01251-2	56	42	44	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	38					5799	5808		10.1038/sj.onc.1208738	http://dx.doi.org/10.1038/sj.onc.1208738			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960KW	15897873				2022-12-17	WOS:000231590400002
J	Christensen, C; Guldberg, P				Christensen, C; Guldberg, P			Growth factors rescue cutaneous melanoma cells from apoptosis induced by knockdown of mutated (V600E) B-RAF	ONCOGENE			English	Article						malignant melanoma; B-RAF; RNA interference; apoptosis; senescence; growth factors	POLYMERASE-III TRANSCRIPTION; ACTIVATED PROTEIN-KINASE; SHORT-INTERFERING RNAS; MALIGNANT-MELANOMA; HUMAN MELANOCYTES; METASTATIC MELANOMA; BRAF MUTATIONS; ONCOGENIC MUTATIONS; THERAPEUTIC TARGET; A-RAF	Constitutive activation of the RAS-RAF-MEK-ERK signaling cascade is a hallmark of cutaneous malignant melanoma. A single activating mutation (c. 1799T > A; p. V600E) in the gene encoding the serine/threonine kinase B-RAF occurs in > 60% of the tumors. Previous work has shown that knockdown of B-V600E-RAFby RNA interference induces a variety of phenotypic changes in cultured melanoma cells, including lower proliferation rates, reduced anchorage-independent growth and apoptosis. Here, we show that the majority of melanomas harboring the B-V600E-RAF mutation have retained the wild-type (WT) B-RAF allele, and that these cells can be rescued from the effects of B-V600E-RAF knockdown by stimulation with growth factors. Ectopic expression of short hairpin RNAs specifically suppressing B-V600E-RAF in melanoma cell lines reduced colony formation by similar to 80%. This response could be rescued by basic fibroblast growth factor, hepatocyte growth factor or, to a lesser extent, endothelin-1. Rescue with growth factors was not possible in cell lines lacking B-WT-RAF. Single-cell clones with efficient knockdown of B-V600E-RAF could be propagated in the presence of basic fibroblast growth factor but underwent apoptosis or senescence-like growth arrest upon withdrawal of this growth factor. The ability of growth factors to modulate the response of B-V600E-RAF knockdown in melanoma cells may have both experimental and therapeutic implications.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark	Danish Cancer Society	Guldberg, P (corresponding author), Danish Canc Soc, Inst Canc Biol, Strandboulevarden 49, DK-2100 Copenhagen, Denmark.	perg@cancer.dk						ALBINO AP, 1991, CANCER RES, V51, P4815; Bastian BC, 1998, CANCER RES, V58, P2170; Berking C, 2001, AM J PATHOL, V158, P943, DOI 10.1016/S0002-9440(10)64041-2; Bielenberg DR, 1998, J INVEST DERMATOL, V111, P864, DOI 10.1046/j.1523-1747.1998.00378.x; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Collisson EA, 2003, CANCER RES, V63, P5669; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dong JL, 2003, CANCER RES, V63, P3883; Easty DJ, 2000, MELANOMA RES, V10, P401, DOI 10.1097/00008390-200010000-00001; EISINGER M, 1985, SCIENCE, V229, P984, DOI 10.1126/science.4023718; Garnett MJ, 2004, CANCER CELL, V6, P313, DOI 10.1016/j.ccr.2004.09.022; Gorden A, 2003, CANCER RES, V63, P3955; Guldberg P, 1997, CANCER RES, V57, P3660; Halaban R, 2000, PIGM CELL RES, V13, P4, DOI 10.1034/j.1600-0749.2000.130103.x; Halaban R, 1996, SEMIN ONCOL, V23, P673; Hingorani SR, 2003, CANCER RES, V63, P5198; Huang SY, 1996, ONCOGENE, V13, P2339; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Imokawa G, 2000, J BIOL CHEM, V275, P33321, DOI 10.1074/jbc.M004346200; IMOKAWA G, 1992, J BIOL CHEM, V267, P24675; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; Kumar R, 2003, CLIN CANCER RES, V9, P3362; Li G, 2003, ONCOGENE, V22, P3162, DOI 10.1038/sj.onc.1206455; Li G, 2001, ONCOGENE, V20, P8125, DOI 10.1038/sj.onc.1205034; Meier F, 2000, AM J PATHOL, V156, P193, DOI 10.1016/S0002-9440(10)64719-0; Mercer K, 2002, ONCOGENE, V21, P347, DOI 10.1038/sj.onc.1205101; Nesbit M, 1999, ONCOGENE, V18, P6469, DOI 10.1038/sj.onc.1203066; Otsuka T, 1998, CANCER RES, V58, P5157; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; Satyamoorthy K, 2003, CANCER RES, V63, P756; Satyamoorthy K, 2001, CANCER RES, V61, P7318; Scott PH, 2001, J BIOL CHEM, V276, P1005, DOI 10.1074/jbc.M005417200; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; STORM SM, 1990, ONCOGENE, V5, P345; Sumimoto H, 2004, ONCOGENE, V23, P6031, DOI 10.1038/sj.onc.1207812; Sutcliffe JE, 2000, MOL CELL BIOL, V20, P9192, DOI 10.1128/MCB.20.24.9192-9202.2000; Tuveson DA, 2003, CANCER CELL, V4, P95, DOI 10.1016/S1535-6108(03)00189-2; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Zhang XD, 2003, ONCOGENE, V22, P2869, DOI 10.1038/sj.onc.1206427	46	42	44	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	41					6292	6302		10.1038/sj.onc.1208758	http://dx.doi.org/10.1038/sj.onc.1208758			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964JM	16007203				2022-12-17	WOS:000231877100010
J	Echizenya, M; Kondo, S; Takahashi, R; Oh, J; Kawashima, S; Kitayama, H; Takahashi, C; Noda, M				Echizenya, M; Kondo, S; Takahashi, R; Oh, J; Kawashima, S; Kitayama, H; Takahashi, C; Noda, M			The membrane-anchored MMP-regulator RECK is a target of myogenic regulatory factors	ONCOGENE			English	Article						RECK; MyoD; MRF4; myogenesis	SKELETAL-MUSCLE; MYOTENDINOUS JUNCTIONS; MRF4; CELL; EXPRESSION; GENE; DIFFERENTIATION; MEMBER; SP1; MATRIX-METALLOPROTEINASE-9	The membrane-anchored MMP-regulator RECK is down regulated in many solid tumors; the extent of RECK down regulation correlates with poor prognosis. Forced expression of RECK in tumor cells results in suppression of angiogenesis, invasion, and metastasis. Studies on the roles and the mechanisms of regulation of the RECK gene during normal development may therefore yield important insights into how the malignant behaviors of tumor cells arise and how they can be controlled. Our previous studies indicate that mice lacking RECK die around E10.5 with reduced tissue integrity. In the present study, we have found that in later stage wild-type embryos, RECK is abundantly expressed in skeletal muscles, especially in the areas where the myoblast differentiation factor MRF4 is expressed. Consistent with this finding, the RECK-promoter is activated by MRF4 in cultured cells. In contrast, a myoblast determination factor MyoD suppresses the RECK-promoter. Myoblastic cells lacking RECK expression give rise to myotubes at higher efficiency than the cells expressing RECK, indicating that RECK suppresses myotube formation. These findings suggest that MyoD down regulates RECK to facilitate myotube formation, whereas MRF4 up regulates RECK to promote other aspects of myogenesis that require extracellular matrix integrity.	Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Dept Cellular Differentiat, Inst Frontier Med Sci, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Med, Dept Pathol & Tumor Biol, Sakyo Ku, Kyoto 6068501, Japan; Korea Univ, Grad Sch Med, Ansan, South Korea; Kyoto Univ, Grad Sch Med, COE Program, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University; Kyoto University; Kyoto University; Korea University; Korea University Medicine (KU Medicine); Kyoto University	Noda, M (corresponding author), Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan.	mnoda@virus.kyoto-u.ac.jp		Oh, Junseo/0000-0002-0754-4946				Biesiada E, 1999, MOL CELL BIOL, V19, P2577; Birk DE, 1997, EUR J CELL BIOL, V72, P352; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; Buckingham M, 2003, J ANAT, V202, P59, DOI 10.1046/j.1469-7580.2003.00139.x; Caron NJ, 1999, CELL TRANSPLANT, V8, P465, DOI 10.1177/096368979900800502; Chang THT, 2004, DEV BIOL, V269, P595, DOI 10.1016/j.ydbio.2004.02.013; Chen EH, 2004, TRENDS CELL BIOL, V14, P452, DOI 10.1016/j.tcb.2004.07.008; Chin JR, 1997, DEVELOPMENT, V124, P1519; COUCH CB, 1983, CELL, V32, P257, DOI 10.1016/0092-8674(83)90516-0; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; El Fahime E, 2000, EXP CELL RES, V258, P279, DOI 10.1006/excr.2000.4962; Ferguson JW, 2003, CELL TISSUE RES, V313, P93, DOI 10.1007/s00441-003-0743-z; Fomin M, 2004, DEV BIOL, V272, P498, DOI 10.1016/j.ydbio.2004.04.017; Horsley V, 2004, CELLS TISSUES ORGANS, V176, P67, DOI 10.1159/000075028; Kassar-Duchossoy L, 2004, NATURE, V431, P466, DOI 10.1038/nature02876; Lewis MP, 2000, J MUSCLE RES CELL M, V21, P223, DOI 10.1023/A:1005670507906; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; Oh J, 2004, ONCOGENE, V23, P5041, DOI 10.1038/sj.onc.1207688; Osses N, 2002, AM J PHYSIOL-CELL PH, V282, pC383, DOI 10.1152/ajpcell.00322.2001; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; Sasahara RM, 1999, BIOCHEM BIOPH RES CO, V264, P668, DOI 10.1006/bbrc.1999.1552; SCHOLLMEYER JE, 1986, EXP CELL RES, V162, P411, DOI 10.1016/0014-4827(86)90346-0; Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221; TIDBALL JG, 1994, DEV BIOL, V163, P447, DOI 10.1006/dbio.1994.1161; Vinals F, 1997, J BIOL CHEM, V272, P12913, DOI 10.1074/jbc.272.20.12913; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; Zhu ZM, 1997, DEV DYNAM, V209, P233, DOI 10.1002/(SICI)1097-0177(199706)209:2<233::AID-AJA9>3.3.CO;2-D	33	42	44	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	38					5850	5857		10.1038/sj.onc.1208733	http://dx.doi.org/10.1038/sj.onc.1208733			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960KW	16007210	Green Submitted, Bronze			2022-12-17	WOS:000231590400007
J	Hastie, C; Saxton, M; Akpan, A; Cramer, R; Masters, JR; Naaby-Hansen, S				Hastie, C; Saxton, M; Akpan, A; Cramer, R; Masters, JR; Naaby-Hansen, S			Combined affinity labelling and mass spectrometry analysis of differential cell surface protein expression in normal and prostate cancer cells	ONCOGENE			English	Article						affinity labelling; mass spectrometry; cell surface proteins; prostate cancer; interferons; CD9	MEMBRANE PROTEINS; IDENTIFICATION; PROTEOMICS; ELECTROPHORESIS; MAP	Differences in the expression of cell surface proteins between a normal prostate epithelial (1542-NP2TX) and a prostate cancer cell line (1542-CP3TX) derived from the same patient were investigated. A combination of affinity chromatographic purification of biotin-tagged surface proteins with mass spectrometry analysis identified 26 integral membrane proteins and 14 peripheral surface proteins. The findings confirm earlier reports of altered expression in prostate cancer for several cell surface proteins, including ALCAM/CD166, the Ephrin type A receptor, EGFR and the prostaglandin F2 receptor regulatory protein. In addition, several novel findings of differential expression were made, including the voltage-dependent anion selective channel proteins Porin 1 and 2, ecto-5'-nucleotidase (CD73) and Scavenger receptor B1. Cell surface protein expression changed both qualitatively and quantitatively when the cells were grown in the presence of either or both interferon INF alpha and INF gamma. Costimulation with type I and II interferons had additive or synergistic effects on the membrane density of several, mainly peripherally attached surface proteins. Concerted upregulation of surface exposed antigens may be of benefit in immuno-adjuvant-based treatment of interferon-responsive prostate cancer. In conclusion, this study demonstrates that differences in the expression of membrane proteins between normal and prostate cancer cells are reproducibly detectable following vectorial labelling with biotin, and that detailed analysis of extracellular-induced surface changes can be achieved by combining surface-specific labelling with high-resolution two-dimensional gel electrophoresis and mass spectrometry.	Royal Free & UCL, Sch Med, Ludwig Inst Canc Res, London W1W 7BS, England; Royal Free & UCL, Sch Med, Prostate Canc Res Ctr, London W1W 7BS, England	Ludwig Institute for Cancer Research; University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School	Naaby-Hansen, S (corresponding author), Royal Free & UCL, Sch Med, Ludwig Inst Canc Res, 91 Riding House St, London W1W 7BS, England.	soren@ludwig.ucl.ac.uk	aukim-hastie, claire/A-7485-2011; Masters, John R/C-5694-2011	Cramer, Rainer/0000-0002-8037-2511	MRC [G0100116] Funding Source: UKRI; Medical Research Council [G0100116] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bright RK, 1997, CANCER RES, V57, P995; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; Coonrod SA, 1999, DEV BIOL, V207, P334, DOI 10.1006/dbio.1998.9161; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Hippler M, 2001, PLANT J, V28, P595, DOI 10.1046/j.1365-313X.2001.01175.x; HOCHSTRASSER DF, 1988, ANAL BIOCHEM, V173, P424, DOI 10.1016/0003-2697(88)90209-6; Jans R, 2004, ARCH DERMATOL RES, V296, P30, DOI 10.1007/s00403-004-0469-0; NaabyHansen S, 1997, BIOL REPROD, V56, P771, DOI 10.1095/biolreprod56.3.771; NAABYHANSEN S, 1990, J REPROD IMMUNOL, V17, P167, DOI 10.1016/0165-0378(90)90001-M; NAABYHANSEN S, 2003, PROSTATE CANC METHOD, V81, P277; Nagano K, 2004, ONCOGENE, V23, P1693, DOI 10.1038/sj.onc.1207297; Nouwens AS, 2000, ELECTROPHORESIS, V21, P3797, DOI 10.1002/1522-2683(200011)21:17<3797::AID-ELPS3797>3.0.CO;2-P; Ong SE, 2003, METHODS, V29, P124, DOI 10.1016/S1046-2023(02)00303-1; Page MJ, 1999, P NATL ACAD SCI USA, V96, P12589, DOI 10.1073/pnas.96.22.12589; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Quaranta S, 2001, ELECTROPHORESIS, V22, P1810, DOI 10.1002/1522-2683(200105)22:9&lt;1810::AID-ELPS1810&gt;3.0.CO;2-M; Righetti PG, 1997, J CHROMATOGR B, V699, P77, DOI 10.1016/S0378-4347(96)00151-X; Scadden ADJ, 2001, METHOD ENZYMOL, V341, P126, DOI 10.1016/S0076-6879(01)41149-9; Shetty J, 2001, ELECTROPHORESIS, V22, P3053, DOI 10.1002/1522-2683(200108)22:14<3053::AID-ELPS3053>3.0.CO;2-K; Zhao YX, 2004, ANAL CHEM, V76, P1817, DOI 10.1021/ac0354037	20	42	46	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	38					5905	5913		10.1038/sj.onc.1208747	http://dx.doi.org/10.1038/sj.onc.1208747			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960KW	16007208				2022-12-17	WOS:000231590400013
J	Ceruti, JM; Scassa, ME; Flo, JM; Varone, CL; Canepa, ET				Ceruti, JM; Scassa, ME; Flo, JM; Varone, CL; Canepa, ET			Induction of p19INK4d in response to ultraviolet light improves DNA repair and confers resistance to apoptosis in neuroblastoma cells	ONCOGENE			English	Article						apoptosis; CDK4/6; DNA repair; INK4; neuroblastoma; UV	NUCLEOTIDE EXCISION-REPAIR; D-DEPENDENT KINASES; NF-KAPPA-B; TUMOR-SUPPRESSOR; CDK INHIBITORS; 5-AMINOLEVULINATE SYNTHASE; INK4 INHIBITORS; DEFICIENT CELLS; CANCER; CYCLE	The genetic instability driving tumorigenesis is fuelled by DNA damage and by errors made by the DNA replication. Upon DNA damage the cell organizes an integrated response not only by the classical DNA repair mechanisms but also involving mechanisms of replication, transcription, chromatin structure dynamics, cell cycle progression, and apoptosis. In the present study, we investigated the role of p19INK4d in the response driven by neuroblastoma cells against DNA injury caused by UV irradiation. We show that p19INK4d is the only INK4 protein whose expression is induced by UV light in neuroblastoma cells. Furthermore, p19INK4d translocation from cytoplasm to nucleus is observed after UV irradiation. Ectopic expression of p19INK4d clearly reduces the UV-induced apoptosis as well as enhances the cellular ability to repair the damaged DNA. It is clearly shown that DNA repair is the main target of p19INK4d effect and that diminished apoptosis is a downstream event. Importantly, experiments performed with CDK4 mutants suggest that these p19INK4d effects would be independent of its role as a cell cycle checkpoint gene. The results presented herein uncover a new role of p19INK4d as regulator of DNA-damage-induced apoptosis and suggest that it protects cells from undergoing apoptosis by allowing a more efficient DNA repair. We propose that, in addition to its role as cell cycle inhibitor, p19INK4d is involved in maintenance of DNA integrity and, therefore, would contribute to cancer prevention.	Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Biol, Mol Biol Lab, RA-1428 Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Biol, Lab Inmunoquim, RA-1428 Buenos Aires, DF, Argentina	University of Buenos Aires; University of Buenos Aires	Canepa, ET (corresponding author), Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Biol, Mol Biol Lab, Ciudad Univ Pabellon 2 Piso 4, RA-1428 Buenos Aires, DF, Argentina.	ecanepa@qb.fcen.uba.ar		Canepa, Eduardo T./0000-0002-4322-1650; Varone, Cecilia/0000-0001-5930-4082				Al-Mohanna MA, 2004, ONCOGENE, V23, P201, DOI 10.1038/sj.onc.1206927; Bai F, 2003, MOL CELL BIOL, V23, P1269, DOI 10.1128/MCB.23.4.1269-1277.2003; Barret JM, 2002, BIOCHEM PHARMACOL, V63, P251, DOI 10.1016/S0006-2952(01)00835-8; Bernstein C, 2002, MUTAT RES-REV MUTAT, V511, P145, DOI 10.1016/S1383-5742(02)00009-1; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; Chaussade L, 2001, ONCOGENE, V20, P6587, DOI 10.1038/sj.onc.1204798; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Connor B, 1998, BRAIN RES REV, V27, P1, DOI 10.1016/S0165-0173(98)00004-6; Cunningham JJ, 2001, CELL GROWTH DIFFER, V12, P387; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Dunkern TR, 2001, ONCOGENE, V20, P6026, DOI 10.1038/sj.onc.1204754; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fan CG, 2002, J CELL SCI, V115, P4843, DOI 10.1242/jcs.00151; Friedberg EC, 2001, NAT REV CANCER, V1, P22, DOI 10.1038/35094000; Guan KL, 1996, MOL BIOL CELL, V7, P57, DOI 10.1091/mbc.7.1.57; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Hengst L, 1998, CURR TOP MICROBIOL, V227, P25; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; HOSOI G, 1994, CANCER, V73, P3087, DOI 10.1002/1097-0142(19940615)73:12<3087::AID-CNCR2820731230>3.0.CO;2-9; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lim MA, 2003, P NATL ACAD SCI USA, V100, P14006, DOI 10.1073/pnas.2335486100; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lutzen A, 2004, EXP CELL RES, V292, P123, DOI 10.1016/j.yexcr.2003.08.018; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Martin G. Steven, 2003, Cancer Cell, V4, P167, DOI 10.1016/S1535-6108(03)00216-2; Matsuzaki Y, 2002, FEBS LETT, V517, P272, DOI 10.1016/S0014-5793(02)02647-9; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Milligan A, 1998, MUTAT RES-FUND MOL M, V422, P43, DOI 10.1016/S0027-5107(98)00174-2; Minella AC, 2002, CURR BIOL, V12, P1817, DOI 10.1016/S0960-9822(02)01225-3; Miyamoto Y, 2004, J CELL BIOL, V165, P617, DOI 10.1083/jcb.200312008; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Nakayama K, 1998, BIOESSAYS, V20, P1020, DOI 10.1002/(SICI)1521-1878(199812)20:12<1020::AID-BIES8>3.0.CO;2-D; Nayak BK, 2002, ONCOGENE, V21, P7226, DOI 10.1038/sj.onc.1205889; Newton-Bishop JA, 1999, BRIT J CANCER, V80, P295, DOI 10.1038/sj.bjc.6690354; Norbury CJ, 2004, ONCOGENE, V23, P2797, DOI 10.1038/sj.onc.1207532; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; Rittie L, 2002, AGEING RES REV, V1, P705, DOI 10.1016/S1568-1637(02)00024-7; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Rubbi CP, 2003, EMBO J, V22, P975, DOI 10.1093/emboj/cdg082; SADEE W, 1987, CANCER RES, V47, P5207; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sandal T, 2002, ONCOLOGIST, V7, P73, DOI 10.1634/theoncologist.7-1-73; Scassa ME, 2004, J BIOL CHEM, V279, P28082, DOI 10.1074/jbc.M401792200; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; Shapiro GI, 1998, MOL CELL BIOL, V18, P378, DOI 10.1128/MCB.18.1.378; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sharpless NE, 2004, ONCOGENE, V23, P379, DOI 10.1038/sj.onc.1207074; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sotillo R, 2001, EMBO J, V20, P6637, DOI 10.1093/emboj/20.23.6637; Sun YQ, 2004, MOL CELL BIOL, V24, P1531, DOI 10.1128/MCB.24.4.1531-1539.2004; Thullberg M, 2000, ONCOGENE, V19, P2870, DOI 10.1038/sj.onc.1203579; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Varone CL, 1999, ARCH BIOCHEM BIOPHYS, V372, P261, DOI 10.1006/abbi.1999.1470; Wang GD, 2004, ONCOL REP, V12, P955; Wilson AJ, 2003, CANCER RES, V63, P5401; Wu SY, 2004, J BIOL CHEM, V279, P34898, DOI 10.1074/jbc.M405616200; Yokota T, 2004, ONCOGENE, V23, P5340, DOI 10.1038/sj.onc.1207689; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zindy F, 1999, P NATL ACAD SCI USA, V96, P13462, DOI 10.1073/pnas.96.23.13462; Zindy F, 1997, CELL GROWTH DIFFER, V8, P1139; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	69	42	44	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2005	24	25					4065	4080		10.1038/sj.onc.1208570	http://dx.doi.org/10.1038/sj.onc.1208570			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15750620	Green Published			2022-12-17	WOS:000229680300006
J	Lin, L; Ozaki, T; Takada, Y; Kageyama, H; Nakamura, Y; Hata, A; Zhang, JH; Simonds, WF; Nakagawara, A; Koseki, H				Lin, L; Ozaki, T; Takada, Y; Kageyama, H; Nakamura, Y; Hata, A; Zhang, JH; Simonds, WF; Nakagawara, A; Koseki, H			topors, a p53 and topoisomerase I-binding RING finger protein, is a coactivator of p53 in growth suppression induced by DNA damage	ONCOGENE			English	Article						topors; p53; tumor suppressor; DNA damage; cell cycle; apoptosis	TUMOR-SUPPRESSOR; SUMO-1 MODIFICATION; NUCLEAR-BODIES; GENE; EXPRESSION; SUMOYLATION; INTERACTS; LIGASE; CANCER; DEATH	The RING family zinc-finger protein topors (topoisomerase I-binding protein) binds not only topoisomerase I, but also p53 and the AAV-2 Rep78/68 proteins. topors maps to human chromosome 9p21, which contains candidate tumor suppressor genes implicated in small cell lung cancers. In this study, we isolated the murine counterpart of topors and investigated its impact on p53 function. The deduced amino-acid sequence of mouse topors exhibits extensive similarity to human topors. Overexpressed myc-tagged topors associates with and stabilizes p53, and enhances the p53-dependent transcriptional activities of p21(Waf1), MDM2 and Bax promoters and elevates endogenous p21(Waf1) mRNA levels. Overexpression of topors consequently results in the suppression of cell growth by cell cycle arrest and/or by the induction of apoptosis. Taken together, these studies identify topors as a positive regulator of p53. The expression of topors is induced by exposure to the genotoxic reagents cisplatin and camptothecin, a DNA topoisomerase I inhibitor. We therefore postulate that topors mediates p53-dependent cellular responses induced by DNA damage, suggesting its physiological role as a tumor suppressor.	RIKEN Yokohama Inst, RIKEN Res Ctr Allergy & Immunol, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; Chiba Univ, Grad Sch Med, Dept Mol Embryol, Chuo Ku, Chiba 2608670, Japan; NIDDKD, Metab Dis Branch, NIH, Bethesda, MD 20892 USA; Chiba Canc Ctr Res Inst, Div Biochem, Chuoh Ku, Chiba 2608717, Japan; Chiba Univ, Grad Sch Med, Dept Publ Hlth, Chuo Ku, Chiba 2608670, Japan	RIKEN; Chiba University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Chiba Cancer Center; Chiba University	Koseki, H (corresponding author), RIKEN Yokohama Inst, RIKEN Res Ctr Allergy & Immunol, Tsurumi Ku, 1-7-22 Suehiro, Yokohama, Kanagawa 2300045, Japan.	koseki@rcai.riken.jp	Koseki, Haruhiko/I-3825-2014	Koseki, Haruhiko/0000-0001-8424-5854	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK043012, ZIADK043012] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Batchu RB, 1999, CANCER RES, V59, P3592; Chu D, 2001, J BIOL CHEM, V276, P14004, DOI 10.1074/jbc.M010262200; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Engelhardt OG, 2001, EXP CELL RES, V271, P286, DOI 10.1006/excr.2001.5380; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Haluska P, 1999, NUCLEIC ACIDS RES, V27, P2538, DOI 10.1093/nar/27.12.2538; HARPER JW, 1993, CELL, V75, P805; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kingma PS, 1998, BBA-GENE STRUCT EXPR, V1400, P223, DOI 10.1016/S0167-4781(98)00138-9; Klibanov SA, 2001, J CELL SCI, V114, P1867; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Mann KK, 2004, CANCER CELL, V5, P307, DOI 10.1016/S1535-6108(04)00089-3; Matthews JM, 2002, IUBMB LIFE, V54, P351, DOI 10.1080/15216540216035; MIYASHITA T, 1995, CELL, V80, P293; Oyanagi H, 2004, LUNG CANCER, V46, P21, DOI 10.1016/j.lungcan.2004.03.009; Rajendra R, 2004, J BIOL CHEM, V279, P36440, DOI 10.1074/jbc.C400300200; Rasheed ZA, 2002, EXP CELL RES, V277, P152, DOI 10.1006/excr.2002.5550; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Saleem A, 2004, ONCOGENE, V23, P5293, DOI 10.1038/sj.onc.1207700; SCHLEHOFER JR, 1994, MUTAT RES, V305, P303, DOI 10.1016/0027-5107(94)90250-X; Secombe J, 2004, J BIOL CHEM, V279, P17126, DOI 10.1074/jbc.M310097200; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Watanabe K, 2002, J BIOL CHEM, V277, P15113, DOI 10.1074/jbc.M111281200; Weger S, 2003, EXP CELL RES, V290, P13, DOI 10.1016/S0014-4827(03)00292-1; Weger S, 2002, J GEN VIROL, V83, P511, DOI 10.1099/0022-1317-83-3-511; Yamaki M, 2002, GENE, V288, P103, DOI 10.1016/S0378-1119(02)00458-4; Zhou R, 1999, GENE, V235, P93, DOI 10.1016/S0378-1119(99)00203-6	33	42	47	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3385	3396		10.1038/sj.onc.1208554	http://dx.doi.org/10.1038/sj.onc.1208554			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15735665				2022-12-17	WOS:000229038800001
J	Mohr, A; Zwacka, RM; Jarmy, G; Buneker, C; Schrezenmeier, H; Dohner, K; Beltinger, C; Wiesneth, M; Debatin, KM; Stahnke, K				Mohr, A; Zwacka, RM; Jarmy, G; Buneker, C; Schrezenmeier, H; Dohner, K; Beltinger, C; Wiesneth, M; Debatin, KM; Stahnke, K			Caspase-8L expression protects CD34+hematopoietic progenitor cells and leukemic cells from CD95-mediated apoptosis	ONCOGENE			English	Article						caspase-8; stem cell; apoptosis; splice variant; leukaemia; CD95	AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; TUMOR-NECROSIS-FACTOR; DIFFERENTIAL EXPRESSION; NORMAL HEMATOPOIESIS; DOMINANT EXPRESSION; COMPLEX-FORMATION; INTERFERON-GAMMA; CD34(+) CELLS; MARROW-CELLS; FAS ANTIGEN	Regulation of sensitivity or resistance for apoptosis by death receptor ligand systems is a key control mechanism in the hematopoietic system. Dysfunctional or deregulated apoptosis can potentially contribute to the development of immune deficiencies, autoimmune diseases, and leukemia. Control of homeostasis starts at the level of hematopoietic stem cells (HSC). To this end, we found that CD34+ hematopoietic progenitor cells are constitutively resistant to CD95-mediated apoptosis and cannot be sensitized during short-term culture to death receptor-mediated apoptosis by cytokines. Detailed analysis of the death machinery revealed that CD34+ cells do not express caspase-8a/b, a crucial constituent of the death-inducing signaling complex (DISC) of death receptors. Instead, we found a smaller splice variant termed caspase-8L to be present in HSC. Forced expression of caspase-8L using a recombinant lentiviral vector was able to protect hematopoietic cells from death receptor-induced apoptosis even in the presence of caspase-8a/b. Furthermore, we found that caspase-8L is recruited to the DISC after CD95 triggering, thereby preventing CD95 from connecting to the caspase cascade. These results demonstrate an antiapoptotic function of caspase-8L and suggest a critical role as apoptosis regulator in HSC. Similar to CD34+ HSC, stem cell-derived leukemic blasts from AML(M0) patients only expressed caspase-8L. Additionally we found, caspase-8L expression in several AML and ALL samples. Thus, caspase-8L expression might explain constitutive resistance to CD95-mediated apoptosis in CD34+ progenitor cells and might participate in the development of stem cell-derived and other leukemias by providing protection from regulatory apoptosis.	Univ Ulm, Childrens Hosp, D-89075 Ulm, Germany; Univ Ulm, Div Gene Therapy, D-89081 Ulm, Germany; Univ Ulm, Inst Clin Transfus Med & Immunogenet, D-89081 Ulm, Germany; Univ Hosp Ulm, Dept Internal Med 3, D-89081 Ulm, Germany	Ulm University; Ulm University; Ulm University; Ulm University	Debatin, KM (corresponding author), Univ Ulm, Childrens Hosp, Prittwitzstr 43, D-89075 Ulm, Germany.	klaus-michael.debatin@medizin.uni-ulm.de	Debatin, Klaus-Michael/J-9704-2014	Debatin, Klaus-Michael/0000-0002-8397-1886; Zwacka, Ralf/0000-0003-2821-0387; Mohr, Andrea/0000-0002-4295-0341				AMEISEN JC, 1991, IMMUNOL TODAY, V12, P102; Barcena A, 1999, EXP HEMATOL, V27, P1428, DOI 10.1016/S0301-472X(99)00080-6; Bouscary D, 1997, LEUKEMIA, V11, P839, DOI 10.1038/sj.leu.2400654; Breckenridge DG, 2002, P NATL ACAD SCI USA, V99, P4331, DOI 10.1073/pnas.072088099; COHEN PL, 1992, IMMUNOL TODAY, V13, P427, DOI 10.1016/0167-5699(92)90066-G; DEBATIN KM, 1994, EUR J IMMUNOL, V24, P753, DOI 10.1002/eji.1830240339; Debatin KM, 2003, SEMIN CANCER BIOL, V13, P149, DOI 10.1016/S1044-579X(02)00132-3; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Dror Y, 2001, BLOOD, V97, P3011, DOI 10.1182/blood.V97.10.3011; Dybedal I, 2003, BLOOD, V102, P118, DOI 10.1182/blood-2002-07-2286; FALK MH, 1992, BLOOD, V79, P3300; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; Fulda S, 1998, J BIOL CHEM, V273, P33942, DOI 10.1074/jbc.273.51.33942; Himeji D, 2002, BLOOD, V99, P4070, DOI 10.1182/blood.V99.11.4070; Horiuchi T, 2000, BIOCHEM BIOPH RES CO, V272, P877, DOI 10.1006/bbrc.2000.2841; IWAI K, 1994, BLOOD, V84, P1201; Jarmy G, 2001, J MED VIROL, V64, P223, DOI 10.1002/jmv.1040; Josefsen D, 1999, EXP HEMATOL, V27, P1451, DOI 10.1016/S0301-472X(99)00073-9; Kim H, 2002, STEM CELLS, V20, P174, DOI 10.1634/stemcells.20-2-174; Kirchhoff S, 2000, J IMMUNOL, V165, P6293, DOI 10.4049/jimmunol.165.11.6293; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; KRAMMER PH, 1994, CURR OPIN IMMUNOL, V6, P279, DOI 10.1016/0952-7915(94)90102-3; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; Lotem J, 2002, ONCOGENE, V21, P3284, DOI 10.1038/sj.onc.1205319; MACIEJEWSKI J, 1995, BLOOD, V85, P3183, DOI 10.1182/blood.V85.11.3183.bloodjournal85113183; MACIEJEWSKI JP, 1995, BRIT J HAEMATOL, V91, P245, DOI 10.1111/j.1365-2141.1995.tb05277.x; Martin DA, 1999, P NATL ACAD SCI USA, V96, P4552, DOI 10.1073/pnas.96.8.4552; Mohr A, 2004, GENE THER, V11, P534, DOI 10.1038/sj.gt.3302154; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OWEN JJT, 1992, ANN NY ACAD SCI, V663, P305, DOI 10.1111/j.1749-6632.1992.tb38673.x; Perlman H, 2001, EUR J IMMUNOL, V31, P2421, DOI 10.1002/1521-4141(200108)31:8<2421::AID-IMMU2421>3.0.CO;2-W; Philpott NJ, 1997, BRIT J HAEMATOL, V97, P146, DOI 10.1046/j.1365-2141.1997.d01-2126.x; Pietschmann T, 1999, J VIROL, V73, P2613, DOI 10.1128/JVI.73.4.2613-2621.1999; Sato T, 1997, BRIT J HAEMATOL, V97, P356, DOI 10.1046/j.1365-2141.1997.562704.x; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Stahnke K, 1998, EXP HEMATOL, V26, P844; Stahnke K, 2004, APOPTOSIS, V9, P457, DOI 10.1023/B:APPT.0000031454.62937.fa; Straus SE, 1999, ANN INTERN MED, V130, P591, DOI 10.7326/0003-4819-130-7-199904060-00020; Straus SE, 2001, BLOOD, V98, P194, DOI 10.1182/blood.V98.1.194; Strauss G, 2003, J IMMUNOL, V171, P1172, DOI 10.4049/jimmunol.171.3.1172; Sugahara K, 2002, INT J HEMATOL, V76, P50, DOI 10.1007/BF02982718; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Vaishnaw AK, 1999, J CLIN INVEST, V103, P355, DOI 10.1172/JCI5121; VIBHUTI A, 2002, BRIT J HAEMATOL, V117, P993; Wickremasinghe RG, 1999, BLOOD, V93, P3587, DOI 10.1182/blood.V93.11.3587.411k46_3587_3600; Zwacka RM, 2000, J GENE MED, V2, P334, DOI 10.1002/1521-2254(200009/10)2:5<334::AID-JGM129>3.0.CO;2-Q	49	42	44	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2005	24	14					2421	2429		10.1038/sj.onc.1208432	http://dx.doi.org/10.1038/sj.onc.1208432			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15735742				2022-12-17	WOS:000227877400014
J	Ma, YX; Tomita, Y; Fan, SJ; Wu, KM; Tong, YZ; Zhao, ZG; Song, LN; Goldberg, ID; Rosen, EM				Ma, YX; Tomita, Y; Fan, SJ; Wu, KM; Tong, YZ; Zhao, ZG; Song, LN; Goldberg, ID; Rosen, EM			Structural determinants of the BRCA1: estrogen receptor interaction	ONCOGENE			English	Article						breast cancer susceptibility gene-1 ( BRCA1); estrogen receptor ( ER); ER-alpha; interaction; nuclear export sequence; nuclear receptor corepressor motif	BREAST-CANCER; INHIBITION; CELLS; PROTEINS; MUTATION; CARRIERS; GENE; IDENTIFICATION; RECOGNITION; BRCA1-BARD1	Previously, we showed that the BRCA1 protein interacts directly and functionally with estrogen receptor-alpha (ER-alpha), resulting in the inhibition of estradiol (E2)-stimulated ER-alpha transcriptional activity. The interaction sites were mapped to the N-terminus of BRCA1 ( within amino acids (aa) 1-302) and the ligand-binding domain/ activation function-2 (LBD/AF-2) region ( within aa 282-420) of ER-alpha. In this study, we have further characterized the structure/function relationship for the BRCA1 : ER-alpha interaction. We found that the N-terminal RING domain (aa 20-64) is not required for the BRCA1 : ER-alpha interaction. We identified two separate contact points for ER-alpha, one within aa 1-100 and the other within aa 100-200 of BRCA1; and we showed that each of these BRCA1 peptides interacts with BRCA1 in vitro and in vivo. By using different fragments of the BRCA1 N-terminus, we found that aa 67-100 and 101-133 are required for the interaction with ER-alpha, but that aa 1-67 and 134-302 are dispensible. Previously, we showed that BRCA1 aa 1-302 does not inhibit E2-stimulated ER-alpha transcriptional activity but does bind to ER-alpha and acts as a dominant negative inhibitor of the full-length BRCA1 protein. Somewhat surprisingly, we found that BRCA1 aa 1-100 and BRCA1 aa 101-200 (but not aa 201-300) each inhibited ER-alpha activity, although not as effciently as full-length BRCA1. Mutations within an HIV Rev-like nuclear export signal that resembles a nuclear receptor corepressor motif (aa 86-95) impaired the ability of both truncated (aa 1-100) and full-length (aa 1-1863) BRCA1 proteins to interact with and/or repress ER-alpha activity. Based on these findings, a partial BRCA1 : ER-alpha three-dimensional structure is proposed. The implications of these findings for understanding the BRCA1 : ER-alpha interaction are discussed.	Georgetown Univ, Dept Oncol, Lombardi Canc Ctr, Washington, DC 20057 USA; Albert Einstein Coll Med, Dept Radiat Oncol, Long Isl Jewish Med Ctr, New York, NY 11040 USA	Georgetown University; Northwell Health; Yeshiva University	Rosen, EM (corresponding author), Georgetown Univ, Dept Oncol, Lombardi Canc Ctr, 3970 Reservoir Rd NW,Box 571469, Washington, DC 20057 USA.	emr36@georgetown.edu		Zhao, Zeguo/0000-0002-2901-5033	NCI NIH HHS [R01-CA80000, R01-CA82599] Funding Source: Medline; NIEHS NIH HHS [R01-ES09169] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082599, R01CA080000] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009169] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Brzovic PS, 2001, NAT STRUCT BIOL, V8, P833, DOI 10.1038/nsb1001-833; Deming PB, 2001, P NATL ACAD SCI USA, V98, P12044, DOI 10.1073/pnas.221430898; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fan SJ, 2002, CANCER RES, V62, P141; Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073; Fan SJ, 2001, ONCOGENE, V20, P8215, DOI 10.1038/sj.onc.1205033; Fan SJ, 1998, ONCOGENE, V16, P3069, DOI 10.1038/sj.onc.1202116; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195; Kawai H, 2002, ONCOGENE, V21, P7730, DOI 10.1038/sj.onc.1205971; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Morris JR, 2002, J BIOL CHEM, V277, P9382, DOI 10.1074/jbc.M109249200; Narod SA, 2001, ANN NY ACAD SCI, V952, P36, DOI 10.1111/j.1749-6632.2001.tb02726.x; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Rebbeck TR, 2002, NEW ENGL J MED, V346, P1616, DOI 10.1056/NEJMoa012158; Rodriguez JA, 2000, J BIOL CHEM, V275, P38589, DOI 10.1074/jbc.M003851200; Rodriguez JA, 2004, ONCOGENE, V23, P1809, DOI 10.1038/sj.onc.1207302; Rosen EM, 2003, J CELL PHYSIOL, V196, P19, DOI 10.1002/jcp.10257; Tanenbaum DM, 1998, P NATL ACAD SCI USA, V95, P5998, DOI 10.1073/pnas.95.11.5998; Thompson D, 2002, JNCI-J NATL CANCER I, V94, P1358, DOI 10.1093/jnci/94.18.1358; Tomlinson GE, 1998, CANCER RES, V58, P3237; Vakser IA, 1999, P NATL ACAD SCI USA, V96, P8477, DOI 10.1073/pnas.96.15.8477; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Xiong JB, 2003, MOL CELL BIOL, V23, P8668, DOI 10.1128/MCB.23.23.8668-8690.2003; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298	31	42	45	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 10	2005	24	11					1831	1846		10.1038/sj.onc.1208190	http://dx.doi.org/10.1038/sj.onc.1208190			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15674350				2022-12-17	WOS:000227542000003
J	Farias, EF; Marzan, C; Mira-y-Lopez, R				Farias, EF; Marzan, C; Mira-y-Lopez, R			Cellular retinol-binding protein-I inhibits PI3K/Akt signaling through a retinoic acid receptor-dependent mechanism that regulates p85-p110 heterodimerization	ONCOGENE			English	Article						breast cancer; vitamin A; differentiation; anoikis; SV40; T47D	GROWTH-FACTOR RECEPTOR; BREAST-CANCER CELLS; PHOSPHOINOSITIDE 3-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; EPITHELIAL-CELLS; ACTIVATION; KINASE; PROLIFERATION; APOPTOSIS; PATHWAYS	Downregulation of the cellular retinol-binding protein-I (CRBP-I) occurs in breast and other human cancers, but its significance is not well understood. Recently, we showed that restoration of CRBP-I expression in transformed MTSV1-7 breast epithelial cells increased retinoic receptor activity, inhibited anoikis, promoted acinar differentiation and inhibited tumorigenicity, suggesting that CRBP-I suppresses tumor progression. However, the mechanism underlying these effects of CRBP-I was not elucidated. Here we demonstrate, using genetic and pharmacological approaches, that CRBP-I inhibits, in a retinoic acid receptor-dependent manner, the PI3K/Akt survival pathway. Inhibition of PI3K/Akt was necessary and sufficient to explain the antitumor effects of CRBP-I and was mediated by decreased p85 regulatory and p110 catalytic subunit heterodimerization. We present evidence consistent with the idea that this effect is due to CRBP-I inhibition of p85 phosphorylation at Y688. To our knowledge, this is the first demonstration of PI3K regulation at the level of p85-p110 heterodimerization. These findings lead us to hypothesize that CRBP-I downregulation in cancer promotes tumor progression through inhibition of retinoic acid receptor activity and derepression of PI3K/Akt signaling via a novel mechanism.	CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Mira-y-Lopez, R (corresponding author), CUNY Mt Sinai Sch Med, Dept Med, 1 Gustave Levy Pl,Annenberg Bldg,Room 24-74,Box 1, New York, NY 10029 USA.	eduardo.farias@mssm.edu; rafael.mira@mssm.edu			NCI NIH HHS [R01 CA119018, R24 CA88302, R01 CA54273] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054273, R24CA088302, R01CA119018] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acosta JJ, 2003, MOL ENDOCRINOL, V17, P2268, DOI 10.1210/me.2002-0422; APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chan TO, 2002, CANCER CELL, V1, P181, DOI 10.1016/S1535-6108(02)00033-8; Cuevas BD, 2001, J BIOL CHEM, V276, P27455, DOI 10.1074/jbc.M100556200; Debnath J, 2003, J CELL BIOL, V163, P315, DOI 10.1083/jcb.200304159; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; del Rincon SV, 2003, ONCOGENE, V22, P3353, DOI 10.1038/sj.onc.1206485; Dirami G, 2004, AM J PHYSIOL-LUNG C, V286, pL249, DOI 10.1152/ajplung.00140.2003; Esteller M, 2002, CANCER RES, V62, P5902; FARIAS EF, 2005, IN PRESS J NATL CANC, V97; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Ghyselinck NB, 1999, EMBO J, V18, P4903, DOI 10.1093/emboj/18.18.4903; Ignatoski KMW, 2003, MOL CANCER RES, V1, P551; Jimenez C, 2002, J BIOL CHEM, V277, P41556, DOI 10.1074/jbc.M205893200; Kuppumbatti YS, 2000, J NATL CANCER I, V92, P475, DOI 10.1093/jnci/92.6.475; Kuppumbatti YS, 2001, ONCOGENE, V20, P7413, DOI 10.1038/sj.onc.1204749; KURLANDSKY SB, 1995, J BIOL CHEM, V270, P17850, DOI 10.1074/jbc.270.30.17850; Lango M, 2003, CLIN CANCER RES, V9, P4205; Liu H, 2004, J CELL BIOL, V164, P603, DOI 10.1083/jcb.200306090; MANGELSDORF DJ, 1994, NUTR REV, V52, P32; Mira-y-Lopez R, 2000, J CELL PHYSIOL, V185, P302, DOI 10.1002/1097-4652(200011)185:2<302::AID-JCP15>3.0.CO;2-#; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Napoli JL, 1999, BBA-MOL CELL BIOL L, V1440, P139, DOI 10.1016/S1388-1981(99)00117-1; Neve RM, 2002, ONCOGENE, V21, P4567, DOI 10.1038/sj.onc.1205555; Nguyen KT, 2000, ONCOGENE, V19, P5385, DOI 10.1038/sj.onc.1203911; Nilsson A, 1997, INT J BIOCHEM CELL B, V29, P381, DOI 10.1016/S1357-2725(96)00068-4; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Singh B, 2002, GENE DEV, V16, P984, DOI 10.1101/gad.973602; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Wang F, 1998, P NATL ACAD SCI USA, V95, P14821, DOI 10.1073/pnas.95.25.14821; Wang F, 2002, JNCI-J NATL CANCER I, V94, P1494, DOI 10.1093/jnci/94.19.1494; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Yu YJ, 2002, J VIROL, V76, P3731, DOI 10.1128/JVI.76.8.3731-3738.2002; Zhao JJ, 2003, CANCER CELL, V3, P483, DOI 10.1016/S1535-6108(03)00088-6	39	42	46	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1598	1606		10.1038/sj.onc.1208347	http://dx.doi.org/10.1038/sj.onc.1208347			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15608670				2022-12-17	WOS:000227218200013
J	Wang, GZ; Zhang, S; Fernig, DG; Martin-Fernandez, M; Rudland, PS; Barraclough, R				Wang, GZ; Zhang, S; Fernig, DG; Martin-Fernandez, M; Rudland, PS; Barraclough, R			Mutually antagonistic actions of S100A4 and S100A1 on normal and metastatic phenotypes	ONCOGENE			English	Article						S100A1; S100A4; metastasis; motility	CALCIUM-BINDING PROTEIN; NONMUSCLE MYOSIN; PROGNOSTIC-SIGNIFICANCE; HEAVY-CHAIN; IN-VITRO; MTS1 S100A4; HEPARAN-SULFATE; MAMMARY CELLS; BREAST-CANCER; KINASE-C	Increased levels of the homodimeric calcium-binding protein, S100A4, have been shown to cause a metastatic phenotype in at least three independent model systems of breast cancer and its presence in carcinoma cells has been shown to be associated with a reduction in the survival of patients suffering from a range of different cancers. S100A4 has been shown to interact in vitro with another member of the S100 family of proteins, S100A1. The purpose of the present study was to find out whether S100A1 could affect S100A4 function. Fluorescence resonance energy transfer was used to show the interaction of S100A4 and S100A1 in living cells and the binding affinities between S100A4 and S100A1 were determined using a biosensor. S100A1 reduced the S100A4 inhibition of nonmuscle myosin A self-association and phosphorylation in vitro. S100A1 reduced S100A4 induced motility and growth in soft agar and metastasis in vivo. The results show for the first time that interactions between different S100 proteins can affect cancer-related activity, and that the presence of S100A1 protein in carcinoma cells might modulate the effect of S100A4 on their metastatic abilities.	Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England; Daresbury Lab, Warrington WA4 4AD, Cheshire, England	University of Liverpool; STFC Daresbury Laboratory	Barraclough, R (corresponding author), Univ Liverpool, Sch Biol Sci, Crown St, Liverpool L69 7ZB, Merseyside, England.	brb@liv.ac.uk	Fernig, David G/A-3590-2008; Barraclough, Roger/AAH-6516-2020	Fernig, David G/0000-0003-4875-4293; Barraclough, Roger/0000-0002-7203-1194; martin-fernandez, marisa/0000-0001-5496-6300				Ambartsumian NS, 1996, ONCOGENE, V13, P1621; BECKER D, 1993, GENE TRANSCRIPTION P, P295; Chen HL, 2001, BIOCHEM BIOPH RES CO, V286, P1212, DOI 10.1006/bbrc.2001.5517; DAVIES BR, 1993, ONCOGENE, V8, P999; Davies BR, 2002, J PATHOL, V196, P292, DOI 10.1002/path.1051; Davies MPA, 1996, ONCOGENE, V13, P1631; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; DUNNINGTON DJ, 1983, J NATL CANCER I, V71, P1227; Endo H, 2002, J BIOL CHEM, V277, P26396, DOI 10.1074/jbc.M202244200; FORD HL, 1995, ONCOGENE, V10, P1597; GIBBS FEM, 1994, J BIOL CHEM, V269, P18992; Gongoll S, 2002, GASTROENTEROLOGY, V123, P1478, DOI 10.1053/gast.2002.36606; Grigorian M, 2001, J BIOL CHEM, V276, P22699, DOI 10.1074/jbc.M010231200; Jenkinson SR, 2004, BRIT J CANCER, V90, P253, DOI 10.1038/sj.bjc.6601483; Kimura K, 2000, INT J ONCOL, V16, P1125; Kriajevska M, 1998, J BIOL CHEM, V273, P9852, DOI 10.1074/jbc.273.16.9852; Kriajevska M, 2002, J BIOL CHEM, V277, P5229, DOI 10.1074/jbc.M110976200; Kriajevska M, 2000, BBA-MOL CELL RES, V1498, P252, DOI 10.1016/S0167-4889(00)00100-2; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lloyd BH, 1998, ONCOGENE, V17, P465, DOI 10.1038/sj.onc.1201948; Most P, 2003, J BIOL CHEM, V278, P33809, DOI 10.1074/jbc.M301788200; Most P, 2001, P NATL ACAD SCI USA, V98, P13889, DOI 10.1073/pnas.241393598; Murakami N, 1995, BIOCHEMISTRY-US, V34, P16046, DOI 10.1021/bi00049a019; Nakamura T, 2002, INT J ONCOL, V20, P937; Nakanishi K, 2002, CANCER RES, V62, P2971; Ninomiya I, 2001, INT J ONCOL, V18, P715; Pepperkok R, 1999, CURR BIOL, V9, P269, DOI 10.1016/S0960-9822(99)80117-1; Rahmoune H, 1998, BIOCHEMISTRY-US, V37, P6003, DOI 10.1021/bi972468t; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; Rudland PS, 2000, CANCER RES, V60, P1595; RUDLAND PS, 1984, CANCER RES, V44, P2089; Rustandi RR, 2002, BIOCHEMISTRY-US, V41, P788, DOI 10.1021/bi0118308; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SELINFREUND RH, 1991, P NATL ACAD SCI USA, V88, P3554, DOI 10.1073/pnas.88.9.3554; Sorci G, 1999, CELL CALCIUM, V25, P93, DOI 10.1054/ceca.1998.0012; TAKENAGA K, 1994, J CELL BIOL, V124, P757, DOI 10.1083/jcb.124.5.757; Tarabykina S, 2000, FEBS LETT, V475, P187, DOI 10.1016/S0014-5793(00)01652-5; Tarabykina S, 2001, J BIOL CHEM, V276, P24212, DOI 10.1074/jbc.M009477200; Vallely KM, 2002, BIOCHEMISTRY-US, V41, P12670, DOI 10.1021/bi020365r; Wang GZ, 2004, BIOCHEM J, V382, P375, DOI 10.1042/BJ20040142; Wang GZ, 2000, J BIOL CHEM, V275, P11141, DOI 10.1074/jbc.275.15.11141; ZHANG S, 2004, IN PRESS EUR BIOPHYS	43	42	46	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2005	24	8					1445	1454		10.1038/sj.onc.1208291	http://dx.doi.org/10.1038/sj.onc.1208291			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898QZ	15608682				2022-12-17	WOS:000227092600014
J	Barnes, EA; Heidtman, KJ; Donoghue, DJ				Barnes, EA; Heidtman, KJ; Donoghue, DJ			Constitutive activation of the shh-ptc1 pathway by a patched1 mutation identified in BCC	ONCOGENE			English	Article						Gli1; hedgehog; nevoid basal cell carcinoma syndrome	BASAL-CELL CARCINOMA; HUMAN EMBRYONAL CARCINOMA; SONIC-HEDGEHOG GENE; D-TYPE CYCLINS; HUMAN HOMOLOG; NUCLEAR-LOCALIZATION; MISSENSE MUTATIONS; SIGNALING PATHWAY; PREMATURE MITOSIS; RECEPTOR COMPLEX	Mutations in the transmembrane receptor patched1 (ptc1) are responsible for the majority of basal cell carcinoma (BCC) cases. Many of these mutations, including ptc1-Q688X, result in premature truncation of the ptc1 protein. ptc1-Q688X has been identified in patients with both BCC and nevoid basal cell carcinoma syndrome, an inheritable disorder causing a predisposition to cancer susceptibility. Here we describe a mechanism by which ptc1-Q688X causes constitutive cellular signaling. Cells expressing ptc1-Q688X demonstrate an increase in cell cycle progression and induce cell transformation. The ptc1-Q688X mutant enhances Gli1 activity, a downstream reporter of sonic hedgehog (shh)-ptc1 signaling, independent of shh stimulation. In contrast to wild-type ptc1, ptc1-Q688X fails to associate with endogenous cyclin B1. Expression of nuclear-targeted cyclin B1 derivatives promotes Gli1-dependent transcription, which correlates temporally with cyclin B1-cdk1 kinase activity. Coexpression of wild-type ptc1 with a nuclear-targeted cyclin B1 derivative, mutated to mimic constitutive phosphorylation, dramatically decreases Gli1 activity. In addition, the coexpression of this constitutively nuclear cyclin B1 derivative with ptc1-Q688X substantially enhances foci formation. These studies therefore describe a molecular mechanism for the aberrant activity of ptc1-Q688X that includes the premature activation of the transcription factor Gli1.	Univ Calif San Diego, Ctr Mol Genet, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Donoghue, DJ (corresponding author), Univ Calif San Diego, Ctr Mol Genet, Dept Chem & Biochem, 9500 Gilman Dr,Urey Hall,6114, La Jolla, CA 92093 USA.	ddonoghue@ucsd.edu			NCI NIH HHS [T32-CA09523, P30CA23100-18, T32 CA009523] Funding Source: Medline; NIGMS NIH HHS [GM65490] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA023100, T32CA009523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065490] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bailey EC, 2003, CANCER RES, V63, P1636; Bailey EC, 2002, J BIOL CHEM, V277, P33632, DOI 10.1074/jbc.M202203200; Barnes EA, 2001, EMBO J, V20, P2214, DOI 10.1093/emboj/20.9.2214; Bell CA, 2000, MOL BIOL CELL, V11, P3589, DOI 10.1091/mbc.11.10.3589; Borgne A, 1999, J BIOL CHEM, V274, P11977, DOI 10.1074/jbc.274.17.11977; Chen Y, 1998, DEVELOPMENT, V125, P4943; Chidambaram A, 1996, CANCER RES, V56, P4599; Cimini D, 1998, CHROMOSOMA, V107, P479, DOI 10.1007/s004120050332; Cohen MM, 1999, INT J ORAL MAX SURG, V28, P216, DOI 10.1034/j.1399-0020.1999.283280314.x; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Denef N, 2000, CELL, V102, P521, DOI 10.1016/S0092-8674(00)00056-8; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; Duman-Scheel M, 2002, NATURE, V417, P299, DOI 10.1038/417299a; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Freemantle SJ, 2002, ONCOGENE, V21, P2880, DOI 10.1038/sj.onc.1205408; Gailani MR, 1997, JNCI-J NATL CANCER I, V89, P1103, DOI 10.1093/jnci/89.15.1103; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Ghosh S, 1996, EXP CELL RES, V227, P165, DOI 10.1006/excr.1996.0262; GORLIN RJ, 1995, DERMATOL CLIN, V13, P113, DOI 10.1016/S0733-8635(18)30114-1; Green J, 1998, BRIT J DERMATOL, V139, P911; Hagting A, 1999, CURR BIOL, V9, P680, DOI 10.1016/S0960-9822(99)80308-X; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hahn H, 1996, J BIOL CHEM, V271, P12125, DOI 10.1074/jbc.271.21.12125; Hiwasa T, 1996, CANCER LETT, V99, P87, DOI 10.1016/0304-3835(95)04041-2; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Incardona JP, 2002, CURR BIOL, V12, P983, DOI 10.1016/S0960-9822(02)00895-3; Ito N, 1999, CELL, V96, P529, DOI 10.1016/S0092-8674(00)80657-1; JHA MN, 1994, CANCER RES, V54, P5011; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kenney AM, 2000, MOL CELL BIOL, V20, P9055, DOI 10.1128/MCB.20.23.9055-9067.2000; Lam CW, 1999, ONCOGENE, V18, P833, DOI 10.1038/sj.onc.1202360; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; LI JK, 1995, MOL BIOL CELL, V6, P1111, DOI 10.1091/mbc.6.9.1111; Liu CZ, 1998, GENE, V209, P1, DOI 10.1016/S0378-1119(97)00668-9; Lowrey JA, 2002, J IMMUNOL, V169, P1869, DOI 10.4049/jimmunol.169.4.1869; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Murone M, 1999, CURR BIOL, V9, P76, DOI 10.1016/S0960-9822(99)80018-9; Nanni L, 1999, HUM MOL GENET, V8, P2479, DOI 10.1093/hmg/8.13.2479; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Reifenberger J, 1998, CANCER RES, V58, P1798; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Rieder CL, 2000, CURR BIOL, V10, P1067, DOI 10.1016/S0960-9822(00)00678-3; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Satoh J, 2000, J NEUROSCI METH, V94, P155, DOI 10.1016/S0165-0270(99)00143-0; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Taipale J, 2002, NATURE, V418, P892, DOI 10.1038/nature00989; TAM SW, 1995, J CELL BIOCHEM, V59, P339, DOI 10.1002/jcb.240590306; Thibert C, 2003, SCIENCE, V301, P843, DOI 10.1126/science.1085405; TOBEY RA, 1990, P NATL ACAD SCI USA, V87, P5104, DOI 10.1073/pnas.87.13.5104; Unden AB, 1996, CANCER RES, V56, P4562; Wicking C, 2001, CANCER LETT, V173, P1, DOI 10.1016/S0304-3835(01)00676-0; Wicking C, 1997, AM J HUM GENET, V60, P21; Wicking C, 1997, AM J MED GENET, V73, P304; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Zeng X, 2001, NATURE, V411, P716, DOI 10.1038/35079648; Zhang H, 2001, AM J PATHOL, V158, P381, DOI 10.1016/S0002-9440(10)63980-6	63	42	42	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					902	915		10.1038/sj.onc.1208240	http://dx.doi.org/10.1038/sj.onc.1208240			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15592520				2022-12-17	WOS:000226577100016
J	Vey, N; Mozziconacci, MJ; Groulet-Martinec, A; Debono, S; Finetti, P; Carbuccia, N; Beillard, E; Devilard, E; Arnoulet, C; Coso, D; Sainty, D; Xerri, L; Stoppa, AM; Lafage-Pochitaloff, M; Nguyen, C; Houlgatte, R; Blaise, D; Maraninchi, D; Birg, F; Birnbaum, D; Bertucci, F				Vey, N; Mozziconacci, MJ; Groulet-Martinec, A; Debono, S; Finetti, P; Carbuccia, N; Beillard, E; Devilard, E; Arnoulet, C; Coso, D; Sainty, D; Xerri, L; Stoppa, AM; Lafage-Pochitaloff, M; Nguyen, C; Houlgatte, R; Blaise, D; Maraninchi, D; Birg, F; Birnbaum, D; Bertucci, F			Identification of new classes among acute myelogenous leukaemias with normal karyotype using gene expression profiling	ONCOGENE			English	Article						acute myelogenous leukaemia; gene expression; DNA microarrays; chemotherapy; normal karyotype; FLT3	ACUTE MYELOID-LEUKEMIA; ACUTE PROMYELOCYTIC LEUKEMIA; TOPOISOMERASE-II; NITRIC-OXIDE; AML 10; CANCER; CHEMOTHERAPY; CYTOGENETICS; PREDICTION; SURVIVAL	Conventional cytogenetic analysis currently stratifies acute myelogenous leukaemia (AML) into prognostically relevant groups. However, approximately 50% of adult AMLs have normal cytogenetics (NC-AMLs), and represent a heterogeneous and poorly understood group. We analysed gene expression in 55 AML samples including 53 cases from adult patients with NC-AML (n=36), trisomy 8, t(15;17), t(8;21), t(11;19), 7q deletion, and two cell lines using 9000-gene DNA microarrays. Global hierarchical clustering showed that NC-AMLs are a heterogeneous group. Supervised analysis distinguished two subgroups of NC-AML: one subgroup constituted a homogeneous NC cluster ('pure NC-AML'), and the other NC-AMLs were close to the AML cases with translocations ('translocation like'). Gene expression signatures were also derived for patients with trisomy 8, as well as FLT3 and MLL gene duplications. Importantly, samples from 24 NC-AML patients who could be evaluated for clinical outcome were analysed. In all, 43 genes that discriminated two classes of patients with significantly different prognosis were identified. The poor prognosis class contained a majority of 'pure NC-AMLs', whereas the 'translocation-like' AMLs were in the good prognosis class. Discriminator genes included genes involved in drug resistance (TOP2B), protein transport (MTX2, SLC35A2), and cell signalling (MAPK1, PRKAB2). Our results demonstrate the transcriptional heterogeneity of NC-AMLs, and suggest the existence of 'translocation-like' NC-AMLs and of a gene expression signature that may predict response to chemotherapy.	Inst J Paoli I Calmettes, INSERM, UMR599, Dept Mol Oncol,Marseille Canc Inst, F-13009 Marseille, France; Inst J Paoli I Calmettes, INSERM, UMR599, Dept Haematol,Marseille Canc Inst, F-13009 Marseille, France; Inst J Paoli I Calmettes, INSERM, UMR599, Dept Biopathol,Marseille Canc Inst, F-13009 Marseille, France; IPSOGEN SAS, Marseille, France; ERT MEIDIA, Marseille, France; Univ Mediterranee, Marseille, France; ERM206, Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite	Birnbaum, D (corresponding author), Inst J Paoli I Calmettes, INSERM, UMR599, Dept Mol Oncol,Marseille Canc Inst, 27 Bd Lei Roure,IFR137, F-13009 Marseille, France.	birnbaum@marseille.inserm.fr	Blaise, Didier/R-2483-2016; Vey, Norbert/AGE-3573-2022; Carbuccia, Nadine/O-4459-2017; Houlgatte, Remi/P-3020-2017; Nguyen, Catherine/M-4119-2016; Finetti, Pascal/O-8669-2017	Blaise, Didier/0000-0002-5684-9447; Vey, Norbert/0000-0001-7027-040X; Carbuccia, Nadine/0000-0002-3561-4315; Nguyen, Catherine/0000-0001-9376-6360; Finetti, Pascal/0000-0002-2674-3123; Bertucci, Francois/0000-0002-0157-0959; Birnbaum, Daniel/0000-0001-7920-9883				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Bachrati CZ, 2003, BIOCHEM J, V374, P577, DOI 10.1042/BJ20030491; Bertucci F, 2001, LANCET ONCOL, V2, P674, DOI 10.1016/S1470-2045(01)00557-5; Bertucci F, 2002, HUM MOL GENET, V11, P863, DOI 10.1093/hmg/11.8.863; Bertucci F, 2000, HUM MOL GENET, V9, P2981, DOI 10.1093/hmg/9.20.2981; Bonilla E, 2003, BIOCHEM PHARMACOL, V65, P1701, DOI 10.1016/S0006-2952(03)00119-9; Bullinger L, 2004, NEW ENGL J MED, V350, P1605, DOI 10.1056/NEJMoa031046; Debernardi S, 2003, GENE CHROMOSOME CANC, V37, P149, DOI 10.1002/gcc.10198; Dingemans AMC, 1999, CLIN CANCER RES, V5, P2048; Downing JR, 2002, CANCER CELL, V2, P437, DOI 10.1016/S1535-6108(02)00211-8; GOASGUEN JE, 1992, LEUKEMIA, V6, P520; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Haferlach T, 2003, SEMIN HEMATOL, V40, P281, DOI 10.1016/S0037-1963(03)00193-8; Haferlach T, 2003, J CLIN ONCOL, V21, P256, DOI 10.1200/JCO.2003.08.005; Iyer L, 1998, J CLIN INVEST, V101, P847, DOI 10.1172/JCI915; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; Kato K, 2002, ONCOGENE, V21, P6082, DOI 10.1038/sj.onc.1205737; Kaufmann SH, 1998, LEUKEMIA LYMPHOMA, V29, P217, DOI 10.3109/10428199809068560; Kohlmann A, 2003, GENE CHROMOSOME CANC, V37, P396, DOI 10.1002/gcc.10225; Kottaridis PD, 2001, BLOOD, V98, P1752, DOI 10.1182/blood.V98.6.1752; LANOTTE M, 1991, BLOOD, V77, P1080; Marcucci G, 2000, CANCER INVEST, V18, P768, DOI 10.3109/07357900009012209; Noguera N, 2002, LEUKEMIA, V16, P2185, DOI 10.1038/sj.leu.2402723; Okutsu J, 2002, MOL CANCER THER, V1, P1035; Pinto A, 2001, CRIT REV ONCOL HEMAT, V39, P275, DOI 10.1016/S1040-8428(00)00122-0; Poirel H, 1996, BLOOD, V87, P2496, DOI 10.1182/blood.V87.6.2496.bloodjournal8762496; Reid HM, 2003, J BIOL CHEM, V278, P51190, DOI 10.1074/jbc.M309314200; Reiffers J, 1996, LEUKEMIA, V10, P389; Reiffers J, 1996, LEUKEMIA, V10, P1874; Sabatti C, 2002, MATH BIOSCI, V176, P17, DOI 10.1016/S0025-5564(01)00102-X; Schoch C, 2002, P NATL ACAD SCI USA, V99, P10008, DOI 10.1073/pnas.142103599; Tanaka K, 2002, BIOCHEM BIOPH RES CO, V292, P776, DOI 10.1006/bbrc.2002.6713; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; Virtaneva K, 2001, P NATL ACAD SCI USA, V98, P1124, DOI 10.1073/pnas.98.3.1124; Wallqvist A, 2003, BIOINFORMATICS, V19, P2212, DOI 10.1093/bioinformatics/btg302; Yagi T, 2003, BLOOD, V102, P1849, DOI 10.1182/blood-2003-02-0578; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6	39	42	46	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9381	9391		10.1038/sj.onc.1207910	http://dx.doi.org/10.1038/sj.onc.1207910			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15543237				2022-12-17	WOS:000225764100009
J	Iwanaga, R; Komori, H; Ohtani, K				Iwanaga, R; Komori, H; Ohtani, K			Differential regulation of expression of the mammalian DNA repair genes by growth stimulation	ONCOGENE			English	Article						DNA repair gene; cell growth; gene expression; E2F	CELL-CYCLE PROGRESSION; TRANSCRIPTION FACTOR E2F; MISMATCH REPAIR; DEPENDENT EXPRESSION; MICROARRAY ANALYSIS; DAMAGE RESPONSE; PROTEIN; RAD51; REPLICATION; PROMOTER	During DNA replication, DNA becomes more vulnerable to certain DNA damages. DNA repair genes involved in repair of the damages may be induced by growth stimulation. However, regulation of DNA repair genes by growth stimulation has not been analysed in detail. In this report, we analysed the regulation of expression of mammalian MSH2, MSH3 and MLH1 genes involved in mismatch repair, and Rad51 and Rad50 genes involved in homologous recombination repair, in relation to cell growth. Unexpectedly, we found a clear difference in regulation of these repair gene expression by growth stimulation even in the same repair system. The expression of MSH2, MLH1 and Rad51 genes was clearly growth regulated, whereas MSH3 and Rad50 genes were constitutively expressed, suggesting differential requirement of the repair gene products for cell proliferation. MSH3 gene is located in a bidirectionally divergent manner with DHFR gene that is regulated by growth stimulation, indicating that bidirectionally divergent promoters are not necessarily coordinately regulated. Promoter analysis showed that the growth-regulated expression of MLH1 and Rad51 genes was mainly mediated by E2F that plays crucial roles in regulation of DNA replication, suggesting close relation between some of the repair genes and DNA replication.	Tokyo Med & Dent Univ, Human Gene Sci Ctr, Bunkyo Ku, Tokyo 1138510, Japan	Tokyo Medical & Dental University (TMDU)	Ohtani, K (corresponding author), Tokyo Med & Dent Univ, Human Gene Sci Ctr, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	kiyo.gene@cmn.tmd.ac.jp						Adachi N, 2002, CELL, V109, P807, DOI 10.1016/S0092-8674(02)00758-4; Benson FE, 1998, NATURE, V391, P401, DOI 10.1038/34937; Brown KD, 2003, NAT GENET, V33, P80, DOI 10.1038/ng1052; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Claij N, 2002, ONCOGENE, V21, P2873, DOI 10.1038/sj.onc.1205395; Clever B, 1997, EMBO J, V16, P2535, DOI 10.1093/emboj/16.9.2535; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; Drummond JT, 1997, P NATL ACAD SCI USA, V94, P10144, DOI 10.1073/pnas.94.19.10144; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; HAWN MT, 1995, CANCER RES, V55, P3721; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Ito E, 1999, BIOCHEM BIOPH RES CO, V256, P488, DOI 10.1006/bbrc.1999.0368; Iwahashi Y, 1998, GENE, V213, P141, DOI 10.1016/S0378-1119(98)00187-5; Iwanaga R, 2001, ONCOGENE, V20, P2055, DOI 10.1038/sj.onc.1204304; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Lin WC, 2001, GENE DEV, V15, P1833; Marra G, 1998, P NATL ACAD SCI USA, V95, P8568, DOI 10.1073/pnas.95.15.8568; Meyers M, 1997, CANCER RES, V57, P206; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Ohtani K, 1998, ONCOGENE, V17, P1777, DOI 10.1038/sj.onc.1202105; Ohtani K, 1999, ONCOGENE, V18, P2299, DOI 10.1038/sj.onc.1202544; Ohtani Kiyoshi, 1999, Frontiers in Bioscience, V4, pd793, DOI 10.2741/Ohtani; Peltomaki P, 2001, MUTAT RES-REV MUTAT, V488, P77, DOI 10.1016/S1383-5742(00)00058-2; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SHIMADA T, 1989, J BIOL CHEM, V264, P20171; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; WILSON TM, 1995, CANCER RES, V55, P5146; Yamamoto A, 1996, MOL GEN GENET, V251, P1; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139	36	42	42	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8581	8590		10.1038/sj.onc.1207976	http://dx.doi.org/10.1038/sj.onc.1207976			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15467751				2022-12-17	WOS:000224988800003
J	Saito, T; Oda, Y; Kawaguchi, K; Sugimachi, K; Yamamoto, H; Tateishi, N; Tanaka, K; Matsuda, S; Iwamoto, Y; Ladanyi, M; Tsuneyoshi, M				Saito, T; Oda, Y; Kawaguchi, K; Sugimachi, K; Yamamoto, H; Tateishi, N; Tanaka, K; Matsuda, S; Iwamoto, Y; Ladanyi, M; Tsuneyoshi, M			E-cadherin mutation and Snail overexpression as alternative mechanisms of E-cadherin inactivation in synovial sarcoma	ONCOGENE			English	Article						E-cadherin; Snail; CpG methylation; mutation; ELF3; synovial sarcoma; epithelial-mesenchymal transition	EPITHELIAL-MESENCHYMAL TRANSITIONS; TRANSCRIPTIONAL REPRESSOR SNAIL; CPG ISLAND METHYLATION; SOFT-TISSUE SARCOMAS; CELL-CELL-ADHESION; SSX FUSION TYPE; GENE-EXPRESSION; BREAST-CANCER; GASTRIC-CANCER; BETA-CATENIN	We have recently reported frequent E-cadherin gene mutations in synovial sarcoma (SS), suggesting mutational inactivation of E-cadherin as a potential mechanism of spindle cell morphology in SS, a spindle cell sarcoma that shows areas of glandular epithelial differentiaton in some cases (biphasic SS) and only pure spindle cell morphology in most cases (monophasic SS). However, the mechanism of downregulation of E-cadherin in SS remains unknown. To further address this issue, we analysed the mechanisms of E-cadherin silencing in 40 SS. Genetic and epigenetic changes in the E-cadherin gene, and the expression level of its transcriptional repressor Snail were examined by polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP), methylation-specific PCR, and real-time quantitative PCR, respectively. Expression of E-cadherin was examined by RT-PCR and immunohistochemistry. We also examined ELF3, a transcription factor associated with epithelial differentiation in SS in a previous cDNA microarray, by RT-PCR. E-cadherin and ELF3 transcripts were detected, respectively, in 27/40 (67.5%) and in 25/40 (62.5%) of SS, and these epithelial-related genes were almost always coexpressed. Hypermethylation of the promoter of the E-cadherin gene was detected in five cases (12.5%) in SS; however, E-cadherin was silenced at mRNA level in only one of the five cases. E-cadherin missense mutations were observed in five cases (12.5%) of SS. In SS, all five cases with E-cadherin missense mutations had the SYT-SSX1 fusion and were monophasic tumors, suggesting a relationship between the SYT-SSX fusion type and E-cadherin missense mutation (P = 0.07). E-cadherin mRNA expression in SS was associated with reduced Snail expression level (P = 0.03). E-cadherin membranous expression was observed in 14/40 (35.0%) of SS, and was also correlated with SYT-SSX1 fusion type and biphasic histology. ELF3 was confirmed to be more highly expressed in biphasic than monophasic SS by real-time quantitative PCR. These results suggest that in SS the loss of E-cadherin expression occurs either by Snail trans-repression or by inactivating mutations. Thus, E-cadherin downregulation is associated with the loss or absence of glandular epithelial differentiation in certain SS.	Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Orthopaed Surg, Fukuoka 8128582, Japan; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	Kyushu University; Kyushu University; Memorial Sloan Kettering Cancer Center	Tsuneyoshi, M (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Higashi Ku, Maidashi 3-1-1, Fukuoka 8128582, Japan.	masazumi@surgpath.med.kyushu-u.ac.jp	Tanaka, Kazuhiro/Q-7387-2019; Ladanyi, Marc/AAG-8585-2019	Tanaka, Kazuhiro/0000-0002-5138-8952; Matsuda, Shuichi/0000-0003-0802-1255	NCI NIH HHS [CA47179] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA047179] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allander SV, 2002, AM J PATHOL, V161, P1587, DOI 10.1016/S0002-9440(10)64437-9; Antonescu CR, 2000, DIAGN MOL PATHOL, V9, P1, DOI 10.1097/00019606-200003000-00001; Auersperg N, 1999, P NATL ACAD SCI USA, V96, P6249, DOI 10.1073/pnas.96.11.6249; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Bornman DM, 2001, AM J PATHOL, V159, P831, DOI 10.1016/S0002-9440(10)61758-0; Brown DT, 2003, BIOCHEM CELL BIOL, V81, P221, DOI 10.1139/o03-049; Bukholm IK, 2000, J PATHOL, V190, P15; BURDSAL CA, 1993, DEVELOPMENT, V118, P829; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carver EA, 2001, MOL CELL BIOL, V21, P8184, DOI 10.1128/MCB.21.23.8184-8188.2001; Cheng CW, 2001, ONCOGENE, V20, P3814, DOI 10.1038/sj.onc.1204505; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; Endo K, 2001, J PATHOL, V193, P310, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH816>3.0.CO;2-K; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Gambarotta G, 1996, ONCOGENE, V13, P1911; Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727; Graff JR, 1998, CANCER RES, V58, P2063; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; GRAFF JR, 1995, CANCER RES, V55, P5195; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Hajra KM, 2002, CANCER RES, V62, P1613; HENNIG G, 1995, ONCOGENE, V11, P475; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hiraguri S, 1998, CANCER RES, V58, P1972; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Kawai A, 1998, NEW ENGL J MED, V338, P153, DOI 10.1056/NEJM199801153380303; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Ladanyi M, 2002, CANCER RES, V62, P135; Ladanyi M, 2001, ONCOGENE, V20, P5755, DOI 10.1038/sj.onc.1204601; Laskin WB, 2002, ARCH PATHOL LAB MED, V126, P425; Lee YF, 2003, BRIT J CANCER, V88, P510, DOI 10.1038/sj.bjc.6600766; Lewis JJ, 2000, J CLIN ONCOL, V18, P2087, DOI 10.1200/JCO.2000.18.10.2087; Locascio A, 2002, J BIOL CHEM, V277, P38803, DOI 10.1074/jbc.M205358200; Machado JC, 1999, LAB INVEST, V79, P459; Machen SK, 1999, AM J SURG PATHOL, V23, P268, DOI 10.1097/00000478-199903000-00004; MAREEL MM, 1991, INT J CANCER, V47, P922, DOI 10.1002/ijc.2910470623; MAYER B, 1993, CANCER RES, V53, P1690; Melki JR, 2000, BLOOD, V95, P3208; Nagayama S, 2002, CANCER RES, V62, P5859; Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140-6736(02)08270-3; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; Noguchi SI, 1997, INT J CANCER, V72, P995; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200; Rodrigo I, 1999, EXP CELL RES, V248, P358, DOI 10.1006/excr.1999.4438; Rosivatz E, 2002, AM J PATHOL, V161, P1881, DOI 10.1016/S0002-9440(10)64464-1; Saito A, 1999, JPN J CANCER RES, V90, P993, DOI 10.1111/j.1349-7006.1999.tb00847.x; Saito T, 2000, J PATHOL, V192, P342, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH705>3.0.CO;2-R; Saito T, 2002, LAB INVEST, V82, P97, DOI 10.1038/labinvest.3780399; Saito T, 2002, HISTOPATHOLOGY, V40, P279, DOI 10.1046/j.1365-2559.2002.01345.x; Saito T, 2001, AM J PATHOL, V159, P2117, DOI 10.1016/S0002-9440(10)63063-5; Sato H, 1999, HUM PATHOL, V30, P1344, DOI 10.1016/S0046-8177(99)90066-7; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; SCOTT GK, 1994, J BIOL CHEM, V269, P19848; Sefton M, 1998, DEVELOPMENT, V125, P3111; Segal NH, 2003, AM J PATHOL, V163, P691, DOI 10.1016/S0002-9440(10)63696-6; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Skytting B, 1999, J NATL CANCER I, V91, P974, DOI 10.1093/jnci/91.11.974; Soares P, 1997, INT J CANCER, V70, P32; Sugimachi K, 2003, CLIN CANCER RES, V9, P2657; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Tamura G, 2000, J NATL CANCER I, V92, P569, DOI 10.1093/jnci/92.7.569; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Trassard M, 2001, J CLIN ONCOL, V19, P525, DOI 10.1200/JCO.2001.19.2.525; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WEISS SW, 2001, ENZINGER WEISSS SOFT; Yakushiji T, 2000, J CLIN PATHOL, V53, P525, DOI 10.1136/jcp.53.7.525; Yoo J, 2002, ARCH PATHOL LAB MED, V126, P33	80	42	48	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8629	8638		10.1038/sj.onc.1207960	http://dx.doi.org/10.1038/sj.onc.1207960			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15467754				2022-12-17	WOS:000224988800009
J	Sachse, C; Echeverri, CJ				Sachse, C; Echeverri, CJ			Oncology studies using siRNA libraries: the dawn of RNAi-based genomics	ONCOGENE			English	Article						RNA interference; gene silencing; siRNA; functional genomics; screening	SHORT-INTERFERING RNAS; DOUBLE-STRANDED-RNA; MAMMALIAN-CELLS; GENE-FUNCTION; VALIDATION; DUPLEXES; PATHWAY; ELEGANS; SCREENS; PLANTS	High-throughput, human cell-based applications of RNA-mediated interference (RNAi) have emerged in recent years as perhaps the most powerful of a 'second wave' of functional genomics technologies. The available reagents and methodologies for RNAi screening studies now enable a wide range of different scopes and scales of investigation, from single-parameter assays applied to focused subsets of genes, to comprehensive genome-wide surveys based on rich, multiparameter readouts. As such, RNAi-based screens are offering important new avenues for the discovery and validation of novel therapeutic targets for several disease areas, including oncology. By enabling a 'clean' determination of gene function, that is the creation of direct causal links between gene and phenotype in human cells, RNAi investigations promise levels of pathophysiological relevance, efficiency, and range of applicability never before possible on this scale. The field of oncology, with its many assays using readily transfectable cell lines, has offered particularly fertile ground for showcasing the potential of RNAi-based genomics. However, like any other technology before it, RNAi is not without its own challenges, limitations, and caveats. Many of these issues stem directly from the choice of silencing reagent to be used in such studies, and the design of the overall screening strategy. Here, we discuss the basic design issues, potential advantages, and technical challenges of large-scale RNAi screens based on the use of chemically synthesized siRNA libraries.	Cenix Biosci GmbH, D-01307 Dresden, Germany		Echeverri, CJ (corresponding author), Cenix Biosci GmbH, Tatzberg 47, D-01307 Dresden, Germany.	echeverri@cenix-bioscience.com						Arts GJ, 2003, GENOME RES, V13, P2325, DOI 10.1101/gr.1332603; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Carpenter AE, 2004, NAT REV GENET, V5, P11, DOI 10.1038/nrg1248; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; English JJ, 1996, PLANT CELL, V8, P179, DOI 10.1105/tpc.8.2.179; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Gonczy P, 2000, NATURE, V408, P331, DOI 10.1038/35042526; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Holen T, 2002, NUCLEIC ACIDS RES, V30, P1757, DOI 10.1093/nar/30.8.1757; Hopkins AL, 2002, NAT REV DRUG DISCOV, V1, P727, DOI 10.1038/nrd892; Hsieh AC, 2004, NUCLEIC ACIDS RES, V32, P893, DOI 10.1093/nar/gkh238; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Kiger A A, 2003, J Biol, V2, P27, DOI 10.1186/1475-4924-2-27; KRONKE A, 2004, DRUG DISCOV WORLD, V5, P53; Lum L, 2003, SCIENCE, V299, P2039, DOI 10.1126/science.1081403; MUELLER E, 1995, PLANT J, V7, P1001, DOI 10.1046/j.1365-313X.1995.07061001.x; Paddison PJ, 2004, NATURE, V428, P427, DOI 10.1038/nature02370; Persengiev SP, 2004, RNA, V10, P12, DOI 10.1261/rna5160904; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; SACHSE C, 2004, IN PRESS METHODS ENZ, V392; Scacheri PC, 2004, P NATL ACAD SCI USA, V101, P1892, DOI 10.1073/pnas.0308698100; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Snove O, 2004, BIOCHEM BIOPH RES CO, V319, P256, DOI 10.1016/j.bbrc.2004.04.175; SONNICHSEN B, UNPUB GENOME WIDE SC; Xin H, 2004, J BIOMOL SCREEN, V9, P286, DOI 10.1177/1087057104263533; Yang D, 2002, P NATL ACAD SCI USA, V99, P9942, DOI 10.1073/pnas.152327299; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206	32	42	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2004	23	51					8384	8391		10.1038/sj.onc.1208072	http://dx.doi.org/10.1038/sj.onc.1208072			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867BA	15517020				2022-12-17	WOS:000224815900009
J	Delaval, B; Ferrand, A; Conte, N; Larroque, C; Hernandez-Verdun, D; Prigent, C; Birnbaum, D				Delaval, B; Ferrand, A; Conte, N; Larroque, C; Hernandez-Verdun, D; Prigent, C; Birnbaum, D			Aurora B TACC1 protein complex in cytokinesis	ONCOGENE			English	Article						Aurora kinase; cell division; cytokinesis; microtubule; midbody; TACC protein; Taxin; RNAi	COILED-COIL; CHROMOSOME SEGREGATION; CENTROSOMAL PROTEIN; BREAST-CANCER; CELL-CYCLE; A KINASE; SPINDLE; MITOSIS; REGULATORS; FAMILY	Taxins are a family of centrosomal proteins important for the regulation of mitosis and microtubule dynamics. Cytokinesis, the last step of M phase, is essential for chromosomal integrity and cell division. It is highly regulated and involves a reorganization of microtubules and actin filaments. We show here that TACC1 localizes diffusely to the midzone spindle in anaphase and strongly to the midbody during cytokinesis, indicating a possible involvement of this protein in the exit of M phase. TACC1 also relocalizes to the nucleolus in interphase. We demonstrate that TACC1 and the mitotic kinase Aurora B belong to the same complex during cytokinesis. We further show that Aurora B knocked down by RNA-mediated interference prevents the formation of the midbody-and consequently affects TACC1 localization at this site-and leads to abnormal cell division and multinucleated cells.	Inst J Paoli I Calmettes, INSERM, U119, Dept Mol Oncol, F-13009 Marseille, France; CRLC Val Aurelle Paul Lamarque, INSERM, E229, Montpellier, France; Univ Rennes 1, Fac Med, CNRS,UMR Genet & Dev 6061, Grp Cycle Cellulaire, Rennes, France; Inst Jacques Monod, CNRS, F-75251 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Centre National de la Recherche Scientifique (CNRS); Universite de Rennes 1; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Birnbaum, D (corresponding author), Inst J Paoli I Calmettes, INSERM, U119, Dept Mol Oncol, 27 Bd Lei Roure,IFR57, F-13009 Marseille, France.	birnbaurn@marseille.inserm.fr		Birnbaum, Daniel/0000-0001-7920-9883; Conte, Nathalie/0000-0002-1010-3121				Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; Bolton MA, 2002, MOL BIOL CELL, V13, P3064, DOI 10.1091/mbc.E02-02-0092; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; CHARRASSE S, 1995, EUR J BIOCHEM, V234, P406, DOI 10.1111/j.1432-1033.1995.406_b.x; Charrasse S, 2000, EXP CELL RES, V254, P249, DOI 10.1006/excr.1999.4740; Chen HM, 2000, MOL BIOL CELL, V11, P1357, DOI 10.1091/mbc.11.4.1357; Conte N, 2002, ONCOGENE, V21, P5619, DOI 10.1038/sj.onc.1205658; Conte N, 2003, ONCOGENE, V22, P8102, DOI 10.1038/sj.onc.1206972; Cremet JY, 2003, MOL CELL BIOCHEM, V243, P123, DOI 10.1023/A:1021608012253; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Gergely F, 2003, GENE DEV, V17, P336, DOI 10.1101/gad.245603; Gergely F, 2002, BIOESSAYS, V24, P915, DOI 10.1002/bies.10162; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; Giet R, 1999, J CELL SCI, V112, P3591; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; Hernandez-Verdun D, 2002, J CELL SCI, V115, P2265; Honda R, 2003, MOL BIOL CELL, V14, P3325, DOI 10.1091/mbc.E02-11-0769; Kallio MJ, 2002, CURR BIOL, V12, P900, DOI 10.1016/S0960-9822(02)00887-4; Katayama Hiroshi, 2003, Cancer and Metastasis Reviews, V22, P451, DOI 10.1023/A:1023789416385; Kawajiri A, 2003, MOL BIOL CELL, V14, P1489, DOI 10.1091/mbc.E02-09-0612; Keryer G, 2003, MOL BIOL CELL, V14, P2436, DOI 10.1091/mbc.E02-09-0614; Lappin TR, 2002, LEUKEMIA LYMPHOMA, V43, P1455, DOI 10.1080/1042819022386644; Lauffart B, 2002, BIOCHEM J, V363, P195, DOI 10.1042/0264-6021:3630195; MARASCO WA, 1994, ARCH VIROL, V139, P133, DOI 10.1007/BF01309460; Maxwell CA, 2003, MOL BIOL CELL, V14, P2262, DOI 10.1091/mbc.e02-07-0377; Minoshima Y, 2003, DEV CELL, V4, P549, DOI 10.1016/S1534-5807(03)00089-3; Murnion ME, 2001, J BIOL CHEM, V276, P26656, DOI 10.1074/jbc.M102288200; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Piekorz RP, 2002, EMBO J, V21, P653, DOI 10.1093/emboj/21.4.653; Robinson DN, 2000, TRENDS CELL BIOL, V10, P228, DOI 10.1016/S0962-8924(00)01747-5; ROUSSEL P, 1993, J CELL SCI, V104, P327; Schumacher JM, 1998, J CELL BIOL, V143, P1635, DOI 10.1083/jcb.143.6.1635; Steadman BT, 2002, J BIOL CHEM, V277, P30165, DOI 10.1074/jbc.M201914200; Stebbins-Boaz B, 1999, MOL CELL, V4, P1017, DOI 10.1016/S1097-2765(00)80230-0; Still IH, 1999, ONCOGENE, V18, P4032, DOI 10.1038/sj.onc.1202801; Still IH, 1999, GENOMICS, V58, P165, DOI 10.1006/geno.1999.5829; Sugiyama K, 2002, ONCOGENE, V21, P3103, DOI 10.1038/sj.onc.1205432; Takahashi M, 1999, J BIOL CHEM, V274, P17267, DOI 10.1074/jbc.274.24.17267; Tatsuka M, 1998, CANCER RES, V58, P4811; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Terada Y, 2001, CELL STRUCT FUNCT, V26, P653, DOI 10.1247/csf.26.653; Tien AC, 2004, MOL CELL PROTEOMICS, V3, P93, DOI 10.1074/mcp.M300072-MCP200; Wheatley SP, 2001, CURR BIOL, V11, P886, DOI 10.1016/S0960-9822(01)00238-X	44	42	46	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2004	23	26					4516	4522		10.1038/sj.onc.1207593	http://dx.doi.org/10.1038/sj.onc.1207593			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15064709				2022-12-17	WOS:000221799000002
J	Dai, ZY; Popkie, AP; Zhu, WG; Timmers, CD; Raval, A; Tannehill-Gregg, S; Morrison, CD; Auer, H; Kratzke, RA; Niehans, G; Amatschek, S; Sommergruber, W; Leone, GW; Rosol, T; Otterson, GA; Plass, C				Dai, ZY; Popkie, AP; Zhu, WG; Timmers, CD; Raval, A; Tannehill-Gregg, S; Morrison, CD; Auer, H; Kratzke, RA; Niehans, G; Amatschek, S; Sommergruber, W; Leone, GW; Rosol, T; Otterson, GA; Plass, C			Bone morphogenetic protein 3B silencing in non-small-cell lung cancer	ONCOGENE			English	Article						bone morphogenetic protein 3B (BMP3B); DNA methylation; non-small-cell lung cancer	GROWTH-FACTOR-BETA; DIFFERENTIALLY METHYLATED SEQUENCES; CPG ISLAND AMPLIFICATION; TUMOR-SUPPRESSOR; DNA METHYLATION; MESSENGER-RNAS; CDNA CLONING; EXPRESSION; GENE; IDENTIFICATION	Bone morphogenetic protein 3B (BMP3B) is a member of the TGF-beta superfamily. The BMP3B promoter sequence was previously identified as a target for aberrant DNA methylation in non-small-cell lung cancer (NSCLC). Aberrant DNA hypermethylation in the BMP3B promoter is associated with downregulation of BMP3B transcription in both primary human lung cancers as well as lung cancer cell lines. In order to understand the mechanisms of BMP3B silencing in lung cancer, a sample set of 91 primary NSCLCs was used to detect aberrant BMP3B promoter methylation, mutations in the coding sequence of BMP3B, and loss of heterozygosity (LOH). Our results showed that 45 of 91 ( or 49.5%) tested primary NSCLCs exhibited increased promoter methylation, and 40% demonstrated LOH in at least one of the flanking microsatellite markers sJRH and D10S196 (63 kb upstream or 3.338 Mbp downstream of BMP3B). The lung cancer cell line A549, a type II alveolar epithelial human lung cancer cell line, is characterized by aberrant DNA promoter methylation. We used retroviral vector constructs containing the BMP3B cDNA to re-express the gene in A549 cells and to investigate the effects on cell growth. No change in the cell growth rate was observed after BMP3B re-expression, as compared to the vector controls. Although the number of colonies formed in anchorage-dependent assays was only slightly decreased, the colony-forming ability of A549 cells after BMP3B expression in anchorage-independent assays in soft agar was significantly reduced to 10% (P<0.005, t-test). Moreover, the in vivo tumorigenicity assay in nude mice indicated that cells re-expressing BMP3B grew significantly slower than cells not expressing BMP3B (P<0.05, t-test). In conclusion, this study provides evidence that BMP3B expression is repressed by different mechanisms in lung cancer, and that the silencing of BMP3B promotes lung tumor development.	Ohio State Univ, Div Human Canc Genet, Dept Mol Virol Immunol & Med Genet, Human Canc Genet Program, Columbus, OH 43210 USA; Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA; Ohio State Univ, Dept Internal Med, Div Hematol Oncol, Columbus, OH 43210 USA; Ohio State Univ, Dept Vet Biosci, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Minneapolis VA Med Ctr, Minneapolis, MN 55417 USA; Boehringer Ingelheim, A-1120 Vienna, Austria; Univ Vienna, Dept Dermatol, A-1090 Vienna, Austria	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; Boehringer Ingelheim; University of Vienna	Plass, C (corresponding author), Ohio State Univ, Div Human Canc Genet, Dept Mol Virol Immunol & Med Genet, Human Canc Genet Program, Med Res Facil 494A,420 W 12th Ave, Columbus, OH 43210 USA.	plass-1@medctr.osu.edu	Rosol, Thomas/G-9585-2011; Plass, Christoph/H-7192-2014; zhu, wei-guo/E-1334-2012	Rosol, Thomas/0000-0003-3737-1190; Zhu, Wei-Guo/0000-0001-8385-6581	NCI NIH HHS [P30 CA16058, R01 CA93548] Funding Source: Medline; NIDCR NIH HHS [R01 DE13123] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016058, R01CA093548] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013123] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Akhurst RJ, 2002, J CLIN INVEST, V109, P1533, DOI 10.1172/JCI200215970; Baylin SB, 1998, ADV CANCER RES, V72, P141; CAULIN C, 1995, CELL GROWTH DIFFER, V6, P1027; Colasante A, 1997, AM J RESP CRIT CARE, V156, P968, DOI 10.1164/ajrccm.156.3.9701122; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Dai ZY, 2001, NEOPLASIA, V3, P314, DOI 10.1038/sj.neo.7900162; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; DERYNCK R, 1987, CANCER RES, V47, P707; Faucheux C, 1997, BIOCHEM BIOPH RES CO, V241, P787, DOI 10.1006/bbrc.1997.7792; Girard L, 2000, CANCER RES, V60, P4894; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hino J, 1996, BIOCHEM BIOPH RES CO, V223, P304, DOI 10.1006/bbrc.1996.0889; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; KESKIOJA J, 1988, J BIOL CHEM, V263, P3111; Kiemer AK, 2001, ONCOGENE, V20, P6679, DOI 10.1038/sj.onc.1204872; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; Liang GG, 2002, METHODS, V27, P150, DOI 10.1016/S1046-2023(02)00068-3; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Miyazono K, 2001, J CELL PHYSIOL, V187, P265, DOI 10.1002/jcp.1080; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Plass C, 2002, EUR J HUM GENET, V10, P6, DOI 10.1038/sj.ejhg.5200768; Ridley A, 2000, NATURE, V406, P466, DOI 10.1038/35020170; Samuel W, 2002, J BIOL CHEM, V277, P59, DOI 10.1074/jbc.M108730200; Sasaki H, 2002, JPN J CLIN ONCOL, V32, P85, DOI 10.1093/jjco/hyf021; SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511; Smiraglia DJ, 2002, ONCOGENE, V21, P5414, DOI 10.1038/sj.onc.1205608; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Toyota M, 1999, CANCER RES, V59, P2307; Toyota Minoru, 2002, Methods Mol Biol, V200, P101; Verrecchia F, 2002, J INVEST DERMATOL, V118, P211, DOI 10.1046/j.1523-1747.2002.01641.x; Zhu WG, 2001, ONCOGENE, V20, P7787, DOI 10.1038/sj.onc.1204970; Zhu WG, 2001, CANCER RES, V61, P1327	36	42	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3521	3529		10.1038/sj.onc.1207441	http://dx.doi.org/10.1038/sj.onc.1207441			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116090				2022-12-17	WOS:000221101700003
J	Huang, HJ; Zegarro-Moro, OL; Benson, D; Tindall, DJ				Huang, HJ; Zegarro-Moro, OL; Benson, D; Tindall, DJ			Androgens repress Bcl-2 expression via activation of the retinoblastoma (RB) protein in prostate cancer cells	ONCOGENE			English	Article						androgen receptor; Bcl-2; RB; transcription regulation; prostate cancer	HAMMERHEAD RIBOZYME; CYCLE PROGRESSION; TUMOR-MODEL; S-PHASE; GENE; APOPTOSIS; PROMOTER; RECEPTOR; OLIGODEOXYNUCLEOTIDES; INDEPENDENCE	The oncogene Bcl- 2 is upregulated frequently in prostate tumors following androgen ablation therapy, and Bcl- 2 overexpression may contribute to the androgen- refractory relapse of the disease. However, the molecular mechanism underlying androgenic regulation of Bcl- 2 in prostate cancer cells is understood poorly. In this study, we demonstrated that no androgen response element ( ARE) was identified in the androgen- regulated region of the P1 promoter of Bcl- 2 gene, whereas, we provided evidence that the androgenic effect is mediated by E2F1 protein through a putative E2F- binding site in the promoter. We further demonstrated that retinoblastoma ( RB) protein plays a critical role in androgen regulation of Bcl- 2. The phosphorylation levels of RB at serine residues 780 and 795 were decreased in LNCaP cells treated with androgens. Ectopic expression of a constitutively active form of RB inhibited expression of Bcl- 2. Knockdown of endogenous RB protein by an Rb small inference RNA ( siRNA) induced an increase in Bcl- 2 levels. Most importantly, the effect of androgens on Bcl- 2 was abolished completely by specific inhibition of RB function with a mutated E1A. Finally, androgen treatment of LNCaP cells upregulated specifically levels of the cyclin-dependent kinase inhibitors ( CDKIs) p15INK4B and p27KIP1. Ectopic expression of p15INK4B and/ or p27KIP1 inhibited Bcl- 2 expression. Knockdown of endogenous p15INK4B or p27KIP1 protein with a pool of siRNAs diminished androgen- induced downregulation of Bcl- 2 expression. Therefore, our data indicate that androgens suppress Bcl- 2 expression through negatively modulating activities of the E2F site in the Bcl- 2 promoter by activating the CDKI- RB axis.	Mayo Clin & Mayo Fdn, Dept Urol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem Mol Biol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Tindall, DJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Urol, 200 1st St SW, Rochester, MN 55905 USA.	tindall.donald@mayo.edu			NATIONAL CANCER INSTITUTE [P50CA091956] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060920] Funding Source: NIH RePORTER; NCI NIH HHS [CA91956] Funding Source: Medline; NIDDK NIH HHS [DK60920] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agus DB, 1999, J NATL CANCER I, V91, P1869, DOI 10.1093/jnci/91.21.1869; Bruckheimer EM, 2003, J UROLOGY, V169, P1553, DOI 10.1097/01.ju.0000055140.91204.c7; Butler R, 2000, CELL GROWTH DIFFER, V11, P49; Cheema SK, 2003, J BIOL CHEM, V278, P19995, DOI 10.1074/jbc.M205865200; Chi KN, 2001, CLIN CANCER RES, V7, P3920; COLOMBEL M, 1993, AM J PATHOL, V143, P390; Cordon-Cardo C, 1998, JNCI-J NATL CANCER I, V90, P1284, DOI 10.1093/jnci/90.17.1284; Decary S, 2002, MOL CELL BIOL, V22, P7877, DOI 10.1128/MCB.22.22.7877-7888.2002; Denmeade SR, 1996, PROSTATE, V28, P251; Dorai T, 1997, PROSTATE, V32, P246, DOI 10.1002/(SICI)1097-0045(19970901)32:4<246::AID-PROS4>3.0.CO;2-H; Dorai T, 1997, ANTICANCER RES, V17, P3307; Fernandez A, 2001, J NATL CANCER I, V93, P208, DOI 10.1093/jnci/93.3.208; Gleave M, 1999, CLIN CANCER RES, V5, P2891; Gleave M, 1999, PROSTATE CANCER P D, V2, pS15, DOI 10.1038/sj.pcan.4500341; Gleave ME, 1999, UROLOGY, V54, P36, DOI 10.1016/S0090-4295(99)00453-7; Gomez-Manzano C, 2001, CANCER RES, V61, P6693; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Haldar S, 1997, CANCER RES, V57, P229; Hiyama H, 1998, ONCOGENE, V16, P1513, DOI 10.1038/sj.onc.1201667; Huang H, 2002, CRIT REV EUKAR GENE, V12, P193, DOI 10.1615/CritRevEukaryotGeneExpr.v12.i3.30; Huang H, 2001, J BIOL CHEM, V276, P38830, DOI 10.1074/jbc.M103632200; Huang HJ, 1999, CANCER RES, V59, P2981; Huggins C, 1941, CANCER RES, V1, P293; ISAACS JT, 1984, PROSTATE, V5, P545, DOI 10.1002/pros.2990050510; Jiang Z, 2002, J CELL BIOL, V156, P185, DOI 10.1083/jcb.200106084; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Kimura K, 2001, CANCER RES, V61, P5611; Krajewska M, 1996, AM J PATHOL, V148, P1567; KYPRIANOU N, 1990, CANCER RES, V50, P3748; Lapointe J, 1999, ENDOCRINOLOGY, V140, P416, DOI 10.1210/en.140.1.416; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Liu SL, 2000, ONCOGENE, V19, P3352, DOI 10.1038/sj.onc.1203675; Lu LF, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-22; Masiello D, 2002, J BIOL CHEM, V277, P26321, DOI 10.1074/jbc.M203310200; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; McDonnell TJ, 1997, J UROLOGY, V157, P569, DOI 10.1016/S0022-5347(01)65204-2; Miyake H, 1999, CANCER RES, V59, P4030; MIYASHITA T, 1994, CANCER RES, V54, P3131; Murillo H, 2001, ENDOCRINOLOGY, V142, P4795, DOI 10.1210/en.142.11.4795; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; RAFFO AJ, 1995, CANCER RES, V55, P4438; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; Swinnen JV, 1997, P NATL ACAD SCI USA, V94, P12975, DOI 10.1073/pnas.94.24.12975; Tsihlias J, 2000, ONCOGENE, V19, P670, DOI 10.1038/sj.onc.1203369; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; WESTIN P, 1995, AM J PATHOL, V146, P1368; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Yang RM, 1998, J UROLOGY, V159, P941, DOI 10.1016/S0022-5347(01)63776-5; Zegarra-Moro OL, 2002, CANCER RES, V62, P1008	53	42	45	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2004	23	12					2161	2176		10.1038/sj.onc.1207326	http://dx.doi.org/10.1038/sj.onc.1207326			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	804EB	14676836				2022-12-17	WOS:000220280900006
J	Peterson, S; Bogenmann, E				Peterson, S; Bogenmann, E			The RET and TRKA pathways collaborate to regulate neuroblastoma differentiation	ONCOGENE			English	Article						neuroblastoma; neurotrophic factors; differentiation; TRKA; RET	NERVE GROWTH-FACTOR; NEUROTROPHIN RECEPTOR P75(NTR); MICE LACKING GDNF; SYMPATHETIC NEURONS; PROTEIN-SYNTHESIS; RETINOIC ACID; NEURAL CREST; C-RET; EXPRESSION; CELLS	Neuroblastoma (NB) is a childhood cancer that arises in the adrenal gland and often shows differentiated neuronal and glial elements. The RET receptor signal pathway is functional in most NB, while loss of nerve growth factor (NGF) receptor (trkA) gene expression correlates with an aggressive phenotype. Thus, we hypothesized that the RET and TRKA signal pathways collaborate to instruct NB differentiation, reminiscent of normal neuronal maturation. Here, we demonstrate that activation of the RET receptor by glial cell line-derived neurotrophic factor (GDNF) increases expression of the RET receptor complex in a panel of malignant human NB cell lines, indicative of a positive feedback mechanism. GDNF also induces growth cessation concomitant with an arrest of cells in the G(0)/G(1) phase of the cell cycle. Furthermore, GDNF synergizes with ciliary neurotrophic factor (CNTF) to enhance TRKA receptor expression, thereby strengthening the NGF-mediated differentiation signal. Differentiated NB cells downregulate expression of the amplified N-myc gene, concurrent with the arrest of cell proliferation, while expressing neuron-specific markers (i.e., SCG10). Interestingly, maintenance of differentiated NB cells in culture is independent of the trophic activity of GDNF, but depends on TRKA signaling, thereby re-enacting the differentiation of normal sympathoadrenal (SA) progenitor cells.	Childrens Hosp Los Angeles, Div Hematol Oncol, Los Angeles, CA 90027 USA	Children's Hospital Los Angeles	Bogenmann, E (corresponding author), Childrens Hosp Los Angeles, Div Hematol Oncol, Smith Res Tower,Mail Stop 57,4650 Sunset Blvd, Los Angeles, CA 90027 USA.	ebogenmann@chla.usc.edu			NINDS NIH HHS [R01 NS36978] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036978] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Anderson DJ, 1997, COLD SPRING HARB SYM, V62, P493; Baldassarre G, 2002, ONCOGENE, V21, P1739, DOI 10.1038/sj.onc.1205226; Barnett MW, 2002, J CELL SCI, V115, P4495, DOI 10.1242/jcs.00114; Barone MV, 2001, ONCOGENE, V20, P6973, DOI 10.1038/sj.onc.1204886; Barrett GL, 2000, PROG NEUROBIOL, V61, P205, DOI 10.1016/S0301-0082(99)00056-8; Beattie MS, 2002, NEURON, V36, P375, DOI 10.1016/S0896-6273(02)01005-X; Berwanger B, 2002, CANCER CELL, V2, P377, DOI 10.1016/S1535-6108(02)00179-4; BIEDLER JL, 1976, SCIENCE, V191, P185, DOI 10.1126/science.942798; Bogenmann E, 1998, ONCOGENE, V17, P2367, DOI 10.1038/sj.onc.1202160; Bogenmann E, 1996, INT J CANCER, V67, P379, DOI 10.1002/(SICI)1097-0215(19960729)67:3<379::AID-IJC12>3.0.CO;2-3; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; BUNONE G, 1995, EXP CELL RES, V217, P92, DOI 10.1006/excr.1995.1067; Cosgaya JM, 2002, SCIENCE, V298, P1245, DOI 10.1126/science.1076595; Creedon DJ, 1997, P NATL ACAD SCI USA, V94, P7018, DOI 10.1073/pnas.94.13.7018; CROWLEY C, 1994, CELL, V76, P1001, DOI 10.1016/0092-8674(94)90378-6; Dechant G, 2002, NAT NEUROSCI, V5, P1131, DOI 10.1038/nn1102-1131; Encinas M, 2001, J NEUROSCI, V21, P1464, DOI 10.1523/JNEUROSCI.21-05-01464.2001; Fukuda T, 2002, J BIOL CHEM, V277, P19114, DOI 10.1074/jbc.M200643200; GOODFELLOW PJ, 1994, CURR OPIN GENET DEV, V4, P446, DOI 10.1016/0959-437X(94)90034-5; Hempstead BL, 2002, CURR OPIN NEUROBIOL, V12, P260, DOI 10.1016/S0959-4388(02)00321-5; Hishiki T, 1998, CANCER RES, V58, P2158; Hofstra RMW, 1996, HUM GENET, V97, P362, DOI 10.1007/BF02185773; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Ip NY, 1996, ANNU REV NEUROSCI, V19, P491; Krieglstein K, 1998, J NEUROSCI, V18, P9822; KUMAR S, 1970, J PEDIATR SURG, V5, P18, DOI 10.1016/0022-3468(70)90515-4; Lee FS, 2001, CURR OPIN NEUROBIOL, V11, P281, DOI 10.1016/S0959-4388(00)00209-9; Manie S, 2001, TRENDS GENET, V17, P580, DOI 10.1016/S0168-9525(01)02420-9; MATSUSHIMA H, 1992, INT J CANCER, V51, P250, DOI 10.1002/ijc.2910510214; MATSUSHIMA H, 1992, INT J CANCER, V51, P727, DOI 10.1002/ijc.2910510511; MATSUSHIMA H, 1993, MOL CELL BIOL, V13, P7447, DOI 10.1128/MCB.13.12.7447; MATSUSHIMA H, 1993, ADV NEUROBLASTOMA RE, V4; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; Miyake M, 1994, Prog Clin Biol Res, V385, P163; Molliver DC, 1997, J COMP NEUROL, V381, P428, DOI 10.1002/(SICI)1096-9861(19970519)381:4<428::AID-CNE3>3.0.CO;2-4; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; NAKAMURA T, 1994, J PATHOL, V172, P255, DOI 10.1002/path.1711720305; Natarajan D, 2002, DEVELOPMENT, V129, P5151; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Roux PP, 2002, PROG NEUROBIOL, V67, P203, DOI 10.1016/S0301-0082(02)00016-3; SANTORO M, 1990, ONCOGENE, V5, P1595; Seeger Robert C., 1993, P2172; SHIMADA H, 1984, J NATL CANCER I, V73, P405, DOI 10.1093/jnci/73.2.405; Sleeman M W, 2000, Pharm Acta Helv, V74, P265, DOI 10.1016/S0031-6865(99)00050-3; SMEYNE RJ, 1994, NATURE, V368, P246, DOI 10.1038/368246a0; STEIN R, 1988, DEV BIOL, V127, P316, DOI 10.1016/0012-1606(88)90318-1; Takahashi M, 2001, CYTOKINE GROWTH F R, V12, P361, DOI 10.1016/S1359-6101(01)00012-0; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; Torres M, 1996, ONCOGENE, V12, P77; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Tsui-Pierchala B, 2002, NEURON, V33, P261, DOI 10.1016/S0896-6273(01)00585-2; Wang KC, 2002, NATURE, V420, P74, DOI 10.1038/nature01176; Westermann F, 2002, CANCER LETT, V184, P127, DOI 10.1016/S0304-3835(02)00199-4	56	42	49	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					213	225		10.1038/sj.onc.1206980	http://dx.doi.org/10.1038/sj.onc.1206980			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712226				2022-12-17	WOS:000187895300022
J	Seminario, MC; Precht, P; Wersto, RP; Gorospe, M; Wange, RL				Seminario, MC; Precht, P; Wersto, RP; Gorospe, M; Wange, RL			PTEN expression in PTEN-null leukaemic T cell lines leads to reduced proliferation via slowed cell cycle progression	ONCOGENE			English	Article						PTEN; proliferation; cell cycle; apoptosis	TUMOR-SUPPRESSOR PTEN; ANTIGEN RECEPTOR; CARCINOMA-CELLS; PHOSPHATASE-ACTIVITY; GROWTH ARREST; APOPTOSIS; ACTIVATION; PATHWAY; SIZE; STIMULATION	The balance of activities between the proto-oncogene phosphoinositide 3-kinase (PI3K) and the tumour suppressor gene PTEN has been shown to affect cellular growth and proliferation, as well as tumorigenesis. Previously, PTEN expression in the PTEN-null Jurkat T cell leukaemia line was shown to cause reduced proliferation without cell cycle arrest. Here, we further these investigations by determining the basis for this phenomenon. By BrdU pulse-chase and cell cycle arrest and release assays, we find that PTEN expression reduced proliferation by slowing progression through all phases of the cell cycle. This was associated with reduced levels of cyclins A, B1 and B2, cdk4, and cdc25A and increased p27(KIP1) expression. Apoptosis played no role in the antiproliferative effect of PTEN, since only marginal increases in the rate of apoptosis were detected upon PTEN expression, and inhibitors of effector caspases did not restore proliferative capacity. Active Akt blocked the antiproliferative effects of PTEN, indicating that PTEN mediates its effects through conventional PI3K-linked signalling pathways. Similar results were obtained from a different PTEN-null leukaemia T cell line, CEM. Together, these results show that PTEN expression in leukaemic T cells leads to reduced proliferation via an apoptosis-independent mechanism involving slower passage through the cell cycle.	NIA, Cellular & Mol Biol Lab, IRP, NIH,DHHS, Baltimore, MD 21224 USA; NIA, Flow Cytometry Lab, IRP, NIH,DHHS, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Wange, RL (corresponding author), NIA, Cellular & Mol Biol Lab, IRP, NIH,DHHS, 5600 Nathan Shock Dr,MSC-12, Baltimore, MD 21224 USA.	wanger@grc.nia.nih.gov	Wange, Ronald/AAI-2505-2021	Wange, Ronald/0000-0001-9593-3572	NATIONAL INSTITUTE ON AGING [Z01AG000509] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; ALLEN GD, 1990, BIOPHARM DRUG DISPOS, V11, P477, DOI 10.1002/bdd.2510110603; Appleman LJ, 2002, J IMMUNOL, V168, P2729, DOI 10.4049/jimmunol.168.6.2729; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cheyney IW, 1999, CANCER RES, V59, P2318; Davies MA, 1999, CANCER RES, V59, P2551; DAVIES MA, 2002, CLIN CANCER RES, V8, P1695; DECKER T, 1988, J IMMUNOL METHODS, V115, P61, DOI 10.1016/0022-1759(88)90310-9; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Furnari FB, 1998, CANCER RES, V58, P5002; Genestier L, 1998, J BIOL CHEM, V273, P5060, DOI 10.1074/jbc.273.9.5060; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; GOLD R, 1993, J HISTOCHEM CYTOCHEM, V41, P1023, DOI 10.1177/41.7.8515045; Gorospe M, 1996, MOL CELL BIOL, V16, P762; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Leslie NR, 2002, CELL SIGNAL, V14, P285, DOI 10.1016/S0898-6568(01)00234-0; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; NORDSTROM T, 1992, EXP CELL RES, V202, P487, DOI 10.1016/0014-4827(92)90103-F; Sakai A, 1998, BLOOD, V92, P3410, DOI 10.1182/blood.V92.9.3410.421a06_3410_3415; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; Shan XC, 2001, MOL CELL BIOL, V21, P7137, DOI 10.1128/MCB.21.21.7137-7149.2001; Stocker H, 2000, CURR OPIN GENET DEV, V10, P529, DOI 10.1016/S0959-437X(00)00123-4; Suzuki A, 2001, IMMUNITY, V14, P523, DOI 10.1016/S1074-7613(01)00134-0; Waite KA, 2002, AM J HUM GENET, V70, P829, DOI 10.1086/340026; Wang XD, 2000, J IMMUNOL, V164, P1934, DOI 10.4049/jimmunol.164.4.1934; WANGE RL, 1995, J BIOL CHEM, V270, P944, DOI 10.1074/jbc.270.2.944; Ward SG, 2001, CURR OPIN IMMUNOL, V13, P332, DOI 10.1016/S0952-7915(00)00223-5; Weng LP, 1999, CANCER RES, V59, P5808; Weng LP, 2001, HUM MOL GENET, V10, P251, DOI 10.1093/hmg/10.3.251; Weng LP, 2001, HUM MOL GENET, V10, P237, DOI 10.1093/hmg/10.3.237; Wersto RP, 1998, J VIROL, V72, P9491, DOI 10.1128/JVI.72.12.9491-9502.1998; WERSTO RP, 1995, CYTOMETRY, V20, P43, DOI 10.1002/cyto.990200108; Wishart MJ, 2002, TRENDS CELL BIOL, V12, P579, DOI 10.1016/S0962-8924(02)02412-1; Wu RC, 2000, MOL CELL BIOCHEM, V203, P59, DOI 10.1023/A:1007024624967; Xu Z, 2002, CELL GROWTH DIFFER, V13, P285; Yamada KM, 2001, J CELL SCI, V114, P2375; Zhang SM, 2000, J IMMUNOL, V165, P6270, DOI 10.4049/jimmunol.165.11.6270; Zhu XY, 2001, CANCER RES, V61, P4569	47	42	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	2003	22	50					8195	8204		10.1038/sj.onc.1206872	http://dx.doi.org/10.1038/sj.onc.1206872			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603260				2022-12-17	WOS:000186403400014
J	Hoornaert, I; Marynen, P; Goris, J; Sciot, R; Baens, M				Hoornaert, I; Marynen, P; Goris, J; Sciot, R; Baens, M			MAPK phosphatase DUSP16/MKP-7, a candidate tumor suppressor for chromosome region 12p12-13, reduces BCR-ABL-induced transformation	ONCOGENE			English	Article						tumor suppressor gene; MAPK phosphatase; chromosome 12p12-13; transformation	ACUTE LYMPHOBLASTIC-LEUKEMIA; DUAL-SPECIFICITY PHOSPHATASES; LUNG-CARCINOMA CELLS; SIGNAL-TRANSDUCTION; KINASE PHOSPHATASE; PROSTATE-CANCER; FREQUENT LOSS; GENE FAMILY; JUN KINASE; SHORT ARM	Recurrent chromosome 12p deletions are associated with distinct tumor types and suggest the presence of a tumor suppressor gene (TSG). Previously, we mapped an EST with similarity to a protein tyrosine phosphatase to the minimally deleted region for all these neoplasms. The corresponding gene, DUSP16/MKP-7, was recently shown to code for a mitogen-activated protein kinase phosphatase, suggestive for a function as tumor suppressor. Overexpression of DUSP16 in BCR-ABL-transformed Rat-1. broblasts reduces their transforming capacity in vitro and in vivo via downregulation of BCR-ABL-induced JNK activation. A role for DUSP16 as a regulator of JNK signaling was further demonstrated via overexpression in Ba/F3 cells, which increased their antiapoptosis. However, no inactivating mutations could be detected in leukemia patients hemizygous for DUSP16, and the effect of hemizygosity on DUSP16 expression level could not be assessed due to the variability of DUSP16 transcript levels observed in leukaemia cell lines and in patients. Taken together, the functional data point to a context-dependent role for DUSP16 on cell transformation and apoptosis, reflecting the dual role of JNK, and therefore suggest that DUSP16 might be haploinsufficient for tumor suppression.	Katholieke Univ Leuven VIB, Dept Human Genet, Human Genome Lab, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Dept Mol Cell Biol, Div Biochem, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Dept Pathol, B-3000 Louvain, Belgium	Flanders Institute for Biotechnology (VIB); KU Leuven; KU Leuven; KU Leuven	Baens, M (corresponding author), Katholieke Univ Leuven VIB, Dept Human Genet, Human Genome Lab, Herestr 49, B-3000 Louvain, Belgium.	Mathijs.Baens@med.kuleuven.ac.be		sciot, raf/0000-0003-2244-5839				Antonyak MA, 1998, J BIOL CHEM, V273, P2817, DOI 10.1074/jbc.273.5.2817; Baens M, 1999, GENOMICS, V56, P40, DOI 10.1006/geno.1998.5685; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Cools J, 2002, BLOOD, V99, P1776, DOI 10.1182/blood.V99.5.1776; Cortez D, 1997, ONCOGENE, V15, P2333, DOI 10.1038/sj.onc.1201400; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Furukawa T, 1998, CYTOGENET CELL GENET, V82, P156, DOI 10.1159/000015091; Guo B, 2001, J BIOL CHEM, V276, P2780, DOI 10.1074/jbc.M005889200; Hatta Y, 1997, BRIT J CANCER, V75, P1256, DOI 10.1038/bjc.1997.214; Hetet G, 2000, Hematol J, V1, P42, DOI 10.1038/sj.thj.6200008; Hoshino R, 2001, J BIOL CHEM, V276, P2686, DOI 10.1074/jbc.M006132200; Huang CS, 1999, J BIOL CHEM, V274, P29672, DOI 10.1074/jbc.274.42.29672; Kibel AS, 1998, CANCER RES, V58, P5652; Kibel AS, 2000, J UROLOGY, V164, P192, DOI 10.1016/S0022-5347(05)67493-9; Kibel AS, 1999, GENE CHROMOSOME CANC, V25, P270, DOI 10.1002/(SICI)1098-2264(199907)25:3<270::AID-GCC9>3.3.CO;2-Q; Latil A, 2001, GENE CHROMOSOME CANC, V31, P199; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LIU Q, 1995, BIOTECHNIQUES, V18, P470; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; Masuda K, 2001, J BIOL CHEM, V276, P39002, DOI 10.1074/jbc.M104600200; Montpetit A, 2002, EUR J HUM GENET, V10, P62, DOI 10.1038/sj.ejhg.5200766; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Nesbit MA, 1997, GENOMICS, V42, P284, DOI 10.1006/geno.1997.4737; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Raynaud S, 1996, BLOOD, V87, P2891, DOI 10.1182/blood.V87.7.2891.bloodjournal8772891; Romana SP, 1996, LEUKEMIA, V10, P167; SATO Y, 1995, BLOOD, V86, P1525, DOI 10.1182/blood.V86.4.1525.bloodjournal8641525; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Smith A, 1997, CURR BIOL, V7, P893, DOI 10.1016/S0960-9822(06)00380-0; Spirin KS, 1996, CANCER RES, V56, P2400; Stegmaier K, 1996, CANCER RES, V56, P1413; Takeuchi S, 1996, CANCER RES, V56, P738; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Tanoue T, 2001, J BIOL CHEM, V276, P26629, DOI 10.1074/jbc.M101981200; Wlodarska I, 1996, CYTOGENET CELL GENET, V72, P229, DOI 10.1159/000134197; Xiao L, 2000, CANCER RES, V60, P400	42	42	43	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2003	22	49					7728	7736		10.1038/sj.onc.1207089	http://dx.doi.org/10.1038/sj.onc.1207089			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586399				2022-12-17	WOS:000186240200003
J	Luo, XQ; Huang, Y; Sheikh, MS				Luo, XQ; Huang, Y; Sheikh, MS			Cloning and characterization of a novel gene PDRG that is differentially regulated by p53 and ultraviolet radiation	ONCOGENE			English	Article						ultraviolet radiation; p53; DNA damage; cell growth; promoter activity	TUMOR-SUPPRESSOR PROTEIN; INDUCED DNA-DAMAGE; WILD-TYPE P53; CELL-CYCLE; TRANSCRIPTIONAL REPRESSION; INDUCIBLE CDNA; BINDING; PHOSPHORYLATION; IDENTIFICATION; EXPRESSION	We report the cloning and characterization of a novel p53 and DNA damage-regulated gene (PDRG). The human and mouse PDRG sequences are highly homologous and contain open reading frames of 133 amino acids each with molecular masses of 15.5 and 15.3 kDa, respectively. PDRG codes for a novel protein that does not show similarity to any known protein in the databases. Human PDRG is predominantly expressed in normal testis and exhibits reduced but detectable expression in other organs. GFP-tagged PDRG was predominantly detected as aggregates that appeared to reside in a distinct subcellular compartment. PDRG mRNA was upregulated by ultraviolet radiation (UV) but downregulated by tumor suppressor p53. UV is known to transcriptionally upregulate the expression of certain genes by activating the transcription factor Oct-1, while p53 has been reported to suppress transcription of certain genes by directly binding to a novel head-to-tail response element. Cloning and sequence analysis of PDRG promoter revealed the presence of Oct-1-binding element and a putative head-to-tail-type p53-binding site. Indeed, UV as well as exogenous Oct-1 independently increased PDRG promoter activity, suggesting that UV could mediate PDRG upregulation via Oct-1. Exogenous wild-type p53 was found to downregulate the PDRG promoter activity indicating that wild-type p53 transcriptionally suppresses the expression of PDRG and may mediate its effect via the putative head-to-tail response element. Furthermore, stable expression of exogenous PDRG was found to decrease the clonogenic survival after UV irradiation, which highlights the significance of PDRG in facilitating UV-induced killing.	SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 12310 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Sheikh, MS (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, 750 E Adams St, Syracuse, NY 13210 USA.				NATIONAL CANCER INSTITUTE [R01CA086945, R21CA089043] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK062136] Funding Source: NIH RePORTER; NCI NIH HHS [CA86945, CA89043] Funding Source: Medline; NIDDK NIH HHS [DK062136] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adimoolam S, 2002, P NATL ACAD SCI USA, V99, P12985, DOI 10.1073/pnas.202485699; Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; Desdouets C, 1996, FEBS LETT, V385, P34, DOI 10.1016/0014-5793(96)00330-4; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Fontanini G, 1999, CLIN CANCER RES, V5, P155; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; Friedberg EC, 2003, NATURE, V421, P436, DOI 10.1038/nature01408; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gottifredi V, 2001, MOL CELL BIOL, V21, P1066, DOI 10.1128/MCB.21.4.1066-1076.2001; GU W, 1997, NATURE, V387, P318; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; He Q, 2002, ONCOGENE, V21, P6032, DOI 10.1038/sj.onc.1205897; Heffernan TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Huang Y, 2001, CANCER RES, V61, P6918; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Johnson RA, 2001, J BIOL CHEM, V276, P27716, DOI 10.1074/jbc.C100121200; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Latchman DS, 1999, J CELL PHYSIOL, V179, P126; Lopez CD, 2000, MOL CELL BIOL, V20, P8018, DOI 10.1128/MCB.20.21.8018-8025.2000; Majumder M, 2001, J VIROL, V75, P1401, DOI 10.1128/JVI.75.3.1401-1407.2001; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Seker H, 2003, ONCOGENE, V22, P1620, DOI 10.1038/sj.onc.1206140; Sheikh MS, 2000, J CELL PHYSIOL, V182, P171, DOI 10.1002/(SICI)1097-4652(200002)182:2<171::AID-JCP5>3.0.CO;2-3; Sheikh MS, 1997, J BIOL CHEM, V272, P26720, DOI 10.1074/jbc.272.42.26720; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; Sheikh MS, 1999, J BIOL CHEM, V274, P16487, DOI 10.1074/jbc.274.23.16487; Takahashi S, 2001, CANCER RES, V61, P1187; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Taylor WR, 2001, J BIOL CHEM, V276, P1998, DOI 10.1074/jbc.M005101200; Unsal-Kacmaz K, 2002, P NATL ACAD SCI USA, V99, P6673, DOI 10.1073/pnas.102167799; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Walworth NC, 2000, CURR OPIN CELL BIOL, V12, P697, DOI 10.1016/S0955-0674(00)00154-X; Wong J, 2002, J BIOL CHEM, V277, P26699, DOI 10.1074/jbc.M203020200; Yang JP, 1999, ONCOGENE, V18, P5177, DOI 10.1038/sj.onc.1202904; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805; Zhao HC, 2000, CANCER RES, V60, P6276; Zilfou JT, 2001, MOL CELL BIOL, V21, P3974, DOI 10.1128/MCB.21.12.3974-3985.2001	50	42	45	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 16	2003	22	46					7247	7257		10.1038/sj.onc.1207010	http://dx.doi.org/10.1038/sj.onc.1207010			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732PP	14562055				2022-12-17	WOS:000185955000018
J	Lynch, J; Keller, M; Guo, RJ; Yang, D; Traber, P				Lynch, J; Keller, M; Guo, RJ; Yang, D; Traber, P			Cdx1 inhibits the proliferation of human colon cancer cells by reducing cyclin D1 gene expression	ONCOGENE			English	Article						homeobox; cyclin D1; antiproliferative; colon cancer	HOMEODOMAIN PROTEIN CDX2; INTESTINAL EPITHELIAL-CELLS; HOMEOBOX GENE; COLORECTAL-CANCER; DOWN-REGULATION; CARCINOMA CELLS; DIFFERENTIATION; TRANSCRIPTION; TRANSACTIVATION; LINE	The transcription factor Cdx1 regulates intestine-specific gene expression and enterocyte differentiation. It has been hypothesized to play a role in regulating intestinal cell proliferation; however, the mechanism for this effect remains elusive. In a prior study, we demonstrated that Cdx1 expression reduced the proliferation of a nontransformed intestinal cell line. This study tests the hypothesis that Cdx1 expression inhibits colon cancer cell proliferation by reducing cyclin D1 gene expression. Cdx1 expression markedly reduced cancer cell proliferation and DNA synthesis and induced an accumulation of cells in G0/G1. A transcriptionally inactive Cdx1 mutant could not elicit this effect, suggesting that it required Cdx1 transcriptional activity. Cdx1 expression increased the hypophosphorylation of the retinoblastoma (pRb) and p130 proteins. Reductions in G1 cyclin-dependant kinase (cdk) activity accompanied this effect. Cyclin D1 mRNA and protein levels were diminished by Cdx1 expression. Restoration of cyclin D1 expression reversed the G0/G1 block and induced pRb hyperphosphorylation. Lastly, Cdx1 expression did not alter cyclin D1 mRNA stability but did reduce cyclin D1 promoter activity, suggesting that Cdx1 acts to diminish cyclin D1 gene transcription. We conclude that Cdx1 reduces the proliferation of human colon cancer cells by reducing cyclin D1 gene transcription.	Univ Penn, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA	University of Pennsylvania	Lynch, J (corresponding author), Univ Penn, Dept Med, Div Gastroenterol, 415 Curie Blvd,660 CRB, Philadelphia, PA 19104 USA.	lynchj@mail.med.upenn.edu		Keller, Matthew/0000-0003-1884-487X	NIDDK NIH HHS [P01-DK49210, DK02695-02, P30-DK50306] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK050306, P01DK049210, K08DK002695] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Albrecht JH, 1999, CELL GROWTH DIFFER, V10, P397; Arber N, 1996, GASTROENTEROLOGY, V110, P669, DOI 10.1053/gast.1996.v110.pm8608874; Bai YQ, 2002, CANCER LETT, V176, P47, DOI 10.1016/S0304-3835(01)00753-4; Beck F, 2000, BIOESSAYS, V22, P431, DOI 10.1002/(SICI)1521-1878(200005)22:5<431::AID-BIES5>3.0.CO;2-X; Boudreau F, 2002, J BIOL CHEM, V277, P31909, DOI 10.1074/jbc.M204622200; Chung DC, 2000, GASTROENTEROLOGY, V119, P854, DOI 10.1053/gast.2000.16507; Clatworthy JP, 2001, MECH DEVELOP, V101, P3, DOI 10.1016/S0925-4773(00)00557-8; Dai CY, 2000, GASTROENTEROLOGY, V119, P929, DOI 10.1053/gast.2000.17952; Dang DT, 2001, ONCOGENE, V20, P4884, DOI 10.1038/sj.onc.1204645; Donnellan R, 1998, J CLIN PATHOL-MOL PA, V51, P1; Drummond FJ, 1998, FEBS LETT, V423, P218, DOI 10.1016/S0014-5793(98)00103-3; Fang RX, 2001, AM J PHYSIOL-GASTR L, V280, pG58, DOI 10.1152/ajpgi.2001.280.1.G58; Freund JN, 1998, BIOCHEM CELL BIOL, V76, P957, DOI 10.1139/bcb-76-6-957; Hu B, 2001, MOL CELL BIOL, V21, P2755, DOI 10.1128/MCB.21.8.2755-2766.2001; Jensen J, 2000, NAT GENET, V24, P36, DOI 10.1038/71657; Kaestner KH, 1997, GENE DEV, V11, P1583, DOI 10.1101/gad.11.12.1583; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Krasinski SD, 2001, AM J PHYSIOL-GASTR L, V281, pG69, DOI 10.1152/ajpgi.2001.281.1.G69; Lickert H, 2000, DEVELOPMENT, V127, P3805; Lorentz O, 1999, ONCOGENE, V18, P87, DOI 10.1038/sj.onc.1202280; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; Lynch J, 2000, J BIOL CHEM, V275, P4499, DOI 10.1074/jbc.275.6.4499; Lynch JP, 2002, HEMATOL ONCOL CLIN N, V16, P775, DOI 10.1016/S0889-8588(02)00029-1; Mallo GV, 1998, J BIOL CHEM, V273, P14030, DOI 10.1074/jbc.273.22.14030; Mariadason JM, 2001, CANCER RES, V61, P3465; MAULBECKER CC, 1993, CELL GROWTH DIFFER, V4, P431; Mutoh H, 1998, GENE DEV, V12, P820, DOI 10.1101/gad.12.6.820; Naishiro Y, 2001, CANCER RES, V61, P2751; Oh EJ, 2002, INT J ONCOL, V20, P23; Phelps DE, 1997, METHOD ENZYMOL, V283, P194; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rings EHHM, 2001, GASTROENTEROLOGY, V121, P1437, DOI 10.1053/gast.2001.29618; Sheaff RJ, 1997, METHOD ENZYMOL, V283, P173; Sherr CJ, 2000, CANCER RES, V60, P3689; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Silberg DG, 2000, GASTROENTEROLOGY, V119, P961, DOI 10.1053/gast.2000.18142; Silberg DG, 1997, GASTROENTEROLOGY, V113, P478, DOI 10.1053/gast.1997.v113.pm9247467; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Soubeyran P, 1999, GASTROENTEROLOGY, V117, P1326, DOI 10.1016/S0016-5085(99)70283-0; Soubeyran P, 2001, ONCOGENE, V20, P4180, DOI 10.1038/sj.onc.1204551; Subramanian V, 1998, DIFFERENTIATION, V64, P11, DOI 10.1046/j.1432-0436.1998.6410011.x; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Suh ER, 2002, J BIOL CHEM, V277, P35795, DOI 10.1074/jbc.M205567200; Sun RG, 2001, J BIOL CHEM, V276, P6897, DOI 10.1074/jbc.C000870200; Taylor JK, 1997, DNA CELL BIOL, V16, P1419, DOI 10.1089/dna.1997.16.1419; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; van den Akker E, 2002, DEVELOPMENT, V129, P2181; Yang Q, 2001, SCIENCE, V294, P2155, DOI 10.1126/science.1065718	51	42	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2003	22	41					6395	6407		10.1038/sj.onc.1206770	http://dx.doi.org/10.1038/sj.onc.1206770			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508520				2022-12-17	WOS:000185535300010
J	Kalinina, OA; Kalinin, SA; Polack, EW; Mikaelian, I; Panda, S; Costa, RH; Adami, GR				Kalinina, OA; Kalinin, SA; Polack, EW; Mikaelian, I; Panda, S; Costa, RH; Adami, GR			Sustained hepatic expression of FoxM1B in transgenic mice has minimal effects on hepatocellular carcinoma development but increases cell proliferation rates in preneoplastic and early neoplastic lesions	ONCOGENE			English	Article						FoxM1B; hepatocytes; cell proliferation; diethylnitrosamine; adenoma; hepatocelluar carcinoma	TRANSFORMING-GROWTH-FACTOR; TRANSCRIPTION FACTOR TRIDENT; LIVER-REGENERATION; FACTOR-ALPHA; S-PHASE; C-MYC; CARBON-TETRACHLORIDE; TUMOR PROGRESSION; HEPATOCYTE ENTRY; GENE-EXPRESSION	Increased hepatic expression of the Forkhead transcription factor FoxM1B in adult mice accelerates hepatocyte proliferation after partial hepatectomy, while in hepatocytes in intact liver the transgenic (Tg) protein is inactive and has no effect on proliferation. To investigate the influence of FoxM1B on liver tumor formation, we examined the effect of sustained enrichment of FoxM1B in the hepatocytes of mice treated with a diethylnitrosamine (DEN)/phenobarbital tumor induction protocol. Tg enrichment of FoxM1B in hepatocytes did not increase the proliferation rate in normal liver tissue even when the protein was localized to the nucleus. However, it did cause an increase in the proliferation rate and size of preneoplastic and early neoplastic lesions, although having no effects on the total numbers of these lesions. As tumors progressed to hepatocellular carcinomas, the additional Tg FoxM1B protein had no effect on cell proliferation, and there was no increase in tumor burden compared to wild-type animals. This suggests that the artificial enrichment of FoxM1B in the liver, which has been suggested as a gene therapy protocol for liver dysfunction with aging, may not be tumorigenic in that organ.	Univ Illinois, Coll Dent, Dept Oral Med & Diagnost Sci, Chicago, IL 60612 USA; Univ Illinois, Coll Dent, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA; Univ Illinois, Coll Vet Med, Vet Diagnost Lab, Urbana, IL 61802 USA; Univ Illinois, Coll Vet Med, Dept Vet Pathobiol, Urbana, IL 61802 USA; Jackson Lab, Dept Pathol, Bar Harbor, ME 04609 USA; Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Jackson Laboratory; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Adami, GR (corresponding author), Univ Illinois, Coll Dent, Dept Oral Med & Diagnost Sci, 801 S Paulina St,M-C 838, Chicago, IL 60612 USA.		Kalinin, Sergey/E-7741-2013		NATIONAL CANCER INSTITUTE [R01CA085529] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054687] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 85529-05] Funding Source: Medline; NIDDK NIH HHS [R01 DK 54687-05] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baudino TA, 2002, GENE DEV, V16, P2530, DOI 10.1101/gad.1024602; Bell A, 1999, ONCOGENE, V18, P887, DOI 10.1038/sj.onc.1202379; Birner P, 2001, AM J PATHOL, V158, P1991, DOI 10.1016/S0002-9440(10)64670-6; Bosch FX, 1999, SEMIN LIVER DIS, V19, P271, DOI 10.1055/s-2007-1007117; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BUCHER NL, 1997, LIVER REGENERATION C; Carlsson P, 2002, DEV BIOL, V250, P1, DOI 10.1006/dbio.2002.0780; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Costa RH, 2001, AM J PHYSIOL-LUNG C, V280, pL823, DOI 10.1152/ajplung.2001.280.5.L823; Cowen T, 2001, TRENDS GENET, V17, P109, DOI 10.1016/S0168-9525(00)02214-9; Deane NG, 2001, CANCER RES, V61, P5389; DRAGANI TA, 1986, CANCER LETT, V31, P171, DOI 10.1016/0304-3835(86)90008-X; Factor VM, 1997, HEPATOLOGY, V26, P1434; Fausto N, 1993, Prog Liver Dis, V11, P115; Fausto N, 1991, Prog Growth Factor Res, V3, P219, DOI 10.1016/0955-2235(91)90008-R; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Fausto N, 1999, SEMIN LIVER DIS, V19, P243, DOI 10.1055/s-2007-1007114; FRITH CH, 1979, J ENVIRON PATHOL TOX, V3, P329; FRY M, 1984, J CELL PHYSIOL, V118, P225, DOI 10.1002/jcp.1041180302; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HUANG SN, 1995, HEPATOLOGY, V21, P620, DOI 10.1002/hep.1840210303; Isenberg JS, 1997, CARCINOGENESIS, V18, P1511, DOI 10.1093/carcin/18.8.1511; Ito T, 1998, HISTOCHEM CELL BIOL, V110, P589, DOI 10.1007/s004180050321; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; Kaestner KH, 2000, GENE DEV, V14, P142; Kanzler S, 2001, ONCOGENE, V20, P5015, DOI 10.1038/sj.onc.1204544; KOIKE K, 1995, J GEN VIROL, V76, P3031, DOI 10.1099/0022-1317-76-12-3031; Korver W, 1997, GENOMICS, V46, P435, DOI 10.1006/geno.1997.5065; Korver W, 1997, IMMUNOBIOLOGY, V198, P157, DOI 10.1016/S0171-2985(97)80036-8; Korver W, 1998, CURR BIOL, V8, P1327, DOI 10.1016/S0960-9822(07)00563-5; Korver W, 1997, NUCLEIC ACIDS RES, V25, P1715, DOI 10.1093/nar/25.9.1715; LEE GH, 1992, CANCER RES, V52, P5162; Leung TWC, 2001, FEBS LETT, V507, P59, DOI 10.1016/S0014-5793(01)02915-5; Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486; MILLS JJ, 1997, LIVER REGENERATION C; Okabe H, 2001, CANCER RES, V61, P2129; PERAINO C, 1981, CARCINOGENESIS, V2, P463, DOI 10.1093/carcin/2.5.463; Pierce RH, 2002, AM J PATHOL, V160, P1555, DOI 10.1016/S0002-9440(10)61101-7; Pitot HC, 1996, J CANCER RES CLIN, V122, P257, DOI 10.1007/BF01261401; Pitot HC, 2001, LANCET, V358, P859, DOI 10.1016/S0140-6736(01)06038-X; PUGH TD, 1983, CANCER RES, V43, P1261; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; SANDGREN EP, 1989, ONCOGENE, V4, P715; SANDGREN EP, 1997, LIVER REGENERATION C, P257; Santoni-Rugiu E, 1998, CANCER RES, V58, P123; SANTONIRUGIU E, 1998, LIVER GROWTH REPAIR, P100; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; SELL S, 1991, CANCER RES, V51, P1278; TAMANO S, 1994, CARCINOGENESIS, V15, P1791, DOI 10.1093/carcin/15.9.1791; TAUB R, 1997, LIVER REGENERATION C; Teh MT, 2002, CANCER RES, V62, P4773; Thorgeirsson SS, 2000, TOXICOL LETT, V112, P553, DOI 10.1016/S0378-4274(99)00224-6; Wang XH, 2002, P NATL ACAD SCI USA, V99, P16881, DOI 10.1073/pnas.252570299; Wang XH, 2002, J BIOL CHEM, V277, P44310, DOI 10.1074/jbc.M207510200; Wang XH, 2001, P NATL ACAD SCI USA, V98, P11468, DOI 10.1073/pnas.201360898; Wang XH, 2001, HEPATOLOGY, V33, P1404, DOI 10.1053/jhep.2001.24666; WEBBER EM, 1994, AM J PATHOL, V145, P398; Yao KM, 1997, J BIOL CHEM, V272, P19827, DOI 10.1074/jbc.272.32.19827; Ye HG, 1999, MOL CELL BIOL, V19, P8570; Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626	60	42	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2003	22	40					6266	6276		10.1038/sj.onc.1206640	http://dx.doi.org/10.1038/sj.onc.1206640			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679865				2022-12-17	WOS:000185506200016
J	Melnikova, VO; Santamaria, AB; Bolshakov, SV; Ananthaswamy, HN				Melnikova, VO; Santamaria, AB; Bolshakov, SV; Ananthaswamy, HN			Mutant p53 is constitutively phosphorylated at Serine 15 in UV-induced mouse skin tumors: involvement of ERK1/2 MAP kinase	ONCOGENE			English	Article						mutant p53; phosphorylation; serine 15; stabilization; ERK; skin tumor; UV	WILD-TYPE P53; DAMAGE-INDUCED PHOSPHORYLATION; NUCLEAR EXPORT SIGNAL; DNA-DAMAGE; TRANSCRIPTIONAL ACTIVATION; ENHANCED PHOSPHORYLATION; P38 KINASE; PROTEIN; MUTATIONS; GROWTH	Upon DNA damage, phosphorylation and nuclear translocation of wild-type p53 tumor suppressor protein signals its functional activation. However, very little is known about phosphorylation and localization of mutant p53. We found that mutant p53 protein in UV-induced murine primary skin tumors and cultured cell tines was constitutively phosphorylated at serine 15 residue and localized in the cell's nuclei. To investigate the mechanism of constitutive phosphorylation of mutant p53, we tested the involvement of a wide range of protein kinases and found that ERK1/2 mitogen-activated protein kinase was physically associated with mutant p53 in the nucleus. Addition of active recombinant ERK2 kinase protein in vitro to immunoprecipitated mutant p53 resulted in increased phosphorylation at serine 15. Furthermore, ERK1/2 activity was higher in tumor cells than normal cells, suggesting that phosphorylation of mutant p53 at serine 15 depends on the level of ERK1/2 activation. Interestingly, accumulation of mutant p53 in tumor cells was paralleled by low levels of Murine Double Minute 2 protein (MDM2) expression. However, when MDM2 was overexpressed, the fraction of mutant p53 that was phosphorylated at serine 15 resisted degradation, whereas the level of total p53 decreased, suggesting that phosphorylation at serine 15 and downregulation of MDM2 protein may both contribute to stabilization of mutant p53 in tumor cells.	Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Ananthaswamy, HN (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunol, 1515 Holcombe Blvd,Box 178, Houston, TX 77030 USA.	hanantha@mdanderson.org			NCI NIH HHS [CA 16672, CA 46523] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA046523] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; Ananthaswamy HN, 1998, PHOTOCHEM PHOTOBIOL, V67, P227, DOI 10.1562/0031-8655(1998)067<0227:MIHSHM>2.3.CO;2; Ananthaswamy HN, 1997, NAT MED, V3, P510, DOI 10.1038/nm0597-510; Araki R, 1999, CANCER RES, V59, P3543; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Blagosklonny MV, 1997, ONCOGENE, V15, P1889, DOI 10.1038/sj.onc.1201374; Brash DE, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P136; Brown DR, 2001, INT J ONCOL, V18, P449; Burma S, 1999, J BIOL CHEM, V274, P17139, DOI 10.1074/jbc.274.24.17139; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Buschmann T, 2000, J MOL BIOL, V295, P1009, DOI 10.1006/jmbi.1999.3387; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; De Guzman RN, 2000, J MOL BIOL, V303, P243, DOI 10.1006/jmbi.2000.4141; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hill LL, 1999, SCIENCE, V285, P898, DOI 10.1126/science.285.5429.898; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; KANJILAL S, 1993, CANCER RES, V53, P2961; Kapoor M, 2000, ONCOGENE, V19, P358, DOI 10.1038/sj.onc.1203300; KIESER A, 1994, ONCOGENE, V9, P963; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Koga H, 2000, ONCOGENE, V19, P4178, DOI 10.1038/sj.onc.1203745; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1995, ONCOGENE, V10, P2387; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; Minamoto T, 2001, ONCOGENE, V20, P3341, DOI 10.1038/sj.onc.1204458; Nagata Y, 1999, ONCOGENE, V18, P6037, DOI 10.1038/sj.onc.1202978; Ouhtit A, 2000, AM J PATHOL, V156, P201, DOI 10.1016/S0002-9440(10)64720-7; Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200; PIERCEALL WE, 1992, CANCER RES, V52, P3946; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PRIVES C, 1999, GENE DEV, V13, P152; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; She QB, 2002, ONCOGENE, V21, P1580, DOI 10.1038/sj.onc.1205239; She QB, 2001, CANCER RES, V61, P1604; Sheikh MS, 1997, ONCOGENE, V15, P1095, DOI 10.1038/sj.onc.1201264; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Sigal A, 2000, CANCER RES, V60, P6788; Steegenga WT, 1996, J MOL BIOL, V263, P103, DOI 10.1006/jmbi.1996.0560; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; Van Orden K, 1999, J BIOL CHEM, V274, P26321, DOI 10.1074/jbc.274.37.26321; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	54	42	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					5958	5966		10.1038/sj.onc.1206595	http://dx.doi.org/10.1038/sj.onc.1206595			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955074				2022-12-17	WOS:000185137800004
J	Sanchez-Carbayo, M; Schwarz, K; Charytonowicz, E; Cordon-Cardo, C; Mundel, P				Sanchez-Carbayo, M; Schwarz, K; Charytonowicz, E; Cordon-Cardo, C; Mundel, P			Tumor suppressor role for myopodin in bladder cancer: loss of nuclear expression of myopodin is cell-cycle dependent and predicts clinical outcome	ONCOGENE			English	Article						bladder cancer; tissue microarrays; myopodin; cell-cycle	GENETIC ALTERATIONS; PARTIAL ALLELOTYPE; PROTEIN; ACTIN; P53; SYNAPTOPODIN; CARCINOMA; PATHWAY; ZYXIN	Myopodin is a dual compartment protein that displays actin-bundling activity and redistributes between the nucleus and the cytoplasm in a differentiation-dependent and stress-induced fashion. We evaluated myopodin expression in initiation and progression of bladder cancer. Normal urothelium expresses myopodin in the cytoplasm and nuclei. Invasive bladder tumors showed decreased nuclear myopodin expression as compared to superficial lesions. This loss of nuclear myopodin expression was significantly associated with histopathological stage, tumor grade and overall patient survival in bladder tumors contained in tissue microarrays. We identified a differential nuclear expression for myopodin among bladder cancer cell lines during cell-cycle. Myopodin was present in the nucleus during G1/S in cells derived from superficial and low-grade lesions but not in those derived from invasive tumors. Loss of nuclear myopodin expression could classify bladder tumors and bladder cancer cell lines based on their histopathology. Most importantly, patients with preserved nuclear myopodin expression showed a longer survival. Nuclear myopodin expression in the context of cell-cycle progression may prove useful for staging bladder tumors and suggest a tumor suppressor role of myopodin in bladder cancer.	Mem Sloan Kettering Canc Ctr, Div Mol Pathol, New York, NY 10021 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA	Memorial Sloan Kettering Cancer Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Sanchez-Carbayo, M (corresponding author), Mem Sloan Kettering Canc Ctr, Div Mol Pathol, 1270 York Ave, New York, NY 10021 USA.		Schwarz, Karin/AAO-2819-2020	Schwarz, Karin/0000-0002-7328-1427				*AM JOINT COMM CAN, 1988, MAN STAG CANC, P194; American Cancer Society, 2000, CANC FACTS FIG; CordonCardo C, 1997, CANCER RES, V57, P1217; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; DALBAGNI G, 1993, LANCET, V342, P469, DOI 10.1016/0140-6736(93)91595-D; Dawson-Saunders B., 1994, BASIC CLIN BIOSTATIS; El-Rifai W, 2000, AM J PATHOL, V156, P871, DOI 10.1016/S0002-9440(10)64956-5; Giroldi LA, 1999, INT J CANCER, V82, P70, DOI 10.1002/(SICI)1097-0215(19990702)82:1<70::AID-IJC13>3.3.CO;2-R; Hoos A, 2001, AM J PATHOL, V158, P1245, DOI 10.1016/S0002-9440(10)64075-8; Koo SH, 1999, CANCER GENET CYTOGEN, V110, P87, DOI 10.1016/S0165-4608(98)00193-9; Lin F, 2001, AM J PATHOL, V159, P1603, DOI 10.1016/S0002-9440(10)63006-4; Lu ML, 2002, CLIN CANCER RES, V8, P171; Markl IDC, 1998, CANCER RES, V58, P5348; McShane LM, 2000, CLIN CANCER RES, V6, P1854; Mostofi FK, 1973, HISTOLOGICAL TYPING; Mundel P, 1997, J CELL BIOL, V139, P193, DOI 10.1083/jcb.139.1.193; Nix DA, 1997, J CELL BIOL, V138, P1139, DOI 10.1083/jcb.138.5.1139; Popov Z, 2000, BRIT J CANCER, V83, P209; REUTER VE, 1989, DIAGNOSTIC SURG PATH, P1355; REZNIKOFF CA, 1994, GENE DEV, V8, P2227, DOI 10.1101/gad.8.18.2227; ROSIN MP, 1995, CANCER RES, V55, P5213; SAHLAS DJ, 1993, J CELL SCI, V105, P347; Shaw ME, 1999, INT J CANCER, V80, P656, DOI 10.1002/(SICI)1097-0215(19990301)80:5&lt;656::AID-IJC4&gt;3.0.CO;2-A; Simon R, 2000, INT J ONCOL, V17, P1025; Simon R, 1998, J PATHOL, V185, P345; WANG Y, 2000, BIOCHIM BIOPHYS ACTA, V1538, P260; Weins A, 2001, J CELL BIOL, V155, P393, DOI 10.1083/jcb.200012039	27	42	44	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 14	2003	22	34					5298	5305		10.1038/sj.onc.1206616	http://dx.doi.org/10.1038/sj.onc.1206616			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917631				2022-12-17	WOS:000184734900009
J	Jandt, E; Denner, K; Kovalenko, M; Ostman, A; Bohmer, FD				Jandt, E; Denner, K; Kovalenko, M; Ostman, A; Bohmer, FD			The protein-tyrosine phosphatase DEP-1 modulates growth factor-stimulated cell migration and cell-matrix adhesion	ONCOGENE			English	Article						protein-tyrosine phosphatase; DEP-1; growth factor; cell migration; cell-matrix adhesion	SRC FAMILY KINASES; PDGF BETA-RECEPTOR; SITE-SELECTIVE DEPHOSPHORYLATION; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE C-GAMMA-1; IN-VIVO; CD148; ACTIVATION; CHEMOTAXIS; PHOSPHORYLATION	Density-enhanced protein-tyrosine phosphatase-1 (DEP-1 also CD148) is a transmembrane molecule with a single intracellular PTP domain. It has recently been proposed to function as a tumor suppressor. We have previously shown that DEP-1 dephosphorylates the activated platelet-derived growth factor (PDGF) beta-receptor in a site-selective manner (Kovalenko et al. (2000). J. Biol. Chem. 275, 16219-16226). We analysed cell lines with inducible DEP-1 expression for cellular functions of DEP-1. Several aspects of PDGFbeta-receptor signaling were negatively affected by DEP-1 expression. These include PDGF-stimulated activation of inositol trisphosphate formation, Erk1/2, p21Ras, and Src. Activation of receptor-associated phosphoinositide-3 kinase activity and of Akt/PKB were weakly attenuated at early time points of stimulation. Inhibition of PDGF-stimulated signaling depended on DEP-1 catalytic activity. Importantly, DEP-1 inhibited PDGF-stimulated cell migration. The catalytically inactive DEP-1 C1239S variant enhanced cell migration and PDGF-stimulated Erk1/2 activation, suggesting a dominant negative interference with endogenous DEP-1. In contrast to cell migration, cell-substrate adhesion was promoted by active DEP-1 and delayed or suppressed by DEP-1 C1239S, correlating with positive effects of DEP-1 on adhesion-stimulated Src kinase. We propose that negative regulation of growth-factor stimulated cell migration and promotion of cell-matrix adhesion may be related to the function of DEP-1 as tumor suppressor.	Univ Jena, Res Unit Mol Cell Biol, Fac Med, D-07747 Jena, Germany; Ludwig Inst Canc Res, Uppsala Branch, S-75123 Uppsala, Sweden	Friedrich Schiller University of Jena; Ludwig Institute for Cancer Research	Bohmer, FD (corresponding author), Univ Jena, Res Unit Mol Cell Biol, Fac Med, Drackendorfer Str 1, D-07747 Jena, Germany.							ARTEAGA CL, 1991, P NATL ACAD SCI USA, V88, P10435, DOI 10.1073/pnas.88.23.10435; Autschbach F, 1999, TISSUE ANTIGENS, V54, P485, DOI 10.1034/j.1399-0039.1999.540506.x; Baker JE, 2001, MOL CELL BIOL, V21, P2393, DOI 10.1128/MCB.21.7.2393-2403.2001; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Borges LG, 1996, CIRC RES, V79, P570, DOI 10.1161/01.RES.79.3.570; Cheng A, 2001, J BIOL CHEM, V276, P25848, DOI 10.1074/jbc.M009734200; Chiarugi P, 2000, J BIOL CHEM, V275, P4640, DOI 10.1074/jbc.275.7.4640; Chiarugi P, 2002, J CELL SCI, V115, P2219; ClaessonWelsh L, 1996, INT J BIOCHEM CELL B, V28, P373, DOI 10.1016/1357-2725(95)00156-5; COOPER JA, 1984, J BIOL CHEM, V259, P7835; COURTNEIDGE SA, 1993, DEVELOPMENT, P57; de la Fuente-Garcia MA, 1998, BLOOD, V91, P2800, DOI 10.1182/blood.V91.8.2800.2800_2800_2809; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779; Graness A, 1997, BIOCHEM J, V327, P147, DOI 10.1042/bj3270147; Gross S, 1999, J BIOL CHEM, V274, P26378, DOI 10.1074/jbc.274.37.26378; Hansen K, 1996, EMBO J, V15, P5299, DOI 10.1002/j.1460-2075.1996.tb00915.x; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; Holsinger LJ, 2002, ONCOGENE, V21, P7067, DOI 10.1038/sj.onc.1205858; Hundt M, 1997, EUR J IMMUNOL, V27, P3532, DOI 10.1002/eji.1830271255; Iuliano R, 2003, CANCER RES, V63, P882; Iuliano R, 2001, FEBS LETT, V500, P41, DOI 10.1016/S0014-5793(01)02580-7; Jallal B, 1997, J BIOL CHEM, V272, P12158, DOI 10.1074/jbc.272.18.12158; Keane MM, 1996, CANCER RES, V56, P4236; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kovalenko M, 2000, J BIOL CHEM, V275, P16219, DOI 10.1074/jbc.275.21.16219; KOVALENKO M, 1994, CANCER RES, V54, P6106; Mahboobi S, 2002, J MED CHEM, V45, P1002, DOI 10.1021/jm010988n; Ostman A, 2001, TRENDS CELL BIOL, V11, P258, DOI 10.1016/S0962-8924(01)01990-0; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; Palka HL, 2003, J BIOL CHEM, V278, P5728, DOI 10.1074/jbc.M210656200; Persson C, 2002, FEBS LETT, V517, P27, DOI 10.1016/S0014-5793(02)02570-X; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; Ronnstrand L, 1999, J BIOL CHEM, V274, P22089, DOI 10.1074/jbc.274.31.22089; RONNSTRAND L, 1988, J BIOL CHEM, V263, P10429; Ronnstrand L, 2001, INT J CANCER, V91, P757, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1136>3.0.CO;2-J; Ronnstrand L, 1999, ONCOGENE, V18, P3696, DOI 10.1038/sj.onc.1202705; Ruivenkamp CAL, 2002, NAT GENET, V31, P295, DOI 10.1038/ng903; Salazar EP, 2001, J BIOL CHEM, V276, P17788, DOI 10.1074/jbc.M100984200; Schraven B, 2000, J BIOL REG HOMEOS AG, V14, P220; Sorby M, 2001, ONCOGENE, V20, P5219, DOI 10.1038/sj.onc.1204581; Takahashi T, 1999, J AM SOC NEPHROL, V10, P2135; Takahashi T, 2003, MOL CELL BIOL, V23, P1817, DOI 10.1128/MCB.23.5.1817-1831.2003; Tangye SG, 1998, J IMMUNOL, V161, P3249; Tangye SG, 1998, J IMMUNOL, V161, P3803; Tenev T, 2000, EUR J CELL BIOL, V79, P261, DOI 10.1078/S0171-9335(04)70029-1; Venable CL, 2000, J BIOL CHEM, V275, P18318, DOI 10.1074/jbc.M908392199; Zhang L, 1997, EXP CELL RES, V235, P62, DOI 10.1006/excr.1997.3659	51	42	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 3	2003	22	27					4175	4185		10.1038/sj.onc.1206652	http://dx.doi.org/10.1038/sj.onc.1206652			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833140				2022-12-17	WOS:000183979800004
J	Ozaki, T; Watanabe, KI; Nakagawa, T; Miyazaki, K; Takahashi, M; Nakagawara, A				Ozaki, T; Watanabe, KI; Nakagawa, T; Miyazaki, K; Takahashi, M; Nakagawara, A			Function of p73, not of p53, is inhibited by the physical interaction with RACK1 and its inhibitory effect is counteracted by pRB	ONCOGENE			English	Article						p53; pRB; p73; RACK1; two-hybrid	PROTEIN-KINASE-C; DNA-BINDING FUNCTION; TRANSCRIPTIONAL ACTIVATION; GROWTH SUPPRESSION; MAMMALIAN-CELLS; CANCER TISSUES; BETA-SUBUNIT; APOPTOSIS; GENE; SUMO-1	The newly identified p53-related gene, p73, encodes a nuclear transcription factor. Unlike p53, p73 has various isoforms with different NH2- and COOH-terminal tails. p73alpha with the longest COOH-terminal extension is most abundantly expressed in many tissues and cells among those splicing isoforms of p73 and the COON-terminal region appears to have an autoregulatory function. To isolate and characterize the cellular protein(s) that interacts with the unique COOH-terminal region of p73alpha, we employed a yeast two-hybrid screen with a human fetal brain and 293 cell cDNA libraries. We identified the receptor for activated C kinase (RACK1) as a new member of p73alpha-binding proteins. The interaction was confirmed by coimmunoprecipitation experiments, whereas RACK1 did not interact with p53 or p73beta. Ectopic overexpression of RACK1 in SAOS-2 cells reduced the p73alpha-mediated transcription from the p53/ p73-responsive promoters, and inhibited the p73alpha-dependent apoptosis. On the other hand, the p53-dependent transcriptional activation as well as apoptosis was unaffected in the presence of RACK1. Furthermore, we found that pRB physically bound to RACK1, and repressed the RACK1-dependent inhibition of p73alpha. Taken together, our observations suggest that pRB diminishes the RACK1-mediated inhibition of p73alpha activity through the interaction with RACK1.	Chiba Canc Ctr, Res Inst, Div Biochem, Chuo Ku, Chiba 2608717, Japan	Chiba Cancer Center	Nakagawara, A (corresponding author), Chiba Canc Ctr, Res Inst, Div Biochem, Chuo Ku, 666-2 Nitona, Chiba 2608717, Japan.							Baumann M, 2000, EUR J BIOCHEM, V267, P3891, DOI 10.1046/j.1432-1327.2000.01430.x; Chang BY, 2001, J BIOL CHEM, V276, P20346, DOI 10.1074/jbc.M101375200; Chen CL, 2000, CLIN CANCER RES, V6, P3910; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Fang L, 1999, J CELL BIOL, V147, P823, DOI 10.1083/jcb.147.4.823; Fontemaggi G, 2001, MOL CELL BIOL, V21, P8461, DOI 10.1128/MCB.21.24.8461-8470.2001; Geijsen N, 1999, ONCOGENE, V18, P5126, DOI 10.1038/sj.onc.1202896; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Ikawa S, 1999, CELL DEATH DIFFER, V6, P1154, DOI 10.1038/sj.cdd.4400631; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kwek SSS, 2001, ONCOGENE, V20, P2587, DOI 10.1038/sj.onc.1204362; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; McLeod M, 2000, MOL CELL BIOL, V20, P4016, DOI 10.1128/MCB.20.11.4016-4027.2000; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; Ozaki T, 1999, CANCER RES, V59, P5902; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Prives C, 1999, J PATHOL, V187, P112; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; RON D, 1995, P NATL ACAD SCI USA, V92, P492, DOI 10.1073/pnas.92.2.492; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Sang NL, 2001, J BIOL CHEM, V276, P27026, DOI 10.1074/jbc.M010346200; Shaw P, 1996, ONCOGENE, V12, P921; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Watanabe K, 2002, J BIOL CHEM, V277, P15113, DOI 10.1074/jbc.M111281200; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; Zaika AI, 1999, CANCER RES, V59, P3257; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhu JH, 1998, CANCER RES, V58, P5061	60	42	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 22	2003	22	21					3231	3242		10.1038/sj.onc.1206382	http://dx.doi.org/10.1038/sj.onc.1206382			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761493				2022-12-17	WOS:000183040000005
J	Vigorito, E; Billadeu, DD; Savoy, D; McAdam, S; Doody, G; Fort, P; Turner, M				Vigorito, E; Billadeu, DD; Savoy, D; McAdam, S; Doody, G; Fort, P; Turner, M			RhoG regulates gene expression and the actin cytoskeleton in lymphocytes	ONCOGENE			English	Article						RhoG; Vav; lymphocytes; signalling; NFAT	ACTIVATED T-CELLS; VAV FAMILY; GTPASE-RHO; THYMOCYTE DEVELOPMENT; INDEPENDENT PATHWAYS; ADP-RIBOSYLATION; EXCHANGE FACTOR; WILD-TYPE; RAC; EFFECTOR	RhoG, a member of the Rho family of GTPases, has been implicated as a regulator of the actin cytoskeleton. In this study, we show a novel function for the small GTPase RhoG on the regulation of the interferon-gamma promoter and nuclear factor of activated T cells (NFAT) gene transcription in lymphocytes. Optimal function of RhoG for the expression of these genes requires a calcium signal, normally provided by the antigen receptor. In addition, RhoG potentiation of NFAT requires the indirect activity of Rac and Cdc42; however, pathways distinct from those activated by Rac and Cdc42 mediate RhoG activation of NFAT-dependent transcription. Using effector domain mutants of RhoG we found that its ability to potentiate NFAT-dependent transcription correlates with its capacity to increase actin polymerization, supporting the suggestion that NFAT-dependent transcription is an actin-dependent process. RhoG also promotes T-cell spreading on fibronectin, a property that is independent of its ability to enhance NFAT-dependent transcription. Hence, these results implicate RhoG in leukocyte trafficking and the control of gene expression induced in response to antigen encounter.	Babraham Inst, Mol Immunol Programme, Lab Lymphocyte Signalling & Dev, Cambridge CB2 4AT, England; Mayo Clin & Mayo Grad Sch Med, Dept Immunol, Rochester, MN 55905 USA; CNRS, Ctr Rech Biochim Macromol, IFR24,UPR 1086, Dept Immunol, F-34293 Montpellier, France	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Mayo Clinic; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Vigorito, E (corresponding author), Babraham Inst, Mol Immunol Programme, Lab Lymphocyte Signalling & Dev, Cambridge CB2 4AT, England.		Turner, Martin/N-9976-2014; Doody, Gina/AAN-8246-2021; Fort, Philippe/M-9498-2015	Turner, Martin/0000-0002-3801-9896; Doody, Gina/0000-0003-0665-6759; Fort, Philippe/0000-0001-5997-8722				Angkachatchai V, 1999, J IMMUNOL, V163, P3819; Arrieumerlou C, 2000, J IMMUNOL, V165, P3182, DOI 10.4049/jimmunol.165.6.3182; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Billadeau DD, 1998, J EXP MED, V188, P549, DOI 10.1084/jem.188.3.549; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Blangy A, 2000, J CELL SCI, V113, P729; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Corre I, 2001, J EXP MED, V194, P903, DOI 10.1084/jem.194.7.903; Costello PS, 2000, J EXP MED, V192, P77, DOI 10.1084/jem.192.1.77; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; Croker BA, 2002, J IMMUNOL, V168, P3376, DOI 10.4049/jimmunol.168.7.3376; D'Souza-Schorey C, 1998, MOL CELL BIOL, V18, P3936, DOI 10.1128/MCB.18.7.3936; Estrach S, 2002, CURR BIOL, V12, P307, DOI 10.1016/S0960-9822(02)00658-9; FAULL RJ, 1994, J EXP MED, V179, P1307, DOI 10.1084/jem.179.4.1307; GABIG TG, 1995, BLOOD, V85, P804, DOI 10.1182/blood.V85.3.804.bloodjournal853804; Galandrini R, 1997, IMMUNITY, V7, P163, DOI 10.1016/S1074-7613(00)80519-1; Gauthier-Rouviere C, 1998, MOL BIOL CELL, V9, P1379, DOI 10.1091/mbc.9.6.1379; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; Gomez M, 2000, NAT IMMUNOL, V1, P348, DOI 10.1038/79808; Gomez M, 2001, IMMUNITY, V15, P703, DOI 10.1016/S1074-7613(01)00235-7; Hashimoto A, 1998, J EXP MED, V188, P1287, DOI 10.1084/jem.188.7.1287; Henning SW, 1998, J EXP MED, V188, P931, DOI 10.1084/jem.188.5.931; Henning SW, 1997, EMBO J, V16, P2397, DOI 10.1093/emboj/16.9.2397; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; Jacinto E, 1998, IMMUNITY, V8, P31, DOI 10.1016/S1074-7613(00)80456-2; Katoh H, 2000, MOL CELL BIOL, V20, P7378, DOI 10.1128/MCB.20.19.7378-7387.2000; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; Krawczyk C, 2000, IMMUNITY, V13, P463, DOI 10.1016/S1074-7613(00)00046-7; Kuhne MR, 2000, J BIOL CHEM, V275, P2185, DOI 10.1074/jbc.275.3.2185; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LANG P, 1992, J BIOL CHEM, V267, P11677; Li BY, 2000, SCIENCE, V288, P2219, DOI 10.1126/science.288.5474.2219; Lores P, 1997, ONCOGENE, V15, P601, DOI 10.1038/sj.onc.1201378; MALY FE, 1994, J BIOL CHEM, V269, P18743; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Na SQ, 1999, ONCOGENE, V18, P7966, DOI 10.1038/sj.onc.1203122; Reynolds LF, 2002, J EXP MED, V195, P1103, DOI 10.1084/jem.20011663; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Schuebel KE, 1996, ONCOGENE, V13, P363; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; Vignal E, 2001, MOL CELL BIOL, V21, P8022, DOI 10.1128/MCB.21.23.8022-8034.2001; Villalba M, 2000, IMMUNITY, V12, P151, DOI 10.1016/S1074-7613(00)80168-5; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; Wardenburg JB, 1998, IMMUNITY, V9, P607, DOI 10.1016/S1074-7613(00)80658-5; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Wielowieyski PA, 2000, J BIOL CHEM, V275, P38474, DOI 10.1074/jbc.M007682200; Yablonski D, 1998, EMBO J, V17, P5647, DOI 10.1093/emboj/17.19.5647	52	42	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 23	2003	22	3					330	342		10.1038/sj.onc.1206116	http://dx.doi.org/10.1038/sj.onc.1206116			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545154				2022-12-17	WOS:000180379100002
J	Labbaye, C; Quaranta, MT; Pagliuca, A; Militi, S; Licht, JD; Testa, U; Peschle, C				Labbaye, C; Quaranta, MT; Pagliuca, A; Militi, S; Licht, JD; Testa, U; Peschle, C			PLZF induces megakaryocytic development, activates Tpo receptor expression and interacts with GATA1 protein	ONCOGENE			English	Article						megakaryopoiesis; PLZF; GATA1; Tpo receptor	ACUTE PROMYELOCYTIC LEUKEMIA; TRANSCRIPTION FACTOR GATA-1; ZINC-FINGER PROTEIN; PURIFIED HEMATOPOIETIC PROGENITORS; NORMAL ADULT HEMATOPOIESIS; PML-RAR-ALPHA; POZ-DOMAIN; HISTONE DEACETYLASE; INTERACTION MOTIF; FUSION PARTNERS	We investigated the expression of the PLZF gene in purified human hematopoietic progenitors induced to unilineage erythroid, granulocytic or megakaryocytic differentiation and maturation in serum-free culture. PLZF is expressed in quiescent progenitors: the expression level progressively rises through megakaryocytic development, whereas it gradually declines in erythroid and granulopoietic culture. To investigate the role of PLZF in megakaryopoiesis, we transduced the PLZF gene into the erythro-megakaryocytic TF1 cell line. PLZF overexpression upmodulates the megakaryocytic specific markers (CD42a, CD42b, CD61, PF4) and induces the thrombopoietin receptor (TpoR). The proximal promoter of the TpoR gene is activated in PLZF-expressing TF1 cells: in this promoter region, a PLZF DNA-binding site was identified by deletion constructs studies. Interestingly, PLZF and GATA1 proteins coimmunoprecipitate in PLZF-expressing TF1 cells: enforced expression of both PLZF and GATA1 in TF1 cells results in increased upregulation of megakaryocytic markers, as compared to exogenous PLZF or GATA1 alone, suggesting a functional role for the PLZF/GATA1 complex. Our data indicate that PLZF plays a significant stimulatory role in megakaryocytic development, seemingly mediated in part by induction of TpoR expression at transcriptional level. This stimulatory effect is potentiated by physical interaction of PLZF and GATA1, which are possibly assembled in a multiprotein transcriptional complex.	Ist Super Sanita, Dept Hematol Oncol, I-00161 Rome, Italy; Mt Sinai Sch Med, New York, NY USA; Thomas Jefferson Univ, Philadelphia, PA 19107 USA	Istituto Superiore di Sanita (ISS); Icahn School of Medicine at Mount Sinai; Jefferson University	Labbaye, C (corresponding author), Ist Super Sanita, Dept Hematol Oncol, Viale Regina Elena 299, I-00161 Rome, Italy.		Pagliuca, Alfredo/AAI-3689-2020; Testa, Ugo/J-6472-2016; Licht, Jonathan/AAL-9184-2020; pagliuca, alfredo/J-3107-2012; Labbaye, Catherine/J-9930-2016; Quaranta, Maria Teresa/AAC-2134-2019; Licht, Jonathan/L-4239-2019	Testa, Ugo/0000-0001-7900-8942; Licht, Jonathan/0000-0002-3942-1369; pagliuca, alfredo/0000-0002-8703-2077; Quaranta, Maria Teresa/0000-0002-5886-507X; Labbaye, Catherine/0000-0003-1255-4396	NATIONAL CANCER INSTITUTE [R01CA059936] Funding Source: NIH RePORTER; NCI NIH HHS [CA 59936] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad KF, 1998, P NATL ACAD SCI USA, V95, P12123, DOI 10.1073/pnas.95.21.12123; Albagli O, 1999, ONCOGENE, V18, P5063, DOI 10.1038/sj.onc.1202892; Ball HJ, 1999, NUCLEIC ACIDS RES, V27, P4106, DOI 10.1093/nar/27.20.4106; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; CHEN SJ, 1993, J CLIN INVEST, V91, P2260, DOI 10.1172/JCI116453; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; CHEN ZX, 1991, BLOOD, V78, P1413; Condorelli GL, 1997, MOL CELL BIOL, V17, P2954, DOI 10.1128/MCB.17.5.2954; COOK M, 1995, P NATL ACAD SCI USA, V92, P2249, DOI 10.1073/pnas.92.6.2249; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; Davies JM, 1999, ONCOGENE, V18, P365, DOI 10.1038/sj.onc.1202332; Deveaux S, 1996, BLOOD, V87, P4678, DOI 10.1182/blood.V87.11.4678.bloodjournal87114678; Dhordain P, 2000, ONCOGENE, V19, P6240, DOI 10.1038/sj.onc.1203976; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; GABBIANELLI M, 1990, SCIENCE, V249, P1561, DOI 10.1126/science.2218497; GODIN IE, 1993, NATURE, V364, P67, DOI 10.1038/364067a0; GREGORY RC, 1996, BLOOD, V87, P1763; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grignani F, 1998, CANCER RES, V58, P14; GUERRIERO R, 1995, BLOOD, V86, P3725, DOI 10.1182/blood.V86.10.3725.bloodjournal86103725; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; Hawe N, 1996, BLOOD, V88, P1151; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hoatlin ME, 1999, BLOOD, V94, P3737, DOI 10.1182/blood.V94.11.3737.423k39_3737_3747; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Ivins S, 1998, BLOOD, V92, p308A; Koken MHM, 1997, P NATL ACAD SCI USA, V94, P10255, DOI 10.1073/pnas.94.19.10255; KOTANI H, 1994, HUM GENE THER, V5, P19, DOI 10.1089/hum.1994.5.1-19; Labbaye C, 1999, ONCOGENE, V18, P3529, DOI 10.1038/sj.onc.1202682; LABBAYE C, 1995, J CLIN INVEST, V95, P2346, DOI 10.1172/JCI117927; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Long JJ, 1998, MOL CELL BIOL, V18, P1467, DOI 10.1128/MCB.18.3.1467; MAOUCHE L, 1991, BLOOD, V78, P2557; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MIGNOTTE V, 1994, GENOMICS, V20, P5, DOI 10.1006/geno.1994.1120; ORKIN SH, 1992, BLOOD, V80, P575; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; TABILIO A, 1984, EMBO J, V3, P453, DOI 10.1002/j.1460-2075.1984.tb01827.x; Takahashi S, 1998, BLOOD, V92, P434, DOI 10.1182/blood.V92.2.434.414k24_434_442; Testa U, 1996, BLOOD, V88, P3391, DOI 10.1182/blood.V88.9.3391.bloodjournal8893391; TSANG AH, 1997, CELL, V90, P459; VALTIERI M, 1994, CANCER RES, V54, P4398; Vignon I, 1992, P NATL ACAD SCI USA, V89, P5640; Vyas P, 1999, BLOOD, V93, P2867; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Ward JO, 2001, BLOOD, V98, P3290, DOI 10.1182/blood.V98.12.3290; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; Yamaguchi Y, 1998, BLOOD, V91, P450, DOI 10.1182/blood.V91.2.450.450_450_457; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705; Zhang T, 1999, P NATL ACAD SCI USA, V96, P11422, DOI 10.1073/pnas.96.20.11422; Zimmet J, 2000, EXP HEMATOL, V28, P3, DOI 10.1016/S0301-472X(99)00124-1	61	42	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2002	21	43					6669	6679		10.1038/sj.onc.1205884	http://dx.doi.org/10.1038/sj.onc.1205884			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242665				2022-12-17	WOS:000178202300013
J	Gemmill, RM; Bemis, LT; Lee, JP; Sozen, MA; Baron, A; Zeng, C; Erickson, PF; Hooper, JE; Drabkin, HA				Gemmill, RM; Bemis, LT; Lee, JP; Sozen, MA; Baron, A; Zeng, C; Erickson, PF; Hooper, JE; Drabkin, HA			The TRC8 hereditary kidney cancer gene suppresses growth and functions with VHL in a common pathway	ONCOGENE			English	Article						TRC8; VHL; renal cell carcinoma; JAB1/CSN-5; patched; RING-H2 finger	26S PROTEASOME; HUMAN HOMOLOG; RENAL-CARCINOMA; JAB1 INTERACTS; CNS MIDLINE; CELL-CYCLE; HIF-ALPHA; DROSOPHILA; PROTEIN; COMPLEX	VHL is part of an SCF related E3-ubiquitin ligase complex with 'gatekeeper' function in renal carcinoma. However, no mutations have been identified in VHL interacting proteins in wild type VHL tumors. We previously reported that the TRC8 gene was interrupted by a t(3;8) translocation in a family with hereditary renal and non-medullary thyroid cancer. TRC8 encodes a multi-membrane spanning protein containing a RING-H2 finger with in vitro ubiquitin ligase activity. We isolated the Drosophila homologue, DTrc8, and studied its function by genetic manipulations and a yeast 2-hybrid screen. Human and Drosophila TRC8 proteins localize to the endoplasmic reticulum. Loss of either DTrc8 or DVhl resulted in an identical ventral midline defect. Direct interaction between DTrc8 and DVhl was confirmed by GST-pulldown and co-immunoprecipitation experiments. CSN-5/JAB1 is a component of the COP9 signalosome, recently shown to regulate SCF function. We found that DTrc8 physically interacts with CSN-5 and that human JAB1 localization is dependent on VHL mutant status. Lastly, overexpression of DTrc8 inhibited growth consistent with its presumed role as a tumor suppressor gene. Thus, VHL, TRC8, and JAB1 appear to be linked both physically and functionally and all three may participate in the development of kidney cancer.	Univ Colorado, Hlth Sci Ctr, Div Med Oncol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Cellular & Struct Biol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Gemmill, RM (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Med Oncol, Box B-171,4200 E 9th Ave, Denver, CO 80262 USA.	robert.gemmill@uchsc.edu		Bemis, Lynne/0000-0001-9986-7154	NATIONAL CANCER INSTITUTE [R01CA076035, P30CA046934] Funding Source: NIH RePORTER; NCI NIH HHS [CA76035, CA46934] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adryan B, 2000, ONCOGENE, V19, P2803, DOI 10.1038/sj.onc.1203611; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; Bae MK, 2002, J BIOL CHEM, V277, P9, DOI 10.1074/jbc.C100442200; Bays NW, 2001, NAT CELL BIOL, V3, P24, DOI 10.1038/35050524; Bianchi E, 2000, NATURE, V404, P617, DOI 10.1038/35007098; BRAND AH, 1993, DEVELOPMENT, V118, P401; Bruni P, 2000, ONCOGENE, V19, P3146, DOI 10.1038/sj.onc.1203633; Chauchereau A, 2000, J BIOL CHEM, V275, P8540, DOI 10.1074/jbc.275.12.8540; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Clifford SC, 2001, ONCOGENE, V20, P5067, DOI 10.1038/sj.onc.1204602; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; Davy A, 2001, EMBO REP, V2, P821, DOI 10.1093/embo-reports/kve184; Deak PM, 2001, J BIOL CHEM, V276, P10663, DOI 10.1074/jbc.M008608200; Ferrell K, 2000, TRENDS BIOCHEM SCI, V25, P83, DOI 10.1016/S0968-0004(99)01529-7; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Gemmill RM, 1998, P NATL ACAD SCI USA, V95, P9572, DOI 10.1073/pnas.95.16.9572; Gorospe M, 1999, MOL CELL BIOL, V19, P1289; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P204, DOI 10.1016/S0968-0004(98)01217-1; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Ivan M, 2001, CURR OPIN GENET DEV, V11, P27, DOI 10.1016/S0959-437X(00)00152-0; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; LI FP, 1993, ANN INTERN MED, V118, P106, DOI 10.7326/0003-4819-118-2-199301150-00005; Li SH, 2000, J BIOL CHEM, V275, P13386, DOI 10.1074/jbc.275.18.13386; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Nambu JR, 1996, GENE, V172, P249, DOI 10.1016/0378-1119(96)00060-1; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Schoenfeld AR, 2001, INT J CANCER, V91, P457, DOI 10.1002/1097-0215(20010215)91:4<457::AID-IJC1072>3.0.CO;2-P; Schwechheimer C, 2001, SCIENCE, V292, P1379, DOI 10.1126/science.1059776; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Sonnenfeld M, 1997, DEVELOPMENT, V124, P4571; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413; Zelzer E, 1997, GENE DEV, V11, P2079, DOI 10.1101/gad.11.16.2079	48	42	47	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3507	3516		10.1038/sj.onc.1205437	http://dx.doi.org/10.1038/sj.onc.1205437			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032852				2022-12-17	WOS:000175793700001
J	Sunesen, M; Stevnsner, T; Brosh, RM; Dianov, GL; Bohr, VA				Sunesen, M; Stevnsner, T; Brosh, RM; Dianov, GL; Bohr, VA			Global genome repair of 8-oxoG in hamster cells requires a functional CSB gene product	ONCOGENE			English	Article						oxidative DNA damage; repair; DNA instability; Cockayne syndrome	BASE EXCISION-REPAIR; OXIDATIVE DNA-DAMAGE; TRANSCRIPTION-COUPLED REPAIR; POLYMERASE-II TRANSCRIPTION; COCKAYNE-SYNDROME PATIENTS; RETRACTED ARTICLE. SEE; RNA-POLYMERASE; MITOCHONDRIAL REPAIR; FACTOR CSB/ERCC6; ACIDIC REGION	Cockayne syndrome (CS) is an autosomal recessive human disease characterized by UV-sensitivity as well as neurological and developmental abnormalities. Two complementation groups have been established, designated CS-A and CS-B. Traditionally, CSA and CSB have been ascribed a function in the transcription-coupled repair (TCR) pathway of nucleotide excision repair (NER) that efficiently removes bulky lesions from the transcribed strand of RNA polymerase 11 transcribed genes. To assess the role of the CSB protein in the repair of the highly mutagenic base lesion 7,8-dihydro-8-oxoguanine (8-oxoG), we have investigated the removal of this lesion using an in vitro incision approach with cell extracts as well as an in vivo approach with a modified protocol of the gene-specific repair assay, which allows the measurement of base lesion repair in intragenomic sequences. Our results demonstrate that the integrity of the CSB protein is pivotal for processes leading to incision at the site of 8-oxoG and that the global genome repair (GGR) of this lesion requires a functional CSB gene product in vivo.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; Aarhus Univ, Dept Biol Mol & Struct, DK-8000 Aarhus C, Denmark	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Aarhus University	Bohr, VA (corresponding author), NIA, Lab Mol Gerontol, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	Vbohr@nih.gov	Bohr, Vilhelm/AAP-5931-2020	Stevnsner, Tinna/0000-0003-1007-0427				Anson RM, 1998, NUCLEIC ACIDS RES, V26, P662, DOI 10.1093/nar/26.2.662; Anson RM, 1999, METH MOL B, V113, P257; Balajee AS, 1997, P NATL ACAD SCI USA, V94, P4306, DOI 10.1073/pnas.94.9.4306; BESSHO T, 1993, P NATL ACAD SCI USA, V90, P8901, DOI 10.1073/pnas.90.19.8901; Bessho T, 1999, NUCLEIC ACIDS RES, V27, P979, DOI 10.1093/nar/27.4.979; Bjoras M, 1997, EMBO J, V16, P6314, DOI 10.1093/emboj/16.20.6314; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; Bohr VA, 1999, BIOCHIMIE, V81, P155, DOI 10.1016/S0300-9084(99)80048-0; BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016; Boiteux S, 1999, BIOCHIMIE, V81, P59, DOI 10.1016/S0300-9084(99)80039-X; Brosh RM, 1999, MOL BIOL CELL, V10, P3583, DOI 10.1091/mbc.10.11.3583; CHENG KC, 1992, J BIOL CHEM, V267, P166; Citterio E, 1998, J BIOL CHEM, V273, P11844, DOI 10.1074/jbc.273.19.11844; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; Dianov G, 1999, NUCLEIC ACIDS RES, V27, P1365, DOI 10.1093/nar/27.5.1365; Dianov G, 1998, J BIOL CHEM, V273, P33811, DOI 10.1074/jbc.273.50.33811; Dianov GL, 1997, NUCLEIC ACIDS RES, V25, P3636, DOI 10.1093/nar/25.18.3636; Engelward BP, 1997, P NATL ACAD SCI USA, V94, P13087, DOI 10.1073/pnas.94.24.13087; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; Grishko VI, 1997, MUTAT RES-DNA REPAIR, V384, P73, DOI 10.1016/S0921-8777(97)00017-7; Hazra IK, 1998, NUCLEIC ACIDS RES, V26, P5116, DOI 10.1093/nar/26.22.5116; HENNING KA, 1995, CELL, V82, P555, DOI 10.1016/0092-8674(95)90028-4; HTUN H, 1992, METHOD ENZYMOL, V212, P272; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Krokan HE, 2000, FEBS LETT, V476, P73, DOI 10.1016/S0014-5793(00)01674-4; Krokan HE, 1997, BIOCHEM J, V325, P1; Kung HC, 1997, J BIOL CHEM, V272, P9227; Le Page F, 1999, BIOCHIMIE, V81, P147, DOI 10.1016/S0300-9084(99)80047-9; Le Page F, 2000, P NATL ACAD SCI USA, V97, P8397, DOI 10.1073/pnas.140137297; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; LEHMANN AR, 1982, MUTAT RES, V106, P347, DOI 10.1016/0027-5107(82)90115-4; LIN JJ, 1989, BIOCHEMISTRY-US, V28, P7979, DOI 10.1021/bi00446a002; Ljungman M, 1996, ONCOGENE, V13, P823; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MAYNE LV, 1982, CANCER RES, V42, P1473; Memisoglu A, 2000, MUTAT RES-FUND MOL M, V451, P39, DOI 10.1016/S0027-5107(00)00039-7; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; Nouspikel T, 1997, P NATL ACAD SCI USA, V94, P3116, DOI 10.1073/pnas.94.7.3116; Reardon JT, 1997, P NATL ACAD SCI USA, V94, P9463, DOI 10.1073/pnas.94.17.9463; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Rolig RL, 2000, TRENDS NEUROSCI, V23, P417, DOI 10.1016/S0166-2236(00)01625-8; Selby CP, 1997, P NATL ACAD SCI USA, V94, P11205, DOI 10.1073/pnas.94.21.11205; Selby CP, 1997, J BIOL CHEM, V272, P1885, DOI 10.1074/jbc.272.3.1885; SHIVJI MKK, 1994, J BIOL CHEM, V269, P22749; Sunesen M, 2000, NUCLEIC ACIDS RES, V28, P3151, DOI 10.1093/nar/28.16.3151; Taffe BG, 1996, MUTAT RES-DNA REPAIR, V364, P183, DOI 10.1016/S0921-8777(96)00031-6; Tantin D, 1998, J BIOL CHEM, V273, P27794, DOI 10.1074/jbc.273.43.27794; Tantin D, 1997, MOL CELL BIOL, V17, P6803, DOI 10.1128/MCB.17.12.6803; THORSLUND T, 2002, IN PRESS DNA REPAIR; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; vanGool AJ, 1997, EMBO J, V16, P4155, DOI 10.1093/emboj/16.14.4155; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; Viswanathan A, 1998, J BIOL CHEM, V273, P21276, DOI 10.1074/jbc.273.33.21276; Will O, 1999, MUTAT RES-DNA REPAIR, V435, P89, DOI 10.1016/S0921-8777(99)00039-7; Woods CG, 1998, ARCH DIS CHILD, V78, P178, DOI 10.1136/adc.78.2.178	57	42	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3571	3578		10.1038/sj.onc.1205443	http://dx.doi.org/10.1038/sj.onc.1205443			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032859				2022-12-17	WOS:000175793700008
J	Wang, ZO; Kyo, S; Maida, Y; Takakura, M; Tanaka, M; Yatabe, N; Kanaya, T; Nakamura, M; Koike, K; Hisamoto, K; Ohmichi, M; Inoue, M				Wang, ZO; Kyo, S; Maida, Y; Takakura, M; Tanaka, M; Yatabe, N; Kanaya, T; Nakamura, M; Koike, K; Hisamoto, K; Ohmichi, M; Inoue, M			Tamoxifen regulates human telomerase reverse transcriptase (hTERT) gene expression differently in breast and endometrial cancer cells	ONCOGENE			English	Article						tamoxifen; telomerase; hTERT; endometrial cancer; breast cancer	ACTIVATED PROTEIN-KINASE; HUMAN ESTROGEN-RECEPTOR; PROMOTER-CONTEXT; IMMORTAL CELLS; PATHWAY; PHOSPHORYLATION; GROWTH	Tamoxifen is widely applied as an antiestrogenic agent for adjuvant therapy in the treatment of breast cancer, while its estrogen-agonistic activity occasionally causes proliferative disorders or carcinogenesis at other sites, such as the uterus. We reported that estrogen activates telomerase in breast and endometrial cancer cells. The present study examines the effects of tamoxifen on the gene expression of human telomerase reverse transcriptase (hTERT) in breast and endometrial cancer cells. Tamoxifen inhibited the cell growth of MCF-7 cells, as well as hTERT mRNA expression in the presence of estrogen (E2), antagonizing the E2 effects. In contrast, tamoxifen stimulated the growth of Ishikawa cells and activated hTERT mRNA expression in the absence or presence of E2, exhibiting estrogen-agonistic action. Transient expression assays revealed that these actions of tamoxifen are achieved by transcriptional regulation of the hTERT promoter. An estrogen responsive element (ERE) in the hTERT 5' regulatory region was partly responsible for both the E2-antagonistic and -agonistic actions of tamoxifen. Tamoxifen activated the MAP kinase cascade in Ishikawa cells, but not in MCF-7 cells, and the activation of hTERT mRNA expression was effectively blocked by MEK inhibitor, suggesting that the MAP kinase pathway is involved in the tamoxifen-induced activation of hTERT. These findings indicate that tamoxifen regulates hTERT expression in a cell-type specific manner. Tamoxifen-induced activation of hTERT may be one component of estrogen agonistic function of tamoxifen that is involved in endometrial carcinogenesis induced by this agent.	Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, Kanazawa, Ishikawa 9208641, Japan; Osaka Univ, Sch Med, Dept Obstet & Gynecol, Suita, Osaka 6560871, Japan	Kanazawa University; Osaka University	Kyo, S (corresponding author), Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan.	satoruky@med.kanazawa-u.ac.jp	Takakura, Masahiro/E-1080-2011					Bergman L, 2000, LANCET, V356, P881, DOI 10.1016/S0140-6736(00)02677-5; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Colacurci N, 2000, PANMINERVA MED, V42, P45; Collins P, 1999, NAT MED, V5, P1130, DOI 10.1038/13453; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Endoh H, 1997, BIOCHEM BIOPH RES CO, V235, P99, DOI 10.1006/bbrc.1997.6746; Goldstein SR, 2000, EUR J CANCER, V36, pS54; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; Ito H, 1998, CLIN CANCER RES, V4, P1603; JAMIL A, 1991, J MOL ENDOCRINOL, V6, P215, DOI 10.1677/jme.0.0060215; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kyo S, 1999, INT J CANCER, V80, P60, DOI 10.1002/(SICI)1097-0215(19990105)80:1<60::AID-IJC12>3.3.CO;2-5; Kyo S, 1999, CANCER RES, V59, P5917; Lasset C, 2001, LANCET, V357, P66, DOI 10.1016/S0140-6736(05)71563-4; Mandlekar S, 2000, CANCER RES, V60, P5995; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Norris JD, 1996, MOL ENDOCRINOL, V10, P1605, DOI 10.1210/mend.10.12.8961270; Norris JD, 1999, SCIENCE, V285, P744, DOI 10.1126/science.285.5428.744; Schwartz LB, 1997, AM J OBSTET GYNECOL, V176, P129, DOI 10.1016/S0002-9378(97)80025-7; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Singer CA, 1999, J NEUROSCI, V19, P2455; Smith SMR, 2000, AM J SURG, V180, P249, DOI 10.1016/S0002-9610(00)00453-0; Soda H, 2000, PROSTATE, V43, P161, DOI 10.1002/(SICI)1097-0045(20000515)43:3<161::AID-PROS1>3.0.CO;2-O; Sundaresan S, 1996, ENDOCRINOLOGY, V137, P304, DOI 10.1210/en.137.1.304; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Wang Z, 2000, CANCER RES, V60, P5376; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; Zhang CC, 2000, J BIOL CHEM, V275, P479, DOI 10.1074/jbc.275.1.479	36	42	46	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3517	3524		10.1038/sj.onc.1205463	http://dx.doi.org/10.1038/sj.onc.1205463			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032853				2022-12-17	WOS:000175793700002
J	Liebermann, DA; Hoffman, B				Liebermann, DA; Hoffman, B			Myeloid differentiation (MyD) primary response genes in hematopoiesis	ONCOGENE			English	Review						IRF-1; EGR-1; Jun; MyD88; MyD118; GADD45	NF-KAPPA-B; FINGER TRANSCRIPTION FACTOR; HERPES-SIMPLEX-VIRUS; IMMEDIATE-EARLY RESPONSE; CELL NUCLEAR ANTIGEN; REGULATORY FACTOR-I; SIGNAL-TRANSDUCTION PATHWAY; RECEPTOR ACCESSORY PROTEIN; LEUKEMIA INHIBITORY FACTOR; INTERLEUKIN-1 RECEPTOR	Myeloid Differentiation (MyD) primary response and Growth Arrest DNA-Damage (Gadd) genes comprise a set of overlapping genes, including known (IRF-1, EGR-1, Jun) and novel (MyD88, Gadd45alpha MyD118/ Gadd45beta, GADD45gamma, MyD1161/Gadd34) genes, that have been cloned by virtue of there being co-ordinately induced upon the onset of terminal myeloid differentiation. This review delineates the role MyD genes play in blood cell development, where they function as positive regulators of terminal differentiation, lineage specific blood cell development and control of blood cell homeostasis, including growth inhibition and apoptosis.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Liebermann, DA (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.	lieberma@unix.temple.edu; hoffman@unix.temple.edu			NATIONAL CANCER INSTITUTE [R01CA059774, R01CA043618] Funding Source: NIH RePORTER; NCI NIH HHS [1R01CA43618, 1R01CA59774] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDOLLAHI A, 1991, ONCOGENE, V6, P165; ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Adler HT, 1999, MOL CELL BIOL, V19, P7050; Aizawa S, 1997, J BIOL CHEM, V272, P2042; Amundson SA, 2000, CANCER RES, V60, P6101; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; Azam N, 2001, J BIOL CHEM, V276, P2766, DOI 10.1074/jbc.M005626200; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BEADLING C, 1993, P NATL ACAD SCI USA, V90, P2719, DOI 10.1073/pnas.90.7.2719; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; Brown SM, 1997, J VIROL, V71, P9442, DOI 10.1128/JVI.71.12.9442-9449.1997; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Carrier F, 1999, MOL CELL BIOL, V19, P1673; Chan TA, 2000, GENE DEV, V14, P1584; Cheung KJ, 2001, CANCER RES, V61, P4974; CHOU J, 1994, P NATL ACAD SCI USA, V91, P5247, DOI 10.1073/pnas.91.12.5247; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; DIXON LK, 1994, J GEN VIROL, V75, P1655, DOI 10.1099/0022-1317-75-7-1655; Duckett CS, 1997, MOL CELL BIOL, V17, P1535, DOI 10.1128/MCB.17.3.1535; Dupraz P, 2000, J BIOL CHEM, V275, P37672, DOI 10.1074/jbc.M005150200; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDON E, 1994, DEVELOPMENT, V120, P885; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Fantuzzi G, 2001, EUR J IMMUNOL, V31, P369, DOI 10.1002/1521-4141(200102)31:2<369::AID-IMMU369>3.0.CO;2-Y; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; FORNACE AJ, 1992, ANN NY ACAD SCI, V663, P139, DOI 10.1111/j.1749-6632.1992.tb38657.x; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GALINDO RL, 1995, DEVELOPMENT, V121, P2209; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; GRIGORIADIS AE, 1995, TRENDS GENET, V11, P436, DOI 10.1016/S0168-9525(00)89142-8; Grimm S, 1996, P NATL ACAD SCI USA, V93, P10923, DOI 10.1073/pnas.93.20.10923; GROSSHANS J, 1994, NATURE, V372, P563, DOI 10.1038/372563a0; GUILLOUF C, 1995, BLOOD, V85, P2691, DOI 10.1182/blood.V85.10.2691.bloodjournal85102691; HARADA H, 1994, ONCOGENE, V9, P3313; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; Hardiman G, 1996, ONCOGENE, V13, P2467; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HARPER JW, 1993, CELL, V75, P805; Hasegawa T, 1999, BIOCHEM BIOPH RES CO, V256, P249, DOI 10.1006/bbrc.1999.0275; Hasegawa T, 1999, BBA-GEN SUBJECTS, V1428, P161, DOI 10.1016/S0304-4165(99)00060-4; Hasegawa T, 2000, BIOCHEM BIOPH RES CO, V267, P593, DOI 10.1006/bbrc.1999.1991; Hasegawa T, 2000, BIOCHEM J, V352, P795, DOI 10.1042/0264-6021:3520795; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; He B, 1997, P NATL ACAD SCI USA, V94, P843, DOI 10.1073/pnas.94.3.843; He B, 1996, J VIROL, V70, P84, DOI 10.1128/JVI.70.1.84-90.1996; HOFMANN K, 1995, FEBS LETT, V371, P321, DOI 10.1016/0014-5793(95)00931-X; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Hollander MC, 2001, INT J CANCER, V96, P22, DOI 10.1002/1097-0215(20010220)96:1<22::AID-IJC3>3.0.CO;2-K; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Huang JN, 1997, P NATL ACAD SCI USA, V94, P12829, DOI 10.1073/pnas.94.24.12829; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; HULTMARK D, 1994, BIOCHEM BIOPH RES CO, V199, P144, DOI 10.1006/bbrc.1994.1206; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; ITOH N, 1993, J BIOL CHEM, V268, P10932; Janeway C.A., 1999, IMMUNOBIOLOGY IMMUNE; Jaunin F, 1998, EXP CELL RES, V243, P67, DOI 10.1006/excr.1998.4131; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Kaisho T, 2001, TRENDS IMMUNOL, V22, P78, DOI 10.1016/S1471-4906(00)01811-1; Karin M, 1998, CANCER J SCI AM, V4, pS92; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kelman Z, 1998, TRENDS BIOCHEM SCI, V23, P236, DOI 10.1016/S0968-0004(98)01223-7; Kojima S, 1999, FEBS LETT, V446, P313, DOI 10.1016/S0014-5793(99)00234-3; Korherr C, 1997, EUR J IMMUNOL, V27, P262, DOI 10.1002/eji.1830270139; Kovalsky O, 2001, J BIOL CHEM, V276, P39330, DOI 10.1074/jbc.M105115200; Krishnaraju K, 1998, BLOOD, V92, P1957, DOI 10.1182/blood.V92.6.1957.418k24_1957_1966; KRISHNARAJU K, 1995, MOL CELL BIOL, V15, P5499; Krishnaraju K, 2001, BLOOD, V97, P1298, DOI 10.1182/blood.V97.5.1298; Krishnaraju K, 1997, BLOOD, V90, P1840, DOI 10.1182/blood.V90.5.1840; Lee SL, 1996, MOL CELL BIOL, V16, P4566; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; LETSOU A, 1993, EMBO J, V12, P3449, DOI 10.1002/j.1460-2075.1993.tb06019.x; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Liebermann DA, 1998, INT J ONCOL, V12, P685; Liebermann DA, 1998, ONCOGENE, V17, P3319, DOI 10.1038/sj.onc.1202574; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; Liu CT, 1998, CANCER GENE THER, V5, P3; Lohoff M, 1997, IMMUNITY, V6, P681, DOI 10.1016/S1074-7613(00)80444-6; LORD KA, 1990, ONCOGENE, V5, P387; LORD KA, 1990, ONCOGENE, V5, P1095; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; LORD KA, 1990, NUCLEIC ACIDS RES, V18, P2823, DOI 10.1093/nar/18.9.2823; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; Lovenberg TW, 1996, J NEUROIMMUNOL, V70, P113, DOI 10.1016/S0165-5728(96)00047-1; Lu BF, 2001, IMMUNITY, V14, P583, DOI 10.1016/S1074-7613(01)00141-8; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MAYEDA A, 1993, MOL CELL BIOL, V13, P2993, DOI 10.1128/MCB.13.5.2993; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; Mitcham JL, 1996, J BIOL CHEM, V271, P5777, DOI 10.1074/jbc.271.10.5777; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Nakanishi K, 2001, NAT IMMUNOL, V2, P140, DOI 10.1038/84236; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; Norris JL, 1996, GENE DEV, V10, P862, DOI 10.1101/gad.10.7.862; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; Parker JE, 1997, PLANT CELL, V9, P879, DOI 10.1105/tpc.9.6.879; Parnet P, 1996, J BIOL CHEM, V271, P3967; Passegue E, 2001, CELL, V104, P21, DOI 10.1016/S0092-8674(01)00188-X; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; Schmidt A, 2001, MOL CELL BIOL, V21, P438, DOI 10.1128/MCB.21.2.438-448.2001; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; Shaulian E, 1999, J BIOL CHEM, V274, P29595, DOI 10.1074/jbc.274.42.29595; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Smith ML, 1996, ONCOGENE, V13, P2255; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; SQUIER MKT, 1995, J LEUKOCYTE BIOL, V57, P2, DOI 10.1002/jlb.57.1.2; Su ZZ, 1997, P NATL ACAD SCI USA, V94, P9125, DOI 10.1073/pnas.94.17.9125; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SUSSMAN MD, 1992, J VIROL, V66, P5586, DOI 10.1128/JVI.66.9.5586-5589.1992; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Taki S, 1997, IMMUNITY, V6, P673, DOI 10.1016/S1074-7613(00)80443-4; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Tendler DS, 2001, CANCER RES, V61, P3682; Tourtellotte WG, 2000, MOL CELL BIOL, V20, P5261, DOI 10.1128/MCB.20.14.5261-5268.2000; Vairapandi M, 1996, ONCOGENE, V12, P2579; Vairapandi M, 2000, J BIOL CHEM, V275, P16810, DOI 10.1074/jbc.275.22.16810; VYDELINGUM S, 1993, J GEN VIROL, V74, P2125, DOI 10.1099/0022-1317-74-10-2125; Wang XT, 1999, J BIOL CHEM, V274, P29599, DOI 10.1074/jbc.274.42.29599; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WASSERMAN SA, 1993, MOL BIOL CELL, V4, P767, DOI 10.1091/mbc.4.8.767; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wesche H, 1997, J BIOL CHEM, V272, P7727, DOI 10.1074/jbc.272.12.7727; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xu YW, 2000, NATURE, V408, P111, DOI 10.1038/35040600; YAMAGATA M, 1994, GENE, V139, P223, DOI 10.1016/0378-1119(94)90760-9; YANAGISAWA K, 1993, FEBS LETT, V318, P83, DOI 10.1016/0014-5793(93)81333-U; Yang JF, 2001, NAT IMMUNOL, V2, P157, DOI 10.1038/84264; Yang Q, 2000, J BIOL CHEM, V275, P36892, DOI 10.1074/jbc.M005319200; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zhang W, 1999, ONCOGENE, V18, P4899, DOI 10.1038/sj.onc.1202885; Zhang W, 2001, INT J ONCOL, V18, P749; ZHANG W, 2000, THESIS TEMPLE U; Zsak L, 1996, J VIROL, V70, P8865, DOI 10.1128/JVI.70.12.8865-8871.1996	173	42	43	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2002	21	21					3391	3402		10.1038/sj.onc.1205312	http://dx.doi.org/10.1038/sj.onc.1205312			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	552RL	12032777				2022-12-17	WOS:000175633300012
J	Chan, AS; Thorner, PS; Squire, JA; Zielenska, M				Chan, AS; Thorner, PS; Squire, JA; Zielenska, M			Identification of a novel gene NCRMS on chromosome 12q21 with differential expression between Rhabdomyosarcoma subtypes	ONCOGENE			English	Article						rhabdomyosarcoma; non-coding transcripts; chromosome 12q21; alternative splicing; novel gene	CANCER; SEQUENCES; CDNA; IGF2; RNA; H19	Rhabdomyosarcoma (RMS) is a malignant soft tissue tumor showing varying degrees of skeletal muscle differentiation. Two major histologic subtypes exist, alveolar and embryonal, each with associated molecular genetic changes. We have used Representational Difference Analysis (RDA) to compare gene expression between the two RMS subtypes and have identified the novel gene NCRMS (non-coding RNA in RMS) that has increased expression in the alveolar subtype relative to the embryonal subtype. Multiple alternatively spliced forms of NCRMS were identified through library screening, RACE, and comparison to human expressed sequence tags (ESTs). Northern blot analysis indicated the transcript size to be 1.25 kb in alveolar RMS. There was no sequence homology to any of the known genes in GenBank, but extensive homology to ESTs from various species. Comparison to human genomic sequences identified at least 11 exons mapping to chromosomal region 12q21. Differential expression of NCRMS was noted between various tumor types. Since NCRMS RNA possesses limited potential for protein coding, yet with conserved sequences between different species, it is likely that NCRMS is a functional non-coding RNA. Known genes in its proximity include myogenic regulators Myf5 and Myf6, growth factor Igf1, and another potential differentially expressed gene (ATP2B1) in RMS isolated by RDA.	Hosp Sick Children, Dept Paediat Lab Med, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1L5, Canada; Ontario Canc Inst, Dept Pathol Oncol, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Zielenska, M (corresponding author), Hosp Sick Children, Dept Paediat Lab Med, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	m.zielenska@utoronto.ca	Squire, Jeremy A/A-9352-2012; Squire, Jeremy A/F-4437-2012	Squire, Jeremy A/0000-0002-9863-468X; 				Anderson J, 1999, GENE CHROMOSOME CANC, V26, P275, DOI 10.1002/(SICI)1098-2264(199912)26:4<275::AID-GCC1>3.0.CO;2-3; Anderson John, 1999, Neoplasia (New York), V1, P340, DOI 10.1038/sj.neo.7900052; Barr FG, 1997, INT J BIOCHEM CELL B, V29, P1449, DOI 10.1016/S1357-2725(97)00095-2; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Dagher R, 1999, Oncologist, V4, P34; Erdmann VA, 2001, NUCLEIC ACIDS RES, V29, P189, DOI 10.1093/nar/29.1.189; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; LISITSYN N, 1995, METHOD ENZYMOL, V254, P291; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Lucas S, 1998, CANCER RES, V58, P743; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Pandita Ajay, 1999, Neoplasia (New York), V1, P262, DOI 10.1038/sj.neo.7900036; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Srivastava M, 2000, GENE DEV, V14, P1186; Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693; Visser M, 1997, ONCOGENE, V15, P1309, DOI 10.1038/sj.onc.1201302	20	42	51	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					3029	3037		10.1038/sj.onc.1205460	http://dx.doi.org/10.1038/sj.onc.1205460			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082533				2022-12-17	WOS:000175262700010
J	Arai, A; Kanda, E; Miura, O				Arai, A; Kanda, E; Miura, O			Rac is activated by erythropoietin or interleukin-3 and is involved in activation of the Erk signaling pathway	ONCOGENE			English	Article						rac; erythropoietin; IL-3; signal transduction; hematopoietic cells	GUANOSINE TRIPHOSPHATASES; TYROSINE PHOSPHORYLATION; DEPENDENT ACTIVATION; CELL ADHESION; RHO GTPASES; PROTEIN; RECEPTOR; BINDING; EXCHANGE; CRKL	Previous studies have shown that hematopoietic cytokines, including erythropoietin (Epo) and interleukin (IL)-3, activate the Ras GTPase and the downstream Raf/Erk/Elk-1 signaling pathway. Here we report that Epo or IL-3 rapidly and transiently activates Rac, a Rho family GTPase, in hernatopoietic cell lines, 32D/EpoR-Wt and UT-7. The cytokine-induced activation of Rac was augmented in a 32D/EpoR-Wt clone that inducibly overexpresses the adaptor protein CrkL or the Ras guanine nucleotide exchange factor C3G, which forms a complex with CrkL. Furthermore, the Rac activation was enhanced or inhibited in cells inducibly expressing an activated Ras mutant, H-Ras61L, or a dominant negative Ras mutant, H-Ras17N, respectively. In addition, the cytokine-induced Rac activation was inhibited by a phosphatidyl-inositol 3'-kinase (PI3K) inhibitor, LY294002, which also inhibited the Erk activation. A dominant negative Rac mutant, Rac17N, also inhibited the cytokine-induced activation of Erk as well as Elk-1. On the other hand, activation of Akt downstream of PI3K was found to play an inhibitory role in cytokine activation of Erk/Elk-1. Together, these results indicate that Rac is activated by Epo or IL-3 at downstream of the Ras/PI3K pathway in parallel with Akt and plays a role in activation of the Erk/Elk-1 signaling pathway in hematopoietic cells.	Tokyo Med & Dent Univ, Dept Hematol & Oncol, Bunkyo Ku, Tokyo 1138519, Japan	Tokyo Medical & Dental University (TMDU)	Miura, O (corresponding author), Tokyo Med & Dent Univ, Dept Hematol Oncol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 113, Japan.	miura.med1@med.tmd.ac.jp		Miura, Osamu/0000-0002-0981-3054				Akasaki T, 1999, J BIOL CHEM, V274, P18055, DOI 10.1074/jbc.274.25.18055; Arai A, 1999, BLOOD, V93, P3713, DOI 10.1182/blood.V93.11.3713.411a36_3713_3722; Arai A, 2001, J BIOL CHEM, V276, P33282, DOI 10.1074/jbc.M102924200; Arai A, 2001, J BIOL CHEM, V276, P10453, DOI 10.1074/jbc.M004627200; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Chin H, 1998, BLOOD, V91, P3734; Craddock BL, 2001, J BIOL CHEM, V276, P24274, DOI 10.1074/jbc.M009098200; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Geijsen N, 1999, BLOOD, V94, P1121, DOI 10.1182/blood.V94.3.1121.415k04_1121_1130; Gu Y, 2001, J BIOL CHEM, V276, P15929, DOI 10.1074/jbc.M010445200; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hasegawa T, 1996, IEEE T POWER DELIVER, V11, P1776, DOI 10.1109/61.544257; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; KOMATSU N, 1991, CANCER RES, V51, P341; Kwon T, 2000, J BIOL CHEM, V275, P423, DOI 10.1074/jbc.275.1.423; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; Matsuzaki T, 2000, ONCOGENE, V19, P1500, DOI 10.1038/sj.onc.1203461; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIURA O, 1994, J BIOL CHEM, V269, P614; MIURA O, 1994, BLOOD, V84, P4135, DOI 10.1182/blood.V84.12.4135.bloodjournal84124135; MIURA Y, 1994, J BIOL CHEM, V269, P29962; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Nishida K, 1999, ONCOGENE, V18, P407, DOI 10.1038/sj.onc.1202301; Nosaka Y, 1999, J BIOL CHEM, V274, P30154, DOI 10.1074/jbc.274.42.30154; Nosaka Y, 2001, BIOCHEM BIOPH RES CO, V285, P675, DOI 10.1006/bbrc.2001.5222; Romanova LY, 1999, J CELL PHYSIOL, V179, P157, DOI 10.1002/(SICI)1097-4652(199905)179:2<157::AID-JCP6>3.0.CO;2-4; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Skorski T, 1998, P NATL ACAD SCI USA, V95, P11858, DOI 10.1073/pnas.95.20.11858; Sugihara K, 1998, ONCOGENE, V17, P3427, DOI 10.1038/sj.onc.1202595; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; VAN AL, 1997, GENE DEV, V11, P2295; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	40	42	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2002	21	17					2641	2651		10.1038/sj.onc.1205346	http://dx.doi.org/10.1038/sj.onc.1205346			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965537				2022-12-17	WOS:000174996500004
J	Teitz, T; Wei, T; Liu, D; Valentine, V; Valentine, M; Grenet, J; Lahti, JM; Kidd, VJ				Teitz, T; Wei, T; Liu, D; Valentine, V; Valentine, M; Grenet, J; Lahti, JM; Kidd, VJ			Caspase-9 and Apaf-1 are expressed and functionally active in human neuroblastoma tumor cell lines with 1p36 LOH and amplified MYCN	ONCOGENE			English	Article						tumor suppressors; apoptosis; caspases; neuroblastoma; MYCN; Apaf-1; cytochrome c	CYTOCHROME-C RELEASE; INDUCED APOPTOSIS; BCL-2 FAMILY; P53-DEPENDENT APOPTOSIS; MEDIATED APOPTOSIS; ANTICANCER AGENTS; ALLELIC LOSS; ACTIVATION; MITOCHONDRIA; NECROSIS	Important roles have been suggested for caspase-8, caspase-9 and Apaf-1 in controlling tumor development and their sensitivity to chemotherapeutic agents. Methylation and deletion of Apaf-1 and CASP8 results in the loss of their expression in melanoma and neuroblastoma, respectively, while CASP9 localization to 1p36.1 suggests it is a good candidate tumor suppressor. The status of CASP9 and Apaf-1 expression in numerous neuroblastoma cell lines with/without amplified MYCN and chromosome 1p36 loss-of-heterozygosity (LOH) was therefore examined to test the hypothesis that one or both of these genes are tumor suppressors in neuroblastoma. Although CASP9 is included in the region encompassing 1p36 LOH in all neuroblastoma cell lines examined, the remaining CASP9 allele(s) express a functional caspase-9 enzyme. Apaf-1 is also expressed in all neuroblastoma tumor cell lines examined. Thus, the CASP9 or Apaf-1 genes do not appear to function as tumor suppressors in MYCN amplified neuroblastomas. However, similar to20% of the neuroblastoma cell lines with methylated CASP8 alleles are also highly resistant to staurosporine (STS)- and radiation-induced cell death, presumably because cytochrome c is not released from mitochondria. This suggests that a second, smaller subgroup of MYCN amplified neuroblastoma tumors exists with defect(s) in apoptotic signaling components upstream of caspase-9 and Apaf-l. Since no consistent differences in Bcl-2, BCI-x(L) or Bax expression were seen in the STS- and radiation-resistant neuroblastomas, it suggests that a unique mitochondrial signaling factor(s) is responsible for the defect in cytochrome c release in this sub-group of tumors.	St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Kidd, VJ (corresponding author), St Jude Childrens Res Hosp, Dept Tumor Cell Biol, 332 N Lauderdale, Memphis, TN 38105 USA.	vincent.kidd@stjude.org			NATIONAL CANCER INSTITUTE [R01CA067938, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [5 PO1 CA21765, 5 R01 CA67938] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Asselin E, 2001, CANCER RES, V61, P1862; Bala S, 2000, GENE CHROMOSOME CANC, V28, P258, DOI 10.1002/1098-2264(200007)28:3<258::AID-GCC3>3.0.CO;2-R; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; BRODEUR GM, 1992, CANCER-AM CANCER SOC, V70, P1685, DOI 10.1002/1097-0142(19920915)70:4+<1685::AID-CNCR2820701607>3.0.CO;2-H; CARON H, 1995, MED PEDIATR ONCOL, V24, P215, DOI 10.1002/mpo.2950240402; CARON H, 1993, NAT GENET, V4, P187, DOI 10.1038/ng0693-187; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eggert A, 2001, CANCER RES, V61, P1314; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Ferreira CG, 2000, CANCER RES, V60, P7133; Gastman BR, 2000, CANCER RES, V60, P6811; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Grotzer MA, 2000, ONCOGENE, V19, P4604, DOI 10.1038/sj.onc.1203816; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; KNUDSON AG, 1980, NEW ENGL J MED, V302, P1254, DOI 10.1056/NEJM198005293022210; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; LaBonne C, 1999, ANNU REV CELL DEV BI, V15, P81, DOI 10.1146/annurev.cellbio.15.1.81; Lacour S, 2001, CANCER RES, V61, P1645; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Stegh AH, 2000, MOL CELL BIOL, V20, P5665, DOI 10.1128/MCB.20.15.5665-5679.2000; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Takita J, 2001, ONCOGENE, V20, P4424, DOI 10.1038/sj.onc.1204521; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Tang DM, 1999, J BIOL CHEM, V274, P7245, DOI 10.1074/jbc.274.11.7245; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Tweddle DA, 2001, CANCER RES, V61, P8; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zhang H, 2000, P NATL ACAD SCI USA, V97, P2597, DOI 10.1073/pnas.97.6.2597; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483	45	42	43	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 14	2002	21	12					1848	1858		10.1038/sj.onc.1205180	http://dx.doi.org/10.1038/sj.onc.1205180			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896617				2022-12-17	WOS:000174284500007
J	Miyazaki, YJ; Hamada, J; Tada, M; Furuuchi, K; Takahashi, Y; Kondo, S; Katoh, H; Moriuchi, T				Miyazaki, YJ; Hamada, J; Tada, M; Furuuchi, K; Takahashi, Y; Kondo, S; Katoh, H; Moriuchi, T			HOXD3 enhances motility and invasiveness through the TGF-beta-dependent and -independent pathways in A549 cells	ONCOGENE			English	Article						homeobox gene; HOXD3; microarray; lung cancer cells; TGF-beta; invasion	GROWTH-FACTOR-BETA; GENE-EXPRESSION; HOMEOBOX GENES; MYELOID-LEUKEMIA; CARCINOMA-CELLS; TUMOR BEHAVIOR; LATENT; FACTOR-BETA-1; ACTIVATION; TGF-BETA-1	Homeobox genes regulate sets of genes that determine cellular fates in embryonic morphogenesis and maintenance of adult tissue architecture by regulating cellular motility and cell-cell interactions. Our previous studies showed that a specific member, HOXD3, when overexpressed, upregulates integrin beta3 expression in human erythroleukemia HEL cells and lung cancer A549 cells, and enhances their motility and invasiveness. We performed a microarray study of over 7075 genes to determine the mechanisms underlying the HOXD3-enhanced motility and invasiveness in A549 cells. RT - PCR-based tracking gene analyses highlighted a set of TGF-beta-upregulated genes, which included matrix metalloproteinase-2, syndecan-1, CD44, and TGF-beta-induced 68 kDa protein. Exogenous TGF-beta also caused this pattern of upregulation in A549 cells and enhanced their migratory and invasive activity, confirming the involvement of TGF-beta signaling. However, HOXD3 reduced the expression of TGF-beta-independent genes coding for desmosomal components such as desmoglein, desmoplakin and plakoglobin which are known to suppress tumor invasion and metastasis. These results suggest that HOXD3 enhances the invasive and metastatic potential of cancer cells through the TGF-beta-dependent and -independent pathways.	Hokkaido Univ, Inst Med Genet, Div Canc Related Genes, Kita Ku, Sapporo, Hokkaido 0600815, Japan; Hokkaido Univ, Grad Sch Med, Div Canc Med, Kita Ku, Sapporo, Hokkaido 0608638, Japan	Hokkaido University; Hokkaido University	Hamada, J (corresponding author), Hokkaido Univ, Inst Med Genet, Div Canc Related Genes, Kita Ku, Kita 15,Nishi 7, Sapporo, Hokkaido 0600815, Japan.	jhamada@med.hokudai.ac.jp	Kondo, Satoshi/B-1114-2008; Hamada, Jun-ichi/D-7452-2012					ALBINI A, 1987, CANCER RES, V47, P3239; Apiou F, 1996, CYTOGENET CELL GENET, V73, P114, DOI 10.1159/000134320; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; Boudreau N, 1997, J CELL BIOL, V139, P257, DOI 10.1083/jcb.139.1.257; CILLO C, 1994, INVAS METAST, V14, P38; CILLO C, 1992, INT J CANCER, V51, P892, DOI 10.1002/ijc.2910510610; Cillo C, 1999, EXP CELL RES, V248, P1, DOI 10.1006/excr.1999.4451; CONN IG, 1990, BRIT J UROL, V65, P176, DOI 10.1111/j.1464-410X.1990.tb14694.x; DEVITA G, 1993, EUR J CANCER, V29A, P887, DOI 10.1016/S0959-8049(05)80432-0; GEHRING WJ, 1986, ANNU REV GENET, V20, P147, DOI 10.1146/annurev.ge.20.120186.001051; GEORGE MD, 1990, J BIOL CHEM, V265, P11098; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; Hamada J, 2001, INT J CANCER, V93, P516, DOI 10.1002/ijc.1357; HARADA T, 1992, INT J ORAL MAX SURG, V21, P346, DOI 10.1016/S0901-5027(05)80759-3; Hidai C, 1998, GENE DEV, V12, P21, DOI 10.1101/gad.12.1.21; Hiraki A, 1996, BRIT J CANCER, V73, P1491, DOI 10.1038/bjc.1996.282; KESKIOJA J, 1988, J BIOL CHEM, V263, P3111; Khalil N, 1999, MICROBES INFECT, V1, P1255, DOI 10.1016/S1286-4579(99)00259-2; Kimelman D, 2000, CURR OPIN GENET DEV, V10, P350, DOI 10.1016/S0959-437X(00)00095-2; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; LUCAS C, 1991, METHOD ENZYMOL, V198, P303; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; Mark M, 1997, PEDIATR RES, V42, P421, DOI 10.1203/00006450-199710000-00001; Massague J, 2000, GENE DEV, V14, P627; MCCAFFREY TA, 1992, J CELL PHYSIOL, V152, P430, DOI 10.1002/jcp.1041520226; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460-2075.1991.tb08049.x; MOORADIAN DL, 1992, J NATL CANCER I, V84, P523, DOI 10.1093/jnci/84.7.523; Moses HL, 1996, CURR OPIN GENET DEV, V6, P581, DOI 10.1016/S0959-437X(96)80087-6; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Nagayasu H, 1998, BRIT J CANCER, V77, P1371, DOI 10.1038/bjc.1998.229; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; Nakashio T, 1997, INT J CANCER, V70, P612, DOI 10.1002/(SICI)1097-0215(19970304)70:5<612::AID-IJC20>3.3.CO;2-Y; NEGOESCU A, 1995, EXP CELL RES, V217, P404, DOI 10.1006/excr.1995.1103; OVERALL CM, 1991, J BIOL CHEM, V266, P14064; Penta K, 1999, J BIOL CHEM, V274, P11101, DOI 10.1074/jbc.274.16.11101; SCHULTZCHERRY S, 1995, J BIOL CHEM, V270, P7304, DOI 10.1074/jbc.270.13.7304; Shinohara M, 1998, J PATHOL, V184, P369, DOI 10.1002/(SICI)1096-9896(199804)184:4<369::AID-PATH1236>3.0.CO;2-L; SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511; TANIGUCHI Y, 1995, BLOOD, V85, P2786, DOI 10.1182/blood.V85.10.2786.bloodjournal85102786; TIBERIO C, 1994, INT J CANCER, V58, P608, DOI 10.1002/ijc.2910580426; Tselepis C, 1998, P NATL ACAD SCI USA, V95, P8064, DOI 10.1073/pnas.95.14.8064; Yehualaeshet T, 1999, AM J PATHOL, V155, P841, DOI 10.1016/S0002-9440(10)65183-8; Yu Q, 2000, GENE DEV, V14, P163	46	42	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2002	21	5					798	808		10.1038/sj.onc.1205126	http://dx.doi.org/10.1038/sj.onc.1205126			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850808				2022-12-17	WOS:000173427000011
J	Brasher, BB; Roumiantsev, S; Van Etten, RA				Brasher, BB; Roumiantsev, S; Van Etten, RA			Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain	ONCOGENE			English	Article						abelson; tyrosine kinase; retrovirus; chronic myeloid leukemia	TYROSINE KINASE-ACTIVITY; PROLINE-RICH LIGANDS; SH3 DOMAIN; TRANSFORMING ACTIVITY; PROTEIN-BINDING; GENE-PRODUCT; CELL-LINE; ACTIVATION; ABILITY; LYMPHOCYTES	The catalytic activity of the c-Abl tyrosine kinase is tightly regulated by its Src homology 3 (SH3) domain through a complex mechanism that may involve intramolecular binding to Pro242 in the linker region between the SH2 and catalytic domains as well as interactions with a trans-inhibitor. We analysed the effect of mutation or replacement of SH3 on c-Abl tyrosine kinase activity and transformation. Random mutagenesis of SH3 identified several novel point mutations that dysregulated c-Abl kinase activity in vivo, but the RT loop was insensitive to mutational activation. Activating SH3 mutations abolished binding of proline-rich SH3 ligands in vitro, while mutations at Ser140 in the connector between the SH3 and SH2 domains activated Abl kinase activity in vivo and in vitro but did not impair SH3 ligand-binding. Abl was regulated efficiently when its SH3 domain was replaced with a heterologous SH3 from c-Src that binds a different spectrum of proline-rich ligands, but not by substitution of a modular WW domain with similar ligand-binding specificity. These results suggest that the SH3 domain regulates Abl principally by binding to the atypical intramolecular ligand Pro242 rather than a canonical PxxP ligand. Coordination between the SH3 and SH2 domains mediated by the connector region may be required for regulation of Abl even in the absence of SH2 ligand binding.	Enanta Pharmaceut, Watertown, MA 02472 USA; Harvard Univ, Sch Med, Dept Genet, Ctr Blood Res, Boston, MA 02114 USA; Enanta Pharmaceut, Watertown, MA 02472 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Van Etten, RA (corresponding author), Harvard Univ, Sch Med, Dept Genet, Ctr Blood Res, 200 Longwood Ave, Boston, MA 02114 USA.	vanetten@cbr.med.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA072465] Funding Source: NIH RePORTER; NCI NIH HHS [CA72465] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; Brasher BB, 2000, J BIOL CHEM, V275, P35631, DOI 10.1074/jbc.M005401200; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; DALEY GQ, 1992, MOL CELL BIOL, V12, P1864, DOI 10.1128/MCB.12.4.1864; Dalgarno DC, 1997, BIOPOLYMERS, V43, P383; Dorey K, 1999, BIOL CHEM, V380, P223; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; FINER MH, 1994, BLOOD, V83, P43; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LEE JC, 1982, J IMMUNOL, V128, P2393; Leung DW, 1989, TECHNIQUE, V1, P11; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; LIM WA, 1994, NAT STRUCT BIOL, V1, P221, DOI 10.1038/nsb0494-221; LIU XQ, 1993, ONCOGENE, V8, P1119; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; Pisabarro MT, 1996, BIOCHEMISTRY-US, V35, P10634, DOI 10.1021/bi960203t; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; Potts W M, 1988, Oncogene Res, V3, P343; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1995, ONCOGENE, V10, P1977; Walkenhorst J, 1996, ONCOGENE, V12, P1513; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; WENG ZG, 1995, MOL CELL BIOL, V15, P5627; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Young MA, 2001, CELL, V105, P115, DOI 10.1016/S0092-8674(01)00301-4; Zhu JY, 1996, MOL CELL BIOL, V16, P7054	44	42	44	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2001	20	53					7744	7752		10.1038/sj.onc.1204978	http://dx.doi.org/10.1038/sj.onc.1204978			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492HE	11753652	Green Published			2022-12-17	WOS:000172161700005
J	Baisden, JM; Gatesman, AS; Cherezova, L; Jiang, BH; Flynn, DC				Baisden, JM; Gatesman, AS; Cherezova, L; Jiang, BH; Flynn, DC			The intrinsic ability of AFAP-110 to alter actin filament integrity is linked with its ability to also activate cellular tyrosine kinases	ONCOGENE			English	Article						AFAP-110; Src; actin filaments	PP60C-SRC PROTEIN-KINASE; TRANSFORMED FIBROBLASTS; STABLE ASSOCIATION; STRESS FIBERS; SH3 DOMAINS; V-SRC; C-SRC; COMPLEX; PP60SRC; MOTIF	The actin filament-associated protein of 110 kDa (AFAP-110) is a Src binding partner that represents a potential modulator of actin filament integrity in response to cellular signals. Previous reports have demonstrated that AFAP-110 is capable of directly binding and altering actin filaments. Deletion of the leucine zipper motif of AFAP-110 (AFAP-110(Delta lzip)) has been shown to induce a phenotype which resembles Src-transformed cells, by repositioning actin filaments into rosettes. This deletion also mimics a conformational change in AFAP-110 that is detected in Src-transformed cells. The results presented here indicate that unlike AFAP-110, AFAP-110 Delta lzip is capable of activating cellular tyrosine kinases, including Src family members, and that AFAP-110 Delta lzip itself is hyperphosphorylated. The newly tyrosine phosphorylated proteins and activated Src-family members appear to be associated with actin-rich lamellipodia. A point mutation that alters the SH3-binding motif of AFAP-110 Delta lzip prevents it from activating tyrosine kinases and altering actin filament integrity. In addition, a deletion within a pleckstrin homology (PH) domain of AFAP-110 Delta lzip will also revert its effects upon actin filaments. Lastly, dominant-positive RhoA(V14) will block the ability of AFAP-110(Delta lzip) from inducing actin filament rosettes, but does not inhibit Src activation. Thus, conformational changes in AFAP-110 enable it to activate cellular kinases in a mechanism requiring SH3 and/or PH domain interactions. We hypothesize that cellular signals which alter AFAP-110 conformation, enable it to activate cellular kinases such as cSrc, which then direct changes in actin filament integrity in a Rho-dependent fashion.	W Virginia Univ, Dept Microbiol & Immunol, Morgantown, WV 26506 USA	West Virginia University	Flynn, DC (corresponding author), W Virginia Univ, Dept Microbiol & Immunol, 2822 MBRCC, Morgantown, WV 26506 USA.	dflynn@hsc.wvu.edu	Baisden, Joseph/AAN-7747-2021	Baisden, Joseph/0000-0002-8986-407X; Jiang, Bing-Hua/0000-0003-4526-2031	NCI NIH HHS [CA60731] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA060731, R01CA060731] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAISDEN JM, 2001, IN PRESS ONCOGENE; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BOSCHEK CB, 1981, CELL, V24, P175, DOI 10.1016/0092-8674(81)90513-4; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; FELICE GR, 1990, EUR J CELL BIOL, V52, P47; Fincham VJ, 1999, J CELL SCI, V112, P947; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; Guappone AC, 1998, MOL CARCINOGEN, V22, P110, DOI 10.1002/(SICI)1098-2744(199806)22:2<110::AID-MC6>3.0.CO;2-Q; Guappone AC, 1997, MOL CELL BIOCHEM, V175, P243, DOI 10.1023/A:1006840104666; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; He H, 2000, CANCER J, V6, P243; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; LIU XQ, 1994, RECENT PROG HORM RES, V49, P149; Mayer T, 1999, ONCOGENE, V18, P2117, DOI 10.1038/sj.onc.1202537; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Qian Y, 1999, HYBRIDOMA, V18, P167, DOI 10.1089/hyb.1999.18.167; Qian Y, 1998, ONCOGENE, V16, P2185, DOI 10.1038/sj.onc.1201753; Qian Y, 2000, EXP CELL RES, V255, P102, DOI 10.1006/excr.1999.4795; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROSEN N, 1986, J BIOL CHEM, V261, P3754; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; Schwartzberg PL, 1997, GENE DEV, V11, P2835, DOI 10.1101/gad.11.21.2835; TARONE G, 1985, EXP CELL RES, V159, P141, DOI 10.1016/S0014-4827(85)80044-6; Thomas JW, 1998, J BIOL CHEM, V273, P577, DOI 10.1074/jbc.273.1.577; Xing LZ, 2000, MOL CELL BIOL, V20, P7363, DOI 10.1128/MCB.20.19.7363-7377.2000	30	42	44	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2001	20	45					6607	6616		10.1038/sj.onc.1204802	http://dx.doi.org/10.1038/sj.onc.1204802			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641786				2022-12-17	WOS:000171404200014
J	Lambert, S; Lopez, BS				Lambert, S; Lopez, BS			Role of RAD51 in sister-chromatid exchanges in mammalian cells	ONCOGENE			English	Article						homologous recombination; SCE; RAD51; mammalian cells; alkylating agent	DOUBLE-STRAND BREAK; HOMOLOGY-DIRECTED REPAIR; SACCHAROMYCES-CEREVISIAE; IONIZING-RADIATION; VERTEBRATE CELLS; GENE CONVERSION; DNA; RECOMBINATION; DISRUPTION; PROMOTES	To measure the impact of the RAD51 pathway on Sister-Chromatid Exchanges (SCE), we used hamster cells expressing either the wild-type MmRAD51, which stimulates, or the dominant negative SMRAD51, which inhibits, gene conversion without affecting cell viability of untreated as well as T-rays irradiated cells. We show that MmRAD51 did not affect the rate of spontaneous SCE while it strongly stimulated spontaneous recombination between tandem repeats. No spontaneous recombinant was detected when expressing SMRAD51 while spontaneous SCE were only slightly diminished. After treatment by an alkylating agent (MNU), MmRAD51 stimulated MNU-induced recombination whereas no recombinant was detected when expressing SMRAD51. MNU induced SCE in all cell lines, even in the SMRAD51 expressing lines, but the induction of SCE was slightly more efficient in lines expressing MmRAD51 and less efficient in lines expressing SMRAD51. Thus, in mammalian cells, the RAD51-dependent gene conversion pathway drastically affects recombination between intrachromosomal tandem repeats, whereas it only partially participates in SCE formation, measured at a chromosomal level. These results show that RAD51-gene conversion can participate in induced SCE but that alternative pathways should exist.	CEA, UMR 217 CNRS, Direct Sci Vivant, Dept Radiobiol & Radiopathol, F-92265 Fontenay Aux Roses, France	CEA; UDICE-French Research Universities; Universite Paris Saclay	Lopez, BS (corresponding author), CEA, UMR 217 CNRS, Direct Sci Vivant, Dept Radiobiol & Radiopathol, 60-68 Ave Gen Leclerc, F-92265 Fontenay Aux Roses, France.		Lopez, Bernard S/O-7308-2017; lambert, sarah/K-7750-2017	Lopez, Bernard S/0000-0001-5088-0155; lambert, sarah/0000-0002-1403-3204				BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; CONNELL JR, 1982, CARCINOGENESIS, V3, P385, DOI 10.1093/carcin/3.4.385; DILLEHAY LE, 1989, MUTAT RES, V215, P15, DOI 10.1016/0027-5107(89)90213-3; Dronkert MLG, 2000, MOL CELL BIOL, V20, P3147, DOI 10.1128/MCB.20.9.3147-3156.2000; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; FABRE F, 1984, MOL GEN GENET, V195, P139, DOI 10.1007/BF00332736; FULLER LF, 1988, MUTAT RES, V193, P109, DOI 10.1016/0167-8817(88)90041-7; Golub EI, 1997, NUCLEIC ACIDS RES, V25, P4106, DOI 10.1093/nar/25.20.4106; Haber JE, 2000, TRENDS GENET, V16, P259, DOI 10.1016/S0168-9525(00)02022-9; Johnson RD, 2000, EMBO J, V19, P3398, DOI 10.1093/emboj/19.13.3398; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; KADYK LC, 1992, GENETICS, V132, P387; Lambert S, 2000, EMBO J, V19, P3090, DOI 10.1093/emboj/19.12.3090; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; Zhang H, 1996, CARCINOGENESIS, V17, P2229, DOI 10.1093/carcin/17.10.2229	19	42	44	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 4	2001	20	45					6627	6631		10.1038/sj.onc.1204813	http://dx.doi.org/10.1038/sj.onc.1204813			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641788				2022-12-17	WOS:000171404200016
J	Chernova, OB; Hunyadi, A; Malaj, E; Pan, HQ; Crooks, C; Roe, B; Cowell, JK				Chernova, OB; Hunyadi, A; Malaj, E; Pan, HQ; Crooks, C; Roe, B; Cowell, JK			A novel member of the WD-repeat gene family, WDR11, maps to the 10q26 region and is disrupted by a chromosome translocation in human glioblastoma cells	ONCOGENE			English	Article						brain tumors; gene cloning; WD40 repeat; translocation; chromosome 10	TUMOR-SUPPRESSOR GENE; MARINER TRANSPOSON; PROTEIN FAMILY; HUMAN GLIOMAS; LOW-GRADE; DELETION; BRAIN; SEQUENCE; 19Q; ASTROCYTOMAS	Allelic deletions of 10q25-26 and 19q13.3-13.4 are the most common genetic alterations in glial tumors. We have identified a balanced t(10;19) reciprocal translocation in the A172 glioblastoma cell line which involves both critical regions on chromosomes 10 and 19. In addition, loss of an entire copy of chromosome 10 has occurred in this cell line suggesting that the translocation event may provide a highly specific critical inactivating event in a gene responsible for tumorigenesis. Positional cloning of this translocation breakpoint resulted in the identification of a novel chromosome 10 gene, WDR11, which is a member of the WD-repeat gene family. The WDR11 gene is ubiquitously expressed, including normal brain and glial tumors. WDR11 is composed of 29 exons distributed over 58 kilobases and oriented towards the telomere. The translocation resulted in deletion of exon 5 and consequently fusion of intron 4 of WDR11 to the 3' untranslated region of a novel member, ZNF320, of the Kruppel-like zinc finger gene family. Since ZNF320 is oriented toward the centromere of chromosome 19, both genes appeared on the same derivative chromosome der(10). The chimeric transcript encodes the WDR11 polypeptide, which is truncated after the second of six WD-repeats. ZNF320 is also expressed in A172 cells, although it is not clear if the translocation affects the expression of the altered gene because of the presence of another unrearranged gene on chromosome 19. We suggest that, because of its localization in a region frequently showing LOH and the observation of inactivation of this gene in glioblastoma cells, WDR11 is a candidate gene for the frequently proposed tumor suppressor gene in 10q25-26 which is involved in tumorigenesis of glial and other tumors showing frequent alterations in the distal 10q region.	Cleveland Clin Fdn, Lerner Res Inst, Ctr Mol Genet, Cleveland, OH 44195 USA; Univ Oklahoma, Dept Chem, Norman, OK 73019 USA	Cleveland Clinic Foundation; University of Oklahoma System; University of Oklahoma - Norman	Cowell, JK (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Elm & Carlton St, Buffalo, NY 14263 USA.			Koculi, Eda/0000-0001-9477-555X; Cowell, John/0000-0002-2079-5950; Pan, Huaqin/0000-0002-7166-108X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BELLO MJ, 1995, INT J CANCER, V64, P207; Bodenteich A, 1993, AUTOMATED DNA SEQUEN, P42; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Cairncross JG, 1998, J NATL CANCER I, V90, P1473, DOI 10.1093/jnci/90.19.1473; Carver EA, 1997, GENOME RES, V7, P1123, DOI 10.1101/gr.7.12.1123; Chen KS, 1997, NAT GENET, V17, P154, DOI 10.1038/ng1097-154; Cheng Y, 1999, HUM PATHOL, V30, P1284, DOI 10.1016/S0046-8177(99)90057-6; Chernova O, 1998, CANCER GENET CYTOGEN, V105, P60, DOI 10.1016/S0165-4608(97)00479-2; Chernova OB, 1998, ONCOGENE, V17, P2873, DOI 10.1038/sj.onc.1202481; CHISSOE SL, 1995, GENOMICS, V27, P67, DOI 10.1006/geno.1995.1008; DEEN DF, 1993, J NEURO-ONCOL, V16, P243, DOI 10.1007/BF01057041; Dong JT, 1998, ONCOGENE, V17, P1979, DOI 10.1038/sj.onc.1202119; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Fujisawa H, 1999, AM J PATHOL, V155, P387, DOI 10.1016/S0002-9440(10)65135-8; Fujiwara Y, 2000, JPN J CANCER RES, V91, P287, DOI 10.1111/j.1349-7006.2000.tb00943.x; FULTS D, 1993, GENE CHROMOSOME CANC, V7, P173, DOI 10.1002/gcc.2870070311; FULTS D, 1990, CANCER RES, V50, P5784; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; HENIKOFF S, 1994, GENOMICS, V19, P97, DOI 10.1006/geno.1994.1018; Herbst RA, 1999, ARCH DERMATOL RES, V291, P567, DOI 10.1007/s004030050456; Ichimura K, 1998, GENE CHROMOSOME CANC, V22, P9, DOI 10.1002/(SICI)1098-2264(199805)22:1<9::AID-GCC2>3.0.CO;2-1; KARLBOM AE, 1993, HUM GENET, V92, P169; Kazazian HH, 1998, NAT GENET, V19, P19, DOI 10.1038/ng0598-19; Kiyosawa H, 1996, HUM MOL GENET, V5, P745, DOI 10.1093/hmg/5.6.745; KLEIHUES P, 1993, BRAIN PATHOL, V3, P255, DOI 10.1111/j.1750-3639.1993.tb00752.x; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KRAUS JA, 1995, J NEUROPATH EXP NEUR, V54, P91, DOI 10.1097/00005072-199501000-00011; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liu WG, 1997, CANCER RES, V57, P5254; LOUIS DN, 1995, TRENDS GENET, V11, P412, DOI 10.1016/S0168-9525(00)89125-8; Maier D, 1998, ONCOGENE, V16, P3331, DOI 10.1038/sj.onc.1201832; Maier D, 1997, ONCOGENE, V15, P997, DOI 10.1038/sj.onc.1201209; Maintz D, 1997, J NEUROPATH EXP NEUR, V56, P1098, DOI 10.1097/00005072-199710000-00003; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Nagane Motoo, 1997, Current Opinion in Oncology, V9, P215, DOI 10.1097/00001622-199709030-00001; Nakamura M, 2000, J NEUROPATH EXP NEUR, V59, P539, DOI 10.1093/jnen/59.6.539; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; OHGAKI H, 1995, VIRCHOWS ARCH, V427, P113, DOI 10.1007/BF00196514; OOSUMI T, 1995, NATURE, V378, P672, DOI 10.1038/378672a0; PAN HQ, 1994, GENET ANAL-BIOMOL E, V11, P181; Petersen S, 2000, INT J CANCER, V88, P71, DOI 10.1002/1097-0215(20001001)88:1<71::AID-IJC11>3.0.CO;2-X; Purandare SM, 1997, GENOME RES, V7, P773, DOI 10.1101/gr.7.8.773; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Raff T, 1997, BIOTECHNIQUES, V23, P456, DOI 10.2144/97233st02; RASHEED BKA, 1995, ONCOGENE, V10, P2243; Reiter LT, 1996, NAT GENET, V12, P288, DOI 10.1038/ng0396-288; Roberts T, 1998, HUM MOL GENET, V7, P1169, DOI 10.1093/hmg/7.7.1169; Robertson HM, 1997, GENE, V205, P219, DOI 10.1016/S0378-1119(97)00471-X; ROE BA, 1996, DNA ISOLATION SEQUEN; Rosenberg JE, 1996, ONCOGENE, V13, P2483; Saxena A, 1999, ONCOGENE, V18, P1385, DOI 10.1038/sj.onc.1202440; Shannon M, 1998, DNA SEQUENCE, V8, P303, DOI 10.3109/10425179809034075; SIPKINS SB, 1998, GYNECOL ONCOL, V3, P391; Smith JS, 2000, J CLIN ONCOL, V18, P636, DOI 10.1200/JCO.2000.18.3.636; Smith JS, 1999, ONCOGENE, V18, P4144, DOI 10.1038/sj.onc.1202759; Smith JS, 2000, GENE CHROMOSOME CANC, V29, P16, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1007>3.3.CO;2-9; Smith JS, 2000, FRONT BIOSCI-LANDMRK, V5, pD213, DOI 10.2741/Smith; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Somerville RPT, 1998, ONCOGENE, V17, P1755, DOI 10.1038/sj.onc.1202066; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Sonoda Y, 1996, JPN J CANCER RES, V87, P363, DOI 10.1111/j.1349-7006.1996.tb00231.x; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Still IH, 1998, BLOOD, V92, P1456, DOI 10.1182/blood.V92.4.1456.splL3_1456_1458; Suminaga R, 2000, J HUM GENET, V45, P331, DOI 10.1007/s100380070003; Tohma Y, 1998, J NEUROPATH EXP NEUR, V57, P684, DOI 10.1097/00005072-199807000-00005; von Deimling A, 2000, J NEUROPATH EXP NEUR, V59, P544, DOI 10.1093/jnen/59.6.544; VONDEIMLING A, 1992, CANCER RES, V52, P4277; VONDEIMLING A, 1994, CANCER RES, V54, P1397; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WORLEY KC, 1995, GENOME RES, V5, P173, DOI 10.1101/gr.5.2.173; Xu Y, 1994, Genet Eng (N Y), V16, P241; Yeh KT, 2000, CANCER INVEST, V18, P123, DOI 10.3109/07357900009038243	75	42	48	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2001	20	38					5378	5392		10.1038/sj.onc.1204694	http://dx.doi.org/10.1038/sj.onc.1204694			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536051				2022-12-17	WOS:000170575500014
J	Soucek, T; Rosner, M; Miloloza, A; Kubista, M; Cheadle, JP; Sampson, JR; Hengstschlager, M				Soucek, T; Rosner, M; Miloloza, A; Kubista, M; Cheadle, JP; Sampson, JR; Hengstschlager, M			Tuberous sclerosis causing mutants of the TSC2 gene product affect proliferation and p27 expression	ONCOGENE			English	Article						tuberous sclerosis; TSC2; tuberin; proliferation; p27	EKER RAT MODEL; CELL-CYCLE; RENAL-CARCINOMA; HAMARTIN; IDENTIFICATION; SUPPRESSION; GAP	The autosomal dominant disease tuberous sclerosis (TSC) is caused by mutations in either TSC1 on chromosome 9q34, encoding hamartin, or TSC2 on chromosome 16p13.3, encoding tuberin. TSC is characterized by hamartomas that occur in many organs of affected patients and these have been considered to likely result from defects in proliferation control. Although the true biochemical functions of the two TSC proteins have not been clarified, a series of independent investigations demonstrated that modulated hamartin or tuberin expression cause deregulation of proliferation/cell cycle in human, rodent and Drosophila cells. In support of tuberin acting as a tumor suppressor, ectopic overexpression of TSC2 has been shown to decrease proliferation rates of mammalian cells. Furthermore, overexpression of TSC2 has been demonstrated to trigger upregulation of the cyclin-dependent kinase inhibitor p27. We report that three different naturally occurring and TSC causing mutations within the TSC2 gene elliminate neither the anti-proliferative capacity of tuberin nor tuberin's effects on p27 expression. For the first time these data provide strong evidence that deregulation of proliferation and/or upregulation of p27 are not likely to be the primary/only mechanisms of hamartoma development in TSC. These results demand reassessment of previous hypotheses of the pathogenesis of TSC.	Univ Vienna, A-1090 Vienna, Austria; Univ Wales Hosp, Inst Med Genet, Cardiff CF14 4XW, S Glam, Wales	University of Vienna; Cardiff University	Hengstschlager, M (corresponding author), Univ Vienna, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.		Kubista, Mikael/A-5689-2008	Kubista, Mikael/0000-0002-2940-352X				AICHER LD, 2001, IN PRESS J BIOL CHEM; Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Benvenuto G, 2000, ONCOGENE, V19, P6306, DOI 10.1038/sj.onc.1204009; Cheadle JP, 2000, HUM GENET, V107, P97, DOI 10.1007/s004390000348; Gomez M. R., 1999, TUBEROUS SCLEROSIS C; Hengstschlager M, 1999, MUTAT RES-REV MUTAT, V436, P1, DOI 10.1016/S1383-5742(98)00022-2; Henry KW, 1998, J BIOL CHEM, V273, P20535, DOI 10.1074/jbc.273.32.20535; Ito N, 1999, CELL, V96, P529, DOI 10.1016/S0092-8674(00)80657-1; Jin F, 1996, P NATL ACAD SCI USA, V93, P9154, DOI 10.1073/pnas.93.17.9154; Kalejta RF, 1997, CYTOMETRY, V29, P286, DOI 10.1002/(SICI)1097-0320(19971201)29:4<286::AID-CYTO4>3.0.CO;2-8; KOBAYASHI T, 1995, NAT GENET, V9, P70, DOI 10.1038/ng0195-70; Lamb RF, 2000, NAT CELL BIOL, V2, P281, DOI 10.1038/35010550; Maheshwar MM, 1997, HUM MOL GENET, V6, P1991, DOI 10.1093/hmg/6.11.1991; Miloloza A, 2000, HUM MOL GENET, V9, P1721, DOI 10.1093/hmg/9.12.1721; Nellist M, 1999, J BIOL CHEM, V274, P35647, DOI 10.1074/jbc.274.50.35647; NELLIST M, 1993, CELL, V75, P1305; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; Orimoto K, 1996, BIOCHEM BIOPH RES CO, V219, P70, DOI 10.1006/bbrc.1996.0183; Pajak L, 1997, AM J PHYSIOL-HEART C, V273, pH1619, DOI 10.1152/ajpheart.1997.273.3.H1619; Pasumarthi KBS, 2000, CIRC RES, V86, P1069, DOI 10.1161/01.RES.86.10.1069; Plank TL, 1998, CANCER RES, V58, P4766; Sambrook J, 1989, MOL CLONING LAB MANU; Soucek T, 1998, ONCOGENE, V16, P2197, DOI 10.1038/sj.onc.1201743; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; Soucek T, 1997, J BIOL CHEM, V272, P29301, DOI 10.1074/jbc.272.46.29301; Tsuchiya H, 1996, CANCER RES, V56, P429; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413; Young J, 1998, MOL MED TODAY, V4, P313, DOI 10.1016/S1357-4310(98)01245-3	32	42	42	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2001	20	35					4904	4909		10.1038/sj.onc.1204627	http://dx.doi.org/10.1038/sj.onc.1204627			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521203				2022-12-17	WOS:000170271800016
J	Grubb, DR; Ly, JD; Vaillant, F; Johnson, KL; Lawen, A				Grubb, DR; Ly, JD; Vaillant, F; Johnson, KL; Lawen, A			Mitochondrial cytochrome c release is caspase-dependent and does not involve mitochondrial permeability transition in didemnin B-induced apoptosis	ONCOGENE			English	Article						didemnin B; apoptosis; mitochondria; cytochrome c; permeability transition; caspases	ANTIPROLIFERATIVE AGENT DIDEMNIN; CELL-DEATH; NEURONAL APOPTOSIS; BONGKREKIC ACID; HL-60 CELLS; ACTIVATION; BCL-2; INDUCTION; DNA; REDUCTION	Permeability transition, and a subsequent drop in mitochondrial membrane potential (Delta Psi (m)), have been suggested to be mechanisms by which cytochrome c is released from the mitochondria into the cytosol during ;apoptosis, Furthermore, a drop in Delta Psi (m) has been suggested to be an obligate early step in the apoptotic pathway. Didemnin B, a branched cyclic peptolide described to have immunosuppressive, anti-tumour, and anti-viral properties, induces rapid apoptosis in a range of mammalian cell lines. Induction of apoptosis by didemnin B in cultured human pro-myeloid HL-60 cells is the fastest and most complete ever described with all cells being apoptotic after 3 h of treatment, By utilizing the system of didemnin B-induced apoptosis in HL-60 cells,;and the potent inhibitors of mitochondrial permeability transition, cyclosporin A and bongkrekic acid, we show that permeability transition as determined by changes in Delta Psi (m) and mitochondrial Ca2+ fluxing, is not a requirement for apoptosis or cytochrome c release. In this system, changes in mitochondrial membrane potential and cytochrome c release are shown to be dependent on caspase activation, and to occur concurrently with the release of caspase-9 from mitochondria, genomic DNA fragmentation and apoptotic body formation.	Monash Univ, Sch Biomed Sci, Dept Biochem & Mol Biol, Melbourne, Vic 3800, Australia	Monash University	Lawen, A (corresponding author), Monash Univ, Sch Biomed Sci, Dept Biochem & Mol Biol, POB 13D, Melbourne, Vic 3800, Australia.		Lawen, Alfons/A-6598-2008	Lawen, Alfons/0000-0001-6553-9945				Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Chen Q, 2000, CELL DEATH DIFFER, V7, P227, DOI 10.1038/sj.cdd.4400629; Crews CM, 1996, P NATL ACAD SCI USA, V93, P4316, DOI 10.1073/pnas.93.9.4316; CREWS CM, 1994, J BIOL CHEM, V269, P15411; de Bruijn J, 1973, TETRAHEDRON, V29, P1541; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; FOURNIER N, 1987, J BIOENERG BIOMEMBR, V19, P297, DOI 10.1007/BF00762419; Gamen S, 2000, EXP CELL RES, V258, P223, DOI 10.1006/excr.2000.4924; GAMEN S, 1995, FEBS LETT, V376, P15, DOI 10.1016/0014-5793(95)01236-1; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; GRUBB DR, 1995, BIOCHEM BIOPH RES CO, V215, P1130, DOI 10.1006/bbrc.1995.2580; HENDERSON PJ, 1970, J BIOL CHEM, V245, P1319; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; Jiang SN, 1999, J BIOL CHEM, V274, P29905, DOI 10.1074/jbc.274.42.29905; Johnson KL, 1999, J CELL BIOCHEM, V72, P269; Johnson KL, 1996, FEBS LETT, V383, P1, DOI 10.1016/0014-5793(96)00203-7; Johnson KL, 1999, IMMUNOL CELL BIOL, V77, P242, DOI 10.1046/j.1440-1711.1999.00821.x; Kim TH, 2000, J BIOL CHEM, V275, P39474, DOI 10.1074/jbc.M003370200; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; KLINGENBERG M, 1970, BIOCHEM BIOPH RES CO, V39, P344, DOI 10.1016/0006-291X(70)90582-6; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Krohn AJ, 1999, J NEUROSCI, V19, P7394, DOI 10.1523/JNEUROSCI.19-17-07394.1999; LARM JA, 1994, J BIOL CHEM, V269, P30097; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIJMBACH GW, 1970, TETRAHEDRON, V26, P5993; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Meng LH, 1998, BIOCHEMISTRY-US, V37, P10488, DOI 10.1021/bi9804479; MONTGOMERY DW, 1985, TRANSPLANTATION, V40, P49, DOI 10.1097/00007890-198507000-00011; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; RINEHART KL, 1983, FED PROC, V42, P87; Robertson JD, 2000, J BIOL CHEM, V275, P32438, DOI 10.1074/jbc.C000518200; RUSSEL WC, 1975, NATURE, V253, P4671; Rytomaa M, 2000, ONCOGENE, V19, P4461, DOI 10.1038/sj.onc.1203805; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Scarlett JL, 1997, FEBS LETT, V418, P282, DOI 10.1016/S0014-5793(97)01391-4; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; VAILLANT F, 1995, HUM MOL GENET, V4, P903, DOI 10.1093/hmg/4.5.903; WEED SD, 1983, ANTIVIR RES, V3, P269, DOI 10.1016/0166-3542(83)90005-0; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zamzami N, 1996, FEBS LETT, V384, P53, DOI 10.1016/0014-5793(96)00280-3; Zhai DY, 2000, FEBS LETT, V472, P293, DOI 10.1016/S0014-5793(00)01471-X; Zhuang JG, 1998, CELL DEATH DIFFER, V5, P953, DOI 10.1038/sj.cdd.4400440; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	57	42	44	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 5	2001	20	30					4085	4094		10.1038/sj.onc.1204545	http://dx.doi.org/10.1038/sj.onc.1204545			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494136				2022-12-17	WOS:000169681500016
J	Inga, A; Resnick, MA				Inga, A; Resnick, MA			Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants	ONCOGENE			English	Article						p53; yeast functional assays; p53 toxic mutants; enhanced transactivation; p53 mutants reactivation	CELL-CYCLE ARREST; DNA-BINDING SITES; FUNCTIONAL ASSAY; GENE-EXPRESSION; SEQUENCE-SPECIFICITY; SUPPRESSOR PROTEIN; TERMINAL DOMAIN; GROWTH ARREST; CANCER-CELLS; TARGET GENE	Since highly expressed human p53 can inhibit human and yeast cell growth, we predicted that p53 mutants could be generated with increased growth inhibition of the yeast Saccharomyces cerevisiae and that these would be useful for characterizing p53 functions and tumor p53 mutants. A random mutagenesis screen led to the isolation of mutations in the DIVA binding domain that result in p53 being lethal even at moderate expression levels in yeast. Three independent mutants had an alanine change at the evolutionary invariant V122 in the L1 loop. The other toxic mutations affected codons 277 (C277R, C277W) and 279 (G279R). This latter amino acid change was also reported in tumors, while all the other mutations are novel. A recently developed rheostatable GALI promoter system that provides graded increases in expression of p53 was used to examine the transactivation function of the toxic mutations when expression was greatly reduced and cells were viable. At low expression levels the toxic mutants lacked transactivation from a 3xRGC responsive element (RE). Surprisingly some exhibited enhanced transactivation with p21 and bax REs. The V122A mutant was able to re-activate transactivation of various p53 tumor mutants and retained growth inhibition when co-expressed with dominant-negative tumor mutations. Upon expression in human Saos-2 cells the V122A p53 mutant caused growth suppression, was capable of transactivation and exhibited higher than wild type activity with the bax promoter in luciferase assays. A non-functional p53 tumor mutant was partially reactivated by V122A for both transactivation and growth suppression. Thus, the screen for toxic p53 mutants in yeast can identify novel p53 variants that may be useful in dissecting p53 regulated cellular responses and in developing p53-based cancer therapies.	NIEHS, Genet Mol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Resnick, MA (corresponding author), NIEHS, Genet Mol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.		Inga, Alberto/AAC-3815-2022; resnick, Michael/F-1668-2019	Inga, Alberto/0000-0002-8767-1637; resnick, Michael/0000-0002-8473-7506	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES065079, Z01ES065079] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Aurelio ON, 2000, MOL CELL BIOL, V20, P770, DOI 10.1128/MCB.20.3.770-778.2000; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BISCHOFF JR, 1992, MOL CELL BIOL, V12, P1405, DOI 10.1128/MCB.12.4.1405; Brachmann RK, 1996, P NATL ACAD SCI USA, V93, P4091, DOI 10.1073/pnas.93.9.4091; Brachmann RK, 1998, EMBO J, V17, P1847, DOI 10.1093/emboj/17.7.1847; Chappuis PO, 1999, INT J CANCER, V84, P587, DOI 10.1002/(SICI)1097-0215(19991222)84:6<587::AID-IJC8>3.0.CO;2-8; Chene P, 1999, BIOCHEM BIOPH RES CO, V263, P1, DOI 10.1006/bbrc.1999.1294; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Clayman GL, 1998, J CLIN ONCOL, V16, P2221, DOI 10.1200/JCO.1998.16.6.2221; Cortes U, 2000, MOL CARCINOGEN, V27, P57, DOI 10.1002/(SICI)1098-2744(200002)27:2<57::AID-MC1>3.3.CO;2-9; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Flaman JM, 1998, ONCOGENE, V16, P1369, DOI 10.1038/sj.onc.1201889; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; FREEMAN J, 1994, EMBO J, V13, P5393, DOI 10.1002/j.1460-2075.1994.tb06874.x; Gagnebin J, 1998, ONCOGENE, V16, P685, DOI 10.1038/sj.onc.1201568; Gallagher WM, 1999, ANN ONCOL, V10, P139, DOI 10.1023/A:1008368500557; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Guardavaccaro D, 2000, MOL CELL BIOL, V20, P1797, DOI 10.1128/MCB.20.5.1797-1815.2000; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hernandez-Boussard T, 1999, HUM MUTAT, V14, P1; Inga A, 1997, CARCINOGENESIS, V18, P2019, DOI 10.1093/carcin/18.10.2019; Inga A, 1997, ONCOGENE, V14, P1307, DOI 10.1038/sj.onc.1200952; Inga A, 2001, ONCOGENE, V20, P501, DOI 10.1038/sj.onc.1204116; ISHIOKA C, 1995, ONCOGENE, V10, P1485; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; LIN JY, 1995, ONCOGENE, V10, P2387; LinGoerke JL, 1997, BIOTECHNIQUES, V23, P409, DOI 10.2144/97233bm12; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; Meek DW, 1998, INT J RADIAT BIOL, V74, P729, DOI 10.1080/095530098141005; NIGRO JM, 1992, MOL CELL BIOL, V12, P1357, DOI 10.1128/MCB.12.3.1357; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ohki R, 2000, J BIOL CHEM, V275, P22627, DOI 10.1074/jbc.C000235200; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Prives C, 1999, J PATHOL, V187, P112; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; Robert V, 2000, CARCINOGENESIS, V21, P563, DOI 10.1093/carcin/21.4.563; ROLLEY N, 1995, ONCOGENE, V11, P763; Saller E, 1999, EMBO J, V18, P4424, DOI 10.1093/emboj/18.16.4424; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; Selivanova G, 1999, MOL CELL BIOL, V19, P3395; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; Swisher SG, 1999, J NATL CANCER I, V91, P763, DOI 10.1093/jnci/91.9.763; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Thornborrow EC, 1999, J BIOL CHEM, V274, P33747, DOI 10.1074/jbc.274.47.33747; THUKRAL SK, 1995, MOL CELL BIOL, V15, P5196; Velasco-Miguel S, 1999, ONCOGENE, V18, P127, DOI 10.1038/sj.onc.1202274; Vinyals A, 1999, GENE THER, V6, P22, DOI 10.1038/sj.gt.3300786; Walker DR, 1999, ONCOGENE, V18, P211, DOI 10.1038/sj.onc.1202298; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Wieczorek AM, 1996, NAT MED, V2, P1143, DOI 10.1038/nm1096-1143; Wolf JK, 1999, GYNECOL ONCOL, V75, P261, DOI 10.1006/gyno.1999.5565; Wong KB, 1999, P NATL ACAD SCI USA, V96, P8438, DOI 10.1073/pnas.96.15.8438; Zhu JH, 2000, MOL CELL BIOL, V20, P5602, DOI 10.1128/MCB.20.15.5602-5618.2000	62	42	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2001	20	26					3409	3419		10.1038/sj.onc.1204457	http://dx.doi.org/10.1038/sj.onc.1204457			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423991				2022-12-17	WOS:000169248800011
J	Agarwal, ML; Ramana, CV; Hamilton, M; Taylor, WR; DePrimo, SE; Bean, LJH; Agarwal, A; Agarwal, MK; Wolfman, A; Stark, GR				Agarwal, ML; Ramana, CV; Hamilton, M; Taylor, WR; DePrimo, SE; Bean, LJH; Agarwal, A; Agarwal, MK; Wolfman, A; Stark, GR			Regulation of p53 expression by the RAS-MAP kinase pathway	ONCOGENE			English	Article						mutant cells; p53; mRNA levels; p21 expression	TUMOR-SUPPRESSOR P53; ALPHA-INTERFERON; SIGNALING PATHWAY; MAMMALIAN-CELLS; IN-VIVO; PROTEIN; GENE; TRANSFORMATION; SENESCENCE; CASCADE	Activation of MAP kinase leads to the activation of p53-dependent pathways, and vice-versa. Although the amount of p53 protein increases in response to MAP kinase-dependent signaling, the basis of this increase is not yet fully understood. We have isolated the mutant cell line AP14, defective in p53 expression, from human HT1080 fibrosarcoma cells, which have an activated ras allele, The expression of p53 mRNA and protein is similar to 10-fold lower in AP14 cells than in the parental cells. The high constitutive phosphorylation and activities of the MAP kinases ERK1 and ERK2 in HT1080 cells are greatly reduced in AP14 cells, although the levels of these proteins are unchanged, suggesting that the defect in the mutant cells affects the steady-state phosphorylation of ERK1 and ERK2, Overexpression of ERK2 in AP14 cells restored both MAP kinase activity and p53 expression, and incubation of the mutant cells with the phosphatase inhibitor orthovanadate resulted in strong coordinate elevation of MAP kinase activity and p53 expression. The levels of expression of the p53-regulated gene p21 parallel those of p53 throughout, showing that basal p21 expression depends on p53, The levels of p53 mRNA increased by 5-8-fold when activated ras was introduced into wild-type cells, and the levels of the p53 and p21 proteins decreased substantially in wild-type cells treated with the MEK inhibitor U0216, We conclude that MAP kinase-dependent pathways help to regulate p53 levels by regulating the expression of p53 mRNA.	Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Stark, GR (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.			chilakamarti, ramana/0000-0002-5153-8252	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051277] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51277] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; ANDERSON MJ, 1994, GENE CHROMOSOME CANC, V9, P266, DOI 10.1002/gcc.2870090407; CASEY G, 1993, CANCER LETT, V69, P151, DOI 10.1016/0304-3835(93)90168-9; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Fukasawa K, 1997, MOL CELL BIOL, V17, P506, DOI 10.1128/MCB.17.1.506; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Hamilton M, 1998, ONCOGENE, V16, P1417, DOI 10.1038/sj.onc.1201653; Harlow E LD, 1988, ANTIBODIES LAB MANUA; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; Lee SW, 2000, P NATL ACAD SCI USA, V97, P8302, DOI 10.1073/pnas.150024397; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li XX, 1999, MOL CELL BIOL, V19, P4643; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; Plattner R, 1996, P NATL ACAD SCI USA, V93, P6665, DOI 10.1073/pnas.93.13.6665; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; SAMBROOK J, 1989, MOL CLONING, V9, P14; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2000, CANCER RES, V60, P3689; Stark GR, 1999, HUM MOL GENET, V8, P1925, DOI 10.1093/hmg/8.10.1925; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Tang H, 1998, J BIOL CHEM, V273, P29156, DOI 10.1074/jbc.273.44.29156; Venanzoni MC, 1996, ONCOGENE, V12, P1199; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	42	42	43	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 3	2001	20	20					2527	2536		10.1038/sj.onc.1204353	http://dx.doi.org/10.1038/sj.onc.1204353			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VM	11420662				2022-12-17	WOS:000168652500003
J	Bilanges, B; Varrault, A; Mazumdar, A; Pantaloni, C; Hoffmann, A; Bockaert, J; Spengler, D; Journot, L				Bilanges, B; Varrault, A; Mazumdar, A; Pantaloni, C; Hoffmann, A; Bockaert, J; Spengler, D; Journot, L			Alternative splicing of the imprinted candidate tumor suppressor gene ZAC regulates its antiproliferative and DNA binding activities	ONCOGENE			English	Article						ZAC; cell cycle; apoptosis; breast cancer; transient neonatal diabetes; imprinting	ZINC-FINGER PROTEIN; TRANSCRIPTION FACTOR-I; BREAST-CANCER; CHROMOSOME 6Q; CELLS; HETEROZYGOSITY; IDENTIFICATION; SPECIFICITY; EXPRESSION; CARCINOMAS	ZAC encodes a zinc finger protein with antiproliferative activity, is maternally imprinted and is a candidate for the tumor suppressor gene on 6q24, ZAC expression is frequently lost in breast and ovary tumor-derived cell lines and down-regulated in breast primary tumors. In this report, we describe ZAC Delta2, an alternatively spliced variant of ZAC lacking the sequence encoding the two IV-terminal zinc fingers. Messenger RNAs encoding ZAC or ZAC Delta2 mere equally abundant and both proteins were nuclear. ZAC Delta2 displayed an improved transactivation activity and an enhanced affinity for a ZAC binding site, suggesting that the two N-terminal zinc fingers negatively regulated ZAC binding to its target DNA sequences. Both proteins were equally efficient in preventing colony formation, indicating similar overall antiproliferative activities. However, these activities resulted from a differential regulation of apoptosis vs cell cycle progression since ZAC Delta2 was more efficient at induction of cell cycle arrest than ZAC, whereas it was the reverse for apoptosis induction. Hence, these data further underline that ZAC gene is critically controlled, both at the transcriptional level through imprinting and at the functional level through alternative splicing.	CNRS, UPR 9023, F-34094 Montpellier 05, France; Max Planck Inst Psychiat, D-80804 Munich, Germany	Centre National de la Recherche Scientifique (CNRS); Max Planck Society	Journot, L (corresponding author), CNRS, UPR 9023, 141 Rue Cardonille, F-34094 Montpellier 05, France.		Journot, Laurent/T-9652-2018; Bilanges, Benoit/AAP-6078-2020	Journot, Laurent/0000-0003-3499-8887; Bilanges, Benoit/0000-0003-4400-3716				Abdollahi A, 1997, CANCER RES, V57, P2029; Abdollahi A, 1999, ONCOGENE, V18, P6477, DOI 10.1038/sj.onc.1203067; Abdollahi A, 1997, ONCOGENE, V14, P1973, DOI 10.1038/sj.onc.1201034; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; Bilanges B, 1999, ONCOGENE, V18, P3979, DOI 10.1038/sj.onc.1202933; Cabanillas AM, 1996, DNA CELL BIOL, V15, P643, DOI 10.1089/dna.1996.15.643; Cave H, 2000, DIABETES, V49, P108, DOI 10.2337/diabetes.49.1.108; Chappell SA, 1997, BRIT J CANCER, V75, P1324, DOI 10.1038/bjc.1997.224; Chen XH, 1999, BIOCHEMISTRY-US, V38, P12915, DOI 10.1021/bi9913000; Chen XH, 1998, BIOCHEMISTRY-US, V37, P11152, DOI 10.1021/bi980843r; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DEVILEE P, 1991, ONCOGENE, V6, P1705; FERGUSON AW, 1970, ARCH DIS CHILD, V45, P80, DOI 10.1136/adc.45.239.80; Fujii H, 1996, GENE CHROMOSOME CANC, V16, P35, DOI 10.1002/(SICI)1098-2264(199605)16:1<35::AID-GCC5>3.0.CO;2-4; Gardner RJ, 2000, HUM MOL GENET, V9, P589, DOI 10.1093/hmg/9.4.589; GOGOS JA, 1992, SCIENCE, V257, P1951, DOI 10.1126/science.1290524; HANAS JS, 1983, J BIOL CHEM, V258, P4120; HSU T, 1992, SCIENCE, V257, P1946, DOI 10.1126/science.1411512; Huang SM, 2000, MOL CELL BIOL, V20, P1855, DOI 10.1128/MCB.20.5.1855-1867.2000; Kamiya M, 2000, HUM MOL GENET, V9, P453, DOI 10.1093/hmg/9.3.453; Kas K, 1997, NAT GENET, V15, P170, DOI 10.1038/ng0297-170; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; Lassus P, 1998, NUCLEIC ACIDS RES, V26, P5233, DOI 10.1093/nar/26.22.5233; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; NEGRINI M, 1994, CANCER RES, V54, P1331; Nishizaki T, 1997, GENE CHROMOSOME CANC, V19, P267, DOI 10.1002/(SICI)1098-2264(199708)19:4<267::AID-GCC9>3.0.CO;2-V; Noviello C, 1996, CLIN CANCER RES, V2, P1601; ORPHANOS V, 1995, BRIT J CANCER, V71, P290, DOI 10.1038/bjc.1995.58; Queimado L, 1999, LAB INVEST, V79, P583; READ D, 1992, EMBO J, V11, P1035, DOI 10.1002/j.1460-2075.1992.tb05142.x; Scharnhorst V, 1997, CELL GROWTH DIFFER, V8, P133; Sheng ZM, 1996, BRIT J CANCER, V73, P144, DOI 10.1038/bjc.1996.27; Spengler D, 1997, EMBO J, V16, P2814, DOI 10.1093/emboj/16.10.2814; Theile M, 1996, ONCOGENE, V13, P677; Trainor CD, 2000, J BIOL CHEM, V275, P28157; Varrault A, 1998, P NATL ACAD SCI USA, V95, P8835, DOI 10.1073/pnas.95.15.8835	39	42	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2001	20	10					1246	1253		10.1038/sj.onc.1204237	http://dx.doi.org/10.1038/sj.onc.1204237			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412TH	11313869				2022-12-17	WOS:000167570100012
J	Nguyen, KT; Wang, WJ; Chan, JLK; Wang, LH				Nguyen, KT; Wang, WJ; Chan, JLK; Wang, LH			Differential requirements of the MAP kinase and PI3 kinase signaling pathways in Src- versus insulin and IGF-1 receptors-induced growth and transformation of rat intestinal epithelial cells	ONCOGENE			English	Article						Src; IR; IGFR; MAPK; PI3K; transformation	FACTOR-I RECEPTOR; ACTIVATED PROTEIN-KINASE; AVIAN-SARCOMA VIRUS; C-SRC; TYROSINE KINASES; STAT3 ACTIVATION; ONCOGENIC ROS; V-SRC; GENE; TUMOR	There have been few studies on the specific signaling pathways involved in the transformation of epithelial cells by oncogenic protein tyrosine kinases. Here we investigate the requirement of MAP (MAPK) and phosphatidylinositol 3-(PI3K) kinases in the transformation of rat intestinal epithelial (RIE) cells by oncogenic forms of insulin receptor (gag-IR), insulin-like growth factor-1 receptor (gag-ICFR), and v-Src. MAPK is not significantly activated in cells transformed by gag-IR and gag-IGFR but is activated in v-Src transformed cells. Treatment with PD98059, a MEK inhibitor, at concentrations where MAPK activity was reduced below the basal level showed that MAPK is partially required for the monolayer growth of parental and transformed RIE cells. However, MAPK is not essential for the focus forming ability of the three oncogene-transformed cells. It is also not necessary for the colony forming ability of gag-IR- and gag-IGFR-, but is partially required for v-Src-transformed cells. PI3K is significantly activated in all three oncogene transformed RIE cells. LY294002, a PI3K inhibitor, potently inhibited monolayer growth of all three oncogene-transformed cells. However, at concentrations of LY294002 where activated forms of Akt, a downstream component of the PI3K pathway, were undetectable, colony and focus forming abilities of the v-Src-RIE cells were only slightly affected whereas those of gag-IR/IGFR-RIE cells were greatly inhibited. These results were confirmed using a different pharmacological inhibitor, wortmannin, and a dominant negative form of PI3K, Delta p85. Similarly, rapamycin, known to inhibit p70S6 kinase, a downstream component of the PI3K-Akt pathway, also inhibited gag-IR/IGFR-induced, but not v-Src-induced, focus and colony formation. We conclude that the MAPK and PI3K signaling pathways are differentially required for transformation of RIE cells by oncogenic IR and IGFR versus Src and the pattern of requirements is different from that of fibroblast transformation.	CUNY Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Wang, LH (corresponding author), CUNY Mt Sinai Sch Med, Dept Microbiol, 1 Gustave L Levy Pl, New York, NY 10029 USA.				NATIONAL CANCER INSTITUTE [R01CA055054] Funding Source: NIH RePORTER; NCI NIH HHS [CA55054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aftab DT, 1997, P NATL ACAD SCI USA, V94, P3028, DOI 10.1073/pnas.94.7.3028; AMFO K, 1995, ONCOGENE, V11, P351; BASERGA R, 1995, CANCER RES, V55, P249; BECK EP, 1994, GYNECOL ONCOL, V53, P196, DOI 10.1006/gyno.1994.1115; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Chan JLK, 1997, J BIOL CHEM, V272, P146; Chen J, 1997, P NATL ACAD SCI USA, V94, P2295, DOI 10.1073/pnas.94.6.2295; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Conway AM, 1999, BIOCHEM J, V337, P171, DOI 10.1042/0264-6021:3370171; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Frittitta L, 1999, CANCER-AM CANCER SOC, V85, P492, DOI 10.1002/(SICI)1097-0142(19990115)85:2<492::AID-CNCR30>3.0.CO;2-I; FUKUI Y, 1989, ONCOGENE RES, V4, P283; GARCIA R, 1991, ONCOGENE, V6, P1983; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; Greulich H, 1996, ONCOGENE, V12, P1689; GUO YS, 1992, GASTROENTEROLOGY, V102, P1101; Jiang YX, 1996, J BIOL CHEM, V271, P160, DOI 10.1074/jbc.271.1.160; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Ligon AH, 1998, J NEUROVIROL, V4, P217, DOI 10.3109/13550289809114521; LIN X, 1997, CANCER RES, V57, P2402; LIU DL, 1992, J VIROL, V66, P374, DOI 10.1128/JVI.66.1.374-385.1992; LIU DL, 1993, J VIROL, V67, P6835, DOI 10.1128/JVI.67.11.6835-6840.1993; Louvi A, 1997, DEV BIOL, V189, P33, DOI 10.1006/dbio.1997.8666; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; Oldham SM, 1998, ONCOGENE, V16, P2565, DOI 10.1038/sj.onc.1201784; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PAPA V, 1993, CANCER RES, V53, P3736; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; Peterson JE, 1996, J BIOL CHEM, V271, P31562, DOI 10.1074/jbc.271.49.31562; POON B, 1991, P NATL ACAD SCI USA, V88, P877, DOI 10.1073/pnas.88.3.877; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; ROTSCH M, 1992, J CANCER RES CLIN, V118, P502, DOI 10.1007/BF01225264; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Sciacca L, 1999, ONCOGENE, V18, P2471, DOI 10.1038/sj.onc.1202600; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SHOJI S, 1990, BIOCHEM BIOPH RES CO, V173, P894, DOI 10.1016/S0006-291X(05)80870-8; Staley CA, 1997, CELL GROWTH DIFFER, V8, P269; Stofega MR, 1997, CELL GROWTH DIFFER, V8, P113; TAKEYA T, 1982, J VIROL, V44, P1; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WANG LH, 1987, P NATL ACAD SCI USA, V84, P5725, DOI 10.1073/pnas.84.16.5725; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; Werner H, 1996, ADV CANCER RES, V68, P183, DOI 10.1016/S0065-230X(08)60354-1; YAMAGUCHI Y, 1991, ENDOCRINOLOGY, V129, P2058, DOI 10.1210/endo-129-4-2058; YASHIRO T, 1989, ACTA ENDOCRINOL-COP, V121, P112, DOI 10.1530/acta.0.1210112; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065	55	42	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2000	19	47					5385	5397		10.1038/sj.onc.1203911	http://dx.doi.org/10.1038/sj.onc.1203911			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	373RH	11103940				2022-12-17	WOS:000165302300010
J	Oertli, B; Han, J; Marte, BM; Sethi, T; Downward, J; Ginsberg, M; Hughes, PE				Oertli, B; Han, J; Marte, BM; Sethi, T; Downward, J; Ginsberg, M; Hughes, PE			The effector loop and prenylation site of R-Ras are involved in the regulation of integrin function	ONCOGENE			English	Article						R-Ras; integrin activation; effector binding	NUCLEOTIDE DISSOCIATION STIMULATOR; PHOSPHOINOSITIDE 3-KINASE; CELLULAR-TRANSFORMATION; CYTOPLASMIC DOMAINS; SIGNAL-TRANSDUCTION; PUTATIVE EFFECTOR; EPITHELIAL-CELLS; PROTEIN; ACTIVATION; IDENTIFICATION	The closely related small GTP-binding proteins H-Ras and R-Ras have opposing effects on the regulation of integrin cell adhesion receptors, To gain insight into the properties of R-Ras with respect to the regulation of integrin function and interactions with downstream effecters we performed an analysis of R-Ras variants containing mutations in the effector binding domain and C-terminal prenylation site. We found that the activation of the downstream effector PI 3-kinase was sensitive to mutations in the effector binding domain, as was the binding to the effecters, Ral-GDS, Raf-1 and the novel effector Norel, Furthermore, specific mutations in the effector binding loop and C-terminal prenylation motif impaired the ability of R-Ras to regulate integrin function in CHO cells. However, the ability of the R-Ras effector loop mutants to bind, and activate known effecters did not correlate with their ability to regulate integrin function. Thus, the known R-Ras effecters are not critical for regulating integrin activation, at least in CHO cells, Consequently, these studies provide insight into the structural basis of the interactions between R-Ras and its candidate effecters and suggest the existence of novel mechanisms through which this GTPase could regulate cell adhesion.	Scripps Res Inst, Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; Imperial Canc Res Fund, Signal Transduct Lab, London WC2A 3PX, England; Univ Edinburgh, Sch Med, Dept Resp Med, Edinburgh EH8 9AG, Midlothian, Scotland	Scripps Research Institute; Cancer Research UK; University of Edinburgh	Hughes, PE (corresponding author), Scripps Res Inst, Res Inst, Dept Vasc Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Downward, Julian/A-3251-2012	Downward, Julian/0000-0002-2331-4729	NHLBI NIH HHS [HL57900] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057900] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baker EK, 1997, P NATL ACAD SCI USA, V94, P1973, DOI 10.1073/pnas.94.5.1973; BOS JL, 1997, BIOCHIM BIOPHYS ACTA, V1333, P19; COX AD, 1994, ONCOGENE, V9, P3281; Gietz RD, 1997, MOL CELL BIOCHEM, V172, P67, DOI 10.1023/A:1006859319926; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Huff SY, 1997, ONCOGENE, V14, P133, DOI 10.1038/sj.onc.1200815; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Keely PJ, 1999, J CELL BIOL, V145, P1077, DOI 10.1083/jcb.145.5.1077; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KINASHI T, 2000, IN PRESS J BIOL CHEM; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; LOWE DG, 1987, MOL CELL BIOL, V7, P2845, DOI 10.1128/MCB.7.8.2845; Magee T, 1999, CELL, V98, P9, DOI 10.1016/S0092-8674(00)80601-7; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Osada M, 1999, MOL CELL BIOL, V19, P6333; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Park SH, 1995, ONCOGENE, V11, P2349; Peterson SN, 1996, J BIOL CHEM, V271, P29903, DOI 10.1074/jbc.271.47.29903; REY I, 1994, ONCOGENE, V9, P685; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Seabra MC, 1998, CELL SIGNAL, V10, P167, DOI 10.1016/S0898-6568(97)00120-4; Sethi T, 1999, MOL BIOL CELL, V10, P1799, DOI 10.1091/mbc.10.6.1799; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; SPAARGAREN M, 1994, BIOCHEM J, V300, P303, DOI 10.1042/bj3000303; Takayama S, 1997, Methods Mol Biol, V69, P171; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wolthuis RMF, 1996, ONCOGENE, V13, P353; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zou JX, 1999, P NATL ACAD SCI USA, V96, P13813, DOI 10.1073/pnas.96.24.13813	38	42	43	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 12	2000	19	43					4961	4969		10.1038/sj.onc.1203876	http://dx.doi.org/10.1038/sj.onc.1203876			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363KF	11042683				2022-12-17	WOS:000089834300003
J	Garcia-Guzman, M; Larsen, E; Vuori, K				Garcia-Guzman, M; Larsen, E; Vuori, K			The proto-oncogene c-Cbl is a positive regulator of Met-induced MAP kinase activation: a role for the adaptor protein Crk	ONCOGENE			English	Article						kinase; oncogenesis; signal transduction; tyrosine phosphorylation	GROWTH-FACTOR RECEPTOR; UBIQUITIN-PROTEASOME PATHWAY; SIGNALING COMPLEX-FORMATION; PAPILLARY RENAL CARCINOMAS; SRC-FAMILY KINASES; GRB2 BINDING-SITE; TYROSINE KINASE; T-CELL; PROTOONCOGENE PRODUCT; EGF-RECEPTOR	Hepatocyte growth factor triggers a complex biological program leading to invasive cell growth by activating the c-Met receptor tyrosine kinase. Following activation, Met signaling is elicited via its interactions with SH2- containing proteins, or via the phosphorylation of the docking protein Gab1, and the subsequent interaction of Gab1 with additional SH2-containing effector molecules. We have previously shown that the interaction between phosphorylated Gab1 and the adaptor protein Crk mediates activation of the JNK pathway downstream of Met. We report here that c-Cbl, which is a Gab1-like docking protein, also becomes tyrosine-phosphorylated in response to Met activation and serves as a docking molecule for various SH2-containing molecules, including Crk. We further show that Cbl is similarly capable of enhancing Met-induced JNK activation, and several lines of experimentation suggests that it does so by interacting with Crk. We also show that both Cbl and Gab1 enhance Met-induced activation of another MAP kinase cascade, the ERK pathway, in a Crk-independent manner. Taken together, our studies demonstrate a previously unidentified functional role for Cbl in Met signaling and suggest that Met utilizes at least two docking proteins, Gab1 and Cbl, to activate downstream signaling pathways.	Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Vuori, K (corresponding author), Burnham Inst, Canc Res Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NCI NIH HHS [CA71560, CA76037] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071560, R01CA076037] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; Bustelo XR, 1997, ONCOGENE, V15, P2511, DOI 10.1038/sj.onc.1201430; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Ettenberg SA, 1999, ONCOGENE, V18, P1855, DOI 10.1038/sj.onc.1202499; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; Feshchenko EA, 1999, ONCOGENE, V18, P3703, DOI 10.1038/sj.onc.1202672; Fischer J, 1998, ONCOGENE, V17, P733, DOI 10.1038/sj.onc.1201983; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; Garcia-Guzman M, 1999, ONCOGENE, V18, P7775, DOI 10.1038/sj.onc.1203198; Grishin A, 2000, ONCOGENE, V19, P97, DOI 10.1038/sj.onc.1203254; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Jeffers M, 1998, ONCOGENE, V17, P2691, DOI 10.1038/sj.onc.1202209; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lupher ML, 1998, INT J BIOCHEM CELL B, V30, P439, DOI 10.1016/S1357-2725(97)00075-7; Matsuda M, 1996, CELL SIGNAL, V8, P335, DOI 10.1016/0898-6568(96)00067-8; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Sakkab D, 2000, J BIOL CHEM, V275, P10772, DOI 10.1074/jbc.275.15.10772; Sawasdikosol S, 1996, J IMMUNOL, V157, P110; Scaife RM, 2000, J CELL SCI, V113, P215; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0; Thien CBF, 1997, ONCOGENE, V15, P2909, DOI 10.1038/sj.onc.1201468; Ueno H, 1998, BLOOD, V91, P46, DOI 10.1182/blood.V91.1.46.46_46_53; Ueno H, 1997, J BIOL CHEM, V272, P8739, DOI 10.1074/jbc.272.13.8739; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; VANDEWOUDE GF, 1997, CIBA F SYMP, V212, P130; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Zell T, 1998, CURR BIOL, V8, P814, DOI 10.1016/S0960-9822(98)70323-9; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU H, 1994, J BIOL CHEM, V269, P29943; Zhuang ZP, 1998, NAT GENET, V20, P66, DOI 10.1038/1727	69	42	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2000	19	35					4058	4065		10.1038/sj.onc.1203750	http://dx.doi.org/10.1038/sj.onc.1203750			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962563				2022-12-17	WOS:000088825300012
J	Schulte, AM; Malerczyk, C; Cabal-Manzano, R; Gajarsa, JJ; List, HJ; Riegel, AT; Wellstein, A				Schulte, AM; Malerczyk, C; Cabal-Manzano, R; Gajarsa, JJ; List, HJ; Riegel, AT; Wellstein, A			Influence of the human endogenous retrovirus-like element HERV-E.PTN on the expression of growth factor pleiotrophin: a critical role of a retroviral Sp1-binding site	ONCOGENE			English	Article						pleiotrophin; HERV-E.PTN; promoter; Sp1; choriocarcinoma	TRANSCRIPTION FACTORS SP1; AFFIN REGULATORY PEPTIDE; HUMAN SALIVARY; MESSENGER-RNA; FACTOR GENE; ADULT-RAT; SP-FAMILY; CELLS; CANCER; ACTIVATION	Germ line insertion of a human endogenous retrovirus-like element (HERV-E.PTN) into the growth factor pleiotrophin (PTN) gene generated a phylogenetically new promoter driving the expression of functional HERV-PTN fusion transcripts. Here we show by in situ hybridization, that HERV-PTN fusion transcripts are expressed in malignant trophoblasts (i.e. choriocarcinoma) and in the proliferative and in the invasive trophoblasts of gestational trophoblastic tissue. Additionally, a 1.9 kb fragment of the HERV-derived PTN promoter was analysed which has strong activity when transiently transfected into choriocarcinoma JEG-3 cells in contrast to HeLa cells. Deletion of the retrovirally-derived promoter portion abolished its activity and an enhancer (+443 to +486) was identified in this region. Electrophoretic mobility shift and supershift experiments identified a Spl binding site in this enhancer and site specific mutation of this site abolished its activity in choriocarcinoma cells. Sp1 overexpression in Drosophila SL2 cells showed that the enhancer activity is mediated via Sp1 binding in vivo. Furthermore, mutation of the Sp1 binding site reduced the activity of a promoter test fragment in choriocarcinoma cells by 80%. Our result shows that a retroviral Sp1 binding site in the PTN promoter is important for the expression of growth factor pleiotrophin in human choriocarcinoma cells.	Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Dept Oncol, Washington, DC 20007 USA	Georgetown University	Schulte, AM (corresponding author), Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Dept Oncol, Res Bldg Room E312,3970 Reservoir Rd NW, Washington, DC 20007 USA.			Wellstein, Anton/0000-0002-0570-4950	NCI NIH HHS [CA58185] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058185] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLOCH B, 1992, DEV BRAIN RES, V70, P267, DOI 10.1016/0165-3806(92)90206-C; BOEHLEN P, 1991, GROWTH FACTORS, V4, P97; BOYD MT, 1993, VIROLOGY, V196, P905, DOI 10.1006/viro.1993.1556; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAUHAN AK, 1993, P NATL ACAD SCI USA, V90, P679, DOI 10.1073/pnas.90.2.679; Choudhuri R, 1997, CANCER RES, V57, P1814; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; COURTY J, 1991, BIOCHEM BIOPH RES CO, V180, P145, DOI 10.1016/S0006-291X(05)81267-7; Czubayko F, 1996, P NATL ACAD SCI USA, V93, P14753, DOI 10.1073/pnas.93.25.14753; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DICRISTOFANO A, 1995, NUCLEIC ACIDS RES, V23, P2823, DOI 10.1093/nar/23.15.2823; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; FANG WJ, 1992, J BIOL CHEM, V267, P25889; FEUCHTERMURTHY AE, 1993, NUCLEIC ACIDS RES, V21, P135, DOI 10.1093/nar/21.1.135; GATTONICELLI S, 1986, P NATL ACAD SCI USA, V83, P6127, DOI 10.1073/pnas.83.16.6127; GRAHAM CH, 1992, BIOCHEM CELL BIOL, V70, P867, DOI 10.1139/o92-135; Harris JR, 1998, BIOESSAYS, V20, P307, DOI 10.1002/(SICI)1521-1878(199804)20:4<307::AID-BIES7>3.3.CO;2-6; Herbst H, 1996, AM J PATHOL, V149, P1727; JANSON L, 1990, P NATL ACAD SCI USA, V87, P4732, DOI 10.1073/pnas.87.12.4732; JOHANSEN T, 1989, GENE, V79, P259, DOI 10.1016/0378-1119(89)90208-4; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; LAAROUBI K, 1994, GROWTH FACTORS, V10, P89, DOI 10.3109/08977199409010982; LEISER R, 1994, EXP CLIN ENDOCRINOL, V102, P122, DOI 10.1055/s-0029-1211275; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; Lin SY, 1996, MOL CELL BIOL, V16, P1668; LIU AY, 1991, CANCER RES, V51, P4107; Loewer Roswitha, 1996, Proceedings of the National Academy of Sciences of the United States of America, V93, P5177; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Nuchprayoon I, 1999, J BIOL CHEM, V274, P1085, DOI 10.1074/jbc.274.2.1085; PANOSKALTSISMORTARI A, 1995, BIOTECHNIQUES, V18, P300; Patience C, 1997, TRENDS GENET, V13, P116, DOI 10.1016/S0168-9525(97)01057-3; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; RABSON AB, 1983, NATURE, V306, P604, DOI 10.1038/306604a0; SAMUELSON LC, 1990, MOL CELL BIOL, V10, P2513, DOI 10.1128/MCB.10.6.2513; Schulte AM, 1997, TUMOUR ANGIOGENESIS, P273; Schulte AM, 1996, P NATL ACAD SCI USA, V93, P14759, DOI 10.1073/pnas.93.25.14759; Schulte AM, 1998, J VIROL, V72, P6065, DOI 10.1128/JVI.72.7.6065-6072.1998; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; Silverberg SG, 1992, ATLAS TUMOR PATHOL, P219; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; TING CN, 1992, GENE DEV, V6, P1457, DOI 10.1101/gad.6.8.1457; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; Vacherot F, 1999, PROSTATE, V38, P126, DOI 10.1002/(SICI)1097-0045(19990201)38:2<126::AID-PROS6>3.0.CO;2-C; VANDERWINDEN JM, 1992, ANAT EMBRYOL, V186, P387; WELLSTEIN A, 1992, J BIOL CHEM, V267, P2582; Wilkinson D. A., 1994, RETROVIRIDAE, P465; Zhang N, 1997, J BIOL CHEM, V272, P16733, DOI 10.1074/jbc.272.27.16733; Zhou Y, 1997, J CLIN INVEST, V99, P2139, DOI 10.1172/JCI119387	50	42	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2000	19	35					3988	3998		10.1038/sj.onc.1203742	http://dx.doi.org/10.1038/sj.onc.1203742			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962555				2022-12-17	WOS:000088825300004
J	Bemark, M; Neuberger, MS				Bemark, M; Neuberger, MS			The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a Burkitt's lymphoma line	ONCOGENE			English	Article						somatic hypermutation; immunoglobulin genes; c-MYC	HEAVY-CHAIN LOCUS; RNA-POLYMERASE-II; SOMATIC HYPERMUTATION; IMMUNOGLOBULIN GENES; CHROMOSOME-TRANSLOCATION; B-CELLS; TRANSCRIPTION; MUTATION; REGION; ACTIVATION	Burkitt's lymphomas harbour chromosomal translocations bringing c-MYC into the vicinity of one of the immunoglobulin gene loci. Point mutations have been described within c-MYC in several Burkitt's lymphomas and it has been proposed that translocation into the Ig loci might have transformed c-MYC into a substrate for the antibody hypermutation mechanism. Here we test this hypothesis by exploiting a Burkitt's lymphoma line (Ramos) that,ve have previously shown to hypermutate its immunoglobulin genes constitutively, We find that, during in vitro culture, Ramos mutates the c-MYC allele that is translocated into the IgH locus whilst leaving the untranslocated c-MYC and other control genes essentially unaffected. The mutations are introduced downstream of the c-MYC transcription start with the pattern of substitutions being characteristic of the antibody hypermutation mechanism; the mutation frequency is 2-3-fold lower than for the endogenous functional IgH allele, Thus chromosomal translocations involving the Ig loci may not only contribute to transformation by deregulating oncogene expression but could also act by potentiating subsequent oncogene hypermutation.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Bemark, M (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.		Bemark, Mats/B-2578-2019	Bemark, Mats/0000-0001-7416-9819				Bahram F, 2000, BLOOD, V95, P2104, DOI 10.1182/blood.V95.6.2104; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BETZ AG, 1994, CELL, V77, P239, DOI 10.1016/0092-8674(94)90316-6; BETZ AG, 1993, P NATL ACAD SCI USA, V90, P2385, DOI 10.1073/pnas.90.6.2385; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; CHUNG J, 1987, CELL, V51, P1001, DOI 10.1016/0092-8674(87)90586-1; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Frey S, 1998, IMMUNITY, V9, P127, DOI 10.1016/S1074-7613(00)80594-4; Fukita Y, 1998, IMMUNITY, V9, P105, DOI 10.1016/S1074-7613(00)80592-0; Goossens T, 1998, P NATL ACAD SCI USA, V95, P2463, DOI 10.1073/pnas.95.5.2463; Goyenechea B, 1997, EMBO J, V16, P3987, DOI 10.1093/emboj/16.13.3987; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; HAMLYN PH, 1983, NATURE, V304, P135, DOI 10.1038/304135a0; JOHNSTON JM, 1992, LEUKEMIA LYMPHOMA, V8, P431, DOI 10.3109/10428199209051025; JOHNSTON JM, 1991, BLOOD, V78, P2419; Keene RG, 1999, NUCLEIC ACIDS RES, V27, P3173, DOI 10.1093/nar/27.15.3173; KERPPOLA TK, 1988, MOL CELL BIOL, V8, P4389, DOI 10.1128/MCB.8.10.4389; LEBECQUE SG, 1990, J EXP MED, V172, P1717, DOI 10.1084/jem.172.6.1717; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; MORSE B, 1989, MOL CELL BIOL, V9, P74, DOI 10.1128/MCB.9.1.74; MULLER JR, 1995, P NATL ACAD SCI USA, V92, P6577, DOI 10.1073/pnas.92.14.6577; NEUBERGER MS, 1983, NATURE, V305, P240, DOI 10.1038/305240a0; PARHAM P, 1998, IMMUNOL REV; Pasqualucci L, 1998, P NATL ACAD SCI USA, V95, P11816, DOI 10.1073/pnas.95.20.11816; Peters A, 1996, IMMUNITY, V4, P57, DOI 10.1016/S1074-7613(00)80298-8; PETTERSSON S, 1990, NATURE, V344, P165, DOI 10.1038/344165a0; RABBITTS TH, 1983, NATURE, V306, P806, DOI 10.1038/306806a0; RABBITTS TH, 1984, NATURE, V309, P592, DOI 10.1038/309592a0; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; Rada C, 1997, EUR J IMMUNOL, V27, P3115, DOI 10.1002/eji.1830271206; Rada C, 1998, IMMUNITY, V9, P135, DOI 10.1016/S1074-7613(00)80595-6; Sale JE, 1998, IMMUNITY, V9, P859, DOI 10.1016/S1074-7613(00)80651-2; Shen HM, 1998, SCIENCE, V280, P1750, DOI 10.1126/science.280.5370.1750; SHOWE LC, 1987, P NATL ACAD SCI USA, V84, P2824, DOI 10.1073/pnas.84.9.2824; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; TACHIBANA K, 1993, GENE, V124, P231, DOI 10.1016/0378-1119(93)90398-M; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; Tumas-Brundage K, 1996, Semin Immunol, V8, P141, DOI 10.1006/smim.1996.0018; TumasBrundage K, 1997, J EXP MED, V185, P239, DOI 10.1084/jem.185.2.239; Wagner SD, 1996, INT IMMUNOL, V8, P701, DOI 10.1093/intimm/8.5.701; Wagner SD, 1996, ANNU REV IMMUNOL, V14, P441, DOI 10.1146/annurev.immunol.14.1.441; Wilson PC, 1998, J EXP MED, V187, P59, DOI 10.1084/jem.187.1.59; WIMAN KG, 1984, P NATL ACAD SCI-BIOL, V81, P6798, DOI 10.1073/pnas.81.21.6798; YELAMOS J, 1995, NATURE, V376, P225; ZAJECKAYE M, 1988, SCIENCE, V240, P1776	48	42	44	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 13	2000	19	30					3404	3410		10.1038/sj.onc.1203686	http://dx.doi.org/10.1038/sj.onc.1203686			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QX	10918597				2022-12-17	WOS:000088198100008
J	Su, ZZ; Shi, YJ; Fisher, PB				Su, ZZ; Shi, YJ; Fisher, PB			Cooperation between AP1 and PEA3 sites within the progression elevated gene-3 (PEG-3) promoter regulate basal and differential expression of PEG-3 during progression of the oncogenic phenotype in transformed rat embryo cells	ONCOGENE			English	Article						cancer progression; promoter analysis; transcriptional regulation	ANCHORAGE-INDEPENDENT GROWTH; TYPE-5 ADENOVIRUS; TUMOR PROMOTERS; BINDING-SITES; TRANSCRIPTION; AP-1; CANCER; INDUCTION; SUPPRESSION; PROTEIN	Cancer is a progressive disease in which a tumor cell temporally develops qualitatively new transformation related phenotypes or a further elaboration of existing transformation associated properties. Subtraction hybridization identified a novel gene associated with transformation progression in mutant adenovirus type 5, H5ts125, transformed rat embryo cells, progression elevated gene-3 (PEG-3). To define the mechanism by which expression of PEG-3 is enhanced as a function of cancer progression a 5'-flanking promoter region of similar to 2.0-kb, PEG-Prom, was Isolated, cloned and characterized. The full-length and various mutated regions of the PEG-From mere linked to a luciferase reporter construct and evaluated for promoter activity during cancer progression. These assays demonstrate a requirement for API and PEA3 sites adjacent to the TATA bos region of PEG-3 in mediating basal promoter activity and the enhanced expression of PEG-3 in progressed H5ts125-transformed rat embryo cells. An involvement of AP1 and PF Lambda 3 in PEG3 regulation was also confirmed by electrophoretic mobility shift assays (EMSA) and transfection studies with cJun and PEA3 expression vectors, Our findings document the importance of both AP1 and PEA3 transcription factors in mediating basal and elevated expression of PEG3 in H5ts125-transformed rat embryo cells displaying an aggressive and progressed cancer phenotype.	Columbia Univ Coll Phys & Surg, Dept Pathol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Urol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Neurosurg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Fisher, PB (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, Herbert Irving Comprehens Canc Ctr, BB-15-1501,630 W 168th St, New York, NY 10032 USA.				NATIONAL CANCER INSTITUTE [R01CA035675, R01CA074468] Funding Source: NIH RePORTER; NCI NIH HHS [CA74468, CA35675] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BABISS LE, 1985, SCIENCE, V228, P1099, DOI 10.1126/science.2581317; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; D'Orazio D, 1997, GENE, V201, P179, DOI 10.1016/S0378-1119(97)00445-9; DeCesare D, 1996, ONCOGENE, V13, P2551; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUIGOU GJ, 1991, ONCOGENE, V6, P1813; DUIGOU GJ, 1990, MOL CELL BIOL, V10, P2027, DOI 10.1128/MCB.10.5.2027; DUIGOU GJ, 1989, ANN NY ACAD SCI, V567, P302, DOI 10.1111/j.1749-6632.1989.tb16487.x; EDWARDS DR, 1992, BIOCHIM BIOPHYS ACTA, V1171, P41, DOI 10.1016/0167-4781(92)90138-P; FISHER PB, 1979, CELL, V18, P695, DOI 10.1016/0092-8674(79)90124-7; FISHER PB, 1982, P NATL ACAD SCI-BIOL, V79, P3527, DOI 10.1073/pnas.79.11.3527; FISHER PB, 1978, P NATL ACAD SCI USA, V75, P2311, DOI 10.1073/pnas.75.5.2311; FISHER PB, 1979, NATURE, V281, P591, DOI 10.1038/281591a0; FISHER PB, 1979, CANCER RES, V39, P3051; Fisher PB, 1984, TUMOR PROMOTION COCA, P57; Gopalkrishnan RV, 1999, NUCLEIC ACIDS RES, V27, P4775, DOI 10.1093/nar/27.24.4775; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HIGASHINO F, 1995, ONCOGENE, V10, P1461; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; Kang DC, 1998, P NATL ACAD SCI USA, V95, P13788, DOI 10.1073/pnas.95.23.13788; Kang DC, 1998, INT J ONCOL, V13, P1117; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KOHN EC, 1995, CANCER RES, V55, P1856; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; Matrisian L M, 1990, Semin Cancer Biol, V1, P107; MATRISIAN LM, 1994, ANN NY ACAD SCI, V91, P10129; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; REDDY PG, 1993, METHODS MOL GENETICS, V1, P68; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SIRUMCONNOLLY K, 1991, NUCLEIC ACIDS RES, V19, P335, DOI 10.1093/nar/19.2.335; STACEY KJ, 1995, MOL CELL BIOL, V15, P3430; SU ZZ, 1994, ONCOGENE, V9, P1123; Su ZZ, 1997, P NATL ACAD SCI USA, V94, P9125, DOI 10.1073/pnas.94.17.9125; SU ZZ, 1995, INT J ONCOL, V7, P1279; Su ZZ, 1999, P NATL ACAD SCI USA, V96, P15115, DOI 10.1073/pnas.96.26.15115; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x	45	42	47	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2000	19	30					3411	3421		10.1038/sj.onc.1203666	http://dx.doi.org/10.1038/sj.onc.1203666			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QX	10918598				2022-12-17	WOS:000088198100009
J	Broome, MA; Courtneidge, SA				Broome, MA; Courtneidge, SA			No requirement for Src family kinases for PDGF signaling in fibroblasts expressing SV40 large T antigen	ONCOGENE			English	Article						p53; PDGF; mitogenesis; Src	EPIDERMAL GROWTH-FACTOR; DNA-SYNTHESIS; SH3 DOMAIN; CELLS; TRANSDUCTION; GENE; P53	A growing body of literature suggests that the ubiquitously expressed Src family kinases (Src, Fyn and Yes) are required for agents such as platelet-derived growth factor (PDGF) to stimulate DNA synthesis. Yet Klinghoffer and colleagues recently presented evidence that fibroblasts derived from mice null for Src, Fyn and Yes responded normally to PDGF (Klinghoffer et al,, 1999, EMBO J,, 18: 2459-2471), What is the reason for this discrepancy? We noted that Klinghoffer ef al, (1999) used SV40 large T antigen (largeT) to facilitate derivation of cell lines from the embryos. We therefore tested the effect of largeT on PDGF receptor signaling, We found that expression of largeT overcame the inhibitory effects of interfering forms of both Ras (N17Ras) and Src (SrcK-). Furthermore, injection of SrcK- or the cst.1 antibody (which inhibits Src, Fyn and Yes) failed to inhibit PDGF-stimulated DNA synthesis in NIH3T3 cells expressing dominant negative p53, and fibroblasts derived from p53 null embryos. These data suggest firstly that caution should be used in interpretation of experiments conducted in cell lines expressing largeT, and secondly that the role of Src family kinases in growth factor signaling may be to oppose the effects of negative growth regulators such as p53.	SUGEN Inc, San Francisco, CA 94080 USA	Pfizer	Courtneidge, SA (corresponding author), SUGEN Inc, 230 E Grand Ave, San Francisco, CA 94080 USA.							BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DICKMANNS A, 1994, J VIROL, V68, P5496, DOI 10.1128/JVI.68.9.5496-5508.1994; Dilworth S M, 1990, Semin Cancer Biol, V1, P407; Erpel T, 1996, J BIOL CHEM, V271, P16807, DOI 10.1074/jbc.271.28.16807; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Prives C, 1999, J PATHOL, V187, P112; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991	15	42	43	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2000	19	24					2867	2869		10.1038/sj.onc.1203608	http://dx.doi.org/10.1038/sj.onc.1203608			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	320LX	10851090				2022-12-17	WOS:000087403600008
J	Yoon, Y; Ao, ZH; Cheng, Y; Schlossman, SF; Prasad, KVS				Yoon, Y; Ao, ZH; Cheng, Y; Schlossman, SF; Prasad, KVS			Murine Siva-1 and Siva-2, alternate splice forms of the mouse Siva gene, both bind to CD27 but differentially transduce apoptosis	ONCOGENE			English	Article						Siva; CD27; apoptosis; alternate splice forms; murine Siva gene; TNFR family	NECROSIS-FACTOR RECEPTOR; NF-KAPPA-B; DOMAIN-CONTAINING RECEPTOR; T-CELL ACTIVATION; RING FINGER PROTEIN; DEATH-DOMAIN; CYTOPLASMIC DOMAIN; SIGNAL-TRANSDUCTION; KINASE RIP; FAMILY	CD27, a member of the TNFR family known to provide essential co-stimulatory signals for T cell growth and B cell Ig synthesis, can also mediate cell death. Using the CD27 cytoplasmic tail as the bait in yeast two hybrid assay, me previously cloned human Siva, a pro-apoptotic molecule. Here me report the characterization of the mouse Siva gene as a 4 kb sequence containing 4 exons and 3 introns. RT-PCR has revealed the presence of two forms of mouse Siva mRNA, the longer full length form Siva-1 and the shorter Siva-2 lacking the sequence coded by exon 2. Immunoblotting with anti-Siva (human) antibodies clearly demonstrate the presence of both Siva-1 and Siva-2. Cotransfection experiments in 293T cells reveal that mouse CD27 receptor can interact with both forms of Siva. Although mouse Siva-1 can trigger apoptosis in Rat-1 cells and in some of the mouse cell lines in transient transfection experiments, similar to the observation made with human Siva, intriguingly its alternate splice form, Siva-2 appears to be much less toxic. It is therefore likely that Siva-2 could regulate the function of Siva-1.	Dana Farber Canc Inst, Div Tumor Immunol, Dept Canc Immunol & Aids, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Prasad, KVS (corresponding author), Dana Farber Canc Inst, Div Tumor Immunol, Dept Canc Immunol & Aids, M552,44 Binney St, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056706] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56706] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGEMATSU K, 1994, J IMMUNOL, V153, P1421; Akiba H, 1998, J BIOL CHEM, V273, P13353, DOI 10.1074/jbc.273.21.13353; Baker SJ, 1996, ONCOGENE, V12, P1; Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CAMERINI D, 1991, J IMMUNOL, V147, P3165; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; Gedrich RW, 1996, J BIOL CHEM, V271, P12852, DOI 10.1074/jbc.271.22.12852; GRAVESTEIN LA, 1993, EUR J IMMUNOL, V23, P943, DOI 10.1002/eji.1830230427; HINTZEN RQ, 1995, J IMMUNOL, V154, P2612; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HU HM, 1994, J BIOL CHEM, V269, P30069; ITOH N, 1993, J BIOL CHEM, V268, P10932; Jacquot S, 1997, J IMMUNOL, V159, P2652; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; KOBATA T, 1995, P NATL ACAD SCI USA, V92, P11249, DOI 10.1073/pnas.92.24.11249; KOBATA T, 1994, J IMMUNOL, V153, P5422; Lee SY, 1996, J EXP MED, V183, P669, DOI 10.1084/jem.183.2.669; Lee SY, 1996, P NATL ACAD SCI USA, V93, P9699, DOI 10.1073/pnas.93.18.9699; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Nocentini G, 1997, P NATL ACAD SCI USA, V94, P6216, DOI 10.1073/pnas.94.12.6216; Padanilam BJ, 1998, KIDNEY INT, V54, P1967, DOI 10.1046/j.1523-1755.1998.00197.x; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Prasad KVS, 1997, P NATL ACAD SCI USA, V94, P6346, DOI 10.1073/pnas.94.12.6346; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; Screaton GR, 1997, P NATL ACAD SCI USA, V94, P4615, DOI 10.1073/pnas.94.9.4615; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SONG HY, 1995, BIOCHEM J, V309, P825, DOI 10.1042/bj3090825; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Walsh CM, 1998, IMMUNITY, V8, P439, DOI 10.1016/S1074-7613(00)80549-X; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681	49	42	46	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7174	7179		10.1038/sj.onc.1203144	http://dx.doi.org/10.1038/sj.onc.1203144			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597319				2022-12-17	WOS:000083901900025
J	Ohta, T; Michel, JJ; Xiong, Y				Ohta, T; Michel, JJ; Xiong, Y			Association with cullin partners protects ROC proteins from proteasome-dependent degradation	ONCOGENE			English	Article						ROC family; cullins; proteasome-dependent degradation	CELL-CYCLE; UBIQUITIN-LIGASE; S-PHASE; F-BOX; COMPLEX; PROTEOLYSIS; FAMILY; KINASE; IDENTIFICATION; CONJUGATION	Cullin 1/CDC53 represents a multigene family and has been linked to the ubiquitin-mediated proteolysis of several different proteins. We recently identified two closely related RING finger proteins, ROC1 and ROC2, that share considerable sequence similarity to an APC subunit, APC11, and demonstrated ROC1 as an essential subunit of CUL1 and CDC53 ubiquitin ligases. We report here that the expression of ROC1, ROC2 and APC11 genes are induced by mitogens and remain constant during the cell cycle. Unlike other subunits of SCF and APC E3 ligases, ectopically expressed ROC family proteins are degraded by a proteasome-inhibitor sensitive pathway and are stabilized by associating with cullins. Mutations at the conserved Phe79 and His80 residues in the RING finger of ROC1 diminish its binding with cullins, resulting in a loss of cullin protection and ubiquitin ligase activity. These results suggest a potential mechanism for regulating the activity of ROC-cullin ligases through complex assembly and ROC/APC11 subunit ubiquitination.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Program Mol Biol & Biotechnol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Xiong, Y (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.			Ohta, Tomohiko/0000-0002-9700-7342	NCI NIH HHS [CA68377, CA65572] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068377, R01CA065572] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; JENKINS CW, 1995, CELL CYCLE MAT METHO, P250; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; LI Y, 1994, ONCOGENE, V9, P2261; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Mathias N, 1996, MOL CELL BIOL, V16, P6634; Mathias N, 1999, MOL CELL BIOL, V19, P1759; Michel JJ, 1998, CELL GROWTH DIFFER, V9, P435; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Yu HT, 1998, SCIENCE, V279, P1219, DOI 10.1126/science.279.5354.1219; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2	33	42	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	1999	18	48					6758	6766		10.1038/sj.onc.1203115	http://dx.doi.org/10.1038/sj.onc.1203115			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597284				2022-12-17	WOS:000083792000018
J	Furth, PA; Bar-Peled, U; Li, ML; Lewis, A; Laucirica, R; Jager, R; Weiher, H; Russell, RG				Furth, PA; Bar-Peled, U; Li, ML; Lewis, A; Laucirica, R; Jager, R; Weiher, H; Russell, RG			Loss of anti-mitotic effects of Bcl-2 with retention of anti-apoptotic activity during tumor progression in a mouse model	ONCOGENE			English	Article						Bcl-2; cancer progression; mitosis; apoptosis; mouse model	DEPENDENT PROTEIN-KINASES; CELL-CYCLE PROGRESSION; LYMPH-NODE METASTASES; LARGE-T-ANTIGEN; BREAST-CANCER; MAMMARY-GLAND; REDUCES PROLIFERATION; TRANSGENE EXPRESSION; SUPPRESSION; FAMILY	Bcl-2 is an anti-apoptotic and anti-proliferative protein over-expressed in several different human cancers including breast, Gain of Bcl-2 function in mammary epithelial cells was superimposed on the WAP-TAg transgenic mouse model of breast cancer progression to determine its effect on epithelial cell survival and proliferation at three key stages in oncogenesis: the initial proliferative process, hyperplasia, and cancer. During the initial proliferative process, Bcl-2 strongly inhibited both apoptosis and mitotic activity. However as tumorigenesis progressed to hyperplasia and adenocarcinoma, the inhibitory effects on mitotic activity were lost. In contrast, anti-apoptotic activity persisted in both hyperplasias and adenocarcinomas. These results demonstrate that the inhibitory effect of Bcl-2 on epithelial cell proliferation and apoptosis can separate during cancer progression. In this model, retention of anti-apoptotic activity with loss of anti-proliferative action resulted in earlier tumor presentation.	Univ Maryland, Ctr Med Biotechnol, Inst Human Virol, Sch Med,Dept Med,Div Infect Dis, Baltimore, MD 21201 USA; Baltimore Vet Affairs Med Ctr, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Baylor Coll Med, Houston, TX 77030 USA; Methodist Hosp, Houston, TX 77030 USA; Forschungszentrum Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany; Inst Diabet Forsch, D-80804 Munich, Germany	University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baltimore VA Medical Center; University System of Maryland; University of Maryland Baltimore; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Helmholtz Association; Karlsruhe Institute of Technology	Furth, PA (corresponding author), Univ Maryland, Ctr Med Biotechnol, Inst Human Virol, Sch Med,Dept Med,Div Infect Dis, 725 W Lombard St,Room N545, Baltimore, MD 21201 USA.		Jager, Richard/B-9478-2009	Jager, Richard/0000-0002-1623-1917	NATIONAL CANCER INSTITUTE [R29CA068033] Funding Source: NIH RePORTER; NCI NIH HHS [CA-68033] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; BASOLO F, 1994, INT J CANCER, V56, P736, DOI 10.1002/ijc.2910560521; Bonetti A, 1998, CLIN CANCER RES, V4, P2331; Borner C, 1996, J BIOL CHEM, V271, P12695, DOI 10.1074/jbc.271.22.12695; Bottinger EP, 1997, CANCER RES, V57, P5564; Castano E, 1998, MOL CELL BIOL, V18, P5380, DOI 10.1128/MCB.18.9.5380; Coats S, 1999, CURR BIOL, V9, P163, DOI 10.1016/S0960-9822(99)80086-4; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; DEMERIL D, 1996, CANCER, V77, P1494; FRANCH HA, 1995, J CELL BIOL, V129, P245, DOI 10.1083/jcb.129.1.245; Frankfurt OS, 1997, CLIN CANCER RES, V3, P465; GASPARINI G, 1995, CLIN CANCER RES, V1, P189; Gil-Gomez G, 1998, EMBO J, V17, P7209, DOI 10.1093/emboj/17.24.7209; Hakem A, 1999, J EXP MED, V189, P957, DOI 10.1084/jem.189.6.957; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Jager R, 1997, ONCOGENE, V15, P1787, DOI 10.1038/sj.onc.1201353; JERRY DJ, 1994, MOL CARCINOGEN, V9, P175, DOI 10.1002/mc.2940090309; Kitada S, 1998, AM J PATHOL, V152, P51; KORSMEYER SJ, 1992, BLOOD, V80, P879; Li ML, 1996, CELL GROWTH DIFFER, V7, P3; Li ML, 1996, CELL GROWTH DIFFER, V7, P13; Lind EF, 1999, J IMMUNOL, V162, P5374; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MOSES HL, 1992, MOL REPROD DEV, V32, P179, DOI 10.1002/mrd.1080320215; OReilly LA, 1997, J IMMUNOL, V159, P2301; OReilly LA, 1997, INT IMMUNOL, V9, P1291, DOI 10.1093/intimm/9.9.1291; PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254; PIETENPOL JA, 1994, CANCER RES, V54, P3714; Pillai MR, 1996, CANCER EPIDEM BIOMAR, V5, P329; Ravaioli A, 1998, CELL PROLIFERAT, V31, P113; SAEGUSA M, 1995, CANCER, V76, P2297, DOI 10.1002/1097-0142(19951201)76:11<2297::AID-CNCR2820761118>3.0.CO;2-B; Schorr K, 1999, CANCER RES, V59, P2541; Schorr K, 1999, J MAMMARY GLAND BIOL, V4, P153, DOI 10.1023/A:1018773123899; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SHANKEY TV, 1993, CYTOMETRY, V14, P472, DOI 10.1002/cyto.990140503; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; Sierra A, 1996, CLIN CANCER RES, V2, P1887; Strom DK, 1998, CELL GROWTH DIFFER, V9, P59; Theodorakis P, 1996, ONCOGENE, V12, P1707; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TZENG YJ, 1993, ONCOGENE, V8, P1965; Uhlmann EJ, 1996, CANCER RES, V56, P2506; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408; Zapata JM, 1998, BREAST CANCER RES TR, V47, P129, DOI 10.1023/A:1005940832123; Zhang GJ, 1998, ONCOL REP, V5, P1211	48	42	42	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6589	6596		10.1038/sj.onc.1203073	http://dx.doi.org/10.1038/sj.onc.1203073			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597263				2022-12-17	WOS:000083709200023
J	Irie, M; Hata, Y; Deguchi, M; Ide, N; Hirao, K; Yao, I; Nishioka, H; Takai, Y				Irie, M; Hata, Y; Deguchi, M; Ide, N; Hirao, K; Yao, I; Nishioka, H; Takai, Y			Isolation and characterization of mammalian homologues of Caenorhabditis elegans lin-7: localization at cell-cell junctions	ONCOGENE			English	Article						lin-7; cadherin; cell-cell junction	SYNAPTIC VESICLE EXOCYTOSIS; FILAMENT-BINDING PROTEIN; TUMOR-SUPPRESSOR PROTEIN; VULVAR INDUCTION; EPITHELIAL-CELLS; PDZ DOMAIN; TIGHT JUNCTION; MOLECULAR ARCHITECTURE; RECEPTOR LOCALIZATION; BASOLATERAL MEMBRANE	In Caenorhabditis elegans, the vulval induction is mediated by the let-23 receptor tyrosine kinase (RTK)/ Ras signaling pathway. The precise localization of the let-23 RTK at the epithelial junctions is essential for the vulval induction, and requires three genes including lin-2, -7, and -10. The mammalian homologue of lin-2 has been identified as a protein interacting with a neuronal adhesion molecule, neurexin, and named CASK. CASK has recently been reported to interact with syndecans and an actin-binding protein, band 4.1, at epithelial and synaptic junctions, and to play central roles in the formation of cell-cell junctions. The product of C. elegans lin-7 directly interacts with let-23 RTK and localize it at epithelial junctions. Here, we report three rat homologues of lin-7 ubiquitously expressed in various tissues, These homologues are accumulated at the junctional complex region in cultured Madin-Darby canine kidney cells, and are also localized at the synaptic junctions in neurons. The mammalian homologues of lin-7 may be implicated in the formation of cell-cell junctions.	JCR Pharmaceut Co Ltd, Japan Sci & Technol Corp, ERATO, Takai Biotimer Project,Nishi Ku, Kobe, Hyogo 6512241, Japan; Osaka Univ, Sch Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan	Japan Science & Technology Agency (JST); Osaka University	Takai, Y (corresponding author), JCR Pharmaceut Co Ltd, Japan Sci & Technol Corp, ERATO, Takai Biotimer Project,Nishi Ku, 2-2-10 Murotani, Kobe, Hyogo 6512241, Japan.							Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; Anderson JM, 1993, CURR OPIN CELL BIOL, V5, P772, DOI 10.1016/0955-0674(93)90024-K; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; Beatch M, 1996, J BIOL CHEM, V271, P25723, DOI 10.1074/jbc.271.42.25723; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; DUCLOS F, 1993, P NATL ACAD SCI USA, V90, P109, DOI 10.1073/pnas.90.1.109; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; GARNER C, 1996, TRENDS CELL BIOL, V19, P429; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; Hata Y, 1998, NEUROSCI RES, V32, P1, DOI 10.1016/S0168-0102(98)00069-8; Hata Y, 1996, J NEUROSCI, V16, P2488; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; Hoskins R, 1996, DEVELOPMENT, V122, P97; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; KARTENBECK J, 1991, J CELL BIOL, V113, P881, DOI 10.1083/jcb.113.4.881; KENNEDY MB, 1994, ANNU REV BIOCHEM, V63, P571, DOI 10.1146/annurev.biochem.63.1.571; KENNEDY MB, 1995, TRENDS BIOCHEM SCI, V20, P350, DOI 10.1016/S0968-0004(00)89074-X; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; Reuver SM, 1998, J CELL SCI, V111, P1071; Rongo C, 1998, CELL, V94, P751, DOI 10.1016/S0092-8674(00)81734-1; Rousset R, 1998, ONCOGENE, V16, P643, DOI 10.1038/sj.onc.1201567; SAKISAKA T, 1999, IN PRESS ONCOGENE, V18; Satoh A, 1998, J BIOL CHEM, V273, P3470, DOI 10.1074/jbc.273.6.3470; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tsukita S, 1997, SOC GEN PHY, V52, P69; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834	47	42	49	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	1999	18	18					2811	2817		10.1038/sj.onc.1202652	http://dx.doi.org/10.1038/sj.onc.1202652			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FK	10362251				2022-12-17	WOS:000080125100003
J	Rutberg, SE; Adams, TL; Olive, M; Alexander, N; Vinson, C; Yuspa, SH				Rutberg, SE; Adams, TL; Olive, M; Alexander, N; Vinson, C; Yuspa, SH			CRE DNA binding proteins bind to the AP-1 target sequence and suppress AP-1 transcriptional activity in mouse keratinocytes	ONCOGENE			English	Article						keratinocyte; differentiation; AP-1; transcription	DIFFERENTIATION-SPECIFIC EXPRESSION; HUMAN INVOLUCRIN GENE; C-JUN; EPIDERMAL DIFFERENTIATION; REPRESSES TRANSCRIPTION; SKIN CARCINOGENESIS; PROXIMAL PROMOTER; PROFILAGGRIN GENE; RESPONSE ELEMENT; CARCINOMA-CELLS	Previously, we have shown that nuclear extracts from cultured mouse keratinocytes induced to differentiate by increasing the levels of extra-cellular calcium contain Fra-1, Fra-2, Jun B, Jun D and c-Jun proteins that bind to the AP-1 DNA binding sequence. Despite this DNA binding activity, AP-1 reporter activity was suppressed in these cells. Here, we have detected the CREB family proteins CREB and CREM alpha as additional participants in the AP-1 DNA binding complex in differentiating keratinocytes, AP-1 and CRE DNA binding activity correlated with the induction of CREB, CREM alpha and ATF-1 and CREB phosphorylation at ser(133) (ser(133) phospho-CREB) in the transition from basal to differentiating keratinocytes, but the activity of a CRE reporter remained unchanged. In contrast, the CRE reporter was activated in the presence of the dominant-negative (DN) CREB mutants, KCREB and A-CREB, proteins that dimerize with CREB family members and block their ability to bind to DNA. The increase in CRE reporter activity in the presence of these mutants suggests that CRE-mediated transcriptional activity is suppressed in keratinocytes through protein-protein interactions involving a factor that dimerizes with the CREB leucine zipper. In experiments where the A-CREB mutant was co-transfected with an AP-1 reporter construct, transcriptional activity was also increased indicating that a CREB family member binds AP-1 sites and represses AP-1 transcriptional activity as well. Exogenous expression of the transcriptional repressor CREM alpha down-regulated both CRE and AP-1 reporters in keratinocytes suggesting that this factor may contribute to the suppression of AP-1 transcriptional activity observed in differentiating keratinocytes.	NCI, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bethesda, MD 20892 USA; NCI, Biochem Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Yuspa, SH (corresponding author), Bldg 37,Room 3B25,37 Convent Dr MSC 4255, Bethesda, MD 20892 USA.				NATIONAL CANCER INSTITUTE [Z01BC005445, ZIABC005445] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Andersen B, 1997, GENE DEV, V11, P1873, DOI 10.1101/gad.11.14.1873; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Barton K, 1996, NATURE, V379, P81, DOI 10.1038/379081a0; Bernerd Francoise, 1993, Gene Expression, V3, P187; BROWN AD, 1995, ONCOGENE, V10, P1749; CASATORRES J, 1994, J BIOL CHEM, V269, P20489; CHATTON B, 1994, ONCOGENE, V9, P375; DISEPIO D, 1995, J BIOL CHEM, V270, P10792, DOI 10.1074/jbc.270.18.10792; FISHER C, 1991, DEVELOPMENT, V111, P253; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; Foulkes NS, 1996, NATURE, V381, P83, DOI 10.1038/381083a0; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; HADMAN M, 1993, ONCOGENE, V8, P1895; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HUFF CA, 1993, J BIOL CHEM, V268, P377; Jang SI, 1996, J BIOL CHEM, V271, P24105, DOI 10.1074/jbc.271.39.24105; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; KELLY D, 1995, MOL REPROD DEV, V40, P135, DOI 10.1002/mrd.1080400202; KRYLOV D, 1995, EMBO J, V14, P5329, DOI 10.1002/j.1460-2075.1995.tb00217.x; LAFYATIS R, 1990, J BIOL CHEM, V265, P19128; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; LopezBayghen E, 1996, J BIOL CHEM, V271, P512, DOI 10.1074/jbc.271.1.512; LU B, 1994, J BIOL CHEM, V269, P7443; MASQUILIER D, 1992, J BIOL CHEM, V267, P22460; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; NAVARRO JM, 1995, J BIOL CHEM, V270, P21362, DOI 10.1074/jbc.270.36.21362; OFIR R, 1991, GENE EXPRESSION, V1, P55; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; OSHIMA RG, 1990, GENE DEV, V4, P835, DOI 10.1101/gad.4.5.835; PESTELL RG, 1994, J BIOL CHEM, V269, P31090; PRESLAND RB, 1992, J BIOL CHEM, V267, P23772; REDDY SPM, 1995, J BIOL CHEM, V270, P26451, DOI 10.1074/jbc.270.44.26451; Rutberg SE, 1997, ONCOGENE, V15, P1337, DOI 10.1038/sj.onc.1201293; Rutberg SE, 1996, ONCOGENE, V13, P167; RYSECK RP, 1991, ONCOGENE, V6, P533; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; TAKAHASHI H, 1993, J INVEST DERMATOL, V100, P10, DOI 10.1111/1523-1747.ep12349867; TENNENBAUM T, 1993, CANCER RES, V53, P4803; Walker WH, 1996, J BIOL CHEM, V271, P20145, DOI 10.1074/jbc.271.33.19668; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; WATT FM, 1993, DEVELOPMENT, P185; YAMADA K, 1994, BIOCHEM MOL BIOL INT, V34, P827; YAMANISHI K, 1992, J BIOL CHEM, V267, P17858; YUSPA SH, 1994, CANCER RES, V54, P1178; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; ZHANG XK, 1994, CANCER RES, V54, P5663	56	42	42	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 25	1999	18	8					1569	1579		10.1038/sj.onc.1202463	http://dx.doi.org/10.1038/sj.onc.1202463			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102627				2022-12-17	WOS:000078770700007
J	Hosono, S; Luo, X; Hyink, DP; Schnapp, LM; Wilson, PD; Burrow, CR; Reddy, JC; Atweh, GF; Licht, JD				Hosono, S; Luo, X; Hyink, DP; Schnapp, LM; Wilson, PD; Burrow, CR; Reddy, JC; Atweh, GF; Licht, JD			WT1 expression induces features of renal epithelial differentiation in mesenchymal fibroblasts	ONCOGENE			English	Article						WT1; Wilms'; differentiation; epithelium	WILMS-TUMOR GENE; MICE LACKING GDNF; GROWTH-FACTOR-I; KIDNEY DEVELOPMENT; SUPPRESSOR WT1; TRANSCRIPTIONAL ACTIVATION; BASEMENT-MEMBRANE; PROTO-ONCOGENE; CELL-ADHESION; RECEPTOR GENE	The WT1 tumor suppressor gene, implicated in hereditofamilial and sporadic Wilms' tumor, is required for normal renal development and is up-regulated during the mesenchymal-epithelial transition. NIH3T3 fibroblasts overexpressing WT1 were less proliferative, larger in size and more firmly attached to tissue culture plastic, suggesting an alteration of their state of differentiation. These cells were studied in vivo by subcutaneous injection into nude mice, The resulting tumors exhibited epithelioid histopathology and formed desmosome-like structures. Molecular analyses of these WT1 expressing fibroblasts grown in culture and in nude mice revealed significant alterations in the expression of many kidney epithelial markers. These studies indicate that WT1 expression can initiate features of a program of epithelial differentiation consistent with a prominent role for WT1 in the mesenchymal epithelial transition that occurs during renal development. Through this work we identified a number of novel target genes for the WT1 transcription factor, including uvomorulin, integrin alpha 8 and perlecan, and suggest that WT1 may activate the IGF-II gene, also implicated in the development of Wilms' tumor.	CUNY Mt Sinai Sch Med, Brookdale Ctr Dev & Mol Biol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Licht, JD (corresponding author), CUNY Mt Sinai Sch Med, Brookdale Ctr Dev & Mol Biol, Box 1126, New York, NY 10029 USA.		Hyink, Deborah/AAT-6821-2021; Licht, Jonathan/L-4239-2019	Hyink, Deborah/0000-0001-5820-4995; Licht, Jonathan/0000-0002-3942-1369	NATIONAL CANCER INSTITUTE [R01CA059936] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054184] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA59936] Funding Source: Medline; NHLBI NIH HHS [R01 HL54184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGREZ M, 1994, J CELL BIOL, V127, P547, DOI 10.1083/jcb.127.2.547; ALBELDA SM, 1993, LAB INVEST, V68, P4; Ausubel FM, 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BECKWITH J B, 1990, Pediatric Pathology, V10, P1; BIRCHMEIER C, 1993, ANNU REV CELL BIOL, V9, P511, DOI 10.1146/annurev.cb.09.110193.002455; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Cook DM, 1996, ONCOGENE, V13, P1789; COPPES MJ, 1993, FASEB J, V7, P886, DOI 10.1096/fasebj.7.10.8393819; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; EKBLOM P, 1989, FASEB J, V3, P2141, DOI 10.1096/fasebj.3.10.2666230; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; GABBIANI G, 1972, CANCER-AM CANCER SOC, V30, P486, DOI 10.1002/1097-0142(197208)30:2<486::AID-CNCR2820300229>3.0.CO;2-F; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GERALD WL, 1992, AM J PATHOL, V140, P1031; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GOODYER P, 1995, ONCOGENE, V10, P1125; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HASTIE ND, 1994, ANNU REV GENET, V28, P523; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; Hewitt SM, 1996, ANTICANCER RES, V16, P621; HIRVONEN H, 1989, J CELL BIOL, V108, P1093, DOI 10.1083/jcb.108.3.1093; HUFF V, 1992, CANCER RES, V52, P6117; HUFF V, 1993, BIOCHIM BIOPHYS ACTA, V1155, P295, DOI 10.1016/0304-419X(93)90011-Z; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Iozzo RV, 1997, J BIOL CHEM, V272, P5219, DOI 10.1074/jbc.272.8.5219; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; Johnstone RW, 1998, J BIOL CHEM, V273, P10880, DOI 10.1074/jbc.273.18.10880; KLYMKOWSKY MW, 1989, CELL MOTIL CYTOSKEL, V14, P309, DOI 10.1002/cm.970140302; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Little M, 1997, HUM MUTAT, V9, P209, DOI 10.1002/(SICI)1098-1004(1997)9:3<209::AID-HUMU2>3.0.CO;2-2; LUO XN, 1995, ONCOGENE, V11, P743; LYONS KM, 1995, MECH DEVELOP, V50, P71, DOI 10.1016/0925-4773(94)00326-I; MACHINAMI R, 1982, VIRCHOWS ARCH A, V397, P109, DOI 10.1007/BF00430898; MAW MA, 1992, CANCER RES, V52, P3094; Menke AL, 1996, ONCOGENE, V12, P537; MIWA H, 1992, J NATL CANCER I, V84, P181, DOI 10.1093/jnci/84.3.181; Miyamoto N, 1997, DEVELOPMENT, V124, P1653; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; Muller U, 1997, CELL, V88, P603, DOI 10.1016/S0092-8674(00)81903-0; NICHOLS KE, 1995, CANCER RES, V55, P4540; OOSTERWEGEL M, 1992, DEV IMMUNOL, V3, P1, DOI 10.1155/1992/27903; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; PritchardJones K, 1997, LEUKEMIA LYMPHOMA, V27, P207, DOI 10.3109/10428199709059677; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; ROGERS SA, 1991, J CELL BIOL, V113, P1447, DOI 10.1083/jcb.113.6.1447; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; RUBIN H, 1993, DIFFERENTIATION, V53, P123, DOI 10.1111/j.1432-0436.1993.tb00652.x; RYAN G, 1995, DEVELOPMENT, V121, P867; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SANTOS E, 1983, P NATL ACAD SCI-BIOL, V80, P4679, DOI 10.1073/pnas.80.15.4679; Saxen L., 1987, ORGANOGENESIS KIDNEY; SCHNAPP LM, 1995, J CELL SCI, V108, P537; SCHNAPP LM, 1995, J BIOL CHEM, V270, P23196, DOI 10.1074/jbc.270.39.23196; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Shiozaki H, 1996, CANCER, V77, P1605, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1605::AID-CNCR4>3.3.CO;2-R; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; Torban E, 1998, BBA-MOL CELL RES, V1401, P53, DOI 10.1016/S0167-4889(97)00119-5; TSARFATY I, 1994, SCIENCE, V263, P98, DOI 10.1126/science.7505952; VANDENBORN J, 1992, KIDNEY INT, V41, P115, DOI 10.1038/ki.1992.15; vandenHeuvel LPWJ, 1995, NEPHROL DIAL TRANSPL, V10, P2205, DOI 10.1093/ndt/10.12.2205; VARNER JA, 1995, MOL BIOL CELL, V6, P725, DOI 10.1091/mbc.6.6.725; WAHRMAN MZ, 1985, TUMOUR BIOL, V6, P41; WANG ZY, 1992, J BIOL CHEM, V267, P21999; Ward A, 1995, GENE, V167, P239, DOI 10.1016/0378-1119(95)00645-1; WEKSBERG R, 1993, NAT GENET, V5, P143, DOI 10.1038/ng1093-143; WERNER H, 1995, MOL CELL BIOL, V15, P3516; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; YURCHENCO PD, 1987, J CELL BIOL, V105, P2559, DOI 10.1083/jcb.105.6.2559	73	42	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					417	427		10.1038/sj.onc.1202311	http://dx.doi.org/10.1038/sj.onc.1202311			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927198				2022-12-17	WOS:000078166500014
J	Spencer, W; Kwon, H; Crepieux, P; Leclerc, N; Lin, RT; Hiscott, J				Spencer, W; Kwon, H; Crepieux, P; Leclerc, N; Lin, RT; Hiscott, J			Taxol selectively blocks microtubule dependent NF-kappa B activation by phorbol ester via inhibition of I kappa-B alpha phosphorylation and degradation	ONCOGENE			English	Article						NF-kappa B; taxol; I kappa B; microtubules; gene regulation	PROTEIN-KINASE-C; SIGNAL-INDUCED PHOSPHORYLATION; TUMOR-NECROSIS-FACTOR; TRANSCRIPTION FACTOR; GENE-EXPRESSION; TRANSDUCTION PATHWAY; ARACHIDONIC-ACID; CANCER CELLS; MAP KINASE; TNF-ALPHA	Activation of the NF-kappa B transcription factors has been shown to be directly influenced by changes in the microtubule cytoskeleton network, To better understand cytoskeletal regulation of NF-kappa B, experiments were performed to determine whether the microtubule (MT) stabilizing agent taxol could modulate NF-kappa B activation in the presence of different NF-kappa B inducers. Pretreatment of murine NIH3T3 and human 293 cells with 5 mu M taxol resulted in complete inhibition of phorbol, 12-myristate, 13-acetate (PMA) mediated NF-kappa B activation, detected as the loss of DNA binding and reduced NF-kappa B dependent reporter gene activity. Furthermore, in COS-7 and NIH3T3 cells, PMA-induced I kappa B alpha turnover was dramatically reduced in taxol treated cells, mediated via the inhibition of I kappa-B alpha phosphorylation, However, taxol did not prevent TNF-alpha induced I kappa B alpha phosphorylation, degradation, or NF-kappa B activation, indicating that TNF-alpha acts through a microtubule-independent pathway. In vitro kinase assays with PMA stimulated cell extracts demonstrated that taxol reduced protein kinase C activity by 30%, thus implicating the loss of PKC activity as a possible regulatory target of taxol-mediated suppression of NF-kappa B, Since PMA causes modulation of cytoarchitecture through PKC activation, microtubule integrity and cell morphology was analysed by indirect immunofluorescence. Both PMA and nocodazole, a MT depolymerizing agent, caused microtubule depolymerization, whereas TNF-alpha did not alter MT integrity; concomitant taxol treatment blocked both nocodazole and PMA induced depolymerization of MTs, as well as NF-kappa B induction, thus demonstrating a link between microtubule depolymerization and NF-kappa B activation, These observations illustrate a novel biological activity of taxol as a selective inhibitor of NF-kappa B activity, suggesting a link between the state of microtubule integrity and gene regulation.	McGill Univ, Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Microbiol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada; Univ Montreal, Dept Pathol, Montreal, PQ H3C 3J7, Canada	Lady Davis Institute; McGill University; McGill University; McGill University; Universite de Montreal	Hiscott, J (corresponding author), McGill Univ, Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada.		Crepieux, Pascale/X-3217-2019; Lin, Rongtuan/A-1442-2008	Lin, Rongtuan/0000-0002-2238-3503; Spencer, Will/0000-0003-0633-1575				ALEXANDROVA AY, 1993, CELL MOTIL CYTOSKEL, V25, P254, DOI 10.1002/cm.970250306; ARNAL I, 1995, CURR BIOL, V5, P900, DOI 10.1016/S0960-9822(95)00180-1; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Basu A, 1996, CELL GROWTH DIFFER, V7, P1507; BASU A, 1990, J BIOL CHEM, V265, P8451; Beauparlant Pierre, 1996, Cytokine and Growth Factor Reviews, V7, P175, DOI 10.1016/1359-6101(96)00020-2; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BITAR R, 1995, CELL GROWTH DIFFER, V6, P965; BJORBAEK C, 1995, J BIOL CHEM, V270, P18848, DOI 10.1074/jbc.270.32.18848; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Bouron A, 1997, FEBS LETT, V404, P221, DOI 10.1016/S0014-5793(97)00135-X; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; Crepieux P, 1997, MOL CELL BIOL, V17, P7375, DOI 10.1128/MCB.17.12.7375; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; Debal V, 1997, ANTICANCER RES, V17, P1147; DEBRABANDER MJ, 1976, CANCER RES, V36, P905; DEVENTE J, 1995, CELL GROWTH DIFFER, V6, P371; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DwyerNield LD, 1996, AM J PHYSIOL-LUNG C, V270, pL526, DOI 10.1152/ajplung.1996.270.4.L526; FINCO TS, 1993, J BIOL CHEM, V268, P17676; FOGUEIRA L, 1996, J VIROL, V70, P223; Forgacs G, 1995, BIOCHEM CELL BIOL, V73, P317, DOI 10.1139/o95-040; GAROUFALIS E, 1994, J VIROL, V68, P4707, DOI 10.1128/JVI.68.8.4707-4715.1994; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; Haldar S, 1996, CANCER RES, V56, P1253; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HUGHES DA, 1995, SEMIN CELL BIOL, V6, P89, DOI 10.1016/1043-4682(95)90005-5; HYMAN AA, 1992, MOL BIOL CELL, V3, P1155, DOI 10.1091/mbc.3.10.1155; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; JUN CD, 1995, J IMMUNOL, V154, P6541; KAWASUGI K, 1995, CELL MOTIL CYTOSKEL, V31, P215, DOI 10.1002/cm.970310305; Kiley SC, 1997, CELL GROWTH DIFFER, V8, P231; Lee LF, 1997, MOL CELL BIOL, V17, P5097, DOI 10.1128/MCB.17.9.5097; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; Liu DC, 1996, CELL IMMUNOL, V174, P73, DOI 10.1006/cimm.1996.0295; Lyss G, 1997, BIOL CHEM, V378, P951, DOI 10.1515/bchm.1997.378.9.951; MANGOURA D, 1995, DEV BRAIN RES, V87, P1, DOI 10.1016/0165-3806(95)00046-G; MANIE S, 1993, J BIOL CHEM, V268, P13675; McGowan K, 1996, J CELL PHYSIOL, V167, P113, DOI 10.1002/(SICI)1097-4652(199604)167:1<113::AID-JCP13>3.0.CO;2-C; MELAMED I, 1995, BIOCHEM BIOPH RES CO, V209, P1102, DOI 10.1006/bbrc.1995.1611; MOORE GD, 1995, DEV BIOL, V170, P519, DOI 10.1006/dbio.1995.1233; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; NIU MY, 1994, CELL MOTIL CYTOSKEL, V27, P327, DOI 10.1002/cm.970270405; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Reszka AA, 1997, MOL BIOL CELL, V8, P1219, DOI 10.1091/mbc.8.7.1219; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; ROSETTE C, 1995, J CELL BIOL, V128, P1111, DOI 10.1083/jcb.128.6.1111; ROULSTON A, 1993, J VIROL, V67, P5235, DOI 10.1128/JVI.67.9.5235-5246.1993; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; Seufferlein T, 1996, CANCER RES, V56, P5758; Shibata Y, 1996, J IMMUNOL, V156, P772; Simms H, 1996, J LAB CLIN MED, V127, P364, DOI 10.1016/S0022-2143(96)90185-7; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; Sun SC, 1996, MOL CELL BIOL, V16, P1058; SWEET MJ, 1995, J INFLAMM, V45, P126; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; Vani K, 1997, BBA-MOL CELL RES, V1358, P67, DOI 10.1016/S0167-4889(97)00079-7; Veis N, 1996, J INFLAMM, V46, P106; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Young SW, 1996, FEBS LETT, V384, P181, DOI 10.1016/0014-5793(96)00287-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0	78	42	42	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	1999	18	2					495	505		10.1038/sj.onc.1202335	http://dx.doi.org/10.1038/sj.onc.1202335			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927206				2022-12-17	WOS:000078166500022
J	Han, JH; Modha, D; White, E				Han, JH; Modha, D; White, E			Interaction of E1B 19K with Bax is required to block Bax-induced loss of mitochondrial membrane potential and apoptosis	ONCOGENE			English	Article						Bax; E1B 19K; mitochondrial membrane potential; apoptosis	PROGRAMMED CELL-DEATH; CYTOCHROME-C; INTERMEDIATE FILAMENTS; 19-KILODALTON PROTEIN; BCL-2 FAMILY; DNA-DAMAGE; IN-VIVO; BCL-X(L); INHIBITION; INDUCTION	The Bcl-2 homologous region 3 (BH3) is sufficient fbr interaction of pro-apoptotic with anti-apoptotic Bcl-2 family members, and functional antagonism may determine whether cell survival or death is the outcome of this protein-protein interaction. To address the biological role of BH3, two Bax-Bcl2 chimeras were generated in which 13 amino acids encompassing BH3 was swapped between anti-apoptotic Bcl-2 and pro-apoptotic Bax, thereby generating Bax with BH3 of Bcl-2 (Bax-BH3Bcl2), and Bcl-2 with BH3 of Bax (Bcl2-BH3Bax). Function and binding of the chimeras was then assessed utilizing the adenoviral Bcl-2 homologue, E1B 19K, which blocks apoptosis, and interacts with Bax, but not with Bcl-2. E1B 19K did not interact with Bax-BH3Bcl2 but did interact with Bcl2-BH3Bax. Bax-BH3Bcl2 retained pro-apoptotic function, while Bcl2-BH3Bax did not exhibit either pro- or anti-apoptotic activity. Thus, BH3 of Bcl-2 encodes binding specificity but not the apoptotic propensity. E1B 19K could not block Bax-P3H3Bc12-induced apoptosis, suggesting that E1B 19K may act to antagonize pro-apoptotic proteins rather than as an effector of survival. Furthermore, Bax expression disrupted the mitochondrial membrane potential, which could be rescued by E1B 19K expression. Thus, BH3 controls the binding specificity among Bcl-2 family members, and direct interaction between pro-apoptotic and anti-apoptotic proteins is a mechanism to regulate mitochondrial membrane potential and apoptosis.	Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA; Rutgers State Univ, Canc Inst New Jersey, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	White, E (corresponding author), Rutgers State Univ, Ctr Adv Biotechnol & Med, 679 Hoes Lane, Piscataway, NJ 08854 USA.		White, Eileen/ABD-6745-2021	White, Eileen/0000-0003-2961-3065	NATIONAL CANCER INSTITUTE [R01CA053370, R37CA053370] Funding Source: NIH RePORTER; NCI NIH HHS [CA53370] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BOYD JM, 1995, ONCOGENE, V11, P1921; Chen G, 1996, J BIOL CHEM, V271, P24221, DOI 10.1074/jbc.271.39.24221; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; Han J, 1996, MOL CELL BIOL, V16, P5857; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Hunter JJ, 1996, J BIOL CHEM, V271, P8521, DOI 10.1074/jbc.271.15.8521; Kaushal GP, 1997, KIDNEY INT, V52, P438, DOI 10.1038/ki.1997.350; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kim CN, 1997, CANCER RES, V57, P3115; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Shimizu S, 1996, ONCOGENE, V13, P21; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; WHITE E, 1990, MOL CELL BIOL, V10, P120, DOI 10.1128/MCB.10.1.120; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WHITE E, 1989, P NATL ACAD SCI USA, V86, P9886, DOI 10.1073/pnas.86.24.9886; WHITE E, 1984, MOL CELL BIOL, V4, P2865, DOI 10.1128/MCB.4.12.2865; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha HB, 1996, MOL CELL BIOL, V16, P6494; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	43	42	42	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 10	1998	17	23					2993	3005		10.1038/sj.onc.1202215	http://dx.doi.org/10.1038/sj.onc.1202215			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146KL	9881701				2022-12-17	WOS:000077427800006
J	Le Gall, M; Grall, D; Chambard, JC; Pouyssegur, J; Van Obberghen-Schilling, E				Le Gall, M; Grall, D; Chambard, JC; Pouyssegur, J; Van Obberghen-Schilling, E			An anchorage-dependent signal distinct from p42/44 MAP kinase activation is required for cell cycle progression	ONCOGENE			English	Article						anchorage; cell cycle; MAP kinase; cyclin D1; pRb; p21(Cip/Wafl)	PROTEIN-KINASE; EXTRACELLULAR-MATRIX; ADHESION COMPLEXES; GROWTH-FACTORS; D1 EXPRESSION; PROLIFERATION; PATHWAY; ARREST; CYTOSKELETON; FIBROBLASTS	Most normal cells require both mitogens and integrin-mediated attachment for growth. It is generally accepted that the p42/p44 MAP kinase module, which can be activated by both growth factors and adhesion, prays a critical role in G0 to S phase progression of quiescent cells, Studies on various cultured fibroblasts have shown that removal of anchorage leads to cell cycle arrest in G1 and it has been proposed that adhesion-dependent G1 progression requires the joint regulation of p42/p44 MAP kinase by integrins and growth factors. In quiescent CCL39 lung fibroblasts, MAP kinase activation in response to serum becomes compromised when cells are placed in suspension. Under these conditions, serum-stimulated cells arrest their growth in mid-G1 with reduced cyclin D1 expression and increased p21(Cip/Waf1) expression, as compared to their attached counterparts. To determine whether a casual link exists between suboptimal activation of MAP kinase in non-adherent cells and the observed G1 block,we used a variant of CCL39 stably expressing an estrogen-inducible activated-Raf-1 construct (Delta Raf-1:ER), We found that even strong and sustained activation of MAP kinase with estradiol, in addition to serum, is not able to boost cyclin D1 expression levels or stimulate hyperphosphorylation of pRb in suspended CCL39-Delta Raf-1:ER cells. These results indicate that p42/p44 MAP kinase activation is not a limiting factor for G1 to S phase transit in absence of anchorage. Thus, at least one adhesion-mediated signalling event, distinct from MAP kinase activation is required for maximal cyclin D1 induction and hyperphosphorylation of pRb.	CNRS, UMR 6543, Ctr Biochim, F-06108 Nice 2, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Van Obberghen-Schilling, E (corresponding author), CNRS, UMR 6543, Ctr Biochim, Parc Valrose, F-06108 Nice 2, France.		Le Gall, Maude/C-3917-2017; Van Obberghen-Schilling, Ellen/O-1581-2016; Van Obberghen-Schilling, Ellen/Q-4372-2019; Le Gall, Maude/W-2593-2019	Le Gall, Maude/0000-0002-5372-4585; Van Obberghen-Schilling, Ellen/0000-0003-2961-0059; Van Obberghen-Schilling, Ellen/0000-0003-2961-0059; Le Gall, Maude/0000-0002-5372-4585; CHAMBARD, Jean Claude/0000-0003-4722-2308				Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; Bottazzi ME, 1997, TRENDS CELL BIOL, V7, P348, DOI 10.1016/S0962-8924(97)01114-8; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAllemain G, 1997, ONCOGENE, V14, P1981, DOI 10.1038/sj.onc.1201038; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lenormand P, 1996, J BIOL CHEM, V271, P15762, DOI 10.1074/jbc.271.26.15762; Lin TH, 1997, J BIOL CHEM, V272, P8849; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Resnitzky D, 1997, MOL CELL BIOL, V17, P5640, DOI 10.1128/MCB.17.9.5640; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHULZE A, 1996, MOL CELL BIOL, V16, P4632; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; VANOBBERGHENSCHILLING E, 1983, J CELL PHYSIOL, V115, P123, DOI 10.1002/jcp.1041150204; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	38	42	42	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	1998	17	10					1271	1277		10.1038/sj.onc.1202057	http://dx.doi.org/10.1038/sj.onc.1202057			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771970				2022-12-17	WOS:000075803300009
J	Troppmair, J; Hartkamp, J; Rapp, UR				Troppmair, J; Hartkamp, J; Rapp, UR			Activation of NF-Kappa B by oncogenic Raf in HEK 293 cells occurs through autocrine recruitment of the stress kinase cascade	ONCOGENE			English	Article						Raf; stress kinase pathway; NF-Kappa B	TRANSCRIPTION FACTOR; C-JUN; MAMMALIAN-CELLS; TYROSINE KINASE; REQUIRES RAF-1; TRANSFORMATION; EXPRESSION; SITE; PROTEINS; PATHWAY	Raf-l kinase has been implicated in the induction of NF-kappa B activity by serum growth factors, phorbol ester and PTK oncogenes. Here we show that Raf activation of NF-kappa B, as measured in reporter gene assays, occurs indirectly and requires the stress kinase cascade. The stress pathway presumably becomes activated through induction of an autocrine loop by activated Raf (Raf-BXB) as suramin, the tyrphostin AG1478 and a dominant negative mutant of the EGF-R blocked NF-kappa B activation. Raf-BXB synergizes with SAPKs and a dominant negative mutant of SEK significantly reduces activation of NF-kappa B consistent with a role of this signaling pathway in the activation of NF-kappa B.	Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany	University of Wurzburg	Rapp, UR (corresponding author), Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, Versbacher Str 5, D-97078 Wurzburg, Germany.			Troppmair, Jakob/0000-0002-0611-3837; Hartkamp, Joerg/0000-0002-6863-9228				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; BRUDER JT, 1993, NUCLEIC ACIDS RES, V21, P5229, DOI 10.1093/nar/21.22.5229; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; FINCO TS, 1993, J BIOL CHEM, V268, P17676; FLORY E, 1998, IN PRESS J VIROL; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; GARRETT JS, 1984, P NATL ACAD SCI-BIOL, V81, P7466, DOI 10.1073/pnas.81.23.7466; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HEIDECKER G, 1989, GENES SIGNAL TRANSDU, P339; Janosch P, 1996, J BIOL CHEM, V271, P13868, DOI 10.1074/jbc.271.23.13868; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LEE S, 1997, CELL, V88, P213; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LIU ZG, 1996, CELL, V87, P567; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; PAHL HL, 1995, EMBO J, V14, P2580, DOI 10.1002/j.1460-2075.1995.tb07256.x; QUI RG, 1995, NATURE, V374, P457; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; SCHRECK R, 1997, IN PRESS TRANSCRIPTI; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7070; WIRTH T, 1988, EMBO J, V7, P3109, DOI 10.1002/j.1460-2075.1988.tb03177.x; Wulczyn FG, 1996, J MOL MED, V74, P749, DOI 10.1007/s001090050078; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	48	42	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 13	1998	17	6					685	690		10.1038/sj.onc.1201981	http://dx.doi.org/10.1038/sj.onc.1201981			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715269				2022-12-17	WOS:000075337200002
J	Landgren, E; Klint, P; Yokote, K; Claesson-Welsh, L				Landgren, E; Klint, P; Yokote, K; Claesson-Welsh, L			Fibroblast growth factor receptor 1 mediates chemotaxis independently of direct SH2 domain protein binding	ONCOGENE			English	Article						FGF receptor; chemotaxis	PHOSPHOLIPASE-C-GAMMA; PDGF BETA-RECEPTOR; SIGNAL-TRANSDUCTION; POINT MUTATION; AUTOPHOSPHORYLATION SITES; KINASE INSERT; CDNA CLONING; ACTIVATION; EXPRESSION; FAMILY	Endothelial cells expressing fibroblast growth factor receptor-1 (FGFR-1) migrate and proliferate in response to treatment with FGF. We analysed ligand-induced migration and proliferation of porcine aortic endothelial cells expressing wild-type FGFR-1, point-mutated Y766F FGFR-1, unable to activate phospholipase C-gamma 1 (PLC-gamma 1), or carboxyl-terminally truncated FGFR-1, lacking either 48 (from amino acid 774 in the FGFR-1 sequence) or 63 (from amino acid 759) amino acid residues of the C-terminal tail. The truncated CT63 FGFR-1 mutant failed to mediate chemotaxis, but was in response to ligand stimulation capable of mediating proliferation of the cells, stimulation of MAP kinase activity and tyrosine phosphorylation of FRS2, an FGFR-1 specific signaling molecule. The defect in migration-capacity of CT63 was not due to loss of Y766, and thereby PLC-gamma 1 activation, since cells expressing the mutant Y7766F FGFR-1 migrated as efficiently as the wild-type receptor cells. Induction of phospholipase A(2) (PLA(2)) activity by the activated FGFR-1 was dependent on the presence of Y766, and was therefore also not critical for the chemotactic response. Although the FGFR-1 only very inefficiently mediates activation of phosphatidylinositol 3' kinase (PI 3-kinase), the PI 3-kinase inhibitor wortmannin suppressed wild-type FGFR-1 mediated migration. We conclude that the signal transduction pathway for FGFR-1 mediated migration is independent of phosphotyrosine residues in the receptor and requires activation of a wortmannin-sensitive enzyme.	Biomed Ctr, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden; Chiba Univ, Sch Med, Dept Internal Med, Chuo Ku, Chiba 260, Japan	Chiba University	Claesson-Welsh, L (corresponding author), Biomed Ctr, Dept Med Biochem & Microbiol, Box 575, S-75123 Uppsala, Sweden.							ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; AUERBACH R, 1991, PHARMACOL THERAPEUT, V51, P1, DOI 10.1016/0163-7258(91)90038-N; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CLYMAN RI, 1994, CELL ADHES COMMUN, V1, P333, DOI 10.3109/15419069409097264; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; HUANG JT, 1995, J BIOL CHEM, V270, P5065, DOI 10.1074/jbc.270.10.5065; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kanda S, 1997, J BIOL CHEM, V272, P23347, DOI 10.1074/jbc.272.37.23347; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LANDGREN E, 1995, ONCOGENE, V10, P2027; MIYAZONO K, 1987, J BIOL CHEM, V262, P4098; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; Roghani M, 1996, J BIOL CHEM, V271, P31154, DOI 10.1074/jbc.271.49.31154; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; SA G, 1994, J BIOL CHEM, V269, P3219; SHAOUL E, 1995, ONCOGENE, V10, P1553; SOROKIN A, 1994, J BIOL CHEM, V269, P17056; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; WENNSTROM S, 1992, J BIOL CHEM, V267, P13749; WENNSTROM S, 1994, ONCOGENE, V9, P651; Wennstrom S, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104816	34	42	42	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 23	1998	17	3					283	291		10.1038/sj.onc.1201936	http://dx.doi.org/10.1038/sj.onc.1201936			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	102VV	9690510				2022-12-17	WOS:000074947500003
J	Kunimura, C; Kikuchi, K; Ahmed, N; Shimizu, A; Yasumoto, S				Kunimura, C; Kikuchi, K; Ahmed, N; Shimizu, A; Yasumoto, S			Telomerase activity in a specific cell subset co-expressing integrin beta 1/EGFR but not p75(NGFR)/bcl2/integrin beta 4 in normal human epithelial cells	ONCOGENE			English	Article						bcl-2; epithelial cells; integrin beta 1, beta 4; p75(NGFR); telomerase regulation	GROWTH-FACTOR RECEPTOR; STEM-CELLS; IMMORTAL CELLS; HUMAN FIBROBLASTS; HUMAN SKIN; INTEGRIN; DIFFERENTIATION; ALPHA-6-BETA-4; HEMIDESMOSOMES; KERATINOCYTES	Telomerase activity is correlated with the immortality of various cultured cells and cancer cells. The activity, however, is also demonstrated in various normal regenerating cells which normally have a finite life span in vivo and in vitro, though its biological implication remains unclear. Using cultured normal human epithelial cells, we show that telomerase activity is associated with epithelial cell subsets which actively proliferate in vitro. Unlike in most cancer cell lines, telomerase activity was evidently up-regulated when the cells entered into S phase in primary human epithelial cells. To characterize the cells which have telomerase activity, the primary human epithelial cell population of uterine cervix was dissociated into several distinctive cellular subsets by means of immunocytochemical cell fractionation. Telomerase activity was found to be closely associated with the subset which expressed predominantly integrin pi and epidermal growth factor receptor. We further identified the telomerase-negative subpopulation which contained a small subset that strongly coexpresses p75(NGFR) low affinity nerve growth factor receptor, integrin beta 4 and bcl-2 protein. The location of the p75(NGFR)-expressing cells contrasts to that of the Ki-67 positive cells in vivo and is distinctive of telomerase positive cycling cells, indicating that these cells remain at the G0 phase, The present study supports the notion that telomerase activity is linked to cell cycle regulation, implying that telomerase is activated upon cell proliferation in regenerating normal human epithelial cells.	Kanagawa Canc Ctr, Res Inst, Lab Mol Cell Biol, Asahi Ku, Yokohama, Kanagawa 241, Japan	Kanagawa Prefectural Cancer Center	Yasumoto, S (corresponding author), Kanagawa Canc Ctr, Res Inst, Lab Mol Cell Biol, Asahi Ku, 1-1-2 Nakao, Yokohama, Kanagawa 241, Japan.							Albanell J, 1996, CANCER RES, V56, P1503; ALLSHIRE RC, 1988, NATURE, V332, P656, DOI 10.1038/332656a0; ALLSHIRE RC, 1989, NUCLEIC ACIDS RES, V17, P4611, DOI 10.1093/nar/17.12.4611; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; BARRANDON Y, 1987, P NATL ACAD SCI USA, V84, P2302, DOI 10.1073/pnas.84.8.2302; Bestilny LJ, 1996, CANCER RES, V56, P3796; BUCK CR, 1987, P NATL ACAD SCI USA, V84, P3060, DOI 10.1073/pnas.84.9.3060; CARTER WG, 1990, J CELL BIOL, V111, P3141, DOI 10.1083/jcb.111.6.3141; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559; Harada H, 1998, J ORAL PATHOL MED, V27, P11; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HARLEY CB, 1995, TELOMERES, P247; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Holt SE, 1997, P NATL ACAD SCI USA, V94, P10687, DOI 10.1073/pnas.94.20.10687; Holt SE, 1996, MOL CELL BIOL, V16, P2932; JONES JCR, 1991, CELL REGUL, V2, P427, DOI 10.1091/mbc.2.6.427; JONES PH, 1995, CELL, V80, P83, DOI 10.1016/0092-8674(95)90453-0; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; KAJIJI S, 1989, EMBO J, V8, P673, DOI 10.1002/j.1460-2075.1989.tb03425.x; Kikuchi K, 1997, CELL GROWTH DIFFER, V8, P571; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; KRUK PA, 1995, P NATL ACAD SCI USA, V92, P258, DOI 10.1073/pnas.92.1.258; Kyo S, 1997, CANCER RES, V57, P610; LAVKER RM, 1991, ANN NY ACAD SCI, V642, P214; LAVKER RM, 1982, SCIENCE, V215, P1239, DOI 10.1126/science.7058342; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; Loeffler Markus, 1997, P1, DOI 10.1016/B978-012563455-7/50002-7; Mandal M, 1997, J BIOL CHEM, V272, P14183, DOI 10.1074/jbc.272.22.14183; Morrison SJ, 1996, IMMUNITY, V5, P207, DOI 10.1016/S1074-7613(00)80316-7; Morrison SJ, 1996, NAT MED, V2, P1011, DOI 10.1038/nm0996-1011; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; Ohta Y, 1997, JPN J CANCER RES, V88, P644, DOI 10.1111/j.1349-7006.1997.tb00432.x; POLAKOWSKA RR, 1994, DEV DYNAM, V199, P176, DOI 10.1002/aja.1001990303; POTTEN CS, 1988, J CELL SCI, P45; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SARIOLA H, 1991, SCIENCE, V254, P571, DOI 10.1126/science.1658930; Sharma HW, 1995, P NATL ACAD SCI USA, V92, P12343, DOI 10.1073/pnas.92.26.12343; SONNENBERG A, 1991, J CELL BIOL, V113, P907, DOI 10.1083/jcb.113.4.907; STEPP MA, 1990, P NATL ACAD SCI USA, V87, P8970, DOI 10.1073/pnas.87.22.8970; TSUTSUMI K, 1993, AM J PATHOL, V143, P1150; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; WILKIE AOM, 1990, NATURE, V346, P868, DOI 10.1038/346868a0; YASUMOTO S, 1991, J VIROL, V65, P2000, DOI 10.1128/JVI.65.4.2000-2009.1991; Yasumoto S, 1996, ONCOGENE, V13, P433; YASUMOTO S, 1992, TISSUE CULT RES COMM, V11, P13; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; Zhu XL, 1996, P NATL ACAD SCI USA, V93, P6091, DOI 10.1073/pnas.93.12.6091	59	42	43	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 16	1998	17	2					187	197		10.1038/sj.onc.1201916	http://dx.doi.org/10.1038/sj.onc.1201916			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZZ211	9674703				2022-12-17	WOS:000074706700007
J	Schmidt-Kastner, PK; Jardine, K; Cormier, M; McBurney, MW				Schmidt-Kastner, PK; Jardine, K; Cormier, M; McBurney, MW			Absence of p53-dependent cell cycle regulation in pluripotent mouse cell lines	ONCOGENE			English	Article						embryonal carcinoma; stem cells; insertional mutation; DNA methylation	EMBRYONAL CARCINOMA-CELLS; WILD-TYPE P53; MURINE LEUKEMIA-VIRUS; DNA-DAMAGE; GENE-EXPRESSION; INDUCED APOPTOSIS; STEM-CELLS; TUMOR SUPPRESSORS; FACTOR FAMILY; MUTANT P53	We examined the expression of p53 in three lines of pluripotent embryonal carcinoma (EC) and ES cells, p53 mRNA and protein levels were constitutively high in two lines but absent from one. In the P19 line of EC cells neither p53 protein nor mRNA was detected. The first intron of the p53 gene in these cells had been invaded by murine leukemia virus and there was extensive hypermethylation of the p53 gene accompanying its inactivation. In all three cell lines, irradiation resulted in arrest of the cells in the G2 but not in the G1 phase of the cell cycle despite the induction of p21(cip1) in the cell lines expressing p53. Thus, the chromosomal stability of EC and ES cells appears to be not dependent on the p53 protein and we interpret our results to suggest that these cells may require the deletion of p53 dependent cell cycle regulation in order to become immortalized.	Univ Ottawa, Ottawa Reg Canc Ctr, Ottawa, ON K1H 8L6, Canada; Univ Ottawa, Dept Med, Ottawa, ON K1H 8L6, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa	McBurney, MW (corresponding author), Univ Ottawa, Ottawa Reg Canc Ctr, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.							AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BELL JC, 1986, MOL CELL BIOL, V6, P617, DOI 10.1128/MCB.6.2.617; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; BOND JA, 1994, ONCOGENE, V9, P1885; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; CZOSNEK HH, 1984, MOL CELL BIOL, V4, P1638, DOI 10.1128/MCB.4.8.1638; DAVID YB, 1988, ONCOGENE, V3, P179; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GAUTSCH JW, 1983, NATURE, V301, P32, DOI 10.1038/301032a0; GUILLOUF C, 1995, ONCOGENE, V10, P2263; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HAGGARTY A, 1991, CELL GROWTH DIFFER, V2, P503; Hall PA, 1997, CURR BIOL, V7, pR144, DOI 10.1016/S0960-9822(97)70074-5; HARPER JW, 1993, CELL, V75, P805; HARTUNG S, 1986, NATURE, V320, P365, DOI 10.1038/320365a0; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hawley RS, 1996, GENE DEV, V10, P2383, DOI 10.1101/gad.10.19.2383; HUPPI K, 1994, ONCOGENE, V9, P3017; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; MCBURNEY MW, 1976, J CELL PHYSIOL, V89, P441, DOI 10.1002/jcp.1040890310; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; MITREITER K, 1994, VIROLOGY, V200, P837, DOI 10.1006/viro.1994.1253; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; NELSON N, 1993, MOL CELL BIOL, V13, P588, DOI 10.1128/MCB.13.1.588; NICOLAS JF, 1975, ANN INST PASTEUR MIC, VA126, P3; Okazawa H, 1996, J CELL BIOL, V132, P955, DOI 10.1083/jcb.132.5.955; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; Sabapathy K, 1997, EMBO J, V16, P6217, DOI 10.1093/emboj/16.20.6217; Sambrook J, 1989, MOL CLONING LAB MANU; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SITHANANDAM G, 1988, J VIROL, V62, P932, DOI 10.1128/JVI.62.3.932-943.1988; SLACK RS, 1995, J CELL BIOL, V129, P779, DOI 10.1083/jcb.129.3.779; SLACK RS, 1993, ONCOGENE, V8, P1585; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; Staines WA, 1996, NEUROSCIENCE, V71, P845, DOI 10.1016/0306-4522(95)00494-7; Stevens L C, 1967, Adv Morphog, V6, P1; STEWART N, 1995, ONCOGENE, V10, P109; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WOLF D, 1984, MOL CELL BIOL, V4, P1402, DOI 10.1128/MCB.4.7.1402; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yamagata T, 1996, MOL CELL BIOL, V16, P1283; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	60	42	43	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 11	1998	16	23					3003	3011		10.1038/sj.onc.1201835	http://dx.doi.org/10.1038/sj.onc.1201835			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662333				2022-12-17	WOS:000074125300007
J	Ruthardt, M; Orleth, A; Tomassoni, L; Puccetti, E; Riganelli, D; Alcalay, M; Mannucci, R; Nicoletti, I; Grignani, F; Fagioli, M; Pelicci, PG				Ruthardt, M; Orleth, A; Tomassoni, L; Puccetti, E; Riganelli, D; Alcalay, M; Mannucci, R; Nicoletti, I; Grignani, F; Fagioli, M; Pelicci, PG			The acute promyelocytic leukaemia specific PML and PLZF proteins localize to adjacent and functionally distinct nuclear bodies	ONCOGENE			English	Article						PML; PLZF; PML/RAR alpha; PLZF/RAR alpha; DNA-virus; INF	ALPHA FUSION PROTEIN; RAR-ALPHA; ZINC-FINGER; HEMATOPOIETIC PROGENITORS; INTERACTION MOTIF; LEUKEMIA-CELLS; POZ-DOMAIN; GENE; TRANSLOCATION; GROWTH	Acute promyelocytic leukaemia is characterized by translocations that involve the retinoic acid receptor a (RAR alpha) locus on chromosome 17 and the PML locus on 15 or the PLZF locus on 11. The resulting abnormal translocation products encode for PML/ RAR alpha or PLZF/RAR alpha fusion proteins. There is increasing experimental evidence that the APL-specific fusion proteins have similar biologic activities on differentiation and survival and that both components of the fusion proteins (PML or PLZF and RAR alpha) are indispensable for these biological activities. The physiologic function of PML or PLZF or whether PML and PLZF; contribute common structural or functional features to the corresponding fusion proteins is not known. We report here immunofluorescence studies on the cellular localization of PLZF and PLZF/RAR alpha and compare it with the localization of PML and PML/RAR alpha. PLZF localizes to nuclear domains of 0.3-0.5 microns, approximately 14 per cell in the KG1 myeloid cell line. These PLZF-bodies are morphologically similar to the domains reported for PML (PML-NBs). There is tight spatial relationship between about 30% of PLZ-NBs and PML-NBs: they partially overlap. However, PML and PLZF do not form soluble complexes in vivo. PLZF- and PML-NBs are functionally distinct. Adenovirus E4-ORF3 protein expression alters the structure of the PML-NBs and-interferon increases the number of PML-NBs and neither has any effect on PLZF NBs. The localization of PLZF/RAR alpha is different to that of PLZF and RAR alpha. The nuclear distribution pattern of PLZF/RAR alpha is one of hundreds of small dots (microspeckles) less than 0.1 micron. Expression of PLZF/RAR alpha did not provoke disruption of the PML-NBs. Go-expression of PML/RAR alpha and PLZF/RAR alpha in U937 cells revealed apparent colocalization. Overall the results suggest that the PML-and PLZF-NBs are distinct functional nuclear domains, but that they may share common regulatory pathways and/or targeting sequences, as revealed by the common localization of their corresponding fusion proteins.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Univ Perugia, Monteluce Policlin, Ist Med Interna & Sci Oncol, I-06100 Perugia, Italy; Univ Frankfurt, Dept Hematol, D-6000 Frankfurt, Germany	IRCCS European Institute of Oncology (IEO); University of Perugia; Goethe University Frankfurt	Pelicci, PG (corresponding author), European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy.		Alcalay, Myriam/AAB-4300-2019; Alcalay, Myriam/B-3182-2016; Pelicci, Pier Giuseppe/AAL-6572-2020; Grignani, Francesco/AAC-2565-2022	Alcalay, Myriam/0000-0002-5558-4272; Alcalay, Myriam/0000-0002-5558-4272; Ruthardt, Martin/0000-0003-1021-3811				ALCALAY M, 1997, UNPUB MOL CELL BIOL; Altabef M, 1996, EMBO J, V15, P2707, DOI 10.1002/j.1460-2075.1996.tb00631.x; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Boddy MN, 1996, ONCOGENE, V13, P971; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; DANIEL MT, 1993, BLOOD, V82, P1858; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EVERETT R, 1995, J VIROL, V69, P7339, DOI 10.1128/JVI.69.11.7339-7344.1995; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; FAGIOLI M, 1992, ONCOGENE, V7, P1083; Ferrucci PF, 1997, P NATL ACAD SCI USA, V94, P10901, DOI 10.1073/pnas.94.20.10901; FLENGHI L, 1995, BLOOD, V85, P1871, DOI 10.1182/blood.V85.7.1871.bloodjournal8571871; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; GRIGNANI F, 1994, BLOOD, V83, P10; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Grignani F, 1996, EMBO J, V15, P4949, DOI 10.1002/j.1460-2075.1996.tb00875.x; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; GUIOCHONMANTEL A, 1995, MOL ENDOCRINOL, V9, P1791, DOI 10.1210/me.9.12.1791; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LAVAU C, 1995, ONCOGENE, V11, P871; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; OHMAN K, 1993, VIROLOGY, V194, P50, DOI 10.1006/viro.1993.1234; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; PUVIONDUTILLEUL F, 1995, EXP CELL RES, V218, P9, DOI 10.1006/excr.1995.1125; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; ROGAIA D, 1995, LEUKEMIA, V9, P1467; Ruthardt M, 1997, MOL CELL BIOL, V17, P4859, DOI 10.1128/MCB.17.8.4859; Sambrook J., 1989, MOL CLONING; Schul W, 1996, EMBO J, V15, P2883, DOI 10.1002/j.1460-2075.1996.tb00649.x; Sitterlin D, 1997, ONCOGENE, V14, P1067, DOI 10.1038/sj.onc.1200916; Stadler M, 1995, ONCOGENE, V11, P2565; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430	54	42	42	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 16	1998	16	15					1945	1953		10.1038/sj.onc.1201722	http://dx.doi.org/10.1038/sj.onc.1201722			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZH166	9591778				2022-12-17	WOS:000073079400006
J	Kagan, J; Liu, JH; Stein, JD; Wagner, SS; Babkowski, R; Grossman, BH; Katz, RL				Kagan, J; Liu, JH; Stein, JD; Wagner, SS; Babkowski, R; Grossman, BH; Katz, RL			Cluster of allele losses within a 2.5 cM region of chromosome 10 in high-grade invasive bladder cancer	ONCOGENE			English	Article						chromosome 10; LOH; microsatellite; bladder cancer; tumor suppressor gene (TSG)	TUMOR-SUPPRESSOR GENES; TRANSITIONAL CELL-CARCINOMA; HUMAN PROSTATE-CANCER; LONG ARM; HETEROZYGOSITY; DELETIONS; GLIOMAS; MARKERS	A limited number of previous studies have indicated a low frequency of chromosome 10 allele losses and deletions in bladder cancers. We investigated the involvement of chromosome 10 in advanced bladder cancers. Loss of heterozygosity (LOH) was analysed in 19 microsatellite loci in 20 grade III invasive transitional cell carcinomas. Nine (45%) of the 20 tumors had at least one allele loss on the long arm of chromosome 10. The short arm of chromosome 10 was not affected, The most frequent LOH occurred at D10S215, where four (29%) of 14 of the informative cases had an allele loss. The minimal region with allele losses was located between the centromeric marker D10S1644 and the telomeric marker D10S541, which are separated by 2.52 cM. The results strongly suggest the existence within that region of a tumor suppressor gene or genes for advanced bladder cancer.	Univ Texas, MD Anderson Cancer Ctr, Div Lab Med, Sect Expt Lab Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Urol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Kagan, J (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Div Lab Med, Sect Expt Lab Med, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [U01CA056973] Funding Source: NIH RePORTER; NCI NIH HHS [UO1 CA-56973] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albarosa R, 1996, AM J HUM GENET, V58, P1260; BABU VR, 1987, CANCER RES, V47, P6800; Beahrs O. H., 1992, MANUAL STAGING CANC, V4th; BERGER CS, 1986, CANCER GENET CYTOGEN, V23, P1, DOI 10.1016/0165-4608(86)90145-7; Collins A, 1996, P NATL ACAD SCI USA, V93, P14771, DOI 10.1073/pnas.93.25.14771; FULTS D, 1993, GENE CHROMOSOME CANC, V7, P173, DOI 10.1002/gcc.2870070311; GIBAS Z, 1984, CANCER RES, V44, P1257; GRAY IC, 1995, CANCER RES, V55, P4800; ISSHIKI K, 1993, GENE CHROMOSOME CANC, V8, P178, DOI 10.1002/gcc.2870080307; Ittmann MM, 1996, PROSTATE, V28, P275; KAGAN J, 1995, ONCOGENE, V11, P2121; KALLIONIEMI A, 1995, GENE CHROMOSOME CANC, V12, P213, DOI 10.1002/gcc.2870120309; KNOWLES MA, 1994, CANCER RES, V54, P531; Lacombe L, 1996, INT J CANCER, V69, P110, DOI 10.1002/(SICI)1097-0215(19960422)69:2<110::AID-IJC7>3.0.CO;2-3; LEVINE AJ, 1992, CANCER SURV, V12, P1; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Nagase S, 1996, BRIT J CANCER, V74, P1979, DOI 10.1038/bjc.1996.663; PARKER SL, 1997, J CLIN, V47, P5; RASHEED BKA, 1995, ONCOGENE, V10, P2243; Raskind WH, 1996, GENE CHROMOSOME CANC, V16, P138, DOI 10.1002/(SICI)1098-2264(199606)16:2<138::AID-GCC8>3.0.CO;2-0; SANDBERG AA, 1990, CHROMOSOMES HUMAN CA, P805; SMEETS W, 1987, CANCER GENET CYTOGEN, V29, P29, DOI 10.1016/0165-4608(87)90028-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Trybus TM, 1996, CANCER RES, V56, P2263; VANNI R, 1988, CANCER GENET CYTOGEN, V30, P35, DOI 10.1016/0165-4608(88)90090-8; WANG MR, 1994, CANCER GENET CYTOGEN, V73, P8, DOI 10.1016/0165-4608(94)90175-9; Zedenius J, 1996, HUM GENET, V97, P299, DOI 10.1007/BF02185758	27	42	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	1998	16	7					909	913		10.1038/sj.onc.1201606	http://dx.doi.org/10.1038/sj.onc.1201606			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484782				2022-12-17	WOS:000072053200010
J	Monaco, L; SassoneCorsi, P				Monaco, L; SassoneCorsi, P			Cross-talk in signal transduction: Ras-dependent induction of cAMP-responsive transcriptional repressor ICER by nerve growth factor	ONCOGENE			English	Article						transcription factors; cyclic AMP; CREM; nerve growth factor; Ras; c-fos	INDUCED NEURONAL DIFFERENTIATION; LONG-TERM DESENSITIZATION; PROTO-ONCOGENE FOS; PC12 CELLS; TYROSINE PHOSPHORYLATION; MAP KINASE; CYCLIC-AMP; CREM GENE; NEURITE OUTGROWTH; EXPRESSION	The CREM gene encodes both activators and repressors of cAMP-induced transcription. By virtue of an alternative, intronic promoter within the gene, the ICER (Inducible cAMP Early Repressor) isoform is generated. ICER acts as a dominant negative regulator and is cAMP-inducible in various neuroendocrine cells and tissues. ICER negatively autoregulates its own expression, and appears to participate in the molecular events governing oscillatory hormonal regulations. Here we report that ICER is inducible with nerve growth factor (NGF). This is the first example of cAMP-independent induction of ICER expression. Importantly, induction by NGF occurs via a subset of the CREs present in the ICER promoter which were previously shown to direct cAMP-inducibility. ICER induction correlates with a NGF-mediated phosphorylation of CREB. Both CREB phosphorylation and ICER inducibility require an intact Ras-dependent signalling pathway. We show that increased ICER levels result in the attenuation of c-fos expression. The activation of a powerful repressor of cAMP-responsive transcription by NGF, whose transduction signalling is cAMP-independent, constitutes a notable example of nuclear cross-talk and thus is likely to have relevant physiological implications.	INST GENET & BIOL MOL & CELLULAIRE,CNRS,INSERM,F-67404 ILLKIRCH GRAFFENS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)			Monaco, Lucia/A-4031-2010					BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DEGROOT RP, 1994, CELL, V79, P81, DOI 10.1016/0092-8674(94)90402-2; DELMAS V, 1992, P NATL ACAD SCI USA, V89, P4226, DOI 10.1073/pnas.89.10.4226; DEUTSCH PJ, 1992, J BIOL CHEM, V267, P5108; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FOULKES NS, 1991, P NATL ACAD SCI USA, V88, P5448, DOI 10.1073/pnas.88.12.5448; Foulkes NS, 1996, NATURE, V381, P83, DOI 10.1038/381083a0; FRODIN M, 1994, J BIOL CHEM, V269, P6207; FUKUDA M, 1995, ONCOGENE, V11, P239; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GINTY DD, 1991, J BIOL CHEM, V266, P15325; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KNIPPER M, 1993, FEBS LETT, V324, P147, DOI 10.1016/0014-5793(93)81382-A; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; LALLI E, 1995, P NATL ACAD SCI USA, V92, P9633, DOI 10.1073/pnas.92.21.9633; LALLI E, 1994, J BIOL CHEM, V269, P17356; Lamas M, 1997, MOL ENDOCRINOL, V11, P1415, DOI 10.1210/me.11.10.1415; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MONACO L, 1995, P NATL ACAD SCI USA, V92, P10673, DOI 10.1073/pnas.92.23.10673; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; QIU MS, 1991, NEURON, V7, P937, DOI 10.1016/0896-6273(91)90339-2; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SCHUBERT D, 1980, BRAIN RES, V190, P67, DOI 10.1016/0006-8993(80)91160-9; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; VISVADER J, 1988, P NATL ACAD SCI USA, V85, P9474, DOI 10.1073/pnas.85.24.9474; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	46	42	42	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 13	1997	15	20					2493	2500		10.1038/sj.onc.1201636	http://dx.doi.org/10.1038/sj.onc.1201636			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE963	9395245				2022-12-17	WOS:A1997YE96300011
J	Kovalchuk, AL; Muller, JR; Janz, S				Kovalchuk, AL; Muller, JR; Janz, S			Deletional remodeling of c-myc-deregulating chromosomal translocations	ONCOGENE			English	Article						BALB/c plasmacytomas; chromosomal translocation; deregulation of c-myc; isotype switching	IMMUNOGLOBULIN HEAVY-CHAIN; CLASS SWITCH RECOMBINATION; MURINE PLASMACYTOMA; ABERRANT REARRANGEMENT; ENHANCER ELEMENT; IGH 3'-ENHANCER; B-CELLS; REGION; LOCUS; GENE	Evidence is presented for the existence of a novel remodeling-by-deletion mechanism that alters the fine structure of c-myc-deregulating chromosomal translocations in t(12;15)-positive BALB/c plasmacytomas. DNA sequence analysis of the t(12;15) in five primary tumors revealed the co-existence of precursor cells harboring genetic recombinations between the immunoglobulin heavy-chain mu locus (Igh mu) and c-myc with clonally related progenitors containing rearrangements between the immunoglobulin heavy-chain alpha locus (Igh alpha) and c-myc. Clonal relatedness was based upon unique junction fragments between the snitch region of Igh mu and c-myc. S mu/c-myc junctions are thus useful clonotypic markers for monitoring the conversion of Igh mu/c-myc-positive tumor precursor clones into Igh alpha/c-myc-positive plasmacytomas. Aberrant isotype switch recombination appears to be the most likely mechanism effecting this conversion event (other possibilities are discussed) which may help to explain the preferred usage of the Igh alpha locus in recombinations with c-myc in t(12;15)-positive plasma cell tumors in BALB/c mice.	NCI,GENET LAB,DIV BASIC SCI,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Kovalchuk, Alexander/0000-0003-2761-0442				Akasaka T, 1996, BLOOD, V88, P985; Arulampalam V, 1995, MOL IMMUNOL, V32, P1369, DOI 10.1016/0161-5890(95)00102-6; BARD JA, 1995, J IMMUNOL, V154, P201; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; CORCORAN LM, 1985, CELL, V40, P71, DOI 10.1016/0092-8674(85)90310-1; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; CROSSEN PE, 1993, GENE CHROMOSOME CANC, V8, P60, DOI 10.1002/gcc.2870080110; DARIAVACH P, 1991, EUR J IMMUNOL, V21, P1499, DOI 10.1002/eji.1830210625; DUNNICK W, 1989, MOL CELL BIOL, V9, P1850, DOI 10.1128/MCB.9.5.1850; DUNNICK W, 1993, NUCLEIC ACIDS RES, V21, P365, DOI 10.1093/nar/21.3.365; ELENICH LA, 1991, NUCLEIC ACIDS RES, V19, P396; FAHRLANDER PD, 1985, P NATL ACAD SCI USA, V82, P3746, DOI 10.1073/pnas.82.11.3746; GERSTEIN RM, 1990, CELL, V63, P537, DOI 10.1016/0092-8674(90)90450-S; GREENBERG R, 1982, NUCLEIC ACIDS RES, V10, P7751, DOI 10.1093/nar/10.23.7751; HARRIMAN W, 1993, ANNU REV IMMUNOL, V11, P361, DOI 10.1146/annurev.iy.11.040193.002045; JANZ S, 1993, P NATL ACAD SCI USA, V90, P7361, DOI 10.1073/pnas.90.15.7361; KOTTMANN AH, 1994, EUR J IMMUNOL, V24, P817, DOI 10.1002/eji.1830240407; Kovalchuk AL, 1996, IMMUNOGENETICS, V44, P151, DOI 10.1007/s002510050104; Liyanage M, 1996, NAT GENET, V14, P312, DOI 10.1038/ng1196-312; MADISEN L, 1994, GENE DEV, V8, P2212, DOI 10.1101/gad.8.18.2212; MATTHIAS P, 1993, MOL CELL BIOL, V13, P1547, DOI 10.1128/MCB.13.3.1547; Mautner J, 1996, ONCOGENE, V12, P1299; MAUTNER J, 1995, NUCLEIC ACIDS RES, V23, P72, DOI 10.1093/nar/23.1.72; Michaelson JS, 1996, J IMMUNOL, V156, P2828; MICHAELSON JS, 1995, NUCLEIC ACIDS RES, V23, P975, DOI 10.1093/nar/23.6.975; MORSE HC, 1976, J IMMUNOL, V117, P541; Muller JR, 1997, BLOOD, V89, P291, DOI 10.1182/blood.V89.1.291.291_291_296; MULLER JR, 1995, CANCER RES, V55, P5012; MULLER JR, 1994, P NATL ACAD SCI USA, V91, P12066, DOI 10.1073/pnas.91.25.12066; OHNO S, 1989, ONCOGENE, V4, P1513; OHNO S, 1991, INT J CANCER, V49, P102, DOI 10.1002/ijc.2910490119; PEAR WS, 1988, ONCOGENE, V2, P499; PETTERSSON S, 1990, NATURE, V344, P165, DOI 10.1038/344165a0; POTTER M, 1983, J NATL CANCER I, V71, P391; POTTER M, 1992, CARCINOGENESIS, V13, P1681, DOI 10.1093/carcin/13.10.1681; POTTER M, 1994, CANCER RES, V54, P969; RADBRUCH A, 1986, IMMUNOL REV, V89, P69, DOI 10.1111/j.1600-065X.1986.tb01473.x; SIGURDARDOTTIR D, 1995, J IMMUNOL, V154, P2217; Singh M, 1996, P NATL ACAD SCI USA, V93, P4392, DOI 10.1073/pnas.93.9.4392; VANNESS BG, 1983, NATURE, V301, P425, DOI 10.1038/301425a0; WIENER F, 1984, J EXP MED, V159, P276, DOI 10.1084/jem.159.1.276; WINTER E, 1987, EMBO J, V6, P1663, DOI 10.1002/j.1460-2075.1987.tb02415.x; YANG JQ, 1985, EMBO J, V4, P1441, DOI 10.1002/j.1460-2075.1985.tb03800.x; ZELENETZ AD, 1993, GENE CHROMOSOME CANC, V6, P140, DOI 10.1002/gcc.2870060303	44	42	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 6	1997	15	19					2369	2377		10.1038/sj.onc.1201409	http://dx.doi.org/10.1038/sj.onc.1201409			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE157	9393881				2022-12-17	WOS:A1997YE15700011
J	Huang, YY; Yuan, ZM; Ishiko, T; Nakada, S; Utsugisawa, T; Kato, T; Kharbanda, S; Kufe, DW				Huang, YY; Yuan, ZM; Ishiko, T; Nakada, S; Utsugisawa, T; Kato, T; Kharbanda, S; Kufe, DW			Pro-apoptotic effect of the c-Abl tyrosine kinase in the cellular response to 1-beta-D-arabinofuranosylcytosine	ONCOGENE			English	Article						ara-C; c-Abl kinase; apoptosis; p53	NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; INDEPENDENT MECHANISMS; DNA-DAMAGE; P53; STRESS; CYCLE; GROWTH; DEATH; LOCALIZATION	Treatment of cells with the antimetabolite 1-beta-D-arabinofuranosylcytosine (ara-C) and other genotoxic agents is associated with activation of the c-Abl protein tyrosine kinase. The functional role of c-Abl in the response to DNA damage, however, remains unclear. The present studies demonstrate that cells expressing a dominant negative, kinase-inactive c-Abl (K-R) are resistant to killing by ara-C. The expression of c-Abl (K-R) blocked ara-C-induced apoptosis by a mechanism that is at least in part independent of the p53 tumor suppressor. Cells null for c-Abl also exhibited resistance to induction of apoptosis. These findings provide support for a pro-apoptotic function of c-Abl in the response to certain genotoxic drugs.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CANC PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School			Utsugisawa, Taiju/ABD-7059-2021	Kato, Tomohisa/0000-0002-3047-9847	NCI NIH HHS [CA66996, CA29431] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA066996, R01CA029431] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; GOGA A, 1995, ONCOGENE, V11, P791; GUNJI H, 1991, CANCER RES, V51, P741; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KUFE DW, 1984, MOL PHARMACOL, V26, P128; KUFE DW, 1980, J BIOL CHEM, V255, P8997; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MATTIONI T, 1995, ONCOGENE, V10, P1325; OHNO Y, 1988, CANCER RES, V48, P1494; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yuan ZM, 1996, J BIOL CHEM, V271, P26457, DOI 10.1074/jbc.271.43.26457; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	34	42	42	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	1997	15	16					1947	1952		10.1038/sj.onc.1201376	http://dx.doi.org/10.1038/sj.onc.1201376			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA872	9365241				2022-12-17	WOS:A1997YA87200009
J	Waber, P; Dlugosz, S; Cheng, QC; Truelson, J; Nisen, PD				Waber, P; Dlugosz, S; Cheng, QC; Truelson, J; Nisen, PD			Genetic alterations of chromosome band 9p21-22 in head and neck cancer are not restricted to p16(INK4a)	ONCOGENE			English	Article						p16(INK4a); cyclin-dependent kinase inhibitors; chromosome 9; loss of heterozygosity; squamous cell carcinoma of the head and neck	SQUAMOUS-CELL CARCINOMA; TUMOR-SUPPRESSOR GENE; ALLELIC LOSS; HOMOZYGOUS DELETIONS; LUNG-CANCER; P16 GENE; CDKN2; MUTATIONS; FREQUENCY; LINES	Although genetic alterations of chromosome band 9p21-22 occur frequently in head and neck squamous cell carcinoma (HNSCC) cell lines, alterations of the cyclin-dependent kinase inhibitor p16(INK4a) located in this region are less common in corresponding primary tumors. To further investigate genetic alterations at 9p21-22 and p16(INK4a) in primary HNSCC, a paired set of 21 tumors and blood specimens that were shown previously to exhibit allelic loss at 3p and elsewhere, were tested for LOH at 9p21-22 using eight different highly polymorphic marker. Sixteen of the samples (81%) exhibited LOH for at least one marker. Frequent LOH was found surrounding p16(INK4a) and at three additional noncontiguous regions of 9p21-22. No homozygous deletions were identified. SSCP screening and direct sequence analysis led to the identification of mutations the p16(INK4a) gene in two tumors. p16(INK4a) was not hypermethylated in any of the samples studied. Furthermore, there was no correlation between LOH at 9p21-22 and the RB1 tumor suppressor gene. These findings indicate that in the set of tumors that we tested, LOH at 9p21-22 is common in primary HNSCC but that genetic alterations of p16(INK4a) located in this region are unusual. Additional tumor suppressor genes at 9p21-22 may therefore be involved in the pathogenesis of this tumor.	UNIV TEXAS,SW MED CTR,DEPT PEDIAT,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT OTOLARYNGOL HEAD & NECK SURG,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,ACAD COMP SERV,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								BARTKOVA J, 1995, CANCER RES, V55, P949; BORING CC, 1992, CA-CANCER J CLIN, V42, P19, DOI 10.3322/canjclin.42.1.19; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CAIRNS P, 1995, CANCER RES, V55, P224; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CALLENDER T, 1994, CANCER-AM CANCER SOC, V74, P152, DOI 10.1002/1097-0142(19940701)74:1<152::AID-CNCR2820740124>3.0.CO;2-K; COWAN JM, 1992, J NATL CANCER I, V84, P793, DOI 10.1093/jnci/84.10.793; DEVOS S, 1995, GENE CHROMOSOME CANC, V14, P164; GONZALEZZULUETA M, 1995, J NATL CANCER I, V87, P1385; HERMAN JG, 1995, CANCER RES, V55, P4525; HUANG DP, 1994, CANCER RES, V54, P4003; HUSSUSSIAN C, 1997, NAT GENET, V8, P15; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KIRKPATRIC H, 1997, IN PRESS ONCOGENE; LEE NK, 1994, INT J ONCOL, V5, P205; LEE NK, 1994, ONCOL REP, V1, P637; LEE NK, 1993, ARCH OTOLARYNGOL, V119, P1125; LI XH, 1994, J NATL CANCER I, V86, P1524, DOI 10.1093/jnci/86.20.1524; Liggett WH, 1996, CANCER RES, V56, P4119; LIU Q, 1995, ONCOGENE, V10, P1061; LO E, 1995, CANCER RES, V55, P2039; LYDIATT WM, 1995, GENE CHROMOSOME CANC, V13, P94, DOI 10.1002/gcc.2870130204; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MUSCAT JE, 1992, CANCER, V69, P2244, DOI 10.1002/1097-0142(19920501)69:9&lt;2244::AID-CNCR2820690906&gt;3.0.CO;2-O; NAWROZ H, 1994, CANCER RES, V54, P1152; OTTERSON GA, 1995, ONCOGENE, V11, P1211; Reed AL, 1996, CANCER RES, V56, P3630; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sidransky David, 1995, Current Opinion in Oncology, V7, P229, DOI 10.1097/00001622-199505000-00007; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; SUN Y, 1995, ONCOGENE, V10, P785; UCHIDA T, 1995, BLOOD, V86, P2724, DOI 10.1182/blood.V86.7.2724.bloodjournal8672724; VANDERRIET P, 1994, CANCER RES, V54, P1156; Waber PG, 1996, ONCOGENE, V12, P365; WABER PG, 1993, CANCER RES, V53, P6028; WEBER JL, 1989, AM J HUM GENET, V44, P388; ZHANG SY, 1994, CANCER RES, V54, P5050	42	42	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 2	1997	15	14					1699	1704		10.1038/sj.onc.1201336	http://dx.doi.org/10.1038/sj.onc.1201336			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349503				2022-12-17	WOS:A1997XY63100009
J	Qi, XM; He, HL; Zhong, HY; Distelhorst, CW				Qi, XM; He, HL; Zhong, HY; Distelhorst, CW			Baculovirus p35 and Z-VAD-fmk inhibit thapsigargin-induced apoptosis of breast cancer cells	ONCOGENE			English	Article						thapsigargin; apoptosis; Bcl-1; ICE-like protease	ICE FAMILY PROTEASES; ENDOPLASMIC-RETICULUM; CAENORHABDITIS-ELEGANS; LYMPHOMA-CELLS; DEATH; PROTEIN; CALCIUM; EXPRESSION; BCL-2; ACTIVATION	Programmed cell death, or apoptosis, is inhibited by the antiapoptotic oncogene, Bcl-2, and is mediated by a cascade of aspartate-specific cysteine proteases, or caspases, related to interleukin 1-beta converting enzyme, Depending on cell type, apoptosis can be induced by treatment with thapsigargin (TG); a selective inhibitor of the endoplasmic reticulum-associated calcium-ATPase. The role of caspases in mediating TG-induced apoptosis was investigated in the Bcl-2-negative human breast cancer cell line, MDA-MB-468. Apoptosis developed in MDA-MB-468 cells over a period of 24-72 h following treatment with 100 nM TG, and was prevented by Bcl-2 overexpression, TG-induced apoptosis was associated with activation of caspase-3 and was inhibited by stable expression of the baculovirus p35 protein, an inhibitor of caspase activity, Also, TG-induced apoptosis was inhibited by treating cells with Z-VAD-fmk, a cell-permeable fluoromethylketone inhibitor of caspases, These findings indicate that TG-induced apoptosis of MDA-MB-468 breast cancer cells is subject to inhibition by Bcl-2 and is mediated by caspase activity, This model system should be useful for further investigation directed toward understanding the role of calcium in signaling apoptosis, and its relationship to Bcl-2 and the caspase proteolytic cascade.	CASE WESTERN RESERVE UNIV,IRELAND CANC CTR,DEPT MED,CLEVELAND,OH 44106	Case Western Reserve University					NATIONAL CANCER INSTITUTE [R21CA066221, T32CA059366] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA59366, R21 CA/AG66221] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMSTRONG DK, 1994, CANCER RES, V54, P5280; ARMSTRONG DK, 1992, CANCER RES, V52, P3418; BEIDLER DR, 1995, J BIOL CHEM, V270, P16526, DOI 10.1074/jbc.270.28.16526; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CARTIER JL, 1994, J VIROL, V68, P7728, DOI 10.1128/JVI.68.12.7728-7737.1994; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; CUENDE E, 1993, EMBO J, V12, P1555, DOI 10.1002/j.1460-2075.1993.tb05799.x; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; FURUYA Y, 1994, CANCER RES, V54, P6167; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; HAY BA, 1994, DEVELOPMENT, V120, P2121; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HERSHBERGER PA, 1994, J VIROL, V68, P3467, DOI 10.1128/JVI.68.6.3467-3477.1994; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; JIANG S, 1994, EXP CELL RES, V212, P84, DOI 10.1006/excr.1994.1121; LAM M, 1993, MOL ENDOCRINOL, V7, P686, DOI 10.1210/me.7.5.686; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LI WWF, 1993, J BIOL CHEM, V268, P12003; LITTLE E, 1995, J BIOL CHEM, V270, P9526, DOI 10.1074/jbc.270.16.9526; LODISH HF, 1992, J BIOL CHEM, V267, P12753; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; McCloskey DE, 1996, RECENT PROG HORM RES, V51, P493; McCormick TS, 1997, J BIOL CHEM, V272, P6087, DOI 10.1074/jbc.272.9.6087; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; RABIZADEH S, 1993, J NEUROCHEM, V61, P2318, DOI 10.1111/j.1471-4159.1993.tb07477.x; Reynolds JE, 1996, J BIOL CHEM, V271, P27739, DOI 10.1074/jbc.271.44.27739; SCHONTHAL A, 1991, P NATL ACAD SCI USA, V88, P7096, DOI 10.1073/pnas.88.16.7096; Shimizu S, 1996, ONCOGENE, V12, P2251; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SUGIMOTO A, 1994, EMBO J, V13, P2023, DOI 10.1002/j.1460-2075.1994.tb06475.x; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WALDRON RT, 1995, J BIOL CHEM, V270, P11955, DOI 10.1074/jbc.270.20.11955; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZHU HJ, 1995, FEBS LETT, V374, P303, DOI 10.1016/0014-5793(95)01116-V	40	42	47	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 4	1997	15	10					1207	1212		10.1038/sj.onc.1201290	http://dx.doi.org/10.1038/sj.onc.1201290			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XU991	9294614				2022-12-17	WOS:A1997XU99100010
J	Kitamura, Y; Goodfellow, PJ; Shimizu, K; Nagahama, M; Ito, K; Kitagawa, W; Akasu, H; Takami, H; Tanaka, S; Wells, SA				Kitamura, Y; Goodfellow, PJ; Shimizu, K; Nagahama, M; Ito, K; Kitagawa, W; Akasu, H; Takami, H; Tanaka, S; Wells, SA			Novel germline RET proto-oncogene mutations associated with medullary thyroid carcinoma (MTC): Mutation analysis in Japanese patients with MTC	ONCOGENE			English	Article						RET proto-oncogene; medullary thyroid carcinoma; mutations; multiple endocrine neoplasia type 2	TYROSINE KINASE DOMAIN; NEOPLASIA TYPE 2B; MEN 2A; CLINICAL-FEATURES; POINT MUTATION; PROTOONCOGENE; FMTC; FAMILY	Germ-like and somatic mutations in the RET protooncogene are associated with inherited and sporadic medullary thyroid carcinoma (MTC). The majority of patients with multiple endocrine neoplasia type 2A (MEN2A) and familial medullary thyroid carcinoma (FMTC) carry germ-line point mutations that result in the substitution of one of five cysteine residues. We investigated exons 10, 11, 13, 14 and 16 of the RET proto-oncogene in 33 unrelated Japanese patients with MTC. Eleven of the 33 cases (33%) were found to have germ-line mutations. Three previously unreported mutations in exon 10 and 11 were identified: one in codon 620, (TGC-->GGC), resulting in a cysteine to glycine substitution, and two in codon 630, (TGC-->TCC) and (TGC-->TAC), resulting in cysteine to serine and cysteine to tyrosine changes, respectively. The new mutations were present in the germ-line DNA of four unrelated patients for whom a family history of MTC had not been documented. Because the new RET alleles described here involve cysteine residues in a region of protein previously associated with FMTC and MEN2A, it is very likely that they represent mutations that predispose to the development of MTC.	WASHINGTON UNIV,SCH MED,DEPT SURG,DIV GEN SURG,ST LOUIS,MO 63110; NIPPON MED COLL,DEPT SURG 2,TOKYO 113,JAPAN; TEIKYO UNIV,SCH MED,DEPT SURG 1,TOKYO 162,JAPAN	Washington University (WUSTL); Nippon Medical School; Teikyo University								BERGHOLM U, 1989, CANCER, V63, P1196, DOI 10.1002/1097-0142(19890315)63:6<1196::AID-CNCR2820630626>3.0.CO;2-O; BOLINO A, 1995, ONCOGENE, V10, P2415; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CECCHERINI I, 1994, ONCOGENE, V9, P3025; DECKER RA, 1995, SURGERY, V118, P257, DOI 10.1016/S0039-6060(05)80332-0; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; ENG C, 1995, CLIN ENDOCRINOL, V43, P123, DOI 10.1111/j.1365-2265.1995.tb01903.x; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ENG C, 1995, ONCOGENE, V10, P509; ENG C, 1995, GENE CHROMOSOME CANC, V12, P209, DOI 10.1002/gcc.2870120308; FrankRaue K, 1996, J CLIN ENDOCR METAB, V81, P1780, DOI 10.1210/jc.81.5.1780; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; KOMMINOTH P, 1995, CANCER, V76, P479; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; PONDER BAJ, 1988, Q J MED, V67, P299; RAUE F, 1994, ENDOCRIN METAB CLIN, V23, P137, DOI 10.1016/S0889-8529(18)30121-X; SAAD MF, 1984, MEDICINE, V63, P319, DOI 10.1097/00005792-198411000-00001; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHUFFENECKER I, 1994, HUM MOL GENET, V3, P1939, DOI 10.1093/hmg/3.11.1939; TAKAHASHI M, 1989, ONCOGENE, V4, P805; WELLS SA, 1994, ANN SURG, V220, P237, DOI 10.1097/00000658-199409000-00002; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153; ZEDENIUS J, 1994, HUM MOL GENET, V3, P1259, DOI 10.1093/hmg/3.8.1259	24	42	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 26	1997	14	25					3103	3106		10.1038/sj.onc.1201102	http://dx.doi.org/10.1038/sj.onc.1201102			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XG100	9223675				2022-12-17	WOS:A1997XG10000014
J	Chernov, MV; Stark, GR				Chernov, MV; Stark, GR			The p53 activation and apoptosis induced by DNA damage are reversibly inhibited by salicylate	ONCOGENE			English	Article						p53 accumulation; transcriptional activation; DNA binding; mouse (12)1/CA cells; DNA damaging agents	WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; CELL-CYCLE ARREST; NF-KAPPA-B; BINDING FUNCTION; IN-VITRO; GAMMA-IRRADIATION; SODIUM-SALICYLATE; GENE-EXPRESSION; KINASE-C	Treatment of mouse (12)1/CA cells with adriamycin or irradiation with U.V.C. induces p53-dependent transcription of a beta-galactosidase reporter and the endogenous p21/Waf1/Cip1 gene. Despite the induction of Waf1, the cells arrest only transiently in G(1) or G(2), then resume growth and eventually undergo apoptosis. In situ analysis of beta-galactosidase activity in U.V.C.-irradiated cells revealed a much higher level of p53-dependent transcription in cells undergoing apoptosis compared to transiently arrested cells. Incubation of the treated cells with salicylate, which inhibits the activation of protein kinases and transcription factors involved in stress responses, inhibits both p53-dependent transcription and apoptosis. The inhibition of transcription is due mainly to impairment of the ability of p53 to bind to DNA. The treated cells resume their p53-dependent programs whenever the salicylate is removed, even after as long as 60 h after the DNA has been damaged. Therefore, the p53-activating signals generated by adriamycin or U.V.C. are very long lived. The resumption of p53-dependent transcription is not accompanied by additional accumulation of the p53 protein, indicating that the activation of p53 is regulated by a separate pathway.	CLEVELAND CLIN FDN,RES INST,DEPT MOL BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049345] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM49345] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRANTZ B, 1995, SCIENCE, V270, P2017, DOI 10.1126/science.270.5244.2017; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gottlieb E, 1996, CELL GROWTH DIFFER, V7, P301; GUILLOUF C, 1995, ONCOGENE, V10, P2263; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAMAL S, 1995, ONCOGENE, V10, P2095; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KOMAROVA EA, 1996, IN PRESS EMBO J; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LIN YP, 1995, MOL CELL BIOL, V15, P6045; LIU M, 1994, CARCINOGENESIS, V15, P1089, DOI 10.1093/carcin/15.6.1089; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Maki CG, 1996, CANCER RES, V56, P2649; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1994, J BIOL CHEM, V269, P9253; Milne DM, 1996, ONCOGENE, V13, P205; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OSIFCHIN NE, 1994, J BIOL CHEM, V269, P6383; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; PRICE BD, 1995, ONCOGENE, V11, P73; ROLFE M, 1995, P NATL ACAD SCI USA, V92, P3264, DOI 10.1073/pnas.92.8.3264; Sambrook J, 1989, MOL CLONING LAB MANU; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schwenger P, 1996, J BIOL CHEM, V271, P8089, DOI 10.1074/jbc.271.14.8089; Soddu S, 1996, MOL CELL BIOL, V16, P487; STEWART N, 1995, ONCOGENE, V10, P109; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; TISCHLER RB, 1993, CANCER RES, V53, P2212; Tu YQ, 1996, EMBO J, V15, P675, DOI 10.1002/j.1460-2075.1996.tb00400.x; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1996, ONCOGENE, V12, P2197; ZHAN QM, 1994, ONCOGENE, V9, P3743	61	42	48	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 29	1997	14	21					2503	2510		10.1038/sj.onc.1201104	http://dx.doi.org/10.1038/sj.onc.1201104			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA949	9191050				2022-12-17	WOS:A1997XA94900002
J	Chaturvedi, V; Li, L; Hodges, S; Johnston, D; Ro, JY; Logothetis, C; vonEschenbach, AC; Batsakis, JG; Czerniak, B				Chaturvedi, V; Li, L; Hodges, S; Johnston, D; Ro, JY; Logothetis, C; vonEschenbach, AC; Batsakis, JG; Czerniak, B			Superimposed histologic and genetic mapping of chromosome 17 alterations in human urinary bladder neoplasia	ONCOGENE			English	Article						bladder cancer; chromosome 17; microsatellites; multistep carcinogenesis; superimposed histologic and genetic mapping	MICROSATELLITE INSTABILITY; POSITIONAL CLONING; SUPPRESSOR LOCI; HUMAN GENOME; LINKAGE MAP; CANCER; CARCINOMAS; MUTATIONS; HETEROZYGOSITY; DELETION	Multistep alterations of chromosome 17 in the progression of human urinary bladder neoplasia were studied by superimposed histologic and genetic mapping. The p53 gene was included in the analysis as a model tumor suppressor gene that is frequently involved in urothelial carcinogenesis. The strategy provided a systematic approach to the study of multistep genomic alterations that occur as neoplasia progresses from precursor intraurothelial conditions to invasive cancer. This was accomplished by sampling the entire mucosa of the organ and displaying microscopically identified invasive cancer and precursor conditions in the form of a histologic map. Subsequent isolation of DNA provided a set of samples in which the search for genetic alterations was performed and superimposed on the histologic map. This approach disclosed multifocal allelic losses of chromosome 17 in the early preinvasive phases of urothelial neoplasia. The alterations were predominantly confined to the p12-13, q22-11 and q24-25 regions. Mutations and allelic losses of the p53 gene were mapped to early preinvasive phases of urothelial neoplasia. The data provide detailed analysis of chromosome 17 allelic losses that occur in the development and progression of urothelial neoplasia and represent the first step for genome-wide modeling of multistep human urothelial carcinogenesis.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT PATHOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT BIOMATH,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT GENITOURINARY MED ONCOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT UROL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [R29CA066723, R01CA066723] Funding Source: NIH RePORTER; NCI NIH HHS [CA66723-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CAIRNS P, 1994, CANCER RES, V54, P1422; CHANG WYH, 1995, CANCER RES, V55, P3246; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; CROPP CS, 1994, CANCER RES, V54, P2548; CZERNIAK B, 1992, HUM PATHOL, V23, P1199, DOI 10.1016/0046-8177(92)90285-B; Czerniak B, 1995, DIAGNOSTIC CYTOLOGY, P345; DALBAGNI G, 1993, DIAGN MOL PATHOL, V2, P4, DOI 10.1097/00019606-199300020-00002; DALBAGNI G, 1993, LANCET, V342, P469, DOI 10.1016/0140-6736(93)91595-D; ELDER PA, 1994, ONCOGENE, V9, P3433; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; GONZALEZZULUETA M, 1993, CANCER RES, V53, P5620; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; KNOWLES MA, 1993, ONCOGENE, V8, P1357; KOLBERG R, 1993, J NIH RES, V5, P32; KOSS L G, 1977, Urology, V9, P442, DOI 10.1016/0090-4295(77)90227-8; KOSS LG, 1991, NEW ENGL J MED, V324, P125; KOSS LG, 1974, JAMA-J AM MED ASSOC, V227, P281; KOSS LG, 1979, HUM PATHOL, V10, P533, DOI 10.1016/S0046-8177(79)80097-0; KOSS LG, 1995, DIAGNOSTIC CYTOLOGY; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LINNENBACH AJ, 1994, NATURE, V367, P419, DOI 10.1038/367419b0; MAO L, 1994, P NATL ACAD SCI USA, V91, P9871, DOI 10.1073/pnas.91.21.9871; METZ CE, 1989, INVEST RADIOL, V24, P234, DOI 10.1097/00004424-198903000-00012; MIYAO N, 1993, CANCER RES, V53, P4066; OLUMI AF, 1990, CANCER RES, V50, P7081; Ott J., 1991, ANAL HUMAN GENETIC L; PRESTI JC, 1991, CANCER RES, V51, P5405; RUPPERT JM, 1993, CANCER RES, V53, P5093; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SPRUCK CH, 1994, CANCER RES, V54, P784; STALLINGS RL, 1990, P NATL ACAD SCI USA, V87, P6218, DOI 10.1073/pnas.87.16.6218; Swets J., 1982, EVALUATION DIAGNOSTI; SWIFT A, 1995, BRIT J CANCER, V71, P995, DOI 10.1038/bjc.1995.191; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; TSAI YC, 1990, CANCER RES, V50, P44; UCHIDA T, 1995, ONCOGENE, V10, P1019; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; YEE CJ, 1994, CANCER RES, V54, P1641; Zar J. H., 1996, BIOSTATISTICAL ANAL	42	42	44	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 1	1997	14	17					2059	2070		10.1038/sj.onc.1201044	http://dx.doi.org/10.1038/sj.onc.1201044			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW809	9160886				2022-12-17	WOS:A1997WW80900008
J	Savio, M; Stivala, LA; Scovassi, AI; Bianchi, L; Prosperi, E				Savio, M; Stivala, LA; Scovassi, AI; Bianchi, L; Prosperi, E			P21(waf1/cip1) protein associates with the detergent-insoluble form of PCNA concomitantly with disassembly of PCNA at nucleotide excision repair sites	ONCOGENE			English	Article						PCNA; p21waf1/cip1; DNA damage; nucleotide excision repair	CELL NUCLEAR ANTIGEN; CYCLIN-DEPENDENT KINASES; DNA-POLYMERASE-DELTA; P53-MEDIATED G(1) ARREST; HUMAN FIBROBLASTS; COMPLEX-FORMATION; BINDING DOMAINS; LEUKEMIA-CELLS; GROWTH ARREST; HELA-CELLS	Evidence is presented that after exposure of normal human fibroblasts to UV-C light, nuclear binding of the proliferating cell nuclear antigen (PCNA) required for nucleotide excision repair, was rapidly triggered in the G(1) and G(2) phases of the cell cycle. Association to repair sites of the detergent-insoluble form of PCNA reached a peak 15-30 min after irradiation, and then decreased to basal levels within 24-48 h. In contrast, the nuclear association of p21 protein showed a slower kinetics, reaching maximal levels between 24 and 48h but, similarly to PCNA, occurring only in G(1) and G(2) phases. Although the two proteins are known to be associated as detergent-soluble proteins, it is unknown whether they associate also in the detergent-insoluble form. To address this question, the chromatin-bound form of PCNA was released by using DNAse I. DNA digestion resulted in the almost complete release of PCNA from its binding sites, while only about 60% of nuclear-bound p21 could be solubilized. Immunoprecipitation of PCNA and p21 released by enzymatic digestion showed that p21 was associated with PCNA bound to late DNA repair sites. These results indicate that during nucleotide excision repair, nuclear binding of PCNA precedes that of p21 protein, and suggest that temporal association of p21 with the detergent-insoluble fraction is coincident with the disassembly of PCNA from DNA repair sites.	CNR,CTR STUDIO ISTOCHIM,I-27100 PAVIA,ITALY; CNR,IST GENET BIOCHIM & EVOLUZIONIST,I-27100 PAVIA,ITALY; UNIV PAVIA,IST PATOL GEN,I-27100 PAVIA,ITALY	Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR); University of Pavia			Prosperi, Ennio/A-3439-2014; Scovassi, Anna Ivana/F-2458-2010	Prosperi, Ennio/0000-0001-5391-5157; Scovassi, Anna Ivana/0000-0003-3484-9881				BOHR V A, 1988, Trends in Biochemical Sciences, V13, P429, DOI 10.1016/0968-0004(88)90216-2; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; CELIS JE, 1986, FEBS LETT, V209, P277, DOI 10.1016/0014-5793(86)81127-9; Chen IT, 1996, ONCOGENE, V12, P595; CHEN IT, 1995, ONCOGENE, V11, P1931; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FANG F, 1993, J CELL SCI, V106, P983; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GOUBIN F, 1995, ONCOGENE, V10, P2281; HALL PA, 1995, ONCOGENE, V10, P2427; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HAVELY O, 1995, SCIENCE, V267, P1018; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; JAUMOT M, 1994, BIOCHEM BIOPH RES CO, V203, P1527, DOI 10.1006/bbrc.1994.2359; JENSEN KA, 1990, BIOCHEMISTRY-US, V29, P4773, DOI 10.1021/bi00472a005; JIANG HP, 1994, ONCOGENE, V9, P3397; KEARSEY JM, 1995, ONCOGENE, V11, P1675; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LANDBERG G, 1991, CANCER RES, V51, P4750; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI Y, 1994, ONCOGENE, V9, P2216; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MICHIELI P, 1994, CANCER RES, V54, P3391; MIURA M, 1992, EXP CELL RES, V201, P541, DOI 10.1016/0014-4827(92)90308-U; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2442; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PROSPERI E, 1993, EXP CELL RES, V205, P320, DOI 10.1006/excr.1993.1092; PROSPERI E, 1994, EXP CELL RES, V215, P352; SADAIE MR, 1986, EXP CELL RES, V163, P423, DOI 10.1016/0014-4827(86)90073-X; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SOBCZAKTHEPOT J, 1993, EXP CELL RES, V206, P43, DOI 10.1006/excr.1993.1118; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; TOSCHI L, 1988, J CELL BIOL, V107, P1623, DOI 10.1083/jcb.107.5.1623; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WALDMAN T, 1995, CANCER RES, V55, P5187; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZENG XR, 1994, J BIOL CHEM, V269, P24027; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHANG W, 1995, CANCER RES, V55, P668	64	42	43	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1591	1598						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895503				2022-12-17	WOS:A1996VM88700002
J	Latham, KE; Litvin, J; Orth, JM; Patel, B; Mettus, R; Reddy, EP				Latham, KE; Litvin, J; Orth, JM; Patel, B; Mettus, R; Reddy, EP			Temporal patterns of A-myb and B-myb gene expression during testis development	ONCOGENE			English	Article						myb; fertility; sterility; gene expression; testis development; meiosis	C-MYB; TRANSCRIPTIONAL ACTIVATOR; PROTEIN; CELLS; MOUSE; SPERMATOGENESIS; PROLIFERATION; LYMPHOCYTES; SUBUNIT; DOMAINS	We recently reported the cloning and sequencing of the mouse A-myb proto-oncogene cDNA and the abundant expression of this mRNA primarily in the testis of adult mice. The A-myb mRNA is detectable by in situ hybridization specifically in the spermatogenic cells, and is downregulated during terminal differentiation. A low level of expression is observed in a few other tissues, including ovary, spleen and brain. We have extended those studies by examining A-myb and B-myb expression during testis development in the mouse. The A-myb and B-myb genes are both expressed in a cell- and stage-specific manner during testis development. The B-myb mRNA is expressed most highly in gonocytes of the fetal testis and in spermatogonia and early spermatocytes in the adult. B-myb expression decreases at day 18 post partum, coincident with the initial appearance of Late pachytene spermatocytes. B-myb expression was also detectable in some interstitial cells of the fetal and adult testis. The A-myb mRNA was not detectable by in situ hybridization in fetal day 15.5 gonocytes but was detectable at a low abundance by RT-PCR in fetal and newborn mice. A-myb mRNA expression increased at post-natal day 10, when primary spermatocytes first appear. In the adult, the A-myb mRNA was expressed highly in a sub-population of spermatogonia and in primary spermatocytes, but was not detectable in spermatids. This expression of A-myb is consistent with the meiotic arrest that is observed in A-myb-deficient male mice. We conclude that B-myb may play a critical role in controlling the proliferation or differentiation of gonocytes and spermatogonia and possibly the somatic lineages as well, whereas A-myb is required for progression through the first meiotic prophase. These distinct roles for B-myb and A-myb during spermatogenesis may reflect distinct transactivation potentials of the two proteins. Further studies to determine the functions of A-myb and B-myb in the developing testis should improve our understanding of the molecular events associated with spermatogenesis and differentiation of the Sertoli and other somatic cell types of the testis.	TEMPLE UNIV,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT ANAT & CELL BIOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Latham, KE (corresponding author), TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOL BIOL,PHILADELPHIA,PA 19140, USA.		Reddy, E. Premkumar/F-6233-2011		NCI NIH HHS [P30-CA12227] Funding Source: Medline; NICHD NIH HHS [HD15563] Funding Source: Medline; NIGMS NIH HHS [GM49489] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD015563] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA012227] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049489] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; BARLETTA C, 1991, CANCER RES, V51, P3821; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; DAHL HHM, 1990, GENOMICS, V8, P225, DOI 10.1016/0888-7543(90)90275-Y; Dix DJ, 1996, P NATL ACAD SCI USA, V93, P3264, DOI 10.1073/pnas.93.8.3264; FOOS G, 1994, ONCOGENE, V9, P2481; FOOS G, 1993, ONCOGENE, V8, P1775; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; FRAMPTON J, 1989, NATURE, V342, P134, DOI 10.1038/342134a0; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GOLAY J, 1994, ONCOGENE, V9, P2469; KLAMPNAUER KH, 1987, EMBO J, V6, P2719; MCCARREY JR, 1992, DEV BIOL, V154, P160, DOI 10.1016/0012-1606(92)90056-M; METTUS RV, 1994, ONCOGENE, V9, P3077; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; ORTH JM, 1982, ANAT REC, V203, P485, DOI 10.1002/ar.1092030408; ORTH JM, 1996, IN PRESS MOL REPROD; RAMBHATLA L, 1995, MOL REPROD DEV, V41, P314, DOI 10.1002/mrd.1080410306; RASCHELLA G, 1995, J BIOL CHEM, V270, P8540, DOI 10.1074/jbc.270.15.8540; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; Sitzmann J, 1996, ONCOGENE, V12, P1889; Sitzmann J, 1995, ONCOGENE, V11, P2273; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; TAKAHASHI T, 1995, FEBS LETT, V358, P89, DOI 10.1016/0014-5793(94)01402-M; THIELE CJ, 1988, MOL CELL BIOL, V8, P1677, DOI 10.1128/MCB.8.4.1677; TOSCANI A, UNPUB NATURE; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; XU LZ, 1995, MOL CELL BIOL, V15, P6572	32	42	45	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1161	1168						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808690				2022-12-17	WOS:A1996VJ20200007
J	Chackalaparampil, I; Peri, A; Nemir, M; Mckee, MD; Lin, PH; Mukherjee, BB; Mukherjee, AB				Chackalaparampil, I; Peri, A; Nemir, M; Mckee, MD; Lin, PH; Mukherjee, BB; Mukherjee, AB			Cells in vivo and in vitro from osteopetrotic mice homozygous for c-src disruption show suppression of synthesis of osteopontin, a multifunctional extracellular matrix protein	ONCOGENE			English	Article						osteopontin; src-deficient; epidermal growth factor (EGF); homozygous; osteopetrosis	TYROSINE KINASE; GROWTH-FACTOR; PHOSPHOPROTEIN; BONE; OSTEOCLASTS; EXPRESSION; ACTIVATION; INDUCTION; PATHWAYS	Mice carrying homozygous disruption of the c-src protooncogene (Src-/-) develop osteopetrosis due to an impaired ability of osteoclasts to adhere to the bone surface and/or to form bone-resorbing ruffled border. It has also been reported that osteopontin (OPN), a secreted phosphoprotein, mediates osteoclast adherence to the bone matrix. We report here that cells from Src-/- mice, both in vitro and in vivo, express OPN mRNA and protein at a significantly reduced level as compared to cells from Src+/- and +/+ animals, suggesting a potential role for the proto-oncogene c-src in the regulation of OPN gene expression. Our data also show that OPN gene expression can be induced by treatment of Src -/- cells with epidermal growth factor (EGF) and 12-O-tetradecanoyl phorbol-13-acetate (TPA). Results obtained from studies using inhibitors of receptor tyrosine kinases (RTKs) and protein kinase C (PKC) suggest that PKC and RTK are positioned in a pathway with PKC as the downstream effector for the EGF-induced OPN gene expression in Src-/- cells, and that pp60(c-src) and EGF may regulate OPN gene expression through a common signalling pathway. Furthermore, contrary to published reports, our study shows that EGF-mediated cell signalling does not require functional interaction between the EGF-receptor and pp60(c-src).	MCGILL UNIV, DEPT BIOL, MONTREAL, PQ H3A 1B1, CANADA; NICHHD, SECT DEV GENET, HERITABLE DISORDERS BRANCH, NIH, BETHESDA, MD 20892 USA; UNIV MONTREAL, FAC DENT, DEPT STOMATOL, MONTREAL, PQ H3C 3J7, CANADA; RUTGERS STATE UNIV, WAKSMAN INST, DEPT MICROBIOL, PISCATAWAY, NJ 08855 USA	McGill University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Universite de Montreal; Rutgers State University New Brunswick			McKee, Marc D/E-2187-2011; Lin, Pei-Hui/I-3011-2015	McKee, Marc D/0000-0001-8349-965X; Lin, Pei-Hui/0000-0002-3894-5099				BARON R, 1989, ANAT RECORD, V224, P317, DOI 10.1002/ar.1092240220; BENDAYAN M, 1989, COLLOIDAL GOLD PRINC, V1, P33; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CRAIG AM, 1991, GENE, V100, P163, DOI 10.1016/0378-1119(91)90362-F; CRAIG AM, 1989, J BIOL CHEM, V264, P9682; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; DENHARDT DT, 1995, ANN NY ACAD SCI, V760, P127, DOI 10.1111/j.1749-6632.1995.tb44625.x; Dveksler G S, 1992, PCR Methods Appl, V1, P283; GADEAU AP, 1993, ARTERIOSCLER THROMB, V13, P120, DOI 10.1161/01.ATV.13.1.120; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; LAVERDURE GR, 1987, FEBS LETT, V222, P261, DOI 10.1016/0014-5793(87)80382-4; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOPEZ CA, 1995, ANN NY ACAD SCI, V760, P324, DOI 10.1111/j.1749-6632.1995.tb44648.x; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MARKS S C JR, 1987, Applied Pathology, V5, P172; MCKEE MD, 1990, ANAT REC, V228, P77, DOI 10.1002/ar.1092280112; MCKEE MD, 1992, ANAT REC, V234, P479, DOI 10.1002/ar.1092340404; MCKEE MD, 1995, ANN NY ACAD SCI, V760, P177, DOI 10.1111/j.1749-6632.1995.tb44629.x; MCKEE MD, 1993, ANAT REC, V3, P219; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; Nanci A, 1996, MICROSC RES TECHNIQ, V33, P214; QURESHI SA, 1991, ONCOGENE, V6, P995; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; SINGH K, 1990, J BIOL CHEM, V265, P18696; SINGH K, 1993, J BIOCHEM-TOKYO, V114, P702, DOI 10.1093/oxfordjournals.jbchem.a124240; SINGH K, 1992, J BIOL CHEM, V267, P23847; SMITH JH, 1989, J CELL PHYSIOL, V139, P189, DOI 10.1002/jcp.1041390126; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	38	42	44	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	1996	12	7					1457	1467						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622862				2022-12-17	WOS:A1996UF07600010
J	Wu, HK; Heng, HHQ; Siderovski, DP; Dong, WF; Okuno, Y; Shi, XM; Tsui, LC; Minden, MD				Wu, HK; Heng, HHQ; Siderovski, DP; Dong, WF; Okuno, Y; Shi, XM; Tsui, LC; Minden, MD			Identification of a human LIM-Hox gene, hLH-2, aberrantly expressed in chronic myelogenous Leukaemia and located on 9q33-34.1	ONCOGENE			English	Article						fluorescence in situ hybridization; hematological malignancies; hLH-2; Philadelphia chromosome; reverse transcription polymerase chain reaction	T-CELL LEUKEMIA; HOMEOBOX GENE; TRANSGENIC MICE; BCR-ABL; PROTEINS; TRANSLOCATION; INDUCTION; LYMPHOMA; ELEGANS; MEMBER	We describe the isolation of human LH-2, a putative transcription factor containing two cysteine-rich regions (LIM domains) and a homeobox (Hox) DNA-binding domain. High levels of hLH-2 expression were observed in all cases of chronic myelogenous leukaemia (CML) tested, regardless of disease status. hLH-2 was mapped to chromosome 9q33-34.1, in the same region as the reciprocal translocation that creates the BCR-ABL chimera of the Philadelphia chromosome (Ph'), the hallmark of CML; hLH-2 was retained on the derivative 9 chromosome and is therefore centromeric of c-ABL. The proximity of hLH-2 to the breakpoint on chromosome 9 raises the possibility of cis-activation by the t(9;22)(q34;q11) translocation. In addition to finding hLH-2 expression in all cases of CML, expression was observed in lymphoid malignancies and myeloid cell lines, but not in primary cases of acute myelogenous leukaemia. The role of hLH-2 in the development or progression of leukaemia is not known. However, hLH-2 may prove useful as a marker of CML for monitoring residual disease.	UNIV TORONTO,PRINCESS MARGARET HOSP,ONTARIO CANC INST,DEPT MED,TORONTO,ON M5G 2M9,CANADA; UNIV TORONTO,PRINCESS MARGARET HOSP,ONTARIO CANC INST,DEPT MED BIOPHYS,TORONTO,ON M5G 2M9,CANADA; HOSP SICK CHILDREN,DEPT GENET,TORONTO,ON M5G 1X8,CANADA; HOSP SICK CHILDREN,DEPT MOLEC & MED GENET,TORONTO,ON M5G 1X8,CANADA; AMGEN INST,QUANTITAT BIOL LAB,TORONTO,ON M5G 2C1,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Siderovski, David Peter/AAA-9603-2019	Siderovski, David Peter/0000-0002-0688-8210				BARNES JD, 1994, DEV BIOL, V161, P168, DOI 10.1006/dbio.1994.1018; BENDAVID L, 1991, VIROLOGY, V182, P382, DOI 10.1016/0042-6822(91)90686-6; BOEHM T, 1990, ONCOGENE, V5, P1103; BRADY G, 1993, METHOD ENZYMOL, V225, P611; CARLESSO N, 1994, ONCOGENE, V9, P149; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; ELEFANTY AG, 1992, MOL CELL BIOL, V12, P1755, DOI 10.1128/MCB.12.4.1755; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; FISCH P, 1992, ONCOGENE, V7, P2389; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HENG HHQ, 1994, HUM MOL GENET, V3, P61, DOI 10.1093/hmg/3.1.61; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; LI H, 1994, EMBO J, V13, P2876, DOI 10.1002/j.1460-2075.1994.tb06582.x; LI PM, 1991, P NATL ACAD SCI USA, V88, P9210, DOI 10.1073/pnas.88.20.9210; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; MAGLI MC, 1991, P NATL ACAD SCI USA, V88, P6348, DOI 10.1073/pnas.88.14.6348; MATULONIS U, 1993, EXP HEMATOL, V21, P1460; MAVILIO F, 1986, NATURE, V324, P664, DOI 10.1038/324664a0; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MINDEN MD, 1979, BLOOD, V54, P186; PERKINS A, 1990, P NATL ACAD SCI USA, V87, P8393; RASSOOL F, 1990, LEUKEMIA, V4, P273; ROBERSON MS, 1994, MOL CELL BIOL, V14, P2985, DOI 10.1128/MCB.14.5.2985; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Sambrook J, 1989, MOL CLONING LAB MANU; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SIMEONE A, 1987, P NATL ACAD SCI USA, V84, P4914, DOI 10.1073/pnas.84.14.4914; TAKESHITA K, 1993, P NATL ACAD SCI USA, V90, P3535, DOI 10.1073/pnas.90.8.3535; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WU HK, 1995, LEUKEMIA, V9, P1291; XU WM, 1994, BONE MARROW TRANSPL, V14, P299; XU Y, 1993, P NATL ACAD SCI USA, V90, P227, DOI 10.1073/pnas.90.1.227	39	42	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1205	1212						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649822				2022-12-17	WOS:A1996UC06700005
J	Menke, AL; Riteco, N; vanHam, RCA; deBruyne, C; Rauscher, FJ; vanderEb, AJ; Jochemsen, AG				Menke, AL; Riteco, N; vanHam, RCA; deBruyne, C; Rauscher, FJ; vanderEb, AJ; Jochemsen, AG			Wilms' Tumor 1 splice variants have opposite effects on the tumorigenicity of adenovirus-transformed baby-rat kidney cells	ONCOGENE			English	Article						Wilm's tumor; WT1; adenovirus, tumorigenicity; serum-dependency	ZINC FINGER PROTEIN; GENE WT1; EXPRESSION; SUPPRESSOR; BINDING; LOCUS; P53; INDUCTION; ANTIGEN; PRODUCT	The Wilms' Tumor 1 gene (WT1) encodes a transcription factor of the zinc-finger family, As a result of alternative RNA splicing, the gene can be expressed as four polypeptides which differ in the presence or absence of two stretches of amino acids: one of 17 residues (17aa) just N-terminal of the four zinc-fingers and of three residues (K-T-S) between zinc finger 3 and 4. In this study, four human cDNA constructs encoding the Wilms' tumor 1 splice variants were stably transfected into adenovirus-transformed baby rat kidney (Ad-BRK) cells. The in vivo produced WT1 proteins that lacked the KTS residues were found to bind efficiently to both the Egr-1 consensus sequence and the recently described WTE DNA sequence, as determined by electrophoretic mobility shift assays. Our studies show distinct effects of the different WT1 isoforms. Expression of the WT1 (-/+) protein, lacking the 17aa insert, strongly suppressed the tumorigenic phenotype of the Ad-BRK cells. Intriguingly, expression of the WT1 (-/-) protein, lacking both inserts, increased the tumor growth rate. In contrast to the growth in vivo, the growth rate of the transfectants in tissue culture is not influenced by any of the WT1 isoforms. However, the suppression of tumorigenicity appears to be correlated with a reduced ability of the cells to grow in serum-free medium.	LEIDEN UNIV,SYLVIUS LABS,MOLEC CARCINOGENESIS LAB,2300 RA LEIDEN,NETHERLANDS; WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104	Leiden University; Leiden University - Excl LUMC; The Wistar Institute			Menke, Aswin/AAC-6809-2021	Menke, Aswin/0000-0002-0724-0897				AMIN KM, 1995, AM J PATHOL, V146, P344; BAUER M, 1987, J VIROL, V61, P1821, DOI 10.1128/JVI.61.6.1821-1827.1987; BERNARDS R, 1982, VIROLOGY, V120, P422, DOI 10.1016/0042-6822(82)90042-3; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER B, 1992, ONCOGENE, V7, P1431; BRENNER BM, 1990, J AM SOC NEPHROL, V1, P127; BRIEGER J, 1994, LEUKEMIA, V8, P2138; BRUENING W, 1992, NAT GENET, V1, P144, DOI 10.1038/ng0592-144; BRUENING W, 1993, CANCER INVEST, V11, P393, DOI 10.3109/07357909309018871; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; EKBLOM P, 1980, DEV BIOL, V74, P263, DOI 10.1016/0012-1606(80)90429-7; GESSLER M, 1992, GENOMICS, V12, P807, DOI 10.1016/0888-7543(92)90313-H; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HASTIE ND, 1994, ANNU REV GENET, V28, P523; KONG A, 1993, HUM MOL GENET, V2, P1967; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LARSSON SH, 1995, CELL, V81, P1; MADDEN SL, 1993, ONCOGENE, V8, P1713; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MENKE AL, 1995, INT J CANCER, V63, P76, DOI 10.1002/ijc.2910630115; MENSSEN HD, 1995, LEUKEMIA, V9, P1060; MIWA H, 1992, LEUKEMIA, V6, P405; MORRIS JF, 1991, ONCOGENE, V6, P2339; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; PRITCHARDJONES K, 1991, ONCOGENE, V6, P2211; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; REDDY JC, 1995, J BIOL CHEM, V270, P10878, DOI 10.1074/jbc.270.18.10878; RODECK U, 1994, INT J CANCER, V59, P78, DOI 10.1002/ijc.2910590116; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; SABATTINI P, 1995, MOL CELL BIOL, V15, P1060; SHARMA PM, 1992, CANCER RES, V52, P6407; STEEGENGA WT, 1995, VIROLOGY, V212, P543, DOI 10.1006/viro.1995.1512; STEWART CL, 1982, P NATL ACAD SCI-BIOL, V79, P4098, DOI 10.1073/pnas.79.13.4098; VANDENHEUVEL SJL, 1993, J VIROL, V67, P5226, DOI 10.1128/JVI.67.9.5226-5234.1993; VANLEER EHG, 1993, EXP NEPHROL, V1, P292; WALKER C, 1994, CANCER RES, V54, P3101; WANG ZY, 1995, ONCOGENE, V10, P415; WANG ZY, 1995, ONCOGENE, V10, P1243; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084; ZHOU YL, 1994, P NATL ACAD SCI USA, V91, P4165, DOI 10.1073/pnas.91.10.4165	48	42	46	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					537	546						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637710				2022-12-17	WOS:A1996TV59700010
J	Subramanian, T; Boyd, JM; Chinnadurai, G				Subramanian, T; Boyd, JM; Chinnadurai, G			Functional substitution identifies a cell survival promoting domain common to adenovirus E1B 19 kDa and Bcl-2 proteins	ONCOGENE			English	Article						apoptosis; Bcl-2 family; E1B 19 kDa protein; p53; NH1 domain	TUMOR-NECROSIS-FACTOR; EARLY REGION E1B; LP+ LOCUS; DEATH; GENE; TRANSFORMATION; APOPTOSIS; ANTIGEN; DNA; ONCOGENE	The adenovirus E1B 19 kDa protein provides a cell survival function during adenovirus infection and facilitates efficient virus replication by preventing premature cell death. These functions resemble those performed by the protein coded by the proto-oncogene Bcl-2. The Bcl-2 protein, which provides a survival function in cells exposed to a number of cell death-inducing stimuli, can substitute for the 19 kDa protein during adenovirus infection, Although these two survival-promoting proteins are not overtly related by primary amino acid sequence, they appear to share short homologous sequences. In order to determine if these sequence motifs constitute common functional domains, we carried out domain exchanges between the 19 kDa and Bcl-2 proteins, Our results indicate that a seven amino acid region of the Bcl-2 protein (108-YRRDFAE-114) can efficiently substitute for the corresponding 19 kDa domain (47-YKWEFEE-53). Mutagenizing this domain in Bcl-2 abolishes the survival promoting activity of Bcl-2, Substitution of the 19 kDa sequences into Bcl-2 restores the survival promoting activity, albeit at reduced levels, Our results suggest that this domain (designated NH1) may constitute a common functional domain for the 19 kDa protein and survival promoting members of the Bcl-2 family of proteins.	ST LOUIS UNIV,MED CTR,INST MOLEC VIROL,ST LOUIS,MO 63110	Saint Louis University					NATIONAL CANCER INSTITUTE [R01CA031719, R01CA033616] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA033616, CA-31719, CA-33616] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1992, CURRENT PROTOCOLS MO; BABISS LE, 1984, J VIROL, V52, P389, DOI 10.1128/JVI.52.2.389-395.1984; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BOYD JM, 1995, IN PRESS ONCOGENE; CHINNADURAI G, 1983, CELL, V33, P759, DOI 10.1016/0092-8674(83)90018-1; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GOODING LR, 1991, J VIROL, V65, P3083, DOI 10.1128/JVI.65.6.3083-3094.1991; GREEN M, 1983, J VIROL, V48, P604, DOI 10.1128/JVI.48.3.604-615.1983; HASHIMOTO S, 1991, INT IMMUNOL, V3, P343, DOI 10.1093/intimm/3.4.343; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; MCLORIE W, 1991, J GEN VIROL, V72, P1467, DOI 10.1099/0022-1317-72-6-1467; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PILDER S, 1984, J VIROL, V52, P664, DOI 10.1128/JVI.52.2.664-671.1984; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; SUBRAMANIAN T, 1984, J BIOL CHEM, V259, P1777; SUBRAMANIAN T, 1993, GENE, V124, P173, DOI 10.1016/0378-1119(93)90391-F; SUBRAMANIAN T, 1984, J VIROL, V52, P336, DOI 10.1128/JVI.52.2.336-343.1984; SUBRAMANIAN T, 1995, CELL GROWTH DIFFER, V6, P131; TAKEMORI N, 1984, J VIROL, V52, P793, DOI 10.1128/JVI.52.3.793-805.1984; TARODI B, 1993, INT J ONCOL, V3, P467; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WHITE E, 1984, J VIROL, V52, P410, DOI 10.1128/JVI.52.2.410-419.1984; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	38	42	43	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2403	2409						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570192				2022-12-17	WOS:A1995TK70200025
J	HERZOG, CR; WANG, Y; YOU, M				HERZOG, CR; WANG, Y; YOU, M			ALLELIC LOSS OF DISTAL CHROMOSOME-4 IN MOUSE LUNG-TUMORS LOCALIZE A PUTATIVE TUMOR-SUPPRESSOR GENE TO A REGION HOMOLOGOUS WITH HUMAN-CHROMOSOME 1P36	ONCOGENE			English	Article						LOH; CHROMOSOME 4; MOUSE LUNG; TUMOR SUPPRESSOR GENE	SHORT ARM; HETEROZYGOSITY; DELETION; PHEOCHROMOCYTOMAS; NEOPLASIA; CARCINOMA; BREAST; CANCER	Loss of heterozygosity (LOH) of distal chromosome 4 was studied to localize a putative tumor suppressor gene in mouse lung neoplasia. Previous studies have implicated this region and its homologue on human chromosome 1p36-34 as sites of potential tumor suppressor genes. One hundred adenocarcinomas and 38 adenomas of the mouse lung mere examined for LOH using nine simple sequence length polymorphism markers in a polymerase chain reaction-based approach. Forty-four adenocarcinomas displayed allele loss, all of which included losses at marker D4MIT54, which defined a critical region of 3 centiMorgans as the likely location of a putative tumor suppressor gene. In 58% of the tumors displaying LOH, all markers used in this study incurred allele loss. In contrast, retention of heterozygosity was observed at all markers tested in each of the adenomas studied, which suggests that the inactivation of this tumor suppressor gene participates in mouse lung tumor progression.	MED COLL OHIO, DEPT PATHOL, TOLEDO, OH 43699 USA						NATIONAL CANCER INSTITUTE [R29CA058554, R01CA058554] Funding Source: NIH RePORTER; NCI NIH HHS [CA58554] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBOTT CM, 1994, MAMM GENOME, V5, pS51; BELLO MJ, 1994, INT J CANCER, V57, P172, DOI 10.1002/ijc.2910570207; BELLO MJ, 1994, GENE CHROMOSOME CANC, V9, P296, DOI 10.1002/gcc.2870090411; BIECHE I, 1993, CANCER RES, V53, P1990; Biegel J., 1994, American Journal of Human Genetics, V55, pA51; BUNNELL BA, 1990, SOMAT CELL MOLEC GEN, V16, P151, DOI 10.1007/BF01233045; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; DING SF, 1992, BRIT J CANCER, V65, P809, DOI 10.1038/bjc.1992.173; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; DRACOPOLI NC, 1994, CYTOGENET CELL GENET, V67, P143, DOI 10.1159/000133816; ENOMOTO H, 1994, ONCOGENE, V9, P2785; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; GENUARDI M, 1989, AM J HUM GENET, V45, P73; GIBAS Z, 1994, GENE CHROMOSOME CANC, V9, P216, DOI 10.1002/gcc.2870090310; HERZOG CR, 1994, CANCER RES, V54, P4007; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KHOSLA S, 1991, J CLIN INVEST, V87, P1691, DOI 10.1172/JCI115186; LAHTI JM, 1994, NAT GENET, V7, P370, DOI 10.1038/ng0794-370; LEE GH, 1995, GENETICS, V139, P387; LEISTER I, 1990, CANCER RES, V50, P7232; LUONGO C, 1994, CANCER RES, V54, P5947; MATHEW S, 1994, CANCER RES, V54, P6265; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MOCK BA, 1994, MAMM GENOME, V5, P191, DOI 10.1007/BF00352357; MOLEY JF, 1992, CANCER RES, V52, P770; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; SIMON D, 1991, ONCOGENE, V6, P765; WEITH A, 1989, GENE CHROMOSOME CANC, V1, P159, DOI 10.1002/gcc.2870010209; YOU M, 1992, P NATL ACAD SCI USA, V89, P5804, DOI 10.1073/pnas.89.13.5804	31	42	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	1995	11	9					1811	1815						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478609				2022-12-17	WOS:A1995TD09400016
J	SOLOMON, DLC; PHILIPP, A; LAND, H; EILERS, M				SOLOMON, DLC; PHILIPP, A; LAND, H; EILERS, M			EXPRESSION OF CYCLIN D1 MESSENGER-RNA IS NOT UP-REGULATED BY MYC IN RAT FIBROBLASTS	ONCOGENE			English	Note						CYCLIN D1; MYC; ESTROGEN RECEPTOR; TAMOXIFEN	HUMAN C-MYC; DNA-BINDING; ESTROGEN-RECEPTOR; STEROID BINDING; GENE-EXPRESSION; CELL-CYCLE; MAX; SEQUENCE; PROTEIN; DIMERIZATION	Conflicting results have been published regarding the regulation of cyclin D1 mRNA in rat fibroblasts expressing a hormone-regulated Myc protein, MycER. We confirm that activation of MycER with oestrogen rapidly induces cyclin D1 mRNA, even in the presence of cycloheximide. However, we show that this is an artefact resulting from an oestrogen-activated transcriptional activation domain in the oestrogen receptor part of the MycER chimaera. First, addition of 4-hydroxy-tamoxifen (4OHT), which does not activate this domain, allows association of MycER with Max and induces cell proliferation in serum-starved Rat-1-MycER cells without affecting cyclin D1 mRNA levels or the activity of D1 promoter-luciferase constructs. Second, Rat-1 cells expressing a mutant MycER with a hormone-binding domain that still binds 4OHT but no longer binds oestrogen, are driven into the cell cycle in response to 4OHT but fail to up-regulate cyclin D1 mRNA. Finally, Rat-1 cells in which wild-type human c-Myc expression can be induced, also progress into the cell cycle without increased D1 mRNA expression.	ZENTRUM MOLEK BIOL HEIDELBERG,D-69120 HEIDELBERG,GERMANY; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Ruprecht Karls University Heidelberg; Cancer Research UK				Eilers, Martin/0000-0002-0376-6533				AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRASELMANN S, 1993, P NATL ACAD SCI USA, V90, P1657, DOI 10.1073/pnas.90.5.1657; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DANIELIAN PS, 1993, MOL ENDOCRINOL, V7, P232, DOI 10.1210/me.7.2.232; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FAWELL SE, 1990, P NATL ACAD SCI USA, V87, P6883, DOI 10.1073/pnas.87.17.6883; GAUBATZ S, 1994, MOL CELL BIOL, V6, P3853; HANSON KD, 1994, MOL CELL BIOL, V14, P5748, DOI 10.1128/MCB.14.9.5748; HERBER B, 1994, ONCOGENE, V9, P1295; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; JIANG W, 1993, ONCOGENE, V8, P3447; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LOVEC H, 1994, ONCOGENE, V9, P323; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SMITH R, 1995, GENOMICS, V25, P85, DOI 10.1016/0888-7543(95)80112-Y; SOLOMON DLC, 1993, NUCLEIC ACIDS RES, V21, P5372, DOI 10.1093/nar/21.23.5372; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	44	42	43	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1893	1897						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478619				2022-12-17	WOS:A1995TD09400026
J	SIEGEL, J; FRITSCHE, M; MAI, S; BRANDNER, G; HESS, RD				SIEGEL, J; FRITSCHE, M; MAI, S; BRANDNER, G; HESS, RD			ENHANCED P53 ACTIVITY AND ACCUMULATION IN RESPONSE TO DNA-DAMAGE UPON DNA TRANSFECTION	ONCOGENE			English	Article						P53; P53 ACCUMULATION; P53 SENSITIZATION; DNA DAMAGE; DNA TRANSFECTION; CALICHEAMICIN GAMMA-1	CELLULAR TUMOR-ANTIGEN; DOUBLE-STRAND BREAKS; MONOCLONAL-ANTIBODIES; MAMMALIAN-CELLS; RESTRICTION ENDONUCLEASES; CHROMOSOMAL-ABERRATIONS; SUPPRESSOR PROTEIN; IONIZING-RADIATION; MOUSE CELLS; CHO CELLS	In response to DNA damage the wild-type tumor suppressor protein p53 accumulates in the nucleus of rodent and primate cells. To investigate the minimal requirement for this reaction the cellular DNA was restricted by two alternative ways: (i) by calicheamicin gamma 1, an enediyne, which causes direct, sequence-specific DNA damage, as shown by fluorimetric analysis of DNA unwinding and by poly(ADP-ribose) polymerase activation. The dose-dependent DNA damage correlated with the nuclear p53 accumulation. In addition, restriction was generated (ii) by the intracellular introduction of the restriction enzyme PvuII, which generates blunt-ended DNA breaks, applying a mild hypotonic shock (pellet method). Previous transfection of linear or circular, single- or ds, DNA, followed by mitomycin C-treatment, lead to a dramatic increase in nuclear p53 accumulation and p53 activity according to electrophoretic mobility shift analysis. The nature of transfected DNA was irrelevant for enhanced accumulation. The data suggest, that the cellular p53 response to DNA damage is sensitized by uptake of exogenous DNA.	UNIV FREIBURG,INST MED MIKROBIOL & HYG,VIROL ABT,D-79104 FREIBURG,GERMANY; INST EXPTL KREBSFORSCH,TUMORBIOL KLIN,D-79106 FREIBURG,GERMANY; BASEL INST IMMUNOL,CH-4058 BASEL,SWITZERLAND	University of Freiburg			mai, sj/HGE-8908-2022					ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; ALVAREZGONZALEZ R, 1989, MUTAT RES, V218, P67, DOI 10.1016/0921-8777(89)90012-8; AUER D, 1976, NATURWISSENSCHAFTEN, V63, P391, DOI 10.1007/BF00607946; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BHATTACHARYYA D, 1988, CARCINOGENESIS, V9, P683, DOI 10.1093/carcin/9.4.683; BIRNBOIM HC, 1981, CANCER RES, V41, P1889; BRAIN R, 1994, ONCOGENE, V9, P1775; BRYANT PE, 1989, MUTAT RES, V213, P233, DOI 10.1016/0027-5107(89)90155-3; BURKLE A, 1993, CARCINOGENESIS, V14, P559, DOI 10.1093/carcin/14.4.559; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; CHEN TR, 1977, EXP CELL RES, V104, P255, DOI 10.1016/0014-4827(77)90089-1; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; COLEMAN WB, 1994, CARCINOGENESIS, V15, P145, DOI 10.1093/carcin/15.2.145; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; COSTA ND, 1990, INT J RADIAT BIOL, V57, P933, DOI 10.1080/09553009014551051; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DONEHOWER LA, 1992, NATURE, V356, P79; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; FRITSCHE M, 1993, ONCOGENE, V8, P307; FRITSCHE M, 1991, THESIS FREIBURG; FRITSCHE M, 1991, J CANCER RES CLIN S, V117, pS30; GANNON JV, 1990, EMBO J, V9, P1591; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HESS R, 1994, TOXICOL LETT, V72, P43, DOI 10.1016/0378-4274(94)90008-6; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KASTAN MB, 1991, CANCER RES, V51, P6304; KRAMER M, 1990, RADIAT ENVIRON BIOPH, V29, P303, DOI 10.1007/BF01210410; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; LEHMANN AR, 1985, MUTAT RES, V150, P61, DOI 10.1016/0027-5107(85)90101-0; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LJUNGMAN M, 1989, CARCINOGENESIS, V10, P447, DOI 10.1093/carcin/10.3.447; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUCKEHUHLE C, 1989, MOL CELL BIOL, V9, P4812; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MCWHIR J, 1993, NAT GENET, V3, P217; MESSMER UK, 1994, FEBS LETT, V355, P23; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MONDAL S, 1976, NATURE, V260, P710, DOI 10.1038/260710a0; MORA PT, 1982, MOL CELL BIOL, V2, P763, DOI 10.1128/MCB.2.7.763; MORTEN JEN, 1988, CARCINOGENESIS, V9, P45, DOI 10.1093/carcin/9.1.45; MOSNER J, 1995, J CANCER RES CLIN S2, V121, pB20; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NICOLAOU KC, 1992, SCIENCE, V256, P1172, DOI 10.1126/science.256.5060.1172; Nicolau K.C., 1991, ANGEW CHEM, V103, P1453; OBE G, 1985, MUTAT RES, V150, P359; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; SACHSENMAIER C, 1994, BIOCHEM PHARMACOL, V47, P129, DOI 10.1016/0006-2952(94)90446-4; SCHMIDT RJ, 1995, J CANC RES CLIN O S2, V121, pA12; SCHULZELUTUM A, 1994, INT J ONCOL, V5, P1405; SHERLEY JL, 1991, J BIOL CHEM, V266, P24815; SIEGEL J, 1993, J CANCER RES CLIN S2, V119, pS84; STARK GR, 1993, ADV CANCER RES, V61, P87, DOI 10.1016/S0065-230X(08)60956-2; STEWART N, 1995, ONCOGENE, V10, P109; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WILSON RE, 1993, ONCOGENE, V8, P3229; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; YAMAIZUMI M, 1994, ONCOGENE, V10, P2775; ZEIN N, 1988, SCIENCE, V240, P1198, DOI 10.1126/science.3240341; ZHAN QM, 1994, ONCOGENE, V9, P3743	72	42	42	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1363	1370						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478558				2022-12-17	WOS:A1995RY96700018
J	KISTLER, B; PFISTERER, P; WIRTH, T				KISTLER, B; PFISTERER, P; WIRTH, T			LYMPHOID-AND MYELOID-SPECIFIC ACTIVITY OF THE PU.1 PROMOTER IS DETERMINED BY THE COMBINATORIAL ACTION OF OCTAMER AND ETS TRANSCRIPTION FACTORS	ONCOGENE			English	Article						GENE REGULATION; CELL-TYPE-SPECIFIC TRANSCRIPTION; ETS-TRANSCRIPTION FACTORS; POU-DOMAIN PROTEINS	PUTATIVE ONCOGENE SPI-1; CHAIN GENE ENHANCER; DNA-BINDING MOTIF; REGULATES EXPRESSION; CD11B PROMOTER; DOMAIN; ACTIVATION; ERYTHROLEUKEMIAS; COMPONENT; PROTEINS	The putative oncogene PU.1/Spi-1 is a member of the ets-family of transcription factors normally expressed in a subset of hematopoietic cell types. Here we have characterized the role of the PU.1 promoter region for the eel-type specific expression. The proximal 120 bp are sufficient to mediate a high level of activity specifically in B cells and macrophages. Three important motifs could be identified within this region. Two of them, an ets binding site (EBS) and a variant octamer motif were most important for cell-type-specific promoter activity in B cells and macrophages, An additional Spl motif stimulates basal activity of this promoter element. The relative contribution to overall activity of octamer motif and EBS differs in B cells and macrophages. In B cells, both octamer motif and EBS combine to mediate high level activity, whereas in macrophages the EBS predominantly confers promoter activity. Both the Oct1 and Oct2 transcription factors, presumably in combination with a B-cell-restricted coactivator, are responsible for the activity of the variant octamer motif in B cells. Interestingly, the PU.1 transcription factor can functionally interact with the EBS in its own promoter, suggesting a positive feedback regulation.	UNIV HEIDELBERG,ZMBH,D-69120 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg			Wirth, Thomas/X-7172-2019					ANNWEILER A, 1993, J BIOL CHEM, V268, P2525; ANNWEILER A, 1992, MOL CELL BIOL, V12, P3107, DOI 10.1128/MCB.12.7.3107; Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; GERSTER T, 1987, EMBO J, V6, P1323, DOI 10.1002/j.1460-2075.1987.tb02371.x; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; JOANNSEN E, 1995, J VIROL, V69, P253; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOMINATO Y, 1995, MOL CELL BIOL, V15, P58; LAUX G, 1994, EMBO J, V13, P5624, DOI 10.1002/j.1460-2075.1994.tb06900.x; LU Y, 1972, CELL, V71, P231; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PETTERSSON M, 1987, GENE DEV, V1, P962, DOI 10.1101/gad.1.9.962; PFISTERER P, 1994, EMBO J, V13, P1654, DOI 10.1002/j.1460-2075.1994.tb06429.x; PFISTERER P, 1995, UNPUB; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; RADOMSKA HS, 1994, IMMUNITY, V1, P623, DOI 10.1016/1074-7613(94)90034-5; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; ROSMARIN AG, 1995, P NATL ACAD SCI USA, V92, P801, DOI 10.1073/pnas.92.3.801; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SCHWARZENBACH H, 1995, J BIOL CHEM, V270, P898, DOI 10.1074/jbc.270.2.898; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; WIRTH T, 1995, IN PRESS IMMUNOBIOLO; YU H, 1989, CELL, V58, P441, DOI 10.1016/0092-8674(89)90425-X	43	42	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1095	1106						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566969				2022-12-17	WOS:A1995RX18000012
J	GAWLER, DJ; ZHANG, LJ; REEDIJK, M; TUNG, PS; MORAN, MF				GAWLER, DJ; ZHANG, LJ; REEDIJK, M; TUNG, PS; MORAN, MF			CALB - A 43 AMINO-ACID CALCIUM-DEPENDENT MEMBRANE PHOSPHOLIPID-BINDING DOMAIN IN P120 RAS GTPASE-ACTIVATING PROTEIN	ONCOGENE			English	Article						RAS; SRC; CALCIUM; CALB; C2; RAS-GAP	GUANINE-NUCLEOTIDE EXCHANGE; GROWTH-FACTOR RECEPTORS; SIGNAL TRANSDUCTION; TYROSINE KINASE; MYRISTYLATION SIGNAL; SYNAPTOTAGMIN P65; REGULATORY DOMAIN; PLASMA-MEMBRANE; GENE-PRODUCT; EGF RECEPTOR	CaLB was originally observed as a conserved sequence motif in various calcium-responsive signalling proteins and also in p120 Ras GTPase activating protein (p120(GAP)) (Clark et al. Cell 65: 1043-1051, 1991). Here we show the 43 residue CaLB motif in p120(GAP) is a functional protein domain that when expressed as a fusion protein in vitro confers Ca2+-dependent interactions with cellular membranes and phosphatidylserine and phosphatidylinositol vesicles. p120(GAP), but not a mutant lacking the CaLB domain, associates with the particulate fraction of cells in response to elevated intracellular Ca2+ suggesting that p120(GAP) may be regulated in part by calcium signals. Addition of the p120(GAP) CaLB domain was able to restore transforming activity and particulate localization to an otherwise transformation-defective and cytosolic mutant v-Src tyrosine kinase. The CaLB domain appears to be a prevalent protein module that may affect the molecular interactions and subcellular localization of signalling proteins.	UNIV TORONTO, BANTING & BEST DEPT MED RES, TORONTO, ON M5G 1L6, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO, ON M5G 1L6, CANADA	University of Toronto; University of Toronto			Moran, Michael/GYD-3631-2022					ALBLAS J, 1993, J BIOL CHEM, V268, P22235; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BROOKSWILSON AR, 1989, MOL CELL BIOL, V9, P2214, DOI 10.1128/MCB.9.5.2214; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK GJ, 1993, P NATL ACAD SCI USA, V90, P4887, DOI 10.1073/pnas.90.11.4887; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; COURTNEIDGE SA, 1980, P NATL ACAD SCI-BIOL, V77, P3783, DOI 10.1073/pnas.77.7.3783; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; Downward J, 1992, CURR OPIN GENET DEV, V2, P13, DOI 10.1016/S0959-437X(05)80315-6; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; FEIG LA, 1994, NATURE, V370, P508, DOI 10.1038/370508a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; HAN JW, 1991, SCIENCE, V252, P576, DOI 10.1126/science.1902323; HUANG DCS, 1993, MOL CELL BIOL, V13, P2420, DOI 10.1128/MCB.13.4.2420; JOHNSTONE SA, 1993, BIOCHEM J, V294, P801, DOI 10.1042/bj2940801; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN JM, 1988, MOL CELL BIOL, V8, P2435, DOI 10.1128/MCB.8.6.2435; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LUO JH, 1993, J BIOL CHEM, V268, P3715; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MOCHLYROSEN D, 1992, BIOCHEMISTRY-US, V31, P8120, DOI 10.1021/bi00150a003; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NORI M, 1990, MOL CELL BIOL, V10, P4155, DOI 10.1128/MCB.10.8.4155; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PERIN MS, 1991, J BIOL CHEM, V266, P615; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STONE JC, 1991, METHOD ENZYMOL, V200, P673; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TSAI MH, 1991, MOL CELL BIOL, V11, P2785, DOI 10.1128/MCB.11.5.2785; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; WANG HCR, 1989, J VIROL, V63, P291, DOI 10.1128/JVI.63.1.291-302.1989; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	68	42	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	1995	10	5					817	825						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898923				2022-12-17	WOS:A1995QL03800002
J	WANG, XJ; GREENHALGH, DA; LU, XR; BICKENBACH, JR; ROOP, DR				WANG, XJ; GREENHALGH, DA; LU, XR; BICKENBACH, JR; ROOP, DR			TGF-ALPHA AND V-FOS COOPERATION IN TRANSGENIC MOUSE EPIDERMIS INDUCES ABERRANT KERATINOCYTE DIFFERENTIATION AND STABLE, AUTONOMOUS PAPILLOMAS	ONCOGENE			English	Article						CARCINOGENESIS; DIFFERENTIATION; ONCOGENE; GROWTH FACTOR	GROWTH-FACTOR-ALPHA; GRB2 ADAPTER PROTEIN; C-FOS; SKIN CARCINOGENESIS; HA-RAS; GENE-EXPRESSION; NUCLEOTIDE EXCHANGE; ALTERED REGULATION; PHORBOL ESTERS; MICE	To assess the synergistic effect of growth and transcription factor deregulation on carcinogenesis in vivo, mating experiments were performed between transgenic mice expressing human TGF alpha or v-fos exclusively in the epidermis by means of a human keratin K1-based targeting vector (HK1.fos, HK1.TGF alpha and HK1.fos/alpha). While HK1.TGF alpha mice exhibited mild epidermal hyperplasia resulting in a wrinkled appearance, this hyperplasia was significantly increased in HK1,fos/alpha mice which also exhibited a novel opalescent and peeling skin phenotype, HK1.fos/alpha keratinocyte differentiation was considerably deregulated with cornified cells appearing in the granular layer, granular cells in the spinous layer and a sixfold increase in BrdU labeling over normal. In addition, hyperplastic HK1.fos/alpha epidermis exhibited aberrant loricrin, filagrin and novel K13 expression associated with v-fos expression, Unlike adult HK1.TGF alpha controls, hyperplasia persisted in HK1,fos/alpha adults which also rapidly developed autonomous squamous cell papillomas, These results demonstrate that v-fos and TGF alpha over-expression can cooperate to reprogram keratinocyte differentiation and elicit the early stages of neoplasia. Moreover, TGF alpha over-expression appeared to play an early, initiating role in HK1.fos/alpha papilloma etiology, and a promotion role in the accelerated appearance of v-fos wound-associated preneoplastic phenotypes, However, the stable persistence of HK1.fos/alpha papillomas for up to 12 months, suggests that additional events are required for malignant conversion.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT DERMATOL,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine					NCI NIH HHS [CA52607] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052607] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILLEUL B, 1990, CELL, V62, P697, DOI 10.1016/0092-8674(90)90115-U; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BASSETSEGUIN N, 1994, ONCOGENE, V9, P765; BASSETSEGUIN N, 1990, J INVEST DERMATOL, V94, P418, DOI 10.1111/1523-1747.ep12874493; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHANG EH, 1982, NATURE, V297, P478; CHARDIN P, 1993, SCIENCE, V260, P1358; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHRISTOFORI G, 1994, SEMIN CANCER BIOL, V5, P3; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; CUTRY AF, 1988, BIOCHEM BIOPH RES CO, V152, P216, DOI 10.1016/S0006-291X(88)80702-2; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; DOMINEY AM, 1993, CELL GROWTH DIFFER, V4, P1071; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FINZI E, 1988, MOL CARCINOGEN, V1, P7, DOI 10.1002/mc.2940010105; FISHER C, 1991, DEVELOPMENT, V111, P253; FRIEDBERG T, 1990, ARCH BIOCHEM BIOPHYS, V279, P167, DOI 10.1016/0003-9861(90)90477-G; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; FURSTENBERGER G, 1989, INT J CANCER, V43, P915; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GLICK AB, 1991, MOL CARCINOGEN, V4, P210, DOI 10.1002/mc.2940040308; GREENHALGH DA, 1990, P NATL ACAD SCI USA, V87, P643, DOI 10.1073/pnas.87.2.643; GREENHALGH DA, 1994, ADV CANCER RES, V64, P247, DOI 10.1016/S0065-230X(08)60840-4; GREENHALGH DA, 1993, CANCER RES, V53, P5071; GREENHALGH DA, 1993, ONCOGENE, V8, P2145; GREENHALGH DA, 1993, MOL CARCINOGEN, V7, P99, DOI 10.1002/mc.2940070208; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HAYAT MA, 1972, BASIC ELECTRON MICRO; HOGAN B, 1982, MANIPULATING MOUSE E; HUITFELDT HS, 1991, CARCINOGENESIS, V12, P2063, DOI 10.1093/carcin/12.11.2063; IMAMOTO A, 1991, MOL CARCINOGEN, V4, P52, DOI 10.1002/mc.2940040109; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; JHAPPAN C, 1994, CELL GROWTH DIFFER, V5, P385; KIM SH, 1993, J CELL BIOL, V123, P87; LAND H, 1983, NATURE, V304, P546; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LU B, 1994, J BIOL CHEM, V269, P7443; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; NISCHT R, 1988, MOL CARCINOGEN, V1, P96, DOI 10.1002/mc.2940010205; PITTELKOW MR, 1989, J BIOL CHEM, V264, P5164; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; ROOP DR, 1987, DIFFERENTIATION, V35, P143, DOI 10.1111/j.1432-0436.1987.tb00162.x; ROOP DR, 1988, CANCER RES, V48, P3245; ROSEJOHN S, 1988, CARCINOGENESIS, V9, P831, DOI 10.1093/carcin/9.5.831; ROTHNAGEL JA, 1987, J BIOL CHEM, V262, P15643; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SAGER SM, 1991, NEUROSCI RES, V29, P549; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SELLHEYER K, 1993, P NATL ACAD SCI USA, V90, P5237, DOI 10.1073/pnas.90.11.5237; SHAUI K, 1993, SCIENCE, V261, P1744; SINN E, 1987, CELL, V49, P415; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SMITH GH, 1990, CELL GROWTH DIFFER, V1, P161; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; TOFTGARD R, 1985, CARCINOGENESIS, V6, P655, DOI 10.1093/carcin/6.4.655; VASSAR R, 1992, MOL CELL BIOL, V12, P4643, DOI 10.1128/MCB.12.10.4643; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; VAUGHAN TJ, 1992, BIOCHIM BIOPHYS ACTA, V1132, P322, DOI 10.1016/0167-4781(92)90170-5; WANG XJ, 1994, MOL CARCINOGEN, V10, P15, DOI 10.1002/mc.2940100104; WEINBERG RA, 1989, CANCER RES, V49, P3713; WEISS RA, 1984, J CELL BIOL, V98, P1397, DOI 10.1083/jcb.98.4.1397; YUSPA SH, 1980, TRANSPLANT P, V12, P114	68	42	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					279	289						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7530825				2022-12-17	WOS:A1995QC62400007
J	ELDER, PA; BELL, SM; KNOWLES, MA				ELDER, PA; BELL, SM; KNOWLES, MA			DELETION OF 2 REGIONS ON CHROMOSOME-4 IN BLADDER-CARCINOMA - DEFINITION OF A CRITICAL 750-KB REGION AT 4P16.3	ONCOGENE			English	Article							HUNTINGTON DISEASE REGION; HEPATOCELLULAR-CARCINOMA; INDEFINITE DIVISION; GENETIC-ANALYSIS; HUMAN-CELLS; HETEROZYGOSITY; CANCER; ALLELOTYPE	Loss of heterozygosity (LOH) of chromosome 4 has been identified in several human tumours including carcinomas of colorectum, ovary, liver and head and neck. LOH at loci on chromosome 4p has previously been identified in 22% of primary bladder tumours. We have assessed LOH in 178 bladder tumours using a panel of six microsatellite markers. Thirty-four tumours (19%) showed LOH at one or more loci. Twenty-three deletions involved restricted regions of 4p and could be used to define two common regions of deletion. A very small common region between D4S43 and D4S127 (estimated to be similar to 750 kB) was involved in 14/23 (61%) of 4p deletions. A second common region centromeric to D4S174 was deleted in 7/23 (30%) of tumours with deletions. Two tumours (9%) had deletions involving both regions independently. Previous functional studies have demonstrated both a senescence function and a suppressor of tumorigenicity on human chromosome 4. Localisation of the common regions of deletion in bladder tumours provides a starting point for positional cloning of the gene(s) concerned and for more precise comparative functional studies.	MARIE CURIE RES INST,GENET MOLEC LAB,OXTED RH8 0TL,SURREY,ENGLAND					Knowles, Margaret/0000-0002-9363-8657; Bell, Sandra/0000-0002-3022-9864				BUETOW KH, 1989, P NATL ACAD SCI USA, V86, P8852, DOI 10.1073/pnas.86.22.8852; CAIRNS P, 1991, ONCOGENE, V6, P2305; CAIRNS P, 1993, CANCER RES, V53, P1230; FUJIMOTO Y, 1994, CANCER RES, V54, P281; HAYASHI K, 1989, NUCLEIC ACIDS RES, V17, P3605, DOI 10.1093/nar/17.9.3605; KIRKNESS EF, 1991, GENOMICS, V10, P985, DOI 10.1016/0888-7543(91)90189-L; KLINGER HP, 1983, JNCI-J NATL CANCER I, V71, P559; KNOWLES MA, 1994, CANCER RES, V54, P531; KNOWLES MA, 1993, ONCOGENE, V8, P1357; LOCKE PA, 1993, SOMAT CELL MOLEC GEN, V19, P95, DOI 10.1007/BF01233958; NAWROZ H, 1994, CANCER RES, V54, P1152; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; OLUMI AF, 1990, CANCER RES, V50, P7081; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; Pershouse M. A., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P539; PROCTOR AJ, 1991, ONCOGENE, V6, P789; SATO T, 1991, CANCER RES, V51, P5118; TSAI YC, 1990, CANCER RES, V50, P44; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WALKER GJ, 1991, CANCER RES, V51, P4367; ZUO J, 1992, HUM MOL GENET, V1, P149, DOI 10.1093/hmg/1.3.149; ZUO JA, 1993, HUM MOL GENET, V2, P889, DOI 10.1093/hmg/2.7.889; 1978, TNM CLASSIFICATION M, P113; 1973, WHO INT CLASSIFICATI, V10	24	42	43	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3433	3436						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970702				2022-12-17	WOS:A1994PT39200004
J	NEHLS, M; PFEIFER, D; BOEHM, T				NEHLS, M; PFEIFER, D; BOEHM, T			EXON AMPLIFICATION FROM COMPLETE LIBRARIES OF GENOMIC DNA USING A NOVEL PHAGE VECTOR WITH AUTOMATIC PLASMID EXCISION FACILITY - APPLICATION TO THE MOUSE NEUROFIBROMATOSIS-1 LOCUS	ONCOGENE			English	Article							CDNAS; GENES; YEAST; EXPRESSION; FRAGMENTS; SELECTION; DELETION; PCR	The identification of transcription units in the vicinity of chromosomal lesions found in tumours is an essential step in the identification of new oncogenes. Here, we describe a lambda phage vector system for genomic exon-trapping (lambda GET), which dramatically simplifies the task of exon amplification from genomic DNA. The vector accommodates about 6.5 to 19 kb of DNA and allows inserts to be automatically subcloned as multi-copy plasmids containing splice donor and acceptor sites positioned flanking the inserted genomic DNA, RNA transcripts derived from such plasmids are processed in vivo and exons contained within the inserted genomic fragments become flanked by known sequences in the resulting mRNAs. RNA-based PCR can then be used for subsequent cloning and sequence analysis of trapped exons. We have exploited the large cloning capacity of lambda GET to construct highly redundant complete genomic libraries from Sau3AI partially digested vertebrate DNAs. Using this system, we have analysed a region of about 1 MB around the mouse neurofibromatosis-1 locus and have identified novel transcription units flanking the Nf-1 gene.	UNIV FREIBURG,DEPT MED 1,MOLEC MED GRP,D-79106 FREIBURG,GERMANY	University of Freiburg								ANDREADIS A, 1993, NUCLEIC ACIDS RES, V21, P2217, DOI 10.1093/nar/21.9.2217; AUCH D, 1990, NUCLEIC ACIDS RES, V18, P6743, DOI 10.1093/nar/18.22.6743; BIRD A, 1986, NATURE, V321, P309; BOEHM T, 1991, ONCOGENE, V6, P695; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P3927, DOI 10.1073/pnas.88.9.3927; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; CLARKE L, 1976, CELL, V9, P91, DOI 10.1016/0092-8674(76)90055-6; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; DUYK GM, 1990, P NATL ACAD SCI USA, V87, P8995, DOI 10.1073/pnas.87.22.8995; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; FORSTER A, 1993, ONCOGENE, V8, P3157; HOESS RH, 1982, P NATL ACAD SCI-BIOL, V79, P3398, DOI 10.1073/pnas.79.11.3398; KARN J, 1984, GENE, V32, P219; KAYES LM, 1992, J MED GENET, V29, P686, DOI 10.1136/jmg.29.10.686; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0; NEHLS M, 1993, TRENDS GENET, V9, P336, DOI 10.1016/0168-9525(93)90024-C; PARIMOO S, 1991, P NATL ACAD SCI USA, V88, P9623, DOI 10.1073/pnas.88.21.9623; RUBY SW, 1991, TRENDS GENET, V7, P79; Sambrook J., 1989, MOL CLONING	22	42	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2169	2175						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036002				2022-12-17	WOS:A1994NX62900007
J	CROMME, FV; SNIJDERS, PJF; VANDENBRULE, AJC; KENEMANS, P; MEIJER, CJLM; WALBOOMERS, JMM				CROMME, FV; SNIJDERS, PJF; VANDENBRULE, AJC; KENEMANS, P; MEIJER, CJLM; WALBOOMERS, JMM			MHC CLASS-I EXPRESSION IN HPV-16 POSITIVE CERVICAL CARCINOMAS IS POSTTRANSCRIPTIONALLY CONTROLLED AND INDEPENDENT FROM C-MYC OVEREXPRESSION	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS GENOTYPES; POLYMERASE CHAIN-REACTION; INTRAEPITHELIAL NEOPLASIA; ONCOGENE EXPRESSION; UTERINE CERVIX; HISTOCOMPATIBILITY ANTIGENS; SILVER INTENSIFICATION; INSITU HYBRIDIZATION; COLORECTAL-CANCER; HEAVY-CHAINS	Squamous cell carcinomas of the uterine cervix (n = 23) were selected for the presence of human papillomavirus type 16 (HPV 16) using the polymerase chain reaction (PCR). Localization of transcripts coding for the E7 protein was demonstrated in neoplastic cells with RNA in situ hybridization. Consecutive tissue sections were investigated for expression of the major histocompatibility complex class I (MHC-I) and c-myc using immunohistochemical double staining procedures, since a role has been suggested for the c-myc protein in MHC-I down-regulation and c-myc overexpression has been described in cervical carcinomas. Reduced expression of class I heavy chains was observed in neoplastic cells from 18 out of 23 carcinomas (78%). Varying levels of c-myc overexpression were observed in 12 carcinomas (52%), from which four showed positive MHC-I expression in c-myc overexpressing cells. In the remaining eight c-myc overexpressing carcinomas MHC-I down-regulation was observed. Additional RNA in situ hybridization with class I heavy chain locus-specific RNA-probes revealed presence of class I mRNAs in those neoplastic cells that show negative staining for MHC-I protein. These data strongly indicate that MHC-I down-regulation in cervical carcinomas involves post-transcriptional mechanisms, not directly related to E7 transcription and overexpression of c-myc.	FREE UNIV AMSTERDAM HOSP, INST PATHOL,DEPT PATHOL,MOLEC PATHOL SECT, DE BOELELAAN 1117, 1081 HV AMSTERDAM, NETHERLANDS; FREE UNIV AMSTERDAM HOSP, DEPT GYNAECOL & OBSTET, 1081 HV AMSTERDAM, NETHERLANDS	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER								BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; BERGERON C, 1992, AM J SURG PATHOL, V16, P641, DOI 10.1097/00000478-199207000-00002; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BROKER TR, 1989, CANCER CEL, V7, P197; CONNOR ME, 1990, INT J CANCER, V46, P1029, DOI 10.1002/ijc.2910460614; COUTURIER J, 1991, J VIROL, V65, P4534, DOI 10.1128/JVI.65.8.4534-4538.1991; CROMME FV, 1993, BRIT J CANCER, V67, P1372, DOI 10.1038/bjc.1993.254; DURST M, 1987, P NATL ACAD SCI USA, V84, P1070, DOI 10.1073/pnas.84.4.1070; DURST M, 1987, ONCOGENE, V1, P251; FELTNER DE, 1989, J IMMUNOL, V143, P4292; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HAUSEN HZ, 1989, CANCER RES, V49, P4677; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; IWASAKA T, 1992, GYNECOL ONCOL, V46, P298, DOI 10.1016/0090-8258(92)90220-D; KLAR D, 1989, EMBO J, V8, P475, DOI 10.1002/j.1460-2075.1989.tb03400.x; KOLLER BH, 1984, P NATL ACAD SCI-BIOL, V81, P5175, DOI 10.1073/pnas.81.16.5175; LENARDO M, 1989, EMBO J, V8, P3351, DOI 10.1002/j.1460-2075.1989.tb08497.x; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LORINCZ AT, 1992, OBSTET GYNECOL, V79, P328, DOI 10.1097/00006250-199203000-00002; LUNGU O, 1992, JAMA-J AM MED ASSOC, V267, P2493, DOI 10.1001/jama.267.18.2493; MAUDSLEY DJ, 1991, IMMUNOL TODAY, V12, P429, DOI 10.1016/0167-5699(91)90013-J; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; MERCHENTHALER I, 1989, J HISTOCHEM CYTOCHEM, V37, P1563, DOI 10.1177/37.10.2674275; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; MORRIS A, 1990, ANTICANCER RES, V10, P1161; MULLINK H, 1992, J HISTOCHEM CYTOCHEM, V40, P495, DOI 10.1177/40.4.1532404; MULLINK H, 1987, APPLICATION MONOCLON, P37; MUNGER K, 1989, J VIROL, V64, P519; NEEFJES JJ, 1988, EUR J IMMUNOL, V18, P801, DOI 10.1002/eji.1830180522; OCADIZ R, 1987, CANCER RES, V47, P4173; OUDEJANS CBM, 1989, J EXP MED, V169, P447, DOI 10.1084/jem.169.2.447; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PILLAI R, 1991, CANCER LETT, V59, P171, DOI 10.1016/0304-3835(91)90183-I; PINION SB, 1991, LANCET, V337, P819, DOI 10.1016/0140-6736(91)92518-7; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; REDONDO M, 1991, CANCER RES, V51, P2463; RIOU G, 1987, LANCET, V1, P761; RIOU GF, 1988, CANCER SURV, V7, P441; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SCHRIER PI, 1993, ADV CANCER RES, V60, P181; SIKORA K, 1987, CANCER-AM CANCER SOC, V59, P1289, DOI 10.1002/1097-0142(19870401)59:7<1289::AID-CNCR2820590710>3.0.CO;2-O; SNIJDERS PJF, 1990, J GEN VIROL, V71, P173, DOI 10.1099/0022-1317-71-1-173; SOONG TW, 1991, CANCER DETECT PREV, V15, P231; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; STAM NJ, 1986, J IMMUNOL, V137, P2299; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VANDENBRULE AJC, 1991, INT J CANCER, V48, P404, DOI 10.1002/ijc.2910480317; VANDENBRULE AJC, 1990, J CLIN MICROBIOL, V28, P2739, DOI 10.1128/JCM.28.12.2739-2743.1990; VANDENBRULE AJC, 1991, AM J PATHOL, V139, P1037; VERSTEEG R, 1988, EMBO J, V7, P1023, DOI 10.1002/j.1460-2075.1988.tb02909.x; VERSTEEG R, 1989, J EXP MED, V170, P621, DOI 10.1084/jem.170.3.621; WOODWORTH CD, 1990, CANCER RES, V50, P3709	56	42	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1993	8	11					2969	2975						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414499				2022-12-17	WOS:A1993MC09300010
J	WILLIAMS, AC; BROWNE, SJ; YEUDAL, WA; PATERSON, IC; MARSHALL, CJ; LANE, DP; PARASKEVA, C				WILLIAMS, AC; BROWNE, SJ; YEUDAL, WA; PATERSON, IC; MARSHALL, CJ; LANE, DP; PARASKEVA, C			MOLECULAR EVENTS INCLUDING P53 AND K-RAS ALTERATIONS IN THE IN-VITRO PROGRESSION OF A HUMAN COLORECTAL ADENOMA CELL-LINE TO AN ADENOCARCINOMA	ONCOGENE			English	Article							POLYPOSIS COLI PATIENTS; HUMAN COLONIC ADENOMA; GENE-MUTATIONS; CYTOGENETIC ABNORMALITIES; POSSIBLE INVOLVEMENT; HUMAN CHROMOSOME-1; TUMOR PROGRESSION; LUNG-CANCER; HUMAN DNA; CARCINOMA	The aim of the current study was to identify genetic abnormalities in human colorectal adenoma and carcinoma derived cell lines, and to determine whether the genetic changes which occur in vitro are relevant to the in vivo situation. Loss of 1p(33-35) region was shown to be the most common chromosome 1 abnormality and loss of heterozygosity (LOH) of the DCC gene and/or adjacent sequences was detected in all adenoma derived cells as well as the carcinoma cell lines. The level of p53 protein was also investigated as increased cellular p53 protein had previously been associated with mutation of the p53 gene. A further aim was to investigate genetic changes in our in vitro model of tumour progression, where the adenoma derived PC/AA cell line has previously been converted in vitro to two distinct tumorigenic phenotypes, producing either an adenocarcinoma or a mucinous carcinoma in athymic nude mice. Progression to the adenocarcinoma phenotype was shown to involve a specific chromosome 1 rearrangement, loss of both normal copies of chromosome 18 (although DCC gene sequences were retained), loss of the remaining wild type allele of k-ras resulting in homozygosity for the k-ras codon 12 mutation and increased cellular p53 protein as detected by SDS-PAGE Western blotting. The increase in p53 protein was shown not to be due to the acquisition of a mutation in the p53 gene. Interestingly, progression of the adenoma derived PC/AA cell line to the mucinous malignant phenotype did not involve any of these molecular rearrangements, suggesting that different genetically distinct pathways are involved in colorectal carcinogenesis. These studies show that the genetic changes in our in vitro model of human colorectal tumour progression are similar to those observed in in vivo studies.	UNIV BRISTOL,DEPT ORAL MED PATHOL & MICROBIOL,BRISTOL BS2 8HW,AVON,ENGLAND; INST CANC RES,CHESTER BEATTY LABS,CELL & MOLEC BIOL SECT,LONDON SW3 6JB,ENGLAND; UNIV DUNDEE,INST MED SCI,DEPT BIOCHEM,CRC,CELL TRANSFORMAT RES GRP,DUNDEE DD1 4HN,SCOTLAND	University of Bristol; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Dundee	WILLIAMS, AC (corresponding author), UNIV BRISTOL,SCH MED SCI,DEPT PATHOL & MICROBIOL,UNIV WALK,BRISTOL BS8 1TD,AVON,ENGLAND.		Lane, David P/C-4920-2008; Paterson, Ian/G-8688-2011	Paterson, Ian/0000-0001-9156-401X; Williams, Ann/0000-0002-6009-7137; Lane, David/0000-0003-0551-3545				BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; CHEN TR, 1977, EXP CELL RES, V104, P255, DOI 10.1016/0014-4827(77)90089-1; DELATTRE O, 1987, NUCLEIC ACIDS RES, V15, P1343, DOI 10.1093/nar/15.3.1343; EHRHART JC, 1988, ONCOGENE, V3, P595; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FARR CJ, 1988, ONCOGENE, V3, P673; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEARON ER, 1992, FASEB J, V6, P2783, DOI 10.1096/fasebj.6.10.1321771; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FRITSCHE M, 1993, ONCOGENE, V8, P307; GENDLER SJ, 1987, P NATL ACAD SCI USA, V84, P6060, DOI 10.1073/pnas.84.17.6060; HAGUE A, 1992, INT J ONCOL, V1, P201; HALVORSEN TB, 1988, J CLIN PATHOL, V41, P1068, DOI 10.1136/jcp.41.10.1068; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; KASTAN MB, 1991, CANCER RES, V51, P6304; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3965; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEISTER I, 1990, CANCER RES, V50, P7232; LEVI S, 1991, CANCER RES, V51, P3497; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; MANNING AM, 1991, ONCOGENE, V6, P1471; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MULERIS M, 1990, CANCER GENET CYTOGEN, V44, P107, DOI 10.1016/0165-4608(90)90203-M; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P5707, DOI 10.1093/nar/16.12.5707; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P4747, DOI 10.1093/nar/16.10.4747; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OLAH E, 1989, CANCER GENET CYTOGEN, V43, P179, DOI 10.1016/0165-4608(89)90029-0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PARASKEVA C, 1990, INT J CANCER, V46, P753, DOI 10.1002/ijc.2910460434; PARASKEVA C, 1992, INT J CANCER, V51, P661, DOI 10.1002/ijc.2910510426; PARASKEVA C, 1988, INT J CANCER, V41, P908; PARASKEVA C, 1984, INT J CANCER, V34, P49, DOI 10.1002/ijc.2910340109; PARASKEVA C, 1989, INT J CANCER, V43, P743, DOI 10.1002/ijc.2910430434; PARASKEVA C, 1989, CANCER RES, V49, P1282; QUNITILLA M, 1986, NATURE, V322, P78; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SAKAI E, 1992, ONCOGENE, V7, P927; SEABRIGH.M, 1971, LANCET, V2, P971; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; SUNDBLAD AS, 1982, CANCER, V50, P2504, DOI 10.1002/1097-0142(19821201)50:11<2504::AID-CNCR2820501141>3.0.CO;2-A; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WILLIAMS AC, 1990, CANCER RES, V50, P4724; WILLIAMS AC, 1992, INT J CANCER, V52, P785, DOI 10.1002/ijc.2910520519; WONG Z, 1987, ANN HUM GENET, V51, P269, DOI 10.1111/j.1469-1809.1987.tb01062.x; YOUNG J, 1992, CANCER RES, V52, P285	58	42	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3063	3072						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414507				2022-12-17	WOS:A1993MC09300022
J	MURAKAMI, K; MAVROTHALASSITIS, G; BHAT, NK; FISHER, RJ; PAPAS, TS				MURAKAMI, K; MAVROTHALASSITIS, G; BHAT, NK; FISHER, RJ; PAPAS, TS			HUMAN ERG-2 PROTEIN IS A PHOSPHORYLATED DNA-BINDING PROTEIN - A DISTINCT MEMBER OF THE ETS FAMILY	ONCOGENE			English	Article							LONG TERMINAL REPEAT; LEUKEMIA-VIRUS; C-FOS; ONCOGENE; GENE; SEQUENCE; ONCOPROTEIN; ACTIVATION; ERYTHROBLASTOSIS; RETROVIRUS-E26	We describe the identification of the ERG-2 gene products using an antibody raised against recombinant human ERG-2 protein. ERG-2 is a nuclear phosphoprotein and binds to purine-rich sequences (C/G)(C/a)GG-AA(G/a)T. ERG-2 protein, with a half-life of 21 h, is considerably more stable than the short-lived ETS-1 or ETS-2 proteins. Its phosphorylation is stimulated by phorbal myristate acetate (PMA), but not by Ca2+ ion-phore treatment. ETS-1 protein is phosphorylated by Ca2+-dependent events, whereas ERG-2 protein is phosphorylated by activation of protein kinase C, suggesting their involvement in distinct signal transduction mechanisms. The expression of ERG-2 protein is restricted to few cell types and is high in early myeloid cells, indicating that it may function at an early stage of hematopoietic lineage determination. The DNA-binding sequence for ERG-2 protein is identified by using a random oligonucleotide selection procedure. The selected sequence is very similar to the binding sequence determined for human ETS-1 using the same method. Like other ets proteins, ERG-2 is a sequence-specific DNA-binding protein and is expressed at higher levels in early myeloid cells than in mature lymphoid cells. These results suggest that it may act as a regulator of genes required for maintenance and/or differentiation of early hematopoietic cells.	NCI,MOLEC ONCOL LAB,FREDERICK,MD 21702; INC DYNCORP,PROGRAM RESOURCES,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Fisher, Robert/B-1431-2009					BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FISHER RJ, 1991, ONCOGENE, V6, P1001; FUJIWARA S, 1988, ONCOGENE, V2, P99; FUJIWARA S, 1990, HYBRIDOMA, V9, P559, DOI 10.1089/hyb.1990.9.559; FUJIWARA S, 1990, MOL CELL BIOL, V10, P1249, DOI 10.1128/MCB.10.3.1249; FUJIWARA S, 1988, MOL CELL BIOL, V8, P4700, DOI 10.1128/MCB.8.11.4700; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; GUTMAN A, 1991, MOL CELL BIOL, V11, P5381, DOI 10.1128/MCB.11.10.5381; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOIZUMI S, 1990, ONCOGENE, V5, P675; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; MAVROTHALASSITIS G, 1990, DNA CELL BIOL, V9, P783, DOI 10.1089/dna.1990.9.783; MOSCOVICI C, 1981, VIROLOGY, V113, P765, DOI 10.1016/0042-6822(81)90205-1; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDKE K, 1982, CELL, V31, P643; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SISK WP, 1986, GENE, V48, P183, DOI 10.1016/0378-1119(86)90076-4; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699	40	42	43	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1559	1566						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502479				2022-12-17	WOS:A1993LE06400019
J	COHEN, DR; VANDERMARK, SE; MCGOVERN, JD; BRADLEY, MP				COHEN, DR; VANDERMARK, SE; MCGOVERN, JD; BRADLEY, MP			TRANSCRIPTIONAL REGULATION IN THE TESTIS - A ROLE FOR TRANSCRIPTION FACTOR AP-1 COMPLEXES AT VARIOUS STAGES OF SPERMATOGENESIS	ONCOGENE			English	Article							MALE GERM LINE; C-FOS PROTEIN; IMMEDIATE-EARLY GENE; LEUCINE ZIPPER; JUN-B; DIFFERENTIAL EXPRESSION; BINDING AFFINITIES; MESSENGER-RNA; ONC GENES; CELLS	The products of two proto-oncogenes, c-fos and c-jun, have been implicated in signal transduction pathways as regulators of gene expression. Both proto-oncogenes are members of gene families encoding closely related proteins that together make up transcription factor AP-1. The expression of members of this transcription factor has been associated with cellular pathways that result in both mitosis and differentiation. We have been studying the process of spermatogenesis, which is a complex, continual cycle of cell renewal, proliferation and differentiation. Using a seasonal breeder, the European red fox (Vulpes vulpes), as our model, we have examined the expression of five AP-1 family members (c-fos, fra-1, fra-2, c-jun and junB) with a view to elucidating their role in the regulation of spermatogenesis. Unique patterns of expression, falling into three broad categories, were observed for the five genes: (i) continuous expression throughout the spermatogenic cycle (c-fos); (ii) expression only at times corresponding to the onset and shutdown of spermatogenesis (fra-1, fra-2 and c-jun); and (iii) expression only at the onset of the cycle (junB). Furthermore, the proteins were expressed in both premeiotic and post-meiotic cell types, suggesting a role in haploid, as well as diploid, gene expression in this tissue. The data suggest distinct, although not necessarily unrelated, roles for the different components of transcription factor AP-1 in the regulation of spermatogenesis.	CSIRO,DIV WILDLIFE & ECOL,COOPERAT RES CTR BIO CONTROL VERTEBRATE PESTS,LYNEHAM,ACT 2602,AUSTRALIA	Commonwealth Scientific & Industrial Research Organisation (CSIRO)	COHEN, DR (corresponding author), AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV CELL BIOL,CANBERRA,ACT 2601,AUSTRALIA.			Cohen, Donna/0000-0002-0419-9542				ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ALCIVAR AA, 1990, J BIOL CHEM, V265, P20160; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COHEN D R, 1989, Critical Reviews in Oncogenesis, V1, P65; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COHEN DR, 1990, ONCOGENE, V5, P929; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; Curran T, 1988, ONCOGENE HDB, P307; Englund J., 1970, Viltrevy, V8, P1; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; Hecht NB., 1986, EXPT APPROACHES MAMM, P151; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HUNT SP, 1987, NATURE, V328, P632, DOI 10.1038/328632a0; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MASON I, 1985, DIFFERENTIATION, V30, P76, DOI 10.1111/j.1432-0436.1985.tb00516.x; MATSUI M, 1990, ONCOGENE, V5, P249; MELLSTROM B, 1991, ONCOGENE, V6, P1959; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; MULLER R, 1983, NATURE, V304, P454, DOI 10.1038/304454a0; MULLER R, 1983, EMBO J, V2, P679, DOI 10.1002/j.1460-2075.1983.tb01484.x; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; PELTOHUIKKO M, 1991, ACTA PHYSIOL SCAND, V141, P283, DOI 10.1111/j.1748-1716.1991.tb09080.x; PONZETTO C, 1985, MOL CELL BIOL, V5, P1791, DOI 10.1128/MCB.5.7.1791; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RUBIN MR, 1986, SCIENCE, V233, P663, DOI 10.1126/science.3726554; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1991, ONCOGENE, V6, P533; SAGAR SM, 1988, SCIENCE, V240, P1328, DOI 10.1126/science.3131879; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SHIN C, 1990, J NEUROCHEM, V55, P1050, DOI 10.1111/j.1471-4159.1990.tb04595.x; SONNENBERG JL, 1989, NEURON, V3, P359, DOI 10.1016/0896-6273(89)90260-2; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; SORRENTINO V, 1988, P NATL ACAD SCI USA, V85, P2191, DOI 10.1073/pnas.85.7.2191; STEWART TA, 1984, SCIENCE, V226, P707, DOI 10.1126/science.6494906; WOLFES H, 1989, SCIENCE, V245, P740, DOI 10.1126/science.2475907; ZAKERI ZF, 1987, MOL CELL BIOL, V7, P1791, DOI 10.1128/MCB.7.5.1791; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	52	42	45	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					443	455						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426749				2022-12-17	WOS:A1993KN00600024
J	LAVIGUEUR, A; BERNSTEIN, A				LAVIGUEUR, A; BERNSTEIN, A			P53 TRANSGENIC MICE - ACCELERATED ERYTHROLEUKEMIA INDUCTION BY FRIEND-VIRUS	ONCOGENE			English	Article							MURINE LEUKEMIA-VIRUS; 2 DISTINCT STRAINS; WILD-TYPE P53; PUTATIVE ONCOGENE; BLAST CRISIS; CELL-GROWTH; LUNG-CANCER; GENE; MUTATIONS; LINE	Mutations in the p53 tumor-suppressor gene have been implicated in the pathogenesis of a significant proportion of human cancers and in a dominantly inherited familial cancer syndrome (Li-Fraumeni syndrome). Frequent rearrangements and point mutations have also been detected in the p53 gene in the murine erythroleukemias induced by Friend leukemia virus. We have previously reported that transgenic mice overproducing a mutated p53 protein are predisposed to the development of lung carcinomas, bone and soft-tissue sarcomas, as well as lymphoid malignancies. Here we report that p53 transgenic mice infected with the polycythemia-inducing strain of Friend virus (FV-P) progress to the late stage of erythroleukemia more rapidly than do normal mice. In addition, Friend leukemic cell lines derived from p53 transgenic mice overproduce mutant p53 protein and show a high frequency of rearrangement of the ets-related Spi-1 oncogene, as previously reported in Friend cell lines derived from non-transgenic animals. These results suggest that the same genetic changes involved in the evolution of Friend leukemia in normal mice are also required in mice with an inherited predisposition to cancer. The data also indicate that p53 transgenic mice provide an animal model in which to analyse the role that genetic and environmental factors play in influencing cancer predisposition.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, 600 UNIV AVE, TORONTO M5G 1X5, ONTARIO, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5S 1A1, ONTARIO, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto								AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; Ausubel F.M., 1987, CURRENT PROTOCOLS MO; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BEN-DAVID Y, 1990, New Biologist, V2, P1015; BENDAVID Y, 1989, ANN NY ACAD SCI, V567, P165, DOI 10.1111/j.1749-6632.1989.tb16468.x; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; DAVID YB, 1988, ONCOGENE, V3, P179; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; HABER DA, 1991, CELL, V64, P5, DOI 10.1016/0092-8674(91)90200-I; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HICKS GG, 1988, J VIROL, V62, P4752, DOI 10.1128/JVI.62.12.4752-4755.1988; HOATLIN ME, 1990, P NATL ACAD SCI USA, V87, P9985, DOI 10.1073/pnas.87.24.9985; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KABAT D, 1989, CURR TOP MICROBIOL, V148, P1; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KNUDSON AG, 1985, CANCER RES, V45, P1437; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; MAGER D, 1981, MOL CELL BIOL, V1, P721, DOI 10.1128/MCB.1.8.721; MAGER DL, 1981, P NATL ACAD SCI-BIOL, V78, P1703, DOI 10.1073/pnas.78.3.1703; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MASHAL R, 1990, BLOOD, V75, P180; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILLER CW, 1990, CANCER RES, V50, P7950; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROVINSKI B, 1988, ONCOGENE, V2, P445; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STRATTON MR, 1990, ONCOGENE, V5, P1297; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; WEINBERG RA, 1989, CANCER RES, V49, P3713; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	52	42	42	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1991	6	12					2197	2201						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766668				2022-12-17	WOS:A1991GX73500004
J	THOMAS, NSB; BURKE, LC; BYBEE, A; LINCH, DC				THOMAS, NSB; BURKE, LC; BYBEE, A; LINCH, DC			THE PHOSPHORYLATION STATE OF THE RETINOBLASTOMA (RB) PROTEIN IN G0 G1 IS DEPENDENT ON GROWTH STATUS	ONCOGENE			English	Article							SUSCEPTIBILITY GENE-PRODUCT; CELL-CYCLE; OSTEO-SARCOMA; EXPRESSION; DIFFERENTIATION; PROLIFERATION; INTERFERON; SEQUENCE; MITOSIS; KINASE	The product of the retinoblastoma gene (RB) is a nuclear phosphoprotein which is thought to regulate the proliferation of cells. Its phosphorylation state changes with passage through the cell cycle and it has been proposed that RB protein in its hypo-phosphorylated form prevents cells proliferating. We have investigated the phosphorylation state of the RB protein in an actively-dividing human B-lymphoblastoid cell line and after cell cycle arrest caused by alpha-Interferon (alpha-IFN). We show that the phosphorylation state of the RB protein in cells with 2N DNA content depends on whether the cells are actively cycling. Our data is compatible with the proposal that dephosphorylation of the RB protein allows cells to enter a quiescent state. This study sheds light on the molecular mechanisms which may mediate the cytostatic effects of alpha-IFN.			THOMAS, NSB (corresponding author), UNIV COLL & MIDDLESEX SCH MED,DEPT HAEMATOL,98 CHENIES MEWS,LONDON WC1E 6HX,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BOOKSTEIN R, 1989, MOL CELL BIOL, V9, P1628, DOI 10.1128/MCB.9.4.1628; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CLEMENS MJ, 1985, BIOCHEM J, V226, P345, DOI 10.1042/bj2260345; COOPER JA, 1989, CELL, V58, P1009, DOI 10.1016/0092-8674(89)90495-9; DARZYNKIEWICZ Z, 1982, J CELL PHYSIOL, V113, P465, DOI 10.1002/jcp.1041130316; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DRYJA TP, 1986, P NATL ACAD SCI USA, V83, P7391, DOI 10.1073/pnas.83.19.7391; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GERDES J, 1984, J IMMUNOL, V133, P1710; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1988, J CELL BIOCHEM, V38, P213, DOI 10.1002/jcb.240380309; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MASON DY, 1975, BRIT J HAEMATOL, V31, P361, DOI 10.1111/j.1365-2141.1975.tb00867.x; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SILVERMAN RH, 1982, EUR J BIOCHEM, V126, P333; TANG A, 1989, ONCOGENE, V4, P401; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; THOMAS NSB, 1989, J BIOL CHEM, V264, P13697; TOGUCHIDA J, 1989, NATURE, V338, P156, DOI 10.1038/338156a0; VARLEY JM, 1989, ONCOGENE, V4, P725; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XU HJ, 1989, ONCOGENE, V4, P807; YOKOTA J, 1988, ONCOGENE, V3, P471	35	42	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1991	6	2					317	322						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	2000225				2022-12-17	WOS:A1991FZ13400019
J	ERLANDSSON, R; BERGERHEIM, USR; BOLDOG, F; MARCSEK, Z; KUNIMI, K; LIN, BYT; INGVARSSON, S; CASTRESANA, JS; LEE, WH; LEE, E; KLEIN, G; SUMEGI, J				ERLANDSSON, R; BERGERHEIM, USR; BOLDOG, F; MARCSEK, Z; KUNIMI, K; LIN, BYT; INGVARSSON, S; CASTRESANA, JS; LEE, WH; LEE, E; KLEIN, G; SUMEGI, J			A GENE NEAR THE D3F15S2 SITE ON 3P IS EXPRESSED IN NORMAL HUMAN KIDNEY BUT NOT OR ONLY AT A SEVERELY REDUCED LEVEL IN 11 OF 15 PRIMARY RENAL-CELL CARCINOMAS (RCC)	ONCOGENE			English	Article									KAROLINSKA HOSP, LUNDIG INST CANC RES, S-10401 STOCKHOLM 60, SWEDEN; UNIV CALIF SAN DIEGO, SCH MED, DEPT PATHOL, LA JOLLA, CA 92093 USA	Karolinska Institutet; Karolinska University Hospital; University of California System; University of California San Diego	ERLANDSSON, R (corresponding author), KAROLINSKA INST, DEPT TUMOR BIOL, BOX 60400, S-10401 STOCKHOLM 60, SWEDEN.		Ingvarsson, Sigurdur/E-7448-2011; Castresana, Javier S/AFT-2167-2022	Ingvarsson, Sigurdur/0000-0003-4125-1714; Castresana, Javier S./0000-0002-2373-482X				BABU VR, 1987, CANCER RES, V47, P6800; BERGERHEIM U, 1989, CANCER RES, V49, P1390; BOLDOG F, 1989, CANCER GENET CYTOGEN, V42, P295, DOI 10.1016/0165-4608(89)90098-8; BULLERDIEK J, 1987, CANCER GENET CYTOGEN, V27, P177, DOI 10.1016/0165-4608(87)90273-1; CARRITT B, 1986, AM J HUM GENET, V38, P428; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; ERLANDSSON R, 1988, CANCER GENET CYTOGEN, V36, P197, DOI 10.1016/0165-4608(88)90145-8; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GOODE ME, 1986, AM J HUM GENET, V38, P437; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HEIM S, 1989, ADV CANCER RES, V52, P1; KIDD KK, 1985, CYTOGENET CELL GENET, V40, P107, DOI 10.1159/000132171; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; MULERIS M, 1987, INT J CANCER, V39, P595, DOI 10.1002/ijc.2910390509; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; NAYLOR SL, 1989, GENOMICS, V4, P355, DOI 10.1016/0888-7543(89)90342-X; OHYASHIKI K, 1986, CANCER RES, V46, P5282; PATHAK S, 1982, SCIENCE, V217, P939, DOI 10.1126/science.7112106; POPESCU NC, 1988, CANCER RES, V48, P142; QUINN LA, 1979, CANCER RES, V39, P4914; RHIM JS, 1975, INT J CANCER, V15, P23, DOI 10.1002/ijc.2910150104; ROWE M, 1989, ADV VIRAL ONCOL, V8, P237; SEIZINGER BR, 1988, NATURE, V332, P268, DOI 10.1038/332268a0; TORY K, 1989, J NATL CANCER I, V81, P1097, DOI 10.1093/jnci/81.14.1097; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VANDERHOUT AH, 1988, CANCER GENET CYTOGEN, V32, P281, DOI 10.1016/0165-4608(88)90292-0; WANG N, 1984, CANCER GENET CYTOGEN, V11, P479, DOI 10.1016/0165-4608(84)90028-1; WHANGPENG J, 1988, J NATL CANCER I, V80, P1253, DOI 10.1093/jnci/80.15.1253; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0; ZHANG R, 1989, CANCER RES, V49, P444	36	42	42	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1990	5	8					1207	1211						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX361	2392324				2022-12-17	WOS:A1990DX36100014
J	HEROLD, KM; ROTHBERG, PG				HEROLD, KM; ROTHBERG, PG			EVIDENCE FOR A LABILE INTERMEDIATE IN THE BUTYRATE INDUCED REDUCTION OF THE LEVEL OF C-MYC RNA IN SW837 RECTAL-CARCINOMA CELLS	ONCOGENE			English	Article									NEW YORK STATE DEPT HLTH, ROSWELL PK MEM INST, DEPT HUMAN GENET, BUFFALO, NY 14263 USA	Roswell Park Cancer Institute					NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA16056] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARSHAVIT Z, 1986, ENDOCRINOLOGY, V118, P679, DOI 10.1210/endo-118-2-679; BERGER J, 1987, P NATL ACAD SCI USA, V84, P695, DOI 10.1073/pnas.84.3.695; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CHUNG YS, 1985, CANCER RES, V45, P2976; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DEBUSTROS A, 1985, J BIOL CHEM, V260, P98; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DOTTO GP, 1986, EMBO J, V5, P2853, DOI 10.1002/j.1460-2075.1986.tb04579.x; ENDO T, 1986, MOL CELL BIOL, V6, P1412, DOI 10.1128/MCB.6.5.1412; ERISMAN MD, 1985, MOL CELL BIOL, V5, P1969, DOI 10.1128/MCB.5.8.1969; GHOSH NK, 1977, BIOCHEM J, V166, P265, DOI 10.1042/bj1660265; GRIEP AE, 1986, P NATL ACAD SCI USA, V83, P5539, DOI 10.1073/pnas.83.15.5539; GUM JR, 1987, J BIOL CHEM, V262, P1092; HUBER BE, 1987, CANCER RES, V47, P3414; JOHNSON BE, 1986, J CLIN INVEST, V78, P525, DOI 10.1172/JCI112604; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KIM YS, 1980, CANCER-AM CANCER SOC, V45, P1185, DOI 10.1002/1097-0142(19800315)45:5+<1185::AID-CNCR2820451324>3.0.CO;2-W; KRUH J, 1982, MOL CELL BIOCHEM, V42, P65; LACHMAN HM, 1986, P NATL ACAD SCI USA, V83, P6480, DOI 10.1073/pnas.83.17.6480; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LEIBOVITZ A, 1976, CANCER RES, V36, P4562; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; MAKINO R, 1984, NATURE, V310, P697, DOI 10.1038/310697a0; MASON WS, 1982, P NATL ACAD SCI-BIOL, V79, P3997, DOI 10.1073/pnas.79.13.3997; MATLASHEWSKI G, 1984, EMBO J, V3, P3257, DOI 10.1002/j.1460-2075.1984.tb02287.x; MULDER KM, 1988, INT J CANCER, V42, P64, DOI 10.1002/ijc.2910420113; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NATH P, 1987, EXP CELL RES, V169, P215, DOI 10.1016/0014-4827(87)90239-4; NISHIMURA S, 1987, BIOCHEM J, V243, P313, DOI 10.1042/bj2430313; PFEIFEROHLSSON S, 1985, P NATL ACAD SCI USA, V82, P5050, DOI 10.1073/pnas.82.15.5050; REED JC, 1985, P NATL ACAD SCI USA, V82, P4221, DOI 10.1073/pnas.82.12.4221; REITSMA PH, 1983, NATURE, V306, P492, DOI 10.1038/306492a0; ROEDIGER WEW, 1982, GASTROENTEROLOGY, V83, P424; ROTHBERG PG, 1984, MOL CELL BIOL, V4, P1096, DOI 10.1128/MCB.4.6.1096; ROTHBERG PG, 1987, SEMIN SURG ONCOL, V3, P152, DOI 10.1002/ssu.2980030305; ROTHBERG PG, 1985, BRIT J CANCER, V52, P629, DOI 10.1038/bjc.1985.237; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; RUBINSTEIN R, 1969, CLIN SCI, V37, P549; SEALY L, 1978, CELL, V14, P115, DOI 10.1016/0092-8674(78)90306-9; SIKORA K, 1987, CANCER-AM CANCER SOC, V59, P1289, DOI 10.1002/1097-0142(19870401)59:7<1289::AID-CNCR2820590710>3.0.CO;2-O; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; STEWART J, 1986, BRIT J CANCER, V53, P1, DOI 10.1038/bjc.1986.1; STEWART TA, 1984, SCIENCE, V226, P707, DOI 10.1126/science.6494906; TSAO D, 1983, CANCER RES, V43, P1217; TSAO D, 1982, CANCER RES, V42, P1052; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490	51	42	42	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1988	3	4					423	428						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q7739	3078950				2022-12-17	WOS:A1988Q773900010
J	VANTUINEN, P; JOHNSON, KR; LEDBETTER, SA; NUSSBAUM, RL; ROVERA, G; LEDBETTER, DH				VANTUINEN, P; JOHNSON, KR; LEDBETTER, SA; NUSSBAUM, RL; ROVERA, G; LEDBETTER, DH			LOCALIZATION OF MYELOPEROXIDASE TO THE LONG ARM OF HUMAN CHROMOSOME-17 - RELATIONSHIP TO THE 15-17 TRANSLOCATION OF ACUTE PROMYELOCYTIC LEUKEMIA	ONCOGENE			English	Article									WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104; UNIV PENN,HOWARD HUGHES MED INST,DEPT PEDIAT,PHILADELPHIA,PA 19104; UNIV PENN,DEPT HUMAN GENET,PHILADELPHIA,PA 19104	The Wistar Institute; Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania	VANTUINEN, P (corresponding author), BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030, USA.				NICHD NIH HHS [HD20619, HDO6755, HDO6814] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020619, F32HD006814, F32HD006755] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CHENG ZY, 1986, CYTOGENET CELL GENET, V41, P101, DOI 10.1159/000132211; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; CRAMER E, 1985, BLOOD, V65, P423; CROCE CM, 1985, BLOOD, V65, P1; DAYTON AI, 1984, P NATL ACAD SCI-BIOL, V81, P4495, DOI 10.1073/pnas.81.14.4495; DEBRAEKELEER M, 1986, CANCER GENET CYTOGEN, V23, P275, DOI 10.1016/0165-4608(86)90190-1; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GOLOMB HM, 1979, CANCER GENET CYTOGEN, V1, P69, DOI 10.1016/0165-4608(79)90012-8; GOSDEN JR, 1986, CYTOGENET CELL GENET, V43, P150, DOI 10.1159/000132313; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HARNDEN DG, 1985, CYTOGENET CELL GENET; HARPER ME, 1981, CHROMOSOMA, V83, P431, DOI 10.1007/BF00327364; HUEBNER K, 1986, P NATL ACAD SCI USA, V83, P1403, DOI 10.1073/pnas.83.5.1403; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; JOHNSON KR, 1987, NUCLEIC ACIDS RES, V15, P2013, DOI 10.1093/nar/15.5.2013; KLEBANOFF SJ, 1980, RETICULOENDOTHELIAL, V2, P279; LEBEAU MM, 1985, NATURE, V316, P826, DOI 10.1038/316826a0; LEBEAU MM, 1986, CANCER GENET CYTOGEN, V20, P175, DOI 10.1016/0165-4608(86)90124-X; MANIATIS T, 1982, MOL CLONING LABORATO; MARTINIUK F, 1986, P NATL ACAD SCI USA, V83, P9641, DOI 10.1073/pnas.83.24.9641; MATTEI MG, 1985, HUM GENET, V69, P327, DOI 10.1007/BF00291650; MCBRIDE OW, 1986, P NATL ACAD SCI USA, V83, P130, DOI 10.1073/pnas.83.1.130; MINDEN MD, 1986, BLOOD, V68, P327; MITELMAN F, 1986, CANCER GENET CYTOGEN, V22, P95, DOI 10.1016/0165-4608(86)90168-8; NUSSBAUM RL, 1986, AM J MED GENET, V23, P457, DOI 10.1002/ajmg.1320230137; PELLICER A, 1978, CELL, V14, P133, DOI 10.1016/0092-8674(78)90308-2; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROWLEY JD, 1977, INT J CANCER, V20, P869, DOI 10.1002/ijc.2910200608; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SHEER D, 1985, ANN HUM GENET, V49, P167, DOI 10.1111/j.1469-1809.1985.tb01690.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SU TS, 1984, AM J HUM GENET, V36, P954; SUN LK, 1986, NUCLEIC ACIDS RES, V14, P4037, DOI 10.1093/nar/14.10.4037; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VANTUINEN P, 1986, AM J HUM GENET S, V39, pA172; WOLFF S, 1974, CHROMOSOMA, V48, P341, DOI 10.1007/BF00290991; YAMADA M, 1982, J BIOL CHEM, V257, P5980; YANGFENG TL, 1986, P NATL ACAD SCI USA, V83, P8679, DOI 10.1073/pnas.83.22.8679; ZABEL BU, 1983, P NATL ACAD SCI-BIOL, V80, P6932, DOI 10.1073/pnas.80.22.6932; 1984, CANCER GENET CYTOGEN, V11, P288	40	42	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene		1987	1	3					319	322						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	J9705	2838781				2022-12-17	WOS:A1987J970500014
J	Tumbrink, HL; Heimsoeth, A; Sos, ML				Tumbrink, Hannah L.; Heimsoeth, Alena; Sos, Martin L.			The next tier of EGFR resistance mutations in lung cancer	ONCOGENE			English	Review							ACQUIRED-RESISTANCE; ONCOGENIC MUTATIONS; G724S MUTATION; L718Q MUTATION; NSCLC PATIENT; OSIMERTINIB; T790M; INHIBITOR; MECHANISM; AZD9291	EGFRmutations account for the majority of druggable targets in lung adenocarcinoma. Over the past decades the optimization of EGFR inhibitors revolutionized the treatment options for patients suffering from this disease. The pace of this development was largely dictated by the inevitable emergence of resistance mutations during drug treatment. As a result, a rapid understanding of the structural and molecular biology of the individual mutations is the key for the development of next-generation inhibitors. Currently, the field faces an unprecedented number of combinations of activating mutations with distinct resistance mutations in parallel to the approval of osimertinib as a first-line drug forEGFR-mutant lung cancer. In this review, we present a survey of the diverse landscape of EGFR resistance mechanisms with a focus on new insights into on-targetEGFRkinase mutations. We discuss array of mutations, their structural effects on the EGFR kinase domain as well as the most promising strategies to overcome the individual resistance profiles found in lung cancer patients.	[Tumbrink, Hannah L.; Heimsoeth, Alena; Sos, Martin L.] Univ Hosp Cologne, Inst Pathol, Mol Pathol, D-50937 Cologne, Germany; [Tumbrink, Hannah L.; Heimsoeth, Alena; Sos, Martin L.] Univ Cologne, Fac Med, Dept Translat Genom, Ctr Integrated Oncol Cologne Bonn, D-50931 Cologne, Germany; [Tumbrink, Hannah L.; Heimsoeth, Alena; Sos, Martin L.] Univ Cologne, Ctr Mol Med Cologne, D-50931 Cologne, Germany	University of Cologne; University of Cologne; University of Cologne	Sos, ML (corresponding author), Univ Hosp Cologne, Inst Pathol, Mol Pathol, D-50937 Cologne, Germany.; Sos, ML (corresponding author), Univ Cologne, Fac Med, Dept Translat Genom, Ctr Integrated Oncol Cologne Bonn, D-50931 Cologne, Germany.; Sos, ML (corresponding author), Univ Cologne, Ctr Mol Med Cologne, D-50931 Cologne, Germany.	martin.sos@uni-koeln.de	Sos, Martin L/I-1852-2014		Bundesministerium fur Bildung und Forschung (e:Med initative) [01ZX1901A]; Thyssen Foundation [10.19.2.025MN]; German Research Foundation (DFG) within the collaborative research center 1399; Deutsche Krebshilfe [70112888]	Bundesministerium fur Bildung und Forschung (e:Med initative)(Federal Ministry of Education & Research (BMBF)); Thyssen Foundation; German Research Foundation (DFG) within the collaborative research center 1399(German Research Foundation (DFG)); Deutsche Krebshilfe(Deutsche Krebshilfe)	We thank all members of the Sos Lab for fruitful comments, especially Johannes Bragelmann and Katia Garbert. This work was supported by the Bundesministerium fur Bildung und Forschung (e:Med initative; 01ZX1901A), a research grant by the Thyssen Foundation (10.19.2.025MN), the German Research Foundation (DFG) within the collaborative research center 1399 and the Deutsche Krebshilfe (70112888).	Arulananda S, 2017, J THORAC ONCOL, V12, P1728, DOI 10.1016/j.jtho.2017.08.006; Banno E, 2016, CANCER SCI, V107, P1134, DOI 10.1111/cas.12980; Bean J, 2007, P NATL ACAD SCI USA, V104, P20932, DOI 10.1073/pnas.0710370104; Bennouna J, 2020, CLIN LUNG CANCER, V21, pE10, DOI 10.1016/j.cllc.2019.09.007; Bersanelli M, 2016, J THORAC ONCOL, V11, pE121, DOI 10.1016/j.jtho.2016.05.019; Brown BP, 2019, CLIN CANCER RES, V25, P3341, DOI 10.1158/1078-0432.CCR-18-3829; Callegari D, 2018, CHEM SCI, V9, P2740, DOI 10.1039/c7sc04761d; Chen Kai, 2017, J Thorac Oncol, V12, pe65, DOI 10.1016/j.jtho.2016.12.024; Chen YF, 2017, EUR J MED CHEM, V139, P674, DOI 10.1016/j.ejmech.2017.08.035; Cross DAE, 2014, CANCER DISCOV, V4, P1046, DOI 10.1158/2159-8290.CD-14-0337; Engelhardt H, 2019, J MED CHEM, V62, P10272, DOI 10.1021/acs.jmedchem.9b01169; Engelman JA, 2007, CANCER RES, V67, P11924, DOI 10.1158/0008-5472.CAN-07-1885; Ercan D, 2015, CLIN CANCER RES, V21, P3913, DOI 10.1158/1078-0432.CCR-14-2789; Fairclough SR, 2019, EXP HEMATOL ONCOL, V8, DOI 10.1186/s40164-019-0148-7; Fang WF, 2020, J THORAC ONCOL, V15, pE36, DOI 10.1016/j.jtho.2019.09.198; Fassunke J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07078-0; Foster SA, 2016, CANCER CELL, V29, P477, DOI 10.1016/j.ccell.2016.02.010; Guibert N, 2018, ANN ONCOL, V29, P1049, DOI 10.1093/annonc/mdy005; Ho CC, 2017, J THORAC ONCOL, V12, P567, DOI 10.1016/j.jtho.2016.11.2231; Janne PA, 2015, NEW ENGL J MED, V372, P1689, DOI 10.1056/NEJMoa1411817; Jia Y, 2016, NATURE, V534, P129, DOI 10.1038/nature17960; Klempner SJ, 2017, LUNG CANCER-TARGETS, V8, P241, DOI 10.2147/LCTT.S147129; Kobayashi Y, 2017, MOL CANCER THER, V16, P357, DOI 10.1158/1535-7163.MCT-16-0407; Lee J, 2020, CANCER-AM CANCER SOC, V126, P2704, DOI 10.1002/cncr.32809; Leonetti A, 2019, BRIT J CANCER, V121, P725, DOI 10.1038/s41416-019-0573-8; Leventakos K, 2016, J THORAC ONCOL, V11, P1798, DOI 10.1016/j.jtho.2016.05.007; Liu B, 2006, PROTEINS, V65, P331, DOI 10.1002/prot.21111; Liu YT, 2018, LUNG CANCER, V118, P1, DOI 10.1016/j.lungcan.2018.01.015; Ma L, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.04.37; Mehlman C, 2019, LUNG CANCER, V137, P149, DOI 10.1016/j.lungcan.2019.09.019; Minari R, 2020, CLIN LUNG CANCER, V21, P30072; Niederst MJ, 2015, CLIN CANCER RES, V21, P3924, DOI 10.1158/1078-0432.CCR-15-0560; Nishino M, 2018, LUNG CANCER, V126, P149, DOI 10.1016/j.lungcan.2018.10.026; Offin M, 2018, JCO PRECIS ONCOL, V2, DOI 10.1200/PO.18.00126; Ortiz-Cuaran S, 2016, CLIN CANCER RES, V22, P4837, DOI 10.1158/1078-0432.CCR-15-1915; Ou SHI, 2017, LUNG CANCER, V108, P228, DOI 10.1016/j.lungcan.2017.04.003; Oxnard GR, 2018, JAMA ONCOL, V4, P1527, DOI 10.1001/jamaoncol.2018.2969; Oztan A, 2017, LUNG CANCER, V111, P84, DOI 10.1016/j.lungcan.2017.07.002; Peled Nir, 2017, J Thorac Oncol, V12, pe81, DOI 10.1016/j.jtho.2017.02.023; Piotrowska Z, 2018, CANCER DISCOV, V8, P1529, DOI 10.1158/2159-8290.CD-18-1022; Ramalingam SS, 2018, J CLIN ONCOL, V36, P841, DOI 10.1200/JCO.2017.74.7576; Roper N, 2020, CELL REP MED, V1, DOI 10.1016/j.xcrm.2020.100007; Schoenfeld AJ, 2020, CLIN CANCER RES, V26, P2654, DOI [10.1158/10780432.CCR-19-3563, 10.1158/1078-0432.CCR-19-3563]; Sequist LV, 2015, NEW ENGL J MED, V373, P578, DOI 10.1056/NEJMc1506831; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Shan YB, 2013, P NATL ACAD SCI USA, V110, P7270, DOI 10.1073/pnas.1220843110; Shan YB, 2012, CELL, V149, P860, DOI 10.1016/j.cell.2012.02.063; Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137; Sos ML, 2009, CANCER RES, V69, P3256, DOI 10.1158/0008-5472.CAN-08-4055; Starrett JH, 2020, CANCER RES, V80, P2017, DOI 10.1158/0008-5472.CAN-19-3819; Sutto L, 2013, P NATL ACAD SCI USA, V110, P10616, DOI 10.1073/pnas.1221953110; Takezawa K, 2012, CANCER DISCOV, V2, P922, DOI 10.1158/2159-8290.CD-12-0108; Thress KS, 2015, NAT MED, V21, P560, DOI 10.1038/nm.3854; To C, 2019, CANCER DISCOV, V9, P926, DOI 10.1158/2159-8290.CD-18-0903; Uchibori K, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14768; Wagener-Ryczek S, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-06920-3; Walter AO, 2013, CANCER DISCOV, V3, P1404, DOI 10.1158/2159-8290.CD-13-0314; Wang XF, 2019, J THORAC ONCOL, V14, pE85, DOI 10.1016/j.jtho.2019.01.015; Yang X, 2020, CLIN LUNG CANCER, V21, pE258, DOI 10.1016/j.cllc.2019.12.002; Yang Z, 2018, CLIN CANCER RES, V24, P3097, DOI 10.1158/1078-0432.CCR-17-2310; Zhai X, 2020, BIOCHEMISTRY-US, V59, P1428, DOI 10.1021/acs.biochem.0c00104; Zhang Q, 2018, J THORAC ONCOL, V13, P1415, DOI 10.1016/j.jtho.2018.05.024; Zhang Y, 2019, ONCOTARGETS THER, V12, P51, DOI 10.2147/OTT.S188612; Zhao ZR, 2019, ONCOLOGIST, V24, P1368, DOI 10.1634/theoncologist.2018-0567; Zheng D, 2017, ONCOTARGET, V8, P49671, DOI 10.18632/oncotarget.17913	65	41	43	2	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2021	40	1					1	11		10.1038/s41388-020-01510-w	http://dx.doi.org/10.1038/s41388-020-01510-w		OCT 2020	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PR5VS	33060857				2022-12-17	WOS:000577946300001
J	Leon, LM; Gautier, M; Allan, R; Ilie, M; Nottet, N; Pons, N; Paquet, A; Lebrigand, K; Truchi, M; Fassy, J; Magnone, V; Kinnebrew, G; Radovich, M; Cheok, MHC; Barbry, P; Vassaux, G; Marquette, CH; Ponzio, G; Ivan, M; Pottier, N; Hofman, P; Mari, B; Rezzonico, R				Leon, Laura Moreno; Gautier, Marine; Allan, Richard; Ilie, Marius; Nottet, Nicolas; Pons, Nicolas; Paquet, Agnes; Lebrigand, Kevin; Truchi, Marin; Fassy, Julien; Magnone, Virginie; Kinnebrew, Garrett; Radovich, Milan; Cheok, Meyling Hua-Chen; Barbry, Pascal; Vassaux, Georges; Marquette, Charles-Hugo; Ponzio, Gilles; Ivan, Mircea; Pottier, Nicolas; Hofman, Paul; Mari, Bernard; Rezzonico, Roger			The nuclear hypoxia-regulated NLUCAT1 long non-coding RNA contributes to an aggressive phenotype in lung adenocarcinoma through regulation of oxidative stress	ONCOGENE			English	Article							NF-KAPPA-B; CIGARETTE-SMOKE; GENE-EXPRESSION; CELL-PROLIFERATION; EPITHELIAL-CELLS; DRUG-RESISTANCE; POOR-PROGNOSIS; CANCER; TRANSCRIPTION; ANNOTATION	Lung cancer is the leading cause of cancer death worldwide, with poor prognosis and a high rate of recurrence despite early surgical removal. Hypoxic regions within tumors represent sources of aggressiveness and resistance to therapy. Although long non-coding RNAs (lncRNAs) are increasingly recognized as major gene expression regulators, their regulation and function following hypoxic stress are still largely unexplored. Combining profiling studies on early-stage lung adenocarcinoma (LUAD) biopsies and on A549 LUAD cell lines cultured in normoxic or hypoxic conditions, we identified a subset of lncRNAs that are both correlated with the hypoxic status of tumors and regulated by hypoxia in vitro. We focused on a new transcript, NLUCAT1, which is strongly upregulated by hypoxia in vitro and correlated with hypoxic markers and poor prognosis in LUADs. Full molecular characterization showed that NLUCAT1 is a large nuclear transcript composed of six exons and mainly regulated by NF-kappa B and NRF2 transcription factors. CRISPR-Cas9-mediated invalidation of NLUCAT1 revealed a decrease in proliferative and invasive properties, an increase in oxidative stress and a higher sensitivity to cisplatin-induced apoptosis. Transcriptome analysis of NLUCAT1-deficient cells showed repressed genes within the antioxidant and/or cisplatin-response networks. We demonstrated that the concomitant knockdown of four of these genes products, GPX2, GLRX, ALDH3A1, and PDK4, significantly increased ROS-dependent caspase activation, thus partially mimicking the consequences of NLUCAT1 inactivation in LUAD cells. Overall, we demonstrate that NLUCAT1 contributes to an aggressive phenotype in early-stage hypoxic tumors, suggesting it may represent a new potential therapeutic target in LUADs.	[Leon, Laura Moreno; Gautier, Marine; Allan, Richard; Nottet, Nicolas; Pons, Nicolas; Paquet, Agnes; Lebrigand, Kevin; Truchi, Marin; Fassy, Julien; Magnone, Virginie; Barbry, Pascal; Ponzio, Gilles; Mari, Bernard] Univ Cote Azur, CNRS, UMR7275, IPMC, Valbonne, France; [Leon, Laura Moreno; Gautier, Marine; Allan, Richard; Ilie, Marius; Nottet, Nicolas; Pons, Nicolas; Paquet, Agnes; Lebrigand, Kevin; Truchi, Marin; Fassy, Julien; Magnone, Virginie; Barbry, Pascal; Vassaux, Georges; Marquette, Charles-Hugo; Ponzio, Gilles; Hofman, Paul; Mari, Bernard; Rezzonico, Roger] FHU OncoAge, Nice, France; [Ilie, Marius; Marquette, Charles-Hugo; Hofman, Paul] Univ Cote Azur, CNRS, INSERM, IRCAN, Nice, France; [Ilie, Marius; Hofman, Paul] Pasteur Hosp, Hosp Related Biobank BB 0033 00025, Nice, France; [Kinnebrew, Garrett; Radovich, Milan] Indiana Univ Sch Med, Dept Surg Med & Mol Genet, Indianapolis, IN 46202 USA; [Cheok, Meyling Hua-Chen] Inst Canc Res Lille, Factors Leukemia Cell Persistence, INSERM, UMR S1172, Lille, France; [Vassaux, Georges; Rezzonico, Roger] Univ Cote Azur, INSERM, CNRS, UMR7275,IPMC, Valbonne, France; [Marquette, Charles-Hugo] CHU Nice, Dept Pneumol, Nice, France; [Ivan, Mircea] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA; [Ivan, Mircea] Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; [Pottier, Nicolas] Fac Med Lille, Pole Rech, EA4483, Lille, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; Indiana University System; Indiana University Bloomington; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Universite de Lille - ISITE; Universite de Lille	Mari, B (corresponding author), Univ Cote Azur, CNRS, UMR7275, IPMC, Valbonne, France.; Mari, B; Rezzonico, R (corresponding author), FHU OncoAge, Nice, France.; Rezzonico, R (corresponding author), Univ Cote Azur, INSERM, CNRS, UMR7275,IPMC, Valbonne, France.	mari@unice.fr; rezzonico@ipmc.cnrs.fr	Hofman, Paul/P-7654-2018; Mari, Bernard/Q-5832-2019; Moreno Leon, Laura/AGP-7137-2022; Mari, Bernard P/GVS-3100-2022; Cheok, Meyling/AFS-4025-2022; REZZONICO, Roger/N-9626-2016; Cheok, Meyling h/C-3822-2014; Vassaux, Georges/N-9724-2016; Barbry, Pascal/O-5021-2016	Hofman, Paul/0000-0003-0431-9353; Mari, Bernard/0000-0002-0422-9182; Moreno Leon, Laura/0000-0002-5560-1765; Mari, Bernard P/0000-0002-0422-9182; Cheok, Meyling/0000-0002-7820-8026; REZZONICO, Roger/0000-0002-8460-1641; Cheok, Meyling h/0000-0002-7820-8026; Vassaux, Georges/0000-0002-1149-7716; Barbry, Pascal/0000-0001-9632-6483; Nottet, Nicolas/0000-0002-8699-6747; GAUTIER-ISOLA, Marine/0000-0003-3768-8809; Kinnebrew, Garrett/0000-0001-7384-6582	Plan Cancer 2018 "ARN non-codants en cancerologie: du fondamental au translationnel" [18CN045]; Canceropole PACA; Fondation ARC pour la Recherche sur le Cancer; Fondation Unice (AIR project); Ligue contre le cancer (comite departemental du Nord); French Government (Agence Nationale de Recherche, ANR) through the Investments for the Future LABEX SIGNALIFE [ANR-11-LABX-0028-01]; French Government (Agence Nationale de Recherche, ANR) through the FRANCE GENOMIQUE [ANR-10-INBS-09-03, ANR-10-INBS-09-02]; Fondation pour la Recherche Medicale	Plan Cancer 2018 "ARN non-codants en cancerologie: du fondamental au translationnel"; Canceropole PACA(Region Grand-Est); Fondation ARC pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le Cancer); Fondation Unice (AIR project); Ligue contre le cancer (comite departemental du Nord); French Government (Agence Nationale de Recherche, ANR) through the Investments for the Future LABEX SIGNALIFE(French National Research Agency (ANR)); French Government (Agence Nationale de Recherche, ANR) through the FRANCE GENOMIQUE(French National Research Agency (ANR)); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale)	We gratefully acknowledge the outstanding technical support of the UCA GenomiX platform and MICA imaging facility of the University Cote d'Azur, and the staff from the CHU Nice Biobank. This work was supported by Plan Cancer 2018 "ARN non-codants en cancerologie: du fondamental au translationnel" (number 18CN045), Canceropole PACA, Fondation ARC pour la Recherche sur le Cancer, Fondation Unice (AIR project), Ligue contre le cancer (comite departemental du Nord), and the French Government (Agence Nationale de Recherche, ANR) through the Investments for the Future LABEX SIGNALIFE (ANR-11-LABX-0028-01) and FRANCE GENOMIQUE (ANR-10-INBS-09-03 and ANR-10-INBS-09-02). LML was a recipient of the Fondation pour la Recherche Medicale.	Akagi I, 2013, CANCER RES, V73, P3821, DOI 10.1158/0008-5472.CAN-13-0031; Ashouri A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13197; Bertero T, 2013, CELL DEATH DIFFER, V20, P800, DOI 10.1038/cdd.2013.5; Bertero T, 2017, INT REV CEL MOL BIO, V333, P91, DOI 10.1016/bs.ircmb.2017.03.006; Blanco MR, 2017, EMBO J, V36, P964, DOI 10.15252/embj.201796796; Buelna-Chontal M, 2013, CELL SIGNAL, V25, P2548, DOI 10.1016/j.cellsig.2013.08.007; Buffa FM, 2010, BRIT J CANCER, V102, P428, DOI 10.1038/sj.bjc.6605450; Burke JR, 2003, J BIOL CHEM, V278, P1450, DOI 10.1074/jbc.M209677200; Cabili MN, 2011, GENE DEV, V25, P1915, DOI 10.1101/gad.17446611; Chang MY, 2007, J THORAC CARDIOV SUR, V134, P850, DOI 10.1016/j.jtcvs.2007.03.044; Chang YN, 2016, GENE, V575, P1, DOI 10.1016/j.gene.2015.08.049; Choi YM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135083; Clark MB, 2012, GENOME RES, V22, P885, DOI 10.1101/gr.131037.111; Davidovich C, 2013, NAT STRUCT MOL BIOL, V20, P1250, DOI 10.1038/nsmb.2679; Derrien T, 2012, GENOME RES, V22, P1775, DOI 10.1101/gr.132159.111; Dong J, 2016, TUMOR BIOL, V37, P1379, DOI 10.1007/s13277-015-4457-0; Du Z, 2013, NAT STRUCT MOL BIOL, V20, P908, DOI 10.1038/nsmb.2591; Eltzschig HK, 2011, NEW ENGL J MED, V364, P656, DOI 10.1056/NEJMra0910283; Engreitz JM, 2016, NATURE, V539, P452, DOI 10.1038/nature20149; Fang JH, 2014, FREE RADICAL BIO MED, V68, P80, DOI 10.1016/j.freeradbiomed.2013.11.028; Fang SS, 2018, NUCLEIC ACIDS RES, V46, pD308, DOI 10.1093/nar/gkx1107; Ferdin J, 2013, CELL DEATH DIFFER, V20, P1675, DOI 10.1038/cdd.2013.119; Fitzpatrick SF, 2011, J IMMUNOL, V186, P1091, DOI 10.4049/jimmunol.1002256; Galluzzi L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.428; Gastaldi C, 2014, CARCINOGENESIS, V35, P1110, DOI 10.1093/carcin/bgt490; Gee HE, 2014, ANTIOXID REDOX SIGN, V21, P1220, DOI 10.1089/ars.2013.5639; Gorlach Agnes, 2008, Biochem J, V412, pe17, DOI 10.1042/BJ20080920; Grosso S, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.71; Guttman M, 2012, NATURE, V482, P339, DOI 10.1038/nature10887; Hangauer MJ, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003569; Harrow J, 2012, GENOME RES, V22, P1760, DOI 10.1101/gr.135350.111; Heery R, 2017, CANCERS, V9, DOI 10.3390/cancers9040038; Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599; Duong HQ, 2017, ANTIOXIDANTS-BASEL, V6, DOI 10.3390/antiox6030052; Hu Y, 2018, ONCOTARGETS THER, V11, P3185, DOI 10.2147/OTT.S158104; Ilie M, 2010, BRIT J CANCER, V102, P1627, DOI 10.1038/sj.bjc.6605690; Iyer MK, 2015, NAT GENET, V47, P199, DOI 10.1038/ng.3192; Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106; Lassen N, 2006, FREE RADICAL BIO MED, V41, P1459, DOI 10.1016/j.freeradbiomed.2006.08.009; Leclerc D, 2017, BRIT J CANCER, V116, P930, DOI 10.1038/bjc.2017.38; Li WB, 2016, NAT REV GENET, V17, P207, DOI 10.1038/nrg.2016.4; Lin AF, 2016, NAT CELL BIOL, V18, P213, DOI 10.1038/ncb3295; Lin CX, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003231; Liu XB, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111835; Liu XB, 2015, INVEST OPHTH VIS SCI, V56, P2821, DOI 10.1167/iovs.14-15876; Loewen G, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0090-4; Lugthart S, 2005, CANCER CELL, V7, P375, DOI 10.1016/j.ccr.2005.03.002; Marullo R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081162; Muzio G, 2012, FREE RADICAL BIO MED, V52, P735, DOI 10.1016/j.freeradbiomed.2011.11.033; Naiki T, 2014, CARCINOGENESIS, V35, P1962, DOI 10.1093/carcin/bgu048; Nakajima S, 2013, FREE RADICAL BIO MED, V65, P162, DOI 10.1016/j.freeradbiomed.2013.06.020; Oliver KM, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2575; Ou SHI, 2007, CANCER-AM CANCER SOC, V110, P1532, DOI 10.1002/cncr.22938; Patten DA, 2010, MOL BIOL CELL, V21, P3247, DOI 10.1091/mbc.E10-01-0025; Portoso M, 2017, EMBO J, V36, P981, DOI 10.15252/embj.201695335; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Puissegur MP, 2011, CELL DEATH DIFFER, V18, P465, DOI 10.1038/cdd.2010.119; Quinn JJ, 2016, NAT REV GENET, V17, P47, DOI 10.1038/nrg.2015.10; Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006; Rius J, 2008, NATURE, V453, P807, DOI 10.1038/nature06905; Schmidt LH, 2011, J THORAC ONCOL, V6, P1984, DOI 10.1097/JTO.0b013e3182307eac; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Shelton P, 2013, FASEB J, V27, P414, DOI 10.1096/fj.12-217257; Singh A, 2006, AM J RESP CELL MOL, V35, P639, DOI 10.1165/rcmb.2005-0325OC; Sun Y, 2017, ONCOTARGET, V8, P28297, DOI 10.18632/oncotarget.16044; Tafani M, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3907147; Tani H, 2012, GENOME RES, V22, P947, DOI 10.1101/gr.130559.111; Thai P, 2013, AM J RESP CELL MOL, V49, P204, DOI 10.1165/rcmb.2013-0159RC; Toth RK, 2017, ANTIOXIDANTS-BASEL, V6, DOI 10.3390/antiox6020027; Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020; Volders PJ, 2015, NUCLEIC ACIDS RES, V43, P4363, DOI 10.1093/nar/gkv295; Volders PJ, 2013, NUCLEIC ACIDS RES, V41, pD246, DOI 10.1093/nar/gks915; Wang YM, 2006, METHODS, V39, P356, DOI 10.1016/j.ymeth.2006.06.010; White NM, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0429-8; Woolbright BL, 2018, MOL CANCER THER, V17, P2004, DOI 10.1158/1535-7163.MCT-18-0063; Wu X, 2018, ANTIOXID REDOX SIGN, V29, P922, DOI 10.1089/ars.2017.7293; Yan WS, 2006, J BIOL CHEM, V281, P7856, DOI 10.1074/jbc.M512655200; Yang F, 2014, MOL CELL, V53, P88, DOI 10.1016/j.molcel.2013.11.004; Yang F, 2013, MOL CELL, V49, P1083, DOI 10.1016/j.molcel.2013.01.010; Zhang Y, 2016, J BIOL CHEM, V291, P17405, DOI 10.1074/jbc.M116.713735; Zheng ZG, 2016, SCI REP-UK, V6, DOI 10.1038/srep26093	81	41	41	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2019	38	46					7146	7165		10.1038/s41388-019-0935-y	http://dx.doi.org/10.1038/s41388-019-0935-y			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JN5HX	31417181				2022-12-17	WOS:000496930500003
J	Skrott, Z; Majera, D; Gursky, J; Buchtova, T; Hajduch, M; Mistrik, M; Bartek, J				Skrott, Zdenek; Majera, Dusana; Gursky, Jan; Buchtova, Tereza; Hajduch, Marian; Mistrik, Martin; Bartek, Jiri			Disulfiram's anti-cancer activity reflects targeting NPL4, not inhibition of aldehyde dehydrogenase	ONCOGENE			English	Article							CANCER STEM-CELLS; INITIATING CELLS; MITOCHONDRIAL; DRUG; ACETALDEHYDE; METASTASIS; METABOLISM; RESISTANCE; REVERSES; ADDUCTS	Aldehyde dehydrogenase (ALDH) is a proposed biomarker and possible target to eradicate cancer stem cells. ALDH inhibition as a treatment approach is supported by anti-cancer effects of the alcohol-abuse drug disulfiram (DSF, Antabuse). Given that metabolic products of DSF, rather than DSF itself inhibit ALDH in vivo, and that DSF's anti-cancer activity is potentiated by copper led us to investigate the relevance of ALDH as the suggested molecular cancer-relevant target of DSF. Here we show that DSF does not directly inhibit ALDH activity in diverse human cell types, while DSF's in vivo metabolite, S-methyl-N, N-diethylthiocarbamate-sulfoxide inhibits ALDH activity yet does not impair cancer cell viability. Our data indicate that the anti-cancer activity of DSF does not involve ALDH inhibition, and rather reflects the impact of DSF's copper-containing metabolite (CuET), that forms spontaneously in vivo and in cell culture media, and kills cells through aggregation of NPL4, a subunit of the p97/VCP segregase. We also show that the CuET-mediated, rather than any ALDH-inhibitory activity of DSF underlies the preferential cytotoxicity of DSF towards BRCA1-and BRCA2-deficient cells. These findings provide evidence clarifying the confusing literature about the anti-cancer mechanism of DSF, a drug currently tested in clinical trials for repositioning in oncology.	[Skrott, Zdenek; Majera, Dusana; Gursky, Jan; Buchtova, Tereza; Hajduch, Marian; Mistrik, Martin; Bartek, Jiri] Palacky Univ, Fac Med & Dent, Inst Mol & Translat Med, Olomouc, Czech Republic; [Bartek, Jiri] Danish Canc Soc Res Ctr, Copenhagen, Denmark; [Bartek, Jiri] Karolinska Inst, Dept Med Biochem & Biophys, Div Genome Biol, Sci Life Lab, Stockholm, Sweden	Palacky University Olomouc; Danish Cancer Society; Karolinska Institutet	Mistrik, M; Bartek, J (corresponding author), Palacky Univ, Fac Med & Dent, Inst Mol & Translat Med, Olomouc, Czech Republic.; Bartek, J (corresponding author), Danish Canc Soc Res Ctr, Copenhagen, Denmark.; Bartek, J (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Genome Biol, Sci Life Lab, Stockholm, Sweden.	martin.mistrik@upol.cz; jb@cancer.dk	Hajduch, Marian/J-4015-2014; Buchtová, Tereza/GSI-5771-2022; MAJERA, Dusana/U-1079-2019	Hajduch, Marian/0000-0002-4834-908X; Buchtova, Tereza/0000-0001-5233-1504; Mistrik, Martin/0000-0002-2321-0348; Skrott, Zdenek/0000-0001-6004-3609	Grant agency of Czech Rep. GACR [17-25976 S]; MEYS CR [LM2015062, DRO-61989592]; Internal grant of University of Palacky [IGA_LF_2019_026]; Cancer Research Czech Republic, Ministry of School, Education, Youth and Sports of the Czech Republic [LM2015064, CZ.02.1.01/0.0/0.0/16_019/0000868]; Novo Nordisk Foundation [16854]; Danish National Research Foundation [DNRF125]; Danish Cancer Society [R204-A12617]; Swedish Research Council [VR-MH 2014-46602-117891-30]; Swedish Cancer Society [170176]	Grant agency of Czech Rep. GACR; MEYS CR; Internal grant of University of Palacky; Cancer Research Czech Republic, Ministry of School, Education, Youth and Sports of the Czech Republic; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Danish National Research Foundation(Danmarks Grundforskningsfond); Danish Cancer Society(Danish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society)	We thank Dr. M. Tarsounas (Oxford, UK) for the human H1299 cell lines with regulatable expression of shBRCA1 and shBRCA2. The study was supported by grants from: Grant agency of Czech Rep. GACR 17-25976 S, MEYS CR (LM2015062 Czech-BioImaging and DRO-61989592), Internal grant of University of Palacky IGA_LF_2019_026, Cancer Research Czech Republic, Ministry of School, Education, Youth and Sports of the Czech Republic (EATRIS-CZ No. LM2015064 and ENOCH No. CZ.02.1.01/0.0/0.0/16_019/0000868), the Novo Nordisk Foundation (no. 16854), the Danish National Research Foundation (project CARD: no. DNRF125), the Danish Cancer Society (R204-A12617) the Swedish Research Council (VR-MH 2014-46602-117891-30), and the Swedish Cancer Society (no. 170176).	Allensworth JL, 2015, MOL ONCOL, V9, P1155, DOI 10.1016/j.molonc.2015.02.007; Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409; Bista R, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0493-5; Brooks PJ, 2005, ALCOHOL, V35, P187, DOI 10.1016/j.alcohol.2005.03.009; Bryan N, 2011, BIOSCIENCE REP, V31, P199, DOI 10.1042/BSR20100064; Chang JS, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0327-y; Charafe-Jauffret E, 2010, CLIN CANCER RES, V16, P45, DOI 10.1158/1078-0432.CCR-09-1630; Chen D, 2006, CANCER RES, V66, P10425, DOI 10.1158/0008-5472.CAN-06-2126; Chen W, 2018, ACS APPL MATER INTER, V10, P41118, DOI 10.1021/acsami.8b14940; Choi SA, 2015, NEURO-ONCOLOGY, V17, P810, DOI 10.1093/neuonc/nou305; Duan JJ, 2016, INT J CANCER, V139, P965, DOI 10.1002/ijc.30091; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; HART BW, 1993, BIOCHEM PHARMACOL, V46, P2285, DOI 10.1016/0006-2952(93)90619-8; Huddle BC, 2018, J MED CHEM, V61, P8754, DOI 10.1021/acs.jmedchem.8b00930; Jin N, 2018, J CELL BIOCHEM, V119, P6882, DOI 10.1002/jcb.26885; Koppaka V, 2012, PHARMACOL REV, V64, P520, DOI 10.1124/pr.111.005538; Lai CL, 2014, ALCOHOL CLIN EXP RES, V38, P44, DOI 10.1111/acer.12215; Lam JP, 1997, BIOCHEMISTRY-US, V36, P13748, DOI 10.1021/bi970948e; Lipsky JJ, 2001, CHEM-BIOL INTERACT, V130, P93, DOI 10.1016/S0009-2797(00)00225-8; Liu P, 2013, BRIT J CANCER, V109, P1876, DOI 10.1038/bjc.2013.534; Liu P, 2012, BRIT J CANCER, V107, P1488, DOI 10.1038/bjc.2012.442; Liu P, 2014, ONCOTARGET, V5, P7471, DOI 10.18632/oncotarget.2166; Liu XW, 2016, ONCOTARGET, V7, P58516, DOI 10.18632/oncotarget.11305; MacDonagh L, 2017, ONCOTARGET, V8, P72544, DOI 10.18632/oncotarget.19881; Majera D, 2019, PROSTATE, V79, P352, DOI 10.1002/pros.23741; Marchitti SA, 2008, EXPERT OPIN DRUG MET, V4, P697, DOI [10.1517/17425255.4.6.697, 10.1517/17425255.4.6.697 ]; Marques DS, 2010, LEUKEMIA RES, V34, P757, DOI 10.1016/j.leukres.2009.11.004; MAYS DC, 1995, BIOCHEM PHARMACOL, V49, P693, DOI 10.1016/0006-2952(94)00504-F; Peng XY, 2019, BIOMACROMOLECULES, V20, P2372, DOI 10.1021/acs.biomac.9b00367; Pors K, 2014, DRUG DISCOV TODAY, V19, P1953, DOI 10.1016/j.drudis.2014.09.009; Raha D, 2014, CANCER RES, V74, P3579, DOI 10.1158/0008-5472.CAN-13-3456; Shen ML, 2001, BIOCHEM PHARMACOL, V61, P537, DOI 10.1016/S0006-2952(00)00586-4; Skrott Z, 2017, NATURE, V552, P194, DOI 10.1038/nature25016; Suh JJ, 2006, J CLIN PSYCHOPHARM, V26, P290, DOI 10.1097/01.jcp.0000222512.25649.08; Tacconi EMC, 2017, EMBO MOL MED, V9, P1398, DOI 10.15252/emmm.201607446; Tirino V, 2013, FASEB J, V27, P13, DOI 10.1096/fj.12-218222; van den Hoogen C, 2010, CANCER RES, V70, P5163, DOI 10.1158/0008-5472.CAN-09-3806; Wang NN, 2018, EXP CELL RES, V362, P72, DOI 10.1016/j.yexcr.2017.11.004; Wu L, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-35619-6; Yip NC, 2011, BRIT J CANCER, V104, P1564, DOI 10.1038/bjc.2011.126; YOURICK JJ, 1991, BIOCHEM PHARMACOL, V42, P1361, DOI 10.1016/0006-2952(91)90446-C; Zhou L, 2019, CELL BIOL TOXICOL, V35, P161, DOI 10.1007/s10565-018-9444-y	43	41	41	3	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2019	38	40					6711	6722		10.1038/s41388-019-0915-2	http://dx.doi.org/10.1038/s41388-019-0915-2			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JC0EY	31391554				2022-12-17	WOS:000488953500005
J	Barry, S; Carlsen, E; Marques, P; Stiles, CE; Gadaleta, E; Berney, DM; Roncaroli, F; Chelala, C; Solomou, A; Herincs, M; Caimari, F; Grossman, AB; Crnogorac-Jurcevic, T; Haworth, O; Gaston-Massuet, C; Korbonits, M				Barry, Sayka; Carlsen, Eivind; Marques, Pedro; Stiles, Craig E.; Gadaleta, Emanuela; Berney, Dan M.; Roncaroli, Federico; Chelala, Claude; Solomou, Antonia; Herincs, Maria; Caimari, Francisca; Grossman, Ashley B.; Crnogorac-Jurcevic, Tatjana; Haworth, Oliver; Gaston-Massuet, Carles; Korbonits, Marta			Tumor microenvironment defines the invasive phenotype of AIP-mutation-positive pituitary tumors	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL-TRANSITION; DIFFERENTIAL GENE-EXPRESSION; INTERACTING PROTEIN; GROWTH-HORMONE; T-CELLS; SOMATOTROPH ADENOMAS; COLON-CANCER; MACROPHAGES; FLI-1; PROGRESSION	The molecular mechanisms leading to aryl hydrocarbon receptor interacting protein (AIP) mutation-induced aggressive, young-onset growth hormone-secreting pituitary tumors are not fully understood. In this study, we have identified that AIP-mutation-positive tumors are infiltrated by a large number of macrophages compared to sporadic tumors. Tissue from pituitary-specific Aip-knockout (Aip(Flox/Flox) ; Hesx1(cre/+)) mice recapitulated this phenotype. Our human pituitary tumor transcriptome data revealed the "epithelial-to-mesenchymal transition (EMT) pathway" as one of the most significantly altered pathways in AIP(pos) tumors. Our in vitro data suggest that bone marrow-derived macrophage-conditioned media induces more prominent EMT-like phenotype and enhanced migratory and invasive properties in Aip-knockdown somatomammotroph cells compared to non-targeting controls. We identified that tumor-derived cytokine CCL5 is upregulated in AIP-mutation-positive human adenomas. Aip-knockdown GH3 cell-conditioned media increases macrophage migration, which is inhibited by the CCL5/CCR5 antagonist maraviroc. Our results suggest that a crosstalk between the tumor and its microenvironment plays a key role in the invasive nature of AIP-mutation-positive tumors and the CCL5/CCR5 pathway is a novel potential therapeutic target.	[Barry, Sayka; Marques, Pedro; Stiles, Craig E.; Solomou, Antonia; Herincs, Maria; Caimari, Francisca; Grossman, Ashley B.; Haworth, Oliver; Gaston-Massuet, Carles; Korbonits, Marta] Queen Mary Univ London, William Harvey Res Inst, Barts & London Sch Med, Ctr Endocrinol, London EC1M 6BQ, England; [Carlsen, Eivind] STHF, Dept Pathol, N-3710 Skien, Norway; [Gadaleta, Emanuela; Berney, Dan M.; Chelala, Claude; Crnogorac-Jurcevic, Tatjana] Queen Mary Univ London, Barts Canc Inst, Barts & London Sch Med, Mol Oncol, London EC1M 6BQ, England; [Roncaroli, Federico] Univ Manchester, Div Neurosci & Expt Psychol, Manchester M13 9PL, Lancs, England	University of London; Queen Mary University London; University of London; Queen Mary University London; University of Manchester	Korbonits, M (corresponding author), Queen Mary Univ London, William Harvey Res Inst, Barts & London Sch Med, Ctr Endocrinol, London EC1M 6BQ, England.	m.korbonits@qmul.ac.uk		Marques, Pedro/0000-0002-4959-5725; Korbonits, Marta/0000-0002-4101-9432; Roncaroli, Federico/0000-0003-3650-5572; Caimari, Francisca/0000-0003-3327-9098; Gadaleta, Emanuela/0000-0002-5740-6293	Medical Research Council [MR/M018539/1]; Wellcome Trust [097970/Z/11/Z]; Fundacion Alfonso Martin Escudero Fellowship; Rosetrees Trust [M505]; Barts and the London Charity; Pfizer UK [WS 733753]; MRC [MR/M018539/1] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); Fundacion Alfonso Martin Escudero Fellowship; Rosetrees Trust(Rosetrees Trust); Barts and the London Charity; Pfizer UK(Pfizer); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by the Medical Research Council (MR/M018539/1 to MK), Wellcome Trust (Clinical Training fellowship 097970/Z/11/Z to CES), Fundacion Alfonso Martin Escudero Fellowship (to FC), Rosetrees Trust (M505 to MK and CG-M), Barts and the London Charity (to PM and MK) and Pfizer UK (WS 733753 to MK).	Aldinucci D, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/292376; Azorin E, 2012, ARCH BIOCHEM BIOPHYS, V528, P148, DOI 10.1016/j.abb.2012.08.011; Balkwill FR, 2012, J CELL SCI, V125, P5591, DOI 10.1242/jcs.116392; Barry S, 2012, END ABSTR, pP1349; Basu R, 2017, ONCOTARGET, V8, P21579, DOI 10.18632/oncotarget.15375; Bingle L, 2002, J PATHOL, V196, P254, DOI 10.1002/path.1027; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Bonde AK, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-35; Brittain AL, 2017, J CLIN ENDOCR METAB, V102, P3662, DOI 10.1210/jc.2017-01000; Brown JM, 2017, CLIN CANCER RES, V23, P3241, DOI 10.1158/1078-0432.CCR-16-3122; Chahal HS, 2012, J CLIN ENDOCR METAB, V97, pE1411, DOI 10.1210/jc.2012-1111; Chahal HS, 2011, NEW ENGL J MED, V364, P43, DOI 10.1056/NEJMoa1008020; Chang LY, 2012, CANCER RES, V72, P1092, DOI 10.1158/0008-5472.CAN-11-2493; Chesnokova V, 2016, P NATL ACAD SCI USA, V113, pE3250, DOI 10.1073/pnas.1600561113; Condeelis J, 2003, NAT REV CANCER, V3, P921, DOI 10.1038/nrc1231; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Daly AF, 2010, J CLIN ENDOCR METAB, V95, pE373, DOI 10.1210/jc.2009-2556; Evans CO, 2008, PITUITARY, V11, P231, DOI 10.1007/s11102-007-0082-2; Evans CO, 2001, J CLIN ENDOCR METAB, V86, P3097, DOI 10.1210/jc.86.7.3097; Fan QM, 2014, CANCER LETT, V352, P160, DOI 10.1016/j.canlet.2014.05.008; Fidler IJ, 2002, SEMIN CANCER BIOL, V12, P89, DOI 10.1006/scbi.2001.0416; Fukunishi T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158555; Galland F, 2010, ENDOCR-RELAT CANCER, V17, P361, DOI 10.1677/ERC-10-0018; Grigore AD, 2016, J CLIN MED, V5, P51, DOI 10.3390/jcm5050051; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Heliovaara E, 2009, AM J PATHOL, V175, P2501, DOI 10.2353/ajpath.2009.081131; Heshmati HM, 1998, ENDOCR J, V45, P357, DOI 10.1507/endocrj.45.357; Igreja S, 2010, HUM MUTAT, V31, P950, DOI 10.1002/humu.21292; Jaffrain-Rea ML, 2009, ENDOCR-RELAT CANCER, V16, P1029, DOI 10.1677/ERC-09-0094; Jiang ZQ, 2010, EXP THER MED, V1, P905, DOI 10.3892/etm.2010.137; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Keophiphath M, 2010, ARTERIOSCL THROM VAS, V30, P39, DOI 10.1161/ATVBAHA.109.197442; Kimura A, 2014, INT IMMUNOL, V26, P209, DOI 10.1093/intimm/dxt067; Lekva T, 2013, ENDOCRINOLOGY, V154, P3331, DOI 10.1210/en.2013-1051; Lekva T, 2012, J CLIN ENDOCR METAB, V97, pE1506, DOI 10.1210/jc.2012-1760; Leontiou CA, 2008, J CLIN ENDOCR METAB, V93, P2390, DOI 10.1210/jc.2007-2611; Li Y, 2015, ONCOGENE, V34, P2022, DOI 10.1038/onc.2014.162; Liu WP, 2005, J MED INVESTIG, V52, P151, DOI 10.2152/jmi.52.151; Lu JQ, 2015, ENDOCR PATHOL, V26, P263, DOI 10.1007/s12022-015-9383-6; Lupi I, 2010, J CLIN ENDOCR METAB, V95, P289, DOI 10.1210/jc.2009-1583; Moreno CS, 2005, CANCER RES, V65, P10214, DOI 10.1158/0008-5472.CAN-05-0884; Moreno-Bueno G, 2009, NAT PROTOC, V4, P1591, DOI 10.1038/nprot.2009.152; Morris DG, 2005, EUR J ENDOCRINOL, V153, P143, DOI 10.1530/eje.1.01937; Ojalvo LS, 2010, J IMMUNOL, V184, P702, DOI 10.4049/jimmunol.0902360; Oriola J, 2013, EUR J ENDOCRINOL, V168, P9, DOI 10.1530/EJE-12-0457; Osorio Joana, 2012, Nat Rev Endocrinol, V8, P444, DOI 10.1038/nrendo.2012.94; Pasqualato A, 2013, CELL ADHES MIGR, V7, P450, DOI 10.4161/cam.26765; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Richard MLL, 2014, J IMMUNOL, V193, P2661, DOI 10.4049/jimmunol.1302779; ROSSI ML, 1990, TUMORI, V76, P543, DOI 10.1177/030089169007600605; Rossi R, 2011, CLIN EXP IMMUNOL, V166, P184, DOI 10.1111/j.1365-2249.2011.04409.x; Ruebel KH, 2006, ENDOCRINE, V29, P435, DOI 10.1385/ENDO:29:3:435; Sato S, 2014, CLIN EXP IMMUNOL, V177, P102, DOI 10.1111/cei.12310; Stockinger B, 2014, ANNU REV IMMUNOL, V32, P403, DOI 10.1146/annurev-immunol-032713-120245; Subramani R, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2014.61; Tan MCB, 2009, J IMMUNOL, V182, P1746, DOI 10.4049/jimmunol.182.3.1746; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Torlakovic EE, 2008, HISTOL HISTOPATHOL, V23, P1309, DOI 10.14670/HH-23.1309; Tsai CH, 2017, SCI REP-UK, V7, DOI 10.1038/srep41927; Tsai HP, 2017, ONCOTARGET, V8, P29174, DOI 10.18632/oncotarget.16303; Tuominen I, 2015, ONCOGENE, V34, P1174, DOI 10.1038/onc.2014.50; Wang JJ, 2017, ONCOTARGET, V8; Wartenberg M, 2015, ONCOTARGET, V6, P4190, DOI 10.18632/oncotarget.2775; Wierinckx A, 2007, ENDOCR-RELAT CANCER, V14, P887, DOI 10.1677/ERC-07-0062; Wolf D, 2005, CLIN CANCER RES, V11, P8326, DOI 10.1158/1078-0432.CCR-05-1244; Xu WW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046609; Zhan XQ, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-13; Zhan XQ, 2005, MASS SPECTROM REV, V24, P783, DOI 10.1002/mas.20039	68	41	42	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2019	38	27					5381	5395		10.1038/s41388-019-0779-5	http://dx.doi.org/10.1038/s41388-019-0779-5			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IG5KR	30867568	Green Accepted, Green Submitted, Green Published, hybrid			2022-12-17	WOS:000473842500004
J	Nishimura, T; Nakata, A; Chen, XX; Nishi, K; Meguro-Horike, M; Sasaki, S; Kita, K; Horike, S; Saitoh, K; Kato, K; Igarashi, K; Murayama, T; Kohno, S; Takahashi, C; Mukaida, N; Yano, SJ; Soga, T; Tojo, A; Gotoh, N				Nishimura, Tatsunori; Nakata, Asuka; Chen, Xiaoxi; Nishi, Kurumi; Meguro-Horike, Makiko; Sasaki, Soichiro; Kita, Kenji; Horike, Shin-ichi; Saitoh, Kaori; Kato, Keiko; Igarashi, Kaori; Murayama, Takahiko; Kohno, Susumu; Takahashi, Chiaki; Mukaida, Naofumi; Yano, Seiji; Soga, Tomoyoshi; Tojo, Arinobu; Gotoh, Noriko			Cancer stem-like properties and gefitinib resistance are dependent on purine synthetic metabolism mediated by the mitochondrial enzyme MTHFD2	ONCOGENE			English	Article							CELL LUNG-CANCER; TUMOR-INITIATING CELLS; METHYLENETETRAHYDROFOLATE DEHYDROGENASE; ACQUIRED-RESISTANCE; GLYCINE; AMPK; GROWTH; SERINE; MAINTENANCE; MECHANISMS	Tumor recurrence is attributable to cancer stem-like cells (CSCs), the metabolic mechanisms of which currently remain obscure. Here, we uncovered the critical role of folate-mediated one-carbon (1C) metabolism involving mitochondrial methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) and its downstream purine synthesis pathway. MTHFD2 knockdown greatly reduced tumorigenesis and stem-like properties, which were associated with purine nucleotide deficiency, and caused marked accumulation of 5-aminoimidazole carboxamide ribonucleotide (AICAR)-the final intermediate of the purine synthesis pathway. Lung cancer cells with acquired resistance to the targeted drug gefitinib, caused by elevated expression of components of the beta-catenin pathway, exhibited increased stem-like properties and enhanced expression of MTHFD2. MTHFD2 knockdown or treatment with AICAR reduced the stem-like properties and restored gefitinib sensitivity in these gefitinib-resistant cancer cells. Moreover, overexpression of MTHFD2 in gefitinib-sensitive lung cancer cells conferred resistance to gefitinib. Thus, MTHFD2-mediated mitochondrial 1C metabolism appears critical for cancer stem-like properties and resistance to drugs including gefitinib through consumption of AICAR, leading to depletion of the intracellular pool of AICAR. Because CSCs are dependent on MTHFD2, therapies targeting MTHFD2 may eradicate tumors and prevent recurrence.	[Nishimura, Tatsunori; Nakata, Asuka; Chen, Xiaoxi; Nishi, Kurumi; Gotoh, Noriko] Kanazawa Univ, Canc Res Inst, Div Canc Cell Biol, Kanazawa, Ishikawa 9201192, Japan; [Meguro-Horike, Makiko; Horike, Shin-ichi] Kanazawa Univ, Adv Sci Res Ctr, Div Funct Genom, Kanazawa, Ishikawa 9201192, Japan; [Sasaki, Soichiro; Mukaida, Naofumi] Kanazawa Univ, Canc Res Inst, Div Mol Bioregulat, Kanazawa, Ishikawa 9201192, Japan; [Kita, Kenji; Yano, Seiji] Kanazawa Univ, Canc Res Inst, Div Med Oncol, 13-1 Takaramachi, Kanazawa, Ishikawa 9200934, Japan; [Saitoh, Kaori; Kato, Keiko; Igarashi, Kaori; Soga, Tomoyoshi] Keio Univ, Inst Adv Biosci, 246-2 Minakami, Tsuruoka, Yamagata 9970052, Japan; [Murayama, Takahiko; Tojo, Arinobu; Gotoh, Noriko] Univ Tokyo, Inst Med Sci, Div Mol Therapy, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan; [Kohno, Susumu; Takahashi, Chiaki] Kanazawa Univ, Canc Res Inst, Div Oncol & Mol Biol, Kanazawa, Ishikawa 9201192, Japan	Kanazawa University; Kanazawa University; Kanazawa University; Kanazawa University; Keio University; University of Tokyo; Kanazawa University	Gotoh, N (corresponding author), Kanazawa Univ, Canc Res Inst, Div Canc Cell Biol, Kanazawa, Ishikawa 9201192, Japan.; Gotoh, N (corresponding author), Univ Tokyo, Inst Med Sci, Div Mol Therapy, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	ngotoh@staff.kanazawa-u.ac.jp	GOTOH, Noriko/D-8430-2015; KITA, Kenji/D-8437-2015; Mukaida, Naofumi/D-7623-2011	KITA, Kenji/0000-0002-4622-6633; Mukaida, Naofumi/0000-0002-4193-1851; Murayama, Takahiko/0000-0003-0764-8646	Extramural Collaborative Research Grant from the Cancer Research Institute, Kanazawa University; MEXT [22130009]; JSPS [15H04294, 17K19587, 17K15021]; AMED Project for Development of Innovative Research on Cancer Therapeutics	Extramural Collaborative Research Grant from the Cancer Research Institute, Kanazawa University; MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); AMED Project for Development of Innovative Research on Cancer Therapeutics	We thank H. Miyoshi for his kind gift of pCMV-VSV-G-RSV-Rev and pCAG-HIVgp and J. Yokota and T. Kohno for their kind gift of lung cancer cell lines. We are grateful to K. Kitamura and Y. Tanabe for their technical assistance. This work was supported in part by an Extramural Collaborative Research Grant from the Cancer Research Institute, Kanazawa University, Hokkoku Gan-Kikin, a Grant-in-Aid for Scientific Research on Innovative Areas from MEXT (22130009), a Grant-in-Aid for Scientific Research (B) from JSPS (15H04294, 17K19587), and a research grant from AMED Project for Development of Innovative Research on Cancer Therapeutics to NG. This work was supported in part by a Grant-in-Aid for Scientific Research for Young Scientists (B) from JSPS (17K15021) to TN.	Ablett MP, 2012, EUR J CANCER, V48, P2104, DOI 10.1016/j.ejca.2012.03.019; Amelio I, 2014, TRENDS BIOCHEM SCI, V39, P191, DOI 10.1016/j.tibs.2014.02.004; Arnold K, 2006, BIOINFORMATICS, V22, P195, DOI 10.1093/bioinformatics/bti770; Biasini M, 2014, NUCLEIC ACIDS RES, V42, pW252, DOI 10.1093/nar/gku340; Bordoli L, 2009, NAT PROTOC, V4, P1, DOI 10.1038/nprot.2008.197; Camidge DR, 2014, NAT REV CLIN ONCOL, V11, P473, DOI 10.1038/nrclinonc.2014.104; Carling D, 2017, CURR OPIN CELL BIOL, V45, P31, DOI 10.1016/j.ceb.2017.01.005; Chae HD, 2012, STEM CELLS, V30, P140, DOI 10.1002/stem.778; Christensen KE, 2005, J BIOL CHEM, V280, P34316, DOI 10.1074/jbc.M505210200; Di Pietro E, 2002, MOL CELL BIOL, V22, P4158, DOI 10.1128/MCB.22.12.4158-4166.2002; Ducker GS, 2016, CELL METAB, V23, P1140, DOI 10.1016/j.cmet.2016.04.016; Engelman JA, 2008, CLIN CANCER RES, V14, P2895, DOI 10.1158/1078-0432.CCR-07-2248; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; Gotoh N, 2011, CANC STEM CELLS THEO, P261; Guo DL, 2009, P NATL ACAD SCI USA, V106, P12932, DOI 10.1073/pnas.0906606106; Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311; Hinohara K, 2012, P NATL ACAD SCI USA, V109, P6584, DOI 10.1073/pnas.1113271109; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Hussein HA, 2015, NUCLEIC ACIDS RES, V43, pW436, DOI 10.1093/nar/gkv462; Jain M, 2012, SCIENCE, V336, P1040, DOI 10.1126/science.1218595; Jin L, 2016, ONCOGENE, V35, P3619, DOI 10.1038/onc.2015.447; Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233; Kim D, 2015, NATURE, V520, P363, DOI 10.1038/nature14363; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Korkaya H, 2011, J CLIN INVEST, V121, P3804, DOI 10.1172/JCI57099; Koufaris C, 2016, J PROTEOME RES, V15, P2618, DOI 10.1021/acs.jproteome.6b00188; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Labuschagne CF, 2014, CELL REP, V7, P1248, DOI 10.1016/j.celrep.2014.04.045; Lehtinen L, 2013, ONCOTARGET, V4, P48, DOI 10.18632/oncotarget.756; Liu XN, 2014, P NATL ACAD SCI USA, V111, pE435, DOI 10.1073/pnas.1311121111; Locasale JW, 2013, NAT REV CANCER, V13, P572, DOI 10.1038/nrc3557; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Ma I, 2011, STEM CELL REV REP, V7, P292, DOI 10.1007/s12015-010-9208-4; MEJIA NR, 1985, J BIOL CHEM, V260, P4616; Moran DM, 2014, MOL CANCER THER, V13, P1611, DOI 10.1158/1535-7163.MCT-13-0649; Murayama T, 2016, CANCER RES, V76, P974, DOI 10.1158/0008-5472.CAN-15-2135; Murohashi M, 2010, BRIT J CANCER, V102, P206, DOI 10.1038/sj.bjc.6605468; Nakata A, 2015, SCI REP-UK, V5, DOI 10.1038/srep13076; Nakayama S, 2014, CANCER RES, V74, P5891, DOI 10.1158/0008-5472.CAN-14-0184; Nilsson R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4128; Okayama H, 2012, CANCER RES, V72, P100, DOI 10.1158/0008-5472.CAN-11-1403; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pikman Y, 2016, J EXP MED, V213, P1285, DOI 10.1084/jem.20151574; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Russo A, 2015, ONCOTARGET, V6, P26814, DOI 10.18632/oncotarget.4254; Sebastian C, 2012, CELL, V151, P1185, DOI 10.1016/j.cell.2012.10.047; Shedden K, 2008, NAT MED, V14, P822, DOI 10.1038/nm.1790; Shen BW, 1999, PROTEIN SCI, V8, P1342, DOI 10.1110/ps.8.6.1342; Sheppard NG, 2015, SCI REP-UK, V5, DOI 10.1038/srep15029; SMITH GK, 1990, ARCH BIOCHEM BIOPHYS, V283, P367, DOI 10.1016/0003-9861(90)90656-J; Soga T, 2002, ANAL CHEM, V74, P2233, DOI 10.1021/ac020064n; Soga T, 2003, J PROTEOME RES, V2, P488, DOI 10.1021/pr034020m; Soga T, 2000, ANAL CHEM, V72, P1236, DOI 10.1021/ac990976y; Soga T, 2006, J BIOL CHEM, V281, P16768, DOI 10.1074/jbc.M601876200; Soga T, 2009, ANAL CHEM, V81, P6165, DOI 10.1021/ac900675k; Stewart B. W., 2014, WORLD CANC REPORT 20, P630; Suski M, 2017, EUR J PHARM SCI, V104, P406, DOI 10.1016/j.ejps.2017.04.021; Tibbetts AS, 2010, ANNU REV NUTR, V30, P57, DOI 10.1146/annurev.nutr.012809.104810; Tominaga K, 2017, ONCOGENE, V36, P1276, DOI 10.1038/onc.2016.293; Valent P, 2012, NAT REV CANCER, V12, P767, DOI 10.1038/nrc3368; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; Wang XX, 2017, NAT NEUROSCI, V20, P661, DOI 10.1038/nn.4537; Yamauchi M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043923; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang WC, 2012, CELL, V148, P259, DOI 10.1016/j.cell.2011.11.050	65	41	44	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2019	38	14					2464	2481		10.1038/s41388-018-0589-1	http://dx.doi.org/10.1038/s41388-018-0589-1			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HR7LI	30532069	hybrid, Green Published			2022-12-17	WOS:000463335200003
J	Shao, YW; Wood, GA; Lu, JC; Tang, QL; Liu, J; Molyneux, S; Chen, Y; Fang, H; Adissu, H; McKee, T; Waterhouse, P; Khokha, R				Shao, Yang W.; Wood, Geoffrey A.; Lu, Jinchang; Tang, Qing-Lian; Liu, Jonathan; Molyneux, Sam; Chen, Yan; Fang, Hui; Adissu, Hibret; McKee, Trevor; Waterhouse, Paul; Khokha, Rama			Cross-species genomics identifies DLG2 as a tumor suppressor in osteosarcoma	ONCOGENE			English	Article							GENE-EXPRESSION; COPY NUMBER; G-PROTEINS; HYBRIDIZATION; REARRANGEMENT; POLARITY; GTPASES; CANCER; CANINE; EVENT	Leveraging the conserved cancer genomes across mammals has the potential to transform driver gene discovery in orphan cancers. Here, we combine cross-species genomics with validation across human-dog-mouse systems to uncover a new bone tumor suppressor gene. Comparative genomics of spontaneous human and dog osteosarcomas (OS) expose Disks Large Homolog 2 (DLG2) as a tumor suppressor candidate. DLG2 copy number loss occurs in 42% of human and 56% of canine OS. Functional validation through pertinent human and canine OS DLG2-deficient cell lines identifies a regulatory role of DLG2 in cell division, migration and tumorigenesis. Moreover, osteoblast-specific deletion of Dlg2 in a clinically relevant genetically engineered mouse model leads to acceleration of OS development, establishing DLG2 as a critical determinant of OS. This widely applicable cross-species approach serves as a platform to expedite the search of cancer drivers in rare human malignancies, offering new targets for cancer therapy.	[Shao, Yang W.; Lu, Jinchang; Tang, Qing-Lian; Molyneux, Sam; Chen, Yan; Fang, Hui; McKee, Trevor; Waterhouse, Paul; Khokha, Rama] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON M5G 1L7, Canada; [Wood, Geoffrey A.; Liu, Jonathan; Adissu, Hibret] Univ Guelph, Ontario Vet Coll, Dept Pathobiol, Guelph, ON N1G 2W1, Canada; [Lu, Jinchang; Tang, Qing-Lian] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Orthoped Oncol, Guangzhou 510080, Guangdong, Peoples R China	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Guelph; Sun Yat Sen University	Khokha, R (corresponding author), Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON M5G 1L7, Canada.	rama.khokha@utoronto.ca	adissu, hibret a/R-3282-2018; Wood, Geoffrey/ABB-2052-2021	adissu, hibret a/0000-0003-3365-7466; Wood, Geoffrey/0000-0003-1756-8607; Waterhouse, Paul/0000-0001-8745-5224	Canadian Institutes of Health Research (CIHR); Ontario Institute for Cancer Research (OICR); Global Leadership Round in Genomics and Life Sciences (GL2); OVC Pet Trust; National Natural Science Foundation of China [81702665]; National Postdoctoral Program for Innovative Talents [BX201600196]; China Postdoctoral Science Foundation [2017M610571]	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Ontario Institute for Cancer Research (OICR); Global Leadership Round in Genomics and Life Sciences (GL2); OVC Pet Trust; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Postdoctoral Program for Innovative Talents; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This study is supported by funding from the Canadian Institutes of Health Research (CIHR), Ontario Institute for Cancer Research (OICR), and Global Leadership Round in Genomics and Life Sciences (GL2) to RK and the OVC Pet Trust to GW. J. Lu is also supported by National Natural Science Foundation of China (81702665), National Postdoctoral Program for Innovative Talents (BX201600196) and China Postdoctoral Science Foundation (2017M610571).	Aguiar SD, 2007, CANCER GENET CYTOGEN, V175, P35, DOI 10.1016/j.cancergencyto.2007.01.007; Aljubran AH, 2009, ANN ONCOL, V20, P1136, DOI 10.1093/annonc/mdn731; Angstadt AY, 2012, CANCER GENET-NY, V205, P572, DOI 10.1016/j.cancergen.2012.09.005; Angstadt AY, 2011, GENE CHROMOSOME CANC, V50, P859, DOI 10.1002/gcc.20908; Beroukhim R, 2007, P NATL ACAD SCI USA, V104, P20007, DOI 10.1073/pnas.0710052104; Chen X, 2014, CELL REP, V7, P104, DOI 10.1016/j.celrep.2014.03.003; Chen X, 2014, CELL, V158, P1187, DOI 10.1016/j.cell.2014.07.034; Chen Y, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad0295; Coleman ML, 2004, NAT REV MOL CELL BIO, V5, P355, DOI 10.1038/nrm1365; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Dunn HA, 2015, MOL PHARMACOL, V88, P624, DOI 10.1124/mol.115.098509; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Freeman SS, 2008, CANCER-AM CANCER SOC, V113, P1453, DOI 10.1002/cncr.23782; Hooks SB, 2003, J BIOL CHEM, V278, P10087, DOI 10.1074/jbc.M211382200; Hupe P, 2004, BIOINFORMATICS, V20, P3413, DOI 10.1093/bioinformatics/bth418; Kuijjer ML, 2012, GENE CHROMOSOME CANC, V51, P696, DOI 10.1002/gcc.21956; Mohseny AB, 2010, GENE CHROMOSOME CANC, V49, P1095, DOI 10.1002/gcc.20817; Nathrath MH, 2002, ONCOGENE, V21, P5975, DOI 10.1038/sj.onc.1205764; Ray P, 2004, CANCER RES, V64, P1323, DOI 10.1158/0008-5472.CAN-03-1816; Roberts S, 2012, FEBS J, V279, P3549, DOI 10.1111/j.1742-4658.2012.08729.x; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Scott MC, 2011, BONE, V49, P356, DOI 10.1016/j.bone.2011.05.008; Shimizu T, 2010, ONCOGENE, V29, P5687, DOI 10.1038/onc.2010.312; Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055; Stramer B, 2005, J CELL BIOL, V168, P567, DOI 10.1083/jcb.200405120; TOGUCHIDA J, 1989, NATURE, V338, P156, DOI 10.1038/338156a0; Tsai PC, 2012, AM J VET RES, V73, P1335, DOI 10.2460/ajvr.73.9.1335; van Dam Teunis J P, 2011, Small GTPases, V2, P4; Venkatraman ES, 2007, BIOINFORMATICS, V23, P657, DOI 10.1093/bioinformatics/btl646; Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469	31	41	42	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2019	38	2					291	298		10.1038/s41388-018-0444-4	http://dx.doi.org/10.1038/s41388-018-0444-4			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG9XX	30093633	hybrid, Green Published			2022-12-17	WOS:000455366700010
J	Liu, ZJ; Wei, YJ; Zhang, L; Yee, PP; Johnson, M; Zhang, XX; Gulley, M; Atkinson, JM; Trebak, M; Wang, HG; Li, W				Liu, Zhijun; Wei, Yiju; Zhang, Lei; Yee, Patricia P.; Johnson, Martin; Zhang, Xuexin; Gulley, Melissa; Atkinson, Jennifer M.; Trebak, Mohamed; Wang, Hong-Gang; Li, Wei			Induction of store-operated calcium entry (SOCE) suppresses glioblastoma growth by inhibiting the Hippo pathway transcriptional coactivators YAP/TAZ	ONCOGENE			English	Article							PROTEIN-KINASE-C; CELL-PROLIFERATION; 2-AMINOETHYLDIPHENYL BORATE; TAZ; YAP; STIM1; CA2+; ACTIVATION; AMLODIPINE; CHANNELS	Glioblastomas (GBM) are the most aggressive brain cancers without effective therapeutics. The Hippo pathway transcriptional coactivators YAP/TAZ were implicated as drivers in GBM progression and could be therapeutic targets. Here we found in an unbiased screen of 1650 compounds that amlodipine is able to inhibit survival of GBM cells by suppressing YAP/TAZ activities. Instead of its known function as an L-type calcium channel blocker, we found that amlodipine is able to activate Ca2+ entry by enhancing store-operated Ca2+ entry (SOCE). Amlodipine as well as approaches that cause store depletion and activate SOCE trigger phosphorylation and activation of Lats1/2, which in turn phosphorylate YAP/TAZ and prevent their accumulation in the cell nucleus. Furthermore, we identified that protein kinase C (PKC) beta II is a major mediator of Ca2+-induced Lats1/2 activation. Ca2+ induces accumulation of PKC beta II in an actin cytoskeletal compartment. Such translocation depends on inverted formin-2 (INF2). Depletion of INF2 disrupts both PKC beta II translocation and Lats1/2 activation. Functionally, we found that elevation of cytosolic Ca2+ or PKC beta II expression inhibits YAP/TAZ-mediated gene transcription. In vivo PKC beta II expression inhibits GBM tumor growth and prolongs mouse survival through inhibition of YAP/TAZ in an orthotopic mouse xenograft model. Our studies indicate that Ca2+ is a crucial intracellular cue that regulates the Hippo pathway and that triggering SOCE could be a strategy to target YAP/TAZ in GBM.	[Liu, Zhijun; Wei, Yiju; Zhang, Lei; Yee, Patricia P.; Gulley, Melissa; Atkinson, Jennifer M.; Wang, Hong-Gang; Li, Wei] Penn State Coll Med, Div Pediat Hematol Oncol, Dept Pediat, Penn State Hlth Hershey Med Ctr, Hershey, PA 17033 USA; [Zhang, Lei] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hepat Surg Ctr, Wuhan 430030, Hubei, Peoples R China; [Johnson, Martin; Zhang, Xuexin; Trebak, Mohamed] Penn State Coll Med, Penn State Hlth Hershey Med Ctr, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA; [Wang, Hong-Gang] Penn State Coll Med, Penn State Hlth Hershey Med Ctr, Dept Pharmacol, Hershey, PA 17033 USA; [Li, Wei] Penn State Coll Med, Penn State Hlth Hershey Med Ctr, Dept Biochem & Mol Biol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Huazhong University of Science & Technology; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Li, W (corresponding author), Penn State Coll Med, Div Pediat Hematol Oncol, Dept Pediat, Penn State Hlth Hershey Med Ctr, Hershey, PA 17033 USA.; Li, W (corresponding author), Penn State Coll Med, Penn State Hlth Hershey Med Ctr, Dept Biochem & Mol Biol, Hershey, PA 17033 USA.	weili@pennstatehealth.psu.edu	Zhang, Lei/AAJ-2148-2020; Atkinson, Jennifer/AAE-5466-2019	Atkinson, Jennifer/0000-0001-5164-5114; ZHANG zhang xue xin, XUEXIN/0000-0001-8276-3885; Zhang, Lei/0000-0002-2227-0613; Li, Wei/0000-0001-5696-4309	National Institutes of Health MSTP [5T32GM118294]; National Institutes of Health [R01HL097111, R01HL123364, K22 5K22CA190440]; AACR-Aflac, Inc. Career Development Award for Pediatric Cancer Research [14-20-10-LI]; Four Diamonds Fund for Pediatric Cancer Research; NATIONAL CANCER INSTITUTE [K22CA190440] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [TL1TR002016, UL1TR002014] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL123364, R01HL097111] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM118294] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R21AG050072] Funding Source: NIH RePORTER	National Institutes of Health MSTP(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AACR-Aflac, Inc. Career Development Award for Pediatric Cancer Research; Four Diamonds Fund for Pediatric Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Thomas Abraham and Wade Edris in the Microscopy Imaging Core Facility, Kang Li in the Molecular and Histopathology Core Facility, and Wesley Raup-Konsavage in the Drug Discovery, Development and Delivery Core Facility of Penn State College of Medicine for technical support and sample analysis. This work was supported by the National Institutes of Health MSTP Grant 5T32GM118294 (to P.P.Y. through PSU), National Institutes of Health Grants R01HL097111 and R01HL123364 (to M.T.), K22 5K22CA190440 (to W.L.), AACR-Aflac, Inc. Career Development Award for Pediatric Cancer Research 14-20-10-LI (to W.L.), and the Four Diamonds Fund for Pediatric Cancer Research (to W.L.).	Abdullaev IF, 2008, CIRC RES, V103, P1289, DOI 10.1161/01.RES.0000338496.95579.56; Asai M, 2008, N-S ARCH PHARMACOL, V377, P423, DOI 10.1007/s00210-007-0243-x; Bhat KPL, 2011, GENE DEV, V25, P2594, DOI 10.1101/gad.176800.111; Blobe GC, 1996, J BIOL CHEM, V271, P15823, DOI 10.1074/jbc.271.26.15823; Chan EH, 2005, ONCOGENE, V24, P2076, DOI 10.1038/sj.onc.1208445; DeHaven WI, 2008, J BIOL CHEM, V283, P19265, DOI 10.1074/jbc.M801535200; FAULKNER JK, 1986, BRIT J CLIN PHARMACO, V22, P21, DOI 10.1111/j.1365-2125.1986.tb02874.x; Fernandez A, 2012, ONCOGENE, V31, P1923, DOI 10.1038/onc.2011.379; Gong R, 2015, CELL RES, V25, P985, DOI 10.1038/cr.2015.88; Halder G, 2012, NAT REV MOL CELL BIO, V13, P591, DOI 10.1038/nrm3416; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Jardin I, 2016, BBA-MOL CELL RES, V1863, P1418, DOI 10.1016/j.bbamcr.2015.10.003; Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161; Kapoor A, 2014, CELL, V158, P185, DOI 10.1016/j.cell.2014.06.003; Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874-07; Li W, 2014, CANCER CELL, V26, P48, DOI 10.1016/j.ccr.2014.05.001; Li WJ, 2016, ONCOTARGET, V7, P82686, DOI 10.18632/oncotarget.12625; Liu HL, 2011, EXP MOL PATHOL, V91, P753, DOI 10.1016/j.yexmp.2011.09.005; Mana-Capelli S, 2014, MOL BIOL CELL, V25, P1676, DOI 10.1091/mbc.E13-11-0701; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Meng ZP, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9357; Monteith GR, 2017, NAT REV CANCER, V17, P367, DOI 10.1038/nrc.2017.18; MORGAN AJ, 1994, BIOCHEM J, V300, P665, DOI 10.1042/bj3000665; Motiani RK, 2013, PFLUG ARCH EUR J PHY, V465, P1249, DOI 10.1007/s00424-013-1254-8; Ohgaki H, 2005, ACTA NEUROPATHOL, V109, P93, DOI 10.1007/s00401-005-0991-y; Orr BA, 2011, J NEUROPATH EXP NEUR, V70, P568, DOI 10.1097/NEN.0b013e31821ff8d8; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Potier M, 2008, PFLUG ARCH EUR J PHY, V457, P405, DOI 10.1007/s00424-008-0533-2; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; Riedl J, 2008, NAT METHODS, V5, P605, DOI 10.1038/nmeth.1220; Roderick HL, 2008, NAT REV CANCER, V8, P361, DOI 10.1038/nrc2374; Shao DD, 2014, CELL, V158, P171, DOI 10.1016/j.cell.2014.06.004; Shao XW, 2015, P NATL ACAD SCI USA, V112, pE2595, DOI 10.1073/pnas.1504837112; Smyth JT, 2008, J CELL SCI, V121, P762, DOI 10.1242/jcs.023903; Soh JW, 2003, J BIOL CHEM, V278, P34709, DOI 10.1074/jbc.M302016200; Steinberg SF, 2008, PHYSIOL REV, V88, P1341, DOI 10.1152/physrev.00034.2007; Sun SG, 2016, TRENDS CELL BIOL, V26, P694, DOI 10.1016/j.tcb.2016.05.003; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; Tian T, 2015, BIOCHEM BIOPH RES CO, V463, P638, DOI 10.1016/j.bbrc.2015.05.115; Trebak M, 2002, J BIOL CHEM, V277, P21617, DOI 10.1074/jbc.M202549200; Trebak M, 2017, PHYSIOLOGY, V32, P332, DOI 10.1152/physiol.00011.2017; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wales P, 2016, ELIFE, V5, DOI 10.7554/eLife.19850; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2012, GENE DEV, V26, P54, DOI 10.1101/gad.173435.111; Zheng YG, 2015, DEV CELL, V34, P642, DOI 10.1016/j.devcel.2015.08.014	48	41	41	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2019	38	1					120	139		10.1038/s41388-018-0425-7	http://dx.doi.org/10.1038/s41388-018-0425-7			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG2EL	30082911	Green Accepted			2022-12-17	WOS:000454775900009
J	Shi, L; Tang, XL; Qian, MX; Liu, ZJ; Meng, FB; Fu, L; Wang, ZM; Zhu, WG; Huang, JD; Zhou, ZJ; Liu, BH				Shi, Lei; Tang, Xiaolong; Qian, Minxian; Liu, Zuojun; Meng, Fanbiao; Fu, Li; Wang, Zimei; Zhu, Wei-Guo; Huang, Jian-Dong; Zhou, Zhongjun; Liu, Baohua			A SIRT1-centered circuitry regulates breast cancer stemness and metastasis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR-CELLS; SIRT1; EXPRESSION; PROTEIN; IDENTIFICATION; DEACETYLASE; INDUCTION; HETEROGENEITY; LOCALIZATION	Cancer stem cell (CSC)-dictated intratumor heterogeneity accounts for the majority of drug-resistance and distant metastases of breast cancers. Here, we identify a SIRT1-PRRX1-KLF4-ALDH1 circuitry, which couples CSCs, chemo-resistance, metastasis and aging. Pro-longevity protein SIRT1 deacetylates and stabilizes the epithelial-to-mesenchymal-transition (EMT) inducer PRRX1, which inhibits the transcription of core stemness factor KLF4. Loss of SIRT1 destabilizes PRRX1, disinhibits KLF4, and activates the transcription of ALDH1, which induces and functionally marks CSCs, resulting in chemo-resistance and metastatic relapse. Clinically, the level of PRRX1 is positively linked to SIRT1, whereas KLF4 is reversely correlated. Importantly, KLF4 inhibitor Kenpaullone sensitizes breast cancer cells and xenograft tumors to Paclitaxel and improves therapeutic effects. Our findings delineate a SIRT1-centered circuitry that regulates CSC origination, and targeting this pathway might be a promising therapeutic strategy.	[Shi, Lei; Tang, Xiaolong; Qian, Minxian; Liu, Zuojun; Meng, Fanbiao; Fu, Li; Wang, Zimei; Zhu, Wei-Guo; Liu, Baohua] Shenzhen Univ, Hlth Sci Ctr, Guangdong Key Lab Genome Stabil & Human Dis Preve, Shenzhen 518060, Peoples R China; [Shi, Lei; Tang, Xiaolong; Qian, Minxian; Liu, Zuojun; Meng, Fanbiao; Fu, Li; Liu, Baohua] Shenzhen Univ, Hlth Sci Ctr, MRC, Shenzhen 518060, Peoples R China; [Shi, Lei; Huang, Jian-Dong; Zhou, Zhongjun] Univ Hong Kong, Sch Biomed Sci, LKS Fac Med, Hong Kong, Hong Kong, Peoples R China; [Tang, Xiaolong; Qian, Minxian; Liu, Zuojun; Wang, Zimei; Zhu, Wei-Guo; Liu, Baohua] Shenzhen Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shenzhen 518060, Peoples R China; [Liu, Baohua] Shenzhen Univ, Hlth Sci Ctr, Carson Int Canc Ctr, Shenzhen 518060, Peoples R China	Shenzhen University; Shenzhen University; University of Hong Kong; Shenzhen University; Shenzhen University	Liu, BH (corresponding author), Shenzhen Univ, Hlth Sci Ctr, Guangdong Key Lab Genome Stabil & Human Dis Preve, Shenzhen 518060, Peoples R China.; Liu, BH (corresponding author), Shenzhen Univ, Hlth Sci Ctr, MRC, Shenzhen 518060, Peoples R China.; Liu, BH (corresponding author), Shenzhen Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shenzhen 518060, Peoples R China.; Liu, BH (corresponding author), Shenzhen Univ, Hlth Sci Ctr, Carson Int Canc Ctr, Shenzhen 518060, Peoples R China.	ppliew@szu.edu.cn	Liu, Baohua/C-9594-2014; Fu, Li/F-7182-2010; Liu, Baohua/AAH-3685-2020; /C-4277-2009; Zhou, Zhongjun/C-4476-2009	Liu, Baohua/0000-0002-1599-8059; Fu, Li/0000-0003-2643-6278; Liu, Baohua/0000-0002-1599-8059; /0000-0001-7531-2816; Zhou, Zhongjun/0000-0001-7092-8128; Zhu, Wei-Guo/0000-0001-8385-6581; Shi, Lei/0000-0002-6043-8819	National Natural Science Foundation of China [81422016, 91439133, 81571374, 81501206, 81702909]; National Key R&D Program of China [2017YFA0503900, 2016YFC0904600]; Research Grant Council of Hong Kong [773313, HKU2/CRF/13G]; Natural Science Foundation of Guangdong Province [2014A030308011, 2015A030308007]; Shenzhen Science and Technology Innovation Commission [CXZZ20140903103747568, JCYJ20160226191451487, JCYJ20130329104732074]; Discipline Construction Funding of Shenzhen (2016); China Postdoctoral Science Foundation [2015M582419]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key R&D Program of China; Research Grant Council of Hong Kong(Hong Kong Research Grants Council); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Shenzhen Science and Technology Innovation Commission; Discipline Construction Funding of Shenzhen (2016); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	The authors thank Dr Qi-Wei Zhai (Shanghai Institutes for Biological Sciences, China) for EGFP-SIRT1 construct and Dr Zhen-Kun Lou (Mayo Clinic College of Medicine, USA) for FLAG-SIRT1 construct. This project is supported by research grants from National Natural Science Foundation of China (81422016, 91439133, 81571374, 81501206 and 81702909), National Key R&D Program of China (2017YFA0503900 and 2016YFC0904600), Research Grant Council of Hong Kong (773313 and HKU2/CRF/13G), Natural Science Foundation of Guangdong Province (2014A030308011 and 2015A030308007), Shenzhen Science and Technology Innovation Commission (CXZZ20140903103747568, JCYJ20160226191451487 and JCYJ20130329104732074), Discipline Construction Funding of Shenzhen (2016) and China Postdoctoral Science Foundation (2015M582419).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850; Baccelli I, 2013, NAT BIOTECHNOL, V31, P539, DOI 10.1038/nbt.2576; Banks AS, 2008, CELL METAB, V8, P333, DOI 10.1016/j.cmet.2008.08.014; Bradbury C, 2005, LEUKEMIA, V19, P1751, DOI 10.1038/sj.leu.2403910; Byles V, 2010, INT J BIOL SCI, V6, P599; Cao YW, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0097-2; Celia-Terrassa T, 2012, J CLIN INVEST, V122, P1849, DOI 10.1172/JCI59218; Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005; Deng CX, 2009, INT J BIOL SCI, V5, P147, DOI 10.7150/ijbs.5.147; Ellsworth RE, 2017, SEMIN CELL DEV BIOL, V64, P65, DOI 10.1016/j.semcdb.2016.08.025; Ertel A, 2012, CELL CYCLE, V11, P253, DOI 10.4161/cc.11.2.19006; Finicelli M, 2014, ONCOTARGET, V5, P9678, DOI 10.18632/oncotarget.1936; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Foster KW, 2005, ONCOGENE, V24, P1491, DOI 10.1038/sj.onc.1208307; Giordano SH, 2012, J CLIN ONCOL, V30, P2232, DOI 10.1200/JCO.2011.40.1273; Haigis MC, 2010, ANNU REV PATHOL-MECH, V5, P253, DOI 10.1146/annurev.pathol.4.110807.092250; Heiser LM, 2012, P NATL ACAD SCI USA, V109, P2724, DOI 10.1073/pnas.1018854108; Hida Y, 2007, ARCH DERMATOL RES, V299, P103, DOI 10.1007/s00403-006-0725-6; Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085; Islam F, 2015, EXP MOL PATHOL, V98, P184, DOI 10.1016/j.yexmp.2015.02.002; Jang SH, 2012, J CLIN PATHOL, V65, P735, DOI 10.1136/jclinpath-2012-200685; Jolly MK, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00155; Lee H, 2011, HUM PATHOL, V42, P204, DOI 10.1016/j.humpath.2010.05.023; Li P, 2014, EXP BIOL MED, V239, P813, DOI 10.1177/1535370214538727; Li RH, 2010, CELL STEM CELL, V7, P51, DOI 10.1016/j.stem.2010.04.014; Liu SL, 2014, STEM CELL REP, V2, P78, DOI 10.1016/j.stemcr.2013.11.009; Liu XP, 2013, NAT CELL BIOL, V15, P829, DOI 10.1038/ncb2765; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Nishi M, 2014, ONCOGENE, V33, P643, DOI 10.1038/onc.2012.614; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Ohnishi K, 2014, CELL, V156, P663, DOI 10.1016/j.cell.2014.01.005; Pandya AY, 2004, CLIN CANCER RES, V10, P2709, DOI 10.1158/1078-0432.CCR-03-0484; Pfluger PT, 2008, P NATL ACAD SCI USA, V105, P9793, DOI 10.1073/pnas.0802917105; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Ren RT, 2017, CELL METAB, V26, P460, DOI 10.1016/j.cmet.2017.07.019; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Schatton T, 2008, NATURE, V451, P345, DOI 10.1038/nature06489; Shackleton M, 2009, CELL, V138, P822, DOI 10.1016/j.cell.2009.08.017; Son MJ, 2009, CELL STEM CELL, V4, P440, DOI 10.1016/j.stem.2009.03.003; Stuenkel Walter, 2007, Biotechnology Journal, V2, P1360, DOI 10.1002/biot.200700087; Szasz AM, 2016, ONCOTARGET, V7, P49322, DOI 10.18632/oncotarget.10337; Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003; Tacutu R, 2013, NUCLEIC ACIDS RES, V41, pD1027, DOI 10.1093/nar/gks1155; Tang XL, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00396-9; Wang GY, 2011, CANCER CELL, V19, P114, DOI 10.1016/j.ccr.2010.11.007; Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001; Wu MQ, 2012, MED ONCOL, V29, P3240, DOI 10.1007/s12032-012-0260-6; Yamanaka S, 2010, NATURE, V465, P704, DOI 10.1038/nature09229; Yau C, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2753; Zhao D, 2014, J CLIN INVEST, V124, P5453, DOI 10.1172/JCI76611	51	41	43	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2018	37	49					6299	6315		10.1038/s41388-018-0370-5	http://dx.doi.org/10.1038/s41388-018-0370-5			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HD3AP	30038266	Green Published, hybrid			2022-12-17	WOS:000452384400002
J	Tan, ZY; Song, LB; Wu, WJ; Zhou, YQ; Zhu, JR; Wu, GY; Cao, LX; Song, JW; Li, J; Zhang, W				Tan, Zhanyao; Song, Libing; Wu, Wenjiao; Zhou, Yanqing; Zhu, Jinrong; Wu, Geyan; Cao, Lixue; Song, Junwei; Li, Jun; Zhang, Wei			TRIM14 promotes chemoresistance in gliomas by activating Wnt/beta-catenin signaling via stabilizing Dvl2	ONCOGENE			English	Article							MEDIATES CHEMORESISTANCE; MALIGNANT GLIOMA; BREAST-CANCER; CELL; AUTOPHAGY; OVEREXPRESSION; PROLIFERATION; RADIOTHERAPY; PROTEINS; GENETICS	Gliomas are a lethal class of brain cancer, with a median survival below 15 months in spite of therapeutic advances. The poor prognosis of this disease is largely attributed to acquired chemotherapy resistance, and new strategies are urgently needed to target resistant glioma cells. Herein, our study demonstrated that tripartite motif-containing 14 (TRIM14) overexpressed in glioma specimens (including tissues and cell lines), and that high level of TRIM14 predicted poor outcome of glioma patients. Furthermore, we found that upregulation of TRIM14 in glioma cells conferred chemoresistance to temozolomide in vitro and in vivo; conversely, silencing TRIM14 sensitized glioma cells to temozolomide. These findings demonstrated that TRIM14 stabilized dishevelled (Dvl2) and subsequently activated the canonical Wnt signaling and promoted chemoresistance. Moreover, inhibition of Dvl2 reversed the oncogenic effect of TRIM14 on chemoresistance. Importantly, consistent with the abovementioned results, we found that TRIM14 expression was significantly associated with hyperactivation of canonical Wnt pathway in clinical glioma specimens. Collectively, the study reveals a new molecular mechanism driving chemotherapy resistance in gliomas, and suggests an opportunity to develop novel therapeutic interventions against gliomas.	[Tan, Zhanyao; Zhu, Jinrong; Wu, Geyan; Cao, Lixue; Song, Junwei; Li, Jun] Sun Yat Sen Univ, Key Lab Liver Dis Guangdong Prov, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China; [Tan, Zhanyao; Zhu, Jinrong; Wu, Geyan; Cao, Lixue; Song, Junwei; Li, Jun] Sun Yat Sen Univ, Guangdong Prov Key Lab Brain Funct & Dis, Dept Biochem, Zhongshan Sch Med, Guangzhou, Guangdong, Peoples R China; [Song, Libing] Sun Yat Sen Univ, State Key Lab Oncol Southern China, Dept Expt Res, Canc Ctr, Guangzhou, Guangdong, Peoples R China; [Song, Libing] Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Key Lab Prot Modificat & Degradat, Sch Basic Med Sci, Guangzhou, Guangdong, Peoples R China; [Wu, Wenjiao] Jinan Univ, Dept Neurosurg, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China; [Zhou, Yanqing; Zhang, Wei] Guangdong Pharmaceut Univ, Neurosurg Res Inst, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Guangzhou Medical University; Jinan University; Guangdong Pharmaceutical University	Li, J (corresponding author), Sun Yat Sen Univ, Key Lab Liver Dis Guangdong Prov, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China.; Li, J (corresponding author), Sun Yat Sen Univ, Guangdong Prov Key Lab Brain Funct & Dis, Dept Biochem, Zhongshan Sch Med, Guangzhou, Guangdong, Peoples R China.; Zhang, W (corresponding author), Guangdong Pharmaceut Univ, Neurosurg Res Inst, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.	lijun37@mail.sysu.edu.cn; 18666003902@163.com	wu, ge/ABE-3285-2020; Song, LB/AAL-1968-2020		Natural Science Foundation of China [91740119, 91529301, 91740118, 81530082, 81621004]; Guangzhou Science and Technology Plan Projects [201803010098, 201510010292]; Natural Science Foundation of Guangdong Province [2017A030313799]; Fundamental Research Funds for the Central Universities [17ykjc02]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangzhou Science and Technology Plan Projects; Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	This work was supported by Natural Science Foundation of China (Nos. 91740119, 91529301, 91740118, 81530082 and 81621004); Guangzhou Science and Technology Plan Projects (201803010098, 201510010292); Natural Science Foundation of Guangdong Province (2017A030313799); The Fundamental Research Funds for the Central Universities [No. 17ykjc02].	Ahn SM, 2014, HEPATOLOGY, V60, P1972, DOI 10.1002/hep.27198; [Anonymous], 2016, Cancer Discov, V6, pOF2, DOI 10.1158/2159-8290.CD-NB2016-053; Belanich M, 1996, CANCER RES, V56, P783; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Cadigan KM, 2006, J CELL SCI, V119, P395, DOI 10.1242/jcs.02826; Chen MX, 2016, MOL CELL, V64, P105, DOI 10.1016/j.molcel.2016.08.025; Chen XT, 2013, J CLIN INVEST, V123, P2576, DOI 10.1172/JCI68143; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Edamoto Y, 2003, INT J CANCER, V106, P334, DOI 10.1002/ijc.11254; Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901; Fevr T, 2007, MOL CELL BIOL, V27, P7551, DOI 10.1128/MCB.01034-07; Flahaut M, 2009, ONCOGENE, V28, P2245, DOI 10.1038/onc.2009.80; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Gao C, 2010, NAT CELL BIOL, V12, P781, DOI 10.1038/ncb2082; Goodenberger ML, 2012, CANCER GENET-NY, V205, P613, DOI 10.1016/j.cancergen.2012.10.009; Hai J, 2017, SCI REP-UK, V7, DOI 10.1038/srep39692; Han P, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0583-1; Harris TM, 2015, ARCH PATHOL LAB MED, V139, P494, DOI 10.5858/arpa.2014-0131-OA; Hatakeyama S, 2017, TRENDS BIOCHEM SCI, V42, P297, DOI 10.1016/j.tibs.2017.01.002; Huse JT, 2010, NAT REV CANCER, V10, P319, DOI 10.1038/nrc2818; Kramer N, 2017, ONCOGENE, V36, P5460, DOI 10.1038/onc.2017.144; Laperriere N, 2002, RADIOTHER ONCOL, V64, P259, DOI 10.1016/S0167-8140(02)00078-6; Lau T, 2013, CANCER RES, V73, P3132, DOI 10.1158/0008-5472.CAN-12-4562; Lei ZJ, 2015, ONCOGENE, V34, P3188, DOI 10.1038/onc.2015.129; Lin C, 2015, ONCOGENE, V34, P332, DOI 10.1038/onc.2013.559; Malbon CC, 2006, CURR TOP DEV BIOL, V72, P153, DOI 10.1016/S0070-2153(05)72002-0; Metcalfe C, 2010, CANCER RES, V70, P6629, DOI 10.1158/0008-5472.CAN-10-1616; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nenasheva VV, 2014, IN VITRO CELL DEV-AN, V50, P121, DOI 10.1007/s11626-013-9683-4; Sardiello M, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-225; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Song XM, 2015, ONCOL LETT, V10, P2283, DOI 10.3892/ol.2015.3623; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Su X, 2016, ONCOTARGET, V7, P9939, DOI 10.18632/oncotarget.6941; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Tao JY, 2016, HEPATOLOGY, V64, P1587, DOI 10.1002/hep.28601; Tauriello DVF, 2010, MOL CELL, V37, P607, DOI 10.1016/j.molcel.2010.01.035; Wang NX, 2008, DRUG NEWS PERSPECT, V21, P137, DOI 10.1358/dnp.2008.21.3.1203409; Wang Y, 2017, ONCOTARGET, V8, P37511, DOI 10.18632/oncotarget.16400; Wickstrom M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9904; Xing JJ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00101-w; Xu GX, 2017, SCI REP-UK, V7, DOI 10.1038/srep42411; Zeng ZL, 2012, CLIN CANCER RES, V18, P4059, DOI 10.1158/1078-0432.CCR-11-3156; Zhang ZM, 2016, ONCOGENE, V35, P4787, DOI 10.1038/onc.2016.10; Zhou Z, 2014, P NATL ACAD SCI USA, V111, pE245, DOI 10.1073/pnas.1316941111	45	41	44	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2018	37	40					5403	5415		10.1038/s41388-018-0344-7	http://dx.doi.org/10.1038/s41388-018-0344-7			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV7MY	29867201				2022-12-17	WOS:000446312900003
J	Shi, JL; Li, FP; Yao, XX; Mou, TY; Xu, ZJ; Han, Z; Chen, SY; Li, WD; Yu, J; Qi, XL; Liu, H; Li, GX				Shi, Jiaolong; Li, Fengping; Yao, Xingxing; Mou, Tingyu; Xu, Zhijun; Han, Zheng; Chen, Siyu; Li, Wende; Yu, Jiang; Qi, Xiaolong; Liu, Hao; Li, Guoxin			The HER4-YAP1 axis promotes trastuzumab resistance in HER2-positive gastric cancer by inducing epithelial and mesenchymal transition	ONCOGENE			English	Article							BREAST-CANCER; GROWTH-FACTOR; GASTROESOPHAGEAL CANCER; ACQUIRED-RESISTANCE; COLORECTAL-CANCER; TYROSINE KINASE; INHIBITION; HER2; EXPRESSION; DIFFERENTIATION	Trastuzumab is the only target to be approved as the first-line treatment of HER2 positive metastatic gastric cancer, but ubiquitous resistance decreases its therapeutic benefit. In this study, we found HER4, phosphorylation HER4 (p-HER4) and the mesenchymal marker Vimentin increased in trastuzumab-resistant cells (MKN45TR and NCI-N87TR), while epithelial markers expressions in trastuzumab-resistant cell lines and animal models decreased. Additionally, silencing HER4 prevented the epithelial-mesenchymal transition and led to decreased proliferation and migration in vitro and in vivo. The expression of YAP1, a vital downstream interacted target of HER4, decreased when HER4 was knocked down. Interestingly, stimulation of NRG1 could compromise the inhibitory impact and rescue cell survival; whereas, transfection of siYAP1 sensitized trastuzumab-treated cells. Expression analysis of the proteins in patient-derived xenograft model (PDX) mice showed that HER4, p-HER4, YAP1, and Vimentin were clearly upregulated in the trastuzumab-resistant mice compared to mice without trastuzumab resistance. However, HER2 and E-cadherin were downregulated in response to continuous treatment with trastuzumab. These findings elucidated that the central role of the HER4-YAP1 axis in trastuzumab resistance of HER2-positive gastric cancer cells through induction of EMT. Hence, regulating the HER4-YAP1 axis might be a promising strategy for clinical interventions in patients with HER2-positive gastric cancer.	[Shi, Jiaolong; Li, Fengping; Yao, Xingxing; Mou, Tingyu; Xu, Zhijun; Han, Zheng; Yu, Jiang; Qi, Xiaolong; Liu, Hao; Li, Guoxin] Southern Med Univ, Nanfang Hosp, Dept Gen Surg, Guangdong Prov Engn Technol Res Ctr Minimally Inv, Guangzhou, Guangdong, Peoples R China; [Chen, Siyu; Li, Wende] Guangdong Key Lab Lab Anim, Dept Guangdong Lab Anim Monitoring Inst, Guangzhou, Guangdong, Peoples R China	Southern Medical University - China	Li, GX (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Gen Surg, Guangdong Prov Engn Technol Res Ctr Minimally Inv, Guangzhou, Guangdong, Peoples R China.	gzliguoxin@163.com	Liu, Hao/I-9884-2019	Liu, Hao/0000-0003-1227-2954; Qi, Xiaolong/0000-0002-3559-5855	State's Key Project of Research and Development Plan [2017YFC0108300, 2017YFC0108301]; National Natural Science Foundation of China [81672446]; Guangdong Provincial Science and Technology Key Project [2014A020215014, 2016A030313843]; Research Fund of Public Welfare in the Health Industry; National Health and Family Planning Commission of China [201402015]; Southern Medical University Clinical Research Start-Up Project [LC2016ZD003]; Guangzhou Science and Technology Project [201400000004-5]; Key Clinical Specialty Discipline Construction Program [[2011]170]; Guangzhou Science and Technology Program [201400000004-5]	State's Key Project of Research and Development Plan; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Provincial Science and Technology Key Project; Research Fund of Public Welfare in the Health Industry; National Health and Family Planning Commission of China; Southern Medical University Clinical Research Start-Up Project; Guangzhou Science and Technology Project; Key Clinical Specialty Discipline Construction Program; Guangzhou Science and Technology Program	This work was supported by the grants from the State's Key Project of Research and Development Plan (2017YFC0108300, 2017YFC0108301), National Natural Science Foundation of China (81672446), Guangdong Provincial Science and Technology Key Project (2014A020215014, 2016A030313843), Research Fund of Public Welfare in the Health Industry, the National Health and Family Planning Commission of China (201402015), the Southern Medical University Clinical Research Start-Up Project (LC2016ZD003), Guangzhou Science and Technology Project (201400000004-5) and the Key Clinical Specialty Discipline Construction Program([2011]170). Guangzhou Science and Technology Program(no. 201400000004-5)	Bang YJ, 2010, LANCET, V376, P1302; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Bossi D, 2016, CANCER DISCOV, V6, P650, DOI 10.1158/2159-8290.CD-15-1200; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; Canfield K, 2015, CELL CYCLE, V14, P648, DOI 10.4161/15384101.2014.994966; De Mattos-Arruda L, 2015, ONCOTARGET, V6, P37269, DOI 10.18632/oncotarget.5495; Fu CP, 2017, INT J NANOMED, V12, P3365, DOI 10.2147/IJN.S130322; Garrett JT, 2011, P NATL ACAD SCI USA, V108, P5021, DOI 10.1073/pnas.1016140108; Gravalos C, 2008, ANN ONCOL, V19, P1523, DOI 10.1093/annonc/mdn169; Haskins JW, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005770; He XX, 2015, J CLIN PATHOL, V68, P374, DOI 10.1136/jclinpath-2014-202657; Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186; Janjigian YY, 2012, ANN ONCOL, V23, P2656, DOI 10.1093/annonc/mds104; Jiang YM, 2017, JAMA SURG, V152, DOI 10.1001/jamasurg.2017.1087; Jiang YM, 2018, ANN SURG, V267, P504, DOI 10.1097/SLA.0000000000002116; Kim J, 2014, J CLIN INVEST, V124, P5145, DOI 10.1172/JCI75200; Ling HH, 2017, EXP CELL RES, V350, P218, DOI 10.1016/j.yexcr.2016.11.024; Liu H, 2016, ONCOTARGET, V7, P43894, DOI 10.18632/oncotarget.9707; Lordick F, 2016, NAT REV CLIN ONCOL, V13, P348, DOI 10.1038/nrclinonc.2016.15; Muraoka-Cook RS, 2008, J MAMMARY GLAND BIOL, V13, P235, DOI 10.1007/s10911-008-9080-x; Nafi SNM, 2014, ONCOTARGET, V5, P5934; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Noh SH, 2014, LANCET ONCOL, V15, P1389, DOI 10.1016/S1470-2045(14)70473-5; Okines AFC, 2010, LANCET, V376, P1736, DOI 10.1016/S0140-6736(10)62127-7; Oliveras-Ferraros C, 2012, CELL CYCLE, V11, P4020, DOI 10.4161/cc.22225; Pasini F, 2011, ANTICANCER RES, V31, P3543; Piro G, 2016, CLIN CANCER RES, V22, P6164, DOI 10.1158/1078-0432.CCR-16-0178; Sassen A, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2339; Sato Y, 2013, CANCER SCI, V104, P1618, DOI 10.1111/cas.12290; Scaltriti M, 2007, J NATL CANCER I, V99, P628, DOI 10.1093/jnci/djk134; Shen ZY, 2015, ONCOTARGET, V6, P20672, DOI 10.18632/oncotarget.3967; Takahashi N, 2016, ONCOTARGET, V7, P4925, DOI 10.18632/oncotarget.6753; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Wang H, 2014, CLIN CANCER RES, V20, P5835, DOI 10.1158/1078-0432.CCR-14-0485; Wang ZX, 2017, METHODS MOL BIOL, V1652, P3, DOI 10.1007/978-1-4939-7219-7_1; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Xiong BH, 2016, GROWTH FACTORS, V34, P187, DOI 10.1080/08977194.2016.1251916; Zheng L, 2014, CANCER IMMUNOL IMMUN, V63, P581, DOI 10.1007/s00262-014-1541-z; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064; Zhou WL, 2000, J BIOL CHEM, V275, P34737, DOI 10.1074/jbc.M003756200; Zhu Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep08542; Zuo Q, 2015, SCI REP-UK, V5, DOI 10.1038/srep11634	43	41	41	2	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	22					3022	3038		10.1038/s41388-018-0204-5	http://dx.doi.org/10.1038/s41388-018-0204-5			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GH8RM	29535422	hybrid, Green Published			2022-12-17	WOS:000433936300009
J	Russo, A; Czarnecki, AA; Dean, M; Modi, DA; Lantvit, DD; Hardy, L; Baligod, S; Davis, DA; Wei, JJ; Burdette, JE				Russo, Angela; Czarnecki, Austin A.; Dean, Matthew; Modi, Dimple A.; Lantvit, Daniel D.; Hardy, Laura; Baligod, Seth; Davis, David A.; Wei, Jian-Jun; Burdette, Joanna E.			PTEN loss in the fallopian tube induces hyperplasia and ovarian tumor formation	ONCOGENE			English	Article							GRADE SEROUS CARCINOMA; FOCAL ADHESION KINASE; INTRAEPITHELIAL CARCINOMA; SURFACE EPITHELIUM; BORDERLINE TUMORS; MOUSE MODEL; CANCER; EXPRESSION; ORIGIN; TRANSFORMATION	The signaling events involved in the onset of ovarian cancer from the fallopian tube epithelium (FTE) are crucial for early detection and treatment of the disease, but they remain poorly defined. Conditional homozygous knockout of PTEN mediated by PAX8-cre recombinase was sufficient to drive endometrioid and serous borderline ovarian carcinoma, providing the first model of FTE-derived borderline tumors. In addition, heterozygous PTEN deletion in the FTE resulted in hyperplasia, providing a model to study early events of human ovarian pathogenesis. To uncover the mechanism underlying the invasion of cancerous oviductal cells to the ovary, PTEN-deficient murine oviductal cells were developed and tagged with green fluorescent protein. Loss of PTEN increased cell migration, invasion, and upregulated WNT4, a key regulator of Mullerian duct development during embryogenesis. Further investigation revealed that WNT4 was required for increased migration and colonization of the ovary by PTEN-deficient oviductal cells in a a-catenin independent manner. Human tumor microarrays and ovarian cancer cells lines confirmed WNT4 expression in cancer and its role in migration. Together, these findings provide a novel model to study the mechanism of fallopian tube tumor initiation and invasion to the ovary mediated by loss of PTEN, which may help to define early events of human ovarian carcinogenesis.	[Russo, Angela; Czarnecki, Austin A.; Dean, Matthew; Modi, Dimple A.; Lantvit, Daniel D.; Hardy, Laura; Baligod, Seth; Davis, David A.; Burdette, Joanna E.] Univ Illinois, Coll Pharm, Dept Med Chem & Pharmacognosy, Chicago, IL 60607 USA; [Davis, David A.] J Hopkins Med Inst, Reference Histol Lab, Dept Pathol, Baltimore, MD USA; [Wei, Jian-Jun] Northwestern Univ, Dept Pathol, Chicago, IL 60611 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Johns Hopkins University; Northwestern University	Burdette, JE (corresponding author), Univ Illinois, Coll Pharm, Dept Med Chem & Pharmacognosy, Chicago, IL 60607 USA.	joannab@uic.edu	WEI, JJ/AAN-2638-2020	Dean, Matthew/0000-0001-5014-9311	Tell Every Amazing Lady About Ovarian Cancer Louisa M. McGregor Ovarian Cancer Foundation; American Cancer Society [ACS RSG-12-230-01-TBG]; NIH [UG3 ES029073-01, T32 AT007533]; NATIONAL CANCER INSTITUTE [R21CA208610] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [T32AT007533] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [UG3ES029073] Funding Source: NIH RePORTER	Tell Every Amazing Lady About Ovarian Cancer Louisa M. McGregor Ovarian Cancer Foundation; American Cancer Society(American Cancer Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by Tell Every Amazing Lady (T.E.A.L.) About Ovarian Cancer Louisa M. McGregor Ovarian Cancer Foundation, The American Cancer Society ACS RSG-12-230-01-TBG, the NIH UG3 ES029073-01 and the NIH T32 AT007533. We would also like to thank the Northwestern NUseq Core Facility and Dr. Matthew Schipma.	Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Boone JD, 2016, LAB INVEST, V96, P249, DOI 10.1038/labinvest.2015.150; Bouchard M, 2004, GENESIS, V38, P105, DOI 10.1002/gene.20008; Cho KR, 2009, ARCH PATHOL LAB MED, V133, P1775, DOI 10.1043/1543-2165-133.11.1775; Coffman LG, 2016, TRANSL RES, V175, P92, DOI 10.1016/j.trsl.2016.03.016; Cohen ED, 2002, DEV CELL, V2, P437, DOI 10.1016/S1534-5807(02)00142-9; Daikoku T, 2008, CANCER RES, V68, P5619, DOI 10.1158/0008-5472.CAN-08-1274; Eddie SL, 2015, ONCOTARGET, V6, P20500, DOI 10.18632/oncotarget.3985; Endsley MP, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00154; Fathalla MF, 2013, FACTS VIEWS VIS OBGY, V5, P292; Filippone MG, 2014, BMC MOL BIOL, V15, DOI 10.1186/1471-2199-15-21; Haley J, 2016, ONCOTARGET, V7, P32810, DOI 10.18632/oncotarget.9053; Hanrahan AJ, 2014, CANCER DISCOV, V2, P56; Hilliard TS, 2013, INT J MOL SCI, V14, P4762, DOI 10.3390/ijms14034762; Karthikeyan S, 2016, ONCOTARGET, V7, P69871, DOI 10.18632/oncotarget.11499; Kim J, 2012, P NATL ACAD SCI USA, V109, P3921, DOI 10.1073/pnas.1117135109; Kindelberger DW, 2007, AM J SURG PATHOL, V31, P161, DOI 10.1097/01.pas.0000213335.40358.47; King SM, 2013, CARCINOGENESIS, V34, P1125, DOI 10.1093/carcin/bgt003; Kispert A, 1998, DEVELOPMENT, V125, P4225; Kobayashi A, 2003, NAT REV GENET, V4, P969, DOI 10.1038/nrg1225; Kuchenbaecker KB, 2015, NAT GENET, V47, P164, DOI 10.1038/ng.3185; Kuhn E, 2012, J PATHOL, V226, P421, DOI 10.1002/path.3023; Kurman RJ, 2011, AM J SURG PATHOL, V35, P1605, DOI 10.1097/PAS.0b013e318229449f; Kurman RJ, 2010, AM J SURG PATHOL, V34, P433, DOI 10.1097/PAS.0b013e3181cf3d79; Laury AR, 2011, AM J SURG PATHOL, V35, P1759, DOI 10.1097/PAS.0b013e318233b0f7; Li J, 2011, MODERN PATHOL, V24, P1488, DOI 10.1038/modpathol.2011.106; Martins FC, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0526-8; McDaniel AS, 2015, JAMA ONCOL, V1, P1128, DOI 10.1001/jamaoncol.2015.1618; Modi DA, 2017, ONCOGENE, V36, P3015, DOI 10.1038/onc.2016.455; Mullany LK, 2012, ENDOCRINOLOGY, V153, P1585, DOI 10.1210/en.2011-2121; Ng A, 2015, NAT REV MOL CELL BIO, V16, P625, DOI 10.1038/nrm4056; Perets R, 2013, CANCER CELL, V24, P751, DOI 10.1016/j.ccr.2013.10.013; Prunskaite-Hyyrylainen R, 2016, HUM MOL GENET, V25, P1059, DOI 10.1093/hmg/ddv621; Przybycin CG, 2010, AM J SURG PATHOL, V34, P1407, DOI 10.1097/PAS.0b013e3181ef7b16; Quartuccio SM, 2015, INT J CANCER, V137, P1528, DOI 10.1002/ijc.29528; Quartuccio SM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065067; ROBEY SS, 1989, INT J GYNECOL PATHOL, V8, P214, DOI 10.1097/00004347-198909000-00004; Roh MH, 2010, MODERN PATHOL, V23, P1316, DOI 10.1038/modpathol.2010.119; Seidman JD, 2004, INT J GYNECOL PATHOL, V23, P41, DOI 10.1097/01.pgp.0000101080.35393.16; Seidman JD, 2011, GYNECOL ONCOL, V120, P470, DOI 10.1016/j.ygyno.2010.11.020; Sherman-Baust CA, 2014, J PATHOL, V233, P228, DOI 10.1002/path.4353; Shield-Artin KL, 2012, PROTEOM CLIN APPL, V6, P170, DOI 10.1002/prca.201100008; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Sood AK, 2004, AM J PATHOL, V165, P1087, DOI 10.1016/S0002-9440(10)63370-6; Sukerkar PA, 2011, BIOCONJUGATE CHEM, V22, P2304, DOI 10.1021/bc2003555; Tada M, 2000, DEVELOPMENT, V127, P2227; Torban E, 2006, J BIOL CHEM, V281, P12705, DOI 10.1074/jbc.M513181200; Vang R, 2013, HISTOPATHOLOGY, V62, P44, DOI 10.1111/his.12046; Ward KK, 2013, CLIN EXP METASTAS, V30, P579, DOI 10.1007/s10585-012-9562-5; Wu R, 2016, J PATHOL, V240, P341, DOI 10.1002/path.4783; Yang-Hartwich Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep06116; Zhai YL, 2017, J PATHOL, V243, P16, DOI 10.1002/path.4927; Zhang L, 2016, ONCOGENE, V35, P5010, DOI 10.1038/onc.2016.53	54	41	43	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	15					1976	1990		10.1038/s41388-017-0097-8	http://dx.doi.org/10.1038/s41388-017-0097-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GC6KH	29367766	Green Accepted			2022-12-17	WOS:000429899400003
J	Perego, M; Maurer, M; Wang, JX; Shaffer, S; Muller, AC; Parapatics, K; Li, L; Hristova, D; Shin, S; Keeney, F; Liu, S; Xu, X; Raj, A; Jensen, JK; Bennett, KL; Wagner, SN; Somasundaram, R; Herlyn, M				Perego, M.; Maurer, M.; Wang, J. X.; Shaffer, S.; Mueller, A. C.; Parapatics, K.; Li, L.; Hristova, D.; Shin, S.; Keeney, F.; Liu, S.; Xu, X.; Raj, A.; Jensen, J. K.; Bennett, K. L.; Wagner, S. N.; Somasundaram, R.; Herlyn, M.			A slow-cycling subpopulation of melanoma cells with highly invasive properties	ONCOGENE			English	Article							BONE MORPHOGENETIC PROTEIN-1; PROTEASE NEXIN-1; PROGNOSTIC-SIGNIFICANCE; PLASMINOGEN-ACTIVATOR; SAMPLE PREPARATION; INITIATING CELLS; MESSENGER-RNA; LOW NUMBER; CANCER; EXPRESSION	Melanoma is a heterogeneous tumor with different subpopulations showing different proliferation rates. Slow-cycling cells were previously identified in melanoma, but not fully biologically characterized. Using the label-retention method, we identified a subpopulation of slow-cycling cells, defined as label-retaining cells (LRC), with strong invasive properties. We demonstrate through live imaging that LRC are leaving the primary tumor mass at a very early stage and disseminate to peripheral organs. Through global proteome analyses, we identified the secreted protein SerpinE2/protease nexin-1 as causative for the highly invasive potential of LRC in melanomas.	[Perego, M.; Wang, J. X.; Li, L.; Hristova, D.; Shin, S.; Keeney, F.; Somasundaram, R.; Herlyn, M.] Wistar Inst Anat & Biol, Melanoma Res Ctr, 3601 Spruce St, Philadelphia, PA 19104 USA; [Maurer, M.; Wagner, S. N.] Med Univ Vienna, Div Immunol Allergy & Infect Dis, Vienna, Austria; [Shaffer, S.; Raj, A.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Mueller, A. C.; Parapatics, K.; Bennett, K. L.] Austrian Acad Sci, CeMM Res Ctr Mol Med, Vienna, Austria; [Liu, S.; Xu, X.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Jensen, J. K.] Aarhus Univ, Dept Mol Biol & Genet, Aarhus, Denmark	The Wistar Institute; Medical University of Vienna; University of Pennsylvania; Austrian Academy of Sciences; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences; University of Pennsylvania; Aarhus University	Herlyn, M (corresponding author), Wistar Inst Anat & Biol, Melanoma Res Ctr, 3601 Spruce St, Philadelphia, PA 19104 USA.	herlynm@wistar.org	perego, michela/W-4650-2019	perego, michela/0000-0002-5671-928X; Shaffer, Sydney/0000-0003-3539-9886; Liu, Shujing/0000-0002-2958-093X; Shin, Sally/0000-0002-9306-2264; Mueller, Andre/0000-0002-0608-8176; Somasundaram, Rajasekharan/0000-0002-8444-8472	NIH [P01 CA114046, P01 CA025874, P30 CA010815, R01 CA047159, CA076674, CA182890]; Melanoma Research Alliance; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Vienna Science and Technology Fund (WWTF) [LS11-045]; Vienna Hans Mayr-Fund; APART fellowship of the Austrian Academy of Sciences; NATIONAL CANCER INSTITUTE [R01CA076674, R01CA182890, R01CA047159, P30CA010815, P01CA025874, P50CA174523, P01CA114046] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [S10OD017998] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Melanoma Research Alliance; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Vienna Science and Technology Fund (WWTF); Vienna Hans Mayr-Fund; APART fellowship of the Austrian Academy of Sciences; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Jeffrey Faust, Scott Weiss and Christopher Corcoran from Wistar's Flow Cytometry Facility; James Hayden from Wistar's Imaging Facility and Dmitri Gourevitch from Wistar's Histopathology Core Facility for technical support; and Rachel E Locke and Jessica L Kohn for editorial assistance. This work was supported by NIH grants P01 CA114046, P01 CA025874, P30 CA010815, R01 CA047159, CA076674, CA182890, by the Melanoma Research Alliance and by the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, Vienna Science and Technology Fund (WWTF through project LS11-045 to SNW), Vienna Hans Mayr-Fund, and by APART fellowship of the Austrian Academy of Sciences (OAW to MM).	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; Bergeron S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-271; Bianchi-Smiraglia A, 2017, ONCOGENE, V5, P36; Boiko AD, 2010, NATURE, V466, P133, DOI 10.1038/nature09161; Bouton MC, 2012, BLOOD, V119, P2452, DOI 10.1182/blood-2011-10-387464; Breitwieser FP, 2011, J PROTEOME RES, V10, P2758, DOI 10.1021/pr1012784; Buchholz M, 2003, CANCER RES, V63, P4945; Chapman A, 2014, CELL REP, V8, P688, DOI 10.1016/j.celrep.2014.06.045; Cheli Y, 2001, ONCOGENE, V19, P30; Cheli Y, 2012, ONCOGENE, V10, P31; Chou CT, 2015, ANN SURG ONCOL, V22, P4335, DOI 10.1245/s10434-015-4505-4; Colinge J, 2006, J PROTEOME RES, V5, P619, DOI 10.1021/pr0504236; Croteau W, 2013, J CELL PHYSIOL, V228, P773, DOI 10.1002/jcp.24225; Czekay RP, 2009, J CELL PHYSIOL, V220, P655, DOI 10.1002/jcp.21806; Dembinski Jennifer L, 2010, Cancers (Basel), V2, P2011, DOI 10.3390/cancers2042011; EVANS DL, 1991, J BIOL CHEM, V266, P22307; Falletta P, 2017, GENE DEV, V1, P31; Fane ME, 2017, EBIOMEDICINE, V16, P63, DOI 10.1016/j.ebiom.2017.01.013; Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343; Faries MB, 2013, J AM COLL SURGEONS, V217, P27, DOI 10.1016/j.jamcollsurg.2013.03.007; Fayard B, 2009, CANCER RES, V69, P5690, DOI 10.1158/0008-5472.CAN-08-4573; Gao S, 2008, ORAL ONCOL, V44, P309, DOI 10.1016/j.oraloncology.2007.02.009; Garrigue-Antar L, 2001, J BIOL CHEM, V276, P26237, DOI 10.1074/jbc.M010814200; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; Goodall J, 2008, CANCER RES, V1, P68; Heit C, 2013, HUM GENOMICS, V7, DOI 10.1186/1479-7364-7-22; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491; Ito M, 2005, NAT MED, V11, P1351, DOI 10.1038/nm1328; Johannessen CM, 2013, NATURE, V504, P138, DOI 10.1038/nature12688; Kersey P, 2000, BIOINFORMATICS, V16, P1048, DOI 10.1093/bioinformatics/16.11.1048; Konieczkowski DJ, 2014, CANCER DISCOV, V4, P816, DOI 10.1158/2159-8290.CD-13-0424; Kousted TM, 2014, THROMB HAEMOSTASIS, V111, P29, DOI 10.1160/TH13-04-0340; Kousted TM, 2012, ANDREASEN PAPROTEASE, P251; Krauthammer M, 2015, NAT GENET, V47, P996, DOI 10.1038/ng.3361; Lee JJ, 2015, ONCOTARGET, V6, P37995, DOI 10.18632/oncotarget.6062; Leroy C, 2015, ONCOGENE, V34, P5593, DOI 10.1038/onc.2015.19; Manza LL, 2005, PROTEOMICS, V5, P1742, DOI 10.1002/pmic.200401063; Maurer M, 2014, J PROTEOME RES, V13, P2830, DOI 10.1021/pr401270y; Maurer M, 2013, J PROTEOME RES, V12, P1040, DOI 10.1021/pr301009u; Monzani E, 2007, EUR J CANCER, V43, P935, DOI 10.1016/j.ejca.2007.01.017; Nagahara A, 2010, BIOCHEM BIOPH RES CO, V391, P1641, DOI 10.1016/j.bbrc.2009.12.105; Neesse A, 2007, PANCREATOLOGY, V7, P380, DOI 10.1159/000107400; Olsen R, 2005, ANALYST, V130, P941, DOI 10.1039/b419145e; Ostyn P, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/s12964-014-0052-z; Pagliara V, 2014, BBA-MOL CELL RES, V1843, P2631, DOI 10.1016/j.bbamcr.2014.07.008; Pierard-Franchimont C, 2014, ONCOL REV, V8, P54, DOI 10.4081/oncol.2014.252; Raj A, 2008, NAT METHODS, V5, P877, DOI 10.1038/NMETH.1253; Rocken M, 2010, J CLIN INVEST, V120, P1800, DOI 10.1172/JCI43424; Roesch A, 2013, CANCER CELL, V23, P811, DOI 10.1016/j.ccr.2013.05.003; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Rossignol P, 2004, J BIOL CHEM, V279, P10346, DOI 10.1074/jbc.M310964200; Scott C F, 1985, Trans Assoc Am Physicians, V98, P344; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; Selzer-Plon J, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-201; Shain AH, 2015, NEW ENGL J MED, V373, P1926, DOI 10.1056/NEJMoa1502583; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Strickland DK, 2003, J THROMB HAEMOST, V1, P1663, DOI 10.1046/j.1538-7836.2003.00330.x; Vaillant C, 2007, DEVELOPMENT, V134, P1745, DOI 10.1242/dev.02840; Vaillant C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124870; Valiente M, 2014, CELL, V156, P1002, DOI 10.1016/j.cell.2014.01.040; Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095; Van Allen EM, 2014, CANCER DISCOV, V4, P94, DOI 10.1158/2159-8290.CD-13-0617; Wagenblast E, 2015, NATURE, V520, P358, DOI 10.1038/nature14403; Wagle N, 2014, CANCER DISCOV, V4, P61, DOI 10.1158/2159-8290.CD-13-0631; Wang K, 2015, J CANCER RES CLIN, V141, P805, DOI 10.1007/s00432-014-1858-1; Webster MR, 2015, PIGM CELL MELANOMA R, V28, P184, DOI 10.1111/pcmr.12330; Wilson BJ, 2014, CANCER RES, V74, P4196, DOI 10.1158/0008-5472.CAN-14-0582; Wisniewski JR, 2009, J PROTEOME RES, V8, P5674, DOI 10.1021/pr900748n; Wu QW, 2016, AM J TRANSL RES, V8, P1985; Wu X, 2014, ONCOGENE, V33, P1506, DOI 10.1038/onc.2013.108; Xu DM, 2010, CANCER RES, V70, P6988, DOI 10.1158/0008-5472.CAN-10-0242; Yang SF, 2009, NUCL MED BIOL, V36, P313, DOI 10.1016/j.nucmedbio.2008.12.007; Zhou MY, 2006, INVEST OPHTH VIS SCI, V47, P2997, DOI 10.1167/iovs.06-0130	75	41	42	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2018	37	3					302	312		10.1038/onc.2017.341	http://dx.doi.org/10.1038/onc.2017.341			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS9QS	28925403	Green Published, hybrid			2022-12-17	WOS:000422753900003
J	Maurus, K; Hufnagel, A; Geiger, F; Graf, S; Berking, C; Heinemann, A; Paschen, A; Kneitz, S; Stigloher, C; Geissinger, E; Otto, C; Bosserhoff, A; Schartl, M; Meierjohann, S				Maurus, K.; Hufnagel, A.; Geiger, F.; Graf, S.; Berking, C.; Heinemann, A.; Paschen, A.; Kneitz, S.; Stigloher, C.; Geissinger, E.; Otto, C.; Bosserhoff, A.; Schartl, M.; Meierjohann, S.			The AP-1 transcription factor FOSL1 causes melanocyte reprogramming and transformation	ONCOGENE			English	Article							C-JUN; METASTATIC MELANOMA; CANCER METASTASIS; CELLS; ACTIVATION; FRA-1; MITF; GENE; DEDIFFERENTIATION; PHOSPHORYLATION	The MAPK pathway is activated in the majority of melanomas and is the target of therapeutic approaches. Under normal conditions, it initiates the so-called immediate early response, which encompasses the transient transcription of several genes belonging to the AP-1 transcription factor family. Under pathological conditions, such as continuous MAPK pathway overactivation due to oncogenic alterations occurring in melanoma, these genes are constitutively expressed. The consequences of a permanent expression of these genes are largely unknown. Here, we show that FOSL1 is the main immediate early AP-1 member induced by melanoma oncogenes. We first examined its role in established melanoma cells. We found that FOSL1 is involved in melanoma cell migration as well as cell proliferation and anoikis-independent growth, which is mediated by the gene product of its target gene HMGA1, encoding a multipotent chromatin modifier. As FOSL1 expression is increased in patient melanoma samples compared to nevi, we investigated the effect of enhanced FOSL1 expression on melanocytes. Intriguingly, we found that FOSL1 acts oncogenic and transforms melanocytes, enabling subcutaneous tumor growth in vivo. During the process of transformation, FOSL1 reprogrammed the melanocytes and downregulated MITF in a HMGA1-dependent manner. At the same time, AXL was upregulated, leading to a shift in the MITF/AXL balance. Furthermore, FOSL1 re-enforced pro-tumorigenic transcription factors MYC, E2F3 and AP-1. Together, this led to the enhancement of several growth-promoting processes, such as ribosome biogenesis, cellular detachment and pyrimidine metabolism. Overall, we demonstrate that FOSL1 is a novel reprogramming factor for melanocytes with potent tumor transformation potential.	[Maurus, K.; Hufnagel, A.; Geiger, F.; Kneitz, S.; Schartl, M.; Meierjohann, S.] Univ Wurzburg, Dept Phys Chem, Wurzburg, Germany; [Maurus, K.; Geissinger, E.] Univ Wurzburg, Inst Pathol, Wurzburg, Germany; [Graf, S.; Berking, C.] Munich Univ Hosp LMU, Dept Dermatol & Allergy, Munich, Germany; [Heinemann, A.] Paul Ehrlich Inst, Div Immunol, Langen, Germany; [Paschen, A.] Univ Duisburg Essen, Univ Hosp Essen, Dept Dermatol, Partner Site Essen, Essen, Germany; [Paschen, A.] German Canc Consortium DKTK, Partner Site Essen Dusseldorf, Essen, Germany; [Stigloher, C.] Univ Wurzburg, Div Elect Microscopy, Dept Cell & Dev Biol, Wurzburg, Germany; [Otto, C.] Univ Hosp Wurzburg, Dept Gen Visceral Vasc & Pediat Surg, Expt Surg, Wurzburg, Germany; [Bosserhoff, A.] Friedrich Alexander Univ Erlangen Nurnberg, Emil Fischer Ctr, Inst Biochem, Nurnberg, Germany; [Bosserhoff, A.] Univ Erlangen Nurnberg, Comprehens Canc Ctr Erlangen EMN, Erlangen, Germany; [Schartl, M.; Meierjohann, S.] Univ Hosp Wurzburg, Comprehens Canc Ctr Mainfranken, Wurzburg, Germany; [Schartl, M.] Texas A&M Univ, Texas A&M Inst Adv Studies, College Stn, TX USA; [Schartl, M.] Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA	University of Wurzburg; University of Wurzburg; University of Munich; Paul Ehrlich Institute; University of Duisburg Essen; Helmholtz Association; German Cancer Research Center (DKFZ); University of Wurzburg; University of Wurzburg; University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Wurzburg; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Meierjohann, S (corresponding author), Univ Wurzburg, Dept Physiol Chem, Bioctr, D-97074 Wurzburg, Bavaria, Germany.	svenja.meierjohann@biozentrum.uni-wuerzburg.de	Bosserhoff, Anja/GNH-4801-2022	Geiger, Fabienne/0000-0002-7550-9739; Bosserhoff, Anja/0000-0001-8147-394X	Melanoma Research Network of the Deutsche Krebshilfe eV (German Cancer Aid); research unit FOR2314, German Research Foundation	Melanoma Research Network of the Deutsche Krebshilfe eV (German Cancer Aid)(Deutsche Krebshilfe); research unit FOR2314, German Research Foundation	This work was supported by the Melanoma Research Network of the Deutsche Krebshilfe eV (German Cancer Aid) and by the research unit FOR2314, project 5 (German Research Foundation). We are furthermore grateful to Manfred Gessler (Dept of Developmental Biochemistry, University of Wurzburg) for providing us with the pSB-ET-iE vector and to Stefan Gaubatz (Dept. of Physiological Chemistry, University of Wurzburg) for the E2F3 antibody. We would also like to thank Marie-Christine Dabauvalle (Dept of Zoology and Developmental Biology, University of Wurzburg) for sharing the fibrillarin antibody with us.	Basbous J, 2007, MOL CELL BIOL, V27, P3936, DOI 10.1128/MCB.01776-06; Belton A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030034; Bianchi-Smiraglia A, 2017, ONCOGENE, V36, P84, DOI 10.1038/onc.2016.178; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Das KC, 2010, MOL CELL BIOCHEM, V337, P53, DOI 10.1007/s11010-009-0285-0; Desmet CJ, 2013, P NATL ACAD SCI USA, V110, P5139, DOI 10.1073/pnas.1222085110; Elkon R, 2015, EMBO REP, V16, P1723, DOI 10.15252/embr.201540717; Gentilella A, 2015, BBA-GENE REGUL MECH, V1849, P812, DOI 10.1016/j.bbagrm.2015.02.005; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Iskit S, 2015, ONCOTARGET, V6, P43146, DOI 10.18632/oncotarget.6454; Kapoor A, 2014, CELL, V158, P185, DOI 10.1016/j.cell.2014.06.003; Kappelmann M, 2013, ONCOGENE, V32, P2984, DOI 10.1038/onc.2012.307; Landsberg J, 2012, NATURE, V490, P412, DOI 10.1038/nature11538; Leikam C, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.71; Lister JA, 2014, J INVEST DERMATOL, V134, P133, DOI 10.1038/jid.2013.293; Lopez-Bergami P, 2010, J BIOL CHEM, V285, P903, DOI 10.1074/jbc.M109.075630; Mandal R, 2016, ONCOGENE, V35, P2547, DOI 10.1038/onc.2015.329; Martin RM, 2007, HISTOCHEM CELL BIOL, V127, P243, DOI 10.1007/s00418-006-0256-4; Muller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6712; NAKABEPPU Y, 1993, MOL CELL BIOL, V13, P4157, DOI 10.1128/MCB.13.7.4157; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; Ploper D, 2015, P NATL ACAD SCI USA, V112, pE420, DOI 10.1073/pnas.1424576112; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Renaud SJ, 2014, J BIOL CHEM, V289, P5025, DOI 10.1074/jbc.M113.523746; Riesenberg S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9755; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Sensi M, 2011, J INVEST DERMATOL, V131, P2448, DOI 10.1038/jid.2011.218; Shah SN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048533; Shain AH, 2015, NEW ENGL J MED, V373, P1926, DOI 10.1056/NEJMoa1502583; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Spangler B, 2011, PIGM CELL MELANOMA R, V24, P148, DOI 10.1111/j.1755-148X.2010.00787.x; Spangler B, 2012, INT J CANCER, V130, P2801, DOI 10.1002/ijc.26277; Thomas S, 2008, HUM MOL GENET, V17, P3411, DOI 10.1093/hmg/ddn235; Tice DA, 2002, J BIOL CHEM, V277, P6118, DOI 10.1074/jbc.M111255200; Ting CH, 2016, ONCOTARGET, V7, P40329, DOI 10.18632/oncotarget.9612; Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501; Vincek V, 2010, J CUTAN PATHOL, V37, P3, DOI 10.1111/j.1600-0560.2009.01299.x; Vogt PK, 2002, NAT REV CANCER, V2, P465, DOI 10.1038/nrc818; Vredeveld LCW, 2012, GENE DEV, V26, P1055, DOI 10.1101/gad.187252.112; Wellbrock C, 2015, PIGM CELL MELANOMA R, V28, P390, DOI 10.1111/pcmr.12370; Widmer DS, 2012, PIGM CELL MELANOMA R, V25, P343, DOI 10.1111/j.1755-148X.2012.00986.x; Yang S, 2013, ONCOGENE, V32, P4294, DOI 10.1038/onc.2012.432; Zanconato F, 2015, NAT CELL BIOL, V17, P1218, DOI 10.1038/ncb3216	45	41	43	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	2017	36	36					5110	5121		10.1038/onc.2017.135	http://dx.doi.org/10.1038/onc.2017.135			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF9XD	28481878				2022-12-17	WOS:000409371100003
J	Itoh, G; Chida, S; Yanagihara, K; Yashiro, M; Aiba, N; Tanaka, M				Itoh, G.; Chida, S.; Yanagihara, K.; Yashiro, M.; Aiba, N.; Tanaka, M.			Cancer-associated fibroblasts induce cancer cell apoptosis that regulates invasion mode of tumours	ONCOGENE			English	Article							MESENCHYMAL STEM-CELLS; EXTRACELLULAR VESICLES; CARCINOMA; MICROVESICLES; METASTASIS; ACTIVATION; BODIES	In the process of cancer spreading, different modes of invasion exist. One is expansive invasion, in which a group of cancer cells gradually expands along with cancer cell proliferation. Invasion of cancer cells is also modified by their interaction with stromal cells including cancer-associated fibroblasts (CAFs). Cancer cells co-invade with CAFs, and invasion by CAFs frequently precede invasion by cancer cells, which indicates CAF-led cancer cell invasion. Here, we show that CAFs induce apoptosis in gastric cancer cells, which prevented expansive invasion by cancer cells and instead facilitated CAF-led invasion. Death receptor 4 and activation of caspase-8 in cancer cells mediated cancer cell apoptosis induced by CAFs, which was dependent on contact between cancer cells and CAFs. Apoptotic cancer cells in turn released apoptotic vesicles and stimulated invasion of CAFs. Accordingly, cancer cells followed the migrating CAFs. Treatment with a caspase inhibitor, ZVAD, or forced expression of a death domain fragment in cancer cells prevented cancer cell apoptosis induced by CAFs and increased expansive invasion by cancer cells in extracellular gel invasion assays, while the rate of cancer cell invasion led by CAFs was decreased. Death domain-fragment expression also prevented intramural invasion by gastric cancer cells in the stomach. Because CAF-led invasion is characterized by the movement of individual cancer cells away from the tumour, adequate cancer cell apoptosis may promote cancer dissemination.	[Itoh, G.; Aiba, N.; Tanaka, M.] Akita Univ, Grad Sch Med, Dept Mol Med & Biochem, Akita, Japan; [Chida, S.] Akita Univ, Grad Sch Med, Biosci Educ & Res Support Ctr, Akita, Japan; [Yanagihara, K.] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Div Pathol, Chiba, Japan; [Yashiro, M.] Osaka City Univ, Grad Sch Med, Dept Surg Oncol, Abeno Ku, Osaka, Japan	Akita University; Akita University; National Cancer Center - Japan; Osaka Metropolitan University	Tanaka, M (corresponding author), Akita Univ, Mol Med & Biochem, 1-1-1 Hondo, Akita, Akita 0108543, Japan.	mastanak@med.akita-u.ac.jp			JSPS KAKENHI [26640068, 16H04691]; Research Grant of the Princess Takamatsu Cancer Research Fund [14-24620]; Project Mirai Cancer Research grant; Grants-in-Aid for Scientific Research [17K19579] Funding Source: KAKEN	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Research Grant of the Princess Takamatsu Cancer Research Fund; Project Mirai Cancer Research grant; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by JSPS KAKENHI grants (nos. 26640068 and 16H04691 to MT), a Research Grant of the Princess Takamatsu Cancer Research Fund (14-24620 to MT), and Project Mirai Cancer Research grants to MT	Alexander S, 2013, CURR OPIN CELL BIOL, V25, P659, DOI 10.1016/j.ceb.2013.07.001; Antwi-Baffour SS, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929-015-0174-7; Ciardiello C, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020175; Clark AG, 2015, CURR OPIN CELL BIOL, V36, P13, DOI 10.1016/j.ceb.2015.06.004; Crescitelli R, 2013, J EXTRACELL VESICLES, V2, DOI 10.3402/jev.v2i0.20677; Ding SM, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0588-8; Fuyuhiro Y, 2011, BRIT J CANCER, V105, P996, DOI 10.1038/bjc.2011.330; Gaggioli C, 2007, NAT CELL BIOL, V9, P1392, DOI 10.1038/ncb1658; Geraldo S, 2012, EUR J CELL BIOL, V91, P930, DOI 10.1016/j.ejcb.2012.07.005; Hsu HS, 2012, LUNG CANCER, V75, P167, DOI 10.1016/j.lungcan.2011.07.001; Hwang RF, 2008, CANCER RES, V68, P918, DOI 10.1158/0008-5472.CAN-07-5714; Jain MV, 2013, J CELL MOL MED, V17, P12, DOI 10.1111/jcmm.12001; Lee RH, 2012, CELL STEM CELL, V11, P825, DOI 10.1016/j.stem.2012.10.001; Lin JT, 2013, EXP CELL RES, V319, P2216, DOI 10.1016/j.yexcr.2013.06.003; Liu SL, 2011, CANCER RES, V71, P614, DOI 10.1158/0008-5472.CAN-10-0538; Lo YC, 2015, APOPTOSIS, V20, P124, DOI 10.1007/s10495-014-1054-4; Muhsin-Sharafaldine MR, 2016, ONCOTARGET, V7, P56279, DOI 10.18632/oncotarget.10783; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Qian ZR, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/649161; Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021; Sakamaki K, 2004, GENES CELLS, V9, P1249, DOI 10.1111/j.1365-2443.2004.00802.x; Sanchez-Lopez E, 2016, ONCOGENE, V35, P2634, DOI 10.1038/onc.2015.326; Satoyoshi R, 2015, ONCOGENE, V34, P650, DOI 10.1038/onc.2013.584; Sidani M, 2006, J MAMMARY GLAND BIOL, V11, P151, DOI 10.1007/s10911-006-9021-5; Siegelin MD, 2009, NEUROCHEM INT, V55, P423, DOI 10.1016/j.neuint.2009.04.011; Subramaniam KS, 2016, AM J CANCER RES, V6, P200; Tanaka M, 2016, CANCER SCI, V107, P803, DOI 10.1111/cas.12940; Thery C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567; Tsai KS, 2011, GASTROENTEROLOGY, V141, P1046, DOI 10.1053/j.gastro.2011.05.045; Turiak L, 2011, J PROTEOMICS, V74, P2025, DOI 10.1016/j.jprot.2011.05.023; Waghray M, 2016, CANCER DISCOV, V6, P886, DOI 10.1158/2159-8290.CD-15-0947; Walczak Henning, 2008, V414, P221; Walczak H, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008698; Yanagihara K, 2005, CANCER SCI, V96, P323, DOI 10.1111/j.1349-7006.2005.00054.x; Yanagihara K, 2004, CANCER SCI, V95, P575, DOI 10.1111/j.1349-7006.2004.tb02489.x; Yoon N, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.90	36	41	46	4	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2017	36	31					4434	4444		10.1038/onc.2017.49	http://dx.doi.org/10.1038/onc.2017.49			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FC4JL	28368418				2022-12-17	WOS:000406806000006
J	Sankpal, NV; Fleming, TP; Sharma, PK; Wiedner, HJ; Gillanders, WE				Sankpal, N. V.; Fleming, T. P.; Sharma, P. K.; Wiedner, H. J.; Gillanders, W. E.			A double-negative feedback loop between EpCAM and ERK contributes to the regulation of epithelial-mesenchymal transition in cancer	ONCOGENE			English	Article							BREAST-CANCER; STEM-CELLS; E-CADHERIN; CLAUDIN-LOW; THERAPEUTIC TARGET; EXPRESSION; METASTASIS; RESISTANCE; PROGNOSIS; ADHESION	Epithelial-mesenchymal transition (EMT) is an important biological process that has been implicated in cancer metastasis. Epithelial cell adhesion molecule (EpCAM) is expressed at the basolateral membrane of most normal epithelial cells but is overexpressed in many epithelial cancers. In our studies on the role of EpCAM in cancer biology, we observed that EpCAM expression is decreased in mesenchymal-like primary cancer specimens in vivo and following induction of EMT in cancer cell lines in vitro. Extracellular signal-related kinase (ERK) is a key regulator of EMT. We observed that EpCAM expression is decreased with activation of the ERK pathway in primary cancer specimens in vivo and in cancer cell lines in vitro. In experimental models, growth factor stimulation and/or oncogene-induced ERK2 activation suppressed EpCAM expression, whereas genetic or pharmacological inhibition of the ERK pathway restored EpCAM expression. In detailed studies of the EpCAM promoter region, we observed that ERK2 suppresses EpCAM transcription directly by binding to a consensus ERK2-binding site in the EpCAM promoter and indirectly through activation of EMT-associated transcription factors SNAI1, SNAI2, TWIST1 and ZEB1, which bind to E-box sites in the EpCAM promoter. Surprisingly, EpCAM appears to modulate ERK activity. Using multiple cell lines, we demonstrated that specific ablation of EpCAM resulted in increased ERK pathway activity and SNAI2 expression, migration and invasion, whereas forced expression of EpCAM resulted in decreased ERK pathway activity and SNAI2 expression, migration and invasion. These observations provide important insights into the regulation of EpCAM expression during EMT, demonstrate an unexpected role for EpCAM in the regulation of ERK and define a novel double-negative feedback loop between EpCAM and ERK that contributes to the regulation of EMT. These studies have important translational implications as both EpCAM and ERK are currently being targeted in human clinical trials.	[Sankpal, N. V.; Fleming, T. P.; Sharma, P. K.; Wiedner, H. J.; Gillanders, W. E.] Washington Univ, Sch Med, Dept Surg, 660 South Euclid Ave,Campus Box 8109, St Louis, MO 63110 USA; [Gillanders, W. E.] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA	Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL)	Gillanders, WE (corresponding author), Washington Univ, Sch Med, Dept Surg, 660 South Euclid Ave,Campus Box 8109, St Louis, MO 63110 USA.	gillandersw@wustl.edu		Wiedner, Hannah/0000-0002-5919-5944; Sharma, Piyush/0000-0002-6247-3503	Susan G Komen for the Cure [BCTR0707917]; Siteman Cancer Center fund [P30CA91842]; NATIONAL CANCER INSTITUTE [P30CA091842] Funding Source: NIH RePORTER	Susan G Komen for the Cure(Susan G. Komen Breast Cancer Foundation); Siteman Cancer Center fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Kerry Kornfeld, Dr Jason Weber and Dr Gregory Longmore for reviewing the manuscript and providing valuable advice. This work was supported by a grant from Susan G Komen for the Cure (BCTR0707917) and Siteman Cancer Center fund (P30CA91842).	Armstrong A, 2003, CANCER BIOL THER, V2, P320, DOI 10.4161/cbt.2.4.451; Asiedu MK, 2011, CANCER RES, V71, P4707, DOI 10.1158/0008-5472.CAN-10-4554; Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; Caramel J, 2013, CANCER CELL, V24, P466, DOI 10.1016/j.ccr.2013.08.018; Carlson SM, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002010; Cheng JC, 2013, ONCOGENE, V32, P1041, DOI 10.1038/onc.2012.127; Courcelles M, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.25; Cristofanilli M, 2004, NEW ENGL J MED, V351, P781, DOI 10.1056/NEJMoa040766; Dry JR, 2010, CANCER RES, V70, P2264, DOI 10.1158/0008-5472.CAN-09-1577; Eberlein C, 2015, ONCOGENE, V34, P704, DOI 10.1038/onc.2013.600; Feldman S, 2011, CANCER-AM CANCER SOC, V117, P2599, DOI 10.1002/cncr.25822; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Gao JJ, 2015, J CELL PHYSIOL, V230, P775, DOI 10.1002/jcp.24802; Gemmill RM, 2011, CANCER LETT, V300, P66, DOI 10.1016/j.canlet.2010.09.007; Grotegut S, 2006, EMBO J, V25, P3534, DOI 10.1038/sj.emboj.7601213; Hajra KM, 2002, CANCER RES, V62, P1613; Hook KE, 2012, MOL CANCER THER, V11, P710, DOI 10.1158/1535-7163.MCT-11-0184; Hu SH, 2009, CELL, V139, P610, DOI 10.1016/j.cell.2009.08.037; Klymkowsky MW, 2009, AM J PATHOL, V174, P1588, DOI 10.2353/ajpath.2009.080545; Kusewitt DF, 2009, J INVEST DERMATOL, V129, P491, DOI 10.1038/jid.2008.222; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Li SQ, 2013, CELL REP, V4, P1116, DOI 10.1016/j.celrep.2013.08.022; Liu SL, 2014, STEM CELL REP, V2, P78, DOI 10.1016/j.stemcr.2013.11.009; Lyons JG, 2008, CANCER RES, V68, P4525, DOI 10.1158/1078-0432.CCR-07-6735; Maetzel D, 2009, NAT CELL BIOL, V11, P162, DOI 10.1038/ncb1824; Maghzal N, 2013, DEV CELL, V27, P263, DOI 10.1016/j.devcel.2013.10.003; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Massoner P, 2014, BRIT J CANCER, V111, P955, DOI 10.1038/bjc.2014.366; Munz M, 2010, CANCER CELL INT, V10, DOI 10.1186/1475-2867-10-44; Munz M, 2009, CANCER RES, V69, P5627, DOI 10.1158/0008-5472.CAN-09-0654; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Osta WA, 2004, CANCER RES, V64, P5818, DOI 10.1158/0008-5472.CAN-04-0754; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Raponi M, 2006, CANCER RES, V66, P7466, DOI 10.1158/0008-5472.CAN-06-1191; Roskoski R, 2012, PHARMACOL RES, V66, P105, DOI 10.1016/j.phrs.2012.04.005; Sankpal NV, 2013, MOL CANCER RES, V11, P418, DOI 10.1158/1541-7786.MCR-12-0518; Sankpal NV, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3070; Sankpal NV, 2009, CANCER RES, V69, P753, DOI 10.1158/0008-5472.CAN-08-2708; Santisteban M, 2009, CANCER RES, V69, P2887, DOI 10.1158/0008-5472.CAN-08-3343; Shi L, 2014, CANCER RES, V74, P532, DOI 10.1158/0008-5472.CAN-13-2203; Shin J, 2013, CELL SIGNAL, V25, P2540, DOI 10.1016/j.cellsig.2013.08.014; Shin S, 2010, MOL CELL, V38, P114, DOI 10.1016/j.molcel.2010.02.020; Siemens H, 2011, CELL CYCLE, V10, P4256, DOI 10.4161/cc.10.24.18552; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Songun I, 2005, BRIT J CANCER, V92, P1767, DOI 10.1038/sj.bjc.6602519; Soysal SD, 2013, BRIT J CANCER, V108, P1480, DOI 10.1038/bjc.2013.80; Spizzo G, 2004, BREAST CANCER RES TR, V86, P207, DOI 10.1023/B:BREA.0000036787.59816.01; Tarcic G, 2012, FASEB J, V26, P1582, DOI 10.1096/fj.11-194654; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Vannier C, 2013, J BIOL CHEM, V288, P18643, DOI 10.1074/jbc.M113.467787; Yang XJ, 2010, CANCER RES, V70, P9463, DOI 10.1158/0008-5472.CAN-10-2388; Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897; Zhang K, 2013, NAT CELL BIOL, V15, P677, DOI 10.1038/ncb2743; Zhang PJ, 2015, CELL CYCLE, V14, P481, DOI 10.1080/15384101.2015.1006048; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064	59	41	42	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2017	36	26					3706	3717		10.1038/onc.2016.504	http://dx.doi.org/10.1038/onc.2016.504			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY9WM	28192403	Green Accepted			2022-12-17	WOS:000404349700006
J	Zhou, H; Liu, Y; Zhu, R; Ding, F; Wan, Y; Li, Y; Liu, Z				Zhou, H.; Liu, Y.; Zhu, R.; Ding, F.; Wan, Y.; Li, Y.; Liu, Z.			FBXO32 suppresses breast cancer tumorigenesis through targeting KLF4 to proteasomal degradation	ONCOGENE			English	Article							F-BOX PROTEIN; SCF UBIQUITIN LIGASE; P38-ALPHA MAP KINASE; INDUCED DNA-DAMAGE; TUMOR-SUPPRESSOR; CELL PROLIFERATION; DOWN-REGULATION; MUSCLE ATROPHY; GENE; IDENTIFICATION	Kruppel- like factor 4 (KLF4, GKLF) is a zinc-finger transcription factor involved in a large variety of cellular processes, including apoptosis, cell cycle progression, as well as stem cell renewal. KLF4 is critical for cell fate decision and has an ambivalent role in tumorigenesis. Emerging data keep reminding us that KLF4 dysregulation either facilitates or impedes tumor progression, making it important to clarify the regulating network of KLF4. Like most transcription factors, KLF4 has a rather short half-life within the cell and its turnover must be carefully orchestrated by ubiquitination and ubiquitin-proteasome system. To better understand the mechanism of KLF4 ubiquitination, we performed a genome-wide screen of E3 ligase small interfering RNA library based on western blot and identified SCF-FBXO32 to be a new E3 ligase, which is responsible for KLF4 ubiquitination and degradation. The F-box domain is critical for FBXO32-dependent KLF4 ubiquitination and degradation. Furthermore, we demonstrated that FBXO32 physically interacts with the N-terminus (1-60 aa) of KLF4 via its C-terminus (228-355 aa) and directly targets KLF4 for ubiquitination and degradation. We also found out that p38 mitogen-activated protein kinase pathway may be implicated in FBXO32-mediated ubiquitination of KLF4, as p38 kinase inhibitor coincidently abrogates endogenous KLF4 ubiquitination and degradation, as well as FBXO32-dependent exogenous KLF4 ubiquitination and degradation. Finally, FBXO32 inhibits colony formation in vitro and primary tumor initiation and growth in vivo through targeting KLF4 into degradation. Our findings thus further elucidate the tumor-suppressive function of FBXO32 in breast cancer. These results expand our understanding of the posttranslational modification of KLF4 and of its role in breast cancer development and provide a potential target for diagnosis and therapeutic treatment of breast cancer.	[Zhou, H.; Liu, Y.; Zhu, R.; Ding, F.; Li, Y.; Liu, Z.] Chinese Acad Med Sci, Canc Hosp, Natl Canc Ctr, State Key Lab Mol Oncol, Beijing 100021, Peoples R China; [Zhou, H.; Liu, Y.; Zhu, R.; Ding, F.; Li, Y.; Liu, Z.] Peking Union Med Coll, Collaborat Innovat Ctr Canc Med, Beijing 100021, Peoples R China; [Wan, Y.] Univ Pittsburgh, Dept Cell Biol, Sch Med, Pittsburgh, PA USA; [Wan, Y.] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA 15260 USA	Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Li, Y; Liu, Z (corresponding author), Chinese Acad Med Sci, Canc Hosp, Natl Canc Ctr, State Key Lab Mol Oncol, Beijing 100021, Peoples R China.; Li, Y; Liu, Z (corresponding author), Peking Union Med Coll, Collaborat Innovat Ctr Canc Med, Beijing 100021, Peoples R China.	liyi@cicams.ac.cn; liuzh@cicams.ac.cn	Liu, Yongshuo/GRX-6416-2022; Liu, Yongshuo/AGZ-8274-2022	Liu, Yongshuo/0000-0001-8190-0139; Liu, Yongshuo/0000-0001-8190-0139	National Natural Science Foundation of China [81130043, 81420108025]; Ministry of Science and Technology [2016YFC1302100, 2013CB911004]; NATIONAL CANCER INSTITUTE [R01CA154695, R01CA202963] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This project was funded by National Natural Science Foundation of China (81130043 and 81420108025) and grants from the Ministry of Science and Technology (2016YFC1302100 and 2013CB911004).	Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Chen ZY, 2005, CANCER RES, V65, P10394, DOI 10.1158/0008-5472.CAN-05-2059; Chou JL, 2010, LAB INVEST, V90, P414, DOI 10.1038/labinvest.2009.138; Derbre F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046668; Dolado I, 2007, CANCER CELL, V11, P191, DOI 10.1016/j.ccr.2006.12.013; Foster KW, 2005, ONCOGENE, V24, P1491, DOI 10.1038/sj.onc.1208307; Foster KW, 2000, CANCER RES, V60, P6488; Gamper AM, 2012, MOL CELL, V45, P233, DOI 10.1016/j.molcel.2011.11.031; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Ghaleb AM, 2007, ONCOGENE, V26, P2365, DOI 10.1038/sj.onc.1210022; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; Guo W, 2015, NEOPLASMA, V62, P646, DOI 10.4149/neo_2015_078; Hu D, 2012, J BIOL CHEM, V287, P13584, DOI 10.1074/jbc.M112.343566; Hu D, 2011, J BIOL CHEM, V286, P6890, DOI 10.1074/jbc.M110.179952; Hu WX, 2009, CLIN CANCER RES, V15, P5688, DOI 10.1158/1078-0432.CCR-09-0310; Hui LJ, 2007, NAT GENET, V39, P741, DOI 10.1038/ng2033; Jogo M, 2009, FEBS LETT, V583, P2715, DOI 10.1016/j.febslet.2009.07.033; Kim MO, 2012, NAT STRUCT MOL BIOL, V19, P283, DOI 10.1038/nsmb.2217; Kipreos ET, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-5-reviews3002; Li Y, 2005, GLOBAL BIOGEOCHEM CY, V19, DOI 10.1029/2004GB002392; Luo AP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096610; McConnell BB, 2010, PHYSIOL REV, V90, P1337, DOI 10.1152/physrev.00058.2009; Mei ZC, 2015, J BIOL CHEM, V290, P16202, DOI 10.1074/jbc.M115.645978; Ohnishi S, 2003, BIOCHEM BIOPH RES CO, V308, P251, DOI 10.1016/S0006-291X(03)01356-1; Rowland BD, 2006, NAT REV CANCER, V6, P11, DOI 10.1038/nrc1780; Rowland BD, 2005, NAT CELL BIOL, V7, P1074, DOI 10.1038/ncb1314; Santner SJ, 2001, BREAST CANCER RES TR, V65, P101, DOI 10.1023/A:1006461422273; Sarikas A, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-220; Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806, DOI 10.1152/ajpgi.2000.279.4.G806; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Skaar JR, 2009, CELL, V137, DOI 10.1016/j.cell.2009.05.039; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107; Tetreault MP, 2010, GASTROENTEROLOGY, V139, P171, DOI 10.1053/j.gastro.2010.03.048; Tian X, 2015, ONCOTARGET, V6, P22767, DOI 10.18632/oncotarget.4082; Ventura JJ, 2007, NAT GENET, V39, P750, DOI 10.1038/ng2037; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wang N, 2002, WORLD J GASTROENTERO, V8, P966, DOI 10.3748/wjg.v8.i6.966; Wei DY, 2016, CANCER CELL, V29, P324, DOI 10.1016/j.ccell.2016.02.005; Wei DY, 2006, CARCINOGENESIS, V27, P23, DOI 10.1093/carcin/bgi243; Wu Z, 2011, CELL DEATH DIFFER, V18, P1771, DOI 10.1038/cdd.2011.48; Yoon HS, 2005, ONCOGENE, V24, P4017, DOI 10.1038/sj.onc.1208576; Yoon HS, 2004, J BIOL CHEM, V279, P5035, DOI 10.1074/jbc.M307631200; Yu F, 2011, ONCOGENE, V30, P2161, DOI 10.1038/onc.2010.591; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zhao WD, 2004, ONCOGENE, V23, P395, DOI 10.1038/sj.onc.1207067; Zheng HQ, 2014, CANCER CELL, V26, P358, DOI 10.1016/j.ccr.2014.07.022; Zhou QB, 2009, CANCER RES, V69, P8284, DOI 10.1158/0008-5472.CAN-09-1345	50	41	43	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2017	36	23					3312	3321		10.1038/onc.2016.479	http://dx.doi.org/10.1038/onc.2016.479			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW9WJ	28068319	Green Accepted			2022-12-17	WOS:000402869800010
J	Zou, M; Bhatia, A; Dong, H; Jayaprakash, P; Guo, J; Sahu, D; Hou, Y; Tsen, F; Tong, C; O'Brien, K; Situ, AJ; Schmidt, T; Chen, M; Ying, Q; Ulmer, TS; Woodley, DT; Li, W				Zou, M.; Bhatia, A.; Dong, H.; Jayaprakash, P.; Guo, J.; Sahu, D.; Hou, Y.; Tsen, F.; Tong, C.; O'Brien, K.; Situ, A. J.; Schmidt, T.; Chen, M.; Ying, Q.; Ulmer, T. S.; Woodley, D. T.; Li, W.			Evolutionarily conserved dual lysine motif determines the non-chaperone function of secreted Hsp90alpha in tumour progression	ONCOGENE			English	Article							CANCER-CELL INVASION; MONOCLONAL-ANTIBODY; MOLECULAR CHAPERONE; HSP90-ALPHA; GROWTH; MIGRATION; MOTILITY; MECHANISM; RECEPTOR	Both intracellular and extracellular heat shock protein-90 (Hsp90) family proteins (alpha and beta) have been shown to support tumour progression. The tumour-supporting activity of the intracellular Hsp90 is attributed to their N-terminal ATPase-driven chaperone function. What molecular entity determines the extracellular function of secreted Hsp90 and the distinction between Hsp90 alpha and Hsp90 beta was unclear. Here we demonstrate that CRISPR/Case9 knocking out Hsp90 alpha nullifies tumour cells' ability to migrate, invade and metastasize without affecting the cell survival and growth. Knocking out Hsp90 beta leads to tumour cell death. Extracellular supplementation with recombinant Hsp90 alpha, but not Hsp90 alpha, protein recovers tumourigenicity of the Hsp90 alpha-knockout cells. Sequential mutagenesis identifies two evolutionarily conserved lysine residues, lys-270 and lys-277, in the Hsp90 alpha subfamily that determine the extracellular Hsp90 alpha function. Hsp90 beta subfamily lacks the dual lysine motif and the extracellular function. Substitutions of gly-262 and thr-269 in Hsp90 beta with lysines convert Hsp90 beta to a Hsp90 alpha-like protein. Newly constructed monoclonal antibody, 1G6-D7, against the dual lysine region of secreted Hsp90 alpha inhibits both de novo tumour formation and expansion of already formed tumours in mice. This study suggests an alternative therapeutic approach to target Hsp90 in cancer, that is, the tumour-secreted Hsp90 alpha, instead of the intracellular Hsp90 alpha and Hsp90 beta.	[Zou, M.; Bhatia, A.; Dong, H.; Jayaprakash, P.; Guo, J.; Sahu, D.; Hou, Y.; Tsen, F.; O'Brien, K.; Chen, M.; Woodley, D. T.; Li, W.] Dept Dermatol, Los Angeles, CA USA; [Zou, M.; Bhatia, A.; Dong, H.; Jayaprakash, P.; Guo, J.; Sahu, D.; Hou, Y.; Tsen, F.; O'Brien, K.; Chen, M.; Woodley, D. T.; Li, W.] Norris Comprehens Canc Ctr, Los Angeles, CA USA; [Tong, C.; Ying, Q.] Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, Los Angeles, CA USA; [Tong, C.; Ying, Q.] Dept Cell & Neurobiol, Los Angeles, CA USA; [Situ, A. J.; Schmidt, T.; Ulmer, T. S.] Univ Southern Calif, Keck Med Ctr, Dept Biochem & Mol Biol, Los Angeles, CA USA; [Situ, A. J.; Schmidt, T.; Ulmer, T. S.] Univ Southern Calif, Keck Med Ctr, Zilkha Neurogenet Inst, Los Angeles, CA USA; [Chen, M.; Woodley, D. T.; Li, W.] Greater Los Angeles Vet Affairs Heath Care Syst, Dept Med Res, Los Angeles, CA USA; [Zou, M.; Dong, H.] Southern Med Univ, Nanfang Hosp, Dept Endocrinol & Metab, Guangzhou 510515, Guangdong, Peoples R China	University of Southern California; University of Southern California; Southern Medical University - China	Li, W (corresponding author), Univ Southern Calif, Dept Dermatol, 1441 Eastlake Ave, Los Angeles, CA 90089 USA.	wli@usc.edu		Jayaprakash, Priyamvada/0000-0003-3729-2943	NIH [GM066193, GM067100, AR059853, AR33625]; VA Merit Award [I01 BX002028]; National Cancer Institute [P30CA014089]; NATIONAL CANCER INSTITUTE [P30CA014089] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046538, R01AR033625, R01AR059853] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066193, R01GM067100] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002028] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); VA Merit Award(US Department of Veterans Affairs); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Veterans Affairs(US Department of Veterans Affairs)	This work is supported by NIH grants GM066193, GM067100 and AR059853 (to WL), AR33625 (MC and DTW) and VA Merit Award I01 BX002028 (to DTW). The project described was also supported in part by award number P30CA014089 from the National Cancer Institute (to USC).	ALBRECHTBUEHLER G, 1977, CELL, V11, P395, DOI 10.1016/0092-8674(77)90057-5; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; Chen JS, 2010, J BIOL CHEM, V285, P25458, DOI 10.1074/jbc.M110.139345; Cheng CF, 2008, MOL CELL BIOL, V28, P3344, DOI 10.1128/MCB.01287-07; Cheng CF, 2011, J CLIN INVEST, V121, P4348, DOI 10.1172/JCI46475; Clayton A, 2005, J CELL SCI, V118, P3631, DOI 10.1242/jcs.02494; Devarakonda CV, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1608-z; Dong HM, 2016, SCI REP-UK, V6, DOI 10.1038/srep20605; Drysdale MJ, 2006, CURR OPIN DRUG DISC, V9, P483; El Hamidieh A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042722; Eustace BK, 2004, NAT CELL BIOL, V6, P507, DOI 10.1038/ncb1131; Grad I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015770; Imai T, 2011, P NATL ACAD SCI USA, V108, P16363, DOI 10.1073/pnas.1108372108; Li W, 2004, MOL BIOL CELL, V15, P294, DOI 10.1091/mbc.e03-05-0352; Li W, 2012, BBA-MOL CELL RES, V1823, P730, DOI 10.1016/j.bbamcr.2011.09.009; Liu R, 2013, CLIN CANCER RES, V19, P6802, DOI 10.1158/1078-0432.CCR-13-1106; Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033; McCready J, 2014, CANCERS, V6, P1031, DOI 10.3390/cancers6021031; McCready J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-294; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Neckers L, 2012, CLIN CANCER RES, V18, P64, DOI 10.1158/1078-0432.CCR-11-1000; Nolan KD, 2015, J BIOL CHEM, V290, P8271, DOI 10.1074/jbc.M115.637496; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Sahu D, 2012, MOL BIOL CELL, V23, P602, DOI 10.1091/mbc.E11-06-0575; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shi YK, 2014, CLIN CANCER RES, V20, P6016, DOI 10.1158/1078-0432.CCR-14-0174; Sidera K, 2008, J BIOL CHEM, V283, P2031, DOI 10.1074/jbc.M701803200; Stellas D, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-51; Tsen F, 2013, MOL CELL BIOL, V33, P4947, DOI 10.1128/MCB.00559-13; Tseng D, 2013, P NATL ACAD SCI USA, V110, P11103, DOI 10.1073/pnas.1305569110; Tsutsumi S, 2008, ONCOGENE, V27, P2478, DOI 10.1038/sj.onc.1210897; Tsutsumi S, 2007, CANCER SCI, V98, P1536, DOI 10.1111/j.1349-7006.2007.00561.x; Voss AK, 2000, DEVELOPMENT, V127, P1; Wang XF, 2009, P NATL ACAD SCI USA, V106, P21288, DOI 10.1073/pnas.0908151106; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; WOODLEY DT, 1988, J CELL PHYSIOL, V136, P140, DOI 10.1002/jcp.1041360118; Workman P, 2004, TRENDS MOL MED, V10, P47, DOI 10.1016/j.molmed.2003.12.005; Ye X, 2010, ONCOGENE, V29, P5254, DOI 10.1038/onc.2010.268; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079; Yu X, 2006, CANCER RES, V66, P4795, DOI 10.1158/0008-5472.CAN-05-4579; Zagouri F, 2011, IN VIVO, V25, P669	41	41	41	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2017	36	15					2160	2171		10.1038/onc.2016.375	http://dx.doi.org/10.1038/onc.2016.375			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DK	27721406	hybrid, Green Published, Green Accepted			2022-12-17	WOS:000399782500011
J	Tran, TQ; Lowman, XH; Reid, MA; Mendez-Dorantes, C; Pan, M; Yang, Y; Kong, M				Tran, T. Q.; Lowman, X. H.; Reid, M. A.; Mendez-Dorantes, C.; Pan, M.; Yang, Y.; Kong, M.			Tumor-associated mutant p53 promotes cancer cell survival upon glutamine deprivation through p21 induction	ONCOGENE			English	Article							GAIN-OF-FUNCTION; METABOLIC ADAPTATION; PANCREATIC-CANCER; INHIBITION; DRIVES; MUTATIONS; ARREST; GROWTH; GENES	Cancer cells depend on glutamine to sustain their increased proliferation and manage oxidative stress, yet glutamine is often depleted at tumor sites owing to excessive cellular consumption and poor vascularization. We have previously reported that p53 protein, although a well-known tumor suppressor, can contribute to cancer cell survival and adaptation to low-glutamine conditions. However, the TP53 gene is frequently mutated in tumors, and the role of mutant p53 (mutp53) in response to metabolic stress remains unclear. Here, we demonstrate that tumor-associated mutp53 promotes cancer cell survival upon glutamine deprivation both in vitro and in vivo. Interestingly, cancer cells expressing mutp53 proteins are more resistant to glutamine deprivation than cells with wild-type p53. Depletion of endogenous mutp53 protein in human lymphoma cells leads to cell sensitivity to glutamine withdrawal, whereas expression of mutp53 in p53 null cells results in resistance to glutamine deprivation. Furthermore, we found that mutp53 proteins hyper-transactivate p53-target gene CDKN1A upon glutamine deprivation, thus triggering cell cycle arrest and promoting cell survival. Together, our results reveal an unidentified mechanism by which mutp53 confers oncogenic functions by promoting cancer cell adaptation to metabolic stress.	[Tran, T. Q.; Lowman, X. H.; Reid, M. A.; Mendez-Dorantes, C.; Pan, M.; Yang, Y.; Kong, M.] City Hope Canc Ctr, Dept Canc Biol, Beckman Res Inst, 1500 E Duarte Rd, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Kong, M (corresponding author), City Hope Canc Ctr, Dept Canc Biol, Beckman Res Inst, 1500 E Duarte Rd, Duarte, CA 91010 USA.	mekong@coh.org	Yang, Ying/I-8380-2019	MENDEZ-DORANTES, CARLOS/0000-0002-8190-8568; Reid, Michael/0000-0001-6222-9538	National Institutes of Health (NIH) [R01CA183989]; V Foundation for Cancer Research; NIH/NCI [P30CA33572]; NATIONAL CANCER INSTITUTE [P30CA033572, T32CA186895, R01CA183989] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); V Foundation for Cancer Research; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank members of the Kong laboratory for helpful comments on the manuscript. We also thank Dr Zhaohui Feng (Rutgers University, New Jersey) for the mutp53 constructs. This work was supported by National Institutes of Health (NIH)/R01CA183989 to MK and the V Foundation for Cancer Research to MK. MK is the Pew Scholar in Biomedical Sciences and American Cancer Society Research Scholar (RSG-16-085-01-TBE). Research reported here includes work carried out in Core Facilities, supported by the NIH/NCI under grant number P30CA33572.	Assaily W, 2011, MOL CELL, V44, P491, DOI 10.1016/j.molcel.2011.08.038; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Budanov Andrei V, 2014, Subcell Biochem, V85, P337, DOI 10.1007/978-94-017-9211-0_18; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Campomenosi P, 2001, ONCOGENE, V20, P3573, DOI 10.1038/sj.onc.1204468; Chakrabarti G, 2015, CANCER METAB, V3, DOI 10.1186/s40170-015-0137-1; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; Gross MI, 2014, MOL CANCER THER, V13, P890, DOI 10.1158/1535-7163.MCT-13-0870; HARPER JW, 1993, CELL, V75, P805; Hernandez-Davies JE, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0581-2; Hu WW, 2010, P NATL ACAD SCI USA, V107, P7455, DOI 10.1073/pnas.1001006107; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Kamphorst JJ, 2015, CANCER RES, V75, P544, DOI 10.1158/0008-5472.CAN-14-2211; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Korangath P, 2015, CLIN CANCER RES, V21, P3263, DOI 10.1158/1078-0432.CCR-14-1200; Le A, 2012, CELL METAB, V15, P110, DOI 10.1016/j.cmet.2011.12.009; Lukey MJ, 2013, FUTURE MED CHEM, V5, P1685, DOI 10.4155/fmc.13.130; Maddocks ODK, 2013, NATURE, V493, P542, DOI 10.1038/nature11743; Maddocks ODK, 2011, J MOL MED, V89, P237, DOI 10.1007/s00109-011-0735-5; Mates JM, 2002, INT J BIOCHEM CELL B, V34, P439, DOI 10.1016/S1357-2725(01)00143-1; Mauro C, 2011, NAT CELL BIOL, V13, P1272, DOI 10.1038/ncb2324; Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Reid MA, 2013, MOL CELL, V50, P200, DOI 10.1016/j.molcel.2013.02.008; Resnick MA, 2003, P NATL ACAD SCI USA, V100, P9934, DOI 10.1073/pnas.1633803100; ROBERTS E, 1949, CANCER RES, V9, P350; Robinson MM, 2007, BIOCHEM J, V406, P407, DOI 10.1042/BJ20070039; Rosales KR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145938; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Sen N, 2011, MOL CELL, V44, P621, DOI 10.1016/j.molcel.2011.08.044; Strano S, 2007, ONCOGENE, V26, P2212, DOI 10.1038/sj.onc.1210296; Thangavelu K, 2014, SCI REP-UK, V4, DOI 10.1038/srep03827; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang JB, 2010, CANCER CELL, V18, P207, DOI 10.1016/j.ccr.2010.08.009; Wise DR, 2010, TRENDS BIOCHEM SCI, V35, P427, DOI 10.1016/j.tibs.2010.05.003; Xiang Y, 2015, J CLIN INVEST, V125, P2293, DOI 10.1172/JCI75836; Young VR, 2001, J NUTR, V131, p2449S, DOI 10.1093/jn/131.9.2449S; Zhang C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3935; Zheng TS, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3996; Zhou G, 2014, MOL CELL, V54, P960, DOI 10.1016/j.molcel.2014.04.024	44	41	44	0	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2017	36	14					1991	2001		10.1038/onc.2016.360	http://dx.doi.org/10.1038/onc.2016.360			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ER6EQ	27721412	Green Accepted, Green Submitted			2022-12-17	WOS:000398898500009
J	Safferthal, C; Rohde, K; Fulda, S				Safferthal, C.; Rohde, K.; Fulda, S.			Therapeutic targeting of necroptosis by Smac mimetic bypasses apoptosis resistance in acute myeloid leukemia cells	ONCOGENE			English	Article							ALPHA-DEPENDENT APOPTOSIS; TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; TNF-ALPHA; PHASE-I; DEATH; CANCER; ACTIVATION; EXPRESSION; PATHWAYS	Resistance to apoptosis, for example due to overexpression of Inhibitor of Apoptosis (IAP) proteins, is associated with poor prognosis in acute myeloid leukemia (AML). Here, we identify that Smac mimetics such as BV6, which antagonizes IAP proteins, elicit necroptosis in AML cells, in which apoptosis is inhibited pharmacologically by caspase inhibitors or genetically by caspase-8 knockdown. Importantly, BV6 triggers necroptosis also in apoptosis-resistant patient-derived AML blasts, underlining the clinical relevance of our findings. Mechanistically, we show that BV6-induced cell death depends on key components of necroptosis signaling such as RIP1, RIP3 and MLKL, since pharmacological or genetic inhibition of these proteins significantly protects AML cells from BV6-mediated cell death, whereas PGAM5 is dispensable. Interestingly, we identify constitutive tumor necrosis factor-alpha (TNF alpha) secretion and an autocrine/paracrine TNF alpha loop as critical mediators of BV6-induced necroptosis in AML cell lines and patient-derived blasts, as the TNF alpha-blocking antibody Enbrel or tumor necrosis factor-alpha receptor 1 (TNFR1) knockdown significantly rescue cell death. Notably, AML cells exhibit high basal levels of TNF alpha compared to non-malignant CD34+ cells, which is further increased by BV6. In conclusion, this is the first report showing that Smac mimetics circumvent apoptosis resistance in AML cells by inducing necroptosis in a TNF alpha- dependent manner, which has important implications for the development of new strategies to overcome treatment resistance in AML.	[Safferthal, C.; Rohde, K.; Fulda, S.] Goethe Univ, Inst Expt Canc Res Pediat, Komturstr 3a, D-60528 Frankfurt, Hesse, Germany; [Fulda, S.] German Canc Consortium DKTK, Heidelberg, Germany; [Fulda, S.] German Canc Res Ctr, Heidelberg, Germany	Goethe University Frankfurt; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Fulda, S (corresponding author), Goethe Univ, Inst Expt Canc Res Pediat, Komturstr 3a, D-60528 Frankfurt, Hesse, Germany.	simone.fulda@kgu.de		Fulda, Simone/0000-0002-0459-6417	BMBF (German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ)) [CI3 131A029B]; IUAP VII	BMBF (German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ)); IUAP VII	We thank X Wang (Beijing, China) for kindly providing PGAM5 antibody and C Hugenberg for expert secretarial assistance. This work has been partially supported by grants from the BMBF (German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) and CI3 131A029B), IUAP VII (to SF).	Belz K, 2014, BLOOD, V124, P240, DOI 10.1182/blood-2013-05-500918; Bertrand MJM, 2008, MOL CELL, V30, P689, DOI 10.1016/j.molcel.2008.05.014; Bullinger L, 2007, BLOOD, V110, P1291, DOI 10.1182/blood-2006-10-049783; Carter BZ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt440; Cho Y, 2009, CELL, V137, P1112, DOI 10.1016/j.cell.2009.05.037; Chromik J, 2014, CANCER LETT, V344, P101, DOI 10.1016/j.canlet.2013.10.018; Chu WM, 2013, CANCER LETT, V328, P222, DOI 10.1016/j.canlet.2012.10.014; DiPersio JF, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.7029; Estey E, 2006, LANCET, V368, P1894, DOI 10.1016/S0140-6736(06)69780-8; Fakler M, 2009, BLOOD, V113, P1710, DOI 10.1182/blood-2007-09-114314; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Fulda S, 2012, LEUKEMIA, V26, P1155, DOI 10.1038/leu.2012.4; Fulda S, 2000, BLOOD, V95, P301, DOI 10.1182/blood.V95.1.301.001k24_301_308; Fulda S, 2015, CLIN CANCER RES, V21, P5030, DOI 10.1158/1078-0432.CCR-15-0365; Fulda S, 2012, NAT REV DRUG DISCOV, V11, P109, DOI 10.1038/nrd3627; He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021; Hess CJ, 2007, J CLIN ONCOL, V25, P1209, DOI 10.1200/JCO.2006.08.4061; Infante JR, 2014, J CLIN ONCOL, V32, P3103, DOI 10.1200/JCO.2013.52.3993; Lalaoui N, 2016, CANCER CELL, V29, P145, DOI 10.1016/j.ccell.2016.01.006; Laukens B, 2011, NEOPLASIA, V13, P971, DOI 10.1593/neo.11610; Moriwaki K, 2016, J IMMUNOL, V196, P407, DOI 10.4049/jimmunol.1501662; Oberst A, 2011, NATURE, V471, P363, DOI 10.1038/nature09852; Petersen SL, 2007, CANCER CELL, V12, P445, DOI 10.1016/j.ccr.2007.08.029; Schenk B, 2015, ONCOGENE, V34, P5796, DOI 10.1038/onc.2015.35; Servida F, 2011, INVEST NEW DRUG, V29, P1264, DOI 10.1007/s10637-010-9475-6; Steinhart L, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.320; Steinwascher S, 2015, CANCER LETT, V366, P32, DOI 10.1016/j.canlet.2015.05.020; Tamm I, 2000, CLIN CANCER RES, V6, P1796; Tamm I, 2004, HEMATOL J, V5, P489, DOI 10.1038/sj.thj.6200549; Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312; Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970; Varfolomeev E, 2007, CELL, V131, P669, DOI 10.1016/j.cell.2007.10.030; Vince JE, 2007, CELL, V131, P682, DOI 10.1016/j.cell.2007.10.037; Volk A, 2014, J EXP MED, V211, P1093, DOI 10.1084/jem.20130990; Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036; Wang ZG, 2012, CELL, V148, P228, DOI 10.1016/j.cell.2011.11.030; Weisberg E, 2010, LEUKEMIA, V24, P2100, DOI 10.1038/leu.2010.212; Weisberg E, 2007, MOL CANCER THER, V6, P1951, DOI 10.1158/1535-7163.MCT-06-0810; Zhang DW, 2009, SCIENCE, V325, P332, DOI 10.1126/science.1172308	39	41	43	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	11					1487	1502		10.1038/onc.2016.310	http://dx.doi.org/10.1038/onc.2016.310			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP5ZR	27869161				2022-12-17	WOS:000397458100004
J	Zeng, Q; Chen, J; Li, Y; Werle, KD; Zhao, RX; Quan, CS; Wang, YS; Zhai, YX; Wang, JW; Youssef, M; Cui, R; Liang, J; Genovese, N; Chow, LT; Li, YL; Xu, ZX				Zeng, Q.; Chen, J.; Li, Y.; Werle, K. D.; Zhao, R-X; Quan, C-S; Wang, Y-S; Zhai, Y-X; Wang, J-W; Youssef, M.; Cui, R.; Liang, J.; Genovese, N.; Chow, L. T.; Li, Y-L; Xu, Z-X			LKB1 inhibits HPV-associated cancer progression by targeting cellular metabolism	ONCOGENE			English	Article							HUMAN-PAPILLOMAVIRUS; CERVICAL-CANCER; HEXOKINASE II; TUMOR INITIATION; LUNG-CANCER; ONCOPROTEIN; PATHWAYS; GROWTH; ROS; IDENTIFICATION	Liver kinase B1 (LKB1) is mutationally inactivated in Peutz-Jeghers syndrome and in a variety of cancers including human papillomavirus (HPV)-caused cervical cancer. However, the significance of LKB1 mutations in cervical cancer initiation and progress has not been examined. Herein, we demonstrated that, in mouse embryonic fibroblasts, loss of LKB1 and transduction of HPV16 E6/E7 had an additive effect on constraining cell senescence while promoting cell proliferation and increasing glucose consumption, lactate production and ATP generation. Knockdown of LKB1 increased and ectopic expression of LKB1 decreased glycolysis, anchorage-independent cell growth, and cell migration and invasion in HPV-transformed cells. In the tumorigenesis and lung metastasis model in syngeneic mice, depletion of LKB1 markedly increased tumor metastatic colonies in lungs without affecting subcutaneous tumor growth. We showed that HPV16 E6/E7 enhanced the expression of hexokinase-II (HK-II) in the glycolytic pathway through elevated c-MYC. Ectopic LKB1 reduced HK-II along with glycolysis. The inverse relationship between HK-II and LKB1 was also observed in normal and HPV-associated cervical lesions. We propose that LKB1 acts as a safeguard against HPV-stimulated aerobic glycolysis and tumor progression. These findings may eventually aid in the development of therapeutic strategy for HPV-associated malignancies by targeting cell metabolism.	[Zeng, Q.; Quan, C-S; Wang, Y-S; Zhai, Y-X; Wang, J-W; Li, Y-L; Xu, Z-X] Jilin Univ, Norman Bethune Coll Med, Minist Educ, Key Lab Pathobiol, 126 Xin Min Ave, Changchun, Peoples R China; [Zeng, Q.; Chen, J.; Li, Y.; Werle, K. D.; Zhao, R-X; Youssef, M.; Xu, Z-X] Univ Alabama Birmingham, Comprehens Canc Ctr, Div Hematol & Oncol, Birmingham, AL USA; [Cui, R.] Boston Univ, Sch Med, Dept Dermatol, Boston, MA USA; [Liang, J.] UT MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX USA; [Genovese, N.; Chow, L. T.] Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL USA	Jilin University; University of Alabama System; University of Alabama Birmingham; Boston University; University of Texas System; UTMD Anderson Cancer Center; University of Alabama System; University of Alabama Birmingham	Li, YL; Xu, ZX (corresponding author), Jilin Univ, Norman Bethune Coll Med, Minist Educ, Key Lab Pathobiol, 126 Xin Min Ave, Changchun, Peoples R China.; Chow, LT (corresponding author), Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL USA.	ltchow@uab.edu; ylli@jlu.edu.cn; zhixiangxu08@gmail.com			National Cancer Institute [R01CA133053, R01CA83679]; UAB Comprehensive Cancer Center Pilot Program Project [IRG-60-001-50]; National Natural Science Foundation of China [81271853, 81272243, 81573087]; National 863 Program of China [2004AA205020]; NATIONAL CANCER INSTITUTE [R01CA133053, P30CA013148, R01CA083679] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); UAB Comprehensive Cancer Center Pilot Program Project; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National 863 Program of China(National High Technology Research and Development Program of China); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from National Cancer Institute R01CA133053, R01CA83679, and the UAB Comprehensive Cancer Center Pilot Program Project IRG-60-001-50. The work was also supported by the National Natural Science Foundation of China Nos 81271853, 81272243 and 81573087, and the National 863 Program of China No. 2004AA205020.	Altman BJ, 2015, CELL METAB, V22, P1009, DOI 10.1016/j.cmet.2015.09.003; Andrade-Vieira R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056567; Anflous-Pharayra K, 2007, BBA-BIOENERGETICS, V1767, P136, DOI 10.1016/j.bbabio.2006.11.013; Arbyn M, 2011, ANN ONCOL, V22, P2675, DOI 10.1093/annonc/mdr015; AYRE HA, 1966, BRIT J CANCER, V20, P743, DOI 10.1038/bjc.1966.85; Balko JM, 2012, NAT MED, V18, P1052, DOI 10.1038/nm.2795; Bardeesy N, 2002, NATURE, V419, P162, DOI 10.1038/nature01045; Boroughs LK, 2015, NAT CELL BIOL, V17, P351, DOI 10.1038/ncb3124; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Carretero J, 2010, CANCER CELL, V17, P547, DOI 10.1016/j.ccr.2010.04.026; Cheung EC, 2012, P NATL ACAD SCI USA, V109, P20491, DOI 10.1073/pnas.1206530109; Dendele B, 2012, TOXICOL IN VITRO, V26, P94, DOI 10.1016/j.tiv.2011.11.001; Dorr JR, 2013, NATURE, V501, P421, DOI 10.1038/nature12437; Dupuy F, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-18; Faubert B, 2014, P NATL ACAD SCI USA, V111, P2554, DOI 10.1073/pnas.1312570111; Gabay M, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014241; Galloway DA, 2015, CURR OPIN VIROL, V14, P87, DOI 10.1016/j.coviro.2015.09.001; Hardie DG, 2014, J INTERN MED, V276, P543, DOI 10.1111/joim.12268; Hardie DG, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-36; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Ji HX, 1998, INT J CANCER, V78, P41, DOI 10.1002/(SICI)1097-0215(19980925)78:1<41::AID-IJC8>3.3.CO;2-K; John S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017674; Kaplon J, 2013, NATURE, V498, P109, DOI 10.1038/nature12154; Liu WJ, 2012, CANCER CELL, V21, P751, DOI 10.1016/j.ccr.2012.03.048; Lu ZM, 2004, J BIOL CHEM, V279, P35664, DOI 10.1074/jbc.M403385200; Mack HID, 2013, VIROLOGY, V446, P9, DOI 10.1016/j.virol.2013.07.009; Mathupala SP, 2001, J BIOL CHEM, V276, P43407, DOI 10.1074/jbc.M108181200; Mazurek S, 2001, BIOCHEM J, V356, P247, DOI 10.1042/0264-6021:3560247; McCabe MT, 2010, CANCER GENET CYTOGEN, V197, P130, DOI 10.1016/j.cancergencyto.2009.11.017; McLaughlin-Drubin ME, 2009, VIRUS RES, V143, P195, DOI 10.1016/j.virusres.2009.06.008; Mohseni M, 2014, NAT CELL BIOL, V16, P108, DOI 10.1038/ncb2884; Moody CA, 2010, NAT REV CANCER, V10, P550, DOI 10.1038/nrc2886; Ojesina AI, 2014, NATURE, V506, P371, DOI 10.1038/nature12881; Partanen JI, 2007, P NATL ACAD SCI USA, V104, P14694, DOI 10.1073/pnas.0704677104; Patra KC, 2013, CANCER CELL, V24, P213, DOI 10.1016/j.ccr.2013.06.014; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Psyrri A, 2008, NAT CLIN PRACT ONCOL, V5, P24, DOI 10.1038/ncponc0984; Roberts DJ, 2015, CELL DEATH DIFFER, V22, P248, DOI 10.1038/cdd.2014.173; Salama R, 2014, GENE DEV, V28, P99, DOI 10.1101/gad.235184.113; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Shackelford DB, 2013, CANCER CELL, V23, P143, DOI 10.1016/j.ccr.2012.12.008; Shackelford DB, 2009, P NATL ACAD SCI USA, V106, P11137, DOI 10.1073/pnas.0900465106; Spangle JM, 2010, J VIROL, V84, P9398, DOI 10.1128/JVI.00974-10; Walenta S, 2000, CANCER RES, V60, P916; Wingo SN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005137; Wolf A, 2011, J EXP MED, V208, P313, DOI 10.1084/jem.20101470; Wu RX, 2012, EMBO MOL MED, V4, P633, DOI 10.1002/emmm.201200240; Xiao XX, 2012, GYNECOL ONCOL, V127, P249, DOI 10.1016/j.ygyno.2012.06.032; Xu HG, 2015, ONCOGENE, V34, P3848, DOI 10.1038/onc.2014.315; Yuan P, 2013, P NATL ACAD SCI USA, V110, P18226, DOI 10.1073/pnas.1317577110; Zeng QH, 2016, P NATL ACAD SCI USA, V113, P9333, DOI 10.1073/pnas.1606801113; Zheng L, 2008, GENES CELLS, V13, P285, DOI 10.1111/j.1365-2443.2008.01162.x; zur Hausen H, 2009, VIROLOGY, V384, P260, DOI 10.1016/j.virol.2008.11.046; Zwerschke W, 1999, P NATL ACAD SCI USA, V96, P1291, DOI 10.1073/pnas.96.4.1291	55	41	44	2	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	9					1245	1255		10.1038/onc.2016.290	http://dx.doi.org/10.1038/onc.2016.290			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2SV	27546620	Green Accepted			2022-12-17	WOS:000395861300008
J	Pan, Y; Wang, S; Su, B; Zhou, F; Zhang, R; Xu, T; Zhang, R; Leventaki, V; Drakos, E; Liu, W; Claret, FX				Pan, Y.; Wang, S.; Su, B.; Zhou, F.; Zhang, R.; Xu, T.; Zhang, R.; Leventaki, V.; Drakos, E.; Liu, W.; Claret, F. X.			Stat3 contributes to cancer progression by regulating Jab1/Csn5 expression	ONCOGENE			English	Article							DOMAIN-BINDING PROTEIN-1; NASOPHARYNGEAL CARCINOMA; SIGNAL TRANSDUCER; CONSTITUTIVE ACTIVATION; MOLECULAR TARGETS; DNA-DAMAGE; GROWTH; P27(KIP1); APOPTOSIS; RADIOTHERAPY	Our previous studies demonstrated that Jab1/Csn5 overexpression is correlated with low survival rates in cancer patients, including nasopharyngeal carcinoma (NPC), breast cancer and hepatocellular carcinoma, and contributes to NPC's resistance to radiotherapy and cisplatin by regulating DNA damage and repair pathways. However, the molecular mechanism by which Jab1/Csn5 expression is upregulated in NPCs has yet to be determined. In the present study, we identified the upstream regulator of Jab1/Csn5 expression and demonstrated its role in intrinsic resistance of NPC cells to treatment with cisplatin. Signal transducer and activator of transcription-3 (Stat3) expression correlates with and contributes to Jab1/Csn5 transcription. Consistently, silencing of Stat3 in tumors reduced Jab1/Csn5 expression, thereby sensitizing NPC cells to cisplatin-induced apoptosis both in vitro and in vivo. Mechanistically, Stat3 transcriptionally regulated Jab1/Csn5. Furthermore, high mRNA expression levels of Stat3 or Jab1 in colon cancer, breast cancer and glioblastoma are associated with significantly shorter survival times from the R2 online database. These findings identify a novel Stat3-Jab1/Csn5 signaling axis in cancer pathogenesis with therapeutic and prognostic relevance.	[Pan, Y.] Jiangnan Univ, Affiliated Hosp, Sch Med, Dept Pathol, Wuxi, Peoples R China; [Pan, Y.; Wang, S.; Su, B.; Zhang, R.; Xu, T.; Claret, F. X.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, 7435 Fannin St Unit 950, Houston, TX 77030 USA; [Wang, S.] Guangdong Prov Hosp Chinese Med, Dept Oncol, Guangzhou, Guangdong, Peoples R China; [Zhou, F.] Wuhan Univ, Zhongnan Hosp, Dept Hematol, Wuhan, Peoples R China; [Zhang, R.] Sun Yat Sen Univ, Ctr Canc, Dept Endoscopy, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China; [Leventaki, V.; Drakos, E.] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA; [Liu, W.] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Claret, F. X.] Univ Texas Houston, Grad Sch Biomed Sci, Experimental Therapeut Acad Program & Canc Biol P, Houston, TX USA; [Leventaki, V.] St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; [Drakos, E.] Univ Crete, Sch Med, Dept Pathol, Iraklion, Greece	Jiangnan University; University of Texas System; UTMD Anderson Cancer Center; Guangzhou University of Chinese Medicine; Wuhan University; State Key Lab Oncology South China; Sun Yat Sen University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; St Jude Children's Research Hospital; University of Crete	Claret, FX (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, 7435 Fannin St Unit 950, Houston, TX 77030 USA.	fxclaret@mdanderson.org	Claret, Francois X/R-2104-2016; Wang, Sumei/V-2800-2019; Leventaki, Vasiliki/N-8175-2018	Claret, Francois X/0000-0003-4629-6495; Wang, Sumei/0000-0002-2011-4019; Zhou, Fuling/0000-0003-0982-0382; Pan, Yunbao/0000-0002-6311-2945	National Natural Science Foundation of China [81372816]; Fundamental Research Funds for the Central Universities [JUSRP115A31]; NIH [R01CA90853, P30CA016672]; University Cancer Foundation via the Sister Institution Network Fund of The University of Texas MD Anderson Cancer Center; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA090853] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University Cancer Foundation via the Sister Institution Network Fund of The University of Texas MD Anderson Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Kwok-Wai Lo, The Chinese University of Hong Kong for providing EBV-positive NPC cell line C666.1. We thank Markeda Wade in the Department of Scientific Publications at MD Anderson Cancer Center for editing the manuscript. This study was supported by in part by grants from the National Natural Science Foundation of China (81372816), Fundamental Research Funds for the Central Universities (JUSRP115A31), NIH grant R01CA90853, University Cancer Foundation via the Sister Institution Network Fund of The University of Texas MD Anderson Cancer Center and by the NIH award P30CA016672.	Adachi M, 2012, ORAL ONCOL, V48, P1220, DOI 10.1016/j.oraloncology.2012.06.006; Al-Sarraf M, 1998, J CLIN ONCOL, V16, P1310, DOI 10.1200/JCO.1998.16.4.1310; Aoki Y, 2003, BLOOD, V101, P1535, DOI 10.1182/blood-2002-07-2130; Bhardwaj A, 2007, BLOOD, V109, P2293, DOI 10.1182/blood-2006-02-003988; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Buettner R, 2002, CLIN CANCER RES, V8, P945; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Cheng SH, 2000, INT J RADIAT ONCOL, V48, P1323, DOI 10.1016/S0360-3016(00)00779-3; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Fletcher S, 2009, BIOCHEM CELL BIOL, V87, P825, DOI [10.1139/O09-044, 10.1139/o09-044]; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Hsiao JR, 2003, BRIT J CANCER, V89, P344, DOI 10.1038/sj.bjc.6601003; Ji T, 2013, CANCER LETT, V341, P231, DOI 10.1016/j.canlet.2013.08.022; Jing N, 2005, ANTI-CANCER DRUG, V16, P601, DOI 10.1097/00001813-200507000-00002; Kouvaraki MA, 2003, CANCER RES, V63, P2977; Kouvaraki MA, 2006, CANCER RES, V66, P8581, DOI 10.1158/0008-5472.CAN-06-0975; Liu YP, 2008, INT J MOL MED, V21, P153; Lo AKF, 2006, NEOPLASIA, V8, P173, DOI 10.1593/neo.05625; Lui VWY, 2009, CARCINOGENESIS, V30, P2085, DOI 10.1093/carcin/bgp253; Lui VWY, 2009, INT J CANCER, V125, P1884, DOI 10.1002/ijc.24567; Niu G, 2002, ONCOGENE, V21, P7001, DOI 10.1038/sj.onc.1205859; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Ong YK, 2003, EUR J CANCER, V39, P1535, DOI 10.1016/S0959-8049(03)00310-1; Page BDG, 2011, EXPERT OPIN THER PAT, V21, P65, DOI 10.1517/13543776.2011.539205; Pan Y, 2013, ONCOGENE, V32, P2756, DOI 10.1038/onc.2012.294; Pan YB, 2014, CANCER BIOL THER, V15, P256, DOI 10.4161/cbt.27823; Pan YB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054565; Pan YB, 2012, CANCER LETT, V326, P155, DOI 10.1016/j.canlet.2012.07.033; Pan YB, 2012, CANCER RES, V72, P1890, DOI 10.1158/0008-5472.CAN-11-3472; Rassidakis GZ, 2003, CLIN CANCER RES, V9, P1121; Real PJ, 2002, ONCOGENE, V21, P7611, DOI 10.1038/sj.onc.1206004; Schlessinger K, 2005, CANCER RES, V65, P5828, DOI 10.1158/0008-5472.CAN-05-0317; Shackleford TJ, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2902; Shackleford TJ, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-26; Spano JP, 2003, EUR J CANCER, V39, P2121, DOI 10.1016/S0959-8049(03)00367-8; Steinman RA, 2003, ONCOGENE, V22, P3608, DOI 10.1038/sj.onc.1206523; Sui L, 2001, CLIN CANCER RES, V7, P4130; Vultur A, 2004, ONCOGENE, V23, P2600, DOI 10.1038/sj.onc.1207378; Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976; Weerasinghe P, 2007, INT J ONCOL, V31, P129; Wei WI, 2005, LANCET, V365, P2041, DOI 10.1016/S0140-6736(05)66698-6; Xie TX, 2006, CANCER RES, V66, P3188, DOI 10.1158/0008-5472.CAN-05-2674; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275	43	41	41	0	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2017	36	8					1069	1079		10.1038/onc.2016.271	http://dx.doi.org/10.1038/onc.2016.271			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EM5SA	27524414	Green Accepted			2022-12-17	WOS:000395371500005
J	Meng, Y; Wang, L; Chen, D; Chang, Y; Zhang, M; Xu, JJ; Zhou, R; Zhang, QY				Meng, Y.; Wang, L.; Chen, D.; Chang, Y.; Zhang, M.; Xu, J-J; Zhou, R.; Zhang, Q-Y			LAPTM4B: an oncogene in various solid tumors and its functions	ONCOGENE			English	Review							INDEPENDENT PROGNOSTIC MARKER; GENE POLYMORPHISM; POOR-PROGNOSIS; CANCER SUSCEPTIBILITY; OVEREXPRESSION; CARCINOMA; AUTOPHAGY; METASTASIS; ANGIOGENESIS; ASSOCIATION	The oncogene Lysosome-associated protein transmembrane-4 beta (LAPTM4B) gene was identified, and the polymorphism region in the 5'-UTR of this gene was certified to be associated with tumor susceptibility. LAPTM4B-35 protein was found to be highly expressed in various solid tumors and could be a poor prognosis marker. The functions of LAPTM4B in solid tumors were also explored. It is suggested that LAPTM4B could promote the proliferation of tumor cells, boost invasion and metastasis, resist apoptosis, initiate autophagy and assist drug resistance.	[Meng, Y.; Wang, L.; Chen, D.; Chang, Y.; Zhang, M.; Xu, J-J; Zhang, Q-Y] Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst,Dept Clin Lab, Key Lab Carcinogenesis & Translat Res,Minist Educ, 52 Fucheng Rd, Beijing 100142, Peoples R China; [Zhou, R.] Peking Univ, Sch Basic Med Sci, Dept Cell Biol, Beijing, Peoples R China	Peking University; Peking University	Zhang, QY (corresponding author), Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst,Dept Clin Lab, Key Lab Carcinogenesis & Translat Res,Minist Educ, 52 Fucheng Rd, Beijing 100142, Peoples R China.	zhqy_208@163.com		Meng, Zhang/0000-0003-1653-9230	National Natural Science Foundation of China [81572910]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank all subjects who participated in this study. This work was supported by the National Natural Science Foundation of China (No. 81572910).	Blom T, 2015, NAT CHEM BIOL, V11, P799, DOI [10.1038/NCHEMBIO.1889, 10.1038/nchembio.1889]; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Cheng XJ, 2008, ANN ONCOL, V19, P527, DOI 10.1093/annonc/mdm469; Fan MR, 2012, CANCER EPIDEMIOL, V36, P364, DOI 10.1016/j.canep.2011.12.004; Goldsmith J, 2014, METHOD ENZYMOL, V542, P25, DOI 10.1016/B978-0-12-416618-9.00002-9; Hu GH, 2009, CANCER CELL, V15, P9, DOI 10.1016/j.ccr.2008.11.013; Kadara H, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju004; Kang Y, 2012, AM J SURG, V204, P677, DOI 10.1016/j.amjsurg.2012.02.003; Kasper G, 2005, CANCER LETT, V224, P93, DOI 10.1016/j.canlet.2004.10.004; Lebovitz CB, 2015, AUTOPHAGY, V11, P1668, DOI 10.1080/15548627.2015.1067362; Lee HM, 2010, BLOOD, V116, P720, DOI 10.1182/blood-2009-11-253872; Leone RD, 2013, TRENDS ENDOCRIN MET, V24, P209, DOI 10.1016/j.tem.2013.01.008; Li L, 2010, ONCOGENE, V29, P5785, DOI 10.1038/onc.2010.303; Li X, 2012, ORG MED CHEM LETT, V2, P2, DOI DOI 10.1371/J0URNAL.P0NE.0044916; Li Y, 2011, CANCER RES, V71, P7481, DOI 10.1158/0008-5472.CAN-11-0940; Li Y, 2010, NAT MED, V16, P214, DOI 10.1038/nm.2090; Liu JJ, 2000, J BEIJING MED U, V32, P411; Liu LY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118026; Liu XD, 2009, ENVIRON RES LETT, V4, DOI 10.1088/1748-9326/4/4/045203; Liu Xinrong, 2003, Beijing Da Xue Xue Bao Yi Xue Ban, V35, P340; Liu Y, 2007, ANN ONCOL, V18, P311, DOI 10.1093/annonc/mdl394; Meng FL, 2010, INT J GYNECOL CANCER, V20, P745, DOI 10.1111/IGC.0b013e3181e02f90; Meng FL, 2016, TUMOR BIOL, V37, P4849, DOI 10.1007/s13277-015-4319-9; Meng FL, 2015, CELL PHYSIOL BIOCHEM, V37, P890, DOI 10.1159/000430216; Meng FL, 2013, BIOMARKERS, V18, P136, DOI 10.3109/1354750X.2012.752526; Meng FL, 2011, CANCER-AM CANCER SOC, V117, P2652, DOI 10.1002/cncr.25833; Meng FL, 2010, INT J GYNECOL PATHOL, V29, P587, DOI 10.1097/PGP.0b013e3181e0898e; Milkereit R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8250; Milkereit R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027478; Shaker O, 2015, J MED BIOCHEM, V34, P393, DOI 10.2478/jomb-2014-0067; Shao GZ, 2003, ONCOGENE, V22, P5060, DOI 10.1038/sj.onc.1206832; SUN L, 2007, ZHONG LIU FANG ZHI Y, V4, P245; Tan XJ, 2016, TRENDS CELL BIOL, V26, P352, DOI 10.1016/j.tcb.2015.12.006; Tan XJ, 2015, EMBO J, V34, P475, DOI 10.15252/embj.201489425; Tan XJ, 2015, CELL, V160, P145, DOI 10.1016/j.cell.2014.12.006; Tang H, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0974-8; Tang H, 2014, ONCOL REP, V31, P2454, DOI 10.3892/or.2014.3116; Wang B, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0470-6; Wang S, 2012, ANN ONCOL, V23, P1864, DOI 10.1093/annonc/mdr538; Xia LZ, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-0941-7; Xiao M, 2013, J CANCER RES CLIN, V139, P661, DOI 10.1007/s00432-012-1368-y; Xu Y, 2012, JPN J CLIN ONCOL, V42, P413, DOI 10.1093/jjco/hys026; Xue Shi-Lin, 2007, Zhongguo Shengwu Huaxue yu Fenzi Shengwu Xuebao, V23, P45; Yang H, 2012, MED ONCOL, V29, P2809, DOI 10.1007/s12032-012-0173-4; Yang H, 2010, CANCER LETT, V294, P236, DOI 10.1016/j.canlet.2010.02.006; Yang H, 2010, J SURG ONCOL, V101, P363, DOI 10.1002/jso.21489; Yang H, 2010, J CANCER RES CLIN, V136, P275, DOI 10.1007/s00432-009-0659-4; Yang Y, 2008, ONCOL REP, V20, P1077, DOI 10.3892/or_00000112; Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047; Yin MZ, 2012, INT J GYNECOL CANCER, V22, P54, DOI 10.1097/IGC.0b013e318234f9ac; Yin MZ, 2011, INT J CANCER, V129, P629, DOI 10.1002/ijc.25689; Zhai GJ, 2012, MED ONCOL, V29, P2744, DOI 10.1007/s12032-011-0139-y; Zhang G, 2012, J INT MED RES, V40, P1275, DOI 10.1177/147323001204000406; Zhang H, LAPTM4B 35 PROTEIN P; Zhang HG, 2014, SPRINGER THESES-RECO, P1, DOI [10.1007/978-3-319-07200-5_1, 10.1155/2014/183580]; Zhang HT, 2015, ONCOTARGET, V6, P6092, DOI 10.18632/oncotarget.3341; Zhang M, 2013, MERIT RES J PHARM PH, V1, P1, DOI DOI 10.1371/J0URNAL.P0NE.0057520; Zhang M, 2014, TRANSL ONCOL, V7, P638, DOI 10.1016/j.tranon.2014.07.001; Zhou L, 2008, CANCER LETT, V264, P209, DOI 10.1016/j.canlet.2008.01.025; Zhou L, 2007, EUR J CANCER, V43, P809, DOI 10.1016/j.ejca.2006.10.025; Zhou L, 2011, SURGERY, V150, P25, DOI 10.1016/j.surg.2010.12.010; Zhou L, 2010, AM J SURG, V199, P515, DOI 10.1016/j.amjsurg.2009.03.031	62	41	46	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2016	35	50					6359	6365		10.1038/onc.2016.189	http://dx.doi.org/10.1038/onc.2016.189			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EF3TP	27212036	hybrid, Green Published			2022-12-17	WOS:000390247600001
J	Zhou, R; Curry, JM; Roy, LD; Grover, P; Haider, J; Moore, LJ; Wu, ST; Kamesh, A; Yazdanifar, M; Ahrens, WA; Leung, T; Mukherjee, P				Zhou, R.; Curry, J. M.; Roy, L. D.; Grover, P.; Haider, J.; Moore, L. J.; Wu, S-t; Kamesh, A.; Yazdanifar, M.; Ahrens, W. A.; Leung, T.; Mukherjee, P.			A novel association of neuropilin-1 and MUC1 in pancreatic ductal adenocarcinoma: role in induction of VEGF signaling and angiogenesis	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; ADVANCED SOLID TUMORS; CANCER STEM-CELLS; TYROSINE KINASE; FACTOR RECEPTOR; IN-VITRO; EXPRESSION; PROGRESSION; MICE; TRANSDUCTION	We report that Mucin1 (MUC1), a transmembrane glycoprotein that is overexpressed in >80% of pancreatic ductal adenocarcinoma (PDA), induced a pro-angiogenic tumor microenvironment by increasing the levels of neuropilin-1 (NRP1, a co-receptor of vascular endothelial growth factor (VEGF)) and its ligand VEGF. Expression of tumor-associated MUC1 (tMUC1) positively correlated with NRP1 levels in human and mouse PDA. Further, tMUC1(hi) PDA cells secreted high levels of VEGF and expressed high levels of VEGF receptor 2 (VEGFR2) and its phosphorylated forms as compared with tMUC1(low/null) PDA. This enabled the tMUC1(hi)/NRP1(hi) PDA cells to (a) induce endothelial cell tube formation, (b) generate long ectopic blood vessels and (c) enhance distant metastasis in a zebrafish xenograft model. Concurrently, the proteins associated with epithelial-to-mesenchymal transition, N-cadherin and Vimentin, were highly induced in these tMUC1/NRP1(hi) PDA cells. Hence, blocking signaling via the NRP1-VEGF axis significantly reduced tube formation, new vessel generation and metastasis induced by tMUC1(hi) PDA cells. Finally, we show that blocking the interaction between VEGF(165) and NRP1 with a NRP1 antagonist significantly reduced VEGFR signaling and PDA tumor growth in vivo. Taken together, our data suggest a novel molecular mechanism by which tMUC1 may modulate NRP1-dependent VEGFR signaling in PDA cells.	[Zhou, R.; Curry, J. M.; Roy, L. D.; Grover, P.; Moore, L. J.; Wu, S-t; Kamesh, A.; Yazdanifar, M.; Mukherjee, P.] Univ N Carolina, Dept Biol Sci, 9201 Univ City Blvd, Charlotte, NC 28223 USA; [Haider, J.; Leung, T.] North Carolina Cent Univ, Julius L Chambers Biomed Biotechnol Res Inst, Kannapolis, NC USA; [Ahrens, W. A.] Carolinas Med Ctr, Dept Surg, Sect Hepatobiliary & Pancreas Surg, Charlotte, NC 28203 USA	University of North Carolina; University of North Carolina Charlotte; University of North Carolina; North Carolina Central University; Carolinas Medical Center	Mukherjee, P (corresponding author), Univ N Carolina, Dept Biol Sci, 9201 Univ City Blvd, Charlotte, NC 28223 USA.	pmukherj@uncc.edu			NIH [CA118944-01A1, CA173668-01]; Office of the Assistant Secretary of Defense for Health Affairs through the Pancreatic Cancer Research Program [W81XWH-12-1-0220]; NATIONAL CANCER INSTITUTE [R15CA173668, R03CA110832, R01CA118944] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Office of the Assistant Secretary of Defense for Health Affairs through the Pancreatic Cancer Research Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by NIH CA118944-01A1 and NIH CA173668-01. This work was also supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Pancreatic Cancer Research Program under Award No. W81XWH-12-1-0220. Opinions, interpretations, conclusions, and recommendations are those of the author and are not necessarily endorsed by the Department of Defense. We thank Dr Tim D Eubank (Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA) for the valuable support with angiogenesis study. We thank Dr Lloye Dillon (OncoTAB, Inc., Charlotte, NC, USA) for the critical review of the manuscript. We thank all the technicians in the animal facility for their assistance in maintaining our colonies.	Adham SAI, 2014, J HISTOCHEM CYTOCHEM, V62, P619, DOI 10.1369/0022155414538821; Bagri A, 2009, CLIN CANCER RES, V15, P1860, DOI 10.1158/1078-0432.CCR-08-0563; Beck B, 2011, NATURE, V478, P399, DOI 10.1038/nature10525; Bernatchez PN, 1999, J BIOL CHEM, V274, P31047, DOI 10.1074/jbc.274.43.31047; Besmer DM, 2011, CANCER RES, V71, P4432, DOI 10.1158/0008-5472.CAN-10-4439; Bielenberg DR, 2006, EXP CELL RES, V312, P584, DOI 10.1016/j.yexcr.2005.11.024; Binetruy-Tournaire R, 2000, EMBO J, V19, P1525, DOI 10.1093/emboj/19.7.1525; Bruder D, 2004, EUR J IMMUNOL, V34, P623, DOI 10.1002/eji.200324799; Chang BW, 2010, J PANCREAS, V11, P313; Curry JM, 2013, J SURG ONCOL, V107, P713, DOI 10.1002/jso.23316; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Guidolin D, 2004, MICROVASC RES, V67, P117, DOI 10.1016/j.mvr.2003.11.002; Hamerlik P, 2012, J EXP MED, V209, P507, DOI 10.1084/jem.20111424; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Hess-Stumpp H, 2005, CHEMBIOCHEM, V6, P550, DOI 10.1002/cbic.200400305; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; LAN MS, 1990, J BIOL CHEM, V265, P15294; Latil A, 2000, INT J CANCER, V89, P167, DOI 10.1002/(SICI)1097-0215(20000320)89:2<167::AID-IJC11>3.0.CO;2-9; Lau SK, 2004, AM J CLIN PATHOL, V122, P61, DOI 10.1309/9R6673QEC06D86Y4; Mak P, 2010, CANCER CELL, V17, P319, DOI 10.1016/j.ccr.2010.02.030; Miao HQ, 2000, FASEB J, V14, P2532, DOI 10.1096/fj.00-0250com; Moshal Karni S, 2011, Cancers (Basel), V3, P4102, DOI 10.3390/cancers3044102; Moshal KS, 2010, TRENDS CARDIOVAS MED, V20, P114, DOI 10.1016/j.tcm.2010.10.001; Nath S, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.16; PAJUSOLA K, 1992, CANCER RES, V52, P5738; Pan Q, 2007, CANCER CELL, V11, P53, DOI 10.1016/j.ccr.2006.10.018; Parikh AA, 2003, CANCER, V98, P720, DOI 10.1002/cncr.11560; PARK JE, 1994, J BIOL CHEM, V269, P25646; Patnaik A, 2014, CANCER CHEMOTH PHARM, V73, P951, DOI 10.1007/s00280-014-2426-8; Pellet-Many C, 2008, BIOCHEM J, V411, P211, DOI 10.1042/BJ20071639; Prud'homme GJ, 2012, ONCOTARGET, V3, P921, DOI 10.18632/oncotarget.626; Prud'homme GJ, 2012, CURR PHARM DESIGN, V18, P2838; Robinson CJ, 2001, J CELL SCI, V114, P853; Roskoski R, 2007, CRIT REV ONCOL HEMAT, V62, P179, DOI 10.1016/j.critrevonc.2007.01.006; Roy LD, 2011, ONCOGENE, V30, P1449, DOI 10.1038/onc.2010.526; Sahraei M, 2012, ONCOGENE, V31, P4935, DOI 10.1038/onc.2011.651; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; SEETHARAM L, 1995, ONCOGENE, V10, P135; Shibuya M, 2006, EXP CELL RES, V312, P549, DOI 10.1016/j.yexcr.2005.11.012; Solorzano CC, 2001, CANCER BIOTHER RADIO, V16, P359, DOI 10.1089/108497801753354267; SPICER AP, 1995, J BIOL CHEM, V270, P30093; Starzec A, 2006, LIFE SCI, V79, P2370, DOI 10.1016/j.lfs.2006.08.005; Staton CA, 2007, J PATHOL, V212, P237, DOI 10.1002/path.2182; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Tinder TL, 2008, J IMMUNOL, V181, P3116, DOI 10.4049/jimmunol.181.5.3116; Tordjman R, 2002, NAT IMMUNOL, V3, P477, DOI 10.1038/ni789; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Weekes CD, 2014, INVEST NEW DRUG, V32, P653, DOI 10.1007/s10637-014-0071-z; Whittle C, 1999, CLIN SCI, V97, P303, DOI 10.1042/CS19990016; Wild JRL, 2012, INT J EXP PATHOL, V93, P81, DOI 10.1111/j.1365-2613.2012.00810.x; Woo JK, 2012, ONCOGENE, V31, P2187, DOI 10.1038/onc.2011.410; Xin Y, 2012, CLIN CANCER RES, V18, P6040, DOI 10.1158/1078-0432.CCR-12-1652	53	41	44	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2016	35	43					5608	5618		10.1038/onc.2015.516	http://dx.doi.org/10.1038/onc.2015.516			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XP	26804176	Green Accepted			2022-12-17	WOS:000386998300004
J	Vaidyanathan, S; Cato, K; Tang, L; Pavey, S; Haass, NK; Gabrielli, BG; Duijf, PHG				Vaidyanathan, S.; Cato, K.; Tang, L.; Pavey, S.; Haass, N. K.; Gabrielli, B. G.; Duijf, P. H. G.			In vivo overexpression of Emi1 promotes chromosome instability and tumorigenesis	ONCOGENE			English	Article							GENE-EXPRESSION; CELL-CYCLE; CANCER; ANEUPLOIDY; COMPLEX/CYCLOSOME; P53; PROGRESSION; INHIBITOR; ORIGIN; LEADS	Cell cycle genes are often aberrantly expressed in cancer, but how their misexpression drives tumorigenesis mostly remains unclear. From S phase to early mitosis, EMI1 (also known as FBXO5) inhibits the anaphase-promoting complex/ cyclosome, which controls cell cycle progression through the sequential degradation of various substrates. By analyzing 7403 human tumor samples, we find that EMI1 overexpression is widespread in solid tumors but not in blood cancers. In solid cancers, EMI1 overexpression is a strong prognostic marker for poor patient outcome. To investigate causality, we generated a transgenic mouse model in which we overexpressed Emi1. Emi1-overexpressing animals develop a wide variety of solid tumors, in particular adenomas and carcinomas with inflammation and lymphocyte infiltration, but not blood cancers. These tumors are significantly larger and more penetrant, abundant, proliferative and metastatic than control tumors. In addition, they are highly aneuploid with tumor cells frequently being in early mitosis and showing mitotic abnormalities, including lagging and incorrectly segregating chromosomes. We further demonstrate in vitro that even though EMI1 overexpression may cause mitotic arrest and cell death, it also promotes chromosome instability (CIN) following delayed chromosome alignment and anaphase onset. In human solid tumors, EMI1 is co-expressed with many markers for CIN and EMI1 overexpression is a stronger marker for CIN than most well-established ones. The fact that Emi1 overexpression promotes CIN and the formation of solid cancers in vivo indicates that Emi1 overexpression actively drives solid tumorigenesis. These novel mechanistic insights have important clinical implications.	[Vaidyanathan, S.; Cato, K.; Tang, L.; Pavey, S.; Haass, N. K.; Gabrielli, B. G.; Duijf, P. H. G.] Univ Queensland, Translat Res Inst, Diamantina Inst, 37 Kent St, Brisbane, Qld 4102, Australia; [Tang, L.] Fudan Univ, Sch Basic Med Sci, Shanghai, Peoples R China	University of Queensland; Fudan University	Duijf, PHG (corresponding author), Univ Queensland, Translat Res Inst, Diamantina Inst, 37 Kent St, Brisbane, Qld 4102, Australia.	p.duijf@uq.edu.au	Haass, Nikolas K/M-8507-2015; Gabrielli, Brian/B-3655-2011; Duijf, Pascal/E-7110-2012	Haass, Nikolas K/0000-0002-3928-5360; Gabrielli, Brian/0000-0003-3933-1651; Duijf, Pascal/0000-0001-8646-9843; vaidyanathan, srividya/0000-0003-3931-5942	IPRS; University of Queensland (UQ) Centennial Scholarships; UQ Diamantina Institute; UQ; National Breast Cancer Foundation; National Breast Cancer Foundation [ECF-14-008] Funding Source: researchfish	IPRS; University of Queensland (UQ) Centennial Scholarships; UQ Diamantina Institute; UQ; National Breast Cancer Foundation; National Breast Cancer Foundation	We thank Robert Benezra for support, Kym French for animal husbandry, Andrew Brooks for plasmids, Sandrine Roy, Ali Ju, Loredana Spoerri, Yvette Chin and Nicole Chee for technical assistance, Kim-Anh Le Cao for statistical advice, Marianna Datseris for general support and Pulari Thangavelu and Mehlika Hazar-Rethinam for critically reading the manuscript. This work was supported by IPRS and University of Queensland (UQ) Centennial Scholarships (to SV), grants from UQ Diamantina Institute and UQ and a Career Development Fellowship from the National Breast Cancer Foundation (to PHGD).	Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Birkbak NJ, 2011, CANCER RES, V71, P3447, DOI 10.1158/0008-5472.CAN-10-3667; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; DETRE S, 1995, J CLIN PATHOL, V48, P876, DOI 10.1136/jcp.48.9.876; Dexter TJ, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-127; Di Fiore B, 2007, J CELL BIOL, V177, P425, DOI 10.1083/jcb.200611166; Duijf PHG, 2013, ONCOGENE, V32, P4727, DOI 10.1038/onc.2012.616; Duijf PHG, 2013, INT J CANCER, V132, P2316, DOI 10.1002/ijc.27924; Foijer F, 2008, BBA-REV CANCER, V1786, P73, DOI 10.1016/j.bbcan.2008.07.004; Frye JJ, 2013, NAT STRUCT MOL BIOL, V20, P827, DOI 10.1038/nsmb.2593; GALEA MH, 1992, BREAST CANCER RES TR, V22, P207, DOI 10.1007/BF01840834; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Harris TJR, 2010, NAT REV CLIN ONCOL, V7, P251, DOI 10.1038/nrclinonc.2010.41; Holland AJ, 2012, EMBO REP, V13, P501, DOI 10.1038/embor.2012.55; Hsu JY, 2002, NAT CELL BIOL, V4, P358, DOI 10.1038/ncb785; Janssen A, 2009, P NATL ACAD SCI USA, V106, P19108, DOI 10.1073/pnas.0904343106; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lee H, 2006, MOL CELL BIOL, V26, P5373, DOI 10.1128/MCB.00043-06; Lehman NL, 2007, AM J PATHOL, V170, P1793, DOI 10.2353/ajpath.2007.060767; Machida YJ, 2007, GENE DEV, V21, P184, DOI 10.1101/gad.1495007; Malumbres M, 2011, CANCER CELL, V19, P691, DOI 10.1016/j.ccr.2011.05.023; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Manning AL, 2014, ONCOGENE, V33, P2487, DOI 10.1038/onc.2013.201; Margottin-Goguet F, 2003, DEV CELL, V4, P813, DOI 10.1016/S1534-5807(03)00153-9; Miller JJ, 2006, GENE DEV, V20, P2410, DOI 10.1101/gad.1454006; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Neelsen KJ, 2013, GENE DEV, V27, P2537, DOI 10.1101/gad.226373.113; Network TCGAR, 2014, NATURE, V511, P1; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Perez de Castro I, 2007, CARCINOGENESIS, V28, P899, DOI 10.1093/carcin/bgm019; Pfau SJ, 2012, EMBO REP, V13, P515, DOI 10.1038/embor.2012.65; Ravdin PM, 2001, J CLIN ONCOL, V19, P980, DOI 10.1200/JCO.2001.19.4.980; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Ricke RM, 2013, J CELL BIOL, V201, P11, DOI 10.1083/jcb.201301061; Robu ME, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047658; RUSSELL PJ, 1986, CANCER RES, V46, P2035; Schvartzman JM, 2011, CANCER CELL, V19, P701, DOI 10.1016/j.ccr.2011.04.017; Sotillo R, 2010, NATURE, V464, P436, DOI 10.1038/nature08803; Swanton C, 2009, P NATL ACAD SCI USA, V106, P8671, DOI 10.1073/pnas.0811835106; Teixeira LK, 2013, ANNU REV BIOCHEM, V82, P387, DOI 10.1146/annurev-biochem-060410-105307; Verschuren EW, 2007, MOL CELL BIOL, V27, P7955, DOI 10.1128/MCB.00908-07; Wang WP, 2013, NAT CELL BIOL, V15, P797, DOI 10.1038/ncb2755; Weaver BAA, 2007, CANCER RES, V67, P10103, DOI 10.1158/0008-5472.CAN-07-2266	48	41	41	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2016	35	41					5446	5455		10.1038/onc.2016.94	http://dx.doi.org/10.1038/onc.2016.94			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA5QU	27065322				2022-12-17	WOS:000386677800010
J	Sakurai, T; Isogaya, K; Sakai, S; Morikawa, M; Morishita, Y; Ehata, S; Miyazono, K; Koinuma, D				Sakurai, T.; Isogaya, K.; Sakai, S.; Morikawa, M.; Morishita, Y.; Ehata, S.; Miyazono, K.; Koinuma, D.			RNA-binding motif protein 47 inhibits Nrf2 activity to suppress tumor growth in lung adenocarcinoma	ONCOGENE			English	Article							FACTOR-BETA; MESENCHYMAL TRANSITION; EXPRESSION; DEGRADATION; LIGASE; RBM47	RNA-binding proteins provide a new layer of posttranscriptional regulation of RNA during cancer progression. We identified RNA-binding motif protein 47 (RBM47) as a target gene of transforming growth factor (TGF)-beta in mammary gland epithelial cells (NMuMG cells) that have undergone the epithelial-to-mesenchymal transition. TGF-beta repressed RBM47 expression in NMuMG cells and lung cancer cell lines. Expression of RBM47 correlated with good prognosis in patients with lung, breast and gastric cancer. RBM47 suppressed the expression of cell metabolism-related genes, which were the direct targets of nuclear factor erythroid 2-related factor 2 (Nrf2; also known as NFE2L2). RBM47 bound to KEAP1 and Cullin 3 mRNAs, and knockdown of RBM47 inhibited their protein expression, which led to enhanced binding of Nrf2 to target genomic regions. Knockdown of RBM47 also enhanced the expression of some Nrf2 activators, p21/CDKN1A and MafK induced by TGF-beta. Both mitochondrial respiration rates and the side population cells in lung cancer cells increased in the absence of RBM47. Our findings, together with the enhanced tumor formation and metastasis of xenografted mice by knockdown of the RBM47 expression, suggested tumor-suppressive roles for RBM47 through the inhibition of Nrf2 activity.	[Sakurai, T.; Isogaya, K.; Sakai, S.; Morishita, Y.; Ehata, S.; Miyazono, K.; Koinuma, D.] Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Tokyo, Japan; [Morikawa, M.] Uppsala Univ, Ludwig Inst Canc Res, Sci Life Lab, Uppsala, Sweden	University of Tokyo; Ludwig Institute for Cancer Research; Uppsala University	Miyazono, K (corresponding author), Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	miyazono@m.u-tokyo.ac.jp	Koinuma, Daizo/Y-8716-2018; Morikawa, Masato/D-1932-2011	Koinuma, Daizo/0000-0001-5611-2122; Morikawa, Masato/0000-0002-6191-7176; Ehata, Shogo/0000-0002-6740-9391	KAKENHI from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT) [22112002, 15K06831, 15H05774, 24890039]; Japan Agency for Medical Research and Development (AMED) [15ak0101001h0005]; Kanae Foundation for Research Abroad; Japan Society for the Promotion of Science (JSPS); ITO Genboku and SAGARA Chian Memorial Scholarship; Grants-in-Aid for Scientific Research [15K08393, 15H05774, 22112002] Funding Source: KAKEN	KAKENHI from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Kanae Foundation for Research Abroad; Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); ITO Genboku and SAGARA Chian Memorial Scholarship; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We are grateful to Dr Hiroyuki Aburatani, Shuichi Tsutsumi and Aya Nonaka (The University of Tokyo) for the ChIP-seq data and advice regarding RIP-seq analysis, and to Dr Hiroyuki Suzuki (Tsukuba University) for discussion and advice. We also thank Akiyoshi Komuro for a lentiviral luciferase expression plasmid and Keiko Yuki for technical assistance, and members of the Miyazono laboratory for discussion and advice. This work was supported by KAKENHI grants-in-aid for scientific research in Innovative Area (Integrative Research on Cancer Microenvironment Network, (22112002) to KM), Scientific Research (C) ((15K06831) to DK) and (S) ((15H05774) to KM), a Research Activity Start-up grant ((24890039), KI) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT); and a grant from the Japan Agency for Medical Research and Development (AMED) (15ak0101001h0005 to DK). This study was performed as a research program of the Project for Development of Innovative Research on Cancer Therapeutics (P-Direct), AMED; MM is supported by the Kanae Foundation for Research Abroad and the ITO Genboku and SAGARA Chian Memorial Scholarship; TS is supported by a grant from the Japan Society for the Promotion of Science (JSPS).	Arase M, 2014, CANCER SCI, V105, P974, DOI 10.1111/cas.12454; Chen WM, 2009, MOL CELL, V34, P663, DOI 10.1016/j.molcel.2009.04.029; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086; Ehata S, 2011, ONCOGENE, V30, P1693, DOI 10.1038/onc.2010.546; Fossat N, 2014, EMBO REP, V15, P903, DOI 10.15252/embr.201438450; Guan R, 2013, DEV DYNAM, V242, P1395, DOI 10.1002/dvdy.24039; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hast BE, 2014, CANCER RES, V74, P808, DOI 10.1158/0008-5472.CAN-13-1655; Hayes JD, 2012, CELL METAB, V16, P139, DOI 10.1016/j.cmet.2012.07.009; Horiguchi K, 2012, ONCOGENE, V31, P3190, DOI 10.1038/onc.2011.493; Isogaya K, 2014, CELL RES, V24, P994, DOI 10.1038/cr.2014.97; Katayama R, 2009, CANCER SCI, V100, P2060, DOI 10.1111/j.1349-7006.2009.01288.x; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Koinuma D, 2011, J BIOL CHEM, V286, P32502, DOI 10.1074/jbc.M111.227561; Koinuma D, 2009, MOL CELL BIOL, V29, P172, DOI 10.1128/MCB.01038-08; Malhotra D, 2010, NUCLEIC ACIDS RES, V38, P5718, DOI 10.1093/nar/gkq212; Mitsuishi Y, 2012, CANCER CELL, V22, P66, DOI 10.1016/j.ccr.2012.05.016; Mizutani A, 2011, J BIOL CHEM, V286, P29848, DOI 10.1074/jbc.M110.217745; Morikawa M, 2013, ONCOGENE, V32, P1609, DOI 10.1038/onc.2012.191; Okita Y, 2013, J BIOL CHEM, V288, P20658, DOI 10.1074/jbc.M113.450478; Oshimori N, 2015, CELL, V160, P963, DOI 10.1016/j.cell.2015.01.043; Petit V, 2009, J MOL BIOL, V385, P65, DOI 10.1016/j.jmb.2008.10.043; Ray D, 2013, NATURE, V499, P172, DOI 10.1038/nature12311; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Saito RA, 2009, CANCER RES, V69, P2783, DOI 10.1158/0008-5472.CAN-08-3490; Shirai Y, 2011, AM J PATHOL, V179, P2920, DOI 10.1016/j.ajpath.2011.08.022; Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420; Singh A, 2006, AM J RESP CELL MOL, V35, P639, DOI 10.1165/rcmb.2005-0325OC; Singh A, 2009, FREE RADICAL BIO MED, V46, P376, DOI 10.1016/j.freeradbiomed.2008.10.026; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sung JM, 2008, BIOCHEM BIOPH RES CO, V371, P163, DOI 10.1016/j.bbrc.2008.04.038; Valdmanis PN, 2015, ONCOGENE, V34, P94, DOI 10.1038/onc.2013.523; Vanharanta S, 2014, ELIFE, V3, DOI 10.7554/eLife.02734; Yang PY, 2012, CANCER CELL, V22, P291, DOI 10.1016/j.ccr.2012.07.023; Yatabe Y, 2002, AM J SURG PATHOL, V26, P767, DOI 10.1097/00000478-200206000-00010; Yeganeh M, 2013, MOL BIOL REP, V40, P4391, DOI 10.1007/s11033-013-2528-0; Zhang P, 2010, MOL CANCER THER, V9, P336, DOI 10.1158/1535-7163.MCT-09-0589	39	41	41	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2016	35	38					5000	5009		10.1038/onc.2016.35	http://dx.doi.org/10.1038/onc.2016.35			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW9GT	26923328	hybrid, Green Published			2022-12-17	WOS:000383965300004
J	Franciosa, G; Diluvio, G; Del Gaudio, F; Giuli, MV; Palermo, R; Grazioli, P; Campese, AF; Talora, C; Bellavia, D; D'Amati, G; Besharat, ZM; Nicoletti, C; Siebel, CW; Choy, L; Rustighi, A; Del Sal, G; Screpanti, I; Checquolo, S				Franciosa, G.; Diluvio, G.; Del Gaudio, F.; Giuli, M. V.; Palermo, R.; Grazioli, P.; Campese, A. F.; Talora, C.; Bellavia, D.; D'Amati, G.; Besharat, Z. M.; Nicoletti, C.; Siebel, C. W.; Choy, L.; Rustighi, A.; Del Sal, G.; Screpanti, I.; Checquolo, S.			Prolyl-isomerase Pin1 controls Notch3 protein expression and regulates T-ALL progression	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE PROMYELOCYTIC LEUKEMIA; TRANS-RETINOIC ACID; FACTOR-KAPPA-B; CELL LEUKEMIA; BREAST-CANCER; DOWN-REGULATION; PRE-TCR; DRUG-SENSITIVITY; INVASION	Deregulated Notch signaling is associated with T-cell Acute Lymphoblastic Leukemia (T-ALL) development and progression. Increasing evidence reveals that Notch pathway has an important role in the invasion ability of tumor cells, including leukemia, although the underlying molecular mechanisms remain mostly unclear. Here, we show that Notch3 is a novel target protein of the prolyl-isomerase Pin1, which is able to regulate Notch3 protein processing and to stabilize the cleaved product, leading to the increased expression of the intracellular domain (N3(IC)), finally enhancing Notch3-dependent invasiveness properties. We demonstrate that the combined inhibition of Notch3 and Pin1 in the Notch3-overexpressing human leukemic TALL-1 cells reduces their high invasive potential, by decreasing the expression of the matrix metalloprotease MMP9. Consistently, Pin1 depletion in a mouse model of Notch3-induced T-ALL, by reducing N3(IC) expression and signaling, impairs the expansion/invasiveness of CD4(+)CD8(+) DP cells in peripheral lymphoid and non-lymphoid organs. Notably, in in silico gene expression analysis of human T-ALL samples we observed a significant correlation between Pin1 and Notch3 expression levels, which may further suggest a key role of the newly identified Notch3-Pin1 axis in T-ALL aggressiveness and progression. Thus, combined suppression of Pin1 and Notch3 proteins may be exploited as an additional target therapy for T-ALL.	[Franciosa, G.; Diluvio, G.; Del Gaudio, F.; Giuli, M. V.; Grazioli, P.; Campese, A. F.; Talora, C.; Bellavia, D.; Besharat, Z. M.; Screpanti, I.] Sapienza Univ, Dept Mol Med, Lab Mol Pathol, Rome, Italy; [Palermo, R.; Screpanti, I.] Ist Italiano Tecnol, Ctr Life Nano Sci Sapienza, Rome, Italy; [D'Amati, G.] Sapienza Univ, Dept Radiol Oncol & Pathol Sci, Rome, Italy; [Nicoletti, C.] Sapienza Univ, Dept Anat Histol Forens Med & Orthopaed, Unit Histol & Med Embryol, Rome, Italy; [Siebel, C. W.; Choy, L.] Genentech Inc, Dept Discovery Oncol, San Francisco, CA USA; [Rustighi, A.; Del Sal, G.] Univ Trieste, Lab Nazl CIB Area Sci Pk Trieste, Trieste, Italy; [Rustighi, A.; Del Sal, G.] Univ Trieste, Dept Life Sci, Trieste, Italy; [Screpanti, I.] Sapienza Univ, Inst Pasteur, Fdn Cenci Bolognetti, Rome, Italy; [Checquolo, S.] Sapienza Univ, Dept Med Surg Sci & Biotechnol, Corso Repubbl 69, I-04100 Latina, Italy	Sapienza University Rome; Istituto Italiano di Tecnologia - IIT; Sapienza University Rome; Sapienza University Rome; Roche Holding; Genentech; University of Trieste; University of Trieste; Fondazione Cenci Bolognetti; Sapienza University Rome; Sapienza University Rome	Checquolo, S (corresponding author), Sapienza Univ, Dept Med Surg Sci & Biotechnol, Corso Repubbl 69, I-04100 Latina, Italy.; Screpanti, I (corresponding author), Sapienza Univ, Dept Mol Med, Viale Regina Elena 291, I-00161 Rome, Italy.	isabella.screpanti@uniroma1.it; saula.checquolo@uniroma1.it	Del Gaudio, Francesca/AAD-3685-2022; Besharat, Zein Mersini/G-5413-2013; d'Amati, Giulia/F-1251-2011; Palermo, Rocco/I-5140-2016; Bellavia, Diana/AAO-6348-2021; Talora, Claduio/AIC-4932-2022; Franciosa, Giulia/AAV-1211-2021	Del Gaudio, Francesca/0000-0001-8342-1377; Besharat, Zein Mersini/0000-0003-0317-9854; d'Amati, Giulia/0000-0002-6959-691X; Palermo, Rocco/0000-0003-0134-9370; Talora, Claduio/0000-0002-6973-2184; Franciosa, Giulia/0000-0001-5309-5558; CAMPESE, Antonio Francesco/0000-0002-8535-6609; DILUVIO, GIULIA/0000-0002-9541-848X; CHECQUOLO, Saula/0000-0001-5109-8392; NICOLETTI, Carmine/0000-0001-5896-2040	Italian Association for Cancer Research (AIRC) [13214]; Italian Ministry of University and Research (MIUR); FIRB Program [RBAP11WCRZ]; PRIN (MCLPLB) Program; AIRC Special Program Molecular Clinical Oncology '5 per mille'; Italian Ministry of Health Ricerca-Finalizzata	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of University and Research (MIUR)(Ministry of Education, Universities and Research (MIUR)); FIRB Program(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); PRIN (MCLPLB) Program(Ministry of Education, Universities and Research (MIUR)); AIRC Special Program Molecular Clinical Oncology '5 per mille'(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of Health Ricerca-Finalizzata(Ministry of Health, Italy)	This work was supported by the Italian Association for Cancer Research (AIRC) IG 13214, the Italian Ministry of University and Research (MIUR), FIRB (RBAP11WCRZ) and PRIN (2010 MCLPLB) Programs to IS, AIRC Special Program Molecular Clinical Oncology '5 per mille', and Italian Ministry of Health Ricerca-Finalizzata 2011 to GDS.	Agnusdei V, 2014, LEUKEMIA, V28, P278, DOI 10.1038/leu.2013.183; Aifantis L, 1998, IMMUNITY, V9, P649, DOI 10.1016/S1074-7613(00)80662-7; Arasada RR, 2014, CANCER RES, V74, P5572, DOI 10.1158/0008-5472.CAN-13-3724; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Aster JC, 2000, MOL CELL BIOL, V20, P7505, DOI 10.1128/MCB.20.20.7505-7515.2000; Atchison FW, 2003, DEVELOPMENT, V130, P3579, DOI 10.1242/dev.00584; Baik SH, 2015, ANN NEUROL, V77, P504, DOI 10.1002/ana.24347; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; Bellavia D, 2002, P NATL ACAD SCI USA, V99, P3788, DOI 10.1073/pnas.062050599; Beverly LJ, 2005, CANCER RES, V65, P7159, DOI 10.1158/0008-5472.CAN-05-1664; Buonamici S, 2009, NATURE, V459, P1000, DOI 10.1038/nature08020; Campese AF, 2009, INT IMMUNOL, V21, P727, DOI 10.1093/intimm/dxp042; Checquolo S, 2010, ONCOGENE, V29, P1463, DOI 10.1038/onc.2009.446; Cialfi S, 2013, LEUKEMIA, V27, P485, DOI 10.1038/leu.2012.192; Demarest RM, 2011, BLOOD, V117, P2901, DOI 10.1182/blood-2010-05-286351; Fan G, 2009, CANCER RES, V69, P4589, DOI 10.1158/0008-5472.CAN-08-4117; Fortini ME, 2009, DEV CELL, V16, P633, DOI 10.1016/j.devcel.2009.03.010; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Ghisi M, 2011, BLOOD, V117, P7053, DOI 10.1182/blood-2010-12-326629; Grabher C, 2006, NAT REV CANCER, V6, P347, DOI 10.1038/nrc1880; HIRAKI S, 1978, GANN, V69, P115; Homminga I, 2011, CANCER CELL, V19, P484, DOI 10.1016/j.ccr.2011.02.008; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Joutel A, 2000, J CLIN INVEST, V105, P597, DOI 10.1172/JCI8047; Kumar V, 2014, LEUKEMIA, V28, P2324, DOI 10.1038/leu.2014.133; Lee SY, 2005, LEUKEMIA, V19, P1841, DOI 10.1038/sj.leu.2403896; Lin LI, 2002, BRIT J HAEMATOL, V117, P835, DOI 10.1046/j.1365-2141.2002.03510.x; Liou YC, 2011, TRENDS BIOCHEM SCI, V36, P501, DOI 10.1016/j.tibs.2011.07.001; Lopez-Guerra M, 2015, LEUKEMIA, V29, P96, DOI 10.1038/leu.2014.143; Louvi A, 2012, SEMIN CELL DEV BIOL, V23, P473, DOI 10.1016/j.semcdb.2012.02.005; Lu KP, 2007, NAT REV MOL CELL BIO, V8, P904, DOI 10.1038/nrm2261; Mansour MR, 2006, LEUKEMIA, V20, P537, DOI 10.1038/sj.leu.2404101; Martin-Blanco NM, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.438; Min SH, 2012, MOL CELL, V46, P771, DOI 10.1016/j.molcel.2012.04.012; O'Neil J, 2007, J EXP MED, V204, P1813, DOI 10.1084/jem.20070876; Palermo R, 2014, CURR MOL MED, V14, P34, DOI 10.2174/1566524013666131118105216; Palermo R, 2012, ONCOGENE, V31, P3807, DOI 10.1038/onc.2011.533; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Pelullo M, 2014, NEOPLASIA, V16, P1007, DOI 10.1016/j.neo.2014.10.004; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Redondo-Munoz J, 2010, CANCER CELL, V17, P160, DOI 10.1016/j.ccr.2009.12.044; Rustighi A, 2014, EMBO MOL MED, V6, P99, DOI 10.1002/emmm.201302909; Rustighi A, 2009, NAT CELL BIOL, V11, P133, DOI 10.1038/ncb1822; Santarpia L, 2012, BREAST CANCER RES TR, V134, P333, DOI 10.1007/s10549-012-2035-3; Screpanti I, 2003, TRENDS MOL MED, V9, P30, DOI 10.1016/S1471-4914(02)00003-5; Sorrentino G, 2014, MITOCHONDRION, V19, P88, DOI 10.1016/j.mito.2014.08.003; Talora C, 2003, EMBO REP, V4, P1067, DOI 10.1038/sj.embor.7400013; Vacca A, 2006, EMBO J, V25, P1000, DOI 10.1038/sj.emboj.7600996; Vacca A, 2000, Dev Immunol, V7, P77, DOI 10.1155/2000/74372; Wang J, 2011, ONCOL REP, V26, P1295, DOI 10.3892/or.2011.1399; Wang XW, 2015, ONCOL REP, V33, P1402, DOI 10.3892/or.2015.3731; Wang ZW, 2006, CANCER RES, V66, P2778, DOI 10.1158/0008-5472.CAN-05-4281; Wei S, 2015, NAT MED, V21, P457, DOI 10.1038/nm.3839; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wulf G, 2005, NAT CELL BIOL, V7, P435, DOI 10.1038/ncb0505-435; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Yin CC, 2015, EXP CELL RES, V332, P39, DOI 10.1016/j.yexcr.2015.01.008; Zampieri M, 2014, BBA-GENE REGUL MECH, V1839, P813, DOI 10.1016/j.bbagrm.2014.06.017; Zhang ZY, 2010, AM J PATHOL, V177, P1459, DOI 10.2353/ajpath.2010.090476; Zhou L, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0073724, 10.1371/journal.pone.0057382]; Zou J, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-3	65	41	43	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2016	35	36					4741	4751		10.1038/onc.2016.5	http://dx.doi.org/10.1038/onc.2016.5			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0IS	26876201	Green Published, hybrid			2022-12-17	WOS:000383324700007
J	Grassilli, E; Pisano, F; Cialdella, A; Bonomo, S; Missaglia, C; Cerrito, MG; Masiero, L; Ianzano, L; Giordano, F; Cicirelli, V; Narloch, R; D'Amato, F; Noli, B; Ferri, GL; Leone, BE; Stanta, G; Bonin, S; Helin, K; Giovannoni, R; Lavitrano, M				Grassilli, E.; Pisano, F.; Cialdella, A.; Bonomo, S.; Missaglia, C.; Cerrito, M. G.; Masiero, L.; Ianzano, L.; Giordano, F.; Cicirelli, V.; Narloch, R.; D'Amato, F.; Noli, B.; Ferri, G. L.; Leone, B. E.; Stanta, G.; Bonin, S.; Helin, K.; Giovannoni, R.; Lavitrano, M.			A novel oncogenic BTK isoform is overexpressed in colon cancers and required for RAS-mediated transformation	ONCOGENE			English	Article							BRUTONS TYROSINE KINASE; SIGNALING PATHWAYS; POINT MUTATION; HNRNP-K; TRANSLATION; ACTIVATION; INHIBITION; DEFICIENCY; REGION; GENE	Bruton's tyrosine kinase (BTK) is essential for B-cell proliferation/differentiation and it is generally believed that its expression and function are limited to bone marrow-derived cells. Here, we report the identification and characterization of p65BTK, a novel isoform abundantly expressed in colon carcinoma cell lines and tumour tissue samples. p65BTK protein is expressed, through heterogeneous nuclear ribonucleoprotein K (hnRNPK)-dependent and internal ribosome entry site-driven translation, from a transcript containing an alternative first exon in the 5'-untranslated region, and is post-transcriptionally regulated, via hnRNPK, by the mitogen-activated protein kinase (MAPK) pathway. p65BTK is endowed with strong transforming activity that depends on active signal-regulated protein kinases-1/2 (ERK1/2) and its inhibition abolishes RAS transforming activity. Accordingly, p65BTK overexpression in colon cancer tissues correlates with ERK1/2 activation. Moreover, p65BTK inhibition affects growth and survival of colon cancer cells. Our data reveal that BTK, via p65BTK expression, is a novel and powerful oncogene acting downstream of the RAS/MAPK pathway and suggest that its targeting may be a promising therapeutic approach.	[Grassilli, E.; Pisano, F.; Cialdella, A.; Bonomo, S.; Missaglia, C.; Cerrito, M. G.; Masiero, L.; Ianzano, L.; Giordano, F.; Cicirelli, V.; Narloch, R.; Leone, B. E.; Giovannoni, R.; Lavitrano, M.] Univ Milano Bicocca, Sch Med & Surg, Via Cadore 48, I-20900 Monza, MB, Italy; [Grassilli, E.; Pisano, F.; Cialdella, A.] BiOnSil Srl, Monza, Italy; [D'Amato, F.; Noli, B.; Ferri, G. L.] Univ Cagliari, Dept Biomed Sci, NEF Lab, Monserrato, Italy; [Stanta, G.; Bonin, S.] Univ Trieste, Cattinara Hosp, Dept Med Sci, Trieste, Italy; [Helin, K.] Univ Copenhagen, BRIC, Copenhagen, Denmark; [Helin, K.] Univ Copenhagen, Ctr Epigenet, Copenhagen, Denmark; [Helin, K.] Univ Copenhagen, Danish Stem Cell Ctr Danstem, Copenhagen, Denmark	University of Milano-Bicocca; University of Cagliari; University of Trieste; University of Copenhagen; University of Copenhagen; University of Copenhagen	Grassilli, E; Lavitrano, M (corresponding author), Univ Milano Bicocca, Sch Med & Surg, Via Cadore 48, I-20900 Monza, MB, Italy.	emanuela.grassilli@unimib.it; marialuisa.lavitrano@unimib.it	Helin, Kristian/K-2526-2019; Giovannoni, Roberto/A-1413-2009; Helin, Kristian/HDM-8306-2022; grassilli, emanuela/ABB-7845-2020; Grassilli, Emanuela/L-7296-2013; Bonin, Serena/C-9332-2015; Cerrito, Maria Grazia/AAA-1190-2019; Ferri, Luca Angelo/AAC-5890-2022; LEONE, BIAGIO EUGENIO/J-8803-2018	Giovannoni, Roberto/0000-0002-7706-0672; Helin, Kristian/0000-0003-1975-6097; grassilli, emanuela/0000-0001-5387-5925; Grassilli, Emanuela/0000-0001-5387-5925; Bonin, Serena/0000-0002-7349-0296; Cerrito, Maria Grazia/0000-0002-3347-5817; Ferri, Luca Angelo/0000-0001-9031-6284; LEONE, BIAGIO EUGENIO/0000-0002-6978-2405; Lavitrano, Marialuisa/0000-0003-4852-1318; FERRI, Gian-Luca/0000-0003-2768-349X; cicirelli, vincenzo/0000-0003-2792-8848; STANTA, GIORGIO/0000-0002-3261-4272	MIUR [PON01_02782]; Ministry of Health [RF-2010-2305526]; University of Milano-Bicocca, FAR grants; Novo Nordisk Foundation Section for Basic Stem Cell Biology [Helin group NNF] Funding Source: researchfish	MIUR(Ministry of Education, Universities and Research (MIUR)); Ministry of Health; University of Milano-Bicocca, FAR grants; Novo Nordisk Foundation Section for Basic Stem Cell Biology	We thank BiOnSil, srl, spin-off of the University of Milano-Bicocca, for making available BN49 anti-p65BTK antibody in the frame of the Scientific agreement with the University of Cagliari, and Dr Elena Sacco and Dr Luca Mologni from the University of Milano-Bicocca for the gift of the RAS-DN and pS-shRAS plasmids. This work was funded by MIUR, PON01_02782, by Ministry of Health, RF-2010-2305526 and by University of Milano-Bicocca, FAR grants to ML.	Barbosa C, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003529; Bomsztyk K, 2004, BIOESSAYS, V26, P629, DOI 10.1002/bies.20048; Burger JA, 2014, CURR HEMATOL MALIG R, V9, P44, DOI 10.1007/s11899-013-0188-8; Carpenter B, 2006, BRIT J CANCER, V95, P921, DOI 10.1038/sj.bjc.6603349; De Luca A, 2012, EXPERT OPIN THER TAR, V16, pS17, DOI 10.1517/14728222.2011.639361; Didiot MC, 2013, J BIOMOL SCREEN, V18, P407, DOI 10.1177/1087057112466698; Dingjan GM, 1998, EMBO J, V17, P5309, DOI 10.1093/emboj/17.18.5309; Eifert C, 2013, GENE CHROMOSOME CANC, V52, P961, DOI 10.1002/gcc.22091; Fang JY, 2005, LANCET ONCOL, V6, P322, DOI 10.1016/S1470-2045(05)70168-6; Feldhahn N, 2005, P NATL ACAD SCI USA, V102, P13266, DOI 10.1073/pnas.0505196102; Gao B, 2014, BIOCHIM BIOPHYS ACTA, V1849, P753; Guha M, 2014, NAT BIOTECHNOL, V32, P113, DOI 10.1038/nbt0214-113; Habelhah H, 2001, NAT CELL BIOL, V3, P325, DOI 10.1038/35060131; Kang SW, 2001, EMBO J, V20, P5692, DOI 10.1093/emboj/20.20.5692; Komar AA, 2012, GENE, V502, P75, DOI 10.1016/j.gene.2012.04.039; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; Liu WM, 2001, NAT IMMUNOL, V2, P939, DOI 10.1038/ni1001-939; Marash L, 2008, MOL CELL, V30, P447, DOI 10.1016/j.molcel.2008.03.018; Mohamed AJ, 2009, IMMUNOL REV, V228, P58, DOI 10.1111/j.1600-065X.2008.00741.x; Notari M, 2006, BLOOD, V107, P2507, DOI 10.1182/blood-2005-09-3732; Novero A, 2014, EXP HEMATOL ONCOL, V3, DOI 10.1186/2162-3619-3-4; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; POW DV, 1993, J NEUROSCI METH, V48, P51, DOI 10.1016/S0165-0270(05)80007-X; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; Salamov AA, 1998, BIOINFORMATICS, V14, P384, DOI 10.1093/bioinformatics/14.5.384; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; Shi YJ, 2005, J BIOL CHEM, V280, P10964, DOI 10.1074/jbc.M407874200; Silvera D, 2010, NAT REV CANCER, V10, P254, DOI 10.1038/nrc2824; Smith L, 2008, BIOCHEM SOC T, V36, P708, DOI 10.1042/BST0360708; Spatuzza C, 2008, NUCLEIC ACIDS RES, V36, P4402, DOI 10.1093/nar/gkn413; Spriggs KA, 2008, BIOL CELL, V100, P27, DOI 10.1042/BC20070098; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; Wurth L, 2015, BBA-GENE REGUL MECH, V1849, P881, DOI 10.1016/j.bbagrm.2014.10.001; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; Yu L, 2006, J BIOL CHEM, V281, P18201, DOI 10.1074/jbc.M603090200	37	41	41	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	33					4368	4378		10.1038/onc.2015.504	http://dx.doi.org/10.1038/onc.2015.504			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3ZU	26804170	Green Published, hybrid			2022-12-17	WOS:000382152100008
J	Du, J; Yang, M; Chen, S; Li, D; Chang, Z; Dong, Z				Du, J.; Yang, M.; Chen, S.; Li, D.; Chang, Z.; Dong, Z.			PDK1 promotes tumor growth and metastasis in a spontaneous breast cancer model	ONCOGENE			English	Article							MAMMARY EPITHELIAL-CELLS; ACTIVATED PROTEIN-KINASE; PHARMACOLOGICAL INHIBITION; SIGNALING PATHWAYS; SUPPRESSOR GENE; PHOSPHORYLATION; IDENTIFICATION; TRANSFORMATION; INACTIVATION; EXPRESSION	Because malignant cells have altered, usually accelerated, energy consumption, targeting metabolic signaling represents a prevailing strategy for tumor therapy. Phosphoinositide-dependent kinase 1 (PDK1) is a proximal signaling molecule of phosphatidylinositol 3-kinase, which is required for metabolic activation. It is still lacking definitive evidence whether inactivation of PDK1 can overwhelm tumorigenesis in vivo. Herein we revealed that mammary-specific ablation of PDK1 could delay tumor initiation, progression and metastasis in a spontaneous mouse tumor model. We also demonstrated that inducible deletion of PDK1 could noticeably shrink the growing breast tumors. However, a small portion of PDK1-deficient tumorigenic cells eventually established tumor lesions, albeit at a relatively later phase, most likely owing to compensatory upregulation of extracellular signalregulated kinase 1/2 (Erk1/2) phosphorylation. Consequently, simultaneous inhibition of PDK1 and Erk1/2 impeded the survival of breast cancer cells. Thus we identify PDK1 as a potential therapeutic target for breast cancer, particularly in combination with an Erk1/2 inhibitor.	[Du, J.; Yang, M.; Chen, S.; Li, D.; Dong, Z.] Tsinghua Univ, Sch Med, Biotech Bldg 4-314,1 Tsinghuayuan, Beijing 100086, Peoples R China; [Chen, S.] Tsinghua Univ, Tsinghua Peking Ctr Life Sci, Beijing 100084, Peoples R China; [Chang, Z.] Tsinghua Univ, Ctr Anim Facil, Beijing 100084, Peoples R China	Tsinghua University; Tsinghua University; Tsinghua University	Dong, Z (corresponding author), Tsinghua Univ, Sch Med, Biotech Bldg 4-314,1 Tsinghuayuan, Beijing 100086, Peoples R China.	dongzj@biomed.tsinghua.edu.cn	Chang, Zhijie/AAH-8109-2019		Natural Science Foundation of China [81322041, 81273198, 81361128016, 81471523]; Beijing Natural Science Foundation [5132018]; Postdoctoral Foundation at Tsinghua-Peking Center for Life Sciences;  [2013CB944901]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Natural Science Foundation(Beijing Natural Science Foundation); Postdoctoral Foundation at Tsinghua-Peking Center for Life Sciences; 	We thank Dr Dario R Alessi (University of Dundee) for sharing the PDK1<SUP>fl/fl</SUP> mice. This work was supported by grants to Dr Zhongjun Dong's laboratory from Natural Science Foundation of China (81322041, 81273198, 81361128016 and 81471523), Minister of Science and Technology of China (2013CB944901) and Beijing Natural Science Foundation (5132018). Juan Du and Meixiang Yang were supported by Postdoctoral Foundation at Tsinghua-Peking Center for Life Sciences.	Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Bayascas JR, 2005, CURR BIOL, V15, P1839, DOI 10.1016/j.cub.2005.08.066; Cairns P, 1997, CANCER RES, V57, P4997; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Cope CL, 2014, J CELL SCI, V127, P788, DOI 10.1242/jcs.137588; Dennis MD, 2013, J BIOL CHEM, V288, P10, DOI 10.1074/jbc.M112.402461; Di Nicolantonio F, 2010, J CLIN INVEST, V120, P2858, DOI 10.1172/JCI37539; Elkabets M, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005747; Ellwood-Yen K, 2011, CANCER RES, V71, P3052, DOI 10.1158/0008-5472.CAN-10-2282; Emerling BM, 2011, CANCER RES, V71, P7351, DOI 10.1158/0008-5472.CAN-11-1699; Faivre S, 2006, NAT REV DRUG DISCOV, V5, P671, DOI 10.1038/nrd2062; Fyffe Chanse, 2013, Cancer Manag Res, V5, P271, DOI 10.2147/CMAR.S35026; Gagliardi PA, 2012, NEOPLASIA, V14, P719, DOI 10.1593/neo.12856; Gee JMW, 2001, INT J CANCER, V95, P247, DOI 10.1002/1097-0215(20010720)95:4<247::AID-IJC1042>3.0.CO;2-S; Gulhati P, 2011, CANCER RES, V71, P3246, DOI 10.1158/0008-5472.CAN-10-4058; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Halachmi N, 1998, GENE CHROMOSOME CANC, V23, P239, DOI 10.1002/(SICI)1098-2264(199811)23:3<239::AID-GCC5>3.0.CO;2-2; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Hoeflich KP, 2009, CLIN CANCER RES, V15, P4649, DOI 10.1158/1078-0432.CCR-09-0317; Ito K, 2009, P NATL ACAD SCI USA, V106, P8689, DOI 10.1073/pnas.0900064106; Kim MS, 2003, CANCER RES, V63, P5454; Lamouille S, 2007, J CELL BIOL, V178, P437, DOI 10.1083/jcb.200611146; Lin HJ, 2005, BRIT J CANCER, V93, P1372, DOI 10.1038/sj.bjc.6602862; Liu Y, 2009, MOL CANCER RES, V7, P944, DOI 10.1158/1541-7786.MCR-08-0368; Maurer M, 2009, CANCER RES, V69, P6299, DOI 10.1158/0008-5472.CAN-09-0820; Mikaelian I, 2013, CANCER RES, V73, P6621, DOI 10.1158/0008-5472.CAN-13-0560; Mora A, 2003, EMBO J, V22, P4666, DOI 10.1093/emboj/cdg469; Nagashima K, 2011, J BIOL CHEM, V286, P6433, DOI 10.1074/jbc.M110.156463; O'Neil RG, 2005, MOL IMAGING BIOL, V7, P388, DOI 10.1007/s11307-005-0011-6; Park WS, 2008, MOL CELL, V30, P381, DOI 10.1016/j.molcel.2008.04.008; Pazarentzos E, 2016, ONCOGENE, V35, P1198, DOI 10.1038/onc.2015.173; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Qiu TH, 2004, CANCER RES, V64, P5973, DOI 10.1158/0008-5472.CAN-04-0242; Raimondi C, 2010, BREAST CANCER RES, V12, pS3, DOI 10.1186/bcr2500; Bayascas JR, 2010, CURR TOP MICROBIOL, V346, P9, DOI 10.1007/82_2010_43; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Rodriguez-Viciana P, 2006, P NATL ACAD SCI USA, V103, P19290, DOI 10.1073/pnas.0609343103; Saitoh M, 2002, J BIOL CHEM, V277, P20104, DOI 10.1074/jbc.M201745200; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Schulze A, 2012, NATURE, V491, P364, DOI 10.1038/nature11706; Scortegagna M, 2014, ONCOGENE, V33, P4330, DOI 10.1038/onc.2013.383; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Xie ZH, 2003, CANCER RES, V63, P5370; Xie ZH, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-77; Zeng X, 2002, CANCER RES, V62, P3538; Zhang HY, 2013, ONCOL LETT, V6, P161, DOI 10.3892/ol.2013.1331; Zhang XB, 2013, CURR CANCER DRUG TAR, V13, P175, DOI 10.2174/1568009611313020007	50	41	41	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 23	2016	35	25					3314	3323		10.1038/onc.2015.393	http://dx.doi.org/10.1038/onc.2015.393			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP2GN	26455327				2022-12-17	WOS:000378306400010
J	Olcina, MM; Leszczynska, KB; Senra, JM; Isa, NF; Harada, H; Hammond, EM				Olcina, M. M.; Leszczynska, K. B.; Senra, J. M.; Isa, N. F.; Harada, H.; Hammond, E. M.			H3K9me3 facilitates hypoxia-induced p53-dependent apoptosis through repression of APAK	ONCOGENE			English	Article							CHROMATIN-STRUCTURE; ATM ACTIVATION; SOLID TUMORS; HUMAN GENOME; HISTONE H3; STRESS; P53; HETEROCHROMATIN; METHYLTRANSFERASE; REPLICATION	Regions of hypoxia occur in most solid tumors, and they are associated with a poor prognostic outcome. Despite the absence of detectable DNA damage, severe hypoxia (<0.1% O-2) induces a DNA damage response, including the activation of p53 and subsequent induction of p53-dependent apoptosis. Factors affecting hypoxia-induced p53-dependent apoptosis are unclear. Here we asked whether H3K9me3, through mediating gene repression, could regulate hypoxia-induced p53-dependent apoptosis. Under hypoxic conditions, increases in H3K9me3 occur in an oxygen-dependent but HIF-1-independent manner. We demonstrate that under hypoxic conditions, which induce p53 activity, the negative regulator of p53, APAK, is repressed by increases in H3K9me3 along the APAK loci. APAK repression in hypoxia is mediated by the methyltransferase SETDB1 but not Suv39h1 or G9a. Interestingly, increasing hypoxia-induced H3K9me3 through pharmacological inhibition of JMJD2 family members leads to an increase in apoptosis and decreased clonogenic survival and again correlates with APAK expression. The relevance of understanding the mechanisms of APAK expression regulation to human disease was suggested by analysis of patients with colorectal cancer, which demonstrates that high APAK expression correlates with poor prognosis. Together, these data demonstrate the functional importance of H3K9me3 in hypoxia, and they provide a novel mechanistic link between H3K9me3, p53 and apoptosis in physiologically relevant conditions of hypoxia.	[Olcina, M. M.; Leszczynska, K. B.; Senra, J. M.; Isa, N. F.; Hammond, E. M.] Univ Oxford, Dept Oncol, CR UK & MRC Oxford Inst Radiat Oncol, Oxford, England; [Harada, H.] Kyoto Univ, Grad Sch Med, Dept Radiat Oncol & Image Applied Therapy, Kyoto, Japan	University of Oxford; Kyoto University	Hammond, EM (corresponding author), Univ Oxford, CR UK & MRC Oxford Inst Radiat Oncol, Dept Oncol, ORCRB, Off Roosevelt Dr, Oxford OX3 7DQ, England.	Ester.Hammond@oncology.ox.ac.uk	isa, nur firdaus/HGU-0902-2022; Leszczynska, Katarzyna/AAK-9655-2020; Isa, Nur Firdaus/AAV-2880-2021	Leszczynska, Katarzyna/0000-0002-3504-1553; Isa, Nur Firdaus/0000-0003-3476-6306; Hammond, Ester/0000-0002-2335-3146	Cancer Research UK grant; MRC; MRC Centenary award; Cancer Research UK [19276] Funding Source: researchfish; Medical Research Council [891635] Funding Source: researchfish	Cancer Research UK grant(Cancer Research UK); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC Centenary award(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We are grateful to Chunyan Tian for the APAK constructs and Amato Giaccia and Laura Castellini for helpful discussions. KBL, JMS and EMH are supported by a Cancer Research UK grant (awarded to EMH). MO is supported by the MRC with an additional MRC Centenary award (awarded to MMO).	Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bencokova Z, 2009, MOL CELL BIOL, V29, P526, DOI 10.1128/MCB.01301-08; Brown JM, 1998, CANCER RES, V58, P1408; Ernst J, 2010, NAT BIOTECHNOL, V28, P817, DOI 10.1038/nbt.1662; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hammond EM, 2006, MOL CELL BIOL, V26, P3492, DOI 10.1128/MCB.26.9.3492-3504.2006; Hammond EM, 2002, MOL CELL BIOL, V22, P1834, DOI 10.1128/MCB.22.6.1834-1843.2002; Jenuwein T, 1998, CELL MOL LIFE SCI, V54, P80, DOI 10.1007/s000180050127; Johnson AB, 2007, MUTAT RES-FUND MOL M, V618, P149, DOI 10.1016/j.mrfmmm.2006.10.007; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Loyola A, 2009, EMBO REP, V10, P769, DOI 10.1038/embor.2009.90; Lu YH, 2014, CELL REP, V8, P500, DOI 10.1016/j.celrep.2014.06.035; Lu YH, 2011, MOL CELL BIOL, V31, P3339, DOI 10.1128/MCB.01121-10; Mizuno H, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-18; Mungamuri SK, 2012, NAT STRUCT MOL BIOL, V19, P478, DOI 10.1038/nsmb.2271; Olcina MM, 2013, MOL CELL, V52, P758, DOI 10.1016/j.molcel.2013.10.019; Rai G, 2010, PROBE REPORTS NIH MO; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; Smith JJ, 2010, GASTROENTEROLOGY, V138, P958, DOI 10.1053/j.gastro.2009.11.005; Squatrito M, 2010, CANCER CELL, V18, P619, DOI 10.1016/j.ccr.2010.10.034; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Tian C, 2009, NAT CELL BIOL, V11, P580, DOI 10.1038/ncb1864; Vaupel P, 2004, METHOD ENZYMOL, V381, P335; Wang S, 2010, FEBS LETT, V584, P3909, DOI 10.1016/j.febslet.2010.08.015; Yuan L, 2012, EMBO REP, V13, P363, DOI 10.1038/embor.2012.10	29	41	45	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2016	35	6					793	799		10.1038/onc.2015.134	http://dx.doi.org/10.1038/onc.2015.134			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RF	25961932	Green Published, hybrid			2022-12-17	WOS:000370331300012
J	Jiang, Y; Yan, B; Lai, W; Shi, Y; Xiao, D; Jia, J; Liu, S; Li, H; Lu, J; Li, Z; Chen, L; Chen, X; Sun, L; Muegge, K; Cao, Y; Tao, Y				Jiang, Y.; Yan, B.; Lai, W.; Shi, Y.; Xiao, D.; Jia, J.; Liu, S.; Li, H.; Lu, J.; Li, Z.; Chen, L.; Chen, X.; Sun, L.; Muegge, K.; Cao, Y.; Tao, Y.			Repression of Hox genes by LMP1 in nasopharyngeal carcinoma and modulation of glycolytic pathway genes by HoxC8	ONCOGENE			English	Article							RNA-POLYMERASE-II; DNA METHYLATION; EXPRESSION; DEMETHYLATION; POLYCOMB; HISTONE; CELLS; 5-HYDROXYMETHYLCYTOSINE; TRANSCRIPTION; EPIGENETICS	Epstein-Barr virus (EBV) causes human lymphoid malignancies, and the EBV product latent membrane protein 1 (LMP1) has been identified as an oncogene in epithelial carcinomas such as nasopharyngeal carcinoma (NPC). EBV can epigenetically reprogram lymphocyte-specific processes and induce cell immortalization. However, the interplay between LMP1 and the NPC host cell remains largely unknown. Here, we report that LMP1 is important to establish the Hox gene expression signature in NPC cell lines and tumor biopsies. LMP1 induces repression of several Hox genes in part via stalling of RNA polymerase II (RNA Pol II). Pol II stalling can be overcome by irradiation involving the epigenetic regulator TET3. Furthermore, we report that HoxC8, one of the genes silenced by LMP1, has a role in tumor growth. Ectopic expression of HoxC8 inhibits NPC cell growth in vitro and in vivo, modulates glycolysis and regulates the expression of tricarboxylic acid (TCA) cycle-related genes. We propose that viral latency products may repress via stalling key mediators that in turn modulate glycolysis.	[Jiang, Y.; Yan, B.; Lai, W.; Shi, Y.; Jia, J.; Li, H.; Lu, J.; Chen, L.; Chen, X.; Cao, Y.; Tao, Y.] Cent S Univ, Canc Res Inst, Changsha 410078, Hunan, Peoples R China; [Jiang, Y.; Yan, B.; Lai, W.; Shi, Y.; Li, H.; Lu, J.; Chen, L.; Chen, X.; Cao, Y.; Tao, Y.] Cent S Univ, Ctr Mol Imaging, Changsha 410078, Hunan, Peoples R China; [Xiao, D.] Cent S Univ, Xiangya Hosp, Dept Pathol, Changsha 410078, Hunan, Peoples R China; [Jia, J.; Liu, S.] Cent S Univ, Xiangya Hosp, Ctr Med Res, Changsha 410078, Hunan, Peoples R China; [Sun, L.] Cent S Univ, Xiangya Hosp, Ctr Mol Med, Changsha 410078, Hunan, Peoples R China; [Muegge, K.] NCI, Mouse Canc Genet Program, Basic Sci Program, Leidos Biomed Res Inc,Frederick Natl Lab Canc Res, Frederick, MD 21701 USA	Central South University; Central South University; Central South University; Central South University; Central South University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Cao, Y (corresponding author), Cent S Univ, Xiangya Sch Med, Xiangya Rd 110, Changsha 410078, Hunan, Peoples R China.	ycao98@vip.sina.com; taoyong@csu.edu.cn	Lu, Jianhong/AAM-8841-2020	Lu, Jianhong/0000-0002-4436-1217; Jiang, Yiqun/0000-0003-3262-9498	National Basic Research Program of China [2011CB504300, 2015CB553903]; Hunan Natural Science Foundation of China [12JJ1013]; Fundamental Research Funds for the Central Universities [2011JQ019, 2013ZZTS074, 2013ZZTS284]; National Natural Science Foundation of China [81171881, 81372427, 81271763, 81302354]; Hunan Provincial Innovation Foundation For Postgraduate [71380100002]; Frederick National Laboratory for Cancer Research, National Institutes of Health [HHSN261200800001E]; NATIONAL CANCER INSTITUTE [ZIABC010014] Funding Source: NIH RePORTER	National Basic Research Program of China(National Basic Research Program of China); Hunan Natural Science Foundation of China(Natural Science Foundation of Hunan Province); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Hunan Provincial Innovation Foundation For Postgraduate; Frederick National Laboratory for Cancer Research, National Institutes of Health; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Basic Research Program of China (2011CB504300 (YT); 2015CB553903 (YT)); the Hunan Natural Science Foundation of China (12JJ1013 (YT)); the Fundamental Research Funds for the Central Universities (2011JQ019 (YT), 2013ZZTS074 (BY), 2013ZZTS284 (WL)); and the National Natural Science Foundation of China (81171881 and 81372427 (YT), 81271763 (SL), 81302354 (YS)); and the Hunan Provincial Innovation Foundation For Postgraduate (71380100002 (YJ)). This project has been funded in part with Federal funds from the Frederick National Laboratory for Cancer Research, National Institutes of Health, under contract HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the US Government.	Adwan H, 2011, BRIT J CANCER, V105, P288, DOI 10.1038/bjc.2011.217; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Bijl J, 2008, ONCOGENE, V27, P6356, DOI 10.1038/onc.2008.233; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Chen J, 2013, CANCER LETT, V330, P217, DOI 10.1016/j.canlet.2012.11.051; Chopra VS, 2009, GENE DEV, V23, P1505, DOI 10.1101/gad.1807309; Chopra VS, 2009, CURR BIOL, V19, P688, DOI 10.1016/j.cub.2009.02.055; Core LJ, 2008, SCIENCE, V322, P1845, DOI 10.1126/science.1162228; Cortazar D, 2011, NATURE, V470, P419, DOI 10.1038/nature09672; Cortellino S, 2011, CELL, V146, P67, DOI 10.1016/j.cell.2011.06.020; DeBerardinis RJ, 2012, CELL, V148, P1132, DOI 10.1016/j.cell.2012.02.032; Du YB, 2014, J SURG RES, V188, P442, DOI 10.1016/j.jss.2014.01.017; Feng SH, 2010, P NATL ACAD SCI USA, V107, P8689, DOI 10.1073/pnas.1002720107; Galluzzi L, 2013, NAT REV DRUG DISCOV, V12, P829, DOI 10.1038/nrd4145; Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042; Hajkova P, 2010, SCIENCE, V329, P78, DOI 10.1126/science.1187945; Hau PM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021176; Zheng H, 2007, CELL MOL IMMUNOL, V4, P185; Hyland PL, 2011, J VIROL, V85, P10999, DOI 10.1128/JVI.00160-11; Carmona FJ, 2012, J PATHOL, V228, P230, DOI 10.1002/path.4011; Jiang YQ, 2013, BBA-REV CANCER, V1835, P155, DOI 10.1016/j.bbcan.2012.12.003; Klein E, 2007, ONCOGENE, V26, P1297, DOI 10.1038/sj.onc.1210240; Lai WW, 2013, INT J MOL SCI, V14, P2355, DOI 10.3390/ijms14022355; Levine M, 2011, CELL, V145, P502, DOI 10.1016/j.cell.2011.04.021; Li L, 2012, ONCOGENE, V31, P3901, DOI 10.1038/onc.2011.541; Li Y, 2014, ONCOTARGET, V5, P2596, DOI 10.18632/oncotarget.1841; Lian CG, 2012, CELL, V150, P1135, DOI 10.1016/j.cell.2012.07.033; Lin XC, 2012, CANCER SCI, V103, P993, DOI 10.1111/j.1349-7006.2012.02271.x; Liu S, 2013, BIOL REV, V88, P40, DOI 10.1111/j.1469-185X.2012.00237.x; Liu S, 2012, MOL BIOL REP, V39, P6179, DOI 10.1007/s11033-011-1435-5; Ma XQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024647; Marra L, 2013, CURR MED CHEM, V20, P833; McLaughlin-Drubin ME, 2011, P NATL ACAD SCI USA, V108, P2130, DOI 10.1073/pnas.1009933108; Merrifield Matt, 2013, Frontiers in Genetics, V4, P40, DOI 10.3389/fgene.2013.00040; Mesri EA, 2014, CELL HOST MICROBE, V15, P266, DOI 10.1016/j.chom.2014.02.011; Misteli T, 2009, NAT REV MOL CELL BIO, V10, P243, DOI 10.1038/nrm2651; Mohn F, 2008, MOL CELL, V30, P755, DOI 10.1016/j.molcel.2008.05.007; Muse GW, 2007, NAT GENET, V39, P1507, DOI 10.1038/ng.2007.21; Niller HH, 2009, SEMIN CANCER BIOL, V19, P158, DOI 10.1016/j.semcancer.2009.02.012; Oermann EK, 2012, SEMIN CELL DEV BIOL, V23, P370, DOI 10.1016/j.semcdb.2012.01.013; Olive PL, 2006, NAT PROTOC, V1, P23, DOI 10.1038/nprot.2006.5; Palermo RD, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002334; Pastor WA, 2013, NAT REV MOL CELL BIO, V14, P341, DOI 10.1038/nrm3589; Plottel CS, 2011, CELL HOST MICROBE, V10, P324, DOI 10.1016/j.chom.2011.10.003; Pogribny I, 2004, BIOCHEM BIOPH RES CO, V320, P1253, DOI 10.1016/j.bbrc.2004.06.081; Popp C, 2010, NATURE, V463, P1101, DOI 10.1038/nature08829; Poteet E, 2013, J BIOL CHEM, V288, P9153, DOI 10.1074/jbc.M112.440354; Raab-Traub Nancy, 2009, P259, DOI 10.1007/978-0-387-68945-6_12; Rodini CO, 2012, INT J ONCOL, V40, P1180, DOI 10.3892/ijo.2011.1321; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Shah N, 2010, NAT REV CANCER, V10, P361, DOI 10.1038/nrc2826; Shi Y, 2012, CARCINOGENESIS, V33, P1468, DOI 10.1093/carcin/bgs171; Skalska L, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000951; Smits KM, 2014, RADIOTHER ONCOL, V111, P168, DOI 10.1016/j.radonc.2014.05.001; Song SJ, 2013, CELL, V154, P311, DOI 10.1016/j.cell.2013.06.026; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Takeshima H, 2009, GENOME RES, V19, P1974, DOI 10.1101/gr.093310.109; Tanay A, 2007, P NATL ACAD SCI USA, V104, P5521, DOI 10.1073/pnas.0609746104; Tao YG, 2011, NUCLEIC ACIDS RES, V39, P9508, DOI 10.1093/nar/gkr611; Tao YG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009163; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Uchida J, 1999, SCIENCE, V286, P300, DOI 10.1126/science.286.5438.300; Verweij FJ, 2011, EMBO J, V30, P2115, DOI 10.1038/emboj.2011.123; Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990; Williams K, 2011, NATURE, V473, P343, DOI 10.1038/nature10066; Xiao L, 2014, ONCOGENE, V33, P4568, DOI 10.1038/onc.2014.32; Xiao MT, 2012, GENE DEV, V26, P1326, DOI 10.1101/gad.191056.112; Xu JW, 2002, J VIROL, V76, P4080, DOI 10.1128/JVI.76.8.4080-4086.2002; Yang H, 2013, ONCOGENE, V32, P663, DOI 10.1038/onc.2012.67; Zemach A, 2010, SCIENCE, V328, P916, DOI 10.1126/science.1186366	70	41	45	4	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2015	34	50					6079	6091		10.1038/onc.2015.53	http://dx.doi.org/10.1038/onc.2015.53			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CY0RQ	25745994	Green Accepted			2022-12-17	WOS:000366113800005
J	Salpeter, SJ; Pozniak, Y; Merquiol, E; Ben-Nun, Y; Geiger, T; Blum, G				Salpeter, S. J.; Pozniak, Y.; Merquiol, E.; Ben-Nun, Y.; Geiger, T.; Blum, G.			A novel cysteine cathepsin inhibitor yields macrophage cell death and mammary tumor regression	ONCOGENE			English	Article							PROTEASE ACTIVITY; METASTASIS; AUTOPHAGY; PROLIFERATION; POLARIZATION; PROGRESSION; IDENTIFICATION; FRACTIONATION; PLASTICITY; INVASION	Although cysteine cathepsins have been identified as key regulators of cancer growth, their specific role in tumor development remains unclear. Recent studies have shown that high activity levels of tumor cathepsins are primarily a result of increased cathepsin activity in cancer-promoting tumor-associated macrophages (TAMs). To further investigate the role of cysteine cathepsin activity in normal and polarized macrophages, we established in vitro and in vivo models of macrophage differentiation and polarization and used a novel cysteine cathepsin inhibitor, GB111-NH2, to block the activity of cathepsins B, L and S. Here we show that in vitro, cysteine cathepsin inhibition yields both apoptosis and proliferation of macrophages, owing to increased oxidative stress. Proteomic analysis of cathepsin-inhibited macrophages demonstrates inhibition of autophagy, suggesting a likely cause of elevated reactive oxygen species (ROS) levels. In vivo models of mammary cancer further show that cathepsin inhibition yields TAM death owing to increased ROS levels. Strikingly, apoptosis in TAMs yields a seemingly cell non-autonomous death of neighboring cancer cells, and regression of the primary growth. These results show that cysteine cathepsin inhibitors can specifically trigger macrophage cell death and may function as an effective anticancer therapy in tumors with high levels of TAMs.	[Salpeter, S. J.; Merquiol, E.; Ben-Nun, Y.; Blum, G.] Hebrew Univ Jerusalem, Inst Drug Res, Sch Pharm, Fac Med, IL-91120 Jerusalem, Israel; [Pozniak, Y.; Geiger, T.] Tel Aviv Univ, Sackler Sch Med, Dept Human Mol Genet & Biochem, Ramat Aviv, Israel	Hebrew University of Jerusalem; Tel Aviv University; Sackler Faculty of Medicine	Blum, G (corresponding author), Hebrew Univ Jerusalem, Inst Drug Res, Sch Pharm, Fac Med, IL-91120 Jerusalem, Israel.	galiabl@ekmd.huji.ac.il		Ben-Nun, Yael/0000-0002-5123-649X	Israel Cancer Research Foundation (ICRF); European Research Council (Marie Curie International Reintegration Grant)	Israel Cancer Research Foundation (ICRF); European Research Council (Marie Curie International Reintegration Grant)	We thank Dr Michael Berger (The Hebrew University) for providing reagents and advice regarding the project. We would like to acknowledge Boris Turk (Lubljana, Slovenia) for supplying the recombinant cathepsins. This work was supported by the Israel Cancer Research Foundation (ICRF) (to GB, SJS and TG) and the European Research Council (Marie Curie International Reintegration Grant) (to GB).	Bell-McGuinn KM, 2007, CANCER RES, V67, P7378, DOI 10.1158/0008-5472.CAN-07-0602; Blum G, 2005, NAT CHEM BIOL, V1, P203, DOI 10.1038/nchembio728; Blum G, 2007, NAT CHEM BIOL, V3, P668, DOI 10.1038/nchembio.2007.26; Concha C, 2005, J CELL PHYSIOL, V204, P693, DOI 10.1002/jcp.20338; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Dennemarker J, 2010, BIOL CHEM, V391, P913, DOI 10.1515/BC.2010.097; Dragin N, 2006, FEBS LETT, V580, P3845, DOI 10.1016/j.febslet.2006.06.006; Elie BT, 2010, BIOCHIMIE, V92, P1618, DOI 10.1016/j.biochi.2010.04.023; Galdiero MR, 2013, J CELL PHYSIOL, V228, P1404, DOI 10.1002/jcp.24260; Gocheva V, 2010, GENE DEV, V24, P241, DOI 10.1101/gad.1874010; Goulet B, 2004, MOL CELL, V14, P207, DOI 10.1016/S1097-2765(04)00209-6; Goulet B, 2007, MOL CANCER RES, V5, P899, DOI 10.1158/1541-7786.MCR-07-0160; Goulet B, 2006, BIOL CHEM, V387, P1285, DOI 10.1515/BC.2006.159; Hawker KM, 1998, AM J PHYSIOL-LUNG C, V275, pL469, DOI 10.1152/ajplung.1998.275.3.L469; Hsu KF, 2009, AUTOPHAGY, V5, P451, DOI 10.4161/auto.5.4.7666; Jacquel A, 2012, BLOOD, V119, P4527, DOI 10.1182/blood-2011-11-392167; Jedeszko C, 2004, BIOL CHEM, V385, P1017, DOI 10.1515/BC.2004.132; Katunuma Nobuhiko, 2010, J Signal Transduct, V2010, P375345, DOI 10.1155/2010/375345; Larghi P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045279; Liao XH, 2012, CELL METAB, V15, P545, DOI 10.1016/j.cmet.2012.01.022; Lin YY, 2013, CANCER SCI, V104, P1217, DOI 10.1111/cas.12202; Mantovani A, 2013, J PATHOL, V229, P176, DOI 10.1002/path.4133; Meara JP, 1996, J MED CHEM, V39, P3357, DOI 10.1021/jm950445b; MIKKELSEN T, 1995, J NEUROSURG, V83, P285, DOI 10.3171/jns.1995.83.2.0285; Palermo C, 2008, TRENDS PHARMACOL SCI, V29, P22, DOI 10.1016/j.tips.2007.10.011; Pan LL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035315; Pollard JW, 2009, NAT REV IMMUNOL, V9, P259, DOI 10.1038/nri2528; Porta C, 2009, P NATL ACAD SCI USA, V106, P14978, DOI 10.1073/pnas.0809784106; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Rappsilber J, 2007, NAT PROTOC, V2, P1896, DOI 10.1038/nprot.2007.261; Schurigt U, 2008, BIOL CHEM, V389, P1067, DOI 10.1515/BC.2008.115; Sevenich L, 2010, P NATL ACAD SCI USA, V107, P2497, DOI 10.1073/pnas.0907240107; Shree T, 2011, GENE DEV, V25, P2465, DOI 10.1101/gad.180331.111; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Turk B, 2006, NAT REV DRUG DISCOV, V5, P785, DOI 10.1038/nrd2092; Vasiljeva O, 2008, ONCOGENE, V27, P4191, DOI 10.1038/onc.2008.59; Vasiljeva O, 2007, CURR PHARM DESIGN, V13, P387, DOI 10.2174/138161207780162962; Vasiljeva O, 2006, CANCER RES, V66, P5242, DOI 10.1158/0008-5472.CAN-05-4463; White ES, 2013, J PATHOL, V229, P141, DOI 10.1002/path.4126; Wisniewski JR, 2009, J PROTEOME RES, V8, P5674, DOI 10.1021/pr900748n; Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/nmeth.1322, 10.1038/NMETH.1322]; Withana NP, 2012, CANCER RES, V72, P1199, DOI 10.1158/0008-5472.CAN-11-2759; Zavasnik-Bergant T, 2007, BIOL CHEM, V388, P1141, DOI 10.1515/BC.2007.144; Zhang Y, 2012, BLOOD, V119, P2895, DOI 10.1182/blood-2011-08-372383	45	41	41	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2015	34	50					6066	6078		10.1038/onc.2015.51	http://dx.doi.org/10.1038/onc.2015.51			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CY0RQ	25798843				2022-12-17	WOS:000366113800004
J	Strohecker, AM; Joshi, S; Possemato, R; Abraham, RT; Sabatini, D; White, E				Strohecker, A. M.; Joshi, S.; Possemato, R.; Abraham, R. T.; Sabatini, D. M.; White, E.			Identification of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase as a novel autophagy regulator by high content shRNA screening	ONCOGENE			English	Article							ADVANCED SOLID TUMORS; PHASE-I TRIAL; SIRNA SCREEN; TARGETING AUTOPHAGY; PROTEIN-DEGRADATION; SELECTIVE AUTOPHAGY; HUNTINGTONS-DISEASE; BODY FORMATION; CELL-DEATH; CANCER	Deregulation of autophagy has been linked to multiple degenerative diseases and cancer, thus the identification of novel autophagy regulators for potential therapeutic intervention is important. To meet this need, we developed a high content image-based short hairpin RNA screen monitoring levels of the autophagy substrate p62/SQSTM1. We identified 186 genes whose loss caused p62 accumulation indicative of autophagy blockade, and 67 genes whose loss enhanced p62 elimination indicative of autophagy stimulation. One putative autophagy stimulator, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 (PFKFB4), drives flux through pentose phosphate pathway. Knockdown of PFKFB4 in prostate cancer cells increased p62 and reactive oxygen species (ROS), but surprisingly increased autophagic flux. Addition of the ROS scavenger N-acetyl cysteine prevented p62 accumulation in PFKFB4-depleted cells, suggesting that the upregulation of p62 and autophagy was a response to oxidative stress caused by PFKFB4 elimination. Thus, PFKFB4 suppresses oxidative stress and p62 accumulation, without which autophagy is stimulated likely as a ROS detoxification response.	[Strohecker, A. M.; Joshi, S.; White, E.] Rutgers Canc Inst New Jersey, New Brunswick, NJ 08903 USA; [Strohecker, A. M.; Joshi, S.; White, E.] Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08855 USA; [Strohecker, A. M.] Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; [Strohecker, A. M.] Ohio State Univ, Dept Surg, Columbus, OH 43210 USA; [Strohecker, A. M.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; [Strohecker, A. M.] Ohio State Univ, Arthur G James Canc Hosp, Columbus, OH 43210 USA; [Strohecker, A. M.] Ohio State Univ, Richard J Solove Res Inst, Columbus, OH 43210 USA; [Possemato, R.; Sabatini, D. M.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; [Possemato, R.; Sabatini, D. M.] Broad Inst Harvard & MIT, Cambridge, MA USA; [Sabatini, D. M.] MIT, Dept Biol, Cambridge, MA USA; [Possemato, R.] NYU, Dept Pathol, New York, NY 10016 USA; [Abraham, R. T.] Pfizer, Oncol Res Unit, San Diego, CA USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Massachusetts Institute of Technology (MIT); New York University; Pfizer	White, E (corresponding author), Rutgers Canc Inst New Jersey, 195 Little Albany St, New Brunswick, NJ 08903 USA.	eileenpwhite@gmail.com	White, Eileen/ABD-6745-2021	White, Eileen/0000-0003-2961-3065; Possemato, Richard/0000-0002-2401-0030; /0000-0002-1446-7256	NIH [R37 CA53370, RC1 CA147961, R01 CA163591, R01 CA130893]; Rutgers Cancer Institute of New Jersey [P30 CA072720]; Johnson Johnson; New Jersey Commission on Cancer Research [09-2406-CCR-E0, DFHS13PPCO24]; NATIONAL CANCER INSTITUTE [P30CA072720, R37CA053370, RC1CA147961, R01CA130893, R01CA163591] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Rutgers Cancer Institute of New Jersey; Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); New Jersey Commission on Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank M Komatsu (conditional Atg7 mice) and Z Yue (Beclin1<SUP>+/-</SUP>) for mice and T Yoshimori for providing the ptf-LC3 plasmid. We also thank the staff of the Genetic Perturbation Platform of the Broad Institute (formerly the RNAi Platform) particularly S Silver and O Alkan for assistance with execution and analysis of screen data, The Genome Core of the Whitehead Institute for assistance with the Arrayscan, A Roberts for fluorescence-activated cell sorting (FACS) analysis, P Chin for technical assistance and members of the White and Sabatini laboratories for helpful discussions. This work was supported by NIH grants R37 CA53370, RC1 CA147961, R01 CA163591, R01 CA130893, the Rutgers Cancer Institute of New Jersey (P30 CA072720), Johnson & Johnson, and a gift to DMS and EW from Pfizer. AMS and SJ were supported by postdoctoral fellowships from the New Jersey Commission on Cancer Research (09-2406-CCR-E0 to AMS, DFHS13PPCO24 to SJ).	Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833; Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634; Barnard RA, 2014, AUTOPHAGY, V10, P1415, DOI 10.4161/auto.29165; Bellodi C, 2009, J CLIN INVEST, V119, P1109, DOI 10.1172/JCI35660; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Bensaad K, 2009, EMBO J, V28, P3015, DOI 10.1038/emboj.2009.242; Bernardi P, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a011387; Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002; Carew JS, 2007, BLOOD, V110, P313, DOI 10.1182/blood-2006-10-050260; Chan EYW, 2007, J BIOL CHEM, V282, P25464, DOI 10.1074/jbc.M703663200; Chen Y, 2009, CELL DEATH DIFFER, V16, P1040, DOI 10.1038/cdd.2009.49; Cheong H, 2012, NAT BIOTECHNOL, V30, P671, DOI 10.1038/nbt.2285; Criollo A, 2010, EMBO J, V29, P619, DOI 10.1038/emboj.2009.364; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Degtyarev M, 2008, J CELL BIOL, V183, P101, DOI 10.1083/jcb.200801099; Ding WX, 2009, MOL CANCER THER, V8, P2036, DOI 10.1158/1535-7163.MCT-08-1169; Duran A, 2008, CANCER CELL, V13, P343, DOI 10.1016/j.ccr.2008.02.001; Duran A, 2011, MOL CELL, V44, P134, DOI 10.1016/j.molcel.2011.06.038; Fallon L, 2002, J BIOL CHEM, V277, P486, DOI 10.1074/jbc.M109806200; Ganley IG, 2011, MOL CELL, V42, P731, DOI 10.1016/j.molcel.2011.04.024; Goidts V, 2012, ONCOGENE, V31, P3235, DOI 10.1038/onc.2011.490; Grumati P, 2010, NAT MED, V16, P1313, DOI 10.1038/nm.2247; Guo JY, 2013, GENE DEV, V27, P1447, DOI 10.1101/gad.219642.113; Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311; Gutierrez MG, 2004, J CELL SCI, V117, P2687, DOI 10.1242/jcs.01114; He PF, 2009, AUTOPHAGY, V5, P52, DOI 10.4161/auto.5.1.7247; Hoang B, 2009, MOL CANCER THER, V8, P1974, DOI 10.1158/1535-7163.MCT-08-1177; Hoyer-Hansen M, 2007, MOL CELL, V25, P193, DOI 10.1016/j.molcel.2006.12.009; Huo YY, 2013, CANCER DISCOV, V3, P894, DOI 10.1158/2159-8290.CD-13-0011; Jager S, 2004, J CELL SCI, V117, P4837, DOI 10.1242/jcs.01370; Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976; Jeon YK, 2011, BBA-PROTEINS PROTEOM, V1814, P1340, DOI 10.1016/j.bbapap.2011.05.015; Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707; Karsli-Uzunbas G, 2014, CANCER DISCOV, V4, P914, DOI 10.1158/2159-8290.CD-14-0363; Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451; Klarer AC, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-2; Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035; Komatsu M, 2007, P NATL ACAD SCI USA, V104, P14489, DOI 10.1073/pnas.0701311104; Lamark T, 2009, CELL CYCLE, V8, P1986, DOI 10.4161/cc.8.13.8892; Law BYK, 2010, MOL CANCER THER, V9, P718, DOI 10.1158/1535-7163.MCT-09-0700; Lee J, 2012, BIOCHEM J, V441, P523, DOI 10.1042/BJ20111451; Li L, 2013, J BIOL CHEM, V288, P703, DOI 10.1074/jbc.C112.396903; Li LJ, 2013, CANCER CELL, V24, P738, DOI 10.1016/j.ccr.2013.10.025; Linares JF, 2013, MOL CELL, V51, P283, DOI 10.1016/j.molcel.2013.06.020; Lipinski MM, 2010, DEV CELL, V18, P1041, DOI 10.1016/j.devcel.2010.05.005; Lu Z, 2008, J CLIN INVEST, V118, P3917, DOI 10.1172/JCI35512; Luo B, 2008, P NATL ACAD SCI USA, V105, P20380, DOI 10.1073/pnas.0810485105; Maclean KH, 2008, J CLIN INVEST, V118, P79, DOI 10.1172/JCI33700; Mahalingam D, 2014, AUTOPHAGY, V10, P1403, DOI 10.4161/auto.29231; Masiero E, 2009, CELL METAB, V10, P507, DOI 10.1016/j.cmet.2009.10.008; Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254; Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048; McKnight NC, 2012, EMBO J, V31, P1931, DOI 10.1038/emboj.2012.36; Mi HY, 2013, NAT PROTOC, V8, P1551, DOI 10.1038/nprot.2013.092; Minchenko OH, 2005, BIOCHIMIE, V87, P1005, DOI 10.1016/j.biochi.2005.04.007; Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028; Okar DA, 1999, BIOFACTORS, V10, P1, DOI 10.1002/biof.5520100101; Okar DO, 2001, TRENDS BIOCHEM SCI, V26, P30, DOI 10.1016/S0968-0004(00)01699-6; Orvedahl A, 2011, NATURE, V480, P113, DOI 10.1038/nature10546; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Qin QY, 2006, J CELL BIOL, V172, P497, DOI 10.1083/jcb.200505079; Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497; Rangwala R, 2014, AUTOPHAGY, V10, P1391, DOI 10.4161/auto.29119; Rangwala R, 2014, AUTOPHAGY, V10, P1369, DOI 10.4161/auto.29118; Rao S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4056; Rodriguez A, 2006, CELL METAB, V3, P211, DOI 10.1016/j.cmet.2006.01.011; Ros S, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-8; Ros S, 2012, CANCER DISCOV, V2, P328, DOI 10.1158/2159-8290.CD-11-0234; Rosenfeld MR, 2014, AUTOPHAGY, V10, P1359, DOI 10.4161/auto.28984; Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865; Rubinsztein DC, 2011, CELL, V146, P682, DOI 10.1016/j.cell.2011.07.030; Rusten TE, 2012, NAT CELL BIOL, V14, P38, DOI 10.1038/ncb2381; Rusten TE, 2009, J CELL SCI, V122, P2179, DOI 10.1242/jcs.050021; Sahani MH, 2014, AUTOPHAGY, V10, P431, DOI 10.4161/auto.27344; Sanchez P, 1998, MOL CELL BIOL, V18, P3069, DOI 10.1128/MCB.18.5.3069; Sandri M, 2013, J CELL SCI, V126, P5325, DOI 10.1242/jcs.114041; Sarkar S, 2007, NAT CHEM BIOL, V3, P331, DOI 10.1038/nchembio883; Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623; Shanmugam M, 2009, J BIOL CHEM, V284, P26816, DOI 10.1074/jbc.M109.000646; Strohecker AM, 2013, CANCER DISCOV, V3, P1272, DOI 10.1158/2159-8290.CD-13-0397; Szyniarowski P, 2011, AUTOPHAGY, V7, P892, DOI 10.4161/auto.7.8.15770; Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211; Tamai K, 2007, BIOCHEM BIOPH RES CO, V360, P721, DOI 10.1016/j.bbrc.2007.06.105; Vogl DT, 2014, AUTOPHAGY, V10, P1380, DOI 10.4161/auto.29264; Warmoes MO, 2014, BIOCHEM PHARMACOL, V92, P12, DOI 10.1016/j.bcp.2014.07.019; Wei HJ, 2011, GENE DEV, V25, P1510, DOI 10.1101/gad.2051011; White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262; White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023; Williams A, 2008, NAT CHEM BIOL, V4, P295, DOI 10.1038/nchembio.79; Wooten MW, 2005, J BIOL CHEM, V280, P35625, DOI 10.1074/jbc.C500237200; Yalcin A, 2009, EXP MOL PATHOL, V86, P174, DOI 10.1016/j.yexmp.2009.01.003; Yang A, 2014, CANCER DISCOV, V4, P905, DOI 10.1158/2159-8290.CD-14-0362; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Yang Z, 2014, AUTOPHAGY, V10, P382, DOI 10.4161/auto.27345; Yang Z, 2013, J EXP MED, V210, P2119, DOI 10.1084/jem.20130252; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707; Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663	97	41	41	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 5	2015	34	45					5662	5676		10.1038/onc.2015.23	http://dx.doi.org/10.1038/onc.2015.23			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9GA	25772235	Green Submitted, Green Accepted			2022-12-17	WOS:000364594300007
J	Chen, X; Pappo, A; Dyer, MA				Chen, X.; Pappo, A.; Dyer, M. A.			Pediatric solid tumor genomics and developmental pliancy	ONCOGENE			English	Review							EMBRYONAL RHABDOMYOSARCOMA; RETINOBLASTOMA; MUTATIONS; ATRX; NEUROBLASTOMA; CELL; SARCOMA; CHILDHOOD; SURVIVAL; THERAPY	Pediatric solid tumors are remarkably diverse in their cellular origins, developmental timing and clinical features. Over the last 5 years, there have been significant advances in our understanding of the genetic lesions that contribute to the initiation and progression of pediatric solid tumors. To date, over 1000 pediatric solid tumors have been analyzed by Next-Generation Sequencing. These genomic data provide the foundation to launch new research efforts to address one of the fundamental questions in cancer biology-why are some cells more susceptible to malignant transformation by particular genetic lesions at discrete developmental stages than others? Because of their developmental, molecular, cellular and genetic diversity, pediatric solid tumors provide an ideal platform to begin to answer this question. In this review, we highlight the diversity of pediatric solid tumors and provide a new framework for studying the cellular and developmental origins of pediatric cancer. We also introduce a new unifying concept called cellular pliancy as a possible explanation for susceptibility to cancer and the developmental origins of pediatric solid tumors.	[Chen, X.] St Jude Childrens Res Hosp, Dept Computat Biol & Bioinformat, Memphis, TN 38105 USA; [Pappo, A.] St Jude Childrens Res Hosp, Dept Oncol, Memphis, TN 38105 USA; [Dyer, M. A.] St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA; [Dyer, M. A.] Howard Hughes Med Inst, Chevy Chase, MD USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; Howard Hughes Medical Institute	Dyer, MA (corresponding author), St Jude Childrens Res Hosp, Dept Dev Neurobiol, MS 323,262 Danny Thomas Pl, Memphis, TN 38105 USA.	michael.dyer@stjude.org	Dyer, Michael/N-8134-2018; Chen, Xiang/N-2524-2018	Chen, Xiang/0000-0002-2499-8261	NATIONAL CANCER INSTITUTE [R01CA168875] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY018599, R01EY023619, R01EY014867] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NCI NIH HHS [R01 CA168875] Funding Source: Medline; NEI NIH HHS [R01 EY018599, R01 EY023619, R01 EY014867] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Abramson DH, 2002, ARCH OPHTHALMOL-CHIC, V120, P1232; Ajioka I, 2007, CELL, V131, P378, DOI 10.1016/j.cell.2007.09.036; Argentaro A, 2007, P NATL ACAD SCI USA, V104, P11939, DOI 10.1073/pnas.0704057104; Baca SC, 2013, CELL, V153, P666, DOI 10.1016/j.cell.2013.03.021; Barr FG, 1997, INT J BIOCHEM CELL B, V29, P1449, DOI 10.1016/S1357-2725(97)00095-2; Berger MF, 2011, NATURE, V470, P214, DOI 10.1038/nature09744; Carpenter EL, 2012, NAT REV CLIN ONCOL, V9, P391, DOI 10.1038/nrclinonc.2012.72; Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; Chen X, 2014, CELL REP, V7, P104, DOI 10.1016/j.celrep.2014.03.003; Chen X, 2013, CANCER CELL, V24, P710, DOI 10.1016/j.ccr.2013.11.002; Cheung NKV, 2013, NAT REV CANCER, V13, P397, DOI 10.1038/nrc3526; Cheung NKV, 2012, JAMA-J AM MED ASSOC, V307, P1062, DOI 10.1001/jama.2012.228; Cole KA, 2012, CLIN CANCER RES, V18, P2423, DOI 10.1158/1078-0432.CCR-11-1409; Costa DB, 2006, EUR J HAEMATOL, V76, P53; Crasta K, 2012, NATURE, V482, P53, DOI 10.1038/nature10802; Donovan SL, 2006, BMC BIOL, V4, DOI 10.1186/1741-7007-4-14; Downing JR, 2012, NAT GENET, V44, P619, DOI 10.1038/ng.2287; Dyer MA, 2005, NAT REV CANCER, V5, P91, DOI 10.1038/nrc1545; Eustermann S, 2011, NAT STRUCT MOL BIOL, V18, P777, DOI 10.1038/nsmb.2070; Fan ZP, 2009, NAT CELL BIOL, V11, P1002, DOI 10.1038/ncb1913; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Garrick D, 2006, PLOS GENET, V2, P438, DOI 10.1371/journal.pgen.0020058; Gibbons RJ, 2003, NAT GENET, V34, P446, DOI 10.1038/ng1213; Gibbons RJ, 2000, NAT GENET, V24, P368, DOI 10.1038/74191; Hanna JH, 2010, CELL, V143, P508, DOI 10.1016/j.cell.2010.10.008; Hatley ME, 2012, CANCER CELL, V22, P536, DOI 10.1016/j.ccr.2012.09.004; Howlader N, 2013, SEER CANC STAT REV 1; Johnson DA, 2007, CANCER RES, V67, P2701, DOI 10.1158/0008-5472.CAN-06-3754; Kempf-Bielack B, 2005, J CLIN ONCOL, V23, P559, DOI 10.1200/JCO.2005.04.063; Lada AG, 2012, BIOL DIRECT, V7, DOI 10.1186/1745-6150-7-47; Leavey PJ, 2008, PEDIATR BLOOD CANCER, V51, P334, DOI 10.1002/pbc.21618; Lewis PW, 2010, P NATL ACAD SCI USA, V107, P14075, DOI 10.1073/pnas.1008850107; MacPherson D, 2007, CANCER RES, V67, P7547, DOI 10.1158/0008-5472.CAN-07-0276; McEvoy J, 2014, ONCOTARGET, V5, P438, DOI 10.18632/oncotarget.1686; McEvoy J, 2011, CANCER CELL, V20, P260, DOI 10.1016/j.ccr.2011.07.005; Mikkelsen TS, 2008, NATURE, V454, P49, DOI 10.1038/nature07056; Mirabello L, 2009, CANCER-AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121; Molenaar JJ, 2012, NATURE, V483, P589, DOI 10.1038/nature10910; Mosse YP, 2013, LANCET ONCOL, V14, P472, DOI 10.1016/S1470-2045(13)70095-0; Ng D, 2004, NAT GENET, V36, P411, DOI 10.1038/ng1321; Nik-Zainal S, 2012, CELL, V149, P979, DOI 10.1016/j.cell.2012.04.024; Ognjanovic S, 2009, CANCER-AM CANCER SOC, V115, P4218, DOI 10.1002/cncr.24465; Orkin SH, 2011, CELL, V145, P835, DOI 10.1016/j.cell.2011.05.019; Pappo AS, 1999, J CLIN ONCOL, V17, P3487, DOI 10.1200/JCO.1999.17.11.3487; Pickett H, 2009, TELOMERES TELOMERASE; Raney RB, 2001, J PEDIAT HEMATOL ONC, V23, P215, DOI 10.1097/00043426-200105000-00008; Riggi N, 2008, CANCER RES, V68, P2176, DOI 10.1158/0008-5472.CAN-07-1761; Ruza E, 2003, J PEDIAT HEMATOL ONC, V25, P780, DOI 10.1097/00043426-200310000-00007; Scollon S, 2014, GENOME MED, V6, DOI 10.1186/s13073-014-0069-3; SCRABLE H, 1989, P NATL ACAD SCI USA, V86, P7480, DOI 10.1073/pnas.86.19.7480; Shukla N, 2012, CLIN CANCER RES, V18, P748, DOI 10.1158/1078-0432.CCR-11-2056; Singhal N, 2010, CELL, V141, P943, DOI 10.1016/j.cell.2010.04.037; Smith MA, 2014, CANCER-AM CANCER SOC, V120, P2497, DOI 10.1002/cncr.28748; Steensma DP, 2004, BLOOD, V103, P2019, DOI 10.1182/blood-2003-09-3360; Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055; Tirode F, 2014, CANCER DISCOV, V4, P1342, DOI 10.1158/2159-8290.CD-14-0622; Wamstad JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002814; Xue YT, 2003, P NATL ACAD SCI USA, V100, P10635, DOI 10.1073/pnas.1937626100; Zhang JH, 2012, NATURE, V481, P329, DOI 10.1038/nature10733; Zhang JK, 2004, NAT GENET, V36, P351, DOI 10.1038/ng1318	60	41	42	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2015	34	41					5207	5215		10.1038/onc.2014.474	http://dx.doi.org/10.1038/onc.2014.474			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CT1QL	25639868	hybrid, Green Published, Green Accepted			2022-12-17	WOS:000362575400001
J	Bianco, S; Jangal, M; Garneau, D; Gevry, N				Bianco, S.; Jangal, M.; Garneau, D.; Gevry, N.			LRH-1 controls proliferation in breast tumor cells by regulating CDKN1A gene expression	ONCOGENE			English	Article							LIVER RECEPTOR HOMOLOG-1; KINASE INHIBITOR P21; CANCER CELLS; GENOMICS DATA; ALPHA; TRANSCRIPTION; ENHANCERS; CHROMATIN; TARGET; PROGRESSION	Liver receptor homolog-1 (LRH-1, NR5A2) is an orphan nuclear receptor that has an essential role in cancer progression, notably in breast cancer. Although its role in promoting cancer cell proliferation and migration is well documented, the molecular basis is not completely established. Here, we report that LRH-1 inhibition affects two-and three-dimensional cell proliferation of different types of breast cancer cells, including estrogen receptor alpha (ER alpha)-positive and triple-negative cells. This phenotype is accompanied by the upregulation of the cyclin-dependent kinase inhibitor CDKN1A (aka p21(CIP1/WAF1)) in a p53-independent manner. Chromatin immunoprecipitation analysis shows that LRH-1 cooperates with FOXA1 and binds directly to CDKN1A promoter and a distal regulatory region found at - 62 kb from its transcriptional start sites, allowing repression of CDKN1A transcription. LRH-1 or FOXA1 depletion induces CDKN1A upregulation by removing histone deacetylase 2 from the promoter and distal regulatory elements and permitting histone acetylation in these regions. Analysis of breast cancer samples reveals that a high LRH-1 level is inversely correlated with CDKN1A expression in breast cancer patients and is associated with poor prognosis. This study reveals a novel mechanism of control of cell proliferation by LRH-1 regulating CDKN1A transcription in breast cancer cells, independent of ERa and p53 status. Targeting LRH-1 may provide an attractive prospect for treatment of tumors that are resistant to hormonal and targeted therapy.	[Bianco, S.; Jangal, M.; Garneau, D.; Gevry, N.] Univ Sherbrooke, Fac Sci, Dept Biol, Sherbrooke, PQ J1K 2R1, Canada	University of Sherbrooke	Gevry, N (corresponding author), Univ Sherbrooke, Fac Sci, Dept Biol, 2500 Blvd Univ, Sherbrooke, PQ J1K 2R1, Canada.	nicolas.gevry@usherbrooke.ca			Canadian Institute of Health Research (CIHR); Reseau Quebecois en Reproduction (RQR)	Canadian Institute of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Reseau Quebecois en Reproduction (RQR)	We thank Alain Lavigueur and Bruce Murphy for critical comments on the manuscript. We are also grateful to Robert Clark for providing the MCF7/LCC2 and MCF7/LCC9 cell lines and Mien-Chie Hung for the MCF7/HER2-18 cell line. This work was supported with fund from the Canadian Institute of Health Research (CIHR) to NG. SB was the recipient of a postdoctoral fellowship from the Reseau Quebecois en Reproduction (RQR).	Ai NP, 2011, NUCLEIC ACIDS RES, V39, P9592, DOI 10.1093/nar/gkr698; Annicotte JS, 2005, ONCOGENE, V24, P8167, DOI 10.1038/sj.onc.1208950; Atkin SD, 2013, MOL ENDOCRINOL, V27, P598, DOI 10.1210/me.2012-1371; Benod C, 2011, P NATL ACAD SCI USA, V108, P16927, DOI 10.1073/pnas.1112047108; Bianco S, 2012, TRANSCRIPTION, V3, P4165; Bianco S, 2014, CANCER RES, V74, P2015, DOI 10.1158/0008-5472.CAN-13-2351; Botrugno OA, 2004, MOL CELL, V15, P499, DOI 10.1016/j.molcel.2004.07.009; Boyle AP, 2008, BIOINFORMATICS, V24, P2537, DOI 10.1093/bioinformatics/btn480; Brunner N, 1997, CANCER RES, V57, P3486; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chand AL, 2010, ENDOCR-RELAT CANCER, V17, P965, DOI 10.1677/ERC-10-0179; Chand AL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031593; Chand AL, 2011, STEROIDS, V76, P741, DOI 10.1016/j.steroids.2011.02.024; Creyghton MP, 2010, P NATL ACAD SCI USA, V107, P21931, DOI 10.1073/pnas.1016071107; De Santa F, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000384; Duggavathi R, 2008, GENE DEV, V22, P1871, DOI 10.1101/gad.472008; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gomes NP, 2006, GENE DEV, V20, P601, DOI 10.1101/gad.1398206; Han SW, 2004, CLIN CANCER RES, V10, P1911, DOI 10.1158/1078-0432.CCR-03-0985; Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966; Heintzman ND, 2009, NATURE, V459, P108, DOI 10.1038/nature07829; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hlobilkova A, 2006, ANTICANCER RES, V26, P1015; Holmstrom SR, 2011, GENE DEV, V25, P1674, DOI 10.1101/gad.16860911; Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730; Jangal M, 2014, NUCLEIC ACIDS RES, V42, P11339, DOI 10.1093/nar/gku791; Jung YS, 2010, CELL SIGNAL, V22, P1003, DOI 10.1016/j.cellsig.2010.01.013; Kawai H, 2003, INT J CANCER, V107, P353, DOI 10.1002/ijc.11403; Knower KC, 2013, BREAST CANCER RES TR, V142, P211, DOI 10.1007/s10549-013-2716-6; Lai CF, 2013, NUCLEIC ACIDS RES, V41, P10228, DOI 10.1093/nar/gkt827; Lam SW, 2014, CANCER TREAT REV, V40, P129, DOI 10.1016/j.ctrv.2013.06.006; Lazarus KA, 2013, BIOCHEM BIOPH RES CO, V438, P533, DOI 10.1016/j.bbrc.2013.07.101; Lazarus KA, 2012, J STEROID BIOCHEM, V130, P138, DOI 10.1016/j.jsbmb.2011.12.017; Li GL, 2012, CELL, V148, P84, DOI 10.1016/j.cell.2011.12.014; Lu S, 2000, MOL ENDOCRINOL, V14, P753, DOI 10.1210/me.14.5.753; Madden SF, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3444; Mandal S, 2010, J CELL PHYSIOL, V224, P28, DOI 10.1002/jcp.22078; Miki Y, 2006, CANCER LETT, V244, P24, DOI 10.1016/j.canlet.2005.11.038; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Oosterveer MH, 2012, J CLIN INVEST, V122, P2817, DOI 10.1172/JCI62368; Osborne CK, 2011, ANNU REV MED, V62, P233, DOI 10.1146/annurev-med-070909-182917; Robinson Jessica L L, 2012, Front Endocrinol (Lausanne), V3, P68, DOI 10.3389/fendo.2012.00068; Sanders DA, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-1-r6; Schoonjans K, 2005, P NATL ACAD SCI USA, V102, P2058, DOI 10.1073/pnas.0409756102; Sidler D, 2012, ONCOIMMUNOLOGY, V1, DOI 10.4161/onci.19459; Svotelis A, 2011, EMBO J, V30, P3947, DOI 10.1038/emboj.2011.284; Thiruchelvam PTR, 2011, BREAST CANCER RES TR, V127, P385, DOI 10.1007/s10549-010-0994-9; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; Wang D, 2011, NATURE, V474, P390, DOI 10.1038/nature10006; Wang SL, 2008, MOL CELL BIOCHEM, V308, P93, DOI 10.1007/s11010-007-9616-1; Yamaguchi T, 2010, GENE DEV, V24, P455, DOI 10.1101/gad.552310; Zhang C, 2013, NAT MED, V19, P1061, DOI 10.1038/nm.3192; Zupkovitz G, 2010, MOL CELL BIOL, V30, P1171, DOI 10.1128/MCB.01500-09	54	41	42	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2015	34	34					4509	4518		10.1038/onc.2014.382	http://dx.doi.org/10.1038/onc.2014.382			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BR	25435372				2022-12-17	WOS:000360189200010
J	Jiang, W; Huang, H; Ding, L; Zhu, P; Saiyin, H; Ji, G; Zuo, J; Han, D; Pan, Y; Ding, D; Ma, X; Zhang, Y; Wu, J; Yi, Q; Liu, JO; Huang, H; Dang, Y; Yu, L				Jiang, W.; Huang, H.; Ding, L.; Zhu, P.; Saiyin, H.; Ji, G.; Zuo, J.; Han, D.; Pan, Y.; Ding, D.; Ma, X.; Zhang, Y.; Wu, J.; Yi, Q.; Liu, J. O.; Huang, H.; Dang, Y.; Yu, L.			Regulation of cell cycle of hepatocellular carcinoma by NF90 through modulation of cyclin E1 mRNA stability	ONCOGENE			English	Article							BREAST-CANCER CELLS; GENE-EXPRESSION; MITOTIC CONTROL; NUCLEAR EXPORT; BINDING; PROTEIN; PHOSPHORYLATION; STABILIZATION; OVEREXPRESSION; IDENTIFICATION	Activation of cyclin E1, a key regulator of the G1/S cell-cycle transition, has been implicated in many cancers including hepatocellular carcinoma (HCC). Although much is known about the regulation of cyclin E1 expression and stability, its post-transcriptional regulation mechanism remains incompletely understood. Here, we report that nuclear factor 90 (NF90), a double-stranded RNA (dsRNA) binding protein, regulates cyclin E1 in HCC. We demonstrate that NF90 is upregulated in HCC specimens and that suppression of NF90 decreases HCC cell growth and delays G1/S transition. We identified cyclin E1 as a new target of NF90 and found a significant correlation between NF90 and cyclin E1 expression in HCC. The mRNA and protein levels of cyclin E1 were downregulated upon NF90 knockdown. Suppression of NF90 caused a decrease in the half-life of cyclin E1 mRNA, which was rescued by ectopic expression of NF90. Furthermore, NF90 bound to the 3' untranslated regions (3' UTRs) of cyclin E1 mRNA in vitro and in vivo. Knockdown of NF90 also inhibited tumor growth of HCC cell lines in mouse xenograft model. Moreover, we showed that inhibition of NF90 sensitized HCC cells to the cyclin-dependent kinase 2 (CDK2) inhibitor, roscovitine. Taken together, downregulation of NF90 in HCC cell lines can delay cell-cycle progression, inhibit cell proliferation, and reduce tumorigenic capacity in vivo. These results suggest that NF90 has an important role in HCC pathogenesis and that it can serve as a novel therapeutic target for HCC.	[Jiang, W.; Huang, H.; Ding, L.; Zhu, P.; Saiyin, H.; Ji, G.; Zuo, J.; Han, D.; Pan, Y.; Ding, D.; Ma, X.; Zhang, Y.; Wu, J.; Huang, H.; Dang, Y.; Yu, L.] Fudan Univ, State Key Lab Genet Engn,Inst Genet,Sch Life Sci, Key Lab Metab & Mol Med,Minist Educ, Dept Biochem & Mol Biol,Sch Basic Med Sci, Shanghai 200032, Peoples R China; [Ding, L.; Pan, Y.] Mayo Clin, Coll Med, Ctr Canc, Dept Biochem & Mol Biol,Dept Urol, Rochester, NY USA; [Yi, Q.] Cleveland Clin, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44106 USA; [Liu, J. O.] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA	Fudan University; Mayo Clinic; Cleveland Clinic Foundation; Johns Hopkins University	Dang, Y (corresponding author), Fudan Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Key Lab Metab & Mol Med, 130 Dongan Rd, Shanghai 200032, Peoples R China.	yongjundang@fudan.edu.cn; longyu@fudan.edu.cn	Han, Dingding/HGD-2042-2022; dang, yongjun/M-6531-2016	Han, Dingding/0000-0003-0963-6286; dang, yongjun/0000-0001-7237-1132; Saiyin, Hexige/0000-0003-2993-6817	National Key Sci-Tech Special Project of China [2013ZX10002010]; National Natural Science Foundation of China [31270830]; NATIONAL CANCER INSTITUTE [P30CA015083, P30CA006973] Funding Source: NIH RePORTER	National Key Sci-Tech Special Project of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Key Sci-Tech Special Project of China (2013ZX10002010), and the National Natural Science Foundation of China (31270830). We thank Dr Tilman Schneider-Poetsch, Sarah Head and Yang Xianmei for generously editing the manuscript.	AKAMA Y, 1995, JPN J CANCER RES, V86, P617, DOI 10.1111/j.1349-7006.1995.tb02442.x; Benson C, 2007, BRIT J CANCER, V96, P29, DOI 10.1038/sj.bjc.6603509; Bose SK, 2006, BIOCHEM J, V396, P99, DOI 10.1042/BJ20051548; Cam WR, 2001, DIGEST DIS SCI, V46, P2187, DOI 10.1023/A:1011962915280; CORTHESY B, 1994, J BIOL CHEM, V269, P20682; Duchange N, 2000, GENE, V261, P345, DOI 10.1016/S0378-1119(00)00495-9; Fung LF, 2000, LIFE SCI, V67, P923, DOI 10.1016/S0024-3205(00)00684-6; Guan DY, 2008, MOL CELL BIOL, V28, P4629, DOI 10.1128/MCB.00120-08; Guo X, 2006, CANCER RES, V66, P7948, DOI 10.1158/0008-5472.CAN-05-4362; Guzi Timothy, 2004, Curr Opin Investig Drugs, V5, P1311; He J, 2005, NEW ENGL J MED, V353, P1124, DOI 10.1056/NEJMsa050467; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; Kuwano Y, 2008, MOL CELL BIOL, V28, P4562, DOI 10.1128/MCB.00165-08; Kuwano Y, 2010, NUCLEIC ACIDS RES, V38, P225, DOI 10.1093/nar/gkp861; Larcher JC, 2004, FASEB J, V18, P1761, DOI 10.1096/fj.04-1763fje; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; Nanda S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003442; Pei Y, 2008, J IMMUNOL, V180, P222, DOI 10.4049/jimmunol.180.1.222; Peng SY, 1998, J HEPATOL, V29, P281, DOI 10.1016/S0168-8278(98)80014-7; Shamanna RA, 2013, ONCOGENE, V32, P5176, DOI 10.1038/onc.2012.533; Shi LF, 2005, J BIOL CHEM, V280, P18981, DOI 10.1074/jbc.M411034200; Shim J, 2002, MOL CELL, V10, P1331, DOI 10.1016/S1097-2765(02)00730-X; Shiohama A, 2007, EXP CELL RES, V313, P4196, DOI 10.1016/j.yexcr.2007.07.020; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Sui L, 2001, GYNECOL ONCOL, V83, P56, DOI 10.1006/gyno.2001.6308; Ting NSY, 1998, J BIOL CHEM, V273, P2136, DOI 10.1074/jbc.273.4.2136; Vumbaca F, 2008, MOL CELL BIOL, V28, P772, DOI 10.1128/MCB.02078-06; Whittaker SR, 2007, CELL CYCLE, V6, P3114, DOI 10.4161/cc.6.24.5142; Xu BS, 2009, RNA, V15, P357, DOI 10.1261/rna.1368009; Xu YH, 1999, MOL GENET METAB, V68, P441, DOI 10.1006/mgme.1999.2934; Zhu P, 2010, J IMMUNOL, V185, P5140, DOI 10.4049/jimmunol.1000849	32	41	41	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2015	34	34					4460	4470		10.1038/onc.2014.373	http://dx.doi.org/10.1038/onc.2014.373			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BR	25399696	Green Accepted			2022-12-17	WOS:000360189200005
J	Yun, EJ; Baek, ST; Xie, D; Tseng, SF; Dobin, T; Hernandez, E; Zhou, J; Zhang, L; Yang, J; Sun, H; Xiao, G; He, D; Kittler, R; Hsieh, JT				Yun, E-J; Baek, S. T.; Xie, D.; Tseng, S-F; Dobin, T.; Hernandez, E.; Zhou, J.; Zhang, L.; Yang, J.; Sun, H.; Xiao, G.; He, D.; Kittler, R.; Hsieh, J-T			DAB2IP regulates cancer stem cell phenotypes through modulating stem cell factor receptor and ZEB1	ONCOGENE			English	Article							ABERRANT PROMOTER METHYLATION; PROTEIN HDAB2IP GENE; PROSTATE-CANCER; C-KIT; TYROSINE KINASE; PROSPECTIVE IDENTIFICATION; MESENCHYMAL TRANSITION; MAMMALIAN TARGET; DOWN-REGULATION; GROWTH-FACTOR	Cancer stem cell (CSC), the primary source of cancer-initiating population, is involved in cancer recurrence and drug-resistant phenotypes. This study demonstrates that the loss of DAB2IP, a novel Ras-GTPase activating protein frequently found in many cancer types, is associated with CSC properties. Mechanistically, DAB2IP is able to suppress stem cell factor receptor (c-kit or CD117) gene expression by interacting with a newly identified silencer in the c-kit gene. Moreover, DAB2IP is able to inhibit c-kit-PI3K-Akt-mTOR signaling pathway that increases c-myc protein to activate ZEB1 gene expression leading to the elevated CSC phenotypes. An inverse correlation between CD117 or ZEB1 and DAB2IP is also found in clinical specimens. Similarly, Elevated expression of ZEB1 and CD117 are found in the prostate basal cell population of DAB2IP knockout mice. Our study reveals that DAB2IP has a critical role in modulating CSC properties via CD117-mediated ZEB1 signaling pathway.	[Yun, E-J; Tseng, S-F; Dobin, T.; Hernandez, E.; Zhou, J.; Zhang, L.; Hsieh, J-T] Univ Texas SW Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA; [Baek, S. T.] Univ Texas SW Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA; [Xie, D.] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Canc Res Inst, Dept Gen Surg, Wuhan 430074, Hubei, Peoples R China; [Zhou, J.; Zhang, L.; He, D.] Xi An Jiao Tong Univ, Sch Med, Affiliated Hosp 1, Dept Urol, Xian 710049, Peoples R China; [Yang, J.; Sun, H.; Xiao, G.] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA; [Kittler, R.] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA; [Kittler, R.] Univ Texas SW Med Ctr Dallas, Eugene McDermott Ctr Human Growth, Dallas, TX 75390 USA; [Kittler, R.] Univ Texas SW Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dev, Dallas, TX 75390 USA; [Hsieh, J-T] China Med Univ Hosp, Grad Inst Canc Biol, Taichung, Taiwan	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; Huazhong University of Science & Technology; Xi'an Jiaotong University; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; China Medical University Taiwan; China Medical University Hospital - Taiwan	Hsieh, JT (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Urol, J8-134 Dallas,5323 Harry Hines Blvd, Dallas, TX 75390 USA.	jt.hsieh@utsouthwestern.edu	Kittler, Ralf/I-4662-2013; Kittler, Ralf/AAD-4258-2020	Kittler, Ralf/0000-0002-0098-6792; Kittler, Ralf/0000-0002-0098-6792; Baek, Seung Tae/0000-0003-0040-1501	United States Army [W81XWH-11-1-0491]; National Institutes of Health [CA182670]; NATIONAL CANCER INSTITUTE [R01CA182670] Funding Source: NIH RePORTER	United States Army(United States Department of DefenseUnited States Army); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Mrs Mary Barnes for editing this manuscript. This work was supported in part by grants from the United States Army (W81XWH-11-1-0491 to J-TH) and National Institutes of Health (CA182670 to J-TH).	Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bjerkvig R, 2005, NAT REV CANCER, V5, P899, DOI 10.1038/nrc1740; Burger PE, 2005, P NATL ACAD SCI USA, V102, P7180, DOI 10.1073/pnas.0502761102; Chambeyron S, 2004, CURR OPIN CELL BIOL, V16, P256, DOI 10.1016/j.ceb.2004.03.004; Chen H, 2006, DNA CELL BIOL, V25, P232, DOI 10.1089/dna.2006.25.232; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Dote H, 2004, CLIN CANCER RES, V10, P2082, DOI 10.1158/1078-0432.CCR-03-0236; Dote H, 2005, BRIT J CANCER, V92, P1117, DOI 10.1038/sj.bjc.6602458; Efeyan A, 2010, CURR OPIN CELL BIOL, V22, P169, DOI 10.1016/j.ceb.2009.10.007; Eramo A, 2008, CELL DEATH DIFFER, V15, P504, DOI 10.1038/sj.cdd.4402283; Feng LX, 2000, J BIOL CHEM, V275, P25572, DOI 10.1074/jbc.M002218200; GLEASON DF, 1992, HUM PATHOL, V23, P273, DOI 10.1016/0046-8177(92)90108-F; Goldstein AS, 2010, SCIENCE, V329, P568, DOI 10.1126/science.1189992; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Hassan HT, 1996, ACTA HAEMATOL-BASEL, V95, P257; Hua SJ, 2009, CELL, V137, P1259, DOI 10.1016/j.cell.2009.04.043; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Joensuu H, 2001, ANN MED, V33, P451, DOI 10.3109/07853890109002093; Kim M, 2002, CLIN CANCER RES, V8, P22; Klonisch T, 2008, TRENDS MOL MED, V14, P450, DOI 10.1016/j.molmed.2008.08.003; Kong DJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012445; Kong ZL, 2010, INT J RADIAT ONCOL, V78, P1210, DOI 10.1016/j.ijrobp.2010.06.019; Kong ZL, 2010, CANCER RES, V70, P2829, DOI 10.1158/0008-5472.CAN-09-2919; Kyprianou N, 2010, P NATL ACAD SCI USA, V107, P2731, DOI 10.1073/pnas.0914721107; Lawson DA, 2007, P NATL ACAD SCI USA, V104, P181, DOI 10.1073/pnas.0609684104; Leong KG, 2008, NATURE, V456, P804, DOI 10.1038/nature07427; Li JM, 2007, AM J PHYSIOL-ENDOC M, V293, pE475, DOI 10.1152/ajpendo.00172.2007; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Ma FX, 2012, INT J ENDOCRINOL, V2012, DOI 10.1155/2012/948683; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Munugalavadla V, 2005, MOL CELL BIOL, V25, P6747, DOI 10.1128/MCB.25.15.6747-6759.2005; NAGLE RB, 1987, CANCER RES, V47, P281; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Patrawala L, 2006, ONCOGENE, V25, P1696, DOI 10.1038/sj.onc.1209327; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Rangel EB, 2013, STEM CELLS, V31, P1644, DOI 10.1002/stem.1412; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; STROBL H, 1992, BRIT J HAEMATOL, V82, P287, DOI 10.1111/j.1365-2141.1992.tb06420.x; Sundstrom M, 2003, IMMUNOLOGY, V108, P89, DOI 10.1046/j.1365-2567.2003.01559.x; Van der Poel HG, 2004, J UROLOGY, V172, P1333, DOI 10.1097/01.ju.0000138829.97838.19; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wang Z, 2002, J BIOL CHEM, V277, P12622, DOI 10.1074/jbc.M110568200; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Wright JL, 2010, J UROLOGY, V183, P2213, DOI 10.1016/j.juro.2010.02.017; Wu K, 2013, ONCOGENE, V33, P1954; Wu KJ, 2013, CLIN CANCER RES, V19, P4740, DOI 10.1158/1078-0432.CCR-13-0954; Xie DX, 2010, P NATL ACAD SCI USA, V107, P2485, DOI 10.1073/pnas.0908133107; Xie DX, 2009, P NATL ACAD SCI USA, V106, P19878, DOI 10.1073/pnas.0908458106; Xin L, 2007, STEM CELLS, V25, P2760, DOI 10.1634/stemcells.2007-0355; YAMAMOTO K, 1993, JPN J CANCER RES, V84, P1136, DOI 10.1111/j.1349-7006.1993.tb02813.x; Yano M, 2005, INT J CANCER, V113, P59, DOI 10.1002/ijc.20531; YOSHINAGA K, 1991, DEVELOPMENT, V113, P689; Yu M, 2009, GENE DEV, V23, P1737, DOI 10.1101/gad.1809309; Zhang HF, 2008, J CLIN INVEST, V118, P3904, DOI 10.1172/JCI36168; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	60	41	42	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	2015	34	21					2741	2752		10.1038/onc.2014.215	http://dx.doi.org/10.1038/onc.2014.215			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI7XN	25043300				2022-12-17	WOS:000354979500007
J	Mishra, R; Thorat, D; Soundararajan, G; Pradhan, SJ; Chakraborty, G; Lohite, K; Karnik, S; Kundu, GC				Mishra, R.; Thorat, D.; Soundararajan, G.; Pradhan, S. J.; Chakraborty, G.; Lohite, K.; Karnik, S.; Kundu, G. C.			Semaphorin 3A upregulates FOXO 3a-dependent MelCAM expression leading to attenuation of breast tumor growth and angiogenesis	ONCOGENE			English	Article							PROSTATE-CANCER CELLS; TRANSCRIPTION FACTORS; ANDROGEN RECEPTOR; HUMAN-MELANOMA; PTEN; AKT; APOPTOSIS; NEUROPILIN-1; KINASE; PHOSPHORYLATION	Semaphorin 3A (Sema 3A), a member of semaphorin family, serves as a guidance clue during embryonic development and is known as a candidate tumor suppressor that attenuates breast tumor progression by binding with its co-receptor, neuropilin-1 (NRP-1). However, the underlying mechanism by which Sema 3A suppresses breast tumor growth is still unexplored. In this study, we report that Sema 3A regulates phosphorylation and nuclear translocation of phosphatase and tensin homolog (PTEN) and FOXO 3a. Moreover, Sema 3A controls NRP-1-mediated PTEN-dependent FOXO 3a activation. Overexpression of PTEN and FOXO 3a enhances Sema 3A-induced attenuation of breast cancer cell migration. Chromatin immunoprecipitation and electrophoretic mobility shift assay data revealed that FOXO 3a regulates MelCAM at the transcriptional level. Furthermore, Sema 3A induces NRP-1-mediated MelCAM expression through PTEN and FOXO 3a. The data also showed that vascular endothelial growth factor-induced angiogenesis is inhibited by Sema 3A. Loss of or gain in function study revealed that Sema 3A modulates phosphorylation of PTEN and FOXO 3a and expression of MelCAM, leading to suppression of tumor growth and angiogenesis using in vivo mice model. Clinical specimen analysis revealed that reduced expression of Sema 3A and p-PTEN are correlated with enhanced breast cancer progression, further strengthening our in vitro and in vivo findings. Correlation of relapse-free survival of breast cancer patients (n = 2878) with expression levels of Sema 3A, NRP-1, FOXO 3a and MelCAM were studied by Kaplan-Meier analysis. Statistical analysis revealed a close association between reduced expression of Sema 3A and MelCAM with that of poor patient's survival. Our study demonstrated a novel mechanism of regulation of tumor suppression by Sema 3A in coordination with a chain of tumor-suppressor genes, which in turn inhibits breast cancer cell migration, tumor growth and angiogenesis.	[Mishra, R.; Thorat, D.; Soundararajan, G.; Pradhan, S. J.; Kundu, G. C.] Natl Ctr Cell Sci, Lab Tumor Biol Angiogenesis & Nanomed Res, Pune 411007, Maharashtra, India; [Chakraborty, G.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; [Lohite, K.; Karnik, S.] Ruby Hall Clin, Grant Med Fdn, Pune, Maharashtra, India	Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS); Memorial Sloan Kettering Cancer Center	Kundu, GC (corresponding author), Natl Ctr Cell Sci, Lab Tumor Biol Angiogenesis & Nanomed Res, NCCS Complex, Pune 411007, Maharashtra, India.	kundu@nccs.res.in	Kundu, Gopal C./ABA-9897-2020; Chakraborty, Goutam/U-5559-2019; MISHRA, ROSALIN/L-4319-2017	MISHRA, ROSALIN/0000-0002-9808-8797; Pradhan, Saurabh Jagdish/0000-0002-5306-9138	Council of Scientific and Industrial Research (CSIR); Department of Science and Technology (DST), Government of India; CSIR; DST, Government of India	Council of Scientific and Industrial Research (CSIR)(Council of Scientific & Industrial Research (CSIR) - India); Department of Science and Technology (DST), Government of India(Department of Science & Technology (India)); CSIR(Council of Scientific & Industrial Research (CSIR) - India); DST, Government of India(Department of Science & Technology (India))	We thank Dr B Ramanamurthy, In-charge, Experimental Animal Facility, NCCS for breeding and maintaining NOD-SCID mice. This work was supported by a grant from the Council of Scientific and Industrial Research (CSIR) (to RM and GS) and the Department of Science and Technology (DST) (to DT), Government of India. Financial support: This project was funded by the CSIR and DST, Government of India.	Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Acevedo LM, 2008, BLOOD, V111, P2674, DOI 10.1182/blood-2007-08-110205; American Cancer Society, 2013, CANC FACTS FIG 2013; Arden KC, 2007, CELL, V128, P235, DOI 10.1016/j.cell.2007.01.009; Bachelder RE, 2003, CANCER RES, V63, P5230; Blanco-Aparicio C, 2007, CARCINOGENESIS, V28, P1379, DOI 10.1093/carcin/bgm052; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Bouchard C, 2004, EMBO J, V23, P2830, DOI 10.1038/sj.emboj.7600279; Castro-Rivera E, 2008, CANCER RES, V68, P8295, DOI 10.1158/0008-5472.CAN-07-6601; Chadborn NH, 2006, J CELL SCI, V119, P951, DOI 10.1242/jcs.02801; Chakraborty G, 2006, J BIOL CHEM, V281, P11322, DOI 10.1074/jbc.M512546200; Chakraborty G, 2008, CANCER RES, V68, P152, DOI 10.1158/0008-5472.CAN-07-2126; Chakraborty G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033633; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Emerling BM, 2008, P NATL ACAD SCI USA, V105, P2622, DOI 10.1073/pnas.0706790105; Essers MAG, 2005, SCIENCE, V308, P1181, DOI 10.1126/science.1109083; Fu Z, 2008, ONCOGENE, V27, P2312, DOI 10.1038/onc.2008.24; Gabrovska PN, 2011, GENE, V489, P63, DOI 10.1016/j.gene.2011.08.024; Gil A, 2006, MOL BIOL CELL, V17, P4002, DOI 10.1091/mbc.E06-05-0380; Glauser DA, 2007, J ENDOCRINOL, V193, P195, DOI 10.1677/JOE-06-0191; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Jain S, 2008, CANCER RES, V68, P7750, DOI 10.1158/0008-5472.CAN-07-6689; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Kumar V, 2010, CANCER RES, V70, P10381, DOI 10.1158/0008-5472.CAN-10-1470; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; Li G, 2003, ONCOGENE, V22, P6891, DOI 10.1038/sj.onc.1206819; Li PF, 2003, MOL CELL BIOL, V23, P104, DOI 10.1128/MCB.23.1.104-118.2003; Liu JL, 2005, MOL CELL BIOL, V25, P6211, DOI 10.1128/MCB.25.14.6211-6224.2005; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Miao HQ, 1999, J CELL BIOL, V146, P233, DOI 10.1083/jcb.146.1.233; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Nasarre C, 2010, ONCOGENE, V29, P2381, DOI 10.1038/onc.2010.9; Nho RS, 2010, J BIOL CHEM, V285, P14195, DOI 10.1074/jbc.M109.052845; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Potente M, 2005, J CLIN INVEST, V115, P2382, DOI 10.1172/JCI23126; Raja R, 2014, ONCOGENE, V33, P2053, DOI 10.1038/onc.2013.171; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Rampalli S, 2005, MOL CELL BIOL, V25, P8415, DOI 10.1128/MCB.25.19.8415-8429.2005; Rena G, 2002, EMBO J, V21, P2263, DOI 10.1093/emboj/21.9.2263; Satyamoorthy K, 2001, ONCOGENE, V20, P4676, DOI 10.1038/sj.onc.1204616; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Sharma P, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-178; Shi IM, 1999, J PATHOL, V189, P4, DOI 10.1002/(SICI)1096-9896(199909)189:1<4::AID-PATH332>3.0.CO;2-P; Shih IM, 1997, AM J PATHOL, V151, P745; Sinha S, 2010, EMBO J, V29, P830, DOI 10.1038/emboj.2009.395; Staton CA, 2011, HISTOPATHOLOGY, V59, P274, DOI 10.1111/j.1365-2559.2011.03922.x; Tang TTL, 2002, J BIOL CHEM, V277, P14255, DOI 10.1074/jbc.M110901200; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; Vacca A, 2006, BLOOD, V108, P1661, DOI 10.1182/blood-2006-04-014563; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Wang L, 2007, 2007 IEEE SYMPOSIUM ON COMPUTATIONAL INTELLIGENCE IN SECURITY AND DEFENSE APPLICATIONS, P1; Xie SH, 1997, CANCER RES, V57, P2295; Yacoub M, 2009, HISTOPATHOLOGY, V55, P392, DOI 10.1111/j.1365-2559.2009.03406.x; Yang L, 2005, J BIOL CHEM, V280, P33558, DOI 10.1074/jbc.M504461200; Yazdani U, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-3-211	59	41	44	0	23	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 19	2015	34	12					1584	1595		10.1038/onc.2014.79	http://dx.doi.org/10.1038/onc.2014.79			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD9KI	24727891				2022-12-17	WOS:000351416800011
J	Chen, CC; Liu, HP; Chao, M; Liang, Y; Tsang, NM; Huang, HY; Wu, CC; Chang, YS				Chen, C-C; Liu, H-P; Chao, M.; Liang, Y.; Tsang, N-M; Huang, H-Y; Wu, C-C; Chang, Y-S			NF-kappa B-mediated transcriptional upregulation of TNFAIP2 by the Epstein-Barr virus oncoprotein, LMP1, promotes cell motility in nasopharyngeal carcinoma	ONCOGENE			English	Article						TNFAIP2; LMP1; NPC; NF-kappa B; actin; migration	LYMPH-NODE METASTASIS; PRIMARY RESPONSE GENE; NECROSIS-FACTOR-ALPHA; MEMBRANE-PROTEIN 1; EBV LATENT-MEMBRANE-PROTEIN-1; LATENT MEMBRANE-PROTEIN-1; TUNNELING NANOTUBULES; ORGANELLE TRANSFER; EPITHELIAL-CELLS; FILOPODIA	Nasopharyngeal carcinoma (NPC), which is closely associated with Epstein-Barr virus (EBV), is a metastasis-prone epithelial cancer. We previously showed that tumor necrosis factor alpha-induced protein 2 (TNFAIP2) is highly expressed in NPC tumor tissues and is correlated with metastasis and poor survival in NPC patients. However, the underlying mechanism remains unclear. In this study, we demonstrate that the EBV oncoprotein, latent membrane protein 1 (LMP1), can transcriptionally induce TNFAIP2 expression via NF-kappa B. Quantitative RT-PCR and western blotting revealed that LMP1 induces TNFAIP2 expression through its C-terminal- activating region (CTAR2) domain, which is required for transduction of NF-kappa B (nuclear factor kappa-light-chain-enhancer of activated B cells) signaling. Inhibition of NF-kappa B activation or depletion of p65 (a component of NF-kappa B) by RNA interference abolished the LMP1-induced expression of TNFAIP2, whereas ectopic expression of p65 was sufficient to induce TNFAIP2 expression. Luciferase reporter assays showed that LMP1 transcriptionally induces TNFAIP2 expression through a newly identified NF-kappa B-binding site within the TNFAIP2 promoter (- 3.869 to - 3.860 bp). Immunohistochemical analysis of NPC biopsy specimens further revealed a significant correlation between the protein levels of TNFAIP2 and activated p65 (R = 0.689, P < 0.001), indicating that our findings are clinically relevant. Immunofluorescence microscopy and co-immunoprecipitation assays showed that TNFAIP2 associates with actin and is involved in the formation of actin-based membrane protrusions. Furthermore, transwell migration assays demonstrated that TNFAIP2 contributes to LMP1-induced cell motility. Collectively, these findings provide novel insights into the regulation of TNFAIP2 and its role in promoting NPC tumor progression.	[Chen, C-C; Liu, H-P; Liang, Y.; Chang, Y-S] Chang Gung Univ, Grad Inst Biomed Sci, Chang Gung Mol Med Res Ctr, Taoyuan 333, Taiwan; [Chao, M.; Huang, H-Y] Chang Gung Univ, Grad Inst Biomed Sci, Taoyuan 333, Taiwan; [Tsang, N-M] Chang Gung Mem Hosp Lin Kou, Dept Radiat Oncol, Kwei Shan, Taiwan; [Wu, C-C] Chang Gung Univ, Dept Med Biotechnol & Lab Sci, Taoyuan 333, Taiwan	Chang Gung Memorial Hospital; Chang Gung University; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University	Chang, YS (corresponding author), Chang Gung Univ, Grad Inst Biomed Sci, Chang Gung Mol Med Res Ctr, 259,Wen Hwa 1st Rd, Taoyuan 333, Taiwan.	ysc@mail.cgu.edu.tw	Liu, Hao-Ping/AAJ-3038-2020	Liu, Hao-Ping/0000-0001-5915-5128; Chao, Mei/0000-0002-2143-0531; Chang, Yu-Sun/0000-0002-6457-3890; Wu, Chih-Ching/0000-0002-7264-9672	Ministry of Education of Taiwan	Ministry of Education of Taiwan(Ministry of Education, Taiwan)	We are grateful to Ms Jennifer Cheng for her technical assistance in image acquisition and analysis using the IN Cell Analyzer 2000. This work was supported by the grant from the Ministry of Education of Taiwan (to Chang Gung University).	Abounit S, 2012, J CELL SCI, V125, P1089, DOI 10.1242/jcs.083279; Arjonen A, 2011, CELL ADHES MIGR, V5, P421, DOI 10.4161/cam.5.5.17723; Beckers J, 2005, INT J CANCER, V114, P590, DOI 10.1002/ijc.20798; Chen CC, 2010, CELL SIGNAL, V22, P1132, DOI 10.1016/j.cellsig.2010.03.008; Chen HL, 2010, EXP MOL PATHOL, V89, P367, DOI 10.1016/j.yexmp.2010.09.004; Chen LC, 2011, MODERN PATHOL, V24, P175, DOI 10.1038/modpathol.2010.193; Chen MC, 2008, ANN ONCOL, V19, P1180, DOI 10.1093/annonc/mdn003; Chen P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056929; Cheng YH, 2011, J MOL ENDOCRINOL, V46, P139, DOI 10.1530/JME-10-0064; Chevrier N, 2011, CELL, V147, P853, DOI 10.1016/j.cell.2011.10.022; Chinnery HR, 2008, J IMMUNOL, V180, P5779, DOI 10.4049/jimmunol.180.9.5779; Davis DM, 2008, NAT REV MOL CELL BIO, V9, P431, DOI 10.1038/nrm2399; Faix J, 2006, CURR OPIN CELL BIOL, V18, P18, DOI 10.1016/j.ceb.2005.11.002; Gourzones C, 2012, SEMIN CANCER BIOL, V22, P127, DOI 10.1016/j.semcancer.2012.01.002; Hase K, 2009, NAT CELL BIOL, V11, P1427, DOI 10.1038/ncb1990; Ho FCH, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-98; Hong EJ, 2011, MOL ENDOCRINOL, V25, P269, DOI 10.1210/me.2010-0483; Hui EP, 2002, CLIN CANCER RES, V8, P2595; Zheng H, 2007, CELL MOL IMMUNOL, V4, P185; Jia WH, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-178; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kimura S, 2012, EXP CELL RES, V318, P1699, DOI 10.1016/j.yexcr.2012.05.013; Kondratiev S, 2011, AM J SURG PATHOL, V35, P1531, DOI 10.1097/PAS.0b013e31822bd476; Larkin JD, 2012, MOL CELL BIOL, V32, P2738, DOI 10.1128/MCB.00179-12; LEE AWM, 1992, INT J RADIAT ONCOL, V23, P261, DOI 10.1016/0360-3016(92)90740-9; Li HP, 2003, J BIOMED SCI, V10, P490, DOI 10.1159/000072376; Lin SY, 2001, HEAD NECK-J SCI SPEC, V23, P194, DOI 10.1002/1097-0347(200103)23:3<194::AID-HED1018>3.0.CO;2-X; Liu HP, 2006, EMBO J, V25, P4120, DOI 10.1038/sj.emboj.7601282; Liu HP, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002690; Liu ZS, 2011, CARCINOGENESIS, V32, P1668, DOI 10.1093/carcin/bgr209; Lo AKF, 2006, NEOPLASIA, V8, P173, DOI 10.1593/neo.05625; Lui VWY, 2011, ONCOGENE, V30, P1518, DOI 10.1038/onc.2010.529; Ma Y, 2003, ONCOGENE, V22, P4924, DOI 10.1038/sj.onc.1206728; Marsman J, 2012, BBA-GENE REGUL MECH, V1819, P1217, DOI 10.1016/j.bbagrm.2012.10.008; Mattila PK, 2008, NAT REV MOL CELL BIO, V9, P446, DOI 10.1038/nrm2406; Mookherjee N, 2006, J IMMUNOL, V176, P2455, DOI 10.4049/jimmunol.176.4.2455; Mothes W, 2010, J VIROL, V84, P8360, DOI 10.1128/JVI.00443-10; Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731; Ranzinger J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029537; Rusiniak ME, 2000, CANCER RES, V60, P1824; SARMA V, 1992, J IMMUNOL, V148, P3302; Sherer NM, 2008, TRENDS CELL BIOL, V18, P414, DOI 10.1016/j.tcb.2008.07.003; Sherer NM, 2010, J VIROL, V84, P3248, DOI 10.1128/JVI.02155-09; Singh SK, 2010, FASEB J, V24, P3756, DOI 10.1096/fj.10-159046; Slaby O, 2013, NUTR CANCER, V65, P247, DOI 10.1080/01635581.2013.756530; Smith IF, 2011, BIOPHYS J, V100, pL37, DOI 10.1016/j.bpj.2011.03.007; Sowinski S, 2008, NAT CELL BIOL, V10, P211, DOI 10.1038/ncb1682; Spano JP, 2003, EUR J CANCER, V39, P2121, DOI 10.1016/S0959-8049(03)00367-8; Tsai CL, 2006, CANCER RES, V66, P11668, DOI 10.1158/0008-5472.CAN-06-2194; Tsuji A, 2008, CLIN CANCER RES, V14, P5368, DOI 10.1158/1078-0432.CCR-08-0198; Van Prooyen N, 2010, P NATL ACAD SCI USA, V107, P20738, DOI 10.1073/pnas.1009635107; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; Wang Y, 2011, CELL DEATH DIFFER, V18, P732, DOI 10.1038/cdd.2010.147; Watkins SC, 2005, IMMUNITY, V23, P309, DOI 10.1016/j.immuni.2005.08.009; WOLF FW, 1994, J BIOL CHEM, V269, P3633; Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452	56	41	43	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2014	33	28					3648	3659		10.1038/onc.2013.345	http://dx.doi.org/10.1038/onc.2013.345			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2GC	23975427				2022-12-17	WOS:000338942900004
J	de Graauw, M; Cao, L; Winkel, L; van Miltenburg, MHAM; le Devedec, SE; Klop, M; Yan, K; Pont, C; Rogkoti, VM; Tijsma, A; Chaudhuri, A; Lalai, R; Price, L; Verbeek, F; van de Water, B				de Graauw, M.; Cao, L.; Winkel, L.; van Miltenburg, M. H. A. M.; le Devedec, S. E.; Klop, M.; Yan, K.; Pont, C.; Rogkoti, V-M; Tijsma, A.; Chaudhuri, A.; Lalai, R.; Price, L.; Verbeek, F.; van de Water, B.			Annexin A2 depletion delays EGFR endocytic trafficking via cofilin activation and enhances EGFR signaling and metastasis formation	ONCOGENE			English	Article						AnxA2; breast cancer; EGFR; endocytosis; metastasis	GROWTH-FACTOR RECEPTOR; BREAST-CANCER CELLS; EARLY ENDOSOMES; PHOSPHORYLATION; INVASION; PATHWAY; ADHESION; RECRUITMENT; EXPRESSION; CARCINOMA	Enhanced epidermal growth factor receptor (EGFR) activity has been strongly linked to breast cancer progression and mediators of EGFR endocytosis may well be involved. We developed a semi-automated high-content fluorescence microscopy-based EGFR endocytosis screen to identify proteins that mediate EGFR endocytosis in human HBL100 breast cancer cells. Knockdown of 172 individual endocytosis and actin-regulatory genes with small interfering RNAs led to the identification of 14 genes of which the contribution to EGFR endocytosis in breast cancer is until now poorly defined, including DNAJC6, GDI2, FGD6, HAX1, NECAP2 and AnxA2. We show that depletion of the actin and endocytosis regulatory protein annexin A2 (AnxA2) in a panel of four triple negative breast cancer (TNBC) cell lines affected EGFR endocytosis. Depletion of AnxA2 in the aggressive and highly metastatic MDA-MB-231 TNBC cell line resulted in the inhibition of EGFR transport beyond the early endosomes. This inhibition coincided with enhanced epidermal growth factor (EGF)-induced cell migration and downstream signaling via c-Jun N-terminal kinase (JNK) and Akt. Moreover, AnxA2 knockdown increased lung metastasis formation in mice. The effect of AnxA2 knockdown on EGFR endocytosis in MDA-MB-231 was related to dephosphorylation/activation of the actin-severing protein cofilin, as re-expression of an inactive S3E-cofilin mutant, but not an active S3A-cofilin mutant, re-established EGFR endocytosis to control levels. Together, our data provide evidence for AnxA2 as a mediator of EGFR endocytosis and signaling in breast cancer via regulation of cofilin activation.	[de Graauw, M.; le Devedec, S. E.; Klop, M.; Pont, C.; Rogkoti, V-M; Tijsma, A.; Chaudhuri, A.; Lalai, R.; Price, L.; van de Water, B.] Leiden Univ, LACDR, Div Toxicol, NL-2300 RA Leiden, Netherlands; [Cao, L.; Yan, K.; Verbeek, F.] Leiden Univ, LIACS, Imaging & Bioinformat Grp, NL-2300 RA Leiden, Netherlands; [Winkel, L.] Erasmus MC, Biomech Lab, Rotterdam, Netherlands; [van Miltenburg, M. H. A. M.] Netherland Canc Inst, Dept Mol Pathol, Amsterdam, Netherlands	Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC; Erasmus University Rotterdam; Erasmus MC; Netherlands Cancer Institute	van de Water, B (corresponding author), Leiden Univ, LACDR, Div Toxicol, Einsteinweg 55,POB 9502, NL-2300 RA Leiden, Netherlands.	m.de.graauw@lacdr.leidenuniv.nl; b.water@lacdr.leidenuniv.nl		Yan, Kuan/0000-0003-4143-3569; Le Devedec, Sylvia/0000-0002-0615-9616	Dutch Cancer Society (KWF) [UL 2006-3538, UL 2007-3860]; EU [201862]; EUFP7 Systems Microscopy NoE [258068]; TI Pharma project [T3-107]; Dutch Organization for Scientific Research [NWO 911-02-022]; Horizon Breakthrough [NWO 93518003]; Centre for Biomedical Genetics	Dutch Cancer Society (KWF)(KWF Kankerbestrijding); EU(European Commission); EUFP7 Systems Microscopy NoE; TI Pharma project; Dutch Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Horizon Breakthrough; Centre for Biomedical Genetics	We thank Dr Erik Danen and Dr Leo Price for critically reading the manuscript. This work was supported by grants from the Dutch Cancer Society (KWF; grant UL 2006-3538 and UL 2007-3860), EU FP7-Metafight (grant no 201862), EUFP7 Systems Microscopy NoE (258068), TI Pharma project T3-107, the Dutch Organization for Scientific Research (NWO 911-02-022), Horizon Breakthrough (NWO 93518003) and Centre for Biomedical Genetics.	Babbin BA, 2007, AM J PATHOL, V170, P951, DOI 10.2353/ajpath.2007.060647; Badovinac-Crnjevic T, 2011, MED ONCOL, V28, pS121, DOI 10.1007/s12032-010-9738-2; Cao L, 2012, P 6 IAPR INT C PATT, P330; Croxtall JD, 2000, BRIT J PHARMACOL, V130, P289, DOI 10.1038/sj.bjp.0703272; de Graauw M, 2005, J BIOL CHEM, V280, P29885, DOI 10.1074/jbc.M412708200; de Graauw M, 2008, MOL CELL BIOL, V28, P1029, DOI 10.1128/MCB.01247-07; de Graauw M, 2010, P NATL ACAD SCI USA, V107, P6340, DOI 10.1073/pnas.0913360107; Eccles SA, 2011, INT J DEV BIOL, V55, P685, DOI 10.1387/ijdb.113396se; Emoto K, 2001, CANCER, V92, P1419, DOI 10.1002/1097-0142(20010915)92:6<1419::AID-CNCR1465>3.0.CO;2-J; Geldner N, 2006, CURR OPIN PLANT BIOL, V9, P589, DOI 10.1016/j.pbi.2006.09.011; Goswami S, 2005, CANCER RES, V65, P5278, DOI 10.1158/0008-5472.CAN-04-1853; Grandal MV, 2008, J CELL MOL MED, V12, P1527, DOI 10.1111/j.1582-4934.2008.00298.x; Grewal T, 2010, INT J BIOCHEM CELL B, V42, P580, DOI 10.1016/j.biocel.2009.12.020; Grieve Adam G, 2012, Int J Cell Biol, V2012, P852430, DOI 10.1155/2012/852430; HARDER T, 1993, J CELL BIOL, V123, P1119, DOI 10.1083/jcb.123.5.1119; Huigsloot M, 2002, J BIOL CHEM, V277, P35869, DOI 10.1074/jbc.M200378200; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; Jost M, 1997, J CELL SCI, V110, P221; Le Devedec SE, 2009, CLIN EXP METASTAS, V26, P673, DOI 10.1007/s10585-009-9267-6; Llado A, 2008, MOL BIOL CELL, V19, P17, DOI 10.1091/mbc.E07-05-0411; Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996; Marcoux N, 2005, CELL SIGNAL, V17, P1449, DOI 10.1016/j.cellsig.2005.03.001; Mayran N, 2003, EMBO J, V22, P3242, DOI 10.1093/emboj/cdg321; Minn AJ, 2007, P NATL ACAD SCI USA, V104, P6740, DOI 10.1073/pnas.0701138104; Miyamoto Y, 2003, J BIOL CHEM, V278, P29890, DOI 10.1074/jbc.M301559200; Mosesson Y, 2008, NAT REV CANCER, V8, P835, DOI 10.1038/nrc2521; Murphy JE, 2009, P NATL ACAD SCI USA, V106, P17615, DOI 10.1073/pnas.0906541106; Nishimura Y, 2006, HISTOCHEM CELL BIOL, V126, P627, DOI 10.1007/s00418-006-0198-x; Okreglak V, 2007, J CELL BIOL, V178, P1251, DOI 10.1083/jcb.200703092; PEPINSKY RB, 1986, NATURE, V321, P81, DOI 10.1038/321081a0; Rescher U, 2008, J CELL SCI, V121, P2177, DOI 10.1242/jcs.028415; Richnau N, 2001, J BIOL CHEM, V276, P35060, DOI 10.1074/jbc.M103540200; Sharma MR, 2006, EXP MOL PATHOL, V81, P146, DOI 10.1016/j.yexmp.2006.03.003; Shetty PK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044299; Sidani M, 2007, J CELL BIOL, V179, P777, DOI 10.1083/jcb.200707009; van Roosmalen W, 2011, METHODS MOL BIOL, V769, P435, DOI 10.1007/978-1-61779-207-6_29; Vila de MS, 2009, ONCOGENE, V28, P363; Wang WG, 2007, NAT REV CANCER, V7, P429, DOI 10.1038/nrc2148; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; White IJ, 2006, EMBO J, V25, P1, DOI 10.1038/sj.emboj.7600759; Wu B, 2012, CELL PROLIFERAT, V45, P189, DOI 10.1111/j.1365-2184.2012.00820.x; Zheng L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019390	42	41	41	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2014	33	20					2610	2619		10.1038/onc.2013.219	http://dx.doi.org/10.1038/onc.2013.219			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH9YT	23792445				2022-12-17	WOS:000336502700007
J	Velghe, AI; Van Cauwenberghe, S; Polyansky, AA; Chand, D; Montano-Almendras, CP; Charni, S; Hallberg, B; Essaghir, A; Demoulin, JB				Velghe, A. I.; Van Cauwenberghe, S.; Polyansky, A. A.; Chand, D.; Montano-Almendras, C. P.; Charni, S.; Hallberg, B.; Essaghir, A.; Demoulin, J-B			PDGFRA alterations in cancer: characterization of a gain-of-function V536E transmembrane mutant as well as loss-of-function and passenger mutations	ONCOGENE			English	Article						PDGF receptor; tyrosine kinase inhibitors; glioblastoma; leukemia; GIST	RECEPTOR TYROSINE KINASE; HYPEREOSINOPHILIC SYNDROME; CELL PROLIFERATION; EGF RECEPTOR; IMATINIB; ACTIVATION; MEMBRANE; DOMAIN; BETA; GENE	Activating mutations in the platelet-derived growth factor (PDGF) receptor alpha (PDGFRA) have been described in patients with gastrointestinal stromal tumors or myeloid malignancies associated with hypereosinophilia. These patients respond well to imatinib mesylate, raising the question as to whether patients with a PDGF receptor mutation in other tumor types should receive a tyrosine kinase inhibitor treatment. We characterized 10 novel somatic point mutations in PDGFRA that have been reported in isolated cases of glioblastoma, melanoma, acute myeloid leukemia, peripheral nerve sheath tumors and neuroendocrine carcinoma. The PDGFRA transmembrane domain mutation V536E stimulated Ba/F3 cell growth and signaling via ERK and STAT5 in the absence of ligand. This mutant, identified in glioblastoma, was strongly inhibited by imatinib. Modeling suggested that the mutation modulates the packing of the transmembrane domain helices in the receptor dimer. By contrast, two mutations in highly conserved residues affected the receptor traffic to the cell surface or kinase activity, thereby preventing the response to PDGF. The other mutations had no significant impact on the receptor activity. This functional analysis matched the predictions of SIFT and PolyPhen for only five mutations and these algorithms do not discriminate gain from loss of function. Finally, an E996K variant that had been identified in a melanoma cell line was not expressed in these cells. Altogether, several newly identified PDGFRA mutations do not activate the receptor and may therefore represent passenger mutations. Our results also underline the importance of characterizing novel kinase alterations in cancer patients.	[Velghe, A. I.; Van Cauwenberghe, S.; Montano-Almendras, C. P.; Charni, S.; Essaghir, A.; Demoulin, J-B] Catholic Univ Louvain, de Duve Inst, BE-1200 Brussels, Belgium; [Polyansky, A. A.] Univ Vienna, Max F Perutz Labs, Dept Struct & Computat Biol, Vienna, Austria; [Polyansky, A. A.] Russian Acad Sci, MM Shemyakin & Yu A Ovchinnikov Inst Bioorgan Che, Moscow, Russia; [Chand, D.; Hallberg, B.] Umea Univ, Dept Mol Biol, Umea, Sweden	Universite Catholique Louvain; Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Umea University	Demoulin, JB (corresponding author), Catholic Univ Louvain, de Duve Inst, MEXP B1-74-05,Ave Hippocrate 75, BE-1200 Brussels, Belgium.	jb.demoulin@uclouvain.be	Polyansky, Anton A/J-2145-2018	Polyansky, Anton A/0000-0002-1011-2706; Demoulin, Jean-Baptiste/0000-0002-8016-6689	Salus Sanguinis Foundation; 'Action de Recherches Concertees' (Communaute Francaise de Belgique, Belgium)	Salus Sanguinis Foundation; 'Action de Recherches Concertees' (Communaute Francaise de Belgique, Belgium)	We thank Francis Brasseur (Ludwig Institute for Cancer Research, Brussels, Belgium) for the LB373-MEL cell line and Stefan Constantinescu (de Duve Institute) for advices. This work was supported by the Salus Sanguinis Foundation and a grant from 'Action de Recherches Concertees' (Communaute Francaise de Belgique, Belgium).	Alentorn A, 2012, NEURO-ONCOLOGY, V14, P1393, DOI 10.1093/neuonc/nos217; Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708; Arkhipov A, 2013, CELL, V152, P557, DOI 10.1016/j.cell.2012.12.030; Bell CA, 2000, MOL BIOL CELL, V11, P3589, DOI 10.1091/mbc.11.10.3589; Burke CL, 1997, ONCOGENE, V14, P687, DOI 10.1038/sj.onc.1200873; Chiara F, 2004, J BIOL CHEM, V279, P19732, DOI 10.1074/jbc.M314070200; Clarke ID, 2003, ONCOGENE, V22, P722, DOI 10.1038/sj.onc.1206160; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Corless CL, 2005, J CLIN ONCOL, V23, P5357, DOI 10.1200/JCO.2005.14.068; David M, 2007, BLOOD, V109, P61, DOI 10.1182/blood-2006-05-024828; Demoulin JB, 2004, J BIOL CHEM, V279, P35392, DOI 10.1074/jbc.M405924200; Demoulin JB, 2003, BIOCHEM J, V376, P505, DOI 10.1042/BJ20030385; Demoulin JB, 1996, MOL CELL BIOL, V16, P4710; Demoulin JB, 2012, AM J BLOOD RES, V2, P44; Dresemann G, 2010, J NEURO-ONCOL, V96, P393, DOI 10.1007/s11060-009-9976-3; Elling C, 2011, BLOOD, V117, P2935, DOI 10.1182/blood-2010-05-286757; Endres NF, 2013, CELL, V152, P543, DOI 10.1016/j.cell.2012.12.032; Frohling S, 2007, CANCER CELL, V12, P501, DOI 10.1016/j.ccr.2007.11.005; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Hiwatari M, 2005, LEUKEMIA, V19, P476, DOI 10.1038/sj.leu.2403638; Holtkamp N, 2006, CARCINOGENESIS, V27, P664, DOI 10.1093/carcin/bgi273; Huss S, 2012, HISTOPATHOLOGY, V61, P59, DOI 10.1111/j.1365-2559.2012.04203.x; KEATING MT, 1989, J BIOL CHEM, V264, P9129; Medves S, 2012, J CELL MOL MED, V16, P237, DOI 10.1111/j.1582-4934.2011.01415.x; Medves S, 2011, HAEMATOL-HEMATOL J, V96, P1406, DOI 10.3324/haematol.2011.040147; Metzgeroth G, 2008, BRIT J HAEMATOL, V143, P707, DOI 10.1111/j.1365-2141.2008.07294.x; Montano-Almendras CR, 2012, HAEMATOL-HEMATOL J, V97, P1064, DOI 10.3324/haematol.2011.047530; Muhle-Goll C, 2012, J BIOL CHEM, V287, P26178, DOI 10.1074/jbc.M111.325555; Omura T, 1997, J BIOL CHEM, V272, P12676, DOI 10.1074/jbc.272.19.12676; Ozawa T, 2010, GENE DEV, V24, P2205, DOI 10.1101/gad.1972310; Paulsson J, 2011, INT J CANCER, V128, P1981, DOI 10.1002/ijc.25528; Polyansky AA, 2012, J AM CHEM SOC, V134, P14390, DOI 10.1021/ja303483k; Ramensky V, 2002, NUCLEIC ACIDS RES, V30, P3894, DOI 10.1093/nar/gkf493; Rand V, 2005, P NATL ACAD SCI USA, V102, P14344, DOI 10.1073/pnas.0507200102; Schonerr C, 2012, ONCOGENE, V31, P5193, DOI 10.1038/onc.2012.12; Schonherr C, 2011, TRANSL ONCOL, V4, P248, DOI 10.1593/tlo.11139; Takahashi Y, 2006, EMBO J, V25, P910, DOI 10.1038/sj.emboj.7600979; Toffalini F, 2010, BLOOD, V116, P2429, DOI 10.1182/blood-2010-04-279752; Toffalini F, 2010, J BIOL CHEM, V285, P12268, DOI 10.1074/jbc.M109.076638; Toffalini F, 2009, HAEMATOL-HEMATOL J, V94, P1085, DOI 10.3324/haematol.2008.001149; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Yang Y, 2008, P NATL ACAD SCI USA, V105, P7681, DOI 10.1073/pnas.0802896105; Yuzawa S, 2007, CELL, V130, P323, DOI 10.1016/j.cell.2007.05.055; Zhang J, 2013, P NATL ACAD SCI USA, V110, P1398, DOI 10.1073/pnas.1205299110	44	41	43	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2014	33	20					2568	2576		10.1038/onc.2013.218	http://dx.doi.org/10.1038/onc.2013.218			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH9YT	23752188				2022-12-17	WOS:000336502700003
J	Teshima, K; Nara, M; Watanabe, A; Ito, M; Ikeda, S; Hatano, Y; Oshima, K; Seto, M; Sawada, K; Tagawa, H				Teshima, K.; Nara, M.; Watanabe, A.; Ito, M.; Ikeda, S.; Hatano, Y.; Oshima, K.; Seto, M.; Sawada, K.; Tagawa, H.			Dysregulation of BMI1 and microRNA-16 collaborate to enhance an anti-apoptotic potential in the side population of refractory mantle cell lymphoma	ONCOGENE			English	Article						BMI1; miR-16; Noxa; apoptosis; side population; mantle cell lymphoma	CANCER STEM-CELLS; HOMOZYGOUS DELETIONS; SELF-RENEWAL; MESENCHYMAL TRANSITION; DOWN-REGULATION; MOUSE MODEL; PHASE-II; GENE; PROLIFERATION; MIR-16	The proto-oncogene BMI1 and its product, Bmi1, is overexpressed in various types of tumors, particularly in aggressive tumors and tumors resistant to conventional chemotherapy. BMI1/Bmi1 is also crucially involved in cancer-initiating cell maintenance, and is recurrently upregulated in mantle cell lymphoma (MCL), especially aggressive variants. Recently, side population (SP) cells were shown to exhibit tumor-initiating characteristics in various types of tumors. In this study, we show that recurrent MCL cases significantly exhibit upregulation of BMI1/Bmi1. We further demonstrate that clonogenic MCL SP shows such tumor-initiating characteristics as high tumorigenicity and self-renewal capability, and that BMI1 was upregulated in the SP from recurrent MCL cases and MCL cell lines. On screening for upstream regulators of BMI1, we found that expression of microRNA-16 (miR-16) was downregulated in MCL SP cells by regulating Bmi1 in the SPs, leading to reductions in tumor size following lymphoma xenografts. Moreover, to investigate downstream targets of BMI1 in MCL, we performed cross-linking/chromatin immunoprecipitation assay against MCL cell lines and demonstrated that Bmi1 directly regulated pro-apoptotic genes such as BCL2L11/Bim and PMAIP1/Noxa, leading to enhance anti-apoptotic potential of MCL. Finally, we found that a proteasome inhibitor bortezomib, which has been recently used for relapsed MCL, effectively induced apoptosis among MCL cells while reducing expression of Bmi1 and increasing miR-16 in MCL SP. These results suggest that upregulation of BMI1 and downregulation of miR-16 in MCL SP has a key role in the disease's progression by reducing MCL cell apoptosis. Our results provide important new insight into the pathogenesis of MCL and strongly suggest that targeting BMI1/Bmi1 might be an effective approach to treating MCL, particularly refractory and recurrent cases.	[Teshima, K.; Nara, M.; Watanabe, A.; Ito, M.; Ikeda, S.; Sawada, K.; Tagawa, H.] Akita Univ, Grad Sch Med, Dept Hematol Nephrol & Rheumatol, Hondo, Akita 0108543, Japan; [Hatano, Y.] Yamamoto Kumiai Gen Hosp, Dept Internal Med, Noshiro, Akita, Japan; [Oshima, K.] Kurume Univ, Sch Med, Dept Pathol, Kurume, Fukuoka 830, Japan; [Seto, M.] Aichi Canc Ctr, Res Inst, Dept Mol Med, Nagoya, Aichi 464, Japan	Kurume University; Aichi Cancer Center	Tagawa, H (corresponding author), Akita Univ, Grad Sch Med, Dept Hematol Nephrol & Rheumatol, Hondo, Akita 0108543, Japan.	htagawa0279jp@yahoo.co.jp			Japan Society for the Promotion of Science	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work is supported by a Grant-in-Aid from the Japan Society for the Promotion of Science (HT). We wish to express our appreciation to Ms E Kobayashi, Y Abc, K Iwamoto, H Kataho and Mr J Yamashita for their outstanding technical assistance, Drs T Nanjo (Akita University, Akita, Japan), S Nakamura (Nagoya University, Nagoya, Japan) and R Ichinohasama (Tohoku University, Sendai, Japan) for their histological and/or clinical diagnosis of MCL. Drs N Takahashi (Akita University), N Takahashi (Akita University), Y Michishita (Akita University), K Honda (Akita University), M Kume (Hiraka General Hospital), H Oyagi (Hiraka General Hospital), M Katayama (Aichi Cancer Center) and F Arakawa (Kurume University) for collection of primary lymphoma samples and constructive discussion.	Bea S, 2001, CANCER RES, V61, P2409; Bea S, 2009, BLOOD, V113, P3059, DOI 10.1182/blood-2008-07-170183; Bhattacharya R, 2009, CANCER RES, V69, P9090, DOI 10.1158/0008-5472.CAN-09-2552; Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507; Bruggeman SWM, 2007, CANCER CELL, V12, P328, DOI 10.1016/j.ccr.2007.08.032; Chen RW, 2008, BLOOD, V112, P822, DOI 10.1182/blood-2008-03-142182; Chiba T, 2008, CANCER RES, V68, P7742, DOI 10.1158/0008-5472.CAN-07-5882; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Dong PX, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-99; Douglas D, 2008, CANCER RES, V68, P6507, DOI 10.1158/0008-5472.CAN-07-6152; Dovey JS, 2008, P NATL ACAD SCI USA, V105, P11857, DOI 10.1073/pnas.0803574105; Feuring-Buske M, 2001, BLOOD, V97, P3882, DOI 10.1182/blood.V97.12.3882; Fisher RI, 2006, J CLIN ONCOL, V24, P4867, DOI 10.1200/JCO.2006.07.9665; Godlewski J, 2008, CANCER RES, V68, P9125, DOI 10.1158/0008-5472.CAN-08-2629; Goodell Margaret A, 2005, Methods Mol Biol, V290, P343; Haraguchi N, 2006, STEM CELLS, V24, P506, DOI 10.1634/stemcells.2005-0282; Ho MM, 2007, CANCER RES, V67, P4827, DOI 10.1158/0008-5472.CAN-06-3557; Hoenerhoff MJ, 2009, ONCOGENE, V28, P3022, DOI 10.1038/onc.2009.165; Inomata M, 2009, BLOOD, V113, P396, DOI 10.1182/blood-2008-07-163907; Ito M, 2002, BLOOD, V100, P3175, DOI 10.1182/blood-2001-12-0207; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Jagani Z, 2010, CANCER RES, V70, P5528, DOI 10.1158/0008-5472.CAN-09-4229; Jares P, 2008, BRIT J HAEMATOL, V142, P149, DOI 10.1111/j.1365-2141.2008.07124.x; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; Kim KW, 2012, ENVIRON GEOCHEM HLTH, V34, P1, DOI 10.1007/s10653-011-9402-6; Kimura M, 2011, CANCER SCI, V102, P983, DOI 10.1111/j.1349-7006.2011.01891.x; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Leung C, 2004, NATURE, V428, P337, DOI 10.1038/nature02385; Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054; Mestre-Escorihuela C, 2007, BLOOD, V109, P271, DOI 10.1182/blood-2006-06-026500; Mitsutake N, 2007, ENDOCRINOLOGY, V148, P1797, DOI 10.1210/en.2006-1553; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; O'Connor OA, 2005, J CLIN ONCOL, V23, P676, DOI 10.1200/JCO.2005.02.050; Ofir M, 2011, MOL CANCER RES, V9, P440, DOI 10.1158/1541-7786.MCR-10-0344; Patrawala L, 2005, CANCER RES, V65, P6207, DOI 10.1158/0008-5472.CAN-05-0592; Pothof J, 2009, EMBO J, V28, P2090, DOI 10.1038/emboj.2009.156; Pouliot LM, 2012, CANCER RES, V72, P5945, DOI 10.1158/0008-5472.CAN-12-1400; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rivas MA, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3187; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Song LB, 2009, J CLIN INVEST, V119, P3626, DOI 10.1172/JCI39374; Sun L, 2012, ONCOGENE, V31, P432, DOI 10.1038/onc.2011.263; Swerdlow SH, 2008, WHO CLASSIFICATION T, P158; Szotek PP, 2006, P NATL ACAD SCI USA, V103, P11154, DOI 10.1073/pnas.0603672103; Tagawa H, 2005, LEUKEMIA, V19, P2013, DOI 10.1038/sj.leu.2403942; Tagawa H, 2005, ONCOGENE, V24, P1348, DOI 10.1038/sj.onc.1208300; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; Wang J, 2007, CANCER RES, V67, P3716, DOI 10.1158/0008-5472.CAN-06-4343; Wu CL, 2007, CANCER RES, V67, P8216, DOI 10.1158/0008-5472.CAN-07-0999; Wu ZH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014648; Yamashita M, 2008, J EXP MED, V205, P1109, DOI 10.1084/jem.20072000; Young LE, 2012, MOL CANCER RES, V10, P167, DOI 10.1158/1541-7786.MCR-11-0337; Zhang XN, 2010, CANCER RES, V70, P7176, DOI 10.1158/0008-5472.CAN-10-0697; Zhao JJ, 2010, BLOOD, V115, P2630, DOI 10.1182/blood-2009-09-243147; Zhou R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030772; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028; Zhu YH, 2011, CLIN CANCER RES, V17, P7105, DOI 10.1158/1078-0432.CCR-11-0071	58	41	44	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2014	33	17					2191	2203		10.1038/onc.2013.177	http://dx.doi.org/10.1038/onc.2013.177			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF8WJ	23686310				2022-12-17	WOS:000334996000005
